broad_id	pert_iname	clinical_phase	moa	target	disease_area	indication	qc_incompatible	purity	vendor	catalog_no	vendor_name	expected_mass	smiles	InChIKey	pubchem_cid	deprecated_broad_id	InChIKey14
BRD-K76022557-003-28-9	(R)-(-)-apomorphine	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A	neurology/psychiatry	Parkinson's Disease	0	98.9	MedChemEx	HY-12723A	Apomorphine (hydrochloride hemihydrate)	267.126	CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	VMWNQDUVQKEIOC-CYBMUJFWSA-N	6005.0		VMWNQDUVQKEIOC
BRD-K76022557-003-02-7	(R)-(-)-apomorphine	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A	neurology/psychiatry	Parkinson's Disease	0	97.34	Tocris	2073	(R)-(-)-Apomorphine hydrochloride	267.126	CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	VMWNQDUVQKEIOC-CYBMUJFWSA-N	6005.0		VMWNQDUVQKEIOC
BRD-K76022557-003-29-9	(R)-(-)-apomorphine	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A	neurology/psychiatry	Parkinson's Disease	0	97.36	Tocris	2073	(R)-(-)-Apomorphine hydrochloride	267.126	CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	VMWNQDUVQKEIOC-CYBMUJFWSA-N	6005.0		VMWNQDUVQKEIOC
BRD-K76022557-001-03-9	(R)-(-)-apomorphine	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A	neurology/psychiatry	Parkinson's Disease	0	95.8	Selleck	S4350	R-(-)-Apomorphine HCl Hemihydrate	267.126	CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	VMWNQDUVQKEIOC-CYBMUJFWSA-N	6005.0		VMWNQDUVQKEIOC
BRD-K75516118-001-04-1	(R)-(-)-rolipram	Phase 1	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D|PDE5A			0	93.92	Tocris	1349	(R)-(-)-Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	HJORMJIFDVBMOB-LBPRGKRZSA-N	448055.0		HJORMJIFDVBMOB
BRD-K75516118-001-05-9	(R)-(-)-rolipram	Phase 1	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D|PDE5A			0	93.75	Tocris	1349	(R)-(-)-Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	HJORMJIFDVBMOB-LBPRGKRZSA-N	448055.0		HJORMJIFDVBMOB
BRD-K75516118-001-03-3	(R)-(-)-rolipram	Phase 1	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D|PDE5A			0	97.48	Tocris	1349	(R)-(-)-Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	HJORMJIFDVBMOB-LBPRGKRZSA-N	448055.0		HJORMJIFDVBMOB
BRD-K62353271-001-04-7	(R)-baclofen	Phase 3	benzodiazepine receptor agonist	GABBR1|GABBR2			0	96.78	Selleck	S3072	(R)-baclofen	213.056	NC[C@H](CC(O)=O)c1ccc(Cl)cc1	KPYSYYIEGFHWSV-QMMMGPOBSA-N	6918881.0		KPYSYYIEGFHWSV
BRD-K62353271-001-02-1	(R)-baclofen	Phase 3	benzodiazepine receptor agonist	GABBR1|GABBR2			0	17.08	Selleck	S3072	(R)-baclofen	213.056	NC[C@H](CC(O)=O)c1ccc(Cl)cc1	KPYSYYIEGFHWSV-QMMMGPOBSA-N	6918881.0		KPYSYYIEGFHWSV
BRD-K65856711-001-05-9	(S)-(+)-rolipram	Phase 1	phosphodiesterase inhibitor	PDE4B|PDE4D			0	94.78	Tocris	1350	(S)-(+)-Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	HJORMJIFDVBMOB-GFCCVEGCSA-N	158758.0		HJORMJIFDVBMOB
BRD-K65856711-001-03-6	(S)-(+)-rolipram	Phase 1	phosphodiesterase inhibitor	PDE4B|PDE4D			0	96.99	Selleck	S2127	S- (+)-Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	HJORMJIFDVBMOB-GFCCVEGCSA-N	158758.0		HJORMJIFDVBMOB
BRD-K65856711-001-04-4	(S)-(+)-rolipram	Phase 1	phosphodiesterase inhibitor	PDE4B|PDE4D			0	98.17	Tocris	1350	(S)-(+)-Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	HJORMJIFDVBMOB-GFCCVEGCSA-N	158758.0		HJORMJIFDVBMOB
BRD-K89787693-001-01-1	[sar9,met(o2)11]-substance-p	Preclinical	tachykinin antagonist	TACR1			0		Tocris	1178	2-({5-amino-2-[({1-[6-amino-2-({[1-(2-amino-5-{[amino(imino)methyl]amino}pentanoyl)-2-pyrrolidinyl]carbonyl}amino)hexanoyl]-2-pyrrolidinyl}carbonyl)amino]-5-oxopentanoyl}amino)-N~1~-[13-(aminocarbonyl;)-1,4-dibenzyl-10-isobutyl-6-methyl-16,16-dioxido-2,5,	1392.734	CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O	OUPXSLGGCPUZJJ-SARDKLJWSA-N	163829.0		OUPXSLGGCPUZJJ
BRD-K89787693-001-02-9	[sar9,met(o2)11]-substance-p	Preclinical	tachykinin antagonist	TACR1			0	43.63	Bachem	H-9410.0005	(Sar9, Met(O2)11)-substance P	1392.734	CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O	OUPXSLGGCPUZJJ-SARDKLJWSA-N	163829.0		OUPXSLGGCPUZJJ
BRD-K70329400-001-02-5	A-1070722	Preclinical	glycogen synthase kinase inhibitor	GSK3A|GSK3B			0	97.36	Tocris	4431	A 1070722	362.099	COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1	VQPBIJGXSXEOCU-UHFFFAOYSA-N	49830684.0		VQPBIJGXSXEOCU
BRD-K70329400-001-01-7	A-1070722	Preclinical	glycogen synthase kinase inhibitor	GSK3A|GSK3B			0	98.53	Stanley		A 1070722	362.099	COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1	VQPBIJGXSXEOCU-UHFFFAOYSA-N	49830684.0		VQPBIJGXSXEOCU
BRD-K59060513-001-02-5	A-1120	Preclinical	retinoid receptor ligand	RBP4			0	83.72	Tocris	3793	A 1120	392.135	OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F	MEAQCLPMSVEOQF-UHFFFAOYSA-N	25138295.0		MEAQCLPMSVEOQF
BRD-K59060513-001-01-7	A-1120	Preclinical	retinoid receptor ligand	RBP4			0		Sigma	A3111	A1120	392.135	OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F	InChI=1S/C20H19F3N2O3/c21-20(22,23)16-7-3-1-5-14(16)13-9-11-25(12-10-13)19(28)24-17-8-4-2-6-15(17)18(26)27/h1-8,13H,9-12H2,(H,24,28)(H,26,27)	25138295.0		MEAQCLPMSVEOQF
BRD-K38019854-323-01-4	A-317491	Preclinical	purinergic receptor antagonist	P2RX3			0	98.69	MedChemEx	HY-15568A	A-317491 (sodium salt hydrate)	565.174	OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12	VQGBOYBIENNKMI-LJAQVGFWSA-N	9829395.0		VQGBOYBIENNKMI
BRD-K38019854-001-01-6	A-317491	Preclinical	purinergic receptor antagonist	P2RX3			0	98.06	MedChemEx	HY-15568	A-317491	565.174	OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12	VQGBOYBIENNKMI-LJAQVGFWSA-N	9829395.0		VQGBOYBIENNKMI
BRD-A40302156-001-01-9	A-33903	Phase 2					0	96.18	Maybridge	RJC01921	N-(2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)acetamide	293.116	CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O |&1:4,r,t:5|	MMXSDWJOQSEPSM-MRXNPFEDSA-N	6923850.0		MMXSDWJOQSEPSM
BRD-K06182768-001-06-4	A-366	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	91.4	MedChemEx	HY-12583	A-366	329.21	COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	BKCDJTRMYWSXMC-UHFFFAOYSA-N	76285486.0		BKCDJTRMYWSXMC
BRD-K06182768-001-02-3	A-366	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	72.61	Tocris	5163	A-366	329.21	COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	BKCDJTRMYWSXMC-UHFFFAOYSA-N	76285486.0		BKCDJTRMYWSXMC
BRD-K06182768-001-03-1	A-366	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	54.93	MedChemEx	HY-12583	A-366	329.21	COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	BKCDJTRMYWSXMC-UHFFFAOYSA-N	76285486.0		BKCDJTRMYWSXMC
BRD-K06182768-001-01-5	A-366	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	60.31	MedChemEx	HY-12583	A-366	329.21	COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	BKCDJTRMYWSXMC-UHFFFAOYSA-N	76285486.0		BKCDJTRMYWSXMC
BRD-K06182768-001-04-9	A-366	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	16.9	Tocris	5163	A 366	329.21	COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	BKCDJTRMYWSXMC-UHFFFAOYSA-N	76285486.0		BKCDJTRMYWSXMC
BRD-K00005339-001-01-9	A-381393	Preclinical	dopamine receptor antagonist				0	95.93	MedChemEx	HY-116941	A-381393	320.2	Cc1ccc(cc1C)N1CCN(Cc2nc3ccccc3[nH]2)CC1	SAQMCVDGOIRQTC-UHFFFAOYSA-N	11301655.0		SAQMCVDGOIRQTC
BRD-K62066682-300-02-9	A-412997	Preclinical	dopamine receptor agonist	DRD4			0	95.13	Tocris	4552	A 412997 dihydrochloride	309.184	Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1	JFCDMGGMCUKHST-UHFFFAOYSA-N	10425450.0		JFCDMGGMCUKHST
BRD-K62066682-300-01-0	A-412997	Preclinical	dopamine receptor agonist	DRD4			0	95.39	Tocris	4552	A 412997 dihydrochloride	309.184	Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1	JFCDMGGMCUKHST-UHFFFAOYSA-N	10425450.0		JFCDMGGMCUKHST
BRD-K13223831-003-01-7	A-438079	Preclinical	purinergic receptor antagonist	P2RX7			0	93.4	Tocris	2972	A 438079 hydrochloride	305.024	Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl	MMPAULQSJLVKHP-UHFFFAOYSA-N	11673921.0		MMPAULQSJLVKHP
BRD-K13223831-003-02-9	A-438079	Preclinical	purinergic receptor antagonist	P2RX7			0	97.34	Tocris	2972	A 438079 hydrochloride	305.024	Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl	MMPAULQSJLVKHP-UHFFFAOYSA-N	11673921.0		MMPAULQSJLVKHP
BRD-K30233223-001-04-9	A-485	Preclinical	histone acetyltransferase inhibitor				0	98.15	MedChemEx	HY-107455	A-485	536.168	CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1	VRVJKILQRBSEAG-LFPIHBKWSA-N	118958122.0		VRVJKILQRBSEAG
BRD-K79743788-001-01-2	A-582941	Preclinical	nicotinic receptor agonist	CHRNA7			0	84.25	Tocris	4341	A 582941	280.169	CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1	GTMRUYCIJSNXGB-GASCZTMLSA-N	44190553.0		GTMRUYCIJSNXGB
BRD-K79743788-001-02-9	A-582941	Preclinical	nicotinic receptor agonist	CHRNA7			0	91.53	Tocris	4341	A 582941	280.169	CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1	GTMRUYCIJSNXGB-GASCZTMLSA-N	44190553.0		GTMRUYCIJSNXGB
BRD-K00004225-004-01-9	A-61603	Preclinical	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D			0	100.0	Tocris	1052	A 61603 hydrobromide	309.115	CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11,r,t:18|	OQFCXJDXHCDLHX-NSHDSACASA-N	10804826.0		OQFCXJDXHCDLHX
BRD-K78177893-003-03-9	A-674563	Preclinical	AKT inhibitor	AKT1|PKIA|PRKACA			0	94.06	MedChemEx	HY-13254A	A-674563 (hydrochloride)	358.179	Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	BPNUQXPIQBZCMR-IBGZPJMESA-N	11314340.0		BPNUQXPIQBZCMR
BRD-K78177893-001-02-4	A-674563	Preclinical	AKT inhibitor	AKT1|PKIA|PRKACA			0	96.74	Selleck	S2670	A-674563	358.179	Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	BPNUQXPIQBZCMR-IBGZPJMESA-N	11314340.0		BPNUQXPIQBZCMR
BRD-K03301001-003-03-3	A-7	Preclinical	calmodulin antagonist				0	92.11	Tocris	378	A-7 hydrochloride	396.164	NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	JLUUJHIQVIXTGT-UHFFFAOYSA-N	2735313.0		JLUUJHIQVIXTGT
BRD-K03301001-003-02-5	A-7	Preclinical	calmodulin antagonist				0	92.44	Tocris	378	A-7 hydrochloride	396.164	NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	JLUUJHIQVIXTGT-UHFFFAOYSA-N	2735313.0		JLUUJHIQVIXTGT
BRD-K03301001-003-04-9	A-7	Preclinical	calmodulin antagonist				0	95.2	Tocris	378	A-7 hydrochloride	396.164	NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	JLUUJHIQVIXTGT-UHFFFAOYSA-N	2735313.0		JLUUJHIQVIXTGT
BRD-K41918892-001-06-7	A-769662	Preclinical	AMPK activator				0	84.48	Tocris	3336	A 769662	360.057	Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	CTESJDQKVOEUOY-UHFFFAOYSA-N	54708532.0		CTESJDQKVOEUOY
BRD-K41918892-001-05-9	A-769662	Preclinical	AMPK activator				0	90.56	Selleck	S2697	A-769662	360.057	Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	CTESJDQKVOEUOY-UHFFFAOYSA-N	54708532.0		CTESJDQKVOEUOY
BRD-K41918892-001-09-9	A-769662	Preclinical	AMPK activator				0	96.91	Tocris	3336	A 769662	360.057	Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	CTESJDQKVOEUOY-UHFFFAOYSA-N	54708532.0		CTESJDQKVOEUOY
BRD-K87665527-001-01-3	A-784168	Preclinical	transient receptor potential channel antagonist	TRPV1			0	90.02	Tocris	4319	A 784168	479.074	FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|	SDUAWRFBHRAFBM-UHFFFAOYSA-N	11420211.0		SDUAWRFBHRAFBM
BRD-K87665527-001-02-9	A-784168	Preclinical	transient receptor potential channel antagonist	TRPV1			0	95.13	Tocris	4319	A 784168	479.074	FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|	SDUAWRFBHRAFBM-UHFFFAOYSA-N	11420211.0		SDUAWRFBHRAFBM
BRD-K28570407-001-04-6	A-803467	Preclinical	sodium channel blocker	SCN10A			0	96.66	Tocris	2976	A 803467	357.077	COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1	VHKBTPQDHDSBSP-UHFFFAOYSA-N	16038374.0		VHKBTPQDHDSBSP
BRD-K28570407-001-02-0	A-803467	Preclinical	sodium channel blocker	SCN10A			0	97.96	Selleck	S2785	A-803467	357.077	COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1	VHKBTPQDHDSBSP-UHFFFAOYSA-N	16038374.0		VHKBTPQDHDSBSP
BRD-K94313941-001-03-9	A-804598	Preclinical	purinergic receptor antagonist	P2RX7			0	98.07	Tocris	4473	A 804598	315.148	C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1	PQYCRDPLPKGSME-AWEZNQCLSA-N	53325874.0		PQYCRDPLPKGSME
BRD-K76894955-001-02-1	A-804598	Preclinical	purinergic receptor antagonist	P2RX7			0	98.54	Tocris	4473	A 804598	315.148	C[C@H](\N=C(\NC#N)Nc1cccc2ncccc12)c1ccccc1	PQYCRDPLPKGSME-AWEZNQCLSA-N	53325874.0	BRD-K94313941-001-01-9	PQYCRDPLPKGSME
BRD-K60427831-001-01-0	A-839977	Preclinical	purinergic receptor antagonist	P2RX7			0	92.75	Tocris	4232	A 839977	412.061	Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1	GMVNBKZQJFRFAR-UHFFFAOYSA-N	53325875.0		GMVNBKZQJFRFAR
BRD-K60427831-001-02-9	A-839977	Preclinical	purinergic receptor antagonist	P2RX7			0	98.12	Tocris	4232	A 839977	412.061	Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1	GMVNBKZQJFRFAR-UHFFFAOYSA-N	53325875.0		GMVNBKZQJFRFAR
BRD-K33059059-001-02-9	A-867744	Preclinical	acetylcholine receptor allosteric modulator	CHRNA3|CHRNA4|CHRNA7			0	94.57	Tocris	4571	A 867744	402.08	CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O	ABACVOXFUHDKNZ-UHFFFAOYSA-N	23642319.0		ABACVOXFUHDKNZ
BRD-K33059059-001-01-0	A-867744	Preclinical	acetylcholine receptor allosteric modulator	CHRNA3|CHRNA4|CHRNA7			0	96.03	Tocris	4571	A 867744	402.08	CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O	ABACVOXFUHDKNZ-UHFFFAOYSA-N	23642319.0		ABACVOXFUHDKNZ
BRD-K20239555-001-01-2	A-887826	Preclinical	sodium channel blocker	SCN10A			0	91.61	Tocris	4249	A 887826	480.193	CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1	JPJGFWKHSMUKFO-UHFFFAOYSA-N	46919335.0		JPJGFWKHSMUKFO
BRD-K20239555-001-02-9	A-887826	Preclinical	sodium channel blocker	SCN10A			0	97.78	Tocris	4249	A 887826	480.193	CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1	JPJGFWKHSMUKFO-UHFFFAOYSA-N	46919335.0		JPJGFWKHSMUKFO
BRD-K81614372-001-02-1	A-922500	Preclinical	diacylglycerol O acyltransferase inhibitor	DGAT1			0	96.89	Tocris	3587	A 922500	428.174	OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	BOZRFEQDOFSZBV-DHIUTWEWSA-N	24768261.0		BOZRFEQDOFSZBV
BRD-K81614372-001-04-9	A-922500	Preclinical	diacylglycerol O acyltransferase inhibitor	DGAT1			0	95.18	Tocris	3587	A 922500	428.174	OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	BOZRFEQDOFSZBV-DHIUTWEWSA-N	24768261.0		BOZRFEQDOFSZBV
BRD-K81614372-001-03-9	A-922500	Preclinical	diacylglycerol O acyltransferase inhibitor	DGAT1			0	95.56	Selleck	S2674	A922500	428.174	OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	BOZRFEQDOFSZBV-DHIUTWEWSA-N	24768261.0		BOZRFEQDOFSZBV
BRD-K99308908-001-02-9	A-939572	Preclinical	stearoyl-CoA desaturase inhibitor	SCD			0	97.11	Tocris	4845	A 939572	387.135	CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1	DPYTYQFYDLYWHZ-UHFFFAOYSA-N	24905400.0		DPYTYQFYDLYWHZ
BRD-K99308908-001-01-5	A-939572	Preclinical	stearoyl-CoA desaturase inhibitor	SCD			0	94.18	Tocris	4845	A 939572	387.135	CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1	DPYTYQFYDLYWHZ-UHFFFAOYSA-N	24905400.0		DPYTYQFYDLYWHZ
BRD-K70744942-001-02-9	A-967079	Preclinical	transient receptor potential channel antagonist	TRPA1			0	87.42	Tocris	4716	A 967079	207.106	CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1	HKROEBDHHKMNBZ-CHBKHGQFSA-N	42641861.0		HKROEBDHHKMNBZ
BRD-K70744942-001-01-2	A-967079	Preclinical	transient receptor potential channel antagonist	TRPA1			0	97.41	Tocris	4716	A 967079	207.106	CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1	HKROEBDHHKMNBZ-CHBKHGQFSA-N	42641861.0		HKROEBDHHKMNBZ
BRD-K68982262-001-01-4	A-987306	Preclinical	histamine receptor antagonist	ADORA1|AVPR1A|CCR1|CHRM1|CHRM2|CHRM3|CHRM4|DRD3|HTR1A|HTR1B|HTR2A|HTR2B|HTR3A|TACR2			0	86.49	Tocris	3640	A 987306	327.206	Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|	DJKJVWJQAVGLHJ-YPMHNXCESA-N	25109291.0		DJKJVWJQAVGLHJ
BRD-K68982262-001-02-9	A-987306	Preclinical	histamine receptor antagonist	ADORA1|AVPR1A|CCR1|CHRM1|CHRM2|CHRM3|CHRM4|DRD3|HTR1A|HTR1B|HTR2A|HTR2B|HTR3A|TACR2			0	92.15	Tocris	3640	A 987306	327.206	Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|	DJKJVWJQAVGLHJ-YPMHNXCESA-N	25109291.0		DJKJVWJQAVGLHJ
BRD-K13944729-001-01-7	AA-29504	Preclinical	GABA receptor positive allosteric modulator	GABRA1|GABRA4|GABRB3			0	19.95	Tocris	3972	AA 29504	327.195	CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N	SCOOTUMXCXKEAD-UHFFFAOYSA-N	23188887.0		SCOOTUMXCXKEAD
BRD-K13944729-001-02-9	AA-29504	Preclinical	GABA receptor positive allosteric modulator	GABRA1|GABRA4|GABRB3			0	75.45	Tocris	3972	AA 29504	327.195	CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N	SCOOTUMXCXKEAD-UHFFFAOYSA-N	23188887.0		SCOOTUMXCXKEAD
BRD-K00003450-001-01-9	AAI101	Phase 3	lactamase inhibitor				0	40.4	MedChemEx	HY-103095	AAI101	315.076	[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(Cn1cc[n+](C)n1)S2(=O)=O	HFZITXBUTWITPT-YWVKMMECSA-O	23653541.0		HFZITXBUTWITPT
BRD-K00003109-001-01-9	AB-423	Preclinical	HBV capsid assembly inhibitor				0	97.73	MedChemEx	HY-112142	AB-423	386.091	CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(c1)C(=O)Nc1ccc(F)c(F)c1	BBLXLHYPDOMJMO-SNVBAGLBSA-N	90259477.0		BBLXLHYPDOMJMO
BRD-K17443395-065-03-0	abacavir	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	95.95	Tocris	4148	Abacavir hemisulfate	286.154	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|	MCGSCOLBFJQGHM-SCZZXKLOSA-N	441300.0	BRD-M55852627-065-01-7	MCGSCOLBFJQGHM
BRD-K17443395-065-02-2	abacavir	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	98.81	MicroSource	1502410	ABACAVIR SULFATE	286.154	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|	MCGSCOLBFJQGHM-SCZZXKLOSA-N	441300.0	BRD-A95032015-065-01-2	MCGSCOLBFJQGHM
BRD-K17443395-065-01-4	abacavir	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	96.52	Selleck	S3165	Abacavir sulfate	286.154	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|	MCGSCOLBFJQGHM-SCZZXKLOSA-N	441300.0	BRD-M42309903-065-03-5	MCGSCOLBFJQGHM
BRD-K77432251-001-01-2	abafungin	Phase 3	sterol methyltransferase inhibitor				0	92.48	ChemImpex	28441	4-[2-(2,4-dimethylphenoxy)phenyl]-N-tetrahydro-2(1H)-pyrimidinylidene-1,3-thiazol-2-amine	378.151	Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1 |t:18|	TYBHXIFFPVFXQW-UHFFFAOYSA-N	159326.0		TYBHXIFFPVFXQW
BRD-K00004970-001-01-9	abamectin	Launched	benzodiazepine receptor agonist	GABBR1|GABBR2	infectious disease	gastrointestinal parasites	0	0.0	MedChemEx	HY-15311	Avermectin B1	858.477	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,54,t:6,37,64|	ZFUKERYTFURFGA-PVVXTEPVSA-N	6858005.0		ZFUKERYTFURFGA
BRD-K65498798-001-01-7	abametapir	Phase 3	metalloproteinase inhibitor	MMP9			0	92.8	Sigma	MFCD01740554	5,5'-dimethyl-2,2'-bipyridine	184.1	Cc1ccc(nc1)-c1ccc(C)cn1	PTRATZCAGVBFIQ-UHFFFAOYSA-N	15664.0		PTRATZCAGVBFIQ
BRD-K00003158-001-01-9	abarelix	Phase 3	gonadotropin releasing factor hormone receptor antagonist	GNRHR			0	80.78	MedChemEx	HY-13534	Abarelix	1414.684	CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	AIWRTTMUVOZGPW-HSPKUQOVSA-N	16131215.0		AIWRTTMUVOZGPW
BRD-K00003108-001-01-9	ABBV-744	Phase 1	bromodomain inhibitor				0	93.59	MedChemEx	HY-112090	ABBV-744	491.222	CCNC(=O)c1cc2c(cn(C)c(O)c2n1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O	LQPFCYWRBQRRGE-UHFFFAOYSA-N			LQPFCYWRBQRRGE
BRD-K01825984-001-01-9	ABC-294640	Phase 2	sphingosine kinase inhibitor	SPHK2			0	99.82	Selleck	S7174		380.166	Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7,9,11,13|	CAOTVXGYTWCKQE-BRNYJPRKSA-N			CAOTVXGYTWCKQE
BRD-K33622447-066-01-9	abemaciclib	Launched	CDK inhibitor	CDK4|CDK6	oncology	breast cancer	0	94.43	Selleck	S7158	LY2835219	506.272	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	UZWDCWONPYILKI-UHFFFAOYSA-N	46220502.0		UZWDCWONPYILKI
BRD-K33622447-001-03-9	abemaciclib	Launched	CDK inhibitor	CDK4|CDK6	oncology	breast cancer	0	91.47	MedChemEx	HY-16297A	Abemaciclib	506.272	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	UZWDCWONPYILKI-UHFFFAOYSA-N	46220502.0		UZWDCWONPYILKI
BRD-K50071428-001-04-9	abiraterone	Launched	androgen biosynthesis inhibitor	CYP11B1|CYP17A1	oncology	prostate cancer	0	91.44	MedChemEx	HY-70013	Abiraterone	349.241	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|	GZOSMCIZMLWJML-VJLLXTKPSA-N	132971.0		GZOSMCIZMLWJML
BRD-K50071428-001-03-3	abiraterone	Launched	androgen biosynthesis inhibitor	CYP11B1|CYP17A1	oncology	prostate cancer	0	92.23	Selleck	S1123	Abiraterone (CB-7598)	349.241	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21,t:7|	GZOSMCIZMLWJML-VJLLXTKPSA-N	132971.0	BRD-K00111504-001-01-9	GZOSMCIZMLWJML
BRD-K24048528-001-03-9	abiraterone-acetate	Launched	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	0	88.37	MedChemEx	HY-75054	Abiraterone (acetate)	391.251	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|	UVIQSJCZCSLXRZ-UBUQANBQSA-N	9821849.0		UVIQSJCZCSLXRZ
BRD-K24048528-001-01-7	abiraterone-acetate	Launched	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	0	98.65	Selleck	S2246	Abiraterone Acetate	391.251	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|	UVIQSJCZCSLXRZ-UBUQANBQSA-N	9821849.0		UVIQSJCZCSLXRZ
BRD-K24048528-001-02-5	abiraterone-acetate	Launched	androgen biosynthesis inhibitor	CYP17A1	oncology	prostate cancer	0	89.93	Selleck	S2246	Abiraterone Acetate	391.251	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16,29|	UVIQSJCZCSLXRZ-UBUQANBQSA-N	9821849.0	BRD-K16133773-001-01-9	UVIQSJCZCSLXRZ
BRD-K00004730-001-01-9	ABT-072	Phase 2	RNA polymerase inhibitor				0	90.96	MedChemEx	HY-101634	ABT-072	469.167	COc1c(\C=C\c2ccc(NS(C)(=O)=O)cc2)cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O	XMZSTQYSBYEENY-RMKNXTFCSA-N	57775240.0		XMZSTQYSBYEENY
BRD-A29844814-300-01-5	ABT-202	Phase 1	acetylcholine receptor agonist				0	88.87	Enamine	EN300-69225		163.111	N[C@H]1CCN(C1)c1cccnc1 |&1:1|	LVGMMVAWLISWJD-QMMMGPOBSA-N	39220800.0		LVGMMVAWLISWJD
BRD-K22749967-046-02-3	ABT-239	Phase 1	histamine receptor antagonist	HRH1|HRH2|HRH3			0	99.38	Axon	1510		330.173	C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N	KFHYZKCRXNRKRC-MRXNPFEDSA-N	9818903.0		KFHYZKCRXNRKRC
BRD-K97233161-003-01-5	ABT-491	Phase 1	platelet activating factor receptor antagonist	PTAFR			0	93.81	EMDBio	511071-2MG	PAF Receptor Antagonist, ABT-491	479.176	CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C	GDLNHSUSOZEAOR-UHFFFAOYSA-N	154087.0		GDLNHSUSOZEAOR
BRD-K97233161-003-02-3	ABT-491	Phase 1	platelet activating factor receptor antagonist	PTAFR			0	92.38	SantaCruz	sc-214459	ABT-491 hydrochloride	479.176	CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C	GDLNHSUSOZEAOR-UHFFFAOYSA-N	154087.0		GDLNHSUSOZEAOR
BRD-K11792081-001-01-4	ABT-639	Phase 2	calcium channel blocker	CACNA1G|CACNA1H|CACNA1I			0	96.74	MedChemEx	HY-19721	ABT-639	455.088	Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F	AGPIHNZOZNKRGT-CYBMUJFWSA-N	46851313.0		AGPIHNZOZNKRGT
BRD-K36021395-300-03-2	ABT-702	Preclinical	adenosine kinase inhibitor	ADK			0	87.52	Tocris	2372	5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]pyrido[2,3-d]pyrimidin-4-amine dihydrochloride	462.08	Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1	RQCXKDWOCUJWQZ-UHFFFAOYSA-N	1973.0		RQCXKDWOCUJWQZ
BRD-K36021395-300-02-4	ABT-702	Preclinical	adenosine kinase inhibitor	ADK			0	84.0	Tocris	2372	ABT 702 dihydrochloride	462.08	Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1	RQCXKDWOCUJWQZ-UHFFFAOYSA-N	1973.0		RQCXKDWOCUJWQZ
BRD-K37714784-305-02-1	ABT-724	Phase 2	dopamine receptor agonist	DRD4			0	97.43	Tocris	2214	ABT 724 trihydrochloride	293.164	C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1	FRPJGTNLZNXQEX-UHFFFAOYSA-N	5025739.0		FRPJGTNLZNXQEX
BRD-K37714784-305-08-9	ABT-724	Phase 2	dopamine receptor agonist	DRD4			0	95.37	Tocris	2214	ABT 724 trihydrochloride	293.164	C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1	FRPJGTNLZNXQEX-UHFFFAOYSA-N	5025739.0		FRPJGTNLZNXQEX
BRD-K56301217-001-10-8	ABT-737	Phase 1/Phase 2	BCL inhibitor	BCL2|BCL2L1|BCL2L2			0	86.42	Selleck	S1002	ABT-737	812.258	CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	HPLNQCPCUACXLM-PGUFJCEWSA-N	11228183.0		HPLNQCPCUACXLM
BRD-K56301217-001-07-4	ABT-737	Phase 1/Phase 2	BCL inhibitor	BCL2|BCL2L1|BCL2L2			0	95.24	Selleck	S1002	ABT-737	812.258	CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	HPLNQCPCUACXLM-PGUFJCEWSA-N	11228183.0		HPLNQCPCUACXLM
BRD-K56301217-001-01-7	ABT-737	Phase 1/Phase 2	BCL inhibitor	BCL2|BCL2L1|BCL2L2			0	100.0	Toronto	A112550	A112550.cdx	812.258	CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	HPLNQCPCUACXLM-PGUFJCEWSA-N	11228183.0		HPLNQCPCUACXLM
BRD-K56301217-001-12-4	ABT-737	Phase 1/Phase 2	BCL inhibitor	BCL2|BCL2L1|BCL2L2			0		MedChemEx	HY-50907	ABT-737	812.258	CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	InChI=1S/C42H45ClN6O5S2/c1-46(2)23-22-35(30-55-37-9-4-3-5-10-37)44-40-21-20-38(28-41(40)49(51)52)56(53,54)45-42(50)32-14-18-36(19-15-32)48-26-24-47(25-27-48)29-33-8-6-7-11-39(33)31-12-16-34(43)17-13-31/h3-21,28,35,44H,22-27,29-30H2,1-2H3,(H,45,50)/t35-/m1/s1	11228183.0		HPLNQCPCUACXLM
BRD-K91623615-001-06-8	ABT-751	Phase 2	tubulin polymerization inhibitor	TUBB			0	91.6	Tocris	4138	ABT 751	371.094	COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	URCVCIZFVQDVPM-UHFFFAOYSA-N	3035714.0		URCVCIZFVQDVPM
BRD-K91623615-001-05-0	ABT-751	Phase 2	tubulin polymerization inhibitor	TUBB			0	96.81	Selleck	S1165	ABT-751	371.094	COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	URCVCIZFVQDVPM-UHFFFAOYSA-N	3035714.0		URCVCIZFVQDVPM
BRD-K91623615-001-09-9	ABT-751	Phase 2	tubulin polymerization inhibitor	TUBB			0	94.45	Tocris	4138	ABT 751	371.094	COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	URCVCIZFVQDVPM-UHFFFAOYSA-N	3035714.0		URCVCIZFVQDVPM
BRD-K91623615-001-04-3	ABT-751	Phase 2	tubulin polymerization inhibitor	TUBB			0	74.29	Selleck	S1165	ABT-751 (E7010)	371.094	COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	URCVCIZFVQDVPM-UHFFFAOYSA-N	3035714.0		URCVCIZFVQDVPM
BRD-K00004603-001-01-9	ABX-1431	Phase 2	monoacylglycerol lipase inhibitor				0	92.26	MedChemEx	HY-117632	ABX-1431	507.157	FC(F)(F)C(OC(=O)N1CCN(Cc2ccc(cc2N2CCCC2)C(F)(F)F)CC1)C(F)(F)F	SQZJGTOZFRNWCX-UHFFFAOYSA-N	71657619.0		SQZJGTOZFRNWCX
BRD-K00003394-001-01-9	ABX464	Phase 2	antiviral				0	98.68	MedChemEx	HY-100870	ABX464	338.043	FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1	OZOGDCZJYVSUBR-UHFFFAOYSA-N	49846599.0		OZOGDCZJYVSUBR
BRD-K53788420-001-02-9	AC-186	Preclinical	estrogen receptor agonist	ESR2			0	91.88	Tocris	5053	AC 186	306.123	Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F	HSMUKSLNDJOZQG-UHFFFAOYSA-N	71245042.0		HSMUKSLNDJOZQG
BRD-K53788420-001-01-1	AC-186	Preclinical	estrogen receptor agonist	ESR2			0	94.66	Tocris	5053	AC 186	306.123	Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F	HSMUKSLNDJOZQG-UHFFFAOYSA-N	71245042.0		HSMUKSLNDJOZQG
BRD-K31144453-001-02-2	AC-261066	Preclinical	retinoid receptor agonist	RARB			0	92.33	Tocris	4046	AC 261066	353.11	CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1	HSAOETBFVAWNRP-UHFFFAOYSA-N	11530459.0		HSAOETBFVAWNRP
BRD-K31144453-001-03-9	AC-261066	Preclinical	retinoid receptor agonist	RARB			0	92.09	Tocris	4046	AC 261066	353.11	CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1	HSAOETBFVAWNRP-UHFFFAOYSA-N	11530459.0		HSAOETBFVAWNRP
BRD-K81548480-001-02-0	AC-264613	Preclinical	PAR agonist	F2RL1			0	69.89	Tocris	3370	AC 264613	399.058	C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	RQKXQCSEZPQBNZ-QSBCOWLBSA-N	25108278.0		RQKXQCSEZPQBNZ
BRD-K81548480-001-01-2	AC-264613	Preclinical	PAR agonist	F2RL1			0	95.07	Tocris	3370	AC 264613	399.058	C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	RQKXQCSEZPQBNZ-QSBCOWLBSA-N	25108278.0		RQKXQCSEZPQBNZ
BRD-K81548480-001-03-9	AC-264613	Preclinical	PAR agonist	F2RL1			0	89.57	Tocris	3370	AC 264613	399.058	C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	RQKXQCSEZPQBNZ-QSBCOWLBSA-N	25108278.0		RQKXQCSEZPQBNZ
BRD-A27911617-001-01-7	AC-55541	Preclinical	PARP inhibitor	PARP2			0	97.05	MedChemEx	HY-14350	AC-55541	517.075	C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6,r|	UCUHFWIFSHROPY-SQEMJAKJSA-N	129362181.0		UCUHFWIFSHROPY
BRD-K93176058-001-04-4	AC-55649	Preclinical	retinoid receptor agonist	RARA|RARB			0	97.99	Tocris	2436	AC 55649	310.193	CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	HXBKPYIEQLLNBK-UHFFFAOYSA-N	1714884.0		HXBKPYIEQLLNBK
BRD-K93176058-001-03-6	AC-55649	Preclinical	retinoid receptor agonist	RARA|RARB			0	98.46	Tocris	2436	AC 55649	310.193	CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	HXBKPYIEQLLNBK-UHFFFAOYSA-N	1714884.0		HXBKPYIEQLLNBK
BRD-K93176058-001-05-9	AC-55649	Preclinical	retinoid receptor agonist	RARA|RARB			0	94.4	Tocris	2436	AC 55649	310.193	CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	HXBKPYIEQLLNBK-UHFFFAOYSA-N	1714884.0		HXBKPYIEQLLNBK
BRD-K15819326-001-02-9	AC-710	Preclinical	PDGFR tyrosine kinase receptor inhibitor	CSF1R|FLT3|KIT|PDGFRA|PDGFRB			0	95.31	Tocris	5013	AC 710	562.327	CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1	JVCWPUFNLFSKFS-UHFFFAOYSA-N	54760053.0		JVCWPUFNLFSKFS
BRD-K15819326-001-01-6	AC-710	Preclinical	PDGFR tyrosine kinase receptor inhibitor	CSF1R|FLT3|KIT|PDGFRA|PDGFRB			0	98.87	Tocris	5013	AC 710	562.327	CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1	JVCWPUFNLFSKFS-UHFFFAOYSA-N	54760053.0		JVCWPUFNLFSKFS
BRD-A49544621-003-03-6	AC-7954-(+/-)	Preclinical	urotensin receptor agonist	UTS2R			0	93.04	Tocris	2484	(+/-)-AC 7954 hydrochloride	329.118	CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|	HIVBATDUVFEJFZ-IBGZPJMESA-N	10937426.0		HIVBATDUVFEJFZ
BRD-A49544621-003-02-8	AC-7954-(+/-)	Preclinical	urotensin receptor agonist	UTS2R			0	95.87	Tocris	2484	(?)-AC 7954 hydrochloride	329.118	CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|	HIVBATDUVFEJFZ-IBGZPJMESA-N	10937426.0		HIVBATDUVFEJFZ
BRD-A49544621-003-04-9	AC-7954-(+/-)	Preclinical	urotensin receptor agonist	UTS2R			0	94.73	Tocris	2484	(+/-)-AC 7954 hydrochloride	329.118	CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|	HIVBATDUVFEJFZ-IBGZPJMESA-N	10937426.0		HIVBATDUVFEJFZ
BRD-K53448858-001-08-8	acadesine	Phase 3	AMPK activator				0	50.7	Tocris	2840	AICAR	258.096	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	RTRQQBHATOEIAF-UUOKFMHZSA-N	17513.0		RTRQQBHATOEIAF
BRD-K53448858-001-09-6	acadesine	Phase 3	AMPK activator				0	39.3	Selleck	S1802	Acadesine	258.096	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	RTRQQBHATOEIAF-UUOKFMHZSA-N	17513.0	BRD-K04797704-001-01-9	RTRQQBHATOEIAF
BRD-K53448858-001-07-0	acadesine	Phase 3	AMPK activator				0	100.0	Selleck	S1802	AICAR (Acadesine)	258.096	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	RTRQQBHATOEIAF-UUOKFMHZSA-N	17513.0		RTRQQBHATOEIAF
BRD-K64034691-001-01-9	acalabrutinib	Launched	Bruton's tyrosine kinase (BTK) inhibitor	BTK	hematologic malignancy	mantle cell lymphoma (MCL)	0	88.47	MedChemEx	HY-17600	Acalabrutinib	465.191	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12	WDENQIQQYWYTPO-IBGZPJMESA-N	71226662.0		WDENQIQQYWYTPO
BRD-K92517771-001-01-2	acalisib	Phase 1	PI3K inhibitor	PIK3CB|PIK3CD			0	98.55	MedChemEx	HY-12644	Acalisib	401.14	C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1	DOCINCLJNAXZQF-LBPRGKRZSA-N	11618268.0		DOCINCLJNAXZQF
BRD-K26262077-238-01-5	acamprosate	Launched	glutamate receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM5	neurology/psychiatry	abstinence from alcohol	1	0.0	MicroSource	1505711	ACAMPROSATE CALCIUM	181.041	CC(=O)NCCCS(O)(=O)=O	AFCGFAGUEYAMAO-UHFFFAOYSA-N	71158.0	BRD-M41783010-238-03-5	AFCGFAGUEYAMAO
BRD-K26262077-001-01-7	acamprosate	Launched	glutamate receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM5	neurology/psychiatry	abstinence from alcohol	1	89.21	Sigma	MFCD00867423	3-(acetylamino)-1-propanesulfonic acid	181.041	CC(=O)NCCCS(O)(=O)=O	AFCGFAGUEYAMAO-UHFFFAOYSA-N	71158.0		AFCGFAGUEYAMAO
BRD-K26262077-238-03-9	acamprosate	Launched	glutamate receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM5	neurology/psychiatry	abstinence from alcohol	1	100.0	Tocris	3618	Acamprosate calcium	181.041	CC(=O)NCCCS(O)(=O)=O	AFCGFAGUEYAMAO-UHFFFAOYSA-N	71158.0		AFCGFAGUEYAMAO
BRD-K44276885-001-06-6	acarbose	Launched	glucosidase inhibitor	AMY2A|MGAM	endocrinology	diabetes mellitus	0	100.0	Tocris	2673	Acarbose	645.248	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|	XUFXOAAUWZOOIT-SXARVLRPSA-N	444254.0		XUFXOAAUWZOOIT
BRD-K44276885-001-08-2	acarbose	Launched	glucosidase inhibitor	AMY2A|MGAM	endocrinology	diabetes mellitus	0	100.0	MicroSource	1505172	ACARBOSE	645.248	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|	XUFXOAAUWZOOIT-SXARVLRPSA-N	444254.0	BRD-A16444946-001-09-7	XUFXOAAUWZOOIT
BRD-K44276885-001-05-8	acarbose	Launched	glucosidase inhibitor	AMY2A|MGAM	endocrinology	diabetes mellitus	0	97.08	Tocris	2673	Acarbose	645.248	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|	XUFXOAAUWZOOIT-SXARVLRPSA-N	444254.0		XUFXOAAUWZOOIT
BRD-K44276885-001-07-4	acarbose	Launched	glucosidase inhibitor	AMY2A|MGAM	endocrinology	diabetes mellitus	0	100.0	Selleck	S1271	Acarbose	645.248	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|	XUFXOAAUWZOOIT-SXARVLRPSA-N	444254.0	BRD-K01621533-001-01-1	XUFXOAAUWZOOIT
BRD-K68633617-003-02-9	ACDPP	Preclinical	glutamate receptor antagonist	GRM5			0	95.36	Tocris	2254	ACDPP hydrochloride	292.084	CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	RNGRUHWJJPTYNR-UHFFFAOYSA-N	16759169.0		RNGRUHWJJPTYNR
BRD-K68633617-003-03-9	ACDPP	Preclinical	glutamate receptor antagonist	GRM5			0	94.64	Tocris	2254	ACDPP hydrochloride	292.084	CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	RNGRUHWJJPTYNR-UHFFFAOYSA-N	16759169.0		RNGRUHWJJPTYNR
BRD-K00003255-001-01-9	acebilustat	Phase 2	leukotriene inhibitor				0	97.48	MedChemEx	HY-17625	Acebilustat	481.2	[H][C@]12CN(Cc3ccc(cc3)C(O)=O)[C@]([H])(CN1Cc1ccc(Oc3ccc(cc3)-c3ncco3)cc1)C2	GERJIEKMNDGSCS-DQEYMECFSA-N	68488178.0		GERJIEKMNDGSCS
BRD-A29260609-003-26-0	acebutolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	hypertension|ventricular arrhythmias	0	98.29	MicroSource	1500665	ACEBUTOLOL HYDROCHLORIDE	336.205	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	GOEMGAFJFRBGGG-UHFFFAOYSA-N	657184.0		GOEMGAFJFRBGGG
BRD-A29260609-003-25-2	acebutolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	hypertension|ventricular arrhythmias	0	96.66	Selleck	S4010	Acebutolol HCl	336.205	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	GOEMGAFJFRBGGG-UHFFFAOYSA-N	657184.0		GOEMGAFJFRBGGG
BRD-K07753030-003-17-6	acecainide	Phase 3	polarization inhibitor	SCN5A			0	98.55	MicroSource	2300154	ACECAINIDE HYDROCHLORIDE	277.179	CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1	KEECCEWTUVWFCV-UHFFFAOYSA-N	4342.0		KEECCEWTUVWFCV
BRD-K01825000-001-02-9	aceclidine	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	ophthalmology	glaucoma	0	92.9	MicroSource	1501124	ACECLIDINE	169.11	CC(=O)O[C@H]1CN2CCC1CC2 |&1:4,r|	WRJPSSPFHGNBMG-VIFPVBQESA-N	1273944.0		WRJPSSPFHGNBMG
BRD-K68538666-001-14-9	aceclofenac	Launched	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|periarthritis|lumbago|ischiadynia	0	97.43	MedChemEx	HY-B0634	Aceclofenac	353.022	OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	MNIPYSSQXLZQLJ-UHFFFAOYSA-N	71771.0		MNIPYSSQXLZQLJ
BRD-K68538666-001-12-3	aceclofenac	Launched	prostanoid receptor antagonist	PTGS2	rheumatology	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|periarthritis|lumbago|ischiadynia	0	98.5	MicroSource	1502375	ACECLOFENAC	353.022	OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	MNIPYSSQXLZQLJ-UHFFFAOYSA-N	71771.0		MNIPYSSQXLZQLJ
BRD-K97417064-001-02-4	acedapsone	Launched			infectious disease	leprosy	0	77.47	MicroSource	1505376	ACEDAPSONE	332.083	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	AMTPYFGPPVFBBI-UHFFFAOYSA-N	6477.0		AMTPYFGPPVFBBI
BRD-K97417064-001-05-9	acedapsone	Launched			infectious disease	leprosy	0	98.36	Sigma	MFCD00057689	N-(4-(4-ACETYLAMINO-BENZENESULFONYL)-PHENYL)-ACETAMIDE	332.083	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	AMTPYFGPPVFBBI-UHFFFAOYSA-N	6477.0		AMTPYFGPPVFBBI
BRD-K47195926-001-06-6	acedoben	Phase 2					0	95.14	MicroSource	1502412	ACEDOBEN	179.058	CC(=O)Nc1ccc(cc1)C(O)=O	QCXJEYYXVJIFCE-UHFFFAOYSA-N	19266.0		QCXJEYYXVJIFCE
BRD-K47195926-001-07-9	acedoben	Phase 2					0	95.89	Sigma	MFCD00002534	4-Acetamidobenzoic acid	179.058	CC(=O)Nc1ccc(cc1)C(O)=O	QCXJEYYXVJIFCE-UHFFFAOYSA-N	19266.0		QCXJEYYXVJIFCE
BRD-K44004064-001-08-9	acefylline	Launched	adenosine receptor agonist	ADORA1	pulmonary	asthma	0	94.73	MedChemEx	HY-B1505	Acefylline	238.07	Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	HCYFGRCYSCXKNQ-UHFFFAOYSA-N	69550.0		HCYFGRCYSCXKNQ
BRD-K44004064-001-07-3	acefylline	Launched	adenosine receptor agonist	ADORA1	pulmonary	asthma	0	97.34	Prestwick	Prestw-1507	Acefylline	238.07	Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	HCYFGRCYSCXKNQ-UHFFFAOYSA-N	69550.0		HCYFGRCYSCXKNQ
BRD-K13619941-001-02-9	aceglutamide	Launched			gastroenterology	peptic ulcer disease (PUD)	0	88.1	MedChemEx	HY-B1065	Aceglutamide	188.08	CC(=O)N[C@@H](CCC(N)=O)C(O)=O	KSMRODHGGIIXDV-YFKPBYRVSA-N	182230.0		KSMRODHGGIIXDV
BRD-K13619941-213-01-8	aceglutamide	Launched			gastroenterology	peptic ulcer disease (PUD)	0	100.0	MicroSource	1502368	ACEGLUTAMIDE	188.08	CC(=O)N[C@@H](CCC(N)=O)C(O)=O	KSMRODHGGIIXDV-YFKPBYRVSA-N	182230.0		KSMRODHGGIIXDV
BRD-K00003531-001-01-9	acelarin	Phase 2/Phase 3	anticancer agent				0	97.41	MedChemEx	HY-100885	Acelarin	580.153	C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1 |a:1,7,9,21,&1:3|	NHTKGYOMICWFQZ-LHFSRKHSSA-N	134694283.0		NHTKGYOMICWFQZ
BRD-K67563174-001-19-9	acemetacin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis	0	95.85	MedChemEx	HY-B0482	Acemetacin	415.082	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	FSQKKOOTNAMONP-UHFFFAOYSA-N	1981.0		FSQKKOOTNAMONP
BRD-K67563174-001-17-6	acemetacin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis	0	98.86	MicroSource	1500666	ACEMETACIN	415.082	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	FSQKKOOTNAMONP-UHFFFAOYSA-N	1981.0		FSQKKOOTNAMONP
BRD-K67563174-001-16-8	acemetacin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis	0	97.25	Selleck	S2602	Acemetacin	415.082	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	FSQKKOOTNAMONP-UHFFFAOYSA-N	1981.0		FSQKKOOTNAMONP
BRD-K36262466-001-06-3	aceneuramic-acid	Phase 3		CES1|SELE|SELP			0	100.0	OxChem	AX8013467		309.106	CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	SQVRNKJHWKZAKO-PFQGKNLYSA-N	445063.0		SQVRNKJHWKZAKO
BRD-A65051990-001-12-9	acenocoumarol	Launched	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	0	99.56	MicroSource	1502411	ACENOCOUMAROL	353.09	CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|	VABCILAOYCMVPS-HNNXBMFYSA-N	54683745.0		VABCILAOYCMVPS
BRD-A65051990-001-20-9	acenocoumarol	Launched	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	0	97.39	MedChemEx	HY-B1014	Acenocoumarol	353.09	CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4,r|	VABCILAOYCMVPS-HNNXBMFYSA-N	54683745.0		VABCILAOYCMVPS
BRD-K37814297-050-09-6	acepromazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A	neurology/psychiatry	sedative	0	90.02	MicroSource	1505498	ACEPROMAZINE MALEATE	326.145	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	NOSIYYJFMPDDSA-UHFFFAOYSA-N	6077.0		NOSIYYJFMPDDSA
BRD-K37814297-050-10-9	acepromazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A	neurology/psychiatry	sedative	0	87.77	MedChemEx	HY-B1506A	Acepromazine maleate	326.145	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	NOSIYYJFMPDDSA-UHFFFAOYSA-N	6077.0		NOSIYYJFMPDDSA
BRD-K50850824-237-03-0	acesulfame-potassium	Phase 3					0	16.3	MicroSource	1506104	ACESULFAME POTASSIUM	162.994	CC1=CC(=O)NS(=O)(=O)O1 |t:1|	YGCFIWIQZPHFLU-UHFFFAOYSA-N	36573.0		YGCFIWIQZPHFLU
BRD-K50850824-237-02-2	acesulfame-potassium	Phase 3					0	39.42	Selleck	S2884	Acesulfame Potassium	162.994	CC1=CC(=O)NS(=O)(=O)O1 |t:1|	YGCFIWIQZPHFLU-UHFFFAOYSA-N	36573.0		YGCFIWIQZPHFLU
BRD-K50850824-237-04-8	acesulfame-potassium	Phase 3					0	88.18	Selleck	S2884	Acesulfame Potassium	162.994	CC1=CC(=O)NS(=O)(=O)O1 |t:1|	YGCFIWIQZPHFLU-UHFFFAOYSA-N	36573.0		YGCFIWIQZPHFLU
BRD-K11094367-001-11-9	acetanilide	Preclinical	hydrogen peroxide decomposition inhibitor				0	87.56	MedChemEx	HY-D0196	Acetanilide	135.068	CC(=O)Nc1ccccc1	FZERHIULMFGESH-UHFFFAOYSA-N	904.0		FZERHIULMFGESH
BRD-K11094367-001-10-1	acetanilide	Preclinical	hydrogen peroxide decomposition inhibitor				0	96.78	MicroSource	1501173	ACETANILIDE	135.068	CC(=O)Nc1ccccc1	FZERHIULMFGESH-UHFFFAOYSA-N	904.0		FZERHIULMFGESH
BRD-K11094367-001-09-3	acetanilide	Preclinical	hydrogen peroxide decomposition inhibitor				0	92.97	Selleck	S2538	Acetanilide	135.068	CC(=O)Nc1ccccc1	FZERHIULMFGESH-UHFFFAOYSA-N	904.0		FZERHIULMFGESH
BRD-K99048103-001-19-2	acetarsol	Launched			gastroenterology	diarrhea	0	100.0	MicroSource	1500616	ACETARSOL	274.977	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	ODFJOVXVLFUVNQ-UHFFFAOYSA-N	1985.0		ODFJOVXVLFUVNQ
BRD-K99048103-001-18-4	acetarsol	Launched			gastroenterology	diarrhea	0	100.0	Selleck	S4386	Acetarsone	274.977	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	ODFJOVXVLFUVNQ-UHFFFAOYSA-N	1985.0		ODFJOVXVLFUVNQ
BRD-K99048103-001-20-0	acetarsol	Launched			gastroenterology	diarrhea	0	0.0	Selleck	S4386	Acetarsone	274.977	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	ODFJOVXVLFUVNQ-UHFFFAOYSA-N	1985.0		ODFJOVXVLFUVNQ
BRD-K43457670-001-27-8	acetazolamide	Launched	carbonic anhydrase inhibitor	AQP1|CA1|CA12|CA14|CA2|CA3|CA4|CA7	ophthalmology	glaucoma	0	97.61	MicroSource	1500102	ACETAZOLAMIDE	221.988	CC(=O)Nc1nnc(s1)S(N)(=O)=O	BZKPWHYZMXOIDC-UHFFFAOYSA-N	1986.0		BZKPWHYZMXOIDC
BRD-K52960356-001-13-0	acetohexamide	Launched	ATP channel blocker	ABCC8|KCNJ1|KCNJ10|KCNJ11	endocrinology	diabetes mellitus	0	0.44	MicroSource	1505425	ACETOHEXAMIDE	324.114	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	VGZSUPCWNCWDAN-UHFFFAOYSA-N	1989.0		VGZSUPCWNCWDAN
BRD-K52960356-001-15-5	acetohexamide	Launched	ATP channel blocker	ABCC8|KCNJ1|KCNJ10|KCNJ11	endocrinology	diabetes mellitus	0	92.87	MedChemEx	HY-B0881	Acetohexamide	324.114	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	VGZSUPCWNCWDAN-UHFFFAOYSA-N	1989.0		VGZSUPCWNCWDAN
BRD-K21615095-001-08-4	acetohydroxamic-acid	Launched	urease inhibitor	MMP12	infectious disease	urinary tract infections	1	0.0	MicroSource	1500103	ACETOHYDROXAMIC ACID	75.032	CC(=O)NO	RRUDCFGSUDOHDG-UHFFFAOYSA-N	1990.0		RRUDCFGSUDOHDG
BRD-K42938903-332-01-1	acetophenazine	Launched	dopamine receptor antagonist	DRD1|DRD2	neurology/psychiatry	psychosis	0	85.87	MicroSource	1503860	ACETOPHENAZINE MALEATE	411.198	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	WNTYBHLDCKXEOT-UHFFFAOYSA-N	17676.0	BRD-K92986184-050-01-7	WNTYBHLDCKXEOT
BRD-K42938903-332-02-9	acetophenazine	Launched	dopamine receptor antagonist	DRD1|DRD2	neurology/psychiatry	psychosis	0	91.12	MedChemEx	HY-B1262	Acetophenazine (dimaleate)	411.198	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	WNTYBHLDCKXEOT-UHFFFAOYSA-N	17676.0		WNTYBHLDCKXEOT
BRD-K46416130-001-06-9	acetriazoic-acid	Preclinical					0	0.0	MicroSource	1504142	ACETRIAZOIC ACID	556.748	CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I	GNOGSFBXBWBTIG-UHFFFAOYSA-N	6806.0		GNOGSFBXBWBTIG
BRD-K46416130-001-07-7	acetriazoic-acid	Preclinical					0	96.57	MedChemEx	HY-B1406	Acetrizoic acid	556.748	CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I	GNOGSFBXBWBTIG-UHFFFAOYSA-N	6806.0		GNOGSFBXBWBTIG
BRD-K79437791-001-05-7	acetyl-farnesyl-cysteine	Launched	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	0	81.86	Enzo	G200	Acetyl-farnesyl-cysteine	367.218	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O	XTURYZYJYQRJDO-BNAHBJSTSA-N	6438381.0		XTURYZYJYQRJDO
BRD-K79437791-001-06-5	acetyl-farnesyl-cysteine	Launched	methyltransferase inhibitor	PPARG	dermatology	acne vulgaris (AV)	0	77.06	Cayman	63270	(2R)-2-(acetylamino)-3-{[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]sulfanyl}propanoic acid	367.218	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O	XTURYZYJYQRJDO-BNAHBJSTSA-N	6438381.0		XTURYZYJYQRJDO
BRD-K27406233-001-08-9	acetyl-l-leucine	Launched			neurology/psychiatry	vertigo	0	85.36	MedChemEx	HY-59291	N-Acetyl-L-leucine	173.105	CC(C)C[C@H](NC(C)=O)C(O)=O	WXNXCEHXYPACJF-ZETCQYMHSA-N	70912.0		WXNXCEHXYPACJF
BRD-K27406233-001-07-7	acetyl-l-leucine	Launched			neurology/psychiatry	vertigo	0	100.0	MicroSource	1502001	ACETYL-L-LEUCINE	173.105	CC(C)C[C@H](NC(C)=O)C(O)=O	WXNXCEHXYPACJF-ZETCQYMHSA-N	70912.0		WXNXCEHXYPACJF
BRD-A44696962-001-01-4	acetyl-11-keto-beta-boswellic-acid	Phase 2	lipoxygenase inhibitor	HSD11B1|HSD11B2			0	0.0	AnalytiCon	NP-008611		512.35	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1,4,8,15,19,24,29,34,35,&1:14,&2:26,c:10|	HMMGKOVEOFBCAU-OQJDUFEHSA-N			HMMGKOVEOFBCAU
BRD-K82381502-003-25-9	acetylcholine	Launched	acetylcholine receptor agonist	ACHE|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion	0	54.3	MedChemEx	HY-B0282	Acetylcholine (chloride)	146.118	CC(=O)OCC[N+](C)(C)C	OIPILFWXSMYKGL-UHFFFAOYSA-N	187.0		OIPILFWXSMYKGL
BRD-K82381502-003-24-9	acetylcholine	Launched	acetylcholine receptor agonist	ACHE|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion	0	0.0	MicroSource	1500104	ACETYLCHOLINE CHLORIDE	146.118	CC(=O)OCC[N+](C)(C)C	OIPILFWXSMYKGL-UHFFFAOYSA-N	187.0		OIPILFWXSMYKGL
BRD-K82381502-003-23-1	acetylcholine	Launched	acetylcholine receptor agonist	ACHE|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2	neurology/psychiatry|gastroenterology|pulmonary	drowsiness|fatigue|headache|indigestion|chest congestion	0	100.0	Selleck	S1805	Acetylcholine Chloride	146.118	CC(=O)OCC[N+](C)(C)C	OIPILFWXSMYKGL-UHFFFAOYSA-N	187.0		OIPILFWXSMYKGL
BRD-K59058747-001-20-9	acetylcysteine	Launched	mucolytic agent	ACY1|CHUK|GRIN1|GRIN2A|GRIN2B|GRIN2D|GRIN3A|GSS|IKBKB|RELA|SLC7A11	gastroenterology	acetaminophen overdose|hepatic injury	0	88.97	MicroSource	1500105	ACETYLCYSTEINE	163.03	CC(=O)N[C@@H](CS)C(O)=O	PWKSKIMOESPYIA-BYPYZUCNSA-N	12035.0	BRD-K67174965-001-02-7	PWKSKIMOESPYIA
BRD-K59058747-001-19-1	acetylcysteine	Launched	mucolytic agent	ACY1|CHUK|GRIN1|GRIN2A|GRIN2B|GRIN2D|GRIN3A|GSS|IKBKB|RELA|SLC7A11	gastroenterology	acetaminophen overdose|hepatic injury	1	0.0	Selleck	S1623	Acetylcysteine	163.03	CC(=O)N[C@@H](CS)C(O)=O	PWKSKIMOESPYIA-BYPYZUCNSA-N	12035.0		PWKSKIMOESPYIA
BRD-K59058747-001-18-3	acetylcysteine	Launched	mucolytic agent	ACY1|CHUK|GRIN1|GRIN2A|GRIN2B|GRIN2D|GRIN3A|GSS|IKBKB|RELA|SLC7A11	gastroenterology	acetaminophen overdose|hepatic injury	1	0.0	Selleck	S1623	Acetylcysteine	163.03	CC(=O)N[C@@H](CS)C(O)=O	PWKSKIMOESPYIA-BYPYZUCNSA-N	12035.0		PWKSKIMOESPYIA
BRD-K46585355-001-15-9	acetylsalicylsalicylic-acid	Preclinical	cyclooxygenase inhibitor				0	87.11	CombiBlocks	QB-3224	Acetylsalicylsalicylic acid	300.063	CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	DDSFKIFGAPZBSR-UHFFFAOYSA-N	10745.0		DDSFKIFGAPZBSR
BRD-K46585355-001-14-3	acetylsalicylsalicylic-acid	Preclinical	cyclooxygenase inhibitor				0	93.66	Prestwick	Prestw-98	Acetylsalicylsalicylic acid	300.063	CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	DDSFKIFGAPZBSR-UHFFFAOYSA-N	10745.0		DDSFKIFGAPZBSR
BRD-K00004968-001-01-9	acetylspiramycin	Preclinical	other antibiotic				0	0.7	MedChemEx	HY-B1916	Acetylspiramycin	884.525	[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@@]3([H])CC[C@@H]([C@@H](C)O3)N(C)C)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:42,44|	ZPCCSZFPOXBNDL-VGQMBGNASA-N			ZPCCSZFPOXBNDL
BRD-K72215350-001-07-9	acexamic-acid	Launched	5 alpha reductase inhibitor	GAST	dermatology	wound healing	0	100.0	MedChemEx	HY-B1259	6-Acetamidohexanoic acid	173.105	CC(=O)NCCCCCC(O)=O	WDSCBUNMANHPFH-UHFFFAOYSA-N	2005.0		WDSCBUNMANHPFH
BRD-K72215350-001-06-5	acexamic-acid	Launched	5 alpha reductase inhibitor	GAST	dermatology	wound healing	0	100.0	MicroSource	1503045	ACEXAMIC ACID	173.105	CC(=O)NCCCCCC(O)=O	WDSCBUNMANHPFH-UHFFFAOYSA-N	2005.0		WDSCBUNMANHPFH
BRD-A29520968-001-03-5	acifran	Phase 3	cholesterol inhibitor	HCAR2|HCAR3			0	89.35	Tocris	1762	Acifran	218.058	C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|	DFDGRKNOFOJBAJ-LBPRGKRZSA-N	76969700.0		DFDGRKNOFOJBAJ
BRD-A29520968-001-04-9	acifran	Phase 3	cholesterol inhibitor	HCAR2|HCAR3			0	78.16	Tocris	1762	Acifran	218.058	C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|	DFDGRKNOFOJBAJ-LBPRGKRZSA-N	76969700.0		DFDGRKNOFOJBAJ
BRD-A29520968-001-02-7	acifran	Phase 3	cholesterol inhibitor	HCAR2|HCAR3			0	98.05	Tocris	1762	Acifran	218.058	C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1,r,c:3|	DFDGRKNOFOJBAJ-LBPRGKRZSA-N	76969700.0		DFDGRKNOFOJBAJ
BRD-K63736853-001-06-3	acipimox	Launched	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	0	56.13	Tocris	2784	Acipimox	154.038	Cc1cnc(c[n+]1[O-])C(O)=O	DJQOOSBJCLSSEY-UHFFFAOYSA-N	5310993.0		DJQOOSBJCLSSEY
BRD-K63736853-001-04-8	acipimox	Launched	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	0	98.26	MicroSource	1504831	ACIPIMOX	154.038	Cc1cnc(c[n+]1[O-])C(O)=O	DJQOOSBJCLSSEY-UHFFFAOYSA-N	5310993.0		DJQOOSBJCLSSEY
BRD-K63736853-001-07-9	acipimox	Launched	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	0	94.16	Tocris	2784	Acipimox	154.038	Cc1cnc(c[n+]1[O-])C(O)=O	DJQOOSBJCLSSEY-UHFFFAOYSA-N	5310993.0		DJQOOSBJCLSSEY
BRD-K63736853-001-03-0	acipimox	Launched	cholesterol inhibitor	HCAR2	endocrinology	hyperlipidemia	0	97.97	Selleck	S1806	Acipimox	154.038	Cc1cnc(c[n+]1[O-])C(O)=O	DJQOOSBJCLSSEY-UHFFFAOYSA-N	5310993.0		DJQOOSBJCLSSEY
BRD-K74236708-001-02-7	acitazanolast	Launched	mediator release inhibitor		allergy	allergic rhinitis	0	96.68	LifeChem	F2119-0003	oxo[3-(1H-tetraazol-5-yl)anilino]acetic acid	233.055	OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1	VWQZJJZGISNFOE-UHFFFAOYSA-N	2006.0		VWQZJJZGISNFOE
BRD-K74236708-001-01-9	acitazanolast	Launched	mediator release inhibitor		allergy	allergic rhinitis	0	79.13	LifeChem	F2119-0003		233.055	OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1	VWQZJJZGISNFOE-UHFFFAOYSA-N	2006.0		VWQZJJZGISNFOE
BRD-K62012036-001-14-4	acitretin	Launched	retinoid receptor agonist	RARA|RARB|RARG|RBP1|RXRA|RXRB|RXRG|STAT3	dermatology	psoriasis	0	96.4	Selleck	S1368	Acitretin	326.188	COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C	IHUNBGSDBOWDMA-AQFIFDHZSA-N	5284513.0		IHUNBGSDBOWDMA
BRD-K62012036-001-13-6	acitretin	Launched	retinoid receptor agonist	RARA|RARB|RARG|RBP1|RXRA|RXRB|RXRG|STAT3	dermatology	psoriasis	0	40.63	Selleck	S1368	Acitretin	326.188	COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C	IHUNBGSDBOWDMA-AQFIFDHZSA-N	5284513.0		IHUNBGSDBOWDMA
BRD-K13050541-001-01-9	acivicin	Phase 2	gamma glutamyltransferase inhibitor	CTPS1			0	100.0	Enzo	EI113	Acivicin	178.015	N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|	QAWIHIJWNYOLBE-ZAFYKAAXSA-N	16758175.0		QAWIHIJWNYOLBE
BRD-K31965398-001-03-9	aclarubicin	Launched	topoisomerase inhibitor	TOP1|TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	0	48.88	Vitas-M	STK177207	Aclacinomycin A	811.342	CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC	USZYSDMBJDPRIF-SVEJIMAYSA-N	86289437.0		USZYSDMBJDPRIF
BRD-K74363950-004-02-9	aclidinium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	pulmonary	bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)	0	96.49	MedChemEx	HY-14144	Aclidinium (Bromide)	484.162	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	ASMXXROZKSBQIH-VITNCHFBSA-N	11434515.0		ASMXXROZKSBQIH
BRD-K74363950-004-01-0	aclidinium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	pulmonary	bronchitis|emphysema|chronic obstructive pulmonary disease (COPD)	0	95.22	Selleck	S4031	Aclidinium Bromide	484.162	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	ASMXXROZKSBQIH-VITNCHFBSA-N	11434515.0		ASMXXROZKSBQIH
BRD-K00004720-001-01-9	acolbifene	Phase 3	estrogen receptor antagonist				0	92.23	Cayman	23931	(2S)-3-(4-hydroxyphenyl)-4-methyl-2-{4-[2-(1-piperidinyl)ethoxy]phenyl}-2H-chromen-7-ol	457.225	CC1=C([C@@H](Oc2cc(O)ccc12)c1ccc(OCCN2CCCCC2)cc1)c1ccc(O)cc1 |t:1|	DUYNJNWVGIWJRI-LJAQVGFWSA-N	155435.0		DUYNJNWVGIWJRI
BRD-K00003303-001-01-9	acoziborole	Preclinical	antitrypanosomal				0	97.98	MedChemEx	HY-19910	Acoziborole	367.1	CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc12	PTYGDEXEGLDNAZ-UHFFFAOYSA-N	44178354.0		PTYGDEXEGLDNAZ
BRD-K66465025-001-08-9	ACPC	Phase 1	glutamate receptor antagonist				0	100.0	MedChemEx	HY-30004	1-Aminocyclopropane-1-carboxylic acid	101.048	NC1(CC1)C(O)=O	PAJPWUMXBYXFCZ-UHFFFAOYSA-N	6971063.0		PAJPWUMXBYXFCZ
BRD-K66465025-001-05-1	ACPC	Phase 1	glutamate receptor antagonist				0	85.02	Enzo	AC387	1-Aminocyclopropanecarboxylic acid	101.048	NC1(CC1)C(O)=O	PAJPWUMXBYXFCZ-UHFFFAOYSA-N	6971063.0		PAJPWUMXBYXFCZ
BRD-M87138257-003-01-1	acriflavine	Launched	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	0	70.4	Sigma	MFCD00064307	3,6-diamino-10-methylacridinium chloride compound with 3,6-acridinediamine (1:1)	433.214	Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	BCBIBQWDFMQRSJ-UHFFFAOYSA-O	452192.0		BCBIBQWDFMQRSJ
BRD-K97874492-300-10-7	acriflavinium	Launched	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	0	53.49	TCI	A0677	Acriflavine hydrochloride	224.119	C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	XSIOKTWDEOJMGG-UHFFFAOYSA-O	2016.0		XSIOKTWDEOJMGG
BRD-K97874492-003-12-3	acriflavinium	Launched	hypoxia inducible factor inhibitor	HIF1A	infectious disease	fungal infection	0	37.65	MicroSource	1500618	ACRIFLAVINIUM HYDROCHLORIDE	224.119	C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	XSIOKTWDEOJMGG-UHFFFAOYSA-O	2016.0		XSIOKTWDEOJMGG
BRD-M49658242-001-04-1	acrisorcin	Launched	other antifungal		infectious disease	fungal infection	0	61.47	MicroSource	1504218	ACRISORCIN	388.215	CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12	YZODJQFXMFEJRM-UHFFFAOYSA-N	24144.0		YZODJQFXMFEJRM
BRD-K50163129-001-02-9	acrivastine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	93.58	MedChemEx	HY-B1510	Acrivastine	348.184	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	PWACSDKDOHSSQD-IUTFFREVSA-N	5284514.0		PWACSDKDOHSSQD
BRD-K50163129-001-01-4	acrivastine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	100.0	Enzo	AC3005	ACRIVASTINE	348.184	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	PWACSDKDOHSSQD-IUTFFREVSA-N	5284514.0		PWACSDKDOHSSQD
BRD-M00184283-001-01-1	acrylate	Phase 3	mucus protecting agent				1	0.0	Sigma	MFCD00067207	sodium acrylate	95.011	[Na].OC(=O)C=C	MNNFZYTXMPWOTA-UHFFFAOYSA-N			MNNFZYTXMPWOTA
BRD-K34843150-001-03-0	ACT-132577	Launched	endothelin receptor antagonist	EDNRA|EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	0	80.39	MedChemEx	HY-15895	ACT-132577	543.916	NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	DKULOVKANLVDEA-UHFFFAOYSA-N	25099191.0		DKULOVKANLVDEA
BRD-K34843150-001-02-2	ACT-132577	Launched	endothelin receptor antagonist	EDNRA|EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	0	42.36	MedChemEx	HY-15895	ACT-132577	543.916	NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	DKULOVKANLVDEA-UHFFFAOYSA-N	25099191.0		DKULOVKANLVDEA
BRD-K34843150-001-01-4	ACT-132577	Launched	endothelin receptor antagonist	EDNRA|EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	0	0.0	MedChemEx	HY-15895	ACT-132577	543.916	NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	DKULOVKANLVDEA-UHFFFAOYSA-N	25099191.0		DKULOVKANLVDEA
BRD-K19781342-001-02-2	ACT-462206	Phase 1	orexin receptor antagonist	HCRTR1|HCRTR2			0	96.89	Tocris	5319	ACT 462206	388.146	COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	NHPQGZOBHSVTAQ-IBGZPJMESA-N	40924317.0		NHPQGZOBHSVTAQ
BRD-K19781342-001-01-4	ACT-462206	Phase 1	orexin receptor antagonist	HCRTR1|HCRTR2			0	97.06	Sigma	MFCD28502270	(S)-N-(3,5-dimethylphenyl)-1-((4-methoxyphenyl)sulfonyl)pyrrolidine-2-carboxamide	388.146	COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	NHPQGZOBHSVTAQ-IBGZPJMESA-N	40924317.0		NHPQGZOBHSVTAQ
BRD-K19781342-001-03-9	ACT-462206	Phase 1	orexin receptor antagonist	HCRTR1|HCRTR2			0		Tocris	5319	ACT 462206	388.146	COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	NHPQGZOBHSVTAQ-IBGZPJMESA-N	40924317.0		NHPQGZOBHSVTAQ
BRD-K33483813-001-13-9	actarit	Launched	interleukin receptor agonist		rheumatology	rheumatoid arthritis	0	92.17	MedChemEx	HY-76938	2-(4-Acetamidophenyl)acetic acid	193.074	CC(=O)Nc1ccc(CC(O)=O)cc1	MROJXXOCABQVEF-UHFFFAOYSA-N	2018.0		MROJXXOCABQVEF
BRD-K33483813-001-10-0	actarit	Launched	interleukin receptor agonist		rheumatology	rheumatoid arthritis	0	96.94	MicroSource	1502413	ACTARIT	193.074	CC(=O)Nc1ccc(CC(O)=O)cc1	MROJXXOCABQVEF-UHFFFAOYSA-N	2018.0		MROJXXOCABQVEF
BRD-K35936936-001-01-6	ACTB-1003	Phase 1	FGFR inhibitor|VEGFR inhibitor	KDR|TEK			0	95.17	MedChemEx	HY-16025	ACTB-1003	591.202	COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1	GZPJCJKUZPUFAL-UHFFFAOYSA-N	23653175.0		GZPJCJKUZPUFAL
BRD-K35936936-001-02-9	ACTB-1003	Phase 1	FGFR inhibitor|VEGFR inhibitor	KDR|TEK			0	90.63	MedChemEx	HY-16025	ACTB-1003	591.202	COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1	GZPJCJKUZPUFAL-UHFFFAOYSA-N	23653175.0		GZPJCJKUZPUFAL
BRD-K16547679-001-01-5	actinomycin-d	Launched	RNA polymerase inhibitor		oncology	Wilm's tumor|Ewing's sarcoma|rhabdomyosarcoma|testicular carcinoma	0	81.15	MedChemEx	HY-17559	Actinomycin D	1254.628	CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	RJURFGZVJUQBHK-DCUCITLNSA-N	78357827.0		RJURFGZVJUQBHK
BRD-K16547679-001-02-9	actinomycin-d	Launched	RNA polymerase inhibitor		oncology	Wilm's tumor|Ewing's sarcoma|rhabdomyosarcoma|testicular carcinoma	0	88.46	MedChemEx	HY-17559	Actinomycin D	1254.628	CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	RJURFGZVJUQBHK-DCUCITLNSA-N	78357827.0		RJURFGZVJUQBHK
BRD-K16547679-001-03-9	actinomycin-d	Launched	RNA polymerase inhibitor		oncology	Wilm's tumor|Ewing's sarcoma|rhabdomyosarcoma|testicular carcinoma	0	77.79	Tocris	1229	Actinomycin D	1254.628	CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	RJURFGZVJUQBHK-DCUCITLNSA-N	78357827.0		RJURFGZVJUQBHK
BRD-K08837089-236-01-6	actinoquinol	Preclinical					0	85.47	MicroSource	1505401	ACTINOQUINOL SODIUM	253.041	CCOc1ccc(c2cccnc12)S(O)(=O)=O	YAMVZYRZAMBCED-UHFFFAOYSA-N	23674.0		YAMVZYRZAMBCED
BRD-K08837089-001-03-9	actinoquinol	Preclinical					0	95.87	Sigma	MFCD00065059	8-ETHOXY-5-QUINOLINESULFONIC ACID	253.041	CCOc1ccc(c2cccnc12)S(O)(=O)=O	YAMVZYRZAMBCED-UHFFFAOYSA-N	23674.0		YAMVZYRZAMBCED
BRD-K00003220-001-01-9	acumapimod	Phase 1	p38 MAPK inhibitor				0	97.64	MedChemEx	HY-16715	Acumapimod	385.154	Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1	VGUSQKZDZHAAEE-UHFFFAOYSA-N	11338127.0		VGUSQKZDZHAAEE
BRD-K82928847-001-04-7	ACY-1215	Phase 1/Phase 2	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC6|HDAC8			0	95.76	Selleck	S8001	Rocilinostat (ACY-1215)	433.211	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	QGZYDVAGYRLSKP-UHFFFAOYSA-N	53340666.0		QGZYDVAGYRLSKP
BRD-K82928847-001-07-9	ACY-1215	Phase 1/Phase 2	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC6|HDAC8			0	92.56	MedChemEx	HY-16026	Ricolinostat	433.211	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	QGZYDVAGYRLSKP-UHFFFAOYSA-N	53340666.0		QGZYDVAGYRLSKP
BRD-K32318651-001-26-0	acyclovir	Launched	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes|shingles|chicken pox	0	98.02	Tocris	2513	Acyclovir	225.086	Nc1nc(=O)c2ncn(COCCO)c2[nH]1	MKUXAQIIEYXACX-UHFFFAOYSA-N	135398513.0		MKUXAQIIEYXACX
BRD-K32318651-001-23-7	acyclovir	Launched	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes|shingles|chicken pox	0	88.29	MicroSource	1503603	ACYCLOVIR	225.086	Nc1nc(=O)c2ncn(COCCO)c2[nH]1	MKUXAQIIEYXACX-UHFFFAOYSA-N	135398513.0		MKUXAQIIEYXACX
BRD-K32318651-001-22-9	acyclovir	Launched	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes|shingles|chicken pox	0	82.8	Tocris	2513	Acyclovir	225.086	Nc1nc(=O)c2ncn(COCCO)c2[nH]1	MKUXAQIIEYXACX-UHFFFAOYSA-N	135398513.0		MKUXAQIIEYXACX
BRD-K32318651-001-21-1	acyclovir	Launched	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes|shingles|chicken pox	0	87.64	Selleck	S1807	Aciclovir	225.086	Nc1nc(=O)c2ncn(COCCO)c2[nH]1	MKUXAQIIEYXACX-UHFFFAOYSA-N	135398513.0		MKUXAQIIEYXACX
BRD-K32318651-001-24-5	acyclovir	Launched	DNA polymerase inhibitor	PNP	infectious disease	genitial herpes|shingles|chicken pox	0	100.0	Selleck	S1807	Acyclovir (Aciclovir)	225.086	Nc1nc(=O)c2ncn(COCCO)c2[nH]1	MKUXAQIIEYXACX-UHFFFAOYSA-N	135398513.0		MKUXAQIIEYXACX
BRD-K10226125-245-01-5	AC1NDSS5	Phase 1					0	75.43	Sigma	MFCD00157250	[2-(ethoxycarbonyl)phenyl](octadecyl)propylsulfonium tetrafluoroborate	477.377	CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC	VZXULFIUJKSVJY-UHFFFAOYSA-N	4581100.0		VZXULFIUJKSVJY
BRD-K00004583-001-01-9	AC260584	Preclinical	cholinergic receptor agonist				0	93.47	MedChemEx	HY-100336	AC260584	348.221	CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc23)CC1	BWAKMLKESHKOHK-UHFFFAOYSA-N	9928284.0		BWAKMLKESHKOHK
BRD-A80280426-001-03-8	AD-5467	Phase 2	aldose reductase inhibitor	AKR1B1			0	88.22	Maybridge	KM06746	(2,8-diisopropyl-3-thioxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid	307.124	CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|	CLDJCRWXLDLJLO-CQSZACIVSA-N	6933882.0		CLDJCRWXLDLJLO
BRD-A80280426-001-02-0	AD-5467	Phase 2	aldose reductase inhibitor	AKR1B1			0	8.57	Maybridge	KM06746		307.124	CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3,r|	CLDJCRWXLDLJLO-CQSZACIVSA-N	6933882.0		CLDJCRWXLDLJLO
BRD-K33127281-001-06-4	adapalene	Launched	retinoid receptor agonist	RARA|RARB|RARG|RXRA|RXRB|RXRG	dermatology	acne vulgaris (AV)	0	97.8	Tocris	2852	Adapalene	412.204	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	LZCDAPDGXCYOEH-UHFFFAOYSA-N	60164.0		LZCDAPDGXCYOEH
BRD-K33127281-001-05-6	adapalene	Launched	retinoid receptor agonist	RARA|RARB|RARG|RXRA|RXRB|RXRG	dermatology	acne vulgaris (AV)	0	99.81	MicroSource	1502376	ADAPALENE	412.204	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	LZCDAPDGXCYOEH-UHFFFAOYSA-N	60164.0		LZCDAPDGXCYOEH
BRD-K33127281-001-04-9	adapalene	Launched	retinoid receptor agonist	RARA|RARB|RARG|RXRA|RXRB|RXRG	dermatology	acne vulgaris (AV)	0	98.53	Selleck	S1276	Adapalene	412.204	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	LZCDAPDGXCYOEH-UHFFFAOYSA-N	60164.0		LZCDAPDGXCYOEH
BRD-A73427433-240-01-3	adaprev	Phase 3	TGF beta receptor inhibitor	AKR1B1|GPI|HK1|M6PR|PYGM			0	59.36	TCI	G0052		260.03	O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3,10,12,14,&1:1|	NBSCHQHZLSJFNQ-DVKNGEFBSA-N	439284.0		NBSCHQHZLSJFNQ
BRD-K37151368-001-01-7	adaptavir	Phase 2	CC chemokine receptor antagonist	CCR5			0	89.21	Tocris	2423	(2S)-N~1~-[(1S)-2-{[(1S,2R)-1-(aminocarbonyl)-2-hydroxypropyl]amino}-1-(4-hydroxybenzyl)-2-oxoethyl]-2-{[(2S,5S,8S,11S,14R)-14-amino-2,5,8-tris[(1R)-1-hydroxyethyl]-11-(hydroxymethyl)-4,7,10,13-tetrao	856.393	C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	AKWRNBWMGFUAMF-ZESMOPTKSA-N	184644.0		AKWRNBWMGFUAMF
BRD-K37151368-001-02-9	adaptavir	Phase 2	CC chemokine receptor antagonist	CCR5			0	81.2	MedChemEx	HY-P1034	DAPTA	856.393	C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	AKWRNBWMGFUAMF-ZESMOPTKSA-N	184644.0		AKWRNBWMGFUAMF
BRD-K00152668-001-01-5	adarotene	Phase 1	retinoid receptor agonist	RARB|RARG			0	93.85	MedChemEx	HY-14808	Adarotene	374.188	OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	QAWBIEIZDDIEMW-FPYGCLRLSA-N	9864378.0		QAWBIEIZDDIEMW
BRD-K00152668-001-02-9	adarotene	Phase 1	retinoid receptor agonist	RARB|RARG			0	95.05	MedChemEx	HY-14808	Adarotene	374.188	OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	QAWBIEIZDDIEMW-FPYGCLRLSA-N	9864378.0		QAWBIEIZDDIEMW
BRD-K67789209-001-01-0	adatanserin	Phase 2	serotonin receptor agonist|serotonin receptor antagonist	HTR1A|HTR2A			0	87.69	Enamine	Z749259376		369.253	O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2	HPFLVTSWRFCPCV-UHFFFAOYSA-N	130918.0		HPFLVTSWRFCPCV
BRD-K00003499-001-01-9	adavivint	Phase 1	WNT pathway inhibitor				0	97.16	MedChemEx	HY-109049	Adavivint	505.203	CC(C)CC(=O)Nc1cncc(c1)-c1ccc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1	AQDWDWAYVBQMAM-UHFFFAOYSA-N	135565709.0		AQDWDWAYVBQMAM
BRD-K43055376-001-01-2	ADD-233089	Phase 1	benzodiazepine receptor agonist				0	98.53	MedChemEx	HY-14953	AWD 131-138	279.077	Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1	OKVOKULYZXODKU-UHFFFAOYSA-N	54155633.0		OKVOKULYZXODKU
BRD-K43055376-001-02-9	ADD-233089	Phase 1	benzodiazepine receptor agonist				0	97.53	MedChemEx	HY-14953	Imepitoin	279.077	Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1	OKVOKULYZXODKU-UHFFFAOYSA-N	54155633.0		OKVOKULYZXODKU
BRD-K77484724-001-03-8	adefovir	Launched	DNA polymerase inhibitor		infectious disease	hepatitis B	0	99.1	Sigma	MFCD00866943	[2-(6-amino-9H-purin-9-yl)ethoxy]methylphosphonic acid	273.063	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	SUPKOOSCJHTBAH-UHFFFAOYSA-N	60172.0		SUPKOOSCJHTBAH
BRD-K77484724-001-02-0	adefovir	Launched	DNA polymerase inhibitor		infectious disease	hepatitis B	0	0.0	AKSci	H714		273.063	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	SUPKOOSCJHTBAH-UHFFFAOYSA-N	60172.0		SUPKOOSCJHTBAH
BRD-K96159438-001-08-9	adefovir-dipivoxil	Launched	DNA polymerase inhibitor		infectious disease	hepatitis B	0	90.59	MedChemEx	HY-B0255	Adefovir dipivoxil	501.199	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	WOZSCQDILHKSGG-UHFFFAOYSA-N	60871.0		WOZSCQDILHKSGG
BRD-K96159438-001-07-1	adefovir-dipivoxil	Launched	DNA polymerase inhibitor		infectious disease	hepatitis B	0	84.46	Selleck	S1718	Adefovir Dipivoxil (Preveon, Hepsera)	501.199	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	WOZSCQDILHKSGG-UHFFFAOYSA-N	60871.0		WOZSCQDILHKSGG
BRD-K96159438-001-06-3	adefovir-dipivoxil	Launched	DNA polymerase inhibitor		infectious disease	hepatitis B	0	86.36	Selleck	S1718	Adefovir Dipivoxil	501.199	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	WOZSCQDILHKSGG-UHFFFAOYSA-N	60871.0		WOZSCQDILHKSGG
BRD-K78097265-001-02-9	adelmidrol	Launched	anti-inflammatory agent		dermatology	dermatitis	0	88.06	MedChemEx	HY-B1026	Adelmidrol	274.189	OCCNC(=O)CCCCCCCC(=O)NCCO	PAHZPHDAJQIETD-UHFFFAOYSA-N	176874.0		PAHZPHDAJQIETD
BRD-K78097265-001-01-6	adelmidrol	Launched	anti-inflammatory agent		dermatology	dermatitis	0	53.55	MicroSource	1301013	ADELMIDROL	274.189	OCCNC(=O)CCCCCCCC(=O)NCCO	PAHZPHDAJQIETD-UHFFFAOYSA-N	176874.0		PAHZPHDAJQIETD
BRD-K78185697-001-02-5	ademetionine	Launched	methyltransferase stimulant|phosphodiesterase inhibitor		neurology/psychiatry	depression|attention-deficit/hyperactivity disorder (ADHD)	0	0.0	MedChemEx	HY-B0617	Ademetionine	399.145	C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	MEFKEPWMEQBLKI-AIRLBKTGSA-O	34756.0		MEFKEPWMEQBLKI
BRD-K78185697-001-01-7	ademetionine	Launched	methyltransferase stimulant|phosphodiesterase inhibitor		neurology/psychiatry	depression|attention-deficit/hyperactivity disorder (ADHD)	0	0.0	MedChemEx	HY-B0617	Ademetionine	399.145	C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	MEFKEPWMEQBLKI-AIRLBKTGSA-O	34756.0		MEFKEPWMEQBLKI
BRD-K26060080-065-05-6	adenine	Preclinical	protein synthesis stimulant	ACACB|ACP1|APRT|MTAP|PECR|SRPK2			0	97.86	Selleck	S1982	Adenine sulfate	135.054	Nc1ncnc2nc[nH]c12	GFFGJBXGBJISGV-UHFFFAOYSA-N	190.0	BRD-M27046829-065-02-5	GFFGJBXGBJISGV
BRD-K26060080-001-11-9	adenine	Preclinical	protein synthesis stimulant	ACACB|ACP1|APRT|MTAP|PECR|SRPK2			0	94.2	MicroSource	1500807	ADENINE	135.054	Nc1ncnc2nc[nH]c12	GFFGJBXGBJISGV-UHFFFAOYSA-N	190.0		GFFGJBXGBJISGV
BRD-K26060080-003-07-3	adenine	Preclinical	protein synthesis stimulant	ACACB|ACP1|APRT|MTAP|PECR|SRPK2			0	95.4	Selleck	S1983	Adenine HCl	135.054	Nc1ncnc2nc[nH]c12	GFFGJBXGBJISGV-UHFFFAOYSA-N	190.0		GFFGJBXGBJISGV
BRD-K26060080-001-10-1	adenine	Preclinical	protein synthesis stimulant	ACACB|ACP1|APRT|MTAP|PECR|SRPK2			0	97.6	Selleck	S1981	Adenine	135.054	Nc1ncnc2nc[nH]c12	GFFGJBXGBJISGV-UHFFFAOYSA-N	190.0		GFFGJBXGBJISGV
BRD-K01577834-001-15-1	adenosine	Launched	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3|PI4K2A|PI4K2B|TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	0	96.7	MicroSource	1500107	ADENOSINE	267.097	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	OIRDTQYFTABQOQ-KQYNXXCUSA-N	60961.0		OIRDTQYFTABQOQ
BRD-K01577834-001-16-9	adenosine	Launched	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3|PI4K2A|PI4K2B|TRPM4	cardiology	Wolff-Parkinson-White Syndrome (WPW)	0	94.77	Selleck	S1647	Adenosine	267.097	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	OIRDTQYFTABQOQ-KQYNXXCUSA-N	60961.0	BRD-K63038995-001-01-4	OIRDTQYFTABQOQ
BRD-K85767870-001-14-9	adenosine-phosphate	Launched	adenosine receptor agonist	ACSL1|ACSS1|ACSS2|ADCY1|ADK|CREB1|FBP1|HINT1|PDE4B|PDE4D|PIM1|PRKAA1|PRKAB1|PRKAB2|PYGL|TRPM4			0	100.0	MedChemEx	HY-A0181	Adenosine monophosphate	347.063	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	UDMBCSSLTHHNCD-KQYNXXCUSA-N	6083.0		UDMBCSSLTHHNCD
BRD-K00003709-001-01-9	adenosine-triphosphate	Phase 2	adenosine receptor agonist	ABCA1|ABCB1|ABCB11|ABCC2|ABCC8|ABCC9|ABCG1|ABL1|ABL2|ACSL1|ACSS1|ACSS2|ACVR1|ACVR1B|ACVRL1|ADCY1|ADRBK1|ADRBK2|AFG3L2|AKT1|ALK|AMHR2|APAF1|ARAF|ASNA1|ASNS|ASS1|CDK15|GPR17|ITPR1|NAE1|NT5C2|P2RY1|P2RY11|P2RY13|P2RY2|P2RY4|PRKAA1|RYR1|RYR2|RYR3|SLC25A4|TNK2|TRPM4|TRPM7			0	79.1	MedChemEx	HY-B2176	ATP	506.996	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	ZKHQWZAMYRWXGA-KQYNXXCUSA-N	5957.0		ZKHQWZAMYRWXGA
BRD-K60907894-003-24-9	adiphenine	Launched	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	0	95.9	MedChemEx	HY-B0379A	Adiphenine (hydrochloride)	311.189	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	JGOAIQNSOGZNBX-UHFFFAOYSA-N	2031.0		JGOAIQNSOGZNBX
BRD-K60907894-003-23-5	adiphenine	Launched	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	0	94.95	MicroSource	1503073	ADIPHENINE HYDROCHLORIDE	311.189	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	JGOAIQNSOGZNBX-UHFFFAOYSA-N	2031.0		JGOAIQNSOGZNBX
BRD-K60907894-003-22-7	adiphenine	Launched	acetylcholine receptor antagonist	CHRNA1	neurology/psychiatry	spasms	0	94.79	Selleck	S2082	Adiphenine HCl	311.189	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	JGOAIQNSOGZNBX-UHFFFAOYSA-N	2031.0		JGOAIQNSOGZNBX
BRD-K10656395-001-02-1	adipic-acid	Preclinical	solute carrier family member inhibitor	SLC22A6			0	100.0	Enamine	Z57127533		146.058	OC(=O)CCCCC(O)=O	WNLRTRBMVRJNCN-UHFFFAOYSA-N	22494954.0		WNLRTRBMVRJNCN
BRD-K68810443-003-03-9	adiporon	Preclinical	adiponectin receptor agonist	ADIPOR1|ADIPOR2			0	96.64	Tocris	5096	AdipoRon hydrochloride	428.21	O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	SHHUPGSHGSNPDB-UHFFFAOYSA-N	16307093.0		SHHUPGSHGSNPDB
BRD-K68810443-001-01-9	adiporon	Preclinical	adiponectin receptor agonist	ADIPOR1|ADIPOR2			0	88.41	Selleck	S7365	AdipoRon	428.21	O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	SHHUPGSHGSNPDB-UHFFFAOYSA-N	16307093.0		SHHUPGSHGSNPDB
BRD-K68810443-003-01-5	adiporon	Preclinical	adiponectin receptor agonist	ADIPOR1|ADIPOR2			0	96.7	Tocris	5096	AdipoRon hydrochloride	428.21	O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	SHHUPGSHGSNPDB-UHFFFAOYSA-N	16307093.0		SHHUPGSHGSNPDB
BRD-K68810443-001-02-7	adiporon	Preclinical	adiponectin receptor agonist	ADIPOR1|ADIPOR2			0	98.48	Selleck	S7365	Adiporon	428.21	O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	SHHUPGSHGSNPDB-UHFFFAOYSA-N	16307093.0		SHHUPGSHGSNPDB
BRD-K39624409-003-02-6	ADL5859	Phase 2	opioid receptor agonist	OPRD1			0	86.8	Selleck	S1139	ADL5859 HCl	392.21	CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|	OPIKUXLJQFYMSC-UHFFFAOYSA-N	11417954.0		OPIKUXLJQFYMSC
BRD-K39624409-003-03-4	ADL5859	Phase 2	opioid receptor agonist	OPRD1			0	96.95	Selleck	S1139	ADL5859 HCl	392.21	CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|	OPIKUXLJQFYMSC-UHFFFAOYSA-N	11417954.0		OPIKUXLJQFYMSC
BRD-K39624409-003-04-2	ADL5859	Phase 2	opioid receptor agonist	OPRD1			0	96.21	Selleck	S1139	ADL5859 HCl	392.21	CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|	OPIKUXLJQFYMSC-UHFFFAOYSA-N	11417954.0		OPIKUXLJQFYMSC
BRD-K00003302-001-01-9	adomeglivant	Preclinical	glucagon receptor antagonist				0	98.11	MedChemEx	HY-19904	Adomeglivant	555.26	Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-c1ccc(cc1)C(C)(C)C	FASLTMSUPQDLIB-MHZLTWQESA-N	91933867.0		FASLTMSUPQDLIB
BRD-K34870043-001-01-8	adoprazine	Phase 2	dopamine receptor antagonist|serotonin receptor agonist	DRD2|HTR1A			0	95.25	MedChemEx	HY-14782	Adoprazine	405.185	Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	IUVSEUFHPNITEQ-UHFFFAOYSA-N	9887537.0		IUVSEUFHPNITEQ
BRD-K34870043-001-02-9	adoprazine	Phase 2	dopamine receptor antagonist|serotonin receptor agonist	DRD2|HTR1A			0	95.53	MedChemEx	HY-14782	Adoprazine	405.185	Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	IUVSEUFHPNITEQ-UHFFFAOYSA-N	9887537.0		IUVSEUFHPNITEQ
BRD-A90926615-001-02-7	adrafinil	Launched	adrenergic receptor agonist		neurology/psychiatry	fatigue	0	96.69	MedChemEx	HY-17549	Adrafinil	289.077	ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|	CGNMLOKEMNBUAI-HXUWFJFHSA-N	25271624.0		CGNMLOKEMNBUAI
BRD-A90926615-001-03-9	adrafinil	Launched	adrenergic receptor agonist		neurology/psychiatry	fatigue	0	72.4	MedChemEx	HY-17549	Adrafinil	289.077	ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|	CGNMLOKEMNBUAI-HXUWFJFHSA-N	25271624.0		CGNMLOKEMNBUAI
BRD-A90926615-001-01-9	adrafinil	Launched	adrenergic receptor agonist		neurology/psychiatry	fatigue	0	84.76	MedChemEx	HY-17549	Adrafinil	289.077	ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|	CGNMLOKEMNBUAI-HXUWFJFHSA-N	25271624.0		CGNMLOKEMNBUAI
BRD-K82343404-003-06-9	adrenalone	Launched	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	0	96.6	MedChemEx	HY-B1308	Adrenalone (hydrochloride)	181.074	CNCC(=O)c1ccc(O)c(O)c1	PZMVOUYYNKPMSI-UHFFFAOYSA-N	7436.0		PZMVOUYYNKPMSI
BRD-K82343404-003-03-2	adrenalone	Launched	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	0	88.41	MicroSource	1506124	ADRENALONE HYDROCHLORIDE	181.074	CNCC(=O)c1ccc(O)c(O)c1	PZMVOUYYNKPMSI-UHFFFAOYSA-N	7436.0		PZMVOUYYNKPMSI
BRD-K82343404-003-02-4	adrenalone	Launched	adrenergic receptor agonist	ADRA1A	hematology	hemorrhage	0	91.31	Selleck	S3185	Adrenalone HCl	181.074	CNCC(=O)c1ccc(O)c(O)c1	PZMVOUYYNKPMSI-UHFFFAOYSA-N	7436.0		PZMVOUYYNKPMSI
BRD-K17368287-001-18-3	adrenosterone	Preclinical	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1|HSD11B2			0	98.71	MedChemEx	HY-17462	Adrenosterone	300.173	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	RZRPTBIGEANTGU-IRIMSJTPSA-N	223997.0		RZRPTBIGEANTGU
BRD-K17368287-001-19-9	adrenosterone	Preclinical	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1|HSD11B2			0	83.42	MedChemEx	HY-17462	Adrenosterone	300.173	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	RZRPTBIGEANTGU-IRIMSJTPSA-N	223997.0		RZRPTBIGEANTGU
BRD-K77911775-003-02-9	ADX-10059	Phase 2	glutamate receptor negative allosteric modulator	GRM5			0	96.26	Tocris	4416	ADX 10059 hydrochloride	240.106	Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1	MEDCLNYIYBERKO-UHFFFAOYSA-N	10331863.0		MEDCLNYIYBERKO
BRD-K77911775-003-01-8	ADX-10059	Phase 2	glutamate receptor negative allosteric modulator	GRM5			0	94.68	Tocris	4416	ADX 10059 hydrochloride	240.106	Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1	MEDCLNYIYBERKO-UHFFFAOYSA-N	10331863.0		MEDCLNYIYBERKO
BRD-K56543881-001-03-9	ADX-47273	Preclinical	glutamate receptor modulator	GRM5			0	95.37	MedChemEx	HY-13058	ADX-47273	369.129	Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	VXQCCZHCFBHTTD-HNNXBMFYSA-N	11383075.0		VXQCCZHCFBHTTD
BRD-K56543881-001-02-7	ADX-47273	Preclinical	glutamate receptor modulator	GRM5			0	96.63	Selleck	S2690	ADX-47273	369.129	Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	VXQCCZHCFBHTTD-HNNXBMFYSA-N	11383075.0		VXQCCZHCFBHTTD
BRD-K40718343-001-05-9	AEE788	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR			0	96.08	Tocris	5318	AEE 788	440.269	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	OONFNUWBHFSNBT-HXUWFJFHSA-N	10297043.0		OONFNUWBHFSNBT
BRD-K40718343-001-04-2	AEE788	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR			0	96.82	Tocris	5318	AEE 788	440.269	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	OONFNUWBHFSNBT-HXUWFJFHSA-N	10297043.0		OONFNUWBHFSNBT
BRD-K40718343-001-03-4	AEE788	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR			0	81.32	Selleck	S1486	AEE788 (NVP-AEE788)	440.269	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	OONFNUWBHFSNBT-HXUWFJFHSA-N	10297043.0		OONFNUWBHFSNBT
BRD-K40718343-001-02-6	AEE788	Phase 1/Phase 2	EGFR inhibitor|VEGFR inhibitor	EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR			0	87.81	Selleck	S1486	AEE788 (NVP-AEE788)	440.269	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	OONFNUWBHFSNBT-HXUWFJFHSA-N	10297043.0		OONFNUWBHFSNBT
BRD-K77634909-001-05-0	AEG3482	Preclinical	HSP inducer				0	92.32	Tocris	2651	AEG 3482	280.009	NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	MQUYTXDAVCOCMX-UHFFFAOYSA-N	698112.0		MQUYTXDAVCOCMX
BRD-K77634909-001-03-5	AEG3482	Preclinical	HSP inducer				0	97.67	Tocris	2651	AEG 3482	280.009	NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	MQUYTXDAVCOCMX-UHFFFAOYSA-N	698112.0		MQUYTXDAVCOCMX
BRD-K77634909-001-06-9	AEG3482	Preclinical	HSP inducer				0	90.83	Tocris	2651	AEG 3482	280.009	NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	MQUYTXDAVCOCMX-UHFFFAOYSA-N	698112.0		MQUYTXDAVCOCMX
BRD-K53205568-001-02-6	afalanine	Phase 3	dopamine receptor agonist	DRD2			0	98.01	MicroSource	1506105	AFALANINE	207.09	CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	CBQJSKKFNMDLON-JTQLQIEISA-N	74839.0		CBQJSKKFNMDLON
BRD-K53205568-001-04-9	afalanine	Phase 3	dopamine receptor agonist	DRD2			0	98.9	MedChemEx	HY-Y0068	NSC 45699	207.09	CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	CBQJSKKFNMDLON-JTQLQIEISA-N	74839.0		CBQJSKKFNMDLON
BRD-K00003330-001-01-9	afamelanotide	Launched	melanocyte-stimulating hormone mimetic				0	78.21	MedChemEx	HY-N2466	Melanotan I	1645.837	CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O	UAHFGYDRQSXQEB-LEBBXHLNSA-N	91898441.0		UAHFGYDRQSXQEB
BRD-K66175015-332-01-6	afatinib	Launched	EGFR inhibitor	EGFR|ERBB2|ERBB4	oncology	non-small cell lung cancer (NSCLC)	0	99.28	MedChemEx	HY-10261A	Afatinib (dimaleate)	485.163	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	ULXXDDBFHOBEHA-CWDCEQMOSA-N	10184653.0		ULXXDDBFHOBEHA
BRD-K66175015-001-13-2	afatinib	Launched	EGFR inhibitor	EGFR|ERBB2|ERBB4	oncology	non-small cell lung cancer (NSCLC)	0	98.26	Selleck	S1011	afatinib	485.163	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	ULXXDDBFHOBEHA-CWDCEQMOSA-N	10184653.0		ULXXDDBFHOBEHA
BRD-K66175015-001-09-0	afatinib	Launched	EGFR inhibitor	EGFR|ERBB2|ERBB4	oncology	non-small cell lung cancer (NSCLC)	0	97.22	Selleck	S1011	Afatinib (BIBW2992)	485.163	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	ULXXDDBFHOBEHA-CWDCEQMOSA-N	10184653.0		ULXXDDBFHOBEHA
BRD-K04210847-001-21-9	afimoxifene	Phase 2	estrogen receptor antagonist	ESR1|ESR2|ESRRG|PLD1|PRKCD|PRKCE|PRKCQ|PRKCZ			0	47.39	Sigma	H7904	4-((1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenyl-1-butenyl)phenol	387.22	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	TXUZVZSFRXZGTL-QPLCGJKRSA-N	449459.0		TXUZVZSFRXZGTL
BRD-K69247067-001-01-8	afloqualone	Launched	acetylcholine receptor antagonist		neurology/psychiatry	sedative	0	97.87	AKSci	67719		283.112	Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O	VDOSWXIDETXFET-UHFFFAOYSA-N	2040.0		VDOSWXIDETXFET
BRD-K23791635-001-01-3	AFN-1252	Phase 2	FABI inhibitor				0	95.38	MedChemEx	HY-16911	AFN-1252	375.158	CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1	QXTWSUQCXCWEHF-JXMROGBWSA-N	10407120.0		QXTWSUQCXCWEHF
BRD-K37793595-003-01-7	afobazole	Launched	anxiolytic		neurology/psychiatry	anxiety	0	98.16	MedChemEx	HY-14895A	Afobazole (hydrochloride)	307.135	CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1	WWNUCVSRRUDYPP-UHFFFAOYSA-N	9862937.0		WWNUCVSRRUDYPP
BRD-K37793595-003-02-9	afobazole	Launched	anxiolytic		neurology/psychiatry	anxiety	0	97.23	MedChemEx	HY-14895A	Fabomotizole (hydrochloride)	307.135	CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1	WWNUCVSRRUDYPP-UHFFFAOYSA-N	9862937.0		WWNUCVSRRUDYPP
BRD-K47816470-001-01-8	AF38469	Preclinical	sortilin inhibitor	SORT1			0	96.02	MedChemEx	HY-12802	AF38469	324.072	Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1	JWCUSQCZMQIBMR-UHFFFAOYSA-N	72706115.0		JWCUSQCZMQIBMR
BRD-K08310154-001-03-8	AG-1024	Preclinical	insulin growth factor receptor inhibitor	IGF1R			0	91.46	Selleck	S1234	AG-1024	304.021	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O	ABBADGFSRBWENF-UHFFFAOYSA-N	2044.0		ABBADGFSRBWENF
BRD-K00615600-001-12-9	AG-14361	Preclinical	PARP inhibitor	PARP1			0	81.68	Selleck	S2178	AG-14361	320.164	CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	SEKJSSBJKFLZIT-UHFFFAOYSA-N	9840076.0		SEKJSSBJKFLZIT
BRD-K00615600-001-13-7	AG-14361	Preclinical	PARP inhibitor	PARP1			0	95.36	Selleck	S2178	AG14361	320.164	CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	SEKJSSBJKFLZIT-UHFFFAOYSA-N	9840076.0		SEKJSSBJKFLZIT
BRD-K47105409-001-15-2	AG-490	Preclinical	EGFR inhibitor|JAK inhibitor	EGFR|JAK2|JAK3			0	79.4	Selleck	S1143	AG-490	294.1	Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O	TUCIOBMMDDOEMM-RIYZIHGNSA-N	5328779.0		TUCIOBMMDDOEMM
BRD-K47105409-001-14-5	AG-490	Preclinical	EGFR inhibitor|JAK inhibitor	EGFR|JAK2|JAK3			0	90.64	Tocris	414	AG 490	294.1	Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O	TUCIOBMMDDOEMM-RIYZIHGNSA-N	5328779.0		TUCIOBMMDDOEMM
BRD-K47105409-001-13-7	AG-490	Preclinical	EGFR inhibitor|JAK inhibitor	EGFR|JAK2|JAK3			0	68.4	Selleck	S1143	AG-490 (Tyrphostin B42)	294.1	Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O	TUCIOBMMDDOEMM-RIYZIHGNSA-N	5328779.0		TUCIOBMMDDOEMM
BRD-K47105409-001-16-9	AG-490	Preclinical	EGFR inhibitor|JAK inhibitor	EGFR|JAK2|JAK3			0	92.57	Tocris	414	AG 490	294.1	Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O	TUCIOBMMDDOEMM-RIYZIHGNSA-N	5328779.0		TUCIOBMMDDOEMM
BRD-K34428485-001-18-4	AG-555	Preclinical	tyrosine kinase inhibitor	CDK2			0	58.16	Tocris	618	AG 555	322.132	Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O	GSQOBTOAOGXIFL-LFIBNONCSA-N	5328770.0		GSQOBTOAOGXIFL
BRD-K81048131-001-03-9	AG-556	Preclinical	tyrosine kinase inhibitor				0	93.77	Tocris	616	AG 556	336.147	Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O	GWCNJMUSWLTSCW-SFQUDFHCSA-N	5328775.0		GWCNJMUSWLTSCW
BRD-K81048131-001-02-4	AG-556	Preclinical	tyrosine kinase inhibitor				0	57.92	Tocris	616	AG 556	336.147	Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O	GWCNJMUSWLTSCW-SFQUDFHCSA-N	5328775.0		GWCNJMUSWLTSCW
BRD-A56371469-001-03-3	AGI-5198	Preclinical	isocitrate dehydrogenase inhibitor	IDH1			0	98.97	Selleck	S7185	AGI-5198	462.243	Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10,r|	FNYGWXSATBUBER-AREMUKBSSA-N	97161269.0		FNYGWXSATBUBER
BRD-K04691817-001-01-8	AGI-6780	Preclinical	isocitrate dehydrogenase inhibitor	IDH2			0	96.02	Selleck	S7241	AGI-6780	481.074	FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	CCAWRGNYALGPQH-UHFFFAOYSA-N	71299339.0		CCAWRGNYALGPQH
BRD-K04691817-001-03-9	AGI-6780	Preclinical	isocitrate dehydrogenase inhibitor	IDH2			0	91.16	MedChemEx	HY-15734	AGI-6780	481.074	FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	CCAWRGNYALGPQH-UHFFFAOYSA-N	71299339.0		CCAWRGNYALGPQH
BRD-A78111609-001-01-2	AGM-1470	Phase 2	cell cycle inhibitor	METAP2			0	58.76	Enzo	WN111	TNP-470	401.161	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2,3,6,10,13,&1:9|	MSHZHSPISPJWHW-FRDQJGBZSA-N	14942882.0		MSHZHSPISPJWHW
BRD-K49738308-065-04-9	agmatine	Phase 3	nitric oxide synthase inhibitor	ADRA2C|ASIC3|CACNA1B|CHRNA1|GRIN1|KCNJ1|NISCH			1	0.0	Enzo	AC162	Agmatine sulfate	130.122	NCCCCNC(N)=N	QYPPJABKJHAVHS-UHFFFAOYSA-N	199.0		QYPPJABKJHAVHS
BRD-A18074780-003-02-0	AGN-192403	Preclinical	imidazoline receptor ligand	NISCH			0	100.0	Tocris	1072	AGN 192403 hydrochloride	153.152	CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|	SHXVJSFOJHMEEQ-AXTSPUMRSA-N	124581813.0	BRD-A79038507-003-02-3	SHXVJSFOJHMEEQ
BRD-A18074780-003-04-6	AGN-192403	Preclinical	imidazoline receptor ligand	NISCH			0		Tocris	1072	AGN 192403 Hydrochloride	153.152	CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3,9,&1:4,&2:7|	SHXVJSFOJHMEEQ-AXTSPUMRSA-N	124581813.0	BRD-A79038507-003-03-1	SHXVJSFOJHMEEQ
BRD-K70262971-001-01-9	AGN-194310	Phase 3	retinoid receptor antagonist	RXRA|RXRB|RXRG			0	97.17	MedChemEx	HY-16681	AGN 194310	424.15	CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|	LHUPKWKWYWOMSK-UHFFFAOYSA-N	9867046.0		LHUPKWKWYWOMSK
BRD-K32533226-001-01-3	AGN-195183	Phase 1/Phase 2	retinoid receptor agonist	RARA			0	94.51	MedChemEx	HY-16684	AGN 195183	437.121	CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1	PNAWUIKCVQSLFG-UHFFFAOYSA-N	9867758.0		PNAWUIKCVQSLFG
BRD-K84698278-001-03-4	agomelatine	Launched	melatonin receptor agonist|serotonin receptor antagonist	HTR2A|HTR2B|HTR2C|MTNR1A|MTNR1B	neurology/psychiatry	depression	0	98.23	Selleck	S1243	Agomelatine	243.126	COc1ccc2cccc(CCNC(C)=O)c2c1	YJYPHIXNFHFHND-UHFFFAOYSA-N	82148.0		YJYPHIXNFHFHND
BRD-K84698278-001-05-9	agomelatine	Launched	melatonin receptor agonist|serotonin receptor antagonist	HTR2A|HTR2B|HTR2C|MTNR1A|MTNR1B	neurology/psychiatry	depression	0	98.15	MedChemEx	HY-17038	Agomelatine	243.126	COc1ccc2cccc(CCNC(C)=O)c2c1	YJYPHIXNFHFHND-UHFFFAOYSA-N	82148.0		YJYPHIXNFHFHND
BRD-K91495480-001-03-9	AGP-103	Launched	membrane permeability inhibitor				0	100.0	Sigma	MFCD00002807	Behenic acid	340.334	CCCCCCCCCCCCCCCCCCCCCC(O)=O	UKMSUNONTOPOIO-UHFFFAOYSA-N	8215.0		UKMSUNONTOPOIO
BRD-K91495480-001-02-2	AGP-103	Launched	membrane permeability inhibitor				0	91.5	Enzo	BL147	Docosanoic acid	340.334	CCCCCCCCCCCCCCCCCCCCCC(O)=O	UKMSUNONTOPOIO-UHFFFAOYSA-N	8215.0		UKMSUNONTOPOIO
BRD-K10852420-001-03-9	AH-7614	Preclinical	free fatty acid receptor antagonist	FFAR4			0	97.69	Tocris	5256	AH 7614	351.093	Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12	OZCQEUZTOAAWDK-UHFFFAOYSA-N	233085.0		OZCQEUZTOAAWDK
BRD-K10852420-001-02-5	AH-7614	Preclinical	free fatty acid receptor antagonist	FFAR4			0	95.83	Tocris	5256	AH 7614	351.093	Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12	OZCQEUZTOAAWDK-UHFFFAOYSA-N	233085.0		OZCQEUZTOAAWDK
BRD-A64808605-003-03-9	AH11110	Preclinical	adrenergic receptor ligand	ADRA1B			0	98.87	Tocris	998	AH 11110 hydrochloride	338.199	O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|	HSVZQQYIMKLNLN-GOSISDBHSA-N	6604792.0		HSVZQQYIMKLNLN
BRD-A64808605-003-02-7	AH11110	Preclinical	adrenergic receptor ligand	ADRA1B			0	98.96	Tocris	998	AH 11110 hydrochloride	338.199	O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|	HSVZQQYIMKLNLN-GOSISDBHSA-N	6604792.0		HSVZQQYIMKLNLN
BRD-K59339270-001-03-4	AH6809	Preclinical	prostanoid receptor antagonist	PTGDR|PTGER1|PTGER2|PTGER3			0	94.5	Tocris	671	AH 6809	298.084	CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	AQFFXPQJLZFABJ-UHFFFAOYSA-N	119461.0		AQFFXPQJLZFABJ
BRD-K59339270-001-04-9	AH6809	Preclinical	prostanoid receptor antagonist	PTGDR|PTGER1|PTGER2|PTGER3			0	92.14	Tocris	671	AH 6809	298.084	CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	AQFFXPQJLZFABJ-UHFFFAOYSA-N	119461.0		AQFFXPQJLZFABJ
BRD-K59339270-001-02-6	AH6809	Preclinical	prostanoid receptor antagonist	PTGDR|PTGER1|PTGER2|PTGER3			0	96.06	Tocris	671	AH 6809	298.084	CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	AQFFXPQJLZFABJ-UHFFFAOYSA-N	119461.0		AQFFXPQJLZFABJ
BRD-K89899948-001-01-7	AI-10-49	Preclinical	core binding factor inhibitor	CBFB			0	92.82	MedChemEx	HY-16786	AI-10-49	660.156	FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1	WJBSSBFGPKTMQQ-UHFFFAOYSA-N	49806644.0		WJBSSBFGPKTMQQ
BRD-K85139301-001-02-9	AIM-100	Preclinical	tyrosine kinase inhibitor	TNK2			0	96.49	Tocris	4946	AIM 100	371.163	C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1	XNFHHOXCDUAYSR-SFHVURJKSA-N	11501591.0		XNFHHOXCDUAYSR
BRD-K85139301-001-01-3	AIM-100	Preclinical	tyrosine kinase inhibitor	TNK2			0	98.41	Tocris	4946	AIM 100	371.163	C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1	XNFHHOXCDUAYSR-SFHVURJKSA-N	11501591.0		XNFHHOXCDUAYSR
BRD-K00005347-001-01-9	ajmaline	Launched	sodium channel blocker		cardiology	Wolff-Parkinson-White Syndrome (WPW)	0	93.33	Toronto	a448000	ajmaline	326.199	[H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41	CJDRUOGAGYHKKD-BDXZSHBPSA-N	98054312.0		CJDRUOGAGYHKKD
BRD-K76677554-003-03-9	AJ76-(+)	Preclinical	dopamine receptor antagonist	DRD2|DRD3|DRD4			0	91.57	Tocris	678	(+)-AJ 76 hydrochloride	233.178	CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	YGHLYBIUVOLKCV-SMDDNHRTSA-N	122334.0		YGHLYBIUVOLKCV
BRD-K76677554-003-02-1	AJ76-(+)	Preclinical	dopamine receptor antagonist	DRD2|DRD3|DRD4			0	94.73	Tocris	678	(+)-AJ 76 hydrochloride	233.178	CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	YGHLYBIUVOLKCV-SMDDNHRTSA-N	122334.0		YGHLYBIUVOLKCV
BRD-K09143580-001-02-9	AK-7	Preclinical	SIRT inhibitor	SIRT2			0	96.21	Tocris	4754	AK 7	436.046	Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1	IYAYHZZWYNXHEQ-UHFFFAOYSA-N	1328033.0		IYAYHZZWYNXHEQ
BRD-K09143580-001-01-0	AK-7	Preclinical	SIRT inhibitor	SIRT2			0	96.33	Tocris	4754	AK 7	436.046	Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1	IYAYHZZWYNXHEQ-UHFFFAOYSA-N	1328033.0		IYAYHZZWYNXHEQ
BRD-K54907283-001-01-2	AKBA	Phase 3	lipoxygenase inhibitor	ALOX5			0	90.39	MedChemEx	HY-N0892	AKBA	512.35	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|	HMMGKOVEOFBCAU-BCDBGHSCSA-N	11168203.0		HMMGKOVEOFBCAU
BRD-K54907283-001-02-9	AKBA	Phase 3	lipoxygenase inhibitor	ALOX5			0	83.04	Toronto	a185015	3-acetyl-11-keto-b-boswellic acid	512.35	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|	HMMGKOVEOFBCAU-BCDBGHSCSA-N	11168203.0		HMMGKOVEOFBCAU
BRD-K26807903-001-04-3	aklomide	Launched			infectious disease	coccidiosis	0	98.9	MicroSource	1503014	AKLOMIDE	199.999	NC(=O)c1ccc(cc1Cl)[N+]([O-])=O	GFGSZUNNBQXGMK-UHFFFAOYSA-N	2075.0		GFGSZUNNBQXGMK
BRD-K44731351-001-02-9	AL-8697	Preclinical	p38 MAPK inhibitor	MAPK14			0	0.0	Tocris	4753	AL 8697	402.167	Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1	ZVBTZTQYHOXIBC-UHFFFAOYSA-N	25060093.0		ZVBTZTQYHOXIBC
BRD-K44731351-001-01-6	AL-8697	Preclinical	p38 MAPK inhibitor	MAPK14			0	99.77	Tocris	4753	AL 8697	402.167	Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1	ZVBTZTQYHOXIBC-UHFFFAOYSA-N	25060093.0		ZVBTZTQYHOXIBC
BRD-K51784806-001-01-6	alacepril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	98.51	Key	KS-1321	(2S)-2-[({(2S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-2-pyrrolidinyl}carbonyl)amino]-3-phenylpropanoic acid	406.156	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	FHHHOYXPRDYHEZ-COXVUDFISA-N	71992.0		FHHHOYXPRDYHEZ
BRD-K51784806-001-02-9	alacepril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	95.43	Key	KS-1321	(2S)-2-[({(2S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-2-pyrrolidinyl}carbonyl)amino]-3-phenylpropanoic acid	406.156	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	FHHHOYXPRDYHEZ-COXVUDFISA-N	71992.0		FHHHOYXPRDYHEZ
BRD-K80403280-001-02-1	alafosfalin	Phase 1	bacterial cell wall synthesis inhibitor				0	93.9	Sigma	MFCD01569244	(1R)-1-{[(2S)-2-aminopropanoyl]amino}ethylphosphonic acid	196.061	C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O	BHAYDBSYOBONRV-IUYQGCFVSA-N	71957.0		BHAYDBSYOBONRV
BRD-K96029467-003-01-9	alagebrium	Phase 2/Phase 3	glycosylation inhibitor				0	87.59	OxChem	AX8020322		232.08	Cc1sc[n+](CC(=O)c2ccccc2)c1C	LYLFQLCLUXOFOL-UHFFFAOYSA-N	216305.0		LYLFQLCLUXOFOL
BRD-A33317514-001-01-3	alanine	Launched					0	69.19	Sigma	V900641	alanine	89.048	C[C@@H](N)C(O)=O |&1:1,r|	QNAYBMKLOCPYGJ-UWTATZPHSA-N	7311725.0		QNAYBMKLOCPYGJ
BRD-K00004718-001-01-9	alanosine	Phase 2	antimetabolite				0	0.0	Cayman	19545	(2S)-2-amino-3-(1-hydroxy-2-oxohydrazino)propanoic acid	149.044	N[C@@H](CN(O)[N+][O-])C(O)=O	MLFKVJCWGUZWNV-REOHCLBHSA-N	90657278.0		MLFKVJCWGUZWNV
BRD-K53731810-001-05-9	alantolactone	Preclinical	apoptosis stimulant|STAT inhibitor	STAT3			0	91.14	Tocris	4490	Alantolactone	232.146	C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|	PXOYOCNNSUAQNS-AGNJHWRGSA-N	72724.0		PXOYOCNNSUAQNS
BRD-K53731810-001-04-3	alantolactone	Preclinical	apoptosis stimulant|STAT inhibitor	STAT3			0	86.65	Tocris	4490	Alantolactone	232.146	C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|	PXOYOCNNSUAQNS-AGNJHWRGSA-N	72724.0		PXOYOCNNSUAQNS
BRD-K01826783-003-07-9	alaproclate	Phase 2	serotonin receptor antagonist	SLC6A4			0	95.15	AlfaAesar	J62741		291.079	C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|	FZSPJBYOKQPKCD-SECBINFHSA-N	23622192.0		FZSPJBYOKQPKCD
BRD-K42140276-402-01-4	alarelin	Launched	gonadotropin releasing factor hormone receptor antagonist	GNRH1			0	96.08	MedChemEx	HY-17405	Alarelin (Acetate)	1166.599	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	QLGKMLRGKPKGKI-QWQCQAQZSA-N	9855027.0		QLGKMLRGKPKGKI
BRD-K79131256-001-20-9	albendazole	Launched	tubulin polymerization inhibitor	TUBA1A|TUBB|TUBB4B	infectious disease	cystic hydatid disease|parenchymal neurocysticercosis	0	94.73	MedChemEx	HY-B0223	Albendazole	265.088	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	HXHWSAZORRCQMX-UHFFFAOYSA-N	2082.0		HXHWSAZORRCQMX
BRD-K79131256-001-18-7	albendazole	Launched	tubulin polymerization inhibitor	TUBA1A|TUBB|TUBB4B	infectious disease	cystic hydatid disease|parenchymal neurocysticercosis	0	84.18	MicroSource	1503903	ALBENDAZOLE	265.088	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	HXHWSAZORRCQMX-UHFFFAOYSA-N	2082.0		HXHWSAZORRCQMX
BRD-K79131256-001-17-9	albendazole	Launched	tubulin polymerization inhibitor	TUBA1A|TUBB|TUBB4B	infectious disease	cystic hydatid disease|parenchymal neurocysticercosis	0	93.82	Selleck	S1640	Albendazole	265.088	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	HXHWSAZORRCQMX-UHFFFAOYSA-N	2082.0		HXHWSAZORRCQMX
BRD-A67060370-001-02-9	albendazole-oxide	Launched	anthelmintic agent		infectious disease	cystic hydatid disease|parenchymal neurocysticercosis	0	97.13	Selleck	S1836	Albendazole Oxide	281.083	CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|	VXTGHWHFYNYFFV-LJQANCHMSA-N	13805917.0		VXTGHWHFYNYFFV
BRD-A67060370-001-04-5	albendazole-oxide	Launched	anthelmintic agent		infectious disease	cystic hydatid disease|parenchymal neurocysticercosis	0	97.1	Selleck	S1836	Albendazole Oxide (Ricobendazole)	281.083	CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|	VXTGHWHFYNYFFV-LJQANCHMSA-N	13805917.0		VXTGHWHFYNYFFV
BRD-K01825118-065-05-9	albuterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma	0	87.09	Tocris	634	Salbutamol hemisulfate	239.152	CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|	NDAUXUAQIAJITI-GFCCVEGCSA-N	182176.0		NDAUXUAQIAJITI
BRD-K01825118-065-04-9	albuterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma	0	90.96	Selleck	S2507	Salbutamol sulfate (Albuterol)	337.12	CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|	NDAUXUAQIAJITI-GFCCVEGCSA-N	182176.0		NDAUXUAQIAJITI
BRD-K55991142-001-01-6	alcaftadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic conjunctivitis	0	99.28	MedChemEx	HY-17039	11-(1-methyl-4-piperidinylidene)-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carbaldehyde	307.168	CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12	MWTBKTRZPHJQLH-UHFFFAOYSA-N	19371515.0		MWTBKTRZPHJQLH
BRD-K47492008-001-02-7	alclofenac	Launched	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis	0	96.73	Sigma	MFCD00071612	[4-(allyloxy)-3-chlorophenyl]acetic acid	226.04	OC(=O)Cc1ccc(OCC=C)c(Cl)c1	ARHWPKZXBHOEEE-UHFFFAOYSA-N	30951.0		ARHWPKZXBHOEEE
BRD-A17407635-001-04-0	alclometasone-dipropionate	Launched	glucocorticoid receptor agonist	CYP3A4|NR3C1|SERPINA6	dermatology	corticosteroid-responsive dermatoses	0	97.41	Prestwick	Prestw-771	Alclometasone dipropionate	520.223	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14,17,19,28,30,31,34,&1:8,&2:18,c:26,t:22|	DJHCCTTVDRAMEH-FQEREKBASA-N			DJHCCTTVDRAMEH
BRD-A84907376-300-03-8	alcuronium	Launched	muscle relaxant	CHRM1|CHRM2|CHRM3|CHRM4|CHRNA7	neurology/psychiatry	muscle relaxant	0	89.64	Prestwick	Prestw-1036	Alcuronium chloride	666.393	OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5,11,12,14,29,31,32,35,&1:18,&2:22,c:21,t:17,TLB:2:3:13:11.15.22,20:19:30:35.39.40,10:11:3.4.5:13,41:40:30:18.19.32,28:11:3.4.5:13,THB:34:35:30:18.19.32,16:15:3.4.5:13,33:32:30:35.39.40,36:35:30:18.19.32,6:5:13:11.15.22,9:5:13:11.15.22,44:32:30:35.39.40|	MUQUYTSLDVKIOF-JGNNFNAWSA-N			MUQUYTSLDVKIOF
BRD-K06890060-001-09-1	alda-1	Preclinical	aldehyde dehydrogenase activator	ALDH2			0	96.06	Tocris	4005	Alda 1	323.012	Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1	NMKJFZCBCIUYHI-UHFFFAOYSA-N	831629.0		NMKJFZCBCIUYHI
BRD-K06890060-001-10-9	alda-1	Preclinical	aldehyde dehydrogenase activator	ALDH2			0	97.13	Tocris	4005	Alda 1	323.012	Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1	NMKJFZCBCIUYHI-UHFFFAOYSA-N	831629.0		NMKJFZCBCIUYHI
BRD-K68928792-001-03-2	aldoxorubicin	Phase 3	topoisomerase inhibitor	TOP2A			0	55.08	MedChemEx	HY-16261	INNO-206	750.275	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|	OBMJQRLIQQTJLR-USGQOSEYSA-N	9810709.0		OBMJQRLIQQTJLR
BRD-K68928792-001-02-4	aldoxorubicin	Phase 3	topoisomerase inhibitor	TOP2A			0	6.19	MedChemEx	HY-16261	INNO-206	750.275	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|	OBMJQRLIQQTJLR-USGQOSEYSA-N	9810709.0		OBMJQRLIQQTJLR
BRD-K68928792-001-01-6	aldoxorubicin	Phase 3	topoisomerase inhibitor	TOP2A			0	14.25	MedChemEx	HY-16261	INNO-206	750.275	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|	OBMJQRLIQQTJLR-USGQOSEYSA-N	9810709.0		OBMJQRLIQQTJLR
BRD-K11267252-001-06-9	alectinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|MET	oncology	non-small cell lung cancer (NSCLC)	0	98.17	Selleck	S2762	alectinib	482.268	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	KDGFLJKFZUIJMX-UHFFFAOYSA-N	49806720.0		KDGFLJKFZUIJMX
BRD-K11267252-001-04-4	alectinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|MET	oncology	non-small cell lung cancer (NSCLC)	0	92.4	Selleck	S2762	Alectinib (CH5424802)	482.268	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	KDGFLJKFZUIJMX-UHFFFAOYSA-N	49806720.0		KDGFLJKFZUIJMX
BRD-K75527158-360-05-6	alendronate	Launched	bone resorption inhibitor	ATP6V1A|FDPS|PTPN4|PTPRE|PTPRS	orthopedics	osteoporosis	1	0.0	MicroSource	1505166	ALENDRONATE SODIUM	249.017	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	OGSPWJRAVKPPFI-UHFFFAOYSA-N	44400013.0		OGSPWJRAVKPPFI
BRD-K75527158-360-06-4	alendronate	Launched	bone resorption inhibitor	ATP6V1A|FDPS|PTPN4|PTPRE|PTPRS	orthopedics	osteoporosis	1	0.0	Selleck	S1624	Alendronate (Fosamax)	249.017	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	OGSPWJRAVKPPFI-UHFFFAOYSA-N	44400013.0		OGSPWJRAVKPPFI
BRD-K75527158-360-04-9	alendronate	Launched	bone resorption inhibitor	ATP6V1A|FDPS|PTPN4|PTPRE|PTPRS	orthopedics	osteoporosis	1	0.0	Selleck	S1624	Alendronate (Fosamax)	249.017	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	OGSPWJRAVKPPFI-UHFFFAOYSA-N	44400013.0		OGSPWJRAVKPPFI
BRD-K75527158-360-07-2	alendronate	Launched	bone resorption inhibitor	ATP6V1A|FDPS|PTPN4|PTPRE|PTPRS	orthopedics	osteoporosis	1	0.0	Selleck	S1624	Alendronate (Fosamax)	249.017	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	OGSPWJRAVKPPFI-UHFFFAOYSA-N	44400013.0		OGSPWJRAVKPPFI
BRD-A42335949-300-10-6	alexidine	Preclinical	phosphatidylglycerophosphatase inhibitor	PTPMT1			0	91.99	Selleck	S4302	Alexidine HCl	508.469	CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|	LFVVNPBBFUSSHL-SZPZYZBQSA-N	40488318.0		LFVVNPBBFUSSHL
BRD-A42335949-300-09-8	alexidine	Preclinical	phosphatidylglycerophosphatase inhibitor	PTPMT1			0	90.98	Selleck	S4302	Alexidine HCl	508.469	CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29,&2:4,&3:11,&4:24,w:11.10,24.24|	LFVVNPBBFUSSHL-SZPZYZBQSA-N	40488318.0		LFVVNPBBFUSSHL
BRD-K49522529-001-02-9	alfacalcidol	Launched	vitamin D receptor agonist	CYP27B1|VDR	endocrinology	vitamin D deficiency	0	85.72	Selleck	S1468	Alfacalcidol	400.334	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	OFHCOWSQAMBJIW-AVJTYSNKSA-N	5282181.0	BRD-K92644009-001-02-6	OFHCOWSQAMBJIW
BRD-K49522529-001-01-1	alfacalcidol	Launched	vitamin D receptor agonist	CYP27B1|VDR	endocrinology	vitamin D deficiency	0	91.26	MedChemEx	HY-10003	Alfacalcidol	400.334	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	OFHCOWSQAMBJIW-AVJTYSNKSA-N	5282181.0		OFHCOWSQAMBJIW
BRD-K49522529-001-03-7	alfacalcidol	Launched	vitamin D receptor agonist	CYP27B1|VDR	endocrinology	vitamin D deficiency	0	80.48	Selleck	S1468	Alfacalcidol	400.334	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	OFHCOWSQAMBJIW-AVJTYSNKSA-N	5282181.0	BRD-K84280765-001-01-5	OFHCOWSQAMBJIW
BRD-K51751936-001-09-1	alfadolone-acetate	Phase 2	benzodiazepine receptor agonist				0	100.0	Prestwick	Prestw-1001	Alfadolone acetate	390.241	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	QRJOQYLXZPQQMX-FWROMSNXSA-N	24733.0		QRJOQYLXZPQQMX
BRD-K01826519-003-08-9	alfuzosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	urology	benign prostatic hyperplasia (BPH)	0	70.49	MicroSource	1505263	ALFUZOSIN HYDROCHLORIDE	425.183	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|	WNMJYKCGWZFFKR-CQSZACIVSA-N	37888195.0		WNMJYKCGWZFFKR
BRD-K01826519-003-07-9	alfuzosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	urology	benign prostatic hyperplasia (BPH)	0	93.3	Selleck	S1409	Alfuzosin HCl	425.183	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|	WNMJYKCGWZFFKR-CQSZACIVSA-N	37888195.0		WNMJYKCGWZFFKR
BRD-K00005348-001-01-9	algestone-acetophenide	Launched			endocrinology	contraceptive	0	93.41	Toronto	a532040	algestone acetophenide	448.261	CC(=O)[C@@]12O[C@@](C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1 |t:15|	AHBKIEXBQNRDNL-FVCOMRFXSA-N	5284538.0		AHBKIEXBQNRDNL
BRD-K60102752-001-02-2	alibendol	Launched	antispasmodic		gastroenterology	bile stimulation	0	97.28	Selleck	S1928	Alibendol	251.116	COc1cc(CC=C)cc(C(=O)NCCO)c1O	UMJHTFHIQDEGKB-UHFFFAOYSA-N	71916.0		UMJHTFHIQDEGKB
BRD-K01827280-046-12-9	alimemazine	Launched	histamine receptor agonist|histamine receptor antagonist	HRH1	neurology/psychiatry|allergy|pulmonary	sedative|urticaria|itching|cough suppressant	0	0.0	Sigma	MFCD00242594		298.15	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|	ZZHLYYDVIOPZBE-AWEZNQCLSA-N	6604496.0		ZZHLYYDVIOPZBE
BRD-K01827280-046-11-9	alimemazine	Launched	histamine receptor agonist|histamine receptor antagonist	HRH1	neurology/psychiatry|allergy|pulmonary	sedative|urticaria|itching|cough suppressant	0	92.88	MedChemEx	HY-12752A	Alimemazine hemitartrate	298.15	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|	ZZHLYYDVIOPZBE-AWEZNQCLSA-N	6604496.0		ZZHLYYDVIOPZBE
BRD-K01827280-045-07-9	alimemazine	Launched	histamine receptor agonist|histamine receptor antagonist	HRH1	neurology/psychiatry|allergy|pulmonary	sedative|urticaria|itching|cough suppressant	0	80.57	MicroSource	1500593	TRIMEPRAZINE TARTRATE	448.167	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|	ZZHLYYDVIOPZBE-AWEZNQCLSA-N	6604496.0		ZZHLYYDVIOPZBE
BRD-K00004709-001-01-9	alinidine	Phase 3	bradycardic effect 				0	86.45	AMS	Q69674	N-allyl-N-(2,6-dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine	269.049	Clc1cccc(Cl)c1N(CC=C)C1=NCCN1 |t:13|	OXTYVEUAQHPPMV-UHFFFAOYSA-N	36354.0		OXTYVEUAQHPPMV
BRD-K75295174-001-05-0	alisertib	Phase 3	Aurora kinase inhibitor	AURKA			0	98.27	Selleck	S1133	Alisertib (MLN8237)	518.116	COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|	ZLHFILGSQDJULK-UHFFFAOYSA-N	24771867.0		ZLHFILGSQDJULK
BRD-K75295174-001-01-9	alisertib	Phase 3	Aurora kinase inhibitor	AURKA			0		Selleck	S1133	MLN8237	518.116	COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|	InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)	24771867.0		ZLHFILGSQDJULK
BRD-K30020243-051-04-1	aliskiren-hemifumarate	Launched	renin inhibitor	REN	cardiology	hypertension	0	84.0	Tocris	5491	Aliskiren hemifumarate	551.393	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	UXOWGYHJODZGMF-QORCZRPOSA-N	5493444.0	BRD-M18497616-051-03-6	UXOWGYHJODZGMF
BRD-K30020243-051-05-9	aliskiren-hemifumarate	Launched	renin inhibitor	REN	cardiology	hypertension	0	100.0	Tocris	5491	Aliskiren hemifumarate	551.393	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	UXOWGYHJODZGMF-QORCZRPOSA-N	5493444.0		UXOWGYHJODZGMF
BRD-K30020243-051-02-5	aliskiren-hemifumarate	Launched	renin inhibitor	REN	cardiology	hypertension	0	95.42	MicroSource	1505710	ALISKIREN HEMIFUMARATE	551.393	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	UXOWGYHJODZGMF-QORCZRPOSA-N	5493444.0		UXOWGYHJODZGMF
BRD-K30020243-051-03-3	aliskiren-hemifumarate	Launched	renin inhibitor	REN	cardiology	hypertension	0	90.97	Selleck	S2199	Aliskiren Hemifumarate	551.393	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	UXOWGYHJODZGMF-QORCZRPOSA-N	5493444.0	BRD-K30020243-001-01-2|BRD-K30020243-001-01-2|BRD-K30020243-001-01-2|BRD-K30020243-001-01-2	UXOWGYHJODZGMF
BRD-K00003135-001-01-9	alisporivir	Phase 3	cyclophilin inhibitor				0	91.48	MedChemEx	HY-12559	Alisporivir	1215.857	[H][C@]1(C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	OLROWHGDTNFZBH-XEMWPYQTSA-N	11513676.0		OLROWHGDTNFZBH
BRD-K00003607-003-01-9	alizapride	Launched	dopamine receptor antagonist		gastroenterology	nausea	0	97.78	MedChemEx	HY-A0125A	Alizapride hydrochloride	315.17	COc1cc2[nH]nnc2cc1C(=O)NC[C@H]1CCCN1CC=C |&1:15,r|	KSEYRUGYKHXGFW-LLVKDONJSA-N	25323018.0		KSEYRUGYKHXGFW
BRD-K73191876-001-12-0	alizarin	Preclinical					0	92.04	Selleck	S2526	Alizarin	240.042	Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	RGCKGOZRHPZPFP-UHFFFAOYSA-N	6293.0		RGCKGOZRHPZPFP
BRD-K73191876-001-11-2	alizarin	Preclinical					0	79.05	Selleck	S2526	Alizarin	240.042	Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	RGCKGOZRHPZPFP-UHFFFAOYSA-N	6293.0		RGCKGOZRHPZPFP
BRD-K73191876-001-13-8	alizarin	Preclinical					0	88.98	Selleck	S2526	ALIZARIN	240.042	Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	RGCKGOZRHPZPFP-UHFFFAOYSA-N	6293.0		RGCKGOZRHPZPFP
BRD-A96407378-001-15-1	allantoin	Launched	cosmetic		dermatology	skin protectant	0	97.81	MicroSource	1500801	ALLANTOIN	158.044	NC(=O)N[C@H]1NC(=O)NC1=O |r|	POJWUDADGALRAB-SFOWXEAESA-N	439714.0		POJWUDADGALRAB
BRD-A60402836-001-01-0	allicin	Phase 2	cytokine production inhibitor	TRPA1|TRPV1			1	0.0	AKSci	P489		162.017	C=CCS[S@@](=O)CC=C |&1:4,r|	JDLKFOPOAOFWQN-SECBINFHSA-N	51399529.0		JDLKFOPOAOFWQN
BRD-K86307448-001-17-5	allopurinol	Launched	xanthine oxidase inhibitor	XDH	rheumatology|urology	gout|kidney stones	0	89.11	MicroSource	1500108	ALLOPURINOL	136.039	O=c1nc[nH]c2n[nH]cc12	OFCNXPDARWKPPY-UHFFFAOYSA-N	135401907.0		OFCNXPDARWKPPY
BRD-K86307448-001-19-1	allopurinol	Launched	xanthine oxidase inhibitor	XDH	rheumatology|urology	gout|kidney stones	0	100.0	Selleck	S1630	Allopurinol (Zyloprim)	136.039	O=c1nc[nH]c2n[nH]cc12	OFCNXPDARWKPPY-UHFFFAOYSA-N	135401907.0		OFCNXPDARWKPPY
BRD-K86307448-001-16-7	allopurinol	Launched	xanthine oxidase inhibitor	XDH	rheumatology|urology	gout|kidney stones	0	85.21	Selleck	S1630	Allopurinol	136.039	O=c1nc[nH]c2n[nH]cc12	OFCNXPDARWKPPY-UHFFFAOYSA-N	135401907.0		OFCNXPDARWKPPY
BRD-K00004728-001-01-9	allopurinol-riboside	Phase 2	anti-leishmanial agent|phosphorylase inhibitor				0	100.0	MedChemEx	HY-101397	Allopurinol riboside	268.081	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ncc2c(O)ncnc12	KFQUAMTWOJHPEJ-DAGMQNCNSA-N	135407110.0		KFQUAMTWOJHPEJ
BRD-A93407926-001-01-1	allopurinol-riboside	Phase 2	anti-leishmanial agent|phosphorylase inhibitor				0	100.0	Berry	PRA 10011		268.081	OC[C@H]1O[C@H]([C@@H](O)[C@H]1O)n1ncc2c1[nH]cnc2=O |a:2,4,7,&1:5|	KFQUAMTWOJHPEJ-NBBQQVJHSA-N			KFQUAMTWOJHPEJ
BRD-K12872829-001-01-0	allylestrenol	Launched	steroidal progestin	ESR1|PGR|SLC6A9	obstetrics/gynecology	premature labor	0	0.0	ChemImpex	28191	(17beta)-17-allylestr-4-en-17-ol	300.245	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|	ATXHVCQZZJYMCF-XUDSTZEESA-N	235905.0		ATXHVCQZZJYMCF
BRD-K33219225-001-01-9	allylisothiocyanate	Preclinical	TRPV agonist	TRPA1			1	0.0	MicroSource	1506103	ALLYLISOTHIOCYANATE	99.014	C=CCN=C=S	ZOJBYZNEUISWFT-UHFFFAOYSA-N	5971.0		ZOJBYZNEUISWFT
BRD-K33219225-001-02-9	allylisothiocyanate	Preclinical	TRPV agonist	TRPA1			1	0.0	Labotest	LTBB002332	3-isothiocyanato-1-propene	99.014	C=CCN=C=S	ZOJBYZNEUISWFT-UHFFFAOYSA-N	5971.0		ZOJBYZNEUISWFT
BRD-K89634775-001-10-9	allylthiourea	Preclinical	nitrification inhibitor				0	99.31	MedChemEx	HY-B0543	Allylthiourea	116.041	NC(=S)NCC=C	HTKFORQRBXIQHD-UHFFFAOYSA-N	1549517.0		HTKFORQRBXIQHD
BRD-K89634775-001-08-1	allylthiourea	Preclinical	nitrification inhibitor				0	96.5	Selleck	S4017	Allylthiourea	116.041	NC(=S)NCC=C	HTKFORQRBXIQHD-UHFFFAOYSA-N	1549517.0		HTKFORQRBXIQHD
BRD-K89634775-001-09-9	allylthiourea	Preclinical	nitrification inhibitor				0	99.28	MicroSource	1506125	ALLYLTHIOUREA	116.041	NC(=S)NCC=C	HTKFORQRBXIQHD-UHFFFAOYSA-N	1549517.0		HTKFORQRBXIQHD
BRD-K82677201-001-01-6	almitrine	Launched	neurotransmitter agonist	ATP1A1	pulmonary	chronic obstructive pulmonary disease (COPD)	0	99.06	AKSci	H525		477.245	Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1	OBDOVFRMEYHSQB-UHFFFAOYSA-N	33887.0		OBDOVFRMEYHSQB
BRD-K84810405-003-02-9	almorexant	Phase 3	orexin receptor antagonist	HCRTR1|HCRTR2			0	97.62	MedChemEx	HY-10805A	Almorexant (hydrochloride)	512.229	CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	DKMACHNQISHMDN-RPLLCQBOSA-N	23727689.0		DKMACHNQISHMDN
BRD-K84810405-003-01-1	almorexant	Phase 3	orexin receptor antagonist	HCRTR1|HCRTR2			0	90.95	MedChemEx	HY-10805A	Almorexant (hydrochloride)	512.229	CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	DKMACHNQISHMDN-RPLLCQBOSA-N	23727689.0		DKMACHNQISHMDN
BRD-K67601717-001-03-8	almotriptan	Launched	serotonin receptor agonist	HTR1B|HTR1D	neurology/psychiatry	migraine headache	0	91.68	MicroSource	1505204	ALMOTRIPTAN	335.167	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	WKEMJKQOLOHJLZ-UHFFFAOYSA-N	123606.0		WKEMJKQOLOHJLZ
BRD-K67601717-037-02-4	almotriptan	Launched	serotonin receptor agonist	HTR1B|HTR1D	neurology/psychiatry	migraine headache	0	93.42	Selleck	S2096	Almotriptan Malate	335.167	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	WKEMJKQOLOHJLZ-UHFFFAOYSA-N	123606.0		WKEMJKQOLOHJLZ
BRD-K67601717-037-04-9	almotriptan	Launched	serotonin receptor agonist	HTR1B|HTR1D	neurology/psychiatry	migraine headache	0	98.32	MedChemEx	HY-B0383	Almotriptan (malate)	335.167	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	WKEMJKQOLOHJLZ-UHFFFAOYSA-N	123606.0		WKEMJKQOLOHJLZ
BRD-K04851519-001-06-8	aloe-emodin	Preclinical	anticancer agent	CASP8			0	94.34	Selleck	S2259	Aloe-emodin	270.053	OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	YDQWDHRMZQUTBA-UHFFFAOYSA-N	10207.0		YDQWDHRMZQUTBA
BRD-K83003151-057-03-9	alogliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	76.01	MedChemEx	HY-A0023	Alogliptin (Benzoate)	339.17	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	ZSBOMTDTBDDKMP-OAHLLOKOSA-N	11450633.0		ZSBOMTDTBDDKMP
BRD-K83003151-057-02-4	alogliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	89.39	Selleck	S2868	Alogliptin??SYR-322??	339.17	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	ZSBOMTDTBDDKMP-OAHLLOKOSA-N	11450633.0	BRD-K83003151-001-03-0|BRD-K83003151-001-03-0|BRD-K83003151-001-03-0	ZSBOMTDTBDDKMP
BRD-K83003151-057-01-6	alogliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	93.62	Selleck	S2868	Alogliptin	339.17	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	ZSBOMTDTBDDKMP-OAHLLOKOSA-N	11450633.0	BRD-K83003151-001-02-2|BRD-K83003151-001-02-2|BRD-K83003151-001-02-2	ZSBOMTDTBDDKMP
BRD-K02074536-001-04-9	aloin	Preclinical	angiogenesis inhibitor				0	49.45	MedChemEx	HY-N0123	Aloin	418.126	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	AFHJQYHRLPMKHU-OSYMLPPYSA-N	12305761.0		AFHJQYHRLPMKHU
BRD-K02074536-001-01-9	aloin	Preclinical	angiogenesis inhibitor				0	0.0	MicroSource	1503427	ALOIN	418.126	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	AFHJQYHRLPMKHU-OSYMLPPYSA-N	12305761.0		AFHJQYHRLPMKHU
BRD-K02074536-001-02-7	aloin	Preclinical	angiogenesis inhibitor				0	50.52	Selleck	S2375	Aloin (Barbaloin)	418.126	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	AFHJQYHRLPMKHU-OSYMLPPYSA-N	12305761.0	BRD-A63615100-001-03-9	AFHJQYHRLPMKHU
BRD-K02074536-001-03-5	aloin	Preclinical	angiogenesis inhibitor				0	0.0	Selleck	S2375	Aloin	418.126	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	AFHJQYHRLPMKHU-OSYMLPPYSA-N	12305761.0	BRD-A63615100-001-02-1|BRD-A82191553-001-01-4	AFHJQYHRLPMKHU
BRD-K96391852-001-02-8	aloperine	Preclinical					0	97.73	Selleck	S2420	Aloperine	232.194	C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|	SKOLRLSBMUGVOY-GBJTYRQASA-N	162147.0		SKOLRLSBMUGVOY
BRD-K96391852-001-03-6	aloperine	Preclinical					0	100.0	Selleck	S2420	Aloperine	232.194	C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|	SKOLRLSBMUGVOY-GBJTYRQASA-N	162147.0		SKOLRLSBMUGVOY
BRD-K46742498-003-12-9	alosetron	Withdrawn	serotonin receptor antagonist	HTR3A			0	97.93	MedChemEx	HY-70050C	Alosetron (Hydrochloride)	294.148	Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C	JSWZEAMFRNKZNL-UHFFFAOYSA-N	2099.0		JSWZEAMFRNKZNL
BRD-K46742498-003-11-0	alosetron	Withdrawn	serotonin receptor antagonist	HTR3A			0	99.02	Enzo	AC3010	ALOSETRON HYDROCHLORIDE	294.148	Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C	JSWZEAMFRNKZNL-UHFFFAOYSA-N	2099.0		JSWZEAMFRNKZNL
BRD-K00004697-001-01-9	alovudine	Phase 2	DNA synthesis marker				0	94.48	CombiBlocks	QC-5890	3'-Deoxy-3'-fluorothymidine	244.086	Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O	UXCAQJAQSWSNPQ-XLPZGREQSA-N	33039.0		UXCAQJAQSWSNPQ
BRD-K91188791-001-15-9	aloxistatin	Phase 3	protease inhibitor	CTSG			0	84.88	Adooq	A13259	ethyl (2S,3S)-3-[({(1S)-1-[(isopentylamino)carbonyl]-3-methylbutyl}amino)carbonyl]-2-oxiranecarboxylate	342.215	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	SRVFFFJZQVENJC-IHRRRGAJSA-N	65663.0		SRVFFFJZQVENJC
BRD-K91188791-001-18-3	aloxistatin	Phase 3	protease inhibitor	CTSG			0	78.35	Selleck	S7393	Aloxistatin	342.215	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	SRVFFFJZQVENJC-IHRRRGAJSA-N	65663.0	BRD-A12987505-001-01-9	SRVFFFJZQVENJC
BRD-K91188791-001-17-5	aloxistatin	Phase 3	protease inhibitor	CTSG			0	86.09	MedChemEx	HY-100229	Aloxistatin	342.215	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	SRVFFFJZQVENJC-IHRRRGAJSA-N	65663.0		SRVFFFJZQVENJC
BRD-K91188791-001-14-2	aloxistatin	Phase 3	protease inhibitor	CTSG			0	83.73	Selleck	S7393	E-64d(Aloxistatin,Loxistatin??	342.215	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	SRVFFFJZQVENJC-IHRRRGAJSA-N	65663.0		SRVFFFJZQVENJC
BRD-K54997624-001-06-0	alpelisib	Launched	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG	oncology	breast cancer	0	91.09	Selleck	S2814	BYL719	441.145	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	STUWGJZDJHPWGZ-LBPRGKRZSA-N	56649450.0		STUWGJZDJHPWGZ
BRD-K72536715-001-01-5	alpha-asarone	Preclinical	cytochrome P450 inhibitor|HMGCR inhibitor	HMGCR			0	94.23	Cayman	11681	alpha-Asarone	208.11	COc1cc(OC)c(\C=C\C)cc1OC	RKFAZBXYICVSKP-AATRIKPKSA-N	636822.0		RKFAZBXYICVSKP
BRD-K87424134-001-01-0	alpha-D-glucopyranose	Preclinical					0	0.0	Sigma	MFCD00081554	alpha-D-glucopyranose	180.063	OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	WQZGKKKJIJFFOK-DVKNGEFBSA-N	79025.0		WQZGKKKJIJFFOK
BRD-K00005238-001-01-9	alpha-glucosyl-hesperidin	Preclinical	antioxidant				0	76.75	ChemImpex	32412	alpha-Glucosyl hesperidin	772.243	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)cc2O1	IMMBLRJLSYJQIZ-RBWYFKFWSA-N	53477097.0		IMMBLRJLSYJQIZ
BRD-K33396764-001-11-1	alpha-linolenic-acid	Phase 3	omega 3 fatty acid stimulant	ELOVL4|FADS1|FADS2|FFAR1|FFAR4|PTGS2|SLC8A1|TRPV1			0	19.04	Sigma	MFCD00065720	(9Z,12Z,15Z)-9,12,15-octadecatrienoic acid	278.225	CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	DTOSIQBPPRVQHS-PDBXOOCHSA-N	5280934.0		DTOSIQBPPRVQHS
BRD-K33396764-001-08-7	alpha-linolenic-acid	Phase 3	omega 3 fatty acid stimulant	ELOVL4|FADS1|FADS2|FFAR1|FFAR4|PTGS2|SLC8A1|TRPV1			0	84.81	Enzo	FA005	Linolenic acid (18:3 n-3)	278.225	CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	DTOSIQBPPRVQHS-PDBXOOCHSA-N	5280934.0		DTOSIQBPPRVQHS
BRD-K80028314-303-08-9	alpha-methylhistamine-dihydrobromide-(R)-(-)	Preclinical	histamine receptor agonist	HRH3			0	100.0	Tocris	569	(R)-(-)-alpha-Methylhistamine dihydrobromide	125.095	C[C@@H](N)Cc1cnc[nH]1	XNQIOISZPFVUFG-RXMQYKEDSA-N	156615.0		XNQIOISZPFVUFG
BRD-K80028314-303-02-6	alpha-methylhistamine-dihydrobromide-(R)-(-)	Preclinical	histamine receptor agonist	HRH3			0	90.81	Tocris	569	(R)-(-)-?-Methylhistamine dihydrobromide	125.095	C[C@@H](N)Cc1cnc[nH]1	XNQIOISZPFVUFG-RXMQYKEDSA-N	156615.0		XNQIOISZPFVUFG
BRD-K28308851-303-02-9	alpha-methylhistamine-dihydrobromide-(S)-(+)	Preclinical	histamine receptor agonist	HRH3			0	85.67	Tocris	572	(S)-(+)-alpha-Methylhistamine dihydrobromide	125.095	C[C@H](N)Cc1cnc[nH]1	XNQIOISZPFVUFG-YFKPBYRVSA-N	6603865.0		XNQIOISZPFVUFG
BRD-K28308851-303-01-8	alpha-methylhistamine-dihydrobromide-(S)-(+)	Preclinical	histamine receptor agonist	HRH3			0	91.26	Tocris	572	(S)-(+)-?-Methylhistamine dihydrobromide	125.095	C[C@H](N)Cc1cnc[nH]1	XNQIOISZPFVUFG-YFKPBYRVSA-N	6603865.0		XNQIOISZPFVUFG
BRD-K01826806-050-02-9	alpha-methylserotonin	Preclinical	serotonin receptor agonist	HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR4			0	95.4	Tocris	557	alpha-Methyl-5-hydroxytryptamine maleate	190.111	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	LYPCGXKCQDYTFV-SSDOTTSWSA-N	14083218.0		LYPCGXKCQDYTFV
BRD-A82892199-001-04-1	alpha-tochopherol	Launched	antioxidant		endocrinology	vitamin E deficiency	0	65.25	MicroSource	310039	alpha-TOCHOPHEROL [4 mM]	430.381	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	GVJHHUAWPYXKBD-QLVXXPONSA-N	1548900.0		GVJHHUAWPYXKBD
BRD-A82892199-001-05-9	alpha-tochopherol	Launched	antioxidant		endocrinology	vitamin E deficiency	0	0.0	Sigma	T3251	(+/-)-alpha-Tocopherol	430.381	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	GVJHHUAWPYXKBD-QLVXXPONSA-N	1548900.0		GVJHHUAWPYXKBD
BRD-A61850409-001-10-7	alpha-tochopheryl-acetate	Launched	antioxidant		endocrinology	vitamin E deficiency	0	93.36	MicroSource	310040	alpha-TOCHOPHERYL ACETATE [4mM]	472.392	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1 |&1:6,&2:11,&3:16,r|	ZAKOWWREFLAJOT-PKIAKLFDSA-N	9804881.0		ZAKOWWREFLAJOT
BRD-K66896751-001-02-4	alpidem	Withdrawn	benzodiazepine receptor agonist	GABRA1			0	98.59	Sigma	A1862	2-[6-chloro-2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylacetamide	403.122	CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1	JRTIDHTUMYMPRU-UHFFFAOYSA-N	54897.0		JRTIDHTUMYMPRU
BRD-K01825817-003-02-9	alprenolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	cardiology	angina pectoris	0	94.74	Tocris	2806	Alprenolol hydrochloride	249.173	CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5,r|	PAZJSJFMUHDSTF-CQSZACIVSA-N	203685.0		PAZJSJFMUHDSTF
BRD-K52459643-001-15-1	alprostadil	Launched	prostanoid receptor agonist	CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGER1|PTGER2|PTGER4|PTGIR	cardiology	congenital heart defects	0	100.0	Tocris	1620	Alprostadil	354.241	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	GMVPRGQOIOIIMI-DWKJAMRDSA-N	5280723.0		GMVPRGQOIOIIMI
BRD-K52459643-001-18-9	alprostadil	Launched	prostanoid receptor agonist	CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGER1|PTGER2|PTGER4|PTGIR	cardiology	congenital heart defects	0	96.2	Tocris	1620	Alprostadil	354.241	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	GMVPRGQOIOIIMI-DWKJAMRDSA-N	5280723.0		GMVPRGQOIOIIMI
BRD-K52459643-001-17-7	alprostadil	Launched	prostanoid receptor agonist	CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGER1|PTGER2|PTGER4|PTGIR	cardiology	congenital heart defects	0	100.0	Selleck	S1508	Alprostadil	354.241	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	GMVPRGQOIOIIMI-DWKJAMRDSA-N	5280723.0	BRD-K73691377-001-01-6	GMVPRGQOIOIIMI
BRD-K35498378-001-07-9	alrestatin	Preclinical	aldose reductase inhibitor	AKR1B1			0	91.02	MicroSource	1502053	ALRESTATIN	255.053	OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	GCUCIFQCGJIRNT-UHFFFAOYSA-N	2120.0		GCUCIFQCGJIRNT
BRD-K35498378-001-08-9	alrestatin	Preclinical	aldose reductase inhibitor	AKR1B1			0	95.6	Tocris	485	Alrestatin	255.053	OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	GCUCIFQCGJIRNT-UHFFFAOYSA-N	2120.0		GCUCIFQCGJIRNT
BRD-K35498378-001-06-1	alrestatin	Preclinical	aldose reductase inhibitor	AKR1B1			0	98.57	Tocris	485	Alrestatin	255.053	OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	GCUCIFQCGJIRNT-UHFFFAOYSA-N	2120.0		GCUCIFQCGJIRNT
BRD-K21415491-001-01-4	ALS-8112	Phase 1					0	95.6	MedChemEx	HY-12983	ALS-8176 (active form)	293.058	Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1	AWSRKKBIPSQHOJ-IBCQBUCCSA-N	71621663.0		AWSRKKBIPSQHOJ
BRD-K00004605-001-01-9	ALS-8176	Phase 1	RNA polymerase inhibitor				0	92.76	MedChemEx	HY-12983A	Lumicaitabine	433.142	CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O	MJVKYGMNSQJLIN-KYZVSKTDSA-N	89658382.0		MJVKYGMNSQJLIN
BRD-K00610438-003-03-3	altanserin	Phase 2	serotonin receptor antagonist	HTR2A			0	96.63	Tocris	1809	Altanserin hydrochloride	411.142	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	SMYALUSCZJXWHG-UHFFFAOYSA-N	3033677.0		SMYALUSCZJXWHG
BRD-K00610438-003-06-9	altanserin	Phase 2	serotonin receptor antagonist	HTR2A			0	96.97	Tocris	1809	Altanserin hydrochloride	411.142	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	SMYALUSCZJXWHG-UHFFFAOYSA-N	3033677.0		SMYALUSCZJXWHG
BRD-K00610438-003-02-5	altanserin	Phase 2	serotonin receptor antagonist	HTR2A			0	97.52	Tocris	1809	Altanserin hydrochloride	411.142	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	SMYALUSCZJXWHG-UHFFFAOYSA-N	3033677.0		SMYALUSCZJXWHG
BRD-A56675431-001-13-9	althiazide	Launched	diuretic		cardiology	hypertension	0	97.12	Sigma	Y0000606	Altizide	382.983	NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|	VGLGVJVUHYTIIU-LLVKDONJSA-N	6604323.0		VGLGVJVUHYTIIU
BRD-A56675431-001-12-3	althiazide	Launched	diuretic		cardiology	hypertension	0	99.56	MicroSource	1500804	ALTHIAZIDE	382.983	NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9,r|	VGLGVJVUHYTIIU-LLVKDONJSA-N	6604323.0		VGLGVJVUHYTIIU
BRD-K52681925-050-02-9	altinicline	Phase 2	nicotinic receptor agonist	CHRNA4|CHRNB2			0	93.05	Tocris	4766	SIB 1508Y maleate	186.116	CN1CCC[C@H]1c1cncc(c1)C#C	NUPUDYKEEJNZRG-LBPRGKRZSA-N	3036156.0		NUPUDYKEEJNZRG
BRD-K52681925-050-01-6	altinicline	Phase 2	nicotinic receptor agonist	CHRNA4|CHRNB2			0	95.59	Tocris	4766	(S)-3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine maleate	186.116	CN1CCC[C@H]1c1cncc(c1)C#C	NUPUDYKEEJNZRG-LBPRGKRZSA-N	3036156.0		NUPUDYKEEJNZRG
BRD-K78627070-001-01-5	altiratinib	Phase 1	MET inhibitor|VEGFR inhibitor	KDR|MET|TEK			0	93.9	MedChemEx	HY-B0791	Altiratinib	510.151	Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1	GNNDEPIMDAZHRQ-UHFFFAOYSA-N	54576299.0		GNNDEPIMDAZHRQ
BRD-K50276048-001-02-9	altrenogest	Launched	progestogen hormone	PGR	endocrinology	estrus	0	84.93	MedChemEx	HY-B0521	Altrenogest	310.193	C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2,4,10|	VWAUPFMBXBWEQY-ANULTFPQSA-N	10041070.0		VWAUPFMBXBWEQY
BRD-K67043667-001-26-4	altretamine	Launched	DNA synthesis inhibitor		oncology	ovarian cancer	0	99.9	MicroSource	1503065	ALTRETAMINE	210.159	CN(C)c1nc(nc(n1)N(C)C)N(C)C	UUVWYPNAQBNQJQ-UHFFFAOYSA-N	2123.0		UUVWYPNAQBNQJQ
BRD-K67043667-001-25-6	altretamine	Launched	DNA synthesis inhibitor		oncology	ovarian cancer	0	95.52	Selleck	S1278	Altretamine	210.159	CN(C)c1nc(nc(n1)N(C)C)N(C)C	UUVWYPNAQBNQJQ-UHFFFAOYSA-N	2123.0		UUVWYPNAQBNQJQ
BRD-K89055274-048-23-5	alverine	Launched	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome|diverticular disease	0	90.26	MicroSource	1500109	ALVERINE CITRATE	281.214	CCN(CCCc1ccccc1)CCCc1ccccc1	ZPFXAOWNKLFJDN-UHFFFAOYSA-N	3678.0		ZPFXAOWNKLFJDN
BRD-K89055274-048-24-9	alverine	Launched	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome|diverticular disease	0	91.76	MedChemEx	HY-B0500	Alverine (citrate)	281.214	CCN(CCCc1ccccc1)CCCc1ccccc1	ZPFXAOWNKLFJDN-UHFFFAOYSA-N	3678.0		ZPFXAOWNKLFJDN
BRD-K89055274-048-22-7	alverine	Launched	muscle relaxant	HTR1A	gastroenterology	irritable bowel syndrome|diverticular disease	0	94.35	Selleck	S3054	Alverine Citrate	281.214	CCN(CCCc1ccccc1)CCCc1ccccc1	ZPFXAOWNKLFJDN-UHFFFAOYSA-N	3678.0		ZPFXAOWNKLFJDN
BRD-K83988098-003-03-4	alvespimycin	Phase 2	HSP inhibitor	HSP90AA1			0	96.5	Selleck	S1142	17-DMAG HCl (Alvespimycin)	616.347	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|	KUFRQPKVAWMTJO-UBNVGODQSA-N	59996481.0		KUFRQPKVAWMTJO
BRD-K83988098-001-02-0	alvespimycin	Phase 2	HSP inhibitor	HSP90AA1			0	85.6	Selleck	S1142	17-DMAG (Alvespimycin) HCl	616.347	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|	KUFRQPKVAWMTJO-UBNVGODQSA-N	59996481.0	BRD-K23499943-003-01-6	KUFRQPKVAWMTJO
BRD-K83988098-003-07-9	alvespimycin	Phase 2	HSP inhibitor	HSP90AA1			0	88.28	MedChemEx	HY-12024	Alvespimycin (hydrochloride)	616.347	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,25,t:17,23,36|	KUFRQPKVAWMTJO-UBNVGODQSA-N	59996481.0		KUFRQPKVAWMTJO
BRD-K07857022-002-02-9	alvimopan	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1	gastroenterology	postoperative ileus	0	97.29	MedChemEx	HY-76657	Alvimopan (monohydrate)	424.236	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	UPNUIXSCZBYVBB-JVFUWBCBSA-N	5488548.0		UPNUIXSCZBYVBB
BRD-K07857022-002-01-1	alvimopan	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1	gastroenterology	postoperative ileus	0	97.74	MedChemEx	HY-76657	Alvimopan (monohydrate)	424.236	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	UPNUIXSCZBYVBB-JVFUWBCBSA-N	5488548.0		UPNUIXSCZBYVBB
BRD-K87909389-003-09-9	alvocidib	Phase 2	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CDK6|CDK7|CDK8|CDK9|EGFR|PYGM			0	93.54	Tocris	3094	Flavopiridol hydrochloride	401.103	CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	BIIVYFLTOXDAOV-YVEFUNNKSA-N	5287969.0		BIIVYFLTOXDAOV
BRD-K87909389-003-04-2	alvocidib	Phase 2	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CDK6|CDK7|CDK8|CDK9|EGFR|PYGM			0	93.06	Tocris	3094	Flavopiridol hydrochloride	401.103	CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	BIIVYFLTOXDAOV-YVEFUNNKSA-N	5287969.0		BIIVYFLTOXDAOV
BRD-K87909389-003-03-4	alvocidib	Phase 2	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CDK6|CDK7|CDK8|CDK9|EGFR|PYGM			0	96.3	Selleck	S2679	Flavopiridol HCl	401.103	CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	BIIVYFLTOXDAOV-YVEFUNNKSA-N	5287969.0		BIIVYFLTOXDAOV
BRD-K00003337-019-01-9	ALX-40-4C	Preclinical	CC chemokine receptor antagonist				0	0.0	MedChemEx	HY-P7061A	ALX 40-4C Trifluoroacetate	1463.947	CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	LGLVVVCSQBZONM-HCCLCSBVSA-N	25077385.0		LGLVVVCSQBZONM
BRD-K53979406-003-03-6	ALX-5407	Phase 1	glycine transporter inhibitor	SLC6A9			0	98.56	Tocris	1757	ALX 5407 hydrochloride	393.174	CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	FDORQEIHOKEJNX-HSZRJFAPSA-N	86306255.0		FDORQEIHOKEJNX
BRD-K53979406-003-04-9	ALX-5407	Phase 1	glycine transporter inhibitor	SLC6A9			0	96.89	Tocris	1757	ALX 5407 hydrochloride	393.174	CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	FDORQEIHOKEJNX-HSZRJFAPSA-N	86306255.0		FDORQEIHOKEJNX
BRD-K53979406-003-02-8	ALX-5407	Phase 1	glycine transporter inhibitor	SLC6A9			0	96.02	Tocris	1757	ALX 5407 hydrochloride	393.174	CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	FDORQEIHOKEJNX-HSZRJFAPSA-N	86306255.0		FDORQEIHOKEJNX
BRD-A66116161-001-02-3	AM-1241	Preclinical	cannabinoid receptor agonist	CNR1|CNR2			0	94.55	Selleck	S1544	AM1241	503.071	CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|	ZUHIXXCLLBMBDW-MRXNPFEDSA-N	23583507.0		ZUHIXXCLLBMBDW
BRD-A66116161-001-03-1	AM-1241	Preclinical	cannabinoid receptor agonist	CNR1|CNR2			0	97.24	Selleck	S1544	AM-1241	503.071	CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6,r|	ZUHIXXCLLBMBDW-MRXNPFEDSA-N	23583507.0		ZUHIXXCLLBMBDW
BRD-K59013864-001-01-1	AM-24	Phase 2	lipoxygenase inhibitor	ALOX5			0	99.73	Enamine	EN300-19379		471.732	Oc1c(I)cc(I)cc1I	VAPDZNUFNKUROY-UHFFFAOYSA-N	11862.0		VAPDZNUFNKUROY
BRD-K92000912-001-14-9	AM-251	Preclinical	cannabinoid receptor antagonist	CNR1|GPR18|GPR55			0	98.46	Tocris	1117	AM 251	554.014	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	BUZAJRPLUGXRAB-UHFFFAOYSA-N	2125.0		BUZAJRPLUGXRAB
BRD-K92000912-001-11-8	AM-251	Preclinical	cannabinoid receptor antagonist	CNR1|GPR18|GPR55			0	92.46	Selleck	S2819	AM251	554.014	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	BUZAJRPLUGXRAB-UHFFFAOYSA-N	2125.0		BUZAJRPLUGXRAB
BRD-K92000912-001-12-6	AM-251	Preclinical	cannabinoid receptor antagonist	CNR1|GPR18|GPR55			0	94.81	Tocris	1117	AM 251	554.014	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	BUZAJRPLUGXRAB-UHFFFAOYSA-N	2125.0		BUZAJRPLUGXRAB
BRD-K59419204-001-03-9	AM-281	Preclinical	cannabinoid receptor antagonist	CNR1|CNR2|GPR55			0	95.57	Tocris	1115	AM 281	555.993	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	AJFFBPZYXRNAIC-UHFFFAOYSA-N	4302962.0		AJFFBPZYXRNAIC
BRD-K59419204-001-02-7	AM-281	Preclinical	cannabinoid receptor antagonist	CNR1|CNR2|GPR55			0	95.08	Tocris	1115	AM 281	555.993	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	AJFFBPZYXRNAIC-UHFFFAOYSA-N	4302962.0		AJFFBPZYXRNAIC
BRD-K55462201-001-08-9	AM-404	Preclinical	cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist	CNR1|CNR2|FAAH|TRPV1			0	95.22	Tocris	1116	AM 404	395.282	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	IJBZOOZRAXHERC-DOFZRALJSA-N	6604822.0		IJBZOOZRAXHERC
BRD-K55462201-001-07-3	AM-404	Preclinical	cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist	CNR1|CNR2|FAAH|TRPV1			0	94.19	Tocris	1116	AM 404	395.282	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	IJBZOOZRAXHERC-DOFZRALJSA-N	6604822.0		IJBZOOZRAXHERC
BRD-K06854232-001-22-3	AM-580	Preclinical	retinoid receptor agonist	RARA			0	98.56	Tocris	760	AM 580	351.183	CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	SZWKGOZKRMMLAJ-UHFFFAOYSA-N	2126.0		SZWKGOZKRMMLAJ
BRD-K06854232-001-19-9	AM-580	Preclinical	retinoid receptor agonist	RARA			0	98.13	Tocris	760	AM 580	351.183	CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	SZWKGOZKRMMLAJ-UHFFFAOYSA-N	2126.0		SZWKGOZKRMMLAJ
BRD-K63533170-001-03-7	AM-630	Preclinical	cannabinoid receptor antagonist	CNR1|CNR2			0	97.26	Tocris	1120	{6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl}(4-methoxyphenyl)methanone	504.091	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	JHOTYHDSLIUKCJ-UHFFFAOYSA-N	4302963.0		JHOTYHDSLIUKCJ
BRD-K63533170-001-02-9	AM-630	Preclinical	cannabinoid receptor antagonist	CNR1|CNR2			0	94.94	Tocris	1120	AM 630	504.091	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	JHOTYHDSLIUKCJ-UHFFFAOYSA-N	4302963.0		JHOTYHDSLIUKCJ
BRD-K01826811-003-03-9	AM-92016	Preclinical	potassium channel blocker	GRIN1			0	71.25	Tocris	876	AM 92016 hydrochloride	482.06	CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|	BQBSHJUQVIWEFM-MRXNPFEDSA-N	6604771.0		BQBSHJUQVIWEFM
BRD-K01826811-003-02-9	AM-92016	Preclinical	potassium channel blocker	GRIN1			0	94.4	Tocris	876	AM 92016 hydrochloride	482.06	CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|	BQBSHJUQVIWEFM-MRXNPFEDSA-N	6604771.0		BQBSHJUQVIWEFM
BRD-K70330367-003-08-7	amantadine	Launched	glutamate receptor antagonist	DRD2|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease	0	99.66	MicroSource	1500110	AMANTADINE HYDROCHLORIDE	151.136	NC12CC3CC(CC(C3)C1)C2	DKNWSYNQZKUICI-UHFFFAOYSA-N	2130.0		DKNWSYNQZKUICI
BRD-K70330367-003-07-9	amantadine	Launched	glutamate receptor antagonist	DRD2|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A	infectious disease|neurology/psychiatry	influenza A virus infection|Parkinson's Disease	0	100.0	Selleck	S2451	Amantadine HCl	151.136	NC12CC3CC(CC(C3)C1)C2	DKNWSYNQZKUICI-UHFFFAOYSA-N	2130.0		DKNWSYNQZKUICI
BRD-K11244467-002-01-8	ambazone	Phase 1	DNA damage inducer				0	83.39	Kemprotec	TC861	(E)-2-((E)-4-(2-carbamimidoylhydrazono)cyclohexa-2,5-dien-1-ylidene)hydrazine-1-carbothioamide hydrate	237.08	NC(=S)NNc1ccc(cc1)N=NC(N)=N	HQDSAVMTLKVTGJ-UHFFFAOYSA-N			HQDSAVMTLKVTGJ
BRD-K11244467-001-09-3	ambazone	Phase 1	DNA damage inducer				0	84.0	Vitas-M	STL200147	2-{4-[(aminocarbothioyl)hydrazono]-2,5-cyclohexadien-1-ylidene}hydrazinecarboximidamide	237.08	NC(=S)NNc1ccc(cc1)N=NC(N)=N	HQDSAVMTLKVTGJ-UHFFFAOYSA-N			HQDSAVMTLKVTGJ
BRD-K11244467-001-08-5	ambazone	Phase 1	DNA damage inducer				0	82.4	Vitas-M	STL200147		237.08	NC(=S)NNc1ccc(cc1)N=NC(N)=N	HQDSAVMTLKVTGJ-UHFFFAOYSA-N			HQDSAVMTLKVTGJ
BRD-K11292736-300-02-8	ambenonium	Launched	cholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	0	93.62	Tocris	388	Ambenonium dichloride	536.268	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl	OMHBPUNFVFNHJK-UHFFFAOYSA-P	2131.0		OMHBPUNFVFNHJK
BRD-K11292736-300-04-9	ambenonium	Launched	cholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	0	93.49	Tocris	388	Ambenonium dichloride	536.268	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl	OMHBPUNFVFNHJK-UHFFFAOYSA-P	2131.0		OMHBPUNFVFNHJK
BRD-K41185545-001-03-9	ambrisentan	Launched	endothelin receptor antagonist	EDNRA|EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	0	96.82	MedChemEx	HY-13209	Ambrisentan	378.158	COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1	OUJTZYPIHDYQMC-LJQANCHMSA-N	6918493.0		OUJTZYPIHDYQMC
BRD-K41185545-001-02-3	ambrisentan	Launched	endothelin receptor antagonist	EDNRA|EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	0	97.47	Selleck	S2097	Ambrisentan	378.158	COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1	OUJTZYPIHDYQMC-LJQANCHMSA-N	6918493.0		OUJTZYPIHDYQMC
BRD-K56558538-003-14-3	ambroxol	Launched	sodium channel blocker	CYP3A4	pulmonary	bronchitis	0	96.02	MicroSource	1503080	AMBROXOL HYDROCHLORIDE	375.979	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	JBDGDEWWOUBZPM-XYPYZODXSA-N		BRD-K11223672-003-05-2	JBDGDEWWOUBZPM
BRD-K56558538-003-13-5	ambroxol	Launched	sodium channel blocker	CYP3A4	pulmonary	bronchitis	0	81.4	Tocris	2404	Ambroxol hydrochloride	375.979	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	JBDGDEWWOUBZPM-XYPYZODXSA-N			JBDGDEWWOUBZPM
BRD-K56558538-003-12-7	ambroxol	Launched	sodium channel blocker	CYP3A4	pulmonary	bronchitis	0	96.34	Tocris	2404	Ambroxol hydrochloride	375.979	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	JBDGDEWWOUBZPM-XYPYZODXSA-N			JBDGDEWWOUBZPM
BRD-K56558538-003-15-9	ambroxol	Launched	sodium channel blocker	CYP3A4	pulmonary	bronchitis	0	97.58	Tocris	2404	Ambroxol hydrochloride	375.979	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	JBDGDEWWOUBZPM-XYPYZODXSA-N			JBDGDEWWOUBZPM
BRD-K56558538-003-11-9	ambroxol	Launched	sodium channel blocker	CYP3A4	pulmonary	bronchitis	0	97.34	Selleck	S3064	Ambroxol HCl	375.979	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	JBDGDEWWOUBZPM-XYPYZODXSA-N			JBDGDEWWOUBZPM
BRD-K00003244-001-01-9	amcasertib	Phase 2	kinase inhibitor				0	89.6	MedChemEx	HY-17602	Amcasertib	539.235	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C	QDWKGEFGLQMDAM-JJIBRWJFSA-N	122412734.0		QDWKGEFGLQMDAM
BRD-A36010170-001-04-0	amcinonide	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	96.95	MicroSource	1503816	AMCINONIDE	502.237	CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7,15,27,29,31,34,&1:17,&2:18,c:27,t:23|	ILKJAFIWWBXGDU-KNPIAJNZSA-N	40469418.0		ILKJAFIWWBXGDU
BRD-K03019184-439-01-0	AMD-3465	Preclinical	CC chemokine receptor antagonist	CXCR4			0	65.06	Tocris	4179	AMD 3465 hexahydrobromide	410.316	C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	CWJJHESJXJQCJA-UHFFFAOYSA-N	483559.0		CWJJHESJXJQCJA
BRD-K03019184-439-02-9	AMD-3465	Preclinical	CC chemokine receptor antagonist	CXCR4			0	100.0	Tocris	4179	AMD 3465 hexahydrobromide	410.316	C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	CWJJHESJXJQCJA-UHFFFAOYSA-N	483559.0		CWJJHESJXJQCJA
BRD-K41051431-001-02-4	amdinocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|gram-negative bacterial infections	0	61.16	Sigma	MFCD00056869	(2S,5R,6R)-6-{[(E)-1-azepanylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid	325.146	CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O	BWWVAEOLVKTZFQ-ISVUSNJMSA-N			BWWVAEOLVKTZFQ
BRD-K41051431-001-03-9	amdinocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|gram-negative bacterial infections	0	56.73	Sigma	MFCD00056869	Mecillinam	325.146	CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O	BWWVAEOLVKTZFQ-ISVUSNJMSA-N			BWWVAEOLVKTZFQ
BRD-K42948882-305-02-9	AMD11070	Phase 3	CC chemokine receptor antagonist	CCR5|CXCR4			0	94.61	MedChemEx	HY-50101A	Mavorixafor (trihydrochloride)	349.227	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12	WVLHHLRVNDMIAR-IBGZPJMESA-N	11256587.0		WVLHHLRVNDMIAR
BRD-K42948882-305-01-1	AMD11070	Phase 3	CC chemokine receptor antagonist	CCR5|CXCR4			0	92.59	MedChemEx	HY-50101A	AMD-070 (hydrochloride)	349.227	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12	WVLHHLRVNDMIAR-IBGZPJMESA-N	11256587.0		WVLHHLRVNDMIAR
BRD-K48173020-001-02-9	ameltolide	Preclinical	anticonvulsant				0	94.88	Vitas-M	STK360030	4-amino-N-(2,6-dimethylphenyl)benzamide	240.126	Cc1cccc(C)c1NC(=O)c1ccc(N)cc1	HZIWGOAXOBPQGY-UHFFFAOYSA-N	13086.0		HZIWGOAXOBPQGY
BRD-K48173020-001-01-8	ameltolide	Preclinical	anticonvulsant				0	98.29	Vitas-M	STK360030		240.126	Cc1cccc(C)c1NC(=O)c1ccc(N)cc1	HZIWGOAXOBPQGY-UHFFFAOYSA-N	13086.0		HZIWGOAXOBPQGY
BRD-K00004966-001-01-9	amenamevir	Phase 1	helicase primase inhibitor				0	87.31	MedChemEx	HY-14809	Amenamevir	482.162	Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1	MNHNIVNAFBSLLX-UHFFFAOYSA-N	11397521.0		MNHNIVNAFBSLLX
BRD-K00004726-001-01-9	ametantrone	Preclinical	anticancer agent				0	87.98	Astatech	I11677	AMETANTRONE(NSC 196473)	412.211	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3ccccc3C(=O)c12	FFGSXKJJVBXWCY-UHFFFAOYSA-N	2134.0		FFGSXKJJVBXWCY
BRD-K51387999-067-01-6	amezinium	Launched	adrenergic receptor agonist	ADRB2	cardiology	hypotension	0	74.42	CombiBlocks	QH-7299	4-amino-6-methoxy-1-phenylpyridazin-1-ium methyl sulfate	202.098	COc1cc(N)cn[n+]1-c1ccccc1	VXROHTDSRBRJLN-UHFFFAOYSA-O	71927.0		VXROHTDSRBRJLN
BRD-K82122102-323-01-1	amfenac	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	96.17	Selleck	S4149	Amfenac Sodium Monohydrate	255.09	Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	SOYCMDCMZDHQFP-UHFFFAOYSA-N	2136.0		SOYCMDCMZDHQFP
BRD-K82122102-323-02-9	amfenac	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	94.65	MedChemEx	HY-17479A	Amfenac Sodium Hydrate	255.09	Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	SOYCMDCMZDHQFP-UHFFFAOYSA-N	2136.0		SOYCMDCMZDHQFP
BRD-K50813454-001-01-9	amflutizole	Phase 2	xanthine oxidase inhibitor	XDH			0	96.22	Enamine	Z2327605029	4-amino-3-[3-(trifluoromethyl)phenyl]-5-isothiazolecarboxylic acid	288.018	Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O	KVMCEGAWQYTFKC-UHFFFAOYSA-N	54833.0		KVMCEGAWQYTFKC
BRD-K04374714-003-02-9	AMG-PERK-44	Preclinical	PERK inhibitor	EIF2AK4			0	96.83	Tocris	5517	AMG PERK 44	524.221	Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N	YPPSMYLMSKHYAY-UHFFFAOYSA-N	86583045.0		YPPSMYLMSKHYAY
BRD-K04374714-003-01-1	AMG-PERK-44	Preclinical	PERK inhibitor	EIF2AK4			0	97.69	Tocris	5517	AMG PERK 44	524.221	Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N	YPPSMYLMSKHYAY-UHFFFAOYSA-N	86583045.0		YPPSMYLMSKHYAY
BRD-K43900408-001-02-9	AMG-176	Phase 1	MCL1 inhibitor				0	96.01	Broad Institute	HY-101565	AMG-176	612.242	CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2 |t:3|	JQNINBDKGLWYMU-PTJFNUENSA-N			JQNINBDKGLWYMU
BRD-K32285926-001-02-1	AMG-208	Phase 1	tyrosine kinase inhibitor	MET			0	99.83	MedChemEx	HY-12035	AMG-208	383.138	COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	HEAIZQNMNCHNFD-UHFFFAOYSA-N	24864821.0		HEAIZQNMNCHNFD
BRD-K32285926-001-03-9	AMG-208	Phase 1	tyrosine kinase inhibitor	MET			0	97.2	MedChemEx	HY-12035	AMG-208	383.138	COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	HEAIZQNMNCHNFD-UHFFFAOYSA-N	24864821.0		HEAIZQNMNCHNFD
BRD-K64925568-001-01-8	AMG-232	Phase 2	MDM inhibitor	MDM2			0	98.92	MedChemEx	HY-12296	AMG 232	567.161	CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	DRLCSJFKKILATL-YWCVFVGNSA-N	58573469.0		DRLCSJFKKILATL
BRD-K64925568-001-02-6	AMG-232	Phase 2	MDM inhibitor	MDM2			0	98.34	MedChemEx	HY-12296	AMG 232	567.161	CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	DRLCSJFKKILATL-YWCVFVGNSA-N	58573469.0		DRLCSJFKKILATL
BRD-K21077415-001-01-5	AMG-319	Phase 2	PI3K inhibitor	PIK3CD			0	98.62	MedChemEx	HY-12948		385.145	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1	KWRYMZHCQIOOEB-LBPRGKRZSA-N	68947304.0		KWRYMZHCQIOOEB
BRD-K27061362-001-01-6	AMG-337	Phase 2	MET inhibitor	MET			0	97.7	MedChemEx	HY-18696	AMG-337	463.177	COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1	DWHXUGDWKAIASB-CQSZACIVSA-N	44181686.0		DWHXUGDWKAIASB
BRD-K90239174-001-01-8	AMG-487	Phase 2	CC chemokine receptor antagonist				0	98.21	MedChemEx	HY-15319	AMG 487	603.209	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	WQTKNBPCJKRYPA-OAQYLSRUSA-N	24957182.0		WQTKNBPCJKRYPA
BRD-K90239174-001-02-9	AMG-487	Phase 2	CC chemokine receptor antagonist				0	97.35	MedChemEx	HY-15319	AMG 487	603.209	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	WQTKNBPCJKRYPA-OAQYLSRUSA-N	24957182.0		WQTKNBPCJKRYPA
BRD-A01307728-001-02-9	AMG-487-(+/-)	Phase 2	CC chemokine receptor antagonist	CXCR3			0	97.24	Tocris	4487	(+/-)-AMG 487	603.209	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|	WQTKNBPCJKRYPA-OAQYLSRUSA-N	24957182.0		WQTKNBPCJKRYPA
BRD-A01307728-001-01-4	AMG-487-(+/-)	Phase 2	CC chemokine receptor antagonist	CXCR3			0	97.4	Tocris	4487	(+/-)-AMG 487	603.209	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20,r|	WQTKNBPCJKRYPA-OAQYLSRUSA-N	24957182.0		WQTKNBPCJKRYPA
BRD-K00010385-001-01-9	AMG-510	Phase 1/Phase 2	K-Ras inhibitor				0	99.17	MedChemEx	HY-114277	AMG-510	560.235	CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F	NXQKSXLFSAEQCZ-SFHVURJKSA-N	137278711.0		NXQKSXLFSAEQCZ
BRD-K34185671-001-03-9	AMG-517	Phase 1	TRPV antagonist	TRPV1			0	97.41	Tocris	5995	AMG 517	430.071	CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1	YUTIXVXZQIQWGY-UHFFFAOYSA-N	16007367.0		YUTIXVXZQIQWGY
BRD-K34185671-001-02-8	AMG-517	Phase 1	TRPV antagonist	TRPV1			0	98.16	Selleck	S7115	AMG-517	430.071	CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1	YUTIXVXZQIQWGY-UHFFFAOYSA-N	16007367.0		YUTIXVXZQIQWGY
BRD-K86673452-001-01-7	AMG-548	Phase 1	MAP kinase inhibitor	MAPK11|MAPK12|MAPK13|MAPK14			0	87.61	Tocris	3920	(S)-2-((2-amino-3-phenylpropyl)amino)-3-methyl-5-(naphthalen-2-yl)-6-(pyridin-4-yl)pyrimidin-4(3H)-one	461.222	Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O	RQVKVJIRFKVPBF-VWLOTQADSA-N	11167112.0		RQVKVJIRFKVPBF
BRD-K86673452-001-02-5	AMG-548	Phase 1	MAP kinase inhibitor	MAPK11|MAPK12|MAPK13|MAPK14			0	87.4	Tocris	3920	AMG 548	461.222	Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O	RQVKVJIRFKVPBF-VWLOTQADSA-N	11167112.0		RQVKVJIRFKVPBF
BRD-K43802723-238-02-9	AMG-837	Phase 1	free fatty acid receptor agonist	FFAR1			0	95.82	Tocris	6082	AMG 837 hemicalcium salt	438.144	CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1	ZOPNBMMVVZRSGH-NRFANRHFSA-N	46854655.0		ZOPNBMMVVZRSGH
BRD-K43802723-340-01-9	AMG-837	Phase 1	free fatty acid receptor agonist	FFAR1			0	97.49	MedChemEx	HY-13967B	AMG 837 (calcium hydrate)	438.144	CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1	ZOPNBMMVVZRSGH-NRFANRHFSA-N	46854655.0	BRD-M56591481-002-01-8	ZOPNBMMVVZRSGH
BRD-K97452254-001-01-3	AMG-925	Phase 1	CDK inhibitor|FLT3 inhibitor	CDK4|CDK6|FLT3			0	94.57	MedChemEx	HY-15889	AMG 925	471.238	C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|	BBUVDDPUURMFOX-SAABIXHNSA-N			BBUVDDPUURMFOX
BRD-K01995783-001-02-4	AMG-9810	Preclinical	TRPV antagonist	TRPV1			0	94.56	Tocris	2316	AMG 9810	337.168	CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1	GZTFUVZVLYUPRG-IZZDOVSWSA-N	680502.0		GZTFUVZVLYUPRG
BRD-K01995783-001-01-6	AMG-9810	Preclinical	TRPV antagonist	TRPV1			0	98.34	Tocris	2316	AMG 9810	337.168	CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1	GZTFUVZVLYUPRG-IZZDOVSWSA-N	680502.0		GZTFUVZVLYUPRG
BRD-K01995783-001-03-9	AMG-9810	Preclinical	TRPV antagonist	TRPV1			0	94.41	Tocris	2316	AMG 9810	337.168	CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1	GZTFUVZVLYUPRG-IZZDOVSWSA-N	680502.0		GZTFUVZVLYUPRG
BRD-A58947127-001-01-6	AMG319	Phase 2	PI3K inhibitor	PIK3CD			0	99.26	Selleck	S7813	AMG319	385.145	C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1,r|	KWRYMZHCQIOOEB-GFCCVEGCSA-N	133547162.0		KWRYMZHCQIOOEB
BRD-K21782625-001-02-4	AMG458	Preclinical	MET inhibitor	MET			0	87.29	Selleck	S2747	AMG-458	539.217	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	GLBZSOQDAOLMGC-UHFFFAOYSA-N	24764449.0		GLBZSOQDAOLMGC
BRD-K21782625-001-03-2	AMG458	Preclinical	MET inhibitor	MET			0	93.71	Selleck	S2747	AMG458	539.217	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	GLBZSOQDAOLMGC-UHFFFAOYSA-N	24764449.0		GLBZSOQDAOLMGC
BRD-K21782625-001-04-0	AMG458	Preclinical	MET inhibitor	MET			0	96.9	Selleck	S2747	AMG458	539.217	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	GLBZSOQDAOLMGC-UHFFFAOYSA-N	24764449.0		GLBZSOQDAOLMGC
BRD-K21728777-001-03-9	AMG900	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	96.52	MedChemEx	HY-13253	AMG 900	503.153	Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	IVUGFMLRJOCGAS-UHFFFAOYSA-N	24856041.0		IVUGFMLRJOCGAS
BRD-K21728777-001-02-3	AMG900	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	92.63	Selleck	S2719	AMG-900	503.153	Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	IVUGFMLRJOCGAS-UHFFFAOYSA-N	24856041.0		IVUGFMLRJOCGAS
BRD-K75114721-304-02-6	AMI-1	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT1			0	83.1	ChemBridge	FT47-8059	AMI-1	504.03	Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O	PCGISRHGYLRXSR-UHFFFAOYSA-N	67254.0		PCGISRHGYLRXSR
BRD-K24610819-003-02-6	amibegron	Phase 3	adrenergic receptor agonist	ADRB3			0	90.69	Tocris	3986	SR 58611A	403.155	CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1	RDJQCOBTKKAQAH-FPOVZHCZSA-N	3035442.0		RDJQCOBTKKAQAH
BRD-K24610819-003-01-8	amibegron	Phase 3	adrenergic receptor agonist	ADRB3			0	97.85	Sigma	MFCD00886563	ethyl [((7S)-7-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]acetate hydrochloride	403.155	CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1	RDJQCOBTKKAQAH-FPOVZHCZSA-N	3035442.0		RDJQCOBTKKAQAH
BRD-K12568846-001-17-9	amidopyrine	Launched	analgesic agent		dermatology	dermatitis herpetiformis (DH)	0	95.76	MedChemEx	HY-B0533	Amidopyrine	231.137	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	RMMXTBMQSGEXHJ-UHFFFAOYSA-N	6009.0		RMMXTBMQSGEXHJ
BRD-K12568846-001-15-3	amidopyrine	Launched	analgesic agent		dermatology	dermatitis herpetiformis (DH)	0	0.0	MicroSource	1500621	AMINOPYRINE	231.137	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	RMMXTBMQSGEXHJ-UHFFFAOYSA-N	6009.0		RMMXTBMQSGEXHJ
BRD-K12568846-001-14-6	amidopyrine	Launched	analgesic agent		dermatology	dermatitis herpetiformis (DH)	0	86.35	Selleck	S3209	Amidopyrine	231.137	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	RMMXTBMQSGEXHJ-UHFFFAOYSA-N	6009.0		RMMXTBMQSGEXHJ
BRD-K12568846-001-16-1	amidopyrine	Launched	analgesic agent		dermatology	dermatitis herpetiformis (DH)	0	94.77	Selleck	S3209	Amidopyrine	231.137	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	RMMXTBMQSGEXHJ-UHFFFAOYSA-N	6009.0		RMMXTBMQSGEXHJ
BRD-K80262108-001-07-0	amifampridine	Launched	potassium channel blocker		neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	0	89.6	MedChemEx	HY-14946	Amifampridine	109.064	Nc1ccncc1N	OYTKINVCDFNREN-UHFFFAOYSA-N	5918.0		OYTKINVCDFNREN
BRD-K80262108-001-08-9	amifampridine	Launched	potassium channel blocker		neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	0	100.0	MedChemEx	HY-14946	Pyridine-3,4-diamine	109.064	Nc1ccncc1N	OYTKINVCDFNREN-UHFFFAOYSA-N	5918.0		OYTKINVCDFNREN
BRD-A19401019-001-01-3	amiflamine	Phase 1	monoamine oxidase inhibitor	MAOA|SLC6A2			0	69.64	Enamine	Z2327040082	N-[4-(2-aminopropyl)-3-methylphenyl]-N,N-dimethylamine	192.163	C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1,r|	HFQMYSHATTXRTC-SNVBAGLBSA-N	6336525.0		HFQMYSHATTXRTC
BRD-K73947551-001-04-4	amifostine	Launched	reducing agent	ALPPL2|ENPP1	nephrology	renal toxicity	1	0.0	MicroSource	1503081	AMIFOSTINE	214.054	NCCCNCCSP(O)(O)=O	JKOQGQFVAUAYPM-UHFFFAOYSA-N	29927142.0		JKOQGQFVAUAYPM
BRD-K88043978-002-08-9	amikacin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	100.0	MicroSource	1500111	AMIKACIN HYDRATE	585.286	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	LKCWBDHBTVXHDL-RMDFUYIESA-N	37768.0		LKCWBDHBTVXHDL
BRD-K88043978-002-09-7	amikacin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	11.49	Selleck	S3122	Amikacin hydrate	585.286	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	LKCWBDHBTVXHDL-RMDFUYIESA-N	37768.0	BRD-U46375448-000-01-5	LKCWBDHBTVXHDL
BRD-K88043978-315-02-8	amikacin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	Selleck	S3065	Amikacin sulfate	585.286	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	LKCWBDHBTVXHDL-RMDFUYIESA-N	37768.0		LKCWBDHBTVXHDL
BRD-K88043978-315-11-9	amikacin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-B0509B	Amikacin (sulfate)	585.286	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	LKCWBDHBTVXHDL-RMDFUYIESA-N	37768.0		LKCWBDHBTVXHDL
BRD-K88043978-315-03-6	amikacin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	Selleck	S3065	Amikacin sulfate	585.286	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	LKCWBDHBTVXHDL-RMDFUYIESA-N	37768.0	BRD-K50698959-315-01-8	LKCWBDHBTVXHDL
BRD-K88043978-002-10-5	amikacin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	Selleck	S3122	Amikacin hydrate	585.286	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	LKCWBDHBTVXHDL-RMDFUYIESA-N	37768.0	BRD-U73512331-000-01-9	LKCWBDHBTVXHDL
BRD-K97181089-003-24-7	amiloride	Launched	sodium channel blocker	AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2	cardiology	hypertension|congestive heart failure	0	99.74	MicroSource	1500112	AMILORIDE HYDROCHLORIDE	229.048	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	XSDQTOBWRPYKKA-UHFFFAOYSA-N	16231.0		XSDQTOBWRPYKKA
BRD-K97181089-003-25-9	amiloride	Launched	sodium channel blocker	AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2	cardiology	hypertension|congestive heart failure	0	94.61	Tocris	890	Amiloride hydrochloride	229.048	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	XSDQTOBWRPYKKA-UHFFFAOYSA-N	16231.0		XSDQTOBWRPYKKA
BRD-K97181089-310-06-3	amiloride	Launched	sodium channel blocker	AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2	cardiology	hypertension|congestive heart failure	0	97.73	Selleck	S2560	Amiloride hydrochloride dihydrate	229.048	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	XSDQTOBWRPYKKA-UHFFFAOYSA-N	16231.0		XSDQTOBWRPYKKA
BRD-K97181089-003-22-1	amiloride	Launched	sodium channel blocker	AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2	cardiology	hypertension|congestive heart failure	0	97.32	Selleck	S1811	Amiloride HCl	229.048	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	XSDQTOBWRPYKKA-UHFFFAOYSA-N	16231.0		XSDQTOBWRPYKKA
BRD-K97181089-003-23-9	amiloride	Launched	sodium channel blocker	AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2	cardiology	hypertension|congestive heart failure	0	96.11	Tocris	890	Amiloride hydrochloride	229.048	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	XSDQTOBWRPYKKA-UHFFFAOYSA-N	16231.0		XSDQTOBWRPYKKA
BRD-K24219278-001-01-6	amineptine	Withdrawn	dopamine receptor agonist	SLC6A2|SLC6A4			0	97.45	MedChemEx	HY-16044	Amineptine	337.204	OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12	ONNOFKFOZAJDHT-UHFFFAOYSA-N	38988248.0		ONNOFKFOZAJDHT
BRD-K24219278-001-02-9	amineptine	Withdrawn	dopamine receptor agonist	SLC6A2|SLC6A4			0	96.32	MedChemEx	HY-16044	Amineptine	337.204	OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12	ONNOFKFOZAJDHT-UHFFFAOYSA-N	38988248.0		ONNOFKFOZAJDHT
BRD-K64931368-003-01-4	aminocaproic-acid	Launched	plasminogen activator inhibitor	LPA|PLAT|PLG	hematology	fibrinolytic bleeding	0	100.0	MicroSource	1500114	AMINOCAPROIC ACID HYDROCHLORIDE	131.095	NCCCCCC(O)=O	SLXKOJJOQWFEFD-UHFFFAOYSA-N	564.0		SLXKOJJOQWFEFD
BRD-K64931368-001-14-1	aminocaproic-acid	Launched	plasminogen activator inhibitor	LPA|PLAT|PLG	hematology	fibrinolytic bleeding	0	0.0	Selleck	S1671	??6-????-Aminocaproic acid	131.095	NCCCCCC(O)=O	SLXKOJJOQWFEFD-UHFFFAOYSA-N	564.0		SLXKOJJOQWFEFD
BRD-K64931368-001-13-3	aminocaproic-acid	Launched	plasminogen activator inhibitor	LPA|PLAT|PLG	hematology	fibrinolytic bleeding	0	0.0	Selleck	S1671	?6-??-?Aminocaproic acid	131.095	NCCCCCC(O)=O	SLXKOJJOQWFEFD-UHFFFAOYSA-N	564.0		SLXKOJJOQWFEFD
BRD-A25234499-001-18-3	aminoglutethimide	Launched	glucocorticoid receptor antagonist	CYP11A1|CYP19A1	endocrinology|oncology	Cushing's syndrome|breast cancer	0	93.51	MicroSource	1500115	AMINOGLUTETHIMIDE	232.121	CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|	ROBVIMPUHSLWNV-ZDUSSCGKSA-N	1548995.0		ROBVIMPUHSLWNV
BRD-A25234499-001-19-1	aminoglutethimide	Launched	glucocorticoid receptor antagonist	CYP11A1|CYP19A1	endocrinology|oncology	Cushing's syndrome|breast cancer	0	94.21	Selleck	S1672	Aminoglutethimide (Cytadren)	232.121	CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|	ROBVIMPUHSLWNV-ZDUSSCGKSA-N	1548995.0		ROBVIMPUHSLWNV
BRD-A25234499-001-17-5	aminoglutethimide	Launched	glucocorticoid receptor antagonist	CYP11A1|CYP19A1	endocrinology|oncology	Cushing's syndrome|breast cancer	0	87.53	Selleck	S1672	Aminoglutethimide	232.121	CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|	ROBVIMPUHSLWNV-ZDUSSCGKSA-N	1548995.0		ROBVIMPUHSLWNV
BRD-A25234499-001-21-9	aminoglutethimide	Launched	glucocorticoid receptor antagonist	CYP11A1|CYP19A1	endocrinology|oncology	Cushing's syndrome|breast cancer	0	90.92	MedChemEx	HY-B0237	Aminoglutethimide	232.121	CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2,r|	ROBVIMPUHSLWNV-ZDUSSCGKSA-N	1548995.0		ROBVIMPUHSLWNV
BRD-K25114078-003-08-1	aminoguanidine	Phase 3	nitric oxide synthase inhibitor	AKR1B1|NOS2|TIMP3			0	100.0	MicroSource	1506176	PIMAGEDINE HYDROCHLORIDE	74.059	NN=C(N)N	HAMNKKUPIHEESI-UHFFFAOYSA-N	2146.0		HAMNKKUPIHEESI
BRD-K25114078-003-10-9	aminoguanidine	Phase 3	nitric oxide synthase inhibitor	AKR1B1|NOS2|TIMP3			0	0.0	Tocris	787	Aminoguanidine hydrochloride	74.059	NN=C(N)N	HAMNKKUPIHEESI-UHFFFAOYSA-N	2146.0		HAMNKKUPIHEESI
BRD-K25114078-003-07-3	aminoguanidine	Phase 3	nitric oxide synthase inhibitor	AKR1B1|NOS2|TIMP3			0	94.99	Tocris	787	Aminoguanidine hydrochloride	74.059	NN=C(N)N	HAMNKKUPIHEESI-UHFFFAOYSA-N	2146.0		HAMNKKUPIHEESI
BRD-A40777960-001-04-2	aminohydroxybutyric-acid	Launched			neurology/psychiatry	epilepsy	0	78.63	MicroSource	1503041	AMINOHYDROXYBUTYRIC ACID	119.058	NC[C@@H](O)CC(O)=O |&1:2,r|	YQGDEPYYFWUPGO-VKHMYHEASA-N	6971281.0		YQGDEPYYFWUPGO
BRD-A40777960-001-05-9	aminohydroxybutyric-acid	Launched			neurology/psychiatry	epilepsy	0	28.96	Sigma	MFCD00008141	DL-4-AMINO-3-HYDROXYBUTYRIC ACID	119.058	NC[C@@H](O)CC(O)=O |&1:2,r|	YQGDEPYYFWUPGO-VKHMYHEASA-N	6971281.0		YQGDEPYYFWUPGO
BRD-K59998349-003-01-4	aminolevulinic-acid-benzyl-ester	Phase 1					0	94.33	ChemImpex	20989		221.105	NCC(=O)CCC(=O)OCc1ccccc1	AFFZCQDLQIEQGB-UHFFFAOYSA-N	9964521.0		AFFZCQDLQIEQGB
BRD-A28318179-003-09-9	aminomethyltransferase	Preclinical	nitric oxide synthase inhibitor	NOS2			0	96.29	Tocris	871	AMT hydrochloride	130.056	C[C@H]1CCN=C(N)S1 |&1:1,t:4|	BATVOUKHGLKDGQ-BYPYZUCNSA-N	7059445.0		BATVOUKHGLKDGQ
BRD-A28318179-003-08-5	aminomethyltransferase	Preclinical	nitric oxide synthase inhibitor	NOS2			0	92.48	Tocris	871	AMT hydrochloride	130.056	C[C@H]1CCN=C(N)S1 |&1:1,t:4|	BATVOUKHGLKDGQ-BYPYZUCNSA-N	7059445.0		BATVOUKHGLKDGQ
BRD-A69917777-065-02-2	aminopentamide	Launched	acetylcholine receptor antagonist	CHRM1	gastroenterology	acute abdominal visceral spasm|hypertrophic gastritis (GHG)|nausea	0	97.37	MicroSource	1505650	AMINOPENTAMIDE SULFATE	296.189	CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C	NARHAGIVSFTMIG-UHFFFAOYSA-N	176163.0		NARHAGIVSFTMIG
BRD-K97799481-205-02-7	aminophylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	pulmonary	asthma|bronchitis|emphysema	0	97.33	Key	KS-1426	2-hydroxy-N,N,N-trimethylethanaminium 1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurin-7-ide	180.065	Cn1c2nc[nH]c2c(=O)n(C)c1=O	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	2153.0		ZFXYFBGIUFBOJW
BRD-K97799481-205-01-9	aminophylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	pulmonary	asthma|bronchitis|emphysema	0	60.29	MicroSource	1505759	OXTRIPHYLLINE	180.065	Cn1c2nc[nH]c2c(=O)n(C)c1=O	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	2153.0		ZFXYFBGIUFBOJW
BRD-K97799481-230-01-7	aminophylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	pulmonary	asthma|bronchitis|emphysema	0	97.12	Selleck	S1673	Aminophylline	180.065	Cn1c2nc[nH]c2c(=O)n(C)c1=O	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	2153.0	BRD-M53001068-230-06-8	ZFXYFBGIUFBOJW
BRD-K97799481-001-16-0	aminophylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	pulmonary	asthma|bronchitis|emphysema	0	98.81	MicroSource	1500568	THEOPHYLLINE	180.065	Cn1c2nc[nH]c2c(=O)n(C)c1=O	ZFXYFBGIUFBOJW-UHFFFAOYSA-N	2153.0		ZFXYFBGIUFBOJW
BRD-K87544030-001-02-8	aminopterin	Phase 3	dihydrofolate reductase inhibitor	DHFR|SLC46A1			0	0.0	MicroSource	1500679	AMINOPTERIN	440.156	Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	TVZGACDUOSZQKY-LBPRGKRZSA-N	169371.0	BRD-A86736466-001-05-9	TVZGACDUOSZQKY
BRD-K87544030-001-01-0	aminopterin	Phase 3	dihydrofolate reductase inhibitor	DHFR|SLC46A1			0	0.0	Sigma	MFCD00036692	(2S)-2-[(4-{[(2,4-diamino-6-pteridinyl)methyl]amino}benzoyl)amino]pentanedioic acid	440.156	Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	TVZGACDUOSZQKY-LBPRGKRZSA-N	169371.0		TVZGACDUOSZQKY
BRD-K07762753-001-06-9	aminopurvalanol-a	Preclinical	CDK inhibitor|tyrosine kinase inhibitor	CDK1|CDK2|CDK5			0	95.56	Tocris	2072	Aminopurvalanol A	403.189	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	RAMROQQYRRQPDL-HNNXBMFYSA-N	6604931.0		RAMROQQYRRQPDL
BRD-K07762753-001-05-1	aminopurvalanol-a	Preclinical	CDK inhibitor|tyrosine kinase inhibitor	CDK1|CDK2|CDK5			0	94.2	Tocris	2072	Aminopurvalanol A	403.189	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	RAMROQQYRRQPDL-HNNXBMFYSA-N	6604931.0		RAMROQQYRRQPDL
BRD-K07762753-001-04-4	aminopurvalanol-a	Preclinical	CDK inhibitor|tyrosine kinase inhibitor	CDK1|CDK2|CDK5			0	94.83	Tocris	2072	Aminopurvalanol A	403.189	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	RAMROQQYRRQPDL-HNNXBMFYSA-N	6604931.0		RAMROQQYRRQPDL
BRD-K80267133-001-17-7	aminosalicylate	Launched	cyclooxygenase inhibitor	ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2	gastroenterology	inflammatory bowel disease|ulcerative colitis	0	87.06	MicroSource	1500116	AMINOSALICYLATE SODIUM	153.043	Nc1ccc(C(O)=O)c(O)c1	WUBBRNOQWQTFEX-UHFFFAOYSA-N	4649.0	BRD-M65097687-001-19-1	WUBBRNOQWQTFEX
BRD-K80267133-325-22-9	aminosalicylate	Launched	cyclooxygenase inhibitor	ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2	gastroenterology	inflammatory bowel disease|ulcerative colitis	0	97.38	MedChemEx	HY-I0447A	Sodium 4-aminosalicylate dihydrate	153.043	Nc1ccc(C(O)=O)c(O)c1	WUBBRNOQWQTFEX-UHFFFAOYSA-N	4649.0		WUBBRNOQWQTFEX
BRD-K80267133-001-18-5	aminosalicylate	Launched	cyclooxygenase inhibitor	ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2	gastroenterology	inflammatory bowel disease|ulcerative colitis	0	79.77	Selleck	S4073	Sodium 4-Aminosalicylate	153.043	Nc1ccc(C(O)=O)c(O)c1	WUBBRNOQWQTFEX-UHFFFAOYSA-N	4649.0	BRD-M65097687-001-18-3	WUBBRNOQWQTFEX
BRD-K80267133-001-19-3	aminosalicylate	Launched	cyclooxygenase inhibitor	ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2	gastroenterology	inflammatory bowel disease|ulcerative colitis	0	97.87	Selleck	S4073	Aminosalicylate Sodium	153.043	Nc1ccc(C(O)=O)c(O)c1	WUBBRNOQWQTFEX-UHFFFAOYSA-N	4649.0	BRD-M65097687-001-20-9	WUBBRNOQWQTFEX
BRD-K94837153-001-02-8	aminothiadiazole	Phase 2	inosine monophosphate dehydrogenase inhibitor	ADORA3|IMPDH1			0	0.0	Enamine	EN300-17228	1,3,4-thiadiazol-2-amine	101.005	Nc1nncs1	QUKGLNCXGVWCJX-UHFFFAOYSA-N	19909.0		QUKGLNCXGVWCJX
BRD-K94837153-001-01-0	aminothiadiazole	Phase 2	inosine monophosphate dehydrogenase inhibitor	ADORA3|IMPDH1			0	0.0	Vitas-M	STK398099		101.005	Nc1nncs1	QUKGLNCXGVWCJX-UHFFFAOYSA-N	19909.0		QUKGLNCXGVWCJX
BRD-K13421763-001-06-2	aminothiazole	Preclinical	cyclin D inhibitor	NOS2			0	98.31	MicroSource	1503017	AMINOTHIAZOLE	100.01	Nc1nccs1	RAIPHJJURHTUIC-UHFFFAOYSA-N	2155.0		RAIPHJJURHTUIC
BRD-K13421763-001-05-4	aminothiazole	Preclinical	cyclin D inhibitor	NOS2			0	72.72	Selleck	S4198	Aminothiazole	100.01	Nc1nccs1	RAIPHJJURHTUIC-UHFFFAOYSA-N	2155.0		RAIPHJJURHTUIC
BRD-K13421763-001-07-0	aminothiazole	Preclinical	cyclin D inhibitor	NOS2			0	0.0	Selleck	S4198	Aminothiazole	100.01	Nc1nccs1	RAIPHJJURHTUIC-UHFFFAOYSA-N	2155.0		RAIPHJJURHTUIC
BRD-K17561142-003-33-3	amiodarone	Launched	potassium channel blocker	ADRB1|CACNA1H|CACNA2D2|KCNA7|KCNH2	cardiology	ventricular arrhythmias	0	82.49	MicroSource	2300165	AMIODARONE HYDROCHLORIDE	645.024	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	IYIKLHRQXLHMJQ-UHFFFAOYSA-N	2157.0		IYIKLHRQXLHMJQ
BRD-K17561142-003-35-8	amiodarone	Launched	potassium channel blocker	ADRB1|CACNA1H|CACNA2D2|KCNA7|KCNH2	cardiology	ventricular arrhythmias	0	97.72	Selleck	S1979	Amiodarone HCl	645.024	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	IYIKLHRQXLHMJQ-UHFFFAOYSA-N	2157.0		IYIKLHRQXLHMJQ
BRD-K17561142-003-32-5	amiodarone	Launched	potassium channel blocker	ADRB1|CACNA1H|CACNA2D2|KCNA7|KCNH2	cardiology	ventricular arrhythmias	0	87.98	Selleck	S1979	Amiodarone HCl	645.024	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	IYIKLHRQXLHMJQ-UHFFFAOYSA-N	2157.0		IYIKLHRQXLHMJQ
BRD-K97643133-003-09-3	amiprilose	Phase 3	CD antagonist				0	96.74	Prestwick	Prestw-845	Amiprilose hydrochloride	305.184	CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	YXBQLONCIPUQKO-UJPOAAIJSA-N	121928.0		YXBQLONCIPUQKO
BRD-K00003223-003-01-9	amiselimod	Phase 2	sphingosine 1-phosphate receptor modulator				0	90.67	MedChemEx	HY-16734A	Amiselimod (hydrochloride)	377.218	CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F	JVCPIJKPAKAIIP-UHFFFAOYSA-N	16129483.0		JVCPIJKPAKAIIP
BRD-A60197193-001-13-8	amisulpride	Launched	dopamine receptor antagonist	DRD2	neurology/psychiatry	psychosis|bipolar disorder|schizophrenia	0	92.5	Selleck	S1280	Amisulpride	369.172	CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|	NTJOBXMMWNYJFB-GFCCVEGCSA-N	5746246.0		NTJOBXMMWNYJFB
BRD-A60197193-001-14-6	amisulpride	Launched	dopamine receptor antagonist	DRD2	neurology/psychiatry	psychosis|bipolar disorder|schizophrenia	0	94.44	Tocris	2132	Amisulpride	369.172	CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6,r|	NTJOBXMMWNYJFB-GFCCVEGCSA-N	5746246.0		NTJOBXMMWNYJFB
BRD-A68942014-003-01-7	amitifadine	Phase 3	serotonin transporter (SERT) inhibitor	SLC6A2|SLC6A3|SLC6A4			0	97.84	TygerSci	D40030	1-(3,4-Dichloro-phenyl)-3-aza-bicyclo[3.1.0]hexane HCl	227.027	Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8,&2:10|	BSMNRYCSBFHEMQ-KCJUWKMLSA-N	11658655.0		BSMNRYCSBFHEMQ
BRD-K33335792-001-04-0	amitraz	Launched	adrenergic receptor agonist	ADRA1A|ADRA2A	infectious disease	generalized demodicosis	0	0.09	MicroSource	1505299	AMITRAZ	293.189	CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C	QXAITBQSYVNQDR-ZIOPAAQOSA-N			QXAITBQSYVNQDR
BRD-K33335792-001-05-9	amitraz	Launched	adrenergic receptor agonist	ADRA1A|ADRA2A	infectious disease	generalized demodicosis	0	69.18	MedChemEx	HY-B1111	Amitraz	293.189	CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C	QXAITBQSYVNQDR-ZIOPAAQOSA-N			QXAITBQSYVNQDR
BRD-K53737926-003-27-8	amitriptyline	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4	neurology/psychiatry	depression	0	98.47	MicroSource	1500117	AMITRIPTYLINE HYDROCHLORIDE	277.183	CN(C)CCC=C1c2ccccc2CCc2ccccc12	KRMDCWKBEZIMAB-UHFFFAOYSA-N	2160.0		KRMDCWKBEZIMAB
BRD-K53737926-003-25-2	amitriptyline	Launched	norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotoninnorepinephrine reuptake inhibitor (SNRI)	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4	neurology/psychiatry	depression	0	97.28	Selleck	S3183	Amitriptyline HCl	277.183	CN(C)CCC=C1c2ccccc2CCc2ccccc12	KRMDCWKBEZIMAB-UHFFFAOYSA-N	2160.0		KRMDCWKBEZIMAB
BRD-K29530284-001-08-9	amlexanox	Launched	histamine receptor modulator	FGF1|IL3|PDE4A|PDE4B|PDE4C|PDE4D|S100A12|S100A13	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis	0	95.58	Tocris	4857	Amlexanox	298.095	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	SGRYPYWGNKJSDL-UHFFFAOYSA-N	2161.0		SGRYPYWGNKJSDL
BRD-K29530284-001-06-2	amlexanox	Launched	histamine receptor modulator	FGF1|IL3|PDE4A|PDE4B|PDE4C|PDE4D|S100A12|S100A13	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis	0	99.58	MicroSource	1502377	AMLEXANOX	298.095	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	SGRYPYWGNKJSDL-UHFFFAOYSA-N	2161.0		SGRYPYWGNKJSDL
BRD-K29530284-001-07-0	amlexanox	Launched	histamine receptor modulator	FGF1|IL3|PDE4A|PDE4B|PDE4C|PDE4D|S100A12|S100A13	dental|pulmonary|ophthalmology|allergy	aphthous ulcers|asthma|conjunctivitis|allergic rhinitis	0	97.67	Tocris	4857	Amlexanox	298.095	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	SGRYPYWGNKJSDL-UHFFFAOYSA-N	2161.0		SGRYPYWGNKJSDL
BRD-K01825117-074-11-9	amlodipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNA2D1	cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)	0	89.83	Tocris	2571	O3-ethyl O5-methyl rac-(4R)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate	408.145	CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|	HTIQEAQVCYTUBX-QGZVFWFLSA-N	9801597.0		HTIQEAQVCYTUBX
BRD-K01825117-001-06-9	amlodipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNA2D1	cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)	0	74.12	Selleck	S1905	O3-ethyl O5-methyl rac-(4R)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate	408.145	CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|	HTIQEAQVCYTUBX-QGZVFWFLSA-N	9801597.0		HTIQEAQVCYTUBX
BRD-K01825117-001-07-9	amlodipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNA2D1	cardiology	hypertension|chronic stable angina|vasospastic angina|coronary artery disease (CAD)	0	80.32	Selleck	S1905	O3-ethyl O5-methyl rac-(4R)-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate	408.145	CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16,r,c:5,14|	HTIQEAQVCYTUBX-QGZVFWFLSA-N	9801597.0		HTIQEAQVCYTUBX
BRD-K83486494-001-02-9	ammonium-glycyrrhizinate	Launched	thrombin inhibitor	HSD11B1|HSD11B2|SLCO1B1|SLCO1B3	dermatology	cosmetic	0	66.0	MedChemEx	HY-N0184	Glycyrrhizic acid	822.404	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|	LPLVUJXQOOQHMX-QWBHMCJMSA-N	14982.0		LPLVUJXQOOQHMX
BRD-M29182745-001-01-4	ammonium-lactate	Launched		HCAR1	dermatology	xerosis cutis|ichthyosis vulgaris	1	0.0	MicroSource	1506202	AMMONIUM LACTATE	107.058	N.C[C@@H](O)C(O)=O |&1:2,r|	RZOBLYBZQXQGFY-HSHFZTNMSA-N	10313098.0		RZOBLYBZQXQGFY
BRD-M29182745-001-02-2	ammonium-lactate	Launched		HCAR1	dermatology	xerosis cutis|ichthyosis vulgaris	1	0.0	Selleck	S5625	AMMONIUM LACTATE	107.058	N.C[C@@H](O)C(O)=O |&1:2,r|	RZOBLYBZQXQGFY-HSHFZTNMSA-N	10313098.0		RZOBLYBZQXQGFY
BRD-K32531356-001-03-9	ammonium-perfluorocaprylate	Phase 1	Pim kinase inhibitor	PIM1			0	100.0	Sigma	MFCD00004174	Perfluorooctanoic acid	413.974	OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	SNGREZUHAYWORS-UHFFFAOYSA-N	9554.0		SNGREZUHAYWORS
BRD-K32531356-001-01-9	ammonium-perfluorocaprylate	Phase 1	Pim kinase inhibitor	PIM1			0	54.3	Enamine	Z104477538		413.974	OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	SNGREZUHAYWORS-UHFFFAOYSA-N	9554.0		SNGREZUHAYWORS
BRD-K23335153-300-03-3	AMN-082	Preclinical	glutamate receptor modulator	GRM7			0	91.68	Tocris	2385	AMN 082 dihydrochloride	392.225	C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	DTZDSNQYNPNCPK-UHFFFAOYSA-N	1894361.0		DTZDSNQYNPNCPK
BRD-K23335153-300-02-5	AMN-082	Preclinical	glutamate receptor modulator	GRM7			0	91.79	Tocris	2385	AMN 082 dihydrochloride	392.225	C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	DTZDSNQYNPNCPK-UHFFFAOYSA-N	1894361.0		DTZDSNQYNPNCPK
BRD-K23335153-300-08-9	AMN-082	Preclinical	glutamate receptor modulator	GRM7			0	94.33	Tocris	2385	AMN 082 dihydrochloride	392.225	C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	DTZDSNQYNPNCPK-UHFFFAOYSA-N	1894361.0		DTZDSNQYNPNCPK
BRD-K91290917-300-01-8	amodiaquine	Launched	histamine receptor agonist	HNMT	infectious disease	malaria	0	98.24	MicroSource	1500119	AMODIAQUINE DIHYDROCHLORIDE	355.145	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	OVCDSSHSILBFBN-UHFFFAOYSA-N	3647519.0	BRD-K73443792-300-04-9	OVCDSSHSILBFBN
BRD-K91290917-336-05-3	amodiaquine	Launched	histamine receptor agonist	HNMT	infectious disease	malaria	0	98.0	Prestwick	Prestw-309	Amodiaquin dihydrochloride dihydrate	355.145	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	OVCDSSHSILBFBN-UHFFFAOYSA-N	3647519.0		OVCDSSHSILBFBN
BRD-K56334280-001-05-1	amonafide	Phase 3	topoisomerase inhibitor	TOP2A|TOP2B			0	90.78	Selleck	S1367	Amonafide	283.132	CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	UPALIKSFLSVKIS-UHFFFAOYSA-N	50515.0		UPALIKSFLSVKIS
BRD-A37390343-003-03-5	amorolfine	Launched	membrane integrity inhibitor		infectious disease	onychomycosis	0	96.04	MicroSource	1502371	AMOROLFINE HYDROCHLORIDE	317.272	CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|	MQHLMHIZUIDKOO-KURKYZTESA-N	25790581.0		MQHLMHIZUIDKOO
BRD-A37390343-003-02-7	amorolfine	Launched	membrane integrity inhibitor		infectious disease	onychomycosis	0	94.99	Selleck	S1676	Amorolfine HCl	317.272	CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|	MQHLMHIZUIDKOO-KURKYZTESA-N	25790581.0		MQHLMHIZUIDKOO
BRD-A37390343-003-04-3	amorolfine	Launched	membrane integrity inhibitor		infectious disease	onychomycosis	0	97.1	Selleck	S1676	Amorolfine Hydrochloride	317.272	CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15,18,&1:10|	MQHLMHIZUIDKOO-KURKYZTESA-N	25790581.0		MQHLMHIZUIDKOO
BRD-K02265150-001-26-5	amoxapine	Launched	norepinephrine reputake inhibitor	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH4|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	92.24	MicroSource	2300161	AMOXAPINE	313.098	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|	QWGDMFLQWFTERH-UHFFFAOYSA-N	2170.0		QWGDMFLQWFTERH
BRD-K02265150-001-25-7	amoxapine	Launched	norepinephrine reputake inhibitor	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH4|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	76.75	Selleck	S4218	Amoxapine	313.098	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|	QWGDMFLQWFTERH-UHFFFAOYSA-N	2170.0		QWGDMFLQWFTERH
BRD-K02265150-001-27-3	amoxapine	Launched	norepinephrine reputake inhibitor	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH4|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	96.84	Selleck	S4218	Amoxapine	313.098	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|	QWGDMFLQWFTERH-UHFFFAOYSA-N	2170.0		QWGDMFLQWFTERH
BRD-K55044200-001-16-1	amoxicillin	Launched	penicillin binding protein inhibitor	CYP2C19|SLC15A1|SLC15A2|SLC22A6	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections	0	54.76	MicroSource	1500120	AMOXICILLIN	365.105	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	40467057.0	BRD-K08635111-001-04-8	LSQZJLSUYDQPKJ
BRD-K55044200-236-03-1	amoxicillin	Launched	penicillin binding protein inhibitor	CYP2C19|SLC15A1|SLC15A2|SLC22A6	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections	0	77.12	MedChemEx	HY-B0467	Amoxicillin (sodium)	365.105	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	40467057.0		LSQZJLSUYDQPKJ
BRD-K55044200-236-02-3	amoxicillin	Launched	penicillin binding protein inhibitor	CYP2C19|SLC15A1|SLC15A2|SLC22A6	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections	0	64.88	Selleck	S2565	Amoxicillin sodium (Amox)	365.105	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	40467057.0		LSQZJLSUYDQPKJ
BRD-K55044200-236-04-9	amoxicillin	Launched	penicillin binding protein inhibitor	CYP2C19|SLC15A1|SLC15A2|SLC22A6	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections	0	55.7	Selleck	S2565	Amoxicillin Sodium	365.105	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	40467057.0	BRD-K39234907-236-01-9	LSQZJLSUYDQPKJ
BRD-K55044200-001-15-3	amoxicillin	Launched	penicillin binding protein inhibitor	CYP2C19|SLC15A1|SLC15A2|SLC22A6	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections	0	78.91	Selleck	S3015	Amoxicillin	365.105	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	40467057.0	BRD-K58632460-001-01-7	LSQZJLSUYDQPKJ
BRD-K55044200-001-14-6	amoxicillin	Launched	penicillin binding protein inhibitor	CYP2C19|SLC15A1|SLC15A2|SLC22A6	infectious disease|gastroenterology	skin infections|duodenal ulcer disease|gonorrhea|ear infections|throat infections|genitourinary tract infections|respiratory tract infections	0	96.19	Selleck	S3015	Amoxicillin (Amoxycillin)	365.105	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	LSQZJLSUYDQPKJ-NJBDSQKTSA-N	40467057.0		LSQZJLSUYDQPKJ
BRD-K01826817-001-04-9	AMPA-(RS)	Preclinical	glutamate receptor agonist	GRIN1			0	100.0	Tocris	169	(RS)-AMPA	186.064	Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|	UUDAMDVQRQNNHZ-RXMQYKEDSA-N	7059442.0		UUDAMDVQRQNNHZ
BRD-K01826817-004-03-9	AMPA-(RS)	Preclinical	glutamate receptor agonist	GRIN1			0	86.94	Tocris	1074	(RS)-AMPA hydrobromide	265.99	Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|	UUDAMDVQRQNNHZ-RXMQYKEDSA-N	7059442.0		UUDAMDVQRQNNHZ
BRD-K92493880-001-03-0	AMPA-(S)	Preclinical	glutamate receptor agonist	GRIA2|GRIN1			0	87.14	Tocris	254	(S)-AMPA	186.064	Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O	UUDAMDVQRQNNHZ-YFKPBYRVSA-N	7000183.0		UUDAMDVQRQNNHZ
BRD-K92493880-001-04-9	AMPA-(S)	Preclinical	glutamate receptor agonist	GRIA2|GRIN1			0	100.0	Tocris	254	(S)-AMPA	186.064	Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O	UUDAMDVQRQNNHZ-YFKPBYRVSA-N	7000183.0		UUDAMDVQRQNNHZ
BRD-K24771047-001-02-9	ampalex	Phase 2	glutamate receptor agonist	GRIA1|GRIA2|GRIA3|GRIA4			0	96.36	MedChemEx	HY-10933	Ampalex	241.122	O=C(N1CCCCC1)c1ccc2nccnc2c1	ANDGGVOPIJEHOF-UHFFFAOYSA-N	148184.0		ANDGGVOPIJEHOF
BRD-K24771047-001-01-6	ampalex	Phase 2	glutamate receptor agonist	GRIA1|GRIA2|GRIA3|GRIA4			0	99.54	MedChemEx	HY-10933	Ampalex	241.122	O=C(N1CCCCC1)c1ccc2nccnc2c1	ANDGGVOPIJEHOF-UHFFFAOYSA-N	148184.0		ANDGGVOPIJEHOF
BRD-K52397688-003-06-4	amperozide	Launched	dopamine receptor antagonist	FAAH|HTR2A	neurology/psychiatry	psychosis	0	98.96	Enzo	AC1367	Amperozide	401.228	CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	NNAIYOXJNVGUOM-UHFFFAOYSA-N	73333.0		NNAIYOXJNVGUOM
BRD-K52397688-003-07-2	amperozide	Launched	dopamine receptor antagonist	FAAH|HTR2A	neurology/psychiatry	psychosis	0	95.92	SantaCruz	sc-203512	Amperozide hydrochloride	401.228	CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	NNAIYOXJNVGUOM-UHFFFAOYSA-N	73333.0		NNAIYOXJNVGUOM
BRD-K27352494-001-04-4	amphotericin-b	Launched	membrane permeability enhancer		infectious disease	fungal infection	0	0.0	MicroSource	1500122	AMPHOTERICIN B	923.488	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|	APKFDSVGJQXUKY-ZNVUZQDLSA-N	91827561.0	BRD-A75647097-001-03-3	APKFDSVGJQXUKY
BRD-K27352494-001-03-6	amphotericin-b	Launched	membrane permeability enhancer		infectious disease	fungal infection	0	74.84	Selleck	S1636	Amphotericin B	923.488	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|	APKFDSVGJQXUKY-ZNVUZQDLSA-N	91827561.0		APKFDSVGJQXUKY
BRD-K27352494-001-05-1	amphotericin-b	Launched	membrane permeability enhancer		infectious disease	fungal infection	0	0.0	MedChemEx	HY-B0221	Amphotericin B	923.488	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|	APKFDSVGJQXUKY-ZNVUZQDLSA-N	91827561.0	BRD-K94561406-001-01-1	APKFDSVGJQXUKY
BRD-K27352494-001-06-9	amphotericin-b	Launched	membrane permeability enhancer		infectious disease	fungal infection	0	0.0	Selleck	S1636	Amphotericin B	923.488	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,50,52,54,56,58|	APKFDSVGJQXUKY-ZNVUZQDLSA-N	91827561.0	BRD-K82702594-001-02-5|BRD-K69849489-001-01-1	APKFDSVGJQXUKY
BRD-K68432770-236-24-9	ampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	0	84.41	MedChemEx	HY-B0522A	Ampicillin (sodium)	349.11	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N	7048611.0		AVKUERGKIZMTKX
BRD-K68432770-236-20-7	ampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	0	11.12	MicroSource	1500123	AMPICILLIN SODIUM	349.11	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N	7048611.0		AVKUERGKIZMTKX
BRD-K68432770-236-23-1	ampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	0	76.31	MedChemEx	HY-B0522A	Ampicillin (sodium)	349.11	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N	7048611.0		AVKUERGKIZMTKX
BRD-K68432770-236-22-3	ampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	0	73.48	Sigma	MFCD00064313	sodium (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylethanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	349.11	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N	7048611.0		AVKUERGKIZMTKX
BRD-K68432770-236-21-5	ampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	0	19.53	Selleck	S3170	Ampicillin sodium	349.11	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N	7048611.0		AVKUERGKIZMTKX
BRD-K68432770-236-19-9	ampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	0	61.66	Selleck	S3170	Ampicillin sodium	349.11	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N	7048611.0		AVKUERGKIZMTKX
BRD-K68432770-341-07-2	ampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	0	34.05	Selleck	S4148	Ampicillin Trihydrate	349.11	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N	7048611.0	BRD-K94927753-341-01-3	AVKUERGKIZMTKX
BRD-K68432770-341-05-6	ampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|meningitis|bacterial septicemia|endocarditis|urinary tract infections|gastrointestinal infections	0	31.52	Selleck	S4148	Ampicillin Trihydrate	349.11	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	AVKUERGKIZMTKX-NJBDSQKTSA-N	7048611.0		AVKUERGKIZMTKX
BRD-A39172021-001-14-5	ampiroxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	78.57	MedChemEx	HY-17484	Ampiroxicam	447.11	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|	LSNWBKACGXCGAJ-ZDUSSCGKSA-N	25273583.0		LSNWBKACGXCGAJ
BRD-A39172021-001-13-7	ampiroxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	4.82	MedChemEx	HY-17484	Ampiroxicam	447.11	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|	LSNWBKACGXCGAJ-ZDUSSCGKSA-N	25273583.0		LSNWBKACGXCGAJ
BRD-A39172021-001-10-3	ampiroxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	10.36	MicroSource	1504830	AMPIROXICAM	447.11	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|	LSNWBKACGXCGAJ-ZDUSSCGKSA-N	25273583.0		LSNWBKACGXCGAJ
BRD-A39172021-001-09-5	ampiroxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	0.0	Selleck	S4011	Ampiroxicam	447.11	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|	LSNWBKACGXCGAJ-ZDUSSCGKSA-N	25273583.0		LSNWBKACGXCGAJ
BRD-A39172021-001-11-1	ampiroxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	61.74	Selleck	S4011	Ampiroxicam	447.11	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6,r,t:9|	LSNWBKACGXCGAJ-ZDUSSCGKSA-N	25273583.0		LSNWBKACGXCGAJ
BRD-K47827687-001-02-2	amprenavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	95.63	Selleck	S1639	Amprenavir	505.225	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	YMARZQAQMVYCKC-OEMFJLHTSA-N	65016.0		YMARZQAQMVYCKC
BRD-K47827687-001-04-9	amprenavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	88.76	MedChemEx	HY-17430	Amprenavir	505.225	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	YMARZQAQMVYCKC-OEMFJLHTSA-N	65016.0		YMARZQAQMVYCKC
BRD-K90027121-300-14-9	amprolium	Launched	thiamine uptake blocker		infectious disease	coccidiosis	0	93.96	MedChemEx	HY-B0937A	Amprolium (hydrochloride)	243.161	CCCc1ncc(C[n+]2ccccc2C)c(N)n1	IPZFPROOBOUEIG-UHFFFAOYSA-N	2178.0		IPZFPROOBOUEIG
BRD-K90027121-300-13-2	amprolium	Launched	thiamine uptake blocker		infectious disease	coccidiosis	0	93.77	Selleck	S4144	Amprolium HCl	243.161	CCCc1ncc(C[n+]2ccccc2C)c(N)n1	IPZFPROOBOUEIG-UHFFFAOYSA-N	2178.0		IPZFPROOBOUEIG
BRD-K90027121-003-01-7	amprolium	Launched	thiamine uptake blocker		infectious disease	coccidiosis	0	95.82	MicroSource	1500124	AMPROLIUM	243.161	CCCc1ncc(C[n+]2ccccc2C)c(N)n1	IPZFPROOBOUEIG-UHFFFAOYSA-N	2178.0		IPZFPROOBOUEIG
BRD-K20484910-001-16-9	ampyrone	Preclinical	cyclooxygenase inhibitor				0	94.82	MedChemEx	HY-B1398	Ampyrone	203.106	Cc1c(N)c(=O)n(-c2ccccc2)n1C	RLFWWDJHLFCNIJ-UHFFFAOYSA-N	2151.0		RLFWWDJHLFCNIJ
BRD-K20484910-001-14-7	ampyrone	Preclinical	cyclooxygenase inhibitor				0	70.49	Prestwick	Prestw-181	Ampyrone	203.106	Cc1c(N)c(=O)n(-c2ccccc2)n1C	RLFWWDJHLFCNIJ-UHFFFAOYSA-N	2151.0		RLFWWDJHLFCNIJ
BRD-K45924332-001-16-8	amrinone	Launched	phosphodiesterase inhibitor	PDE3A|PDE3B|PDE4B|TNF	cardiology	congestive heart failure	0	92.25	MicroSource	1503084	INAMRINONE	187.075	Nc1cc(c[nH]c1=O)-c1ccncc1	RNLQIBCLLYYYFJ-UHFFFAOYSA-N	3698.0		RNLQIBCLLYYYFJ
BRD-K45924332-001-24-9	amrinone	Launched	phosphodiesterase inhibitor	PDE3A|PDE3B|PDE4B|TNF	cardiology	congestive heart failure	0	81.72	Sigma	MFCD00083228	Amrinone	187.075	Nc1cc(c[nH]c1=O)-c1ccncc1	RNLQIBCLLYYYFJ-UHFFFAOYSA-N	3698.0		RNLQIBCLLYYYFJ
BRD-K13843533-001-02-5	amrubicin	Launched	topoisomerase inhibitor	TOP2A|TOP2B	oncology	small cell lung cancer	0	7.43	MedChemEx	HY-B0067	Amrubicin	483.153	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1	VJZITPJGSQKZMX-XDPRQOKASA-N	3035016.0		VJZITPJGSQKZMX
BRD-K13843533-001-01-7	amrubicin	Launched	topoisomerase inhibitor	TOP2A|TOP2B	oncology	small cell lung cancer	0	74.78	MedChemEx	HY-B0067	Amrubicin	483.153	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1	VJZITPJGSQKZMX-XDPRQOKASA-N	3035016.0		VJZITPJGSQKZMX
BRD-K68346641-001-02-2	amsacrine	Launched	topoisomerase inhibitor	KCNH2|TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	95.69	MicroSource	1503256	AMSACRINE	393.115	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	XCPGHVQEEXUHNC-UHFFFAOYSA-N	2179.0	BRD-K98490050-001-02-6	XCPGHVQEEXUHNC
BRD-K68346641-001-01-4	amsacrine	Launched	topoisomerase inhibitor	KCNH2|TOP2A	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	89.75	Enzo	AC2018	Amsacrine	393.115	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	XCPGHVQEEXUHNC-UHFFFAOYSA-N	2179.0		XCPGHVQEEXUHNC
BRD-K39670393-303-03-9	amthamine	Preclinical	histamine receptor agonist	HRH2			0	57.3	Tocris	668	Amthamine dihydrobromide	157.067	Cc1nc(N)sc1CCN	LHVRFUVVRXGZPV-UHFFFAOYSA-N	126688.0		LHVRFUVVRXGZPV
BRD-K39670393-303-02-1	amthamine	Preclinical	histamine receptor agonist	HRH2			0	90.06	Tocris	668	Amthamine dihydrobromide	157.067	Cc1nc(N)sc1CCN	LHVRFUVVRXGZPV-UHFFFAOYSA-N	126688.0		LHVRFUVVRXGZPV
BRD-K70924353-001-01-2	amtolmetin-guacil	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	94.69	OxChem	AX8076550		420.169	COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C	CWJNMKKMGIAGDK-UHFFFAOYSA-N	65655.0		CWJNMKKMGIAGDK
BRD-K66538826-001-07-2	amuvatinib	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor	KIT|MET			0	97.82	Selleck	S1244	Amuvatinib (MP-470)	447.137	S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	FOFDIMHVKGYHRU-UHFFFAOYSA-N	11282283.0		FOFDIMHVKGYHRU
BRD-K66538826-001-01-5	amuvatinib	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor	KIT|MET			0		Selleck	S1244	MP-470	447.137	S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	InChI=1S/C23H21N5O3S/c32-23(24-12-15-5-6-18-19(11-15)30-14-29-18)28-9-7-27(8-10-28)22-21-20(25-13-26-22)16-3-1-2-4-17(16)31-21/h1-6,11,13H,7-10,12,14H2,(H,24,32)	11282283.0		FOFDIMHVKGYHRU
BRD-K03504028-001-09-9	amygdalin	Phase 2	caspase activator	CASP3			0	87.18	MedChemEx	HY-N0190	Amygdalin	457.158	OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	XUCIJNAGGSZNQT-JHSLDZJXSA-N	656516.0		XUCIJNAGGSZNQT
BRD-K03504028-001-07-6	amygdalin	Phase 2	caspase activator	CASP3			0	95.98	Selleck	S2260	Amygdalin	457.158	OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	XUCIJNAGGSZNQT-JHSLDZJXSA-N	656516.0		XUCIJNAGGSZNQT
BRD-K03504028-001-08-4	amygdalin	Phase 2	caspase activator	CASP3			0	0.0	Selleck	S2260	Laetrile	457.158	OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	XUCIJNAGGSZNQT-JHSLDZJXSA-N	656516.0	BRD-K11478426-001-01-4	XUCIJNAGGSZNQT
BRD-K03326591-001-01-4	amyl-nitrite	Preclinical	atrial natriuretic peptide receptor agonist				0	0.0	Sigma	MFCD00036132	pentyl nitrite	117.079	CCCCCO[NH2+][O-]	GVGUCRAJNQYOSE-UHFFFAOYSA-N	129010055.0		GVGUCRAJNQYOSE
BRD-A09062839-003-10-0	amyleine	Preclinical	local anesthetic				0	98.68	Prestwick	Prestw-49	Amyleine hydrochloride	235.157	CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|	FDMBBCOBEAVDAO-AWEZNQCLSA-N	66584276.0		FDMBBCOBEAVDAO
BRD-A09062839-003-11-9	amyleine	Preclinical	local anesthetic				0	88.12	Toronto	a636700	amylocaine hydrochloride	235.157	CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|	FDMBBCOBEAVDAO-AWEZNQCLSA-N	66584276.0		FDMBBCOBEAVDAO
BRD-K93502141-001-02-4	amylene-hydrate	Preclinical	local anesthetic				1	0.0	Sigma	MFCD00004478	2-methyl-2-butanol	88.089	CCC(C)(C)O	MSXVEPNJUHWQHW-UHFFFAOYSA-N	6405.0		MSXVEPNJUHWQHW
BRD-K93502141-001-01-6	amylene-hydrate	Preclinical	local anesthetic				1	0.0	MicroSource	1301017	AMYLENE HYDRATE	88.089	CCC(C)(C)O	MSXVEPNJUHWQHW-UHFFFAOYSA-N	6405.0		MSXVEPNJUHWQHW
BRD-K00256256-001-06-1	AMZ30	Preclinical	protein phosphatase inhibitor				0	88.11	MedChemEx	HY-12833	AMZ30	461.015	[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1	GUCUORSUHTZMBW-YBFXNURJSA-N	44607965.0		GUCUORSUHTZMBW
BRD-K23952234-236-03-4	AM095	Preclinical	lysophosphatidic acid receptor antagonist				0	96.92	MedChemEx	HY-16039	AM095	456.169	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	LNDDRUPAICPXIN-GOSISDBHSA-N	46213949.0		LNDDRUPAICPXIN
BRD-K23952234-236-02-6	AM095	Preclinical	lysophosphatidic acid receptor antagonist				0	96.31	MedChemEx	HY-16039	AM095	456.169	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	LNDDRUPAICPXIN-GOSISDBHSA-N	46213949.0		LNDDRUPAICPXIN
BRD-K23952234-236-01-8	AM095	Preclinical	lysophosphatidic acid receptor antagonist				0	76.19	MedChemEx	HY-16039	AM095	456.169	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	LNDDRUPAICPXIN-GOSISDBHSA-N	46213949.0		LNDDRUPAICPXIN
BRD-K00003152-001-01-9	AM211	Preclinical	prostaglandin inhibitor				0	98.69	MedChemEx	HY-13213	AM211	500.192	CCN(Cc1cc(ccc1-c1cc(CC(O)=O)ccc1OC)C(F)(F)F)C(=O)NCc1ccccc1	OPXIRFWNLBDKQB-UHFFFAOYSA-N	44158492.0		OPXIRFWNLBDKQB
BRD-K88443722-001-01-7	AM679	Preclinical	cannabinoid receptor agonist|lipoxygenase inhibitor	ALOX5AP|CNR1|CNR2			0	96.62	MedChemEx	HY-14460	AM679	692.303	COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1	VYXWHVDEWWHDLH-LJAQVGFWSA-N	44627267.0		VYXWHVDEWWHDLH
BRD-A19609491-001-02-9	ANA-12	Preclinical	tropomyosin receptor kinase inhibitor	NTRK2			0	98.36	Tocris	4781	ANA 12	407.13	O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|	TUSCYCAIGRVBMD-KRWDZBQOSA-N	6977265.0		TUSCYCAIGRVBMD
BRD-A19609491-001-01-8	ANA-12	Preclinical	tropomyosin receptor kinase inhibitor	NTRK2			0	96.82	Tocris	4781	ANA 12	407.13	O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12,r|	TUSCYCAIGRVBMD-KRWDZBQOSA-N	6977265.0		TUSCYCAIGRVBMD
BRD-K01826509-001-09-9	anabasine	Preclinical	acetylcholine receptor agonist				0	90.14	Enzo	AC1068	(R,S)-3-(2-Piperidinyl) pyridine [(-)-Anabasine]	162.116	C1CC[C@@H](NC1)c1cccnc1 |&1:3,r|	MTXSIJUGVMTTMU-SNVBAGLBSA-N	641266.0		MTXSIJUGVMTTMU
BRD-K77118600-001-02-9	anacetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	97.66	MedChemEx	HY-12090	Anacetrapib	637.167	COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C	MZZLGJHLQGUVPN-HAWMADMCSA-N	11556427.0		MZZLGJHLQGUVPN
BRD-K05355328-001-02-9	anagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	82.68	MedChemEx	HY-14877	Anagliptin	383.207	Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	LDXYBEHACFJIEL-HNNXBMFYSA-N	44513473.0		LDXYBEHACFJIEL
BRD-K05355328-001-01-1	anagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	63.33	MedChemEx	HY-14877	Anagliptin	383.207	Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	LDXYBEHACFJIEL-HNNXBMFYSA-N	44513473.0		LDXYBEHACFJIEL
BRD-K62200014-003-11-3	anagrelide	Launched	phosphodiesterase inhibitor	PDE3A	hematology|hematologic malignancy	thrombocythemia|myeloproliferative neoplasms	0	93.31	MicroSource	1505590	ANAGRELIDE HYDROCHLORIDE	254.997	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|	OTBXOEAOVRKTNQ-UHFFFAOYSA-N	135409400.0		OTBXOEAOVRKTNQ
BRD-K62200014-001-02-6	anagrelide	Launched	phosphodiesterase inhibitor	PDE3A	hematology|hematologic malignancy	thrombocythemia|myeloproliferative neoplasms	0	98.12	Selleck	S3172	Anagrelide	254.997	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|	OTBXOEAOVRKTNQ-UHFFFAOYSA-N	135409400.0		OTBXOEAOVRKTNQ
BRD-K62200014-003-10-5	anagrelide	Launched	phosphodiesterase inhibitor	PDE3A	hematology|hematologic malignancy	thrombocythemia|myeloproliferative neoplasms	0	94.48	Selleck	S3172	Anagrelide HCl	254.997	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|	OTBXOEAOVRKTNQ-UHFFFAOYSA-N	135409400.0		OTBXOEAOVRKTNQ
BRD-K01174345-001-01-9	anamorelin	Phase 3	growth hormone secretagogue receptor agonist	GHSR			0	90.17	MedChemEx	HY-14734	Anamorelin	546.332	CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	VQPFSIRUEPQQPP-MXBOTTGLSA-N	9828911.0		VQPFSIRUEPQQPP
BRD-K01174345-001-02-9	anamorelin	Phase 3	growth hormone secretagogue receptor agonist	GHSR			0	98.0	MedChemEx	HY-14734	Anamorelin	546.332	CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	VQPFSIRUEPQQPP-MXBOTTGLSA-N	9828911.0		VQPFSIRUEPQQPP
BRD-K42352790-001-05-3	anandamide	Phase 2	cannabinoid receptor agonist	CACNA1G|CACNA1H|CACNA1I|CNR1|CNR2|GLRA1|GPR18|GPR55|KCNA2|KCNK3|KCNK9|TRPM8|TRPV1			0	97.08	Enzo	FA017	Anandamide	347.282	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	LGEQQWMQCRIYKG-DOFZRALJSA-N	5281969.0		LGEQQWMQCRIYKG
BRD-K42352790-001-11-9	anandamide	Phase 2	cannabinoid receptor agonist	CACNA1G|CACNA1H|CACNA1I|CNR1|CNR2|GLRA1|GPR18|GPR55|KCNA2|KCNK3|KCNK9|TRPM8|TRPV1			0	6.19	Sigma	A0580	Arachidonylethanolamide	347.282	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	LGEQQWMQCRIYKG-DOFZRALJSA-N	5281969.0		LGEQQWMQCRIYKG
BRD-K52172416-001-14-8	anastrozole	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	83.77	Tocris	3388	Anastrozole	293.164	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	YBBLVLTVTVSKRW-UHFFFAOYSA-N	2187.0		YBBLVLTVTVSKRW
BRD-K52172416-001-11-4	anastrozole	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	99.51	MicroSource	1502278	ANASTROZOLE	293.164	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	YBBLVLTVTVSKRW-UHFFFAOYSA-N	2187.0		YBBLVLTVTVSKRW
BRD-K52172416-001-10-6	anastrozole	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	96.82	Selleck	S1188	Anastrozole	293.164	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	YBBLVLTVTVSKRW-UHFFFAOYSA-N	2187.0		YBBLVLTVTVSKRW
BRD-K82164249-001-03-5	andarine	Phase 1	androgen receptor modulator	AR			0	97.06	Selleck	S1140	Andarine	441.115	CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	YVXVTLGIDOACBJ-SFHVURJKSA-N	9824562.0		YVXVTLGIDOACBJ
BRD-K82164249-001-04-9	andarine	Phase 1	androgen receptor modulator	AR			0	97.56	MedChemEx	HY-12023	Andarine	441.115	CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	YVXVTLGIDOACBJ-SFHVURJKSA-N	9824562.0		YVXVTLGIDOACBJ
BRD-K89282837-001-04-9	andrographolide	Phase 2	tumor necrosis factor production inhibitor	IL1B|IL6|NFKB1|NFKB2|TNF			0	92.89	Tocris	4626	Andrographolide	350.209	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12	BOJKULTULYSRAS-OTESTREVSA-N	5318517.0		BOJKULTULYSRAS
BRD-A64011898-001-01-0	androstenone	Preclinical	steroid				0	100.0	SantaCruz	sc-227030	5 -Androst-16-en-3-one	272.214	C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1,&2:4,&3:5,&4:8,&5:14,&6:16,r,c:21|	HFVMLYAGWXSTQI-UGRKVPRCSA-N			HFVMLYAGWXSTQI
BRD-K12329651-001-19-9	androsterone	Preclinical	androgen receptor agonist				0	100.0	MedChemEx	HY-N0933	Androsterone	290.225	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-HLUDHZFRSA-N	5879.0		QGXBDMJGAMFCBF
BRD-K12329651-001-18-8	androsterone	Preclinical	androgen receptor agonist				0	100.0	Prestwick	Prestw-411	Androsterone	290.225	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-HLUDHZFRSA-N	5879.0		QGXBDMJGAMFCBF
BRD-K00005346-001-01-9	anecortave-acetate	Launched	angiogenesis inhibitor		ophthalmology	macular degeneration	0	76.87	Toronto	a637640	anecortave	386.209	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C |c:25,t:15|	YUWPMEXLKGOSBF-GACAOOTBSA-N	111332.0		YUWPMEXLKGOSBF
BRD-K49060658-001-08-0	anethole	Launched	glutathione transferase stimulant				0	0.0	MedChemEx	HY-B0900	Anethole	148.089	COc1ccc(\C=C\C)cc1	RUVINXPYWBROJD-ONEGZZNKSA-N	637563.0		RUVINXPYWBROJD
BRD-K49060658-001-05-6	anethole	Launched	glutathione transferase stimulant				0	0.0	MicroSource	1503705	ANETHOLE	148.089	COc1ccc(\C=C\C)cc1	RUVINXPYWBROJD-ONEGZZNKSA-N	637563.0		RUVINXPYWBROJD
BRD-K49060658-001-07-2	anethole	Launched	glutathione transferase stimulant				0	0.0	MedChemEx	HY-B0900	Anethole	148.089	COc1ccc(\C=C\C)cc1	RUVINXPYWBROJD-ONEGZZNKSA-N	637563.0		RUVINXPYWBROJD
BRD-K92490248-001-04-1	anethole-trithione	Launched	glutathione transferase stimulant		dental	xerostomia	0	52.71	Enzo	DL151	Anethole-trithione (anetholtrithion)	239.974	COc1ccc(cc1)-c1cc(=S)ss1	KYLIZBIRMBGUOP-UHFFFAOYSA-N	2194.0		KYLIZBIRMBGUOP
BRD-K92490248-001-06-6	anethole-trithione	Launched	glutathione transferase stimulant		dental	xerostomia	0	97.57	MedChemEx	HY-B1223	Anethole (trithione)	239.974	COc1ccc(cc1)-c1cc(=S)ss1	KYLIZBIRMBGUOP-UHFFFAOYSA-N	2194.0		KYLIZBIRMBGUOP
BRD-K45724504-001-01-6	anguidine	Phase 2	protein synthesis inhibitor	SLC5A1			0	100.0	Enzo	NP563	Diacetoxyscirpenol	366.168	CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|	AUGQEEXBDZWUJY-ZLJUKNTDSA-N	91518.0		AUGQEEXBDZWUJY
BRD-K00003560-001-01-9	anidulafungin	Launched	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia|fungal infection|esophageal candidiasis	0	97.45	MedChemEx	HY-13553	Anidulafungin	1139.506	CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O |r|	JHVAMHSQVVQIOT-MFAJLEFUSA-N	166548.0		JHVAMHSQVVQIOT
BRD-K88611939-001-25-7	aniracetam	Launched	glutamate receptor agonist	DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A			0	95.85	Tocris	867	Aniracetam	219.09	COc1ccc(cc1)C(=O)N1CCCC1=O	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	2196.0		ZXNRTKGTQJPIJK
BRD-K88611939-001-26-9	aniracetam	Launched	glutamate receptor agonist	DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A			0	89.98	Tocris	867	Aniracetam	219.09	COc1ccc(cc1)C(=O)N1CCCC1=O	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	2196.0		ZXNRTKGTQJPIJK
BRD-K88611939-001-23-2	aniracetam	Launched	glutamate receptor agonist	DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A			0	96.69	Tocris	867	Aniracetam	219.09	COc1ccc(cc1)C(=O)N1CCCC1=O	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	2196.0		ZXNRTKGTQJPIJK
BRD-K88611939-001-22-4	aniracetam	Launched	glutamate receptor agonist	DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A			0	97.89	Selleck	S1281	Aniracetam	219.09	COc1ccc(cc1)C(=O)N1CCCC1=O	ZXNRTKGTQJPIJK-UHFFFAOYSA-N	2196.0		ZXNRTKGTQJPIJK
BRD-K47458712-001-22-3	anisindione	Launched	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	0	89.62	MedChemEx	HY-B0924	Anisindione	252.079	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N	2197.0		XRCFXMGQEVUZFC
BRD-K47458712-001-17-3	anisindione	Launched	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	0	34.21	Selleck	S4304	Anisindione	252.079	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N	2197.0		XRCFXMGQEVUZFC
BRD-K47458712-001-20-7	anisindione	Launched	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	0	73.7	Vitas-M	STK363125	2-(4-methoxyphenyl)-1H-indene-1,3(2H)-dione	252.079	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N	2197.0		XRCFXMGQEVUZFC
BRD-K47458712-001-21-5	anisindione	Launched	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	0	63.02	MedChemEx	HY-B0924	Anisindione	252.079	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N	2197.0		XRCFXMGQEVUZFC
BRD-K47458712-001-18-1	anisindione	Launched	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	0	66.4	MicroSource	1502198	ANISINDIONE	252.079	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N	2197.0		XRCFXMGQEVUZFC
BRD-K47458712-001-19-9	anisindione	Launched	vitamin K antagonist	GGCX	hematology	deep vein thrombosis (DVT)	0	36.71	Selleck	S4304	anisindione	252.079	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	XRCFXMGQEVUZFC-UHFFFAOYSA-N	2197.0		XRCFXMGQEVUZFC
BRD-A29623586-001-01-3	anisodamine	Phase 3	lipid peroxidase inhibitor	ADRA1A			0	86.1	MicroSource	300047	ANISODAMINE HYDROBROMIDE	305.163	CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4,6,8,13,&1:2,THB:5:4:1:7.8.9|	WTQYWNWRJNXDEG-JKJDWNRSSA-N			WTQYWNWRJNXDEG
BRD-K91370081-001-25-1	anisomycin	Preclinical	DNA synthesis inhibitor	NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1			0	87.39	Tocris	1290	Anisomycin	265.131	COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	YKJYKKNCCRKFSL-RDBSUJKOSA-N	253602.0		YKJYKKNCCRKFSL
BRD-K91370081-001-26-9	anisomycin	Preclinical	DNA synthesis inhibitor	NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1			0	91.81	Tocris	1290	Anisomycin	265.131	COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	YKJYKKNCCRKFSL-RDBSUJKOSA-N	253602.0		YKJYKKNCCRKFSL
BRD-K71125570-004-15-6	anisotropine	Launched	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	0	100.0	Oakwood	103172	Anisotropine methylbromide	282.243	CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C	XGGHHHBGPSNXFE-ZSHCYNCHSA-N			XGGHHHBGPSNXFE
BRD-K36949735-001-02-9	anlotinib	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	KDR|PDGFRB			0	94.76	MedChemEx	HY-19716	Anlotinib	407.165	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1	KSMZEXLVHXZPEF-UHFFFAOYSA-N	25017411.0		KSMZEXLVHXZPEF
BRD-K36949735-001-01-1	anlotinib	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	KDR|PDGFRB			0	98.34	MedChemEx	HY-19716	Anlotinib	407.165	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1	KSMZEXLVHXZPEF-UHFFFAOYSA-N	25017411.0		KSMZEXLVHXZPEF
BRD-K55424922-003-03-6	anpirtoline	Phase 1	serotonin receptor agonist	HTR1B			0	83.46	Tocris	703	Anpirtoline hydrochloride	228.049	Clc1cccc(SC2CCNCC2)n1	GGALEXMXDMUMDM-UHFFFAOYSA-N	65854.0		GGALEXMXDMUMDM
BRD-K55424922-003-04-9	anpirtoline	Phase 1	serotonin receptor agonist	HTR1B			0	85.82	Tocris	703	Anpirtoline hydrochloride	228.049	Clc1cccc(SC2CCNCC2)n1	GGALEXMXDMUMDM-UHFFFAOYSA-N	65854.0		GGALEXMXDMUMDM
BRD-K55424922-003-02-8	anpirtoline	Phase 1	serotonin receptor agonist	HTR1B			0	93.59	Tocris	703	Anpirtoline hydrochloride	228.049	Clc1cccc(SC2CCNCC2)n1	GGALEXMXDMUMDM-UHFFFAOYSA-N	65854.0		GGALEXMXDMUMDM
BRD-K31170746-001-01-6	ANR-94	Preclinical	adenosine receptor antagonist	ADORA2A			0	96.91	Tocris	3937	ANR 94	207.112	CCOc1nc2c(N)ncnc2n1CC	QUGDTMONBLMLLD-UHFFFAOYSA-N	11805896.0		QUGDTMONBLMLLD
BRD-K31170746-001-03-9	ANR-94	Preclinical	adenosine receptor antagonist	ADORA2A			0	96.29	Tocris	3937	ANR 94	207.112	CCOc1nc2c(N)ncnc2n1CC	QUGDTMONBLMLLD-UHFFFAOYSA-N	11805896.0		QUGDTMONBLMLLD
BRD-K00003196-001-01-9	ansamitocin-p-3	Preclinical	apoptosis stimulant				0	77.64	MedChemEx	HY-15739	Ansamitocin P-3	634.266	[H][C@@]12O[C@@]1(C)[C@H](CC(=O)N(C)c1cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@]([H])(OC(=O)N3)[C@H]2C)cc(OC)c1Cl)OC(=O)C(C)C |t:17,19|	OPQNCARIZFLNLF-HSBZPDDFSA-N	131857169.0		OPQNCARIZFLNLF
BRD-K25863791-001-01-8	antagonist-g	Phase 1	neuropeptide receptor antagonist	MAPK8			0	77.63	Tocris	1954	(6S,9R,12S,15R,18S,21S)-1,6-diamino-12-benzyl-1-imino-9,15-bis(1H-indol-3-ylmethyl)-18-isobutyl-11-methyl-21-[2-(methylsulfanyl)ethyl]-7,10,13,16,19-pentaoxo-2,8,11,14,17,20-hexaazadocosan-22-amide	950.495	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	CUCSSYAUKKIDJV-FAXBSAIASA-N	163960.0		CUCSSYAUKKIDJV
BRD-K01363385-003-01-5	antalarmin	Preclinical	corticotropin releasing factor receptor antagonist	CRHR1			0	95.23	Tocris	2778	Antalarmin hydrochloride	378.278	CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C	IXPROWGEHNVJOY-UHFFFAOYSA-N	177990.0		IXPROWGEHNVJOY
BRD-K01363385-003-02-9	antalarmin	Preclinical	corticotropin releasing factor receptor antagonist	CRHR1			0	93.23	Tocris	2778	Antalarmin hydrochloride	378.278	CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C	IXPROWGEHNVJOY-UHFFFAOYSA-N	177990.0		IXPROWGEHNVJOY
BRD-K99300445-001-01-2	antazoline	Launched	antihistamine	HRH1	ophthalmology|otolaryngology	conjunctivitis|nasal congestion	0	89.7	MicroSource	1500126	ANTAZOLINE	265.158	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|	REYFJDPCWQRWAA-UHFFFAOYSA-N	2200.0		REYFJDPCWQRWAA
BRD-K99300445-003-22-9	antazoline	Launched	antihistamine	HRH1	ophthalmology|otolaryngology	conjunctivitis|nasal congestion	0	95.88	Tocris	791	Antazoline hydrochloride	265.158	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|	REYFJDPCWQRWAA-UHFFFAOYSA-N	2200.0		REYFJDPCWQRWAA
BRD-K99300445-003-21-6	antazoline	Launched	antihistamine	HRH1	ophthalmology|otolaryngology	conjunctivitis|nasal congestion	0	92.85	Tocris	791	Antazoline hydrochloride	265.158	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|	REYFJDPCWQRWAA-UHFFFAOYSA-N	2200.0		REYFJDPCWQRWAA
BRD-K99300445-003-20-8	antazoline	Launched	antihistamine	HRH1	ophthalmology|otolaryngology	conjunctivitis|nasal congestion	0	90.98	Selleck	S4199	Antazoline HCl	265.158	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|	REYFJDPCWQRWAA-UHFFFAOYSA-N	2200.0		REYFJDPCWQRWAA
BRD-K04725460-001-12-1	anthralin	Launched	DNA synthesis inhibitor		dermatology	psoriasis	0	0.0	MedChemEx	HY-B0738	Dithranol	226.063	Oc1cccc2Cc3cccc(O)c3C(=O)c12	NUZWLKWWNNJHPT-UHFFFAOYSA-N	2202.0		NUZWLKWWNNJHPT
BRD-K04725460-001-10-5	anthralin	Launched	DNA synthesis inhibitor		dermatology	psoriasis	0	0.0	MicroSource	1500127	ANTHRALIN	226.063	Oc1cccc2Cc3cccc(O)c3C(=O)c12	NUZWLKWWNNJHPT-UHFFFAOYSA-N	2202.0		NUZWLKWWNNJHPT
BRD-K04725460-001-11-3	anthralin	Launched	DNA synthesis inhibitor		dermatology	psoriasis	0	0.0	MedChemEx	HY-B0738	Dithranol	226.063	Oc1cccc2Cc3cccc(O)c3C(=O)c12	NUZWLKWWNNJHPT-UHFFFAOYSA-N	2202.0		NUZWLKWWNNJHPT
BRD-K15957397-001-05-9	anthraquinone	Preclinical	CDC inhibitor	CDC25B			0	86.59	Sigma	MFCD00001188	Anthraquinone	208.052	O=C1c2ccccc2C(=O)c2ccccc12	RZVHIXYEVGDQDX-UHFFFAOYSA-N	6780.0		RZVHIXYEVGDQDX
BRD-K15957397-001-04-2	anthraquinone	Preclinical	CDC inhibitor	CDC25B			0	83.65	Vitas-M	STK398385		208.052	O=C1c2ccccc2C(=O)c2ccccc12	RZVHIXYEVGDQDX-UHFFFAOYSA-N	6780.0		RZVHIXYEVGDQDX
BRD-K00003675-409-01-9	antimony-potassium	Phase 2					0	0.0	MedChemEx	HY-B1082	Antimonyl (potassium tartrate trihydrate)	535.794	[H][C@]12O[SbH]3(OC1=O)OC(=O)[C@]([H])(O3)[C@@]1([H])O[SbH]3(OC(=O)[C@]2([H])O3)OC1=O |r|	ZCIXFSVENQDMCK-SOMOIXMJSA-J			ZCIXFSVENQDMCK
BRD-A74328360-409-01-0	antimonyl	Phase 1					1	0.0	MedChemEx	HY-B1082	Antimonyl (potassium tartrate trihydrate)	535.794	O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O	ZCIXFSVENQDMCK-UHFFFAOYSA-J		BRD-U39828521-000-01-2	ZCIXFSVENQDMCK
BRD-A74328360-409-02-8	antimonyl	Phase 1					1	100.0	Sigma	383376-100G	Potassium antimonyl tartrate dihydrate	535.794	O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O	ZCIXFSVENQDMCK-UHFFFAOYSA-J			ZCIXFSVENQDMCK
BRD-K90152265-001-01-3	antimycin-A	Preclinical	ATP synthase inhibitor	CYCS			0	25.76	Enzo	ALX-380-075-M010	Antimycin A	548.273	CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O	UIFFUZWRFRDZJC-SBOOETFBSA-N	14957.0		UIFFUZWRFRDZJC
BRD-K15541734-001-02-0	antioxine	Launched					0	0.0	Sigma	42632	5-isopropyl-2-methylphenol	150.104	CC(C)c1ccc(C)c(O)c1	RECUKUPTGUEGMW-UHFFFAOYSA-N	10364.0		RECUKUPTGUEGMW
BRD-K15541734-001-01-2	antioxine	Launched					0	0.0	Enamine	Z104496566		150.104	CC(C)c1ccc(C)c(O)c1	RECUKUPTGUEGMW-UHFFFAOYSA-N	10364.0		RECUKUPTGUEGMW
BRD-K21920947-001-02-1	AN2718	Phase 1	leucyl-tRNA synthetase inhibitor				0	96.45	Enamine	Z1739256298	5-chloro-2,1-benzoxaborol-1(3H)-ol	168.015	OB1OCc2cc(Cl)ccc12	HMAFTPZYFJFEHK-UHFFFAOYSA-N	11845944.0		HMAFTPZYFJFEHK
BRD-K21920947-001-01-3	AN2718	Phase 1	leucyl-tRNA synthetase inhibitor				0	0.0	Enamine	EN300-117650		168.015	OB1OCc2cc(Cl)ccc12	HMAFTPZYFJFEHK-UHFFFAOYSA-N	11845944.0		HMAFTPZYFJFEHK
BRD-K32143970-001-01-9	AP-18	Preclinical	transient receptor potential channel antagonist	TRPA1			0	91.72	Tocris	3296	AP 18	209.061	C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O	MHTJEUOFLVQMCL-NJHPPEEMSA-N	9584673.0		MHTJEUOFLVQMCL
BRD-K32143970-001-02-9	AP-18	Preclinical	transient receptor potential channel antagonist	TRPA1			0	96.53	Tocris	3296	AP 18	209.061	C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O	MHTJEUOFLVQMCL-NJHPPEEMSA-N	9584673.0		MHTJEUOFLVQMCL
BRD-K20001883-001-02-7	apabetalone	Phase 3	apolipoprotein expression enhancer	BRD3			0	96.24	Selleck	S7295	RVX-208	370.153	COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1	NETXMUIMUZJUTB-UHFFFAOYSA-N	135564749.0		NETXMUIMUZJUTB
BRD-K28115081-001-03-5	apafant	Phase 3	platelet activating factor receptor antagonist	PTAFR			0	96.78	Tocris	2339	WEB 2086	455.118	Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|	JGPJQFOROWSRRS-UHFFFAOYSA-N	65889.0		JGPJQFOROWSRRS
BRD-K28115081-001-02-7	apafant	Phase 3	platelet activating factor receptor antagonist	PTAFR			0	98.5	Tocris	2339	WEB 2086	455.118	Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|	JGPJQFOROWSRRS-UHFFFAOYSA-N	65889.0		JGPJQFOROWSRRS
BRD-K28115081-001-04-9	apafant	Phase 3	platelet activating factor receptor antagonist	PTAFR			0	97.32	Tocris	2339	WEB 2086	455.118	Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|	JGPJQFOROWSRRS-UHFFFAOYSA-N	65889.0		JGPJQFOROWSRRS
BRD-K91308639-001-02-7	apalutamide	Launched	androgen receptor antagonist		oncology	prostate cancer	0	97.61	Selleck	S2840	ARN-509	477.088	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	HJBWBFZLDZWPHF-UHFFFAOYSA-N	24872560.0		HJBWBFZLDZWPHF
BRD-K91308639-001-04-9	apalutamide	Launched	androgen receptor antagonist		oncology	prostate cancer	0	95.18	MedChemEx	HY-16060	Apalutamide	477.088	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	HJBWBFZLDZWPHF-UHFFFAOYSA-N	24872560.0		HJBWBFZLDZWPHF
BRD-K00003492-001-01-9	apararenone	Preclinical	mineralocorticoid receptor antagonist				0	97.55	MedChemEx	HY-109002	Apararenone	364.089	CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(C1=O)c1ccc(F)cc1	AZNHWXAFPBYFGH-UHFFFAOYSA-N	24744336.0		AZNHWXAFPBYFGH
BRD-K25244359-066-02-6	apatinib	Phase 3	RET tyrosine kinase inhibitor	CSK|KDR|KIT|RET			0	69.33	Selleck	S2221	Apatinib	397.19	O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	WPEWQEMJFLWMLV-UHFFFAOYSA-N	11315474.0		WPEWQEMJFLWMLV
BRD-K25244359-066-03-4	apatinib	Phase 3	RET tyrosine kinase inhibitor	CSK|KDR|KIT|RET			0	97.58	Selleck	S2221	Apatinib (YN968D1)	397.19	O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	WPEWQEMJFLWMLV-UHFFFAOYSA-N	11315474.0		WPEWQEMJFLWMLV
BRD-K25244359-066-04-9	apatinib	Phase 3	RET tyrosine kinase inhibitor	CSK|KDR|KIT|RET			0	97.5	MedChemEx	HY-13342	Apatinib	397.19	O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	WPEWQEMJFLWMLV-UHFFFAOYSA-N	11315474.0		WPEWQEMJFLWMLV
BRD-K07449869-001-01-5	APC-100	Phase 1/Phase 2	androgen receptor antagonist|anti-inflammatory agent	AR			0	93.42	Sigma	MFCD00210347	2,2,5,7,8-pentamethyl-6-chromanol	220.146	Cc1c(C)c2OC(C)(C)CCc2c(C)c1O	SEBPXHSZHLFWRL-UHFFFAOYSA-N	99479.0		SEBPXHSZHLFWRL
BRD-K72748448-001-01-0	APcK-110	Preclinical	KIT inhibitor	KIT|STAT3			0	95.57	Tocris	3704	APcK 110	349.123	COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1	CAMGZGMEPKFVMF-UHFFFAOYSA-N	24786010.0		CAMGZGMEPKFVMF
BRD-K72748448-001-02-9	APcK-110	Preclinical	KIT inhibitor	KIT|STAT3			0	95.08	Tocris	3704	APcK 110	349.123	COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1	CAMGZGMEPKFVMF-UHFFFAOYSA-N	24786010.0		CAMGZGMEPKFVMF
BRD-K86226872-001-01-6	APD597	Phase 1	glucose dependent insulinotropic receptor agonist	GPR119			0	96.93	MedChemEx	HY-15566	APD597	479.184	COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C	WPDCHTSXOPUOII-UHFFFAOYSA-N	11691484.0		WPDCHTSXOPUOII
BRD-K10859802-001-01-0	APD668	Phase 1	glucose dependent insulinotropic receptor agonist	GPR119			0	98.92	MedChemEx	HY-15565	APD668	477.148	CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	XTRUQJBVQBUKSQ-UHFFFAOYSA-N	11705608.0		XTRUQJBVQBUKSQ
BRD-K10859802-001-02-9	APD668	Phase 1	glucose dependent insulinotropic receptor agonist	GPR119			0	95.09	MedChemEx	HY-15565	APD668	477.148	CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	XTRUQJBVQBUKSQ-UHFFFAOYSA-N	11705608.0		XTRUQJBVQBUKSQ
BRD-K85140930-001-12-7	aphidicolin	Phase 1	RNA synthesis inhibitor				0	100.0	Enzo	CC101	Aphidicolin	338.246	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	NOFOAYPPHIUXJR-APNQCZIXSA-N	457964.0		NOFOAYPPHIUXJR
BRD-K85140930-001-13-9	aphidicolin	Phase 1	RNA synthesis inhibitor				0	100.0	Sigma	A0781	Aphidicolin Nigrospora sphaerica	338.246	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	NOFOAYPPHIUXJR-APNQCZIXSA-N	457964.0		NOFOAYPPHIUXJR
BRD-K26325692-003-02-9	API-001	Phase 2	sigma receptor antagonist	SIGMAR1			0	99.32	MedChemEx	HY-18099A	S1RA (hydrochloride)	337.179	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	DGPGXHRHNRYVDH-UHFFFAOYSA-N	44247568.0		DGPGXHRHNRYVDH
BRD-K26325692-003-01-3	API-001	Phase 2	sigma receptor antagonist	SIGMAR1			0	96.83	MedChemEx	HY-18099A	S1RA (hydrochloride)	337.179	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	DGPGXHRHNRYVDH-UHFFFAOYSA-N	44247568.0		DGPGXHRHNRYVDH
BRD-K97840621-001-01-5	API-1	Preclinical	AKT inhibitor	AKT1|AKT2|AKT3			0	88.7	Tocris	3897	API-1	337.102	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O	SPBWHPXCWJLQRU-FITJORAGSA-N	24773090.0		SPBWHPXCWJLQRU
BRD-K97840621-001-02-9	API-1	Preclinical	AKT inhibitor	AKT1|AKT2|AKT3			0	96.5	Tocris	3897	API-1	337.102	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O	SPBWHPXCWJLQRU-FITJORAGSA-N	24773090.0		SPBWHPXCWJLQRU
BRD-K01493881-001-29-4	apigenin	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	AKR1B1|AR|CDK6|CFTR|CYP19A1|CYP1B1|HSD17B1			0	96.49	Tocris	1227	Apigenin	270.053	Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	KZNIFHPLKGYRTM-UHFFFAOYSA-N	5280443.0		KZNIFHPLKGYRTM
BRD-K01493881-001-28-6	apigenin	Preclinical	casein kinase inhibitor|cell proliferation inhibitor	AKR1B1|AR|CDK6|CFTR|CYP19A1|CYP1B1|HSD17B1			0	94.78	Selleck	S2262	Apigenin	270.053	Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	KZNIFHPLKGYRTM-UHFFFAOYSA-N	5280443.0		KZNIFHPLKGYRTM
BRD-K67121414-001-04-9	apixaban	Launched	coagulation factor inhibitor	F10	neurology/psychiatry|hematology|cardiology	stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT)	0	99.16	MedChemEx	HY-50667	Apixaban	459.191	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	QNZCBYKSOIHPEH-UHFFFAOYSA-N	10182969.0		QNZCBYKSOIHPEH
BRD-K67121414-001-02-5	apixaban	Launched	coagulation factor inhibitor	F10	neurology/psychiatry|hematology|cardiology	stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT)	0	97.55	Selleck	S1593	Apixaban	459.191	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	QNZCBYKSOIHPEH-UHFFFAOYSA-N	10182969.0		QNZCBYKSOIHPEH
BRD-K67121414-001-03-3	apixaban	Launched	coagulation factor inhibitor	F10	neurology/psychiatry|hematology|cardiology	stroke|systemic embolism|pulmonary embolism (PE)|atrial fibrillation (AF)|deep vein thrombosis (DVT)	0	99.06	MicroSource	1506317	APIXABAN	459.191	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	QNZCBYKSOIHPEH-UHFFFAOYSA-N	10182969.0		QNZCBYKSOIHPEH
BRD-K64990520-001-11-9	apocynin	Phase 1	NADPH oxidase inhibitor	NOX4			0	0.0	MedChemEx	HY-N0088	Apocynin	166.063	COc1cc(ccc1O)C(C)=O	DFYRUELUNQRZTB-UHFFFAOYSA-N	2214.0		DFYRUELUNQRZTB
BRD-K64990520-001-12-9	apocynin	Phase 1	NADPH oxidase inhibitor	NOX4			0	96.42	MedChemEx	HY-N0088	Apocynin	166.063	COc1cc(ccc1O)C(C)=O	DFYRUELUNQRZTB-UHFFFAOYSA-N	2214.0		DFYRUELUNQRZTB
BRD-K64990520-001-08-4	apocynin	Phase 1	NADPH oxidase inhibitor	NOX4			0	94.64	Selleck	S2425	Apocynin	166.063	COc1cc(ccc1O)C(C)=O	DFYRUELUNQRZTB-UHFFFAOYSA-N	2214.0		DFYRUELUNQRZTB
BRD-K15164005-001-06-4	apoptosis-activator-II	Preclinical	carboxylesterase inhibitor	BCHE|CES1			0	96.46	Tocris	2098	Apoptosis Activator 2	305.001	Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	KGRJPLRFGLMQMV-UHFFFAOYSA-N	1901244.0		KGRJPLRFGLMQMV
BRD-K15164005-001-08-9	apoptosis-activator-II	Preclinical	carboxylesterase inhibitor	BCHE|CES1			0	96.73	Tocris	2098	Apoptosis Activator 2	305.001	Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	KGRJPLRFGLMQMV-UHFFFAOYSA-N	1901244.0		KGRJPLRFGLMQMV
BRD-K15164005-001-04-9	apoptosis-activator-II	Preclinical	carboxylesterase inhibitor	BCHE|CES1			0	96.73	Selleck	S2927	Apoptosis Activator 2	305.001	Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	KGRJPLRFGLMQMV-UHFFFAOYSA-N	1901244.0		KGRJPLRFGLMQMV
BRD-K15164005-001-05-6	apoptosis-activator-II	Preclinical	carboxylesterase inhibitor	BCHE|CES1			0	97.54	Tocris	2098	Apoptosis Activator 2	305.001	Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	KGRJPLRFGLMQMV-UHFFFAOYSA-N	1901244.0		KGRJPLRFGLMQMV
BRD-A09004963-001-01-3	APR-246	Phase 3	p53 activator	TP53			0	97.6	Adooq	A13636	2-(hydroxymethyl)-2-(methoxymethyl)quinuclidin-3-one	199.121	COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3,r,TLB:2:3:7.8:10.11|	BGBNULCRKBVAKL-SNVBAGLBSA-N	76965201.0		BGBNULCRKBVAKL
BRD-K38911213-003-01-6	apraclonidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA2A|ADRA2B|ADRA2C	ophthalmology	glaucoma|intraocular pressure	0	85.91	Ark	AK143283		244.028	Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|	IEJXVRYNEISIKR-UHFFFAOYSA-N	2216.0		IEJXVRYNEISIKR
BRD-K96737756-065-02-9	apramycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	22.8	MedChemEx	HY-B1329	Apramycin (sulfate)	539.28	CN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O	XZNUGFQTQHRASN-XQENGBIVSA-N	3081545.0		XZNUGFQTQHRASN
BRD-K06883221-001-02-9	apratastat	Phase 2	matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor	ADAM17|MMP1|MMP13|MMP9			0	100.0	Sigma	MFCD13152357	Apratastat	414.092	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	MAVDNGWEBZTACC-HNNXBMFYSA-N	11452716.0		MAVDNGWEBZTACC
BRD-K06883221-001-01-9	apratastat	Phase 2	matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor	ADAM17|MMP1|MMP13|MMP9			0	92.98	Sigma	SML1543	(3S)-N-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholinecarboxamide	414.092	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	MAVDNGWEBZTACC-HNNXBMFYSA-N	11452716.0		MAVDNGWEBZTACC
BRD-K93208532-001-02-5	apremilast	Launched	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D	dermatology|rheumatology	psoriasis|psoriatic arthritis	0	93.31	Selleck	S8034	Apremilast (CC-10004)	460.13	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	IMOZEMNVLZVGJZ-QGZVFWFLSA-N	11561674.0		IMOZEMNVLZVGJZ
BRD-K93208532-001-05-9	apremilast	Launched	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D	dermatology|rheumatology	psoriasis|psoriatic arthritis	0	97.87	MedChemEx	HY-12085	Apremilast	460.13	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	IMOZEMNVLZVGJZ-QGZVFWFLSA-N	11561674.0		IMOZEMNVLZVGJZ
BRD-K52827117-001-04-9	aprepitant	Launched	tachykinin antagonist	TACR1	gastroenterology	nausea|vomiting	0	97.69	MedChemEx	HY-10052	Aprepitant	534.15	C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	ATALOFNDEOCMKK-OITMNORJSA-N	135413536.0		ATALOFNDEOCMKK
BRD-K55172746-001-01-3	apricitabine	Phase 3	nucleoside reverse transcriptase inhibitor				0	98.8	Key	AS-2749	4-amino-1-[(2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]-2(1H)-pyrimidinone	229.052	Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1	RYMCFYKJDVMSIR-RNFRBKRXSA-N	455041.0		RYMCFYKJDVMSIR
BRD-K53236343-003-03-7	aprindine	Launched	voltage-gated sodium channel blocker	CALM1|SCN5A	cardiology	cardiac arrythmia	0	82.34	Sigma	A7606	N~1~-(2,3-dihydro-1H-inden-2-yl)-N~3~,N~3~-diethyl-N~1~-phenyl-1,3-propanediamine hydrochloride	322.241	CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1	NZLBHDRPUJLHCE-UHFFFAOYSA-N	2218.0		NZLBHDRPUJLHCE
BRD-K00003524-001-01-9	apronal	Preclinical	cytochrome P450 modulator				0	94.07	MedChemEx	HY-B2177	Apronal	184.121	CC(C)[C@H](CC=C)C(=O)NC(N)=O |&1:3,r|	KSUUMAWCGDNLFK-ZETCQYMHSA-N	76961142.0		KSUUMAWCGDNLFK
BRD-K63919159-003-08-8	aptiganel	Phase 3	glutamate receptor antagonist	GRIN1			0	91.02	Tocris	4492	Cerestat	303.174	CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	BFNCJMURTMZBTE-UHFFFAOYSA-N	60840.0		BFNCJMURTMZBTE
BRD-K63919159-003-07-0	aptiganel	Phase 3	glutamate receptor antagonist	GRIN1			0	99.3	EMDBio	504522-10MG	CNS-1102	303.174	CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	BFNCJMURTMZBTE-UHFFFAOYSA-N	60840.0		BFNCJMURTMZBTE
BRD-K68003372-001-01-6	APTO-253	Phase 1	krppel-like factor expression enhancer	KLF4			0	96.57	MedChemEx	HY-16291	APTO-253	367.123	Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21	NIRXBXIPHUTNNI-UHFFFAOYSA-N	11960271.0		NIRXBXIPHUTNNI
BRD-K17511755-001-02-9	APY-29	Preclinical	serine/threonine kinase inhibitor	ERN1			0	97.84	Tocris	4865	APY 29	332.15	C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1	WJNBSTLIALIIEW-UHFFFAOYSA-N	42627755.0		WJNBSTLIALIIEW
BRD-K17511755-001-01-7	APY-29	Preclinical	serine/threonine kinase inhibitor	ERN1			0	94.48	Tocris	4865	APY 29	332.15	C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1	WJNBSTLIALIIEW-UHFFFAOYSA-N	42627755.0		WJNBSTLIALIIEW
BRD-K00004738-001-01-9	apyramide	Preclinical	cyclooxygenase inhibitor				0	94.26	MedChemEx	HY-U00046	Apyramide	490.13	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)Oc3ccc(NC(C)=O)cc3)c2c1	KWUFTKVMXUYTBF-UHFFFAOYSA-N	50204.0		KWUFTKVMXUYTBF
BRD-K38627885-001-01-9	APY0201	Preclinical	phosphoinositide dependent kinase inhibitor	IL12A|IL12B|PIKFYVE			0	88.96	MedChemEx	HY-15982	APY0201	413.196	Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1	RFZQYGBLRIKROZ-PCLIKHOPSA-N	56927660.0		RFZQYGBLRIKROZ
BRD-K28383148-001-01-4	AP1903	Phase 1/Phase 2		MTOR			0	89.09	MedChemEx	HY-16046	AP1903	1410.677	CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	GQLCLPLEEOUJQC-ZTQDTCGGSA-N	16135625.0		GQLCLPLEEOUJQC
BRD-K28383148-001-02-9	AP1903	Phase 1/Phase 2		MTOR			0	94.14	MedChemEx	HY-16046	Rimiducid	1410.677	CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	GQLCLPLEEOUJQC-ZTQDTCGGSA-N	16135625.0		GQLCLPLEEOUJQC
BRD-K56032964-001-02-1	AP26113	Phase 2	ALK tyrosine kinase receptor inhibitor	ALK|EGFR			0	90.42	Selleck	S7000	AP26113	528.217	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	OVDSPTSBIQCAIN-UHFFFAOYSA-N	57390074.0		OVDSPTSBIQCAIN
BRD-K56032964-001-01-3	AP26113	Phase 2	ALK tyrosine kinase receptor inhibitor	ALK|EGFR			0	96.68	BayerPharma		BAY 1747866	528.217	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	OVDSPTSBIQCAIN-UHFFFAOYSA-N	57390074.0		OVDSPTSBIQCAIN
BRD-K81729199-001-03-6	AQ-RA741	Preclinical	acetylcholine receptor antagonist	CHRM2			0	94.68	Tocris	2292	AQ-RA 741	463.295	CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	BCUGCHZRMKTPMU-UHFFFAOYSA-N	129989.0		BCUGCHZRMKTPMU
BRD-K81729199-001-02-8	AQ-RA741	Preclinical	acetylcholine receptor antagonist	CHRM2			0	89.3	Tocris	2292	AQ-RA 741	463.295	CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	BCUGCHZRMKTPMU-UHFFFAOYSA-N	129989.0		BCUGCHZRMKTPMU
BRD-K81729199-001-04-9	AQ-RA741	Preclinical	acetylcholine receptor antagonist	CHRM2			0	96.35	Tocris	2292	AQ-RA 741	463.295	CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	BCUGCHZRMKTPMU-UHFFFAOYSA-N	129989.0		BCUGCHZRMKTPMU
BRD-K00003365-300-01-9	AQ-13	Phase 2	antimalarial agent				0	96.51	MedChemEx	HY-100358	AQ-13 dihydrochloride	291.15	CCN(CC)CCCNc1ccnc2cc(Cl)ccc12	NCPLTAGJJVCHOW-UHFFFAOYSA-N	3805581.0		NCPLTAGJJVCHOW
BRD-K00004705-001-01-9	AQW-051	Preclinical	nicotinic receptor agonist				0	77.97	AMS	L14549	AQW-051	294.173	Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1	NPDLTEZXGWRMLQ-IBGZPJMESA-N	50914822.0		NPDLTEZXGWRMLQ
BRD-K67860401-001-07-2	AR-A014418	Preclinical	glycogen synthase kinase inhibitor	GSK3B			0	96.97	Tocris	3966	AR-A 014418	308.058	COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	YAEMHJKFIIIULI-UHFFFAOYSA-N	448014.0		YAEMHJKFIIIULI
BRD-K67860401-001-05-6	AR-A014418	Preclinical	glycogen synthase kinase inhibitor	GSK3B			0	96.36	Selleck	S7435	AR-A014418	308.058	COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	YAEMHJKFIIIULI-UHFFFAOYSA-N	448014.0		YAEMHJKFIIIULI
BRD-K42325600-001-02-9	AR-C155858	Preclinical	monocarboxylate transporter inhibitor	SLC16A1|SLC16A7			0	91.34	MedChemEx	HY-13248	AR-C155858	461.173	CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O	ISIVOJWVBJIOFM-ZDUSSCGKSA-N	10226546.0		ISIVOJWVBJIOFM
BRD-K42325600-001-01-8	AR-C155858	Preclinical	monocarboxylate transporter inhibitor	SLC16A1|SLC16A7			0	93.13	MedChemEx	HY-13248	AR-C155858	461.173	CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O	ISIVOJWVBJIOFM-ZDUSSCGKSA-N	10226546.0		ISIVOJWVBJIOFM
BRD-K90497590-001-08-3	AR-12	Phase 1	phosphoinositide dependent kinase inhibitor	PDPK1			0	88.78	Tocris	5682	OSU 03012	460.151	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	YULUCECVQOCQFQ-UHFFFAOYSA-N	10027278.0		YULUCECVQOCQFQ
BRD-K90497590-001-05-9	AR-12	Phase 1	phosphoinositide dependent kinase inhibitor	PDPK1			0	72.13	Selleck	S1106	OSU-03012 (AR-12)	460.151	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	YULUCECVQOCQFQ-UHFFFAOYSA-N	10027278.0		YULUCECVQOCQFQ
BRD-K90497590-001-07-5	AR-12	Phase 1	phosphoinositide dependent kinase inhibitor	PDPK1			0	92.43	Adooq	A10681	2-amino-N-{4-[5-(2-phenanthryl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide	460.151	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	YULUCECVQOCQFQ-UHFFFAOYSA-N	10027278.0		YULUCECVQOCQFQ
BRD-K90497590-001-04-2	AR-12	Phase 1	phosphoinositide dependent kinase inhibitor	PDPK1			0	78.85	Selleck	S1106	OSU-03012 (AR-12)	460.151	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	YULUCECVQOCQFQ-UHFFFAOYSA-N	10027278.0		YULUCECVQOCQFQ
BRD-K13167095-001-03-9	AR-42	Phase 1	HDAC inhibitor	HDAC1			0	97.9	MedChemEx	HY-13265	AR-42	312.147	CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	LAMIXXKAWNLXOC-INIZCTEOSA-N	6918848.0		LAMIXXKAWNLXOC
BRD-K13167095-001-02-9	AR-42	Phase 1	HDAC inhibitor	HDAC1			0	94.12	Selleck	S2244	AR-42	312.147	CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	LAMIXXKAWNLXOC-INIZCTEOSA-N	6918848.0		LAMIXXKAWNLXOC
BRD-K03070961-001-10-1	arachidonic-acid	Phase 1	cytochrome P450 inhibitor	CLCN2|KCNJ4|KCNK10|KCNK18|KCNK2|PRKCZ|PTGS1|TRPC6|TRPM2			0	21.3	Sigma	MFCD00004417	(5Z,8Z,11Z,14Z)-5,8,11,14-icosatetraenoic acid	304.24	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	YZXBAPSDXZZRGB-DOFZRALJSA-N	444899.0		YZXBAPSDXZZRGB
BRD-K03070961-001-08-5	arachidonic-acid	Phase 1	cytochrome P450 inhibitor	CLCN2|KCNJ4|KCNK10|KCNK18|KCNK2|PRKCZ|PTGS1|TRPC6|TRPM2			0	50.81	Enzo	FA003	5(Z),8(Z),11(Z),14(Z)-Eicosatetraenoic acid	304.24	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	YZXBAPSDXZZRGB-DOFZRALJSA-N	444899.0		YZXBAPSDXZZRGB
BRD-K00004646-001-01-9	aramchol	Phase 2/Phase 3	stearoyl-CoA desaturase inhibitor				0	100.0	Sigma	SML2352	(4R)-4-[(3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid	701.596	CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1	SHKXZIQNFMOPBS-OOMQYRRCSA-N	18738120.0		SHKXZIQNFMOPBS
BRD-K73881242-003-06-1	arbidol	Launched	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	0	72.6	MedChemEx	HY-14904A	Arbidol (hydrochloride)	476.077	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	KCFYEAOKVJSACF-UHFFFAOYSA-N	28446253.0		KCFYEAOKVJSACF
BRD-K73881242-003-02-0	arbidol	Launched	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	0	57.79	Selleck	S2120	Arbidol HCl	476.077	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	KCFYEAOKVJSACF-UHFFFAOYSA-N	28446253.0		KCFYEAOKVJSACF
BRD-K73881242-003-04-6	arbidol	Launched	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	0	80.95	MedChemEx	HY-14904A	Arbidol (hydrochloride)	476.077	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	KCFYEAOKVJSACF-UHFFFAOYSA-N	28446253.0		KCFYEAOKVJSACF
BRD-K73881242-003-03-8	arbidol	Launched	cytochrome P450 inhibitor	CYP3A4	infectious disease	influenza A virus infection	0	79.43	Selleck	S2120	Arbidol HCl	476.077	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	KCFYEAOKVJSACF-UHFFFAOYSA-N	28446253.0		KCFYEAOKVJSACF
BRD-K08037784-001-13-9	arbutin	Phase 2/Phase 3	melanin inhibitor	TYR			0	100.0	MedChemEx	HY-N0192	Arbutin	272.09	OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	BJRNKVDFDLYUGJ-RMPHRYRLSA-N	440936.0		BJRNKVDFDLYUGJ
BRD-K08037784-001-12-6	arbutin	Phase 2/Phase 3	melanin inhibitor	TYR			0	100.0	Selleck	S2263	Arbutin	272.09	OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	BJRNKVDFDLYUGJ-RMPHRYRLSA-N	440936.0		BJRNKVDFDLYUGJ
BRD-K93188295-300-03-9	ARC-239	Preclinical	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C			0	95.8	Tocris	928	ARC 239 dihydrochloride	407.221	COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	JFNKXGOEOQCXDM-UHFFFAOYSA-N	609483.0		JFNKXGOEOQCXDM
BRD-K93188295-300-02-2	ARC-239	Preclinical	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C			0	96.55	Tocris	928	ARC 239 dihydrochloride	407.221	COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	JFNKXGOEOQCXDM-UHFFFAOYSA-N	609483.0		JFNKXGOEOQCXDM
BRD-K53523901-001-05-1	arctigenin	Preclinical	MEK inhibitor	CHUK|MAP2K1			0	94.87	Tocris	1777	Arctigenin	372.157	COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC	NQWVSMVXKMHKTF-JKSUJKDBSA-N	64981.0		NQWVSMVXKMHKTF
BRD-K53523901-001-04-4	arctigenin	Preclinical	MEK inhibitor	CHUK|MAP2K1			0	98.04	Tocris	1777	Arctigenin	372.157	COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC	NQWVSMVXKMHKTF-JKSUJKDBSA-N	64981.0		NQWVSMVXKMHKTF
BRD-K72726508-001-02-1	arcyriaflavin-a	Preclinical	CDK inhibitor	CCND1|CDK4			0	87.45	Tocris	2457	Arcyriaflavin A	325.085	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	KAJXOWFGKYKMMZ-UHFFFAOYSA-N	5327723.0		KAJXOWFGKYKMMZ
BRD-K72726508-001-06-9	arcyriaflavin-a	Preclinical	CDK inhibitor	CCND1|CDK4			0	89.04	Tocris	2457	Arcyriaflavin A	325.085	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	KAJXOWFGKYKMMZ-UHFFFAOYSA-N	5327723.0		KAJXOWFGKYKMMZ
BRD-K72726508-001-03-9	arcyriaflavin-a	Preclinical	CDK inhibitor	CCND1|CDK4			0	83.77	Tocris	2457	Arcyriaflavin A	325.085	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	KAJXOWFGKYKMMZ-UHFFFAOYSA-N	5327723.0		KAJXOWFGKYKMMZ
BRD-K00003590-314-01-9	ardeparin	Withdrawn	thrombin inhibitor	SERPIND1			0	0.0	MedChemEx	HY-17567A	Heparin (sodium salt)	623.013	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	HXSDFQWQRCUQHF-IDOMHHBZSA-N	100942142.0		HXSDFQWQRCUQHF
BRD-K63792901-075-02-1	arecaidine-but-2-ynyl-ester	Preclinical	acetylcholine receptor agonist	CHRM2			0	87.97	Tocris	382	Arecaidine but-2-ynyl ester tosylate	193.11	CC#CCOC(=O)C1=CCCN(C)C1 |t:7|	LBFWTPRSXIRKMZ-UHFFFAOYSA-N	4214594.0		LBFWTPRSXIRKMZ
BRD-K23922020-075-03-7	arecaidine-propargyl-ester	Preclinical	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	84.89	Tocris	383	2-propynyl 1-methyl-1,2,5,6-tetrahydro-3-pyridinecarboxylate 4-methylbenzenesulfonate	179.095	CN1CCC=C(C1)C(=O)OCC#C |c:4|	SPHRJZBOFYIKMC-UHFFFAOYSA-N	2229.0		SPHRJZBOFYIKMC
BRD-K23922020-075-02-9	arecaidine-propargyl-ester	Preclinical	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	84.41	Tocris	383	Arecaidine propargyl ester tosylate	179.095	CN1CCC=C(C1)C(=O)OCC#C |c:4|	SPHRJZBOFYIKMC-UHFFFAOYSA-N	2229.0		SPHRJZBOFYIKMC
BRD-K88646909-004-17-9	arecoline	Phase 1	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	92.5	MedChemEx	HY-B0489	Arecoline (hydrobromide)	155.095	COC(=O)C1=CCCN(C)C1 |t:4|	HJJPJSXJAXAIPN-UHFFFAOYSA-N	2230.0		HJJPJSXJAXAIPN
BRD-K88646909-004-15-4	arecoline	Phase 1	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	94.77	Selleck	S2614	Arecoline	155.095	COC(=O)C1=CCCN(C)C1 |t:4|	HJJPJSXJAXAIPN-UHFFFAOYSA-N	2230.0		HJJPJSXJAXAIPN
BRD-K88646909-004-16-2	arecoline	Phase 1	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	99.05	MicroSource	1500680	ARECOLINE HYDROBROMIDE	155.095	COC(=O)C1=CCCN(C)C1 |t:4|	HJJPJSXJAXAIPN-UHFFFAOYSA-N	2230.0		HJJPJSXJAXAIPN
BRD-A48261811-001-07-3	argatroban	Launched	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	0	94.02	Tocris	1637	Argatroban	508.247	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|	KXNPVXPOPUZYGB-XYVMCAHJSA-N	152951.0		KXNPVXPOPUZYGB
BRD-A48261811-001-08-1	argatroban	Launched	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	0	97.13	Selleck	S2069	Argatroban	508.247	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|	KXNPVXPOPUZYGB-XYVMCAHJSA-N	152951.0	BRD-A10012892-001-01-9	KXNPVXPOPUZYGB
BRD-A48261811-001-09-9	argatroban	Launched	thrombin inhibitor	F2	hematology	heparin-induced thrombocytopenia (HIT)	0	77.04	Tocris	1637	Argatroban	508.247	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1,5,12,&1:30|	KXNPVXPOPUZYGB-XYVMCAHJSA-N	152951.0		KXNPVXPOPUZYGB
BRD-K00003332-001-01-9	argireline	Phase 3	neurotransmitter release inhibitor				0	100.0	MedChemEx	HY-P0033	Argireline	888.424	CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O	RJZNPROJTJSYLC-LLINQDLYSA-N	11228338.0		RJZNPROJTJSYLC
BRD-K62734952-001-01-0	arglabin	Launched	farnesyltransferase inhibitor	FNTA|NFKB1			0	97.88	MedChemEx	HY-16059	Arglabin	246.126	CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|	UVJYAKBJSGRTHA-CUZKYEQNSA-N	5574924.0		UVJYAKBJSGRTHA
BRD-K62734952-001-02-9	arglabin	Launched	farnesyltransferase inhibitor	FNTA|NFKB1			0	79.75	MedChemEx	HY-16059	Arglabin	246.126	CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|	UVJYAKBJSGRTHA-CUZKYEQNSA-N	5574924.0		UVJYAKBJSGRTHA
BRD-K70358946-001-17-3	aripiprazole	Launched	serotonin receptor agonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7	neurology/psychiatry	depression|schizophrenia|bipolar disorder	0	95.78	Tocris	5584	Aripiprazole	447.148	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	CEUORZQYGODEFX-UHFFFAOYSA-N	60795.0		CEUORZQYGODEFX
BRD-K70358946-001-15-7	aripiprazole	Launched	serotonin receptor agonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7	neurology/psychiatry	depression|schizophrenia|bipolar disorder	0	98.35	MicroSource	1505851	ARIPIPRAZOLE	447.148	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	CEUORZQYGODEFX-UHFFFAOYSA-N	60795.0		CEUORZQYGODEFX
BRD-K70358946-001-14-0	aripiprazole	Launched	serotonin receptor agonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7	neurology/psychiatry	depression|schizophrenia|bipolar disorder	0	95.09	Selleck	S1975	Aripiprazole	447.148	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	CEUORZQYGODEFX-UHFFFAOYSA-N	60795.0		CEUORZQYGODEFX
BRD-K00004574-001-01-9	aripiprazole-lauroxil	Launched	serotonin receptor agonist		neurology/psychiatry	schizophrenia	0	73.03	Astatech	42552	ARIPIPRAZOLE LAUROXIL	659.326	CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(CC3)c3cccc(Cl)c3Cl)cc12	DDINXHAORAAYAD-UHFFFAOYSA-N	49831411.0		DDINXHAORAAYAD
BRD-K33852358-001-09-9	arofylline	Phase 3	phosphodiesterase inhibitor	PDE4A			0	98.45	Maybridge	KM09088		304.073	CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O	GVTLDPJNRVMCAL-UHFFFAOYSA-N	166553.0		GVTLDPJNRVMCAL
BRD-A28044053-001-01-7	arotinolol	Launched	adrenergic receptor antagonist	ADRB3	cardiology|neurology/psychiatry	hypertension|tremors	0	96.65	AKSci	K136		371.08	CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6,r|	BHIAIPWSVYSKJS-SECBINFHSA-N	12797283.0		BHIAIPWSVYSKJS
BRD-K60171656-001-01-6	ARQ-092	Phase 1	AKT inhibitor	AKT2			0	97.73	MedChemEx	HY-19719	ARQ-092	432.206	Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1	HNFMVVHMKGFCMB-UHFFFAOYSA-N	53262401.0		HNFMVVHMKGFCMB
BRD-K43436647-001-01-7	ARQ-621	Phase 1	kinesin-like spindle protein inhibitor	KIF11			0	80.29	Selleck	S7355	ARQ 621	551.129	NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F	UPJSUQWHUVLLNW-XMMPIXPASA-N	25110841.0		UPJSUQWHUVLLNW
BRD-K43436647-001-02-5	ARQ-621	Phase 1	kinesin-like spindle protein inhibitor	KIF11			0	89.24	Selleck	S7355	ARQ 621	551.129	NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F	UPJSUQWHUVLLNW-XMMPIXPASA-N	25110841.0		UPJSUQWHUVLLNW
BRD-K46386702-001-03-9	ARRY-334543	Phase 2/Phase 3	EGFR inhibitor	ERBB2			0	92.24	MedChemEx	HY-10530	Varlitinib	466.098	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|	UWXSAYUXVSFDBQ-CYBMUJFWSA-N	42642648.0		UWXSAYUXVSFDBQ
BRD-K46386702-001-02-1	ARRY-334543	Phase 2/Phase 3	EGFR inhibitor	ERBB2			0	93.97	Selleck	S2755	Varlitinib	466.098	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|	UWXSAYUXVSFDBQ-CYBMUJFWSA-N	42642648.0		UWXSAYUXVSFDBQ
BRD-K24179883-001-17-9	arsanilic-acid	Phase 1		LYZ			0	94.0	MedChemEx	HY-B1536	Arsanilic acid	216.972	Nc1ccc(cc1)[As](O)(O)=O	XKNKHVGWJDPIRJ-UHFFFAOYSA-N	7389.0		XKNKHVGWJDPIRJ
BRD-K24179883-001-16-7	arsanilic-acid	Phase 1		LYZ			0	100.0	MicroSource	1505652	ARSANILIC ACID	216.972	Nc1ccc(cc1)[As](O)(O)=O	XKNKHVGWJDPIRJ-UHFFFAOYSA-N	7389.0		XKNKHVGWJDPIRJ
BRD-K32786395-001-01-2	arsenic-trioxide	Launched	apoptosis stimulant	AKT1|CCND1|IKBKB|JUN|MAPK1|MAPK3|TXNRD1	gastroenterology	diarrhea	0	0.0	Sigma	202673-5G	Arsenic (III) oxide	197.828	O=[As]O[As]=O	IKWTVSLWAPBBKU-UHFFFAOYSA-N	261004.0		IKWTVSLWAPBBKU
BRD-K39621635-001-09-7	artemether	Launched	antimalarial agent	ATP1A1	infectious disease	malaria	0	0.0	MicroSource	1505032	ARTEMETHER	298.178	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	SXYIRMFQILZOAM-HVNFFKDJSA-N	68911.0	BRD-A45966947-001-02-8	SXYIRMFQILZOAM
BRD-K39621635-001-07-1	artemether	Launched	antimalarial agent	ATP1A1	infectious disease	malaria	0	0.0	MedChemEx	HY-N0402	Artemether	298.178	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	SXYIRMFQILZOAM-HVNFFKDJSA-N	68911.0		SXYIRMFQILZOAM
BRD-K39621635-001-05-5	artemether	Launched	antimalarial agent	ATP1A1	infectious disease	malaria	0	0.0	MedChemEx	HY-N0402	Artemether	298.178	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	SXYIRMFQILZOAM-HVNFFKDJSA-N	68911.0		SXYIRMFQILZOAM
BRD-K39621635-001-08-9	artemether	Launched	antimalarial agent	ATP1A1	infectious disease	malaria	0	0.0	Selleck	S2264	Artemether	298.178	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	SXYIRMFQILZOAM-HVNFFKDJSA-N	68911.0	BRD-K17916327-001-02-5	SXYIRMFQILZOAM
BRD-K39621635-001-06-3	artemether	Launched	antimalarial agent	ATP1A1	infectious disease	malaria	0	0.0	Selleck	S2264	Artemether	298.178	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	SXYIRMFQILZOAM-HVNFFKDJSA-N	68911.0	BRD-K12393844-001-01-8	SXYIRMFQILZOAM
BRD-K13112821-001-18-2	artemisinin	Launched	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	0	100.0	MicroSource	1503042	ARTEMISININ	282.147	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BLUAFEHZUWYNDE-NNWCWBAJSA-N	68827.0	BRD-K27678847-001-06-1	BLUAFEHZUWYNDE
BRD-K13112821-001-16-6	artemisinin	Launched	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	0	86.2	Tocris	2668	Artemisinin	282.147	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BLUAFEHZUWYNDE-NNWCWBAJSA-N	68827.0		BLUAFEHZUWYNDE
BRD-K13112821-001-14-1	artemisinin	Launched	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	0	94.31	Tocris	2668	Artemisinin	282.147	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BLUAFEHZUWYNDE-NNWCWBAJSA-N	68827.0		BLUAFEHZUWYNDE
BRD-K13112821-001-19-9	artemisinin	Launched	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	0	100.0	Tocris	2668	Artemisinin	282.147	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BLUAFEHZUWYNDE-NNWCWBAJSA-N	68827.0		BLUAFEHZUWYNDE
BRD-K13112821-001-17-4	artemisinin	Launched	DNA synthesis inhibitor	CYP2B6	infectious disease	malaria	0	100.0	Selleck	S1282	Artemisinin	282.147	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BLUAFEHZUWYNDE-NNWCWBAJSA-N	68827.0	BRD-K01715490-001-01-2	BLUAFEHZUWYNDE
BRD-K96006160-001-03-7	artemotil	Launched			infectious disease	malaria	0	0.0	MedChemEx	HY-B0770	Artemotil	312.194	CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	NLYNIRQVMRLPIQ-XQLAAWPRSA-N	3000469.0		NLYNIRQVMRLPIQ
BRD-K96006160-001-01-1	artemotil	Launched			infectious disease	malaria	0	0.0	AKSci	N732		312.194	CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	NLYNIRQVMRLPIQ-XQLAAWPRSA-N	3000469.0		NLYNIRQVMRLPIQ
BRD-K96006160-001-02-9	artemotil	Launched			infectious disease	malaria	0	0.0	MedChemEx	HY-B0770	Artemotil	312.194	CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	NLYNIRQVMRLPIQ-XQLAAWPRSA-N	3000469.0		NLYNIRQVMRLPIQ
BRD-K54634444-001-05-9	artesunate	Launched	DNA synthesis inhibitor		infectious disease	malaria	0	100.0	MicroSource	1504829	ARTESUNATE	384.178	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	FIHJKUPKCHIPAT-AHIGJZGOSA-N	6917864.0	BRD-K17944737-001-02-1	FIHJKUPKCHIPAT
BRD-K54634444-001-04-2	artesunate	Launched	DNA synthesis inhibitor		infectious disease	malaria	0	99.56	Selleck	S2265	Artesunate	384.178	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	FIHJKUPKCHIPAT-AHIGJZGOSA-N	6917864.0	BRD-K65768634-001-01-1	FIHJKUPKCHIPAT
BRD-A70514680-003-12-9	articaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	91.48	MedChemEx	HY-B0516	Articaine (hydrochloride)	284.119	CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|	QTGIAADRBBLJGA-VIFPVBQESA-N	6604377.0		QTGIAADRBBLJGA
BRD-A70514680-003-11-2	articaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	90.48	Selleck	S3150	Articaine HCl	284.119	CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|	QTGIAADRBBLJGA-VIFPVBQESA-N	6604377.0		QTGIAADRBBLJGA
BRD-K49223707-001-01-0	arundic-acid	Phase 2/Phase 3	astrocyte modulating agent	PTGS2|S100B			0	17.19	Tocris	4530	(2R)-2-propyloctanoic acid	186.162	CCCCCC[C@@H](CCC)C(O)=O	YCYMCMYLORLIJX-SNVBAGLBSA-N	208925.0		YCYMCMYLORLIJX
BRD-A00047421-001-01-7	ARV-825	Preclinical	bromodomain inhibitor	BRD4			0	96.88	MedChemEx	HY-16954	ARV-825	922.288	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9,&1:39,c:8|	RWLOGRLTDKDANT-ZPGRZCPFSA-N	124870683.0		RWLOGRLTDKDANT
BRD-K07656463-001-01-5	AS-1269574	Preclinical	glucose dependent insulinotropic receptor agonist	GPR119			0	97.58	Tocris	4177	AS 1269574	307.032	Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1	DUKPGOOUJNUIOI-UHFFFAOYSA-N	5332859.0		DUKPGOOUJNUIOI
BRD-K07656463-001-02-9	AS-1269574	Preclinical	glucose dependent insulinotropic receptor agonist	GPR119			0	95.46	Tocris	4177	AS 1269574	307.032	Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1	DUKPGOOUJNUIOI-UHFFFAOYSA-N	5332859.0		DUKPGOOUJNUIOI
BRD-K27051047-001-02-9	AS-1892802	Preclinical	rho associated kinase inhibitor	ROCK1			0	96.36	Tocris	4927	AS 1892802	333.148	OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1	WDTFYYZHMRBVHK-LJQANCHMSA-N	46911016.0		WDTFYYZHMRBVHK
BRD-K27051047-001-01-0	AS-1892802	Preclinical	rho associated kinase inhibitor	ROCK1			0	98.94	Tocris	4927	AS 1892802	333.148	OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1	WDTFYYZHMRBVHK-LJQANCHMSA-N	46911016.0		WDTFYYZHMRBVHK
BRD-K61936403-001-02-5	AS-1949490	Preclinical	SHIP2 phosphatase inhibitor	INPP5D			0	97.1	Tocris	3718	AS 1949490	371.075	C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	RFZPGNRLOKVZJY-AWEZNQCLSA-N	44473434.0		RFZPGNRLOKVZJY
BRD-K61936403-001-01-7	AS-1949490	Preclinical	SHIP2 phosphatase inhibitor	INPP5D			0	98.99	Tocris	3718	AS 1949490	371.075	C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	RFZPGNRLOKVZJY-AWEZNQCLSA-N	44473434.0		RFZPGNRLOKVZJY
BRD-K75254015-001-02-9	AS-2034178	Preclinical	free fatty acid receptor agonist	FFAR1			0	95.79	Tocris	5035	AS 2034178	448.216	OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F	VENOXIKBBUVHRY-UHFFFAOYSA-N	24808572.0		VENOXIKBBUVHRY
BRD-K75254015-001-01-9	AS-2034178	Preclinical	free fatty acid receptor agonist	FFAR1			0	94.69	Tocris	5035	AS 2034178	448.216	OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F	VENOXIKBBUVHRY-UHFFFAOYSA-N	24808572.0		VENOXIKBBUVHRY
BRD-K73565918-003-01-4	AS-2444697	Preclinical	interleukin inhibitor	IRAK4			0	92.16	Tocris	5430	AS 2444697	396.155	Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1	JANBIXNDYNRYQP-UHFFFAOYSA-N	52913874.0		JANBIXNDYNRYQP
BRD-K73565918-003-02-9	AS-2444697	Preclinical	interleukin inhibitor	IRAK4			0	97.27	Tocris	5430	AS 2444697	396.155	Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1	JANBIXNDYNRYQP-UHFFFAOYSA-N	52913874.0		JANBIXNDYNRYQP
BRD-K14988953-001-04-4	AS-252424	Preclinical	PI3K inhibitor	PIK3CG			0	82.97	Selleck	S2671	AS-252424	305.016	Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1	OYYVWNDMOQPMGE-SDQBBNPISA-N	11630874.0		OYYVWNDMOQPMGE
BRD-K14988953-001-03-6	AS-252424	Preclinical	PI3K inhibitor	PIK3CG			0	74.6	Selleck	S2671	AS-252424	305.016	Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1	OYYVWNDMOQPMGE-SDQBBNPISA-N	11630874.0		OYYVWNDMOQPMGE
BRD-K63915849-001-03-7	AS-604850	Preclinical	PI3K inhibitor	PIK3CA|PIK3CG			0	94.13	Selleck	S2681	AS-604850	284.991	FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1	SRLVNYDXMUGOFI-YWEYNIOJSA-N	5287855.0		SRLVNYDXMUGOFI
BRD-K89014967-001-05-9	AS-703026	Phase 2	MEK inhibitor	MAP2K1|MAP2K2			0	97.12	MedChemEx	HY-12042	Pimasertib	431.014	OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	VIUAUNHCRHHYNE-JTQLQIEISA-N	44187362.0		VIUAUNHCRHHYNE
BRD-K89014967-001-04-3	AS-703026	Phase 2	MEK inhibitor	MAP2K1|MAP2K2			0	97.03	Selleck	S1475	Pimasertib (AS-703026)	431.014	OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	VIUAUNHCRHHYNE-JTQLQIEISA-N	44187362.0		VIUAUNHCRHHYNE
BRD-K62427771-001-02-9	AS-77	Phase 1	potassium channel blocker	KCNA3|KCNA5|KCNN4			0	97.74	MedChemEx	HY-10015	PAP-1	350.115	O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	KINMYBBFQRSVLL-UHFFFAOYSA-N	11302540.0		KINMYBBFQRSVLL
BRD-K62427771-001-01-0	AS-77	Phase 1	potassium channel blocker	KCNA3|KCNA5|KCNN4			0	99.13	MedChemEx	HY-10015	PAP-1	350.115	O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	KINMYBBFQRSVLL-UHFFFAOYSA-N	11302540.0		KINMYBBFQRSVLL
BRD-K27938825-001-04-9	ASA-404	Phase 3	angiogenesis inhibitor				0	92.48	MedChemEx	HY-10964	Vadimezan	282.089	Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	XGOYIMQSIKSOBS-UHFFFAOYSA-N	123964.0		XGOYIMQSIKSOBS
BRD-K27938825-001-02-4	ASA-404	Phase 3	angiogenesis inhibitor				0	95.25	Selleck	S1537	DMXAA (Vadimezan)	282.089	Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	XGOYIMQSIKSOBS-UHFFFAOYSA-N	123964.0		XGOYIMQSIKSOBS
BRD-K00003230-001-01-9	asapiprant	Preclinical	prostaglandin inhibitor				0	97.14	MedChemEx	HY-16763	Asapiprant	501.157	CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(-c2ncco2)c(OCC(O)=O)c1	ZMZNWNTZRWXTJU-UHFFFAOYSA-N	59232326.0		ZMZNWNTZRWXTJU
BRD-K88219015-001-11-9	asaraldehyde	Preclinical	cyclooxygenase inhibitor	PTGS2			0	93.79	MedChemEx	HY-100580	Asaraldehyde	196.074	COc1cc(OC)c(C=O)cc1OC	IAJBQAYHSQIQRE-UHFFFAOYSA-N	20525.0		IAJBQAYHSQIQRE
BRD-K88219015-001-10-8	asaraldehyde	Preclinical	cyclooxygenase inhibitor	PTGS2			0	95.62	Selleck	S2531	Asaraldehyde	196.074	COc1cc(OC)c(C=O)cc1OC	IAJBQAYHSQIQRE-UHFFFAOYSA-N	20525.0		IAJBQAYHSQIQRE
BRD-K30331124-001-04-9	ASC-J9	Phase 2	androgen receptor enhancer	AR			0	86.89	Sigma	MFCD28964095	(1E,4E,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one	396.157	COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC	ZMGUKFHHNQMKJI-URFDALOKSA-N	74891315.0		ZMGUKFHHNQMKJI
BRD-K30331124-001-01-7	ASC-J9	Phase 2	androgen receptor enhancer	AR			0	89.77	MedChemEx	HY-15194	ASC-J9	396.157	COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC	ZMGUKFHHNQMKJI-URFDALOKSA-N	74891315.0		ZMGUKFHHNQMKJI
BRD-K30331124-001-03-3	ASC-J9	Phase 2	androgen receptor enhancer	AR			0	91.45	MedChemEx	HY-15194	ASC-J9	396.157	COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC	ZMGUKFHHNQMKJI-URFDALOKSA-N	74891315.0		ZMGUKFHHNQMKJI
BRD-K30331124-001-02-5	ASC-J9	Phase 2	androgen receptor enhancer	AR			0	68.87	Adooq	A11300	(1E,4E,6E)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxy-1,4,6-heptatrien-3-one	396.157	COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC	ZMGUKFHHNQMKJI-URFDALOKSA-N	74891315.0		ZMGUKFHHNQMKJI
BRD-K00003456-001-01-9	asciminib	Phase 2	Bcr-Abl kinase inhibitor				0	98.07	MedChemEx	HY-104010	Asciminib	449.107	O[C@@H]1CCN(C1)c1ncc(cc1-c1cc[nH]n1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1	VOVZXURTCKPRDQ-CQSZACIVSA-N	72165228.0		VOVZXURTCKPRDQ
BRD-K88882192-001-03-3	ascomycin	Preclinical	calcineurin inhibitor	FKBP1A			0	100.0	Selleck	S7411	Ascomycin (FK520)	791.482	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|	ZDQSOHOQTUFQEM-MONOPTSESA-N	134129697.0		ZDQSOHOQTUFQEM
BRD-A85242401-001-11-5	ascorbic-acid	Launched	antioxidant	SLC23A1|SLC23A2	endocrinology	scurvy	0	33.8	MedChemEx	HY-B0166	L-Ascorbic acid	176.032	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	KRGQEOSDQHTZMX-TXQLHFEISA-N			KRGQEOSDQHTZMX
BRD-A85242401-001-10-7	ascorbic-acid	Launched	antioxidant	SLC23A1|SLC23A2	endocrinology	scurvy	0	0.0	MedChemEx	HY-B0166	L-Ascorbic acid	176.032	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	KRGQEOSDQHTZMX-TXQLHFEISA-N			KRGQEOSDQHTZMX
BRD-A85242401-001-09-9	ascorbic-acid	Launched	antioxidant	SLC23A1|SLC23A2	endocrinology	scurvy	0	0.0	Sigma	95209	(5R)-5-((S)-1,2-dihydroxyethyl)-4-hydroxydihydrofuran-2,3-dione	176.032	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	KRGQEOSDQHTZMX-TXQLHFEISA-N			KRGQEOSDQHTZMX
BRD-A85242401-001-12-3	ascorbic-acid	Launched	antioxidant	SLC23A1|SLC23A2	endocrinology	scurvy	0	100.0	MicroSource	1502230	ASCORBIC ACID	176.032	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	KRGQEOSDQHTZMX-TXQLHFEISA-N		BRD-A08112603-001-04-5	KRGQEOSDQHTZMX
BRD-A85242401-001-05-7	ascorbic-acid	Launched	antioxidant	SLC23A1|SLC23A2	endocrinology	scurvy	0	0.0	Selleck	S3114	Vitamin C	176.032	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	KRGQEOSDQHTZMX-TXQLHFEISA-N			KRGQEOSDQHTZMX
BRD-A85242401-001-07-3	ascorbic-acid	Launched	antioxidant	SLC23A1|SLC23A2	endocrinology	scurvy	0	0.0	Selleck	S3114	Vitamin C (Ascorbic acid)	176.032	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2,4,&1:10|	KRGQEOSDQHTZMX-TXQLHFEISA-N			KRGQEOSDQHTZMX
BRD-K00003551-050-01-9	asenapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A	neurology/psychiatry	schizophrenia|bipolar disorder	0	93.71	MedChemEx	HY-11100	Asenapine (maleate)	285.092	[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	163091.0		VSWBSWWIRNCQIJ
BRD-K00003551-050-02-9	asenapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A	neurology/psychiatry	schizophrenia|bipolar disorder	0	94.5	Tocris	3737	Asenapine maleate	285.092	[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1,6|	VSWBSWWIRNCQIJ-HUUCEWRRSA-N	163091.0		VSWBSWWIRNCQIJ
BRD-K35079116-001-02-5	asiatic-acid	Preclinical	apoptosis stimulant	PYGM			0	92.85	Selleck	S2266	Asiatic acid	488.35	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	JXSVIVRDWWRQRT-UYDOISQJSA-N	119034.0		JXSVIVRDWWRQRT
BRD-K35079116-001-03-3	asiatic-acid	Preclinical	apoptosis stimulant	PYGM			0	84.94	Selleck	S2266	Asiatic Acid	488.35	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	JXSVIVRDWWRQRT-UYDOISQJSA-N	119034.0	BRD-K88350560-001-01-9	JXSVIVRDWWRQRT
BRD-K35079116-001-04-1	asiatic-acid	Preclinical	apoptosis stimulant	PYGM			0	85.05	Selleck	S2266	Asiatic acid	488.35	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	JXSVIVRDWWRQRT-UYDOISQJSA-N	119034.0		JXSVIVRDWWRQRT
BRD-K00003477-001-01-9	asimadoline	Phase 3	opioid receptor agonist	OPRK1			0	90.34	MedChemEx	HY-107384	Asimadoline	414.231	CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1	JHLHNYVMZCADTC-LOSJGSFVSA-N	179340.0		JHLHNYVMZCADTC
BRD-K00003138-001-01-9	asivatrep	Phase 3	transient receptor potential channel antagonist				0	90.4	MedChemEx	HY-12777	Asivatrep	491.13	CCCc1nc(ccc1\C=C\C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1)C(F)(F)F	UKGJZDSUJSPAJL-YPUOHESYSA-N	56649347.0		UKGJZDSUJSPAJL
BRD-K07150325-001-02-5	ASP-2535	Phase 1	glycine transporter inhibitor	SLC6A9			0	93.17	Tocris	5308	ASP 2535	382.154	CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12	FQGLDGKVKDPVLO-UHFFFAOYSA-N	9800113.0		FQGLDGKVKDPVLO
BRD-K07150325-001-01-7	ASP-2535	Phase 1	glycine transporter inhibitor	SLC6A9			0	98.79	Tocris	5308	4-(3-isopropyl-5-(6-phenylpyridin-3-yl)-4H-1,2,4-triazol-4-yl)benzo[c][1,2,5]oxadiazole	382.154	CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12	FQGLDGKVKDPVLO-UHFFFAOYSA-N	9800113.0		FQGLDGKVKDPVLO
BRD-K82239282-001-02-9	ASP-6537	Preclinical	cyclooxygenase inhibitor				0	95.01	AMS	Q69277	3-methoxy-1,5-bis(4-methoxyphenyl)-1H-1,2,4-triazole	311.127	COc1nc(-c2ccc(OC)cc2)n(n1)-c1ccc(OC)cc1	OBAICMYWONZOSZ-UHFFFAOYSA-N	9922739.0		OBAICMYWONZOSZ
BRD-K00003301-001-01-9	ASP-9521	Preclinical	aldo-keto reductase inhibitor				0	84.47	MedChemEx	HY-19903	ASP-9521	330.194	COc1ccc2[nH]c(cc2c1)C(=O)N1CCC(CC(C)(C)O)CC1	OXSCPDKUZWPWFR-UHFFFAOYSA-N	25210792.0		OXSCPDKUZWPWFR
BRD-K78841970-001-12-0	aspartame	Launched		TAS1R2|TRPV1			0	17.78	MicroSource	1505306	ASPARTAME	294.122	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	IAOZJIPTCAWIRG-QWRGUYRKSA-N	6992066.0		IAOZJIPTCAWIRG
BRD-K78841970-001-14-6	aspartame	Launched		TAS1R2|TRPV1			0	85.8	Sigma	A1320000	(3S)-3-amino-4-{[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino}-4-oxobutanoic acid	294.122	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	IAOZJIPTCAWIRG-QWRGUYRKSA-N	6992066.0		IAOZJIPTCAWIRG
BRD-K78841970-001-13-8	aspartame	Launched		TAS1R2|TRPV1			0	83.92	Selleck	S2036	Aspartame	294.122	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	IAOZJIPTCAWIRG-QWRGUYRKSA-N	6992066.0		IAOZJIPTCAWIRG
BRD-K78841970-001-11-2	aspartame	Launched		TAS1R2|TRPV1			0	14.47	Selleck	S2036	Aspartame	294.122	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	IAOZJIPTCAWIRG-QWRGUYRKSA-N	6992066.0		IAOZJIPTCAWIRG
BRD-K11433652-001-23-8	aspirin	Launched	cyclooxygenase inhibitor	AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain	0	0.0	Tocris	4092	Aspirin	180.042	CC(=O)Oc1ccccc1C(O)=O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	2244.0		BSYNRYMUTXBXSQ
BRD-K11433652-001-17-0	aspirin	Launched	cyclooxygenase inhibitor	AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain	0	99.34	MicroSource	1500130	ASPIRIN	180.042	CC(=O)Oc1ccccc1C(O)=O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	2244.0		BSYNRYMUTXBXSQ
BRD-K11433652-001-16-2	aspirin	Launched	cyclooxygenase inhibitor	AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain	0	0.0	Selleck	S3017	Aspirin	180.042	CC(=O)Oc1ccccc1C(O)=O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	2244.0		BSYNRYMUTXBXSQ
BRD-K11433652-001-18-8	aspirin	Launched	cyclooxygenase inhibitor	AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53	neurology/psychiatry|endocrinology|dental	headache|fever|toothache|muscle pain	0	0.0	Selleck	S3017	Aspirin (Acetylsalicylic acid)	180.042	CC(=O)Oc1ccccc1C(O)=O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	2244.0		BSYNRYMUTXBXSQ
BRD-K06542892-001-03-9	ASP3026	Phase 1	ALK tyrosine kinase receptor inhibitor	ALK			0	92.22	Tocris	5310	ASP 3026	580.294	COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	MGGBYMDAPCCKCT-UHFFFAOYSA-N	25134326.0		MGGBYMDAPCCKCT
BRD-K06542892-001-02-7	ASP3026	Phase 1	ALK tyrosine kinase receptor inhibitor	ALK			0	94.84	Tocris	5310	ASP 3026	580.294	COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	MGGBYMDAPCCKCT-UHFFFAOYSA-N	25134326.0		MGGBYMDAPCCKCT
BRD-K06542892-001-01-9	ASP3026	Phase 1	ALK tyrosine kinase receptor inhibitor	ALK			0	95.38	MedChemEx	HY-13326	ASP3026	580.294	COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	MGGBYMDAPCCKCT-UHFFFAOYSA-N	25134326.0		MGGBYMDAPCCKCT
BRD-K26838195-075-05-9	AST-1306	Phase 1	EGFR inhibitor	EGFR|ERBB2			0	83.37	MedChemEx	HY-13427	Allitinib tosylate	448.11	Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	MVZGYPSXNDCANY-UHFFFAOYSA-N	24739943.0		MVZGYPSXNDCANY
BRD-K26838195-075-04-9	AST-1306	Phase 1	EGFR inhibitor	EGFR|ERBB2			0	97.14	Selleck	S2185	AST-1306	448.11	Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	MVZGYPSXNDCANY-UHFFFAOYSA-N	24739943.0		MVZGYPSXNDCANY
BRD-K51832961-001-01-4	astaxanthin	Launched	antioxidant				0	26.68	Cayman	70685		596.387	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C |c:9,34|	MQZIGYBFDRPAKN-UWFIBFSHSA-N	5281224.0		MQZIGYBFDRPAKN
BRD-K37249724-001-25-7	astemizole	Withdrawn	histamine receptor antagonist	HRH1|KCNH1|KCNH2			0	97.58	MicroSource	2300094	ASTEMIZOLE	458.248	COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	GXDALQBWZGODGZ-UHFFFAOYSA-N	2247.0		GXDALQBWZGODGZ
BRD-K37249724-001-28-1	astemizole	Withdrawn	histamine receptor antagonist	HRH1|KCNH1|KCNH2			0	98.54	Tocris	3489	Astemizole	458.248	COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	GXDALQBWZGODGZ-UHFFFAOYSA-N	2247.0		GXDALQBWZGODGZ
BRD-K37249724-001-24-0	astemizole	Withdrawn	histamine receptor antagonist	HRH1|KCNH1|KCNH2			0	97.19	Tocris	3489	Astemizole	458.248	COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	GXDALQBWZGODGZ-UHFFFAOYSA-N	2247.0		GXDALQBWZGODGZ
BRD-K44845912-001-02-9	astilbin	Preclinical	nuclear factor erythroid derived|like (NRF2) activator				0	96.64	MedChemEx	HY-N0509	Astilbin	450.116	C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	ZROGCCBNZBKLEL-MPRHSVQHSA-N	119258.0		ZROGCCBNZBKLEL
BRD-K08188887-001-03-9	astragaloside-a	Preclinical	anti-inflammatory agent				0	100.0	MedChemEx	HY-N0099	Astragaloside A	784.461	CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	QMNWISYXSJWHRY-AUJDEUPOSA-N	13943299.0		QMNWISYXSJWHRY
BRD-K08188887-001-02-4	astragaloside-a	Preclinical	anti-inflammatory agent				0	100.0	Selleck	S2415	Astragaloside A	784.461	CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	QMNWISYXSJWHRY-AUJDEUPOSA-N	13943299.0	BRD-K56653660-001-01-3	QMNWISYXSJWHRY
BRD-K00003508-001-01-9	ASTX660	Phase 1/Phase 2	apoptosis inhibitor				0	92.43	MedChemEx	HY-109565	ASTX660	539.327	C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1	YCXOHEXZVKOGEV-DNRQZRRGSA-N	118169620.0		YCXOHEXZVKOGEV
BRD-K87028197-001-01-3	asunaprevir	Phase 3	HCV inhibitor				0	97.98	MedChemEx	HY-14434	Asunaprevir	747.27	COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	XRWSZZJLZRKHHD-WVWIJVSJSA-N	16076883.0		XRWSZZJLZRKHHD
BRD-K87028197-001-02-9	asunaprevir	Phase 3	HCV inhibitor				0	97.63	MedChemEx	HY-14434	Asunaprevir	747.27	COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	XRWSZZJLZRKHHD-WVWIJVSJSA-N	16076883.0		XRWSZZJLZRKHHD
BRD-K36269323-300-02-6	asymmetrical-dimethylarginine	Phase 1	nitric oxide synthase inhibitor	NOS2|NOS3			0	100.0	EMDBio	311203-25MG	NG,NG-Dimethyl-L-arginine, Dihydrochloride	202.143	CN(C)C(=N)NCCC[C@H](N)C(O)=O	YDGMGEXADBMOMJ-LURJTMIESA-N	123831.0		YDGMGEXADBMOMJ
BRD-K06496777-003-02-9	AT-1015	Preclinical	serotonin receptor antagonist	HTR2A			0	95.2	Tocris	4468	AT 1015	455.257	O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|	BSPMYKLEFGUTSI-UHFFFAOYSA-N	9805664.0		BSPMYKLEFGUTSI
BRD-K06496777-003-01-4	AT-1015	Preclinical	serotonin receptor antagonist	HTR2A			0	77.53	Tocris	4468	AT 1015	455.257	O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|	BSPMYKLEFGUTSI-UHFFFAOYSA-N	9805664.0		BSPMYKLEFGUTSI
BRD-K83030136-001-02-9	AT-406	Phase 1	IAP antagonist 				0	93.59	Adooq	A11163	AT406	561.332	CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C	LSXUTRRVVSPWDZ-MKKUMYSQSA-N	25022340.0		LSXUTRRVVSPWDZ
BRD-K13390322-001-07-9	AT-7519	Phase 2	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CDK6|CDK9			0	62.94	MedChemEx	HY-50940	AT7519	381.076	Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1	OVPNQJVDAFNBDN-UHFFFAOYSA-N	11338033.0		OVPNQJVDAFNBDN
BRD-K13390322-001-06-3	AT-7519	Phase 2	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CDK6|CDK9			0	92.34	Selleck	S1524	AT7519	381.076	Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1	OVPNQJVDAFNBDN-UHFFFAOYSA-N	11338033.0		OVPNQJVDAFNBDN
BRD-K24576554-001-04-8	AT-9283	Phase 2	Aurora kinase inhibitor|JAK inhibitor	AURKA|AURKB|JAK2|JAK3|RPS6KA6|STK17A			0	93.76	Selleck	S1134	AT9283	381.191	O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1	LOLPPWBBNUVNQZ-UHFFFAOYSA-N	135398495.0		LOLPPWBBNUVNQZ
BRD-K24576554-001-05-5	AT-9283	Phase 2	Aurora kinase inhibitor|JAK inhibitor	AURKA|AURKB|JAK2|JAK3|RPS6KA6|STK17A			0		Adooq	A10095	(Z)-1-cyclopropyl-3-(3-(5-(morpholinomethyl)-2H-benzo[d]imidazol-2-ylidene)-2,3-dihydro-1H-pyrazol-4-yl)urea	381.191	O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1	InChI=1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)	135398495.0		LOLPPWBBNUVNQZ
BRD-K94830329-001-04-9	ataluren	Launched	CFTR channel agonist|dystrophin stimulant	DMD	genetics|pulmonary	duchenne muscular dystrophy (DMD)|cystic fibrosis	0	97.8	MedChemEx	HY-14832	Ataluren	284.06	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	OOUGLTULBSNHNF-UHFFFAOYSA-N	11219835.0		OOUGLTULBSNHNF
BRD-K94830329-001-03-0	ataluren	Launched	CFTR channel agonist|dystrophin stimulant	DMD	genetics|pulmonary	duchenne muscular dystrophy (DMD)|cystic fibrosis	0	97.28	Selleck	S6003	Ataluren (PTC124)	284.06	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	OOUGLTULBSNHNF-UHFFFAOYSA-N	11219835.0		OOUGLTULBSNHNF
BRD-K09757388-065-05-9	atazanavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	97.98	MedChemEx	HY-17367A	Atazanavir (sulfate)	704.39	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	AXRYRYVKAWYZBR-GASGPIRDSA-N	148192.0		AXRYRYVKAWYZBR
BRD-K09757388-065-04-0	atazanavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	97.57	Selleck	S1457	Atazanavir Sulfate	704.39	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	AXRYRYVKAWYZBR-GASGPIRDSA-N	148192.0		AXRYRYVKAWYZBR
BRD-A52551912-001-02-9	ATB-346	Phase 2	cyclooxygenase inhibitor	PTGER2			0	94.79	MedChemEx	HY-15028	ATB-346	365.109	COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|	YCNMAPLPQYQJFC-CYBMUJFWSA-N	76963724.0		YCNMAPLPQYQJFC
BRD-A52551912-001-01-1	ATB-346	Phase 2	cyclooxygenase inhibitor	PTGER2			0	57.44	MedChemEx	HY-15028	ATB-346	365.109	COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12,r|	YCNMAPLPQYQJFC-CYBMUJFWSA-N	76963724.0		YCNMAPLPQYQJFC
BRD-K68075732-001-11-8	atenolol-(+)	Preclinical	adrenergic receptor antagonist				0	81.19	Selleck	S4301	(R)-(+)-Atenolol	266.163	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-GFCCVEGCSA-N	180559.0		METKIMKYRPQLGS
BRD-A20239487-001-25-6	atenolol-(+/-)	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|LTF|PLA2G2E	cardiology	hypertension|angina pectoris	0	78.0	MicroSource	1501127	ATENOLOL	266.163	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|	METKIMKYRPQLGS-GFCCVEGCSA-N	180559.0		METKIMKYRPQLGS
BRD-A20239487-001-24-9	atenolol-(+/-)	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|LTF|PLA2G2E	cardiology	hypertension|angina pectoris	0	85.31	Tocris	387	(RS)-Atenolol	266.163	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5,r|	METKIMKYRPQLGS-GFCCVEGCSA-N	180559.0		METKIMKYRPQLGS
BRD-K44993696-001-13-1	atenolol-(-)	Launched	adrenergic receptor antagonist		cardiology	hypertension	0	92.98	Sigma	MFCD00074918	2-(4-{[(2S)-2-hydroxy-3-(isopropylamino)propyl]oxy}phenyl)acetamide	266.163	CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-LBPRGKRZSA-N	175540.0		METKIMKYRPQLGS
BRD-K44993696-001-12-3	atenolol-(-)	Launched	adrenergic receptor antagonist		cardiology	hypertension	0	80.37	Tocris	393	(S)-(-)-Atenolol	266.163	CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	METKIMKYRPQLGS-LBPRGKRZSA-N	175540.0		METKIMKYRPQLGS
BRD-K43363084-001-01-3	atglistatin	Preclinical	adipose triglyceride lipase inhibitor				0	88.05	Selleck	S7364	Atglistatin	283.168	CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	AWOPBSAJHCUSAS-UHFFFAOYSA-N	71699712.0		AWOPBSAJHCUSAS
BRD-K43363084-001-02-1	atglistatin	Preclinical	adipose triglyceride lipase inhibitor				0	89.13	Selleck	S7364	Atglistatin	283.168	CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	AWOPBSAJHCUSAS-UHFFFAOYSA-N	71699712.0		AWOPBSAJHCUSAS
BRD-K43363084-001-03-9	atglistatin	Preclinical	adipose triglyceride lipase inhibitor				0	91.11	MedChemEx	HY-15859	Atglistatin	283.168	CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	AWOPBSAJHCUSAS-UHFFFAOYSA-N	71699712.0		AWOPBSAJHCUSAS
BRD-K00003342-001-01-9	aticaprant	Phase 2	opioid receptor antagonist				0	96.33	MedChemEx	HY-101718	Aticaprant	418.206	Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(Oc2ccc(cc2F)C(N)=O)cc1	ZHPMYDSXGRRERG-DEOSSOPVSA-N	44129648.0		ZHPMYDSXGRRERG
BRD-K39252998-003-02-3	atipamezole	Launched	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	0	89.75	Tocris	2937	Atipamezole hydrochloride	212.131	CCC1(Cc2ccccc2C1)c1cnc[nH]1	HSWPZIDYAHLZDD-UHFFFAOYSA-N	71310.0		HSWPZIDYAHLZDD
BRD-K39252998-003-01-5	atipamezole	Launched	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	0	99.36	MedChemEx	HY-12380	Atipamezole (hydrochloride)	212.131	CCC1(Cc2ccccc2C1)c1cnc[nH]1	HSWPZIDYAHLZDD-UHFFFAOYSA-N	71310.0		HSWPZIDYAHLZDD
BRD-K39252998-003-03-9	atipamezole	Launched	adrenergic receptor antagonist		neurology/psychiatry	reverse sedative	0	91.37	Tocris	2937	Atipamezole hydrochloride	212.131	CCC1(Cc2ccccc2C1)c1cnc[nH]1	HSWPZIDYAHLZDD-UHFFFAOYSA-N	71310.0		HSWPZIDYAHLZDD
BRD-K38527262-300-01-0	atiprimod	Phase 2	JAK inhibitor|STAT inhibitor	JAK2|STAT3			0	100.0	Tocris	4580	3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-N,N-diethylpropan-1-amine dihydrochloride	336.35	CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	SERHTTSLBVGRBY-UHFFFAOYSA-N	129869.0		SERHTTSLBVGRBY
BRD-K76614248-001-01-2	atizoram	Phase 2	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D			0	97.53	Cayman	13183	5-{3-[(1S,2S,4R)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl}tetrahydro-2(1H)-pyrimidinone	316.179	COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	LITNEAPWQHVPOK-FFSVYQOJSA-N	9861730.0		LITNEAPWQHVPOK
BRD-K76614248-001-02-9	atizoram	Phase 2	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D			0		Tocris	2729	CP-80633	316.179	COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	LITNEAPWQHVPOK-FFSVYQOJSA-N	9861730.0		LITNEAPWQHVPOK
BRD-K00521308-019-01-9	ATN-161	Phase 2	integrin antagonist	ITGA5|ITGAV|ITGB1|ITGB3			0	93.15	MedChemEx	HY-13535A	ATN-161 (trifluoroacetate salt)	597.233	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	MMHDBUJXLOFTLC-WOYTXXSLSA-N	9960285.0		MMHDBUJXLOFTLC
BRD-K00521308-019-03-5	ATN-161	Phase 2	integrin antagonist	ITGA5|ITGAV|ITGB1|ITGB3			0	87.94	MedChemEx	HY-13535A	ATN-161 (trifluoroacetate salt)	597.233	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	MMHDBUJXLOFTLC-WOYTXXSLSA-N	9960285.0		MMHDBUJXLOFTLC
BRD-K20141153-001-01-6	atomoxetine	Launched	norepinephrine transporter inhibitor	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	0	0.0	MicroSource	1505385	ATOMOXETINE HYDROCHLORIDE	255.162	CNCC[C@@H](Oc1ccccc1C)c1ccccc1	VHGCDTVCOLNTBX-QGZVFWFLSA-N	54841.0		VHGCDTVCOLNTBX
BRD-K20141153-003-14-9	atomoxetine	Launched	norepinephrine transporter inhibitor	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	0	92.15	Tocris	2011	Tomoxetine hydrochloride	255.162	CNCC[C@@H](Oc1ccccc1C)c1ccccc1	VHGCDTVCOLNTBX-QGZVFWFLSA-N	54841.0		VHGCDTVCOLNTBX
BRD-K20141153-003-12-9	atomoxetine	Launched	norepinephrine transporter inhibitor	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	0	96.75	Selleck	S3175	Atomoxetine HCl	255.162	CNCC[C@@H](Oc1ccccc1C)c1ccccc1	VHGCDTVCOLNTBX-QGZVFWFLSA-N	54841.0		VHGCDTVCOLNTBX
BRD-K20141153-003-13-7	atomoxetine	Launched	norepinephrine transporter inhibitor	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)	0	97.04	Tocris	2011	Tomoxetine hydrochloride	255.162	CNCC[C@@H](Oc1ccccc1C)c1ccccc1	VHGCDTVCOLNTBX-QGZVFWFLSA-N	54841.0		VHGCDTVCOLNTBX
BRD-K69726342-238-05-9	atorvastatin	Launched	HMGCR inhibitor	AHR|DPP4|HMGCR	neurology/psychiatry|cardiology	stroke|heart attack	0	87.24	Pharmeks	PHAR261720	calcium bis{(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate}	558.253	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	XUKUURHRXDUEBC-KAYWLYCHSA-N	60823.0		XUKUURHRXDUEBC
BRD-K69726342-238-03-2	atorvastatin	Launched	HMGCR inhibitor	AHR|DPP4|HMGCR	neurology/psychiatry|cardiology	stroke|heart attack	0	98.24	Tocris	3776	Atorvastatin hemicalcium salt	558.253	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	XUKUURHRXDUEBC-KAYWLYCHSA-N	60823.0	BRD-M94983326-238-03-6	XUKUURHRXDUEBC
BRD-K69726342-001-03-4	atorvastatin	Launched	HMGCR inhibitor	AHR|DPP4|HMGCR	neurology/psychiatry|cardiology	stroke|heart attack	0	95.77	MicroSource	1503722	ATORVASTATIN CALCIUM	558.253	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	XUKUURHRXDUEBC-KAYWLYCHSA-N	60823.0		XUKUURHRXDUEBC
BRD-K69726342-238-02-4	atorvastatin	Launched	HMGCR inhibitor	AHR|DPP4|HMGCR	neurology/psychiatry|cardiology	stroke|heart attack	0	97.04	Selleck	S2077	Atorvastatin Calcium	558.253	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	XUKUURHRXDUEBC-KAYWLYCHSA-N	60823.0	BRD-M94983326-238-02-8	XUKUURHRXDUEBC
BRD-A85261566-001-02-5	atosiban	Launched	oxytocin receptor antagonist	AVPR1A|AVPR1B|AVPR2|OXTR	neurology/psychiatry|cardiology|endocrinology	stroke|angina pectoris|myocardial infarction|hyperlipidemia	0	56.62	MedChemEx	HY-17572	Atosiban	993.441	CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N			VWXRQYYUEIYXCZ
BRD-A85261566-001-03-3	atosiban	Launched	oxytocin receptor antagonist	AVPR1A|AVPR1B|AVPR2|OXTR	neurology/psychiatry|cardiology|endocrinology	stroke|angina pectoris|myocardial infarction|hyperlipidemia	0	75.28	MedChemEx	HY-17572	Atosiban	993.441	CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N			VWXRQYYUEIYXCZ
BRD-A85261566-001-01-7	atosiban	Launched	oxytocin receptor antagonist	AVPR1A|AVPR1B|AVPR2|OXTR	neurology/psychiatry|cardiology|endocrinology	stroke|angina pectoris|myocardial infarction|hyperlipidemia	0	41.11	MedChemEx	HY-17572	Atosiban	993.441	CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8,17,21,33,37,41,50,54,&1:29|	VWXRQYYUEIYXCZ-ZJBFWUDNSA-N			VWXRQYYUEIYXCZ
BRD-A19795905-001-08-0	atovaquone	Launched	mitochondrial electron transport inhibitor		infectious disease	pneumonia	0	97.44	MicroSource	1504210	ATOVAQUONE	366.102	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|	UYFLKEIEOREOFC-ZXYWRSMDSA-N			UYFLKEIEOREOFC
BRD-A19795905-001-07-2	atovaquone	Launched	mitochondrial electron transport inhibitor		infectious disease	pneumonia	0	94.46	Selleck	S3079	Atovaquone	366.102	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7,10,&1:13,wU:7.7,wD:10.14,13.15,(-11.75,6.01,;-10.68,5.39,;-10.68,3.85,;-9.35,3.08,;-8.02,3.85,;-8.01,5.39,;-9.35,6.16,;-6.68,3.08,;-5.35,3.85,;-4.01,3.08,;-4.01,1.54,;-5.35,.77,;-6.68,1.54,;-2.68,.77,;-2.68,-.77,;-3.75,-1.39,;-1.33,-1.54,;-1.33,-2.77,;,-.77,;1.33,-1.54,;2.66,-.77,;2.66,.77,;1.33,1.54,;,.77,;-1.33,1.54,;-1.33,2.77,)|	UYFLKEIEOREOFC-ZXYWRSMDSA-N			UYFLKEIEOREOFC
BRD-A65145453-001-07-9	ATPA	Preclinical	glutamate receptor agonist	GRIK1			0	95.4	Tocris	1107	3-(5-tert-butyl-3-hydroxy-4-isoxazolyl)alanine	228.111	CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|	PIXJURSCCVBKRF-ZCFIWIBFSA-N	11345201.0		PIXJURSCCVBKRF
BRD-A65145453-001-06-1	ATPA	Preclinical	glutamate receptor agonist	GRIK1			0	75.25	Tocris	1107	ATPA	228.111	CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11,r|	PIXJURSCCVBKRF-ZCFIWIBFSA-N	11345201.0		PIXJURSCCVBKRF
BRD-K00003732-001-01-9	atractylenolide-i	Preclinical	JAK inhibitor				0	39.48	MedChemEx	HY-N0201	Atractylenolide I	230.131	[H][C@@]12CC3=C(C)C(=O)OC3=C[C@@]1(C)CCCC2=C |c:3,10|	ZTVSGQPHMUYCRS-SWLSCSKDSA-N	5321018.0		ZTVSGQPHMUYCRS
BRD-K01826774-344-07-9	atracurium	Launched	acetylcholine receptor antagonist		critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	0	68.11	MedChemEx	HY-B0292A	Atracurium (besylate)	928.509	COc1ccc(C[C@H]2c3cc(OC)c(OC)cc3CC[N@@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@@H]2Cc2ccc(OC)c(OC)c2)cc1OC |&1:7,&2:20,&3:37,&4:51|	YXSLJKQTIDHPOT-MWAPPURBSA-N	73416109.0		YXSLJKQTIDHPOT
BRD-K16295392-003-01-3	atrasentan	Phase 3	endothelin receptor antagonist	EDNRA			0	97.8	MedChemEx	HY-15403A	Atrasentan (hydrochloride)	510.273	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1	MOTJMGVDPWRKOC-QPVYNBJUSA-N	159594.0		MOTJMGVDPWRKOC
BRD-K01825666-330-02-9	atropine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	ophthalmology	cycloplegia|mydriasis|amblyopia	0	97.48	MicroSource	1500131	ATROPINE SULFATE	405.146	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	RKUNBYITZUJHSG-JJXSEGSLSA-N		BRD-A93739713-065-04-3	RKUNBYITZUJHSG
BRD-K01825666-001-03-9	atropine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	ophthalmology	cycloplegia|mydriasis|amblyopia	0	96.01	MedChemEx	HY-B1205	Atropine	289.168	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	RKUNBYITZUJHSG-JJXSEGSLSA-N			RKUNBYITZUJHSG
BRD-K01825666-330-01-9	atropine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	ophthalmology	cycloplegia|mydriasis|amblyopia	0	93.85	Selleck	S2130	Atropine	405.146	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	RKUNBYITZUJHSG-JJXSEGSLSA-N		BRD-A27290375-065-01-3|BRD-M93222215-330-02-1	RKUNBYITZUJHSG
BRD-K00004526-001-01-9	atropine-oxide	Preclinical	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5			0	100.0	Sigma	MFCD03939063	(-)-HYOSCYAMINE-N-OXIDE HYDROCHLORIDE	305.163	C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3,6,8,&2:1,&3:13|	HGWPFSBHDACWNL-JFBPSJKJSA-N			HGWPFSBHDACWNL
BRD-K00003144-001-01-9	atuveciclib	Phase 1	CDK9 inhibitor				0	97.73	MedChemEx	HY-12871B	Atuveciclib	387.117	COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1	ACWKGTGIJRCOOM-HHHXNRCGSA-N	121488167.0		ACWKGTGIJRCOOM
BRD-K32127727-001-02-6	AT13148	Phase 1	protein kinase inhibitor	AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3			0	76.52	MedChemEx	HY-16071	(S)-1-(4-(1H-pyrazol-4-yl)phenyl)-2-amino-1-(4-chlorophenyl)ethan-1-ol	313.098	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	24905401.0		IIRWNGPLJQXWFJ
BRD-K32127727-001-03-4	AT13148	Phase 1	protein kinase inhibitor	AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3			0	91.13	MedChemEx	HY-16071	AT13148	313.098	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	24905401.0		IIRWNGPLJQXWFJ
BRD-K32127727-001-04-2	AT13148	Phase 1	protein kinase inhibitor	AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3			0	90.23	Selleck	S7563	AT13148	313.098	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	24905401.0	BRD-A77091532-001-01-9	IIRWNGPLJQXWFJ
BRD-K32127727-001-01-8	AT13148	Phase 1	protein kinase inhibitor	AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3			0	74.21	MedChemEx	HY-16071	AT13148	313.098	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	IIRWNGPLJQXWFJ-KRWDZBQOSA-N	24905401.0		IIRWNGPLJQXWFJ
BRD-K58435339-001-06-3	AT13387	Phase 2	HSP inhibitor	HSP90AA1			0	81.89	Selleck	S1163	Onalespib (AT13387)	409.237	CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	IFRGXKKQHBVPCQ-UHFFFAOYSA-N	11955716.0		IFRGXKKQHBVPCQ
BRD-K58435339-001-03-0	AT13387	Phase 2	HSP inhibitor	HSP90AA1			0	92.6	Selleck	S1163	AT13387	409.237	CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	IFRGXKKQHBVPCQ-UHFFFAOYSA-N	11955716.0		IFRGXKKQHBVPCQ
BRD-K12040459-001-07-8	AT7867	Preclinical	AKT inhibitor	AKT2|GSK3B|PKIA|PRKACA			0	92.8	Selleck	S1558	AT7867	337.135	Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	LZMOSYUFVYJEPY-UHFFFAOYSA-N	11175137.0		LZMOSYUFVYJEPY
BRD-K12040459-001-06-0	AT7867	Preclinical	AKT inhibitor	AKT2|GSK3B|PKIA|PRKACA			0	88.68	Selleck	S1558	AT7867	337.135	Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	LZMOSYUFVYJEPY-UHFFFAOYSA-N	11175137.0		LZMOSYUFVYJEPY
BRD-K45995181-001-06-9	auranofin	Launched	NFkB pathway inhibitor	IKBKB|PRDX5|TRPA1	rheumatology	rheumatoid arthritis	1	0.0	MedChemEx	HY-B1123		678.133	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	AUJRCFUBUPVWSZ-XTZHGVARSA-M	6918453.0	BRD-U68276368-000-01-4	AUJRCFUBUPVWSZ
BRD-K45995181-001-04-6	auranofin	Launched	NFkB pathway inhibitor	IKBKB|PRDX5|TRPA1	rheumatology	rheumatoid arthritis	0	73.57	Selleck	S4307	Auranofin	678.133	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	AUJRCFUBUPVWSZ-XTZHGVARSA-M	6918453.0	BRD-A28431708-001-01-5	AUJRCFUBUPVWSZ
BRD-K45995181-001-05-3	auranofin	Launched	NFkB pathway inhibitor	IKBKB|PRDX5|TRPA1	rheumatology	rheumatoid arthritis	1	0.0	MedChemEx	HY-B1123	Auranofin	678.133	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	AUJRCFUBUPVWSZ-XTZHGVARSA-M	6918453.0	BRD-K63171558-001-01-2	AUJRCFUBUPVWSZ
BRD-K53561341-001-09-1	aurora-a-inhibitor-i	Preclinical	Aurora kinase inhibitor	AURKA			0	99.42	Tocris	5286	TC-S 7010	587.221	CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	AKSIZPIFQAYJGF-UHFFFAOYSA-N	44139710.0		AKSIZPIFQAYJGF
BRD-K53561341-001-07-5	aurora-a-inhibitor-i	Preclinical	Aurora kinase inhibitor	AURKA			0	97.07	Selleck	S1451	Aurora A Inhibitor I	587.221	CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	AKSIZPIFQAYJGF-UHFFFAOYSA-N	44139710.0		AKSIZPIFQAYJGF
BRD-K00003601-001-01-9	aurothioglucose	Launched	PKC inhibitor	PRKCI	rheumatology	rheumatoid arthritis	0	0.0	MedChemEx	HY-A0068	Aurothioglucose	391.999	OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O	XHVAWZZCDCWGBK-WYRLRVFGSA-M	6916934.0		XHVAWZZCDCWGBK
BRD-K00005330-001-01-9	AUT-1	Preclinical	potassium channel activator				0	97.89	MedChemEx	HY-117639	AUT1	341.138	CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1	AMAOXEGBJHLCSF-CQSZACIVSA-N	53230344.0		AMAOXEGBJHLCSF
BRD-A94640958-001-01-7	autotaxin-modulator-1	Preclinical	autotaxin inhibitor	ENPP2			0	97.37	MedChemEx	HY-12812	Autotaxin modulator 1	543.221	C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1,21,24,&1:3,&2:6,&3:8,wU:8.11,21.22,24.29,wD:1.0,3.2,6.6,(6.23,2.09,;5.61,1.02,;4.07,1.02,;3.25,-.38,;2.26,.16,;2.26,1.96,;3.29,2.4,;1.65,2.4,;.83,1.02,;1.62,-.38,;-.71,1.02,;-1.33,2.09,;-1.33,-.04,;6.38,-.31,;5.62,-1.65,;6.4,-2.98,;7.94,-2.98,;8.71,-4.31,;10.25,-4.31,;11.01,-2.97,;12.56,-2.97,;13.33,-4.31,;14.87,-4.31,;15.64,-5.64,;14.86,-6.98,;13.32,-6.97,;12.56,-5.64,;15.63,-8.31,;16.86,-8.31,;15.02,-9.38,;16.25,-9.38,;10.24,-1.64,;8.71,-1.65,;7.94,-.32,;11.01,-.31,;12.24,-.3,;10.39,.76,;11.62,.76,)|	PZASAAIJIFDWSB-PQGZPOPSSA-N			PZASAAIJIFDWSB
BRD-K23190681-001-02-9	AV-412	Phase 1	protein tyrosine kinase inhibitor	EGFR|ERBB2			0	96.98	Tocris	4397	AV 412	506.2	CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	ZAJXXUDARPGGOC-UHFFFAOYSA-N	9806229.0		ZAJXXUDARPGGOC
BRD-K23190681-001-01-1	AV-412	Phase 1	protein tyrosine kinase inhibitor	EGFR|ERBB2			0	94.87	MedChemEx	HY-10346A	AV-412 (free base)	506.2	CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	ZAJXXUDARPGGOC-UHFFFAOYSA-N	9806229.0		ZAJXXUDARPGGOC
BRD-K96615647-001-02-9	AV-608	Phase 2	tachykinin antagonist	TACR1			0	98.85	MedChemEx	HY-18006	NKP608	619.146	FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	NXLUTEDAEFXMQR-BJKOFHAPSA-N	9917079.0		NXLUTEDAEFXMQR
BRD-K96615647-001-01-2	AV-608	Phase 2	tachykinin antagonist	TACR1			0	99.39	MedChemEx	HY-18006	NKP608	619.146	FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	NXLUTEDAEFXMQR-BJKOFHAPSA-N	9917079.0		NXLUTEDAEFXMQR
BRD-K00003256-001-01-9	avacopan	Phase 2	complement inhibitor				0	54.12	MedChemEx	HY-17627	Avacopan	581.267	Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F	PUKBOVABABRILL-YZNIXAGQSA-N	49841217.0		PUKBOVABABRILL
BRD-A88644406-001-02-9	avadomide	Phase 2	antitumor agent				0	95.76	MedChemEx	HY-100507	Avadomide	286.107	Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O |&1:13,r|	RSNPAKAFCAAMBH-JTQLQIEISA-N	24967954.0		RSNPAKAFCAAMBH
BRD-K83720053-001-07-9	avagacestat	Phase 2	gamma secretase inhibitor	PSEN1			0	94.15	MedChemEx	HY-50845	Avagacestat	520.06	NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	XEAOPVUAMONVLA-QGZVFWFLSA-N	46883536.0		XEAOPVUAMONVLA
BRD-K83720053-001-03-8	avagacestat	Phase 2	gamma secretase inhibitor	PSEN1			0	96.39	Selleck	S1262	Avagacestat (BMS-708163)	520.06	NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	XEAOPVUAMONVLA-QGZVFWFLSA-N	46883536.0		XEAOPVUAMONVLA
BRD-K65781196-001-04-8	avanafil	Launched	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	0	53.08	MicroSource	1506321	AVANAFIL	483.179	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	WEAJZXNPAWBCOA-INIZCTEOSA-N	9869929.0		WEAJZXNPAWBCOA
BRD-K65781196-001-03-0	avanafil	Launched	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	0	92.35	Selleck	S4019	Avanafil	483.179	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	WEAJZXNPAWBCOA-INIZCTEOSA-N	9869929.0		WEAJZXNPAWBCOA
BRD-K00003419-001-01-9	avapritinib	Launched	KIT inhibitor				0	96.7	MedChemEx	HY-101561	Avapritinib	498.24	Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1	DWYRIWUZIJHQKQ-SANMLTNESA-N	118023034.0		DWYRIWUZIJHQKQ
BRD-K67901620-001-04-9	avasimibe	Phase 3	ACAT inhibitor	CES1			0	94.73	MedChemEx	HY-13215	Avasimibe	501.291	CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	PTQXTEKSNBVPQJ-UHFFFAOYSA-N	166558.0		PTQXTEKSNBVPQJ
BRD-K67901620-001-03-8	avasimibe	Phase 3	ACAT inhibitor	CES1			0	96.76	Selleck	S2187	Avasimibe (CI-1011)	501.291	CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	PTQXTEKSNBVPQJ-UHFFFAOYSA-N	166558.0		PTQXTEKSNBVPQJ
BRD-K67901620-001-02-0	avasimibe	Phase 3	ACAT inhibitor	CES1			0	86.86	Selleck	S2187	Avasimibe	501.291	CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	PTQXTEKSNBVPQJ-UHFFFAOYSA-N	166558.0		PTQXTEKSNBVPQJ
BRD-K68544925-001-01-1	avatrombopag	Launched	thrombopoietin receptor agonist	MPL	hematology	thrombocytopenia	0	95.01	MedChemEx	HY-13463	Avatrombopag	648.151	OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1	OFZJKCQENFPZBH-UHFFFAOYSA-N	9852519.0		OFZJKCQENFPZBH
BRD-K36154108-001-01-7	AVE-0991	Preclinical	angiotensin receptor agonist	MRGPRX1			0	93.56	MedChemEx	HY-15778	AVE 0991	580.181	CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1	QTOZBSNPDCWHPV-UHFFFAOYSA-N	9851724.0		QTOZBSNPDCWHPV
BRD-K36154108-001-02-9	AVE-0991	Preclinical	angiotensin receptor agonist	MRGPRX1			0	92.82	MedChemEx	HY-15778	AVE 0991	580.181	CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1	QTOZBSNPDCWHPV-UHFFFAOYSA-N	9851724.0		QTOZBSNPDCWHPV
BRD-K00004734-001-01-9	AVE-3085	Preclinical	nitric oxide synthase stimulant				0	97.28	MedChemEx	HY-19504	AVE-3085	317.086	FC1(F)Oc2ccc(cc2O1)C(=O)NC1Cc2ccccc2C1	OKCJNSDIVCXYAL-UHFFFAOYSA-N	3510704.0		OKCJNSDIVCXYAL
BRD-K00003435-003-01-9	AVex-73	Preclinical	sigma receptor agonist				0	91.52	MedChemEx	HY-101864	AVex-73 hydrochloride	281.178	CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1 |&1:4,r|	BOTHKNZTGGXFEQ-GOSISDBHSA-N	76968108.0		BOTHKNZTGGXFEQ
BRD-K85882401-323-01-5	avibactam	Launched	beta lactamase inhibitor		infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	0	100.0	MedChemEx	HY-14879B	Avibactam (sodium hydrate)	265.037	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	NDCUAPJVLWFHHB-UHNVWZDZSA-N	9835049.0		NDCUAPJVLWFHHB
BRD-K85882401-236-01-9	avibactam	Launched	beta lactamase inhibitor		infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	0	98.4	MedChemEx	HY-14879A	Avibactam (sodium)	265.037	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	NDCUAPJVLWFHHB-UHNVWZDZSA-N	9835049.0		NDCUAPJVLWFHHB
BRD-K85882401-236-02-7	avibactam	Launched	beta lactamase inhibitor		infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	0	96.4	MedChemEx	HY-14879A	Avibactam (sodium)	265.037	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	NDCUAPJVLWFHHB-UHNVWZDZSA-N	9835049.0		NDCUAPJVLWFHHB
BRD-K00003294-050-01-9	avitinib	Phase 2	EGFR inhibitor				0	91.08	MedChemEx	HY-19816A	Avitinib (maleate)	487.213	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F	UOFYSRZSLXWIQB-UHFFFAOYSA-N	72734520.0		UOFYSRZSLXWIQB
BRD-K87782578-001-03-9	AVL-292	Phase 2	Bruton's tyrosine kinase (BTK) inhibitor	BTK|YES1			0	97.44	MedChemEx	HY-18012	Spebrutinib	423.171	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	KXBDTLQSDKGAEB-UHFFFAOYSA-N	59174488.0		KXBDTLQSDKGAEB
BRD-K87782578-001-01-4	AVL-292	Phase 2	Bruton's tyrosine kinase (BTK) inhibitor	BTK|YES1			0	95.48	Selleck	S7173	AVL-292	423.171	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	KXBDTLQSDKGAEB-UHFFFAOYSA-N	59174488.0		KXBDTLQSDKGAEB
BRD-K00003436-001-01-9	AVN-492	Preclinical	serotonin receptor antagonist				0	95.85	MedChemEx	HY-101924	AVN-492	359.142	CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1	SNPPEHMSSOEYDH-UHFFFAOYSA-N	56655571.0		SNPPEHMSSOEYDH
BRD-K62196610-001-01-6	AVN-944	Phase 2	inosine monophosphate dehydrogenase inhibitor	IMPDH1|IMPDH2			0	99.41	MedChemEx	HY-13560	AVN-944	477.201	CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	GYCPCOJTCINIFZ-OXJNMPFZSA-N	9918559.0		GYCPCOJTCINIFZ
BRD-K62196610-001-02-9	AVN-944	Phase 2	inosine monophosphate dehydrogenase inhibitor	IMPDH1|IMPDH2			0	98.88	MedChemEx	HY-13560	AVN-944	477.201	CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	GYCPCOJTCINIFZ-OXJNMPFZSA-N	9918559.0		GYCPCOJTCINIFZ
BRD-K14401183-001-12-9	avobenzone	Launched	topical sunscreen agent		dermatology	cosmetic|sunscreen lotion	0	77.6	MedChemEx	HY-B0316	Avobenzone	310.157	COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C	LKIIIESDXWZZRE-UHFFFAOYSA-N			LKIIIESDXWZZRE
BRD-K14401183-001-11-5	avobenzone	Launched	topical sunscreen agent		dermatology	cosmetic|sunscreen lotion	0	0.0	MicroSource	1504190	AVOBENZONE	310.157	COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C	LKIIIESDXWZZRE-UHFFFAOYSA-N			LKIIIESDXWZZRE
BRD-K14401183-001-10-7	avobenzone	Launched	topical sunscreen agent		dermatology	cosmetic|sunscreen lotion	0	90.89	Selleck	S1904	Avobenzone	310.157	COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C	LKIIIESDXWZZRE-UHFFFAOYSA-N			LKIIIESDXWZZRE
BRD-K00003224-001-01-9	avoralstat	Phase 3	kallikrein inhibitor				0	88.22	MedChemEx	HY-16735	Avoralstat	513.201	COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(N)=N)-c1ccc(nc1C(O)=O)C(=O)NCC1CC1	TUWMKPVJGGWGNL-UHFFFAOYSA-N	86566678.0		TUWMKPVJGGWGNL
BRD-K26665484-001-01-8	avridine	Preclinical	immunostimulant				0	0.0	Sigma	PZ0123	2,2'-((3-(dioctadecylamino)propyl)azanediyl)bis(ethan-1-ol)	666.7	CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO	WXNRAKRZUCLRBP-UHFFFAOYSA-N	37186.0		WXNRAKRZUCLRBP
BRD-K00003479-003-01-9	AX-024	Preclinical	cytokine production inhibitor				0	94.57	MedChemEx	HY-107390A	AX-024 hydrochloride	339.163	COc1ccc2OCC(CN3CCCC3)=C(c3ccc(F)cc3)c2c1 |t:15|	VMMKGVRPILDZML-UHFFFAOYSA-N	56949412.0		VMMKGVRPILDZML
BRD-K29905972-001-10-5	axitinib	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1|FLT1|FLT4|KDR|PLK4	oncology	renal cell carcinoma (RCC)	0	96.08	Selleck	S1005	axitinib	386.12	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	RITAVMQDGBJQJZ-FMIVXFBMSA-N	6450551.0		RITAVMQDGBJQJZ
BRD-K29905972-001-06-3	axitinib	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1|FLT1|FLT4|KDR|PLK4	oncology	renal cell carcinoma (RCC)	0	93.31	Selleck	S1005	Axitinib	386.12	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	RITAVMQDGBJQJZ-FMIVXFBMSA-N	6450551.0		RITAVMQDGBJQJZ
BRD-K29905972-001-12-1	axitinib	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1|FLT1|FLT4|KDR|PLK4	oncology	renal cell carcinoma (RCC)	0	95.86	Tocris	4350	Axitinib	386.12	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	RITAVMQDGBJQJZ-FMIVXFBMSA-N	6450551.0		RITAVMQDGBJQJZ
BRD-K29905972-001-08-9	axitinib	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1|FLT1|FLT4|KDR|PLK4	oncology	renal cell carcinoma (RCC)	0	89.66	Selleck	S1005	Axitinib	386.12	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	RITAVMQDGBJQJZ-FMIVXFBMSA-N	6450551.0		RITAVMQDGBJQJZ
BRD-K29905972-001-11-3	axitinib	Launched	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1|FLT1|FLT4|KDR|PLK4	oncology	renal cell carcinoma (RCC)	0	92.1	Adooq	A10103	N-methyl-2-({3-[(E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide	386.12	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	RITAVMQDGBJQJZ-FMIVXFBMSA-N	6450551.0		RITAVMQDGBJQJZ
BRD-K77012840-300-02-9	AY-9944	Preclinical	hedgehog pathway modulator				0	93.27	Tocris	1639	AY 9944 dihydrochloride	390.163	Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|	RZRPZWGIOOZIBE-IYARVYRRSA-N			RZRPZWGIOOZIBE
BRD-K77012840-300-01-6	AY-9944	Preclinical	hedgehog pathway modulator				0	94.24	Tocris	1639	AY 9944 dihydrochloride	390.163	Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|	RZRPZWGIOOZIBE-IYARVYRRSA-N			RZRPZWGIOOZIBE
BRD-K36258877-001-04-9	AZ-10417808	Preclinical	caspase inhibitor	CASP3			0	97.36	Tocris	2172	AZ 10417808	433.034	[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1	VUBILPOZTRGZJK-UHFFFAOYSA-N	135665263.0		VUBILPOZTRGZJK
BRD-K36258877-001-03-1	AZ-10417808	Preclinical	caspase inhibitor	CASP3			0	96.01	Tocris	2172	AZ 10417808	433.034	[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1	VUBILPOZTRGZJK-UHFFFAOYSA-N	135665263.0		VUBILPOZTRGZJK
BRD-K09907507-300-01-4	AZ-10606120	Preclinical	purinergic receptor antagonist	P2RX7			0	94.2	Tocris	3323	AZ 10606120 dihydrochloride	422.268	OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1	FQMZXMVHHKXGTM-UHFFFAOYSA-N	10310632.0		FQMZXMVHHKXGTM
BRD-K09907507-300-02-9	AZ-10606120	Preclinical	purinergic receptor antagonist	P2RX7			0	95.84	Tocris	3323	AZ 10606120 dihydrochloride	422.268	OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1	FQMZXMVHHKXGTM-UHFFFAOYSA-N	10310632.0		FQMZXMVHHKXGTM
BRD-K05973499-300-02-9	AZ-12080282	Preclinical	hedgehog pathway inhibitor	DHH			0	97.14	Tocris	4838	AZ 12080282 dihydrochloride	384.159	Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1	KMSKKYBHDQYHMC-UHFFFAOYSA-N	25253556.0		KMSKKYBHDQYHMC
BRD-K05973499-300-01-0	AZ-12080282	Preclinical	hedgehog pathway inhibitor	DHH			0	97.72	Tocris	4838	AZ 12080282 dihydrochloride	384.159	Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1	KMSKKYBHDQYHMC-UHFFFAOYSA-N	25253556.0		KMSKKYBHDQYHMC
BRD-K05804044-001-12-8	AZ-628	Preclinical	RAF inhibitor	BRAF|RAF1			0	94.27	Selleck	S2746	AZ-628	451.201	Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	ZGBGPEDJXCYQPH-UHFFFAOYSA-N	11676786.0		ZGBGPEDJXCYQPH
BRD-K05804044-001-06-0	AZ-628	Preclinical	RAF inhibitor	BRAF|RAF1			0	86.4	Selleck	S2746	AZ 628	451.201	Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	ZGBGPEDJXCYQPH-UHFFFAOYSA-N	11676786.0		ZGBGPEDJXCYQPH
BRD-K05804044-001-14-4	AZ-628	Preclinical	RAF inhibitor	BRAF|RAF1			0	98.18	Tocris	4836	AZ 628	451.201	Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	ZGBGPEDJXCYQPH-UHFFFAOYSA-N	11676786.0		ZGBGPEDJXCYQPH
BRD-K05804044-001-09-4	AZ-628	Preclinical	RAF inhibitor	BRAF|RAF1			0	92.9	Selleck	S2746	AZ628	451.201	Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	ZGBGPEDJXCYQPH-UHFFFAOYSA-N	11676786.0		ZGBGPEDJXCYQPH
BRD-K14661019-001-02-9	AZ-7371	Preclinical	antibacterial 				0	99.11	MedChemEx	HY-19750	DprE1-IN-1	355.164	COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc23)c1C	VDRYGTNDKXIPSK-UHFFFAOYSA-N	72792692.0		VDRYGTNDKXIPSK
BRD-K03406345-001-21-1	azacitidine	Launched	DNA methyltransferase inhibitor	DNMT1|DNMT3A	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL)	0	100.0	MicroSource	1502111	AZACITIDINE	244.081	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	NMUSYJAQQFHJEW-KVTDHHQDSA-N	9444.0		NMUSYJAQQFHJEW
BRD-K03406345-001-24-5	azacitidine	Launched	DNA methyltransferase inhibitor	DNMT1|DNMT3A	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL)	0	93.17	Tocris	3842	5-Azacytidine	244.081	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	NMUSYJAQQFHJEW-KVTDHHQDSA-N	9444.0		NMUSYJAQQFHJEW
BRD-K03406345-001-27-8	azacitidine	Launched	DNA methyltransferase inhibitor	DNMT1|DNMT3A	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myelomonocytic leukemia (CMMoL)	0	100.0	Selleck	S1782	Azacitidine	244.081	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	NMUSYJAQQFHJEW-KVTDHHQDSA-N	9444.0	BRD-K55026842-001-01-4	NMUSYJAQQFHJEW
BRD-K97061094-001-22-9	azacyclonol	Preclinical	histamine receptor antagonist	HRH1			0	84.05	MedChemEx	HY-B0530	Azacyclonol	267.162	OC(C1CCNCC1)(c1ccccc1)c1ccccc1	ZMISODWVFHHWNR-UHFFFAOYSA-N	15723.0		ZMISODWVFHHWNR
BRD-K97061094-001-20-6	azacyclonol	Preclinical	histamine receptor antagonist	HRH1			0	71.47	Selleck	S3196	Azacyclonol	267.162	OC(C1CCNCC1)(c1ccccc1)c1ccccc1	ZMISODWVFHHWNR-UHFFFAOYSA-N	15723.0		ZMISODWVFHHWNR
BRD-K97061094-001-21-4	azacyclonol	Preclinical	histamine receptor antagonist	HRH1			0	93.2	Selleck	S3196	Azacyclonol	267.162	OC(C1CCNCC1)(c1ccccc1)c1ccccc1	ZMISODWVFHHWNR-UHFFFAOYSA-N	15723.0		ZMISODWVFHHWNR
BRD-K53114651-001-11-9	azaguanine-8	Preclinical	purine antagonist	PNP			0	64.41	Selleck	S4194	Azaguanine-8	152.045	Nc1nc2nn[nH]c2c(=O)[nH]1	LPXQRXLUHJKZIE-UHFFFAOYSA-N	135403646.0		LPXQRXLUHJKZIE
BRD-K53114651-001-12-7	azaguanine-8	Preclinical	purine antagonist	PNP			0	84.14	Selleck	S4194	Azaguanine-8	152.045	Nc1nc2nn[nH]c2c(=O)[nH]1	LPXQRXLUHJKZIE-UHFFFAOYSA-N	135403646.0		LPXQRXLUHJKZIE
BRD-K38292725-001-02-4	azalomycin-B	Preclinical	bacterial 50S ribosomal subunit inhibitor				0	81.4	Selleck	S1448	Elaiophylin	1024.597	CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1 |t:32,34,42,44|	OSERMIPXNLXAPD-MJMYBOKFSA-N	6444206.0		OSERMIPXNLXAPD
BRD-K45861246-001-17-9	azaperone	Launched	dopamine receptor antagonist	DRD2|DRD3	neurology/psychiatry	sedative	0	89.04	MedChemEx	HY-B1470	Azaperone	327.175	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	XTKDAFGWCDAMPY-UHFFFAOYSA-N	15443.0		XTKDAFGWCDAMPY
BRD-K45861246-001-14-2	azaperone	Launched	dopamine receptor antagonist	DRD2|DRD3	neurology/psychiatry	sedative	0	50.7	MicroSource	1505332	AZAPERONE	327.175	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	XTKDAFGWCDAMPY-UHFFFAOYSA-N	15443.0		XTKDAFGWCDAMPY
BRD-K45861246-001-13-4	azaperone	Launched	dopamine receptor antagonist	DRD2|DRD3	neurology/psychiatry	sedative	0	88.64	Selleck	S4219	Azaperone	327.175	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	XTKDAFGWCDAMPY-UHFFFAOYSA-N	15443.0		XTKDAFGWCDAMPY
BRD-K45861246-001-15-9	azaperone	Launched	dopamine receptor antagonist	DRD2|DRD3	neurology/psychiatry	sedative	0	98.29	Selleck	S4219	Azaperone	327.175	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	XTKDAFGWCDAMPY-UHFFFAOYSA-N	15443.0		XTKDAFGWCDAMPY
BRD-A70182876-001-11-9	azapropazone	Withdrawn	cyclooxygenase inhibitor	PTGS2			0	98.31	Broad Institute	534	azapropazone	300.159	CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|	MPHPHYZQRGLTBO-LLVKDONJSA-N	6604340.0		MPHPHYZQRGLTBO
BRD-A70182876-001-10-8	azapropazone	Withdrawn	cyclooxygenase inhibitor	PTGS2			0	0.0	Prestwick	Prestw-1003	Azapropazone	300.159	CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r,c:19|	MPHPHYZQRGLTBO-LLVKDONJSA-N	6604340.0		MPHPHYZQRGLTBO
BRD-K47464228-001-14-9	azaserine	Preclinical	purine antagonist				0	100.0	MedChemEx	HY-B0919	Azaserine	174.051	N[C@@H](COC(=O)C[N+]#N)C(O)=O	YXEASJLRXGZRHS-VKHMYHEASA-O			YXEASJLRXGZRHS
BRD-K01826751-003-08-9	azasetron	Launched	serotonin receptor antagonist	HTR3A|HTR3B	infectious disease	genitial herpes	0	96.14	Tocris	380	Y-25130 hydrochloride	349.119	CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|	WUKZPHOXUVCQOR-ZDUSSCGKSA-N	25271863.0		WUKZPHOXUVCQOR
BRD-K01826751-003-07-9	azasetron	Launched	serotonin receptor antagonist	HTR3A|HTR3B	infectious disease	genitial herpes	0	98.4	Selleck	S2106	Azasetron HCl (Y-25130)	385.096	CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|	WUKZPHOXUVCQOR-ZDUSSCGKSA-N	25271863.0		WUKZPHOXUVCQOR
BRD-K77821588-050-01-7	azatadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	86.27	MicroSource	1503862	AZATADINE MALEATE	290.178	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	SEBMTIQKRHYNIT-UHFFFAOYSA-N	19861.0		SEBMTIQKRHYNIT
BRD-K77821588-364-01-2	azatadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	91.41	Selleck	S3186	Azatadine dimaleate	290.178	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	SEBMTIQKRHYNIT-UHFFFAOYSA-N	19861.0		SEBMTIQKRHYNIT
BRD-K77821588-332-02-9	azatadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	95.55	MedChemEx	HY-B0170A	Azatadine (dimaleate)	290.178	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	SEBMTIQKRHYNIT-UHFFFAOYSA-N	19861.0		SEBMTIQKRHYNIT
BRD-K32821942-001-22-1	azathioprine	Launched	dehydrogenase inhibitor	HPRT1|IMPDH1|PPAT	transplant|rheumatology	renal homotransplantation|rheumatoid arthritis	0	90.32	Tocris	4099	Azathioprine	277.038	Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O	LMEKQMALGUDUQG-UHFFFAOYSA-N	2265.0		LMEKQMALGUDUQG
BRD-K32821942-001-21-3	azathioprine	Launched	dehydrogenase inhibitor	HPRT1|IMPDH1|PPAT	transplant|rheumatology	renal homotransplantation|rheumatoid arthritis	0	98.13	MicroSource	1500133	AZATHIOPRINE	277.038	Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O	LMEKQMALGUDUQG-UHFFFAOYSA-N	2265.0		LMEKQMALGUDUQG
BRD-K32821942-001-20-5	azathioprine	Launched	dehydrogenase inhibitor	HPRT1|IMPDH1|PPAT	transplant|rheumatology	renal homotransplantation|rheumatoid arthritis	0	98.54	Selleck	S1721	Azathioprine	277.038	Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O	LMEKQMALGUDUQG-UHFFFAOYSA-N	2265.0		LMEKQMALGUDUQG
BRD-K69555850-001-02-9	AZD0156	Phase 1	ATM kinase inhibitor				0	91.98	MedChemEx	HY-100016	AZD0156	461.243	CN(C)CCCOc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCOCC4)c3c2c1	AOTRIQLYUAFVSC-UHFFFAOYSA-N	118502708.0		AOTRIQLYUAFVSC
BRD-K61041538-001-05-5	AZD1080	Phase 1	glycogen synthase kinase inhibitor	GSK3A|GSK3B			0	53.31	MedChemEx	HY-13862	AZD1080	334.143	O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N	RDXUCTYBYOIJGA-UHFFFAOYSA-N	10065474.0		RDXUCTYBYOIJGA
BRD-K61041538-001-04-8	AZD1080	Phase 1	glycogen synthase kinase inhibitor	GSK3A|GSK3B			0	19.85	MedChemEx	HY-13862	AZD1080	334.143	O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N	RDXUCTYBYOIJGA-UHFFFAOYSA-N	10065474.0		RDXUCTYBYOIJGA
BRD-K61041538-001-01-4	AZD1080	Phase 1	glycogen synthase kinase inhibitor	GSK3A|GSK3B			0	29.6	Selleck	S7145	AZD1080	334.143	O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N	RDXUCTYBYOIJGA-UHFFFAOYSA-N	10065474.0		RDXUCTYBYOIJGA
BRD-K61041538-001-03-0	AZD1080	Phase 1	glycogen synthase kinase inhibitor	GSK3A|GSK3B			0	71.86	Selleck	S7145	AZD1080	334.143	O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N	RDXUCTYBYOIJGA-UHFFFAOYSA-N	10065474.0		RDXUCTYBYOIJGA
BRD-K21908111-001-03-9	AZD1208	Phase 1	Pim kinase inhibitor	PIM1|PIM2|PIM3			0	96.23	Tocris	6310	AZD 1208	379.135	N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1	MCUJKPPARUPFJM-UWCCDQBKSA-N	58423153.0		MCUJKPPARUPFJM
BRD-K21908111-001-01-8	AZD1208	Phase 1	Pim kinase inhibitor	PIM1|PIM2|PIM3			0	88.58	MedChemEx	HY-15604	AZD1208	379.135	N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1	MCUJKPPARUPFJM-UWCCDQBKSA-N	58423153.0		MCUJKPPARUPFJM
BRD-K77060810-001-04-9	AZD1283	Preclinical	purinergic receptor antagonist	P2RY12			0	96.26	Tocris	6085	AZD 1283	470.162	CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1	NEMHKCNXXRQYRF-UHFFFAOYSA-N	23649325.0		NEMHKCNXXRQYRF
BRD-K77060810-001-01-5	AZD1283	Preclinical	purinergic receptor antagonist	P2RY12			0	99.81	MedChemEx	HY-15799	AZD1283	470.162	CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1	NEMHKCNXXRQYRF-UHFFFAOYSA-N	23649325.0		NEMHKCNXXRQYRF
BRD-K00003509-001-01-9	AZD1390	Phase 1	ATM kinase inhibitor				0	95.58	MedChemEx	HY-109566	AZD1390	477.254	CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O	VQSZIPCGAGVRRP-UHFFFAOYSA-N	126689157.0		VQSZIPCGAGVRRP
BRD-A44188509-001-01-2	AZD1446	Phase 2	acetylcholine receptor agonist	CHRNA4|CHRNB2			0	81.54	Key	KG-0039	2-(5-chloro-2-furoyl)octahydropyrrolo[3,4-c]pyrrole	240.067	Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10,&2:14,r|	GTUIQNHJSXQMKW-HTQZYQBOSA-N	96568205.0		GTUIQNHJSXQMKW
BRD-K65928735-001-06-8	AZD1480	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	92.19	Tocris	5617	AZD 1480	348.101	C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1	PDOQBOJDRPLBQU-QMMMGPOBSA-N	16659841.0		PDOQBOJDRPLBQU
BRD-K65928735-001-04-3	AZD1480	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	98.38	MedChemEx	HY-10193	AZD-1480	348.101	C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1	PDOQBOJDRPLBQU-QMMMGPOBSA-N	16659841.0		PDOQBOJDRPLBQU
BRD-K83186168-001-01-8	AZD1981	Phase 2	CRTH receptor antagonist	PTGDR2			0	95.7	Selleck	S7263	AZD1981	388.065	CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12	JWYIGNODXSRKGP-UHFFFAOYSA-N	11292191.0		JWYIGNODXSRKGP
BRD-K83186168-001-02-9	AZD1981	Phase 2	CRTH receptor antagonist	PTGDR2			0	96.49	MedChemEx	HY-15950	AZD1981	388.065	CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12	JWYIGNODXSRKGP-UHFFFAOYSA-N	11292191.0		JWYIGNODXSRKGP
BRD-K99113996-001-03-9	AZD2014	Phase 2	mTOR inhibitor	MTOR			0	95.58	MedChemEx	HY-15247	Vistusertib	462.238	CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	JUSFANSTBFGBAF-IRXDYDNUSA-N	25262792.0		JUSFANSTBFGBAF
BRD-K99113996-001-02-0	AZD2014	Phase 2	mTOR inhibitor	MTOR			0	95.74	Selleck	S2783	AZD2014	462.238	CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	JUSFANSTBFGBAF-IRXDYDNUSA-N	25262792.0		JUSFANSTBFGBAF
BRD-K85014146-001-03-9	AZD2461	Phase 1	PARP inhibitor				0	97.32	Tocris	6060	AZD 2461	395.165	COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	HYNBNUYQTQIHJK-UHFFFAOYSA-N	44199317.0		HYNBNUYQTQIHJK
BRD-K85014146-001-02-5	AZD2461	Phase 1	PARP inhibitor				0	98.71	Selleck	S7029	AZD2461	395.165	COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	HYNBNUYQTQIHJK-UHFFFAOYSA-N	44199317.0		HYNBNUYQTQIHJK
BRD-K85849709-001-02-9	AZD2858	Preclinical	glycogen synthase kinase inhibitor	GSK3B			0	89.07	MedChemEx	HY-15761	AZD2858	453.158	CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	FHCSBLWRGCOVPT-UHFFFAOYSA-N	10138980.0		FHCSBLWRGCOVPT
BRD-K85849709-001-01-5	AZD2858	Preclinical	glycogen synthase kinase inhibitor	GSK3B			0	94.49	Selleck	S7253	AZD2858	453.158	CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	FHCSBLWRGCOVPT-UHFFFAOYSA-N	10138980.0		FHCSBLWRGCOVPT
BRD-K14287049-001-01-3	AZD3264	Preclinical	IKK inhibitor	IKBKB			0	90.52	MedChemEx	HY-19362	AZD3264	441.147	Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1	NMFIXEFNQPDISY-ZDUSSCGKSA-N	91666658.0		NMFIXEFNQPDISY
BRD-K24593301-001-01-5	AZD3463	Preclinical	ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor	ALK|IGF1R			0	62.81	Selleck	S7106	AZD3463	448.178	COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	GCYIGMXOIWJGBU-UHFFFAOYSA-N	56599293.0		GCYIGMXOIWJGBU
BRD-K24593301-001-04-9	AZD3463	Preclinical	ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor	ALK|IGF1R			0	86.82	MedChemEx	HY-15609	AZD-3463	448.178	COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	GCYIGMXOIWJGBU-UHFFFAOYSA-N	56599293.0		GCYIGMXOIWJGBU
BRD-K24593301-001-02-3	AZD3463	Preclinical	ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor	ALK|IGF1R			0	94.52	Selleck	S7106	AZD3463	448.178	COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	GCYIGMXOIWJGBU-UHFFFAOYSA-N	56599293.0		GCYIGMXOIWJGBU
BRD-K84996356-001-01-1	AZD3514	Phase 1	androgen receptor modulator	AR			0	96.18	Selleck	S7040	AZD3514	519.257	CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|	JMEYDSHPKCSIJC-UHFFFAOYSA-N	46893585.0		JMEYDSHPKCSIJC
BRD-K84996356-001-03-9	AZD3514	Phase 1	androgen receptor modulator	AR			0	95.16	MedChemEx	HY-16079	AZD3514	519.257	CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|	JMEYDSHPKCSIJC-UHFFFAOYSA-N	46893585.0		JMEYDSHPKCSIJC
BRD-K41626799-001-01-1	AZD3759	Phase 2/Phase 3	EGFR inhibitor	EGFR			0	98.14	MedChemEx	HY-18750	AZD3759	459.147	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	MXDSJQHFFDGFDK-CYBMUJFWSA-N	78209992.0		MXDSJQHFFDGFDK
BRD-K00004606-001-01-9	AZD3839	Phase 1	beta-secretase inhibitor	BACE1			0	98.3	MedChemEx	HY-13438	AZD3839	431.136	NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|	MRXBCEQZNKUUIP-DEOSSOPVSA-N	46202416.0		MRXBCEQZNKUUIP
BRD-K00004606-001-02-9	AZD3839	Phase 1	beta-secretase inhibitor	BACE1			0	0.0	Selleck	S7731	(3S)-3-[2-(difluoromethyl)-4-pyridyl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine	431.136	NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|	MRXBCEQZNKUUIP-DEOSSOPVSA-N	46202416.0		MRXBCEQZNKUUIP
BRD-K25210703-001-01-9	AZD3965	Phase 1	monocarboxylate transporter inhibitor	SLC16A1			0	97.59	MedChemEx	HY-12750	AZD3965	515.145	CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O	PRNXOFBDXNTIFG-FQEVSTJZSA-N	10369242.0		PRNXOFBDXNTIFG
BRD-K73984371-001-02-9	AZD3988	Preclinical	diacylglycerol kinase inhibitor	DGAT1			0	94.74	Tocris	4837	AZD 3988	456.161	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|	NGEBYTLALFOQKI-HDJSIYSDSA-N			NGEBYTLALFOQKI
BRD-K73984371-001-01-1	AZD3988	Preclinical	diacylglycerol kinase inhibitor	DGAT1			0	97.67	Tocris	4837	AZD 3988	456.161	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|	NGEBYTLALFOQKI-HDJSIYSDSA-N			NGEBYTLALFOQKI
BRD-K72369578-001-04-1	AZD4282	Phase 1	glutamate receptor antagonist	AGXT|AGXT2|ALAS1|ALAS2|BAAT|GARS|GATM|GCAT|GCSH|GLDC|GLRA1|GLRA2|GLRA3|GLRB|GLYAT|GLYATL1|GLYATL2|GNMT|GPR18|GPRC6A|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3B|GSS|PIPOX|SHMT1|SHMT2|SLC32A1|SLC36A1|SLC6A5|SLC6A9			1	0.0	Enzo	AC389	Glycine	75.032	NCC(O)=O	DHMQDGOQFOQNFH-UHFFFAOYSA-N	750.0		DHMQDGOQFOQNFH
BRD-K28392481-001-05-1	AZD4547	Phase 2/Phase 3	FGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|IGF1R|KDR			0	92.48	Selleck	S2801	AZD4547	463.258	COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1	VRQMAABPASPXMW-HDICACEKSA-N	51039095.0		VRQMAABPASPXMW
BRD-K28392481-001-03-6	AZD4547	Phase 2/Phase 3	FGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|IGF1R|KDR			0	94.33	Selleck	S2801	AZD4547	463.258	COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1	InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+	51039095.0		VRQMAABPASPXMW
BRD-K00003106-001-01-9	AZD4573	Phase 1	CDK9 inhibitor				0	95.42	MedChemEx	HY-112088	AZD4573	429.193	CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1	AVIWDYSJSPOOAR-LSDHHAIUSA-N	124155204.0		AVIWDYSJSPOOAR
BRD-K00003443-001-01-9	AZD4635	Phase 1/Phase 2	adenosine receptor antagonist				0	96.52	MedChemEx	HY-101980	AZD4635	315.069	Cc1cc(cc(Cl)n1)-c1nnc(N)nc1-c1ccc(F)cc1	NCWQLHHDGDXIJN-UHFFFAOYSA-N	86676119.0		NCWQLHHDGDXIJN
BRD-K00003297-001-01-9	AZD5069	Phase 2	CC chemokine receptor antagonist	CXCR2			0	97.69	MedChemEx	HY-19855	AZD-5069	476.1	C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	QZECRCLSIGFCIO-RISCZKNCSA-N	56645576.0		QZECRCLSIGFCIO
BRD-K00003528-457-01-9	AZD5153	Phase 1	bromodomain inhibitor				0	92.79	MedChemEx	HY-100653A	AZD5153 (6-Hydroxy-2-naphthoic acid)	479.264	[H][C@]1(C)N(CCOc2ccc(cc2)C2CCN(CC2)c2ccc3nnc(OC)n3n2)CCN(C)C1=O |r|	RSMYFSPOTCDHHJ-GOSISDBHSA-N	118693659.0		RSMYFSPOTCDHHJ
BRD-K99023089-001-03-7	AZD5363	Phase 3	AKT inhibitor	AKT1|AKT2|AKT3			0	94.65	Selleck	S8019	AZD5363	428.173	NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	JDUBGYFRJFOXQC-KRWDZBQOSA-N	25227436.0		JDUBGYFRJFOXQC
BRD-K99023089-001-06-9	AZD5363	Phase 3	AKT inhibitor	AKT1|AKT2|AKT3			0	97.69	MedChemEx	HY-15431	Capivasertib	428.173	NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	JDUBGYFRJFOXQC-KRWDZBQOSA-N	25227436.0		JDUBGYFRJFOXQC
BRD-K72414522-001-08-3	AZD5438	Phase 1	CDK inhibitor	KCNH2			0	78.63	Selleck	S2621	AZD5438	371.142	CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	WJRRGYBTGDJBFX-UHFFFAOYSA-N	16747683.0		WJRRGYBTGDJBFX
BRD-K72414522-001-10-9	AZD5438	Phase 1	CDK inhibitor	KCNH2			0	97.1	Tocris	3968	AZD 5438	371.142	CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	WJRRGYBTGDJBFX-UHFFFAOYSA-N	16747683.0		WJRRGYBTGDJBFX
BRD-K72414522-001-06-7	AZD5438	Phase 1	CDK inhibitor	KCNH2			0	87.42	Selleck	S2621	AZD5438	371.142	CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	WJRRGYBTGDJBFX-UHFFFAOYSA-N	16747683.0		WJRRGYBTGDJBFX
BRD-K72414522-001-04-2	AZD5438	Phase 1	CDK inhibitor	KCNH2			0		Selleck	S2621	AZD5438	371.142	CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)	16747683.0		WJRRGYBTGDJBFX
BRD-K88767641-001-01-7	AZD5582	Preclinical	XIAP inhibitor	BIRC2|BIRC3|XIAP			0	93.19	MedChemEx	HY-12600	AZD5582	1014.594	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1	WLMCRYCCYXHPQF-ZVMUOSSASA-N	49847690.0		WLMCRYCCYXHPQF
BRD-K00005264-001-02-9	AZD5991	Phase 1	MCL1 inhibitor				0	97.34	MedChemEx	HY-101533	AZD-5991	671.179	Cc1c-2c(CSCc3cc(CSc4cc(OCCCc5c(C(O)=O)n(C)c6c-2c(Cl)ccc56)c2ccccc2c4)n(C)n3)nn1C	KBQCEQAXHPIRTF-UHFFFAOYSA-N	131634760.0		KBQCEQAXHPIRTF
BRD-K58772419-001-08-8	AZD6482	Phase 1	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	99.6	Tocris	4839	AZD 6482	408.18	C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	IRTDIKMSKMREGO-OAHLLOKOSA-N	44137675.0		IRTDIKMSKMREGO
BRD-K58772419-001-07-0	AZD6482	Phase 1	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	98.16	Selleck	S1462	AZD6482	408.18	C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	IRTDIKMSKMREGO-OAHLLOKOSA-N	44137675.0		IRTDIKMSKMREGO
BRD-A36013532-001-01-3	AZD6738	Phase 2	ATR kinase inhibitor	ATR			0	97.61	Selleck	S7693	AZD6738	412.168	C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1,&1:25|	OHUHVTCQTUDPIJ-MUWSIPGASA-N	54761305.0		OHUHVTCQTUDPIJ
BRD-A94033181-001-01-4	AZD6765	Phase 2	glutamate receptor antagonist	GRIN1			0	84.3	Enamine	EN300-123342		198.116	N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1,r|	FWUQWDCOOWEXRY-ZDUSSCGKSA-N	9794203.0		FWUQWDCOOWEXRY
BRD-K52836380-001-05-9	AZD7545	Phase 1	pyruvate dehydrogenase kinase inhibitor	PDK1			0	96.52	MedChemEx	HY-16082	AZD7545	478.058	CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1	DTDZLJHKVNTQGZ-GOSISDBHSA-N	16741245.0		DTDZLJHKVNTQGZ
BRD-K00003100-001-01-9	AZD7594	Phase 2	glucocorticoid receptor modulator				0	86.17	MedChemEx	HY-111453	AZD7594	606.229	C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2n(ncc2c1)-c1cccc(c1)C(=O)N[C@@H]1CCOC1)c1ccc2OCCOc2c1	ZZWJKLGCDHYVMB-BWGXUDETSA-N	67041274.0		ZZWJKLGCDHYVMB
BRD-K31495718-001-01-1	AZD7687	Phase 1	diacylglycerol O acyltransferase inhibitor	DGAT1			0	99.55	MedChemEx	HY-15497	AZD7687	367.19	Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|	YXFNPRHZMOGREC-SHTZXODSSA-N			YXFNPRHZMOGREC
BRD-K31495718-001-02-9	AZD7687	Phase 1	diacylglycerol O acyltransferase inhibitor	DGAT1			0	96.39	MedChemEx	HY-15497	AZD7687	367.19	Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|	YXFNPRHZMOGREC-SHTZXODSSA-N			YXFNPRHZMOGREC
BRD-K86525559-003-11-9	AZD7762	Phase 1	CHK inhibitor	CHEK1|CHEK2			0	91.08	Tocris	5199	AZD 7762 hydrochloride	362.121	NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	IAYGCINLNONXHY-LBPRGKRZSA-N	11152667.0		IAYGCINLNONXHY
BRD-K86525559-001-04-5	AZD7762	Phase 1	CHK inhibitor	CHEK1|CHEK2			0	86.93	Selleck	S1532	AZD7762	362.121	NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	IAYGCINLNONXHY-LBPRGKRZSA-N	11152667.0		IAYGCINLNONXHY
BRD-K86525559-003-01-7	AZD7762	Phase 1	CHK inhibitor	CHEK1|CHEK2			0	94.21	Tocris	5199	AZD 7762 hydrochloride	362.121	NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	IAYGCINLNONXHY-LBPRGKRZSA-N	11152667.0		IAYGCINLNONXHY
BRD-K86525559-001-07-8	AZD7762	Phase 1	CHK inhibitor	CHEK1|CHEK2			0	92.5	Selleck	S1532	AZD7762	362.121	NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	IAYGCINLNONXHY-LBPRGKRZSA-N	11152667.0		IAYGCINLNONXHY
BRD-K00003398-001-01-9	AZD7986	Phase 1	dipeptidyl peptidase inhibitor				0	95.46	MedChemEx	HY-101056	AZD7986	420.18	Cn1c2cc(ccc2oc1=O)-c1ccc(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)cc1	AEXFXNFMSAAELR-RXVVDRJESA-N	118253852.0		AEXFXNFMSAAELR
BRD-K69932463-001-10-6	AZD8055	Phase 1	mTOR inhibitor	MTOR			0	97.5	Selleck	S1555	AZD8055	465.238	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	KVLFRAWTRWDEDF-IRXDYDNUSA-N	25262965.0		KVLFRAWTRWDEDF
BRD-K69932463-001-17-1	AZD8055	Phase 1	mTOR inhibitor	MTOR			0	98.72	Focus	Oct-4816	AZD8055	465.238	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	KVLFRAWTRWDEDF-IRXDYDNUSA-N	25262965.0		KVLFRAWTRWDEDF
BRD-K47289408-001-01-5	AZD8186	Phase 1	PI3K inhibitor	PIK3CB|PIK3CD			0	99.82	Adooq	A14164		457.181	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C	LMJFJIDLEAWOQJ-CQSZACIVSA-N	52913813.0		LMJFJIDLEAWOQJ
BRD-K47289408-001-02-3	AZD8186	Phase 1	PI3K inhibitor	PIK3CB|PIK3CD			0	99.37	Selleck	S7694	AZD8186	457.181	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C	LMJFJIDLEAWOQJ-CQSZACIVSA-N	52913813.0	BRD-A57210235-001-01-9	LMJFJIDLEAWOQJ
BRD-K37687095-001-07-7	AZD8330	Phase 1	MEK inhibitor	MAP3K1			0	97.4	Selleck	S2134	AZD8330	461.025	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O	RWEVIPRMPFNTLO-UHFFFAOYSA-N	16666708.0		RWEVIPRMPFNTLO
BRD-K37687095-001-06-9	AZD8330	Phase 1	MEK inhibitor	MAP3K1			0	90.37	Selleck	S2134	AZD8330	461.025	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O	RWEVIPRMPFNTLO-UHFFFAOYSA-N	16666708.0		RWEVIPRMPFNTLO
BRD-K03336321-001-02-9	AZD8797	Preclinical	CC chemokine receptor antagonist				0	94.44	MedChemEx	HY-13848	AZD8797	403.15	CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12	ZMQSLMZOWVGBSM-GXTWGEPZSA-N	11965767.0		ZMQSLMZOWVGBSM
BRD-K82894950-001-01-0	AZD8835	Phase 1	PI3K inhibitor	PIK3CA|PIK3CD			0	97.11	MedChemEx	HY-12869	AZD-8835	469.255	CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO	ZGRDYKFVDCFJCZ-UHFFFAOYSA-N	76685059.0		ZGRDYKFVDCFJCZ
BRD-K98572433-001-03-9	AZD8931	Phase 2	EGFR inhibitor	EGFR|ERBB2|ERBB3			0	99.24	MedChemEx	HY-13050	Sapitinib	473.163	CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	DFJSJLGUIXFDJP-UHFFFAOYSA-N	11488320.0		DFJSJLGUIXFDJP
BRD-K98572433-001-02-9	AZD8931	Phase 2	EGFR inhibitor	EGFR|ERBB2|ERBB3			0	96.79	Selleck	S2192	AZD8931 (Sapitinib)	473.163	CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	DFJSJLGUIXFDJP-UHFFFAOYSA-N	11488320.0		DFJSJLGUIXFDJP
BRD-K13699028-003-02-9	AZD9056	Phase 2	purinergic receptor antagonist				0	95.95	MedChemEx	HY-19427A	AZD9056 (hydrochloride)	418.239	OCCCNCCCc1ccc(Cl)c(c1)C(=O)NCC12CC3CC(CC(C3)C1)C2	HSQAARMBHJCUOK-UHFFFAOYSA-N	10161381.0		HSQAARMBHJCUOK
BRD-K61043483-001-01-5	AZD9272	Preclinical	glutamate receptor antagonist	GRM5			0	97.51	Tocris	5613	AZD 9272	284.051	Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N	RBSPCALDSNXWEP-UHFFFAOYSA-N	9838729.0		RBSPCALDSNXWEP
BRD-K61043483-001-02-9	AZD9272	Preclinical	glutamate receptor antagonist	GRM5			0	96.21	Tocris	5613	AZD 9272	284.051	Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N	RBSPCALDSNXWEP-UHFFFAOYSA-N	9838729.0		RBSPCALDSNXWEP
BRD-K73235735-001-02-7	AZD9496	Phase 1	estrogen receptor agonist	ESR1			0	97.14	MedChemEx	HY-12870	AZD9496	442.187	C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F	DFBDRVGWBHBJNR-BBNFHIFMSA-N	86287635.0		DFBDRVGWBHBJNR
BRD-K73235735-050-01-6	AZD9496	Phase 1	estrogen receptor agonist	ESR1			0	91.55	MedChemEx	HY-12870A	AZD9496 (maleate)	442.187	C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F	DFBDRVGWBHBJNR-BBNFHIFMSA-N	86287635.0		DFBDRVGWBHBJNR
BRD-K31476763-001-01-5	AZD9668	Phase 2	elastase inhibitor	ELANE			0	98.48	MedChemEx	HY-15651	Alvelestat	545.134	Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	QNQZWEGMKJBHEM-UHFFFAOYSA-N	46861623.0		QNQZWEGMKJBHEM
BRD-K31476763-001-02-9	AZD9668	Phase 2	elastase inhibitor	ELANE			0	91.86	MedChemEx	HY-15651	Alvelestat	545.134	Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	QNQZWEGMKJBHEM-UHFFFAOYSA-N	46861623.0		QNQZWEGMKJBHEM
BRD-K08976401-001-18-5	azelaic-acid	Launched	tyrosinase inhibitor	AKR1D1|SRD5A2|TYR	dermatology	rosacea	0	97.8	MicroSource	1500648	AZELAIC ACID	188.105	OC(=O)CCCCCCCC(O)=O	BDJRBEYXGGNYIS-UHFFFAOYSA-N	2266.0		BDJRBEYXGGNYIS
BRD-A68888262-003-16-9	azelastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	79.44	MicroSource	1505340	AZELASTINE HYDROCHLORIDE	381.161	CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|	MBUVEWMHONZEQD-SFHVURJKSA-N	12831281.0		MBUVEWMHONZEQD
BRD-A68888262-003-15-1	azelastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	96.67	Selleck	S2552	Azelastine HCl	381.161	CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|	MBUVEWMHONZEQD-SFHVURJKSA-N	12831281.0		MBUVEWMHONZEQD
BRD-A68888262-003-17-9	azelastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	98.0	MedChemEx	HY-B0462	Azelastine (hydrochloride)	381.161	CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|	MBUVEWMHONZEQD-SFHVURJKSA-N	12831281.0		MBUVEWMHONZEQD
BRD-K51899933-001-02-6	azeliragon	Phase 3	RAGE receptor antagonist	AGER			0	90.27	MedChemEx	HY-50682	Azeliragon	531.265	CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1	KJNNWYBAOPXVJY-UHFFFAOYSA-N	11180124.0		KJNNWYBAOPXVJY
BRD-A01098288-001-06-0	azelnidipine	Launched	calcium channel blocker	CACNA1C	cardiology	hypertension	0	95.94	MedChemEx	HY-B0023	Azelnidipine	582.248	CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|	ZKFQEACEUNWPMT-MUUNZHRXSA-N	9873077.0		ZKFQEACEUNWPMT
BRD-A01098288-001-04-5	azelnidipine	Launched	calcium channel blocker	CACNA1C	cardiology	hypertension	0	81.05	Selleck	S3053	Azelnidipine	582.248	CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|	ZKFQEACEUNWPMT-MUUNZHRXSA-N	9873077.0		ZKFQEACEUNWPMT
BRD-A01098288-001-02-9	azelnidipine	Launched	calcium channel blocker	CACNA1C	cardiology	hypertension	0	83.79	Selleck	S3053	Azelnidipine	582.248	CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r,c:6,11|	ZKFQEACEUNWPMT-MUUNZHRXSA-N	9873077.0		ZKFQEACEUNWPMT
BRD-K81074237-001-04-9	azilsartan	Launched	angiotensin receptor antagonist	AGTR1|AGTR2	cardiology	hypertension	0	97.01	Tocris	4553	Azilsartan	456.143	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	KGSXMPPBFPAXLY-UHFFFAOYSA-N	135415867.0		KGSXMPPBFPAXLY
BRD-K81074237-001-03-1	azilsartan	Launched	angiotensin receptor antagonist	AGTR1|AGTR2	cardiology	hypertension	0	91.72	Tocris	4553	Azilsartan	456.143	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	KGSXMPPBFPAXLY-UHFFFAOYSA-N	135415867.0		KGSXMPPBFPAXLY
BRD-K81074237-001-02-3	azilsartan	Launched	angiotensin receptor antagonist	AGTR1|AGTR2	cardiology	hypertension	0	97.15	Selleck	S3046	Azilsartan	456.143	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	KGSXMPPBFPAXLY-UHFFFAOYSA-N	135415867.0		KGSXMPPBFPAXLY
BRD-K25723200-237-01-9	azilsartan-medoxomil	Launched	angiotensin receptor antagonist	AGTR1|AGTR2	cardiology	hypertension	0	77.15	MicroSource	1504108	AZILSARTAN MEDOXOMIL	568.159	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	QJFSABGVXDWMIW-UHFFFAOYSA-N	135409642.0		QJFSABGVXDWMIW
BRD-K25723200-001-03-5	azilsartan-medoxomil	Launched	angiotensin receptor antagonist	AGTR1|AGTR2	cardiology	hypertension	0	92.61	Selleck	S3057	Azilsartan Medoxomil (TAK-491)	568.159	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	QJFSABGVXDWMIW-UHFFFAOYSA-N	135409642.0		QJFSABGVXDWMIW
BRD-K25723200-001-02-7	azilsartan-medoxomil	Launched	angiotensin receptor antagonist	AGTR1|AGTR2	cardiology	hypertension	0	80.92	Selleck	S3057	Azilsartan Medoxomil	568.159	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	QJFSABGVXDWMIW-UHFFFAOYSA-N	135409642.0		QJFSABGVXDWMIW
BRD-K25723200-001-04-3	azilsartan-medoxomil	Launched	angiotensin receptor antagonist	AGTR1|AGTR2	cardiology	hypertension	0	97.22	Selleck	S3057	Azilsartan Medoxomil (TAK-491)	568.159	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	QJFSABGVXDWMIW-UHFFFAOYSA-N	135409642.0		QJFSABGVXDWMIW
BRD-K38913877-300-02-9	azimilide	Phase 3	potassium channel blocker	KCNA5			0	94.02	Tocris	6318	Azimilide dihydrochloride	457.188	CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1	MREBEPTUUMTTIA-PCLIKHOPSA-N	9571004.0		MREBEPTUUMTTIA
BRD-K38913877-300-01-9	azimilide	Phase 3	potassium channel blocker	KCNA5			0	97.19	MedChemEx	HY-18600A	Azimilide (Dihydrochloride)	457.188	CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1	MREBEPTUUMTTIA-PCLIKHOPSA-N	9571004.0		MREBEPTUUMTTIA
BRD-K74501079-001-17-3	azithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease|pneumonia	0	99.26	Tocris	3771	Azithromycin	748.509	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	MQTOSJVFKKJCRP-CBLJCGFISA-N	71206984.0		MQTOSJVFKKJCRP
BRD-K74501079-001-15-7	azithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease|pneumonia	0	97.53	MicroSource	1503679	AZITHROMYCIN	748.509	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	MQTOSJVFKKJCRP-CBLJCGFISA-N	71206984.0		MQTOSJVFKKJCRP
BRD-K74501079-335-01-9	azithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease|pneumonia	0	100.0	Selleck	S4147	Azithromycin Dihydrate	748.509	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	MQTOSJVFKKJCRP-CBLJCGFISA-N	71206984.0	BRD-A37438244-335-01-2	MQTOSJVFKKJCRP
BRD-K74501079-001-19-9	azithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease|pneumonia	0	100.0	Tocris	3771	Azithromycin	748.509	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	MQTOSJVFKKJCRP-CBLJCGFISA-N	71206984.0		MQTOSJVFKKJCRP
BRD-K74501079-001-18-1	azithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	pelvic inflammatory disease|pneumonia	0	100.0	Selleck	S1835	Azithromycin	748.509	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	MQTOSJVFKKJCRP-CBLJCGFISA-N	71206984.0	BRD-K73794685-001-01-5	MQTOSJVFKKJCRP
BRD-K60663764-236-04-7	azlocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	0	37.97	MicroSource	1503101	AZLOCILLIN SODIUM	461.137	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	JTWOMNBEOCYFNV-NFFDBFGFSA-N	6479523.0	BRD-A95218818-236-05-4	JTWOMNBEOCYFNV
BRD-K60663764-236-05-4	azlocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	0	36.55	MicroSource	1503101	AZLOCILLIN SODIUM	461.137	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	JTWOMNBEOCYFNV-NFFDBFGFSA-N	6479523.0	BRD-A95218818-001-01-1	JTWOMNBEOCYFNV
BRD-K60663764-236-03-9	azlocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	0	85.42	Selleck	S3195	Azlocillin sodium salt	461.137	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	JTWOMNBEOCYFNV-NFFDBFGFSA-N	6479523.0	BRD-A46717658-236-03-3	JTWOMNBEOCYFNV
BRD-K60663764-236-07-9	azlocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	0	74.39	MedChemEx	HY-B0529A	Azlocillin (sodium salt)	461.137	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	JTWOMNBEOCYFNV-NFFDBFGFSA-N	6479523.0		JTWOMNBEOCYFNV
BRD-K51329597-001-01-3	AZM-475271	Preclinical	SRC inhibitor	SRC			0	93.7	Tocris	3963	AZM 475271	442.177	COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1	WPOXAFXHRJYEIC-UHFFFAOYSA-N	5330175.0		WPOXAFXHRJYEIC
BRD-K51329597-001-02-9	AZM-475271	Preclinical	SRC inhibitor	SRC			0	97.05	Tocris	3963	AZM 475271	442.177	COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1	WPOXAFXHRJYEIC-UHFFFAOYSA-N	5330175.0		WPOXAFXHRJYEIC
BRD-K87036601-001-02-4	azodicarbonamide	Phase 2	DNA synthesis inhibitor				1	0.0	AMS	A001025136	(E)-1,2-diazenedicarboxamide	116.033	NC(=O)\N=N\C(N)=O	XOZUGNYVDXMRKW-AATRIKPKSA-N	5462814.0		XOZUGNYVDXMRKW
BRD-K87036601-001-01-6	azodicarbonamide	Phase 2	DNA synthesis inhibitor				1	0.0	MatrixSci	99173		116.033	NC(=O)\N=N\C(N)=O	XOZUGNYVDXMRKW-AATRIKPKSA-N	5462814.0		XOZUGNYVDXMRKW
BRD-K26824830-001-02-0	azomycin-(2-nitroimidazole)	Preclinical	protein synthesis inhibitor				0	88.92	Selleck	S2267	Azomycin	113.023	[O-][N+](=O)c1ncc[nH]1	YZEUHQHUFTYLPH-UHFFFAOYSA-N	10701.0		YZEUHQHUFTYLPH
BRD-K26824830-001-03-8	azomycin-(2-nitroimidazole)	Preclinical	protein synthesis inhibitor				0	96.5	Selleck	S2267	Azomycin (2-Nitroimidazole)	113.023	[O-][N+](=O)c1ncc[nH]1	YZEUHQHUFTYLPH-UHFFFAOYSA-N	10701.0		YZEUHQHUFTYLPH
BRD-K68770713-001-01-8	azosemide	Launched	electrolyte reabsorption inhibitor	SLC12A1|SLC12A2	cardiology	edema	0	95.2	AKSci	69592		370.007	NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl	HMEDEBAJARCKCT-UHFFFAOYSA-N	2273.0		HMEDEBAJARCKCT
BRD-K62607865-001-11-9	aztreonam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|respiratory tract infections|bacterial septicemia|skin infections|intra-abdominal infections|gynecologic infections	0	81.57	MedChemEx	HY-B0129	Aztreonam	435.052	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	WZPBZJONDBGPKJ-VEHQQRBSSA-N	5742832.0		WZPBZJONDBGPKJ
BRD-K62607865-236-02-4	aztreonam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|respiratory tract infections|bacterial septicemia|skin infections|intra-abdominal infections|gynecologic infections	0	69.22	MicroSource	1505122	AZTREONAM	435.052	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	WZPBZJONDBGPKJ-VEHQQRBSSA-N	5742832.0	BRD-K36547807-001-03-2	WZPBZJONDBGPKJ
BRD-K62607865-001-09-7	aztreonam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|respiratory tract infections|bacterial septicemia|skin infections|intra-abdominal infections|gynecologic infections	0	90.6	Selleck	S1505	Aztreonam (Azactam, Cayston)	435.052	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	WZPBZJONDBGPKJ-VEHQQRBSSA-N	5742832.0		WZPBZJONDBGPKJ
BRD-K62607865-236-01-6	aztreonam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|respiratory tract infections|bacterial septicemia|skin infections|intra-abdominal infections|gynecologic infections	0	54.85	Selleck	S1505	Aztreonam	435.052	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	WZPBZJONDBGPKJ-VEHQQRBSSA-N	5742832.0	BRD-K41270709-001-01-7	WZPBZJONDBGPKJ
BRD-K80935598-001-04-9	AZ191	Preclinical	DYRK inhibitor	DYRK1B			0	97.06	Tocris	5232	AZ 191	429.228	COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	ZYVXTMKTGDARKR-UHFFFAOYSA-N	72716071.0		ZYVXTMKTGDARKR
BRD-K80935598-001-02-9	AZ191	Preclinical	DYRK inhibitor	DYRK1B			0	90.61	Tocris	5232	AZ 191	429.228	COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	ZYVXTMKTGDARKR-UHFFFAOYSA-N	72716071.0		ZYVXTMKTGDARKR
BRD-K80935598-001-01-1	AZ191	Preclinical	DYRK inhibitor	DYRK1B			0	92.78	Selleck	S7338	AZ191	429.228	COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	ZYVXTMKTGDARKR-UHFFFAOYSA-N	72716071.0		ZYVXTMKTGDARKR
BRD-K42436189-001-03-8	AZ20	Preclinical	ATR kinase inhibitor	ATR|MTOR			0	98.44	Tocris	5198	AZ 20	412.157	C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O	SCGCBAAYLFTIJU-CQSZACIVSA-N	46244454.0		SCGCBAAYLFTIJU
BRD-K42436189-001-01-2	AZ20	Preclinical	ATR kinase inhibitor	ATR|MTOR			0	97.81	Selleck	S7050	AZ20	412.157	C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O	SCGCBAAYLFTIJU-CQSZACIVSA-N	46244454.0		SCGCBAAYLFTIJU
BRD-K59146805-001-04-5	AZ3146	Preclinical	monopolar spindle 1 kinase inhibitor				0	93.84	Selleck	S2731	AZ 3146	452.254	COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	YUKWVHPTFRQHMF-UHFFFAOYSA-N	56973724.0		YUKWVHPTFRQHMF
BRD-K59146805-001-03-7	AZ3146	Preclinical	monopolar spindle 1 kinase inhibitor				0	75.56	Selleck	S2731	AZ 3146	452.254	COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	YUKWVHPTFRQHMF-UHFFFAOYSA-N	56973724.0		YUKWVHPTFRQHMF
BRD-K59146805-001-05-2	AZ3146	Preclinical	monopolar spindle 1 kinase inhibitor				0	94.31	Tocris	3994	AZ 3146	452.254	COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	YUKWVHPTFRQHMF-UHFFFAOYSA-N	56973724.0		YUKWVHPTFRQHMF
BRD-K76244476-362-02-5	AZ505	Preclinical	histone lysine methyltransferase inhibitor	SMYD2			0	97.71	MedChemEx	HY-15226A	AZ505 (ditrifluoroacetate)	576.227	Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12	LIBVHXXKHSODII-UHFFFAOYSA-N	24961094.0		LIBVHXXKHSODII
BRD-K76244476-362-01-7	AZ505	Preclinical	histone lysine methyltransferase inhibitor	SMYD2			0	87.42	MedChemEx	HY-15226A	AZ505 (ditrifluoroacetate)	576.227	Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12	LIBVHXXKHSODII-UHFFFAOYSA-N	24961094.0		LIBVHXXKHSODII
BRD-K81958169-001-01-1	AZ5104	Preclinical	EGFR inhibitor	EGFR			0	79.95	Selleck	S7298	AZ5104	485.254	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12	IQNVEOMHJHBNHC-UHFFFAOYSA-N	71496460.0		IQNVEOMHJHBNHC
BRD-K00003515-003-01-9	AZ7550	Phase 1	insulin growth factor receptor inhibitor				0	95.84	MedChemEx	HY-B0794A	AZ7550 hydrochloride	485.254	CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C	ZROCWKZRGJYPTG-UHFFFAOYSA-N	71496459.0		ZROCWKZRGJYPTG
BRD-K64888243-001-05-9	AZ960	Preclinical	JAK inhibitor	JAK2			0	93.2	MedChemEx	HY-10411	AZ960	354.14	C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1	SUNXHXDJOIXABJ-NSHDSACASA-N	25099184.0		SUNXHXDJOIXABJ
BRD-K64888243-001-04-5	AZ960	Preclinical	JAK inhibitor	JAK2			0	94.66	Selleck	S2214	AZ 960	354.14	C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1	SUNXHXDJOIXABJ-NSHDSACASA-N	25099184.0		SUNXHXDJOIXABJ
BRD-K64888243-001-03-7	AZ960	Preclinical	JAK inhibitor	JAK2			0	90.05	Selleck	S2214	AZ 960	354.14	C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1	SUNXHXDJOIXABJ-NSHDSACASA-N	25099184.0		SUNXHXDJOIXABJ
BRD-K57865272-001-02-0	A0001	Phase 2					0	0.0	Sigma	MFCD00135657	2-[(3R,7R,11R)-3-hydroxy-3,7,11,15-tetramethylhexadecyl]-3,5,6-trimethylbenzo-1,4-quinone	446.376	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|	LTVDFSLWFKLJDQ-IEOSBIPESA-N	2734086.0		LTVDFSLWFKLJDQ
BRD-K57865272-001-01-2	A0001	Phase 2					0	40.81	Enzo	FR115	Tocopherylquinone	446.376	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21,t:27|	LTVDFSLWFKLJDQ-IEOSBIPESA-N	2734086.0		LTVDFSLWFKLJDQ
BRD-A30000356-001-02-9	A12B4C3	Preclinical	polynucleotide kinase/phosphatase inhibitor	PNKP			0	90.41	Tocris	5097	A12B4C3	534.284	CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|	KVHGJAKTBPFFNV-KUXCXQDQSA-N			KVHGJAKTBPFFNV
BRD-A30000356-001-01-9	A12B4C3	Preclinical	polynucleotide kinase/phosphatase inhibitor	PNKP			0	89.26	Tocris	5097	A12B4C3	534.284	CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10,&2:12,r,c:13|	KVHGJAKTBPFFNV-KUXCXQDQSA-N			KVHGJAKTBPFFNV
BRD-K77627880-001-05-7	A205804	Preclinical	ICAM1 expression inhibitor	ICAM1|SELE			0	96.5	Tocris	2524	A 205804	300.039	Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	QQGWEXFLMJGCAL-UHFFFAOYSA-N	9839311.0		QQGWEXFLMJGCAL
BRD-K77627880-001-04-0	A205804	Preclinical	ICAM1 expression inhibitor	ICAM1|SELE			0	98.68	Tocris	2524	A 205804	300.039	Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	QQGWEXFLMJGCAL-UHFFFAOYSA-N	9839311.0		QQGWEXFLMJGCAL
BRD-K77627880-001-06-9	A205804	Preclinical	ICAM1 expression inhibitor	ICAM1|SELE			0	96.96	Tocris	2524	A 205804	300.039	Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	QQGWEXFLMJGCAL-UHFFFAOYSA-N	9839311.0		QQGWEXFLMJGCAL
BRD-K77627880-001-03-2	A205804	Preclinical	ICAM1 expression inhibitor	ICAM1|SELE			0	97.7	Selleck	S2885	A-205804	300.039	Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	QQGWEXFLMJGCAL-UHFFFAOYSA-N	9839311.0		QQGWEXFLMJGCAL
BRD-A83650191-004-03-6	A61603	Preclinical	adrenergic receptor agonist	ADRA1A			0	96.39	Tocris	1052	N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide hydrobromide	309.115	CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|	OQFCXJDXHCDLHX-LLVKDONJSA-N	6604803.0		OQFCXJDXHCDLHX
BRD-A83650191-004-02-8	A61603	Preclinical	adrenergic receptor agonist	ADRA1A			0	80.43	Tocris	1052	A 61603 hydrobromide	309.115	CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r,t:18|	OQFCXJDXHCDLHX-LLVKDONJSA-N	6604803.0		OQFCXJDXHCDLHX
BRD-K49055432-001-04-2	A66	Preclinical	PI3K inhibitor	PIK3CA			0	90.0	Selleck	S2636	A66	393.129	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C	HBPXWEPKNBHKAX-NSHDSACASA-N	42636535.0		HBPXWEPKNBHKAX
BRD-K49055432-001-07-5	A66	Preclinical	PI3K inhibitor	PIK3CA			0	94.01	Tocris	5595	A66	393.129	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C	HBPXWEPKNBHKAX-NSHDSACASA-N	42636535.0		HBPXWEPKNBHKAX
BRD-A78952587-001-02-3	A740003	Preclinical	purinergic receptor antagonist	P2RX7			0	94.76	Tocris	3701	A 740003	474.238	COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|	PUHSRMSFDASMAE-DEOSSOPVSA-N	98050091.0		PUHSRMSFDASMAE
BRD-A78952587-001-01-5	A740003	Preclinical	purinergic receptor antagonist	P2RX7			0	97.5	Tocris	3701	A 740003	474.238	COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|	PUHSRMSFDASMAE-DEOSSOPVSA-N	98050091.0		PUHSRMSFDASMAE
BRD-A78952587-001-03-9	A740003	Preclinical	purinergic receptor antagonist	P2RX7			0	92.24	Tocris	3701	A 740003	474.238	COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10,r|	PUHSRMSFDASMAE-DEOSSOPVSA-N	98050091.0		PUHSRMSFDASMAE
BRD-K72226571-003-02-9	A77636	Preclinical	dopamine receptor agonist	CALY			0	86.81	Tocris	1701	A 77636 hydrochloride	329.199	NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2	QLJOSZATCBCBDR-KLONBWLYSA-N			QLJOSZATCBCBDR
BRD-K72226571-003-01-2	A77636	Preclinical	dopamine receptor agonist	CALY			0	39.87	Tocris	1701	A 77636 hydrochloride	329.199	NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2	QLJOSZATCBCBDR-KLONBWLYSA-N			QLJOSZATCBCBDR
BRD-K28861668-001-01-9	A922500	Preclinical	diacylglycerol O acyltransferase inhibitor	DGAT1			0	92.69	Selleck	S2674	A922500	428.174	OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	BOZRFEQDOFSZBV-PKTZIBPZSA-N	24768273.0		BOZRFEQDOFSZBV
BRD-A41698174-003-13-8	bacampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	0	74.93	MicroSource	1503102	BACAMPICILLIN HYDROCHLORIDE	465.157	CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|	PFOLLRNADZZWEX-XIJZRVNUSA-N	66586207.0	BRD-A10481343-003-03-3	PFOLLRNADZZWEX
BRD-A41698174-003-11-2	bacampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	0	70.33	Sigma	S______B1885	1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylethanoyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate hydrochloride	465.157	CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|	PFOLLRNADZZWEX-XIJZRVNUSA-N	66586207.0		PFOLLRNADZZWEX
BRD-A41698174-003-12-0	bacampicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections	0	81.26	MedChemEx	HY-B1149A	Bacampicillin (hydrochloride)	465.157	CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11,13,18,22,&1:6|	PFOLLRNADZZWEX-XIJZRVNUSA-N	66586207.0		PFOLLRNADZZWEX
BRD-K14079729-001-01-1	bacitracin	Launched	bacterial cell wall synthesis inhibitor	IDE	infectious disease	first-aid antibiotic	0	43.52	Selleck	S4146	Bacitracin	1421.749	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|	CLKOFPXJLQSYAH-BBLSSJOMSA-N			CLKOFPXJLQSYAH
BRD-K00003625-001-01-9	bacitracin-zinc	Launched	bacterial cell wall synthesis inhibitor		infectious disease	first-aid antibiotic	0	51.16	MedChemEx	HY-B0278	Bacitracin (Zinc)	1483.662	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)[C@@H](C)CC |t:6|	UCRLQOPRDMGYOA-PIGMFEANSA-L			UCRLQOPRDMGYOA
BRD-K01826724-001-08-9	baclofen	Launched	benzodiazepine receptor agonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8	neurology/psychiatry	multiple sclerosis|spasms	0	47.4	Tocris	417	(RS)-Baclofen	213.056	NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|	KPYSYYIEGFHWSV-MRVPVSSYSA-N	6923772.0		KPYSYYIEGFHWSV
BRD-K01826724-003-07-9	baclofen	Launched	benzodiazepine receptor agonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8	neurology/psychiatry	multiple sclerosis|spasms	0	0.0	MicroSource	1500135	BACLOFEN HYDROCHLORIDE (+/-)	249.032	NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|	KPYSYYIEGFHWSV-MRVPVSSYSA-N	6923772.0		KPYSYYIEGFHWSV
BRD-A16694057-001-08-9	BADGE	Preclinical	PPAR receptor antagonist	PPARG			0	0.0	Sigma	MFCD00080480	Bisphenol A diglycidyl ether	340.167	CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|	LCFVJGUPQDGYKZ-PMACEKPBSA-N	6994088.0		LCFVJGUPQDGYKZ
BRD-A16694057-001-06-8	BADGE	Preclinical	PPAR receptor antagonist	PPARG			0	94.12	Tocris	1326	BADGE	340.167	CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9,&2:20,r|	LCFVJGUPQDGYKZ-PMACEKPBSA-N	6994088.0		LCFVJGUPQDGYKZ
BRD-K82196541-001-04-9	bafetinib	Phase 2	Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor	ABL1|BCR|LYN			0	91.07	Selleck	S1369		576.257	CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	11387605.0		ZGBAJMQHJDFTQJ
BRD-K82196541-001-03-9	bafetinib	Phase 2	Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor	ABL1|BCR|LYN			0	93.85	MedChemEx	HY-50868	Bafetinib	576.257	CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1	ZGBAJMQHJDFTQJ-DEOSSOPVSA-N	11387605.0		ZGBAJMQHJDFTQJ
BRD-K00010387-001-01-9	bafilomycin-a1	Preclinical	ATPase inhibitor				0	87.42	MedChemEx	HY-100558	Bafilomycin A1	622.408	[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10,t:7,20,22|	XDHNQDDQEHDUTM-UTRUWJARSA-N	90656913.0		XDHNQDDQEHDUTM
BRD-K00652956-001-01-5	BAG-956	Preclinical	phosphoinositide dependent kinase inhibitor	PIK3CG			0	97.92	Tocris	3606	BAG 956	427.18	Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1	GVPAGJWVBUZHNQ-UHFFFAOYSA-N	24882589.0		GVPAGJWVBUZHNQ
BRD-K00652956-001-02-9	BAG-956	Preclinical	phosphoinositide dependent kinase inhibitor	PIK3CG			0	97.33	Tocris	3606	BAG 956	427.18	Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1	GVPAGJWVBUZHNQ-UHFFFAOYSA-N	24882589.0		GVPAGJWVBUZHNQ
BRD-K72327355-001-15-4	baicalein	Preclinical	lipoxygenase inhibitor	ALOX5|GLO1|PREP|SELL|SELP|TNF|XDH			0	97.14	Selleck	S2268	Baicalein	270.053	Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1	WTNAEULBGCSUSK-UHFFFAOYSA-N			WTNAEULBGCSUSK
BRD-K72327355-001-13-9	baicalein	Preclinical	lipoxygenase inhibitor	ALOX5|GLO1|PREP|SELL|SELP|TNF|XDH			0	91.86	Selleck	S2268	Baicalein	270.053	Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1	WTNAEULBGCSUSK-UHFFFAOYSA-N			WTNAEULBGCSUSK
BRD-K72327355-001-14-7	baicalein	Preclinical	lipoxygenase inhibitor	ALOX5|GLO1|PREP|SELL|SELP|TNF|XDH			0	93.36	Tocris	1761	Baicalein	270.053	Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1	WTNAEULBGCSUSK-UHFFFAOYSA-N			WTNAEULBGCSUSK
BRD-K49962337-001-03-9	baicalin	Launched	beta glucuronidase inhibitor	PREP	neurology/psychiatry	anxiety	0	96.41	MedChemEx	HY-N0197	Baicalin	446.085	O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	DAIGSUHCWOZEQG-ZFORQUDYSA-N			DAIGSUHCWOZEQG
BRD-K49962337-001-02-9	baicalin	Launched	beta glucuronidase inhibitor	PREP	neurology/psychiatry	anxiety	0	86.92	Selleck	S2269	Baicalin	446.085	O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	DAIGSUHCWOZEQG-ZFORQUDYSA-N		BRD-K99455969-001-02-8	DAIGSUHCWOZEQG
BRD-K49962337-001-01-1	baicalin	Launched	beta glucuronidase inhibitor	PREP	neurology/psychiatry	anxiety	0	87.7	Selleck	S2269	Baicalin	446.085	O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	DAIGSUHCWOZEQG-ZFORQUDYSA-N		BRD-K98733875-001-01-4	DAIGSUHCWOZEQG
BRD-K09785578-001-02-0	bakuchiol	Phase 2	DNA polymerase inhibitor	HIF1A			0	89.43	MedChemEx	HY-N0235	Bakuchiol	256.183	CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1	LFYJSSARVMHQJB-QIXNEVBVSA-N	5468522.0		LFYJSSARVMHQJB
BRD-K09785578-001-01-2	bakuchiol	Phase 2	DNA polymerase inhibitor	HIF1A			0	83.69	Enzo	350-144	Bakuchiol	256.183	CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1	LFYJSSARVMHQJB-QIXNEVBVSA-N	5468522.0		LFYJSSARVMHQJB
BRD-A00147595-001-01-5	balaglitazone	Phase 3	insulin sensitizer|PPAR receptor partial agonist	PPARG			0	96.17	MedChemEx	HY-16086	Balaglitazone	395.094	Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|	IETKPTYAGKZLKY-MRXNPFEDSA-N	76968728.0		IETKPTYAGKZLKY
BRD-A00147595-001-02-9	balaglitazone	Phase 3	insulin sensitizer|PPAR receptor partial agonist	PPARG			0	98.36	MedChemEx	HY-16086	Balaglitazone	395.094	Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|	IETKPTYAGKZLKY-MRXNPFEDSA-N	76968728.0		IETKPTYAGKZLKY
BRD-K47976015-001-02-9	balapiravir	Phase 2	RNA polymerase inhibitor				0	88.61	MedChemEx	HY-10443	Balapiravir	494.213	CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	VKXWOLCNTHXCLF-DXEZIKHYSA-N	53297462.0		VKXWOLCNTHXCLF
BRD-K47976015-001-01-2	balapiravir	Phase 2	RNA polymerase inhibitor				0	95.37	MedChemEx	HY-10443	Balapiravir	494.213	CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	VKXWOLCNTHXCLF-DXEZIKHYSA-N	53297462.0		VKXWOLCNTHXCLF
BRD-K27204852-001-02-7	balicatib	Phase 2	cathepsin inhibitor	CTSK			0	85.86	Tocris	5585	Balicatib	411.263	CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	LLCRBOWRJOUJAE-UHFFFAOYSA-N	10201696.0		LLCRBOWRJOUJAE
BRD-K27204852-001-03-9	balicatib	Phase 2	cathepsin inhibitor	CTSK			0	88.47	Tocris	5585	Balicatib	411.263	CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	LLCRBOWRJOUJAE-UHFFFAOYSA-N	10201696.0		LLCRBOWRJOUJAE
BRD-K27204852-001-01-9	balicatib	Phase 2	cathepsin inhibitor	CTSK			0	97.04	MedChemEx	HY-15100	Balicatib	411.263	CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	LLCRBOWRJOUJAE-UHFFFAOYSA-N	10201696.0		LLCRBOWRJOUJAE
BRD-A47790386-001-02-8	balofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	45.87	Selleck	S2064	Balofloxacin	389.175	CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|	MGQLHRYJBWGORO-NSHDSACASA-N	40490624.0		MGQLHRYJBWGORO
BRD-A47790386-001-05-9	balofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	64.13	MedChemEx	HY-B0159	Balofloxacin	389.175	CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|	MGQLHRYJBWGORO-NSHDSACASA-N	40490624.0		MGQLHRYJBWGORO
BRD-A47790386-001-03-6	balofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	97.5	Selleck	S2064	Balofloxacin	389.175	CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2,r|	MGQLHRYJBWGORO-NSHDSACASA-N	40490624.0		MGQLHRYJBWGORO
BRD-K00003496-001-01-9	baloxavir	Phase 3	endonuclease inhibitor				0	98.4	MedChemEx	HY-109025A	Baloxavir	483.106	[H][C@@]12COCCN1C(=O)c1c(O)c(=O)ccn1N2[C@@H]1c2ccccc2SCc2c(F)c(F)ccc12	FIDLLEYNNRGVFR-CTNGQTDRSA-N	124081876.0		FIDLLEYNNRGVFR
BRD-K00003495-001-01-9	baloxavir-marboxil	Launched	endonuclease inhibitor		infectious disease	influenza A virus infection	0	98.17	MedChemEx	HY-109025	Baloxavir marboxil	571.122	[H][C@@]12COCCN1C(=O)c1c(OCOC(=O)OC)c(=O)ccn1N2[C@H]1c2ccc(F)c(F)c2CSc2ccccc12	RZVPBGBYGMDSBG-GGAORHGYSA-N	124081896.0		RZVPBGBYGMDSBG
BRD-K00003656-001-01-9	balsalazide	Launched	cyclooxygenase inhibitor	ALOX5|PPARG|PTGS1|PTGS2	gastroenterology	ulcerative colitis	0	86.18	MedChemEx	HY-B0667	Balsalazide	357.096	OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O	IPOKCKJONYRRHP-FMQUCBEESA-N			IPOKCKJONYRRHP
BRD-K00003411-001-01-9	bamaquimast	Preclinical	proton pump inhibitor				0	97.09	MedChemEx	HY-101427	Bamaquimast	303.158	CCCn1c2ccccc2nc(CCCOC(=O)NC)c1=O	HNQSZPBGDAJIJO-UHFFFAOYSA-N	184838.0		HNQSZPBGDAJIJO
BRD-A17462676-003-11-6	bambuterol	Launched	adrenergic receptor agonist	ADRB2|BCHE	pulmonary	asthma	0	97.14	MicroSource	1505173	BAMBUTEROL HYDROCHLORIDE	367.211	CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C	ANZXOIAKUNOVQU-UHFFFAOYSA-N	57515921.0		ANZXOIAKUNOVQU
BRD-K07442505-001-03-6	BAM7	Preclinical	BAX activator	BAX			0	97.43	Selleck	S7105	BAM7	405.126	CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|	KOCVKGYKBLJEPK-LYBHJNIJSA-N			KOCVKGYKBLJEPK
BRD-K07442505-001-05-9	BAM7	Preclinical	BAX activator	BAX			0	97.46	MedChemEx	HY-15341	BAM7	405.126	CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|	KOCVKGYKBLJEPK-LYBHJNIJSA-N			KOCVKGYKBLJEPK
BRD-K47049295-300-02-3	BAN-ORL-24	Preclinical	nociceptin/orphanin FQ receptor antagonist	OPRL1			0	57.78	Tocris	3661	BAN ORL 24	433.273	O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	MAKMQGKJURAJEN-RUZDIDTESA-N	10296561.0		MAKMQGKJURAJEN
BRD-K47049295-300-03-1	BAN-ORL-24	Preclinical	nociceptin/orphanin FQ receptor antagonist	OPRL1			0	83.83	MedChemEx	HY-13222	BAN ORL 24	433.273	O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	MAKMQGKJURAJEN-RUZDIDTESA-N	10296561.0		MAKMQGKJURAJEN
BRD-K47049295-300-01-5	BAN-ORL-24	Preclinical	nociceptin/orphanin FQ receptor antagonist	OPRL1			0	82.84	Tocris	3661	BAN ORL 24	433.273	O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	MAKMQGKJURAJEN-RUZDIDTESA-N	10296561.0		MAKMQGKJURAJEN
BRD-K00003159-300-01-9	banoxantrone	Phase 1/Phase 2	topoisomerase inhibitor	TOP2A			0	80.96	MedChemEx	HY-13562A	Banoxantrone (dihydrochloride)	444.201	C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12	YZBAXVICWUUHGG-UHFFFAOYSA-N	9955116.0		YZBAXVICWUUHGG
BRD-K31928526-001-02-1	barasertib	Phase 2/Phase 3	Aurora kinase inhibitor	AURKA|AURKB			0	89.07	MedChemEx	HY-10127	AZD1152	587.206	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O	GBJVVSCPOBPEIT-UHFFFAOYSA-N	11497983.0		GBJVVSCPOBPEIT
BRD-K63923597-001-10-0	barasertib-HQPA	Phase 2/Phase 3	Aurora kinase inhibitor	AURKB			0	96.94	Selleck	S1147	Barasertib (AZD1152-HQPA)	507.239	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1	QYZOGCMHVIGURT-UHFFFAOYSA-N	16007391.0		QYZOGCMHVIGURT
BRD-K63923597-001-11-8	barasertib-HQPA	Phase 2/Phase 3	Aurora kinase inhibitor	AURKB			0	96.55	Selleck	S1147	Barasertib (AZD1152-HQPA)	507.239	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1	QYZOGCMHVIGURT-UHFFFAOYSA-N	16007391.0		QYZOGCMHVIGURT
BRD-K63923597-001-08-4	barasertib-HQPA	Phase 2/Phase 3	Aurora kinase inhibitor	AURKB			0	96.66	Selleck	S1147	Barasertib (AZD1152-HQPA)	507.239	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1	InChI=1S/C26H30FN7O3/c1-2-34(10-11-35)9-4-12-37-21-7-8-22-23(16-21)28-17-29-26(22)31-24-14-20(32-33-24)15-25(36)30-19-6-3-5-18(27)13-19/h3,5-8,13-14,16-17,35H,2,4,9-12,15H2,1H3,(H,30,36)(H2,28,29,31,32,33)	16007391.0		QYZOGCMHVIGURT
BRD-K20545304-001-01-6	bardoxolone	Phase 1	nuclear factor erythroid derived|like (NRF2) activator	NOS2|PPARG			0	85.92	MedChemEx	HY-14909	Bardoxolone	491.304	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|	TXGZJQLMVSIZEI-UQMAOPSPSA-N	400010.0		TXGZJQLMVSIZEI
BRD-K20545304-001-02-4	bardoxolone	Phase 1	nuclear factor erythroid derived|like (NRF2) activator	NOS2|PPARG			0		MedChemEx	HY-14909	Bardoxolone	491.304	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17,21|	InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1	400010.0		TXGZJQLMVSIZEI
BRD-K69694239-001-02-2	bardoxolone-methyl	Phase 3	nuclear factor erythroid derived|like (NRF2) activator	PPARG|STAT3			0	90.44	Selleck	S8078	Bardoxolone Methyl	505.319	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|	WPTTVJLTNAWYAO-KPOXMGGZSA-N	400769.0	BRD-K22848513-001-01-9	WPTTVJLTNAWYAO
BRD-K69694239-001-03-0	bardoxolone-methyl	Phase 3	nuclear factor erythroid derived|like (NRF2) activator	PPARG|STAT3			0		MedChemEx	HY-13324	Bardoxolone methyl	505.319	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16,20|	InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1	400769.0		WPTTVJLTNAWYAO
BRD-K53581288-001-02-9	baricitinib	Launched	JAK inhibitor	JAK1|JAK2	rheumatology	rheumatoid arthritis	0	97.36	Selleck	S2851	Baricitinib (LY3009104, INCB028050)	371.116	CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	XUZMWHLSFXCVMG-UHFFFAOYSA-N	44205240.0		XUZMWHLSFXCVMG
BRD-K67760597-240-01-5	barium-6-O-phosphonato-D-glucose	Preclinical					0	0.0	TCI	G0052	barium 6-O-phosphonato-D-glucose	260.03	O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O	VFRROHXSMXFLSN-SLPGGIOYSA-N	439958.0		VFRROHXSMXFLSN
BRD-K78781788-003-01-9	barnidipine	Launched	calcium channel blocker		cardiology	hypertension	0	92.07	AKSci	O375		491.206	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4,9|	VXMOONUMYLCFJD-DHLKQENFSA-N	443869.0		VXMOONUMYLCFJD
BRD-K26362911-003-01-1	basic-fuchsin	Preclinical					0	0.0	SantaCruz	sc-203731	Basic Fuchsin	301.158	CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1 |c:4,t:1|	YDCMWLQSPFTWCS-UHFFFAOYSA-N	12448.0		YDCMWLQSPFTWCS
BRD-K62387885-001-01-9	basimglurant	Phase 2	glutamate receptor antagonist	GRM5			0	99.2	MedChemEx	HY-15446	RG7090	325.078	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1	UPZWINBEAHDTLA-UHFFFAOYSA-N	11438771.0		UPZWINBEAHDTLA
BRD-K00003221-001-01-9	basmisanil	Phase 2	GABA receptor inverse agonist				0	98.76	MedChemEx	HY-16716	Basmisanil	445.111	Cc1onc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)-c1ccc(F)cc1	VCGRFBXVSFAGGA-UHFFFAOYSA-N	57336276.0		VCGRFBXVSFAGGA
BRD-K00003148-001-01-9	batefenterol	Phase 2	acetylcholine receptor antagonist|adrenergic receptor agonist				0	90.34	MedChemEx	HY-12980	Batefenterol	739.277	COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2-c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12	URWYQGVSPQJGGB-DHUJRADRSA-N	10372836.0		URWYQGVSPQJGGB
BRD-K82818427-001-04-8	batimastat	Phase 3	matrix metalloprotease inhibitor	ADAM28|ADAMTS5|MMP12|MMP16|MMP2|MMP8			0	92.91	Selleck	S7155	Batimastat (BB-94)	477.176	CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	XFILPEOLDIKJHX-QYZOEREBSA-N	5362422.0	BRD-K25361343-001-01-6	XFILPEOLDIKJHX
BRD-K82818427-001-05-9	batimastat	Phase 3	matrix metalloprotease inhibitor	ADAM28|ADAMTS5|MMP12|MMP16|MMP2|MMP8			0	95.3	Tocris	2961	Batimastat	477.176	CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	XFILPEOLDIKJHX-QYZOEREBSA-N	5362422.0		XFILPEOLDIKJHX
BRD-K82818427-001-02-2	batimastat	Phase 3	matrix metalloprotease inhibitor	ADAM28|ADAMTS5|MMP12|MMP16|MMP2|MMP8			0	91.11	Selleck	S7155	Batimastat (BB-94)	477.176	CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	XFILPEOLDIKJHX-QYZOEREBSA-N	5362422.0		XFILPEOLDIKJHX
BRD-K79595931-312-01-3	bavisant	Phase 2	histamine receptor antagonist	HRH3			0	99.79	MedChemEx	HY-14880B	Bavisant (dihydrochloride hydrate)	329.21	O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1	BGBVSGSIXIIREO-UHFFFAOYSA-N	16061509.0		BGBVSGSIXIIREO
BRD-K79595931-312-02-9	bavisant	Phase 2	histamine receptor antagonist	HRH3			0	83.4	MedChemEx	HY-14880B	Bavisant (dihydrochloride hydrate)	329.21	O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1	BGBVSGSIXIIREO-UHFFFAOYSA-N	16061509.0		BGBVSGSIXIIREO
BRD-K01826533-300-02-9	BAX-channel-blocker	Preclinical	cytochrome C release inhibitor	BAX			0	90.53	Tocris	2160	Bax channel blocker	465.005	O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|	KUUJEXLRLIPQQJ-HNNXBMFYSA-N	981054.0		KUUJEXLRLIPQQJ
BRD-A05457250-001-08-4	BAY-K-8644-(+/-)	Preclinical	L-type calcium channel blocker				0	92.92	Tocris	1544	(?)-Bay K 8644	356.098	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r,c:4,9|	ZFLWDHHVRRZMEI-CYBMUJFWSA-N	6604881.0		ZFLWDHHVRRZMEI
BRD-K14329163-001-03-9	BAY-K-8644-(s)-(-)	Preclinical	L-type calcium channel activator	CACNA1C			0	90.62	Tocris	1546	(S)-(-)-Bay K 8644	356.098	COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4,9|	ZFLWDHHVRRZMEI-ZDUSSCGKSA-N	6603728.0		ZFLWDHHVRRZMEI
BRD-K44471774-001-01-8	BAY-W-9798	Phase 2	antioxidant				0	98.03	Vitas-M	STK060545	dimethyl 1,2,6-trimethyl-4-[4-(trifluoromethyl)phenyl]-1,4-dihydro-3,5-pyridinedicarboxylate	383.134	COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC |c:4,10|	AVFYPHPSIBAAME-UHFFFAOYSA-N	2167221.0		AVFYPHPSIBAAME
BRD-K15025317-001-15-1	BAY-11-7082	Preclinical	NFkB pathway inhibitor	RELA			0	95.23	Tocris	1744	Bay 11-7821	207.035	Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	DOEWDSDBFRHVAP-KRXBUXKQSA-N	5353431.0		DOEWDSDBFRHVAP
BRD-K15025317-001-14-4	BAY-11-7082	Preclinical	NFkB pathway inhibitor	RELA			0	0.0	Selleck	S2913	BAY 11-7082	207.035	Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	DOEWDSDBFRHVAP-KRXBUXKQSA-N	5353431.0		DOEWDSDBFRHVAP
BRD-K15025317-001-17-7	BAY-11-7082	Preclinical	NFkB pathway inhibitor	RELA			0	100.0	Selleck	S2913	BAY 11-7082 (BAY 11-7821)	207.035	Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	DOEWDSDBFRHVAP-KRXBUXKQSA-N	5353431.0		DOEWDSDBFRHVAP
BRD-K48684885-001-04-2	BAY-11-7085	Preclinical	NFkB pathway inhibitor	NFKBIA			0	91.4	Tocris	1743	Bay 11-7085	249.082	CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N	VHKZGNPOHPFPER-ONNFQVAWSA-N	5353432.0		VHKZGNPOHPFPER
BRD-K00003533-001-01-9	BAY-1251152	Phase 1	CDK9 inhibitor				0	97.4	MedChemEx	HY-103019A	(?)-BAY-1251152	404.112	COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F |r|	YZCUMZWULWOUMD-MUUNZHRXSA-N			YZCUMZWULWOUMD
BRD-K00003359-001-01-9	BAY-1436032	Phase 1	isocitrate dehydrogenase inhibitor				0	97.89	MedChemEx	HY-100020	BAY-1436032	489.224	C[C@H]1C[C@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(O)=O)ccc12	RNMAUIMMNAHKQR-QFBILLFUSA-N	118310260.0		RNMAUIMMNAHKQR
BRD-K00003422-003-01-9	BAY-1895344	Phase 1	ATR kinase inhibitor				0	91.76	MedChemEx	HY-101566A	BAY-1895344 (hydrochloride)	375.181	C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	YBXRSCXGRPSTMW-CYBMUJFWSA-N	118869362.0		YBXRSCXGRPSTMW
BRD-K22379844-001-04-9	BAY-2402234	Phase 1	dihydroorotate dehydrogenase inhibitor				0	95.74	MedChemEx	HY-112645	BAY-2402234	520.094	CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O	KNVJMHHAXCPZHF-JTQLQIEISA-N	134470179.0		KNVJMHHAXCPZHF
BRD-K32033120-001-02-9	BAY-41-2272	Preclinical	guanylyl cyclase activator	GUCY1A3|GUCY1B3			0	99.07	Tocris	4430	BAY 41-2272	360.15	Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12	ATOAHNRJAXSBOR-UHFFFAOYSA-N	9798973.0		ATOAHNRJAXSBOR
BRD-K32033120-001-01-1	BAY-41-2272	Preclinical	guanylyl cyclase activator	GUCY1A3|GUCY1B3			0	96.5	Tocris	4430	BAY 41-2272	360.15	Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12	ATOAHNRJAXSBOR-UHFFFAOYSA-N	9798973.0		ATOAHNRJAXSBOR
BRD-K32952627-001-02-9	BAY-60-6583	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	96.22	Tocris	4472	BAY 60-6583	379.11	NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N	ZTYHZMAZUWOXNC-UHFFFAOYSA-N	11717831.0		ZTYHZMAZUWOXNC
BRD-K32952627-001-01-0	BAY-60-6583	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	92.52	Tocris	4472	BAY 60-6583	379.11	NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N	ZTYHZMAZUWOXNC-UHFFFAOYSA-N	11717831.0		ZTYHZMAZUWOXNC
BRD-K86932920-001-02-9	BAY-60-7550	Preclinical	phosphodiesterase inhibitor	PDE2A			0	93.86	MedChemEx	HY-14992	Bay 60-7550	476.242	COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC	MYTWFJKBZGMYCS-NQIIRXRSSA-N	135564787.0		MYTWFJKBZGMYCS
BRD-K53281329-300-01-5	BAY-61-3606	Preclinical	SYK inhibitor	SYK			0	91.87	MedChemEx	HY-14985	BAY 61-3606 (dihydrochloride)	390.144	COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1	JWQOJVOKBAAAAR-UHFFFAOYSA-N	10200390.0		JWQOJVOKBAAAAR
BRD-K00005331-001-01-9	BAY-8002	Preclinical	monocarboxylate transporter inhibitor				0	91.78	MedChemEx	HY-122312	BAY-8002	415.028	OC(=O)c1ccccc1NC(=O)c1cc(ccc1Cl)S(=O)(=O)c1ccccc1	CLAUJSRBKSRTGQ-UHFFFAOYSA-N	992293.0		CLAUJSRBKSRTGQ
BRD-A11731518-001-01-7	BAY-85-8050	Phase 1					0	100.0	AlfaAesar	L10517		165.044	N[C@@H](C[C@@H](F)C(O)=O)C(O)=O |&1:1,&2:3,r|	JPSHPWJJSVEEAX-GBXIJSLDSA-N	7005049.0		JPSHPWJJSVEEAX
BRD-K70463136-001-01-5	BAY-87-2243	Phase 1	hypoxia inducible factor inhibitor	HIF1A			0	96.05	MedChemEx	HY-15836	BAY 87-2243	525.21	Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	CDJNNOJINJAXPV-UHFFFAOYSA-N	67377767.0		CDJNNOJINJAXPV
BRD-K70463136-001-02-9	BAY-87-2243	Phase 1	hypoxia inducible factor inhibitor	HIF1A			0	95.92	MedChemEx	HY-15836	BAY 87-2243	525.21	Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	CDJNNOJINJAXPV-UHFFFAOYSA-N	67377767.0		CDJNNOJINJAXPV
BRD-K00003357-001-01-9	BAY1125976	Phase 1	AKT inhibitor				0	93.59	MedChemEx	HY-100018	BAY1125976	383.175	NC(=O)c1ccc2nc(c(-c3ccccc3)n2n1)-c1ccc(cc1)C1(N)CCC1	JBGYKRAZYDNCNV-UHFFFAOYSA-N	70817911.0		JBGYKRAZYDNCNV
BRD-K00003143-001-01-9	BAY1217389	Phase 1	kinase inhibitor				0	97.87	MedChemEx	HY-12859	BAY1217389	561.18	COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F	WNEILUNVMHVMPH-UHFFFAOYSA-N	78320750.0		WNEILUNVMHVMPH
BRD-K90195324-015-04-9	bazedoxifene	Launched	selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|endocrinology	osteoporosis|menopause	0	85.18	Tocris	5263	Bazedoxifene acetate	470.257	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	UCJGJABZCDBEDK-UHFFFAOYSA-N	154257.0		UCJGJABZCDBEDK
BRD-K90195324-015-01-1	bazedoxifene	Launched	selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|endocrinology	osteoporosis|menopause	0	81.53	Tocris	5263	Bazedoxifene acetate	470.257	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	UCJGJABZCDBEDK-UHFFFAOYSA-N	154257.0		UCJGJABZCDBEDK
BRD-K90195324-003-02-5	bazedoxifene	Launched	selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|endocrinology	osteoporosis|menopause	0	87.25	Selleck	S2128	Bazedoxifene HCl	470.257	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	UCJGJABZCDBEDK-UHFFFAOYSA-N	154257.0		UCJGJABZCDBEDK
BRD-K90195324-003-03-3	bazedoxifene	Launched	selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|endocrinology	osteoporosis|menopause	0	93.15	Selleck	S2128	Bazedoxifene HCl	470.257	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	UCJGJABZCDBEDK-UHFFFAOYSA-N	154257.0		UCJGJABZCDBEDK
BRD-K66830666-001-01-9	BAZ2-ICR	Preclinical	bromodomain inhibitor	ZNF215			0	86.63	Tocris	5266	BAZ2-ICR	357.17	Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1	RRZVGDGTWNQAPW-UHFFFAOYSA-N	91654625.0		RRZVGDGTWNQAPW
BRD-K66830666-001-02-7	BAZ2-ICR	Preclinical	bromodomain inhibitor	ZNF215			0	98.89	Tocris	5266	BAZ2-ICR	357.17	Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1	RRZVGDGTWNQAPW-UHFFFAOYSA-N	91654625.0		RRZVGDGTWNQAPW
BRD-K14646328-004-02-9	BC-11	Preclinical	urokinase inhibitor	PLAU			0	95.59	Tocris	4372	BC 11 hydrobromide	210.063	NC(=N)SCc1ccc(cc1)B(O)O	KDQVMGQHPAKJAN-UHFFFAOYSA-N	60126757.0		KDQVMGQHPAKJAN
BRD-K14646328-004-01-6	BC-11	Preclinical	urokinase inhibitor	PLAU			0	78.51	Tocris	4372	BC 11 hydrobromide	210.063	NC(=N)SCc1ccc(cc1)B(O)O	KDQVMGQHPAKJAN-UHFFFAOYSA-N	60126757.0		KDQVMGQHPAKJAN
BRD-K23672206-001-02-9	BCI-540	Phase 2	glutamate receptor agonist				0	97.48	MedChemEx	HY-17553	Coluracetam	341.174	Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C	PSPGQHXMUKWNDI-UHFFFAOYSA-N	214346.0		PSPGQHXMUKWNDI
BRD-K23672206-001-01-4	BCI-540	Phase 2	glutamate receptor agonist				0	99.63	MedChemEx	HY-17553	Coluracetam	341.174	Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C	PSPGQHXMUKWNDI-UHFFFAOYSA-N	214346.0		PSPGQHXMUKWNDI
BRD-K66541497-001-01-7	BCTC	Preclinical	TRPV antagonist	TRPV1			0	89.31	Tocris	3875	BCTC	372.172	CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1	ROGUAPYLUCHQGK-UHFFFAOYSA-N	9929425.0		ROGUAPYLUCHQGK
BRD-K66541497-001-02-9	BCTC	Preclinical	TRPV antagonist	TRPV1			0	93.69	Tocris	3875	BCTC	372.172	CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1	ROGUAPYLUCHQGK-UHFFFAOYSA-N	9929425.0		ROGUAPYLUCHQGK
BRD-K90472149-066-01-0	BCX-1470	Phase 1	complement inhibitor|serine protease inhibitor	CFD			0	94.08	MedChemEx	HY-50875	BCX 1470 (methanesulfonate)	302.018	NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1	OTGQTQBPQCRNRG-UHFFFAOYSA-N	9822205.0		OTGQTQBPQCRNRG
BRD-K17008822-303-02-1	BD-1008	Preclinical	sigma receptor antagonist				0	91.0	Tocris	511	BD 1008 dihydrobromide	300.116	CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1	ASGIQUHBAVIOTI-UHFFFAOYSA-N	126388.0		ASGIQUHBAVIOTI
BRD-K36864847-303-03-3	BD-1047	Preclinical	adrenergic receptor antagonist	SIGMAR1			0	77.27	Tocris	956	BD 1047 dihydrobromide	274.1	CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1	MGVRNMUKTZOQOW-UHFFFAOYSA-N	188914.0		MGVRNMUKTZOQOW
BRD-K36864847-303-02-5	BD-1047	Preclinical	adrenergic receptor antagonist	SIGMAR1			0	94.48	Tocris	956	BD 1047 dihydrobromide	274.1	CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1	MGVRNMUKTZOQOW-UHFFFAOYSA-N	188914.0		MGVRNMUKTZOQOW
BRD-K29668683-300-02-2	BD-1063	Preclinical	sigma receptor antagonist	SIGMAR1			0	96.05	Tocris	883	BD 1063 dihydrochloride	272.085	CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1	SUIZRDJCBVPASY-UHFFFAOYSA-N	574780.0		SUIZRDJCBVPASY
BRD-A24429032-003-03-2	BE-2254	Phase 2	adrenergic receptor antagonist	ADRA1A			0	0.0	Biotrend	BN0248	2-({[2-(4-hydroxyphenyl)ethyl]amino}methyl)-3,4-dihydro-1(2H)-naphthalenone hydrochloride	295.157	Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|	PZZOEXPDTYIBPI-MRXNPFEDSA-N	86308637.0		PZZOEXPDTYIBPI
BRD-A24429032-003-02-4	BE-2254	Phase 2	adrenergic receptor antagonist	ADRA1A			0	32.4	Tocris	535	HEAT hydrochloride	295.157	Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|	PZZOEXPDTYIBPI-MRXNPFEDSA-N	86308637.0		PZZOEXPDTYIBPI
BRD-K00003291-001-01-9	BEBT-908	Preclinical	PI3K inhibitor				0	92.39	MedChemEx	HY-19763	BEBT-908	507.18	CNc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	TWJZFXHSPBBPNI-UHFFFAOYSA-N	59474330.0		TWJZFXHSPBBPNI
BRD-K00003128-001-01-9	beclabuvir	Phase 2	antiviral				0	95.47	MedChemEx	HY-12429	Beclabuvir	659.314	COc1ccc2-c3c(C4CCCCC4)c4ccc(cc4n3C[C@]3(C[C@H]3c2c1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C |THB:27:29:31.32:34.35.37|	ZTTKEBYSXUCBSE-QDFUAKMASA-N	56934415.0		ZTTKEBYSXUCBSE
BRD-K44824027-001-03-9	beclamide	Launched	anticonvulsant		neurology/psychiatry	sedative|seizures	0	94.3	MedChemEx	HY-B1185	Beclamide	197.061	ClCCC(=O)NCc1ccccc1	JPYQFYIEOUVJDU-UHFFFAOYSA-N	10391.0		JPYQFYIEOUVJDU
BRD-K44824027-001-02-1	beclamide	Launched	anticonvulsant		neurology/psychiatry	sedative|seizures	0	96.76	MicroSource	1505827	BECLAMIDE	197.061	ClCCC(=O)NCc1ccccc1	JPYQFYIEOUVJDU-UHFFFAOYSA-N	10391.0		JPYQFYIEOUVJDU
BRD-A73385064-001-01-5	beclomethasone	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	allergy	allergic rhinitis	0	90.36	AvaChem	3053	9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one	408.17	C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1,&2:3,&3:4,&4:13,&5:15,&6:17,&7:20,&8:22,r,c:11,t:7|	NBMKJKDGKREAPL-DGLOSGAVSA-N			NBMKJKDGKREAPL
BRD-K97810537-001-13-6	beclomethasone-dipropionate	Launched	glucocorticoid receptor agonist	GPR97|NR3C1	allergy	allergic rhinitis	0	94.29	MicroSource	1500136	BECLOMETHASONE DIPROPIONATE	520.223	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|	KUVIULQEHSCUHY-XYWKZLDCSA-N	21700.0	BRD-A11319535-001-03-6	KUVIULQEHSCUHY
BRD-K97810537-001-15-9	beclomethasone-dipropionate	Launched	glucocorticoid receptor agonist	GPR97|NR3C1	allergy	allergic rhinitis	0	92.83	MedChemEx	HY-13571A	Beclometasone dipropionate	520.223	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|	KUVIULQEHSCUHY-XYWKZLDCSA-N	21700.0		KUVIULQEHSCUHY
BRD-K97810537-001-12-8	beclomethasone-dipropionate	Launched	glucocorticoid receptor agonist	GPR97|NR3C1	allergy	allergic rhinitis	0	98.04	Selleck	S3078	Beclomethasone dipropionate	520.223	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|	KUVIULQEHSCUHY-XYWKZLDCSA-N	21700.0		KUVIULQEHSCUHY
BRD-K97810537-001-14-4	beclomethasone-dipropionate	Launched	glucocorticoid receptor agonist	GPR97|NR3C1	allergy	allergic rhinitis	0	89.03	Selleck	S3078	Beclomethasone dipropionate	520.223	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25,t:21|	KUVIULQEHSCUHY-XYWKZLDCSA-N	21700.0	BRD-K97429934-001-01-9|BRD-K76747609-001-02-1	KUVIULQEHSCUHY
BRD-K90817094-001-05-9	bedaquiline	Launched	ATPase inhibitor		infectious disease	tuberculosis	0	92.56	MedChemEx	HY-14881	Bedaquiline	554.157	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	QUIJNHUBAXPXFS-XLJNKUFUSA-N	5388906.0		QUIJNHUBAXPXFS
BRD-K90817094-001-02-6	bedaquiline	Launched	ATPase inhibitor		infectious disease	tuberculosis	0	79.81	MedChemEx	HY-14881	Bedaquiline	554.157	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	QUIJNHUBAXPXFS-XLJNKUFUSA-N	5388906.0		QUIJNHUBAXPXFS
BRD-K90817094-001-03-4	bedaquiline	Launched	ATPase inhibitor		infectious disease	tuberculosis	0	38.09	MedChemEx	HY-14881	Bedaquiline	554.157	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	QUIJNHUBAXPXFS-XLJNKUFUSA-N	5388906.0		QUIJNHUBAXPXFS
BRD-K99077012-001-01-9	befuraline	Phase 2					0	96.8	Enamine	Z27763746	1-(1-benzofuran-2-ylcarbonyl)-4-benzylpiperazine	320.152	O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1	SRIJFPBZWUFLFD-UHFFFAOYSA-N	68664.0		SRIJFPBZWUFLFD
BRD-K58319700-001-02-9	begacestat	Phase 1	gamma secretase inhibitor	PSEN1			0	73.79	Tocris	4283	Begacestat	390.954	OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F	PSXOKXJMVRSARX-SCSAIBSYSA-N	11269353.0		PSXOKXJMVRSARX
BRD-K58319700-001-01-1	begacestat	Phase 1	gamma secretase inhibitor	PSEN1			0	89.43	Sigma	PZ0187	5-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]-2-thiophenesulfonamide	390.954	OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F	PSXOKXJMVRSARX-SCSAIBSYSA-N	11269353.0		PSXOKXJMVRSARX
BRD-K73425385-001-05-9	bekanamycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	99.2	MedChemEx	HY-B1174	Bekanamycin	483.254	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	SKKLOUVUUNMCJE-FQSMHNGLSA-N	439318.0		SKKLOUVUUNMCJE
BRD-K73425385-001-01-9	bekanamycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	94.5	Selleck	S4383	Bekanamycin	483.254	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	SKKLOUVUUNMCJE-FQSMHNGLSA-N	439318.0	BRD-K47908102-001-01-9	SKKLOUVUUNMCJE
BRD-K73425385-065-04-8	bekanamycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	100.0	MicroSource	1500812	BEKANAMYCIN SULFATE	483.254	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	SKKLOUVUUNMCJE-FQSMHNGLSA-N	439318.0		SKKLOUVUUNMCJE
BRD-K17743125-001-08-4	belinostat	Launched	HDAC inhibitor	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	0	94.73	Selleck	S1085	Belinostat (PXD101)	318.067	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	NCNRHFGMJRPRSK-MDZDMXLPSA-N	6918638.0		NCNRHFGMJRPRSK
BRD-K17743125-001-01-9	belinostat	Launched	HDAC inhibitor	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	0		CMLD/Broad		RLM-2-89	318.067	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+	6918638.0		NCNRHFGMJRPRSK
BRD-K00003245-001-01-9	belizatinib	Preclinical	receptor tyrosine protein kinase inhibitor				0	95.9	MedChemEx	HY-17603	Belizatinib	577.343	CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r|	WSTUJEXAPHIEIM-FEGDYQJNSA-N			WSTUJEXAPHIEIM
BRD-K00003160-003-01-9	belotecan	Phase 3	topoisomerase inhibitor				0	97.3	MedChemEx	HY-13566A	Belotecan (hydrochloride)	433.2	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CCNC(C)C)c3Cn1c2=O	LNHWXBUNXOXMRL-VWLOTQADSA-N	6456014.0		LNHWXBUNXOXMRL
BRD-K14993104-001-06-9	bemegride	Launched	chemoreceptor agonist	GABRA1	critical care	poison antidote	0	86.59	MedChemEx	HY-B1326	Bemegride	155.095	CCC1(C)CC(=O)NC(=O)C1	ORRZGUBHBVWWOP-UHFFFAOYSA-N	2310.0		ORRZGUBHBVWWOP
BRD-K14993104-001-05-9	bemegride	Launched	chemoreceptor agonist	GABRA1	critical care	poison antidote	0	90.86	Selleck	S4197	Bemegride	155.095	CCC1(C)CC(=O)NC(=O)C1	ORRZGUBHBVWWOP-UHFFFAOYSA-N	2310.0		ORRZGUBHBVWWOP
BRD-K00004211-001-01-9	bemesetron	Phase 3	serotonin receptor antagonist	HTR3A|HTR3B			0	95.61	Tocris	640	MDL 72222	313.064	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r,THB:0:1:3.4:6.7.8|	MNJNPLVXBISNSX-WDNDVIMCSA-N			MNJNPLVXBISNSX
BRD-A92974210-396-01-0	bemotrizinol	Launched			dermatology	sunscreen lotion	0	0.0	MicroSource	1503863	BEMOTRIZINOL	627.367	CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|	XVAMCHGMPYWHNL-MKPDMIMOSA-N	136218979.0		XVAMCHGMPYWHNL
BRD-A92974210-001-02-9	bemotrizinol	Launched			dermatology	sunscreen lotion	0	0.0	Sigma	51825	Bemotrizinol	627.367	CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28,&2:4|	XVAMCHGMPYWHNL-MKPDMIMOSA-N	136218979.0		XVAMCHGMPYWHNL
BRD-K63177377-001-01-8	bempedoic-acid	Launched	AMPK inhibitor	ACLY			0	98.6	MedChemEx	HY-12357	ETC-1002	344.256	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	HYHMLYSLQUKXKP-UHFFFAOYSA-N	10472693.0		HYHMLYSLQUKXKP
BRD-K85030058-003-16-9	benactyzine	Preclinical	butyrylcholinesterase inhibitor				0	93.3	MedChemEx	HY-B1542A	Benactyzine hydrochloride	327.183	CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	IVQOFBKHQCTVQV-UHFFFAOYSA-N	9330.0		IVQOFBKHQCTVQV
BRD-K00004531-001-01-9	benaxibine	Phase 1					0	100.0	Labotest	LT00112883	N-(4-carboxyphenyl)-beta-D-glucopyranosylamine	299.101	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	VXMVXDITZWJXJN-RMPHRYRLSA-N	7566768.0		VXMVXDITZWJXJN
BRD-K49807096-003-16-3	benazepril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	17.6	MicroSource	1505200	BENAZEPRIL HYDROCHLORIDE	424.2	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	XPCFTKFZXHTYIP-PMACEKPBSA-N	5362124.0		XPCFTKFZXHTYIP
BRD-K49807096-003-17-1	benazepril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	97.52	Tocris	2578	Benazepril hydrochloride	424.2	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	XPCFTKFZXHTYIP-PMACEKPBSA-N	5362124.0		XPCFTKFZXHTYIP
BRD-K49807096-003-15-5	benazepril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	98.78	Tocris	2578	Benazepril hydrochloride	424.2	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	XPCFTKFZXHTYIP-PMACEKPBSA-N	5362124.0		XPCFTKFZXHTYIP
BRD-K49807096-003-14-8	benazepril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	97.88	Selleck	S1284	Benazepril HCl	424.2	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	XPCFTKFZXHTYIP-PMACEKPBSA-N	5362124.0		XPCFTKFZXHTYIP
BRD-K49807096-003-18-9	benazepril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	97.59	Tocris	2578	Benazepril hydrochloride	424.2	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	XPCFTKFZXHTYIP-PMACEKPBSA-N	5362124.0		XPCFTKFZXHTYIP
BRD-K17068645-003-05-9	bendamustine	Launched	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL)|non-Hodgkin lymphoma (NHL)	0	87.97	Selleck	S1212	Bendamustine HCL	357.101	Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl	YTKUWDBFDASYHO-UHFFFAOYSA-N	65628.0		YTKUWDBFDASYHO
BRD-K17068645-003-04-2	bendamustine	Launched	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL)|non-Hodgkin lymphoma (NHL)	0	88.19	Selleck	S1212	Bendamustine HCl	357.101	Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl	YTKUWDBFDASYHO-UHFFFAOYSA-N	65628.0		YTKUWDBFDASYHO
BRD-K19515365-001-02-6	bendazac	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology	muscle pain|joint pain	0	97.29	Key	KS-1230	[(1-benzyl-1H-indazol-3-yl)oxy]acetic acid	282.1	OC(=O)COc1nn(Cc2ccccc2)c2ccccc12	BYFMCKSPFYVMOU-UHFFFAOYSA-N	2313.0		BYFMCKSPFYVMOU
BRD-K60379054-001-09-9	bendazol	Launched	nitric oxide synthase stimulant				0	98.22	MedChemEx	HY-B2141	Bendazol	208.1	C(c1nc2ccccc2[nH]1)c1ccccc1	YTLQFZVCLXFFRK-UHFFFAOYSA-N	12132.0		YTLQFZVCLXFFRK
BRD-A80017228-001-25-7	bendroflumethiazide	Launched	sodium/potassium/chloride transporter inhibitor	SLC12A1|SLC12A3	cardiology	hypertension	0	98.28	MicroSource	1503104	BENDROFLUMETHIAZIDE	421.038	NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|	HDWIHXWEUNVBIY-CQSZACIVSA-N	9845085.0		HDWIHXWEUNVBIY
BRD-A80017228-001-24-0	bendroflumethiazide	Launched	sodium/potassium/chloride transporter inhibitor	SLC12A1|SLC12A3	cardiology	hypertension	0	97.11	Selleck	S4387	Bendroflumethiazide	421.038	NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|	HDWIHXWEUNVBIY-CQSZACIVSA-N	9845085.0		HDWIHXWEUNVBIY
BRD-A80017228-001-27-3	bendroflumethiazide	Launched	sodium/potassium/chloride transporter inhibitor	SLC12A1|SLC12A3	cardiology	hypertension	0	98.72	Selleck	S4387	BENDROFUMETHIAZIDE	421.038	NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9,r|	HDWIHXWEUNVBIY-CQSZACIVSA-N	9845085.0		HDWIHXWEUNVBIY
BRD-K13473780-001-02-1	benethamine	Preclinical					0	99.27	Enamine	Z57055797		211.136	C(Cc1ccccc1)NCc1ccccc1	UPABQMWFWCMOFV-UHFFFAOYSA-N	65055.0	BRD-M11305712-001-07-7	UPABQMWFWCMOFV
BRD-K00003672-003-01-9	benfluorex	Withdrawn	gluconeogenesis inhibitor	HMGCR			0	96.62	MedChemEx	HY-B1058	Benfluorex hydrochloride	351.145	C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|	CJAVTWRYCDNHSM-AWEZNQCLSA-N	6604374.0		CJAVTWRYCDNHSM
BRD-K33903083-001-03-5	benfluralin	Phase 3		CYP1A1|CYP1A2|CYP2B6|CYP3A4|ESR1|MMP1|SULT2A1|UGT1A1			0	97.41	Sigma	MFCD00078630	N-butyl-N-[2,6-dinitro-4-(trifluoromethyl)phenyl]-N-ethylamine	335.109	CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O	SMDHCQAYESWHAE-UHFFFAOYSA-N	2319.0		SMDHCQAYESWHAE
BRD-K05319475-396-01-2	benfotiamine	Launched	antioxidant	AGER	rheumatology	lumbago	0	12.53	MicroSource	1503105	BENFOTIAMINE	466.108	C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1	BTNNPSLJPBRMLZ-LGMDPLHJSA-N	3032771.0		BTNNPSLJPBRMLZ
BRD-K05319475-001-04-2	benfotiamine	Launched	antioxidant	AGER	rheumatology	lumbago	0	24.5	Selleck	S4300	Benfotiamine	466.108	C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1	BTNNPSLJPBRMLZ-LGMDPLHJSA-N	3032771.0		BTNNPSLJPBRMLZ
BRD-K05319475-001-06-9	benfotiamine	Launched	antioxidant	AGER	rheumatology	lumbago	0	92.65	MedChemEx	HY-17374	Benfotiamine	466.108	C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1	BTNNPSLJPBRMLZ-LGMDPLHJSA-N	3032771.0		BTNNPSLJPBRMLZ
BRD-K05319475-001-05-9	benfotiamine	Launched	antioxidant	AGER	rheumatology	lumbago	0	93.58	Selleck	S4300	benfotiamine	466.108	C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1	BTNNPSLJPBRMLZ-LGMDPLHJSA-N	3032771.0		BTNNPSLJPBRMLZ
BRD-K97181463-003-02-9	benidipine	Launched	calcium channel blocker	CACNA1C|CACNA1G	cardiology	hypertension	0	98.18	Selleck	S2017	Benidipine hydrochloride	505.221	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	QZVNQOLPLYWLHQ-ZEQKJWHPSA-N	656667.0		QZVNQOLPLYWLHQ
BRD-K97181463-003-01-1	benidipine	Launched	calcium channel blocker	CACNA1C|CACNA1G	cardiology	hypertension	0	89.02	Selleck	S2017	Benidipine HCl	505.221	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	QZVNQOLPLYWLHQ-ZEQKJWHPSA-N	656667.0		QZVNQOLPLYWLHQ
BRD-K97181463-003-03-7	benidipine	Launched	calcium channel blocker	CACNA1C|CACNA1G	cardiology	hypertension	0	0.0	Selleck	S2017	Benidipine HCl	505.221	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	QZVNQOLPLYWLHQ-ZEQKJWHPSA-N	656667.0		QZVNQOLPLYWLHQ
BRD-K79425933-001-11-9	benperidol	Launched	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	0	96.81	Sigma	MFCD00866672	1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one	381.185	Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	FEBOTPHFXYHVPL-UHFFFAOYSA-N	16363.0		FEBOTPHFXYHVPL
BRD-K79425933-001-09-3	benperidol	Launched	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	0	88.46	Prestwick	Prestw-484	Benperidol	381.185	Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	FEBOTPHFXYHVPL-UHFFFAOYSA-N	16363.0		FEBOTPHFXYHVPL
BRD-K01826024-001-01-9	benproperine	Launched	antitussive	SCN5A	pulmonary	cough suppressant	0	97.04	AvaChem	1567	1-[2-(2-benzylphenoxy)-1-methylethyl]piperidine	309.209	C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1,r|	JTUQXGZRVLWBCR-SFHVURJKSA-N	14456347.0		JTUQXGZRVLWBCR
BRD-A61194565-003-28-8	benserazide	Launched	DOPA decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	0	0.0	MicroSource	1500137	BENSERAZIDE HYDROCHLORIDE	257.101	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	BNQDCRGUHNALGH-UHFFFAOYSA-N	657280.0		BNQDCRGUHNALGH
BRD-A61194565-003-27-0	benserazide	Launched	DOPA decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	0	93.52	Selleck	S2453	Benserazide HCl	257.101	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	BNQDCRGUHNALGH-UHFFFAOYSA-N	657280.0		BNQDCRGUHNALGH
BRD-K58794715-001-01-8	bentiromide	Launched		HPN	gastroenterology	pancreas diagnostic agent	0	85.66	Selleck	S4388	Bentiromide	404.137	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	SPPTWHFVYKCNNK-FQEVSTJZSA-N	6957673.0		SPPTWHFVYKCNNK
BRD-K58794715-001-03-4	bentiromide	Launched		HPN	gastroenterology	pancreas diagnostic agent	0	98.07	Selleck	S4388	Bentiromide	404.137	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	SPPTWHFVYKCNNK-FQEVSTJZSA-N	6957673.0		SPPTWHFVYKCNNK
BRD-K58794715-001-02-6	bentiromide	Launched		HPN	gastroenterology	pancreas diagnostic agent	0	93.46	Selleck	S4388	bentiromide	404.137	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	SPPTWHFVYKCNNK-FQEVSTJZSA-N	6957673.0		SPPTWHFVYKCNNK
BRD-K88553858-001-02-7	benurestat	Phase 1	urease inhibitor				0	92.03	MicroSource	1505410	BENURESTAT	228.03	ONC(=O)CNC(=O)c1ccc(Cl)cc1	JFZGBMJPJZDNNT-UHFFFAOYSA-N	38000.0		JFZGBMJPJZDNNT
BRD-K88553858-001-03-9	benurestat	Phase 1	urease inhibitor				0	94.64	LifeChem	F1923-0191	4-chloro-N-(2-(hydroxyamino)-2-oxoethyl)benzamide	228.03	ONC(=O)CNC(=O)c1ccc(Cl)cc1	JFZGBMJPJZDNNT-UHFFFAOYSA-N	38000.0		JFZGBMJPJZDNNT
BRD-K34234316-003-04-7	benzalkonium	Launched	cationic surfactant		dermatology	abrasions|superficial cuts	0	0.0	MicroSource	1503610	BENZALKONIUM CHLORIDE	318.316	CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	VVZBFOKBSDGVGZ-UHFFFAOYSA-N	2330.0		VVZBFOKBSDGVGZ
BRD-K34234316-003-05-4	benzalkonium	Launched	cationic surfactant		dermatology	abrasions|superficial cuts	0	0.0	Selleck	S5626	BENZALKONIUM CHLORIDE	318.316	CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	VVZBFOKBSDGVGZ-UHFFFAOYSA-N	2330.0		VVZBFOKBSDGVGZ
BRD-K87158025-003-08-7	benzamil	Phase 2	sodium channel blocker	ASIC1|PKD2L1|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC8A1			0	94.27	Tocris	3380	Benzamil	319.095	NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	KXDROGADUISDGY-UHFFFAOYSA-N	108107.0		KXDROGADUISDGY
BRD-K87158025-001-01-6	benzamil	Phase 2	sodium channel blocker	ASIC1|PKD2L1|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC8A1			0	97.72	Enzo	NA103	Benzamil HCl	319.095	NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	KXDROGADUISDGY-UHFFFAOYSA-N	108107.0	BRD-K97688263-001-03-7	KXDROGADUISDGY
BRD-K87158025-003-09-9	benzamil	Phase 2	sodium channel blocker	ASIC1|PKD2L1|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC8A1			0	95.31	Tocris	3380	Benzamil	319.095	NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	KXDROGADUISDGY-UHFFFAOYSA-N	108107.0		KXDROGADUISDGY
BRD-K11717138-001-31-9	benzbromarone	Launched	chloride channel blocker	ABCC1	rheumatology	gout	0	96.33	Tocris	5420	Benzbromarone	421.915	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	WHQCHUCQKNIQEC-UHFFFAOYSA-N	2333.0		WHQCHUCQKNIQEC
BRD-K11717138-001-30-3	benzbromarone	Launched	chloride channel blocker	ABCC1	rheumatology	gout	0	96.2	MicroSource	1505971	BENZBROMARONE	421.915	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	WHQCHUCQKNIQEC-UHFFFAOYSA-N	2333.0		WHQCHUCQKNIQEC
BRD-K11717138-001-29-5	benzbromarone	Launched	chloride channel blocker	ABCC1	rheumatology	gout	0	95.24	Selleck	S4221	Benzbromarone	421.915	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	WHQCHUCQKNIQEC-UHFFFAOYSA-N	2333.0		WHQCHUCQKNIQEC
BRD-A98083480-001-01-3	benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]	Preclinical					0	83.87	Enamine	Z1020681722		207.162	CC(C)NC[C@@H](O)c1cc(C)ccc1C |&1:5,r|	PHFWPIKQCFQPJY-CYBMUJFWSA-N	92279095.0		PHFWPIKQCFQPJY
BRD-K72723676-003-17-8	benzethonium	Launched	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	0	99.48	MicroSource	1500138	BENZETHONIUM CHLORIDE	412.322	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	SIYLLGKDQZGJHK-UHFFFAOYSA-N	2335.0		SIYLLGKDQZGJHK
BRD-K72723676-003-18-9	benzethonium	Launched	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	0	97.46	MedChemEx	HY-B0942	Benzethonium chloride	412.322	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	SIYLLGKDQZGJHK-UHFFFAOYSA-N	2335.0		SIYLLGKDQZGJHK
BRD-K72723676-003-16-0	benzethonium	Launched	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	0	96.04	Selleck	S4162	Benzethonium Chloride	412.322	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	SIYLLGKDQZGJHK-UHFFFAOYSA-N	2335.0		SIYLLGKDQZGJHK
BRD-K56156805-001-09-6	benznidazole	Launched	DNA synthesis inhibitor		infectious disease	Chagas disease	0	86.94	Toronto	B197925	Benznidazole	260.091	[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1	CULUWZNBISUWAS-UHFFFAOYSA-N	31593.0		CULUWZNBISUWAS
BRD-K55160477-001-04-7	benzo[d]thiazole-2(3H)-thione	Phase 1					0	95.36	Ark	AK-47877	Benzo[d]thiazole-2(3H)-thione	166.986	S=c1[nH]c2ccccc2s1	YXIWHUQXZSMYRE-UHFFFAOYSA-N	697993.0		YXIWHUQXZSMYRE
BRD-K75466013-001-14-4	benzocaine	Launched	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	0	99.51	MicroSource	1500139	BENZOCAINE	165.079	CCOC(=O)c1ccc(N)cc1	BLFLLBZGZJTVJG-UHFFFAOYSA-N	2337.0		BLFLLBZGZJTVJG
BRD-K75466013-001-16-9	benzocaine	Launched	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	0	96.55	MedChemEx	HY-Y0258	Benzocaine	165.079	CCOC(=O)c1ccc(N)cc1	BLFLLBZGZJTVJG-UHFFFAOYSA-N	2337.0		BLFLLBZGZJTVJG
BRD-K75466013-001-13-6	benzocaine	Launched	sodium channel blocker	SCN10A	infectious disease	first-aid antiseptic	0	93.06	Selleck	S4210	Benzocaine	165.079	CCOC(=O)c1ccc(N)cc1	BLFLLBZGZJTVJG-UHFFFAOYSA-N	2337.0		BLFLLBZGZJTVJG
BRD-A45929034-001-09-5	benzoclidine	Preclinical					0	35.21	MicroSource	1506155	BENZOCLIDINE	231.126	O=C(O[C@H]1CN2CCC1CC2)c1ccccc1 |&1:3,r|	AHKAOMZZTQULDS-ZDUSSCGKSA-N	6928653.0		AHKAOMZZTQULDS
BRD-K26556907-001-01-8	benzofenac	Phase 1					0	99.01	Sigma	PH006029	[4-(benzyloxy)-3-chlorophenyl]acetic acid	276.055	OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1	DFHBBMJTBBLQSA-UHFFFAOYSA-N	91676.0		DFHBBMJTBBLQSA
BRD-K53397409-001-12-3	benzoic-acid	Launched	food preservative	DAO|HRSP12|PRDX5|RAB9A	infectious disease	tinea pedis	0	93.95	MicroSource	1503001	BENZOIC ACID	122.037	OC(=O)c1ccccc1	WPYMKLBDIGXBTP-UHFFFAOYSA-N	243.0		WPYMKLBDIGXBTP
BRD-K53397409-001-11-5	benzoic-acid	Launched	food preservative	DAO|HRSP12|PRDX5|RAB9A	infectious disease	tinea pedis	0	89.71	Selleck	S4161	Benzoic Acid	122.037	OC(=O)c1ccccc1	WPYMKLBDIGXBTP-UHFFFAOYSA-N	243.0		WPYMKLBDIGXBTP
BRD-K53397409-001-13-1	benzoic-acid	Launched	food preservative	DAO|HRSP12|PRDX5|RAB9A	infectious disease	tinea pedis	0	98.16	Selleck	S4161	Benzoic acid	122.037	OC(=O)c1ccccc1	WPYMKLBDIGXBTP-UHFFFAOYSA-N	243.0		WPYMKLBDIGXBTP
BRD-A55748233-001-08-7	benzoin	Preclinical		CES1			0	99.28	Enamine	Z57160197		212.084	O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|	ISAOCJYIOMOJEB-CYBMUJFWSA-N	640038.0		ISAOCJYIOMOJEB
BRD-A55748233-001-12-9	benzoin	Preclinical		CES1			0	96.94	MedChemEx	HY-B1550	Benzoin	212.084	O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1,r|	ISAOCJYIOMOJEB-CYBMUJFWSA-N	640038.0		ISAOCJYIOMOJEB
BRD-K91699951-001-10-2	benzonatate	Launched	local anesthetic	SCN5A	pulmonary	cough suppressant	0	99.74	MicroSource	1503864	BENZONATATE	603.362	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	MAFMQEKGGFWBAB-UHFFFAOYSA-N	7699.0		MAFMQEKGGFWBAB
BRD-K18772613-303-03-9	benzoquinonium-dibromide	Preclinical	cholinergic receptor antagonist	CHRNA1			0	92.73	Tocris	424	Benzoquinonium dibromide	546.393	CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|	YERABYSOHUZTPQ-UHFFFAOYSA-P	9394.0		YERABYSOHUZTPQ
BRD-K18772613-303-02-4	benzoquinonium-dibromide	Preclinical	cholinergic receptor antagonist	CHRNA1			0	91.5	Tocris	424	Benzoquinonium dibromide	546.393	CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30,t:9|	YERABYSOHUZTPQ-UHFFFAOYSA-P	9394.0		YERABYSOHUZTPQ
BRD-K33219230-001-07-9	benzotript	Phase 1	CCK receptor antagonist	CCKAR|CCKBR			0	97.86	Vitas-M	STK096133	CR 501	342.077	OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	QJERBBQXOMUURJ-INIZCTEOSA-N	2060890.0		QJERBBQXOMUURJ
BRD-K70327191-001-02-2	benzoxiquine	Preclinical	antiinfective drug				0	99.67	MicroSource	1505411	BENZOXIQUINE	249.079	O=C(Oc1cccc2cccnc12)c1ccccc1	BHKPHCKISVSDGV-UHFFFAOYSA-N	6855.0		BHKPHCKISVSDGV
BRD-K59986511-001-04-9	benzoyl-peroxide	Launched	oxidizing agent		dermatology	acne vulgaris (AV)	0	0.0	MicroSource	1503004	BENZOYL PEROXIDE	242.058	O=C(OOC(=O)c1ccccc1)c1ccccc1	OMPJBNCRMGITSC-UHFFFAOYSA-N	7187.0		OMPJBNCRMGITSC
BRD-K59986511-001-06-4	benzoyl-peroxide	Launched	oxidizing agent		dermatology	acne vulgaris (AV)	0	0.0	Sigma	MFCD00003071	diphenylperoxyanhydride	242.058	O=C(OOC(=O)c1ccccc1)c1ccccc1	OMPJBNCRMGITSC-UHFFFAOYSA-N	7187.0		OMPJBNCRMGITSC
BRD-K20431737-001-08-1	benzoylpas	Preclinical					0	84.56	MicroSource	1505413	BENZOYLPAS	257.069	OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	GNZCRYWFWKFIDM-UHFFFAOYSA-N	10718.0		GNZCRYWFWKFIDM
BRD-K20431737-001-09-9	benzoylpas	Preclinical					0	97.57	Vitas-M	STL062186	4-(benzoylamino)-2-hydroxybenzoic acid	257.069	OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	GNZCRYWFWKFIDM-UHFFFAOYSA-N	10718.0		GNZCRYWFWKFIDM
BRD-K21450440-001-14-6	benzthiazide	Launched	carbonic anhydrase inhibitor	CA2	cardiology	hypertension|edema	0	99.29	MicroSource	1500141	BENZTHIAZIDE	430.983	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl	MQMCZGVMQZPYQA-UHFFFAOYSA-N	132458842.0		MQMCZGVMQZPYQA
BRD-K21450440-001-13-8	benzthiazide	Launched	carbonic anhydrase inhibitor	CA2	cardiology	hypertension|edema	0	97.93	Selleck	S4308	Benzthiazide	430.983	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl	MQMCZGVMQZPYQA-UHFFFAOYSA-N	132458842.0		MQMCZGVMQZPYQA
BRD-K21450440-001-15-3	benzthiazide	Launched	carbonic anhydrase inhibitor	CA2	cardiology	hypertension|edema	0	98.68	Selleck	S4308	BENZTHIAZIDE	430.983	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl	MQMCZGVMQZPYQA-UHFFFAOYSA-N	132458842.0		MQMCZGVMQZPYQA
BRD-K68804560-066-03-9	benztropine-mesylate	Launched	acetylcholine receptor antagonist	CHRM1|HRH1|SLC6A3	neurology/psychiatry	extrapyramidal symptoms (EPS)|Parkinson's Disease	0	94.73	MedChemEx	HY-B0520A	Benztropine (mesylate)	307.194	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1	GIJXKZJWITVLHI-PMOLBWCYSA-N			GIJXKZJWITVLHI
BRD-K28542495-003-13-5	benzydamine	Launched	prostanoid receptor antagonist		dental|otolaryngology	mouth inflammation|throat inflammation	0	98.35	MicroSource	1505975	BENZYDAMINE HYDROCHLORIDE	309.184	CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12	CNBGNNVCVSKAQZ-UHFFFAOYSA-N	12555.0		CNBGNNVCVSKAQZ
BRD-K28542495-003-12-7	benzydamine	Launched	prostanoid receptor antagonist		dental|otolaryngology	mouth inflammation|throat inflammation	0	95.53	Selleck	S4165	Benzydamine HCl	309.184	CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12	CNBGNNVCVSKAQZ-UHFFFAOYSA-N	12555.0		CNBGNNVCVSKAQZ
BRD-K98494274-001-03-6	benzyl-alcohol	Launched	local anesthetic		infectious disease	virus herpes simplex (HSV)	0	0.0	MicroSource	1502555	BENZYL ALCOHOL	108.058	OCc1ccccc1	WVDDGKGOMKODPV-UHFFFAOYSA-N	244.0		WVDDGKGOMKODPV
BRD-K98494274-001-05-1	benzyl-alcohol	Launched	local anesthetic		infectious disease	virus herpes simplex (HSV)	0	0.0	Sigma	V800080	phenylmethanol	108.058	OCc1ccccc1	WVDDGKGOMKODPV-UHFFFAOYSA-N	244.0		WVDDGKGOMKODPV
BRD-K52072429-001-10-3	benzyl-benzoate	Launched	lipase inhibitor	LIPE	allergy	sweet itch	0	0.0	MicroSource	1503002	BENZYL BENZOATE	212.084	O=C(OCc1ccccc1)c1ccccc1	SESFRYSPDFLNCH-UHFFFAOYSA-N	2345.0		SESFRYSPDFLNCH
BRD-K52072429-001-12-9	benzyl-benzoate	Launched	lipase inhibitor	LIPE	allergy	sweet itch	0	0.0	MedChemEx	HY-B0935	Benzyl benzoate	212.084	O=C(OCc1ccccc1)c1ccccc1	SESFRYSPDFLNCH-UHFFFAOYSA-N	2345.0		SESFRYSPDFLNCH
BRD-K52072429-001-11-1	benzyl-benzoate	Launched	lipase inhibitor	LIPE	allergy	sweet itch	0	0.0	Sigma	B6630	benzyl benzoate	212.084	O=C(OCc1ccccc1)c1ccccc1	SESFRYSPDFLNCH-UHFFFAOYSA-N	2345.0		SESFRYSPDFLNCH
BRD-K80253852-001-04-4	benzyl-isothiocyanate	Preclinical	methylazoxymethanol acetate inhibitor				0	2.87	MicroSource	1503006	BENZYL ISOTHIOCYANATE	149.03	S=C=NCc1ccccc1	MDKCFLQDBWCQCV-UHFFFAOYSA-N	2346.0		MDKCFLQDBWCQCV
BRD-K80253852-001-05-9	benzyl-isothiocyanate	Preclinical	methylazoxymethanol acetate inhibitor				0	0.0	CombiBlocks	QE-3408	Benzyl isothiocyanate	149.03	S=C=NCc1ccccc1	MDKCFLQDBWCQCV-UHFFFAOYSA-N	2346.0		MDKCFLQDBWCQCV
BRD-K23403298-003-01-9	benzyldimethylhexadecylammonium	Preclinical	cationic surfactant				0	98.49	Acros	40207	Benzyldimethylhexadecylammonium chloride, hydrate, 97%	360.363	CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	QDYLMAYUEZBUFO-UHFFFAOYSA-N	31203.0		QDYLMAYUEZBUFO
BRD-K11576103-003-01-1	benzyldimethyloctylammonium	Preclinical					0	96.76	Sigma	689599	N-benzyl-N,N-dimethyl-1-octanaminium chloride	248.238	CCCCCCCC[N+](C)(C)Cc1ccccc1	SHFLYPPECXRCFO-UHFFFAOYSA-N	13741.0		SHFLYPPECXRCFO
BRD-K55191674-236-06-0	benzylpenicillin	Launched	penicillin binding protein inhibitor		infectious disease	celluitis|meningitis|endocarditis|syphilis|pneumonia|bacterial septicemia	0	85.82	Selleck	S4160	Penicillin G Sodium	334.099	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	JGSARLDLIJGVTE-MBNYWOFBSA-N	5904.0		JGSARLDLIJGVTE
BRD-K55191674-237-18-3	benzylpenicillin	Launched	penicillin binding protein inhibitor		infectious disease	celluitis|meningitis|endocarditis|syphilis|pneumonia|bacterial septicemia	0	97.54	MicroSource	1500465	PENICILLIN G POTASSIUM	334.099	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	JGSARLDLIJGVTE-MBNYWOFBSA-N	5904.0		JGSARLDLIJGVTE
BRD-K55191674-236-07-8	benzylpenicillin	Launched	penicillin binding protein inhibitor		infectious disease	celluitis|meningitis|endocarditis|syphilis|pneumonia|bacterial septicemia	0	51.7	Selleck	S4160	Benzylpenicillin sodium	334.099	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	JGSARLDLIJGVTE-MBNYWOFBSA-N	5904.0		JGSARLDLIJGVTE
BRD-K47878171-086-08-9	bephenium-hydroxynaphthoate	Launched	anthelmintic agent		infectious disease	ascariasis	0	53.1	MedChemEx	HY-12639A	Bephenium (hydroxynaphthoate)	256.17	C[N+](C)(CCOc1ccccc1)Cc1ccccc1	AVWWVJUMXRXPNF-UHFFFAOYSA-N	19667.0		AVWWVJUMXRXPNF
BRD-K47878171-086-06-0	bephenium-hydroxynaphthoate	Launched	anthelmintic agent		infectious disease	ascariasis	0	97.09	MicroSource	1505778	BEPHENIUM HYDROXYNAPTHOATE	256.17	C[N+](C)(CCOc1ccccc1)Cc1ccccc1	AVWWVJUMXRXPNF-UHFFFAOYSA-N	19667.0		AVWWVJUMXRXPNF
BRD-K47878171-086-05-2	bephenium-hydroxynaphthoate	Launched	anthelmintic agent		infectious disease	ascariasis	0	51.25	Selleck	S4389	Bephenium Hydroxynaphthoate	256.17	C[N+](C)(CCOc1ccccc1)Cc1ccccc1	AVWWVJUMXRXPNF-UHFFFAOYSA-N	19667.0		AVWWVJUMXRXPNF
BRD-K47878171-086-07-8	bephenium-hydroxynaphthoate	Launched	anthelmintic agent		infectious disease	ascariasis	0	48.39	Selleck	S4389	bephenium hydroxynaphthoate	256.17	C[N+](C)(CCOc1ccccc1)Cc1ccccc1	AVWWVJUMXRXPNF-UHFFFAOYSA-N	19667.0		AVWWVJUMXRXPNF
BRD-K98624455-074-02-8	bepotastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	90.86	Selleck	S3037	Bepotastine Besilate	388.155	OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1	YWGDOWXRIALTES-NRFANRHFSA-N	25273609.0		YWGDOWXRIALTES
BRD-K98624455-074-03-6	bepotastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	99.09	Selleck	S3037	Bepotastine Besilate	388.155	OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1	YWGDOWXRIALTES-NRFANRHFSA-N	25273609.0		YWGDOWXRIALTES
BRD-A91008255-003-24-8	bepridil	Launched	calcium channel blocker	KCNQ4	cardiology	angina pectoris	0	84.07	MicroSource	1503106	BEPRIDIL HYDROCHLORIDE	366.267	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	UIEATEWHFDRYRU-UHFFFAOYSA-N	50088.0		UIEATEWHFDRYRU
BRD-A91008255-003-26-3	bepridil	Launched	calcium channel blocker	KCNQ4	cardiology	angina pectoris	0	91.49	Tocris	4117	Bepridil hydrochloride	366.267	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	UIEATEWHFDRYRU-UHFFFAOYSA-N	50088.0		UIEATEWHFDRYRU
BRD-A91008255-003-25-5	bepridil	Launched	calcium channel blocker	KCNQ4	cardiology	angina pectoris	0	96.17	Sigma	MFCD00065498	N-benzyl-N-[3-isobutoxy-2-(1-pyrrolidinyl)propyl]aniline hydrochloride	366.267	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	UIEATEWHFDRYRU-UHFFFAOYSA-N	50088.0		UIEATEWHFDRYRU
BRD-K14796088-311-27-9	berberine	Launched	LDL receptor activator	LDLR			0	94.36	MedChemEx	HY-17577	Berberine (chloride hydrate)	336.124	COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	YBHILYKTIRIUTE-UHFFFAOYSA-N	2353.0		YBHILYKTIRIUTE
BRD-K14796088-003-26-8	berberine	Launched	LDL receptor activator	LDLR			0	95.66	MicroSource	1500811	BERBERINE CHLORIDE	336.124	COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	YBHILYKTIRIUTE-UHFFFAOYSA-N	2353.0		YBHILYKTIRIUTE
BRD-K14796088-003-25-0	berberine	Launched	LDL receptor activator	LDLR			0	93.84	Selleck	S2271	Berberine HCl	336.124	COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	YBHILYKTIRIUTE-UHFFFAOYSA-N	2353.0		YBHILYKTIRIUTE
BRD-K12968785-001-13-3	bergapten	Phase 3					0	96.13	MicroSource	300546	BERGAPTEN	216.042	COc1c2ccoc2cc2oc(=O)ccc12	BGEBZHIAGXMEMV-UHFFFAOYSA-N	2355.0		BGEBZHIAGXMEMV
BRD-K12968785-001-15-9	bergapten	Phase 3					0	98.83	MedChemEx	HY-N0370	Bergapten	216.042	COc1c2ccoc2cc2oc(=O)ccc12	BGEBZHIAGXMEMV-UHFFFAOYSA-N	2355.0		BGEBZHIAGXMEMV
BRD-K12968785-001-12-5	bergapten	Phase 3					0	93.7	Selleck	S4239	Bergapten	216.042	COc1c2ccoc2cc2oc(=O)ccc12	BGEBZHIAGXMEMV-UHFFFAOYSA-N	2355.0		BGEBZHIAGXMEMV
BRD-K04176066-001-09-1	bergenin	Preclinical	interleukin inhibitor	IL1B|TNF			0	89.95	MicroSource	1500819	BERGENIN	328.079	COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	YWJXCIXBAKGUKZ-HJJNZUOJSA-N	66065.0	BRD-K18550767-001-03-6	YWJXCIXBAKGUKZ
BRD-K04176066-001-10-9	bergenin	Preclinical	interleukin inhibitor	IL1B|TNF			0	97.41	MedChemEx	HY-N0017	Bergenin	328.079	COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	YWJXCIXBAKGUKZ-HJJNZUOJSA-N	66065.0		YWJXCIXBAKGUKZ
BRD-K04176066-001-08-3	bergenin	Preclinical	interleukin inhibitor	IL1B|TNF			0	97.98	Selleck	S2270	Bergenin	328.079	COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	YWJXCIXBAKGUKZ-HJJNZUOJSA-N	66065.0		YWJXCIXBAKGUKZ
BRD-K10196357-003-02-0	besifloxacin	Launched	bacterial DNA gyrase inhibitor		ophthalmology	conjunctivitis	0	93.81	Selleck	S3055	Besifloxacin HCl (Besivance)	393.126	N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	QFFGVLORLPOAEC-SNVBAGLBSA-N	10178705.0		QFFGVLORLPOAEC
BRD-K10196357-003-03-9	besifloxacin	Launched	bacterial DNA gyrase inhibitor		ophthalmology	conjunctivitis	0	83.46	MedChemEx	HY-17028	Besifloxacin (Hydrochloride)	393.126	N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	QFFGVLORLPOAEC-SNVBAGLBSA-N	10178705.0		QFFGVLORLPOAEC
BRD-K72735080-001-01-0	BET-BAY-002	Preclinical	bromodomain inhibitor				0	98.68	MedChemEx	HY-12421	BET-BAY 002	403.12	Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|	AGYIAWHWIUZNSD-INIZCTEOSA-N	73425805.0		AGYIAWHWIUZNSD
BRD-K72735080-001-02-9	BET-BAY-002	Preclinical	bromodomain inhibitor				0	98.81	MedChemEx	HY-12421	BET-BAY 002	403.12	Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|	AGYIAWHWIUZNSD-INIZCTEOSA-N	73425805.0		AGYIAWHWIUZNSD
BRD-K38687824-001-02-5	beta-amyloid-synthesis-inhibitor	Preclinical	beta amyloid synthesis inhibitor	APP			0	94.44	Maybridge	MO08553		294.112	Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1	GYNDFOLSPPBBIK-UHFFFAOYSA-N	9882580.0		GYNDFOLSPPBBIK
BRD-K38687824-001-04-9	beta-amyloid-synthesis-inhibitor	Preclinical	beta amyloid synthesis inhibitor	APP			0		Broad Institute	RS0406	RS0406	294.112	Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1	GYNDFOLSPPBBIK-UHFFFAOYSA-N	9882580.0		GYNDFOLSPPBBIK
BRD-K74225533-001-08-8	beta-carotene	Launched					0	0.0	Selleck	S1767	Beta Carotene	536.438	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|	OENHQHLEOONYIE-JLTXGRSLSA-N	5280489.0		OENHQHLEOONYIE
BRD-K74225533-001-10-4	beta-carotene	Launched					0	0.0	Selleck	S1767	Beta Carotene	536.438	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|	OENHQHLEOONYIE-JLTXGRSLSA-N	5280489.0		OENHQHLEOONYIE
BRD-K74225533-001-12-0	beta-carotene	Launched					0	0.0	MedChemEx	HY-N0411	?-Carotene	536.438	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|	OENHQHLEOONYIE-JLTXGRSLSA-N	5280489.0	BRD-K34538779-001-01-1	OENHQHLEOONYIE
BRD-K74225533-001-09-6	beta-carotene	Launched					0	0.0	MicroSource	1500143	beta-CAROTENE [2mM]	536.438	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9,32|	OENHQHLEOONYIE-JLTXGRSLSA-N	5280489.0		OENHQHLEOONYIE
BRD-K87349602-001-03-8	beta-CCB	Launched	benzodiazepine receptor ligand	GABRA1|GABRG2			0	98.04	Tocris	405	?-CCB	268.121	CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21	WGNGIELOOKACSB-UHFFFAOYSA-N	128618.0		WGNGIELOOKACSB
BRD-K87349602-001-04-9	beta-CCB	Launched	benzodiazepine receptor ligand	GABRA1|GABRG2			0	95.28	Tocris	405	beta-CCB	268.121	CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21	WGNGIELOOKACSB-UHFFFAOYSA-N	128618.0		WGNGIELOOKACSB
BRD-K21045639-001-01-2	beta-elemene	Launched	apoptosis stimulant	MMP2|MMP9			0	0.0	Sigma	63965	(1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane	204.188	CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C	OPFTUNCRGUEPRZ-QLFBSQMISA-N	6918391.0		OPFTUNCRGUEPRZ
BRD-K95110148-003-02-3	beta-funaltrexamine	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0	89.19	Tocris	926	?-Funaltrexamine hydrochloride	454.21	COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	PQKHESYTSKMWFP-WZJCLRDWSA-N	5311018.0		PQKHESYTSKMWFP
BRD-K95110148-003-03-9	beta-funaltrexamine	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0	95.47	Tocris	926	beta-Funaltrexamine hydrochloride	454.21	COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	PQKHESYTSKMWFP-WZJCLRDWSA-N	5311018.0		PQKHESYTSKMWFP
BRD-K95110148-003-01-5	beta-funaltrexamine	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0	95.83	Tocris	926	?-Funaltrexamine hydrochloride	454.21	COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	PQKHESYTSKMWFP-WZJCLRDWSA-N	5311018.0		PQKHESYTSKMWFP
BRD-K39061174-001-01-0	beta-glycerophosphoric-acid	Preclinical					1	0.0	Vitas-M	STL280247		172.014	OCC(CO)OP(O)(O)=O	DHCLVCXQIBBOPH-UHFFFAOYSA-N	2526.0		DHCLVCXQIBBOPH
BRD-M02899238-238-01-6	beta-hydroxy-beta-methylbutyrate	Launched	protein synthesis stimulant	MTOR			0	97.1	CombiBlocks	QC-1944	calcium bis(3-hydroxy-3-methylbutanoate)	118.063	CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O	KORPMXSVHOHPMS-UHFFFAOYSA-N	129010087.0		KORPMXSVHOHPMS
BRD-A41387824-001-06-0	beta-hydroxybutyrate	Phase 1		HCAR2			1	0.0	Vitas-M	STL377875		104.047	CC(O)CC(O)=O	WHBMMWSBFZVSSR-UHFFFAOYSA-N	441.0		WHBMMWSBFZVSSR
BRD-K28061410-001-07-4	beta-lapachone	Phase 2	topoisomerase inhibitor	TOP1			0	56.43	MedChemEx	HY-13555	?-Lapachone	242.094	CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|	QZPQTZZNNJUOLS-UHFFFAOYSA-N	3885.0		QZPQTZZNNJUOLS
BRD-K28061410-001-09-0	beta-lapachone	Phase 2	topoisomerase inhibitor	TOP1			0	24.09	MedChemEx	HY-13555	?-Lapachone	242.094	CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|	QZPQTZZNNJUOLS-UHFFFAOYSA-N	3885.0		QZPQTZZNNJUOLS
BRD-K28061410-001-05-8	beta-lapachone	Phase 2	topoisomerase inhibitor	TOP1			0	0.0	Selleck	S7261	Beta-Lapachone	242.094	CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|	QZPQTZZNNJUOLS-UHFFFAOYSA-N	3885.0		QZPQTZZNNJUOLS
BRD-K28061410-001-06-6	beta-lapachone	Phase 2	topoisomerase inhibitor	TOP1			0	82.91	Selleck	S7261	Beta-Lapachone	242.094	CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|	QZPQTZZNNJUOLS-UHFFFAOYSA-N	3885.0		QZPQTZZNNJUOLS
BRD-K21164796-001-02-8	beta-naphthol	Preclinical					0	90.98	MicroSource	1504501	beta-NAPHTHOL	144.058	Oc1ccc2ccccc2c1	JWAZRIHNYRIHIV-UHFFFAOYSA-N	8663.0		JWAZRIHNYRIHIV
BRD-K91315211-300-15-9	betahistine	Launched	histamine receptor agonist|histamine receptor antagonist	HRH1|HRH3	neurology/psychiatry	Meniere's disease	0	54.6	MedChemEx	HY-B0524A	Betahistine (dihydrochloride)	136.1	CNCCc1ccccn1	UUQMNUMQCIQDMZ-UHFFFAOYSA-N	2366.0		UUQMNUMQCIQDMZ
BRD-K91315211-300-06-5	betahistine	Launched	histamine receptor agonist|histamine receptor antagonist	HRH1|HRH3	neurology/psychiatry	Meniere's disease	0	99.79	MicroSource	1500670	BETAHISTINE HYDROCHLORIDE	136.1	CNCCc1ccccn1	UUQMNUMQCIQDMZ-UHFFFAOYSA-N	2366.0		UUQMNUMQCIQDMZ
BRD-K91315211-300-05-7	betahistine	Launched	histamine receptor agonist|histamine receptor antagonist	HRH1|HRH3	neurology/psychiatry	Meniere's disease	0	100.0	Selleck	S3176	Betahistine 2HCl	136.1	CNCCc1ccccn1	UUQMNUMQCIQDMZ-UHFFFAOYSA-N	2366.0		UUQMNUMQCIQDMZ
BRD-K12014493-001-02-2	betaine	Launched	nitric oxide donor		metabolism	homocystinuria	1	0.0	MicroSource	1503007	BETAINE HYDROCHLORIDE	118.087	C[N+](C)(C)CC(O)=O	KWIUHFFTVRNATP-UHFFFAOYSA-O	248.0	BRD-M80997309-001-09-2	KWIUHFFTVRNATP
BRD-K39188321-001-14-9	betamethasone	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	93.39	MedChemEx	HY-13570	Betamethasone	392.2	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-DVTGEIKXSA-N	9782.0		UREBDLICKHMUKA
BRD-K00025439-001-01-9	betamethasone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	93.74	TCI	B3165		434.21	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	AKUJBENLRBOFTD-QZIXMDIESA-N	443967.0	BRD-M00025439-001-01-9	AKUJBENLRBOFTD
BRD-K00004736-001-01-9	betamethasone-butyrate-propionate	Launched			rheumatology	rheumatoid arthritis	0	81.08	MedChemEx	HY-B0775	Betamethasone-17-butyrate-21-propionate	518.268	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |c:18,t:14|	VXOWJCTXWVWLLC-REGDIAEZSA-N	71470.0		VXOWJCTXWVWLLC
BRD-K58148589-001-03-6	betamethasone-dipropionate	Launched	anti-inflammatory agent	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	96.86	MicroSource	1503210	BETAMETHASONE 17,21-DIPROPIONATE	504.252	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|	CIWBQSYVNNPZIQ-XYWKZLDCSA-N	21800.0	BRD-A66861218-001-04-3	CIWBQSYVNNPZIQ
BRD-K58148589-001-04-9	betamethasone-dipropionate	Launched	anti-inflammatory agent	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	94.48	MedChemEx	HY-13571	Betamethasone dipropionate	504.252	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|	CIWBQSYVNNPZIQ-XYWKZLDCSA-N	21800.0		CIWBQSYVNNPZIQ
BRD-K58148589-001-02-8	betamethasone-dipropionate	Launched	anti-inflammatory agent	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	92.71	Selleck	S1688	Betamethasone Dipropionate (Diprolene)	504.252	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25,t:21|	CIWBQSYVNNPZIQ-XYWKZLDCSA-N	21800.0	BRD-K95691366-001-01-3	CIWBQSYVNNPZIQ
BRD-K00005349-304-01-9	betamethasone-phosphate	Launched			rheumatology	rheumatoid arthritis	0	88.21	Toronto	b327030	betamethasone 21-phosphate disodium salt	472.166	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11,t:7|	VQODGRNSFPNSQE-DVTGEIKXSA-N	107782.0		VQODGRNSFPNSQE
BRD-K34032314-001-04-1	betamethasone-valerate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	86.11	MicroSource	1500145	BETAMETHASONE VALERATE	476.257	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|	SNHRLVCMMWUAJD-SUYDQAKGSA-N	16533.0	BRD-A80594172-001-04-6	SNHRLVCMMWUAJD
BRD-K34032314-001-02-5	betamethasone-valerate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	76.09	Selleck	S1690	Betamethasone valerate (Betnovate)	476.257	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|	SNHRLVCMMWUAJD-SUYDQAKGSA-N	16533.0		SNHRLVCMMWUAJD
BRD-K34032314-001-03-3	betamethasone-valerate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	78.95	Selleck	S1690	Betamethasone valerate (Betnovate)	476.257	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|	SNHRLVCMMWUAJD-SUYDQAKGSA-N	16533.0	BRD-K57769959-001-01-6	SNHRLVCMMWUAJD
BRD-K34032314-001-05-8	betamethasone-valerate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	94.78	Selleck	S1690	Betamethasone valerate (Betnovate)	476.257	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19,t:15|	SNHRLVCMMWUAJD-SUYDQAKGSA-N	16533.0		SNHRLVCMMWUAJD
BRD-K82142815-001-20-9	betamipron	Launched	panipenem uptake inhibitor		nephrology	renal toxicity	0	96.28	MedChemEx	HY-B1127	Betamipron	193.074	OC(=O)CCNC(=O)c1ccccc1	CWXYHOHYCJXYFQ-UHFFFAOYSA-N	71651.0		CWXYHOHYCJXYFQ
BRD-K82142815-001-19-1	betamipron	Launched	panipenem uptake inhibitor		nephrology	renal toxicity	0	96.24	MicroSource	1504244	BETAMIPRON	193.074	OC(=O)CCNC(=O)c1ccccc1	CWXYHOHYCJXYFQ-UHFFFAOYSA-N	71651.0		CWXYHOHYCJXYFQ
BRD-K82142815-001-18-3	betamipron	Launched	panipenem uptake inhibitor		nephrology	renal toxicity	0	94.7	Selleck	S4191	Betamipron	193.074	OC(=O)CCNC(=O)c1ccccc1	CWXYHOHYCJXYFQ-UHFFFAOYSA-N	71651.0		CWXYHOHYCJXYFQ
BRD-K01825592-001-02-9	betaxolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	79.72	Selleck	S2091	Betaxolol	307.215	CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|	NWIUTZDMDHAVTP-QGZVFWFLSA-N	6093355.0		NWIUTZDMDHAVTP
BRD-K01825592-001-04-9	betaxolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	95.61	Selleck	S2091	Betaxolol (Betoptic)	307.215	CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5,r|	NWIUTZDMDHAVTP-QGZVFWFLSA-N	6093355.0		NWIUTZDMDHAVTP
BRD-K20075662-300-04-0	betazole	Launched	histamine receptor agonist	HRH2	gastroenterology	gastric hypersecretion diagnostic	0	97.19	Prestwick	Prestw-43	Betazole hydrochloride	111.08	NCCc1ccn[nH]1	JXDFEQONERDKSS-UHFFFAOYSA-N	7741.0		JXDFEQONERDKSS
BRD-K00003637-003-01-9	bethanechol	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4	urology	urinary retention	0	68.7	MedChemEx	HY-B0406A	Bethanechol (chloride)	161.129	C[C@@H](C[N+](C)(C)C)OC(N)=O |r|	NZUPCNDJBJXXRF-LURJTMIESA-O	6603779.0		NZUPCNDJBJXXRF
BRD-K00004305-001-01-9	BETP	Preclinical	GLP receptor positive allosteric modulator	GLP1R			0	96.39	Tocris	4778	BETP	406.096	CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2,r|	NTDFYGSSDDMNHI-NDEPHWFRSA-N	97182196.0		NTDFYGSSDDMNHI
BRD-K45275534-001-02-9	betrixaban	Launched	coagulation factor inhibitor	KCNH2	hematology	deep vein thrombosis (DVT)	0	94.98	MedChemEx	HY-10268	Betrixaban	451.141	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	XHOLNRLADUSQLD-UHFFFAOYSA-N	10275777.0		XHOLNRLADUSQLD
BRD-K45275534-001-01-3	betrixaban	Launched	coagulation factor inhibitor	KCNH2	hematology	deep vein thrombosis (DVT)	0	85.59	MedChemEx	HY-10268	Betrixaban	451.141	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	XHOLNRLADUSQLD-UHFFFAOYSA-N	10275777.0		XHOLNRLADUSQLD
BRD-K45401373-001-21-7	betulinic-acid	Phase 1/Phase 2	apoptosis stimulant|NFkB pathway inhibitor	GPBAR1			0	90.5	Tocris	3906	Betulinic acid	456.36	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	QGJZLNKBHJESQX-FZFNOLFKSA-N	64971.0	BRD-K15168723-001-01-7	QGJZLNKBHJESQX
BRD-K45401373-001-20-9	betulinic-acid	Phase 1/Phase 2	apoptosis stimulant|NFkB pathway inhibitor	GPBAR1			0	96.07	Selleck	S3603	Betulinic acid	456.36	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	QGJZLNKBHJESQX-FZFNOLFKSA-N	64971.0		QGJZLNKBHJESQX
BRD-K45401373-001-22-5	betulinic-acid	Phase 1/Phase 2	apoptosis stimulant|NFkB pathway inhibitor	GPBAR1			0	85.97	Selleck	S3603	Betulinic acid	456.36	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	QGJZLNKBHJESQX-FZFNOLFKSA-N	64971.0	BRD-K38744518-001-01-7	QGJZLNKBHJESQX
BRD-K01825622-003-02-9	bevantolol	Launched	adrenergic receptor antagonist		cardiology	angina pectoris|hypertension	0	94.05	AKSci	69996		381.171	COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|	HXLAFSUPPDYFEO-QGZVFWFLSA-N	36690919.0		HXLAFSUPPDYFEO
BRD-K00004680-001-01-9	bevenopran	Phase 1	opioid receptor antagonist				0	96.99	AMS	A119986	5-(2-methoxy-4-(((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)methyl)phenoxy)pyrazine-2-carboxamide	386.195	COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(N)=O	ZGCYVRNZWGUXNQ-UHFFFAOYSA-N	10452732.0		ZGCYVRNZWGUXNQ
BRD-K16898998-001-02-9	bevirimat-dimeglumine	Phase 2	HIV capsid assembly inhibitor				0	71.55	MedChemEx	HY-N0842	Bevirimat	584.408	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	YJEJKUQEXFSVCJ-WRFMNRASSA-N	457928.0		YJEJKUQEXFSVCJ
BRD-K16898998-001-01-6	bevirimat-dimeglumine	Phase 2	HIV capsid assembly inhibitor				0	87.82	MedChemEx	HY-N0842	Bevirimat	584.408	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	YJEJKUQEXFSVCJ-WRFMNRASSA-N	457928.0		YJEJKUQEXFSVCJ
BRD-K00003246-001-01-9	bexagliflozin	Phase 3	solute carrier family member inhibitor				0	97.26	MedChemEx	HY-17604	Bexagliflozin	464.16	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(OCCOC3CC3)cc2)c1	BTCRKOKVYTVOLU-SJSRKZJXSA-N	25195624.0		BTCRKOKVYTVOLU
BRD-K92441787-001-08-9	bexarotene	Launched	retinoid receptor agonist	RXRA|RXRB|RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	0	96.86	Tocris	5819	Bexarotene	348.209	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	NAVMQTYZDKMPEU-UHFFFAOYSA-N	82146.0		NAVMQTYZDKMPEU
BRD-K92441787-001-04-1	bexarotene	Launched	retinoid receptor agonist	RXRA|RXRB|RXRG	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	0	98.35	Selleck	S2098	Bexarotene	348.209	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	NAVMQTYZDKMPEU-UHFFFAOYSA-N	82146.0		NAVMQTYZDKMPEU
BRD-K46018455-001-29-9	bezafibrate	Launched	PPAR receptor agonist	PPARA|PPARD|PPARG	cardiology	cholesterol	0	95.9	MedChemEx	HY-B0637	Bezafibrate	361.108	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	IIBYAHWJQTYFKB-UHFFFAOYSA-N	39042.0		IIBYAHWJQTYFKB
BRD-K46018455-001-27-6	bezafibrate	Launched	PPAR receptor agonist	PPARA|PPARD|PPARG	cardiology	cholesterol	0	99.25	MicroSource	1502046	BEZAFIBRATE	361.108	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	IIBYAHWJQTYFKB-UHFFFAOYSA-N	39042.0		IIBYAHWJQTYFKB
BRD-K46018455-001-26-8	bezafibrate	Launched	PPAR receptor agonist	PPARA|PPARD|PPARG	cardiology	cholesterol	0	96.76	Selleck	S4159	Bezafibrate	361.108	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	IIBYAHWJQTYFKB-UHFFFAOYSA-N	39042.0		IIBYAHWJQTYFKB
BRD-K00003368-001-01-9	BFH772	Phase 2	VEGFR inhibitor				0	93.37	MedChemEx	HY-100419	BFH772	439.114	OCc1cc(Oc2ccc3c(cccc3c2)C(=O)Nc2cccc(c2)C(F)(F)F)ncn1	JNLSTLQFDDAULK-UHFFFAOYSA-N	24756034.0		JNLSTLQFDDAULK
BRD-K00003393-300-01-9	BGP-15	Phase 2	PARP inhibitor				0	97.8	MedChemEx	HY-100828	BGP-15	278.174	O[C@H](CONC(=N)c1cccnc1)CN1CCCCC1 |&1:1,r|	MVLOQULXIYSERZ-ZDUSSCGKSA-N	92211270.0		MVLOQULXIYSERZ
BRD-K29415052-050-05-5	BGT226	Phase 1/Phase 2	PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CG			0	98.31	Selleck	S2749	NVP-BGT226	534.199	COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	BMMXYEBLEBULND-UHFFFAOYSA-N	11978790.0		BMMXYEBLEBULND
BRD-K29415052-050-04-8	BGT226	Phase 1/Phase 2	PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CG			0	88.0	Selleck	S2749	BGT226 (NVP-BGT226)	534.199	COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	BMMXYEBLEBULND-UHFFFAOYSA-N	11978790.0		BMMXYEBLEBULND
BRD-K29415052-050-06-3	BGT226	Phase 1/Phase 2	PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CG			0	94.7	Selleck	S2749	NVP-BGT226 (BGT226)	534.199	COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	BMMXYEBLEBULND-UHFFFAOYSA-N	11978790.0		BMMXYEBLEBULND
BRD-K95603879-001-08-9	BHQ	Preclinical	ATPase inhibitor	ATP2A1			0	100.0	Tocris	1236	BHQ	222.162	CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C	JZODKRWQWUWGCD-UHFFFAOYSA-N	2374.0		JZODKRWQWUWGCD
BRD-K95603879-001-07-5	BHQ	Preclinical	ATPase inhibitor	ATP2A1			0	1.34	Tocris	1236	BHQ	222.162	CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C	JZODKRWQWUWGCD-UHFFFAOYSA-N	2374.0		JZODKRWQWUWGCD
BRD-A81370665-001-06-9	BI-D1870	Preclinical	ribosomal protein inhibitor	RPS6KA1|RPS6KA2|RPS6KA3|RPS6KA6			0	88.65	MedChemEx	HY-10510	BI-D1870	391.182	CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|	DTEKTGDVSARYDS-NSHDSACASA-N	44141268.0		DTEKTGDVSARYDS
BRD-A81370665-001-04-4	BI-D1870	Preclinical	ribosomal protein inhibitor	RPS6KA1|RPS6KA2|RPS6KA3|RPS6KA6			0	72.25	Selleck	S2843	BI-D1870	391.182	CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|	DTEKTGDVSARYDS-NSHDSACASA-N	44141268.0		DTEKTGDVSARYDS
BRD-A81370665-001-03-6	BI-D1870	Preclinical	ribosomal protein inhibitor	RPS6KA1|RPS6KA2|RPS6KA3|RPS6KA6			0	81.63	Selleck	S2843	BI-D1870	391.182	CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6,r|	DTEKTGDVSARYDS-NSHDSACASA-N	44141268.0		DTEKTGDVSARYDS
BRD-K53422148-001-01-8	BI-224436	Phase 1	HIV integrase inhibitor				0	93.15	MedChemEx	HY-18595	BI 224436	442.189	Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O	MIXIIJCBELCMCZ-VWLOTQADSA-N	66561902.0		MIXIIJCBELCMCZ
BRD-K64890080-001-13-8	BI-2536	Phase 2	PLK inhibitor	BRD4|PLK1|PLK2|PLK3			0	97.91	Selleck	S1109	BI 2536	521.311	CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	XQVVPGYIWAGRNI-JOCHJYFZSA-N	11364421.0		XQVVPGYIWAGRNI
BRD-K64890080-001-02-1	BI-2536	Phase 2	PLK inhibitor	BRD4|PLK1|PLK2|PLK3			0		Axon		BI-2536	521.311	CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1	11364421.0		XQVVPGYIWAGRNI
BRD-K00003120-001-01-9	BI-409306	Phase 1	phosphodiesterase inhibitor				0	98.6	MedChemEx	HY-112831	BI-409306	311.138	Oc1nc(Cc2ccccn2)nc2n(ncc12)C1CCOCC1	BZTIJCSHNVZMES-UHFFFAOYSA-N	135908617.0		BZTIJCSHNVZMES
BRD-K73982490-001-02-9	BI-78D3	Preclinical	JNK inhibitor	MAPK8			0	93.17	Tocris	3314	BI 78D3	379.005	[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1	QFRLDZGQEZCCJZ-UHFFFAOYSA-N	2747117.0		QFRLDZGQEZCCJZ
BRD-K73982490-001-03-7	BI-78D3	Preclinical	JNK inhibitor	MAPK8			0	94.21	Tocris	3314	BI 78D3	379.005	[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1	QFRLDZGQEZCCJZ-UHFFFAOYSA-N	2747117.0		QFRLDZGQEZCCJZ
BRD-K73982490-001-01-1	BI-78D3	Preclinical	JNK inhibitor	MAPK8			0	98.15	Sigma	B3063	BI-78D3	379.005	[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1	QFRLDZGQEZCCJZ-UHFFFAOYSA-N	2747117.0		QFRLDZGQEZCCJZ
BRD-K37492701-001-01-1	BI-847325	Phase 1	Aurora kinase inhibitor|MEK inhibitor	AURKA|AURKB|AURKC|MAP2K1|MAP2K2			0	91.92	Selleck	S7843	BI-847325	464.221	CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1	FLBNLJLONKAPLR-BYYHNAKLSA-N			FLBNLJLONKAPLR
BRD-K37492701-001-02-9	BI-847325	Phase 1	Aurora kinase inhibitor|MEK inhibitor	AURKA|AURKB|AURKC|MAP2K1|MAP2K2			0	93.58	Selleck	S7843		464.221	CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1	FLBNLJLONKAPLR-BYYHNAKLSA-N			FLBNLJLONKAPLR
BRD-K00004735-001-01-9	BIA-10-2474	Preclinical	Fatty acid hydrolase inhibitor				0	94.87	MedChemEx	HY-19740	BIA 10-2474	300.159	CN(C1CCCCC1)C(=O)n1cnc(c1)-c1ccc[n+]([O-])c1	DOWVMJFBDGWVML-UHFFFAOYSA-N	46831476.0		DOWVMJFBDGWVML
BRD-A80321291-001-05-7	biapenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia|pneumonia|urinary tract infections	0	0.0	MedChemEx	HY-13573	Biapenem	351.113	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	MRMBZHPJVKCOMA-YJFSRANCSA-O	71340.0		MRMBZHPJVKCOMA
BRD-A80321291-001-04-0	biapenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia|pneumonia|urinary tract infections	0	26.2	Sigma	MFCD00864863	(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-(5H,6H,7H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-ylsulfanyl)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate	351.113	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	MRMBZHPJVKCOMA-YJFSRANCSA-O	71340.0		MRMBZHPJVKCOMA
BRD-A80321291-001-06-5	biapenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia|pneumonia|urinary tract infections	0	0.0	MedChemEx	HY-13573	Biapenem	351.113	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	MRMBZHPJVKCOMA-YJFSRANCSA-O	71340.0		MRMBZHPJVKCOMA
BRD-A80321291-001-01-6	biapenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia|pneumonia|urinary tract infections	0	0.0	MedChemEx	HY-13573	Biapenem	351.113	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	MRMBZHPJVKCOMA-YJFSRANCSA-O	71340.0		MRMBZHPJVKCOMA
BRD-A80321291-001-02-4	biapenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia|pneumonia|urinary tract infections	0	0.0	Selleck	S1370	Biapenem	351.113	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	MRMBZHPJVKCOMA-YJFSRANCSA-O	71340.0	BRD-A66479836-001-03-8	MRMBZHPJVKCOMA
BRD-A80321291-001-03-2	biapenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia|pneumonia|urinary tract infections	0	74.7	Selleck	S1370	Biapenem	351.113	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1,3,4,5,&1:9,c:18|	MRMBZHPJVKCOMA-YJFSRANCSA-O	71340.0		MRMBZHPJVKCOMA
BRD-K43927145-001-02-0	BIBN4096	Phase 2	calcitonin antagonist	CALCA|CALCRL|RAMP1			0	77.99	MedChemEx	HY-10095	Olcegepant	867.207	NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	ITIXDWVDFFXNEG-JHOUSYSJSA-N	6918509.0		ITIXDWVDFFXNEG
BRD-K43927145-001-03-8	BIBN4096	Phase 2	calcitonin antagonist	CALCA|CALCRL|RAMP1			0	86.32	MedChemEx	HY-10095	Olcegepant	867.207	NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	ITIXDWVDFFXNEG-JHOUSYSJSA-N	6918509.0		ITIXDWVDFFXNEG
BRD-K43927145-001-01-2	BIBN4096	Phase 2	calcitonin antagonist	CALCA|CALCRL|RAMP1			0	77.11	MedChemEx	HY-10095	Olcegepant	867.207	NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	ITIXDWVDFFXNEG-JHOUSYSJSA-N	6918509.0		ITIXDWVDFFXNEG
BRD-K04623885-001-10-9	BIBR-1532	Preclinical	telomerase inhibitor	TERT			0	94.94	Tocris	2981	BIBR 1532	331.121	C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	PGFQXGLPJUCTOI-WYMLVPIESA-N	9927531.0		PGFQXGLPJUCTOI
BRD-K04623885-001-07-5	BIBR-1532	Preclinical	telomerase inhibitor	TERT			0	92.79	Selleck	S1186	BIBR 1532	331.121	C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	PGFQXGLPJUCTOI-WYMLVPIESA-N	9927531.0		PGFQXGLPJUCTOI
BRD-K49294207-300-04-6	BIBU-1361	Preclinical	EGFR inhibitor	EGFR			0	87.14	Tocris	2417	BIBU 1361 dihydrochloride	443.2	CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	JUGSLZCFNSTKBN-UHFFFAOYSA-N	17756796.0		JUGSLZCFNSTKBN
BRD-K49294207-300-03-8	BIBU-1361	Preclinical	EGFR inhibitor	EGFR			0	96.69	Tocris	2417	BIBU 1361 dihydrochloride	443.2	CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	JUGSLZCFNSTKBN-UHFFFAOYSA-N	17756796.0		JUGSLZCFNSTKBN
BRD-K49294207-300-05-9	BIBU-1361	Preclinical	EGFR inhibitor	EGFR			0	89.81	Tocris	2417	BIBU 1361 dihydrochloride	443.2	CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	JUGSLZCFNSTKBN-UHFFFAOYSA-N	17756796.0		JUGSLZCFNSTKBN
BRD-K70914287-300-02-8	BIBX-1382	Phase 1	EGFR inhibitor	EGFR|ERBB2			0	94.43	Tocris	2416	BIBX 1382 dihydrochloride	387.137	CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	FTFRZXFNZVCRSK-UHFFFAOYSA-N	6918508.0		FTFRZXFNZVCRSK
BRD-K70914287-300-04-9	BIBX-1382	Phase 1	EGFR inhibitor	EGFR|ERBB2			0	94.76	Tocris	2416	BIBX 1382 dihydrochloride	387.137	CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	FTFRZXFNZVCRSK-UHFFFAOYSA-N	6918508.0		FTFRZXFNZVCRSK
BRD-K70914287-300-03-6	BIBX-1382	Phase 1	EGFR inhibitor	EGFR|ERBB2			0	93.78	Tocris	2416	BIBX 1382 dihydrochloride	387.137	CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	FTFRZXFNZVCRSK-UHFFFAOYSA-N	6918508.0		FTFRZXFNZVCRSK
BRD-A29485665-001-14-4	bicalutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	95.1	Tocris	3389	Bicalutamide	430.061	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|	LKJPYSCBVHEWIU-UHFFFAOYSA-N	2375.0		LKJPYSCBVHEWIU
BRD-A29485665-001-12-8	bicalutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	98.74	MicroSource	1504827	BICALUTAMIDE	430.061	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|	LKJPYSCBVHEWIU-UHFFFAOYSA-N	2375.0		LKJPYSCBVHEWIU
BRD-A29485665-001-11-0	bicalutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	98.04	Selleck	S1190	Bicalutamide	430.061	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|	LKJPYSCBVHEWIU-UHFFFAOYSA-N	2375.0		LKJPYSCBVHEWIU
BRD-K00004299-003-01-9	bicifadine	Phase 3	dopamine reuptake inhibitor|serotonin receptor antagonist				0	83.5	Tocris	4357	Bicifadine hydrochloride	173.12	[H][C@@]12C[C@@]1(CNC2)c1ccc(C)cc1 |&1:1,3,r|	OFYVIGTWSQPCLF-NWDGAFQWSA-N	11715257.0		OFYVIGTWSQPCLF
BRD-K00003247-001-01-9	bictegravir	Launched	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	100.0	MedChemEx	HY-17605	Bictegravir	449.12	[H][C@@]12CC[C@@]([H])(C1)N1C(=O)c3c(O)c(=O)c(cn3C[C@@]1([H])O2)C(=O)NCc1c(F)cc(F)cc1F	SOLUWJRYJLAZCX-LYOVBCGYSA-N	90311989.0		SOLUWJRYJLAZCX
BRD-K84363966-001-12-9	bicuculline-(+)	Preclinical	GABA receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|KCNN1			0	97.87	Tocris	130	(+)-Bicuculline	367.106	CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	IYGYMKDQCDOMRE-ZWKOTPCHSA-N	10237.0		IYGYMKDQCDOMRE
BRD-K19094907-003-16-9	bicuculline-methochloride-(-)	Preclinical	GABA receptor antagonist				0	97.01	Tocris	131	(-)-Bicuculline methochloride	382.129	C[N+]1(C)CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	WDIQXKYUSINZME-RBUKOAKNSA-N	104872.0		WDIQXKYUSINZME
BRD-K16546375-001-01-4	bicyclol	Launched	NFkB pathway inhibitor	HSPA1A|HSPB1	infectious disease	hepatitis B|hepatitis C	0	98.42	Sigma	B3313	methyl 5'-(hydroxymethyl)-7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5-carboxylate	390.095	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO	KXMTXZACPVCDMH-UHFFFAOYSA-N	9821754.0		KXMTXZACPVCDMH
BRD-K18779551-003-08-6	bifemelane	Launched	acetylcholine release enhancer	MAOA|MAOB	ophthalmology|neurology/psychiatry	glaucoma|senile dementia	0	95.87	Tocris	767	Bifemelane hydrochloride	269.178	CNCCCCOc1ccccc1Cc1ccccc1	QSQQPMHPCBLLGX-UHFFFAOYSA-N	2377.0		QSQQPMHPCBLLGX
BRD-K18779551-003-09-9	bifemelane	Launched	acetylcholine release enhancer	MAOA|MAOB	ophthalmology|neurology/psychiatry	glaucoma|senile dementia	0	96.76	Tocris	767	Bifemelane hydrochloride	269.178	CNCCCCOc1ccccc1Cc1ccccc1	QSQQPMHPCBLLGX-UHFFFAOYSA-N	2377.0		QSQQPMHPCBLLGX
BRD-K18779551-003-07-8	bifemelane	Launched	acetylcholine release enhancer	MAOA|MAOB	ophthalmology|neurology/psychiatry	glaucoma|senile dementia	0	94.62	Tocris	767	Bifemelane	269.178	CNCCCCOc1ccccc1Cc1ccccc1	QSQQPMHPCBLLGX-UHFFFAOYSA-N	2377.0		QSQQPMHPCBLLGX
BRD-K26581543-001-01-6	bifendate	Launched			infectious disease	hepatitis B|hepatitis C	0	99.86	AKSci	H367		418.09	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC	JMZOMFYRADAWOG-UHFFFAOYSA-N	108213.0		JMZOMFYRADAWOG
BRD-A94543220-001-24-7	bifonazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis|tinea cruris	0	98.98	MicroSource	1505309	BIFONAZOLE	310.147	c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|	OCAPBUJLXMYKEJ-QFIPXVFZSA-N	5459391.0		OCAPBUJLXMYKEJ
BRD-A94543220-001-23-9	bifonazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis|tinea cruris	0	97.69	Selleck	S1854	Bifonazole	310.147	c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|	OCAPBUJLXMYKEJ-QFIPXVFZSA-N	5459391.0		OCAPBUJLXMYKEJ
BRD-A94543220-001-26-9	bifonazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis|tinea cruris	0	99.27	MedChemEx	HY-B0301	Bifonazole	310.147	c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5,r|	OCAPBUJLXMYKEJ-QFIPXVFZSA-N	5459391.0		OCAPBUJLXMYKEJ
BRD-K51967704-001-04-4	BIIB021	Phase 2	HSP inhibitor	HSP90AA1			0	96.56	Tocris	4608	BIIB 021	318.1	COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	QULDDKSCVCJTPV-UHFFFAOYSA-N	16736529.0		QULDDKSCVCJTPV
BRD-K51967704-001-03-6	BIIB021	Phase 2	HSP inhibitor	HSP90AA1			0	97.64	Selleck	S1175	BIIB021	318.1	COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	QULDDKSCVCJTPV-UHFFFAOYSA-N	16736529.0		QULDDKSCVCJTPV
BRD-K51937257-001-01-4	bilastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	99.77	MedChemEx	HY-14447	Bilastine	463.283	CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	ACCMWZWAEFYUGZ-UHFFFAOYSA-N	40467029.0		ACCMWZWAEFYUGZ
BRD-K51937257-001-02-9	bilastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	99.37	MedChemEx	HY-14447	Bilastine	463.283	CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	ACCMWZWAEFYUGZ-UHFFFAOYSA-N	40467029.0		ACCMWZWAEFYUGZ
BRD-K32039267-001-07-9	bilobalide	Preclinical	GABA receptor modulator	GLRA1|GLRA2|GLRB|HTR3A|HTR3B			0	100.0	MedChemEx	HY-N0076	Bilobalide	326.1	CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123	MOLPUWBMSBJXER-YDGSQGCISA-N	73581.0		MOLPUWBMSBJXER
BRD-K00003616-001-01-9	bimatoprost	Launched	prostanoid receptor agonist	AKR1C3|PTGER1|PTGER3|PTGFR	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	96.15	MedChemEx	HY-B0191	Bimatoprost	415.272	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1	AQOKCDNYWBIDND-FTOWTWDKSA-N	5311027.0		AQOKCDNYWBIDND
BRD-K00004300-003-01-9	BIMU-8	Preclinical	serotonin receptor agonist	HTR4			0	97.3	Tocris	4374	BIMU 8	342.206	CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14,16,19|	AFOFVIBWSLOHFR-QDMKHBRRSA-N			AFOFVIBWSLOHFR
BRD-K00004296-001-01-9	BINA	Preclinical	glutamate receptor positive allosteric modulator	GRM2			0	98.64	Tocris	4048	BINA	454.214	Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5,r|	KMKBEESNZAPKMP-AREMUKBSSA-N	86311024.0		KMKBEESNZAPKMP
BRD-K36467523-001-03-9	bindarit	Phase 2	NFkB pathway inhibitor	CCL2|CCL7|CCL8			0	96.36	MedChemEx	HY-B0498	Bindarit	324.147	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	MTHORRSSURHQPZ-UHFFFAOYSA-N	71354.0		MTHORRSSURHQPZ
BRD-K36467523-001-02-8	bindarit	Phase 2	NFkB pathway inhibitor	CCL2|CCL7|CCL8			0	97.84	Selleck	S3032	Bindarit	324.147	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	MTHORRSSURHQPZ-UHFFFAOYSA-N	71354.0		MTHORRSSURHQPZ
BRD-K82244583-001-02-9	binimetinib	Launched	MEK inhibitor	MAP2K1|MAP2K2	oncology	melanoma	0	97.0	MedChemEx	HY-15202	Binimetinib	440.03	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	ACWZRVQXLIRSDF-UHFFFAOYSA-N	10288191.0		ACWZRVQXLIRSDF
BRD-K82244583-001-01-3	binimetinib	Launched	MEK inhibitor	MAP2K1|MAP2K2	oncology	melanoma	0	94.6	Selleck	S7007	MEK162 (ARRY-162, ARRY-438162)	440.03	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	ACWZRVQXLIRSDF-UHFFFAOYSA-N	10288191.0		ACWZRVQXLIRSDF
BRD-K03399463-001-01-6	BIO-1211	Phase 2	integrin antagonist	ITGA4|ITGB1			0	93.1	Tocris	3910	(2S)-1-((2S)-2-{[(2S)-3-carboxy-2-({(2S)-4-methyl-2-[({4-[(2-toluidinocarbonyl)amino]phenyl}acetyl)amino]pentanoyl}amino)propanoyl]amino}-3-methylbutanoyl)-2-pyrrolidinecarboxylic acid	708.348	CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O	NVVGCQABIHSJSQ-KFZSMJGVSA-N	9961766.0		NVVGCQABIHSJSQ
BRD-K21318844-001-02-9	BIO-5192	Preclinical	integrin inhibitor	ITGA4|ITGB1			0	96.87	Tocris	5051	BIO 5192	816.247	CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O	MNQBPRHHZPXCKZ-ZDCRTTOTSA-N	10350459.0		MNQBPRHHZPXCKZ
BRD-K21318844-001-01-4	BIO-5192	Preclinical	integrin inhibitor	ITGA4|ITGB1			0	98.15	Tocris	5051	BIO 5192	816.247	CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O	MNQBPRHHZPXCKZ-ZDCRTTOTSA-N	10350459.0		MNQBPRHHZPXCKZ
BRD-K89210380-001-14-5	biotin	Launched	vitamin B	ACACA|ACACB|HLCS|MCCC1|MCCC2|PC|PCCA|PCCB|SLC5A6			0	88.29	MicroSource	1503009	BIOTIN	244.088	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	171548.0	BRD-A36603537-001-13-1	YBJHBAHKTGYVGT
BRD-K89210380-001-15-9	biotin	Launched	vitamin B	ACACA|ACACB|HLCS|MCCC1|MCCC2|PC|PCCA|PCCB|SLC5A6			0	84.81	MedChemEx	HY-B0511	Biotin	244.088	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	171548.0		YBJHBAHKTGYVGT
BRD-K89210380-001-13-7	biotin	Launched	vitamin B	ACACA|ACACB|HLCS|MCCC1|MCCC2|PC|PCCA|PCCB|SLC5A6			0	100.0	Selleck	S3130	Biotin (Vitamin B7)	244.088	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	YBJHBAHKTGYVGT-ZKWXMUAHSA-N	171548.0	BRD-K95496960-001-01-7	YBJHBAHKTGYVGT
BRD-K47690382-001-03-0	bipenamol	Phase 2	dipeptidyl peptidase inhibitor	CTSC			0	81.11	Sigma	MFCD00075349	(2-{[2-(aminomethyl)phenyl]sulfanyl}phenyl)methanol	245.087	NCc1ccccc1Sc1ccccc1CO	HLAFSNJRKZLMPT-UHFFFAOYSA-N	43961.0		HLAFSNJRKZLMPT
BRD-K01824983-001-02-9	biperiden	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	neurology/psychiatry	Parkinson's Disease	0	97.94	MicroSource	1505514		311.225	O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|	YSXKPIUOCJLQIE-UYWIDEMCSA-N	12147323.0		YSXKPIUOCJLQIE
BRD-K01824983-001-03-9	biperiden	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	neurology/psychiatry	Parkinson's Disease	0	83.46	Tocris	2853	Biperiden hydrochloride	311.225	O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12,14,&2:10,&3:1,c:17|	YSXKPIUOCJLQIE-UYWIDEMCSA-N	12147323.0		YSXKPIUOCJLQIE
BRD-K71221037-001-01-6	birinapant	Phase 2	XIAP inhibitor	BIRC2|XIAP			0	82.48	Selleck	S7015	Birinapant	806.429	CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	PKWRMUKBEYJEIX-DXXQBUJASA-N	49836020.0		PKWRMUKBEYJEIX
BRD-K71221037-001-02-4	birinapant	Phase 2	XIAP inhibitor	BIRC2|XIAP			0	95.44	Selleck	S7015	Birinapant (TL32711)	806.429	CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	PKWRMUKBEYJEIX-DXXQBUJASA-N	49836020.0		PKWRMUKBEYJEIX
BRD-K71221037-001-06-5	birinapant	Phase 2	XIAP inhibitor	BIRC2|XIAP			0		Selleck	S7015	Birinapant (TL32711)	806.429	CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1	49836020.0		PKWRMUKBEYJEIX
BRD-K64880136-001-02-6	BIRT-377	Preclinical	lymphocyte function-associated antigen negative modulator	ICAM1			0	97.8	Tocris	4776	BIRT 377	439.969	CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1	FJNJHZQMQRVZEE-GOSISDBHSA-N	9803375.0		FJNJHZQMQRVZEE
BRD-K64880136-001-01-8	BIRT-377	Preclinical	lymphocyte function-associated antigen negative modulator	ICAM1			0	99.01	Stanley		ls_0182_012	439.969	CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1	FJNJHZQMQRVZEE-GOSISDBHSA-N	9803375.0		FJNJHZQMQRVZEE
BRD-K16180792-001-01-7	bis(maltolato)oxovanadium(IV)	Phase 2	tyrosine phosphatase inhibitor	PTPN1			0	79.05	Carbosynth	FB18735	2-methyl-3-((2-methyl-4-oxo-4H-pyran-3-yloxy)(oxo)vanadiooxy)-4H-pyran-4-one	316.987	Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O	XUOLEICXAPEOSI-UHFFFAOYSA-L	3035454.0		XUOLEICXAPEOSI
BRD-K39987650-001-24-1	bisacodyl	Launched	laxative		gastroenterology	constipation	0	96.97	MicroSource	1500147	BISACODYL	361.131	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	KHOITXIGCFIULA-UHFFFAOYSA-N	2391.0		KHOITXIGCFIULA
BRD-K39987650-001-26-9	bisacodyl	Launched	laxative		gastroenterology	constipation	0	95.22	MedChemEx	HY-B0557	Bisacodyl	361.131	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	KHOITXIGCFIULA-UHFFFAOYSA-N	2391.0		KHOITXIGCFIULA
BRD-K39987650-001-23-3	bisacodyl	Launched	laxative		gastroenterology	constipation	0	95.89	Selleck	S4047	Bisacodyl	361.131	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	KHOITXIGCFIULA-UHFFFAOYSA-N	2391.0		KHOITXIGCFIULA
BRD-K00003395-001-01-9	bisantrene	Phase 2	topoisomerase inhibitor				0	44.78	MedChemEx	HY-100875	Bisantrene	398.197	C1CN=C(N\N=C\c2c3ccccc3c(\C=N\NC3=NCCN3)c3ccccc23)N1 |t:2,19|	NJSMWLQOCQIOPE-OCHFTUDZSA-N	5351322.0		NJSMWLQOCQIOPE
BRD-K06543683-066-02-1	bisindolylmaleimide-IX	Preclinical	PKC inhibitor	AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1			0	76.37	Selleck	S7207	Ro 31-8220 Mesylate	457.157	Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|	DSXXEELGXBCYNQ-UHFFFAOYSA-N	5083.0		DSXXEELGXBCYNQ
BRD-K06543683-066-05-4	bisindolylmaleimide-IX	Preclinical	PKC inhibitor	AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1			0	87.1	Tocris	2002	Ro 31-8220 mesylate	457.157	Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|	DSXXEELGXBCYNQ-UHFFFAOYSA-N	5083.0		DSXXEELGXBCYNQ
BRD-K06543683-066-03-9	bisindolylmaleimide-IX	Preclinical	PKC inhibitor	AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1			0	75.73	Tocris	2002	Ro 31-8220 mesylate	457.157	Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|	DSXXEELGXBCYNQ-UHFFFAOYSA-N	5083.0		DSXXEELGXBCYNQ
BRD-K06543683-066-04-7	bisindolylmaleimide-IX	Preclinical	PKC inhibitor	AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1			0	95.99	Selleck	S7207	Ro 31-8220 Mesylate	457.157	Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|	DSXXEELGXBCYNQ-UHFFFAOYSA-N	5083.0		DSXXEELGXBCYNQ
BRD-M56276249-001-01-1	bismuth(III)-trifluoromethanesulfonate	Preclinical	direct substitution catalyst				0	99.14	AlfaAesar	L19687	Bismuth(III) trifluoromethanesulfonate, 99%	658.86	[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F	BQFARKYNYLKHRD-UHFFFAOYSA-N			BQFARKYNYLKHRD
BRD-M02179497-001-01-1	bismuth-oxalate	Preclinical					1	0.0	MPBio	5201335	BISMUTH OXALATE	687.947	[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O	PEBMBOMJLWXKFI-UHFFFAOYSA-N			PEBMBOMJLWXKFI
BRD-K01666936-453-01-9	bismuth-subcitrate-potassium	Launched			gastroenterology	duodenal ulcer disease	0	0.0	Selleck	S4093		590.011	OC(=O)C[C@](O)(CC(=O)O[Bi]1OC(=O)C[C@@](O)(CC(O)=O)C(=O)O1)C(O)=O |&1:4,&2:15|	KNOSZBQOKCZXTI-UHFFFAOYSA-K	129856537.0		KNOSZBQOKCZXTI
BRD-K65978409-001-01-9	bismuth-subgallate	Launched	nitric oxide synthase inhibitor	NOS1	gastroenterology	internal deoderant	1	0.0	Sigma	MFCD00044980	2,7-dihydroxy-1,3,2-benzodioxabismole-5-carboxylic acid	393.989	O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O	JAONZGLTYYUPCT-UHFFFAOYSA-K	73415769.0		JAONZGLTYYUPCT
BRD-K80528473-001-03-0	bismuth-subsalicylate	Launched	antacid		gastroenterology	diarrhea	1	0.0	MicroSource	1505412	BISMUTH SUBSALICYLATE	361.999	O[Bi]1OC(=O)c2ccccc2O1	ZREIPSZUJIFJNP-UHFFFAOYSA-K	53629521.0		ZREIPSZUJIFJNP
BRD-K80528473-001-08-9	bismuth-subsalicylate	Launched	antacid		gastroenterology	diarrhea	0	0.0	MedChemEx	HY-B0550	Bismuth Subsalicylate	361.999	O[Bi]1OC(=O)c2ccccc2O1	ZREIPSZUJIFJNP-UHFFFAOYSA-K	53629521.0		ZREIPSZUJIFJNP
BRD-K80528473-001-04-8	bismuth-subsalicylate	Launched	antacid		gastroenterology	diarrhea	1	5.83	Selleck	S4032	Bismuth Subsalicylate	361.999	O[Bi]1OC(=O)c2ccccc2O1	ZREIPSZUJIFJNP-UHFFFAOYSA-K	53629521.0	BRD-M10663475-001-02-8	ZREIPSZUJIFJNP
BRD-K80528473-001-07-1	bismuth-subsalicylate	Launched	antacid		gastroenterology	diarrhea	1	0.0	MedChemEx	HY-B0550	Bismuth Subsalicylate	361.999	O[Bi]1OC(=O)c2ccccc2O1	ZREIPSZUJIFJNP-UHFFFAOYSA-K	53629521.0		ZREIPSZUJIFJNP
BRD-K80528473-001-05-5	bismuth-subsalicylate	Launched	antacid		gastroenterology	diarrhea	1	0.0	Selleck	S4032	Bismuth Subsalicylate	361.999	O[Bi]1OC(=O)c2ccccc2O1	ZREIPSZUJIFJNP-UHFFFAOYSA-K	53629521.0	BRD-M10663475-001-03-6	ZREIPSZUJIFJNP
BRD-K00228584-001-02-9	bisoctrizole	Phase 2					0	0.0	MedChemEx	HY-B0897	Bisoctrizole	658.4	CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1	FQUNFJULCYSSOP-UHFFFAOYSA-N	3571576.0		FQUNFJULCYSSOP
BRD-K00228584-396-01-8	bisoctrizole	Phase 2					0	0.0	MicroSource	1503866	BISOCTRIZOLE	658.4	CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1	FQUNFJULCYSSOP-UHFFFAOYSA-N	3571576.0		FQUNFJULCYSSOP
BRD-A89175223-051-14-8	bisoprolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	0	90.56	MicroSource	1505704	BISOPROLOL FUMARATE	325.225	CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|	VHYCDWMUTMEGQY-QGZVFWFLSA-N	6604464.0		VHYCDWMUTMEGQY
BRD-A89175223-051-15-5	bisoprolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	0	83.12	Tocris	914	(?)-Bisoprolol hemifumarate	325.225	CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|	VHYCDWMUTMEGQY-QGZVFWFLSA-N	6604464.0	BRD-M21493215-051-04-3	VHYCDWMUTMEGQY
BRD-A89175223-051-13-0	bisoprolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	0	89.72	Selleck	S1206	Bisoprolol fumarate	325.225	CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|	VHYCDWMUTMEGQY-QGZVFWFLSA-N	6604464.0		VHYCDWMUTMEGQY
BRD-A89175223-051-16-3	bisoprolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	0	95.41	Selleck	S1206	Bisoprolol	325.225	CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|	VHYCDWMUTMEGQY-QGZVFWFLSA-N	6604464.0		VHYCDWMUTMEGQY
BRD-K41494493-001-13-8	bisphenol-A	Phase 1	synthetic estrogen	AR|ESR1|ESR2|ESRRG|PPARG			0	95.98	Sigma	42088	4,4'-(propane-2,2-diyl)diphenol	228.115	CC(C)(c1ccc(O)cc1)c1ccc(O)cc1	IISBACLAFKSPIT-UHFFFAOYSA-N	6623.0		IISBACLAFKSPIT
BRD-K39120595-304-04-7	bithionol	Withdrawn	autotaxin inhibitor	ESR1|ESR2|MCL1			0	97.59	MicroSource	1500148	BITHIONATE SODIUM	353.884	Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O	JFIOVJDNOJYLKP-UHFFFAOYSA-N	2406.0		JFIOVJDNOJYLKP
BRD-K39120595-001-03-1	bithionol	Withdrawn	autotaxin inhibitor	ESR1|ESR2|MCL1			0	93.68	MicroSource	1500148	BITHIONOL	353.884	Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O	InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H	2406.0		JFIOVJDNOJYLKP
BRD-K13756951-001-02-9	bitopertin	Phase 3	glycine transporter inhibitor	SLC6A5|SLC6A9			0	90.65	MedChemEx	HY-10809	Bitopertin	543.106	C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	YUUGYIUSCYNSQR-LBPRGKRZSA-N	24946690.0		YUUGYIUSCYNSQR
BRD-K13756951-001-01-4	bitopertin	Phase 3	glycine transporter inhibitor	SLC6A5|SLC6A9			0	99.57	MedChemEx	HY-10809	Bitopertin	543.106	C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	YUUGYIUSCYNSQR-LBPRGKRZSA-N	24946690.0		YUUGYIUSCYNSQR
BRD-K77548206-001-03-9	bitoscanate	Preclinical	anthelmintic agent				0	0.0	MedChemEx	HY-B1160	Bitoscanate	191.982	S=C=Nc1ccc(cc1)N=C=S	OMWQUXGVXQELIX-UHFFFAOYSA-N	19958.0		OMWQUXGVXQELIX
BRD-K77548206-001-02-9	bitoscanate	Preclinical	anthelmintic agent				0	0.0	MicroSource	1504502	BITOSCANATE	191.982	S=C=Nc1ccc(cc1)N=C=S	OMWQUXGVXQELIX-UHFFFAOYSA-N	19958.0		OMWQUXGVXQELIX
BRD-K73504359-019-03-9	bivalirudin	Launched	thrombin inhibitor	F2	cardiology	angina pectoris	0	89.09	MedChemEx	HY-15664		2178.986	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	OIRCOABEOLEUMC-GEJPAHFPSA-N	73952246.0		OIRCOABEOLEUMC
BRD-K73504359-001-01-3	bivalirudin	Launched	thrombin inhibitor	F2	cardiology	angina pectoris	0	93.05	Key	HS-2004	(15S,21S,24S,27S,30S)-15-(2-amino-2-oxoethyl)-1-((S)-1-((S)-2-((S)-1-((R)-2-amino-3-phenylpropanoyl)pyrrolidine-2-carboxamido)-5-guanidinopentanoyl)pyrrolidin-2-yl)-24-benzyl-30-((2S,3S)-1-((S)-2-((S);-4-carboxy-1-((S)-4-carboxy-1-((S)-1-((S)-1-carboxy-3-	2178.986	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	OIRCOABEOLEUMC-GEJPAHFPSA-N	73952246.0		OIRCOABEOLEUMC
BRD-K73504359-019-01-5	bivalirudin	Launched	thrombin inhibitor	F2	cardiology	angina pectoris	0	30.45	MedChemEx	HY-15664	Bivalirudin (Trifluoroacetate)	2178.986	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	OIRCOABEOLEUMC-GEJPAHFPSA-N	73952246.0	BRD-A64231665-019-01-7	OIRCOABEOLEUMC
BRD-K73504359-019-02-9	bivalirudin	Launched	thrombin inhibitor	F2	cardiology	angina pectoris	0	90.12	MedChemEx	HY-15664	Bivalirudin (Trifluoroacetate)	2178.986	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	OIRCOABEOLEUMC-GEJPAHFPSA-N	73952246.0		OIRCOABEOLEUMC
BRD-K26818574-001-06-3	BIX-01294	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	94.12	MedChemEx	HY-10587	BIX-01294	490.306	COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	OSXFATOLZGZLSK-UHFFFAOYSA-N	25150857.0		OSXFATOLZGZLSK
BRD-K26818574-305-08-4	BIX-01294	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	87.71	Tocris	3364	BIX 01294	490.306	COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	OSXFATOLZGZLSK-UHFFFAOYSA-N	25150857.0		OSXFATOLZGZLSK
BRD-K26818574-305-04-3	BIX-01294	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	96.92	Selleck	S8006	BIX 01294	490.306	COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	OSXFATOLZGZLSK-UHFFFAOYSA-N	25150857.0		OSXFATOLZGZLSK
BRD-K26818574-305-07-6	BIX-01294	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	97.03	Selleck	S8006	BIX01294	490.306	COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	OSXFATOLZGZLSK-UHFFFAOYSA-N	25150857.0		OSXFATOLZGZLSK
BRD-K20290250-001-02-1	BIX-02188	Preclinical	MEK inhibitor	MAP2K5			0	89.83	Selleck	S1530	BIX 02188	412.19	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1	FSZPIAXLCCQFCM-FCQUAONHSA-N		BRD-K50394339-001-04-5	FSZPIAXLCCQFCM
BRD-K20290250-001-03-9	BIX-02188	Preclinical	MEK inhibitor	MAP2K5			0	96.97	MedChemEx	HY-12055	BIX02188	412.19	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1	FSZPIAXLCCQFCM-FCQUAONHSA-N			FSZPIAXLCCQFCM
BRD-K20290250-001-01-3	BIX-02188	Preclinical	MEK inhibitor	MAP2K5			0	94.2	Selleck	S1530	BIX 02188	412.19	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1	FSZPIAXLCCQFCM-FCQUAONHSA-N		BRD-K50394339-001-03-7	FSZPIAXLCCQFCM
BRD-K73368362-001-08-3	BIX-02189	Preclinical	MEK inhibitor	MAP2K5|MAPK7			0	98.67	Tocris	4842	BIX 02189	440.221	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1	HOMJAAIVTDVQJA-IZHYLOQSSA-N			HOMJAAIVTDVQJA
BRD-K73368362-001-07-5	BIX-02189	Preclinical	MEK inhibitor	MAP2K5|MAPK7			0	91.44	Selleck	S1531	BIX 02189	440.221	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1	HOMJAAIVTDVQJA-IZHYLOQSSA-N			HOMJAAIVTDVQJA
BRD-K75282704-001-02-4	BL-5583	Preclinical	hypercalcaemic agent				0	99.35	Enamine	Z89265777		178.009	OC(=O)c1cc2ccccc2s1	DYSJMQABFPKAQM-UHFFFAOYSA-N	95864.0		DYSJMQABFPKAQM
BRD-A75817871-001-06-7	blebbistatin-(+/-)	Preclinical	ATPase inhibitor	MYH14|MYH2			0	98.19	Tocris	1760	(?)-Blebbistatin	292.121	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10,r,t:5|	LZAXPYOBKSJSEX-GOSISDBHSA-N	5287792.0		LZAXPYOBKSJSEX
BRD-K61295575-001-03-6	blebbistatin-(-)	Preclinical	ATPase inhibitor				0	94.77	Selleck	S7099	(-)-Blebbistatin	292.121	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|	LZAXPYOBKSJSEX-GOSISDBHSA-N	5287792.0		LZAXPYOBKSJSEX
BRD-K00004533-001-01-9	bleomycetin	Launched	EGFR expression inhibitor				0	69.56	InterBioScreen	STOCK1N-47291	Bleomycin	1439.592	C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN	QYOAUOAXCQAEMW-DDZPZTJXSA-N	92135919.0		QYOAUOAXCQAEMW
BRD-K00003588-065-01-9	bleomycin	Launched	DNA synthesis inhibitor		hematologic malignancy|pulmonary|oncology	non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|pleural effusion|testicular carcinoma|squamous cell carcinoma	0	0.0	MedChemEx	HY-17565	Bleomycin (sulfate)	1414.519	[H][C@]1(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]2O)[C@@H](O[C@H]([C@H](NC(=O)c2nc(nc(N)c2C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@@H](C)O)C(=O)NCCc2nc(cs2)-c2nc(cs2)C(=O)NCCC[S+](C)C)c2c[nH]cn2)O[C@H](CO)[C@H](O)[C@H]1O	OYVAGSVQBOHSSS-WMBAVFRVSA-O			OYVAGSVQBOHSSS
BRD-K25943794-001-03-9	blonanserin	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	98.16	MedChemEx	HY-13575	Blonanserin	367.242	CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	XVGOZDAJGBALKS-UHFFFAOYSA-N	125564.0		XVGOZDAJGBALKS
BRD-K25943794-001-02-3	blonanserin	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	90.29	Selleck	S2112	Blonanserin (Lonasen)	367.242	CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	XVGOZDAJGBALKS-UHFFFAOYSA-N	125564.0		XVGOZDAJGBALKS
BRD-K72898849-001-01-8	BLU9931	Preclinical	FGFR inhibitor	FGFR4			0	93.96	MedChemEx	HY-12823	BLU9931	508.107	COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1	TXEBNKKOLVBTFK-UHFFFAOYSA-N	72710839.0		TXEBNKKOLVBTFK
BRD-K83157152-001-02-9	BLZ945	Phase 1/Phase 2	CSF1R inhibitor				0	88.61	MedChemEx	HY-12768	BLZ945	398.141	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1	ADZBMFGQQWPHMJ-RHSMWYFYSA-N	46184986.0		ADZBMFGQQWPHMJ
BRD-K94379058-001-05-0	BML-190	Preclinical	cannabinoid receptor inverse agonist	CNR2			0	97.66	Selleck	S2854	BML-190	426.135	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	BJSDNVVWJYDOLK-UHFFFAOYSA-N	2415.0		BJSDNVVWJYDOLK
BRD-K94379058-001-07-9	BML-190	Preclinical	cannabinoid receptor inverse agonist	CNR2			0	97.27	MedChemEx	HY-15420	BML-190	426.135	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	BJSDNVVWJYDOLK-UHFFFAOYSA-N	2415.0		BJSDNVVWJYDOLK
BRD-K94379058-001-06-8	BML-190	Preclinical	cannabinoid receptor inverse agonist	CNR2			0	98.01	Tocris	1383	BML-190	426.135	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	BJSDNVVWJYDOLK-UHFFFAOYSA-N	2415.0		BJSDNVVWJYDOLK
BRD-K42624714-001-04-1	BML-284	Preclinical	WNT agonist				0	97.93	MedChemEx	HY-19987	BML-284	350.138	COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1	FABQUVYDAXWUQP-UHFFFAOYSA-N	11210285.0		FABQUVYDAXWUQP
BRD-K15119094-001-01-1	BMS-CCR2-22	Preclinical	CC chemokine receptor antagonist	CCR2			0	98.16	Tocris	3129	BMS CCR2 22	593.228	CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F	IBPXYDUJQWENPM-XZOQPEGZSA-N	24801690.0		IBPXYDUJQWENPM
BRD-K15119094-001-02-9	BMS-CCR2-22	Preclinical	CC chemokine receptor antagonist	CCR2			0	97.89	Tocris	3129	BMS CCR2 22	593.228	CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F	IBPXYDUJQWENPM-XZOQPEGZSA-N	24801690.0		IBPXYDUJQWENPM
BRD-K56509348-003-03-9	BMS-182874	Phase 2	endothelin receptor antagonist	EDNRA			0	78.23	Tocris	1441	BMS 182874 hydrochloride	345.115	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	MJRGSRRZKSJHOE-UHFFFAOYSA-N	122272.0		MJRGSRRZKSJHOE
BRD-K56509348-003-04-9	BMS-182874	Phase 2	endothelin receptor antagonist	EDNRA			0	97.09	Tocris	1441	BMS 182874 hydrochloride	345.115	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	MJRGSRRZKSJHOE-UHFFFAOYSA-N	122272.0		MJRGSRRZKSJHOE
BRD-K56509348-003-02-1	BMS-182874	Phase 2	endothelin receptor antagonist	EDNRA			0	58.96	Tocris	1441	BMS 182874 hydrochloride	345.115	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	MJRGSRRZKSJHOE-UHFFFAOYSA-N	122272.0		MJRGSRRZKSJHOE
BRD-K95609758-001-04-5	BMS-191011	Preclinical	potassium channel activator	KCNMA1			0	95.45	Tocris	2665	BMS 191011	370.033	Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	QKOWACXSXTXRKA-UHFFFAOYSA-N	10474339.0		QKOWACXSXTXRKA
BRD-K95609758-001-03-7	BMS-191011	Preclinical	potassium channel activator	KCNMA1			0	95.41	Tocris	2665	BMS 191011	370.033	Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	QKOWACXSXTXRKA-UHFFFAOYSA-N	10474339.0		QKOWACXSXTXRKA
BRD-K95609758-001-05-9	BMS-191011	Preclinical	potassium channel activator	KCNMA1			0	95.79	Tocris	2665	BMS 191011	370.033	Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	QKOWACXSXTXRKA-UHFFFAOYSA-N	10474339.0		QKOWACXSXTXRKA
BRD-K01231377-001-01-8	BMS-191095	Phase 1	KATP activator|potassium channel agonist				0	96.19	MedChemEx	HY-14256	BMS-191095	408.135	CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N	SMIKIPXIDLITMP-LEWJYISDSA-N	9822753.0		SMIKIPXIDLITMP
BRD-K00004634-001-01-9	BMS-207940	Preclinical	endothelin receptor antagonist				0	96.67	Sigma	BM0014	N-{[2'-{[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl}-4-(1,3-oxazol-2-yl)[1,1'-biphenyl]-2-yl]methyl}-N,3,3-trimethylbutanamide	536.209	CN(Cc1cc(ccc1-c1ccccc1S(=O)(=O)Nc1noc(C)c1C)-c1ncco1)C(=O)CC(C)(C)C	ORJRYNKVKJAJPY-UHFFFAOYSA-N	156690.0		ORJRYNKVKJAJPY
BRD-K00003203-001-01-9	BMS-214662	Phase 1	farnesyltransferase inhibitor				0	98.26	MedChemEx	HY-16111	BMS-214662	489.129	O=S(=O)(N1Cc2cc(ccc2N(Cc2cnc[nH]2)C[C@H]1Cc1ccccc1)C#N)c1cccs1	OLCWFLWEHWLBTO-HSZRJFAPSA-N	448545.0		OLCWFLWEHWLBTO
BRD-K62814476-001-04-1	BMS-265246	Preclinical	CDK inhibitor	CDK1|CDK2			0	97.16	MedChemEx	HY-15275	BMS-265246	345.129	CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F	SCFMWQIQBVZOQR-UHFFFAOYSA-N	5329775.0		SCFMWQIQBVZOQR
BRD-K62814476-001-03-3	BMS-265246	Preclinical	CDK inhibitor	CDK1|CDK2			0	94.75	Selleck	S2014	BMS-265246	345.129	CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F	SCFMWQIQBVZOQR-UHFFFAOYSA-N	5329775.0		SCFMWQIQBVZOQR
BRD-K02950022-001-02-9	BMS-299897	Phase 1	gamma secretase inhibitor				0	97.26	EMDBio	565793-5MG	gamma-Secretase Inhibitor XXIV, BMS299897	511.083	C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O	IZAOBRWCUGOKNH-OAHLLOKOSA-N	11249248.0		IZAOBRWCUGOKNH
BRD-K87956243-001-02-9	BMS-309403	Preclinical	fatty acid binding protein inhibitor	FABP4			0	90.79	Tocris	5258	BMS 309403	474.194	CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1	SJRVJRYZAQYCEE-UHFFFAOYSA-N	16122583.0		SJRVJRYZAQYCEE
BRD-K87956243-001-01-9	BMS-309403	Preclinical	fatty acid binding protein inhibitor	FABP4			0	96.68	Tocris	5258	BMS 309403	474.194	CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1	SJRVJRYZAQYCEE-UHFFFAOYSA-N	16122583.0		SJRVJRYZAQYCEE
BRD-K13566078-003-07-9	BMS-345541	Preclinical	IKK inhibitor	CHUK|IKBKB			0	98.32	Tocris	4806	BMS 345541	255.148	Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	PSPFQEBFYXJZEV-UHFFFAOYSA-N	9813758.0		PSPFQEBFYXJZEV
BRD-K13566078-001-02-3	BMS-345541	Preclinical	IKK inhibitor	CHUK|IKBKB			0	96.8	Selleck	S8044	BMS-345541	255.148	Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	PSPFQEBFYXJZEV-UHFFFAOYSA-N	9813758.0		PSPFQEBFYXJZEV
BRD-K13566078-003-06-0	BMS-345541	Preclinical	IKK inhibitor	CHUK|IKBKB			0	96.97	Tocris	4806	BMS 345541	255.148	Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	PSPFQEBFYXJZEV-UHFFFAOYSA-N	9813758.0		PSPFQEBFYXJZEV
BRD-K43389698-001-07-3	BMS-387032	Phase 1	CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor	CDK2|CDK7|CDK9			0	64.08	Selleck	S1145	SNS-032 (BMS-387032)	380.134	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	OUSFTKFNBAZUKL-UHFFFAOYSA-N	3025986.0		OUSFTKFNBAZUKL
BRD-K43389698-001-09-9	BMS-387032	Phase 1	CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor	CDK2|CDK7|CDK9			0	92.86	Selleck	S1145	SNS-032 (BMS-387032)	380.134	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	OUSFTKFNBAZUKL-UHFFFAOYSA-N	3025986.0		OUSFTKFNBAZUKL
BRD-K22000702-300-01-4	BMS-470539	Preclinical	melanocortin receptor agonist	MC1R			0	81.93	Tocris	4053	BMS 470539 dihydrochloride	559.316	CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1	GULVVTHHUIIMRL-WUFINQPMSA-N	9915813.0		GULVVTHHUIIMRL
BRD-K22000702-300-02-9	BMS-470539	Preclinical	melanocortin receptor agonist	MC1R			0	93.85	Tocris	4053	BMS 470539 dihydrochloride	559.316	CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1	GULVVTHHUIIMRL-WUFINQPMSA-N	9915813.0		GULVVTHHUIIMRL
BRD-K34581968-001-04-6	BMS-536924	Preclinical	IGF-1 inhibitor	AKT1|CCNE1|CDK2|CYP3A4|ERBB2|IGF1R|KDR|LCK|MAPK1|MET|PDGFRA|PDGFRB			0	96.98	MedChemEx	HY-10262	BMS-536924	479.172	Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1	ZWVZORIKUNOTCS-OAQYLSRUSA-N	135440466.0		ZWVZORIKUNOTCS
BRD-K34581968-001-05-3	BMS-536924	Preclinical	IGF-1 inhibitor	AKT1|CCNE1|CDK2|CYP3A4|ERBB2|IGF1R|KDR|LCK|MAPK1|MET|PDGFRA|PDGFRB			0	92.53	Tocris	4774	BMS 536924	479.172	Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1	ZWVZORIKUNOTCS-OAQYLSRUSA-N	135440466.0		ZWVZORIKUNOTCS
BRD-K56932272-001-01-1	BMS-566419	Preclinical	inosine monophosphate dehydrogenase inhibitor	IMPDH1|IMPDH2			0	97.46	Tocris	5492	BMS 566419	487.238	CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F	XEVJUIZOZCFECP-UHFFFAOYSA-N	9913339.0		XEVJUIZOZCFECP
BRD-K56932272-001-02-9	BMS-566419	Preclinical	inosine monophosphate dehydrogenase inhibitor	IMPDH1|IMPDH2			0	93.38	Tocris	5492	BMS 566419	487.238	CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F	XEVJUIZOZCFECP-UHFFFAOYSA-N	9913339.0		XEVJUIZOZCFECP
BRD-K00003168-003-01-9	BMS-582949	Phase 2	p38 MAPK inhibitor				0	96.9	MedChemEx	HY-14305A	BMS-582949 (hydrochloride)	406.212	CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C	GDTQLZHHDRRBEB-UHFFFAOYSA-N	10409068.0		GDTQLZHHDRRBEB
BRD-K20093108-001-02-3	BMS-587101	Phase 2	integrin antagonist	ITGAL|ITGB2			0	92.65	Key	HE-0001	5-{[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]methyl}-3-thiophenecarboxylic acid	554.058	CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1	NXNKJLOEGWSJGI-BKMJKUGQSA-N	11635371.0		NXNKJLOEGWSJGI
BRD-K07106112-300-01-2	BMS-599626	Phase 1	EGFR inhibitor|protein tyrosine kinase inhibitor	EGFR|ERBB2|ERBB4			0	97.06	Tocris	5022	BMS 599626 dihydrochloride	530.219	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	LUJZZYWHBDHDQX-QFIPXVFZSA-N	10437018.0		LUJZZYWHBDHDQX
BRD-K07106112-003-03-8	BMS-599626	Phase 1	EGFR inhibitor|protein tyrosine kinase inhibitor	EGFR|ERBB2|ERBB4			0	94.12	Selleck	S1056	AC480 (BMS-599626)	530.219	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	LUJZZYWHBDHDQX-QFIPXVFZSA-N	10437018.0		LUJZZYWHBDHDQX
BRD-K97883416-001-01-4	BMS-626529	Phase 3	HIV attachment inhibitor				0	98.85	MedChemEx	HY-15440	BMS-626529	473.181	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	QRPZBKAMSFHVRW-UHFFFAOYSA-N	11317439.0		QRPZBKAMSFHVRW
BRD-K97883416-001-02-9	BMS-626529	Phase 3	HIV attachment inhibitor				0	97.03	MedChemEx	HY-15440	Temsavir	473.181	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	QRPZBKAMSFHVRW-UHFFFAOYSA-N	11317439.0		QRPZBKAMSFHVRW
BRD-K00004550-001-01-9	BMS-626531	Phase 1	p38 MAPK inhibitor				0	85.26	Sigma	MFCD18206777	N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-5-methyl-1-[3-(trifluoromethyl)-2-pyridinyl]-1H-pyrazole-4-carboxamide	443.157	Cc1c(cnn1-c1ncccc1C(F)(F)F)C(=O)Nc1cc(ccc1C)C(=O)NC1CC1	ZZZJRULMCGMYRH-UHFFFAOYSA-N	59749702.0		ZZZJRULMCGMYRH
BRD-K25991633-001-02-7	BMS-649	Preclinical	retinoid receptor agonist	RXRA			0	98.38	Tocris	3411	SR 11237	380.199	CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	ZZUKALQMHNSWTK-UHFFFAOYSA-N	127019.0		ZZUKALQMHNSWTK
BRD-K25991633-001-01-9	BMS-649	Preclinical	retinoid receptor agonist	RXRA			0	99.1	Tocris	3411	SR 11237	380.199	CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	ZZUKALQMHNSWTK-UHFFFAOYSA-N	127019.0		ZZUKALQMHNSWTK
BRD-K25991633-001-03-9	BMS-649	Preclinical	retinoid receptor agonist	RXRA			0	95.42	Tocris	3411	SR 11237	380.199	CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	ZZUKALQMHNSWTK-UHFFFAOYSA-N	127019.0		ZZUKALQMHNSWTK
BRD-K85649978-001-02-1	BMS-688521	Preclinical	ICAM1 antagonist|leukocyte function-associated antigen receptor antagonist	ICAM1			0	99.64	Key	KE-0042	6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]nicotinic acid	535.081	CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1	LILGMDXLRPEBNH-HFZDXXHNSA-N	11699447.0		LILGMDXLRPEBNH
BRD-K76239644-001-02-6	BMS-690514	Phase 2	EGFR inhibitor|VEGFR inhibitor	EGFR|ERBB2|FLT3|KDR			0	94.87	MedChemEx	HY-10333	BMS-690514	368.196	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	CSGQVNMSRKWUSH-IAGOWNOFSA-N	11349170.0		CSGQVNMSRKWUSH
BRD-K76239644-001-04-9	BMS-690514	Phase 2	EGFR inhibitor|VEGFR inhibitor	EGFR|ERBB2|FLT3|KDR			0	94.56	MedChemEx	HY-10333	BMS-690514	368.196	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	CSGQVNMSRKWUSH-IAGOWNOFSA-N	11349170.0		CSGQVNMSRKWUSH
BRD-K76239644-001-01-8	BMS-690514	Phase 2	EGFR inhibitor|VEGFR inhibitor	EGFR|ERBB2|FLT3|KDR			0	77.92	MedChemEx	HY-10333	BMS-690514	368.196	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	CSGQVNMSRKWUSH-IAGOWNOFSA-N	11349170.0		CSGQVNMSRKWUSH
BRD-K49555808-001-03-9	BMS-707035	Phase 2	HIV integrase inhibitor				0	96.62	Selleck	S1366	BMS-707035	410.106	Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	VNIWZCGZPBJWBI-UHFFFAOYSA-N	54682040.0		VNIWZCGZPBJWBI
BRD-K13049116-001-04-0	BMS-754807	Phase 2	IGF-1 inhibitor	AKT1|IGF1R			0	95.86	MedChemEx	HY-10200	BMS-754807	461.209	C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	LQVXSNNAFNGRAH-QHCPKHFHSA-N	24785538.0		LQVXSNNAFNGRAH
BRD-K13049116-001-03-2	BMS-754807	Phase 2	IGF-1 inhibitor	AKT1|IGF1R			0	96.93	Selleck	S1124	BMS-754807	461.209	C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	LQVXSNNAFNGRAH-QHCPKHFHSA-N	24785538.0		LQVXSNNAFNGRAH
BRD-K13049116-001-05-7	BMS-754807	Phase 2	IGF-1 inhibitor	AKT1|IGF1R			0	88.03	Selleck	S1124	BMS-754807	461.209	C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	LQVXSNNAFNGRAH-QHCPKHFHSA-N	24785538.0	BRD-K47200824-001-01-8	LQVXSNNAFNGRAH
BRD-K00004655-001-01-9	BMS-770767	Phase 2	11-beta-HSD1 inhibitor				0	94.62	Sigma	BM0023	4-[8-(2-chlorophenoxy)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]norbornan-1-ol	355.109	O[C@@]12CC[C@@](CC1)(C2)c1nnc2c(Oc3ccccc3Cl)cccn12 |r|	HNXGIFYHJKEXNA-KDURUIRLSA-N			HNXGIFYHJKEXNA
BRD-K40738845-001-05-0	BMS-777607	Phase 1/Phase 2	AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor	AXL|MERTK|MET|MST1R|TYRO3			0	98.03	Selleck	S1561	BMS-777607	512.106	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	VNBRGSXVFBYQNN-UHFFFAOYSA-N	24794418.0		VNBRGSXVFBYQNN
BRD-K40738845-001-06-9	BMS-777607	Phase 1/Phase 2	AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor	AXL|MERTK|MET|MST1R|TYRO3			0	96.07	MedChemEx	HY-12076	BMS 777607	512.106	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	VNBRGSXVFBYQNN-UHFFFAOYSA-N	24794418.0		VNBRGSXVFBYQNN
BRD-K00003305-001-01-9	BMS-779788	Phase 1	LXR agonist				0	88.43	MedChemEx	HY-19919	BMS-779788	508.159	CC(C)(O)c1cn(c(n1)C(C)(C)c1ccccc1Cl)-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O	JLPURTXCSILYLW-UHFFFAOYSA-N	59251511.0		JLPURTXCSILYLW
BRD-K55773932-001-03-8	BMS-806	Phase 1	HIV attachment inhibitor				0	97.42	Selleck	S2632	BMS-806 (BMS 378806)	406.164	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	OKGPFTLYBPQBIX-CQSZACIVSA-N	5495818.0		OKGPFTLYBPQBIX
BRD-K55773932-001-04-9	BMS-806	Phase 1	HIV attachment inhibitor				0	97.51	MedChemEx	HY-14134	BMS-378806	406.164	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	OKGPFTLYBPQBIX-CQSZACIVSA-N	5495818.0		OKGPFTLYBPQBIX
BRD-K55773932-001-02-0	BMS-806	Phase 1	HIV attachment inhibitor				0	82.63	Selleck	S2632	BMS-378806	406.164	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	OKGPFTLYBPQBIX-CQSZACIVSA-N	5495818.0		OKGPFTLYBPQBIX
BRD-K00003512-001-01-9	BMS-813160	Phase 2	CC chemokine receptor antagonist				0	96.58	MedChemEx	HY-109593	BMS-813160	484.327	CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C	CMVHFGNTABZQJU-HCXYKTFWSA-N	51039119.0		CMVHFGNTABZQJU
BRD-K81026553-234-01-8	BMS-817378	Phase 1	c-Met inhibitor|VEGFR inhibitor	KDR|MET			0	96.68	MedChemEx	HY-18711A	c-Met inhibitor 2	578.057	Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	KXDZWUPUSDCGDD-UHFFFAOYSA-N	44137813.0		KXDZWUPUSDCGDD
BRD-K33245965-001-03-4	BMS-833923	Phase 2	smoothened receptor antagonist	SMO			0	94.83	MedChemEx	HY-13809	BMS-833923	473.222	CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	KLRRGBHZCJLIEL-UHFFFAOYSA-N	57662985.0		KLRRGBHZCJLIEL
BRD-K33245965-001-01-8	BMS-833923	Phase 2	smoothened receptor antagonist	SMO			0	62.17	Selleck	S7138	BMS-833923	473.222	CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	KLRRGBHZCJLIEL-UHFFFAOYSA-N	57662985.0		KLRRGBHZCJLIEL
BRD-K33245965-001-02-6	BMS-833923	Phase 2	smoothened receptor antagonist	SMO			0	84.31	Selleck	S7138	BMS-833923 (XL139)	473.222	CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	KLRRGBHZCJLIEL-UHFFFAOYSA-N	57662985.0		KLRRGBHZCJLIEL
BRD-K12511835-003-01-2	BMS-863233	Phase 1/Phase 2	CDC inhibitor	CDC7|PIM1			0	98.12	MedChemEx	HY-15260A	XL413 (hydrochloride)	289.062	Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1	JJWLXRKVUJDJKG-VIFPVBQESA-N	135564632.0		JJWLXRKVUJDJKG
BRD-K12511835-003-02-0	BMS-863233	Phase 1/Phase 2	CDC inhibitor	CDC7|PIM1			0	94.02	MedChemEx	HY-15260A	XL413 (hydrochloride)	289.062	Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1	JJWLXRKVUJDJKG-VIFPVBQESA-N	135564632.0		JJWLXRKVUJDJKG
BRD-K29343434-001-02-9	BMS-906024	Phase 1	gamma secretase inhibitor				0	96.07	Sigma	BM0018	(2R,3S)-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide	556.191	CN1c2ccccc2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)c1ccccc1 |c:9|	AYOUDDAETNMCBW-GSHUGGBRSA-N	66550890.0		AYOUDDAETNMCBW
BRD-K00003189-001-01-9	BMS-911543	Phase 1/Phase 2	JAK inhibitor				0	92.83	MedChemEx	HY-15270	BMS-911543	432.239	CCn1c(cc2c1nc(Nc1cc(C)n(C)n1)c1ncn(C)c21)C(=O)N(C1CC1)C1CC1	JCINBYQJBYJGDM-UHFFFAOYSA-N	50922691.0		JCINBYQJBYJGDM
BRD-K00004721-001-01-9	BMS-935177	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor				0	97.18	MedChemEx	HY-101793	BMS-935177	502.2	Cc1c(cccc1-n1cnc2ccccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O	TVJRDCQUZMGBAB-UHFFFAOYSA-N	70647728.0		TVJRDCQUZMGBAB
BRD-K22316123-001-01-9	BMS-983970	Phase 1	notch signaling inhibitor				0	97.52	MedChemEx	HY-12419	BMS-983970	518.194	NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|	RANYIWAZSQWERN-WLENULPWSA-N	73388374.0		RANYIWAZSQWERN
BRD-K00004586-001-01-9	BMS-986020	Phase 2	lysophosphatidic acid receptor antagonist	LPAR1			0	86.34	MedChemEx	HY-100619	BMS-986020	482.184	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1	GQBRZBHEPUQRPL-LJQANCHMSA-N	49792850.0		GQBRZBHEPUQRPL
BRD-K00004591-001-01-9	BMS-986142	Phase 2	Bruton's tyrosine kinase (BTK) inhibitor				0	96.95	MedChemEx	HY-101856	BMS-986142	572.224	Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O	ZRYMMWAJAFUANM-INIZCTEOSA-N	86582336.0		ZRYMMWAJAFUANM
BRD-K00003423-001-01-9	BMS-986158	Phase 1/Phase 2	bromodomain inhibitor				0	92.64	MedChemEx	HY-101567	BMS-986158	495.263	Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O	KGERZPVQIRYWRK-GDLZYMKVSA-N	118196485.0		KGERZPVQIRYWRK
BRD-K00003110-001-01-9	BMS-986195	Phase 1	Bruton's tyrosine kinase (BTK) inhibitor				0	95.18	MedChemEx	HY-112161	BMS-986195	370.181	CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(C(N)=O)c2[nH]c(C)c(C)c12	VJPPLCNBDLZIFG-ZDUSSCGKSA-N	121293929.0		VJPPLCNBDLZIFG
BRD-K00003418-001-01-9	BMS-986205	Phase 3	indoleamine 2,3-dioxygenase inhibitor				0	95.85	MedChemEx	HY-101560	Linrodostat	410.156	[H][C@]1(CC[C@@H](CC1)c1ccnc2ccc(F)cc12)[C@@H](C)C(=O)Nc1ccc(Cl)cc1	KRTIYQIPSAGSBP-ZACQAIPSSA-N			KRTIYQIPSAGSBP
BRD-A15435692-003-03-9	BMY-14802	Phase 2	sigma receptor antagonist	HTR1A			0	91.51	Tocris	1440	BMY 14802 hydrochloride	348.176	O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|	ZXUYYZPJUGQHLQ-KRWDZBQOSA-N	10020651.0		ZXUYYZPJUGQHLQ
BRD-A15435692-003-02-3	BMY-14802	Phase 2	sigma receptor antagonist	HTR1A			0	95.41	Tocris	1440	BMY 14802 hydrochloride	348.176	O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|	ZXUYYZPJUGQHLQ-KRWDZBQOSA-N	10020651.0		ZXUYYZPJUGQHLQ
BRD-K84895041-001-04-9	BMY-45778	Preclinical	IP1 prostacyclin receptor agonist	PTGIR			0	97.74	Tocris	1442	BMY 45778	438.122	OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	DSRSEEYZGWTODH-UHFFFAOYSA-N	127861.0		DSRSEEYZGWTODH
BRD-K84895041-001-02-4	BMY-45778	Preclinical	IP1 prostacyclin receptor agonist	PTGIR			0	87.31	Tocris	1442	BMY 45778	438.122	OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	DSRSEEYZGWTODH-UHFFFAOYSA-N	127861.0		DSRSEEYZGWTODH
BRD-K31054881-300-07-9	BMY-7378	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HTR1A			0	96.27	Tocris	1006	BMY 7378 dihydrochloride	385.237	COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	AYYCFGDXLUPJAQ-UHFFFAOYSA-N	2419.0		AYYCFGDXLUPJAQ
BRD-K31054881-300-03-9	BMY-7378	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HTR1A			0	96.51	Selleck	S2691	BMY 7378	385.237	COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	AYYCFGDXLUPJAQ-UHFFFAOYSA-N	2419.0		AYYCFGDXLUPJAQ
BRD-K31054881-300-04-7	BMY-7378	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HTR1A			0	97.71	Tocris	1006	BMY 7378 dihydrochloride	385.237	COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	AYYCFGDXLUPJAQ-UHFFFAOYSA-N	2419.0		AYYCFGDXLUPJAQ
BRD-K20468903-001-01-6	BNC105	Phase 2	tubulin polymerization inhibitor				0	94.71	MedChemEx	HY-16114	BNC105	372.121	COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	RADMJHVVIZTENA-UHFFFAOYSA-N	24786555.0		RADMJHVVIZTENA
BRD-K20468903-001-02-4	BNC105	Phase 2	tubulin polymerization inhibitor				0	88.9	MedChemEx	HY-16114	BNC105	372.121	COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	RADMJHVVIZTENA-UHFFFAOYSA-N	24786555.0		RADMJHVVIZTENA
BRD-K18722736-050-02-9	BNTX	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0		Tocris	899	BNTX maleate	429.194	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)\C(C[C@@]35O)=C\c1ccccc1	WXOUFNFMPVMGFZ-BDQAUFNLSA-N	5310988.0		WXOUFNFMPVMGFZ
BRD-A09735281-001-03-3	boceprevir	Launched	HCV inhibitor	CMA1|CTSA|CTSF|CTSK|CTSL|CTSS	infectious disease	hepatitis C	0	66.55	MedChemEx	HY-10237	Boceprevir	519.342	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	10324368.0		LHHCSNFAOIFYRV
BRD-A09735281-001-04-1	boceprevir	Launched	HCV inhibitor	CMA1|CTSA|CTSF|CTSK|CTSL|CTSS	infectious disease	hepatitis C	0	37.79	MedChemEx	HY-10237	Boceprevir	519.342	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	10324368.0		LHHCSNFAOIFYRV
BRD-A09735281-001-02-5	boceprevir	Launched	HCV inhibitor	CMA1|CTSA|CTSF|CTSK|CTSL|CTSS	infectious disease	hepatitis C	0	82.09	MedChemEx	HY-10237	Boceprevir	519.342	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8,13,14,15,&1:19|	LHHCSNFAOIFYRV-ZYNAIFEFSA-N	10324368.0		LHHCSNFAOIFYRV
BRD-K34149328-001-01-3	bonaphthone	Phase 3					0	14.06	Vitas-M	STK028617		235.947	Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|	MXWZRRPNVLCHMY-UHFFFAOYSA-N	23384.0		MXWZRRPNVLCHMY
BRD-K34149328-001-02-1	bonaphthone	Phase 3					0	0.0	AMS	A000684624	6-bromo-1,2-naphthalenedione	235.947	Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|	MXWZRRPNVLCHMY-UHFFFAOYSA-N	23384.0		MXWZRRPNVLCHMY
BRD-K01825685-035-01-9	bopindolol	Launched	adrenergic receptor antagonist		cardiology	hypertension|coronary artery disease (CAD)	0	91.96	Enzo	AR100	Bopindolol  malonate	484.221	Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|	UUOJIACWOAYWEZ-GOSISDBHSA-N	13302097.0		UUOJIACWOAYWEZ
BRD-A41385909-001-02-1	bornyl-acetate	Preclinical					1	0.0	Vitas-M	STK079562	1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acetate	196.146	CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|	KGEKLUUHTZCSIP-JFGNBEQYSA-N	247573.0		KGEKLUUHTZCSIP
BRD-A41385909-001-01-3	bornyl-acetate	Preclinical					1	0.0	MicroSource	1502510	BORNYL ACETATE	196.146	CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4,&2:6,&3:9,r,TLB:3:4:7.8:11|	KGEKLUUHTZCSIP-JFGNBEQYSA-N	247573.0		KGEKLUUHTZCSIP
BRD-K50122911-001-01-2	boronophenylalanine	Phase 2					0	99.4	Sigma	MFCD01075172	(2S)-2-amino-3-[4-(dihydroxyboryl)phenyl]propanoic acid	209.086	N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O	NFIVJOSXJDORSP-QMMMGPOBSA-N	150315.0		NFIVJOSXJDORSP
BRD-K50122911-001-02-0	boronophenylalanine	Phase 2					0	0.0	Acros	35892		209.086	N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O	NFIVJOSXJDORSP-QMMMGPOBSA-N	150315.0	BRD-K70071822-001-01-5	NFIVJOSXJDORSP
BRD-K88510285-001-18-6	bortezomib	Launched	NFkB pathway inhibitor|proteasome inhibitor	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)	0	98.4	MedChemEx	HY-10227	Bortezomib	384.197	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	GXJABQQUPOEUTA-RDJZCZTQSA-N	387447.0		GXJABQQUPOEUTA
BRD-K88510285-001-17-8	bortezomib	Launched	NFkB pathway inhibitor|proteasome inhibitor	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)	0	97.65	Selleck	S1013	bortezomib	384.197	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	GXJABQQUPOEUTA-RDJZCZTQSA-N	387447.0		GXJABQQUPOEUTA
BRD-K88510285-001-25-1	bortezomib	Launched	NFkB pathway inhibitor|proteasome inhibitor	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)	0	0.0	Selleck	S1013	Bortezomib	384.197	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	GXJABQQUPOEUTA-RDJZCZTQSA-N	387447.0	BRD-K50691590-001-05-5	GXJABQQUPOEUTA
BRD-K88510285-001-22-8	bortezomib	Launched	NFkB pathway inhibitor|proteasome inhibitor	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)	0	97.62	Selleck	S1013	Bortezomib	384.197	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	GXJABQQUPOEUTA-RDJZCZTQSA-N	387447.0	BRD-K50691590-001-02-2	GXJABQQUPOEUTA
BRD-K88510285-001-11-1	bortezomib	Launched	NFkB pathway inhibitor|proteasome inhibitor	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)	0	96.55	Selleck	S1013	Bortezomib (PS-341)	384.197	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	GXJABQQUPOEUTA-RDJZCZTQSA-N	387447.0		GXJABQQUPOEUTA
BRD-K00003111-001-01-9	BOS-172722	Phase 1	monopolar spindle 1 kinase inhibitor				0	92.49	MedChemEx	HY-112162	BOS-172722	446.254	CCOc1cc(ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1)-c1nncn1C	SGWLRDAOCLITOM-UHFFFAOYSA-N	73386890.0		SGWLRDAOCLITOM
BRD-K74763371-002-04-0	bosentan	Launched	endothelin receptor antagonist	EDNRA|EDNRB	pulmonary	pulmonary arterial hypertension (PAH)	0	97.9	Selleck	S3051	Bosentan Hydrate	551.184	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	GJPICJJJRGTNOD-UHFFFAOYSA-N	104865.0		GJPICJJJRGTNOD
BRD-K99964838-001-15-9	bosutinib	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK	hematologic malignancy	chronic myeloid leukemia (CML)	0	96.43	Tocris	4361	Bosutinib	529.165	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	UBPYILGKFZZVDX-UHFFFAOYSA-N	5328940.0		UBPYILGKFZZVDX
BRD-K99964838-001-12-7	bosutinib	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK	hematologic malignancy	chronic myeloid leukemia (CML)	0	99.19	Tocris	4361	Bosutinib	529.165	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	UBPYILGKFZZVDX-UHFFFAOYSA-N	5328940.0		UBPYILGKFZZVDX
BRD-K99964838-001-11-9	bosutinib	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor	ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK	hematologic malignancy	chronic myeloid leukemia (CML)	0	96.44	Selleck	S1014	Bosutinib (SKI-606)	529.165	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	UBPYILGKFZZVDX-UHFFFAOYSA-N	5328940.0		UBPYILGKFZZVDX
BRD-K45479396-050-02-3	BP-554	Preclinical	serotonin receptor agonist	HTR1A			0	94.12	Tocris	556	BP 554 maleate	340.179	C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	VUSNBQDZGKZEDL-UHFFFAOYSA-N	134117.0		VUSNBQDZGKZEDL
BRD-K45479396-050-03-9	BP-554	Preclinical	serotonin receptor agonist	HTR1A			0	94.59	Tocris	556	BP 554 maleate	340.179	C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	VUSNBQDZGKZEDL-UHFFFAOYSA-N	134117.0		VUSNBQDZGKZEDL
BRD-K45479396-050-01-5	BP-554	Preclinical	serotonin receptor agonist	HTR1A			0	91.56	Tocris	556	BP 554 maleate	340.179	C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	VUSNBQDZGKZEDL-UHFFFAOYSA-N	134117.0		VUSNBQDZGKZEDL
BRD-K17378184-001-06-9	BP-897	Phase 2	dopamine receptor agonist	ADRA1A|ADRA1D|ADRA2A|DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2B			0	98.77	Sigma	B9308	BP897	417.242	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	MNHDKMDLOJSCGN-UHFFFAOYSA-N	3038495.0		MNHDKMDLOJSCGN
BRD-K17378184-300-05-9	BP-897	Phase 2	dopamine receptor agonist	ADRA1A|ADRA1D|ADRA2A|DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2B			0	91.72	Prestwick	Prestw-559	DO 897/99	417.242	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	MNHDKMDLOJSCGN-UHFFFAOYSA-N	3038495.0		MNHDKMDLOJSCGN
BRD-K00003554-001-01-9	BQ-123	Phase 2	endothelin receptor antagonist	EDNRA			0	83.68	MedChemEx	HY-12378	BQ-123	610.311	[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C	VYCMAAOURFJIHD-PJNXIOHISA-N	443289.0		VYCMAAOURFJIHD
BRD-K02490038-236-03-8	BQ-788	Phase 1	endothelin receptor antagonist	EDNRB			0	87.22	MedChemEx	HY-15894	BQ-788 (sodium salt)	641.379	CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O	LPAHKJMGDSJDRG-DJYQTOCQSA-N	5311032.0		LPAHKJMGDSJDRG
BRD-K02490038-236-01-2	BQ-788	Phase 1	endothelin receptor antagonist	EDNRB			0	66.89	MedChemEx	HY-15894	BQ-788 (sodium salt)	641.379	CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O	LPAHKJMGDSJDRG-DJYQTOCQSA-N	5311032.0		LPAHKJMGDSJDRG
BRD-A40257118-001-02-0	BQU57	Preclinical	Ras GTPase inhibitor	RALA|RALB			0	91.26	MedChemEx	HY-12875	BQU57	334.104	Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|	QFUFJOJDXRWBNA-YUZLPWPTSA-N			QFUFJOJDXRWBNA
BRD-A40257118-001-01-2	BQU57	Preclinical	Ras GTPase inhibitor	RALA|RALB			0	83.82	MedChemEx	HY-12875	BQU57	334.104	Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12,r|	QFUFJOJDXRWBNA-YUZLPWPTSA-N			QFUFJOJDXRWBNA
BRD-K72264770-001-03-2	BRD4770	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	99.57	MedChemEx	HY-16705	BRD4770	413.174	COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	UCGWYCMPZXDHNR-UHFFFAOYSA-N	72193870.0		UCGWYCMPZXDHNR
BRD-K72264770-001-04-0	BRD4770	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	98.01	MedChemEx	HY-16705	BRD4770	413.174	COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	UCGWYCMPZXDHNR-UHFFFAOYSA-N	72193870.0		UCGWYCMPZXDHNR
BRD-K15107389-001-03-6	BRD7389	Preclinical	ribosomal protein inhibitor	RPS6KA1|RPS6KA2|RPS6KA3			0	72.56	Tocris	4037	BRD 7389	366.137	O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23	XASCINRGTHLHGM-UHFFFAOYSA-N	1080352.0		XASCINRGTHLHGM
BRD-K15107389-001-02-8	BRD7389	Preclinical	ribosomal protein inhibitor	RPS6KA1|RPS6KA2|RPS6KA3			0		Aurora	kbsa-0113758		366.137	O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23	InChI=1S/C24H18N2O2/c27-23-17-10-5-4-9-16(17)21-20-18(23)11-6-12-19(20)26-24(28)22(21)25-14-13-15-7-2-1-3-8-15/h1-12,25H,13-14H2,(H,26,28)	1080352.0		XASCINRGTHLHGM
BRD-K89329876-001-07-8	BRD9876	Preclinical	kinesin inhibitor	KIF11			0	90.59	Tocris	5454	BRD 9876	234.116	CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N	MKILROQBJOOZKC-UHFFFAOYSA-N	613000.0		MKILROQBJOOZKC
BRD-K89329876-001-08-9	BRD9876	Preclinical	kinesin inhibitor	KIF11			0	90.38	Tocris	5454	BRD 9876	234.116	CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N	MKILROQBJOOZKC-UHFFFAOYSA-N	613000.0		MKILROQBJOOZKC
BRD-K77841042-001-15-8	brefeldin-A	Preclinical	protein synthesis inhibitor	ARF1|CYTH2			0	91.13	Tocris	1231	Brefeldin A	280.167	C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|	KQNZDYYTLMIZCT-KQPMLPITSA-N	5287620.0	BRD-A84228258-001-05-1	KQNZDYYTLMIZCT
BRD-K77841042-001-19-9	brefeldin-A	Preclinical	protein synthesis inhibitor	ARF1|CYTH2			0	87.84	Tocris	1231	Brefeldin A	280.167	C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|	KQNZDYYTLMIZCT-KQPMLPITSA-N	5287620.0		KQNZDYYTLMIZCT
BRD-K77841042-001-11-7	brefeldin-A	Preclinical	protein synthesis inhibitor	ARF1|CYTH2			0	95.76	Selleck	S7046	Brefeldin A	280.167	C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|	KQNZDYYTLMIZCT-KQPMLPITSA-N	5287620.0		KQNZDYYTLMIZCT
BRD-K77841042-001-14-1	brefeldin-A	Preclinical	protein synthesis inhibitor	ARF1|CYTH2			0	97.85	Tocris	1231	Brefeldin A	280.167	C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5,16|	KQNZDYYTLMIZCT-KQPMLPITSA-N	5287620.0	BRD-A84228258-001-04-4	KQNZDYYTLMIZCT
BRD-K06328344-015-01-7	bremelanotide	Launched	melanocortin receptor agonist	MC1R|MC2R|MC3R|MC4R|MC5R	neurology/psychiatry	hypoactive sexual desire disorder	0	91.49	MedChemEx	HY-18678A	Bremelanotide (Acetate)	1024.524	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O	FFHBJDQSGDNCIV-VEUPWBLKSA-N			FFHBJDQSGDNCIV
BRD-K96123349-236-02-8	brequinar	Phase 2	dihydroorotate dehydrogenase inhibitor	DHODH			0	98.43	EMDBio	508321-10MG	Dihydroorotate Dehydrogenase Inhibitor, Brequinar	375.107	Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	PHEZJEYUWHETKO-UHFFFAOYSA-N	57030.0		PHEZJEYUWHETKO
BRD-K96936751-001-02-2	bretazenil	Phase 2	GABA benzodiazepine site receptor partial agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6			0	98.49	Tocris	3568	Bretazenil	417.069	CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	107926.0		LWUDDYHYYNNIQI
BRD-K96936751-001-01-4	bretazenil	Phase 2	GABA benzodiazepine site receptor partial agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6			0	97.67	Tocris	3568	Bretazenil	417.069	CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	107926.0		LWUDDYHYYNNIQI
BRD-K96936751-001-03-9	bretazenil	Phase 2	GABA benzodiazepine site receptor partial agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6			0	97.81	Tocris	3568	Bretazenil	417.069	CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	LWUDDYHYYNNIQI-ZDUSSCGKSA-N	107926.0		LWUDDYHYYNNIQI
BRD-K49669424-075-19-2	bretylium	Launched	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT)	0	40.46	Sigma	MFCD00038731	N-(2-bromobenzyl)-N,N-dimethylethanaminium 4-methylbenzenesulfonate	242.054	CC[N+](C)(C)Cc1ccccc1Br	AAQOQKQBGPPFNS-UHFFFAOYSA-N	2431.0		AAQOQKQBGPPFNS
BRD-K49669424-001-01-6	bretylium	Launched	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT)	0	49.99	MicroSource	1502018	BRETYLIUM TOSYLATE	242.054	CC[N+](C)(C)Cc1ccccc1Br	AAQOQKQBGPPFNS-UHFFFAOYSA-N	2431.0		AAQOQKQBGPPFNS
BRD-K49669424-075-20-9	bretylium	Launched	norepinephrine inhibitor	ATP1A1	cardiology	ventricular arrhythmias|ventricular fibrillation (VF)|ventricular tachycardia (VT)	0	47.82	MedChemEx	HY-12961A	Bretylium (tosylate)	242.054	CC[N+](C)(C)Cc1ccccc1Br	AAQOQKQBGPPFNS-UHFFFAOYSA-N	2431.0		AAQOQKQBGPPFNS
BRD-K00911143-001-01-9	brexpiprazole	Launched	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression|schizophrenia	0	94.37	MedChemEx	HY-15780	Brexpiprazole	433.182	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	ZKIAIYBUSXZPLP-UHFFFAOYSA-N	11978813.0		ZKIAIYBUSXZPLP
BRD-K00911143-001-02-9	brexpiprazole	Launched	dopamine receptor partial agonist	DRD2	neurology/psychiatry	depression|schizophrenia	0	95.38	MedChemEx	HY-15780	Brexpiprazole	433.182	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	ZKIAIYBUSXZPLP-UHFFFAOYSA-N	11978813.0		ZKIAIYBUSXZPLP
BRD-K05531427-001-01-7	briciclib	Phase 1	cyclin D inhibitor	CCND1			0	94.31	MedChemEx	HY-16366	Briciclib	474.075	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1	LXENKEWVEVKKGV-BQYQJAHWSA-N	11248490.0		LXENKEWVEVKKGV
BRD-K56981171-001-01-0	brigatinib	Launched	ALK tyrosine kinase receptor inhibitor|EGFR inhibitor	ALK|EGFR	oncology	non-small cell lung cancer (NSCLC)	0	93.49	MedChemEx	HY-12857	Brigatinib	583.259	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	AILRADAXUVEEIR-UHFFFAOYSA-N	68165256.0		AILRADAXUVEEIR
BRD-K56981171-001-02-8	brigatinib	Launched	ALK tyrosine kinase receptor inhibitor|EGFR inhibitor	ALK|EGFR	oncology	non-small cell lung cancer (NSCLC)	0	84.87	MedChemEx	HY-12857	Brigatinib	583.259	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	AILRADAXUVEEIR-UHFFFAOYSA-N	68165256.0		AILRADAXUVEEIR
BRD-K60348325-065-09-9	brilliant-green	Launched			infectious disease	antiseptic	0	91.76	Acros	22960	Brilliant Green, pure, high purity biological stain	385.264	CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC	HXCILVUBKWANLN-UHFFFAOYSA-N	12450.0		HXCILVUBKWANLN
BRD-K68264559-001-14-2	brimonidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	89.9	Tocris	425	UK 14,304	291.012	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	XYLJNLCSTIOKRM-UHFFFAOYSA-N	2435.0		XYLJNLCSTIOKRM
BRD-K68264559-045-02-4	brimonidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	98.24	Tocris	2466	UK 14,304 tartrate	291.012	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	XYLJNLCSTIOKRM-UHFFFAOYSA-N	2435.0		XYLJNLCSTIOKRM
BRD-K68264559-001-13-4	brimonidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	93.1	Tocris	425	UK 14,304	291.012	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	XYLJNLCSTIOKRM-UHFFFAOYSA-N	2435.0		XYLJNLCSTIOKRM
BRD-K68264559-045-03-2	brimonidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	87.81	Selleck	S4266	Brimonidine Tartrate	291.012	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	XYLJNLCSTIOKRM-UHFFFAOYSA-N	2435.0	BRD-M06829359-001-01-4	XYLJNLCSTIOKRM
BRD-K68264559-045-04-0	brimonidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	99.0	Selleck	S4266	Brimonidine Tartrate	291.012	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	XYLJNLCSTIOKRM-UHFFFAOYSA-N	2435.0	BRD-M06829359-001-02-2	XYLJNLCSTIOKRM
BRD-K00004672-001-01-9	brincidofovir	Phase 3	antiviral				0	10.93	Adooq	A13326	CMX001, Cidofovir-HDP, hexadecyloxypropyl-cidofovir	561.354	CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)Cn1ccc(N)nc1=O	WXJFKKQWPMNTIM-VWLOTQADSA-N	483477.0		WXJFKKQWPMNTIM
BRD-K74913225-001-14-0	brinzolamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA14|CA2|CA4|CA5A|CA7	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	1.74	MicroSource	1502418	BRINZOLAMIDE	383.064	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	HCRKCZRJWPKOAR-JTQLQIEISA-N	68844.0	BRD-A82599487-001-01-9	HCRKCZRJWPKOAR
BRD-K74913225-001-16-9	brinzolamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA14|CA2|CA4|CA5A|CA7	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	80.37	MedChemEx	HY-B0588	Brinzolamide	383.064	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	HCRKCZRJWPKOAR-JTQLQIEISA-N	68844.0		HCRKCZRJWPKOAR
BRD-K74913225-001-12-4	brinzolamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA14|CA2|CA4|CA5A|CA7	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	88.26	Selleck	S3178	Brinzolamide	383.064	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	HCRKCZRJWPKOAR-JTQLQIEISA-N	68844.0		HCRKCZRJWPKOAR
BRD-K74913225-001-13-2	brinzolamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA14|CA2|CA4|CA5A|CA7	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	99.04	Selleck	S3178	Brinzolamide	383.064	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	HCRKCZRJWPKOAR-JTQLQIEISA-N	68844.0		HCRKCZRJWPKOAR
BRD-K28428262-001-04-1	brivanib	Phase 3	FGFR inhibitor|VEGFR inhibitor	CYP3A4|FGFR1|FLT1|KCNH2|KDR			0	97.4	Selleck	S1084	Brivanib (BMS-540215)	370.144	C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	WCWUXEGQKLTGDX-LLVKDONJSA-N	11234052.0		WCWUXEGQKLTGDX
BRD-K57187269-001-04-0	brivanib-alaninate	Phase 3	FGFR inhibitor|VEGFR inhibitor	FGFR3			0	71.96	MedChemEx	HY-10336	Brivanib (alaninate)	441.181	C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	LTEJRLHKIYCEOX-OCCSQVGLSA-N	11154925.0		LTEJRLHKIYCEOX
BRD-K57187269-001-03-2	brivanib-alaninate	Phase 3	FGFR inhibitor|VEGFR inhibitor	FGFR3			0	46.1	Selleck	S1138	Brivanib alaninate (BMS-582664)	441.181	C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	LTEJRLHKIYCEOX-OCCSQVGLSA-N	11154925.0		LTEJRLHKIYCEOX
BRD-K57187269-001-02-4	brivanib-alaninate	Phase 3	FGFR inhibitor|VEGFR inhibitor	FGFR3			0	73.46	Selleck	S1138	Brivanib Alaninate (BMS-582664)	441.181	C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	LTEJRLHKIYCEOX-OCCSQVGLSA-N	11154925.0		LTEJRLHKIYCEOX
BRD-A63675168-001-01-6	brivudine	Launched	DNA directed DNA polymerase inhibitor		infectious disease	shingles	0	95.52	TCI	B3404		332.001	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(\C=C\Br)c(=O)[nH]c1=O |a:2,4,&1:6|	ODZBBRURCPAEIQ-PIXDULNESA-N	446727.0		ODZBBRURCPAEIQ
BRD-K01826777-003-08-9	BRL-15572	Preclinical	serotonin receptor antagonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6			0	96.91	Tocris	1207	BRL 15572 hydrochloride	406.181	O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|	QJHCTHPYUOXOGM-DEOSSOPVSA-N	92844253.0		QJHCTHPYUOXOGM
BRD-K01826777-003-07-9	BRL-15572	Preclinical	serotonin receptor antagonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6			0	98.84	Tocris	1207	BRL 15572 hydrochloride	442.158	O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|	QJHCTHPYUOXOGM-DEOSSOPVSA-N	92844253.0		QJHCTHPYUOXOGM
BRD-A57806482-001-01-4	BRL-26314	Phase 1	cholesterol inhibitor	LPL			0	97.68	Sigma	PH000560	N-(4-chlorobenzyl)phenylalanine	289.087	OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3,r|	SAOHCSVJQIAGDD-OAHLLOKOSA-N	14259155.0		SAOHCSVJQIAGDD
BRD-K07507905-236-03-4	BRL-37344	Phase 2	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	92.21	Tocris	948	sodium [4-((2R)-2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}propyl)phenoxy]acetate	363.124	C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	ZGGNJJJYUVRADP-ACJLOTCBSA-N	9841972.0		ZGGNJJJYUVRADP
BRD-K07507905-236-02-6	BRL-37344	Phase 2	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	85.01	Tocris	948	BRL 37344, sodium salt	363.124	C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	ZGGNJJJYUVRADP-ACJLOTCBSA-N	9841972.0		ZGGNJJJYUVRADP
BRD-K01825677-050-02-9	BRL-44408	Preclinical	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C			0	95.6	Tocris	1133	BRL 44408 maleate	215.142	C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|	SGOFAUSEYBZKDQ-SNVBAGLBSA-N	6604824.0		SGOFAUSEYBZKDQ
BRD-K01825677-050-01-9	BRL-44408	Preclinical	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C			0	12.04	Tocris	1133	BRL 44408 maleate	331.153	C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1,t:4|	SGOFAUSEYBZKDQ-SNVBAGLBSA-N	6604824.0		SGOFAUSEYBZKDQ
BRD-K84266862-001-04-0	BRL-50481	Preclinical	phosphodiesterase inhibitor	PDE7A|PDE7B			0	93.95	Tocris	2237	BRL 50481	244.052	CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	IFIUFCJFLGCQPH-UHFFFAOYSA-N	2921148.0		IFIUFCJFLGCQPH
BRD-K84266862-001-03-2	BRL-50481	Preclinical	phosphodiesterase inhibitor	PDE7A|PDE7B			0	98.33	Tocris	2237	BRL 50481	244.052	CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	IFIUFCJFLGCQPH-UHFFFAOYSA-N	2921148.0		IFIUFCJFLGCQPH
BRD-K84266862-001-06-9	BRL-50481	Preclinical	phosphodiesterase inhibitor	PDE7A|PDE7B			0	91.69	Tocris	2237	BRL 50481	244.052	CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	IFIUFCJFLGCQPH-UHFFFAOYSA-N	2921148.0		IFIUFCJFLGCQPH
BRD-A37347161-003-03-9	BRL-52537	Preclinical	opioid receptor agonist	OPRK1			0	94.1	Tocris	699	BRL 52537 hydrochloride	354.127	Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|	GHCCBWMZKJQGLS-OAHLLOKOSA-N	14810948.0		GHCCBWMZKJQGLS
BRD-A37347161-003-02-6	BRL-52537	Preclinical	opioid receptor agonist	OPRK1			0	95.52	Tocris	699	BRL 52537 hydrochloride	354.127	Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|	GHCCBWMZKJQGLS-OAHLLOKOSA-N	14810948.0		GHCCBWMZKJQGLS
BRD-K17868609-001-04-3	BRL-54443	Preclinical	serotonin receptor agonist	HTR1E|HTR1F			0	95.72	Selleck	S2852	BRL-54443	230.142	CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	WKNFADCGOAHBPG-UHFFFAOYSA-N	2438.0		WKNFADCGOAHBPG
BRD-K17868609-001-06-9	BRL-54443	Preclinical	serotonin receptor agonist	HTR1E|HTR1F			0	96.31	Tocris	1129	BRL 54443	230.142	CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	WKNFADCGOAHBPG-UHFFFAOYSA-N	2438.0		WKNFADCGOAHBPG
BRD-K17868609-001-05-0	BRL-54443	Preclinical	serotonin receptor agonist	HTR1E|HTR1F			0	96.5	Tocris	1129	BRL 54443	230.142	CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	WKNFADCGOAHBPG-UHFFFAOYSA-N	2438.0		WKNFADCGOAHBPG
BRD-K76021681-001-02-2	brolitene	Launched	muscle relaxant	RYR1	rheumatology	lumbago	0	0.0	Vitas-M	STK429148	(2E)-N-(2-hydroxyethyl)-3-phenyl-2-propenamide	191.095	OCCNC(=O)\C=C\c1ccccc1	OSCTXCOERRNGLW-VOTSOKGWSA-N	1550874.0		OSCTXCOERRNGLW
BRD-K76021681-001-01-4	brolitene	Launched	muscle relaxant	RYR1	rheumatology	lumbago	0	0.0	ChemBridge	5334325		191.095	OCCNC(=O)\C=C\c1ccccc1	OSCTXCOERRNGLW-VOTSOKGWSA-N	1550874.0		OSCTXCOERRNGLW
BRD-K86358349-001-02-0	bromantan	Launched	dopamine reuptake inhibitor|serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	0	86.43	Enamine	Z1736662073	(1R,3S,5r,7r)-N-(4-bromophenyl)adamantan-2-amine	305.078	Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	LWJALJDRFBXHKX-UHFFFAOYSA-N	4660557.0		LWJALJDRFBXHKX
BRD-K86358349-001-01-2	bromantan	Launched	dopamine reuptake inhibitor|serotonin reuptake inhibitor		neurology/psychiatry	neurasthenia	0	0.0	Enamine	Z440843598		305.078	Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	LWJALJDRFBXHKX-UHFFFAOYSA-N	4660557.0		LWJALJDRFBXHKX
BRD-K17874929-236-02-0	bromebric-acid	Preclinical	DNA synthesis inhibitor|purine antagonist				0	91.08	Sigma	MFCD00795053	sodium (2Z)-3-bromo-4-(4-methoxyphenyl)-4-oxo-2-butenoate	283.968	COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O	UPZFHUODAYGHDZ-TWGQIWQCSA-N	5284375.0		UPZFHUODAYGHDZ
BRD-K47679368-236-01-7	bromfenac	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	96.65	Selleck	S4248	Bromfenac Sodium	333	Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1	ZBPLOVFIXSTCRZ-UHFFFAOYSA-N	60726.0		ZBPLOVFIXSTCRZ
BRD-K47631482-003-08-9	bromhexine	Launched	mucolytic agent		pulmonary	chest congestion	0	99.28	MedChemEx	HY-B0372A	Bromhexine (hydrochloride)	373.999	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	OJGDCBLYJGHCIH-UHFFFAOYSA-N	2442.0		OJGDCBLYJGHCIH
BRD-K47631482-003-07-0	bromhexine	Launched	mucolytic agent		pulmonary	chest congestion	0	0.56	MicroSource	1503107	BROMHEXINE HYDROCHLORIDE	373.999	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	OJGDCBLYJGHCIH-UHFFFAOYSA-N	2442.0		OJGDCBLYJGHCIH
BRD-K47631482-003-06-2	bromhexine	Launched	mucolytic agent		pulmonary	chest congestion	0	98.44	Selleck	S2060	Bromhexine HCl	373.999	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	OJGDCBLYJGHCIH-UHFFFAOYSA-N	2442.0		OJGDCBLYJGHCIH
BRD-K50490982-001-08-2	bromindione	Phase 2	anticoagulant				0	0.0	MicroSource	1505414	BROMINDIONE	299.979	Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NPUZIGSOEWMFKK-UHFFFAOYSA-N	14369.0		NPUZIGSOEWMFKK
BRD-K50490982-001-09-9	bromindione	Phase 2	anticoagulant				0	93.64	Sigma	MFCD00087378	2-(4-BROMOPHENYL)-1,3-INDANDIONE	299.979	Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NPUZIGSOEWMFKK-UHFFFAOYSA-N	14369.0		NPUZIGSOEWMFKK
BRD-K00003522-001-01-9	bromisoval	Preclinical	anti-inflammatory agent				0	89.47	MedChemEx	HY-B2113	Bromisoval	222	CC(C)[C@@H](Br)C(=O)NC(N)=O |&1:3,r|	CMCCHHWTTBEZNM-SCSAIBSYSA-N	146955.0		CMCCHHWTTBEZNM
BRD-K14496212-066-03-0	bromocriptine	Launched	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly	0	0.81	Tocris	427	Bromocriptine mesylate	653.221	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|	OZVBMTJYIDMWIL-AYFBDAFISA-N	31101.0		OZVBMTJYIDMWIL
BRD-K14496212-066-04-8	bromocriptine	Launched	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly	0	93.48	MicroSource	1500151	BROMOCRIPTINE MESYLATE	653.221	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|	OZVBMTJYIDMWIL-AYFBDAFISA-N	31101.0	BRD-A80151636-066-04-8	OZVBMTJYIDMWIL
BRD-K14496212-066-05-9	bromocriptine	Launched	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly	0	94.85	Tocris	427	Bromocriptine mesylate	653.221	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|	OZVBMTJYIDMWIL-AYFBDAFISA-N	31101.0		OZVBMTJYIDMWIL
BRD-K14496212-066-02-2	bromocriptine	Launched	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7	endocrinology|neurology/psychiatry	hyperprolactinemia|Parkinson's Disease|acromegaly	0	82.65	Tocris	427	Bromocriptine mesylate	653.221	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|	OZVBMTJYIDMWIL-AYFBDAFISA-N	31101.0		OZVBMTJYIDMWIL
BRD-K73642618-001-13-3	bromopride	Launched	dopamine receptor antagonist	DRD2	gastroenterology	nausea|vomiting|gastroesophageal reflux disease (GERD)	0	96.6	MicroSource	1503108	BROMOPRIDE	343.09	CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC	GIYAQDDTCWHPPL-UHFFFAOYSA-N	2446.0		GIYAQDDTCWHPPL
BRD-K73642618-001-14-9	bromopride	Launched	dopamine receptor antagonist	DRD2	gastroenterology	nausea|vomiting|gastroesophageal reflux disease (GERD)	0	97.86	Key	HS-0004	4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide	343.09	CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC	GIYAQDDTCWHPPL-UHFFFAOYSA-N	2446.0		GIYAQDDTCWHPPL
BRD-K44665581-001-03-9	bromosporine	Preclinical	bromodomain inhibitor				0	96.1	Tocris	4758	Bromosporine	404.127	CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	UYBRROMMFMPJAN-UHFFFAOYSA-N	72943187.0		UYBRROMMFMPJAN
BRD-K44665581-001-02-6	bromosporine	Preclinical	bromodomain inhibitor				0	95.34	Tocris	4758	Bromosporine	404.127	CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	UYBRROMMFMPJAN-UHFFFAOYSA-N	72943187.0		UYBRROMMFMPJAN
BRD-K44665581-001-01-8	bromosporine	Preclinical	bromodomain inhibitor				0	98.35	Selleck	S7233	Bromosporine	404.127	CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	UYBRROMMFMPJAN-UHFFFAOYSA-N	72943187.0		UYBRROMMFMPJAN
BRD-K78643075-001-11-6	bromperidol	Launched	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	0	98.85	MicroSource	1505972	BROMPERIDOL	419.09	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1	RKLNONIVDFXQRX-UHFFFAOYSA-N	2448.0		RKLNONIVDFXQRX
BRD-K78643075-001-12-9	bromperidol	Launched	dopamine receptor antagonist	DRD2	neurology/psychiatry	schizophrenia	0	92.33	MedChemEx	HY-B0901	Bromperidol	419.09	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1	RKLNONIVDFXQRX-UHFFFAOYSA-N	2448.0		RKLNONIVDFXQRX
BRD-K01825159-050-02-9	brompheniramine	Launched	histamine receptor antagonist	HRH1	allergy|otolaryngology	allergic rhinitis|common cold	0	85.77	MedChemEx	HY-B0480	Brompheniramine (maleate)	318.073	CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|	ZDIGNSYAACHWNL-HNNXBMFYSA-N	16960.0		ZDIGNSYAACHWNL
BRD-K33457401-001-02-9	bronopol	Launched			obstetrics/gynecology	mastitis	1	90.31	MedChemEx	HY-B1217	Bronopol	198.948	OCC(Br)(CO)[N+]([O-])=O	LVDKZNITIUWNER-UHFFFAOYSA-N	2450.0		LVDKZNITIUWNER
BRD-K33457401-001-01-1	bronopol	Launched			obstetrics/gynecology	mastitis	1	0.0	MicroSource	1503732	BRONOPOL	198.948	OCC(Br)(CO)[N+]([O-])=O	LVDKZNITIUWNER-UHFFFAOYSA-N	2450.0		LVDKZNITIUWNER
BRD-K17500877-001-04-9	bropirimine	Phase 3	interferon inducer				0	97.48	Sigma	MFCD01689128	Bropirimine	264.985	Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1	CIUUIPMOFZIWIZ-UHFFFAOYSA-N	135413497.0		CIUUIPMOFZIWIZ
BRD-K17500877-001-02-1	bropirimine	Phase 3	interferon inducer				0	99.22	LifeChem	F2158-0617		264.985	Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1	CIUUIPMOFZIWIZ-UHFFFAOYSA-N	135413497.0		CIUUIPMOFZIWIZ
BRD-K17500877-001-03-9	bropirimine	Phase 3	interferon inducer				0	96.14	Sigma	SML0218-10MG	Bropirimine	264.985	Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1	CIUUIPMOFZIWIZ-UHFFFAOYSA-N	135413497.0		CIUUIPMOFZIWIZ
BRD-K36222532-001-02-9	broxaldine	Preclinical					0	98.61	MedChemEx	HY-B1143	Broxaldine	418.916	Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	IJTPLVAAROHGGB-UHFFFAOYSA-N	77262.0		IJTPLVAAROHGGB
BRD-K36222532-001-01-8	broxaldine	Preclinical					0	96.22	MicroSource	1503742	BROXALDINE	418.916	Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	IJTPLVAAROHGGB-UHFFFAOYSA-N	77262.0		IJTPLVAAROHGGB
BRD-A08316590-001-01-3	broxaterol	Phase 3	adrenergic receptor agonist	ADRB2			0	98.05	Enamine	Z2417826612	1-(3-bromo-5-isoxazolyl)-2-(tert-butylamino)ethanol	262.032	CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6,r|	JBRBWHCVRGURBA-ZCFIWIBFSA-N	13626987.0		JBRBWHCVRGURBA
BRD-K79095980-001-11-9	broxuridine	Phase 2	antimetabolite				0	0.0	Tocris	5015	5-BrdU	305.985	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O	WOVKYSAHUYNSMH-RRKCRQDMSA-N	6035.0		WOVKYSAHUYNSMH
BRD-K79095980-001-09-6	broxuridine	Phase 2	antimetabolite				0	94.39	MedChemEx	HY-15910	5-BrdU	305.985	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O	WOVKYSAHUYNSMH-RRKCRQDMSA-N	6035.0		WOVKYSAHUYNSMH
BRD-K23301018-001-12-9	broxyquinoline	Phase 1	antiprotozoal agent				0	97.98	MedChemEx	HY-B1212	Broxyquinoline	300.874	Oc1c(Br)cc(Br)c2cccnc12	ZDASUJMDVPTNTF-UHFFFAOYSA-N	2453.0		ZDASUJMDVPTNTF
BRD-K23301018-001-10-9	broxyquinoline	Phase 1	antiprotozoal agent				0	48.21	MicroSource	1500623	BROXYQUINOLINE	300.874	Oc1c(Br)cc(Br)c2cccnc12	ZDASUJMDVPTNTF-UHFFFAOYSA-N	2453.0		ZDASUJMDVPTNTF
BRD-K23301018-001-09-1	broxyquinoline	Phase 1	antiprotozoal agent				0	4.23	Selleck	S4195	Broxyquinoline	300.874	Oc1c(Br)cc(Br)c2cccnc12	ZDASUJMDVPTNTF-UHFFFAOYSA-N	2453.0		ZDASUJMDVPTNTF
BRD-K23301018-001-11-7	broxyquinoline	Phase 1	antiprotozoal agent				0	99.49	Selleck	S4195	Broxyquinoline	300.874	Oc1c(Br)cc(Br)c2cccnc12	ZDASUJMDVPTNTF-UHFFFAOYSA-N	2453.0		ZDASUJMDVPTNTF
BRD-A36057565-001-01-0	bruceantin	Phase 2	protein synthesis inhibitor				0	87.66	MedChemEx	HY-N0840	Bruceantin	548.226	COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|	KMCZIPGKKBSLEX-AOHBHZTBSA-N	124605168.0		KMCZIPGKKBSLEX
BRD-A36057565-001-02-9	bruceantin	Phase 2	protein synthesis inhibitor				0	94.27	MedChemEx	HY-N0840	Bruceantin	548.226	COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4,7,8,9,22,24,32,34,35,37,&1:25|	KMCZIPGKKBSLEX-AOHBHZTBSA-N	124605168.0		KMCZIPGKKBSLEX
BRD-K68077509-330-01-9	brucine	Preclinical	glycine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5			0	97.56	Selleck	S4390	BRUCINE	394.189	COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|	RRKTZKIUPZVBMF-IBTVXLQLSA-N	442021.0		RRKTZKIUPZVBMF
BRD-K31313613-300-06-9	BS-181	Preclinical	CDK inhibitor	CDK7			0	95.62	Tocris	5608	BS 181 dihydrochloride	380.269	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	DNYBIOICMDTDAP-UHFFFAOYSA-N	49867929.0		DNYBIOICMDTDAP
BRD-K31313613-300-01-8	BS-181	Preclinical	CDK inhibitor	CDK7			0	96.53	Tocris	5608	BS 181 dihydrochloride	380.269	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	DNYBIOICMDTDAP-UHFFFAOYSA-N	49867929.0		DNYBIOICMDTDAP
BRD-K31313613-003-05-9	BS-181	Preclinical	CDK inhibitor	CDK7			0	95.69	Selleck	S1572	BS-181 HCl	380.269	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	DNYBIOICMDTDAP-UHFFFAOYSA-N	49867929.0		DNYBIOICMDTDAP
BRD-K31313613-003-04-2	BS-181	Preclinical	CDK inhibitor	CDK7			0	91.47	Selleck	S1572	BS-181 HCl	380.269	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	DNYBIOICMDTDAP-UHFFFAOYSA-N	49867929.0		DNYBIOICMDTDAP
BRD-K00003444-001-01-9	BT-11	Phase 2	cAMP stimulant				0	92.84	MedChemEx	HY-102013	BT-11	528.202	O=C(N1CCN(CC1)C(=O)c1cccc(n1)-c1nc2ccccc2[nH]1)c1cccc(n1)-c1nc2ccccc2[nH]1	MVHWZNBAQIGPOQ-UHFFFAOYSA-N	121299620.0		MVHWZNBAQIGPOQ
BRD-K37933329-001-01-6	BTB06584	Preclinical	ATPase inhibitor	ATP5F1			0	0.0	Selleck	S7460	BTB06584	417.007	[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1	WNDWKKPBLAKXMI-UHFFFAOYSA-N	2799764.0		WNDWKKPBLAKXMI
BRD-K37933329-001-02-4	BTB06584	Preclinical	ATPase inhibitor	ATP5F1			0	0.0	Selleck	S7460	BTB06584	417.007	[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1	WNDWKKPBLAKXMI-UHFFFAOYSA-N	2799764.0		WNDWKKPBLAKXMI
BRD-K37933329-001-03-9	BTB06584	Preclinical	ATPase inhibitor	ATP5F1			0	82.92	MedChemEx	HY-15877	BTB06584	417.007	[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1	WNDWKKPBLAKXMI-UHFFFAOYSA-N	2799764.0		WNDWKKPBLAKXMI
BRD-K89000287-001-01-1	BTB1	Preclinical	mitotic kinesin inhibitor	KIF18A			0	95.56	Tocris	5399	BTB1	296.986	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1	VZDUQPHKUBZMLW-UHFFFAOYSA-N	291461.0		VZDUQPHKUBZMLW
BRD-K89000287-001-02-9	BTB1	Preclinical	mitotic kinesin inhibitor	KIF18A			0	95.75	Tocris	5399	BTB1	296.986	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1	VZDUQPHKUBZMLW-UHFFFAOYSA-N	291461.0		VZDUQPHKUBZMLW
BRD-K00003437-001-01-9	BTK-IN-1	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor				0	93.86	MedChemEx	HY-101941	BTK IN-1	384.147	Clc1cccc(NCC(=O)N[C@@H]2CCCN(C2)c2ncnc3[nH]ccc23)c1 |&1:11,r|	SPSNKQVUYDXOGY-OAHLLOKOSA-N	68064155.0		SPSNKQVUYDXOGY
BRD-K64178227-001-10-8	BTS	Preclinical					0	97.51	Tocris	1870	BTS	261.082	Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	WTHKAJZQYNKTCJ-UHFFFAOYSA-N	95801.0		WTHKAJZQYNKTCJ
BRD-K64178227-001-11-9	BTS	Preclinical					0	89.68	Tocris	1870	BTS	261.082	Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	WTHKAJZQYNKTCJ-UHFFFAOYSA-N	95801.0		WTHKAJZQYNKTCJ
BRD-K64178227-001-09-0	BTS	Preclinical					0	98.75	Tocris	1870	BTS	261.082	Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	WTHKAJZQYNKTCJ-UHFFFAOYSA-N	95801.0		WTHKAJZQYNKTCJ
BRD-A68304895-003-03-0	BTS-54505	Withdrawn	dopamine reuptake inhibitor	SLC6A2|SLC6A3|SLC6A4			0	89.3	Tocris	2322	BTS 54-505 hydrochloride	251.144	CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|	WQSACWZKKZPCHN-CQSZACIVSA-N	9900576.0		WQSACWZKKZPCHN
BRD-A68304895-003-02-2	BTS-54505	Withdrawn	dopamine reuptake inhibitor	SLC6A2|SLC6A3|SLC6A4			0	94.8	Tocris	2322	BTS 54-505 hydrochloride	251.144	CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|	WQSACWZKKZPCHN-CQSZACIVSA-N	9900576.0		WQSACWZKKZPCHN
BRD-A68304895-003-04-9	BTS-54505	Withdrawn	dopamine reuptake inhibitor	SLC6A2|SLC6A3|SLC6A4			0	93.38	Tocris	2322	BTS 54-505 hydrochloride	251.144	CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|	WQSACWZKKZPCHN-CQSZACIVSA-N	9900576.0		WQSACWZKKZPCHN
BRD-K00010938-001-01-9	BTS-71321	Phase 2					0	92.03	Enamine	Z1592576455	BTS-71321	277.135	CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1	GRKYRJREJPZXIU-UHFFFAOYSA-N	9863253.0		GRKYRJREJPZXIU
BRD-A65793993-001-01-6	BTS-72664	Phase 1	GABA receptor antagonist	GABBR1			0	98.2	Key	1D-092	7-[1-(4-chlorophenoxy)ethyl][1,2,4]triazolo[1,5-a]pyrimidine	274.062	C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1,r|	FCEPUTGEUCVRRI-SECBINFHSA-N	1480409.0		FCEPUTGEUCVRRI
BRD-K01492390-001-02-9	BTT-3033	Preclinical	integrin inhibitor	ITGA2|ITGB1			0	96.86	Tocris	4724	BTT 3033	465.127	CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1	NSLIQOPYDUKWTA-UHFFFAOYSA-N	49841251.0		NSLIQOPYDUKWTA
BRD-K01492390-001-01-9	BTT-3033	Preclinical	integrin inhibitor	ITGA2|ITGB1			0	98.48	Tocris	4724	BTT 3033	465.127	CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1	NSLIQOPYDUKWTA-UHFFFAOYSA-N	49841251.0		NSLIQOPYDUKWTA
BRD-A53037217-001-04-9	BTZ043-racemate	Phase 1/Phase 2	DPRE1 inhibitor				0	94.6	MedChemEx	HY-13579A	BTZ043 Racemate	431.076	C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|	GTUIRORNXIOHQR-VIFPVBQESA-N	42609849.0		GTUIRORNXIOHQR
BRD-A53037217-001-02-0	BTZ043-racemate	Phase 1/Phase 2	DPRE1 inhibitor				0	98.56	Selleck	S1097	BTZ043 Racemate	431.076	C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1,r|	GTUIRORNXIOHQR-VIFPVBQESA-N	42609849.0		GTUIRORNXIOHQR
BRD-K55344148-003-02-6	BU-224	Preclinical	imidazoline receptor ligand	MAOA|MAOB			0	98.23	Tocris	725	BU 224 hydrochloride	197.095	C1CN=C(N1)c1ccc2ccccc2n1 |c:2|	OSUVWJGCKQEMHK-UHFFFAOYSA-N	2457.0		OSUVWJGCKQEMHK
BRD-K11696279-003-02-3	BU-239	Preclinical	imidazoline receptor agonist|imidazoline receptor ligand				0	95.93	Tocris	726	BU 239 hydrochloride	198.091	C1CN=C(N1)c1cnc2ccccc2n1 |c:2|	MQSSFHXQKUSFIW-UHFFFAOYSA-N	4520732.0		MQSSFHXQKUSFIW
BRD-K11696279-003-03-1	BU-239	Preclinical	imidazoline receptor agonist|imidazoline receptor ligand				0	97.33	Tocris	726	BU 239 hydrochloride	198.091	C1CN=C(N1)c1cnc2ccccc2n1 |c:2|	InChI=1S/C11H10N4/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,7H,5-6H2,(H,12,13)	4520732.0		MQSSFHXQKUSFIW
BRD-A88684804-001-04-3	bucetin	Withdrawn	analgesic agent				0	98.09	MicroSource	1505772	BUCETIN	223.121	CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|	LIAWQASKBFCRNR-SECBINFHSA-N	6918884.0		LIAWQASKBFCRNR
BRD-A88684804-001-05-9	bucetin	Withdrawn	analgesic agent				0	92.15	MedChemEx	HY-B0906	Bucetin	223.121	CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11,r|	LIAWQASKBFCRNR-SECBINFHSA-N	6918884.0		LIAWQASKBFCRNR
BRD-K24697665-001-02-2	bucillamine	Launched	immunosuppressant		rheumatology	rheumatoid arthritis	1	96.91	Kemprotec	TC508	(2R)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid	223.034	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	VUAFHZCUKUDDBC-BYPYZUCNSA-N	656604.0		VUAFHZCUKUDDBC
BRD-K24697665-001-01-4	bucillamine	Launched	immunosuppressant		rheumatology	rheumatoid arthritis	1	0.0	AKSci	K055		223.034	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	VUAFHZCUKUDDBC-BYPYZUCNSA-N	656604.0		VUAFHZCUKUDDBC
BRD-A94624445-236-18-8	bucladesine	Launched	adenosine receptor agonist|cAMP stimulant	PRKACA	dermatology	skin ulcer	0	85.03	Tocris	1141	Dibutyryl-cAMP, sodium salt	469.136	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|	CJGYSWNGNKCJSB-YVLZZHOMSA-N	9687.0		CJGYSWNGNKCJSB
BRD-A94624445-236-19-9	bucladesine	Launched	adenosine receptor agonist|cAMP stimulant	PRKACA	dermatology	skin ulcer	0	95.32	Tocris	1141	Dibutyryl-cAMP, sodium salt	469.136	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|	CJGYSWNGNKCJSB-YVLZZHOMSA-N	9687.0		CJGYSWNGNKCJSB
BRD-A94624445-236-17-0	bucladesine	Launched	adenosine receptor agonist|cAMP stimulant	PRKACA	dermatology	skin ulcer	0	98.02	Tocris	1141	Dibutyryl-cAMP, sodium salt	469.136	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|	CJGYSWNGNKCJSB-YVLZZHOMSA-N	9687.0		CJGYSWNGNKCJSB
BRD-K01825692-001-01-9	bucladesine	Launched	adenosine receptor agonist|cAMP stimulant	PRKACA	dermatology	skin ulcer	0	85.44	MicroSource	1503043	BUCLADESINE	469.136	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15,17,24,25,&1:20|	CJGYSWNGNKCJSB-YVLZZHOMSA-N	9687.0	BRD-A94624445-001-01-2|BRD-A94624445-001-01-2|BRD-A94624445-001-01-2	CJGYSWNGNKCJSB
BRD-A91444184-300-01-9	buclizine	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry	migraine headache	0	99.32	Key	KS-1250	1-(4-tert-butylbenzyl)-4-[(4-chlorophenyl)(phenyl)methyl]piperazine dihydrochloride	432.233	CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|	MOYGZHXDRJNJEP-MHZLTWQESA-N	3246096.0		MOYGZHXDRJNJEP
BRD-A34299591-001-25-7	budesonide	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	0	54.98	Sigma	MFCD00083259	(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-6b-glycoloyl-5-hydroxy-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one	430.236	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N	63006.0		VOVIALXJUBGFJZ
BRD-A34299591-001-27-3	budesonide	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	0	35.61	Tocris	2671	Budesonide	430.236	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N	63006.0		VOVIALXJUBGFJZ
BRD-A34299591-001-28-1	budesonide	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	0	46.61	MedChemEx	HY-13580	Budesonide	430.236	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N	63006.0		VOVIALXJUBGFJZ
BRD-A34299591-001-26-5	budesonide	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	0	49.14	MedChemEx	HY-13580	Budesonide	430.236	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N	63006.0		VOVIALXJUBGFJZ
BRD-A34299591-001-30-7	budesonide	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	0	47.86	Selleck	S1286	Budesonide	430.236	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N	63006.0		VOVIALXJUBGFJZ
BRD-A34299591-001-22-4	budesonide	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	0	52.1	Tocris	2671	Budesonide	430.236	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N	63006.0		VOVIALXJUBGFJZ
BRD-A34299591-001-29-9	budesonide	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	0	53.99	MicroSource	1500813	BUDESONIDE	430.236	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N	63006.0	BRD-A60571864-001-04-1	VOVIALXJUBGFJZ
BRD-A34299591-001-31-5	budesonide	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology	Crohn's disease	0	46.35	Selleck	S1286	Budesonide	430.236	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5,7,8,17,19,20,23,25,&1:3,c:15,t:11|	VOVIALXJUBGFJZ-AMTWPJRWSA-N	63006.0	BRD-K17742695-001-01-1	VOVIALXJUBGFJZ
BRD-K18324993-001-01-6	budipine	Launched	glutamate receptor antagonist	GRIN1	neurology/psychiatry	Parkinson's Disease	0	94.36	AQBioPharma	ABP10516	BUDIPINE	293.214	CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1	QIHLUZAFSSMXHQ-UHFFFAOYSA-N	68778.0		QIHLUZAFSSMXHQ
BRD-K36660044-001-25-9	bufexamac	Withdrawn	cyclooxygenase inhibitor	HDAC10|HDAC6			0	98.93	MedChemEx	HY-B0494	Bufexamac	223.121	CCCCOc1ccc(CC(=O)NO)cc1	MXJWRABVEGLYDG-UHFFFAOYSA-N	2466.0		MXJWRABVEGLYDG
BRD-K36660044-001-24-2	bufexamac	Withdrawn	cyclooxygenase inhibitor	HDAC10|HDAC6			0	95.88	MicroSource	1502003	BUFEXAMAC	223.121	CCCCOc1ccc(CC(=O)NO)cc1	MXJWRABVEGLYDG-UHFFFAOYSA-N	2466.0		MXJWRABVEGLYDG
BRD-K36660044-001-23-4	bufexamac	Withdrawn	cyclooxygenase inhibitor	HDAC10|HDAC6			0	90.78	Selleck	S3023	Bufexamac	223.121	CCCCOc1ccc(CC(=O)NO)cc1	MXJWRABVEGLYDG-UHFFFAOYSA-N	2466.0		MXJWRABVEGLYDG
BRD-K19462402-003-25-9	buflomedil	Launched	adrenergic receptor antagonist|calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	0	93.45	MedChemEx	HY-B0484	Buflomedil (hydrochloride)	307.178	COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	OWYLAEYXIQKAOL-UHFFFAOYSA-N	2467.0		OWYLAEYXIQKAOL
BRD-K19462402-003-24-6	buflomedil	Launched	adrenergic receptor antagonist|calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	0	98.69	MicroSource	1505992	BUFLOMEDIL HYDROCHLORIDE	307.178	COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	OWYLAEYXIQKAOL-UHFFFAOYSA-N	2467.0		OWYLAEYXIQKAOL
BRD-K19462402-003-23-8	buflomedil	Launched	adrenergic receptor antagonist|calcium channel blocker	ADRA1A	cardiology	peripheral artery disease (PAD)	0	94.83	Selleck	S2607	Buflomedil HCl	307.178	COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	OWYLAEYXIQKAOL-UHFFFAOYSA-N	2467.0		OWYLAEYXIQKAOL
BRD-K38197229-001-31-5	bumetanide	Launched	solute carrier family member inhibitor	CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5	cardiology	edema|congestive heart failure	0	95.93	Tocris	3108	Bumetanide	364.109	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	MAEIEVLCKWDQJH-UHFFFAOYSA-N	2471.0		MAEIEVLCKWDQJH
BRD-K38197229-001-29-9	bumetanide	Launched	solute carrier family member inhibitor	CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5	cardiology	edema|congestive heart failure	0	99.54	MicroSource	1502004	BUMETANIDE	364.109	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	MAEIEVLCKWDQJH-UHFFFAOYSA-N	2471.0		MAEIEVLCKWDQJH
BRD-K38197229-001-32-9	bumetanide	Launched	solute carrier family member inhibitor	CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5	cardiology	edema|congestive heart failure	0	97.58	Tocris	3108	Bumetanide	364.109	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	MAEIEVLCKWDQJH-UHFFFAOYSA-N	2471.0		MAEIEVLCKWDQJH
BRD-K38197229-001-28-1	bumetanide	Launched	solute carrier family member inhibitor	CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5	cardiology	edema|congestive heart failure	0	98.01	Selleck	S1287	Bumetanide	364.109	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	MAEIEVLCKWDQJH-UHFFFAOYSA-N	2471.0		MAEIEVLCKWDQJH
BRD-K35034482-001-01-8	bunazosin	Launched	adrenergic receptor antagonist	ADRA1A	ophthalmology	glaucoma|intraocular pressure	0	97.77	Enamine	Z1172912933		373.211	CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	RHLJLALHBZGAFM-UHFFFAOYSA-N	2472.0		RHLJLALHBZGAFM
BRD-K35034482-003-02-9	bunazosin	Launched	adrenergic receptor antagonist	ADRA1A	ophthalmology	glaucoma|intraocular pressure	0	96.76	Toronto	b689585	bunazosin hydrochloride	373.211	CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	RHLJLALHBZGAFM-UHFFFAOYSA-N	2472.0		RHLJLALHBZGAFM
BRD-K42191735-001-08-7	buparlisib	Phase 3	PI3K inhibitor	PIK3CA|PIK3CG			0	98.65	Selleck	S2247	BKM120 (NVP-BKM120)	410.168	Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	CWHUFRVAEUJCEF-UHFFFAOYSA-N	16654980.0		CWHUFRVAEUJCEF
BRD-K42191735-001-05-3	buparlisib	Phase 3	PI3K inhibitor	PIK3CA|PIK3CG			0	87.93	Selleck	S2247	BKM120 (NVP-BKM120, Buparlisib)	410.168	Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	CWHUFRVAEUJCEF-UHFFFAOYSA-N	16654980.0		CWHUFRVAEUJCEF
BRD-A07947329-001-02-9	buparvaquone	Launched	antiprotozoal agent		infectious disease	protozoan infection	0	52.68	MedChemEx	HY-17581	Buparvaquone	326.188	CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|	OMMKCJLAGTXGLC-MQBCKMQZSA-N			OMMKCJLAGTXGLC
BRD-A07947329-001-01-4	buparvaquone	Launched	antiprotozoal agent		infectious disease	protozoan infection	0	96.77	MedChemEx	HY-17581	Buparvaquone	326.188	CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9,r|	OMMKCJLAGTXGLC-MQBCKMQZSA-N			OMMKCJLAGTXGLC
BRD-A36267905-003-19-2	buphenine	Launched	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	0	89.35	MedChemEx	HY-B1404	Nylidrin (hydrochloride)	299.189	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	PTGXAUBQBSGPKF-UHFFFAOYSA-N	657392.0		PTGXAUBQBSGPKF
BRD-A36267905-003-18-4	buphenine	Launched	adrenergic receptor agonist	ADRB2	rheumatology	Raynaud's disease	0	77.3	MicroSource	1500445	NYLIDRIN HYDROCHLORIDE	299.189	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	PTGXAUBQBSGPKF-UHFFFAOYSA-N	657392.0		PTGXAUBQBSGPKF
BRD-K51700582-001-01-2	bupicomide	Phase 1	adrenergic receptor antagonist	ADRB1			0	95.4	Enamine	Z2408581540	5-butyl-2-pyridinecarboxamide	178.111	CCCCc1ccc(nc1)C(N)=O	VKSPIPWLHGKJQO-UHFFFAOYSA-N	31447.0		VKSPIPWLHGKJQO
BRD-K00003636-001-01-9	bupivacaine	Launched	sodium channel blocker	KCNA5|SCN10A	neurology/psychiatry	peripheral nerve block|caudal epidural block|lumbar epidural block	0	98.85	MedChemEx	HY-B0405	Bupivacaine	288.22	CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9,r|	LEBVLXFERQHONN-INIZCTEOSA-N	92253.0		LEBVLXFERQHONN
BRD-A48420483-001-02-3	bupranolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology|ophthalmology	hypertension|glaucoma	0	96.59	Enamine	Z1650184751	1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)-2-propanol	271.134	Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|	HQIRNZOQPUAHHV-NSHDSACASA-N	66601885.0		HQIRNZOQPUAHHV
BRD-A48420483-001-03-9	bupranolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology|ophthalmology	hypertension|glaucoma	0	91.73	Enamine	EN300-134241	1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol	271.134	Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|	HQIRNZOQPUAHHV-NSHDSACASA-N	66601885.0		HQIRNZOQPUAHHV
BRD-A48420483-001-01-5	bupranolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology|ophthalmology	hypertension|glaucoma	0	21.07	Enamine	Z1497043450		271.134	Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|	HQIRNZOQPUAHHV-NSHDSACASA-N	66601885.0		HQIRNZOQPUAHHV
BRD-A48420483-001-04-9	bupranolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology|ophthalmology	hypertension|glaucoma	0	93.36	Toronto	b689650	bupranolol	271.134	Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9,r|	HQIRNZOQPUAHHV-NSHDSACASA-N	66601885.0		HQIRNZOQPUAHHV
BRD-K01826729-003-06-9	bupropion	Launched	dopamine reuptake inhibitor	SLC6A2|SLC6A3	neurology/psychiatry	depression	0	94.45	Tocris	2831	Bupropion hydrochloride	239.108	C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1,r|	SNPPWIUOZRMYNY-SECBINFHSA-N	688387.0		SNPPWIUOZRMYNY
BRD-K30360804-001-01-3	buramate	Preclinical	antiepileptic				0	65.99	MicroSource	1505415	BURAMATE	195.09	OCCOC(=O)NCc1ccccc1	YFLRYAVDPKONNX-UHFFFAOYSA-N	20787.0		YFLRYAVDPKONNX
BRD-K30360804-001-02-9	buramate	Preclinical	antiepileptic				0	89.56	Enamine	EN300-203841	2-hydroxyethyl N-benzylcarbamate	195.09	OCCOC(=O)NCc1ccccc1	YFLRYAVDPKONNX-UHFFFAOYSA-N	20787.0		YFLRYAVDPKONNX
BRD-K00003161-015-01-9	buserelin	Launched	gonadotropin releasing factor hormone receptor agonist		oncology|obstetrics/gynecology	prostate cancer|endometriosis	0	98.16	MedChemEx	HY-13581A	Buserelin (Acetate)	1238.656	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	CUWODFFVMXJOKD-UVLQAERKSA-N	50225.0		CUWODFFVMXJOKD
BRD-K93461745-003-25-0	buspirone	Launched	serotonin receptor agonist	DRD2|HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	0	99.45	MicroSource	2300173	BUSPIRONE HYDROCHLORIDE	385.248	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	QWCRAEMEVRGPNT-UHFFFAOYSA-N	2477.0		QWCRAEMEVRGPNT
BRD-K93461745-003-23-5	buspirone	Launched	serotonin receptor agonist	DRD2|HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	0	96.3	Selleck	S4256	Buspirone HCl	385.248	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	QWCRAEMEVRGPNT-UHFFFAOYSA-N	2477.0		QWCRAEMEVRGPNT
BRD-K93461745-003-26-9	buspirone	Launched	serotonin receptor agonist	DRD2|HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	0	91.97	Tocris	962	Buspirone hydrochloride	385.248	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	QWCRAEMEVRGPNT-UHFFFAOYSA-N	2477.0		QWCRAEMEVRGPNT
BRD-K93461745-003-24-3	buspirone	Launched	serotonin receptor agonist	DRD2|HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)	0	98.88	Tocris	962	Buspirone hydrochloride	385.248	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	QWCRAEMEVRGPNT-UHFFFAOYSA-N	2477.0		QWCRAEMEVRGPNT
BRD-K23204545-001-16-4	busulfan	Launched	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	0	89.78	MicroSource	1500152	BUSULFAN	246.023	CS(=O)(=O)OCCCCOS(C)(=O)=O	COVZYZSDYWQREU-UHFFFAOYSA-N	2478.0		COVZYZSDYWQREU
BRD-K23204545-001-15-6	busulfan	Launched	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	0	0.0	Selleck	S1692	Busulfan	246.023	CS(=O)(=O)OCCCCOS(C)(=O)=O	COVZYZSDYWQREU-UHFFFAOYSA-N	2478.0		COVZYZSDYWQREU
BRD-K23204545-001-18-0	busulfan	Launched	DNA inhibitor		hematologic malignancy	chronic myeloid leukemia (CML)	0	79.96	Selleck	S1692	Busulfan (Myleran, Busulfex)	246.023	CS(=O)(=O)OCCCCOS(C)(=O)=O	COVZYZSDYWQREU-UHFFFAOYSA-N	2478.0		COVZYZSDYWQREU
BRD-K40581315-034-01-5	butabindide	Preclinical	tripeptidyl peptidase inhibitor	TPP2			0	0.47	Tocris	1323	Butabindide oxalate	303.195	CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC	HAQIRIMIVLFYIX-ZFWWWQNUSA-N	9817923.0		HAQIRIMIVLFYIX
BRD-K40581315-034-02-9	butabindide	Preclinical	tripeptidyl peptidase inhibitor	TPP2			0	90.73	Tocris	1323	Butabindide oxalate	303.195	CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC	HAQIRIMIVLFYIX-ZFWWWQNUSA-N	9817923.0		HAQIRIMIVLFYIX
BRD-K99622919-001-23-0	butacaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	95.48	MicroSource	1503914	BUTACAINE	306.231	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	HQFWVSGBVLEQGA-UHFFFAOYSA-N	2480.0		HQFWVSGBVLEQGA
BRD-K99622919-001-22-2	butacaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	91.73	Selleck	S4310	Butacaine	306.231	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	HQFWVSGBVLEQGA-UHFFFAOYSA-N	2480.0		HQFWVSGBVLEQGA
BRD-K99622919-001-24-8	butacaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	0.0	Selleck	S4310	Butacaine	306.231	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	HQFWVSGBVLEQGA-UHFFFAOYSA-N	2480.0		HQFWVSGBVLEQGA
BRD-K20620780-003-15-6	butaclamol	Phase 2	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A			0	97.77	Sigma	D033-5MG	(+)-Butaclamol hydrochloride	361.241	CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34	ZZJYIKPMDIWRSN-HWBMXIPRSA-N	37459.0		ZZJYIKPMDIWRSN
BRD-K71350836-001-02-4	butalbital	Launched	GABA receptor antagonist	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2	neurology/psychiatry	headache|muscle relaxant	0	98.11	Prestwick	Prestw-1251	Butalbital	224.116	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	UZVHFVZFNXBMQJ-UHFFFAOYSA-N	2481.0		UZVHFVZFNXBMQJ
BRD-K27217864-001-23-9	butamben	Withdrawn	sodium channel blocker				0	98.53	MedChemEx	HY-B1430	Butamben	193.11	CCCCOC(=O)c1ccc(N)cc1	IUWVALYLNVXWKX-UHFFFAOYSA-N	2482.0		IUWVALYLNVXWKX
BRD-K27217864-001-22-3	butamben	Withdrawn	sodium channel blocker				0	99.12	MicroSource	1500767	BUTAMBEN	193.11	CCCCOC(=O)c1ccc(N)cc1	IUWVALYLNVXWKX-UHFFFAOYSA-N	2482.0		IUWVALYLNVXWKX
BRD-K00004715-001-01-9	butaprost	Preclinical	prostaglandin receptor agonist				0	100.0	Sigma	B6309	(R)-Butaprost	408.288	CCCC1(CCC1)[C@H](O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	XRISENIKJUKIHD-LHQZMKCDSA-N	5311035.0		XRISENIKJUKIHD
BRD-K17497770-001-03-6	butein	Preclinical	EGFR inhibitor|SRC inhibitor	ACE			0	88.13	Selleck	S8036	Butein	272.068	Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	AYMYWHCQALZEGT-ORCRQEGFSA-N	5281222.0		AYMYWHCQALZEGT
BRD-K17497770-001-04-4	butein	Preclinical	EGFR inhibitor|SRC inhibitor	ACE			0	92.44	Selleck	S8036	Butein	272.068	Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	AYMYWHCQALZEGT-ORCRQEGFSA-N	5281222.0		AYMYWHCQALZEGT
BRD-K90630139-003-05-9	butenafine	Launched	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis|tinea cruris|tinea corporis	0	98.38	Selleck	S3154	Butenafine HCl	317.214	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	ABJKWBDEJIDSJZ-UHFFFAOYSA-N	2484.0		ABJKWBDEJIDSJZ
BRD-K90630139-003-06-9	butenafine	Launched	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis|tinea cruris|tinea corporis	0	99.5	MedChemEx	HY-17396	Butenafine (Hydrochloride)	317.214	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	ABJKWBDEJIDSJZ-UHFFFAOYSA-N	2484.0		ABJKWBDEJIDSJZ
BRD-A47706533-001-02-6	buthionine-sulfoximine	Phase 1	glutathione transferase inhibitor	GCLM			0	94.36	Enzo	FR117	Buthionine sulfoximine	222.104	CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9,&1:4|	KJQFBVYMGADDTQ-CVSPRKDYSA-N	1548918.0		KJQFBVYMGADDTQ
BRD-A46136514-001-01-2	butibufen	Withdrawn	cyclooxygenase inhibitor				0	95.48	Carbosynth	FB19394	2-(4-isobutylphenyl)butanoic acid	220.146	CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|	UULSXYSSHHRCQK-CYBMUJFWSA-N	71314316.0		UULSXYSSHHRCQK
BRD-A46136514-236-02-9	butibufen	Withdrawn	cyclooxygenase inhibitor				0	91.19	Toronto	b689960	butibufen	220.146	CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2,r|	UULSXYSSHHRCQK-CYBMUJFWSA-N	71314316.0		UULSXYSSHHRCQK
BRD-K01824994-008-03-9	butoconazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	0	98.18	MedChemEx	HY-B0293	Butoconazole (nitrate)	410.018	Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|	SWLMUYACZKCSHZ-INIZCTEOSA-N	476417.0		SWLMUYACZKCSHZ
BRD-K01824994-001-02-9	butoconazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	0	99.34	MicroSource	1504140	BUTOCONAZOLE	410.018	Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7,r|	SWLMUYACZKCSHZ-INIZCTEOSA-N	476417.0		SWLMUYACZKCSHZ
BRD-A27274504-001-01-6	butofilolol	Phase 2	adrenergic receptor antagonist				0	96.62	Sigma	MFCD00864575	1-{2-[3-(tert-butylamino)-2-hydroxypropoxy]-5-fluorophenyl}-1-butanone	311.19	CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C |&1:14,r|	NMBNQRJDEPOXCP-ZDUSSCGKSA-N	66593644.0		NMBNQRJDEPOXCP
BRD-K08287586-001-14-3	butyl-paraben	Preclinical	DNA synthesis inhibitor				0	98.43	MicroSource	1505995	BUTYL PARABEN	194.094	CCCCOC(=O)c1ccc(O)cc1	QFOHBWFCKVYLES-UHFFFAOYSA-N	7184.0		QFOHBWFCKVYLES
BRD-K93035859-001-07-6	butylated-hydroxyanisole	Preclinical	antioxidant				0	88.92	MicroSource	1503740	BUTYLATED HYDROXYANISOLE	180.115	COc1ccc(O)c(c1)C(C)(C)C	MRBKEAMVRSLQPH-UHFFFAOYSA-N	8456.0		MRBKEAMVRSLQPH
BRD-K93035859-001-08-9	butylated-hydroxyanisole	Preclinical	antioxidant				0	49.61	Sigma	MFCD00040484	Butylated hydroxyanisole , 98 %	180.115	COc1ccc(O)c(c1)C(C)(C)C	MRBKEAMVRSLQPH-UHFFFAOYSA-N	8456.0		MRBKEAMVRSLQPH
BRD-K53153417-001-10-4	butylated-hydroxytoluene	Phase 1	carbonic anhydrase inhibitor	CA2			0	97.99	MicroSource	1600716	BUTYLATED HYDROXYTOLUENE	220.183	Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	NLZUEZXRPGMBCV-UHFFFAOYSA-N	31404.0		NLZUEZXRPGMBCV
BRD-K53153417-001-13-9	butylated-hydroxytoluene	Phase 1	carbonic anhydrase inhibitor	CA2			0	96.82	MedChemEx	HY-Y0172	2,6-Di-tert-butyl-4-methylphenol	220.183	Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	NLZUEZXRPGMBCV-UHFFFAOYSA-N	31404.0		NLZUEZXRPGMBCV
BRD-K02260986-001-03-9	butylidenephthalide	Phase 1/Phase 2	cyclooxygenase inhibitor				0	0.0	Sigma	MFCD00047319	N-BUTYLIDENEPHTHALIDE	188.084	CCC\C=C1/OC(=O)c2ccccc12	WMBOCUXXNSOQHM-FLIBITNWSA-N	642376.0		WMBOCUXXNSOQHM
BRD-A59378440-001-01-3	butylphthalide	Launched	potassium channel antagonist	KCNK2	neurology/psychiatry	stroke	0	94.43	MedChemEx	HY-B0647	Butylphthalide	190.099	CCCC[C@H]1OC(=O)c2ccccc12 |&1:4,r|	HJXMNVQARNZTEE-LLVKDONJSA-N	9990075.0		HJXMNVQARNZTEE
BRD-K01825841-004-02-9	butylscopolamine-bromide	Launched	cholinergic receptor antagonist		gastroenterology	abdominal pain	0	97.31	MedChemEx	HY-N0340	Scopolamine butylbromide	360.217	CCCC[N@@+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:4,TLB:3:4:7.8.9:11.13,12:11:4:7.8.9,12:13:4:7.8.9,THB:5:4:7.8.9:11.13,14:8:4:11.13|	YBCNXCRZPWQOBR-FRNBUXIHSA-N			YBCNXCRZPWQOBR
BRD-K56115039-003-03-9	BU226	Preclinical	imidazoline receptor ligand				0	95.88	Tocris	1091	BU 226 hydrochloride	197.095	C1CN=C(N1)c1cc2ccccc2cn1 |c:2|	ZXRSVNHYTSSFMN-UHFFFAOYSA-N	3410883.0		ZXRSVNHYTSSFMN
BRD-K56115039-003-02-1	BU226	Preclinical	imidazoline receptor ligand				0	97.75	Tocris	1091	BU 226 hydrochloride	197.095	C1CN=C(N1)c1cc2ccccc2cn1 |c:2|	ZXRSVNHYTSSFMN-UHFFFAOYSA-N	3410883.0		ZXRSVNHYTSSFMN
BRD-K28965160-001-01-1	BVD-523	Phase 2	MAP kinase inhibitor				0	99.21	MedChemEx	HY-15816	VRT752271	432.112	CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	KSERXGMCDHOLSS-LJQANCHMSA-N	11719003.0		KSERXGMCDHOLSS
BRD-K28965160-001-02-9	BVD-523	Phase 2	MAP kinase inhibitor				0	97.46	MedChemEx	HY-15816	Ulixertinib	432.112	CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	KSERXGMCDHOLSS-LJQANCHMSA-N	11719003.0		KSERXGMCDHOLSS
BRD-K01742705-001-01-7	BVT-2733	Preclinical	11-beta hydroxysteroid dehydrogenase inhibitor	HSD17B1			0	96.59	MedChemEx	HY-18054	BVT 2733	428.074	CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1	YDPRNGAPPNPYQQ-UHFFFAOYSA-N	6918651.0		YDPRNGAPPNPYQQ
BRD-K68567222-001-01-2	BVT-948	Preclinical	tyrosine phosphatase inhibitor	PTPN1|PTPN11|PTPN2			0	90.36	Tocris	2176	BVT 948	241.074	CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|	LLPBUXODFQZPFH-UHFFFAOYSA-N	6604934.0	BRD-A22713669-001-02-7	LLPBUXODFQZPFH
BRD-K80194255-001-01-9	BW-A4C	Phase 1	lipoxygenase inhibitor	ALOX5			0	87.05	Sigma	B7559	N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)-2-propenyl]acetamide	283.121	CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1	CEUDWZXMLMKPNN-SOFGYWHQSA-N	6438354.0		CEUDWZXMLMKPNN
BRD-A55946879-001-04-9	BW-B70C	Preclinical	lipoxygenase inhibitor	ALOX5			0	86.91	Sigma	B4558	BW B70C	316.122	C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|	UAIYNMRLUHHRMF-FYJFLYSWSA-N	88473969.0		UAIYNMRLUHHRMF
BRD-A55946879-001-03-7	BW-B70C	Preclinical	lipoxygenase inhibitor	ALOX5			0	51.53	Tocris	1304	BW-B 70C	316.122	C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1,r|	UAIYNMRLUHHRMF-FYJFLYSWSA-N	88473969.0		UAIYNMRLUHHRMF
BRD-K00003548-001-01-9	BW-180C	Phase 2	opioid receptor agonist	OPRD1|OPRM1			0	89.9	MedChemEx	HY-105343	BW-180C	569.285	CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	ZHUJMSMQIPIPTF-IBURTVSXSA-N	6917707.0		ZHUJMSMQIPIPTF
BRD-K00004593-001-01-9	BW-348U87	Preclinical	antiviral				0	82.15	Key	MS-0738	N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide	378.049	C\C(=N/NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	YYLKOELWSMRYHV-VXLYETTFSA-N	9554761.0		YYLKOELWSMRYHV
BRD-K74990253-001-03-9	BW-373U86	Preclinical	opioid receptor agonist	OPRD1			0	97.24	Tocris	1663	BW 373U86	435.289	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	LBLDMHBSVIVJPM-YZIHRLCOSA-N	119029.0		LBLDMHBSVIVJPM
BRD-K74990253-001-02-8	BW-373U86	Preclinical	opioid receptor agonist	OPRD1			0	96.77	Tocris	1663	BW 373U86	435.289	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	LBLDMHBSVIVJPM-YZIHRLCOSA-N	119029.0		LBLDMHBSVIVJPM
BRD-K07061232-001-01-8	BW-616U	Preclinical	monoamine oxidase inhibitor	MAOA			0	97.3	Enamine	Z30272279	N-methyl-10-oxo-10H-dibenzo[b,e]thiopyran-3-carboxamide 5,5-dioxide	301.041	CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1	MLPSDBJCWIYSEA-UHFFFAOYSA-N	11722381.0		MLPSDBJCWIYSEA
BRD-K01826747-003-10-9	BW-723C86	Preclinical	serotonin receptor agonist	HTR2A|HTR2B|HTR2C			0	62.79	Tocris	1059	BW 723C86 hydrochloride	322.091	C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|	ALFGDCNSEBJYSP-LLVKDONJSA-N	40418385.0		ALFGDCNSEBJYSP
BRD-K01826747-003-11-9	BW-723C86	Preclinical	serotonin receptor agonist	HTR2A|HTR2B|HTR2C			0	90.04	Tocris	1059	BW 723C86 hydrochloride	286.114	C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|	ALFGDCNSEBJYSP-LLVKDONJSA-N	40418385.0		ALFGDCNSEBJYSP
BRD-K01826747-003-09-9	BW-723C86	Preclinical	serotonin receptor agonist	HTR2A|HTR2B|HTR2C			0	88.95	Tocris	1059	BW 723C86 hydrochloride	322.091	C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|	ALFGDCNSEBJYSP-LLVKDONJSA-N	40418385.0		ALFGDCNSEBJYSP
BRD-K47983010-001-15-3	BX-795	Preclinical	IKK inhibitor	CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1			0	94.52	MedChemEx	HY-10514	BX795	591.091	Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	VAVXGGRQQJZYBL-UHFFFAOYSA-N	10077147.0		VAVXGGRQQJZYBL
BRD-K47983010-001-09-6	BX-795	Preclinical	IKK inhibitor	CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1			0	56.03	Selleck	S1274	BX-795	591.091	Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	VAVXGGRQQJZYBL-UHFFFAOYSA-N	10077147.0		VAVXGGRQQJZYBL
BRD-K47983010-001-12-0	BX-795	Preclinical	IKK inhibitor	CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1			0	82.2	Selleck	S1274	BX-795	591.091	Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	VAVXGGRQQJZYBL-UHFFFAOYSA-N	10077147.0		VAVXGGRQQJZYBL
BRD-K47983010-001-14-6	BX-795	Preclinical	IKK inhibitor	CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1			0	73.82	MedChemEx	HY-10514	BX795	591.091	Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	VAVXGGRQQJZYBL-UHFFFAOYSA-N	10077147.0		VAVXGGRQQJZYBL
BRD-K49669041-001-08-4	BX-912	Preclinical	pyruvate dehydrogenase kinase inhibitor	CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1			0	95.26	Selleck	S1275	BX-912	470.118	Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1	DMMILYKXNCVKOJ-UHFFFAOYSA-N	11754511.0		DMMILYKXNCVKOJ
BRD-K61665160-001-02-3	BYK-204165	Preclinical	PARP inhibitor	PARP1			0	94.52	Tocris	3734	BYK 204165	252.09	Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	BTYSIDSTHDDAJW-LCYFTJDESA-N	25113764.0		BTYSIDSTHDDAJW
BRD-K61665160-001-01-5	BYK-204165	Preclinical	PARP inhibitor	PARP1			0	98.46	Tocris	3734	BYK 204165	252.09	Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	BTYSIDSTHDDAJW-LCYFTJDESA-N	25113764.0		BTYSIDSTHDDAJW
BRD-K61665160-001-03-9	BYK-204165	Preclinical	PARP inhibitor	PARP1			0	95.41	Tocris	3734	BYK 204165	252.09	Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	BTYSIDSTHDDAJW-LCYFTJDESA-N	25113764.0		BTYSIDSTHDDAJW
BRD-K98179423-300-01-3	C-021	Preclinical	CC chemokine receptor antagonist	CCR4			0	97.39	Tocris	3581	C 021 dihydrochloride	467.326	COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1	WYVBISCFCHREDA-UHFFFAOYSA-N	25141190.0		WYVBISCFCHREDA
BRD-K98179423-300-02-9	C-021	Preclinical	CC chemokine receptor antagonist	CCR4			0	97.25	Tocris	3581	C 021 dihydrochloride	467.326	COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1	WYVBISCFCHREDA-UHFFFAOYSA-N	25141190.0		WYVBISCFCHREDA
BRD-K72462751-001-03-5	C-1	Preclinical	protein kinase inhibitor	PRKCA			0	98.34	Tocris	543	C-1	277.088	O=S(=O)(N1CCNCC1)c1cccc2cnccc12	UPTYCYWTFGTCCG-UHFFFAOYSA-N	3545.0		UPTYCYWTFGTCCG
BRD-K72462751-001-02-7	C-1	Preclinical	protein kinase inhibitor	PRKCA			0	97.52	Tocris	543	C-1	277.088	O=S(=O)(N1CCNCC1)c1cccc2cnccc12	UPTYCYWTFGTCCG-UHFFFAOYSA-N	3545.0		UPTYCYWTFGTCCG
BRD-K15337272-001-01-3	C-751	Preclinical					0	98.92	Key	PS-5461		140.059	CCOC(=O)c1cnc[nH]1	KLWYPRNPRNPORS-UHFFFAOYSA-N	99170.0		KLWYPRNPRNPORS
BRD-K00003511-001-01-9	CA-4948	Phase 1	kinase inhibitor				0	95.81	MedChemEx	HY-109585	CA-4948	417.155	Nc1ccc(cn1)-c1cccc(n1)C(=O)Nc1cnc2nc(oc2c1)N1CCOCC1	RWIMETUXCNDSLE-UHFFFAOYSA-N	118224238.0		RWIMETUXCNDSLE
BRD-K41504985-005-01-5	cabagin	Launched			gastroenterology	dyspepsia	1	0.0	AlfaAesar	B21342		164.075	C[S+](C)CC[C@H](N)C(O)=O	YDBYJHTYSHBBAU-YFKPBYRVSA-O	7098638.0		YDBYJHTYSHBBAU
BRD-K41504985-003-02-9	cabagin	Launched			gastroenterology	dyspepsia	1	100.0	Toronto	M260470	L-methionine-S-methyl sulfonium chloride	164.075	C[S+](C)CC[C@H](N)C(O)=O	YDBYJHTYSHBBAU-YFKPBYRVSA-O	7098638.0		YDBYJHTYSHBBAU
BRD-K54028654-001-02-6	cabaletta	Phase 2	pharmacological chaperone				0	97.42	Enzo	AC1507	Trehalose	342.116	OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	HDTRYLNUVZCQOY-LIZSDCNHSA-N	7427.0		HDTRYLNUVZCQOY
BRD-K10384176-001-02-9	cabazitaxel	Launched	microtubule inhibitor	TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	prostate cancer	0	95.83	MedChemEx	HY-15459	Cabazitaxel	835.378	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|	BMQGVNUXMIRLCK-OAGWZNDDSA-N	9854073.0		BMQGVNUXMIRLCK
BRD-K86882815-001-05-7	cabergoline	Launched	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR7	endocrinology	hyperprolactinemia	0	92.03	Tocris	2664	Cabergoline	451.295	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	KORNTPPJEAJQIU-KJXAQDMKSA-N	54746.0	BRD-K34586087-001-01-7	KORNTPPJEAJQIU
BRD-K86882815-001-03-2	cabergoline	Launched	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR7	endocrinology	hyperprolactinemia	0	94.48	Enzo	DL219	Cabergoline	451.295	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	KORNTPPJEAJQIU-KJXAQDMKSA-N	54746.0		KORNTPPJEAJQIU
BRD-K86882815-001-06-9	cabergoline	Launched	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR7	endocrinology	hyperprolactinemia	0	0.0	Tocris	2664	Cabergoline	451.295	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	KORNTPPJEAJQIU-KJXAQDMKSA-N	54746.0		KORNTPPJEAJQIU
BRD-K76819217-001-02-2	cabotegravir	Phase 3	HIV integrase inhibitor				0	97.41	MedChemEx	HY-15592	(3S,11aR)-N-(2,4-difluorobenzyl)-3-methyl-5,6,7-trioxo-2,3,5,5a,6,7,11,11a-octahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide	405.114	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	WCWSTNLSLKSJPK-LKFCYVNXSA-N	54713659.0	BRD-A95114378-001-01-4	WCWSTNLSLKSJPK
BRD-K76819217-001-01-4	cabotegravir	Phase 3	HIV integrase inhibitor				0	96.55	Selleck	S7766	Cabotegravir (GSK744, GSK1265744)	405.114	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	WCWSTNLSLKSJPK-LKFCYVNXSA-N	54713659.0	BRD-A07738941-001-01-5	WCWSTNLSLKSJPK
BRD-K51544265-001-06-7	cabozantinib	Launched	RET tyrosine kinase inhibitor|VEGFR inhibitor	KDR|MET|RET	oncology	medullary thyroid cancer (MTC)	0	99.07	Tocris	5422	XL 184	501.17	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	ONIQOQHATWINJY-UHFFFAOYSA-N	25102847.0		ONIQOQHATWINJY
BRD-K51544265-001-04-2	cabozantinib	Launched	RET tyrosine kinase inhibitor|VEGFR inhibitor	KDR|MET|RET	oncology	medullary thyroid cancer (MTC)	0	98.92	Selleck	S1119	Cabozantinib (XL184, BMS-907351)	501.17	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	ONIQOQHATWINJY-UHFFFAOYSA-N	25102847.0		ONIQOQHATWINJY
BRD-K51544265-001-03-4	cabozantinib	Launched	RET tyrosine kinase inhibitor|VEGFR inhibitor	KDR|MET|RET	oncology	medullary thyroid cancer (MTC)	0		Selleck	S1119	XL-184 free base (Cabozantinib)	501.17	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)	25102847.0		ONIQOQHATWINJY
BRD-A90751343-001-02-9	CaCCinh-A01	Preclinical	calcium-activated chloride channel inhibitor	CLCA1			0	95.53	Tocris	4877	CaCCinh-A01	347.119	CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|	ACLUEOBQFRYTQS-JTQLQIEISA-N	747218.0		ACLUEOBQFRYTQS
BRD-A90751343-001-01-0	CaCCinh-A01	Preclinical	calcium-activated chloride channel inhibitor	CLCA1			0	93.54	Tocris	4877	CaCCinh-A01	347.119	CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4,r|	ACLUEOBQFRYTQS-JTQLQIEISA-N	747218.0		ACLUEOBQFRYTQS
BRD-K00003370-001-01-9	cadazolid	Phase 3	antibacterial 				0	91.31	MedChemEx	HY-100436	Cadazolid	585.192	OC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1	XWFCFMXQTBGXQW-GOSISDBHSA-N	44242317.0		XWFCFMXQTBGXQW
BRD-A78134170-001-01-3	cadralazine	Launched	adrenergic receptor antagonist		cardiology	hypertension	0	57.47	Key	KS-1435	ethyl 2-{6-[ethyl(2-hydroxypropyl)amino]-3-pyridazinyl}hydrazinecarboxylate	283.164	CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17,r|	QLTVVOATEHFXLT-SECBINFHSA-N	76968745.0		QLTVVOATEHFXLT
BRD-K46741531-001-02-4	cafestol	Launched	pregnane X receptor agonist				0	95.32	Enzo	NP418	Cafestol	316.204	C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	DNJVYWXIDISQRD-HWUKTEKMSA-N	108052.0		DNJVYWXIDISQRD
BRD-K46741531-001-03-9	cafestol	Launched	pregnane X receptor agonist				0		WuXi	EW21509-6-P1	Cafestol	316.204	C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	DNJVYWXIDISQRD-HWUKTEKMSA-N	108052.0		DNJVYWXIDISQRD
BRD-K09900591-001-29-9	caffeic-acid	Preclinical	HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor	ALOX5|MIF			0	94.78	MedChemEx	HY-N0172	Caffeic acid	180.042	OC(=O)\C=C\c1ccc(O)c(O)c1	QAIPRVGONGVQAS-DUXPYHPUSA-N	689043.0		QAIPRVGONGVQAS
BRD-K09900591-001-26-7	caffeic-acid	Preclinical	HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor	ALOX5|MIF			0	88.37	Selleck	S2277	Caffeic acid	180.042	OC(=O)\C=C\c1ccc(O)c(O)c1	QAIPRVGONGVQAS-DUXPYHPUSA-N	689043.0		QAIPRVGONGVQAS
BRD-K09900591-001-25-9	caffeic-acid	Preclinical	HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor	ALOX5|MIF			0	47.94	Selleck	S2277	Caffeic Acid	180.042	OC(=O)\C=C\c1ccc(O)c(O)c1	QAIPRVGONGVQAS-DUXPYHPUSA-N	689043.0		QAIPRVGONGVQAS
BRD-K96188950-001-16-9	caffeic-acid-phenethyl-ester	Preclinical	HIV integrase inhibitor	RELA			0	96.26	Tocris	2743	Caffeic acid phenethyl ester	284.105	Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	SWUARLUWKZWEBQ-VQHVLOKHSA-N	5281787.0		SWUARLUWKZWEBQ
BRD-K96188950-001-17-9	caffeic-acid-phenethyl-ester	Preclinical	HIV integrase inhibitor	RELA			0	97.3	Tocris	2743	Caffeic acid phenethyl ester	284.105	Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	SWUARLUWKZWEBQ-VQHVLOKHSA-N	5281787.0		SWUARLUWKZWEBQ
BRD-K96188950-001-15-1	caffeic-acid-phenethyl-ester	Preclinical	HIV integrase inhibitor	RELA			0	95.68	Selleck	S7414	Caffeic Acid Phenethyl Ester	284.105	Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	SWUARLUWKZWEBQ-VQHVLOKHSA-N	5281787.0		SWUARLUWKZWEBQ
BRD-K02404261-001-16-7	caffeine	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	ADORA1|ADORA2A|ADORA2B|ADORA3|ATM|ITPR1|ITPR2|ITPR3|PDE10A|PDE11A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|PIK3CA|PIK3CB|PIK3CD|PRKDC|RYR1|RYR2|RYR3	neurology/psychiatry	fatigue|drowsiness	0	99.15	MicroSource	1500155	CAFFEINE	194.08	Cn1cnc2n(C)c(=O)n(C)c(=O)c12	RYYVLZVUVIJVGH-UHFFFAOYSA-N	2519.0		RYYVLZVUVIJVGH
BRD-K77175907-001-08-0	calcifediol	Launched	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	0	93.33	Adooq	A11367	(3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol	400.334	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	JWUBBDSIWDLEOM-DTOXIADCSA-N	5283731.0		JWUBBDSIWDLEOM
BRD-K77175907-002-01-3	calcifediol	Launched	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	0	93.66	MedChemEx	HY-32351A	Calcifediol (monohydrate)	400.334	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	JWUBBDSIWDLEOM-DTOXIADCSA-N	5283731.0		JWUBBDSIWDLEOM
BRD-K77175907-001-06-4	calcifediol	Launched	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	0	79.46	Selleck	S1469	Calcifediol	400.334	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	JWUBBDSIWDLEOM-DTOXIADCSA-N	5283731.0		JWUBBDSIWDLEOM
BRD-K77175907-001-10-6	calcifediol	Launched	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	0	64.7	Selleck	S1469	Calcifediol	400.334	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	JWUBBDSIWDLEOM-DTOXIADCSA-N	5283731.0	BRD-K34907920-001-01-6	JWUBBDSIWDLEOM
BRD-K56429665-001-09-6	calcipotriol	Launched	vitamin D receptor agonist	VDR	dermatology	psoriasis	0	92.24	MedChemEx	HY-10001	Calcipotriol	412.298	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LWQQLNNNIPYSNX-UROSTWAQSA-N	5288783.0		LWQQLNNNIPYSNX
BRD-K56429665-002-01-1	calcipotriol	Launched	vitamin D receptor agonist	VDR	dermatology	psoriasis	0	91.77	MedChemEx	HY-10001A	Calcipotriol (monohydrate)	412.298	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LWQQLNNNIPYSNX-UROSTWAQSA-N	5288783.0		LWQQLNNNIPYSNX
BRD-K56429665-001-07-0	calcipotriol	Launched	vitamin D receptor agonist	VDR	dermatology	psoriasis	0	0.0	Tocris	2700	Calcipotriol	412.298	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LWQQLNNNIPYSNX-UROSTWAQSA-N	5288783.0		LWQQLNNNIPYSNX
BRD-K00005332-019-01-9	calcitonin	Launched	calcitonin agonist		orthopedics	osteoporosis	0	93.78	MedChemEx	HY-P1463A	Calcitonin, eel (TFA)	3412.723	[H]N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC1=O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O |r|	JDJALSWDQPEHEJ-XXZWWZJQSA-N			JDJALSWDQPEHEJ
BRD-K27316855-001-15-8	calcitriol	Launched	vitamin D receptor agonist	VDR	endocrinology|orthopedics	hypocalcemia|hypoparathyroidism|osteoporosis	0	96.4	Selleck	S1466	Calcitriol	416.329	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	GMRQFYUYWCNGIN-NKMMMXOESA-N	5280453.0		GMRQFYUYWCNGIN
BRD-K27316855-001-13-3	calcitriol	Launched	vitamin D receptor agonist	VDR	endocrinology|orthopedics	hypocalcemia|hypoparathyroidism|osteoporosis	0	94.12	Selleck	S1466	Calcitriol (Rocaltrol)	416.329	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	GMRQFYUYWCNGIN-NKMMMXOESA-N	5280453.0		GMRQFYUYWCNGIN
BRD-K27316855-001-19-0	calcitriol	Launched	vitamin D receptor agonist	VDR	endocrinology|orthopedics	hypocalcemia|hypoparathyroidism|osteoporosis	0	85.96	Selleck	S1466	Calcitriol	416.329	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	GMRQFYUYWCNGIN-NKMMMXOESA-N	5280453.0	BRD-K28731095-001-01-7	GMRQFYUYWCNGIN
BRD-K35952844-238-02-0	calcium-gluceptate	Launched					0	100.0	MicroSource	1300012	CALCIUM GLUCEPTATE	226.069	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	KWMLJOLKUYYJFJ-VFUOTHLCSA-N	25588.0	BRD-M41172429-238-02-8	KWMLJOLKUYYJFJ
BRD-K35952844-236-01-6	calcium-gluceptate	Launched					0	100.0	TCI	G0214		226.069	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	KWMLJOLKUYYJFJ-VFUOTHLCSA-N	25588.0		KWMLJOLKUYYJFJ
BRD-K35952844-238-01-2	calcium-gluceptate	Launched					0	100.0	Selleck	S4311	Calcium Gluceptate	226.069	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	KWMLJOLKUYYJFJ-VFUOTHLCSA-N	25588.0	BRD-K74392481-001-01-3	KWMLJOLKUYYJFJ
BRD-K97009491-238-05-9	calcium-levofolinate	Launched					0	85.78	MedChemEx	HY-13667	Levoleucovorin calcium	473.166	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	VVIAGPKUTFNRDU-STQMWFEESA-N	135398559.0		VVIAGPKUTFNRDU
BRD-K97009491-238-03-8	calcium-levofolinate	Launched					0	100.0	Selleck	S2588	Calcium levofolinate (Calcium Folinate)	473.166	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	VVIAGPKUTFNRDU-STQMWFEESA-N	135398559.0		VVIAGPKUTFNRDU
BRD-K97009491-238-02-0	calcium-levofolinate	Launched					0	69.58	Selleck	S2588	Calcium levofolinate (Calcium Folinate)	473.166	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	VVIAGPKUTFNRDU-STQMWFEESA-N	135398559.0		VVIAGPKUTFNRDU
BRD-K97009491-238-04-6	calcium-levofolinate	Launched					0	0.0	Selleck	S2588	Calcium levofolinate (Calcium Folinate)	473.166	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	VVIAGPKUTFNRDU-STQMWFEESA-N	135398559.0		VVIAGPKUTFNRDU
BRD-K19811997-003-02-9	Calhex-231	Preclinical	calcium sensing receptor negative allosteric modulator	CASR			0	97.1	Tocris	4387	Calhex 231 hydrochloride	406.181	C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12	YTFUQWWKTIWYEY-CQLNOVPUSA-N	11849514.0		YTFUQWWKTIWYEY
BRD-K19811997-003-01-3	Calhex-231	Preclinical	calcium sensing receptor negative allosteric modulator	CASR			0	93.49	Tocris	4387	Calhex 231 hydrochloride	406.181	C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12	YTFUQWWKTIWYEY-CQLNOVPUSA-N	11849514.0		YTFUQWWKTIWYEY
BRD-K26134695-001-04-4	calpeptin	Preclinical	calpain inhibitor				0	79.34	Tocris	448	Calpeptin	362.221	CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	PGGUOGKHUUUWAF-ROUUACIJSA-N	73364.0		PGGUOGKHUUUWAF
BRD-K26134695-001-05-9	calpeptin	Preclinical	calpain inhibitor				0	73.69	Tocris	448	Calpeptin	362.221	CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	PGGUOGKHUUUWAF-ROUUACIJSA-N	73364.0		PGGUOGKHUUUWAF
BRD-K26134695-001-03-6	calpeptin	Preclinical	calpain inhibitor				0	53.93	Tocris	448	Calpeptin	362.221	CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	PGGUOGKHUUUWAF-ROUUACIJSA-N	73364.0		PGGUOGKHUUUWAF
BRD-K23248433-001-02-9	camicinal	Phase 2	motilin receptor agonist	MLNR			0	84.77	MedChemEx	HY-10922	Camicinal	424.264	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	RZKDEGZIFSJVNA-IBGZPJMESA-N	15984937.0		RZKDEGZIFSJVNA
BRD-K23248433-001-01-8	camicinal	Phase 2	motilin receptor agonist	MLNR			0	85.54	MedChemEx	HY-10922	GSK962040	424.264	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	RZKDEGZIFSJVNA-IBGZPJMESA-N	15984937.0		RZKDEGZIFSJVNA
BRD-K35772771-001-02-1	CaMKII-IN-1	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	AKT1|CAMK2A|CAMK4|MYLK			0	96.28	MedChemEx	HY-18271	CaMKII-IN-1	547.181	Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12	LGUUETDTMQTHML-UHFFFAOYSA-N	50898538.0		LGUUETDTMQTHML
BRD-K35772771-001-01-3	CaMKII-IN-1	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	AKT1|CAMK2A|CAMK4|MYLK			0	94.53	MedChemEx	HY-18271	CaMKII-IN-1	547.181	Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12	LGUUETDTMQTHML-UHFFFAOYSA-N	50898538.0		LGUUETDTMQTHML
BRD-K00004732-001-01-9	camobucol	Preclinical	anti-inflammatory agent				0	99.03	MedChemEx	HY-14916	Camobucol	574.315	CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	FGBGXESDYFKUFX-UHFFFAOYSA-N	9875498.0		FGBGXESDYFKUFX
BRD-K43806473-066-03-9	camostat-mesilate	Launched	protease inhibitor	PRSS1	gastroenterology	pancreatitis	0	95.28	Tocris	3193	Camostat mesylate	398.159	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	XASIMHXSUQUHLV-UHFFFAOYSA-N	2536.0		XASIMHXSUQUHLV
BRD-K43806473-066-04-9	camostat-mesilate	Launched	protease inhibitor	PRSS1	gastroenterology	pancreatitis	0	96.48	Tocris	3193	Camostat mesylate	398.159	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	XASIMHXSUQUHLV-UHFFFAOYSA-N	2536.0		XASIMHXSUQUHLV
BRD-K43806473-066-02-1	camostat-mesilate	Launched	protease inhibitor	PRSS1	gastroenterology	pancreatitis	0	96.31	Selleck	S2874	Camostat Mesilate	398.159	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	XASIMHXSUQUHLV-UHFFFAOYSA-N	2536.0		XASIMHXSUQUHLV
BRD-K10034334-001-08-9	camphor-(+)	Phase 2					0	0.0	MedChemEx	HY-B1173	(+)-Camphor	152.12	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2	DSSYKIVIOFKYAU-XCBNKYQSSA-N	159055.0		DSSYKIVIOFKYAU
BRD-K10034334-001-03-3	camphor-(+)	Phase 2					0	0.0	MedChemEx	HY-B1173	(+)-Camphor	152.12	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2	DSSYKIVIOFKYAU-XCBNKYQSSA-N	159055.0		DSSYKIVIOFKYAU
BRD-K15714472-001-04-5	camphor-(1R)	Phase 1	TRPV activator	TRPV1			0	0.0	MicroSource	1500156	CAMPHOR	152.12	CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2	DSSYKIVIOFKYAU-GMSGAONNSA-N	5284500.0		DSSYKIVIOFKYAU
BRD-K37890730-001-17-7	camptothecin	Phase 3	topoisomerase inhibitor	TOP1			0	90.8	Selleck	S1288	Camptothecin	348.111	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	VSJKWCGYPAHWDS-FQEVSTJZSA-N	24360.0		VSJKWCGYPAHWDS
BRD-K37890730-001-15-1	camptothecin	Phase 3	topoisomerase inhibitor	TOP1			0	89.88	Selleck	S1288	Camptothecin	348.111	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	VSJKWCGYPAHWDS-FQEVSTJZSA-N	24360.0		VSJKWCGYPAHWDS
BRD-K37890730-001-16-9	camptothecin	Phase 3	topoisomerase inhibitor	TOP1			0	85.88	Tocris	1100	Camptothecin	348.111	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	VSJKWCGYPAHWDS-FQEVSTJZSA-N	24360.0		VSJKWCGYPAHWDS
BRD-A91733352-300-03-7	camylofine-chlorhydrate	Launched			gastroenterology	abdominal pain	0	88.59	Selleck	S4391	Camylofin Chlorhydrate	320.246	CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|	RYOOHIUJEJZCFT-GOSISDBHSA-N	51590030.0		RYOOHIUJEJZCFT
BRD-A91733352-300-04-5	camylofine-chlorhydrate	Launched			gastroenterology	abdominal pain	0	96.03	MicroSource	1505785	CAMYLOFINE DIHYDROCHLORIDE	320.246	CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|	RYOOHIUJEJZCFT-GOSISDBHSA-N	51590030.0		RYOOHIUJEJZCFT
BRD-A91733352-300-05-2	camylofine-chlorhydrate	Launched			gastroenterology	abdominal pain	0	95.09	Selleck	S4391	camylofine chlorhydrate	320.246	CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|	RYOOHIUJEJZCFT-GOSISDBHSA-N	51590030.0		RYOOHIUJEJZCFT
BRD-K90868879-001-04-9	canagliflozin	Launched	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2	endocrinology	diabetes mellitus	0	98.45	MedChemEx	HY-10451	Canagliflozin	444.141	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	24812758.0		XTNGUQKDFGDXSJ
BRD-K90868879-001-03-8	canagliflozin	Launched	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2	endocrinology	diabetes mellitus	0	98.9	MicroSource	1506315	CANAGLIFLOZIN	444.141	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	24812758.0		XTNGUQKDFGDXSJ
BRD-K90868879-001-02-0	canagliflozin	Launched	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2	endocrinology	diabetes mellitus	0	97.67	Selleck	S2760	Canagliflozin	444.141	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	24812758.0		XTNGUQKDFGDXSJ
BRD-K84091759-001-11-9	candesartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure	0	93.78	Tocris	4791	Candesartan	440.16	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	HTQMVQVXFRQIKW-UHFFFAOYSA-N	2541.0		HTQMVQVXFRQIKW
BRD-K84091759-001-10-5	candesartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure	0	90.89	Tocris	4791	Candesartan	440.16	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	HTQMVQVXFRQIKW-UHFFFAOYSA-N	2541.0		HTQMVQVXFRQIKW
BRD-K84091759-001-08-9	candesartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure	0	63.22	MicroSource	1502288	CANDESARTAN	440.16	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	HTQMVQVXFRQIKW-UHFFFAOYSA-N	2541.0		HTQMVQVXFRQIKW
BRD-K84091759-001-07-1	candesartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure	0	98.75	Selleck	S1578	Candesartan	440.16	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	HTQMVQVXFRQIKW-UHFFFAOYSA-N	2541.0		HTQMVQVXFRQIKW
BRD-A65671304-001-08-3	candesartan-cilexetil	Launched	angiotensin receptor antagonist		cardiology	hypertension|congestive heart failure|hypertension	0	65.5	MicroSource	1504261	CANDESARTAN CILEXTIL	610.254	CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|	GHOSNRCGJFBJIB-OAQYLSRUSA-N	51399532.0		GHOSNRCGJFBJIB
BRD-A65671304-001-07-5	candesartan-cilexetil	Launched	angiotensin receptor antagonist		cardiology	hypertension|congestive heart failure|hypertension	0	98.51	Selleck	S2037	Candesartan Cilexetil	610.254	CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|	GHOSNRCGJFBJIB-OAQYLSRUSA-N	51399532.0		GHOSNRCGJFBJIB
BRD-A65671304-001-09-9	candesartan-cilexetil	Launched	angiotensin receptor antagonist		cardiology	hypertension|congestive heart failure|hypertension	0	98.63	MedChemEx	HY-17505	Candesartan (Cilexetil)	610.254	CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13,r|	GHOSNRCGJFBJIB-OAQYLSRUSA-N	51399532.0		GHOSNRCGJFBJIB
BRD-A37348498-015-01-4	candicidin	Launched	fungal ergosterol inhibitor		infectious disease	vulvovaginal candidiasis	0	0.0	MicroSource	1503867	CANDICIDIN	1108.572	C[C@@H](C[C@@H](C)[C@H]1OC(=O)CC(=O)CCCC(=O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)C[C@@H](O)[C@@H]([C@@H](O)C[C@@H](O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@@H]1C)C(O)=O)[C@@H](O)CC(=O)c1ccc(N)cc1 |a:38,40,42,44,46,&1:1,&2:3,&3:5,&4:18,&5:21,&6:24,&7:30,&8:32,&9:33,&10:36,&11:62,&12:67,t:49,51,53,55,57,59,61|	HYIZCDMXFDRDFE-RGXQRFNASA-N			HYIZCDMXFDRDFE
BRD-K50168500-001-07-9	canertinib	Phase 3	EGFR inhibitor	AKT1|EGFR|ERBB2|ERBB4			0	95.13	Selleck	S1019	Canertinib (CI-1033)	485.163	Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	OMZCMEYTWSXEPZ-UHFFFAOYSA-N	156414.0		OMZCMEYTWSXEPZ
BRD-K50168500-001-01-2	canertinib	Phase 3	EGFR inhibitor	AKT1|EGFR|ERBB2|ERBB4			0		Selleck	S1019	CI-1033(Canertinib)	485.163	Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)	156414.0		OMZCMEYTWSXEPZ
BRD-K00004669-001-01-9	cangrelor	Launched	purinergic receptor antagonist		cardiology	myocardial infarction	0	94.41	Adooq	A12843	AR-C 69931	774.948	CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O	PAEBIVWUMLRPSK-IDTAVKCVSA-N	9854012.0		PAEBIVWUMLRPSK
BRD-K81644801-001-08-9	canrenone	Withdrawn	mineralocorticoid receptor antagonist	NR3C2			0	100.0	Tocris	3281	Canrenone	340.204	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6,t:8|	UJVLDDZCTMKXJK-WNHSNXHDSA-N	13789.0		UJVLDDZCTMKXJK
BRD-K80684056-001-09-3	cantharidin	Launched	protein phosphatase inhibitor		dermatology	blisters	0	0.0	MedChemEx	HY-N0209	Cantharidin	196.074	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	DHZBEENLJMYSHQ-XCVPVQRUSA-N	5944.0		DHZBEENLJMYSHQ
BRD-K80684056-001-06-9	cantharidin	Launched	protein phosphatase inhibitor		dermatology	blisters	0	0.0	MedChemEx	HY-N0209	Cantharidin	196.074	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	DHZBEENLJMYSHQ-XCVPVQRUSA-N	5944.0		DHZBEENLJMYSHQ
BRD-K80684056-001-05-1	cantharidin	Launched	protein phosphatase inhibitor		dermatology	blisters	0	47.3	Sigma	MFCD00134968	(3aR,4S,7R,7aS)-3a,7a-dimethylhexahydro-4,7-epoxyisobenzofuran-1,3-dione	196.074	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	DHZBEENLJMYSHQ-XCVPVQRUSA-N	5944.0		DHZBEENLJMYSHQ
BRD-K80684056-001-04-4	cantharidin	Launched	protein phosphatase inhibitor		dermatology	blisters	0	0.0	Tocris	1548	Cantharidin	196.074	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	DHZBEENLJMYSHQ-XCVPVQRUSA-N	5944.0		DHZBEENLJMYSHQ
BRD-K97025174-001-01-4	capadenoson	Phase 2	adenosine receptor agonist	ADORA1			0	99.55	MedChemEx	HY-14917	Capadenoson	519.059	Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	CITWCLNVRIKQAF-UHFFFAOYSA-N	9936489.0		CITWCLNVRIKQAF
BRD-K97025174-001-02-9	capadenoson	Phase 2	adenosine receptor agonist	ADORA1			0	96.73	MedChemEx	HY-14917	Capadenoson	519.059	Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	CITWCLNVRIKQAF-UHFFFAOYSA-N	9936489.0		CITWCLNVRIKQAF
BRD-K61192372-001-06-3	capecitabine	Launched	DNA synthesis inhibitor|thymidylate synthase inhibitor	TYMS	oncology	breast cancer|colorectal cancer	0	85.2	Tocris	4799	Capecitabine	359.149	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	GAGWJHPBXLXJQN-UORFTKCHSA-N	60953.0		GAGWJHPBXLXJQN
BRD-K61192372-001-08-9	capecitabine	Launched	DNA synthesis inhibitor|thymidylate synthase inhibitor	TYMS	oncology	breast cancer|colorectal cancer	0	97.09	MicroSource	1502271	CAPECITABINE	359.149	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	GAGWJHPBXLXJQN-UORFTKCHSA-N	60953.0	BRD-A91877226-001-01-4	GAGWJHPBXLXJQN
BRD-K61192372-001-05-5	capecitabine	Launched	DNA synthesis inhibitor|thymidylate synthase inhibitor	TYMS	oncology	breast cancer|colorectal cancer	0	97.88	Selleck	S1156	Capecitabine (Xeloda)	359.149	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	GAGWJHPBXLXJQN-UORFTKCHSA-N	60953.0		GAGWJHPBXLXJQN
BRD-K61192372-001-07-1	capecitabine	Launched	DNA synthesis inhibitor|thymidylate synthase inhibitor	TYMS	oncology	breast cancer|colorectal cancer	0	87.84	Selleck	S1156	Capecitabine	359.149	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	GAGWJHPBXLXJQN-UORFTKCHSA-N	60953.0	BRD-K15574380-001-01-0	GAGWJHPBXLXJQN
BRD-K04282412-001-16-3	capobenic-acid	Preclinical					0	52.98	MicroSource	1505417	CAPOBENIC ACID	325.153	COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O	MPTXLVRHYGBOQY-UHFFFAOYSA-N	30627.0		MPTXLVRHYGBOQY
BRD-K00005140-065-02-9	capreomycin	Launched	protein synthesis inhibitor		infectious disease	tuberculosis	0	0.0	MedChemEx	HY-17566	Capreomycin (sulfate)	652.352	C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O)=C/NC(N)=O)[C@H]1CCN=C(N)N1 |t:43|	FRXNXDHFQYZYNA-GJTMSUEESA-N			FRXNXDHFQYZYNA
BRD-K00003188-046-01-9	capromorelin	Preclinical	growth hormone secretagogue receptor agonist				0	89.29	MedChemEx	HY-15243	Capromorelin (Tartrate)	505.269	CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N |t:2|	KVLLHLWBPNCVNR-SKCUWOTOSA-N	216208.0		KVLLHLWBPNCVNR
BRD-K35170555-001-12-9	caprylic-acid	Launched					1	8.98	Enamine	Z104495238	octanoic acid	144.115	CCCCCCCC(O)=O	WWZKQHOCKIZLMA-UHFFFAOYSA-N	379.0		WWZKQHOCKIZLMA
BRD-K35170555-001-09-5	caprylic-acid	Launched					1	0.0	Enamine	Z104495238		144.115	CCCCCCCC(O)=O	WWZKQHOCKIZLMA-UHFFFAOYSA-N	379.0		WWZKQHOCKIZLMA
BRD-K50590187-001-20-7	capsaicin	Launched	TRPV agonist	CFTR|TRPV1	neurology/psychiatry|rheumatology	muscle pain|rheumatoid arthritis	0	53.56	MicroSource	1501128	CAPSAICIN	305.199	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	YKPUWZUDDOIDPM-SOFGYWHQSA-N	1548943.0		YKPUWZUDDOIDPM
BRD-K50590187-001-19-9	capsaicin	Launched	TRPV agonist	CFTR|TRPV1	neurology/psychiatry|rheumatology	muscle pain|rheumatoid arthritis	0	95.04	Tocris	462	(E)-Capsaicin	305.199	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	YKPUWZUDDOIDPM-SOFGYWHQSA-N	1548943.0		YKPUWZUDDOIDPM
BRD-K44849676-001-11-3	capsazepine	Preclinical	TRPV agonist	TRPV1|TRPV4			0	77.41	Tocris	464	Capsazepine	376.101	Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	DRCMAZOSEIMCHM-UHFFFAOYSA-N	2733484.0		DRCMAZOSEIMCHM
BRD-K44849676-001-12-9	capsazepine	Preclinical	TRPV agonist	TRPV1|TRPV4			0	97.32	Tocris	464	Capsazepine	376.101	Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	DRCMAZOSEIMCHM-UHFFFAOYSA-N	2733484.0		DRCMAZOSEIMCHM
BRD-K44849676-001-10-5	capsazepine	Preclinical	TRPV agonist	TRPV1|TRPV4			0	92.83	Tocris	464	Capsazepine	376.101	Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	DRCMAZOSEIMCHM-UHFFFAOYSA-N	2733484.0		DRCMAZOSEIMCHM
BRD-K81645907-001-01-1	captamine	Preclinical					1	0.0	MicroSource	1301014	CAPTAMINE	105.061	CN(C)CCS	DENMGZODXQRYAR-UHFFFAOYSA-N	25799.0		DENMGZODXQRYAR
BRD-K81645907-003-01-7	captamine	Preclinical					1	62.6	SantaCruz	sc-213685	2-(Dimethylamino)ethanethiol hydrochloride	105.061	CN(C)CCS	DENMGZODXQRYAR-UHFFFAOYSA-N	25799.0		DENMGZODXQRYAR
BRD-A79857384-001-03-6	captan	Phase 1					0	0.0	AKSci	S329	Captan	298.934	ClC(Cl)(Cl)SN1C(=O)[C@H]2CC=CC[C@@H]2C1=O |r,c:10|	LDVVMCZRFWMZSG-WDSKDSINSA-N	25775509.0		LDVVMCZRFWMZSG
BRD-K54529596-001-25-5	captopril	Launched	angiotensin converting enzyme inhibitor	ACE|LTA4H|MMP2|MMP9	cardiology|endocrinology|nephrology	hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy	0	0.0	MicroSource	1500682	CAPTOPRIL	217.077	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	FAKRSMQSSFJEIM-RQJHMYQMSA-N	44093.0		FAKRSMQSSFJEIM
BRD-K54529596-001-26-3	captopril	Launched	angiotensin converting enzyme inhibitor	ACE|LTA4H|MMP2|MMP9	cardiology|endocrinology|nephrology	hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy	0	100.0	Selleck	S2051	Captopril (Capoten)	217.077	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	FAKRSMQSSFJEIM-RQJHMYQMSA-N	44093.0		FAKRSMQSSFJEIM
BRD-K54529596-001-28-9	captopril	Launched	angiotensin converting enzyme inhibitor	ACE|LTA4H|MMP2|MMP9	cardiology|endocrinology|nephrology	hypertension|congestive heart failure|myocardial infarction|diabetes mellitus|diabetic nephropathy	0	0.0	Selleck	S2051	Captopril	217.077	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	FAKRSMQSSFJEIM-RQJHMYQMSA-N	44093.0	BRD-K96855766-001-01-9	FAKRSMQSSFJEIM
BRD-K62790656-001-01-1	caracemide	Phase 2	ribonucleotide reductase inhibitor	RRM1			0	41.64	Enamine	Z2327673243	1-([(methylamino)carbonyl]{[(methylamino)carbonyl]oxy}amino)-1-oxoethane	189.075	CNC(=O)ON(C(C)=O)C(=O)NC	JURAJLFHWXNPHG-UHFFFAOYSA-N	54747.0		JURAJLFHWXNPHG
BRD-K59895502-001-01-9	caramiphen	Launched	cholinergic receptor antagonist	CHRM1|CHRM2	neurology/psychiatry	Parkinson's Disease	0	87.71	ChemDiv	4435-0092		289.204	CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1	OFAIGZWCDGNZGT-UHFFFAOYSA-N	6472.0		OFAIGZWCDGNZGT
BRD-A50675490-001-01-0	carazolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology	angina pectoris|cardiac arrythmia|hypertension|myocardial infarction	0	95.74	Cayman	18628	1-(9H-carbazol-4-yloxy)-3-(isopropylamino)-2-propanol	298.168	CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5,r|	BQXQGZPYHWWCEB-CYBMUJFWSA-N	13023331.0		BQXQGZPYHWWCEB
BRD-K75037734-003-14-7	carbachol	Launched	cholinergic receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2	ophthalmology	intraocular pressure	0	89.52	MicroSource	1500158	CARBACHOL	147.113	C[N+](C)(C)CCOC(N)=O	VPJXQGSRWJZDOB-UHFFFAOYSA-O	2551.0		VPJXQGSRWJZDOB
BRD-K75037734-003-15-9	carbachol	Launched	cholinergic receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2	ophthalmology	intraocular pressure	0	100.0	MedChemEx	HY-B1208	Carbamoylcholine (chloride)	147.113	C[N+](C)(C)CCOC(N)=O	VPJXQGSRWJZDOB-UHFFFAOYSA-O	2551.0		VPJXQGSRWJZDOB
BRD-K75037734-003-13-9	carbachol	Launched	cholinergic receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2	ophthalmology	intraocular pressure	0	100.0	Selleck	S4359	Carbachol	147.113	C[N+](C)(C)CCOC(N)=O	VPJXQGSRWJZDOB-UHFFFAOYSA-O	2551.0		VPJXQGSRWJZDOB
BRD-K56735750-001-06-8	carbadox	Launched	other antibiotic		infectious disease|gastroenterology	dysentry|enteritis	0	92.9	MicroSource	1505294	CARBADOX	262.07	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	OVGGLBAWFMIPPY-WUXMJOGZSA-N	135511839.0		OVGGLBAWFMIPPY
BRD-K56735750-001-10-9	carbadox	Launched	other antibiotic		infectious disease|gastroenterology	dysentry|enteritis	0	78.27	MedChemEx	HY-B1340	Carbadox	262.07	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	OVGGLBAWFMIPPY-WUXMJOGZSA-N	135511839.0		OVGGLBAWFMIPPY
BRD-K56735750-001-09-2	carbadox	Launched	other antibiotic		infectious disease|gastroenterology	dysentry|enteritis	0	65.7	Selleck	S4312	Carbadox	262.07	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	OVGGLBAWFMIPPY-WUXMJOGZSA-N	135511839.0	BRD-K06386100-001-01-9	OVGGLBAWFMIPPY
BRD-K56735750-001-07-6	carbadox	Launched	other antibiotic		infectious disease|gastroenterology	dysentry|enteritis	0	99.18	Selleck	S4312	carbadox	262.07	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	OVGGLBAWFMIPPY-WUXMJOGZSA-N	135511839.0		OVGGLBAWFMIPPY
BRD-K71799949-001-38-0	carbamazepine	Launched	carboxamide antiepileptic	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	95.99	Tocris	4098	Carbamazepine	236.095	NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|	FFGPTBGBLSHEPO-UHFFFAOYSA-N	2554.0		FFGPTBGBLSHEPO
BRD-K71799949-001-36-4	carbamazepine	Launched	carboxamide antiepileptic	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	99.2	MicroSource	1500159	CARBAMAZEPINE	236.095	NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|	FFGPTBGBLSHEPO-UHFFFAOYSA-N	2554.0		FFGPTBGBLSHEPO
BRD-K71799949-001-35-6	carbamazepine	Launched	carboxamide antiepileptic	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	98.87	Selleck	S1693	Carbamazepine	236.095	NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|	FFGPTBGBLSHEPO-UHFFFAOYSA-N	2554.0		FFGPTBGBLSHEPO
BRD-K54208592-001-09-4	carbaril	Launched	acetylcholinesterase inhibitor				0	54.75	MicroSource	1504347	CARBARIL	201.079	CNC(=O)Oc1cccc2ccccc12	CVXBEEMKQHEXEN-UHFFFAOYSA-N	6129.0		CVXBEEMKQHEXEN
BRD-K54208592-001-10-9	carbaril	Launched	acetylcholinesterase inhibitor				0	94.61	Sigma	MFCD00021467	1-Naphthyl-N-methylcarbamate	201.079	CNC(=O)Oc1cccc2ccccc12	CVXBEEMKQHEXEN-UHFFFAOYSA-N	6129.0		CVXBEEMKQHEXEN
BRD-K94848716-001-11-6	carbarsone	Launched	antiprotozoal agent		infectious disease	amebiasis	0	69.44	MicroSource	1503868	CARBARSONE	259.978	NC(=O)Nc1ccc(cc1)[As](O)(O)=O	WWXBHTZSYYGCSG-UHFFFAOYSA-N	8480.0		WWXBHTZSYYGCSG
BRD-K94848716-001-12-9	carbarsone	Launched	antiprotozoal agent		infectious disease	amebiasis	0	100.0	FrontierSci	500055484	[4-(carbamoylamino)phenyl]arsonic acid	259.978	NC(=O)Nc1ccc(cc1)[As](O)(O)=O	WWXBHTZSYYGCSG-UHFFFAOYSA-N	8480.0		WWXBHTZSYYGCSG
BRD-A11070335-236-02-1	carbazochrome	Launched			hematology	hemorrhage	0	93.38	Selleck	S3000		300.053	CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|	OZCACMPSTYQSMM-DKBJHAQFSA-N			OZCACMPSTYQSMM
BRD-A11070335-236-03-9	carbazochrome	Launched			hematology	hemorrhage	0	97.14	MedChemEx	HY-B0491A	Carbazochrome (sodium sulfonate)	300.053	CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2,t:4,14|	OZCACMPSTYQSMM-DKBJHAQFSA-N			OZCACMPSTYQSMM
BRD-K12906202-001-06-2	carbendazim	Launched	microtubule inhibitor|tubulin polymerization inhibitor	TP53|TUBB	infectious disease	fungicide	0	98.32	Sigma	MFCD00055390	methyl 1H-benzimidazol-2-ylcarbamate	191.069	COC(=O)Nc1nc2ccccc2[nH]1	TWFZGCMQGLPBSX-UHFFFAOYSA-N	25429.0		TWFZGCMQGLPBSX
BRD-A13078313-304-09-9	carbenicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-B0525A	Carbenicillin (disodium)	378.089	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|	FPPNZSSZRUTDAP-BBGACYKPSA-N	12877824.0		FPPNZSSZRUTDAP
BRD-A13078313-304-06-5	carbenicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MicroSource	1500160	CARBENICILLIN DISODIUM	378.089	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|	FPPNZSSZRUTDAP-BBGACYKPSA-N	12877824.0		FPPNZSSZRUTDAP
BRD-A13078313-304-08-1	carbenicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-B0525A	disodium (2S,5R,6R)-3,3-dimethyl-6-[(3-oxido-3-oxo-2-phenylpropanoyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	378.089	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|	FPPNZSSZRUTDAP-BBGACYKPSA-N	12877824.0		FPPNZSSZRUTDAP
BRD-A13078313-304-05-7	carbenicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	Selleck	S3179	Carbenicillin disodium	378.089	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|	FPPNZSSZRUTDAP-BBGACYKPSA-N	12877824.0		FPPNZSSZRUTDAP
BRD-A13078313-304-07-3	carbenicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	Selleck	S3179	Carbenicillin disodium	378.089	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4,5,22,&1:9|	FPPNZSSZRUTDAP-BBGACYKPSA-N	12877824.0		FPPNZSSZRUTDAP
BRD-K12765235-304-04-9	carbenoxolone	Launched	11-beta hydroxysteroid dehydrogenase inhibitor	GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|HSD11B1|PANX1|PANX2|PANX3	gastroenterology|dental	peptic ulcer disease (PUD)|mouth inflammation	0	95.0	Tocris	3096	Carbenoxolone disodium	570.356	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|	OBZHEBDUNPOCJG-WBXJDKIVSA-N	636403.0		OBZHEBDUNPOCJG
BRD-K06181161-048-16-9	carbetapentane	Launched	acetylcholine receptor antagonist	CHRM2	otolaryngology|pulmonary	common cold|nasal congestion|bronchitis	0	42.37	MicroSource	1501129	CARBETAPENTANE CITRATE	333.23	CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1	CFJMRBQWBDQYMK-UHFFFAOYSA-N	2562.0		CFJMRBQWBDQYMK
BRD-K06181161-048-15-1	carbetapentane	Launched	acetylcholine receptor antagonist	CHRM2	otolaryngology|pulmonary	common cold|nasal congestion|bronchitis	0	93.21	Tocris	454	Carbetapentane citrate	333.23	CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1	CFJMRBQWBDQYMK-UHFFFAOYSA-N	2562.0		CFJMRBQWBDQYMK
BRD-K56107812-001-01-7	carbetocin	Launched	oxytocin receptor agonist	OXTR	hematology	hemorrhage	0	93.12	MedChemEx	HY-17573	Carbetocin	987.485	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	NSTRIRCPWQHTIA-CPWZVOFUSA-N			NSTRIRCPWQHTIA
BRD-K78712176-001-13-3	carbidopa	Launched	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	0	0.0	MicroSource	1502150	CARBIDOPA	226.095	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	TZFNLOMSOLWIDK-JTQLQIEISA-N	34359.0		TZFNLOMSOLWIDK
BRD-K78712176-001-14-1	carbidopa	Launched	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	0	0.0	Selleck	S1891	Carbidopa	226.095	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	TZFNLOMSOLWIDK-JTQLQIEISA-N	34359.0		TZFNLOMSOLWIDK
BRD-K78712176-001-11-7	carbidopa	Launched	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	0	0.0	Selleck	S1891	Carbidopa	226.095	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	TZFNLOMSOLWIDK-JTQLQIEISA-N	34359.0		TZFNLOMSOLWIDK
BRD-K78712176-001-15-8	carbidopa	Launched	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	0	0.0	MedChemEx	HY-B0311	Carbidopa	226.095	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	TZFNLOMSOLWIDK-JTQLQIEISA-N	34359.0	BRD-A69512159-001-06-5	TZFNLOMSOLWIDK
BRD-K78712176-001-12-5	carbidopa	Launched	aromatic L-amino acid decarboxylase inhibitor	DDC	neurology/psychiatry	Parkinson's Disease	0	0.0	Tocris	455	(S)-(-)-Carbidopa	226.095	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	TZFNLOMSOLWIDK-JTQLQIEISA-N	34359.0		TZFNLOMSOLWIDK
BRD-K87156652-001-14-9	carbimazole	Launched	antithyroid agent	TPO	endocrinology	hyperthyroidism	0	94.34	MedChemEx	HY-B0558	Carbimazole	186.046	CCOC(=O)n1ccn(C)c1=S	CFOYWRHIYXMDOT-UHFFFAOYSA-N	31072.0		CFOYWRHIYXMDOT
BRD-K87156652-001-11-9	carbimazole	Launched	antithyroid agent	TPO	endocrinology	hyperthyroidism	0	77.48	Selleck	S4048	Carbimazole	186.046	CCOC(=O)n1ccn(C)c1=S	CFOYWRHIYXMDOT-UHFFFAOYSA-N	31072.0		CFOYWRHIYXMDOT
BRD-K87156652-001-12-7	carbimazole	Launched	antithyroid agent	TPO	endocrinology	hyperthyroidism	0	86.2	MicroSource	1505323	CARBIMAZOLE	186.046	CCOC(=O)n1ccn(C)c1=S	CFOYWRHIYXMDOT-UHFFFAOYSA-N	31072.0		CFOYWRHIYXMDOT
BRD-K87156652-001-13-5	carbimazole	Launched	antithyroid agent	TPO	endocrinology	hyperthyroidism	0	58.46	Selleck	S4048	Carbimazole	186.046	CCOC(=O)n1ccn(C)c1=S	CFOYWRHIYXMDOT-UHFFFAOYSA-N	31072.0		CFOYWRHIYXMDOT
BRD-K01826745-050-08-9	carbinoxamine	Launched	histamine receptor antagonist	HRH1	allergy|ophthalmology|otolaryngology|dermatology	allergic rhinitis|conjunctivitis|vasomotor rhinitis|dermatographism	0	94.11	MedChemEx	HY-B1589A	Carbinoxamine maleate salt	290.119	CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|	OJFSXZCBGQGRNV-INIZCTEOSA-N	170336.0		OJFSXZCBGQGRNV
BRD-K90947825-001-03-5	carboplatin	Launched	DNA alkylating agent|DNA inhibitor		oncology	ovarian cancer	1	0.0	MicroSource	1502106	CARBOPLATIN	369.029	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	YAYRGNWWLMLWJE-UHFFFAOYSA-L	73554252.0	BRD-K11626735-318-08-7	YAYRGNWWLMLWJE
BRD-K90947825-001-05-0	carboplatin	Launched	DNA alkylating agent|DNA inhibitor		oncology	ovarian cancer	1	0.0	Selleck	S1215	Carboplatin	369.029	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	YAYRGNWWLMLWJE-UHFFFAOYSA-L	73554252.0	BRD-M80278122-318-03-3	YAYRGNWWLMLWJE
BRD-K90947825-001-02-7	carboplatin	Launched	DNA alkylating agent|DNA inhibitor		oncology	ovarian cancer	1	71.13	Tocris	2626	Carboplatin	369.029	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	YAYRGNWWLMLWJE-UHFFFAOYSA-L	73554252.0	BRD-K64763651-001-01-1	YAYRGNWWLMLWJE
BRD-K90947825-001-07-9	carboplatin	Launched	DNA alkylating agent|DNA inhibitor		oncology	ovarian cancer	1	0.0	Tocris	2626	Carboplatin	369.029	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	YAYRGNWWLMLWJE-UHFFFAOYSA-L	73554252.0		YAYRGNWWLMLWJE
BRD-K90947825-001-04-3	carboplatin	Launched	DNA alkylating agent|DNA inhibitor		oncology	ovarian cancer	1	0.0	Selleck	S1215	Carboplatin	369.029	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	YAYRGNWWLMLWJE-UHFFFAOYSA-L	73554252.0	BRD-M80278122-318-02-5	YAYRGNWWLMLWJE
BRD-K68408772-001-05-4	carboxyamidotriazole	Phase 3	calcium channel blocker	CXCL8			0	99.81	Sigma	MFCD00866325	5-amino-1-[3,5-dichloro-4-(4-chlorobenzoyl)benzyl]-1H-1,2,3-triazole-4-carboxamide	423.006	NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	WNRZHQBJSXRYJK-UHFFFAOYSA-N	108144.0		WNRZHQBJSXRYJK
BRD-K68408772-001-06-9	carboxyamidotriazole	Phase 3	calcium channel blocker	CXCL8			0		Tocris	3086	L-651,582	423.006	NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	WNRZHQBJSXRYJK-UHFFFAOYSA-N	108144.0		WNRZHQBJSXRYJK
BRD-K23533833-001-01-9	carboxylosartan	Phase 1	angiotensin antagonist	AGTR1			0	98.87	Cayman	15957	2-butyl-4-chloro-1-{[2'-(1H-tetraazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid	436.141	CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	ZEUXAIYYDDCIRX-UHFFFAOYSA-N	108185.0		ZEUXAIYYDDCIRX
BRD-K26530649-001-01-6	carboxypyridine-disulfide	Phase 2					0	98.3	Sigma	MFCD00006454	6,6'-disulfanediyldinicotinic acid	307.993	OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	GSASOFRDSIKDSN-UHFFFAOYSA-N	85040.0		GSASOFRDSIKDSN
BRD-K99174507-003-03-8	cardiogenol-C	Preclinical	cardiomyogenesis inducer				0	95.68	Tocris	3851	Cardiogenol C hydrochloride	260.127	COc1ccc(Nc2nccc(NCCO)n2)cc1	LKBSMPFEKIBRGC-UHFFFAOYSA-N	11345983.0		LKBSMPFEKIBRGC
BRD-K99174507-003-02-0	cardiogenol-C	Preclinical	cardiomyogenesis inducer				0	95.96	Tocris	3851	Cardiogenol C hydrochloride	260.127	COc1ccc(Nc2nccc(NCCO)n2)cc1	LKBSMPFEKIBRGC-UHFFFAOYSA-N	11345983.0		LKBSMPFEKIBRGC
BRD-K99174507-003-04-9	cardiogenol-C	Preclinical	cardiomyogenesis inducer				0	94.71	Tocris	3851	Cardiogenol C hydrochloride	260.127	COc1ccc(Nc2nccc(NCCO)n2)cc1	LKBSMPFEKIBRGC-UHFFFAOYSA-N	11345983.0		LKBSMPFEKIBRGC
BRD-K50905564-001-08-9	cardionogen-1	Preclinical	WNT signaling inhibitor	CTNNB1			0	93.1	Tocris	4475	Cardionogen 1	274.089	C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1	SWTUPSNBTSPBIH-UHFFFAOYSA-N	663145.0		SWTUPSNBTSPBIH
BRD-K50905564-001-07-7	cardionogen-1	Preclinical	WNT signaling inhibitor	CTNNB1			0	91.85	Tocris	4475	Cardionogen 1	274.089	C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1	SWTUPSNBTSPBIH-UHFFFAOYSA-N	663145.0		SWTUPSNBTSPBIH
BRD-K49554218-001-01-0	carebastine	Phase 1	histamine receptor antagonist	HRH1			0	98.51	ChemImpex	24186		499.272	CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	XGHOVGYJHWQGCC-UHFFFAOYSA-N	65820.0		XGHOVGYJHWQGCC
BRD-K15179879-001-11-9	carfilzomib	Launched	proteasome inhibitor	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9	hematologic malignancy	multiple myeloma	0	98.07	MedChemEx	HY-10455	Carfilzomib	719.426	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	BLMPQMFVWMYDKT-NZTKNTHTSA-N	11556711.0		BLMPQMFVWMYDKT
BRD-K15179879-001-03-2	carfilzomib	Launched	proteasome inhibitor	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9	hematologic malignancy	multiple myeloma	0	95.76	Selleck	S2853	Carfilzomib (PR-171)	719.426	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	BLMPQMFVWMYDKT-NZTKNTHTSA-N	11556711.0		BLMPQMFVWMYDKT
BRD-K60240222-001-02-9	carglumic-acid	Launched	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	0	0.0	MedChemEx	HY-B0711	Carglumic Acid	190.059	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	LCQLHJZYVOQKHU-VKHMYHEASA-N	121396.0		LCQLHJZYVOQKHU
BRD-K60240222-001-01-4	carglumic-acid	Launched	carbamoyl phosphate synthase activator	CPS1	metabolism	hyperammonemia	0	100.0	MicroSource	1506153	CARGLUMIC ACID	190.059	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	LCQLHJZYVOQKHU-VKHMYHEASA-N	121396.0		LCQLHJZYVOQKHU
BRD-K90215590-001-01-4	caricotamide	Phase 2	NADPH quinone oxidoreductase inhibitor	NQO2			0	0.0	Enamine	Z2306534737	1-(2-amino-2-oxoethyl)-1,4-dihydro-3-pyridinecarboxamide	181.085	NC(=O)CN1C=CCC(=C1)C(N)=O |c:5,8|	WEJRSYKFMCUCRQ-UHFFFAOYSA-N	403128.0		WEJRSYKFMCUCRQ
BRD-K21670884-001-01-9	cariporide	Phase 3	sodium/hydrogen exchanger inhibitor	SLC9A1			0	97.4	SantaCruz	sc-337619A		283.099	CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	IWXNYAIICFKCTM-UHFFFAOYSA-N	151172.0		IWXNYAIICFKCTM
BRD-K57764956-001-02-8	cariprazine	Launched	dopamine receptor antagonist	DRD2|DRD3	neurology/psychiatry	schizophrenia	0	97.64	MedChemEx	HY-14763	Cariprazine	426.195	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|	KPWSJANDNDDRMB-QAQDUYKDSA-N			KPWSJANDNDDRMB
BRD-K11630072-001-12-4	carmofur	Launched	thymidylate synthase inhibitor	TYMS	oncology	breast cancer|colorectal cancer	0	0.0	MicroSource	1505317	CARMOFUR	257.118	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	AOCCBINRVIKJHY-UHFFFAOYSA-N	2577.0		AOCCBINRVIKJHY
BRD-K11630072-001-13-2	carmofur	Launched	thymidylate synthase inhibitor	TYMS	oncology	breast cancer|colorectal cancer	0	86.52	Selleck	S1289	Carmofur	257.118	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	AOCCBINRVIKJHY-UHFFFAOYSA-N	2577.0		AOCCBINRVIKJHY
BRD-K11630072-001-11-6	carmofur	Launched	thymidylate synthase inhibitor	TYMS	oncology	breast cancer|colorectal cancer	0	0.0	Selleck	S1289	Carmofur	257.118	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	AOCCBINRVIKJHY-UHFFFAOYSA-N	2577.0		AOCCBINRVIKJHY
BRD-K25095405-001-01-5	carmoterol	Phase 2	adrenergic receptor agonist	ADRB2			0	24.66	BidePharm	BD239285		368.174	COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1	IHOXNOQMRZISPV-YJYMSZOUSA-N	86306667.0	BRD-A25157829-001-01-3	IHOXNOQMRZISPV
BRD-K82484965-003-04-3	carmoxirole	Phase 2	dopamine receptor agonist	DRD2			0	91.82	Tocris	2193	3-[4-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)butyl]-1H-indole-5-carboxylic acid hydrochloride	374.199	OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|	AFSOIHMEOKEZJF-UHFFFAOYSA-N	86308157.0		AFSOIHMEOKEZJF
BRD-K82484965-003-03-5	carmoxirole	Phase 2	dopamine receptor agonist	DRD2			0	81.89	Tocris	2193	Carmoxirole hydrochloride	374.199	OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|	AFSOIHMEOKEZJF-UHFFFAOYSA-N	86308157.0		AFSOIHMEOKEZJF
BRD-K36234266-001-09-8	carmustine	Launched	DNA alkylating agent|DNA inhibitor	GSR	hematologic malignancy|oncology	non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|multiple myeloma|glioblastoma|brainstem glioma|medulloblastoma|astrocytoma|ependymoma	1	24.61	MicroSource	1503110	CARMUSTINE	213.007	[O-][NH2+]N(CCCl)C(=O)NCCCl	IIJOAQBKDPUMEO-UHFFFAOYSA-N	59087767.0		IIJOAQBKDPUMEO
BRD-K36234266-001-10-6	carmustine	Launched	DNA alkylating agent|DNA inhibitor	GSR	hematologic malignancy|oncology	non-Hodgkin lymphoma (NHL)|Hodgkin's lymphoma|multiple myeloma|glioblastoma|brainstem glioma|medulloblastoma|astrocytoma|ependymoma	1		MicroSource	1503110	CARMUSTINE	213.007	[O-][NH2+]N(CCCl)C(=O)NCCCl	IIJOAQBKDPUMEO-UHFFFAOYSA-N	59087767.0		IIJOAQBKDPUMEO
BRD-A89594340-003-12-3	carnitine-(D/L)	Phase 3					0	100.0	MicroSource	1500624	CARNITINE (dl) HYDROCHLORIDE	162.113	C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|	PHIQHXFUZVPYII-LURJTMIESA-O	160907.0		PHIQHXFUZVPYII
BRD-A89594340-003-11-5	carnitine-(D/L)	Phase 3					0	100.0	Selleck	S2293	DL-Carnitine HCl	162.113	C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|	PHIQHXFUZVPYII-LURJTMIESA-O	160907.0		PHIQHXFUZVPYII
BRD-A89594340-003-13-1	carnitine-(D/L)	Phase 3					0	100.0	Selleck	S2293	CARNITINE HYDROCHLORIDE	162.113	C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|	PHIQHXFUZVPYII-LURJTMIESA-O	160907.0		PHIQHXFUZVPYII
BRD-A96051074-001-02-2	carnosine	Phase 2	antiglycating agent				0	0.0	SantaCruz	sc-202521A		226.107	NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O |&1:6,r|	CQOVPNPJLQNMDC-ZETCQYMHSA-N	6992100.0		CQOVPNPJLQNMDC
BRD-K70161083-003-05-5	caroverin	Phase 3	cytochrome P450 inhibitor				0	86.74	Sigma	MFCD01684929	1-[2-(diethylamino)ethyl]-3-(4-methoxybenzyl)-2(1H)-quinoxalinone hydrochloride	365.21	CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O	MSPRUJDUTKRMLM-UHFFFAOYSA-N	65709.0		MSPRUJDUTKRMLM
BRD-K70161083-001-06-9	caroverin	Phase 3	cytochrome P450 inhibitor				0	92.73	AMS	C0260	Caroverin	365.21	CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O	MSPRUJDUTKRMLM-UHFFFAOYSA-N	65709.0		MSPRUJDUTKRMLM
BRD-K92129045-001-01-6	caroxazone	Withdrawn	monoamine oxidase inhibitor	MAOA|MAOB			0	97.63	Enamine	Z2327531727	2-(2-oxo-2H-1,3-benzoxazin-3(4H)-yl)acetamide	206.069	NC(=O)CN1Cc2ccccc2OC1=O	KYCBWEZLKCTALM-UHFFFAOYSA-N	29083.0		KYCBWEZLKCTALM
BRD-A17411484-001-11-9	carprofen	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	0	98.54	MicroSource	1502006	CARPROFEN	273.056	C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|	PUXBGTOOZJQSKH-MRVPVSSYSA-N	6997572.0		PUXBGTOOZJQSKH
BRD-A17411484-001-10-1	carprofen	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	0	95.61	Selleck	S4136	Carprofen	273.056	C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|	PUXBGTOOZJQSKH-MRVPVSSYSA-N	6997572.0		PUXBGTOOZJQSKH
BRD-A17411484-001-13-9	carprofen	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	0	98.72	MedChemEx	HY-B1227	Carprofen	273.056	C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1,r|	PUXBGTOOZJQSKH-MRVPVSSYSA-N	6997572.0		PUXBGTOOZJQSKH
BRD-K13238618-001-06-9	carsalam	Preclinical	analgesic agent				0	93.9	MedChemEx	HY-B1047	Carsalam	163.027	O=c1[nH]c(=O)c2ccccc2o1	OAYRYNVEFFWSHK-UHFFFAOYSA-N	16258.0		OAYRYNVEFFWSHK
BRD-K13238618-001-05-9	carsalam	Preclinical	analgesic agent				0	99.02	MicroSource	1504504	CARSALAM	163.027	O=c1[nH]c(=O)c2ccccc2o1	OAYRYNVEFFWSHK-UHFFFAOYSA-N	16258.0		OAYRYNVEFFWSHK
BRD-A42167015-003-10-2	carteolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	ophthalmology	intraocular pressure|glaucoma|ocular hypertension	0	98.62	MedChemEx	HY-17495A	Carteolol (hydrochloride)	292.179	CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12	LWAFSWPYPHEXKX-UHFFFAOYSA-N	49852288.0		LWAFSWPYPHEXKX
BRD-K71026158-304-01-0	carumonam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|gram-negative bacterial infections	0	97.4	Sigma	MFCD00875847	disodium ({[(Z)-2-[((2S,3S)-2-{[(aminocarbonyl)oxy]methyl}-4-oxo-1-sulfonato-3-azetidinyl)amino]-1-(2-amino-1,3-thiazol-4-yl)-2-oxoethylidene]amino}oxy)acetate	466.021	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	UIMOJFJSJSIGLV-JNHMLNOCSA-N	6540466.0		UIMOJFJSJSIGLV
BRD-K01826535-001-02-9	carvedilol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology	myocardial infarction|hypertension	0	96.9	Tocris	2685	Carvedilol	406.189	COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|	OGHNVEJMJSYVRP-QGZVFWFLSA-N	185394.0		OGHNVEJMJSYVRP
BRD-K09295674-001-09-8	carzenide	Preclinical		CA1|CA12|CA14|CA2|CA6|CA9			0	92.92	MicroSource	1504505	CARZENIDE	201.01	NS(=O)(=O)c1ccc(cc1)C(O)=O	UCAGLBKTLXCODC-UHFFFAOYSA-N	8739.0		UCAGLBKTLXCODC
BRD-K12413266-001-01-3	casanthranol-variant	Launched			gastroenterology	constipation	0	0.0	MicroSource	1506179	CASANTHRANOL [cascaroside A shown]	434.121	OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O	XMCJWIFCIIXRGI-BAEVKLAGSA-N	132469060.0		XMCJWIFCIIXRGI
BRD-K12413266-001-02-1	casanthranol-variant	Launched			gastroenterology	constipation	0	0.0	Selleck	S5132	CASANTHRANOL [cascaroside A shown]	434.121	OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O	XMCJWIFCIIXRGI-BAEVKLAGSA-N	132469060.0		XMCJWIFCIIXRGI
BRD-A25043798-001-02-9	casin	Preclinical	GTPase inhibitor	CDC42			0	89.58	Tocris	5050	CASIN	306.173	OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|	RXIUMAOXORBRCY-IBGZPJMESA-N	1600664.0		RXIUMAOXORBRCY
BRD-A25043798-001-01-2	casin	Preclinical	GTPase inhibitor	CDC42			0	87.75	Tocris	5050	CASIN	306.173	OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4,r|	RXIUMAOXORBRCY-IBGZPJMESA-N	1600664.0		RXIUMAOXORBRCY
BRD-K00002625-402-02-9	caspofungin	Launched	bacterial cell wall synthesis inhibitor|fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia|esophageal candidiasis|aspergillosis|peritonitis|fungal infection	0	100.0	MedChemEx	HY-17006	Caspofungin (Acetate)	1092.643	[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O	JYIKNQVWKBUSNH-WVDDFWQHSA-N	16119814.0		JYIKNQVWKBUSNH
BRD-K20897876-001-11-8	castanospermine	Phase 2	glucosidase inhibitor	GAA|GBA			0	97.7	Tocris	759	Castanospermine	189.1	O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12	JDVVGAQPNNXQDW-TVNFTVLESA-N	54445.0		JDVVGAQPNNXQDW
BRD-K20897876-001-10-0	castanospermine	Phase 2	glucosidase inhibitor	GAA|GBA			0	100.0	Tocris	759	Castanospermine	189.1	O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12	JDVVGAQPNNXQDW-TVNFTVLESA-N	54445.0		JDVVGAQPNNXQDW
BRD-K92377961-001-04-9	catharanthine	Preclinical	tubulin polymerization inhibitor				0	81.19	MedChemEx	HY-N0252	Catharanthine	336.184	CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|	CMKFQVZJOWHHDV-NQZBTDCJSA-N	5458190.0		CMKFQVZJOWHHDV
BRD-K92377961-001-03-7	catharanthine	Preclinical	tubulin polymerization inhibitor				0	82.42	Selleck	S3202	Catharanthine	336.184	CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|	CMKFQVZJOWHHDV-NQZBTDCJSA-N	5458190.0		CMKFQVZJOWHHDV
BRD-K92377961-001-02-9	catharanthine	Preclinical	tubulin polymerization inhibitor				0	34.13	Selleck	S3202	Catharanthine	336.184	CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|	CMKFQVZJOWHHDV-NQZBTDCJSA-N	5458190.0		CMKFQVZJOWHHDV
BRD-K40269473-001-02-2	cathepsin-inhibitor-1	Preclinical	cathepsin inhibitor	CTSB|CTSL|CTSV			0	97.25	Selleck	S2847	Cathepsin Inhibitor 1	401.162	Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C	MZRVIHRERYCHBL-HNNXBMFYSA-N	44224135.0		MZRVIHRERYCHBL
BRD-K40269473-001-03-0	cathepsin-inhibitor-1	Preclinical	cathepsin inhibitor	CTSB|CTSL|CTSV			0	98.4	Selleck	S2847	Cathepsin Inhibitor 1	401.162	Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C	MZRVIHRERYCHBL-HNNXBMFYSA-N	44224135.0		MZRVIHRERYCHBL
BRD-K40366680-001-05-9	CAY10505	Preclinical	PI3K inhibitor	PIK3CG			0	79.72	MedChemEx	HY-13530	CAY10505	289.021	Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	UFBTYTGRUBUUIL-KPKJPENVSA-N	1204893.0		UFBTYTGRUBUUIL
BRD-K40366680-001-04-1	CAY10505	Preclinical	PI3K inhibitor	PIK3CG			0	92.14	Selleck	S2682	CAY10505	289.021	Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	UFBTYTGRUBUUIL-KPKJPENVSA-N	1204893.0		UFBTYTGRUBUUIL
BRD-K40366680-001-03-3	CAY10505	Preclinical	PI3K inhibitor	PIK3CG			0	80.05	Selleck	S2682	CAY10505	289.021	Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	UFBTYTGRUBUUIL-KPKJPENVSA-N	1204893.0		UFBTYTGRUBUUIL
BRD-K41779183-001-01-2	CB-03-01	Phase 3	androgen receptor antagonist	AR			0	79.66	MedChemEx	HY-13331	17 alpha-propionate	402.241	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|	GPNHMOZDMYNCPO-PDUMRIMRSA-N	11750009.0		GPNHMOZDMYNCPO
BRD-K41779183-001-02-0	CB-03-01	Phase 3	androgen receptor antagonist	AR			0	85.64	MedChemEx	HY-13331	Cortexolone 17 alpha-propionate	402.241	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|	GPNHMOZDMYNCPO-PDUMRIMRSA-N	11750009.0		GPNHMOZDMYNCPO
BRD-K59929863-001-02-9	CB-10-277	Phase 1	DNA synthesis inhibitor				0	93.57	Labotest	LT00039235	4-[(1E)-3,3-dimethyl-1-triazenyl]benzoic acid	193.085	CN(C)\N=N\c1ccc(cc1)C(O)=O	GUAZPUYTLMUTMA-ZHACJKMWSA-N			GUAZPUYTLMUTMA
BRD-K59929863-001-01-9	CB-10-277	Phase 1	DNA synthesis inhibitor				0	99.53	Vitas-M	STK021840		193.085	CN(C)\N=N\c1ccc(cc1)C(O)=O	GUAZPUYTLMUTMA-ZHACJKMWSA-N			GUAZPUYTLMUTMA
BRD-K49048664-001-02-0	CB-5083	Phase 1	valosin-containing protein inhibitor	VCP			0	96.43	MedChemEx	HY-12861	CB-5083	413.185	Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O	RDALZZCKQFLGJP-UHFFFAOYSA-N	73051434.0		RDALZZCKQFLGJP
BRD-K49048664-001-01-2	CB-5083	Phase 1	valosin-containing protein inhibitor	VCP			0	96.62	ApexBio	B6032	CB-5083	413.185	Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O	RDALZZCKQFLGJP-UHFFFAOYSA-N	73051434.0		RDALZZCKQFLGJP
BRD-K58070273-001-03-3	CB-839	Phase 2	glutaminase inhibitor	GLS			0	94.65	Broad Institute		CB-839	571.161	FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1	PRAAPINBUWJLGA-UHFFFAOYSA-N	71577426.0		PRAAPINBUWJLGA
BRD-K58070273-001-04-1	CB-839	Phase 2	glutaminase inhibitor	GLS			0	94.57	MedChemEx	HY-12248	CB-839	571.161	FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1	PRAAPINBUWJLGA-UHFFFAOYSA-N	71577426.0		PRAAPINBUWJLGA
BRD-K34675210-003-01-4	CBiPES	Preclinical	glutamate receptor positive allosteric modulator	GRM2			0	98.08	Tocris	3949	CBiPES hydrochloride	377.12	CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N	HDVYXILCBYGKGU-UHFFFAOYSA-N	9864510.0		HDVYXILCBYGKGU
BRD-K34675210-003-02-9	CBiPES	Preclinical	glutamate receptor positive allosteric modulator	GRM2			0	97.65	Tocris	3949	CBiPES hydrochloride	377.12	CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N	HDVYXILCBYGKGU-UHFFFAOYSA-N	9864510.0		HDVYXILCBYGKGU
BRD-K00003273-003-01-9	cbl0137	Phase 1	histone chaperone inhibitor				0	94.17	MedChemEx	HY-18935A	CBL0137 hydrochloride	336.184	CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O	JKCSODVERGVDLT-UHFFFAOYSA-N	44519124.0		JKCSODVERGVDLT
BRD-K91874254-001-01-4	CBS-1114	Phase 1	lipoxygenase inhibitor	ALOX5			0	50.58	Vitas-M	STL483463	N'-phenylbenzimidohydrazide	211.111	NC(=NNc1ccccc1)c1ccccc1	ZOBKPJRHDMKXQG-UHFFFAOYSA-N	6338223.0		ZOBKPJRHDMKXQG
BRD-K16755045-003-01-7	CC-115	Phase 2	DNA protein kinase inhibitor|mTOR inhibitor	MTOR			0	84.53	MedChemEx	HY-16962A	CC-115 (hydrochloride)	336.145	CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|	GMYLVKUGJMYTFB-UHFFFAOYSA-N	58298318.0		GMYLVKUGJMYTFB
BRD-K16755045-001-01-1	CC-115	Phase 2	DNA protein kinase inhibitor|mTOR inhibitor	MTOR			0	45.35	MedChemEx	HY-16962	CC-115	336.145	CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|	GMYLVKUGJMYTFB-UHFFFAOYSA-N	58298318.0		GMYLVKUGJMYTFB
BRD-K16755045-003-02-5	CC-115	Phase 2	DNA protein kinase inhibitor|mTOR inhibitor	MTOR			0	93.43	MedChemEx	HY-16962A	CC-115 (hydrochloride)	336.145	CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9,t:6,11|	GMYLVKUGJMYTFB-UHFFFAOYSA-N	58298318.0		GMYLVKUGJMYTFB
BRD-K88737571-001-02-2	CC-223	Phase 2	mTOR inhibitor	MTOR			0	84.46	MedChemEx	HY-16956	CC-223	397.211	CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|	UFKLYTOEMRFKAD-SHTZXODSSA-N			UFKLYTOEMRFKAD
BRD-K88737571-001-01-4	CC-223	Phase 2	mTOR inhibitor	MTOR			0	34.57	MedChemEx	HY-16956	CC-223	397.211	CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|	UFKLYTOEMRFKAD-SHTZXODSSA-N			UFKLYTOEMRFKAD
BRD-K00004320-300-01-9	CC-401	Phase 1	JNK inhibitor	MAPK8			0	97.22	Tocris	6258	CC 401 dihydrochloride	388.201	C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1	XDJCLCLBSGGNKS-UHFFFAOYSA-N	10430360.0		XDJCLCLBSGGNKS
BRD-K00003116-001-01-9	CC-90003	Phase 1	MAP kinase inhibitor				0	98.09	MedChemEx	HY-112570	CC-90003	458.168	COc1cc(Nc2ncc(c(Nc3ccc(C)cc3NC(=O)C=C)n2)C(F)(F)F)c(C)cn1	ILUKRINUNLAVMH-UHFFFAOYSA-N	90331177.0		ILUKRINUNLAVMH
BRD-K48213016-001-01-8	CC-930	Phase 2	JNK inhibitor				0	94.72	MedChemEx	HY-15495	CC-930	448.183	O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1	IBGLGMOPHJQDJB-IHRRRGAJSA-N			IBGLGMOPHJQDJB
BRD-K48213016-001-02-9	CC-930	Phase 2	JNK inhibitor				0	94.24	MedChemEx	HY-15495	Tanzisertib	448.183	O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1	IBGLGMOPHJQDJB-IHRRRGAJSA-N			IBGLGMOPHJQDJB
BRD-A79726147-001-02-9	CCG-1423	Preclinical	apoptosis stimulant	RHOC|SRF			0	94.04	Tocris	5233	CCG 1423	454.052	C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|	DSMXVSGJIDFLKP-SECBINFHSA-N	40782280.0		DSMXVSGJIDFLKP
BRD-A79726147-001-01-5	CCG-1423	Preclinical	apoptosis stimulant	RHOC|SRF			0	87.77	Tocris	5233	CCG 1423	454.052	C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1,r|	DSMXVSGJIDFLKP-SECBINFHSA-N	40782280.0		DSMXVSGJIDFLKP
BRD-K08893438-001-08-9	CCG-50014	Preclinical	G protein signaling inhibitor	RGS4|RGS8			0	91.85	Tocris	4567	CCG 50014	316.068	Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	QUIIIYITNGOFEI-UHFFFAOYSA-N	2733079.0		QUIIIYITNGOFEI
BRD-K08893438-001-06-4	CCG-50014	Preclinical	G protein signaling inhibitor	RGS4|RGS8			0	24.05	Tocris	4567	CCG 50014	316.068	Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	QUIIIYITNGOFEI-UHFFFAOYSA-N	2733079.0		QUIIIYITNGOFEI
BRD-K08893438-001-04-9	CCG-50014	Preclinical	G protein signaling inhibitor	RGS4|RGS8			0	97.23	Selleck	S2901	CCG 50014	316.068	Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	QUIIIYITNGOFEI-UHFFFAOYSA-N	2733079.0		QUIIIYITNGOFEI
BRD-K08893438-001-03-1	CCG-50014	Preclinical	G protein signaling inhibitor	RGS4|RGS8			0	1.03	Selleck	S2901	CCG 50014	316.068	Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	QUIIIYITNGOFEI-UHFFFAOYSA-N	2733079.0		QUIIIYITNGOFEI
BRD-K26970495-001-02-7	CCG-63802	Preclinical	G protein signaling inhibitor	RGS4			0	3.27	MedChemEx	HY-70074	CCG-63802	450.115	Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1	VFSVKVQMZDJFQX-NBVRZTHBSA-N	6057678.0		VFSVKVQMZDJFQX
BRD-K26970495-001-01-9	CCG-63802	Preclinical	G protein signaling inhibitor	RGS4			0	0.0	MedChemEx	HY-70074	CCG-63802	450.115	Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1	VFSVKVQMZDJFQX-NBVRZTHBSA-N	6057678.0		VFSVKVQMZDJFQX
BRD-K68474505-001-02-7	CCG-63808	Preclinical	G protein signaling inhibitor	RGS4			0	8.02	MedChemEx	HY-70075	CCG-63808	454.09	Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O	IPZHFKHGSYRBNT-DTQAZKPQSA-N	5948316.0		IPZHFKHGSYRBNT
BRD-K68474505-001-01-9	CCG-63808	Preclinical	G protein signaling inhibitor	RGS4			0	0.62	MedChemEx	HY-70075	CCG-63808	454.09	Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O	IPZHFKHGSYRBNT-DTQAZKPQSA-N	5948316.0		IPZHFKHGSYRBNT
BRD-K16338837-001-01-8	CCMI	Preclinical	acetylcholine receptor allosteric modulator	CHRNA7			0	92.17	Tocris	3837	CCMI	387.054	Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	VMAKIACTLSBBIY-UHFFFAOYSA-N	67042344.0		VMAKIACTLSBBIY
BRD-K16338837-001-02-6	CCMI	Preclinical	acetylcholine receptor allosteric modulator	CHRNA7			0	93.64	Tocris	3837	CCMI	387.054	Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	VMAKIACTLSBBIY-UHFFFAOYSA-N	67042344.0	BRD-K19859123-001-01-3	VMAKIACTLSBBIY
BRD-K16338837-001-03-9	CCMI	Preclinical	acetylcholine receptor allosteric modulator	CHRNA7			0	50.93	Tocris	3837	CCMI	387.054	Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	VMAKIACTLSBBIY-UHFFFAOYSA-N	67042344.0		VMAKIACTLSBBIY
BRD-K06159959-001-03-9	CCMQ	Preclinical	homoquinolinic acid binding inhibitor				0	97.59	Tocris	1238	CCMQ	231.053	OC(=O)Cc1cc2ccccc2nc1C(O)=O	IFXJDEHFADWURH-UHFFFAOYSA-N	3337816.0		IFXJDEHFADWURH
BRD-K06159959-001-02-0	CCMQ	Preclinical	homoquinolinic acid binding inhibitor				0	65.42	Tocris	1238	CCMQ	231.053	OC(=O)Cc1cc2ccccc2nc1C(O)=O	IFXJDEHFADWURH-UHFFFAOYSA-N	3337816.0		IFXJDEHFADWURH
BRD-K90999434-004-02-9	CCT-031374	Preclinical	WNT signaling inhibitor	CTNNB1			0	97.42	Tocris	4675	CCT 031374 hydrobromide	353.153	O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|	JPCYSKNELCOPKJ-UHFFFAOYSA-N	2853753.0		JPCYSKNELCOPKJ
BRD-K90999434-004-01-7	CCT-031374	Preclinical	WNT signaling inhibitor	CTNNB1			0	89.63	Tocris	4675	CCT 031374 hydrobromide	353.153	O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|	JPCYSKNELCOPKJ-UHFFFAOYSA-N	2853753.0		JPCYSKNELCOPKJ
BRD-K65503129-001-07-1	CCT018159	Preclinical	HSP inhibitor	HSP90AA1|HSP90AB1			0	97.39	Tocris	2435	CCT 018159	352.142	CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O	OWPMENVYXDJDOW-UHFFFAOYSA-N	984170.0		OWPMENVYXDJDOW
BRD-K65503129-001-06-3	CCT018159	Preclinical	HSP inhibitor	HSP90AA1|HSP90AB1			0	95.87	Tocris	2435	CCT 018159	352.142	CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O	OWPMENVYXDJDOW-UHFFFAOYSA-N	984170.0		OWPMENVYXDJDOW
BRD-K76406695-001-02-9	CCT128930	Preclinical	AKT inhibitor				0	96.82	Selleck	S2635	CCT128930	341.141	NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	RZIDZIGAXXNODG-UHFFFAOYSA-N	17751819.0		RZIDZIGAXXNODG
BRD-K76406695-001-05-9	CCT128930	Preclinical	AKT inhibitor				0	95.15	MedChemEx	HY-13260	CCT128930	341.141	NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	RZIDZIGAXXNODG-UHFFFAOYSA-N	17751819.0		RZIDZIGAXXNODG
BRD-K57136142-001-02-4	CCT129202	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	82.82	Selleck	S1519	CCT129202	496.156	CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1	QYKHWEFPFAGNEV-UHFFFAOYSA-N	16202152.0		QYKHWEFPFAGNEV
BRD-K57136142-001-03-2	CCT129202	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	40.64	Selleck	S1519	CCT129202	496.156	CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1	QYKHWEFPFAGNEV-UHFFFAOYSA-N	16202152.0		QYKHWEFPFAGNEV
BRD-K57136142-001-04-9	CCT129202	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	92.03	MedChemEx	HY-12049	CCT129202	496.156	CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1	QYKHWEFPFAGNEV-UHFFFAOYSA-N	16202152.0		QYKHWEFPFAGNEV
BRD-K03289018-001-02-7	CCT137690	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	85.27	Selleck	S2744	CCT137690	550.18	CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1	GFLQCBTXTRCREJ-UHFFFAOYSA-N	25154041.0		GFLQCBTXTRCREJ
BRD-K03289018-001-03-5	CCT137690	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	90.43	Selleck	S2744	CCT137690	550.18	CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1	GFLQCBTXTRCREJ-UHFFFAOYSA-N	25154041.0		GFLQCBTXTRCREJ
BRD-K03289018-001-04-3	CCT137690	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	97.74	Tocris	4291	CCT 137690	550.18	CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1	GFLQCBTXTRCREJ-UHFFFAOYSA-N	25154041.0		GFLQCBTXTRCREJ
BRD-K03289018-001-05-9	CCT137690	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	95.41	Tocris	4291	CCT 137690	550.18	CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1	GFLQCBTXTRCREJ-UHFFFAOYSA-N	25154041.0		GFLQCBTXTRCREJ
BRD-K00005244-001-01-9	CCT196969	Preclinical	RAF inhibitor				0	90.52	MedChemEx	HY-12846	CCT196969	513.192	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1	KYYKGSDLXXKQCR-UHFFFAOYSA-N	42628843.0		KYYKGSDLXXKQCR
BRD-K00003276-001-01-9	CCT245737	Preclinical	kinase inhibitor				0	89.88	MedChemEx	HY-18958	CCT245737	379.137	FC(F)(F)c1cnc(Nc2cnc(cn2)C#N)cc1NC[C@H]1CNCCO1	YBYYWUUUGCNAHQ-LLVKDONJSA-N	72165232.0		YBYYWUUUGCNAHQ
BRD-K17751100-001-02-9	CC4	Preclinical	nicotinic receptor agonist	CHRNB2			0	89.23	Tocris	5236	CC4	406.237	O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12	LEXDAVFCJPDCNA-VNTMZGSJSA-N	91654624.0		LEXDAVFCJPDCNA
BRD-K17751100-001-01-1	CC4	Preclinical	nicotinic receptor agonist	CHRNB2			0	82.66	Tocris	5236	CC4	406.237	O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12	LEXDAVFCJPDCNA-VNTMZGSJSA-N	91654624.0		LEXDAVFCJPDCNA
BRD-K09619322-001-03-8	CD-1530	Preclinical	retinoid receptor agonist	RARG			0	92.54	Tocris	2554	CD 1530	398.188	OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2	VCQGNUWOMLYNNG-UHFFFAOYSA-N	9952709.0	BRD-K25737009-001-04-6	VCQGNUWOMLYNNG
BRD-K09619322-001-04-9	CD-1530	Preclinical	retinoid receptor agonist	RARG			0	93.52	Tocris	2554	CD 1530	398.188	OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2	VCQGNUWOMLYNNG-UHFFFAOYSA-N	9952709.0		VCQGNUWOMLYNNG
BRD-K28907958-001-05-0	CD-437	Preclinical	retinoid receptor agonist	RARG			0	94.37	Tocris	1549	CD 437	398.188	OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	LDGIHZJOIQSHPB-UHFFFAOYSA-N	135411.0		LDGIHZJOIQSHPB
BRD-K28907958-001-04-3	CD-437	Preclinical	retinoid receptor agonist	RARG			0	96.59	Tocris	1549	CD 437	398.188	OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	LDGIHZJOIQSHPB-UHFFFAOYSA-N	135411.0		LDGIHZJOIQSHPB
BRD-A08079565-001-01-8	CDBA	Phase 3					0	97.04	EMDBio	239760-25GM	Cyclodextrin	1134.37	OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2,&2:4,&3:6,&4:7,&5:11,&6:13,&7:14,&8:18,&9:20,&10:21,&11:25,&12:27,&13:28,&14:32,&15:34,&16:35,&17:39,&18:41,&19:42,&20:46,&21:48,&22:49,&23:51,&24:53,&25:55,&26:57,&27:59,&28:61,&29:63,&30:65,&31:67,&32:69,&33:71,&34:73,&35:75,r|	WHGYBXFWUBPSRW-GUJBRCDDSA-N			WHGYBXFWUBPSRW
BRD-K87932577-001-04-9	CDK1-5-inhibitor	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	CDK1|CDK5|GSK3B			0	84.79	Tocris	1937	NSC 693868	185.07	Nc1[nH]nc2nc3ccccc3nc12	DWHVZCLBMTZRQM-UHFFFAOYSA-N	438981.0		DWHVZCLBMTZRQM
BRD-K87932577-001-02-4	CDK1-5-inhibitor	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	CDK1|CDK5|GSK3B			0	97.23	Tocris	1937	NSC 693868	185.07	Nc1[nH]nc2nc3ccccc3nc12	DWHVZCLBMTZRQM-UHFFFAOYSA-N	438981.0		DWHVZCLBMTZRQM
BRD-K43914553-001-01-5	CDK9-IN-6	Preclinical	CDK inhibitor	CDK9			0	96.73	MedChemEx	HY-12214	CDK9-IN-6	512.267	COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1	XWQVQSXLXAXOPJ-ACRUOGEOSA-N			XWQVQSXLXAXOPJ
BRD-K02213468-001-02-3	CDPPB	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	96.82	Tocris	3235	CDPPB	364.132	O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N	BKUIZWILNWHFHD-UHFFFAOYSA-N	11245456.0		BKUIZWILNWHFHD
BRD-K02213468-001-03-9	CDPPB	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	96.95	Tocris	3235	CDPPB	364.132	O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N	BKUIZWILNWHFHD-UHFFFAOYSA-N	11245456.0		BKUIZWILNWHFHD
BRD-K48141473-001-01-7	cebranopadol	Phase 3	opioid receptor agonist	OPRL1|OPRM1			0	95.64	MedChemEx	HY-15536	Cebranopadol	378.211	CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|	CSMVOZKEWSOFER-RQNOJGIXSA-N			CSMVOZKEWSOFER
BRD-K48141473-001-02-9	cebranopadol	Phase 3	opioid receptor agonist	OPRL1|OPRM1			0	94.31	MedChemEx	HY-15536	Cebranopadol	378.211	CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|	CSMVOZKEWSOFER-RQNOJGIXSA-N			CSMVOZKEWSOFER
BRD-K86930074-001-06-9	cediranib	Phase 3	KIT inhibitor|VEGFR inhibitor	CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB			0	96.62	MedChemEx	HY-10205	Cediranib	450.207	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	XXJWYDDUDKYVKI-UHFFFAOYSA-N	9933475.0		XXJWYDDUDKYVKI
BRD-K86930074-001-05-0	cediranib	Phase 3	KIT inhibitor|VEGFR inhibitor	CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB			0	90.12	Selleck	S1017	Cediranib (AZD2171)	450.207	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	XXJWYDDUDKYVKI-UHFFFAOYSA-N	9933475.0		XXJWYDDUDKYVKI
BRD-A61188230-001-01-6	cedrol	Phase 2					0	0.0	Vitas-M	STK066400		222.198	C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1,&2:4,&3:8,&4:10,&5:13,r|	SVURIXNDRWRAFU-OBORUHMCSA-N			SVURIXNDRWRAFU
BRD-K96362839-001-01-9	cedrol-(+)	Phase 2	sedative				0	0.0	Sigma	MFCD00077619	(7beta,8alpha)-cedran-8-ol	222.198	C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O	SVURIXNDRWRAFU-OGMFBOKVSA-N	65575.0		SVURIXNDRWRAFU
BRD-K96362839-001-02-9	cedrol-(+)	Phase 2	sedative				0	0.0	Vitas-M	STK066400	Cedrol	222.198	C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O	SVURIXNDRWRAFU-OGMFBOKVSA-N	65575.0		SVURIXNDRWRAFU
BRD-K20338176-001-19-9	cefaclor	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	pneumonia|skin infections|urinary tract infections|respiratory tract infections|tonsillitis|pharyngitis	0	70.5	MedChemEx	HY-B0198	Cefaclor	367.039	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	QYIYFLOTGYLRGG-GPCCPHFNSA-N	7048572.0		QYIYFLOTGYLRGG
BRD-K20338176-001-18-5	cefaclor	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	pneumonia|skin infections|urinary tract infections|respiratory tract infections|tonsillitis|pharyngitis	0	43.36	Selleck	S1499	Cefaclor (Ceclor)	367.039	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	QYIYFLOTGYLRGG-GPCCPHFNSA-N	7048572.0		QYIYFLOTGYLRGG
BRD-K20338176-001-17-7	cefaclor	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	pneumonia|skin infections|urinary tract infections|respiratory tract infections|tonsillitis|pharyngitis	0	89.07	MicroSource	1500771	CEFACLOR	367.039	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	QYIYFLOTGYLRGG-GPCCPHFNSA-N	7048572.0		QYIYFLOTGYLRGG
BRD-K20338176-001-16-9	cefaclor	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	pneumonia|skin infections|urinary tract infections|respiratory tract infections|tonsillitis|pharyngitis	0	73.15	Selleck	S1499	Cefaclor (Ceclor)	367.039	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	QYIYFLOTGYLRGG-GPCCPHFNSA-N	7048572.0		QYIYFLOTGYLRGG
BRD-K63242551-001-10-9	cefadroxil	Launched	bacterial cell wall synthesis inhibitor	SLC15A1|SLC15A2|SLC22A6|SLC22A8	infectious disease|otolaryngology	urinary tract infections|skin infections|tonsillitis|pharyngitis	0	70.0	MedChemEx	HY-B1190	Cefadroxil	363.089	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|	BOEGTKLJZSQCCD-UEKVPHQBSA-N	6560167.0		BOEGTKLJZSQCCD
BRD-K15514357-001-05-6	cefalonium	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	0.0	MicroSource	1505997	CEFALONIUM	459.08	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|	FMZXNVLFJHCSAF-DNVCBOLYSA-O	21744.0		FMZXNVLFJHCSAF
BRD-K15514357-002-06-9	cefalonium	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	58.98	Toronto	c236800	cefalonium hydrate	459.08	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|	FMZXNVLFJHCSAF-DNVCBOLYSA-O	21744.0		FMZXNVLFJHCSAF
BRD-K27130738-236-14-1	cefamandole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|urinary tract infections|respiratory tract infections	0	0.0	Sigma	MFCD07793339	sodium (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylethanoyl]amino}-3-{[(1-methyl-1H-tetraazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate	462.078	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|	OLVCFLKTBJRLHI-AXAPSJFSSA-N	456255.0		OLVCFLKTBJRLHI
BRD-K27130738-236-15-8	cefamandole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|urinary tract infections|respiratory tract infections	0	32.02	MicroSource	1502038	CEFAMANDOLE SODIUM	462.078	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|	OLVCFLKTBJRLHI-AXAPSJFSSA-N	456255.0	BRD-A23933379-236-04-9	OLVCFLKTBJRLHI
BRD-K17903788-236-01-9	cefamandole-nafate	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|urinary tract infections|respiratory tract infections	0	24.28	MedChemEx	HY-B1166	Cefamandole (nafate)	490.073	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|	RRJHESVQVSRQEX-SUYBPPKGSA-N	5284527.0		RRJHESVQVSRQEX
BRD-K17903788-236-02-7	cefamandole-nafate	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|urinary tract infections|respiratory tract infections	0	43.32	MedChemEx	HY-B1166	Cefamandole (nafate)	490.073	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|	RRJHESVQVSRQEX-SUYBPPKGSA-N	5284527.0		RRJHESVQVSRQEX
BRD-K17903788-236-03-5	cefamandole-nafate	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|urinary tract infections|respiratory tract infections	0	0.0	MicroSource	1502041	CEFAMANDOLE NAFATE	490.073	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|	RRJHESVQVSRQEX-SUYBPPKGSA-N	5284527.0	BRD-A02439449-236-04-8	RRJHESVQVSRQEX
BRD-K63835048-001-01-0	cefathiamidine	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	68.39	AKSci	S023		472.145	CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C |c:19|	JYXACOFERDBGGQ-RHSMWYFYSA-N	44537522.0		JYXACOFERDBGGQ
BRD-K99750640-236-20-3	cefazolin	Launched	bacterial cell wall synthesis inhibitor	PON1	infectious disease	urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections	0	87.37	MedChemEx	HY-B1078	Cefazolin (sodium)	454.03	Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|	MLYYVTUWGNIJIB-BXKDBHETSA-N	33255.0		MLYYVTUWGNIJIB
BRD-K99750640-236-18-7	cefazolin	Launched	bacterial cell wall synthesis inhibitor	PON1	infectious disease	urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections	0	35.66	MicroSource	1500164	CEFAZOLIN SODIUM	454.03	Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|	MLYYVTUWGNIJIB-BXKDBHETSA-N	33255.0		MLYYVTUWGNIJIB
BRD-K99750640-236-19-5	cefazolin	Launched	bacterial cell wall synthesis inhibitor	PON1	infectious disease	urinary tract infections|skin infections|bacterial septicemia|endocarditis|surgical prophylaxis|bone and joint infections	0	0.0	MedChemEx	HY-B1078	Cefazolin (sodium)	454.03	Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|	MLYYVTUWGNIJIB-BXKDBHETSA-N	33255.0		MLYYVTUWGNIJIB
BRD-K27515606-311-02-8	cefcapene-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|pneumonia|urinary tract infections	0	88.76	Sigma	MFCD01682041	[(2,2-dimethylpropanoyl)oxy]methyl (6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-pentenoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride; hydrate	567.146	CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|	WVPAABNYMHNFJG-QDVBXLKVSA-N	5282438.0		WVPAABNYMHNFJG
BRD-K27515606-003-01-3	cefcapene-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|pneumonia|urinary tract infections	0	90.61	Astatech	83157	(pivaloyloxy)methyl (6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)pent-2-enamido)-3-((carbamoyloxy)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate hydrochloride	567.146	CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|	WVPAABNYMHNFJG-QDVBXLKVSA-N	5282438.0		WVPAABNYMHNFJG
BRD-K27515606-311-01-0	cefcapene-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|pneumonia|urinary tract infections	0	45.21	AKSci	Q717		567.146	CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|	WVPAABNYMHNFJG-QDVBXLKVSA-N	5282438.0		WVPAABNYMHNFJG
BRD-K15766189-001-09-8	cefdinir	Launched	bacterial cell wall synthesis inhibitor	MPO	infectious disease|otolaryngology|pulmonary	pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis	0	86.04	MicroSource	1505208	CEFDINIR	395.036	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|	RTXOFQZKPXMALH-GHXIOONMSA-N	6915944.0		RTXOFQZKPXMALH
BRD-K15766189-001-10-6	cefdinir	Launched	bacterial cell wall synthesis inhibitor	MPO	infectious disease|otolaryngology|pulmonary	pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis	0	87.42	Selleck	S1605	Cefdinir (Omnicef)	395.036	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|	RTXOFQZKPXMALH-GHXIOONMSA-N	6915944.0		RTXOFQZKPXMALH
BRD-K15766189-001-08-0	cefdinir	Launched	bacterial cell wall synthesis inhibitor	MPO	infectious disease|otolaryngology|pulmonary	pneumonia|tonsillitis|pharyngitis|bronchitis|skin infections|otitis|sinusitis	0	80.71	Selleck	S1605	Cefdinir	395.036	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|	RTXOFQZKPXMALH-GHXIOONMSA-N	6915944.0		RTXOFQZKPXMALH
BRD-K72167406-001-04-7	cefditoren-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease|pulmonary|otolaryngology	pneumonia|bronchitis|skin infections|tonsillitis|pharyngitis	0	74.37	MicroSource	1505360	CEFDITORIN PIVOXIL	620.118	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|	AFZFFLVORLEPPO-UVYJNCLZSA-N	6437877.0	BRD-A39056513-001-04-6	AFZFFLVORLEPPO
BRD-K72167406-001-02-1	cefditoren-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease|pulmonary|otolaryngology	pneumonia|bronchitis|skin infections|tonsillitis|pharyngitis	0	88.24	Selleck	S1768	Cefditoren pivoxil	620.118	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|	AFZFFLVORLEPPO-UVYJNCLZSA-N	6437877.0		AFZFFLVORLEPPO
BRD-K72167406-001-03-9	cefditoren-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease|pulmonary|otolaryngology	pneumonia|bronchitis|skin infections|tonsillitis|pharyngitis	0	87.83	Selleck	S1768	Cefditoren Pivoxil	620.118	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|	AFZFFLVORLEPPO-UVYJNCLZSA-N	6437877.0	BRD-K05878591-001-01-2	AFZFFLVORLEPPO
BRD-K72167406-001-06-9	cefditoren-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease|pulmonary|otolaryngology	pneumonia|bronchitis|skin infections|tonsillitis|pharyngitis	0	90.31	MedChemEx	HY-17452A	Cefditoren (Pivoxil)	620.118	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|	AFZFFLVORLEPPO-UVYJNCLZSA-N	6437877.0		AFZFFLVORLEPPO
BRD-A12077521-003-01-5	cefepime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|urinary tract infections|skin infections|intra-abdominal infections	0	96.32	MicroSource	1502420	CEFEPIME HYDROCHLORIDE	481.133	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |&1:7,&2:8,c:19|	HVFLCNVBZFFHBT-FKULVZFESA-O	5464263.0		HVFLCNVBZFFHBT
BRD-K27798832-001-01-5	cefetamet	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|pulmonary	ear infections|pneumonia|otitis|sinusitis|bronchitis|urinary tract infections	0	91.04	Sigma	MFCD00864836	(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)ethanoyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	397.051	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|	MQLRYUCJDNBWMV-GHXIOONMSA-N	5487888.0		MQLRYUCJDNBWMV
BRD-K27798832-001-02-9	cefetamet	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|pulmonary	ear infections|pneumonia|otitis|sinusitis|bronchitis|urinary tract infections	0	94.12	Sigma	MFCD00864836	(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)ethanoyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	397.051	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|	MQLRYUCJDNBWMV-GHXIOONMSA-N	5487888.0		MQLRYUCJDNBWMV
BRD-K21372554-001-01-1	cefetamet-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	0.0	AvaChem	2005	[(2,2-dimethylpropanoyl)oxy]methyl (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)ethanoyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate	511.12	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|	DASYMCLQENWCJG-XUKDPADISA-N	5486182.0		DASYMCLQENWCJG
BRD-K21372554-003-01-7	cefetamet-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	80.7	AKSci	H785		511.12	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|	DASYMCLQENWCJG-XUKDPADISA-N	5486182.0		DASYMCLQENWCJG
BRD-K21372554-003-02-5	cefetamet-pivoxil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	87.11	MedChemEx	HY-B1894A	Cefetamet pivoxil (hydrochloride)	511.12	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|	DASYMCLQENWCJG-XUKDPADISA-N	5486182.0		DASYMCLQENWCJG
BRD-K00003257-001-01-9	cefiderocol	Launched	antibacterial 				0	62.5	MedChemEx	HY-17628	Cefiderocol	752.158	[H][C@]12SCC(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\c1csc(N)n1)C(O)=O |c:26|	DBPPRLRVDVJOCL-FQRUVTKNSA-O	46195832.0		DBPPRLRVDVJOCL
BRD-K71059170-341-02-5	cefixime	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|pulmonary	urinary tract infections|otitis|pharyngitis|tonsillitis|gonorrhea|bronchitis	0	93.65	Sigma	MFCD03788802	(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]ethanoyl}amino)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid trihydrate	453.041	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|	OKBVVJOGVLARMR-QSWIMTSFSA-N	5362065.0		OKBVVJOGVLARMR
BRD-K71059170-001-11-6	cefixime	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|pulmonary	urinary tract infections|otitis|pharyngitis|tonsillitis|gonorrhea|bronchitis	0	76.71	Enzo	AC3047	CEFIXIME	453.041	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|	OKBVVJOGVLARMR-QSWIMTSFSA-N	5362065.0		OKBVVJOGVLARMR
BRD-K71059170-001-12-4	cefixime	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|pulmonary	urinary tract infections|otitis|pharyngitis|tonsillitis|gonorrhea|bronchitis	0	89.67	MedChemEx	HY-B1381	Cefixime	453.041	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|	OKBVVJOGVLARMR-QSWIMTSFSA-N	5362065.0		OKBVVJOGVLARMR
BRD-K00003661-003-01-9	cefmenoxime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	90.8	MedChemEx	HY-B0875	Cefmenoxime (hydrochloride)	511.051	[H][C@]12SCC(CSc3nnnn3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C(O)=O |c:13|	HJJDBAOLQAWBMH-YCRCPZNHSA-N	9570757.0		HJJDBAOLQAWBMH
BRD-K48470486-236-11-6	cefmetazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|skin infections	0	89.48	MedChemEx	HY-B1257	Cefmetazole (sodium)	471.045	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|	SNBUBQHDYVFSQF-HIFRSBDPSA-N	42008.0		SNBUBQHDYVFSQF
BRD-K48470486-236-10-8	cefmetazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|skin infections	0	0.0	MedChemEx	HY-B1257	Cefmetazole (sodium)	471.045	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|	SNBUBQHDYVFSQF-HIFRSBDPSA-N	42008.0		SNBUBQHDYVFSQF
BRD-K48470486-236-12-4	cefmetazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|skin infections	0	0.0	MicroSource	1502040	CEFMETAZOLE SODIUM	471.045	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|	SNBUBQHDYVFSQF-HIFRSBDPSA-N	42008.0	BRD-A97040294-236-04-6	SNBUBQHDYVFSQF
BRD-K77073709-435-01-2	cefminox	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	83.7	Key	KS-1224	sodium (6R,7S)-7-[({[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetyl)amino]-7-methoxy-3-{[(1-methyl-1H-tetraazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate heptahydrate	519.066	CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|	JSDXOWVAHXDYCU-VXSYNFHWSA-N	71141.0		JSDXOWVAHXDYCU
BRD-K77073709-435-02-9	cefminox	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	43.8	Toronto	c243100	cefminox sodium heptahydrate	519.066	CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|	JSDXOWVAHXDYCU-VXSYNFHWSA-N	71141.0		JSDXOWVAHXDYCU
BRD-K22641081-304-01-8	cefodizime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|skin infections|gonorrhea	0	73.75	Kemprotec	69739-16-8	disodium (6R,7R)-7-{[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)ethanoyl]amino}-3-({[4-methyl-5-(2-oxido-2-oxoethyl)-1,3-thiazol-2-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-;2-carboxylate	584.028	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|	XDZKBRJLTGRPSS-BGZQYGJUSA-N	5361871.0	BRD-K72150952-304-01-5	XDZKBRJLTGRPSS
BRD-K22641081-001-01-0	cefodizime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|skin infections|gonorrhea	0	57.47	AKSci	K170		584.028	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|	XDZKBRJLTGRPSS-BGZQYGJUSA-N	5361871.0	BRD-A42969929-001-01-9	XDZKBRJLTGRPSS
BRD-K34058848-304-03-1	cefonicid	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	83.1	MicroSource	1505474	CEFONICID SODIUM	542.035	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|	DYAIAHUQIPBDIP-AXAPSJFSSA-N	43594.0	BRD-A65872513-304-01-7	DYAIAHUQIPBDIP
BRD-K34058848-304-02-3	cefonicid	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	58.8	MedChemEx	HY-B1300	Cefonicid (sodium)	542.035	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|	DYAIAHUQIPBDIP-AXAPSJFSSA-N	43594.0		DYAIAHUQIPBDIP
BRD-K34058848-304-01-5	cefonicid	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	11.0	MedChemEx	HY-B1300	Cefonicid (sodium)	542.035	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|	DYAIAHUQIPBDIP-AXAPSJFSSA-N	43594.0		DYAIAHUQIPBDIP
BRD-K02292852-001-06-9	cefoperazone	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	97.29	MedChemEx	HY-B0210	Cefoperazone	645.142	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|	GCFBRXLSHGKWDP-XCGNWRKASA-N	44187.0		GCFBRXLSHGKWDP
BRD-K02292852-001-04-7	cefoperazone	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	43.51	MicroSource	1502042	CEFOPERAZONE	645.142	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|	GCFBRXLSHGKWDP-XCGNWRKASA-N	44187.0	BRD-A73079885-001-01-1	GCFBRXLSHGKWDP
BRD-K02292852-001-02-1	cefoperazone	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	95.7	Selleck	S1611	Cefoperazone	645.142	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|	GCFBRXLSHGKWDP-XCGNWRKASA-N	44187.0		GCFBRXLSHGKWDP
BRD-K37848908-001-06-4	ceforanide	Launched	penicillin binding protein inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MicroSource	1502423	CEFORANIDE	519.099	NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|	SLAYUXIURFNXPG-CRAIPNDOSA-N	43507.0	BRD-A38738672-001-01-3	SLAYUXIURFNXPG
BRD-K37848908-001-05-6	ceforanide	Launched	penicillin binding protein inhibitor		infectious disease	gram-negative bacterial infections	0	90.8	AvaChem	2438	(6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetraazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	519.099	NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|	SLAYUXIURFNXPG-CRAIPNDOSA-N	43507.0		SLAYUXIURFNXPG
BRD-K72339976-065-03-9	cefoselis	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	99.54	Selleck	S1371	Cefoselis sulfate	522.11	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|	ZINFAXPQMLDEEJ-GFVOIPPFSA-N	9830520.0	BRD-K37910175-065-03-0	ZINFAXPQMLDEEJ
BRD-K72339976-065-01-3	cefoselis	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	96.68	MedChemEx	HY-B0186B	Cefoselis (sulfate)	522.11	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|	ZINFAXPQMLDEEJ-GFVOIPPFSA-N	9830520.0		ZINFAXPQMLDEEJ
BRD-K72339976-065-04-7	cefoselis	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	90.77	AKSci	O697		522.11	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|	ZINFAXPQMLDEEJ-GFVOIPPFSA-N	9830520.0	BRD-K20284063-065-01-8	ZINFAXPQMLDEEJ
BRD-K72339976-065-02-1	cefoselis	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	83.64	Selleck	S1371	Cefoselis Sulfate	522.11	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|	ZINFAXPQMLDEEJ-GFVOIPPFSA-N	9830520.0	BRD-K02689172-065-01-8	ZINFAXPQMLDEEJ
BRD-K78364995-236-18-3	cefotaxime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|bone and joint infections|pelvic inflammatory disease|intra-abdominal infections|skin infections|meningitis|urinary tract infections|bacterial septicemia|gynecologic infections	0	95.77	MedChemEx	HY-A0088	Cefotaxime (sodium salt)	455.057	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|	GPRBEKHLDVQUJE-QSWIMTSFSA-N	5742673.0		GPRBEKHLDVQUJE
BRD-K78364995-236-19-1	cefotaxime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|bone and joint infections|pelvic inflammatory disease|intra-abdominal infections|skin infections|meningitis|urinary tract infections|bacterial septicemia|gynecologic infections	0	66.74	MicroSource	1500165	CEFOTAXIME SODIUM	455.057	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|	GPRBEKHLDVQUJE-QSWIMTSFSA-N	5742673.0	BRD-K99586414-236-04-9	GPRBEKHLDVQUJE
BRD-K78364995-236-17-5	cefotaxime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|bone and joint infections|pelvic inflammatory disease|intra-abdominal infections|skin infections|meningitis|urinary tract infections|bacterial septicemia|gynecologic infections	0	43.81	MedChemEx	HY-A0088	Cefotaxime (sodium salt)	455.057	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|	GPRBEKHLDVQUJE-QSWIMTSFSA-N	5742673.0		GPRBEKHLDVQUJE
BRD-K78364995-236-16-7	cefotaxime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|bone and joint infections|pelvic inflammatory disease|intra-abdominal infections|skin infections|meningitis|urinary tract infections|bacterial septicemia|gynecologic infections	0	65.5	Sigma	MFCD00079073	sodium (6R,7R)-3-[(acetyloxy)methyl]-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)ethanoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate	455.057	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|	GPRBEKHLDVQUJE-QSWIMTSFSA-N	5742673.0		GPRBEKHLDVQUJE
BRD-A78723049-001-01-2	cefotetan	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|respiratory tract infections|skin infections|gynecologic infections|chlamydia|intra-abdominal infections|bone and joint infections|surgical prophylaxis	0	88.4	MicroSource	1502424	CEFOTETAN	575.002	CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,&1:17,c:30|	SRZNHPXWXCNNDU-IXOPCIAXSA-N			SRZNHPXWXCNNDU
BRD-K02275692-300-01-8	cefotiam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia|bone and joint infections|respiratory tract infections|skin infections|urinary tract infections	0	65.54	Prestwick	Prestw-482	Cefotiam hydrochloride	525.104	CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|	QYQDKDWGWDOFFU-IUODEOHRSA-N	43708.0		QYQDKDWGWDOFFU
BRD-K02275692-300-02-6	cefotiam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	bacterial septicemia|bone and joint infections|respiratory tract infections|skin infections|urinary tract infections	0	88.63	MedChemEx	HY-B0734A	Cefotiam (hydrochloride)	525.104	CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|	QYQDKDWGWDOFFU-IUODEOHRSA-N	43708.0		QYQDKDWGWDOFFU
BRD-A76661185-300-02-4	cefotiam-cilexetil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	22.36	SantaCruz	sc-211042		695.198	C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|	VVFDMWZLBPUKTD-XLHILCRZSA-N			VVFDMWZLBPUKTD
BRD-A76661185-300-01-6	cefotiam-cilexetil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	23.99	SantaCruz	sc-211042		695.198	C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1,&2:31,&3:32,c:16|	VVFDMWZLBPUKTD-XLHILCRZSA-N			VVFDMWZLBPUKTD
BRD-K70976396-236-27-8	cefoxitin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections	0	98.36	MedChemEx	HY-B1117	Cefoxitin (sodium)	427.051	CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N	441199.0		WZOZEZRFJCJXNZ
BRD-K70976396-236-25-2	cefoxitin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections	0	61.17	MicroSource	1502031	CEFOXITIN SODIUM	427.051	CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N	441199.0		WZOZEZRFJCJXNZ
BRD-K70976396-236-26-0	cefoxitin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections	0	94.11	MedChemEx	HY-B1117	Cefoxitin (sodium)	427.051	CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N	441199.0		WZOZEZRFJCJXNZ
BRD-K46970505-003-02-9	cefozopran	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	88.69	MedChemEx	HY-B0771A	Cefozopran (hydrochloride)	516.087	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|	QDUIJCOKQCCXQY-WHJQOFBOSA-O	5491955.0		QDUIJCOKQCCXQY
BRD-K46970505-003-01-9	cefozopran	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	90.83	MedChemEx	HY-B0771A	Cefozopran (hydrochloride)	516.087	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|	QDUIJCOKQCCXQY-WHJQOFBOSA-O	5491955.0		QDUIJCOKQCCXQY
BRD-K92872987-001-02-9	cefpiramide	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	76.3	MicroSource	1503869	CEFPIRAMIDE	612.121	Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|	PWAUCHMQEXVFJR-PMAPCBKXSA-N	636405.0	BRD-A39975020-001-01-9	PWAUCHMQEXVFJR
BRD-K92872987-001-01-1	cefpiramide	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	86.38	Sigma	MFCD00864893	(6R,7R)-7-{[(2R)-2-{[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino}-2-(4-hydroxyphenyl)ethanoyl]amino}-3-{[(1-methyl-1H-tetraazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-car	612.121	Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|	PWAUCHMQEXVFJR-PMAPCBKXSA-N	636405.0		PWAUCHMQEXVFJR
BRD-K92872987-236-03-9	cefpiramide	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	61.86	MedChemEx	HY-B0798	Cefpiramide (sodium)	612.121	Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|	PWAUCHMQEXVFJR-PMAPCBKXSA-N	636405.0		PWAUCHMQEXVFJR
BRD-K56542719-065-01-4	cefpirome	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	91.01	ChemImpex	15154		515.117	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	DKOQGJHPHLTOJR-PUIFZAHNSA-O	6917675.0		DKOQGJHPHLTOJR
BRD-A34205213-001-03-9	cefpodoxime	Launched	bacterial cell wall synthesis inhibitor		otolaryngology|infectious disease|pulmonary	pharyngitis|pneumonia|bronchitis|gonorrhea|skin infections|urinary tract infections|sinusitis|tonsillitis	0	49.13	Key	KS-1149	1-[(isopropoxycarbonyl)oxy]ethyl (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)ethanoyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate	557.125	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|	LTINZAODLRIQIX-OLEGMKQCSA-N	51546414.0		LTINZAODLRIQIX
BRD-A34205213-001-04-7	cefpodoxime	Launched	bacterial cell wall synthesis inhibitor		otolaryngology|infectious disease|pulmonary	pharyngitis|pneumonia|bronchitis|gonorrhea|skin infections|urinary tract infections|sinusitis|tonsillitis	0	48.22	MicroSource	1505637	CEFPODOXIME PROXETIL	557.125	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6,9,&1:28,t:3|	LTINZAODLRIQIX-OLEGMKQCSA-N	51546414.0	BRD-A87387433-001-03-5	LTINZAODLRIQIX
BRD-K24871708-001-01-4	cefprozil	Launched	bacterial cell wall synthesis inhibitor		otolaryngology|infectious disease|pulmonary	pharyngitis|tonsillitis|otitis|sinusitis|respiratory tract infections|skin infections|bronchitis	0	44.09	MicroSource	1505364	CEFPROZIL	389.105	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|	WDLWHQDACQUCJR-ZAMMOSSLSA-N	5281006.0	BRD-A85137183-001-03-8	WDLWHQDACQUCJR
BRD-K24871708-002-03-8	cefprozil	Launched	bacterial cell wall synthesis inhibitor		otolaryngology|infectious disease|pulmonary	pharyngitis|tonsillitis|otitis|sinusitis|respiratory tract infections|skin infections|bronchitis	0	56.44	Selleck	S2544	Cefprozil hydrate (Cefzil)	389.105	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|	WDLWHQDACQUCJR-ZAMMOSSLSA-N	5281006.0		WDLWHQDACQUCJR
BRD-K24871708-002-04-6	cefprozil	Launched	bacterial cell wall synthesis inhibitor		otolaryngology|infectious disease|pulmonary	pharyngitis|tonsillitis|otitis|sinusitis|respiratory tract infections|skin infections|bronchitis	0	76.4	MedChemEx	HY-B0458	Cefprozil (monohydrate)	389.105	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|	WDLWHQDACQUCJR-ZAMMOSSLSA-N	5281006.0		WDLWHQDACQUCJR
BRD-K24871708-002-02-0	cefprozil	Launched	bacterial cell wall synthesis inhibitor		otolaryngology|infectious disease|pulmonary	pharyngitis|tonsillitis|otitis|sinusitis|respiratory tract infections|skin infections|bronchitis	0	43.83	Selleck	S2544	Cefprozil hydrate (Cefzil)	389.105	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|	WDLWHQDACQUCJR-ZAMMOSSLSA-N	5281006.0		WDLWHQDACQUCJR
BRD-K13797099-001-02-9	cefradine	Launched	bacterial cell wall synthesis inhibitor	CYP3A4	infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia	0	65.46	MedChemEx	HY-B1156	Cefradine	349.11	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|	RDLPVSKMFDYCOR-UEKVPHQBSA-N	40467109.0		RDLPVSKMFDYCOR
BRD-K13797099-001-01-1	cefradine	Launched	bacterial cell wall synthesis inhibitor	CYP3A4	infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia	0	13.45	MedChemEx	HY-B1156	Cefradine	349.11	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|	RDLPVSKMFDYCOR-UEKVPHQBSA-N	40467109.0		RDLPVSKMFDYCOR
BRD-K13797099-001-03-9	cefradine	Launched	bacterial cell wall synthesis inhibitor	CYP3A4	infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|urinary tract infections|tonsillitis|pharyngitis|pneumonia	0	29.8	MedChemEx	HY-B1156	Cefradine	349.11	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17,t:1,14|	RDLPVSKMFDYCOR-UEKVPHQBSA-N	40467109.0		RDLPVSKMFDYCOR
BRD-K03907181-236-06-8	cefsulodin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-13588	Cefsulodin (sodium)	533.08	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|	SYLKGLMBLAAGSC-QLVMHMETSA-O	656576.0		SYLKGLMBLAAGSC
BRD-K03907181-236-05-0	cefsulodin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-13588	Cefsulodin (sodium)	533.08	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|	SYLKGLMBLAAGSC-QLVMHMETSA-O	656576.0		SYLKGLMBLAAGSC
BRD-K03907181-236-04-3	cefsulodin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	Sigma	MFCD07793338	sodium (6R,7R)-3-{[4-(aminocarbonyl)-1-pyridiniumyl]methyl}-8-oxo-7-{[(2R)-2-phenyl-2-sulfonatoethanoyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate	533.08	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|	SYLKGLMBLAAGSC-QLVMHMETSA-O	656576.0		SYLKGLMBLAAGSC
BRD-K03907181-236-07-6	cefsulodin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	29.68	MicroSource	1502029	CEFSULODIN SODIUM	533.08	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|	SYLKGLMBLAAGSC-QLVMHMETSA-O	656576.0	BRD-A86462796-236-04-8	SYLKGLMBLAAGSC
BRD-K37252028-349-01-8	ceftaroline-fosamil	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|pneumonia	0	63.93	GLSyntech	JN-0957	4-(2-(((6R,7R)-2-carboxy-7-((E)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)thio)thiazol-4-yl)-1-methylpyridin-1-ium acetate hy;drate	685.018	CCO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Sc3nc(cs3)-c3cc[n+](C)cc3)=C(N2C1=O)C(O)=O)c1nc(=NP(O)(O)=O)s[nH]1 |c:27|	ZCCUWMICIWSJIX-XHNDKCDBSA-O	10033059.0		ZCCUWMICIWSJIX
BRD-K52117081-345-03-1	ceftazidime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|skin infections|bacterial septicemia|bone and joint infections|gynecologic infections|intra-abdominal infections|meningitis	0	47.0	Sigma	MFCD00153936	(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]ethanoyl}amino)-8-oxo-3-(1-pyridiniumylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate pentahydrate	547.107	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	ORFOPKXBNMVMKC-DWVKKRMSSA-O	6321415.0		ORFOPKXBNMVMKC
BRD-K52117081-001-03-0	ceftazidime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|skin infections|bacterial septicemia|bone and joint infections|gynecologic infections|intra-abdominal infections|meningitis	0	74.0	MedChemEx	HY-B0593	Ceftazidime	547.107	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	ORFOPKXBNMVMKC-DWVKKRMSSA-O	6321415.0		ORFOPKXBNMVMKC
BRD-K52117081-396-01-8	ceftazidime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|skin infections|bacterial septicemia|bone and joint infections|gynecologic infections|intra-abdominal infections|meningitis	0	0.0	MicroSource	1505782	CEFTAZIDIME	547.107	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	ORFOPKXBNMVMKC-DWVKKRMSSA-O	6321415.0	BRD-A73933229-396-01-8	ORFOPKXBNMVMKC
BRD-K52117081-001-02-2	ceftazidime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|skin infections|bacterial septicemia|bone and joint infections|gynecologic infections|intra-abdominal infections|meningitis	0	0.0	MedChemEx	HY-B0593	Ceftazidime	547.107	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	ORFOPKXBNMVMKC-DWVKKRMSSA-O	6321415.0		ORFOPKXBNMVMKC
BRD-K52117081-345-04-9	ceftazidime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|skin infections|bacterial septicemia|bone and joint infections|gynecologic infections|intra-abdominal infections|meningitis	0	78.15	Selleck	S4314		547.107	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	ORFOPKXBNMVMKC-DWVKKRMSSA-O	6321415.0		ORFOPKXBNMVMKC
BRD-K11124378-001-04-6	ceftibuten	Launched	bacterial cell wall synthesis inhibitor		pulmonary|otolaryngology	bronchitis|otitis|pharyngitis|tonsillitis	0	78.69	MicroSource	1505207	CEFTIBUTEN	410.035	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	UNJFKXSSGBWRBZ-BJCIPQKHSA-N	5282242.0		UNJFKXSSGBWRBZ
BRD-K11124378-335-03-0	ceftibuten	Launched	bacterial cell wall synthesis inhibitor		pulmonary|otolaryngology	bronchitis|otitis|pharyngitis|tonsillitis	0	55.48	MedChemEx	HY-B0698A	Ceftibuten (dihydrate)	410.035	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	UNJFKXSSGBWRBZ-BJCIPQKHSA-N	5282242.0		UNJFKXSSGBWRBZ
BRD-K11124378-335-01-4	ceftibuten	Launched	bacterial cell wall synthesis inhibitor		pulmonary|otolaryngology	bronchitis|otitis|pharyngitis|tonsillitis	0	44.0	MedChemEx	HY-B0698A	(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxy-2-butenoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid dihydrate	410.035	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	UNJFKXSSGBWRBZ-BJCIPQKHSA-N	5282242.0		UNJFKXSSGBWRBZ
BRD-K11124378-335-02-2	ceftibuten	Launched	bacterial cell wall synthesis inhibitor		pulmonary|otolaryngology	bronchitis|otitis|pharyngitis|tonsillitis	0	78.41	MedChemEx	HY-B0698A	Ceftibuten (dihydrate)	410.035	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	UNJFKXSSGBWRBZ-BJCIPQKHSA-N	5282242.0		UNJFKXSSGBWRBZ
BRD-K11124378-002-01-0	ceftibuten	Launched	bacterial cell wall synthesis inhibitor		pulmonary|otolaryngology	bronchitis|otitis|pharyngitis|tonsillitis	0	95.4	Sigma	MFCD20488049	(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxy-2-butenoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate	410.035	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	UNJFKXSSGBWRBZ-BJCIPQKHSA-N	5282242.0		UNJFKXSSGBWRBZ
BRD-K82960980-003-01-9	ceftiofur	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|respiratory tract infections	0	91.98	MicroSource	1504832	CEFTIOFUR HYDROCHLORIDE	523.029	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|	ZBHXIWJRIFEVQY-IHMPYVIRSA-N	6328657.0	BRD-K75097379-003-01-8	ZBHXIWJRIFEVQY
BRD-K82960980-236-05-9	ceftiofur	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|respiratory tract infections	0	79.64	MedChemEx	HY-B0898	Ceftiofur (sodium)	523.029	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|	ZBHXIWJRIFEVQY-IHMPYVIRSA-N	6328657.0		ZBHXIWJRIFEVQY
BRD-K82960980-003-03-5	ceftiofur	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|respiratory tract infections	0	88.46	Selleck	S2543	Ceftiofur HCl	523.029	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|	ZBHXIWJRIFEVQY-IHMPYVIRSA-N	6328657.0	BRD-K15436267-003-01-6	ZBHXIWJRIFEVQY
BRD-K82960980-003-02-7	ceftiofur	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|respiratory tract infections	0	93.8	Selleck	S2543	Ceftiofur hydrochloride	523.029	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|	ZBHXIWJRIFEVQY-IHMPYVIRSA-N	6328657.0	BRD-K21017401-003-02-1	ZBHXIWJRIFEVQY
BRD-K04301924-236-03-2	ceftizoxim	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|urinary tract infections|gonorrhea|pelvic inflammatory disease|intra-abdominal infections|bacterial septicemia|skin infections|bone and joint infections|meningitis	0	88.85	MedChemEx	HY-B1596A	Ceftizoxime (sodium)	383.036	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|	NNULBSISHYWZJU-LLKWHZGFSA-N	6533629.0		NNULBSISHYWZJU
BRD-K04301924-236-01-6	ceftizoxim	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|urinary tract infections|gonorrhea|pelvic inflammatory disease|intra-abdominal infections|bacterial septicemia|skin infections|bone and joint infections|meningitis	0	40.24	Enzo	AC3053	CEFTIZOXIM SODIUM	383.036	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|	NNULBSISHYWZJU-LLKWHZGFSA-N	6533629.0		NNULBSISHYWZJU
BRD-K04301924-236-02-4	ceftizoxim	Launched	bacterial cell wall synthesis inhibitor		infectious disease	respiratory tract infections|urinary tract infections|gonorrhea|pelvic inflammatory disease|intra-abdominal infections|bacterial septicemia|skin infections|bone and joint infections|meningitis	0	53.23	MedChemEx	HY-B1596A	Ceftizoxime (sodium)	383.036	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|	NNULBSISHYWZJU-LLKWHZGFSA-N	6533629.0		NNULBSISHYWZJU
BRD-K00003117-001-01-9	ceftobiprole	Phase 3	antiinfective drug				0	79.0	MedChemEx	HY-112579	Ceftobiprole	534.11	[H][C@]12SCC(\C=C3/CCN([C@@H]4CCNC4)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\c1nsc(N)n1)C(O)=O |c:18|	VOAZJEPQLGBXGO-SDAWRPRTSA-N	138319339.0		VOAZJEPQLGBXGO
BRD-K96734425-324-01-5	ceftriaxone	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	gonorrhea|pneumonia|otitis|skin infections|urinary tract infections|pelvic inflammatory disease|bacterial septicemia|bone and joint infections|intra-abdominal infections|meningitis|surgical prophylaxis	0	64.12	MicroSource	1503111	CEFTRIAXONE SODIUM TRIHYDRATE	554.046	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	VAAUVRVFOQPIGI-SPQHTLEESA-N	5479530.0	BRD-K38010979-324-03-7	VAAUVRVFOQPIGI
BRD-K96734425-304-01-7	ceftriaxone	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	gonorrhea|pneumonia|otitis|skin infections|urinary tract infections|pelvic inflammatory disease|bacterial septicemia|bone and joint infections|intra-abdominal infections|meningitis|surgical prophylaxis	0	85.48	MedChemEx	HY-B0712B	Ceftriaxone (sodium salt)	554.046	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	VAAUVRVFOQPIGI-SPQHTLEESA-N	5479530.0		VAAUVRVFOQPIGI
BRD-K02733959-236-06-9	cefuroxime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	86.53	MedChemEx	HY-B1256	Cefuroxime (sodium)	424.069	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|	JFPVXVDWJQMJEE-IZRZKJBUSA-N	5479529.0		JFPVXVDWJQMJEE
BRD-K02733959-236-07-7	cefuroxime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	82.75	MicroSource	1502033	CEFUROXIME SODIUM	424.069	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|	JFPVXVDWJQMJEE-IZRZKJBUSA-N	5479529.0	BRD-A76746748-236-04-5	JFPVXVDWJQMJEE
BRD-K02733959-236-05-1	cefuroxime	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	77.86	MedChemEx	HY-B1256	Cefuroxime (sodium)	424.069	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|	JFPVXVDWJQMJEE-IZRZKJBUSA-N	5479529.0		JFPVXVDWJQMJEE
BRD-A22303829-001-01-6	cefuroxime-axetil	Launched	bacterial cell wall synthesis inhibitor		otolaryngology	pharyngitis|tonsillitis|otitis|sinusitis	0	56.52	Sigma	A4237	1-(acetyloxy)ethyl (6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-{[(2Z)-2-(2-furyl)-2-(methoxyimino)ethanoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate	510.106	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|	KEJCWVGMRLCZQQ-QFDKGRJDSA-N	9806360.0		KEJCWVGMRLCZQQ
BRD-A22303829-001-02-4	cefuroxime-axetil	Launched	bacterial cell wall synthesis inhibitor		otolaryngology	pharyngitis|tonsillitis|otitis|sinusitis	0	36.9	MicroSource	1504175	CEFUROXIME AXETIL	510.106	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|	KEJCWVGMRLCZQQ-QFDKGRJDSA-N	9806360.0	BRD-A36322567-001-02-4	KEJCWVGMRLCZQQ
BRD-A22303829-001-03-9	cefuroxime-axetil	Launched	bacterial cell wall synthesis inhibitor		otolaryngology	pharyngitis|tonsillitis|otitis|sinusitis	0	53.54	Sigma	MFCD00864991	Cefuroxime Axetil	510.106	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7,8,&1:24,c:16|	KEJCWVGMRLCZQQ-QFDKGRJDSA-N	9806360.0		KEJCWVGMRLCZQQ
BRD-K02637541-001-22-2	celecoxib	Launched	cyclooxygenase inhibitor	CA12|PDPK1|PTGS2	rheumatology|endocrinology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)	0	95.12	Tocris	3786	Celecoxib	381.076	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	RZEKVGVHFLEQIL-UHFFFAOYSA-N	2662.0		RZEKVGVHFLEQIL
BRD-K02637541-001-18-0	celecoxib	Launched	cyclooxygenase inhibitor	CA12|PDPK1|PTGS2	rheumatology|endocrinology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)	0	99.47	MicroSource	1503678	CELECOXIB	381.076	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	RZEKVGVHFLEQIL-UHFFFAOYSA-N	2662.0		RZEKVGVHFLEQIL
BRD-K02637541-001-17-2	celecoxib	Launched	cyclooxygenase inhibitor	CA12|PDPK1|PTGS2	rheumatology|endocrinology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis|primary dysmenorrhea (PD)	0	98.44	Selleck	S1261	Celecoxib	381.076	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	RZEKVGVHFLEQIL-UHFFFAOYSA-N	2662.0		RZEKVGVHFLEQIL
BRD-K00003204-003-01-9	celgosivir	Phase 2	glucosidase inhibitor				0	98.4	MedChemEx	HY-16134A	Celgosivir (hydrochloride)	259.142	[H][C@]12[C@@H](O)CCN1C[C@H](OC(=O)CCC)[C@@H](O)[C@@H]2O	HTJGLYIJVSDQAE-VWNXEWBOSA-N	60734.0		HTJGLYIJVSDQAE
BRD-A95602221-003-02-1	celiprolol	Launched	adrenergic receptor antagonist	ADRA2A|ADRB1|ADRB2	genetics	Ehlers-Danlos syndrome (EDS)	0	97.27	Prestwick	Prestw-1132	Celiprolol hydrochloride	379.247	CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|	JOATXPAWOHTVSZ-INIZCTEOSA-N	11406333.0		JOATXPAWOHTVSZ
BRD-A95602221-003-03-9	celiprolol	Launched	adrenergic receptor antagonist	ADRA2A|ADRB1|ADRB2	genetics	Ehlers-Danlos syndrome (EDS)	0		WuXi	EW21509-19-P1	Celiprolol hydrochloride	379.247	CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|	JOATXPAWOHTVSZ-INIZCTEOSA-N	11406333.0		JOATXPAWOHTVSZ
BRD-K00003248-001-01-9	cenerimod	Phase 2	sphingosine 1-phosphate receptor modulator				0	90.19	MedChemEx	HY-17606	Cenerimod	453.226	CCc1cc(cc(C)c1OC[C@@H](O)CO)-c1noc(n1)-c1cc(OC)nc(c1)C1CCCC1	KJKKMMMRWISKRF-FQEVSTJZSA-N	49871973.0		KJKKMMMRWISKRF
BRD-K00003181-001-01-9	cenicriviroc	Phase 3	CC chemokine receptor antagonist				0	78.24	MedChemEx	HY-14882	Cenicriviroc	696.371	CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC |c:27|	PNDKCRDVVKJPKG-WHERJAGFSA-N	11285792.0		PNDKCRDVVKJPKG
BRD-K00003249-001-01-9	cenobamate	Launched	GABA receptor modulator|voltage-gated sodium channel blocker				0	100.0	MedChemEx	HY-17607	Cenobamate	267.052	NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl	GFHAXPJGXSQLPT-VIFPVBQESA-N	11962412.0		GFHAXPJGXSQLPT
BRD-K00004588-001-01-9	centanafadine	Phase 3	dopamine reuptake inhibitor				0	97.44	AMS	SY247368	(1R,5S)-1-(2-Naphthyl)-3-azabicyclo[3.1.0]hexane	209.12	C1[C@@H]2CNC[C@]12c1ccc2ccccc2c1	HKHCSWPSUSWGLI-CABCVRRESA-N	16095349.0		HKHCSWPSUSWGLI
BRD-K31329721-001-08-2	centazolone	Phase 1	monoamine oxidase inhibitor				0	95.67	Enamine	Z56813658	3-aminobenzo[g]quinazolin-4(3H)-one	211.075	Nn1cnc2cc3ccccc3cc2c1=O	CZXUQBVMAUWSBX-UHFFFAOYSA-N	72846.0		CZXUQBVMAUWSBX
BRD-K00004619-001-01-9	centhaquin	Phase 1	analgesic agent				0	96.94	Sigma	SML1786	2-{2-[4-(3-methylphenyl)-1-piperazinyl]ethyl}quinoline	331.205	Cc1cccc(c1)N1CCN(CCc2ccc3ccccc3n2)CC1	UJNWGFBJUHIJKK-UHFFFAOYSA-N	162163.0		UJNWGFBJUHIJKK
BRD-A28958257-001-02-0	centpropazine	Phase 3	inositol monophosphatase inhibitor				0	95.61	Enamine	Z31370920	1-{4-[2-hydroxy-3-(4-phenyl-1-piperazinyl)propoxy]phenyl}-1-propanone	368.21	CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|	ZQPXSRTZFYHSFB-FQEVSTJZSA-N	7032530.0		ZQPXSRTZFYHSFB
BRD-A28958257-001-01-2	centpropazine	Phase 3	inositol monophosphatase inhibitor				0	90.58	Enamine	Z31370920		368.21	CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10,r|	ZQPXSRTZFYHSFB-FQEVSTJZSA-N	7032530.0		ZQPXSRTZFYHSFB
BRD-K20722021-001-02-1	CEP-32496	Phase 1/Phase 2	RAF inhibitor	BRAF|RAF1			0	97.13	Selleck	S8015	CEP-32496	517.157	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	DKNUPRMJNUQNHR-UHFFFAOYSA-N	56846693.0		DKNUPRMJNUQNHR
BRD-K20722021-001-03-9	CEP-32496	Phase 1/Phase 2	RAF inhibitor	BRAF|RAF1			0	98.02	MedChemEx	HY-15200	Agerafenib	517.157	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	DKNUPRMJNUQNHR-UHFFFAOYSA-N	56846693.0		DKNUPRMJNUQNHR
BRD-K37237504-001-02-7	CEP-33779	Preclinical	JAK inhibitor	JAK2			0	82.13	Selleck	S2806	CEP-33779	462.184	CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	RFZKSQIFOZZIAQ-UHFFFAOYSA-N	57336812.0		RFZKSQIFOZZIAQ
BRD-K37237504-001-03-5	CEP-33779	Preclinical	JAK inhibitor	JAK2			0	87.81	Selleck	S2806	CEP33779	462.184	CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	RFZKSQIFOZZIAQ-UHFFFAOYSA-N	57336812.0		RFZKSQIFOZZIAQ
BRD-K37237504-001-04-9	CEP-33779	Preclinical	JAK inhibitor	JAK2			0	96.93	MedChemEx	HY-15343	CEP-33779	462.184	CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	RFZKSQIFOZZIAQ-UHFFFAOYSA-N	57336812.0		RFZKSQIFOZZIAQ
BRD-K72827473-001-01-0	CEP-37440	Phase 1	ALK tyrosine kinase receptor inhibitor	ALK			0	97.19	MedChemEx	HY-15841	CEP-37440	579.272	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	BCSHRERPHLTPEE-NRFANRHFSA-N	71721648.0		BCSHRERPHLTPEE
BRD-K72827473-001-02-8	CEP-37440	Phase 1	ALK tyrosine kinase receptor inhibitor	ALK			0		MedChemEx	HY-15841	CEP-37440	579.272	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	InChI=1S/C30H38ClN7O3/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36)/t21-/m0/s1	71721648.0		BCSHRERPHLTPEE
BRD-K00003396-001-01-9	CEP-40783	Preclinical	AXL kinase inhibitor				0	96.21	MedChemEx	HY-100946	CEP-40783	588.182	COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC	FKCWHHYUMFGOPY-UHFFFAOYSA-N	71576419.0		FKCWHHYUMFGOPY
BRD-K90733503-001-08-7	cephalexin	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections	0	75.26	MedChemEx	HY-B0200	Cephalexin	347.094	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N	6560168.0		ZAIPMKNFIOOWCQ
BRD-K90733503-001-07-9	cephalexin	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections	0	4.38	MedChemEx	HY-B0200	Cephalexin	347.094	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N	6560168.0		ZAIPMKNFIOOWCQ
BRD-K90733503-001-06-1	cephalexin	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections	0	22.1	Sigma	MFCD00056877	(6R,7R)-7-{[(2R)-2-amino-2-phenylethanoyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid	347.094	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N	6560168.0		ZAIPMKNFIOOWCQ
BRD-K90733503-001-10-3	cephalexin	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections	0	45.91	MicroSource	1502028	CEPHALEXIN	347.094	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N	6560168.0	BRD-A37536726-001-04-2	ZAIPMKNFIOOWCQ
BRD-K90733503-001-09-5	cephalexin	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections	0	0.0	Selleck	S1502	Cephalexin	347.094	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N	6560168.0	BRD-K64997193-001-01-0	ZAIPMKNFIOOWCQ
BRD-K90733503-001-05-3	cephalexin	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology	respiratory tract infections|otitis|skin infections|bone and joint infections|genitourinary tract infections	0	0.0	Selleck	S1502	Cephalexin (Cefalexin)	347.094	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N	6560168.0		ZAIPMKNFIOOWCQ
BRD-K68904758-001-04-3	cephalomannine	Preclinical	DNA polymerase inhibitor				0	94.06	MedChemEx	HY-77554	Cephalomannine	831.347	C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|	DBXFAPJCZABTDR-WBYYIXQISA-N	6436208.0	BRD-A70157906-001-01-3	DBXFAPJCZABTDR
BRD-K68904758-001-02-7	cephalomannine	Preclinical	DNA polymerase inhibitor				0	84.34	Selleck	S2408	Cephalomannine	831.347	C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|	DBXFAPJCZABTDR-WBYYIXQISA-N	6436208.0		DBXFAPJCZABTDR
BRD-K68904758-001-03-5	cephalomannine	Preclinical	DNA polymerase inhibitor				0	76.79	Selleck	S2408	Cephalomannine	831.347	C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|	DBXFAPJCZABTDR-WBYYIXQISA-N	6436208.0	BRD-K99571587-001-01-6	DBXFAPJCZABTDR
BRD-K00025564-001-01-9	cephalosporin-c-zn	Preclinical	bacterial cell wall synthesis inhibitor				0	0.0	CombiBlocks	QP-8626	[(3R,9S,19R)-9-amino-2,5,10,14-tetraoxo-11,13-dioxa-18-thia-1,4-diaza-12?2-zincatricyclo[13.4.0.03,19]nonadec-15-en-16-yl]methyl acetate	477.018	CC(=O)OCC1=C2N3[C@H](SC1)[C@H](NC(=O)CCC[C@H](N)C(=O)O[Zn]OC2=O)C3=O |t:5|	TVMXJQZBKOMFQK-JFEXGKLBSA-L			TVMXJQZBKOMFQK
BRD-K28210218-236-08-1	cephalothin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|surgical prophylaxis	0	92.86	MicroSource	1500166	CEPHALOTHIN SODIUM	396.045	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|	XIURVHNZVLADCM-IUODEOHRSA-N	6024.0		XIURVHNZVLADCM
BRD-K28210218-236-09-9	cephalothin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|surgical prophylaxis	0	82.68	MedChemEx	HY-B1275	Cephalothin (sodium)	396.045	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|	XIURVHNZVLADCM-IUODEOHRSA-N	6024.0		XIURVHNZVLADCM
BRD-K49880111-236-09-2	cephapirin	Launched	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	0	85.45	MicroSource	1500167	CEPHAPIRIN SODIUM	423.056	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|	UQLLWWBDSUHNEB-CZUORRHYSA-N	30699.0		UQLLWWBDSUHNEB
BRD-K49880111-236-10-0	cephapirin	Launched	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	0	65.4	Selleck	S4393	Cephapirin Sodium	423.056	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|	UQLLWWBDSUHNEB-CZUORRHYSA-N	30699.0	BRD-K25085912-236-01-4	UQLLWWBDSUHNEB
BRD-K49880111-236-11-8	cephapirin	Launched	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	0	88.36	Selleck	S4393	CEPHAPIRIN SODIUM	423.056	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|	UQLLWWBDSUHNEB-CZUORRHYSA-N	30699.0		UQLLWWBDSUHNEB
BRD-K96194081-001-10-2	cepharanthine	Phase 2	NFkB pathway inhibitor				0	85.41	MicroSource	1505322	CEPHARANTHINE	606.273	COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	YVPXVXANRNDGTA-WDYNHAJCSA-N	10206.0		YVPXVXANRNDGTA
BRD-K96194081-001-12-8	cepharanthine	Phase 2	NFkB pathway inhibitor				0	1.0	Selleck	S4238	Cepharanthine	606.273	COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	YVPXVXANRNDGTA-WDYNHAJCSA-N	10206.0	BRD-K78936063-001-01-9	YVPXVXANRNDGTA
BRD-K96194081-001-13-6	cepharanthine	Phase 2	NFkB pathway inhibitor				0	98.07	Selleck	S4238	CEPHARANTHINE	606.273	COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	YVPXVXANRNDGTA-WDYNHAJCSA-N	10206.0		YVPXVXANRNDGTA
BRD-K96194081-001-11-0	cepharanthine	Phase 2	NFkB pathway inhibitor				0	95.81	Selleck	S4238	Cepharanthine	606.273	COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	YVPXVXANRNDGTA-WDYNHAJCSA-N	10206.0		YVPXVXANRNDGTA
BRD-A90807417-001-04-5	cephradine	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|respiratory tract infections|urinary tract infections	0	5.47	MicroSource	1500168	CEPHRADINE	349.11	CC1=C(N2[C@@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |a:7,11,&1:4,c:17,t:1,14|	RDLPVSKMFDYCOR-HFAKWTLXSA-N	12876371.0		RDLPVSKMFDYCOR
BRD-K41707108-001-05-6	ceramide	Launched	phosphoenolpyruvate carboxylase activator|serine/threonine protein phosphatase activator		dermatology	cosmetic	0	100.0	Tocris	744	Ceramide	341.293	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O	BLTCBVOJNNKFKC-QUDYQQOWSA-N	5497136.0		BLTCBVOJNNKFKC
BRD-K22149900-001-06-2	ceritinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|FLT3|IGF1R|INSR|TSSK1B	oncology	non-small cell lung cancer (NSCLC)	0	88.37	MedChemEx	HY-15656	LDK378	557.223	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	VERWOWGGCGHDQE-UHFFFAOYSA-N	57379345.0		VERWOWGGCGHDQE
BRD-K22149900-001-05-4	ceritinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|FLT3|IGF1R|INSR|TSSK1B	oncology	non-small cell lung cancer (NSCLC)	0	95.17	MedChemEx	HY-15656	LDK378	557.223	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	VERWOWGGCGHDQE-UHFFFAOYSA-N	57379345.0		VERWOWGGCGHDQE
BRD-K22149900-001-03-9	ceritinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|FLT3|IGF1R|INSR|TSSK1B	oncology	non-small cell lung cancer (NSCLC)	0	95.07	Selleck	S7083	Ceritinib (LDK378)	557.223	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	VERWOWGGCGHDQE-UHFFFAOYSA-N	57379345.0		VERWOWGGCGHDQE
BRD-K22149900-001-01-3	ceritinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|FLT3|IGF1R|INSR|TSSK1B	oncology	non-small cell lung cancer (NSCLC)	0	38.5	Selleck	S7083	LDK378	557.223	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	VERWOWGGCGHDQE-UHFFFAOYSA-N	57379345.0		VERWOWGGCGHDQE
BRD-K52075040-001-09-7	cerulenin	Launched	fatty acid synthase inhibitor	FASN	infectious disease	fungal infection	0	41.25	Enzo	G237	Cerulenin	223.121	C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O	GVEZIHKRYBHEFX-NQQPLRFYSA-N	5282054.0		GVEZIHKRYBHEFX
BRD-K00003320-001-01-9	ceruletide	Preclinical	CCK receptor agonist	CCKAR			0	93.01	MedChemEx	HY-A0190	Ceruletide	1351.449	[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	YRALAIOMGQZKOW-HYAOXDFASA-N	16129675.0		YRALAIOMGQZKOW
BRD-K86954340-001-01-7	cetaben	Phase 2	ACAT inhibitor|cholesterol inhibitor	PPARA			0	55.82	Adooq	A11137	4-(hexadecylamino)benzoic acid	361.298	CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O	QXWKHSSBFQDQPR-UHFFFAOYSA-N	47263.0		QXWKHSSBFQDQPR
BRD-K94863486-001-02-2	cetilistat	Phase 3	triacylglycerol lipase inhibitor	PNLIP			0	0.0	Key	KS-1251	2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one	401.293	CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1	MVCQKIKWYUURMU-UHFFFAOYSA-N	9952916.0		MVCQKIKWYUURMU
BRD-K94863486-001-01-4	cetilistat	Phase 3	triacylglycerol lipase inhibitor	PNLIP			0	17.4	TCI	C2745		401.293	CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1	MVCQKIKWYUURMU-UHFFFAOYSA-N	9952916.0		MVCQKIKWYUURMU
BRD-K01826520-300-10-9	cetirizine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	98.06	Tocris	2577	Cetirizine dihydrochloride	460.109	OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|	ZKLPARSLTMPFCP-NRFANRHFSA-N	28145930.0		ZKLPARSLTMPFCP
BRD-K01826520-300-11-9	cetirizine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	97.14	MicroSource	1505371	CETIRIZINE HYDROCHLORIDE	460.109	OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|	ZKLPARSLTMPFCP-NRFANRHFSA-N	28145930.0		ZKLPARSLTMPFCP
BRD-K01826520-300-12-9	cetirizine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	96.66	Selleck	S1291	Cetirizine DiHCl	460.109	OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|	ZKLPARSLTMPFCP-NRFANRHFSA-N	28145930.0		ZKLPARSLTMPFCP
BRD-K47079459-004-14-9	cetrimonium	Launched			dermatology	cosmetic	0	97.8	MedChemEx	HY-B1260	Cetrimonium (bromide)	284.332	CCCCCCCCCCCCCCCC[N+](C)(C)C	RLGQACBPNDBWTB-UHFFFAOYSA-N	2681.0		RLGQACBPNDBWTB
BRD-K47079459-004-04-6	cetrimonium	Launched			dermatology	cosmetic	0	100.0	Selleck	S4242	Cetrimonium Bromide (CTAB)	284.332	CCCCCCCCCCCCCCCC[N+](C)(C)C	RLGQACBPNDBWTB-UHFFFAOYSA-N	2681.0		RLGQACBPNDBWTB
BRD-K47079459-004-05-3	cetrimonium	Launched			dermatology	cosmetic	0	98.91	MicroSource	1503200	CETRIMONIUM BROMIDE	284.332	CCCCCCCCCCCCCCCC[N+](C)(C)C	RLGQACBPNDBWTB-UHFFFAOYSA-N	2681.0		RLGQACBPNDBWTB
BRD-K76315403-015-02-5	cetrorelix	Launched	gonadotropin releasing factor hormone receptor antagonist	GNRHR|LHCGR	endocrinology	premature luteinizing hormone surges	0	98.03	Sigma	MFCD08459466	(S)-1-(((R)-2-((S)-2-((S)-2-((R)-2-((R)-2-((R)-2-acetamido-3-(naphthalen-2-yl)propanamido)-3-(4-chlorophenyl)propanamido)-3-(pyridin-3-yl)propanamido)-3-hydroxypropanamido)-3-(4-hydroxyphenyl)propanam;ido)-5-ureidopentanoyl)-L-leucyl-L-arginyl)-N-((R)-1-a	1429.67	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	SBNPWPIBESPSIF-MHWMIDJBSA-N	25074887.0		SBNPWPIBESPSIF
BRD-K76315403-015-03-9	cetrorelix	Launched	gonadotropin releasing factor hormone receptor antagonist	GNRHR|LHCGR	endocrinology	premature luteinizing hormone surges	0	94.5	MedChemEx	HY-P0009A	Cetrorelix (Acetate)	1429.67	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	SBNPWPIBESPSIF-MHWMIDJBSA-N	25074887.0		SBNPWPIBESPSIF
BRD-K87700323-003-05-1	cetylpyridinium	Launched			dental	gingivitis|mouth inflammation	0	97.23	MicroSource	1500169	CETYLPYRIDINIUM CHLORIDE	304.3	CCCCCCCCCCCCCCCC[n+]1ccccc1	NEUSVAOJNUQRTM-UHFFFAOYSA-N	2683.0		NEUSVAOJNUQRTM
BRD-K87700323-311-08-9	cetylpyridinium	Launched			dental	gingivitis|mouth inflammation	0	90.42	MedChemEx	HY-B1289	Cetylpyridinium (chloride monohydrate)	304.3	CCCCCCCCCCCCCCCC[n+]1ccccc1	NEUSVAOJNUQRTM-UHFFFAOYSA-N	2683.0		NEUSVAOJNUQRTM
BRD-K87700323-003-04-4	cetylpyridinium	Launched			dental	gingivitis|mouth inflammation	0	87.01	Selleck	S4172	Cetylpyridinium Chloride	304.3	CCCCCCCCCCCCCCCC[n+]1ccccc1	NEUSVAOJNUQRTM-UHFFFAOYSA-N	2683.0		NEUSVAOJNUQRTM
BRD-K87700323-003-06-9	cetylpyridinium	Launched			dental	gingivitis|mouth inflammation	0	98.97	Selleck	S4172	Cetylpyridinium Chloride	304.3	CCCCCCCCCCCCCCCC[n+]1ccccc1	NEUSVAOJNUQRTM-UHFFFAOYSA-N	2683.0		NEUSVAOJNUQRTM
BRD-K00004291-003-01-9	cevimeline	Launched	acetylcholine receptor agonist	CHRM3	rheumatology	sjogren's syndrome	0	100.0	Tocris	3689	Cevimeline hydrochloride	199.103	C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1,3|	WUTYZMFRCNBCHQ-WPRPVWTQSA-N	18642481.0		WUTYZMFRCNBCHQ
BRD-K00003570-001-01-9	cevipabulin	Phase 1	microtubule stimulant|tubulin polymerization inhibitor	TUBB			0	91.03	MedChemEx	HY-14949	Cevipabulin	464.115	[H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F	ZUZPCOQWSYNWLU-VIFPVBQESA-N	11488110.0		ZUZPCOQWSYNWLU
BRD-A47940219-001-02-9	CE3F4	Preclinical	rap guanine nucleotide exchange factor inhibitor	RAPGEF3			0	96.7	Tocris	4793	CE3F4	348.911	C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|	ZZLQPWXVZCPUGC-LURJTMIESA-N	73669656.0		ZZLQPWXVZCPUGC
BRD-A47940219-001-01-4	CE3F4	Preclinical	rap guanine nucleotide exchange factor inhibitor	RAPGEF3			0	98.53	Tocris	4793	CE3F4	348.911	C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1,r|	ZZLQPWXVZCPUGC-LURJTMIESA-N	73669656.0		ZZLQPWXVZCPUGC
BRD-K27040396-051-02-9	CFI-400945	Phase 2	serine/threonine kinase inhibitor				0	95.21	MedChemEx	HY-12300B	CFI-400945 (fumarate)	534.263	COc1ccc2NC(=O)[C@@]3(C[C@H]3c3ccc4c(\C=C\c5ccc(CN6C[C@H](C)O[C@H](C)C6)cc5)[nH]nc4c3)c2c1	DADASRPKWOGKCU-FVTQAUBDSA-N	58486178.0		DADASRPKWOGKCU
BRD-K00003409-001-01-9	CFI-402257	Phase 1/Phase 2	dual specificity protein kinase inhibitor				0	95.05	MedChemEx	HY-101340	CFI-402257	498.238	Cc1cc(ccc1C(=O)NC1CC1)-c1cnn2c(NC[C@H]3C[C@@](C)(O)C3)cc(Oc3cccnc3)nc12 |r|	PMQUGSPFUBGJCZ-CHOKWEPUSA-N			PMQUGSPFUBGJCZ
BRD-K64341947-003-03-2	CFM-1571	Preclinical	guanylate cyclase activator				0	95.4	Tocris	2586	CFM 1571 hydrochloride	408.216	COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	YZCSJBGQLATPMH-UHFFFAOYSA-N	9844347.0		YZCSJBGQLATPMH
BRD-K64341947-003-02-4	CFM-1571	Preclinical	guanylate cyclase activator				0	93.91	Tocris	2586	CFM 1571 hydrochloride	408.216	COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	YZCSJBGQLATPMH-UHFFFAOYSA-N	9844347.0		YZCSJBGQLATPMH
BRD-K42859542-001-04-9	CFM-2	Preclinical	glutamate receptor antagonist				0	89.34	Tocris	1082	CFM-2	311.127	COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|	MJKADKZSYQWGLL-UHFFFAOYSA-N	4377504.0		MJKADKZSYQWGLL
BRD-K42859542-001-03-3	CFM-2	Preclinical	glutamate receptor antagonist				0	89.65	Tocris	1082	CFM-2	311.127	COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|	MJKADKZSYQWGLL-UHFFFAOYSA-N	4377504.0		MJKADKZSYQWGLL
BRD-K72004355-001-03-5	CFTRinh-172	Preclinical	chloride channel blocker	CFTR			0	79.6	Tocris	3430	CFTRinh 172	409.005	OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1	JIMHYXZZCWVCMI-RIYZIHGNSA-N	1554210.0		JIMHYXZZCWVCMI
BRD-K72004355-001-02-7	CFTRinh-172	Preclinical	chloride channel blocker	CFTR			0	90.02	Tocris	3430	CFTRinh 172	409.005	OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1	JIMHYXZZCWVCMI-RIYZIHGNSA-N	1554210.0		JIMHYXZZCWVCMI
BRD-K72004355-001-04-9	CFTRinh-172	Preclinical	chloride channel blocker	CFTR			0	90.32	Tocris	3430	CFTRinh 172	409.005	OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1	JIMHYXZZCWVCMI-RIYZIHGNSA-N	1554210.0		JIMHYXZZCWVCMI
BRD-K72004355-001-01-9	CFTRinh-172	Preclinical	chloride channel blocker	CFTR			0	90.25	Selleck	S7139	CFTRinh-172	409.005	OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1	JIMHYXZZCWVCMI-RIYZIHGNSA-N	1554210.0		JIMHYXZZCWVCMI
BRD-K52396582-001-07-9	CF102	Phase 2	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	95.0	Tocris	1104	2-Cl-IB-MECA	544.012	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	IPSYPUKKXMNCNQ-PFHKOEEOSA-N	3035850.0		IPSYPUKKXMNCNQ
BRD-K52396582-001-06-7	CF102	Phase 2	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	98.78	Tocris	1104	2-Cl-IB-MECA	544.012	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	IPSYPUKKXMNCNQ-PFHKOEEOSA-N	3035850.0		IPSYPUKKXMNCNQ
BRD-K48888725-001-02-7	CG-400549	Phase 2	FABI inhibitor				0	95.34	Astatech	52038	1-(3-amino-2-methylbenzyl)-4-[2-(2-thienyl)ethoxy]-2(1H)-pyridinone	340.125	Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	YCLREGRRHGLOAK-UHFFFAOYSA-N	11844916.0		YCLREGRRHGLOAK
BRD-K48888725-001-01-9	CG-400549	Phase 2	FABI inhibitor				0	84.19	Astatech	52038	1-(3-AMINO-2-METHYL-BENZYL)-4-(2-THIOPHEN-2-YL-ETHOXY)-2-PYRIDONE	340.125	Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	YCLREGRRHGLOAK-UHFFFAOYSA-N	11844916.0		YCLREGRRHGLOAK
BRD-K82028950-300-03-7	CGH2466	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2B|ADORA3			0	94.17	Tocris	2344	4-(3,4-dichlorophenyl)-5-(4-pyridinyl)-1,3-thiazol-2-amine dihydrochloride	320.989	Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	BEPGKLOHQTXUHX-UHFFFAOYSA-N	5282339.0		BEPGKLOHQTXUHX
BRD-K82028950-300-02-9	CGH2466	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2B|ADORA3			0	82.59	Tocris	2344	CGH 2466 dihydrochloride	320.989	Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	BEPGKLOHQTXUHX-UHFFFAOYSA-N	5282339.0		BEPGKLOHQTXUHX
BRD-A50737080-001-03-0	CGK-733	Preclinical	ATM kinase inhibitor|ATR kinase inhibitor	ATM|ATR			0	88.69	Tocris	2639	CGK 733	554.015	[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|	HLCDNLNLQNYZTK-OAQYLSRUSA-N	92509770.0		HLCDNLNLQNYZTK
BRD-A50737080-001-07-9	CGK-733	Preclinical	ATM kinase inhibitor|ATR kinase inhibitor	ATM|ATR			0	96.41	Tocris	2639	CGK 733	554.015	[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|	HLCDNLNLQNYZTK-OAQYLSRUSA-N	92509770.0		HLCDNLNLQNYZTK
BRD-A50737080-001-06-3	CGK-733	Preclinical	ATM kinase inhibitor|ATR kinase inhibitor	ATM|ATR			0	86.81	Tocris	2639	CGK 733	554.015	[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|	HLCDNLNLQNYZTK-OAQYLSRUSA-N	92509770.0		HLCDNLNLQNYZTK
BRD-A50737080-001-02-2	CGK-733	Preclinical	ATM kinase inhibitor|ATR kinase inhibitor	ATM|ATR			0	83.18	Selleck	S7136	CGK 733	554.015	[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|	HLCDNLNLQNYZTK-OAQYLSRUSA-N	92509770.0		HLCDNLNLQNYZTK
BRD-A50737080-001-05-5	CGK-733	Preclinical	ATM kinase inhibitor|ATR kinase inhibitor	ATM|ATR			0	97.37	Selleck	S7136	CGK 733	554.015	[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10,r|	HLCDNLNLQNYZTK-OAQYLSRUSA-N	92509770.0		HLCDNLNLQNYZTK
BRD-K79584249-001-02-1	CGM097	Phase 1	MDM inhibitor	MDM2			0	92.76	MedChemEx	HY-15954	NVP-CGM097	658.329	COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	CLRSLRWKONPSRQ-IIPSPAQQSA-N			CLRSLRWKONPSRQ
BRD-K79584249-001-01-3	CGM097	Phase 1	MDM inhibitor	MDM2			0	85.96	MedChemEx	HY-15954	NVP-CGM097	658.329	COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	CLRSLRWKONPSRQ-IIPSPAQQSA-N			CLRSLRWKONPSRQ
BRD-A40084411-003-09-9	CGP-12177	Phase 1	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	96.22	Tocris	1134	CGP 12177 hydrochloride	279.158	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|	UMQUQWCJKFOUGV-SECBINFHSA-N	76962943.0		UMQUQWCJKFOUGV
BRD-A40084411-003-07-7	CGP-12177	Phase 1	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	96.6	Tocris	1134	CGP 12177 hydrochloride	279.158	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|	UMQUQWCJKFOUGV-SECBINFHSA-N	76962943.0		UMQUQWCJKFOUGV
BRD-K95851186-001-08-9	CGP-13501	Preclinical	GABA receptor modulator	GABBR1			0	93.42	Tocris	1514	CGP 13501	290.225	CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C	XGWATTXMMMANFJ-UHFFFAOYSA-N	3519541.0		XGWATTXMMMANFJ
BRD-K95851186-001-07-8	CGP-13501	Preclinical	GABA receptor modulator	GABBR1			0	91.07	Tocris	1514	CGP 13501	290.225	CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C	XGWATTXMMMANFJ-UHFFFAOYSA-N	3519541.0		XGWATTXMMMANFJ
BRD-K01827291-066-05-9	CGP-20712A	Preclinical	adrenergic receptor antagonist	ADRB1|ADRB3			0	97.65	Sigma	C231	2-hydroxy-5-{2-[(2-hydroxy-3-{4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]phenoxy}propyl)amino]ethoxy}benzamide methanesulfonate	590.166	CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17,r|	VFPOVCXWKBYDNF-XFULWGLBSA-N	91667713.0		VFPOVCXWKBYDNF
BRD-K00003372-003-01-9	CGP-25454A	Preclinical	dopamine receptor antagonist				0	97.68	MedChemEx	HY-100454	CGP 25454A	309.124	CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC	JEMKCYHUYUPGFN-UHFFFAOYSA-N	9819591.0		JEMKCYHUYUPGFN
BRD-A35623999-001-06-5	CGP-37157	Preclinical	mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor	SLC8A1			0	99.02	Tocris	1114	CGP 37157	322.994	Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|	KQEPIRKXSUIUTH-HNNXBMFYSA-N	6604821.0		KQEPIRKXSUIUTH
BRD-A35623999-001-07-9	CGP-37157	Preclinical	mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor	SLC8A1			0	97.24	Tocris	1114	CGP 37157	322.994	Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|	KQEPIRKXSUIUTH-HNNXBMFYSA-N	6604821.0		KQEPIRKXSUIUTH
BRD-A35623999-001-05-7	CGP-37157	Preclinical	mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor	SLC8A1			0	99.24	Tocris	1114	CGP 37157	322.994	Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10,r|	KQEPIRKXSUIUTH-HNNXBMFYSA-N	6604821.0		KQEPIRKXSUIUTH
BRD-A90272038-001-02-5	CGP-37849	Phase 1	glutamate receptor antagonist	GRIN2A|GRIN2B|GRIN2C|GRIN2D			1	0.0	Tocris	1469	(3E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid	209.045	C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|	BDYHNCZIGYIOGJ-XWCPEMDWSA-N	6604869.0		BDYHNCZIGYIOGJ
BRD-A90272038-001-01-7	CGP-37849	Phase 1	glutamate receptor antagonist	GRIN2A|GRIN2B|GRIN2C|GRIN2D			1	0.0	EMDBio	504842-10MG	CGP 37849	209.045	C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8,r|	BDYHNCZIGYIOGJ-XWCPEMDWSA-N	6604869.0		BDYHNCZIGYIOGJ
BRD-K00004626-001-01-9	CGP-39551	Preclinical	NMDA receptor antagonist				0	0.0	Sigma	SML0058	(2E)-4-amino-5-ethoxy-2-methyl-5-oxo-2-pentenylphosphonic acid	237.077	CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O |&1:5,r|	OKDOWCKDTWNRCB-PTYLAXBQSA-N	6438792.0		OKDOWCKDTWNRCB
BRD-K13087974-001-03-3	CGP-52411	Preclinical	EGFR inhibitor	EGFR			0	94.09	Tocris	3360	CGP 52411	329.116	O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	AAALVYBICLMAMA-UHFFFAOYSA-N	1697.0		AAALVYBICLMAMA
BRD-K13087974-001-02-5	CGP-52411	Preclinical	EGFR inhibitor	EGFR			0	94.94	Tocris	3360	CGP 52411	329.116	O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	AAALVYBICLMAMA-UHFFFAOYSA-N	1697.0		AAALVYBICLMAMA
BRD-K32292990-001-03-6	CGP-53353	Preclinical	EGFR inhibitor|PKC inhibitor	EGFR|PRKCB			0	94.62	Tocris	2442	CGP 53353	365.098	Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	RONQPWQYDRPRGG-UHFFFAOYSA-N	6711154.0		RONQPWQYDRPRGG
BRD-K32292990-001-04-4	CGP-53353	Preclinical	EGFR inhibitor|PKC inhibitor	EGFR|PRKCB			0	91.48	Tocris	2442	CGP 53353	365.098	Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	RONQPWQYDRPRGG-UHFFFAOYSA-N	6711154.0		RONQPWQYDRPRGG
BRD-A74208568-003-02-3	CGP-54626	Preclinical	GABA receptor antagonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8			0	89.91	Tocris	1088	CGP 54626 hydrochloride	407.118	C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|	JGGVBBYJRQOPPA-BBRMVZONSA-N	197584.0		JGGVBBYJRQOPPA
BRD-A74208568-003-04-9	CGP-54626	Preclinical	GABA receptor antagonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8			0	87.89	Tocris	1088	CGP 54626 hydrochloride	407.118	C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|	JGGVBBYJRQOPPA-BBRMVZONSA-N	197584.0		JGGVBBYJRQOPPA
BRD-A74208568-003-01-5	CGP-54626	Preclinical	GABA receptor antagonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8			0	93.07	Tocris	1088	CGP 54626 hydrochloride	407.118	C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1,4,&1:7|	JGGVBBYJRQOPPA-BBRMVZONSA-N	197584.0		JGGVBBYJRQOPPA
BRD-K00004232-003-02-9	CGP-55845	Preclinical	GABA receptor antagonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8			0	97.18	Tocris	1248	CGP55845	401.071	C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	ZODSPDOOCZZEIM-BBRMVZONSA-N	5311042.0		ZODSPDOOCZZEIM
BRD-K00004232-003-01-9	CGP-55845	Preclinical	GABA receptor antagonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8			0	96.85	Tocris	1248	CGP 55845 hydrochloride	401.071	C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	ZODSPDOOCZZEIM-BBRMVZONSA-N	5311042.0		ZODSPDOOCZZEIM
BRD-K42500029-001-04-3	CGP-57380	Preclinical	MAP kinase inhibitor	AURKB|LCK|MKNK1|MKNK2|SGK1			0	85.71	Tocris	2731	CGP 57380	244.087	Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12	UQPMANVRZYYQMD-UHFFFAOYSA-N	11644425.0		UQPMANVRZYYQMD
BRD-K42500029-001-03-5	CGP-57380	Preclinical	MAP kinase inhibitor	AURKB|LCK|MKNK1|MKNK2|SGK1			0	92.47	Selleck	S7421	CGP 57380	244.087	Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12	UQPMANVRZYYQMD-UHFFFAOYSA-N	11644425.0		UQPMANVRZYYQMD
BRD-K42500029-001-06-8	CGP-57380	Preclinical	MAP kinase inhibitor	AURKB|LCK|MKNK1|MKNK2|SGK1			0	91.61	Tocris	2731	CGP 57380	244.087	Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12	UQPMANVRZYYQMD-UHFFFAOYSA-N	11644425.0		UQPMANVRZYYQMD
BRD-K79090631-001-23-9	CGP-60474	Preclinical	CDK inhibitor	CDK1|CDK2			0	95.21	Tocris	5471	CGP 60474	355.12	OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1	IYNDTACKOAXKBJ-UHFFFAOYSA-N	644215.0		IYNDTACKOAXKBJ
BRD-K79090631-001-22-3	CGP-60474	Preclinical	CDK inhibitor	CDK1|CDK2			0	98.36	Tocris	5471	CGP 60474	355.12	OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1	IYNDTACKOAXKBJ-UHFFFAOYSA-N	644215.0		IYNDTACKOAXKBJ
BRD-K34321528-003-02-0	CGP-71683	Preclinical	neuropeptide receptor antagonist	NPY5R			0	97.9	Tocris	2199	CGP 71683 hydrochloride	475.204	Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|	UULIGRNKXHCLQN-WGSAOQKQSA-N			UULIGRNKXHCLQN
BRD-K34321528-003-01-2	CGP-71683	Preclinical	neuropeptide receptor antagonist	NPY5R			0	98.57	Tocris	2199	CGP 71683 hydrochloride	475.204	Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|	UULIGRNKXHCLQN-WGSAOQKQSA-N			UULIGRNKXHCLQN
BRD-K34321528-003-03-9	CGP-71683	Preclinical	neuropeptide receptor antagonist	NPY5R			0	97.77	Tocris	2199	CGP 71683 hydrochloride	475.204	Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|	UULIGRNKXHCLQN-WGSAOQKQSA-N			UULIGRNKXHCLQN
BRD-K56239177-300-02-9	CGP-74514	Preclinical	CDK inhibitor	CDK1			0	96.7	Tocris	5472	CGP 74514 dihydrochloride	385.178	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12	UTBSBSOBZHXMHI-LSDHHAIUSA-N	2794188.0		UTBSBSOBZHXMHI
BRD-K56239177-300-01-3	CGP-74514	Preclinical	CDK inhibitor	CDK1			0	95.63	Tocris	5472	CGP 74514 dihydrochloride	385.178	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12	UTBSBSOBZHXMHI-LSDHHAIUSA-N	2794188.0		UTBSBSOBZHXMHI
BRD-K60946979-003-02-9	CGP-78608	Preclinical	glutamate receptor antagonist				0	97.3	Tocris	1493	CGP 78608 hydrochloride	376.978	C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O	DPFHVUSPVHRVFL-YFKPBYRVSA-N	6604872.0		DPFHVUSPVHRVFL
BRD-K60946979-003-01-7	CGP-78608	Preclinical	glutamate receptor antagonist				0	0.0	Tocris	1493	CGP 78608 hydrochloride	376.978	C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O	DPFHVUSPVHRVFL-YFKPBYRVSA-N	6604872.0		DPFHVUSPVHRVFL
BRD-K65786282-001-08-3	CGP-7930	Preclinical	GABA receptor modulator	GABBR1			0	96.35	Tocris	1513	CGP 7930	292.24	CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	XLWJPQQFJNGUPA-UHFFFAOYSA-N	5024764.0		XLWJPQQFJNGUPA
BRD-K65786282-001-09-9	CGP-7930	Preclinical	GABA receptor modulator	GABBR1			0	85.15	Tocris	1513	CGP 7930	292.24	CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	XLWJPQQFJNGUPA-UHFFFAOYSA-N	5024764.0		XLWJPQQFJNGUPA
BRD-K65786282-001-07-5	CGP-7930	Preclinical	GABA receptor modulator	GABBR1			0	93.65	Tocris	1513	CGP 7930	292.24	CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	XLWJPQQFJNGUPA-UHFFFAOYSA-N	5024764.0		XLWJPQQFJNGUPA
BRD-K49049886-001-08-7	CGS-15943	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	96.89	Tocris	1699	CGS 15943	285.042	Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	MSJODEOZODDVGW-UHFFFAOYSA-N	2690.0		MSJODEOZODDVGW
BRD-K49049886-001-13-7	CGS-15943	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	96.45	WuXi	CGS-15943	CGS-15943	285.042	Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	MSJODEOZODDVGW-UHFFFAOYSA-N	2690.0		MSJODEOZODDVGW
BRD-K68103045-001-03-7	CGS-20625	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6			0	94.19	Tocris	2467	CGS 20625	309.148	COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	163844.0		UBLXQFIFWUEVGJ
BRD-K68103045-001-02-9	CGS-20625	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6			0	94.08	Tocris	2467	CGS 20625	309.148	COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	163844.0		UBLXQFIFWUEVGJ
BRD-K68103045-001-04-9	CGS-20625	Phase 1	benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6			0	93.03	Tocris	2467	CGS 20625	309.148	COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O	UBLXQFIFWUEVGJ-UHFFFAOYSA-N	163844.0		UBLXQFIFWUEVGJ
BRD-K27176996-003-10-9	CGS-21680	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	93.52	Tocris	1063	CGS 21680 hydrochloride	499.218	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12	PAOANWZGLPPROA-RQXXJAGISA-N	3086599.0		PAOANWZGLPPROA
BRD-K54093161-001-01-8	CGS-9896	Preclinical	GABA receptor antagonist	GABRA1|GABRB2|GABRG2			0	96.33	ChemDiv	M436-0007	2-(4-chlorophenyl)-1H-pyrazolo[4,3-c]quinolin-3(2H)-one	295.051	Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O	QCBUAKLOWCOUCR-UHFFFAOYSA-N	108030.0		QCBUAKLOWCOUCR
BRD-K24820488-001-01-7	CH-170	Phase 1					0	99.18	Enamine	Z164701248		276.097	Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	JBXSBZBZASARMY-UHFFFAOYSA-N	139570.0		JBXSBZBZASARMY
BRD-K24820488-001-02-9	CH-170	Phase 1					0		Broad Institute	Chinoin 170	Chinoin 170	276.097	Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	JBXSBZBZASARMY-UHFFFAOYSA-N	139570.0		JBXSBZBZASARMY
BRD-K11683436-001-01-7	CH-5183284	Phase 2	fibroblast growth factor inhibitor	FGFR1|FGFR2|FGFR3			0	98.42	Selleck	S7665	CH5183284 (Debio-1347)	356.139	Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N	BEMNJULZEQTDJY-UHFFFAOYSA-N	66555680.0		BEMNJULZEQTDJY
BRD-K11683436-001-02-5	CH-5183284	Phase 2	fibroblast growth factor inhibitor	FGFR1|FGFR2|FGFR3			0	97.6	Cayman	17120	(5-amino-1-(2-methyl-1H-benzo[d]imidazol-6-yl)-1H-pyrazol-4-yl)(1H-indol-2-yl)methanone	356.139	Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N	BEMNJULZEQTDJY-UHFFFAOYSA-N	66555680.0		BEMNJULZEQTDJY
BRD-K60302405-001-08-6	CHC	Preclinical	monocarboxylate transporter inhibitor	SLC16A1			0	89.98	Tocris	5029	CHC	189.043	OC(=O)C(=C\c1ccc(O)cc1)\C#N	AFVLVVWMAFSXCK-VMPITWQZSA-N	5328791.0		AFVLVVWMAFSXCK
BRD-K60302405-001-04-5	CHC	Preclinical	monocarboxylate transporter inhibitor	SLC16A1			0	97.89	MicroSource	1502096	alpha-CYANO-4-HYDROXYCINNAMIC ACID	189.043	OC(=O)C(=C\c1ccc(O)cc1)\C#N	InChI=1S/C10H7NO3/c11-6-8(10(13)14)5-7-1-3-9(12)4-2-7/h1-5,12H,(H,13,14)/b8-5+	5328791.0		AFVLVVWMAFSXCK
BRD-K18135438-001-14-2	chenodeoxycholic-acid	Launched	11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist	HSD11B1|NR1H4	cardiology|gastroenterology	cerebral cholesterosis|gallstones	0	96.54	MicroSource	1500837	CHENODIOL	392.293	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-BSWAIDMHSA-N	10133.0		RUDATBOHQWOJDD
BRD-K18135438-001-16-7	chenodeoxycholic-acid	Launched	11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist	HSD11B1|NR1H4	cardiology|gastroenterology	cerebral cholesterosis|gallstones	0	100.0	Selleck	S1843	Chenodeoxycholic Acid	392.293	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-BSWAIDMHSA-N	10133.0	BRD-K43723251-001-01-5	RUDATBOHQWOJDD
BRD-K34508702-001-02-4	CHF5074	Phase 2	gamma secretase modulator	PSEN1			0	92.25	MedChemEx	HY-14399	CHF5074	324.012	OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1	LIYLTQQDABRNRX-UHFFFAOYSA-N	9996409.0		LIYLTQQDABRNRX
BRD-K56483981-342-06-4	chicago-sky-blue-6b	Preclinical	glutamate inhibitor|macrophage migration inhibiting factor inhibitor	MIF			0	76.61	Prestwick	Prestw-425	Chicago sky blue 6B	904.044	COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|	BGULJNMSWJQIEK-UHFFFAOYSA-N	6817703.0		BGULJNMSWJQIEK
BRD-K56483981-342-07-2	chicago-sky-blue-6b	Preclinical	glutamate inhibitor|macrophage migration inhibiting factor inhibitor	MIF			0	0.0	Selleck	S5609	Chicago sky blue 6B	904.044	COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12,40|	BGULJNMSWJQIEK-UHFFFAOYSA-N	6817703.0		BGULJNMSWJQIEK
BRD-K28537285-001-01-8	chidamide	Launched	HDAC inhibitor	HDAC10|HDAC3	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	0	91.41	MedChemEx	HY-13592	Chidamide	390.149	Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	WXHHICFWKXDFOW-BJMVGYQFSA-N	9800555.0		WXHHICFWKXDFOW
BRD-K52284881-236-02-4	chiniofon	Launched	antiprotozoal agent		infectious disease	amebiasis	0	95.18	MicroSource	1504510	CHINIOFON	350.906	Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	ZBJWWKFMHOAPNS-UHFFFAOYSA-N	1550821.0		ZBJWWKFMHOAPNS
BRD-K52284881-001-03-9	chiniofon	Launched	antiprotozoal agent		infectious disease	amebiasis	0	97.33	Sigma	MFCD00006793	8-Hydroxy-7-iodo-5-quinolinesulfonic acid	350.906	Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	ZBJWWKFMHOAPNS-UHFFFAOYSA-N	1550821.0		ZBJWWKFMHOAPNS
BRD-K02241333-001-02-7	CHIR-124	Preclinical	CHK inhibitor	CHEK1			0	95.19	Selleck	S2683	CHIR-124	419.151	Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	MOVBBVMDHIRCTG-LJQANCHMSA-N	135399748.0		MOVBBVMDHIRCTG
BRD-K42973005-001-07-9	CHIR-98014	Preclinical	glycogen synthase kinase inhibitor	GSK3A|GSK3B			0	85.59	MedChemEx	HY-13076	CHIR-98014	485.088	Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	MDZCSIDIPDZWKL-UHFFFAOYSA-N	53396311.0		MDZCSIDIPDZWKL
BRD-K42973005-001-04-0	CHIR-98014	Preclinical	glycogen synthase kinase inhibitor	GSK3A|GSK3B			0	94.71	Selleck	S2745	CHIR-98014	485.088	Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	MDZCSIDIPDZWKL-UHFFFAOYSA-N	53396311.0		MDZCSIDIPDZWKL
BRD-K16189898-003-03-3	CHIR-99021	Preclinical	glycogen synthase kinase inhibitor	CDK1|GSK3A|GSK3B|MAPK1			0	95.6	Selleck	S2924	CHIR-99021 (CT99021) HCl	464.103	Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	AQGNHMOJWBZFQQ-UHFFFAOYSA-N	9956119.0		AQGNHMOJWBZFQQ
BRD-K16189898-001-21-9	CHIR-99021	Preclinical	glycogen synthase kinase inhibitor	CDK1|GSK3A|GSK3B|MAPK1			0	89.93	Tocris	4423	CHIR 99021	464.103	Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	AQGNHMOJWBZFQQ-UHFFFAOYSA-N	9956119.0		AQGNHMOJWBZFQQ
BRD-K16189898-001-12-8	CHIR-99021	Preclinical	glycogen synthase kinase inhibitor	CDK1|GSK3A|GSK3B|MAPK1			0	98.29	Stanley		Chiron 99021	464.103	Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	AQGNHMOJWBZFQQ-UHFFFAOYSA-N	9956119.0		AQGNHMOJWBZFQQ
BRD-K00004971-001-01-9	chloralose	Preclinical					0	92.6	MedChemEx	HY-B1020	Chloralose	307.962	OC[C@@H](O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl	OJYGBLRPYBAHRT-IPQSZEQASA-N	7057995.0		OJYGBLRPYBAHRT
BRD-K29458283-001-29-9	chlorambucil	Launched	DNA inhibitor		hematologic malignancy	chronic lymphocytic leukemia (CLL)|Hodgkin's lymphoma	0	94.93	MicroSource	1500171	CHLORAMBUCIL	303.079	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	JCKYGMPEJWAADB-UHFFFAOYSA-N	2708.0		JCKYGMPEJWAADB
BRD-K93546328-236-02-8	chloramine-T	Launched			infectious disease	bacterial gill disease	0	69.13	MicroSource	1504506	CHLORAMINE-T	204.996	Cc1ccc(cc1)S(=O)(=O)NCl	NXTVQNIVUKXOIL-UHFFFAOYSA-N	31388.0		NXTVQNIVUKXOIL
BRD-K93546328-236-03-9	chloramine-T	Launched			infectious disease	bacterial gill disease	0	65.32	MedChemEx	HY-B0959	Chloramine-T	204.996	Cc1ccc(cc1)S(=O)(=O)NCl	NXTVQNIVUKXOIL-UHFFFAOYSA-N	31388.0		NXTVQNIVUKXOIL
BRD-K08111712-001-16-7	chloramphenicol	Launched	bacterial 50S ribosomal subunit inhibitor	CD55	infectious disease|endocrinology	meningitis|fever|cholera	0	99.59	MicroSource	1500174	CHLORAMPHENICOL	322.012	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	WIIZWVCIJKGZOK-RKDXNWHRSA-N	5959.0	BRD-K22969690-001-04-2	WIIZWVCIJKGZOK
BRD-K08111712-001-14-2	chloramphenicol	Launched	bacterial 50S ribosomal subunit inhibitor	CD55	infectious disease|endocrinology	meningitis|fever|cholera	0	96.03	Selleck	S1677	Chloramphenicol	322.012	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	WIIZWVCIJKGZOK-RKDXNWHRSA-N	5959.0		WIIZWVCIJKGZOK
BRD-K33742430-001-01-1	chloramphenicol-palmitate	Launched	protein synthesis inhibitor		infectious disease|endocrinology	meningitis|fever|cholera	0	96.32	TCI	C3258	Chloramphenicol palmitate	560.242	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	PXKHGMGELZGJQE-ILBGXUMGSA-N	443382.0		PXKHGMGELZGJQE
BRD-K25209357-236-01-2	chloramphenicol-sodium-succinate	Launched	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	31.43	MicroSource	1500173	CHLORAMPHENICOL SODIUM SUCCINATE	422.028	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O	LIRCDOVJWUGTMW-ZWNOBZJWSA-N	656580.0		LIRCDOVJWUGTMW
BRD-K21452876-003-01-8	chlorazanil	Preclinical					0	98.95	MicroSource	1503744	CHLORAZANIL HYDROCHLORIDE	221.047	Nc1ncnc(Nc2ccc(Cl)cc2)n1	YRZQHIVOIFJEEE-UHFFFAOYSA-N	10374.0	BRD-K44275059-003-01-5	YRZQHIVOIFJEEE
BRD-A57133233-003-12-9	chlorcyclizine	Launched	histamine receptor antagonist		allergy	allergic rhinitis	0	93.25	MedChemEx	HY-112067A	Chlorcyclizine (hydrochloride)	300.139	CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|	WFNAKBGANONZEQ-SFHVURJKSA-N	688437.0		WFNAKBGANONZEQ
BRD-A57133233-003-11-0	chlorcyclizine	Launched	histamine receptor antagonist		allergy	allergic rhinitis	0	97.82	Enzo	AC2340	Chlorcyclizine hydrochloride	300.139	CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|	WFNAKBGANONZEQ-SFHVURJKSA-N	688437.0		WFNAKBGANONZEQ
BRD-K89409436-001-01-4	chlorfenson	Phase 2	other antifungal				0	0.0	Sigma	MFCD00055266	4-chlorophenyl 4-chlorobenzenesulfonate	301.957	Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1	RZXLPPRPEOUENN-UHFFFAOYSA-N	6635.0		RZXLPPRPEOUENN
BRD-K52256627-300-06-6	chlorhexidine	Launched	membrane integrity inhibitor		dermatology|infectious disease|dental	cosmetic|skin infections|gingivitis	0	97.77	MicroSource	1500177	CHLORHEXIDINE DIHYDROCHLORIDE	504.203	NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1	GHXZTYHSJHQHIJ-UHFFFAOYSA-N	9552079.0		GHXZTYHSJHQHIJ
BRD-K52256627-300-05-8	chlorhexidine	Launched	membrane integrity inhibitor		dermatology|infectious disease|dental	cosmetic|skin infections|gingivitis	0	97.82	InterBioScreen	STOCK1S-18831		504.203	NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1	InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)	9552079.0		GHXZTYHSJHQHIJ
BRD-K01653460-001-01-1	chlorindanol	Preclinical					0	93.98	MicroSource	1503743	CHLORINDANOL	168.034	Oc1ccc(Cl)c2CCCc12	ATAJVFBUUIBIEO-UHFFFAOYSA-N	8961.0		ATAJVFBUUIBIEO
BRD-K01653460-001-02-9	chlorindanol	Preclinical					0	94.71	Sigma	MFCD00021243	7-CHLORO-4-INDANOL	168.034	Oc1ccc(Cl)c2CCCc12	ATAJVFBUUIBIEO-UHFFFAOYSA-N	8961.0		ATAJVFBUUIBIEO
BRD-K61802864-001-09-9	chlorindione	Preclinical					0	94.32	MedChemEx	HY-B0918	Chlorindione	256.029	Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NJDUWAXIURWWLN-UHFFFAOYSA-N	70846.0		NJDUWAXIURWWLN
BRD-K61802864-001-08-8	chlorindione	Preclinical					0	96.83	MicroSource	1504507	CHLORINDIONE	256.029	Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O	NJDUWAXIURWWLN-UHFFFAOYSA-N	70846.0		NJDUWAXIURWWLN
BRD-K18030938-302-03-9	chlorisondamine-diiodide	Preclinical	acetylcholine receptor antagonist	CHRNA1			0	4.63	Tocris	1001	Chlorisondamine diiodide	356.038	C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl	IXWDUZLHWJKVPX-UHFFFAOYSA-N	6244.0		IXWDUZLHWJKVPX
BRD-K18030938-302-02-7	chlorisondamine-diiodide	Preclinical	acetylcholine receptor antagonist	CHRNA1			0	0.0	Tocris	1001	Chlorisondamine diiodide	356.038	C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl	IXWDUZLHWJKVPX-UHFFFAOYSA-N	6244.0		IXWDUZLHWJKVPX
BRD-K38704569-001-18-9	chlormadinone-acetate	Launched	5 alpha reductase inhibitor	PGR	endocrinology	hypermenorrhea|amenorrhea|oligomenorrhea|polymenorrhea	0	93.83	MedChemEx	HY-B1095	Chlormadinone acetate	404.175	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	QMBJSIBWORFWQT-DFXBJWIESA-N	9324.0		QMBJSIBWORFWQT
BRD-A20348246-001-15-8	chlormezanone	Withdrawn	GABA receptor modulator	GABRA1			0	98.9	MicroSource	2300062	CHLORMEZANONE	273.023	CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|	WEQAYVWKMWHEJO-LLVKDONJSA-N	6604211.0		WEQAYVWKMWHEJO
BRD-A20348246-001-16-9	chlormezanone	Withdrawn	GABA receptor modulator	GABRA1			0	90.62	Tocris	456	Chlormezanone	273.023	CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|	WEQAYVWKMWHEJO-LLVKDONJSA-N	6604211.0		WEQAYVWKMWHEJO
BRD-A20348246-001-14-1	chlormezanone	Withdrawn	GABA receptor modulator	GABRA1			0	98.29	Tocris	456	Chlormezanone	273.023	CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|	WEQAYVWKMWHEJO-LLVKDONJSA-N	6604211.0		WEQAYVWKMWHEJO
BRD-A20348246-001-13-3	chlormezanone	Withdrawn	GABA receptor modulator	GABRA1			0	97.48	Selleck	S2021	Chlormezanone	273.023	CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2,r|	WEQAYVWKMWHEJO-LLVKDONJSA-N	6604211.0		WEQAYVWKMWHEJO
BRD-K60443845-001-08-6	chlormidazole	Launched	fungal lanosterol demethylase inhibitor		infectious disease	fungal infection	0	94.26	MicroSource	1503733	CHLORMIDAZOLE	256.077	Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	WNAQOLSMVPFGTE-UHFFFAOYSA-N	71821.0		WNAQOLSMVPFGTE
BRD-K60443845-001-09-9	chlormidazole	Launched	fungal lanosterol demethylase inhibitor		infectious disease	fungal infection	0	91.81	Vitas-M	STK697993	1-(4-chlorobenzyl)-2-methyl-1H-benzimidazole	256.077	Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	WNAQOLSMVPFGTE-UHFFFAOYSA-N	71821.0		WNAQOLSMVPFGTE
BRD-K39495750-001-01-2	chlorobutanol	Launched			neurology/psychiatry	anesthetic|sedative	1	0.0	MicroSource	1502551	CHLOROBUTANOL	175.956	CC(C)(O)C(Cl)(Cl)Cl	OSASVXMJTNOKOY-UHFFFAOYSA-N	5977.0		OSASVXMJTNOKOY
BRD-K39495750-001-02-0	chlorobutanol	Launched			neurology/psychiatry	anesthetic|sedative	1	0.0	Enamine	Z1259084902	1,1,1-trichloro-2-methyl-2-propanol	175.956	CC(C)(O)C(Cl)(Cl)Cl	OSASVXMJTNOKOY-UHFFFAOYSA-N	5977.0		OSASVXMJTNOKOY
BRD-K89056082-001-07-7	chlorocresol	Launched	ryanodine receptor activator		infectious disease	first-aid antiseptic	0	94.58	MicroSource	1500178	CHLOROCRESOL	142.019	Cc1cc(O)ccc1Cl	CFKMVGJGLGKFKI-UHFFFAOYSA-N	1732.0		CFKMVGJGLGKFKI
BRD-K89056082-001-06-9	chlorocresol	Launched	ryanodine receptor activator		infectious disease	first-aid antiseptic	0	89.72	Selleck	S4209	Chlorocresol	142.019	Cc1cc(O)ccc1Cl	CFKMVGJGLGKFKI-UHFFFAOYSA-N	1732.0		CFKMVGJGLGKFKI
BRD-K89056082-001-08-5	chlorocresol	Launched	ryanodine receptor activator		infectious disease	first-aid antiseptic	0	85.44	Selleck	S4209	Chlorocresol	142.019	Cc1cc(O)ccc1Cl	CFKMVGJGLGKFKI-UHFFFAOYSA-N	1732.0		CFKMVGJGLGKFKI
BRD-K47114202-001-16-9	chlorogenic-acid	Launched	antioxidant	SLC37A4	neurology/psychiatry|pulmonary|allergy	headache|chest congestion|allergic rhinitis	0	94.38	MedChemEx	HY-N0055	Chlorogenic acid	354.095	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	CWVRJTMFETXNAD-JUHZACGLSA-N	1794427.0		CWVRJTMFETXNAD
BRD-K47114202-001-14-6	chlorogenic-acid	Launched	antioxidant	SLC37A4	neurology/psychiatry|pulmonary|allergy	headache|chest congestion|allergic rhinitis	0	95.33	Selleck	S2280	Chlorogenic acid	354.095	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	CWVRJTMFETXNAD-JUHZACGLSA-N	1794427.0		CWVRJTMFETXNAD
BRD-K47114202-001-15-3	chlorogenic-acid	Launched	antioxidant	SLC37A4	neurology/psychiatry|pulmonary|allergy	headache|chest congestion|allergic rhinitis	0	41.31	Selleck	S2280	Chlorogenic Acid	354.095	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	CWVRJTMFETXNAD-JUHZACGLSA-N	1794427.0	BRD-K46579573-001-01-9	CWVRJTMFETXNAD
BRD-K23728266-001-01-1	chlorophyllin	Preclinical			urology	urinary incontinence	0	5.35	Adooq	A14018	(7S,8S)-8-(2-carboxyethyl)-10-(carboxymethyl)-17-ethyl-3,7,13,18-tetramethyl-2-vinyl-7H,8H-porphyrin-12-carboxylic acid	596.263	CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4[nH]c(cc1n2)c(C)c4C(O)=O)c(C)c3C=C	HZDQUOWQHHSPIE-HASICPNOSA-N			HZDQUOWQHHSPIE
BRD-A92960111-314-01-2	chlorophyllin-copper	Phase 1	cytochrome P450 inhibitor				0	20.18	MedChemEx	HY-B0911		657.177	CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|	ZDOYGJNADZJRFB-PVMVIUQGSA-L		BRD-U98640356-000-01-9	ZDOYGJNADZJRFB
BRD-A92960111-314-02-0	chlorophyllin-copper	Phase 1	cytochrome P450 inhibitor				0	3.11	Sigma	C6003-5G		657.177	CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18,&2:24,r,c:2,14,16,42,t:5,31,39|	ZDOYGJNADZJRFB-PVMVIUQGSA-L			ZDOYGJNADZJRFB
BRD-K86864073-001-01-1	chloroprocaine	Launched	sodium channel blocker	ATP1A1|CHRNA10|GRIN3A|HTR3A|SCN10A|SLC6A3	neurology/psychiatry	local anesthetic	0	88.33	Enamine	Z1724408123	2-(diethylamino)ethyl 4-amino-2-chlorobenzoate	270.114	CCN(CC)CCOC(=O)c1ccc(N)cc1Cl	VDANGULDQQJODZ-UHFFFAOYSA-N	8612.0		VDANGULDQQJODZ
BRD-K83257731-003-25-9	chloropyramine	Launched	histamine receptor antagonist	HRH1	cardiology|ophthalmology|allergy|pulmonary	edema|conjunctivitis|allergic rhinitis|asthma	0	97.32	MedChemEx	HY-B1305	Chloropyramine hydrochloride	289.135	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	ICKFFNBDFNZJSX-UHFFFAOYSA-N	25295.0		ICKFFNBDFNZJSX
BRD-K83257731-003-23-5	chloropyramine	Launched	histamine receptor antagonist	HRH1	cardiology|ophthalmology|allergy|pulmonary	edema|conjunctivitis|allergic rhinitis|asthma	0	95.27	MicroSource	1506064	CHLOROPYRAMINE HYDROCHLORIDE	289.135	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	ICKFFNBDFNZJSX-UHFFFAOYSA-N	25295.0		ICKFFNBDFNZJSX
BRD-A91699651-316-10-9	chloroquine	Launched	antimalarial agent	MRGPRX1	infectious disease	malaria|amebiasis	0	86.48	MicroSource	1500179	CHLOROQUINE DIPHOSPHATE	319.182	CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|	WHTVZRBIWZFKQO-CQSZACIVSA-N	444810.0		WHTVZRBIWZFKQO
BRD-A91699651-316-09-1	chloroquine	Launched	antimalarial agent	MRGPRX1	infectious disease	malaria|amebiasis	0	94.51	Selleck	S4157	Chloroquine Phosphate	319.182	CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|	WHTVZRBIWZFKQO-CQSZACIVSA-N	444810.0		WHTVZRBIWZFKQO
BRD-A91699651-316-11-7	chloroquine	Launched	antimalarial agent	MRGPRX1	infectious disease	malaria|amebiasis	0	96.54	Selleck	S4157	Chloroquine Phosphate	319.182	CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|	WHTVZRBIWZFKQO-CQSZACIVSA-N	444810.0		WHTVZRBIWZFKQO
BRD-K88682005-001-16-6	chlorothiazide	Launched	diuretic	CA1|CA2|CA4|SLC12A3	cardiology	hypertension	0	89.99	MicroSource	1500180	CHLOROTHIAZIDE	294.949	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|	JBMKAUGHUNFTOL-UHFFFAOYSA-N	2720.0		JBMKAUGHUNFTOL
BRD-K88682005-001-17-9	chlorothiazide	Launched	diuretic	CA1|CA2|CA4|SLC12A3	cardiology	hypertension	0	97.48	MedChemEx	HY-B0224	Chlorothiazide	294.949	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|	JBMKAUGHUNFTOL-UHFFFAOYSA-N	2720.0		JBMKAUGHUNFTOL
BRD-K88682005-001-15-8	chlorothiazide	Launched	diuretic	CA1|CA2|CA4|SLC12A3	cardiology	hypertension	0	95.43	Selleck	S1641	Chlorothiazide	294.949	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|	JBMKAUGHUNFTOL-UHFFFAOYSA-N	2720.0		JBMKAUGHUNFTOL
BRD-K04358951-001-02-9	chlorothymol	Launched					0	18.51	Sigma	MFCD00002326	4-Chloro-2-isopropyl-5-methylphenol	184.065	CC(C)c1cc(Cl)c(C)cc1O	KFZXVMNBUMVKLN-UHFFFAOYSA-N	6982.0		KFZXVMNBUMVKLN
BRD-K04358951-001-01-0	chlorothymol	Launched					0	0.0	Enamine	Z104485030		184.065	CC(C)c1cc(Cl)c(C)cc1O	KFZXVMNBUMVKLN-UHFFFAOYSA-N	6982.0		KFZXVMNBUMVKLN
BRD-K27062708-001-24-9	chlorotrianisene	Launched	estrogenic hormone	ESR1|ESR2	endocrinology|oncology	menopause|prostate cancer	0	95.93	Sigma	MFCD00048044	Chlorotrianisene	380.118	COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1	BFPSDSIWYFKGBC-UHFFFAOYSA-N	11289.0		BFPSDSIWYFKGBC
BRD-K27062708-001-23-1	chlorotrianisene	Launched	estrogenic hormone	ESR1|ESR2	endocrinology|oncology	menopause|prostate cancer	0	98.18	Prestwick	Prestw-757	Chlorotrianisene	380.118	COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1	BFPSDSIWYFKGBC-UHFFFAOYSA-N	11289.0		BFPSDSIWYFKGBC
BRD-K17075857-001-17-6	chloroxine	Launched	opioid receptor antagonist	OPRK1	gastroenterology|infectious disease|dermatology	diarrhea|inflammatory bowel disease|giardiasis|dandruff	0	96.2	MicroSource	1503202	CHLOROXINE	212.975	Oc1c(Cl)cc(Cl)c2cccnc12	WDFKMLRRRCGAKS-UHFFFAOYSA-N	2722.0		WDFKMLRRRCGAKS
BRD-K17075857-001-18-4	chloroxine	Launched	opioid receptor antagonist	OPRK1	gastroenterology|infectious disease|dermatology	diarrhea|inflammatory bowel disease|giardiasis|dandruff	0	99.48	Selleck	S1839	Chloroxine	212.975	Oc1c(Cl)cc(Cl)c2cccnc12	WDFKMLRRRCGAKS-UHFFFAOYSA-N	2722.0		WDFKMLRRRCGAKS
BRD-K17075857-001-16-8	chloroxine	Launched	opioid receptor antagonist	OPRK1	gastroenterology|infectious disease|dermatology	diarrhea|inflammatory bowel disease|giardiasis|dandruff	0	86.74	Selleck	S1839	Chloroxine	212.975	Oc1c(Cl)cc(Cl)c2cccnc12	WDFKMLRRRCGAKS-UHFFFAOYSA-N	2722.0		WDFKMLRRRCGAKS
BRD-K83335125-001-07-0	chloroxoquinoline	Launched					0	97.87	Alinda	ALBB-024683	7-chloroquinolin-4(1H)-one	179.014	Clc1ccc2c(c1)[nH]ccc2=O	XMFXTXKSWIDMER-UHFFFAOYSA-N	66593.0		XMFXTXKSWIDMER
BRD-K17223896-001-11-9	chloroxylenol	Launched	ATP synthase inhibitor		infectious disease	skin infections	0	92.78	MedChemEx	HY-B1414	Chloroxylenol	156.034	Cc1cc(O)cc(C)c1Cl	OSDLLIBGSJNGJE-UHFFFAOYSA-N	2723.0		OSDLLIBGSJNGJE
BRD-K17223896-001-10-0	chloroxylenol	Launched	ATP synthase inhibitor		infectious disease	skin infections	0	95.32	MicroSource	1500182	CHLOROXYLENOL	156.034	Cc1cc(O)cc(C)c1Cl	OSDLLIBGSJNGJE-UHFFFAOYSA-N	2723.0		OSDLLIBGSJNGJE
BRD-K01826567-050-16-9	chlorphenamine	Launched	histamine receptor antagonist		allergy	allergic rhinitis|urticaria	0	95.63	MedChemEx	HY-B0286A	Chlorpheniramine (maleate)	274.124	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:5|	SOYKEARSMXGVTM-HNNXBMFYSA-N	33036.0		SOYKEARSMXGVTM
BRD-A92262698-001-02-5	chlorphenesin	Launched	muscle relaxant		neurology/psychiatry	muscle relaxant|sedative	0	98.16	Sigma	MFCD00021990	3-(4-chlorophenoxy)-1,2-propanediol	202.04	OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|	MXOAEAUPQDYUQM-MRVPVSSYSA-N	6918886.0		MXOAEAUPQDYUQM
BRD-A92262698-001-01-7	chlorphenesin	Launched	muscle relaxant		neurology/psychiatry	muscle relaxant|sedative	0	0.0	Enamine	Z995094004		202.04	OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2,r|	MXOAEAUPQDYUQM-MRVPVSSYSA-N	6918886.0		MXOAEAUPQDYUQM
BRD-K00003537-001-01-9	chlorphenoxamine	Preclinical	histamine receptor antagonist				0	90.0	MedChemEx	HY-B1607	Chlorphenoxamine	303.139	CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1 |r|	KKHPNPMTPORSQE-SFHVURJKSA-N	38988830.0		KKHPNPMTPORSQE
BRD-A39230911-001-10-2	chlorphensin-carbamate	Launched	muscle relaxant		neurology/psychiatry	spasms	0	98.03	Prestwick	Prestw-234	Chlorphensin carbamate	245.045	NC(=O)OC[C@@H](O)COc1ccc(Cl)cc1 |&1:5,r|	SKPLBLUECSEIFO-QMMMGPOBSA-N	73416025.0		SKPLBLUECSEIFO
BRD-K25494650-003-01-8	chlorproguanil	Launched	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	0	97.98	AMS	A000012202		287.07	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1	ISZNZKHCRKXXAU-UHFFFAOYSA-N	9571037.0		ISZNZKHCRKXXAU
BRD-K89997465-001-10-3	chlorpromazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALM1|CHRM1|CHRM3|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR2A|HTR2B|HTR2C|HTR6|HTR7|KCNH2|ORM1|ORM2|SMPD1|TRPC5	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus	0	70.64	MicroSource	1500184	CHLORPROMAZINE	318.096	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	2726.0		ZPEIMTDSQAKGNT
BRD-K89997465-003-43-0	chlorpromazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALM1|CHRM1|CHRM3|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR2A|HTR2B|HTR2C|HTR6|HTR7|KCNH2|ORM1|ORM2|SMPD1|TRPC5	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus	0	85.88	Selleck	S2456	Chlorpromazine HCl	318.096	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	2726.0		ZPEIMTDSQAKGNT
BRD-K89997465-003-44-8	chlorpromazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALM1|CHRM1|CHRM3|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR2A|HTR2B|HTR2C|HTR6|HTR7|KCNH2|ORM1|ORM2|SMPD1|TRPC5	neurology/psychiatry|gastroenterology|hematology|infectious disease	schizophrenia|nausea|vomiting|acute intermittent porphyria (AIP)|tetanus	0	97.33	Selleck	S2456	Chlorpromazine (Sonazine)	318.096	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	ZPEIMTDSQAKGNT-UHFFFAOYSA-N	2726.0		ZPEIMTDSQAKGNT
BRD-K97746869-001-29-9	chlorpropamide	Launched	ATP channel blocker	ABCC8|KCNJ10	endocrinology	diabetes mellitus	0	88.71	MedChemEx	HY-B1429	Chlorpropamide	276.034	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	RKWGIWYCVPQPMF-UHFFFAOYSA-N	2727.0		RKWGIWYCVPQPMF
BRD-K97746869-001-27-0	chlorpropamide	Launched	ATP channel blocker	ABCC8|KCNJ10	endocrinology	diabetes mellitus	0	98.37	MicroSource	1500185	CHLORPROPAMIDE	276.034	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	RKWGIWYCVPQPMF-UHFFFAOYSA-N	2727.0		RKWGIWYCVPQPMF
BRD-K97746869-001-26-2	chlorpropamide	Launched	ATP channel blocker	ABCC8|KCNJ10	endocrinology	diabetes mellitus	0	95.55	Selleck	S4166	Chlorpropamide	276.034	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	RKWGIWYCVPQPMF-UHFFFAOYSA-N	2727.0		RKWGIWYCVPQPMF
BRD-K59590127-001-04-5	chlorpropham	Phase 1	antiviral				0	99.36	Sigma	MFCD00037108	isopropyl 3-chlorophenylcarbamate	213.056	CC(C)OC(=O)Nc1cccc(Cl)c1	CWJSHJJYOPWUGX-UHFFFAOYSA-N	2728.0		CWJSHJJYOPWUGX
BRD-K36207157-001-10-9	chlorprothixene	Launched	dopamine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C	neurology/psychiatry	schizophrenia|bipolar disorder	0	96.73	MedChemEx	HY-B0274	Chlorprothixene	315.085	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	667467.0		WSPOMRSOLSGNFJ
BRD-K36207157-001-09-6	chlorprothixene	Launched	dopamine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C	neurology/psychiatry	schizophrenia|bipolar disorder	0	94.14	MicroSource	1503203	CHLORPROTHIXENE HYDROCHLORIDE	315.085	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	667467.0	BRD-K59058766-003-21-9	WSPOMRSOLSGNFJ
BRD-K36207157-001-07-0	chlorprothixene	Launched	dopamine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C	neurology/psychiatry	schizophrenia|bipolar disorder	0	97.83	Selleck	S1771	Chlorprothixene	315.085	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	667467.0		WSPOMRSOLSGNFJ
BRD-K36207157-001-08-8	chlorprothixene	Launched	dopamine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C	neurology/psychiatry	schizophrenia|bipolar disorder	0	46.95	Selleck	S1771	Chlorprothixene	315.085	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	WSPOMRSOLSGNFJ-AUWJEWJLSA-N	667467.0	BRD-K59058766-001-01-5	WSPOMRSOLSGNFJ
BRD-K08303368-001-10-0	chlorpyrifos	Launched	acetylcholinesterase inhibitor	ACHE			0	79.39	MicroSource	330058	CHLORPYRIFOS	348.926	CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	SBPBAQFWLVIOKP-UHFFFAOYSA-N	2730.0		SBPBAQFWLVIOKP
BRD-K08303368-001-11-9	chlorpyrifos	Launched	acetylcholinesterase inhibitor	ACHE			0	89.93	Astatech	H10426	O,O-DIETHYL O-3,5,6-TRICHLORO-2-PYRIDYL PHOSPHOROTHIOATE	348.926	CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	SBPBAQFWLVIOKP-UHFFFAOYSA-N	2730.0		SBPBAQFWLVIOKP
BRD-K90374350-001-11-9	chlorquinaldol	Launched	other antibiotic		infectious disease	fungal infection	0	96.81	MedChemEx	HY-B1360	Chlorquinaldol	226.99	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	GPTXWRGISTZRIO-UHFFFAOYSA-N	6301.0		GPTXWRGISTZRIO
BRD-K90374350-001-10-0	chlorquinaldol	Launched	other antibiotic		infectious disease	fungal infection	0	38.18	MicroSource	212151	CHLORQUINALDOL	226.99	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	GPTXWRGISTZRIO-UHFFFAOYSA-N	6301.0		GPTXWRGISTZRIO
BRD-K90374350-001-09-2	chlorquinaldol	Launched	other antibiotic		infectious disease	fungal infection	0	96.93	Selleck	S4192	Chlorquinaldol	226.99	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	GPTXWRGISTZRIO-UHFFFAOYSA-N	6301.0		GPTXWRGISTZRIO
BRD-K00003353-003-01-9	chlortetracycline	Launched	protein synthesis inhibitor		ophthalmology	conjunctivitis	0	43.45	MedChemEx	HY-B1327	Chlortetracycline (hydrochloride)	478.114	[H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25,&2:5|	RNPLSXLZRGPQCU-YPOKJENWSA-N			RNPLSXLZRGPQCU
BRD-A26384407-001-25-1	chlorthalidone	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA14|CA2|CA4|CA7|SLC12A1	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure	0	98.01	MicroSource	1500187	CHLORTHALIDONE	338.013	NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|	JIVPVXMEBJLZRO-AWEZNQCLSA-N	688424.0		JIVPVXMEBJLZRO
BRD-A26384407-001-26-9	chlorthalidone	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA14|CA2|CA4|CA7|SLC12A1	cardiology|gastroenterology|rheumatology|nephrology	hypertension|edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure	0	97.93	MedChemEx	HY-15833	Chlorthalidone	338.013	NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11,r|	JIVPVXMEBJLZRO-AWEZNQCLSA-N	688424.0		JIVPVXMEBJLZRO
BRD-K98174813-001-26-9	chlorzoxazone	Launched	bacterial 30S ribosomal subunit inhibitor	KCNMA1|KCNN4	neurology/psychiatry	muscle relaxant	0	97.68	MedChemEx	HY-B1462	Chlorzoxazone	168.993	Clc1ccc2oc(=O)[nH]c2c1	TZFWDZFKRBELIQ-UHFFFAOYSA-N	2733.0		TZFWDZFKRBELIQ
BRD-K98174813-001-18-0	chlorzoxazone	Launched	bacterial 30S ribosomal subunit inhibitor	KCNMA1|KCNN4	neurology/psychiatry	muscle relaxant	0	100.0	MicroSource	1500188	CHLORZOXAZONE	168.993	Clc1ccc2oc(=O)[nH]c2c1	TZFWDZFKRBELIQ-UHFFFAOYSA-N	2733.0		TZFWDZFKRBELIQ
BRD-K98174813-001-17-2	chlorzoxazone	Launched	bacterial 30S ribosomal subunit inhibitor	KCNMA1|KCNN4	neurology/psychiatry	muscle relaxant	0	98.53	Selleck	S4155	Chlorzoxazone	168.993	Clc1ccc2oc(=O)[nH]c2c1	TZFWDZFKRBELIQ-UHFFFAOYSA-N	2733.0		TZFWDZFKRBELIQ
BRD-K62779383-001-08-9	cholecalciferol	Launched		VDR	endocrinology	vitamin D deficiency	0	0.0	MicroSource	1500838	CHOLECALCIFEROL	384.339	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	QYSXJUFSXHHAJI-YRZJJWOYSA-N	5280795.0	BRD-A56749456-001-04-3	QYSXJUFSXHHAJI
BRD-K62779383-001-07-1	cholecalciferol	Launched		VDR	endocrinology	vitamin D deficiency	0	0.0	Selleck	S4063	Vitamin D3	384.339	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	QYSXJUFSXHHAJI-YRZJJWOYSA-N	5280795.0	BRD-K32793810-001-01-5	QYSXJUFSXHHAJI
BRD-K62779383-001-05-5	cholecalciferol	Launched		VDR	endocrinology	vitamin D deficiency	0	92.35	Selleck	S4063	Vitamin D3 (Cholecalciferol)	384.339	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	QYSXJUFSXHHAJI-YRZJJWOYSA-N	5280795.0		QYSXJUFSXHHAJI
BRD-K19338361-001-03-9	cholesterol	Preclinical		RORA			0	0.0	MedChemEx	HY-N0322	Cholesterol	386.355	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	HVYWMOMLDIMFJA-DPAQBDIFSA-N	5997.0		HVYWMOMLDIMFJA
BRD-K43164539-001-12-9	cholic-acid	Launched	bile acid	ADH1C|CES1|COX4I1|COX5A|COX5B|COX6A2|COX6B1|COX6C|COX7A1|COX7B|COX7C|COX8A|ESRRG|FABP6|FECH|GPBAR1|MT-CO1|MT-CO2|MT-CO3|PLA2G1B	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome	0	100.0	MedChemEx	HY-N0324	Cholic acid	408.288	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	BHQCQFFYRZLCQQ-OELDTZBJSA-N	221493.0		BHQCQFFYRZLCQQ
BRD-K43164539-001-11-5	cholic-acid	Launched	bile acid	ADH1C|CES1|COX4I1|COX5A|COX5B|COX6A2|COX6B1|COX6C|COX7A1|COX7B|COX7C|COX8A|ESRRG|FABP6|FECH|GPBAR1|MT-CO1|MT-CO2|MT-CO3|PLA2G1B	gastroenterology|neurology/psychiatry|genetics	bile acid synthesis disorders|peroxisomal disorders|Zellweger syndrome	0	100.0	Enzo	BL051	Cholic acid	408.288	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	BHQCQFFYRZLCQQ-OELDTZBJSA-N	221493.0		BHQCQFFYRZLCQQ
BRD-K77300776-001-01-7	choline	Phase 3	acetylcholine precursor	ACHE|BCHE|CHRNA2|PCYT1A|PCYT1B|PHOSPHO1|PLD1|PLD2			0	99.82	MicroSource	1503428	CHOLINE CHLORIDE	104.108	C[N+](C)(C)CCO	OEYIOHPDSNJKLS-UHFFFAOYSA-N	305.0	BRD-M07056525-001-05-3	OEYIOHPDSNJKLS
BRD-K77300776-001-02-5	choline	Phase 3	acetylcholine precursor	ACHE|BCHE|CHRNA2|PCYT1A|PCYT1B|PHOSPHO1|PLD1|PLD2			0	100.0	Selleck	S4171	Choline Chloride	104.108	C[N+](C)(C)CCO	OEYIOHPDSNJKLS-UHFFFAOYSA-N	305.0	BRD-M07056525-001-04-6	OEYIOHPDSNJKLS
BRD-K77300776-003-03-9	choline	Phase 3	acetylcholine precursor	ACHE|BCHE|CHRNA2|PCYT1A|PCYT1B|PHOSPHO1|PLD1|PLD2			0	100.0	MedChemEx	HY-B1337	Choline (chloride)	104.108	C[N+](C)(C)CCO	OEYIOHPDSNJKLS-UHFFFAOYSA-N	305.0		OEYIOHPDSNJKLS
BRD-K00003587-001-01-9	choline-alfoscerate	Launched	acetylcholine precursor				0	100.0	MedChemEx	HY-17552	sn-Glycero-3-phosphocholine	258.111	C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO	SUHOQUVVVLNYQR-MRVPVSSYSA-O	58381695.0		SUHOQUVVVLNYQR
BRD-A19381518-001-04-9	CHPG	Preclinical	glutamate receptor agonist	GRM5			0	0.0	Tocris	1049	CHPG	201.019	N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|	UNIDAFCQFPGYJJ-SSDOTTSWSA-N	6604802.0		UNIDAFCQFPGYJJ
BRD-A19381518-001-02-1	CHPG	Preclinical	glutamate receptor agonist	GRM5			0	0.0	Tocris	1049	CHPG	201.019	N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1,r|	UNIDAFCQFPGYJJ-SSDOTTSWSA-N	6604802.0		UNIDAFCQFPGYJJ
BRD-K76259716-019-01-1	CHR-6494	Preclinical	serine/threonine kinase inhibitor	GSG2			0	99.14	Tocris	5326	CHR 6494 trifluoroacetate	292.144	CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1	CZZCAOGIEGXMBZ-UHFFFAOYSA-N	70679308.0		CZZCAOGIEGXMBZ
BRD-K76259716-001-01-9	CHR-6494	Preclinical	serine/threonine kinase inhibitor	GSG2			0	94.59	MedChemEx	HY-15217	CHR-6494	292.144	CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1	CZZCAOGIEGXMBZ-UHFFFAOYSA-N	70679308.0		CZZCAOGIEGXMBZ
BRD-M02075109-001-01-1	chromanol-(+/-)	Preclinical	potassium channel blocker				0	98.74	Tocris	1412	Chromanol 293B	324.114	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	VCIPBXUEKWCJAU-DZYJZKBLSA-N	90479790.0		VCIPBXUEKWCJAU
BRD-K27911943-001-02-8	chromanol-293B-(-)-[3R,4S]	Preclinical	potassium channel blocker				0	99.19	Tocris	1475	(-)-[3R,4S]-Chromanol 293B	324.114	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N	HVSJHHXUORMCGK-UONOGXRCSA-N	121846.0		HVSJHHXUORMCGK
BRD-K27911943-001-03-9	chromanol-293B-(-)-[3R,4S]	Preclinical	potassium channel blocker				0	96.03	Tocris	1475	(-)-[3R,4S]-Chromanol 293B	324.114	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N	HVSJHHXUORMCGK-UONOGXRCSA-N	121846.0		HVSJHHXUORMCGK
BRD-K01029106-001-02-9	chromium-picolinate	Launched	insulin sensitizer		endocrinology	diabetes mellitus	0	94.22	Sigma	MFCD00068715	CHROMIUM PICOLINATE	418.013	O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1	CBDQOLKNTOMMTL-UHFFFAOYSA-K	56840998.0		CBDQOLKNTOMMTL
BRD-K01029106-001-01-4	chromium-picolinate	Launched	insulin sensitizer		endocrinology	diabetes mellitus	0	99.23	Vitas-M	STL146656		418.013	O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1	CBDQOLKNTOMMTL-UHFFFAOYSA-K	56840998.0	BRD-M54429190-001-01-7	CBDQOLKNTOMMTL
BRD-K94720315-001-11-9	chromocarb	Launched	antispasmodic				0	97.98	MedChemEx	HY-B1182	Chromocarb	190.027	OC(=O)c1cc(=O)c2ccccc2o1	RVMGXWBCQGAWBR-UHFFFAOYSA-N	2741.0		RVMGXWBCQGAWBR
BRD-K94720315-001-10-4	chromocarb	Launched	antispasmodic				0	97.77	MicroSource	1503044	CHROMOCARB	190.027	OC(=O)c1cc(=O)c2ccccc2o1	RVMGXWBCQGAWBR-UHFFFAOYSA-N	2741.0		RVMGXWBCQGAWBR
BRD-K94720315-001-09-6	chromocarb	Launched	antispasmodic				0	95.8	Selleck	S4208	Chromocarb	190.027	OC(=O)c1cc(=O)c2ccccc2o1	RVMGXWBCQGAWBR-UHFFFAOYSA-N	2741.0		RVMGXWBCQGAWBR
BRD-K22861715-001-18-9	chrysin	Phase 1	breast cancer resistance protein inhibitor	AKR1B1|CDK6|CYP19A1|CYP1B1			0	98.78	MedChemEx	HY-14589	Chrysin	254.058	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1	RTIXKCRFFJGDFG-UHFFFAOYSA-N	5281607.0		RTIXKCRFFJGDFG
BRD-K22861715-001-17-4	chrysin	Phase 1	breast cancer resistance protein inhibitor	AKR1B1|CDK6|CYP19A1|CYP1B1			0	96.12	Selleck	S2281	Chrysin	254.058	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1	RTIXKCRFFJGDFG-UHFFFAOYSA-N	5281607.0		RTIXKCRFFJGDFG
BRD-K59284035-001-08-9	chrysophanic-acid	Preclinical	EGFR inhibitor	EGFR|MTOR			0	93.74	MedChemEx	HY-13595	Chrysophanol	254.058	Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	LQGUBLBATBMXHT-UHFFFAOYSA-N	10208.0		LQGUBLBATBMXHT
BRD-K59284035-001-07-9	chrysophanic-acid	Preclinical	EGFR inhibitor	EGFR|MTOR			0	96.2	Selleck	S2406	Chrysophanic Acid	254.058	Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	LQGUBLBATBMXHT-UHFFFAOYSA-N	10208.0		LQGUBLBATBMXHT
BRD-K25691735-001-12-9	chuanxiongzine	Phase 2					0	53.91	MedChemEx	HY-N0264	Tetramethylpyrazine	136.1	Cc1nc(C)c(C)nc1C	FINHMKGKINIASC-UHFFFAOYSA-N	14296.0		FINHMKGKINIASC
BRD-K25691735-001-09-5	chuanxiongzine	Phase 2					0	97.8	Enzo	RD123	Tetramethylpyrazine	136.1	Cc1nc(C)c(C)nc1C	FINHMKGKINIASC-UHFFFAOYSA-N	14296.0		FINHMKGKINIASC
BRD-K22314899-001-02-4	CH223191	Preclinical	aryl hydrocarbon receptor antagonist	AHR			0	97.94	Tocris	3858	CH 223191	333.159	Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1	LKTNEXPODAWWFM-GHVJWSGMSA-N			LKTNEXPODAWWFM
BRD-K28352084-001-02-3	CH5132799	Phase 1	PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	89.03	Selleck	S2699	CH5132799	377.127	CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	JEGHXKRHKHPBJD-UHFFFAOYSA-N	49784945.0		JEGHXKRHKHPBJD
BRD-K28352084-001-03-1	CH5132799	Phase 1	PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	93.07	Selleck	S2699	CH5132799	377.127	CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	JEGHXKRHKHPBJD-UHFFFAOYSA-N	49784945.0		JEGHXKRHKHPBJD
BRD-K28352084-001-04-9	CH5132799	Phase 1	PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	94.91	MedChemEx	HY-15466	CH5132799	377.127	CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	JEGHXKRHKHPBJD-UHFFFAOYSA-N	49784945.0		JEGHXKRHKHPBJD
BRD-K71487808-001-03-6	CH55	Preclinical	retinoid receptor binder	RARA|RARB			0	92.13	Tocris	2020	Ch 55	364.204	CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O	FOUVTBKPJRMLPE-FMIVXFBMSA-N	6184667.0		FOUVTBKPJRMLPE
BRD-K71487808-001-02-8	CH55	Preclinical	retinoid receptor binder	RARA|RARB			0	63.97	Tocris	2020	Ch 55	364.204	CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O	FOUVTBKPJRMLPE-FMIVXFBMSA-N	6184667.0		FOUVTBKPJRMLPE
BRD-K83022601-001-01-0	CI-844	Phase 2					0	98.44	ChemImpex	26115		171.068	O(c1ccccc1)c1cccnc1	KDGUIKPOZGYLQJ-UHFFFAOYSA-N	200510.0		KDGUIKPOZGYLQJ
BRD-A50016482-001-01-7	CI-923	Phase 1	acetylcholine receptor antagonist				0	86.83	Sigma	PH001437	3-[2-(ethylamino)propyl]-1,2,3,4-tetrahydro-5H-chromeno[3,4-c]pyridin-5-one	286.168	CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3,r|	MJRICTKAEYTJAV-LBPRGKRZSA-N	76971447.0		MJRICTKAEYTJAV
BRD-K00004748-001-01-9	CI-953	Phase 1	voltage-gated sodium channel blocker				0	96.48	MedChemEx	HY-101708	1-(2-chloro-6-methylphenyl)-3-(pyridin-4-yl)urea	261.067	Cc1cccc(Cl)c1NC(=O)Nc1ccncc1	ZSBWDKCIIZYQIR-UHFFFAOYSA-N	130178.0		ZSBWDKCIIZYQIR
BRD-K67680372-003-03-4	CI-966	Phase 1	GAT inhibitor	SLC6A1			0	93.37	Tocris	1296	CI 966 hydrochloride	473.143	OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|	CMHQDSBIBSKHFP-UHFFFAOYSA-N	198693.0		CMHQDSBIBSKHFP
BRD-K67680372-003-04-9	CI-966	Phase 1	GAT inhibitor	SLC6A1			0	95.39	Tocris	1296	CI 966 hydrochloride	473.143	OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|	CMHQDSBIBSKHFP-UHFFFAOYSA-N	198693.0		CMHQDSBIBSKHFP
BRD-K67680372-003-02-6	CI-966	Phase 1	GAT inhibitor	SLC6A1			0	98.04	Tocris	1296	CI 966 hydrochloride	473.143	OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|	CMHQDSBIBSKHFP-UHFFFAOYSA-N	198693.0		CMHQDSBIBSKHFP
BRD-K88544581-001-08-7	CI-976	Phase 1	ACAT inhibitor	ACAT1|CES1			0	97.17	Tocris	2227	CI 976	393.288	CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	WAFNZAURAWBNDZ-UHFFFAOYSA-N	122327.0		WAFNZAURAWBNDZ
BRD-K88544581-001-06-1	CI-976	Phase 1	ACAT inhibitor	ACAT1|CES1			0	98.32	Tocris	2227	CI 976	393.288	CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	WAFNZAURAWBNDZ-UHFFFAOYSA-N	122327.0		WAFNZAURAWBNDZ
BRD-K88544581-001-09-9	CI-976	Phase 1	ACAT inhibitor	ACAT1|CES1			0	97.3	Tocris	2227	CI 976	393.288	CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	WAFNZAURAWBNDZ-UHFFFAOYSA-N	122327.0		WAFNZAURAWBNDZ
BRD-K01423020-001-01-2	ciaftalan-zinc	Phase 1	reactive oxygen species stimulant				0	22.93	Sigma	MFCD00041955	zinc(II) phthalocyanine-29,31-diide	576.079	[Zn]1n2c3\N=C4/N=C(/N=c5\n1\c(=N/C1=N/C(=N\c2c2ccccc32)/c2ccccc12)c1ccccc51)c1ccccc41 |c:3,7,11,15,t:5,13|	PODBBOVVOGJETB-UHFFFAOYSA-N	518924.0		PODBBOVVOGJETB
BRD-K58736316-001-09-5	cianidanol	Withdrawn	fatty acid synthase inhibitor	PTGS1			0	98.72	MicroSource	210205	CIANIDANOL	290.079	O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1	PFTAWBLQPZVEMU-DZGCQCFKSA-N	9064.0		PFTAWBLQPZVEMU
BRD-K58736316-001-10-9	cianidanol	Withdrawn	fatty acid synthase inhibitor	PTGS1			0	99.09	MedChemEx	HY-N0898	Catechin	290.079	O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1	PFTAWBLQPZVEMU-DZGCQCFKSA-N	9064.0		PFTAWBLQPZVEMU
BRD-A20742938-036-03-7	cibenzoline	Launched	sodium channel blocker		cardiology	cardiac arrythmia	0	98.93	Sigma	C1618	2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole succinate	262.147	C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r,t:2|	IPOBOOXFSRWSHL-INIZCTEOSA-N	57357423.0		IPOBOOXFSRWSHL
BRD-K35245662-001-02-9	ciclesonide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	allergy	allergic rhinitis	0	85.1	Tocris	6357	Ciclesonide	540.309	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|	LUKZNWIVRBCLON-GXOBDPJESA-N	6918155.0		LUKZNWIVRBCLON
BRD-K35245662-001-01-2	ciclesonide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	allergy	allergic rhinitis	0	98.53	Enzo	AC3062	CICLESONIDE	540.309	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24,t:20|	LUKZNWIVRBCLON-GXOBDPJESA-N	6918155.0		LUKZNWIVRBCLON
BRD-K13044802-213-21-5	ciclopirox	Launched	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	0	59.94	MicroSource	1500189	CICLOPIROX OLAMINE	207.126	Cc1cc(C2CCCCC2)n(O)c(=O)c1	SCKYRAXSEDYPSA-UHFFFAOYSA-N	2749.0		SCKYRAXSEDYPSA
BRD-K13044802-001-02-4	ciclopirox	Launched	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	0	84.81	Selleck	S2528	Ciclopirox	207.126	Cc1cc(C2CCCCC2)n(O)c(=O)c1	SCKYRAXSEDYPSA-UHFFFAOYSA-N	2749.0		SCKYRAXSEDYPSA
BRD-K13044802-213-25-6	ciclopirox	Launched	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	0	77.25	Sigma	MFCD00078997	6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone compound with 2-aminoethanol (1:1)	207.126	Cc1cc(C2CCCCC2)n(O)c(=O)c1	SCKYRAXSEDYPSA-UHFFFAOYSA-N	2749.0		SCKYRAXSEDYPSA
BRD-K13044802-001-03-2	ciclopirox	Launched	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	0	93.13	Selleck	S2528	Ciclopirox (Penlac)	207.126	Cc1cc(C2CCCCC2)n(O)c(=O)c1	SCKYRAXSEDYPSA-UHFFFAOYSA-N	2749.0		SCKYRAXSEDYPSA
BRD-K13044802-213-24-9	ciclopirox	Launched	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	0	70.21	Selleck	S3019	Ciclopirox ethanolamine	207.126	Cc1cc(C2CCCCC2)n(O)c(=O)c1	SCKYRAXSEDYPSA-UHFFFAOYSA-N	2749.0		SCKYRAXSEDYPSA
BRD-K13044802-213-20-7	ciclopirox	Launched	membrane integrity inhibitor	ATP1A1	infectious disease	onychomycosis	0	84.85	Selleck	S3019	Ciclopirox ethanolamine	207.126	Cc1cc(C2CCCCC2)n(O)c(=O)c1	SCKYRAXSEDYPSA-UHFFFAOYSA-N	2749.0		SCKYRAXSEDYPSA
BRD-A94965935-001-01-6	cicloprofen	Preclinical	cyclooxygenase inhibitor	PTGS1|PTGS2			0	95.97	Enamine	Z2299360563	2-(9H-fluoren-2-yl)propanoic acid	238.099	C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1,r|	LRXFKKPEBXIPMW-SNVBAGLBSA-N	14694110.0		LRXFKKPEBXIPMW
BRD-K00004311-001-01-9	CID-16020046	Preclinical	G protein-coupled receptor antagonist	GPR55			0	98.42	Tocris	4959	CID 16020046	425.138	Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14,r|	VGUQVYZXABOXCX-QHCPKHFHSA-N	51436118.0		VGUQVYZXABOXCX
BRD-K92781136-001-09-9	CID-2011756	Preclinical	protein kinase inhibitor	PKD1			0	96.45	Tocris	4644	CID 2011756	396.124	Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1	XQJWTJLJEYIUDZ-UHFFFAOYSA-N	2011756.0		XQJWTJLJEYIUDZ
BRD-K92781136-001-08-9	CID-2011756	Preclinical	protein kinase inhibitor	PKD1			0	98.57	Tocris	4644	CID 2011756	396.124	Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1	XQJWTJLJEYIUDZ-UHFFFAOYSA-N	2011756.0		XQJWTJLJEYIUDZ
BRD-K06405316-001-03-3	CID-2745687	Preclinical	G protein-coupled receptor antagonist	GPR35			0	90.54	Tocris	4293	CID 2745687	395.123	COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F	CYNLZIBKERMMOA-AWQFTUOYSA-N	9581011.0		CYNLZIBKERMMOA
BRD-K06405316-001-04-9	CID-2745687	Preclinical	G protein-coupled receptor antagonist	GPR35			0	95.19	Tocris	4293	CID 2745687	395.123	COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F	CYNLZIBKERMMOA-AWQFTUOYSA-N	9581011.0		CYNLZIBKERMMOA
BRD-A08840375-001-01-3	CID-5458317	Preclinical	MAP kinase phosphatase inhibitor	MAPK3			0	96.86	EMDBio	317496-10MG	Dual Specificity Protein Phosphatase 1/6 Inhibitor, BCI	317.178	OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1,t:8|	BJJVCNWHNQAAGB-HMMYKYKNSA-N			BJJVCNWHNQAAGB
BRD-K96153583-001-05-1	cidofovir	Launched	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS)|cytomegalovirus retinitis	0	100.0	Selleck	S1516	Cidofovir (Vistide)	279.062	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	VWFCHDSQECPREK-LURJTMIESA-N	60613.0		VWFCHDSQECPREK
BRD-K96153583-001-04-4	cidofovir	Launched	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS)|cytomegalovirus retinitis	0	0.0	Selleck	S1516	Cidofovir (Vistide)	279.062	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	VWFCHDSQECPREK-LURJTMIESA-N	60613.0		VWFCHDSQECPREK
BRD-K96153583-001-06-9	cidofovir	Launched	DNA polymerase inhibitor		infectious disease	acquired immunodeficiency syndrome (AIDS)|cytomegalovirus retinitis	0	0.0	MedChemEx	HY-17438	Cidofovir	279.062	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	VWFCHDSQECPREK-LURJTMIESA-N	60613.0		VWFCHDSQECPREK
BRD-A93000692-001-08-1	ciglitazone	Phase 2	PPAR receptor agonist	PPARG			0	96.7	Tocris	1307	Ciglitazone	333.14	CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|	YZFWTZACSRHJQD-OAHLLOKOSA-N	6604850.0		YZFWTZACSRHJQD
BRD-K85518562-236-08-9	cilastatin	Launched	dehydropeptidase inhibitor	DPEP1			0	0.0	AvaChem	1721	(2Z)-7-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1R)-2,2-dimethylcyclopropyl]carbonyl}amino)-2-heptenoic acid	358.156	CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	DHSUYTOATWAVLW-WFVMDLQDSA-N	6435415.0	BRD-K62370608-001-02-9	DHSUYTOATWAVLW
BRD-K85518562-236-09-7	cilastatin	Launched	dehydropeptidase inhibitor	DPEP1			0	0.0	Tocris	2709	Cilastatin sodium	358.156	CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	DHSUYTOATWAVLW-WFVMDLQDSA-N	6435415.0	BRD-K26556168-236-01-4	DHSUYTOATWAVLW
BRD-K96177243-002-04-9	cilazapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure	0	96.51	MedChemEx	HY-A0043A	Cilazapril (monohydrate)	417.226	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O	HHHKFGXWKKUNCY-FHWLQOOXSA-N	56330.0		HHHKFGXWKKUNCY
BRD-K57252450-001-02-5	cilengitide	Phase 3	integrin antagonist	ITGAV|ITGB3			0	96.22	Selleck	S7077	Cilengitide	588.302	CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	AMLYAMJWYAIXIA-VWNVYAMZSA-N	176873.0		AMLYAMJWYAIXIA
BRD-K00004281-001-01-9	cilnidipine	Launched	calcium channel blocker	CACNA1B	cardiology	hypertension	0	96.47	Tocris	2629	Cilnidipine	492.19	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14,r,c:7,12|	KJEBULYHNRNJTE-HGJFNOKFSA-N	28248392.0		KJEBULYHNRNJTE
BRD-K00004595-001-01-9	cilofexor	Phase 3	FXR agonist				0	94.88	MedChemEx	HY-109083	Cilofexor	585.063	OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl	KZSKGLFYQAYZCO-UHFFFAOYSA-N	71228883.0		KZSKGLFYQAYZCO
BRD-K00003550-001-01-9	cilomilast	Phase 3	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4D			0	89.36	MedChemEx	HY-10790	Cilomilast	343.178	COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|	CFBUZOUXXHZCFB-OYOVHJISSA-N			CFBUZOUXXHZCFB
BRD-K28578425-001-09-6	cilostamide	Preclinical	phosphodiesterase inhibitor	PDE3A|PDE3B			0	91.93	Tocris	915	Cilostamide	342.194	CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1	UIAYVIIHMORPSJ-UHFFFAOYSA-N	2753.0		UIAYVIIHMORPSJ
BRD-K28578425-001-07-0	cilostamide	Preclinical	phosphodiesterase inhibitor	PDE3A|PDE3B			0	95.91	Tocris	915	Cilostamide	342.194	CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1	UIAYVIIHMORPSJ-UHFFFAOYSA-N	2753.0		UIAYVIIHMORPSJ
BRD-K67017579-001-28-1	cilostazol	Launched	phosphodiesterase inhibitor	PDE3A|PDE3B	cardiology	claudication	0	98.71	MicroSource	1505230	CILOSTAZOL	369.216	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	RRGUKTPIGVIEKM-UHFFFAOYSA-N	2754.0		RRGUKTPIGVIEKM
BRD-K67017579-001-29-9	cilostazol	Launched	phosphodiesterase inhibitor	PDE3A|PDE3B	cardiology	claudication	0	94.3	Tocris	1692	Cilostazol	369.216	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	RRGUKTPIGVIEKM-UHFFFAOYSA-N	2754.0		RRGUKTPIGVIEKM
BRD-K67017579-001-26-5	cilostazol	Launched	phosphodiesterase inhibitor	PDE3A|PDE3B	cardiology	claudication	0	97.14	Selleck	S1294	Cilostazol	369.216	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	RRGUKTPIGVIEKM-UHFFFAOYSA-N	2754.0		RRGUKTPIGVIEKM
BRD-K67017579-001-27-3	cilostazol	Launched	phosphodiesterase inhibitor	PDE3A|PDE3B	cardiology	claudication	0	98.49	Tocris	1692	Cilostazol	369.216	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	RRGUKTPIGVIEKM-UHFFFAOYSA-N	2754.0		RRGUKTPIGVIEKM
BRD-K00004667-001-01-9	ciluprevir	Preclinical	serine protease inhibitor				0	0.0	Adooq	A11343.obs1190502	Ciluprevir (BILN 2061)	774.341	COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|	PJZPDFUUXKKDNB-KNINVFKUSA-N	9853710.0		PJZPDFUUXKKDNB
BRD-A75514485-001-01-9	CIM-0216	Preclinical	transient receptor potential channel agonist	TRPM3			0	90.64	Tocris	5521	CIM 0216	347.163	Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|	KSEXDSJYVSEVGF-FQEVSTJZSA-N	25331887.0		KSEXDSJYVSEVGF
BRD-A75514485-001-02-9	CIM-0216	Preclinical	transient receptor potential channel agonist	TRPM3			0	94.89	Tocris	5521	CIM 0216	347.163	Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7,r|	KSEXDSJYVSEVGF-FQEVSTJZSA-N	25331887.0		KSEXDSJYVSEVGF
BRD-A65440446-001-06-9	cimaterol	Preclinical	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	96.13	Tocris	435	Cimaterol	219.137	CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|	BUXRLJCGHZZYNE-GFCCVEGCSA-N	10911051.0		BUXRLJCGHZZYNE
BRD-A65440446-001-04-1	cimaterol	Preclinical	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	89.76	Tocris	435	Cimaterol	219.137	CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5,r|	BUXRLJCGHZZYNE-GFCCVEGCSA-N	10911051.0		BUXRLJCGHZZYNE
BRD-K34157611-001-21-0	cimetidine	Launched	histamine receptor antagonist	HRH2|SLC29A4|SLC47A1|SLC47A2	gastroenterology|hematologic malignancy|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma	0	95.86	Tocris	902	Cimetidine	252.116	CN\C(NCCSCc1[nH]cnc1C)=N/C#N	AQIXAKUUQRKLND-UHFFFAOYSA-N	2756.0		AQIXAKUUQRKLND
BRD-K34157611-001-15-2	cimetidine	Launched	histamine receptor antagonist	HRH2|SLC29A4|SLC47A1|SLC47A2	gastroenterology|hematologic malignancy|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma	0	98.79	Tocris	902	Cimetidine	252.116	CN\C(NCCSCc1[nH]cnc1C)=N/C#N	AQIXAKUUQRKLND-UHFFFAOYSA-N	2756.0		AQIXAKUUQRKLND
BRD-K34157611-001-14-5	cimetidine	Launched	histamine receptor antagonist	HRH2|SLC29A4|SLC47A1|SLC47A2	gastroenterology|hematologic malignancy|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma	0	93.33	Selleck	S1845	Cimetidine	252.116	CN\C(NCCSCc1[nH]cnc1C)=N/C#N	AQIXAKUUQRKLND-UHFFFAOYSA-N	2756.0		AQIXAKUUQRKLND
BRD-K34157611-001-16-0	cimetidine	Launched	histamine receptor antagonist	HRH2|SLC29A4|SLC47A1|SLC47A2	gastroenterology|hematologic malignancy|endocrinology	duodenal ulcer disease|peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)|aggressive systemic mastocytosis (ASM)|Zollinger-Ellison syndrome|endocrine adenoma	0	99.16	MicroSource	1500684	CIMETIDINE	252.116	CN\C(NCCSCc1[nH]cnc1C)=N/C#N	AQIXAKUUQRKLND-UHFFFAOYSA-N	2756.0		AQIXAKUUQRKLND
BRD-A99899486-004-01-9	cimetropium	Launched	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	0	93.27	Sigma	MFCD00869708	(1R,2R,4S,5S)-9-(cyclopropylmethyl)-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0~2,4~]nonane bromide	358.202	C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6,8,10,11,13,17,&1:1,TLB:0:1:7.8.9:11.13,THB:2:1:7.8.9:11.13,12:11:1:7.8.9,12:13:1:7.8.9,14:8:1:11.13|	QVVOZYKELHAIPX-IGDPVYPXSA-N			QVVOZYKELHAIPX
BRD-K73838513-003-05-5	cinacalcet	Launched	calcium channel activator	CASR	endocrinology|nephrology|oncology	hyperparathyroidism|chronic kidney disease (CKD)|parathyroid carcinoma|hypercalcemia	0	98.81	Selleck	S1260	Cinacalcet HCl	357.17	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	VDHAWDNDOKGFTD-MRXNPFEDSA-N	156419.0		VDHAWDNDOKGFTD
BRD-K73838513-003-01-4	cinacalcet	Launched	calcium channel activator	CASR	endocrinology|nephrology|oncology	hyperparathyroidism|chronic kidney disease (CKD)|parathyroid carcinoma|hypercalcemia	0		Selleck	S1260	Cinacalcet hydrochloride	357.17	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1	156419.0		VDHAWDNDOKGFTD
BRD-K73440166-003-02-9	cinaciguat	Phase 2	guanylate cyclase activator	GUCY1A3|GUCY1B3			0	96.81	Tocris	6052	BAY 58-2667 hydrochloride	565.283	OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O	WPYWMXNXEZFMAK-UHFFFAOYSA-N	9808022.0		WPYWMXNXEZFMAK
BRD-K73440166-001-01-3	cinaciguat	Phase 2	guanylate cyclase activator	GUCY1A3|GUCY1B3			0	97.86	MedChemEx	HY-14181	Cinaciguat	565.283	OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O	WPYWMXNXEZFMAK-UHFFFAOYSA-N	9808022.0		WPYWMXNXEZFMAK
BRD-K53720352-001-05-7	cinalukast	Phase 2	leukotriene receptor antagonist	CYSLTR1			0	92.06	Tocris	2025	Cinalukast	412.182	CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	BZMKNPGKXJAIDV-VAWYXSNFSA-N	6436135.0		BZMKNPGKXJAIDV
BRD-K53720352-001-04-0	cinalukast	Phase 2	leukotriene receptor antagonist	CYSLTR1			0	81.73	Tocris	2025	4-{3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]anilino}-2,2-diethyl-4-oxobutanoic acid	412.182	CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	BZMKNPGKXJAIDV-VAWYXSNFSA-N	6436135.0		BZMKNPGKXJAIDV
BRD-K53720352-001-03-2	cinalukast	Phase 2	leukotriene receptor antagonist	CYSLTR1			0	81.35	Tocris	2025	Cinalukast	412.182	CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	BZMKNPGKXJAIDV-VAWYXSNFSA-N	6436135.0		BZMKNPGKXJAIDV
BRD-K40901640-003-06-9	cinanserin	Preclinical	serotonin receptor antagonist	HTR2A			0	97.64	Tocris	460	Cinanserin hydrochloride	340.161	CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1	RSUVYMGADVXGOU-BUHFOSPRSA-N	5475158.0		RSUVYMGADVXGOU
BRD-K40901640-003-01-6	cinanserin	Preclinical	serotonin receptor antagonist	HTR2A			0	96.6	Tocris	460	Cinanserin hydrochloride	340.161	CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1	RSUVYMGADVXGOU-BUHFOSPRSA-N	5475158.0		RSUVYMGADVXGOU
BRD-K99121711-003-20-5	cinchocaine	Launched	sodium channel blocker	CALM1|SCN10A|SCN5A	neurology/psychiatry	local anesthetic	0	96.29	MicroSource	1500236	DIBUCAINE HYDROCHLORIDE	343.226	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	PUFQVTATUTYEAL-UHFFFAOYSA-N	3025.0		PUFQVTATUTYEAL
BRD-K99121711-001-21-9	cinchocaine	Launched	sodium channel blocker	CALM1|SCN10A|SCN5A	neurology/psychiatry	local anesthetic	0	97.32	MedChemEx	HY-B0552	Dibucaine	343.226	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	PUFQVTATUTYEAL-UHFFFAOYSA-N	3025.0		PUFQVTATUTYEAL
BRD-K99121711-003-19-7	cinchocaine	Launched	sodium channel blocker	CALM1|SCN10A|SCN5A	neurology/psychiatry	local anesthetic	0	96.87	Selleck	S4038	Dibucaine HCl	343.226	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	PUFQVTATUTYEAL-UHFFFAOYSA-N	3025.0		PUFQVTATUTYEAL
BRD-K39079086-001-06-8	cinchonidine	Phase 1	P glycoprotein inhibitor				0	91.75	MicroSource	1500839	CINCHONIDINE	294.173	O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	KMPWYEUPVWOPIM-KODHJQJWSA-N	101744.0		KMPWYEUPVWOPIM
BRD-K39079086-001-08-9	cinchonidine	Phase 1	P glycoprotein inhibitor				0	86.44	MedChemEx	HY-N0173	Cinchonidine	294.173	O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	KMPWYEUPVWOPIM-KODHJQJWSA-N	101744.0		KMPWYEUPVWOPIM
BRD-K39079086-001-07-6	cinchonidine	Phase 1	P glycoprotein inhibitor				0	93.36	Selleck	S2282	Cinchonidine	294.173	O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	KMPWYEUPVWOPIM-KODHJQJWSA-N	101744.0	BRD-A54537387-001-02-2	KMPWYEUPVWOPIM
BRD-K36551084-001-04-9	cinchonine	Preclinical	P glycoprotein inhibitor	CYP2D6			0	85.43	MedChemEx	HY-Y0152	Cinchonine	294.173	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	KMPWYEUPVWOPIM-QAMTZSDWSA-N	90454.0		KMPWYEUPVWOPIM
BRD-K72915123-001-19-9	cinchophen	Launched	analgesic agent		rheumatology	gout	0	98.3	MedChemEx	HY-B0972	Cinchophen	249.079	OC(=O)c1cc(nc2ccccc12)-c1ccccc1	YTRMTPPVNRALON-UHFFFAOYSA-N	8593.0		YTRMTPPVNRALON
BRD-K72915123-001-18-1	cinchophen	Launched	analgesic agent		rheumatology	gout	0	99.45	MicroSource	1504508	CINCHOPHEN	249.079	OC(=O)c1cc(nc2ccccc12)-c1ccccc1	YTRMTPPVNRALON-UHFFFAOYSA-N	8593.0		YTRMTPPVNRALON
BRD-K72915123-001-17-3	cinchophen	Launched	analgesic agent		rheumatology	gout	0	97.91	Selleck	S4190	Cinchophen	249.079	OC(=O)c1cc(nc2ccccc12)-c1ccccc1	YTRMTPPVNRALON-UHFFFAOYSA-N	8593.0		YTRMTPPVNRALON
BRD-K00531707-001-01-3	cinepazet	Launched	vasodilator				0	95.1	Sigma	MFCD00864685	ethyl {4-[(2E)-3-(3,4,5-trimethoxyphenyl)-2-propenoyl]-1-piperazinyl}acetate	392.195	CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1	XDUOTWNXVDBCDY-VOTSOKGWSA-N	6434395.0		XDUOTWNXVDBCDY
BRD-K46839850-050-06-9	cinepazide	Withdrawn	calcium channel activator				0	95.46	MedChemEx	HY-66010	Cinepazide (Maleate)	417.226	COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC	RCUDFXMNPQNBDU-VOTSOKGWSA-N	5282459.0		RCUDFXMNPQNBDU
BRD-K46839850-050-04-2	cinepazide	Withdrawn	calcium channel activator				0	87.2	Selleck	S3045	Cinepazide maleate	417.226	COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC	RCUDFXMNPQNBDU-VOTSOKGWSA-N	5282459.0		RCUDFXMNPQNBDU
BRD-K46839850-050-05-9	cinepazide	Withdrawn	calcium channel activator				0	99.15	Selleck	S3045	Cinepazide maleate	417.226	COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC	RCUDFXMNPQNBDU-VOTSOKGWSA-N	5282459.0		RCUDFXMNPQNBDU
BRD-K25154476-001-01-4	cinflumide	Phase 2	muscle relaxant				0	89.23	Enamine	Z32368088	(2E)-N-cyclopropyl-3-(3-fluorophenyl)-2-propenamide	205.09	Fc1cccc(\C=C\C(=O)NC2CC2)c1	NCOOUEIQXVWKTO-QPJJXVBHSA-N	6434871.0		NCOOUEIQXVWKTO
BRD-K26875402-001-13-9	cinnamaldehyde	Preclinical	aldose reductase inhibitor|TRPV agonist	TRPA1			0	86.3	MedChemEx	HY-N0609	Cinnamaldehyde	132.058	O=C\C=C\c1ccccc1	KJPRLNWUNMBNBZ-QPJJXVBHSA-N	637511.0		KJPRLNWUNMBNBZ
BRD-K07220430-001-20-9	cinnarazine	Launched	calcium channel blocker		neurology/psychiatry|gastroenterology|ophthalmology	Meniere's disease|nausea|vomiting|Cogan's syndrome	0	98.35	MedChemEx	HY-B1090	Cinnarizine	368.225	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	DERZBLKQOCDDDZ-JLHYYAGUSA-N	1547484.0		DERZBLKQOCDDDZ
BRD-K07220430-001-19-2	cinnarazine	Launched	calcium channel blocker		neurology/psychiatry|gastroenterology|ophthalmology	Meniere's disease|nausea|vomiting|Cogan's syndrome	0	98.16	MicroSource	1503204	CINNARAZINE	368.225	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	DERZBLKQOCDDDZ-JLHYYAGUSA-N	1547484.0	BRD-K32256916-001-04-0	DERZBLKQOCDDDZ
BRD-K07220430-001-18-4	cinnarazine	Launched	calcium channel blocker		neurology/psychiatry|gastroenterology|ophthalmology	Meniere's disease|nausea|vomiting|Cogan's syndrome	0	96.64	ChemDiv	R033-0071		368.225	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	DERZBLKQOCDDDZ-JLHYYAGUSA-N	1547484.0		DERZBLKQOCDDDZ
BRD-K00003354-001-01-9	cinobufotalin	Phase 1	anticancer agent				0	89.74	MedChemEx	HY-N0880	Cinobufotalin	458.23	[H][C@@]12CC[C@]3(O)C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H]([C@@H](OC(C)=O)[C@H]3O[C@@]213)c1ccc(=O)oc1	KBKUJJFDSHBPPA-ZNCGZLKOSA-N	259776.0		KBKUJJFDSHBPPA
BRD-K08699567-001-01-9	cinoctramide	Preclinical					0	0.0	MicroSource	1506186	CINOCTRAMIDE	333.194	COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC	MDGVCMGGLSOVIQ-MDZDMXLPSA-N	6443803.0	BRD-K15901271-001-01-7	MDGVCMGGLSOVIQ
BRD-K08699567-001-02-9	cinoctramide	Preclinical					0	95.05	MedChemEx	HY-B1084	Cinoctramide	333.194	COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC	MDGVCMGGLSOVIQ-MDZDMXLPSA-N	6443803.0		MDGVCMGGLSOVIQ
BRD-K14704277-001-23-4	cinoxacin	Launched	topoisomerase inhibitor		infectious disease	urinary tract infections	0	73.09	MicroSource	1500190	CINOXACIN	262.059	CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12	VDUWPHTZYNWKRN-UHFFFAOYSA-N	2762.0		VDUWPHTZYNWKRN
BRD-K14704277-001-22-6	cinoxacin	Launched	topoisomerase inhibitor		infectious disease	urinary tract infections	0	93.53	Selleck	S4361	Cinoxacin	262.059	CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12	VDUWPHTZYNWKRN-UHFFFAOYSA-N	2762.0		VDUWPHTZYNWKRN
BRD-K17828029-001-02-9	cinoxate	Launched			dermatology	sunscreen lotion	0	86.65	Sigma	MFCD00868209	Cinoxate	250.121	CCOCCOC(=O)\C=C\c1ccc(OC)cc1	CMDKPGRTAQVGFQ-RMKNXTFCSA-N	5373773.0		CMDKPGRTAQVGFQ
BRD-K17828029-001-01-5	cinoxate	Launched			dermatology	sunscreen lotion	0	95.2	Enamine	Z53833825		250.121	CCOCCOC(=O)\C=C\c1ccc(OC)cc1	CMDKPGRTAQVGFQ-RMKNXTFCSA-N	5373773.0		CMDKPGRTAQVGFQ
BRD-K24570280-001-01-8	CINPA-1	Preclinical	CAR antagonist	NR1H4|NR1I3|PPARG			0	93.64	Tocris	5605	CINPA 1	395.221	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1	AYQBYSPEGRYKFA-UHFFFAOYSA-N	969470.0		AYQBYSPEGRYKFA
BRD-K24570280-001-07-9	CINPA-1	Preclinical	CAR antagonist	NR1H4|NR1I3|PPARG			0	94.15	Tocris	5605	CINPA 1	395.221	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1	AYQBYSPEGRYKFA-UHFFFAOYSA-N	969470.0		AYQBYSPEGRYKFA
BRD-K66241279-001-01-8	cinromide	Phase 3					0	99.12	MicroSource	1502552	CINROMIDE	253.01	CCNC(=O)\C=C\c1cccc(Br)c1	LDCXGZCEMNMWIL-VOTSOKGWSA-N	688145.0		LDCXGZCEMNMWIL
BRD-K66241279-001-02-9	cinromide	Phase 3					0	98.07	MedChemEx	HY-B1274	Cinromide	253.01	CCNC(=O)\C=C\c1cccc(Br)c1	LDCXGZCEMNMWIL-VOTSOKGWSA-N	688145.0		LDCXGZCEMNMWIL
BRD-K00003458-001-01-9	cintirorgon	Phase 1/Phase 2	ROR agonist				0	95.2	MedChemEx	HY-104037	Cintirorgon	603.115	CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O	GULSIMHVQYBADX-FQEVSTJZSA-N	124126348.0		GULSIMHVQYBADX
BRD-K24507548-001-01-8	cintriamide	Preclinical					0	97.46	MicroSource	1502553	CINTRIAMIDE	237.1	COc1cc(\C=C\C(N)=O)cc(OC)c1OC	LRLKZVMLJBNNPE-SNAWJCMRSA-N	6154037.0		LRLKZVMLJBNNPE
BRD-K00004625-001-01-9	cipamfylline	Phase 2	phosphodiesterase inhibitor				0	85.94	Sigma	SML0366	8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro-1H-purine-2,6-dione	275.138	Nc1nc2n(CC3CC3)c(=O)n(CC3CC3)c(=O)c2[nH]1	KSPYMJJKQMWWNB-UHFFFAOYSA-N	71356.0		KSPYMJJKQMWWNB
BRD-K27811785-001-02-9	cipargamin	Phase 2	antimalarial agent				0	95.43	MedChemEx	HY-14430	Cipargamin	389.05	C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc21	CKLPLPZSUQEDRT-WPCRTTGESA-N	44469321.0		CKLPLPZSUQEDRT
BRD-K95362002-001-01-1	cipemastat	Phase 3	metalloproteinase inhibitor	ADAM17|MMP1|MMP13|MMP2|MMP3|MMP8|MMP9			0	86.65	Tocris	2916	(2R,3R)-3-(cyclopentylmethyl)-N-hydroxy-4-oxo-4-(1-piperidinyl)-2-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]butanamide	436.269	CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C	GFUITADOEPNRML-SJORKVTESA-N	9824350.0		GFUITADOEPNRML
BRD-A49358627-001-14-6	ciprofibrate	Launched	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	0	96.78	MicroSource	1502008	CIPROFIBRATE	288.032	CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|	KPSRODZRAIWAKH-SNVBAGLBSA-N	9882424.0		KPSRODZRAIWAKH
BRD-A49358627-001-13-8	ciprofibrate	Launched	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	0	91.39	Selleck	S2665	Ciprofibrate	288.032	CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10,r|	KPSRODZRAIWAKH-SNVBAGLBSA-N	9882424.0		KPSRODZRAIWAKH
BRD-K04804440-001-09-5	ciprofloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	0	88.24	MicroSource	1503614	CIPROFLOXACIN	331.133	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	MYSWGUAQZAJSOK-UHFFFAOYSA-N	4011971.0		MYSWGUAQZAJSOK
BRD-K04804440-001-13-7	ciprofloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	0	98.2	Selleck	S2027	Ciprofloxacin (Cipro)	331.133	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	MYSWGUAQZAJSOK-UHFFFAOYSA-N	4011971.0		MYSWGUAQZAJSOK
BRD-K04804440-001-08-7	ciprofloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology	otitis	0	50.83	Selleck	S2027	Ciprofloxacin (Cipro)	331.133	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	MYSWGUAQZAJSOK-UHFFFAOYSA-N	4011971.0		MYSWGUAQZAJSOK
BRD-K01767299-050-03-9	ciproxifan	Preclinical	histamine receptor antagonist	ADRA2A|ADRA2C|HRH3|HRH4|HTR3A			0	98.18	MedChemEx	HY-15289	Ciproxifan (maleate)	270.137	O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1	ACQBHJXEAYTHCY-UHFFFAOYSA-N	6422124.0		ACQBHJXEAYTHCY
BRD-K01767299-050-02-1	ciproxifan	Preclinical	histamine receptor antagonist	ADRA2A|ADRA2C|HRH3|HRH4|HTR3A			0	94.57	Selleck	S2813	Ciproxifan	270.137	O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1	ACQBHJXEAYTHCY-UHFFFAOYSA-N	6422124.0		ACQBHJXEAYTHCY
BRD-A35425966-001-02-3	CIQ	Preclinical	glutamate receptor potentiator	GRIN2C|GRIN2D			0	98.05	Tocris	4105	CIQ	467.15	COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|	VYMILMYEENZHAR-HSZRJFAPSA-N	40450008.0		VYMILMYEENZHAR
BRD-A35425966-001-01-5	CIQ	Preclinical	glutamate receptor potentiator	GRIN2C|GRIN2D			0	99.27	Sigma	SML0229	CIQ	467.15	COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8,r|	VYMILMYEENZHAR-HSZRJFAPSA-N	40450008.0		VYMILMYEENZHAR
BRD-K54142781-003-13-4	cirazoline	Preclinical	adrenergic receptor agonist	ADRA1A			0	83.93	Tocris	888	Cirazoline hydrochloride	216.126	C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|	YAORIDZYZDUZCM-UHFFFAOYSA-N	2765.0		YAORIDZYZDUZCM
BRD-K54142781-003-11-8	cirazoline	Preclinical	adrenergic receptor agonist	ADRA1A			0	92.59	Tocris	888	Cirazoline hydrochloride	216.126	C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|	YAORIDZYZDUZCM-UHFFFAOYSA-N	2765.0		YAORIDZYZDUZCM
BRD-K71756122-001-02-5	cis-aconitic-acid	Preclinical		ACO2			1	0.0	Enamine	Z57204893		174.016	OC(=O)C\C(=C\C(O)=O)C(O)=O	GTZCVFVGUGFEME-IWQZZHSRSA-N	643757.0		GTZCVFVGUGFEME
BRD-K00004205-001-01-9	cis-ACPD	Preclinical	glutamate receptor agonist	GRM2|GRM3|GRM6|GRM7|GRM8			0	100.0	Tocris	186	cis-ACPD	173.069	[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1,4,r|	YFYNOWXBIBKGHB-CLZZGJSISA-N	231345.0		YFYNOWXBIBKGHB
BRD-K41962502-001-01-8	cis-exo-camphanediol-2,3	Phase 1	nitric oxide stimulant	NOS3			0	0.0	Sigma	MFCD07784411	(1S,2R,3S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-diol	170.131	CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O	AYEOSGBMQHXVER-AZQAYCESSA-N	21626088.0		AYEOSGBMQHXVER
BRD-K52670952-003-02-2	cis-urocanic-acid	Phase 2	serotonin receptor agonist	HTR2A			0	100.0	Enamine	Z607808534		138.043	OC(=O)\C=C\c1cnc[nH]1	LOIYMIARKYCTBW-OWOJBTEDSA-N	736715.0		LOIYMIARKYCTBW
BRD-K52670952-003-01-4	cis-urocanic-acid	Phase 2	serotonin receptor agonist	HTR2A			0	78.28	Enamine	Z607808534		138.043	OC(=O)\C=C\c1cnc[nH]1	LOIYMIARKYCTBW-OWOJBTEDSA-N	736715.0		LOIYMIARKYCTBW
BRD-K25146005-001-01-0	cis-urocanic-acid	Phase 2	serotonin receptor agonist	HTR2A			0	96.8	Sigma	MFCD11045310	(2Z)-3-(1H-imidazol-4-yl)-2-propenoic acid	138.043	OC(=O)\C=C/c1cnc[nH]1	LOIYMIARKYCTBW-UPHRSURJSA-N	1549103.0		LOIYMIARKYCTBW
BRD-K80025777-001-01-4	cis-9,trans-11-conjugated-linoleic-acid	Launched					0	96.37	Enzo	BL119	9(E),11(Z)-Octadecadienoic acid	280.24	CCCCCC\C=C\C=C/CCCCCCCC(O)=O	JBYXPOFIGCOSSB-GOJKSUSPSA-N	5280644.0		JBYXPOFIGCOSSB
BRD-K80025777-001-05-9	cis-9,trans-11-conjugated-linoleic-acid	Launched					0	0.0	Sigma	MFCD00211047	Conjugated (9Z,11E)-Linoleic acid	280.24	CCCCCC\C=C\C=C/CCCCCCCC(O)=O	JBYXPOFIGCOSSB-GOJKSUSPSA-N	5280644.0		JBYXPOFIGCOSSB
BRD-K06895174-001-03-6	cisapride	Withdrawn	serotonin receptor agonist	HTR2A|HTR3A|HTR4|KCNH2			0	98.57	Tocris	1695	Cisapride	465.183	CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC	DCSUBABJRXZOMT-IRLDBZIGSA-N	6917698.0		DCSUBABJRXZOMT
BRD-K06895174-001-04-9	cisapride	Withdrawn	serotonin receptor agonist	HTR2A|HTR3A|HTR4|KCNH2			0	97.38	Tocris	1695	Cisapride	465.183	CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC	DCSUBABJRXZOMT-IRLDBZIGSA-N	6917698.0		DCSUBABJRXZOMT
BRD-K06895174-001-02-8	cisapride	Withdrawn	serotonin receptor agonist	HTR2A|HTR3A|HTR4|KCNH2			0	97.58	Tocris	1695	Cisapride	465.183	CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC	DCSUBABJRXZOMT-IRLDBZIGSA-N	6917698.0		DCSUBABJRXZOMT
BRD-K17498618-344-04-9	cisatracurium	Launched	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry|critical care	muscle relaxant|endotracheal intubation	0	0.0	MedChemEx	HY-13596	Cisatracurium (besylate)	928.509	COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	YXSLJKQTIDHPOT-LJCJQEJUSA-N	62887.0		YXSLJKQTIDHPOT
BRD-K17498618-344-03-4	cisatracurium	Launched	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry|critical care	muscle relaxant|endotracheal intubation	0	64.92	Selleck	S2113	Cisatracurium besylate (Nimbex)	928.509	COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	YXSLJKQTIDHPOT-LJCJQEJUSA-N	62887.0		YXSLJKQTIDHPOT
BRD-K17498618-344-02-6	cisatracurium	Launched	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry|critical care	muscle relaxant|endotracheal intubation	0	88.16	Selleck	S2113	Cisatracurium Besylate	928.509	COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	YXSLJKQTIDHPOT-LJCJQEJUSA-N	62887.0		YXSLJKQTIDHPOT
BRD-K69172251-001-10-5	cisplatin	Launched	DNA alkylating agent|DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma|ovarian cancer|bladder cancer	1	0.0	MicroSource	1502107	CISPLATIN	296.94	N[Pt](N)(Cl)Cl	DQLATGHUWYMOKM-UHFFFAOYSA-L	86820626.0	BRD-K01228321-318-04-3	DQLATGHUWYMOKM
BRD-K69172251-001-11-3	cisplatin	Launched	DNA alkylating agent|DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma|ovarian cancer|bladder cancer	1	0.0	Selleck	S1166	Cisplatin	296.94	N[Pt](N)(Cl)Cl	DQLATGHUWYMOKM-UHFFFAOYSA-L	86820626.0		DQLATGHUWYMOKM
BRD-K69172251-001-09-7	cisplatin	Launched	DNA alkylating agent|DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma|ovarian cancer|bladder cancer	1	0.0	Tocris	2251	Cisplatin	296.94	N[Pt](N)(Cl)Cl	DQLATGHUWYMOKM-UHFFFAOYSA-L	86820626.0	BRD-K33494261-407-01-2	DQLATGHUWYMOKM
BRD-K69172251-001-08-9	cisplatin	Launched	DNA alkylating agent|DNA synthesis inhibitor	XIAP	oncology	testicular carcinoma|ovarian cancer|bladder cancer	1	0.0	Selleck	S1166	Cisplatin	296.94	N[Pt](N)(Cl)Cl	DQLATGHUWYMOKM-UHFFFAOYSA-L	86820626.0		DQLATGHUWYMOKM
BRD-A47598013-004-17-8	citalopram	Launched	selective serotonin reuptake inhibitor (SSRI)	ADRA1A|CHRM1|HRH1|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	96.19	MicroSource	1504172	CITALOPRAM HYDROBROMIDE	324.164	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|	WSEQXVZVJXJVFP-FQEVSTJZSA-N	146570.0		WSEQXVZVJXJVFP
BRD-A47598013-004-18-6	citalopram	Launched	selective serotonin reuptake inhibitor (SSRI)	ADRA1A|CHRM1|HRH1|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	96.48	Enamine	Z905064078		324.164	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|	WSEQXVZVJXJVFP-FQEVSTJZSA-N	146570.0		WSEQXVZVJXJVFP
BRD-A47598013-004-16-0	citalopram	Launched	selective serotonin reuptake inhibitor (SSRI)	ADRA1A|CHRM1|HRH1|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	97.27	Tocris	1427	Citalopram hydrobromide	324.164	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|	WSEQXVZVJXJVFP-FQEVSTJZSA-N	146570.0		WSEQXVZVJXJVFP
BRD-K00003202-001-01-9	citarinostat	Phase 1	HDAC inhibitor				0	96.59	MedChemEx	HY-15994	Citarinostat	467.172	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1Cl	VLIUIBXPEDFJRF-UHFFFAOYSA-N	53340426.0		VLIUIBXPEDFJRF
BRD-K53263234-001-06-0	CITCO	Preclinical	constitutive androstane receptor (CAR) agonist	NR1I3			0	94.15	Tocris	3683	CITCO	434.977	Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	ZQWBOKJVVYNKTL-AUEPDCJTSA-N	9600409.0		ZQWBOKJVVYNKTL
BRD-K53263234-001-05-2	CITCO	Preclinical	constitutive androstane receptor (CAR) agonist	NR1I3			0	89.03	Tocris	3683	CITCO	434.977	Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	ZQWBOKJVVYNKTL-AUEPDCJTSA-N	9600409.0		ZQWBOKJVVYNKTL
BRD-K53263234-001-07-9	CITCO	Preclinical	constitutive androstane receptor (CAR) agonist	NR1I3			0	97.77	Tocris	3683	CITCO	434.977	Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	ZQWBOKJVVYNKTL-AUEPDCJTSA-N	9600409.0		ZQWBOKJVVYNKTL
BRD-K01827268-396-12-9	citicoline	Launched	glutathione transferase stimulant|membrane permeability enhancer	ACHE|SLC1A2	neurology/psychiatry|ophthalmology	stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma	0	0.0	MicroSource	1505244		489.115	C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|	RZZPDXZPRHQOCG-OJAKKHQRSA-O	13805.0	BRD-A74441166-396-01-6	RZZPDXZPRHQOCG
BRD-K01827268-236-03-9	citicoline	Launched	glutathione transferase stimulant|membrane permeability enhancer	ACHE|SLC1A2	neurology/psychiatry|ophthalmology	stroke|Alzheimer's disease|senile dementia|Parkinson's Disease|attention-deficit/hyperactivity disorder (ADHD)|glaucoma	0	99.5	Cayman	14629		512.105	C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16,18,19,21,&1:7,&2:11|	RZZPDXZPRHQOCG-OJAKKHQRSA-O	13805.0		RZZPDXZPRHQOCG
BRD-A57957888-001-08-0	citiolone	Preclinical	lipotropic|mucolytic agent				0	94.67	MicroSource	1503205	CITIOLONE	159.035	CC(=O)N[C@H]1CCSC1=O |&1:4,r|	NRFJZTXWLKPZAV-YFKPBYRVSA-N	7057882.0		NRFJZTXWLKPZAV
BRD-K76792669-001-08-1	citric-acid	Preclinical	coagulation factor inhibitor	AKR1B1|ANG|APRT|BHMT|C8G|CA4|CPB1|CS|CTDSP1|GNMT|HGS|HS3ST3A1|IL4I1|ITPA|LSM6|MDH2|MIF|PDE5A|PKD2L1|PLEKHA1|RNASE1|RNASE3|SRC|TNFSF13B|UCK2			0	0.0	Sigma	MFCD00150031	trisodium 2-hydroxy-1,2,3-propanetricarboxylate dihydrate	192.027	OC(=O)CC(O)(CC(O)=O)C(O)=O	KRKNYBCHXYNGOX-UHFFFAOYSA-N	88113319.0	BRD-M87682871-001-01-8	KRKNYBCHXYNGOX
BRD-K21306330-001-01-0	CJ-033466	Preclinical	serotonin receptor agonist	HTR4			0	87.64	Tocris	3089	CJ 033466	377.198	CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1	ISKHMDNIWXPUGR-UHFFFAOYSA-N	10429706.0		ISKHMDNIWXPUGR
BRD-K21306330-001-02-9	CJ-033466	Preclinical	serotonin receptor agonist	HTR4			0	90.58	Tocris	3089	CJ 033466	377.198	CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1	ISKHMDNIWXPUGR-UHFFFAOYSA-N	10429706.0		ISKHMDNIWXPUGR
BRD-K00004624-001-01-9	CJ-13610	Phase 2	lipoxygenase inhibitor				0	96.54	Sigma	SML0187	4-(3-{[4-(2-methyl-1H-imidazol-1-yl)phenyl]sulfanyl}phenyl)tetrahydro-2H-pyran-4-carboxamide	393.151	Cc1nccn1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	VPTONMHDLLMOOV-UHFFFAOYSA-N	9821945.0		VPTONMHDLLMOOV
BRD-K00005246-001-01-9	CK-101	Preclinical	EGFR inhibitor				0	95.24	MedChemEx	HY-19815	RX-518	530.224	OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F	IDRGFNPZDVBSSE-UHFFFAOYSA-N	117909640.0		IDRGFNPZDVBSSE
BRD-K81572616-001-01-9	CK-636	Preclinical	actin related protein inhibitor	ACTR2|ACTR3|ARPC1B|ARPC2|ARPC3|ARPC4|ARPC5			0	79.68	Selleck	S7497	CK-636	284.098	Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	ACAKNPKRLPMONU-UHFFFAOYSA-N	588963.0		ACAKNPKRLPMONU
BRD-K81572616-001-02-7	CK-636	Preclinical	actin related protein inhibitor	ACTR2|ACTR3|ARPC1B|ARPC2|ARPC3|ARPC4|ARPC5			0	84.46	Selleck	S7497	CK-636	284.098	Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	ACAKNPKRLPMONU-UHFFFAOYSA-N	588963.0		ACAKNPKRLPMONU
BRD-K81572616-001-03-9	CK-636	Preclinical	actin related protein inhibitor	ACTR2|ACTR3|ARPC1B|ARPC2|ARPC3|ARPC4|ARPC5			0	95.64	MedChemEx	HY-15892	CK-636	284.098	Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	ACAKNPKRLPMONU-UHFFFAOYSA-N	588963.0		ACAKNPKRLPMONU
BRD-A26458246-004-02-1	CKD-712	Phase 1	NFkB pathway inhibitor	JAK2|STAT1			0	93.15	MedChemEx	HY-15477	YS-49	305.142	Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|	YGCQFKVNIBDJFW-SFHVURJKSA-N	9861304.0		YGCQFKVNIBDJFW
BRD-A26458246-004-01-3	CKD-712	Phase 1	NFkB pathway inhibitor	JAK2|STAT1			0	22.25	MedChemEx	HY-15477	YS-49	305.142	Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|	YGCQFKVNIBDJFW-SFHVURJKSA-N	9861304.0		YGCQFKVNIBDJFW
BRD-K34303607-300-02-2	CKI-7	Preclinical	casein kinase inhibitor	CSNK1G2			0	93.33	Tocris	5329	CKI 7 dihydrochloride	285.034	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12	OGKYMFFYOWUTKV-UHFFFAOYSA-N	129236.0		OGKYMFFYOWUTKV
BRD-K34303607-300-01-4	CKI-7	Preclinical	casein kinase inhibitor	CSNK1G2			0		Sigma	C0742	CKI-7 dihydrochloride	285.034	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12	OGKYMFFYOWUTKV-UHFFFAOYSA-N	129236.0		OGKYMFFYOWUTKV
BRD-K00662280-001-10-2	CL-218872	Phase 1	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2			0	98.21	Tocris	1709	CL 218872	278.078	Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	GUOQUXNJZHGPQF-UHFFFAOYSA-N	107950.0		GUOQUXNJZHGPQF
BRD-K00662280-001-11-9	CL-218872	Phase 1	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2			0	93.47	Tocris	1709	CL 218872	278.078	Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	GUOQUXNJZHGPQF-UHFFFAOYSA-N	107950.0		GUOQUXNJZHGPQF
BRD-K00662280-001-09-4	CL-218872	Phase 1	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2			0	97.94	Tocris	1709	CL 218872	278.078	Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	GUOQUXNJZHGPQF-UHFFFAOYSA-N	107950.0		GUOQUXNJZHGPQF
BRD-K87573013-001-01-0	CL-225385	Phase 2					0	96.85	Enamine	EN300-17202	3-oxo-3-phenylpropanenitrile	145.053	O=C(CC#N)c1ccccc1	ZJRCIQAMTAINCB-UHFFFAOYSA-N	64799.0		ZJRCIQAMTAINCB
BRD-K93034159-001-31-9	cladribine	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	ADA|PNP|POLA1|POLE|POLE2|POLE3|POLE4|RRM1|RRM2|RRM2B	hematologic malignancy	hairy cell leukemia	0	96.63	Tocris	5292	Cladribine	285.063	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	PTOAARAWEBMLNO-KVQBGUIXSA-N	20279.0		PTOAARAWEBMLNO
BRD-K93034159-001-25-8	cladribine	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	ADA|PNP|POLA1|POLE|POLE2|POLE3|POLE4|RRM1|RRM2|RRM2B	hematologic malignancy	hairy cell leukemia	0	98.23	Selleck	S1199	Cladribine	285.063	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	PTOAARAWEBMLNO-KVQBGUIXSA-N	20279.0		PTOAARAWEBMLNO
BRD-K00004576-001-01-9	clamikalant	Preclinical	ATP-sensitive potassium channel antagonist				0	95.3	Astatech	AB8954	CLAMIKALANT	471.069	CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC	VXTKXGKPBOLHRY-UHFFFAOYSA-N	3037766.0		VXTKXGKPBOLHRY
BRD-K62378877-001-05-9	clanfenur	Preclinical	anticancer agent				0	91.68	AMS	O33768	Clanfenur	335.084	CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1	SRLPZQAEBMZCIJ-UHFFFAOYSA-N	68684.0		SRLPZQAEBMZCIJ
BRD-K49668410-001-16-2	clarithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology|pulmonary|infectious disease	pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis	0	100.0	MicroSource	1504231	CLARITHROMYCIN	747.477	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	AGOYDEPGAOXOCK-AAFHZFQRSA-N			AGOYDEPGAOXOCK
BRD-K49668410-001-18-8	clarithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology|pulmonary|infectious disease	pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis	0	100.0	Selleck	S2555	Clarithromycin	747.477	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	AGOYDEPGAOXOCK-AAFHZFQRSA-N		BRD-K16762525-001-01-6	AGOYDEPGAOXOCK
BRD-K49668410-001-20-9	clarithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	CYP3A4	otolaryngology|pulmonary|infectious disease	pharyngitis|tonsillitis|sinusitis|bronchitis|pneumonia|skin infections|otitis	0	99.1	MedChemEx	HY-17508	Clarithromycin	747.477	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	AGOYDEPGAOXOCK-AAFHZFQRSA-N			AGOYDEPGAOXOCK
BRD-K94250879-235-03-9	clavulanate	Launched	beta lactamase inhibitor		otolaryngology	otitis	0	0.0	MicroSource	1505124	CLAVULANATE LITHIUM	199.048	OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	HZZVJAQRINQKSD-PBFISZAISA-N	5280980.0		HZZVJAQRINQKSD
BRD-K94250879-001-01-9	clavulanate	Launched	beta lactamase inhibitor		otolaryngology	otitis	0	0.0	AvaChem	1995	(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid	199.048	OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	HZZVJAQRINQKSD-PBFISZAISA-N	5280980.0		HZZVJAQRINQKSD
BRD-K17294426-050-12-3	clebopride	Launched	dopamine receptor antagonist	ACHE|DRD2	gastroenterology	nausea	0	99.18	Prestwick	Prestw-380	Clebopride maleate	373.156	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	BVPWJMCABCPUQY-UHFFFAOYSA-N	2780.0		BVPWJMCABCPUQY
BRD-K17294426-037-13-9	clebopride	Launched	dopamine receptor antagonist	ACHE|DRD2	gastroenterology	nausea	0	98.64	MedChemEx	HY-B1613A	Clebopride (malate)	373.156	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	BVPWJMCABCPUQY-UHFFFAOYSA-N	2780.0		BVPWJMCABCPUQY
BRD-K30240666-051-16-7	clemastine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	91.0	Tocris	1453	Clemastine fumarate	343.17	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	YNNUSGIPVFPVBX-NHCUHLMSSA-N	26987.0		YNNUSGIPVFPVBX
BRD-K30240666-051-15-9	clemastine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	96.36	MicroSource	1500191	CLEMASTINE FUMARATE	343.17	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	YNNUSGIPVFPVBX-NHCUHLMSSA-N	26987.0		YNNUSGIPVFPVBX
BRD-K30240666-051-17-9	clemastine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	94.51	Tocris	1453	Clemastine fumarate	343.17	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	YNNUSGIPVFPVBX-NHCUHLMSSA-N	26987.0		YNNUSGIPVFPVBX
BRD-K30240666-051-13-4	clemastine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	91.1	Selleck	S1847	Clemastine Fumarate	343.17	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	YNNUSGIPVFPVBX-NHCUHLMSSA-N	26987.0		YNNUSGIPVFPVBX
BRD-K30240666-051-14-2	clemastine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	93.62	Tocris	1453	Clemastine fumarate	343.17	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	YNNUSGIPVFPVBX-NHCUHLMSSA-N	26987.0		YNNUSGIPVFPVBX
BRD-K04704168-003-15-0	clemizole	Launched	HCV inhibitor		allergy	allergic rhinitis	0	97.9	Tocris	5371	Clemizole hydrochloride	325.135	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	CJXAEXPPLWQRFR-UHFFFAOYSA-N	2782.0		CJXAEXPPLWQRFR
BRD-K04704168-003-16-9	clemizole	Launched	HCV inhibitor		allergy	allergic rhinitis	0	97.45	Tocris	5371	Clemizole hydrochloride	325.135	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	CJXAEXPPLWQRFR-UHFFFAOYSA-N	2782.0		CJXAEXPPLWQRFR
BRD-K04704168-003-14-3	clemizole	Launched	HCV inhibitor		allergy	allergic rhinitis	0	97.65	MicroSource	1505990	CLEMIZOLE HYDROCHLORIDE	325.135	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	CJXAEXPPLWQRFR-UHFFFAOYSA-N	2782.0		CJXAEXPPLWQRFR
BRD-K00003701-003-01-9	clenbuterol	Launched	adrenergic receptor agonist	ABCC8|ADRB2|KCNJ11	pulmonary	chronic obstructive pulmonary disease (COPD)|asthma	0	98.15	MedChemEx	HY-B1614	Clenbuterol hydrochloride	276.08	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|	STJMRWALKKWQGH-SNVBAGLBSA-N	688428.0		STJMRWALKKWQGH
BRD-A01563671-001-02-7	cleviprex	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S	cardiology	hypertension	0	96.26	Selleck	S2080	Clevidipine Butyrate	455.09	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|	KPBZROQVTHLCDU-SFHVURJKSA-N	22884799.0		KPBZROQVTHLCDU
BRD-A01563671-001-03-9	cleviprex	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S	cardiology	hypertension	0	97.71	MedChemEx	HY-17436	Clevidipine	455.09	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17,r,c:10,15|	KPBZROQVTHLCDU-SFHVURJKSA-N	22884799.0		KPBZROQVTHLCDU
BRD-K00003562-001-01-9	clevudine	Launched	DNA polymerase inhibitor		infectious disease	hepatitis B	0	97.96	MedChemEx	HY-13859	Clevudine	260.081	Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O	GBBJCSTXCAQSSJ-XQXXSGGOSA-N	73115.0		GBBJCSTXCAQSSJ
BRD-K01827265-004-09-9	clidinium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM3	gastroenterology	peptic ulcer disease (PUD)|irritable bowel syndrome|enterocolitis	0	99.37	MicroSource	1500192	CLIDINIUM BROMIDE	432.117	C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|	HOOSGZJRQIVJSZ-WEQDKIBNSA-N	24867263.0		HOOSGZJRQIVJSZ
BRD-K01827265-004-10-9	clidinium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM3	gastroenterology	peptic ulcer disease (PUD)|irritable bowel syndrome|enterocolitis	0	97.06	Selleck	S5480	CLIDINIUM BROMIDE	432.117	C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7,THB:9:7:2.3:5.6|	HOOSGZJRQIVJSZ-WEQDKIBNSA-N	24867263.0		HOOSGZJRQIVJSZ
BRD-A61676498-001-06-6	climbazole	Launched	enzyme inducer		dermatology	dandruff|eczema	0	99.56	MicroSource	1504833	CLIMBAZOLE	292.098	CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|	OWEGWHBOCFMBLP-CQSZACIVSA-N	25734913.0		OWEGWHBOCFMBLP
BRD-A61676498-001-05-8	climbazole	Launched	enzyme inducer		dermatology	dandruff|eczema	0	96.63	Selleck	S4178	Climbazole	292.098	CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6,r|	OWEGWHBOCFMBLP-CQSZACIVSA-N	25734913.0		OWEGWHBOCFMBLP
BRD-K01825499-003-02-9	clinafloxacin	Phase 3	bacterial DNA gyrase inhibitor				0	93.62	Selleck	S4315	Clinafoxacin HCl	401.071	N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|	QGPKADBNRMWEQR-QMMMGPOBSA-N	969489.0		QGPKADBNRMWEQR
BRD-K01825499-003-03-9	clinafloxacin	Phase 3	bacterial DNA gyrase inhibitor				0	98.71	MicroSource	1504834	CLINAFOXACIN HYDROCHLORIDE	401.071	N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|	QGPKADBNRMWEQR-QMMMGPOBSA-N	969489.0		QGPKADBNRMWEQR
BRD-K23586533-003-04-9	clindamycin	Launched	protein synthesis inhibitor		infectious disease	respiratory tract infections|pneumonia|skin infections|gynecologic infections|intra-abdominal infections|bacterial septicemia|bone and joint infections	0	92.0	Tocris	4822	Clindamycin hydrochloride	424.18	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	KDLRVYVGXIQJDK-AWPVFWJPSA-N	446598.0		KDLRVYVGXIQJDK
BRD-K23586533-003-01-6	clindamycin	Launched	protein synthesis inhibitor		infectious disease	respiratory tract infections|pneumonia|skin infections|gynecologic infections|intra-abdominal infections|bacterial septicemia|bone and joint infections	0	96.48	MicroSource	1500193	CLINDAMYCIN HYDROCHLORIDE	424.18	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	KDLRVYVGXIQJDK-AWPVFWJPSA-N	446598.0	BRD-A23034328-003-09-1	KDLRVYVGXIQJDK
BRD-K23586533-001-03-6	clindamycin	Launched	protein synthesis inhibitor		infectious disease	respiratory tract infections|pneumonia|skin infections|gynecologic infections|intra-abdominal infections|bacterial septicemia|bone and joint infections	0	100.0	Selleck	S2830	Clindamycin	424.18	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	KDLRVYVGXIQJDK-AWPVFWJPSA-N	446598.0	BRD-A43673346-001-01-1|BRD-A52252998-001-01-3	KDLRVYVGXIQJDK
BRD-K23586533-003-02-4	clindamycin	Launched	protein synthesis inhibitor		infectious disease	respiratory tract infections|pneumonia|skin infections|gynecologic infections|intra-abdominal infections|bacterial septicemia|bone and joint infections	0	99.38	Selleck	S2457	Clindamycin HCl	424.18	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	KDLRVYVGXIQJDK-AWPVFWJPSA-N	446598.0	BRD-A43673346-003-01-7|BRD-A52252998-003-01-9	KDLRVYVGXIQJDK
BRD-K10759270-003-01-1	clindamycin-palmitate	Launched	bacterial 50S ribosomal subunit inhibitor		infectious disease	intra-abdominal infections|skin infections|pneumonia|peritonitis|gynecologic infections	0	98.5	Selleck	S2596	Clindamycin palmitate HCl	662.41	CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]1SC)[C@H](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)[C@H](C)Cl	OYSKUZDIHNKWLV-PRUAPSLNSA-N	16052039.0		OYSKUZDIHNKWLV
BRD-K27771035-001-02-5	clindamycin-phosphate	Launched	protein synthesis inhibitor		obstetrics/gynecology	bacterial vaginosis	0	100.0	Selleck	S2048	Clindamycin phosphate	504.146	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	UFUVLHLTWXBHGZ-MGZQPHGTSA-N	443385.0	BRD-K52542745-001-01-1	UFUVLHLTWXBHGZ
BRD-K27771035-001-04-1	clindamycin-phosphate	Launched	protein synthesis inhibitor		obstetrics/gynecology	bacterial vaginosis	0	100.0	Selleck	S2048	Clindamycin phosphate	504.146	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	UFUVLHLTWXBHGZ-MGZQPHGTSA-N	443385.0		UFUVLHLTWXBHGZ
BRD-A90625545-001-03-9	clinofibrate	Launched	lipase clearing factor inhibitor	LPL	endocrinology	hypertriglyceridemia	0	96.83	MedChemEx	HY-13528	Clinofibrate	468.251	CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|	BMOVQUBVGICXQN-AVJYQCBHSA-N			BMOVQUBVGICXQN
BRD-A90625545-001-02-0	clinofibrate	Launched	lipase clearing factor inhibitor	LPL	endocrinology	hypertriglyceridemia	0	94.72	Selleck	S2664	Clinofibrate	468.251	CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22,&2:2,r|	BMOVQUBVGICXQN-AVJYQCBHSA-N			BMOVQUBVGICXQN
BRD-K09255212-001-16-6	clioquinol	Withdrawn	chelating agent	OPRK1			0	91.44	MicroSource	1505114	CLIOQUINOL	304.91	Oc1c(I)cc(Cl)c2cccnc12	QCDFBFJGMNKBDO-UHFFFAOYSA-N	2788.0		QCDFBFJGMNKBDO
BRD-K71430621-303-04-9	clobenpropit	Preclinical	histamine receptor antagonist	HRH1|HRH2|HRH3|HRH4			0	97.0	Tocris	752	Clobenpropit dihydrobromide	308.086	Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1	UCAIEVHKDLMIFL-UHFFFAOYSA-N	2790.0		UCAIEVHKDLMIFL
BRD-K71430621-303-02-3	clobenpropit	Preclinical	histamine receptor antagonist	HRH1|HRH2|HRH3|HRH4			0	97.23	Tocris	752	Clobenpropit dihydrobromide	308.086	Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1	UCAIEVHKDLMIFL-UHFFFAOYSA-N	2790.0		UCAIEVHKDLMIFL
BRD-K10799896-001-24-7	clobetasol-propionate	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	dermatology	corticosteroid-responsive dermatoses	0	98.0	Sigma	C8037	(11beta,16beta)-21-chloro-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl propionate	466.192	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|	CBGUOGMQLZIXBE-XGQKBEPLSA-N	32798.0		CBGUOGMQLZIXBE
BRD-K10799896-001-26-2	clobetasol-propionate	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	dermatology	corticosteroid-responsive dermatoses	0	98.73	MicroSource	1503918	CLOBETASOL PROPIONATE	466.192	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|	CBGUOGMQLZIXBE-XGQKBEPLSA-N	32798.0	BRD-A26095496-001-04-0	CBGUOGMQLZIXBE
BRD-K10799896-001-25-4	clobetasol-propionate	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	dermatology	corticosteroid-responsive dermatoses	0	94.01	Selleck	S2584	Clobetasol propionate	466.192	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17,t:13|	CBGUOGMQLZIXBE-XGQKBEPLSA-N	32798.0	BRD-K91981767-001-01-7|BRD-K84443303-001-02-6	CBGUOGMQLZIXBE
BRD-K58810291-001-16-2	clobetasone-butyrate	Launched	corticosteroid agonist	NR3C1	dermatology	eczema|psoriasis|dermatitis	0	93.44	Sigma	MFCD00133196	(16beta)-21-chloro-9-fluoro-16-methyl-3,11,20-trioxopregna-1,4-dien-17-yl butyrate	478.192	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18,t:14|	FBRAWBYQGRLCEK-AVVSTMBFSA-N	71386.0		FBRAWBYQGRLCEK
BRD-A43809092-003-02-1	clobutinol	Withdrawn	antitussive				0	96.04	Prestwick	Prestw-1380	Clobutinol hydrochloride	255.139	C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1,&2:6|	KVHHQGIIZCJATJ-ZSOXZCCMSA-N			KVHHQGIIZCJATJ
BRD-K38003476-001-09-1	clocortolone-pivalate	Launched	steroid	NR3C1|PLA2G1B	dermatology	corticosteroid-responsive dermatoses	0	98.68	Prestwick	Prestw-1119	Clocortolone pivalate	494.224	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|	SXYZQZLHAIHKKY-GSTUPEFVSA-N	5282493.0		SXYZQZLHAIHKKY
BRD-K38003476-001-10-9	clocortolone-pivalate	Launched	steroid	NR3C1|PLA2G1B	dermatology	corticosteroid-responsive dermatoses	0	95.15	USP	1138507	Clocortolone pivalate	494.224	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12,t:8|	SXYZQZLHAIHKKY-GSTUPEFVSA-N	5282493.0		SXYZQZLHAIHKKY
BRD-K72542090-304-02-4	clodronic-acid	Launched	bone resorption inhibitor	SLC25A4|SLC25A5|SLC25A6	orthopedics|endocrinology|hematologic malignancy	osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma	1	0.0	Selleck	S4108	Clodronate Disodium	243.886	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	ACSIXWWBWUQEHA-UHFFFAOYSA-N	25419.0		ACSIXWWBWUQEHA
BRD-K72542090-304-04-0	clodronic-acid	Launched	bone resorption inhibitor	SLC25A4|SLC25A5|SLC25A6	orthopedics|endocrinology|hematologic malignancy	osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma	1	0.0	Selleck	S4108	Clodronate Disodium	243.886	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	ACSIXWWBWUQEHA-UHFFFAOYSA-N	25419.0		ACSIXWWBWUQEHA
BRD-K72542090-304-03-2	clodronic-acid	Launched	bone resorption inhibitor	SLC25A4|SLC25A5|SLC25A6	orthopedics|endocrinology|hematologic malignancy	osteoporosis|hyperparathyroidism|hypercalcemia|multiple myeloma	1	0.0	Selleck	S4108	Clodronate Disodium	243.886	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	ACSIXWWBWUQEHA-UHFFFAOYSA-N	25419.0		ACSIXWWBWUQEHA
BRD-K34022604-001-09-0	clofarabine	Launched	ribonucleotide reductase inhibitor	POLA1|POLD1|POLE|RRM1|RRM2|RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	96.64	Tocris	2600	Clofarabine	303.053	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	WDDPHFBMKLOVOX-AYQXTPAHSA-N	119182.0		WDDPHFBMKLOVOX
BRD-K34022604-001-06-6	clofarabine	Launched	ribonucleotide reductase inhibitor	POLA1|POLD1|POLE|RRM1|RRM2|RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	98.71	Tocris	2600	Clofarabine	303.053	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	WDDPHFBMKLOVOX-AYQXTPAHSA-N	119182.0		WDDPHFBMKLOVOX
BRD-K34022604-001-05-8	clofarabine	Launched	ribonucleotide reductase inhibitor	POLA1|POLD1|POLE|RRM1|RRM2|RRM2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	97.93	Selleck	S1218	Clofarabine	303.053	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	WDDPHFBMKLOVOX-AYQXTPAHSA-N	119182.0		WDDPHFBMKLOVOX
BRD-K56614220-001-19-0	clofazimine	Launched	GK0582 inhibitor		infectious disease	leprosy	0	86.22	MicroSource	1505974	CLOFAZIMINE	472.122	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	WDQPAMHFFCXSNU-BGABXYSRSA-N			WDQPAMHFFCXSNU
BRD-K56614220-001-18-2	clofazimine	Launched	GK0582 inhibitor		infectious disease	leprosy	0	75.58	Selleck	S4107	Clofazimine	472.122	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	WDQPAMHFFCXSNU-BGABXYSRSA-N			WDQPAMHFFCXSNU
BRD-K56614220-001-21-6	clofazimine	Launched	GK0582 inhibitor		infectious disease	leprosy	0	60.68	Selleck	S4107	Clofazimine	472.122	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	WDQPAMHFFCXSNU-BGABXYSRSA-N			WDQPAMHFFCXSNU
BRD-A15687940-001-05-6	clofedanol	Launched	histamine receptor antagonist	HRH1	pulmonary	cough suppressant	0	97.05	Sigma	PH010350	1-(2-chlorophenyl)-3-(dimethylamino)-1-phenyl-1-propanol	289.123	CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5,r|	WRCHFMBCVFFYEQ-QGZVFWFLSA-N	688422.0		WRCHFMBCVFFYEQ
BRD-K45252063-001-13-6	clofibrate	Launched	PPAR receptor agonist	LPL|PPARA	endocrinology|cardiology	hyperlipidemia|cholesterol	0	99.05	MicroSource	1503429	CLOFIBRATE	242.071	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	KNHUKKLJHYUCFP-UHFFFAOYSA-N	2796.0		KNHUKKLJHYUCFP
BRD-K45252063-001-14-4	clofibrate	Launched	PPAR receptor agonist	LPL|PPARA	endocrinology|cardiology	hyperlipidemia|cholesterol	0	0.0	Selleck	S1820	Clofibrate	242.071	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	KNHUKKLJHYUCFP-UHFFFAOYSA-N	2796.0		KNHUKKLJHYUCFP
BRD-K45252063-001-12-8	clofibrate	Launched	PPAR receptor agonist	LPL|PPARA	endocrinology|cardiology	hyperlipidemia|cholesterol	0	0.0	Selleck	S1820	Clofibrate (Atromid-S)	242.071	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	KNHUKKLJHYUCFP-UHFFFAOYSA-N	2796.0		KNHUKKLJHYUCFP
BRD-K19111024-001-20-9	clofibric-acid	Launched	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	0	98.95	MicroSource	1500195	CLOFIBRIC ACID	214.04	CC(C)(Oc1ccc(Cl)cc1)C(O)=O	TXCGAZHTZHNUAI-UHFFFAOYSA-N	2797.0		TXCGAZHTZHNUAI
BRD-K19111024-001-22-9	clofibric-acid	Launched	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	0	78.72	Tocris	825	Clofibric acid	214.04	CC(C)(Oc1ccc(Cl)cc1)C(O)=O	TXCGAZHTZHNUAI-UHFFFAOYSA-N	2797.0		TXCGAZHTZHNUAI
BRD-K19111024-001-19-1	clofibric-acid	Launched	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	0	96.53	Tocris	825	Clofibric acid	214.04	CC(C)(Oc1ccc(Cl)cc1)C(O)=O	TXCGAZHTZHNUAI-UHFFFAOYSA-N	2797.0		TXCGAZHTZHNUAI
BRD-K19111024-001-18-3	clofibric-acid	Launched	PPAR receptor agonist	PPARA	endocrinology	hyperlipidemia	0	91.2	Selleck	S4207	Clofibric Acid	214.04	CC(C)(Oc1ccc(Cl)cc1)C(O)=O	TXCGAZHTZHNUAI-UHFFFAOYSA-N	2797.0		TXCGAZHTZHNUAI
BRD-K02680176-075-12-9	clofilium	Phase 2	potassium channel blocker	KCNA5|KCNH1			0	39.14	Sigma	C2365	N-[4-(4-chlorophenyl)butyl]-N,N-diethyl-1-heptanaminium 4-methylbenzenesulfonate	338.261	CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1	WPSYTTKBGAZSCX-UHFFFAOYSA-N	2798.0		WPSYTTKBGAZSCX
BRD-K02680176-075-11-1	clofilium	Phase 2	potassium channel blocker	KCNA5|KCNH1			0	46.21	Prestwick	Prestw-319	Clofilium tosylate	338.261	CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1	WPSYTTKBGAZSCX-UHFFFAOYSA-N	2798.0		WPSYTTKBGAZSCX
BRD-K02900412-001-11-3	clofoctol	Launched	protein synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	97.9	Selleck	S4394	Clofoctol	364.136	CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1	HQVZOORKDNCGCK-UHFFFAOYSA-N	2799.0		HQVZOORKDNCGCK
BRD-K02900412-001-12-1	clofoctol	Launched	protein synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	95.89	MicroSource	1503206	CLOFOCTOL	364.136	CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1	HQVZOORKDNCGCK-UHFFFAOYSA-N	2799.0		HQVZOORKDNCGCK
BRD-K39230570-001-01-1	clomesone	Phase 1	DNA inhibitor				0	0.0	Enamine	Z2306534522	2-chloroethyl (methylsulfonyl)methanesulfonate	235.958	CS(=O)(=O)CS(=O)(=O)OCCCl	SEHSPJCWCBQHPF-UHFFFAOYSA-N	100651.0		SEHSPJCWCBQHPF
BRD-K50422030-003-02-6	clomethiazole	Launched	GABA receptor antagonist|GABA receptor modulator	GABRA1	neurology/psychiatry	Parkinson's Disease|sedative|muscle relaxant	0	0.0	Tocris	881	Chlormethiazole hydrochloride	161.007	Cc1ncsc1CCCl	PCLITLDOTJTVDJ-UHFFFAOYSA-N	10783.0		PCLITLDOTJTVDJ
BRD-K50422030-001-05-3	clomethiazole	Launched	GABA receptor antagonist|GABA receptor modulator	GABRA1	neurology/psychiatry	Parkinson's Disease|sedative|muscle relaxant	0	94.39	Enamine	EN300-60459		161.007	Cc1ncsc1CCCl	PCLITLDOTJTVDJ-UHFFFAOYSA-N	10783.0		PCLITLDOTJTVDJ
BRD-K29950728-048-17-4	clomifene	Launched	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	0	91.78	MicroSource	1500196	CLOMIPHENE CITRATE	405.186	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	GKIRPKYJQBWNGO-QPLCGJKRSA-N	1548955.0		GKIRPKYJQBWNGO
BRD-K29950728-048-16-6	clomifene	Launched	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	0	88.28	Selleck	S2561	Clomifene citrate	405.186	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	GKIRPKYJQBWNGO-QPLCGJKRSA-N	1548955.0		GKIRPKYJQBWNGO
BRD-K29950728-048-18-2	clomifene	Launched	estrogen receptor antagonist	ESR1	obstetrics/gynecology	infertility	0	94.27	Selleck	S2561	Clomifene citrate (Serophene)	405.186	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	GKIRPKYJQBWNGO-QPLCGJKRSA-N	1548955.0		GKIRPKYJQBWNGO
BRD-K52989797-003-28-0	clomipramine	Launched	serotonin transporter (SERT) inhibitor	GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	0	71.92	MicroSource	2300061	CLOMIPRAMINE HYDROCHLORIDE	314.155	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	GDLIGKIOYRNHDA-UHFFFAOYSA-N	2801.0		GDLIGKIOYRNHDA
BRD-K52989797-003-29-9	clomipramine	Launched	serotonin transporter (SERT) inhibitor	GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	0	94.52	Tocris	457	Clomipramine hydrochloride	314.155	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	GDLIGKIOYRNHDA-UHFFFAOYSA-N	2801.0		GDLIGKIOYRNHDA
BRD-K52989797-003-27-2	clomipramine	Launched	serotonin transporter (SERT) inhibitor	GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	0	90.32	Tocris	457	Clomipramine hydrochloride	314.155	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	GDLIGKIOYRNHDA-UHFFFAOYSA-N	2801.0		GDLIGKIOYRNHDA
BRD-K52989797-003-26-4	clomipramine	Launched	serotonin transporter (SERT) inhibitor	GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	0	93.06	Selleck	S2541	Clomipramine HCl	314.155	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	GDLIGKIOYRNHDA-UHFFFAOYSA-N	2801.0		GDLIGKIOYRNHDA
BRD-K98530306-003-18-3	clonidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)	0	99.61	MicroSource	1500198	CLONIDINE HYDROCHLORIDE	229.017	Clc1cccc(Cl)c1NC1=NCCN1 |t:10|	GJSURZIOUXUGAL-UHFFFAOYSA-N	2803.0		GJSURZIOUXUGAL
BRD-K98530306-003-22-9	clonidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)	0	91.18	Tocris	690	Clonidine hydrochloride	229.017	Clc1cccc(Cl)c1NC1=NCCN1 |t:10|	GJSURZIOUXUGAL-UHFFFAOYSA-N	2803.0		GJSURZIOUXUGAL
BRD-K98530306-003-17-5	clonidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)	0	99.29	Tocris	690	Clonidine hydrochloride	229.017	Clc1cccc(Cl)c1NC1=NCCN1 |t:10|	GJSURZIOUXUGAL-UHFFFAOYSA-N	2803.0		GJSURZIOUXUGAL
BRD-K98530306-003-16-7	clonidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	cardiology|neurology/psychiatry	hypertension|attention-deficit/hyperactivity disorder (ADHD)	0	97.61	Selleck	S2458	Clonidine HCl	229.017	Clc1cccc(Cl)c1NC1=NCCN1 |t:10|	GJSURZIOUXUGAL-UHFFFAOYSA-N	2803.0		GJSURZIOUXUGAL
BRD-K18399440-001-11-9	clonixin	Preclinical	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology|infectious disease	rheumatoid arthritis|soft tissue infection	0	97.7	CombiBlocks	OR-2783	Clonixin	262.051	Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	CLOMYZFHNHFSIQ-UHFFFAOYSA-N	28718.0		CLOMYZFHNHFSIQ
BRD-M63173034-001-03-6	clonixin-lysinate	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	1	86.5	Sigma	MFCD07364029	(2S)-2,6-diaminohexanoic acid compound with 2-(3-chloro-2-methylanilino)nicotinic acid (1:1)	408.156	NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	CVNFYQCHAWFYQI-ZSCHJXSPSA-N	9822751.0		CVNFYQCHAWFYQI
BRD-M63173034-001-02-8	clonixin-lysinate	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	1	0.0	Prestwick	Prestw-1104	Clonixin Lysinate	408.156	NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	CVNFYQCHAWFYQI-ZSCHJXSPSA-N	9822751.0		CVNFYQCHAWFYQI
BRD-K15567837-001-19-5	clopamide	Launched	sodium/chloride cotransporter inhibitor		cardiology	hypertension	0	98.33	Selleck	S4316	CLOPAMIDE	345.091	C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	LBXHRAWDUMTPSE-AOOOYVTPSA-N	12492.0		LBXHRAWDUMTPSE
BRD-A80908310-003-13-8	cloperastine	Launched	antitussive		pulmonary	cough suppressant	0	97.64	MicroSource	1503920	CLOPERASTINE HYDROCHLORIDE	329.155	Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|	FLNXBVJLPJNOSI-FQEVSTJZSA-N	688420.0		FLNXBVJLPJNOSI
BRD-A80908310-003-14-6	cloperastine	Launched	antitussive		pulmonary	cough suppressant	0	96.7	Selleck	S5479	CLOPERASTINE HYDROCHLORIDE	329.155	Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|	FLNXBVJLPJNOSI-FQEVSTJZSA-N	688420.0		FLNXBVJLPJNOSI
BRD-K00003529-458-01-9	cloperastine-fendizoate	Preclinical	potassium channel antagonist				0	96.07	MedChemEx	HY-B2179	Cloperastine fendizoate	329.155	Clc1ccc(cc1)C(OCCN1CCCCC1)c1ccccc1	FLNXBVJLPJNOSI-UHFFFAOYSA-N	2805.0		FLNXBVJLPJNOSI
BRD-K27721098-065-09-4	clopidogrel	Launched	purinergic receptor antagonist	P2RY12	cardiology|neurology/psychiatry	myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS)	0	72.42	MicroSource	1503710	CLOPIDOGREL SULFATE	321.059	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	GKTWGGQPFAXNFI-HNNXBMFYSA-N	60606.0		GKTWGGQPFAXNFI
BRD-K27721098-065-08-6	clopidogrel	Launched	purinergic receptor antagonist	P2RY12	cardiology|neurology/psychiatry	myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS)	0	81.96	Selleck	S1415	Clopidogrel	321.059	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	GKTWGGQPFAXNFI-HNNXBMFYSA-N	60606.0		GKTWGGQPFAXNFI
BRD-K27721098-065-10-2	clopidogrel	Launched	purinergic receptor antagonist	P2RY12	cardiology|neurology/psychiatry	myocardial infarction|stroke|peripheral artery disease (PAD)|acute coronary syndrome (ACS)	0	99.2	Selleck	S1415	Clopidogrel (Plavix)	321.059	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	GKTWGGQPFAXNFI-HNNXBMFYSA-N	60606.0		GKTWGGQPFAXNFI
BRD-K80036624-001-04-0	clopidol	Launched			infectious disease	coccidiosis	0	95.89	MicroSource	1505319	CLOPIDOL	190.99	Cc1[nH]c(C)c(Cl)c(=O)c1Cl	ZDPIZLCVJAAHHR-UHFFFAOYSA-N	18087.0		ZDPIZLCVJAAHHR
BRD-K80036624-001-06-9	clopidol	Launched			infectious disease	coccidiosis	0	97.05	MedChemEx	HY-B1088	Clopidol	190.99	Cc1[nH]c(C)c(Cl)c(=O)c1Cl	ZDPIZLCVJAAHHR-UHFFFAOYSA-N	18087.0		ZDPIZLCVJAAHHR
BRD-K17850764-236-11-9	cloprostenol-(+/-)	Launched	prostaglandin receptor agonist	PTGDR|PTGER1|PTGER3|PTGFR|TBXA2R	obstetrics/gynecology	endometriosis	0	93.34	Tocris	2295	(?)-Cloprostenol sodium salt	424.165	O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	VJGGHXVGBSZVMZ-QIZQQNKQSA-N	5311053.0		VJGGHXVGBSZVMZ
BRD-A04971881-003-01-3	cloranolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology	hypertension	0	97.23	Sigma	PH014015	1-(tert-butylamino)-3-(2,5-dichlorophenoxy)-2-propanol hydrochloride	291.079	CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|	XYCMOTOFHFTUIU-SNVBAGLBSA-N	76964677.0		XYCMOTOFHFTUIU
BRD-K73251053-003-21-4	clorgiline	Phase 2	monoamine oxidase inhibitor	MAOA			0	93.83	Selleck	S4317	Clorgyline HCl	271.053	CN(CCCOc1ccc(Cl)cc1Cl)CC#C	BTFHLQRNAMSNLC-UHFFFAOYSA-N	4380.0		BTFHLQRNAMSNLC
BRD-K73251053-003-22-2	clorgiline	Phase 2	monoamine oxidase inhibitor	MAOA			0	97.37	MicroSource	1506065	CLORGILINE HYDROCHLORIDE	271.053	CN(CCCOc1ccc(Cl)cc1Cl)CC#C	BTFHLQRNAMSNLC-UHFFFAOYSA-N	4380.0		BTFHLQRNAMSNLC
BRD-K73251053-003-23-9	clorgiline	Phase 2	monoamine oxidase inhibitor	MAOA			0	97.41	MedChemEx	HY-14197A	Clorgyline hydrochloride	271.053	CN(CCCOc1ccc(Cl)cc1Cl)CC#C	BTFHLQRNAMSNLC-UHFFFAOYSA-N	4380.0		BTFHLQRNAMSNLC
BRD-A19053834-050-09-5	clorotepine	Launched	adrenergic receptor antagonist|dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD2|HRH1|HTR2C|HTR6	neurology/psychiatry	psychosis	0	99.23	Sigma	MFCD00153855	(2Z)-2-butenedioic acid compound with 1-(8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-methylpiperazine (1:1)	344.111	CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|	XRYLGRGAWQSVQW-KRWDZBQOSA-N	12765746.0		XRYLGRGAWQSVQW
BRD-K01825579-003-03-9	clorprenaline	Launched	adrenergic receptor agonist	ADRB1|ADRB2	pulmonary	asthma	0	95.94	Selleck	S4135	Clorprenaline HCl	249.069	CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|	SSMSBSWKLKKXGG-LLVKDONJSA-N	12463921.0		SSMSBSWKLKKXGG
BRD-K97521363-001-16-1	clorsulon	Launched	glycolysis inhibitor		infectious disease	gastrointestinal roundworms|lungworms|liver flukes|lice|mites	0	99.05	MicroSource	1505115	CLORSULON	378.902	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	QOVTVIYTBRHADL-UHFFFAOYSA-N	43231.0		QOVTVIYTBRHADL
BRD-K97521363-001-17-9	clorsulon	Launched	glycolysis inhibitor		infectious disease	gastrointestinal roundworms|lungworms|liver flukes|lice|mites	0	98.87	MedChemEx	HY-B0488	Clorsulon	378.902	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	QOVTVIYTBRHADL-UHFFFAOYSA-N	43231.0		QOVTVIYTBRHADL
BRD-K97521363-001-15-3	clorsulon	Launched	glycolysis inhibitor		infectious disease	gastrointestinal roundworms|lungworms|liver flukes|lice|mites	0	96.72	Selleck	S2613	Clorsulon	378.902	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	QOVTVIYTBRHADL-UHFFFAOYSA-N	43231.0		QOVTVIYTBRHADL
BRD-K01825680-001-02-9	closantel	Launched	chitinase inhibitor|NFkB pathway inhibitor		infectious disease	liver flukes	0	95.75	MedChemEx	HY-17596	Closantel	661.852	Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|	JMPFSEBWVLAJKM-KRWDZBQOSA-N	72715766.0		JMPFSEBWVLAJKM
BRD-K01825680-236-01-9	closantel	Launched	chitinase inhibitor|NFkB pathway inhibitor		infectious disease	liver flukes	0	98.84	Selleck	S4105	Closantel Sodium	684.842	Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|	JMPFSEBWVLAJKM-KRWDZBQOSA-N	72715766.0		JMPFSEBWVLAJKM
BRD-K10990317-001-04-5	clotiapine	Launched			neurology/psychiatry	psychosis	0	98.82	Enzo	D108	Clothiapine	343.091	CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|	KAAZGXDPUNNEFN-UHFFFAOYSA-N	16351.0		KAAZGXDPUNNEFN
BRD-K15916496-001-29-5	clotrimazole	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis	0	95.04	Tocris	4096	Clotrimazole	344.108	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	VNFPBHJOKIVQEB-UHFFFAOYSA-N	2812.0		VNFPBHJOKIVQEB
BRD-K15916496-001-27-9	clotrimazole	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis	0	98.93	MicroSource	1500200	CLOTRIMAZOLE	344.108	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	VNFPBHJOKIVQEB-UHFFFAOYSA-N	2812.0		VNFPBHJOKIVQEB
BRD-K15916496-001-26-1	clotrimazole	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis	0	98.45	Selleck	S1606	Clotrimazole	344.108	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	VNFPBHJOKIVQEB-UHFFFAOYSA-N	2812.0		VNFPBHJOKIVQEB
BRD-K15916496-001-30-9	clotrimazole	Launched	cytochrome P450 inhibitor|imidazoline receptor ligand	CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8	infectious disease	vulvovaginal candidiasis|oropharyngeal candidiasis	0	97.61	Tocris	4096	Clotrimazole	344.108	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	VNFPBHJOKIVQEB-UHFFFAOYSA-N	2812.0		VNFPBHJOKIVQEB
BRD-K01244426-236-12-1	cloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	94.98	MicroSource	1500201	CLOXACILLIN SODIUM	435.066	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	LQOLIRLGBULYKD-JKIFEVAISA-N	6098.0		LQOLIRLGBULYKD
BRD-K01244426-323-14-9	cloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	85.96	MedChemEx	HY-B0466	Cloxacillin (sodium monohydrate)	435.066	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	LQOLIRLGBULYKD-JKIFEVAISA-N	6098.0		LQOLIRLGBULYKD
BRD-K01244426-323-07-7	cloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	91.2	Selleck	S2564	Cloxacillin sodium	435.066	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	LQOLIRLGBULYKD-JKIFEVAISA-N	6098.0		LQOLIRLGBULYKD
BRD-K01244426-323-08-5	cloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	79.89	Selleck	S2564	Cloxacillin Sodium	435.066	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	LQOLIRLGBULYKD-JKIFEVAISA-N	6098.0	BRD-K23933163-323-01-9	LQOLIRLGBULYKD
BRD-K46982791-001-10-9	cloxyquin	Preclinical	potassium channel activator	KCNK18			0	98.46	MedChemEx	HY-B0963	Cloxiquine	179.014	Oc1ccc(Cl)c2cccnc12	CTQMJYWDVABFRZ-UHFFFAOYSA-N	2817.0		CTQMJYWDVABFRZ
BRD-K46982791-001-09-4	cloxyquin	Preclinical	potassium channel activator	KCNK18			0	94.72	MicroSource	1500202	CLOXYQUIN	179.014	Oc1ccc(Cl)c2cccnc12	CTQMJYWDVABFRZ-UHFFFAOYSA-N	2817.0		CTQMJYWDVABFRZ
BRD-K37289225-001-36-4	clozapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	neurology/psychiatry	schizophrenia	0	95.42	MicroSource	1500685	CLOZAPINE	326.13	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|	QZUDBNBUXVUHMW-UHFFFAOYSA-N	135398737.0		QZUDBNBUXVUHMW
BRD-K37289225-001-34-9	clozapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	neurology/psychiatry	schizophrenia	0	87.66	Selleck	S2459	Clozapine	326.13	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|	QZUDBNBUXVUHMW-UHFFFAOYSA-N	135398737.0		QZUDBNBUXVUHMW
BRD-K37289225-001-35-6	clozapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	neurology/psychiatry	schizophrenia	0	93.29	Tocris	444	Clozapine	326.13	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|	QZUDBNBUXVUHMW-UHFFFAOYSA-N	135398737.0		QZUDBNBUXVUHMW
BRD-K37289225-001-37-2	clozapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	neurology/psychiatry	schizophrenia	0	90.86	Selleck	S2459	Clozapine (Clozaril)	326.13	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|	QZUDBNBUXVUHMW-UHFFFAOYSA-N	135398737.0		QZUDBNBUXVUHMW
BRD-K06467130-304-02-7	CL316243	Phase 2	adrenergic receptor agonist	ADRB3|UCP1|UCP2|UCP3			0	96.36	Tocris	1499	disodium 5-((2R)-2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}propyl)-1,3-benzodioxole-2,2-dicarboxylate	421.093	C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1	JEDJMKTVUPSHFW-ABAIWWIYSA-N	5486546.0		JEDJMKTVUPSHFW
BRD-K00003438-001-01-9	CM-4620	Phase 2	calcium release activated channel modulator				0	97.16	MedChemEx	HY-101942	CM-4620	421.044	Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl	QQMKTHUGOQDEIL-UHFFFAOYSA-N	122507647.0		QQMKTHUGOQDEIL
BRD-K54095730-001-04-9	CMPD-1	Preclinical	p38 MAPK inhibitor	GNRHR|MAPK14			0	77.87	Tocris	2186	CMPD-1	349.148	Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	ODYAQBDIXCVKAE-UHFFFAOYSA-N	11382492.0		ODYAQBDIXCVKAE
BRD-K54095730-001-03-1	CMPD-1	Preclinical	p38 MAPK inhibitor	GNRHR|MAPK14			0	96.43	Tocris	2186	CMPD-1	349.148	Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	ODYAQBDIXCVKAE-UHFFFAOYSA-N	11382492.0		ODYAQBDIXCVKAE
BRD-K19438463-304-01-2	CNQX	Phase 1	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	96.68	Tocris	1045	CNQX disodium salt	232.023	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	RPXVIAFEQBNEAX-UHFFFAOYSA-N	3721046.0		RPXVIAFEQBNEAX
BRD-K19438463-001-05-5	CNQX	Phase 1	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	97.7	Tocris	190	CNQX	232.023	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	RPXVIAFEQBNEAX-UHFFFAOYSA-N	3721046.0		RPXVIAFEQBNEAX
BRD-K19438463-001-06-9	CNQX	Phase 1	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	94.56	Tocris	190	CNQX	232.023	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	RPXVIAFEQBNEAX-UHFFFAOYSA-N	3721046.0		RPXVIAFEQBNEAX
BRD-K24869513-001-02-1	CNX-2006	Preclinical	EGFR inhibitor	EGFR			0	88.48	MedChemEx	HY-13897	CNX-2006	545.216	COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	BFSRTTWIPACGMI-UHFFFAOYSA-N	56968072.0		BFSRTTWIPACGMI
BRD-K24869513-001-03-9	CNX-2006	Preclinical	EGFR inhibitor	EGFR			0	95.62	MedChemEx	HY-13897	CNX-2006	545.216	COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	BFSRTTWIPACGMI-UHFFFAOYSA-N	56968072.0		BFSRTTWIPACGMI
BRD-K48443249-001-02-9	CNX-774	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	94.96	MedChemEx	HY-13943	CNX-774	499.177	CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	VVLHQJDAUIPZFH-UHFFFAOYSA-N	59174579.0		VVLHQJDAUIPZFH
BRD-K48443249-001-01-0	CNX-774	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	96.11	Selleck	S7257	CNX-774	499.177	CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	VVLHQJDAUIPZFH-UHFFFAOYSA-N	59174579.0		VVLHQJDAUIPZFH
BRD-K55677650-003-03-7	CO-101244	Preclinical	glutamate receptor antagonist	GRIN2B			0	93.39	Tocris	2456	Co 101244 hydrochloride	341.199	Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	VKMFDKYCIKEDMR-UHFFFAOYSA-N	6918409.0		VKMFDKYCIKEDMR
BRD-K55677650-003-02-9	CO-101244	Preclinical	glutamate receptor antagonist	GRIN2B			0	94.77	Tocris	2456	Co 101244 hydrochloride	341.199	Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	VKMFDKYCIKEDMR-UHFFFAOYSA-N	6918409.0		VKMFDKYCIKEDMR
BRD-K55677650-003-04-9	CO-101244	Preclinical	glutamate receptor antagonist	GRIN2B			0	96.6	Tocris	2456	Co 101244 hydrochloride	341.199	Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	VKMFDKYCIKEDMR-UHFFFAOYSA-N	6918409.0		VKMFDKYCIKEDMR
BRD-K70912147-001-01-8	CO-102862	Phase 1	sodium channel blocker	SCN4A|SCN9A			0	97.69	Tocris	2642	Co 102862	273.091	NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1	MHUUDVZSPFRUSK-RQZCQDPDSA-N	9816959.0		MHUUDVZSPFRUSK
BRD-K51040301-001-03-9	cobicistat	Launched	cytochrome P450 inhibitor	CYP3A4|CYP3A43|CYP3A5|CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	0	93.59	MedChemEx	HY-10493	Cobicistat	775.355	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	ZCIGNRJZKPOIKD-CQXVEOKZSA-N	25151504.0		ZCIGNRJZKPOIKD
BRD-K51040301-001-02-1	cobicistat	Launched	cytochrome P450 inhibitor	CYP3A4|CYP3A43|CYP3A5|CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	0	95.36	Selleck	S2900	Cobicistat (GS-9350)	775.355	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	ZCIGNRJZKPOIKD-CQXVEOKZSA-N	25151504.0		ZCIGNRJZKPOIKD
BRD-K03390685-001-01-7	cobimetinib	Launched	MEK inhibitor	MAP2K1	oncology	melanoma	0	91.82	MedChemEx	HY-13064	Cobimetinib	531.063	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	BSMCAPRUBJMWDF-KRWDZBQOSA-N	16222096.0		BSMCAPRUBJMWDF
BRD-K03390685-001-03-9	cobimetinib	Launched	MEK inhibitor	MAP2K1	oncology	melanoma	0	95.46	MedChemEx	HY-13064	Cobimetinib	531.063	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	BSMCAPRUBJMWDF-KRWDZBQOSA-N	16222096.0		BSMCAPRUBJMWDF
BRD-A67956599-002-01-3	coenzyme-A	Launched		ACAT2|CRAT|CS|DBI|HMGCR|KAT2A|KAT2B|KAT5			0	0.0	ChemImpex	644	Coenzyme A hydrate	767.115	CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14,16,17,19,35,&1:5,&2:9|	RGJOEKWQDUBAIZ-IBOSZNHHSA-N	87642.0		RGJOEKWQDUBAIZ
BRD-K01825730-304-02-9	coenzyme-I	Phase 2		AASS|ACADS|ADH1A|ADH1B|ADH1C|ADH4|ADH5|ADH7|AKR1B1|AKR1C1|AKR1C2|AKR1C3|AKR1C4|ALDH1A1|ALDH1A2|ALDH1A3|ALDH1B1|ALDH2|ALDH3A1|ALDH3A2|ALDH3B1|ALDH3B2|ALDH4A1|ALDH5A1|ALDH6A1|ALDH7A1|ALDH9A1|AMT|BDH1|BLVRA|BLVRB|CDO1|CYB5R3|CYP17A1|CYP4A11|DHCR7|DHFR|DLAT|DLD|EHHADH|GAPDH|GAPDHS|GLUD1|GLUD2|GPD1|GSR|H6PD|HADH|HADHA|HIBADH|HMGCR|HMOX1|HMOX2|HPGD|HSD11B1|HSD11B2|HSD17B1|HSD17B10|HSD17B2|HSD17B3|HSD17B4|HSD17B7|HSD17B8|HSD3B1|HSD3B2|IDH3A|IDH3B|IDH3G|IMPDH1|IMPDH2|LDHA|LDHAL6A|LDHAL6B|LDHB|LDHC|MDH1|MDH2|ME1|ME2|ME3|MSMO1|MT-ND1|MT-ND2|MT-ND3|MT-ND4|MT-ND4L|MT-ND5|MT-ND6|MTHFD1|MTHFD2|NDUFA1|NDUFA10|NDUFA11|NDUFA12|NDUFA13|NDUFA2|NDUFA3|NDUFA4|NDUFA4L2|NDUFA5|NDUFA6|NDUFA7|NDUFA8|NDUFA9|NDUFAB1|NDUFB1|NDUFB10|NDUFB2|NDUFB3|NDUFB4|NDUFB5|NDUFB6|NDUFB7|NDUFB8|NDUFB9|NDUFC1|NDUFC2|NDUFS1|NDUFS2|NDUFS3|NDUFS4|NDUFS5|NDUFS6|NDUFS7|NDUFS8|NDUFV1|NDUFV2|NDUFV3|NNT|NQO2|NSDHL|OGDH|PDHA1|PDHA2|PDHB|PHGDH|PYCR1|PYCR2|QDPR|RDH5|SORD|TSTA3|TYR|UGDH			0	0.0	Apollo	BIB3012		711.104	NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|	BOPGDPNILDQYTO-NNYOXOHSSA-N	439153.0		BOPGDPNILDQYTO
BRD-K01825730-304-01-9	coenzyme-I	Phase 2		AASS|ACADS|ADH1A|ADH1B|ADH1C|ADH4|ADH5|ADH7|AKR1B1|AKR1C1|AKR1C2|AKR1C3|AKR1C4|ALDH1A1|ALDH1A2|ALDH1A3|ALDH1B1|ALDH2|ALDH3A1|ALDH3A2|ALDH3B1|ALDH3B2|ALDH4A1|ALDH5A1|ALDH6A1|ALDH7A1|ALDH9A1|AMT|BDH1|BLVRA|BLVRB|CDO1|CYB5R3|CYP17A1|CYP4A11|DHCR7|DHFR|DLAT|DLD|EHHADH|GAPDH|GAPDHS|GLUD1|GLUD2|GPD1|GSR|H6PD|HADH|HADHA|HIBADH|HMGCR|HMOX1|HMOX2|HPGD|HSD11B1|HSD11B2|HSD17B1|HSD17B10|HSD17B2|HSD17B3|HSD17B4|HSD17B7|HSD17B8|HSD3B1|HSD3B2|IDH3A|IDH3B|IDH3G|IMPDH1|IMPDH2|LDHA|LDHAL6A|LDHAL6B|LDHB|LDHC|MDH1|MDH2|ME1|ME2|ME3|MSMO1|MT-ND1|MT-ND2|MT-ND3|MT-ND4|MT-ND4L|MT-ND5|MT-ND6|MTHFD1|MTHFD2|NDUFA1|NDUFA10|NDUFA11|NDUFA12|NDUFA13|NDUFA2|NDUFA3|NDUFA4|NDUFA4L2|NDUFA5|NDUFA6|NDUFA7|NDUFA8|NDUFA9|NDUFAB1|NDUFB1|NDUFB10|NDUFB2|NDUFB3|NDUFB4|NDUFB5|NDUFB6|NDUFB7|NDUFB8|NDUFB9|NDUFC1|NDUFC2|NDUFS1|NDUFS2|NDUFS3|NDUFS4|NDUFS5|NDUFS6|NDUFS7|NDUFS8|NDUFV1|NDUFV2|NDUFV3|NNT|NQO2|NSDHL|OGDH|PDHA1|PDHA2|PDHB|PHGDH|PYCR1|PYCR2|QDPR|RDH5|SORD|TSTA3|TYR|UGDH			0	0.0	SantaCruz	sc-215562		711.104	NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18,c:6,t:3|	BOPGDPNILDQYTO-NNYOXOHSSA-N	439153.0	BRD-A45839132-304-01-2	BOPGDPNILDQYTO
BRD-K75043328-001-05-9	coenzyme-Q10	Launched					0	0.0	Sigma	MFCD00042919	2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methylbenzo-1,4-quinone	862.684	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|	ACTIUHUUMQJHFO-UPTCCGCDSA-N	5281915.0		ACTIUHUUMQJHFO
BRD-K75043328-001-04-2	coenzyme-Q10	Launched					0	0.0	Selleck	S2398	Coenzyme Q10(CoQ10)	862.684	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|	ACTIUHUUMQJHFO-UPTCCGCDSA-N	5281915.0		ACTIUHUUMQJHFO
BRD-K75043328-001-03-4	coenzyme-Q10	Launched					0	0.0	Selleck	S2398	Coenzyme Q10 (CoQ10)	862.684	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2,t:58|	ACTIUHUUMQJHFO-UPTCCGCDSA-N	5281915.0		ACTIUHUUMQJHFO
BRD-K00003307-001-01-9	COH29	Phase 1	ribonucleotide reductase inhibitor				0	74.48	MedChemEx	HY-19931	COH29	420.078	Oc1ccc(cc1O)C(=O)Nc1nc(c(s1)-c1ccccc1)-c1ccc(O)c(O)c1	LGGDLPSXAGQFSG-UHFFFAOYSA-N	44253415.0		LGGDLPSXAGQFSG
BRD-K00259736-001-16-4	colchicine	Launched	microtubule inhibitor	GLRA1|GLRA2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	rheumatology|endocrinology	gout|fever	0	96.57	MicroSource	1500205	COLCHICINE	399.168	COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC	IAKHMKGGTNLKSZ-INIZCTEOSA-N	6167.0		IAKHMKGGTNLKSZ
BRD-K00259736-001-18-0	colchicine	Launched	microtubule inhibitor	GLRA1|GLRA2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	rheumatology|endocrinology	gout|fever	0	93.41	Tocris	1364	Colchicine	399.168	COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC	IAKHMKGGTNLKSZ-INIZCTEOSA-N	6167.0	BRD-A46684810-001-12-9	IAKHMKGGTNLKSZ
BRD-A55416093-001-06-4	colforsin	Phase 2	adenylyl cyclase activator	ADCY2|ADCY5			0	100.0	MicroSource	1503804	COLFORSIN	410.23	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4,5,13,15,17,22,25,&1:7|	OHCQJHSOBUTRHG-KGGHGJDLSA-N	47936.0		OHCQJHSOBUTRHG
BRD-K19388745-003-01-7	colforsin-daproate	Launched	adenylyl cyclase activator				0	100.0	EMDBio	344281-5MG	Forskolin, NKH477	509.299	CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C	RSOZZQTUMVBTMR-XGUNBQNXSA-N	444029.0		RSOZZQTUMVBTMR
BRD-K01825113-001-02-9	colfosceril-palmitate	Launched	pulmonary surfactant		pulmonary	respiratory distress syndrome (RDS)	0	0.0	Acros	24057		734.57	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|	KILNVBDSWZSGLL-KXQOOQHDSA-O	160339.0		KILNVBDSWZSGLL
BRD-K01825113-001-03-9	colfosceril-palmitate	Launched	pulmonary surfactant		pulmonary	respiratory distress syndrome (RDS)	0	0.0	Sigma	MFCD00036903	(R)-2,3-bis(palmitoyloxy)propyl 2-(trimethylammonio)ethyl phosphate	734.57	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19,&1:22|	KILNVBDSWZSGLL-KXQOOQHDSA-O	160339.0		KILNVBDSWZSGLL
BRD-K01666924-319-01-9	colistimethate	Launched	bacterial permeability inducer		infectious disease	gram-negative bacterial infections	0	0.0	USP	1147009		1610.597	[H][C@@](CCNCS(O)(=O)=O)(NC(=O)CCCC(C)C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@]([H])(CCNCS(O)(=O)=O)C(=O)N[C@@]1([H])CCNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O	PTQGBRPUALXNCZ-INRRNNIXSA-N		BRD-K01666924-001-01-9	PTQGBRPUALXNCZ
BRD-K01666935-065-02-9	colistin	Launched	bacterial permeability inducer		infectious disease	gram-negative bacterial infections|gram-negative bacterial infections	0	66.4	MedChemEx	HY-A0089	Colistin (sulfate)	1,154.75	CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|	YKQOSKADJPQZHB-TULBBYNTSA-N			YKQOSKADJPQZHB
BRD-K01666935-326-01-9	colistin	Launched	bacterial permeability inducer		infectious disease	gram-negative bacterial infections|gram-negative bacterial infections	0	74.4	Selleck	S4029	Colistin Sulfate	1,448.65	CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10,17,18,24,31,37,41,48,55,63,71,78,&1:2|	YKQOSKADJPQZHB-TULBBYNTSA-N			YKQOSKADJPQZHB
BRD-K61195623-001-02-9	combretastatin-A-4	Phase 2	tubulin polymerization inhibitor				0	97.9	MedChemEx	HY-N2146	Combretastatin A4	316.131	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O	HVXBOLULGPECHP-WAYWQWQTSA-N	5351344.0		HVXBOLULGPECHP
BRD-K61195623-001-01-4	combretastatin-A-4	Phase 2	tubulin polymerization inhibitor				0	87.15	ChemDiv	8020-3786		316.131	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O	HVXBOLULGPECHP-WAYWQWQTSA-N	5351344.0		HVXBOLULGPECHP
BRD-K98143539-001-02-2	compound-w	Preclinical	beta-secretase inhibitor	BACE1			0	98.85	Tocris	2654	Compound W	396.059	OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1	JOSXKPZXMVHRKU-UHFFFAOYSA-N	16760376.0		JOSXKPZXMVHRKU
BRD-K98143539-001-03-9	compound-w	Preclinical	beta-secretase inhibitor	BACE1			0	97.26	Tocris	2654	Compound W	396.059	OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1	JOSXKPZXMVHRKU-UHFFFAOYSA-N	16760376.0		JOSXKPZXMVHRKU
BRD-K19655798-001-01-9	compound-401	Preclinical	DNA dependent protein kinase inhibitor	MTOR|PRKDC			0	99.02	Tocris	3271	Compound 401	281.116	O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1	BVRDQVRQVGRNHG-UHFFFAOYSA-N	10039361.0		BVRDQVRQVGRNHG
BRD-K19655798-001-02-9	compound-401	Preclinical	DNA dependent protein kinase inhibitor	MTOR|PRKDC			0	96.07	Tocris	3271	Compound 401	281.116	O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1	BVRDQVRQVGRNHG-UHFFFAOYSA-N	10039361.0		BVRDQVRQVGRNHG
BRD-K76139886-003-01-3	compound-58112	Preclinical					0	97.83	Sigma	MFCD10465434	4-(3-methoxybenzyl)-2,2,6,6-tetramethyl-1,4,2,6-oxazadisilinane hydrochloride	295.142	COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1	CUYLJVJMQPPTOS-UHFFFAOYSA-N	155931.0		CUYLJVJMQPPTOS
BRD-K37385792-003-03-9	conivaptan	Launched	vasopressin receptor antagonist	AVPR1A|AVPR2	endocrinology	hyponatremia	0	99.33	MedChemEx	HY-18347A	Conivaptan (hydrochloride)	498.206	Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1	IKENVDNFQMCRTR-UHFFFAOYSA-N	151171.0		IKENVDNFQMCRTR
BRD-K37385792-003-02-1	conivaptan	Launched	vasopressin receptor antagonist	AVPR1A|AVPR2	endocrinology	hyponatremia	0	98.26	Selleck	S2116	Conivaptan HCl	498.206	Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1	IKENVDNFQMCRTR-UHFFFAOYSA-N	151171.0		IKENVDNFQMCRTR
BRD-K00004559-001-01-9	convallatoxin	Preclinical	cardiac glycoside				0	78.4	Sigma	MFCD00069477	Convallatoxin	550.278	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:31|	HULMNSIAKWANQO-JQKSAQOKSA-N	441852.0		HULMNSIAKWANQO
BRD-K24666289-001-02-3	copanlisib	Launched	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG	hematologic malignancy	follicular lymphoma	0	70.27	MedChemEx	HY-15346	BAY 80-6946	480.223	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|	PZBCKZWLPGJMAO-UHFFFAOYSA-N			PZBCKZWLPGJMAO
BRD-K24666289-001-04-9	copanlisib	Launched	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG	hematologic malignancy	follicular lymphoma	0	97.22	MedChemEx	HY-15346	BAY 80-6946	480.223	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|	PZBCKZWLPGJMAO-UHFFFAOYSA-N			PZBCKZWLPGJMAO
BRD-K24666289-001-05-9	copanlisib	Launched	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG	hematologic malignancy	follicular lymphoma	0	74.15	MedChemEx	HY-15346	Copanlisib	480.223	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35,t:18|	PZBCKZWLPGJMAO-UHFFFAOYSA-N			PZBCKZWLPGJMAO
BRD-K36449075-001-01-0	copper-histidine	Phase 3		SLC15A3|SLC15A4|SLC38A5			0	93.67	Enzo	AC1014	D-Histidine	155.069	N[C@H](Cc1cnc[nH]1)C(O)=O	HNDVDQJCIGZPNO-RXMQYKEDSA-N	71083.0		HNDVDQJCIGZPNO
BRD-K36449075-001-02-9	copper-histidine	Phase 3		SLC15A3|SLC15A4|SLC38A5			0	100.0	Vitas-M	STL141076	D-histidine	155.069	N[C@H](Cc1cnc[nH]1)C(O)=O	HNDVDQJCIGZPNO-RXMQYKEDSA-N	71083.0		HNDVDQJCIGZPNO
BRD-K74965187-001-02-9	COR-170	Preclinical	cannabinoid receptor inverse agonist	CNR2			0	96.93	Tocris	4756	COR 170	468.278	CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1	MSJISJDTJJYBFT-UHFFFAOYSA-N	25033736.0		MSJISJDTJJYBFT
BRD-K74965187-001-01-3	COR-170	Preclinical	cannabinoid receptor inverse agonist	CNR2			0	98.6	Tocris	4756	COR 170	468.278	CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1	MSJISJDTJJYBFT-UHFFFAOYSA-N	25033736.0		MSJISJDTJJYBFT
BRD-K65428967-001-09-2	cordycepin	Phase 1/Phase 2	DNA inhibitor				0	95.42	Tocris	2294	Cordycepin	251.102	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	OFEZSBMBBKLLBJ-BAJZRUMYSA-N	6303.0		OFEZSBMBBKLLBJ
BRD-K65428967-001-08-4	cordycepin	Phase 1/Phase 2	DNA inhibitor				0	98.83	Tocris	2294	Cordycepin	251.102	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	OFEZSBMBBKLLBJ-BAJZRUMYSA-N	6303.0		OFEZSBMBBKLLBJ
BRD-K65428967-001-10-9	cordycepin	Phase 1/Phase 2	DNA inhibitor				0	98.07	Tocris	2294	Cordycepin	251.102	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	OFEZSBMBBKLLBJ-BAJZRUMYSA-N	6303.0		OFEZSBMBBKLLBJ
BRD-K27885593-001-06-8	corosolic-acid	Phase 2	PKC inhibitor|protein tyrosine kinase inhibitor	HSD11B1|PTPN1			0	96.17	MedChemEx	HY-N0280	Corosolic acid	472.355	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	HFGSQOYIOKBQOW-ZSDYHTTISA-N	6918774.0		HFGSQOYIOKBQOW
BRD-K00004700-001-01-9	CORT-108297	Preclinical	glucocorticoid receptor antagonist				0	79.93	AMS	L13976	CORT-108297	535.155	CCOC[C@@]12CN(CCC1=Cc1c(C2)cnn1-c1ccc(F)cc1)S(=O)(=O)c1ccc(cc1)C(F)(F)F |c:10|	SLKURXRZHJOZOD-RUZDIDTESA-N	44454750.0		SLKURXRZHJOZOD
BRD-K73589401-001-25-1	corticosterone	Preclinical	mineralocorticoid receptor agonist	HSD11B1|NCOA1|NR3C2			0	79.65	Tocris	3685	Corticosterone	346.214	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|	OMFXVFTZEKFJBZ-HJTSIMOOSA-N	5753.0		OMFXVFTZEKFJBZ
BRD-K73589401-001-23-6	corticosterone	Preclinical	mineralocorticoid receptor agonist	HSD11B1|NCOA1|NR3C2			0	98.1	Prestwick	Prestw-432	Corticosterone	346.214	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|	OMFXVFTZEKFJBZ-HJTSIMOOSA-N	5753.0		OMFXVFTZEKFJBZ
BRD-K73589401-001-26-9	corticosterone	Preclinical	mineralocorticoid receptor agonist	HSD11B1|NCOA1|NR3C2			0	93.5	Tocris	3685	Corticosterone	346.214	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|	OMFXVFTZEKFJBZ-HJTSIMOOSA-N	5753.0		OMFXVFTZEKFJBZ
BRD-K00025572-001-01-9	cortisone	Launched	glucocorticoid receptor agonist	NR3C1	gastroenterology|rheumatology|dermatology	ulcerative colitis|rheumatoid arthritis|psoriasis|joint inflammation|eczema	0	93.34	Sigma	C2755-250MG		360.194	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	MFYSYFVPBJMHGN-ZPOLXVRWSA-N	222786.0	BRD-A00025572-001-01-9	MFYSYFVPBJMHGN
BRD-K86161929-001-13-3	cortisone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease	asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis	0	94.14	MicroSource	1500207	CORTISONE ACETATE	402.204	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|	ITRJWOMZKQRYTA-RFZYENFJSA-N	5745.0	BRD-A54487287-001-04-7	ITRJWOMZKQRYTA
BRD-K86161929-001-11-7	cortisone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease	asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis	0	87.13	Selleck	S2559	Cortisone acetate (Cortone)	402.204	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|	ITRJWOMZKQRYTA-RFZYENFJSA-N	5745.0		ITRJWOMZKQRYTA
BRD-K86161929-001-12-5	cortisone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease	asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis	0	82.18	Selleck	S2559	Cortisone acetate	402.204	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|	ITRJWOMZKQRYTA-RFZYENFJSA-N	5745.0	BRD-K83872210-001-01-1	ITRJWOMZKQRYTA
BRD-K86161929-001-15-9	cortisone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	pulmonary|rheumatology|allergy|dermatology|ophthalmology|gastroenterology|infectious disease	asthma|rheumatoid arthritis|urticaria|osteoarthritis|psoriasis|allergic rhinitis|conjunctivitis|ulcerative colitis|meningitis	0	91.19	MedChemEx	HY-17461A	Cortisone (acetate)	402.204	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|	ITRJWOMZKQRYTA-RFZYENFJSA-N	5745.0		ITRJWOMZKQRYTA
BRD-K32891457-001-16-3	cortodoxone	Phase 3	androgen receptor antagonist	AR			0	86.88	MedChemEx	HY-77839	Cortodoxone	346.214	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|	WHBHBVVOGNECLV-OBQKJFGGSA-N	440707.0		WHBHBVVOGNECLV
BRD-K32891457-001-15-5	cortodoxone	Phase 3	androgen receptor antagonist	AR			0	94.37	Sigma	MFCD00003662	17,21-dihydroxypregn-4-ene-3,20-dione	346.214	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|	WHBHBVVOGNECLV-OBQKJFGGSA-N	440707.0		WHBHBVVOGNECLV
BRD-K26833429-001-04-4	costunolide	Preclinical	telomerase inhibitor				0	79.55	Selleck	S1319	Costunolide	232.146	C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|	HRYLQFBHBWLLLL-AHNJNIBGSA-N	5281437.0	BRD-K44887666-001-02-4	HRYLQFBHBWLLLL
BRD-K26833429-001-03-6	costunolide	Preclinical	telomerase inhibitor				0	56.06	Tocris	2483	Costunolide	232.146	C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|	HRYLQFBHBWLLLL-AHNJNIBGSA-N	5281437.0		HRYLQFBHBWLLLL
BRD-K26833429-001-07-9	costunolide	Preclinical	telomerase inhibitor				0	71.46	Tocris	2483	Costunolide	232.146	C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|	HRYLQFBHBWLLLL-AHNJNIBGSA-N	5281437.0		HRYLQFBHBWLLLL
BRD-K26833429-001-02-8	costunolide	Preclinical	telomerase inhibitor				0	89.25	Selleck	S1319	Costunolide	232.146	C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1,t:6|	HRYLQFBHBWLLLL-AHNJNIBGSA-N	5281437.0		HRYLQFBHBWLLLL
BRD-K98710228-001-01-6	cot-inhibitor-1	Preclinical	MAPK-interacting kinase inhibitor	MAP3K8			0	90.4	MedChemEx	HY-32015	Cot inhibitor-1	552.172	Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl	ZWFKJFUFYPOTKL-UHFFFAOYSA-N	11584834.0		ZWFKJFUFYPOTKL
BRD-K49468759-001-05-9	cot-inhibitor-2	Preclinical	MAPK-interacting kinase inhibitor	MAP3K8			0	88.06	MedChemEx	HY-32018	Cot inhibitor-2	538.156	CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1	PHNZIIMWDVXPGG-UHFFFAOYSA-N	44143370.0		PHNZIIMWDVXPGG
BRD-K49468759-001-04-2	cot-inhibitor-2	Preclinical	MAPK-interacting kinase inhibitor	MAP3K8			0	93.1	MedChemEx	HY-32018	Cot inhibitor-2	538.156	CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1	PHNZIIMWDVXPGG-UHFFFAOYSA-N	44143370.0		PHNZIIMWDVXPGG
BRD-K00003348-001-01-9	COTI-2	Phase 1	anticancer agent				0	45.94	MedChemEx	HY-19896	COTI-2	366.163	S=C(N\N=C1/CCCc2cccnc12)N1CCN(CC1)c1ccccn1	UTDAKQMBNSHJJB-CJLVFECKSA-N	91810660.0		UTDAKQMBNSHJJB
BRD-K94144010-001-14-9	cotinine	Phase 2	nicotine metabolite				0	91.69	MedChemEx	HY-B1178	Cotinine	176.095	CN1[C@@H](CCC1=O)c1cccnc1	UIKROCXWUNQSPJ-VIFPVBQESA-N	854019.0		UIKROCXWUNQSPJ
BRD-K94144010-001-13-9	cotinine	Phase 2	nicotine metabolite				0	97.89	MicroSource	1500208	COTININE	176.095	CN1[C@@H](CCC1=O)c1cccnc1	UIKROCXWUNQSPJ-VIFPVBQESA-N	854019.0		UIKROCXWUNQSPJ
BRD-K23913458-001-20-7	coumarin	Launched	vitamin K antagonist	CA1|CA12|CA14|CA2|CA4|CA6|CA9|CYP2A6	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease	0	99.45	MicroSource	1400208	COUMARIN	146.037	O=c1ccc2ccccc2o1	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	323.0		ZYGHJZDHTFUPRJ
BRD-K23913458-001-19-9	coumarin	Launched	vitamin K antagonist	CA1|CA12|CA14|CA2|CA4|CA6|CA9|CYP2A6	gastroenterology|pulmonary	ulcerative colitis|asthma|celiac disease	0	97.12	Selleck	S4170	Coumarin	146.037	O=c1ccc2ccccc2o1	ZYGHJZDHTFUPRJ-UHFFFAOYSA-N	323.0		ZYGHJZDHTFUPRJ
BRD-K41567533-001-08-3	coumophos	Preclinical	cholinesterase inhibitor				0	89.12	MicroSource	330012	COUMOPHOS	362.014	CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1	BXNANOICGRISHX-UHFFFAOYSA-N	2871.0		BXNANOICGRISHX
BRD-K41567533-001-11-9	coumophos	Preclinical	cholinesterase inhibitor				0	88.98	Sigma	MFCD00041820	Coumaphos	362.014	CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1	BXNANOICGRISHX-UHFFFAOYSA-N	2871.0		BXNANOICGRISHX
BRD-K00004654-001-01-9	CP-105,696	Preclinical	leukotriene receptor antagonist				0	97.8	Sigma	PZ0363	1-((3S,4R)-3-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxychroman-7-yl)cyclopentane-1-carboxylic acid	428.199	O[C@@H]1[C@@H](Cc2ccc(cc2)-c2ccccc2)COc2cc(ccc12)C1(CCCC1)C(O)=O	KMNLXCBYBKHKSK-BKMJKUGQSA-N	9867257.0		KMNLXCBYBKHKSK
BRD-K53913008-001-01-5	CP-316819	Preclinical	glycogen phosphorylase inhibitor	PYGL			0	95.8	Tocris	3542	CP 316819	415.13	CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	WEQLRDLTRCEUHG-PKOBYXMFSA-N	10273347.0		WEQLRDLTRCEUHG
BRD-K53913008-001-02-9	CP-316819	Preclinical	glycogen phosphorylase inhibitor	PYGL			0	96.53	Tocris	3542	CP 316819	415.13	CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	WEQLRDLTRCEUHG-PKOBYXMFSA-N	10273347.0		WEQLRDLTRCEUHG
BRD-K00004233-003-01-9	CP-339818	Preclinical	potassium channel blocker	KCNA3			0	98.69	Tocris	1399	CP 339818 hydrochloride	304.194	CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12	MMGAVKCAGQCFHS-LSDHQDQOSA-N			MMGAVKCAGQCFHS
BRD-K31394475-001-01-9	CP-376395	Phase 1	corticotropin releasing factor receptor antagonist	CRHR1			0	98.61	Key	GD-0065	N-(1-ethylpropyl)-2-(mesityloxy)-3,6-dimethyl-4-pyridinamine	326.236	CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C	VIZBSVDBNLAVAW-UHFFFAOYSA-N	9862166.0		VIZBSVDBNLAVAW
BRD-K31394475-003-01-5	CP-376395	Phase 1	corticotropin releasing factor receptor antagonist	CRHR1			0	97.61	Tocris	3212	CP 376395 hydrochloride	326.236	CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C	VIZBSVDBNLAVAW-UHFFFAOYSA-N	9862166.0		VIZBSVDBNLAVAW
BRD-K33234937-001-01-7	CP-471474	Preclinical	matrix metalloprotease inhibitor	MMP1|MMP13|MMP2|MMP3|MMP9			0	89.85	Tocris	3780	CP 471474	368.084	CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO	QCOQJYRPDUMCNP-UHFFFAOYSA-N	9907286.0		QCOQJYRPDUMCNP
BRD-K33234937-001-02-9	CP-471474	Preclinical	matrix metalloprotease inhibitor	MMP1|MMP13|MMP2|MMP3|MMP9			0	93.4	Tocris	3780	CP 471474	368.084	CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO	QCOQJYRPDUMCNP-UHFFFAOYSA-N	9907286.0		QCOQJYRPDUMCNP
BRD-K36611520-001-01-6	CP-532623	Phase 1	cholesteryl ester transfer protein inhibitor	CETP			0	98.71	Sigma	PZ0225	isopropyl (2R,4S)-4-(N-(3,5-bis(trifluoromethyl)benzyl)acetamido)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	598.188	CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F	TUPKOWFPVAXQFP-OFNKIYASSA-N	10145345.0		TUPKOWFPVAXQFP
BRD-K00004719-001-01-9	CP-547632	Phase 2	kinase inhibitor				0	88.53	Cayman	21773	3-[(4-bromo-2,6-difluorobenzyl)oxy]-5-[({[4-(1-pyrrolidinyl)butyl]amino}carbonyl)amino]-4-isothiazolecarboxamide	531.075	NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc1c(F)cc(Br)cc1F	HXHAJRMTJXHJJZ-UHFFFAOYSA-N	9811611.0		HXHAJRMTJXHJJZ
BRD-K26921335-003-01-2	CP-640186	Preclinical	acetyl-CoA carboxylase inhibitor	ACACA|ACACB			0	91.31	MedChemEx	HY-15259A	CP-640186 (hydrochloride)	485.268	O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1	LDQKDRLEMKIYMC-XMMPIXPASA-N	449097.0		LDQKDRLEMKIYMC
BRD-K43621685-001-05-9	CP-673451	Preclinical	PDGFR tyrosine kinase receptor inhibitor	KIT|PDGFRA|PDGFRB			0	94.46	Tocris	5993	CP 673451	417.216	COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	DEEOXSOLTLIWMG-UHFFFAOYSA-N	10158940.0		DEEOXSOLTLIWMG
BRD-K43621685-001-02-5	CP-673451	Preclinical	PDGFR tyrosine kinase receptor inhibitor	KIT|PDGFRA|PDGFRB			0	88.95	Selleck	S1536	CP-673451	417.216	COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	DEEOXSOLTLIWMG-UHFFFAOYSA-N	10158940.0		DEEOXSOLTLIWMG
BRD-K43621685-001-03-3	CP-673451	Preclinical	PDGFR tyrosine kinase receptor inhibitor	KIT|PDGFRA|PDGFRB			0	93.35	Selleck	S1536	CP 673451	417.216	COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	DEEOXSOLTLIWMG-UHFFFAOYSA-N	10158940.0		DEEOXSOLTLIWMG
BRD-K76908866-001-08-9	CP-724714	Phase 2	EGFR inhibitor|protein tyrosine kinase inhibitor	ERBB2			0	96.99	Tocris	5973	CP 724714	469.211	COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	LLVZBTWPGQVVLW-SNAWJCMRSA-N	9874913.0		LLVZBTWPGQVVLW
BRD-K76908866-001-07-6	CP-724714	Phase 2	EGFR inhibitor|protein tyrosine kinase inhibitor	ERBB2			0	97.14	Selleck	S1167	CP-724714	469.211	COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	LLVZBTWPGQVVLW-SNAWJCMRSA-N	9874913.0		LLVZBTWPGQVVLW
BRD-K96843359-001-02-6	CP-775146	Preclinical	PPAR receptor agonist	PPARA			0	97.47	Tocris	4190	CP 775146	423.241	CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1	OISHBINQIFNIPV-JOCHJYFZSA-N	10410059.0		OISHBINQIFNIPV
BRD-K96843359-001-03-9	CP-775146	Preclinical	PPAR receptor agonist	PPARA			0	95.02	Tocris	4190	CP 775146	423.241	CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1	OISHBINQIFNIPV-JOCHJYFZSA-N	10410059.0		OISHBINQIFNIPV
BRD-K19171642-001-02-3	CP-91149	Preclinical	glycogen phosphorylase inhibitor	PYGL			0	97.95	Selleck	S2717	CP-91149	399.135	CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	HINJNZFCMLSBCI-PKOBYXMFSA-N	9843900.0		HINJNZFCMLSBCI
BRD-K19171642-001-03-1	CP-91149	Preclinical	glycogen phosphorylase inhibitor	PYGL			0	96.48	Selleck	S2717	CP-91149	399.135	CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	HINJNZFCMLSBCI-PKOBYXMFSA-N	9843900.0		HINJNZFCMLSBCI
BRD-K81876028-300-03-9	CP-93129	Preclinical	serotonin receptor agonist	HTR1A			0	96.73	Tocris	1032	CP 93129 dihydrochloride	215.106	O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|	PJYVGMRFPFNZCT-UHFFFAOYSA-N	124007.0		PJYVGMRFPFNZCT
BRD-K81876028-300-02-0	CP-93129	Preclinical	serotonin receptor agonist	HTR1A			0	87.99	Tocris	1032	CP 93129 dihydrochloride	215.106	O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|	PJYVGMRFPFNZCT-UHFFFAOYSA-N	124007.0		PJYVGMRFPFNZCT
BRD-K33860217-003-04-0	CP-94253	Preclinical	serotonin receptor agonist	HTR1B			0	92.31	Tocris	1317	CP 94253 hydrochloride	257.153	CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|	KWQWBZIGHIOKIO-UHFFFAOYSA-N	4029677.0		KWQWBZIGHIOKIO
BRD-K33860217-003-03-2	CP-94253	Preclinical	serotonin receptor agonist	HTR1B			0	72.81	Tocris	1317	CP 94253 hydrochloride	257.153	CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|	KWQWBZIGHIOKIO-UHFFFAOYSA-N	4029677.0		KWQWBZIGHIOKIO
BRD-K09090949-001-02-9	CP-945,598	Phase 3	cannabinoid receptor antagonist	CNR1			0	95.42	MedChemEx	HY-10871	Otenabant	509.15	CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	UNAZAADNBYXMIV-UHFFFAOYSA-N	10052040.0		UNAZAADNBYXMIV
BRD-K09090949-001-01-9	CP-945,598	Phase 3	cannabinoid receptor antagonist	CNR1			0	98.78	MedChemEx	HY-10871	Otenabant	509.15	CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	UNAZAADNBYXMIV-UHFFFAOYSA-N	10052040.0		UNAZAADNBYXMIV
BRD-K09946180-300-01-6	CP-99994	Phase 2	tachykinin antagonist	TACR1			0	94.58	Tocris	3417	CP 99994 dihydrochloride	296.189	COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1	DTQNEFOKTXXQKV-HKUYNNGSSA-N	5311057.0		DTQNEFOKTXXQKV
BRD-K09946180-300-02-9	CP-99994	Phase 2	tachykinin antagonist	TACR1			0	93.89	Tocris	3417	CP 99994 dihydrochloride	296.189	COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1	DTQNEFOKTXXQKV-HKUYNNGSSA-N	5311057.0		DTQNEFOKTXXQKV
BRD-A69126730-001-01-3	CPA-inhibitor	Preclinical	carboxypeptidase inhibitor	CPA1|CPA2			0	95.18	MedChemEx	HY-70005	CPA inhibitor	313.131	ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3,r|	PONANXDRJJIGPG-MRXNPFEDSA-N	124386386.0		PONANXDRJJIGPG
BRD-K00004223-001-01-9	CPCCOEt	Preclinical	glutamate receptor antagonist	GRM1			0	91.15	Tocris	1028	CPCCOEt	247.084	CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5,7,r|	FXCTZFMSAHZQTR-PFJVYOFESA-N	10106002.0		FXCTZFMSAHZQTR
BRD-K19871656-001-01-3	CPI-0610	Phase 2	bromodomain inhibitor	BRD4			0	99.18	MedChemEx	HY-12863	CPI-0610	365.093	Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|	GCWIQUVXWZWCLE-INIZCTEOSA-N	57389999.0		GCWIQUVXWZWCLE
BRD-K19871656-001-02-9	CPI-0610	Phase 2	bromodomain inhibitor	BRD4			0	97.97	MedChemEx	HY-12863	CPI-0610	365.093	Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|	GCWIQUVXWZWCLE-INIZCTEOSA-N	57389999.0		GCWIQUVXWZWCLE
BRD-K11073688-001-02-9	CPI-1189	Phase 2	tumor necrosis factor release inhibitor	TNF			0	95.36	Vitas-M	STK087738	4-(acetylamino)-N-tert-butylbenzamide	234.137	CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	DJKNRCWSXSZACF-UHFFFAOYSA-N	151118.0		DJKNRCWSXSZACF
BRD-K11073688-001-01-6	CPI-1189	Phase 2	tumor necrosis factor release inhibitor	TNF			0	98.62	ChemDiv	Y030-2548		234.137	CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	DJKNRCWSXSZACF-UHFFFAOYSA-N	151118.0		DJKNRCWSXSZACF
BRD-K00003360-001-01-9	CPI-1205	Phase 1/Phase 2	EZH2 inhibitor				0	96.89	MedChemEx	HY-100021	CPI-1205	518.25	COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12	HPODOLXTMDHLLC-QGZVFWFLSA-N	78320408.0		HPODOLXTMDHLLC
BRD-K97181972-001-01-9	CPI-169	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	93.82	MedChemEx	HY-15956A	CPI-169	528.241	CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12	LHGUZCKPFXXVPV-GOSISDBHSA-N	71712226.0		LHGUZCKPFXXVPV
BRD-K15811707-001-02-0	CPI-203	Preclinical	bromodomain inhibitor	BRD4			0	94.7	Tocris	5331	CPI 203	399.092	Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|	QECMENZMDBOLDR-AWEZNQCLSA-N	71291068.0		QECMENZMDBOLDR
BRD-K15811707-001-01-2	CPI-203	Preclinical	bromodomain inhibitor	BRD4			0	95.34	MedChemEx	HY-15846	CPI-203	399.092	Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|	QECMENZMDBOLDR-AWEZNQCLSA-N	71291068.0		QECMENZMDBOLDR
BRD-K18319422-001-01-7	CPI-360	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	94.64	MedChemEx	HY-15955	CPI-360	437.231	COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12	PFPSFENQCNMITC-MRXNPFEDSA-N	73442743.0		PFPSFENQCNMITC
BRD-K00003442-001-01-9	CPI-444	Phase 1/Phase 2	adenosine receptor antagonist				0	92.74	MedChemEx	HY-101978	CPI-444	407.171	Cc1ccc(o1)-c1nc(N)nc2n(Cc3cccc(CO[C@H]4CCOC4)n3)nnc12	KURQKNMKCGYWRJ-HNNXBMFYSA-N	44537963.0		KURQKNMKCGYWRJ
BRD-A06916187-001-03-9	CPI-613	Phase 3	pyruvate dehydrogenase inhibitor	PDHA1			0	96.2	Tocris	5348	6,8-Bis(benzylthio)octanoic acid	388.153	OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|	ZYRLHJIMTROTBO-NRFANRHFSA-N	70881528.0		ZYRLHJIMTROTBO
BRD-A06916187-001-02-9	CPI-613	Phase 3	pyruvate dehydrogenase inhibitor	PDHA1			0	95.51	Selleck	S2776	CPI-613	388.153	OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7,r|	ZYRLHJIMTROTBO-NRFANRHFSA-N	70881528.0		ZYRLHJIMTROTBO
BRD-K66094457-001-02-3	CPP	Phase 2	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	93.04	Tocris	247	(2R)-4-(3-phosphonopropyl)-2-piperazinecarboxylic acid	252.088	OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1	CUVGUPIVTLGRGI-SSDOTTSWSA-N	6603754.0		CUVGUPIVTLGRGI
BRD-K66094457-001-01-5	CPP	Phase 2	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	0.0	EMDBio	504839-10MG	(R)-CPP	252.088	OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1	CUVGUPIVTLGRGI-SSDOTTSWSA-N	6603754.0		CUVGUPIVTLGRGI
BRD-A81603255-001-02-9	CPSI-1306-(+/-)	Preclinical	macrophage migration inhibiting factor inhibitor	MIF			0	96.17	Tocris	4400	(+/-)-CPSI 1306	310.113	Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|	GUWOSEVHCSNYFK-LLVKDONJSA-N	52936269.0		GUWOSEVHCSNYFK
BRD-A81603255-001-01-0	CPSI-1306-(+/-)	Preclinical	macrophage migration inhibiting factor inhibitor	MIF			0	96.78	Tocris	4400	(+/-)-CPSI 	310.113	Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8,r,t:5|	GUWOSEVHCSNYFK-LLVKDONJSA-N	52936269.0		GUWOSEVHCSNYFK
BRD-K56839624-001-06-9	CQS	Preclinical					0	91.22	Sigma	MFCD01657676	4-amino-N-(5-chloroquinoxalin-2-yl)benzenesulfonamide	334.029	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(Cl)cccc2n1	CTSNHMQGVWXIEG-UHFFFAOYSA-N	72462.0		CTSNHMQGVWXIEG
BRD-K19615002-001-02-3	creatine	Launched		CKB|CKM|CKMT1A|CKMT2|GAMT|SLC6A8			0	100.0	Vitas-M	STL163516		131.069	CN(CC(O)=O)C(N)=N	CVSVTCORWBXHQV-UHFFFAOYSA-N	586.0		CVSVTCORWBXHQV
BRD-K13495773-001-15-9	creatinine	Preclinical					0	100.0	MedChemEx	HY-B0504	Creatinine	113.059	CN1CC(=O)NC1=N	DDRJAANPRJIHGJ-UHFFFAOYSA-N	588.0		DDRJAANPRJIHGJ
BRD-K13495773-001-12-2	creatinine	Preclinical					0	0.0	MicroSource	1600300	CREATININE	113.059	CN1CC(=O)NC1=N	DDRJAANPRJIHGJ-UHFFFAOYSA-N	588.0		DDRJAANPRJIHGJ
BRD-K13495773-001-11-4	creatinine	Preclinical					0	100.0	Selleck	S3102	Creatinine	113.059	CN1CC(=O)NC1=N	DDRJAANPRJIHGJ-UHFFFAOYSA-N	588.0		DDRJAANPRJIHGJ
BRD-K42991124-001-04-8	creatinol-phosphate	Launched					1	100.0	CombiBlocks	QA-2638	2-[[amino(imino)methyl](methyl)amino]ethyl dihydrogen phosphate	197.057	CN(CCOP(O)(O)=O)C(N)=N	FOIPWTMKYXWFGC-UHFFFAOYSA-N	23342.0		FOIPWTMKYXWFGC
BRD-K42991124-001-03-0	creatinol-phosphate	Launched					1	0.0	CombiBlocks	QA-2638		197.057	CN(CCOP(O)(O)=O)C(N)=N	FOIPWTMKYXWFGC-UHFFFAOYSA-N	23342.0		FOIPWTMKYXWFGC
BRD-K00003129-001-01-9	crenigacestat	Preclinical	notch signaling inhibitor				0	95.66	MedChemEx	HY-12449	Crenigacestat	464.167	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O	YCBAQKQAINQRFW-UGSOOPFHSA-N	71236992.0		YCBAQKQAINQRFW
BRD-K22127577-001-03-7	crenolanib	Phase 3	PDGFR tyrosine kinase receptor inhibitor	CSF1R|FLT3|KIT|PDGFRA|PDGFRB			0	93.31	Selleck	S2730	Crenolanib (CP-868596)	443.232	CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	DYNHJHQFHQTFTP-UHFFFAOYSA-N	10366136.0		DYNHJHQFHQTFTP
BRD-K22127577-001-06-9	crenolanib	Phase 3	PDGFR tyrosine kinase receptor inhibitor	CSF1R|FLT3|KIT|PDGFRA|PDGFRB			0	72.51	MedChemEx	HY-13223	Crenolanib	443.232	CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	DYNHJHQFHQTFTP-UHFFFAOYSA-N	10366136.0		DYNHJHQFHQTFTP
BRD-K22127577-001-02-9	crenolanib	Phase 3	PDGFR tyrosine kinase receptor inhibitor	CSF1R|FLT3|KIT|PDGFRA|PDGFRB			0	75.64	Selleck	S2730	Crenolanib (CP-868596)	443.232	CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	DYNHJHQFHQTFTP-UHFFFAOYSA-N	10366136.0		DYNHJHQFHQTFTP
BRD-K56940914-001-04-2	cresol	Launched					0	78.99	MicroSource	1500209	CRESOL	108.058	Cc1ccc(O)cc1	IWDCLRJOBJJRNH-UHFFFAOYSA-N	2879.0		IWDCLRJOBJJRNH
BRD-K58648841-001-04-7	cresopirine	Preclinical					0	94.31	MicroSource	1401414	CRESOPIRINE	194.058	CC(=O)Oc1c(C)cccc1C(O)=O	XRBMKGUDDJPAMH-UHFFFAOYSA-N	78094.0		XRBMKGUDDJPAMH
BRD-K58648841-001-05-9	cresopirine	Preclinical					0	0.0	Sigma	MFCD00085683	3-METHYLACETYLSALICYLIC ACID	194.058	CC(=O)Oc1c(C)cccc1C(O)=O	XRBMKGUDDJPAMH-UHFFFAOYSA-N	78094.0		XRBMKGUDDJPAMH
BRD-K97939847-001-12-0	cridanimod	Launched	progesterone receptor agonist	PGR	infectious disease	influenza A virus infection	0	98.36	Sigma	17927	(9-oxo-10(9H)-acridinyl)acetic acid	253.074	OC(=O)Cn1c2ccccc2c(=O)c2ccccc12	UOMKBIIXHQIERR-UHFFFAOYSA-N	38072.0		UOMKBIIXHQIERR
BRD-K97939847-001-11-2	cridanimod	Launched	progesterone receptor agonist	PGR	infectious disease	influenza A virus infection	0	47.79	ChemDiv	0099-0157		253.074	OC(=O)Cn1c2ccccc2c(=O)c2ccccc12	UOMKBIIXHQIERR-UHFFFAOYSA-N	38072.0		UOMKBIIXHQIERR
BRD-K43230258-001-01-4	crisaborole	Launched	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D	dermatology	dermatitis	0	93.42	MedChemEx	HY-10978	AN-2728	251.075	OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12	USZAGAREISWJDP-UHFFFAOYSA-N	44591583.0		USZAGAREISWJDP
BRD-K00004545-001-01-9	crisdesalazine	Preclinical	free radical scavenger				0	89.23	Sigma	MFCD18633186	2-hydroxy-5-({2-[4-(trifluoromethyl)phenyl]ethyl}amino)benzoic acid	325.093	OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O	UTMVACIBQLDZLP-UHFFFAOYSA-N	16042343.0		UTMVACIBQLDZLP
BRD-K78431006-001-21-9	crizotinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|MET	oncology	non-small cell lung cancer (NSCLC)	0	93.46	MedChemEx	HY-50878	Crizotinib	449.119	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-GFCCVEGCSA-N	11626560.0		KTEIFNKAUNYNJU
BRD-K78431006-001-15-1	crizotinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|MET	oncology	non-small cell lung cancer (NSCLC)	0	88.86	MedChemEx	HY-50878	Crizotinib	449.119	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-GFCCVEGCSA-N	11626560.0		KTEIFNKAUNYNJU
BRD-K78431006-001-10-2	crizotinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|MET	oncology	non-small cell lung cancer (NSCLC)	0	93.81	Selleck	S1068	Crizotinib (PF-02341066)	449.119	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-GFCCVEGCSA-N	11626560.0		KTEIFNKAUNYNJU
BRD-K78431006-001-11-0	crizotinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK|MET	oncology	non-small cell lung cancer (NSCLC)	0	89.1	Selleck	S1068	Crizotinib (PF-02341066)	449.119	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-GFCCVEGCSA-N	11626560.0		KTEIFNKAUNYNJU
BRD-K40308497-001-03-9	crizotinib-(S)	Preclinical	MTH1 inhibitor	NUDT1			0	92.63	Tocris	6025	(S)-Crizotinib	449.119	C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-LBPRGKRZSA-N	56671814.0		KTEIFNKAUNYNJU
BRD-K40308497-001-02-0	crizotinib-(S)	Preclinical	MTH1 inhibitor	NUDT1			0	92.52	Selleck	S7505	(S)-crizotinib	449.119	C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-LBPRGKRZSA-N	56671814.0	BRD-A75349800-001-01-8	KTEIFNKAUNYNJU
BRD-K40308497-001-01-2	crizotinib-(S)	Preclinical	MTH1 inhibitor	NUDT1			0	96.6	Selleck	S7505	(S)-crizotinib	449.119	C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	KTEIFNKAUNYNJU-LBPRGKRZSA-N	56671814.0		KTEIFNKAUNYNJU
BRD-K73701464-003-01-3	croconazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	fungal infection	0	0.0	AKSci	K341		310.087	Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1	WHPAGCJNPTUGGD-UHFFFAOYSA-N	2880.0		WHPAGCJNPTUGGD
BRD-K73701464-003-02-1	croconazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	fungal infection	0	0.0	SantaCruz	sc-4958483	Cloconazole HCl	310.087	Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1	WHPAGCJNPTUGGD-UHFFFAOYSA-N	2880.0		WHPAGCJNPTUGGD
BRD-K00003162-001-01-9	crolibulin	Phase 1/Phase 2	tubulin polymerization inhibitor				0	63.57	MedChemEx	HY-13603	Crolibulin	416.048	COc1cc(cc(Br)c1OC)[C@H]1C(C#N)=C(N)Oc2c(N)c(N)ccc12 |t:15|	JXONINOYTKKXQQ-CQSZACIVSA-N	23649181.0		JXONINOYTKKXQQ
BRD-M89827113-001-01-5	cromakalim	Phase 2		KCNJ8			0	99.22	Tocris	1377	Cromakalim	286.132	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N	BVMDRSUIADWFLV-PNSAJKJISA-N	76968376.0		BVMDRSUIADWFLV
BRD-K20920669-304-12-9	cromoglicic-acid	Launched	immunosuppressant	KCNMA1|S100P	pulmonary|ophthalmology|allergy|gastroenterology	asthma|conjunctivitis|urticaria|ulcerative colitis	0	82.3	MedChemEx	HY-B0320A	Cromolyn (sodium)	468.069	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	IMZMKUWMOSJXDT-UHFFFAOYSA-N	2882.0		IMZMKUWMOSJXDT
BRD-K20920669-304-10-9	cromoglicic-acid	Launched	immunosuppressant	KCNMA1|S100P	pulmonary|ophthalmology|allergy|gastroenterology	asthma|conjunctivitis|urticaria|ulcerative colitis	0	95.57	MicroSource	1500210	CROMOLYN SODIUM	468.069	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	IMZMKUWMOSJXDT-UHFFFAOYSA-N	2882.0		IMZMKUWMOSJXDT
BRD-K20920669-304-09-1	cromoglicic-acid	Launched	immunosuppressant	KCNMA1|S100P	pulmonary|ophthalmology|allergy|gastroenterology	asthma|conjunctivitis|urticaria|ulcerative colitis	0	100.0	Selleck	S1911	Disodium Cromoglycate	468.069	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	IMZMKUWMOSJXDT-UHFFFAOYSA-N	2882.0		IMZMKUWMOSJXDT
BRD-K57179821-001-15-4	crotamiton	Launched	antipruritic		infectious disease	scabies	0	85.06	MicroSource	1505271	CROTAMITON	203.131	CCN(C(=O)\C=C\C)c1ccccc1C	DNTGGZPQPQTDQF-XBXARRHUSA-N	688020.0		DNTGGZPQPQTDQF
BRD-K57179821-001-17-9	crotamiton	Launched	antipruritic		infectious disease	scabies	0	95.53	MedChemEx	HY-B1177	Crotamiton	203.131	CCN(C(=O)\C=C\C)c1ccccc1C	DNTGGZPQPQTDQF-XBXARRHUSA-N	688020.0		DNTGGZPQPQTDQF
BRD-K02816415-001-01-9	CRT0044876	Preclinical					0	96.56	Selleck	S7449	CRT0044876	206.033	OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1	BIUCOFQROHIAEO-UHFFFAOYSA-N	81409.0		BIUCOFQROHIAEO
BRD-K02816415-001-02-7	CRT0044876	Preclinical					0	94.84	Selleck	S7449	CRT0044876	206.033	OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1	BIUCOFQROHIAEO-UHFFFAOYSA-N	81409.0		BIUCOFQROHIAEO
BRD-K33336844-001-11-1	cryptotanshinone	Preclinical	acetylcholinesterase inhibitor|STAT inhibitor	STAT3			0	66.48	MedChemEx	HY-N0174	Cryptotanshinone	296.141	C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|	GVKKJJOMQCNPGB-JTQLQIEISA-N	160254.0		GVKKJJOMQCNPGB
BRD-K33336844-001-10-3	cryptotanshinone	Preclinical	acetylcholinesterase inhibitor|STAT inhibitor	STAT3			0	3.4	MedChemEx	HY-N0174	Cryptotanshinone	296.141	C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|	GVKKJJOMQCNPGB-JTQLQIEISA-N	160254.0		GVKKJJOMQCNPGB
BRD-K33336844-001-09-5	cryptotanshinone	Preclinical	acetylcholinesterase inhibitor|STAT inhibitor	STAT3			0	51.1	Selleck	S2285	Cryptotanshinone	296.141	C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|	GVKKJJOMQCNPGB-JTQLQIEISA-N	160254.0		GVKKJJOMQCNPGB
BRD-K33336844-001-12-9	cryptotanshinone	Preclinical	acetylcholinesterase inhibitor|STAT inhibitor	STAT3			0	3.09	Selleck	S2285	Cryptotanshinone	296.141	C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|	GVKKJJOMQCNPGB-JTQLQIEISA-N	160254.0	BRD-K53562481-001-01-6	GVKKJJOMQCNPGB
BRD-K00003324-003-01-9	crystal-violet	Launched	other antibiotic				0	91.8	MedChemEx	HY-B0324A	Crystal Violet	372.244	CN(C)c1ccc(cc1)C(=C1C=CC(C=C1)=[N+](C)C)c1ccc(cc1)N(C)C |c:12,15|	LGLFFNDHMLKUMI-UHFFFAOYSA-N	3468.0		LGLFFNDHMLKUMI
BRD-K40331046-305-02-3	CR8-(R)	Preclinical	CDK inhibitor	CCNA2			0	94.42	Tocris	3605	(R)-CR8	431.243	CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	HOCBJBNQIQQQGT-LJQANCHMSA-N	10224714.0		HOCBJBNQIQQQGT
BRD-K40331046-305-01-5	CR8-(R)	Preclinical	CDK inhibitor	CCNA2			0	96.87	Tocris	3605	(R)-CR8	431.243	CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	HOCBJBNQIQQQGT-LJQANCHMSA-N	10224714.0		HOCBJBNQIQQQGT
BRD-K40331046-305-03-9	CR8-(R)	Preclinical	CDK inhibitor	CCNA2			0	95.89	Tocris	3605	(R)-CR8	431.243	CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	HOCBJBNQIQQQGT-LJQANCHMSA-N	10224714.0		HOCBJBNQIQQQGT
BRD-K15519488-050-02-1	CS-110266	Preclinical	dopamine receptor agonist	SLC6A3			0	91.98	Tocris	702	BTCP maleate	299.171	C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	RGSVXQJPSWZXOP-UHFFFAOYSA-N	123692.0		RGSVXQJPSWZXOP
BRD-K15519488-001-03-2	CS-110266	Preclinical	dopamine receptor agonist	SLC6A3			0	96.55	Sigma	B138-10MG	BTCP hydrochloride	299.171	C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	RGSVXQJPSWZXOP-UHFFFAOYSA-N	123692.0		RGSVXQJPSWZXOP
BRD-K15519488-050-01-3	CS-110266	Preclinical	dopamine receptor agonist	SLC6A3			0	94.58	Tocris	702	BTCP maleate	299.171	C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	RGSVXQJPSWZXOP-UHFFFAOYSA-N	123692.0		RGSVXQJPSWZXOP
BRD-K35601925-001-02-7	CS-917	Phase 2	fructose biphosphate inhibitor	FBP1			0	92.89	MedChemEx	HY-16307	MB05032	302.049	CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O	XJMYIJPPDSZOPN-UHFFFAOYSA-N	11289630.0		XJMYIJPPDSZOPN
BRD-K35601925-001-01-9	CS-917	Phase 2	fructose biphosphate inhibitor	FBP1			0	76.18	MedChemEx	HY-16307	MB05032	302.049	CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O	XJMYIJPPDSZOPN-UHFFFAOYSA-N	11289630.0		XJMYIJPPDSZOPN
BRD-K40870905-001-02-9	CT-7758	Phase 2	integrin antagonist	ITGA4			0	97.57	MedChemEx	HY-70073	Zaurategrast	520.111	OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|	KYHVWHYLKOHLKA-FQEVSTJZSA-N	10186367.0		KYHVWHYLKOHLKA
BRD-K40870905-001-01-7	CT-7758	Phase 2	integrin antagonist	ITGA4			0	96.91	MedChemEx	HY-70073	Zaurategrast	520.111	OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|	KYHVWHYLKOHLKA-FQEVSTJZSA-N	10186367.0		KYHVWHYLKOHLKA
BRD-K30572193-001-02-0	CTEP	Preclinical	glutamate receptor antagonist	GRM5			0	96.37	Selleck	S2861	CTEP (RO4956371)	391.07	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1	GOHCTCOGYKAJLZ-UHFFFAOYSA-N	11646823.0		GOHCTCOGYKAJLZ
BRD-K30572193-001-03-9	CTEP	Preclinical	glutamate receptor antagonist	GRM5			0	97.17	MedChemEx	HY-15445	CTEP	391.07	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1	GOHCTCOGYKAJLZ-UHFFFAOYSA-N	11646823.0		GOHCTCOGYKAJLZ
BRD-K53508936-001-02-8	CTS-1027	Phase 2	metalloproteinase inhibitor	MMP1|MMP13|MMP2|MMP3|MMP9			0	97.14	MedChemEx	HY-10398	CTS-1027	425.07	ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1	ROSNVSQTEGHUKU-UHFFFAOYSA-N	3342298.0		ROSNVSQTEGHUKU
BRD-K53508936-001-01-0	CTS-1027	Phase 2	metalloproteinase inhibitor	MMP1|MMP13|MMP2|MMP3|MMP9			0	94.61	MedChemEx	HY-10398	CTS-1027	425.07	ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1	ROSNVSQTEGHUKU-UHFFFAOYSA-N	3342298.0		ROSNVSQTEGHUKU
BRD-K89071957-001-01-1	CTS21166	Phase 1	beta-secretase inhibitor	BACE1			0	78.39	EMDBio	496000-250UG	InSolution OM99-2	892.454	CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O	NIOCOJFPGCXNKL-ZKZXETMPSA-N	445649.0		NIOCOJFPGCXNKL
BRD-K00003453-003-01-9	CT7001	Phase 1/Phase 2	CDK inhibitor				0	96.6	MedChemEx	HY-103712A	CT7001 hydrochloride	394.248	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12	YCVGLKWJKIKVBI-MJGOQNOKSA-N	91844733.0		YCVGLKWJKIKVBI
BRD-K58234744-001-02-9	CU-CPT-4a	Preclinical	toll-like receptor inhibitor	TLR3			0	95.81	Tocris	4883	CU CPT 4a	377.029	OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl	IAASQMCXDRISAV-CYBMUJFWSA-N	53242268.0		IAASQMCXDRISAV
BRD-K58234744-001-01-0	CU-CPT-4a	Preclinical	toll-like receptor inhibitor	TLR3			0	91.08	Tocris	4883	CU CPT 4a	377.029	OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl	IAASQMCXDRISAV-CYBMUJFWSA-N	53242268.0		IAASQMCXDRISAV
BRD-K89462779-001-01-8	CU-T12-9	Preclinical	toll-like receptor agonist	TLR1|TLR2			0	94.4	Tocris	5414	CU-T12-9	362.099	CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O	LITXVDAFEYLWQE-UHFFFAOYSA-N	91826088.0		LITXVDAFEYLWQE
BRD-K89462779-001-02-9	CU-T12-9	Preclinical	toll-like receptor agonist	TLR1|TLR2			0	97.26	Tocris	5414	CU-T12-9	362.099	CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O	LITXVDAFEYLWQE-UHFFFAOYSA-N	91826088.0		LITXVDAFEYLWQE
BRD-K41278234-001-04-9	CUDC-101	Phase 1	EGFR inhibitor	EGFR|ERBB2			0	95.43	MedChemEx	HY-10223	CUDC-101	434.195	COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	PLIVFNIUGLLCEK-UHFFFAOYSA-N	24756910.0		PLIVFNIUGLLCEK
BRD-K41278234-001-03-0	CUDC-101	Phase 1	EGFR inhibitor	EGFR|ERBB2			0	94.69	Selleck	S1194	CUDC-101	434.195	COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	PLIVFNIUGLLCEK-UHFFFAOYSA-N	24756910.0		PLIVFNIUGLLCEK
BRD-K69351586-001-02-8	CUDC-427	Phase 1	apoptosis inhibitor	XIAP			0	52.21	MedChemEx	HY-15835	CUDC-427	564.252	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1	HSHPBORBOJIXSQ-HARLFGEKSA-N	71600094.0		HSHPBORBOJIXSQ
BRD-K69351586-001-01-0	CUDC-427	Phase 1	apoptosis inhibitor	XIAP			0	86.1	MedChemEx	HY-15835	CUDC-427	564.252	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1	HSHPBORBOJIXSQ-HARLFGEKSA-N	71600094.0		HSHPBORBOJIXSQ
BRD-K77638923-001-03-9	CUDC-907	Phase 2	PI3K inhibitor	HDAC2|PIK3R1			0	95.45	MedChemEx	HY-13522	Fimepinostat	508.164	COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	JOWXJLIFIIOYMS-UHFFFAOYSA-N	54575456.0		JOWXJLIFIIOYMS
BRD-K77638923-001-02-0	CUDC-907	Phase 2	PI3K inhibitor	HDAC2|PIK3R1			0	95.02	Selleck	S2759	CUDC-907	508.164	COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	JOWXJLIFIIOYMS-UHFFFAOYSA-N	54575456.0		JOWXJLIFIIOYMS
BRD-K69624312-001-01-1	CUR-61414	Phase 1	smoothened receptor antagonist	DHH|IHH|SMO			0	97.61	Cayman	14931	N-[(3S,5S)-1-(1,3-benzodioxol-5-ylmethyl)-5-(1-piperazinylcarbonyl)-3-pyrrolidinyl]-N-(3-methoxybenzyl)-3,3-dimethylbutanamide	550.316	COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1	WPHXYKUPFJRJDK-AHWVRZQESA-N	10392802.0		WPHXYKUPFJRJDK
BRD-K07572174-001-43-6	curcumin	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH			0	66.71	Enzo	EI135	Curcumin	368.126	COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	6971205.0	BRD-K69690935-001-03-5	ZIUSSTSXXLLKKK
BRD-K07572174-001-39-4	curcumin	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH			0	91.77	Selleck	S1848	Curcumin	368.126	COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	6971205.0		ZIUSSTSXXLLKKK
BRD-K07572174-001-38-6	curcumin	Launched	cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor	APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH			0	64.98	Selleck	S1848	Curcumin	368.126	COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O	ZIUSSTSXXLLKKK-SMSFQYLMSA-N	6971205.0		ZIUSSTSXXLLKKK
BRD-K41933240-001-04-9	curcumol	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	75.0	MedChemEx	HY-N0104	Curcumol	236.178	CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C	QRMPRVXWPCLVNI-YYFQZIEXSA-N	14240392.0		QRMPRVXWPCLVNI
BRD-K41933240-001-02-4	curcumol	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	82.1	Selleck	S2407	Curcumol	236.178	CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C	QRMPRVXWPCLVNI-YYFQZIEXSA-N	14240392.0		QRMPRVXWPCLVNI
BRD-K41933240-001-03-2	curcumol	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	64.97	Selleck	S2407	Curcumol	236.178	CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C	QRMPRVXWPCLVNI-YYFQZIEXSA-N	14240392.0	BRD-K07241895-001-01-4	QRMPRVXWPCLVNI
BRD-K90777969-300-03-9	cutamesine	Phase 2	sigma receptor agonist	SIGMAR1			0	94.84	Tocris	4951	SA 4503 dihydrochloride	368.246	COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	UVSWWUWQVAQPJR-UHFFFAOYSA-N	9907323.0		UVSWWUWQVAQPJR
BRD-K90777969-300-01-2	cutamesine	Phase 2	sigma receptor agonist	SIGMAR1			0	95.88	MedChemEx	HY-13510	SA4503 (dihydrochloride)	368.246	COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	UVSWWUWQVAQPJR-UHFFFAOYSA-N	9907323.0		UVSWWUWQVAQPJR
BRD-K90777969-300-02-0	cutamesine	Phase 2	sigma receptor agonist	SIGMAR1			0	91.99	Tocris	4951	SA 4503 dihydrochloride	368.246	COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	UVSWWUWQVAQPJR-UHFFFAOYSA-N	9907323.0		UVSWWUWQVAQPJR
BRD-K49197823-001-10-9	CV-1808	Preclinical	adenosine receptor agonist	ADORA2A			0	95.42	Tocris	1710	CV 1808	358.139	Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	SCNILGOVBBRMBK-SDBHATRESA-N	6917803.0		SCNILGOVBBRMBK
BRD-K49197823-001-09-8	CV-1808	Preclinical	adenosine receptor agonist	ADORA2A			0	95.83	Tocris	1710	CV 1808	358.139	Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	SCNILGOVBBRMBK-SDBHATRESA-N	6917803.0		SCNILGOVBBRMBK
BRD-K60659193-001-01-0	CVT-10216	Phase 1	aldehyde dehydrogenase inhibitor	ALDH2			0	96.41	Sigma	SML1366	3-(((3-(4-(methylsulfonamido)phenyl)-4-oxo-4H-chromen-7-yl)oxy)methyl)benzoic acid	465.088	CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O	YYOOFJZTRCPVFD-UHFFFAOYSA-N	23661666.0		YYOOFJZTRCPVFD
BRD-K60659193-001-02-8	CVT-10216	Phase 1	aldehyde dehydrogenase inhibitor	ALDH2			0	96.71	Tocris	5164	CVT 10216	465.088	CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O	YYOOFJZTRCPVFD-UHFFFAOYSA-N	23661666.0		YYOOFJZTRCPVFD
BRD-K84068331-001-02-9	CW-008	Preclinical	PKA activator	PRKACA			0	93.01	Tocris	5495	CW 008	420.115	COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1	KCIMKTNQCUDTFI-UHFFFAOYSA-N	59528098.0		KCIMKTNQCUDTFI
BRD-K84068331-001-01-9	CW-008	Preclinical	PKA activator	PRKACA			0	92.05	Tocris	5495	CW 008	420.115	COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1	KCIMKTNQCUDTFI-UHFFFAOYSA-N	59528098.0		KCIMKTNQCUDTFI
BRD-K81458380-001-12-9	CX-4945	Phase 1/Phase 2	casein kinase inhibitor	CSNK2A1|CSNK2A2|DAPK3|HIPK3			0	98.48	MedChemEx	HY-50855	Silmitasertib	349.062	OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	MUOKSQABCJCOPU-UHFFFAOYSA-N	24748573.0		MUOKSQABCJCOPU
BRD-K81458380-001-04-9	CX-4945	Phase 1/Phase 2	casein kinase inhibitor	CSNK2A1|CSNK2A2|DAPK3|HIPK3			0	98.07	Selleck	S2248	CX-4945 (Silmitasertib)	349.062	OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	MUOKSQABCJCOPU-UHFFFAOYSA-N	24748573.0		MUOKSQABCJCOPU
BRD-K25140590-001-04-9	CX-516	Phase 2/Phase 3	glutamate receptor modulator				0	92.58	Tocris	1048	1-BCP	233.105	O=C(N1CCCCC1)c1ccc2OCOc2c1	BXBNADAPIHHXJQ-UHFFFAOYSA-N	1370.0		BXBNADAPIHHXJQ
BRD-K25140590-001-03-0	CX-516	Phase 2/Phase 3	glutamate receptor modulator				0	98.29	Tocris	1048	1-BCP	233.105	O=C(N1CCCCC1)c1ccc2OCOc2c1	BXBNADAPIHHXJQ-UHFFFAOYSA-N	1370.0		BXBNADAPIHHXJQ
BRD-K12787259-001-04-3	CX-5461	Phase 1	RNA polymerase inhibitor				0	96.98	MedChemEx	HY-13323	CX-5461	513.195	CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	XGPBJCHFROADCK-UHFFFAOYSA-N	25257557.0		XGPBJCHFROADCK
BRD-K12787259-001-05-9	CX-5461	Phase 1	RNA polymerase inhibitor				0	85.34	MedChemEx	HY-13323	CX-5461	513.195	CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	XGPBJCHFROADCK-UHFFFAOYSA-N	25257557.0		XGPBJCHFROADCK
BRD-K00003388-001-01-9	CXD101	Phase 1/Phase 2	HDAC inhibitor				0	97.26	MedChemEx	HY-100748	HDAC-IN-4	403.237	Cc1nn(C)cc1CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N	JHDZMASHNBKTPS-UHFFFAOYSA-N	16225380.0		JHDZMASHNBKTPS
BRD-K39371216-001-02-9	cyacetacide	Preclinical					0	0.0	MedChemEx	HY-B0994	Cyanoacetohydrazide	99.043	NNC(=O)CC#N	HPHBOJANXDKUQD-UHFFFAOYSA-N	8820.0		HPHBOJANXDKUQD
BRD-K39371216-001-01-3	cyacetacide	Preclinical					0	93.04	MicroSource	1502372	CYACETACIDE	99.043	NNC(=O)CC#N	HPHBOJANXDKUQD-UHFFFAOYSA-N	8820.0		HPHBOJANXDKUQD
BRD-A42881122-001-01-1	cyamemazine	Launched	serotonin receptor antagonist	HTR1A|HTR2A|HTR2C|HTR7	neurology/psychiatry	schizophrenia|anxiety	0	87.23	Sigma	MFCD00868180	10-[3-(dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile	323.146	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1,r|	SLFGIOIONGJGRT-AWEZNQCLSA-N	14050069.0		SLFGIOIONGJGRT
BRD-A18627414-001-05-6	cyanocobalamin	Launched	methylmalonyl CoA mutase stimulant|vitamin B	MUT	hematology|infectious disease|gastroenterology	anemia|fish tapeworm infestation|celiac disease	0	0.0	MicroSource	1500844	CYANOCOBALAMIN	1355.575	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|	RMRCNWBMXRMIRW-WZHZPDAFSA-M		BRD-A59561452-001-01-9	RMRCNWBMXRMIRW
BRD-A18627414-001-06-4	cyanocobalamin	Launched	methylmalonyl CoA mutase stimulant|vitamin B	MUT	hematology|infectious disease|gastroenterology	anemia|fish tapeworm infestation|celiac disease	0	95.39	Sigma	V6629-250MG	Vitamin B12	1355.575	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|	RMRCNWBMXRMIRW-WZHZPDAFSA-M			RMRCNWBMXRMIRW
BRD-A18627414-001-04-9	cyanocobalamin	Launched	methylmalonyl CoA mutase stimulant|vitamin B	MUT	hematology|infectious disease|gastroenterology	anemia|fish tapeworm infestation|celiac disease	0	97.22	Selleck	S1902	Vitamin B12	1355.575	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1,8,10,15,30,36,42,48,54,63,74,75,79,80,&1:70,c:16,20,24,t:22,26,29|	RMRCNWBMXRMIRW-WZHZPDAFSA-M		BRD-M14495474-001-01-4|BRD-A97502381-001-01-3|BRD-M38660727-001-01-0	RMRCNWBMXRMIRW
BRD-K01825675-051-01-9	cyanopindolol	Phase 2	adrenergic receptor antagonist	ADRB1|HTR1A|HTR1D			0	96.81	Tocris	993	Cyanopindolol hemifumarate	403.174	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|	QXIUMMLTJVHILT-GFCCVEGCSA-N	6604791.0	BRD-M87382116-051-02-3	QXIUMMLTJVHILT
BRD-K01825675-051-02-9	cyanopindolol	Phase 2	adrenergic receptor antagonist	ADRB1|HTR1A|HTR1D			0	87.91	Tocris	993	Cyanopindolol hemifumarate	287.163	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|	QXIUMMLTJVHILT-GFCCVEGCSA-N	6604791.0		QXIUMMLTJVHILT
BRD-K50785021-001-04-7	cyclamic-acid	Preclinical					0	75.73	MicroSource	1502367	SODIUM CYCLAMATE	179.062	OS(=O)(=O)NC1CCCCC1	HCAJEUSONLESMK-UHFFFAOYSA-N	7533.0	BRD-M61995960-001-03-2	HCAJEUSONLESMK
BRD-K50785021-001-05-9	cyclamic-acid	Preclinical					0	95.8	MedChemEx	HY-B0541	Cyclamic acid	179.062	OS(=O)(=O)NC1CCCCC1	HCAJEUSONLESMK-UHFFFAOYSA-N	7533.0		HCAJEUSONLESMK
BRD-K50785021-001-03-9	cyclamic-acid	Preclinical					0	77.36	MicroSource	1301015	CYCLAMIC ACID	179.062	OS(=O)(=O)NC1CCCCC1	HCAJEUSONLESMK-UHFFFAOYSA-N	7533.0		HCAJEUSONLESMK
BRD-K50785021-001-02-1	cyclamic-acid	Preclinical					0	100.0	Selleck	S4015	Cyclamic  acid	179.062	OS(=O)(=O)NC1CCCCC1	HCAJEUSONLESMK-UHFFFAOYSA-N	7533.0		HCAJEUSONLESMK
BRD-A27370296-001-03-0	cyclandelate	Launched	calcium channel blocker		cardiology|rheumatology	claudication|arteriosclerosis|Raynaud's disease	0	96.09	MicroSource	1505082	CYCLANDELATE	276.173	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|	WZHCOOQXZCIUNC-QEJZJMRPSA-N	41097974.0		WZHCOOQXZCIUNC
BRD-A27370296-001-02-2	cyclandelate	Launched	calcium channel blocker		cardiology|rheumatology	claudication|arteriosclerosis|Raynaud's disease	0	89.21	Selleck	S4189	Cyclandelate	276.173	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|	WZHCOOQXZCIUNC-QEJZJMRPSA-N	41097974.0		WZHCOOQXZCIUNC
BRD-A27370296-001-04-8	cyclandelate	Launched	calcium channel blocker		cardiology|rheumatology	claudication|arteriosclerosis|Raynaud's disease	0	96.1	Selleck	S4189	Cyclandelate	276.173	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:12,r|	WZHCOOQXZCIUNC-QEJZJMRPSA-N	41097974.0		WZHCOOQXZCIUNC
BRD-A41840684-001-01-8	cyclic-AMP	Preclinical		CNGA3|TRPM7			0	100.0	ChemDiv	6048-0067		329.053	Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10,&2:12,&3:15,&4:19,&5:20,r|	IVOMOUWHDPKRLL-DEGSGYPDSA-N	40467852.0		IVOMOUWHDPKRLL
BRD-K79501723-001-04-6	cyclizine	Launched	histamine receptor modulator	HRH1|SULT1E1	gastroenterology|neurology/psychiatry	nausea|vomiting|vertigo|motion sickness	0	99.27	MicroSource	1500211	CYCLIZINE	266.178	CN1CCN(CC1)C(c1ccccc1)c1ccccc1	UVKZSORBKUEBAZ-UHFFFAOYSA-N	6726.0		UVKZSORBKUEBAZ
BRD-K79501723-300-01-8	cyclizine	Launched	histamine receptor modulator	HRH1|SULT1E1	gastroenterology|neurology/psychiatry	nausea|vomiting|vertigo|motion sickness	0	95.97	Selleck	S4139	Cyclizine 2HCl	266.178	CN1CCN(CC1)C(c1ccccc1)c1ccccc1	UVKZSORBKUEBAZ-UHFFFAOYSA-N	6726.0		UVKZSORBKUEBAZ
BRD-K79501723-300-02-6	cyclizine	Launched	histamine receptor modulator	HRH1|SULT1E1	gastroenterology|neurology/psychiatry	nausea|vomiting|vertigo|motion sickness	0	97.09	Selleck	S4139	CYCLIZINE	266.178	CN1CCN(CC1)C(c1ccccc1)c1ccccc1	UVKZSORBKUEBAZ-UHFFFAOYSA-N	6726.0		UVKZSORBKUEBAZ
BRD-K42348709-003-13-1	cyclobenzaprine	Launched	adrenergic receptor agonist|serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	0	97.11	MicroSource	1503207	CYCLOBENZAPRINE HYDROCHLORIDE	275.167	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|	JURKNVYFZMSNLP-UHFFFAOYSA-N	2895.0		JURKNVYFZMSNLP
BRD-K42348709-003-14-9	cyclobenzaprine	Launched	adrenergic receptor agonist|serotonin receptor agonist	HTR2A	neurology/psychiatry	spasms	0	98.15	MedChemEx	HY-B0740	Cyclobenzaprine (hydrochloride)	275.167	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|	JURKNVYFZMSNLP-UHFFFAOYSA-N	2895.0		JURKNVYFZMSNLP
BRD-K14379200-001-04-7	cyclocreatine	Phase 1	creatine kinase substrate				0	96.8	Sigma	MFCD00134455	(2-imino-1-imidazolidinyl)acetic acid	143.069	NC1=NCCN1CC(O)=O |t:1|	AMHZIUVRYRVYBA-UHFFFAOYSA-N	2896.0		AMHZIUVRYRVYBA
BRD-K67536197-003-11-4	cyclocytidine	Preclinical	DNA synthesis inhibitor|RNA synthesis inhibitor				0	99.31	MicroSource	1504137	ANCITABINE HYDROCHLORIDE	225.075	OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	BBDAGFIXKZCXAH-CCXZUQQUSA-N	25051.0	BRD-K67536197-001-02-7|BRD-K67536197-001-02-7|BRD-K67536197-001-02-7	BBDAGFIXKZCXAH
BRD-K67536197-003-12-9	cyclocytidine	Preclinical	DNA synthesis inhibitor|RNA synthesis inhibitor				0	100.0	MedChemEx	HY-N0093	Ancitabine (hydrochloride)	225.075	OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	BBDAGFIXKZCXAH-CCXZUQQUSA-N	25051.0		BBDAGFIXKZCXAH
BRD-K67536197-003-10-6	cyclocytidine	Preclinical	DNA synthesis inhibitor|RNA synthesis inhibitor				0	100.0	Selleck	S1973	Cyclocytidine HCl	225.075	OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	BBDAGFIXKZCXAH-CCXZUQQUSA-N	25051.0	BRD-K80834753-003-01-3	BBDAGFIXKZCXAH
BRD-K36055864-001-19-2	cycloheximide	Preclinical	protein synthesis inhibitor	RPL3			0	83.87	MicroSource	1502112	CYCLOHEXIMIDE	281.163	C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	YPHMISFOHDHNIV-FSZOTQKASA-N	6197.0		YPHMISFOHDHNIV
BRD-K36055864-001-20-0	cycloheximide	Preclinical	protein synthesis inhibitor	RPL3			0	89.79	Sigma	MFCD00082346	4-{(2R)-2-[(1S,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl}-2,6-piperidinedione	281.163	C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	YPHMISFOHDHNIV-FSZOTQKASA-N	6197.0		YPHMISFOHDHNIV
BRD-K58938839-001-06-9	cyclopamine	Preclinical	hedgehog pathway inhibitor				0	87.32	Apollo	BIC1011	Cyclopamine	411.314	C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C |c:32,t:18|	QASFUMOKHFSJGL-LAFRSMQTSA-N	442972.0		QASFUMOKHFSJGL
BRD-A41250306-001-11-7	cyclopenthiazide	Launched	thiazide diuretic		cardiology	hypertension|congestive heart failure	0	99.7	Prestwick	Prestw-994	Cyclopenthiazide	379.043	NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|	BKYKPTRYDKTTJY-CYBMUJFWSA-N	6604279.0		BKYKPTRYDKTTJY
BRD-A41250306-001-12-9	cyclopenthiazide	Launched	thiazide diuretic		cardiology	hypertension|congestive heart failure	0	96.49	Toronto	c988420	cyclopenthiazide	379.043	NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9,r|	BKYKPTRYDKTTJY-CYBMUJFWSA-N	6604279.0		BKYKPTRYDKTTJY
BRD-A77291778-003-22-0	cyclopentolate	Launched	acetylcholine receptor antagonist		ophthalmology	mydriasis|cycloplegia	0	94.68	MicroSource	1500212	CYCLOPENTOLATE HYDROCHLORIDE	291.183	CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|	SKYSRIRYMSLOIN-OAHLLOKOSA-N	6604325.0		SKYSRIRYMSLOIN
BRD-A77291778-001-23-9	cyclopentolate	Launched	acetylcholine receptor antagonist		ophthalmology	mydriasis|cycloplegia	0	83.98	Sigma	MFCD00599448	CYCLOPENTOLATE	291.183	CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|	SKYSRIRYMSLOIN-OAHLLOKOSA-N	6604325.0		SKYSRIRYMSLOIN
BRD-A09722536-002-18-0	cyclophosphamide	Launched	DNA alkylating agent	CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP3A4|CYP3A5|CYP3A7	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer	0	83.88	MicroSource	1500213	CYCLOPHOSPHAMIDE	260.025	ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|	CMSMOCZEIVJLDB-CQSZACIVSA-N	9554282.0		CMSMOCZEIVJLDB
BRD-A09722536-002-19-8	cyclophosphamide	Launched	DNA alkylating agent	CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP3A4|CYP3A5|CYP3A7	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer	0	93.6	Selleck	S2057	Cyclophosphamide monohydrate	260.025	ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|	CMSMOCZEIVJLDB-CQSZACIVSA-N	9554282.0		CMSMOCZEIVJLDB
BRD-A09722536-002-17-2	cyclophosphamide	Launched	DNA alkylating agent	CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP3A4|CYP3A5|CYP3A7	hematologic malignancy|oncology	Hodgkin's lymphoma|small lymphocytic lymphoma (SLL)|breast cancer|neuroblastoma|Burkitt's lymphoma|multiple myeloma|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)|true histiocytic lymphoma (THL)|retinoblastoma|ovarian cancer	0	10.02	Selleck	S2057	Cyclophosphamide monohydrate	260.025	ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|	CMSMOCZEIVJLDB-CQSZACIVSA-N	9554282.0		CMSMOCZEIVJLDB
BRD-A10420615-001-05-1	cyclopiazonic-acid	Preclinical	ATPase inhibitor	ATP2A1			0	99.1	Tocris	1235	(6aR,10Z,11aS,11bR)-10-(1-hydroxyethylidene)-7,7-dimethyl-6a,7,11a,11b-tetrahydro-6H-pyrrolo[1',2':2,3]isoindolo[4,5,6-cd]indol	336.147	CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|	SZINUGQCTHLQAZ-DQYPLSBCSA-N	54682463.0	BRD-K93666001-001-01-8	SZINUGQCTHLQAZ
BRD-A10420615-001-04-4	cyclopiazonic-acid	Preclinical	ATPase inhibitor	ATP2A1			0	81.26	Tocris	1235	Cyclopiazonic acid	336.147	CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6,7,8,&1:3,c:3|	SZINUGQCTHLQAZ-DQYPLSBCSA-N	54682463.0		SZINUGQCTHLQAZ
BRD-K87226815-001-21-3	cycloserine-(D)	Launched	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis|tuberculosis	0	0.0	MedChemEx	HY-B0030	D-Cycloserine	102.043	N[C@@H]1CONC1=O	DYDCUQKUCUHJBH-UWTATZPHSA-N	6234.0		DYDCUQKUCUHJBH
BRD-K87226815-001-17-1	cycloserine-(D)	Launched	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis|tuberculosis	0	0.0	MicroSource	1500215	CYCLOSERINE (D)	102.043	N[C@@H]1CONC1=O	DYDCUQKUCUHJBH-UWTATZPHSA-N	6234.0		DYDCUQKUCUHJBH
BRD-K87226815-001-20-5	cycloserine-(D)	Launched	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis|tuberculosis	0	0.0	MedChemEx	HY-B0030	D-Cycloserine	102.043	N[C@@H]1CONC1=O	DYDCUQKUCUHJBH-UWTATZPHSA-N	6234.0		DYDCUQKUCUHJBH
BRD-K87226815-001-18-9	cycloserine-(D)	Launched	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis|tuberculosis	0	0.0	Selleck	S1998	D-Cycloserine	102.043	N[C@@H]1CONC1=O	DYDCUQKUCUHJBH-UWTATZPHSA-N	6234.0	BRD-K53226837-001-08-4	DYDCUQKUCUHJBH
BRD-K87226815-001-19-7	cycloserine-(D)	Launched	bacterial cell wall synthesis inhibitor	GRIN1	infectious disease	tuberculosis|tuberculosis	0	0.0	Selleck	S1998	D-Cycloserine	102.043	N[C@@H]1CONC1=O	DYDCUQKUCUHJBH-UWTATZPHSA-N	6234.0		DYDCUQKUCUHJBH
BRD-K13533483-001-19-9	cyclosporin-A	Launched	calcineurin inhibitor	ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3	rheumatology|dermatology	rheumatoid arthritis|psoriasis	0	99.24	MicroSource	1502202	CYCLOSPORINE	1201.841	CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|	PMATZTZNYRCHOR-MAYCVHQQSA-N			PMATZTZNYRCHOR
BRD-K13533483-001-20-9	cyclosporin-A	Launched	calcineurin inhibitor	ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3	rheumatology|dermatology	rheumatoid arthritis|psoriasis	0	99.52	Tocris	1101	Cyclosporin A	1201.841	CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2,&2:6,&3:7,&4:9,&5:19,&6:27,&7:36,&8:45,&9:50,&10:55,&11:64,&12:68,r|	PMATZTZNYRCHOR-MAYCVHQQSA-N			PMATZTZNYRCHOR
BRD-K13533483-001-18-9	cyclosporin-A	Launched	calcineurin inhibitor	ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3	rheumatology|dermatology	rheumatoid arthritis|psoriasis	0	94.88	Tocris	1101	Cyclosporin A	1201.841	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PMATZTZNYRCHOR-CGLBZJNRSA-N	5284373.0		PMATZTZNYRCHOR
BRD-K13533483-001-16-2	cyclosporin-A	Launched	calcineurin inhibitor	ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3	rheumatology|dermatology	rheumatoid arthritis|psoriasis	0	98.93	Selleck	S2286	Cyclosporin A	1201.841	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PMATZTZNYRCHOR-CGLBZJNRSA-N	5284373.0	BRD-K03152136-001-01-6	PMATZTZNYRCHOR
BRD-K13533483-001-17-0	cyclosporin-A	Launched	calcineurin inhibitor	ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3	rheumatology|dermatology	rheumatoid arthritis|psoriasis	0	98.67	Selleck	S1514	Cyclosporine	1201.841	CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C	PMATZTZNYRCHOR-CGLBZJNRSA-N	5284373.0	BRD-A11864475-001-02-5	PMATZTZNYRCHOR
BRD-A38675539-001-13-5	cyclothiazide	Launched	glutamate receptor modulator	CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3	cardiology	hypertension	0	56.71	Tocris	713	Cyclothiazide	389.027	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|	BOCUKUHCLICSIY-JWUFEOHASA-N	101691640.0		BOCUKUHCLICSIY
BRD-A38675539-001-11-9	cyclothiazide	Launched	glutamate receptor modulator	CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3	cardiology	hypertension	0	63.11	MicroSource	1503263	CYCLOTHIAZIDE	389.027	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|	BOCUKUHCLICSIY-JWUFEOHASA-N	101691640.0		BOCUKUHCLICSIY
BRD-A38675539-001-14-3	cyclothiazide	Launched	glutamate receptor modulator	CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3	cardiology	hypertension	0	59.05	Sigma	MFCD00210192	3-[(1S,4S)-bicyclo[2.2.1]hept-5-en-2-yl]-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide	389.027	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|	BOCUKUHCLICSIY-JWUFEOHASA-N	101691640.0	BRD-A38639147-001-17-6	BOCUKUHCLICSIY
BRD-A38675539-001-12-7	cyclothiazide	Launched	glutamate receptor modulator	CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3	cardiology	hypertension	0	65.61	DuPont	A001186324	3-(bicyclo[2.2.1]hept-5-en-2-yl)-6-chloro-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide	389.027	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|	BOCUKUHCLICSIY-JWUFEOHASA-N	101691640.0		BOCUKUHCLICSIY
BRD-A38675539-001-10-1	cyclothiazide	Launched	glutamate receptor modulator	CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3	cardiology	hypertension	0	59.16	Tocris	713	Cyclothiazide	389.027	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9,&2:14,&3:16,&4:18,r,c:21|	BOCUKUHCLICSIY-JWUFEOHASA-N	101691640.0		BOCUKUHCLICSIY
BRD-K59866480-001-07-3	cyclovalone	Launched	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	0	97.7	Sigma	MFCD00019515	(2E,6E)-2,6-bis(4-hydroxy-3-methoxybenzylidene)cyclohexanone	366.147	COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O	DHKKONBXGAAFTB-OTYYAQKOSA-N	1550234.0		DHKKONBXGAAFTB
BRD-K59866480-001-09-9	cyclovalone	Launched	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	0	95.38	Sigma	MFCD00019515	2,6-DIVANILLYLIDENECYCLOHEXANONE	366.147	COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O	DHKKONBXGAAFTB-OTYYAQKOSA-N	1550234.0		DHKKONBXGAAFTB
BRD-K59866480-001-08-1	cyclovalone	Launched	breast cancer resistance protein inhibitor	ABCG2	gastroenterology	bile stimulation	0	0.0	Enamine	Z46041679		366.147	COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O	DHKKONBXGAAFTB-OTYYAQKOSA-N	1550234.0	BRD-K84397942-001-01-3	DHKKONBXGAAFTB
BRD-K27799744-001-02-8	cyclovirobuxin-D	Preclinical	calcium channel modulator				0	100.0	Selleck	S2402	Cyclovirobuxin D (Bebuxine)	402.361	CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	GMNAPBAUIVITMI-ABNIRSKTSA-N	260439.0		GMNAPBAUIVITMI
BRD-K27799744-001-03-6	cyclovirobuxin-D	Preclinical	calcium channel modulator				0	0.0	Selleck	S2402	Cyclovirobuxin D	402.361	CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	GMNAPBAUIVITMI-ABNIRSKTSA-N	260439.0	BRD-K35479987-001-01-5	GMNAPBAUIVITMI
BRD-K27799744-001-04-4	cyclovirobuxin-D	Preclinical	calcium channel modulator				0	100.0	Selleck	S2402	Cyclovirobuxin D (Bebuxine)	402.361	CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	GMNAPBAUIVITMI-ABNIRSKTSA-N	260439.0		GMNAPBAUIVITMI
BRD-K00005335-001-01-9	CycLuc1	Preclinical					0	85.83	MedChemEx	HY-111653	CycLuc1	305.029	OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 |c:6|	HBZBAMXERPYTFS-SECBINFHSA-N	91885395.0		HBZBAMXERPYTFS
BRD-K00003404-001-01-9	CYC065	Phase 1	CDK inhibitor				0	95.63	MedChemEx	HY-101212	CYC065	397.259	CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O	DLPIYBKBHMZCJI-WBVHZDCISA-N	24983461.0		DLPIYBKBHMZCJI
BRD-K64866502-001-04-7	CYC116	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|KDR			0	93.87	Selleck	S1171	CYC116	368.142	Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	GPSZYOIFQZPWEJ-UHFFFAOYSA-N	6420138.0		GPSZYOIFQZPWEJ
BRD-K64866502-001-03-9	CYC116	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|KDR			0	86.93	Selleck	S1171	CYC116	368.142	Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	GPSZYOIFQZPWEJ-UHFFFAOYSA-N	6420138.0		GPSZYOIFQZPWEJ
BRD-K69877120-001-02-9	CYM-50260	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR4			0	94.06	Tocris	4677	CYM 50260	348.984	FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1	FHPOTBQOUBMMCI-UHFFFAOYSA-N	44620894.0		FHPOTBQOUBMMCI
BRD-K69877120-001-01-7	CYM-50260	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR4			0	96.41	Tocris	4677	CYM 50260	348.984	FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1	FHPOTBQOUBMMCI-UHFFFAOYSA-N	44620894.0		FHPOTBQOUBMMCI
BRD-K80666802-003-02-9	CYM-50358	Preclinical	sphingosine 1-phosphate receptor antagonist	S1PR4			0	95.52	Tocris	4679	CYM 50358 hydrochloride	388.075	Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl	QWJOPXDAQCDRRM-UHFFFAOYSA-N	53358422.0		QWJOPXDAQCDRRM
BRD-K80666802-003-01-0	CYM-50358	Preclinical	sphingosine 1-phosphate receptor antagonist	S1PR4			0	97.71	Tocris	4679	CYM 50358 hydrochloride	388.075	Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl	QWJOPXDAQCDRRM-UHFFFAOYSA-N	53358422.0		QWJOPXDAQCDRRM
BRD-K27732927-001-04-9	CYM-50769	Preclinical	neuropeptide receptor antagonist	NPBWR1			0	98.57	Tocris	4948	CYM 50769	416.093	COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1	QHVSQUYCVUHYKT-UHFFFAOYSA-N	50904505.0		QHVSQUYCVUHYKT
BRD-K27732927-001-03-6	CYM-50769	Preclinical	neuropeptide receptor antagonist	NPBWR1			0	98.77	Tocris	4948	CYM 50769	416.093	COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1	QHVSQUYCVUHYKT-UHFFFAOYSA-N	50904505.0		QHVSQUYCVUHYKT
BRD-A43005764-003-01-5	CYM-5442	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR1			0	97.43	Tocris	3601	CYM 5442 hydrochloride	409.2	CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|	NUIKTBLZSPQGCP-LJQANCHMSA-N	93977386.0		NUIKTBLZSPQGCP
BRD-A43005764-003-02-9	CYM-5442	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR1			0	96.42	Tocris	3601	CYM 5442 hydrochloride	409.2	CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|	NUIKTBLZSPQGCP-LJQANCHMSA-N	93977386.0		NUIKTBLZSPQGCP
BRD-K29151923-001-01-5	CYM-5520	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR2			0	96.49	Tocris	5418	CYM 5520	345.148	Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1	FMYGNANMYYHBSU-UHFFFAOYSA-N	25110470.0		FMYGNANMYYHBSU
BRD-K29151923-001-02-9	CYM-5520	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR2			0	98.49	Tocris	5418	CYM5520	345.148	Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1	FMYGNANMYYHBSU-UHFFFAOYSA-N	25110470.0		FMYGNANMYYHBSU
BRD-K75940276-001-04-9	CYM-5541	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR3			0	84.02	Tocris	4897	CYM 5541	316.215	O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1	NDKGACIWVAOUQH-UHFFFAOYSA-N	17253208.0		NDKGACIWVAOUQH
BRD-K75940276-001-03-3	CYM-5541	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR3			0	93.59	Tocris	4897	CYM 5541	316.215	O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1	NDKGACIWVAOUQH-UHFFFAOYSA-N	17253208.0		NDKGACIWVAOUQH
BRD-A62798249-001-04-4	cypermethrin	Launched			infectious disease	flea control	0	42.23	MicroSource	1503606	CYPERMETHRIN	415.074	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|	KAATUXNTWXVJKI-CMKODMSKSA-N	12617361.0		KAATUXNTWXVJKI
BRD-A62798249-001-05-9	cypermethrin	Launched			infectious disease	flea control	0	0.0	LKT	C9660	Cypermethrin	415.074	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3,&2:8,&3:12,r|	KAATUXNTWXVJKI-CMKODMSKSA-N	12617361.0		KAATUXNTWXVJKI
BRD-K28143534-003-26-7	cyproheptadine	Launched	histamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism	0	0.0	MicroSource	1505973	CYPROHEPTADINE HYDROCHLORIDE	287.167	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|	JJCFRYNCJDLXIK-UHFFFAOYSA-N	2913.0		JJCFRYNCJDLXIK
BRD-K28143534-001-02-2	cyproheptadine	Launched	histamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism	0	98.68	MicroSource	1505973	CYPROHEPTADINE HYDROCHLORIDE	287.167	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|	JJCFRYNCJDLXIK-UHFFFAOYSA-N	2913.0		JJCFRYNCJDLXIK
BRD-K28143534-003-25-9	cyproheptadine	Launched	histamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism	0	98.46	Tocris	996	Cyproheptadine hydrochloride	287.167	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|	JJCFRYNCJDLXIK-UHFFFAOYSA-N	2913.0		JJCFRYNCJDLXIK
BRD-K28143534-003-24-2	cyproheptadine	Launched	histamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7	allergy|otolaryngology|ophthalmology|dermatology	allergic rhinitis|vasomotor rhinitis|conjunctivitis|urticaria|dermatographism	0	98.41	Selleck	S2044	Cyproheptadine HCl	287.167	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|	JJCFRYNCJDLXIK-UHFFFAOYSA-N	2913.0		JJCFRYNCJDLXIK
BRD-K41141507-001-17-0	cyproterone-acetate	Launched	androgen receptor antagonist	ADORA1|AR	oncology	prostate cancer	0	92.44	MicroSource	1500216	CYPROTERONE ACETATE	416.175	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	UWFYSQMTEOIJJG-FDTZYFLXSA-N	9880.0	BRD-A95207036-001-04-4	UWFYSQMTEOIJJG
BRD-K41141507-001-15-4	cyproterone-acetate	Launched	androgen receptor antagonist	ADORA1|AR	oncology	prostate cancer	0	89.99	Sigma	MFCD00864671	(2aR,3aS,3bS,3cS,5aS,6R,8aS,8bR)-6-acetyl-10-chloro-3b,5a-dimethyl-2-oxo-2,2a,3,3a,3b,3c,4,5,5a,6,7,8,8a,8b-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-6-yl acetate	416.175	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	UWFYSQMTEOIJJG-FDTZYFLXSA-N	9880.0		UWFYSQMTEOIJJG
BRD-K41141507-001-18-9	cyproterone-acetate	Launched	androgen receptor antagonist	ADORA1|AR	oncology	prostate cancer	0	0.0	MedChemEx	HY-13604	Cyproterone (acetate)	416.175	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	UWFYSQMTEOIJJG-FDTZYFLXSA-N	9880.0		UWFYSQMTEOIJJG
BRD-K41141507-001-16-2	cyproterone-acetate	Launched	androgen receptor antagonist	ADORA1|AR	oncology	prostate cancer	0	94.11	Selleck	S2042	Cyproterone Acetate	416.175	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	UWFYSQMTEOIJJG-FDTZYFLXSA-N	9880.0	BRD-K59573506-001-01-8	UWFYSQMTEOIJJG
BRD-K36711084-001-02-0	cyromazine	Launched					0	99.31	MicroSource	1505903	CYROMAZINE	166.097	Nc1nc(N)nc(NC2CC2)n1	LVQDKIWDGQRHTE-UHFFFAOYSA-N	47866.0		LVQDKIWDGQRHTE
BRD-K36711084-001-01-2	cyromazine	Launched					0	97.92	Selleck	S4167	Cyromazine	166.097	Nc1nc(N)nc(NC2CC2)n1	LVQDKIWDGQRHTE-UHFFFAOYSA-N	47866.0		LVQDKIWDGQRHTE
BRD-K92611362-003-03-9	cysteamine	Launched	tissue transglutaminase inhibitor	NPY2R|SST	metabolism	cystinosis	1	100.0	MedChemEx	HY-77591	Cysteamine hydrochloride	77.03	NCCS	UFULAYFCSOUIOV-UHFFFAOYSA-N	6058.0		UFULAYFCSOUIOV
BRD-K92611362-001-02-6	cysteamine	Launched	tissue transglutaminase inhibitor	NPY2R|SST	metabolism	cystinosis	1	0.0	MicroSource	1504226	CYSTEAMINE HYDROCHLORIDE	77.03	NCCS	UFULAYFCSOUIOV-UHFFFAOYSA-N	6058.0	BRD-M77687198-001-11-4	UFULAYFCSOUIOV
BRD-K23363278-001-02-1	CYT-997	Phase 2	tubulin polymerization inhibitor	TUBB			0	96.56	Selleck	S2195		434.243	CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	MTJHLONVHHPNSI-IBGZPJMESA-N	11351021.0		MTJHLONVHHPNSI
BRD-K33106058-001-20-0	cytarabine	Launched	ribonucleotide reductase inhibitor	POLA1|POLB|POLD1|POLE	hematologic malignancy	acute lymphoblastic leukemia (ALL)|chronic lymphocytic leukemia (CLL)|acute myeloid leukemia (AML)|non-Hodgkin lymphoma (NHL)	0	90.88	Selleck	S1648	Cytarabine	243.086	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	UHDGCWIWMRVCDJ-CCXZUQQUSA-N	6253.0	BRD-K71847383-001-07-5	UHDGCWIWMRVCDJ
BRD-K71847383-001-12-5	cytidine	Launched					0	100.0	Selleck	S2053	Cytidine	243.086	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	UHDGCWIWMRVCDJ-XVFCMESISA-N	6175.0	BRD-K33106058-001-16-8	UHDGCWIWMRVCDJ
BRD-K71847383-001-03-4	cytidine	Launched					0		Sigma	C4654	Cytidine	243.086	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m1/s1	6175.0		UHDGCWIWMRVCDJ
BRD-K71847383-001-13-3	cytidine	Launched					0		MicroSource	1500217	CYTARABINE	243.086	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7-,8-/m1/s1	6175.0		UHDGCWIWMRVCDJ
BRD-K74186897-001-13-2	cytisine	Launched	acetylcholine receptor agonist	CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4	neurology/psychiatry	nicotinism	0	93.11	MicroSource	1504027	CYTISINE	190.111	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	ANJTVLIZGCUXLD-DTWKUNHWSA-N	10235.0	BRD-A55579717-001-04-0	ANJTVLIZGCUXLD
BRD-K74186897-001-11-6	cytisine	Launched	acetylcholine receptor agonist	CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4	neurology/psychiatry	nicotinism	0	89.64	Tocris	1390	(-)-Cytisine	190.111	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	ANJTVLIZGCUXLD-DTWKUNHWSA-N	10235.0		ANJTVLIZGCUXLD
BRD-K74186897-001-10-8	cytisine	Launched	acetylcholine receptor agonist	CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4	neurology/psychiatry	nicotinism	0	79.25	Selleck	S2287	Cytisine	190.111	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	ANJTVLIZGCUXLD-DTWKUNHWSA-N	10235.0		ANJTVLIZGCUXLD
BRD-K74186897-001-12-4	cytisine	Launched	acetylcholine receptor agonist	CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4	neurology/psychiatry	nicotinism	0	98.23	Selleck	S2287	Cytisine (Baphitoxine, Sophorine)	190.111	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	ANJTVLIZGCUXLD-DTWKUNHWSA-N	10235.0		ANJTVLIZGCUXLD
BRD-K26664453-001-13-9	cytochalasin-B	Phase 2	microtubule inhibitor	ACTB			0	93.35	Tocris	5474	Cytochalasin B	479.267	C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20,30|	GBOGMAARMMDZGR-TYHYBEHESA-N	5311281.0		GBOGMAARMMDZGR
BRD-K48988407-001-01-2	cytochlor	Phase 1					0	100.0	Berry	PY 7114		261.052	Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	NGGRGTWYSXYVDK-FSDSQADBSA-N	92132144.0		NGGRGTWYSXYVDK
BRD-K87737963-001-09-9	cyt387	Phase 3	JAK inhibitor	JAK1|JAK2|JAK3			0	95.39	MedChemEx	HY-10961	Momelotinib	414.18	O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	ZVHNDZWQTBEVRY-UHFFFAOYSA-N	25062766.0		ZVHNDZWQTBEVRY
BRD-K87737963-001-07-8	cyt387	Phase 3	JAK inhibitor	JAK1|JAK2|JAK3			0	90.97	Selleck	S2219	Momelotinib (CYT387)	414.18	O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	ZVHNDZWQTBEVRY-UHFFFAOYSA-N	25062766.0		ZVHNDZWQTBEVRY
BRD-K87737963-001-06-0	cyt387	Phase 3	JAK inhibitor	JAK1|JAK2|JAK3			0	95.48	Selleck	S2219	CYT387	414.18	O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	ZVHNDZWQTBEVRY-UHFFFAOYSA-N	25062766.0		ZVHNDZWQTBEVRY
BRD-K79353516-001-05-0	CY208-243	Phase 2	dopamine receptor agonist	CALY			0	66.95	Tocris	1249	(6aR,12bR)-7-methyl-4,6,6a,7,8,12b-hexahydroindolo[4,3-ab]phenanthridine	274.147	CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	WRNKIDLXXXIELU-IEBWSBKVSA-N	58144.0		WRNKIDLXXXIELU
BRD-K79353516-001-04-3	CY208-243	Phase 2	dopamine receptor agonist	CALY			0	12.69	Tocris	1249	CY 208-243	274.147	CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	WRNKIDLXXXIELU-IEBWSBKVSA-N	58144.0		WRNKIDLXXXIELU
BRD-K87021635-003-03-9	CZC-54252	Preclinical	leucine rich repeat kinase inhibitor	LRRK2			0	98.82	Tocris	4534	CZC 54252 hydrochloride	504.135	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1	CLGWUCNXOBLWFM-UHFFFAOYSA-N	44252734.0		CLGWUCNXOBLWFM
BRD-K87021635-003-02-2	CZC-54252	Preclinical	leucine rich repeat kinase inhibitor	LRRK2			0	96.05	Tocris	4534	CZC 54252 hydrochloride	504.135	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1	CLGWUCNXOBLWFM-UHFFFAOYSA-N	44252734.0		CLGWUCNXOBLWFM
BRD-K01377300-001-01-1	CZC24832	Preclinical	PI3K inhibitor	PIK3CG			0	96.68	Selleck	S7018	CZC24832	364.112	CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	RXRZPHQBTHQXSV-UHFFFAOYSA-N	42623951.0		RXRZPHQBTHQXSV
BRD-K01377300-001-02-9	CZC24832	Preclinical	PI3K inhibitor	PIK3CG			0	98.69	Tocris	4674	CZC 24832	364.112	CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	RXRZPHQBTHQXSV-UHFFFAOYSA-N	42623951.0		RXRZPHQBTHQXSV
BRD-M12328004-001-01-8	C106	Phase 3					0	0.0	Enzo	C106	(+)-Nicotine di-p-toluoyl-D-tartrate	548.216	CN1CCC[C@@H]1c1cccnc1.Cc1ccc(cc1)C(=O)O[C@@H]([C@@H](OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O |&1:5,&2:22,&3:23,r|	GEGPCGHEPLKDLY-DRHSTVBOSA-N	11957647.0		GEGPCGHEPLKDLY
BRD-K83914624-415-01-3	C11-Acetate	Phase 3		ABAT|ACE|AKR1C3|CA2|CELA1|ESR2|FFAR2|FFAR3|HPRT1|LTA4H|MMP12|NOS1|NOS3|PLA2G1B|PTPN1|SOD1|TXN			1	0.0	SantaCruz	sc-258338	Yttrium Acetate Tetrahydrate	88.906	[Y+3]	GRTBAGCGDOYUBE-UHFFFAOYSA-N	168049.0		GRTBAGCGDOYUBE
BRD-K00003114-001-01-9	C188-9	Preclinical	STAT inhibitor				0	91.21	MedChemEx	HY-112288	C188-9	471.114	COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12	QDCJDYWGYVPBDO-UHFFFAOYSA-N	1324494.0		QDCJDYWGYVPBDO
BRD-K43167535-001-01-3	C34	Preclinical	toll-like receptor inhibitor	TLR4			0	100.0	Tocris	5373	C34	389.169	CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O	KMIQMFHPUJUDMC-HHARLNAUSA-N	91691128.0		KMIQMFHPUJUDMC
BRD-K43167535-001-02-9	C34	Preclinical	toll-like receptor inhibitor	TLR4			0	95.6	Tocris	5373	C34	389.169	CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O	KMIQMFHPUJUDMC-HHARLNAUSA-N	91691128.0		KMIQMFHPUJUDMC
BRD-K73383190-001-03-1	C646	Preclinical	histone acetyltransferase inhibitor	EP300			0	88.09	Selleck	S7152	C646	445.127	CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|	HEKJYZZSCQBJGB-UHFFFAOYSA-N	2871948.0	BRD-K68548958-001-04-6	HEKJYZZSCQBJGB
BRD-K73383190-001-04-9	C646	Preclinical	histone acetyltransferase inhibitor	EP300			0	14.83	Tocris	4200	C 646	445.127	CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|	HEKJYZZSCQBJGB-UHFFFAOYSA-N	2871948.0		HEKJYZZSCQBJGB
BRD-K73383190-001-02-3	C646	Preclinical	histone acetyltransferase inhibitor	EP300			0	88.71	Selleck	S7152	C646	445.127	CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|	HEKJYZZSCQBJGB-UHFFFAOYSA-N	2871948.0	BRD-K19202888-001-01-1	HEKJYZZSCQBJGB
BRD-A05674712-001-06-0	D,L-mevalonic-acid-lactone	Preclinical					1	0.0	Prestwick	Prestw-750	Mevalonic-D, L acid lactone	130.063	C[C@@]1(O)CCOC(=O)C1 |&1:1,r|	JYVXNLLUYHCIIH-ZCFIWIBFSA-N	6419891.0		JYVXNLLUYHCIIH
BRD-K74377520-001-01-7	D-(+)-maltose	Preclinical		MGAM			0	100.0	MicroSource	1301024	D-(+)-MALTOSE	342.116	OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O	GUBGYTABKSRVRQ-QUYVBRFLSA-N	6255.0		GUBGYTABKSRVRQ
BRD-K74377520-001-02-9	D-(+)-maltose	Preclinical		MGAM			0	100.0	Sigma	MFCD00062317	(2R,3R,4R,5S,6R)-6-(hydroxymethyl)-5-(((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2,3,4-triol	342.116	OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O	GUBGYTABKSRVRQ-QUYVBRFLSA-N	6255.0		GUBGYTABKSRVRQ
BRD-K64636206-001-02-7	D-alpha-tocopheryl-succinate	Launched					0	93.52	SantaCruz	sc-200141	D-??-Tocopheryl Succinate	530.397	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1	IELOKBJPULMYRW-NJQVLOCASA-N	20353.0		IELOKBJPULMYRW
BRD-K04657451-001-01-0	D-delta-tocopherol	Launched					0	91.79	Acros	42105	D-delta-Tocopherol, 93%	402.35	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1	GZIFEOYASATJEH-VHFRWLAGSA-N	92094.0		GZIFEOYASATJEH
BRD-K20879694-001-01-7	D-limonene	Phase 1					0	0.0	Sigma	MFCD00062991	(4R)-4-isopropenyl-1-methyl-1-cyclohexene	136.125	CC(=C)[C@@H]1CCC(C)=CC1 |c:7|	XMGQYMWWDOXHJM-JTQLQIEISA-N	440917.0		XMGQYMWWDOXHJM
BRD-K20879694-001-02-5	D-limonene	Phase 1					0	0.0	MicroSource	307080	d-LIMONENE	136.125	CC(=C)[C@@H]1CCC(C)=CC1 |c:7|	XMGQYMWWDOXHJM-JTQLQIEISA-N	440917.0	BRD-A81494260-001-02-5	XMGQYMWWDOXHJM
BRD-K00911807-003-01-2	D-phenylalanine	Preclinical	enkephalinase inhibitor	CCBL1|CRH|HCAR3			0	84.31	MicroSource	1503391	D-PHENYLALANINE	165.079	N[C@H](Cc1ccccc1)C(O)=O	COLNVLDHVKWLRT-MRVPVSSYSA-N	71567.0		COLNVLDHVKWLRT
BRD-K00911807-001-03-2	D-phenylalanine	Preclinical	enkephalinase inhibitor	CCBL1|CRH|HCAR3			0	72.63	Selleck	S4153	D-Phenylalanine	165.079	N[C@H](Cc1ccccc1)C(O)=O	COLNVLDHVKWLRT-MRVPVSSYSA-N	71567.0		COLNVLDHVKWLRT
BRD-K00911807-001-04-0	D-phenylalanine	Preclinical	enkephalinase inhibitor	CCBL1|CRH|HCAR3			0	100.0	Selleck	S4153	D-Phenylalanine	165.079	N[C@H](Cc1ccccc1)C(O)=O	COLNVLDHVKWLRT-MRVPVSSYSA-N	71567.0		COLNVLDHVKWLRT
BRD-K71822263-001-03-2	D-serine	Launched	glutamate receptor agonist	GLRA1|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|SERPINB3			0	100.0	Enzo	AC392	D-Serine	105.043	N[C@H](CO)C(O)=O	MTCFGRXMJLQNBG-UWTATZPHSA-N	71077.0		MTCFGRXMJLQNBG
BRD-K71822263-001-04-9	D-serine	Launched	glutamate receptor agonist	GLRA1|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|SERPINB3			0	0.0	Tocris	226	D-Serine	105.043	N[C@H](CO)C(O)=O	MTCFGRXMJLQNBG-UWTATZPHSA-N	71077.0		MTCFGRXMJLQNBG
BRD-K29066607-001-02-9	D-157495	Preclinical	decapping scavenger enzyme inhibitor				0	94.7	MedChemEx	HY-102020	RG3039	431.128	Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1	MNLHFGXIUJNDAF-UHFFFAOYSA-N	53258905.0		MNLHFGXIUJNDAF
BRD-K00003205-003-01-9	D-3263	Phase 1	transient receptor potential channel agonist				0	90.23	MedChemEx	HY-16162A	D-3263 (hydrochloride)	373.237	COc1ccc2n(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)c(=O)n(CCN)c2c1	ZGTYTFYRCIRWBL-HYVNUMGLSA-N	44137358.0		ZGTYTFYRCIRWBL
BRD-K09132007-001-07-5	D-4476	Preclinical	TGF beta receptor inhibitor	CSNK1A1|CSNK1D|TGFB1			0	96.91	Tocris	2902	D 4476	398.138	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1	DPDZHVCKYBCJHW-UHFFFAOYSA-N	6419753.0		DPDZHVCKYBCJHW
BRD-K09132007-001-11-7	D-4476	Preclinical	TGF beta receptor inhibitor	CSNK1A1|CSNK1D|TGFB1			0	95.61	Tocris	2902	D 4476	398.138	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1	DPDZHVCKYBCJHW-UHFFFAOYSA-N	6419753.0		DPDZHVCKYBCJHW
BRD-K26997899-001-03-9	D-64131	Preclinical	microtubule inhibitor	TUBB			0	95.78	Tocris	1643	D-64131	251.095	COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	ICMIJSRDISNKOC-UHFFFAOYSA-N	3921152.0		ICMIJSRDISNKOC
BRD-K26997899-001-02-2	D-64131	Preclinical	microtubule inhibitor	TUBB			0	98.74	Tocris	1643	D-64131	251.095	COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	ICMIJSRDISNKOC-UHFFFAOYSA-N	3921152.0		ICMIJSRDISNKOC
BRD-K32372024-001-01-0	D-7193	Phase 2					1	0.0	ChemImpex	4347		324.045	CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	YTPQSLLEROSACP-YUMQZZPRSA-N	6995101.0		YTPQSLLEROSACP
BRD-K01080633-001-02-9	DAA-1106	Preclinical	benzodiazepine receptor agonist	TSPO			0	95.53	MedChemEx	HY-19945	DAA-1106	395.153	COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	DCRZYADKQRHHSF-UHFFFAOYSA-N	10430788.0		DCRZYADKQRHHSF
BRD-K01080633-001-01-9	DAA-1106	Preclinical	benzodiazepine receptor agonist	TSPO			0	98.31	MedChemEx	HY-19945	DAA-1106	395.153	COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	DCRZYADKQRHHSF-UHFFFAOYSA-N	10430788.0		DCRZYADKQRHHSF
BRD-K38168441-001-04-5	dabigatran	Launched	thrombin inhibitor	F2	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	0	66.71	MedChemEx	HY-10163	Dabigatran	471.202	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	YBSJFWOBGCMAKL-UHFFFAOYSA-N	216210.0		YBSJFWOBGCMAKL
BRD-K38168441-001-02-9	dabigatran	Launched	thrombin inhibitor	F2	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	0	69.2	Selleck	S2196	BIBR 953 (Dabigatran etexilate, Pradaxa)	471.202	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	YBSJFWOBGCMAKL-UHFFFAOYSA-N	216210.0		YBSJFWOBGCMAKL
BRD-K38168441-001-05-2	dabigatran	Launched	thrombin inhibitor	F2	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	0	65.98	MedChemEx	HY-10163	Dabigatran	471.202	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	YBSJFWOBGCMAKL-UHFFFAOYSA-N	216210.0		YBSJFWOBGCMAKL
BRD-K38168441-001-03-7	dabigatran	Launched	thrombin inhibitor	F2	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	0	77.34	Selleck	S2196	BIBR 953 (Dabigatran etexilate, Pradaxa)	471.202	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	YBSJFWOBGCMAKL-UHFFFAOYSA-N	216210.0		YBSJFWOBGCMAKL
BRD-K57041787-001-03-9	dabigatran-etexilate	Launched	thrombin inhibitor	F2	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	0	98.31	MedChemEx	HY-10274	Dabigatran etexilate	627.317	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	KSGXQBZTULBEEQ-UHFFFAOYSA-N	9578572.0		KSGXQBZTULBEEQ
BRD-K57041787-066-01-1	dabigatran-etexilate	Launched	thrombin inhibitor	F2	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	0	22.21	MicroSource	1503900	DABIGATRAN ETEXILATE MESYLATE	627.317	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	KSGXQBZTULBEEQ-UHFFFAOYSA-N	9578572.0		KSGXQBZTULBEEQ
BRD-K57041787-001-02-6	dabigatran-etexilate	Launched	thrombin inhibitor	F2	neurology/psychiatry|hematology	stroke|systemic embolism|pulmonary embolism (PE)|deep vein thrombosis (DVT)	0	92.78	Selleck	S2154	Dabigatran Etexilate	627.317	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	KSGXQBZTULBEEQ-UHFFFAOYSA-N	9578572.0		KSGXQBZTULBEEQ
BRD-K09951645-001-11-8	dabrafenib	Launched	RAF inhibitor	BRAF|LIMK1|NEK11|RAF1|SIK1	oncology	melanoma	0	97.66	Selleck	S2807	Dabrafenib	519.101	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	BFSMGDJOXZAERB-UHFFFAOYSA-N	44462760.0		BFSMGDJOXZAERB
BRD-K09951645-001-08-4	dabrafenib	Launched	RAF inhibitor	BRAF|LIMK1|NEK11|RAF1|SIK1	oncology	melanoma	0	98.14	MedChemEx	HY-14660	dabrafenib	519.101	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	BFSMGDJOXZAERB-UHFFFAOYSA-N	44462760.0		BFSMGDJOXZAERB
BRD-K09951645-001-06-8	dabrafenib	Launched	RAF inhibitor	BRAF|LIMK1|NEK11|RAF1|SIK1	oncology	melanoma	0	91.96	Selleck	S2807	Dabrafenib (GSK2118436)	519.101	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	BFSMGDJOXZAERB-UHFFFAOYSA-N	44462760.0		BFSMGDJOXZAERB
BRD-K35520305-001-17-7	dacarbazine	Launched	DNA alkylating agent	PGD|POLA2	oncology|hematologic malignancy	melanoma|Hodgkin's lymphoma	0	98.92	MicroSource	1500218	DACARBAZINE	182.092	CN(C)\N=N\c1nc[nH]c1C(N)=O	FDKXTQMXEQVLRF-ZHACJKMWSA-N	135398738.0		FDKXTQMXEQVLRF
BRD-K35520305-001-16-9	dacarbazine	Launched	DNA alkylating agent	PGD|POLA2	oncology|hematologic malignancy	melanoma|Hodgkin's lymphoma	0	93.54	Selleck	S1221	Dacarbazine	182.092	CN(C)\N=N\c1nc[nH]c1C(N)=O	FDKXTQMXEQVLRF-ZHACJKMWSA-N	135398738.0		FDKXTQMXEQVLRF
BRD-K56957086-001-09-7	dacinostat	Phase 1	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9			0	87.84	Selleck	S1095	LAQ824 (NVP-LAQ824, Dacinostat)	379.19	OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1	BWDQBBCUWLSASG-MDZDMXLPSA-N	6445533.0		BWDQBBCUWLSASG
BRD-K56957086-001-06-3	dacinostat	Phase 1	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9			0	87.31	Selleck	S1095	LAQ824 (Dacinostat)	379.19	OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1	BWDQBBCUWLSASG-MDZDMXLPSA-N	6445533.0		BWDQBBCUWLSASG
BRD-K82861010-001-02-5	daclatasvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	94.53	Selleck	S1482	Daclatasvir (BMS-790052)	738.385	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	FKRSSPOQAMALKA-CUPIEXAXSA-N	25154714.0		FKRSSPOQAMALKA
BRD-K82861010-001-03-3	daclatasvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	94.8	Selleck	S1482	Daclatasvir (BMS-790052)	738.385	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	FKRSSPOQAMALKA-CUPIEXAXSA-N	25154714.0		FKRSSPOQAMALKA
BRD-K57169635-001-05-9	dacomitinib	Launched	EGFR inhibitor	EGFR|ERBB2|ERBB4			0	97.34	Tocris	6231	Dacomitinib	469.168	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	LVXJQMNHJWSHET-AATRIKPKSA-N	11511120.0		LVXJQMNHJWSHET
BRD-K57169635-001-04-5	dacomitinib	Launched	EGFR inhibitor	EGFR|ERBB2|ERBB4			0	95.48	Selleck	S2727	Dacomitinib (PF299804, PF299)	469.168	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	LVXJQMNHJWSHET-AATRIKPKSA-N	11511120.0		LVXJQMNHJWSHET
BRD-K70578146-001-06-7	dactinomycin	Launched	RNA polymerase inhibitor	POLR2A	oncology	testicular carcinoma|Wilm's tumor|rhabdomyosarcoma|Ewing's sarcoma|gestational trophoblastic disease (GTD)	0	77.87	MicroSource	330001	DACTINOMYCIN	1254.628	CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	RJURFGZVJUQBHK-IIXSONLDSA-N	457193.0		RJURFGZVJUQBHK
BRD-K42095107-001-22-1	daidzein	Phase 2	estrogen receptor agonist	ESRRA|ESRRB|ESRRG|TRPC5			0	93.17	Tocris	1417	Daidzein	254.058	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	5281708.0		ZQSIJRDFPHDXIC
BRD-K42095107-001-18-9	daidzein	Phase 2	estrogen receptor agonist	ESRRA|ESRRB|ESRRG|TRPC5			0	87.82	Enzo	T110	Daidzein	254.058	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	5281708.0		ZQSIJRDFPHDXIC
BRD-K42095107-001-21-3	daidzein	Phase 2	estrogen receptor agonist	ESRRA|ESRRB|ESRRG|TRPC5			0	97.99	Selleck	S1849	Daidzein	254.058	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	5281708.0		ZQSIJRDFPHDXIC
BRD-K42095107-001-16-3	daidzein	Phase 2	estrogen receptor agonist	ESRRA|ESRRB|ESRRG|TRPC5			0	89.48	Selleck	S1849	Daidzein	254.058	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	5281708.0		ZQSIJRDFPHDXIC
BRD-K42095107-001-17-1	daidzein	Phase 2	estrogen receptor agonist	ESRRA|ESRRB|ESRRG|TRPC5			0	94.14	Tocris	1417	Daidzein	254.058	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	ZQSIJRDFPHDXIC-UHFFFAOYSA-N	5281708.0		ZQSIJRDFPHDXIC
BRD-K12979078-001-02-9	daidzin	Phase 1	antioxidant	ALDH2			0	90.05	MedChemEx	HY-N0018	Daidzin	416.111	OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O	KYQZWONCHDNPDP-QNDFHXLGSA-N	107971.0		KYQZWONCHDNPDP
BRD-A89196962-300-01-7	dalargin	Phase 2	opioid receptor agonist	OPRM1			0	79.63	InterBioScreen	STOCK1N-27439		725.386	CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23,41,&1:4,&2:8,&3:28|	GDPHPXYFLPDZGH-ABDYMBPTSA-N			GDPHPXYFLPDZGH
BRD-K30177383-001-02-9	dalbavancin	Launched	bacterial cell wall synthesis inhibitor	PNLIP	infectious disease	skin infections	0	92.67	MedChemEx	HY-17586	Dalbavancin	1814.609	CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2	KGPGQDLTDHGEGT-SZUNQUCBSA-N	16134627.0		KGPGQDLTDHGEGT
BRD-K30177383-001-01-0	dalbavancin	Launched	bacterial cell wall synthesis inhibitor	PNLIP	infectious disease	skin infections	0	68.91	MedChemEx	HY-17586	Dalbavancin	1814.609	CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2	KGPGQDLTDHGEGT-SZUNQUCBSA-N	16134627.0		KGPGQDLTDHGEGT
BRD-K18849474-001-05-9	dalcetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	92.83	MedChemEx	HY-14950	Dalcetrapib	389.239	CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	YZQLWPMZQVHJED-UHFFFAOYSA-N	6918540.0		YZQLWPMZQVHJED
BRD-K18849474-001-04-4	dalcetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	95.55	Selleck	S2772	Dalcetrapib??JTT-705??	389.239	CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	YZQLWPMZQVHJED-UHFFFAOYSA-N	6918540.0		YZQLWPMZQVHJED
BRD-K18849474-001-03-6	dalcetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	58.55	Selleck	S2772	Dalcetrapib (JTT-705, RO4607381)	389.239	CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	YZQLWPMZQVHJED-UHFFFAOYSA-N	6918540.0		YZQLWPMZQVHJED
BRD-K22482860-001-21-4	dalfampridine	Launched	potassium channel blocker	KCNA1|KCNA10|KCNA2|KCNA3|KCNA4|KCNA5|KCNA6|KCNA7|KCNB1|KCNB2|KCNC1|KCNC2|KCNC3|KCNC4|KCND1|KCND2|KCND3|KCNF1|KCNG1|KCNG2|KCNG3|KCNG4|KCNH1|KCNH2|KCNH3|KCNH4|KCNH5|KCNH6|KCNH7|KCNH8|KCNJ13|KCNJ5|KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5|KCNS1|KCNS2|KCNS3|KCNV1|KCNV2	neurology/psychiatry	multiple sclerosis	0	97.14	MicroSource	1501130	FAMPRIDINE	94.053	Nc1ccncc1	NUKYPUAOHBNCPY-UHFFFAOYSA-N	1727.0		NUKYPUAOHBNCPY
BRD-K22482860-001-20-6	dalfampridine	Launched	potassium channel blocker	KCNA1|KCNA10|KCNA2|KCNA3|KCNA4|KCNA5|KCNA6|KCNA7|KCNB1|KCNB2|KCNC1|KCNC2|KCNC3|KCNC4|KCND1|KCND2|KCND3|KCNF1|KCNG1|KCNG2|KCNG3|KCNG4|KCNH1|KCNH2|KCNH3|KCNH4|KCNH5|KCNH6|KCNH7|KCNH8|KCNJ13|KCNJ5|KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5|KCNS1|KCNS2|KCNS3|KCNV1|KCNV2	neurology/psychiatry	multiple sclerosis	0	96.6	Tocris	940	4-Aminopyridine	94.053	Nc1ccncc1	NUKYPUAOHBNCPY-UHFFFAOYSA-N	1727.0		NUKYPUAOHBNCPY
BRD-K00003321-001-01-9	dalfopristin	Preclinical	antibacterial 				0	79.72	MedChemEx	HY-A0241	Dalfopristin	690.33	[H][C@]12[C@@H](CCN1C(=O)c1coc(CC(=O)C[C@H](O)\C=C(/C)\C=C/CNC(=O)\C=C\[C@@H](C)[C@@H](OC2=O)C(C)C)n1)S(=O)(=O)CCN(CC)CC |c:19,22,t:28|	SUYRLXYYZQTJHF-FENKCRFESA-N	124201618.0		SUYRLXYYZQTJHF
BRD-K26813177-001-03-2	daltroban	Phase 3	thromboxane receptor antagonist	TBXA2R			0	94.94	Sigma	D7441	[4-(2-{[(4-chlorophenyl)sulfonyl]amino}ethyl)phenyl]acetic acid	353.049	OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1	IULOBWFWYDMECP-UHFFFAOYSA-N	54343.0		IULOBWFWYDMECP
BRD-K83452553-001-07-9	daminozide	Preclinical	KDM2A inhibitor	KDM2A|KDM7A|PHF8			0	100.0	Tocris	4684	Daminozide	160.085	CN(C)NC(=O)CCC(O)=O	NOQGZXFMHARMLW-UHFFFAOYSA-N	72200802.0		NOQGZXFMHARMLW
BRD-K83452553-001-05-8	daminozide	Preclinical	KDM2A inhibitor	KDM2A|KDM7A|PHF8			0	63.13	Tocris	4684	Daminozide	160.085	CN(C)NC(=O)CCC(O)=O	NOQGZXFMHARMLW-UHFFFAOYSA-N	72200802.0		NOQGZXFMHARMLW
BRD-K48970916-001-14-9	danazol	Launched	estrogen receptor antagonist|progesterone receptor agonist	AR|CCL2|ESR1|GNRHR|GNRHR2|PGR	obstetrics/gynecology|cardiology	endometriosis|angioedema	0	92.26	MedChemEx	HY-B1029	Danazol	337.204	C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	POZRVZJJTULAOH-LHZXLZLDSA-N	28417.0		POZRVZJJTULAOH
BRD-K35589454-003-02-9	danegaptide	Phase 2	gap junction modulator				0	88.96	MedChemEx	HY-10913A	Danegaptide Hydrochloride	291.122	NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1	BIZKIHUJGMSVFD-MNOVXSKESA-N	16656685.0		BIZKIHUJGMSVFD
BRD-K35589454-003-01-1	danegaptide	Phase 2	gap junction modulator				0	85.91	MedChemEx	HY-10913A	GAP-134 (Hydrochloride)	291.122	NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1	BIZKIHUJGMSVFD-MNOVXSKESA-N	16656685.0		BIZKIHUJGMSVFD
BRD-K13769342-001-01-5	danirixin	Phase 2	CC chemokine receptor antagonist	CXCR2			0	94.48	MedChemEx	HY-19768	Danirixin	441.093	Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1	NGYNBSHYFOFVLS-LBPRGKRZSA-N	24780598.0		NGYNBSHYFOFVLS
BRD-K45916615-066-04-9	danofloxacin	Launched	bacterial DNA gyrase inhibitor		pulmonary	bovine respiratory disease (BRD)	0	94.89	MedChemEx	HY-B0501	Danofloxacin (mesylate)	357.149	CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	QMLVECGLEOSESV-RYUDHWBXSA-N	71335.0		QMLVECGLEOSESV
BRD-K45916615-066-02-5	danofloxacin	Launched	bacterial DNA gyrase inhibitor		pulmonary	bovine respiratory disease (BRD)	0	95.15	Selleck	S3058	Danofloxacin Mesylate	357.149	CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	QMLVECGLEOSESV-RYUDHWBXSA-N	71335.0		QMLVECGLEOSESV
BRD-K08111240-001-03-9	danoprevir	Phase 3	HCV inhibitor				0	92.83	MedChemEx	HY-10238	Danoprevir	731.3	CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|	ZVTDLPBHTSMEJZ-JSZLBQEHSA-N	11285588.0		ZVTDLPBHTSMEJZ
BRD-K08111240-001-02-8	danoprevir	Phase 3	HCV inhibitor				0	94.01	Selleck	S1183	Danoprevir (ITMN-191)	731.3	CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|	ZVTDLPBHTSMEJZ-JSZLBQEHSA-N	11285588.0		ZVTDLPBHTSMEJZ
BRD-K81272440-236-13-5	dantrolene	Launched	calcium channel blocker	RYR1|RYR3	neurology/psychiatry|endocrinology	spasms|malignant hyperthermia (MH)	0	97.08	MicroSource	1503209	DANTROLENE SODIUM	314.065	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	OZOMQRBLCMDCEG-VIZOYTHASA-N	6914273.0		OZOMQRBLCMDCEG
BRD-K81272440-236-14-9	dantrolene	Launched	calcium channel blocker	RYR1|RYR3	neurology/psychiatry|endocrinology	spasms|malignant hyperthermia (MH)	0	94.15	Tocris	507	Dantrolene, sodium salt	314.065	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	OZOMQRBLCMDCEG-VIZOYTHASA-N	6914273.0		OZOMQRBLCMDCEG
BRD-K81272440-236-12-7	dantrolene	Launched	calcium channel blocker	RYR1|RYR3	neurology/psychiatry|endocrinology	spasms|malignant hyperthermia (MH)	0	93.13	Tocris	507	Dantrolene, sodium salt	314.065	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	OZOMQRBLCMDCEG-VIZOYTHASA-N	6914273.0		OZOMQRBLCMDCEG
BRD-K10065684-001-07-4	dantron	Withdrawn	laxative				0	96.26	MicroSource	211468	DANTHRON	240.042	Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12	QBPFLULOKWLNNW-UHFFFAOYSA-N	2950.0		QBPFLULOKWLNNW
BRD-K10065684-001-08-9	dantron	Withdrawn	laxative				0	94.95	MedChemEx	HY-B0923	Danthron	240.042	Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12	QBPFLULOKWLNNW-UHFFFAOYSA-N	2950.0		QBPFLULOKWLNNW
BRD-K07881437-001-03-8	danusertib	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	AURKA|AURKB|AURKC|FGFR1|NTRK1|RET|SLK			0	88.9	Selleck	S1107	Danusertib (PHA-739358)	474.238	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	XKFTZKGMDDZMJI-HSZRJFAPSA-N	11442891.0		XKFTZKGMDDZMJI
BRD-K07881437-001-04-6	danusertib	Phase 2	Aurora kinase inhibitor|growth factor receptor inhibitor	AURKA|AURKB|AURKC|FGFR1|NTRK1|RET|SLK			0	93.08	Selleck	S1107	Danusertib (PHA-739358)	474.238	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	XKFTZKGMDDZMJI-HSZRJFAPSA-N	11442891.0		XKFTZKGMDDZMJI
BRD-K58160573-001-04-7	dapagliflozin	Launched	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2	endocrinology	diabetes mellitus	0	89.07	MicroSource	1506320	DAPAGLIFLOZIN	408.134	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1	JVHXJTBJCFBINQ-ADAARDCZSA-N	9887712.0		JVHXJTBJCFBINQ
BRD-K58160573-001-05-4	dapagliflozin	Launched	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2	endocrinology	diabetes mellitus	0	98.0	Selleck	S1548	Dapagliflozin	408.134	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1	JVHXJTBJCFBINQ-ADAARDCZSA-N	9887712.0	BRD-K46604138-001-01-3	JVHXJTBJCFBINQ
BRD-K00004659-001-01-9	dapansutrile	Phase 2	anti-inflammatory agent				0	0.0	Enamine	EN300-332757	3-methanesulfonylpropanenitrile	133.02	CS(=O)(=O)CCC#N	LQFRYKBDZNPJSW-UHFFFAOYSA-N	12714644.0		LQFRYKBDZNPJSW
BRD-K61269089-001-05-5	daphnetin	Preclinical	protein kinase inhibitor				0	91.06	Selleck	S2554	Daphnetin	178.027	Oc1ccc2ccc(=O)oc2c1O	ATEFPOUAMCWAQS-UHFFFAOYSA-N	5280569.0		ATEFPOUAMCWAQS
BRD-K61269089-001-06-9	daphnetin	Preclinical	protein kinase inhibitor				0	96.19	MedChemEx	HY-N0281	Daphnetin	178.027	Oc1ccc2ccc(=O)oc2c1O	ATEFPOUAMCWAQS-UHFFFAOYSA-N	5280569.0		ATEFPOUAMCWAQS
BRD-K33133047-001-01-8	dapiprazole	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D	ophthalmology	mydriasis	0	99.76	AvaChem	3081B	3-{2-[4-(2-methylphenyl)-1-piperazinyl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine	325.227	Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1	RFWZESUMWJKKRN-UHFFFAOYSA-N	3033538.0		RFWZESUMWJKKRN
BRD-K12885236-001-02-7	dapivirine	Phase 3	non-nucleoside reverse transcriptase inhibitor	CYP3A4|CYP3A5			0	97.99	Selleck	S2914	Dapivirine (TMC120)	329.164	Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	ILAYIAGXTHKHNT-UHFFFAOYSA-N	214347.0		ILAYIAGXTHKHNT
BRD-K12885236-001-03-9	dapivirine	Phase 3	non-nucleoside reverse transcriptase inhibitor	CYP3A4|CYP3A5			0	99.06	MedChemEx	HY-14266	Dapivirine	329.164	Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	ILAYIAGXTHKHNT-UHFFFAOYSA-N	214347.0		ILAYIAGXTHKHNT
BRD-K51579475-003-02-4	dapoxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	HTR1A|HTR1B|HTR2C|SLC6A4	urology	premature ejaculation (PE)	0	98.79	Selleck	S1869	Dapoxetine HCl	305.178	CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1	USRHYDPUVLEVMC-FQEVSTJZSA-N	71353.0		USRHYDPUVLEVMC
BRD-K51579475-003-03-2	dapoxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	HTR1A|HTR1B|HTR2C|SLC6A4	urology	premature ejaculation (PE)	0	99.38	Selleck	S1869	Dapoxetine hydrochloride (Priligy)	305.178	CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1	USRHYDPUVLEVMC-FQEVSTJZSA-N	71353.0		USRHYDPUVLEVMC
BRD-K06455935-001-02-9	daprodustat	Phase 3	hypoxia inducible factor inhibitor	EGLN1			0	94.74	MedChemEx	HY-17608	Daprodustat	393.19	OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O	NVTKJBXOBFRPLQ-UHFFFAOYSA-N	24831508.0		NVTKJBXOBFRPLQ
BRD-K06455935-001-01-3	daprodustat	Phase 3	hypoxia inducible factor inhibitor	EGLN1			0	93.43	MedChemEx	HY-17608	Daprodustat	393.19	OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O	NVTKJBXOBFRPLQ-UHFFFAOYSA-N	24831508.0		NVTKJBXOBFRPLQ
BRD-K62363391-001-26-9	dapsone	Launched	bacterial antifolate	DHFR	dermatology|infectious disease	dermatitis herpetiformis (DH)|leprosy	0	96.82	MedChemEx	HY-B0688	Dapsone	248.062	Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1	MQJKPEGWNLWLTK-UHFFFAOYSA-N	2955.0		MQJKPEGWNLWLTK
BRD-K62363391-001-24-9	dapsone	Launched	bacterial antifolate	DHFR	dermatology|infectious disease	dermatitis herpetiformis (DH)|leprosy	0	98.4	MicroSource	1500222	DAPSONE	248.062	Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1	MQJKPEGWNLWLTK-UHFFFAOYSA-N	2955.0		MQJKPEGWNLWLTK
BRD-K47177710-001-04-9	DAPT	Preclinical	gamma secretase inhibitor				0	95.24	Tocris	2634	DAPT	432.186	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	DWJXYEABWRJFSP-XOBRGWDASA-N	5311272.0		DWJXYEABWRJFSP
BRD-K47177710-001-03-1	DAPT	Preclinical	gamma secretase inhibitor				0	96.31	Tocris	2634	DAPT	432.186	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	DWJXYEABWRJFSP-XOBRGWDASA-N	5311272.0		DWJXYEABWRJFSP
BRD-K47177710-001-05-9	DAPT	Preclinical	gamma secretase inhibitor				0	95.69	Tocris	2634	DAPT	432.186	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	DWJXYEABWRJFSP-XOBRGWDASA-N	5311272.0		DWJXYEABWRJFSP
BRD-K47177710-001-02-3	DAPT	Preclinical	gamma secretase inhibitor				0	96.05	Selleck	S2215	DAPT (GSI-IX)	432.186	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	DWJXYEABWRJFSP-XOBRGWDASA-N	5311272.0		DWJXYEABWRJFSP
BRD-K00003611-001-01-9	daptomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|endocarditis	0	74.27	MedChemEx	HY-B0108	Daptomycin	1619.71	[H][C@]1(CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CCCCCCCCC)[C@@H](C)OC(=O)[C@]([H])(CC(=O)c2ccccc2N)NC(=O)[C@@]([H])(NC1=O)[C@H](C)CC(O)=O	DOAKLVKFURWEDJ-QCMAZARJSA-N	21585658.0		DOAKLVKFURWEDJ
BRD-K19085898-001-02-9	darapladib	Phase 3	phospholipase inhibitor	PLA2G7			0	97.95	MedChemEx	HY-10521	Darapladib	666.265	CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	WDPFJWLDPVQCAJ-UHFFFAOYSA-N	9939609.0		WDPFJWLDPVQCAJ
BRD-K19085898-001-01-8	darapladib	Phase 3	phospholipase inhibitor	PLA2G7			0	94.14	MedChemEx	HY-10521	Darapladib	666.265	CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	WDPFJWLDPVQCAJ-UHFFFAOYSA-N	9939609.0		WDPFJWLDPVQCAJ
BRD-K82908348-001-01-9	darglitazone	Phase 2	PPAR receptor antagonist	PPARG			0	96.02	Cayman	17681	5-{4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]benzyl}-1,3-thiazolidine-2,4-dione	420.114	Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1	QQKNSPHAFATFNQ-UHFFFAOYSA-N	60870.0		QQKNSPHAFATFNQ
BRD-K95773607-004-05-9	darifenacin	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence	0	98.26	MedChemEx	HY-A0012	Darifenacin (hydrobromide)	426.231	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	HXGBXQDTNZMWGS-RUZDIDTESA-N	444031.0		HXGBXQDTNZMWGS
BRD-K95773607-004-04-6	darifenacin	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence	0	94.16	MicroSource	1505714	DARIFENACIN HYDROBROMIDE	426.231	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	HXGBXQDTNZMWGS-RUZDIDTESA-N	444031.0	BRD-K95773607-001-03-4|BRD-K95773607-001-03-4|BRD-K95773607-001-03-4	HXGBXQDTNZMWGS
BRD-K95773607-004-03-8	darifenacin	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence	0	95.96	Selleck	S3144	Darifenacin HBr	426.231	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	HXGBXQDTNZMWGS-RUZDIDTESA-N	444031.0		HXGBXQDTNZMWGS
BRD-A44971162-001-01-9	darolutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	98.18	MedChemEx	HY-16985		398.126	C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|	BLIJXOOIHRSQRB-NWDGAFQWSA-N	121489720.0		BLIJXOOIHRSQRB
BRD-A44971162-001-02-7	darolutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	98.62	Selleck	S7559	ODM-201	398.126	C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1,&1:25|	BLIJXOOIHRSQRB-NWDGAFQWSA-N	121489720.0	BRD-A01259528-001-01-9	BLIJXOOIHRSQRB
BRD-K84986517-001-01-8	darunavir	Launched	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	98.7	Selleck	S1620	Darunavir Ethanolate	547.235	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1	CJBJHOAVZSMMDJ-HEXNFIEUSA-N	213039.0	BRD-M22677129-001-01-6	CJBJHOAVZSMMDJ
BRD-K84986517-001-02-9	darunavir	Launched	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	96.65	MedChemEx	HY-17040	Darunavir	547.235	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1	CJBJHOAVZSMMDJ-HEXNFIEUSA-N	213039.0		CJBJHOAVZSMMDJ
BRD-K54863166-001-01-9	darusentan	Phase 3	endothelin receptor antagonist	EDNRA			0	98.96	Key	EE-0200	(2S)-2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]-3-methoxy-3,3-diphenylpropanoic acid	410.148	COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1	FEJVSJIALLTFRP-LJQANCHMSA-N	177236.0		FEJVSJIALLTFRP
BRD-K02943813-001-01-9	dasabuvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	91.31	MedChemEx	HY-13998	ABT-333	493.167	COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1	NBRBXGKOEOGLOI-UHFFFAOYSA-N	56640146.0		NBRBXGKOEOGLOI
BRD-K02943813-001-02-9	dasabuvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	92.69	MedChemEx	HY-13998	Dasabuvir	493.167	COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1	NBRBXGKOEOGLOI-UHFFFAOYSA-N	56640146.0		NBRBXGKOEOGLOI
BRD-K49328571-001-19-2	dasatinib	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)	0	97.07	Selleck	S1021	Dasatinib (BMS-354825)	487.156	Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	3062316.0		ZBNZXTGUTAYRHI
BRD-K49328571-001-15-0	dasatinib	Launched	Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor	ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)	0	97.6	Selleck	S1021	Dasatinib	487.156	Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1	ZBNZXTGUTAYRHI-UHFFFAOYSA-N	3062316.0		ZBNZXTGUTAYRHI
BRD-K00003142-003-01-9	dasotraline	Phase 3	dopamine-norepinephrine-serotonin reuptake inhibitor				0	97.59	MedChemEx	HY-12850A	Dasotraline (hydrochloride)	291.058	N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	SRPXSILJHWNFMK-MEDUHNTESA-N	9947999.0		SRPXSILJHWNFMK
BRD-K31633810-003-03-6	DAU-5884	Preclinical	acetylcholine receptor antagonist	CHRM3			0	97.49	Tocris	2096	DAU 5884 hydrochloride	315.158	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	NWXCDQHBVVPPTL-WDNDVIMCSA-N			NWXCDQHBVVPPTL
BRD-K31633810-003-04-9	DAU-5884	Preclinical	acetylcholine receptor antagonist	CHRM3			0	96.02	Tocris	2096	DAU 5884 hydrochloride	315.158	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	NWXCDQHBVVPPTL-WDNDVIMCSA-N			NWXCDQHBVVPPTL
BRD-K31633810-003-02-8	DAU-5884	Preclinical	acetylcholine receptor antagonist	CHRM3			0	96.79	Tocris	2096	DAU 5884 hydrochloride	315.158	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	NWXCDQHBVVPPTL-WDNDVIMCSA-N			NWXCDQHBVVPPTL
BRD-K14276241-001-01-2	daucosterol	Phase 2	apoptosis stimulant				0	89.9	MedChemEx	HY-N0410	Daucosterol	576.439	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|	NPJICTMALKLTFW-OFUAXYCQSA-N	5742590.0		NPJICTMALKLTFW
BRD-K43389675-001-02-1	daunorubicin	Launched	RNA synthesis inhibitor|topoisomerase inhibitor	TOP2A|TOP2B	hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)	0	90.99	MicroSource	1500223	DAUNORUBICIN	527.179	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	STQGQHZAVUOBTE-VGBVRHCVSA-N	30323.0		STQGQHZAVUOBTE
BRD-K43389675-003-19-1	daunorubicin	Launched	RNA synthesis inhibitor|topoisomerase inhibitor	TOP2A|TOP2B	hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)	0	94.76	Selleck	S3035	Daunorubicin HCl	527.179	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	STQGQHZAVUOBTE-VGBVRHCVSA-N	30323.0	BRD-K91966436-003-02-3	STQGQHZAVUOBTE
BRD-K43389675-003-20-9	daunorubicin	Launched	RNA synthesis inhibitor|topoisomerase inhibitor	TOP2A|TOP2B	hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)	0	90.21	Tocris	1467	Daunorubicin hydrochloride	527.179	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	STQGQHZAVUOBTE-VGBVRHCVSA-N	30323.0	BRD-K79347022-003-01-4|BRD-A68009927-003-03-7	STQGQHZAVUOBTE
BRD-K43389675-003-16-7	daunorubicin	Launched	RNA synthesis inhibitor|topoisomerase inhibitor	TOP2A|TOP2B	hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)	0	95.52	Selleck	S3035	Daunorubicin HCl (Daunomycin HCl)	527.179	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	STQGQHZAVUOBTE-VGBVRHCVSA-N	30323.0		STQGQHZAVUOBTE
BRD-K20738689-001-01-2	dazmegrel	Phase 2	thromboxane synthase inhibitor	TBXAS1			0	98.91	Vitas-M	STK094650		283.132	Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O	DEQLGSOHGTZKFB-UHFFFAOYSA-N	53555.0		DEQLGSOHGTZKFB
BRD-K82767007-001-01-1	dazoxiben	Phase 2	thromboxane synthase inhibitor	TBXAS1			0	95.24	AKSci	K385		232.085	OC(=O)c1ccc(OCCn2ccnc2)cc1	XQGZSYKGWHUSDH-UHFFFAOYSA-N	53001.0		XQGZSYKGWHUSDH
BRD-K59204667-001-05-6	DBeQ	Preclinical	ATPase inhibitor	CASP3			0	96.56	Tocris	4417	DBeQ	340.169	C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1	QAIMUUJJAJBPCL-UHFFFAOYSA-N	676352.0		QAIMUUJJAJBPCL
BRD-K59204667-001-03-1	DBeQ	Preclinical	ATPase inhibitor	CASP3			0	96.36	Selleck	S7199	DBeQ	340.169	C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1	QAIMUUJJAJBPCL-UHFFFAOYSA-N	676352.0		QAIMUUJJAJBPCL
BRD-K00004704-001-01-9	DBPR-211	Preclinical	cannabinoid receptor antagonist				0	95.16	AMS	Q65619	1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-1H-pyrazole-3-carboxamide	750.123	FC(F)(F)c1ccc(cc1)C#Cc1ccc(s1)-c1c(CNS(=O)(=O)N2CCCC2)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	KAIYFJUWIBTYPK-UHFFFAOYSA-N	71515460.0		KAIYFJUWIBTYPK
BRD-K83020231-001-01-2	DBPR108	Phase 1	dipeptidyl peptidase inhibitor	DPP4			0	95.35	MedChemEx	HY-12528	DBPR108	324.196	CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N	VQKSCYBKUIDZEI-STQMWFEESA-N	44201003.0		VQKSCYBKUIDZEI
BRD-K10596918-001-01-9	DC-260126	Preclinical	free fatty acid receptor antagonist	FFAR1			0	94.07	Tocris	5357	DC 260126	307.104	CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1	CNGHPXKWPGIDSK-UHFFFAOYSA-N	2843133.0		CNGHPXKWPGIDSK
BRD-K10596918-001-02-9	DC-260126	Preclinical	free fatty acid receptor antagonist	FFAR1			0	95.9	Tocris	5357	DC 260126	307.104	CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1	CNGHPXKWPGIDSK-UHFFFAOYSA-N	2843133.0		CNGHPXKWPGIDSK
BRD-K49246350-001-01-1	DCC-2618	Phase 1	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	KIT|PDGFRA			0	97.17	MedChemEx	HY-15240	c-Kit-IN-1	489.161	Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1	WWOXKWLDMLMYQY-UHFFFAOYSA-N	46208890.0		WWOXKWLDMLMYQY
BRD-K89299012-001-08-6	DCEBIO	Preclinical	potassium channel activator	KCNN2|KCNN3|KCNN4			0	97.49	Tocris	1422	DCEBIO	230.001	CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O	LKHRMULASXZCLG-UHFFFAOYSA-N	656765.0		LKHRMULASXZCLG
BRD-K89299012-001-07-8	DCEBIO	Preclinical	potassium channel activator	KCNN2|KCNN3|KCNN4			0	99.81	Tocris	1422	DCEBIO	230.001	CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O	LKHRMULASXZCLG-UHFFFAOYSA-N	656765.0		LKHRMULASXZCLG
BRD-K89299012-001-06-0	DCEBIO	Preclinical	potassium channel activator	KCNN2|KCNN3|KCNN4			0	99.43	Tocris	1422	DCEBIO	230.001	CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O	LKHRMULASXZCLG-UHFFFAOYSA-N	656765.0		LKHRMULASXZCLG
BRD-K00005344-001-01-9	DCP-LA	Preclinical	protein kinase activator				0	100.0	MedChemEx	HY-108599	DCP-LA	308.272	CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(O)=O |&1:11,&2:9,&3:7,&4:5,r|	CONYTTFKIUJZOF-ZSYWTGECSA-N	53732028.0		CONYTTFKIUJZOF
BRD-A39255369-001-03-1	DCPIB	Preclinical	chloride channel blocker|gap junction modulator|glutamate inhibitor	SLC1A2			0	88.14	Tocris	1540	DCPIB	426.136	CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4,r|	KHKGTPJPBOQECW-QFIPXVFZSA-N	12761153.0		KHKGTPJPBOQECW
BRD-K61845293-300-03-9	DDR1-IN-1	Preclinical	discoidin domain receptor inhibitor	DDR1|DDR2			0	96.23	Tocris	5077	DDR1-IN-1 dihydrochloride	552.235	CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1	AOZPVMOOEJAZGK-UHFFFAOYSA-N	72836888.0		AOZPVMOOEJAZGK
BRD-K61845293-300-01-9	DDR1-IN-1	Preclinical	discoidin domain receptor inhibitor	DDR1|DDR2			0	92.41	Tocris	5077	DDR1-IN-1	552.235	CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1	AOZPVMOOEJAZGK-UHFFFAOYSA-N	72836888.0		AOZPVMOOEJAZGK
BRD-K00004562-001-01-9	deazaguanine	Preclinical	DNA synthesis inhibitor				0	73.0	Sigma	MFCD22194349	6-amino-1H-imidazo[4,5-c]pyridin-4-ol	150.054	Nc1cc2[nH]cnc2c(O)n1	KXBCLNRMQPRVTP-UHFFFAOYSA-N	55710.0		KXBCLNRMQPRVTP
BRD-K00003157-001-01-9	Debio-0932	Phase 1	HSP inhibitor				0	94.04	MedChemEx	HY-13469	Debio 0932	442.215	CN(C)c1cc2OCOc2cc1Sc1nc2c(N)nccc2n1CCNCC(C)(C)C	RVJIQAYFTOPTKK-UHFFFAOYSA-N	44156921.0		RVJIQAYFTOPTKK
BRD-K80419150-001-02-4	debrisoquin	Launched	adrenergic neuron blocker	SLC6A2	cardiology	hypertension	0	80.31	PrincetonBio	OSSK_732122	3,4-dihydro-2(1H)-isoquinolinecarboximidamide	175.111	NC(=N)N1CCc2ccccc2C1	JWPGJSVJDAJRLW-UHFFFAOYSA-N	2966.0		JWPGJSVJDAJRLW
BRD-K80419150-065-03-7	debrisoquin	Launched	adrenergic neuron blocker	SLC6A2	cardiology	hypertension	0	67.33	MicroSource	1506066	DEBRISOQUIN SULFATE	175.111	NC(=N)N1CCc2ccccc2C1	JWPGJSVJDAJRLW-UHFFFAOYSA-N	2966.0		JWPGJSVJDAJRLW
BRD-K49783248-303-15-9	decamethonium	Launched	acetylcholine receptor agonist	ACHE|CHRNA2	neurology/psychiatry	muscle relaxant	0	99.4	MedChemEx	HY-B0570	Decamethonium (Bromide)	258.303	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	MTCUAOILFDZKCO-UHFFFAOYSA-N	2968.0		MTCUAOILFDZKCO
BRD-K49783248-303-08-4	decamethonium	Launched	acetylcholine receptor agonist	ACHE|CHRNA2	neurology/psychiatry	muscle relaxant	0	99.47	MicroSource	1505991	DECAMETHONIUM BROMIDE	258.303	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	MTCUAOILFDZKCO-UHFFFAOYSA-N	2968.0		MTCUAOILFDZKCO
BRD-K49783248-303-07-6	decamethonium	Launched	acetylcholine receptor agonist	ACHE|CHRNA2	neurology/psychiatry	muscle relaxant	0	97.69	Selleck	S4072	Decamethonium Bromide	258.303	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	MTCUAOILFDZKCO-UHFFFAOYSA-N	2968.0		MTCUAOILFDZKCO
BRD-A56320380-300-01-6	decamethoxine	Phase 2	antiseptic				0	0.0	Innovapharm	BBS-00029292	N1,N10-bis(2-(2-isopropyl-5-methylcyclohexyloxy)-2-oxoethyl)-N1,N1,N10,N10-tetramethyldecane-1,10-diaminium chloride	622.565	CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@H](C)CC[C@@H]1C(C)C |&1:40,&2:36,&3:34,&4:9,&5:6,&6:3|	ZADGGFKUEYIBJC-BPBUSIJASA-N			ZADGGFKUEYIBJC
BRD-A95300432-001-01-3	decernotinib	Phase 2/Phase 3	JAK inhibitor	JAK3			0	97.54	MedChemEx	HY-12469	Decernotinib	392.157	CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2,r|	ASUGUQWIHMTFJL-QGZVFWFLSA-N	59422203.0		ASUGUQWIHMTFJL
BRD-K79254416-001-24-2	decitabine	Launched	DNA methyltransferase inhibitor	DNMT1|DNMT3A	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)	0	72.95	Tocris	2624	Decitabine	228.086	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	XAUDJQYHKZQPEU-KVQBGUIXSA-N	451668.0		XAUDJQYHKZQPEU
BRD-K79254416-001-22-6	decitabine	Launched	DNA methyltransferase inhibitor	DNMT1|DNMT3A	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)	0	100.0	Tocris	2624	Decitabine	228.086	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	XAUDJQYHKZQPEU-KVQBGUIXSA-N	451668.0		XAUDJQYHKZQPEU
BRD-K79254416-001-31-9	decitabine	Launched	DNA methyltransferase inhibitor	DNMT1|DNMT3A	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)	0	82.0	Tocris	2624	Decitabine	228.086	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	XAUDJQYHKZQPEU-KVQBGUIXSA-N	451668.0		XAUDJQYHKZQPEU
BRD-K79254416-001-21-8	decitabine	Launched	DNA methyltransferase inhibitor	DNMT1|DNMT3A	hematologic malignancy|hematology	myelodysplastic diseases (MDS)|anemia|chronic myeloid leukemia (CML)	0	99.02	Selleck	S1200	Decitabine	228.086	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	XAUDJQYHKZQPEU-KVQBGUIXSA-N	451668.0		XAUDJQYHKZQPEU
BRD-K00004661-001-01-9	declopramide	Preclinical	cell cycle inhibitor				0	93.64	Enamine	Z3027746501	4-amino-3-chloro-N-[2-(diethylamino)ethyl]benzamide	269.129	CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1	YEYAKZXEBSVURO-UHFFFAOYSA-N	70177.0		YEYAKZXEBSVURO
BRD-K00003318-300-01-9	decloxizine	Preclinical	histamine receptor antagonist				0	94.56	MedChemEx	HY-A0075	Decloxizine (dihydrochloride)	340.215	OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	OXBBIHZWNDPBMQ-UHFFFAOYSA-N	71135.0		OXBBIHZWNDPBMQ
BRD-K17641316-213-01-5	decoquinate	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	3.61	MicroSource	1505356	DECOQUINATE [5mM]	417.252	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	JHAYEQICABJSTP-UHFFFAOYSA-N	29112.0		JHAYEQICABJSTP
BRD-K17641316-001-05-9	decoquinate	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	18.62	MedChemEx	HY-B1036	Decoquinate	417.252	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	JHAYEQICABJSTP-UHFFFAOYSA-N	29112.0		JHAYEQICABJSTP
BRD-K17641316-001-04-8	decoquinate	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	100.0	MedChemEx	HY-B1036	Decoquinate	417.252	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	JHAYEQICABJSTP-UHFFFAOYSA-N	29112.0		JHAYEQICABJSTP
BRD-K17641316-001-02-2	decoquinate	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	27.28	Selleck	S4145	Decoquinate	417.252	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	JHAYEQICABJSTP-UHFFFAOYSA-N	29112.0		JHAYEQICABJSTP
BRD-K17641316-001-03-0	decoquinate	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	6.87	Selleck	S4145	Decoquinate	417.252	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	JHAYEQICABJSTP-UHFFFAOYSA-N	29112.0		JHAYEQICABJSTP
BRD-K43578482-001-02-2	defactinib	Phase 2	focal adhesion kinase inhibitor	PTK2			0	97.29	MedChemEx	HY-12289	Defactinib	510.141	CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	FWLMVFUGMHIOAA-UHFFFAOYSA-N	25117126.0		FWLMVFUGMHIOAA
BRD-K43578482-001-01-4	defactinib	Phase 2	focal adhesion kinase inhibitor	PTK2			0	98.24	MedChemEx	HY-12289	Defactinib	510.141	CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	FWLMVFUGMHIOAA-UHFFFAOYSA-N	25117126.0		FWLMVFUGMHIOAA
BRD-K43578482-001-04-9	defactinib	Phase 2	focal adhesion kinase inhibitor	PTK2			0	93.47	MedChemEx	HY-12289	Defactinib	510.141	CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	FWLMVFUGMHIOAA-UHFFFAOYSA-N	25117126.0		FWLMVFUGMHIOAA
BRD-K97010173-001-04-1	deferasirox	Launched	chelating agent	CYP3A4	hematology	transfusional hemosiderosis|thalassemia|iron overload	0	98.39	Selleck	S1712	Deferasirox	373.106	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	BOFQWVMAQOTZIW-UHFFFAOYSA-N	214348.0		BOFQWVMAQOTZIW
BRD-K97010173-001-06-9	deferasirox	Launched	chelating agent	CYP3A4	hematology	transfusional hemosiderosis|thalassemia|iron overload	0	98.55	MedChemEx	HY-17359	Deferasirox	373.106	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	BOFQWVMAQOTZIW-UHFFFAOYSA-N	214348.0		BOFQWVMAQOTZIW
BRD-K00003219-001-01-9	deferasirox-iron-chelate	Launched					0	0.45	MedChemEx	HY-16564	Deferasirox (Fe3+ chelate)	427.026	OC(=O)c1ccc(cc1)-n1nc-2nc1-c1ccccc1O[Fe]Oc1ccccc-21	XLHBYAVMDSNIEM-UHFFFAOYSA-L			XLHBYAVMDSNIEM
BRD-K06878038-001-20-9	deferiprone	Launched	chelating agent	UGT1A6	hematology	transfusional hemosiderosis|thalassemia|iron overload	0	98.95	MedChemEx	HY-B0568	Deferiprone	139.063	Cc1c(O)c(=O)ccn1C	TZXKOCQBRNJULO-UHFFFAOYSA-N	2972.0		TZXKOCQBRNJULO
BRD-K06878038-001-18-6	deferiprone	Launched	chelating agent	UGT1A6	hematology	transfusional hemosiderosis|thalassemia|iron overload	0	95.65	MicroSource	1504512	DEFERIPRONE	139.063	Cc1c(O)c(=O)ccn1C	TZXKOCQBRNJULO-UHFFFAOYSA-N	2972.0		TZXKOCQBRNJULO
BRD-K06878038-001-17-8	deferiprone	Launched	chelating agent	UGT1A6	hematology	transfusional hemosiderosis|thalassemia|iron overload	0	95.25	Selleck	S4067	Deferiprone	139.063	Cc1c(O)c(=O)ccn1C	TZXKOCQBRNJULO-UHFFFAOYSA-N	2972.0		TZXKOCQBRNJULO
BRD-K09821361-066-24-1	deferoxamine-mesylate	Launched	chelating agent		hematology	acute iron intoxication|iron overload	0	76.96	Sigma	D9533	N~1~-{5-[acetyl(hydroxy)amino]pentyl}-N~4~-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N~4~-hydroxysuccinamide methanesulfonate	560.353	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	UBQYURCVBFRUQT-UHFFFAOYSA-N	2973.0		UBQYURCVBFRUQT
BRD-K09821361-066-23-3	deferoxamine-mesylate	Launched	chelating agent		hematology	acute iron intoxication|iron overload	0	56.23	MicroSource	1500224	DEFEROXAMINE MESYLATE	560.353	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	UBQYURCVBFRUQT-UHFFFAOYSA-N	2973.0		UBQYURCVBFRUQT
BRD-K09821361-066-25-8	deferoxamine-mesylate	Launched	chelating agent		hematology	acute iron intoxication|iron overload	0	95.48	MedChemEx	HY-B0988	Deferoxamine (mesylate)	560.353	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	UBQYURCVBFRUQT-UHFFFAOYSA-N	2973.0		UBQYURCVBFRUQT
BRD-K30468934-001-02-9	deflazacort	Launched	glucocorticoid receptor agonist	NR3C1	rheumatology	joint inflammation	0	96.0	MedChemEx	HY-13609	Deflazacort	441.215	CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23,t:8,19|	FBHSPRKOSMHSIF-GRMWVWQJSA-N	189821.0		FBHSPRKOSMHSIF
BRD-K62304154-001-03-4	deforolimus	Phase 3	mTOR inhibitor	MTOR			0	31.14	Selleck	S1022	Deforolimus (MK-8669)	989.563	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|	BUROJSBIWGDYCN-LKLUGXJSSA-N			BUROJSBIWGDYCN
BRD-K62304154-001-04-2	deforolimus	Phase 3	mTOR inhibitor	MTOR			0	89.39	Selleck	S1022	Ridaforolimus (Deforolimus, MK-8669)	989.563	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14,33,t:29,31|	BUROJSBIWGDYCN-LKLUGXJSSA-N		BRD-K09078998-001-01-4	BUROJSBIWGDYCN
BRD-K00003578-001-01-9	degarelix	Launched	gonadotropin releasing factor hormone receptor antagonist	GNRHR	oncology	prostate cancer	0	93.66	MedChemEx	HY-16168A	Degarelix	1630.749	CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	MEUCPCLKGZSHTA-XYAYPHGZSA-N	16136245.0		MEUCPCLKGZSHTA
BRD-K00025573-001-04-9	dehydroacetic-acid	Preclinical					0	86.69	MicroSource	1301016		168.042	CC(=O)c1c(O)cc(C)oc1=O	PKLPQOJFHFGVBS-UHFFFAOYSA-N	54678494.0		PKLPQOJFHFGVBS
BRD-K00025573-001-05-9	dehydroacetic-acid	Preclinical					0	0.0	MedChemEx	HY-B1211	Dehydroacetic acid	168.042	CC(=O)c1c(O)cc(C)oc1=O	PKLPQOJFHFGVBS-UHFFFAOYSA-N	54678494.0		PKLPQOJFHFGVBS
BRD-A64125466-236-04-6	dehydrocholate	Preclinical					0	85.01	MicroSource	1500225	DEHYDROCHOLATE SODIUM	402.241	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@@H]1CC3=O |a:1,7,16,18,&1:10,&2:11,&3:12,&4:25|	OHXPGWPVLFPUSM-IVFZZBRKSA-N	7048656.0		OHXPGWPVLFPUSM
BRD-K90976994-236-19-9	dehydrocholate-acid	Preclinical					0	79.34	MedChemEx	HY-B0998	Dehydrocholate (sodium)	402.241	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	OHXPGWPVLFPUSM-KLRNGDHRSA-N	6674.0		OHXPGWPVLFPUSM
BRD-K90976994-001-20-9	dehydrocholate-acid	Preclinical					0	78.3	MedChemEx	HY-B1393	Dehydrocholic acid	402.241	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	OHXPGWPVLFPUSM-KLRNGDHRSA-N	6674.0		OHXPGWPVLFPUSM
BRD-K67186445-001-01-3	dehydrocorydaline	Phase 3	acetylcholinesterase inhibitor	ACHE			0	89.27	MedChemEx	HY-N0674	2,3,9,10-tetramethoxy-13-methyl-5H,6H-isoquino[3,2-a]isoquinolinium	366.171	COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC	RFKQJTRWODZPHF-UHFFFAOYSA-N	34781.0		RFKQJTRWODZPHF
BRD-K67186445-001-02-1	dehydrocorydaline	Phase 3	acetylcholinesterase inhibitor	ACHE			0	91.32	MedChemEx	HY-N0674	Dehydrocorydaline	366.171	COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC	RFKQJTRWODZPHF-UHFFFAOYSA-N	34781.0		RFKQJTRWODZPHF
BRD-K41256143-001-13-5	dehydroepiandrosterone	Launched	protein synthesis stimulant	ESR1|ESR2|G6PD|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|HSD17B1|NR1I2|NR1I3|PPARA|SIGMAR1|SULT2A1|SULT2B1	endocrinology	menopause	0	84.51	MicroSource	1505083	PRASTERONE	288.209	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|	FMGSKLZLMKYGDP-USOAJAOKSA-N	5881.0	BRD-A79445307-001-01-8	FMGSKLZLMKYGDP
BRD-K41256143-001-12-7	dehydroepiandrosterone	Launched	protein synthesis stimulant	ESR1|ESR2|G6PD|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|HSD17B1|NR1I2|NR1I3|PPARA|SIGMAR1|SULT2A1|SULT2B1	endocrinology	menopause	0	100.0	Selleck	S2604	Dehydroepiandrosterone (DHEA)	288.209	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|	FMGSKLZLMKYGDP-USOAJAOKSA-N	5881.0	BRD-K85833139-001-01-9	FMGSKLZLMKYGDP
BRD-K15360631-325-01-4	dehydroepiandrosterone-sulfate	Launched	androgen receptor agonist|estrogen receptor agonist	AR|ESR1|ESR2	endocrinology	menopause	0	99.5	Sigma	MFCD11045975	sodium (3beta)-17-oxoandrost-5-en-3-yl sulfate dihydrate	368.166	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|	CZWCKYRVOZZJNM-USOAJAOKSA-N	12594.0		CZWCKYRVOZZJNM
BRD-K90991629-100-02-9	delafloxacin	Phase 3	antiinfective drug				0	94.91	MedChemEx	HY-14814A	Delafloxacin (meglumine)	440.05	Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12	DYDCPNMLZGFQTM-UHFFFAOYSA-N	487101.0		DYDCPNMLZGFQTM
BRD-K17480742-001-01-1	delamanid	Launched	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	0	97.31	Adooq	A12864	(2R)-2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole	534.173	C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O	XDAOLTSRNUSPPH-XMMPIXPASA-N	6480466.0		XDAOLTSRNUSPPH
BRD-K59325863-001-04-4	delanzomib	Phase 1/Phase 2	proteasome inhibitor	CMA1|CTSG|CYP3A4|ELANE			0	83.82	MedChemEx	HY-10454	Delanzomib	413.212	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	SJFBTAPEPRWNKH-CCKFTAQKSA-N	24800541.0		SJFBTAPEPRWNKH
BRD-K59325863-001-01-0	delanzomib	Phase 1/Phase 2	proteasome inhibitor	CMA1|CTSG|CYP3A4|ELANE			0	61.62	MedChemEx	HY-10454	Delanzomib	413.212	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	SJFBTAPEPRWNKH-CCKFTAQKSA-N	24800541.0		SJFBTAPEPRWNKH
BRD-K59325863-001-03-6	delanzomib	Phase 1/Phase 2	proteasome inhibitor	CMA1|CTSG|CYP3A4|ELANE			0	89.99	Selleck	S1157	Delanzomib (CEP-18770)	413.212	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	SJFBTAPEPRWNKH-CCKFTAQKSA-N	24800541.0	BRD-K84591635-001-02-1	SJFBTAPEPRWNKH
BRD-K59325863-001-02-8	delanzomib	Phase 1/Phase 2	proteasome inhibitor	CMA1|CTSG|CYP3A4|ELANE			0	92.52	Selleck	S1157	CEP-18770 (Delanzomib)	413.212	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	SJFBTAPEPRWNKH-CCKFTAQKSA-N	24800541.0	BRD-K84591635-001-01-3	SJFBTAPEPRWNKH
BRD-K00573984-003-01-5	delapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	94.88	AKSci	R741		452.231	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1	WOUOLAUOZXOLJQ-MBSDFSHPSA-N	5362116.0		WOUOLAUOZXOLJQ
BRD-K34068325-066-04-5	delavirdine	Launched	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	0.0	Tocris	4149	Delavirdine mesylate	456.194	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	WHBIGIKBNXZKFE-UHFFFAOYSA-N	5625.0		WHBIGIKBNXZKFE
BRD-K34068325-066-02-9	delavirdine	Launched	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	91.35	Sigma	MFCD00866948	N-[2-({4-[3-(isopropylamino)-2-pyridinyl]-1-piperazinyl}carbonyl)-1H-indol-5-yl]methanesulfonamide methanesulfonate	456.194	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	WHBIGIKBNXZKFE-UHFFFAOYSA-N	5625.0		WHBIGIKBNXZKFE
BRD-K34068325-066-01-1	delavirdine	Launched	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	25.84	Enzo	GR314	Delavirdine mesylate	456.194	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	WHBIGIKBNXZKFE-UHFFFAOYSA-N	5625.0		WHBIGIKBNXZKFE
BRD-K34068325-066-03-7	delavirdine	Launched	non-nucleoside reverse transcriptase inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	95.35	MedChemEx	HY-10571A	Delavirdine (mesylate)	456.194	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	WHBIGIKBNXZKFE-UHFFFAOYSA-N	5625.0		WHBIGIKBNXZKFE
BRD-K00003468-001-01-9	delcasertib	Phase 1	PKC inhibitor				0	46.99	MedChemEx	HY-106262	Delcasertib	2878.467	CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(O)=O	XPXZTVWPRKJTAA-PJKOMPQUSA-N	56843747.0		XPXZTVWPRKJTAA
BRD-K00003500-001-01-9	delgocitinib	Phase 2	JAK inhibitor				0	96.08	MedChemEx	HY-109053	Delgocitinib	310.154	C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)c1ncnc2[nH]ccc12	LOWWYYZBZNSPDT-ZBEGNZNMSA-N	50914062.0		LOWWYYZBZNSPDT
BRD-K45503887-001-01-1	delivert	Launched	angiotensin receptor agonist	AGTR1|AGTR2	critical care	sepsis	0	88.91	MedChemEx	HY-13948	Angiotensin II human	1045.535	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O	CZGUSIXMZVURDU-FCWOTDAASA-N	78357780.0		CZGUSIXMZVURDU
BRD-K45503887-001-02-9	delivert	Launched	angiotensin receptor agonist	AGTR1|AGTR2	critical care	sepsis	0	88.63	MedChemEx	HY-13948	Angiotensin II human	1045.535	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O	CZGUSIXMZVURDU-FCWOTDAASA-N	78357780.0		CZGUSIXMZVURDU
BRD-K00003363-001-01-9	delpazolid	Phase 2	antibacterial				0	92.44	MedChemEx	HY-100180	Delpazolid	308.128	CN1CCN(C=N1)c1ccc(cc1F)N1C[C@H](CO)OC1=O |c:5|	QLUWQAFDTNAYPN-LLVKDONJSA-N	44205191.0		QLUWQAFDTNAYPN
BRD-K79107392-003-02-2	delphinidin	Phase 2	membrane permeability inhibitor	GLO1			0	0.0	Cayman	11012	3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromenium chloride	303.05	Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1	JKHRCGUTYDNCLE-UHFFFAOYSA-O	128853.0		JKHRCGUTYDNCLE
BRD-K79107392-003-01-4	delphinidin	Phase 2	membrane permeability inhibitor	GLO1			0	0.0	Cayman	11012		303.05	Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1	JKHRCGUTYDNCLE-UHFFFAOYSA-O	128853.0		JKHRCGUTYDNCLE
BRD-K85776940-001-01-9	delta-tocotrienol	Phase 1	HMGCR inhibitor	HMGCR			0	0.25	AnalytiCon	NP-013307		396.303	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1	ODADKLYLWWCHNB-LDYBVBFYSA-N	5282350.0		ODADKLYLWWCHNB
BRD-K90830492-305-01-4	deltarasin	Preclinical	phosphodiesterase inhibitor	KRAS			0	98.28	Tocris	5424	Deltarasin	603.3	C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1	LTZKEDSUXKTTTC-KXQOOQHDSA-N	73292904.0		LTZKEDSUXKTTTC
BRD-K90830492-305-02-9	deltarasin	Preclinical	phosphodiesterase inhibitor	KRAS			0	98.91	Tocris	5424	Deltarasin	603.3	C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1	LTZKEDSUXKTTTC-KXQOOQHDSA-N	73292904.0		LTZKEDSUXKTTTC
BRD-K51471001-303-07-9	demecarium	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	ophthalmology	intraocular pressure|glaucoma	0	93.17	MedChemEx	HY-B1626A	Demecarium Bromide	556.399	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	RWZVPVOZTJJMNU-UHFFFAOYSA-N	5966.0		RWZVPVOZTJJMNU
BRD-K51471001-303-04-7	demecarium	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	ophthalmology	intraocular pressure|glaucoma	0	94.41	Prestwick	Prestw-616	Demecarium bromide	556.399	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	RWZVPVOZTJJMNU-UHFFFAOYSA-N	5966.0		RWZVPVOZTJJMNU
BRD-K00003347-003-01-9	demeclocycline	Launched	bacterial 30S ribosomal subunit inhibitor		endocrinology|infectious disease|ophthalmology|urology	fever|respiratory tract infections|psittacosis|trachoma|conjunctivitis|urethritis|chancroid|cholera|syphilis|listeria|anthrax|actinomycosis|tularemia|brucellosis	0	55.5	MedChemEx	HY-17560	Demeclocycline (hydrochloride)	464.099	[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(=O)[C@@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)ccc(Cl)c1[C@H]2O |&1:11,&2:21|	JHOHXJYRVSLQCB-AWLLFJHESA-N			JHOHXJYRVSLQCB
BRD-K34122555-057-11-5	denatonium-benzoate	Preclinical					0	81.39	MicroSource	1505987	DENATONIUM BENZOATE	325.228	CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1	ZFQMTVNLDNXRNQ-UHFFFAOYSA-O	15488.0		ZFQMTVNLDNXRNQ
BRD-K34122555-057-12-9	denatonium-benzoate	Preclinical					0	76.25	MedChemEx	HY-B1146	Denatonium (benzoate)	325.228	CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1	ZFQMTVNLDNXRNQ-UHFFFAOYSA-O	15488.0		ZFQMTVNLDNXRNQ
BRD-K00004656-001-01-9	denopamine	Launched	adrenergic receptor agonist		cardiology	angina pectoris	0	89.63	Sigma	D7815	4-((1R)-2-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-1-hydroxyethyl)phenol	317.163	COc1ccc(CCNC[C@H](O)c2ccc(O)cc2)cc1OC	VHSBBVZJABQOSG-INIZCTEOSA-N	5311064.0		VHSBBVZJABQOSG
BRD-K01773083-001-01-4	denotivir	Launched	antiviral		infectious disease	virus herpes simplex (HSV)|skin infections	0	98.5	Vitas-M	STL450987	5-(benzoylamino)-N-(4-chlorophenyl)-3-methyl-4-isothiazolecarboxamide	371.05	Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1	ZPBLNADJHWHOEP-UHFFFAOYSA-N	39976.0		ZPBLNADJHWHOEP
BRD-A62562325-001-03-3	deoxyarbutin	Preclinical	tyrosinase inhibitor				0	0.0	Selleck	S4132	Deoxyarbutin	194.094	Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|	GFBCWCDNXDKFRH-NSHDSACASA-N	11521237.0		GFBCWCDNXDKFRH
BRD-A62562325-001-02-5	deoxyarbutin	Preclinical	tyrosinase inhibitor				0	62.84	Selleck	S4132	Deoxyarbutin	194.094	Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6,r|	GFBCWCDNXDKFRH-NSHDSACASA-N	11521237.0		GFBCWCDNXDKFRH
BRD-K41170226-001-13-8	deoxycholic-acid	Launched	biliverdin reductase A activator|G protein-coupled receptor agonist	FPR1|GPBAR1	endocrinology	submental fat	0	100.0	Enzo	BL052	Deoxycholic acid	392.293	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	KXGVEGMKQFWNSR-LLQZFEROSA-N	222528.0		KXGVEGMKQFWNSR
BRD-K24556098-001-19-1	deoxycorticosterone-acetate	Preclinical	progestogen hormone	NR3C2			0	96.9	MicroSource	300029	DESOXYCORTICOSTERONE ACETATE	372.23	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	VPGRYOFKCNULNK-ACXQXYJUSA-N	5952.0	BRD-A75402480-001-04-6	VPGRYOFKCNULNK
BRD-K24556098-001-17-5	deoxycorticosterone-acetate	Preclinical	progestogen hormone	NR3C2			0	98.53	Selleck	S4243	Deoxycorticosterone acetate	372.23	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	VPGRYOFKCNULNK-ACXQXYJUSA-N	5952.0		VPGRYOFKCNULNK
BRD-K24556098-001-18-3	deoxycorticosterone-acetate	Preclinical	progestogen hormone	NR3C2			0	88.64	Selleck	S4243	Deoxycorticosterone acetate	372.23	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	VPGRYOFKCNULNK-ACXQXYJUSA-N	5952.0	BRD-K54733518-001-01-9	VPGRYOFKCNULNK
BRD-K24556098-001-20-9	deoxycorticosterone-acetate	Preclinical	progestogen hormone	NR3C2			0	89.01	Selleck	S4243	Deoxycorticosterone	372.23	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	VPGRYOFKCNULNK-ACXQXYJUSA-N	5952.0		VPGRYOFKCNULNK
BRD-K24556098-001-16-7	deoxycorticosterone-acetate	Preclinical	progestogen hormone	NR3C2			0	96.47	Selleck	S4243	Deoxycorticosterone acetate	372.23	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	VPGRYOFKCNULNK-ACXQXYJUSA-N	5952.0		VPGRYOFKCNULNK
BRD-K33151569-003-09-7	deoxyepinephrine	Preclinical	adrenergic receptor agonist|dopamine receptor agonist	ADRA1A|DRD1|DRD2			0	83.38	Enzo	AC835	N-Methyldopamine HCl	167.095	CNCCc1ccc(O)c(O)c1	NGKZFDYBISXGGS-UHFFFAOYSA-N	4382.0		NGKZFDYBISXGGS
BRD-K33151569-003-10-5	deoxyepinephrine	Preclinical	adrenergic receptor agonist|dopamine receptor agonist	ADRA1A|DRD1|DRD2			0	94.36	CombiBlocks	QB-1311	N-Methyldopamine hydrochloride	167.095	CNCCc1ccc(O)c(O)c1	NGKZFDYBISXGGS-UHFFFAOYSA-N	4382.0		NGKZFDYBISXGGS
BRD-K00005351-050-01-9	deptropine	Preclinical	histamine receptor antagonist	HRH1			0	95.55	Toronto	d288360	deptropine maleate	333.209	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r,THB:0:1:3.4:6.7.8|	ZWPODSUQWXAZNC-PMOLBWCYSA-N			ZWPODSUQWXAZNC
BRD-K77685957-300-10-9	dequalinium	Launched	PKC inhibitor	KCNN1|KCNN3	infectious disease	first-aid antiseptic	0	91.47	MedChemEx	HY-B0567	Dequalinium (Chloride)	456.325	Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	PCSWXVJAIHCTMO-UHFFFAOYSA-P	2993.0		PCSWXVJAIHCTMO
BRD-K77685957-300-09-1	dequalinium	Launched	PKC inhibitor	KCNN1|KCNN3	infectious disease	first-aid antiseptic	0	95.31	MicroSource	1503127	DEQUALINIUM CHLORIDE	456.325	Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	PCSWXVJAIHCTMO-UHFFFAOYSA-P	2993.0		PCSWXVJAIHCTMO
BRD-K77685957-300-08-3	dequalinium	Launched	PKC inhibitor	KCNN1|KCNN3	infectious disease	first-aid antiseptic	0	91.21	Selleck	S4066	Dequalinium chloride	456.325	Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	PCSWXVJAIHCTMO-UHFFFAOYSA-P	2993.0		PCSWXVJAIHCTMO
BRD-K68558722-001-04-0	deracoxib	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	0	99.74	MicroSource	1505222	DERACOXIB	397.071	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F	WAZQAZKAZLXFMK-UHFFFAOYSA-N	3058754.0		WAZQAZKAZLXFMK
BRD-K68558722-001-05-9	deracoxib	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	0	96.11	MedChemEx	HY-17509	Deracoxib	397.071	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F	WAZQAZKAZLXFMK-UHFFFAOYSA-N	3058754.0		WAZQAZKAZLXFMK
BRD-K00003310-001-01-9	derazantinib	Phase 2	tyrosine kinase inhibitor				0	81.15	MedChemEx	HY-19981	Derazantinib	468.233	COCCNCCc1cccc(Nc2ncc3C[C@@H](c4ccccc4F)c4ccccc4-c3n2)c1	KPJDVVCDVBFRMU-AREMUKBSSA-N	46834118.0		KPJDVVCDVBFRMU
BRD-K29462201-001-02-7	deserpidine	Launched	angiotensin converting enzyme inhibitor	ACE|SLC18A2	cardiology	hypertension	0	96.99	Key	MD-0232	methyl (3beta,16beta,17alpha,18beta,20alpha)-17-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate	578.263	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	CVBMAZKKCSYWQR-WCGOZPBSSA-N	8550.0		CVBMAZKKCSYWQR
BRD-K29462201-001-01-9	deserpidine	Launched	angiotensin converting enzyme inhibitor	ACE|SLC18A2	cardiology	hypertension	0	90.18	AKSci	71845		578.263	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	CVBMAZKKCSYWQR-WCGOZPBSSA-N	8550.0		CVBMAZKKCSYWQR
BRD-K00003452-001-01-9	desidustat	Preclinical	hypoxia inducible factor prolyl hydroxylase inhibitor				0	93.55	MedChemEx	HY-103227	Desidustat	332.101	OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O	IKRKQQLJYBAPQT-UHFFFAOYSA-N	75593290.0		IKRKQQLJYBAPQT
BRD-K60762818-003-25-2	desipramine	Launched	tricyclic antidepressant	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A4|SMPD1	neurology/psychiatry	depression	0	49.2	MicroSource	1500227	DESIPRAMINE HYDROCHLORIDE	266.178	CNCCCN1c2ccccc2CCc2ccccc12	HCYAFALTSJYZDH-UHFFFAOYSA-N	2995.0		HCYAFALTSJYZDH
BRD-K60762818-003-26-0	desipramine	Launched	tricyclic antidepressant	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A4|SMPD1	neurology/psychiatry	depression	0	94.4	Sigma	MFCD00058108	3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methyl-1-propanamine hydrochloride	266.178	CNCCCN1c2ccccc2CCc2ccccc12	HCYAFALTSJYZDH-UHFFFAOYSA-N	2995.0		HCYAFALTSJYZDH
BRD-K00003103-001-01-9	desisobutyryl-ciclesonide	Launched	cytochrome P450 inhibitor		allergy	allergic rhinitis	0	84.9	MedChemEx	HY-111490	Desisobutyryl-ciclesonide	470.267	[H][C@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)CO |c:13,t:9|	OXPLANUPKBHPMS-FYSAVPLMSA-N	24848783.0		OXPLANUPKBHPMS
BRD-K99919177-001-01-3	deslanoside	Launched	Na/K-ATPase inhibitor	ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2	cardiology	congestive heart failure|cardiac arrythmia	0	98.38	AvaChem	1544	(3beta,5beta,12beta)-3-({2,6-dideoxy-4-O-[2,6-dideoxy-4-O-(2,6-dideoxy-4-O-beta-D-glucopyranosyl-beta-D-ribo-hexopyranosyl)-beta-D-ribo-hexopyranosyl]-beta-D-ribo-hexopyranosyl}oxy)-12,14-dihydroxycar	942.482	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|	OBATZBGFDSVCJD-LALPQLPRSA-N	28620.0		OBATZBGFDSVCJD
BRD-K82357231-001-18-3	desloratadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	67.71	MicroSource	1505393	DESLORATIDINE	310.124	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	JAUOIFJMECXRGI-UHFFFAOYSA-N	124087.0		JAUOIFJMECXRGI
BRD-K82357231-001-21-9	desloratadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	98.28	Tocris	5958	Desloratadine	310.124	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	JAUOIFJMECXRGI-UHFFFAOYSA-N	124087.0		JAUOIFJMECXRGI
BRD-K82357231-001-19-1	desloratadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	95.53	Selleck	S4012	Desloratadine	310.124	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	JAUOIFJMECXRGI-UHFFFAOYSA-N	124087.0		JAUOIFJMECXRGI
BRD-K82357231-001-17-5	desloratadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	81.2	Selleck	S4012	Desloratadine	310.124	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	JAUOIFJMECXRGI-UHFFFAOYSA-N	124087.0		JAUOIFJMECXRGI
BRD-K00003134-001-01-9	deslorelin	Phase 2	gonadotropin releasing factor hormone receptor agonist				0	98.49	MedChemEx	HY-12556	Deslorelin	1281.641	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	GJKXGJCSJWBJEZ-XRSSZCMZSA-N	25077495.0		GJKXGJCSJWBJEZ
BRD-K10042277-001-05-0	desmethylclozapine	Phase 2	acetylcholine receptor agonist	HTR2C			0	67.09	Tocris	1007	N-Desmethylclozapine	312.114	Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|	JNNOSTQEZICQQP-UHFFFAOYSA-N	135409468.0		JNNOSTQEZICQQP
BRD-K00003582-015-01-9	desmopressin-acetate	Launched	vasopressin receptor agonist	AVPR1A|AVPR1B|AVPR2|OXTR	endocrinology|urology	central diabetes insipidus|nocturnal enuresis	0	90.81	MedChemEx	HY-17370	Desmopressin (Acetate)	1068.427	NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|	NFLWUMRGJYTJIN-AIOUAYLGSA-N			NFLWUMRGJYTJIN
BRD-K46061689-001-01-9	desogestrel	Launched	progesterone receptor agonist	ESR1|PGR	endocrinology	contraceptive	0	97.27	Enzo	AC3084	DESOGESTREL	310.23	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|	RPLCPCMSCLEKRS-BPIQYHPVSA-N	40973.0		RPLCPCMSCLEKRS
BRD-K46061689-001-02-9	desogestrel	Launched	progesterone receptor agonist	ESR1|PGR	endocrinology	contraceptive	0	82.81	MedChemEx	HY-12516	Desogestrel	310.23	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|	RPLCPCMSCLEKRS-BPIQYHPVSA-N	40973.0		RPLCPCMSCLEKRS
BRD-K21528677-001-05-9	desonide	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	gastroenterology	Crohn's disease	0	94.6	MedChemEx	HY-B0248	Desonide	416.22	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	WBGKWQHBNHJJPZ-LECWWXJVSA-N	5311066.0		WBGKWQHBNHJJPZ
BRD-K21528677-001-04-4	desonide	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	gastroenterology	Crohn's disease	0	89.25	MicroSource	1505726	DESONIDE	416.22	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	WBGKWQHBNHJJPZ-LECWWXJVSA-N	5311066.0	BRD-A26858303-001-02-8	WBGKWQHBNHJJPZ
BRD-K21528677-001-02-8	desonide	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	gastroenterology	Crohn's disease	0	97.37	Selleck	S1701	Desonide	416.22	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	WBGKWQHBNHJJPZ-LECWWXJVSA-N	5311066.0		WBGKWQHBNHJJPZ
BRD-K21528677-001-03-6	desonide	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	gastroenterology	Crohn's disease	0	89.62	Selleck	S1701	Desonide	416.22	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	WBGKWQHBNHJJPZ-LECWWXJVSA-N	5311066.0	BRD-K30131328-001-01-5	WBGKWQHBNHJJPZ
BRD-K30697463-001-19-9	desoximetasone	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	dermatology	corticosteroid-responsive dermatoses	0	92.11	MedChemEx	HY-17570	Desoximetasone	376.205	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11,t:7|	VWVSBHGCDBMOOT-IIEHVVJPSA-N	5311067.0		VWVSBHGCDBMOOT
BRD-K26024145-001-01-9	desoxycorticosterone-pivalate	Launched	corticosteroid agonist	NR3C2	endocrinology	Addison's disease	0	98.85	InterBioScreen	STOCK1N-55228	3,20-dioxopregn-4-en-21-yl pivalate	414.277	CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|	VVOIQBFMTVCINR-WWMZEODYSA-N	11876263.0		VVOIQBFMTVCINR
BRD-K98521173-001-19-4	desoxycortone	Preclinical	mineralocorticoid receptor agonist	NR3C1|NR3C2			0	98.09	Prestwick	Prestw-957	Deoxycorticosterone	330.219	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|	ZESRJSPZRDMNHY-YFWFAHHUSA-N	6166.0		ZESRJSPZRDMNHY
BRD-K13819402-003-10-2	desoxypeganine	Phase 1	acetylcholinesterase inhibitor|monoamine oxidase inhibitor	ACHE			0	96.73	Enzo	NP073	Desoxypeganine HCl	172.1	C1CN2Cc3ccccc3N=C2C1 |c:11|	WUFQLZTXIWKION-UHFFFAOYSA-N	442894.0		WUFQLZTXIWKION
BRD-K13819402-003-11-9	desoxypeganine	Phase 1	acetylcholinesterase inhibitor|monoamine oxidase inhibitor	ACHE			0	95.63	Vitas-M	STK801663	1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline	172.1	C1CN2Cc3ccccc3N=C2C1 |c:11|	WUFQLZTXIWKION-UHFFFAOYSA-N	442894.0		WUFQLZTXIWKION
BRD-K01825598-036-02-9	desvenlafaxine	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	78.4	Selleck	S4112	Desvenlafaxine Succinate	381.215	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	KYYIDSXMWOZKMP-HNNXBMFYSA-N	12018336.0		KYYIDSXMWOZKMP
BRD-K01825598-036-04-9	desvenlafaxine	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	76.88	Selleck	S4112	Desvenlafaxine Succinate	381.215	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	KYYIDSXMWOZKMP-HNNXBMFYSA-N	12018336.0		KYYIDSXMWOZKMP
BRD-K01825598-036-03-9	desvenlafaxine	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	92.25	MicroSource	1504280	DESVENLAFAXINE SUCCINATE	381.215	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	KYYIDSXMWOZKMP-HNNXBMFYSA-N	12018336.0		KYYIDSXMWOZKMP
BRD-K01825598-036-05-9	desvenlafaxine	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	72.38	Tocris	4194	WY 45233 succinate	381.215	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	KYYIDSXMWOZKMP-HNNXBMFYSA-N	12018336.0		KYYIDSXMWOZKMP
BRD-K01825598-036-06-9	desvenlafaxine	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	84.28	Tocris	4194	WY 45233 succinate	263.189	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	KYYIDSXMWOZKMP-HNNXBMFYSA-N	12018336.0		KYYIDSXMWOZKMP
BRD-K77597856-003-03-9	detomidine	Launched	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	sedative	0	94.38	MedChemEx	HY-B0163A	Detomidine (hydrochloride)	186.116	Cc1cccc(Cc2cnc[nH]2)c1C	RHDJRPPFURBGLQ-UHFFFAOYSA-N	56032.0		RHDJRPPFURBGLQ
BRD-K77597856-003-02-5	detomidine	Launched	adrenergic receptor agonist	ADRA2A	neurology/psychiatry	sedative	0	98.34	Selleck	S2092	Detomidine HCl	186.116	Cc1cccc(Cc2cnc[nH]2)c1C	RHDJRPPFURBGLQ-UHFFFAOYSA-N	56032.0		RHDJRPPFURBGLQ
BRD-K31238592-001-02-9	devazepide	Preclinical	CCK receptor antagonist				0	98.14	Tocris	2304	L-364,718 | MK 329 |	408.159	CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|	NFHRQQKPEBFUJK-HSZRJFAPSA-N	443375.0		NFHRQQKPEBFUJK
BRD-K38775274-001-24-7	dexamethasone	Launched	glucocorticoid receptor agonist	ANXA1|NOS2|NR0B1|NR3C1|NR3C2	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	0	81.22	Tocris	1126	Dexamethasone	392.2	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-CXSFZGCWSA-N	5743.0	BRD-A27572786-001-02-0	UREBDLICKHMUKA
BRD-K38775274-001-29-9	dexamethasone	Launched	glucocorticoid receptor agonist	ANXA1|NOS2|NR0B1|NR3C1|NR3C2	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	0	83.0	Tocris	1126	Dexamethasone	392.2	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-CXSFZGCWSA-N	5743.0		UREBDLICKHMUKA
BRD-K38775274-001-22-1	dexamethasone	Launched	glucocorticoid receptor agonist	ANXA1|NOS2|NR0B1|NR3C1|NR3C2	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	0	95.93	Tocris	1126	Dexamethasone	392.2	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-CXSFZGCWSA-N	5743.0	BRD-A27572786-001-01-2	UREBDLICKHMUKA
BRD-K38775274-001-23-9	dexamethasone	Launched	glucocorticoid receptor agonist	ANXA1|NOS2|NR0B1|NR3C1|NR3C2	endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	0	92.38	Selleck	S1322	Dexamethasone (DHAP)	392.2	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	UREBDLICKHMUKA-CXSFZGCWSA-N	5743.0	BRD-K45192137-001-01-1	UREBDLICKHMUKA
BRD-K47635719-001-21-1	dexamethasone-acetate	Launched	glucocorticoid receptor agonist		endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	0	97.02	MicroSource	1500231	DEXAMETHASONE ACETATE	434.21	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	AKUJBENLRBOFTD-RPRRAYFGSA-N	236702.0	BRD-A93424738-001-04-8	AKUJBENLRBOFTD
BRD-K47635719-001-22-9	dexamethasone-acetate	Launched	glucocorticoid receptor agonist		endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	0	96.14	MedChemEx	HY-14648A	Dexamethasone (acetate)	434.21	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	AKUJBENLRBOFTD-RPRRAYFGSA-N	236702.0		AKUJBENLRBOFTD
BRD-K47635719-001-20-3	dexamethasone-acetate	Launched	glucocorticoid receptor agonist		endocrinology|rheumatology|allergy|gastroenterology|hematology|neurology/psychiatry|dermatology	hypercalcemia|rheumatoid arthritis|psoriatic arthritis|osteoarthritis|allergic rhinitis|ulcerative colitis|anemia|multiple sclerosis|enteritis|lupus|dermatitis herpetiformis (DH)|nephrotic syndrome|psoriasis	0	92.16	Selleck	S3124	Dexamethasone acetate	434.21	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11,t:7|	AKUJBENLRBOFTD-RPRRAYFGSA-N	236702.0	BRD-K40063336-001-01-8	AKUJBENLRBOFTD
BRD-K39462424-050-09-8	dexchlorpheniramine	Launched	histamine receptor antagonist		allergy|cardiology	allergic conjunctivitis|allergic rhinitis|urticaria|angioedema	0	95.84	MicroSource	1500183	DEXCHLORPHENIRAMINE MALEATE	274.124	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	SOYKEARSMXGVTM-HNNXBMFYSA-N	33036.0		SOYKEARSMXGVTM
BRD-K39462424-050-10-9	dexchlorpheniramine	Launched	histamine receptor antagonist		allergy|cardiology	allergic conjunctivitis|allergic rhinitis|urticaria|angioedema	0	99.06	MedChemEx	HY-B1062	Dexchlorpheniramine (maleate)	274.124	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	SOYKEARSMXGVTM-HNNXBMFYSA-N	33036.0		SOYKEARSMXGVTM
BRD-K30019776-001-01-9	dexfosfoserine	Preclinical	membrane integrity inhibitor	CFTR|GRM4|GRM6|GRM7|GRM8|KCNC4|PDPK1|PIM1|PRKACA|PRKCQ|PYGL|PYGM|REG1A|RHO|SERPINB3|SMAD2|TAOK2			1	0.0	Sigma	MFCD00065935	(2S)-2-amino-3-(phosphonooxy)propanoic acid	185.009	N[C@@H](COP(O)(O)=O)C(O)=O	BZQFBWGGLXLEPQ-REOHCLBHSA-N	68841.0		BZQFBWGGLXLEPQ
BRD-K30019776-003-01-5	dexfosfoserine	Preclinical	membrane integrity inhibitor	CFTR|GRM4|GRM6|GRM7|GRM8|KCNC4|PDPK1|PIM1|PRKACA|PRKCQ|PYGL|PYGM|REG1A|RHO|SERPINB3|SMAD2|TAOK2			1	0.0	MicroSource	1506151	DEXFOSFOSERINE HYDROCHLORIDE	185.009	N[C@@H](COP(O)(O)=O)C(O)=O	BZQFBWGGLXLEPQ-REOHCLBHSA-N	68841.0		BZQFBWGGLXLEPQ
BRD-K05900209-001-02-6	dexlansoprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)	0	1.2	MicroSource	1504282	DEXLANSOPRAZOLE	369.076	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	MJIHNNLFOKEZEW-RUZDIDTESA-N	9578005.0		MJIHNNLFOKEZEW
BRD-K05900209-001-01-8	dexlansoprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)	0	0.0	Selleck	S4099	Dexlansoprazole	369.076	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	MJIHNNLFOKEZEW-RUZDIDTESA-N	9578005.0		MJIHNNLFOKEZEW
BRD-K05900209-001-04-2	dexlansoprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)	0	94.54	Selleck	S4099	Dexlansoprazole	369.076	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	MJIHNNLFOKEZEW-RUZDIDTESA-N	9578005.0		MJIHNNLFOKEZEW
BRD-K05900209-001-03-4	dexlansoprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)	0	95.4	Selleck	S4099	Dexlansoprazole	369.076	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	MJIHNNLFOKEZEW-RUZDIDTESA-N	9578005.0		MJIHNNLFOKEZEW
BRD-K07609981-001-01-7	dexloxiglumide	Phase 3	CCK receptor antagonist	CCKAR			0	96.36	AdvChemBlocks	G-6604		460.153	CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	QNQZBKQEIFTHFZ-GOSISDBHSA-N	65937.0		QNQZBKQEIFTHFZ
BRD-K18423410-003-03-3	dexmedetomidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	sedative	0	93.69	Tocris	2749	Dexmedetomidine hydrochloride	200.131	C[C@H](c1cnc[nH]1)c1cccc(C)c1C	CUHVIMMYOGQXCV-NSHDSACASA-N	5311068.0		CUHVIMMYOGQXCV
BRD-K18423410-003-04-9	dexmedetomidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	sedative	0	93.47	Tocris	2749	Dexmedetomidine hydrochloride	200.131	C[C@H](c1cnc[nH]1)c1cccc(C)c1C	CUHVIMMYOGQXCV-NSHDSACASA-N	5311068.0		CUHVIMMYOGQXCV
BRD-K18423410-003-02-5	dexmedetomidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	sedative	0	98.01	Selleck	S2090	Dexmedetomidine HCl (Precedex)	200.131	C[C@H](c1cnc[nH]1)c1cccc(C)c1C	CUHVIMMYOGQXCV-NSHDSACASA-N	5311068.0		CUHVIMMYOGQXCV
BRD-K18423410-001-02-9	dexmedetomidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	sedative	0	97.7	Selleck	S3075	Dexmedetomidine	200.131	C[C@H](c1cnc[nH]1)c1cccc(C)c1C	CUHVIMMYOGQXCV-NSHDSACASA-N	5311068.0		CUHVIMMYOGQXCV
BRD-K44309363-003-02-1	dexniguldipine	Phase 2	calmodulin antagonist	ADORA3			0	92.38	Tocris	1124	(R)-(-)-Niguldipine hydrochloride	609.284	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	SVJMLYUFVDMUHP-MGBGTMOVSA-N	6918097.0		SVJMLYUFVDMUHP
BRD-K71210479-001-05-5	dexpanthenol	Launched			gastroenterology	paralytic ileus	0	89.08	MicroSource	1505420	DEXPANTHENOL	205.131	CC(C)(CO)[C@@H](O)C(=O)NCCCO	SNPLKNRPJHDVJA-ZETCQYMHSA-N	131204.0		SNPLKNRPJHDVJA
BRD-K71210479-001-06-9	dexpanthenol	Launched			gastroenterology	paralytic ileus	0	100.0	MedChemEx	HY-B1391	D-Panthenol	205.131	CC(C)(CO)[C@@H](O)C(=O)NCCCO	SNPLKNRPJHDVJA-ZETCQYMHSA-N	131204.0		SNPLKNRPJHDVJA
BRD-K07265709-003-05-6	dexrazoxane	Launched	chelating agent|topoisomerase inhibitor	TOP2A|TOP2B	cardiology	cardiomyopathy	0	94.57	Selleck	S1222	Dexrazoxane Hydrochloride	268.117	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	BMKDZUISNHGIBY-ZETCQYMHSA-N	71384.0		BMKDZUISNHGIBY
BRD-K07265709-003-03-1	dexrazoxane	Launched	chelating agent|topoisomerase inhibitor	TOP2A|TOP2B	cardiology	cardiomyopathy	0	48.5	Selleck	S1222	Dexrazoxane HCl (ICRF-187, ADR-529)	268.117	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	BMKDZUISNHGIBY-ZETCQYMHSA-N	71384.0		BMKDZUISNHGIBY
BRD-K07265709-003-04-9	dexrazoxane	Launched	chelating agent|topoisomerase inhibitor	TOP2A|TOP2B	cardiology	cardiomyopathy	0	0.0	Tocris	3857	Dexrazoxane hydrochloride	268.117	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	BMKDZUISNHGIBY-ZETCQYMHSA-N	71384.0		BMKDZUISNHGIBY
BRD-K67117832-001-01-9	dextran	Launched			hematology|critical care	thrombosis|hypovolemia	0	100.0	ANpharma	AN-19460	(2R,3S,4R,5R)-2,3,4,5-tetrahydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)hexana;l	504.169	OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	FZWBNHMXJMCXLU-BLAUPYHCSA-N	5460037.0		FZWBNHMXJMCXLU
BRD-K33211335-337-13-9	dextromethorphan	Launched	glutamate receptor antagonist|sigma receptor agonist	CHRNA2|CHRNA3|CHRNA4|CHRNA7|CHRNB2|CHRNB4|CYBA|CYBB|GRIN3A|NCF1|NCF2|NCF4|OPRD1|OPRK1|OPRM1|PGRMC1|RAC1|RAC2|SIGMAR1|SLC6A2|SLC6A4	pulmonary	cough suppressant	0	93.97	MedChemEx	HY-B1333	Dextromethorphan (hydrobromide hydrate)	271.194	COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1	MKXZASYAUGDDCJ-NJAFHUGGSA-N	5360696.0		MKXZASYAUGDDCJ
BRD-K33211335-004-01-7	dextromethorphan	Launched	glutamate receptor antagonist|sigma receptor agonist	CHRNA2|CHRNA3|CHRNA4|CHRNA7|CHRNB2|CHRNB4|CYBA|CYBB|GRIN3A|NCF1|NCF2|NCF4|OPRD1|OPRK1|OPRM1|PGRMC1|RAC1|RAC2|SIGMAR1|SLC6A2|SLC6A4	pulmonary	cough suppressant	0	99.02	MicroSource	1500233	DEXTROMETHORPHAN HYDROBROMIDE	271.194	COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1	MKXZASYAUGDDCJ-NJAFHUGGSA-N	5360696.0		MKXZASYAUGDDCJ
BRD-K00003272-001-01-9	dextrorotation-nimorazole-phosphate-ester	Preclinical	antiinfective drug				0	93.3	MedChemEx	HY-18716	Dextrorotation nimorazole phosphate ester	350.099	Cc1ncc(n1C[C@@H](CN1CCOCC1)OP(O)(O)=O)[N+]([O-])=O	CCDHHPOGWLYHAX-SNVBAGLBSA-N	25191609.0		CCDHHPOGWLYHAX
BRD-K51431759-001-03-9	dextrose	Launched			endocrinology	hypoglycemia	0	100.0	MedChemEx	HY-B0389	Dextrose	180.063	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O	GZCGUPFRVQAUEE-SLPGGIOYSA-N	107526.0		GZCGUPFRVQAUEE
BRD-K51431759-001-02-9	dextrose	Launched			endocrinology	hypoglycemia	0	96.3	Selleck	S2123	Dextrose	180.063	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O	GZCGUPFRVQAUEE-SLPGGIOYSA-N	107526.0		GZCGUPFRVQAUEE
BRD-K82002057-001-03-9	DFB	Preclinical	glutamate receptor agonist	GRM5			0	90.4	Tocris	1625	DFB	244.081	Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1	YYMCVDNIIFNDJK-BEQMOXJMSA-N	6604893.0		YYMCVDNIIFNDJK
BRD-K82002057-001-01-2	DFB	Preclinical	glutamate receptor agonist	GRM5			0	98.04	Tocris	1625	DFB	244.081	Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1	YYMCVDNIIFNDJK-BEQMOXJMSA-N	6604893.0		YYMCVDNIIFNDJK
BRD-K75748943-300-01-3	DG-172	Preclinical	PPAR receptor inverse agonist	PPARD			0	79.69	Tocris	5566	DG 172 dihydrochloride	381.084	CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1	ZJMDTBBCNMGFMS-SAPNQHFASA-N	57342889.0		ZJMDTBBCNMGFMS
BRD-K75748943-300-02-9	DG-172	Preclinical	PPAR receptor inverse agonist	PPARD			0	87.99	Tocris	5566	DG 172 dihydrochloride	381.084	CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1	ZJMDTBBCNMGFMS-SAPNQHFASA-N	57342889.0		ZJMDTBBCNMGFMS
BRD-K00003486-003-01-9	DG051	Preclinical	leukotriene synthesis inhibitor				0	95.07	MedChemEx	HY-10825	DG051	389.139	OC(=O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1	PVCTYSQBVIGZRU-KRWDZBQOSA-N	72199860.0		PVCTYSQBVIGZRU
BRD-K06014311-001-03-8	DH-97	Preclinical	melatonin receptor antagonist	MTNR1B			0	96.0	Tocris	1218	DH 97	334.205	CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	HDOIPCLEKCEANF-UHFFFAOYSA-N	3467177.0		HDOIPCLEKCEANF
BRD-K06014311-001-04-9	DH-97	Preclinical	melatonin receptor antagonist	MTNR1B			0	96.23	Tocris	1218	DH 97	334.205	CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	HDOIPCLEKCEANF-UHFFFAOYSA-N	3467177.0		HDOIPCLEKCEANF
BRD-K06014311-001-02-0	DH-97	Preclinical	melatonin receptor antagonist	MTNR1B			0	73.31	Tocris	1218	DH 97	334.205	CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	HDOIPCLEKCEANF-UHFFFAOYSA-N	3467177.0		HDOIPCLEKCEANF
BRD-K41262162-303-11-9	DHBP	Preclinical	ryanodine receptor blocker				0	84.11	Tocris	839	DHBP dibromide	354.303	CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1	XJGZGUSMZSXHJI-UHFFFAOYSA-N	80263.0		XJGZGUSMZSXHJI
BRD-K41262162-303-02-2	DHBP	Preclinical	ryanodine receptor blocker				0	0.0	Tocris	839	DHBP dibromide	354.303	CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1	XJGZGUSMZSXHJI-UHFFFAOYSA-N	80263.0		XJGZGUSMZSXHJI
BRD-K69122748-001-10-1	diacerein	Launched	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	0	95.35	MicroSource	1502010	DIACERIN	368.053	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	TYNLGDBUJLVSMA-UHFFFAOYSA-N	26248.0		TYNLGDBUJLVSMA
BRD-K69122748-001-12-9	diacerein	Launched	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	0	89.62	MedChemEx	HY-N0283	Diacerein	368.053	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	TYNLGDBUJLVSMA-UHFFFAOYSA-N	26248.0		TYNLGDBUJLVSMA
BRD-K69122748-001-09-3	diacerein	Launched	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	0	87.14	Selleck	S4267	Diacerein	368.053	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	TYNLGDBUJLVSMA-UHFFFAOYSA-N	26248.0		TYNLGDBUJLVSMA
BRD-K69122748-001-11-9	diacerein	Launched	interleukin inhibitor	IL1B	rheumatology	osteoarthritis	0	93.69	Selleck	S4267	Diacerein	368.053	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	TYNLGDBUJLVSMA-UHFFFAOYSA-N	26248.0		TYNLGDBUJLVSMA
BRD-K93611241-001-02-2	diacetamate	Preclinical					0	98.65	MicroSource	1504515	DIACETAMATE	193.074	CC(=O)Nc1ccc(OC(C)=O)cc1	UJAOSPFULOFZRR-UHFFFAOYSA-N	17499.0		UJAOSPFULOFZRR
BRD-K93611241-001-03-9	diacetamate	Preclinical					0	84.56	Sigma	MFCD00059205	4-ACETAMIDOPHENYL ACETATE	193.074	CC(=O)Nc1ccc(OC(C)=O)cc1	UJAOSPFULOFZRR-UHFFFAOYSA-N	17499.0		UJAOSPFULOFZRR
BRD-A52394261-419-01-7	diadenosine-tetraphosphate	Phase 1	adenosine kinase inhibitor	P2RY13|P2RY2			0	100.0	Sigma	D1262-10MG	P1,P4-Di(adenosine-5') tetraphosphate ammonium salt	836.048	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10,12,32,34,35,37,49,51,&1:15,&2:19,&3:23,&4:27|	YOAHKNVSNCMZGQ-XPWFQUROSA-N	21706.0		YOAHKNVSNCMZGQ
BRD-K68502831-001-01-2	dianhydrogalactitol	Phase 3	DNA alkylating agent				1	0.0	MedChemEx	HY-16513	VAL-083	146.058	O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	AAFJXZWCNVJTMK-GUCUJZIJSA-N	15942827.0		AAFJXZWCNVJTMK
BRD-K68502831-001-02-9	dianhydrogalactitol	Phase 3	DNA alkylating agent				1	78.8	MedChemEx	HY-16513	VAL-083	146.058	O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	AAFJXZWCNVJTMK-GUCUJZIJSA-N	15942827.0		AAFJXZWCNVJTMK
BRD-A27143604-001-02-0	diarylpropionitrile	Preclinical	estrogen receptor agonist	ESR2			0	94.36	Tocris	1494	DPN	239.095	Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|	GHZHWDWADLAOIQ-ZDUSSCGKSA-N	6604873.0		GHZHWDWADLAOIQ
BRD-A27143604-001-03-9	diarylpropionitrile	Preclinical	estrogen receptor agonist	ESR2			0	90.17	Tocris	1494	DPN	239.095	Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6,r|	GHZHWDWADLAOIQ-ZDUSSCGKSA-N	6604873.0		GHZHWDWADLAOIQ
BRD-K48247567-001-08-9	diatrizoic-acid	Launched			radiology	contrast agent	0	98.63	MedChemEx	HY-B0926	Diatrizoic acid	613.77	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	YVPYQUNUQOZFHG-UHFFFAOYSA-N	2140.0		YVPYQUNUQOZFHG
BRD-K48247567-001-01-9	diatrizoic-acid	Launched			radiology	contrast agent	0	97.75	MicroSource	1505777	DIATRIZOIC ACID	613.77	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	YVPYQUNUQOZFHG-UHFFFAOYSA-N	2140.0		YVPYQUNUQOZFHG
BRD-K97464279-001-04-9	diaveridine	Launched	dihydrofolate reductase inhibitor		infectious disease	coccidiosis	0	94.52	MedChemEx	HY-B1902	Diaveridine	260.127	COc1ccc(Cc2cnc(N)nc2N)cc1OC	LDBTVAXGKYIFHO-UHFFFAOYSA-N	21453.0		LDBTVAXGKYIFHO
BRD-K97464279-001-03-5	diaveridine	Launched	dihydrofolate reductase inhibitor		infectious disease	coccidiosis	0	99.41	MicroSource	1502300	DIAVERIDINE	260.127	COc1ccc(Cc2cnc(N)nc2N)cc1OC	LDBTVAXGKYIFHO-UHFFFAOYSA-N	21453.0		LDBTVAXGKYIFHO
BRD-K73109821-001-22-7	diazoxide	Launched	potassium channel activator	ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3	endocrinology	hypoglycemia	0	89.52	Tocris	964	Diazoxide	229.992	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|	GDLBFKVLRPITMI-UHFFFAOYSA-N	3019.0		GDLBFKVLRPITMI
BRD-K73109821-001-20-1	diazoxide	Launched	potassium channel activator	ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3	endocrinology	hypoglycemia	0	99.38	MicroSource	2300206	DIAZOXIDE	229.992	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|	GDLBFKVLRPITMI-UHFFFAOYSA-N	3019.0		GDLBFKVLRPITMI
BRD-K73109821-001-23-9	diazoxide	Launched	potassium channel activator	ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3	endocrinology	hypoglycemia	0	97.02	Tocris	964	Diazoxide	229.992	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|	GDLBFKVLRPITMI-UHFFFAOYSA-N	3019.0		GDLBFKVLRPITMI
BRD-K73109821-001-19-3	diazoxide	Launched	potassium channel activator	ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3	endocrinology	hypoglycemia	0	99.21	Tocris	964	Diazoxide	229.992	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|	GDLBFKVLRPITMI-UHFFFAOYSA-N	3019.0		GDLBFKVLRPITMI
BRD-K48427910-001-01-1	dibekacin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MicroSource	1503114	DIBEKACIN	451.264	NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1	JJCQSGDBDPYCEO-XVZSLQNASA-N	470999.0		JJCQSGDBDPYCEO
BRD-K79145749-003-02-2	dibenzepine	Preclinical	norepinephrine reputake inhibitor				0	96.96	Selleck	S4319	Dibenzepine HCl	295.168	CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O	QPGGEKPRGVJKQB-UHFFFAOYSA-N	9419.0		QPGGEKPRGVJKQB
BRD-K79145749-003-03-0	dibenzepine	Preclinical	norepinephrine reputake inhibitor				0	99.06	Selleck	S4319	Dibenzepine HCl	295.168	CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O	QPGGEKPRGVJKQB-UHFFFAOYSA-N	9419.0		QPGGEKPRGVJKQB
BRD-K46863940-001-05-4	dibenzothiophene	Preclinical					0	0.0	MicroSource	1500235	DIBENZOTHIOPHENE	184.035	c1ccc2c(c1)sc1ccccc21	IYYZUPMFVPLQIF-UHFFFAOYSA-N	3023.0		IYYZUPMFVPLQIF
BRD-K46863940-001-04-7	dibenzothiophene	Preclinical					0	0.0	Selleck	S4205	Dibenzothiophene	184.035	c1ccc2c(c1)sc1ccccc21	IYYZUPMFVPLQIF-UHFFFAOYSA-N	3023.0		IYYZUPMFVPLQIF
BRD-K46863940-001-06-2	dibenzothiophene	Preclinical					0	99.86	Selleck	S4205	Dibenzothiophene	184.035	c1ccc2c(c1)sc1ccccc21	IYYZUPMFVPLQIF-UHFFFAOYSA-N	3023.0		IYYZUPMFVPLQIF
BRD-K73477617-001-09-9	dibutyl-phthalate	Preclinical		TRPA1			0	98.55	MedChemEx	HY-Y0304	Dibutyl phthalate	278.152	CCCCOC(=O)c1ccccc1C(=O)OCCCC	DOIRQSBPFJWKBE-UHFFFAOYSA-N	3026.0		DOIRQSBPFJWKBE
BRD-K73477617-001-08-5	dibutyl-phthalate	Preclinical		TRPA1			0	99.18	MicroSource	330086	DIBUTYL PHTHALATE	278.152	CCCCOC(=O)c1ccccc1C(=O)OCCCC	DOIRQSBPFJWKBE-UHFFFAOYSA-N	3026.0		DOIRQSBPFJWKBE
BRD-K54187111-001-10-9	dichlorisone-acetate	Phase 2					0	90.68	MedChemEx	HY-B1383	Dichlorisone acetate	454.131	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|	YNNURTVKPVJVEI-GSLJADNHSA-N	5388959.0		YNNURTVKPVJVEI
BRD-K54187111-001-09-2	dichlorisone-acetate	Phase 2					0	88.29	MicroSource	1505779	DICHLORISONE ACETATE	454.131	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|	YNNURTVKPVJVEI-GSLJADNHSA-N	5388959.0	BRD-A40195998-001-02-7	YNNURTVKPVJVEI
BRD-K54187111-001-07-6	dichlorisone-acetate	Phase 2					0	82.88	Selleck	S4395	Dichlorisone Acetate	454.131	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|	YNNURTVKPVJVEI-GSLJADNHSA-N	5388959.0		YNNURTVKPVJVEI
BRD-K54187111-001-08-4	dichlorisone-acetate	Phase 2					0	91.61	Selleck	S4395	dichlorisone acetate	454.131	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19,t:15|	YNNURTVKPVJVEI-GSLJADNHSA-N	5388959.0		YNNURTVKPVJVEI
BRD-M97302542-001-04-4	dichloroacetate	Phase 3	pyruvate dehydrogenase kinase inhibitor				1	96.5	Sigma	MFCD00070489	sodium dichloroacetate	150.933	[Na].OC(=O)C(Cl)Cl	FLWQSOHPGISTPX-UHFFFAOYSA-N			FLWQSOHPGISTPX
BRD-M97302542-001-03-6	dichloroacetate	Phase 3	pyruvate dehydrogenase kinase inhibitor				1	0.0	Tocris	2755	DCA	150.933	[Na].OC(=O)C(Cl)Cl	FLWQSOHPGISTPX-UHFFFAOYSA-N			FLWQSOHPGISTPX
BRD-K62326629-001-20-8	dichlorophen	Launched	anticestodal agent		infectious disease	hookworm|tapeworm	0	92.97	Sigma	MFCD00002322	2,2'-methylenebis(4-chlorophenol)	268.006	Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O	MDNWOSOZYLHTCG-UHFFFAOYSA-N	3037.0		MDNWOSOZYLHTCG
BRD-K62326629-001-19-0	dichlorophen	Launched	anticestodal agent		infectious disease	hookworm|tapeworm	0	75.11	MicroSource	1500626	DICHLOROPHEN	268.006	Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O	MDNWOSOZYLHTCG-UHFFFAOYSA-N	3037.0		MDNWOSOZYLHTCG
BRD-K23779958-001-05-8	dichlorvos	Launched	acetylcholinesterase inhibitor				1	0.0	MicroSource	330018	DICHLORVOS	219.946	COP(=O)(OC)OC=C(Cl)Cl	OEBRKCOSUFCWJD-UHFFFAOYSA-N	3039.0		OEBRKCOSUFCWJD
BRD-K23779958-001-08-9	dichlorvos	Launched	acetylcholinesterase inhibitor				1	0.0	AMS	A000317286	2,2-dichlorovinyl dimethyl phosphate	219.946	COP(=O)(OC)OC=C(Cl)Cl	OEBRKCOSUFCWJD-UHFFFAOYSA-N	3039.0		OEBRKCOSUFCWJD
BRD-A06426627-001-04-3	diclazuril	Launched	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	0	94.34	MicroSource	1502348	DICLAZURIL	405.979	Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	ZSZFUDFOPOMEET-GFCCVEGCSA-N	25273624.0		ZSZFUDFOPOMEET
BRD-A06426627-001-06-9	diclazuril	Launched	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	0	96.37	MedChemEx	HY-B0357	Diclazuril	405.979	Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	ZSZFUDFOPOMEET-GFCCVEGCSA-N	25273624.0		ZSZFUDFOPOMEET
BRD-A06426627-001-03-5	diclazuril	Launched	antiprotozoal agent		infectious disease	equine protozoal myeloencephalitis (EPM)	0	98.14	Selleck	S2028	Diclazuril	405.979	Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	ZSZFUDFOPOMEET-GFCCVEGCSA-N	25273624.0		ZSZFUDFOPOMEET
BRD-K08252256-236-33-8	diclofenac	Launched	cyclooxygenase inhibitor	AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache	0	99.61	MicroSource	1500237	DICLOFENAC SODIUM	295.017	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	DCOPUUMXTXDBNB-UHFFFAOYSA-N	3033.0		DCOPUUMXTXDBNB
BRD-K08252256-237-02-1	diclofenac	Launched	cyclooxygenase inhibitor	AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache	0	97.9	Selleck	S3062	Diclofenac Potassium	295.017	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	DCOPUUMXTXDBNB-UHFFFAOYSA-N	3033.0		DCOPUUMXTXDBNB
BRD-K08252256-224-02-9	diclofenac	Launched	cyclooxygenase inhibitor	AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache	0	97.96	Selleck	S3063	Diclofenac Diethylamine	295.017	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	DCOPUUMXTXDBNB-UHFFFAOYSA-N	3033.0		DCOPUUMXTXDBNB
BRD-K08252256-236-32-0	diclofenac	Launched	cyclooxygenase inhibitor	AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A	rheumatology|neurology/psychiatry	rheumatoid arthritis|osteoarthritis|migraine headache	0	98.33	Selleck	S1903	Diclofenac Sodium	295.017	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	DCOPUUMXTXDBNB-UHFFFAOYSA-N	3033.0		DCOPUUMXTXDBNB
BRD-K71499074-001-13-9	diclofenamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA2|CA4|CA7	ophthalmology|neurology/psychiatry	glaucoma|epilepsy	0	87.25	MedChemEx	HY-B0397	Dichlorphenamide	303.915	NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O	GJQPMPFPNINLKP-UHFFFAOYSA-N	3038.0		GJQPMPFPNINLKP
BRD-K71499074-001-12-9	diclofenamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA2|CA4|CA7	ophthalmology|neurology/psychiatry	glaucoma|epilepsy	0	98.21	Selleck	S2177	Dichlorphenamide	303.915	NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O	GJQPMPFPNINLKP-UHFFFAOYSA-N	3038.0		GJQPMPFPNINLKP
BRD-A51078674-003-01-0	diclofensine	Phase 3	dopamine reuptake inhibitor	DRD1|MAOA|MAOB			0	97.06	MedChemEx	HY-18610	Diclofensine (hydrochloride)	321.069	COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|	ZJDCGVDEEHWEIG-HNNXBMFYSA-N	23872188.0		ZJDCGVDEEHWEIG
BRD-A51078674-003-02-9	diclofensine	Phase 3	dopamine reuptake inhibitor	DRD1|MAOA|MAOB			0	97.83	MedChemEx	HY-18610	Diclofensine (hydrochloride)	321.069	COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|	ZJDCGVDEEHWEIG-HNNXBMFYSA-N	23872188.0		ZJDCGVDEEHWEIG
BRD-A41657926-001-03-0	dicloralurea	Preclinical					1	0.0	MicroSource	1503738	DICLORALUREA	351.851	O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|	PPJXIHLNYDVTDI-XIXRPRMCSA-N	7059662.0		PPJXIHLNYDVTDI
BRD-A41657926-001-04-9	dicloralurea	Preclinical					1	100.0	Labotest	LT00044260	N'-[(Z)-2,2,2-trichloro-1-hydroxyethyl]-N-(2,2,2-trichloro-1-hydroxyethyl)carbamimidic acid	351.851	O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1,&2:6,r|	PPJXIHLNYDVTDI-XIXRPRMCSA-N	7059662.0		PPJXIHLNYDVTDI
BRD-K05673000-323-14-9	dicloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	83.52	MedChemEx	HY-B0977	Dicloxacillin (Sodium hydrate)	469.027	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	YFAGHNZHGGCZAX-JKIFEVAISA-N	18381.0		YFAGHNZHGGCZAX
BRD-K05673000-236-12-1	dicloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	87.83	MicroSource	1500238	DICLOXACILLIN SODIUM	469.027	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	YFAGHNZHGGCZAX-JKIFEVAISA-N	18381.0		YFAGHNZHGGCZAX
BRD-K05673000-323-13-5	dicloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	60.29	Selleck	S4111	Dicloxacillin Sodium	469.027	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	YFAGHNZHGGCZAX-JKIFEVAISA-N	18381.0	BRD-K59843513-323-01-4	YFAGHNZHGGCZAX
BRD-K05673000-323-12-7	dicloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	51.56	Selleck	S4111	Dicloxacillin Sodium	469.027	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	YFAGHNZHGGCZAX-JKIFEVAISA-N	18381.0		YFAGHNZHGGCZAX
BRD-K82236179-001-08-9	dicoumarol	Launched	NADPH inhibitor	CRYZ|NQO1|VKORC1	hematology	deep vein thrombosis (DVT)	0	96.81	MedChemEx	HY-N0645	Dicoumarol	336.063	Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12	DOBMPNYZJYQDGZ-UHFFFAOYSA-N	54676038.0		DOBMPNYZJYQDGZ
BRD-K82236179-213-01-0	dicoumarol	Launched	NADPH inhibitor	CRYZ|NQO1|VKORC1	hematology	deep vein thrombosis (DVT)	0	99.51	MicroSource	1500239	DICUMAROL	336.063	Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12	DOBMPNYZJYQDGZ-UHFFFAOYSA-N	54676038.0		DOBMPNYZJYQDGZ
BRD-K57091285-001-07-7	dicyclohexylamine	Preclinical					0	96.38	Vitas-M	STK379549		181.183	C1CCC(CC1)NC1CCCCC1	XBPCUCUWBYBCDP-UHFFFAOYSA-N	7582.0		XBPCUCUWBYBCDP
BRD-K57091285-001-08-9	dicyclohexylamine	Preclinical					0	0.0	Labotest	LTBB000396	N-cyclohexylcyclohexanamine	181.183	C1CCC(CC1)NC1CCCCC1	XBPCUCUWBYBCDP-UHFFFAOYSA-N	7582.0		XBPCUCUWBYBCDP
BRD-K68507560-003-25-3	dicycloverine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	gastroenterology	irritable bowel syndrome	0	100.0	MicroSource	1500240	DICYCLOMINE HYDROCHLORIDE	309.267	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	CURUTKGFNZGFSE-UHFFFAOYSA-N	3042.0		CURUTKGFNZGFSE
BRD-K68507560-003-24-6	dicycloverine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	gastroenterology	irritable bowel syndrome	0	100.0	Selleck	S4373	Dicyclomine HCl	309.267	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	CURUTKGFNZGFSE-UHFFFAOYSA-N	3042.0		CURUTKGFNZGFSE
BRD-K68507560-003-26-1	dicycloverine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	gastroenterology	irritable bowel syndrome	0	100.0	Selleck	S4373	DICYCLOMINE HYDROCHLORIDE	309.267	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	CURUTKGFNZGFSE-UHFFFAOYSA-N	3042.0		CURUTKGFNZGFSE
BRD-K99063460-001-16-9	didanosine	Launched	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	0	94.81	MedChemEx	HY-B0249	Didanosine	236.091	OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O	BXZVVICBKDXVGW-NKWVEPMBSA-N	135398739.0		BXZVVICBKDXVGW
BRD-K99063460-001-13-1	didanosine	Launched	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	0	99.4	Selleck	S1702	Didanosine (Videx)	236.091	OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O	BXZVVICBKDXVGW-NKWVEPMBSA-N	135398739.0		BXZVVICBKDXVGW
BRD-K99063460-001-12-3	didanosine	Launched	nucleoside reverse transcriptase inhibitor	PNP	infectious disease	human immunodeficiency virus (HIV-1)	0	95.19	Selleck	S1702	Didanosine	236.091	OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O	BXZVVICBKDXVGW-NKWVEPMBSA-N	135398739.0		BXZVVICBKDXVGW
BRD-K84794093-001-07-5	dideoxyadenosine	Phase 1	nucleoside reverse transcriptase inhibitor				0	97.9	Berry	PR 3495		235.107	Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1	WVXRAFOPTSTNLL-NKWVEPMBSA-N	20039.0		WVXRAFOPTSTNLL
BRD-K94146583-001-01-6	didox	Launched	ribonucleotide reductase inhibitor	RRM1	oncology	breast cancer	0	95.72	MedChemEx	HY-19387	Didox	169.038	ONC(=O)c1ccc(O)c(O)c1	QJMCKEPOKRERLN-UHFFFAOYSA-N	3045.0		QJMCKEPOKRERLN
BRD-K95309561-001-27-9	dienestrol	Launched	estrogen receptor agonist	ESR1	endocrinology	menopause	0	93.72	MedChemEx	HY-B1403	Dienestrol	266.131	C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1	NFDFQCUYFHCNBW-SCGPFSFSSA-N	667476.0		NFDFQCUYFHCNBW
BRD-K95309561-001-24-7	dienestrol	Launched	estrogen receptor agonist	ESR1	endocrinology	menopause	0	90.26	MicroSource	1500241	DIENESTROL	266.131	C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1	NFDFQCUYFHCNBW-SCGPFSFSSA-N	667476.0		NFDFQCUYFHCNBW
BRD-K50853363-001-03-9	dienogest	Launched	progesterone receptor agonist	PGR	endocrinology|obstetrics/gynecology	contraceptive|endometriosis	0	95.22	MedChemEx	HY-B0084	Dienogest	311.189	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|	AZFLJNIPTRTECV-FUMNGEBKSA-N	68861.0		AZFLJNIPTRTECV
BRD-K50853363-001-02-3	dienogest	Launched	progesterone receptor agonist	PGR	endocrinology|obstetrics/gynecology	contraceptive|endometriosis	0	92.69	Selleck	S1251	Dienogest	311.189	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4,10|	AZFLJNIPTRTECV-FUMNGEBKSA-N	68861.0	BRD-K64504314-001-01-8	AZFLJNIPTRTECV
BRD-K45542189-048-23-9	diethylcarbamazine	Launched	lipoxygenase inhibitor	ALOX5|PTGS1	infectious disease	filariasis	0	96.21	MedChemEx	HY-12642	Diethylcarbamazine (citrate)	199.168	CCN(CC)C(=O)N1CCN(C)CC1	RCKMWOKWVGPNJF-UHFFFAOYSA-N	3052.0		RCKMWOKWVGPNJF
BRD-K45542189-048-22-1	diethylcarbamazine	Launched	lipoxygenase inhibitor	ALOX5|PTGS1	infectious disease	filariasis	0	99.23	MicroSource	1500242	DIETHYLCARBAMAZINE CITRATE	199.168	CCN(CC)C(=O)N1CCN(C)CC1	RCKMWOKWVGPNJF-UHFFFAOYSA-N	3052.0		RCKMWOKWVGPNJF
BRD-K45330754-001-22-5	diethylstilbestrol	Withdrawn	estrogen receptor agonist	ESR1|ESR2|ESRRB|ESRRG			0	78.29	MicroSource	1500244	DIETHYLSTILBESTROL	268.146	CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1	RGLYKWWBQGJZGM-ISLYRVAYSA-N	448537.0		RGLYKWWBQGJZGM
BRD-K45330754-001-21-7	diethylstilbestrol	Withdrawn	estrogen receptor agonist	ESR1|ESR2|ESRRB|ESRRG			0	93.73	Selleck	S1859	Diethylstilbestrol	268.146	CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1	RGLYKWWBQGJZGM-ISLYRVAYSA-N	448537.0		RGLYKWWBQGJZGM
BRD-K94080537-001-11-9	diethyltoluamide	Launched	ionotropic receptor IR40a activator		dermatology	sunscreen lotion	0	97.32	MedChemEx	HY-B0978	Diethyltoluamide	191.131	CCN(CC)C(=O)c1cccc(C)c1	MMOXZBCLCQITDF-UHFFFAOYSA-N	4284.0		MMOXZBCLCQITDF
BRD-K94080537-001-09-7	diethyltoluamide	Launched	ionotropic receptor IR40a activator		dermatology	sunscreen lotion	0	98.89	MicroSource	1601020	DIETHYLTOLUAMIDE	191.131	CCN(CC)C(=O)c1cccc(C)c1	MMOXZBCLCQITDF-UHFFFAOYSA-N	4284.0		MMOXZBCLCQITDF
BRD-K96206066-001-07-9	difenpiramide	Launched	cyclooxygenase inhibitor|prostaglandin inhibitor		neurology/psychiatry	pain relief	0	85.55	Enamine	Z60744762	2-[1,1'-biphenyl]-4-yl-N-(2-pyridinyl)acetamide	288.126	O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1	PWHROYKAGRUWDQ-UHFFFAOYSA-N	100472.0		PWHROYKAGRUWDQ
BRD-A66869276-001-02-9	diflorasone-diacetate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	97.55	MicroSource	1505880	DIFLORASONE DIACETATE	494.212	C[C@H]1C[C@H]2[C@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(C)=O)C(=O)COC(C)=O |a:1,6,14,16,18,21,23,&1:3,&2:4,c:12,t:8|	BOBLHFUVNSFZPJ-OAEHMYPASA-N	51895260.0		BOBLHFUVNSFZPJ
BRD-K73923631-003-02-9	difloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	skin infections|urinary tract infections	0	97.01	MicroSource	1502359	DIFLOXACIN HYDROCHLORIDE	399.139	CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	NOCJXYPHIIZEHN-UHFFFAOYSA-N	56206.0		NOCJXYPHIIZEHN
BRD-K73923631-003-01-1	difloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	skin infections|urinary tract infections	0	95.11	Selleck	S4384	Difloxacin HCl	399.139	CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	NOCJXYPHIIZEHN-UHFFFAOYSA-N	56206.0		NOCJXYPHIIZEHN
BRD-K73923631-003-03-7	difloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	skin infections|urinary tract infections	0	96.14	Selleck	S4384	2-(6-chloro-9H-carbazol-2-yl)propanoic acid	399.139	CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	NOCJXYPHIIZEHN-UHFFFAOYSA-N	56206.0		NOCJXYPHIIZEHN
BRD-K22031190-001-23-6	diflunisal	Launched	prostanoid receptor antagonist	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	98.97	MicroSource	1500245	DIFLUNISAL	250.044	OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F	HUPFGZXOMWLGNK-UHFFFAOYSA-N	3059.0		HUPFGZXOMWLGNK
BRD-K72992801-001-16-9	difluprednate	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology	endogenous uveitis	0	91.09	MedChemEx	HY-17569	Difluprednate	508.227	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18,t:14|	WYQPLTPSGFELIB-JTQPXKBDSA-N	443936.0		WYQPLTPSGFELIB
BRD-K80076813-001-08-8	diftalone	Launched	cyclooxygenase inhibitor		endocrinology	thyroiditis	0	98.16	Vitas-M	STL175186	phthalazino[2,3-b]phthalazine-5,12(7H,14H)-dione	264.09	O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12	CXSJGNHRBWJXEA-UHFFFAOYSA-N	30717.0		CXSJGNHRBWJXEA
BRD-K18518344-001-16-9	digitoxigenin	Preclinical	ATPase inhibitor	ATP1A1			0	93.04	Sigma	MFCD00003687	Digitoxigenin	374.246	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|	XZTUSOXSLKTKJQ-CESUGQOBSA-N	4369270.0		XZTUSOXSLKTKJQ
BRD-K18518344-001-15-9	digitoxigenin	Preclinical	ATPase inhibitor	ATP1A1			0	93.94	Prestwick	Prestw-436	Digitoxigenin	374.246	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|	XZTUSOXSLKTKJQ-CESUGQOBSA-N	4369270.0		XZTUSOXSLKTKJQ
BRD-K63668566-001-03-9	digitoxin	Launched	ATPase inhibitor	ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2	cardiology	congestive heart failure|cardiac arrythmia	0	84.91	MedChemEx	HY-B1357	Digitoxin	764.435	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|	WDJUZGPOPHTGOT-XUDUSOBPSA-N	441207.0		WDJUZGPOPHTGOT
BRD-K18619710-001-15-9	digoxigenin	Preclinical	steroid				0	95.53	MedChemEx	HY-B1025	Digoxigenin	390.241	C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|	SHIBSTMRCDJXLN-KCZCNTNESA-N	15478.0		SHIBSTMRCDJXLN
BRD-K18619710-001-14-4	digoxigenin	Preclinical	steroid				0	97.81	Selleck	S4396	Digoxigenin	390.241	C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|	SHIBSTMRCDJXLN-KCZCNTNESA-N	15478.0		SHIBSTMRCDJXLN
BRD-K00004302-001-01-9	digoxin	Launched	ATPase inhibitor	ATP1A1	cardiology	congestive heart failure|atrial fibrillation (AF)	0	86.19	Tocris	4583	Digoxin	780.43	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|	LTMHDMANZUZIPE-SYUUTQQWSA-N	12940973.0		LTMHDMANZUZIPE
BRD-K20152659-001-10-3	dihomo-gamma-linolenic-acid	Phase 2	prostanoid receptor agonist	PTGS1|PTGS2			0	0.0	Sigma	MFCD00065721	(8Z,11Z,14Z)-8,11,14-icosatrienoic acid	306.256	CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	HOBAELRKJCKHQD-QNEBEIHSSA-N	5280581.0		HOBAELRKJCKHQD
BRD-K20152659-001-07-9	dihomo-gamma-linolenic-acid	Phase 2	prostanoid receptor agonist	PTGS1|PTGS2			0	24.38	Sigma	MFCD00065721	(8Z,11Z,14Z)-8,11,14-icosatrienoic acid	306.256	CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	HOBAELRKJCKHQD-QNEBEIHSSA-N	5280581.0		HOBAELRKJCKHQD
BRD-K20152659-001-04-6	dihomo-gamma-linolenic-acid	Phase 2	prostanoid receptor agonist	PTGS1|PTGS2			0	81.2	Enzo	FA009	8(Z),11(Z),14(Z)-Eicosatrienoic acid	306.256	CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	HOBAELRKJCKHQD-QNEBEIHSSA-N	5280581.0		HOBAELRKJCKHQD
BRD-K31471398-003-06-9	dihydrexidine	Phase 2	dopamine receptor agonist	DRD1|DRD2|DRD3|DRD4|DRD5			0	100.0	Tocris	884	Dihydrexidine hydrochloride	267.126	Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O	BGOQGUHWXBGXJW-RHSMWYFYSA-N	6603820.0		BGOQGUHWXBGXJW
BRD-K31471398-003-01-5	dihydrexidine	Phase 2	dopamine receptor agonist	DRD1|DRD2|DRD3|DRD4|DRD5			0	67.11	Tocris	884	Dihydrexidine hydrochloride	267.126	Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O	BGOQGUHWXBGXJW-RHSMWYFYSA-N	6603820.0		BGOQGUHWXBGXJW
BRD-K62213621-001-03-9	dihydroartemisinin	Launched	antimalarial agent		infectious disease	malaria	0	82.5	MedChemEx	HY-N0176	Dihydroartemisinin	284.162	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BJDCWCLMFKKGEE-ISOSDAIHSA-N	3000518.0		BJDCWCLMFKKGEE
BRD-K62213621-001-02-4	dihydroartemisinin	Launched	antimalarial agent		infectious disease	malaria	0	91.37	MicroSource	1504143	ARTENIMOL	284.162	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BJDCWCLMFKKGEE-ISOSDAIHSA-N	3000518.0	BRD-A82452087-001-02-3	BJDCWCLMFKKGEE
BRD-K62213621-001-01-6	dihydroartemisinin	Launched	antimalarial agent		infectious disease	malaria	0	94.91	Selleck	S2290	Dihydroartemisinin (DHA)	284.162	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	BJDCWCLMFKKGEE-ISOSDAIHSA-N	3000518.0	BRD-K45089490-001-02-8|BRD-K11421397-001-01-9	BJDCWCLMFKKGEE
BRD-K97440753-066-19-9	dihydroergocristine	Launched	adrenergic receptor antagonist|prolactin inhibitor	ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7	neurology/psychiatry	senile dementia|cerebrovascular insufficiency	0	96.31	Tocris	474	Dihydroergocristine mesylate	611.311	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	DEQITUUQPICUMR-HJPBWRTMSA-N	107715.0		DEQITUUQPICUMR
BRD-K97440753-066-20-9	dihydroergocristine	Launched	adrenergic receptor antagonist|prolactin inhibitor	ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7	neurology/psychiatry	senile dementia|cerebrovascular insufficiency	0	88.58	Tocris	474	Dihydroergocristine mesylate	611.311	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	DEQITUUQPICUMR-HJPBWRTMSA-N	107715.0		DEQITUUQPICUMR
BRD-K97440753-066-18-1	dihydroergocristine	Launched	adrenergic receptor antagonist|prolactin inhibitor	ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7	neurology/psychiatry	senile dementia|cerebrovascular insufficiency	0	90.32	Tocris	474	Dihydroergocristine mesylate	611.311	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	DEQITUUQPICUMR-HJPBWRTMSA-N	107715.0		DEQITUUQPICUMR
BRD-K72166146-066-06-2	dihydroergotamine	Launched	serotonin receptor agonist	ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	97.15	Tocris	475	Dihydroergotamine mesylate	583.279	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	LUZRJRNZXALNLM-JGRZULCMSA-N	10531.0		LUZRJRNZXALNLM
BRD-K72166146-066-05-4	dihydroergotamine	Launched	serotonin receptor agonist	ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	94.59	MicroSource	1500248	DIHYDROERGOTAMINE MESYLATE	583.279	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	LUZRJRNZXALNLM-JGRZULCMSA-N	10531.0		LUZRJRNZXALNLM
BRD-K72166146-066-07-9	dihydroergotamine	Launched	serotonin receptor agonist	ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	96.85	Tocris	475	Dihydroergotamine mesylate	583.279	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	LUZRJRNZXALNLM-JGRZULCMSA-N	10531.0		LUZRJRNZXALNLM
BRD-K72166146-066-04-7	dihydroergotamine	Launched	serotonin receptor agonist	ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	85.55	Tocris	475	Dihydroergotamine mesylate	583.279	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	LUZRJRNZXALNLM-JGRZULCMSA-N	10531.0		LUZRJRNZXALNLM
BRD-K01614093-001-05-9	dihydromyricetin	Preclinical					0	80.78	MedChemEx	HY-N0112	Dihydromyricetin	320.053	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	KJXSIXMJHKAJOD-LSDHHAIUSA-N	161557.0		KJXSIXMJHKAJOD
BRD-K01614093-001-04-2	dihydromyricetin	Preclinical					0	0.0	MedChemEx	HY-N0112	Dihydromyricetin	320.053	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	KJXSIXMJHKAJOD-LSDHHAIUSA-N	161557.0		KJXSIXMJHKAJOD
BRD-K01614093-001-02-6	dihydromyricetin	Preclinical					0	75.51	Selleck	S2399	Dihydromyricetin	320.053	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	KJXSIXMJHKAJOD-LSDHHAIUSA-N	161557.0		KJXSIXMJHKAJOD
BRD-K01614093-001-03-4	dihydromyricetin	Preclinical					0	79.27	Selleck	S2399	Dihydromyricetin (Ampeloptin)	320.053	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	KJXSIXMJHKAJOD-LSDHHAIUSA-N	161557.0		KJXSIXMJHKAJOD
BRD-M15413738-326-05-0	dihydrostreptomycin	Withdrawn	bacterial 30S ribosomal subunit inhibitor				0	54.8	Selleck	S4523	DIHYDROSTREPTOMYCIN [5mM]	583.281	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO	DLNWBHHJUACHNB-SNGKZNBCSA-N	73707353.0		DLNWBHHJUACHNB
BRD-A34455052-001-01-8	dihydrotachysterol	Launched	vitamin analog	VDR	orthopedics|endocrinology	rickets|hypocalcemia|osteomalacia	0	0.0	Sigma	MFCD00867069	(5E,7E,22E)-9,10-secoergosta-5,7,22-trien-3-ol	398.355	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3,&2:7,&3:9,&4:12,&5:17,&6:23,&7:27,r|	ILYCWAKSDCYMBB-CEQNRCNESA-N			ILYCWAKSDCYMBB
BRD-K18637542-001-01-7	dihydroxyacetone	Launched			dermatology	skin protectant	1	0.0	Sigma	MFCD00004670	1,3-dihydroxyacetone	90.032	OCC(=O)CO	RXKJFZQQPQGTFL-UHFFFAOYSA-N	670.0		RXKJFZQQPQGTFL
BRD-A20589515-001-02-9	dihydroxyphenylglycine	Preclinical	glutamate receptor agonist	GRM1|GRM5			0	0.0	Tocris	342	(RS)-3,5-DHPG	183.053	N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|	HOOWCUZPEFNHDT-SSDOTTSWSA-N	10197959.0		HOOWCUZPEFNHDT
BRD-A20589515-001-03-9	dihydroxyphenylglycine	Preclinical	glutamate receptor agonist	GRM1|GRM5			0	100.0	Tocris	342	(RS)-3,5-DHPG	183.053	N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1,r|	HOOWCUZPEFNHDT-SSDOTTSWSA-N	10197959.0		HOOWCUZPEFNHDT
BRD-K36802417-001-01-7	diiodothyropropionic-acid	Phase 2	thyroid hormone stimulant				0	3.17	Sigma	MFCD00045945	3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid	509.882	OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1	WONYMNWUJVKVII-UHFFFAOYSA-N	160565.0		WONYMNWUJVKVII
BRD-K48722258-300-11-0	dilazep	Launched	adenosine reuptake inhibitor	SLC29A1	cardiology	coronary heart disease	0	90.89	MicroSource	1502263	DILAZEP DIHYDROCHLORIDE	604.3	COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1	QVZCXCJXTMIDME-UHFFFAOYSA-N	3074.0		QVZCXCJXTMIDME
BRD-K48722258-300-10-2	dilazep	Launched	adenosine reuptake inhibitor	SLC29A1	cardiology	coronary heart disease	0	92.84	Tocris	481	Dilazep	604.3	COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1	QVZCXCJXTMIDME-UHFFFAOYSA-N	3074.0		QVZCXCJXTMIDME
BRD-K00003459-001-01-9	dilmapimod	Phase 1	p38 MAPK inhibitor				0	95.74	MedChemEx	HY-10404	Dilmapimod	456.141	Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2n(-c3c(F)cccc3F)c(=O)ccc12	ORVNHOYNEHYKJG-UHFFFAOYSA-N	10297982.0		ORVNHOYNEHYKJG
BRD-K10974103-001-21-1	diloxanide	Launched	protein synthesis inhibitor		infectious disease	amebiasis	0	98.59	MicroSource	1505532	DILOXANIDE FUROATE	327.007	CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1	BDYYDXJSHYEDGB-UHFFFAOYSA-N	19529.0		BDYYDXJSHYEDGB
BRD-K24023109-003-28-6	diltiazem	Launched	calcium channel blocker	CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5	cardiology	hypertension|angina pectoris	0	99.25	Tocris	685	Diltiazem hydrochloride	414.161	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	HSUGRBWQSSZJOP-RTWAWAEBSA-N	39186.0		HSUGRBWQSSZJOP
BRD-K24023109-003-30-9	diltiazem	Launched	calcium channel blocker	CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5	cardiology	hypertension|angina pectoris	0	97.12	Tocris	685	Diltiazem hydrochloride	414.161	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	HSUGRBWQSSZJOP-RTWAWAEBSA-N	39186.0		HSUGRBWQSSZJOP
BRD-K24023109-003-25-2	diltiazem	Launched	calcium channel blocker	CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5	cardiology	hypertension|angina pectoris	0	97.11	Selleck	S1865	Diltiazem HCl	414.161	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	HSUGRBWQSSZJOP-RTWAWAEBSA-N	39186.0		HSUGRBWQSSZJOP
BRD-K24023109-003-26-0	diltiazem	Launched	calcium channel blocker	CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5	cardiology	hypertension|angina pectoris	0	95.79	Tocris	685	Diltiazem hydrochloride	414.161	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	HSUGRBWQSSZJOP-RTWAWAEBSA-N	39186.0		HSUGRBWQSSZJOP
BRD-K00005337-001-01-9	DIM-C-pPhCO2Me	Preclinical	nuclear receptor antagonist				0	95.06	MedChemEx	HY-112056	DIM-C-pPhCO2Me	380.152	COC(=O)c1ccc(cc1)C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	BBAOKSZCULLDIW-UHFFFAOYSA-N	15637614.0		BBAOKSZCULLDIW
BRD-K23541596-300-07-2	dimaprit	Preclinical	histamine receptor agonist	HRH2|HRH3|HRH4			0	100.0	Selleck	S4320	Dimaprit 2HCl	161.099	CN(C)CCCSC(N)=N	OLHQOJYVQUNWPL-UHFFFAOYSA-N	3077.0		OLHQOJYVQUNWPL
BRD-K23541596-300-09-9	dimaprit	Preclinical	histamine receptor agonist	HRH2|HRH3|HRH4			0	100.0	Tocris	506	Dimaprit dihydrochloride	161.099	CN(C)CCCSC(N)=N	OLHQOJYVQUNWPL-UHFFFAOYSA-N	3077.0		OLHQOJYVQUNWPL
BRD-K23541596-300-08-0	dimaprit	Preclinical	histamine receptor agonist	HRH2|HRH3|HRH4			0	100.0	Tocris	506	Dimaprit dihydrochloride	161.099	CN(C)CCCSC(N)=N	OLHQOJYVQUNWPL-UHFFFAOYSA-N	3077.0		OLHQOJYVQUNWPL
BRD-K29812331-011-01-7	dimemorfan	Launched	sigma receptor agonist	SIGMAR1	pulmonary	cough suppressant	0	98.52	Key	KS-1259	phosphoric acid compound with (9alpha,13alpha,14alpha)-3,17-dimethylmorphinan (1:1)	255.199	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31	KBEZZLAAKIIPFK-NJAFHUGGSA-N	3037918.0		KBEZZLAAKIIPFK
BRD-M98649031-001-08-6	dimenhydrinate	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry|gastroenterology	motion sickness|nausea|vomiting	0	57.26	MicroSource	1500251	DIMENHYDRINATE	469.188	Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1	NFLLKCVHYJRNRH-UHFFFAOYSA-N	10660.0		NFLLKCVHYJRNRH
BRD-M98649031-001-10-2	dimenhydrinate	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry|gastroenterology	motion sickness|nausea|vomiting	0	59.15	MedChemEx	HY-B1215	Dimenhydrinate	469.188	Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1	NFLLKCVHYJRNRH-UHFFFAOYSA-N	10660.0		NFLLKCVHYJRNRH
BRD-M98649031-001-09-4	dimenhydrinate	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry|gastroenterology	motion sickness|nausea|vomiting	0	0.0	MedChemEx	HY-B1215	Dimenhydrinate	469.188	Cn1c2nc(Cl)[nH]c2c(=O)n(C)c1=O.CN(C)CCOC(c1ccccc1)c1ccccc1	NFLLKCVHYJRNRH-UHFFFAOYSA-N	10660.0		NFLLKCVHYJRNRH
BRD-A56152450-001-03-8	dimercaprol	Launched	chelating agent		neurology/psychiatry	metal toxicity	1	0.0	Sigma	MFCD00004864	2,3-disulfanyl-1-propanol	124.002	OC[C@@H](S)CS |&1:2,r|	WQABCVAJNWAXTE-GSVOUGTGSA-N	6971262.0		WQABCVAJNWAXTE
BRD-A56152450-001-02-0	dimercaprol	Launched	chelating agent		neurology/psychiatry	metal toxicity	1	0.0	MicroSource	1500252	DIMERCAPROL	124.002	OC[C@@H](S)CS |&1:2,r|	WQABCVAJNWAXTE-GSVOUGTGSA-N	6971262.0		WQABCVAJNWAXTE
BRD-K88701661-001-03-7	dimercaptosuccinic-acid	Launched	chelating agent	DNMT1	neurology/psychiatry	metal toxicity	1	0.0	AlfaAesar	A17909	(2R,3S)-2,3-disulfanylbutanedioic acid	181.971	OC(=O)[C@@H](S)[C@@H](S)C(O)=O	ACTRVOBWPAIOHC-XIXRPRMCSA-N	2724354.0		ACTRVOBWPAIOHC
BRD-K88701661-001-02-9	dimercaptosuccinic-acid	Launched	chelating agent	DNMT1	neurology/psychiatry	metal toxicity	1	0.0	AlfaAesar	A17909		181.971	OC(=O)[C@@H](S)[C@@H](S)C(O)=O	ACTRVOBWPAIOHC-XIXRPRMCSA-N	2724354.0		ACTRVOBWPAIOHC
BRD-K30126819-304-04-9	dimesna	Phase 3	tubulin polymerization inhibitor				0	100.0	MedChemEx	HY-B1022	Dimesna	281.936	OS(=O)(=O)CCSSCCS(O)(=O)=O	BYUKOOOZTSTOOH-UHFFFAOYSA-N	65626.0		BYUKOOOZTSTOOH
BRD-K30126819-304-03-5	dimesna	Phase 3	tubulin polymerization inhibitor				0	93.12	MicroSource	1502283	DIMESNA	281.936	OS(=O)(=O)CCSSCCS(O)(=O)=O	BYUKOOOZTSTOOH-UHFFFAOYSA-N	65626.0		BYUKOOOZTSTOOH
BRD-K30126819-304-02-7	dimesna	Phase 3	tubulin polymerization inhibitor				0	100.0	Selleck	S1201	Dimesna	281.936	OS(=O)(=O)CCSSCCS(O)(=O)=O	BYUKOOOZTSTOOH-UHFFFAOYSA-N	65626.0		BYUKOOOZTSTOOH
BRD-K43687498-001-09-8	dimethadione	Preclinical	oxazolidine antiepileptic				0	0.0	MicroSource	1500253	DIMETHADIONE	129.043	CC1(C)OC(=O)NC1=O	JYJFNDQBESEHJQ-UHFFFAOYSA-N	3081.0		JYJFNDQBESEHJQ
BRD-K26674746-001-01-4	dimethicone	Launched			dermatology	cosmetic	0	0.0	Sigma	MFCD00008265	1,1,1,3,3,3-hexamethyldisiloxane	162.09	C[Si](C)(C)O[Si](C)(C)C	UQEAIHBTYFGYIE-UHFFFAOYSA-N	24764.0		UQEAIHBTYFGYIE
BRD-K83192048-050-03-5	dimethindene-(S)-(+)	Preclinical	acetylcholine receptor antagonist	HRH1			0	97.21	Tocris	1425	(2Z)-2-butenedioic acid compound with N,N-dimethyl-2-{3-[(1S)-1-(2-pyridinyl)ethyl]-1H-inden-2-yl}ethanamine (1:1)	292.194	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|	MVMQESMQSYOVGV-OAHLLOKOSA-N	6604866.0		MVMQESMQSYOVGV
BRD-K83192048-050-02-7	dimethindene-(S)-(+)	Preclinical	acetylcholine receptor antagonist	HRH1			0	84.97	Tocris	1425	(S)-(+)-Dimethindene maleate	292.194	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|	MVMQESMQSYOVGV-OAHLLOKOSA-N	6604866.0		MVMQESMQSYOVGV
BRD-K73391359-003-10-2	dimethisoquin	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	95.73	Prestwick	Prestw-630	Dimethisoquin hydrochloride	272.189	CCCCc1cc2ccccc2c(OCCN(C)C)n1	XNMYNYSCEJBRPZ-UHFFFAOYSA-N	6857.0		XNMYNYSCEJBRPZ
BRD-K73391359-003-11-9	dimethisoquin	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	97.5	Toronto	d460475	dimethisoquin hydrochloride	272.189	CCCCc1cc2ccccc2c(OCCN(C)C)n1	XNMYNYSCEJBRPZ-UHFFFAOYSA-N	6857.0		XNMYNYSCEJBRPZ
BRD-K31111078-001-04-2	dimethyl-fumarate	Launched	nuclear factor erythroid derived|like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	0	97.66	MicroSource	1506154	DIMETHYL FUMARATE	144.042	COC(=O)\C=C\C(=O)OC	LDCRTTXIJACKKU-ONEGZZNKSA-N	637568.0		LDCRTTXIJACKKU
BRD-K31111078-001-05-9	dimethyl-fumarate	Launched	nuclear factor erythroid derived|like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	0	0.0	Selleck	S2586	Dimethyl Fumarate	144.042	COC(=O)\C=C\C(=O)OC	LDCRTTXIJACKKU-ONEGZZNKSA-N	637568.0		LDCRTTXIJACKKU
BRD-K31111078-001-03-4	dimethyl-fumarate	Launched	nuclear factor erythroid derived|like (NRF2) activator	KEAP1	neurology/psychiatry	multiple sclerosis	0	0.0	Selleck	S2586	Dimethyl Fumarate	144.042	COC(=O)\C=C\C(=O)OC	LDCRTTXIJACKKU-ONEGZZNKSA-N	637568.0		LDCRTTXIJACKKU
BRD-A17224697-001-01-0	dimethyl-isosorbide	Preclinical	cosmetic moisturizer				0	0.0	AMS	A000684285	3,6-dimethoxyhexahydrofuro[3,2-b]furan	174.089	CO[C@@H]1CO[C@H]2[C@H](CO[C@@H]12)OC |&1:6,&2:9,&3:2,&4:5,r|	MEJYDZQQVZJMPP-YWIQKCBGSA-N	59968542.0		MEJYDZQQVZJMPP
BRD-K01826026-001-01-9	dimetindene	Launched	cholinergic receptor antagonist|histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	52.79	AMS	A002862705	N,N-dimethyl-2-{3-[1-(2-pyridinyl)ethyl]-1H-inden-2-yl}ethanamine	292.194	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1,r,c:2|	MVMQESMQSYOVGV-OAHLLOKOSA-N	6604866.0		MVMQESMQSYOVGV
BRD-K72728560-001-01-4	dimetridazole	Launched	bacterial DNA inhibitor		infectious disease	protozoan infection	0	96.89	MicroSource	1506152	DIMETRIDAZOLE	141.054	Cc1ncc(n1C)[N+]([O-])=O	IBXPYPUJPLLOIN-UHFFFAOYSA-N	3090.0	BRD-U80626937-000-01-6	IBXPYPUJPLLOIN
BRD-K92848252-001-01-9	diminazene-aceturate	Phase 3	angiotensin converting enzyme activator	AOC1|PRDX5|PRSS1			0	87.59	MicroSource	1502349	DIMINAZENE ACETURATE	281.139	NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	XNYZHCFCZNMTFY-UHFFFAOYSA-N	2354.0	BRD-M65846159-001-02-6	XNYZHCFCZNMTFY
BRD-K92848252-001-02-7	diminazene-aceturate	Phase 3	angiotensin converting enzyme activator	AOC1|PRDX5|PRSS1			0	87.18	Selleck	S4104	Diminazene Aceturate	281.139	NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	XNYZHCFCZNMTFY-UHFFFAOYSA-N	2354.0	BRD-M65846159-001-01-8	XNYZHCFCZNMTFY
BRD-K92848252-001-03-5	diminazene-aceturate	Phase 3	angiotensin converting enzyme activator	AOC1|PRDX5|PRSS1			0	80.7	Selleck	S4104	Diminazene Aceturate	281.139	NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	XNYZHCFCZNMTFY-UHFFFAOYSA-N	2354.0	BRD-M65846159-001-03-4	XNYZHCFCZNMTFY
BRD-K60567437-001-10-2	dimpylate	Launched	acetylcholinesterase inhibitor	ACHE	infectious disease	flea control	0	89.72	MicroSource	330017	DIMPYLATE	304.101	CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C	FHIVAFMUCKRCQO-UHFFFAOYSA-N	3017.0		FHIVAFMUCKRCQO
BRD-K60567437-001-13-9	dimpylate	Launched	acetylcholinesterase inhibitor	ACHE	infectious disease	flea control	0	91.18	Sigma	MFCD00036204	Diazinon	304.101	CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C	FHIVAFMUCKRCQO-UHFFFAOYSA-N	3017.0		FHIVAFMUCKRCQO
BRD-K13662825-001-07-5	dinaciclib	Phase 3	CDK inhibitor	CDK1|CDK2|CDK5|CDK9			0	97.43	Selleck	S2768	Dinaciclib (SCH727965)	396.227	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	PIMQWRZWLQKKBJ-SFHVURJKSA-N	46926350.0		PIMQWRZWLQKKBJ
BRD-K13662825-001-04-2	dinaciclib	Phase 3	CDK inhibitor	CDK1|CDK2|CDK5|CDK9			0		Selleck	S2768	Dinaciclib (SCH727965)	396.227	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1	46926350.0		PIMQWRZWLQKKBJ
BRD-K93240442-001-09-9	dinitolmide	Launched			infectious disease	coccidiosis	0	92.58	MedChemEx	HY-B1004	Dinitolmide	225.039	Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O	ZEFNOZRLAWVAQF-UHFFFAOYSA-N	3092.0		ZEFNOZRLAWVAQF
BRD-K93240442-001-08-4	dinitolmide	Launched			infectious disease	coccidiosis	0	98.55	MicroSource	1503036	DINITOLMIDE	225.039	Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O	ZEFNOZRLAWVAQF-UHFFFAOYSA-N	3092.0		ZEFNOZRLAWVAQF
BRD-K81672972-001-03-1	dinoprost	Launched	prostacyclin analog	PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R	obstetrics/gynecology	labor induction	0	100.0	Enzo	PG008	Dinoprost	354.241	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	PXGPLTODNUVGFL-YNNPMVKQSA-N	5280363.0		PXGPLTODNUVGFL
BRD-K81672972-234-15-9	dinoprost	Launched	prostacyclin analog	PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R	obstetrics/gynecology	labor induction	0	85.0	Tocris	4214	Prostaglandin F2alpha	354.241	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	PXGPLTODNUVGFL-YNNPMVKQSA-N	5280363.0		PXGPLTODNUVGFL
BRD-K26521938-001-07-2	dinoprostone	Withdrawn	prostanoid receptor agonist	CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R			0	32.25	Tocris	2296	Prostaglandin E2	352.225	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	XEYBRNLFEZDVAW-ARSRFYASSA-N	5280360.0		XEYBRNLFEZDVAW
BRD-K26521938-001-09-8	dinoprostone	Withdrawn	prostanoid receptor agonist	CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R			0	98.3	Cayman	10007211	(5Z,11beta,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid	352.225	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	XEYBRNLFEZDVAW-ARSRFYASSA-N	5280360.0		XEYBRNLFEZDVAW
BRD-K67340225-001-02-9	dioscin	Preclinical	apoptosis stimulant	CXCR3			0	100.0	MedChemEx	HY-N0124	Dioscin	868.482	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|	VNONINPVFQTJOC-ZGXDEBHDSA-N	119245.0		VNONINPVFQTJOC
BRD-K28690501-001-03-9	diosgenin	Preclinical	steroid				0	100.0	MedChemEx	HY-N0177	Diosgenin	414.313	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|	WQLVFSAGQJTQCK-VKROHFNGSA-N	99474.0		WQLVFSAGQJTQCK
BRD-K28690501-001-02-1	diosgenin	Preclinical	steroid				0	95.08	Selleck	S2291	Diosgenin	414.313	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|	WQLVFSAGQJTQCK-VKROHFNGSA-N	99474.0	BRD-K15864401-001-01-0	WQLVFSAGQJTQCK
BRD-K26862302-001-06-9	diosmetin	Launched	aryl hydrocarbon receptor agonist	CYP1B1	dermatology	cosmetic	0	98.29	MedChemEx	HY-N0125	Diosmetin	300.063	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1	MBNGWHIJMBWFHU-UHFFFAOYSA-N	5281612.0		MBNGWHIJMBWFHU
BRD-K26862302-001-05-2	diosmetin	Launched	aryl hydrocarbon receptor agonist	CYP1B1	dermatology	cosmetic	0	97.56	Selleck	S2380	Diosmetin	300.063	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1	MBNGWHIJMBWFHU-UHFFFAOYSA-N	5281612.0		MBNGWHIJMBWFHU
BRD-K94436377-001-10-2	diosmin	Launched	aryl hydrocarbon receptor agonist|capillary stabilizing agent	AHR	cardiology|hematology|dermatology	chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome	0	88.29	MicroSource	1503219	DIOSMIN	608.174	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	GZSOSUNBTXMUFQ-YFAPSIMESA-N	5281613.0		GZSOSUNBTXMUFQ
BRD-K94436377-001-13-9	diosmin	Launched	aryl hydrocarbon receptor agonist|capillary stabilizing agent	AHR	cardiology|hematology|dermatology	chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome	0	89.97	MedChemEx	HY-N0178	Diosmin	608.174	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	GZSOSUNBTXMUFQ-YFAPSIMESA-N	5281613.0		GZSOSUNBTXMUFQ
BRD-K94436377-001-11-0	diosmin	Launched	aryl hydrocarbon receptor agonist|capillary stabilizing agent	AHR	cardiology|hematology|dermatology	chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome	0	89.84	Selleck	S2292	Diosmin	608.174	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	GZSOSUNBTXMUFQ-YFAPSIMESA-N	5281613.0		GZSOSUNBTXMUFQ
BRD-K94436377-001-12-8	diosmin	Launched	aryl hydrocarbon receptor agonist|capillary stabilizing agent	AHR	cardiology|hematology|dermatology	chronic venous insufficiency (CVI)|edema|deep vein thrombosis (DVT)|statis dermatitis|heavy leg syndrome	0	78.93	Selleck	S2292	Diosmin	608.174	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	GZSOSUNBTXMUFQ-YFAPSIMESA-N	5281613.0	BRD-K22902927-001-01-4|BRD-A35279169-001-07-8	GZSOSUNBTXMUFQ
BRD-K22193694-001-14-9	dioxybenzone	Preclinical	topical sunscreen agent				0	98.11	MedChemEx	HY-B0966	Dioxybenzone	244.074	COc1ccc(C(=O)c2ccccc2O)c(O)c1	MEZZCSHVIGVWFI-UHFFFAOYSA-N	8569.0		MEZZCSHVIGVWFI
BRD-K22193694-001-13-6	dioxybenzone	Preclinical	topical sunscreen agent				0	96.11	MicroSource	1500255	DIOXYBENZONE	244.074	COc1ccc(C(=O)c2ccccc2O)c(O)c1	MEZZCSHVIGVWFI-UHFFFAOYSA-N	8569.0		MEZZCSHVIGVWFI
BRD-K11595419-001-02-2	dipeptamin	Launched					1	0.0	ChemImpex	1676	(2S)-5-amino-2-{[(2S)-2-aminopropanoyl]amino}-5-oxopentanoic acid	217.106	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	HJCMDXDYPOUFDY-WHFBIAKZSA-N	7014883.0		HJCMDXDYPOUFDY
BRD-K11595419-001-01-4	dipeptamin	Launched					1	0.0	ChemImpex	1676		217.106	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	HJCMDXDYPOUFDY-WHFBIAKZSA-N	7014883.0		HJCMDXDYPOUFDY
BRD-A30693873-003-11-0	diperodon	Preclinical	local anesthetic				0	95.2	Selleck	S4397	Diperodon HCl	397.2	O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|	YUGZHQHSNYIFLG-HXUWFJFHSA-N	40479653.0		YUGZHQHSNYIFLG
BRD-A30693873-003-12-8	diperodon	Preclinical	local anesthetic				0	98.2	MicroSource	1505780	DIPERODON HYDROCHLORIDE	397.2	O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|	YUGZHQHSNYIFLG-HXUWFJFHSA-N	40479653.0		YUGZHQHSNYIFLG
BRD-A30693873-003-13-6	diperodon	Preclinical	local anesthetic				0	92.9	Selleck	S4397	Diperodon hydrochloride	397.2	O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|	YUGZHQHSNYIFLG-HXUWFJFHSA-N	40479653.0		YUGZHQHSNYIFLG
BRD-K93441486-067-13-9	diphemanil	Launched	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	0	87.66	MedChemEx	HY-16171	Diphenmanil (methylsulfate)	278.191	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	LCTZPQRFOZKZNK-UHFFFAOYSA-N	6127.0		LCTZPQRFOZKZNK
BRD-K93441486-067-12-8	diphemanil	Launched	acetylcholine receptor antagonist	CHRM3	neurology/psychiatry	spasms	0	96.64	Selleck	S4034	Diphemanil Methylsulfate	278.191	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	LCTZPQRFOZKZNK-UHFFFAOYSA-N	6127.0		LCTZPQRFOZKZNK
BRD-K51730347-001-06-4	diphencyprone	Phase 2	immunostimulant				0	98.43	Sigma	42910	2,3-diphenyl-2-cyclopropen-1-one	206.073	O=c1c(c1-c1ccccc1)-c1ccccc1	HCIBTBXNLVOFER-UHFFFAOYSA-N	65057.0		HCIBTBXNLVOFER
BRD-K51730347-001-05-6	diphencyprone	Phase 2	immunostimulant				0	0.0	Vitas-M	STK289679		206.073	O=c1c(c1-c1ccccc1)-c1ccccc1	HCIBTBXNLVOFER-UHFFFAOYSA-N	65057.0		HCIBTBXNLVOFER
BRD-K47278471-003-26-3	diphenhydramine	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry	headache	0	98.11	MicroSource	1500256	DIPHENHYDRAMINE HYDROCHLORIDE	255.162	CN(C)CCOC(c1ccccc1)c1ccccc1	ZZVUWRFHKOJYTH-UHFFFAOYSA-N	3100.0		ZZVUWRFHKOJYTH
BRD-K47278471-003-25-5	diphenhydramine	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry	headache	0	96.69	Selleck	S1866	Diphenhydramine HCl	255.162	CN(C)CCOC(c1ccccc1)c1ccccc1	ZZVUWRFHKOJYTH-UHFFFAOYSA-N	3100.0		ZZVUWRFHKOJYTH
BRD-K01663662-003-20-2	diphenidol	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4	neurology/psychiatry	vertigo	0	99.63	Enamine	Z57257314		309.209	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	OGAKLTJNUQRZJU-UHFFFAOYSA-N	3055.0		OGAKLTJNUQRZJU
BRD-K01663662-003-21-0	diphenidol	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4	neurology/psychiatry	vertigo	0	96.93	Selleck	S4292	Diphenidol hydrochloride	309.209	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	OGAKLTJNUQRZJU-UHFFFAOYSA-N	3055.0		OGAKLTJNUQRZJU
BRD-K65814004-003-03-9	diphenyleneiodonium	Preclinical	nitric oxide synthase inhibitor	NOS2|NOS3			0	97.71	Tocris	504	Diphenyleneiodonium chloride	278.967	[I]1c2ccccc2-c2ccccc12 |^1:0|	ZSZPLBNCHKXQRY-UHFFFAOYSA-N			ZSZPLBNCHKXQRY
BRD-K65814004-003-02-9	diphenyleneiodonium	Preclinical	nitric oxide synthase inhibitor	NOS2|NOS3			0	100.0	Tocris	504	Diphenyleneiodonium chloride	278.967	[I]1c2ccccc2-c2ccccc12 |^1:0|	ZSZPLBNCHKXQRY-UHFFFAOYSA-N			ZSZPLBNCHKXQRY
BRD-K12362304-001-07-3	diphenylguanidine	Preclinical					0	85.15	Vitas-M	STK802182		211.111	N=C(Nc1ccccc1)Nc1ccccc1	OWRCNXZUPFZXOS-UHFFFAOYSA-N	7594.0		OWRCNXZUPFZXOS
BRD-K12362304-001-08-9	diphenylguanidine	Preclinical					0	95.16	Sigma	43029	1,3-Diphenylguanidine	211.111	N=C(Nc1ccccc1)Nc1ccccc1	OWRCNXZUPFZXOS-UHFFFAOYSA-N	7594.0		OWRCNXZUPFZXOS
BRD-K22936972-003-23-6	diphenylpyraline	Launched	dopamine reuptake inhibitor	HRH1|SLC6A3	allergy	allergic rhinitis	0	97.93	MicroSource	1500258	DIPHENYLPYRALINE HYDROCHLORIDE	281.178	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	OWQUZNMMYNAXSL-UHFFFAOYSA-N	3103.0		OWQUZNMMYNAXSL
BRD-K22936972-003-22-8	diphenylpyraline	Launched	dopamine reuptake inhibitor	HRH1|SLC6A3	allergy	allergic rhinitis	0	96.12	Selleck	S4321	Diphenylpyraline HCl	281.178	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	OWQUZNMMYNAXSL-UHFFFAOYSA-N	3103.0		OWQUZNMMYNAXSL
BRD-K22936972-003-24-4	diphenylpyraline	Launched	dopamine reuptake inhibitor	HRH1|SLC6A3	allergy	allergic rhinitis	0	96.57	Selleck	S4321	DIPHENYLPYRALINE HYDROCHLORIDE	281.178	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	OWQUZNMMYNAXSL-UHFFFAOYSA-N	3103.0		OWQUZNMMYNAXSL
BRD-A47494775-003-11-3	dipivefrine	Launched	adrenergic receptor agonist		ophthalmology	glaucoma|intraocular pressure	0	94.37	Prestwick	Prestw-632	Dipivefrin hydrochloride	351.205	CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1 |&1:3|	OCUJLLGVOUDECM-CYBMUJFWSA-N	969492.0		OCUJLLGVOUDECM
BRD-A47494775-003-12-9	dipivefrine	Launched	adrenergic receptor agonist		ophthalmology	glaucoma|intraocular pressure	0		WuXi	EW21509-20-P1	Dipivefrin hydrochloride	351.205	CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1 |&1:3|	OCUJLLGVOUDECM-CYBMUJFWSA-N	969492.0		OCUJLLGVOUDECM
BRD-K64838454-001-01-0	dipraglurant	Phase 2	glutamate receptor negative allosteric modulator	GRM5			0	94.48	MedChemEx	HY-14859	Dipraglurant	265.102	Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	LZXMUJCJAWVHPZ-UHFFFAOYSA-N	44557636.0		LZXMUJCJAWVHPZ
BRD-K64838454-001-02-9	dipraglurant	Phase 2	glutamate receptor negative allosteric modulator	GRM5			0	94.24	MedChemEx	HY-14859	Dipraglurant	265.102	Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	LZXMUJCJAWVHPZ-UHFFFAOYSA-N	44557636.0		LZXMUJCJAWVHPZ
BRD-K75385383-001-01-5	DIPT	Launched	dopamine reuptake inhibitor|serotonin reuptake inhibitor	HTR1A|HTR2A|HTR2C			0	88.49	Cayman	11550	N-[2-(1H-indol-3-yl)ethyl]-N-isopropyl-2-propanamine	244.194	CC(C)N(CCc1c[nH]c2ccccc12)C(C)C	ZRVAAGAZUWXRIP-UHFFFAOYSA-N	26903.0		ZRVAAGAZUWXRIP
BRD-K86301799-001-39-7	dipyridamole	Launched	phosphodiesterase inhibitor	ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension	0	45.46	Tocris	691	Dipyridamole	504.317	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	IZEKFCXSFNUWAM-UHFFFAOYSA-N	3108.0		IZEKFCXSFNUWAM
BRD-K86301799-001-36-3	dipyridamole	Launched	phosphodiesterase inhibitor	ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension	0	83.92	MicroSource	1500259	DIPYRIDAMOLE	504.317	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	IZEKFCXSFNUWAM-UHFFFAOYSA-N	3108.0		IZEKFCXSFNUWAM
BRD-K86301799-001-37-1	dipyridamole	Launched	phosphodiesterase inhibitor	ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension	0	91.41	Selleck	S1895	Dipyridamole (Persantine)	504.317	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	IZEKFCXSFNUWAM-UHFFFAOYSA-N	3108.0		IZEKFCXSFNUWAM
BRD-K86301799-001-40-9	dipyridamole	Launched	phosphodiesterase inhibitor	ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension	0	81.85	Tocris	691	Dipyridamole	504.317	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	IZEKFCXSFNUWAM-UHFFFAOYSA-N	3108.0		IZEKFCXSFNUWAM
BRD-K86301799-001-34-8	dipyridamole	Launched	phosphodiesterase inhibitor	ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension	0	85.04	Selleck	S1895	Dipyridamole	504.317	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	IZEKFCXSFNUWAM-UHFFFAOYSA-N	3108.0		IZEKFCXSFNUWAM
BRD-K86301799-001-35-5	dipyridamole	Launched	phosphodiesterase inhibitor	ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1	cardiology	coronary artery disease (CAD)|peripheral artery disease (PAD)|hypertension	0	50.43	Tocris	691	Dipyridamole	504.317	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	IZEKFCXSFNUWAM-UHFFFAOYSA-N	3108.0		IZEKFCXSFNUWAM
BRD-K47608922-001-05-9	dipyrocetyl	Launched	chelating agent		endocrinology|neurology/psychiatry	fever|pain relief	0	80.37	MedChemEx	HY-B1179	Dipyrocetyl	238.048	CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O	NYIZXMGNIUSNKL-UHFFFAOYSA-N	68093.0		NYIZXMGNIUSNKL
BRD-K47608922-001-04-7	dipyrocetyl	Launched	chelating agent		endocrinology|neurology/psychiatry	fever|pain relief	0	46.15	MicroSource	1503032	DIPYROCETYL	238.048	CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O	NYIZXMGNIUSNKL-UHFFFAOYSA-N	68093.0		NYIZXMGNIUSNKL
BRD-K00003514-342-01-9	diquafosol	Phase 3	purinergic receptor activator				0	97.3	MedChemEx	HY-B0606	Diquafosol (tetrasodium)	789.994	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2ccc(=O)[nH]c2=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O	NMLMACJWHPHKGR-NCOIDOBVSA-N	148197.0		NMLMACJWHPHKGR
BRD-K52756523-001-27-0	dirithromycin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	0	86.6	AvaChem	2876	(1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-3-ethyl-2,10-dihydroxy-15-[(2-methoxyethoxy)methyl]-2,6,8,10,12,17-hexamethyl-5-oxo-	834.545	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N	132274085.0		WLOHNSSYAXHWNR
BRD-K52756523-001-24-7	dirithromycin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	0	82.32	MicroSource	1504144	DIRITHROMYCIN	834.545	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N	132274085.0		WLOHNSSYAXHWNR
BRD-K52756523-001-28-8	dirithromycin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	0	95.4	Sigma	MFCD00865041	(1R,2R,3R,6R,7S,8S,9R,10R,12R,13S,15R,17S)-9-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-3-ethyl-2,10-dihydroxy-7-(((2R,4S,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl;tetrahydro-2H-pyran-2-yl)oxy)-15-((2-methoxyethoxy)met	834.545	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N	132274085.0	BRD-K15706428-001-01-2	WLOHNSSYAXHWNR
BRD-K52756523-001-25-4	dirithromycin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	0	91.3	MedChemEx	HY-B0643	Dirithromycin	834.545	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N	132274085.0	BRD-A77786295-001-01-1	WLOHNSSYAXHWNR
BRD-K52756523-001-31-9	dirithromycin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	0	100.0	MedChemEx	HY-B0643	Dirithromycin	834.545	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N	132274085.0		WLOHNSSYAXHWNR
BRD-K52756523-001-26-2	dirithromycin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	0	71.47	Selleck	S4213	Dirithromycin	834.545	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N	132274085.0	BRD-A83603976-001-01-6	WLOHNSSYAXHWNR
BRD-K52756523-001-29-6	dirithromycin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	0	75.68	Selleck	S4213	Dirithromycin	834.545	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	WLOHNSSYAXHWNR-FDEBZETHSA-N	132274085.0	BRD-A44120870-001-01-6	WLOHNSSYAXHWNR
BRD-K87386013-001-01-7	diroximel-fumarate	Phase 3	anti-inflammatory agent				0	97.29	WuXi	WXC04774		255.074	COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O	YIMYDTCOUQIDMT-SNAWJCMRSA-N	73330464.0		YIMYDTCOUQIDMT
BRD-K66672047-304-01-3	disodium-sebacate	Phase 1		HBB			0	68.1	Sigma	MFCD00070501	disodium sebacate	202.121	OC(=O)CCCCCCCCC(O)=O	CXMXRPHRNRROMY-UHFFFAOYSA-N	5192.0		CXMXRPHRNRROMY
BRD-A29734509-011-13-6	disopyramide	Launched	sodium channel blocker	CHRM1|CHRM2|CHRM3|KCND2|KCND3|KCNH2|SCN5A	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias	0	97.94	MicroSource	1500261	DISOPYRAMIDE PHOSPHATE	339.231	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|	UVTNFZQICZKOEM-UHFFFAOYSA-N	3114.0		UVTNFZQICZKOEM
BRD-A29734509-011-12-8	disopyramide	Launched	sodium channel blocker	CHRM1|CHRM2|CHRM3|KCND2|KCND3|KCNH2|SCN5A	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias	0	94.3	Selleck	S4322	Disopyramide Phosphate	339.231	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|	UVTNFZQICZKOEM-UHFFFAOYSA-N	3114.0		UVTNFZQICZKOEM
BRD-A29734509-011-14-4	disopyramide	Launched	sodium channel blocker	CHRM1|CHRM2|CHRM3|KCND2|KCND3|KCNH2|SCN5A	cardiology	ventricular tachycardia (VT)|ventricular arrhythmias	0	95.79	Selleck	S4322	Disopyramide	339.231	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|	UVTNFZQICZKOEM-UHFFFAOYSA-N	3114.0		UVTNFZQICZKOEM
BRD-K32744045-001-31-2	disulfiram	Launched	aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist	ALDH2|DBH	neurology/psychiatry	abstinence from alcohol	0	99.04	MicroSource	1500262	DISULFIRAM	296.051	CCN(CC)C(=S)SSC(=S)N(CC)CC	AUZONCFQVSMFAP-UHFFFAOYSA-N	3117.0		AUZONCFQVSMFAP
BRD-K32744045-001-30-4	disulfiram	Launched	aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist	ALDH2|DBH	neurology/psychiatry	abstinence from alcohol	0	90.47	Selleck	S1680	Disulfiram	296.051	CCN(CC)C(=S)SSC(=S)N(CC)CC	AUZONCFQVSMFAP-UHFFFAOYSA-N	3117.0		AUZONCFQVSMFAP
BRD-K32744045-001-34-6	disulfiram	Launched	aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist	ALDH2|DBH	neurology/psychiatry	abstinence from alcohol	0	93.01	Selleck	S1680	disulfiram	296.051	CCN(CC)C(=S)SSC(=S)N(CC)CC	AUZONCFQVSMFAP-UHFFFAOYSA-N	3117.0		AUZONCFQVSMFAP
BRD-K51807679-001-06-8	dithranol	Launched	DNA synthesis inhibitor		dermatology	psoriasis	0	0.0	Sigma	D2953000	1,8,9-anthracenetriol	226.063	Oc1cccc2cc3cccc(O)c3c(O)c12	YUTJCNNFTOIOGT-UHFFFAOYSA-N	10187.0		YUTJCNNFTOIOGT
BRD-K40654626-236-02-3	ditiocarb-sodium-trihydrate	Phase 3	immunostimulant	CA1|CA2|CA4			1	0.0	Enamine	Z104495648	sodium diethyldithiocarbamate	149.033	CCN(CC)C(S)=S	LMBWSYZSUOEYSN-UHFFFAOYSA-N	8987.0		LMBWSYZSUOEYSN
BRD-K40654626-236-01-5	ditiocarb-sodium-trihydrate	Phase 3	immunostimulant	CA1|CA2|CA4			1	0.0	Enamine	Z104495648		149.033	CCN(CC)C(S)=S	LMBWSYZSUOEYSN-UHFFFAOYSA-N	8987.0		LMBWSYZSUOEYSN
BRD-K33459542-001-08-9	ditolylguanidine	Preclinical	sigma receptor agonist	GRIN1|GRIN2A|GRIN2B|SIGMAR1			0	93.56	Tocris	841	DTG	239.142	Cc1ccccc1NC(=N)Nc1ccccc1C	OPNUROKCUBTKLF-UHFFFAOYSA-N	7333.0		OPNUROKCUBTKLF
BRD-K33459542-001-07-4	ditolylguanidine	Preclinical	sigma receptor agonist	GRIN1|GRIN2A|GRIN2B|SIGMAR1			0	89.42	Tocris	841	DTG	239.142	Cc1ccccc1NC(=N)Nc1ccccc1C	OPNUROKCUBTKLF-UHFFFAOYSA-N	7333.0		OPNUROKCUBTKLF
BRD-K05919151-001-01-6	dixanthogen	Preclinical					1	0.0	MicroSource	1503891	DIXANTHOGEN	241.956	CCOC(=S)SSC(=S)OCC	FVIGODVHAVLZOO-UHFFFAOYSA-N	10404.0		FVIGODVHAVLZOO
BRD-K05919151-001-02-9	dixanthogen	Preclinical					1	0.0	Sigma	MFCD00022144	O,O-DIETHYL DITHIOBIS-(THIOFORMATE)	241.956	CCOC(=S)SSC(=S)OCC	FVIGODVHAVLZOO-UHFFFAOYSA-N	10404.0		FVIGODVHAVLZOO
BRD-K00003339-001-01-9	dixyrazine	Preclinical	antipsychotic				0	96.92	MedChemEx	HY-U00153	Dixyrazine	427.229	C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc12 |&1:1,r|	MSYUMPGNGDNTIQ-HXUWFJFHSA-N	9932302.0		MSYUMPGNGDNTIQ
BRD-K58930050-050-16-6	dizocilpine-(+)	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	98.29	Tocris	924	(+)-MK 801 maleate	221.12	C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-CVEARBPZSA-N	180081.0		LBOJYSIDWZQNJS
BRD-K58930050-050-17-9	dizocilpine-(+)	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	97.41	Tocris	924	(+)-MK 801 maleate	221.12	C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-CVEARBPZSA-N	180081.0		LBOJYSIDWZQNJS
BRD-K58930050-050-15-8	dizocilpine-(+)	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	98.82	Tocris	924	(+)-MK 801 maleate	221.12	C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-CVEARBPZSA-N	180081.0		LBOJYSIDWZQNJS
BRD-K58930050-001-05-2	dizocilpine-(+)	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	97.47	Selleck	S2857	MK-801 (Dizocilpine)	221.12	C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-CVEARBPZSA-N	180081.0		LBOJYSIDWZQNJS
BRD-K23163214-050-16-9	dizocilpine-(-)	Phase 1	glutamate receptor antagonist				0	97.62	Tocris	955	(-)-MK 801 maleate	221.12	C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-JKSUJKDBSA-N	6337640.0		LBOJYSIDWZQNJS
BRD-K23163214-050-15-1	dizocilpine-(-)	Phase 1	glutamate receptor antagonist				0	99.01	Tocris	955	(-)-MK 801 maleate	221.12	C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-JKSUJKDBSA-N	6337640.0		LBOJYSIDWZQNJS
BRD-K23163214-051-01-9	dizocilpine-(-)	Phase 1	glutamate receptor antagonist				0	98.43	Selleck	S2876	(-)-MK 801 Maleate	221.12	C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	LBOJYSIDWZQNJS-JKSUJKDBSA-N	6337640.0		LBOJYSIDWZQNJS
BRD-K26573499-300-03-9	DMAB-anabaseine	Preclinical	adrenergic receptor agonist	CHRNA7			0	74.7	Tocris	2241	DMAB-anabaseine dihydrochloride	291.174	CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|	KHUUTHZSRXABAC-DTQAZKPQSA-N	9926048.0		KHUUTHZSRXABAC
BRD-K26573499-300-02-1	DMAB-anabaseine	Preclinical	adrenergic receptor agonist	CHRNA7			0	90.18	Tocris	2241	DMAB-anabaseine dihydrochloride	291.174	CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|	KHUUTHZSRXABAC-DTQAZKPQSA-N	9926048.0		KHUUTHZSRXABAC
BRD-K26573499-300-04-9	DMAB-anabaseine	Preclinical	adrenergic receptor agonist	CHRNA7			0	91.34	Tocris	2241	DMAB-anabaseine dihydrochloride	291.174	CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|	KHUUTHZSRXABAC-DTQAZKPQSA-N	9926048.0		KHUUTHZSRXABAC
BRD-K36775483-001-02-9	DMeOB	Preclinical	glutamate receptor modulator	GRM5			0	94.04	Tocris	1953	DMeOB	268.121	COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1	FBNPHFBYHYNMHC-JYFOCSDGSA-N	6891506.0		FBNPHFBYHYNMHC
BRD-K36775483-001-01-4	DMeOB	Preclinical	glutamate receptor modulator	GRM5			0	98.09	Tocris	1953	DMeOB	268.121	COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1	FBNPHFBYHYNMHC-JYFOCSDGSA-N	6891506.0	BRD-K77961099-001-01-6	FBNPHFBYHYNMHC
BRD-K39381259-001-01-0	DMH1	Preclinical	ALK tyrosine kinase receptor inhibitor	ACVR1			0	98.8	Selleck	S7146	DMH1	380.164	CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	JMIFGARJSWXZSH-UHFFFAOYSA-N	50997747.0		JMIFGARJSWXZSH
BRD-K39381259-001-02-8	DMH1	Preclinical	ALK tyrosine kinase receptor inhibitor	ACVR1			0	96.91	Tocris	4126	DMH-1	380.164	CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	JMIFGARJSWXZSH-UHFFFAOYSA-N	50997747.0		JMIFGARJSWXZSH
BRD-K39381259-001-03-9	DMH1	Preclinical	ALK tyrosine kinase receptor inhibitor	ACVR1			0	97.41	Tocris	4126	DMH-1	380.164	CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	JMIFGARJSWXZSH-UHFFFAOYSA-N	50997747.0		JMIFGARJSWXZSH
BRD-K40575944-001-02-9	DMH4	Preclinical	VEGFR inhibitor	KDR			0	96.4	Tocris	4471	DMH4	400.19	C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1	SKZQZGSPYYHTQG-UHFFFAOYSA-N	5329447.0		SKZQZGSPYYHTQG
BRD-K40575944-001-01-5	DMH4	Preclinical	VEGFR inhibitor	KDR			0	97.3	Tocris	4471	DMH4	400.19	C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1	SKZQZGSPYYHTQG-UHFFFAOYSA-N	5329447.0		SKZQZGSPYYHTQG
BRD-K03564313-001-04-9	DMNB	Preclinical	DNA dependent protein kinase inhibitor				0	84.23	Tocris	2088	DMNB	211.048	COc1cc(C=O)c(cc1OC)[N+]([O-])=O	YWSPWKXREVSQCA-UHFFFAOYSA-N	88505.0		YWSPWKXREVSQCA
BRD-K03564313-001-03-3	DMNB	Preclinical	DNA dependent protein kinase inhibitor				0	94.25	Tocris	2088	DMNB	211.048	COc1cc(C=O)c(cc1OC)[N+]([O-])=O	YWSPWKXREVSQCA-UHFFFAOYSA-N	88505.0		YWSPWKXREVSQCA
BRD-K89274813-001-03-1	DMP-543	Phase 2	acetylcholine release enhancer				0	96.22	Tocris	2330	DMP 543	412.139	Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	MUJBUUDUXGDXLW-UHFFFAOYSA-N	9887884.0		MUJBUUDUXGDXLW
BRD-K89274813-001-02-3	DMP-543	Phase 2	acetylcholine release enhancer				0	98.35	Tocris	2330	DMP 543	412.139	Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	MUJBUUDUXGDXLW-UHFFFAOYSA-N	9887884.0		MUJBUUDUXGDXLW
BRD-K89274813-001-04-9	DMP-543	Phase 2	acetylcholine release enhancer				0	96.58	Tocris	2330	DMP 543	412.139	Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	MUJBUUDUXGDXLW-UHFFFAOYSA-N	9887884.0		MUJBUUDUXGDXLW
BRD-K54936858-001-02-9	DMP-777	Phase 2	elastase inhibitor	MPO			0	87.92	MedChemEx	HY-75957	DMP 777	564.295	CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1	ZSDCIRYNTCVTMF-GIGWZHCTSA-N	177992.0		ZSDCIRYNTCVTMF
BRD-K54936858-001-01-6	DMP-777	Phase 2	elastase inhibitor	MPO			0	87.47	MedChemEx	HY-75957	DMP 777	564.295	CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1	ZSDCIRYNTCVTMF-GIGWZHCTSA-N	177992.0		ZSDCIRYNTCVTMF
BRD-A22971209-001-01-0	DMPS	Phase 1	chelating agent				1	0.0	Vitas-M	STK386918		187.964	OS(=O)(=O)C[C@@H](S)CS |&1:5,r|	JLVSRWOIZZXQAD-VKHMYHEASA-N	1549058.0		JLVSRWOIZZXQAD
BRD-M56212252-001-01-0	DMSO	Preclinical	control vehicle				0	0.0	Sigma	41639	(methylsulfinyl)methane	78.014	CS(C)=O.CS(C)=O	CETRZFQIITUQQL-UHFFFAOYSA-N	21584481.0	BRD-K08970894-001-03-4	CETRZFQIITUQQL
BRD-K64400208-001-09-1	DNQX	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B			0	86.83	Tocris	189	DNQX	252.013	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	RWVIMCIPOAXUDG-UHFFFAOYSA-N	3899541.0		RWVIMCIPOAXUDG
BRD-K64400208-304-01-6	DNQX	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B			0	95.18	Tocris	2312	DNQX disodium salt	252.013	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	RWVIMCIPOAXUDG-UHFFFAOYSA-N	3899541.0		RWVIMCIPOAXUDG
BRD-K64400208-001-08-3	DNQX	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B			0	95.86	Tocris	189	DNQX	252.013	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	RWVIMCIPOAXUDG-UHFFFAOYSA-N	3899541.0		RWVIMCIPOAXUDG
BRD-K64400208-001-10-9	DNQX	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B			0	90.36	Tocris	189	DNQX	252.013	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	RWVIMCIPOAXUDG-UHFFFAOYSA-N	3899541.0		RWVIMCIPOAXUDG
BRD-A78322124-003-16-5	dobutamine	Launched	adrenergic receptor agonist	ADRB1|ADRB2	cardiology	congestive heart failure	0	0.0	Tocris	515	Dobutamine hydrochloride	301.168	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	JRWZLRBJNMZMFE-UHFFFAOYSA-N	65324.0		JRWZLRBJNMZMFE
BRD-A78322124-003-18-1	dobutamine	Launched	adrenergic receptor agonist	ADRB1|ADRB2	cardiology	congestive heart failure	0	79.75	MedChemEx	HY-15746	Dobutamine (hydrochloride)	301.168	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	JRWZLRBJNMZMFE-UHFFFAOYSA-N	65324.0		JRWZLRBJNMZMFE
BRD-A78322124-003-17-3	dobutamine	Launched	adrenergic receptor agonist	ADRB1|ADRB2	cardiology	congestive heart failure	0	56.06	Tocris	515	4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)-1,2-benzenediol hydrochloride	301.168	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	JRWZLRBJNMZMFE-UHFFFAOYSA-N	65324.0		JRWZLRBJNMZMFE
BRD-A78322124-003-15-7	dobutamine	Launched	adrenergic receptor agonist	ADRB1|ADRB2	cardiology	congestive heart failure	0	76.94	MedChemEx	HY-15746	Dobutamine (hydrochloride)	301.168	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	JRWZLRBJNMZMFE-UHFFFAOYSA-N	65324.0		JRWZLRBJNMZMFE
BRD-A78322124-003-14-0	dobutamine	Launched	adrenergic receptor agonist	ADRB1|ADRB2	cardiology	congestive heart failure	0	92.61	Tocris	515	Dobutamine hydrochloride	301.168	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	JRWZLRBJNMZMFE-UHFFFAOYSA-N	65324.0		JRWZLRBJNMZMFE
BRD-K08290224-001-14-5	docebenone	Phase 2	lipoxygenase inhibitor	ALOX5			0	62.9	Enzo	EI216	Docebenone	326.188	CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1,t:19|	WDEABJKSGGRCQA-UHFFFAOYSA-N	1967.0		WDEABJKSGGRCQA
BRD-K30577245-341-01-9	docetaxel	Launched	tubulin polymerization inhibitor	BCL2|MAP2|MAP4|MAPT|NR1I2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)	0	92.04	MicroSource	1502273	DOCETAXEL	807.347	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	148124.0	BRD-A05821830-341-01-5	ZDZOTLJHXYCWBA
BRD-K30577245-001-04-3	docetaxel	Launched	tubulin polymerization inhibitor	BCL2|MAP2|MAP4|MAPT|NR1I2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)	0	99.62	Selleck	S1148	Docetaxel (Taxotere)	807.347	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	148124.0	BRD-A05821830-001-05-6	ZDZOTLJHXYCWBA
BRD-K30577245-001-05-0	docetaxel	Launched	tubulin polymerization inhibitor	BCL2|MAP2|MAP4|MAPT|NR1I2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	breast cancer|non-small cell lung cancer (NSCLC)|prostate cancer|gastric adenocarcinoma|head and neck squamous cell carcinoma (HNSCC)	0	84.28	Selleck	S1148	Docetaxel	807.347	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|	ZDZOTLJHXYCWBA-VCVYQWHSSA-N	148124.0	BRD-K63265447-001-07-4|BRD-A28612473-001-01-3	ZDZOTLJHXYCWBA
BRD-K39965020-001-09-1	doconexent	Launched	PPAR receptor agonist	FFAR1|PTGS1|PTGS2			0	47.46	MicroSource	1503885	DOCONEXENT	328.24	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O	MBMBGCFOFBJSGT-KUBAVDMBSA-N	445580.0		MBMBGCFOFBJSGT
BRD-K39965020-001-12-5	doconexent	Launched	PPAR receptor agonist	FFAR1|PTGS1|PTGS2			0	56.12	Sigma	D2534	(4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-docosahexaenoic acid	328.24	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O	MBMBGCFOFBJSGT-KUBAVDMBSA-N	445580.0		MBMBGCFOFBJSGT
BRD-K61937613-001-01-1	doconexent-ethyl-ester	Launched	omega 3 fatty acid stimulant		endocrinology	hypertriglyceridemia	1	0.0	Cayman	9090310		356.272	CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	ITNKVODZACVXDS-YNUSHXQLSA-N	9831416.0		ITNKVODZACVXDS
BRD-K50050533-001-05-9	docosanol	Launched	lipase clearing factor inhibitor	TLR7	dental	cold sore	1	0.0	MedChemEx	HY-B0222	1-Docosanol	326.355	CCCCCCCCCCCCCCCCCCCCCCO	NOPFSRXAKWQILS-UHFFFAOYSA-N	12620.0		NOPFSRXAKWQILS
BRD-K50050533-001-03-9	docosanol	Launched	lipase clearing factor inhibitor	TLR7	dental	cold sore	1	0.0	MicroSource	1505729	DOCOSANOL	326.355	CCCCCCCCCCCCCCCCCCCCCCO	NOPFSRXAKWQILS-UHFFFAOYSA-N	12620.0		NOPFSRXAKWQILS
BRD-K50050533-001-04-7	docosanol	Launched	lipase clearing factor inhibitor	TLR7	dental	cold sore	1	0.0	Selleck	S1637	Docosanol (Abreva)	326.355	CCCCCCCCCCCCCCCCCCCCCCO	NOPFSRXAKWQILS-UHFFFAOYSA-N	12620.0		NOPFSRXAKWQILS
BRD-K50050533-001-02-1	docosanol	Launched	lipase clearing factor inhibitor	TLR7	dental	cold sore	1	0.0	Selleck	S1637	Docosanol (Abreva)	326.355	CCCCCCCCCCCCCCCCCCCCCCO	NOPFSRXAKWQILS-UHFFFAOYSA-N	12620.0		NOPFSRXAKWQILS
BRD-A00092689-236-04-9	docusate	Launched	laxative		gastroenterology	constipation	0	93.4	MedChemEx	HY-B1268	Docusate (Sodium)	422.234	CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|	HNSDLXPSAYFUHK-SQNIBIBYSA-N	40473171.0		HNSDLXPSAYFUHK
BRD-A00092689-236-03-8	docusate	Launched	laxative		gastroenterology	constipation	0	60.87	MicroSource	1503881	DOCUSATE SODIUM	422.234	CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4,&2:12,&3:17|	HNSDLXPSAYFUHK-SQNIBIBYSA-N	40473171.0		HNSDLXPSAYFUHK
BRD-K05680146-001-01-2	dodecyl-sulfate	Preclinical		LYZ			0	0.0	Sigma	MFCD00067711	dodecyl hydrogen sulfate	266.155	CCCCCCCCCCCCOS(O)(=O)=O	MOTZDAYCYVMXPC-UHFFFAOYSA-N	8778.0		MOTZDAYCYVMXPC
BRD-A14941520-051-01-0	dofequidar	Phase 3	MRP inhibitor|P glycoprotein inhibitor	ABCB1			0	98.23	MedChemEx	HY-17013A	Dofequidar (fumarate)	481.237	OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1	KLWUUPVJTLHYIM-UHFFFAOYSA-N	9960287.0		KLWUUPVJTLHYIM
BRD-K86887724-001-12-2	dofetilide	Withdrawn	potassium channel blocker	KCNH1|KCNH2|KCNJ12|KCNK2			0	88.95	Tocris	3757	Dofetilide	441.139	CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	IXTMWRCNAAVVAI-UHFFFAOYSA-N	71329.0		IXTMWRCNAAVVAI
BRD-K86887724-001-10-6	dofetilide	Withdrawn	potassium channel blocker	KCNH1|KCNH2|KCNJ12|KCNK2			0	93.46	Selleck	S1658	Dofetilide (Tikosyn)	441.139	CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	IXTMWRCNAAVVAI-UHFFFAOYSA-N	71329.0		IXTMWRCNAAVVAI
BRD-K86887724-001-13-9	dofetilide	Withdrawn	potassium channel blocker	KCNH1|KCNH2|KCNJ12|KCNK2			0	95.15	Tocris	3757	Dofetilide	441.139	CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	IXTMWRCNAAVVAI-UHFFFAOYSA-N	71329.0		IXTMWRCNAAVVAI
BRD-K86887724-001-09-8	dofetilide	Withdrawn	potassium channel blocker	KCNH1|KCNH2|KCNJ12|KCNK2			0	25.43	Selleck	S1658	Dofetilide	441.139	CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	IXTMWRCNAAVVAI-UHFFFAOYSA-N	71329.0		IXTMWRCNAAVVAI
BRD-K28029915-066-03-3	dolasetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting	0	98.54	Tocris	5629	Dolasetron mesylate	324.147	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	UKTAZPQNNNJVKR-YXSUXZIUSA-N		BRD-K37792492-066-01-0|BRD-A03259768-066-01-9	UKTAZPQNNNJVKR
BRD-K28029915-066-04-9	dolasetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting	0	96.78	Tocris	5629	Dolasetron mesylate	324.147	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	UKTAZPQNNNJVKR-YXSUXZIUSA-N			UKTAZPQNNNJVKR
BRD-K28029915-001-02-2	dolasetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting	0	99.45	Enzo	DL199	Dolasetron	324.147	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	UKTAZPQNNNJVKR-YXSUXZIUSA-N		BRD-K34008116-001-01-7	UKTAZPQNNNJVKR
BRD-K78567475-001-01-4	dolastatin-10	Phase 2	tubulin polymerization inhibitor	TUBB			0	94.05	MedChemEx	HY-15580	Dolastatin 10	784.492	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	OFDNQWIFNXBECV-VFSYNPLYSA-N	9810929.0		OFDNQWIFNXBECV
BRD-K78567475-001-02-9	dolastatin-10	Phase 2	tubulin polymerization inhibitor	TUBB			0	91.4	MedChemEx	HY-15580	Dolastatin 10	784.492	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	OFDNQWIFNXBECV-VFSYNPLYSA-N	9810929.0		OFDNQWIFNXBECV
BRD-K67463151-001-02-9	dolutegravir	Launched	HIV integrase inhibitor	CYP3A4|CYP3A5|CYP3A7|POU2F2|UGT1A1	infectious disease	human immunodeficiency virus (HIV-1)	0	98.59	MedChemEx	HY-13238	Dolutegravir	419.129	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	RHWKPHLQXYSBKR-BMIGLBTASA-N	54726191.0		RHWKPHLQXYSBKR
BRD-K30431096-004-02-9	domiphen	Preclinical					0	98.79	MedChemEx	HY-B1467	Domiphen (bromide)	334.311	CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	YXUPZGKORWTXID-UHFFFAOYSA-N	3149.0		YXUPZGKORWTXID
BRD-K30431096-004-01-3	domiphen	Preclinical					0	93.67	Selleck	S4186	Domiphen Bromide	334.311	CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	YXUPZGKORWTXID-UHFFFAOYSA-N	3149.0		YXUPZGKORWTXID
BRD-K38305202-001-18-2	domperidone	Launched	dopamine receptor antagonist	DRD2|DRD3	infectious disease	fescue toxicosis	0	97.15	MicroSource	2300212	DOMPERIDONE	425.162	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	FGXWKSZFVQUSTL-UHFFFAOYSA-N	3151.0		FGXWKSZFVQUSTL
BRD-K38305202-001-17-4	domperidone	Launched	dopamine receptor antagonist	DRD2|DRD3	infectious disease	fescue toxicosis	0	97.24	Tocris	2536	Domperidone	425.162	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	FGXWKSZFVQUSTL-UHFFFAOYSA-N	3151.0		FGXWKSZFVQUSTL
BRD-K38305202-001-16-6	domperidone	Launched	dopamine receptor antagonist	DRD2|DRD3	infectious disease	fescue toxicosis	0	97.09	Selleck	S2461	Domperidone	425.162	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	FGXWKSZFVQUSTL-UHFFFAOYSA-N	3151.0		FGXWKSZFVQUSTL
BRD-A49160188-003-12-7	donepezil	Launched	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	Alzheimer's disease	0	97.71	MicroSource	1504403	DONEPEZIL HYDROCHLORIDE	379.215	COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|	ADEBPBSSDYVVLD-HXUWFJFHSA-N	1150567.0		ADEBPBSSDYVVLD
BRD-A49160188-003-11-9	donepezil	Launched	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	Alzheimer's disease	0	97.48	Selleck	S2462	Donepezil HCl (Aricept)	379.215	COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|	ADEBPBSSDYVVLD-HXUWFJFHSA-N	1150567.0		ADEBPBSSDYVVLD
BRD-K31092604-003-03-5	donitriptan	Phase 2	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR5A|HTR6			0	97.35	Tocris	3665	Donitriptan hydrochloride	403.201	NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12	SOHCKWZVTCTQBG-UHFFFAOYSA-N	197706.0		SOHCKWZVTCTQBG
BRD-K43887077-003-26-3	dopamine	Launched	dopamine receptor agonist	DBH|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR7|SLC6A2|SLC6A3|SLC6A4	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors	0	100.0	MicroSource	1500263	DOPAMINE HYDROCHLORIDE	153.079	NCCc1ccc(O)c(O)c1	VYFYYTLLBUKUHU-UHFFFAOYSA-N	681.0		VYFYYTLLBUKUHU
BRD-K43887077-003-27-1	dopamine	Launched	dopamine receptor agonist	DBH|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR7|SLC6A2|SLC6A3|SLC6A4	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors	0	85.26	Selleck	S2529	Dopamine hydrochloride (Inotropin)	153.079	NCCc1ccc(O)c(O)c1	VYFYYTLLBUKUHU-UHFFFAOYSA-N	681.0		VYFYYTLLBUKUHU
BRD-K43887077-003-25-5	dopamine	Launched	dopamine receptor agonist	DBH|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR7|SLC6A2|SLC6A3|SLC6A4	cardiology|neurology/psychiatry	ventricular arrhythmias|depression|headache|tremors	0	0.0	Selleck	S2529	Dopamine HCl	153.079	NCCc1ccc(O)c(O)c1	VYFYYTLLBUKUHU-UHFFFAOYSA-N	681.0		VYFYYTLLBUKUHU
BRD-K74065929-001-10-9	doramapimod	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK12|MAPK13|MAPK14			0	96.66	Tocris	5989	BIRB 796	527.29	Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	156422.0		MVCOAUNKQVWQHZ
BRD-K74065929-001-08-0	doramapimod	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK12|MAPK13|MAPK14			0	93.78	Selleck	S1574	BIRB 796 (Doramapimod)	527.29	Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	156422.0		MVCOAUNKQVWQHZ
BRD-K74065929-001-07-2	doramapimod	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK12|MAPK13|MAPK14			0	87.92	Selleck	S1574	BIRB 796 (Doramapimod)	527.29	Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	MVCOAUNKQVWQHZ-UHFFFAOYSA-N	156422.0		MVCOAUNKQVWQHZ
BRD-K00003581-001-01-9	doramectin	Launched			infectious disease	gastrointestinal roundworms	0	85.08	MedChemEx	HY-17035	Doramectin	898.508	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C6CCCCC6)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,58,t:6,37,68|	QLFZZSKTJWDQOS-YDBLARSUSA-N	9832750.0		QLFZZSKTJWDQOS
BRD-K00003231-001-01-9	doravirine	Launched	non-nucleoside reverse transcriptase inhibitor				0	88.76	MedChemEx	HY-16767	Doravirine	425.05	Cn1c(Cn2ccc(c(Oc3cc(Cl)cc(c3)C#N)c2=O)C(F)(F)F)n[nH]c1=O	ZIAOVIPSKUPPQW-UHFFFAOYSA-N	58460047.0		ZIAOVIPSKUPPQW
BRD-K45319714-002-02-7	doripenem	Launched	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	0	24.7	Sigma	MFCD09749887	(4R,5S,6S)-3-[((3S,5S)-5-{[(aminosulfonyl)amino]methyl}-3-pyrrolidinyl)sulfanyl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate	420.114	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	AVAACINZEOAHHE-VFZPANTDSA-N	73303.0		AVAACINZEOAHHE
BRD-K45319714-002-04-3	doripenem	Launched	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	0	18.82	MedChemEx	HY-B0187A	Doripenem (monohydrate)	420.114	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	AVAACINZEOAHHE-VFZPANTDSA-N	73303.0		AVAACINZEOAHHE
BRD-K45319714-002-03-5	doripenem	Launched	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	0	37.18	MedChemEx	HY-B0187A	Doripenem (monohydrate)	420.114	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	AVAACINZEOAHHE-VFZPANTDSA-N	73303.0		AVAACINZEOAHHE
BRD-K45319714-002-05-0	doripenem	Launched	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	0	0.0	Selleck	S1374	Doripenem Hydrate	420.114	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	AVAACINZEOAHHE-VFZPANTDSA-N	73303.0	BRD-K20901660-002-03-3	AVAACINZEOAHHE
BRD-K45319714-002-01-9	doripenem	Launched	bacterial cell wall synthesis inhibitor	DPEP1	infectious disease	intra-abdominal infections|urinary tract infections|pyelonephritis	0	42.28	Selleck	S1374	Doripenem Hydrate	420.114	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	AVAACINZEOAHHE-VFZPANTDSA-N	73303.0		AVAACINZEOAHHE
BRD-K54233340-300-05-1	dorsomorphin	Preclinical	AMPK inhibitor	ACVR1|BMPR1A|BMPR1B|EPHA2|FKBP1A|FLT1|FLT3|KDR|LCK|MKNK1|PRKAA1|RPS6KA1|SRC			0	91.96	Tocris	3093	Dorsomorphin dihydrochloride	399.206	C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1	XHBVYDAKJHETMP-UHFFFAOYSA-N	11524144.0		XHBVYDAKJHETMP
BRD-K54233340-001-07-9	dorsomorphin	Preclinical	AMPK inhibitor	ACVR1|BMPR1A|BMPR1B|EPHA2|FKBP1A|FLT1|FLT3|KDR|LCK|MKNK1|PRKAA1|RPS6KA1|SRC			0		MedChemEx	HY-13418A 		399.206	C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1	InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2	11524144.0		XHBVYDAKJHETMP
BRD-K48617017-003-14-9	dorzolamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA14|CA2|CA4|CA7	ophthalmology	intraocular pressure|glaucoma	0	78.1	MedChemEx	HY-B0109A	Dorzolamide (hydrochloride)	324.027	CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	IAVUPMFITXYVAF-XPUUQOCRSA-N	5284549.0		IAVUPMFITXYVAF
BRD-K54759182-003-08-0	dosulepin	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4	neurology/psychiatry	depression	0	97.97	Prestwick	Prestw-488	Dosulepin hydrochloride	295.139	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	5284550.0		PHTUQLWOUWZIMZ
BRD-K54759182-003-09-8	dosulepin	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4	neurology/psychiatry	depression	0	65.86	SantaCruz	sc-300503	Dothiepin hydrochloride	295.139	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	PHTUQLWOUWZIMZ-GZTJUZNOSA-N	5284550.0		PHTUQLWOUWZIMZ
BRD-K00004678-001-01-9	DOTMP	Preclinical					0	0.0	AMS	A100369	[4,7,10-tris(phosphonomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]methylphosphonic acid	548.097	OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1	RCXMQNIDOFXYDO-UHFFFAOYSA-N	124761.0		RCXMQNIDOFXYDO
BRD-K85402309-406-01-8	dovitinib	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB			0	96.83	Selleck	S7765	Dovitinib (TKI258) Lactate	392.176	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N	135398510.0		PIQCTGMSNWUMAF
BRD-K85402309-001-07-4	dovitinib	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB			0	86.31	Selleck	S1018	Dovitinib (TKI-258)	392.176	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N	135398510.0		PIQCTGMSNWUMAF
BRD-K85402309-389-03-2	dovitinib	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB			0	79.33	Selleck	S2769	Dovitinib (TKI-258) Dilactic Acid	392.176	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N	135398510.0		PIQCTGMSNWUMAF
BRD-K85402309-001-06-6	dovitinib	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB			0	90.23	Selleck	S1018	Dovitinib (TKI-258, CHIR-258)	392.176	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N	135398510.0		PIQCTGMSNWUMAF
BRD-K85402309-389-04-0	dovitinib	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB			0	77.54	Selleck	S2769	Dovitinib Dilactic acid (TKI258 Dilactic aci	392.176	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N	135398510.0		PIQCTGMSNWUMAF
BRD-K85402309-043-01-9	dovitinib	Phase 3	EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB			0	96.74	Selleck	S7765	2-hydroxypropanoic acid compound with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2-quinolinol (1:1)	392.176	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	PIQCTGMSNWUMAF-UHFFFAOYSA-N	135398510.0		PIQCTGMSNWUMAF
BRD-K01825594-311-04-9	doxapram	Launched	potassium channel blocker		pulmonary|neurology/psychiatry	respiratory depression|central nervous system depression|acute hypercapnia (AHC)	0	95.19	MedChemEx	HY-B0551A	Doxapram (hydrochloride hydrate)	378.231	CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|	XFDJYSQDBULQSI-JOCHJYFZSA-N	28248394.0		XFDJYSQDBULQSI
BRD-K01825594-311-02-9	doxapram	Launched	potassium channel blocker		pulmonary|neurology/psychiatry	respiratory depression|central nervous system depression|acute hypercapnia (AHC)	0	97.8	Selleck	S4037	Doxapram HCl	432.218	CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|	XFDJYSQDBULQSI-JOCHJYFZSA-N	28248394.0		XFDJYSQDBULQSI
BRD-K01825594-311-03-9	doxapram	Launched	potassium channel blocker		pulmonary|neurology/psychiatry	respiratory depression|central nervous system depression|acute hypercapnia (AHC)	0	72.83	MicroSource	1505534	DOXAPRAM HYDROCHLORIDE	432.218	CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|	XFDJYSQDBULQSI-JOCHJYFZSA-N	28248394.0	BRD-A47978079-003-01-9	XFDJYSQDBULQSI
BRD-K01825125-066-05-9	doxazosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension	0	96.8	Tocris	2964	Doxazosin mesylate	451.186	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23,r|	RUZYUOTYCVRMRZ-HXUWFJFHSA-N	6604102.0		RUZYUOTYCVRMRZ
BRD-K37694030-003-12-7	doxepin	Launched	histamine receptor antagonist	HRH1|SLC6A2|SLC6A4	neurology/psychiatry	depression|anxiety	0	98.99	MicroSource	1500264	DOXEPIN HYDROCHLORIDE	279.162	CN(C)CC\C=C1\c2ccccc2COc2ccccc12	ODQWQRRAPPTVAG-BOPFTXTBSA-N	667468.0		ODQWQRRAPPTVAG
BRD-K37694030-003-11-9	doxepin	Launched	histamine receptor antagonist	HRH1|SLC6A2|SLC6A4	neurology/psychiatry	depression|anxiety	0	97.2	Tocris	508	Doxepin hydrochloride	279.162	CN(C)CC\C=C1\c2ccccc2COc2ccccc12	ODQWQRRAPPTVAG-BOPFTXTBSA-N	667468.0		ODQWQRRAPPTVAG
BRD-K82928892-001-02-5	doxercalciferol	Launched	vitamin D receptor agonist	VDR	nephrology|endocrinology	chronic kidney disease (CKD)|hyperparathyroidism	0	85.38	Selleck	S1467	Doxercalciferol (Hectorol)	412.334	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C	HKXBNHCUPKIYDM-ZKVKAWQFSA-N	46931009.0		HKXBNHCUPKIYDM
BRD-K82928892-001-04-1	doxercalciferol	Launched	vitamin D receptor agonist	VDR	nephrology|endocrinology	chronic kidney disease (CKD)|hyperparathyroidism	0	95.96	Selleck	S1467	Doxercalciferol (Hectorol)	412.334	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C	HKXBNHCUPKIYDM-ZKVKAWQFSA-N	46931009.0		HKXBNHCUPKIYDM
BRD-K82928892-001-03-3	doxercalciferol	Launched	vitamin D receptor agonist	VDR	nephrology|endocrinology	chronic kidney disease (CKD)|hyperparathyroidism	0	0.0	Selleck	S1467	Doxercalciferol	412.334	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C	HKXBNHCUPKIYDM-ZKVKAWQFSA-N	46931009.0	BRD-K07234650-001-01-4	HKXBNHCUPKIYDM
BRD-K58262659-001-12-9	doxifluridine	Launched	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	0	97.12	MedChemEx	HY-B0021	Doxifluridine	246.065	C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ZWAOHEXOSAUJHY-ZIYNGMLESA-N	18343.0		ZWAOHEXOSAUJHY
BRD-K58262659-001-10-5	doxifluridine	Launched	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	0	96.34	MicroSource	1501189	DOXIFLURIDINE	246.065	C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ZWAOHEXOSAUJHY-ZIYNGMLESA-N	18343.0	BRD-A68537732-001-03-6	ZWAOHEXOSAUJHY
BRD-K58262659-001-09-7	doxifluridine	Launched	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	0	96.4	Selleck	S2045	Doxifluridine	246.065	C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ZWAOHEXOSAUJHY-ZIYNGMLESA-N	18343.0	BRD-K83057217-001-01-2	ZWAOHEXOSAUJHY
BRD-K70507123-001-11-9	doxofylline	Launched	adenosine receptor antagonist	ADORA1|PDE4A|PDE4B|PDE4C|PDE4D	pulmonary	asthma	0	98.66	MedChemEx	HY-B0004	Doxofylline	266.102	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	HWXIGFIVGWUZAO-UHFFFAOYSA-N	50942.0		HWXIGFIVGWUZAO
BRD-K70507123-001-09-7	doxofylline	Launched	adenosine receptor antagonist	ADORA1|PDE4A|PDE4B|PDE4C|PDE4D	pulmonary	asthma	0	99.7	MicroSource	1502358	DOXOFYLLINE	266.102	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	HWXIGFIVGWUZAO-UHFFFAOYSA-N	50942.0		HWXIGFIVGWUZAO
BRD-K70507123-001-08-9	doxofylline	Launched	adenosine receptor antagonist	ADORA1|PDE4A|PDE4B|PDE4C|PDE4D	pulmonary	asthma	0	97.83	Selleck	S4164	Doxofylline	266.102	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	HWXIGFIVGWUZAO-UHFFFAOYSA-N	50942.0		HWXIGFIVGWUZAO
BRD-K92093830-003-33-2	doxorubicin	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy|oncology	acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma	0	93.34	Selleck	S1208	doxorubicin	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-TZSSRYMLSA-N	31703.0		AOJJSUZBOXZQNB
BRD-K92093830-001-05-4	doxorubicin	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy|oncology	acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma	0	89.09	MicroSource	1505483	DOXORUBICIN	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-TZSSRYMLSA-N	31703.0	BRD-A52530684-001-02-9	AOJJSUZBOXZQNB
BRD-K92093830-003-34-0	doxorubicin	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy|oncology	acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma	0	87.44	Tocris	2252	Doxorubicin hydrochloride	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-TZSSRYMLSA-N	31703.0		AOJJSUZBOXZQNB
BRD-K92093830-003-35-7	doxorubicin	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy|oncology	acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma	0	92.9	Selleck	S1208	Doxorubicin (Adriamycin)	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-TZSSRYMLSA-N	31703.0	BRD-K61468417-003-01-1	AOJJSUZBOXZQNB
BRD-K92093830-003-31-6	doxorubicin	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy|oncology	acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma	0	92.86	Selleck	S1208	Doxorubicin (Adriamycin)	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-TZSSRYMLSA-N	31703.0		AOJJSUZBOXZQNB
BRD-K92093830-003-30-8	doxorubicin	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy|oncology	acute lymphoblastic leukemia (ALL)|acute myeloid leukemia (AML)|Wilm's tumor|breast cancer|ovarian cancer|Hodgkin's lymphoma|bladder cancer|multiple myeloma	0	96.83	Tocris	2252	Doxorubicin hydrochloride	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-TZSSRYMLSA-N	31703.0		AOJJSUZBOXZQNB
BRD-K01825679-003-04-9	doxycycline	Launched	bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor	MMP8	dental	periodontitis	0	0.0	MedChemEx	HY-N0565B		444.153	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|	JBIWCJUYHHGXTC-AKNGSSGZSA-N			JBIWCJUYHHGXTC
BRD-K01825679-311-02-9	doxycycline	Launched	bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor	MMP8	dental	periodontitis	0	99.0	Selleck	S4163	Doxycycline hyclate	498.141	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|	JBIWCJUYHHGXTC-AKNGSSGZSA-N		BRD-M28128163-312-03-8	JBIWCJUYHHGXTC
BRD-K01825679-311-01-9	doxycycline	Launched	bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor	MMP8	dental	periodontitis	0	88.97	Selleck	S4163	Doxycycline Hyclate	498.141	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1,2,3,5,6,18,&1:12,&2:22,c:22,t:11|	JBIWCJUYHHGXTC-AKNGSSGZSA-N		BRD-M28128163-312-01-2|BRD-M68646745-311-09-6	JBIWCJUYHHGXTC
BRD-A44008656-036-25-8	doxylamine	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry	sedative	0	98.3	MicroSource	1500267	DOXYLAMINE SUCCINATE	270.173	CN(C)CCOC(C)(c1ccccc1)c1ccccn1	HCFDWZZGGLSKEP-UHFFFAOYSA-N	43833352.0		HCFDWZZGGLSKEP
BRD-A44008656-036-24-1	doxylamine	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry	sedative	0	91.81	Selleck	S4240	Doxylamine Succinate	270.173	CN(C)CCOC(C)(c1ccccc1)c1ccccn1	HCFDWZZGGLSKEP-UHFFFAOYSA-N	43833352.0		HCFDWZZGGLSKEP
BRD-K00004636-001-01-9	DpC	Phase 1					0	100.0	Sigma	SML0483	3-[bis(2-pyridyl)methyleneamino]-1-cyclohexyl-1-methyl-thiourea	353.167	CN(C1CCCCC1)C(=S)NN=C(c1ccccn1)c1ccccn1	GNLZNQJBZNOUBM-UHFFFAOYSA-N	57380301.0		GNLZNQJBZNOUBM
BRD-K37087535-001-01-1	DPC-681	Phase 1	HIV protease inhibitor				0	97.55	MedChemEx	HY-19400	DPC-681	669.336	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1	PNIFFZXGBAYVMQ-RKKDRKJOSA-N	456215.0		PNIFFZXGBAYVMQ
BRD-K01824921-001-19-9	DPCPX	Phase 1	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	97.2	Tocris	439	DPCPX	304.19	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1	FFBDFADSZUINTG-UHFFFAOYSA-N	1329.0		FFBDFADSZUINTG
BRD-K01824921-001-18-5	DPCPX	Phase 1	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	99.02	Tocris	439	DPCPX	304.19	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1	FFBDFADSZUINTG-UHFFFAOYSA-N	1329.0		FFBDFADSZUINTG
BRD-A64553394-001-04-4	DPI-201106	Phase 2	sodium channel activator	ADRB2			0	94.82	Enzo	NA116	SDZ-201106	466.237	O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1,r|	BYBYHCOEAFHGJL-RUZDIDTESA-N	10389826.0		BYBYHCOEAFHGJL
BRD-K99922388-001-02-0	DPO-1	Preclinical	potassium channel blocker	KCNA5			0	98.66	Tocris	2533	DPO-1	340.196	CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	BPCNGVCAHAIZEE-COPCDDAFSA-N	21678144.0		BPCNGVCAHAIZEE
BRD-K99922388-001-03-9	DPO-1	Preclinical	potassium channel blocker	KCNA5			0	93.22	Tocris	2533	DPO-1	340.196	CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	BPCNGVCAHAIZEE-COPCDDAFSA-N	21678144.0		BPCNGVCAHAIZEE
BRD-K80315159-051-03-9	DPPE	Phase 3	histamine receptor antagonist	ABCB1|HRH1			0	94.69	Tocris	743	DPPE fumarate	283.194	CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	NFIXBCVWIPOYCD-UHFFFAOYSA-N	108092.0		NFIXBCVWIPOYCD
BRD-K80315159-051-02-0	DPPE	Phase 3	histamine receptor antagonist	ABCB1|HRH1			0	92.86	Tocris	743	DPPE fumarate	283.194	CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	NFIXBCVWIPOYCD-UHFFFAOYSA-N	108092.0		NFIXBCVWIPOYCD
BRD-A67976398-001-02-9	DQP-1105	Preclinical	glutamate receptor antagonist	GRIN2C|GRIN2D			0	94.9	Tocris	4491	DQP 1105	557.095	Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|	MVYNQMRZRULRIE-DEOSSOPVSA-N	136902743.0		MVYNQMRZRULRIE
BRD-A67976398-001-01-6	DQP-1105	Preclinical	glutamate receptor antagonist	GRIN2C|GRIN2D			0	93.59	Tocris	4491	DQP 1105	557.095	Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12,r,t:9|	MVYNQMRZRULRIE-DEOSSOPVSA-N	136902743.0		MVYNQMRZRULRIE
BRD-K94920105-001-03-9	DR-2313	Preclinical	PARP inhibitor	PARP1|PARP3			0	64.58	Tocris	2496	DR 2313	182.051	Cc1nc(=O)c2CSCCc2[nH]1	HRYKZAKEAVZGJD-UHFFFAOYSA-N	135522417.0		HRYKZAKEAVZGJD
BRD-K94920105-001-05-9	DR-2313	Preclinical	PARP inhibitor	PARP1|PARP3			0	86.89	Tocris	2496	DR 2313	182.051	Cc1nc(=O)c2CSCCc2[nH]1	HRYKZAKEAVZGJD-UHFFFAOYSA-N	135522417.0		HRYKZAKEAVZGJD
BRD-A39794701-003-02-9	DR-4485	Preclinical	serotonin receptor antagonist	HTR7			0	97.46	Tocris	5005	DR 4485 hydrochloride	454.158	Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|	SBTRHJHOLCAPFT-AREMUKBSSA-N	92211523.0		SBTRHJHOLCAPFT
BRD-A39794701-003-01-6	DR-4485	Preclinical	serotonin receptor antagonist	HTR7			0	98.04	Tocris	5005	DR 4485 hydrochloride	454.158	Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15,t:8|	SBTRHJHOLCAPFT-AREMUKBSSA-N	92211523.0		SBTRHJHOLCAPFT
BRD-K25486274-300-02-8	DRF053-(R)	Preclinical	CDK inhibitor	CSNK1A1			0	92.37	Tocris	3610	(R)-DRF053 dihydrochloride	417.228	CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	LWANFAFTTOKZAX-QGZVFWFLSA-N	25168304.0		LWANFAFTTOKZAX
BRD-K25486274-300-01-0	DRF053-(R)	Preclinical	CDK inhibitor	CSNK1A1			0	94.78	Tocris	3610	(R)-DRF053 dihydrochloride	417.228	CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	LWANFAFTTOKZAX-QGZVFWFLSA-N	25168304.0		LWANFAFTTOKZAX
BRD-K25486274-300-03-9	DRF053-(R)	Preclinical	CDK inhibitor	CSNK1A1			0	95.49	Tocris	3610	(R)-DRF053 dihydrochloride	417.228	CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	LWANFAFTTOKZAX-QGZVFWFLSA-N	25168304.0		LWANFAFTTOKZAX
BRD-A22267103-003-13-1	drofenine	Launched			neurology/psychiatry	spasms	0	93.04	MicroSource	1500999	DROFENINE HYDROCHLORIDE	317.235	CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|	AGJBLWCLQCKRJP-LJQANCHMSA-N	38988270.0		AGJBLWCLQCKRJP
BRD-A22267103-003-14-9	drofenine	Launched			neurology/psychiatry	spasms	0	88.88	MedChemEx	HY-B1239	Drofenine (hydrochloride)	317.235	CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|	AGJBLWCLQCKRJP-LJQANCHMSA-N	38988270.0		AGJBLWCLQCKRJP
BRD-K38477637-001-01-0	droloxifene	Phase 3	selective estrogen receptor modulator (SERM)	ESR1			0	82.82	LKT	D6957	3-((1E)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenyl-1-butenyl)phenol	387.22	CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1	ZQZFYGIXNQKOAV-OCEACIFDSA-N	3033767.0		ZQZFYGIXNQKOAV
BRD-A38706605-001-01-2	dromostanolone-propionate	Launched	androgen receptor modulator	AR	oncology	breast cancer	0	99.15	ANpharma	AN-45527	2-methyl-3-oxoandrostan-17-yl propionate	360.266	CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5,&2:8,&3:9,&4:12,&5:16,&6:19,&7:21,&8:24,r|	NOTIQUSPUUHHEH-QOMQUSCHSA-N			NOTIQUSPUUHHEH
BRD-K05524748-001-05-9	dronedarone	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|KCNA5|KCNH2|KCNK2|SCN1A	cardiology	atrial fibrillation (AF)	0	98.57	MedChemEx	HY-A0016	Dronedarone	556.297	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	208898.0		ZQTNQVWKHCQYLQ
BRD-K05524748-003-04-4	dronedarone	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|KCNA5|KCNH2|KCNK2|SCN1A	cardiology	atrial fibrillation (AF)	0	98.4	Selleck	S2114	Dronedarone HCl	556.297	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	ZQTNQVWKHCQYLQ-UHFFFAOYSA-N	208898.0		ZQTNQVWKHCQYLQ
BRD-K97158071-001-19-9	droperidol	Launched	dopamine receptor antagonist	ADRA1A|DRD2|DRD3|DRD4|HTR2A	gastroenterology	nausea|vomiting	0	91.45	Tocris	5858	Droperidol	379.17	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|	RMEDXOLNCUSCGS-UHFFFAOYSA-N	3168.0		RMEDXOLNCUSCGS
BRD-K97158071-001-18-1	droperidol	Launched	dopamine receptor antagonist	ADRA1A|DRD2|DRD3|DRD4|HTR2A	gastroenterology	nausea|vomiting	0	94.72	MicroSource	1501002	DROPERIDOL	379.17	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|	RMEDXOLNCUSCGS-UHFFFAOYSA-N	3168.0		RMEDXOLNCUSCGS
BRD-K97158071-001-17-3	droperidol	Launched	dopamine receptor antagonist	ADRA1A|DRD2|DRD3|DRD4|HTR2A	gastroenterology	nausea|vomiting	0	91.46	Selleck	S4096	Droperidol	379.17	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|	RMEDXOLNCUSCGS-UHFFFAOYSA-N	3168.0		RMEDXOLNCUSCGS
BRD-A29349577-001-23-0	dropropizine	Launched	antitussive		pulmonary	cough suppressant	0	90.5	MicroSource	1501004	DROPROPIZINE	236.152	OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|	PTVWPYVOOKLBCG-ZDUSSCGKSA-N	65859.0		PTVWPYVOOKLBCG
BRD-A29349577-001-22-2	dropropizine	Launched	antitussive		pulmonary	cough suppressant	0	89.09	Selleck	S4138	Dropropizine	236.152	OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|	PTVWPYVOOKLBCG-ZDUSSCGKSA-N	65859.0		PTVWPYVOOKLBCG
BRD-A29349577-001-25-9	dropropizine	Launched	antitussive		pulmonary	cough suppressant	0	95.89	MedChemEx	HY-B1032	Dropropizine	236.152	OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|	PTVWPYVOOKLBCG-ZDUSSCGKSA-N	65859.0		PTVWPYVOOKLBCG
BRD-A29349577-001-24-8	dropropizine	Launched	antitussive		pulmonary	cough suppressant	0	95.27	Selleck	S4138	Dropropizine	236.152	OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2,r|	PTVWPYVOOKLBCG-ZDUSSCGKSA-N	65859.0		PTVWPYVOOKLBCG
BRD-K04394237-001-04-5	drospirenone	Launched	mineralocorticoid receptor antagonist	AR|NR3C2|PGR	endocrinology	contraceptive	0	97.89	Selleck	S1377	Drospirenone	366.219	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|	METQSPRSQINEEU-HXCATZOESA-N	68873.0		METQSPRSQINEEU
BRD-K04394237-001-06-0	drospirenone	Launched	mineralocorticoid receptor antagonist	AR|NR3C2|PGR	endocrinology	contraceptive	0	98.46	MicroSource	1503831	DROSPIRENONE	366.219	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|	METQSPRSQINEEU-HXCATZOESA-N	68873.0	BRD-A00938334-001-01-3	METQSPRSQINEEU
BRD-K04394237-001-03-7	drospirenone	Launched	mineralocorticoid receptor antagonist	AR|NR3C2|PGR	endocrinology	contraceptive	0	99.66	Selleck	S1377	Drospirenone	366.219	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|	METQSPRSQINEEU-HXCATZOESA-N	68873.0		METQSPRSQINEEU
BRD-K04394237-001-05-2	drospirenone	Launched	mineralocorticoid receptor antagonist	AR|NR3C2|PGR	endocrinology	contraceptive	0	86.58	Selleck	S1377	Drospirenone	366.219	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|	METQSPRSQINEEU-HXCATZOESA-N	68873.0	BRD-K70875526-001-01-8	METQSPRSQINEEU
BRD-K00633793-003-03-4	drotaverine	Launched	phosphodiesterase inhibitor		obstetrics/gynecology	labor induction	0	84.01	Enamine	EN300-260709	(1E)-1-(3,4-diethoxybenzylidene)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride	397.225	CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|	NCVXEYAKRVJMTQ-UHFFFAOYSA-N	13492.0		NCVXEYAKRVJMTQ
BRD-K00633793-001-01-2	drotaverine	Launched	phosphodiesterase inhibitor		obstetrics/gynecology	labor induction	0	88.7	Vitas-M	STK301594		397.225	CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|	NCVXEYAKRVJMTQ-UHFFFAOYSA-N	13492.0		NCVXEYAKRVJMTQ
BRD-K17219082-001-02-9	droxicam	Launched	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis|osteoarthritis	0	0.0	Sigma	MFCD00866032	5-methyl-3-(2-pyridinyl)-2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide	357.042	CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O	OEHFRZLKGRKFAS-UHFFFAOYSA-N	65679.0		OEHFRZLKGRKFAS
BRD-K17219082-001-01-1	droxicam	Launched	cyclooxygenase inhibitor	PTGS1	rheumatology	rheumatoid arthritis|osteoarthritis	0	0.0	Ark	AK129765		357.042	CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O	OEHFRZLKGRKFAS-UHFFFAOYSA-N	65679.0		OEHFRZLKGRKFAS
BRD-K20372197-001-04-9	droxidopa	Launched	norepinephrine precursor	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease	0	100.0	MedChemEx	HY-13458	Droxidopa	213.064	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	QXWYKJLNLSIPIN-JGVFFNPUSA-N	92974.0		QXWYKJLNLSIPIN
BRD-K20372197-001-02-3	droxidopa	Launched	norepinephrine precursor	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease	0	0.0	Selleck	S3041	Droxidopa (L-DOPS)	213.064	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	QXWYKJLNLSIPIN-JGVFFNPUSA-N	92974.0		QXWYKJLNLSIPIN
BRD-K20372197-001-03-1	droxidopa	Launched	norepinephrine precursor	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH	cardiology|neurology/psychiatry	hypertension|Parkinson's Disease	0	100.0	Selleck	S3041	Droxidopa (L-DOPS)	213.064	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	QXWYKJLNLSIPIN-JGVFFNPUSA-N	92974.0		QXWYKJLNLSIPIN
BRD-K11558771-001-13-9	droxinostat	Preclinical	HDAC inhibitor	HDAC6|HDAC8			0	90.4	Selleck	S1422	Droxinostat	243.066	Cc1cc(Cl)ccc1OCCCC(=O)NO	JHSXDAWGLCZYSM-UHFFFAOYSA-N	568416.0		JHSXDAWGLCZYSM
BRD-K35498911-001-02-9	DSM265	Phase 2	dihydroorotate dehydrogenase inhibitor				0	97.71	MedChemEx	HY-100184	DSM265	415.07	Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2nc(nc2n1)C(C)(F)F	OIZSVTOIBNSVOS-UHFFFAOYSA-N	51347395.0		OIZSVTOIBNSVOS
BRD-K00004570-001-01-9	DSPC	Preclinical					0	0.0	ChemImpex	10927	1,2-Distearoyl-rac-glycero-3-phosphocholine	790.633	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |&1:21,r|	NRJAVPSFFCBXDT-WBCKFURZSA-O	5313335.0		NRJAVPSFFCBXDT
BRD-K46384285-001-02-9	DSR-6434	Preclinical	toll-like receptor agonist	TLR7			0	95.77	Tocris	4809	DSR 6434	400.234	CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1	SSZHESNDOMBSRV-UHFFFAOYSA-N	25071151.0		SSZHESNDOMBSRV
BRD-K46384285-001-01-3	DSR-6434	Preclinical	toll-like receptor agonist	TLR7			0	90.78	Tocris	4809	DSR 6434	400.234	CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1	SSZHESNDOMBSRV-UHFFFAOYSA-N	25071151.0		SSZHESNDOMBSRV
BRD-K09619578-001-02-1	DS2-(806622)	Preclinical					0	87.43	Tocris	3679	DS2	353.039	Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	AZKMWHRDICVYEI-UHFFFAOYSA-N	979718.0		AZKMWHRDICVYEI
BRD-K09619578-001-01-3	DS2-(806622)	Preclinical					0	89.78	Tocris	3679	DS2	353.039	Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	AZKMWHRDICVYEI-UHFFFAOYSA-N	979718.0		AZKMWHRDICVYEI
BRD-K09619578-001-03-9	DS2-(806622)	Preclinical					0	90.61	Tocris	3679	DS2	353.039	Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	AZKMWHRDICVYEI-UHFFFAOYSA-N	979718.0		AZKMWHRDICVYEI
BRD-K08859203-001-01-9	DU-728	Phase 1	structural glycoprotein antagonist	ITGA2B|ITGB3			0	100.0	MedChemEx	HY-12290	Arg-Gly-Asp-Ser	433.192	N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	NNRFRJQMBSBXGO-CIUDSAMLSA-N	107775.0		NNRFRJQMBSBXGO
BRD-K08859203-001-02-9	DU-728	Phase 1	structural glycoprotein antagonist	ITGA2B|ITGB3			0	99.1	MedChemEx	HY-12290	Arg-Gly-Asp-Ser	433.192	N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	NNRFRJQMBSBXGO-CIUDSAMLSA-N	107775.0		NNRFRJQMBSBXGO
BRD-K71103788-003-13-8	duloxetine	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy	0	98.43	Tocris	4798	(S)-Duloxetine hydrochloride	297.119	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	ZEUITGRIYCTCEM-KRWDZBQOSA-N	60835.0		ZEUITGRIYCTCEM
BRD-K71103788-003-12-0	duloxetine	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy	0	98.4	MicroSource	1505387	DULOXETINE HYDROCHLORIDE	297.119	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	ZEUITGRIYCTCEM-KRWDZBQOSA-N	60835.0		ZEUITGRIYCTCEM
BRD-K71103788-003-11-2	duloxetine	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|muscle pain|peripheral neuropathy	0	98.66	Selleck	S2084	Duloxetine HCl	297.119	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	ZEUITGRIYCTCEM-KRWDZBQOSA-N	60835.0		ZEUITGRIYCTCEM
BRD-K06221026-001-07-6	DUP-697	Phase 1	cyclooxygenase inhibitor	PTGS2			0	97.02	Tocris	1430	DuP 697	409.945	CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	AJFTZWGGHJXZOB-UHFFFAOYSA-N	3177.0		AJFTZWGGHJXZOB
BRD-K06221026-001-08-9	DUP-697	Phase 1	cyclooxygenase inhibitor	PTGS2			0	94.71	Tocris	1430	DuP 697	409.945	CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	AJFTZWGGHJXZOB-UHFFFAOYSA-N	3177.0		AJFTZWGGHJXZOB
BRD-K06221026-001-06-8	DUP-697	Phase 1	cyclooxygenase inhibitor	PTGS2			0	92.68	Tocris	1430	DuP 697	409.945	CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	AJFTZWGGHJXZOB-UHFFFAOYSA-N	3177.0		AJFTZWGGHJXZOB
BRD-K30373883-001-03-9	dutasteride	Launched	5 alpha reductase inhibitor	SRD5A1|SRD5A2|SRD5A3	urology	benign prostatic hyperplasia (BPH)	0	97.49	MedChemEx	HY-13613	Dutasteride	528.221	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|	JWJOTENAMICLJG-QWBYCMEYSA-N	6918296.0		JWJOTENAMICLJG
BRD-K30373883-001-02-8	dutasteride	Launched	5 alpha reductase inhibitor	SRD5A1|SRD5A2|SRD5A3	urology	benign prostatic hyperplasia (BPH)	0	97.58	Selleck	S1202	Dutasteride	528.221	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|	JWJOTENAMICLJG-QWBYCMEYSA-N	6918296.0	BRD-K28984613-001-01-5	JWJOTENAMICLJG
BRD-K93468883-001-02-0	duvelisib	Launched	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	95.49	Selleck	S7028	IPI-145 (INK1197)	416.115	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	SJVQHLPISAIATJ-ZDUSSCGKSA-N	50905713.0		SJVQHLPISAIATJ
BRD-K93468883-001-05-9	duvelisib	Launched	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	98.68	MedChemEx	HY-17044	Duvelisib	416.115	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	SJVQHLPISAIATJ-ZDUSSCGKSA-N	50905713.0		SJVQHLPISAIATJ
BRD-K22520627-001-01-7	DVD-111	Phase 2					0	99.45	MedChemEx	HY-17456	Noopept	318.158	CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	PJNSMUBMSNAEEN-AWEZNQCLSA-N	180496.0		PJNSMUBMSNAEEN
BRD-K22520627-001-02-9	DVD-111	Phase 2					0	93.54	MedChemEx	HY-17456	Omberacetam	318.158	CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	PJNSMUBMSNAEEN-AWEZNQCLSA-N	180496.0		PJNSMUBMSNAEEN
BRD-K00003171-001-01-9	DWK-1339	Preclinical	beta amyloid aggregation inhibitor				0	95.08	MedChemEx	HY-14503	DWK-1339	326.152	COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1	CUEPJIGXQLIOIK-UHFFFAOYSA-N	24764491.0		CUEPJIGXQLIOIK
BRD-K72259270-003-27-2	dyclonine	Launched	sodium channel blocker	SCN10A|SCN5A	neurology/psychiatry	local anesthetic	0	79.73	MedChemEx	HY-B0364A	Dyclonine (hydrochloride)	289.204	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	BZEWSEKUUPWQDQ-UHFFFAOYSA-N	3180.0		BZEWSEKUUPWQDQ
BRD-K72259270-003-24-9	dyclonine	Launched	sodium channel blocker	SCN10A|SCN5A	neurology/psychiatry	local anesthetic	0	61.31	MicroSource	1500268	DYCLONINE HYDROCHLORIDE	289.204	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	BZEWSEKUUPWQDQ-UHFFFAOYSA-N	3180.0		BZEWSEKUUPWQDQ
BRD-K72259270-003-25-6	dyclonine	Launched	sodium channel blocker	SCN10A|SCN5A	neurology/psychiatry	local anesthetic	0	93.29	Selleck	S2041	Dyclonine hydrochloride	289.204	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	BZEWSEKUUPWQDQ-UHFFFAOYSA-N	3180.0		BZEWSEKUUPWQDQ
BRD-K72259270-003-23-1	dyclonine	Launched	sodium channel blocker	SCN10A|SCN5A	neurology/psychiatry	local anesthetic	0	72.66	Selleck	S2041	Dyclonine HCl	289.204	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	BZEWSEKUUPWQDQ-UHFFFAOYSA-N	3180.0		BZEWSEKUUPWQDQ
BRD-K72259270-003-26-4	dyclonine	Launched	sodium channel blocker	SCN10A|SCN5A	neurology/psychiatry	local anesthetic	0	72.43	MedChemEx	HY-B0364A	Dyclonine (hydrochloride)	289.204	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	BZEWSEKUUPWQDQ-UHFFFAOYSA-N	3180.0		BZEWSEKUUPWQDQ
BRD-K68620903-001-11-4	dydrogesterone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	0	98.97	MicroSource	1505535	DYDROGESTERONE	312.209	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|	JGMOKGBVKVMRFX-HQZYFCCVSA-N	9051.0	BRD-A86597857-001-01-1	JGMOKGBVKVMRFX
BRD-K68620903-001-12-9	dydrogesterone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	0	100.0	MedChemEx	HY-B0257A	Dydrogesterone	312.209	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|	JGMOKGBVKVMRFX-HQZYFCCVSA-N	9051.0		JGMOKGBVKVMRFX
BRD-K68620903-001-10-6	dydrogesterone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	0	0.0	Selleck	S4097	Dydrogesterone	312.209	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|	JGMOKGBVKVMRFX-HQZYFCCVSA-N	9051.0	BRD-K27038879-001-01-0	JGMOKGBVKVMRFX
BRD-K68620903-001-09-8	dydrogesterone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	infertility	0	0.0	Selleck	S4097	Dydrogesterone	312.209	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8,t:10|	JGMOKGBVKVMRFX-HQZYFCCVSA-N	9051.0		JGMOKGBVKVMRFX
BRD-K87718015-001-04-9	dynasore	Preclinical	dynamin inhibitor	DNM1|DNM1L|DNM2			0	76.38	Tocris	2897	Dynasore	322.095	Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O	SYNDQCRDGGCQRZ-VXLYETTFSA-N	135533054.0		SYNDQCRDGGCQRZ
BRD-K87718015-001-01-9	dynasore	Preclinical	dynamin inhibitor	DNM1|DNM1L|DNM2			0	57.82	Selleck	S8047	Dynasore	322.095	Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O	SYNDQCRDGGCQRZ-VXLYETTFSA-N	135533054.0		SYNDQCRDGGCQRZ
BRD-K87718015-001-02-7	dynasore	Preclinical	dynamin inhibitor	DNM1|DNM1L|DNM2			0	89.1	Selleck	S8047	Dynasore	322.095	Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O	SYNDQCRDGGCQRZ-VXLYETTFSA-N	135533054.0		SYNDQCRDGGCQRZ
BRD-K23479488-001-01-3	dynole-34-2	Preclinical	dynamin inhibitor	DNM1			0	45.25	Tocris	4222	Dynole 34-2	408.289	CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N	MYIMRONQBLZJFI-DYTRJAOYSA-N	44157463.0		MYIMRONQBLZJFI
BRD-K23479488-001-02-9	dynole-34-2	Preclinical	dynamin inhibitor	DNM1			0	92.06	Tocris	4222	Dynole 34-2	408.289	CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N	MYIMRONQBLZJFI-DYTRJAOYSA-N	44157463.0		MYIMRONQBLZJFI
BRD-A00827783-001-24-6	dyphylline	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	PDE4A	pulmonary	asthma|bronchitis|emphysema	0	99.68	MicroSource	1500269	DYPHYLLINE	254.102	Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|	KSCFJBIXMNOVSH-ZCFIWIBFSA-N	688353.0		KSCFJBIXMNOVSH
BRD-A00827783-001-23-8	dyphylline	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	PDE4A	pulmonary	asthma|bronchitis|emphysema	0	97.44	Selleck	S1504	Dyphylline	254.102	Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|	KSCFJBIXMNOVSH-ZCFIWIBFSA-N	688353.0		KSCFJBIXMNOVSH
BRD-A00827783-001-25-9	dyphylline	Launched	adenosine receptor antagonist|phosphodiesterase inhibitor	PDE4A	pulmonary	asthma|bronchitis|emphysema	0	96.86	MedChemEx	HY-B0128	Diphylline	254.102	Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7,r|	KSCFJBIXMNOVSH-ZCFIWIBFSA-N	688353.0		KSCFJBIXMNOVSH
BRD-K58343622-001-02-4	DY131	Preclinical	estrogen-related receptor agonist	ESRRB|ESRRG			0	79.07	Tocris	2266	DY131	311.163	CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1	WLKOCYWYAWBGKY-CPNJWEJPSA-N	5497124.0		WLKOCYWYAWBGKY
BRD-K58343622-001-01-6	DY131	Preclinical	estrogen-related receptor agonist	ESRRB|ESRRG			0	88.82	Tocris	2266	DY131	311.163	CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1	WLKOCYWYAWBGKY-CPNJWEJPSA-N	5497124.0		WLKOCYWYAWBGKY
BRD-K58343622-001-03-9	DY131	Preclinical	estrogen-related receptor agonist	ESRRB|ESRRG			0	83.02	Tocris	2266	DY131	311.163	CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1	WLKOCYWYAWBGKY-CPNJWEJPSA-N	5497124.0		WLKOCYWYAWBGKY
BRD-A77118605-237-09-5	D609	Preclinical	phospholipase inhibitor				0	86.67	MedChemEx	HY-70072	D609	228.064	SC(=S)OC1CC2CC1C1CCCC21	PWLXJBSAUKKGCM-UHFFFAOYSA-N	4234241.0		PWLXJBSAUKKGCM
BRD-A77118605-237-08-7	D609	Preclinical	phospholipase inhibitor				0	77.18	MedChemEx	HY-70072	D609	228.064	SC(=S)OC1CC2CC1C1CCCC21	PWLXJBSAUKKGCM-UHFFFAOYSA-N	4234241.0		PWLXJBSAUKKGCM
BRD-A77118605-237-07-9	D609	Preclinical	phospholipase inhibitor				0	57.69	Enzo	ST330	D609	228.064	SC(=S)OC1CC2CC1C1CCCC21	PWLXJBSAUKKGCM-UHFFFAOYSA-N	4234241.0		PWLXJBSAUKKGCM
BRD-A77118605-237-06-1	D609	Preclinical	phospholipase inhibitor				0	37.75	Tocris	1437	D609	228.064	SC(=S)OC1CC2CC1C1CCCC21	PWLXJBSAUKKGCM-UHFFFAOYSA-N	4234241.0		PWLXJBSAUKKGCM
BRD-K00004561-001-01-9	E-2001	Preclinical	antioxidant				0	31.37	Sigma	MFCD28047721	2-[4-(4-fluorobenzoyl)-1-piperidyl]-1-naphthalen-2-yl-ethanone	375.163	Fc1ccc(cc1)C(=O)C1CCN(CC(=O)c2ccc3ccccc3c2)CC1	WPFPDSUMDURRRW-UHFFFAOYSA-N	129687.0		WPFPDSUMDURRRW
BRD-K50564936-001-02-9	E-2012	Phase 1	gamma secretase modulator	APH1A|APH1B|PSENEN			0	91.68	MedChemEx	HY-10016	E 2012	419.201	COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1	PUOAETJYKQITMO-LANLRWRYSA-N	11560787.0		PUOAETJYKQITMO
BRD-K50564936-001-01-6	E-2012	Phase 1	gamma secretase modulator	APH1A|APH1B|PSENEN			0	90.8	MedChemEx	HY-10016	E 2012	419.201	COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1	PUOAETJYKQITMO-LANLRWRYSA-N	11560787.0		PUOAETJYKQITMO
BRD-K41713976-300-03-4	E-4031	Phase 1	potassium channel blocker	KCNH1|KCNH2			0	92.7	Tocris	1808	E-4031 dihydrochloride	401.177	Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	SRUISGSHWFJION-UHFFFAOYSA-N	3185.0		SRUISGSHWFJION
BRD-K41713976-300-06-9	E-4031	Phase 1	potassium channel blocker	KCNH1|KCNH2			0	92.15	Tocris	1808	E-4031 dihydrochloride	401.177	Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	SRUISGSHWFJION-UHFFFAOYSA-N	3185.0		SRUISGSHWFJION
BRD-K41713976-300-02-6	E-4031	Phase 1	potassium channel blocker	KCNH1|KCNH2			0	96.27	Tocris	1808	E-4031 dihydrochloride	401.177	Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	SRUISGSHWFJION-UHFFFAOYSA-N	3185.0		SRUISGSHWFJION
BRD-K00004314-001-01-9	E-64	Preclinical	calpain inhibitor|cysteine protease inhibitor	CTSS			0	83.7	Tocris	5208	E 64	357.201	CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N	LTLYEAJONXGNFG-DCAQKATOSA-N	123985.0		LTLYEAJONXGNFG
BRD-K53030960-001-02-9	eact	Preclinical	calcium-activated chloride channel inhibitor	ANO1			0	97.95	Tocris	4876	Eact	428.141	COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1	ZUXNHFFVQWADJL-UHFFFAOYSA-N	3173542.0		ZUXNHFFVQWADJL
BRD-K53030960-001-01-4	eact	Preclinical	calcium-activated chloride channel inhibitor	ANO1			0	96.51	Tocris	4876	Eact	428.141	COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1	ZUXNHFFVQWADJL-UHFFFAOYSA-N	3173542.0		ZUXNHFFVQWADJL
BRD-K66998413-300-01-6	EB-47	Preclinical	PARP inhibitor	PARP1			0	95.65	Tocris	4140	EB 47	537.208	Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1	DDFLFKTXUWPNMV-LFALDJFMSA-N	53229989.0		DDFLFKTXUWPNMV
BRD-K66998413-300-02-9	EB-47	Preclinical	PARP inhibitor	PARP1			0	96.22	Tocris	4140	EB 47	537.208	Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1	DDFLFKTXUWPNMV-LFALDJFMSA-N	53229989.0		DDFLFKTXUWPNMV
BRD-K13314656-001-02-9	ebastine	Launched	histamine receptor antagonist	CYP3A4|HRH1	allergy	allergic rhinitis|urticaria	0	97.98	MedChemEx	HY-B0674	Ebastine	469.298	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	MJJALKDDGIKVBE-UHFFFAOYSA-N	3191.0		MJJALKDDGIKVBE
BRD-K13314656-001-01-0	ebastine	Launched	histamine receptor antagonist	CYP3A4|HRH1	allergy	allergic rhinitis|urticaria	0	92.12	Selleck	S4262	Ebastine	469.298	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	MJJALKDDGIKVBE-UHFFFAOYSA-N	3191.0		MJJALKDDGIKVBE
BRD-K00004209-001-01-9	EBPC	Preclinical	aldose reductase inhibitor	AKR1B1			0	90.37	Tocris	518	EBPC	261.1	CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5,r|	FQMSSTZJKSWSMP-LLVKDONJSA-N	6919079.0		FQMSSTZJKSWSMP
BRD-K22421059-001-03-1	ebrotidine	Withdrawn	histamine receptor antagonist	HRH2			0	78.38	MedChemEx	HY-15538	Ebrotidine	475.976	NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1	ZQHFZHPUZXNPMF-UHFFFAOYSA-N	65869.0		ZQHFZHPUZXNPMF
BRD-K22421059-001-02-3	ebrotidine	Withdrawn	histamine receptor antagonist	HRH2			0	83.9	MedChemEx	HY-15538	Ebrotidine	475.976	NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1	ZQHFZHPUZXNPMF-UHFFFAOYSA-N	65869.0		ZQHFZHPUZXNPMF
BRD-K22421059-001-01-5	ebrotidine	Withdrawn	histamine receptor antagonist	HRH2			0	65.02	MedChemEx	HY-15538	Ebrotidine	475.976	NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1	ZQHFZHPUZXNPMF-UHFFFAOYSA-N	65869.0		ZQHFZHPUZXNPMF
BRD-K29359156-001-30-1	ebselen	Phase 2/Phase 3	cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor	ALB			0	93.11	MicroSource	1501188	EBSELEN	274.985	O=c1n([se]c2ccccc12)-c1ccccc1	DYEFUKCXAQOFHX-UHFFFAOYSA-N	3194.0		DYEFUKCXAQOFHX
BRD-K41705163-001-02-9	EC-144	Preclinical	HSP inhibitor	HSP90AA1|HSP90AB1			0	94.11	Tocris	4701	EC 144	413.162	COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C	VOASEWXFCTZRDF-UHFFFAOYSA-N	11517212.0		VOASEWXFCTZRDF
BRD-K41705163-001-01-1	EC-144	Preclinical	HSP inhibitor	HSP90AA1|HSP90AB1			0	96.8	Tocris	4701	EC 144	413.162	COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C	VOASEWXFCTZRDF-UHFFFAOYSA-N	11517212.0		VOASEWXFCTZRDF
BRD-K81004638-001-01-7	EC-23	Preclinical	retinoid receptor agonist	RARA|RARB|RARG			0	98.05	Sigma	MFCD18086921	4-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)ethynyl]benzoic acid	332.178	CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O	OQVLOWLEEHYBJH-UHFFFAOYSA-N	10314719.0		OQVLOWLEEHYBJH
BRD-K81004638-001-02-5	EC-23	Preclinical	retinoid receptor agonist	RARA|RARB|RARG			0	97.56	Tocris	4011	EC 23	332.178	CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O	OQVLOWLEEHYBJH-UHFFFAOYSA-N	10314719.0		OQVLOWLEEHYBJH
BRD-K47371940-001-01-6	ecabapide	Phase 3					0	87.95	Enamine	Z52799962		371.185	CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1	JTAGHJPZEDNHHA-UHFFFAOYSA-N	65885.0		JTAGHJPZEDNHHA
BRD-K03353589-236-01-4	ecabet	Launched	gastrin inhibitor|urease inhibitor	NOXO1	ophthalmology	dry eye syndrome	0	98.28	OxChem	AX8127117		380.166	CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O	IWCWQNVIUXZOMJ-MISYRCLQSA-N	65781.0		IWCWQNVIUXZOMJ
BRD-A60635434-001-01-1	ecamsule-triethanolamine	Launched			dermatology	skin protectant|sunscreen lotion	0	77.09	Sigma	55901-25MG	[rac-(1R,3E,4R)-7,7-dimethyl-2-oxo-3-[[4-[rac-(E)-[rac-(1R,4R)-7,7-dimethyl-3-oxo-4-(sulfomethyl)norbornan-2-ylidene]methyl]phenyl]methylene]norbornan-1-yl]methanesulfonic acid	562.17	CC1(C)[C@H]2CC[C@]1(CS(O)(=O)=O)C(=O)C2=Cc1ccc(C=C2[C@@H]3CC[C@](CS(O)(=O)=O)(C2=O)C3(C)C)cc1 |&1:3,6,&2:22,25,r|	HEAHZSUCFKFERC-MPPVQRIUSA-N	131634633.0		HEAHZSUCFKFERC
BRD-K00010937-001-01-9	echinomycin	Phase 2	DNA intercalating agent				0	96.61	Tocris	5520	echinomycin	1100.421	[H][C@]1(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]2([H])N(C)C(=O)[C@H](C)NC(=O)[C@@]([H])(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]([H])(CS[C@]2([H])SC)N(C)C(=O)[C@H](C)NC1=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 |&1:45,@:8,34|	AUJXLBOHYWTPFV-DYWXRLDNSA-N			AUJXLBOHYWTPFV
BRD-A51820102-008-28-9	econazole	Launched	lanosterol demethylase inhibitor|sterol demethylase inhibitor	NPY1R|NPY2R|TRPM2|TRPV5	infectious disease	tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis	0	99.93	MicroSource	1501185	ECONAZOLE NITRATE	380.025	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	LEZWWPYKPKIXLL-SFHVURJKSA-N	6604378.0		LEZWWPYKPKIXLL
BRD-A51820102-008-29-9	econazole	Launched	lanosterol demethylase inhibitor|sterol demethylase inhibitor	NPY1R|NPY2R|TRPM2|TRPV5	infectious disease	tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis	0	97.92	MedChemEx	HY-B0453	Econazole (nitrate)	380.025	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	LEZWWPYKPKIXLL-SFHVURJKSA-N	6604378.0		LEZWWPYKPKIXLL
BRD-A51820102-008-27-1	econazole	Launched	lanosterol demethylase inhibitor|sterol demethylase inhibitor	NPY1R|NPY2R|TRPM2|TRPV5	infectious disease	tinea pedis|tinea cruris|tinea corporis|tinea versicolor|cutaneous candidiasis	0	98.03	Selleck	S2535	Econazole nitrate	380.025	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	LEZWWPYKPKIXLL-SFHVURJKSA-N	6604378.0		LEZWWPYKPKIXLL
BRD-K34566599-001-03-9	ectoine	Launched	anti-inflammatory agent				0	100.0	Sigma	81619	(4S)-2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid	142.074	CC1=NCC[C@H](N1)C(O)=O |t:1|	WQXNXVUDBPYKBA-YFKPBYRVSA-N	6993223.0		WQXNXVUDBPYKBA
BRD-K34566599-001-02-8	ectoine	Launched	anti-inflammatory agent				0	98.7	Sigma	MFCD03419286	(4S)-2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid	142.074	CC1=NCC[C@H](N1)C(O)=O |t:1|	WQXNXVUDBPYKBA-YFKPBYRVSA-N	6993223.0		WQXNXVUDBPYKBA
BRD-K00004306-001-01-9	edaglitazone	Phase 2	PPAR receptor agonist	PPARG			0	97.51	Tocris	4784	Edaglitazone	464.086	Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14,r|	HAAXAFNSRADSMK-FQEVSTJZSA-N	76961439.0		HAAXAFNSRADSMK
BRD-K35458079-001-34-9	edaravone	Launched	nootropic agent	BCL2	neurology/psychiatry	stroke	0	19.81	MedChemEx	HY-B0099	Edaravone	174.079	Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N	70335.0		KZQYIMCESJLPQH
BRD-K35458079-001-33-1	edaravone	Launched	nootropic agent	BCL2	neurology/psychiatry	stroke	0	65.37	MedChemEx	HY-B0099	Edaravone	174.079	Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N	70335.0		KZQYIMCESJLPQH
BRD-K35458079-001-29-9	edaravone	Launched	nootropic agent	BCL2	neurology/psychiatry	stroke	0	64.17	MicroSource	1503635	EDARAVONE	174.079	Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N	70335.0		KZQYIMCESJLPQH
BRD-K35458079-001-35-6	edaravone	Launched	nootropic agent	BCL2	neurology/psychiatry	stroke	0	26.35	Sigma	Y0001138	5-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one	174.079	Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N	70335.0		KZQYIMCESJLPQH
BRD-K35458079-001-31-5	edaravone	Launched	nootropic agent	BCL2	neurology/psychiatry	stroke	0	0.0	Selleck	S1326	Edaravone (MCI-186)	174.079	Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N	70335.0		KZQYIMCESJLPQH
BRD-K35458079-001-28-1	edaravone	Launched	nootropic agent	BCL2	neurology/psychiatry	stroke	0	5.75	Tocris	786	Edaravone	174.079	Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N	70335.0		KZQYIMCESJLPQH
BRD-K35458079-001-27-3	edaravone	Launched	nootropic agent	BCL2	neurology/psychiatry	stroke	0	38.22	Selleck	S1326	Edaravone	174.079	Cc1cc(=O)n([nH]1)-c1ccccc1	KZQYIMCESJLPQH-UHFFFAOYSA-N	70335.0		KZQYIMCESJLPQH
BRD-K00003258-001-01-9	edasalonexent	Phase 3	NFkB pathway inhibitor				0	0.0	MedChemEx	HY-17630	Edasalonexent	490.32	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O	JQLBBYLGWHUHRW-KUBAVDMBSA-N	44626120.0		JQLBBYLGWHUHRW
BRD-K01825687-001-02-9	edelfosine	Phase 2	phospholipase inhibitor				0	100.0	Cayman	60912	(R)-2-methoxy-3-(octadecyloxy)propyl 2-(trimethylammonio)ethyl phosphate	524.408	CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|	MHFRGQHAERHWKZ-HHHXNRCGSA-O	6610230.0		MHFRGQHAERHWKZ
BRD-K01825687-001-01-9	edelfosine	Phase 2	phospholipase inhibitor				0	0.0	Enzo	L108	1-Octadecyl-2-methylglycero-3 PC	524.408	CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20,&1:23|	MHFRGQHAERHWKZ-HHHXNRCGSA-O	6610230.0		MHFRGQHAERHWKZ
BRD-A78588743-001-03-4	editol	Preclinical					0	91.55	MicroSource	1301023	EDITOL	292.236	C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|	NSOXQYCFHDMMGV-AAVRWANBSA-N	7014872.0		NSOXQYCFHDMMGV
BRD-A78588743-001-04-9	editol	Preclinical					0	100.0	MedChemEx	HY-B2149	Quadrol	292.236	C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1,&2:9,&3:13,&4:17,r|	NSOXQYCFHDMMGV-AAVRWANBSA-N	7014872.0		NSOXQYCFHDMMGV
BRD-K00003432-001-01-9	EDO-S101	Phase 1/Phase 2	HDAC inhibitor				0	55.12	MedChemEx	HY-101780	EDO-S101	414.159	Cn1c(CCCCCCC(=O)NO)nc2cc(ccc12)N(CCCl)CCCl	GISXTRIGVCKQBX-UHFFFAOYSA-N	46836227.0		GISXTRIGVCKQBX
BRD-K00003259-050-01-9	edonerpic-maleate	Preclinical	beta amyloid inhibitor				0	94.04	MedChemEx	HY-17631A	Edonerpic maleate	291.129	OC1CN(CCCOCCc2ccc3sccc3c2)C1	HQNACSFBDBYLJP-UHFFFAOYSA-N	9901946.0		HQNACSFBDBYLJP
BRD-K97058489-454-01-6	edoxaban	Launched	coagulation factor inhibitor	F10	neurology/psychiatry|hematology|cardiology	stroke|pulmonary embolism (PE)|systemic embolism|deep vein thrombosis (DVT)|atrial fibrillation (AF)	0	89.81	Selleck	S7280	Edoxaban	547.177	CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1	HGVDHZBSSITLCT-JLJPHGGASA-N	10280735.0		HGVDHZBSSITLCT
BRD-K86892782-001-18-9	edoxudine	Launched	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	0	94.25	MedChemEx	HY-B1011	Edoxudine	256.106	CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O	XACKNLSZYYIACO-DJLDLDEBSA-N	66377.0		XACKNLSZYYIACO
BRD-K86892782-001-17-0	edoxudine	Launched	DNA directed DNA polymerase inhibitor		infectious disease	virus herpes simplex (HSV)	0	98.02	MicroSource	1503214	EDOXUDINE	256.106	CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O	XACKNLSZYYIACO-DJLDLDEBSA-N	66377.0	BRD-A62505706-001-04-9	XACKNLSZYYIACO
BRD-K81128206-003-25-9	edrophonium	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	myasthenia gravis	0	95.49	MedChemEx	HY-B0882	Edrophonium (chloride)	166.123	CC[N+](C)(C)c1cccc(O)c1	VWLHWLSRQJQWRG-UHFFFAOYSA-O	3202.0		VWLHWLSRQJQWRG
BRD-K81128206-003-24-4	edrophonium	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	myasthenia gravis	0	98.99	MicroSource	2300219	EDROPHONIUM CHLORIDE	166.123	CC[N+](C)(C)c1cccc(O)c1	VWLHWLSRQJQWRG-UHFFFAOYSA-O	3202.0		VWLHWLSRQJQWRG
BRD-K54542929-001-02-9	EDTMP	Preclinical	chelating agent				0	0.0	Vitas-M	STK368766	[ethane-1,2-diylbis(nitrilodimethanediyl)]tetrakis(phosphonic acid)	435.997	OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O	NFDRPXJGHKJRLJ-UHFFFAOYSA-N	15025.0		NFDRPXJGHKJRLJ
BRD-K54542929-001-01-7	EDTMP	Preclinical	chelating agent				0	0.0	Vitas-M	STK368766		435.997	OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O	NFDRPXJGHKJRLJ-UHFFFAOYSA-N	15025.0		NFDRPXJGHKJRLJ
BRD-K19002914-001-01-3	EED226	Preclinical	polycomb protein inhibitor	EED			0	96.75	MedChemEx	HY-101117	EED226	369.09	CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12	DYIRSNMPIZZNBK-UHFFFAOYSA-N	123132228.0		DYIRSNMPIZZNBK
BRD-K37355418-001-02-9	efaproxiral	Phase 3	hemoglobin oxygen release stimulant	HBA1|HBB			0	97.48	MedChemEx	HY-13619	Efaproxiral	341.163	Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1	BNFRJXLZYUTIII-UHFFFAOYSA-N	122335.0		BNFRJXLZYUTIII
BRD-K37355418-236-01-6	efaproxiral	Phase 3	hemoglobin oxygen release stimulant	HBA1|HBB			0	97.94	Selleck	S4263	Efaproxiral Sodium	341.163	Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1	BNFRJXLZYUTIII-UHFFFAOYSA-N	122335.0		BNFRJXLZYUTIII
BRD-A10739734-003-10-6	efaroxan	Phase 2	adrenergic receptor antagonist	ADORA2A			0	98.28	MicroSource	2300218	EFAROXAN HYDROCHLORIDE	216.126	CCC1(Cc2ccccc2O1)C1=NCCN1	RATZLMXRALDSJW-UHFFFAOYSA-N	11957548.0		RATZLMXRALDSJW
BRD-A10739734-003-09-8	efaroxan	Phase 2	adrenergic receptor antagonist	ADORA2A			0	96.93	Tocris	792	Efaroxan hydrochloride	216.126	CCC1(Cc2ccccc2O1)C1=NCCN1	RATZLMXRALDSJW-UHFFFAOYSA-N	11957548.0		RATZLMXRALDSJW
BRD-A24560335-300-02-9	efatutazone	Phase 2	PPAR receptor agonist	PPARG			0	96.26	MedChemEx	HY-14792B	Inolitazone (dihydrochloride)	502.167	Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|	JCYNMRJCUYVDBC-HSZRJFAPSA-N	76962475.0		JCYNMRJCUYVDBC
BRD-A24560335-300-01-2	efatutazone	Phase 2	PPAR receptor agonist	PPARG			0	95.58	MedChemEx	HY-14792B	Inolitazone (dihydrochloride)	502.167	Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|	JCYNMRJCUYVDBC-HSZRJFAPSA-N	76962475.0		JCYNMRJCUYVDBC
BRD-K40758068-001-10-9	efavirenz	Launched	HIV protease inhibitor	CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	91.94	MedChemEx	HY-10572	Efavirenz	315.027	FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1	XPOQHMRABVBWPR-ZDUSSCGKSA-N	64139.0		XPOQHMRABVBWPR
BRD-K40758068-001-08-2	efavirenz	Launched	HIV protease inhibitor	CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	98.9	Enzo	DL535	Efavirenz	315.027	FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1	XPOQHMRABVBWPR-ZDUSSCGKSA-N	64139.0		XPOQHMRABVBWPR
BRD-A30774155-001-01-2	efinaconazole	Launched	lanosterol demethylase inhibitor	CYP51A1	infectious disease	onychomycosis	0	92.45	MedChemEx	HY-15660	Efinaconazole	348.176	C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1,&1:9|	NFEZZTICAUWDHU-KDOFPFPSSA-N	9819704.0		NFEZZTICAUWDHU
BRD-K00004551-001-01-9	efletirizine	Phase 3	antihistamine				0	100.0	Sigma	MFCD00868363	(2-{4-[bis(4-fluorophenyl)methyl]-1-piperazinyl}ethoxy)acetic acid	390.175	OC(=O)COCCN1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1	BAWMMJAUVBLLEE-UHFFFAOYSA-N	66003.0		BAWMMJAUVBLLEE
BRD-A96292436-003-16-1	eflornithine	Launched	ornithine decarboxylase inhibitor	ARG2|ODC1	dermatology	facial hair reduction	0	100.0	Enzo	AC3107	EFLORNITHINE HYDROCHLORIDE	182.087	NCCCC(N)(C(F)F)C(O)=O |&1:4|	VLCYCQAOQCDTCN-UHFFFAOYSA-N	3009.0		VLCYCQAOQCDTCN
BRD-K55166090-001-09-0	efloxate	Preclinical	vasodilator				0	97.67	MicroSource	1504518	EFLOXATE	324.1	CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1	ZVXBAHLOGZCFTP-UHFFFAOYSA-N	8395.0		ZVXBAHLOGZCFTP
BRD-K00004292-003-02-9	efonidipine	Launched	calcium channel blocker		cardiology	hypertension	0	97.16	MedChemEx	HY-12502A	Efonidipine hydrochloride monoethanolate	631.245	CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|	NSVFSAJIGAJDMR-HKBQPEDESA-N	11764616.0		NSVFSAJIGAJDMR
BRD-K00004292-003-01-9	efonidipine	Launched	calcium channel blocker		cardiology	hypertension	0	91.75	Tocris	3733	Efonidipine hydrochloride monoethanolate	631.245	CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3,r,t:1,4|	NSVFSAJIGAJDMR-HKBQPEDESA-N	11764616.0		NSVFSAJIGAJDMR
BRD-K00004643-001-01-9	EF5	Phase 2	cytochrome P450 activator				0	100.0	Sigma	SML1961	2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide	302.044	[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F	JGGDSDPOPRWSCX-UHFFFAOYSA-N	389053.0		JGGDSDPOPRWSCX
BRD-K22514639-001-05-7	EGF816	Phase 2	EGFR inhibitor	EGFR			0	92.84	MedChemEx	HY-12872	EGF816	494.22	CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12	IOMMMLWIABWRKL-WUTDNEBXSA-N	72703790.0		IOMMMLWIABWRKL
BRD-K22514639-001-04-0	EGF816	Phase 2	EGFR inhibitor	EGFR			0	87.44	MedChemEx	HY-12872	EGF816	494.22	CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12	IOMMMLWIABWRKL-WUTDNEBXSA-N	72703790.0		IOMMMLWIABWRKL
BRD-K65359424-001-02-1	eglumetad	Phase 2	glutamate receptor agonist	GRM2|GRM3|GRM6|GRM8			0	100.0	MedChemEx	HY-18941	LY354740	185.069	N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	VTAARTQTOOYTES-RGDLXGNYSA-N	213056.0		VTAARTQTOOYTES
BRD-K65359424-001-01-3	eglumetad	Phase 2	glutamate receptor agonist	GRM2|GRM3|GRM6|GRM8			0	69.68	EMDBio	504685-10MG	LY 354740	185.069	N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	VTAARTQTOOYTES-RGDLXGNYSA-N	213056.0		VTAARTQTOOYTES
BRD-K50653584-019-01-4	EG00229	Preclinical	neuropilin receptor antagonist	NRP1			0	94.54	MedChemEx	HY-10799	EG00229	497.061	NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O	ZWWMEDURALZMEV-NSHDSACASA-N	44631827.0		ZWWMEDURALZMEV
BRD-K50653584-001-01-2	EG00229	Preclinical	neuropilin receptor antagonist	NRP1			0	96.86	Tocris	4931	EG 00229	497.061	NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O	ZWWMEDURALZMEV-NSHDSACASA-N	44631827.0		ZWWMEDURALZMEV
BRD-K32289541-001-01-0	EHop-016	Preclinical	Ras GTPase inhibitor	RAC1|RAC3			0	93.91	Selleck	S7319	EHop-016	430.248	CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12	AFTZZRFCMOAFCR-UHFFFAOYSA-N	51031035.0		AFTZZRFCMOAFCR
BRD-K32289541-001-02-8	EHop-016	Preclinical	Ras GTPase inhibitor	RAC1|RAC3			0		Selleck	S7319	EHop-016	430.248	CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12	InChI=1S/C25H30N6O/c1-2-31-22-7-4-3-6-20(22)21-18-19(8-9-23(21)31)28-24-10-12-27-25(29-24)26-11-5-13-30-14-16-32-17-15-30/h3-4,6-10,12,18H,2,5,11,13-17H2,1H3,(H2,26,27,28,29)	51031035.0		AFTZZRFCMOAFCR
BRD-K88120876-001-09-8	EIPA	Preclinical	sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor	ADRA2A|ASIC1|PKD2L1			0	65.7	Tocris	3378	EIPA	299.126	CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N	QDERNBXNXJCIQK-UHFFFAOYSA-N	1795.0		QDERNBXNXJCIQK
BRD-K88120876-001-10-9	EIPA	Preclinical	sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor	ADRA2A|ASIC1|PKD2L1			0	93.61	Tocris	3378	EIPA	299.126	CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N	QDERNBXNXJCIQK-UHFFFAOYSA-N	1795.0		QDERNBXNXJCIQK
BRD-K81623406-004-09-9	EIT-hydrobromide	Preclinical	nitric oxide synthase inhibitor	NOS2|NOS3			0	93.66	Tocris	873	EIT hydrobromide	104.041	CCSC(N)=N	VFIZBHJTOHUOEK-UHFFFAOYSA-N	5139.0		VFIZBHJTOHUOEK
BRD-K81623406-004-08-3	EIT-hydrobromide	Preclinical	nitric oxide synthase inhibitor	NOS2|NOS3			0	90.43	Tocris	873	EIT hydrobromide	104.041	CCSC(N)=N	VFIZBHJTOHUOEK-UHFFFAOYSA-N	5139.0		VFIZBHJTOHUOEK
BRD-K91535048-001-01-2	EI1	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	93.04	MedChemEx	HY-15573	EI1	390.206	CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O	PFHDWRIVDDIFRP-UHFFFAOYSA-N	72199293.0		PFHDWRIVDDIFRP
BRD-K00003295-300-01-9	elacestrant	Phase 3	estrogen receptor degrader				0	97.32	MedChemEx	HY-19822A	Elacestrant (dihydrochloride)	458.293	CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1	SIFNOOUKXBRGGB-AREMUKBSSA-N	23642301.0		SIFNOOUKXBRGGB
BRD-K88807631-001-03-9	elacridar	Phase 1	P glycoprotein inhibitor	ABCB1			0	90.69	MedChemEx	HY-50879	Elacridar	563.242	COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	OSFCMRGOZNQUSW-UHFFFAOYSA-N	119373.0		OSFCMRGOZNQUSW
BRD-K88807631-001-02-1	elacridar	Phase 1	P glycoprotein inhibitor	ABCB1			0	70.94	Selleck	S7772	elacridar	563.242	COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	OSFCMRGOZNQUSW-UHFFFAOYSA-N	119373.0		OSFCMRGOZNQUSW
BRD-K88807631-001-01-3	elacridar	Phase 1	P glycoprotein inhibitor	ABCB1			0	94.19	MedChemEx	HY-50879	Elacridar	563.242	COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	OSFCMRGOZNQUSW-UHFFFAOYSA-N	119373.0		OSFCMRGOZNQUSW
BRD-K63876426-001-01-6	elactocin	Phase 1	exportin antagonist	XPO1			0		EMDBio	431050-5UG	InSolution Leptomycin B, Streptomyces sp.	540.345	CC\C(\C=C\[C@H]1OC(=O)C=C[C@@H]1C)=C\[C@H](C)C\C=C\C(\C)=C\[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C\C(C)=C\C(O)=O |c:9|	YACHGFWEQXFSBS-ZNDZZNGASA-N	16760536.0		YACHGFWEQXFSBS
BRD-K00004609-001-01-9	elacytarabine	Phase 3	antineoplastic agent	DCK			0	93.33	MedChemEx	HY-14941	Elacytarabine	507.331	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O	FLFGNMFWNBOBGE-FNNZEKJRSA-N	6438895.0		FLFGNMFWNBOBGE
BRD-K03165895-001-01-9	elafibranor	Phase 3	PPAR receptor agonist	PPARA|PPARD|PPARG			0	92.97	MedChemEx	HY-16737	Elafibranor	384.14	CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1	AFLFKFHDSCQHOL-IZZDOVSWSA-N	9864881.0		AFLFKFHDSCQHOL
BRD-K55808645-001-02-2	elagolix	Launched	gonadotropin releasing factor hormone receptor antagonist	GNRHR			0	95.19	MedChemEx	HY-14789	Elagolix	631.211	COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O	HEAUOKZIVMZVQL-VWLOTQADSA-N	11250647.0		HEAUOKZIVMZVQL
BRD-K55808645-001-01-4	elagolix	Launched	gonadotropin releasing factor hormone receptor antagonist	GNRHR			0	81.73	MedChemEx	HY-14789	Elagolix	631.211	COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O	HEAUOKZIVMZVQL-VWLOTQADSA-N	11250647.0		HEAUOKZIVMZVQL
BRD-K09735259-001-01-3	elbasvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	95.63	MedChemEx	HY-15789	Elbasvir	881.422	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	BVAZQCUMNICBAQ-PZHYSIFUSA-N	71661251.0		BVAZQCUMNICBAQ
BRD-K00003316-001-01-9	eldecalcitol	Phase 3	bone formation stimulant	VDR			0	94.13	MedChemEx	HY-A0020	Eldecalcitol	490.366	[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C	FZEXGDDBXLBRTD-AYIMTCTASA-N	6918141.0		FZEXGDDBXLBRTD
BRD-K00003225-003-01-9	eleclazine	Phase 3	late sodium current inhibitor				0	98.9	MedChemEx	HY-16738A	Eleclazine (hydrochloride)	415.114	FC(F)(F)Oc1ccc(cc1)-c1ccc2OCCN(Cc3ncccn3)C(=O)c2c1	YNUAEEJQYHYLMS-UHFFFAOYSA-N	71183216.0		YNUAEEJQYHYLMS
BRD-K79565391-001-01-8	elemene	Phase 3	VEGFR inhibitor				0	0.0	Enamine	EN300-179368		204.188	CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C	OPFTUNCRGUEPRZ-RBSFLKMASA-N	6431152.0		OPFTUNCRGUEPRZ
BRD-K82135108-001-04-3	elesclomol	Phase 3	oxidative stress inducer	HSPA1A			0	90.81	Selleck	S1052	Elesclomol (STA-4783)	400.103	CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	BKJIXTWSNXCKJH-UHFFFAOYSA-N	300471.0		BKJIXTWSNXCKJH
BRD-K82135108-001-07-9	elesclomol	Phase 3	oxidative stress inducer	HSPA1A			0	95.47	MedChemEx	HY-12040	Elesclomol	400.103	CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	BKJIXTWSNXCKJH-UHFFFAOYSA-N	300471.0		BKJIXTWSNXCKJH
BRD-K30652337-004-03-9	eletriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	85.32	Tocris	3862	Eletriptan hydrobromide	382.171	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	PWVXXGRKLHYWKM-LJQANCHMSA-N	77993.0		PWVXXGRKLHYWKM
BRD-K30652337-001-01-9	eletriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	93.42	MicroSource	1505819	ELETRIPTAN HYDROBROMIDE	382.171	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	PWVXXGRKLHYWKM-LJQANCHMSA-N	77993.0		PWVXXGRKLHYWKM
BRD-K30652337-004-01-3	eletriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	92.93	Selleck	S3180	Eletriptan HBr	382.171	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	PWVXXGRKLHYWKM-LJQANCHMSA-N	77993.0		PWVXXGRKLHYWKM
BRD-K30652337-004-04-9	eletriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	94.9	Tocris	3862	Eletriptan hydrobromide	382.171	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	PWVXXGRKLHYWKM-LJQANCHMSA-N	77993.0		PWVXXGRKLHYWKM
BRD-K30652337-004-02-1	eletriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	neurology/psychiatry	migraine headache	0	97.64	Tocris	3862	Eletriptan hydrobromide	382.171	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	PWVXXGRKLHYWKM-LJQANCHMSA-N	77993.0		PWVXXGRKLHYWKM
BRD-K86410485-001-01-5	eliglustat	Launched	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	0	89.58	MedChemEx	HY-14885	Eliglustat	404.268	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	FJZZPCZKBUKGGU-AUSIDOKSSA-N	23652731.0		FJZZPCZKBUKGGU
BRD-K86410485-046-01-0	eliglustat	Launched	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	0	93.73	MedChemEx	HY-14885A	Eliglustat (hemitartrate)	404.268	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	FJZZPCZKBUKGGU-AUSIDOKSSA-N	23652731.0	BRD-M75840137-046-01-1	FJZZPCZKBUKGGU
BRD-K59271229-001-02-3	elinogrel	Phase 2	purinergic receptor antagonist	P2RY12			0	0.0	Tocris	5316	Elinogrel	523.019	CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F	LGSDFTPAICUONK-UHFFFAOYSA-N	16066663.0		LGSDFTPAICUONK
BRD-K59271229-001-01-5	elinogrel	Phase 2	purinergic receptor antagonist	P2RY12			0	13.9	Tocris	5316	3-{4-[({[(5-chloro-2-thienyl)sulfonyl]amino}carbonyl)amino]phenyl}-6-fluoro-7-(methylamino)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline	523.019	CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F	LGSDFTPAICUONK-UHFFFAOYSA-N	16066663.0		LGSDFTPAICUONK
BRD-A61392169-001-02-7	eliprodil	Phase 3	glutamate receptor antagonist	GRIN1|GRIN2B			0	90.15	Tocris	2195	Eliprodil	347.145	O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|	GGUSQTSTQSHJAH-FQEVSTJZSA-N	9798372.0		GGUSQTSTQSHJAH
BRD-A61392169-001-03-9	eliprodil	Phase 3	glutamate receptor antagonist	GRIN1|GRIN2B			0	94.59	Tocris	2195	Eliprodil	347.145	O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1,r|	GGUSQTSTQSHJAH-FQEVSTJZSA-N	9798372.0		GGUSQTSTQSHJAH
BRD-K30466858-001-11-9	ellagic-acid	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK			0	95.86	MedChemEx	HY-B0183	Ellagic acid	302.006	Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	AFSDNFLWKVMVRB-UHFFFAOYSA-N	5281855.0		AFSDNFLWKVMVRB
BRD-K30466858-001-09-6	ellagic-acid	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK			0	87.79	MicroSource	1502245	ELLAGIC ACID	302.006	Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	AFSDNFLWKVMVRB-UHFFFAOYSA-N	5281855.0		AFSDNFLWKVMVRB
BRD-K30466858-001-10-4	ellagic-acid	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK			0	98.25	Selleck	S1327	Ellagic acid	302.006	Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	AFSDNFLWKVMVRB-UHFFFAOYSA-N	5281855.0		AFSDNFLWKVMVRB
BRD-K30466858-001-08-8	ellagic-acid	Phase 2	glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor	CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK			0	69.46	Selleck	S1327	Ellagic acid	302.006	Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	AFSDNFLWKVMVRB-UHFFFAOYSA-N	5281855.0		AFSDNFLWKVMVRB
BRD-K50699835-001-01-2	ELN-441958	Preclinical	bradykinin receptor antagonist	BDKRB1			0	97.7	MedChemEx	HY-15043	ELN-441958	500.198	Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1	ARYQHSWJGHCGJS-UHFFFAOYSA-N	11848206.0		ARYQHSWJGHCGJS
BRD-K00003369-001-01-9	eltanexor	Preclinical	exportin inhibitor				0	88.82	MedChemEx	HY-100423A	Eltanexor Z-isomer	428.082	NC(=O)C(=C/n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1	JFBAVWVBLRIWHM-MLPAPPSSSA-N	117763569.0		JFBAVWVBLRIWHM
BRD-K30827431-001-01-2	eltanolone	Phase 3	GABA receptor positive allosteric modulator	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2			0	97.4	Tocris	3652	Pregnanolone	318.256	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	AURFZBICLPNKBZ-YZRLXODZSA-N	31402.0		AURFZBICLPNKBZ
BRD-K86171477-001-01-3	eltoprazine	Phase 2	serotonin receptor agonist	HTR1A|HTR1B			0	97.53	MedChemEx	HY-16687	1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine	220.121	C1CN(CCN1)c1cccc2OCCOc12	WVLHGCRWEHCIOT-UHFFFAOYSA-N	65853.0		WVLHGCRWEHCIOT
BRD-K86171477-001-03-9	eltoprazine	Phase 2	serotonin receptor agonist	HTR1A|HTR1B			0	96.77	MedChemEx	HY-16687	Eltoprazine	220.121	C1CN(CCN1)c1cccc2OCCOc12	WVLHGCRWEHCIOT-UHFFFAOYSA-N	65853.0		WVLHGCRWEHCIOT
BRD-K86171477-001-02-1	eltoprazine	Phase 2	serotonin receptor agonist	HTR1A|HTR1B			0	95.95	MedChemEx	HY-16687	Eltoprazine	220.121	C1CN(CCN1)c1cccc2OCCOc12	WVLHGCRWEHCIOT-UHFFFAOYSA-N	65853.0		WVLHGCRWEHCIOT
BRD-K00003572-001-01-9	eltrombopag	Launched	thrombopoietin receptor agonist	MPL	hematology|infectious disease	anemia|hepatitis C|thrombocytopenia	0	98.21	MedChemEx	HY-15306	Eltrombopag	442.164	CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|	XDXWLKQMMKQXPV-QYQHSDTDSA-N			XDXWLKQMMKQXPV
BRD-K39560679-001-01-1	eluxadoline	Launched	opioid receptor agonist|opioid receptor antagonist	OPRD1|OPRK1|OPRM1	gastroenterology	irritable bowel syndrome	0	94.62	MedChemEx	HY-12247	Eluxadoline	569.264	COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O	QFNHIDANIVGXPE-FNZWTVRRSA-N	130406582.0		QFNHIDANIVGXPE
BRD-K54472332-001-03-4	elvitegravir	Launched	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	94.69	Selleck	S2001	Elvitegravir (GS-9137, JTK-303)	447.125	COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C	JUZYLCPPVHEVSV-LJQANCHMSA-N	5277135.0		JUZYLCPPVHEVSV
BRD-K00003516-057-01-9	emamectin	Preclinical	GABA receptor agonist				0	1.78	MedChemEx	HY-B0837	Emamectin (Benzoate)	871.508	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@]([H])(O[C@H]4C[C@H](OC)[C@@]([H])(O[C@H]5C[C@@H](OC)[C@H](NC)[C@@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C(C)C)[C@@H](C)C=C5)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O |c:4,55,t:6,38,62|	DXIOOXFZLKCVHK-HGIWSLISSA-N	118704765.0		DXIOOXFZLKCVHK
BRD-K86727142-001-12-4	embelin	Preclinical	HCV inhibitor|XIAP inhibitor	XIAP			0	94.95	Tocris	2156	Embelin	294.183	CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|	HQWGBIUMYSOPFP-UHFFFAOYSA-N			HQWGBIUMYSOPFP
BRD-K86727142-001-16-9	embelin	Preclinical	HCV inhibitor|XIAP inhibitor	XIAP			0	90.9	Tocris	2156	Embelin	294.183	CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|	HQWGBIUMYSOPFP-UHFFFAOYSA-N			HQWGBIUMYSOPFP
BRD-K86727142-001-11-6	embelin	Preclinical	HCV inhibitor|XIAP inhibitor	XIAP			0	85.26	Selleck	S7025	Embelin	294.183	CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|	HQWGBIUMYSOPFP-UHFFFAOYSA-N			HQWGBIUMYSOPFP
BRD-K86727142-001-13-2	embelin	Preclinical	HCV inhibitor|XIAP inhibitor	XIAP			0	83.65	Selleck	S7025	Embelin	294.183	CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|	HQWGBIUMYSOPFP-UHFFFAOYSA-N			HQWGBIUMYSOPFP
BRD-K97963946-001-01-3	EMD-1214063	Phase 2	hepatocyte growth factor receptor inhibitor	MET			0	95.6	MedChemEx	HY-14721	EMD-1214063	492.227	CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1	AHYMHWXQRWRBKT-UHFFFAOYSA-N	25171648.0		AHYMHWXQRWRBKT
BRD-K97963946-001-02-9	EMD-1214063	Phase 2	hepatocyte growth factor receptor inhibitor	MET			0	92.3	MedChemEx	HY-14721	Tepotinib	492.227	CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1	AHYMHWXQRWRBKT-UHFFFAOYSA-N	25171648.0		AHYMHWXQRWRBKT
BRD-K47659338-003-03-6	EMD-386088	Preclinical	serotonin receptor agonist	HTR6			0	90.04	Tocris	2382	EMD 386088 hydrochloride	246.092	Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|	BPPGPYJBCVXILI-UHFFFAOYSA-N	10131112.0		BPPGPYJBCVXILI
BRD-K47659338-003-02-8	EMD-386088	Preclinical	serotonin receptor agonist	HTR6			0	87.97	Tocris	2382	EMD 386088 hydrochloride	246.092	Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|	BPPGPYJBCVXILI-UHFFFAOYSA-N	10131112.0		BPPGPYJBCVXILI
BRD-K47659338-003-04-9	EMD-386088	Preclinical	serotonin receptor agonist	HTR6			0	95.96	Tocris	2382	EMD 386088 hydrochloride	246.092	Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|	BPPGPYJBCVXILI-UHFFFAOYSA-N	10131112.0		BPPGPYJBCVXILI
BRD-A65248799-001-01-7	EMD-53998	Phase 1	phosphodiesterase inhibitor	TNNC1			0	97.01	EMDBio	530657-10MG	Myosin ATPase Activator, EMD57003	425.141	COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r,t:25|	IZLRMTJLQCLMKF-CYBMUJFWSA-N	446286.0		IZLRMTJLQCLMKF
BRD-K88759641-003-03-6	EMD-66684	Preclinical	angiotensin receptor antagonist	AGTR1			0	99.17	Tocris	1849	EMD 66684	510.249	CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	CQVJTTOZTTVVBK-UHFFFAOYSA-N	9892554.0		CQVJTTOZTTVVBK
BRD-K88759641-003-04-9	EMD-66684	Preclinical	angiotensin receptor antagonist	AGTR1			0	97.67	Tocris	1849	EMD 66684	510.249	CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	CQVJTTOZTTVVBK-UHFFFAOYSA-N	9892554.0		CQVJTTOZTTVVBK
BRD-K88759641-003-02-8	EMD-66684	Preclinical	angiotensin receptor antagonist	AGTR1			0	98.66	Tocris	1849	EMD 66684	510.249	CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	CQVJTTOZTTVVBK-UHFFFAOYSA-N	9892554.0		CQVJTTOZTTVVBK
BRD-K00003185-001-01-9	EMD534085	Preclinical	kinesin inhibitor				0	93.34	MedChemEx	HY-15000	EMD534085	476.24	[H][C@@]12CC[C@H](CNC(=O)NCCN(C)C)O[C@]1([H])c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F	MARIUIDCPUZLKZ-FUKQBSRTSA-N	23634407.0		MARIUIDCPUZLKZ
BRD-K15010214-364-01-9	emedastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	79.37	Prestwick	Prestw-1274	Emedastine	302.211	CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1	KBUZBQVCBVDWKX-UHFFFAOYSA-N	3219.0		KBUZBQVCBVDWKX
BRD-K15010214-364-02-7	emedastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	86.56	TCI	E0936		302.211	CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1	KBUZBQVCBVDWKX-UHFFFAOYSA-N	3219.0		KBUZBQVCBVDWKX
BRD-K00003226-001-01-9	emeramide	Phase 2	antioxidant				0	29.63	MedChemEx	HY-16739	Emeramide	284.065	SCCNC(=O)c1cccc(c1)C(=O)NCCS	JUTBAVRYDAKVGQ-UHFFFAOYSA-N	21133161.0		JUTBAVRYDAKVGQ
BRD-K03067624-312-22-9	emetine	Phase 2	protein synthesis inhibitor	RPS2			0	93.32	MedChemEx	HY-B1479B	Emetine (dihydrochloride hydrate)	480.299	CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12	AUVVAXYIELKVAI-CKBKHPSWSA-N	10219.0		AUVVAXYIELKVAI
BRD-K03067624-001-02-3	emetine	Phase 2	protein synthesis inhibitor	RPS2			0	97.59	Selleck	S4323	Emetine	480.299	CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12	AUVVAXYIELKVAI-CKBKHPSWSA-N	10219.0		AUVVAXYIELKVAI
BRD-K00003206-001-01-9	emiglitate	Preclinical	alpha glucoside inhibitor				0	90.99	MedChemEx	HY-16194	Emiglitate	355.163	CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1	NWWORXYTJRPSMC-QKPAOTATSA-N	72004.0		NWWORXYTJRPSMC
BRD-K00003290-003-01-9	emixustat	Phase 3	retinoid isomerohydrolase inhibitor				0	92.6	MedChemEx	HY-19720A	Emixustat (hydrochloride)	263.189	NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1	WJIGGYYSZBWCGC-MRXNPFEDSA-N	25221720.0		WJIGGYYSZBWCGC
BRD-K00003414-001-01-9	emodepside	Phase 1	nematocide				0	95.47	MedChemEx	HY-101476	Emodepside	1118.652	[H][C@]1(C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C1=O	ZMQMTKVVAMWKNY-CZOLZNPPSA-N	122594832.0		ZMQMTKVVAMWKNY
BRD-K58685305-001-20-4	emodin	Preclinical	11-beta hydroxysteroid dehydrogenase inhibitor	CSNK2A1			0	97.91	Selleck	S2295	Emodin	270.053	Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1	RHMXXJGYXNZAPX-UHFFFAOYSA-N	3220.0		RHMXXJGYXNZAPX
BRD-K90629600-001-01-4	emorfazone	Launched	anti-inflammatory agent|cyclooxygenase inhibitor		dental	mouth inflammation	0	99.42	Sigma	PH011085	4-ethoxy-2-methyl-5-(4-morpholinyl)-3(2H)-pyridazinone	239.127	CCOc1c(cnn(C)c1=O)N1CCOCC1	URJQOOISAKEBKW-UHFFFAOYSA-N	3221.0		URJQOOISAKEBKW
BRD-K28982731-001-01-6	emoxipin	Phase 3					0	95.96	Vitas-M	STK037982		137.084	CCc1nc(C)ccc1O	JPGDYIGSCHWQCC-UHFFFAOYSA-N	114681.0		JPGDYIGSCHWQCC
BRD-K53765467-001-02-1	empagliflozin	Launched	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2	endocrinology	diabetes mellitus	0	96.18	Selleck	S8022	Empagliflozin (BI 10773)	450.145	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1	OBWASQILIWPZMG-QZMOQZSNSA-N	11949646.0		OBWASQILIWPZMG
BRD-K53765467-001-03-9	empagliflozin	Launched	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2	endocrinology	diabetes mellitus	0	96.99	MedChemEx	HY-15409	Empagliflozin	450.145	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1	OBWASQILIWPZMG-QZMOQZSNSA-N	11949646.0		OBWASQILIWPZMG
BRD-K00023644-001-01-9	emricasan	Phase 2	caspase inhibitor	CASP1|CASP3|CASP7			0	89.04	Cayman	22204	Emricasan	569.179	C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F	SCVHJVCATBPIHN-SJCJKPOMSA-N	12000240.0		SCVHJVCATBPIHN
BRD-K61452026-001-04-6	emtricitabine	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	96.41	Selleck	S1704	Emtricitabine	247.043	Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1	XQSPYNMVSIKCOC-NTSWFWBYSA-N	60877.0		XQSPYNMVSIKCOC
BRD-K61452026-001-06-9	emtricitabine	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	95.33	MedChemEx	HY-17427	Emtricitabine	247.043	Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1	XQSPYNMVSIKCOC-NTSWFWBYSA-N	60877.0		XQSPYNMVSIKCOC
BRD-K57545991-050-23-1	enalapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD)	0	94.83	Selleck	S1941	Enalapril Maleate	376.2	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	GBXSMTUPTTWBMN-XIRDDKMYSA-N	5388962.0		GBXSMTUPTTWBMN
BRD-K57545991-050-24-9	enalapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD)	0	83.18	MicroSource	1501214	ENALAPRIL MALEATE	376.2	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	GBXSMTUPTTWBMN-XIRDDKMYSA-N	5388962.0		GBXSMTUPTTWBMN
BRD-K57545991-050-25-9	enalapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure|left ventricular systolic dysfunction (LVSD)	0	84.54	MedChemEx	HY-B0331A	Enalapril (maleate)	376.2	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	GBXSMTUPTTWBMN-XIRDDKMYSA-N	5388962.0		GBXSMTUPTTWBMN
BRD-K99447003-335-03-3	enalaprilat	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	54.33	MicroSource	1503833	ENALAPRILAT	348.169	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	LZFZMUMEGBBDTC-QEJZJMRPSA-N	5462501.0		LZFZMUMEGBBDTC
BRD-K99447003-335-05-8	enalaprilat	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	48.56	MedChemEx	HY-B0231	Enalaprilat (dihydrate)	348.169	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	LZFZMUMEGBBDTC-QEJZJMRPSA-N	5462501.0		LZFZMUMEGBBDTC
BRD-K99447003-335-02-5	enalaprilat	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	18.39	Selleck	S1657	Enalaprilat Dihydrate	348.169	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	LZFZMUMEGBBDTC-QEJZJMRPSA-N	5462501.0		LZFZMUMEGBBDTC
BRD-K99447003-335-06-6	enalaprilat	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	80.9	MedChemEx	HY-B0231	Enalaprilat (dihydrate)	348.169	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	LZFZMUMEGBBDTC-QEJZJMRPSA-N	5462501.0		LZFZMUMEGBBDTC
BRD-K99447003-335-04-1	enalaprilat	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	83.84	Selleck	S1657	Enalaprilat dihydrate	348.169	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	LZFZMUMEGBBDTC-QEJZJMRPSA-N	5462501.0		LZFZMUMEGBBDTC
BRD-K70601687-001-01-3	enasidenib	Launched	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	0	97.57	MedChemEx	HY-18690	Enasidenib	473.14	CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F	DYLUUSLLRIQKOE-UHFFFAOYSA-N	89683805.0		DYLUUSLLRIQKOE
BRD-K66918327-001-01-3	enbucrilate	Launched			dermatology	skin lacerations|tissue adhesive	0	0.0	Ark	AK162172	butyl 2-cyanoacrylate	153.079	CCCCOC(=O)C(=C)C#N	JJJFUHOGVZWXNQ-UHFFFAOYSA-N	23087.0		JJJFUHOGVZWXNQ
BRD-A62197763-001-01-1	enciprazine	Phase 3	GABA receptor modulator	GABRA1			0	97.6	Key	KE-0221	1-[4-(2-methoxyphenyl)-1-piperazinyl]-3-(3,4,5-trimethoxyphenoxy)-2-propanol	432.226	COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13,r|	KSQCNASWXSCJTD-QGZVFWFLSA-N	29919953.0		KSQCNASWXSCJTD
BRD-K00003576-001-01-9	encorafenib	Launched	RAF inhibitor	BRAF	oncology	melanoma	0	97.1	MedChemEx	HY-15605	Encorafenib	539.152	COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C	CMJCXYNUCSMDBY-ZDUSSCGKSA-N	50922675.0		CMJCXYNUCSMDBY
BRD-K61314889-001-06-9	endo-IWR-1	Preclinical	PARP inhibitor	TNKS|TNKS2			0	94.74	Tocris	3532	endo-IWR 1	409.143	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-ALFLXDJESA-N	44483163.0	BRD-M14816435-001-02-7	ZGSXEXBYLJIOGF
BRD-K61314889-001-05-1	endo-IWR-1	Preclinical	PARP inhibitor	TNKS|TNKS2			0	97.95	Tocris	3532	endo-IWR 1	409.143	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-ALFLXDJESA-N	44483163.0	BRD-M14816435-001-01-9	ZGSXEXBYLJIOGF
BRD-K61314889-001-04-4	endo-IWR-1	Preclinical	PARP inhibitor	TNKS|TNKS2			0	97.96	Selleck	S7086	IWR-1-endo	409.143	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-ALFLXDJESA-N	44483163.0	BRD-K27544219-001-01-6	ZGSXEXBYLJIOGF
BRD-K62752296-003-01-3	endoxifen	Phase 2	estrogen receptor antagonist	ESR1			0	47.41	MedChemEx	HY-18719A	Endoxifen (hydrochloride)	373.204	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1	MHJBZVSGOZTKRH-IZHYLOQSSA-N	10090750.0		MHJBZVSGOZTKRH
BRD-K62752296-003-02-1	endoxifen	Phase 2	estrogen receptor antagonist	ESR1			0	52.03	Selleck	S7839	Endoxifen HCl	373.204	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1	MHJBZVSGOZTKRH-IZHYLOQSSA-N	10090750.0	BRD-K91486246-003-01-4	MHJBZVSGOZTKRH
BRD-A51831848-001-02-9	enflurane	Launched	membrane permeability inhibitor	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9	neurology/psychiatry	anesthetic	1	0.0	Sigma	MFCD00069095	2-CHLORO-1,1,2-TRIFLUOROETHYL DIFLUOROMETHYL ETHER	183.971	FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|	JPGQOUSTVILISH-PVQJCKRUSA-N	7059516.0		JPGQOUSTVILISH
BRD-A51831848-001-01-7	enflurane	Launched	membrane permeability inhibitor	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9	neurology/psychiatry	anesthetic	1	0.0	Apollo	PC2040		183.971	FC(F)OC(F)(F)[C@@H](F)Cl |&1:7,r|	JPGQOUSTVILISH-PVQJCKRUSA-N	7059516.0		JPGQOUSTVILISH
BRD-K01825690-001-02-9	enilconazole	Launched	sterol demethylase inhibitor	CYP19A1|CYP1A2|CYP2B6|CYP2C9|CYP2J2|CYP3A4|CYP3A5|NR1I2|PPARA|PTGER2	infectious disease	skin infections	0	87.01	MedChemEx	HY-B1134	Enilconazole (imazalil)	296.048	Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|	PZBPKYOVPCNPJY-CQSZACIVSA-N	6992070.0		PZBPKYOVPCNPJY
BRD-K01825690-065-01-9	enilconazole	Launched	sterol demethylase inhibitor	CYP19A1|CYP1A2|CYP2B6|CYP2C9|CYP2J2|CYP3A4|CYP3A5|NR1I2|PPARA|PTGER2	infectious disease	skin infections	0	98.23	MicroSource	1506067	ENILCONAZOLE SULFATE	394.016	Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|	PZBPKYOVPCNPJY-CQSZACIVSA-N	6992070.0		PZBPKYOVPCNPJY
BRD-K26425819-001-01-3	eniluracil	Phase 3	dihydropyrimidine dehydrogenase inhibitor	AOX1|DPYD|XDH			0	0.0	Sigma	MFCD19160708	5-ethynyl-2,4(1H,3H)-pyrimidinedione	136.027	O=c1[nH]cc(C#C)c(=O)[nH]1	JOZGNYDSEBIJDH-UHFFFAOYSA-N	43157.0		JOZGNYDSEBIJDH
BRD-K00004568-001-01-9	eniporide	Preclinical	sodium/hydrogen antiport inhibitor				0	96.24	Sigma	MFCD08690425	N-[2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzoyl]guanidine	320.094	Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)-n1cccc1	UADMBZFZZOBWBB-UHFFFAOYSA-N	6433092.0		UADMBZFZZOBWBB
BRD-K10029415-005-06-9	enisamium-iodide	Launched					0	96.66	Vitas-M	STL194198		227.118	C[n+]1ccc(cc1)C(=O)NCc1ccccc1	QOEJDHLJOKRPJG-UHFFFAOYSA-O	2132298.0		QOEJDHLJOKRPJG
BRD-K10029415-005-07-9	enisamium-iodide	Launched					0		Broad Institute	Enisamium	Enisamium	227.118	C[n+]1ccc(cc1)C(=O)NCc1ccccc1	QOEJDHLJOKRPJG-UHFFFAOYSA-O	2132298.0		QOEJDHLJOKRPJG
BRD-K68488863-001-04-9	ENMD-2076	Phase 2	Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor	AURKA|FLT3|KDR|PDGFRA|PTK2|SRC			0	96.02	Selleck	S1181	ENMD-2076	375.217	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1	BLQYVHBZHAISJM-CMDGGOBGSA-N	16041424.0		BLQYVHBZHAISJM
BRD-K32007074-001-02-9	enocitabine	Launched	DNA synthesis inhibitor	CMPK1|RRM1|TYMS	hematologic malignancy	acute myeloid leukemia (AML)	0	7.01	AKSci	67699		565.409	CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	SAMRUMKYXPVKPA-VFKOLLTISA-N	71734.0	BRD-A77582494-001-01-3	SAMRUMKYXPVKPA
BRD-K32007074-001-01-1	enocitabine	Launched	DNA synthesis inhibitor	CMPK1|RRM1|TYMS	hematologic malignancy	acute myeloid leukemia (AML)	0	97.2	Carbosynth	ENOCITABINE	N-(1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)docosanamide	565.409	CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	SAMRUMKYXPVKPA-VFKOLLTISA-N	71734.0		SAMRUMKYXPVKPA
BRD-K78113049-002-20-9	enoxacin	Launched	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections|gonorrhea	0	86.42	MedChemEx	HY-B0268A	Enoxacin (hydrate)	320.128	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	IDYZIJYBMGIQMJ-UHFFFAOYSA-N	3229.0		IDYZIJYBMGIQMJ
BRD-K78113049-001-16-2	enoxacin	Launched	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections|gonorrhea	0	89.69	MicroSource	1503215	ENOXACIN	320.128	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	IDYZIJYBMGIQMJ-UHFFFAOYSA-N	3229.0		IDYZIJYBMGIQMJ
BRD-K78113049-001-15-4	enoxacin	Launched	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections|gonorrhea	0	0.0	Selleck	S1756	Enoxacin	320.128	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	IDYZIJYBMGIQMJ-UHFFFAOYSA-N	3229.0		IDYZIJYBMGIQMJ
BRD-K78113049-001-17-0	enoxacin	Launched	topoisomerase inhibitor	TOP2A	infectious disease	urinary tract infections|gonorrhea	0	0.0	Selleck	S1756	Enoxacin (Penetrex)	320.128	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	IDYZIJYBMGIQMJ-UHFFFAOYSA-N	3229.0		IDYZIJYBMGIQMJ
BRD-K21152241-001-07-3	enoximone	Launched	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	0	92.01	Sigma	MFCD00867130	4-methyl-5-[4-(methylsulfanyl)benzoyl]-1,3-dihydro-2H-imidazol-2-one	248.062	CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C	ZJKNESGOIKRXQY-UHFFFAOYSA-N	53708.0		ZJKNESGOIKRXQY
BRD-K21152241-001-09-9	enoximone	Launched	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	0		Tocris	1693	enoximone	248.062	CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C	ZJKNESGOIKRXQY-UHFFFAOYSA-N	53708.0		ZJKNESGOIKRXQY
BRD-K96137854-001-18-9	enoxolone	Launched	gap junction modulator	HSD11B1	gastroenterology|otolaryngology	peptic ulcer disease (PUD)|common cold	0	86.83	MicroSource	1500990	ENOXOLONE	470.34	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|	MPDGHEJMBKOTSU-YKLVYJNSSA-N	10114.0	BRD-A20200672-001-05-5	MPDGHEJMBKOTSU
BRD-K96137854-001-20-9	enoxolone	Launched	gap junction modulator	HSD11B1	gastroenterology|otolaryngology	peptic ulcer disease (PUD)|common cold	0	82.56	MedChemEx	HY-N0180	18?-Glycyrrhetinic acid	470.34	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|	MPDGHEJMBKOTSU-YKLVYJNSSA-N	10114.0		MPDGHEJMBKOTSU
BRD-K96137854-001-17-1	enoxolone	Launched	gap junction modulator	HSD11B1	gastroenterology|otolaryngology	peptic ulcer disease (PUD)|common cold	0	99.76	Selleck	S2296	Enoxolone	470.34	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|	MPDGHEJMBKOTSU-YKLVYJNSSA-N	10114.0	BRD-K80535353-001-01-4	MPDGHEJMBKOTSU
BRD-K35007173-001-07-5	enprofylline	Phase 3	phosphodiesterase inhibitor	ADORA1|ADORA2A|ADORA2B|ADORA3|PDE4A|PDE4B			0	98.71	Enzo	AC635	3-N-Propylxanthine	194.08	CCCn1c2nc[nH]c2c(=O)[nH]c1=O	SIQPXVQCUCHWDI-UHFFFAOYSA-N	1676.0		SIQPXVQCUCHWDI
BRD-K35007173-001-08-9	enprofylline	Phase 3	phosphodiesterase inhibitor	ADORA1|ADORA2A|ADORA2B|ADORA3|PDE4A|PDE4B			0	97.2	Sigma	MFCD00043205	3-Propylxanthine	194.08	CCCn1c2nc[nH]c2c(=O)[nH]c1=O	SIQPXVQCUCHWDI-UHFFFAOYSA-N	1676.0		SIQPXVQCUCHWDI
BRD-K76534306-001-22-7	enrofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	96.46	MicroSource	1503721	ENROFLOXACIN	359.165	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	SPFYMRJSYKOXGV-UHFFFAOYSA-N	71188.0		SPFYMRJSYKOXGV
BRD-K76534306-001-25-9	enrofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	94.19	MedChemEx	HY-B0502	Enrofloxacin	359.165	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	SPFYMRJSYKOXGV-UHFFFAOYSA-N	71188.0		SPFYMRJSYKOXGV
BRD-K76534306-001-21-9	enrofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	95.96	Selleck	S3059	Enrofloxacin	359.165	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	SPFYMRJSYKOXGV-UHFFFAOYSA-N	71188.0		SPFYMRJSYKOXGV
BRD-K83636919-001-07-9	entacapone	Launched	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	0	94.8	Tocris	4720	Entacapone	305.101	CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N	JRURYQJSLYLRLN-BJMVGYQFSA-N	5281081.0		JRURYQJSLYLRLN
BRD-K83636919-001-04-8	entacapone	Launched	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	0	84.39	MicroSource	1502381	ENTACAPONE	305.101	CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N	JRURYQJSLYLRLN-BJMVGYQFSA-N	5281081.0		JRURYQJSLYLRLN
BRD-K83636919-001-05-5	entacapone	Launched	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	0	97.02	Selleck	S3147	Entacapone	305.101	CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N	JRURYQJSLYLRLN-BJMVGYQFSA-N	5281081.0		JRURYQJSLYLRLN
BRD-K83636919-001-03-0	entacapone	Launched	catechol O methyltransferase inhibitor	COMT	neurology/psychiatry	Parkinson's Disease	0	81.21	Selleck	S3147	Entacapone	305.101	CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N	JRURYQJSLYLRLN-BJMVGYQFSA-N	5281081.0		JRURYQJSLYLRLN
BRD-K00004610-001-01-9	entasobulin	Preclinical	tubulin polymerization inhibitor				0	97.5	MedChemEx	HY-16777	Entasobulin	439.109	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccc4ncccc4c3)c3ccccc23)cc1	LJIUXAHLYIPHOK-UHFFFAOYSA-N	10203597.0		LJIUXAHLYIPHOK
BRD-K08206212-002-01-0	entecavir	Launched	DNA replication inhibitor|nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	0	99.22	Selleck	S1252	Entecavir Hydrate	277.117	Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1	QDGZDCVAUDNJFG-FXQIFTODSA-N	135398508.0		QDGZDCVAUDNJFG
BRD-K77908580-001-10-4	entinostat	Phase 3	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC9			0	91.5	Selleck	S1053	Entinostat (MS-275, SNDX-275)	376.154	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	INVTYAOGFAGBOE-UHFFFAOYSA-N	4261.0		INVTYAOGFAGBOE
BRD-K77908580-001-15-9	entinostat	Phase 3	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC9			0	94.13	MedChemEx	HY-12163	Entinostat	376.154	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	INVTYAOGFAGBOE-UHFFFAOYSA-N	4261.0		INVTYAOGFAGBOE
BRD-K77908580-001-09-6	entinostat	Phase 3	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC9			0	94.4	Selleck	S1053	Entinostat (MS-275)	376.154	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	INVTYAOGFAGBOE-UHFFFAOYSA-N	4261.0		INVTYAOGFAGBOE
BRD-K39009484-001-01-4	entrectinib	Launched	ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor	ALK|NTRK1|NTRK2|NTRK3|ROS1	oncology	non-small cell lung cancer (NSCLC)	0	87.23	Selleck	S7998	Entrectinib (RXDX-101)	560.271	CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1	HAYYBYPASCDWEQ-UHFFFAOYSA-N	25141092.0		HAYYBYPASCDWEQ
BRD-K56851771-001-06-8	enzalutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	95.96	Selleck	S1250	Enzalutamide (MDV3100)	464.093	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	WXCXUHSOUPDCQV-UHFFFAOYSA-N	15951529.0		WXCXUHSOUPDCQV
BRD-K79404599-001-15-9	enzastaurin	Phase 3	PKC inhibitor	AKT1|GSK3B|PRKCA|PRKCB|PRKCD|PRKCG			0	98.11	Tocris	5994	Enzastaurin	515.232	Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|	AXRCEOKUDYDWLF-UHFFFAOYSA-N	176167.0		AXRCEOKUDYDWLF
BRD-K79404599-001-09-3	enzastaurin	Phase 3	PKC inhibitor	AKT1|GSK3B|PRKCA|PRKCB|PRKCD|PRKCG			0	96.53	Selleck	S1055	Enzastaurin (LY317615)	515.232	Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|	AXRCEOKUDYDWLF-UHFFFAOYSA-N	176167.0		AXRCEOKUDYDWLF
BRD-K86063171-001-03-7	EN460	Preclinical	endoplasmic reticulum oxidation inhibitor	ERO1A			0	10.46	MedChemEx	HY-12837	EN460	460.044	OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|	RSLFQCNAOMQAIH-WJDWOHSUSA-N	1016023.0		RSLFQCNAOMQAIH
BRD-K86063171-001-02-9	EN460	Preclinical	endoplasmic reticulum oxidation inhibitor	ERO1A			0	49.85	MedChemEx	HY-12837	EN460	460.044	OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|	RSLFQCNAOMQAIH-WJDWOHSUSA-N	1016023.0		RSLFQCNAOMQAIH
BRD-K42452249-001-02-5	EO-1428	Preclinical	p38 MAPK inhibitor	MAPK11|MAPK14			0	96.45	Tocris	2908	EO 1428	414.013	Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	HDCLCHNAEZNGNV-UHFFFAOYSA-N	9801969.0		HDCLCHNAEZNGNV
BRD-K42452249-001-03-3	EO-1428	Preclinical	p38 MAPK inhibitor	MAPK11|MAPK14			0	83.51	Tocris	2908	EO 1428	414.013	Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	HDCLCHNAEZNGNV-UHFFFAOYSA-N	9801969.0		HDCLCHNAEZNGNV
BRD-K42452249-001-04-9	EO-1428	Preclinical	p38 MAPK inhibitor	MAPK11|MAPK14			0	97.01	Tocris	2908	EO 1428	414.013	Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	HDCLCHNAEZNGNV-UHFFFAOYSA-N	9801969.0		HDCLCHNAEZNGNV
BRD-K79450420-001-03-4	epacadostat	Phase 3	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	96.85	MedChemEx	HY-15689		436.992	NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1	FBKMWOJEPMPVTQ-UHFFFAOYSA-N	135564890.0	BRD-A15458132-001-01-9	FBKMWOJEPMPVTQ
BRD-K79450420-001-01-8	epacadostat	Phase 3	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	97.16	MedChemEx	HY-15689	INCB 024360	436.992	NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1	FBKMWOJEPMPVTQ-UHFFFAOYSA-N	135564890.0		FBKMWOJEPMPVTQ
BRD-K79450420-001-02-6	epacadostat	Phase 3	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	97.41	Selleck	S7910	Epacadostat (INCB024360)	436.992	NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1	FBKMWOJEPMPVTQ-UHFFFAOYSA-N	135564890.0	BRD-K67385813-001-01-5	FBKMWOJEPMPVTQ
BRD-K98054437-001-11-5	epalrestat	Launched	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	0	51.13	MedChemEx	HY-66009	Epalrestat	319.034	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	CHNUOJQWGUIOLD-NFZZJPOKSA-N	1549120.0		CHNUOJQWGUIOLD
BRD-K98054437-001-12-3	epalrestat	Launched	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	0	70.05	MedChemEx	HY-66009	Epalrestat	319.034	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	CHNUOJQWGUIOLD-NFZZJPOKSA-N	1549120.0		CHNUOJQWGUIOLD
BRD-K98054437-001-09-9	epalrestat	Launched	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	0	81.25	Selleck	S2035	Epalrestat	319.034	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	CHNUOJQWGUIOLD-NFZZJPOKSA-N	1549120.0		CHNUOJQWGUIOLD
BRD-K98054437-001-08-1	epalrestat	Launched	aldose reductase inhibitor	AKR1B1	nephrology	diabetic nephropathy	0	59.65	Selleck	S2035	Epalrestat	319.034	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	CHNUOJQWGUIOLD-NFZZJPOKSA-N	1549120.0		CHNUOJQWGUIOLD
BRD-K47554101-001-02-9	eperezolid	Phase 1	bacterial 30S ribosomal subunit inhibitor				0	90.25	MedChemEx	HY-10393	Eperezolid	394.165	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	SIMWTRCFFSTNMG-AWEZNQCLSA-N	73214.0		SIMWTRCFFSTNMG
BRD-K47554101-001-01-2	eperezolid	Phase 1	bacterial 30S ribosomal subunit inhibitor				0	91.48	MedChemEx	HY-10393	Eperezolid	394.165	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	SIMWTRCFFSTNMG-AWEZNQCLSA-N	73214.0		SIMWTRCFFSTNMG
BRD-K01825729-003-01-9	eperisone	Launched	acetylcholine receptor antagonist	CYP2J2	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)|spasms|head injury|spinal injury	0	99.0	CombiBlocks	OR-1313		295.17	CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|	SQUNAWUMZGQQJD-AWEZNQCLSA-N	37888265.0		SQUNAWUMZGQQJD
BRD-K00003130-003-01-9	epetraborole	Preclinical	leucyl-tRNA synthetase inhibitor				0	94.68	MedChemEx	HY-12479A	Epetraborole (hydrochloride)	237.117	NC[C@H]1OB(O)c2c1cccc2OCCCO	FXQIIDINBDJDKL-SNVBAGLBSA-N	46836890.0		FXQIIDINBDJDKL
BRD-K45014108-003-01-8	ephedrine	Launched	adrenergic receptor agonist	ACHE|ADRA1A|ADRB2|SLC18A2|SLC6A2	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity	0	97.68	MicroSource	1500273	EPHEDRINE (1R,2S) HYDROCHLORIDE	165.115	CN[C@@H](C)[C@H](O)c1ccccc1	KWGRBVOPPLSCSI-WPRPVWTQSA-N	9294.0		KWGRBVOPPLSCSI
BRD-A54236247-003-04-3	ephedrine-(racemic)	Launched	adrenergic receptor agonist	ADRA1A|ADRA2A|ADRB1|ADRB2|ATF1|ATF2|ATF3|ATF4|ATF5|ATF6|ATF7|FOS|IL2|JDP2|JUN|NFATC1|SLC6A2|SLC6A3|SLC6A4|TNF	cardiology|pulmonary|neurology/psychiatry|endocrinology	hypotension|asthma|narcolepsy|obesity	0	97.69	MicroSource	1500525	RACEPHEDRINE HYDROCHLORIDE	165.115	CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2,&2:4|	KWGRBVOPPLSCSI-WCBMZHEXSA-N	7028.0		KWGRBVOPPLSCSI
BRD-K03972660-001-12-9	epiandrosterone	Preclinical	steroid	G6PD			0	100.0	MedChemEx	HY-I0352	Epiandrosterone	290.225	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	QGXBDMJGAMFCBF-LUJOEAJASA-N	441302.0		QGXBDMJGAMFCBF
BRD-K50660797-001-04-4	epicatechin-gallate-(-)	Phase 2	bacterial DNA gyrase inhibitor	BACE1|FASN			0	0.0	AnalytiCon	NP-002326		442.09	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	LSHVYAFMTMFKBA-TZIWHRDSSA-N	107905.0		LSHVYAFMTMFKBA
BRD-K50660797-001-05-1	epicatechin-gallate-(-)	Phase 2	bacterial DNA gyrase inhibitor	BACE1|FASN			0	96.2	MedChemEx	HY-N0002	(-)-Epicatechin gallate	442.09	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	LSHVYAFMTMFKBA-TZIWHRDSSA-N	107905.0		LSHVYAFMTMFKBA
BRD-K00005352-001-01-9	epiestriol	Preclinical					0	91.12	Toronto	e586500	16-epiestriol	288.173	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZMSHIADSSA-N	68929.0		PROQIPRRNZUXQM
BRD-K27529556-001-04-9	epigallocatechin-(-)	Phase 2					0	91.93	MedChemEx	HY-N0225	(-)-Epigallocatechin	306.074	O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1	XMOCLSLCDHWDHP-IUODEOHRSA-N	72277.0		XMOCLSLCDHWDHP
BRD-K55591206-001-20-7	epigallocatechin-gallate-(-)	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	ELANE|EP300|FASN|KAT2B|MMP14|MMP2			0	81.58	MedChemEx	HY-13653	(-)-Epigallocatechin Gallate	458.085	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	WMBWREPUVVBILR-WIYYLYMNSA-N	65064.0		WMBWREPUVVBILR
BRD-K55591206-001-22-3	epigallocatechin-gallate-(-)	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	ELANE|EP300|FASN|KAT2B|MMP14|MMP2			0	70.62	MedChemEx	HY-13653	(-)-Epigallocatechin Gallate	458.085	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	WMBWREPUVVBILR-WIYYLYMNSA-N	65064.0		WMBWREPUVVBILR
BRD-K55591206-001-19-9	epigallocatechin-gallate-(-)	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	ELANE|EP300|FASN|KAT2B|MMP14|MMP2			0	63.3	Selleck	S2250	(-)-Epigallocatechin gallate	458.085	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	WMBWREPUVVBILR-WIYYLYMNSA-N	65064.0		WMBWREPUVVBILR
BRD-K55591206-001-18-1	epigallocatechin-gallate-(-)	Phase 2/Phase 3	bacterial DNA gyrase inhibitor	ELANE|EP300|FASN|KAT2B|MMP14|MMP2			0	64.77	Selleck	S2250	(-)-Epigallocatechin Gallate	458.085	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	WMBWREPUVVBILR-WIYYLYMNSA-N	65064.0		WMBWREPUVVBILR
BRD-A98990573-003-01-3	epinastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	95.95	Selleck	S4253	Epinastine HCl	249.127	NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|	WHWZLSFABNNENI-OAHLLOKOSA-N	15629776.0		WHWZLSFABNNENI
BRD-A98990573-001-02-9	epinastine	Launched	histamine receptor antagonist	HRH1	ophthalmology	conjunctivitis	0	98.59	MedChemEx	HY-B0640	Epinastine	249.127	NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4,t:1|	WHWZLSFABNNENI-OAHLLOKOSA-N	15629776.0		WHWZLSFABNNENI
BRD-K63126190-001-04-4	epinephrine	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma	0	0.0	MicroSource	1500274	EPINEPHRINE BITARTRATE	183.09	CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N	5816.0		UCTWMZQNUQWSLP
BRD-K63126190-046-03-1	epinephrine	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma	0	98.6	Selleck	S2521	Epinephrine bitartrate (Adrenalinium)	183.09	CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N	5816.0		UCTWMZQNUQWSLP
BRD-K63126190-001-05-1	epinephrine	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma	0	0.0	Selleck	S2522	L-Adrenaline (Epinephrine)	183.09	CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N	5816.0		UCTWMZQNUQWSLP
BRD-K63126190-046-02-3	epinephrine	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma	0	0.0	Selleck	S2521	Epinephrine Bitartrate	183.09	CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N	5816.0		UCTWMZQNUQWSLP
BRD-K63126190-001-03-6	epinephrine	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma	0	0.0	Selleck	S2522	L-Adrenaline	183.09	CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N	5816.0		UCTWMZQNUQWSLP
BRD-K63126190-003-01-6	epinephrine	Launched	adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF	cardiology|allergy|pulmonary	cardiac arrest|anaphylactic shock|asthma	0	100.0	Selleck	S3061	Epinephrine HCl	183.09	CNC[C@H](O)c1ccc(O)c(O)c1	UCTWMZQNUQWSLP-VIFPVBQESA-N	5816.0		UCTWMZQNUQWSLP
BRD-K39339537-001-22-9	epirizole	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	85.98	Labotest	LT00772143	4-methoxy-2-(5-methoxy-3-methyl-1H-pyrazol-1-yl)-6-methylpyrimidine	234.112	COc1cc(C)nn1-c1nc(C)cc(OC)n1	RHAXSHUQNIEUEY-UHFFFAOYSA-N	3242.0		RHAXSHUQNIEUEY
BRD-K39339537-001-21-0	epirizole	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	98.14	Prestwick	Prestw-32	Epirizole	234.112	COc1cc(C)nn1-c1nc(C)cc(OC)n1	RHAXSHUQNIEUEY-UHFFFAOYSA-N	3242.0		RHAXSHUQNIEUEY
BRD-K04548931-003-13-2	epirubicin	Launched	topoisomerase inhibitor	CHD1|TOP2A	oncology	breast cancer	0	23.34	MicroSource	1505708	EPIRUBICIN HYDROCHLORIDE	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-VTZDEGQISA-N	41867.0		AOJJSUZBOXZQNB
BRD-K04548931-003-16-5	epirubicin	Launched	topoisomerase inhibitor	CHD1|TOP2A	oncology	breast cancer	0	90.55	Selleck	S1223	Epirubicin HCl	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	AOJJSUZBOXZQNB-VTZDEGQISA-N	41867.0	BRD-K56844688-003-01-2	AOJJSUZBOXZQNB
BRD-K04548931-003-08-2	epirubicin	Launched	topoisomerase inhibitor	CHD1|TOP2A	oncology	breast cancer	0		Selleck	S1223	Epirubicin Hydrocholoride (Ellence)	543.174	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1	41867.0		AOJJSUZBOXZQNB
BRD-K02314383-001-01-3	epitiostanol	Launched	androgen receptor agonist	AR	oncology	breast cancer	0	90.16	Prestwick	Prestw-1006	Epitiostanol	306.202	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O	OBMLHUPNRURLOK-XGRAFVIBSA-N	443935.0		OBMLHUPNRURLOK
BRD-K19761926-001-03-6	eplerenone	Launched	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure|hypertension	0	99.75	Selleck	S1707	Eplerenone	414.204	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|	JUKPWJGBANNWMW-VWBFHTRKSA-N	443872.0		JUKPWJGBANNWMW
BRD-K19761926-001-02-8	eplerenone	Launched	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure|hypertension	0	95.59	Tocris	2397	Eplerenone	414.204	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|	JUKPWJGBANNWMW-VWBFHTRKSA-N	443872.0		JUKPWJGBANNWMW
BRD-K19761926-001-07-9	eplerenone	Launched	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure|hypertension	0	84.17	Tocris	2397	Eplerenone	414.204	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|	JUKPWJGBANNWMW-VWBFHTRKSA-N	443872.0		JUKPWJGBANNWMW
BRD-K19761926-001-04-4	eplerenone	Launched	cytochrome P450 inhibitor	NR3C2	cardiology	congestive heart failure|hypertension	0	86.27	Selleck	S1707	Eplerenone	414.204	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|	JUKPWJGBANNWMW-VWBFHTRKSA-N	443872.0	BRD-K82139003-001-01-7	JUKPWJGBANNWMW
BRD-A59329714-001-01-5	epomediol	Launched	cholesterol inhibitor	CYP7A1	neurology/psychiatry	itching	0	0.0	TimTec	ST50983621	1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane-6,7-diol	186.126	CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11,&2:9,&3:6,r,THB:12:11:1.3:8.6,7:6:1.3:11.10|	JSNQSLSBBZFGBM-XAKJDZQGSA-N			JSNQSLSBBZFGBM
BRD-K64054020-001-03-5	epoprostenol	Launched	prostacyclin analog	P2RY12|PTGER1|PTGER4|PTGIR|PTGIS	cardiology	hypertension	0	36.41	Enzo	PG011	Prostaglandin I2 Na	352.225	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	KAQKFAOMNZTLHT-OZUDYXHBSA-N	5282411.0		KAQKFAOMNZTLHT
BRD-K64054020-236-01-1	epoprostenol	Launched	prostacyclin analog	P2RY12|PTGER1|PTGER4|PTGIR|PTGIS	cardiology	hypertension	0		Biomol	PG011-0001	PG1-prostacyclin	352.225	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1	5282411.0		KAQKFAOMNZTLHT
BRD-K71823332-001-03-7	epothilone-A	Preclinical	microtubule stabilizing agent				0	97.44	Selleck	S1297	Epothilone A	493.25	C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	HESCAJZNRMSMJG-QJCAGBKWSA-N	45489244.0	BRD-K87031376-001-01-0	HESCAJZNRMSMJG
BRD-K48935217-001-03-9	epothilone-B	Phase 3	microtubule stabilizing agent|tubulin polymerization inhibitor	TUBB			0	95.52	MedChemEx	HY-17029	Epothilone B	507.265	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	QXRSDHAAWVKZLJ-QBNZTRRJSA-N	118184795.0		QXRSDHAAWVKZLJ
BRD-K52762805-001-01-2	epothilone-D	Phase 2	microtubule stabilizing agent|tubulin polymerization inhibitor	TUBB			0	97.71	MedChemEx	HY-15278	Epothilone D	491.271	C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|	XOZIUKBZLSUILX-HFHFCCBWSA-N			XOZIUKBZLSUILX
BRD-K52762805-001-02-9	epothilone-D	Phase 2	microtubule stabilizing agent|tubulin polymerization inhibitor	TUBB			0	95.25	MedChemEx	HY-15278	Epothilone D	491.271	C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|	XOZIUKBZLSUILX-HFHFCCBWSA-N			XOZIUKBZLSUILX
BRD-K42536037-001-02-9	EPPTB	Preclinical	trace amine associated receptor antagonist	TAAR1			0	97.76	Tocris	4518	EPPTB	378.156	CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1	KLFVWQCQUXXLOU-UHFFFAOYSA-N	25175634.0		KLFVWQCQUXXLOU
BRD-K42536037-001-01-3	EPPTB	Preclinical	trace amine associated receptor antagonist	TAAR1			0	95.64	Tocris	4518	EPPTB	378.156	CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1	KLFVWQCQUXXLOU-UHFFFAOYSA-N	25175634.0		KLFVWQCQUXXLOU
BRD-A72212290-300-01-4	eprazinone	Launched	mucolytic agent		pulmonary	bronchospasm	0	86.92	Selleck	S4137	Eprazinone 2HCl	380.246	CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|	BSHWLCACYCVCJE-OFNKIYASSA-N	29962149.0		BSHWLCACYCVCJE
BRD-A72212290-300-03-0	eprazinone	Launched	mucolytic agent		pulmonary	bronchospasm	0	93.13	Selleck	S4137	Eprazinone 2HCl	380.246	CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|	BSHWLCACYCVCJE-OFNKIYASSA-N	29962149.0		BSHWLCACYCVCJE
BRD-A72212290-300-02-2	eprazinone	Launched	mucolytic agent		pulmonary	bronchospasm	0	94.62	Selleck	S4137	Eprazinone 2HCl	380.246	CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10,&1:3|	BSHWLCACYCVCJE-OFNKIYASSA-N	29962149.0		BSHWLCACYCVCJE
BRD-K00003555-001-01-9	eprinomectin	Launched	benzodiazepine receptor agonist		infectious disease	gastrointestinal roundworms|lungworms	0	66.82	MedChemEx	HY-12643	Eprinomectin	913.519	[H][C@@]12OC\C3=C/C=C/[C@]([H])(C)[C@]([H])(O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(O4)O[C@]([H])([C@@H](C)CC)[C@@]([H])(C)C=C5)OC(=O)[C@]([H])(C=C(C)[C@@]1([H])O)[C@@]23O |c:4,64,t:6,42,72|	ZKWQQXZUCOBISE-NQMKODOQSA-N	86289908.0		ZKWQQXZUCOBISE
BRD-K00003478-001-01-9	epristeride	Preclinical	5 alpha reductase inhibitor				0	79.7	MedChemEx	HY-107385	Epristeride	399.277	[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C=C(CC[C@]12C)C(O)=O |c:25,t:23|	VAPSMQAHNAZRKC-PQWRYPMOSA-N	68741.0		VAPSMQAHNAZRKC
BRD-K17979676-001-02-9	eprobemide	Launched	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	0	95.29	MedChemEx	HY-B1413	Eprobemide	282.114	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	YYFGRAGNYHYWEZ-UHFFFAOYSA-N	65659.0		YYFGRAGNYHYWEZ
BRD-K17979676-001-01-2	eprobemide	Launched	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	0	96.11	MicroSource	1503886	EPROBEMIDE	282.114	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	YYFGRAGNYHYWEZ-UHFFFAOYSA-N	65659.0		YYFGRAGNYHYWEZ
BRD-K11463116-304-01-9	eprodisate	Phase 3	amyloid protein inhibitor|antiamyloidogenic agent	SAA1			0	24.9	MicroSource	1506180	EPRODISATE DISODIUM	203.976	OS(=O)(=O)CCCS(O)(=O)=O	MGNVWUDMMXZUDI-UHFFFAOYSA-N	428573.0		MGNVWUDMMXZUDI
BRD-K11463116-304-02-7	eprodisate	Phase 3	amyloid protein inhibitor|antiamyloidogenic agent	SAA1			0	90.1	Sigma	MFCD00191483	disodium 1,3-propanedisulfonate	203.976	OS(=O)(=O)CCCS(O)(=O)=O	MGNVWUDMMXZUDI-UHFFFAOYSA-N	428573.0		MGNVWUDMMXZUDI
BRD-K11463116-304-03-5	eprodisate	Phase 3	amyloid protein inhibitor|antiamyloidogenic agent	SAA1			0	95.43	MedChemEx	HY-B1141	Eprodisate (disodium)	203.976	OS(=O)(=O)CCCS(O)(=O)=O	MGNVWUDMMXZUDI-UHFFFAOYSA-N	428573.0		MGNVWUDMMXZUDI
BRD-K67977190-066-02-3	eprosartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	92.89	Selleck	S4102	Eprosartan Mesylate	424.146	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	OROAFUQRIXKEMV-LDADJPATSA-N	5281037.0		OROAFUQRIXKEMV
BRD-K67977190-066-03-1	eprosartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	99.15	Selleck	S4102	Eprosartan Mesylate	424.146	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	OROAFUQRIXKEMV-LDADJPATSA-N	5281037.0		OROAFUQRIXKEMV
BRD-K68830460-015-01-5	eptifibatide	Launched	platelet aggregation inhibitor	ITGA2B|ITGB3	cardiology	acute coronary syndrome (ACS)|percutaneous coronary intervention (PCI)	0	96.92	Selleck	P1011	Eptifibatide(Integrilin)	831.316	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	CZKPOZZJODAYPZ-IQENKEMDSA-N	134812820.0		CZKPOZZJODAYPZ
BRD-K26531771-001-01-4	EPZ-5676	Phase 1	histone lysine methyltransferase inhibitor	DOT1L			0	93.17	Selleck	S7062	EPZ5676	562.338	CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1	LXFOLMYKSYSZQS-LURJZOHASA-N			LXFOLMYKSYSZQS
BRD-K26531771-001-03-9	EPZ-5676	Phase 1	histone lysine methyltransferase inhibitor	DOT1L			0	91.6	MedChemEx	HY-15593	Pinometostat	562.338	CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1	LXFOLMYKSYSZQS-LURJZOHASA-N			LXFOLMYKSYSZQS
BRD-K26531771-001-02-2	EPZ-5676	Phase 1	histone lysine methyltransferase inhibitor	DOT1L			0	95.25	Selleck	S7062	EPZ-5676	562.338	CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1	LXFOLMYKSYSZQS-LURJZOHASA-N		BRD-K63457253-001-01-3	LXFOLMYKSYSZQS
BRD-K69070623-003-01-7	EPZ004777	Preclinical	histone lysine methyltransferase inhibitor	DOT1L			0	94.61	Selleck	S7032	EPZ004777 HCl	539.322	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	WXRGFPHDRFQODR-ICLZECGLSA-N	56962336.0		WXRGFPHDRFQODR
BRD-K69070623-001-01-1	EPZ004777	Preclinical	histone lysine methyltransferase inhibitor	DOT1L			0	92.62	Selleck	S7353	EPZ004777	539.322	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	WXRGFPHDRFQODR-ICLZECGLSA-N	56962336.0		WXRGFPHDRFQODR
BRD-K69070623-001-02-9	EPZ004777	Preclinical	histone lysine methyltransferase inhibitor	DOT1L			0	90.2	Selleck	S7353	EPZ004777	539.322	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	WXRGFPHDRFQODR-ICLZECGLSA-N	56962336.0		WXRGFPHDRFQODR
BRD-K57754230-001-02-7	EPZ005687	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	95.53	Selleck	S7004	EPZ005687	539.29	Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1	ZOIBZSZLMJDVDQ-UHFFFAOYSA-N	60160561.0		ZOIBZSZLMJDVDQ
BRD-K87468701-001-01-0	EPZ011989	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	95.82	MedChemEx	HY-16986	EPZ011989	605.394	CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|	XQFINGFCBFHOPE-WXUXXXNLSA-N			XQFINGFCBFHOPE
BRD-K70446295-001-01-7	EPZ015666	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT5			0	95.64	MedChemEx	HY-12727	EPZ015666	383.196	O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1	ZKXZLIFRWWKZRY-KRWDZBQOSA-N	90241673.0		ZKXZLIFRWWKZRY
BRD-K33586289-003-02-8	EPZ020411	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT6			0	90.26	MedChemEx	HY-12970A	EPZ020411 (hydrochloride)	442.294	CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|	QMDKVNSQXPVCRD-RQNOJGIXSA-N			QMDKVNSQXPVCRD
BRD-K33586289-003-01-0	EPZ020411	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT6			0	86.88	MedChemEx	HY-12970A	EPZ020411 (hydrochloride)	442.294	CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|	QMDKVNSQXPVCRD-RQNOJGIXSA-N			QMDKVNSQXPVCRD
BRD-A88080608-001-04-2	equilin	Preclinical	estrogen receptor agonist	HSD17B1			0	86.71	MicroSource	1500275	EQUILIN	268.146	C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1,&2:4,&3:15,r,c:5|	WKRLQDKEXYKHJB-UWWQBHOKSA-N	41097932.0		WKRLQDKEXYKHJB
BRD-K54847683-001-04-0	equol	Launched	estrogen receptor agonist	ESR1|ESR2			0	94.86	Selleck	S2450	Equol	242.094	Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	ADFCQWZHKCXPAJ-GFCCVEGCSA-N	91469.0		ADFCQWZHKCXPAJ
BRD-K54847683-001-03-2	equol	Launched	estrogen receptor agonist	ESR1|ESR2			0	89.34	Selleck	S2450	Equol	242.094	Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	ADFCQWZHKCXPAJ-GFCCVEGCSA-N	91469.0		ADFCQWZHKCXPAJ
BRD-K11927976-050-04-5	ER-27319	Preclinical	mediator release inhibitor|SYK inhibitor	SYK			0	100.0	Tocris	2471	(2Z)-2-butenedioic acid compound with 10-(3-aminopropyl)-3,4-dimethyl-9(10H)-acridinone (1:1)	280.158	Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	CFPDEQBPNROZDC-UHFFFAOYSA-N	9799509.0		CFPDEQBPNROZDC
BRD-K11927976-050-02-9	ER-27319	Preclinical	mediator release inhibitor|SYK inhibitor	SYK			0	82.32	Tocris	2471	ER 27319 maleate	280.158	Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	CFPDEQBPNROZDC-UHFFFAOYSA-N	9799509.0		CFPDEQBPNROZDC
BRD-K11927976-050-03-7	ER-27319	Preclinical	mediator release inhibitor|SYK inhibitor	SYK			0	82.73	Tocris	2471	ER 27319 maleate	280.158	Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	CFPDEQBPNROZDC-UHFFFAOYSA-N	9799509.0		CFPDEQBPNROZDC
BRD-K18347943-001-01-8	ER-50891	Preclinical	retinoid receptor antagonist	RARA			0	66.53	Tocris	3823	ER 50891	432.184	CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1	LSGNKLDHMQVTEK-UHFFFAOYSA-N	10094345.0		LSGNKLDHMQVTEK
BRD-K18347943-001-02-9	ER-50891	Preclinical	retinoid receptor antagonist	RARA			0	96.07	Tocris	3823	ER 50891	432.184	CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1	LSGNKLDHMQVTEK-UHFFFAOYSA-N	10094345.0		LSGNKLDHMQVTEK
BRD-A25004090-001-08-4	erastin	Preclinical	ion channel antagonist	VDAC2			0	90.33	Selleck	S7242	Erastin	546.203	CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|	BKQFRNYHFIQEKN-OAQYLSRUSA-N	91669533.0		BKQFRNYHFIQEKN
BRD-A25004090-001-09-2	erastin	Preclinical	ion channel antagonist	VDAC2			0	98.74	Selleck	S7242	Erastin	546.203	CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20,r|	BKQFRNYHFIQEKN-OAQYLSRUSA-N	91669533.0		BKQFRNYHFIQEKN
BRD-K00003240-300-01-9	eravacycline	Launched	antibacterial				0	0.0	MedChemEx	HY-16980A	Eravacycline (dihydrochloride)	558.213	[H][C@@]12Cc3c(F)cc(NC(=O)CN4CCCC4)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:29,&2:22|	LSZZJAUTRJAFCO-KKCFVTAMSA-N			LSZZJAUTRJAFCO
BRD-K35573744-001-06-8	erbstatin-analog	Preclinical	EGFR inhibitor|tyrosine kinase inhibitor	EGFR			0	63.51	Tocris	577	Methyl 2,5-dihydroxycinnamate	194.058	COC(=O)\C=C\c1cc(O)ccc1O	BQCNSTFWSKOWMA-GORDUTHDSA-N	5353609.0		BQCNSTFWSKOWMA
BRD-K84163249-001-03-5	ercalcitriol	Phase 1	vitamin D receptor agonist	VDR			0	89.45	MedChemEx	HY-32350	Ercalcitriol	428.329	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	ZGLHBRQAEXKACO-XJRQOBMKSA-N	9547243.0		ZGLHBRQAEXKACO
BRD-K84163249-001-01-9	ercalcitriol	Phase 1	vitamin D receptor agonist	VDR			0	92.34	MedChemEx	HY-32350	Ercalcitriol	428.329	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	ZGLHBRQAEXKACO-XJRQOBMKSA-N	9547243.0		ZGLHBRQAEXKACO
BRD-K84868168-001-01-0	erdafitinib	Launched	FGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4			0	95.96	MedChemEx	HY-18708	Erdafitinib	446.243	COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	OLAHOMJCDNXHFI-UHFFFAOYSA-N	67462786.0		OLAHOMJCDNXHFI
BRD-A05515753-001-03-2	erdosteine	Launched	mucolytic agent		pulmonary|infectious disease	bronchitis|cough suppressant|chronic obstructive pulmonary disease (COPD)|respiratory tract infections	0	94.0	MicroSource	1502383	ERDOSTEINE	249.013	OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|	QGFORSXNKQLDNO-YFKPBYRVSA-N	40467037.0		QGFORSXNKQLDNO
BRD-A05515753-001-02-4	erdosteine	Launched	mucolytic agent		pulmonary|infectious disease	bronchitis|cough suppressant|chronic obstructive pulmonary disease (COPD)|respiratory tract infections	0	86.34	Selleck	S1825	Erdosteine	249.013	OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|	QGFORSXNKQLDNO-YFKPBYRVSA-N	40467037.0		QGFORSXNKQLDNO
BRD-A05515753-001-04-0	erdosteine	Launched	mucolytic agent		pulmonary|infectious disease	bronchitis|cough suppressant|chronic obstructive pulmonary disease (COPD)|respiratory tract infections	0	99.06	Selleck	S1825	Erdosteine	249.013	OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|	QGFORSXNKQLDNO-YFKPBYRVSA-N	40467037.0		QGFORSXNKQLDNO
BRD-A05515753-001-05-9	erdosteine	Launched	mucolytic agent		pulmonary|infectious disease	bronchitis|cough suppressant|chronic obstructive pulmonary disease (COPD)|respiratory tract infections	0	96.22	MedChemEx	HY-B0289	Erdosteine	249.013	OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9,r|	QGFORSXNKQLDNO-YFKPBYRVSA-N	40467037.0		QGFORSXNKQLDNO
BRD-K56155962-001-15-4	ergocalciferol	Launched	vitamin analog	VDR	endocrinology|orthopedics	hypoparathyroidism|rickets|hypophosphatemia	0	0.0	MicroSource	1500276	ERGOCALCIFEROL	396.339	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	MECHNRXZTMCUDQ-RKHKHRCZSA-N	5280793.0	BRD-A87199639-001-04-4	MECHNRXZTMCUDQ
BRD-K56155962-001-12-1	ergocalciferol	Launched	vitamin analog	VDR	endocrinology|orthopedics	hypoparathyroidism|rickets|hypophosphatemia	0	0.0	Sigma	MFCD00166988	(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol	396.339	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	MECHNRXZTMCUDQ-RKHKHRCZSA-N	5280793.0		MECHNRXZTMCUDQ
BRD-K56155962-001-16-2	ergocalciferol	Launched	vitamin analog	VDR	endocrinology|orthopedics	hypoparathyroidism|rickets|hypophosphatemia	0	0.0	Selleck	S4035	Vitamin D2	396.339	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	MECHNRXZTMCUDQ-RKHKHRCZSA-N	5280793.0	BRD-K05243578-001-01-6	MECHNRXZTMCUDQ
BRD-K56155962-001-11-3	ergocalciferol	Launched	vitamin analog	VDR	endocrinology|orthopedics	hypoparathyroidism|rickets|hypophosphatemia	0	79.58	Selleck	S4035	Vitamin D2 (Ergocalciferol)	396.339	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	MECHNRXZTMCUDQ-RKHKHRCZSA-N	5280793.0		MECHNRXZTMCUDQ
BRD-K17311468-050-01-7	ergonovine	Launched	adrenergic receptor agonist|serotonin receptor agonist	ADRA1A|HTR1E	hematology	postpartum hemorrhage (PPH)	0	97.04	USP	1240004	Ergonovine maleate	325.179	C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|	WVVSZNPYNCNODU-XTQGRXLLSA-N	443884.0		WVVSZNPYNCNODU
BRD-K03039262-001-03-7	ergosterol	Preclinical	vitamin D precursor				0	0.0	Selleck	S2297	Ergosterol	396.339	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|	DNVPQKQSNYMLRS-APGDWVJJSA-N	444679.0		DNVPQKQSNYMLRS
BRD-K03039262-001-04-5	ergosterol	Preclinical	vitamin D precursor				0	0.0	Selleck	S2297	Ergosterol	396.339	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|	DNVPQKQSNYMLRS-APGDWVJJSA-N	444679.0	BRD-K09161066-001-01-5	DNVPQKQSNYMLRS
BRD-K03039262-001-05-2	ergosterol	Preclinical	vitamin D precursor				0	0.0	Selleck	S2297	DL-carnetine HCl	396.339	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13,15|	DNVPQKQSNYMLRS-APGDWVJJSA-N	444679.0		DNVPQKQSNYMLRS
BRD-K15380626-046-02-9	ergotamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|DRD1|DRD2|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|SLC6A2	neurology/psychiatry	migraine headache	0	79.0	Sigma	BCBN2989V	ergotamine D-tartrate	581.264	CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|	XCGSFFUVFURLIX-VFGNJEKYSA-N	8223.0		XCGSFFUVFURLIX
BRD-K00003156-066-01-9	eribulin	Launched	microtubule inhibitor		oncology	breast cancer	0	100.0	MedChemEx	HY-13442A	Eribulin mesylate	729.409	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2 |THB:43:44:51.53:48.49.56.58,50:49:44:51.53,50:51:44:48.49.56.58,53:54:46.48.49.58:41.43.59,59:56:44:51.53|	UFNVPOGXISZXJD-JBQZKEIOSA-N	11354606.0		UFNVPOGXISZXJD
BRD-K64857848-001-06-4	ERK5-IN-1	Preclinical	MAP kinase inhibitor	MAPK7			0	87.52	MedChemEx	HY-14403	ERK5-IN-1	459.238	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1	DDTPGANIPBKTNU-UHFFFAOYSA-N	46844147.0		DDTPGANIPBKTNU
BRD-K70401845-001-15-7	erlotinib	Launched	EGFR inhibitor	EGFR|NR1I2	oncology	non-small cell lung cancer (NSCLC)|pancreatic cancer	0	99.27	Selleck	S1023	Erlotinib	393.169	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	AAKJLRGGTJKAMG-UHFFFAOYSA-N	176870.0		AAKJLRGGTJKAMG
BRD-K70401845-003-09-6	erlotinib	Launched	EGFR inhibitor	EGFR|NR1I2	oncology	non-small cell lung cancer (NSCLC)|pancreatic cancer	0	99.25	Selleck	S1023	Erlotinib HCl (OSI-744)	393.169	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	AAKJLRGGTJKAMG-UHFFFAOYSA-N	176870.0		AAKJLRGGTJKAMG
BRD-K70401845-001-09-0	erlotinib	Launched	EGFR inhibitor	EGFR|NR1I2	oncology	non-small cell lung cancer (NSCLC)|pancreatic cancer	0		Selleck	S1023	Erlotinib HCl	393.169	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)	176870.0		AAKJLRGGTJKAMG
BRD-A40472231-304-01-7	ertapenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections|skin infections|pneumonia|urinary tract infections|gynecologic infections|postpartum endomyometritis	0	0.0	SantaCruz	sc-391428		475.141	C[C@@H](O)[C@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O |a:1,4,5,9,12,&1:3,c:27|	JUZNIMUFDBIJCM-FKTXGUMASA-N	124518153.0		JUZNIMUFDBIJCM
BRD-A40472231-304-02-5	ertapenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections|skin infections|pneumonia|urinary tract infections|gynecologic infections|postpartum endomyometritis	0		SantaCruz	sc-391428		475.141	C[C@@H](O)[C@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O |a:1,4,5,9,12,&1:3,c:27|	JUZNIMUFDBIJCM-FKTXGUMASA-N	124518153.0		JUZNIMUFDBIJCM
BRD-K80608265-001-01-6	erteberel	Phase 2	estrogen receptor agonist	ESR1|ESR2			0	97.54	Selleck	S1598		282.126	Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	XIESSJVMWNJCGZ-VKJFTORMSA-N	10286159.0		XIESSJVMWNJCGZ
BRD-K00003574-001-01-9	ertugliflozin	Launched	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	0	97.81	MedChemEx	HY-15461	Ertugliflozin	436.129	CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1	MCIACXAZCBVDEE-CUUWFGFTSA-N	44814423.0		MCIACXAZCBVDEE
BRD-K79315489-001-09-9	erythritol	Launched					0	100.0	MedChemEx	HY-100551	meso-Erythritol	122.058	OC[C@H](O)[C@H](O)CO	UNXHWFMMPAWVPI-ZXZARUISSA-N	222285.0		UNXHWFMMPAWVPI
BRD-K79315489-001-07-8	erythritol	Launched					0	0.0	Selleck	S4224	Erythritol	122.058	OC[C@H](O)[C@H](O)CO	UNXHWFMMPAWVPI-ZXZARUISSA-N	222285.0		UNXHWFMMPAWVPI
BRD-K79315489-001-08-6	erythritol	Launched					0	92.41	Selleck	S4224	Erythritol	122.058	OC[C@H](O)[C@H](O)CO	UNXHWFMMPAWVPI-ZXZARUISSA-N	222285.0		UNXHWFMMPAWVPI
BRD-K63550407-001-16-9	erythromycin	Launched	NFkB pathway inhibitor	MLNR	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	86.8	MedChemEx	HY-B0220	Erythromycin	733.461	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	ULGZDMOVFRHVEP-BCQGSPHWSA-N			ULGZDMOVFRHVEP
BRD-K63550407-001-12-7	erythromycin	Launched	NFkB pathway inhibitor	MLNR	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	88.23	MicroSource	1500280	ERYTHROMYCIN	733.461	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	ULGZDMOVFRHVEP-BCQGSPHWSA-N			ULGZDMOVFRHVEP
BRD-K63550407-028-04-7	erythromycin	Launched	NFkB pathway inhibitor	MLNR	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	68.47	MicroSource	1500281	ERYTHROMYCIN STEARATE	733.461	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	ULGZDMOVFRHVEP-BCQGSPHWSA-N			ULGZDMOVFRHVEP
BRD-K63550407-001-13-5	erythromycin	Launched	NFkB pathway inhibitor	MLNR	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	86.16	Selleck	s1635	Erythromycin	733.461	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	ULGZDMOVFRHVEP-BCQGSPHWSA-N		BRD-K05127550-001-02-1	ULGZDMOVFRHVEP
BRD-K63550407-001-14-3	erythromycin	Launched	NFkB pathway inhibitor	MLNR	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	81.29	Selleck	S1635	Erythromycin	733.461	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	ULGZDMOVFRHVEP-BCQGSPHWSA-N		BRD-K05127550-001-03-9|BRD-A20485507-001-01-2	ULGZDMOVFRHVEP
BRD-K39746403-084-05-6	erythromycin-estolate	Launched	bacterial 50S ribosomal subunit inhibitor	ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	66.36	AlfaAesar	J66548	Erythromycin estolate	789.487	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	TYQXKHPOXXXCTP-JKQIPHDKSA-N			TYQXKHPOXXXCTP
BRD-K39746403-084-04-9	erythromycin-estolate	Launched	bacterial 50S ribosomal subunit inhibitor	ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	0.0	MicroSource	1501176	ERYTHROMYCIN ESTOLATE	789.487	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	TYQXKHPOXXXCTP-JKQIPHDKSA-N			TYQXKHPOXXXCTP
BRD-K51677086-001-15-9	erythromycin-ethylsuccinate	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	88.6	MedChemEx	HY-B0957	Erythromycin Ethylsuccinate	861.509	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	NSYZCCDSJNWWJL-ZBFNRKITSA-N	132274075.0		NSYZCCDSJNWWJL
BRD-K51677086-001-12-0	erythromycin-ethylsuccinate	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	93.05	MicroSource	1500279	ERYTHROMYCIN ETHYLSUCCINATE	861.509	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	NSYZCCDSJNWWJL-ZBFNRKITSA-N	132274075.0		NSYZCCDSJNWWJL
BRD-K51677086-001-13-8	erythromycin-ethylsuccinate	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	5.58	Selleck	S4060	Erythromycin Ethylsuccinate	861.509	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	NSYZCCDSJNWWJL-ZBFNRKITSA-N	132274075.0		NSYZCCDSJNWWJL
BRD-K51677086-001-14-6	erythromycin-ethylsuccinate	Launched	cytochrome P450 inhibitor|protein synthesis inhibitor	ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1	infectious disease	listeria|respiratory tract infections|skin infections|syphilis|amebiasis|pelvic inflammatory disease|chlamydia|diphtheria|erythrasma	0	79.02	Selleck	S4060	Erythromycin Ethylsuccinate	861.509	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	NSYZCCDSJNWWJL-ZBFNRKITSA-N	132274075.0	BRD-K13846766-001-01-8	NSYZCCDSJNWWJL
BRD-K07549832-304-03-9	erythrosine	Preclinical	coloring agent				0	92.35	MedChemEx	HY-D0259	Erythrosin B	835.655	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3ccccc23)c1I	OALHHIHQOFIMEF-UHFFFAOYSA-N	3259.0		OALHHIHQOFIMEF
BRD-K92426617-001-06-3	esaprazole	Phase 2					0	89.47	Enamine	Z234896745	N-cyclohexyl-2-(1-piperazinyl)acetamide	225.184	O=C(CN1CCNCC1)NC1CCCCC1	RTFADALJKSFJDZ-UHFFFAOYSA-N	68835.0		RTFADALJKSFJDZ
BRD-K92426617-001-05-5	esaprazole	Phase 2					0	11.31	Enamine	Z234896745		225.184	O=C(CN1CCNCC1)NC1CCCCC1	RTFADALJKSFJDZ-UHFFFAOYSA-N	68835.0		RTFADALJKSFJDZ
BRD-K00003374-001-01-9	esaxerenone	Preclinical	mineralocorticoid receptor antagonist				0	95.72	MedChemEx	HY-100471	Esaxerenone	466.117	Cc1c(cn(CCO)c1-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(cc1)S(C)(=O)=O	NOSNHVJANRODGR-UHFFFAOYSA-N	25052023.0		NOSNHVJANRODGR
BRD-K00010936-001-01-9	escin	Launched	nitric oxide synthase stimulant		dermatology	varicose veins	0	34.39	Sigma	none	escin	1130.551	CC=C(C)C(=O)O[C@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2CC1(C)C |c:21|	AXNVHPCVMSNXNP-FDGZCRRKSA-N	441903.0		AXNVHPCVMSNXNP
BRD-K70301876-034-13-7	escitalopram	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)	0	95.18	MicroSource	1505216	ESCITALOPRAM OXALATE	324.164	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	WSEQXVZVJXJVFP-FQEVSTJZSA-N	146570.0		WSEQXVZVJXJVFP
BRD-K70301876-034-15-9	escitalopram	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)	0	96.09	Tocris	4796	Escitalopram oxalate	324.164	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	WSEQXVZVJXJVFP-FQEVSTJZSA-N	146570.0		WSEQXVZVJXJVFP
BRD-K70301876-034-14-5	escitalopram	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)	0	98.5	Tocris	4796	Escitalopram oxalate	324.164	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	WSEQXVZVJXJVFP-FQEVSTJZSA-N	146570.0		WSEQXVZVJXJVFP
BRD-K01825597-034-02-9	escitalopram	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)	0	96.59	Selleck	S4064	Escitalopram Oxalate	414.159	OC(=O)C(O)=O.CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:12,r|	KTGRHKOEFSJQNS-BDQAORGHSA-N	146571.0	BRD-A47598013-034-02-7|BRD-A47598013-034-02-7|BRD-A47598013-034-02-7	KTGRHKOEFSJQNS
BRD-K51742987-001-05-6	esculin	Phase 1	antioxidant				0	89.73	Selleck	S2258	Esculin	340.079	OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O	XHCADAYNFIFUHF-TVKJYDDYSA-N	5281417.0		XHCADAYNFIFUHF
BRD-K13629382-051-06-6	eseroline-(-)	Preclinical	acetylcholinesterase inhibitor	OPRD1|OPRM1			0	0.0	Prestwick	Prestw-1082	(-)-Eseroline fumarate salt	218.142	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21	HKGWQUVGHPDEBZ-OLZOCXBDSA-N	119198.0	BRD-K76359782-051-03-7	HKGWQUVGHPDEBZ
BRD-K77139516-001-01-4	ESI-09	Preclinical	EPAC inhibitor	RAPGEF3|RAPGEF4			0	91.97	MedChemEx	HY-16704	ESI-09	330.088	CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N	DXEATJQGQHDURZ-DEDYPNTBSA-N	6077765.0		DXEATJQGQHDURZ
BRD-K77139516-001-02-2	ESI-09	Preclinical	EPAC inhibitor	RAPGEF3|RAPGEF4			0	96.93	Tocris	4773	ESI 09	330.088	CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N	DXEATJQGQHDURZ-DEDYPNTBSA-N	6077765.0		DXEATJQGQHDURZ
BRD-K61237927-001-02-9	eslicarbazepine-acetate	Launched	sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	96.87	MedChemEx	HY-B0703	Eslicarbazepine (acetate)	296.116	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	QIALRBLEEWJACW-INIZCTEOSA-N	179344.0		QIALRBLEEWJACW
BRD-K61237927-001-01-7	eslicarbazepine-acetate	Launched	sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	99.86	MedChemEx	HY-B0703	Eslicarbazepine (acetate)	296.116	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	QIALRBLEEWJACW-INIZCTEOSA-N	179344.0		QIALRBLEEWJACW
BRD-K01825842-003-02-9	esmolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	ventricular tachycardia (VT)|hypertension	0	95.93	MedChemEx	HY-B1392	Esmolol (hydrochloride)	295.178	COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12,r|	AQNDDEOPVVGCPG-AWEZNQCLSA-N	28125476.0		AQNDDEOPVVGCPG
BRD-K61443506-236-02-0	esomeprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD)	0	98.56	Selleck	S2233	Esomeprazole Sodium	345.115	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	SUBDBMMJDZJVOS-DEOSSOPVSA-N	9568614.0	BRD-A55962179-236-02-5|BRD-A55962179-236-02-5|BRD-A55962179-236-02-5|BRD-A55962179-236-02-5	SUBDBMMJDZJVOS
BRD-K61443506-237-01-0	esomeprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD)	0	85.63	MicroSource	1502361	ESOMEPRAZOLE POTASSIUM	345.115	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	SUBDBMMJDZJVOS-DEOSSOPVSA-N	9568614.0	BRD-A55962179-239-01-1|BRD-A55962179-239-01-1|BRD-A55962179-239-01-1|BRD-A55962179-239-01-1	SUBDBMMJDZJVOS
BRD-K61443506-239-01-6	esomeprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD)	0	98.67	Selleck	S1743	Esomeprazole magnesium (Nexium)	345.115	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	SUBDBMMJDZJVOS-DEOSSOPVSA-N	9568614.0	BRD-A55962179-239-02-9|BRD-A55962179-239-02-9|BRD-A55962179-239-02-9|BRD-A55962179-239-02-9	SUBDBMMJDZJVOS
BRD-K61443506-239-03-9	esomeprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|Zollinger-Ellison syndrome|peptic ulcer disease (PUD)	0	98.22	MedChemEx	HY-17022	Esomeprazole (Magnesium trihydrate)	345.115	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	SUBDBMMJDZJVOS-DEOSSOPVSA-N	9568614.0	BRD-A55962179-239-38-9|BRD-A55962179-239-38-9|BRD-A55962179-239-38-9|BRD-A55962179-239-38-9	SUBDBMMJDZJVOS
BRD-K00003282-001-01-9	esonarimod	Preclinical	antirheumatic drug				0	96.22	MedChemEx	HY-19440	Esonarimod	280.077	CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(O)=O |&1:5,r|	YRSSFEUQNAXQMX-LBPRGKRZSA-N	9795701.0		YRSSFEUQNAXQMX
BRD-K75445017-001-01-1	estetrol	Phase 3	selective estrogen receptor modulator (SERM)	ESR1			0	86.38	Sigma	SML1523	(15alpha,16alpha,17beta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol	304.167	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	AJIPIJNNOJSSQC-NYLIRDPKSA-N	27125.0		AJIPIJNNOJSSQC
BRD-K18910433-001-43-2	estradiol	Launched	estrogen receptor agonist	ESR1|ESR2|GPER1|KCNMA1|NR1I2	endocrinology	contraceptive	0	92.44	MicroSource	1500282	ESTRADIOL	272.178	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	VOXZDWNPVJITMN-ZBRFXRBCSA-N	5757.0	BRD-A18917088-001-04-9	VOXZDWNPVJITMN
BRD-K18910433-001-36-6	estradiol	Launched	estrogen receptor agonist	ESR1|ESR2|GPER1|KCNMA1|NR1I2	endocrinology	contraceptive	0	87.73	Selleck	S1709	Estradiol	272.178	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	VOXZDWNPVJITMN-ZBRFXRBCSA-N	5757.0		VOXZDWNPVJITMN
BRD-K18910433-001-42-4	estradiol	Launched	estrogen receptor agonist	ESR1|ESR2|GPER1|KCNMA1|NR1I2	endocrinology	contraceptive	0	87.2	Selleck	S1709	Estradiol	272.178	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	VOXZDWNPVJITMN-ZBRFXRBCSA-N	5757.0	BRD-K60633875-001-01-0	VOXZDWNPVJITMN
BRD-K53319039-001-01-8	estradiol-acetate	Launched	estrogen receptor agonist	ESR1	endocrinology|obstetrics/gynecology	menopause|vaginal atrophy	0	96.27	Sigma	MFCD00198969	(17beta)-17-hydroxyestra-1,3,5(10)-trien-3-yl acetate	314.188	CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1	FHXBMXJMKMWVRG-SLHNCBLASA-N	9818306.0		FHXBMXJMKMWVRG
BRD-K44412991-001-11-9	estradiol-benzoate	Preclinical	contraceptive agent	ESR1			0	87.32	MedChemEx	HY-B1192	Estradiol benzoate	376.204	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O	UYIFTLBWAOGQBI-BZDYCCQFSA-N	222757.0		UYIFTLBWAOGQBI
BRD-K64984393-001-07-9	estradiol-cypionate	Launched	estrogen receptor agonist	ESR1	endocrinology	hypoestrogenism|menopause	0	97.01	MedChemEx	HY-B1100	Estradiol cypionate	396.266	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1	UOACKFBJUYNSLK-XRKIENNPSA-N	9403.0		UOACKFBJUYNSLK
BRD-K66766661-001-21-9	estradiol-valerate	Launched	estrogen receptor agonist	ESR1	oncology|endocrinology|obstetrics/gynecology	prostate cancer|hypoestrogenism|menopause|vaginal atrophy	0	79.63	MedChemEx	HY-B0672	Estradiol valerianate	356.235	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	RSEPBGGWRJCQGY-RBRWEJTLSA-N	13791.0		RSEPBGGWRJCQGY
BRD-K66766661-001-19-2	estradiol-valerate	Launched	estrogen receptor agonist	ESR1	oncology|endocrinology|obstetrics/gynecology	prostate cancer|hypoestrogenism|menopause|vaginal atrophy	0	96.27	MicroSource	1500284	ESTRADIOL VALERATE	356.235	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	RSEPBGGWRJCQGY-RBRWEJTLSA-N	13791.0	BRD-A39747742-001-04-3	RSEPBGGWRJCQGY
BRD-K66766661-001-20-0	estradiol-valerate	Launched	estrogen receptor agonist	ESR1	oncology|endocrinology|obstetrics/gynecology	prostate cancer|hypoestrogenism|menopause|vaginal atrophy	0	95.69	Selleck	S3149	Estradiol valerate	356.235	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	RSEPBGGWRJCQGY-RBRWEJTLSA-N	13791.0	BRD-K12790232-001-01-5	RSEPBGGWRJCQGY
BRD-K00004741-001-01-9	estradiol-3-O-sulfamate	Phase 2	steryl sulfatase inhibitor				0	81.52	MedChemEx	HY-U00112	Estradiol 3-sulfamate	351.15	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(N)(=O)=O)ccc34)[C@@H]1CC[C@@H]2O	YXYXCSOJKUAPJI-ZBRFXRBCSA-N	6918339.0		YXYXCSOJKUAPJI
BRD-A70858459-001-01-7	estramustine	Launched	DNA alkylating agent	ESR1|ESR2|MAP1A|MAP2	oncology	prostate cancer	0	94.83	MicroSource	1502384	ESTRAMUSTINE	439.168	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2O |a:1,27,&1:4,&2:5,&3:24|	FRPJXPJMRWBBIH-RBRWEJTLSA-N	259331.0		FRPJXPJMRWBBIH
BRD-K00077635-304-01-2	estramustine-phosphate	Launched	DNA synthesis inhibitor|microtubule inhibitor	ESR1|ESR2|MAP1A|MAP2	oncology	prostate cancer	0	93.37	Enzo	AC1524	Estramustine phosphate sodium	519.134	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	ADFOJJHRTBFFOF-RBRWEJTLSA-N	259329.0		ADFOJJHRTBFFOF
BRD-K00077635-304-02-9	estramustine-phosphate	Launched	DNA synthesis inhibitor|microtubule inhibitor	ESR1|ESR2|MAP1A|MAP2	oncology	prostate cancer	0	82.85	MedChemEx	HY-13627	Estramustine (phosphate sodium)	519.134	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	ADFOJJHRTBFFOF-RBRWEJTLSA-N	259329.0		ADFOJJHRTBFFOF
BRD-K17016787-001-17-9	estriol	Launched	estrogen receptor agonist	ESR1|ESR2	endocrinology|obstetrics/gynecology|infectious disease	menopause|vaginal atrophy|urinary tract infections	0	82.01	MedChemEx	HY-B0412	Estriol	288.173	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZXXIGWHRSA-N	5756.0		PROQIPRRNZUXQM
BRD-K17016787-001-16-7	estriol	Launched	estrogen receptor agonist	ESR1|ESR2	endocrinology|obstetrics/gynecology|infectious disease	menopause|vaginal atrophy|urinary tract infections	0	88.19	MicroSource	1500285	ESTRIOL	288.173	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZXXIGWHRSA-N	5756.0	BRD-A18620900-001-05-2	PROQIPRRNZUXQM
BRD-K17016787-001-13-4	estriol	Launched	estrogen receptor agonist	ESR1|ESR2	endocrinology|obstetrics/gynecology|infectious disease	menopause|vaginal atrophy|urinary tract infections	0	81.41	Selleck	S2466	Estriol	288.173	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZXXIGWHRSA-N	5756.0		PROQIPRRNZUXQM
BRD-K17016787-001-15-9	estriol	Launched	estrogen receptor agonist	ESR1|ESR2	endocrinology|obstetrics/gynecology|infectious disease	menopause|vaginal atrophy|urinary tract infections	0	82.92	Selleck	S2466	Estriol	288.173	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	PROQIPRRNZUXQM-ZXXIGWHRSA-N	5756.0	BRD-K03411175-001-01-8	PROQIPRRNZUXQM
BRD-K81839095-001-31-9	estrone	Launched	estrogen receptor agonist|estrogenic hormone	ESR1|ESR2	endocrinology	menopause	0	95.52	MedChemEx	HY-B0234	Estrone	270.162	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	DNXHEGUUPJUMQT-CBZIJGRNSA-N	5870.0		DNXHEGUUPJUMQT
BRD-K81839095-001-30-1	estrone	Launched	estrogen receptor agonist|estrogenic hormone	ESR1|ESR2	endocrinology	menopause	0	91.87	MicroSource	1500286	ESTRONE	270.162	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	DNXHEGUUPJUMQT-CBZIJGRNSA-N	5870.0	BRD-A37959677-001-04-5	DNXHEGUUPJUMQT
BRD-K81839095-001-25-1	estrone	Launched	estrogen receptor agonist|estrogenic hormone	ESR1|ESR2	endocrinology	menopause	0	90.88	Selleck	S1665	Estrone	270.162	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	DNXHEGUUPJUMQT-CBZIJGRNSA-N	5870.0		DNXHEGUUPJUMQT
BRD-K81839095-001-29-3	estrone	Launched	estrogen receptor agonist|estrogenic hormone	ESR1|ESR2	endocrinology	menopause	0	87.06	Selleck	S1665	Estrone	270.162	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	DNXHEGUUPJUMQT-CBZIJGRNSA-N	5870.0	BRD-K15236393-001-01-1	DNXHEGUUPJUMQT
BRD-K51095933-231-16-9	estropipate	Launched	estrogen receptor agonist	ESR1|ESR2	orthopedics|endocrinology|obstetrics/gynecology	osteoporosis|menopause|vaginal atrophy|hypoestrogenism	0	90.34	Tocris	3588	Estropipate	350.119	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O	JKKFKPJIXZFSSB-CBZIJGRNSA-N	3001028.0		JKKFKPJIXZFSSB
BRD-K63630713-001-27-9	etacrynic-acid	Launched	sodium/potassium/chloride transporter inhibitor	ATP1A1|SLC12A1	cardiology|gastroenterology|nephrology|rheumatology	hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome	0	94.88	MedChemEx	HY-B1640	Ethacrynic acid	302.011	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	AVOLMBLBETYQHX-UHFFFAOYSA-N	3278.0		AVOLMBLBETYQHX
BRD-K63630713-001-25-8	etacrynic-acid	Launched	sodium/potassium/chloride transporter inhibitor	ATP1A1|SLC12A1	cardiology|gastroenterology|nephrology|rheumatology	hypertension|congestive heart failure|edema|hepatic cirrhosis|chronic renal failure|nephrotic syndrome	0	98.7	MicroSource	1500287	ETHACRYNIC ACID	302.011	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	AVOLMBLBETYQHX-UHFFFAOYSA-N	3278.0		AVOLMBLBETYQHX
BRD-K84971356-001-01-4	etafenone	Launched	calcium channel blocker				0	98.74	Vitas-M	STK321191	1-{2-[2-(diethylamino)ethoxy]phenyl}-3-phenyl-1-propanone	325.204	CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1	OEGDFSLNGABBKJ-UHFFFAOYSA-N	3275.0		OEGDFSLNGABBKJ
BRD-K71055333-224-07-9	etamsylate	Launched	hemostatic agent		hematology	hemorrhage	0	92.6	MedChemEx	HY-B1074	Ethamsylate	189.994	Oc1ccc(O)c(c1)S(O)(=O)=O	IKQCSJBQLWJEPU-UHFFFAOYSA-N	17507.0		IKQCSJBQLWJEPU
BRD-K71055333-224-05-8	etamsylate	Launched	hemostatic agent		hematology	hemorrhage	0	79.22	Selleck	S4152	Ethamsylate	189.994	Oc1ccc(O)c(c1)S(O)(=O)=O	IKQCSJBQLWJEPU-UHFFFAOYSA-N	17507.0		IKQCSJBQLWJEPU
BRD-K71055333-224-06-6	etamsylate	Launched	hemostatic agent		hematology	hemorrhage	0	98.66	Selleck	S4152	Ethamsylate	189.994	Oc1ccc(O)c(c1)S(O)(=O)=O	IKQCSJBQLWJEPU-UHFFFAOYSA-N	17507.0		IKQCSJBQLWJEPU
BRD-K96042922-001-09-8	etanidazole	Phase 3	bacterial cell wall synthesis inhibitor				0	97.03	Prestwick	Prestw-649	Etanidazole	214.07	OCCNC(=O)Cn1ccnc1[N+]([O-])=O	WCDWBPCFGJXFJZ-UHFFFAOYSA-N	3276.0		WCDWBPCFGJXFJZ
BRD-K96042922-001-10-9	etanidazole	Phase 3	bacterial cell wall synthesis inhibitor				0	100.0	Toronto	e889230	etanidazole	214.07	OCCNC(=O)Cn1ccnc1[N+]([O-])=O	WCDWBPCFGJXFJZ-UHFFFAOYSA-N	3276.0		WCDWBPCFGJXFJZ
BRD-K64755930-003-04-9	etazolate	Phase 2	phosphodiesterase inhibitor	GABRB3|PDE4A			0	91.77	Tocris	438	Etazolate hydrochloride	289.154	CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	OPQRBXUBWHDHPQ-UHFFFAOYSA-N	3277.0		OPQRBXUBWHDHPQ
BRD-K64755930-003-03-2	etazolate	Phase 2	phosphodiesterase inhibitor	GABRB3|PDE4A			0	91.67	Tocris	438	Etazolate hydrochloride	289.154	CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	OPQRBXUBWHDHPQ-UHFFFAOYSA-N	3277.0		OPQRBXUBWHDHPQ
BRD-K54264768-001-01-2	ETC-159	Phase 1	beta catenin inhibitor|porcupine inhibitor	PORCN			0	97.74	MedChemEx	HY-18988	ETC-159	391.139	Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O	QTRXIFVSTWXRJJ-UHFFFAOYSA-N	86280523.0		QTRXIFVSTWXRJJ
BRD-K00003115-001-01-9	ETC-206	Phase 1	MAPK-interacting kinase inhibitor				0	97.55	MedChemEx	HY-112424	ETC-206	408.159	O=C(N1CCOCC1)c1ccc(cc1)-c1ccc2ncc(-c3ccc(cc3)C#N)n2c1	FWRFPHJSGLYXTD-UHFFFAOYSA-N	71766360.0		FWRFPHJSGLYXTD
BRD-K24443618-001-10-2	etebenecid	Preclinical	uricosuric blocker				0	98.34	MicroSource	1504349	ETEBENECID	257.072	CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O	UACOQEQOBAQRDQ-UHFFFAOYSA-N	14604.0		UACOQEQOBAQRDQ
BRD-K64834129-001-19-6	eterobarb	Phase 2	anticonvulsant				0	94.62	Vitas-M	STK091981	5-ethyl-1,3-bis(methoxymethyl)-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione	320.137	CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1	DACOQFZGGLCXMA-UHFFFAOYSA-N	33925.0		DACOQFZGGLCXMA
BRD-K10667240-001-01-7	ethacizin	Launched	anticonvulsant		cardiology	ventricular tachycardia (VT)|Wolff-Parkinson-White Syndrome (WPW)	0	97.41	Vitas-M	STK995917	ethyl 10-[3-(diethylamino)propanoyl]-10H-phenothiazin-2-ylcarbamate	413.177	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1	PQXGNJKJMFUPPM-UHFFFAOYSA-N	107841.0		PQXGNJKJMFUPPM
BRD-K24715592-043-02-2	ethacridine-lactate-monohydrate	Preclinical	DNA intercalating agent				0	58.45	MicroSource	1505168	ETHACRIDINE LACTATE	253.122	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	CIKWKGFPFXJVGW-UHFFFAOYSA-N	2017.0		CIKWKGFPFXJVGW
BRD-K24715592-406-01-3	ethacridine-lactate-monohydrate	Preclinical	DNA intercalating agent				0	41.83	Selleck	S4196	Ethacridine lactate monohydrate	253.122	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	CIKWKGFPFXJVGW-UHFFFAOYSA-N	2017.0		CIKWKGFPFXJVGW
BRD-K24715592-406-03-9	ethacridine-lactate-monohydrate	Preclinical	DNA intercalating agent				0	91.12	Selleck	S4196	(2S)-3-methyl-2-[({4-[(5-methyl-1,2-oxazol-3-yl)sulfamoyl]phenyl}carbamoyl)amino]butanoic acid	253.122	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	CIKWKGFPFXJVGW-UHFFFAOYSA-N	2017.0		CIKWKGFPFXJVGW
BRD-K24715592-406-02-1	ethacridine-lactate-monohydrate	Preclinical	DNA intercalating agent				0	87.55	Selleck	S4196	Ethacridine lactate monohydrate	253.122	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	CIKWKGFPFXJVGW-UHFFFAOYSA-N	2017.0		CIKWKGFPFXJVGW
BRD-K93231391-300-06-4	ethambutol	Launched	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	0	100.0	MicroSource	1500288	ETHAMBUTOL HYDROCHLORIDE	204.184	CC[C@@H](CO)NCCN[C@@H](CC)CO	AEUTYOVWOVBAKS-UWVGGRQHSA-N	14052.0		AEUTYOVWOVBAKS
BRD-K93231391-300-08-9	ethambutol	Launched	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	0	68.4	MedChemEx	HY-B0535A	Ethambutol (dihydrochloride)	204.184	CC[C@@H](CO)NCCN[C@@H](CC)CO	AEUTYOVWOVBAKS-UWVGGRQHSA-N	14052.0		AEUTYOVWOVBAKS
BRD-K93231391-300-05-6	ethambutol	Launched	bacterial cell wall synthesis inhibitor		infectious disease	tuberculosis	0	100.0	Selleck	S4004	Ethambutol HCl	204.184	CC[C@@H](CO)NCCN[C@@H](CC)CO	AEUTYOVWOVBAKS-UWVGGRQHSA-N	14052.0		AEUTYOVWOVBAKS
BRD-K38055836-001-22-9	ethamivan	Preclinical	respiratory stimulant				0	87.48	Sigma	MFCD00026727	N,N-diethyl-4-hydroxy-3-methoxybenzamide	223.121	CCN(CC)C(=O)c1ccc(O)c(OC)c1	BQJODPIMMWWMFC-UHFFFAOYSA-N	9363.0		BQJODPIMMWWMFC
BRD-K38055836-001-21-1	ethamivan	Preclinical	respiratory stimulant				0	83.41	MicroSource	1505994	ETHAMIVAN	223.121	CCN(CC)C(=O)c1ccc(O)c(OC)c1	BQJODPIMMWWMFC-UHFFFAOYSA-N	9363.0		BQJODPIMMWWMFC
BRD-M75061779-001-01-2	ethanolamine-oleate	Launched	immunostimulant	F12|FABP4|FFAR1|FFAR4|PLD2	gastroenterology	esophageal varices	1	0.0	MicroSource	1506170	ETHANOLAMINE OLEATE	343.309	NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O	KGWDUNBJIMUFAP-KVVVOXFISA-N	5282489.0		KGWDUNBJIMUFAP
BRD-K36756879-003-08-7	ethaverine	Launched	calcium channel blocker		neurology/psychiatry	muscle relaxant|spasms	0	99.19	MicroSource	1501000	ETHAVERINE HYDROCHLORIDE	395.21	CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	ZOWYFYXTIWQBEP-UHFFFAOYSA-N	3280.0		ZOWYFYXTIWQBEP
BRD-K36756879-001-09-9	ethaverine	Launched	calcium channel blocker		neurology/psychiatry	muscle relaxant|spasms	0	96.9	Toronto	e676700	ethaverine	395.21	CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	ZOWYFYXTIWQBEP-UHFFFAOYSA-N	3280.0		ZOWYFYXTIWQBEP
BRD-K88308881-001-08-9	ethenzamide	Launched	analgesic agent		neurology/psychiatry|endocrinology|otolaryngology	headache|fever|common cold	0	96.51	MedChemEx	HY-B1428	2-Ethoxybenzamide	165.079	CCOc1ccccc1C(N)=O	SBNKFTQSBPKMBZ-UHFFFAOYSA-N	3282.0		SBNKFTQSBPKMBZ
BRD-K88308881-001-06-8	ethenzamide	Launched	analgesic agent		neurology/psychiatry|endocrinology|otolaryngology	headache|fever|common cold	0	99.07	MicroSource	1502735	ETHENZAMIDE	165.079	CCOc1ccccc1C(N)=O	SBNKFTQSBPKMBZ-UHFFFAOYSA-N	3282.0		SBNKFTQSBPKMBZ
BRD-K19672466-001-02-3	ethimizol	Phase 1					0	99.78	MedChemEx	HY-13918	Etimizol	210.112	CCn1cnc(C(=O)NC)c1C(=O)NC	RYRFAMRQBZNEPX-UHFFFAOYSA-N	6168.0		RYRFAMRQBZNEPX
BRD-K19672466-001-04-9	ethimizol	Phase 1					0	97.86	MedChemEx	HY-13918	Etimizol	210.112	CCn1cnc(C(=O)NC)c1C(=O)NC	RYRFAMRQBZNEPX-UHFFFAOYSA-N	6168.0		RYRFAMRQBZNEPX
BRD-K48195008-001-19-9	ethinyl-estradiol	Launched	estrogen receptor agonist|estrogenic hormone	ESR1|ESR2|NR1I2	endocrinology	contraceptive	0	96.04	MicroSource	1500291	ETHINYL ESTRADIOL	296.178	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	BFPYWIDHMRZLRN-SLHNCBLASA-N	5991.0	BRD-A02367930-001-04-5	BFPYWIDHMRZLRN
BRD-K48195008-001-17-3	ethinyl-estradiol	Launched	estrogen receptor agonist|estrogenic hormone	ESR1|ESR2|NR1I2	endocrinology	contraceptive	0	80.36	Selleck	S1625	Ethinyl Estradiol	296.178	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	BFPYWIDHMRZLRN-SLHNCBLASA-N	5991.0		BFPYWIDHMRZLRN
BRD-K48195008-001-18-1	ethinyl-estradiol	Launched	estrogen receptor agonist|estrogenic hormone	ESR1|ESR2|NR1I2	endocrinology	contraceptive	0	87.81	Selleck	S1625	Ethinyl Estradiol	296.178	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	BFPYWIDHMRZLRN-SLHNCBLASA-N	5991.0	BRD-K42555202-001-01-2	BFPYWIDHMRZLRN
BRD-K33710385-001-05-9	ethionamide	Launched	mycolic synthesis inhibitor		infectious disease	tuberculosis	0	98.1	MicroSource	1500292	ETHIONAMIDE	166.056	CCc1cc(ccn1)C(N)=S	AEOCXXJPGCBFJA-UHFFFAOYSA-N	2761171.0		AEOCXXJPGCBFJA
BRD-K33710385-001-06-9	ethionamide	Launched	mycolic synthesis inhibitor		infectious disease	tuberculosis	0	94.18	Selleck	S1777	Ethionamide	166.056	CCc1cc(ccn1)C(N)=S	AEOCXXJPGCBFJA-UHFFFAOYSA-N	2761171.0		AEOCXXJPGCBFJA
BRD-K33710385-001-28-9	ethionamide	Launched	mycolic synthesis inhibitor		infectious disease	tuberculosis	0	95.01	MedChemEx	HY-B0276	Ethionamide	166.056	CCc1cc(ccn1)C(N)=S	AEOCXXJPGCBFJA-UHFFFAOYSA-N	2761171.0		AEOCXXJPGCBFJA
BRD-K03981224-001-19-3	ethisterone	Launched	progestogen hormone	TYR	endocrinology	amenorrhea	0	83.11	Selleck	S2611	Ethisterone	312.209	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	CHNXZKVNWQUJIB-CEGNMAFCSA-N	5284557.0		CHNXZKVNWQUJIB
BRD-K03981224-001-22-9	ethisterone	Launched	progestogen hormone	TYR	endocrinology	amenorrhea	0	79.54	MedChemEx	HY-B0487	Ethisterone	312.209	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	CHNXZKVNWQUJIB-CEGNMAFCSA-N	5284557.0		CHNXZKVNWQUJIB
BRD-K03981224-001-21-9	ethisterone	Launched	progestogen hormone	TYR	endocrinology	amenorrhea	0	81.08	Selleck	S2611	Ethisterone	312.209	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	CHNXZKVNWQUJIB-CEGNMAFCSA-N	5284557.0	BRD-K00456604-001-01-7	CHNXZKVNWQUJIB
BRD-K02475039-001-01-0	ethopabate	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	97.78	MicroSource	1505424	ETHOPABATE	237.1	CCOc1cc(NC(C)=O)ccc1C(=O)OC	GOVWOKSKFSBNGD-UHFFFAOYSA-N	6034.0		GOVWOKSKFSBNGD
BRD-K02475039-001-02-9	ethopabate	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	96.41	MedChemEx	HY-B2138	Ethopabate	237.1	CCOc1cc(NC(C)=O)ccc1C(=O)OC	GOVWOKSKFSBNGD-UHFFFAOYSA-N	6034.0		GOVWOKSKFSBNGD
BRD-A99633051-001-08-8	ethosuximide	Launched	succinimide antiepileptic	CACNA1G|CACNA1H|CACNA1I	neurology/psychiatry	epilepsy	0	99.47	Sigma	MFCD00072123	4-ethyl-5-hydroxy-4-methyl-3,4-dihydro-2H-pyrrol-2-one	141.079	CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|	HAPOVYFOVVWLRS-ZETCQYMHSA-N	10630591.0		HAPOVYFOVVWLRS
BRD-A99633051-001-07-0	ethosuximide	Launched	succinimide antiepileptic	CACNA1G|CACNA1H|CACNA1I	neurology/psychiatry	epilepsy	0	75.49	MicroSource	1502196	ETHOSUXIMIDE	141.079	CC[C@@]1(C)CC(=O)NC1=O |&1:2,r|	HAPOVYFOVVWLRS-ZETCQYMHSA-N	10630591.0		HAPOVYFOVVWLRS
BRD-A30205217-001-11-2	ethotoin	Launched	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	0	83.77	MicroSource	1505428	ETHOTOIN	204.09	CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|	SZQIFWWUIBRPBZ-SECBINFHSA-N	12309784.0		SZQIFWWUIBRPBZ
BRD-A30205217-001-12-0	ethotoin	Launched	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	0	97.23	AMS	A001578171	3-ethyl-5-phenyl-2,4-imidazolidinedione	204.09	CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|	SZQIFWWUIBRPBZ-SECBINFHSA-N	12309784.0		SZQIFWWUIBRPBZ
BRD-K56792340-001-14-9	ethoxyquin	Preclinical	antioxidant				0	93.42	MedChemEx	HY-B1425	Ethoxyquin	217.147	CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|	DECIPOUIJURFOJ-UHFFFAOYSA-N	3293.0		DECIPOUIJURFOJ
BRD-K56792340-001-13-2	ethoxyquin	Preclinical	antioxidant				0	42.49	Prestwick	Prestw-765	Ethoxyquin	217.147	CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|	DECIPOUIJURFOJ-UHFFFAOYSA-N	3293.0		DECIPOUIJURFOJ
BRD-K18131774-001-18-4	ethoxzolamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease	0	83.88	MicroSource	1505426	ETHOXZOLAMIDE	258.013	CCOc1ccc2nc(sc2c1)S(N)(=O)=O	OUZWUKMCLIBBOG-UHFFFAOYSA-N	3295.0		OUZWUKMCLIBBOG
BRD-K18131774-001-17-6	ethoxzolamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9	ophthalmology|gastroenterology	glaucoma|duodenal ulcer disease	0	96.7	Selleck	S4326	Ethoxzolamide	258.013	CCOc1ccc2nc(sc2c1)S(N)(=O)=O	OUZWUKMCLIBBOG-UHFFFAOYSA-N	3295.0		OUZWUKMCLIBBOG
BRD-K02464583-001-03-9	ethyl-paraben	Preclinical					0	88.85	MedChemEx	HY-B0934	Ethylparaben	166.063	CCOC(=O)c1ccc(O)cc1	NUVBSKCKDOMJSU-UHFFFAOYSA-N	8434.0		NUVBSKCKDOMJSU
BRD-K02464583-001-02-2	ethyl-paraben	Preclinical					0	99.39	MicroSource	1400151	ETHYL PARABEN	166.063	CCOC(=O)c1ccc(O)cc1	NUVBSKCKDOMJSU-UHFFFAOYSA-N	8434.0		NUVBSKCKDOMJSU
BRD-K47738867-001-01-5	ethyl-pyruvate	Phase 2	tumor necrosis factor production inhibitor				0	0.0	Sigma	W245735	ethyl 2-oxopropanoate	116.047	CCOC(=O)C(O)=C	PSYUBHDPOIZRST-UHFFFAOYSA-N	11228779.0		PSYUBHDPOIZRST
BRD-K82104468-001-08-9	ethyl-vanillin	Preclinical					0	96.99	MedChemEx	HY-B0940	Ethylvanillin	166.063	CCOc1cc(C=O)ccc1O	CBOQJANXLMLOSS-UHFFFAOYSA-N	8467.0		CBOQJANXLMLOSS
BRD-K82104468-001-05-0	ethyl-vanillin	Preclinical					0	97.9	MicroSource	1503887	ETHYL VANILLIN	166.063	CCOc1cc(C=O)ccc1O	CBOQJANXLMLOSS-UHFFFAOYSA-N	8467.0		CBOQJANXLMLOSS
BRD-K21892374-001-01-6	ethyl-2-(carbamoyloxy)benzoate	Phase 1					0	0.0	Enamine	Z2306534743	ethyl 2-[(aminocarbonyl)oxy]benzoate	209.069	CCOC(=O)c1ccccc1OC(N)=O	JFMIIMPCFQKAAD-UHFFFAOYSA-N	145917.0		JFMIIMPCFQKAAD
BRD-K82603084-408-01-1	ethylenediaminetetraacetic-acid	Launched	PKC inhibitor		neurology/psychiatry	metal toxicity	0	100.0	MicroSource	1500270	ETHYLENEDIAMINE TETRACETATE TETRA-ETHANOLAMINE	292.091	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	KCXVZYZYPLLWCC-UHFFFAOYSA-N	6049.0		KCXVZYZYPLLWCC
BRD-K82603084-001-04-9	ethylenediaminetetraacetic-acid	Launched	PKC inhibitor		neurology/psychiatry	metal toxicity	0	0.0	MedChemEx	HY-Y0682	Ethylenediaminetetraacetic acid	292.091	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	KCXVZYZYPLLWCC-UHFFFAOYSA-N	6049.0		KCXVZYZYPLLWCC
BRD-A68509429-003-03-9	ethylnorepinephrine	Preclinical	bronchodilator				0	95.14	MicroSource	1504088	ETHYLNOREPINEPHRINE HYDROCHLORIDE	197.105	CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:4|	LENNRXOJHWNHSD-XCBNKYQSSA-N	25271661.0		LENNRXOJHWNHSD
BRD-K46331928-001-09-9	ethynodiol-diacetate	Launched		ESR1|PGR	endocrinology	contraceptive	0	84.02	MedChemEx	HY-B1089	Ethynodiol (diacetate)	384.23	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|	ONKUMRGIYFNPJW-KIEAKMPYSA-N	9270.0		ONKUMRGIYFNPJW
BRD-K46331928-001-05-8	ethynodiol-diacetate	Launched		ESR1|PGR	endocrinology	contraceptive	0	96.02	MicroSource	1505979	ETHYNODIOL DIACETATE	384.23	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|	ONKUMRGIYFNPJW-KIEAKMPYSA-N	9270.0		ONKUMRGIYFNPJW
BRD-K46331928-001-06-6	ethynodiol-diacetate	Launched		ESR1|PGR	endocrinology	contraceptive	0	99.51	Selleck	S3160	Ethynodiol diacetate	384.23	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|	ONKUMRGIYFNPJW-KIEAKMPYSA-N	9270.0		ONKUMRGIYFNPJW
BRD-K46331928-001-08-2	ethynodiol-diacetate	Launched		ESR1|PGR	endocrinology	contraceptive	0	0.0	Selleck	S3160	Ethynodiol diacetate	384.23	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|	ONKUMRGIYFNPJW-KIEAKMPYSA-N	9270.0	BRD-K06056310-001-01-4	ONKUMRGIYFNPJW
BRD-K00003207-001-01-9	ethynylcytidine	Preclinical	antimetabolite				0	88.5	MedChemEx	HY-16200	Ethynylcytidine	267.086	Nc1ccn([C@@H]2O[C@H](CO)[C@](O)(C#C)[C@H]2O)c(=O)n1	JFIWEPHGRUDAJN-DYUFWOLASA-N	176885.0		JFIWEPHGRUDAJN
BRD-K50417881-003-18-9	eticlopride	Preclinical	dopamine receptor antagonist	DRD2|DRD3|DRD4			0	98.13	Tocris	1847	Eticlopride hydrochloride	340.155	CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	AADCDMQTJNYOSS-LBPRGKRZSA-N	57267.0		AADCDMQTJNYOSS
BRD-K50417881-003-17-4	eticlopride	Preclinical	dopamine receptor antagonist	DRD2|DRD3|DRD4			0	97.96	Tocris	1847	Eticlopride hydrochloride	340.155	CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	AADCDMQTJNYOSS-LBPRGKRZSA-N	57267.0		AADCDMQTJNYOSS
BRD-K37949327-304-06-1	etidronic-acid	Launched	bone resorption inhibitor	ATP6V1A|PTPRS	endocrinology|orthopedics	Paget's disease|heterotopic ossification	1	0.0	MicroSource	1505537	ETIDRONATE DISODIUM	205.975	CC(O)(P(O)(O)=O)P(O)(O)=O	DBVJJBKOTRCVKF-UHFFFAOYSA-N	3305.0		DBVJJBKOTRCVKF
BRD-K37949327-001-09-9	etidronic-acid	Launched	bone resorption inhibitor	ATP6V1A|PTPRS	endocrinology|orthopedics	Paget's disease|heterotopic ossification	1	100.0	MedChemEx	HY-B0302	Etidronic acid	205.975	CC(O)(P(O)(O)=O)P(O)(O)=O	DBVJJBKOTRCVKF-UHFFFAOYSA-N	3305.0		DBVJJBKOTRCVKF
BRD-K37949327-001-07-1	etidronic-acid	Launched	bone resorption inhibitor	ATP6V1A|PTPRS	endocrinology|orthopedics	Paget's disease|heterotopic ossification	1	0.0	Selleck	S1857	Etidronate (Didronel)	205.975	CC(O)(P(O)(O)=O)P(O)(O)=O	DBVJJBKOTRCVKF-UHFFFAOYSA-N	3305.0		DBVJJBKOTRCVKF
BRD-K37949327-001-06-3	etidronic-acid	Launched	bone resorption inhibitor	ATP6V1A|PTPRS	endocrinology|orthopedics	Paget's disease|heterotopic ossification	1	0.0	Selleck	S1857	Etidronate (Didronel)	205.975	CC(O)(P(O)(O)=O)P(O)(O)=O	DBVJJBKOTRCVKF-UHFFFAOYSA-N	3305.0		DBVJJBKOTRCVKF
BRD-K63979671-001-11-9	etifenin	Preclinical	renal function diagnostic agent				0	90.72	CombiBlocks	QF-7906	N-(2,6-Diethylphenylcarbamoylmethyl)iminodiacetic acid	322.153	CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O	WNIDXAKKFOKNEF-UHFFFAOYSA-N	170344.0		WNIDXAKKFOKNEF
BRD-K63979671-001-10-1	etifenin	Preclinical	renal function diagnostic agent				0	46.68	Prestwick	Prestw-504	Etifenin	322.153	CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O	WNIDXAKKFOKNEF-UHFFFAOYSA-N	170344.0		WNIDXAKKFOKNEF
BRD-K01826330-001-01-9	etifoxine	Launched	GABA receptor modulator	GABRA1|GABRA2|GABRA3|GABRA5	neurology/psychiatry	anxiety	0	98.68	MedChemEx	HY-16579A	Etifoxine	300.103	CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12,r,t:3|	IBYCYJFUEJQSMK-KRWDZBQOSA-N	135564604.0		IBYCYJFUEJQSMK
BRD-A09925278-003-05-6	etilefrine	Launched	adrenergic receptor agonist	ADRA1A|ADRB1	neurology/psychiatry|otolaryngology|endocrinology|pulmonary	headache|nasal congestion|fever|cough suppressant|common cold	0	88.17	Prestwick	Prestw-1017	Etilefrine hydrochloride	181.11	CCNCC(O)c1cccc(O)c1	SQVIAVUSQAWMKL-UHFFFAOYSA-N	164652.0		SQVIAVUSQAWMKL
BRD-K90982969-003-01-8	etilevodopa	Phase 3	dopamine receptor agonist	DRD3			0	71.67	Enamine	Z756916070		225.1	CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	NULMGOSOSZBEQL-QMMMGPOBSA-N	170345.0		NULMGOSOSZBEQL
BRD-K90982969-001-01-2	etilevodopa	Phase 3	dopamine receptor agonist	DRD3			0	95.55	Sigma	SML0091	ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate	225.1	CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	NULMGOSOSZBEQL-QMMMGPOBSA-N	170345.0		NULMGOSOSZBEQL
BRD-K68232413-001-02-9	etizolam	Launched	benzodiazepine receptor agonist	GABRA1	neurology/psychiatry	insomnia|anxiety	0	97.53	MedChemEx	HY-B0677	Etizolam	342.071	CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|	VMZUTJCNQWMAGF-UHFFFAOYSA-N	3307.0		VMZUTJCNQWMAGF
BRD-K68232413-001-01-2	etizolam	Launched	benzodiazepine receptor agonist	GABRA1	neurology/psychiatry	insomnia|anxiety	0	99.78	MedChemEx	HY-B0677	Etizolam	342.071	CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|	VMZUTJCNQWMAGF-UHFFFAOYSA-N	3307.0		VMZUTJCNQWMAGF
BRD-A74667430-001-25-1	etodolac	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	97.85	Selleck	S1328	Etodolac	287.152	CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|	NNYBQONXHNTVIJ-KRWDZBQOSA-N	688461.0	BRD-K36911961-001-01-6	NNYBQONXHNTVIJ
BRD-A74667430-001-23-6	etodolac	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	99.16	MicroSource	1501005	ETODOLAC	287.152	CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|	NNYBQONXHNTVIJ-KRWDZBQOSA-N	688461.0		NNYBQONXHNTVIJ
BRD-A74667430-001-26-9	etodolac	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	96.34	Tocris	3871	Etodolac	287.152	CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11,r|	NNYBQONXHNTVIJ-KRWDZBQOSA-N	688461.0		NNYBQONXHNTVIJ
BRD-K73541271-001-03-6	etofenamate	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology	muscle pain|joint pain	0	97.04	MedChemEx	HY-17361	Etofenamate	369.119	OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	XILVEPYQJIOVNB-UHFFFAOYSA-N	35375.0		XILVEPYQJIOVNB
BRD-K73541271-001-04-9	etofenamate	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology	muscle pain|joint pain	0	98.02	MedChemEx	HY-17361	Etofenamate	369.119	OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	XILVEPYQJIOVNB-UHFFFAOYSA-N	35375.0		XILVEPYQJIOVNB
BRD-K49338325-001-03-4	etofibrate	Launched	PPAR receptor agonist	PPARA	endocrinology	hypertriglyceridemia	0	95.38	Selleck	S4264	Etofibrate	363.087	CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1	XXRVYAFBUDSLJX-UHFFFAOYSA-N	65777.0		XXRVYAFBUDSLJX
BRD-K83064458-001-24-9	etofylline	Launched	adenosine receptor antagonist	ADORA1	pulmonary	asthma|bronchitis	0	98.19	MedChemEx	HY-B1209	Etofylline	224.091	Cn1c2ncn(CCO)c2c(=O)n(C)c1=O	NWPRCRWQMGIBOT-UHFFFAOYSA-N	1892.0		NWPRCRWQMGIBOT
BRD-K83064458-001-23-0	etofylline	Launched	adenosine receptor antagonist	ADORA1	pulmonary	asthma|bronchitis	0	98.82	Enzo	AC627	7-(b-Hydroxyethyl)theophylline	224.091	Cn1c2ncn(CCO)c2c(=O)n(C)c1=O	NWPRCRWQMGIBOT-UHFFFAOYSA-N	1892.0		NWPRCRWQMGIBOT
BRD-K49840922-001-05-1	etofylline-clofibrate	Launched	platelet aggregation inhibitor	PPARA	endocrinology	hyperlipidemia	0	99.43	Enamine	Z51093246		420.12	Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	KYAKGJDISSNVPZ-UHFFFAOYSA-N	41109.0		KYAKGJDISSNVPZ
BRD-K49840922-001-06-9	etofylline-clofibrate	Launched	platelet aggregation inhibitor	PPARA	endocrinology	hyperlipidemia	0	96.59	SantaCruz	sc-337840A	Etofylline clofibrate	420.12	Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	KYAKGJDISSNVPZ-UHFFFAOYSA-N	41109.0		KYAKGJDISSNVPZ
BRD-K55055802-001-09-4	etomidate	Launched	GABA receptor modulator	ADRA2B|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	neurology/psychiatry	general anaesthetic	0	17.23	MicroSource	1505599	ETOMIDATE	244.121	CCOC(=O)c1cncn1[C@H](C)c1ccccc1	NPUKDXXFDDZOKR-LLVKDONJSA-N	667484.0		NPUKDXXFDDZOKR
BRD-K55055802-001-10-2	etomidate	Launched	GABA receptor modulator	ADRA2B|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	neurology/psychiatry	general anaesthetic	0	95.99	Selleck	S1329	Etomidate	244.121	CCOC(=O)c1cncn1[C@H](C)c1ccccc1	NPUKDXXFDDZOKR-LLVKDONJSA-N	667484.0	BRD-A54880345-001-20-9	NPUKDXXFDDZOKR
BRD-K55055802-001-08-6	etomidate	Launched	GABA receptor modulator	ADRA2B|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	neurology/psychiatry	general anaesthetic	0	94.92	Tocris	1471	Etomidate	244.121	CCOC(=O)c1cncn1[C@H](C)c1ccccc1	NPUKDXXFDDZOKR-LLVKDONJSA-N	667484.0		NPUKDXXFDDZOKR
BRD-K32405725-001-02-8	etomoxir	Phase 2	carnitine palmitoyltransferase inhibitor	CPT1A			0	98.66	MedChemEx	HY-50202	Etomoxir	326.128	CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1	DZLOHEOHWICNIL-QGZVFWFLSA-N	9840324.0		DZLOHEOHWICNIL
BRD-K00003655-001-01-9	etonogestrel	Launched	progesterone receptor agonist	ESR1|PGR	endocrinology	contraceptive	0	76.12	MedChemEx	HY-B0652	Etonogestrel	324.209	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|	GCKFUYQCUCGESZ-BPIQYHPVSA-N	6917715.0		GCKFUYQCUCGESZ
BRD-K37798499-001-24-9	etoposide	Launched	topoisomerase inhibitor	TOP2A|TOP2B	oncology	non-small cell lung cancer (NSCLC)	0	92.06	Tocris	1226	Etoposide	588.184	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	VJJPUSNTGOMMGY-MRVIYFEKSA-N	36462.0		VJJPUSNTGOMMGY
BRD-K37798499-001-25-6	etoposide	Launched	topoisomerase inhibitor	TOP2A|TOP2B	oncology	non-small cell lung cancer (NSCLC)	0	99.86	MedChemEx	HY-13629	etoposide	588.184	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	VJJPUSNTGOMMGY-MRVIYFEKSA-N	36462.0		VJJPUSNTGOMMGY
BRD-K37798499-001-18-1	etoposide	Launched	topoisomerase inhibitor	TOP2A|TOP2B	oncology	non-small cell lung cancer (NSCLC)	0	82.35	Selleck	S1225	Etoposide (VP-16);Etoposide	588.184	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	VJJPUSNTGOMMGY-MRVIYFEKSA-N	36462.0		VJJPUSNTGOMMGY
BRD-K37798499-001-27-2	etoposide	Launched	topoisomerase inhibitor	TOP2A|TOP2B	oncology	non-small cell lung cancer (NSCLC)	0	97.77	MicroSource	1500903	ETOPOSIDE	588.184	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	VJJPUSNTGOMMGY-MRVIYFEKSA-N	36462.0	BRD-A33280134-001-04-7	VJJPUSNTGOMMGY
BRD-K37798499-001-22-3	etoposide	Launched	topoisomerase inhibitor	TOP2A|TOP2B	oncology	non-small cell lung cancer (NSCLC)	0	77.0	Selleck	S1225	Etoposide	588.184	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	VJJPUSNTGOMMGY-MRVIYFEKSA-N	36462.0	BRD-K36186323-001-01-8	VJJPUSNTGOMMGY
BRD-K37798499-001-21-5	etoposide	Launched	topoisomerase inhibitor	TOP2A|TOP2B	oncology	non-small cell lung cancer (NSCLC)	0	80.82	Tocris	1226	Etoposide	588.184	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	VJJPUSNTGOMMGY-MRVIYFEKSA-N	36462.0	BRD-A26175277-001-02-9|BRD-A35357953-001-01-5	VJJPUSNTGOMMGY
BRD-K72533376-001-01-2	etoposide-phosphate	Launched	topoisomerase inhibitor	TOP2A	oncology	testicular carcinoma|small cell lung cancer	0	94.37	ChemImpex	28305	4-[(5R,5aR,8aR,9S)-9-({4,6-O-[(1R)-ethylidene]-beta-D-glucopyranosyl}oxy)-6-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl]-2,6-dimethoxyphenyl dihydrogen phosphate	668.151	COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	LIQODXNTTZAGID-OCBXBXKTSA-N	6918092.0		LIQODXNTTZAGID
BRD-K54770957-001-04-3	etoricoxib	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis|psoriatic arthritis|osteoarthritis|gout|ankylosing spondylitis	0	99.25	MedChemEx	HY-15321	Etoricoxib	358.054	Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O	MNJVRJDLRVPLFE-UHFFFAOYSA-N	123619.0		MNJVRJDLRVPLFE
BRD-K60914966-001-01-4	etosalamide	Preclinical	anti-inflammatory agent				0	95.92	MicroSource	1503888	ETOSALAMIDE	209.105	CCOCCOc1ccccc1C(N)=O	XBNRCMFFZFCWMH-UHFFFAOYSA-N	208946.0		XBNRCMFFZFCWMH
BRD-K60914966-001-02-9	etosalamide	Preclinical	anti-inflammatory agent				0	90.7	MedChemEx	HY-B1015	Etosalamide	209.105	CCOCCOc1ccccc1C(N)=O	XBNRCMFFZFCWMH-UHFFFAOYSA-N	208946.0		XBNRCMFFZFCWMH
BRD-K51364817-001-01-4	etoxybamide	Phase 2					0	69.8	Sigma	PH008175	4-hydroxy-N-(2-hydroxyethyl)butanamide	147.09	OCCCC(=O)NCCO	MFHPPMMWHSHDSI-UHFFFAOYSA-N	522232.0		MFHPPMMWHSHDSI
BRD-K15858023-001-02-9	ETP-45658	Preclinical	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	94.87	Tocris	4702	ETP 45658	311.138	Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1	BJVRNXSHJLDZJR-UHFFFAOYSA-N	25229608.0		BJVRNXSHJLDZJR
BRD-K15858023-001-01-0	ETP-45658	Preclinical	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	97.88	Tocris	4702	ETP 45658	311.138	Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1	BJVRNXSHJLDZJR-UHFFFAOYSA-N	25229608.0		BJVRNXSHJLDZJR
BRD-K24556407-001-02-3	ETP-46464	Preclinical	ATR kinase inhibitor				0	97.39	Selleck	S8050	ETP-46464	470.174	CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	DPLMXAYKJZOTKO-UHFFFAOYSA-N	72199292.0		DPLMXAYKJZOTKO
BRD-K24556407-001-01-5	ETP-46464	Preclinical	ATR kinase inhibitor				0		CNIO		ETP	470.174	CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	InChI=1S/C30H22N4O2/c1-30(2,18-31)23-8-10-24(11-9-23)34-28-22(17-36-29(34)35)16-33-27-12-7-19(14-25(27)28)21-13-20-5-3-4-6-26(20)32-15-21/h3-16H,17H2,1-2H3	72199292.0		DPLMXAYKJZOTKO
BRD-K00004658-001-01-9	etrabamine	Phase 2	dopamine receptor agonist				0	100.0	Enamine	EN300-1268571	N-methyl-4,5,6,7-tetrahydro-1,3-benzothiazol-6-amine	168.072	CN[C@H]1CCc2ncsc2C1 |&1:2,r|	YDSVAKPJAOSZJA-LURJTMIESA-N	92274373.0		YDSVAKPJAOSZJA
BRD-K00003139-001-01-9	etrasimod	Phase 3	sphingosine 1-phosphate receptor antagonist				0	95.59	MedChemEx	HY-12789	Etrasimod	457.186	OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21	MVGWUTBTXDYMND-QGZVFWFLSA-N	44623998.0		MVGWUTBTXDYMND
BRD-K74717603-001-03-9	etravirine	Launched	non-nucleoside reverse transcriptase inhibitor	CYP2C19|CYP2C9|CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	97.45	MedChemEx	HY-90005	Etravirine	434.049	Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N	PYGWGZALEOIKDF-UHFFFAOYSA-N	193962.0		PYGWGZALEOIKDF
BRD-K74717603-001-02-2	etravirine	Launched	non-nucleoside reverse transcriptase inhibitor	CYP2C19|CYP2C9|CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	92.21	Selleck	S3080	Etravirine (TMC125)	434.049	Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N	PYGWGZALEOIKDF-UHFFFAOYSA-N	193962.0		PYGWGZALEOIKDF
BRD-K49076555-001-05-6	etretinate	Withdrawn	protein synthesis inhibitor	RARA|RXRG			0	87.97	MedChemEx	HY-B0797	Etretinate	354.219	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C	HQMNCQVAMBCHCO-DJRRULDNSA-N	5282375.0		HQMNCQVAMBCHCO
BRD-K49076555-001-03-1	etretinate	Withdrawn	protein synthesis inhibitor	RARA|RXRG			0	44.02	MedChemEx	HY-B0797	ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate	354.219	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C	HQMNCQVAMBCHCO-DJRRULDNSA-N	5282375.0		HQMNCQVAMBCHCO
BRD-K49076555-001-01-5	etretinate	Withdrawn	protein synthesis inhibitor	RARA|RXRG			0	54.9	Prestwick	Prestw-1409	Etretinate	354.219	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C	HQMNCQVAMBCHCO-DJRRULDNSA-N	5282375.0		HQMNCQVAMBCHCO
BRD-K49076555-001-04-9	etretinate	Withdrawn	protein synthesis inhibitor	RARA|RXRG			0	47.98	MedChemEx	HY-B0797	Etretinate	354.219	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C	HQMNCQVAMBCHCO-DJRRULDNSA-N	5282375.0		HQMNCQVAMBCHCO
BRD-K29996876-001-10-1	eucalyptol	Launched	acetylcholinesterase inhibitor	ACHE	dental	gingivitis	0	0.0	MicroSource	1500294	EUCALYPTOL	154.136	CC12CCC(CC1)C(C)(C)O2	WEEGYLXZBRQIMU-UHFFFAOYSA-N	2758.0	BRD-K15671046-001-03-6	WEEGYLXZBRQIMU
BRD-K29996876-001-09-3	eucalyptol	Launched	acetylcholinesterase inhibitor	ACHE	dental	gingivitis	0	0.0	AMS	A001464384	1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane	154.136	CC12CCC(CC1)C(C)(C)O2	WEEGYLXZBRQIMU-UHFFFAOYSA-N	2758.0		WEEGYLXZBRQIMU
BRD-A37942872-001-21-9	eucatropine	Preclinical	acetylcholine receptor antagonist				0	46.92	AMS	A001585243	Eucatropine	291.183	C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|	QSAVEGSLJISCDF-QEJZJMRPSA-N	42105272.0		QSAVEGSLJISCDF
BRD-A37942872-003-20-6	eucatropine	Preclinical	acetylcholine receptor antagonist				0	54.26	Prestwick	Prestw-794	Eucatropine hydrochloride	291.183	C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1,&2:3,&3:13|	QSAVEGSLJISCDF-QEJZJMRPSA-N	42105272.0		QSAVEGSLJISCDF
BRD-K32977963-001-05-0	eugenol	Launched	androgen receptor antagonist	AR	dental	toothache	0	92.11	MicroSource	1500296	EUGENOL	164.084	COc1cc(CC=C)ccc1O	RRAFCDWBNXTKKO-UHFFFAOYSA-N	3314.0		RRAFCDWBNXTKKO
BRD-K32977963-001-10-9	eugenol	Launched	androgen receptor antagonist	AR	dental	toothache	0	47.4	MedChemEx	HY-N0337	Eugenol	164.084	COc1cc(CC=C)ccc1O	RRAFCDWBNXTKKO-UHFFFAOYSA-N	3314.0		RRAFCDWBNXTKKO
BRD-K19741031-001-02-2	EUK-134	Preclinical	catalase stimulant	APP|SOD2			1	59.9	Selleck	S4261	EUK 134	416.034	COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|	QCAWBJDECIOVBU-GAMUHHASSA-K		BRD-U78472365-000-01-0	QCAWBJDECIOVBU
BRD-K19741031-001-01-4	EUK-134	Preclinical	catalase stimulant	APP|SOD2			1	0.0	Selleck	S4261	EUK 134	416.034	COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|	QCAWBJDECIOVBU-GAMUHHASSA-K		BRD-U78671345-000-01-2	QCAWBJDECIOVBU
BRD-K19741031-001-03-0	EUK-134	Preclinical	catalase stimulant	APP|SOD2			1	0.0	Selleck	S4261	EUK 134	416.034	COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7,11|	QCAWBJDECIOVBU-GAMUHHASSA-K			QCAWBJDECIOVBU
BRD-K47031502-001-02-4	eupatilin	Launched	mucus protecting agent				0	94.26	MedChemEx	HY-N0783	Eupatilin	344.09	COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1	DRRWBCNQOKKKOL-UHFFFAOYSA-N	5273755.0		DRRWBCNQOKKKOL
BRD-K47031502-001-01-6	eupatilin	Launched	mucus protecting agent				0	80.03	Astatech	SC3971		344.09	COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1	DRRWBCNQOKKKOL-UHFFFAOYSA-N	5273755.0		DRRWBCNQOKKKOL
BRD-K16551357-001-04-9	evacetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	63.87	MedChemEx	HY-13327	Evacetrapib	638.28	Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	IHIUGIVXARLYHP-YBXDKENTSA-N			IHIUGIVXARLYHP
BRD-K16551357-001-02-4	evacetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	0.3	Selleck	S2925	Evacetrapib (LY2484595)	638.28	Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	IHIUGIVXARLYHP-YBXDKENTSA-N			IHIUGIVXARLYHP
BRD-K16551357-001-03-2	evacetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	94.86	Selleck	S2925	Evacetrapib (LY2484595)	638.28	Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	IHIUGIVXARLYHP-YBXDKENTSA-N			IHIUGIVXARLYHP
BRD-K24548560-342-02-1	evans-blue	Launched	glutamate receptor negative allosteric modulator	GRIA1|PTPN1			0	92.8	MicroSource	1300017	EVANS BLUE	872.055	Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|	LIRUWPZKVZZTHC-UHFFFAOYSA-N	6804600.0		LIRUWPZKVZZTHC
BRD-K24548560-342-03-9	evans-blue	Launched	glutamate receptor negative allosteric modulator	GRIA1|PTPN1			0	85.53	Tocris	845	Evans Blue tetrasodium salt	872.055	Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11,39|	LIRUWPZKVZZTHC-UHFFFAOYSA-N	6804600.0		LIRUWPZKVZZTHC
BRD-K11452913-001-01-9	evatanepag	Phase 2	prostaglandin inhibitor	PTGER2|PTGER4			0	96.84	MedChemEx	HY-14839	Evatanepag	468.172	CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1	WOHRHWDYFNWPNG-UHFFFAOYSA-N	9890801.0		WOHRHWDYFNWPNG
BRD-K00004688-001-01-9	evenamide	Phase 2	voltage-gated sodium channel blocker				0	87.12	Astatech	F50592	2-((3-BUTOXYPHENETHYL)AMINO)-N,N-DIMETHYLACETAMIDE	278.199	CCCCOc1cccc(CCNCC(=O)N(C)C)c1	GRHBODILPPXVKN-UHFFFAOYSA-N	25105689.0		GRHBODILPPXVKN
BRD-K13514097-001-09-9	everolimus	Launched	mTOR inhibitor	MTOR	oncology|neurology/psychiatry|genetics|urology	breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma	0	82.99	Tocris	6188	Everolimus	957.581	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|	HKVAMNSJSFKALM-FLOWVUKKSA-N			HKVAMNSJSFKALM
BRD-K13514097-001-04-6	everolimus	Launched	mTOR inhibitor	MTOR	oncology|neurology/psychiatry|genetics|urology	breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma	0	95.59	Selleck	S1120	Everolimus	957.581	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|	HKVAMNSJSFKALM-FLOWVUKKSA-N		BRD-K13154216-001-03-9	HKVAMNSJSFKALM
BRD-K13514097-001-05-3	everolimus	Launched	mTOR inhibitor	MTOR	oncology|neurology/psychiatry|genetics|urology	breast cancer|neuroendocrine tumors of pancreatic origin (PNET)|renal cell carcinoma (RCC)|subependymal giant cell astrocytoma (SEGA)|tuberous sclerosis complex (TSC)|renal angiomyolipoma	0	91.39	Selleck	S1120	Everolimus (RAD001)	957.581	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14,33,t:29,31|	HKVAMNSJSFKALM-FLOWVUKKSA-N		BRD-K13154216-001-01-3	HKVAMNSJSFKALM
BRD-K00003405-001-01-9	evobrutinib	Phase 2	Bruton's tyrosine kinase (BTK) inhibitor				0	97.4	MedChemEx	HY-101215	Evobrutinib	429.216	Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1	QUIWHXQETADMGN-UHFFFAOYSA-N	71479709.0		QUIWHXQETADMGN
BRD-K00003250-001-01-9	evocalcet	Phase 3	calcium sensitizer				0	96.3	MedChemEx	HY-17613	Evocalcet	374.199	C[C@@H](N[C@H]1CCN(C1)c1ccc(CC(O)=O)cc1)c1cccc2ccccc12	RZNUIYPHQFXBAN-XLIONFOSSA-N	71242808.0		RZNUIYPHQFXBAN
BRD-A68631409-001-05-4	evodiamine	Preclinical	ATPase inhibitor|TRPV agonist	TRPV1			0	77.71	Selleck	S2382	Evodiamine	303.137	CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|	TXDUTHBFYKGSAH-SFHVURJKSA-N	442088.0		TXDUTHBFYKGSAH
BRD-A68631409-001-06-2	evodiamine	Preclinical	ATPase inhibitor|TRPV agonist	TRPV1			0	99.0	Selleck	S2382	Evodiamine (Isoevodiamine)	303.137	CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2,r|	TXDUTHBFYKGSAH-SFHVURJKSA-N	442088.0		TXDUTHBFYKGSAH
BRD-K71603915-003-01-8	EVP-6124	Phase 3	acetylcholine receptor agonist	CHRNA7			0	95.74	MedChemEx	HY-15430A	EVP-6124 (hydrochloride)	320.075	Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2	SSRDSYXGYPJKRR-ZDUSSCGKSA-N	46196517.0		SSRDSYXGYPJKRR
BRD-K71603915-003-02-9	EVP-6124	Phase 3	acetylcholine receptor agonist	CHRNA7			0	94.38	MedChemEx	HY-15430A	Encenicline hydrochloride	320.075	Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2	SSRDSYXGYPJKRR-ZDUSSCGKSA-N	46196517.0		SSRDSYXGYPJKRR
BRD-K68395654-001-06-4	EVP4593	Preclinical	NFkB pathway inhibitor				0	87.46	MedChemEx	HY-13812	QNZ	356.164	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	IBAKVEUZKHOWNG-UHFFFAOYSA-N	509554.0		IBAKVEUZKHOWNG
BRD-K68395654-001-03-1	EVP4593	Preclinical	NFkB pathway inhibitor				0	77.11	Selleck	S4902	QNZ (EVP4593)	356.164	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	IBAKVEUZKHOWNG-UHFFFAOYSA-N	509554.0		IBAKVEUZKHOWNG
BRD-K68395654-001-05-6	EVP4593	Preclinical	NFkB pathway inhibitor				0	8.13	Selleck	S4902	QNZ (EVP4593)	356.164	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	IBAKVEUZKHOWNG-UHFFFAOYSA-N	509554.0		IBAKVEUZKHOWNG
BRD-K74396648-001-01-4	EW-7197	Phase 2	TGF beta receptor inhibitor	ACVR1B|TGFBR1			0	89.86	Selleck	S7530	EW-7197	399.161	Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1	FJCDSQATIJKQKA-UHFFFAOYSA-N	54766013.0		FJCDSQATIJKQKA
BRD-A73908300-001-09-1	EX-527	Phase 2	SIRT inhibitor	SIRT1			0	94.26	Selleck	S1541	EX 527	248.072	NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|	FUZYTVDVLBBXDL-VIFPVBQESA-N	707029.0		FUZYTVDVLBBXDL
BRD-A73908300-001-06-7	EX-527	Phase 2	SIRT inhibitor	SIRT1			0	89.2	Selleck	S1541	EX 527 (Selisistat)	248.072	NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3,r|	FUZYTVDVLBBXDL-VIFPVBQESA-N	707029.0		FUZYTVDVLBBXDL
BRD-K12609457-001-03-1	exalamide	Launched	membrane permeability inhibitor				0	98.99	MicroSource	1503403	EXALAMIDE	221.142	CCCCCCOc1ccccc1C(N)=O	CKSJXOVLXUMMFF-UHFFFAOYSA-N	3316.0		CKSJXOVLXUMMFF
BRD-K12609457-001-04-9	exalamide	Launched	membrane permeability inhibitor				0	95.17	MedChemEx	HY-B1224	Exalamide	221.142	CCCCCCOc1ccccc1C(N)=O	CKSJXOVLXUMMFF-UHFFFAOYSA-N	3316.0		CKSJXOVLXUMMFF
BRD-K35304636-001-01-0	examorelin	Phase 2	growth hormone releasing factor agonist	GHRHR|GHSR			0	85.7	Sigma	80666	(S)-2-((2R,5S,8S,11R,14S)-5-((1H-indol-3-yl)methyl)-14-amino-2-benzyl-15-(1H-imidazol-5-yl)-8-methyl-11-((2-methyl-1H-indol-3-yl)methyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadecanamido)-6-aminohex;anamide	886.46	C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	RVWNMGKSNGWLOL-GIIHNPQRSA-N	6918297.0		RVWNMGKSNGWLOL
BRD-K92150287-066-02-0	exatecan-mesylate	Phase 3	topoisomerase inhibitor	TOP1			0	86.47	MedChemEx	HY-13631A	Exatecan (Mesylate)	435.159	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	ZVYVPGLRVWUPMP-FYSMJZIKSA-N	151115.0		ZVYVPGLRVWUPMP
BRD-K92150287-066-01-2	exatecan-mesylate	Phase 3	topoisomerase inhibitor	TOP1			0	87.61	MedChemEx	HY-13631A	Exatecan (Mesylate)	435.159	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	ZVYVPGLRVWUPMP-FYSMJZIKSA-N	151115.0		ZVYVPGLRVWUPMP
BRD-K92150287-066-03-9	exatecan-mesylate	Phase 3	topoisomerase inhibitor	TOP1			0	91.3	MedChemEx	HY-13631A	Exatecan (Mesylate)	435.159	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	ZVYVPGLRVWUPMP-FYSMJZIKSA-N	151115.0		ZVYVPGLRVWUPMP
BRD-K33425534-001-10-9	exemestane	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	85.03	Tocris	3759	Exemestane	296.178	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|	BFYIZQONLCFLEV-DAELLWKTSA-N	60198.0		BFYIZQONLCFLEV
BRD-K33425534-001-12-5	exemestane	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	98.07	MicroSource	1505012	EXEMESTANE	296.178	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|	BFYIZQONLCFLEV-DAELLWKTSA-N	60198.0	BRD-A73741725-001-02-8	BFYIZQONLCFLEV
BRD-K33425534-001-11-7	exemestane	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	94.7	Selleck	S1196	Exemestane	296.178	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13,t:9|	BFYIZQONLCFLEV-DAELLWKTSA-N	60198.0	BRD-K93923542-001-02-7|BRD-K35247444-001-01-3	BFYIZQONLCFLEV
BRD-K00003559-001-01-9	exenatide	Launched	GLP receptor agonist	GLP1R	endocrinology	diabetes mellitus	0	79.7	MedChemEx	HY-13443	Exendin-4	4184.027	[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|	HTQBXNHDCUEHJF-XWLPCZSASA-N	91935542.0		HTQBXNHDCUEHJF
BRD-K81795818-019-02-9	exherin	Phase 2	cadherin antagonist	CDH2			0	75.49	MedChemEx	HY-13541A	ADH-1 trifluoroacetate	570.204	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	FQVLRGLGWNWPSS-XDKAFHOCSA-N			FQVLRGLGWNWPSS
BRD-K81795818-019-01-4	exherin	Phase 2	cadherin antagonist	CDH2			0	94.47	MedChemEx	HY-13541A	Exherin (trifluoroacetate)	570.204	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	FQVLRGLGWNWPSS-XDKAFHOCSA-N			FQVLRGLGWNWPSS
BRD-K65716359-001-04-7	exifone	Withdrawn	nootropic agent	TYR			0	95.11	Sigma	MFCD00082966	(2,3,4-trihydroxyphenyl)(3,4,5-trihydroxyphenyl)methanone	278.043	Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O	XEDWWPGWIXPVRQ-UHFFFAOYSA-N	40399.0		XEDWWPGWIXPVRQ
BRD-K65716359-001-02-1	exifone	Withdrawn	nootropic agent	TYR			0	83.42	Enzo	AC1540	Exifone	278.043	Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O	XEDWWPGWIXPVRQ-UHFFFAOYSA-N	40399.0		XEDWWPGWIXPVRQ
BRD-K37708699-001-01-4	exisulind	Phase 3	phosphodiesterase inhibitor	PDE5A			0	96.77	LKT	S8146	(Z)-2-(5-fluoro-2-methyl-1-(4-(methylsulfonyl)benzylidene)-1H-inden-3-yl)acetic acid	372.083	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|	MVGSNCBCUWPVDA-MFOYZWKCSA-N	5472495.0		MVGSNCBCUWPVDA
BRD-K96155658-001-01-5	exo-IWR-1	Preclinical	WNT signaling inhibitor negative control	TNKS			0	91.1	Tocris	3947	exo-IWR 1	409.143	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-BTYSMDAFSA-N	1163034.0		ZGSXEXBYLJIOGF
BRD-K96155658-001-02-9	exo-IWR-1	Preclinical	WNT signaling inhibitor negative control	TNKS			0	95.46	Tocris	3947	exo-IWR 1	409.143	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|	ZGSXEXBYLJIOGF-BTYSMDAFSA-N	1163034.0		ZGSXEXBYLJIOGF
BRD-K78633253-001-11-1	EXO-1	Preclinical	ARF inhibitor				0	99.03	Tocris	1850	Exo1	273.08	COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	KIAPWMKFHIKQOZ-UHFFFAOYSA-N	310557.0		KIAPWMKFHIKQOZ
BRD-K78633253-001-12-9	EXO-1	Preclinical	ARF inhibitor				0	92.11	Tocris	1850	Exo1	273.08	COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	KIAPWMKFHIKQOZ-UHFFFAOYSA-N	310557.0		KIAPWMKFHIKQOZ
BRD-K78633253-001-10-3	EXO-1	Preclinical	ARF inhibitor				0	98.16	Tocris	1850	Exo1	273.08	COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	KIAPWMKFHIKQOZ-UHFFFAOYSA-N	310557.0		KIAPWMKFHIKQOZ
BRD-K98963219-001-03-8	ezatiostat	Phase 2	glutathione transferase inhibitor	GSTP1			0	88.92	MedChemEx	HY-13634A	Ezatiostat	529.225	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	GWEJFLVSOGNLSS-WPFOTENUSA-N	5310939.0		GWEJFLVSOGNLSS
BRD-K98963219-001-02-0	ezatiostat	Phase 2	glutathione transferase inhibitor	GSTP1			0	78.65	MedChemEx	HY-13634A	Ezatiostat	529.225	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	GWEJFLVSOGNLSS-WPFOTENUSA-N	5310939.0		GWEJFLVSOGNLSS
BRD-K98963219-001-01-2	ezatiostat	Phase 2	glutathione transferase inhibitor	GSTP1			0	83.15	MedChemEx	HY-13634A	Ezatiostat	529.225	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	GWEJFLVSOGNLSS-WPFOTENUSA-N	5310939.0		GWEJFLVSOGNLSS
BRD-K42260897-001-08-4	ezetimibe	Launched	cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist	ANPEP|NPC1L1|SOAT1	endocrinology|metabolism	hyperlipidemia|hypercholesterolemia|sitosterolemia	0	96.2	Adooq	A10379	(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone	409.149	O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	OLNTVTPDXPETLC-XPWALMASSA-N	150311.0		OLNTVTPDXPETLC
BRD-K42260897-001-07-6	ezetimibe	Launched	cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist	ANPEP|NPC1L1|SOAT1	endocrinology|metabolism	hyperlipidemia|hypercholesterolemia|sitosterolemia	0	97.97	Selleck	S1655	Ezetimibe (Zetia)	409.149	O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	OLNTVTPDXPETLC-XPWALMASSA-N	150311.0		OLNTVTPDXPETLC
BRD-K42260897-001-10-9	ezetimibe	Launched	cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist	ANPEP|NPC1L1|SOAT1	endocrinology|metabolism	hyperlipidemia|hypercholesterolemia|sitosterolemia	0	94.2	MedChemEx	HY-17376	Ezetimibe	409.149	O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	OLNTVTPDXPETLC-XPWALMASSA-N	150311.0		OLNTVTPDXPETLC
BRD-K42260897-001-09-2	ezetimibe	Launched	cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist	ANPEP|NPC1L1|SOAT1	endocrinology|metabolism	hyperlipidemia|hypercholesterolemia|sitosterolemia	0	84.03	Selleck	S1655	Ezetimibe	409.149	O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	OLNTVTPDXPETLC-XPWALMASSA-N	150311.0	BRD-K32180660-001-01-6	OLNTVTPDXPETLC
BRD-K25570267-001-01-4	ezutromid	Phase 2	utrophin enhancer	UTRN			0	77.14	Vitas-M	STK101977	N-[4-(5-amino-6-methyl-2H-1,2,3-benzotriazol-2-yl)phenyl]-N,N-diethylamine	295.18	CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1	WRIPKYOZKAJHRL-UHFFFAOYSA-N	886736.0		WRIPKYOZKAJHRL
BRD-K00004649-001-01-9	E3330	Preclinical	NFkB pathway inhibitor				0	79.51	Sigma	E8534	(2E)-3-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-2-nonyl-2-propenoic acid	378.204	CCCCCCCCC\C(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O |c:11,t:18|	AALSSIXXBDPENJ-FYWRMAATSA-N	6439397.0		AALSSIXXBDPENJ
BRD-K00003449-001-01-9	E7046	Phase 1	prostanoid receptor antagonist				0	97.54	MedChemEx	HY-103088	E7046	483.122	C[C@H](NC(=O)c1c(nn(C)c1Oc1cccc(c1)C(F)(F)F)C(F)F)c1ccc(cc1)C(O)=O	MKLKAQMPKHNQPR-NSHDSACASA-N	56944705.0		MKLKAQMPKHNQPR
BRD-K05444225-001-03-3	E7449	Phase 2	PARP inhibitor	PARP1|PARP2|TNKS|TNKS2			0	94.48	MedChemEx	HY-12418	E7449	317.128	O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	JLFSBHQQXIAQEC-UHFFFAOYSA-N	135565981.0		JLFSBHQQXIAQEC
BRD-K05444225-001-02-5	E7449	Phase 2	PARP inhibitor	PARP1|PARP2|TNKS|TNKS2			0	83.95	MedChemEx	HY-12418	E7449	317.128	O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	JLFSBHQQXIAQEC-UHFFFAOYSA-N	135565981.0		JLFSBHQQXIAQEC
BRD-K05444225-001-01-7	E7449	Phase 2	PARP inhibitor	PARP1|PARP2|TNKS|TNKS2			0	45.71	MedChemEx	HY-12418	E7449	317.128	O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	JLFSBHQQXIAQEC-UHFFFAOYSA-N	135565981.0		JLFSBHQQXIAQEC
BRD-K00003172-001-01-9	E7820	Phase 2	angiogenesis inhibitor				0	97.34	MedChemEx	HY-14571	E7820	336.068	Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12	LWGUASZLXHYWIV-UHFFFAOYSA-N	196970.0		LWGUASZLXHYWIV
BRD-K87948281-001-02-9	F-11440	Phase 2	serotonin receptor agonist	HTR1A			0	91.09	MedChemEx	HY-19946	Eptapirone	345.191	Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O	NMYAHEULKSYAPP-UHFFFAOYSA-N	208928.0		NMYAHEULKSYAPP
BRD-K87948281-001-01-9	F-11440	Phase 2	serotonin receptor agonist	HTR1A			0	92.26	MedChemEx	HY-19946	F 11440	345.191	Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O	NMYAHEULKSYAPP-UHFFFAOYSA-N	208928.0		NMYAHEULKSYAPP
BRD-K00003299-001-01-9	F-16915	Preclinical					0	100.0	MedChemEx	HY-19886	F 16915	419.282	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCc1cccnc1	BUWVEXMRBAWBPJ-KUBAVDMBSA-N	14671646.0		BUWVEXMRBAWBPJ
BRD-A25619068-003-03-4	fadrozole	Launched	aromatase inhibitor	CYP11B1|CYP19A1	oncology	breast cancer	0	98.89	SantaCruz	sc-252819		223.111	N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|	CLPFFLWZZBQMAO-CQSZACIVSA-N	9815923.0		CLPFFLWZZBQMAO
BRD-K61536264-001-01-3	fagomine	Phase 2	glucosidase inhibitor	GLB1			0	99.3	MedChemEx	HY-13005	Fagomine	147.09	OC[C@H]1NCC[C@@H](O)[C@@H]1O	YZNNBIPIQWYLDM-HSUXUTPPSA-N	72259.0		YZNNBIPIQWYLDM
BRD-K08251020-001-02-8	falecalcitriol	Launched	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	0	89.51	MedChemEx	HY-32342	Falecalcitriol	524.273	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	XPYGGHVSFMUHLH-UUSULHAXSA-N	5282190.0		XPYGGHVSFMUHLH
BRD-K08251020-001-01-0	falecalcitriol	Launched	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	0	75.5	MedChemEx	HY-32342	Falecalcitriol	524.273	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	XPYGGHVSFMUHLH-UUSULHAXSA-N	5282190.0		XPYGGHVSFMUHLH
BRD-K45033733-001-12-2	famciclovir	Launched	DNA polymerase inhibitor		dental|infectious disease	cold sore|genitial herpes|shingles	0	99.1	MicroSource	1505201	FAMCICLOVIR	321.144	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	GGXKWVWZWMLJEH-UHFFFAOYSA-N	3324.0		GGXKWVWZWMLJEH
BRD-K45033733-001-11-4	famciclovir	Launched	DNA polymerase inhibitor		dental|infectious disease	cold sore|genitial herpes|shingles	0	96.7	Selleck	S2467	Famciclovir	321.144	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	GGXKWVWZWMLJEH-UHFFFAOYSA-N	3324.0		GGXKWVWZWMLJEH
BRD-K45033733-001-14-9	famciclovir	Launched	DNA polymerase inhibitor		dental|infectious disease	cold sore|genitial herpes|shingles	0	97.1	MedChemEx	HY-17426	Famciclovir	321.144	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	GGXKWVWZWMLJEH-UHFFFAOYSA-N	3324.0		GGXKWVWZWMLJEH
BRD-K00673382-001-17-1	famotidine	Launched	histamine receptor antagonist	HRH2	gastroenterology	heartburn	0	97.26	Selleck	S2078	Famotidine	337.045	NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1	XUFQPHANEAPEMJ-UHFFFAOYSA-N	5702160.0		XUFQPHANEAPEMJ
BRD-K00673382-001-18-9	famotidine	Launched	histamine receptor antagonist	HRH2	gastroenterology	heartburn	0	99.08	MicroSource	1501003	FAMOTIDINE	337.045	NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1	XUFQPHANEAPEMJ-UHFFFAOYSA-N	5702160.0		XUFQPHANEAPEMJ
BRD-A08255417-001-13-9	famprofazone	Preclinical	cyclooxygenase inhibitor				0	91.88	Selleck	S4327	Famprofazone	377.247	CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|	GNUXVOXXWGNPIV-IBGZPJMESA-N	6604370.0		GNUXVOXXWGNPIV
BRD-A08255417-001-14-7	famprofazone	Preclinical	cyclooxygenase inhibitor				0	95.25	MicroSource	1505773	FAMPROFAZONE	377.247	CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|	GNUXVOXXWGNPIV-IBGZPJMESA-N	6604370.0		GNUXVOXXWGNPIV
BRD-A08255417-001-15-4	famprofazone	Preclinical	cyclooxygenase inhibitor				0	95.03	Selleck	S4327	Famprofazone	377.247	CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8,r|	GNUXVOXXWGNPIV-IBGZPJMESA-N	6604370.0		GNUXVOXXWGNPIV
BRD-K08998509-001-03-2	fananserin	Phase 2	dopamine receptor antagonist|serotonin receptor antagonist	HTR2A			0	93.07	Tocris	2645	2-{3-[4-(4-fluorophenyl)-1-piperazinyl]propyl}-2H-naphtho[1,8-cd]isothiazole 1,1-dioxide	425.157	Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1	VGIGHGMPMUCLIQ-UHFFFAOYSA-N	60785.0		VGIGHGMPMUCLIQ
BRD-K08998509-001-02-4	fananserin	Phase 2	dopamine receptor antagonist|serotonin receptor antagonist	HTR2A			0	80.37	Tocris	2645	Fananserin	425.157	Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1	VGIGHGMPMUCLIQ-UHFFFAOYSA-N	60785.0		VGIGHGMPMUCLIQ
BRD-K60798049-001-03-8	fanetizole	Phase 3	neutrophil superoxide production				0	94.26	Enamine	Z48859353	N-(2-phenylethyl)-N-(4-phenyl-1,3-thiazol-2-yl)amine	280.103	C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1	WEEYMMXMBFJUAI-UHFFFAOYSA-N	54339.0		WEEYMMXMBFJUAI
BRD-K00003465-001-01-9	fantofarone	Preclinical	calcium channel blocker				0	96.18	MedChemEx	HY-105117	Fantofarone	550.25	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3ccccc23)C(C)C)cc1OC	ITAMRBIZWGDOHW-UHFFFAOYSA-N	119349.0		ITAMRBIZWGDOHW
BRD-K00003507-001-01-9	farampator	Preclinical	ionotropic glutamate receptor agonist				0	98.96	MedChemEx	HY-10937	Farampator	231.101	O=C(N1CCCCC1)c1ccc2nonc2c1	XFVRBYKKGGDPAJ-UHFFFAOYSA-N	4118151.0		XFVRBYKKGGDPAJ
BRD-K14590126-001-01-6	farnesyl-thiosalicylic-acid-amide	Phase 1	Ras GTPase inhibitor	HRAS			0	96.81	Cayman	13175	2-{[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl]sulfanyl}benzamide	357.213	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O	GZTMFRUGZMZCRD-CFBAGHHKSA-N	25187973.0		GZTMFRUGZMZCRD
BRD-A49622760-001-01-9	faropenem	Launched	lactamase inhibitor		infectious disease|pulmonary|otolaryngology	pneumonia|bronchitis|skin infections|urinary tract infections|sinusitis	0	98.06	Astatech	41111		285.067	C[C@@H](O)[C@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O |&1:1,&2:3,&3:4,&4:7,r,c:12|	HGGAKXAHAYOLDJ-OJKLQORTSA-N	14659032.0		HGGAKXAHAYOLDJ
BRD-K59045783-001-03-7	faropenem-medoxomil	Launched	lactamase inhibitor		otolaryngology|infectious disease|pulmonary	sinusitis|pneumonia|bronchitis|skin infections|urinary tract infections	0	82.42	MedChemEx	HY-10004	Faropenem daloxate	397.083	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|	JQBKWZPHJOEQAO-DVPVEWDBSA-N	6918218.0		JQBKWZPHJOEQAO
BRD-K59045783-001-02-9	faropenem-medoxomil	Launched	lactamase inhibitor		otolaryngology|infectious disease|pulmonary	sinusitis|pneumonia|bronchitis|skin infections|urinary tract infections	0	80.71	MedChemEx	HY-10004	Faropenem daloxate	397.083	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|	JQBKWZPHJOEQAO-DVPVEWDBSA-N	6918218.0		JQBKWZPHJOEQAO
BRD-K59045783-001-01-1	faropenem-medoxomil	Launched	lactamase inhibitor		otolaryngology|infectious disease|pulmonary	sinusitis|pneumonia|bronchitis|skin infections|urinary tract infections	0	81.02	MedChemEx	HY-10004	Faropenem daloxate	397.083	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|	JQBKWZPHJOEQAO-DVPVEWDBSA-N	6918218.0		JQBKWZPHJOEQAO
BRD-K00004571-001-01-9	fasoracetam	Preclinical	GABA receptor antagonist				0	92.33	Astatech	40951	FASORACETAM	196.121	O=C([C@H]1CCC(=O)N1)N1CCCCC1	GOWRRBABHQUJMX-MRVPVSSYSA-N	198695.0		GOWRRBABHQUJMX
BRD-K76617868-001-05-5	fasudil	Launched	rho associated kinase inhibitor	PKIA|PRKACA|ROCK1|ROCK2	neurology/psychiatry	cerebral vasospasm	0	97.58	MicroSource	1502366	FASUDIL HYDROCHLORIDE	291.104	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	NGOGFTYYXHNFQH-UHFFFAOYSA-N	3547.0		NGOGFTYYXHNFQH
BRD-K76617868-003-15-9	fasudil	Launched	rho associated kinase inhibitor	PKIA|PRKACA|ROCK1|ROCK2	neurology/psychiatry	cerebral vasospasm	0	98.21	Tocris	541	Fasudil hydrochloride	291.104	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	NGOGFTYYXHNFQH-UHFFFAOYSA-N	3547.0		NGOGFTYYXHNFQH
BRD-K76617868-003-10-1	fasudil	Launched	rho associated kinase inhibitor	PKIA|PRKACA|ROCK1|ROCK2	neurology/psychiatry	cerebral vasospasm	0	97.53	Selleck	S1573	Fasudil (HA-1077) HCl	291.104	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	NGOGFTYYXHNFQH-UHFFFAOYSA-N	3547.0		NGOGFTYYXHNFQH
BRD-K76617868-003-14-3	fasudil	Launched	rho associated kinase inhibitor	PKIA|PRKACA|ROCK1|ROCK2	neurology/psychiatry	cerebral vasospasm	0	98.59	Tocris	541	Fasudil hydrochloride	291.104	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	NGOGFTYYXHNFQH-UHFFFAOYSA-N	3547.0		NGOGFTYYXHNFQH
BRD-K76617868-003-11-9	fasudil	Launched	rho associated kinase inhibitor	PKIA|PRKACA|ROCK1|ROCK2	neurology/psychiatry	cerebral vasospasm	0	97.81	Tocris	541	Fasudil hydrochloride	291.104	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	NGOGFTYYXHNFQH-UHFFFAOYSA-N	3547.0		NGOGFTYYXHNFQH
BRD-K04264130-001-01-4	favipiravir	Phase 3	RNA polymerase inhibitor				0	95.67	AdvChemBlocks	F-4501	6-fluoro-3-hydroxypyrazine-2-carboxamide	157.029	NC(=O)c1nc(F)c[nH]c1=O	ZCGNOVWYSGBHAU-UHFFFAOYSA-N	492405.0		ZCGNOVWYSGBHAU
BRD-K00004537-001-01-9	FCE-22250	Phase 1	DNA directed DNA polymerase inhibitor				0	68.34	Vitas-M	STK177296	FCE 22250	834.405	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:34,t:3,36|	JEGGQYICWGMXOZ-KLZPLVFYSA-N			JEGGQYICWGMXOZ
BRD-K18157228-001-01-7	fdcyd	Phase 2	DNA methyltransferase inhibitor				0	94.9	SantaCruz	sc-252267		245.081	Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1	IDYKCXHJJGMAEV-RRKCRQDMSA-N	515328.0		IDYKCXHJJGMAEV
BRD-K00004566-001-01-9	febuprol	Launched	choleretic agent				0	93.98	Sigma	MFCD00867165	1-butoxy-3-phenoxy-2-propanol	224.141	CCCCOC[C@@H](O)COc1ccccc1 |&1:6,r|	WBLXZPHICYCDGN-GFCCVEGCSA-N	36688222.0		WBLXZPHICYCDGN
BRD-K48367671-001-08-9	febuxostat	Launched	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	0	97.16	Tocris	4427	Febuxostat	316.088	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	BQSJTQLCZDPROO-UHFFFAOYSA-N	134018.0		BQSJTQLCZDPROO
BRD-K48367671-001-07-5	febuxostat	Launched	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	0	96.04	Tocris	4427	Febuxostat	316.088	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	BQSJTQLCZDPROO-UHFFFAOYSA-N	134018.0		BQSJTQLCZDPROO
BRD-K48367671-001-06-7	febuxostat	Launched	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	0	92.92	MicroSource	1504286	FEBUXOSTAT	316.088	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	BQSJTQLCZDPROO-UHFFFAOYSA-N	134018.0		BQSJTQLCZDPROO
BRD-K48367671-001-05-9	febuxostat	Launched	xanthine oxidase inhibitor	XDH	nephrology	hyperuricemia	0	98.36	Selleck	S1547	Febuxostat	316.088	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	BQSJTQLCZDPROO-UHFFFAOYSA-N	134018.0		BQSJTQLCZDPROO
BRD-K12502280-001-11-4	fedratinib	Launched	FLT3 inhibitor|JAK inhibitor	BRD4|JAK1|JAK2|JAK3|TYK2	hematologic malignancy	myelofibrosis	0	91.26	Selleck	S2736	Fedratinib (SAR302503, TG101348)	524.257	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C	JOOXLOJCABQBSG-UHFFFAOYSA-N	16722836.0		JOOXLOJCABQBSG
BRD-K12502280-001-08-0	fedratinib	Launched	FLT3 inhibitor|JAK inhibitor	BRD4|JAK1|JAK2|JAK3|TYK2	hematologic malignancy	myelofibrosis	0	84.28	Selleck	S2736	TG101348 (SAR302503)	524.257	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C	JOOXLOJCABQBSG-UHFFFAOYSA-N	16722836.0		JOOXLOJCABQBSG
BRD-K99107520-001-27-4	felbamate	Launched	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	neurology/psychiatry	epilepsy	0	81.55	Tocris	869	Felbamate	238.095	NC(=O)OCC(COC(N)=O)c1ccccc1	WKGXYQFOCVYPAC-UHFFFAOYSA-N	3331.0		WKGXYQFOCVYPAC
BRD-K99107520-001-29-9	felbamate	Launched	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	neurology/psychiatry	epilepsy	0	100.0	Tocris	869	Felbamate	238.095	NC(=O)OCC(COC(N)=O)c1ccccc1	WKGXYQFOCVYPAC-UHFFFAOYSA-N	3331.0		WKGXYQFOCVYPAC
BRD-K99107520-001-24-1	felbamate	Launched	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	neurology/psychiatry	epilepsy	0	94.42	Tocris	869	Felbamate	238.095	NC(=O)OCC(COC(N)=O)c1ccccc1	WKGXYQFOCVYPAC-UHFFFAOYSA-N	3331.0		WKGXYQFOCVYPAC
BRD-K99107520-001-25-8	felbamate	Launched	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	neurology/psychiatry	epilepsy	0	94.7	Selleck	S1330	Felbamate	238.095	NC(=O)OCC(COC(N)=O)c1ccccc1	WKGXYQFOCVYPAC-UHFFFAOYSA-N	3331.0		WKGXYQFOCVYPAC
BRD-K99107520-001-23-3	felbamate	Launched	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	neurology/psychiatry	epilepsy	0	87.24	Selleck	S1330	Felbamate	238.095	NC(=O)OCC(COC(N)=O)c1ccccc1	WKGXYQFOCVYPAC-UHFFFAOYSA-N	3331.0		WKGXYQFOCVYPAC
BRD-K91740057-001-21-9	felbinac	Launched	cyclooxygenase inhibitor	CTSL	rheumatology|neurology/psychiatry	rheumatoid arthritis|muscle pain	0	98.67	MedChemEx	HY-B0641	Felbinac	212.084	OC(=O)Cc1ccc(cc1)-c1ccccc1	QRZAKQDHEVVFRX-UHFFFAOYSA-N	3332.0		QRZAKQDHEVVFRX
BRD-K91740057-001-19-8	felbinac	Launched	cyclooxygenase inhibitor	CTSL	rheumatology|neurology/psychiatry	rheumatoid arthritis|muscle pain	0	99.79	MicroSource	1506160	FELBINAC	212.084	OC(=O)Cc1ccc(cc1)-c1ccccc1	QRZAKQDHEVVFRX-UHFFFAOYSA-N	3332.0		QRZAKQDHEVVFRX
BRD-K26404903-001-01-5	felbinac-ethyl	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2			0	47.98	AMS	A000379137	ethyl [1,1'-biphenyl]-4-ylacetate	240.115	CCOC(=O)Cc1ccc(cc1)-c1ccccc1	NPPJLSILDPVHCM-UHFFFAOYSA-N	26436.0		NPPJLSILDPVHCM
BRD-A30815329-001-12-1	felodipine	Launched	calcium channel blocker	CFTR	cardiology	hypertension	0	94.24	Tocris	2960	Felodipine	383.069	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|	RZTAMFZIAATZDJ-HNNXBMFYSA-N	941699.0		RZTAMFZIAATZDJ
BRD-A30815329-001-10-5	felodipine	Launched	calcium channel blocker	CFTR	cardiology	hypertension	0	98.85	MicroSource	1505887	FELODIPINE	383.069	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|	RZTAMFZIAATZDJ-HNNXBMFYSA-N	941699.0		RZTAMFZIAATZDJ
BRD-A30815329-001-08-9	felodipine	Launched	calcium channel blocker	CFTR	cardiology	hypertension	0	97.95	Selleck	S1885	Felodipine	383.069	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12,r,c:5,10|	RZTAMFZIAATZDJ-HNNXBMFYSA-N	941699.0		RZTAMFZIAATZDJ
BRD-K00003319-001-01-9	felypressin	Preclinical	vasopressin receptor agonist				0	82.6	MedChemEx	HY-A0182	Felypressin	1039.437	[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	SFKQVVDKFKYTNA-HLQBGFAYSA-N			SFKQVVDKFKYTNA
BRD-K08791496-001-01-0	fenaclon	Preclinical					0	88.3	MicroSource	1503901	FENACLON	211.076	ClCCC(=O)NCCc1ccccc1	BITWVVLBVUMFHU-UHFFFAOYSA-N	9376.0		BITWVVLBVUMFHU
BRD-K08791496-001-02-9	fenaclon	Preclinical					0	89.95	Enamine	EN300-57073	3-chloro-N-(2-phenylethyl)propanamide	211.076	ClCCC(=O)NCCc1ccccc1	BITWVVLBVUMFHU-UHFFFAOYSA-N	9376.0		BITWVVLBVUMFHU
BRD-K51318897-001-14-6	fenbendazole	Launched	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites|gastrointestinal roundworms	0	97.19	Selleck	S2468	Fenbendazole	299.073	COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1	HDDSHPAODJUKPD-UHFFFAOYSA-N	3334.0		HDDSHPAODJUKPD
BRD-K51318897-001-15-3	fenbendazole	Launched	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites|gastrointestinal roundworms	0	98.69	MicroSource	1501016	FENBENDAZOLE	299.073	COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1	HDDSHPAODJUKPD-UHFFFAOYSA-N	3334.0		HDDSHPAODJUKPD
BRD-K12513978-001-26-9	fenbufen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	97.35	MedChemEx	HY-B1138	Fenbufen	254.094	OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1	ZPAKPRAICRBAOD-UHFFFAOYSA-N	3335.0		ZPAKPRAICRBAOD
BRD-K12513978-001-24-1	fenbufen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	99.5	MicroSource	1501008	FENBUFEN	254.094	OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1	ZPAKPRAICRBAOD-UHFFFAOYSA-N	3335.0		ZPAKPRAICRBAOD
BRD-K01825694-003-01-9	fenclonine-(+/-)	Preclinical	tryptophan hydroxylase inhibitor	PAH|TPH1|TPH2			0	89.42	MicroSource	1502162	FENCLONINE (+/-)	235.017	N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|	NIGWMJHCCYYCSF-QMMMGPOBSA-N	736190.0		NIGWMJHCCYYCSF
BRD-K01825694-001-02-9	fenclonine-(+/-)	Preclinical	tryptophan hydroxylase inhibitor	PAH|TPH1|TPH2			0	88.03	Tocris	938	p-Chlorophenylalanine	199.04	N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|	NIGWMJHCCYYCSF-QMMMGPOBSA-N	736190.0		NIGWMJHCCYYCSF
BRD-A71033472-003-24-9	fendiline	Preclinical	calcium channel blocker	HTR2B			0	91.01	Tocris	6407	Fendiline Hydrochloride	315.199	C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|	NMKSAYKQLCHXDK-LJQANCHMSA-N	36687769.0		NMKSAYKQLCHXDK
BRD-A71033472-003-23-9	fendiline	Preclinical	calcium channel blocker	HTR2B			0	97.49	MicroSource	1501026	FENDILINE HYDROCHLORIDE	315.199	C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|	NMKSAYKQLCHXDK-LJQANCHMSA-N	36687769.0		NMKSAYKQLCHXDK
BRD-K25290930-001-03-9	fenebrutinib	Phase 2	Bruton's tyrosine kinase (BTK) inhibitor				0	95.35	MedChemEx	HY-19834	Fenebrutinib	664.349	C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1	WNEODWDFDXWOLU-QHCPKHFHSA-N	86567195.0		WNEODWDFDXWOLU
BRD-A66920069-003-02-9	fenigam	Launched	benzodiazepine receptor agonist	GABBR1|GABBR2	neurology/psychiatry	posttraumatic stress disorder|anxiety|depression	0	83.85	Vitas-M	STK182861	4-amino-3-phenylbutanoic acid	179.095	NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|	DAFOCGYVTAOKAJ-SECBINFHSA-N	685623.0		DAFOCGYVTAOKAJ
BRD-A66920069-001-01-3	fenigam	Launched	benzodiazepine receptor agonist	GABBR1|GABBR2	neurology/psychiatry	posttraumatic stress disorder|anxiety|depression	0	92.36	Enamine	Z1255487817		179.095	NC[C@@H](CC(O)=O)c1ccccc1 |&1:2,r|	DAFOCGYVTAOKAJ-SECBINFHSA-N	685623.0		DAFOCGYVTAOKAJ
BRD-A66284731-001-02-0	fenipentol	Launched	choleretic agent		gastroenterology	bile stimulation	0	0.0	MicroSource	1503890	FENIPENTOL	164.12	CCCC[C@@H](O)c1ccccc1 |&1:4,r|	OVGORFFCBUIFIA-LLVKDONJSA-N	6999795.0		OVGORFFCBUIFIA
BRD-A66284731-001-03-9	fenipentol	Launched	choleretic agent		gastroenterology	bile stimulation	0	0.0	Sigma	MFCD00021935	1-PHENYL-1-PENTANOL	164.12	CCCC[C@@H](O)c1ccccc1 |&1:4,r|	OVGORFFCBUIFIA-LLVKDONJSA-N	6999795.0		OVGORFFCBUIFIA
BRD-K41160163-001-07-6	fenobam	Phase 2	glutamate receptor antagonist	GRM5			0	94.73	Tocris	2386	Fenobam	266.057	CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|	DWPQODZAOSWNHB-UHFFFAOYSA-N	135659063.0		DWPQODZAOSWNHB
BRD-K41160163-001-06-8	fenobam	Phase 2	glutamate receptor antagonist	GRM5			0	91.27	Tocris	2386	Fenobam	266.057	CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|	DWPQODZAOSWNHB-UHFFFAOYSA-N	135659063.0		DWPQODZAOSWNHB
BRD-K41160163-001-08-9	fenobam	Phase 2	glutamate receptor antagonist	GRM5			0	96.49	Tocris	2386	Fenobam	266.057	CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|	DWPQODZAOSWNHB-UHFFFAOYSA-N	135659063.0		DWPQODZAOSWNHB
BRD-K50388907-001-32-0	fenofibrate	Launched	PPAR receptor agonist	MMP25|PPARA	endocrinology	hypercholesterolemia|hypertriglyceridemia	0	93.15	Tocris	4113	Fenofibrate	360.113	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	YMTINGFKWWXKFG-UHFFFAOYSA-N	3339.0		YMTINGFKWWXKFG
BRD-K50388907-001-30-4	fenofibrate	Launched	PPAR receptor agonist	MMP25|PPARA	endocrinology	hypercholesterolemia|hypertriglyceridemia	0	99.56	MicroSource	1501010	FENOFIBRATE	360.113	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	YMTINGFKWWXKFG-UHFFFAOYSA-N	3339.0		YMTINGFKWWXKFG
BRD-K50388907-001-29-6	fenofibrate	Launched	PPAR receptor agonist	MMP25|PPARA	endocrinology	hypercholesterolemia|hypertriglyceridemia	0	97.15	Selleck	S1794	Fenofibrate	360.113	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	YMTINGFKWWXKFG-UHFFFAOYSA-N	3339.0		YMTINGFKWWXKFG
BRD-K30213273-001-01-6	fenofibric-acid	Launched	cytochrome P450 inhibitor	CLCN1|PPARA	cardiology	dyslipidemia	0	94.36	MicroSource	1504414	FENOFIBRIC ACID	318.066	CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O	MQOBSOSZFYZQOK-UHFFFAOYSA-N	64929.0		MQOBSOSZFYZQOK
BRD-K30213273-001-02-9	fenofibric-acid	Launched	cytochrome P450 inhibitor	CLCN1|PPARA	cardiology	dyslipidemia	0	97.53	MedChemEx	HY-B0760	Fenofibric acid	318.066	CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O	MQOBSOSZFYZQOK-UHFFFAOYSA-N	64929.0		MQOBSOSZFYZQOK
BRD-K01826790-066-06-9	fenoldopam	Launched	dopamine receptor agonist	DRD1|DRD4	cardiology	hypertension	0	94.04	MicroSource	1505539		305.082	Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|	TVURRHSHRRELCG-CYBMUJFWSA-N	30026875.0		TVURRHSHRRELCG
BRD-K01827286-340-05-9	fenoprofen	Launched	prostaglandin inhibitor	PTGS1|SLC5A8	rheumatology	rheumatoid arthritis|osteoarthritis	0	95.93	MedChemEx	HY-B0288B	Fenoprofen (Calcium hydrate)	242.094	C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|	RDJGLLICXDHJDY-LLVKDONJSA-N	41097863.0		RDJGLLICXDHJDY
BRD-K00003668-004-01-9	fenoterol	Withdrawn	adrenergic receptor agonist	ADRB2			0	96.59	MedChemEx	HY-B0976A	Fenoterol (hydrobromide)	303.147	C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1,12,r|	LSLYOANBFKQKPT-APPDUMDISA-N	688469.0		LSLYOANBFKQKPT
BRD-K77564118-001-03-1	fenoverine	Launched	acetylcholine receptor antagonist		neurology/psychiatry	spasms	0	94.91	Vitas-M	STK210707	10-{[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]acetyl}-10H-phenothiazine	459.162	O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12	UBAJTZKNDCEGKL-UHFFFAOYSA-N	72098.0		UBAJTZKNDCEGKL
BRD-K44777569-001-01-7	fenoxaprop-p-ethyl	Preclinical		NOS3			0	94.27	MedChemEx	HY-B2013	Fenoxaprop-P-ethyl	361.072	CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1	PQKBPHSEKWERTG-LLVKDONJSA-N	91707.0		PQKBPHSEKWERTG
BRD-K89085489-001-24-0	fenretinide	Phase 3	apoptosis stimulant|retinoid receptor agonist	RARA			0	82.07	MedChemEx	HY-15373	Fenretinide	391.251	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|	AKJHMTWEGVYYSE-FXILSDISSA-N	5288209.0		AKJHMTWEGVYYSE
BRD-K89085489-001-23-2	fenretinide	Phase 3	apoptosis stimulant|retinoid receptor agonist	RARA			0	82.51	MedChemEx	HY-15373	Fenretinide	391.251	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|	AKJHMTWEGVYYSE-FXILSDISSA-N	5288209.0		AKJHMTWEGVYYSE
BRD-K89085489-001-22-4	fenretinide	Phase 3	apoptosis stimulant|retinoid receptor agonist	RARA			0	33.49	Adooq	A12163	15-(4-hydroxyanilino)retinal	391.251	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|	AKJHMTWEGVYYSE-FXILSDISSA-N	5288209.0		AKJHMTWEGVYYSE
BRD-K89085489-001-19-0	fenretinide	Phase 3	apoptosis stimulant|retinoid receptor agonist	RARA			0	56.72	Tocris	1396	Fenretinide	391.251	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|	AKJHMTWEGVYYSE-FXILSDISSA-N	5288209.0		AKJHMTWEGVYYSE
BRD-K26739552-003-16-9	fenspiride	Launched	bronchodilator		pulmonary|otolaryngology	asthma|otitis|sinusitis|rhinopharyngitis|laryngitis	0	74.99	MedChemEx	HY-A0027	Fenspiride (Hydrochloride)	260.152	O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	FVNFBBAOMBJTST-UHFFFAOYSA-N	3344.0		FVNFBBAOMBJTST
BRD-K26739552-003-14-7	fenspiride	Launched	bronchodilator		pulmonary|otolaryngology	asthma|otitis|sinusitis|rhinopharyngitis|laryngitis	0	95.46	Selleck	S4090	Fenspiride HCl	260.152	O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	FVNFBBAOMBJTST-UHFFFAOYSA-N	3344.0		FVNFBBAOMBJTST
BRD-K26739552-003-15-4	fenspiride	Launched	bronchodilator		pulmonary|otolaryngology	asthma|otitis|sinusitis|rhinopharyngitis|laryngitis	0	98.6	MicroSource	1501021	FENSPIRIDE HYDROCHLORIDE	260.152	O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	FVNFBBAOMBJTST-UHFFFAOYSA-N	3344.0		FVNFBBAOMBJTST
BRD-K67217586-001-08-0	fenthion	Launched	cholinesterase inhibitor				0	78.04	MicroSource	330064	FENTHION	278.02	COP(=S)(OC)Oc1ccc(SC)c(C)c1	PNVJTZOFSHSLTO-UHFFFAOYSA-N	3346.0		PNVJTZOFSHSLTO
BRD-K16077845-001-08-9	fentiazac	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology	muscle pain|joint pain	0	97.7	PrincetonBio	PBMR177063	[4-(4-Chloro-phenyl)-2-phenyl-thiazol-5-yl]-acetic acid	329.028	OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1	JIEKMACRVQTPRC-UHFFFAOYSA-N	28871.0		JIEKMACRVQTPRC
BRD-K16077845-001-06-1	fentiazac	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology	muscle pain|joint pain	0	92.65	Prestwick	Prestw-1254	Fentiazac	329.028	OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1	JIEKMACRVQTPRC-UHFFFAOYSA-N	28871.0		JIEKMACRVQTPRC
BRD-A33697453-008-03-9	fenticonazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	0	89.74	MedChemEx	HY-B0359	Fenticonazole (Nitrate)	454.067	Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|	ZCJYUTQZBAIHBS-XMMPIXPASA-N	36688220.0		ZCJYUTQZBAIHBS
BRD-A33697453-008-04-9	fenticonazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	vulvovaginal candidiasis	0	98.76	Selleck	S2031		454.067	Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|	ZCJYUTQZBAIHBS-XMMPIXPASA-N	36688220.0	BRD-A33697453-008-02-4|BRD-A33697453-008-02-4	ZCJYUTQZBAIHBS
BRD-K61642990-001-02-8	FERb-033	Preclinical	EGFR inhibitor	ERBB2			0	91.22	Tocris	3523	FERb 033	281.025	O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1	LRRMQNGSYOUANY-OMCISZLKSA-N	135931707.0		LRRMQNGSYOUANY
BRD-K61642990-001-01-0	FERb-033	Preclinical	EGFR inhibitor	ERBB2			0	94.02	Tocris	3523	FERb 033	281.025	O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1	LRRMQNGSYOUANY-OMCISZLKSA-N	135931707.0		LRRMQNGSYOUANY
BRD-K61642990-001-03-9	FERb-033	Preclinical	EGFR inhibitor	ERBB2			0	92.69	Tocris	3523	FERb 033	281.025	O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1	LRRMQNGSYOUANY-OMCISZLKSA-N	135931707.0		LRRMQNGSYOUANY
BRD-K00003281-001-01-9	ferroquine	Phase 2	antimalarial agent				0	97.4	MedChemEx	HY-19364	Ferroquine	433.101	CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1 |&1:8,r,c:6,27,29,t:4|	UZTPLPOYSVSMBU-UHFFFAOYSA-N	92043331.0		UZTPLPOYSVSMBU
BRD-K97375133-001-04-9	ferrostatin-1	Preclinical	ferroptosis inhibitor				0	87.75	Tocris	5180	Ferrostatin 1	262.168	CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	UJHBVMHOBZBWMX-UHFFFAOYSA-N	4068248.0		UJHBVMHOBZBWMX
BRD-K97375133-001-01-3	ferrostatin-1	Preclinical	ferroptosis inhibitor				0	74.09	Selleck	S7243	Ferrostatin-1 (Fer-1)	262.168	CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	UJHBVMHOBZBWMX-UHFFFAOYSA-N	4068248.0		UJHBVMHOBZBWMX
BRD-K97375133-001-03-9	ferrostatin-1	Preclinical	ferroptosis inhibitor				0	83.4	Tocris	5180	Ferrostatin 1	262.168	CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	UJHBVMHOBZBWMX-UHFFFAOYSA-N	4068248.0		UJHBVMHOBZBWMX
BRD-K97375133-001-02-1	ferrostatin-1	Preclinical	ferroptosis inhibitor				0	79.61	Selleck	S7243	Ferrostatin-1 (Fer-1)	262.168	CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	UJHBVMHOBZBWMX-UHFFFAOYSA-N	4068248.0		UJHBVMHOBZBWMX
BRD-K66295376-236-02-6	ferulic-acid	Phase 2	antioxidant	CA1|CA12|CA14|CA2|CA4|CA6|CA9			0	91.67	MedChemEx	HY-N0060A	Ferulic acid (sodium)	194.058	COc1cc(\C=C\C(O)=O)ccc1O	KSEBMYQBYZTDHS-HWKANZROSA-N	445858.0		KSEBMYQBYZTDHS
BRD-K66295376-236-01-8	ferulic-acid	Phase 2	antioxidant	CA1|CA12|CA14|CA2|CA4|CA6|CA9			0	0.0	MedChemEx	HY-N0060A	Ferulic acid (sodium)	194.058	COc1cc(\C=C\C(O)=O)ccc1O	KSEBMYQBYZTDHS-HWKANZROSA-N	445858.0		KSEBMYQBYZTDHS
BRD-K66295376-001-13-1	ferulic-acid	Phase 2	antioxidant	CA1|CA12|CA14|CA2|CA4|CA6|CA9			0	95.29	Selleck	S2300	Fumalic acid (Ferulic acid)	194.058	COc1cc(\C=C\C(O)=O)ccc1O	KSEBMYQBYZTDHS-HWKANZROSA-N	445858.0		KSEBMYQBYZTDHS
BRD-K66295376-001-12-3	ferulic-acid	Phase 2	antioxidant	CA1|CA12|CA14|CA2|CA4|CA6|CA9			0	65.55	Selleck	S2300	Ferulic Acid	194.058	COc1cc(\C=C\C(O)=O)ccc1O	KSEBMYQBYZTDHS-HWKANZROSA-N	445858.0		KSEBMYQBYZTDHS
BRD-K46731503-001-05-9	fesoterodine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence	0	91.18	MedChemEx	HY-70053	Fesoterodine	411.277	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	DCCSDBARQIPTGU-HSZRJFAPSA-N	6918558.0		DCCSDBARQIPTGU
BRD-K46731503-050-01-8	fesoterodine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence	0	85.76	Selleck	S2240	Fesoterodine Fumarate	411.277	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	DCCSDBARQIPTGU-HSZRJFAPSA-N	6918558.0		DCCSDBARQIPTGU
BRD-K46731503-051-04-0	fesoterodine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence	0	88.03	Selleck	S2240	Fesoterodine Fumarate	411.277	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	DCCSDBARQIPTGU-HSZRJFAPSA-N	6918558.0		DCCSDBARQIPTGU
BRD-K00003232-001-01-9	fevipiprant	Phase 2	prostaglandin inhibitor				0	95.33	MedChemEx	HY-16768	Fevipiprant	426.086	Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O	GFPPXZDRVCSVNR-UHFFFAOYSA-N	23582412.0		GFPPXZDRVCSVNR
BRD-K08864679-001-03-0	fexaramine	Preclinical	FXR agonist	NR1H4			0	83.57	Tocris	2563	Fexaramine	496.273	COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1	VLQTUNDJHLEFEQ-KGENOOAVSA-N	5326713.0		VLQTUNDJHLEFEQ
BRD-K08864679-001-02-2	fexaramine	Preclinical	FXR agonist	NR1H4			0	86.74	Tocris	2563	Fexaramine	496.273	COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1	VLQTUNDJHLEFEQ-KGENOOAVSA-N	5326713.0		VLQTUNDJHLEFEQ
BRD-K37069697-001-01-3	fexinidazole	Phase 3					0	99.04	Ark	AK116408		279.068	CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1	MIWWSGDADVMLTG-UHFFFAOYSA-N	68792.0		MIWWSGDADVMLTG
BRD-A73368467-003-18-4	fexofenadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	96.16	MicroSource	1504179	FEXOFENADINE HYDROCHLORIDE	501.288	CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|	RWTNPBWLLIMQHL-LJAQVGFWSA-N	6603853.0		RWTNPBWLLIMQHL
BRD-A73368467-003-19-2	fexofenadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	95.4	Tocris	2429	Fexofenadine hydrochloride	501.288	CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|	RWTNPBWLLIMQHL-LJAQVGFWSA-N	6603853.0		RWTNPBWLLIMQHL
BRD-A73368467-003-17-6	fexofenadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	98.09	Tocris	2429	Fexofenadine hydrochloride	501.288	CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|	RWTNPBWLLIMQHL-LJAQVGFWSA-N	6603853.0		RWTNPBWLLIMQHL
BRD-A73368467-003-16-8	fexofenadine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	98.06	Selleck	S3208	Fexofenadine HCl	501.288	CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|	RWTNPBWLLIMQHL-LJAQVGFWSA-N	6603853.0		RWTNPBWLLIMQHL
BRD-K00003287-001-01-9	fezolinetant	Phase 2	neurokinin receptor antagonist				0	95.34	MedChemEx	HY-19632	Fezolinetant	358.101	C[C@H]1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1	PPSNFPASKFYPMN-SECBINFHSA-N	117604931.0		PPSNFPASKFYPMN
BRD-K56807945-001-01-2	FG-2216	Phase 2	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1|EGLN2|HIF1A			0	96.03	MedChemEx	HY-15641	FG-2216	280.025	OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O	OUQVKRKGTAUJQA-UHFFFAOYSA-N	6914666.0		OUQVKRKGTAUJQA
BRD-K14385366-001-04-4	FG-4592	Phase 3	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1|EGLN2|EGLN3			0	93.33	Selleck	S1007	Roxadustat (FG-4592)	352.106	Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12	YOZBGTLTNGAVFU-UHFFFAOYSA-N	11256664.0		YOZBGTLTNGAVFU
BRD-K14385366-001-02-8	FG-4592	Phase 3	hypoxia inducible factor prolyl hydroxylase inhibitor	EGLN1|EGLN2|EGLN3			0	61.54	Selleck	S1007	FG-4592	352.106	Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12	YOZBGTLTNGAVFU-UHFFFAOYSA-N	11256664.0		YOZBGTLTNGAVFU
BRD-K61951118-001-08-7	FG-7142	Preclinical	GABA benzodiazepine site receptor inverse agonist				0	97.25	Tocris	554	FG 7142	225.09	CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	QMCOPDWHWYSJSA-UHFFFAOYSA-N	4375.0		QMCOPDWHWYSJSA
BRD-K61951118-001-09-9	FG-7142	Preclinical	GABA benzodiazepine site receptor inverse agonist				0	94.73	Tocris	554	FG 7142	225.09	CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	QMCOPDWHWYSJSA-UHFFFAOYSA-N	4375.0		QMCOPDWHWYSJSA
BRD-K61951118-001-07-9	FG-7142	Preclinical	GABA benzodiazepine site receptor inverse agonist				0	97.73	Tocris	554	FG 7142	225.09	CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	QMCOPDWHWYSJSA-UHFFFAOYSA-N	4375.0		QMCOPDWHWYSJSA
BRD-K09778810-001-11-4	FGIN-1-27	Preclinical	inositol monophosphatase inhibitor	TSPO			0	96.53	Tocris	658	FGIN-1-27	436.289	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1	VUWXAQFLTSBUDB-UHFFFAOYSA-N	132496.0		VUWXAQFLTSBUDB
BRD-K09778810-001-10-6	FGIN-1-27	Preclinical	inositol monophosphatase inhibitor	TSPO			0	95.16	Tocris	658	FGIN-1-27	436.289	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1	VUWXAQFLTSBUDB-UHFFFAOYSA-N	132496.0		VUWXAQFLTSBUDB
BRD-K66093087-001-04-9	FGIN-1-43	Preclinical	benzodiazepine receptor agonist	TSPO			0	98.62	Tocris	659	FGIN-1-43	486.22	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	XTZUPNNVXIMWAR-UHFFFAOYSA-N	3995234.0		XTZUPNNVXIMWAR
BRD-K66093087-001-05-9	FGIN-1-43	Preclinical	benzodiazepine receptor agonist	TSPO			0	95.27	Tocris	659	FGIN-1-43	486.22	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	XTZUPNNVXIMWAR-UHFFFAOYSA-N	3995234.0		XTZUPNNVXIMWAR
BRD-K66093087-001-03-1	FGIN-1-43	Preclinical	benzodiazepine receptor agonist	TSPO			0	98.23	Tocris	659	FGIN-1-43	486.22	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	XTZUPNNVXIMWAR-UHFFFAOYSA-N	3995234.0		XTZUPNNVXIMWAR
BRD-K48112880-001-02-3	FH-535	Preclinical	PPAR receptor antagonist|WNT signaling inhibitor	PPARD|PPARG			0	93.75	Tocris	4344	FH 535	359.974	Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O	AXNUEXXEQGQWPA-UHFFFAOYSA-N	3463933.0		AXNUEXXEQGQWPA
BRD-K48112880-001-04-9	FH-535	Preclinical	PPAR receptor antagonist|WNT signaling inhibitor	PPARD|PPARG			0	95.44	Tocris	4344	FH 535	359.974	Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O	AXNUEXXEQGQWPA-UHFFFAOYSA-N	3463933.0		AXNUEXXEQGQWPA
BRD-K44777625-001-03-5	FH1	Preclinical	hepatocyte function enhancer				0	97.97	Selleck	S7450	FH1(BRD-K4477)	282.137	CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1	OEXMNSOPAKOPEF-UHFFFAOYSA-N	94990.0		OEXMNSOPAKOPEF
BRD-K44777625-001-05-0	FH1	Preclinical	hepatocyte function enhancer				0	95.23	Tocris	5254	FH 1	282.137	CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1	OEXMNSOPAKOPEF-UHFFFAOYSA-N	94990.0		OEXMNSOPAKOPEF
BRD-K07160047-001-02-9	fiacitabine	Phase 2	DNA synthesis inhibitor				0	95.07	MedChemEx	HY-50735	Fiacitabine	370.978	Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	GIMSJJHKKXRFGV-BYPJNBLXSA-N	50312.0		GIMSJJHKKXRFGV
BRD-K07160047-001-01-3	fiacitabine	Phase 2	DNA synthesis inhibitor				0	99.3	MedChemEx	HY-50735	Fiacitabine	370.978	Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	GIMSJJHKKXRFGV-BYPJNBLXSA-N	50312.0		GIMSJJHKKXRFGV
BRD-A63752151-001-01-2	fidarestat	Phase 3	aldose reductase inhibitor	AKR1B1			0	88.01	Vitas-M	STK692948		279.066	NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3,&2:5,r|	WAAPEIZFCHNLKK-PELKAZGASA-N	449156.0		WAAPEIZFCHNLKK
BRD-K00003591-001-01-9	fidaxomicin	Launched	RNA polymerase inhibitor		gastroenterology	diarrhea	0	88.01	MedChemEx	HY-17580	Fidaxomicin	1056.425	CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O |c:3,11,47,50,t:9|	ZVGNESXIJDCBKN-UUEYKCAUSA-N	10034073.0		ZVGNESXIJDCBKN
BRD-K37379014-001-01-2	filanesib	Phase 3	kinesin inhibitor|kinesin-like spindle protein inhibitor	KIF11			0	84.06	MedChemEx	HY-15187	ARRY-520	420.143	CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|	LLXISKGBWFTGEI-FQEVSTJZSA-N	44224257.0		LLXISKGBWFTGEI
BRD-K37379014-001-02-0	filanesib	Phase 3	kinesin inhibitor|kinesin-like spindle protein inhibitor	KIF11			0	85.47	MedChemEx	HY-15187	ARRY-520	420.143	CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|	LLXISKGBWFTGEI-FQEVSTJZSA-N	44224257.0		LLXISKGBWFTGEI
BRD-K16803204-001-02-9	filgotinib	Phase 3	JAK inhibitor	JAK1|JAK2|JAK3|TYK2			0	93.27	MedChemEx	HY-18300	Filgotinib	425.152	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	RIJLVEAXPNLDTC-UHFFFAOYSA-N	49831257.0		RIJLVEAXPNLDTC
BRD-K16803204-001-01-6	filgotinib	Phase 3	JAK inhibitor	JAK1|JAK2|JAK3|TYK2			0	96.83	MedChemEx	HY-18300	GLPG0634	425.152	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	RIJLVEAXPNLDTC-UHFFFAOYSA-N	49831257.0		RIJLVEAXPNLDTC
BRD-K21586122-001-02-7	fimasartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure	0	82.66	MedChemEx	HY-B0780	2-(3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butylidene-6-methyl-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N,N-dimethylethanethioamide	501.231	CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	AMEROGPZOLAFBN-UHFFFAOYSA-N	9870652.0	BRD-K76786967-001-01-7	AMEROGPZOLAFBN
BRD-K21586122-001-01-9	fimasartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure	0	89.33	MedChemEx	HY-B0780	Fimasartan	501.231	CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	AMEROGPZOLAFBN-UHFFFAOYSA-N	9870652.0		AMEROGPZOLAFBN
BRD-K98384930-001-02-9	finafloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease|pulmonary	intra-abdominal infections|chronic obstructive pulmonary disease (COPD)|cystic fibrosis	0	95.28	MedChemEx	HY-13451	Finafloxacin	398.139	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	FYMHQCNFKNMJAV-HOTGVXAUSA-N	11567473.0		FYMHQCNFKNMJAV
BRD-K98384930-003-01-5	finafloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease|pulmonary	intra-abdominal infections|chronic obstructive pulmonary disease (COPD)|cystic fibrosis	0	93.21	SantaCruz	sc-211507		398.139	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	FYMHQCNFKNMJAV-HOTGVXAUSA-N	11567473.0		FYMHQCNFKNMJAV
BRD-K01095011-001-15-9	finasteride	Launched	5 alpha reductase inhibitor	AKR1D1|SRD5A1|SRD5A2	endocrinology	androgenetic alopecia	0	98.24	MicroSource	1506069	FINASTERIDE	372.278	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|	DBEPLOCGEIEOCV-WSBQPABSSA-N	57363.0	BRD-A83081521-001-02-3	DBEPLOCGEIEOCV
BRD-K01095011-001-16-9	finasteride	Launched	5 alpha reductase inhibitor	AKR1D1|SRD5A1|SRD5A2	endocrinology	androgenetic alopecia	0	95.46	Tocris	3293	Finasteride	372.278	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|	DBEPLOCGEIEOCV-WSBQPABSSA-N	57363.0		DBEPLOCGEIEOCV
BRD-K01095011-001-14-2	finasteride	Launched	5 alpha reductase inhibitor	AKR1D1|SRD5A1|SRD5A2	endocrinology	androgenetic alopecia	0	97.61	Selleck	S1197	Finasteride	372.278	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|	DBEPLOCGEIEOCV-WSBQPABSSA-N	57363.0	BRD-K37882277-001-01-7	DBEPLOCGEIEOCV
BRD-K88025533-001-07-9	fingolimod	Launched	immunosuppressant|sphingosine 1-phosphate receptor agonist	S1PR1|S1PR5	neurology/psychiatry	multiple sclerosis	0	93.94	MedChemEx	HY-11063	Fingolimod	307.251	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	KKGQTZUTZRNORY-UHFFFAOYSA-N	107970.0		KKGQTZUTZRNORY
BRD-K88025533-003-04-1	fingolimod	Launched	immunosuppressant|sphingosine 1-phosphate receptor agonist	S1PR1|S1PR5	neurology/psychiatry	multiple sclerosis	0	95.28	Selleck	S5002	Fingolimod (FTY720)	307.251	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	KKGQTZUTZRNORY-UHFFFAOYSA-N	107970.0		KKGQTZUTZRNORY
BRD-K88025533-003-03-3	fingolimod	Launched	immunosuppressant|sphingosine 1-phosphate receptor agonist	S1PR1|S1PR5	neurology/psychiatry	multiple sclerosis	0	94.04	Selleck	S5002	Fingolimod (FTY720) HCl	307.251	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	KKGQTZUTZRNORY-UHFFFAOYSA-N	107970.0		KKGQTZUTZRNORY
BRD-K37688416-003-13-1	fipexide	Withdrawn	psychoactive drug				0	98.95	MicroSource	1503222	FIPEXIDE HYDROCHLORIDE	388.119	Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1	BFUJHVVEMMWLHC-UHFFFAOYSA-N	3351.0		BFUJHVVEMMWLHC
BRD-K61560897-003-01-4	FIPI	Preclinical	phospholipase inhibitor	PLD1|PLD2			0	97.57	Tocris	3600	FIPI	421.191	Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	LHABRXRGDLASIH-UHFFFAOYSA-N	16739265.0		LHABRXRGDLASIH
BRD-K61560897-003-02-9	FIPI	Preclinical	phospholipase inhibitor	PLD1|PLD2			0	97.99	Tocris	3600	FIPI	421.191	Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	LHABRXRGDLASIH-UHFFFAOYSA-N	16739265.0		LHABRXRGDLASIH
BRD-A50675702-001-07-1	fipronil	Launched	chloride channel blocker|GABA gated chloride channel blocker		infectious disease	flea control	0	96.39	MicroSource	1505354	FIPRONIL	435.939	Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|	ZOCSXAVNDGMNBV-AREMUKBSSA-N	15278226.0		ZOCSXAVNDGMNBV
BRD-A50675702-001-08-9	fipronil	Launched	chloride channel blocker|GABA gated chloride channel blocker		infectious disease	flea control	0	97.11	Sigma	MFCD00867812	Fipronil	435.939	Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20,r|	ZOCSXAVNDGMNBV-AREMUKBSSA-N	15278226.0		ZOCSXAVNDGMNBV
BRD-K17513304-001-01-9	firategrast	Phase 2	integrin antagonist	ITGA4			0	99.31	MedChemEx	HY-14951	Firategrast	499.181	CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1	YLFZHHDVRSYTKT-NRFANRHFSA-N	9935681.0		YLFZHHDVRSYTKT
BRD-K17513304-001-02-9	firategrast	Phase 2	integrin antagonist	ITGA4			0	98.13	MedChemEx	HY-14951	Firategrast	499.181	CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1	YLFZHHDVRSYTKT-NRFANRHFSA-N	9935681.0		YLFZHHDVRSYTKT
BRD-K09090523-001-02-1	firocoxib	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	osteoarthritis	0	99.46	MicroSource	1504526	FIROCOXIB	336.103	CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|	FULAPETWGIGNMT-UHFFFAOYSA-N	208910.0		FULAPETWGIGNMT
BRD-K00003236-001-01-9	firsocostat	Phase 2	acetyl-CoA carboxylase inhibitor				0	94.78	MedChemEx	HY-16901	Firsocostat	569.183	COc1ccccc1[C@H](Cn1c2sc(c(C)c2c(=O)n(c1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1	ZZWWXIBKLBMSCS-FQEVSTJZSA-N	71528744.0		ZZWWXIBKLBMSCS
BRD-K31836715-001-07-9	fisetin	Preclinical	Aurora kinase inhibitor	CDK6|FASN			0	79.11	MedChemEx	HY-N0182	Fisetin	286.048	Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	XHEFDIBZLJXQHF-UHFFFAOYSA-N	5281614.0		XHEFDIBZLJXQHF
BRD-K31836715-001-05-0	fisetin	Preclinical	Aurora kinase inhibitor	CDK6|FASN			0	68.95	Selleck	S2298	Fisetin	286.048	Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	XHEFDIBZLJXQHF-UHFFFAOYSA-N	5281614.0		XHEFDIBZLJXQHF
BRD-K31836715-001-06-8	fisetin	Preclinical	Aurora kinase inhibitor	CDK6|FASN			0	84.91	Selleck	S2298	Fisetin (Fustel)	286.048	Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	XHEFDIBZLJXQHF-UHFFFAOYSA-N	5281614.0		XHEFDIBZLJXQHF
BRD-K00003377-001-01-9	fisogatinib	Phase 1	fibroblast growth factor inhibitor				0	93.64	MedChemEx	HY-100492	Fisogatinib	502.117	COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1	MGZKYOAQVGSSGC-DLBZAZTESA-N	91885617.0		MGZKYOAQVGSSGC
BRD-K17896185-001-02-0	FIT	Preclinical	opioid receptor agonist	OPRD1			0	8.53	Tocris	1480	FIT	393.187	CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1	VDKBIFPJULZUPU-UHFFFAOYSA-N	84008.0		VDKBIFPJULZUPU
BRD-A01907367-001-01-7	FK-33-824	Phase 2	opioid receptor agonist	OPRM1			0	81.78	Enzo	AC906	(D-Ala2,N-Me-Phe4, Methionin (O)-ol5)-enkephalin	603.273	C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1,5,23,34,&1:39|	HYZHONGSQNXMPH-YJRDZJJMSA-N			HYZHONGSQNXMPH
BRD-K38350380-001-01-8	FK-3311	Phase 2	cyclooxygenase inhibitor	PTGS2			0	94.36	MedChemEx	HY-14445	FK 3311	341.053	CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	DIIYLGZNZGPXRR-UHFFFAOYSA-N	164009.0		DIIYLGZNZGPXRR
BRD-K38350380-001-02-9	FK-3311	Phase 2	cyclooxygenase inhibitor	PTGS2			0	95.84	Tocris	2776	FK 3311	341.053	CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	DIIYLGZNZGPXRR-UHFFFAOYSA-N	164009.0		DIIYLGZNZGPXRR
BRD-K00005243-001-01-9	FK-409	Phase 2	guanylyl cyclase activator				0	100.0	Sigma	E2895	NOR-3	215.091	CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10,r|	MZAGXDHQGXUDDX-FGCOBAPNSA-N	94621715.0		MZAGXDHQGXUDDX
BRD-K58550667-001-08-7	FK-866	Phase 2	niacinamide phosphoribosyltransferase inhibitor	NAMPT			0	93.54	Enzo	270-501	FK-866	391.226	O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1	KPBNHDGDUADAGP-VAWYXSNFSA-N	6914657.0		KPBNHDGDUADAGP
BRD-K83508485-001-03-5	FK-888	Phase 2	tachykinin antagonist	TACR1|TACR2			0	97.91	Tocris	2400	FK 888	588.274	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	BFNKQTIJVFGCKQ-PDJGWCFMSA-N	107967.0		BFNKQTIJVFGCKQ
BRD-K83508485-001-02-7	FK-888	Phase 2	tachykinin antagonist	TACR1|TACR2			0	97.62	Tocris	2400	FK 888	588.274	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	BFNKQTIJVFGCKQ-PDJGWCFMSA-N	107967.0		BFNKQTIJVFGCKQ
BRD-K83508485-001-04-9	FK-888	Phase 2	tachykinin antagonist	TACR1|TACR2			0	96.31	Tocris	2400	FK 888	588.274	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	BFNKQTIJVFGCKQ-PDJGWCFMSA-N	107967.0		BFNKQTIJVFGCKQ
BRD-K80607346-001-01-1	FK-962	Phase 2	somatostatin receptor agonist				0	98.54	Enamine	Z90645000	N-(1-acetyl-4-piperidinyl)-4-fluorobenzamide	264.127	CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1	VBHVOHJOTMCSBQ-UHFFFAOYSA-N	9816738.0		VBHVOHJOTMCSBQ
BRD-K01666925-304-01-9	flavin-adenine-dinucleotide	Preclinical		ACAD8|ACADM|ACADS|ACOX1|AIFM1|CYB5R1|CYB5R3|DAO|DLD|DPYD|ERO1LB|FDXR|GCDH|GFER|GSR|IL4I1|IVD|MAOA|MAOB|NOS1|NQO1|NQO2|POR|TXNRD1|XDH			0	73.4	CombiBlocks	SS-0619	Flavin adenine dinucleotide disodium salt	831.137	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15,17,19,32,34,35,37,&1:23,&2:27|	VWWQXMAJTJZDQX-UYBVJOGSSA-N	643975.0		VWWQXMAJTJZDQX
BRD-K47639036-003-06-6	flavoxate	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2	urology	urinary incontinence|interstitial cystitis (IC)|urethritis|prostatitis	0	96.85	Selleck	S4027	Flavoxate HCl	391.178	Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1	SPIUTQOUKAMGCX-UHFFFAOYSA-N	3354.0		SPIUTQOUKAMGCX
BRD-A09472452-015-26-7	flecainide	Launched	sodium channel blocker	KCNA5|KCNA7|SCN5A	cardiology	ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias	0	96.6	Tocris	1470	Flecainide acetate	414.138	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	DJBNUMBKLMJRSA-UHFFFAOYSA-N	46864232.0		DJBNUMBKLMJRSA
BRD-A09472452-015-23-4	flecainide	Launched	sodium channel blocker	KCNA5|KCNA7|SCN5A	cardiology	ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias	0	93.89	MicroSource	1505540	FLECAINIDE ACETATE	414.138	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	DJBNUMBKLMJRSA-UHFFFAOYSA-N	46864232.0		DJBNUMBKLMJRSA
BRD-A09472452-015-22-6	flecainide	Launched	sodium channel blocker	KCNA5|KCNA7|SCN5A	cardiology	ventricular tachycardia (VT)|atrial fibrillation (AF)|ventricular arrhythmias	0	66.16	Tocris	1470	Flecainide acetate	414.138	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	DJBNUMBKLMJRSA-UHFFFAOYSA-N	46864232.0		DJBNUMBKLMJRSA
BRD-K61717546-001-07-9	fleroxacin	Launched	topoisomerase inhibitor	TOP2A	infectious disease|gastroenterology	gonorrhea|enteritis|diarrhea|respiratory tract infections	0	94.11	MedChemEx	HY-B0414	Fleroxacin	369.13	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	XBJBPGROQZJDOJ-UHFFFAOYSA-N	40466912.0		XBJBPGROQZJDOJ
BRD-K61717546-001-04-3	fleroxacin	Launched	topoisomerase inhibitor	TOP2A	infectious disease|gastroenterology	gonorrhea|enteritis|diarrhea|respiratory tract infections	0	78.3	Selleck	S2469	Fleroxacin (Quinodis)	369.13	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	XBJBPGROQZJDOJ-UHFFFAOYSA-N	40466912.0		XBJBPGROQZJDOJ
BRD-K61717546-001-05-0	fleroxacin	Launched	topoisomerase inhibitor	TOP2A	infectious disease|gastroenterology	gonorrhea|enteritis|diarrhea|respiratory tract infections	0	99.55	Selleck	S2469	Fleroxacin (Quinodis)	369.13	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	XBJBPGROQZJDOJ-UHFFFAOYSA-N	40466912.0		XBJBPGROQZJDOJ
BRD-A44500574-001-04-9	FLI-06	Preclinical	notch signaling inhibitor				0	94.08	Tocris	5172	FLI 06	438.215	CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|	DUGBYNJMBYPWGS-FOIFJWKZSA-N	6966819.0		DUGBYNJMBYPWGS
BRD-A44500574-001-01-8	FLI-06	Preclinical	notch signaling inhibitor				0	90.57	Selleck	S7399	FLI-06	438.215	CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|	DUGBYNJMBYPWGS-FOIFJWKZSA-N	6966819.0		DUGBYNJMBYPWGS
BRD-A44500574-001-03-4	FLI-06	Preclinical	notch signaling inhibitor				0	94.81	Tocris	5172	FLI 06	438.215	CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|	DUGBYNJMBYPWGS-FOIFJWKZSA-N	6966819.0		DUGBYNJMBYPWGS
BRD-A44500574-001-02-6	FLI-06	Preclinical	notch signaling inhibitor				0	97.33	Selleck	S7399	FLI-06	438.215	CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5,r,c:3,t:1|	DUGBYNJMBYPWGS-FOIFJWKZSA-N	6966819.0		DUGBYNJMBYPWGS
BRD-K33637378-001-01-7	flibanserin	Launched	serotonin receptor agonist	DRD4|HTR1A|HTR2A	neurology/psychiatry	hypoactive sexual desire disorder	0	96.14	MedChemEx	HY-A0095	Flibanserin	390.167	FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1	PPRRDFIXUUSXRA-UHFFFAOYSA-N	6918248.0		PPRRDFIXUUSXRA
BRD-K56740996-001-02-1	flindokalner	Phase 3	potassium channel agonist	KCNMA1|KCNN4|KCNQ2|KCNQ4|KCNQ5			0	97.23	Tocris	4949	MaxiPost	359.034	COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F	ULYONBAOIMCNEH-HNNXBMFYSA-N	214350.0		ULYONBAOIMCNEH
BRD-K56740996-001-01-3	flindokalner	Phase 3	potassium channel agonist	KCNMA1|KCNN4|KCNQ2|KCNQ4|KCNQ5			0	98.77	Sigma	SML1313	(3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1,3-dihydro-2H-indol-2-one	359.034	COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F	ULYONBAOIMCNEH-HNNXBMFYSA-N	214350.0		ULYONBAOIMCNEH
BRD-A23418262-001-01-5	floctafenine	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	99.43	Carbosynth	FF23305	2,3-dihydroxypropyl 2-{[8-(trifluoromethyl)-4-quinolinyl]amino}benzoate	406.114	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2,r|	APQPGQGAWABJLN-GFCCVEGCSA-N	76958517.0		APQPGQGAWABJLN
BRD-K43383936-001-05-2	flopropione	Launched	serotonin receptor antagonist	HTR1A	neurology/psychiatry	spasms	0	98.95	MicroSource	1500629	FLOPROPIONE	182.058	CCC(=O)c1c(O)cc(O)cc1O	PTHLEKANMPKYDB-UHFFFAOYSA-N	3362.0		PTHLEKANMPKYDB
BRD-K43383936-001-04-5	flopropione	Launched	serotonin receptor antagonist	HTR1A	neurology/psychiatry	spasms	0	93.48	Selleck	S4249	Flopropione	182.058	CCC(=O)c1c(O)cc(O)cc1O	PTHLEKANMPKYDB-UHFFFAOYSA-N	3362.0		PTHLEKANMPKYDB
BRD-K11298197-001-16-9	florfenicol	Launched	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	0	96.31	MedChemEx	HY-B1374	Florfenicol	357	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl	AYIRNRDRBQJXIF-NXEZZACHSA-N	114811.0		AYIRNRDRBQJXIF
BRD-K11298197-001-12-0	florfenicol	Launched	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	0	95.26	Selleck	S4201	Florfenicol	357	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl	AYIRNRDRBQJXIF-NXEZZACHSA-N	114811.0		AYIRNRDRBQJXIF
BRD-K11298197-001-15-3	florfenicol	Launched	protein synthesis inhibitor		pulmonary	bovine respiratory disease (BRD)	0	97.3	Selleck	S4201	FLORFENICOL	357	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl	AYIRNRDRBQJXIF-NXEZZACHSA-N	114811.0		AYIRNRDRBQJXIF
BRD-K00004567-001-01-9	florifenine	Preclinical	anti-inflammatory agent				0	75.09	Sigma	MFCD00869108	2-(1-pyrrolidinyl)ethyl 2-{[7-(trifluoromethyl)-4-quinolinyl]amino}benzoate	429.166	FC(F)(F)c1ccc2c(Nc3ccccc3C(=O)OCCN3CCCC3)ccnc2c1	DQOYUDHAZMAVLD-UHFFFAOYSA-N	216222.0		DQOYUDHAZMAVLD
BRD-A79643124-001-01-9	flosequinan	Withdrawn	phosphodiesterase inhibitor				0	99.63	Key	FE-0065	7-fluoro-1-methyl-3-(methylsulfinyl)-4(1H)-quinolinone	239.042	Cn1cc([S@@](C)=O)c(=O)c2ccc(F)cc12 |r|	UYGONJYYUKVHDD-MRXNPFEDSA-N	11776383.0		UYGONJYYUKVHDD
BRD-K47832606-001-30-1	floxuridine	Launched	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	0	100.0	Selleck	S1299	Floxuridine	246.065	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	ODKNJVUHOIMIIZ-RRKCRQDMSA-N	5790.0	BRD-K73088654-001-01-9	ODKNJVUHOIMIIZ
BRD-K47832606-001-26-9	floxuridine	Launched	DNA synthesis inhibitor	TYMS	oncology	colorectal cancer	0		Sigma	F0503	Floxuridine	246.065	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1	5790.0		ODKNJVUHOIMIIZ
BRD-K00003510-001-01-9	FLT3-IN-1	Preclinical	FLT3 inhibitor				0	97.13	MedChemEx	HY-109584	FLT3-IN-1	530.312	CCCNc1nc(Nc2ccc(cc2)C#N)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C	HJFSVYUFOXAVAA-YUAYGMJFSA-N	90052320.0		HJFSVYUFOXAVAA
BRD-K86003836-001-10-5	flubendazole	Launched	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	0	97.49	MicroSource	1505043	FLUBENDAZOLE	313.086	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1	CPEUVMUXAHMANV-UHFFFAOYSA-N	35802.0	BRD-K99928247-001-01-0	CPEUVMUXAHMANV
BRD-K86003836-001-13-9	flubendazole	Launched	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	0	97.46	MedChemEx	HY-B0294	Flubendazole	313.086	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1	CPEUVMUXAHMANV-UHFFFAOYSA-N	35802.0		CPEUVMUXAHMANV
BRD-K86003836-001-09-7	flubendazole	Launched	tubulin polymerization inhibitor	TUBB	infectious disease	gastrointestinal parasites	0	96.48	Selleck	S1837	Flubendazole	313.086	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1	CPEUVMUXAHMANV-UHFFFAOYSA-N	35802.0		CPEUVMUXAHMANV
BRD-K27871792-236-01-0	flucloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|dermatology|gastroenterology	gram-positive bacterial infections|tonsillitis|sinusitis|pneumonia|eczema|endocarditis|meningitis|enteritis|bacterial septicemia	0	74.99	Sigma	MFCD01682108	sodium (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	453.056	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl	UIOFUWFRIANQPC-JKIFEVAISA-N	21319.0		UIOFUWFRIANQPC
BRD-K27871792-001-01-8	flucloxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|dermatology|gastroenterology	gram-positive bacterial infections|tonsillitis|sinusitis|pneumonia|eczema|endocarditis|meningitis|enteritis|bacterial septicemia	0	78.07	Prestwick	Prestw-1011	Flucloxacillin sodium	453.056	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl	UIOFUWFRIANQPC-JKIFEVAISA-N	21319.0	BRD-A13650332-236-09-6	UIOFUWFRIANQPC
BRD-K05977355-001-19-0	fluconazole	Launched	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis|meningitis	0	97.95	MicroSource	1503975	FLUCONAZOLE	306.104	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	RFHAOTPXVQNOHP-UHFFFAOYSA-N	3365.0		RFHAOTPXVQNOHP
BRD-K05977355-001-23-2	fluconazole	Launched	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis|meningitis	0	95.83	Sigma	Y0000557	2-(2,4-difluorophenyl)-1,3-di(1H-1,2,4-triazol-1-yl)-2-propanol	306.104	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	RFHAOTPXVQNOHP-UHFFFAOYSA-N	3365.0		RFHAOTPXVQNOHP
BRD-K05977355-001-18-2	fluconazole	Launched	sterol demethylase inhibitor	CYP51A1	infectious disease	esophageal candidiasis|meningitis	0	90.64	Selleck	S1331	Fluconazole	306.104	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	RFHAOTPXVQNOHP-UHFFFAOYSA-N	3365.0		RFHAOTPXVQNOHP
BRD-K82143716-001-30-9	flucytosine	Launched	other antifungal	DNMT1	infectious disease	bacterial septicemia|endocarditis|urinary tract infections|meningitis	0	100.0	MedChemEx	HY-B0139	Flucytosine	129.034	Nc1nc(=O)[nH]cc1F	XRECTZIEBJDKEO-UHFFFAOYSA-N	3366.0		XRECTZIEBJDKEO
BRD-K82143716-001-20-7	flucytosine	Launched	other antifungal	DNMT1	infectious disease	bacterial septicemia|endocarditis|urinary tract infections|meningitis	0	92.98	MicroSource	1505429	FLUCYTOSINE	129.034	Nc1nc(=O)[nH]cc1F	XRECTZIEBJDKEO-UHFFFAOYSA-N	3366.0		XRECTZIEBJDKEO
BRD-K82143716-001-19-9	flucytosine	Launched	other antifungal	DNMT1	infectious disease	bacterial septicemia|endocarditis|urinary tract infections|meningitis	0	100.0	Selleck	S1666	Flucytosine	129.034	Nc1nc(=O)[nH]cc1F	XRECTZIEBJDKEO-UHFFFAOYSA-N	3366.0		XRECTZIEBJDKEO
BRD-K66788707-001-15-0	fludarabine	Launched	ribonucleotide reductase inhibitor	ADA|DCK|POLA1|RRM1|RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	83.64	Tocris	3495	Fludarabine	285.087	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	HBUBKKRHXORPQB-FJFJXFQQSA-N	657237.0		HBUBKKRHXORPQB
BRD-K66788707-001-14-3	fludarabine	Launched	ribonucleotide reductase inhibitor	ADA|DCK|POLA1|RRM1|RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	98.32	Tocris	3495	Fludarabine	285.087	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	HBUBKKRHXORPQB-FJFJXFQQSA-N	657237.0		HBUBKKRHXORPQB
BRD-K66788707-001-17-6	fludarabine	Launched	ribonucleotide reductase inhibitor	ADA|DCK|POLA1|RRM1|RRM2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	96.09	Selleck	S1491	Fludarabine (Fludara)	285.087	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	HBUBKKRHXORPQB-FJFJXFQQSA-N	657237.0	BRD-K51927012-001-02-9	HBUBKKRHXORPQB
BRD-K71106091-001-06-1	fludarabine-phosphate	Launched	ribonucleotide reductase inhibitor	POLA1|POLD1|POLE|RRM1|RRM2|RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	96.99	MicroSource	1505705	FLUDARABINE PHOSPHATE	365.054	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	GIUYCYHIANZCFB-FJFJXFQQSA-N	30751.0		GIUYCYHIANZCFB
BRD-K71106091-001-09-5	fludarabine-phosphate	Launched	ribonucleotide reductase inhibitor	POLA1|POLD1|POLE|RRM1|RRM2|RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	93.84	Selleck	S1229	Fludarabine Phosphate (Fludara)	365.054	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	GIUYCYHIANZCFB-FJFJXFQQSA-N	30751.0		GIUYCYHIANZCFB
BRD-K71106091-001-05-3	fludarabine-phosphate	Launched	ribonucleotide reductase inhibitor	POLA1|POLD1|POLE|RRM1|RRM2|RRM2B	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	86.16	Selleck	S1229	Fludarabine Phosphate	365.054	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	GIUYCYHIANZCFB-FJFJXFQQSA-N	30751.0		GIUYCYHIANZCFB
BRD-K06408664-001-03-5	fludrocortisone-acetate	Launched		NR3C2	endocrinology	Addison's disease|adrenogenital syndrome	0	92.71	MicroSource	1500299	FLUDROCORTISONE ACETATE	422.21	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|	SYWHXTATXSMDSB-GSLJADNHSA-N	225609.0	BRD-A38749782-001-04-1	SYWHXTATXSMDSB
BRD-K06408664-001-04-9	fludrocortisone-acetate	Launched		NR3C2	endocrinology	Addison's disease|adrenogenital syndrome	0	86.36	MedChemEx	HY-B1203A	Fludrocortisone (acetate)	422.21	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|	SYWHXTATXSMDSB-GSLJADNHSA-N	225609.0		SYWHXTATXSMDSB
BRD-K06408664-001-02-7	fludrocortisone-acetate	Launched		NR3C2	endocrinology	Addison's disease|adrenogenital syndrome	0	92.19	Sigma	MFCD00864160	(11beta)-9-fluoro-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl acetate	422.21	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|	SYWHXTATXSMDSB-GSLJADNHSA-N	225609.0		SYWHXTATXSMDSB
BRD-K00824317-001-18-9	fludroxycortide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	infectious disease|dermatology	skin infections|psoriasis	0	91.88	MedChemEx	HY-B1013	Flurandrenolide	436.226	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|	POPFMWWJOGLOIF-XWCQMRHXSA-N	15209.0		POPFMWWJOGLOIF
BRD-K44067360-001-30-3	flufenamic-acid	Preclinical	chloride channel blocker	AKR1C3|ANO1|AR|GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|PANX1|PANX2|PANX3|PKD2L1|PTGS1|PTGS2|TRPC5|TRPM2|TRPM5			0	99.37	MicroSource	1501015	FLUFENAMIC ACID	281.066	OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	LPEPZBJOKDYZAD-UHFFFAOYSA-N	3371.0		LPEPZBJOKDYZAD
BRD-K44067360-001-29-5	flufenamic-acid	Preclinical	chloride channel blocker	AKR1C3|ANO1|AR|GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|PANX1|PANX2|PANX3|PKD2L1|PTGS1|PTGS2|TRPC5|TRPM2|TRPM5			0	97.61	Selleck	S4268	Flufenamic acid	281.066	OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	LPEPZBJOKDYZAD-UHFFFAOYSA-N	3371.0		LPEPZBJOKDYZAD
BRD-K68870568-066-01-5	flumatinib	Phase 3	Bcr-Abl kinase inhibitor	ABL1|PDGFRB			0	94.43	MedChemEx	HY-13905	Flumatinib (mesylate)	562.242	CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	BJCJYEYYYGBROF-UHFFFAOYSA-N	46848036.0		BJCJYEYYYGBROF
BRD-K68870568-066-02-9	flumatinib	Phase 3	Bcr-Abl kinase inhibitor	ABL1|PDGFRB			0	97.8	MedChemEx	HY-13905	Flumatinib (mesylate)	562.242	CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	BJCJYEYYYGBROF-UHFFFAOYSA-N	46848036.0		BJCJYEYYYGBROF
BRD-K98769987-001-25-2	flumazenil	Launched	benzodiazepine receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	neurology/psychiatry	sedative	0	96.94	Tocris	1328	Flumazenil	303.102	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	OFBIFZUFASYYRE-UHFFFAOYSA-N	3373.0		OFBIFZUFASYYRE
BRD-K98769987-001-23-7	flumazenil	Launched	benzodiazepine receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	neurology/psychiatry	sedative	0	99.3	MicroSource	1505701	FlUMAZENIL	303.102	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	OFBIFZUFASYYRE-UHFFFAOYSA-N	3373.0		OFBIFZUFASYYRE
BRD-K98769987-001-26-9	flumazenil	Launched	benzodiazepine receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	neurology/psychiatry	sedative	0	96.93	Tocris	1328	Flumazenil	303.102	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	OFBIFZUFASYYRE-UHFFFAOYSA-N	3373.0		OFBIFZUFASYYRE
BRD-K98769987-001-21-1	flumazenil	Launched	benzodiazepine receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	neurology/psychiatry	sedative	0	98.36	Selleck	S1332	Flumazenil	303.102	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	OFBIFZUFASYYRE-UHFFFAOYSA-N	3373.0		OFBIFZUFASYYRE
BRD-K98769987-001-22-9	flumazenil	Launched	benzodiazepine receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	neurology/psychiatry	sedative	0	99.29	Tocris	1328	Flumazenil	303.102	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	OFBIFZUFASYYRE-UHFFFAOYSA-N	3373.0		OFBIFZUFASYYRE
BRD-A44181516-001-01-8	flumecinol	Launched					0	97.8	Enamine	Z2301518221	1-phenyl-1-[3-(trifluoromethyl)phenyl]-1-propanol	280.107	CC[C@@](O)(c1ccccc1)c1cccc(c1)C(F)(F)F |&1:2,r|	DVASNQYQOZHAJN-OAHLLOKOSA-N	76961845.0		DVASNQYQOZHAJN
BRD-A69777949-001-25-9	flumequine	Launched	topoisomerase inhibitor		infectious disease	urinary tract infections	0	97.02	MicroSource	1500992	FLUMEQUINE	261.08	C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	DPSPPJIUMHPXMA-ZETCQYMHSA-N	6918894.0		DPSPPJIUMHPXMA
BRD-A69777949-001-27-9	flumequine	Launched	topoisomerase inhibitor		infectious disease	urinary tract infections	0	96.53	MedChemEx	HY-B0526	Flumequine	261.08	C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	DPSPPJIUMHPXMA-ZETCQYMHSA-N	6918894.0		DPSPPJIUMHPXMA
BRD-A69777949-001-24-2	flumequine	Launched	topoisomerase inhibitor		infectious disease	urinary tract infections	0	98.1	Selleck	S3181	Flumequine	261.08	C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	DPSPPJIUMHPXMA-ZETCQYMHSA-N	6918894.0		DPSPPJIUMHPXMA
BRD-K61496577-001-21-9	flumethasone	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	otolaryngology|infectious disease|dermatology	otitis|ear infections|corticosteroid-responsive dermatoses	0	85.67	MedChemEx	HY-B1051	Flumethasone	410.19	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|	WXURHACBFYSXBI-GQKYHHCASA-N	16490.0		WXURHACBFYSXBI
BRD-K61496577-001-20-2	flumethasone	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	otolaryngology|infectious disease|dermatology	otitis|ear infections|corticosteroid-responsive dermatoses	0	97.76	MicroSource	1501196	FLUMETHASONE	410.19	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|	WXURHACBFYSXBI-GQKYHHCASA-N	16490.0	BRD-A01346607-001-04-2	WXURHACBFYSXBI
BRD-K61496577-001-19-4	flumethasone	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	otolaryngology|infectious disease|dermatology	otitis|ear infections|corticosteroid-responsive dermatoses	0	95.06	Selleck	S4088	Flumethasone	410.19	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12,t:8|	WXURHACBFYSXBI-GQKYHHCASA-N	16490.0	BRD-K09237689-001-01-0	WXURHACBFYSXBI
BRD-K00025599-001-01-9	flumethasone-pivalate	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	allergy	allergic rhinitis	0	94.44	Sigma	F0891-100MG		494.248	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12,t:8|	JWRMHDSINXPDHB-OJAGFMMFSA-N	443980.0		JWRMHDSINXPDHB
BRD-A43518428-001-02-7	flumexadol	Preclinical					0	29.46	Enamine	Z1318513963	2-[3-(trifluoromethyl)phenyl]morpholine	231.087	FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|	GXPYCYWPUGKQIJ-SNVBAGLBSA-N	76971765.0		GXPYCYWPUGKQIJ
BRD-A43518428-001-01-9	flumexadol	Preclinical					0	16.22	Enamine	Z397586650		231.087	FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10,r|	GXPYCYWPUGKQIJ-SNVBAGLBSA-N	76971765.0		GXPYCYWPUGKQIJ
BRD-K29582677-300-11-4	flunarizine	Launched	calcium channel blocker	CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)	0	96.48	Tocris	522	Flunarizine dihydrochloride	404.206	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	SMANXXCATUTDDT-QPJJXVBHSA-N	941361.0		SMANXXCATUTDDT
BRD-K29582677-300-08-0	flunarizine	Launched	calcium channel blocker	CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)	0	97.61	Selleck	S2030	Flunarizine 2HCl	404.206	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	SMANXXCATUTDDT-QPJJXVBHSA-N	941361.0		SMANXXCATUTDDT
BRD-K29582677-300-10-6	flunarizine	Launched	calcium channel blocker	CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)	0	97.81	MicroSource	1500993	FLUNARIZINE HYDROCHLORIDE	404.206	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	SMANXXCATUTDDT-QPJJXVBHSA-N	941361.0		SMANXXCATUTDDT
BRD-K29582677-300-09-8	flunarizine	Launched	calcium channel blocker	CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1	neurology/psychiatry|cardiology	migraine headache|vertigo|peripheral artery disease (PAD)	0	97.68	Tocris	522	Flunarizine dihydrochloride	404.206	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	SMANXXCATUTDDT-QPJJXVBHSA-N	941361.0		SMANXXCATUTDDT
BRD-K49577446-001-12-9	flunisolide	Launched	cytochrome P450 inhibitor	NR3C1	allergy	allergic rhinitis	0	91.32	MedChemEx	HY-B1121	Flunisolide	434.21	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	XSFJVAJPIHIPKU-XWCQMRHXSA-N	82153.0		XSFJVAJPIHIPKU
BRD-K99984802-100-13-5	flunixin-meglumin	Launched	prostanoid receptor antagonist		pulmonary	bovine respiratory disease (BRD)	0	99.53	MicroSource	1505113	FLUNIXIN MEGLUMINE	296.077	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	NOOCSNJCXJYGPE-UHFFFAOYSA-N	38081.0		NOOCSNJCXJYGPE
BRD-K99984802-100-14-9	flunixin-meglumin	Launched	prostanoid receptor antagonist		pulmonary	bovine respiratory disease (BRD)	0	96.82	MedChemEx	HY-B0386	Flunixin (meglumine)	296.077	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	NOOCSNJCXJYGPE-UHFFFAOYSA-N	38081.0		NOOCSNJCXJYGPE
BRD-K99984802-100-12-7	flunixin-meglumin	Launched	prostanoid receptor antagonist		pulmonary	bovine respiratory disease (BRD)	0	97.97	Selleck	S2108	Flunixin Meglumin	296.077	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	NOOCSNJCXJYGPE-UHFFFAOYSA-N	38081.0		NOOCSNJCXJYGPE
BRD-K94353609-001-22-9	fluocinolone-acetonide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	dermatology	seborrheic dermatitis	0	92.74	MedChemEx	HY-B0415	Fluocinolone (Acetonide)	452.201	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	FEBLZLNTKCEFIT-VSXGLTOVSA-N	6215.0		FEBLZLNTKCEFIT
BRD-K94353609-001-21-6	fluocinolone-acetonide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	dermatology	seborrheic dermatitis	0	97.2	MicroSource	1500302	FLUOCINOLONE ACETONIDE	452.201	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	FEBLZLNTKCEFIT-VSXGLTOVSA-N	6215.0	BRD-A77824596-001-04-0	FEBLZLNTKCEFIT
BRD-K94353609-001-20-8	fluocinolone-acetonide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	dermatology	seborrheic dermatitis	0	92.88	Selleck	S2470	Fluocinolone Acetonide	452.201	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15,t:11|	FEBLZLNTKCEFIT-VSXGLTOVSA-N	6215.0	BRD-K95627890-001-01-2	FEBLZLNTKCEFIT
BRD-K57886322-001-18-9	fluocinonide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6|SMO	dermatology	seborrheic dermatitis|eczema	0	86.43	MedChemEx	HY-B0485	Fluocinonide	494.212	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|	WJOHZNCJWYWUJD-IUGZLZTKSA-N	9642.0		WJOHZNCJWYWUJD
BRD-K57886322-001-16-6	fluocinonide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6|SMO	dermatology	seborrheic dermatitis|eczema	0	93.28	Selleck	S2608	Fluocinonide	494.212	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|	WJOHZNCJWYWUJD-IUGZLZTKSA-N	9642.0	BRD-K68865937-001-01-6	WJOHZNCJWYWUJD
BRD-K57886322-001-17-4	fluocinonide	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6|SMO	dermatology	seborrheic dermatitis|eczema	0	91.13	Selleck	S2608	FLUOCINONIDE	494.212	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25,t:21|	WJOHZNCJWYWUJD-IUGZLZTKSA-N	9642.0		WJOHZNCJWYWUJD
BRD-K21913543-001-02-4	fluorescein	Launched		SLC22A6	ophthalmology	ophthalmology diagnostic	0	95.86	MicroSource	1505396	FLUORESCEIN	332.068	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	GNBHRKFJIUUOQI-UHFFFAOYSA-N	16850.0		GNBHRKFJIUUOQI
BRD-K21913543-001-03-9	fluorescein	Launched		SLC22A6	ophthalmology	ophthalmology diagnostic	0	75.99	MedChemEx	HY-D0251	Fluorescein	332.068	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	GNBHRKFJIUUOQI-UHFFFAOYSA-N	16850.0		GNBHRKFJIUUOQI
BRD-K64862097-001-20-9	fluorometholone	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology	eye inflammation	0		WuXi	EW21509-4-P1	FLUOROMETHOLONE	376.205	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|	FAOZLTXFLGPHNG-KNAQIMQKSA-N	9878.0		FAOZLTXFLGPHNG
BRD-K02528732-001-01-6	fluorometholone-acetate	Launched		NR3C1	ophthalmology	eye inflammation	0	0.0	Selleck	S4228	Fluorometholone Acetate	418.216	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|	YRFXGQHBPBMFHW-SBTZIJSASA-N	240767.0		YRFXGQHBPBMFHW
BRD-K02528732-001-03-2	fluorometholone-acetate	Launched		NR3C1	ophthalmology	eye inflammation	0	88.61	Selleck	S4228	Fluorometholone Acetate	418.216	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|	YRFXGQHBPBMFHW-SBTZIJSASA-N	240767.0		YRFXGQHBPBMFHW
BRD-K02528732-001-02-4	fluorometholone-acetate	Launched		NR3C1	ophthalmology	eye inflammation	0	97.54	Selleck	S4228	Fluorometholone Acetate	418.216	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26,t:30|	YRFXGQHBPBMFHW-SBTZIJSASA-N	240767.0		YRFXGQHBPBMFHW
BRD-K51199656-003-01-4	fluoromethylcholine	Launched					0	100.0	MatrixSci	8941		122.098	C[N+](C)(CF)CCO	PBVFROWIWWGIFK-UHFFFAOYSA-N	404592.0		PBVFROWIWWGIFK
BRD-A31159102-003-30-4	fluoxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	ANO1|HTR2B|SLC6A4	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder	0	98.86	MicroSource	1504173	FLUOXETINE HYDROCHLORIDE	309.134	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	RTHCYVBBDHJXIQ-UHFFFAOYSA-N	657320.0		RTHCYVBBDHJXIQ
BRD-A31159102-003-28-8	fluoxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	ANO1|HTR2B|SLC6A4	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder	0	94.97	Selleck	S1333	Fluoxetine HCl	309.134	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	RTHCYVBBDHJXIQ-UHFFFAOYSA-N	657320.0		RTHCYVBBDHJXIQ
BRD-A31159102-003-31-2	fluoxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	ANO1|HTR2B|SLC6A4	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder	0	92.65	Tocris	927	Fluoxetine hydrochloride	309.134	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	RTHCYVBBDHJXIQ-UHFFFAOYSA-N	657320.0		RTHCYVBBDHJXIQ
BRD-A31159102-003-29-6	fluoxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	ANO1|HTR2B|SLC6A4	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|bulimia nervosa|panic disorders|bipolar disorder	0	97.29	Tocris	927	Fluoxetine hydrochloride	309.134	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	RTHCYVBBDHJXIQ-UHFFFAOYSA-N	657320.0		RTHCYVBBDHJXIQ
BRD-K70487031-001-02-8	flupentixol	Launched	dopamine receptor antagonist	ADRA1A|CHRM1|DRD1|DRD2|DRD3|DRD5|HTR2A	neurology/psychiatry	schizophrenia|depression	0	93.69	Enzo	AC750	cis-(Z)-Flupenthixol 2HCl	434.164	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	NJMYODHXAKYRHW-DVZOWYKESA-N	5281881.0		NJMYODHXAKYRHW
BRD-K55127134-300-11-2	fluphenazine	Launched	dopamine receptor antagonist	CALM1|DRD1|DRD2|DRD5|HRH1|HTR2A|HTR6|HTR7	neurology/psychiatry	schizophrenia	0	95.33	MicroSource	1500994	FLUPHENAZINE HYDROCHLORIDE	437.175	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	PLDUPXSUYLZYBN-UHFFFAOYSA-N	3372.0		PLDUPXSUYLZYBN
BRD-K27898013-001-01-4	fluphenazine-decanoate	Launched	dopamine receptor antagonist	DRD2|HTR1B|HTR4	neurology/psychiatry	schizophrenia	0	59.41	AKSci	67470		591.311	CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	VIQCGTZFEYDQMR-UHFFFAOYSA-N	3388.0		VIQCGTZFEYDQMR
BRD-K50720187-001-02-8	flupirtine	Launched	glutamate receptor antagonist	ADRA2A|KCNQ1|KCNQ2	neurology/psychiatry	pain relief	0	8.67	Tocris	2867	Flupirtine maleate	304.134	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	JUUFBMODXQKSTD-UHFFFAOYSA-N	53276.0		JUUFBMODXQKSTD
BRD-K50720187-050-09-0	flupirtine	Launched	glutamate receptor antagonist	ADRA2A|KCNQ1|KCNQ2	neurology/psychiatry	pain relief	0	85.76	MedChemEx	HY-17001	Flupirtine (Maleate)	304.134	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	JUUFBMODXQKSTD-UHFFFAOYSA-N	53276.0		JUUFBMODXQKSTD
BRD-K50720187-051-03-1	flupirtine	Launched	glutamate receptor antagonist	ADRA2A|KCNQ1|KCNQ2	neurology/psychiatry	pain relief	0	73.55	Selleck	S1334	Flupirtine maleate	304.134	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	JUUFBMODXQKSTD-UHFFFAOYSA-N	53276.0		JUUFBMODXQKSTD
BRD-K50720187-050-08-2	flupirtine	Launched	glutamate receptor antagonist	ADRA2A|KCNQ1|KCNQ2	neurology/psychiatry	pain relief	0	36.42	MedChemEx	HY-17001	Flupirtine (Maleate)	304.134	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	JUUFBMODXQKSTD-UHFFFAOYSA-N	53276.0		JUUFBMODXQKSTD
BRD-K50720187-051-02-3	flupirtine	Launched	glutamate receptor antagonist	ADRA2A|KCNQ1|KCNQ2	neurology/psychiatry	pain relief	0	0.63	Selleck	S1334	Flupirtine maleate	304.134	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	JUUFBMODXQKSTD-UHFFFAOYSA-N	53276.0		JUUFBMODXQKSTD
BRD-K44091134-001-01-9	fluprazine	Phase 1	serotonin receptor agonist	HTR1A|HTR1B			0	92.16	Enamine	Z432843176	N-(2-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)urea	316.151	NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F	CHQKHXJPWDSTPY-UHFFFAOYSA-N	71153.0		CHQKHXJPWDSTPY
BRD-K00003239-001-01-9	fluralaner	Preclinical	GABA receptor antagonist				0	99.1	MedChemEx	HY-16973	Fluralaner	555.055	Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C1=NO[C@](C1)(c1cc(Cl)cc(Cl)c1)C(F)(F)F |&1:22,r,t:20|	MLBZKOGAMRTSKP-HXUWFJFHSA-N	71300892.0		MLBZKOGAMRTSKP
BRD-A86044036-001-26-5	flurbiprofen-(+/-)	Launched	cyclooxygenase inhibitor		rheumatology	rheumatoid arthritis|osteoarthritis	0	98.21	Tocris	1769	Flurbiprofen	244.09	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	SYTBZMRGLBWNTM-SNVBAGLBSA-N	92337.0		SYTBZMRGLBWNTM
BRD-A86044036-001-30-9	flurbiprofen-(+/-)	Launched	cyclooxygenase inhibitor		rheumatology	rheumatoid arthritis|osteoarthritis	0	92.79	Tocris	1769	Flurbiprofen	244.09	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	SYTBZMRGLBWNTM-SNVBAGLBSA-N	92337.0		SYTBZMRGLBWNTM
BRD-A86044036-001-27-3	flurbiprofen-(+/-)	Launched	cyclooxygenase inhibitor		rheumatology	rheumatoid arthritis|osteoarthritis	0	0.0	MicroSource	1500308	FLURBIPROFEN	244.09	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	SYTBZMRGLBWNTM-SNVBAGLBSA-N	92337.0		SYTBZMRGLBWNTM
BRD-K69907333-001-07-2	flurbiprofen-(S)-(+)	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	0.0	Selleck	S1679	Flurbiprofen	244.09	C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-JTQLQIEISA-N	72099.0		SYTBZMRGLBWNTM
BRD-K69907333-001-10-6	flurbiprofen-(S)-(+)	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	99.2	Selleck	S1679	(S)-(+)-Flurbiprofen	244.09	C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-JTQLQIEISA-N	72099.0		SYTBZMRGLBWNTM
BRD-K00004724-001-01-9	flurbiprofen-axetil	Launched	analgesic agent				0	50.9	CombiBlocks	QJ-7645	Flurbiprofen axetil	330.127	C[C@H](OC(C)=O)OC(=O)[C@H](C)c1ccc(c(F)c1)-c1ccccc1 |&1:9,&2:1,r|	ALIVXCSEERJYHU-TZMCWYRMSA-N	40468023.0		ALIVXCSEERJYHU
BRD-K75410565-001-03-9	flurizan	Phase 3	gamma secretase inhibitor	APH1B|BACE1|IKBKG|PSEN1|PSEN2|PTGS1|PTGS2			0	96.34	Tocris	4495	Flurizan	244.09	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-SNVBAGLBSA-N	92337.0		SYTBZMRGLBWNTM
BRD-K75410565-001-02-9	flurizan	Phase 3	gamma secretase inhibitor	APH1B|BACE1|IKBKG|PSEN1|PSEN2|PTGS1|PTGS2			0	95.1	Tocris	4495	Flurizan	244.09	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	SYTBZMRGLBWNTM-SNVBAGLBSA-N	92337.0		SYTBZMRGLBWNTM
BRD-K67445247-001-04-7	flurofamide	Preclinical	urease inhibitor				0	43.87	Tocris	478	Flurofamide	217.042	NP(N)(=O)NC(=O)c1ccc(F)cc1	QWZFVMCWPLMLTL-UHFFFAOYSA-N	51173.0		QWZFVMCWPLMLTL
BRD-K67445247-001-03-9	flurofamide	Preclinical	urease inhibitor				0	73.24	Tocris	478	N-(4-fluorobenzoyl)phosphoric triamide	217.042	NP(N)(=O)NC(=O)c1ccc(F)cc1	QWZFVMCWPLMLTL-UHFFFAOYSA-N	51173.0		QWZFVMCWPLMLTL
BRD-K67445247-001-02-1	flurofamide	Preclinical	urease inhibitor				0	40.15	Tocris	478	Flurofamide	217.042	NP(N)(=O)NC(=O)c1ccc(F)cc1	QWZFVMCWPLMLTL-UHFFFAOYSA-N	51173.0		QWZFVMCWPLMLTL
BRD-K14763542-001-02-3	flurothyl	Preclinical					1	0.0	MicroSource	1505430	FLUROTHYL	182.017	FC(F)(F)COCC(F)(F)F	KGPPDNUWZNWPSI-UHFFFAOYSA-N	9528.0		KGPPDNUWZNWPSI
BRD-K14763542-001-03-1	flurothyl	Preclinical					1	0.0	TCI	B1293	1,1,1-trifluoro-2-(2,2,2-trifluoroethoxy)ethane	182.017	FC(F)(F)COCC(F)(F)F	KGPPDNUWZNWPSI-UHFFFAOYSA-N	9528.0		KGPPDNUWZNWPSI
BRD-K56908511-001-01-2	fluroxene	Preclinical	local anesthetic				1	0.0	MicroSource	1506162	FLUROXENE	126.029	FC(F)(F)COC=C	DLEGDLSLRSOURQ-UHFFFAOYSA-N	9844.0		DLEGDLSLRSOURQ
BRD-K56908511-001-02-0	fluroxene	Preclinical	local anesthetic				1	0.0	MedChemEx	HY-B1163	Fluroxene	126.029	FC(F)(F)COC=C	DLEGDLSLRSOURQ-UHFFFAOYSA-N	9844.0		DLEGDLSLRSOURQ
BRD-K77947974-001-16-3	fluspirilene	Launched	dopamine receptor antagonist	CACNG1|DRD2|HRH1|HTR1A|HTR1D|HTR1E|HTR2A	neurology/psychiatry	schizophrenia	0	95.2	Enzo	AC116	Fluspirilene	475.244	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	QOYHHIBFXOOADH-UHFFFAOYSA-N	3396.0		QOYHHIBFXOOADH
BRD-K77947974-001-18-9	fluspirilene	Launched	dopamine receptor antagonist	CACNG1|DRD2|HRH1|HTR1A|HTR1D|HTR1E|HTR2A	neurology/psychiatry	schizophrenia	0	96.22	Sigma	F100	Fluspirilene	475.244	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	QOYHHIBFXOOADH-UHFFFAOYSA-N	3396.0		QOYHHIBFXOOADH
BRD-K28307902-001-23-3	flutamide	Launched	androgen receptor antagonist	AHR|AR	oncology	prostate cancer	0	84.58	Tocris	4094	Flutamide	276.072	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	MKXKFYHWDHIYRV-UHFFFAOYSA-N	3397.0		MKXKFYHWDHIYRV
BRD-K28307902-001-21-7	flutamide	Launched	androgen receptor antagonist	AHR|AR	oncology	prostate cancer	0	99.28	MicroSource	1500995	FLUTAMIDE	276.072	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	MKXKFYHWDHIYRV-UHFFFAOYSA-N	3397.0		MKXKFYHWDHIYRV
BRD-K28307902-001-20-9	flutamide	Launched	androgen receptor antagonist	AHR|AR	oncology	prostate cancer	0	96.45	Selleck	S1908	Flutamide	276.072	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	MKXKFYHWDHIYRV-UHFFFAOYSA-N	3397.0		MKXKFYHWDHIYRV
BRD-K62310379-001-12-1	fluticasone-propionate	Launched	glucocorticoid receptor agonist	NR3C1|NR3C2|PGR|PLA2G4A	dermatology	corticosteroid-responsive dermatoses	0	89.09	Tocris	2007	Fluticasone propionate	500.184	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|	WMWTYOKRWGGJOA-CENSZEJFSA-N	444036.0		WMWTYOKRWGGJOA
BRD-K62310379-001-14-9	fluticasone-propionate	Launched	glucocorticoid receptor agonist	NR3C1|NR3C2|PGR|PLA2G4A	dermatology	corticosteroid-responsive dermatoses	0	91.24	Tocris	2007	Fluticasone propionate	500.184	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|	WMWTYOKRWGGJOA-CENSZEJFSA-N	444036.0		WMWTYOKRWGGJOA
BRD-K62310379-001-13-9	fluticasone-propionate	Launched	glucocorticoid receptor agonist	NR3C1|NR3C2|PGR|PLA2G4A	dermatology	corticosteroid-responsive dermatoses	0	93.69	Selleck	S1992	Fluticasone propionate	500.184	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|	WMWTYOKRWGGJOA-CENSZEJFSA-N	444036.0	BRD-K40517875-001-01-0	WMWTYOKRWGGJOA
BRD-K62310379-001-10-5	fluticasone-propionate	Launched	glucocorticoid receptor agonist	NR3C1|NR3C2|PGR|PLA2G4A	dermatology	corticosteroid-responsive dermatoses	0	96.66	Tocris	2007	Fluticasone propionate	500.184	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18,t:14|	WMWTYOKRWGGJOA-CENSZEJFSA-N	444036.0		WMWTYOKRWGGJOA
BRD-A00218260-001-03-4	flutrimazole	Launched	sterol demethylase inhibitor		infectious disease	mycosis	0	99.39	SantaCruz	sc-358236		346.128	Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1 |&1:7|	QHMWCHQXCUNUAK-UHFFFAOYSA-N	3401.0		QHMWCHQXCUNUAK
BRD-K66296774-001-07-9	fluvastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology|cardiology	hypercholesterolemia|congenital heart defects	0	9.71	MicroSource	1504911	FLUVASTATIN	411.185	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	FJLGEFLZQAZZCD-MCBHFWOFSA-N	446155.0		FJLGEFLZQAZZCD
BRD-K66296774-236-12-1	fluvastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology|cardiology	hypercholesterolemia|congenital heart defects	0	93.58	Tocris	3309	Fluvastatin sodium	411.185	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	FJLGEFLZQAZZCD-MCBHFWOFSA-N	446155.0	BRD-M74726084-304-01-9	FJLGEFLZQAZZCD
BRD-K66296774-236-11-3	fluvastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology|cardiology	hypercholesterolemia|congenital heart defects	0	97.47	Selleck	S1909	Fluvastatin sodium (Lescol)	411.185	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	FJLGEFLZQAZZCD-MCBHFWOFSA-N	446155.0		FJLGEFLZQAZZCD
BRD-K66296774-236-10-5	fluvastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology|cardiology	hypercholesterolemia|congenital heart defects	0	28.49	Selleck	S1909	Fluvastatin Sodium	411.185	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	FJLGEFLZQAZZCD-MCBHFWOFSA-N	446155.0		FJLGEFLZQAZZCD
BRD-K53517854-050-21-4	fluvoxamine	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	0	0.0	MicroSource	1505604	FLUVOXAMINE MALEATE	318.156	COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F	CJOFXWAVKWHTFT-XSFVSMFZSA-N	5324346.0		CJOFXWAVKWHTFT
BRD-K53517854-050-22-9	fluvoxamine	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	0	95.13	Tocris	1033	Fluvoxamine maleate	318.156	COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F	CJOFXWAVKWHTFT-XSFVSMFZSA-N	5324346.0		CJOFXWAVKWHTFT
BRD-K53517854-050-20-6	fluvoxamine	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	0	93.04	Tocris	1033	Fluvoxamine maleate	318.156	COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F	CJOFXWAVKWHTFT-XSFVSMFZSA-N	5324346.0		CJOFXWAVKWHTFT
BRD-K53517854-051-01-4	fluvoxamine	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A4	neurology/psychiatry	obsessive compulsive disorder (OCD)	0	93.31	Selleck	S1336	Fluvoxamine maleate	318.156	COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F	CJOFXWAVKWHTFT-XSFVSMFZSA-N	5324346.0		CJOFXWAVKWHTFT
BRD-K15327298-001-05-5	fmoc-L-leucine	Phase 2	PPAR receptor agonist				0	99.78	Sigma	MFCD00204311	(2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-methylpentanoic acid	353.163	CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	CBPJQFCAFFNICX-IBGZPJMESA-N	1549133.0		CBPJQFCAFFNICX
BRD-K00003096-001-01-9	FN-1501	Phase 1	tyrosine kinase inhibitor				0	95.77	MedChemEx	HY-111361	FN-1501	431.218	CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1	VXLAKHWYGRKCGI-UHFFFAOYSA-N	72195175.0		VXLAKHWYGRKCGI
BRD-K18673820-001-15-5	folic-acid	Launched	folate receptor ligand	FOLR2|FOLR3|SLC19A1|SLC46A1	hematology	megaloblastic anemia	0	89.21	MicroSource	1502020	FOLIC ACID	441.14	Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1	OVBPIULPVIDEAO-LBPRGKRZSA-N	6037.0		OVBPIULPVIDEAO
BRD-K56810756-003-07-7	fomepizole	Launched	alcohol dehydrogenase inhibitor	ADH1A|ADH1B|ADH1C|AKR1A1|CAT	critical care	poison antidote	0	98.99	MicroSource	1505432	FOMEPIZOLE HYDROCHLORIDE	82.053	Cc1cn[nH]c1	RIKMMFOAQPJVMX-UHFFFAOYSA-N	3406.0		RIKMMFOAQPJVMX
BRD-K56810756-001-08-9	fomepizole	Launched	alcohol dehydrogenase inhibitor	ADH1A|ADH1B|ADH1C|AKR1A1|CAT	critical care	poison antidote	0	92.35	MedChemEx	HY-B0876	Fomepizole	82.053	Cc1cn[nH]c1	RIKMMFOAQPJVMX-UHFFFAOYSA-N	3406.0		RIKMMFOAQPJVMX
BRD-K56810756-001-03-0	fomepizole	Launched	alcohol dehydrogenase inhibitor	ADH1A|ADH1B|ADH1C|AKR1A1|CAT	critical care	poison antidote	0	98.21	MicroSource	1506159	FOMEPIZOLE	82.053	Cc1cn[nH]c1	RIKMMFOAQPJVMX-UHFFFAOYSA-N	3406.0		RIKMMFOAQPJVMX
BRD-K44942188-001-10-9	fomocaine	Launched	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	0	94.06	Sigma	A_____329983	Fomocaine	311.189	C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	CVHGCWVMTZWGAY-UHFFFAOYSA-N	71693.0		CVHGCWVMTZWGAY
BRD-K44942188-001-09-1	fomocaine	Launched	voltage-gated sodium channel modulator		neurology/psychiatry	local anesthetic	0	96.22	ChemDiv	1822-0278		311.189	C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	CVHGCWVMTZWGAY-UHFFFAOYSA-N	71693.0		CVHGCWVMTZWGAY
BRD-K00003513-363-01-9	fondaparinux	Launched	coagulation factor inhibitor	F10|SERPINC1	hematology	deep vein thrombosis (DVT)	0	93.3	MedChemEx	HY-B0597	Fondaparinux (sodium)	1506.951	[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O	KANJSNBRCNMZMV-ABRZTLGGSA-N	5282448.0		KANJSNBRCNMZMV
BRD-K03449891-001-08-6	foretinib	Phase 2	VEGFR inhibitor	FLT1|FLT4|KDR|MET			0	96.33	Selleck	S1111	Foretinib (GSK1363089)	632.245	COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	CXQHYVUVSFXTMY-UHFFFAOYSA-N	42642645.0		CXQHYVUVSFXTMY
BRD-K03449891-001-06-0	foretinib	Phase 2	VEGFR inhibitor	FLT1|FLT4|KDR|MET			0		Selleck	S1111	Foretinib (GSK1363089, XL880)	632.245	COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)	42642645.0		CXQHYVUVSFXTMY
BRD-A26503646-001-16-6	formestane	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	100.0	MicroSource	1504116	FORMESTANE	302.188	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|	ZMEULISFKSVRLQ-LZBOESDWSA-N			ZMEULISFKSVRLQ
BRD-A26503646-001-20-9	formestane	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	71.92	MedChemEx	HY-B0697	Formestane	302.188	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|	ZMEULISFKSVRLQ-LZBOESDWSA-N			ZMEULISFKSVRLQ
BRD-A26503646-001-18-2	formestane	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	96.73	Selleck	S2208	Formestane	302.188	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1,4,5,15,17,&1:8|	ZMEULISFKSVRLQ-LZBOESDWSA-N		BRD-A87468186-001-01-6	ZMEULISFKSVRLQ
BRD-K55567017-001-14-9	formononetin	Preclinical	alcohol dehydrogenase inhibitor	ADH1C|SLC5A2			0	96.41	MedChemEx	HY-N0183	Formononetin	268.074	COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	HKQYGTCOTHHOMP-UHFFFAOYSA-N	5280378.0		HKQYGTCOTHHOMP
BRD-K55567017-001-12-3	formononetin	Preclinical	alcohol dehydrogenase inhibitor	ADH1C|SLC5A2			0	96.93	Selleck	S2299	Formononetin	268.074	COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	HKQYGTCOTHHOMP-UHFFFAOYSA-N	5280378.0		HKQYGTCOTHHOMP
BRD-K54006094-051-06-6	formoterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	94.6	Tocris	1448	Formoterol hemifumarate	344.174	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	BPZSYCZIITTYBL-ORAYPTAESA-N	3034756.0	BRD-M00539986-051-06-0	BPZSYCZIITTYBL
BRD-K54006094-051-01-7	formoterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	89.53	Selleck	S2020	Formoterol Hemifumarate	344.174	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	BPZSYCZIITTYBL-ORAYPTAESA-N	3034756.0	BRD-M00539986-051-03-7	BPZSYCZIITTYBL
BRD-K54006094-051-10-9	formoterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	97.81	Tocris	1448	Formoterol hemifumarate	344.174	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	BPZSYCZIITTYBL-ORAYPTAESA-N	3034756.0		BPZSYCZIITTYBL
BRD-K54006094-051-03-3	formoterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	98.09	Selleck	S2020	Formoterol hemifumarate	344.174	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	BPZSYCZIITTYBL-ORAYPTAESA-N	3034756.0	BRD-M00539986-051-05-2	BPZSYCZIITTYBL
BRD-K54006094-051-02-5	formoterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	84.08	Tocris	1448	Formoterol hemifumarate	344.174	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	BPZSYCZIITTYBL-ORAYPTAESA-N	3034756.0	BRD-M00539986-051-04-5	BPZSYCZIITTYBL
BRD-K16505263-003-01-1	forodesine	Launched	purinergic receptor antagonist	PNP	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	0	97.5	MedChemEx	HY-16209	Forodesine (hydrochloride)	266.102	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	IWKXDMQDITUYRK-KUBHLMPHSA-N	135409409.0		IWKXDMQDITUYRK
BRD-K16505263-003-02-9	forodesine	Launched	purinergic receptor antagonist	PNP	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	0	100.0	MedChemEx	HY-16209	Forodesine (hydrochloride)	266.102	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	IWKXDMQDITUYRK-KUBHLMPHSA-N	135409409.0		IWKXDMQDITUYRK
BRD-K57774929-001-01-3	foropafant	Phase 3	platelet activating factor receptor antagonist	PTAFR			0	97.36	Sigma	SML0542	N~1~,N~1~-dimethyl-N~2~-(3-pyridinylmethyl)-N~2~-[4-(2,4,6-triisopropylphenyl)-1,3-thiazol-2-yl]-1,2-ethanediamine	464.297	CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C	VVBFISAUNSXQGZ-UHFFFAOYSA-N	119368.0		VVBFISAUNSXQGZ
BRD-K09602097-001-20-1	forskolin	Launched	adenylyl cyclase activator	ADCY2|ADCY5|GNAS			0	99.68	Tocris	1099	Forskolin	410.23	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	OHCQJHSOBUTRHG-KGGHGJDLSA-N	47936.0		OHCQJHSOBUTRHG
BRD-K09602097-001-13-6	forskolin	Launched	adenylyl cyclase activator	ADCY2|ADCY5|GNAS			0	100.0	Tocris	1099	Forskolin	410.23	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	OHCQJHSOBUTRHG-KGGHGJDLSA-N	47936.0		OHCQJHSOBUTRHG
BRD-K09602097-001-23-5	forskolin	Launched	adenylyl cyclase activator	ADCY2|ADCY5|GNAS			0	99.1	Selleck	S2449	Forskolin	410.23	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	OHCQJHSOBUTRHG-KGGHGJDLSA-N	47936.0	BRD-K77830450-001-05-7|BRD-K62498766-001-01-8	OHCQJHSOBUTRHG
BRD-K59110290-238-01-7	fosamprenavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	93.28	MedChemEx	HY-17431	Fosamprenavir (Calcium Salt)	585.191	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	MLBVMOWEQCZNCC-OEMFJLHTSA-N	131536.0		MLBVMOWEQCZNCC
BRD-K59110290-238-02-9	fosamprenavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	96.18	MedChemEx	HY-17431	Fosamprenavir (Calcium Salt)	585.191	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	MLBVMOWEQCZNCC-OEMFJLHTSA-N	131536.0		MLBVMOWEQCZNCC
BRD-K23848629-401-05-2	fosaprepitant-dimeglumine	Launched	tachykinin antagonist	TACR1	gastroenterology	nausea|vomiting	0	77.8	MedChemEx	HY-14407A	Fosaprepitant (dimeglumine)	614.117	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	BARDROPHSZEBKC-OITMNORJSA-N	135413538.0		BARDROPHSZEBKC
BRD-K23848629-401-04-5	fosaprepitant-dimeglumine	Launched	tachykinin antagonist	TACR1	gastroenterology	nausea|vomiting	0	0.0	MedChemEx	HY-14407A	Fosaprepitant (dimeglumine)	614.117	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	BARDROPHSZEBKC-OITMNORJSA-N	135413538.0		BARDROPHSZEBKC
BRD-K23848629-401-02-9	fosaprepitant-dimeglumine	Launched	tachykinin antagonist	TACR1	gastroenterology	nausea|vomiting	0	0.0	Selleck	S3038	Fosaprepitant dimeglumine salt	614.117	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	BARDROPHSZEBKC-OITMNORJSA-N	135413538.0		BARDROPHSZEBKC
BRD-K23848629-401-03-7	fosaprepitant-dimeglumine	Launched	tachykinin antagonist	TACR1	gastroenterology	nausea|vomiting	0	78.2	Selleck	S3038	Fosaprepitant dimeglumine salt	614.117	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	BARDROPHSZEBKC-OITMNORJSA-N	135413538.0		BARDROPHSZEBKC
BRD-K06814349-304-02-7	fosbretabulin	Phase 3	tubulin polymerization inhibitor|VE-cadherin antagonist	CDH5			0	90.79	MedChemEx	HY-17449	Fosbretabulin (disodium)	396.097	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O	WDOGQTQEKVLZIJ-WAYWQWQTSA-N	5351387.0		WDOGQTQEKVLZIJ
BRD-K06814349-304-01-9	fosbretabulin	Phase 3	tubulin polymerization inhibitor|VE-cadherin antagonist	CDH5			0	79.41	MedChemEx	HY-17449	Fosbretabulin (disodium)	396.097	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O	WDOGQTQEKVLZIJ-WAYWQWQTSA-N	5351387.0		WDOGQTQEKVLZIJ
BRD-K85146014-314-06-2	foscarnet	Launched	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis|acquired immunodeficiency syndrome (AIDS)|virus herpes simplex (HSV)	1	0.0	MicroSource	1502019	FOSCARNET SODIUM	125.972	OC(=O)P(O)(O)=O	ZJAOAACCNHFJAH-UHFFFAOYSA-N	3415.0		ZJAOAACCNHFJAH
BRD-K85146014-314-05-4	foscarnet	Launched	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis|acquired immunodeficiency syndrome (AIDS)|virus herpes simplex (HSV)	1	0.0	Selleck	S3076	Foscarnet Sodium	125.972	OC(=O)P(O)(O)=O	ZJAOAACCNHFJAH-UHFFFAOYSA-N	3415.0		ZJAOAACCNHFJAH
BRD-K85146014-314-07-0	foscarnet	Launched	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis|acquired immunodeficiency syndrome (AIDS)|virus herpes simplex (HSV)	1	0.0	Selleck	S3076	Foscarnet Sodium	125.972	OC(=O)P(O)(O)=O	ZJAOAACCNHFJAH-UHFFFAOYSA-N	3415.0		ZJAOAACCNHFJAH
BRD-K85146014-314-08-8	foscarnet	Launched	DNA polymerase inhibitor		infectious disease	cytomegalovirus retinitis|acquired immunodeficiency syndrome (AIDS)|virus herpes simplex (HSV)	1	0.0	Selleck	S3076	Foscarnet Sodium	125.972	OC(=O)P(O)(O)=O	ZJAOAACCNHFJAH-UHFFFAOYSA-N	3415.0		ZJAOAACCNHFJAH
BRD-K20801936-001-01-9	fosfestrol	Launched	synthetic estrogen	ESR1|ESR2	oncology	prostate cancer	0	0.0	MatrixSci	59774		428.079	CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1	NLORYLAYLIXTID-ISLYRVAYSA-N	3032325.0		NLORYLAYLIXTID
BRD-K00003384-001-01-9	fosfluconazole	Preclinical	other antifungal				0	63.38	MedChemEx	HY-100666	Fosfluconazole	386.07	OP(O)(=O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	GHJWNRRCRIGGIO-UHFFFAOYSA-N	214356.0		GHJWNRRCRIGGIO
BRD-K81101512-238-06-9	fosfomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	0	8.3	MedChemEx	HY-B1075	Fosfomycin (calcium)	138.008	C[C@@H]1O[C@@H]1P(O)(O)=O	YMDXZJFXQJVXBF-STHAYSLISA-N	446987.0		YMDXZJFXQJVXBF
BRD-K81101512-234-01-9	fosfomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	0	100.0	Selleck	S4385	Fosfomycin Tromethamine	138.008	C[C@@H]1O[C@@H]1P(O)(O)=O	YMDXZJFXQJVXBF-STHAYSLISA-N	446987.0	BRD-K48461310-234-01-3	YMDXZJFXQJVXBF
BRD-K81101512-304-02-8	fosfomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections	0	0.0	CombiBlocks	OR-4912	Fosfomycin sodium	138.008	C[C@@H]1O[C@@H]1P(O)(O)=O	YMDXZJFXQJVXBF-STHAYSLISA-N	446987.0		YMDXZJFXQJVXBF
BRD-K28687144-001-07-9	fosfosal	Launched	phosphodiesterase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	64.03	MicroSource	1502012	FOSFOSAL	217.998	OC(=O)c1ccccc1OP(O)(O)=O	FFKUDWZICMJVPA-UHFFFAOYSA-N	3418.0		FFKUDWZICMJVPA
BRD-K28687144-001-08-7	fosfosal	Launched	phosphodiesterase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	84.64	Sigma	MFCD00042645	2-(phosphonooxy)benzoic acid	217.998	OC(=O)c1ccccc1OP(O)(O)=O	FFKUDWZICMJVPA-UHFFFAOYSA-N	3418.0		FFKUDWZICMJVPA
BRD-K27963513-236-01-3	fosfructose	Phase 3	fructose diphosphate stimulant				0	1.47	CombiBlocks	QC-8918	Fructose-1,6-diphosphate sodium salt	339.996	O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O	XPYBSIWDXQFNMH-UYFOZJQFSA-N	84951.0		XPYBSIWDXQFNMH
BRD-A51382177-236-03-0	fosinopril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure	0	88.75	Selleck	S2095	Fosinopril sodium (Monopril)	563.301	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|	BIDNLKIUORFRQP-AJTMIRJTSA-N	6708482.0		BIDNLKIUORFRQP
BRD-A51382177-236-04-8	fosinopril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure	0	97.48	Selleck	S2095	Fosinopril sodium (Monopril)	563.301	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5,24,26,&1:7|	BIDNLKIUORFRQP-AJTMIRJTSA-N	6708482.0		BIDNLKIUORFRQP
BRD-A33506612-001-01-2	fosinoprilat	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	61.88	AvaChem	2813	(2S,4S)-4-cyclohexyl-1-{[hydroxy(4-phenylbutyl)phosphoryl]acetyl}-2-pyrrolidinecarboxylic acid	435.217	OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3,5,&1:11|	WOIWWYDXDVSWAZ-RTWAWAEBSA-N	62956.0		WOIWWYDXDVSWAZ
BRD-K53809807-304-02-4	fosphenytoin	Launched	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy|seizures	0	94.91	CombiBlocks	QA-8988	sodium (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate	362.067	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	XWLUWCNOOVRFPX-UHFFFAOYSA-N	56339.0		XWLUWCNOOVRFPX
BRD-K53809807-304-01-6	fosphenytoin	Launched	sodium channel blocker	SCN5A	neurology/psychiatry	epilepsy|seizures	0	0.0	AKSci	K681		362.067	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	XWLUWCNOOVRFPX-UHFFFAOYSA-N	56339.0		XWLUWCNOOVRFPX
BRD-K85178109-001-03-1	fostamatinib	Launched	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	0	92.92	Selleck	S2625	R788 (Fostamatinib)	580.148	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	GKDRMWXFWHEQQT-UHFFFAOYSA-N	11671467.0		GKDRMWXFWHEQQT
BRD-K85178109-304-04-9	fostamatinib	Launched	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	0	80.92	MedChemEx	HY-13038	Fostamatinib Disodium	580.148	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	GKDRMWXFWHEQQT-UHFFFAOYSA-N	11671467.0		GKDRMWXFWHEQQT
BRD-K85178109-001-02-3	fostamatinib	Launched	SYK inhibitor	SYK	hematology	chronic immune thrombocytopenia (ITP)	0	75.97	Selleck	S2625	Fostamatinib (R788)	580.148	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	GKDRMWXFWHEQQT-UHFFFAOYSA-N	11671467.0		GKDRMWXFWHEQQT
BRD-K00003191-001-01-9	fostemsavir	Phase 3	antiviral				0	97.19	MedChemEx	HY-15440A	Fostemsavir	583.158	COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	SWMDAPWAQQTBOG-UHFFFAOYSA-N	11319217.0		SWMDAPWAQQTBOG
BRD-A62893078-001-02-3	fotemustine	Launched	thioredoxin inhibitor		oncology	melanoma	0	36.92	MedChemEx	HY-B0733	Fotemustine	315.075	CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|	UETIXAMLWBFWOE-QMMMGPOBSA-N			UETIXAMLWBFWOE
BRD-A62893078-001-01-5	fotemustine	Launched	thioredoxin inhibitor		oncology	melanoma	0	0.0	MedChemEx	HY-B0733	Fotemustine	315.075	CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8,r|	UETIXAMLWBFWOE-QMMMGPOBSA-N			UETIXAMLWBFWOE
BRD-K13005598-001-02-3	foxy-5	Phase 2	WNT5a peptide mimetic	WNT5A			0	99.26	Tocris	5461		694.23	CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	WFZPJYYCTSHDJI-ATIWLJMLSA-N	44628955.0		WFZPJYYCTSHDJI
BRD-M17926088-001-02-1	FPA-124	Preclinical	AKT inhibitor				1	0.0	Tocris	2926	4-oxo-4H-chromene-3-carbaldehyde thiosemicarbazone compound with dichlorocopper (1:1)	379.909	Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O	HZRXQEVFXXQYFS-VBPDOGLUSA-L	73438499.0		HZRXQEVFXXQYFS
BRD-M17926088-001-01-3	FPA-124	Preclinical	AKT inhibitor				1	0.0	Tocris	2926	FPA 124	379.909	Cl[Cu]Cl.NC(=S)N\N=C\c1coc2ccccc2c1=O	HZRXQEVFXXQYFS-VBPDOGLUSA-L	73438499.0		HZRXQEVFXXQYFS
BRD-K61250484-001-02-3	FPH1-(BRD-6125)	Preclinical	hepatocyte function enhancer				0	96.07	Selleck	S7451	FPH1 (BRD-6125)	388.046	Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	WAOBCCBUTHNTFO-UHFFFAOYSA-N	2210370.0		WAOBCCBUTHNTFO
BRD-K61250484-001-03-1	FPH1-(BRD-6125)	Preclinical	hepatocyte function enhancer				0	95.96	Selleck	S7451	FPH1	388.046	Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	WAOBCCBUTHNTFO-UHFFFAOYSA-N	2210370.0		WAOBCCBUTHNTFO
BRD-A09368919-001-01-7	FPL-12495	Phase 1	glutamate receptor antagonist				0	92.23	Enamine	Z2379179579	1,2-diphenyl-2-propanamine	211.136	CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|	JINQHBRSXWQJAZ-UHFFFAOYSA-N	164087.0		JINQHBRSXWQJAZ
BRD-A96456596-001-02-2	FPL-55712	Phase 1	leukotriene receptor antagonist				0	97.14	Tocris	2276	FPL 55712	498.189	CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|	LMQBMWHHGVZWMR-MRXNPFEDSA-N	92460042.0		LMQBMWHHGVZWMR
BRD-A96456596-001-03-9	FPL-55712	Phase 1	leukotriene receptor antagonist				0	95.49	Tocris	2276	FPL 55712	498.189	CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7,r|	LMQBMWHHGVZWMR-MRXNPFEDSA-N	92460042.0		LMQBMWHHGVZWMR
BRD-K59875992-001-01-8	FPL-62064	Phase 2	cyclooxygenase inhibitor|lipoxygenase inhibitor				0	86.14	Astatech	FD7168	N-(4-METHOXYPHENYL)-1-PHENYL-1H-PYRAZOL-3-AMINE	265.122	COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1	WKLGNFJHVJIZPK-UHFFFAOYSA-N	128268.0		WKLGNFJHVJIZPK
BRD-K78959463-001-15-7	FPL-64176	Preclinical	calcium channel activator	CACNA1C|CACNA1S			0	98.96	Tocris	1403	FPL 64176	347.152	COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	MDMWHKZANMNXTF-UHFFFAOYSA-N	3423.0		MDMWHKZANMNXTF
BRD-K78959463-001-16-9	FPL-64176	Preclinical	calcium channel activator	CACNA1C|CACNA1S			0	98.13	Tocris	1403	FPL 64176	347.152	COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	MDMWHKZANMNXTF-UHFFFAOYSA-N	3423.0		MDMWHKZANMNXTF
BRD-K78959463-001-13-2	FPL-64176	Preclinical	calcium channel activator	CACNA1C|CACNA1S			0	98.64	Tocris	1403	FPL 64176	347.152	COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	MDMWHKZANMNXTF-UHFFFAOYSA-N	3423.0		MDMWHKZANMNXTF
BRD-K87691185-001-01-2	FPS-ZM1	Preclinical	RAGE receptor antagonist	AGER			0	97.01	MedChemEx	HY-19370	FPS-ZM1	327.139	Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1	XDFKWGIBQMHSOH-UHFFFAOYSA-N	24752728.0		XDFKWGIBQMHSOH
BRD-K30990140-003-03-9	FR-122047	Preclinical	cyclooxygenase inhibitor				0	94.55	Tocris	1507	FR 122047 hydrochloride	423.162	COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	UBHKJRYGKOSQDJ-UHFFFAOYSA-N	196841.0		UBHKJRYGKOSQDJ
BRD-K30990140-003-02-4	FR-122047	Preclinical	cyclooxygenase inhibitor				0	98.1	Tocris	1507	FR 122047 hydrochloride	423.162	COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	UBHKJRYGKOSQDJ-UHFFFAOYSA-N	196841.0		UBHKJRYGKOSQDJ
BRD-K19318328-001-02-1	FR-139317	Phase 1	endothelin receptor antagonist	EDNRA			0	97.59	Tocris	1210	FR 139317	604.337	CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	LIOKMIQQPDDTNO-UPRLRBBYSA-N	107810.0		LIOKMIQQPDDTNO
BRD-K19318328-001-03-9	FR-139317	Phase 1	endothelin receptor antagonist	EDNRA			0	94.71	Tocris	1210	FR 139317	604.337	CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	LIOKMIQQPDDTNO-UPRLRBBYSA-N	107810.0		LIOKMIQQPDDTNO
BRD-K19318328-001-01-3	FR-139317	Phase 1	endothelin receptor antagonist	EDNRA			0	93.35	Tocris	1210	FR 139317	604.337	CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	LIOKMIQQPDDTNO-UPRLRBBYSA-N	107810.0		LIOKMIQQPDDTNO
BRD-K68756823-001-10-5	FR-180204	Preclinical	MAP kinase inhibitor	MAPK1|MAPK3			0	85.02	Tocris	3706	FR 180204	327.123	Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	XVECMUKVOMUNLE-UHFFFAOYSA-N	53338808.0		XVECMUKVOMUNLE
BRD-K68756823-001-07-1	FR-180204	Preclinical	MAP kinase inhibitor	MAPK1|MAPK3			0	97.63	Tocris	3706	FR 180204	327.123	Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	XVECMUKVOMUNLE-UHFFFAOYSA-N	53338808.0		XVECMUKVOMUNLE
BRD-K68756823-001-11-3	FR-180204	Preclinical	MAP kinase inhibitor	MAPK1|MAPK3			0	78.44	Adooq	A14119	5-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-2H-pyrazolo[3,4-c]pyridazin-3-amine	327.123	Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	XVECMUKVOMUNLE-UHFFFAOYSA-N	53338808.0		XVECMUKVOMUNLE
BRD-K57243773-001-02-4	FRAX486	Preclinical	serine/threonine kinase inhibitor	PAK1|PAK2|PAK3|PAK4			0	79.06	Tocris	5190	FRAX 486	512.129	CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O	DHKFOIHIUYFSOF-UHFFFAOYSA-N	68060125.0		DHKFOIHIUYFSOF
BRD-K57243773-001-01-6	FRAX486	Preclinical	serine/threonine kinase inhibitor	PAK1|PAK2|PAK3|PAK4			0	93.24	MedChemEx	HY-15542B	FRAX486	512.129	CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O	DHKFOIHIUYFSOF-UHFFFAOYSA-N	68060125.0		DHKFOIHIUYFSOF
BRD-K07202345-001-19-4	frentizole	Phase 1	immunosuppressant				0	87.55	MedChemEx	HY-15374	Frentizole	299.073	COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	JHBWYQRKOUBPCA-UHFFFAOYSA-N	33334.0		JHBWYQRKOUBPCA
BRD-K00004668-001-01-9	freselestat	Preclinical	elastase inhibitor	CELA1|ELANE			0	92.52	Adooq	A12780.obs1190502	Freselestat	454.233	CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C	HMPQTEPEMQZWQH-QZTJIDSGSA-N	46936829.0		HMPQTEPEMQZWQH
BRD-K08255599-365-01-1	frovatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D	neurology/psychiatry	migraine headache	0	91.96	Sigma	SML1291	(3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide succinate hydrate	243.137	CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O	XPSQPHWEGNHMSK-SECBINFHSA-N	77992.0		XPSQPHWEGNHMSK
BRD-K70504253-001-01-3	fruquintinib	Launched	VEGFR inhibitor	KDR	oncology	colorectal cancer	0	97.88	MedChemEx	HY-19912	Fruquintinib	393.132	CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12	BALLNEJQLSTPIO-UHFFFAOYSA-N	44480399.0		BALLNEJQLSTPIO
BRD-K05724540-001-09-9	ftaxilide	Preclinical					0	91.41	MedChemEx	HY-B1040	Ftaxilide	269.105	Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O	LLECMGGNFBKPRH-UHFFFAOYSA-N	71895.0		LLECMGGNFBKPRH
BRD-K05724540-001-08-5	ftaxilide	Preclinical					0	66.74	MicroSource	1504523	FTAXILIDE	269.105	Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O	LLECMGGNFBKPRH-UHFFFAOYSA-N	71895.0		LLECMGGNFBKPRH
BRD-K99383816-001-03-5	ftorafur	Launched	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	0	100.0	Selleck	S1300	Tegafur (FT-207, NSC 148958)	200.06	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	WFWLQNSHRPWKFK-ZCFIWIBFSA-N	288216.0		WFWLQNSHRPWKFK
BRD-K99383816-001-02-7	ftorafur	Launched	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	0	89.97	Selleck	S1300	FT-207 (NSC 148958)	200.06	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	WFWLQNSHRPWKFK-ZCFIWIBFSA-N	288216.0		WFWLQNSHRPWKFK
BRD-K99383816-001-04-9	ftorafur	Launched	thymidylate synthase inhibitor	TYMS	oncology	colorectal cancer	0	100.0	MedChemEx	HY-17400	Tegafur	200.06	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	WFWLQNSHRPWKFK-ZCFIWIBFSA-N	288216.0		WFWLQNSHRPWKFK
BRD-K00003378-001-01-9	FT011	Preclinical	TGF beta receptor inhibitor				0	95.13	MedChemEx	HY-100495	FT011	351.111	COc1cc(\C=C\C(=O)Nc2ccccc2C(O)=O)ccc1OCC#C	UIWZIDIJCUEOMT-PKNBQFBNSA-N	23648966.0		UIWZIDIJCUEOMT
BRD-K00003355-001-01-9	fucoxanthin	Phase 2	anticancer agent				0	100.0	MedChemEx	HY-N2302	Fucoxanthin	658.423	[H]C(=[C@@]=C1C(C)(C)C[C@@H](C[C@@]1(C)O)OC(C)=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]12O[C@@]1(C)C[C@H](O)CC2(C)C	SJWWTRQNNRNTPU-BWRPRJLXSA-N	5364094.0		SJWWTRQNNRNTPU
BRD-K54838207-001-04-9	fudosteine	Launched	mucolytic agent		pulmonary	chest congestion	0	100.0	MedChemEx	HY-B0393	Fudosteine	179.062	N[C@@H](CSCCCO)C(O)=O	KINWYTAUPKOPCQ-YFKPBYRVSA-N	36689154.0		KINWYTAUPKOPCQ
BRD-K54838207-001-03-8	fudosteine	Launched	mucolytic agent		pulmonary	chest congestion	0	100.0	Selleck	S2129	Fudosteine	179.062	N[C@@H](CSCCCO)C(O)=O	KINWYTAUPKOPCQ-YFKPBYRVSA-N	36689154.0		KINWYTAUPKOPCQ
BRD-K54838207-001-02-0	fudosteine	Launched	mucolytic agent		pulmonary	chest congestion	0	79.81	Selleck	S2129	Fudosteine	179.062	N[C@@H](CSCCCO)C(O)=O	KINWYTAUPKOPCQ-YFKPBYRVSA-N	36689154.0		KINWYTAUPKOPCQ
BRD-A85667082-001-10-1	fulvestrant	Launched	estrogen receptor antagonist	ESR1|ESR2|GPER1	oncology	breast cancer	0	93.37	Tocris	1047	ICI 182,780	606.317	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|	VWUXBMIQPBEWFH-CIAKRVSBSA-N	57300161.0	BRD-A03249105-001-02-7	VWUXBMIQPBEWFH
BRD-A85667082-001-11-9	fulvestrant	Launched	estrogen receptor antagonist	ESR1|ESR2|GPER1	oncology	breast cancer	0	91.53	MicroSource	1502281	FULVESTRANT	606.317	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|	VWUXBMIQPBEWFH-CIAKRVSBSA-N	57300161.0	BRD-A50947932-001-01-9	VWUXBMIQPBEWFH
BRD-A85667082-001-12-7	fulvestrant	Launched	estrogen receptor antagonist	ESR1|ESR2|GPER1	oncology	breast cancer	0	97.7	Tocris	1047	ICI 182,780	606.317	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|	VWUXBMIQPBEWFH-CIAKRVSBSA-N	57300161.0	BRD-A03249105-001-01-9	VWUXBMIQPBEWFH
BRD-A85667082-001-13-5	fulvestrant	Launched	estrogen receptor antagonist	ESR1|ESR2|GPER1	oncology	breast cancer	0	94.65	Selleck	S1191	Fulvestrant	606.317	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1,4,5,6,9,11,&1:21|	VWUXBMIQPBEWFH-CIAKRVSBSA-N	57300161.0	BRD-A17828570-001-02-8|BRD-A52958897-001-01-7	VWUXBMIQPBEWFH
BRD-A99367815-001-04-9	fumagillin	Launched	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	0	86.8	MedChemEx	HY-B0751	Fumagillin	458.23	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|	NGGMYCMLYOUNGM-FKSJYSFPSA-N	12015870.0		NGGMYCMLYOUNGM
BRD-A99367815-001-01-5	fumagillin	Launched	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	0	65.41	Enzo	CT100	Fumagillin	458.23	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|	NGGMYCMLYOUNGM-FKSJYSFPSA-N	12015870.0		NGGMYCMLYOUNGM
BRD-A99367815-001-03-1	fumagillin	Launched	methionine aminopeptidase inhibitor	METAP2	infectious disease	microsporidiosis	0	75.6	MedChemEx	HY-B0751	Fumagillin	458.23	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2,3,6,10,13,&1:9|	NGGMYCMLYOUNGM-FKSJYSFPSA-N	12015870.0		NGGMYCMLYOUNGM
BRD-K61915943-001-02-9	fumonisin-B1	Preclinical		CERS1			0	0.0	MedChemEx	HY-N6719	Fumonisin B1	721.388	CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O	UVBUBMSSQKOIBE-DSLOAKGESA-N	2733487.0		UVBUBMSSQKOIBE
BRD-K00004702-001-01-9	funapide	Preclinical	sodium channel blocker				0	94.46	AMS	L14544	Funapide	429.082	FC(F)(F)c1ccc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c3ccccc23)o1	NEBUOXBYNAHKFV-NRFANRHFSA-N	49836093.0		NEBUOXBYNAHKFV
BRD-K00003314-001-01-9	furagin	Preclinical	antibacterial				0	84.97	MedChemEx	HY-77036	Furagin	264.049	[O-][N+](=O)c1ccc(\C=C\C=N\N2CC(=O)NC2=O)o1	DECBQELQORZLLP-UAIOPKHMSA-N	6870646.0		DECBQELQORZLLP
BRD-K01824979-003-03-9	furaltadone	Launched	bacterial DNA inhibitor		infectious disease	gram-negative bacterial infections	0	81.13	MedChemEx	HY-B1148	Furaltadone (hydrochloride)	324.107	[O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|	YVQVOQKFMFRVGR-LLUUXILJSA-N	6604316.0		YVQVOQKFMFRVGR
BRD-K01824979-001-02-9	furaltadone	Launched	bacterial DNA inhibitor		infectious disease	gram-negative bacterial infections	0	83.59	MicroSource	1505770	FURALTADONE	324.107	[O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11,r|	YVQVOQKFMFRVGR-LLUUXILJSA-N	6604316.0		YVQVOQKFMFRVGR
BRD-K77758223-300-02-9	furamidine	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT1			0	93.75	Tocris	5202	Furamidine dihydrochloride	304.132	NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N	ZJHZBDRZEZEDGB-UHFFFAOYSA-N	126437.0		ZJHZBDRZEZEDGB
BRD-K77758223-300-01-1	furamidine	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT1			0	76.91	Tocris	5202	Furamidine dihydrochloride	304.132	NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N	ZJHZBDRZEZEDGB-UHFFFAOYSA-N	126437.0		ZJHZBDRZEZEDGB
BRD-K11756522-001-10-9	furazolidone	Launched	bacterial DNA inhibitor		gastroenterology|infectious disease	diarrhea|enteritis|cholera	0	76.07	MedChemEx	HY-B1336	Furazolidone	225.039	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	PLHJDBGFXBMTGZ-WEVVVXLNSA-N	5323714.0		PLHJDBGFXBMTGZ
BRD-K11756522-001-09-9	furazolidone	Launched	bacterial DNA inhibitor		gastroenterology|infectious disease	diarrhea|enteritis|cholera	0	91.67	MicroSource	1500309	FURAZOLIDONE	225.039	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	PLHJDBGFXBMTGZ-WEVVVXLNSA-N	5323714.0		PLHJDBGFXBMTGZ
BRD-K55529781-236-03-8	furegrelate	Phase 1	thromboxane synthase inhibitor	TBXAS1			0	98.91	Cayman	70540	sodium 5-(3-pyridinylmethyl)-1-benzofuran-2-carboxylate	253.074	OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1	VHWFITPGPFLBGT-UHFFFAOYSA-N	3437.0		VHWFITPGPFLBGT
BRD-K78010432-001-24-9	furosemide	Launched	diuretic	CA2|GPR35|SLC12A1|SLC12A2	cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome	0	94.46	Tocris	3109	Furosemide	330.008	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	ZZUFCTLCJUWOSV-UHFFFAOYSA-N	3440.0		ZZUFCTLCJUWOSV
BRD-K78010432-001-20-7	furosemide	Launched	diuretic	CA2|GPR35|SLC12A1|SLC12A2	cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome	0	97.15	Selleck	S1603	Furosemide	330.008	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	ZZUFCTLCJUWOSV-UHFFFAOYSA-N	3440.0		ZZUFCTLCJUWOSV
BRD-K78010432-001-27-9	furosemide	Launched	diuretic	CA2|GPR35|SLC12A1|SLC12A2	cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome	0	96.34	Tocris	3109	Furosemide	330.008	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	ZZUFCTLCJUWOSV-UHFFFAOYSA-N	3440.0		ZZUFCTLCJUWOSV
BRD-K78010432-001-21-5	furosemide	Launched	diuretic	CA2|GPR35|SLC12A1|SLC12A2	cardiology|rheumatology	edema|hypertension|congestive heart failure|nephrotic syndrome	0	99.55	MicroSource	1500310	FUROSEMIDE	330.008	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	ZZUFCTLCJUWOSV-UHFFFAOYSA-N	3440.0		ZZUFCTLCJUWOSV
BRD-A71157293-003-10-0	fursultiamine	Launched	vitamin B		metabolism	thiamine deficiency	0	99.61	Prestwick	Prestw-1007	Fursultiamine Hydrochloride	398.145	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|	JTLXCMOFVBXEKD-XYGUXCPDSA-N	38988761.0		JTLXCMOFVBXEKD
BRD-A71157293-001-11-9	fursultiamine	Launched	vitamin B		metabolism	thiamine deficiency	0	94.91	MedChemEx	HY-B2082	Fursultiamine	398.145	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|	JTLXCMOFVBXEKD-XYGUXCPDSA-N	38988761.0		JTLXCMOFVBXEKD
BRD-K00004693-001-01-9	furvina	Preclinical	quorum sensing signaling inhibitor				0	0.0	Labotest	LT00894715	2-bromo-5-[(E)-2-bromo-2-nitroethenyl]furan	294.848	[O-][N+](=O)C(\Br)=C/c1ccc(Br)o1	MJPPGVVIDGQOQT-HYXAFXHYSA-N	6438461.0		MJPPGVVIDGQOQT
BRD-K78355918-236-09-9	fusidic-acid	Launched	bacterial 30S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	0	94.82	MedChemEx	HY-B1350A	Fusidic acid (sodium salt)	516.345	C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O	IECPWNUMDGFDKC-MZJAQBGESA-N	3000226.0		IECPWNUMDGFDKC
BRD-K00003392-001-01-9	futibatinib	Phase 3	FGFR inhibitor				0	96.33	MedChemEx	HY-100818	Futibatinib	418.175	COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12	KEIPNCCJPRMIAX-HNNXBMFYSA-N	71621331.0		KEIPNCCJPRMIAX
BRD-K41267922-001-01-4	F351	Phase 2	TGF beta receptor inhibitor	TGFB1			0	95.15	Carbosynth	FH24467	1-(4-hydroxyphenyl)-5-methyl-2(1H)-pyridinone	201.079	Cc1ccc(=O)n(c1)-c1ccc(O)cc1	NETTXQJYJRFTFS-UHFFFAOYSA-N	11217901.0		NETTXQJYJRFTFS
BRD-K41267922-001-02-9	F351	Phase 2	TGF beta receptor inhibitor	TGFB1			0	95.12	Toronto	H949400	N-(4-hydroxyphenyl)-5-methyl-2-1H-pyridone	201.079	Cc1ccc(=O)n(c1)-c1ccc(O)cc1	NETTXQJYJRFTFS-UHFFFAOYSA-N	11217901.0		NETTXQJYJRFTFS
BRD-K26878113-001-01-6	g-caryophyllene	Preclinical	acetylcholinesterase inhibitor	ACHE			0	0.0	Sigma	MFCD00075925	(1R,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene	204.188	C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|	NPNUFJAVOOONJE-GFUGXAQUSA-N	5281515.0		NPNUFJAVOOONJE
BRD-K62696033-001-01-4	G-1	Preclinical	G protein-coupled receptor agonist	GPER1			0	97.15	Tocris	3577	G-1	411.047	CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|	VHSVKVWHYFBIFJ-HKZYLEAXSA-N	5322399.0		VHSVKVWHYFBIFJ
BRD-K62696033-001-02-9	G-1	Preclinical	G protein-coupled receptor agonist	GPER1			0	96.53	Tocris	3577	G-1	411.047	CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|	VHSVKVWHYFBIFJ-HKZYLEAXSA-N	5322399.0		VHSVKVWHYFBIFJ
BRD-K00004290-001-01-9	G-15	Preclinical	estrogen receptor antagonist	GPER1			0	95.87	Tocris	3678	G-15	369.036	Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10,18,22,c:22|	YOLTZIVRJAPVPH-MVBJNABHSA-N	25727983.0		YOLTZIVRJAPVPH
BRD-K00003126-001-01-9	G-749	Preclinical	tyrosine kinase inhibitor				0	92.89	MedChemEx	HY-12333	G-749	520.122	CN1CCC(CC1)Nc1nc(Nc2ccc(Oc3ccccc3)cc2)c2c(O)ncc(Br)c2n1	SXWMIXPJPNCXQQ-UHFFFAOYSA-N	78357765.0		SXWMIXPJPNCXQQ
BRD-K46254452-001-01-5	GABA-linoleamide	Phase 2	benzodiazepine receptor agonist				1	0.0	Enzo	EL131	Linoleoyl GABA	365.293	CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O	YGFYZZQGVSUXJE-HZJYTTRNSA-N	6438152.0		YGFYZZQGVSUXJE
BRD-K62737565-001-09-5	gabapentin	Launched	calcium channel blocker	ADORA1|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1E|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CACNG2|CACNG3|CACNG4|CACNG5|CACNG6|CACNG7|CACNG8|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome	0	100.0	Selleck	S2133	Gabapentin (Neurontin)	171.126	NCC1(CC(O)=O)CCCCC1	UGJMXCAKCUNAIE-UHFFFAOYSA-N	6919078.0		UGJMXCAKCUNAIE
BRD-K62737565-001-10-3	gabapentin	Launched	calcium channel blocker	ADORA1|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1E|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CACNG2|CACNG3|CACNG4|CACNG5|CACNG6|CACNG7|CACNG8|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome	0	100.0	MicroSource	1505805	GABAPENTIN	171.126	NCC1(CC(O)=O)CCCCC1	UGJMXCAKCUNAIE-UHFFFAOYSA-N	6919078.0		UGJMXCAKCUNAIE
BRD-K62737565-003-02-6	gabapentin	Launched	calcium channel blocker	ADORA1|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1E|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CACNG2|CACNG3|CACNG4|CACNG5|CACNG6|CACNG7|CACNG8|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	infectious disease|neurology/psychiatry	virus herpes simplex (HSV)|shingles|seizures|restless leg syndrome	0	100.0	Selleck	S1338	Gabapentin Hydrochloride	171.126	NCC1(CC(O)=O)CCCCC1	UGJMXCAKCUNAIE-UHFFFAOYSA-N	6919078.0		UGJMXCAKCUNAIE
BRD-A86665761-001-01-1	gabapentin-enacarbil	Launched	adrenergic receptor agonist	CACNA1G	neurology/psychiatry	restless leg syndrome|postherpetic neuralgia	0	89.16	AdvChemBlocks	G-5813	{1-[({[1-(isobutyryloxy)ethoxy]carbonyl}amino)methyl]cyclohexyl}acetic acid	329.184	CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6,r|	TZDUHAJSIBHXDL-GFCCVEGCSA-N	66864580.0		TZDUHAJSIBHXDL
BRD-K79905821-004-04-4	gabazine	Preclinical	GABA receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRG2			0	96.69	Tocris	1262	SR 95531 hydrobromide	287.127	COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	ACVGNKYJVGNLIL-UHFFFAOYSA-N	107896.0		ACVGNKYJVGNLIL
BRD-K79905821-004-14-9	gabazine	Preclinical	GABA receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRG2			0	95.58	Tocris	1262	SR 95531 hydrobromide	287.127	COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	ACVGNKYJVGNLIL-UHFFFAOYSA-N	107896.0		ACVGNKYJVGNLIL
BRD-K79905821-004-03-6	gabazine	Preclinical	GABA receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRG2			0	98.53	Tocris	1262	SR 95531 hydrobromide	287.127	COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	ACVGNKYJVGNLIL-UHFFFAOYSA-N	107896.0		ACVGNKYJVGNLIL
BRD-K59256312-066-17-3	gabexate	Launched	serine protease inhibitor	PRSS1|TPSAB1	gastroenterology	pancreatitis	0	71.6	MedChemEx	HY-B0385	Gabexate (mesylate)	321.169	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	YKGYIDJEEQRWQH-UHFFFAOYSA-N	3447.0		YKGYIDJEEQRWQH
BRD-K59256312-066-13-2	gabexate	Launched	serine protease inhibitor	PRSS1|TPSAB1	gastroenterology	pancreatitis	0	71.13	Selleck	S2101	Gabexate Mesylate	321.169	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	YKGYIDJEEQRWQH-UHFFFAOYSA-N	3447.0		YKGYIDJEEQRWQH
BRD-K59256312-066-16-5	gabexate	Launched	serine protease inhibitor	PRSS1|TPSAB1	gastroenterology	pancreatitis	0	58.11	MedChemEx	HY-B0385	Gabexate (mesylate)	321.169	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	YKGYIDJEEQRWQH-UHFFFAOYSA-N	3447.0		YKGYIDJEEQRWQH
BRD-K59256312-066-15-7	gabexate	Launched	serine protease inhibitor	PRSS1|TPSAB1	gastroenterology	pancreatitis	0	85.7	Selleck	S2101	Gabexate mesylate	321.169	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	YKGYIDJEEQRWQH-UHFFFAOYSA-N	3447.0		YKGYIDJEEQRWQH
BRD-K59256312-066-14-0	gabexate	Launched	serine protease inhibitor	PRSS1|TPSAB1	gastroenterology	pancreatitis	0	65.77	Tocris	1798	Gabexate mesylate	321.169	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	YKGYIDJEEQRWQH-UHFFFAOYSA-N	3447.0		YKGYIDJEEQRWQH
BRD-K89104321-003-16-3	gaboxadol	Phase 3	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3			0	97.8	Tocris	807	THIP hydrochloride	140.059	O=c1[nH]oc2CNCCc12	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	3448.0		ZXRVKCBLGJOCEE
BRD-K89104321-003-15-5	gaboxadol	Phase 3	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3			0	100.0	MicroSource	1503648	GABOXADOL HYDROCHLORIDE	140.059	O=c1[nH]oc2CNCCc12	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	3448.0		ZXRVKCBLGJOCEE
BRD-K89104321-003-18-9	gaboxadol	Phase 3	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3			0	100.0	Tocris	807	THIP hydrochloride	140.059	O=c1[nH]oc2CNCCc12	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	3448.0		ZXRVKCBLGJOCEE
BRD-K89104321-003-14-8	gaboxadol	Phase 3	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3			0	100.0	Tocris	807	THIP hydrochloride	140.059	O=c1[nH]oc2CNCCc12	ZXRVKCBLGJOCEE-UHFFFAOYSA-N	3448.0		ZXRVKCBLGJOCEE
BRD-K00003579-001-01-9	gadobutrol	Launched	radiopaque medium		radiology	MRI contrast agent	0	81.6	MedChemEx	HY-16217	Gadobutrol	605.133	[H]O[C@@H](CO)[C@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2 |&1:2,5|	ZPDFIIGFYAHNSK-YYLIZZNMSA-K	70678987.0		ZPDFIIGFYAHNSK
BRD-K38140108-001-02-9	gadodiamide	Launched	radiopaque medium		radiology	MRI contrast agent	0	99.3	MedChemEx	HY-B0787	Gadodiamide	574.102	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	HZHFFEYYPYZMNU-UHFFFAOYSA-K	24847884.0		HZHFFEYYPYZMNU
BRD-K38140108-002-01-2	gadodiamide	Launched	radiopaque medium		radiology	MRI contrast agent	0	100.0	Selleck	S1751	Gadodiamide	574.102	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	HZHFFEYYPYZMNU-UHFFFAOYSA-K	24847884.0	BRD-M27076668-002-02-9	HZHFFEYYPYZMNU
BRD-K25106841-001-01-2	gadopentetic-acid	Launched	contrast agent	PGD	radiology	contrast agent	0	0.0	Sigma	MFCD02092653	gadolinium (bis{2-[(carboxymethyl)(2-oxido-2-oxoethyl)amino]ethyl}amino)acetate hydrate	548.039	OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	IZOOGPBRAOKZFK-UHFFFAOYSA-K	6857474.0	BRD-M44547596-002-01-7	IZOOGPBRAOKZFK
BRD-K11099631-001-08-4	gadoterate-meglumine	Launched	radiopaque medium		radiology	MRI contrast agent	0	97.1	Sigma	86734	2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid	404.191	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	WDLRUFUQRNWCPK-UHFFFAOYSA-N	121841.0		WDLRUFUQRNWCPK
BRD-K11099631-001-07-6	gadoterate-meglumine	Launched	radiopaque medium		radiology	MRI contrast agent	0	0.0	TCI	T1875		404.191	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	WDLRUFUQRNWCPK-UHFFFAOYSA-N	121841.0		WDLRUFUQRNWCPK
BRD-A72401848-001-02-2	gadoteridol	Launched	radiopaque medium		radiology	MRI contrast agent	0	86.8	Kemprotec	120066-54-8	gadolinium(III) 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate	559.128	C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|	DPNNNPAKRZOSMO-PFEQFJNWSA-K	101671780.0	BRD-M87846614-001-02-9	DPNNNPAKRZOSMO
BRD-A72401848-001-01-4	gadoteridol	Launched	radiopaque medium		radiology	MRI contrast agent	1	0.0	MicroSource	1503834	GADOTERIDOL	559.128	C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1,r|	DPNNNPAKRZOSMO-PFEQFJNWSA-K	101671780.0	BRD-M87846614-001-01-1	DPNNNPAKRZOSMO
BRD-K00003410-001-01-9	GAL-021	Preclinical	calcium channel blocker				0	95.98	MedChemEx	HY-101422	GAL-021	254.186	CCCNc1nc(NCCC)nc(n1)N(C)OC	FJNLCHNQVJVCPY-UHFFFAOYSA-N	57340959.0		FJNLCHNQVJVCPY
BRD-K49481516-001-01-5	galantamine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE|CHRNA1|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB1|CHRNB2|CHRNB3|CHRNB4|CHRND|CHRNE|CHRNG	neurology/psychiatry	senile dementia	0	97.2	MicroSource	1501202	GALANTAMINE	287.152	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|	ASUTZQLVASHGKV-JDFRZJQESA-N	9651.0		ASUTZQLVASHGKV
BRD-K49481516-004-18-3	galantamine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE|CHRNA1|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB1|CHRNB2|CHRNB3|CHRNB4|CHRND|CHRNE|CHRNG	neurology/psychiatry	senile dementia	0	98.59	Tocris	686	Galanthamine hydrobromide	287.152	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|	ASUTZQLVASHGKV-JDFRZJQESA-N	9651.0		ASUTZQLVASHGKV
BRD-K00004319-001-01-9	galeterone	Phase 3	androgen receptor modulator	AR|CYP17A1			0	95.97	Tocris	6108	Galeterone	388.251	[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3,27|	PAFKTGFSEFKSQG-PAASFTFBSA-N	11188409.0		PAFKTGFSEFKSQG
BRD-K00003270-003-01-9	galidesivir	Phase 1	antiviral				0	100.0	MedChemEx	HY-18649	Galidesivir (hydrochloride)	265.117	Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O	AMFDITJFBUXZQN-KUBHLMPHSA-N	10445549.0		AMFDITJFBUXZQN
BRD-K43106192-320-12-9	gallamine-triethiodide	Launched	acetylcholine receptor antagonist	CHRM2|CHRNA1	neurology/psychiatry	muscle relaxant	0	0.0	MedChemEx	HY-B0416	Gallamine Triethiodide	510.463	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	OZLPUNFFCJDMJD-UHFFFAOYSA-N	3450.0		OZLPUNFFCJDMJD
BRD-K43106192-320-09-2	gallamine-triethiodide	Launched	acetylcholine receptor antagonist	CHRM2|CHRNA1	neurology/psychiatry	muscle relaxant	0	0.0	Selleck	S2471	Gallamine Triethiodide	510.463	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	OZLPUNFFCJDMJD-UHFFFAOYSA-N	3450.0		OZLPUNFFCJDMJD
BRD-K43106192-320-10-0	gallamine-triethiodide	Launched	acetylcholine receptor antagonist	CHRM2|CHRNA1	neurology/psychiatry	muscle relaxant	0	0.0	MicroSource	1500312	GALLAMINE TRIETHIODIDE	510.463	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	OZLPUNFFCJDMJD-UHFFFAOYSA-N	3450.0		OZLPUNFFCJDMJD
BRD-K43106192-320-11-8	gallamine-triethiodide	Launched	acetylcholine receptor antagonist	CHRM2|CHRNA1	neurology/psychiatry	muscle relaxant	0	98.46	Selleck	S2471	Gallamine triethiodide (Flaxedil)	510.463	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	OZLPUNFFCJDMJD-UHFFFAOYSA-N	3450.0		OZLPUNFFCJDMJD
BRD-K77345217-001-05-0	gallic-acid	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	CA1|CA12|CA14|CA2|CA4|CA6|CA9|SELP			0	98.82	MicroSource	210369	GALLIC ACID	170.022	OC(=O)c1cc(O)c(O)c(O)c1	LNTHITQWFMADLM-UHFFFAOYSA-N	370.0		LNTHITQWFMADLM
BRD-K77345217-001-06-9	gallic-acid	Preclinical	beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist	CA1|CA12|CA14|CA2|CA4|CA6|CA9|SELP			0	99.0	MedChemEx	HY-N0523	Gallic acid	170.022	OC(=O)c1cc(O)c(O)c(O)c1	LNTHITQWFMADLM-UHFFFAOYSA-N	370.0		LNTHITQWFMADLM
BRD-K46648676-001-01-8	gallium-triquinolin-8-olate	Phase 1					1	0.0	Sigma	MFCD00919188	gallium triquinolin-8-olate	501.06	O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12	KWQNQSDKCINQQP-UHFFFAOYSA-K	9806063.0		KWQNQSDKCINQQP
BRD-A52922642-001-03-7	gallopamil	Launched	L-type calcium channel blocker	ATP2A2	cardiology	hypertension|cardiac arrythmia	0	97.61	Enzo	AC103	Methoxy verapamil	484.294	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|	XQLWNAFCTODIRK-UHFFFAOYSA-N	1234.0		XQLWNAFCTODIRK
BRD-A52922642-001-04-5	gallopamil	Launched	L-type calcium channel blocker	ATP2A2	cardiology	hypertension|cardiac arrythmia	0	99.13	Sigma	M5644-50MG	(+/-)-Methoxyverapamil hydrochloride	484.294	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|	XQLWNAFCTODIRK-UHFFFAOYSA-N	1234.0		XQLWNAFCTODIRK
BRD-K08542803-001-01-5	gambogic-acid	Phase 2	caspase activator	BCL2			0	81.89	MedChemEx	HY-N0087	Gambogic Acid	628.304	CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|	GEZHEQNLKAOMCA-RRZNCOCZSA-N	9852185.0		GEZHEQNLKAOMCA
BRD-K08542803-001-02-3	gambogic-acid	Phase 2	caspase activator	BCL2			0	76.37	MedChemEx	HY-N0087	Gambogic Acid	628.304	CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|	GEZHEQNLKAOMCA-RRZNCOCZSA-N	9852185.0		GEZHEQNLKAOMCA
BRD-K08542803-001-03-1	gambogic-acid	Phase 2	caspase activator	BCL2			0	51.83	Enzo	AP305	Gambogic acid	628.304	CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22,33|	GEZHEQNLKAOMCA-RRZNCOCZSA-N	9852185.0	BRD-A76999758-001-01-1	GEZHEQNLKAOMCA
BRD-K00003489-001-01-9	gamithromycin	Preclinical	antibacterial 				0	98.9	MedChemEx	HY-108365	Gamithromycin	776.54	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C	VWAMTBXLZPEDQO-RHJMDXJBSA-N			VWAMTBXLZPEDQO
BRD-K77245796-003-01-6	gamma-aminobutyric-acid	Preclinical	benzodiazepine receptor agonist	GABBR1|GABBR2|GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2|GATM|KCTD12|KCTD16|KCTD8|SLC6A1			0	100.0	MicroSource	1500678	gamma-AMINOBUTYRIC ACID HYDROCHLORIDE	103.063	NCCCC(O)=O	BTCSSZJGUNDROE-UHFFFAOYSA-N	6992099.0		BTCSSZJGUNDROE
BRD-K77245796-001-23-9	gamma-aminobutyric-acid	Preclinical	benzodiazepine receptor agonist	GABBR1|GABBR2|GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2|GATM|KCTD12|KCTD16|KCTD8|SLC6A1			0	0.0	MedChemEx	HY-N0067	?-Aminobutyric acid	103.063	NCCCC(O)=O	BTCSSZJGUNDROE-UHFFFAOYSA-N	6992099.0		BTCSSZJGUNDROE
BRD-K18059238-001-13-8	gamma-linolenic-acid	Phase 2	cyclooxygenase inhibitor|prostanoid receptor agonist	PTGS1|PTGS2			0	31.38	Sigma	MFCD00065718	(6Z,9Z,12Z)-6,9,12-octadecatrienoic acid	278.225	CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	VZCCETWTMQHEPK-QNEBEIHSSA-N	5280933.0		VZCCETWTMQHEPK
BRD-K18059238-001-10-4	gamma-linolenic-acid	Phase 2	cyclooxygenase inhibitor|prostanoid receptor agonist	PTGS1|PTGS2			0	87.22	Enzo	FA006	gamma-Linolenic acid (18:3 n-6)	278.225	CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	VZCCETWTMQHEPK-QNEBEIHSSA-N	5280933.0		VZCCETWTMQHEPK
BRD-K18059238-001-11-2	gamma-linolenic-acid	Phase 2	cyclooxygenase inhibitor|prostanoid receptor agonist	PTGS1|PTGS2			0	0.0	Cayman	90220		278.225	CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	VZCCETWTMQHEPK-QNEBEIHSSA-N	5280933.0		VZCCETWTMQHEPK
BRD-K28217197-001-01-4	ganaxolone	Phase 3	GABA receptor modulator	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6			0	100.0	Tocris	2531	Ganaxolone	332.272	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PGTVWKLGGCQMBR-FLBATMFCSA-N	6918305.0		PGTVWKLGGCQMBR
BRD-K28217197-001-02-9	ganaxolone	Phase 3	GABA receptor modulator	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6			0	100.0	Tocris	2531	Ganaxolone	332.272	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	PGTVWKLGGCQMBR-FLBATMFCSA-N	6918305.0		PGTVWKLGGCQMBR
BRD-K22662435-001-18-3	ganciclovir	Launched	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	0	92.78	MicroSource	1502362	GANCICLOVIR	255.097	Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1	IRSCQMHQWWYFCW-UHFFFAOYSA-N	135398740.0		IRSCQMHQWWYFCW
BRD-K22662435-001-17-5	ganciclovir	Launched	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	0	71.69	Selleck	S1878	Ganciclovir	255.097	Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1	IRSCQMHQWWYFCW-UHFFFAOYSA-N	135398740.0		IRSCQMHQWWYFCW
BRD-K22662435-001-19-1	ganciclovir	Launched	DNA polymerase inhibitor		infectious disease	cytomegalovirus (CMV)	0	100.0	Selleck	S1878	Ganciclovir	255.097	Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1	IRSCQMHQWWYFCW-UHFFFAOYSA-N	135398740.0		IRSCQMHQWWYFCW
BRD-K38852836-001-02-1	ganetespib	Phase 3	HSP inhibitor	HSP90AA1			0	97.44	Selleck	S1159	Ganetespib (STA-9090)	364.154	CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	RVAQIUULWULRNW-UHFFFAOYSA-N	135564985.0		RVAQIUULWULRNW
BRD-K38852836-001-04-9	ganetespib	Phase 3	HSP inhibitor	HSP90AA1			0	98.5	MedChemEx	HY-15205	Ganetespib	364.154	CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	RVAQIUULWULRNW-UHFFFAOYSA-N	135564985.0		RVAQIUULWULRNW
BRD-K00003733-001-01-9	ganoderic-acid-a	Preclinical	JAK inhibitor				0	66.53	MedChemEx	HY-N1447	Ganoderic acid A	516.309	[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](C[C@H](O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C |t:5|	DYOKDAQBNHPJFD-JNTBEZBXSA-N	471002.0		DYOKDAQBNHPJFD
BRD-K64451768-001-05-4	GANT-58	Preclinical	GLI antagonist	GLI1			0	96.49	Tocris	3889	GANT 58	392.11	c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1	USWLOKMMUTWFMD-UHFFFAOYSA-N	253078.0		USWLOKMMUTWFMD
BRD-K64451768-001-03-9	GANT-58	Preclinical	GLI antagonist	GLI1			0		Sigma	G8923	GANT 58	392.11	c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1	USWLOKMMUTWFMD-UHFFFAOYSA-N	253078.0		USWLOKMMUTWFMD
BRD-K09485525-001-03-9	GANT-61	Preclinical	GLI antagonist	GLI1|GLI2			0	89.02	Tocris	3191	GANT 61	429.289	CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1	KVQOGDQTWWCZFX-UHFFFAOYSA-N	421610.0		KVQOGDQTWWCZFX
BRD-K09485525-001-02-1	GANT-61	Preclinical	GLI antagonist	GLI1|GLI2			0	100.0	Tocris	3191	GANT 61	429.289	CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1	KVQOGDQTWWCZFX-UHFFFAOYSA-N	421610.0		KVQOGDQTWWCZFX
BRD-K77038618-356-01-3	garenoxacin	Launched	topoisomerase inhibitor	TOP2A	infectious disease	respiratory tract infections	0	96.9	MedChemEx	HY-17460A	Garenoxacin (Mesylate hydrate)	426.139	C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1	NJDRXTDGYFKORP-LLVKDONJSA-N	40461170.0		NJDRXTDGYFKORP
BRD-K15447284-001-02-9	gastrodin	Phase 2					0	91.72	MedChemEx	HY-N0115	Gastrodin	286.105	OC[C@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	PUQSUZTXKPLAPR-UJPOAAIJSA-N	115067.0		PUQSUZTXKPLAPR
BRD-K01825698-213-01-9	gatifloxacin	Withdrawn	bacterial DNA gyrase inhibitor				0	77.22	MicroSource	1504272	GATIFLOXACIN	436.212	COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|	XUBOMFCQGDBHNK-JTQLQIEISA-N	6971135.0		XUBOMFCQGDBHNK
BRD-K01825698-001-02-9	gatifloxacin	Withdrawn	bacterial DNA gyrase inhibitor				0	94.86	Tocris	3849	Gatifloxacin	375.159	COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|	XUBOMFCQGDBHNK-JTQLQIEISA-N	6971135.0		XUBOMFCQGDBHNK
BRD-K81981783-236-02-9	gavestinel	Phase 3	glutamate receptor antagonist	GLRB|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B			0	92.51	Tocris	2348	sodium 3-[(1E)-3-anilino-3-oxo-1-propenyl]-4,6-dichloro-1H-indole-2-carboxylate	374.022	OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	WZBNEZWCNKUOSM-VOTSOKGWSA-N	6450546.0		WZBNEZWCNKUOSM
BRD-K81981783-236-03-7	gavestinel	Phase 3	glutamate receptor antagonist	GLRB|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B			0	91.89	Tocris	2348	Gavestinel	374.022	OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	WZBNEZWCNKUOSM-VOTSOKGWSA-N	6450546.0		WZBNEZWCNKUOSM
BRD-K81981783-236-01-1	gavestinel	Phase 3	glutamate receptor antagonist	GLRB|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B			0	73.61	Tocris	2348	Gavestinel	374.022	OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	WZBNEZWCNKUOSM-VOTSOKGWSA-N	6450546.0		WZBNEZWCNKUOSM
BRD-K92015269-300-02-9	GBR-12783	Preclinical	dopamine reuptake inhibitor				0	97.22	Tocris	513	GBR 12783 dihydrochloride	412.251	C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	XFBDGHFDKJITGC-JLHYYAGUSA-N	5788723.0		XFBDGHFDKJITGC
BRD-K92015269-300-01-2	GBR-12783	Preclinical	dopamine reuptake inhibitor				0	97.13	Tocris	513	GBR 12783 dihydrochloride	412.251	C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	XFBDGHFDKJITGC-JLHYYAGUSA-N	5788723.0		XFBDGHFDKJITGC
BRD-K50135270-300-09-9	GBR-12935	Preclinical	dopamine reuptake inhibitor	AGTR1|SLC6A3			0	95.94	Tocris	514	GBR 12935 dihydrochloride	414.267	C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	RAQPOZGWANIDQT-UHFFFAOYSA-N	3456.0		RAQPOZGWANIDQT
BRD-K50135270-300-02-3	GBR-12935	Preclinical	dopamine reuptake inhibitor	AGTR1|SLC6A3			0	97.4	Tocris	514	GBR 12935 dihydrochloride	414.267	C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	RAQPOZGWANIDQT-UHFFFAOYSA-N	3456.0		RAQPOZGWANIDQT
BRD-K92577649-300-01-2	GBR-13069	Preclinical	dopamine reuptake inhibitor	SLC6A3			0	95.51	Tocris	420	GBR 13069 dihydrochloride	448.233	Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	DASHZBBQOARCMQ-QPJJXVBHSA-N	5974189.0		DASHZBBQOARCMQ
BRD-K92577649-300-03-9	GBR-13069	Preclinical	dopamine reuptake inhibitor	SLC6A3			0	93.76	Tocris	420	GBR 13069 dihydrochloride	448.233	Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	DASHZBBQOARCMQ-QPJJXVBHSA-N	5974189.0		DASHZBBQOARCMQ
BRD-K43002773-001-05-9	GDC-0068	Phase 3	AKT inhibitor	AKT1|AKT2|AKT3|PRKG1			0	75.09	MedChemEx	HY-15186	Ipatasertib	457.224	CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	GRZXWCHAXNAUHY-NSISKUIASA-N	24788740.0		GRZXWCHAXNAUHY
BRD-K00003420-001-01-9	GDC-0077	Phase 1	PI3K inhibitor				0	87.83	MedChemEx	HY-101562	GDC-0077	407.141	C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O	SGEUNORSOZVTOL-CABZTGNLSA-N	124173720.0		SGEUNORSOZVTOL
BRD-K00003309-001-01-9	GDC-0084	Phase 2	mTOR inhibitor|PI3K inhibitor				0	94.21	MedChemEx	HY-19962	GDC-0084	382.187	CC1(C)OCCn2c1nc1c(nc(nc21)-c1cnc(N)nc1)N1CCOCC1	LGWACEZVCMBSKW-UHFFFAOYSA-N	57384863.0		LGWACEZVCMBSKW
BRD-K68938568-001-01-7	GDC-0152	Phase 1	XIAP inhibitor	BIRC2|BIRC3|BIRC7|XIAP			0	94.69	Selleck	S7010	GDC-0152	498.241	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	WZRFLSDVFPIXOV-LRQRDZAKSA-N	46940575.0		WZRFLSDVFPIXOV
BRD-K68938568-001-02-9	GDC-0152	Phase 1	XIAP inhibitor	BIRC2|BIRC3|BIRC7|XIAP			0	97.08	MedChemEx	HY-13638	GDC-0152	498.241	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	WZRFLSDVFPIXOV-LRQRDZAKSA-N	46940575.0		WZRFLSDVFPIXOV
BRD-K43187018-001-02-5	GDC-0349	Phase 1	Pim kinase inhibitor	PIK3CA			0	69.42	Selleck	S8040	GDC-0349	452.254	CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	RGJOJUGRHPQXGF-INIZCTEOSA-N	59239165.0		RGJOJUGRHPQXGF
BRD-K43187018-001-03-3	GDC-0349	Phase 1	Pim kinase inhibitor	PIK3CA			0	89.78	Selleck	S8040	GDC-0349	452.254	CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	RGJOJUGRHPQXGF-INIZCTEOSA-N	59239165.0		RGJOJUGRHPQXGF
BRD-K43187018-001-04-9	GDC-0349	Phase 1	Pim kinase inhibitor	PIK3CA			0	77.97	MedChemEx	HY-15248	GDC-0349	452.254	CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	RGJOJUGRHPQXGF-INIZCTEOSA-N	59239165.0		RGJOJUGRHPQXGF
BRD-K00003112-001-01-9	GDC-0575	Phase 1	CHK inhibitor				0	93.2	MedChemEx	HY-112167	GDC-0575	377.085	N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12	BAZRWWGASYWYGB-SNVBAGLBSA-N	46917793.0		BAZRWWGASYWYGB
BRD-K46908090-001-03-0	GDC-0623	Phase 1	MEK inhibitor				0	54.85	MedChemEx	HY-15610	5-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide	456.009	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	RFWVETIZUQEJEF-UHFFFAOYSA-N	42642654.0		RFWVETIZUQEJEF
BRD-K46908090-001-04-8	GDC-0623	Phase 1	MEK inhibitor				0	92.75	MedChemEx	HY-15610	GDC-0623	456.009	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	RFWVETIZUQEJEF-UHFFFAOYSA-N	42642654.0		RFWVETIZUQEJEF
BRD-K46908090-001-02-2	GDC-0623	Phase 1	MEK inhibitor				0	90.56	Selleck	S7553	GDC-0623	456.009	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	RFWVETIZUQEJEF-UHFFFAOYSA-N	42642654.0		RFWVETIZUQEJEF
BRD-K46908090-001-01-4	GDC-0623	Phase 1	MEK inhibitor				0	71.66	MedChemEx	HY-15610	GDC-0623	456.009	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	RFWVETIZUQEJEF-UHFFFAOYSA-N	42642654.0		RFWVETIZUQEJEF
BRD-K61923022-001-02-4	GDC-0810	Phase 2	selective estrogen receptor destabilizer	ESR1			0	96.55	MedChemEx	HY-12864	GDC-0810	446.12	CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl	BURHGPHDEVGCEZ-KJGLQBJMSA-N	56941241.0		BURHGPHDEVGCEZ
BRD-A30984645-001-01-5	GDC-0834	Phase 1	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	89.57	MedChemEx	HY-15427A	GDC-0834 (Racemate)	596.257	CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|	CDOOFZZILLRUQH-LJAQVGFWSA-N	25234917.0		CDOOFZZILLRUQH
BRD-A30984645-001-02-3	GDC-0834	Phase 1	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	90.56	MedChemEx	HY-15427A	GDC-0834 (Racemate)	596.257	CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|	CDOOFZZILLRUQH-LJAQVGFWSA-N	25234917.0		CDOOFZZILLRUQH
BRD-A30984645-001-03-9	GDC-0834	Phase 1	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	81.1	MedChemEx	HY-15427A	GDC-0834 (Racemate)	596.257	CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8,r|	CDOOFZZILLRUQH-LJAQVGFWSA-N	25234917.0		CDOOFZZILLRUQH
BRD-K67578145-001-10-5	GDC-0879	Preclinical	RAF inhibitor	BRAF			0	97.55	Tocris	4453	GDC 0879	334.143	OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O	DEZZLWQELQORIU-RELWKKBWSA-N	11717001.0		DEZZLWQELQORIU
BRD-K67578145-001-09-7	GDC-0879	Preclinical	RAF inhibitor	BRAF			0	93.63	Selleck	S1104	GDC-0879	334.143	OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O	DEZZLWQELQORIU-RELWKKBWSA-N	11717001.0		DEZZLWQELQORIU
BRD-K67578145-001-12-1	GDC-0879	Preclinical	RAF inhibitor	BRAF			0	89.83	Selleck	S1104	GDC-0879	334.143	OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O	DEZZLWQELQORIU-RELWKKBWSA-N	11717001.0	BRD-K14399170-001-01-7	DEZZLWQELQORIU
BRD-K00003101-001-02-9	GDC-0927	Phase 1	estrogen receptor antagonist				0	90.96	MedChemEx	HY-111484	GDC-0927	461.2	CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|	KJAAPZIFCQQQKX-NDEPHWFRSA-N	87055263.0		KJAAPZIFCQQQKX
BRD-K00003101-001-01-9	GDC-0927	Phase 1	estrogen receptor antagonist				0	92.6	MedChemEx	HY-111484	GDC-0927	461.2	CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|	KJAAPZIFCQQQKX-NDEPHWFRSA-N	87055263.0		KJAAPZIFCQQQKX
BRD-K52911425-001-09-8	GDC-0941	Phase 2	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	95.23	Selleck	S1065	GDC-0941	513.162	CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1	LHNIIDJUOCFXAP-UHFFFAOYSA-N	17755052.0		LHNIIDJUOCFXAP
BRD-K52911425-001-01-5	GDC-0941	Phase 2	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0		Selleck	S1065	GDC-0941	513.162	CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1	InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)	17755052.0		LHNIIDJUOCFXAP
BRD-K23228615-001-02-8	GDC-0980	Phase 2	mTOR inhibitor|PI3K inhibitor	FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK			0	87.14	Selleck	S2696	GDC-0980 (RG7422)	498.216	C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	YOVVNQKCSKSHKT-HNNXBMFYSA-N	25254071.0		YOVVNQKCSKSHKT
BRD-K23228615-001-04-9	GDC-0980	Phase 2	mTOR inhibitor|PI3K inhibitor	FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK			0	94.37	MedChemEx	HY-13246	Apitolisib	498.216	C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	YOVVNQKCSKSHKT-HNNXBMFYSA-N	25254071.0		YOVVNQKCSKSHKT
BRD-K23228615-001-03-6	GDC-0980	Phase 2	mTOR inhibitor|PI3K inhibitor	FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK			0	94.13	Selleck	S2696	Apitolisib (GDC-0980, RG7422)	498.216	C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	YOVVNQKCSKSHKT-HNNXBMFYSA-N	25254071.0		YOVVNQKCSKSHKT
BRD-A20830788-001-01-9	GDC-0994	Phase 1	MAP kinase inhibitor	MAPK1|MAPK3			0	98.7	Selleck	S7554	GDC-0994	440.116	Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17,r|	RZUOCXOYPYGSKL-SFHVURJKSA-N	124583908.0		RZUOCXOYPYGSKL
BRD-K02703275-001-07-5	gedunin	Preclinical	HSP inhibitor	HSP90AA1			0	95.65	Tocris	3387	Gedunin	482.23	CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|	YJXDGWUNRYLINJ-BHAPSIHVSA-N	12004512.0		YJXDGWUNRYLINJ
BRD-K00004589-001-01-9	gefapixant	Phase 3	purinergic receptor antagonist				0	97.87	MedChemEx	HY-101588	Gefapixant	353.116	COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O	HLWURFKMDLAKOD-UHFFFAOYSA-N	24764487.0		HLWURFKMDLAKOD
BRD-K64052750-001-22-5	gefitinib	Launched	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	0	99.54	Selleck	S1025	Gefitinib	446.152	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	XGALLCVXEZPNRQ-UHFFFAOYSA-N	123631.0		XGALLCVXEZPNRQ
BRD-K64052750-001-17-5	gefitinib	Launched	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	0	99.36	Tocris	3000	Iressa	446.152	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	XGALLCVXEZPNRQ-UHFFFAOYSA-N	123631.0		XGALLCVXEZPNRQ
BRD-K64052750-001-16-7	gefitinib	Launched	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	0	97.12	Selleck	S1025	Gefitinib (ZD1839)	446.152	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	XGALLCVXEZPNRQ-UHFFFAOYSA-N	123631.0		XGALLCVXEZPNRQ
BRD-K64052750-001-23-3	gefitinib	Launched	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	0	95.92	Tocris	3000	Iressa	446.152	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	XGALLCVXEZPNRQ-UHFFFAOYSA-N	123631.0		XGALLCVXEZPNRQ
BRD-K43570081-001-02-4	geldanamycin	Preclinical	HSP inhibitor	HSP90AA1			0	85.51	Selleck	S2713	Geldanamycin	560.273	CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|	QTQAWLPCGQOSGP-SLOAUYBXSA-N			QTQAWLPCGQOSGP
BRD-K43570081-001-04-0	geldanamycin	Preclinical	HSP inhibitor	HSP90AA1			0	4.29	Selleck	S2713	Geldanamycin	560.273	CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|	QTQAWLPCGQOSGP-SLOAUYBXSA-N		BRD-K82847623-001-01-5|BRD-A77524860-001-03-7	QTQAWLPCGQOSGP
BRD-K43570081-001-05-9	geldanamycin	Preclinical	HSP inhibitor	HSP90AA1			0	0.0	MedChemEx	HY-15230	Geldanamycin	560.273	CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,t:13,19,21,32|	QTQAWLPCGQOSGP-SLOAUYBXSA-N			QTQAWLPCGQOSGP
BRD-K43890836-001-01-6	gemcadiol	Phase 2	antilipemic				0	93.3	Sigma	PH000291	2,2,9,9-tetramethyl-1,10-decanediol	230.225	CC(C)(CO)CCCCCCC(C)(C)CO	DJKWDKJYFYUEBQ-UHFFFAOYSA-N	37147.0		DJKWDKJYFYUEBQ
BRD-K15108141-001-08-2	gemcitabine	Launched	ribonucleotide reductase inhibitor	CMPK1|RRM1|RRM2|TYMS	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer	0	100.0	MedChemEx	HY-17026	gemcitabine	263.072	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	SDUQYLNIPVEERB-QPPQHZFASA-N	60750.0		SDUQYLNIPVEERB
BRD-K15108141-003-04-7	gemcitabine	Launched	ribonucleotide reductase inhibitor	CMPK1|RRM1|RRM2|TYMS	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer	0	63.0	Tocris	3259	Gemcitabine hydrochloride	263.072	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	SDUQYLNIPVEERB-QPPQHZFASA-N	60750.0	BRD-K67681739-003-01-4	SDUQYLNIPVEERB
BRD-K15108141-001-06-6	gemcitabine	Launched	ribonucleotide reductase inhibitor	CMPK1|RRM1|RRM2|TYMS	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer	0	100.0	Selleck	S1714	Gemcitabine	263.072	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	SDUQYLNIPVEERB-QPPQHZFASA-N	60750.0		SDUQYLNIPVEERB
BRD-K15108141-003-05-4	gemcitabine	Launched	ribonucleotide reductase inhibitor	CMPK1|RRM1|RRM2|TYMS	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)|pancreatic cancer	0	100.0	Selleck	S1149	Gemcitabine HCl (Gemzar)	263.072	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	SDUQYLNIPVEERB-QPPQHZFASA-N	60750.0	BRD-K11238904-003-01-9	SDUQYLNIPVEERB
BRD-K09456915-001-01-2	gemcitabine-elaidate	Phase 1	apoptosis inhibitor|DNA synthesis inhibitor	CMPK1|RRM1|TYMS			0	94.93	MedChemEx	HY-13538	Gemcitabine (elaidate)	527.317	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O	HESSNRGIEVBPRB-QDDPNBLJSA-N	9828310.0		HESSNRGIEVBPRB
BRD-K11129031-001-26-7	gemfibrozil	Launched	lipoprotein lipase activator	LPL|PPARA|SLCO1B1|SLCO1B3|SLCO2B1	endocrinology|cardiology	hyperlipidemia|coronary heart disease	0	96.38	Selleck	S1729	Gemfibrozil	250.157	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1	HEMJJKBWTPKOJG-UHFFFAOYSA-N	3463.0		HEMJJKBWTPKOJG
BRD-K11129031-001-27-5	gemfibrozil	Launched	lipoprotein lipase activator	LPL|PPARA|SLCO1B1|SLCO1B3|SLCO2B1	endocrinology|cardiology	hyperlipidemia|coronary heart disease	0	97.18	MicroSource	1500313	GEMFIBROZIL	250.157	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1	HEMJJKBWTPKOJG-UHFFFAOYSA-N	3463.0		HEMJJKBWTPKOJG
BRD-A40787240-066-04-6	gemifloxacin	Launched	bacterial DNA gyrase inhibitor		pulmonary|infectious disease	bronchitis|pneumonia	0	94.6	MicroSource	1505802	GEMIFLOXACIN MESYLATE	389.15	CO\N=C1/CN(C[C@@H]1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1 |&1:7|	ZRCVYEYHRGVLOC-NOTZLVJDSA-N	42066947.0		ZRCVYEYHRGVLOC
BRD-K00003182-001-01-9	gemigliptin	Launched	dipeptidyl peptidase inhibitor				0	23.21	MedChemEx	HY-14892	Gemigliptin	489.141	N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F	ZWPRRQZNBDYKLH-VIFPVBQESA-N	11953153.0		ZWPRRQZNBDYKLH
BRD-K28824103-001-03-6	genipin	Preclinical	choleretic agent				0	96.16	MedChemEx	HY-17389	Genipin	226.084	COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|	AZKVWQKMDGGDSV-BCMRRPTOSA-N	442424.0		AZKVWQKMDGGDSV
BRD-K28824103-001-04-4	genipin	Preclinical	choleretic agent				0	83.93	Selleck	S2412	Genipin	226.084	COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|	AZKVWQKMDGGDSV-BCMRRPTOSA-N	442424.0	BRD-K70886785-001-01-1	AZKVWQKMDGGDSV
BRD-K28824103-001-02-8	genipin	Preclinical	choleretic agent				0	99.08	Selleck	S2412	Genipin	226.084	COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13,t:4|	AZKVWQKMDGGDSV-BCMRRPTOSA-N	442424.0		AZKVWQKMDGGDSV
BRD-K57275767-001-04-9	geniposide	Preclinical	GLP receptor agonist	GLP1R			0	85.9	MedChemEx	HY-N0009	Geniposide	388.137	COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|	IBFYXTRXDNAPMM-BVTMAQQCSA-N	107848.0		IBFYXTRXDNAPMM
BRD-K57275767-001-02-4	geniposide	Preclinical	GLP receptor agonist	GLP1R			0	97.9	Selleck	S2411	Geniposide	388.137	COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|	IBFYXTRXDNAPMM-BVTMAQQCSA-N	107848.0		IBFYXTRXDNAPMM
BRD-K57275767-001-03-2	geniposide	Preclinical	GLP receptor agonist	GLP1R			0	88.06	Selleck	S2411	Geniposide	388.137	COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25,t:4|	IBFYXTRXDNAPMM-BVTMAQQCSA-N	107848.0	BRD-K35205465-001-01-5	IBFYXTRXDNAPMM
BRD-K73771095-001-03-3	geniposidic-acid	Preclinical	cyclooxygenase inhibitor				0	86.68	Selleck	S2413	Geniposidic acid	374.121	OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|	ZJDOESGVOWAULF-OGJQONSISA-N	443354.0	BRD-K02342990-001-01-9	ZJDOESGVOWAULF
BRD-K73771095-001-04-9	geniposidic-acid	Preclinical	cyclooxygenase inhibitor				0	97.09	MedChemEx	HY-N0010	Geniposidic acid	374.121	OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|	ZJDOESGVOWAULF-OGJQONSISA-N	443354.0		ZJDOESGVOWAULF
BRD-K73771095-001-02-5	geniposidic-acid	Preclinical	cyclooxygenase inhibitor				0	86.14	Selleck	S2413	Geniposidic acid	374.121	OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8,t:12|	ZJDOESGVOWAULF-OGJQONSISA-N	443354.0		ZJDOESGVOWAULF
BRD-K43797669-001-28-8	genistein	Phase 2/Phase 3	tyrosine kinase inhibitor	CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5			0	97.25	Selleck	S1342	Genistein	270.053	Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	TZBJGXHYKVUXJN-UHFFFAOYSA-N	5280961.0		TZBJGXHYKVUXJN
BRD-K43797669-001-30-4	genistein	Phase 2/Phase 3	tyrosine kinase inhibitor	CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5			0	97.71	MicroSource	210296	GENISTEIN	270.053	Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	TZBJGXHYKVUXJN-UHFFFAOYSA-N	5280961.0		TZBJGXHYKVUXJN
BRD-K43797669-001-29-6	genistein	Phase 2/Phase 3	tyrosine kinase inhibitor	CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5			0	97.38	Tocris	1110	Genistein	270.053	Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	TZBJGXHYKVUXJN-UHFFFAOYSA-N	5280961.0		TZBJGXHYKVUXJN
BRD-K43797669-001-31-2	genistein	Phase 2/Phase 3	tyrosine kinase inhibitor	CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5			0	88.25	Tocris	1110	Genistein	270.053	Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	TZBJGXHYKVUXJN-UHFFFAOYSA-N	5280961.0		TZBJGXHYKVUXJN
BRD-K97891829-065-02-9	gentamycin	Launched	bacterial 50S ribosomal subunit inhibitor	HSPA8	infectious disease|critical care	bone and joint infections|endocarditis|pelvic inflammatory disease|meningitis|pneumonia|urinary tract infections|sepsis	0	0.0	MedChemEx	HY-A0276	Gentamicin (sulfate)	477.316	CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	CEAZRRDELHUEMR-CAMVTXANSA-N	72395.0		CEAZRRDELHUEMR
BRD-K33131085-001-07-2	gentiopicrin	Phase 3	glutamate receptor downregulator	GRIN2B			0	97.46	Sigma	SMB00416	(5R,6S)-1-oxo-5-vinyl-5,6-dihydro-1H,3H-pyrano[3,4-c]pyran-6-yl beta-D-glucopyranoside	356.111	OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14,t:8|	DUAGQYUORDTXOR-GPQRQXLASA-N	88708.0		DUAGQYUORDTXOR
BRD-K70693421-001-01-1	genz-123346	Preclinical	glucosylceramidase inhibitor	UGCG			0	85.93	MedChemEx	HY-12744	Genz-123346 (free base)	418.283	CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	JMNXWOFCUJJYEO-HYBUGGRVSA-N	23652732.0		JMNXWOFCUJJYEO
BRD-K70693421-001-02-9	genz-123346	Preclinical	glucosylceramidase inhibitor	UGCG			0	85.61	MedChemEx	HY-12744	Genz-123346 (free base)	418.283	CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	JMNXWOFCUJJYEO-HYBUGGRVSA-N	23652732.0		JMNXWOFCUJJYEO
BRD-K99475619-001-01-2	genz-644282	Phase 1	topoisomerase inhibitor	TOP1			0	97.15	MedChemEx	HY-16228	Genz-644282	407.148	CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O	BAORCAMWLWRZQG-UHFFFAOYSA-N	10294813.0		BAORCAMWLWRZQG
BRD-K99475619-001-03-9	genz-644282	Phase 1	topoisomerase inhibitor	TOP1			0	81.42	MedChemEx	HY-16228	Genz-644282	407.148	CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O	BAORCAMWLWRZQG-UHFFFAOYSA-N	10294813.0		BAORCAMWLWRZQG
BRD-A04447196-001-01-8	gepefrine	Launched	adrenergic receptor agonist		cardiology	hypotension	0	84.77	Sigma	MFCD00047912	3-(2-aminopropyl)phenol	151.1	C[C@@H](N)Cc1cccc(O)c1 |&1:1,r|	WTDGMHYYGNJEKQ-SSDOTTSWSA-N	10057685.0		WTDGMHYYGNJEKQ
BRD-A56754222-001-01-2	gepon	Phase 1					0	99.2	InterBioScreen	STOCK1N-32610		1816.976	CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3,11,20,51,69,80,100,118,&1:7,&2:31,&3:42,&4:60,&5:71,&6:74,&7:89,&8:109|	HTQONPPEZULJKY-MUPFFGQUSA-N			HTQONPPEZULJKY
BRD-K33499285-001-02-9	gepotidacin	Phase 2	topoisomerase inhibitor				0	94.47	MedChemEx	HY-16742	Gepotidacin	448.222	O=c1ccc2ncc(=O)n3[C@H](CN4CCC(CC4)NCc4cc5CCCOc5cn4)Cn1c23	PZFAZQUREQIODZ-LJQANCHMSA-N	25101874.0		PZFAZQUREQIODZ
BRD-K02780233-001-02-5	geranyl-farnesylacetate	Phase 2	mucin production enhancer				0	0.0	Adooq	A13666	(2E)-3,7-dimethyl-2,6-octadienyl (4E,8E)-5,9,13-trimethyl-4,8,12-tetradecatrienoate	400.334	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C	ZPACYDRSPFRDHO-ROBAGEODSA-N	5282182.0		ZPACYDRSPFRDHO
BRD-K02780233-001-01-7	geranyl-farnesylacetate	Phase 2	mucin production enhancer				0	49.56	AKSci	R260		400.334	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C	ZPACYDRSPFRDHO-ROBAGEODSA-N	5282182.0		ZPACYDRSPFRDHO
BRD-K97197005-001-04-9	gestodene	Launched	contraceptive agent		endocrinology	contraceptive	0	94.36	MedChemEx	HY-B0110	Gestodene	310.193	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|	SIGSPDASOTUPFS-XUDSTZEESA-N	3033968.0		SIGSPDASOTUPFS
BRD-K97197005-001-03-2	gestodene	Launched	contraceptive agent		endocrinology	contraceptive	0	95.03	Selleck	S1376	Gestodene	310.193	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20,t:9|	SIGSPDASOTUPFS-XUDSTZEESA-N	3033968.0	BRD-K81077266-001-01-2	SIGSPDASOTUPFS
BRD-K97472745-001-03-9	gestrinone	Launched	progesterone receptor antagonist	AR|ESR1|PGR	obstetrics/gynecology	endometriosis	0	94.9	MedChemEx	HY-101405	Gestrinone	308.178	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|	BJJXHLWLUDYTGC-ANULTFPQSA-N	27812.0		BJJXHLWLUDYTGC
BRD-K97472745-001-01-8	gestrinone	Launched	progesterone receptor antagonist	AR|ESR1|PGR	obstetrics/gynecology	endometriosis	0	95.29	Prestwick	Prestw-1267	Gestrinone	308.178	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3,5,11|	BJJXHLWLUDYTGC-ANULTFPQSA-N	27812.0		BJJXHLWLUDYTGC
BRD-K31342827-001-13-8	GF109203X	Preclinical	PKC inhibitor	PDPK1|PIM1|PRKCI|PRKCZ			0	73.04	Tocris	741	GF 109203X	412.19	CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|	QMGUOJYZJKLOLH-UHFFFAOYSA-N	2396.0		QMGUOJYZJKLOLH
BRD-K31342827-001-15-3	GF109203X	Preclinical	PKC inhibitor	PDPK1|PIM1|PRKCI|PRKCZ			0	88.34	Tocris	741	GF 109203X	412.19	CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|	QMGUOJYZJKLOLH-UHFFFAOYSA-N	2396.0		QMGUOJYZJKLOLH
BRD-K31342827-001-06-2	GF109203X	Preclinical	PKC inhibitor	PDPK1|PIM1|PRKCI|PRKCZ			0		Tocris	741	GF 109203X	412.19	CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|	InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)	2396.0		QMGUOJYZJKLOLH
BRD-A25625670-001-01-9	GGsTop	Preclinical	gamma glutamyltransferase Inhibitor	GGT1			0	15.75	Tocris	4452	GGsTop	331.082	COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|	NTFPDEDRMYYPAC-FAYKFVSFSA-N	139340107.0		NTFPDEDRMYYPAC
BRD-A25625670-001-02-7	GGsTop	Preclinical	gamma glutamyltransferase Inhibitor	GGT1			0	82.42	Tocris	4452	GGsTop	331.082	COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2,&2:6,r|	NTFPDEDRMYYPAC-FAYKFVSFSA-N	139340107.0		NTFPDEDRMYYPAC
BRD-K19669037-001-02-9	GGTI-298	Preclinical	GGTase inhibitor	CDKN1A			0	51.61	MedChemEx	HY-100876	GGTI298	479.224	COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	XVWPFYDMUFBHBF-CLOONOSVSA-N	9811606.0		XVWPFYDMUFBHBF
BRD-K19669037-001-01-1	GGTI-298	Preclinical	GGTase inhibitor	CDKN1A			0	38.97	EMDBio	345883-250UG	GGTI-298	479.224	COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	XVWPFYDMUFBHBF-CLOONOSVSA-N	9811606.0		XVWPFYDMUFBHBF
BRD-K72280606-001-01-2	gilteritinib	Launched	FLT3 inhibitor	FLT3			0	90.94	MedChemEx	HY-12432	Gilteritinib	552.354	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1	GYQYAJJFPNQOOW-UHFFFAOYSA-N	49803313.0		GYQYAJJFPNQOOW
BRD-K35687421-001-02-5	gimeracil	Launched	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	0	87.44	Selleck	S2055	Gimeracil	144.993	Oc1cc(=O)[nH]cc1Cl	ZPLQIPFOCGIIHV-UHFFFAOYSA-N	54679224.0		ZPLQIPFOCGIIHV
BRD-K35687421-001-03-3	gimeracil	Launched	dihydropyrimidine dehydrogenase inhibitor	DPYD	oncology	gastric adenocarcinoma	0	98.28	Selleck	S2055	Gimeracil	144.993	Oc1cc(=O)[nH]cc1Cl	ZPLQIPFOCGIIHV-UHFFFAOYSA-N	54679224.0		ZPLQIPFOCGIIHV
BRD-K42679315-001-08-9	ginkgolide-A	Preclinical	GABA receptor antagonist	GLRA1|GLRB			0	99.2	MedChemEx	HY-B0355	Ginkgolide A	408.142	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	FPUXKXIZEIDQKW-UEHATNFXSA-N			FPUXKXIZEIDQKW
BRD-K93816012-001-09-9	ginkgolide-B	Phase 3	platelet activating factor receptor antagonist	GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B			0	15.01	Tocris	1657	Ginkgolide B	424.137	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	SQOJOAFXDQDRGF-AIQFLADASA-N			SQOJOAFXDQDRGF
BRD-K93816012-001-10-9	ginkgolide-B	Phase 3	platelet activating factor receptor antagonist	GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B			0	100.0	Tocris	1657	Ginkgolide B	424.137	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	SQOJOAFXDQDRGF-AIQFLADASA-N			SQOJOAFXDQDRGF
BRD-K93816012-001-07-3	ginkgolide-B	Phase 3	platelet activating factor receptor antagonist	GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B			0	100.0	Selleck	S1343	Ginkgolide B	424.137	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	SQOJOAFXDQDRGF-AIQFLADASA-N		BRD-A82395837-001-01-9	SQOJOAFXDQDRGF
BRD-K93816012-001-08-1	ginkgolide-B	Phase 3	platelet activating factor receptor antagonist	GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B			0	100.0	Tocris	1657	Ginkgolide B	424.137	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	SQOJOAFXDQDRGF-AIQFLADASA-N			SQOJOAFXDQDRGF
BRD-K01942833-001-01-8	ginsenoside-C-K	Phase 1	NFkB pathway inhibitor|nitric oxide synthase inhibitor	PTGS2			0	99.5	MedChemEx	HY-N0904	Ginsenoside C-K	622.444	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	FVIZARNDLVOMSU-IRFFNABBSA-N	9852086.0		FVIZARNDLVOMSU
BRD-A84810646-001-01-6	ginsenoside-RD	Phase 3	calcium channel blocker				0	100.0	MedChemEx	HY-N0043	Ginsenoside Rd	946.55	CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,11,14,16,18,20,23,25,26,29,30,34,36,38,41,43,45,47,49,52,54,56,61,64,&1:6|	RLDVZILFNVRJTL-ZMHPOSLNSA-N			RLDVZILFNVRJTL
BRD-K00003326-001-01-9	ginsenoside-RE	Phase 1	anti-inflammatory agent				0	100.0	MedChemEx	HY-N0044	Ginsenoside Re	946.55	[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	PWAOOJDMFUQOKB-WCZZMFLVSA-N	441921.0		PWAOOJDMFUQOKB
BRD-A44511856-001-01-4	ginsenoside-RE3	Launched	angiogenesis inhibitor|apoptosis stimulant	KCNH2			0	99.4	MedChemEx	HY-N0603	Ginsenoside Rg3	784.497	CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9,12,14,15,18,19,23,25,27,30,32,34,36,38,41,43,45,50,53,&1:6|	RWXIFXNRCLMQCD-CZIWJLDFSA-N	46887680.0		RWXIFXNRCLMQCD
BRD-K13810148-311-03-2	givinostat	Phase 3	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9			0	94.01	Selleck	S2170	Givinostat (ITF2357)	421.2	CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	YALNUENQHAQXEA-UHFFFAOYSA-N	9804992.0		YALNUENQHAQXEA
BRD-K13810148-001-02-1	givinostat	Phase 3	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9			0		Stanley		BRD-10-79	421.2	CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28)	9804992.0		YALNUENQHAQXEA
BRD-K03827870-001-02-9	GKA-50	Preclinical	glucokinase activator	GCK			0	95.95	Tocris	5133	GKA 50	464.195	COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O	OCBMECSFDVUYQN-ROUUACIJSA-N	11340230.0		OCBMECSFDVUYQN
BRD-K03827870-001-01-3	GKA-50	Preclinical	glucokinase activator	GCK			0	93.93	Tocris	5133	GKA 50	464.195	COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O	OCBMECSFDVUYQN-ROUUACIJSA-N	11340230.0		OCBMECSFDVUYQN
BRD-K79710622-001-03-7	GKT137831	Phase 2	NADPH oxidase inhibitor	NOX1|NOX4			0	90.0	MedChemEx	HY-12298	GKT137831	394.12	CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	RGYQPQARIQKJKH-UHFFFAOYSA-N	58496428.0		RGYQPQARIQKJKH
BRD-K79710622-001-02-9	GKT137831	Phase 2	NADPH oxidase inhibitor	NOX1|NOX4			0	84.05	Selleck	S7171	GKT137831	394.12	CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	RGYQPQARIQKJKH-UHFFFAOYSA-N	58496428.0		RGYQPQARIQKJKH
BRD-K79710622-001-01-1	GKT137831	Phase 2	NADPH oxidase inhibitor	NOX1|NOX4			0	64.59	MedChemEx	HY-12298	GKT137831	394.12	CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	RGYQPQARIQKJKH-UHFFFAOYSA-N	58496428.0		RGYQPQARIQKJKH
BRD-K38272302-001-02-7	GK921	Preclinical	transglutaminase inhibitor	TGM2			0	94.48	MedChemEx	HY-12337	GK921	344.164	C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1	MNYJJHBAEYKXEG-UHFFFAOYSA-N	56682080.0		MNYJJHBAEYKXEG
BRD-K38272302-001-01-9	GK921	Preclinical	transglutaminase inhibitor	TGM2			0	77.27	MedChemEx	HY-12337	GK921	344.164	C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1	MNYJJHBAEYKXEG-UHFFFAOYSA-N	56682080.0		MNYJJHBAEYKXEG
BRD-K01826515-003-11-9	glafenine	Withdrawn	DeltaF508-CFTR Correctors	CFTR			0	92.08	MedChemEx	HY-B1153A	Glafenine (hydrochloride)	372.088	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|	GWOFUCIGLDBNKM-CYBMUJFWSA-N	969495.0		GWOFUCIGLDBNKM
BRD-K01826515-003-10-9	glafenine	Withdrawn	DeltaF508-CFTR Correctors	CFTR			0	98.69	Selleck	S4362	Glafenine HCl	408.064	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|	GWOFUCIGLDBNKM-CYBMUJFWSA-N	969495.0		GWOFUCIGLDBNKM
BRD-K34341643-001-01-4	glasdegib	Launched	hedgehog pathway inhibitor	SMO	hematologic malignancy	acute myeloid leukemia (AML)	0	90.62	MedChemEx	HY-16391	PF-04449913	374.186	CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N	SFNSLLSYNZWZQG-VQIMIIECSA-N	25166913.0		SFNSLLSYNZWZQG
BRD-K34341643-001-02-9	glasdegib	Launched	hedgehog pathway inhibitor	SMO	hematologic malignancy	acute myeloid leukemia (AML)	0	96.0	MedChemEx	HY-16391	Glasdegib	374.186	CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N	SFNSLLSYNZWZQG-VQIMIIECSA-N	25166913.0		SFNSLLSYNZWZQG
BRD-K00003260-001-01-9	glecaprevir	Launched	serine protease inhibitor		infectious disease	hepatitis C	0	96.9	MedChemEx	HY-17634	Glecaprevir	838.298	[H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|	MLSQGNCUYAMAHD-ITNVBOSISA-N	66828839.0		MLSQGNCUYAMAHD
BRD-K00003288-003-01-9	glesatinib	Phase 2	tyrosine kinase inhibitor				0	76.83	MedChemEx	HY-19642A	Glesatinib (hydrochloride)	619.152	COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccc(F)cc4)cc3F)c2s1	YRCHYHRCBXNYNU-UHFFFAOYSA-N	25181472.0		YRCHYHRCBXNYNU
BRD-A61154809-001-15-9	gliclazide	Launched	ATP channel blocker|insulin secretagogue		endocrinology	diabetes mellitus	0	88.04	MicroSource	1504145	GLICLAZIDE	323.13	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|	BOVGTQGAOIONJV-CHWSQXEVSA-N	931837.0		BOVGTQGAOIONJV
BRD-A61154809-001-16-7	gliclazide	Launched	ATP channel blocker|insulin secretagogue		endocrinology	diabetes mellitus	0	85.79	Selleck	S2601	Gliclazide (Diamicron)	323.13	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|	BOVGTQGAOIONJV-CHWSQXEVSA-N	931837.0		BOVGTQGAOIONJV
BRD-A61154809-001-18-9	gliclazide	Launched	ATP channel blocker|insulin secretagogue		endocrinology	diabetes mellitus	0	87.94	MedChemEx	HY-B0753	Gliclazide	323.13	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|	BOVGTQGAOIONJV-CHWSQXEVSA-N	931837.0		BOVGTQGAOIONJV
BRD-A61154809-001-14-2	gliclazide	Launched	ATP channel blocker|insulin secretagogue		endocrinology	diabetes mellitus	0	58.75	Selleck	S2601	Gliclazide	323.13	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16,&2:20,r|	BOVGTQGAOIONJV-CHWSQXEVSA-N	931837.0		BOVGTQGAOIONJV
BRD-K34776109-001-16-6	glimepiride	Launched	insulin secretagogue	ABCC8|KCNJ1|KCNJ11	endocrinology	diabetes mellitus	0	96.93	MicroSource	1504915	GLIMEPIRIDE	490.225	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|	WIGIZIANZCJQQY-RUCARUNLSA-N			WIGIZIANZCJQQY
BRD-K34776109-001-15-8	glimepiride	Launched	insulin secretagogue	ABCC8|KCNJ1|KCNJ11	endocrinology	diabetes mellitus	0	96.42	Tocris	2396	Glimepiride	490.225	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|	WIGIZIANZCJQQY-RUCARUNLSA-N			WIGIZIANZCJQQY
BRD-K34776109-001-19-9	glimepiride	Launched	insulin secretagogue	ABCC8|KCNJ1|KCNJ11	endocrinology	diabetes mellitus	0	95.45	Tocris	2396	Glimepiride	490.225	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|	WIGIZIANZCJQQY-RUCARUNLSA-N			WIGIZIANZCJQQY
BRD-K34776109-001-14-1	glimepiride	Launched	insulin secretagogue	ABCC8|KCNJ1|KCNJ11	endocrinology	diabetes mellitus	0	94.39	Selleck	S1344	Glimepiride	490.225	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r,c:2|	WIGIZIANZCJQQY-RUCARUNLSA-N			WIGIZIANZCJQQY
BRD-K12219985-001-28-9	glipizide	Launched	sulfonylurea	ABCC8|KCNJ10|KCNJ11|PPARG	endocrinology	diabetes mellitus|hyperglycemia	0	93.75	MedChemEx	HY-B0254	Glipizide	445.178	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZJJXGWJIGJFDTL-UHFFFAOYSA-N	3478.0		ZJJXGWJIGJFDTL
BRD-K12219985-001-26-1	glipizide	Launched	sulfonylurea	ABCC8|KCNJ10|KCNJ11|PPARG	endocrinology	diabetes mellitus|hyperglycemia	0	98.53	MicroSource	1505433	GLIPIZIDE	445.178	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZJJXGWJIGJFDTL-UHFFFAOYSA-N	3478.0		ZJJXGWJIGJFDTL
BRD-K12219985-001-25-3	glipizide	Launched	sulfonylurea	ABCC8|KCNJ10|KCNJ11|PPARG	endocrinology	diabetes mellitus|hyperglycemia	0	94.35	Selleck	S1715	Glipizide	445.178	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZJJXGWJIGJFDTL-UHFFFAOYSA-N	3478.0		ZJJXGWJIGJFDTL
BRD-K80396088-001-13-9	gliquidone	Launched	sulfonylurea	ABCC8|KCNJ10|KCNJ8	endocrinology	diabetes mellitus	0	98.3	MedChemEx	HY-B1114	Gliquidone	527.209	COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	LLJFMFZYVVLQKT-UHFFFAOYSA-N	91610.0		LLJFMFZYVVLQKT
BRD-K80396088-001-12-0	gliquidone	Launched	sulfonylurea	ABCC8|KCNJ10|KCNJ8	endocrinology	diabetes mellitus	0	94.47	Selleck	S3151	Gliquidone	527.209	COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	LLJFMFZYVVLQKT-UHFFFAOYSA-N	91610.0		LLJFMFZYVVLQKT
BRD-K00004731-001-01-9	Gln-1062	Preclinical	cholinesterase inhibitor				0	97.73	MedChemEx	HY-101710	GLN-1062	391.178	COc1ccc2CN(C)CC[C@@]34C=C[C@@H](C[C@@H]3Oc1c24)OC(=O)c1ccccc1 |c:12|	JKVNJTYHRABHIY-WXVUKLJWSA-N	44240142.0		JKVNJTYHRABHIY
BRD-K00003380-001-01-9	GLPG0187	Phase 1	integrin antagonist				0	100.0	MedChemEx	HY-100506	GLPG0187	595.258	COc1ccc(cc1)S(=O)(=O)N[C@@H](CNc1nc(C)nc(N2CCC(CC2)c2ccc3CCCNc3n2)c1C)C(O)=O	CXHCNOMGODVIKB-VWLOTQADSA-N	53340771.0		CXHCNOMGODVIKB
BRD-K15893360-001-01-8	GLPG0492	Phase 1	androgen receptor modulator	AR			0	95.84	MedChemEx	HY-18102	GLPG0492	389.099	CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	VAJGULUVTFDTAS-GOSISDBHSA-N	59317190.0		VAJGULUVTFDTAS
BRD-K04643927-001-01-6	GLPG0492-R-enantiomer	Phase 1	androgen receptor modulator	AR			0	90.37	MedChemEx	HY-18102A	GLPG0492 (R enantiomer)	389.099	CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	VAJGULUVTFDTAS-SFHVURJKSA-N	59317173.0		VAJGULUVTFDTAS
BRD-K00003095-001-01-9	GLPG1837	Phase 2	CFTR channel potentiator				0	95.97	MedChemEx	HY-111099	GLPG1837	348.126	CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1	GHTGYZMBQPXTCQ-UHFFFAOYSA-N	117857370.0		GHTGYZMBQPXTCQ
BRD-K60150658-432-01-5	glucaric-acid	Phase 1					0	0.0	Sigma	MFCD00150704	calcium (2R,3S,4S,5S)-2,3,4,5-tetrahydroxyhexanedioate tetrahydrate	210.038	O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O	DSLZVSRJTYRBFB-LLEIAEIESA-N	33037.0		DSLZVSRJTYRBFB
BRD-K04288422-001-04-4	gluconolactone	Launched		LCT			0	0.0	MicroSource	1503092	GLUCONOLACTONE	178.048	OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O	PHOQVHQSTUBQQK-KLVWXMOXSA-N	1549082.0		PHOQVHQSTUBQQK
BRD-K29918010-003-04-1	glucosamine	Launched	glycosylated protein precursor	IL1B	neurology/psychiatry|rheumatology	muscle pain|rheumatoid arthritis|joint pain|backache	0	100.0	MicroSource	1500316	GLUCOSAMINE HYDROCHLORIDE	179.079	N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	MSWZFWKMSRAUBD-QZABAPFNSA-N	441477.0		MSWZFWKMSRAUBD
BRD-K29918010-003-05-9	glucosamine	Launched	glycosylated protein precursor	IL1B	neurology/psychiatry|rheumatology	muscle pain|rheumatoid arthritis|joint pain|backache	0	100.0	MedChemEx	HY-N0733	Glucosamine (hydrochloride)	179.079	N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	MSWZFWKMSRAUBD-QZABAPFNSA-N	441477.0		MSWZFWKMSRAUBD
BRD-K69346723-001-04-8	glutathione	Phase 3	antioxidant	ESD|GGT1|GLO1|GLRX|GLRX2|GPX1|GPX2|GPX3|GPX4|GPX5|GPX6|GPX7|GPX8|GSR|GSS|GSTA1|GSTA2|GSTA3|GSTA4|GSTA5|GSTK1|GSTM1|GSTM2|GSTM3|GSTM4|GSTM5|GSTO1|GSTO2|GSTP1|GSTT1|GSTZ1|HAGH|HPGDS|LTC4S|MGST1|MGST2|MGST3|TXNDC12			1	0.0	MicroSource	1502248	GLUTATHIONE	307.084	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	RWSXRVCMGQZWBV-WDSKDSINSA-N	25246407.0		RWSXRVCMGQZWBV
BRD-K58937086-001-02-2	glutathione-monoisopropyl-ester	Phase 2	lipid peroxidase inhibitor				0	0.0	Sigma	MFCD00237073	(2S)-2-amino-5-{[(1R)-2-[(2-isopropoxy-2-oxoethyl)amino]-2-oxo-1-(sulfanylmethyl)ethyl]amino}-5-oxopentanoic acid	349.131	CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	MVNCPACIPXNJIW-IUCAKERBSA-N	40466869.0		MVNCPACIPXNJIW
BRD-K58937086-001-01-4	glutathione-monoisopropyl-ester	Phase 2	lipid peroxidase inhibitor				0	79.96	ChemImpex	8169		349.131	CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	MVNCPACIPXNJIW-IUCAKERBSA-N	40466869.0		MVNCPACIPXNJIW
BRD-K85066592-001-01-6	gly-gln	Phase 2					0	100.0	Ark	AK-44843		203.091	NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	PNMUAGGSDZXTHX-BYPYZUCNSA-N	7018836.0		PNMUAGGSDZXTHX
BRD-K36927236-001-36-7	glyburide	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1	endocrinology	diabetes mellitus|hyperglycemia	0	95.33	Tocris	911	Glibenclamide	493.144	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	3488.0		ZNNLBTZKUZBEKO
BRD-K36927236-001-30-0	glyburide	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1	endocrinology	diabetes mellitus|hyperglycemia	0	94.51	Selleck	S1716	Glyburide	493.144	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	3488.0		ZNNLBTZKUZBEKO
BRD-K36927236-001-32-6	glyburide	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1	endocrinology	diabetes mellitus|hyperglycemia	0	97.94	MicroSource	2300229	GLYBURIDE	493.144	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	3488.0		ZNNLBTZKUZBEKO
BRD-K36927236-001-31-8	glyburide	Launched	ATP channel blocker|insulin secretagogue|sulfonylurea	ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1	endocrinology	diabetes mellitus|hyperglycemia	0	96.81	Tocris	911	Glibenclamide	493.144	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	ZNNLBTZKUZBEKO-UHFFFAOYSA-N	3488.0		ZNNLBTZKUZBEKO
BRD-A10773072-001-03-4	glycerol-monolaurate	Launched	beta lactamase inhibitor				0	98.1	Sigma	MFCD00037815	2,3-dihydroxypropyl laurate	274.214	CCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:15,r|	ARIWANIATODDMH-AWEZNQCLSA-N	656773.0		ARIWANIATODDMH
BRD-K00003520-001-01-9	glycerol-phenylbutyrate	Phase 1	sigma receptor ligand				0	88.43	MedChemEx	HY-B2087	Glycerol phenylbutyrate	530.267	O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1	ZSDBFLMJVAGKOU-UHFFFAOYSA-N	10482134.0		ZSDBFLMJVAGKOU
BRD-K78303961-001-02-3	glycitein	Phase 3	tumor necrosis factor release inhibitor	TNF			0	97.95	Cayman	14162		284.068	COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O	DXYUAIFZCFRPTH-UHFFFAOYSA-N	5317750.0		DXYUAIFZCFRPTH
BRD-A81233518-004-16-1	glycopyrrolate	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	gastroenterology	peptic ulcer disease (PUD)	0	98.36	MicroSource	1505753	GLYCOPYRROLATE	318.207	C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|	ANGKOCUUWGHLCE-HKUYNNGSSA-N	9933193.0		ANGKOCUUWGHLCE
BRD-A81233518-004-17-9	glycopyrrolate	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	gastroenterology	peptic ulcer disease (PUD)	0	100.0	MedChemEx	HY-17465	Glycopyrrolate	318.207	C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5,&2:10|	ANGKOCUUWGHLCE-HKUYNNGSSA-N	9933193.0		ANGKOCUUWGHLCE
BRD-K00004613-001-01-9	GM-1485	Preclinical	immunophilin ligand	FKBP1A			0	67.58	Key	EG-0058	(2S)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarboxylic acid	241.131	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O	FOPALECPEUVCTL-QMMMGPOBSA-N	9837656.0		FOPALECPEUVCTL
BRD-K69832040-001-01-9	GMX1778	Phase 1/Phase 2	NAMPT inhibitor	NAMPT			0	97.04	MedChemEx	HY-10079	GMX1778	371.151	Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1	BOIPLTNGIAPDBY-UHFFFAOYSA-N	148198.0		BOIPLTNGIAPDBY
BRD-K33963447-001-03-9	GNE-7915	Preclinical	leucine rich repeat kinase inhibitor				0	97.87	Adooq	A13748	GNE7915, GMS 7915	443.158	CCNc1nc(Nc2cc(F)c(cc2OC)C(=O)N2CCOCC2)ncc1C(F)(F)F	XCFLWTZSJYBCPF-UHFFFAOYSA-N	58539171.0		XCFLWTZSJYBCPF
BRD-K97056771-001-15-9	GNF-2	Preclinical	Bcr-Abl kinase inhibitor	ABL1|BCR			0	96.9	Tocris	4399	GNF 2	374.099	NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	WEVYNIUIFUYDGI-UHFFFAOYSA-N	5311510.0		WEVYNIUIFUYDGI
BRD-K97056771-001-14-9	GNF-2	Preclinical	Bcr-Abl kinase inhibitor	ABL1|BCR			0	96.55	Tocris	4399	GNF 2	374.099	NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	WEVYNIUIFUYDGI-UHFFFAOYSA-N	5311510.0		WEVYNIUIFUYDGI
BRD-K97056771-001-13-1	GNF-2	Preclinical	Bcr-Abl kinase inhibitor	ABL1|BCR			0	95.91	Selleck	S2899	GNF-2	374.099	NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	WEVYNIUIFUYDGI-UHFFFAOYSA-N	5311510.0		WEVYNIUIFUYDGI
BRD-K87632963-001-05-9	GNF-5	Preclinical	Bcr-Abl kinase inhibitor	ABL1|BCR			0	98.82	Tocris	4908	GNF 5	418.125	OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	IIQUYGWWHIHOCF-UHFFFAOYSA-N	44129660.0		IIQUYGWWHIHOCF
BRD-K87632963-001-03-0	GNF-5	Preclinical	Bcr-Abl kinase inhibitor	ABL1|BCR			0	99.44	Tocris	4908	GNF 5	418.125	OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	IIQUYGWWHIHOCF-UHFFFAOYSA-N	44129660.0		IIQUYGWWHIHOCF
BRD-K19975102-001-01-2	GNF-5837	Preclinical	growth factor receptor inhibitor	NTRK1|NTRK2|NTRK3			0	75.24	Tocris	4559	GNF 5837	535.163	Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1	YYDUWLSETXNJJT-MTJSOVHGSA-N	59397065.0		YYDUWLSETXNJJT
BRD-K19975102-001-02-0	GNF-5837	Preclinical	growth factor receptor inhibitor	NTRK1|NTRK2|NTRK3			0	70.42	MedChemEx	HY-13491/CS-1728	GNF-5837	535.163	Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1	InChI=1S/C28H21F4N5O2/c1-15-4-6-19(35-27(39)37-25-11-16(28(30,31)32)5-9-22(25)29)13-23(15)34-18-7-8-20-21(12-17-3-2-10-33-17)26(38)36-24(20)14-18/h2-14,33-34H,1H3,(H,36,38)(H2,35,37,39)/b21-12-	59397065.0		YYDUWLSETXNJJT
BRD-K69075588-001-01-3	GNF-7	Preclinical	glucokinase inhibitor|protein kinase inhibitor	GCK|TNK2			0	90.81	Tocris	5607	GNF 7	547.194	CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C	SZNYUUZOQHNEKB-UHFFFAOYSA-N	11478363.0		SZNYUUZOQHNEKB
BRD-K69075588-001-02-9	GNF-7	Preclinical	glucokinase inhibitor|protein kinase inhibitor	GCK|TNK2			0	94.3	Tocris	5607	GNF 7	547.194	CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C	SZNYUUZOQHNEKB-UHFFFAOYSA-N	11478363.0		SZNYUUZOQHNEKB
BRD-K64748124-300-06-9	GNTI	Preclinical	opioid receptor antagonist	OPRK1|OPRM1			0	91.42	Tocris	1282	GNTI dihydrochloride	471.227	NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O	VLNHDKDBGWXJEE-GYHUNEDQSA-N	9826034.0		VLNHDKDBGWXJEE
BRD-K64748124-300-01-7	GNTI	Preclinical	opioid receptor antagonist	OPRK1|OPRM1			0	0.0	Tocris	1282	GNTI dihydrochloride	471.227	NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O	VLNHDKDBGWXJEE-GYHUNEDQSA-N	9826034.0	BRD-A80271098-300-01-4	VLNHDKDBGWXJEE
BRD-K36984403-001-02-7	go-6983	Preclinical	protein kinase inhibitor	PRKCA|PRKCB|PRKCD|PRKCG|PRKCZ			0	80.23	Selleck	S2911	Go 6983	442.2	COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|	LLJJDLHGZUOMQP-UHFFFAOYSA-N	3499.0		LLJJDLHGZUOMQP
BRD-K36984403-001-03-5	go-6983	Preclinical	protein kinase inhibitor	PRKCA|PRKCB|PRKCD|PRKCG|PRKCZ			0	93.45	Selleck	S2911	Go 6983	442.2	COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|	LLJJDLHGZUOMQP-UHFFFAOYSA-N	3499.0		LLJJDLHGZUOMQP
BRD-A57886255-001-01-1	golgicide-A	Preclinical	ARF inhibitor	GBF1			0	96.27	Tocris	3584	Golgicide A	284.113	Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|	NJZHEQOUHLZCOX-WOSRLPQWSA-N	1085377.0		NJZHEQOUHLZCOX
BRD-A57886255-001-02-9	golgicide-A	Preclinical	ARF inhibitor	GBF1			0	97.26	Selleck	S7266	Golgicide A	284.113	Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|	NJZHEQOUHLZCOX-WOSRLPQWSA-N	1085377.0	BRD-A53244165-001-01-6	NJZHEQOUHLZCOX
BRD-A57886255-001-03-9	golgicide-A	Preclinical	ARF inhibitor	GBF1			0	96.29	Tocris	3584	Golgicide A	284.113	Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8,12,&1:7,c:10|	NJZHEQOUHLZCOX-WOSRLPQWSA-N	1085377.0		NJZHEQOUHLZCOX
BRD-K69001009-001-03-9	golvatinib	Phase 2	VEGFR inhibitor	KDR|MET			0	93.46	MedChemEx	HY-13068	Golvatinib	633.288	CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	UQRCJCNVNUFYDX-UHFFFAOYSA-N	16118392.0		UQRCJCNVNUFYDX
BRD-K69001009-001-02-8	golvatinib	Phase 2	VEGFR inhibitor	KDR|MET			0	97.57	Selleck	S2859	Golvatinib (E7050)	633.288	CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	UQRCJCNVNUFYDX-UHFFFAOYSA-N	16118392.0		UQRCJCNVNUFYDX
BRD-K96874295-015-01-0	gonadorelin	Launched	gonadotropin releasing factor hormone receptor agonist	GNRHR	obstetrics/gynecology	cystic ovaries|reproductive synchrony	0	95.93	MedChemEx	HY-12555	Gonadorelin (acetate)	1181.573	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	XLXSAKCOAKORKW-AQJXLSMYSA-N	638793.0		XLXSAKCOAKORKW
BRD-K99504665-001-01-2	goserelin-acetate	Launched	gonadotropin releasing factor hormone receptor agonist	GNRHR|LHCGR	oncology|obstetrics/gynecology	prostate cancer|breast cancer|endometriosis	0	97.19	Enzo	DL282	Goserelin acetate	1268.641	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	BLCLNMBMMGCOAS-URPVMXJPSA-N	5311128.0		BLCLNMBMMGCOAS
BRD-K99504665-015-02-9	goserelin-acetate	Launched	gonadotropin releasing factor hormone receptor agonist	GNRHR|LHCGR	oncology|obstetrics/gynecology	prostate cancer|breast cancer|endometriosis	0	96.33	MedChemEx	HY-13673A	Goserelin (acetate)	1268.641	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	BLCLNMBMMGCOAS-URPVMXJPSA-N	5311128.0		BLCLNMBMMGCOAS
BRD-K19295594-001-17-6	gossypol	Phase 2	BCL inhibitor|MCL1 inhibitor	BCL2			0	83.11	Tocris	3367	AT 101	518.194	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N	3503.0		QBKSWRVVCFFDOT
BRD-K19295594-015-13-5	gossypol	Phase 2	BCL inhibitor|MCL1 inhibitor	BCL2			0	80.96	Selleck	S2812	AT101	518.194	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N	3503.0		QBKSWRVVCFFDOT
BRD-K19295594-001-16-8	gossypol	Phase 2	BCL inhibitor|MCL1 inhibitor	BCL2			0	48.77	Tocris	3367	AT 101	518.194	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N	3503.0		QBKSWRVVCFFDOT
BRD-K19295594-001-15-0	gossypol	Phase 2	BCL inhibitor|MCL1 inhibitor	BCL2			0	57.51	Selleck	S2303	Gossypol	518.194	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N	3503.0		QBKSWRVVCFFDOT
BRD-K19295594-015-14-3	gossypol	Phase 2	BCL inhibitor|MCL1 inhibitor	BCL2			0	96.16	Selleck	S2303	Gossypol Acetate	518.194	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N	3503.0		QBKSWRVVCFFDOT
BRD-K19295594-015-12-7	gossypol	Phase 2	BCL inhibitor|MCL1 inhibitor	BCL2			0	66.13	Selleck	S2812	AT101	518.194	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	QBKSWRVVCFFDOT-UHFFFAOYSA-N	3503.0		QBKSWRVVCFFDOT
BRD-K67397687-001-02-9	GPBAR-A	Preclinical	G protein-coupled receptor agonist	GPBAR1			0	98.67	Tocris	4478	GPBAR-A	484.102	Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12	ZIXNJVGTAXRKAP-UHFFFAOYSA-N	11656002.0		ZIXNJVGTAXRKAP
BRD-K67397687-001-01-3	GPBAR-A	Preclinical	G protein-coupled receptor agonist	GPBAR1			0	96.41	Tocris	4478	GPBAR-A	484.102	Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12	ZIXNJVGTAXRKAP-UHFFFAOYSA-N	11656002.0		ZIXNJVGTAXRKAP
BRD-K44869961-001-01-6	GPI-1046	Preclinical	FKBP inhibitor	FKBP1A			0	97.78	Key	ES-0040	(S)-3-(pyridin-3-yl)propyl 1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylate	360.205	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1	OQAHHWOPVDDWHD-INIZCTEOSA-N	445501.0		OQAHHWOPVDDWHD
BRD-A90201073-001-01-2	GPi-688	Preclinical	glycogen phosphorylase inhibitor				0	93.41	Tocris	3967	GPi 688	419.071	OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|	UICNBXVDHCBKCE-TZMCWYRMSA-N	24901657.0		UICNBXVDHCBKCE
BRD-A90201073-001-02-9	GPi-688	Preclinical	glycogen phosphorylase inhibitor				0	96.63	Tocris	3967	GPi 688	419.071	OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2,&1:8|	UICNBXVDHCBKCE-TZMCWYRMSA-N	24901657.0		UICNBXVDHCBKCE
BRD-K83289131-003-04-9	GPP-78	Preclinical	NAMPT inhibitor	NAMPT			0	96.86	Tocris	4835	GPP 78 hydrochloride	439.237	O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1	SJOLTIOPWDLDEB-UHFFFAOYSA-N	44819697.0		SJOLTIOPWDLDEB
BRD-K83289131-003-01-0	GPP-78	Preclinical	NAMPT inhibitor	NAMPT			0	98.04	Tocris	4835	GPP 78 hydrochloride	439.237	O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1	SJOLTIOPWDLDEB-UHFFFAOYSA-N	44819697.0		SJOLTIOPWDLDEB
BRD-K19409553-001-01-6	GPR120-modulator-1	Preclinical	G protein-coupled receptor modulator	FFAR4			0	96.16	MedChemEx	HY-50162	GPR120 modulator 1	389.049	Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O	FONSSTYHKIFEBM-UHFFFAOYSA-N	25017320.0		FONSSTYHKIFEBM
BRD-K65285700-001-02-3	GP1a	Preclinical	cannabinoid receptor agonist	CNR2			0	98.0	Tocris	2764	GP 1a	440.117	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	FNOMTMVRTBHRET-UHFFFAOYSA-N	10252734.0		FNOMTMVRTBHRET
BRD-K65285700-001-03-1	GP1a	Preclinical	cannabinoid receptor agonist	CNR2			0	95.64	SantaCruz	sc-203980	GP 1a	440.117	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	FNOMTMVRTBHRET-UHFFFAOYSA-N	10252734.0		FNOMTMVRTBHRET
BRD-K34608650-001-02-4	GP2a	Preclinical	cannabinoid receptor agonist	CNR2			0	98.53	Tocris	2678	GP 2a	439.122	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	SPEFJYZGXZENAF-UHFFFAOYSA-N	16094766.0		SPEFJYZGXZENAF
BRD-K34608650-001-03-9	GP2a	Preclinical	cannabinoid receptor agonist	CNR2			0	98.57	Tocris	2678	GP 2a	439.122	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	SPEFJYZGXZENAF-UHFFFAOYSA-N	16094766.0		SPEFJYZGXZENAF
BRD-K50891186-001-04-4	GR-103691	Preclinical	dopamine receptor antagonist	DRD3			0	85.45	Tocris	1109	GR 103691	485.268	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1	JARNORYOPMINDY-UHFFFAOYSA-N	4302960.0		JARNORYOPMINDY
BRD-K49945136-001-11-9	GR-113808	Preclinical	serotonin receptor antagonist	HTR4			0	96.58	Tocris	1322	GR 113808	393.172	Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	MOZPSIXKYJUTKI-UHFFFAOYSA-N	119376.0		MOZPSIXKYJUTKI
BRD-K49945136-001-10-0	GR-113808	Preclinical	serotonin receptor antagonist	HTR4			0	94.87	Tocris	1322	GR 113808	393.172	Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	MOZPSIXKYJUTKI-UHFFFAOYSA-N	119376.0		MOZPSIXKYJUTKI
BRD-K11911061-003-12-9	GR-127935	Preclinical	serotonin receptor antagonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6			0	96.65	Tocris	1477	GR 127935 hydrochloride	497.243	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	YDBCEBYHYKAFRX-UHFFFAOYSA-N	107780.0		YDBCEBYHYKAFRX
BRD-K11911061-003-11-9	GR-127935	Preclinical	serotonin receptor antagonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6			0	97.68	Tocris	1477	GR 127935 hydrochloride	497.243	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	YDBCEBYHYKAFRX-UHFFFAOYSA-N	107780.0		YDBCEBYHYKAFRX
BRD-K83023055-001-03-9	GR-135531	Preclinical	melatonin receptor agonist				0	90.31	Tocris	896	GR 135531	275.127	COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	MPZVHKLZCUEJFO-UHFFFAOYSA-N	4284525.0		MPZVHKLZCUEJFO
BRD-K83023055-001-02-7	GR-135531	Preclinical	melatonin receptor agonist				0	90.72	Tocris	896	GR 135531	275.127	COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	MPZVHKLZCUEJFO-UHFFFAOYSA-N	4284525.0		MPZVHKLZCUEJFO
BRD-K12120659-305-03-9	GR-144053	Preclinical	integrin antagonist	ITGA2B|ITGB3			0	91.99	Tocris	1263	GR 144053 trihydrochloride	345.216	NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	QGEGSJUSWLLZLH-UHFFFAOYSA-N	173614.0		QGEGSJUSWLLZLH
BRD-K12120659-305-02-2	GR-144053	Preclinical	integrin antagonist	ITGA2B|ITGB3			0	94.59	Tocris	1263	GR 144053 trihydrochloride	345.216	NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	QGEGSJUSWLLZLH-UHFFFAOYSA-N	173614.0		QGEGSJUSWLLZLH
BRD-K52394958-001-03-5	GR-159897	Preclinical	tachykinin antagonist	TAC1|TACR2			0	92.73	Tocris	1274	GR 159897	414.178	COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	BANYJBHWTOJQDU-GDLZYMKVSA-N	9953599.0		BANYJBHWTOJQDU
BRD-K52394958-001-04-9	GR-159897	Preclinical	tachykinin antagonist	TAC1|TACR2			0	95.15	Tocris	1274	GR 159897	414.178	COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	BANYJBHWTOJQDU-GDLZYMKVSA-N	9953599.0		BANYJBHWTOJQDU
BRD-K52394958-001-02-7	GR-159897	Preclinical	tachykinin antagonist	TAC1|TACR2			0	93.42	Tocris	1274	GR 159897	414.178	COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	BANYJBHWTOJQDU-GDLZYMKVSA-N	9953599.0		BANYJBHWTOJQDU
BRD-K00004242-001-01-9	GR-235	Launched	estrogen receptor agonist|FXR antagonist|progesterone receptor agonist	NR1H4			0	51.94	Tocris	2013	Guggulsterone	312.209	[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|	WDXRGPWQVHZTQJ-NRJJLHBYSA-N	146898.0		WDXRGPWQVHZTQJ
BRD-K40578143-001-03-9	GR-79236	Phase 1	adenosine receptor agonist	ADORA1|ADORA2A			0	95.65	Tocris	1957	GR 79236	351.154	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	GYWXTRVEUURNEW-TVDBPQCTSA-N	9884817.0		GYWXTRVEUURNEW
BRD-K40578143-001-02-6	GR-79236	Phase 1	adenosine receptor agonist	ADORA1|ADORA2A			0	98.53	Tocris	1957	GR 79236	351.154	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	GYWXTRVEUURNEW-TVDBPQCTSA-N	9884817.0		GYWXTRVEUURNEW
BRD-K45170529-001-01-3	gramicidin	Launched	bacterial permeability inducer		infectious disease	first-aid antibiotic	0	50.33	Enzo	ALX-350-233-M005	Gramicidin A	1881.071	CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO	ZWCXYZRRTRDGQE-LUPIJMBPSA-N	45479317.0		ZWCXYZRRTRDGQE
BRD-K26005076-001-12-8	gramine	Preclinical	norepinephrine reputake inhibitor				0	90.98	Selleck	S2304	Gramine	174.116	CN(C)Cc1c[nH]c2ccccc12	OCDGBSUVYYVKQZ-UHFFFAOYSA-N	6890.0		OCDGBSUVYYVKQZ
BRD-A10967948-003-06-3	granisetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting	0	97.08	MicroSource	1502365	GRANISETRON HYDROCHLORIDE	312.195	CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|	MFWNKCLOYSRHCJ-BTTYYORXSA-N			MFWNKCLOYSRHCJ
BRD-A10967948-003-05-5	granisetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting	0	90.76	Selleck	S1345	Granisetron HCl	312.195	CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2,&2:6,&3:8|	MFWNKCLOYSRHCJ-BTTYYORXSA-N			MFWNKCLOYSRHCJ
BRD-K62050508-001-01-0	grapiprant	Launched	prostaglandin inhibitor	PTGER4	rheumatology	osteoarthritis	0	96.45	MedChemEx	HY-16781	Grapiprant	491.199	CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1	HZVLFTCYCLXTGV-UHFFFAOYSA-N	11677589.0		HZVLFTCYCLXTGV
BRD-K24943235-237-01-3	grazoprevir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	97.13	MedChemEx	HY-15298A	MK-5172 (potassium salt)	766.336	COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	OBMNJSNZOWALQB-NCQNOWPTSA-N	44603531.0		OBMNJSNZOWALQB
BRD-K24943235-001-01-3	grazoprevir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	98.97	MedChemEx	HY-15298	MK-5172	766.336	COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	OBMNJSNZOWALQB-NCQNOWPTSA-N	44603531.0		OBMNJSNZOWALQB
BRD-K24943235-001-02-9	grazoprevir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	98.1	MedChemEx	HY-15298	Grazoprevir	766.336	COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	OBMNJSNZOWALQB-NCQNOWPTSA-N	44603531.0		OBMNJSNZOWALQB
BRD-K08273968-001-16-6	griseofulvin	Launched	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm|tinea pedis	0	92.38	MicroSource	200046	GRISEOFULVIN	352.071	COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|	DDUHZTYCFQRHIY-RBHXEPJQSA-N	441140.0		DDUHZTYCFQRHIY
BRD-K08273968-001-19-0	griseofulvin	Launched	tubulin polymerization inhibitor	KRT12	infectious disease	ringworm|tinea pedis	0	95.44	Selleck	S4071	Griseofulvin	352.071	COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|	DDUHZTYCFQRHIY-RBHXEPJQSA-N	441140.0	BRD-K12423485-001-01-7	DDUHZTYCFQRHIY
BRD-K62594868-082-09-9	GR125487	Preclinical	serotonin receptor antagonist	HTR4			0	90.05	Tocris	1658	GR 125487 sulfamate	427.158	COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	SSPCCAYAIDNNJX-UHFFFAOYSA-N	4284721.0		SSPCCAYAIDNNJX
BRD-K62594868-082-08-6	GR125487	Preclinical	serotonin receptor antagonist	HTR4			0	98.3	Tocris	1658	GR 125487 sulfamate	427.158	COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	SSPCCAYAIDNNJX-UHFFFAOYSA-N	4284721.0		SSPCCAYAIDNNJX
BRD-K98155362-001-08-5	GR46611	Preclinical	serotonin receptor agonist	HTR1D			0	89.81	Tocris	864	GR 46611	377.21	COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	LBVZWEWTNUDWNS-YRNVUSSQSA-N	6160690.0		LBVZWEWTNUDWNS
BRD-K98155362-001-09-9	GR46611	Preclinical	serotonin receptor agonist	HTR1D			0	93.65	Tocris	864	GR 46611	377.21	COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	LBVZWEWTNUDWNS-YRNVUSSQSA-N	6160690.0		LBVZWEWTNUDWNS
BRD-K98155362-001-07-7	GR46611	Preclinical	serotonin receptor agonist	HTR1D			0	91.27	Tocris	864	GR 46611	377.21	COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	LBVZWEWTNUDWNS-YRNVUSSQSA-N	6160690.0		LBVZWEWTNUDWNS
BRD-K99916169-001-01-9	GS-143	Preclinical	ubiquitin ligase inhibitor	BTRC|NFKBIA			0	67.28	Tocris	5636	GS 143	466.133	OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|	IZPMWFSVTDOCDI-HAVVHWLPSA-N	121513876.0		IZPMWFSVTDOCDI
BRD-K99916169-001-02-9	GS-143	Preclinical	ubiquitin ligase inhibitor	BTRC|NFKBIA			0	23.31	Tocris	5636	GS 143	466.133	OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|	IZPMWFSVTDOCDI-HAVVHWLPSA-N	121513876.0		IZPMWFSVTDOCDI
BRD-K75478907-001-03-9	GS-39783	Preclinical	GABA receptor modulator	GABBR1			0	94.88	Tocris	2001	GS 39783	337.157	CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	GSGVDKOCBKBMGG-UHFFFAOYSA-N	6604928.0		GSGVDKOCBKBMGG
BRD-K75478907-001-02-3	GS-39783	Preclinical	GABA receptor modulator	GABBR1			0	98.14	Tocris	2001	GS 39783	337.157	CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	GSGVDKOCBKBMGG-UHFFFAOYSA-N	6604928.0		GSGVDKOCBKBMGG
BRD-K68453341-001-01-1	GS-6201	Phase 1	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	99.12	Tocris	4727	3-ethyl-1-propyl-8-{1-[3-(trifluoromethyl)benzyl]-1H-pyrazol-4-yl}-3,7-dihydro-1H-purine-2,6-dione	446.168	CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1	KOYXXLLNCXWUNF-UHFFFAOYSA-N	11270783.0		KOYXXLLNCXWUNF
BRD-K73585091-001-02-3	GS-9620	Phase 2	toll-like receptor agonist	TLR7			0	86.83	MedChemEx	HY-15601	GS-9620	410.243	CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	VFOKSTCIRGDTBR-UHFFFAOYSA-N	46241268.0		VFOKSTCIRGDTBR
BRD-K73585091-001-01-5	GS-9620	Phase 2	toll-like receptor agonist	TLR7			0	62.06	MedChemEx	HY-15601	GS-9620	410.243	CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	VFOKSTCIRGDTBR-UHFFFAOYSA-N	46241268.0		VFOKSTCIRGDTBR
BRD-K26526496-001-03-9	GS-967	Preclinical	voltage-gated sodium channel blocker				0	92.97	Adooq	A14361	GS-967, GS 967	347.049	FC(F)(F)Oc1ccc(cc1)-c1ccc2nnc(n2c1)C(F)(F)F	FEVBKJITJDHASC-UHFFFAOYSA-N	58118983.0		FEVBKJITJDHASC
BRD-K76719364-001-06-6	GS-9973	Phase 2	SYK inhibitor	SYK			0	82.6	MedChemEx	HY-15968	GS-9973	411.181	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1	XSMSNFMDVXXHGJ-UHFFFAOYSA-N	59473233.0		XSMSNFMDVXXHGJ
BRD-K76719364-001-01-7	GS-9973	Phase 2	SYK inhibitor	SYK			0	73.36	Selleck	S7523	GS-9973	411.181	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1	XSMSNFMDVXXHGJ-UHFFFAOYSA-N	59473233.0		XSMSNFMDVXXHGJ
BRD-K76719364-001-04-1	GS-9973	Phase 2	SYK inhibitor	SYK			0	83.98	MedChemEx	HY-15968	GS-9973	411.181	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1	XSMSNFMDVXXHGJ-UHFFFAOYSA-N	59473233.0		XSMSNFMDVXXHGJ
BRD-K76719364-001-02-5	GS-9973	Phase 2	SYK inhibitor	SYK			0	92.11	Selleck	S7523	Entospletinib (GS-9973)	411.181	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1	XSMSNFMDVXXHGJ-UHFFFAOYSA-N	59473233.0		XSMSNFMDVXXHGJ
BRD-K32847255-001-01-1	GSK-J1	Preclinical	histone demethylase inhibitor	KDM6B			0	94.8	MedChemEx	HY-15648	GSK-J1	389.185	OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	AVZCPICCWKMZDT-UHFFFAOYSA-N	56963315.0		AVZCPICCWKMZDT
BRD-K32847255-001-02-9	GSK-J1	Preclinical	histone demethylase inhibitor	KDM6B			0	83.18	Tocris	4593	GSK J1	389.185	OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	AVZCPICCWKMZDT-UHFFFAOYSA-N	56963315.0		AVZCPICCWKMZDT
BRD-K82484347-001-02-0	GSK-J2	Preclinical	histone demethylase inhibitor				0	94.82	Tocris	4688	GSK J2	389.185	OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	LJIFOCRGDDQFJF-UHFFFAOYSA-N	73010924.0		LJIFOCRGDDQFJF
BRD-K82484347-001-01-2	GSK-J2	Preclinical	histone demethylase inhibitor				0	95.52	MedChemEx	HY-15648A	GSK-J2	389.185	OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	LJIFOCRGDDQFJF-UHFFFAOYSA-N	73010924.0		LJIFOCRGDDQFJF
BRD-K98203492-001-06-9	GSK-J4	Preclinical	histone lysine demethylase inhibitor	KDM6A|KDM6B			0	95.75	Tocris	4594	GSK J4	417.216	CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	WBKCKEHGXNWYMO-UHFFFAOYSA-N	71729975.0		WBKCKEHGXNWYMO
BRD-K98203492-001-02-9	GSK-J4	Preclinical	histone lysine demethylase inhibitor	KDM6A|KDM6B			0	83.42	Tocris	4594	GSK J4	417.216	CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	WBKCKEHGXNWYMO-UHFFFAOYSA-N	71729975.0		WBKCKEHGXNWYMO
BRD-K98203492-003-04-1	GSK-J4	Preclinical	histone lysine demethylase inhibitor	KDM6A|KDM6B			0	94.39	Selleck	S7070	GSK J4 HCl	417.216	CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	WBKCKEHGXNWYMO-UHFFFAOYSA-N	71729975.0		WBKCKEHGXNWYMO
BRD-K55438324-001-01-8	GSK-J5	Preclinical	histone demethylase control				0	95.18	Tocris	4689	GSK J5	417.216	CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	LQPGVGSKBNXQDU-UHFFFAOYSA-N	78243729.0		LQPGVGSKBNXQDU
BRD-K33521504-300-02-4	GSK-LSD-1	Preclinical	histone lysine demethylase inhibitor	KDM1A			0	37.79	Tocris	5361	GSK LSD 1 dihydrochloride	216.163	C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1	BASFYRLYJAZPPL-UONOGXRCSA-N	71522234.0		BASFYRLYJAZPPL
BRD-K33521504-300-01-6	GSK-LSD-1	Preclinical	histone lysine demethylase inhibitor	KDM1A			0	94.74	Cayman	16439	GSK-LSD1 hydrochloride	216.163	C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1	InChI=1S/C14H20N2/c1-2-4-11(5-3-1)13-10-14(13)16-12-6-8-15-9-7-12/h1-5,12-16H,6-10H2/t13-,14+/m0/s1	71522234.0		BASFYRLYJAZPPL
BRD-K04923131-001-15-4	GSK-3-inhibitor-IX	Preclinical	glycogen synthase kinase inhibitor|lipoxygenase inhibitor	GSK3A|GSK3B			0	96.66	Tocris	3194	BIO	354.996	O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12	DDLZLOKCJHBUHD-UJZLGWIISA-N			DDLZLOKCJHBUHD
BRD-K04923131-001-14-7	GSK-3-inhibitor-IX	Preclinical	glycogen synthase kinase inhibitor|lipoxygenase inhibitor	GSK3A|GSK3B			0	90.59	Selleck	S7198	BIO	354.996	O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12	DDLZLOKCJHBUHD-UJZLGWIISA-N			DDLZLOKCJHBUHD
BRD-K98684188-001-03-7	GSK0660	Preclinical	PPAR receptor antagonist	PPARD			0	89.0	Tocris	3433	GSK 0660	418.066	COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	NDFKBGWLUHKMFY-UHFFFAOYSA-N	46233311.0		NDFKBGWLUHKMFY
BRD-K98684188-001-02-9	GSK0660	Preclinical	PPAR receptor antagonist	PPARD			0	96.98	Tocris	3433	GSK 0660	418.066	COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	NDFKBGWLUHKMFY-UHFFFAOYSA-N	46233311.0		NDFKBGWLUHKMFY
BRD-K98684188-001-04-9	GSK0660	Preclinical	PPAR receptor antagonist	PPARD			0	86.93	Tocris	3433	GSK 0660	418.066	COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	NDFKBGWLUHKMFY-UHFFFAOYSA-N	46233311.0		NDFKBGWLUHKMFY
BRD-K06750613-001-04-0	GSK1059615	Phase 1	PI3K inhibitor	PIK3CG			0	66.8	Selleck	S1360	GSK1059615	333.057	O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1	QDITZBLZQQZVEE-YBEGLDIGSA-N	23582824.0		QDITZBLZQQZVEE
BRD-K06750613-001-07-3	GSK1059615	Phase 1	PI3K inhibitor	PIK3CG			0	82.73	Selleck	S1360	GSK1059615	333.057	O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1	QDITZBLZQQZVEE-YBEGLDIGSA-N	23582824.0		QDITZBLZQQZVEE
BRD-K36740062-001-07-9	GSK1070916	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|AURKC|CYP2D6|CYP3A4			0	96.02	MedChemEx	HY-70044	GSK-1070916	507.275	CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	QTBWCSQGBMPECM-UHFFFAOYSA-N	46885626.0		QTBWCSQGBMPECM
BRD-K36740062-001-06-6	GSK1070916	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|AURKC|CYP2D6|CYP3A4			0	96.68	Selleck	S2740	GSK1070916	507.275	CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	QTBWCSQGBMPECM-UHFFFAOYSA-N	46885626.0		QTBWCSQGBMPECM
BRD-K60341624-001-03-9	GSK1292263	Phase 2	glucose dependent insulinotropic receptor agonist	GRPR			0	93.62	MedChemEx	HY-12066	GSK1292263	456.183	CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	AYJRTVVIBJSSKN-UHFFFAOYSA-N	24996872.0		AYJRTVVIBJSSKN
BRD-K60341624-001-02-2	GSK1292263	Phase 2	glucose dependent insulinotropic receptor agonist	GRPR			0	97.16	Selleck	S2149	GSK1292263	456.183	CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	AYJRTVVIBJSSKN-UHFFFAOYSA-N	24996872.0		AYJRTVVIBJSSKN
BRD-K36697397-003-02-9	GSK1562590	Preclinical	urotensin receptor antagonist	UTS2R			0	96.68	Tocris	5110	GSK 1562590 hydrochloride	580.164	CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12	QDUMEBKFKOODFN-SANMLTNESA-N	46846503.0		QDUMEBKFKOODFN
BRD-K36697397-003-01-1	GSK1562590	Preclinical	urotensin receptor antagonist	UTS2R			0	93.97	Tocris	5110	GSK 1562590 hydrochloride	580.164	CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12	QDUMEBKFKOODFN-SANMLTNESA-N	46846503.0		QDUMEBKFKOODFN
BRD-K69669039-001-01-8	GSK163090	Phase 2	serotonin receptor antagonist	HTR1A|HTR1B|HTR1D			0	98.29	MedChemEx	HY-14348	GSK163090	415.237	Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1	ANGUXJDGJCHGOG-UHFFFAOYSA-N	11292933.0		ANGUXJDGJCHGOG
BRD-K06749501-001-06-9	GSK1838705A	Preclinical	insulin growth factor receptor inhibitor	ALK|IGF1R|INSR|RPS6KA1			0	91.02	Tocris	5111	GSK 1838705	532.235	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	HZTYDQRUAWIZRE-UHFFFAOYSA-N	25182616.0		HZTYDQRUAWIZRE
BRD-K06749501-001-05-4	GSK1838705A	Preclinical	insulin growth factor receptor inhibitor	ALK|IGF1R|INSR|RPS6KA1			0	94.21	Tocris	5111	GSK 1838705	532.235	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	HZTYDQRUAWIZRE-UHFFFAOYSA-N	25182616.0		HZTYDQRUAWIZRE
BRD-K06749501-001-02-1	GSK1838705A	Preclinical	insulin growth factor receptor inhibitor	ALK|IGF1R|INSR|RPS6KA1			0	81.53	Selleck	S2703	GSK1838705A	532.235	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	HZTYDQRUAWIZRE-UHFFFAOYSA-N	25182616.0		HZTYDQRUAWIZRE
BRD-K06749501-001-03-9	GSK1838705A	Preclinical	insulin growth factor receptor inhibitor	ALK|IGF1R|INSR|RPS6KA1			0	80.85	Selleck	S2703	GSK1838705A	532.235	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	HZTYDQRUAWIZRE-UHFFFAOYSA-N	25182616.0		HZTYDQRUAWIZRE
BRD-K00003166-001-01-9	GSK189254	Phase 2	histamine receptor antagonist				0	96.08	MedChemEx	HY-14111	6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide	351.195	CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	WROHEWWOCPRMIA-UHFFFAOYSA-N	9798547.0		WROHEWWOCPRMIA
BRD-K04833372-001-07-9	GSK1904529A	Preclinical	IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand	IGF1R|INSR			0	93.76	MedChemEx	HY-10524	GSK1904529A	851.339	CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	MOSKATHMXWSZTQ-UHFFFAOYSA-N	25124816.0		MOSKATHMXWSZTQ
BRD-K04833372-001-06-2	GSK1904529A	Preclinical	IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand	IGF1R|INSR			0	93.1	Selleck	S1093	GSK1904529A	851.339	CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	MOSKATHMXWSZTQ-UHFFFAOYSA-N	25124816.0		MOSKATHMXWSZTQ
BRD-K25412176-001-01-9	GSK2110183	Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	86.22	MedChemEx	HY-15727	Afuresertib	426.048	Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	AFJRDFWMXUECEW-LBPRGKRZSA-N	46843057.0		AFJRDFWMXUECEW
BRD-K25412176-001-04-9	GSK2110183	Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	84.36	MedChemEx	HY-15727	Afuresertib	426.048	Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	AFJRDFWMXUECEW-LBPRGKRZSA-N	46843057.0		AFJRDFWMXUECEW
BRD-K07972848-001-03-9	GSK2126458	Phase 1	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	95.97	MedChemEx	HY-10297	Omipalisib	505.102	COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	CGBJSGAELGCMKE-UHFFFAOYSA-N	25167777.0		CGBJSGAELGCMKE
BRD-K07972848-001-02-0	GSK2126458	Phase 1	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	95.77	Selleck	S2658	GSK2126458 (GSK458)	505.102	COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	CGBJSGAELGCMKE-UHFFFAOYSA-N	25167777.0		CGBJSGAELGCMKE
BRD-K15691453-236-01-6	GSK2190915	Phase 2	lipoxygenase inhibitor	ALOX5AP			0	97.5	MedChemEx	HY-15874A	GSK2190915 (sodium salt)	637.297	CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1	DFQGDHBGRSTTHX-UHFFFAOYSA-N	44473151.0		DFQGDHBGRSTTHX
BRD-K90737788-001-02-9	GSK2193874	Preclinical	transient receptor potential channel antagonist	TRPV4			0	95.96	Tocris	5106	GSK 2193874	690.218	FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1	UIVOZBSCHXCGPS-UHFFFAOYSA-N	53464483.0		UIVOZBSCHXCGPS
BRD-K90737788-001-01-9	GSK2193874	Preclinical	transient receptor potential channel antagonist	TRPV4			0	92.6	Tocris	5106	GSK 2193874	690.218	FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1	UIVOZBSCHXCGPS-UHFFFAOYSA-N	53464483.0		UIVOZBSCHXCGPS
BRD-K95123482-001-01-6	GSK2194069	Preclinical	fatty acid synthase inhibitor	FASN			0	98.51	Tocris	5303	GSK 2194069	428.185	O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1	AQTPWCUIYUOEMG-INIZCTEOSA-N	67376285.0		AQTPWCUIYUOEMG
BRD-K95123482-001-02-9	GSK2194069	Preclinical	fatty acid synthase inhibitor	FASN			0	98.1	Tocris	5303	GSK 2194069	428.185	O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1	AQTPWCUIYUOEMG-INIZCTEOSA-N	67376285.0		AQTPWCUIYUOEMG
BRD-K00003364-001-01-9	GSK2239633A	Preclinical	CC chemokine receptor antagonist				0	93.36	MedChemEx	HY-100183	GSK2239633A	548.095	COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12	YTEVTHHGQMUPHC-UHFFFAOYSA-N	46861584.0		YTEVTHHGQMUPHC
BRD-K00003379-001-01-9	GSK2256098	Phase 2	kinase inhibitor				0	94.24	MedChemEx	HY-100498	GSK2256098	414.157	CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl	BVAHPPKGOOJSPU-UHFFFAOYSA-N	46214930.0		BVAHPPKGOOJSPU
BRD-K62738477-001-01-7	GSK2256294A	Phase 1	epoxide hydolase inhibitor	EPHX2			0	96.85	MedChemEx	HY-19644	GSK2256294A	447.199	CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1	LQHDJQIMETZMPH-ZBFHGGJFSA-N	59448236.0		LQHDJQIMETZMPH
BRD-K05858796-001-01-7	GSK2330672	Phase 2	bile acid transporter inhibitor	SLC10A2			0	96.72	MedChemEx	HY-16643	GSK2330672	546.24	CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1	CZGVOBIGEBDYTP-VSGBNLITSA-N	53492727.0		CZGVOBIGEBDYTP
BRD-K70642949-001-04-5	GSK2334470	Preclinical	phosphoinositide dependent kinase inhibitor	AURKA|AURKB|PDPK1			0	97.09	Tocris	4143	GSK 2334470	462.286	CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1	QLPHOXTXAKOFMU-WBVHZDCISA-N	46215815.0		QLPHOXTXAKOFMU
BRD-K70642949-001-05-2	GSK2334470	Preclinical	phosphoinositide dependent kinase inhibitor	AURKA|AURKB|PDPK1			0	92.65	Focus	Oct-4725	GSK2334470	462.286	CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1	QLPHOXTXAKOFMU-WBVHZDCISA-N	46215815.0		QLPHOXTXAKOFMU
BRD-K00004689-001-01-9	GSK239512	Preclinical	histamine receptor antagonist				0	87.06	AMS	L13378	GSK-239512	377.21	O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	YFRBKEVUUCQYOW-UHFFFAOYSA-N	9976892.0		YFRBKEVUUCQYOW
BRD-K37590257-001-03-9	GSK256066	Phase 2	phosphodiesterase inhibitor	PDE4A			0	95.91	MedChemEx	HY-10469	GSK256066	518.162	COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	JFHROPTYMMSOLG-UHFFFAOYSA-N	9827968.0		JFHROPTYMMSOLG
BRD-K37590257-001-02-8	GSK256066	Phase 2	phosphodiesterase inhibitor	PDE4A			0	92.4	Selleck	S2620	GSK256066	518.162	COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	JFHROPTYMMSOLG-UHFFFAOYSA-N	9827968.0		JFHROPTYMMSOLG
BRD-K30185465-001-04-9	GSK2578215A	Preclinical	leucine rich repeat kinase inhibitor	LRRK2			0	96.66	Tocris	4629	GSK2578215A	399.138	Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1	WCIGMFCFPXZRMQ-UHFFFAOYSA-N	68107965.0		WCIGMFCFPXZRMQ
BRD-K30185465-001-03-0	GSK2578215A	Preclinical	leucine rich repeat kinase inhibitor	LRRK2			0	98.57	Tocris	4629	GSK2578215A	399.138	Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1	WCIGMFCFPXZRMQ-UHFFFAOYSA-N	68107965.0		WCIGMFCFPXZRMQ
BRD-K81689258-001-04-8	GSK2606414	Preclinical	protein kinase inhibitor	EIF2AK3|MYLK2			0	90.4	MedChemEx	HY-18072	GSK2606414	451.162	Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	SIXVRXARNAVBTC-UHFFFAOYSA-N	53469448.0		SIXVRXARNAVBTC
BRD-K81689258-001-03-0	GSK2606414	Preclinical	protein kinase inhibitor	EIF2AK3|MYLK2			0	90.36	Tocris	5107	GSK 2606414	451.162	Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	SIXVRXARNAVBTC-UHFFFAOYSA-N	53469448.0		SIXVRXARNAVBTC
BRD-K81689258-001-02-2	GSK2606414	Preclinical	protein kinase inhibitor	EIF2AK3|MYLK2			0	51.53	MedChemEx	HY-18072	GSK2606414	451.162	Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	SIXVRXARNAVBTC-UHFFFAOYSA-N	53469448.0		SIXVRXARNAVBTC
BRD-K49215523-001-04-2	GSK2636771	Phase 2	PI3K inhibitor	PIK3CB			0	89.37	Selleck	S8002	GSK2636771	433.161	Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	XTKLTGBKIDQGQL-UHFFFAOYSA-N	56949517.0		XTKLTGBKIDQGQL
BRD-K49215523-001-05-9	GSK2636771	Phase 2	PI3K inhibitor	PIK3CB			0	91.39	Selleck	S8002	GSK2636771	433.161	Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	XTKLTGBKIDQGQL-UHFFFAOYSA-N	56949517.0		XTKLTGBKIDQGQL
BRD-K41104902-001-01-3	GSK2656157	Preclinical	PERK inhibitor				0	95.49	Selleck	S7033	GSK2656157	416.176	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	PRWSIEBRGXYXAJ-UHFFFAOYSA-N	53469059.0		PRWSIEBRGXYXAJ
BRD-K89464729-001-03-1	GSK269962	Preclinical	rho associated kinase inhibitor	ROCK1|ROCK2			0	98.12	Tocris	4009	GSK 269962	570.234	CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N	YOVNFNXUCOWYSG-UHFFFAOYSA-N	16095342.0		YOVNFNXUCOWYSG
BRD-K89464729-001-04-9	GSK269962	Preclinical	rho associated kinase inhibitor	ROCK1|ROCK2			0	96.29	Tocris	4009	GSK 269962	570.234	CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N	YOVNFNXUCOWYSG-UHFFFAOYSA-N	16095342.0		YOVNFNXUCOWYSG
BRD-K48062199-001-01-8	GSK2801	Preclinical	bromodomain inhibitor	BAZ2A|BAZ2B			0	97.85	MedChemEx	HY-15658	GSK2801	371.119	CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O	KHWCPNJRJCNVRI-UHFFFAOYSA-N	73010930.0		KHWCPNJRJCNVRI
BRD-K21867462-001-03-7	GSK2816126	Phase 1	histone lysine methyltransferase inhibitor	EZH2			0	88.86	MedChemEx	HY-13470	GSK126	526.306	CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	FKSFKBQGSFSOSM-QFIPXVFZSA-N	68210102.0		FKSFKBQGSFSOSM
BRD-K21867462-001-02-9	GSK2816126	Phase 1	histone lysine methyltransferase inhibitor	EZH2			0	79.89	MedChemEx	HY-13470	GSK126	526.306	CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	FKSFKBQGSFSOSM-QFIPXVFZSA-N	68210102.0		FKSFKBQGSFSOSM
BRD-K17472821-001-01-2	GSK2830371	Preclinical	protein phosphatase inhibitor	PPM1D			0	93.44	MedChemEx	HY-15832	GSK 2830371	460.17	Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	IVDUVEGCMXCMSO-FQEVSTJZSA-N	70983932.0		IVDUVEGCMXCMSO
BRD-K17472821-001-02-0	GSK2830371	Preclinical	protein phosphatase inhibitor	PPM1D			0	91.99	Tocris	5140	GSK 2830371	460.17	Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	IVDUVEGCMXCMSO-FQEVSTJZSA-N	70983932.0		IVDUVEGCMXCMSO
BRD-K50679358-001-02-9	GSK2837808A	Preclinical	lactate dehydrogenase inhibitor	LDHA			0	97.34	Tocris	5189	GSK 2837808A	649.144	COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1	RZBCPMYJIARMGV-UHFFFAOYSA-N	71533725.0		RZBCPMYJIARMGV
BRD-K50679358-001-01-1	GSK2837808A	Preclinical	lactate dehydrogenase inhibitor	LDHA			0	92.69	Tocris	5189	GSK 2837808A	649.144	COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1	RZBCPMYJIARMGV-UHFFFAOYSA-N	71533725.0		RZBCPMYJIARMGV
BRD-K08398903-001-02-9	GSK2838232	Phase 2	HIV gag inhibitor				0	53.19	MedChemEx	HY-15884	GSK2838232	808.516	CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|	MEOWKUXNVNJAMY-PZFKGGKESA-N	71580991.0		MEOWKUXNVNJAMY
BRD-K08398903-001-01-1	GSK2838232	Phase 2	HIV gag inhibitor				0	81.68	MedChemEx	HY-15884	GSK2838232	808.516	CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|	MEOWKUXNVNJAMY-PZFKGGKESA-N	71580991.0		MEOWKUXNVNJAMY
BRD-K09223495-001-01-4	GSK2879552	Phase 1/Phase 2	histone lysine demethylase inhibitor	KDM1A			0	97.24	MedChemEx	HY-18632	GSK2879552	364.215	OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1	LRULVYSBRWUVGR-FCHUYYIVSA-N	66571643.0		LRULVYSBRWUVGR
BRD-K97656802-001-02-9	GSK2881078	Phase 2	androgen receptor modulator				0	95.08	MedChemEx	HY-100186	GSK-2881078	330.065	C[C@H](CS(C)(=O)=O)n1ccc2c(c(ccc12)C#N)C(F)(F)F	SKDVMPZQJMZEAC-SECBINFHSA-N	86709174.0		SKDVMPZQJMZEAC
BRD-K00003292-001-01-9	GSK2981278	Phase 1/Phase 2	ROR modulator				0	97.67	MedChemEx	HY-19770	GSK2981278	461.224	CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(CO)c1	LZLBRISQTJVZNP-UHFFFAOYSA-N	89875987.0		LZLBRISQTJVZNP
BRD-K00003429-001-01-9	GSK2982772	Phase 2	RIPK inhibitor				0	89.05	MedChemEx	HY-101760	GSK2982772	377.149	CN1c2ccccc2OC[C@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)C1=O	LYPAFUINURXJSG-AWEZNQCLSA-N	77108121.0		LYPAFUINURXJSG
BRD-K00004614-001-01-9	GSK3117391	Phase 1/Phase 2	HDAC inhibitor				0	94.45	MedChemEx	HY-19772	HDAC-IN-3	403.247	ONC(=O)CCc1ccc(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)cn1	AFDPFLDWOXXHQM-NRFANRHFSA-N	53630042.0		AFDPFLDWOXXHQM
BRD-K00003373-001-01-9	GSK3179106	Phase 1	RET tyrosine kinase inhibitor				0	98.7	MedChemEx	HY-100459	GSK3179106	467.147	CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)c(F)c1	IDXKJSSOUXWLDB-UHFFFAOYSA-N	78427026.0		IDXKJSSOUXWLDB
BRD-K00003421-001-01-9	GSK3326595	Phase 1/Phase 2	protein arginine N-methyltransferase inhibitor				0	92.53	MedChemEx	HY-101563	GSK3326595	452.254	CC(=O)N1CCC(CC1)Nc1cc(ncn1)C(=O)NC[C@H](O)CN1CCc2ccccc2C1	JLCCNYVTIWRPIZ-NRFANRHFSA-N	90241742.0		JLCCNYVTIWRPIZ
BRD-K00004711-001-01-9	GSK356278	Preclinical	phosphodiesterase inhibitor				0	86.68	AMS	M15716	GSK-356278	439.179	CCn1ncc2c(NC3CCOCC3)c(cnc12)-c1nnc(Cc2sc(C)nc2C)o1	AWDJJMXJUOHGLC-UHFFFAOYSA-N	10252640.0		AWDJJMXJUOHGLC
BRD-K00003121-300-01-9	GSK369796	Phase 1	potassium channel antagonist				0	98.23	MedChemEx	HY-12082A	GSK369796 Dihydrochloride	355.145	CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	ZVMMVSSEAMUNGI-UHFFFAOYSA-N	10316203.0		ZVMMVSSEAMUNGI
BRD-K26514105-001-02-9	GSK37647	Preclinical	free fatty acid receptor agonist	FFAR4			0	96.74	Tocris	5257	GSK 137647	305.109	COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C	FQUAFMNPXPXOJE-UHFFFAOYSA-N	743974.0		FQUAFMNPXPXOJE
BRD-K26514105-001-01-7	GSK37647	Preclinical	free fatty acid receptor agonist	FFAR4			0	98.11	Tocris	5257	GSK 137647	305.109	COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C	FQUAFMNPXPXOJE-UHFFFAOYSA-N	743974.0		FQUAFMNPXPXOJE
BRD-K03155172-001-03-0	GSK3787	Preclinical	PPAR receptor antagonist	PPARD			0	90.79	Tocris	3961	GSK 3787	392.021	FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	JFUIMTGOQCQTPF-UHFFFAOYSA-N	2800647.0		JFUIMTGOQCQTPF
BRD-K03155172-001-02-2	GSK3787	Preclinical	PPAR receptor antagonist	PPARD			0	95.61	Selleck	S8025	GSK3787	392.021	FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	JFUIMTGOQCQTPF-UHFFFAOYSA-N	2800647.0		JFUIMTGOQCQTPF
BRD-K03155172-001-05-9	GSK3787	Preclinical	PPAR receptor antagonist	PPARD			0	95.4	Tocris	3961	GSK 3787	392.021	FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	JFUIMTGOQCQTPF-UHFFFAOYSA-N	2800647.0		JFUIMTGOQCQTPF
BRD-A10523515-001-11-1	GSK429286A	Preclinical	rho associated kinase inhibitor	ROCK1			0	96.54	MedChemEx	HY-11000	GSK429286A	432.121	CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|	OLIIUAHHAZEXEX-AWEZNQCLSA-N	92472001.0		OLIIUAHHAZEXEX
BRD-A10523515-001-10-3	GSK429286A	Preclinical	rho associated kinase inhibitor	ROCK1			0	96.14	Tocris	3726	GSK 429286	432.121	CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|	OLIIUAHHAZEXEX-AWEZNQCLSA-N	92472001.0		OLIIUAHHAZEXEX
BRD-A10523515-001-07-9	GSK429286A	Preclinical	rho associated kinase inhibitor	ROCK1			0	95.31	Selleck	S1474	GSK429286A	432.121	CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3,r,t:1|	OLIIUAHHAZEXEX-AWEZNQCLSA-N	92472001.0		OLIIUAHHAZEXEX
BRD-K92428232-001-14-9	GSK461364	Phase 1	PLK inhibitor	PLK1			0	97.9	MedChemEx	HY-50877	GSK461364	543.192	C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	ZHJGWYRLJUCMRT-QGZVFWFLSA-N	15983966.0		ZHJGWYRLJUCMRT
BRD-K92428232-001-10-6	GSK461364	Phase 1	PLK inhibitor	PLK1			0	94.3	Selleck	S2193	GSK461364	543.192	C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	ZHJGWYRLJUCMRT-QGZVFWFLSA-N	15983966.0		ZHJGWYRLJUCMRT
BRD-K72293620-001-01-7	GSK503	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	94.9	MedChemEx	HY-12856	GSK503	526.306	CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	HRDQQHUKUIKFHT-UHFFFAOYSA-N	67469117.0		HRDQQHUKUIKFHT
BRD-K14991967-001-04-2	GSK650394	Preclinical	serum/glucocorticoid regulated kinase inhibitor	SGK1|SGK2			0	97.46	MedChemEx	HY-15192	GSK 650394	382.168	OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	WVSBGSNVCDAMCF-UHFFFAOYSA-N	25022668.0		WVSBGSNVCDAMCF
BRD-K14991967-001-02-6	GSK650394	Preclinical	serum/glucocorticoid regulated kinase inhibitor	SGK1|SGK2			0	97.21	Tocris	3572	GSK 650394	382.168	OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	WVSBGSNVCDAMCF-UHFFFAOYSA-N	25022668.0		WVSBGSNVCDAMCF
BRD-K14991967-001-03-4	GSK650394	Preclinical	serum/glucocorticoid regulated kinase inhibitor	SGK1|SGK2			0	97.79	Tocris	3572	GSK 650394	382.168	OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	WVSBGSNVCDAMCF-UHFFFAOYSA-N	25022668.0		WVSBGSNVCDAMCF
BRD-K00003483-003-01-9	GSK656	Preclinical	leucyl-tRNA synthetase inhibitor				0	73.31	MedChemEx	HY-107775	GSK656	257.063	NC[C@H]1OB(O)c2c1c(Cl)ccc2OCCO	DJUOWOXTPXUHDQ-MRVPVSSYSA-N	133080621.0		DJUOWOXTPXUHDQ
BRD-K25325018-001-05-6	GSK690693	Phase 1	AKT inhibitor	AKT1|AKT2|AKT3|PAK4|PAK6|PAK7|PRKCQ|PRKG1|PRKX			0	97.21	Selleck	S1113	GSK690693	425.218	CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	16725726.0		KGPGFQWBCSZGEL
BRD-K25325018-001-02-3	GSK690693	Phase 1	AKT inhibitor	AKT1|AKT2|AKT3|PAK4|PAK6|PAK7|PRKCQ|PRKG1|PRKX			0	62.13	Selleck	S1113	GSK690693	425.218	CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	16725726.0		KGPGFQWBCSZGEL
BRD-K25325018-001-06-4	GSK690693	Phase 1	AKT inhibitor	AKT1|AKT2|AKT3|PAK4|PAK6|PAK7|PRKCQ|PRKG1|PRKX			0	73.67	Tocris	4144	GSK 690693	425.218	CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	KGPGFQWBCSZGEL-ZDUSSCGKSA-N	16725726.0	BRD-K29174426-001-01-9	KGPGFQWBCSZGEL
BRD-K29328421-001-01-6	GSK9027	Preclinical	glucocorticoid receptor agonist	NR3C1			0	96.16	Tocris	4116	GSK 9027	525.113	Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F	DXBJGDVBQPEMOB-UHFFFAOYSA-N	24882669.0		DXBJGDVBQPEMOB
BRD-K29328421-001-02-9	GSK9027	Preclinical	glucocorticoid receptor agonist	NR3C1			0	97.08	Tocris	4116	GSK 9027	525.113	Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F	DXBJGDVBQPEMOB-UHFFFAOYSA-N	24882669.0		DXBJGDVBQPEMOB
BRD-K89015388-001-02-9	GSK923295	Phase 1	centromere associated protein inhibitor	CENPE			0	97.04	MedChemEx	HY-10299	GSK-923295	591.261	CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	WHMXDBPHBVLYRC-OFVILXPXSA-N	46898058.0		WHMXDBPHBVLYRC
BRD-K89015388-001-01-7	GSK923295	Phase 1	centromere associated protein inhibitor	CENPE			0	88.45	MedChemEx	HY-10299	GSK-923295	591.261	CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	WHMXDBPHBVLYRC-OFVILXPXSA-N	46898058.0		WHMXDBPHBVLYRC
BRD-K16664969-001-04-1	GTP-14564	Preclinical	FLT3 inhibitor|tyrosine kinase inhibitor	CSF1R|FLT3|KIT|PDGFRB			0	98.68	Tocris	2086	GTP 14564	234.079	c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12	DZQLVVLATXPWBK-UHFFFAOYSA-N	3385203.0		DZQLVVLATXPWBK
BRD-K16664969-001-07-9	GTP-14564	Preclinical	FLT3 inhibitor|tyrosine kinase inhibitor	CSF1R|FLT3|KIT|PDGFRB			0	96.1	Tocris	2086	GTP 14564	234.079	c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12	DZQLVVLATXPWBK-UHFFFAOYSA-N	3385203.0		DZQLVVLATXPWBK
BRD-K16664969-001-03-3	GTP-14564	Preclinical	FLT3 inhibitor|tyrosine kinase inhibitor	CSF1R|FLT3|KIT|PDGFRB			0	98.47	Tocris	2086	GTP 14564	234.079	c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12	DZQLVVLATXPWBK-UHFFFAOYSA-N	3385203.0		DZQLVVLATXPWBK
BRD-K14235254-001-01-2	GTS21	Phase 1/Phase 2	cholinergic receptor agonist	CHRNA7			0	98.14	ChemDiv	Y010-1225		308.152	COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|	RPYWXZCFYPVCNQ-RVDMUPIBSA-N	5310985.0		RPYWXZCFYPVCNQ
BRD-K14235254-300-02-9	GTS21	Phase 1/Phase 2	cholinergic receptor agonist	CHRNA7			0	94.74	MedChemEx	HY-14564A	GTS-21 (dihydrochloride)	308.152	COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|	RPYWXZCFYPVCNQ-RVDMUPIBSA-N	5310985.0		RPYWXZCFYPVCNQ
BRD-K00739965-001-01-9	guacetisal	Launched	immunosuppressant		pulmonary	cough suppressant	0	96.88	AvaChem	2814	2-methoxyphenyl 2-(acetyloxy)benzoate	286.084	COc1ccccc1OC(=O)c1ccccc1OC(C)=O	HSJFYRYGGKLQBT-UHFFFAOYSA-N	68749.0		HSJFYRYGGKLQBT
BRD-K00003187-236-01-9	guadecitabine	Phase 3	DNA methyltransferase inhibitor				0	100.0	MedChemEx	HY-15229	Guadecitabine sodium	557.138	Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1	GUWXKKAWLCENJA-WGWHJZDNSA-N	135564655.0		GUWXKKAWLCENJA
BRD-K96282009-001-08-8	guaiacol	Launched	local anesthetic	CA2	pulmonary	cough suppressant	0	0.0	MicroSource	1506165	GUAIACOL	124.052	COc1ccccc1O	LHGVFZTZFXWLCP-UHFFFAOYSA-N	460.0		LHGVFZTZFXWLCP
BRD-K96282009-001-12-9	guaiacol	Launched	local anesthetic	CA2	pulmonary	cough suppressant	0	0.0	MedChemEx	HY-N1380	Guaiacol	124.052	COc1ccccc1O	LHGVFZTZFXWLCP-UHFFFAOYSA-N	460.0		LHGVFZTZFXWLCP
BRD-A90515964-001-18-9	guaifenesin	Launched	expectorant		pulmonary	cough suppressant	0	93.74	MedChemEx	HY-B0264	Guaifenesin	198.089	COc1ccccc1OC[C@@H](O)CO |&1:10,r|	HSRJKNPTNIJEKV-QMMMGPOBSA-N	6950715.0		HSRJKNPTNIJEKV
BRD-A90515964-001-16-5	guaifenesin	Launched	expectorant		pulmonary	cough suppressant	0	98.9	MicroSource	1500321	GUAIFENESIN	198.089	COc1ccccc1OC[C@@H](O)CO |&1:10,r|	HSRJKNPTNIJEKV-QMMMGPOBSA-N	6950715.0		HSRJKNPTNIJEKV
BRD-A90515964-001-15-7	guaifenesin	Launched	expectorant		pulmonary	cough suppressant	0	94.26	Selleck	S1740	Guaifenesin	198.089	COc1ccccc1OC[C@@H](O)CO |&1:10,r|	HSRJKNPTNIJEKV-QMMMGPOBSA-N	6950715.0		HSRJKNPTNIJEKV
BRD-K62736196-015-10-2	guanaben-acetate	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	85.09	Tocris	885	Guanabenz acetate	230.013	NC(=N)N\N=C\c1c(Cl)cccc1Cl	WDZVGELJXXEGPV-YIXHJXPBSA-N	5702063.0		WDZVGELJXXEGPV
BRD-K62736196-015-09-4	guanaben-acetate	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	65.39	Selleck	S4065	Guanabenz Acetate	230.013	NC(=N)N\N=C\c1c(Cl)cccc1Cl	WDZVGELJXXEGPV-YIXHJXPBSA-N	5702063.0		WDZVGELJXXEGPV
BRD-K62736196-015-13-6	guanaben-acetate	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	91.73	MicroSource	1500322	GUANABENZ ACETATE	230.013	NC(=N)N\N=C\c1c(Cl)cccc1Cl	WDZVGELJXXEGPV-YIXHJXPBSA-N	5702063.0	BRD-K56800335-015-04-9	WDZVGELJXXEGPV
BRD-K62736196-015-11-0	guanaben-acetate	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	95.27	Selleck	S4065	Guanabenz (WY-8678) Acetate	230.013	NC(=N)N\N=C\c1c(Cl)cccc1Cl	WDZVGELJXXEGPV-YIXHJXPBSA-N	5702063.0		WDZVGELJXXEGPV
BRD-A14262390-065-01-8	guanadrel	Launched	adrenergic inhibitor		cardiology	hypertension	0	100.0	MicroSource	1505544	GUANADREL SULFATE	213.148	NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|	HPBNRIOWIXYZFK-QMMMGPOBSA-N	45356255.0		HPBNRIOWIXYZFK
BRD-K00005334-001-01-9	guancydine	Preclinical	antihypertensive agent				0	90.34	MedChemEx	HY-101554	Guancydine	154.122	CCC(C)(C)NC(=N)NC#N	VZVGEDRCVUKSEL-UHFFFAOYSA-N	14211.0		VZVGEDRCVUKSEL
BRD-K62676709-001-01-9	guanethidine	Launched	adrenergic inhibitor	SLC6A2	cardiology	hypertension	0	0.0	MicroSource	1500323	GUANETHIDINE	198.184	NC(=N)NCCN1CCCCCCC1	ACGDKVXYNVEAGU-UHFFFAOYSA-N	3518.0		ACGDKVXYNVEAGU
BRD-K62676709-065-05-5	guanethidine	Launched	adrenergic inhibitor	SLC6A2	cardiology	hypertension	0	100.0	Selleck	S4328	Guanethidine Sulfate	198.184	NC(=N)NCCN1CCCCCCC1	ACGDKVXYNVEAGU-UHFFFAOYSA-N	3518.0	BRD-M18219129-065-04-2	ACGDKVXYNVEAGU
BRD-K62676709-065-06-9	guanethidine	Launched	adrenergic inhibitor	SLC6A2	cardiology	hypertension	0	23.07	MedChemEx	HY-B0800	Guanethidine (sulfate)	198.184	NC(=N)NCCN1CCCCCCC1	ACGDKVXYNVEAGU-UHFFFAOYSA-N	3518.0		ACGDKVXYNVEAGU
BRD-K32830106-003-21-2	guanfacine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	19.92	MicroSource	1505435	GUANFACINE HYDROCHLORIDE	245.012	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	INJOMKTZOLKMBF-UHFFFAOYSA-N	3519.0		INJOMKTZOLKMBF
BRD-K32830106-001-02-6	guanfacine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	100.0	MicroSource	1505435	GUANFACINE	245.012	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	INJOMKTZOLKMBF-UHFFFAOYSA-N	3519.0		INJOMKTZOLKMBF
BRD-K32830106-003-20-4	guanfacine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	99.04	Tocris	1030	Guanfacine hydrochloride	245.012	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	INJOMKTZOLKMBF-UHFFFAOYSA-N	3519.0		INJOMKTZOLKMBF
BRD-K76037122-003-03-9	guanidine	Launched	HSP inhibitor	ALDH2|DLG4|GAMT|RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	0	100.0	MedChemEx	HY-B0178A	Guanidine (hydrochloride)	59.048	NC(N)=N	ZRALSGWEFCBTJO-UHFFFAOYSA-N	3520.0		ZRALSGWEFCBTJO
BRD-K76037122-001-01-7	guanidine	Launched	HSP inhibitor	ALDH2|DLG4|GAMT|RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	0	95.94	MicroSource	1300022	GUANIDINE HYDROCHLORIDE	59.048	NC(N)=N	ZRALSGWEFCBTJO-UHFFFAOYSA-N	3520.0	BRD-M47712611-001-04-1|BRD-M29095938-001-02-3	ZRALSGWEFCBTJO
BRD-K76037122-001-02-5	guanidine	Launched	HSP inhibitor	ALDH2|DLG4|GAMT|RNASE1	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)	0	98.46	Selleck	S4070	Guanidine HCl	59.048	NC(N)=N	ZRALSGWEFCBTJO-UHFFFAOYSA-N	3520.0	BRD-M47712611-001-03-3	ZRALSGWEFCBTJO
BRD-K69191882-065-01-6	guanidinoethyldisulfide-bicarbonate	Phase 2	nitric oxide synthase inhibitor	NOS2			1	0.0	TygerSci	G67400	N-[2-(2-Guanidino-ethyldisulfanyl)-ethyl]guanidine H2SO4	236.088	NC(=N)NCCSSCCNC(N)=N	IRMTXMJNHRISQH-UHFFFAOYSA-N	3521.0		IRMTXMJNHRISQH
BRD-K50781608-001-02-1	guanidinopropionic-acid	Phase 2	creatine kinase inhibitor	CKM			0	0.0	Sigma	MFCD00045939	N-[amino(imino)methyl]-beta-alanine	131.069	NC(=N)NCCC(O)=O	KMXXSJLYVJEBHI-UHFFFAOYSA-N	67701.0		KMXXSJLYVJEBHI
BRD-K67644125-001-03-9	guanosine	Preclinical		PNP			0	91.3	MedChemEx	HY-N0097	Guanosine	283.092	Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	NYHBQMYGNKIUIF-UUOKFMHZSA-N	135398635.0		NYHBQMYGNKIUIF
BRD-K18745919-001-02-9	Gue-1654	Preclinical	oxoeicosanoid receptor modulator	OXER1			0	95.32	Tocris	4742	Gue 1654	447.053	CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1	UFOBDFMYJABXGK-UHFFFAOYSA-N	5066134.0		UFOBDFMYJABXGK
BRD-K18745919-001-01-3	Gue-1654	Preclinical	oxoeicosanoid receptor modulator	OXER1			0	96.81	Tocris	4742	Gue 1654	447.053	CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1	UFOBDFMYJABXGK-UHFFFAOYSA-N	5066134.0		UFOBDFMYJABXGK
BRD-K01980392-003-11-6	guvacine	Preclinical	GABA uptake inhibitor	SLC6A1|SLC6A11|SLC6A12|SLC6A13			0	100.0	Tocris	234	Guvacine hydrochloride	127.063	OC(=O)C1=CCCNC1 |t:3|	QTDZOWFRBNTPQR-UHFFFAOYSA-N	40468028.0		QTDZOWFRBNTPQR
BRD-K01980392-003-12-9	guvacine	Preclinical	GABA uptake inhibitor	SLC6A1|SLC6A11|SLC6A12|SLC6A13			0	100.0	Tocris	234	Guvacine hydrochloride	127.063	OC(=O)C1=CCCNC1 |t:3|	QTDZOWFRBNTPQR-UHFFFAOYSA-N	40468028.0		QTDZOWFRBNTPQR
BRD-K82983861-001-06-8	GW-0742	Preclinical	PPAR receptor agonist	PPARD			0	96.73	Tocris	2229	GW 0742	471.059	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	HWVNEWGKWRGSRK-UHFFFAOYSA-N	9934458.0		HWVNEWGKWRGSRK
BRD-K82983861-001-05-0	GW-0742	Preclinical	PPAR receptor agonist	PPARD			0	90.36	Tocris	2229	GW 0742	471.059	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	HWVNEWGKWRGSRK-UHFFFAOYSA-N	9934458.0		HWVNEWGKWRGSRK
BRD-K82983861-001-04-3	GW-0742	Preclinical	PPAR receptor agonist	PPARD			0	91.3	Selleck	S8020	GW0742	471.059	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	HWVNEWGKWRGSRK-UHFFFAOYSA-N	9934458.0		HWVNEWGKWRGSRK
BRD-K82983861-001-07-9	GW-0742	Preclinical	PPAR receptor agonist	PPARD			0	95.73	Tocris	2229	GW 0742	471.059	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	HWVNEWGKWRGSRK-UHFFFAOYSA-N	9934458.0		HWVNEWGKWRGSRK
BRD-K23614267-001-01-2	GW-1100	Preclinical	G protein-coupled receptor agonist	FFAR1			0	93.14	MedChemEx	HY-50691	GW-1100	520.158	CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1	PTPNCCWOTBBVJR-UHFFFAOYSA-N	11692123.0		PTPNCCWOTBBVJR
BRD-K00004238-003-01-9	GW-1929	Preclinical	PPAR receptor agonist	PPARG			0	94.94	Tocris	1664	GW 1929 hydrochloride	495.216	CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1	QTQMRBZOBKYXCG-MHZLTWQESA-N	6518171.0		QTQMRBZOBKYXCG
BRD-K24242599-001-02-8	GW-2580	Preclinical	cFMS kinase inhibitor	CSF1R			0	94.93	Selleck	S8042	GW2580	366.169	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1	MYQAUKPBNJWPIE-UHFFFAOYSA-N	11617559.0		MYQAUKPBNJWPIE
BRD-K37864785-001-01-0	GW-311616	Phase 1	elastase inhibitor|leukocyte elastase inhibitor	ELANE			0	97.39	MedChemEx	HY-15891	GW311616	397.204	CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O	NDNKNUMSTIMSHQ-URZKGLGPSA-N	9800961.0		NDNKNUMSTIMSHQ
BRD-K37864785-001-02-9	GW-311616	Phase 1	elastase inhibitor|leukocyte elastase inhibitor	ELANE			0	96.0	MedChemEx	HY-15891	GW311616	397.204	CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O	NDNKNUMSTIMSHQ-URZKGLGPSA-N	9800961.0		NDNKNUMSTIMSHQ
BRD-K33818169-003-05-3	GW-3965	Preclinical	LXR agonist	NR1H2|NR1H3			0	97.77	Tocris	2474	GW 3965 hydrochloride	581.194	OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	NAXSRXHZFIBFMI-UHFFFAOYSA-N	72199895.0		NAXSRXHZFIBFMI
BRD-K33818169-003-04-6	GW-3965	Preclinical	LXR agonist	NR1H2|NR1H3			0	98.12	Tocris	2474	GW 3965 hydrochloride	581.194	OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	NAXSRXHZFIBFMI-UHFFFAOYSA-N	72199895.0		NAXSRXHZFIBFMI
BRD-K33818169-003-06-9	GW-3965	Preclinical	LXR agonist	NR1H2|NR1H3			0	96.1	Tocris	2474	GW 3965 hydrochloride	581.194	OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	NAXSRXHZFIBFMI-UHFFFAOYSA-N	72199895.0		NAXSRXHZFIBFMI
BRD-K33818169-003-03-8	GW-3965	Preclinical	LXR agonist	NR1H2|NR1H3			0	96.96	Selleck	S2630	GW3965 HCl	581.194	OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	NAXSRXHZFIBFMI-UHFFFAOYSA-N	72199895.0		NAXSRXHZFIBFMI
BRD-K10705233-001-02-2	GW-405833	Preclinical	cannabinoid receptor agonist	CNR2			0	95.83	Tocris	2374	GW 405833	446.116	COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	FSFZRNZSZYDVLI-UHFFFAOYSA-N	9911463.0		FSFZRNZSZYDVLI
BRD-K88186167-001-05-5	GW-4064	Preclinical	FXR agonist	NR1H4			0	93.5	Tocris	2473	GW 4064	541.061	CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	BYTNEISLBIENSA-MDZDMXLPSA-N	9893571.0		BYTNEISLBIENSA
BRD-K88186167-001-04-8	GW-4064	Preclinical	FXR agonist	NR1H4			0	96.96	Selleck	S2782	GW4064	541.061	CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	BYTNEISLBIENSA-MDZDMXLPSA-N	9893571.0		BYTNEISLBIENSA
BRD-K88186167-001-06-9	GW-4064	Preclinical	FXR agonist	NR1H4			0	98.07	Tocris	2473	GW 4064	541.061	CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	BYTNEISLBIENSA-MDZDMXLPSA-N	9893571.0		BYTNEISLBIENSA
BRD-K13039700-066-01-2	GW-438014A	Preclinical	neuropeptide receptor antagonist	NPY5R			0	96.45	Tocris	4669	GW 438014A	341.153	O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1	CDUDZZGLFOFINU-UHFFFAOYSA-N	6918627.0		CDUDZZGLFOFINU
BRD-K13039700-066-02-0	GW-438014A	Preclinical	neuropeptide receptor antagonist	NPY5R			0	98.07	Sigma	SML0855-5MG	GW438014A	341.153	O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1	CDUDZZGLFOFINU-UHFFFAOYSA-N	6918627.0		CDUDZZGLFOFINU
BRD-K41312087-001-02-7	GW-441756	Preclinical	growth factor receptor inhibitor	NTRK1			0	96.24	Tocris	2238	GW 441756	275.106	Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	NXNQLECPAXXYTR-LCYFTJDESA-N	9943465.0		NXNQLECPAXXYTR
BRD-K41312087-001-01-9	GW-441756	Preclinical	growth factor receptor inhibitor	NTRK1			0	94.81	Selleck	S2891	GW441756	275.106	Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	NXNQLECPAXXYTR-LCYFTJDESA-N	9943465.0		NXNQLECPAXXYTR
BRD-K14880289-001-03-0	GW-501516	Phase 2	PPAR receptor agonist	PPARA|PPARD			0	95.38	MedChemEx	HY-10838	GW 501516	453.068	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	YDBLKRPLXZNVNB-UHFFFAOYSA-N	9803963.0		YDBLKRPLXZNVNB
BRD-K14880289-001-02-2	GW-501516	Phase 2	PPAR receptor agonist	PPARA|PPARD			0	77.86	MedChemEx	HY-10838	GW 501516	453.068	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	YDBLKRPLXZNVNB-UHFFFAOYSA-N	9803963.0		YDBLKRPLXZNVNB
BRD-K39520573-001-05-9	GW-5074	Phase 1/Phase 2	leucine rich repeat kinase inhibitor|RAF inhibitor	NTRK1|RAF1			0	47.84	Tocris	1381	GW 5074	518.797	Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	LMXYVLFTZRPNRV-UHFFFAOYSA-N	5034.0		LMXYVLFTZRPNRV
BRD-K39520573-001-03-8	GW-5074	Phase 1/Phase 2	leucine rich repeat kinase inhibitor|RAF inhibitor	NTRK1|RAF1			0	56.75	Selleck	S2872	GW5074	518.797	Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	LMXYVLFTZRPNRV-UHFFFAOYSA-N	5034.0	BRD-K07859598-001-13-8	LMXYVLFTZRPNRV
BRD-K39520573-001-04-6	GW-5074	Phase 1/Phase 2	leucine rich repeat kinase inhibitor|RAF inhibitor	NTRK1|RAF1			0	54.95	Tocris	1381	GW 5074	518.797	Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	LMXYVLFTZRPNRV-UHFFFAOYSA-N	5034.0	BRD-K07859598-001-12-0	LMXYVLFTZRPNRV
BRD-K39520573-001-02-0	GW-5074	Phase 1/Phase 2	leucine rich repeat kinase inhibitor|RAF inhibitor	NTRK1|RAF1			0	58.05	Selleck	S2872	GW5074	518.797	Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	LMXYVLFTZRPNRV-UHFFFAOYSA-N	5034.0	BRD-K93653303-001-01-1	LMXYVLFTZRPNRV
BRD-K36485341-001-01-2	GW-542573X	Preclinical	calcium channel activator	KCNN1			0	91.84	Tocris	4311	GW 542573X	364.2	COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C	SAXGSDIZIYFNKD-UHFFFAOYSA-N	24885053.0		SAXGSDIZIYFNKD
BRD-K36485341-001-02-9	GW-542573X	Preclinical	calcium channel activator	KCNN1			0	95.23	Tocris	4311	GW 542573X	364.2	COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C	SAXGSDIZIYFNKD-UHFFFAOYSA-N	24885053.0		SAXGSDIZIYFNKD
BRD-K79930101-300-05-9	GW-583340	Preclinical	EGFR inhibitor	EGFR|ERBB2			0	94.85	Tocris	2239	GW 583340 dihydrochloride	597.107	CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	MNNXRVSQOABRRP-UHFFFAOYSA-N	5329480.0		MNNXRVSQOABRRP
BRD-K79930101-300-04-5	GW-583340	Preclinical	EGFR inhibitor	EGFR|ERBB2			0	93.17	Tocris	2239	GW 583340 dihydrochloride	597.107	CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	MNNXRVSQOABRRP-UHFFFAOYSA-N	5329480.0		MNNXRVSQOABRRP
BRD-K79930101-300-03-7	GW-583340	Preclinical	EGFR inhibitor	EGFR|ERBB2			0	89.75	Tocris	2239	GW 583340 dihydrochloride	597.107	CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	MNNXRVSQOABRRP-UHFFFAOYSA-N	5329480.0		MNNXRVSQOABRRP
BRD-K50005760-001-02-9	GW-627368	Preclinical	prostanoid receptor antagonist	PTGER4			0	97.78	Tocris	4668	GW 627368	544.167	CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1	XREWXJVMYAXCJV-UHFFFAOYSA-N	5312130.0		XREWXJVMYAXCJV
BRD-K50005760-001-01-1	GW-627368	Preclinical	prostanoid receptor antagonist	PTGER4			0	99.49	Tocris	4668	GW 627368	544.167	CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1	XREWXJVMYAXCJV-UHFFFAOYSA-N	5312130.0		XREWXJVMYAXCJV
BRD-K20828910-001-03-9	GW-6471	Preclinical	PPAR receptor antagonist	PPARA			0	94.98	Tocris	4618	GW 6471	619.266	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	TYEFSRMOUXWTDN-DYQICHDWSA-N	446738.0		TYEFSRMOUXWTDN
BRD-K20828910-001-02-0	GW-6471	Preclinical	PPAR receptor antagonist	PPARA			0	97.24	Tocris	4618	GW 6471	619.266	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	TYEFSRMOUXWTDN-DYQICHDWSA-N	446738.0		TYEFSRMOUXWTDN
BRD-K20828910-001-01-2	GW-6471	Preclinical	PPAR receptor antagonist	PPARA			0	97.07	Tocris	4618	GW 6471	619.266	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	TYEFSRMOUXWTDN-DYQICHDWSA-N	446738.0		TYEFSRMOUXWTDN
BRD-K96263742-001-15-5	GW-7647	Preclinical	PPAR receptor agonist	PPARA			0	96.23	Tocris	1677	GW 7647	502.323	CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	PKNYXWMTHFMHKD-UHFFFAOYSA-N	3392731.0		PKNYXWMTHFMHKD
BRD-K96263742-001-16-9	GW-7647	Preclinical	PPAR receptor agonist	PPARA			0	94.69	Tocris	1677	GW 7647	502.323	CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	PKNYXWMTHFMHKD-UHFFFAOYSA-N	3392731.0		PKNYXWMTHFMHKD
BRD-K96263742-001-14-8	GW-7647	Preclinical	PPAR receptor agonist	PPARA			0	97.97	Tocris	1677	GW 7647	502.323	CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	PKNYXWMTHFMHKD-UHFFFAOYSA-N	3392731.0		PKNYXWMTHFMHKD
BRD-K78086729-001-03-5	GW-788388	Preclinical	ALK tyrosine kinase receptor inhibitor	LCK|MAPK14|TGFBR1			0	88.33	Tocris	3264	GW 788388	425.185	O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	SAGZIBJAQGBRQA-UHFFFAOYSA-N	10202642.0		SAGZIBJAQGBRQA
BRD-K78086729-001-04-9	GW-788388	Preclinical	ALK tyrosine kinase receptor inhibitor	LCK|MAPK14|TGFBR1			0	97.82	Tocris	3264	GW 788388	425.185	O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	SAGZIBJAQGBRQA-UHFFFAOYSA-N	10202642.0		SAGZIBJAQGBRQA
BRD-K78086729-001-02-7	GW-788388	Preclinical	ALK tyrosine kinase receptor inhibitor	LCK|MAPK14|TGFBR1			0	95.0	Selleck	S2750	GW788388	425.185	O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	SAGZIBJAQGBRQA-UHFFFAOYSA-N	10202642.0		SAGZIBJAQGBRQA
BRD-K65576800-001-01-6	GW-803430	Phase 1	melanin inhibitor	KCNH2|MCHR1			0	93.27	Tocris	4242	6-(4-chlorophenyl)-3-{3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl}thieno[3,2-d]pyrimidin-4(3H)-one	481.123	COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1	MWULMTACIBZPGN-UHFFFAOYSA-N	9826520.0		MWULMTACIBZPGN
BRD-K26823213-001-03-9	GW-842166	Phase 2	cannabinoid receptor agonist	CNR2			0	96.07	MedChemEx	HY-14167	GW842166X	448.068	FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	TWQYWUXBZHPIIV-UHFFFAOYSA-N	10253143.0		TWQYWUXBZHPIIV
BRD-K26823213-001-02-9	GW-842166	Phase 2	cannabinoid receptor agonist	CNR2			0	97.52	Selleck	S2778	GW842166X	448.068	FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	TWQYWUXBZHPIIV-UHFFFAOYSA-N	10253143.0		TWQYWUXBZHPIIV
BRD-K90382497-001-10-7	GW-843682X	Preclinical	PLK inhibitor	PLK1|PLK3			0	98.98	Tocris	2977	GW 843682X	477.097	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	JSKUWFIZUALZLX-UHFFFAOYSA-N	9826308.0		JSKUWFIZUALZLX
BRD-K90382497-001-14-9	GW-843682X	Preclinical	PLK inhibitor	PLK1|PLK3			0	97.9	Tocris	2977	GW 843682X	477.097	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	JSKUWFIZUALZLX-UHFFFAOYSA-N	9826308.0		JSKUWFIZUALZLX
BRD-K90382497-001-13-1	GW-843682X	Preclinical	PLK inhibitor	PLK1|PLK3			0	97.59	Tocris	2977	GW 843682X	477.097	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	JSKUWFIZUALZLX-UHFFFAOYSA-N	9826308.0		JSKUWFIZUALZLX
BRD-K71534238-001-12-6	GW-9508	Preclinical	free fatty acid receptor agonist|G protein-coupled receptor agonist	FFAR1|FFAR4			0	94.14	Tocris	2649	GW 9508	347.152	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	DGENZVKCTGIDRZ-UHFFFAOYSA-N	11595431.0		DGENZVKCTGIDRZ
BRD-K71534238-001-11-8	GW-9508	Preclinical	free fatty acid receptor agonist|G protein-coupled receptor agonist	FFAR1|FFAR4			0	90.01	Tocris	2649	GW 9508	347.152	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	DGENZVKCTGIDRZ-UHFFFAOYSA-N	11595431.0		DGENZVKCTGIDRZ
BRD-K71534238-001-13-9	GW-9508	Preclinical	free fatty acid receptor agonist|G protein-coupled receptor agonist	FFAR1|FFAR4			0	94.17	Tocris	2649	GW 9508	347.152	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	DGENZVKCTGIDRZ-UHFFFAOYSA-N	11595431.0		DGENZVKCTGIDRZ
BRD-K71534238-001-10-0	GW-9508	Preclinical	free fatty acid receptor agonist|G protein-coupled receptor agonist	FFAR1|FFAR4			0	90.37	Selleck	S8014	GW9508	347.152	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	DGENZVKCTGIDRZ-UHFFFAOYSA-N	11595431.0		DGENZVKCTGIDRZ
BRD-K93258693-001-19-9	GW-9662	Preclinical	PPAR receptor antagonist	NCOA2|PPARG|RXRA			0	97.3	Tocris	1508	GW 9662	276.03	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	DNTSIBUQMRRYIU-UHFFFAOYSA-N	644213.0		DNTSIBUQMRRYIU
BRD-K93258693-001-16-5	GW-9662	Preclinical	PPAR receptor antagonist	NCOA2|PPARG|RXRA			0	97.21	Selleck	S2915	GW9662	276.03	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	DNTSIBUQMRRYIU-UHFFFAOYSA-N	644213.0		DNTSIBUQMRRYIU
BRD-K93258693-001-17-3	GW-9662	Preclinical	PPAR receptor antagonist	NCOA2|PPARG|RXRA			0	98.73	Tocris	1508	GW 9662	276.03	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	DNTSIBUQMRRYIU-UHFFFAOYSA-N	644213.0		DNTSIBUQMRRYIU
BRD-K65840970-001-02-9	GW274150	Phase 2	nitric oxide synthase inhibitor				0	0.0	MedChemEx	HY-12119	GW274150	219.104	CC(=N)NCCSCC[C@H](N)C(O)=O	MOLOJNHYNHBPCW-ZETCQYMHSA-N	9797017.0		MOLOJNHYNHBPCW
BRD-K24240364-003-09-6	GYKI-52466	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	68.47	Tocris	1454	GYKI 52466 dihydrochloride	293.116	CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|	LFBZZHVSGAHQPP-UHFFFAOYSA-N	3538.0		LFBZZHVSGAHQPP
BRD-K24240364-003-08-8	GYKI-52466	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	71.41	Tocris	1454	GYKI 52466 hydrochloride	293.116	CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|	LFBZZHVSGAHQPP-UHFFFAOYSA-N	3538.0		LFBZZHVSGAHQPP
BRD-K24240364-003-02-1	GYKI-52466	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0		Tocris	1454	GYKI 52466 hydrochloride	293.116	CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1,3|	InChI=1S/C17H15N3O2/c1-10-6-12-7-15-16(22-9-21-15)8-14(12)17(20-19-10)11-2-4-13(18)5-3-11/h2-5,7-8H,6,9,18H2,1H3	3538.0		LFBZZHVSGAHQPP
BRD-K58775955-001-04-9	gynostemma-extract	Phase 2	calcium channel modulator				0	0.0	MedChemEx	HY-N0167	Gynostemma Extract	916.54	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	ZTQSADJAYQOCDD-HUGMCNGHSA-N	46887681.0		ZTQSADJAYQOCDD
BRD-K58775955-001-02-4	gynostemma-extract	Phase 2	calcium channel modulator				0	2.21	Selleck	S2306	Gynostemma Extract	916.54	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	ZTQSADJAYQOCDD-HUGMCNGHSA-N	46887681.0		ZTQSADJAYQOCDD
BRD-K58775955-001-03-2	gynostemma-extract	Phase 2	calcium channel modulator				0	1.7	Selleck	S2306	Gynostemma Extract	916.54	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	ZTQSADJAYQOCDD-HUGMCNGHSA-N	46887681.0	BRD-K75189747-001-01-2	ZTQSADJAYQOCDD
BRD-K35329391-334-01-7	GZD824	Preclinical	Bcr-Abl kinase inhibitor	ABL1|BCR			0	96.81	Selleck	S7194	GZD824	532.22	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1	TZKBVRDEOITLRB-UHFFFAOYSA-N	51038269.0		TZKBVRDEOITLRB
BRD-K35329391-334-02-5	GZD824	Preclinical	Bcr-Abl kinase inhibitor	ABL1|BCR			0	96.18	Selleck	S7194	GZD824 dimesylate	532.22	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1	TZKBVRDEOITLRB-UHFFFAOYSA-N	51038269.0		TZKBVRDEOITLRB
BRD-K12198961-001-01-8	G007-LK	Preclinical	tankyrase inhibitor	TNKS|TNKS2			0	97.94	MedChemEx	HY-12438	G007-LK	529.072	CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl	HIWVLHPKZNBSBE-OUKQBFOZSA-N	67960134.0		HIWVLHPKZNBSBE
BRD-K00005333-001-01-9	H-151	Preclinical	STING antagonist				0	84.87	MedChemEx	HY-112693	H-151	279.137	CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1	UJZDIKVQFMCLBE-UHFFFAOYSA-N	7616033.0		UJZDIKVQFMCLBE
BRD-K27737647-300-03-0	H-89	Preclinical	PKA inhibitor	GSG2|PKIA|PRKACA			0	97.93	Selleck	S1582	H 89 2HCl	445.046	Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	ZKZXNDJNWUTGDK-NSCUHMNNSA-N	449241.0		ZKZXNDJNWUTGDK
BRD-K27737647-300-04-8	H-89	Preclinical	PKA inhibitor	GSG2|PKIA|PRKACA			0	94.99	Tocris	2910	H 89 dihydrochloride	445.046	Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	ZKZXNDJNWUTGDK-NSCUHMNNSA-N	449241.0		ZKZXNDJNWUTGDK
BRD-K27737647-300-08-9	H-89	Preclinical	PKA inhibitor	GSG2|PKIA|PRKACA			0	96.14	Tocris	2910	H 89 dihydrochloride	445.046	Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	ZKZXNDJNWUTGDK-NSCUHMNNSA-N	449241.0		ZKZXNDJNWUTGDK
BRD-K05434375-001-06-5	HA-1004	Phase 2	calcium channel blocker				0	98.82	Enzo	EI184	HA-1004	293.095	NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12	MZNDNBFMSVMUCX-UHFFFAOYSA-N	3546.0		MZNDNBFMSVMUCX
BRD-K64452997-001-01-4	HA-130	Preclinical	autotaxin inhibitor	ENPP2			0	90.3	Tocris	4196	HA 130	463.106	OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1	VTNKMYWFWQTEHE-XKZIYDEJSA-N	46911532.0		VTNKMYWFWQTEHE
BRD-K64452997-001-02-9	HA-130	Preclinical	autotaxin inhibitor	ENPP2			0	97.61	Tocris	4196	HA 130	463.106	OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1	VTNKMYWFWQTEHE-XKZIYDEJSA-N	46911532.0		VTNKMYWFWQTEHE
BRD-K58046914-001-03-8	HA-966-(R)-(+)	Preclinical	glutamate receptor agonist	GRIA1			0	100.0	Tocris	281	(R)-(+)-HA-966	116.059	N[C@@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-GSVOUGTGSA-N	6603720.0		HCKUBNLZMKAEIN
BRD-K58046914-001-04-9	HA-966-(R)-(+)	Preclinical	glutamate receptor agonist	GRIA1			0	100.0	Tocris	281	(R)-(+)-HA-966	116.059	N[C@@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-GSVOUGTGSA-N	6603720.0		HCKUBNLZMKAEIN
BRD-K41304947-001-03-2	HA-966-(S)-(-)	Preclinical	glutamate receptor antagonist	GRIA1			0	100.0	Tocris	282	(S)-(-)-HA-966	116.059	N[C@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-VKHMYHEASA-N	183351.0		HCKUBNLZMKAEIN
BRD-K41304947-001-04-9	HA-966-(S)-(-)	Preclinical	glutamate receptor antagonist	GRIA1			0	100.0	Tocris	282	(S)-(-)-HA-966	116.059	N[C@H]1CCN(O)C1=O	HCKUBNLZMKAEIN-VKHMYHEASA-N	183351.0		HCKUBNLZMKAEIN
BRD-K68091065-001-05-9	halazone	Launched			infectious disease	disinfectant	0	0.0	Sigma	MFCD00045858	p-(N,N-Dichlorosulfamyl)benzoic acid	268.932	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl	XPDVQPODLRGWPL-UHFFFAOYSA-N	3552.0		XPDVQPODLRGWPL
BRD-K68091065-001-04-7	halazone	Launched			infectious disease	disinfectant	0	0.0	MicroSource	1500324	HALAZONE	268.932	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl	XPDVQPODLRGWPL-UHFFFAOYSA-N	3552.0		XPDVQPODLRGWPL
BRD-K81709173-001-11-9	halcinonide	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	83.69	MedChemEx	HY-B0877	Halcinonide	454.192	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|	MUQNGPZZQDCDFT-JNQJZLCISA-N	443943.0		MUQNGPZZQDCDFT
BRD-K81709173-001-09-5	halcinonide	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	93.96	Selleck	S4098	Halcinonide	454.192	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|	MUQNGPZZQDCDFT-JNQJZLCISA-N	443943.0	BRD-K64408465-001-01-9	MUQNGPZZQDCDFT
BRD-K81709173-001-10-3	halcinonide	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	91.01	Selleck	S4098	HALCINONIDE	454.192	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|	MUQNGPZZQDCDFT-JNQJZLCISA-N	443943.0		MUQNGPZZQDCDFT
BRD-K71487404-001-01-8	halobetasol-propionate	Launched	glucocorticoid receptor agonist	NR3C1|PLA2G1B	dermatology	corticosteroid-responsive dermatoses	0	88.69	Selleck	S4089	Halobetasol Propionate	484.183	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18,t:14|	BDSYKGHYMJNPAB-LICBFIPMSA-N	6918178.0		BDSYKGHYMJNPAB
BRD-A51964809-003-12-6	halofantrine	Launched	antimalarial agent	KCNN4	infectious disease	malaria	0	89.55	Enzo	AC2004	Halofantrine HCl	499.166	CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|	FOHHNHSLJDZUGQ-RUZDIDTESA-N	36688213.0		FOHHNHSLJDZUGQ
BRD-A51964809-003-13-9	halofantrine	Launched	antimalarial agent	KCNN4	infectious disease	malaria	0	98.32	MedChemEx	HY-A0148A	Halofantrine hydrochloride	499.166	CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|	FOHHNHSLJDZUGQ-RUZDIDTESA-N	36688213.0		FOHHNHSLJDZUGQ
BRD-K54247840-004-01-3	halofuginone	Launched	collagenase inhibitor	COL1A1|MMP2	rheumatology	scleroderma	0	95.58	EMDBio	505763-10MG	ProRS Inhibitor, Halofuginone	413.014	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	LVASCWIMLIKXLA-CABCVRRESA-N	456390.0		LVASCWIMLIKXLA
BRD-K50055394-001-03-6	halopemide	Phase 2	phospholipase inhibitor	PLD1|PLD2			0	97.2	Sigma	H3041	N-{2-[4-(5-chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl}-4-fluorobenzamide	416.142	Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O	NBHPRWLFLUBAIE-UHFFFAOYSA-N	65490.0		NBHPRWLFLUBAIE
BRD-K67783091-003-07-7	haloperidol	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4|DRD5|GRIN2B|HRH1|HTR1A|HTR1D|HTR2A|HTR2B|HTR7|KCNH1	neurology/psychiatry	schizophrenia|Tourette's disorder	0	98.55	Tocris	931	Haloperidol hydrochloride	375.14	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	LNEPOXFFQSENCJ-UHFFFAOYSA-N	3559.0		LNEPOXFFQSENCJ
BRD-K67783091-001-25-3	haloperidol	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4|DRD5|GRIN2B|HRH1|HTR1A|HTR1D|HTR2A|HTR2B|HTR7|KCNH1	neurology/psychiatry	schizophrenia|Tourette's disorder	0	95.38	Selleck	S1920	Haloperidol	375.14	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	LNEPOXFFQSENCJ-UHFFFAOYSA-N	3559.0		LNEPOXFFQSENCJ
BRD-K67783091-001-26-1	haloperidol	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4|DRD5|GRIN2B|HRH1|HTR1A|HTR1D|HTR2A|HTR2B|HTR7|KCNH1	neurology/psychiatry	schizophrenia|Tourette's disorder	0	99.67	MicroSource	1500325	HALOPERIDOL	375.14	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	LNEPOXFFQSENCJ-UHFFFAOYSA-N	3559.0		LNEPOXFFQSENCJ
BRD-K80859331-001-01-5	haloperidol-decanoate	Launched	psychoactive drug	DRD2|DRD3|DRD4|HTR2A	neurology/psychiatry	schizophrenia	0	99.05	Key	KS-1419	4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl decanoate	529.276	CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	GUTXTARXLVFHDK-UHFFFAOYSA-N	52919.0		GUTXTARXLVFHDK
BRD-K13238168-001-02-0	haloprogin	Launched	other antifungal		infectious disease	tinea pedis	0	98.19	Prestwick	Prestw-1269	Haloprogin	359.837	Clc1cc(Cl)c(OCC#CI)cc1Cl	CTETYYAZBPJBHE-UHFFFAOYSA-N	3561.0		CTETYYAZBPJBHE
BRD-K13238168-001-03-9	haloprogin	Launched	other antifungal		infectious disease	tinea pedis	0		WuXi	EW21509-8-P1	Haloprogin	359.837	Clc1cc(Cl)c(OCC#CI)cc1Cl	CTETYYAZBPJBHE-UHFFFAOYSA-N	3561.0		CTETYYAZBPJBHE
BRD-A20550616-001-02-9	halothane	Launched	glutamate receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK12|KCNK13|KCNK15|KCNK18|KCNK2|KCNK3|KCNK9	neurology/psychiatry	general anaesthetic	1	0.0	MicroSource	1505434	HALOTHANE	195.89	FC(F)(F)[C@@H](Cl)Br |&1:4,r|	BCQZXOMGPXTTIC-PVQJCKRUSA-N	4369439.0		BCQZXOMGPXTTIC
BRD-A20550616-001-03-7	halothane	Launched	glutamate receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK12|KCNK13|KCNK15|KCNK18|KCNK2|KCNK3|KCNK9	neurology/psychiatry	general anaesthetic	1	0.0	MedChemEx	HY-B1010	Halothane	195.89	FC(F)(F)[C@@H](Cl)Br |&1:4,r|	BCQZXOMGPXTTIC-PVQJCKRUSA-N	4369439.0		BCQZXOMGPXTTIC
BRD-K12630395-001-14-9	harmane	Preclinical	monoamine oxidase inhibitor	MAOA|MAOB			0	97.3	Tocris	1132	Harmane hydrochloride	182.084	Cc1nccc2c3ccccc3[nH]c12	PSFDQSOCUJVVGF-UHFFFAOYSA-N	5281404.0		PSFDQSOCUJVVGF
BRD-K00003715-001-01-9	harringtonine	Phase 3	protein synthesis inhibitor				0	79.53	MedChemEx	HY-N0862	Harringtonine	531.247	[H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|	HAVJATCHLFRDHY-KSZYUSJVSA-N	276389.0		HAVJATCHLFRDHY
BRD-K18163608-001-02-3	HA14-1	Preclinical	BCL inhibitor	BCL2			0	0.0	Selleck	S1071		408.032	CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|	SXJDCULZDFWMJC-AAEUAGOBSA-N	6976314.0		SXJDCULZDFWMJC
BRD-K18163608-001-05-6	HA14-1	Preclinical	BCL inhibitor	BCL2			0	95.14	Selleck	S1071		408.032	CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5,8,r,t:14|	SXJDCULZDFWMJC-AAEUAGOBSA-N	6976314.0		SXJDCULZDFWMJC
BRD-K00004555-001-01-9	HBED	Phase 3	chelating agent				0	77.96	Sigma	MFCD01311876	[{2-[(carboxymethyl)(2-hydroxybenzyl)amino]ethyl}(2-hydroxybenzyl)amino]acetic acid	388.163	OC(=O)CN(CCN(CC(O)=O)Cc1ccccc1O)Cc1ccccc1O	GRUVVLWKPGIYEG-UHFFFAOYSA-N	37336.0		GRUVVLWKPGIYEG
BRD-K73815512-001-03-9	HC-030031	Phase 1	TRPA1 channel blocker	TRPA1			0	88.94	Tocris	2896	HC 030031	355.164	CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	HEQDZPHDVAOBLN-UHFFFAOYSA-N	1150897.0		HEQDZPHDVAOBLN
BRD-K73815512-001-02-5	HC-030031	Phase 1	TRPA1 channel blocker	TRPA1			0	98.73	Selleck	S2918	HC-030031	355.164	CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	HEQDZPHDVAOBLN-UHFFFAOYSA-N	1150897.0		HEQDZPHDVAOBLN
BRD-K03391209-001-02-0	HC-067047	Preclinical	transient receptor potential channel antagonist	TRPV4			0	93.91	Tocris	4100	HC 067047	471.213	Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F	NCZYSQOTAYFTNM-UHFFFAOYSA-N	2742550.0		NCZYSQOTAYFTNM
BRD-K03391209-001-01-2	HC-067047	Preclinical	transient receptor potential channel antagonist	TRPV4			0	99.51	Tocris	4100	HC-067047	471.213	Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F	NCZYSQOTAYFTNM-UHFFFAOYSA-N	2742550.0		NCZYSQOTAYFTNM
BRD-K00004601-001-01-9	HC-070	Preclinical	transient receptor potential channel antagonist				0	96.18	MedChemEx	HY-112302	HC-070	474.086	Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O	VYJPVPHNGWEIBT-UHFFFAOYSA-N	85473309.0		VYJPVPHNGWEIBT
BRD-K49788188-001-01-0	heclin	Preclinical	ubiquitin ligase inhibitor	NEDD4|SMURF2|WWP1			0	91.97	Tocris	5433	Heclin	283.121	CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1	SPTWXRJNCFIDRQ-ZHACJKMWSA-N	7464118.0		SPTWXRJNCFIDRQ
BRD-K49788188-001-02-9	heclin	Preclinical	ubiquitin ligase inhibitor	NEDD4|SMURF2|WWP1			0	92.9	Tocris	5433	Heclin	283.121	CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1	SPTWXRJNCFIDRQ-ZHACJKMWSA-N	7464118.0		SPTWXRJNCFIDRQ
BRD-K34672903-001-02-5	HEMADO	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	96.56	Tocris	1579	HEMADO	361.175	CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	KOCIMZNSNPOGOP-IWCJZZDYSA-N	10981286.0		KOCIMZNSNPOGOP
BRD-K34672903-001-03-9	HEMADO	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	87.66	Tocris	1579	HEMADO	361.175	CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	KOCIMZNSNPOGOP-IWCJZZDYSA-N	10981286.0		KOCIMZNSNPOGOP
BRD-K34672903-001-01-7	HEMADO	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	95.63	Tocris	1579	HEMADO	361.175	CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	KOCIMZNSNPOGOP-IWCJZZDYSA-N	10981286.0		KOCIMZNSNPOGOP
BRD-K01825010-001-02-9	hematoporphyrin	Launched			neurology/psychiatry	depression|psychosis	0	16.61	Sigma	MFCD00005077	3,3'-(7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethylporphyrin-2,18-diyl)dipropionic acid	598.279	C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25,&2:1,r|	DWZDGMDDUHAIQA-XEAGYAAOSA-N			DWZDGMDDUHAIQA
BRD-K78342372-001-03-2	hematoxylin	Preclinical					0	94.58	Selleck	S2384	Hematoxylin (Hydroxybrazilin)	302.079	Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O	WZUVPPKBWHMQCE-XJKSGUPXSA-N	442514.0		WZUVPPKBWHMQCE
BRD-K78342372-001-02-4	hematoxylin	Preclinical					0	87.91	Selleck	S2384	Hematoxylin	302.079	Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O	WZUVPPKBWHMQCE-XJKSGUPXSA-N	442514.0		WZUVPPKBWHMQCE
BRD-K74057164-001-01-6	hemin	Launched	enzyme inducer		hematology|cardiology	acute intermittent porphyria (AIP)|hypertension|ventricular tachycardia (VT)	0	85.19	Sigma	H3281-1G	Hematin porcine	633.18	CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1,20,34,45,t:8,22,24,31|	BMUDPLZKKRQECS-HXFTUNQESA-K			BMUDPLZKKRQECS
BRD-K15231341-001-02-9	hemomex-s	Launched		PPARG			0	73.68	MedChemEx	HY-N0835	(20S)-Protopanaxatriol	476.387	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C	SHCBCKBYTHZQGZ-CJPZEJHVSA-N	11468733.0		SHCBCKBYTHZQGZ
BRD-K15231341-001-01-5	hemomex-s	Launched		PPARG			0	90.75	MedChemEx	HY-N0835	(20S)-Protopanaxatriol	476.387	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C	SHCBCKBYTHZQGZ-CJPZEJHVSA-N	11468733.0		SHCBCKBYTHZQGZ
BRD-K00004739-001-01-9	hepsulfam	Preclinical	DNA cross-linking				0	85.4	MedChemEx	HY-U00095	Hepsulfam	290.061	NS(=O)(=O)OCCCCCCCOS(N)(=O)=O	GOJJWDOZNKBUSR-UHFFFAOYSA-N	100606.0		GOJJWDOZNKBUSR
BRD-A32988684-003-08-7	heptaminol	Launched	vasoconstrictor		cardiology	hypotension	0	100.0	MicroSource	1503218	HEPTAMINOL HYDROCHLORIDE	145.147	C[C@@H](N)CCCC(C)(C)O |&1:1|	LREQLEBVOXIEOM-SSDOTTSWSA-N	7033975.0		LREQLEBVOXIEOM
BRD-A32988684-003-09-9	heptaminol	Launched	vasoconstrictor		cardiology	hypotension	0	100.0	MedChemEx	HY-B1231	Heptaminol (hydrochloride)	145.147	C[C@@H](N)CCCC(C)(C)O |&1:1|	LREQLEBVOXIEOM-SSDOTTSWSA-N	7033975.0		LREQLEBVOXIEOM
BRD-K89709433-001-03-9	HER2-Inhibitor-1	Preclinical	EGFR inhibitor				0	92.93	MedChemEx	HY-10531	ARRY-380 (analog )	569.185	Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1	QVMNYGOVNWWFKF-UHFFFAOYSA-N	42598643.0		QVMNYGOVNWWFKF
BRD-K89709433-001-02-8	HER2-Inhibitor-1	Preclinical	EGFR inhibitor				0	62.06	Selleck	S2752	HER2-Inhibitor-1	569.185	Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1	QVMNYGOVNWWFKF-UHFFFAOYSA-N	42598643.0		QVMNYGOVNWWFKF
BRD-K58122457-001-02-2	hesperadin	Preclinical	Aurora kinase inhibitor	AURKB			0	96.66	Selleck	S1529	Hesperadin	516.22	CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1	GLDSKRNGVVYJAB-DQSJHHFOSA-N			GLDSKRNGVVYJAB
BRD-K58122457-003-01-0	hesperadin	Preclinical	Aurora kinase inhibitor	AURKB			0	96.52	Tocris	3988	Hesperadin hydrochloride	516.22	CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1	GLDSKRNGVVYJAB-DQSJHHFOSA-N			GLDSKRNGVVYJAB
BRD-K58122457-003-03-9	hesperadin	Preclinical	Aurora kinase inhibitor	AURKB			0	78.95	Tocris	3988	Hesperadin hydrochloride	516.22	CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1	GLDSKRNGVVYJAB-DQSJHHFOSA-N			GLDSKRNGVVYJAB
BRD-K30553453-001-14-9	hesperetin	Launched	ACAT inhibitor	DGAT1|MTTP|SOAT1|SOAT2			0	97.23	MedChemEx	HY-N0168	Hesperetin	302.079	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	AIONOLUJZLIMTK-AWEZNQCLSA-N	72281.0		AIONOLUJZLIMTK
BRD-K30553453-001-13-2	hesperetin	Launched	ACAT inhibitor	DGAT1|MTTP|SOAT1|SOAT2			0	98.16	Selleck	S2308	Hesperetin	302.079	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	AIONOLUJZLIMTK-AWEZNQCLSA-N	72281.0		AIONOLUJZLIMTK
BRD-K38903228-001-11-9	hesperidin	Launched	flavanone glycoside	AURKB|CACNA1B			0	0.0	Selleck	S2323	Methyl-Hesperidin	610.19	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	QUQPHWDTPGMPEX-QJBIFVCTSA-N	10621.0	BRD-K43382661-001-02-2|BRD-M12718521-001-02-2	QUQPHWDTPGMPEX
BRD-K38903228-001-13-5	hesperidin	Launched	flavanone glycoside	AURKB|CACNA1B			0	90.93	Selleck	S2309	Hesperidin	610.19	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	QUQPHWDTPGMPEX-QJBIFVCTSA-N	10621.0	BRD-K53229386-001-04-2|BRD-K93633846-001-01-7	QUQPHWDTPGMPEX
BRD-K38903228-001-12-7	hesperidin	Launched	flavanone glycoside	AURKB|CACNA1B			0	0.0	Selleck	S2323	Methyl-Hesperidin	610.19	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	QUQPHWDTPGMPEX-QJBIFVCTSA-N	10621.0	BRD-K43382661-001-01-4|BRD-M45990714-001-01-7	QUQPHWDTPGMPEX
BRD-K38903228-001-14-9	hesperidin	Launched	flavanone glycoside	AURKB|CACNA1B			0	91.49	MedChemEx	HY-15337	Hesperidin	610.19	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	QUQPHWDTPGMPEX-QJBIFVCTSA-N	10621.0		QUQPHWDTPGMPEX
BRD-K00005353-001-01-9	hetacillin	Launched	bacterial cell wall synthesis inhibitor		obstetrics/gynecology	mastitis	0	62.75	Toronto	h289570	hetacillin	389.141	CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O	DXVUYOAEDJXBPY-NFFDBFGFSA-N	443387.0		DXVUYOAEDJXBPY
BRD-K99792991-001-34-9	hexachlorophene	Launched	potassium channel activator	GLUD1|SDHD	infectious disease	gram-positive bacterial infections	0	98.49	MicroSource	1500328	HEXACHLOROPHENE	403.85	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	ACGUYXCXAPNIKK-UHFFFAOYSA-N	3598.0		ACGUYXCXAPNIKK
BRD-K99792991-001-36-9	hexachlorophene	Launched	potassium channel activator	GLUD1|SDHD	infectious disease	gram-positive bacterial infections	0	97.85	MedChemEx	HY-12637	Hexachlorophene	403.85	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	ACGUYXCXAPNIKK-UHFFFAOYSA-N	3598.0		ACGUYXCXAPNIKK
BRD-K10598093-303-08-9	hexamethonium	Preclinical	cholinergic receptor antagonist	CHRNA2|CHRNA3|CHRNA4|CHRNA6			0	89.6	MedChemEx	HY-B0569	Hexamethonium (Bromide)	202.241	C[N+](C)(C)CCCCCC[N+](C)(C)C	VZJFGSRCJCXDSG-UHFFFAOYSA-N	3604.0		VZJFGSRCJCXDSG
BRD-K10598093-303-06-1	hexamethonium	Preclinical	cholinergic receptor antagonist	CHRNA2|CHRNA3|CHRNA4|CHRNA6			0	79.0	MicroSource	1503297	HEXAMETHONIUM BROMIDE	202.241	C[N+](C)(C)CCCCCC[N+](C)(C)C	VZJFGSRCJCXDSG-UHFFFAOYSA-N	3604.0		VZJFGSRCJCXDSG
BRD-K10598093-303-05-3	hexamethonium	Preclinical	cholinergic receptor antagonist	CHRNA2|CHRNA3|CHRNA4|CHRNA6			0	78.12	Selleck	S4069	Hexamethonium bromide	202.241	C[N+](C)(C)CCCCCC[N+](C)(C)C	VZJFGSRCJCXDSG-UHFFFAOYSA-N	3604.0		VZJFGSRCJCXDSG
BRD-K10598093-303-07-9	hexamethonium	Preclinical	cholinergic receptor antagonist	CHRNA2|CHRNA3|CHRNA4|CHRNA6			0	100.0	Selleck	S4069	Hexamethonium Bromide	202.241	C[N+](C)(C)CCCCCC[N+](C)(C)C	VZJFGSRCJCXDSG-UHFFFAOYSA-N	3604.0		VZJFGSRCJCXDSG
BRD-K04710043-001-17-8	hexamethylenebisacetamide	Phase 2	AKT inhibitor|differentiation inducer|NFKB pathway inhibitor	AKT1			0	87.14	Sigma	MFCD00008684	N-[6-(acetylamino)hexyl]acetamide	200.152	CC(=O)NCCCCCCNC(C)=O	BNQSTAOJRULKNX-UHFFFAOYSA-N	3616.0		BNQSTAOJRULKNX
BRD-K73753850-003-01-6	hexaminolevulinate	Launched			radiology	diagnostic agent	0	100.0	MedChemEx	HY-16045	Hexaminolevulinate (hydrochloride)	215.152	CCCCCCOC(=O)CCC(=O)CN	RYQOILLJDKPETL-UHFFFAOYSA-N	6433083.0		RYQOILLJDKPETL
BRD-K70007857-001-01-7	hexasodium-phytate	Phase 2					0	0.0	TCI	P0409		659.861	OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O	IMQLKJBTEOYOSI-GPIVLXJGSA-N			IMQLKJBTEOYOSI
BRD-K69253806-001-02-0	hexestrol	Launched	synthetic estrogen	AKR1C1|ESR1|ESR2	endocrinology	hypoestrogenism	0	79.91	Selleck	S2473	Hexestrol	270.162	CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1	PBBGSZCBWVPOOL-HDICACEKSA-N	192197.0		PBBGSZCBWVPOOL
BRD-K69253806-001-03-8	hexestrol	Launched	synthetic estrogen	AKR1C1|ESR1|ESR2	endocrinology	hypoestrogenism	0	90.48	Selleck	S2473	Hexestrol (Bibenzyl)	270.162	CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1	PBBGSZCBWVPOOL-HDICACEKSA-N	192197.0		PBBGSZCBWVPOOL
BRD-K69253806-001-05-3	hexestrol	Launched	synthetic estrogen	AKR1C1|ESR1|ESR2	endocrinology	hypoestrogenism	0	96.98	Selleck	S2473	HEXESTROL	270.162	CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1	PBBGSZCBWVPOOL-HDICACEKSA-N	192197.0		PBBGSZCBWVPOOL
BRD-A18605525-001-12-4	hexetidine	Launched	local anesthetic		otolaryngology|infectious disease|dental|gastroenterology	pharyngitis|meningitis|laryngitis|gingivitis|ulcerative colitis	0	25.25	MicroSource	1500633	HEXETIDINE	339.361	CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|	DTOUUUZOYKYHEP-AERCQKQUSA-N			DTOUUUZOYKYHEP
BRD-A18605525-001-13-2	hexetidine	Launched	local anesthetic		otolaryngology|infectious disease|dental|gastroenterology	pharyngitis|meningitis|laryngitis|gingivitis|ulcerative colitis	0	2.74	MedChemEx	HY-B0996	Hexetidine	339.361	CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|	DTOUUUZOYKYHEP-AERCQKQUSA-N			DTOUUUZOYKYHEP
BRD-A18605525-001-14-0	hexetidine	Launched	local anesthetic		otolaryngology|infectious disease|dental|gastroenterology	pharyngitis|meningitis|laryngitis|gingivitis|ulcerative colitis	0	0.0	MedChemEx	HY-B0996	Hexetidine	339.361	CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12,&2:4,&3:20,r|	DTOUUUZOYKYHEP-AERCQKQUSA-N			DTOUUUZOYKYHEP
BRD-A63267145-001-01-0	hexonic-acid	Preclinical					0	90.83	Sigma	MFCD00067379		196.058	OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|	RGHNJXZEOKUKBD-TXICZTDVSA-N	5311443.0	BRD-M98748937-001-01-6	RGHNJXZEOKUKBD
BRD-A63267145-001-02-9	hexonic-acid	Preclinical					0	100.0	AMS	A000002878	hexonic acid	196.058	OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2,&2:4,&3:6,&4:8,r|	RGHNJXZEOKUKBD-TXICZTDVSA-N	5311443.0		RGHNJXZEOKUKBD
BRD-A33894669-065-01-9	hexoprenaline	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma	0	79.95	Carbosynth	HEXOPRENALINE SULPHATE	sulfuric acid compound with 4-{2-[(6-{[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino}hexyl)amino]-1-hydroxyethyl}-1,2-benzenediol (1:1)	420.226	O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1,&2:12|	OXLZNBCNGJWPRV-SZPZYZBQSA-N	24993924.0		OXLZNBCNGJWPRV
BRD-A97730597-003-11-5	hexylcaine	Launched	sodium channel blocker	SCN5A	neurology/psychiatry	local anesthetic	0	96.16	Prestwick	Prestw-788	Hexylcaine hydrochloride	261.173	C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|	DKLKMKYDWHYZTD-ZDUSSCGKSA-N	6604266.0		DKLKMKYDWHYZTD
BRD-A97730597-003-12-9	hexylcaine	Launched	sodium channel blocker	SCN5A	neurology/psychiatry	local anesthetic	0	88.49	Toronto	h295690	hexylcaine hydrochloride	261.173	C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|	DKLKMKYDWHYZTD-ZDUSSCGKSA-N	6604266.0		DKLKMKYDWHYZTD
BRD-A14234430-001-01-4	hexylene-glycol	Preclinical		AKR1C3|CTPS1|DLG4|HSP90AA1|NOS3|PGF|PLA2G1B|PTPN1|SELP			0	15.17	MicroSource	1506161	HEXYLENE GLYCOL	118.099	C[C@@H](O)CC(C)(C)O |&1:1,r|	SVTBMSDMJJWYQN-RXMQYKEDSA-N	5288845.0		SVTBMSDMJJWYQN
BRD-A14234430-001-02-9	hexylene-glycol	Preclinical		AKR1C3|CTPS1|DLG4|HSP90AA1|NOS3|PGF|PLA2G1B|PTPN1|SELP			0	0.0	MedChemEx	HY-B0903	Hexylene glycol	118.099	C[C@@H](O)CC(C)(C)O |&1:1,r|	SVTBMSDMJJWYQN-RXMQYKEDSA-N	5288845.0		SVTBMSDMJJWYQN
BRD-K99946902-001-09-9	hexylresorcinol	Launched	local anesthetic	TYR	infectious disease	skin infections|first-aid antiseptic	0	97.28	MedChemEx	HY-B0986	Hexylresorcinol	194.131	CCCCCCc1ccc(O)cc1O	WFJIVOKAWHGMBH-UHFFFAOYSA-N	3610.0		WFJIVOKAWHGMBH
BRD-K99946902-001-07-5	hexylresorcinol	Launched	local anesthetic	TYR	infectious disease	skin infections|first-aid antiseptic	0	98.8	MicroSource	1500330	HEXYLRESORCINOL	194.131	CCCCCCc1ccc(O)cc1O	WFJIVOKAWHGMBH-UHFFFAOYSA-N	3610.0		WFJIVOKAWHGMBH
BRD-A55204514-003-01-2	higenamine	Phase 1	adrenergic receptor agonist	ADRB2			0	94.65	Accela	SY029900	1-(4-hydroxybenzyl)-1,2,3,4-tetrahydro-6,7-isoquinolinediol hydrochloride	271.121	Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|	WZRCQWQRFZITDX-CQSZACIVSA-N	440988.0		WZRCQWQRFZITDX
BRD-K62914667-001-13-9	hippuric-acid	Preclinical					0	97.62	CombiBlocks	QE-9843	(benzoylamino)acetic acid	179.058	OC(=O)CNC(=O)c1ccccc1	QIAFMBKCNZACKA-UHFFFAOYSA-N	464.0		QIAFMBKCNZACKA
BRD-K01674964-300-10-5	histamine	Launched	histamine receptor agonist	HRH1|HRH2|HRH3|HRH4	allergy	allergic rhinitis	0	80.8	Tocris	3545	Histamine dihydrochloride	111.08	NCCc1cnc[nH]1	NTYJJOPFIAHURM-UHFFFAOYSA-N	774.0		NTYJJOPFIAHURM
BRD-K01674964-300-07-1	histamine	Launched	histamine receptor agonist	HRH1|HRH2|HRH3|HRH4	allergy	allergic rhinitis	0	96.86	Tocris	3545	Histamine dihydrochloride	111.08	NCCc1cnc[nH]1	NTYJJOPFIAHURM-UHFFFAOYSA-N	774.0		NTYJJOPFIAHURM
BRD-K01674964-001-19-0	histamine	Launched	histamine receptor agonist	HRH1|HRH2|HRH3|HRH4	allergy	allergic rhinitis	0	0.0	Selleck	S4117	Histamine Phosphate	111.08	NCCc1cnc[nH]1	NTYJJOPFIAHURM-UHFFFAOYSA-N	774.0	BRD-U61402069-000-01-5	NTYJJOPFIAHURM
BRD-K01674964-300-08-9	histamine	Launched	histamine receptor agonist	HRH1|HRH2|HRH3|HRH4	allergy	allergic rhinitis	0	99.36	MicroSource	1500331	HISTAMINE DIHYDROCHLORIDE	111.08	NCCc1cnc[nH]1	NTYJJOPFIAHURM-UHFFFAOYSA-N	774.0		NTYJJOPFIAHURM
BRD-K01674964-316-01-0	histamine	Launched	histamine receptor agonist	HRH1|HRH2|HRH3|HRH4	allergy	allergic rhinitis	0	0.0	Selleck	S4117	Histamine Phosphate	111.08	NCCc1cnc[nH]1	NTYJJOPFIAHURM-UHFFFAOYSA-N	774.0		NTYJJOPFIAHURM
BRD-K01674964-300-06-3	histamine	Launched	histamine receptor agonist	HRH1|HRH2|HRH3|HRH4	allergy	allergic rhinitis	0	100.0	Selleck	S4118	Histamine 2HCl	111.08	NCCc1cnc[nH]1	NTYJJOPFIAHURM-UHFFFAOYSA-N	774.0		NTYJJOPFIAHURM
BRD-K34411045-001-02-9	HJC-0350	Preclinical	GTPase inhibitor	RAPGEF4			0	94.55	Tocris	4844	HJC 0350	277.114	Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C	AFZWZVLPIMHLSE-UHFFFAOYSA-N	22200891.0		AFZWZVLPIMHLSE
BRD-K34411045-001-01-9	HJC-0350	Preclinical	GTPase inhibitor	RAPGEF4			0	95.86	Tocris	4844	HJC 0350	277.114	Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C	AFZWZVLPIMHLSE-UHFFFAOYSA-N	22200891.0		AFZWZVLPIMHLSE
BRD-K58811567-001-01-9	HKI-357	Phase 1	EGFR inhibitor	EGFR			0	98.23	Tocris	3580	(E)-N-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide	573.194	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	NERXPXBELDBEPZ-RMKNXTFCSA-N	11238512.0		NERXPXBELDBEPZ
BRD-K58811567-001-02-7	HKI-357	Phase 1	EGFR inhibitor	EGFR			0	91.15	Tocris	3580	HKI 357	573.194	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	NERXPXBELDBEPZ-RMKNXTFCSA-N	11238512.0		NERXPXBELDBEPZ
BRD-K73746696-003-01-8	HLCL-61	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT5			0	95.64	MedChemEx	HY-100025A	HLCL-61 (hydrochloride)	344.189	CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12	FIOIJUCPVZEPFX-UHFFFAOYSA-N	2250650.0		FIOIJUCPVZEPFX
BRD-K74319597-001-02-9	HM-30181	Phase 1	P glycoprotein inhibitor				0	51.49	MedChemEx	HY-13646	Encequidar	688.265	COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC	AHJUHHDDCJQACA-UHFFFAOYSA-N	11399764.0		AHJUHHDDCJQACA
BRD-K70511574-001-06-9	HMN-214	Phase 1	PLK inhibitor	PLK1			0	90.91	Selleck	S1485	HMN-214	424.109	COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1	OCKHRKSTDPOHEN-BQYQJAHWSA-N	9888590.0		OCKHRKSTDPOHEN
BRD-K00003598-001-01-9	HOKU-81	Preclinical	bronchodilator				0	95.17	MedChemEx	HY-50291	HOKU-81	243.103	CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl |r|	LIXBJWRFCNRAPA-NSHDSACASA-N	3045414.0		LIXBJWRFCNRAPA
BRD-K01826529-004-11-9	homatropine	Launched	acetylcholine receptor antagonist	CHRM1	ophthalmology	uveal tract inflammation|pupil dilation	0	87.22	MedChemEx	HY-B0547A	Homatropine (Bromide)	275.152	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	ZTVIKZXZYLEVOL-YJNKXOJESA-N			ZTVIKZXZYLEVOL
BRD-K01826529-004-10-9	homatropine	Launched	acetylcholine receptor antagonist	CHRM1	ophthalmology	uveal tract inflammation|pupil dilation	0	93.54	MicroSource	1500332	HOMATROPINE HYDROBROMIDE	355.078	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	ZTVIKZXZYLEVOL-YJNKXOJESA-N		BRD-A09539288-004-04-4	ZTVIKZXZYLEVOL
BRD-K01826529-004-09-9	homatropine	Launched	acetylcholine receptor antagonist	CHRM1	ophthalmology	uveal tract inflammation|pupil dilation	0	90.73	Selleck	S4025	Homatropine Bromide	355.078	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2,5,7,&1:12,THB:9:7:1:3.4|	ZTVIKZXZYLEVOL-YJNKXOJESA-N		BRD-A35196708-004-01-9	ZTVIKZXZYLEVOL
BRD-A54234250-004-02-9	homatropine-methylbromide	Launched	acetylcholine receptor antagonist	CHRM5	ophthalmology	uveal tract inflammation	0	97.64	MedChemEx	HY-B1388	Homatropine methylbromide	290.176	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3,6,8,&1:13,THB:10:8:1:4.5|	WKWOJBUWWZTUQV-JJXSEGSLSA-N			WKWOJBUWWZTUQV
BRD-K28354016-004-11-7	homidium	Preclinical					0	69.09	MicroSource	1503806	HOMIDIUM BROMIDE	314.166	CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	QTANTQQOYSUMLC-UHFFFAOYSA-O	3624.0		QTANTQQOYSUMLC
BRD-K28354016-001-12-9	homidium	Preclinical					0	91.36	AMS	A001466636	3,8-diamino-5-ethyl-6-phenylphenanthridinium	314.166	CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	QTANTQQOYSUMLC-UHFFFAOYSA-O	3624.0		QTANTQQOYSUMLC
BRD-K01826562-001-15-9	homochlorcyclizine	Launched	antihistamine	HRH1	allergy	allergic rhinitis	0		WuXi	EW21509-14-P1	Homochlorcyclizine	314.155	CN1CCCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:8|	WEUCDJCFJHYFRL-IBGZPJMESA-N	5393145.0		WEUCDJCFJHYFRL
BRD-K76674262-001-03-3	homoharringtonine	Launched	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	0	87.85	Tocris	1416	Homoharringtonine	545.262	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|	HYFHYPWGAURHIV-JFIAXGOJSA-N	285033.0		HYFHYPWGAURHIV
BRD-K76674262-001-05-9	homoharringtonine	Launched	protein synthesis inhibitor	RPL3	hematologic malignancy	chronic myeloid leukemia (CML)	0	93.79	Tocris	1416	Homoharringtonine	545.262	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|	HYFHYPWGAURHIV-JFIAXGOJSA-N	285033.0		HYFHYPWGAURHIV
BRD-K30519779-001-03-1	homoquinolinic-acid	Preclinical	glutamate receptor agonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	100.0	Tocris	197	Homoquinolinic acid	181.038	OC(=O)Cc1cccnc1C(O)=O	HQPMJFFEXJELOQ-UHFFFAOYSA-N	3080554.0		HQPMJFFEXJELOQ
BRD-K30519779-001-04-9	homoquinolinic-acid	Preclinical	glutamate receptor agonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	67.7	Tocris	197	Homoquinolinic acid	181.038	OC(=O)Cc1cccnc1C(O)=O	HQPMJFFEXJELOQ-UHFFFAOYSA-N	3080554.0		HQPMJFFEXJELOQ
BRD-A34751532-001-06-9	homosalate	Preclinical	HSP inducer				0	85.67	MicroSource	1505020	HOMOSALATE	262.157	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|	WSSJONWNBBTCMG-RYUDHWBXSA-N	41097438.0		WSSJONWNBBTCMG
BRD-A34751532-001-07-9	homosalate	Preclinical	HSP inducer				0	66.95	MedChemEx	HY-B0928	Homosalate	262.157	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1,&2:3,r|	WSSJONWNBBTCMG-RYUDHWBXSA-N	41097438.0		WSSJONWNBBTCMG
BRD-K59570838-001-09-9	homoveratrylamine	Preclinical	monoamine oxidase inhibitor				0	77.78	MedChemEx	HY-Y0935	2-(3,4-Dimethoxyphenyl)ethan-1-amine	181.11	COc1ccc(CCN)cc1OC	ANOUKFYBOAKOIR-UHFFFAOYSA-N	8421.0		ANOUKFYBOAKOIR
BRD-K59570838-003-01-9	homoveratrylamine	Preclinical	monoamine oxidase inhibitor				0	66.18	Prestwick	Prestw-1787	Homoveratrylamine	181.11	COc1ccc(CCN)cc1OC	ANOUKFYBOAKOIR-UHFFFAOYSA-N	8421.0		ANOUKFYBOAKOIR
BRD-K98493452-001-15-9	honokiol	Phase 3	AKT inhibitor	ALOX5|PTGS1|PTGS2			0	80.09	Tocris	4590	Honokiol	266.131	Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O	FVYXIJYOAGAUQK-UHFFFAOYSA-N	72303.0		FVYXIJYOAGAUQK
BRD-K98493452-001-14-9	honokiol	Phase 3	AKT inhibitor	ALOX5|PTGS1|PTGS2			0	97.8	Selleck	S2310	Honokiol	266.131	Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O	FVYXIJYOAGAUQK-UHFFFAOYSA-N	72303.0		FVYXIJYOAGAUQK
BRD-K93631643-001-03-2	hordenine	Preclinical					0	88.33	Selleck	S2385	Hordenine	165.115	CN(C)CCc1ccc(O)cc1	KUBCEEMXQZUPDQ-UHFFFAOYSA-N	68313.0		KUBCEEMXQZUPDQ
BRD-K93631643-001-02-4	hordenine	Preclinical					0	83.98	Selleck	S2385	Hordenine	165.115	CN(C)CCc1ccc(O)cc1	KUBCEEMXQZUPDQ-UHFFFAOYSA-N	68313.0		KUBCEEMXQZUPDQ
BRD-K00004723-001-01-9	HP-228	Preclinical	nitric oxide synthase inhibitor				0	95.69	ChemImpex	32990	Acetyl-(Nle4,Gln5,D-Phe7,D-Trp9)-alpha-MSH (4-10) amide trifluoroacetate salt	983.509	CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O	UHKZNDVUBSEJJO-XAYNKGEHSA-N	9876430.0		UHKZNDVUBSEJJO
BRD-K00003140-001-01-9	hPGDS-IN-1	Preclinical	prostaglandin inhibitor				0	98.83	MedChemEx	HY-12791	hPGDS-IN-1	416.16	CC(C)(O)c1nc(no1)-c1cccc(CNC(=O)c2cnc(nc2)-c2ccccn2)c1	VJCLAPUACUQZOV-UHFFFAOYSA-N	46700750.0		VJCLAPUACUQZOV
BRD-K00003730-001-01-9	HPPH	Phase 2	photosensitizing agent				0	95.16	MedChemEx	HY-13722	HPPH	636.368	CCCCCCO[C@H](C)c1c(C)c2cc3nc([C@@H](CCC(O)=O)[C@@H]3C)c3CC(=O)c4c(C)c(cc5nc(cc1[nH]2)c(C)c5CC)[nH]c34 |&1:7|	PVXGCBZIVFCMJK-AUSGGWNYSA-N			PVXGCBZIVFCMJK
BRD-K44963273-001-07-7	HQK-1001	Phase 2					1	0.0	Enamine	Z995036360	2,2-dimethylbutanoic acid	116.084	CCC(C)(C)C(O)=O	VUAXHMVRKOTJKP-UHFFFAOYSA-N	11684.0		VUAXHMVRKOTJKP
BRD-K44963273-001-06-9	HQK-1001	Phase 2					1	0.0	Enamine	Z995036360		116.084	CCC(C)(C)C(O)=O	VUAXHMVRKOTJKP-UHFFFAOYSA-N	11684.0		VUAXHMVRKOTJKP
BRD-K00004745-001-01-9	HSR6071	Preclinical	antiallergic agent				0	96.28	MedChemEx	HY-U00133	HSR6071	260.113	O=C(Nc1nnn[nH]1)c1cncc(n1)N1CCCC1	LUJDHCXCWJFNOJ-UHFFFAOYSA-N	159466.0		LUJDHCXCWJFNOJ
BRD-K00003386-001-01-9	HT-2157	Phase 1/Phase 2	galanin receptor 3 antagonist				0	51.12	MedChemEx	HY-100717	HT-2157	366.098	FC(F)(F)c1cccc(c1)\N=C1/C(=O)N(c2ccccc12)c1ccccc1	TXCGMRVPXUBHAL-PLRJNAJWSA-N			TXCGMRVPXUBHAL
BRD-K58726989-001-01-9	HTH-01-015	Preclinical	protein kinase inhibitor	NUAK1			0	86.89	Tocris	5622	HTH 01-015	468.239	CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12	CHSDJDLAKKAWCI-UHFFFAOYSA-N	78357766.0		CHSDJDLAKKAWCI
BRD-K58726989-001-02-7	HTH-01-015	Preclinical	protein kinase inhibitor	NUAK1			0	90.24	ApexBio	A8890	HTH-01-015	468.239	CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12	CHSDJDLAKKAWCI-UHFFFAOYSA-N	78357766.0		CHSDJDLAKKAWCI
BRD-K00003389-001-01-9	HTHQ	Preclinical	antioxidant				0	91.66	MedChemEx	HY-100768	HTHQ	236.178	CCCCCCOc1cc(C)c(O)c(C)c1C	ATMNQRRJNBCQJO-UHFFFAOYSA-N	119193.0		ATMNQRRJNBCQJO
BRD-K01825665-332-02-9	HTMT	Preclinical	histamine receptor agonist	HRH4			0	86.57	Tocris	646	(2Z)-2-butenedioic acid compound with 6-{[2-(1H-imidazol-4-yl)ethyl]amino}-N-[4-(trifluoromethyl)phenyl]heptanamide (2:1)	614.22	C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|	PMKJGGBYYNEYPA-AWEZNQCLSA-N	6604743.0		PMKJGGBYYNEYPA
BRD-K01825665-332-01-9	HTMT	Preclinical	histamine receptor agonist	HRH4			0	77.76	Tocris	646	HTMT dimaleate	614.22	C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|	PMKJGGBYYNEYPA-AWEZNQCLSA-N	6604743.0		PMKJGGBYYNEYPA
BRD-K62240499-001-05-9	huperzine-A	Phase 2	acetylcholinesterase inhibitor	ACHE			0	86.35	MedChemEx	HY-17387	(-)-Huperzine A	242.142	C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|	ZRJBHWIHUMBLCN-YQEJDHNASA-N	854026.0	BRD-K45888792-001-03-6	ZRJBHWIHUMBLCN
BRD-K62240499-001-04-2	huperzine-A	Phase 2	acetylcholinesterase inhibitor	ACHE			0	30.08	Selleck	S2251	(-)-Huperzine A	242.142	C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|	ZRJBHWIHUMBLCN-YQEJDHNASA-N	854026.0	BRD-K97618845-001-03-1	ZRJBHWIHUMBLCN
BRD-K62240499-001-06-7	huperzine-A	Phase 2	acetylcholinesterase inhibitor	ACHE			0	17.37	Selleck	S2251	(-)-Huperzine A (HupA)	242.142	C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|	ZRJBHWIHUMBLCN-YQEJDHNASA-N	854026.0	BRD-K45888792-001-02-8	ZRJBHWIHUMBLCN
BRD-K59788572-236-01-3	hyaluronic-acid	Launched		C1QBP|CD44|HABP2|HAPLN1|HAPLN3|HAPLN4|HMMR|ICAM1|NCAN|VCAN	rheumatology|urology	osteoarthritis|interstitial cystitis (IC)	0	0.0	Sigma	MFCD00875848	sodium (2S,3S,4R,5R,6R)-3-((2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4,5,6-trihydroxytetra hydro-2H-pyran-2-carboxylate	381.127	CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O	WCDDVEOXEIYWFB-VXORFPGASA-N	6852395.0		WCDDVEOXEIYWFB
BRD-K50406511-001-26-0	hycanthone	Launched	RNA synthesis inhibitor		infectious disease	schistosomiasis	0	88.6	MicroSource	1503239	HYCANTHONE	356.156	CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12	MFZWMTSUNYWVBU-UHFFFAOYSA-N	3634.0		MFZWMTSUNYWVBU
BRD-K82103381-003-07-8	hydralazine	Launched	vasodilator		cardiology	hypertension	0	0.0	MicroSource	1500334	HYDRALAZINE HYDROCHLORIDE	160.075	NNc1nncc2ccccc12	RPTUSVTUFVMDQK-UHFFFAOYSA-N	9351.0		RPTUSVTUFVMDQK
BRD-K82103381-003-09-4	hydralazine	Launched	vasodilator		cardiology	hypertension	0	87.04	MedChemEx	HY-B0464	Hydralazine (hydrochloride)	160.075	NNc1nncc2ccccc12	RPTUSVTUFVMDQK-UHFFFAOYSA-N	9351.0		RPTUSVTUFVMDQK
BRD-K82103381-003-06-0	hydralazine	Launched	vasodilator		cardiology	hypertension	0	0.0	Selleck	S2562	Hydralazine HCl	160.075	N\N=c1/[nH]ncc2ccccc12	RPTUSVTUFVMDQK-UHFFFAOYSA-N	9351.0		RPTUSVTUFVMDQK
BRD-K82103381-003-08-6	hydralazine	Launched	vasodilator		cardiology	hypertension	0	27.81	Selleck	S2562	Hydralazine hydrochloride	160.075	N\N=c1/[nH]ncc2ccccc12	RPTUSVTUFVMDQK-UHFFFAOYSA-N	9351.0		RPTUSVTUFVMDQK
BRD-K02715688-001-09-9	hydrastine-(1R,9S)	Preclinical	tyrosine hydroxylase inhibitor				0	98.68	MedChemEx	HY-B0927	Hydrastine	383.137	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12	JZUTXVTYJDCMDU-MOPGFXCFSA-N	197835.0		JZUTXVTYJDCMDU
BRD-K02715688-001-02-1	hydrastine-(1R,9S)	Preclinical	tyrosine hydroxylase inhibitor				0	99.03	MicroSource	1500687	HYDRASTINE (1R, 9S)	383.137	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12	JZUTXVTYJDCMDU-MOPGFXCFSA-N	197835.0		JZUTXVTYJDCMDU
BRD-K92726801-311-01-6	hydrastinine	Preclinical	hemostatic agent				0	83.97	Sigma	S438308-10MG	Hydrastinine chloride monohydrate	190.087	C[N+]1=Cc2cc3OCOc3cc2CC1 |t:1|	LGDCROILDUSHQX-UHFFFAOYSA-N	3397945.0		LGDCROILDUSHQX
BRD-K13078532-001-27-6	hydrochlorothiazide	Launched	thiazide diuretic	CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A3	cardiology	hypertension|congestive heart failure	0	96.81	Selleck	S1708	Hydrochlorothiazide	296.964	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl	JZUFKLXOESDKRF-UHFFFAOYSA-N	3639.0		JZUFKLXOESDKRF
BRD-K13078532-001-28-4	hydrochlorothiazide	Launched	thiazide diuretic	CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A3	cardiology	hypertension|congestive heart failure	0	98.34	MicroSource	1500335	HYDROCHLOROTHIAZIDE	296.964	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl	JZUFKLXOESDKRF-UHFFFAOYSA-N	3639.0		JZUFKLXOESDKRF
BRD-K93568044-001-30-4	hydrocortisone	Launched	glucocorticoid receptor agonist	ANXA1|NOS2|NR3C1|NR3C2	dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching	0	74.63	Tocris	4093	Hydrocortisone	362.209	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	JYGXADMDTFJGBT-VWUMJDOOSA-N	5754.0		JYGXADMDTFJGBT
BRD-K93568044-001-32-0	hydrocortisone	Launched	glucocorticoid receptor agonist	ANXA1|NOS2|NR3C1|NR3C2	dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching	0	97.33	MicroSource	300024	HYDROCORTISONE	362.209	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	JYGXADMDTFJGBT-VWUMJDOOSA-N	5754.0	BRD-A75172220-001-04-0	JYGXADMDTFJGBT
BRD-K93568044-001-31-2	hydrocortisone	Launched	glucocorticoid receptor agonist	ANXA1|NOS2|NR3C1|NR3C2	dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching	0	92.6	Selleck	S1696	Hydrocortisone	362.209	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	JYGXADMDTFJGBT-VWUMJDOOSA-N	5754.0	BRD-K97571677-001-01-9	JYGXADMDTFJGBT
BRD-K93568044-001-33-9	hydrocortisone	Launched	glucocorticoid receptor agonist	ANXA1|NOS2|NR3C1|NR3C2	dermatology|neurology/psychiatry	eczema|psoriasis|seborrheic dermatitis|itching	0	79.0	Tocris	4093	Hydrocortisone	362.209	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	JYGXADMDTFJGBT-VWUMJDOOSA-N	5754.0		JYGXADMDTFJGBT
BRD-K11612998-001-26-9	hydrocortisone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	92.06	MedChemEx	HY-B1183	Hydrocortisone acetate	404.22	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|	ALEXXDVDDISNDU-JZYPGELDSA-N	5744.0		ALEXXDVDDISNDU
BRD-K99199077-001-17-9	hydrocortisone-butyrate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses|eczema	0	0.0	MicroSource	1503273	HYDROCORTISONE BUTYRATE	432.251	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|	BMCQMVFGOVHVNG-TUFAYURCSA-N	26133.0	BRD-A34508879-001-04-9	BMCQMVFGOVHVNG
BRD-K99199077-001-16-1	hydrocortisone-butyrate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses|eczema	0	85.87	Sigma	MFCD00083364	(11beta)-11,21-dihydroxy-3,20-dioxopregn-4-en-17-yl butyrate	432.251	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|	BMCQMVFGOVHVNG-TUFAYURCSA-N	26133.0		BMCQMVFGOVHVNG
BRD-K00025601-002-01-9	hydrocortisone-hemisuccinate	Phase 2/Phase 3					0	93.51	Sigma	PHR1926-500MG		462.225	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |t:9|	VWQWXZAWFPZJDA-CGVGKPPMSA-N	16623.0		VWQWXZAWFPZJDA
BRD-K01824977-369-02-9	hydrocortisone-phosphate	Launched			pulmonary|gastroenterology|hematologic malignancy|ophthalmology	asthma|nausea|vomiting|multiple myeloma|contact dermatitis|enteritis|colitis	0	79.61	MicroSource	1500340	HYDROCORTISONE PHOSPHATE TRIETHYLAMINE	644.417	C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]34C)[C@@H]1CC[C@]2(O)C(=O)COP(O)(O)=O |a:3,20,&1:1,&2:5,&3:6,&4:15,&5:17,t:9|	BGSOJVFOEQLVMH-SBXZOHCASA-N			BGSOJVFOEQLVMH
BRD-K09968782-001-17-2	hydrocortisone-valerate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	90.33	USP	1321004	Hydrocortisone valerate	446.267	CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|	FZCHYNWYXKICIO-FZNHGJLXSA-N	5282494.0		FZCHYNWYXKICIO
BRD-K36862742-001-27-9	hydroflumethiazide	Launched	sodium/potassium/chloride transporter inhibitor	ATP1A1|CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A1|SLC12A3	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension	0	95.5	Sigma	H8760	Hydroflumethiazide	330.991	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F	DMDGGSIALPNSEE-UHFFFAOYSA-N	3647.0		DMDGGSIALPNSEE
BRD-K36862742-001-25-6	hydroflumethiazide	Launched	sodium/potassium/chloride transporter inhibitor	ATP1A1|CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A1|SLC12A3	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|chronic renal failure|acute glomerulonephritis (AGN)|hypertension	0	97.64	MicroSource	1500341	HYDROFLUMETHIAZIDE	330.991	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F	DMDGGSIALPNSEE-UHFFFAOYSA-N	3647.0		DMDGGSIALPNSEE
BRD-K65866076-001-03-9	hydroquinidine	Launched	antiarrhythmic		cardiology	cardiac arrythmia	0	85.02	MedChemEx	HY-B0997	Hydroquinidine	326.199	CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	LJOQGZACKSYWCH-LHHVKLHASA-N	91503.0		LJOQGZACKSYWCH
BRD-K11227669-001-07-8	hydroquinone	Launched	melanin inhibitor	TYR	dermatology	dyschromia	0	49.83	MicroSource	1504237	HYDROQUINONE	110.037	Oc1ccc(O)cc1	QIGBRXMKCJKVMJ-UHFFFAOYSA-N	785.0		QIGBRXMKCJKVMJ
BRD-K11227669-001-08-6	hydroquinone	Launched	melanin inhibitor	TYR	dermatology	dyschromia	0	0.0	MedChemEx	HY-B0951	Hydroquinone	110.037	Oc1ccc(O)cc1	QIGBRXMKCJKVMJ-UHFFFAOYSA-N	785.0		QIGBRXMKCJKVMJ
BRD-K00003525-003-01-9	hydroxocobalamin	Launched	vitamin B				0	59.19	MedChemEx	HY-B2209A	Hydroxocobalamin hydrochloride	1346.575	[H]O[Co+]N1\C2=C(C)/C3=N/C(=C/C4=N/C(=C(C)\C5=N[C@@](C)([C@@]1([H])[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)/[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)/C(C)(C)[C@@H]3CCC(N)=O |r,t:4,7,9,11,13,16|	YOZNUFWCRFCGIH-WZHZPDAFSA-L	139031134.0		YOZNUFWCRFCGIH
BRD-A80871782-004-06-9	hydroxyamphetamine	Launched	trace amine associated receptor agonist	TAAR1	ophthalmology	mydriasis	0	97.66	MicroSource	211425	HYDROXYAMPHETAMINE HYDROBROMIDE	151.1	C[C@@H](N)Cc1ccc(O)cc1 |&1:1|	GIKNHHRFLCDOEU-SSDOTTSWSA-N	12234986.0		GIKNHHRFLCDOEU
BRD-A80871782-001-07-9	hydroxyamphetamine	Launched	trace amine associated receptor agonist	TAAR1	ophthalmology	mydriasis	0	100.0	Enamine	EN300-53926	4-(2-aminopropyl)phenol	151.1	C[C@@H](N)Cc1ccc(O)cc1 |&1:1|	GIKNHHRFLCDOEU-SSDOTTSWSA-N	12234986.0		GIKNHHRFLCDOEU
BRD-A99117172-065-04-0	hydroxychloroquine	Launched	antimalarial agent	TLR7|TLR9	infectious disease	malaria	0	76.17	MicroSource	1503978	HYDROXYCHLOROQUINE SULFATE	335.176	CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12	XXSMGPRMXLTPCZ-UHFFFAOYSA-N	12947.0		XXSMGPRMXLTPCZ
BRD-A99117172-065-05-7	hydroxychloroquine	Launched	antimalarial agent	TLR7|TLR9	infectious disease	malaria	0	98.39	Sigma	MFCD00078203	sulfuric acid compound with 2-[{4-[(7-chloro-4-quinolinyl)amino]pentyl}(ethyl)amino]ethanol (1:1)	335.176	CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12	XXSMGPRMXLTPCZ-UHFFFAOYSA-N	12947.0		XXSMGPRMXLTPCZ
BRD-K77793136-003-03-0	hydroxyfasudil	Preclinical	rho associated kinase inhibitor	PKIA|PRKACA|ROCK1			0	97.11	Tocris	2415	HA 1100 hydrochloride	307.099	O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1	ZAVGJDAFCZAWSZ-UHFFFAOYSA-N	3064778.0		ZAVGJDAFCZAWSZ
BRD-K77793136-003-05-9	hydroxyfasudil	Preclinical	rho associated kinase inhibitor	PKIA|PRKACA|ROCK1			0	95.08	Tocris	2415	HA 1100 hydrochloride	307.099	O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1	ZAVGJDAFCZAWSZ-UHFFFAOYSA-N	3064778.0		ZAVGJDAFCZAWSZ
BRD-K44932450-001-16-8	hydroxyprogesterone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	spontaneous preterm birth	0	89.44	TCI	H1250	17alpha-Hydroxyprogesterone	330.219	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|	DBPWSSGDRRHUNT-CEGNMAFCSA-N	6238.0		DBPWSSGDRRHUNT
BRD-K44932450-001-17-9	hydroxyprogesterone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	spontaneous preterm birth	0		WuXi	EW21509-5-P1	17?-Hydroxyprogesterone	330.219	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|	DBPWSSGDRRHUNT-CEGNMAFCSA-N	6238.0		DBPWSSGDRRHUNT
BRD-K92902018-001-01-9	hydroxyprogesterone-acetate	Launched	progesterone receptor agonist	PGR			0	94.0	Sigma	MFCD00021156	3,20-dioxopregn-4-en-17-yl acetate	372.23	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|	VTHUYJIXSMGYOQ-KOORYGTMSA-N	10156152.0		VTHUYJIXSMGYOQ
BRD-A01412266-001-01-0	hydroxypropyl-beta-cyclodextrin	Phase 2/Phase 3					0	98.32	Cayman	16169		1540.663	C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6,8,10,11,19,21,22,30,32,33,41,43,44,52,54,55,63,65,66,74,76,77,79,81,83,85,87,89,91,93,95,97,99,101,103,&1:1,&2:15,&3:26,&4:37,&5:48,&6:59,&7:70|	ODLHGICHYURWBS-LWHSBNEASA-N			ODLHGICHYURWBS
BRD-K00003327-001-01-9	hydroxysafflor-yellow-A	Preclinical	antitumor agent				0	92.8	MedChemEx	HY-N0567	Hydroxysafflor yellow A	612.169	[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@]1(O)C(=O)[C@@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H](C(=O)\C=C\c2ccc(O)cc2)C1=O |&1:12,&2:30,&3:16|	DKEZDPGUJMMUCC-GJVNFNJISA-N			DKEZDPGUJMMUCC
BRD-K62186992-334-02-8	hydroxystilbamidine	Launched					0	93.1	Enzo	ENZ-52253	Hydroxystilbamidine (ultra pure)	280.132	NC(=N)c1ccc(\C=C\c2ccc(cc2O)C(N)=N)cc1	TUESWZZJYCLFNL-DAFODLJHSA-N	5284571.0		TUESWZZJYCLFNL
BRD-K01825165-001-02-9	hydroxytacrine-maleate-(R,S)	Preclinical	cholinesterase inhibitor	ACHE			0	95.7	AMS	A134094	9-amino-1,2,3,4-tetrahydro-1-acridinol	214.111	Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|	HLVVITIHAZBPKB-NSHDSACASA-N	667530.0		HLVVITIHAZBPKB
BRD-K75608666-001-09-9	hydroxytoluic-acid	Preclinical					0	95.96	MedChemEx	HY-B1399	3-Methylsalicylic acid	152.047	Cc1cccc(C(O)=O)c1O	WHSXTWFYRGOBGO-UHFFFAOYSA-N	6738.0		WHSXTWFYRGOBGO
BRD-K75608666-001-08-3	hydroxytoluic-acid	Preclinical					0	99.14	MicroSource	212064	HYDROXYTOLUIC ACID	152.047	Cc1cccc(C(O)=O)c1O	WHSXTWFYRGOBGO-UHFFFAOYSA-N	6738.0		WHSXTWFYRGOBGO
BRD-K51747290-001-12-3	hydroxyurea	Launched	ribonucleotide reductase inhibitor	RRM1|RRM2|RRM2B	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)	0	0.0	Selleck	S1896	Hydroxyurea	76.027	NC(=O)NO	VSNHCAURESNICA-UHFFFAOYSA-N	3657.0		VSNHCAURESNICA
BRD-K51747290-001-15-6	hydroxyurea	Launched	ribonucleotide reductase inhibitor	RRM1|RRM2|RRM2B	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)	0	0.0	Selleck	S1896	Hydroxyurea (Cytodrox)	76.027	NC(=O)NO	VSNHCAURESNICA-UHFFFAOYSA-N	3657.0		VSNHCAURESNICA
BRD-K51747290-001-13-1	hydroxyurea	Launched	ribonucleotide reductase inhibitor	RRM1|RRM2|RRM2B	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|head and neck squamous cell carcinoma (HNSCC)	0	98.2	MicroSource	1500344	HYDROXYUREA	76.027	NC(=O)NO	VSNHCAURESNICA-UHFFFAOYSA-N	3657.0		VSNHCAURESNICA
BRD-K01826510-300-06-9	hydroxyzine	Launched	antihistamine	HRH1	neurology/psychiatry|allergy|dermatology	anxiety|urticaria|itching|dermatosis	0	96.59	Selleck	S4026	Hydroxyzine 2HCl	446.129	OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|	ZQDWXGKKHFNSQK-NRFANRHFSA-N	1548976.0		ZQDWXGKKHFNSQK
BRD-A24252652-001-02-9	hygromycin-B	Preclinical	polypeptide synthesis inhibitor				0	100.0	MedChemEx	HY-B0490	Hygromycin B	527.233	CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O |a:2,4,6,8,10,12,15,17,21,23,24,28,30,32,34,&1:19|	GRRNUXAQVGOGFE-SIGCQSELSA-N	91617579.0		GRRNUXAQVGOGFE
BRD-K46424862-001-15-8	hymecromone	Phase 2	monoamine oxidase inhibitor	MAOA|MAOB			0	94.63	MicroSource	1506174	HYMECHROME	176.047	Cc1cc(=O)oc2cc(O)ccc12	HSHNITRMYYLLCV-UHFFFAOYSA-N	5280567.0		HSHNITRMYYLLCV
BRD-K46424862-001-16-9	hymecromone	Phase 2	monoamine oxidase inhibitor	MAOA|MAOB			0	100.0	MedChemEx	HY-N0187	4-Methylumbelliferone	176.047	Cc1cc(=O)oc2cc(O)ccc12	HSHNITRMYYLLCV-UHFFFAOYSA-N	5280567.0		HSHNITRMYYLLCV
BRD-K46424862-001-14-1	hymecromone	Phase 2	monoamine oxidase inhibitor	MAOA|MAOB			0	95.22	Selleck	S2256	4-Methylumbelliferone (4-MU)	176.047	Cc1cc(=O)oc2cc(O)ccc12	HSHNITRMYYLLCV-UHFFFAOYSA-N	5280567.0		HSHNITRMYYLLCV
BRD-K44009692-001-02-3	hyodeoxycholic-acid	Phase 1	atherosclerosis formation inhibitor				0	96.92	Selleck	S2311	Hyodeoxycholic acid (HDCA)	392.293	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	DGABKXLVXPYZII-SIBKNCMHSA-N	5283820.0	BRD-K49031386-001-01-5	DGABKXLVXPYZII
BRD-K44009692-001-03-1	hyodeoxycholic-acid	Phase 1	atherosclerosis formation inhibitor				0	83.3	Selleck	S2311	Hyodeoxycholic acid (HDCA)	392.293	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	DGABKXLVXPYZII-SIBKNCMHSA-N	5283820.0		DGABKXLVXPYZII
BRD-K40530731-001-12-9	hyoscyamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4	gastroenterology|urology|neurology/psychiatry|allergy	peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis	0	80.11	MedChemEx	HY-N0471	L-Hyoscyamine	289.168	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	RKUNBYITZUJHSG-FXUDXRNXSA-N			RKUNBYITZUJHSG
BRD-K40530731-001-11-6	hyoscyamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4	gastroenterology|urology|neurology/psychiatry|allergy	peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis	0	97.93	MicroSource	1500346	HYOSCYAMINE	289.168	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	RKUNBYITZUJHSG-FXUDXRNXSA-N		BRD-A78303415-001-04-3	RKUNBYITZUJHSG
BRD-K40530731-001-10-8	hyoscyamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4	gastroenterology|urology|neurology/psychiatry|allergy	peptic ulcer disease (PUD)|acute abdominal visceral spasm|ulcerative colitis|interstitial cystitis (IC)|enterocolitis|irritable bowel syndrome|tremors|allergic rhinitis	0	91.99	Selleck	S4014	Hyoscyamine	289.168	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	RKUNBYITZUJHSG-FXUDXRNXSA-N		BRD-A97674763-001-01-8	RKUNBYITZUJHSG
BRD-K29673530-001-06-9	hypericin	Phase 3	tyrosine kinase inhibitor				0	98.33	MedChemEx	HY-N0453	Hypericin	504.085	Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	BTXNYTINYBABQR-UHFFFAOYSA-N			BTXNYTINYBABQR
BRD-K29673530-001-05-4	hypericin	Phase 3	tyrosine kinase inhibitor				0	91.35	Enzo	EI226	Hypericin	504.085	Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	BTXNYTINYBABQR-UHFFFAOYSA-N			BTXNYTINYBABQR
BRD-A63780829-001-11-4	hyperin	Preclinical	aldose reductase inhibitor	ACE|AKR1B1			0	96.75	ChemDiv	0407-0014		464.095	OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:27,&4:29,&5:31,r|	OVSQVDMCBVZWGM-FHYQVQSVSA-N	5742688.0		OVSQVDMCBVZWGM
BRD-K13881745-001-01-1	hypoestoxide	Phase 1	IKK inhibitor	IKBKB|IL1B|TNF			0	87.38	EMD	401006-1MG	Hypoestoxide	376.225	CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C	HNPAHGHFONBTLV-KSJQNFQUSA-N	11199742.0		HNPAHGHFONBTLV
BRD-K03739921-001-06-8	hypoxanthine	Preclinical	PARP inhibitor	PNP			0	96.41	Selleck	S2424	Hypoxanthine	136.039	O=c1nc[nH]c2nc[nH]c12	FDGQSTZJBFJUBT-UHFFFAOYSA-N	790.0		FDGQSTZJBFJUBT
BRD-K26439554-001-02-9	H2L-5765834	Preclinical	lysophosphatidic acid receptor antagonist	LPAR1|LPAR3			0	91.6	Tocris	4870	H2L 5765834	404.064	OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1	HFYPTENHTPNXGP-UHFFFAOYSA-N	1365686.0		HFYPTENHTPNXGP
BRD-K26439554-001-01-3	H2L-5765834	Preclinical	lysophosphatidic acid receptor antagonist	LPAR1|LPAR3			0	95.78	Tocris	4870	H2L 5765834	404.064	OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1	HFYPTENHTPNXGP-UHFFFAOYSA-N	1365686.0		HFYPTENHTPNXGP
BRD-K08109215-001-06-4	I-BET-762	Phase 2	bromodomain inhibitor	BRD2|BRD3|BRD4			0	97.76	Selleck	S7189	I-BET-762	423.146	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|	AAAQFGUYHFJNHI-SFHVURJKSA-N	46943432.0		AAAQFGUYHFJNHI
BRD-K08109215-001-05-6	I-BET-762	Phase 2	bromodomain inhibitor	BRD2|BRD3|BRD4			0		Selleck	S7189	IBET-762	423.146	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|	InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1	46943432.0		AAAQFGUYHFJNHI
BRD-K36363294-300-01-4	I-BET151	Preclinical	bromodomain inhibitor	BRD2|BRD3|BRD4			0	74.08	Tocris	4650	I-BET 151 dihydrochloride	415.164	COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C	VUVUVNZRUGEAHB-CYBMUJFWSA-N	52912189.0		VUVUVNZRUGEAHB
BRD-K36363294-001-04-2	I-BET151	Preclinical	bromodomain inhibitor	BRD2|BRD3|BRD4			0	96.17	Selleck	S2780	I-BET151 (GSK1210151A)	415.164	COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C	VUVUVNZRUGEAHB-CYBMUJFWSA-N	52912189.0		VUVUVNZRUGEAHB
BRD-K04972057-001-02-9	I-BRD9	Preclinical	bromodomain inhibitor	BRD9			0	94.51	Tocris	5591	I-BRD9	497.105	CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1	WRUWGLUCNBMGPS-UHFFFAOYSA-N	91668541.0		WRUWGLUCNBMGPS
BRD-K04972057-001-01-1	I-BRD9	Preclinical	bromodomain inhibitor	BRD9			0	95.93	MedChemEx	HY-18975	I-BRD9	497.105	CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1	WRUWGLUCNBMGPS-UHFFFAOYSA-N	91668541.0		WRUWGLUCNBMGPS
BRD-K14762862-001-01-9	I-BZA	Phase 2					0	89.11	Enamine	Z27720938		346.054	CCN(CC)CCNC(=O)c1ccc(I)cc1	HRVWCNMOEFNEON-UHFFFAOYSA-N	129424.0		HRVWCNMOEFNEON
BRD-K14762862-001-02-9	I-BZA	Phase 2					0		Broad Institute	I-BZA	I-BZA	346.054	CCN(CC)CCNC(=O)c1ccc(I)cc1	HRVWCNMOEFNEON-UHFFFAOYSA-N	129424.0		HRVWCNMOEFNEON
BRD-K71698503-003-02-9	I-BZA2	Phase 3					0	95.32	Vitas-M	STK191932	N-[2-(diethylamino)ethyl]-2-iodobenzamide	346.054	CCN(CC)CCNC(=O)c1ccccc1I	WNSWOZIBBVUJBI-UHFFFAOYSA-N	1816834.0		WNSWOZIBBVUJBI
BRD-K71698503-003-01-6	I-BZA2	Phase 3					0	98.45	ChemBridge	7531337		346.054	CCN(CC)CCNC(=O)c1ccccc1I	WNSWOZIBBVUJBI-UHFFFAOYSA-N	1816834.0		WNSWOZIBBVUJBI
BRD-K57090026-001-04-9	I-CBP-112	Preclinical	bromodomain inhibitor	CREBBP|EP300			0	92.81	Tocris	4891	I-CBP 112	468.262	CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1	YKNAKDFZAWQEEO-IBGZPJMESA-N	90488984.0		YKNAKDFZAWQEEO
BRD-K57090026-001-02-4	I-CBP-112	Preclinical	bromodomain inhibitor	CREBBP|EP300			0	81.05	Tocris	4891	I-CBP 112	468.262	CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1	YKNAKDFZAWQEEO-IBGZPJMESA-N	90488984.0		YKNAKDFZAWQEEO
BRD-K00003105-003-01-9	IACS-10759	Preclinical	mitochondrial complex I inhibitor				0	96.15	MedChemEx	HY-112037A	IACS-10759 Hydrochloride	562.161	Cc1nc(nn1Cc1cccc(c1)N1CCC(CC1)S(C)(=O)=O)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	HWJWNWZJUYCGKV-UHFFFAOYSA-N	86711931.0		HWJWNWZJUYCGKV
BRD-K31135544-001-08-9	IB-MECA	Phase 3	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	94.14	Tocris	1066	IB-MECA	510.051	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12	HUJXGQILHAUCCV-MOROJQBDSA-N	123683.0		HUJXGQILHAUCCV
BRD-K31135544-001-07-0	IB-MECA	Phase 3	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	96.28	Tocris	1066	IB-MECA	510.051	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12	HUJXGQILHAUCCV-MOROJQBDSA-N	123683.0		HUJXGQILHAUCCV
BRD-K08681769-323-04-5	ibandronate	Launched	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	1	0.0	MicroSource	1504818	IBANDRONATE SODIUM	319.095	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	MPBVHIBUJCELCL-UHFFFAOYSA-N	60852.0		MPBVHIBUJCELCL
BRD-K08681769-323-06-9	ibandronate	Launched	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	1	0.0	MedChemEx	HY-B0515	Ibandronate (Sodium Monohydrate)	319.095	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	MPBVHIBUJCELCL-UHFFFAOYSA-N	60852.0		MPBVHIBUJCELCL
BRD-K08681769-323-05-2	ibandronate	Launched	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	1	0.0	Selleck	S3148	Ibandronate sodium	319.095	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	MPBVHIBUJCELCL-UHFFFAOYSA-N	60852.0		MPBVHIBUJCELCL
BRD-K08681769-323-03-7	ibandronate	Launched	bone resorption inhibitor	FDPS	orthopedics	osteoporosis	1	0.0	Selleck	S3148	Ibandronate sodium	319.095	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	MPBVHIBUJCELCL-UHFFFAOYSA-N	60852.0		MPBVHIBUJCELCL
BRD-K15196155-001-02-3	IBC-293	Preclinical	hydroxycarboxylic acid receptor agonist	HCAR3			0	96.09	Tocris	2469	IBC 293	205.085	CC(C)n1nnc2cc(ccc12)C(O)=O	RUTVRAJKELSHCC-UHFFFAOYSA-N	2736690.0		RUTVRAJKELSHCC
BRD-K15196155-001-03-9	IBC-293	Preclinical	hydroxycarboxylic acid receptor agonist	HCAR3			0	98.64	Tocris	2469	IBC 293	205.085	CC(C)n1nnc2cc(ccc12)C(O)=O	RUTVRAJKELSHCC-UHFFFAOYSA-N	2736690.0		RUTVRAJKELSHCC
BRD-K00003408-001-01-9	iberdomide	Preclinical	cereblon modulator				0	96.98	MedChemEx	HY-101291	Iberdomide	449.195	O=C1N(Cc2c1cccc2OCc1ccc(CN2CCOCC2)cc1)[C@H]1CCC(=O)NC1=O	IXZOHGPZAQLIBH-NRFANRHFSA-N	67335295.0		IXZOHGPZAQLIBH
BRD-K14063023-001-02-9	ibiglustat	Preclinical	glucosylceramidase inhibitor				0	90.71	MedChemEx	HY-16743	Ibiglustat	389.157	CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1	YFHRCLAKZBDRHN-MRXNPFEDSA-N	60199242.0		YFHRCLAKZBDRHN
BRD-K94979336-001-20-0	IBMX	Preclinical	phosphodiesterase inhibitor	ADORA1|PDE2A|PDE3B|PDE4D|PDE5A|PDE6G|PDE7A|PDE8A|PDE9A			0	95.56	Tocris	2845	IBMX	222.112	CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O	APIXJSLKIYYUKG-UHFFFAOYSA-N	3758.0		APIXJSLKIYYUKG
BRD-K94979336-001-23-9	IBMX	Preclinical	phosphodiesterase inhibitor	ADORA1|PDE2A|PDE3B|PDE4D|PDE5A|PDE6G|PDE7A|PDE8A|PDE9A			0	97.36	Tocris	2845	IBMX	222.112	CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O	APIXJSLKIYYUKG-UHFFFAOYSA-N	3758.0		APIXJSLKIYYUKG
BRD-A02971356-001-07-2	ibotenic-acid	Preclinical	glutamate receptor agonist	GRIN1			0	0.0	Tocris	285	Ibotenic acid	158.033	N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|	IRJCBFDCFXCWGO-SCSAIBSYSA-N	6971210.0		IRJCBFDCFXCWGO
BRD-A02971356-001-09-9	ibotenic-acid	Preclinical	glutamate receptor agonist	GRIN1			0	100.0	Tocris	285	Ibotenic acid	158.033	N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1,r|	IRJCBFDCFXCWGO-SCSAIBSYSA-N	6971210.0		IRJCBFDCFXCWGO
BRD-K62490786-001-01-1	ibrolipim	Phase 2	lipoprotein lipase activator	LPL			0	97.73	Sigma	N1540	diethyl 4-[(4-bromo-2-cyanoanilino)carbonyl]benzylphosphonate	450.034	CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC	KPRTURMJVWXURQ-UHFFFAOYSA-N	131601.0		KPRTURMJVWXURQ
BRD-K70301465-001-05-9	ibrutinib	Launched	Bruton's tyrosine kinase (BTK) inhibitor	BLK|BMX|BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)	0	99.58	Selleck	S2680	Ibrutinib	440.196	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	XYFPWWZEPKGCCK-GOSISDBHSA-N	24821094.0		XYFPWWZEPKGCCK
BRD-K70301465-001-02-6	ibrutinib	Launched	Bruton's tyrosine kinase (BTK) inhibitor	BLK|BMX|BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)	0	98.19	Selleck	S2680	Ibrutinib (PCI-32765)	440.196	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	XYFPWWZEPKGCCK-GOSISDBHSA-N	24821094.0		XYFPWWZEPKGCCK
BRD-K70301465-001-08-3	ibrutinib	Launched	Bruton's tyrosine kinase (BTK) inhibitor	BLK|BMX|BTK	hematologic malignancy	chronic lymphocytic leukemia (CLL)|mantle cell lymphoma (MCL)|Waldenstrom's macroglobulinemia (WM)	0	99.15	Selleck	S2680	Ibrutinib (PCI-32765)	440.196	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1	24821094.0		XYFPWWZEPKGCCK
BRD-K16444452-001-11-7	ibudilast	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	pulmonary|neurology/psychiatry	asthma|stroke	0	96.95	Tocris	1694	Ibudilast	230.142	CC(C)C(=O)c1c(nn2ccccc12)C(C)C	ZJVFLBOZORBYFE-UHFFFAOYSA-N	3671.0		ZJVFLBOZORBYFE
BRD-K16444452-001-12-9	ibudilast	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	pulmonary|neurology/psychiatry	asthma|stroke	0	91.68	Tocris	1694	Ibudilast	230.142	CC(C)C(=O)c1c(nn2ccccc12)C(C)C	ZJVFLBOZORBYFE-UHFFFAOYSA-N	3671.0		ZJVFLBOZORBYFE
BRD-K16444452-001-09-1	ibudilast	Launched	leukotriene receptor antagonist|phosphodiesterase inhibitor	IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	pulmonary|neurology/psychiatry	asthma|stroke	0	91.99	Tocris	1694	Ibudilast	230.142	CC(C)C(=O)c1c(nn2ccccc12)C(C)C	ZJVFLBOZORBYFE-UHFFFAOYSA-N	3671.0		ZJVFLBOZORBYFE
BRD-A17655518-001-24-4	ibuprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry|rheumatology|otolaryngology|obstetrics/gynecology|endocrinology|dental	headache|muscle pain|rheumatoid arthritis|backache|common cold|menstrual pain|fever|toothache	0	99.41	MicroSource	1500347	IBUPROFEN	206.131	CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|	HEFNNWSXXWATRW-SNVBAGLBSA-N	114864.0		HEFNNWSXXWATRW
BRD-A17655518-001-23-6	ibuprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry|rheumatology|otolaryngology|obstetrics/gynecology|endocrinology|dental	headache|muscle pain|rheumatoid arthritis|backache|common cold|menstrual pain|fever|toothache	0	96.45	Selleck	S1638	Ibuprofen	206.131	CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10,r|	HEFNNWSXXWATRW-SNVBAGLBSA-N	114864.0		HEFNNWSXXWATRW
BRD-K14965640-001-13-2	ibuprofen-(S)	Launched	cyclooxygenase inhibitor	ASIC1|PTGS1|PTGS2|SLC5A8	neurology/psychiatry	pain relief	0	93.31	Tocris	2796	(S)-(+)-Ibuprofen	206.131	CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	HEFNNWSXXWATRW-JTQLQIEISA-N	39912.0		HEFNNWSXXWATRW
BRD-K14965640-001-12-4	ibuprofen-(S)	Launched	cyclooxygenase inhibitor	ASIC1|PTGS1|PTGS2|SLC5A8	neurology/psychiatry	pain relief	0	99.44	MicroSource	1502363	DEXIBUPROFEN	206.131	CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	HEFNNWSXXWATRW-JTQLQIEISA-N	39912.0		HEFNNWSXXWATRW
BRD-K14965640-001-14-9	ibuprofen-(S)	Launched	cyclooxygenase inhibitor	ASIC1|PTGS1|PTGS2|SLC5A8	neurology/psychiatry	pain relief	0	93.91	Tocris	2796	(S)-(+)-Ibuprofen	206.131	CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	HEFNNWSXXWATRW-JTQLQIEISA-N	39912.0		HEFNNWSXXWATRW
BRD-M64062803-001-03-9	ibuprofen-lysine	Launched	cyclooxygenase inhibitor		cardiology	patent ductus arteriosus (PDA)	0	0.0	Selleck	S1518	Ibuprofen Lysine (NeoProfen)	352.236	NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|	IHHXIUAEPKVVII-APFIOPMWSA-N	15009332.0		IHHXIUAEPKVVII
BRD-M64062803-001-02-1	ibuprofen-lysine	Launched	cyclooxygenase inhibitor		cardiology	patent ductus arteriosus (PDA)	0	0.0	Selleck	S1518	Ibuprofen Lysine (NeoProfen)	352.236	NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|	IHHXIUAEPKVVII-APFIOPMWSA-N	15009332.0		IHHXIUAEPKVVII
BRD-M64062803-001-04-7	ibuprofen-lysine	Launched	cyclooxygenase inhibitor		cardiology	patent ductus arteriosus (PDA)	0	0.0	Selleck	S1518	Ibuprofen Lysine (NeoProfen)	352.236	NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5,&1:20|	IHHXIUAEPKVVII-APFIOPMWSA-N	15009332.0		IHHXIUAEPKVVII
BRD-A75224450-001-02-4	ibuprofen-piconol	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	95.32	Enamine	Z1537603096	2-pyridinylmethyl 2-(4-isobutylphenyl)propanoate	297.173	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|	ACEWLPOYLGNNHV-OAHLLOKOSA-N	76968625.0		ACEWLPOYLGNNHV
BRD-A75224450-001-01-6	ibuprofen-piconol	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	0.0	Enamine	Z1537603096		297.173	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10,r|	ACEWLPOYLGNNHV-OAHLLOKOSA-N	76968625.0		ACEWLPOYLGNNHV
BRD-A40940854-001-01-1	ibuproxam	Launched	cyclooxygenase inhibitor|prostaglandin inhibitor	ALOX5	endocrinology|rheumatology|neurology/psychiatry	fever|joint inflammation|pain relief	0	80.93	Enzo	EI375	Ibuproxam	221.142	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|	BYPIURIATSUHDW-SNVBAGLBSA-N	11458696.0		BYPIURIATSUHDW
BRD-K44771174-066-03-9	ibutamoren	Phase 2	growth hormone secretagogue receptor agonist	GHR|GHSR			0	90.41	Tocris	5272	MK 0677	528.241	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	UMUPQWIGCOZEOY-JOCHJYFZSA-N	178024.0		UMUPQWIGCOZEOY
BRD-K44771174-066-02-8	ibutamoren	Phase 2	growth hormone secretagogue receptor agonist	GHR|GHSR			0	91.16	Tocris	5272	MK 0677	528.241	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	UMUPQWIGCOZEOY-JOCHJYFZSA-N	178024.0		UMUPQWIGCOZEOY
BRD-K44771174-066-01-0	ibutamoren	Phase 2	growth hormone secretagogue receptor agonist	GHR|GHSR			0	94.74	MedChemEx	HY-50844	Ibutamoren (Mesylate)	528.241	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	UMUPQWIGCOZEOY-JOCHJYFZSA-N	178024.0		UMUPQWIGCOZEOY
BRD-A74391928-051-03-9	ibutilide	Launched	potassium channel blocker	CACNA1C|KCNH2	cardiology	atrial fibrillation (AF)	0	84.16	Tocris	3908	Ibutilide hemifumarate	384.245	CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|	ALOBUEHUHMBRLE-HXUWFJFHSA-N	21149973.0	BRD-M56587789-051-04-6	ALOBUEHUHMBRLE
BRD-A74391928-051-01-3	ibutilide	Launched	potassium channel blocker	CACNA1C|KCNH2	cardiology	atrial fibrillation (AF)	0	88.74	Selleck	S2118	Ibutilide Fumarate	384.245	CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|	ALOBUEHUHMBRLE-HXUWFJFHSA-N	21149973.0	BRD-M56587789-051-02-0	ALOBUEHUHMBRLE
BRD-A74391928-051-04-9	ibutilide	Launched	potassium channel blocker	CACNA1C|KCNH2	cardiology	atrial fibrillation (AF)	0	92.01	Tocris	3908	Ibutilide hemifumarate	384.245	CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|	ALOBUEHUHMBRLE-HXUWFJFHSA-N	21149973.0		ALOBUEHUHMBRLE
BRD-A74391928-051-02-1	ibutilide	Launched	potassium channel blocker	CACNA1C|KCNH2	cardiology	atrial fibrillation (AF)	0	96.32	Selleck	S2118	Ibutilide fumarate	384.245	CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|	ALOBUEHUHMBRLE-HXUWFJFHSA-N	21149973.0	BRD-M56587789-051-03-8	ALOBUEHUHMBRLE
BRD-K59839632-001-01-0	ICA-069673	Preclinical	voltage-gated potassium channel activator	KCNQ2|KCNQ3			0	87.74	Tocris	4305	ICA 069673	269.017	Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1	IIBSHMFXVWTQSJ-UHFFFAOYSA-N	10149311.0		IIBSHMFXVWTQSJ
BRD-K59839632-001-02-9	ICA-069673	Preclinical	voltage-gated potassium channel activator	KCNQ2|KCNQ3			0	92.32	Tocris	4305	ICA 069673	269.017	Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1	IIBSHMFXVWTQSJ-UHFFFAOYSA-N	10149311.0		IIBSHMFXVWTQSJ
BRD-K71686520-001-02-9	ICA-110381	Preclinical	voltage-gated potassium channel activator	KCNQ2			0	92.86	Tocris	4950	ICA 110381	266.001	Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1	FOYOGIUAMYSVIT-UHFFFAOYSA-N	4314115.0		FOYOGIUAMYSVIT
BRD-K71686520-001-01-4	ICA-110381	Preclinical	voltage-gated potassium channel activator	KCNQ2			0	92.75	Tocris	4950	ICA 110381	266.001	Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1	FOYOGIUAMYSVIT-UHFFFAOYSA-N	4314115.0		FOYOGIUAMYSVIT
BRD-K03149601-001-02-6	ICA-121431	Preclinical	sodium channel blocker	SCN1A|SCN3A			0	97.46	Tocris	5066	ICA 121431	449.087	O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1	URSQNPPONHUJDL-UHFFFAOYSA-N	998021.0		URSQNPPONHUJDL
BRD-K03149601-001-01-8	ICA-121431	Preclinical	sodium channel blocker	SCN1A|SCN3A			0	99.45	Stanley		ICA-121431	449.087	O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1	URSQNPPONHUJDL-UHFFFAOYSA-N	998021.0		URSQNPPONHUJDL
BRD-K65639003-001-11-9	icariin	Phase 3	phosphodiesterase inhibitor	PDE5A			0	88.83	MedChemEx	HY-N0014	Icariin	676.237	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	TZJALUIVHRYQQB-XLRXWWTNSA-N	5318997.0		TZJALUIVHRYQQB
BRD-K65639003-001-10-8	icariin	Phase 3	phosphodiesterase inhibitor	PDE5A			0	89.0	Selleck	S2312	Icariin	676.237	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	TZJALUIVHRYQQB-XLRXWWTNSA-N	5318997.0	BRD-A06210771-001-02-9	TZJALUIVHRYQQB
BRD-K65639003-001-09-0	icariin	Phase 3	phosphodiesterase inhibitor	PDE5A			0	93.32	Selleck	S2312	Icariin	676.237	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	TZJALUIVHRYQQB-XLRXWWTNSA-N	5318997.0	BRD-A88583207-001-01-6	TZJALUIVHRYQQB
BRD-K24476327-001-02-1	icaritin	Phase 3	PPAR receptor antagonist	PDE5A			0	88.81	MedChemEx	HY-N0678	Icaritin	368.126	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	TUUXBSASAQJECY-UHFFFAOYSA-N	5318980.0		TUUXBSASAQJECY
BRD-K24476327-001-01-3	icaritin	Phase 3	PPAR receptor antagonist	PDE5A			0	80.18	MedChemEx	HY-N0678	Icaritin	368.126	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	TUUXBSASAQJECY-UHFFFAOYSA-N	5318980.0		TUUXBSASAQJECY
BRD-K24476327-001-03-9	icaritin	Phase 3	PPAR receptor antagonist	PDE5A			0	62.12	Sigma	MFCD22422519	5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)chromane-3,4-dione	368.126	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	TUUXBSASAQJECY-UHFFFAOYSA-N	5318980.0		TUUXBSASAQJECY
BRD-K63772874-001-03-0	icatibant-acetate	Launched	bradykinin receptor antagonist	BDKRB2	cardiology	angioedema	0	93.99	MedChemEx	HY-17446	Icatibant	1303.661	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	QURWXBZNHXJZBE-SKXRKSCCSA-N	6918173.0		QURWXBZNHXJZBE
BRD-K63772874-001-02-2	icatibant-acetate	Launched	bradykinin receptor antagonist	BDKRB2	cardiology	angioedema	0	76.03	MedChemEx	HY-17446	Icatibant	1303.661	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	QURWXBZNHXJZBE-SKXRKSCCSA-N	6918173.0		QURWXBZNHXJZBE
BRD-K63772874-001-01-4	icatibant-acetate	Launched	bradykinin receptor antagonist	BDKRB2	cardiology	angioedema	0	55.15	MedChemEx	HY-17446	Icatibant	1303.661	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	QURWXBZNHXJZBE-SKXRKSCCSA-N	6918173.0		QURWXBZNHXJZBE
BRD-K73261812-001-05-9	ICG-001	Preclinical	beta-catenin inhibitor	CTNNB1			0	91.46	Tocris	4505	ICG 001	548.242	Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1	HQWTUOLCGKIECB-XZWHSSHBSA-N	11238147.0		HQWTUOLCGKIECB
BRD-K74603273-003-02-9	ICI-118,551	Phase 2	adrenergic receptor antagonist	ADRB2|ADRB3			0	92.56	Tocris	821	ICI 118,551 hydrochloride	277.204	CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12	VFIDUCMKNJIJTO-XJKSGUPXSA-N	5311179.0		VFIDUCMKNJIJTO
BRD-K74603273-003-01-1	ICI-118,551	Phase 2	adrenergic receptor antagonist	ADRB2|ADRB3			0	97.18	Tocris	821	ICI 118,551 hydrochloride	277.204	CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12	VFIDUCMKNJIJTO-XJKSGUPXSA-N	5311179.0		VFIDUCMKNJIJTO
BRD-K66782112-001-03-9	ICI-162846	Phase 1	histamine receptor antagonist	HRH2			0	86.97	Tocris	833	ICI 162,846	306.142	NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1	ALCSGJCIESECFD-UHFFFAOYSA-N	134778.0		ALCSGJCIESECFD
BRD-K66782112-001-02-0	ICI-162846	Phase 1	histamine receptor antagonist	HRH2			0	91.43	Tocris	833	ICI 162,846	306.142	NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1	ALCSGJCIESECFD-UHFFFAOYSA-N	134778.0		ALCSGJCIESECFD
BRD-K00004569-001-01-9	ICI-169369	Phase 2	serotonin receptor antagonist				0	90.63	Sigma	MFCD28047481	N,N-dimethyl-2-(3-phenylquinolin-2-ylthio)ethanamine	308.135	CN(C)CCSc1nc2ccccc2cc1-c1ccccc1	HYOLQGVNMQNERE-UHFFFAOYSA-N	122265.0		HYOLQGVNMQNERE
BRD-K29133151-001-03-2	ICI-185,282	Phase 1	thromboxane receptor antagonist				0	96.78	Tocris	836	ICI 185,282	374.134	OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F	ZWAVGFSZMACJHA-PMNBYGLBSA-N	5311390.0		ZWAVGFSZMACJHA
BRD-K59433843-001-02-5	ICI-192605	Phase 2	thromboxane receptor antagonist	TBXA2R			0	94.82	Tocris	837	ICI 192,605	402.123	OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	WHUIENZXNGAHQI-GKZDNZBASA-N	6604763.0		WHUIENZXNGAHQI
BRD-K59433843-001-03-9	ICI-192605	Phase 2	thromboxane receptor antagonist	TBXA2R			0	94.87	Tocris	837	ICI 192,605	402.123	OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	WHUIENZXNGAHQI-GKZDNZBASA-N	6604763.0		WHUIENZXNGAHQI
BRD-K59433843-001-01-7	ICI-192605	Phase 2	thromboxane receptor antagonist	TBXA2R			0	96.71	Tocris	837	ICI 192,605	402.123	OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	WHUIENZXNGAHQI-GKZDNZBASA-N	6604763.0		WHUIENZXNGAHQI
BRD-K73290745-003-03-4	ICI-199441	Preclinical	opioid receptor agonist	CYP2D6|OPRD1|OPRK1|OPRM1|UTS2R			0	97.12	Tocris	778	ICI 199,441 hydrochloride	390.127	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	AEJOEPSMZCEYJN-HXUWFJFHSA-N	3082718.0		AEJOEPSMZCEYJN
BRD-K73290745-003-04-9	ICI-199441	Preclinical	opioid receptor agonist	CYP2D6|OPRD1|OPRK1|OPRM1|UTS2R			0	97.04	Tocris	778	ICI 199,441 hydrochloride	390.127	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	AEJOEPSMZCEYJN-HXUWFJFHSA-N	3082718.0		AEJOEPSMZCEYJN
BRD-K73290745-003-02-6	ICI-199441	Preclinical	opioid receptor agonist	CYP2D6|OPRD1|OPRK1|OPRM1|UTS2R			0	95.83	Tocris	778	ICI 199,441 hydrochloride	390.127	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	AEJOEPSMZCEYJN-HXUWFJFHSA-N	3082718.0		AEJOEPSMZCEYJN
BRD-K52487250-003-01-2	ICI-215,001	Preclinical	adrenergic receptor agonist	ADRB3			0	98.33	Tocris	929	ICI 215,001 hydrochloride	361.153	O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1	MXWICZOXPUWAHY-HNNXBMFYSA-N	164451.0		MXWICZOXPUWAHY
BRD-K52219182-001-03-2	ICI-63197	Preclinical	phosphodiesterase inhibitor				0	96.67	Tocris	1816	ICI 63197	207.112	CCCn1c2nc(N)nn2cc(C)c1=O	UQDVRVNMIJAGRK-UHFFFAOYSA-N	62824.0		UQDVRVNMIJAGRK
BRD-K52219182-001-04-9	ICI-63197	Preclinical	phosphodiesterase inhibitor				0	91.79	Tocris	1816	ICI 63197	207.112	CCCn1c2nc(N)nn2cc(C)c1=O	UQDVRVNMIJAGRK-UHFFFAOYSA-N	62824.0		UQDVRVNMIJAGRK
BRD-K52219182-001-02-4	ICI-63197	Preclinical	phosphodiesterase inhibitor				0	97.43	Tocris	1816	ICI 63197	207.112	CCCn1c2nc(N)nn2cc(C)c1=O	UQDVRVNMIJAGRK-UHFFFAOYSA-N	62824.0		UQDVRVNMIJAGRK
BRD-A03359064-001-02-3	ICI-89406	Phase 1	adrenergic receptor antagonist	ADRB1|ADRB2			0	88.81	Tocris	832	ICI 89406	354.169	O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|	HTLWRKRZKFAAAH-KRWDZBQOSA-N	92211532.0		HTLWRKRZKFAAAH
BRD-A03359064-001-03-9	ICI-89406	Phase 1	adrenergic receptor antagonist	ADRB1|ADRB2			0	93.98	Tocris	832	ICI 89406	354.169	O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1,r|	HTLWRKRZKFAAAH-KRWDZBQOSA-N	92211532.0		HTLWRKRZKFAAAH
BRD-K48869804-001-09-6	icilin	Phase 1	TRPV agonist	TRPA1|TRPM8			0	10.14	Tocris	1531	Icilin	311.091	Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|	RCEFMOGVOYEGJN-UHFFFAOYSA-N	161930.0		RCEFMOGVOYEGJN
BRD-K00003415-001-01-9	iclaprim	Phase 3	dihydrofolate reductase inhibitor				0	98.18	MedChemEx	HY-101479	Iclaprim	354.169	COc1cc(Cc2cnc(N)nc2N)c2C=C[C@H](Oc2c1OC)C1CC1 |&1:17,r,c:16|	HWJPWWYTGBZDEG-AWEZNQCLSA-N	10247560.0		HWJPWWYTGBZDEG
BRD-K41234004-001-03-1	icomucret	Phase 3	mucin production enhancer	LTB4R2			0	44.0	Enzo	H015	15(S)-HETE	320.235	CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O	JSFATNQSLKRBCI-VAEKSGALSA-N	5280724.0		JSFATNQSLKRBCI
BRD-K47192521-001-05-4	icosapent	Launched	platelet aggregation inhibitor	ACSL3|ACSL4|FADS1|FFAR1|PPARD|PPARG|PTGS1|PTGS2|SLC8A1|TRPV1	endocrinology	hypertriglyceridemia	0	87.46	Enzo	FA001	Eicosapentaenoic acid (20:5 n-3)	302.225	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	JAZBEHYOTPTENJ-JLNKQSITSA-N	446284.0		JAZBEHYOTPTENJ
BRD-K47192521-001-06-2	icosapent	Launched	platelet aggregation inhibitor	ACSL3|ACSL4|FADS1|FFAR1|PPARD|PPARG|PTGS1|PTGS2|SLC8A1|TRPV1	endocrinology	hypertriglyceridemia	0	13.49	Sigma	44864-100MG	Eicosapentaenoic acid (cis-)	302.225	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	JAZBEHYOTPTENJ-JLNKQSITSA-N	446284.0		JAZBEHYOTPTENJ
BRD-K31698212-001-03-9	icotinib	Launched	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	0	95.89	MedChemEx	HY-15164A	Icotinib	391.153	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	QQLKULDARVNMAL-UHFFFAOYSA-N	22024915.0		QQLKULDARVNMAL
BRD-K31698212-001-02-9	icotinib	Launched	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	0	96.95	Selleck	S2922	Icotinib	391.153	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	QQLKULDARVNMAL-UHFFFAOYSA-N	22024915.0		QQLKULDARVNMAL
BRD-K18634484-001-01-4	iCRT-14	Preclinical	beta catenin inhibitor|WNT signaling inhibitor	CTNNB1|TCF4			0	89.36	Tocris	4299	iCRT 14	375.104	Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1	NCSHZXNGQYSKLR-UNOMPAQXSA-N	5967294.0		NCSHZXNGQYSKLR
BRD-K18634484-001-02-9	iCRT-14	Preclinical	beta catenin inhibitor|WNT signaling inhibitor	CTNNB1|TCF4			0	93.93	Tocris	4299	iCRT 14	375.104	Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1	NCSHZXNGQYSKLR-UNOMPAQXSA-N	5967294.0		NCSHZXNGQYSKLR
BRD-K09638361-001-02-2	IC261	Preclinical	casein kinase inhibitor	CSNK1A1|CSNK1D|CSNK1E|CSNK1G2			0	74.58	MedChemEx	HY-12774	IC261	311.116	COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1	JBJYTZXCZDNOJW-JLHYYAGUSA-N	5288600.0		JBJYTZXCZDNOJW
BRD-K09638361-001-03-0	IC261	Preclinical	casein kinase inhibitor	CSNK1A1|CSNK1D|CSNK1E|CSNK1G2			0	70.13	MedChemEx	HY-12774	IC261	311.116	COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1	JBJYTZXCZDNOJW-JLHYYAGUSA-N	5288600.0		JBJYTZXCZDNOJW
BRD-K90305467-001-01-3	ID-1101	Phase 1	insulin sensitizer	INS			0	78.9	Sigma	50118	2-amino-2,3,5-trideoxy-3-methyl-L-ribonic acid	147.09	C[C@H](O)[C@H](C)[C@H](N)C(O)=O	OSCCDBFHNMXNME-YUPRTTJUSA-N	6918732.0		OSCCDBFHNMXNME
BRD-K39166528-001-02-8	ID-8	Preclinical					0	92.58	Tocris	3853	ID 8	298.095	COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	VVZNWYXIOADGSW-UHFFFAOYSA-N	791637.0		VVZNWYXIOADGSW
BRD-K39166528-001-01-0	ID-8	Preclinical					0	97.87	Selleck	S7327	ID-8	298.095	COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	VVZNWYXIOADGSW-UHFFFAOYSA-N	791637.0		VVZNWYXIOADGSW
BRD-K39166528-001-03-9	ID-8	Preclinical					0	98.74	Tocris	3853	ID 8	298.095	COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	VVZNWYXIOADGSW-UHFFFAOYSA-N	791637.0		VVZNWYXIOADGSW
BRD-K79102359-003-01-6	idalopirdine	Phase 3	serotonin receptor antagonist	HTR6			0	95.12	MedChemEx	HY-14338A	Lu AE58054 (Hydrochloride)	398.142	FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1	YBAWYTYNMZWMMJ-UHFFFAOYSA-N	21071390.0		YBAWYTYNMZWMMJ
BRD-K79102359-003-02-9	idalopirdine	Phase 3	serotonin receptor antagonist	HTR6			0	97.15	MedChemEx	HY-14338A	Idalopirdine Hydrochloride	398.142	FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1	YBAWYTYNMZWMMJ-UHFFFAOYSA-N	21071390.0		YBAWYTYNMZWMMJ
BRD-K69650333-003-14-0	idarubicin	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	0	88.11	Selleck	S1228	Idarubicin HCl	497.169	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	XDXDZDZNSLXDNA-TZNDIEGXSA-N	42890.0	BRD-K63126143-003-01-4	XDXDZDZNSLXDNA
BRD-K69650333-003-13-2	idarubicin	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy	acute myeloid leukemia (AML)	0	98.01	Selleck	S1228	Idarubicin HCl	497.169	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	XDXDZDZNSLXDNA-TZNDIEGXSA-N	42890.0		XDXDZDZNSLXDNA
BRD-K62627508-001-01-5	idasanutlin	Phase 3	MDM inhibitor	MDM2|TP53			0	97.79	MedChemEx	HY-15676	RG7388	615.15	COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	TVTXCJFHQKSQQM-LJQIRTBHSA-N	53358942.0		TVTXCJFHQKSQQM
BRD-K62627508-001-06-9	idasanutlin	Phase 3	MDM inhibitor	MDM2|TP53			0		Cayman	21532	idasanutlin	615.15	COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	InChI=1S/C31H29Cl2F2N3O4/c1-30(2,3)14-24-31(15-36,19-10-9-17(32)13-21(19)34)25(18-6-5-7-20(33)26(18)35)27(38-24)28(39)37-22-11-8-16(29(40)41)12-23(22)42-4/h5-13,24-25,27,38H,14H2,1-4H3,(H,37,39)(H,40,41)/t24-,25-,27+,31-/m0/s1	53358942.0		TVTXCJFHQKSQQM
BRD-A18696154-001-02-2	idazoxan	Phase 3	adrenergic receptor antagonist	ADRA2A|PTGS2			0	96.56	AMS	A001595684	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	204.09	C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|	HPMRFMKYPGXPEP-SNVBAGLBSA-N	12866829.0		HPMRFMKYPGXPEP
BRD-A18696154-003-22-6	idazoxan	Phase 3	adrenergic receptor antagonist	ADRA2A|PTGS2			0	84.32	MicroSource	1506073	IDAZOXAN HYDROCHLORIDE	204.09	C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|	HPMRFMKYPGXPEP-SNVBAGLBSA-N	12866829.0		HPMRFMKYPGXPEP
BRD-A18696154-003-21-8	idazoxan	Phase 3	adrenergic receptor antagonist	ADRA2A|PTGS2			0	68.74	Tocris	793	Idazoxan hydrochloride	204.09	C1CN=C(N1)[C@H]1COc2ccccc2O1 |r,c:2|	HPMRFMKYPGXPEP-SNVBAGLBSA-N	12866829.0		HPMRFMKYPGXPEP
BRD-K37516142-001-10-5	idebenone	Launched	calcium channel modulator		neurology/psychiatry|ophthalmology	Alzheimer's disease|Friedreich's ataxia|Leber hereditary optic neuropathy (LHON)	0	95.71	MicroSource	1505755	IDEBENONE	338.209	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|	JGPMMRGNQUBGND-UHFFFAOYSA-N	3686.0		JGPMMRGNQUBGND
BRD-K37516142-001-11-3	idebenone	Launched	calcium channel modulator		neurology/psychiatry|ophthalmology	Alzheimer's disease|Friedreich's ataxia|Leber hereditary optic neuropathy (LHON)	0	85.77	Selleck	S2605	Idebenone	338.209	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|	JGPMMRGNQUBGND-UHFFFAOYSA-N	3686.0		JGPMMRGNQUBGND
BRD-K37516142-001-13-9	idebenone	Launched	calcium channel modulator		neurology/psychiatry|ophthalmology	Alzheimer's disease|Friedreich's ataxia|Leber hereditary optic neuropathy (LHON)	0	82.16	Tocris	3002	Idebenone	338.209	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|	JGPMMRGNQUBGND-UHFFFAOYSA-N	3686.0		JGPMMRGNQUBGND
BRD-K37516142-001-09-7	idebenone	Launched	calcium channel modulator		neurology/psychiatry|ophthalmology	Alzheimer's disease|Friedreich's ataxia|Leber hereditary optic neuropathy (LHON)	0	89.57	Selleck	S2605	Idebenone	338.209	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2,t:19|	JGPMMRGNQUBGND-UHFFFAOYSA-N	3686.0		JGPMMRGNQUBGND
BRD-K60866521-001-07-1	idelalisib	Launched	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	96.97	Selleck	S2226	CAL-101 (Idelalisib, GS-1101)	415.156	CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	IFSDAJWBUCMOAH-HNNXBMFYSA-N	11625818.0		IFSDAJWBUCMOAH
BRD-K60866521-001-04-8	idelalisib	Launched	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0		Selleck	S2226	CAL-101 (GS-1101)	415.156	CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1	11625818.0		IFSDAJWBUCMOAH
BRD-K00003098-001-01-9	IDF-11774	Preclinical	hypoxia inducible factor inhibitor				0	91.96	MedChemEx	HY-111387	IDF-11774	368.246	CN1CCN(CC1)C(=O)COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2	QGBBBLPWBSWERZ-UHFFFAOYSA-N	71542096.0		QGBBBLPWBSWERZ
BRD-K00003457-001-01-9	IDH-305	Phase 2	isocitrate dehydrogenase inhibitor				0	95.98	MedChemEx	HY-104036	IDH-305	490.174	C[C@H](F)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1	DCGDPJCUIKLTDU-SUNYJGFJSA-N	90415637.0		DCGDPJCUIKLTDU
BRD-K76634210-001-15-9	idoxuridine	Launched	DNA directed DNA polymerase inhibitor|DNA synthesis inhibitor		infectious disease	virus herpes simplex (HSV)	0	100.0	MedChemEx	HY-B0307	Idoxuridine	353.971	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	XQFRJNBWHJMXHO-RRKCRQDMSA-N	5905.0		XQFRJNBWHJMXHO
BRD-K76634210-001-12-1	idoxuridine	Launched	DNA directed DNA polymerase inhibitor|DNA synthesis inhibitor		infectious disease	virus herpes simplex (HSV)	0	94.78	Selleck	S1883	Idoxuridine	353.971	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	XQFRJNBWHJMXHO-RRKCRQDMSA-N	5905.0		XQFRJNBWHJMXHO
BRD-K76634210-001-14-7	idoxuridine	Launched	DNA directed DNA polymerase inhibitor|DNA synthesis inhibitor		infectious disease	virus herpes simplex (HSV)	0	98.08	MicroSource	1502350	IDOXURIDINE	353.971	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	XQFRJNBWHJMXHO-RRKCRQDMSA-N	5905.0	BRD-A85439007-001-01-6	XQFRJNBWHJMXHO
BRD-K22356203-001-01-8	IDO5L	Preclinical	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	88.63	MedChemEx	HY-15683	INCB024360	271.027	Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1	HGXSLPIXNPASGZ-UHFFFAOYSA-N	135424953.0		HGXSLPIXNPASGZ
BRD-K22356203-001-02-9	IDO5L	Preclinical	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	95.26	MedChemEx	HY-15683	IDO5L	271.027	Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1	HGXSLPIXNPASGZ-UHFFFAOYSA-N	135424953.0		HGXSLPIXNPASGZ
BRD-A14344385-001-04-0	IDRA-21	Preclinical	glutamate receptor positive allosteric modulator	GRIA1|GRIA2|GRIA3|GRIA4			0	97.41	Tocris	1219	IDRA 21	232.007	C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|	VZRNTCHTJRLTMU-YFKPBYRVSA-N	7048549.0		VZRNTCHTJRLTMU
BRD-A14344385-001-05-9	IDRA-21	Preclinical	glutamate receptor positive allosteric modulator	GRIA1|GRIA2|GRIA3|GRIA4			0	92.3	Tocris	1219	IDRA 21	232.007	C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|	VZRNTCHTJRLTMU-YFKPBYRVSA-N	7048549.0		VZRNTCHTJRLTMU
BRD-A14344385-001-03-2	IDRA-21	Preclinical	glutamate receptor positive allosteric modulator	GRIA1|GRIA2|GRIA3|GRIA4			0	87.78	Tocris	1219	IDRA 21	232.007	C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1,r|	VZRNTCHTJRLTMU-YFKPBYRVSA-N	7048549.0		VZRNTCHTJRLTMU
BRD-K00003671-001-01-9	idramantone	Preclinical					0	100.0	MedChemEx	HY-B1044	Idramantone	166.099	[H][C@@]12C[C@@]3([H])C[C@@](O)(C1)C[C@@]([H])(C2)C3=O |&1:1,3,6,10|	TZBDEVBNMSLVKT-XYYXLIQBSA-N			TZBDEVBNMSLVKT
BRD-K74671368-001-01-8	idronoxil	Phase 3	XIAP inhibitor	ENOX2|SPHK1			0	92.71	Sigma	MFCD06636630	3-(4-hydroxyphenyl)-2H-chromen-7-ol	240.079	Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|	ZZUBHVMHNVYXRR-UHFFFAOYSA-N	219100.0		ZZUBHVMHNVYXRR
BRD-K13829090-303-03-7	IEM1460	Preclinical	glutamate receptor antagonist	GRIA2			0	80.14	Tocris	1636	IEM 1460	293.296	C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	IWYZMMIPAJDJBN-UHFFFAOYSA-N	3248290.0		IWYZMMIPAJDJBN
BRD-K13829090-303-04-9	IEM1460	Preclinical	glutamate receptor antagonist	GRIA2			0	100.0	Tocris	1636	IEM 1460	293.296	C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	IWYZMMIPAJDJBN-UHFFFAOYSA-N	3248290.0		IWYZMMIPAJDJBN
BRD-K13829090-303-02-9	IEM1460	Preclinical	glutamate receptor antagonist	GRIA2			0	98.63	Tocris	1636	IEM 1460	293.296	C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	IWYZMMIPAJDJBN-UHFFFAOYSA-N	3248290.0		IWYZMMIPAJDJBN
BRD-K80060353-303-03-9	IEM1754	Preclinical	glutamate receptor antagonist	GRIA1			0	95.33	Selleck	S2860	IEM 1754 dihydrobroMide	250.241	NCCCCCNCC12CC3CC(CC(C3)C1)C2	UWWMQHVWAYFCDT-UHFFFAOYSA-N	9887868.0		UWWMQHVWAYFCDT
BRD-K80060353-303-02-1	IEM1754	Preclinical	glutamate receptor antagonist	GRIA1			0	0.0	Selleck	S2860	IEM 1754 dihydrobroMide	250.241	NCCCCCNCC12CC3CC(CC(C3)C1)C2	UWWMQHVWAYFCDT-UHFFFAOYSA-N	9887868.0		UWWMQHVWAYFCDT
BRD-K80060353-303-04-9	IEM1754	Preclinical	glutamate receptor antagonist	GRIA1			0	4.78	Tocris	4199	IEM 1754 dihydrobromide	250.241	NCCCCCNCC12CC3CC(CC(C3)C1)C2	UWWMQHVWAYFCDT-UHFFFAOYSA-N	9887868.0		UWWMQHVWAYFCDT
BRD-K00004210-045-01-9	ifenprodil	Launched	adrenergic receptor antagonist|glutamate receptor antagonist	GRIN2B			0	94.12	Tocris	545	Ifenprodil hemitartrate	325.204	C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1,2|	UYNVMODNBIQBMV-KKSFZXQISA-N	6604117.0		UYNVMODNBIQBMV
BRD-A67097164-001-18-7	ifosfamide	Launched	DNA alkylating agent	CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP3A4|CYP3A5|CYP3A7|PTGS1	oncology|urology	testicular carcinoma|hemorrhagic cystitis	0	100.0	MicroSource	1505480	IFOSFAMIDE	260.025	ClCCN[P@@]1(=O)OCCCN1CCCl |r|	HOMGKSMUEGBAAB-CQSZACIVSA-N	9588020.0		HOMGKSMUEGBAAB
BRD-A67097164-001-17-9	ifosfamide	Launched	DNA alkylating agent	CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP3A4|CYP3A5|CYP3A7|PTGS1	oncology|urology	testicular carcinoma|hemorrhagic cystitis	0	99.3	Selleck	S1302	Ifosfamide	260.025	ClCCN[P@@]1(=O)OCCCN1CCCl |r|	HOMGKSMUEGBAAB-CQSZACIVSA-N	9588020.0		HOMGKSMUEGBAAB
BRD-A48376327-003-01-5	igmesine	Phase 2	sigma receptor agonist	SIGMAR1			0	95.83	Tocris	2332	(E)-N-(cyclopropylmethyl)-N-methyl-3,6-diphenylhex-5-en-3-amine hydrochloride	319.23	CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|	VCZSWYIFCKGTJI-JLHYYAGUSA-N	6438340.0		VCZSWYIFCKGTJI
BRD-K15426076-001-01-2	iguratimod	Launched	cyclooxygenase inhibitor|NFkB pathway inhibitor	PTGS2	rheumatology	rheumatoid arthritis	0	96.01	MedChemEx	HY-17009	Iguratimod	374.057	CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1	ANMATWQYLIFGOK-UHFFFAOYSA-N	124246.0		ANMATWQYLIFGOK
BRD-K15426076-001-02-9	iguratimod	Launched	cyclooxygenase inhibitor|NFkB pathway inhibitor	PTGS2	rheumatology	rheumatoid arthritis	0	94.49	MedChemEx	HY-17009	Iguratimod	374.057	CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1	ANMATWQYLIFGOK-UHFFFAOYSA-N	124246.0		ANMATWQYLIFGOK
BRD-K14618467-003-02-6	IKK-16	Preclinical	IKK inhibitor	IKBKB			0	95.29	Tocris	2539	IKK 16	483.209	O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	BWZJBXAPRCVCKQ-UHFFFAOYSA-N	9549298.0		BWZJBXAPRCVCKQ
BRD-K14618467-003-07-9	IKK-16	Preclinical	IKK inhibitor	IKBKB			0	95.84	Tocris	2539	IKK 16	483.209	O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	BWZJBXAPRCVCKQ-UHFFFAOYSA-N	9549298.0		BWZJBXAPRCVCKQ
BRD-K14618467-003-03-4	IKK-16	Preclinical	IKK inhibitor	IKBKB			0	90.07	Tocris	2539	IKK 16	483.209	O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	BWZJBXAPRCVCKQ-UHFFFAOYSA-N	9549298.0		BWZJBXAPRCVCKQ
BRD-K14618467-001-04-6	IKK-16	Preclinical	IKK inhibitor	IKBKB			0	93.32	Selleck	S2882	IKK-16 (IKK Inhibitor VII)	483.209	O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	BWZJBXAPRCVCKQ-UHFFFAOYSA-N	9549298.0		BWZJBXAPRCVCKQ
BRD-K26373640-001-06-9	IKK-2-inhibitor	Preclinical	IKK inhibitor|SYK inhibitor	IKBKB			0	83.04	Tocris	3318	SC 514	224.008	NC(=O)c1sc(cc1N)-c1ccsc1	BMUACLADCKCNKZ-UHFFFAOYSA-N	2807869.0		BMUACLADCKCNKZ
BRD-K26373640-001-05-1	IKK-2-inhibitor	Preclinical	IKK inhibitor|SYK inhibitor	IKBKB			0	86.1	Selleck	S4907	SC-514	224.008	NC(=O)c1sc(cc1N)-c1ccsc1	BMUACLADCKCNKZ-UHFFFAOYSA-N	2807869.0		BMUACLADCKCNKZ
BRD-K26373640-001-07-7	IKK-2-inhibitor	Preclinical	IKK inhibitor|SYK inhibitor	IKBKB			0	94.68	Selleck	S4907	SC-514	224.008	NC(=O)c1sc(cc1N)-c1ccsc1	BMUACLADCKCNKZ-UHFFFAOYSA-N	2807869.0		BMUACLADCKCNKZ
BRD-K74305673-001-07-0	IKK-2-inhibitor-V	Phase 1	IKK inhibitor|NFkB pathway inhibitor	IKBKB			0	96.15	Tocris	2611	IMD 0354	383.015	Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F	CHILCFMQWMQVAL-UHFFFAOYSA-N	5081913.0		CHILCFMQWMQVAL
BRD-K74305673-001-06-2	IKK-2-inhibitor-V	Phase 1	IKK inhibitor|NFkB pathway inhibitor	IKBKB			0	97.99	Selleck	S2864	IMD 0354	383.015	Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F	CHILCFMQWMQVAL-UHFFFAOYSA-N	5081913.0		CHILCFMQWMQVAL
BRD-K00003427-001-01-9	ilaprazole	Launched	proton pump inhibitor		gastroenterology	gastroesophageal reflux disease (GERD)	0	41.08	MedChemEx	HY-101664	Ilaprazole	366.115	COc1ccnc(C[S@@](=O)c2nc3ccc(cc3[nH]2)-n2cccc2)c1C |&1:8,r|	HRRXCXABAPSOCP-AREMUKBSSA-N	76968095.0		HRRXCXABAPSOCP
BRD-K60480335-001-09-9	ilepcimide	Phase 3	anticonvulsant				0	95.17	Vitas-M	STK416971	(2E)-3-(1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)prop-2-en-1-one	259.121	O=C(\C=C\c1ccc2OCOc2c1)N1CCCCC1	BLPUOQGPBJPXRL-FNORWQNLSA-N	641115.0		BLPUOQGPBJPXRL
BRD-K51662849-001-05-4	ilomastat	Phase 3	matrix metalloprotease inhibitor	ACAN|ADAM28|MMP1|MMP12|MMP13|MMP14|MMP2|MMP3|MMP8|MMP9			0	93.3	Selleck	S7157	Ilomastat (GM6001, Galardin)	388.211	CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	NITYDPDXAAFEIT-DYVFJYSZSA-N	132519.0		NITYDPDXAAFEIT
BRD-K51662849-001-08-8	ilomastat	Phase 3	matrix metalloprotease inhibitor	ACAN|ADAM28|MMP1|MMP12|MMP13|MMP14|MMP2|MMP3|MMP8|MMP9			0	94.49	Selleck	S7157	GM6001	388.211	CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	NITYDPDXAAFEIT-DYVFJYSZSA-N	132519.0		NITYDPDXAAFEIT
BRD-K48722833-001-07-6	iloperidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR2A|HTR6|HTR7	neurology/psychiatry	schizophrenia	0	97.56	Selleck	S1483	Iloperidone	426.195	COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O	XMXHEBAFVSFQEX-UHFFFAOYSA-N	71360.0		XMXHEBAFVSFQEX
BRD-A45664787-001-04-8	iloprost	Launched	platelet aggregation inhibitor|prostanoid receptor agonist	PTGDR|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|PTGIR|TBXA2R	pulmonary	pulmonary arterial hypertension (PAH)	0	50.79	MedChemEx	HY-A0096	Iloprost	360.23	CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6,10,11,14,18,&1:4|	HIFJCPQKFCZDDL-GBSCXWAGSA-N	51397006.0		HIFJCPQKFCZDDL
BRD-K92723993-001-12-5	imatinib	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)	0	99.23	Selleck	S2475	Imatinib	493.259	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	KTUFNOKKBVMGRW-UHFFFAOYSA-N	5291.0		KTUFNOKKBVMGRW
BRD-K92723993-001-06-7	imatinib	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)	0	96.55	Selleck	S2475	Imatinib (STI571)	493.259	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	KTUFNOKKBVMGRW-UHFFFAOYSA-N	5291.0		KTUFNOKKBVMGRW
BRD-K92723993-066-22-7	imatinib	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)	0	96.22	Selleck	S1026	Imatinib Mesylate (STI571)	493.259	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	KTUFNOKKBVMGRW-UHFFFAOYSA-N	5291.0		KTUFNOKKBVMGRW
BRD-K92723993-001-28-9	imatinib	Launched	Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET	hematologic malignancy|oncology	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)|myelodysplastic diseases (MDS)|aggressive systemic mastocytosis (ASM)|hypereosinophilic syndrome (HES)|chronic eosinophilic leukemia (CEL)|dermatofibrosarcoma protuberans (DFSP)|gastrointestinal stromal tumors (GIST)	0	98.23	MedChemEx	HY-15463	Imatinib	493.259	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	KTUFNOKKBVMGRW-UHFFFAOYSA-N	5291.0		KTUFNOKKBVMGRW
BRD-K96298462-001-08-9	Imazodan	Phase 1	phosphodiesterase inhibitor				0	91.48	AMS	A125170	6-[4-(1H-imidazol-1-yl)phenyl]-4,5-dihydro-3(2H)-pyridazinone	240.101	O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1 |c:4|	VXMYWVMXSWJFCV-UHFFFAOYSA-N	55918.0		VXMYWVMXSWJFCV
BRD-K55822903-003-02-6	imeglimin	Phase 2	gluconeogenesis inhibitor				0	97.85	MedChemEx	HY-14771A	Imeglimin (hydrochloride)	155.117	C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|	GFICWFZTBXUVIG-SCSAIBSYSA-N	24812808.0		GFICWFZTBXUVIG
BRD-K55822903-003-01-8	imeglimin	Phase 2	gluconeogenesis inhibitor				0	70.27	MedChemEx	HY-14771A	Imeglimin (hydrochloride)	155.117	C[C@H]1NC(=NC(N)=N1)N(C)C |c:3,6|	GFICWFZTBXUVIG-SCSAIBSYSA-N	24812808.0		GFICWFZTBXUVIG
BRD-K33183200-303-06-9	imetit	Preclinical	histamine receptor agonist	HRH3|HRH4			0	90.11	Tocris	729	Imetit dihydrobromide	170.063	NC(=N)SCCc1cnc[nH]1	PEHSVUKQDJULKE-UHFFFAOYSA-N	3692.0		PEHSVUKQDJULKE
BRD-K33183200-303-02-4	imetit	Preclinical	histamine receptor agonist	HRH3|HRH4			0	90.26	Tocris	729	Imetit dihydrobromide	170.063	NC(=N)SCCc1cnc[nH]1	PEHSVUKQDJULKE-UHFFFAOYSA-N	3692.0		PEHSVUKQDJULKE
BRD-A78195072-001-06-2	imexon	Phase 2	apoptosis stimulant|ribonucleotide reductase inhibitor				0	100.0	MicroSource	1506181	IMEXON	111.043	NC1=NC(=O)N2C[C@@H]12 |r,t:1|	BIXBBIPTYBJTRY-VBMBUWLQSA-N	24822698.0		BIXBBIPTYBJTRY
BRD-K76609936-001-08-4	imidacloprid	Launched	acetylcholine receptor antagonist				0	99.22	SantaCruz	sc-211632	Imidacloprid	255.052	[O-][N+](=O)N=C1NCCN1Cc1ccc(Cl)nc1	YWTYJOPNNQFBPC-UHFFFAOYSA-N	86418.0		YWTYJOPNNQFBPC
BRD-K29626940-001-01-5	imidafenacin	Launched	acetylcholine receptor antagonist	CHRM1|CHRM3	neurology/psychiatry	spasms	0	97.97	MedChemEx	HY-B0662	4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide	319.168	Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1	SQKXYSGRELMAAU-UHFFFAOYSA-N	6433090.0		SQKXYSGRELMAAU
BRD-K29626940-001-02-3	imidafenacin	Launched	acetylcholine receptor antagonist	CHRM1|CHRM3	neurology/psychiatry	spasms	0	94.31	MedChemEx	HY-B0662	Imidafenacin	319.168	Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1	SQKXYSGRELMAAU-UHFFFAOYSA-N	6433090.0		SQKXYSGRELMAAU
BRD-K11466259-003-04-1	imidapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure	0	97.97	Selleck	S2109	Imidapril HCl	405.19	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O	KLZWOWYOHUKJIG-BPUTZDHNSA-N	5464343.0		KLZWOWYOHUKJIG
BRD-K00004617-001-01-9	imidazoacridinone	Preclinical	anticancer agent				0	57.63	Sigma	SML0465	5-{[2-(diethylamino)ethyl]amino}-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one	350.174	CCN(CC)CCNc1ccc2ncn3c2c1c(=O)c1cc(O)ccc31	CUNDRHORZHFPLY-UHFFFAOYSA-N	132127.0		CUNDRHORZHFPLY
BRD-K00003682-001-01-9	imidurea	Preclinical	other antibiotic				0	100.0	MedChemEx	HY-B1158	Imidazolidinyl urea	388.109	OCN1[C@@H](NC(=O)NCNC(=O)N[C@@H]2N(CO)C(=O)NC2=O)C(=O)NC1=O |&1:3,&2:13,r|	ZCTXEAQXZGPWFG-RFZPGFLSSA-N	6604401.0		ZCTXEAQXZGPWFG
BRD-A10903566-003-08-9	imiloxan	Phase 1	adrenergic receptor antagonist	ADRA2A|ADRA2B			0	89.04	Tocris	986	Imiloxan hydrochloride	244.121	CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|	UXABARREKCJULM-NSHDSACASA-N	76966048.0		UXABARREKCJULM
BRD-A10903566-003-07-7	imiloxan	Phase 1	adrenergic receptor antagonist	ADRA2A|ADRA2B			0	97.18	Tocris	986	Imiloxan hydrochloride	244.121	CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|	UXABARREKCJULM-NSHDSACASA-N	76966048.0		UXABARREKCJULM
BRD-K23200955-002-01-5	imipenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections|endocarditis	0	0.0	MicroSource	1506001	IMIPENEM	299.094	C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|	ZSKVGTPCRGIANV-ZXFLCMHBSA-N	104838.0		ZSKVGTPCRGIANV
BRD-K23200955-002-02-3	imipenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|urinary tract infections|intra-abdominal infections|gynecologic infections|bacterial septicemia|bone and joint infections|skin infections|endocarditis	0	0.0	Sigma	MFCD09753321	(5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}sulfanyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate	299.094	C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|	ZSKVGTPCRGIANV-ZXFLCMHBSA-N	104838.0		ZSKVGTPCRGIANV
BRD-K38436528-003-25-3	imipramine	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry|urology	depression|nocturnal enuresis	0	81.95	Selleck	S4377	Imipramine HCl	280.194	CN(C)CCCN1c2ccccc2CCc2ccccc12	BCGWQEUPMDMJNV-UHFFFAOYSA-N	3696.0		BCGWQEUPMDMJNV
BRD-K38436528-003-26-1	imipramine	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry|urology	depression|nocturnal enuresis	0	92.52	MicroSource	1500348	IMIPRAMINE HYDROCHLORIDE	280.194	CN(C)CCCN1c2ccccc2CCc2ccccc12	BCGWQEUPMDMJNV-UHFFFAOYSA-N	3696.0		BCGWQEUPMDMJNV
BRD-K38436528-003-27-9	imipramine	Launched	norepinephrine reputake inhibitor|serotonin reuptake inhibitor	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry|urology	depression|nocturnal enuresis	0	91.26	Selleck	S4377	IMipraMine hydrochloride	280.194	CN(C)CCCN1c2ccccc2CCc2ccccc12	BCGWQEUPMDMJNV-UHFFFAOYSA-N	3696.0		BCGWQEUPMDMJNV
BRD-K26657438-003-01-8	imiquimod	Launched	interferon inducer|toll-like receptor agonist	TLR7|TLR8	dermatology|infectious disease|oncology	actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)	0	76.03	MicroSource	1502351	IMIQUIMOD HYDROCHLORIDE	240.137	CC(C)Cn1cnc2c(N)nc3ccccc3c12	DOUYETYNHWVLEO-UHFFFAOYSA-N	57469.0		DOUYETYNHWVLEO
BRD-K26657438-001-17-8	imiquimod	Launched	interferon inducer|toll-like receptor agonist	TLR7|TLR8	dermatology|infectious disease|oncology	actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)	0	98.69	Selleck	S1211	Imiquimod	240.137	CC(C)Cn1cnc2c(N)nc3ccccc3c12	DOUYETYNHWVLEO-UHFFFAOYSA-N	57469.0		DOUYETYNHWVLEO
BRD-K26657438-001-15-2	imiquimod	Launched	interferon inducer|toll-like receptor agonist	TLR7|TLR8	dermatology|infectious disease|oncology	actinic keratosis (AK)|genital warts|basal cell carcinoma (BCC)	0	89.21	Selleck	S1211	Imiquimod	240.137	CC(C)Cn1cnc2c(N)nc3ccccc3c12	DOUYETYNHWVLEO-UHFFFAOYSA-N	57469.0		DOUYETYNHWVLEO
BRD-K00003208-001-01-9	imirestat	Preclinical	aldose reductase inhibitor				0	95.55	MedChemEx	HY-16255	Imirestat	286.055	Fc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1	QCCHBHSAIQIQGO-UHFFFAOYSA-N	65673.0		QCCHBHSAIQIQGO
BRD-K00003154-001-01-9	imisopasem-manganese	Preclinical	superoxide dismutase mimetic				0	0.0	MedChemEx	HY-13336	Imisopasem manganese	478.134	[H][C@@]12CCCC[C@@]1([H])N1Cc3cccc(CN4[C@]5([H])CCCC[C@@]5([H])N5CCN2[Mn]145(Cl)Cl)n3	UWYSKLMRWPKZES-XNPJUPKFSA-L			UWYSKLMRWPKZES
BRD-K25906698-303-03-9	immepip	Preclinical	histamine receptor agonist	HRH3|HRH4			0	52.5	Tocris	932	Immepip dihydrobromide	165.127	C(C1CCNCC1)c1cnc[nH]1	MCNGUYXRBCIGOV-UHFFFAOYSA-N	3035842.0		MCNGUYXRBCIGOV
BRD-K25906698-303-02-7	immepip	Preclinical	histamine receptor agonist	HRH3|HRH4			0	91.38	Tocris	932	Immepip dihydrobromide	165.127	C(C1CCNCC1)c1cnc[nH]1	MCNGUYXRBCIGOV-UHFFFAOYSA-N	3035842.0		MCNGUYXRBCIGOV
BRD-K49519092-303-03-0	immethridine	Phase 1	histamine receptor agonist	HRH3			0	97.64	Tocris	2315	4-(1H-imidazol-5-ylmethyl)pyridine dihydrobromide	159.08	C(c1cnc[nH]1)c1ccncc1	DFVSGZHJSIEEQQ-UHFFFAOYSA-N	9989505.0		DFVSGZHJSIEEQQ
BRD-K49519092-303-02-2	immethridine	Phase 1	histamine receptor agonist	HRH3			0	36.83	Tocris	2315	Immethridine dihydrobromide	159.08	C(c1cnc[nH]1)c1ccncc1	DFVSGZHJSIEEQQ-UHFFFAOYSA-N	9989505.0		DFVSGZHJSIEEQQ
BRD-K20049318-303-03-9	impentamine	Preclinical	histamine receptor antagonist	HRH3			0	87.55	Tocris	1858	Impentamine dihydrobromide	153.127	NCCCCCc1cnc[nH]1	MZCJWLAXZRFUPI-UHFFFAOYSA-N	9793868.0		MZCJWLAXZRFUPI
BRD-K20049318-303-02-1	impentamine	Preclinical	histamine receptor antagonist	HRH3			0	70.44	Tocris	1858	Impentamine dihydrobromide	153.127	NCCCCCc1cnc[nH]1	MZCJWLAXZRFUPI-UHFFFAOYSA-N	9793868.0		MZCJWLAXZRFUPI
BRD-K00926464-001-02-9	IMREG-1	Phase 3					0	85.01	ChemImpex	11256	Tyr-Gly-Gly-OH	295.117	N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O	HIINQLBHPIQYHN-JTQLQIEISA-N	7021857.0		HIINQLBHPIQYHN
BRD-K00926464-001-01-8	IMREG-1	Phase 3					0	97.29	ChemImpex	11256		295.117	N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O	HIINQLBHPIQYHN-JTQLQIEISA-N	7021857.0		HIINQLBHPIQYHN
BRD-K00003532-001-01-9	inarigivir	Phase 2	antiviral				0	61.1	MedChemEx	HY-101954	Inarigivir	587.12	CO[C@@H]1[C@H](O[P@](S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O |a:2,3,10,12,14,26,30,&1:5|	LYMICVBGNUEHGE-NLKZJYKHSA-N			LYMICVBGNUEHGE
BRD-K00004751-001-01-9	inarigivir-soproxil	Phase 2	antiviral				0	93.11	MedChemEx	HY-109035	Inarigivir soproxil	703.167	[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO[P@](=O)(O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(n2ccc(=O)[nH]c2=O)[C@]1([H])OC)SCOC(=O)OC(C)C)n1cnc2c(N)ncnc12 |&1:11,r|	CJCYTUJOSMYXLE-NHMFLIHISA-N			CJCYTUJOSMYXLE
BRD-K81016934-001-03-9	INC-280	Phase 3	c-Met inhibitor	MET			0	91.74	MedChemEx	HY-13404	Capmatinib	412.145	CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	LIOLIMKSCNQPLV-UHFFFAOYSA-N	25145656.0		LIOLIMKSCNQPLV
BRD-K81016934-001-02-0	INC-280	Phase 3	c-Met inhibitor	MET			0	95.86	Selleck	S2788	INCB28060	412.145	CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	LIOLIMKSCNQPLV-UHFFFAOYSA-N	25145656.0		LIOLIMKSCNQPLV
BRD-K33308633-001-03-2	INCA-6	Preclinical	calcineurin inhibitor	NFATC1			0	0.0	Tocris	2162	INCA-6	284.084	O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|	GCHPUOHXXCNSQL-UHFFFAOYSA-N	230748.0		GCHPUOHXXCNSQL
BRD-K33308633-001-02-4	INCA-6	Preclinical	calcineurin inhibitor	NFATC1			0	58.26	Tocris	2162	INCA-6	284.084	O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|	GCHPUOHXXCNSQL-UHFFFAOYSA-N	230748.0		GCHPUOHXXCNSQL
BRD-K33308633-001-04-9	INCA-6	Preclinical	calcineurin inhibitor	NFATC1			0	0.47	Tocris	2162	INCA-6	284.084	O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2,6|	GCHPUOHXXCNSQL-UHFFFAOYSA-N	230748.0		GCHPUOHXXCNSQL
BRD-K28059174-334-01-2	INCB-003284	Phase 2	CC chemokine receptor antagonist				0	83.66	EMDBio	504361-5MG	INCB 3284 dimesylate	520.23	COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	NXZNYBUBXWWKCP-JMOWIOHXSA-N	11527661.0		NXZNYBUBXWWKCP
BRD-K00003102-001-01-9	INCB-057643	Phase 1/Phase 2	bromodomain inhibitor				0	95.91	MedChemEx	HY-111485	INCB-057643	415.12	CN1C(=O)C(C)(C)Oc2c1cc(cc2-c1cn(C)c(O)c2nccc12)S(C)(=O)=O	ZNFWPFHSBWLNSO-UHFFFAOYSA-N			ZNFWPFHSBWLNSO
BRD-K67628093-001-01-9	INCB-3284	Phase 2	CC chemokine receptor antagonist	CCR2			0	92.32	MedChemEx	HY-15450A	INCB 3284	520.23	COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	NXZNYBUBXWWKCP-DNRQZRRGSA-N			NXZNYBUBXWWKCP
BRD-K00003344-001-01-9	incyclinide	Phase 2	matrix metalloprotease inhibitor				0	92.17	MedChemEx	HY-13648	Incyclinide	371.101	[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)C[C@]1([H])C2 |&1:19,&2:12|	MDYVZYDNBUAVCN-WCAKBIDQSA-N			MDYVZYDNBUAVCN
BRD-K89208535-050-02-9	indacaterol	Launched	adrenergic receptor agonist	ADRB1|ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	0	98.27	MedChemEx	HY-14299A	Indacaterol (maleate)	392.21	CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	QZZUEBNBZAPZLX-QFIPXVFZSA-N	6918554.0		QZZUEBNBZAPZLX
BRD-K89208535-051-01-5	indacaterol	Launched	adrenergic receptor agonist	ADRB1|ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	0	95.34	Selleck	S3083	Indacaterol Maleate	392.21	CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	QZZUEBNBZAPZLX-QFIPXVFZSA-N	6918554.0		QZZUEBNBZAPZLX
BRD-K64973364-001-01-4	indalpine	Withdrawn	selective serotonin reuptake inhibitor (SSRI)	SLC6A4			0	90.29	Sigma	PH011694	3-[2-(4-piperidinyl)ethyl]-1H-indole	228.163	C(Cc1c[nH]c2ccccc12)C1CCNCC1	SADQVAVFGNTEOD-UHFFFAOYSA-N	44668.0		SADQVAVFGNTEOD
BRD-A95869247-001-29-9	indapamide	Launched	thiazide diuretic	CA2|HTR3A|KCNQ1	cardiology	hypertension|congestive heart failure	0	99.2	MedChemEx	HY-B0259	Indapamide	365.06	C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|	NDDAHWYSQHTHNT-JTQLQIEISA-N	12598931.0		NDDAHWYSQHTHNT
BRD-A95869247-001-26-9	indapamide	Launched	thiazide diuretic	CA2|HTR3A|KCNQ1	cardiology	hypertension|congestive heart failure	0	96.25	MicroSource	1500349	INDAPAMIDE	365.06	C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|	NDDAHWYSQHTHNT-JTQLQIEISA-N	12598931.0		NDDAHWYSQHTHNT
BRD-A95869247-001-25-1	indapamide	Launched	thiazide diuretic	CA2|HTR3A|KCNQ1	cardiology	hypertension|congestive heart failure	0	93.55	Selleck	S1730	Indapamide	365.06	C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1,r|	NDDAHWYSQHTHNT-JTQLQIEISA-N	12598931.0		NDDAHWYSQHTHNT
BRD-K01649396-003-08-9	indatraline	Preclinical	norepinephrine transporter inhibitor	MAOA|MAOB			0	96.95	Tocris	1588	Indatraline hydrochloride	291.058	CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	SVFXPTLYMIXFRX-XJKSGUPXSA-N	126280.0		SVFXPTLYMIXFRX
BRD-K01649396-003-09-9	indatraline	Preclinical	norepinephrine transporter inhibitor	MAOA|MAOB			0	94.85	Tocris	1588	Indatraline hydrochloride	291.058	CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	SVFXPTLYMIXFRX-XJKSGUPXSA-N	126280.0		SVFXPTLYMIXFRX
BRD-K01649396-003-07-1	indatraline	Preclinical	norepinephrine transporter inhibitor	MAOA|MAOB			0	96.85	Tocris	1588	Indatraline hydrochloride	291.058	CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	SVFXPTLYMIXFRX-XJKSGUPXSA-N	126280.0		SVFXPTLYMIXFRX
BRD-K00003177-001-01-9	indeglitazar	Phase 2	PPAR receptor agonist	NCOA1|PPARA|PPARD|PPARG			0	97.99	MedChemEx	HY-14817	Indeglitazar	389.093	COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12	YMPALHOKRBVHOJ-UHFFFAOYSA-N	11395145.0		YMPALHOKRBVHOJ
BRD-A59747053-003-01-3	indeloxazine	Withdrawn	norepinephrine reuptake inhibitor|serotonin reuptake inhibitor				0	99.26	Sigma	PH013704	2-[(1H-inden-7-yloxy)methyl]morpholine hydrochloride	231.126	C(Oc1cccc2C=CCc12)[C@H]1CNCCO1 |&1:11,c:7|	MADRVGBADLFHMO-GFCCVEGCSA-N	67212739.0		MADRVGBADLFHMO
BRD-K74057757-001-03-9	indibulin	Phase 1/Phase 2	tubulin polymerization inhibitor				0	98.47	AMS	10069	Indibulin	389.093	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	SOLIIYNRSAWTSQ-UHFFFAOYSA-N	2929.0		SOLIIYNRSAWTSQ
BRD-K74057757-001-01-9	indibulin	Phase 1/Phase 2	tubulin polymerization inhibitor				0	97.78	Vitas-M	STK783524		389.093	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	SOLIIYNRSAWTSQ-UHFFFAOYSA-N	2929.0		SOLIIYNRSAWTSQ
BRD-K74057757-001-02-7	indibulin	Phase 1/Phase 2	tubulin polymerization inhibitor				0	93.63	SantaCruz	sc-295179	Indibulin	389.093	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	SOLIIYNRSAWTSQ-UHFFFAOYSA-N	2929.0		SOLIIYNRSAWTSQ
BRD-K33226500-001-01-0	indinavir	Launched	HIV protease inhibitor	CYP3A4|CYP3A5|CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	0	97.93	Enzo	AC2017	INDINAVIR	613.363	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12	CBVCZFGXHXORBI-PXQQMZJSSA-N	5362440.0		CBVCZFGXHXORBI
BRD-K33226500-065-09-8	indinavir	Launched	HIV protease inhibitor	CYP3A4|CYP3A5|CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	0		MedChemEx	HY-B0689A	Indinavir (sulfate)	613.363	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12	InChI=1S/C36H47N5O4/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45)/t28-,29+,31+,32-,33+/m1/s1	5362440.0		CBVCZFGXHXORBI
BRD-K90948141-001-02-2	indiplon	Phase 3	benzodiazepine receptor agonist	GABRA1			0	96.75	Tocris	3597	Indiplon	376.099	CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	CBIAWPMZSFFRGN-UHFFFAOYSA-N	6450813.0		CBIAWPMZSFFRGN
BRD-K90948141-001-01-4	indiplon	Phase 3	benzodiazepine receptor agonist	GABRA1			0	99.26	Tocris	3597	Indiplon	376.099	CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	CBIAWPMZSFFRGN-UHFFFAOYSA-N	6450813.0		CBIAWPMZSFFRGN
BRD-K90948141-001-03-9	indiplon	Phase 3	benzodiazepine receptor agonist	GABRA1			0	97.03	Tocris	3597	Indiplon	376.099	CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	CBIAWPMZSFFRGN-UHFFFAOYSA-N	6450813.0		CBIAWPMZSFFRGN
BRD-K17894950-001-14-3	indirubin	Phase 2/Phase 3	CDK inhibitor|glycogen synthase kinase inhibitor	CDK1|CDK5|GSK3A			0	99.41	Selleck	S2386	Indirubin	262.074	O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O	CRDNMYFJWFXOCH-YPKPFQOOSA-N			CRDNMYFJWFXOCH
BRD-K19136521-001-10-9	indirubin-3-monoxime	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	CDK1|CDK2|CDK5|CDK5R1|GSK3B			0	97.75	Tocris	1813	Indirubin-3'-oxime	277.085	O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12	HBDSHCUSXQATPO-BGBJRWHRSA-N			HBDSHCUSXQATPO
BRD-K19136521-001-08-9	indirubin-3-monoxime	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	CDK1|CDK2|CDK5|CDK5R1|GSK3B			0	97.67	Tocris	1813	Indirubin-3'-oxime	277.085	O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12	HBDSHCUSXQATPO-BGBJRWHRSA-N			HBDSHCUSXQATPO
BRD-K17610631-001-03-3	indisulam	Phase 2	CDK inhibitor	CA1|CA12|CA14|CA2|CA6|CA7|CA9			0	98.25	Sigma	SML1225	N~1~-(3-chloro-1H-indol-7-yl)-1,4-benzenedisulfonamide	384.996	NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12	SETFNECMODOHTO-UHFFFAOYSA-N	216468.0		SETFNECMODOHTO
BRD-M08274809-001-01-7	indium(III)-isopropoxide	Preclinical					1	0.0	AlfaAesar	42098	Indium(III) isopropoxide, 99.9% (metals basis)	295.076	[In].CC(C)O.CC(C)O.CC(C)O	JUUUERJZVKCDOT-UHFFFAOYSA-N			JUUUERJZVKCDOT
BRD-K42332878-001-01-9	indium-tri(2-propanolate)	Preclinical					0	0.0	AlfaAesar	42098	indium(III) propan-2-olate	292.053	CC(C)O[In](OC(C)C)OC(C)C	OVZUSPADPSOQQN-UHFFFAOYSA-N	57346963.0		OVZUSPADPSOQQN
BRD-A16296925-001-01-3	indobufen	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor	PTGS1|PTGS2	hematology	thrombosis	0	99.21	AKSci	65627		295.121	CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2,r|	AYDXAULLCROVIT-OAHLLOKOSA-N	189556.0		AYDXAULLCROVIT
BRD-K80762071-236-02-5	indocyanine-green	Launched	contrast agent	SLCO1B1	cardiology	vascular imaging agent	0	80.38	Sigma	MFCD00013078	sodium 4-((2E)-2-{(2E,4E,6E)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indolium-2-yl]-2,4,6-heptatrienylidene}-1,1-dimethyl-1H-benzo[e]indol-3-yl)-1-butanesulfonate	753.303	CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|	BDBMLMBYCXNVMC-UHFFFAOYSA-O	9919342.0		BDBMLMBYCXNVMC
BRD-K80762071-236-03-3	indocyanine-green	Launched	contrast agent	SLCO1B1	cardiology	vascular imaging agent	0	92.75	MedChemEx	HY-D0711	Cardiogreen	753.303	CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|	BDBMLMBYCXNVMC-UHFFFAOYSA-O	9919342.0		BDBMLMBYCXNVMC
BRD-K80762071-236-01-7	indocyanine-green	Launched	contrast agent	SLCO1B1	cardiology	vascular imaging agent	0	61.74	MedChemEx	HY-D0711	Cardiogreen	753.303	CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|	BDBMLMBYCXNVMC-UHFFFAOYSA-O	9919342.0		BDBMLMBYCXNVMC
BRD-K01815685-001-15-5	indole-3-carbinol	Phase 2/Phase 3	aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor	AHR			0	96.69	Selleck	S2313	Indole-3-carbinol	147.068	OCc1c[nH]c2ccccc12	IVYPNXXAYMYVSP-UHFFFAOYSA-N	3712.0		IVYPNXXAYMYVSP
BRD-K09109825-001-07-3	indole-3-pyrubate	Phase 2	melatonin receptor agonist				0	0.0	Sigma	57300	3-(1H-indol-3-yl)-2-oxopropanoic acid	203.058	OC(=O)C(O)=Cc1c[nH]c2ccccc12	KDCSRTPNDBPWQZ-UHFFFAOYSA-N	85336038.0		KDCSRTPNDBPWQZ
BRD-K57222227-001-29-3	indomethacin	Launched	cyclooxygenase inhibitor	GLO1|PLA2G2A|PPARA|PPARG|PTGDR2|PTGR2|PTGS1|PTGS2|SLC46A1	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis	0	98.25	Tocris	1708	Indomethacin	357.077	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	CGIGDMFJXJATDK-UHFFFAOYSA-N	3715.0		CGIGDMFJXJATDK
BRD-K57222227-001-30-1	indomethacin	Launched	cyclooxygenase inhibitor	GLO1|PLA2G2A|PPARA|PPARG|PTGDR2|PTGR2|PTGS1|PTGS2|SLC46A1	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis	0	99.45	MicroSource	1500350	INDOMETHACIN	357.077	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	CGIGDMFJXJATDK-UHFFFAOYSA-N	3715.0		CGIGDMFJXJATDK
BRD-K57222227-001-28-5	indomethacin	Launched	cyclooxygenase inhibitor	GLO1|PLA2G2A|PPARA|PPARG|PTGDR2|PTGR2|PTGS1|PTGS2|SLC46A1	rheumatology|orthopedics	rheumatoid arthritis|ankylosing spondylitis|osteoarthritis|bursitis|tendinitis	0	98.1	Selleck	S1723	Indomethacin	357.077	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	CGIGDMFJXJATDK-UHFFFAOYSA-N	3715.0		CGIGDMFJXJATDK
BRD-A44090213-001-25-6	indoprofen	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	CXCR1|CXCR2|PTGS1|PTGS2			0	99.31	MicroSource	1500351	INDOPROFEN	281.105	C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|	RJMIEHBSYVWVIN-LLVKDONJSA-N	93283.0		RJMIEHBSYVWVIN
BRD-A44090213-001-27-9	indoprofen	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	CXCR1|CXCR2|PTGS1|PTGS2			0	97.98	MedChemEx	HY-B1104	Indoprofen	281.105	C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1,r|	RJMIEHBSYVWVIN-LLVKDONJSA-N	93283.0		RJMIEHBSYVWVIN
BRD-K76953762-001-09-9	indoramin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2B|ADRA2C	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension	0	97.06	Key	AF-0013	N-{1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl}benzamide	347.2	O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1	JXZZEXZZKAWDSP-UHFFFAOYSA-N	33625.0		JXZZEXZZKAWDSP
BRD-K76953762-001-08-5	indoramin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2B|ADRA2C	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension	0	92.44	Maybridge	RH01633		347.2	O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1	JXZZEXZZKAWDSP-UHFFFAOYSA-N	33625.0		JXZZEXZZKAWDSP
BRD-K93255255-001-02-1	indoximod	Phase 2	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	98.79	Cayman	16456		218.106	Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12	ZADWXFSZEAPBJS-SNVBAGLBSA-N	6920151.0		ZADWXFSZEAPBJS
BRD-K93255255-001-03-9	indoximod	Phase 2	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	89.88	MedChemEx	HY-16724	Indoximod	218.106	Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12	ZADWXFSZEAPBJS-SNVBAGLBSA-N	6920151.0		ZADWXFSZEAPBJS
BRD-K00003329-001-01-9	ingenol	Launched	PKC activator	PRKCD|PRKCE	dermatology	keratosis	0	95.71	MedChemEx	HY-N0865	Ingenol	348.194	[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13,t:2|	VEBVPUXQAPLADL-POYOOMFHSA-N	442042.0		VEBVPUXQAPLADL
BRD-K93779381-001-02-9	ingenol-mebutate	Launched	PKC activator	PRKCA|PRKCB|PRKCD|PRKCE|PRKCG	dermatology	actinic keratosis (AK)	0	95.26	MedChemEx	HY-B0719	Ingenol Mebutate	430.236	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|	VDJHFHXMUKFKET-WDUFCVPESA-N	6918670.0		VDJHFHXMUKFKET
BRD-K93779381-001-01-9	ingenol-mebutate	Launched	PKC activator	PRKCA|PRKCB|PRKCD|PRKCE|PRKCG	dermatology	actinic keratosis (AK)	0	97.23	MedChemEx	HY-B0719	Ingenol Mebutate	430.236	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9,t:18|	VDJHFHXMUKFKET-WDUFCVPESA-N	6918670.0		VDJHFHXMUKFKET
BRD-K70177501-003-01-4	INH1	Preclinical	Hec1 inhibitor	NDC80			0	98.19	Tocris	3551	INH1	308.098	Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1	JPMOKRWIYQGMJL-UHFFFAOYSA-N	959043.0		JPMOKRWIYQGMJL
BRD-K70177501-003-02-9	INH1	Preclinical	Hec1 inhibitor	NDC80			0	97.56	Tocris	3551	INH1	308.098	Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1	JPMOKRWIYQGMJL-UHFFFAOYSA-N	959043.0		JPMOKRWIYQGMJL
BRD-A71407503-001-02-6	inimur	Launched	other antifungal				0	86.95	MedChemEx	HY-A0059	Nifuratel	285.042	CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|	SRQKTCXJCCHINN-ORMNHXAVSA-N	72165119.0		SRQKTCXJCCHINN
BRD-A71407503-001-01-8	inimur	Launched	other antifungal				0	75.65	MedChemEx	HY-A0059	Nifuratel	285.042	CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3,r|	SRQKTCXJCCHINN-ORMNHXAVSA-N	72165119.0		SRQKTCXJCCHINN
BRD-K11153516-001-05-5	iniparib	Phase 3	PARP inhibitor	PARP1			0	97.59	Selleck	S1087	Iniparib (BSI-201)	291.934	NC(=O)c1ccc(I)c(c1)[N+]([O-])=O	MDOJTZQKHMAPBK-UHFFFAOYSA-N	9796068.0		MDOJTZQKHMAPBK
BRD-K79612754-001-22-9	inosine	Launched	neurotrophic agent	PARP1|PNP			0	91.3	MedChemEx	HY-N0092	Inosine	268.081	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O	UGQMRVRMYYASKQ-KQYNXXCUSA-N	135398641.0		UGQMRVRMYYASKQ
BRD-K79612754-001-21-7	inosine	Launched	neurotrophic agent	PARP1|PNP			0	87.76	MicroSource	3100024	INOSINE	268.081	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O	UGQMRVRMYYASKQ-KQYNXXCUSA-N	135398641.0	BRD-A28787076-001-04-8	UGQMRVRMYYASKQ
BRD-K79612754-001-20-9	inosine	Launched	neurotrophic agent	PARP1|PNP			0	77.54	Selleck	S2442	Inosine	268.081	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O	UGQMRVRMYYASKQ-KQYNXXCUSA-N	135398641.0	BRD-K14210676-001-01-5	UGQMRVRMYYASKQ
BRD-K79612754-001-19-1	inosine	Launched	neurotrophic agent	PARP1|PNP			0	94.71	Selleck	S2442	Inosine	268.081	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O	UGQMRVRMYYASKQ-KQYNXXCUSA-N	135398641.0		UGQMRVRMYYASKQ
BRD-K52618540-001-10-9	inositol	Launched	insulin sensitizer	CDIPT	obstetrics/gynecology	polycystic ovary syndrom (PCOS)	0	100.0	MedChemEx	HY-B1411	i-Inositol	180.063	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O	CDAISMWEOUEBRE-GPIVLXJGSA-N			CDAISMWEOUEBRE
BRD-K52618540-001-09-9	inositol	Launched	insulin sensitizer	CDIPT	obstetrics/gynecology	polycystic ovary syndrom (PCOS)	0	98.26	MicroSource	1500352	INOSITOL	180.063	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O	CDAISMWEOUEBRE-GPIVLXJGSA-N			CDAISMWEOUEBRE
BRD-K82800842-001-02-9	inositol-hexanicotinate	Launched			dermatology|cardiology|rheumatology|neurology/psychiatry	statis dermatitis|claudication|Raynaud's disease|hypertension|insomnia|atherosclerosis|restless leg syndrome|schizophrenia|psoriasis|acne vulgaris (AV)	0	87.26	Sigma	MFCD00006387	INOSITOL NICOTINATE	810.192	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	MFZCIDXOLLEMOO-GYSGTQPESA-N			MFZCIDXOLLEMOO
BRD-K82800842-001-01-9	inositol-hexanicotinate	Launched			dermatology|cardiology|rheumatology|neurology/psychiatry	statis dermatitis|claudication|Raynaud's disease|hypertension|insomnia|atherosclerosis|restless leg syndrome|schizophrenia|psoriasis|acne vulgaris (AV)	0	89.29	AKSci	H975		810.192	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	MFZCIDXOLLEMOO-GYSGTQPESA-N			MFZCIDXOLLEMOO
BRD-A29125379-314-01-7	INS316	Phase 2	purinergic receptor antagonist				0	0.0	Enzo	AC998	Uridine-5'-triphosphate Na	483.969	O[C@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:2,18,&1:1,&2:5,&3:9,&4:19|	PGAVKCOVUIYSFO-PXBUCIJWSA-N	10368038.0		PGAVKCOVUIYSFO
BRD-K30968378-001-02-9	INT-747	Phase 3	FXR agonist				0	97.7	MedChemEx	HY-12222	INT-747	420.324	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	ZXERDUOLZKYMJM-ZWECCWDJSA-N	447715.0		ZXERDUOLZKYMJM
BRD-K30968378-001-01-9	INT-747	Phase 3	FXR agonist				0	98.9	MedChemEx	HY-12222	INT-747	420.324	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	ZXERDUOLZKYMJM-ZWECCWDJSA-N	447715.0		ZXERDUOLZKYMJM
BRD-K33067152-236-01-1	INT-767	Phase 1	FXR agonist	GPBAR1			0	98.4	MedChemEx	HY-12434	INT-767	472.286	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	XGIYOABXZNJOHV-APIYUPOTSA-N	23642339.0		XGIYOABXZNJOHV
BRD-K88165431-003-01-4	integrin-antagonist-1	Phase 1	integrin antagonist	ITGAV|ITGB6			0	93.77	MedChemEx	HY-19767A	Integrin Antagonist 1 (hydrochloride)	487.295	Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O	ZMXBIIQMSGOIRZ-RCZVLFRGSA-N	86272865.0		ZMXBIIQMSGOIRZ
BRD-K00004752-001-01-9	INX-08189	Phase 2	antiviral				0	49.13	AMS	I-9801	INX-08189	658.252	[H][C@@](C)(N[P@](=O)(OC[C@@]1([H])O[C@@]([H])(n2cnc3c(OC)nc(N)nc23)[C@](C)(O)[C@]1([H])O)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C |r|	YFXGICNMLCGLHJ-KGSOWIGMSA-N	49862762.0		YFXGICNMLCGLHJ
BRD-K43860855-065-10-1	iobenguane	Launched	antineoplastic agent		oncology|cardiology|endocrinology	neuroblastoma|congestive heart failure|pheochromocytoma	0	92.74	Prestwick	Prestw-490	Iobenguane sulfate	274.992	NC(=N)NCc1cccc(I)c1	PDWUPXJEEYOOTR-UHFFFAOYSA-N	60860.0		PDWUPXJEEYOOTR
BRD-K43860855-065-11-9	iobenguane	Launched	antineoplastic agent		oncology|cardiology|endocrinology	neuroblastoma|congestive heart failure|pheochromocytoma	0	98.26	Axon	1750		274.992	NC(=N)NCc1cccc(I)c1	PDWUPXJEEYOOTR-UHFFFAOYSA-N	60860.0		PDWUPXJEEYOOTR
BRD-A37492983-001-10-3	iocetamic-acid	Launched	radiopaque medium		radiology	contrast agent	0	85.31	Prestwick	Prestw-838	Iocetamic acid	613.806	C[C@@H](CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O |&1:1,r|	GSVQIUGOUKJHRC-YFKPBYRVSA-N	76964490.0		GSVQIUGOUKJHRC
BRD-K67261995-001-12-9	iodipamide	Launched	radiopaque medium	ALB	radiology	contrast agent	0	97.74	MedChemEx	HY-B1292	Iodipamide	1139.512	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	FFINMCNLQNTKLU-UHFFFAOYSA-N	3739.0		FFINMCNLQNTKLU
BRD-K67261995-001-11-7	iodipamide	Launched	radiopaque medium	ALB	radiology	contrast agent	0	99.2	MicroSource	1500772	IODIPAMIDE	1139.512	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	FFINMCNLQNTKLU-UHFFFAOYSA-N	3739.0		FFINMCNLQNTKLU
BRD-A08660406-001-06-7	iodixanol	Launched	radiopaque medium		radiology	contrast agent	0	79.95	Sigma	MFCD00867965	5-{acetyl[3-(acetyl-3,5-bis{[(2,3-dihydroxypropyl)amino]carbonyl}-2,4,6-triiodoanilino)-2-hydroxypropyl]amino}-N~1~,N~3~-bis(2,	1549.713	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|	NBQNWMBBSKPBAY-BRSBDYLESA-N	6604448.0		NBQNWMBBSKPBAY
BRD-A08660406-001-05-9	iodixanol	Launched	radiopaque medium		radiology	contrast agent	0	77.52	MicroSource	1503835	IODIXANOL	1549.713	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|	NBQNWMBBSKPBAY-BRSBDYLESA-N	6604448.0		NBQNWMBBSKPBAY
BRD-A08660406-001-07-9	iodixanol	Launched	radiopaque medium		radiology	contrast agent	0	58.65	Sigma	MFCD00867965	OptiPrep(R) Density Gradient Medium	1549.713	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20,&2:31,&3:45,&4:56,r|	NBQNWMBBSKPBAY-BRSBDYLESA-N	6604448.0		NBQNWMBBSKPBAY
BRD-K69216798-001-01-9	iodoantipyrine	Preclinical					0	98.81	AlfaAesar	L14009	Iodoantipyrine, 99%	313.992	Cc1c(I)c(=O)n(-c2ccccc2)n1C	ZZOBLCHCPLOXCE-UHFFFAOYSA-N	8522.0		ZZOBLCHCPLOXCE
BRD-A46813902-001-02-9	iododexetimide	Phase 2	acetylcholine receptor antagonist				0	93.55	MedChemEx	HY-12426	mAChR-IN-1	488.096	Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|	WJLRTFJPHDSXAF-QHCPKHFHSA-N	14479849.0		WJLRTFJPHDSXAF
BRD-A46813902-001-01-6	iododexetimide	Phase 2	acetylcholine receptor antagonist				0	96.72	MedChemEx	HY-12426	mAChR-IN-1	488.096	Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12,r|	WJLRTFJPHDSXAF-QHCPKHFHSA-N	14479849.0		WJLRTFJPHDSXAF
BRD-K51918615-303-02-9	iodophenpropit	Preclinical	histamine receptor antagonist	HRH3|HRH4			0	95.9	Tocris	779	Iodophenpropit dihydrobromide	414.038	Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1	UBHYDQAARZKHEZ-UHFFFAOYSA-N	3035746.0		UBHYDQAARZKHEZ
BRD-K75855670-001-15-9	iodoquinol	Launched	antiseptic		infectious disease	amebiasis	0	97.07	MedChemEx	HY-B1400	Diiodohydroxyquinoline	396.846	Oc1c(I)cc(I)c2cccnc12	UXZFQZANDVDGMM-UHFFFAOYSA-N	3728.0		UXZFQZANDVDGMM
BRD-K75855670-001-14-2	iodoquinol	Launched	antiseptic		infectious disease	amebiasis	0	88.89	MicroSource	1500353	IODOQUINOL	396.846	Oc1c(I)cc(I)c2cccnc12	UXZFQZANDVDGMM-UHFFFAOYSA-N	3728.0		UXZFQZANDVDGMM
BRD-A60217728-001-11-2	iohexol	Launched	radiopaque medium		radiology	contrast agent	0	98.79	MicroSource	1502304	IOHEXOL	820.88	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|	NTHXOOBQLCIOLC-GMTAPVOTSA-N	6604427.0		NTHXOOBQLCIOLC
BRD-A60217728-001-12-9	iohexol	Launched	radiopaque medium		radiology	contrast agent	0	99.01	MedChemEx	HY-B0594	Iohexol	820.88	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:17,&3:28,r|	NTHXOOBQLCIOLC-GMTAPVOTSA-N	6604427.0		NTHXOOBQLCIOLC
BRD-K75868704-001-06-9	iopamidol	Launched	radiopaque medium		radiology	contrast agent	0	98.4	MedChemEx	HY-B0684	Iopamidol	776.854	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	XQZXYNRDCRIARQ-LURJTMIESA-N	65492.0		XQZXYNRDCRIARQ
BRD-K75868704-001-05-3	iopamidol	Launched	radiopaque medium		radiology	contrast agent	0	100.0	MedChemEx	HY-B0684	Iopamidol	776.854	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	XQZXYNRDCRIARQ-LURJTMIESA-N	65492.0		XQZXYNRDCRIARQ
BRD-A42628519-001-12-4	iopanic-acid	Withdrawn	thyroid hormone inhibitor				0	98.49	MicroSource	1503923	IOPANIC ACID	570.8	CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|	OIRFJRBSRORBCM-YFKPBYRVSA-N	12304727.0		OIRFJRBSRORBCM
BRD-A42628519-001-13-9	iopanic-acid	Withdrawn	thyroid hormone inhibitor				0	88.38	MedChemEx	HY-B1664	Iopanoic acid	570.8	CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2,r|	OIRFJRBSRORBCM-YFKPBYRVSA-N	12304727.0		OIRFJRBSRORBCM
BRD-K51956333-001-03-8	iopodic-acid	Launched			radiology	contrast agent	0	98.86	Vitas-M	STL069537		597.811	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	YQNFBOJPTAXAKV-OMCISZLKSA-N			YQNFBOJPTAXAKV
BRD-K51956333-003-04-9	iopodic-acid	Launched			radiology	contrast agent	0	88.84	Vitas-M	STL069541	3-(3-{[(E)-(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoic acid	597.811	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	YQNFBOJPTAXAKV-OMCISZLKSA-N			YQNFBOJPTAXAKV
BRD-A72075775-001-10-4	iopromide	Launched	radiopaque medium		radiology	contrast agent	0	56.18	Prestwick	Prestw-872	Iopromide	790.87	COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|	DGAIEPBNLOQYER-RKDXNWHRSA-N	6604433.0		DGAIEPBNLOQYER
BRD-A72075775-001-11-2	iopromide	Launched	radiopaque medium		radiology	contrast agent	0	64.8	Sigma	1344804	N~1~,N~3~-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N~1~-methylisophthalamide	790.87	COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|	DGAIEPBNLOQYER-RKDXNWHRSA-N	6604433.0		DGAIEPBNLOQYER
BRD-A72075775-001-12-9	iopromide	Launched	radiopaque medium		radiology	contrast agent	0	53.86	MedChemEx	HY-B1362	Iopromide	790.87	COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14,&2:26,r|	DGAIEPBNLOQYER-RKDXNWHRSA-N	6604433.0		DGAIEPBNLOQYER
BRD-K98250023-001-01-0	iothalamic-acid-d3	Preclinical	radiopaque medium				0	0.0	Toronto	I736202	Iothalamic Acid-d3	613.77	CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	UXIGWFXRQKWHHA-UHFFFAOYSA-N	3737.0		UXIGWFXRQKWHHA
BRD-A65818372-001-05-3	ioversol	Launched	radiopaque medium		radiology	contrast agent	0	97.06	MicroSource	1503837	IOVERSOL	806.865	OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|	AMDBBAQNWSUWGN-RKDXNWHRSA-N	6604447.0		AMDBBAQNWSUWGN
BRD-A65818372-001-06-9	ioversol	Launched	radiopaque medium		radiology	contrast agent	0	95.9	MedChemEx	HY-B1410	Ioversol	806.865	OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16,&2:27,r|	AMDBBAQNWSUWGN-RKDXNWHRSA-N	6604447.0		AMDBBAQNWSUWGN
BRD-K84892605-001-02-9	IOWH032	Phase 2	CFTR channel antagonist	CFTR			0	96.86	MedChemEx	HY-18337	IOWH-032	542.943	Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	DSFNLJXHXBIKDS-UHFFFAOYSA-N	135565181.0		DSFNLJXHXBIKDS
BRD-K84892605-001-01-1	IOWH032	Phase 2	CFTR channel antagonist	CFTR			0	98.55	Selleck	S7329	IOWH032	542.943	Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	DSFNLJXHXBIKDS-UHFFFAOYSA-N	135565181.0		DSFNLJXHXBIKDS
BRD-K79124250-001-08-9	ioxaglic-acid	Launched	radiopaque medium		radiology	contrast agent	0	92.49	Prestwick	Prestw-1062	Ioxaglic acid	1268.566	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	TYYBFXNZMFNZJT-UHFFFAOYSA-N	3742.0		TYYBFXNZMFNZJT
BRD-K79124250-001-09-9	ioxaglic-acid	Launched	radiopaque medium		radiology	contrast agent	0	85.38	Toronto	i737400	ioxaglic acid	1268.566	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	TYYBFXNZMFNZJT-UHFFFAOYSA-N	3742.0		TYYBFXNZMFNZJT
BRD-A09370961-001-02-9	ioxilan	Launched	radiopaque medium		radiology	angiography	0	88.58	USP	34520	Ioxilan	790.87	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|	UUMLTINZBQPNGF-NXEZZACHSA-N	73416261.0		UUMLTINZBQPNGF
BRD-A09370961-001-01-0	ioxilan	Launched	radiopaque medium		radiology	angiography	0	85.72	MicroSource	1503838	IOXILAN	790.87	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5,&2:26,r|	UUMLTINZBQPNGF-NXEZZACHSA-N	73416261.0		UUMLTINZBQPNGF
BRD-K70751730-001-11-2	IOX1	Preclinical	histone demethylase inhibitor	EGLN1|KDM3A|KDM4C|KDM6B			0	57.33	Tocris	4464	IOX 1	189.043	OC(=O)c1ccc(O)c2ncccc12	JGRPKOGHYBAVMW-UHFFFAOYSA-N	459617.0		JGRPKOGHYBAVMW
BRD-K70751730-001-10-4	IOX1	Preclinical	histone demethylase inhibitor	EGLN1|KDM3A|KDM4C|KDM6B			0	87.15	MedChemEx	HY-12304	IOX1	189.043	OC(=O)c1ccc(O)c2ncccc12	JGRPKOGHYBAVMW-UHFFFAOYSA-N	459617.0		JGRPKOGHYBAVMW
BRD-K98251413-001-07-9	IOX2	Preclinical	hypoxia inducible factor inhibitor	EGLN1|KDM2A|KDM5C			0	97.46	Tocris	4451	IOX 2	352.106	OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	CAOSCCRYLYQBES-UHFFFAOYSA-N	54685215.0		CAOSCCRYLYQBES
BRD-K98251413-001-06-5	IOX2	Preclinical	hypoxia inducible factor inhibitor	EGLN1|KDM2A|KDM5C			0	97.26	Tocris	4451	IOX 2	352.106	OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	CAOSCCRYLYQBES-UHFFFAOYSA-N	54685215.0		CAOSCCRYLYQBES
BRD-K98251413-001-04-0	IOX2	Preclinical	hypoxia inducible factor inhibitor	EGLN1|KDM2A|KDM5C			0	97.2	Selleck	S2919	IOX2	352.106	OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	CAOSCCRYLYQBES-UHFFFAOYSA-N	54685215.0		CAOSCCRYLYQBES
BRD-K38727704-001-02-4	IPA-3	Preclinical	p21 activated kinase inhibitor	PAK1			0	0.0	Tocris	3622	IPA 3	350.044	Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	RFAXLXKIAKIUDT-UHFFFAOYSA-N	521106.0		RFAXLXKIAKIUDT
BRD-K38727704-001-01-6	IPA-3	Preclinical	p21 activated kinase inhibitor	PAK1			0	0.0	Selleck	S7093	IPA-3	350.044	Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	RFAXLXKIAKIUDT-UHFFFAOYSA-N	521106.0		RFAXLXKIAKIUDT
BRD-K38727704-001-04-9	IPA-3	Preclinical	p21 activated kinase inhibitor	PAK1			0	79.92	Tocris	3622	IPA 3	350.044	Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	RFAXLXKIAKIUDT-UHFFFAOYSA-N	521106.0		RFAXLXKIAKIUDT
BRD-K38727704-001-03-2	IPA-3	Preclinical	p21 activated kinase inhibitor	PAK1			0	70.81	Selleck	S7093	IPA-3	350.044	Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	RFAXLXKIAKIUDT-UHFFFAOYSA-N	521106.0		RFAXLXKIAKIUDT
BRD-K82421491-001-04-9	IPAG	Preclinical					0	94.22	Tocris	544	IPAG	395.086	Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	UUKPIWYXWLJPJF-UHFFFAOYSA-N	4239764.0		UUKPIWYXWLJPJF
BRD-K82421491-001-02-6	IPAG	Preclinical					0	95.16	Tocris	544	IPAG	395.086	Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	UUKPIWYXWLJPJF-UHFFFAOYSA-N	4239764.0		UUKPIWYXWLJPJF
BRD-K66896231-001-08-1	ipidacrine	Phase 3	acetylcholinesterase inhibitor	ACHE			0	98.46	ChemDiv	8003-7752		188.131	Nc1c2CCCc2nc2CCCCc12	YLUSMKAJIQOXPV-UHFFFAOYSA-N	604519.0		YLUSMKAJIQOXPV
BRD-K00003385-001-01-9	IPI549	Phase 2	PI3K inhibitor				0	94.19	MedChemEx	HY-100716	IPI549	528.202	C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1	XUMALORDVCFWKV-IBGZPJMESA-N	91933883.0		XUMALORDVCFWKV
BRD-K51247865-001-01-2	ipragliflozin-L-proline	Launched	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	0	98.3	MedChemEx	HY-14894	Ipragliflozin	404.109	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	AHFWIQIYAXSLBA-RQXATKFSSA-N	10453870.0		AHFWIQIYAXSLBA
BRD-K51247865-001-02-9	ipragliflozin-L-proline	Launched	sodium/glucose cotransporter inhibitor	SLC5A2	endocrinology	diabetes mellitus	0	97.2	MedChemEx	HY-14894	Ipragliflozin	404.109	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	AHFWIQIYAXSLBA-RQXATKFSSA-N	10453870.0		AHFWIQIYAXSLBA
BRD-K01826778-004-06-9	ipratropium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	pulmonary	bronchospasm|chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema	0	87.46	Tocris	692	Ipratropium bromide	332.223	CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5,8,10,&1:3,&2:15,TLB:4:3:6.7:9.10.11,THB:1:3:6.7:9.10.11,12:10:3:6.7|	OEXHQOGQTVQTAT-KKKDIUQISA-N			OEXHQOGQTVQTAT
BRD-K93618743-001-22-9	ipriflavone	Launched	bone resorption inhibitor		orthopedics	osteoporosis	0	91.92	MedChemEx	HY-N0094	Ipriflavone	280.11	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	SFBODOKJTYAUCM-UHFFFAOYSA-N	3747.0		SFBODOKJTYAUCM
BRD-K93618743-001-21-0	ipriflavone	Launched	bone resorption inhibitor		orthopedics	osteoporosis	0	98.07	MicroSource	1400010	IPRIFLAVONE	280.11	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	SFBODOKJTYAUCM-UHFFFAOYSA-N	3747.0		SFBODOKJTYAUCM
BRD-K93618743-001-20-2	ipriflavone	Launched	bone resorption inhibitor		orthopedics	osteoporosis	0	96.82	Selleck	S2422	Ipriflavone (Osteofix)	280.11	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	SFBODOKJTYAUCM-UHFFFAOYSA-N	3747.0		SFBODOKJTYAUCM
BRD-K88568253-011-19-9	iproniazid	Withdrawn	monoamine oxidase inhibitor	MAOA|MAOB			0	98.08	MicroSource	1500634	IPRONIAZID PHOSPHATE	179.106	CC(C)NNC(=O)c1ccncc1	NYMGNSNKLVNMIA-UHFFFAOYSA-N	3748.0		NYMGNSNKLVNMIA
BRD-K88568253-011-20-9	iproniazid	Withdrawn	monoamine oxidase inhibitor	MAOA|MAOB			0	93.56	MedChemEx	HY-B0886	Iproniazid (phosphate)	179.106	CC(C)NNC(=O)c1ccncc1	NYMGNSNKLVNMIA-UHFFFAOYSA-N	3748.0		NYMGNSNKLVNMIA
BRD-K90574421-001-03-5	ipsapirone	Phase 3	serotonin receptor agonist	HTR1A			0	93.81	Tocris	1869	Ipsapirone	401.152	O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	TZJUVVIWVWFLCD-UHFFFAOYSA-N	56971.0		TZJUVVIWVWFLCD
BRD-K90574421-001-04-9	ipsapirone	Phase 3	serotonin receptor agonist	HTR1A			0	96.7	Tocris	1869	Ipsapirone	401.152	O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	TZJUVVIWVWFLCD-UHFFFAOYSA-N	56971.0		TZJUVVIWVWFLCD
BRD-K60038276-001-09-0	irbesartan	Launched	angiotensin receptor antagonist	AGTR1|JUN|SLC10A1	cardiology|nephrology	hypertension|diabetic nephropathy	0	98.6	MicroSource	1504259	IRBESARTAN	428.232	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|	YOSHYTLCDANDAN-UHFFFAOYSA-N	3749.0		YOSHYTLCDANDAN
BRD-K60038276-001-12-9	irbesartan	Launched	angiotensin receptor antagonist	AGTR1|JUN|SLC10A1	cardiology|nephrology	hypertension|diabetic nephropathy	0	96.43	Tocris	5798	Irbesartan	428.232	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|	YOSHYTLCDANDAN-UHFFFAOYSA-N	3749.0		YOSHYTLCDANDAN
BRD-K60038276-001-08-2	irbesartan	Launched	angiotensin receptor antagonist	AGTR1|JUN|SLC10A1	cardiology|nephrology	hypertension|diabetic nephropathy	0	98.33	Selleck	S1507	Irbesartan	428.232	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|	YOSHYTLCDANDAN-UHFFFAOYSA-N	3749.0		YOSHYTLCDANDAN
BRD-K00004549-001-01-9	irganox-1010	Preclinical	antioxidant				0	0.0	Sigma	MFCD00059345	3-{[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyl]oxy}-2,2-bis({[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyl]oxy}methyl)propyl 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate	1176.784	CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	BGYHLZZASRKEJE-UHFFFAOYSA-N	64819.0		BGYHLZZASRKEJE
BRD-K00003335-001-01-9	iRGD-peptide	Preclinical	integrin signaling activator				0	92.64	MedChemEx	HY-P0122	iRGD peptide	947.359	[H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O	YHTTWXCDIRTOQX-YDZOEDPBSA-N			YHTTWXCDIRTOQX
BRD-K08547377-003-06-5	irinotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	colorectal cancer	0	90.38	Tocris	2688	CPT 11	586.279	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N	60838.0		UWKQSNNFCGGAFS
BRD-K08547377-003-07-3	irinotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	colorectal cancer	0	98.48	MedChemEx	HY-16562A	irinotecan	586.279	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N	60838.0		UWKQSNNFCGGAFS
BRD-K08547377-003-05-7	irinotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	colorectal cancer	0	93.7	MicroSource	1505821	IRINOTECAN HYDROCHLORIDE	586.279	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N	60838.0		UWKQSNNFCGGAFS
BRD-K08547377-001-04-4	irinotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	colorectal cancer	0	81.8	Selleck	S1198	Irinotecan	586.279	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N	60838.0		UWKQSNNFCGGAFS
BRD-K08547377-003-04-0	irinotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	colorectal cancer	0	71.58	Tocris	2688	CPT 11	586.279	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N	60838.0		UWKQSNNFCGGAFS
BRD-K08547377-001-06-9	irinotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	colorectal cancer	0	82.28	Selleck	S1198	Irinotecan	586.279	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N	60838.0	BRD-K72035773-001-01-7	UWKQSNNFCGGAFS
BRD-K08547377-394-03-5	irinotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	colorectal cancer	0	96.59	Selleck	S2217	Irinotecan HCl Trihydrate	586.279	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	UWKQSNNFCGGAFS-XIFFEERXSA-N	60838.0		UWKQSNNFCGGAFS
BRD-K98357249-001-03-9	IRL-2500	Preclinical	endothelin receptor antagonist	EDNRB			0	96.86	Tocris	1838	IRL-2500	573.263	CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	UZDORQWMYRRLQV-JHOUSYSJSA-N	5311192.0		UZDORQWMYRRLQV
BRD-K98357249-001-02-9	IRL-2500	Preclinical	endothelin receptor antagonist	EDNRB			0	94.23	Tocris	1838	IRL-2500	573.263	CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	UZDORQWMYRRLQV-JHOUSYSJSA-N	5311192.0		UZDORQWMYRRLQV
BRD-K87777313-001-02-2	irosustat	Phase 2	steroid sulfatase inhibitor	CA2|STS			0	0.0	Sigma	S1950	6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate	309.067	NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1	DSLPMJSGSBLWRE-UHFFFAOYSA-N	5287541.0		DSLPMJSGSBLWRE
BRD-K74195153-050-13-9	irsogladine	Launched	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	0	97.41	Tocris	2504	Irsogladine maleate	255.008	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	ATCGGEJZONJOCL-UHFFFAOYSA-N	3752.0		ATCGGEJZONJOCL
BRD-K74195153-050-12-1	irsogladine	Launched	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	0	99.31	Tocris	2504	Irsogladine maleate	255.008	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	ATCGGEJZONJOCL-UHFFFAOYSA-N	3752.0		ATCGGEJZONJOCL
BRD-K74195153-050-14-9	irsogladine	Launched	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	0	98.99	Tocris	2504	Irsogladine maleate	255.008	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	ATCGGEJZONJOCL-UHFFFAOYSA-N	3752.0		ATCGGEJZONJOCL
BRD-K74195153-001-04-1	irsogladine	Launched	phosphodiesterase inhibitor	PDE4A	gastroenterology	peptic ulcer disease (PUD)	0	98.88	Selleck	S1929	Irsogladine	255.008	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	ATCGGEJZONJOCL-UHFFFAOYSA-N	3752.0		ATCGGEJZONJOCL
BRD-K01825673-051-02-9	isamoltane	Phase 1	adrenergic receptor antagonist	HTR1A|HTR1B			0	86.61	Tocris	992	Isamoltane hemifumarate	274.168	CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|	XVTVPGKWYHWYAD-CQSZACIVSA-N	6604790.0		XVTVPGKWYHWYAD
BRD-K01825673-051-01-9	isamoltane	Phase 1	adrenergic receptor antagonist	HTR1A|HTR1B			0	89.47	Tocris	992	Isamoltane hemifumarate	390.179	CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|	XVTVPGKWYHWYAD-CQSZACIVSA-N	6604790.0	BRD-M60365050-051-02-7	XVTVPGKWYHWYAD
BRD-A17009129-001-01-3	isavuconazole	Phase 3	cytochrome P450 inhibitor	CYP3A4			0	98.14	MedChemEx	HY-14273	Isavuconazole	437.112	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1,&1:15|	DDFOUSQFMYRUQK-FPTDNZKUSA-N	92043107.0		DDFOUSQFMYRUQK
BRD-K95957366-001-02-6	isaxonine	Withdrawn	nerve growth factor agonist				0	81.09	MicroSource	1504617	ISAXONINE	137.095	CC(C)Nc1ncccn1	FTCYIGBVOHNHCD-UHFFFAOYSA-N	71169.0		FTCYIGBVOHNHCD
BRD-K95957366-001-03-9	isaxonine	Withdrawn	nerve growth factor agonist				0	12.51	AMS	A104021	N-isopropyl-2-pyrimidinamine	137.095	CC(C)Nc1ncccn1	FTCYIGBVOHNHCD-UHFFFAOYSA-N	71169.0		FTCYIGBVOHNHCD
BRD-K06762493-001-10-9	isbufylline	Phase 2	phosphodiesterase inhibitor				0	95.19	Vitas-M	STK868787	1,3-dimethyl-7-(2-methylpropyl)-3,7-dihydro-1H-purine-2,6-dione	236.127	CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	WHUWQSQEVISUMC-UHFFFAOYSA-N	65681.0		WHUWQSQEVISUMC
BRD-K06762493-001-08-1	isbufylline	Phase 2	phosphodiesterase inhibitor				0	97.28	Vitas-M	STK868787		236.127	CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	WHUWQSQEVISUMC-UHFFFAOYSA-N	65681.0		WHUWQSQEVISUMC
BRD-K74759733-001-01-9	isepamicin	Launched	protein synthesis inhibitor		infectious disease	pneumonia|peritonitis	0	85.6	Carbosynth	ISEPAMICIN	(2S)-3-amino-N-((1R,2S,3S,4R,5S)-5-amino-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-3-hydroxycyclohexyl)-2-hydroxypropanamide	569.291	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	UDIIBEDMEYAVNG-ZKFPOVNWSA-N	3037209.0		UDIIBEDMEYAVNG
BRD-K74759733-065-01-4	isepamicin	Launched	protein synthesis inhibitor		infectious disease	pneumonia|peritonitis	0	95.5	Sigma	MFCD01683537	sulfuric acid compound with (2S)-3-amino-N-((1R,2S,3S,4R,5S)-5-amino-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-3-hydroxycycloh	569.291	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	UDIIBEDMEYAVNG-ZKFPOVNWSA-N	3037209.0		UDIIBEDMEYAVNG
BRD-A94055480-001-01-5	ISO-1	Preclinical	macrophage migration inhibiting factor inhibitor	MIF			0	83.05	Tocris	4288	ISO 1	235.084	COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|	AIXMJTYHQHQJLU-SNVBAGLBSA-N	5288525.0		AIXMJTYHQHQJLU
BRD-A94055480-001-02-9	ISO-1	Preclinical	macrophage migration inhibiting factor inhibitor	MIF			0	95.84	Tocris	4288	ISO 1	235.084	COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5,r,c:7|	AIXMJTYHQHQJLU-SNVBAGLBSA-N	5288525.0		AIXMJTYHQHQJLU
BRD-K96714749-001-01-0	isobutamben	Preclinical	local anesthetic				0	99.03	MicroSource	1506196	ISOBUTAMBEN	193.11	CC(C)COC(=O)c1ccc(N)cc1	PUYOAVGNCWPANW-UHFFFAOYSA-N	7176.0		PUYOAVGNCWPANW
BRD-K96714749-001-02-9	isobutamben	Preclinical	local anesthetic				0	93.47	Sigma	MFCD00017110	Isobutyl 4-Aminobenzoate	193.11	CC(C)COC(=O)c1ccc(N)cc1	PUYOAVGNCWPANW-UHFFFAOYSA-N	7176.0		PUYOAVGNCWPANW
BRD-K54057105-001-01-2	isobutyramide	Phase 2	gene expression stimulant	HBE1|HBG1			1	0.0	Otava	1375169		87.068	CC(C)C(N)=O	WFKAJVHLWXSISD-UHFFFAOYSA-N	68424.0		WFKAJVHLWXSISD
BRD-K93332168-001-11-5	isocarboxazid	Launched	monoamine oxidase inhibitor	MAOA|MAOB	neurology/psychiatry	depression	0	74.82	Sigma	MFCD00865409	N'-benzyl-5-methyl-3-isoxazolecarbohydrazide	231.101	Cc1cc(no1)C(=O)NNCc1ccccc1	XKFPYPQQHFEXRZ-UHFFFAOYSA-N	3759.0		XKFPYPQQHFEXRZ
BRD-K93332168-001-10-7	isocarboxazid	Launched	monoamine oxidase inhibitor	MAOA|MAOB	neurology/psychiatry	depression	0	57.67	Enzo	AC3152	ISOCARBOXAZID	231.101	Cc1cc(no1)C(=O)NNCc1ccccc1	XKFPYPQQHFEXRZ-UHFFFAOYSA-N	3759.0		XKFPYPQQHFEXRZ
BRD-K01825590-008-03-9	isoconazole	Launched	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	0	99.12	MedChemEx	HY-B1444	Isoconazole (nitrate)	413.986	Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|	MPIPASJGOJYODL-GOSISDBHSA-N	25273632.0		MPIPASJGOJYODL
BRD-K01825590-008-02-9	isoconazole	Launched	fungal lanosterol demethylase inhibitor	CYP17A1	infectious disease	gram-positive bacterial infections	0	98.55	Selleck	S2534	Isoconazole nitrate	476.982	Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|	MPIPASJGOJYODL-GOSISDBHSA-N	25273632.0		MPIPASJGOJYODL
BRD-K60241851-001-11-9	isodibut	Phase 2	aldehyde reductase inhibitor				0	99.18	Sigma	MFCD00181400	4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)butanoic acid	283.084	OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	ZHXRDXTYPCPBTI-UHFFFAOYSA-N	145949.0		ZHXRDXTYPCPBTI
BRD-K60241851-001-10-1	isodibut	Phase 2	aldehyde reductase inhibitor				0	65.63	Enamine	Z56891243		283.084	OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	ZHXRDXTYPCPBTI-UHFFFAOYSA-N	145949.0		ZHXRDXTYPCPBTI
BRD-A24587114-066-21-7	isoetharine	Launched	adrenergic receptor agonist		pulmonary	bronchospasm|asthma	0	58.82	Selleck	S4330	Isoetharine Mesylate	239.152	CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|	HUYWAWARQUIQLE-MFKMUULPSA-N	71466.0		HUYWAWARQUIQLE
BRD-A24587114-066-22-5	isoetharine	Launched	adrenergic receptor agonist		pulmonary	bronchospasm|asthma	0	88.34	MicroSource	1505977	ISOETHARINE MESYLATE	239.152	CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|	HUYWAWARQUIQLE-MFKMUULPSA-N	71466.0		HUYWAWARQUIQLE
BRD-A24587114-066-24-1	isoetharine	Launched	adrenergic receptor agonist		pulmonary	bronchospasm|asthma	0	93.37	Selleck	S4330	Isoetharine mesylate salt	239.152	CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|	HUYWAWARQUIQLE-MFKMUULPSA-N	71466.0		HUYWAWARQUIQLE
BRD-A24587114-066-23-3	isoetharine	Launched	adrenergic receptor agonist		pulmonary	bronchospasm|asthma	0	94.7	Selleck	S4330	isoetharine mesylate	239.152	CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2,&2:7|	HUYWAWARQUIQLE-MFKMUULPSA-N	71466.0		HUYWAWARQUIQLE
BRD-A07704283-001-01-3	isofloxythepin	Phase 2	dopamine receptor antagonist				0	85.83	Specs	AE-641/00600032		400.198	CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16,r|	XDBMBHVYXPBOPL-OAQYLSRUSA-N	969497.0		XDBMBHVYXPBOPL
BRD-K29173907-001-09-2	isoflupredone-acetate	Preclinical		NR3C1			0	91.96	Prestwick	Prestw-6	Isoflupredone acetate	420.195	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|	ZOCUOMKMBMEYQV-GSLJADNHSA-N	224246.0		ZOCUOMKMBMEYQV
BRD-K29173907-001-10-9	isoflupredone-acetate	Preclinical		NR3C1			0	89.14	Toronto	i816610	isoflupredone acetate	420.195	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19,t:15|	ZOCUOMKMBMEYQV-GSLJADNHSA-N	224246.0		ZOCUOMKMBMEYQV
BRD-A31564021-001-02-6	isoflurane	Launched	inhaled anaesthetic	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9	neurology/psychiatry	general anaesthetic	1	0.0	Sigma	MFCD00066609	2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane	183.971	FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|	PIWKPBJCKXDKJR-PVQJCKRUSA-N	4369440.0		PIWKPBJCKXDKJR
BRD-A31564021-001-01-8	isoflurane	Launched	inhaled anaesthetic	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9	neurology/psychiatry	general anaesthetic	1	0.0	Enamine	EN300-123043		183.971	FC(F)O[C@@H](Cl)C(F)(F)F |&1:4,r|	PIWKPBJCKXDKJR-PVQJCKRUSA-N	4369440.0		PIWKPBJCKXDKJR
BRD-K56575995-001-03-0	isoflurophate	Launched	cholinesterase inhibitor	ACHE|BCHE	ophthalmology	glaucoma	1	0.0	Sigma	MFCD00008873	diisopropyl fluoridophosphate	184.066	CC(C)OP(F)(=O)OC(C)C	MUCZHBLJLSDCSD-UHFFFAOYSA-N	5936.0		MUCZHBLJLSDCSD
BRD-K56575995-001-02-2	isoflurophate	Launched	cholinesterase inhibitor	ACHE|BCHE	ophthalmology	glaucoma	1	0.0	Sigma	MFCD00008873	diisopropyl fluoridophosphate	184.066	CC(C)OP(F)(=O)OC(C)C	MUCZHBLJLSDCSD-UHFFFAOYSA-N	5936.0		MUCZHBLJLSDCSD
BRD-K66480997-003-10-0	isoguvacine	Preclinical	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3			0	100.0	Tocris	235	Isoguvacine hydrochloride	127.063	OC(=O)C1=CCNCC1 |t:3|	KRVDMABBKYMBHG-UHFFFAOYSA-N	7059534.0		KRVDMABBKYMBHG
BRD-K66480997-003-11-9	isoguvacine	Preclinical	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3			0	100.0	Tocris	235	Isoguvacine hydrochloride	127.063	OC(=O)C1=CCNCC1 |t:3|	KRVDMABBKYMBHG-UHFFFAOYSA-N	7059534.0		KRVDMABBKYMBHG
BRD-A02232681-001-01-8	isoleucine	Launched					0	89.82	Enamine	Z1270446358	isoleucine	131.095	CC[C@@H](C)[C@@H](N)C(O)=O |&1:2,&2:4,r|	AGPKZVBTJJNPAG-RFZPGFLSSA-N	76551.0		AGPKZVBTJJNPAG
BRD-K33583600-001-16-1	isoliquiritigenin	Preclinical	guanylate cyclase activator	GABBR1			0	90.32	Selleck	S2404	Isoliquiritigenin	256.074	Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1	DXDRHHKMWQZJHT-FPYGCLRLSA-N	638278.0		DXDRHHKMWQZJHT
BRD-A64743628-001-01-5	isometheptene-mucate	Launched			neurology/psychiatry	headache	0	81.13	Prestwick	Prestw-1023	Isometheptene mucate	141.152	CN[C@@H](C)CCC=C(C)C |&1:2,r|	XVQUOJBERHHONY-VIFPVBQESA-N	6604597.0	BRD-M48029916-001-06-6|BRD-M59543297-001-05-3	XVQUOJBERHHONY
BRD-K87202646-001-39-9	isoniazid	Launched	FABI inhibitor	CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4	infectious disease	tuberculosis	0	100.0	MedChemEx	HY-B0329	Isoniazid	137.059	NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N	3767.0		QRXWMOHMRWLFEY
BRD-K87202646-061-05-6	isoniazid	Launched	FABI inhibitor	CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4	infectious disease	tuberculosis	0	68.91	MicroSource	1503381	PASINIAZID	137.059	NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N	3767.0		QRXWMOHMRWLFEY
BRD-K87202646-001-32-6	isoniazid	Launched	FABI inhibitor	CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4	infectious disease	tuberculosis	0	100.0	Selleck	S1937	Isoniazid	137.059	NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N	3767.0		QRXWMOHMRWLFEY
BRD-K87202646-001-33-4	isoniazid	Launched	FABI inhibitor	CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4	infectious disease	tuberculosis	0	100.0	MicroSource	1500355	ISONIAZID	137.059	NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N	3767.0		QRXWMOHMRWLFEY
BRD-K87202646-061-04-9	isoniazid	Launched	FABI inhibitor	CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4	infectious disease	tuberculosis	0	93.93	Selleck	S4404	Pasiniazid	137.059	NNC(=O)c1ccncc1	QRXWMOHMRWLFEY-UHFFFAOYSA-N	3767.0		QRXWMOHMRWLFEY
BRD-K37851352-001-01-0	isopentyl-4-methoxycinnamate	Launched			dermatology	sunscreen lotion	0	0.0	Enamine	Z212714982		248.141	COc1ccc(\C=C\C(=O)OCCC(C)C)cc1	UBNYRXMKIIGMKK-RMKNXTFCSA-N	1549789.0		UBNYRXMKIIGMKK
BRD-K37851352-001-02-9	isopentyl-4-methoxycinnamate	Launched			dermatology	sunscreen lotion	0	87.91	Sigma	MFCD00583856	ISOPENTYL-4-METHOXYCINNAMATE	248.141	COc1ccc(\C=C\C(=O)OCCC(C)C)cc1	UBNYRXMKIIGMKK-RMKNXTFCSA-N	1549789.0		UBNYRXMKIIGMKK
BRD-A04322457-003-18-7	isoprenaline	Launched	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3	cardiology|pulmonary	bradycardia|heart block|asthma	0	0.0	Selleck	S2566	Isoprenaline hydrochloride	211.121	CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|	JWZZKOKVBUJMES-LLVKDONJSA-N	5808.0		JWZZKOKVBUJMES
BRD-A04322457-003-15-3	isoprenaline	Launched	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3	cardiology|pulmonary	bradycardia|heart block|asthma	0	0.0	Selleck	S2566	Isoprenaline HCl	211.121	CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|	JWZZKOKVBUJMES-LLVKDONJSA-N	5808.0		JWZZKOKVBUJMES
BRD-A04322457-003-17-9	isoprenaline	Launched	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3	cardiology|pulmonary	bradycardia|heart block|asthma	0	94.79	MicroSource	1500357	ISOPROTERENOL HYDROCHLORIDE	211.121	CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|	JWZZKOKVBUJMES-LLVKDONJSA-N	5808.0		JWZZKOKVBUJMES
BRD-A04322457-003-16-1	isoprenaline	Launched	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3	cardiology|pulmonary	bradycardia|heart block|asthma	0	81.74	Tocris	1747	Isoproterenol hydrochloride	211.121	CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|	JWZZKOKVBUJMES-LLVKDONJSA-N	5808.0		JWZZKOKVBUJMES
BRD-K14127446-005-23-9	isopropamide-iodide	Launched	acetylcholine receptor antagonist	CHRM3|CHRM4	gastroenterology	peptic ulcer disease (PUD)|gastrointestinal acidosis	0	100.0	USP	1350002	isopropamide iodine	353.259	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	JTPUMZTWMWIVPA-UHFFFAOYSA-O	3775.0		JTPUMZTWMWIVPA
BRD-K14127446-005-22-7	isopropamide-iodide	Launched	acetylcholine receptor antagonist	CHRM3|CHRM4	gastroenterology	peptic ulcer disease (PUD)|gastrointestinal acidosis	0	97.23	MicroSource	1500356	ISOPROPAMIDE IODIDE	353.259	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	JTPUMZTWMWIVPA-UHFFFAOYSA-O	3775.0		JTPUMZTWMWIVPA
BRD-K13409143-001-02-7	isopropyl-myristate	Launched			dermatology	cosmetic	1	0.0	Sigma	MFCD00008982	isopropyl myristate	270.256	CCCCCCCCCCCCCC(=O)OC(C)C	AXISYYRBXTVTFY-UHFFFAOYSA-N	8042.0		AXISYYRBXTVTFY
BRD-K13409143-001-01-9	isopropyl-myristate	Launched			dermatology	cosmetic	1	0.0	Acros	41285		270.256	CCCCCCCCCCCCCC(=O)OC(C)C	AXISYYRBXTVTFY-UHFFFAOYSA-N	8042.0		AXISYYRBXTVTFY
BRD-K30758549-001-02-6	isopropyl-palmitate	Launched	cosmetic moisturizer		dermatology	cosmetic	1	0.0	Sigma	MFCD00008993	isopropyl palmitate	298.287	CCCCCCCCCCCCCCCC(=O)OC(C)C	XUGNVMKQXJXZCD-UHFFFAOYSA-N	8907.0		XUGNVMKQXJXZCD
BRD-K30758549-001-01-8	isopropyl-palmitate	Launched	cosmetic moisturizer		dermatology	cosmetic	1	0.0	TCI	P0005		298.287	CCCCCCCCCCCCCCCC(=O)OC(C)C	XUGNVMKQXJXZCD-UHFFFAOYSA-N	8907.0		XUGNVMKQXJXZCD
BRD-K73991644-001-07-9	isoquercitrin	Phase 2/Phase 3	antioxidant				0	91.07	ChemDiv	0407-0014	Hirsutrin	464.095	OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	OVSQVDMCBVZWGM-QSOFNFLRSA-N	5280804.0		OVSQVDMCBVZWGM
BRD-K01826521-001-11-9	Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,	Preclinical					0	52.65	MedChemEx	HY-22385	Salsolidine	207.126	COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|	HMYJLVDKPJHJCF-QMMMGPOBSA-N	164752.0		HMYJLVDKPJHJCF
BRD-K01826521-003-10-9	Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,	Preclinical					0	98.3	Prestwick	Prestw-532	Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride	243.103	COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|	HMYJLVDKPJHJCF-QMMMGPOBSA-N	164752.0		HMYJLVDKPJHJCF
BRD-K47178855-001-03-4	isosorbide	Launched	nitric oxide stimulant		cardiology	angina pectoris|coronary artery disease (CAD)	0	0.0	MedChemEx	HY-B1469	Isosorbide	146.058	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	KLDXJTOLSGUMSJ-JGWLITMVSA-N	12597.0		KLDXJTOLSGUMSJ
BRD-K47178855-001-02-6	isosorbide	Launched	nitric oxide stimulant		cardiology	angina pectoris|coronary artery disease (CAD)	0	0.0	MedChemEx	HY-B1469	Isosorbide	146.058	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	KLDXJTOLSGUMSJ-JGWLITMVSA-N	12597.0		KLDXJTOLSGUMSJ
BRD-K47178855-001-04-2	isosorbide	Launched	nitric oxide stimulant		cardiology	angina pectoris|coronary artery disease (CAD)	0	0.0	Selleck	S4204	Isosorbide	146.058	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	KLDXJTOLSGUMSJ-JGWLITMVSA-N	12597.0	BRD-K57344138-001-01-2	KLDXJTOLSGUMSJ
BRD-K47178855-001-01-8	isosorbide	Launched	nitric oxide stimulant		cardiology	angina pectoris|coronary artery disease (CAD)	0	0.0	Selleck	S4204	Isosorbide	146.058	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	KLDXJTOLSGUMSJ-JGWLITMVSA-N	12597.0		KLDXJTOLSGUMSJ
BRD-K55853390-001-13-2	isosorbide-dinitrate	Launched	nitric oxide stimulant	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3|NPR1	cardiology	angina pectoris|coronary artery disease (CAD)	0	0.0	Enamine	Z2433066075	(3R,3aS,6S,6aS)-hexahydrofuro[3,2-b]furan-3,6-diyl dinitrate	236.028	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	MOYKHGMNXAOIAT-JGWLITMVSA-N	6883.0		MOYKHGMNXAOIAT
BRD-K55853390-001-12-4	isosorbide-dinitrate	Launched	nitric oxide stimulant	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3|NPR1	cardiology	angina pectoris|coronary artery disease (CAD)	0	0.0	MicroSource	1500358	ISOSORBIDE DINITRATE	236.028	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	MOYKHGMNXAOIAT-JGWLITMVSA-N	6883.0		MOYKHGMNXAOIAT
BRD-K82225283-001-03-1	isosorbide-mononitrate	Launched	nitric oxide stimulant	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3	cardiology	angina pectoris|coronary artery disease (CAD)	0	97.02	MicroSource	1503807	ISOSORBIDE MONONITRATE	191.043	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	YWXYYJSYQOXTPL-SLPGGIOYSA-N	27661.0		YWXYYJSYQOXTPL
BRD-K82225283-001-04-9	isosorbide-mononitrate	Launched	nitric oxide stimulant	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3	cardiology	angina pectoris|coronary artery disease (CAD)	0	94.1	MedChemEx	HY-B0642	Isosorbide mononitrate	191.043	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	YWXYYJSYQOXTPL-SLPGGIOYSA-N	27661.0		YWXYYJSYQOXTPL
BRD-A96529864-001-01-3	isosteviol	Phase 2					0	100.0	ChemDiv	N062-0006		318.219	C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1,3,9,10,15,&1:20|	KFVUFODCZDRVSS-XGBBNYNSSA-N	99514.0		KFVUFODCZDRVSS
BRD-A02933148-001-01-8	isotiquimide	Phase 1					0	92.3	Enamine	Z2380439294	4-methyl-5,6,7,8-tetrahydro-8-quinolinecarbothioamide	206.088	Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6,r|	PWPWEYFVLITGNU-SECBINFHSA-N	76961135.0		PWPWEYFVLITGNU
BRD-K76723084-001-23-2	isotretinoin	Launched	retinoid receptor agonist	RARA|RARB|RARG	dermatology	acne vulgaris (AV)	0	39.93	MicroSource	1502013	ISOTRETINON	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|	SHGAZHPCJJPHSC-XFYACQKRSA-N	5282379.0		SHGAZHPCJJPHSC
BRD-K76723084-001-25-7	isotretinoin	Launched	retinoid receptor agonist	RARA|RARB|RARG	dermatology	acne vulgaris (AV)	0	46.85	Selleck	S1379	Isotretinoin	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|	SHGAZHPCJJPHSC-XFYACQKRSA-N	5282379.0	BRD-K95366153-001-02-7	SHGAZHPCJJPHSC
BRD-K76723084-001-24-0	isotretinoin	Launched	retinoid receptor agonist	RARA|RARB|RARG	dermatology	acne vulgaris (AV)	0	51.38	MedChemEx	HY-15127	Isotretinoin	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|	SHGAZHPCJJPHSC-XFYACQKRSA-N	5282379.0		SHGAZHPCJJPHSC
BRD-K76723084-001-22-4	isotretinoin	Launched	retinoid receptor agonist	RARA|RARB|RARG	dermatology	acne vulgaris (AV)	0	8.86	Selleck	S1379	Isotretinoin	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|	SHGAZHPCJJPHSC-XFYACQKRSA-N	5282379.0		SHGAZHPCJJPHSC
BRD-K90069354-001-04-5	isovaleramide	Phase 2	alcohol dehydrogenase inhibitor				0	41.57	PrincetonBio	OSSL_789699	3-methylbutanamide	101.084	CC(C)CC(N)=O	SANOUVWGPVYVAV-UHFFFAOYSA-N	10930.0		SANOUVWGPVYVAV
BRD-K90069354-001-01-1	isovaleramide	Phase 2	alcohol dehydrogenase inhibitor				0	20.52	Selleck	S4116	Isovaleramide	101.084	CC(C)CC(N)=O	SANOUVWGPVYVAV-UHFFFAOYSA-N	10930.0		SANOUVWGPVYVAV
BRD-K90069354-001-02-9	isovaleramide	Phase 2	alcohol dehydrogenase inhibitor				0	67.62	MicroSource	1506177	ISOVALERAMIDE	101.084	CC(C)CC(N)=O	SANOUVWGPVYVAV-UHFFFAOYSA-N	10930.0		SANOUVWGPVYVAV
BRD-K90069354-001-03-7	isovaleramide	Phase 2	alcohol dehydrogenase inhibitor				0	79.17	Selleck	S4116	Isovaleramide	101.084	CC(C)CC(N)=O	SANOUVWGPVYVAV-UHFFFAOYSA-N	10930.0		SANOUVWGPVYVAV
BRD-K92116564-001-01-4	isoxepac	Phase 2	anti-inflammatory agent				0	99.77	Ark	AK-35631		268.074	OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1	QFGMXJOBTNZHEL-UHFFFAOYSA-N	41448.0		QFGMXJOBTNZHEL
BRD-A75552914-001-16-8	isoxicam	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	95.11	MicroSource	1503242	ISOXICAM	335.058	CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|	YYUAYBYLJSNDCX-UHFFFAOYSA-N	54677972.0		YYUAYBYLJSNDCX
BRD-A75552914-001-15-0	isoxicam	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	97.77	Selleck	S4398	Isoxicam	335.058	CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|	YYUAYBYLJSNDCX-UHFFFAOYSA-N	54677972.0		YYUAYBYLJSNDCX
BRD-A75552914-001-17-6	isoxicam	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	98.14	Selleck	S4398	ISOXICAM	335.058	CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|	YYUAYBYLJSNDCX-UHFFFAOYSA-N	54677972.0		YYUAYBYLJSNDCX
BRD-K00003690-003-01-9	isoxsuprine	Launched	adrenergic receptor agonist	ADRB2	rheumatology|cardiology	Raynaud's disease|arteriosclerosis|Buerger's disease	0	90.9	MedChemEx	HY-B1270	Isoxsuprine hydrochloride	301.168	C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13,&2:11,&3:1|	BMUKKTUHUDJSNZ-PMUMKWKESA-N	42066885.0		BMUKKTUHUDJSNZ
BRD-K64881305-001-06-0	ispinesib	Phase 2	kinesin inhibitor	KIF11			0	88.11	Tocris	5408	Ispinesib	516.229	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	QJZRFPJCWMNVAV-HHHXNRCGSA-N	6851740.0		QJZRFPJCWMNVAV
BRD-K64881305-001-05-2	ispinesib	Phase 2	kinesin inhibitor	KIF11			0	88.16	Selleck	S1452	Ispinesib (SB-715992)	516.229	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	QJZRFPJCWMNVAV-HHHXNRCGSA-N	6851740.0		QJZRFPJCWMNVAV
BRD-K64881305-001-03-7	ispinesib	Phase 2	kinesin inhibitor	KIF11			0	82.43	Selleck	S1452	Ispinesib (SB-715992)	516.229	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	QJZRFPJCWMNVAV-HHHXNRCGSA-N	6851740.0		QJZRFPJCWMNVAV
BRD-A90799790-001-20-7	isradipine	Launched	calcium channel blocker	CACNA1D|CACNA1F|CACNA2D1	cardiology	hypertension	0	93.26	Tocris	2004	Isradipine	371.148	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|	HMJIYCCIJYRONP-MRXNPFEDSA-N	13773524.0		HMJIYCCIJYRONP
BRD-A90799790-001-19-9	isradipine	Launched	calcium channel blocker	CACNA1D|CACNA1F|CACNA2D1	cardiology	hypertension	0	97.4	MicroSource	2300234	ISRADIPINE	371.148	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|	HMJIYCCIJYRONP-MRXNPFEDSA-N	13773524.0		HMJIYCCIJYRONP
BRD-A90799790-001-16-5	isradipine	Launched	calcium channel blocker	CACNA1D|CACNA1F|CACNA2D1	cardiology	hypertension	0	95.94	Selleck	S1662	Isradipine	371.148	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|	HMJIYCCIJYRONP-MRXNPFEDSA-N	13773524.0		HMJIYCCIJYRONP
BRD-A90799790-001-17-3	isradipine	Launched	calcium channel blocker	CACNA1D|CACNA1F|CACNA2D1	cardiology	hypertension	0	91.57	Tocris	2004	Isradipine	371.148	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r,c:4,9|	HMJIYCCIJYRONP-MRXNPFEDSA-N	13773524.0		HMJIYCCIJYRONP
BRD-K12826175-001-02-4	ISRIB	Preclinical	eukaryotic translation initiation factor inhibitor|PERK inhibitor	EIF2A|EIF2AK3			0	90.08	MedChemEx	HY-12495	ISRIB trans-isomer	450.111	Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|	HJGMCDHQPXTGAV-IYARVYRRSA-N			HJGMCDHQPXTGAV
BRD-K95412502-003-01-5	istaroxime	Phase 2	ATPase inhibitor	ATP1A1			0	97.6	MedChemEx	HY-15718A	Istaroxime (hydrochloride)	360.241	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	MPYLDWFDPHRTEG-PAAYLBSLSA-N	9841834.0		MPYLDWFDPHRTEG
BRD-K95412502-003-02-9	istaroxime	Phase 2	ATPase inhibitor	ATP1A1			0	86.4	MedChemEx	HY-15718A	Istaroxime (hydrochloride)	360.241	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	MPYLDWFDPHRTEG-PAAYLBSLSA-N	9841834.0		MPYLDWFDPHRTEG
BRD-K87774949-001-05-4	istradefylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3	neurology/psychiatry	Parkinson's Disease|dyskinesia	0	78.61	MedChemEx	HY-10888	Istradefylline	384.18	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	IQVRBWUUXZMOPW-PKNBQFBNSA-N	5311037.0		IQVRBWUUXZMOPW
BRD-K87774949-001-07-0	istradefylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3	neurology/psychiatry	Parkinson's Disease|dyskinesia	0	95.36	MedChemEx	HY-10888	Istradefylline	384.18	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	IQVRBWUUXZMOPW-PKNBQFBNSA-N	5311037.0		IQVRBWUUXZMOPW
BRD-K87774949-001-06-2	istradefylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3	neurology/psychiatry	Parkinson's Disease|dyskinesia	0	77.01	MedChemEx	HY-10888	Istradefylline	384.18	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	IQVRBWUUXZMOPW-PKNBQFBNSA-N	5311037.0		IQVRBWUUXZMOPW
BRD-K87774949-001-03-9	istradefylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3	neurology/psychiatry	Parkinson's Disease|dyskinesia	0	82.52	Selleck	S2790	Istradefylline	384.18	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	IQVRBWUUXZMOPW-PKNBQFBNSA-N	5311037.0		IQVRBWUUXZMOPW
BRD-K87774949-001-04-7	istradefylline	Launched	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3	neurology/psychiatry	Parkinson's Disease|dyskinesia	0	83.12	Selleck	S2790	Istradefylline (KW-6002)	384.18	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	IQVRBWUUXZMOPW-PKNBQFBNSA-N	5311037.0		IQVRBWUUXZMOPW
BRD-K53903639-001-04-7	ISX-9	Preclinical	neural stem cell inducer	NEUROD1			0	89.11	Tocris	4439	ISX 9	234.046	O=C(NC1CC1)c1cc(on1)-c1cccs1	SYENTKHGMVKGAQ-UHFFFAOYSA-N	19582717.0		SYENTKHGMVKGAQ
BRD-K53903639-001-01-3	ISX-9	Preclinical	neural stem cell inducer	NEUROD1			0	100.0	EMDBio	480743	480743.cdx	234.046	O=C(NC1CC1)c1cc(on1)-c1cccs1	SYENTKHGMVKGAQ-UHFFFAOYSA-N	19582717.0		SYENTKHGMVKGAQ
BRD-K67482377-001-01-8	itacitinib	Phase 3	JAK inhibitor	JAK1			0	96.98	MedChemEx	HY-16997	Itacitinib	553.196	Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	KTBSXLIQKWEBRB-UHFFFAOYSA-N	53380437.0		KTBSXLIQKWEBRB
BRD-A56690687-001-02-9	ITD-1	Preclinical	TGF beta receptor inhibitor	TGFBR2			0	96.52	Tocris	5068	ITD 1	415.215	CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|	ULFUJLFTRWWLPO-XMMPIXPASA-N	71512660.0		ULFUJLFTRWWLPO
BRD-A56690687-001-01-6	ITD-1	Preclinical	TGF beta receptor inhibitor	TGFBR2			0	93.59	Tocris	5068	ITD 1	415.215	CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11,r,c:5,9|	ULFUJLFTRWWLPO-XMMPIXPASA-N	71512660.0		ULFUJLFTRWWLPO
BRD-K60298136-001-03-3	ITE	Preclinical	aryl hydrocarbon receptor agonist	AHR			0	97.76	Tocris	1803	ITE	286.041	COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12	KDDXOGDIPZSCTM-UHFFFAOYSA-N	4668801.0		KDDXOGDIPZSCTM
BRD-K60298136-001-04-1	ITE	Preclinical	aryl hydrocarbon receptor agonist	AHR			0	97.64	Tocris	1803	ITE	286.041	COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12	KDDXOGDIPZSCTM-UHFFFAOYSA-N	4668801.0		KDDXOGDIPZSCTM
BRD-K77987496-011-01-9	ITI214	Phase 1/Phase 2	phosphodiesterase inhibitor	PDE1A			0	95.75	MedChemEx	HY-12501A	ITI214	507.218	CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|	BBIPVJCGIASXJB-PKTZIBPZSA-N	42639643.0		BBIPVJCGIASXJB
BRD-K96740444-003-09-9	itopride	Launched	dopamine receptor antagonist	CHRM3|DRD2	gastroenterology|neurology/psychiatry	dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia	0	98.7	MedChemEx	HY-B0732	Itopride (hydrochloride)	358.189	COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	QQQIECGTIMUVDS-UHFFFAOYSA-N	3792.0		QQQIECGTIMUVDS
BRD-K96740444-001-02-1	itopride	Launched	dopamine receptor antagonist	CHRM3|DRD2	gastroenterology|neurology/psychiatry	dyspepsia|gastroparesis|heartburn|nausea|vomiting|anorexia	0	97.37	MicroSource	1502353	ITOPRIDE  HYDROCHLORIDE	358.189	COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	QQQIECGTIMUVDS-UHFFFAOYSA-N	3792.0		QQQIECGTIMUVDS
BRD-K00004318-001-01-9	itraconazole	Launched	cytochrome P450 inhibitor		infectious disease	onychomycosis|histoplasmosis|blastomycosis|aspergillosis	0	96.35	Tocris	5981	Itraconazole	704.239	CC[C@H](C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O |&1:26,29,&2:2|	VHVPQPYKVGDNFY-TUJWMRSMSA-N	14179013.0		VHVPQPYKVGDNFY
BRD-K36515744-001-03-5	ITX3	Preclinical	GEF inhibitor	TRIO			0	84.43	MedChemEx	HY-16663	ITX3	371.109	Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1	SJMYMKPBODEZSH-DEDYPNTBSA-N	1362865.0		SJMYMKPBODEZSH
BRD-K36515744-001-02-7	ITX3	Preclinical	GEF inhibitor	TRIO			0	63.44	MedChemEx	HY-16663	ITX3	371.109	Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1	SJMYMKPBODEZSH-DEDYPNTBSA-N	1362865.0		SJMYMKPBODEZSH
BRD-K76911699-003-03-9	ITX5061	Phase 1	SR-BI inhibitor				0	96.17	MedChemEx	HY-19900	ITX5061	583.235	COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C	UUROSJLZNDSXRF-UHFFFAOYSA-N	11786594.0		UUROSJLZNDSXRF
BRD-K73499906-300-02-9	IT1t	Preclinical	CC chemokine receptor antagonist	CXCR4			0	81.68	Tocris	4596	IT1t dihydrochloride	406.222	CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|	OOSUDWRRWZVFEB-UHFFFAOYSA-N	25147749.0		OOSUDWRRWZVFEB
BRD-K73499906-300-01-0	IT1t	Preclinical	CC chemokine receptor antagonist	CXCR4			0	77.71	Tocris	4596	IT1t	406.222	CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24,28|	OOSUDWRRWZVFEB-UHFFFAOYSA-N	25147749.0		OOSUDWRRWZVFEB
BRD-K45841694-001-12-5	IU1	Preclinical	ubiquitin C-terminal hydrolase inhibitor	USP14			0	51.37	Tocris	4088	IU1	300.164	Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	JUWDSDKJBMFLHE-UHFFFAOYSA-N	675434.0		JUWDSDKJBMFLHE
BRD-K45841694-001-11-7	IU1	Preclinical	ubiquitin C-terminal hydrolase inhibitor	USP14			0	87.3	Selleck	S7134	IU1	300.164	Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	JUWDSDKJBMFLHE-UHFFFAOYSA-N	675434.0		JUWDSDKJBMFLHE
BRD-K45841694-001-10-9	IU1	Preclinical	ubiquitin C-terminal hydrolase inhibitor	USP14			0	34.89	Selleck	S7134	IU1	300.164	Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	JUWDSDKJBMFLHE-UHFFFAOYSA-N	675434.0		JUWDSDKJBMFLHE
BRD-K33972682-003-02-9	ivabradine	Launched	HCN channel blocker|potassium channel blocker|sodium channel blocker	HCN1|HCN3|HCN4	cardiology	angina pectoris	0	93.97	MedChemEx	HY-B0162A	Ivabradine (hydrochloride)	468.262	COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC	ACRHBAYQBXXRTO-OAQYLSRUSA-N	132999.0		ACRHBAYQBXXRTO
BRD-K52818472-001-03-9	ivacaftor	Launched	CFTR channel potentiator	CFTR	pulmonary	cystic fibrosis	0	99.16	MedChemEx	HY-13017	Ivacaftor	392.21	CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C	PURKAOJPTOLRMP-UHFFFAOYSA-N	16220172.0		PURKAOJPTOLRMP
BRD-K52818472-001-02-2	ivacaftor	Launched	CFTR channel potentiator	CFTR	pulmonary	cystic fibrosis	0	98.82	Selleck	S1144	Ivacaftor (VX-770)	392.21	CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C	PURKAOJPTOLRMP-UHFFFAOYSA-N	16220172.0		PURKAOJPTOLRMP
BRD-K85554912-001-08-9	ivermectin	Launched	benzodiazepine receptor agonist	CHRNA7|P2RX7	infectious disease	gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies	0	94.01	MicroSource	1300027	IVERMECTIN	874.508	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|	AZSNMRSAGSSBNP-XPNPUAGNSA-N	6321424.0	BRD-A48570745-001-02-9	AZSNMRSAGSSBNP
BRD-K85554912-001-05-5	ivermectin	Launched	benzodiazepine receptor agonist	CHRNA7|P2RX7	infectious disease	gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies	0	92.0	Tocris	1260	Ivermectin	874.508	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|	AZSNMRSAGSSBNP-XPNPUAGNSA-N	6321424.0	BRD-M44211600-001-01-6	AZSNMRSAGSSBNP
BRD-K85554912-001-09-9	ivermectin	Launched	benzodiazepine receptor agonist	CHRNA7|P2RX7	infectious disease	gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies	0	87.84	Tocris	1260	Ivermectin	874.508	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|	AZSNMRSAGSSBNP-XPNPUAGNSA-N	6321424.0		AZSNMRSAGSSBNP
BRD-K85554912-001-06-3	ivermectin	Launched	benzodiazepine receptor agonist	CHRNA7|P2RX7	infectious disease	gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies	0	93.9	Selleck	S1351	Ivermectin	874.508	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|	AZSNMRSAGSSBNP-XPNPUAGNSA-N	6321424.0		AZSNMRSAGSSBNP
BRD-K85554912-001-07-1	ivermectin	Launched	benzodiazepine receptor agonist	CHRNA7|P2RX7	infectious disease	gastrointestinal roundworms|lungworms|cattle grubs|mites|lice|horn flies	0	89.31	Selleck	S1351	Ivermectin	874.508	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17,48,56,t:46|	AZSNMRSAGSSBNP-XPNPUAGNSA-N	6321424.0	BRD-K71544586-001-01-6	AZSNMRSAGSSBNP
BRD-K93073858-001-01-1	ivosidenib	Launched	isocitrate dehydrogenase inhibitor	IDH1	hematologic malignancy	acute myeloid leukemia (AML)	0	97.39	MedChemEx	HY-18767	Ivosidenib	582.139	Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N	WIJZXSAJMHAVGX-DHLKQENFSA-N	71657455.0		WIJZXSAJMHAVGX
BRD-K53234107-001-02-9	IWP-L6	Preclinical	porcupine inhibitor	PORCN			0	97.09	Tocris	4992	IWP L6	472.103	O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1	QESQGTFWEQMCMH-UHFFFAOYSA-N	71601111.0		QESQGTFWEQMCMH
BRD-K53234107-001-01-6	IWP-L6	Preclinical	porcupine inhibitor	PORCN			0	95.25	Selleck	S7301	IWP-L6	472.103	O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1	QESQGTFWEQMCMH-UHFFFAOYSA-N	71601111.0		QESQGTFWEQMCMH
BRD-K03601870-001-02-9	ixabepilone	Launched	microtubule stabilizing agent	TUBB	oncology	breast cancer	0	95.66	MedChemEx	HY-10222	Ixabepilone	506.281	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	FABUFPQFXZVHFB-QBNZTRRJSA-N			FABUFPQFXZVHFB
BRD-K03601870-001-01-2	ixabepilone	Launched	microtubule stabilizing agent	TUBB	oncology	breast cancer	0	98.98	MedChemEx	HY-10222	Ixabepilone	506.281	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	FABUFPQFXZVHFB-QBNZTRRJSA-N			FABUFPQFXZVHFB
BRD-K78659596-001-11-9	ixazomib	Launched	proteasome inhibitor		hematologic malignancy	multiple myeloma	0	99.3	MedChemEx	HY-10453	Ixazomib	360.081	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	MXAYKZJJDUDWDS-LBPRGKRZSA-N	25183872.0		MXAYKZJJDUDWDS
BRD-K78659596-001-03-9	ixazomib	Launched	proteasome inhibitor		hematologic malignancy	multiple myeloma	0	93.99	Selleck	S2180	MLN2238	360.081	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	MXAYKZJJDUDWDS-LBPRGKRZSA-N	25183872.0		MXAYKZJJDUDWDS
BRD-A66419424-001-02-4	ixazomib-citrate	Launched	proteasome inhibitor		hematologic malignancy	multiple myeloma	0	92.47	Selleck	S2181	MLN9708	516.087	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|	YTXSYWAKVMZICI-VBKZILBWSA-N	69040311.0		YTXSYWAKVMZICI
BRD-A66419424-001-03-2	ixazomib-citrate	Launched	proteasome inhibitor		hematologic malignancy	multiple myeloma	0	0.0	Selleck	S2181	MLN9708	516.087	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4,&1:25|	YTXSYWAKVMZICI-VBKZILBWSA-N	69040311.0		YTXSYWAKVMZICI
BRD-K95676198-001-06-9	JAK3-inhibitor-V	Preclinical	JAK inhibitor	JAK3			0	61.67	Tocris	1366	ZM 449829	182.073	C=CC(=O)c1ccc2ccccc2c1	FOTCGZPFSUWZBN-UHFFFAOYSA-N	3799.0		FOTCGZPFSUWZBN
BRD-K95676198-001-05-9	JAK3-inhibitor-V	Preclinical	JAK inhibitor	JAK3			0	0.0	Tocris	1366	ZM 449829	182.073	C=CC(=O)c1ccc2ccccc2c1	FOTCGZPFSUWZBN-UHFFFAOYSA-N	3799.0		FOTCGZPFSUWZBN
BRD-K00003271-001-01-9	JD-5037	Preclinical	cannabinoid receptor antagonist				0	100.0	MedChemEx	HY-18697	JD-5037	571.121	CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |c:21|	GTCSIQFTNPTSLO-RPWUZVMVSA-N	66553204.0		GTCSIQFTNPTSLO
BRD-K95837862-300-03-9	JDTic	Phase 1	opioid receptor antagonist	OPRK1			0	94.46	MedChemEx	HY-10487	JDTic (dihydrochloride)	465.299	CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1	ZLVXBBHTMQJRSX-VMGNSXQWSA-N	9956146.0		ZLVXBBHTMQJRSX
BRD-K95837862-300-01-7	JDTic	Phase 1	opioid receptor antagonist	OPRK1			0	91.5	MedChemEx	HY-10487	JDTic (dihydrochloride)	465.299	CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1	ZLVXBBHTMQJRSX-VMGNSXQWSA-N	9956146.0		ZLVXBBHTMQJRSX
BRD-K32892871-003-01-7	JHW-007	Preclinical	dopamine reuptake inhibitor	SLC6A3			0	89.23	Tocris	4351	JHW 007 hydrochloride	385.222	CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	HZEVDVGPBUFIAW-JKHIJQBDSA-N			HZEVDVGPBUFIAW
BRD-K32892871-003-02-9	JHW-007	Preclinical	dopamine reuptake inhibitor	SLC6A3			0	92.32	Tocris	4351	JHW 007 hydrochloride	385.222	CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	HZEVDVGPBUFIAW-JKHIJQBDSA-N			HZEVDVGPBUFIAW
BRD-K00003209-001-01-9	JI-101	Phase 1/Phase 2	kinase inhibitor				0	99.03	MedChemEx	HY-16265	JI-101	465.08	COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12	ZXBFYBLSJMEBEP-UHFFFAOYSA-N	11691242.0		ZXBFYBLSJMEBEP
BRD-K76180386-001-04-9	JIB04	Preclinical	histone lysine demethylase inhibitor	KDM4E			0	85.13	Tocris	4972	JIB 04	308.083	Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	YHHFKWKMXWRVTJ-OQKWZONESA-N	6519698.0		YHHFKWKMXWRVTJ
BRD-K76180386-001-03-2	JIB04	Preclinical	histone lysine demethylase inhibitor	KDM4E			0	25.34	Tocris	4972	JIB 04	308.083	Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	YHHFKWKMXWRVTJ-OQKWZONESA-N	6519698.0		YHHFKWKMXWRVTJ
BRD-K76180386-001-01-6	JIB04	Preclinical	histone lysine demethylase inhibitor	KDM4E			0	94.7	Selleck	S7281	JIB-04	308.083	Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	YHHFKWKMXWRVTJ-OQKWZONESA-N	6519698.0		YHHFKWKMXWRVTJ
BRD-K76180386-001-02-4	JIB04	Preclinical	histone lysine demethylase inhibitor	KDM4E			0	84.7	Selleck	S7281	JIB04 (NSC693627)	308.083	Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	YHHFKWKMXWRVTJ-OQKWZONESA-N	6519698.0		YHHFKWKMXWRVTJ
BRD-K38860038-001-03-8	JK-184	Preclinical	hedgehog pathway inhibitor				0	81.15	Tocris	3341	N-(4-ethoxyphenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)-1,3-thiazol-2-amine	350.12	CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	ROYXIPOUVGDTAO-UHFFFAOYSA-N	1069686.0		ROYXIPOUVGDTAO
BRD-K38860038-001-02-0	JK-184	Preclinical	hedgehog pathway inhibitor				0	63.33	Tocris	3341	JK 184	350.12	CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	ROYXIPOUVGDTAO-UHFFFAOYSA-N	1069686.0		ROYXIPOUVGDTAO
BRD-K38860038-001-01-2	JK-184	Preclinical	hedgehog pathway inhibitor				0	77.77	Tocris	3341	JK 184	350.12	CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	ROYXIPOUVGDTAO-UHFFFAOYSA-N	1069686.0		ROYXIPOUVGDTAO
BRD-K22010301-001-04-6	JLK-6	Preclinical	gamma secretase inhibitor	PSEN1			0	0.0	Tocris	2677	JLK 6	225.019	COc1oc(=O)c2cc(N)ccc2c1Cl	AMDGKLWVCUXONP-UHFFFAOYSA-N	3803.0		AMDGKLWVCUXONP
BRD-K22010301-001-05-9	JLK-6	Preclinical	gamma secretase inhibitor	PSEN1			0		Tocris	2677	JLK 6	225.019	COc1oc(=O)c2cc(N)ccc2c1Cl	AMDGKLWVCUXONP-UHFFFAOYSA-N	3803.0		AMDGKLWVCUXONP
BRD-K15086322-050-02-1	JNJ-10191584	Preclinical	histamine receptor antagonist	HRH4			0	89.86	Tocris	2441	JNJ 10191584 maleate	278.093	CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	MOIWSUQWIOVGRH-UHFFFAOYSA-N	10446295.0		MOIWSUQWIOVGRH
BRD-K15086322-050-01-3	JNJ-10191584	Preclinical	histamine receptor antagonist	HRH4			0	99.26	Tocris	2441	JNJ 10191584 maleate	278.093	CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	MOIWSUQWIOVGRH-UHFFFAOYSA-N	10446295.0		MOIWSUQWIOVGRH
BRD-K15086322-050-03-9	JNJ-10191584	Preclinical	histamine receptor antagonist	HRH4			0	97.9	Tocris	2441	JNJ 10191584 maleate	278.093	CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	MOIWSUQWIOVGRH-UHFFFAOYSA-N	10446295.0		MOIWSUQWIOVGRH
BRD-K61721596-001-02-8	JNJ-10397049	Preclinical	orexin receptor antagonist	HCRTR1|HCRTR2			0	90.72	Tocris	4317	JNJ 10397049	481.984	CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1	RBKIJGLHFFQHBE-IRXDYDNUSA-N	9869934.0		RBKIJGLHFFQHBE
BRD-K61721596-001-01-0	JNJ-10397049	Preclinical	orexin receptor antagonist	HCRTR1|HCRTR2			0	98.74	Tocris	4317	JNJ 10397049	481.984	CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1	RBKIJGLHFFQHBE-IRXDYDNUSA-N	9869934.0		RBKIJGLHFFQHBE
BRD-K25596805-001-02-6	JNJ-16259685	Preclinical	glutamate receptor antagonist	GRM1			0	94.86	Tocris	2333	JNJ 16259685	325.168	CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|	QOTAQTRFJWLFCR-XFHMXUHZSA-N			QOTAQTRFJWLFCR
BRD-K25596805-001-01-8	JNJ-16259685	Preclinical	glutamate receptor antagonist	GRM1			0	97.98	Tocris	2333	JNJ 16259685	325.168	CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|	QOTAQTRFJWLFCR-XFHMXUHZSA-N			QOTAQTRFJWLFCR
BRD-K25596805-001-03-9	JNJ-16259685	Preclinical	glutamate receptor antagonist	GRM1			0	96.59	Tocris	2333	JNJ 16259685	325.168	CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|	QOTAQTRFJWLFCR-XFHMXUHZSA-N			QOTAQTRFJWLFCR
BRD-K47376733-001-09-9	JNJ-1661010	Preclinical	FAAH inhibitor	FAAH			0	91.68	Tocris	3262	JNJ 1661010	365.131	O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	BHBOSTKQCZEAJM-UHFFFAOYSA-N	2809273.0		BHBOSTKQCZEAJM
BRD-K47376733-001-08-1	JNJ-1661010	Preclinical	FAAH inhibitor	FAAH			0	96.42	Selleck	S2828	JNJ-1661010	365.131	O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	BHBOSTKQCZEAJM-UHFFFAOYSA-N	2809273.0		BHBOSTKQCZEAJM
BRD-K47376733-001-10-9	JNJ-1661010	Preclinical	FAAH inhibitor	FAAH			0	97.03	Tocris	3262	JNJ 1661010	365.131	O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	BHBOSTKQCZEAJM-UHFFFAOYSA-N	2809273.0		BHBOSTKQCZEAJM
BRD-K51770398-001-02-7	JNJ-17203212	Preclinical	TRPV antagonist	TRPV1			0	79.45	Tocris	3361	JNJ 17203212	419.118	FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	JFRYYGVYCWYIDQ-UHFFFAOYSA-N	11339118.0		JFRYYGVYCWYIDQ
BRD-K51770398-001-01-9	JNJ-17203212	Preclinical	TRPV antagonist	TRPV1			0	94.57	Tocris	3361	JNJ 17203212	419.118	FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	JFRYYGVYCWYIDQ-UHFFFAOYSA-N	11339118.0		JFRYYGVYCWYIDQ
BRD-K51770398-001-03-9	JNJ-17203212	Preclinical	TRPV antagonist	TRPV1			0	83.01	Tocris	3361	JNJ 17203212	419.118	FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	JFRYYGVYCWYIDQ-UHFFFAOYSA-N	11339118.0		JFRYYGVYCWYIDQ
BRD-K83837640-001-04-8	JNJ-26481585	Phase 2	HDAC inhibitor	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9|MDM2			0	91.72	Selleck	S1096	Quisinostat (JNJ-26481585)	394.212	Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	PAWIYAYFNXQGAP-UHFFFAOYSA-N	11538455.0		PAWIYAYFNXQGAP
BRD-K83837640-001-05-9	JNJ-26481585	Phase 2	HDAC inhibitor	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9|MDM2			0	94.04	MedChemEx	HY-15433	Quisinostat	394.212	Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	PAWIYAYFNXQGAP-UHFFFAOYSA-N	11538455.0		PAWIYAYFNXQGAP
BRD-K24864897-001-01-0	JNJ-26990990	Phase 2	anticonvulsant				0	93.07	Enamine	Z741322800	N-(1-benzothien-3-ylmethyl)sulfamide	242.018	NS(=O)(=O)NCc1csc2ccccc12	AWSKBQNOSRREEY-UHFFFAOYSA-N	11687376.0		AWSKBQNOSRREEY
BRD-K41895652-001-02-9	JNJ-27141491	Preclinical	CC chemokine receptor antagonist	CCR2			0	92.79	Tocris	5176	JNJ 27141491	379.08	CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1	SYARXICKXVXWNA-LBPRGKRZSA-N	11703589.0		SYARXICKXVXWNA
BRD-K41895652-001-01-8	JNJ-27141491	Preclinical	CC chemokine receptor antagonist	CCR2			0	87.73	Tocris	5176	JNJ 27141491	379.08	CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1	SYARXICKXVXWNA-LBPRGKRZSA-N	11703589.0		SYARXICKXVXWNA
BRD-K31802667-001-01-9	JNJ-37822681	Phase 2	dopamine receptor antagonist	DRD2			0	89.0	Enamine	Z1558691527	N-(1-(3,4-difluorobenzyl)piperidin-4-yl)-6-(trifluoromethyl)pyridazin-3-amine	372.137	Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F	UVUYWJWYRLJHEN-UHFFFAOYSA-N	16058752.0		UVUYWJWYRLJHEN
BRD-K02123250-001-06-7	JNJ-38877605	Phase 1	tyrosine kinase inhibitor	MET			0	97.35	Selleck	S1114	JNJ-38877605	377.12	Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1	JRWCBEOAFGHNNU-UHFFFAOYSA-N	46911863.0		JRWCBEOAFGHNNU
BRD-K00003094-001-01-9	JNJ-38877618	Phase 1	c-Met inhibitor				0	97.64	MedChemEx	HY-111050	JNJ-38877618	374.109	FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1	KOAWAWHSMVKCON-UHFFFAOYSA-N	57654476.0		KOAWAWHSMVKCON
BRD-K00003403-001-01-9	JNJ-39758979	Phase 2	histamine receptor antagonist				0	96.5	MedChemEx	HY-101189	JNJ-39758979	221.164	CC(C)c1cc(nc(N)n1)N1CC[C@@H](N)C1	COOGVHJHSCBOQT-MRVPVSSYSA-N	24994634.0		COOGVHJHSCBOQT
BRD-K55029398-001-01-6	JNJ-40411813	Phase 2	glutamate receptor positive allosteric modulator	GRM2			0	95.69	MedChemEx	HY-15748	JNJ-40411813	344.166	CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O	HYOGJHCDLQSAHX-UHFFFAOYSA-N	25195461.0		HYOGJHCDLQSAHX
BRD-K01036220-001-01-0	JNJ-42041935	Preclinical	hypoxia inducible factor prolyl hydroxylase inhibitor	PDK2			0	98.43	MedChemEx	HY-12832	JNJ-42041935	346.008	OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1	FXHHASJVTYRJHH-UHFFFAOYSA-N	45102710.0		FXHHASJVTYRJHH
BRD-K70330032-001-01-1	JNJ-42165279	Phase 2	FAAH inhibitor	FAAH			0	97.53	MedChemEx	HY-19636	JNJ-42165279	410.096	FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1	YWGYNGCRVZLMCS-UHFFFAOYSA-N	54576693.0		YWGYNGCRVZLMCS
BRD-K83547600-001-01-7	JNJ-47965567	Preclinical	purinergic receptor antagonist	P2RX7			0	93.76	Tocris	5299	JNJ 47965567	488.225	O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1	XREFXUCWSYMIOG-UHFFFAOYSA-N	66553218.0		XREFXUCWSYMIOG
BRD-K83547600-001-02-9	JNJ-47965567	Preclinical	purinergic receptor antagonist	P2RX7			0	96.63	Tocris	5299	JNJ 47965567	488.225	O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1	XREFXUCWSYMIOG-UHFFFAOYSA-N	66553218.0		XREFXUCWSYMIOG
BRD-K00004575-001-01-9	JNJ-54175446	Phase 1	purinergic receptor antagonist				0	97.94	Astatech	43177	(R)-(2-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)(1-(5-FLUOROPYRIMIDIN-2-YL)-4-METHYL-1,4,6,7-TETRAHYDRO-5H-[1,2,3]TRIAZOLO[4,5-C]PYRIDIN-5-YL)METHANONE	440.078	C[C@H]1N(CCc2c1nnn2-c1ncc(F)cn1)C(=O)c1cccc(c1Cl)C(F)(F)F	CWFVVQFVGMFTBD-SECBINFHSA-N	90409366.0		CWFVVQFVGMFTBD
BRD-K19482962-001-02-9	JNJ-63533054	Preclinical	G protein-coupled receptor agonist	GPR139			0	94.34	Tocris	5666	JNJ 63533054	316.098	C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1	MWDVCHRYCKXEBY-LBPRGKRZSA-N	2548547.0		MWDVCHRYCKXEBY
BRD-K19482962-001-01-8	JNJ-63533054	Preclinical	G protein-coupled receptor agonist	GPR139			0	98.12	MedChemEx	HY-19838	JNJ-63533054	316.098	C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1	MWDVCHRYCKXEBY-LBPRGKRZSA-N	2548547.0		MWDVCHRYCKXEBY
BRD-K30421675-001-04-9	JNJ-64619178	Phase 1	protein arginine N-methyltransferase inhibitor				0	97.97	Adooq	A16861	JNJ64619178, JNJ 64619178	482.107	Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br	DBSMLQTUDJVICQ-CJODITQLSA-N	126637809.0		DBSMLQTUDJVICQ
BRD-K00004600-001-01-9	JNJ-678	Phase 1	RSV fusion inhibitor				0	95.6	MedChemEx	HY-112180	JNJ-678	500.09	CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12	GTQTUABHRCWVLL-UHFFFAOYSA-N	118892432.0		GTQTUABHRCWVLL
BRD-K11636097-001-03-1	JNJ-7706621	Preclinical	CDK inhibitor	AURKA|AURKB|CDK1|CDK2			0	96.67	Selleck	S1249	JNJ-7706621	394.066	Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	KDKUVYLMPJIGKA-UHFFFAOYSA-N	5330790.0		KDKUVYLMPJIGKA
BRD-K11636097-001-04-9	JNJ-7706621	Preclinical	CDK inhibitor	AURKA|AURKB|CDK1|CDK2			0		Adooq	A10494	4-(5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-ylamino)benzenesulfonamide	394.066	Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)	5330790.0		KDKUVYLMPJIGKA
BRD-K17774839-001-03-7	JNJ-7777120	Preclinical	histamine receptor antagonist	HRH4			0	94.3	Tocris	4021	JNJ 7777120	277.098	CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	HUQJRYMLJBBEDO-UHFFFAOYSA-N	4908365.0		HUQJRYMLJBBEDO
BRD-K17774839-001-02-9	JNJ-7777120	Preclinical	histamine receptor antagonist	HRH4			0	97.84	Selleck	S2905	JNJ-7777120	277.098	CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	HUQJRYMLJBBEDO-UHFFFAOYSA-N	4908365.0		HUQJRYMLJBBEDO
BRD-K17774839-001-07-9	JNJ-7777120	Preclinical	histamine receptor antagonist	HRH4			0	95.47	Tocris	4021	JNJ 7777120	277.098	CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	HUQJRYMLJBBEDO-UHFFFAOYSA-N	4908365.0		HUQJRYMLJBBEDO
BRD-K00003705-001-01-9	josamycin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bronchitis	0	89.99	MedChemEx	HY-B1920	Josamycin	827.467	[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:36,38|	XJSFLOJWULLJQS-MJKZEBMBSA-N			XJSFLOJWULLJQS
BRD-K00003340-300-01-9	JPH203	Preclinical	solute carrier family member inhibitor				0	92.99	MedChemEx	HY-U00445	JPH203 Dihydrochloride	471.075	N[C@@H](Cc1cc(Cl)c(OCc2cc(N)cc3nc(oc23)-c2ccccc2)c(Cl)c1)C(O)=O	XNRZJPQTMQZBCE-SFHVURJKSA-N	24853505.0		XNRZJPQTMQZBCE
BRD-K54606188-001-16-4	JQ1-(+)	Preclinical	bromodomain inhibitor	BRD4|BRDT			0	94.43	Tocris	4499	(+)-JQ1	456.139	Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|	DNVXATUJJDPFDM-KRWDZBQOSA-N	46907787.0		DNVXATUJJDPFDM
BRD-K54606188-001-13-1	JQ1-(+)	Preclinical	bromodomain inhibitor	BRD4|BRDT			0	97.16	Selleck	S7110	(+)-JQ1	456.139	Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|	DNVXATUJJDPFDM-KRWDZBQOSA-N	46907787.0	BRD-K17588104-001-03-9	DNVXATUJJDPFDM
BRD-K17705806-003-06-9	JTC-801	Phase 2	opioid receptor antagonist	OPRL1			0	96.79	Tocris	2481	JTC 801	411.195	CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	VTGBZWHPJFMTKS-UHFFFAOYSA-N	5311340.0		VTGBZWHPJFMTKS
BRD-K17705806-003-04-4	JTC-801	Phase 2	opioid receptor antagonist	OPRL1			0	96.79	Tocris	2481	JTC 801	411.195	CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	VTGBZWHPJFMTKS-UHFFFAOYSA-N	5311340.0		VTGBZWHPJFMTKS
BRD-K17705806-003-03-6	JTC-801	Phase 2	opioid receptor antagonist	OPRL1			0	96.63	Selleck	S2722	JTC-801	411.195	CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	VTGBZWHPJFMTKS-UHFFFAOYSA-N	5311340.0		VTGBZWHPJFMTKS
BRD-K43330982-001-03-1	JTE-013	Preclinical	lysophospholipid receptor antagonist	P2RY10|S1PR2			0	74.8	Tocris	2392	JTE 013	407.103	CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12	RNSLRQNDXRSASX-UHFFFAOYSA-N	10223146.0		RNSLRQNDXRSASX
BRD-K43330982-001-02-3	JTE-013	Preclinical	lysophospholipid receptor antagonist	P2RY10|S1PR2			0	61.32	Tocris	2392	JTE 013	407.103	CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12	RNSLRQNDXRSASX-UHFFFAOYSA-N	10223146.0		RNSLRQNDXRSASX
BRD-K43330982-001-04-9	JTE-013	Preclinical	lysophospholipid receptor antagonist	P2RY10|S1PR2			0	87.11	Tocris	2392	JTE 013	407.103	CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12	RNSLRQNDXRSASX-UHFFFAOYSA-N	10223146.0		RNSLRQNDXRSASX
BRD-K81405859-300-01-4	JTE-607	Phase 2	cytokine production inhibitor	IL10|IL1B|IL6|TNF			0	98.12	Tocris	5185	ethyl (3,5-dichloro-2-hydroxy-4-(2-(4-methylpiperazin-1-yl)ethoxy)benzoyl)-L-phenylalaninate dihydrochloride	523.164	CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	IPSSXIMJJXSJQB-FQEVSTJZSA-N	9938545.0		IPSSXIMJJXSJQB
BRD-K81405859-300-02-2	JTE-607	Phase 2	cytokine production inhibitor	IL10|IL1B|IL6|TNF			0	95.44	Tocris	5185	JTE 607 dihydrochloride	523.164	CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	IPSSXIMJJXSJQB-FQEVSTJZSA-N	9938545.0		IPSSXIMJJXSJQB
BRD-K81405859-300-03-9	JTE-607	Phase 2	cytokine production inhibitor	IL10|IL1B|IL6|TNF			0		Tocris	5185	JTE 607 dihydrochloride	523.164	CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	IPSSXIMJJXSJQB-FQEVSTJZSA-N	9938545.0		IPSSXIMJJXSJQB
BRD-K63150726-001-03-9	JTE-907	Phase 1	cannabinoid receptor inverse agonist	CNR2			0	96.76	Tocris	2479	JTE 907	438.179	CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	GRAJFFFXJYFVOC-UHFFFAOYSA-N	9867770.0		GRAJFFFXJYFVOC
BRD-K63150726-001-02-1	JTE-907	Phase 1	cannabinoid receptor inverse agonist	CNR2			0	98.31	Tocris	2479	JTE 907	438.179	CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	GRAJFFFXJYFVOC-UHFFFAOYSA-N	9867770.0		GRAJFFFXJYFVOC
BRD-K63150726-001-04-9	JTE-907	Phase 1	cannabinoid receptor inverse agonist	CNR2			0	96.98	Tocris	2479	JTE 907	438.179	CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	GRAJFFFXJYFVOC-UHFFFAOYSA-N	9867770.0		GRAJFFFXJYFVOC
BRD-K53328210-001-04-4	JW-55	Preclinical	tankyrase inhibitor	TNKS|TNKS2			0	96.32	Tocris	4514	JW 55	434.184	COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1	ZJZWZIXSGNFWQQ-UHFFFAOYSA-N	2946601.0		ZJZWZIXSGNFWQQ
BRD-K53328210-001-01-0	JW-55	Preclinical	tankyrase inhibitor	TNKS|TNKS2			0	89.19	ChemBridge	7667791	7667791	434.184	COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1	ZJZWZIXSGNFWQQ-UHFFFAOYSA-N	2946601.0		ZJZWZIXSGNFWQQ
BRD-K48424871-001-04-9	JW-642	Preclinical	monoacylglycerol lipase inhibitor	MGLL			0	95.25	Tocris	4906	JW 642	462.138	FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F	AVSCNEOUWSVZEY-UHFFFAOYSA-N	71656520.0		AVSCNEOUWSVZEY
BRD-K48424871-001-03-1	JW-642	Preclinical	monoacylglycerol lipase inhibitor	MGLL			0	92.32	Tocris	4906	JW 642	462.138	FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F	AVSCNEOUWSVZEY-UHFFFAOYSA-N	71656520.0		AVSCNEOUWSVZEY
BRD-K24554037-001-09-9	JW-67	Preclinical	WNT pathway inhibitor	APC|AXIN1|GSK3B			0	95.0	Tocris	4651	JW 67	394.116	O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12	BTXRSHKJNDFHGA-UHFFFAOYSA-N	644733.0		BTXRSHKJNDFHGA
BRD-K24554037-001-08-3	JW-67	Preclinical	WNT pathway inhibitor	APC|AXIN1|GSK3B			0	96.6	Tocris	4651	JW 67	394.116	O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12	BTXRSHKJNDFHGA-UHFFFAOYSA-N	644733.0		BTXRSHKJNDFHGA
BRD-K75664313-001-02-6	JW-74	Preclinical	tankyrase inhibitor|WNT signaling inhibitor	TNKS|TNKS2			0	99.87	PrincetonBio	OSSL_897842	JW-74	456.137	COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1	KRIKILRRJCIWNB-UHFFFAOYSA-N	16013152.0		KRIKILRRJCIWNB
BRD-K75664313-001-04-9	JW-74	Preclinical	tankyrase inhibitor|WNT signaling inhibitor	TNKS|TNKS2			0	97.06	Tocris	5653	JW 74	456.137	COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1	KRIKILRRJCIWNB-UHFFFAOYSA-N	16013152.0		KRIKILRRJCIWNB
BRD-K75664313-001-03-4	JW-74	Preclinical	tankyrase inhibitor|WNT signaling inhibitor	TNKS|TNKS2			0	96.1	Tocris	5653	JW 74	456.137	COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1	KRIKILRRJCIWNB-UHFFFAOYSA-N	16013152.0		KRIKILRRJCIWNB
BRD-K05464208-001-08-1	JX-401	Preclinical	p38 MAPK inhibitor	MAPK14			0	93.84	Tocris	2657	JX 401	355.161	COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1	OMGLGPKQUFSRNN-UHFFFAOYSA-N	1126109.0		OMGLGPKQUFSRNN
BRD-K05464208-001-05-7	JX-401	Preclinical	p38 MAPK inhibitor	MAPK14			0	98.22	Tocris	2657	JX 401	355.161	COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1	OMGLGPKQUFSRNN-UHFFFAOYSA-N	1126109.0		OMGLGPKQUFSRNN
BRD-K45446451-001-06-8	JZL-184	Preclinical	monoacylglucerol lipase inhibitor	MGLL			0	96.24	Tocris	3836	JZL 184	520.148	OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	SEGYOKHGGFKMCX-UHFFFAOYSA-N	25021165.0		SEGYOKHGGFKMCX
BRD-K45446451-001-05-0	JZL-184	Preclinical	monoacylglucerol lipase inhibitor	MGLL			0	94.17	Selleck	S4904	JZL184	520.148	OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	SEGYOKHGGFKMCX-UHFFFAOYSA-N	25021165.0		SEGYOKHGGFKMCX
BRD-K38875233-001-04-9	JZL-195	Preclinical	FAAH inhibitor|monoacylglycerol lipase inhibitor	FAAH|MGLL			0	96.92	Tocris	4715	JZL 195	433.164	[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1	QNYRAEKLMNDRFY-UHFFFAOYSA-N	46232606.0		QNYRAEKLMNDRFY
BRD-K38875233-001-03-9	JZL-195	Preclinical	FAAH inhibitor|monoacylglycerol lipase inhibitor	FAAH|MGLL			0	98.35	Tocris	4715	JZL 195	433.164	[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1	QNYRAEKLMNDRFY-UHFFFAOYSA-N	46232606.0		QNYRAEKLMNDRFY
BRD-K00004699-001-01-9	J147	Phase 1	BDNF inducer				0	89.09	AMS	O33973	J147	350.124	COc1cccc(\C=N\N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1	HYMZAYGFKNNHDN-SSDVNMTOSA-N	25229652.0		HYMZAYGFKNNHDN
BRD-A45906415-001-01-9	K-MAP	Phase 2					0	92.13	ChemBridge	5728441		299.101	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,&5:19,r|	VXMVXDITZWJXJN-LDMBFOFVSA-N	40510055.0		VXMVXDITZWJXJN
BRD-K90756851-001-01-1	K-Ras(G12C)-inhibitor-12	Preclinical	K-Ras inhibitor	KRAS			0	82.19	MedChemEx	HY-18707	K-Ras(G12C) inhibitor 12	449	Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C	JFIFBWVNHLXJFY-UHFFFAOYSA-N	73555129.0		JFIFBWVNHLXJFY
BRD-K90756851-001-02-9	K-Ras(G12C)-inhibitor-12	Preclinical	K-Ras inhibitor	KRAS			0	61.99	MedChemEx	HY-18707	K-Ras(G12C) inhibitor 12	449	Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C	JFIFBWVNHLXJFY-UHFFFAOYSA-N	73555129.0		JFIFBWVNHLXJFY
BRD-K26305185-001-01-3	K-Ras(G12C)-inhibitor-6	Preclinical	K-Ras inhibitor				0	74.16	Selleck	S7333	K-Ras(G12C) inhibitor 6	404.073	SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	ZPXCEHMKUTXHRZ-UHFFFAOYSA-N	71815954.0		ZPXCEHMKUTXHRZ
BRD-K26305185-001-02-1	K-Ras(G12C)-inhibitor-6	Preclinical	K-Ras inhibitor				0	94.21	Selleck	S7333	K-Ras(G12C) inhibitor 6	404.073	SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	ZPXCEHMKUTXHRZ-UHFFFAOYSA-N	71815954.0		ZPXCEHMKUTXHRZ
BRD-K26305185-001-03-9	K-Ras(G12C)-inhibitor-6	Preclinical	K-Ras inhibitor				0	47.32	Selleck	S7333	K-Ras(G12C) inhibitor 6	404.073	SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	ZPXCEHMKUTXHRZ-UHFFFAOYSA-N	71815954.0		ZPXCEHMKUTXHRZ
BRD-K84595254-001-15-4	K-strophanthidin	Phase 2	ATPase inhibitor	ATP1A1			0	92.93	Sigma	S6626-250MG	Strophanthidin	404.22	C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|	ODJLBQGVINUMMR-HZXDTFASSA-N	6185.0		ODJLBQGVINUMMR
BRD-A74648924-001-02-3	K-247	Phase 1					0	62.72	ChemBridge	5493356		269.09	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:15,&4:17,r|	QNUBRHYSSHJWDH-CHWFTXMASA-N	25767227.0		QNUBRHYSSHJWDH
BRD-A67748489-001-10-0	K-858	Preclinical	kinesin-like spindle protein inhibitor	KIF11			0	98.42	Tocris	3703	K 858	277.088	CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10,r,t:4|	JEFVYQYZCAVNTP-ZDUSSCGKSA-N	686905.0		JEFVYQYZCAVNTP
BRD-K12807006-001-18-5	kaempferol	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1			0	91.45	Tocris	3603	Kaempferol	286.048	Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	IYRMWMYZSQPJKC-UHFFFAOYSA-N	5280863.0		IYRMWMYZSQPJKC
BRD-K12807006-001-17-7	kaempferol	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1			0	87.47	Selleck	S2314	Kaempferol	286.048	Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	IYRMWMYZSQPJKC-UHFFFAOYSA-N	5280863.0		IYRMWMYZSQPJKC
BRD-K12807006-001-22-9	kaempferol	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1			0	95.47	Tocris	3603	Kaempferol	286.048	Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	IYRMWMYZSQPJKC-UHFFFAOYSA-N	5280863.0		IYRMWMYZSQPJKC
BRD-K12807006-001-19-3	kaempferol	Preclinical	bone resorption inhibitor|estrogen-related receptor inverse agonist	AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1			0	97.71	Selleck	S2314	Kaempferol	286.048	Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	IYRMWMYZSQPJKC-UHFFFAOYSA-N	5280863.0		IYRMWMYZSQPJKC
BRD-K00004578-001-01-9	KAF-156	Preclinical	antimalarial agent				0	93.34	Astatech	H11185	2-AMINO-1-[2-(4-FLUOROPHENYL)-3-[(4-FLUOROPHENYL)AMINO]-5,6-DIHYDRO-8,8-DIMETHYLIMIDAZO[1,2-A]PYRAZIN-7(8H)-YL]ETHANONE	411.187	CC1(C)N(CCn2c(Nc3ccc(F)cc3)c(nc12)-c1ccc(F)cc1)C(=O)CN	BUPRVECGWBHCQV-UHFFFAOYSA-N	49856296.0		BUPRVECGWBHCQV
BRD-K52459018-001-09-1	kainic-acid	Preclinical	kainate receptor agonist	GRIA1|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5			0	100.0	Tocris	222	Kainic acid	213.1	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	44338126.0		VLSMHEGGTFMBBZ
BRD-K52459018-001-10-9	kainic-acid	Preclinical	kainate receptor agonist	GRIA1|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5			0	100.0	Tocris	222	Kainic acid	213.1	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	44338126.0		VLSMHEGGTFMBBZ
BRD-A07815743-001-01-1	kakonein	Phase 2	GABA receptor antagonist|serotonin receptor antagonist				0	97.6	Vitas-M	STL146384		416.111	OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2,&2:4,&3:5,&4:7,&5:9,r|	HKEAFJYKMMKDOR-YAJUCGGBSA-N	25790885.0		HKEAFJYKMMKDOR
BRD-K08327065-065-05-0	kanamycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-16566A	Kanamycin (sulfate)	484.238	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	SBUJHOSQTJFQJX-NOAMYHISSA-N	6032.0		SBUJHOSQTJFQJX
BRD-K08327065-065-04-3	kanamycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-16566A	Kanamycin (sulfate)	484.238	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	SBUJHOSQTJFQJX-NOAMYHISSA-N	6032.0		SBUJHOSQTJFQJX
BRD-K08327065-065-06-8	kanamycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MicroSource	1500360	KANAMYCIN A SULFATE	484.238	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	SBUJHOSQTJFQJX-NOAMYHISSA-N	6032.0	BRD-A53533407-065-04-9	SBUJHOSQTJFQJX
BRD-K00003176-001-01-9	karenitecin	Phase 3	topoisomerase inhibitor	TOP1			0	95.49	MedChemEx	HY-14812	Karenitecin	448.182	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O	POADTFBBIXOWFJ-VWLOTQADSA-N	148202.0		POADTFBBIXOWFJ
BRD-K27584835-001-02-9	kartogenin	Preclinical	chondrocyte differentiation stimulator	FLNA			0	94.22	Tocris	4513	Kartogenin	317.105	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1	SLUINPGXGFUMLL-UHFFFAOYSA-N	2826191.0		SLUINPGXGFUMLL
BRD-K27584835-001-01-6	kartogenin	Preclinical	chondrocyte differentiation stimulator	FLNA			0	71.07	Tocris	4513	Kartogenin	317.105	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1	SLUINPGXGFUMLL-UHFFFAOYSA-N	2826191.0		SLUINPGXGFUMLL
BRD-K91644281-311-02-9	kasugamycin	Preclinical	bacterial 30S ribosomal subunit inhibitor				0	100.0	MedChemEx	HY-B1864B	Kasugamycin (hydrochloride hydrate)	379.159	C[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(O)=O	PVTHJAPFENJVNC-MHRBZPPQSA-N			PVTHJAPFENJVNC
BRD-K17743697-066-04-4	KB-R7943	Preclinical	sodium/calcium exchange inhibitor	SLC8A1|TRPC3|TRPC5|TRPC6			0	91.38	Tocris	1244	KB-R7943 mesylate	331.099	NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	UMJUNUMSJDTYTM-UHFFFAOYSA-N	4534086.0		UMJUNUMSJDTYTM
BRD-K17743697-066-05-9	KB-R7943	Preclinical	sodium/calcium exchange inhibitor	SLC8A1|TRPC3|TRPC5|TRPC6			0	95.96	Tocris	1244	KB-R7943 mesylate	331.099	NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	UMJUNUMSJDTYTM-UHFFFAOYSA-N	4534086.0		UMJUNUMSJDTYTM
BRD-K17743697-066-03-6	KB-R7943	Preclinical	sodium/calcium exchange inhibitor	SLC8A1|TRPC3|TRPC5|TRPC6			0	92.36	Tocris	1244	KB-R7943 mesylate	331.099	NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	UMJUNUMSJDTYTM-UHFFFAOYSA-N	4534086.0		UMJUNUMSJDTYTM
BRD-K88154110-001-02-9	KB-SRC-4	Preclinical	SRC inhibitor	SRC			0	96.96	Tocris	4660	KB SRC 4	554.173	Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1	UHIZYQVRKSWIFO-UHFFFAOYSA-N	73349077.0		UHIZYQVRKSWIFO
BRD-K88154110-001-01-0	KB-SRC-4	Preclinical	SRC inhibitor	SRC			0	98.82	Tocris	4660	KB SRC 4	554.173	Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1	UHIZYQVRKSWIFO-UHFFFAOYSA-N	73349077.0		UHIZYQVRKSWIFO
BRD-A00376169-001-01-6	KBG	Phase 2	neprilysin inhibitor	MME			0	97.5	SantaCruz	sc-284473		268.095	O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3,8,9,11,&1:1,&2:6|	FOLRUCXBTYDAQK-PTEOKISQSA-N	92461199.0		FOLRUCXBTYDAQK
BRD-K71164191-001-01-0	KD-023	Phase 2	ACAT inhibitor	ACACA|ACACB			0	100.0	EMDBio	613450-5MG	TOFA	324.23	CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O	CZRCFAOMWRAFIC-UHFFFAOYSA-N	115175.0		CZRCFAOMWRAFIC
BRD-K88506063-001-01-8	KD025	Phase 2	rho associated kinase inhibitor	ROCK2			0	97.3	MedChemEx	HY-15307	SLx-2119	452.196	CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1	GKHIVNAUVKXIIY-UHFFFAOYSA-N	11950170.0		GKHIVNAUVKXIIY
BRD-K88506063-001-02-9	KD025	Phase 2	rho associated kinase inhibitor	ROCK2			0	98.4	MedChemEx	HY-15307	SLx-2119	452.196	CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1	GKHIVNAUVKXIIY-UHFFFAOYSA-N	11950170.0		GKHIVNAUVKXIIY
BRD-K37312348-001-17-6	kenpaullone	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	CCNB1|CDK1|CDK5|GSK3B			0	95.83	Tocris	1398	Kenpaullone	326.005	Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1	QQUXFYAWXPMDOE-UHFFFAOYSA-N	3820.0		QQUXFYAWXPMDOE
BRD-K37312348-001-15-0	kenpaullone	Preclinical	CDK inhibitor|glycogen synthase kinase inhibitor	CCNB1|CDK1|CDK5|GSK3B			0	96.42	Tocris	1398	Kenpaullone	326.005	Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1	QQUXFYAWXPMDOE-UHFFFAOYSA-N	3820.0		QQUXFYAWXPMDOE
BRD-K49671696-046-01-8	ketanserin	Launched	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2	cardiology	hypertension	0	96.67	MicroSource	1505346	KETANSERIN TARTRATE	395.165	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	FPCCSQOGAWCVBH-UHFFFAOYSA-N	3822.0		FPCCSQOGAWCVBH
BRD-K49671696-045-09-9	ketanserin	Launched	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2	cardiology	hypertension	0	96.0	Tocris	908	Ketanserin tartrate	395.165	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	FPCCSQOGAWCVBH-UHFFFAOYSA-N	3822.0		FPCCSQOGAWCVBH
BRD-K49671696-045-08-5	ketanserin	Launched	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2	cardiology	hypertension	0	98.5	Tocris	908	Ketanserin tartrate	395.165	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	FPCCSQOGAWCVBH-UHFFFAOYSA-N	3822.0		FPCCSQOGAWCVBH
BRD-K49671696-001-05-4	ketanserin	Launched	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2	cardiology	hypertension	0	95.74	Selleck	S2232	Ketanserin	395.165	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	FPCCSQOGAWCVBH-UHFFFAOYSA-N	3822.0		FPCCSQOGAWCVBH
BRD-K29113274-001-26-7	ketoconazole	Launched	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	0	75.16	Selleck	S1353		530.149	CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|	XMAYWYJOQHXEEK-ZEQKJWHPSA-N	47576.0		XMAYWYJOQHXEEK
BRD-K29113274-001-28-3	ketoconazole	Launched	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	0	84.13	Selleck	S1353		530.149	CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|	XMAYWYJOQHXEEK-ZEQKJWHPSA-N	47576.0		XMAYWYJOQHXEEK
BRD-K29113274-001-27-5	ketoconazole	Launched	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	0	95.63	Tocris	1103		530.149	CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|	XMAYWYJOQHXEEK-ZEQKJWHPSA-N	47576.0		XMAYWYJOQHXEEK
BRD-K29113274-001-30-9	ketoconazole	Launched	sterol demethylase inhibitor	KCNA10	dermatology	seborrheic dermatitis	0	96.08	Tocris	1103	Ketoconazole	530.149	CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15,18|	XMAYWYJOQHXEEK-ZEQKJWHPSA-N	47576.0		XMAYWYJOQHXEEK
BRD-K00003341-001-01-9	ketohexokinase-inhibitor-1	Preclinical	kinase inhibitor				0	86.61	MedChemEx	HY-U00461	Ketohexokinase inhibitor 1	356.146	[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)c1cc(nc(n1)N1CC[C@@H]1C)C(F)(F)F	MDUYWDNWFXSMJJ-XWLWVQCSSA-N			MDUYWDNWFXSMJJ
BRD-A97739905-001-26-5	ketoprofen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2|SLC5A8	rheumatology	rheumatoid arthritis|osteoarthritis	0	99.39	MicroSource	1501215	KETOPROFEN	254.094	C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	DKYWVDODHFEZIM-LLVKDONJSA-N	180540.0		DKYWVDODHFEZIM
BRD-A97739905-001-25-7	ketoprofen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2|SLC5A8	rheumatology	rheumatoid arthritis|osteoarthritis	0	97.54	Selleck	S1645	Ketoprofen	254.094	C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	DKYWVDODHFEZIM-LLVKDONJSA-N	180540.0		DKYWVDODHFEZIM
BRD-A97739905-001-29-9	ketoprofen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2|SLC5A8	rheumatology	rheumatoid arthritis|osteoarthritis	0	99.11	MedChemEx	HY-B0227	Ketoprofen	254.094	C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	DKYWVDODHFEZIM-LLVKDONJSA-N	180540.0		DKYWVDODHFEZIM
BRD-K01825750-234-03-9	ketorolac	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	90.34	MedChemEx	HY-B0138	Ketorolac (tromethamine salt)	255.09	OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|	OZWKMVRBQXNZKK-NSHDSACASA-N	181817.0		OZWKMVRBQXNZKK
BRD-K01825750-001-01-9	ketorolac	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	95.72	Selleck	S1646	Ketorolac	255.09	OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3,r|	OZWKMVRBQXNZKK-NSHDSACASA-N	181817.0		OZWKMVRBQXNZKK
BRD-K28936863-051-32-2	ketotifen	Launched	histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor	HRH1	neurology/psychiatry	itching	0	97.31	Tocris	784	Ketotifen fumarate	309.119	CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|	OVJRNFMIYGGLDL-UHFFFAOYSA-N	57392700.0		OVJRNFMIYGGLDL
BRD-K28936863-051-33-0	ketotifen	Launched	histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor	HRH1	neurology/psychiatry	itching	0	98.24	MicroSource	1500668	KETOTIFEN FUMARATE	309.119	CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|	OVJRNFMIYGGLDL-UHFFFAOYSA-N	57392700.0		OVJRNFMIYGGLDL
BRD-K28936863-051-31-4	ketotifen	Launched	histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor	HRH1	neurology/psychiatry	itching	0	95.79	Selleck	S2024	Ketotifen Fumarate	309.119	CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|	OVJRNFMIYGGLDL-UHFFFAOYSA-N	57392700.0		OVJRNFMIYGGLDL
BRD-K61339991-003-01-8	kevetrin	Phase 1	p53 activator				0	95.3	MedChemEx	HY-16271	Kevetrin (hydrochloride)	143.052	NC(=N)SCCCC#N	PRDJGNVQBVXXEO-UHFFFAOYSA-N	437740.0		PRDJGNVQBVXXEO
BRD-A54927599-001-17-7	KF-38789	Preclinical	P selectin inhibitor	SELP			0	80.18	Tocris	2748	KF 38789	375.114	COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|	NHFIAAAMCYVRIW-QGZVFWFLSA-N	135565372.0		NHFIAAAMCYVRIW
BRD-A54927599-001-16-9	KF-38789	Preclinical	P selectin inhibitor	SELP			0	92.1	Tocris	2748	KF 38789	375.114	COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|	NHFIAAAMCYVRIW-QGZVFWFLSA-N	135565372.0		NHFIAAAMCYVRIW
BRD-A54927599-001-18-9	KF-38789	Preclinical	P selectin inhibitor	SELP			0	93.49	Tocris	2748	KF 38789	375.114	COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6,r,c:8|	NHFIAAAMCYVRIW-QGZVFWFLSA-N	135565372.0		NHFIAAAMCYVRIW
BRD-K90747162-001-02-9	KG-5	Preclinical	RAF inhibitor	BRAF|FLT3|KIT|PDGFRB			0	99.59	Tocris	5260	KG 5	459.109	CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1	CMYHZFCJPORPHY-UHFFFAOYSA-N	53328059.0		CMYHZFCJPORPHY
BRD-K90747162-001-01-4	KG-5	Preclinical	RAF inhibitor	BRAF|FLT3|KIT|PDGFRB			0	96.24	Tocris	5260	KG 5	459.109	CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1	CMYHZFCJPORPHY-UHFFFAOYSA-N	53328059.0		CMYHZFCJPORPHY
BRD-K66430217-001-03-8	KH-CB19	Preclinical	CDC inhibitor	CLK1|CLK3|DYRK1A			0	54.76	MedChemEx	HY-12828	KH-CB19	337.038	CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C	DXZRBHUCOHBAHP-UHFFFAOYSA-N	91899919.0		DXZRBHUCOHBAHP
BRD-K80353807-001-24-6	khellin	Phase 2	vasodilator				0	42.25	MicroSource	210866	KHELLIN	260.068	COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12	HSMPDPBYAYSOBC-UHFFFAOYSA-N	3828.0		HSMPDPBYAYSOBC
BRD-K80353807-001-25-3	khellin	Phase 2	vasodilator				0	99.43	Sigma	60730	4,9-dimethoxy-7-methyl-5H-furo[3,2-g]chromen-5-one	260.068	COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12	HSMPDPBYAYSOBC-UHFFFAOYSA-N	3828.0		HSMPDPBYAYSOBC
BRD-K84605263-003-01-6	KHK-IN-1	Preclinical	hexokinase inhibitor	KHK			0	93.66	MedChemEx	HY-12841A	KHK-IN-1 (hydrochloride)	422.2	CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1	HFLMLZKGLUEWBU-UHFFFAOYSA-N	53348216.0		HFLMLZKGLUEWBU
BRD-K78978711-003-03-9	KHS-101	Preclinical	neural stem cell inducer	TACC3			0	97.85	Tocris	4888	KHS 101 hydrochloride	339.152	CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1	DGRJOOOHPBSAHD-UHFFFAOYSA-N	71304818.0		DGRJOOOHPBSAHD
BRD-K78978711-003-01-3	KHS-101	Preclinical	neural stem cell inducer	TACC3			0	97.05	Tocris	4888	KHS 101 hydrochloride	339.152	CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1	DGRJOOOHPBSAHD-UHFFFAOYSA-N	71304818.0		DGRJOOOHPBSAHD
BRD-A25569250-001-03-3	KI-16425	Preclinical	lysophosphatidic acid receptor antagonist	LPAR1|LPAR3			0	96.73	Selleck	S1315	Ki16425	474.102	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1,r|	LLIFMNUXGDHTRO-OAHLLOKOSA-N	40467027.0		LLIFMNUXGDHTRO
BRD-A88787317-001-02-9	KI-20227	Preclinical	c-Fms inhibitor	CSF1R|KDR|KIT|PDGFRB			0	97.43	Tocris	4481	Ki 20227	480.147	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|	SHPFDGWALWEPGS-AWEZNQCLSA-N	57881591.0		SHPFDGWALWEPGS
BRD-A88787317-001-01-0	KI-20227	Preclinical	c-Fms inhibitor	CSF1R|KDR|KIT|PDGFRB			0	97.77	Tocris	4481	Ki 20227	480.147	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27,r|	SHPFDGWALWEPGS-AWEZNQCLSA-N	57881591.0		SHPFDGWALWEPGS
BRD-K47150025-001-06-1	KI-8751	Preclinical	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	KDR			0	95.83	Tocris	2542	Ki 8751	469.125	COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	LFKQSJNCVRGFCC-UHFFFAOYSA-N	11317348.0		LFKQSJNCVRGFCC
BRD-K47150025-001-05-3	KI-8751	Preclinical	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	KDR			0	97.42	Selleck	S1363	Ki8751	469.125	COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	LFKQSJNCVRGFCC-UHFFFAOYSA-N	11317348.0		LFKQSJNCVRGFCC
BRD-K47150025-001-09-5	KI-8751	Preclinical	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	KDR			0	95.94	Tocris	2542	Ki 8751	469.125	COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	LFKQSJNCVRGFCC-UHFFFAOYSA-N	11317348.0		LFKQSJNCVRGFCC
BRD-K02898090-001-02-7	kifunensine	Phase 1	mannosidase inhibitor	MAN1B1|MAN2A1			0	100.0	EMDBio	422500-1MG	Kifunensine, Kitasatosporia kifunense	232.07	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	OIURYJWYVIAOCW-PQMKYFCFSA-N	130611.0		OIURYJWYVIAOCW
BRD-K02898090-001-04-9	kifunensine	Phase 1	mannosidase inhibitor	MAN1B1|MAN2A1			0	100.0	Tocris	3207	Kifunensine	232.07	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	OIURYJWYVIAOCW-PQMKYFCFSA-N	130611.0		OIURYJWYVIAOCW
BRD-K65667145-001-14-0	kinetin	Launched	cell division inducer		dermatology	sunburn	0	98.18	Selleck	S2316	Kinetin	215.081	C(Nc1ncnc2nc[nH]c12)c1ccco1	QANMHLXAZMSUEX-UHFFFAOYSA-N	3830.0		QANMHLXAZMSUEX
BRD-A94323479-001-02-8	ki16198	Preclinical	lipoprotein antagonist	LPA			0	96.6	Selleck	S2906	Ki16198	488.117	COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|	HHVJBROTJWPHHX-INIZCTEOSA-N	92461210.0		HHVJBROTJWPHHX
BRD-A94323479-001-03-6	ki16198	Preclinical	lipoprotein antagonist	LPA			0	96.41	Selleck	S2906	Ki16198	488.117	COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24,r|	HHVJBROTJWPHHX-INIZCTEOSA-N	92461210.0		HHVJBROTJWPHHX
BRD-A94580299-001-11-9	KL-001	Preclinical	proteasome inhibitor	CRY1|CRY2			0	96.92	Tocris	4685	KL 001	398.13	CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|	OQAFDLPAPSSOHY-MRXNPFEDSA-N	1367681.0		OQAFDLPAPSSOHY
BRD-A94580299-001-10-4	KL-001	Preclinical	proteasome inhibitor	CRY1|CRY2			0	98.65	Tocris	4685	KL 001	398.13	CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6,r|	OQAFDLPAPSSOHY-MRXNPFEDSA-N	1367681.0		OQAFDLPAPSSOHY
BRD-K00005245-001-01-9	KM-0118	Phase 1	anticancer agent				0	82.7	MedChemEx	HY-19756	OTX008	936.547	CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C	CQVAQQNDZCZBSU-UHFFFAOYSA-N	11953346.0		CQVAQQNDZCZBSU
BRD-K00004747-001-01-9	KME-4	Preclinical	prostaglandin inhibitor				0	89.36	MedChemEx	HY-101587	KME-4	302.188	CC(C)(C)c1cc(\C=C2/CCOC2=O)cc(c1O)C(C)(C)C	DFPYHQJPGCODSB-UKTHLTGXSA-N	6438990.0		DFPYHQJPGCODSB
BRD-K46734292-001-03-6	KML29	Preclinical	monoacylglucerol lipase inhibitor	MGLL			0	96.99	MedChemEx	HY-18977	KML29	549.122	OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	SXHQLPHDBLTFPM-UHFFFAOYSA-N	71656212.0		SXHQLPHDBLTFPM
BRD-A81177136-001-12-7	KN-62	Preclinical	calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist	AKT1|CAMK2A|CHEK1|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|P2RX7|PRKCA|ROCK1|RPS6KB1|SGK1			0	96.68	MedChemEx	HY-13290	KN-62	721.203	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2,r|	RJVLFQBBRSMWHX-DHUJRADRSA-N	5312126.0		RJVLFQBBRSMWHX
BRD-K93480852-003-01-0	KN-93	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	CAMK2A			0	98.69	MedChemEx	HY-15465A	KN-93 (hydrochloride)	500.154	COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1	LLLQTDSSHZREGW-AATRIKPKSA-N	5312122.0		LLLQTDSSHZREGW
BRD-K93480852-001-06-3	KN-93	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	CAMK2A			0	95.99	MedChemEx	HY-15465	KN-93	500.154	COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1	LLLQTDSSHZREGW-AATRIKPKSA-N	5312122.0		LLLQTDSSHZREGW
BRD-K93480852-001-05-5	KN-93	Preclinical	calcium/calmodulin dependent protein kinase inhibitor	CAMK2A			0	97.6	MedChemEx	HY-15465	KN-93	500.154	COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1	LLLQTDSSHZREGW-AATRIKPKSA-N	5312122.0		LLLQTDSSHZREGW
BRD-K64642496-001-04-0	Ko143	Preclinical	BCRP inhibitor	ABCB1|ABCC1			0	97.42	Tocris	3241	Ko 143	469.258	COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O	NXNRAECHCJZNRF-JBACZVJFSA-N	10322450.0		NXNRAECHCJZNRF
BRD-K64642496-001-03-2	Ko143	Preclinical	BCRP inhibitor	ABCB1|ABCC1			0	94.91	MedChemEx	HY-10010	Ko 143	469.258	COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O	NXNRAECHCJZNRF-JBACZVJFSA-N	10322450.0		NXNRAECHCJZNRF
BRD-K46690591-001-01-2	KP-1212	Phase 2					0	100.0	Berry	PY 7106		230.102	NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1 |t:1|	LAOLDMMWVYDDID-HSUXUTPPSA-N	71167912.0		LAOLDMMWVYDDID
BRD-K71467466-001-02-3	KPT-185	Preclinical	exportin antagonist	XPO1			0	95.93	Selleck	S7125	KPT-185	355.114	COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1	NLNGWFLRRRYNIL-PLNGDYQASA-N	53495165.0		NLNGWFLRRRYNIL
BRD-K75352575-001-02-9	KPT-276	Preclinical	exportin antagonist	XPO1			0	92.41	MedChemEx	HY-17539	KPT-276	426.073	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1	JCHAWRDHMUSLMM-UPHRSURJSA-N	71496742.0		JCHAWRDHMUSLMM
BRD-K75352575-001-01-3	KPT-276	Preclinical	exportin antagonist	XPO1			0	95.86	Selleck	S7251	KPT-276	426.073	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1	JCHAWRDHMUSLMM-UPHRSURJSA-N	71496742.0		JCHAWRDHMUSLMM
BRD-K00004701-001-01-9	KPT-9274	Phase 1	NAMPT inhibitor				0	90.7	AMS	P50904	KPT-9274	610.219	Nc1ccc(\C=C\C(=O)NCc2cc3cc(cc(-c4ccc(F)cc4)c3o2)-c2ccc(cc2)C(=O)N2CCC(F)(F)CC2)cn1	MRFOPLWJZULAQD-SWGQDTFXSA-N	117779453.0		MRFOPLWJZULAQD
BRD-K00004587-001-01-9	KR-33494	Preclinical	cell death inhibitor 				0	97.06	MedChemEx	HY-100755	KR-33493	459.025	OC(=O)c1nn(CCc2ccccc2)cc1NC(=O)CSc1ccc(Br)cc1	ZRLJEHIUGYTTSZ-UHFFFAOYSA-N	25009726.0		ZRLJEHIUGYTTSZ
BRD-K40604024-001-02-9	KRCA-0008	Preclinical	ALK inihibitor	ALK			0	93.41	Tocris	5098	KRCA 0008	608.263	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O	TXDIRJCYNAWBOS-UHFFFAOYSA-N	72547474.0		TXDIRJCYNAWBOS
BRD-K40604024-001-01-6	KRCA-0008	Preclinical	ALK inihibitor	ALK			0	89.08	Tocris	5098	KRCA 0008	608.263	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O	TXDIRJCYNAWBOS-UHFFFAOYSA-N	72547474.0		TXDIRJCYNAWBOS
BRD-K90993449-001-03-9	KRN-633	Preclinical	VEGFR inhibitor	FLT1|FLT4|KDR			0	96.26	MedChemEx	HY-12060	KRN-633	416.125	CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl	VPBYZLCHOKSGRX-UHFFFAOYSA-N	9549295.0		VPBYZLCHOKSGRX
BRD-K90993449-001-02-7	KRN-633	Preclinical	VEGFR inhibitor	FLT1|FLT4|KDR			0	93.55	Selleck	S1557	KRN 633	416.125	CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl	VPBYZLCHOKSGRX-UHFFFAOYSA-N	9549295.0		VPBYZLCHOKSGRX
BRD-K81053848-001-01-0	KS-176	Preclinical	BCRP inhibitor	ABCG2			0	96.94	Tocris	4169	KS 176	405.132	OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1	LTWQQWSXYYXVGA-UHFFFAOYSA-N	49779726.0		LTWQQWSXYYXVGA
BRD-K81053848-001-02-9	KS-176	Preclinical	BCRP inhibitor	ABCG2			0	97.1	Tocris	4169	KS 176	405.132	OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1	LTWQQWSXYYXVGA-UHFFFAOYSA-N	49779726.0		LTWQQWSXYYXVGA
BRD-K66437909-001-01-0	KT-433	Phase 2	uricosuric agent				0	97.5	Sigma	MFCD00901289	{4-[(2-ethyl-1-benzofuran-3-yl)carbonyl]phenoxy}acetic acid	324.1	CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1	XSDFWTIKVXKOGJ-UHFFFAOYSA-N	3874929.0		XSDFWTIKVXKOGJ
BRD-K67566344-001-08-3	KU-0063794	Preclinical	mTOR inhibitor	MTOR			0	95.33	Selleck	S1226	Ku-0063794	465.238	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1	RFSMUFRPPYDYRD-CALCHBBNSA-N	16736978.0		RFSMUFRPPYDYRD
BRD-K67566344-001-07-5	KU-0063794	Preclinical	mTOR inhibitor	MTOR			0	86.46	Selleck	S1226	KU-0063794	465.238	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1	RFSMUFRPPYDYRD-CALCHBBNSA-N	16736978.0		RFSMUFRPPYDYRD
BRD-K25311561-001-10-7	KU-55933	Preclinical	ATM kinase inhibitor	ATM|PRKDC			0	98.75	Tocris	3544	KU 55933	395.065	O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1	XRKYMMUGXMWDAO-UHFFFAOYSA-N	5278396.0		XRKYMMUGXMWDAO
BRD-K25311561-001-09-9	KU-55933	Preclinical	ATM kinase inhibitor	ATM|PRKDC			0	97.7	Selleck	S1092	KU-55933 (ATM Kinase Inhibitor)	395.065	O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1	XRKYMMUGXMWDAO-UHFFFAOYSA-N	5278396.0		XRKYMMUGXMWDAO
BRD-K36016295-001-06-0	KU-60019	Preclinical	ATM kinase inhibitor	ATM			0	96.77	Tocris	4176	KU 60019	547.214	C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	SCELLOWTHJGVIC-BGYRXZFFSA-N	15953870.0		SCELLOWTHJGVIC
BRD-K36016295-001-05-2	KU-60019	Preclinical	ATM kinase inhibitor	ATM			0	90.52	Selleck	S1570	KU-60019	547.214	C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	SCELLOWTHJGVIC-BGYRXZFFSA-N	15953870.0		SCELLOWTHJGVIC
BRD-K36016295-001-04-5	KU-60019	Preclinical	ATM kinase inhibitor	ATM			0	77.74	Selleck	S1570	KU-60019	547.214	C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	SCELLOWTHJGVIC-BGYRXZFFSA-N	15953870.0		SCELLOWTHJGVIC
BRD-K51337109-003-01-3	kuromanin	Preclinical	ribosyl cyclase inhibitor	CD38			0	98.1	MedChemEx	HY-N0640	Kuromanin (chloride)	449.108	OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	RKWHWFONKJEUEF-GQUPQBGVSA-O	441667.0		RKWHWFONKJEUEF
BRD-A38747044-001-03-1	KU14R	Preclinical	imidazoline receptor antagonist				0	96.56	Tocris	1131	KU14R	214.111	CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|	JCWVNNMJXQJVNC-ZDUSSCGKSA-N	92179136.0		JCWVNNMJXQJVNC
BRD-A38747044-001-04-9	KU14R	Preclinical	imidazoline receptor antagonist				0	91.81	Tocris	1131	KU14R	214.111	CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|	JCWVNNMJXQJVNC-ZDUSSCGKSA-N	92179136.0		JCWVNNMJXQJVNC
BRD-A38747044-001-02-3	KU14R	Preclinical	imidazoline receptor antagonist				0	98.56	Tocris	1131	KU14R	214.111	CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2,r|	JCWVNNMJXQJVNC-ZDUSSCGKSA-N	92179136.0		JCWVNNMJXQJVNC
BRD-K21718444-001-06-8	KW-2449	Phase 1	Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor	ABL1|AURKA|AURKB|FLT3			0	93.46	Selleck	S2158	KW-2449	332.164	O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1	YYLKKYCXAOBSRM-JXMROGBWSA-N	11427553.0		YYLKKYCXAOBSRM
BRD-K41213548-001-03-9	KW-2478	Phase 1/Phase 2	HSP inhibitor				0	96.9	MedChemEx	HY-13468	KW-2478	574.289	CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	VFUXSYAXEKYYMB-UHFFFAOYSA-N	23116322.0		VFUXSYAXEKYYMB
BRD-K41213548-001-02-0	KW-2478	Phase 1/Phase 2	HSP inhibitor				0	92.87	Selleck	S2685	KW-2478	574.289	CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	VFUXSYAXEKYYMB-UHFFFAOYSA-N	23116322.0		VFUXSYAXEKYYMB
BRD-A95683721-001-03-8	KW-3902	Phase 3	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	98.8	Tocris	4167	KW 3902	356.221	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|	PJBFVWGQFLYWCB-XEDLVCFGSA-N			PJBFVWGQFLYWCB
BRD-A95683721-001-01-2	KW-3902	Phase 3	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	98.5	Axon	1603	8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	356.221	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23,&2:21,&3:19,r|	PJBFVWGQFLYWCB-XEDLVCFGSA-N			PJBFVWGQFLYWCB
BRD-K29968218-001-03-2	KX2-391	Phase 3	SRC inhibitor|tubulin polymerization inhibitor	SRC			0	96.52	Selleck	S2700	KX2-391	431.221	O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	HUNGUWOZPQBXGX-UHFFFAOYSA-N	23635314.0		HUNGUWOZPQBXGX
BRD-K29968218-001-02-4	KX2-391	Phase 3	SRC inhibitor|tubulin polymerization inhibitor	SRC			0		Selleck	S2700	KX2-391	431.221	O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)	23635314.0		HUNGUWOZPQBXGX
BRD-K85872723-001-17-5	kynurenic-acid	Phase 1	glutamate receptor antagonist	GPR35|GRIN1|GRIN2A|GRIN2B			0	98.64	Tocris	223	Kynurenic acid	189.043	OC(=O)c1cc(=O)c2ccccc2[nH]1	HCZHHEIFKROPDY-UHFFFAOYSA-N	3845.0		HCZHHEIFKROPDY
BRD-K85872723-001-15-9	kynurenic-acid	Phase 1	glutamate receptor antagonist	GPR35|GRIN1|GRIN2A|GRIN2B			0	97.06	Tocris	223	Kynurenic acid	189.043	OC(=O)c1cc(=O)c2ccccc2[nH]1	HCZHHEIFKROPDY-UHFFFAOYSA-N	3845.0		HCZHHEIFKROPDY
BRD-K85872723-001-18-9	kynurenic-acid	Phase 1	glutamate receptor antagonist	GPR35|GRIN1|GRIN2A|GRIN2B			0	96.86	Tocris	223	Kynurenic acid	189.043	OC(=O)c1cc(=O)c2ccccc2[nH]1	HCZHHEIFKROPDY-UHFFFAOYSA-N	3845.0		HCZHHEIFKROPDY
BRD-K13302470-001-04-9	KY02111	Preclinical	WNT pathway inhibitor	DKK1			0	96.48	Tocris	4731	KY 02111	376.065	COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	LXFKEVQQSKQXPR-UHFFFAOYSA-N	8582409.0		LXFKEVQQSKQXPR
BRD-K13302470-001-03-5	KY02111	Preclinical	WNT pathway inhibitor	DKK1			0	97.39	Tocris	4731	KY 02111	376.065	COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	LXFKEVQQSKQXPR-UHFFFAOYSA-N	8582409.0		LXFKEVQQSKQXPR
BRD-K13302470-001-02-7	KY02111	Preclinical	WNT pathway inhibitor	DKK1			0	97.58	Selleck	S7096	KY02111	376.065	COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	LXFKEVQQSKQXPR-UHFFFAOYSA-N	8582409.0		LXFKEVQQSKQXPR
BRD-K58568447-001-03-7	K02288	Preclinical	bone morphogenic protein inhibitor	BMP1			0	98.95	MedChemEx	HY-12278	K02288	352.142	COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	CJLMANFTWLNAKC-UHFFFAOYSA-N	46173038.0		CJLMANFTWLNAKC
BRD-K58568447-001-02-9	K02288	Preclinical	bone morphogenic protein inhibitor	BMP1			0	99.48	Tocris	4986	K 02288	352.142	COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	CJLMANFTWLNAKC-UHFFFAOYSA-N	46173038.0		CJLMANFTWLNAKC
BRD-K58568447-001-01-1	K02288	Preclinical	bone morphogenic protein inhibitor	BMP1			0	98.16	Selleck	S7359	K02288	352.142	COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	CJLMANFTWLNAKC-UHFFFAOYSA-N	46173038.0		CJLMANFTWLNAKC
BRD-K12106308-003-01-9	K145	Preclinical	sphingosine kinase inhibitor	SPHK2			0	87.48	MedChemEx	HY-15779A	K145 (hydrochloride)	348.151	CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1	MPZXLTZVPUSTFY-SOFYXZRVSA-N	71714682.0		MPZXLTZVPUSTFY
BRD-K00003714-002-01-9	L-(+)-rhamnose-monohydrate	Preclinical					0	100.0	MedChemEx	HY-N0642	a-L-Rhamnose monohydrate	164.068	C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O	SHZGCJCMOBCMKK-HGVZOGFYSA-N	439710.0		SHZGCJCMOBCMKK
BRD-K25125382-001-02-5	L-alanine	Launched		AARS|AARS2|ABAT|AGXT|AGXT2|GPRC6A|GPT|GPT2|KYNU|NFS1|PHYKPL|SLC1A4|SLC36A1|SLC7A8			1	0.0	Sigma	5130	L-alanine	89.048	C[C@H](N)C(O)=O	QNAYBMKLOCPYGJ-REOHCLBHSA-N	7311724.0		QNAYBMKLOCPYGJ
BRD-K06033833-003-03-3	L-arginine	Launched	nitric oxide precursor	ARG2|ASL|ASS1|AZIN2|GPRC6A|NOS2|NOS3|SLC7A1|SLC7A3|SLC7A4	cardiology|neurology/psychiatry|urology|obstetrics/gynecology|otolaryngology	congestive heart failure|hypertension|coronary artery disease (CAD)|claudication|senile dementia|erectile dysfunction|infertility|common cold	0	100.0	Selleck	S3174	L-Arginine HCl	174.112	N[C@@H](CCCNC(N)=N)C(O)=O	ODKSFYDXXFIFQN-BYPYZUCNSA-N	6322.0		ODKSFYDXXFIFQN
BRD-A45419686-001-04-9	L-ascorbyl-6-palmitate	Preclinical					0	0.0	MicroSource	1505742	ASCORBYL PALMITATE	414.262	CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|	CYJPUZLKFAUFHF-HFSMHLIXSA-N		BRD-A14985772-001-03-3	CYJPUZLKFAUFHF
BRD-A45419686-001-02-3	L-ascorbyl-6-palmitate	Preclinical					0	0.0	Selleck	S2532	L-Ascorbyl 6-palmitate	414.262	CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|	CYJPUZLKFAUFHF-HFSMHLIXSA-N			CYJPUZLKFAUFHF
BRD-A45419686-001-03-1	L-ascorbyl-6-palmitate	Preclinical					0	36.17	Selleck	S2532	L-Ascorbyl 6-palmitate	414.262	CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|	CYJPUZLKFAUFHF-HFSMHLIXSA-N			CYJPUZLKFAUFHF
BRD-A45419686-001-05-9	L-ascorbyl-6-palmitate	Preclinical					0	76.78	MedChemEx	HY-B0987	Ascorbyl palmitate	414.262	CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19,21,&1:27|	CYJPUZLKFAUFHF-HFSMHLIXSA-N			CYJPUZLKFAUFHF
BRD-K06665116-001-02-6	L-asparagine	Phase 3		ASNS|ASRGL1|NARS|NARS2|SLC1A5|SLC38A3			0	0.0	Sigma	MFCD00064401	L-asparagine	132.053	N[C@@H](CC(N)=O)C(O)=O	DCXYFEDJOCDNAF-REOHCLBHSA-N	6992089.0		DCXYFEDJOCDNAF
BRD-K82178523-001-01-6	L-asparagine-N-hydroxy	Preclinical					0	98.6	Sigma	A6508	(2S)-2-amino-4-(hydroxyamino)-4-oxobutanoic acid	148.048	N[C@@H](CC(=O)NO)C(O)=O	ZBYVTTSIVDYQSO-REOHCLBHSA-N	97663.0		ZBYVTTSIVDYQSO
BRD-K97163964-001-04-1	L-aspartic-acid	Launched	metallic radical formation stimulant	ACY1|ACY3|ADSS|ADSSL1|ASNS|ASPA|ASPH|ASRGL1|ASS1|CAD|DARS|DARS2|GOT1|GOT2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|LYZ|PAICS|RNASE1|SLC1A1|SLC25A12|SLC25A13			0	98.1	Sigma	A1330000	(2S)-2-aminobutanedioic acid	133.038	N[C@@H](CC(O)=O)C(O)=O	CKLJMWTZIZZHCS-REOHCLBHSA-N	5960.0		CKLJMWTZIZZHCS
BRD-K97163964-001-03-3	L-aspartic-acid	Launched	metallic radical formation stimulant	ACY1|ACY3|ADSS|ADSSL1|ASNS|ASPA|ASPH|ASRGL1|ASS1|CAD|DARS|DARS2|GOT1|GOT2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|LYZ|PAICS|RNASE1|SLC1A1|SLC25A12|SLC25A13			0	81.45	Enzo	AC367	L-Aspartic acid	133.038	N[C@@H](CC(O)=O)C(O)=O	CKLJMWTZIZZHCS-REOHCLBHSA-N	5960.0		CKLJMWTZIZZHCS
BRD-A12237696-001-05-9	L-citrulline	Launched	nitric oxide stimulant	ASS1|DDAH1|DDAH2|GPRC6A|NOS1|NOS2|NOS3|OTC|PADI1|PADI2|PADI3|PADI4|PADI6	cardiology|urology	hypertension|erectile dysfunction	0	0.0	Sigma	MFCD00007955	DL-CITRULLINE	175.096	N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|	RHGKLRLOHDJJDR-BYPYZUCNSA-N	9750.0		RHGKLRLOHDJJDR
BRD-A12237696-001-04-2	L-citrulline	Launched	nitric oxide stimulant	ASS1|DDAH1|DDAH2|GPRC6A|NOS1|NOS2|NOS3|OTC|PADI1|PADI2|PADI3|PADI4|PADI6	cardiology|urology	hypertension|erectile dysfunction	0	100.0	Vitas-M	STK802460		175.096	N[C@@H](CCCNC(N)=O)C(O)=O |&1:1,r|	RHGKLRLOHDJJDR-BYPYZUCNSA-N	9750.0		RHGKLRLOHDJJDR
BRD-K00795468-001-02-1	L-cysteine	Launched		CARS|CARS2|CBS|CDO-1|CDO1|CSAD|CTH|GCLC|GCLM|GOT1|GSS|MGMT|NFS1|SLC19A3	rheumatology	osteoarthritis|rheumatoid arthritis	0	0.0	Sigma	95437	L-cysteine	121.02	N[C@@H](CS)C(O)=O	XUJNEKJLAYXESH-REOHCLBHSA-N	6419722.0		XUJNEKJLAYXESH
BRD-A25800195-001-02-2	L-cysteinesulfinic-acid	Preclinical	glutamate receptor agonist	GRM1|GRM5|GSR|HMGCS2|PAPOLA|PRDX2			1	0.0	Tocris	216	L-Cysteinesulfinic acid	153.01	N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|	ADVPTQAUNPRNPO-REOHCLBHSA-N	28167170.0		ADVPTQAUNPRNPO
BRD-A25800195-001-03-9	L-cysteinesulfinic-acid	Preclinical	glutamate receptor agonist	GRM1|GRM5|GSR|HMGCS2|PAPOLA|PRDX2			1	100.0	Tocris	216	L-Cysteinesulfinic acid	153.01	N[C@@H](C[S@@](O)=O)C(O)=O |a:1,&1:3|	ADVPTQAUNPRNPO-REOHCLBHSA-N	28167170.0		ADVPTQAUNPRNPO
BRD-K99679910-001-02-3	L-cystine	Launched		CTNS|SLC3A1|SLC7A11|SLC7A9			0	0.0	Sigma	30199	(2R,2'R)-3,3'-disulfanediylbis(2-aminopropanoic acid)	240.024	N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O	LEVWYRKDKASIDU-IMJSIDKUSA-N	6992103.0		LEVWYRKDKASIDU
BRD-K26341917-001-01-3	L-ergothioneine	Phase 3	free radical scavenger				0	100.0	Enzo	FR111	Ergothioneine	230.096	C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O	SSISHJJTAXXQAX-ZETCQYMHSA-O	3037043.0		SSISHJJTAXXQAX
BRD-K62309135-001-05-2	L-glutamic-acid	Launched	glutamate receptor agonist	AADAT|AASS|ABAT|ALDH18A1|ASNS|BCAT1|BCAT2|CCBL2|DNPEP|EARS2|ENPEP|EPRS|FOLH1|FPGS|FTCD|GAD1|GAD2|GATB|GCLC|GCLM|GGCX|GLS|GLS2|GLUD1|GLUD2|GLUL|GMPS|GOT1|GOT2|GPT|GPT2|GRIA1|GRIA2|GRIA3|GRIA4|GRID1|GRID2|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM1|GRM2|GRM3|GRM4|GRM6|GRM7|GRM8|LGSN|NADSYN1|NAGS|OPLAH|PFAS|PGCP|PSAT1|SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7|SLC25A18|SLC25A22|SLC7A11|TAT			0	98.26	Sigma	MFCD00012619	(2S)-2-aminopentanedioic acid hydrochloride	147.053	N[C@@H](CCC(O)=O)C(O)=O	WHUUTDBJXJRKMK-VKHMYHEASA-N	88747398.0	BRD-M12235055-001-06-2	WHUUTDBJXJRKMK
BRD-K83896451-001-06-7	L-glutamine	Launched		CTPS1|GLUL|GPRC6A|PPAT	gastroenterology|dental|neurology/psychiatry|rheumatology	diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia	0	0.0	Selleck	S1749	L-Glutamine	146.069	N[C@@H](CCC(N)=O)C(O)=O	ZDXPYRJPNDTMRX-VKHMYHEASA-N	6992086.0		ZDXPYRJPNDTMRX
BRD-K83896451-001-07-5	L-glutamine	Launched		CTPS1|GLUL|GPRC6A|PPAT	gastroenterology|dental|neurology/psychiatry|rheumatology	diarrhea|mucositis|muscle pain|joint pain|peptic ulcer disease (PUD)|ulcerative colitis|Crohn's disease|anxiety|insomnia	0	93.22	Selleck	S1749	L-Glutamine	146.069	N[C@@H](CCC(N)=O)C(O)=O	ZDXPYRJPNDTMRX-VKHMYHEASA-N	6992086.0		ZDXPYRJPNDTMRX
BRD-A12454076-001-01-9	L-hydroxyproline	Launched					1	0.0	Enamine	Z56899020		131.058	O[C@H]1CN[C@@H](C1)C(O)=O |&1:1,&2:4,r|	PMMYEEVYMWASQN-DMTCNVIQSA-N	6971053.0		PMMYEEVYMWASQN
BRD-K20497775-001-06-9	L-kynurenine	Phase 1	aryl hydrocarbon receptor agonist				0	93.27	MedChemEx	HY-104026	L-Kynurenine	208.085	N[C@@H](CC(=O)c1ccccc1N)C(O)=O	YGPSJZOEDVAXAB-QMMMGPOBSA-N	6971029.0		YGPSJZOEDVAXAB
BRD-K12853841-001-02-2	L-leucine	Phase 3		BCAT1|BCAT2|LARS|LARS2|LCMT1|LCMT2			0	58.9	Sigma	V900431	L-leucine	131.095	CC(C)C[C@H](N)C(O)=O	ROHFNLRQFUQHCH-YFKPBYRVSA-N	7045798.0		ROHFNLRQFUQHCH
BRD-K86016185-001-01-3	L-lysine	Phase 2	serotonin receptor agonist	GPRC6A|KARS|SLC7A1|SLC7A2|SLC7A3|SLC7A4			0	0.0	Sigma	23128	L-lysine	146.106	NCCCC[C@H](N)C(O)=O	KDXKERNSBIXSRK-YFKPBYRVSA-N	71774817.0		KDXKERNSBIXSRK
BRD-K06502269-001-02-6	L-methionine	Launched	voltage-gated calcium channel ligand	BHMT|BHMT2|METAP2|MTR|MTRR	pulmonary|allergy|neurology/psychiatry	asthma|allergic rhinitis|depression|Parkinson's Disease|schizophrenia	0	97.7	Sigma	V900487	L-methionine	149.051	CSCC[C@H](N)C(O)=O	FFEARJCKVFRZRR-BYPYZUCNSA-N	6992087.0		FFEARJCKVFRZRR
BRD-K00004529-001-01-9	L-mimosine	Preclinical	dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor	DBH|EIF5A			0	0.0	Sigma	M0253	L-Mimosine Koa hoale seeds	198.064	N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|	BLYDGIISUNWHLF-YFKPBYRVSA-N	129010056.0		BLYDGIISUNWHLF
BRD-K20946707-001-01-9	L-monomethylarginine	Phase 3	nitric oxide synthase inhibitor	NOS1|NOS2			0	0.0	Tocris	3513	(2S)-5-{[amino(imino)methyl]amino}-2-(methylamino)pentanoic acid	188.127	CN[C@@H](CCCNC(N)=N)C(O)=O	NTWVQPHTOUKMDI-YFKPBYRVSA-N	73046.0		NTWVQPHTOUKMDI
BRD-K33141550-003-06-5	L-NAME	Phase 2/Phase 3	nitric oxide synthase inhibitor	NOS3			0	83.56	Tocris	665	L-NAME hydrochloride	233.112	COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O	KCWZGJVSDFYRIX-YFKPBYRVSA-N	39836.0		KCWZGJVSDFYRIX
BRD-K33141550-003-11-9	L-NAME	Phase 2/Phase 3	nitric oxide synthase inhibitor	NOS3			0	85.56	Tocris	665	L-NAME hydrochloride	233.112	COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O	KCWZGJVSDFYRIX-YFKPBYRVSA-N	39836.0		KCWZGJVSDFYRIX
BRD-K33141550-003-05-7	L-NAME	Phase 2/Phase 3	nitric oxide synthase inhibitor	NOS3			0	96.03	Tocris	665	L-NAME hydrochloride	233.112	COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O	KCWZGJVSDFYRIX-YFKPBYRVSA-N	39836.0		KCWZGJVSDFYRIX
BRD-K60036103-003-02-9	L-NIL	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	100.0	Tocris	1139	L-NIL hydrochloride	187.132	CC(=N)NCCCC[C@H](N)C(O)=O	ONYFNWIHJBLQKE-ZETCQYMHSA-N	2733506.0		ONYFNWIHJBLQKE
BRD-K60036103-003-01-6	L-NIL	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	97.43	Tocris	1139	L-NIL hydrochloride	187.132	CC(=N)NCCCC[C@H](N)C(O)=O	ONYFNWIHJBLQKE-ZETCQYMHSA-N	2733506.0		ONYFNWIHJBLQKE
BRD-K25521961-001-06-9	L-phenylisopropyladenosine	Preclinical					0	86.39	Sigma	P4532	(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-(((R)-1-phenylpropan-2-yl)amino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol	385.175	C[C@H](Cc1ccccc1)Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	RIRGCFBBHQEQQH-SSFGXONLSA-N	93205.0		RIRGCFBBHQEQQH
BRD-K01666412-001-02-0	L-proline	Launched	glutamate receptor agonist	EPRS|L3HYPDH|P3H1|P3H2|P3H3|P4HA1|P4HA2|PARS2|PPIA|PPIB|PPIC|PPIF|PPIG|PPIH|PRODH|PROSC|PYCR1|PYCR2|PYCRL|SLC6A14|SLC6A7			0	99.2	Sigma	V900338	L-proline	115.063	OC(=O)[C@@H]1CCCN1	ONIBWKKTOPOVIA-BYPYZUCNSA-N	6971047.0		ONIBWKKTOPOVIA
BRD-K92404805-001-07-0	L-quisqualic-acid	Preclinical	glutamate receptor agonist	FOLH1|GRIA2|GRIK1|GRIK2|GRM1|GRM2|GRM3|GRM5|GRM7|GRM8			0	100.0	Tocris	188	L-Quisqualic acid	189.039	N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O	ASNFTDCKZKHJSW-REOHCLBHSA-N	6971145.0		ASNFTDCKZKHJSW
BRD-K92404805-001-08-9	L-quisqualic-acid	Preclinical	glutamate receptor agonist	FOLH1|GRIA2|GRIK1|GRIK2|GRM1|GRM2|GRM3|GRM5|GRM7|GRM8			0	100.0	Tocris	188	L-Quisqualic acid	189.039	N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O	ASNFTDCKZKHJSW-REOHCLBHSA-N	6971145.0		ASNFTDCKZKHJSW
BRD-K04843140-001-04-9	L-theanine	Launched	glutamate receptor antagonist				0	100.0	LKT	T2816	N-Ethyl-L-glutamine	174.1	CCNC(=O)CC[C@H](N)C(O)=O	DATAGRPVKZEWHA-YFKPBYRVSA-N	439378.0		DATAGRPVKZEWHA
BRD-K75508643-001-02-6	L-threonine	Phase 2		TARS|TARS2|THNSL1			0	0.0	Sigma	V900466	(2S,3R)-2-amino-3-hydroxybutanoic acid	119.058	C[C@@H](O)[C@H](N)C(O)=O	AYFVYJQAPQTCCC-GBXIJSLDSA-N	6971019.0		AYFVYJQAPQTCCC
BRD-K59424860-001-02-9	L-valine	Phase 2					0	0.0	MedChemEx	HY-N0717A	H-D-Val-OH	117.079	CC(C)[C@@H](N)C(O)=O	KZSNJWFQEVHDMF-SCSAIBSYSA-N	71563.0		KZSNJWFQEVHDMF
BRD-K59424860-001-01-4	L-valine	Phase 2					0	100.0	Enzo	AC1026	D-Valine	117.079	CC(C)[C@@H](N)C(O)=O	KZSNJWFQEVHDMF-SCSAIBSYSA-N	71563.0		KZSNJWFQEVHDMF
BRD-K01827100-001-10-9	L-152804	Preclinical	neuropeptide receptor antagonist	NPY5R			0	78.15	Tocris	1382	L-152,804	366.183	CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|	XQDXIHYKAGHZRX-LJQANCHMSA-N	969478.0		XQDXIHYKAGHZRX
BRD-K01827100-001-16-9	L-152804	Preclinical	neuropeptide receptor antagonist	NPY5R			0	94.15	Tocris	1382	L-152,804	366.183	CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|	XQDXIHYKAGHZRX-LJQANCHMSA-N	969478.0		XQDXIHYKAGHZRX
BRD-K01827100-001-09-9	L-152804	Preclinical	neuropeptide receptor antagonist	NPY5R			0	92.68	Tocris	1382	L-152,804	366.183	CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7,r,t:8|	XQDXIHYKAGHZRX-LJQANCHMSA-N	969478.0		XQDXIHYKAGHZRX
BRD-K39733634-001-03-4	L-161982	Preclinical	prostanoid receptor antagonist	PTGER4			0	98.41	Tocris	2514	L-161,982	654.158	CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	MMDNKTXNUZFVKD-UHFFFAOYSA-N	9961192.0		MMDNKTXNUZFVKD
BRD-K39733634-001-02-6	L-161982	Preclinical	prostanoid receptor antagonist	PTGER4			0	98.21	Tocris	2514	L-161,982	654.158	CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	MMDNKTXNUZFVKD-UHFFFAOYSA-N	9961192.0		MMDNKTXNUZFVKD
BRD-K39733634-001-04-9	L-161982	Preclinical	prostanoid receptor antagonist	PTGER4			0	95.66	Tocris	2514	L-161,982	654.158	CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	MMDNKTXNUZFVKD-UHFFFAOYSA-N	9961192.0		MMDNKTXNUZFVKD
BRD-K98372770-001-09-0	L-165041	Preclinical	PPAR receptor agonist	PPARD			0	97.66	Tocris	1856	L-165,041	402.168	CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O	HBBVCKCCQCQCTJ-UHFFFAOYSA-N	6603901.0	BRD-K40656405-001-03-1	HBBVCKCCQCQCTJ
BRD-K98372770-001-10-9	L-165041	Preclinical	PPAR receptor agonist	PPARD			0	95.26	Tocris	1856	L-165,041	402.168	CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O	HBBVCKCCQCQCTJ-UHFFFAOYSA-N	6603901.0		HBBVCKCCQCQCTJ
BRD-K98372770-001-08-2	L-165041	Preclinical	PPAR receptor agonist	PPARD			0	98.7	Tocris	1856	L-165,041	402.168	CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O	HBBVCKCCQCQCTJ-UHFFFAOYSA-N	6603901.0	BRD-K40656405-001-02-3	HBBVCKCCQCQCTJ
BRD-K18036262-001-03-6	L-168049	Preclinical	glucagon receptor antagonist	GCGR			0	94.42	Tocris	2311	L-168,049	466.045	CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	HHBOWXZOLYQFNY-UHFFFAOYSA-N	5311276.0		HHBOWXZOLYQFNY
BRD-K18036262-001-02-8	L-168049	Preclinical	glucagon receptor antagonist	GCGR			0	96.62	Tocris	2311	L-168,049	466.045	CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	HHBOWXZOLYQFNY-UHFFFAOYSA-N	5311276.0		HHBOWXZOLYQFNY
BRD-K18036262-001-04-9	L-168049	Preclinical	glucagon receptor antagonist	GCGR			0	93.29	Tocris	2311	L-168,049	466.045	CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	HHBOWXZOLYQFNY-UHFFFAOYSA-N	5311276.0		HHBOWXZOLYQFNY
BRD-K34277641-001-01-2	L-365260	Phase 2	CCK receptor antagonist	CCKAR|CCKBR|KCNQ1			0	98.98	Tocris	2767	(R)-1-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-m-tolylurea	398.174	CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|	KDFQABSFVYLGPM-QFIPXVFZSA-N	5311201.0		KDFQABSFVYLGPM
BRD-K34277641-001-02-9	L-365260	Phase 2	CCK receptor antagonist	CCKAR|CCKBR|KCNQ1			0		Tocris	2767	L-365,260	398.174	CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|	KDFQABSFVYLGPM-QFIPXVFZSA-N	5311201.0		KDFQABSFVYLGPM
BRD-K00004282-003-01-9	L-368899	Phase 1	oxytocin receptor antagonist	AVPR1A|AVPR2|OXTR			0	95.02	Tocris	2641	L-368,899 hydrochloride	554.26	Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C	MWIASLNTAGRGGA-ZJPWWDJASA-N	9872389.0		MWIASLNTAGRGGA
BRD-K13474508-001-02-0	L-655,708	Preclinical	GABA receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRG2			0	90.75	Tocris	1327	L-655,708	341.138	CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	YKYOQIXTECBVBB-AWEZNQCLSA-N	5311203.0		YKYOQIXTECBVBB
BRD-K13474508-001-03-9	L-655,708	Preclinical	GABA receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRG2			0	97.15	Tocris	1327	L-655,708	341.138	CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	YKYOQIXTECBVBB-AWEZNQCLSA-N	5311203.0		YKYOQIXTECBVBB
BRD-K13474508-001-01-2	L-655,708	Preclinical	GABA receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRG2			0	98.39	Tocris	1327	L-655,708	341.138	CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	YKYOQIXTECBVBB-AWEZNQCLSA-N	5311203.0		YKYOQIXTECBVBB
BRD-K89402695-001-03-1	L-655240	Phase 1	thromboxane receptor antagonist	PTGES			0	98.81	Tocris	1698	L-655,240	373.124	Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12	JLPYLHLUHJOPNL-UHFFFAOYSA-N	122070.0		JLPYLHLUHJOPNL
BRD-K89402695-001-02-3	L-655240	Phase 1	thromboxane receptor antagonist	PTGES			0	93.13	Tocris	1698	L-655,240	373.124	Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12	JLPYLHLUHJOPNL-UHFFFAOYSA-N	122070.0		JLPYLHLUHJOPNL
BRD-A85472596-001-03-9	L-670596	Preclinical	prostanoid receptor antagonist				0	95.91	Tocris	1949	L-670,596	433.116	CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|	GMJWAIMJHBTYPD-CQSZACIVSA-N	86295146.0		GMJWAIMJHBTYPD
BRD-A85472596-001-02-2	L-670596	Preclinical	prostanoid receptor antagonist				0	98.01	Tocris	1949	L-670,596	433.116	CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11,r|	GMJWAIMJHBTYPD-CQSZACIVSA-N	86295146.0		GMJWAIMJHBTYPD
BRD-K74284736-001-03-1	L-689560	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	95.13	Tocris	742	L-689,560	379.049	OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1	UCKHICKHGAOGAP-UONOGXRCSA-N	6604749.0		UCKHICKHGAOGAP
BRD-K74284736-001-04-9	L-689560	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	98.1	Tocris	742	L-689,560	379.049	OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1	UCKHICKHGAOGAP-UONOGXRCSA-N	6604749.0		UCKHICKHGAOGAP
BRD-K74284736-001-02-3	L-689560	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	66.22	Tocris	742	L-689,560	379.049	OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1	UCKHICKHGAOGAP-UONOGXRCSA-N	6604749.0		UCKHICKHGAOGAP
BRD-K28470988-001-04-6	L-690330	Preclinical	inositol monophosphatase inhibitor	IMPA1			0	0.0	Tocris	681	L-690,330	298.001	CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O	JKOCAAWWDVHWKB-UHFFFAOYSA-N	132449.0		JKOCAAWWDVHWKB
BRD-K83322645-050-02-9	L-693403	Preclinical	sigma receptor agonist|sigma receptor antagonist	DRD2|SIGMAR1			0	94.25	Tocris	426	L-693,403 maleate	277.183	C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1	GSXJSGMDWKPVBY-UHFFFAOYSA-N	4687238.0		GSXJSGMDWKPVBY
BRD-K83322645-050-01-9	L-693403	Preclinical	sigma receptor agonist|sigma receptor antagonist	DRD2|SIGMAR1			0	96.18	Tocris	426	L-693,403 maleate	277.183	C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1	GSXJSGMDWKPVBY-UHFFFAOYSA-N	4687238.0		GSXJSGMDWKPVBY
BRD-K18816859-001-06-9	L-694247	Preclinical	serotonin receptor agonist	HTR1A|HTR1B|HTR1D			0	91.42	Tocris	781	L-694,247	411.137	CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1	HKXMQLISPYELRD-UHFFFAOYSA-N	132059.0		HKXMQLISPYELRD
BRD-K18816859-001-02-2	L-694247	Preclinical	serotonin receptor agonist	HTR1A|HTR1B|HTR1D			0	29.3	Tocris	781	L-694,247	411.137	CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1	HKXMQLISPYELRD-UHFFFAOYSA-N	132059.0		HKXMQLISPYELRD
BRD-K10176267-001-03-3	L-701252	Preclinical	glutamate receptor antagonist	GRIN1			0	97.91	Tocris	705	L-701,252	263.035	Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12	MXEFWCFPCLDOOG-UHFFFAOYSA-N	54687453.0		MXEFWCFPCLDOOG
BRD-K08109516-001-08-6	L-701324	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	98.13	Tocris	907	L-701,324	363.066	Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	FLVRDMUHUXVRET-UHFFFAOYSA-N	54682505.0		FLVRDMUHUXVRET
BRD-K08109516-001-10-9	L-701324	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	97.12	Tocris	907	L-701,324	363.066	Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	FLVRDMUHUXVRET-UHFFFAOYSA-N	54682505.0		FLVRDMUHUXVRET
BRD-K08109516-001-07-8	L-701324	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	98.44	Tocris	907	L-701,324	363.066	Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	FLVRDMUHUXVRET-UHFFFAOYSA-N	54682505.0		FLVRDMUHUXVRET
BRD-K37952347-001-02-2	L-732,138	Preclinical	tachykinin antagonist	TACR1|TACR2			0	97.96	Tocris	868	L-732,138	472.122	CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	BYYQYXVAWXAYQC-LJQANCHMSA-N	44396853.0		BYYQYXVAWXAYQC
BRD-K37952347-001-03-9	L-732,138	Preclinical	tachykinin antagonist	TACR1|TACR2			0	96.34	Tocris	868	L-732,138	472.122	CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	BYYQYXVAWXAYQC-LJQANCHMSA-N	44396853.0		BYYQYXVAWXAYQC
BRD-K37952347-001-01-4	L-732,138	Preclinical	tachykinin antagonist	TACR1|TACR2			0	96.9	Tocris	868	L-732,138	472.122	CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	BYYQYXVAWXAYQC-LJQANCHMSA-N	44396853.0		BYYQYXVAWXAYQC
BRD-K15791587-003-03-9	L-733060	Preclinical	tachykinin antagonist	TACR1			0	93.72	Tocris	1145	L-733,060 hydrochloride	403.137	FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F	FCDRFVCGMLUYPG-ROUUACIJSA-N	132846.0		FCDRFVCGMLUYPG
BRD-K15791587-003-02-5	L-733060	Preclinical	tachykinin antagonist	TACR1			0	96.09	Tocris	1145	L-733,060 hydrochloride	403.137	FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F	FCDRFVCGMLUYPG-ROUUACIJSA-N	132846.0		FCDRFVCGMLUYPG
BRD-K13211965-003-03-9	L-741742	Preclinical	dopamine receptor antagonist	DRD3|DRD4|SCN1A|SCN3A			0	92.12	Tocris	1004	L-741,742 hydrochloride	380.166	Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1	QDMAKDIDFJTXEL-UHFFFAOYSA-N	133008.0		QDMAKDIDFJTXEL
BRD-K13211965-003-02-8	L-741742	Preclinical	dopamine receptor antagonist	DRD3|DRD4|SCN1A|SCN3A			0	97.25	Tocris	1004	L-741,742 hydrochloride	380.166	Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1	QDMAKDIDFJTXEL-UHFFFAOYSA-N	133008.0		QDMAKDIDFJTXEL
BRD-K05528470-305-03-0	L-745870	Preclinical	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR6|HTR7			0	93.03	Tocris	1002	3-{[4-(4-chlorophenyl)-1-piperazinyl]methyl}-1H-pyrrolo[2,3-b]pyridine trihydrochloride	326.13	Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1	OGJGQVFWEPNYSB-UHFFFAOYSA-N	5311200.0		OGJGQVFWEPNYSB
BRD-K05528470-305-02-2	L-745870	Preclinical	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR6|HTR7			0	81.88	Tocris	1002	L-745,870	326.13	Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1	OGJGQVFWEPNYSB-UHFFFAOYSA-N	5311200.0		OGJGQVFWEPNYSB
BRD-K39359968-001-02-6	L-755507	Preclinical	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	76.05	Tocris	2197	L-755,507	584.267	CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1	NYYJKMXNVNFOFQ-MHZLTWQESA-N	9829836.0		NYYJKMXNVNFOFQ
BRD-K39359968-001-01-8	L-755507	Preclinical	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	66.45	Tocris	2197	L-755,507	584.267	CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1	NYYJKMXNVNFOFQ-MHZLTWQESA-N	9829836.0		NYYJKMXNVNFOFQ
BRD-K39359968-001-03-9	L-755507	Preclinical	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3			0	96.7	Tocris	2197	L-755,507	584.267	CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1	NYYJKMXNVNFOFQ-MHZLTWQESA-N	9829836.0		NYYJKMXNVNFOFQ
BRD-K30425481-003-01-0	L-760735	Preclinical	tachykinin antagonist	TACR1			0	72.75	Tocris	4013	L 760735	575.213	C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	USRYEHHMJIRICK-ZNZBMKLDSA-N	9809077.0		USRYEHHMJIRICK
BRD-K30425481-003-02-9	L-760735	Preclinical	tachykinin antagonist	TACR1			0	92.01	Tocris	4013	L 760735	575.213	C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	USRYEHHMJIRICK-ZNZBMKLDSA-N	9809077.0		USRYEHHMJIRICK
BRD-K10958118-003-01-5	L-778123	Phase 1	farnesyltransferase inhibitor	FNTA|FNTB|PGGT1B			0	96.05	MedChemEx	HY-16273A	L-778123 (hydrochloride)	405.136	Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O	JNUGFGAVPBYSHF-UHFFFAOYSA-N	216454.0		JNUGFGAVPBYSHF
BRD-K10958118-003-02-9	L-778123	Phase 1	farnesyltransferase inhibitor	FNTA|FNTB|PGGT1B			0	96.64	MedChemEx	HY-16273A	L-778123 (hydrochloride)	405.136	Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O	JNUGFGAVPBYSHF-UHFFFAOYSA-N	216454.0		JNUGFGAVPBYSHF
BRD-K43905307-001-02-0	L-798106	Preclinical	prostanoid receptor antagonist	PTGER3			0	97.76	Tocris	3342	L-798,106	535.045	COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	ODTKFNUPVBULRJ-NTCAYCPXSA-N	15551229.0		ODTKFNUPVBULRJ
BRD-K43905307-001-01-2	L-798106	Preclinical	prostanoid receptor antagonist	PTGER3			0	99.28	Tocris	3342	L-798,106	535.045	COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	ODTKFNUPVBULRJ-NTCAYCPXSA-N	15551229.0		ODTKFNUPVBULRJ
BRD-K43905307-001-03-9	L-798106	Preclinical	prostanoid receptor antagonist	PTGER3			0	98.55	Tocris	3342	L-798,106	535.045	COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	ODTKFNUPVBULRJ-NTCAYCPXSA-N	15551229.0		ODTKFNUPVBULRJ
BRD-K46647427-001-02-0	L-838417	Preclinical	GABA receptor partial agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	97.33	Tocris	3250	L-838,417	399.162	Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F	BQDUNOMMYOKHEP-UHFFFAOYSA-N	9908880.0		BQDUNOMMYOKHEP
BRD-K46647427-001-03-9	L-838417	Preclinical	GABA receptor partial agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	96.68	Tocris	3250	L-838,417	399.162	Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F	BQDUNOMMYOKHEP-UHFFFAOYSA-N	9908880.0		BQDUNOMMYOKHEP
BRD-K01825098-001-02-9	labetalol	Launched	adrenergic receptor antagonist	ADRA1D|ADRB1|ADRB2	cardiology	hypertension	0	97.47	CombiBlocks	QN-9252	Labetalol	328.179	C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1,&2:12,r|	SGUAFYQXFOLMHL-SCLBCKFNSA-N	134043.0		SGUAFYQXFOLMHL
BRD-K43586850-001-04-9	lacidipine	Launched	calcium channel blocker	CACNA1C	cardiology	hypertension	0	96.37	MedChemEx	HY-B0347	Lacidipine	455.231	CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|	GKQPCPXONLDCMU-CCEZHUSRSA-N	5311217.0		GKQPCPXONLDCMU
BRD-K43586850-001-02-9	lacidipine	Launched	calcium channel blocker	CACNA1C	cardiology	hypertension	0	95.57	Selleck	S1994	Lacidipine	455.231	CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5,10|	GKQPCPXONLDCMU-CCEZHUSRSA-N	5311217.0		GKQPCPXONLDCMU
BRD-K40787673-001-02-1	lacitol	Launched	laxative		gastroenterology	constipation	0	100.0	MicroSource	1505436	D-LACTITOL MONOHYDRATE	344.132	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	VQHSOMBJVWLPSR-JVCRWLNRSA-N	157355.0	BRD-A34513497-002-02-3	VQHSOMBJVWLPSR
BRD-K40787673-001-01-3	lacitol	Launched	laxative		gastroenterology	constipation	0	99.29	MicroSource	1301027	LACITOL	344.132	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	VQHSOMBJVWLPSR-JVCRWLNRSA-N	157355.0		VQHSOMBJVWLPSR
BRD-K40787673-001-07-9	lacitol	Launched	laxative		gastroenterology	constipation	0	100.0	Sigma	19346	Lactitol	344.132	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	VQHSOMBJVWLPSR-JVCRWLNRSA-N	157355.0		VQHSOMBJVWLPSR
BRD-K77258318-001-05-9	lactulose	Launched	laxative		gastroenterology	portal-systemic encephalopathy (PSE)	0	99.4	MedChemEx	HY-B1172	Lactulose	342.116	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O	JCQLYHFGKNRPGE-FCVZTGTOSA-N	11333.0		JCQLYHFGKNRPGE
BRD-K77258318-001-04-6	lactulose	Launched	laxative		gastroenterology	portal-systemic encephalopathy (PSE)	0	100.0	MicroSource	1500363	LACTULOSE	342.116	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O	JCQLYHFGKNRPGE-FCVZTGTOSA-N	11333.0		JCQLYHFGKNRPGE
BRD-K00003615-001-01-9	lafutidine	Launched	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease|peptic ulcer disease (PUD)	0	98.46	MedChemEx	HY-B0160	Lafutidine	431.188	O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|	KMZQAVXSMUKBPD-FCRIZLRQSA-N	40490609.0		KMZQAVXSMUKBPD
BRD-K02992638-001-11-8	lamivudine	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)|hepatitis B	0	96.67	Selleck	S1706	Lamivudine	229.052	Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1	JTEGQNOMFQHVDC-NKWVEPMBSA-N	60825.0		JTEGQNOMFQHVDC
BRD-K02992638-001-13-9	lamivudine	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)|hepatitis B	0	98.68	MedChemEx	HY-B0250	Lamivudine	229.052	Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1	JTEGQNOMFQHVDC-NKWVEPMBSA-N	60825.0		JTEGQNOMFQHVDC
BRD-K93460210-001-23-7	lamotrigine	Launched	serotonin receptor antagonist|sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|bipolar disorder	0	99.52	MicroSource	1505610	LAMOTRIGINE	255.008	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	PYZRQGJRPPTADH-UHFFFAOYSA-N	3878.0		PYZRQGJRPPTADH
BRD-K93460210-001-22-9	lamotrigine	Launched	serotonin receptor antagonist|sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|bipolar disorder	0	98.45	Selleck	S3024	Lamotrigine	255.008	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	PYZRQGJRPPTADH-UHFFFAOYSA-N	3878.0		PYZRQGJRPPTADH
BRD-K93460210-001-27-9	lamotrigine	Launched	serotonin receptor antagonist|sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|bipolar disorder	0	97.16	Tocris	1611	Lamotrigine	255.008	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	PYZRQGJRPPTADH-UHFFFAOYSA-N	3878.0		PYZRQGJRPPTADH
BRD-K00003387-001-01-9	lanabecestat	Phase 3	beta secretase inhibitor				0	97.66	MedChemEx	HY-100740	Lanabecestat	412.226	CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 |c:20,t:16|	WKDNQONLGXOZRG-HRNNMHKYSA-N			WKDNQONLGXOZRG
BRD-A64242993-001-05-6	lanatoside-C	Preclinical	cardiac glycoside				0	98.52	MicroSource	1501205	LANATOSIDE C	984.493	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1,3,5,7,9,11,13,15,17,22,24,26,29,31,33,35,38,42,45,53,55,57,60,&1:47,&2:50,&3:51,t:69|	JAYAGJDXJIDEKI-FUVOQQLASA-N	73707447.0		JAYAGJDXJIDEKI
BRD-K86436199-003-01-3	landiolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	cardiac arrythmia	0	98.94	AKSci	V1307		509.274	CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1	WMDSZGFJQKSLLH-RBBKRZOGSA-N	114905.0		WMDSZGFJQKSLLH
BRD-K00003462-001-01-9	lanifibranor	Phase 2	PPAR receptor agonist				0	90.62	MedChemEx	HY-104049	Lanifibranor	434.016	OC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1	OQDQIFQRNZIEEJ-UHFFFAOYSA-N	68677842.0		OQDQIFQRNZIEEJ
BRD-A54275602-001-01-0	lanoconazole	Launched	sterol demethylase inhibitor		infectious disease	fungal infection	0	96.68	AKSci	71613		319	Clc1ccccc1[C@H]1CS\C(S1)=C(\C#N)n1ccnc1 |&1:7,r|	ZRTQSJFIDWNVJW-MNWMYKRDSA-N	40729546.0		ZRTQSJFIDWNVJW
BRD-K00004280-001-01-9	lansoprazole	Launched	ATPase inhibitor	ATP4A|ATP4B	gastroenterology	heartburn	0	95.82	Tocris	2582	Lansoprazole	369.076	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14,r|	MJIHNNLFOKEZEW-RUZDIDTESA-N	9578005.0		MJIHNNLFOKEZEW
BRD-K19687926-001-10-8	lapatinib	Launched	EGFR inhibitor	EGFR|ERBB2	oncology	breast cancer	0	97.32	Selleck	S1028	Lapatinib	580.135	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	BCFGMOOMADDAQU-UHFFFAOYSA-N	208908.0		BCFGMOOMADDAQU
BRD-K19687926-379-07-4	lapatinib	Launched	EGFR inhibitor	EGFR|ERBB2	oncology	breast cancer	0	94.87	Selleck	S1028	Lapatinib (GW-572016) Ditosylate	580.135	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	BCFGMOOMADDAQU-UHFFFAOYSA-N	208908.0		BCFGMOOMADDAQU
BRD-K19687926-001-04-1	lapatinib	Launched	EGFR inhibitor	EGFR|ERBB2	oncology	breast cancer	0	92.08	Selleck	S2111	Lapatinib	580.135	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	BCFGMOOMADDAQU-UHFFFAOYSA-N	208908.0		BCFGMOOMADDAQU
BRD-K00025602-004-02-9	lappaconite	Phase 2	sodium channel blocker				0	89.72	Selleck	S2387		584.31	CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14)OC(=O)c1ccccc1NC(C)=O	NWBWCXBPKTTZNQ-QOQRDJBUSA-N	90479327.0		NWBWCXBPKTTZNQ
BRD-K60918217-001-02-0	laquinimod	Phase 3	immunosuppressant	CXCL2			0	0.0	Selleck	S2787	Laquinimod	356.093	CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	GKWPCEFFIHSJOE-UHFFFAOYSA-N	54677946.0		GKWPCEFFIHSJOE
BRD-K60918217-001-04-9	laquinimod	Phase 3	immunosuppressant	CXCL2			0	79.38	MedChemEx	HY-13010	Laquinimod	356.093	CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	GKWPCEFFIHSJOE-UHFFFAOYSA-N	54677946.0		GKWPCEFFIHSJOE
BRD-K60918217-001-03-8	laquinimod	Phase 3	immunosuppressant	CXCL2			0	86.53	Selleck	S2787	Laquinimod (ABR-215062)	356.093	CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	GKWPCEFFIHSJOE-UHFFFAOYSA-N	54677946.0		GKWPCEFFIHSJOE
BRD-K00003469-015-01-9	larazotide-acetate	Phase 2	tight junction regulator				0	79.47	MedChemEx	HY-106268A	Larazotide acetate	725.407	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O	ORFLZNAGUTZRLQ-ZMBVWFSWSA-N	9810532.0		ORFLZNAGUTZRLQ
BRD-K48894757-001-02-9	laropiprant	Launched	prostanoid receptor antagonist	PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGFR|PTGIR|TBXA2R	cardiology	cholesterol	0	97.3	MedChemEx	HY-50175	Laropiprant	435.071	CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12	NXFFJDQHYLNEJK-CYBMUJFWSA-N	9867642.0		NXFFJDQHYLNEJK
BRD-K48894757-001-01-8	laropiprant	Launched	prostanoid receptor antagonist	PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGFR|PTGIR|TBXA2R	cardiology	cholesterol	0	98.78	MedChemEx	HY-50175	Laropiprant	435.071	CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12	NXFFJDQHYLNEJK-CYBMUJFWSA-N	9867642.0		NXFFJDQHYLNEJK
BRD-K36574127-001-01-3	larotrectinib	Launched	tropomyosin receptor kinase inhibitor	NTRK1|NTRK2|NTRK3			0	96.21	MedChemEx	HY-12866	LOXO-101	428.177	O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F	NYNZQNWKBKUAII-KBXCAEBGSA-N	46188928.0		NYNZQNWKBKUAII
BRD-K10207760-236-13-9	lasalocid	Launched	bacterial permeability inducer		infectious disease	coccidiosis	0	88.82	MedChemEx	HY-B1071A	Lasalocid (sodium)	590.382	CC[C@H]([C@H]1O[C@@](CC)(C[C@@H]1C)[C@H]1CC[C@](O)(CC)[C@H](C)O1)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O	BBMULGJBVDDDNI-OWKLGTHSSA-N	5360807.0		BBMULGJBVDDDNI
BRD-K00003178-003-01-9	lasmiditan	Launched	serotonin receptor agonist				0	93.04	MedChemEx	HY-14861A	Lasmiditan (hydrochloride)	377.135	CN1CCC(CC1)C(=O)c1cccc(NC(=O)c2c(F)cc(F)cc2F)n1	XEDHVZKDSYZQBF-UHFFFAOYSA-N	11610526.0		XEDHVZKDSYZQBF
BRD-M93148412-001-02-6	lasofoxifene	Launched	selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|oncology	osteoporosis|breast cancer	0	98.71	MedChemEx	HY-A0038	Lasofoxifene (Tartrate)	563.252	O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1	INEHJXCWEVNEDZ-LUDNRVPPSA-N	3081919.0		INEHJXCWEVNEDZ
BRD-M93148412-001-01-8	lasofoxifene	Launched	selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|oncology	osteoporosis|breast cancer	0	0.0	MedChemEx	HY-A0038	Lasofoxifene (Tartrate)	563.252	O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1	INEHJXCWEVNEDZ-LUDNRVPPSA-N	3081919.0		INEHJXCWEVNEDZ
BRD-K10961822-001-05-1	latanoprost	Launched	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension|glaucoma	0	98.27	Enzo	DL281	Latanoprost	432.288	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1	GGXICVAJURFBLW-CEYXHVGTSA-N	5311221.0		GGXICVAJURFBLW
BRD-K55703048-300-02-4	latrepirdine	Phase 3	glutamate receptor antagonist	HRH1|HTR6			0	95.21	Tocris	3201	Dimebon dihydrochloride	319.205	CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	JNODQFNWMXFMEV-UHFFFAOYSA-N	197033.0		JNODQFNWMXFMEV
BRD-K55703048-001-07-7	latrepirdine	Phase 3	glutamate receptor antagonist	HRH1|HTR6			0	80.14	ChemDiv	H025-0000		319.205	CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	JNODQFNWMXFMEV-UHFFFAOYSA-N	197033.0		JNODQFNWMXFMEV
BRD-K55703048-300-01-6	latrepirdine	Phase 3	glutamate receptor antagonist	HRH1|HTR6			0	93.95	Adooq	A10312	2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole dihydrochloride	319.205	CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	JNODQFNWMXFMEV-UHFFFAOYSA-N	197033.0		JNODQFNWMXFMEV
BRD-K61292460-001-02-3	latrunculin-B	Phase 1	actin polymerization inhibitor	ACTA1|MKL1|SPIRE2			0	31.64	EMDBio	428020-1MG	LATRUNCULIN B, LATRUNCULIA MAGNIFICA	395.177	C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|	NSHPHXHGRHSMIK-JRIKCGFMSA-N	6436219.0		NSHPHXHGRHSMIK
BRD-K61292460-001-03-1	latrunculin-B	Phase 1	actin polymerization inhibitor	ACTA1|MKL1|SPIRE2			0	68.21	EMD	428020-1MG	Latrunculin B	395.177	C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27,t:22|	NSHPHXHGRHSMIK-JRIKCGFMSA-N	6436219.0		NSHPHXHGRHSMIK
BRD-K67375056-001-07-9	lauric-acid	Phase 3	bacterial permeability inducer	GPR84|HNF4A|LTF|LY96|PLA2G2A|TLR4			0	58.87	Enzo	BL137	Dodecanoic acid (Lauric acid)	200.178	CCCCCCCCCCCC(O)=O	POULHZVOKOAJMA-UHFFFAOYSA-N	3893.0		POULHZVOKOAJMA
BRD-K11548689-001-02-9	lauric-diethanolamide	Preclinical					0	96.98	MedChemEx	HY-W005513	N,N-Bis(2-hydroxyethyl)dodecanamide	287.246	CCCCCCCCCCCC(=O)N(CCO)CCO	AOMUHOFOVNGZAN-UHFFFAOYSA-N	8430.0		AOMUHOFOVNGZAN
BRD-K11548689-001-01-6	lauric-diethanolamide	Preclinical					0	97.68	Enamine	Z1262465391		287.246	CCCCCCCCCCCC(=O)N(CCO)CCO	AOMUHOFOVNGZAN-UHFFFAOYSA-N	8430.0		AOMUHOFOVNGZAN
BRD-K35698076-001-02-9	laurocapram	Phase 3					0	87.44	CombiBlocks	OR-1589	Laurocapram	281.272	CCCCCCCCCCCCN1CCCCCC1=O	AXTGDCSMTYGJND-UHFFFAOYSA-N	42981.0		AXTGDCSMTYGJND
BRD-K35698076-001-01-2	laurocapram	Phase 3					0	94.26	InterBioScreen	STOCK1S-00317		281.272	CCCCCCCCCCCCN1CCCCCC1=O	AXTGDCSMTYGJND-UHFFFAOYSA-N	42981.0		AXTGDCSMTYGJND
BRD-K51486818-003-03-6	lazabemide	Phase 3	monoamine oxidase inhibitor	MAOB			0	78.47	Tocris	2460	Lazabemide hydrochloride	199.051	NCCNC(=O)c1ccc(Cl)cn1	JZXRLKWWVNUZRB-UHFFFAOYSA-N	71307.0		JZXRLKWWVNUZRB
BRD-K51486818-003-02-8	lazabemide	Phase 3	monoamine oxidase inhibitor	MAOB			0	89.6	Tocris	2460	Lazabemide hydrochloride	199.051	NCCNC(=O)c1ccc(Cl)cn1	JZXRLKWWVNUZRB-UHFFFAOYSA-N	71307.0		JZXRLKWWVNUZRB
BRD-K00003501-001-01-9	lazertinib	Phase 1/Phase 2	tyrosine kinase inhibitor				0	96.15	MedChemEx	HY-109061	Lazertinib	554.275	COc1cc(N2CCOCC2)c(NC(=O)C=C)cc1Nc1nccc(n1)-n1cc(CN(C)C)c(n1)-c1ccccc1	RRMJMHOQSALEJJ-UHFFFAOYSA-N	121269225.0		RRMJMHOQSALEJJ
BRD-K00025603-001-01-9	LB-100	Phase 2	protein phosphatase inhibitor				0	29.5	MedChemEx	HY-18597		268.142	CN1CCN(CC1)C(=O)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:10,13,&2:15,&3:9|	JUQMLSGOTNKJKI-YTWAJWBKSA-N	11923097.0		JUQMLSGOTNKJKI
BRD-K18834913-001-03-7	LB42708	Preclinical	farnesyltransferase inhibitor				0	93.91	Tocris	4294	LB 42708	554.132	Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	GUUIRIMAQGOLHT-UHFFFAOYSA-N	10099206.0		GUUIRIMAQGOLHT
BRD-K18834913-001-01-1	LB42708	Preclinical	farnesyltransferase inhibitor				0	96.49	Selleck	S7467	LB42708	554.132	Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	GUUIRIMAQGOLHT-UHFFFAOYSA-N	10099206.0		GUUIRIMAQGOLHT
BRD-K18834913-001-05-9	LB42708	Preclinical	farnesyltransferase inhibitor				0	97.41	Tocris	4294	LB 42708	554.132	Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	GUUIRIMAQGOLHT-UHFFFAOYSA-N	10099206.0		GUUIRIMAQGOLHT
BRD-K18834913-001-02-9	LB42708	Preclinical	farnesyltransferase inhibitor				0	93.16	Selleck	S7467	LB42708	554.132	Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	GUUIRIMAQGOLHT-UHFFFAOYSA-N	10099206.0		GUUIRIMAQGOLHT
BRD-K08248804-001-01-8	LCL-161	Phase 2	XIAP inhibitor	BIRC2|XIAP			0	95.17	MedChemEx	HY-15518	LCL161	500.226	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	UFPFGVNKHCLJJO-SSKFGXFMSA-N	24737642.0		UFPFGVNKHCLJJO
BRD-K08248804-001-03-9	LCL-161	Phase 2	XIAP inhibitor	BIRC2|XIAP			0	94.25	MedChemEx	HY-15518	LCL161	500.226	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	UFPFGVNKHCLJJO-SSKFGXFMSA-N	24737642.0		UFPFGVNKHCLJJO
BRD-K20008181-001-01-3	LCQ908	Phase 3	diacylglycerol O acyltransferase inhibitor	DGAT1			0	89.0	MedChemEx	HY-16278	LCQ-908	455.182	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|	GXALXAKNHIROPE-QAQDUYKDSA-N			GXALXAKNHIROPE
BRD-K20008181-001-03-9	LCQ908	Phase 3	diacylglycerol O acyltransferase inhibitor	DGAT1			0	90.59	MedChemEx	HY-16278	Pradigastat	455.182	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|	GXALXAKNHIROPE-QAQDUYKDSA-N			GXALXAKNHIROPE
BRD-M31057929-314-01-9	LCZ696	Launched	angiotensin receptor antagonist		cardiology	angioedema|hypotension	0	60.84	MedChemEx	HY-18204A	LCZ696	846.432	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	XTKIDERFOUYBDE-QEPKIHTBSA-N	24755620.0		XTKIDERFOUYBDE
BRD-M31057929-001-01-2	LCZ696	Launched	angiotensin receptor antagonist		cardiology	angioedema|hypotension	0	61.4	MedChemEx	HY-18204A	LCZ696	846.432	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	XTKIDERFOUYBDE-QEPKIHTBSA-N	24755620.0		XTKIDERFOUYBDE
BRD-M31057929-385-01-9	LCZ696	Launched	angiotensin receptor antagonist		cardiology	angioedema|hypotension	0	61.98	MedChemEx	HY-18204A	LCZ696	846.432	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	XTKIDERFOUYBDE-QEPKIHTBSA-N	24755620.0	BRD-M75836831-385-01-0	XTKIDERFOUYBDE
BRD-M31057929-447-01-7	LCZ696	Launched	angiotensin receptor antagonist		cardiology	angioedema|hypotension	0	57.26	Selleck	S7678	LCZ696	846.432	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O.CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	XTKIDERFOUYBDE-QEPKIHTBSA-N	24755620.0	BRD-M42331949-431-01-3	XTKIDERFOUYBDE
BRD-K44715996-001-01-0	LDC1267	Preclinical	protein tyrosine kinase inhibitor	AXL|MERTK|TYRO3			0	98.38	MedChemEx	HY-12494	LDC1267	560.187	CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C	ISPBCAXOSOLFME-UHFFFAOYSA-N	56847486.0		ISPBCAXOSOLFME
BRD-K61795638-300-02-9	LDN-209929	Preclinical	haspin kinase inhibitor	GSG2			0	72.25	Tocris	4828	LDN 209929 dihydrochloride	332.075	COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1	XMMAOXMYUGQGJD-UHFFFAOYSA-N	46871867.0		XMMAOXMYUGQGJD
BRD-K61795638-300-01-0	LDN-209929	Preclinical	haspin kinase inhibitor	GSG2			0	0.0	Tocris	4828	LDN 209929 dihydrochloride	332.075	COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1	XMMAOXMYUGQGJD-UHFFFAOYSA-N	46871867.0		XMMAOXMYUGQGJD
BRD-K59831625-001-03-9	LDN-212854	Preclinical	bone morphogenic protein inhibitor	ABL1|ACVR1|RIPK2			0	92.2	Tocris	6151	LDN 212854	406.191	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	BBDGBGOVJPEFBT-UHFFFAOYSA-N	60182388.0		BBDGBGOVJPEFBT
BRD-K59831625-001-01-6	LDN-212854	Preclinical	bone morphogenic protein inhibitor	ABL1|ACVR1|RIPK2			0	91.54	Selleck	S7147	LDN-212854	406.191	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	BBDGBGOVJPEFBT-UHFFFAOYSA-N	60182388.0		BBDGBGOVJPEFBT
BRD-K59831625-001-02-4	LDN-212854	Preclinical	bone morphogenic protein inhibitor	ABL1|ACVR1|RIPK2			0	97.26	Selleck	S7147	LDN-212854	406.191	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	BBDGBGOVJPEFBT-UHFFFAOYSA-N	60182388.0		BBDGBGOVJPEFBT
BRD-K51485109-001-02-9	LDN-27219	Preclinical	tissue transglutaminase inhibitor	TGM2			0	90.91	Tocris	4602	LDN 27219	408.071	NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1	WLBUICQBNZXIDJ-UHFFFAOYSA-N	1150683.0		WLBUICQBNZXIDJ
BRD-K51485109-001-01-4	LDN-27219	Preclinical	tissue transglutaminase inhibitor	TGM2			0	88.89	Tocris	4602	LDN 27219	408.071	NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1	WLBUICQBNZXIDJ-UHFFFAOYSA-N	1150683.0		WLBUICQBNZXIDJ
BRD-K94485812-001-01-1	LDN-57444	Preclinical	ubiquitin C-terminal hydrolase inhibitor				0	0.0	Selleck	S7135	LDN-57444	395.984	CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	OPQRFPHLZZPCCH-LTGZKZEYSA-N	51537051.0		OPQRFPHLZZPCCH
BRD-K94485812-001-03-7	LDN-57444	Preclinical	ubiquitin C-terminal hydrolase inhibitor				0	0.0	MedChemEx	HY-18637	LDN-57444	395.984	CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	OPQRFPHLZZPCCH-LTGZKZEYSA-N	51537051.0	BRD-K20203690-001-02-2	OPQRFPHLZZPCCH
BRD-K94485812-001-02-9	LDN-57444	Preclinical	ubiquitin C-terminal hydrolase inhibitor				0	99.35	Selleck	S7135	LDN-57444	395.984	CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	OPQRFPHLZZPCCH-LTGZKZEYSA-N	51537051.0		OPQRFPHLZZPCCH
BRD-K04853698-376-01-4	LDN193189	Preclinical	bone morphogenic protein inhibitor	ACVR1|BMPR1A			0	97.1	MedChemEx	HY-12071A	LDN193189 (Hydrochloride)	406.191	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	CDOVNWNANFFLFJ-UHFFFAOYSA-N	25195294.0		CDOVNWNANFFLFJ
BRD-K06593056-001-05-5	LE-135	Preclinical	retinoid receptor agonist	RARB			0	95.85	Tocris	2021	LE 135	438.231	CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|	YZZAIQOVMHVWBS-UHFFFAOYSA-N	10410894.0		YZZAIQOVMHVWBS
BRD-K06593056-001-04-8	LE-135	Preclinical	retinoid receptor agonist	RARB			0	95.75	Tocris	2021	LE 135	438.231	CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|	YZZAIQOVMHVWBS-UHFFFAOYSA-N	10410894.0		YZZAIQOVMHVWBS
BRD-K05446112-001-01-8	ledipasvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	94.99	MedChemEx	HY-15602	Ledipasvir	888.413	COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C	VRTWBAAJJOHBQU-KMWAZVGDSA-N	67505836.0		VRTWBAAJJOHBQU
BRD-K05446112-001-02-9	ledipasvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	99.19	MedChemEx	HY-15602	Ledipasvir	888.413	COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C	VRTWBAAJJOHBQU-KMWAZVGDSA-N	67505836.0		VRTWBAAJJOHBQU
BRD-K78692225-001-24-5	leflunomide	Launched	dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor	AHR|DHODH|PTK2B	rheumatology	rheumatoid arthritis	0	94.48	MicroSource	1503927	LEFLUNOMIDE	270.062	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	VHOGYURTWQBHIL-UHFFFAOYSA-N	3899.0		VHOGYURTWQBHIL
BRD-K78692225-001-23-7	leflunomide	Launched	dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor	AHR|DHODH|PTK2B	rheumatology	rheumatoid arthritis	0	93.56	Tocris	2228	Leflunomide	270.062	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	VHOGYURTWQBHIL-UHFFFAOYSA-N	3899.0		VHOGYURTWQBHIL
BRD-K78692225-001-29-9	leflunomide	Launched	dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor	AHR|DHODH|PTK2B	rheumatology	rheumatoid arthritis	0	88.66	Tocris	2228	Leflunomide	270.062	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	VHOGYURTWQBHIL-UHFFFAOYSA-N	3899.0		VHOGYURTWQBHIL
BRD-K78692225-001-22-9	leflunomide	Launched	dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor	AHR|DHODH|PTK2B	rheumatology	rheumatoid arthritis	0	91.18	Selleck	S1247	Leflunomide	270.062	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	VHOGYURTWQBHIL-UHFFFAOYSA-N	3899.0		VHOGYURTWQBHIL
BRD-K78666663-001-01-6	lemborexant	Launched	orexin receptor antagonist	HCRTR1|HCRTR2			0	96.65	MedChemEx	HY-16725	Lemborexant	410.155	Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1	MUGXRYIUWFITCP-PGRDOPGGSA-N	56944144.0		MUGXRYIUWFITCP
BRD-A17883755-001-06-1	lenalidomide	Launched	anticancer agent	TNF	hematologic malignancy	multiple myeloma|mantle cell lymphoma (MCL)|myelodysplastic diseases (MDS)	0	98.9	Selleck	S1029	Lenalidomide (CC-5013)	259.096	Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11,r|	GOTYRUGSSMKFNF-JTQLQIEISA-N	12044976.0		GOTYRUGSSMKFNF
BRD-K00003261-001-01-9	leniolisib	Phase 2/Phase 3	PI3K inhibitor				0	96.68	MedChemEx	HY-17635	Leniolisib	450.199	CCC(=O)N1CC[C@@H](C1)Nc1ncnc2CCN(Cc12)c1cnc(OC)c(c1)C(F)(F)F	MWKYMZXCGYXLPL-ZDUSSCGKSA-N	57495353.0		MWKYMZXCGYXLPL
BRD-K39974922-001-04-3	lenvatinib	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FLT4|KDR	oncology	thyroid cancer	0	98.78	Selleck	S1164	Lenvatinib (E7080)	426.109	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	WOSKHXYHFSIKNG-UHFFFAOYSA-N	9823820.0		WOSKHXYHFSIKNG
BRD-K39974922-001-01-9	lenvatinib	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FLT4|KDR	oncology	thyroid cancer	0		Selleck	S1164	E7080	426.109	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	WOSKHXYHFSIKNG-UHFFFAOYSA-N	9823820.0		WOSKHXYHFSIKNG
BRD-K00004696-001-01-9	leonurine	Preclinical	anti-inflammatory agent				0	93.59	CombiBlocks	QA-7588	Leonurine	311.148	COc1cc(cc(OC)c1O)C(=O)OCCCCNC(N)=N	WNGSUWLDMZFYNZ-UHFFFAOYSA-N	161464.0		WNGSUWLDMZFYNZ
BRD-K00003269-001-01-9	LEQ506	Phase 1	G protein signaling inhibitor				0	88.91	MedChemEx	HY-18636	LEQ506	432.264	C[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C	POERAARDVFVDLO-QGZVFWFLSA-N	45100669.0		POERAARDVFVDLO
BRD-A18992208-003-02-7	lercanidipine	Launched	calcium channel blocker	CACNA2D1	cardiology	hypertension	0	98.03	Sigma	MFCD07773089	3-{2-[(3,3-diphenylpropyl)(methyl)amino]-1,1-dimethylethyl} 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride	611.3	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r,c:4,9|	ZDXUKAKRHYTAKV-MGBGTMOVSA-N	9809926.0		ZDXUKAKRHYTAKV
BRD-K62398570-001-02-9	lerisetron	Phase 3	serotonin receptor antagonist	HTR3A			0	97.8	Enamine	EN300-242559	1-benzyl-2-(piperazin-1-yl)-1H-1,3-benzodiazole	292.169	C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	PWWDCRQZITYKDV-UHFFFAOYSA-N	65997.0		PWWDCRQZITYKDV
BRD-K62398570-300-01-2	lerisetron	Phase 3	serotonin receptor antagonist	HTR3A			0	91.67	LifeChem	F2145-0456		292.169	C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	PWWDCRQZITYKDV-UHFFFAOYSA-N	65997.0		PWWDCRQZITYKDV
BRD-K62398570-001-01-6	lerisetron	Phase 3	serotonin receptor antagonist	HTR3A			0	98.73	Enamine	EN300-242559	1-Benzyl-2-(piperazin-1-yl)-1H-1,3-benzodiazole	292.169	C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	PWWDCRQZITYKDV-UHFFFAOYSA-N	65997.0		PWWDCRQZITYKDV
BRD-K03289534-001-01-4	lersivirine	Phase 2	non-nucleoside reverse transcriptase inhibitor				0	96.3	MedChemEx	HY-14267	Lersivirine	310.143	CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N	MCPUZZJBAHRIPO-UHFFFAOYSA-N	16739244.0		MCPUZZJBAHRIPO
BRD-K03289534-001-02-9	lersivirine	Phase 2	non-nucleoside reverse transcriptase inhibitor				0	95.42	MedChemEx	HY-14267	Lersivirine	310.143	CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N	MCPUZZJBAHRIPO-UHFFFAOYSA-N	16739244.0		MCPUZZJBAHRIPO
BRD-K75024268-001-01-0	lesinurad	Launched	uric acid diuretic	SLC22A12	rheumatology	gout	0	85.07	MedChemEx	HY-15258	Lesinurad	402.999	OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	FGQFOYHRJSUHMR-UHFFFAOYSA-N	53465279.0		FGQFOYHRJSUHMR
BRD-K75024268-001-02-9	lesinurad	Launched	uric acid diuretic	SLC22A12	rheumatology	gout	0	99.19	MedChemEx	HY-15258	Lesinurad	402.999	OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	FGQFOYHRJSUHMR-UHFFFAOYSA-N	53465279.0		FGQFOYHRJSUHMR
BRD-A27376179-001-01-3	lestaurtinib	Phase 3	FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor	FLT3|NTRK1			0	97.47	EMDBio	219499-5MG	CEP-701	439.153	C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1,5,&1:3|	UIARLYUEJFELEN-DMVVYWCZSA-N	9932888.0		UIARLYUEJFELEN
BRD-K21612934-001-01-1	leteprinim	Phase 2	nerve growth factor agonist				0	97.65	Sigma	MFCD00925649	4-{[3-(6-oxo-1,6-dihydro-9H-purin-9-yl)propanoyl]amino}benzoic acid	327.097	OC(=O)c1ccc(NC(=O)CCn2cnc3c2[nH]cnc3=O)cc1	JMPOIZCOJJMTHI-UHFFFAOYSA-N	135409548.0		JMPOIZCOJJMTHI
BRD-K94288301-001-01-7	letermovir	Launched	CMV terminase inhibitor		infectious disease	cytomegalovirus (CMV)	0	96.6	MedChemEx	HY-15233	Letermovir	572.205	COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|	FWYSMLBETOMXAG-QHCPKHFHSA-N	45138674.0		FWYSMLBETOMXAG
BRD-K94288301-001-02-9	letermovir	Launched	CMV terminase inhibitor		infectious disease	cytomegalovirus (CMV)	0	95.64	MedChemEx	HY-15233	Letermovir	572.205	COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|	FWYSMLBETOMXAG-QHCPKHFHSA-N	45138674.0		FWYSMLBETOMXAG
BRD-A32597168-001-03-6	letosteine	Launched	mucolytic agent		pulmonary|infectious disease	bronchitis|pneumonia	0	96.97	AKSci	R082		279.06	CCOC(=O)CSCC[C@H]1N[C@@H](CS1)C(O)=O |&1:9,&2:11,r|	IKOCLISPVJZJEA-YUMQZZPRSA-N	76956360.0		IKOCLISPVJZJEA
BRD-K00003474-001-01-9	letrazuril	Phase 1	antiinfective drug				0	98.49	MedChemEx	HY-106859	Letrazuril	390.009	Fc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7,r|	XQKYUBTUOHHNDV-GFCCVEGCSA-N	76959723.0		XQKYUBTUOHHNDV
BRD-K88789588-001-17-9	letrozole	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	93.39	Tocris	4382	Letrozole	285.101	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	HPJKCIUCZWXJDR-UHFFFAOYSA-N	3902.0		HPJKCIUCZWXJDR
BRD-K88789588-001-16-4	letrozole	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	94.62	Tocris	4382	Letrozole	285.101	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	HPJKCIUCZWXJDR-UHFFFAOYSA-N	3902.0		HPJKCIUCZWXJDR
BRD-K88789588-001-14-9	letrozole	Launched	aromatase inhibitor	CYP19A1	oncology	breast cancer	0	96.85	Selleck	S1235	Letrozole	285.101	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	HPJKCIUCZWXJDR-UHFFFAOYSA-N	3902.0		HPJKCIUCZWXJDR
BRD-K27460187-334-01-8	leucomethylene-blue	Phase 3	nitric oxide production inhibitor|tau aggregation inhibitor	MAPT			0	0.0	MedChemEx	HY-19948	Leucomethylene blue (Mesylate)	285.13	CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C	QTWZICCBKBYHDM-UHFFFAOYSA-N	164695.0		QTWZICCBKBYHDM
BRD-K01825581-238-05-9	leucovorin	Launched	folate receptor ligand		oncology	osteosarcoma	0	93.02	MedChemEx	HY-13664	Folinic acid (Calcium)	473.166	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|	VVIAGPKUTFNRDU-STQMWFEESA-N	135398559.0		VVIAGPKUTFNRDU
BRD-K01825581-399-03-9	leucovorin	Launched	folate receptor ligand		oncology	osteosarcoma	0	97.3	Selleck	S1236	Leucovorin Calcium	603.181	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|	VVIAGPKUTFNRDU-STQMWFEESA-N	135398559.0		VVIAGPKUTFNRDU
BRD-K01825581-399-02-9	leucovorin	Launched	folate receptor ligand		oncology	osteosarcoma	0	86.8	Selleck	S1236	Leucovorin Calcium	603.181	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21,&1:9|	VVIAGPKUTFNRDU-STQMWFEESA-N	135398559.0		VVIAGPKUTFNRDU
BRD-K81136890-003-01-6	leucylleucine-methyl-ester	Phase 2					0	100.0	ChemImpex	4578		258.194	COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C	AJMOLNFDYWTVQW-QWRGUYRKSA-N	7016877.0		AJMOLNFDYWTVQW
BRD-K45300898-001-04-9	leuprolide	Launched	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology	prostate cancer	0	93.87	Sigma	1358503	(2S)-1-{(2S,5S,8R,11S,14S,17S,20S)-2-(3-{[amino(imino)methyl]amino}propyl)-11-(4-hydroxybenzyl)-14-(hydroxymethyl)-20-(1H-imidazol-4-ylmethyl)-17-(1H-indol-3-ylmethyl)-5,8-diisobutyl-4,7,10,13,16,19,2	1208.645	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	GFIJNRVAKGFPGQ-LIJARHBVSA-N	657181.0		GFIJNRVAKGFPGQ
BRD-K45300898-015-05-9	leuprolide	Launched	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology	prostate cancer	0	94.29	Sigma	L0399-5MG	Leuprolide acetate salt	1208.645	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	GFIJNRVAKGFPGQ-LIJARHBVSA-N	657181.0		GFIJNRVAKGFPGQ
BRD-K34469523-003-03-0	levalbuterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm	0	97.04	MicroSource	1505811	LEVALBUTEROL HYDROCHLORIDE	239.152	CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1	NDAUXUAQIAJITI-LBPRGKRZSA-N	123600.0		NDAUXUAQIAJITI
BRD-K34469523-065-04-9	levalbuterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm	0	94.99	Vitas-M	STK618645	4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol	239.152	CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1	NDAUXUAQIAJITI-LBPRGKRZSA-N	123600.0		NDAUXUAQIAJITI
BRD-K30634073-046-01-0	levallorphan	Launched	opioid receptor antagonist	CHRNA2|OPRM1	pulmonary	respiratory depression	0	93.45	Enzo	AC891	Levallorphan tartrate	283.194	Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1	OZYUPQUCAUTOBP-QXAKKESOSA-N	5359371.0		OZYUPQUCAUTOBP
BRD-K30634073-046-02-8	levallorphan	Launched	opioid receptor antagonist	CHRNA2|OPRM1	pulmonary	respiratory depression	0	81.06	Sigma	L121-5MG	Levallorphan tartrate salt	283.194	Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1	OZYUPQUCAUTOBP-QXAKKESOSA-N	5359371.0		OZYUPQUCAUTOBP
BRD-K73107279-003-12-5	levamisole	Withdrawn	acetylcholine receptor agonist	ALPL			0	99.45	MicroSource	1503245	LEVAMISOLE HYDROCHLORIDE	204.072	C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N	26879.0		HLFSDGLLUJUHTE
BRD-K73107279-003-13-9	levamisole	Withdrawn	acetylcholine receptor agonist	ALPL			0	98.3	MedChemEx	HY-B1194	Tetramisole (hydrochloride)	204.072	C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N	26879.0		HLFSDGLLUJUHTE
BRD-K73107279-003-11-7	levamisole	Withdrawn	acetylcholine receptor agonist	ALPL			0	94.03	Selleck	S1939	(-)-Tetramisole	204.072	C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N	26879.0		HLFSDGLLUJUHTE
BRD-K00005329-074-01-9	levamlodipine	Launched	calcium channel blocker		cardiology	hypertension	0	96.68	MedChemEx	HY-14744A	Levamlodipine besylate	408.145	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1c1ccccc1Cl)C(=O)OC |c:5,14|	HTIQEAQVCYTUBX-KRWDZBQOSA-N	9822750.0		HTIQEAQVCYTUBX
BRD-K24526313-001-18-5	levcromakalim	Phase 3	potassium channel activator	KCNJ5			0	98.45	Sigma	MFCD00133201	(3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-3,4-dihydro-2H-chromene-6-carbonitrile	286.132	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	TVZCRIROJQEVOT-CABCVRRESA-N	93504.0		TVZCRIROJQEVOT
BRD-K24526313-001-17-7	levcromakalim	Phase 3	potassium channel activator	KCNJ5			0	99.04	Tocris	1378	Levcromakalim	286.132	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	TVZCRIROJQEVOT-CABCVRRESA-N	93504.0		TVZCRIROJQEVOT
BRD-K24526313-001-19-9	levcromakalim	Phase 3	potassium channel activator	KCNJ5			0	93.36	Tocris	1377	Cromakalim	286.132	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	TVZCRIROJQEVOT-CABCVRRESA-N	93504.0		TVZCRIROJQEVOT
BRD-K24526313-001-20-9	levcromakalim	Phase 3	potassium channel activator	KCNJ5			0	98.36	Tocris	1378	Levcromakalim	286.132	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	TVZCRIROJQEVOT-CABCVRRESA-N	93504.0		TVZCRIROJQEVOT
BRD-K49404994-001-13-3	levetiracetam	Launched	calcium channel blocker	CACNA1B|SCN1A|SV2A	neurology/psychiatry	seizures	0	61.34	Tocris	2839	Levetiracetam	170.106	CC[C@H](N1CCCC1=O)C(N)=O	HPHUVLMMVZITSG-LURJTMIESA-N	5284583.0		HPHUVLMMVZITSG
BRD-K49404994-001-10-9	levetiracetam	Launched	calcium channel blocker	CACNA1B|SCN1A|SV2A	neurology/psychiatry	seizures	0	95.46	MicroSource	1502265	LEVETIRACETAM	170.106	CC[C@H](N1CCCC1=O)C(N)=O	HPHUVLMMVZITSG-LURJTMIESA-N	5284583.0		HPHUVLMMVZITSG
BRD-K49404994-001-11-7	levetiracetam	Launched	calcium channel blocker	CACNA1B|SCN1A|SV2A	neurology/psychiatry	seizures	0	94.0	Selleck	S1356	Levetiracetam	170.106	CC[C@H](N1CCCC1=O)C(N)=O	HPHUVLMMVZITSG-LURJTMIESA-N	5284583.0		HPHUVLMMVZITSG
BRD-K49404994-001-09-1	levetiracetam	Launched	calcium channel blocker	CACNA1B|SCN1A|SV2A	neurology/psychiatry	seizures	0	79.86	Selleck	S1356	Levetiracetam	170.106	CC[C@H](N1CCCC1=O)C(N)=O	HPHUVLMMVZITSG-LURJTMIESA-N	5284583.0		HPHUVLMMVZITSG
BRD-A64698388-003-01-7	levo-phencynonate	Launched	acetylcholine receptor antagonist	CHRM1			0	87.3	ChemPacific	36081	Bencynoate hydrochloride	357.23	CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7,&2:3,&3:9,&4:13|	ROZOEEGFKDFEFP-AXRVMRSRSA-N			ROZOEEGFKDFEFP
BRD-K43883465-003-02-9	levobetaxolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	ophthalmology	intraocular pressure|glaucoma	0	97.62	MedChemEx	HY-B0381B	Levobetaxolol (hydrochloride)	307.215	CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1	NWIUTZDMDHAVTP-KRWDZBQOSA-N	60657.0		NWIUTZDMDHAVTP
BRD-K43883465-003-01-5	levobetaxolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	ophthalmology	intraocular pressure|glaucoma	0	94.07	Selleck	S4085	Levobetaxolol HCl	307.215	CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1	NWIUTZDMDHAVTP-KRWDZBQOSA-N	60657.0		NWIUTZDMDHAVTP
BRD-K31812033-003-12-9	levobunolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	ophthalmology	glaucoma|ocular hypertension	0	98.38	MedChemEx	HY-B1035	Levobunolol (hydrochloride)	291.183	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	IXHBTMCLRNMKHZ-LBPRGKRZSA-N	39468.0		IXHBTMCLRNMKHZ
BRD-K31812033-003-10-2	levobunolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	ophthalmology	glaucoma|ocular hypertension	0	98.21	Enzo	AC3158	LEVOBUNOLOL HYDROCHLORIDE	291.183	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	IXHBTMCLRNMKHZ-LBPRGKRZSA-N	39468.0		IXHBTMCLRNMKHZ
BRD-K31812033-003-11-0	levobunolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	ophthalmology	glaucoma|ocular hypertension	0	99.36	Prestwick	Prestw-847	(-) -Levobunolol hydrochloride	291.183	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	IXHBTMCLRNMKHZ-LBPRGKRZSA-N	39468.0		IXHBTMCLRNMKHZ
BRD-K73323637-003-10-9	levobunolol-(+)	Preclinical	adrenergic receptor antagonist				0	99.32	Prestwick	Prestw-857	(+) -Levobunolol hydrochloride	291.183	CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12	IXHBTMCLRNMKHZ-GFCCVEGCSA-N	5460339.0		IXHBTMCLRNMKHZ
BRD-A46876182-003-02-8	levobunolol-(+/-)	Preclinical	adrenergic receptor antagonist				0	98.4	MicroSource	1505551	LEVOBUNOLOL HYDROCHLORIDE	291.183	CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|	IXHBTMCLRNMKHZ-GFCCVEGCSA-N	5460339.0		IXHBTMCLRNMKHZ
BRD-K33453211-003-11-5	levocabastine	Launched	histamine receptor antagonist	HRH1|NTSR2	ophthalmology	conjunctivitis	0	98.8	Prestwick	Prestw-1039	Levocabastine hydrochloride	420.221	C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1	ZCGOMHNNNFPNMX-KYTRFIICSA-N			ZCGOMHNNNFPNMX
BRD-K59647213-001-10-5	levocarnitine	Launched		CRAT|CROT	endocrinology	carnitine deficiency	0	100.0	MicroSource	1505437	LEVOCARNITINE	162.113	C[N+](C)(C)C[C@H](O)CC(O)=O	PHIQHXFUZVPYII-ZCFIWIBFSA-O	10918.0		PHIQHXFUZVPYII
BRD-K59647213-001-09-7	levocarnitine	Launched		CRAT|CROT	endocrinology	carnitine deficiency	0	93.16	Selleck	S2388	L-carnitine	162.113	C[N+](C)(C)C[C@H](O)CC(O)=O	PHIQHXFUZVPYII-ZCFIWIBFSA-O	10918.0		PHIQHXFUZVPYII
BRD-K84366268-003-01-0	levocarnitine-propionate	Launched	carnitine palmitoyltransferase inhibitor	CRAT	neurology/psychiatry|endocrinology	peripheral neuropathy|carnitine deficiency	0	61.9	MedChemEx	HY-B0932	Levocarnitine propionate (hydrochloride)	218.139	CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C	UFAHZIUFPNSHSL-MRVPVSSYSA-O	157837.0		UFAHZIUFPNSHSL
BRD-K27184429-300-01-3	levocetirizine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	97.42	MicroSource	1504914	LEVOCETIRIZINE DIHYDROCHLORIDE	388.155	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	ZKLPARSLTMPFCP-OAQYLSRUSA-N	28145931.0	BRD-K18097163-300-02-6	ZKLPARSLTMPFCP
BRD-K27184429-300-02-1	levocetirizine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	96.75	TCI	L0264	Levocetirizine dihydrochloride	388.155	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	ZKLPARSLTMPFCP-OAQYLSRUSA-N	28145931.0		ZKLPARSLTMPFCP
BRD-K34730807-001-16-8	levodopa	Launched	dopamine precursor	DRD1|DRD2|DRD3|DRD4|DRD5|GPR143	neurology/psychiatry	Parkinson's Disease	0	0.0	MicroSource	2300205	LEVODOPA	197.069	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	WTDRDQBEARUVNC-LURJTMIESA-N	6971033.0		WTDRDQBEARUVNC
BRD-K34730807-001-17-6	levodopa	Launched	dopamine precursor	DRD1|DRD2|DRD3|DRD4|DRD5|GPR143	neurology/psychiatry	Parkinson's Disease	0	92.55	Selleck	S1726	Levodopa (Sinemet)	197.069	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	WTDRDQBEARUVNC-LURJTMIESA-N	6971033.0		WTDRDQBEARUVNC
BRD-K34730807-001-15-0	levodopa	Launched	dopamine precursor	DRD1|DRD2|DRD3|DRD4|DRD5|GPR143	neurology/psychiatry	Parkinson's Disease	0	0.0	Selleck	S1726	Levodopa (Sinemet)	197.069	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	WTDRDQBEARUVNC-LURJTMIESA-N	6971033.0		WTDRDQBEARUVNC
BRD-K83551379-001-03-9	levodropropizine	Launched	antitussive		pulmonary	cough suppressant	0	89.36	MedChemEx	HY-B1895	Levodropropizine	236.152	OC[C@@H](O)CN1CCN(CC1)c1ccccc1	PTVWPYVOOKLBCG-ZDUSSCGKSA-N	65859.0		PTVWPYVOOKLBCG
BRD-K83551379-001-02-6	levodropropizine	Launched	antitussive		pulmonary	cough suppressant	0	89.81	Selleck	S4131	Levodropropizine	236.152	OC[C@@H](O)CN1CCN(CC1)c1ccccc1	PTVWPYVOOKLBCG-ZDUSSCGKSA-N	65859.0	BRD-K60537263-001-01-3	PTVWPYVOOKLBCG
BRD-K83551379-001-01-8	levodropropizine	Launched	antitussive		pulmonary	cough suppressant	0	95.16	Selleck	S4131	Levodropropizine	236.152	OC[C@@H](O)CN1CCN(CC1)c1ccccc1	PTVWPYVOOKLBCG-ZDUSSCGKSA-N	65859.0		PTVWPYVOOKLBCG
BRD-K09471561-001-18-2	levofloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|otolaryngology|pulmonary|urology	pneumonia|sinusitis|bronchitis|skin infections|prostatitis|urinary tract infections|pyelonephritis|anthrax|plague	0	97.7	MicroSource	1504260	LEVOFLOXACIN	361.144	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	GSDSWSVVBLHKDQ-JTQLQIEISA-N	6956357.0		GSDSWSVVBLHKDQ
BRD-K09471561-001-20-8	levofloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|otolaryngology|pulmonary|urology	pneumonia|sinusitis|bronchitis|skin infections|prostatitis|urinary tract infections|pyelonephritis|anthrax|plague	0	96.51	Selleck	S1940	Levofloxacin	361.144	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	GSDSWSVVBLHKDQ-JTQLQIEISA-N	6956357.0	BRD-K88565300-001-01-7	GSDSWSVVBLHKDQ
BRD-K62751771-001-01-3	levomenol	Launched			neurology/psychiatry|infectious disease	spasms|skin infections	0	0.0	Sigma	MFCD03412455	(2S)-6-methyl-2-[(1S)-4-methyl-3-cyclohexen-1-yl]-5-hepten-2-ol	222.198	CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 |c:13|	RGZSQWQPBWRIAQ-CABCVRRESA-N	442343.0		RGZSQWQPBWRIAQ
BRD-K50329370-001-08-2	levomenthol	Launched		OPRK1|TRPA1|TRPM8|TRPV3	neurology/psychiatry	pain relief	0	32.51	MicroSource	1503134	LEVOMENTHOL	156.151	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NOOLISFMXDJSKH-KXUCPTDWSA-N	16666.0		NOOLISFMXDJSKH
BRD-K50329370-001-09-0	levomenthol	Launched		OPRK1|TRPA1|TRPM8|TRPV3	neurology/psychiatry	pain relief	0	0.0	Sigma	V900632	(1R,2S,5R)-2-isopropyl-5-methylcyclohexanol	156.151	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	NOOLISFMXDJSKH-KXUCPTDWSA-N	16666.0		NOOLISFMXDJSKH
BRD-K35559145-001-01-3	levomepromazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR2A|HTR2C	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia	0	90.27	Sigma	MFCD00083418	(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethyl-1-propanamine	328.161	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	VRQVVMDWGGWHTJ-CQSZACIVSA-N	72287.0		VRQVVMDWGGWHTJ
BRD-K35559145-050-08-5	levomepromazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR2A|HTR2C	neurology/psychiatry|gastroenterology	psychosis|schizophrenia|bipolar disorder|nausea|insomnia	0	96.44	Prestwick	Prestw-797	Methotrimeprazine maleat salt	328.161	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	VRQVVMDWGGWHTJ-CQSZACIVSA-N	72287.0		VRQVVMDWGGWHTJ
BRD-A67616246-001-07-9	levomequitazine	Phase 2	histamine receptor antagonist	HRH1			0	96.71	Vitas-M	STK324459		322.15	C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|	HOKDBMAJZXIPGC-MRXNPFEDSA-N	3246605.0		HOKDBMAJZXIPGC
BRD-A67616246-001-08-9	levomequitazine	Phase 2	histamine receptor antagonist	HRH1			0	94.1	MedChemEx	HY-B2168	Mequitazine	322.15	C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1,r|	HOKDBMAJZXIPGC-MRXNPFEDSA-N	3246605.0		HOKDBMAJZXIPGC
BRD-K02976377-001-08-2	levonordefrin	Launched	vasodilator	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|SLC6A2	hematology	hemorrhage	0	0.0	Sigma	MFCD00134415	4-[(1R,2S)-2-amino-1-hydroxypropyl]-1,2-benzenediol	183.09	C[C@H](N)[C@H](O)c1ccc(O)c(O)c1	GEFQWZLICWMTKF-CDUCUWFYSA-N	164739.0		GEFQWZLICWMTKF
BRD-K02976377-001-07-4	levonordefrin	Launched	vasodilator	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|SLC6A2	hematology	hemorrhage	0	0.0	MicroSource	1500365	LEVONORDEFRIN	183.09	C[C@H](N)[C@H](O)c1ccc(O)c(O)c1	GEFQWZLICWMTKF-CDUCUWFYSA-N	164739.0		GEFQWZLICWMTKF
BRD-K35189033-001-28-7	levonorgestrel	Launched	estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist	PGR	endocrinology	contraceptive	0	79.79	Tocris	4833	Levonorgestrel	312.209	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N	13109.0		WWYNJERNGUHSAO
BRD-K35189033-001-30-3	levonorgestrel	Launched	estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist	PGR	endocrinology	contraceptive	0	98.56	Selleck	S1727	Levonorgestrel	312.209	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N	13109.0	BRD-K10086084-001-02-7	WWYNJERNGUHSAO
BRD-K35189033-001-26-1	levonorgestrel	Launched	estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist	PGR	endocrinology	contraceptive	0	95.57	MicroSource	1502355	LEVONORGESTREL	312.209	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N	13109.0		WWYNJERNGUHSAO
BRD-K35189033-001-29-5	levonorgestrel	Launched	estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist	PGR	endocrinology	contraceptive	0	92.36	Selleck	S1727	Levonorgestrel	312.209	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N	13109.0	BRD-K10086084-001-01-9	WWYNJERNGUHSAO
BRD-K35189033-001-31-1	levonorgestrel	Launched	estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist	PGR	endocrinology	contraceptive	0	87.21	Selleck	S5709	NORGESTREL	312.209	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N	13109.0		WWYNJERNGUHSAO
BRD-A54635441-078-09-1	levopropoxyphene	Launched	antitussive		pulmonary	cough suppressant	0	28.74	Prestwick	Prestw-1054	Levopropoxyphene napsylate	339.22	CCC(=O)OC(Cc1ccccc1)([C@@H](C)CN(C)C)c1ccccc1 |&1:5,&2:13|	XLMALTXPSGQGBX-HXBUSHRASA-N	133687039.0		XLMALTXPSGQGBX
BRD-K03095347-001-06-1	levosimendan	Launched	calcium sensitizer	KCNJ11|KCNJ8|PDE3A|TNNC1	cardiology	congestive heart failure	0	99.1	MicroSource	1502356	LEVOSIMENDAN	280.107	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|	WHXMKTBCFHIYNQ-SECBINFHSA-N	3033825.0		WHXMKTBCFHIYNQ
BRD-K03095347-001-07-9	levosimendan	Launched	calcium sensitizer	KCNJ11|KCNJ8|PDE3A|TNNC1	cardiology	congestive heart failure	0	86.37	MedChemEx	HY-14286	Levosimendan	280.107	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|	WHXMKTBCFHIYNQ-SECBINFHSA-N	3033825.0		WHXMKTBCFHIYNQ
BRD-K03095347-001-05-3	levosimendan	Launched	calcium sensitizer	KCNJ11|KCNJ8|PDE3A|TNNC1	cardiology	congestive heart failure	0	96.7	Selleck	S2446	Levosimendan	280.107	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|	WHXMKTBCFHIYNQ-SECBINFHSA-N	3033825.0		WHXMKTBCFHIYNQ
BRD-K51671335-001-12-2	levosulpiride	Launched	dopamine receptor antagonist	CA1|CA12|CA7|DRD2|DRD3	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)	0	98.1	Tocris	895	(S)-(-)-Sulpiride	341.141	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	BGRJTUBHPOOWDU-NSHDSACASA-N	688272.0		BGRJTUBHPOOWDU
BRD-K51671335-001-13-9	levosulpiride	Launched	dopamine receptor antagonist	CA1|CA12|CA7|DRD2|DRD3	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)	0	96.27	Tocris	895	(S)-(-)-Sulpiride	341.141	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	BGRJTUBHPOOWDU-NSHDSACASA-N	688272.0		BGRJTUBHPOOWDU
BRD-K51671335-001-09-8	levosulpiride	Launched	dopamine receptor antagonist	CA1|CA12|CA7|DRD2|DRD3	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)	0	97.48	Selleck	S2104	Levosulpiride	341.141	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	BGRJTUBHPOOWDU-NSHDSACASA-N	688272.0		BGRJTUBHPOOWDU
BRD-K51671335-001-10-6	levosulpiride	Launched	dopamine receptor antagonist	CA1|CA12|CA7|DRD2|DRD3	neurology/psychiatry|gastroenterology|urology	schizophrenia|psychosis|anxiety|vertigo|dyspepsia|irritable bowel syndrome|premature ejaculation (PE)	0	97.65	Tocris	895	(S)-(-)-Sulpiride	341.141	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	BGRJTUBHPOOWDU-NSHDSACASA-N	688272.0		BGRJTUBHPOOWDU
BRD-K30685142-001-17-0	levothyroxine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	myxedema coma	0	96.14	Sigma	MFCD00002595	(2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid	776.687	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	XUIIKFGFIJCVMT-LBPRGKRZSA-N	5819.0		XUIIKFGFIJCVMT
BRD-K30685142-001-16-2	levothyroxine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	myxedema coma	0	91.87	Selleck	S2599	L-Thyroxine	776.687	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	XUIIKFGFIJCVMT-LBPRGKRZSA-N	5819.0		XUIIKFGFIJCVMT
BRD-K30685142-001-15-4	levothyroxine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	myxedema coma	0	95.89	MicroSource	1500774	LEVOTHYROXINE	776.687	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	XUIIKFGFIJCVMT-LBPRGKRZSA-N	5819.0		XUIIKFGFIJCVMT
BRD-K30685142-001-14-7	levothyroxine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	myxedema coma	0	26.13	Selleck	S2599	L-Thyroxine	776.687	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	XUIIKFGFIJCVMT-LBPRGKRZSA-N	5819.0		XUIIKFGFIJCVMT
BRD-A30655177-001-14-0	LFM-A13	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	94.77	Tocris	1300	LFM-A13	357.895	CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3,r|	BQLDGDMKDYAGNE-MRVPVSSYSA-N			BQLDGDMKDYAGNE
BRD-K00003132-001-01-9	LGD-6972	Phase 2	glucagon receptor antagonist				0	99.07	MedChemEx	HY-12525	LGD-6972	702.313	Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1	HKJMCBYPVCGZFB-LDLOPFEMSA-N	44625560.0		HKJMCBYPVCGZFB
BRD-K16810791-001-02-9	LGK-974	Phase 2	porcupine inhibitor	PORCN			0	89.92	MedChemEx	HY-17545	LGK974	396.17	Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C	XXYGTCZJJLTAGH-UHFFFAOYSA-N	46926973.0		XXYGTCZJJLTAGH
BRD-K16810791-001-01-0	LGK-974	Phase 2	porcupine inhibitor	PORCN			0	97.22	Selleck	S7143	LGK-974	396.17	Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C	XXYGTCZJJLTAGH-UHFFFAOYSA-N	46926973.0		XXYGTCZJJLTAGH
BRD-K47409078-001-01-8	LH846	Preclinical	casein kinase inhibitor	CSNK1D			0	92.8	MedChemEx	HY-15704	LH846	316.044	Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl	DYHAMRNAHTWYKY-UHFFFAOYSA-N	851474.0		DYHAMRNAHTWYKY
BRD-K47409078-001-02-6	LH846	Preclinical	casein kinase inhibitor	CSNK1D			0	97.64	Tocris	4896	LH 846	316.044	Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl	DYHAMRNAHTWYKY-UHFFFAOYSA-N	851474.0		DYHAMRNAHTWYKY
BRD-K00004284-300-01-9	liarozole	Phase 2/Phase 3	cytochrome P450 inhibitor	CYP19A1|CYP26A1			0	95.35	Tocris	2705	Liarozole dihydrochloride	308.083	Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7,r|	UGFHIPBXIWJXNA-QGZVFWFLSA-N	76956376.0		UGFHIPBXIWJXNA
BRD-A22642447-001-02-7	licarbazepine	Phase 3	voltage-gated sodium channel blocker	SCN5A			0	90.45	Tocris	3865	Licarbazepine	254.106	NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|	BMPDWHIDQYTSHX-CQSZACIVSA-N	9816485.0		BMPDWHIDQYTSHX
BRD-A22642447-001-03-9	licarbazepine	Phase 3	voltage-gated sodium channel blocker	SCN5A			0	96.71	Tocris	3865	Licarbazepine	254.106	NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|	BMPDWHIDQYTSHX-CQSZACIVSA-N	9816485.0		BMPDWHIDQYTSHX
BRD-A22642447-001-01-9	licarbazepine	Phase 3	voltage-gated sodium channel blocker	SCN5A			0	98.65	Tocris	3865	Licarbazepine	254.106	NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11,r|	BMPDWHIDQYTSHX-CQSZACIVSA-N	9816485.0		BMPDWHIDQYTSHX
BRD-K99667445-001-03-9	licochalcone-A	Phase 3	topoisomerase inhibitor	PTPN1			0	95.93	MedChemEx	HY-N0372	Licochalcone A	338.152	COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C	KAZSKMJFUPEHHW-DHZHZOJOSA-N	5318998.0		KAZSKMJFUPEHHW
BRD-K08439945-001-03-9	licofelone	Phase 3	cyclooxygenase inhibitor|lipoxygenase inhibitor	ALOX5|PLA2G2E|PTGS2			0	41.88	Adooq	A11697	[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid	379.134	CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1	UAWXGRJVZSAUSZ-UHFFFAOYSA-N	133021.0		UAWXGRJVZSAUSZ
BRD-K08439945-001-01-3	licofelone	Phase 3	cyclooxygenase inhibitor|lipoxygenase inhibitor	ALOX5|PLA2G2E|PTGS2			0	43.46	Selleck	S2121	Licofelone	379.134	CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1	UAWXGRJVZSAUSZ-UHFFFAOYSA-N	133021.0		UAWXGRJVZSAUSZ
BRD-K08439945-001-02-1	licofelone	Phase 3	cyclooxygenase inhibitor|lipoxygenase inhibitor	ALOX5|PLA2G2E|PTGS2			0	34.98	Selleck	S2121	Licofelone	379.134	CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1	UAWXGRJVZSAUSZ-UHFFFAOYSA-N	133021.0		UAWXGRJVZSAUSZ
BRD-K00003504-001-01-9	licogliflozin	Preclinical	sodium/glucose cotransporter inhibitor				0	96.89	MedChemEx	HY-109092	Licogliflozin	416.184	CCc1ccc(cc1Cc1ccc2OCCOc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	XFJAMQQAAMJFGB-ZQGJOIPISA-N	52913524.0		XFJAMQQAAMJFGB
BRD-K81881550-001-03-9	licostinel	Phase 1	NMDA receptor antagonist 				0	91.53	Sigma	MFCD00672687	6,7-dichloro-5-nitro-1,4-dihydro-2,3-quinoxalinedione	274.95	[O-][N+](=O)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12	CHFSOFHQIZKQCR-UHFFFAOYSA-N	5486198.0		CHFSOFHQIZKQCR
BRD-K68693535-001-03-4	lidamidine	Launched	adrenergic receptor agonist		gastroenterology	diarrhea	0	93.96	ChemDiv	8009-0514		220.132	CNC(=N)NC(=O)Nc1c(C)cccc1C	RRHJHSBDJDZUGL-UHFFFAOYSA-N	47510.0		RRHJHSBDJDZUGL
BRD-K52662033-001-19-0	lidocaine	Launched	histamine receptor agonist	EGFR|SCN10A|SCN5A|SCN9A	neurology/psychiatry|dermatology|hematology	itching|eczema|hemorrhage	0	96.67	Selleck	S1357	Lidocaine	234.173	CCN(CC)CC(=O)Nc1c(C)cccc1C	NNJVILVZKWQKPM-UHFFFAOYSA-N	3676.0		NNJVILVZKWQKPM
BRD-K52662033-003-21-2	lidocaine	Launched	histamine receptor agonist	EGFR|SCN10A|SCN5A|SCN9A	neurology/psychiatry|dermatology|hematology	itching|eczema|hemorrhage	0	99.22	MicroSource	1500689	LIDOCAINE HYDROCHLORIDE	234.173	CCN(CC)CC(=O)Nc1c(C)cccc1C	NNJVILVZKWQKPM-UHFFFAOYSA-N	3676.0		NNJVILVZKWQKPM
BRD-K62996583-001-11-9	lidoflazine	Launched	calcium channel blocker	SCN1A|SCN3A|SLC29A1	cardiology	coronary artery disease (CAD)	0	96.79	Sigma	L9668	Lidoflazine	491.275	Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	ZBIAKUMOEKILTF-UHFFFAOYSA-N	3926.0		ZBIAKUMOEKILTF
BRD-K62996583-001-10-3	lidoflazine	Launched	calcium channel blocker	SCN1A|SCN3A|SLC29A1	cardiology	coronary artery disease (CAD)	0	97.89	Prestwick	Prestw-381	Lidoflazine	491.275	Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	ZBIAKUMOEKILTF-UHFFFAOYSA-N	3926.0		ZBIAKUMOEKILTF
BRD-K00003275-001-01-9	lifirafenib	Phase 1/Phase 2	RAF inhibitor				0	96.41	MedChemEx	HY-18957	Lifirafenib	478.125	FC(F)(F)c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2Oc3ccc(Oc4ccnc5NC(=O)CCc45)cc3[C@@H]12	NGFFVZQXSRKHBM-FKBYEOEOSA-N	89670174.0		NGFFVZQXSRKHBM
BRD-K60265345-001-02-9	lifitegrast	Launched	lymphocyte function-associated antigen negative modulator		ophthalmology	dry eye syndrome	0	97.98	MedChemEx	HY-19344	Lifitegrast	614.068	CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3CN(CCc3c2Cl)C(=O)c2ccc3ccoc3c2)C(O)=O)c1	JFOZKMSJYSPYLN-QHCPKHFHSA-N	11965427.0		JFOZKMSJYSPYLN
BRD-K48875051-001-01-0	ligustilide	Preclinical	tumor necrosis factor production inhibitor	TNF			0	87.42	MedChemEx	HY-N0401	Ligustilide	190.099	CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8,13|	IQVQXVFMNOFTMU-FLIBITNWSA-N	5319022.0		IQVQXVFMNOFTMU
BRD-K25015158-001-01-2	limaprost-alfadex	Launched	prostanoid receptor agonist	PTGER1	cardiology	claudication	0	75.34	MedChemEx	HY-B0683	Limaprost	380.256	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	OJZYRQPMEIEQFC-UAWLTFRCSA-N	6438378.0		OJZYRQPMEIEQFC
BRD-K25015158-001-02-0	limaprost-alfadex	Launched	prostanoid receptor agonist	PTGER1	cardiology	claudication	0	93.26	MedChemEx	HY-B0683	Limaprost	380.256	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	OJZYRQPMEIEQFC-UAWLTFRCSA-N	6438378.0		OJZYRQPMEIEQFC
BRD-K75373031-001-02-9	LIMKi-3	Preclinical	LIM kinase inhibitor	LIMK1			0	96.2	Tocris	4745	LIMKi 3	430.023	CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F	IVUGBSGLHRJSSP-UHFFFAOYSA-N	56965901.0		IVUGBSGLHRJSSP
BRD-K75373031-001-01-7	LIMKi-3	Preclinical	LIM kinase inhibitor	LIMK1			0	98.06	Tocris	4745	LIMKi 3	430.023	CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F	IVUGBSGLHRJSSP-UHFFFAOYSA-N	56965901.0		IVUGBSGLHRJSSP
BRD-K05906022-001-05-1	limonin	Preclinical	HIV protease inhibitor				0	92.68	Selleck	S2319	Limonin	470.194	CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1	KBDSLGBFQAGHBE-MSGMIQHVSA-N	179651.0	BRD-K64094723-001-01-5	KBDSLGBFQAGHBE
BRD-K05906022-001-07-9	limonin	Preclinical	HIV protease inhibitor				0	89.75	MedChemEx	HY-17411	Limonin	470.194	CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1	KBDSLGBFQAGHBE-MSGMIQHVSA-N	179651.0		KBDSLGBFQAGHBE
BRD-K00003592-001-01-9	linaclotide	Launched	guanylate cyclase activator	GUCY2C	gastroenterology	irritable bowel syndrome|constipation	0	0.0	MedChemEx	HY-17584	Linaclotide	1525.39	[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	KXGCNMMJRFDFNR-WDRJZQOASA-N	16158208.0		KXGCNMMJRFDFNR
BRD-K96550715-003-01-4	linagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	62.32	MicroSource	1503880	LINAGLIPTIN HYDROCHLORIDE	472.234	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	LTXREWYXXSTFRX-QGZVFWFLSA-N	10096344.0		LTXREWYXXSTFRX
BRD-K96550715-001-03-4	linagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	0.0	MicroSource	1506323	LINAGLIPTIN	472.234	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	LTXREWYXXSTFRX-QGZVFWFLSA-N	10096344.0	BRD-A23155464-001-01-9	LTXREWYXXSTFRX
BRD-K96550715-001-06-9	linagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	95.25	MedChemEx	HY-10284	Linagliptin	472.234	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	LTXREWYXXSTFRX-QGZVFWFLSA-N	10096344.0		LTXREWYXXSTFRX
BRD-K96550715-001-04-2	linagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	88.62	Selleck	S3031	Linagliptin (BI-1356)	472.234	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	LTXREWYXXSTFRX-QGZVFWFLSA-N	10096344.0		LTXREWYXXSTFRX
BRD-K96550715-001-02-6	linagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	85.19	Selleck	S3031	Linagliptin	472.234	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	LTXREWYXXSTFRX-QGZVFWFLSA-N	10096344.0		LTXREWYXXSTFRX
BRD-K01827427-001-05-9	linalool	Phase 1	anticonvulsant				0	0.0	InterBioScreen	STOCK1N-50425		154.136	CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|	CDOSHBSSFJOMGT-JTQLQIEISA-N	443158.0		CDOSHBSSFJOMGT
BRD-K01827427-001-11-9	linalool	Phase 1	anticonvulsant				0	0.0	Sigma	MFCD00008906	Linalool	154.136	CC(C)=CCC[C@@](C)(O)C=C |&1:6,r|	CDOSHBSSFJOMGT-JTQLQIEISA-N	443158.0		CDOSHBSSFJOMGT
BRD-K00003366-001-01-9	linaprazan	Preclinical	ATP-sensitive potassium channel inhibitor				0	96.59	MedChemEx	HY-100412	Linaprazan	366.206	Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO	GHVIMBCFLRTFHI-UHFFFAOYSA-N	9951066.0		GHVIMBCFLRTFHI
BRD-K49384696-311-03-9	lincomycin	Launched	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	0	87.45	MedChemEx	HY-B1358	Lincomycin (hydrochloride hydrate)	406.214	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	OJMMVQQUTAEWLP-KIDUDLJLSA-N	3000540.0		OJMMVQQUTAEWLP
BRD-K49384696-003-04-9	lincomycin	Launched	bacterial 30S ribosomal subunit inhibitor		gastroenterology	enteritis	0	97.1	Selleck	S2479		406.214	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	OJMMVQQUTAEWLP-KIDUDLJLSA-N	3000540.0		OJMMVQQUTAEWLP
BRD-K93814253-001-06-8	lindane	Launched		GABRB1|GLRA1|GLRA2|GLRA3|GLRB	infectious disease	scabies	0	0.0	MedChemEx	HY-A0085	Lindane	287.86	Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl	JLYXXMFPNIAWKQ-GNIYUCBRSA-N			JLYXXMFPNIAWKQ
BRD-K93814253-001-05-0	lindane	Launched		GABRB1|GLRA1|GLRA2|GLRA3|GLRB	infectious disease	scabies	1	0.0	MedChemEx	HY-A0085	Lindane	287.86	Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl	JLYXXMFPNIAWKQ-GNIYUCBRSA-N			JLYXXMFPNIAWKQ
BRD-K93814253-001-04-3	lindane	Launched		GABRB1|GLRA1|GLRA2|GLRA3|GLRB	infectious disease	scabies	1	0.0	MicroSource	330071	LINDANE	287.86	Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl	JLYXXMFPNIAWKQ-GNIYUCBRSA-N			JLYXXMFPNIAWKQ
BRD-K66876909-001-15-9	linezolid	Launched	bacterial 50S ribosomal subunit inhibitor	MAOA|MAOB	infectious disease	pneumonia|skin infections	0	88.93	Tocris	3765	Linezolid	337.144	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	TYZROVQLWOKYKF-ZDUSSCGKSA-N	441401.0		TYZROVQLWOKYKF
BRD-K66876909-001-12-6	linezolid	Launched	bacterial 50S ribosomal subunit inhibitor	MAOA|MAOB	infectious disease	pneumonia|skin infections	0	98.39	MicroSource	1502385	LINEZOLID	337.144	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	TYZROVQLWOKYKF-ZDUSSCGKSA-N	441401.0		TYZROVQLWOKYKF
BRD-K66876909-001-11-8	linezolid	Launched	bacterial 50S ribosomal subunit inhibitor	MAOA|MAOB	infectious disease	pneumonia|skin infections	0	94.8	Selleck	S1408	Linezolid	337.144	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	TYZROVQLWOKYKF-ZDUSSCGKSA-N	441401.0		TYZROVQLWOKYKF
BRD-K99749624-001-11-9	linifanib	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1|CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RET|TEK			0	99.13	MedChemEx	HY-50751	Linifanib	375.15	Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1	MPVGZUGXCQEXTM-UHFFFAOYSA-N	11485656.0		MPVGZUGXCQEXTM
BRD-K99749624-001-07-0	linifanib	Phase 3	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1|CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RET|TEK			0	96.2	Selleck	S1003	Linifanib (ABT-869)	375.15	Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1	MPVGZUGXCQEXTM-UHFFFAOYSA-N	11485656.0		MPVGZUGXCQEXTM
BRD-K08973992-001-06-2	linoleic-acid	Phase 3	oxidative stress inducer	FABP4|FFAR1|FFAR4|HNF4A|KCNB1|PPARG|TRPM8			0	0.0	Sigma	62230	(9Z,12Z)-9,12-octadecadienoic acid	280.24	CCCCC\C=C/C\C=C/CCCCCCCC(O)=O	OYHQOLUKZRVURQ-HZJYTTRNSA-N	5280450.0		OYHQOLUKZRVURQ
BRD-K59332007-300-03-5	linopirdine	Phase 3	potassium channel blocker	KCNQ2|KCNQ3|KCNQ4|KCNQ5			0	98.07	Tocris	1999	Linopirdine dihydrochloride	391.168	O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	YEJCDKJIEMIWRQ-UHFFFAOYSA-N	3932.0		YEJCDKJIEMIWRQ
BRD-K59332007-300-08-9	linopirdine	Phase 3	potassium channel blocker	KCNQ2|KCNQ3|KCNQ4|KCNQ5			0	97.39	Tocris	1999	Linopirdine dihydrochloride	391.168	O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	YEJCDKJIEMIWRQ-UHFFFAOYSA-N	3932.0		YEJCDKJIEMIWRQ
BRD-K59332007-300-02-7	linopirdine	Phase 3	potassium channel blocker	KCNQ2|KCNQ3|KCNQ4|KCNQ5			0	98.43	Tocris	1999	Linopirdine dihydrochloride	391.168	O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	YEJCDKJIEMIWRQ-UHFFFAOYSA-N	3932.0		YEJCDKJIEMIWRQ
BRD-K72922393-003-16-0	linsidomine	Launched	nitric oxide donor		urology	erectile dysfunction	0	94.73	EMDBio	567028-20MG	SIN-1, Hydrochloride	170.08	Nc1c[n+](no1)N1CCOCC1	XZYRDNUZENBYFI-UHFFFAOYSA-N	65388.0	BRD-K72922393-003-15-2|BRD-K72922393-003-15-2	XZYRDNUZENBYFI
BRD-K72922393-003-17-8	linsidomine	Launched	nitric oxide donor		urology	erectile dysfunction	0	0.0	Cayman	82220		170.08	Nc1c[n+](no1)N1CCOCC1	XZYRDNUZENBYFI-UHFFFAOYSA-N	65388.0		XZYRDNUZENBYFI
BRD-K86118762-001-08-9	linsitinib	Phase 3	IGF-1 inhibitor	IGF1R|INSR|INSRR			0	95.36	MedChemEx	HY-10191	Linsitinib	421.19	C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|	PKCDDUHJAFVJJB-VLZXCDOPSA-N			PKCDDUHJAFVJJB
BRD-K86118762-001-01-8	linsitinib	Phase 3	IGF-1 inhibitor	IGF1R|INSR|INSRR			0	88.41	Selleck	S1091	OSI-906 (Linsitinib)	421.19	C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|	PKCDDUHJAFVJJB-VLZXCDOPSA-N			PKCDDUHJAFVJJB
BRD-K86118762-001-05-9	linsitinib	Phase 3	IGF-1 inhibitor	IGF1R|INSR|INSRR			0	87.1	Selleck	S1091	OSI-906 (Linsitinib)	421.19	C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|	PKCDDUHJAFVJJB-VLZXCDOPSA-N			PKCDDUHJAFVJJB
BRD-K00004744-001-01-9	lintopride	Preclinical	serotonin receptor antagonist				0	42.76	MedChemEx	HY-U00121	Lintopride	310.12	CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC |c:5|	MJCKISCWHDATBN-UHFFFAOYSA-N	65900.0		MJCKISCWHDATBN
BRD-K89152108-236-12-9	liothyronine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	hypothyroidism|myxedema coma	0	94.37	Tocris	5552	Liothyronine sodium	650.79	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-LBPRGKRZSA-N	7048703.0		AUYYCJSJGJYCDS
BRD-K89152108-236-06-8	liothyronine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	hypothyroidism|myxedema coma	0	27.8	MicroSource	1502047	LIOTHYRONINE (L- isomer) SODIUM	650.79	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-LBPRGKRZSA-N	7048703.0		AUYYCJSJGJYCDS
BRD-K89152108-236-08-4	liothyronine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	hypothyroidism|myxedema coma	0	88.33	Sigma	T2752-100MG	3,3',5-triiodo-L-thronine sodium salt	650.79	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-LBPRGKRZSA-N	7048703.0		AUYYCJSJGJYCDS
BRD-K89152108-236-05-0	liothyronine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	hypothyroidism|myxedema coma	0	6.83	Selleck	S4217	Liothyronine Sodium	650.79	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-LBPRGKRZSA-N	7048703.0		AUYYCJSJGJYCDS
BRD-K89152108-236-07-6	liothyronine	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	hypothyroidism|myxedema coma	0	87.3	Selleck	S4217	Liothyronine Sodium	650.79	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-LBPRGKRZSA-N	7048703.0		AUYYCJSJGJYCDS
BRD-K46428823-001-02-5	liothyronine-(isomer)	Preclinical					0	94.02	MicroSource	1500778	LIOTHYRONINE	650.79	N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	AUYYCJSJGJYCDS-GFCCVEGCSA-N	71212.0		AUYYCJSJGJYCDS
BRD-A14440173-001-03-4	lipoamide	Preclinical					0	70.53	MicroSource	1505740	LIPOAMIDE	205.06	NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	FCCDDURTIIUXBY-ZETCQYMHSA-N	446116.0		FCCDDURTIIUXBY
BRD-A14440173-001-04-9	lipoamide	Preclinical					0	80.3	MedChemEx	HY-B1142	Lipoamide	205.06	NC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	FCCDDURTIIUXBY-ZETCQYMHSA-N	446116.0		FCCDDURTIIUXBY
BRD-K39084158-001-08-9	liquiritin	Preclinical	antioxidant				0	0.0	MedChemEx	HY-N0376	Liquiritin	418.126	OC[C@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2CC(=O)c3ccc(O)cc3O2)[C@H](O)[C@@H](O)[C@@H]1O	DEMKZLAVQYISIA-ZRWXNEIDSA-N	503737.0		DEMKZLAVQYISIA
BRD-K00003717-001-01-9	liraglutide	Launched	GLP receptor agonist	GLP1R	endocrinology	weight-loss aid|diabetes mellitus	0	88.44	MedChemEx	HY-P0014	Liraglutide	3748.946	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O	YSDQQAXHVYUZIW-QCIJIYAXSA-N	16153050.0		YSDQQAXHVYUZIW
BRD-K35775715-001-04-9	liranaftate	Launched	fungal squalene epoxidase inhibitor		infectious disease	fungal infection	0	99.2	MedChemEx	HY-B0348	Liranaftate	328.125	COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1	VPHPQNGOVQYUMG-UHFFFAOYSA-N	3936.0		VPHPQNGOVQYUMG
BRD-K35775715-001-03-1	liranaftate	Launched	fungal squalene epoxidase inhibitor		infectious disease	fungal infection	0	97.22	Selleck	S1997	Liranaftate	328.125	COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1	VPHPQNGOVQYUMG-UHFFFAOYSA-N	3936.0		VPHPQNGOVQYUMG
BRD-K31339321-001-03-6	lirimilast	Phase 2	phosphodiesterase inhibitor				0	87.13	Enamine	Z1629752566		441.979	CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl	YPFLFUJKZDAXRA-UHFFFAOYSA-N	6433118.0		YPFLFUJKZDAXRA
BRD-A76533773-001-01-9	lisadimate	Launched	topical sunscreen agent		dermatology	sunscreen lotion	0	78.91	Sigma	MFCD00017109	2,3-dihydroxypropyl 4-aminobenzoate	211.084	Nc1ccc(cc1)C(=O)OC[C@@H](O)CO |&1:11,r|	WHQOKFZWSDOTQP-VIFPVBQESA-N	25021707.0		WHQOKFZWSDOTQP
BRD-K67966701-335-15-9	lisinopril	Launched	angiotensin converting enzyme inhibitor	ACE|ACE2	cardiology|endocrinology	hypertension|congestive heart failure|diabetes mellitus	0	76.98	MedChemEx	HY-18206A	Lisinopril (dihydrate)	405.226	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	RLAWWYSOJDYHDC-BZSNNMDCSA-N	5362119.0		RLAWWYSOJDYHDC
BRD-K67966701-001-11-6	lisinopril	Launched	angiotensin converting enzyme inhibitor	ACE|ACE2	cardiology|endocrinology	hypertension|congestive heart failure|diabetes mellitus	0	96.45	MicroSource	1501217	LISINOPRIL	405.226	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	RLAWWYSOJDYHDC-BZSNNMDCSA-N	5362119.0		RLAWWYSOJDYHDC
BRD-K67966701-001-10-8	lisinopril	Launched	angiotensin converting enzyme inhibitor	ACE|ACE2	cardiology|endocrinology	hypertension|congestive heart failure|diabetes mellitus	0	4.7	Selleck	S2076	Lisinopril (Zestril)	405.226	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	RLAWWYSOJDYHDC-BZSNNMDCSA-N	5362119.0		RLAWWYSOJDYHDC
BRD-K67966701-001-12-4	lisinopril	Launched	angiotensin converting enzyme inhibitor	ACE|ACE2	cardiology|endocrinology	hypertension|congestive heart failure|diabetes mellitus	0	100.0	Selleck	S2076	Lisinopril (Zestril)	405.226	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	RLAWWYSOJDYHDC-BZSNNMDCSA-N	5362119.0		RLAWWYSOJDYHDC
BRD-A05334458-001-02-8	lisofylline	Phase 2	interleukin receptor antagonist|STAT inhibitor				0	99.2	Enzo	LP102	Lisofylline	280.154	C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|	NSMXQKNUPPXBRG-SECBINFHSA-N	501254.0		NSMXQKNUPPXBRG
BRD-A05334458-001-03-9	lisofylline	Phase 2	interleukin receptor antagonist|STAT inhibitor				0	95.91	AMS	H0117	(+/-)-Lisofylline	280.154	C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1,r|	NSMXQKNUPPXBRG-SECBINFHSA-N	501254.0		NSMXQKNUPPXBRG
BRD-K67943528-050-01-4	lisuride	Launched	dopamine receptor agonist	ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6	neurology/psychiatry	Parkinson's Disease	0	92.31	Enzo	AC1560	Lisuride Maleate	338.211	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	BKRGVLQUQGGVSM-KBXCAEBGSA-N	28864.0		BKRGVLQUQGGVSM
BRD-K67943528-050-03-9	lisuride	Launched	dopamine receptor agonist	ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6	neurology/psychiatry	Parkinson's Disease	0	94.64	Tocris	4052	Lisuride maleate	338.211	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	BKRGVLQUQGGVSM-KBXCAEBGSA-N	28864.0		BKRGVLQUQGGVSM
BRD-K73234506-235-02-1	lithium-acetoacetate	Preclinical		FAH			1	0.0	SantaCruz	sc-215253		102.032	CC(=O)CC(O)=O	WDJHALXBUFZDSR-UHFFFAOYSA-N	96.0		WDJHALXBUFZDSR
BRD-M41245765-001-04-2	lithium-citrate	Launched			neurology/psychiatry	bipolar disorder|depression	1	0.0	MicroSource	1504269	LITHIUM CITRATE	213.075	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	PTYJGLZVOMGTRG-UHFFFAOYSA-N			PTYJGLZVOMGTRG
BRD-M41245765-001-05-9	lithium-citrate	Launched			neurology/psychiatry	bipolar disorder|depression	1	0.0	Selleck	S4399	lithium citrate	213.075	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	PTYJGLZVOMGTRG-UHFFFAOYSA-N		BRD-M83658881-001-01-0	PTYJGLZVOMGTRG
BRD-M41245765-001-03-4	lithium-citrate	Launched			neurology/psychiatry	bipolar disorder|depression	1	0.0	Selleck	S4399	Lithium Citrate	213.075	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	PTYJGLZVOMGTRG-UHFFFAOYSA-N			PTYJGLZVOMGTRG
BRD-M41245765-341-06-9	lithium-citrate	Launched			neurology/psychiatry	bipolar disorder|depression	1	0.0	Selleck	S4399		213.075	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	PTYJGLZVOMGTRG-UHFFFAOYSA-N		BRD-M41245765-001-06-9|BRD-M41245765-001-06-9|BRD-M41245765-001-06-9|BRD-M41245765-001-06-9	PTYJGLZVOMGTRG
BRD-K20986251-001-14-9	lithocholic-acid	Preclinical	FXR antagonist|vitamin D receptor agonist	GPBAR1|NR1H4|NR1I2|VDR			0	98.5	MedChemEx	HY-B0172	Lithocholic acid	376.298	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	SMEROWZSTRWXGI-HVATVPOCSA-N	9903.0		SMEROWZSTRWXGI
BRD-K83029223-001-01-3	litronesib	Phase 2	kinesin-like spindle protein inhibitor	KIF11			0	94.34	MedChemEx	HY-14846	Litronesib	511.229	CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|	YVAFBXLHPINSIK-QHCPKHFHSA-N	25167017.0		YVAFBXLHPINSIK
BRD-K59391348-001-01-7	lixivaptan	Phase 3	vasopressin receptor antagonist	AVPR2			0	89.39	Carbosynth	FL24915	N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methylbenzamide	473.131	Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1	PPHTXRNHTVLQED-UHFFFAOYSA-N	172997.0		PPHTXRNHTVLQED
BRD-K70404782-001-02-9	LM-22A4	Preclinical	tropomyosin receptor kinase inhibitor	NTRK2			0	98.49	Tocris	4607	LM 22A4	339.143	OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO	RGWJKANXFYJKHN-UHFFFAOYSA-N	2054170.0		RGWJKANXFYJKHN
BRD-K70404782-001-01-6	LM-22A4	Preclinical	tropomyosin receptor kinase inhibitor	NTRK2			0	98.29	Tocris	4607	LM 22A4	339.143	OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO	RGWJKANXFYJKHN-UHFFFAOYSA-N	2054170.0		RGWJKANXFYJKHN
BRD-K08532119-001-02-9	LMI070	Phase 1/Phase 2	survival motor neuron protein modulator	SMN1			0	96.92	MedChemEx	HY-19620	Branaplam	393.216	CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1	STWTUEAWRAIWJG-UHFFFAOYSA-N	135565042.0		STWTUEAWRAIWJG
BRD-K08532119-001-01-5	LMI070	Phase 1/Phase 2	survival motor neuron protein modulator	SMN1			0	96.89	MedChemEx	HY-19620	LMI070	393.216	CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1	STWTUEAWRAIWJG-UHFFFAOYSA-N	135565042.0		STWTUEAWRAIWJG
BRD-K49921286-001-02-6	LMK-235	Preclinical	HDAC inhibitor	HDAC4|HDAC5			0	82.85	Tocris	4830	LMK 235	294.158	Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO	VRYZCEONIWEUAV-UHFFFAOYSA-N	71520717.0		VRYZCEONIWEUAV
BRD-K49921286-001-01-8	LMK-235	Preclinical	HDAC inhibitor	HDAC4|HDAC5			0		Selleck	S7569	LMK-235	294.158	Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO	InChI=1S/C15H22N2O4/c1-11-8-12(2)10-13(9-11)15(19)17-21-7-5-3-4-6-14(18)16-20/h8-10,20H,3-7H2,1-2H3,(H,16,18)(H,17,19)	71520717.0		VRYZCEONIWEUAV
BRD-A04649065-001-01-7	LM11A-31	Phase 1	neurotrophic agent	NGFR			0	94.1	Enamine	Z393627376	2-amino-3-methyl-N-[2-(4-morpholinyl)ethyl]pentanamide	243.195	CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2,&2:4,r|	YNMUTYLWSRFTPX-GHMZBOCLSA-N	28174760.0		YNMUTYLWSRFTPX
BRD-K66206289-003-22-1	lobeline	Launched	acetylcholine receptor antagonist	CHRNA10|CHRNA9|SLC18A2	neurology/psychiatry	smoking cessation	0	65.76	MedChemEx	HY-B0979	Lobeline (hydrochloride)	337.204	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	MXYUKLILVYORSK-HBMCJLEFSA-N	101616.0		MXYUKLILVYORSK
BRD-K66206289-065-01-4	lobeline	Launched	acetylcholine receptor antagonist	CHRNA10|CHRNA9|SLC18A2	neurology/psychiatry	smoking cessation	0	56.2	Sigma	MFCD00135592	sulfuric acid compound with 2-{(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methyl-2-piperidinyl}-1-phenylethanone (1:2)	337.204	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	MXYUKLILVYORSK-HBMCJLEFSA-N	101616.0	BRD-M82226456-065-01-7	MXYUKLILVYORSK
BRD-K66206289-003-20-5	lobeline	Launched	acetylcholine receptor antagonist	CHRNA10|CHRNA9|SLC18A2	neurology/psychiatry	smoking cessation	0	62.05	Tocris	1077	(-)-Lobeline hydrochloride	337.204	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	MXYUKLILVYORSK-HBMCJLEFSA-N	101616.0		MXYUKLILVYORSK
BRD-K66206289-003-23-9	lobeline	Launched	acetylcholine receptor antagonist	CHRNA10|CHRNA9|SLC18A2	neurology/psychiatry	smoking cessation	0	63.97	Enzo	ALX-420-023-G001	Lobeline hydrochloride	337.204	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	MXYUKLILVYORSK-HBMCJLEFSA-N	101616.0		MXYUKLILVYORSK
BRD-K66206289-003-21-3	lobeline	Launched	acetylcholine receptor antagonist	CHRNA10|CHRNA9|SLC18A2	neurology/psychiatry	smoking cessation	0	63.02	MedChemEx	HY-B0979	Lobeline (hydrochloride)	337.204	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	MXYUKLILVYORSK-HBMCJLEFSA-N	101616.0		MXYUKLILVYORSK
BRD-K15834839-001-02-3	lobendazole	Preclinical	anthelmintic agent				0	93.92	MicroSource	1505440	LOBENDAZOLE	205.085	CCOC(=O)Nc1nc2ccccc2[nH]1	OKOVSTKGUBOSTB-UHFFFAOYSA-N	22752.0		OKOVSTKGUBOSTB
BRD-K15834839-001-04-9	lobendazole	Preclinical	anthelmintic agent				0	96.55	AMS	A001501590	ethyl 1H-benzimidazol-2-ylcarbamate	205.085	CCOC(=O)Nc1nc2ccccc2[nH]1	OKOVSTKGUBOSTB-UHFFFAOYSA-N	22752.0		OKOVSTKGUBOSTB
BRD-K55847762-304-01-7	lobenzarit	Launched	immunosuppressant		rheumatology	rheumatoid arthritis	0	98.34	AKSci	K046		291.03	OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O	UGDPYGKWIHHBMB-UHFFFAOYSA-N	3946.0		UGDPYGKWIHHBMB
BRD-K00004554-001-01-9	lodenosine	Phase 2	antiretroviral 				0	90.21	Sigma	MFCD00871105	((2S,4S,5R)-5-(6-amino-9H-purin-9-yl)-4-fluorotetrahydrofuran-2-yl)methanol	253.098	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@@H]1F	KBEMFSMODRNJHE-JFWOZONXSA-N	72180.0		KBEMFSMODRNJHE
BRD-K66937583-001-01-2	lodoxamide	Launched	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	0	94.05	Prestwick	Prestw-1746	Lodoxamide	310.995	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	RVGLGHVJXCETIO-UHFFFAOYSA-N	44564.0		RVGLGHVJXCETIO
BRD-K66937583-001-02-9	lodoxamide	Launched	histamine receptor antagonist		ophthalmology	vernal keratoconjunctivitis (VKC)	0	88.2	MedChemEx	HY-14270	Lodoxamide	310.995	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	RVGLGHVJXCETIO-UHFFFAOYSA-N	44564.0		RVGLGHVJXCETIO
BRD-K06388517-001-01-2	lofemizole	Phase 3	cyclooxygenase inhibitor				0	98.71	AMS	A001365113	5-(4-chlorophenyl)-4-methyl-1H-imidazole	192.045	Cc1[nH]cnc1-c1ccc(Cl)cc1	MBKWNJVQSFBLQI-UHFFFAOYSA-N	71967.0		MBKWNJVQSFBLQI
BRD-K82147103-003-05-6	lofepramine	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR1A|SLC6A2|SLC6A4	neurology/psychiatry	depression	0	46.37	Key	KS-1301	1-(4-chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl](methyl)amino]ethanone hydrochloride	418.181	CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1	SAPNXPWPAUFAJU-UHFFFAOYSA-N	3947.0		SAPNXPWPAUFAJU
BRD-K82147103-001-02-7	lofepramine	Launched	norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	HTR1A|SLC6A2|SLC6A4	neurology/psychiatry	depression	0	5.55	Tocris	2545	Lofepramine	418.181	CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1	SAPNXPWPAUFAJU-UHFFFAOYSA-N	3947.0		SAPNXPWPAUFAJU
BRD-A02990301-003-05-8	lofexidine	Launched	adrenergic receptor agonist		neurology/psychiatry	opioid withdrawal	0	96.55	Selleck	S4400	Lofexidine  HCl	258.033	C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|	KSMAGQUYOIHWFS-SSDOTTSWSA-N	3038503.0		KSMAGQUYOIHWFS
BRD-A02990301-003-06-6	lofexidine	Launched	adrenergic receptor agonist		neurology/psychiatry	opioid withdrawal	0	97.02	MicroSource	1502357	LOFEXIDINE  HYDROCHLORIDE	258.033	C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|	KSMAGQUYOIHWFS-SSDOTTSWSA-N	3038503.0		KSMAGQUYOIHWFS
BRD-A02990301-003-07-4	lofexidine	Launched	adrenergic receptor agonist		neurology/psychiatry	opioid withdrawal	0	96.51	Selleck	S4400	Lofexidine  HCl	258.033	C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r,t:12|	KSMAGQUYOIHWFS-SSDOTTSWSA-N	3038503.0		KSMAGQUYOIHWFS
BRD-K01825701-003-03-9	lomefloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	respiratory tract infections|urinary tract infections	0	92.58	MedChemEx	HY-B0455	Lomefloxacin (hydrochloride)	351.139	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|	ZEKZLJVOYLTDKK-VIFPVBQESA-N	6603903.0		ZEKZLJVOYLTDKK
BRD-K01825701-213-01-9	lomefloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	respiratory tract infections|urinary tract infections	0	98.31	MicroSource	1502037	LOMEFLOXACIN	412.192	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|	ZEKZLJVOYLTDKK-VIFPVBQESA-N	6603903.0		ZEKZLJVOYLTDKK
BRD-K27955832-001-05-2	lomeguatrib	Phase 2	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			0	71.63	Tocris	4359	Lomeguatrib	324.963	Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	JUJPKFNFCWJBCX-UHFFFAOYSA-N	3025944.0		JUJPKFNFCWJBCX
BRD-K27955832-001-02-9	lomeguatrib	Phase 2	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			0	97.23	Selleck	S8056	Lomeguatrib	324.963	Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	JUJPKFNFCWJBCX-UHFFFAOYSA-N	3025944.0		JUJPKFNFCWJBCX
BRD-K62858456-001-01-8	lomerizine	Launched	calcium channel blocker	CACNA1B|SCN5A	neurology/psychiatry	migraine headache	0	97.88	MicroSource	1502303	LOMERIZINE HYDROCHLORIDE	468.222	COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	JQSAYKKFZOSZGJ-UHFFFAOYSA-N	3949.0		JQSAYKKFZOSZGJ
BRD-K62858456-300-01-4	lomerizine	Launched	calcium channel blocker	CACNA1B|SCN5A	neurology/psychiatry	migraine headache	0	97.44	Selleck	S4084	Lomerizine HCl	468.222	COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	JQSAYKKFZOSZGJ-UHFFFAOYSA-N	3949.0		JQSAYKKFZOSZGJ
BRD-K66036108-001-01-9	lometrexol	Phase 2	glycinamide ribonucleotide formyltransferase inhibitor	GART			0	66.91	Cayman	18049	(2S)-2-[(4-{2-[(6R)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl]ethyl}benzoyl)amino]pentanedioic acid	443.18	Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	ZUQBAQVRAURMCL-DOMZBBRYSA-N	135413518.0		ZUQBAQVRAURMCL
BRD-K92213669-001-01-3	lomitapide	Launched	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	0	91.88	MedChemEx	HY-14667	Lomitapide	693.279	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	MBBCVAKAJPKAKM-UHFFFAOYSA-N	9853053.0		MBBCVAKAJPKAKM
BRD-K92213669-001-02-9	lomitapide	Launched	microsomal trigylceride transfer protein inhibitor	MTTP	endocrinology	hypercholesterolemia	0	97.29	MedChemEx	HY-14667	Lomitapide	693.279	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	MBBCVAKAJPKAKM-UHFFFAOYSA-N	9853053.0		MBBCVAKAJPKAKM
BRD-K51768138-001-10-9	lomustine	Launched	DNA synthesis inhibitor		hematologic malignancy|oncology	Hodgkin's lymphoma|brain tumors	0	0.0	MedChemEx	HY-13669	Lomustine	233.093	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	NEXPKUGJJKVILF-UHFFFAOYSA-N	129009938.0		NEXPKUGJJKVILF
BRD-K51768138-001-09-1	lomustine	Launched	DNA synthesis inhibitor		hematologic malignancy|oncology	Hodgkin's lymphoma|brain tumors	0	0.0	MedChemEx	HY-13669	Lomustine	233.093	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	NEXPKUGJJKVILF-UHFFFAOYSA-N	129009938.0		NEXPKUGJJKVILF
BRD-K51768138-001-04-2	lomustine	Launched	DNA synthesis inhibitor		hematologic malignancy|oncology	Hodgkin's lymphoma|brain tumors	0	0.0	Selleck	S1840	Lomustine	233.093	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	NEXPKUGJJKVILF-UHFFFAOYSA-N	129009938.0		NEXPKUGJJKVILF
BRD-K51768138-001-05-9	lomustine	Launched	DNA synthesis inhibitor		hematologic malignancy|oncology	Hodgkin's lymphoma|brain tumors	0	0.0	MicroSource	1502301	LOMUSTINE	233.093	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	NEXPKUGJJKVILF-UHFFFAOYSA-N	129009938.0		NEXPKUGJJKVILF
BRD-K51768138-001-07-5	lomustine	Launched	DNA synthesis inhibitor		hematologic malignancy|oncology	Hodgkin's lymphoma|brain tumors	0	0.0	Selleck	S1840	Lomustine (CeeNU)	233.093	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	NEXPKUGJJKVILF-UHFFFAOYSA-N	129009938.0		NEXPKUGJJKVILF
BRD-K41599323-001-02-3	lonafarnib	Phase 3	farnesyltransferase inhibitor	FNTA|HRAS|KRAS|NRAS			0	97.47	Selleck	S2797	Lonafarnib	636.05	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	DHMTURDWPRKSOA-RUZDIDTESA-N	148195.0		DHMTURDWPRKSOA
BRD-K41599323-001-03-1	lonafarnib	Phase 3	farnesyltransferase inhibitor	FNTA|HRAS|KRAS|NRAS			0	98.27	Cayman	11746	Lonafarnib	636.05	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1	148195.0		DHMTURDWPRKSOA
BRD-K78513633-001-16-5	lonidamine	Launched	glucokinase inhibitor	GCK			0	97.72	Tocris	1646	Lonidamine	320.012	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	WDRYRZXSPDWGEB-UHFFFAOYSA-N	39562.0		WDRYRZXSPDWGEB
BRD-K78513633-001-15-7	lonidamine	Launched	glucokinase inhibitor	GCK			0	98.47	MicroSource	1503225	LONIDAMINE	320.012	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	WDRYRZXSPDWGEB-UHFFFAOYSA-N	39562.0		WDRYRZXSPDWGEB
BRD-K78513633-001-17-9	lonidamine	Launched	glucokinase inhibitor	GCK			0	96.46	Tocris	1646	Lonidamine	320.012	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	WDRYRZXSPDWGEB-UHFFFAOYSA-N	39562.0		WDRYRZXSPDWGEB
BRD-K78513633-001-13-2	lonidamine	Launched	glucokinase inhibitor	GCK			0	94.96	Selleck	S2610	Lonidamine	320.012	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	WDRYRZXSPDWGEB-UHFFFAOYSA-N	39562.0		WDRYRZXSPDWGEB
BRD-K78513633-001-14-0	lonidamine	Launched	glucokinase inhibitor	GCK			0	97.39	Tocris	1646	Lonidamine	320.012	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	WDRYRZXSPDWGEB-UHFFFAOYSA-N	39562.0		WDRYRZXSPDWGEB
BRD-K61250553-003-32-2	loperamide	Launched	opioid receptor agonist	CACNA1A|CALM1|OPRD1|OPRK1|OPRM1|POMC	gastroenterology	diarrhea	0	98.87	MicroSource	2300241	LOPERAMIDE HYDROCHLORIDE	476.223	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	RDOIQAHITMMDAJ-UHFFFAOYSA-N	3955.0		RDOIQAHITMMDAJ
BRD-K61250553-003-30-6	loperamide	Launched	opioid receptor agonist	CACNA1A|CALM1|OPRD1|OPRK1|OPRM1|POMC	gastroenterology	diarrhea	0	98.09	Tocris	840	Loperamide hydrochloride	476.223	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	RDOIQAHITMMDAJ-UHFFFAOYSA-N	3955.0		RDOIQAHITMMDAJ
BRD-K61250553-003-29-8	loperamide	Launched	opioid receptor agonist	CACNA1A|CALM1|OPRD1|OPRK1|OPRM1|POMC	gastroenterology	diarrhea	0	98.08	Selleck	S2480	Loperamide HCl	476.223	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	RDOIQAHITMMDAJ-UHFFFAOYSA-N	3955.0		RDOIQAHITMMDAJ
BRD-K99451608-001-07-3	lopinavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	98.22	Selleck	S1380	Lopinavir	628.362	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1	KJHKTHWMRKYKJE-SUGCFTRWSA-N	92727.0		KJHKTHWMRKYKJE
BRD-K99451608-001-08-9	lopinavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	98.9	MedChemEx	HY-14588	Lopinavir	628.362	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1	KJHKTHWMRKYKJE-SUGCFTRWSA-N	92727.0		KJHKTHWMRKYKJE
BRD-K28935038-001-02-2	loracarbef	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|pulmonary	ear infections|laryngitis|bronchitis|pneumonia|urinary tract infections|skin infections	0	24.5	Prestwick	Prestw-1431	Loracarbef	349.083	N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	JAPHQRWPEGVNBT-UTUOFQBUSA-N	5284585.0		JAPHQRWPEGVNBT
BRD-K28935038-002-03-9	loracarbef	Launched	bacterial cell wall synthesis inhibitor		infectious disease|otolaryngology|pulmonary	ear infections|laryngitis|bronchitis|pneumonia|urinary tract infections|skin infections	0	90.89	Toronto	L469553	loracarbef monohydrate	349.083	N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	JAPHQRWPEGVNBT-UTUOFQBUSA-N	5284585.0		JAPHQRWPEGVNBT
BRD-K82795137-001-28-8	loratadine	Launched	histamine receptor antagonist	HRH1	allergy|neurology/psychiatry	allergic rhinitis|itching	0	98.19	Tocris	1944	Loratidine	382.145	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	JCCNYMKQOSZNPW-UHFFFAOYSA-N	3957.0		JCCNYMKQOSZNPW
BRD-K82795137-001-26-2	loratadine	Launched	histamine receptor antagonist	HRH1	allergy|neurology/psychiatry	allergic rhinitis|itching	0	99.62	MicroSource	1503712	LORATADINE	382.145	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	JCCNYMKQOSZNPW-UHFFFAOYSA-N	3957.0		JCCNYMKQOSZNPW
BRD-K82795137-001-24-7	loratadine	Launched	histamine receptor antagonist	HRH1	allergy|neurology/psychiatry	allergic rhinitis|itching	0	98.36	Selleck	S1358	Loratadine	382.145	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	JCCNYMKQOSZNPW-UHFFFAOYSA-N	3957.0		JCCNYMKQOSZNPW
BRD-K82795137-001-29-9	loratadine	Launched	histamine receptor antagonist	HRH1	allergy|neurology/psychiatry	allergic rhinitis|itching	0	97.35	Tocris	1944	Loratidine	382.145	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	JCCNYMKQOSZNPW-UHFFFAOYSA-N	3957.0		JCCNYMKQOSZNPW
BRD-K82795137-001-25-4	loratadine	Launched	histamine receptor antagonist	HRH1	allergy|neurology/psychiatry	allergic rhinitis|itching	0	98.38	Tocris	1944	Loratidine	382.145	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	JCCNYMKQOSZNPW-UHFFFAOYSA-N	3957.0		JCCNYMKQOSZNPW
BRD-K09659835-003-02-9	loreclezole	Phase 2	benzodiazepine receptor agonist	GABRB2|GABRB3			0	96.98	Tocris	1295	Loreclezole hydrochloride	272.963	Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl	XGLHZTBDUXXHOM-WMZJFQQLSA-N	3034012.0		XGLHZTBDUXXHOM
BRD-K09659835-003-01-4	loreclezole	Phase 2	benzodiazepine receptor agonist	GABRB2|GABRB3			0	98.11	Tocris	1295	Loreclezole hydrochloride	272.963	Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl	XGLHZTBDUXXHOM-WMZJFQQLSA-N	3034012.0		XGLHZTBDUXXHOM
BRD-K42066335-001-01-0	lorediplon	Phase 2	GABA receptor modulator	GABRA1			0	97.58	MedChemEx	HY-19371	Lorediplon	394.09	CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1	NQPOCLFSADOXBR-UHFFFAOYSA-N	12004146.0		NQPOCLFSADOXBR
BRD-K01825818-236-02-9	lorglumide	Phase 1	CCK receptor antagonist	CCKAR|CCKBR			0	98.26	MedChemEx	HY-B1439B	Lorglumide sodium salt	458.174	CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13,r|	IEKOTSCYBBDIJC-LJQANCHMSA-N	13605417.0		IEKOTSCYBBDIJC
BRD-K99879819-001-03-9	lorlatinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK	oncology	non-small cell lung cancer (NSCLC)	0	95.48	Tocris	5640	PF 06463922	406.155	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	IIXWYSCJSQVBQM-UHFFFAOYSA-N	78162481.0		IIXWYSCJSQVBQM
BRD-K99879819-001-02-1	lorlatinib	Launched	ALK tyrosine kinase receptor inhibitor	ALK	oncology	non-small cell lung cancer (NSCLC)	0	98.73	MedChemEx	HY-12215	(R)-2(6)-amino-5(5)-fluoro-1(1),4,7-trimethyl-6-oxo-1(1)H-3-oxa-7-aza-2(3,5)-pyridina-1(4,3)-pyrazola-5(1,2)-benzenacyclooctaphane-1(5)-carbonitrile	406.155	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	IIXWYSCJSQVBQM-UHFFFAOYSA-N	78162481.0		IIXWYSCJSQVBQM
BRD-A90551241-001-09-0	lornoxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology|neurology/psychiatry	osteoarthritis|sciata	0	95.77	Selleck	S2047	Lornoxicam	370.98	CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|	WLHQHAUOOXYABV-UHFFFAOYSA-N	54690031.0		WLHQHAUOOXYABV
BRD-A90551241-001-10-8	lornoxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology|neurology/psychiatry	osteoarthritis|sciata	0	97.64	MicroSource	1502302	LORNOXICAM	370.98	CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|	WLHQHAUOOXYABV-UHFFFAOYSA-N	54690031.0		WLHQHAUOOXYABV
BRD-K76205745-237-22-9	losartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology|nephrology	hypertension|diabetic nephropathy|hypertension	0	98.08	MedChemEx	HY-17512A	Losartan (potassium)	422.162	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	PSIFNNKUMBGKDQ-UHFFFAOYSA-N	3961.0		PSIFNNKUMBGKDQ
BRD-K76205745-001-06-6	losartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology|nephrology	hypertension|diabetic nephropathy|hypertension	0	94.69	MicroSource	1504268	LOSARTAN	422.162	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	PSIFNNKUMBGKDQ-UHFFFAOYSA-N	3961.0		PSIFNNKUMBGKDQ
BRD-K76205745-237-19-9	losartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology|nephrology	hypertension|diabetic nephropathy|hypertension	0	91.17	Tocris	3798	Losartan potassium	422.162	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	PSIFNNKUMBGKDQ-UHFFFAOYSA-N	3961.0		PSIFNNKUMBGKDQ
BRD-K76205745-237-16-5	losartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology|nephrology	hypertension|diabetic nephropathy|hypertension	0	97.85	Selleck	S1359	Losartan Potassium (DuP 753)	422.162	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	PSIFNNKUMBGKDQ-UHFFFAOYSA-N	3961.0		PSIFNNKUMBGKDQ
BRD-K76205745-237-18-1	losartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology|nephrology	hypertension|diabetic nephropathy|hypertension	0	97.14	Pharmeks	PHBB_SC-09765.obs1160624	potassium 5-(4'-((2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)biphenyl-2-yl)tetrazol-1-ide	422.162	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	PSIFNNKUMBGKDQ-UHFFFAOYSA-N	3961.0		PSIFNNKUMBGKDQ
BRD-K56195681-001-04-9	losmapimod	Phase 3	p38 MAPK inhibitor	MAPK14			0	92.58	MedChemEx	HY-10402	Losmapimod	383.201	Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1	KKYABQBFGDZVNQ-UHFFFAOYSA-N	11552706.0		KKYABQBFGDZVNQ
BRD-K56195681-001-01-0	losmapimod	Phase 3	p38 MAPK inhibitor	MAPK14			0	96.05	MedChemEx	HY-10402	Losmapimod	383.201	Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1	KKYABQBFGDZVNQ-UHFFFAOYSA-N	11552706.0		KKYABQBFGDZVNQ
BRD-K00003137-001-01-9	lotamilast	Preclinical	phosphodiesterase inhibitor				0	90.93	MedChemEx	HY-12740	Lotamilast	472.175	CNc1nc(-c2cccc(NC(=O)c3ccc(cc3)C(=O)OC)c2)c2cc(OC)c(OC)cc2n1	BBTFKAOFCSOZMB-UHFFFAOYSA-N	24864553.0		BBTFKAOFCSOZMB
BRD-K39983086-001-06-1	loteprednol	Launched	glucocorticoid receptor agonist|phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	0	95.55	Selleck	S1669	Loteprednol etabonate	466.176	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|	DMKSVUSAATWOCU-HROMYWEYSA-N	444025.0		DMKSVUSAATWOCU
BRD-K39983086-001-07-9	loteprednol	Launched	glucocorticoid receptor agonist|phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	0	16.47	Selleck	S1669	Loteprednol etabonate	466.176	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|	DMKSVUSAATWOCU-HROMYWEYSA-N	444025.0	BRD-K43659793-001-01-6	DMKSVUSAATWOCU
BRD-K39983086-001-08-9	loteprednol	Launched	glucocorticoid receptor agonist|phospholipase inhibitor	NR3C1	ophthalmology	conjunctivitis	0	90.8	MedChemEx	HY-17358	Loteprednol Etabonate	466.176	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17,t:13|	DMKSVUSAATWOCU-HROMYWEYSA-N	444025.0		DMKSVUSAATWOCU
BRD-K09416995-001-43-1	lovastatin	Launched	HMGCR inhibitor	HDAC2|HMGCR|ITGAL|NR1I2	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia	0	83.52	Tocris	1530	Lovastatin	404.256	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|	PCZOHLXUXFIOCF-BXMDZJJMSA-N	53232.0		PCZOHLXUXFIOCF
BRD-K09416995-001-39-9	lovastatin	Launched	HMGCR inhibitor	HDAC2|HMGCR|ITGAL|NR1I2	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia	0	86.13	MicroSource	1503977	LOVASTATIN	404.256	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|	PCZOHLXUXFIOCF-BXMDZJJMSA-N	53232.0		PCZOHLXUXFIOCF
BRD-K09416995-001-44-9	lovastatin	Launched	HMGCR inhibitor	HDAC2|HMGCR|ITGAL|NR1I2	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia	0	69.68	Selleck	S2061	Lovastatin	404.256	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|	PCZOHLXUXFIOCF-BXMDZJJMSA-N	53232.0	BRD-K74251557-001-01-0	PCZOHLXUXFIOCF
BRD-K09416995-001-40-7	lovastatin	Launched	HMGCR inhibitor	HDAC2|HMGCR|ITGAL|NR1I2	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia	0	89.65	Selleck	S2061	Lovastatin (Mevacor)	404.256	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|	PCZOHLXUXFIOCF-BXMDZJJMSA-N	53232.0		PCZOHLXUXFIOCF
BRD-K09416995-001-38-1	lovastatin	Launched	HMGCR inhibitor	HDAC2|HMGCR|ITGAL|NR1I2	cardiology|endocrinology	coronary heart disease|myocardial infarction|hypercholesterolemia	0	78.66	Tocris	1530	Lovastatin	404.256	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13,t:11|	PCZOHLXUXFIOCF-BXMDZJJMSA-N	53232.0		PCZOHLXUXFIOCF
BRD-K39915878-036-25-1	loxapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	schizophrenia	0	98.5	MicroSource	2300242	LOXAPINE SUCCINATE	327.114	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|	XJGVXQDUIWGIRW-UHFFFAOYSA-N	3964.0		XJGVXQDUIWGIRW
BRD-K39915878-036-24-4	loxapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	schizophrenia	0	98.55	Selleck	S4086	Loxapine Succinate	327.114	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|	XJGVXQDUIWGIRW-UHFFFAOYSA-N	3964.0		XJGVXQDUIWGIRW
BRD-K39915878-001-26-9	loxapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	schizophrenia	0	97.64	MedChemEx	HY-17390	Loxapine	327.114	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|	XJGVXQDUIWGIRW-UHFFFAOYSA-N	3964.0		XJGVXQDUIWGIRW
BRD-K21937671-001-10-0	loxistatin-acid	Preclinical	cysteine peptidase inhibitor	CTSB			0	89.34	Selleck	S7392	Loxistatin Acid (E-64C)	314.184	CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	SCMSYZJDIQPSDI-SRVKXCTJSA-N	123664.0	BRD-A44872635-001-01-8	SCMSYZJDIQPSDI
BRD-K21937671-001-09-2	loxistatin-acid	Preclinical	cysteine peptidase inhibitor	CTSB			0	98.39	Selleck	S7392	Loxistatin Acid (E-64C)	314.184	CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	SCMSYZJDIQPSDI-SRVKXCTJSA-N	123664.0		SCMSYZJDIQPSDI
BRD-K21937671-001-11-8	loxistatin-acid	Preclinical	cysteine peptidase inhibitor	CTSB			0	84.73	Selleck	S7392	Loxistatin Acid (E-64C)	314.184	CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	SCMSYZJDIQPSDI-SRVKXCTJSA-N	123664.0		SCMSYZJDIQPSDI
BRD-K01825691-001-04-9	loxoprofen	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	0	87.89	MedChemEx	HY-B0578	Loxoprofen	246.126	C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|	YMBXTVYHTMGZDW-ZWNOBZJWSA-N	13049027.0		YMBXTVYHTMGZDW
BRD-K01825691-001-01-9	loxoprofen	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	0	98.61	MicroSource	1502386	LOXOPROFEN	246.126	C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|	YMBXTVYHTMGZDW-ZWNOBZJWSA-N	13049027.0	BRD-A18039798-001-01-9	YMBXTVYHTMGZDW
BRD-K01825691-001-02-9	loxoprofen	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	PTGS2	neurology/psychiatry	pain relief	0	98.22	MedChemEx	HY-B0578	Loxoprofen	246.126	C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1,&2:10,r|	YMBXTVYHTMGZDW-ZWNOBZJWSA-N	13049027.0		YMBXTVYHTMGZDW
BRD-K00004673-001-01-9	LP-533401	Preclinical	tryptophan hydroxylase inhibitor				0	93.29	Adooq	A14325.obs1190502	LP-533401	526.163	N[C@@H](Cc1ccc(cc1)-c1cc(O[C@@H](c2ccc(cc2)-c2cccc(F)c2)C(F)(F)F)nc(N)n1)C(O)=O |&1:13|	JZWUKILTKYJLCN-URXFXBBRSA-N	124424929.0		JZWUKILTKYJLCN
BRD-K32322923-001-01-7	LPA2-antagonist-1	Preclinical	lysophosphatidic acid receptor antagonist	LPAR2			0	97.22	MedChemEx	HY-18075	LPA2 antagonist 1	499.067	C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12	BPRNMVDTWIHULJ-AWEZNQCLSA-N	24882686.0		BPRNMVDTWIHULJ
BRD-K01436366-001-22-2	LRRK2-IN-1	Preclinical	leucine rich repeat kinase inhibitor	LRRK2			0	98.57	Tocris	4273	LRRK2-IN-1	570.307	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	IWMCPJZTADUIFX-UHFFFAOYSA-N	46843906.0		IWMCPJZTADUIFX
BRD-K01436366-001-20-6	LRRK2-IN-1	Preclinical	leucine rich repeat kinase inhibitor	LRRK2			0	96.6	MedChemEx	HY-10875	LRRK2-IN-1	570.307	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	IWMCPJZTADUIFX-UHFFFAOYSA-N	46843906.0		IWMCPJZTADUIFX
BRD-K79337272-001-02-9	LSN-2463359	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	94.08	Tocris	5275	LSN 2463359	265.122	CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1	STAFRSGTRKNXHF-UHFFFAOYSA-N	72551298.0		STAFRSGTRKNXHF
BRD-K79337272-001-01-6	LSN-2463359	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	96.1	Tocris	5275	LSN 2463359	265.122	CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1	STAFRSGTRKNXHF-UHFFFAOYSA-N	72551298.0		STAFRSGTRKNXHF
BRD-K00004675-001-01-9	LSZ-102	Phase 1	selective estrogen receptor modulator (SERM)				0	93.38	MedChemEx	HY-111486	(E)-3-[4-[2-[2-(1,1-difluoroethyl)-4-fluoro-phenyl]-6-hydroxy-benzothiophen-3-yl]oxyphenyl]prop-2-enoic acid	470.08	CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1	SJXNPGGVGZXKKI-NYYWCZLTSA-N	118574930.0		SJXNPGGVGZXKKI
BRD-K52914072-001-01-5	LTA	Phase 2					0	94.91	Enamine	Z2372279192	N-phenyl-2-thiophenecarboximidamide	202.056	N=C(Nc1ccccc1)c1cccs1	RCORNHOUCUDCAC-UHFFFAOYSA-N	10219864.0		RCORNHOUCUDCAC
BRD-K53124401-001-03-8	LTB4	Phase 2	leukocyte activator	LTB4R|LTB4R2			0	8.37	Enzo	LB004	Leukotriene B4	336.23	CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O	VNYSSYRCGWBHLG-AMOLWHMGSA-N	5280492.0		VNYSSYRCGWBHLG
BRD-K00003300-001-01-9	LTX-315	Phase 2	anticancer agent				0	95.27	MedChemEx	HY-19894	LTX-315	1438.839	NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	GGAKLYWEFZCVIT-TVEKFXMRSA-N	46200994.0		GGAKLYWEFZCVIT
BRD-K83970940-001-02-9	Lu-AA-47070	Phase 2	adenosine receptor antagonist	ADORA2A			0	80.24	Tocris	4783	Lu AA 47070	463.078	CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O	MSWIQSFUBYCFJE-PGMHBOJBSA-N			MSWIQSFUBYCFJE
BRD-K83970940-001-01-0	Lu-AA-47070	Phase 2	adenosine receptor antagonist	ADORA2A			0	88.17	Tocris	4783	Lu AA 47070	463.078	CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O	MSWIQSFUBYCFJE-PGMHBOJBSA-N			MSWIQSFUBYCFJE
BRD-K33814251-001-03-9	lubiprostone	Launched	chloride channel activator	CLCN2	gastroenterology	constipation|irritable bowel syndrome	0	96.6	MedChemEx	HY-B0679	Lubiprostone	390.222	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	DBVFKLAGQHYVGQ-BFYDXBDKSA-N	9800568.0		DBVFKLAGQHYVGQ
BRD-K33814251-001-01-4	lubiprostone	Launched	chloride channel activator	CLCN2	gastroenterology	constipation|irritable bowel syndrome	0	98.91	Selleck	S1675	Lubiprostone	390.222	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	DBVFKLAGQHYVGQ-BFYDXBDKSA-N	9800568.0		DBVFKLAGQHYVGQ
BRD-K33814251-001-02-2	lubiprostone	Launched	chloride channel activator	CLCN2	gastroenterology	constipation|irritable bowel syndrome	0	82.47	Selleck	S1675	Lubiprostone	390.222	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	DBVFKLAGQHYVGQ-BFYDXBDKSA-N	9800568.0	BRD-K58693165-001-01-7	DBVFKLAGQHYVGQ
BRD-K00003521-001-01-9	lucanthone	Phase 2	endonuclease inhibitor	APEX1|TOP1|TOP2A			0	96.37	MedChemEx	HY-B2098	Lucanthone	340.161	CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12	FBQPGGIHOFZRGH-UHFFFAOYSA-N	10180.0		FBQPGGIHOFZRGH
BRD-K31309378-001-01-5	lucitanib	Phase 2	FGFR inhibitor|VEGFR inhibitor	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET			0	91.38	MedChemEx	HY-15391	E-3810	443.185	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12	CUDVHEFYRIWYQD-UHFFFAOYSA-N	25031915.0		CUDVHEFYRIWYQD
BRD-K31309378-001-02-3	lucitanib	Phase 2	FGFR inhibitor|VEGFR inhibitor	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET			0		MedChemEx	HY-15391	6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxy-4-quinolinyl}oxy)-N-methyl-1-naphthamide	443.185	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12	InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)	25031915.0		CUDVHEFYRIWYQD
BRD-K67079690-001-02-9	LUF-5834	Preclinical	adenosine receptor agonist	ADORA2A|ADORA2B			0	96.51	Tocris	4603	LUF 5834	348.079	Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N	OFHKDLYFKPBXER-UHFFFAOYSA-N	135543624.0		OFHKDLYFKPBXER
BRD-K67079690-001-01-2	LUF-5834	Preclinical	adenosine receptor agonist	ADORA2A|ADORA2B			0	98.27	Tocris	4603	LUF 5834	348.079	Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N	OFHKDLYFKPBXER-UHFFFAOYSA-N	135543624.0		OFHKDLYFKPBXER
BRD-A71774530-001-05-9	lufenuron	Launched	chitin inhibitor		infectious disease	flea control	0	97.07	MicroSource	1505355	LUFENURON	509.978	F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|	PWPJGUXAGUPAHP-AWEZNQCLSA-N	51574136.0		PWPJGUXAGUPAHP
BRD-A71774530-001-06-9	lufenuron	Launched	chitin inhibitor		infectious disease	flea control	0	97.89	Sigma	31662	Lufenuron	509.978	F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1,r|	PWPJGUXAGUPAHP-AWEZNQCLSA-N	51574136.0		PWPJGUXAGUPAHP
BRD-K71058253-001-02-9	luliconazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	98.72	MedChemEx	HY-14283	Luliconazole	352.961	Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1	YTAOBBFIOAEMLL-REQDGWNSSA-N	3003141.0		YTAOBBFIOAEMLL
BRD-K71058253-001-01-9	luliconazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	92.75	Selleck	S4258	Luliconazole	352.961	Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1	YTAOBBFIOAEMLL-REQDGWNSSA-N	3003141.0		YTAOBBFIOAEMLL
BRD-K69236721-001-03-9	lumacaftor	Launched	CFTR channel agonist	CFTR	pulmonary	cystic fibrosis	0	98.1	MedChemEx	HY-13262	Lumacaftor	452.118	Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O	UFSKUSARDNFIRC-UHFFFAOYSA-N	16678941.0		UFSKUSARDNFIRC
BRD-K69236721-001-02-7	lumacaftor	Launched	CFTR channel agonist	CFTR	pulmonary	cystic fibrosis	0	98.26	Selleck	S1565	VX-809 (Lumacaftor)	452.118	Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O	UFSKUSARDNFIRC-UHFFFAOYSA-N	16678941.0		UFSKUSARDNFIRC
BRD-K10031916-075-02-1	lumateperone	Launched	dopamine receptor modulator|serotonin receptor antagonist	DRD2|HTR2A			0	81.32	MedChemEx	HY-19733	lumateperone (Tosylate)	393.222	CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23	HOIIHACBCFLJET-SFTDATJTSA-N	21302490.0		HOIIHACBCFLJET
BRD-K10031916-075-01-3	lumateperone	Launched	dopamine receptor modulator|serotonin receptor antagonist	DRD2|HTR2A			0	74.89	MedChemEx	HY-19733	lumateperone (Tosylate)	393.222	CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23	HOIIHACBCFLJET-SFTDATJTSA-N	21302490.0		HOIIHACBCFLJET
BRD-A05926236-001-04-6	lumefantrine	Launched	antimalarial agent	ATP1A1	infectious disease	malaria	0	58.57	MedChemEx	HY-B0803	Lumefantrine	527.155	CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|	DYLGFOYVTXJFJP-OXTLUBNBSA-N	73416445.0		DYLGFOYVTXJFJP
BRD-A05926236-001-05-3	lumefantrine	Launched	antimalarial agent	ATP1A1	infectious disease	malaria	0	54.26	Enamine	Z1541758602		527.155	CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|	DYLGFOYVTXJFJP-OXTLUBNBSA-N	73416445.0	BRD-A58804007-001-01-4	DYLGFOYVTXJFJP
BRD-A05926236-001-03-8	lumefantrine	Launched	antimalarial agent	ATP1A1	infectious disease	malaria	0	49.03	MedChemEx	HY-B0803	Lumefantrine	527.155	CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10,r|	DYLGFOYVTXJFJP-OXTLUBNBSA-N	73416445.0		DYLGFOYVTXJFJP
BRD-K26901728-001-06-2	lumiracoxib	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	97.35	MicroSource	1502387	LUMIRACOXIB	293.062	Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1	KHPKQFYUPIUARC-UHFFFAOYSA-N	151166.0		KHPKQFYUPIUARC
BRD-K26901728-001-05-4	lumiracoxib	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	94.13	Selleck	S2903	Lumiracoxib	293.062	Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1	KHPKQFYUPIUARC-UHFFFAOYSA-N	151166.0		KHPKQFYUPIUARC
BRD-K00004532-009-01-9	lupanine	Phase 1	sodium channel blocker	INS			0	91.3	ChemDiv	N010-0020	Lupanine	248.189	[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H]	JYIJIIVLEOETIQ-XDQVBPFNSA-N	91471.0		JYIJIIVLEOETIQ
BRD-K51143828-003-03-1	lurasidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA2A|ADRA2C|DRD2|HTR1A|HTR2A|HTR7	neurology/psychiatry	schizophrenia	0	97.97	Selleck	S3044	Lurasidone HCl	492.256	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12	PQXKDMSYBGKCJA-CVTJIBDQSA-N	213046.0		PQXKDMSYBGKCJA
BRD-K00003211-001-01-9	lurbinectedin	Phase 3	DNA binding agent				0	93.93	MedChemEx	HY-16293	Lurbinectedin	784.278	[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1c3[nH]c2ccc(OC)cc12 |THB:16:15:2.3.12:20.19.17|	YDDMIZRDDREKEP-HWTBNCOESA-N	57327016.0		YDDMIZRDDREKEP
BRD-K00004742-001-01-9	lusaperidone	Preclinical	adrenergic receptor antagonist				0	92.42	MedChemEx	HY-U00117	Lusaperidone	359.163	Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1	ZYXHQIPQIKTEDI-UHFFFAOYSA-N	3045401.0		ZYXHQIPQIKTEDI
BRD-K93228461-001-02-9	lusutrombopag	Launched	thrombopoietin receptor agonist				0	97.11	MedChemEx	HY-19883	Lusutrombopag	590.141	CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(\C=C(/C)C(O)=O)c(Cl)c3)n2)c1OC	NOZIJMHMKORZBA-KJCUYJGMSA-N	49843517.0		NOZIJMHMKORZBA
BRD-K16742848-001-02-6	lutein	Launched	antioxidant		ophthalmology	macular degeneration|cataracts|retinitis pigmentosa (RP)	0	0.0	Sigma	X6250	(3R,3'R,6R)-4,5-didehydro-5,6-dihydro-beta,beta-carotene-3,3'-diol	568.428	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|	KBPHJBAIARWVSC-RGZFRNHPSA-N	5281243.0		KBPHJBAIARWVSC
BRD-K16742848-001-01-8	lutein	Launched	antioxidant		ophthalmology	macular degeneration|cataracts|retinitis pigmentosa (RP)	0	0.0	AKSci	N653		568.428	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11,33|	KBPHJBAIARWVSC-RGZFRNHPSA-N	5281243.0		KBPHJBAIARWVSC
BRD-K05236810-001-19-0	luteolin	Phase 2	glucosidase inhibitor	TOP1			0	92.4	Selleck	S2320	Luteolin	286.048	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1	IQPNAANSBPBGFQ-UHFFFAOYSA-N	5280445.0		IQPNAANSBPBGFQ
BRD-K67013324-001-04-9	luzindole	Preclinical	melatonin receptor antagonist	MTNR1A|MTNR1B			0	89.41	Tocris	877	Luzindole	292.158	CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	WVVXBPKOIZGVNS-UHFFFAOYSA-N	122162.0		WVVXBPKOIZGVNS
BRD-K67013324-001-05-9	luzindole	Preclinical	melatonin receptor antagonist	MTNR1A|MTNR1B			0	86.54	Tocris	877	Luzindole	292.158	CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	WVVXBPKOIZGVNS-UHFFFAOYSA-N	122162.0		WVVXBPKOIZGVNS
BRD-K67013324-001-03-1	luzindole	Preclinical	melatonin receptor antagonist	MTNR1A|MTNR1B			0	40.77	Tocris	877	Luzindole	292.158	CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	WVVXBPKOIZGVNS-UHFFFAOYSA-N	122162.0		WVVXBPKOIZGVNS
BRD-K00003107-001-01-9	LXH254	Phase 1	RAF inhibitor				0	97.62	MedChemEx	HY-112089	LXH254	502.183	Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(OCCO)nc(c1)N1CCOCC1	UEPXBTCUIIGYCY-UHFFFAOYSA-N	90456533.0		UEPXBTCUIIGYCY
BRD-K54520417-001-02-9	LXR-623	Phase 1	LXR agonist	AR|NR1H2|NR1H3|NR1I2|NR3C1			0	97.88	MedChemEx	HY-10629	LXR-623	422.061	Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F	KYWWJENKIMRJBI-UHFFFAOYSA-N	16734800.0		KYWWJENKIMRJBI
BRD-K54520417-001-01-2	LXR-623	Phase 1	LXR agonist	AR|NR1H2|NR1H3|NR1I2|NR3C1			0	99.59	MedChemEx	HY-10629	LXR-623	422.061	Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F	KYWWJENKIMRJBI-UHFFFAOYSA-N	16734800.0		KYWWJENKIMRJBI
BRD-K00003425-001-01-9	LXS196	Phase 1	PKC inhibitor				0	94.13	MedChemEx	HY-101569	LXS196	472.195	CC1(N)CCN(CC1)c1cccnc1NC(=O)c1nc(cnc1N)-c1ncccc1C(F)(F)F	XXJXHXJWQSCNPX-UHFFFAOYSA-N	118873253.0		XXJXHXJWQSCNPX
BRD-K32101625-001-01-6	LX1031	Phase 2	tryptophan hydroxylase inhibitor	TPH1			0	93.2	MedChemEx	HY-13041	LX-1031	538.183	COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	XNMUICFMGGQSMZ-WIOPSUGQSA-N	23633604.0		XNMUICFMGGQSMZ
BRD-K32101625-001-02-9	LX1031	Phase 2	tryptophan hydroxylase inhibitor	TPH1			0	92.94	MedChemEx	HY-13041	LX-1031	538.183	COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	XNMUICFMGGQSMZ-WIOPSUGQSA-N	23633604.0		XNMUICFMGGQSMZ
BRD-K21038058-001-02-7	LX7101	Phase 1/Phase 2	LIM kinase inhibitor|rho associated kinase inhibitor	LIMK2|ROCK1|ROCK2			0	81.88	MedChemEx	HY-12659	LX7101	451.233	CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1	PWPNYABQEOGNNC-UHFFFAOYSA-N	56962369.0		PWPNYABQEOGNNC
BRD-K21038058-001-01-9	LX7101	Phase 1/Phase 2	LIM kinase inhibitor|rho associated kinase inhibitor	LIMK2|ROCK1|ROCK2			0	78.88	MedChemEx	HY-12659	LX7101	451.233	CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1	PWPNYABQEOGNNC-UHFFFAOYSA-N	56962369.0		PWPNYABQEOGNNC
BRD-K37083340-001-02-3	lycopene	Launched	free radical scavenger				1	0.0	AKSci	70759		536.438	CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	OAIJSZIZWZSQBC-GYZMGTAESA-N	446925.0		OAIJSZIZWZSQBC
BRD-K62289640-003-05-9	lylamine	Preclinical	cannabinoid receptor agonist	CNR1			0	100.0	Tocris	2139	Leelamine hydrochloride	285.246	CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1	JVVXZOOGOGPDRZ-SLFFLAALSA-N	62034.0		JVVXZOOGOGPDRZ
BRD-K62289640-003-02-7	lylamine	Preclinical	cannabinoid receptor agonist	CNR1			0	69.31	Tocris	2139	Leelamine hydrochloride	285.246	CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1	JVVXZOOGOGPDRZ-SLFFLAALSA-N	62034.0		JVVXZOOGOGPDRZ
BRD-K00004536-001-01-9	lymecycline	Launched	bacterial 50S ribosomal subunit inhibitor		dermatology	acne vulgaris (AV)	0	0.0	Key	KS-1366	(2S)-6-{[({[(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenyl]carbonyl}amino)methyl]amino}-2-aminohexanoic acid	602.259	CN(C)[C@H]1[C@@H]2C[C@H]3[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)[C@H](C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O |&1:7,&2:26|	DZTKAWPWXGIREW-KKSKXDPKSA-N			DZTKAWPWXGIREW
BRD-K39707084-001-05-8	lynestrenol	Launched	progestogen hormone		endocrinology	contraceptive	0	0.0	Sigma	MFCD00051135	(17beta)-17-ethynylestr-4-en-17-ol	284.214	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	YNVGQYHLRCDXFQ-XGXHKTLJSA-N	5857.0		YNVGQYHLRCDXFQ
BRD-K39707084-001-04-1	lynestrenol	Launched	progestogen hormone		endocrinology	contraceptive	0	0.0	Prestwick	Prestw-95	Lynestrenol	284.214	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	YNVGQYHLRCDXFQ-XGXHKTLJSA-N	5857.0		YNVGQYHLRCDXFQ
BRD-K93331255-001-03-9	lypressin	Launched	vasopressin receptor agonist	AVPR1A|AVPR1B|AVPR2	endocrinology	central diabetes insipidus	0	57.73	MedChemEx	HY-P0004	Lysipressin	1055.432	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	BJFIDCADFRDPIO-KKSWSVFASA-N	133588927.0		BJFIDCADFRDPIO
BRD-K93331255-001-02-0	lypressin	Launched	vasopressin receptor agonist	AVPR1A|AVPR1B|AVPR2	endocrinology	central diabetes insipidus	0	70.31	Apollo	BITH3033		1055.432	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	BJFIDCADFRDPIO-KKSWSVFASA-N	133588927.0		BJFIDCADFRDPIO
BRD-K78055238-001-01-8	LY2090314	Phase 2	glycogen synthase kinase inhibitor	GSK3B			0	98.37	MedChemEx	HY-16294	LY2090314	512.197	Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|	HRJWTAWVFDCTGO-UHFFFAOYSA-N	10029385.0		HRJWTAWVFDCTGO
BRD-K78055238-001-03-9	LY2090314	Phase 2	glycogen synthase kinase inhibitor	GSK3B			0	96.21	MedChemEx	HY-16294	LY2090314	512.197	Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|	HRJWTAWVFDCTGO-UHFFFAOYSA-N	10029385.0		HRJWTAWVFDCTGO
BRD-K47557313-001-02-7	LY2109761	Preclinical	TGF beta receptor inhibitor	TGFBR1|TGFBR2			0	98.4	Selleck	S2704	LY2109761	441.216	C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1	IHLVSLOZUHKNMQ-UHFFFAOYSA-N	11655119.0		IHLVSLOZUHKNMQ
BRD-K47557313-001-03-9	LY2109761	Preclinical	TGF beta receptor inhibitor	TGFBR1|TGFBR2			0	94.39	MedChemEx	HY-12075	LY2109761	441.216	C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1	IHLVSLOZUHKNMQ-UHFFFAOYSA-N	11655119.0		IHLVSLOZUHKNMQ
BRD-K49519144-001-04-6	LY2140023	Phase 3	glutamate receptor agonist	GRM3			0	100.0	Selleck	S6001	LY2140023 (LY404039)	235.015	N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	AVDUGNCTZRCAHH-MDASVERJSA-N	9834591.0		AVDUGNCTZRCAHH
BRD-K49519144-001-03-8	LY2140023	Phase 3	glutamate receptor agonist	GRM3			0	0.0	Selleck	S6001	LY404039	235.015	N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	AVDUGNCTZRCAHH-MDASVERJSA-N	9834591.0		AVDUGNCTZRCAHH
BRD-K34313798-001-01-6	LY215490	Phase 1	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4|GRIK1			0	100.0	MedChemEx	HY-75704	Tezampanel	279.17	OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1	ZXFRFPSZAKNPQQ-YTWAJWBKSA-N	127894.0		ZXFRFPSZAKNPQQ
BRD-K78118466-001-03-3	LY2157299	Phase 2/Phase 3	TGF beta receptor inhibitor	TGFBR1			0	97.81	Selleck	S2230	LY2157299	369.159	Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O	IVRXNBXKWIJUQB-UHFFFAOYSA-N	10090485.0		IVRXNBXKWIJUQB
BRD-K78118466-001-04-9	LY2157299	Phase 2/Phase 3	TGF beta receptor inhibitor	TGFBR1			0	97.67	MedChemEx	HY-13226	Galunisertib	369.159	Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O	IVRXNBXKWIJUQB-UHFFFAOYSA-N	10090485.0		IVRXNBXKWIJUQB
BRD-K37865504-001-05-8	LY2183240	Preclinical	FAAH inhibitor|FAAH reuptake inhibitor	FAAH			0	96.05	Tocris	2452	LY 2183240	307.143	CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1	GZNIYOXWFCDBBJ-UHFFFAOYSA-N	11507802.0		GZNIYOXWFCDBBJ
BRD-K37865504-001-04-1	LY2183240	Preclinical	FAAH inhibitor|FAAH reuptake inhibitor	FAAH			0	95.66	Tocris	2452	LY 2183240	307.143	CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1	GZNIYOXWFCDBBJ-UHFFFAOYSA-N	11507802.0		GZNIYOXWFCDBBJ
BRD-K59227464-334-02-4	LY2228820	Phase 2	p38 MAPK inhibitor	MAPK14			0	94.21	Selleck	S1494	LY2228820	420.244	CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C	XPPBBJCBDOEXDN-UHFFFAOYSA-N	11539025.0		XPPBBJCBDOEXDN
BRD-K59227464-334-03-2	LY2228820	Phase 2	p38 MAPK inhibitor	MAPK14			0	76.85	Selleck	S1494	LY2228820	420.244	CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C	XPPBBJCBDOEXDN-UHFFFAOYSA-N	11539025.0		XPPBBJCBDOEXDN
BRD-K59227464-334-04-9	LY2228820	Phase 2	p38 MAPK inhibitor	MAPK14			0	99.32	MedChemEx	HY-13241	Ralimetinib dimesylate	420.244	CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C	XPPBBJCBDOEXDN-UHFFFAOYSA-N	11539025.0		XPPBBJCBDOEXDN
BRD-K35367061-001-01-1	LY223982	Phase 2	leukotriene receptor antagonist	LTB4R			0	95.19	Cayman	10010024	3-(3-(2-carboxyethyl)-4-{[(5E)-6-(4-methoxyphenyl)-5-hexenyl]oxy}benzoyl)benzoic acid	502.199	COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1	SYZSSLLFRVDRHL-QPJJXVBHSA-N	6444688.0		SYZSSLLFRVDRHL
BRD-K33864865-001-03-3	LY225910	Preclinical	CCK receptor antagonist	CCKBR			0	98.13	Tocris	1018	LY 225910	501.105	CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	KUECXUACQOYKNB-UHFFFAOYSA-N	4355450.0		KUECXUACQOYKNB
BRD-K33864865-001-04-9	LY225910	Preclinical	CCK receptor antagonist	CCKBR			0	96.81	Tocris	1018	LY 225910	501.105	CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	KUECXUACQOYKNB-UHFFFAOYSA-N	4355450.0		KUECXUACQOYKNB
BRD-K33864865-001-02-5	LY225910	Preclinical	CCK receptor antagonist	CCKBR			0	97.94	Tocris	1018	LY 225910	501.105	CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	KUECXUACQOYKNB-UHFFFAOYSA-N	4355450.0		KUECXUACQOYKNB
BRD-K85804405-003-01-3	LY231617	Preclinical	lipid peroxidase inhibitor				0	90.52	Otava	4920201	2,6-ditert-butyl-4-[(ethylamino)methyl]phenol hydrochloride	263.225	CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	WQNYIWJBDGLKEB-UHFFFAOYSA-N	3968.0		WQNYIWJBDGLKEB
BRD-K04993719-001-01-7	LY2334737	Phase 1	antitumor agent|ribonucleotide reductase inhibitor				0	95.83	MedChemEx	HY-13672	LY2334737	389.176	CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	MEOYFIHNRBNEPI-UXIGCNINSA-N	11646777.0		MEOYFIHNRBNEPI
BRD-K04993719-001-02-9	LY2334737	Phase 1	antitumor agent|ribonucleotide reductase inhibitor				0	95.54	MedChemEx	HY-13672	LY2334737	389.176	CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	MEOYFIHNRBNEPI-UXIGCNINSA-N	11646777.0		MEOYFIHNRBNEPI
BRD-K13888115-003-03-0	LY2365109	Preclinical	glycine transporter inhibitor	SLC6A9			0	97.65	Tocris	3397	LY 2365109 hydrochloride	385.189	CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O	FKPLJWGRBCQLTL-UHFFFAOYSA-N	11552757.0		FKPLJWGRBCQLTL
BRD-K13888115-003-02-2	LY2365109	Preclinical	glycine transporter inhibitor	SLC6A9			0	96.74	Tocris	3397	LY 2365109 hydrochloride	385.189	CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O	FKPLJWGRBCQLTL-UHFFFAOYSA-N	11552757.0		FKPLJWGRBCQLTL
BRD-K90171280-001-01-4	LY2452473	Phase 2	androgen receptor modulator	AR			0	82.38	Sigma	MFCD14666518	isopropyl (2S)-7-cyano-4-(2-pyridinylmethyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-2-ylcarbamate	374.174	CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N	IHIWYQYVBNODSV-KRWDZBQOSA-N	24963749.0		IHIWYQYVBNODSV
BRD-K00003131-001-01-9	LY2510924	Phase 2	CC chemokine receptor antagonist				0	97.77	MedChemEx	HY-12488	LY2510924	1188.681	[H][C@]1(CCCN=C(N)N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O	IJHWVENTEFSNBC-FHYZPQNHSA-N			IJHWVENTEFSNBC
BRD-K92492521-001-03-7	LY255283	Preclinical	leukotriene receptor antagonist	LTB4R|LTB4R2			0	94.82	Tocris	2208	LY 255283	360.216	CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1	WCGXJPFHTHQNJL-UHFFFAOYSA-N	122023.0		WCGXJPFHTHQNJL
BRD-K92492521-001-02-9	LY255283	Preclinical	leukotriene receptor antagonist	LTB4R|LTB4R2			0	97.51	Tocris	2208	LY 255283	360.216	CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1	WCGXJPFHTHQNJL-UHFFFAOYSA-N	122023.0		WCGXJPFHTHQNJL
BRD-K92492521-001-05-9	LY255283	Preclinical	leukotriene receptor antagonist	LTB4R|LTB4R2			0	94.25	Tocris	2208	LY 255283	360.216	CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1	WCGXJPFHTHQNJL-UHFFFAOYSA-N	122023.0		WCGXJPFHTHQNJL
BRD-K21833260-075-01-1	LY2584702	Phase 1	ribosomal protein inhibitor	RPS6KB1			0	98.81	Selleck	S7704	LY2584702 Tosylate	445.164	Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F	FYXRSVDHGLUMHB-UHFFFAOYSA-N	25118925.0		FYXRSVDHGLUMHB
BRD-K21833260-075-02-9	LY2584702	Phase 1	ribosomal protein inhibitor	RPS6KB1			0	98.31	Adooq	A15527	4-(4-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-1H-imidazol-2-yl)piperidin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine 4-methylbenzenesulfonate	445.164	Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F	FYXRSVDHGLUMHB-UHFFFAOYSA-N	25118925.0		FYXRSVDHGLUMHB
BRD-K14109347-001-05-9	LY2603618	Phase 2	CHK inhibitor	CHEK1			0	90.74	Selleck	S2626	LY2603618 (IC-83)	435.091	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	SYYBDNPGDKKJDU-ZDUSSCGKSA-N	11955855.0		SYYBDNPGDKKJDU
BRD-K14109347-001-06-9	LY2603618	Phase 2	CHK inhibitor	CHEK1			0	90.89	MedChemEx	HY-14720	Rabusertib	435.091	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	SYYBDNPGDKKJDU-ZDUSSCGKSA-N	11955855.0		SYYBDNPGDKKJDU
BRD-K14109347-001-03-4	LY2603618	Phase 2	CHK inhibitor	CHEK1			0	83.7	Selleck	S2626	LY2603618	435.091	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	SYYBDNPGDKKJDU-ZDUSSCGKSA-N	11955855.0		SYYBDNPGDKKJDU
BRD-K20463415-300-01-4	LY2606368	Phase 2	CHK inhibitor	CHEK1			0	97.61	MedChemEx	HY-18174A	LY2606368 (dihydrochloride)	365.16	COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1	DOTGPNHGTYJDEP-UHFFFAOYSA-N	46700756.0		DOTGPNHGTYJDEP
BRD-K20463415-001-01-8	LY2606368	Phase 2	CHK inhibitor	CHEK1			0	86.86	MedChemEx	HY-18174	LY2606368	365.16	COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1	DOTGPNHGTYJDEP-UHFFFAOYSA-N	46700756.0		DOTGPNHGTYJDEP
BRD-K12068470-001-03-3	LY2608204	Phase 2	glucokinase activator	GCK			0	73.7	MedChemEx	HY-13529	LY2608204	559.2	O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	QIIVJLHCZUTGSD-CUBQBAPOSA-N	46832368.0		QIIVJLHCZUTGSD
BRD-K12068470-001-05-9	LY2608204	Phase 2	glucokinase activator	GCK			0	86.45	MedChemEx	HY-13529	LY2608204	559.2	O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	QIIVJLHCZUTGSD-CUBQBAPOSA-N	46832368.0		QIIVJLHCZUTGSD
BRD-K12068470-001-02-5	LY2608204	Phase 2	glucokinase activator	GCK			0	97.57	Selleck	S2155	LY2608204	559.2	O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	QIIVJLHCZUTGSD-CUBQBAPOSA-N	46832368.0		QIIVJLHCZUTGSD
BRD-K12068470-001-04-1	LY2608204	Phase 2	glucokinase activator	GCK			0	82.26	Selleck	S2155	LY2608204	559.2	O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	QIIVJLHCZUTGSD-CUBQBAPOSA-N	46832368.0	BRD-K69247090-001-01-9	QIIVJLHCZUTGSD
BRD-A64004759-003-01-9	LY266097	Preclinical	serotonin receptor antagonist	HTR2B			0	94.79	Tocris	4081	LY 266097 hydrochloride	370.145	COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|	NJLHHCITDFZZSE-QGZVFWFLSA-N	92845961.0		NJLHHCITDFZZSE
BRD-A64004759-003-02-9	LY266097	Preclinical	serotonin receptor antagonist	HTR2B			0	94.88	Tocris	4081	LY 266097 hydrochloride	370.145	COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|	NJLHHCITDFZZSE-QGZVFWFLSA-N	92845961.0		NJLHHCITDFZZSE
BRD-K25630527-001-03-8	LY2784544	Phase 2	JAK inhibitor	JAK2|JAK3			0	97.67	Selleck	S2179	LY2784544	469.179	Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	SQSZANZGUXWJEA-UHFFFAOYSA-N	46213929.0		SQSZANZGUXWJEA
BRD-K25630527-001-02-0	LY2784544	Phase 2	JAK inhibitor	JAK2|JAK3			0		Selleck	S2179	LY2784544	469.179	Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)	46213929.0		SQSZANZGUXWJEA
BRD-K00003195-001-01-9	LY2795050	Preclinical	opioid receptor antagonist				0	95.77	MedChemEx	HY-15708	LY2795050	407.14	NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1	LOOCZNLSXJHWTG-NRFANRHFSA-N	56851583.0		LOOCZNLSXJHWTG
BRD-K18961567-001-01-1	LY2801653	Phase 2	MET inhibitor	MET			0	99.53	MedChemEx	HY-15514	LY2801653	552.172	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	QHADVLVFMKEIIP-UHFFFAOYSA-N	44603533.0		QHADVLVFMKEIIP
BRD-K18961567-001-02-9	LY2801653	Phase 2	MET inhibitor	MET			0	96.6	MedChemEx	HY-15514	Merestinib	552.172	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	QHADVLVFMKEIIP-UHFFFAOYSA-N	44603533.0		QHADVLVFMKEIIP
BRD-K94534639-001-03-9	LY2811376	Phase 1	beta-secretase inhibitor	BACE1			0	95.92	MedChemEx	HY-10472	LY2811376	320.091	C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|	MJQMRGWYPNIERM-HNNXBMFYSA-N	44251605.0		MJQMRGWYPNIERM
BRD-K94534639-001-02-5	LY2811376	Phase 1	beta-secretase inhibitor	BACE1			0	96.96	Selleck	S1528	LY2811376	320.091	C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|	MJQMRGWYPNIERM-HNNXBMFYSA-N	44251605.0		MJQMRGWYPNIERM
BRD-K00005249-001-01-9	LY2828360	Phase 2	cannabinoid receptor agonist				0	95.34	MedChemEx	HY-16642A	LY2828360	426.193	CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl	UCMNDPDJRSEZPL-UHFFFAOYSA-N	46833780.0		UCMNDPDJRSEZPL
BRD-K15382985-001-01-7	LY2857785	Preclinical	CDK inhibitor	CDK9			0	96.73	MedChemEx	HY-12293	LY2857785	448.295	CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|	LHIUZPIDLZYPRL-MXVIHJGJSA-N			LHIUZPIDLZYPRL
BRD-K17203476-001-01-9	LY2874455	Phase 1	FGFR antagonist	FGFR1|FGFR2|FGFR3|FGFR4|KDR			0	90.03	MedChemEx	HY-13304	LY2874455	443.092	C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	GKJCVYLDJWTWQU-CXLRFSCWSA-N	46944259.0		GKJCVYLDJWTWQU
BRD-K17203476-001-02-9	LY2874455	Phase 1	FGFR antagonist	FGFR1|FGFR2|FGFR3|FGFR4|KDR			0	94.98	MedChemEx	HY-13304	LY2874455	443.092	C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	GKJCVYLDJWTWQU-CXLRFSCWSA-N	46944259.0		GKJCVYLDJWTWQU
BRD-K24675965-001-06-9	LY288513	Preclinical	CCK receptor antagonist	CCKBR			0	92.87	Tocris	1524	LY 288513	435.058	Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1	LMUQHXHWJWQXSD-PMACEKPBSA-N	2802894.0		LMUQHXHWJWQXSD
BRD-K24675965-001-04-1	LY288513	Preclinical	CCK receptor antagonist	CCKBR			0	4.58	Tocris	1524	LY 288513	435.058	Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1	LMUQHXHWJWQXSD-PMACEKPBSA-N	2802894.0		LMUQHXHWJWQXSD
BRD-K51258098-001-02-9	LY2886721	Phase 1/Phase 2	beta-secretase inhibitor	BACE1			0	99.23	MedChemEx	HY-13240	LY2886721	390.096	NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|	NIDRNVHMMDAAIK-YPMLDQLKSA-N	49837968.0		NIDRNVHMMDAAIK
BRD-K27305650-001-16-6	LY294002	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1			0	96.09	Selleck	S1105	LY294002	307.121	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	CZQHHVNHHHRRDU-UHFFFAOYSA-N	3973.0		CZQHHVNHHHRRDU
BRD-K27305650-003-03-0	LY294002	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1			0	69.33	Tocris	1130	LY 294002 hydrochloride	307.121	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	CZQHHVNHHHRRDU-UHFFFAOYSA-N	3973.0		CZQHHVNHHHRRDU
BRD-K27305650-003-02-2	LY294002	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1			0	83.24	Tocris	1130	LY 294002 hydrochloride	307.121	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	CZQHHVNHHHRRDU-UHFFFAOYSA-N	3973.0		CZQHHVNHHHRRDU
BRD-K68220839-413-02-8	LY2979165	Phase 1	glutamate receptor agonist	GRM2			0	97.2	MedChemEx	HY-13239	LY2979165	355.095	C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	BBGHHIUQOKQCBW-LDZWZCGGSA-N	53246986.0		BBGHHIUQOKQCBW
BRD-K68220839-413-01-0	LY2979165	Phase 1	glutamate receptor agonist	GRM2			0	14.17	MedChemEx	HY-13239	LY2979165	355.095	C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	BBGHHIUQOKQCBW-LDZWZCGGSA-N	53246986.0		BBGHHIUQOKQCBW
BRD-K21070437-001-01-4	LY3000328	Phase 1	cathepsin inhibitor	CTSS			0	96.06	MedChemEx	HY-15533	Cathepsin S inhibitor	484.212	CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1	NDEBZCZEAVMSQF-GOTSBHOMSA-N	67475270.0		NDEBZCZEAVMSQF
BRD-K38385169-001-04-5	LY3009120	Phase 1	RAF inhibitor	BRAF|RAF1			0	95.74	MedChemEx	HY-12558	1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea	424.239	CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C	HHCBMISMPSAZBF-UHFFFAOYSA-N	71721540.0		HHCBMISMPSAZBF
BRD-K38385169-001-03-7	LY3009120	Phase 1	RAF inhibitor	BRAF|RAF1			0	95.71	Selleck	S7842	LY3009120	424.239	CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C	HHCBMISMPSAZBF-UHFFFAOYSA-N	71721540.0		HHCBMISMPSAZBF
BRD-K82967180-001-01-6	LY3023414	Phase 2	mTOR inhibitor|PI3K inhibitor	MTOR			0	96.66	MedChemEx	HY-12513	LY3023414	406.2	CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O	ACCFLVVUVBJNGT-AWEZNQCLSA-N	57519748.0		ACCFLVVUVBJNGT
BRD-K22385716-001-03-3	LY303511	Preclinical	casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	BRD2|BRD3|BRD4			0	95.92	Tocris	2418	LY 303511	306.137	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	NGAGMBNBKCDCDJ-UHFFFAOYSA-N	3971.0		NGAGMBNBKCDCDJ
BRD-K22385716-001-02-5	LY303511	Preclinical	casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	BRD2|BRD3|BRD4			0	95.98	Tocris	2418	LY 303511	306.137	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	NGAGMBNBKCDCDJ-UHFFFAOYSA-N	3971.0		NGAGMBNBKCDCDJ
BRD-K22385716-001-04-9	LY303511	Preclinical	casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	BRD2|BRD3|BRD4			0	92.73	Tocris	2418	LY 303511	306.137	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	NGAGMBNBKCDCDJ-UHFFFAOYSA-N	3971.0		NGAGMBNBKCDCDJ
BRD-K41194171-003-09-7	LY310762	Preclinical	serotonin receptor antagonist	HTR1D			0	97.19	MedChemEx	HY-13527	LY310762	394.206	CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12	KDXISMANFPJVJY-UHFFFAOYSA-N	4282258.0		KDXISMANFPJVJY
BRD-K00004565-001-01-9	LY311727	Preclinical	phospholipase inhibitor				0	91.26	Sigma	MFCD00943218	3-{[3-(2-amino-2-oxoethyl)-1-benzyl-2-ethyl-1H-indol-5-yl]oxy}propylphosphonic acid	430.166	CCc1c(CC(N)=O)c2cc(OCCCP(O)(O)=O)ccc2n1Cc1ccccc1	OPWQYOUZRHDKBR-UHFFFAOYSA-N	155922.0		OPWQYOUZRHDKBR
BRD-K00003446-001-01-9	LY3200882	Phase 1	TGF beta receptor inhibitor				0	97.88	MedChemEx	HY-103021	LY3200882	435.227	CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1	PNPFMWIDAKQFPY-UHFFFAOYSA-N	121249291.0		PNPFMWIDAKQFPY
BRD-K78637815-001-02-2	LY320135	Preclinical	cannabinoid receptor antagonist	CNR1			0	98.54	Tocris	2387	LY 320135	383.116	COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N	RYNSGDFWBJWWSZ-UHFFFAOYSA-N	5311257.0		RYNSGDFWBJWWSZ
BRD-K78637815-001-03-9	LY320135	Preclinical	cannabinoid receptor antagonist	CNR1			0	97.77	Tocris	2387	LY 320135	383.116	COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N	RYNSGDFWBJWWSZ-UHFFFAOYSA-N	5311257.0		RYNSGDFWBJWWSZ
BRD-K00003416-001-01-9	LY3214996	Phase 1	ERK inhibitor				0	95.21	MedChemEx	HY-101494	LY3214996	453.195	Cn1nccc1Nc1nccc(n1)-c1cc2C(=O)N(CCN3CCOCC3)C(C)(C)c2s1	JNPRPMBJODOFEC-UHFFFAOYSA-N	121408882.0		JNPRPMBJODOFEC
BRD-K00004722-001-01-9	LY3295668	Phase 1/Phase 2	Aurora kinase inhibitor				0	86.53	MedChemEx	HY-114258	LY3295668	489.174	C[C@@H]1C[C@@](Cc2nc(Nc3cc(C)[nH]n3)ccc2F)(CCN1Cc1cccc(Cl)c1F)C(O)=O	YQQZZYYQTCPEAS-OYLFLEFRSA-N	121333423.0		YQQZZYYQTCPEAS
BRD-K00003451-001-01-9	LY334370	Preclinical	serotonin receptor agonist				0	96.67	MedChemEx	HY-103107	LY334370	351.175	CN1CCC(CC1)c1c[nH]c2ccc(NC(=O)c3ccc(F)cc3)cc12	MDMJLMDBRQXOOI-UHFFFAOYSA-N	5311258.0		MDMJLMDBRQXOOI
BRD-K95899059-003-03-6	LY344864	Preclinical	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR7			0	86.9	Tocris	2451	LY 344864 hydrochloride	351.175	CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	GKWHICIUSVVNGX-MRXNPFEDSA-N	5311097.0		GKWHICIUSVVNGX
BRD-K95899059-003-02-8	LY344864	Preclinical	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR7			0	78.37	Tocris	2451	LY 344864 hydrochloride	351.175	CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	GKWHICIUSVVNGX-MRXNPFEDSA-N	5311097.0		GKWHICIUSVVNGX
BRD-K95899059-003-04-9	LY344864	Preclinical	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR7			0	88.86	Tocris	2451	LY 344864 hydrochloride	351.175	CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	GKWHICIUSVVNGX-MRXNPFEDSA-N	5311097.0		GKWHICIUSVVNGX
BRD-K06234293-001-04-2	LY364947	Preclinical	p38 MAPK inhibitor|TGF beta receptor inhibitor	TGFBR1			0	98.09	Tocris	2718	LY 364947	272.106	c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	IBCXZJCWDGCXQT-UHFFFAOYSA-N	447966.0		IBCXZJCWDGCXQT
BRD-K06234293-001-03-4	LY364947	Preclinical	p38 MAPK inhibitor|TGF beta receptor inhibitor	TGFBR1			0	92.55	Selleck	S2805	LY364947	272.106	c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	IBCXZJCWDGCXQT-UHFFFAOYSA-N	447966.0		IBCXZJCWDGCXQT
BRD-K06234293-001-05-9	LY364947	Preclinical	p38 MAPK inhibitor|TGF beta receptor inhibitor	TGFBR1			0	91.4	Tocris	2718	LY 364947	272.106	c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	IBCXZJCWDGCXQT-UHFFFAOYSA-N	447966.0		IBCXZJCWDGCXQT
BRD-K08534264-001-01-4	LY393558	Preclinical	serotonin receptor antagonist	HTR1B|HTR1D|HTR2A|HTR2B			0	15.46	Tocris	3350	LY 393558	546.177	CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|	QUSLYAPLTMMCFE-UHFFFAOYSA-N	10347428.0		QUSLYAPLTMMCFE
BRD-K08534264-001-02-9	LY393558	Preclinical	serotonin receptor antagonist	HTR1B|HTR1D|HTR2A|HTR2B			0	66.97	Tocris	3350	LY 393558	546.177	CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|	QUSLYAPLTMMCFE-UHFFFAOYSA-N	10347428.0		QUSLYAPLTMMCFE
BRD-A50062753-001-01-3	LY404187	Preclinical	glutamate receptor positive allosteric modulator	GRIA1|GRIA2|GRIA3|GRIA4			0	90.87	Tocris	5297	LY 404187	342.14	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|	HOQAVGZLYRYHSO-HNNXBMFYSA-N	66857735.0		HOQAVGZLYRYHSO
BRD-A50062753-001-02-9	LY404187	Preclinical	glutamate receptor positive allosteric modulator	GRIA1|GRIA2|GRIA3|GRIA4			0	94.79	Tocris	5297	LY 404187	342.14	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8,r|	HOQAVGZLYRYHSO-HNNXBMFYSA-N	66857735.0		HOQAVGZLYRYHSO
BRD-K20013301-001-03-9	LY411575	Preclinical	gamma secretase inhibitor				0	97.7	MedChemEx	HY-50752	LY-411575	479.166	C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	ULSSJYNJIZWPSB-CVRXJBIPSA-N	10435235.0		ULSSJYNJIZWPSB
BRD-K20013301-001-02-6	LY411575	Preclinical	gamma secretase inhibitor				0	97.33	Selleck	S2714	LY411575	479.166	C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	ULSSJYNJIZWPSB-CVRXJBIPSA-N	10435235.0		ULSSJYNJIZWPSB
BRD-K54538117-001-01-7	LY450108	Phase 1	glutamate receptor modulator				0	94.81	MedChemEx	HY-10935	LY450108	396.132	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1	ACOXQYLJOQAHST-ZDUSSCGKSA-N	9843690.0		ACOXQYLJOQAHST
BRD-K87696786-003-05-1	LY456236	Preclinical	glutamate receptor antagonist	GRM1			0	96.96	Tocris	2390	LY 456236 hydrochloride	281.116	COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	XPJOMFBGKIABQW-UHFFFAOYSA-N	9926999.0		XPJOMFBGKIABQW
BRD-K87696786-003-04-4	LY456236	Preclinical	glutamate receptor antagonist	GRM1			0	97.15	Tocris	2390	LY 456236 hydrochloride	281.116	COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	XPJOMFBGKIABQW-UHFFFAOYSA-N	9926999.0		XPJOMFBGKIABQW
BRD-K87696786-003-06-9	LY456236	Preclinical	glutamate receptor antagonist	GRM1			0	96.26	Tocris	2390	LY 456236 hydrochloride	281.116	COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	XPJOMFBGKIABQW-UHFFFAOYSA-N	9926999.0		XPJOMFBGKIABQW
BRD-K36965586-003-10-9	m-chlorophenylbiguanide	Preclinical	serotonin receptor agonist	HTR3A|HTR3B			0	96.25	Tocris	440	m-Chlorophenylbiguanide hydrochloride	211.062	NC(N)=NC(=N)Nc1cccc(Cl)c1	DIHXJZHAIHGSAW-UHFFFAOYSA-N	1354.0		DIHXJZHAIHGSAW
BRD-K36965586-003-08-8	m-chlorophenylbiguanide	Preclinical	serotonin receptor agonist	HTR3A|HTR3B			0	93.77	Tocris	440	m-Chlorophenylbiguanide hydrochloride	211.062	NC(N)=NC(=N)Nc1cccc(Cl)c1	DIHXJZHAIHGSAW-UHFFFAOYSA-N	1354.0		DIHXJZHAIHGSAW
BRD-K91147684-001-01-5	m-THP	Phase 1					0	88.76	FrontierSci	T678-1		678.227	Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc1n2	XAEPFBXVLMACNN-LWQDQPMZSA-N			XAEPFBXVLMACNN
BRD-A96977263-001-03-7	M-14157	Phase 2	ATP-sensitive potassium channel antagonist	KCNQ1			1	0.0	Enzo	KC141	5-Hydroxydecanoate	188.141	CCCCCC(O)CCCC(O)=O	LMHJFKYQYDSOQO-UHFFFAOYSA-N	1825.0		LMHJFKYQYDSOQO
BRD-K51265828-001-02-9	M-25	Preclinical	smoothened receptor antagonist	DHH|IHH|SMO			0	98.59	Tocris	4917	M 25	379.226	CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC	WATNXVHKRRTUFK-UHFFFAOYSA-N	44250034.0		WATNXVHKRRTUFK
BRD-K51265828-001-01-0	M-25	Preclinical	smoothened receptor antagonist	DHH|IHH|SMO			0	98.33	Tocris	4917	M 25	379.226	CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC	WATNXVHKRRTUFK-UHFFFAOYSA-N	44250034.0		WATNXVHKRRTUFK
BRD-K09635314-001-04-2	m-3M3FBS	Preclinical	phospholipase activator	PLCB2|PLCB3|PLCD1|PLCG1|PLCG2			0	98.71	Tocris	1941	m-3M3FBS	343.085	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F	ZIIUUSVHCHPIQD-UHFFFAOYSA-N	761523.0		ZIIUUSVHCHPIQD
BRD-K09635314-001-03-4	m-3M3FBS	Preclinical	phospholipase activator	PLCB2|PLCB3|PLCD1|PLCG1|PLCG2			0	98.86	Tocris	1941	m-3M3FBS	343.085	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F	ZIIUUSVHCHPIQD-UHFFFAOYSA-N	761523.0		ZIIUUSVHCHPIQD
BRD-K45528773-001-08-0	M-344	Preclinical	HDAC inhibitor	HDAC8			0	80.39	Tocris	2771	M 344	307.19	CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	MXWDSZWTBOCWBK-UHFFFAOYSA-N	3994.0		MXWDSZWTBOCWBK
BRD-K45528773-001-07-2	M-344	Preclinical	HDAC inhibitor	HDAC8			0	97.25	Selleck	S2779	M344	307.19	CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	MXWDSZWTBOCWBK-UHFFFAOYSA-N	3994.0		MXWDSZWTBOCWBK
BRD-K45528773-001-06-4	M-344	Preclinical	HDAC inhibitor	HDAC8			0	89.82	Selleck	S2779	M344	307.19	CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	MXWDSZWTBOCWBK-UHFFFAOYSA-N	3994.0		MXWDSZWTBOCWBK
BRD-A93683007-001-01-9	mabuprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	91.14	Enamine	Z1537048897	N-(2-hydroxyethyl)-2-(4-isobutylphenyl)propanamide	249.173	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|	JVGUNCHERKJFCM-GFCCVEGCSA-N	11391028.0		JVGUNCHERKJFCM
BRD-A93683007-001-02-7	mabuprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	88.87	Enamine	Z1537048897	Aminoprofen	249.173	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10,r|	JVGUNCHERKJFCM-GFCCVEGCSA-N	11391028.0		JVGUNCHERKJFCM
BRD-A13116749-003-01-6	mabuterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma	0	98.26	Sigma	32573	1-[4-amino-3-chloro-5-(trifluoromethyl)phenyl]-2-(tert-butylamino)ethanol hydrochloride	310.106	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|	JSJCTEKTBOKRST-SNVBAGLBSA-N	11551355.0		JSJCTEKTBOKRST
BRD-K94948151-001-07-4	macelignan	Preclinical	anti-inflammatory agent|antioxidant				0	97.67	MedChemEx	HY-N0064	Macelignan	328.167	COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O	QDDILOVMGWUNGD-UONOGXRCSA-N	10404245.0		QDDILOVMGWUNGD
BRD-K48812570-001-02-3	macitentan	Launched	endothelin receptor antagonist	EDNRA|EDNRB	endocrinology	contraceptive	0	88.56	Selleck	S8051	Macitentan	585.963	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	JGCMEBMXRHSZKX-UHFFFAOYSA-N	16004692.0		JGCMEBMXRHSZKX
BRD-K48812570-001-04-9	macitentan	Launched	endothelin receptor antagonist	EDNRA|EDNRB	endocrinology	contraceptive	0	95.48	MedChemEx	HY-14184	Macitentan	585.963	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	JGCMEBMXRHSZKX-UHFFFAOYSA-N	16004692.0		JGCMEBMXRHSZKX
BRD-K48812570-001-03-1	macitentan	Launched	endothelin receptor antagonist	EDNRA|EDNRB	endocrinology	contraceptive	0	90.02	Selleck	S8051	Macitentan	585.963	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	JGCMEBMXRHSZKX-UHFFFAOYSA-N	16004692.0		JGCMEBMXRHSZKX
BRD-K00003167-001-01-9	macitentan-n-butyl-analogue	Preclinical	endothelin receptor antagonist				0	96.96	MedChemEx	HY-14184A	Macitentan (n-butyl analogue)	584.968	CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	OZBDTKLWBSATSN-UHFFFAOYSA-N	71449713.0		OZBDTKLWBSATSN
BRD-K16343284-001-02-9	macozinone	Preclinical	DPRE1 inhibitor				0	91.6	MedChemEx	HY-12903	Macozinone	456.144	[O-][N+](=O)c1cc(cc2c1sc(nc2=O)N1CCN(CC2CCCCC2)CC1)C(F)(F)F	BJDZBXGJNBMCAV-UHFFFAOYSA-N	57331386.0		BJDZBXGJNBMCAV
BRD-K00003328-001-01-9	madecassoside	Preclinical	anti-inflammatory agent				0	74.02	MedChemEx	HY-N0568	Madecassoside	974.509	[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |t:3|	BNMGUJRJUUDLHW-HCZMHFOYSA-N	24825675.0		BNMGUJRJUUDLHW
BRD-K48905682-001-11-1	madrasin	Preclinical	cell splicing inhibitor				0	96.14	PrincetonBio	OSSM_012298	Madrasin	311.138	COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1	QQJIYKXTEMDJFM-UHFFFAOYSA-N	135444382.0		QQJIYKXTEMDJFM
BRD-K30649484-015-15-9	mafenide	Launched	carbonic anhydrase inhibitor	CA12|CA14|CA2|CA4|CA6|CA9	infectious disease	first-aid antibiotic|skin infections	0	93.2	MedChemEx	HY-B0614A	Mafenide (Acetate)	186.046	NCc1ccc(cc1)S(N)(=O)=O	TYMRLRRVMHJFTF-UHFFFAOYSA-N	3998.0		TYMRLRRVMHJFTF
BRD-K30649484-003-13-7	mafenide	Launched	carbonic anhydrase inhibitor	CA12|CA14|CA2|CA4|CA6|CA9	infectious disease	first-aid antibiotic|skin infections	0	100.0	MicroSource	1500372	MAFENIDE HYDROCHLORIDE	186.046	NCc1ccc(cc1)S(N)(=O)=O	TYMRLRRVMHJFTF-UHFFFAOYSA-N	3998.0		TYMRLRRVMHJFTF
BRD-K26168087-001-09-7	magnolol	Preclinical	PPAR receptor agonist	GABRA1|PPARG			0	93.11	Selleck	S2321	Magnolol	266.131	Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O	VVOAZFWZEDHOOU-UHFFFAOYSA-N	72300.0		VVOAZFWZEDHOOU
BRD-A01976766-001-06-8	malathion	Launched	cholinesterase inhibitor	ACHE	infectious disease	lice	0	47.28	MedChemEx	HY-B0943	Malathion	330.036	CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|	JXSJBGJIGXNWCI-MRVPVSSYSA-N	12358970.0		JXSJBGJIGXNWCI
BRD-A01976766-001-04-3	malathion	Launched	cholinesterase inhibitor	ACHE	infectious disease	lice	0	28.91	MicroSource	330021	MALATHION	330.036	CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|	JXSJBGJIGXNWCI-MRVPVSSYSA-N	12358970.0		JXSJBGJIGXNWCI
BRD-A01976766-001-07-6	malathion	Launched	cholinesterase inhibitor	ACHE	infectious disease	lice	0	78.47	MedChemEx	HY-B0943	Malathion	330.036	CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6,r|	JXSJBGJIGXNWCI-MRVPVSSYSA-N	12358970.0		JXSJBGJIGXNWCI
BRD-A18396475-001-16-1	malic-acid	Launched		PKD2L1			1	100.0	Enamine	Z104473230	malic acid	134.022	O[C@@H](CC(O)=O)C(O)=O |&1:1,r|	BJEPYKJPYRNKOW-REOHCLBHSA-N	222656.0		BJEPYKJPYRNKOW
BRD-A18396475-001-15-3	malic-acid	Launched		PKD2L1			1	0.0	Enamine	Z104473230		134.022	O[C@@H](CC(O)=O)C(O)=O |&1:1,r|	BJEPYKJPYRNKOW-REOHCLBHSA-N	222656.0		BJEPYKJPYRNKOW
BRD-K97884852-001-06-9	malotilate	Launched	protein synthesis stimulant		gastroenterology	hepatic cirrhosis	0	93.58	MedChemEx	HY-A0060	Malotilate	288.049	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|	YPIQVCUJEKAZCP-UHFFFAOYSA-N	4006.0		YPIQVCUJEKAZCP
BRD-K97884852-001-05-4	malotilate	Launched	protein synthesis stimulant		gastroenterology	hepatic cirrhosis	0	96.64	Selleck	S1137	Malotilate	288.049	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|	YPIQVCUJEKAZCP-UHFFFAOYSA-N	4006.0		YPIQVCUJEKAZCP
BRD-K01624185-001-05-7	maltobionic-acid	Launched	matrix metalloprotease inhibitor		dermatology	cosmetic	0	100.0	CombiBlocks	QA-2870		358.111	OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O	JYTUSYBCFIZPBE-AMTLMPIISA-N	7314.0		JYTUSYBCFIZPBE
BRD-A91448670-001-06-4	mandelic-acid	Launched					0	0.0	Enamine	Z104473974		152.047	O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|	IWYDHOAUDWTVEP-SSDOTTSWSA-N	11914.0		IWYDHOAUDWTVEP
BRD-A91448670-001-08-9	mandelic-acid	Launched					0	97.99	MedChemEx	HY-W015591	2-Hydroxy-2-phenylacetic acid	152.047	O[C@@H](C(O)=O)c1ccccc1 |&1:1,r|	IWYDHOAUDWTVEP-SSDOTTSWSA-N	11914.0		IWYDHOAUDWTVEP
BRD-K57365211-314-01-4	mangafodipir	Launched	contrast agent		radiology	contrast agent	0	0.0	MicroSource	1503840	MANGAFODIPIR TRISODIUM	691.061	Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12	CXFKOLCMCRBYPL-UHFFFAOYSA-L	76967443.0		CXFKOLCMCRBYPL
BRD-K57365211-314-03-9	mangafodipir	Launched	contrast agent		radiology	contrast agent	1	0.0	MedChemEx	HY-B0993	Mangafodipir (trisodium)	691.061	Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12	CXFKOLCMCRBYPL-UHFFFAOYSA-L	76967443.0		CXFKOLCMCRBYPL
BRD-K57365211-314-02-2	mangafodipir	Launched	contrast agent		radiology	contrast agent	1	0.0	MedChemEx	HY-B0993	Mangafodipir (trisodium)	691.061	Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12	CXFKOLCMCRBYPL-UHFFFAOYSA-L	76967443.0	BRD-A81339141-314-01-6|BRD-U27874988-000-01-6	CXFKOLCMCRBYPL
BRD-K01825587-300-02-9	manidipine	Launched	calcium channel blocker	CACNA1C|CACNA1D	cardiology	hypertension	0	92.09	Selleck	S2482	Manidipine 2HCl	682.232	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r,c:4,9|	ANEBWFXPVPTEET-JGCGQSQUSA-N	13632719.0		ANEBWFXPVPTEET
BRD-K00004729-001-01-9	manitimus	Preclinical	dehydrogenase inhibitor				0	92.37	MedChemEx	HY-101603	Manitimus	308.077	FC(F)(F)c1ccc(NC(=O)[C@H](C#N)C(=O)CCC#C)cc1 |&1:11,r|	MYMWDZLPEPMSCN-GFCCVEGCSA-N			MYMWDZLPEPMSCN
BRD-K30374899-001-09-3	mannitol-D	Launched	diuretic		neurology/psychiatry|ophthalmology|gastroenterology	intracranial pressure|intraocular pressure|constipation	0	100.0	Selleck	S2381	D-Mannitol	182.079	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-KVTDHHQDSA-N	6251.0		FBPFZTCFMRRESA
BRD-K03319035-003-18-9	maprotiline	Launched	norepinephrine reputake inhibitor|tricyclic antidepressant	SLC6A2	neurology/psychiatry	depression|dysthymic disorder	0	98.66	Tocris	935	Maprotiline hydrochloride	277.183	CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|	QSLMDECMDJKHMQ-GSXCWMCISA-N			QSLMDECMDJKHMQ
BRD-K00004293-001-01-9	maraviroc	Launched	CC chemokine receptor antagonist	CCR5	infectious disease	human immunodeficiency virus (HIV-1)	0	93.43	Tocris	3756	Maraviroc	513.328	CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1	GSNHKUDZZFZSJB-QYOOZWMWSA-N			GSNHKUDZZFZSJB
BRD-K71926323-001-13-8	marbofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	96.71	MicroSource	1506324	MARBOFLOXACIN	362.139	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	BPFYOAJNDMUVBL-UHFFFAOYSA-N	60651.0		BPFYOAJNDMUVBL
BRD-K71926323-001-14-6	marbofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	99.41	Selleck	S1464	Marbofloxacin	362.139	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	BPFYOAJNDMUVBL-UHFFFAOYSA-N	60651.0		BPFYOAJNDMUVBL
BRD-K71926323-001-12-0	marbofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	92.86	Selleck	S1464	Marbofloxacin	362.139	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	BPFYOAJNDMUVBL-UHFFFAOYSA-N	60651.0		BPFYOAJNDMUVBL
BRD-K59524082-001-01-3	maribavir	Phase 3	cytomegalovirus inhibitor|protein kinase inhibitor	PYGM			0	94.38	MedChemEx	HY-16305	Maribavir	375.075	CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O	KJFBVJALEQWJBS-XUXIUFHCSA-N	471161.0		KJFBVJALEQWJBS
BRD-K59524082-001-02-9	maribavir	Phase 3	cytomegalovirus inhibitor|protein kinase inhibitor	PYGM			0	96.75	MedChemEx	HY-16305	Maribavir	375.075	CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O	KJFBVJALEQWJBS-XUXIUFHCSA-N	471161.0		KJFBVJALEQWJBS
BRD-K21396683-001-04-8	marimastat	Phase 3	matrix metalloprotease inhibitor	MMP1|MMP10|MMP11|MMP12|MMP13|MMP14|MMP15|MMP16|MMP17|MMP19|MMP2|MMP20|MMP21|MMP23A|MMP24|MMP25|MMP26|MMP27|MMP28|MMP3|MMP7|MMP8|MMP9			0	92.47	MedChemEx	HY-12169	Marimastat	331.211	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	OCSMOTCMPXTDND-OUAUKWLOSA-N	119031.0		OCSMOTCMPXTDND
BRD-K21396683-001-03-0	marimastat	Phase 3	matrix metalloprotease inhibitor	MMP1|MMP10|MMP11|MMP12|MMP13|MMP14|MMP15|MMP16|MMP17|MMP19|MMP2|MMP20|MMP21|MMP23A|MMP24|MMP25|MMP26|MMP27|MMP28|MMP3|MMP7|MMP8|MMP9			0	94.62	EMDBio	444289	Marimastat	331.211	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1	119031.0		OCSMOTCMPXTDND
BRD-K76594255-001-01-6	maropitant	Launched	neurokinin receptor antagonist	TACR1	gastroenterology	vomiting	0	97.11	MedChemEx	HY-10053	Maropitant	468.314	COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C	OMPCVMLFFSQFIX-CONSDPRKSA-N	204108.0		OMPCVMLFFSQFIX
BRD-K71035033-001-08-9	masitinib	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor	FGFR3|KIT|PDGFRA|PDGFRB	dermatology	mastocytoma	0	92.11	Selleck	S1064	Masitinib (AB1010)	498.22	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1	WJEOLQLKVOPQFV-UHFFFAOYSA-N	10074640.0		WJEOLQLKVOPQFV
BRD-K71035033-001-07-1	masitinib	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor	FGFR3|KIT|PDGFRA|PDGFRB	dermatology	mastocytoma	0	94.17	Selleck	S1064	Masitinib (AB1010)	498.22	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1	WJEOLQLKVOPQFV-UHFFFAOYSA-N	10074640.0		WJEOLQLKVOPQFV
BRD-A87130939-001-07-9	masoprocol	Launched	lipoxygenase inhibitor	ALOX5	dermatology	actinic keratosis (AK)	0	91.85	Enzo	EI101	NDGA	302.152	C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|	HCZKYJDFEPMADG-RYUDHWBXSA-N	688035.0		HCZKYJDFEPMADG
BRD-A87130939-001-08-9	masoprocol	Launched	lipoxygenase inhibitor	ALOX5	dermatology	actinic keratosis (AK)	0	97.16	MedChemEx	HY-N0198	Nordihydroguaiaretic acid	302.152	C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1,&2:11,r|	HCZKYJDFEPMADG-RYUDHWBXSA-N	688035.0		HCZKYJDFEPMADG
BRD-K08623988-001-02-8	matrine	Phase 2	opioid receptor agonist	OPRK1			0	91.99	Selleck	S2322	(+)-Matrine	248.189	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	ZSBXGIUJOOQZMP-JLNYLFASSA-N	91466.0		ZSBXGIUJOOQZMP
BRD-K00003497-001-01-9	mavacamten	Phase 3	myosin inhibitor 				0	95.99	MedChemEx	HY-109037	Mavacamten	273.148	CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O	RLCLASQCAPXVLM-NSHDSACASA-N	117761397.0		RLCLASQCAPXVLM
BRD-K00003237-001-01-9	mavatrep	Preclinical	transient receptor potential channel antagonist				0	99.07	MedChemEx	HY-16935	Mavatrep	422.161	CC(C)(O)c1ccccc1-c1ccc2nc(\C=C\c3ccc(cc3)C(F)(F)F)[nH]c2c1	ORDHXXHTBUZRCN-NTEUORMPSA-N	17751090.0		ORDHXXHTBUZRCN
BRD-K07790550-001-01-6	mavoglurant	Phase 2	glutamate receptor antagonist	GRM5			0	93.0	MedChemEx	HY-15257	Mavoglurant	313.168	COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1	ZFPZEYHRWGMJCV-ZHALLVOQSA-N	9926832.0		ZFPZEYHRWGMJCV
BRD-K47318833-001-04-9	maxacalcitol	Launched	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	0		Cayman	JRSACHER_006-10-1	22-oxacalcitriol	418.308	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	DTXXSJZBSTYZKE-ZDQKKZTESA-N	6398761.0		DTXXSJZBSTYZKE
BRD-K47318833-001-03-9	maxacalcitol	Launched	vitamin D receptor agonist	VDR	endocrinology	hyperparathyroidism	0	91.47	MedChemEx	HY-15329	Maxacalcitol-D6	418.308	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	DTXXSJZBSTYZKE-ZDQKKZTESA-N	6398761.0		DTXXSJZBSTYZKE
BRD-K15898725-001-01-7	maytansinol-isobutyrate	Preclinical					0	78.12	MedChemEx	HY-15739	Ansamitocin P-3	634.266	CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5,t:3|	OPQNCARIZFLNLF-HSBZPDDFSA-N	131857169.0		OPQNCARIZFLNLF
BRD-K32218650-001-01-6	MBX-2982	Phase 2	glucose dependent insulinotropic receptor agonist	GPR119			0	98.92	MedChemEx	HY-15291	MBX-2982	448.179	CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1	NFTMKHWBOINJGM-UHFFFAOYSA-N	25025505.0		NFTMKHWBOINJGM
BRD-K32218650-001-02-9	MBX-2982	Phase 2	glucose dependent insulinotropic receptor agonist	GPR119			0	95.73	MedChemEx	HY-15291	MBX-2982	448.179	CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1	NFTMKHWBOINJGM-UHFFFAOYSA-N	25025505.0		NFTMKHWBOINJGM
BRD-K50712474-002-02-5	MC-1	Phase 3		AADAT|ABAT|AGXT|AGXT2|ALAS1|AZIN2|BCAT1|BCAT2|CBS|CCBL1|CCBL2|CSAD|CTH|DDC|FTCD|GAD1|GAD2|GADL1|GCAT|GLDC|GOT1|GOT2|GPT|GPT2|HDC|IGSF10|KYNU|MOCOS|NFS1|OAT|ODC1|PDXDC1|PDXP|PHYKPL|PNPO|PROSC|PSAT1|PYGB|PYGL|PYGM|SCLY|SDS|SDSL|SEPSECS|SGPL1|SHMT1|SHMT2|SPTLC1|SPTLC2|SPTLC3|SRR|TAT|THNSL1			0	0.0	Sigma	MFCD00149414	(4-formyl-5-hydroxy-6-methyl-3-pyridinyl)methyl dihydrogen phosphate hydrate	247.025	Cc1ncc(COP(O)(O)=O)c(C=O)c1O	NGVDGCNFYWLIFO-UHFFFAOYSA-N	1051.0		NGVDGCNFYWLIFO
BRD-K50712474-001-02-7	MC-1	Phase 3		AADAT|ABAT|AGXT|AGXT2|ALAS1|AZIN2|BCAT1|BCAT2|CBS|CCBL1|CCBL2|CSAD|CTH|DDC|FTCD|GAD1|GAD2|GADL1|GCAT|GLDC|GOT1|GOT2|GPT|GPT2|HDC|IGSF10|KYNU|MOCOS|NFS1|OAT|ODC1|PDXDC1|PDXP|PHYKPL|PNPO|PROSC|PSAT1|PYGB|PYGL|PYGM|SCLY|SDS|SDSL|SEPSECS|SGPL1|SHMT1|SHMT2|SPTLC1|SPTLC2|SPTLC3|SRR|TAT|THNSL1			0	0.0	Vitas-M	STL185213		247.025	Cc1ncc(COP(O)(O)=O)c(C=O)c1O	NGVDGCNFYWLIFO-UHFFFAOYSA-N	1051.0		NGVDGCNFYWLIFO
BRD-K55418700-001-03-0	MCC950	Preclinical	NOD like receptor inhibitor	NLRP3			0	37.23	MedChemEx	HY-12815	MCC950	404.141	CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12	HUUSXLKCTQDPGL-UHFFFAOYSA-N	9910393.0		HUUSXLKCTQDPGL
BRD-K55418700-001-02-2	MCC950	Preclinical	NOD like receptor inhibitor	NLRP3			0	0.0	MedChemEx	HY-12815	MCC950	404.141	CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12	HUUSXLKCTQDPGL-UHFFFAOYSA-N	9910393.0		HUUSXLKCTQDPGL
BRD-K31168993-001-02-8	McN-5652-(+/-)	Preclinical	selective serotonin reuptake inhibitor (SSRI)				0	26.5	Tocris	2148	(?)-McN 5652	295.139	CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12	YVKDUIAAPBKHMJ-MOPGFXCFSA-N	6336338.0		YVKDUIAAPBKHMJ
BRD-K31168993-001-03-9	McN-5652-(+/-)	Preclinical	selective serotonin reuptake inhibitor (SSRI)				0	85.79	Tocris	2148	(+/-)-McN 5652	295.139	CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12	YVKDUIAAPBKHMJ-MOPGFXCFSA-N	6336338.0		YVKDUIAAPBKHMJ
BRD-K73276278-305-01-1	MCOPPB	Preclinical	nociceptin/orphanin FQ receptor agonist	OPRL1			0	96.23	Tocris	3763	MCOPPB trihydrochloride	408.325	CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1	CYYNMPPFEJPBJD-OAQYLSRUSA-N	24800108.0		CYYNMPPFEJPBJD
BRD-K73276278-305-02-9	MCOPPB	Preclinical	nociceptin/orphanin FQ receptor agonist	OPRL1			0	96.78	Tocris	3763	MCOPPB trihydrochloride	408.325	CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1	CYYNMPPFEJPBJD-OAQYLSRUSA-N	24800108.0		CYYNMPPFEJPBJD
BRD-K75844781-001-09-9	mCPP	Phase 2	serotonin receptor agonist	HTR1A|HTR1D|HTR1E|HTR2A|HTR2B|HTR2C|HTR6			0	80.29	Sigma	MFCD00040732	1-(3-CHLOROPHENYL)PIPERAZINE	196.077	Clc1cccc(c1)N1CCNCC1	VHFVKMTVMIZMIK-UHFFFAOYSA-N	1355.0		VHFVKMTVMIZMIK
BRD-K75844781-003-08-0	mCPP	Phase 2	serotonin receptor agonist	HTR1A|HTR1D|HTR1E|HTR2A|HTR2B|HTR2C|HTR6			0	95.44	Enzo	AC547	1-(3-Chlorophenyl)piperazine	196.077	Clc1cccc(c1)N1CCNCC1	VHFVKMTVMIZMIK-UHFFFAOYSA-N	1355.0		VHFVKMTVMIZMIK
BRD-K24031866-001-03-9	MC1568	Preclinical	HDAC inhibitor	HDAC2			0	89.02	MedChemEx	HY-16914	MC1568	314.107	Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1	QQDIFLSJMFDTCQ-FIFLTTCUSA-N	71311876.0		QQDIFLSJMFDTCQ
BRD-K24031866-001-02-1	MC1568	Preclinical	HDAC inhibitor	HDAC2			0	7.76	Selleck	S1484	MC1568	314.107	Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1	QQDIFLSJMFDTCQ-FIFLTTCUSA-N	71311876.0	BRD-K94335714-001-07-4	QQDIFLSJMFDTCQ
BRD-K24031866-001-01-3	MC1568	Preclinical	HDAC inhibitor	HDAC2			0	4.49	Selleck	S1484	MC1568	314.107	Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1	QQDIFLSJMFDTCQ-FIFLTTCUSA-N	71311876.0	BRD-K94335714-001-06-6	QQDIFLSJMFDTCQ
BRD-K92758126-001-18-8	MD-920	Phase 1	NFkB pathway inhibitor	AADACL2			0	96.77	Enzo	NP113	Gibberellic acid, (+)-	346.142	C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|	IXORZMNAPKEEDV-OBDJNFEBSA-N	6466.0		IXORZMNAPKEEDV
BRD-K92758126-001-20-9	MD-920	Phase 1	NFkB pathway inhibitor	AADACL2			0	88.18	Sigma	MFCD00079329	Gibberellic Acid	346.142	C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|	IXORZMNAPKEEDV-OBDJNFEBSA-N	6466.0		IXORZMNAPKEEDV
BRD-K61128465-001-09-9	mdivi-1	Preclinical	dynamin inhibitor	DNM1			0	83.5	Selleck	S7162	Mdivi-1	351.984	COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O	NZJKEVWTYMOYOR-UHFFFAOYSA-N	3825829.0		NZJKEVWTYMOYOR
BRD-K61128465-001-10-7	mdivi-1	Preclinical	dynamin inhibitor	DNM1			0	97.44	Selleck	S7162	Mdivi-1	351.984	COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O	NZJKEVWTYMOYOR-UHFFFAOYSA-N	3825829.0		NZJKEVWTYMOYOR
BRD-A62057054-001-04-9	MDL-11939	Phase 2	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	96.53	Tocris	870	MDL 11,939	295.194	O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|	AXNGJCOYCMDPQG-HXUWFJFHSA-N	76958673.0		AXNGJCOYCMDPQG
BRD-A62057054-001-03-1	MDL-11939	Phase 2	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	98.53	Tocris	870	MDL 11,939	295.194	O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1,r|	AXNGJCOYCMDPQG-HXUWFJFHSA-N	76958673.0		AXNGJCOYCMDPQG
BRD-K50888640-001-01-6	MDL-27531	Preclinical	glycine receptor agonist				0	84.16	Otava	2630816	4-methyl-3-(methylsulfonyl)-5-phenyl-4H-1,2,4-triazole	237.057	Cn1c(nnc1S(C)(=O)=O)-c1ccccc1	DPGDRICHXKQXEN-UHFFFAOYSA-N	164013.0		DPGDRICHXKQXEN
BRD-K59753853-001-02-3	MDL-29951	Preclinical	glutamate receptor antagonist	FBP1			0	96.68	MedChemEx	HY-16312	MDL-29951	300.991	OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O	KNBSYZNKEAWABY-UHFFFAOYSA-N	446916.0		KNBSYZNKEAWABY
BRD-K01825683-003-03-9	MDL-72832	Preclinical	serotonin receptor agonist	HTR1A			0	95.26	Tocris	412	MDL 72832 hydrochloride	386.221	O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|	HCVRCHQFYYZPHT-KRWDZBQOSA-N	6604720.0		HCVRCHQFYYZPHT
BRD-K01825683-003-01-9	MDL-72832	Preclinical	serotonin receptor agonist	HTR1A			0	96.3	Tocris	412	MDL 72832 hydrochloride	422.197	O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|	HCVRCHQFYYZPHT-KRWDZBQOSA-N	6604720.0		HCVRCHQFYYZPHT
BRD-K01826803-003-03-9	MDL-73005EF	Phase 1	serotonin receptor antagonist	HTR1A			0	96.44	Tocris	411	MDL 73005EF hydrochloride	358.189	O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|	BVMYCHKQPGEOSI-HNNXBMFYSA-N	6604719.0		BVMYCHKQPGEOSI
BRD-K01826803-003-02-9	MDL-73005EF	Phase 1	serotonin receptor antagonist	HTR1A			0	96.76	Tocris	411	MDL 73005EF hydrochloride	394.166	O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|	BVMYCHKQPGEOSI-HNNXBMFYSA-N	6604719.0		BVMYCHKQPGEOSI
BRD-K70840370-001-01-9	MDMS	Phase 2	DNA inhibitor				0	0.0	Enamine	Z2327531735	[(methylsulfonyl)oxy]methyl methanesulfonate	203.976	CS(=O)(=O)OCOS(C)(=O)=O	IQLZWWDXNXZGPK-UHFFFAOYSA-N	9083.0		IQLZWWDXNXZGPK
BRD-K24283677-001-02-9	ME-0328	Preclinical	PPAR receptor antagonist	PARP3			0	96.98	MedChemEx	HY-100225	ME0328	321.148	C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	QIHBWVVVRYYYRO-ZDUSSCGKSA-N	135566764.0		QIHBWVVVRYYYRO
BRD-K24283677-001-03-9	ME-0328	Preclinical	PPAR receptor antagonist	PARP3			0	97.75	Tocris	5054	ME 0328	321.148	C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	QIHBWVVVRYYYRO-ZDUSSCGKSA-N	135566764.0		QIHBWVVVRYYYRO
BRD-K24283677-001-01-9	ME-0328	Preclinical	PPAR receptor antagonist	PARP3			0	97.84	Tocris	5054	ME 0328	321.148	C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	QIHBWVVVRYYYRO-ZDUSSCGKSA-N	135566764.0		QIHBWVVVRYYYRO
BRD-K77987382-001-16-9	mebendazole	Launched	tubulin polymerization inhibitor	TUBA1A|TUBB|TUBB4B	infectious disease	pinworm|whipworm|hookworm|ascariasis	0	97.04	MedChemEx	HY-17595	Mebendazole	295.096	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	OPXLLQIJSORQAM-UHFFFAOYSA-N	4030.0		OPXLLQIJSORQAM
BRD-K77987382-001-13-2	mebendazole	Launched	tubulin polymerization inhibitor	TUBA1A|TUBB|TUBB4B	infectious disease	pinworm|whipworm|hookworm|ascariasis	0	96.72	MicroSource	1501110	MEBENDAZOLE	295.096	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	OPXLLQIJSORQAM-UHFFFAOYSA-N	4030.0		OPXLLQIJSORQAM
BRD-A09467419-003-23-9	mebeverine	Launched	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	0	95.61	MedChemEx	HY-A0078	Mebeverine (hydrochloride)	429.252	CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|	VYVKHNNGDFVQGA-IBGZPJMESA-N	6604311.0		VYVKHNNGDFVQGA
BRD-A09467419-003-22-4	mebeverine	Launched	acetylcholine receptor antagonist	CHRM1	gastroenterology	irritable bowel syndrome	0	95.24	MicroSource	1501117	MEBEVERINE HYDROCHLORIDE	429.252	CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|	VYVKHNNGDFVQGA-IBGZPJMESA-N	6604311.0		VYVKHNNGDFVQGA
BRD-K29713308-001-07-9	mebhydrolin	Launched	antihistamine		allergy	allergic rhinitis|urticaria	0	98.78	MedChemEx	HY-B1303A	Mebhydrolin	276.163	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	FQQIIPAOSKSOJM-UHFFFAOYSA-N	22530.0		FQQIIPAOSKSOJM
BRD-K29713308-001-01-7	mebhydrolin	Launched	antihistamine		allergy	allergic rhinitis|urticaria	0	90.08	MicroSource	1501116	MEBHYDROLIN	276.163	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	FQQIIPAOSKSOJM-UHFFFAOYSA-N	22530.0		FQQIIPAOSKSOJM
BRD-K29713308-077-04-1	mebhydrolin	Launched	antihistamine		allergy	allergic rhinitis|urticaria	0	93.45	Prestwick	Prestw-455	Mebhydroline 1,5-naphtalenedisulfonate	276.163	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	FQQIIPAOSKSOJM-UHFFFAOYSA-N	22530.0	BRD-M45580279-077-05-4	FQQIIPAOSKSOJM
BRD-K76606751-001-02-9	mebicar	Launched	anxiolytic		neurology/psychiatry	anxiety	0	100.0	Pharmeks	PHAR005658	1,3,4,6-tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione	198.112	CN1C2C(N(C)C1=O)N(C)C(=O)N2C	XIUUSFJTJXFNGH-UHFFFAOYSA-N	122282.0		XIUUSFJTJXFNGH
BRD-K76606751-001-01-7	mebicar	Launched	anxiolytic		neurology/psychiatry	anxiety	0	94.75	ChemDiv	8645-0066		198.112	CN1C2C(N(C)C1=O)N(C)C(=O)N2C	XIUUSFJTJXFNGH-UHFFFAOYSA-N	122282.0		XIUUSFJTJXFNGH
BRD-K96691275-001-01-2	mebrofenin	Launched			radiology	diagnostic agent	0	69.8	Sigma	MFCD00216974	2,2'-(2-(3-bromo-2,4,6-trimethylphenylamino)-2-oxoethylazanediyl)diacetic acid	386.048	Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br	MHPZZZZLAQGTHT-UHFFFAOYSA-N	54158.0		MHPZZZZLAQGTHT
BRD-A20119038-003-07-8	mecamylamine	Launched	acetylcholine receptor antagonist	CHRNA1|CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB4	cardiology	hypertension	0	100.0	MicroSource	1500374	MECAMYLAMINE HYDROCHLORIDE	167.167	CNC1(C)C2CCC(C2)C1(C)C	IMYZQPCYWPFTAG-UHFFFAOYSA-N	46912050.0		IMYZQPCYWPFTAG
BRD-K28405228-001-06-7	mecarbinate	Preclinical					0	97.97	Selleck	S2074	Mecarbinate	233.105	CCOC(=O)c1c(C)n(C)c2ccc(O)cc12	YTBNTDMBGXAOCG-UHFFFAOYSA-N	616236.0		YTBNTDMBGXAOCG
BRD-K25075681-001-02-0	meclinertant	Phase 2/Phase 3	neurotensin receptor antagonist	NTSR1|NTSR2			0	98.44	Sigma	S____SML0278	2-({[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)-2-adamantanecarboxylic acid	586.198	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O	DYLJVOXRWLXDIG-UHFFFAOYSA-N	119192.0		DYLJVOXRWLXDIG
BRD-K01826560-300-20-9	meclizine	Launched	constitutive androstane receptor (CAR) agonist	NR1I3	gastroenterology|neurology/psychiatry	nausea|vomiting|motion sickness	0	96.5	Tocris	4245	Meclizine dihydrochloride	390.186	Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|	OCJYIGYOJCODJL-VWLOTQADSA-N	6604289.0		OCJYIGYOJCODJL
BRD-A07600638-060-05-2	meclocycline-sulfosalicylate	Launched	bacterial 50S ribosomal subunit inhibitor		dermatology|infectious disease	acne vulgaris (AV)|skin infections	0	78.67	MicroSource	1501118	MECLOCYCLINE SULFOSALICYLATE	476.099	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|	MEFKOOXNVFALTA-IWVLMIASSA-N			MEFKOOXNVFALTA
BRD-A07600638-060-06-0	meclocycline-sulfosalicylate	Launched	bacterial 50S ribosomal subunit inhibitor		dermatology|infectious disease	acne vulgaris (AV)|skin infections	0	82.79	DuPont	A001593196	(4S,4aR,5S,5aS,12aS)-7-chloro-4-(dimethylamino)-5,10,12a-trihydroxy-6-methylene-1,3,11,12-tetraoxo-1,2,3,4,4a,5,5a,6,11,11a,12,12a-dodecahydrotetracene-2-carboxamide 2-hydroxy-5-sulfobenzoate	476.099	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|	MEFKOOXNVFALTA-IWVLMIASSA-N			MEFKOOXNVFALTA
BRD-A07600638-060-04-5	meclocycline-sulfosalicylate	Launched	bacterial 50S ribosomal subunit inhibitor		dermatology|infectious disease	acne vulgaris (AV)|skin infections	0	74.73	Selleck	S4331	Meclocycline Sulfosalicylate	476.099	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3,4,5,7,23,&1:20,&2:27,t:22,29|	MEFKOOXNVFALTA-IWVLMIASSA-N			MEFKOOXNVFALTA
BRD-K50398167-236-23-5	meclofenamic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	ALOX5|CNR1|KCNQ2|KCNQ3|PTGS1|PTGS2	rheumatology|neurology/psychiatry|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)	0	99.02	Sigma	M4531-1G	Meclofenamic acid sodium salt	295.017	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	SBDNJUWAMKYJOX-UHFFFAOYSA-N	4037.0		SBDNJUWAMKYJOX
BRD-K50398167-236-22-7	meclofenamic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	ALOX5|CNR1|KCNQ2|KCNQ3|PTGS1|PTGS2	rheumatology|neurology/psychiatry|endocrinology	joint pain|muscle pain|rheumatoid arthritis|primary dysmenorrhea (PD)	0	98.55	MicroSource	1500377	MECLOFENAMATE SODIUM	295.017	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	SBDNJUWAMKYJOX-UHFFFAOYSA-N	4037.0		SBDNJUWAMKYJOX
BRD-K10314788-003-13-9	meclofenoxate	Launched	nootropic agent		neurology/psychiatry	senile dementia|Alzheimer's disease	0	88.5	MedChemEx	HY-17555	Meclofenoxate (hydrochloride)	257.082	CN(C)CCOC(=O)COc1ccc(Cl)cc1	XZTYGFHCIAKPGJ-UHFFFAOYSA-N	4039.0		XZTYGFHCIAKPGJ
BRD-K10314788-003-12-7	meclofenoxate	Launched	nootropic agent		neurology/psychiatry	senile dementia|Alzheimer's disease	0	87.92	MicroSource	1503226	MECLOFENOXATE HYDROCHLORIDE	257.082	CN(C)CCOC(=O)COc1ccc(Cl)cc1	XZTYGFHCIAKPGJ-UHFFFAOYSA-N	4039.0		XZTYGFHCIAKPGJ
BRD-K81993098-003-15-0	mecysteine	Launched	analgesic agent		pulmonary	chest congestion	0	100.0	CombiBlocks	QA-2631	L-Cysteine methyl ester hydrochloride	135.035	COC(=O)[C@@H](N)CS	MCYHPZGUONZRGO-VKHMYHEASA-N	29145.0		MCYHPZGUONZRGO
BRD-A66563878-003-10-9	medetomidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	sedative	0	92.92	Tocris	5160	Medetomidine hydrochloride	200.131	C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|	CUHVIMMYOGQXCV-LLVKDONJSA-N	60612.0		CUHVIMMYOGQXCV
BRD-A66563878-003-06-9	medetomidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	sedative	0	97.68	Selleck	S3060	Medetomidine HCl	200.131	C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|	CUHVIMMYOGQXCV-LLVKDONJSA-N	60612.0		CUHVIMMYOGQXCV
BRD-A66563878-003-04-9	medetomidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	sedative	0	90.66	Tocris	5160	Medetomidine hydrochloride	200.131	C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|	CUHVIMMYOGQXCV-LLVKDONJSA-N	60612.0		CUHVIMMYOGQXCV
BRD-A66563878-003-05-9	medetomidine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	sedative	0	98.61	Tocris	5160	Medetomidine hydrochloride	200.131	C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|	CUHVIMMYOGQXCV-LLVKDONJSA-N	60612.0		CUHVIMMYOGQXCV
BRD-K92908289-001-01-8	medica-16	Phase 2	ATP citrase lyase inhibitor	FFAR1			0	98.1	Cayman	90290	3,3,14,14-tetramethylhexadecanedioic acid	342.277	CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O	HYSMCRNFENOHJH-UHFFFAOYSA-N	121871.0		HYSMCRNFENOHJH
BRD-K92908289-001-02-9	medica-16	Phase 2	ATP citrase lyase inhibitor	FFAR1			0		Tocris	4615	MEDICA 16	342.277	CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O	HYSMCRNFENOHJH-UHFFFAOYSA-N	121871.0		HYSMCRNFENOHJH
BRD-K40715924-001-02-9	medorinone	Phase 1					0	93.66	Key	3N-012	5-methyl[1,6]naphthyridin-2-ol	160.064	Cc1nccc2[nH]c(=O)ccc12	OCCZJXAHSUCJSA-UHFFFAOYSA-N	5362132.0		OCCZJXAHSUCJSA
BRD-K40715924-001-01-1	medorinone	Phase 1					0	97.74	Key	3N-012		160.064	Cc1nccc2[nH]c(=O)ccc12	OCCZJXAHSUCJSA-UHFFFAOYSA-N	5362132.0		OCCZJXAHSUCJSA
BRD-K94072573-001-09-9	medronic-acid	Launched	bone resorption inhibitor		radiology	skeletal imaging agent	0	98.4	Sigma	MFCD00002139	methylenediphosphonic acid	175.964	OP(O)(=O)CP(O)(O)=O	MBKDYNNUVRNNRF-UHFFFAOYSA-N	16124.0		MBKDYNNUVRNNRF
BRD-K99615199-001-19-9	medroxyprogesterone	Launched	progesterone receptor agonist	PGR	endocrinology	contraceptive	0	87.26	MedChemEx	HY-B0648	Medroxyprogesterone	344.235	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	FRQMUZJSZHZSGN-HBNHAYAOSA-N	10631.0		FRQMUZJSZHZSGN
BRD-K99615199-001-18-5	medroxyprogesterone	Launched	progesterone receptor agonist	PGR	endocrinology	contraceptive	0	95.16	MedChemEx	HY-B0648	Medroxyprogesterone	344.235	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	FRQMUZJSZHZSGN-HBNHAYAOSA-N	10631.0		FRQMUZJSZHZSGN
BRD-K82216340-001-26-9	medroxyprogesterone-acetate	Launched	progesterone receptor agonist	ESR1|PGR	endocrinology	contraceptive	0	88.18	MedChemEx	HY-B0469	Medroxyprogesterone (acetate)	386.246	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|	PSGAAPLEWMOORI-PEINSRQWSA-N	6279.0		PSGAAPLEWMOORI
BRD-K56515112-001-23-9	medrysone	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis|episcleritis	0	90.65	MedChemEx	HY-B1076	Medrysone	344.235	C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	GZENKSODFLBBHQ-ILSZZQPISA-N	247839.0		GZENKSODFLBBHQ
BRD-K56515112-001-21-6	medrysone	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis|episcleritis	0	95.45	MicroSource	1500380	MEDRYSONE	344.235	C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	GZENKSODFLBBHQ-ILSZZQPISA-N	247839.0	BRD-A20126139-001-04-2	GZENKSODFLBBHQ
BRD-K56515112-001-22-4	medrysone	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology	conjunctivitis|episcleritis	0	84.56	Selleck	S4332	Medrysone	344.235	C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	GZENKSODFLBBHQ-ILSZZQPISA-N	247839.0		GZENKSODFLBBHQ
BRD-K92778217-001-35-9	mefenamic-acid	Launched	cyclooxygenase inhibitor	KCNQ1|PTGS1|PTGS2|TRPM3	endocrinology	primary dysmenorrhea (PD)	0	99.15	MedChemEx	HY-B0574	Mefenamic acid	241.11	Cc1cccc(Nc2ccccc2C(O)=O)c1C	HYYBABOKPJLUIN-UHFFFAOYSA-N	4044.0		HYYBABOKPJLUIN
BRD-K92778217-001-32-7	mefenamic-acid	Launched	cyclooxygenase inhibitor	KCNQ1|PTGS1|PTGS2|TRPM3	endocrinology	primary dysmenorrhea (PD)	0	99.01	MicroSource	1501103	MEFENAMIC ACID	241.11	Cc1cccc(Nc2ccccc2C(O)=O)c1C	HYYBABOKPJLUIN-UHFFFAOYSA-N	4044.0		HYYBABOKPJLUIN
BRD-K92778217-001-31-9	mefenamic-acid	Launched	cyclooxygenase inhibitor	KCNQ1|PTGS1|PTGS2|TRPM3	endocrinology	primary dysmenorrhea (PD)	0	98.05	Selleck	S4078	Mefenamic Acid	241.11	Cc1cccc(Nc2ccccc2C(O)=O)c1C	HYYBABOKPJLUIN-UHFFFAOYSA-N	4044.0		HYYBABOKPJLUIN
BRD-K20655524-003-13-9	mefexamide	Preclinical	psychoactive drug				0	92.03	Vitas-M	STK370566	N-[2-(diethylamino)ethyl]-2-(4-methoxyphenoxy)acetamide	280.179	CCN(CC)CCNC(=O)COc1ccc(OC)cc1	HUNIPYLVUPMFCZ-UHFFFAOYSA-N	4045.0		HUNIPYLVUPMFCZ
BRD-K20655524-003-12-0	mefexamide	Preclinical	psychoactive drug				0	99.12	MicroSource	1501108	MEFEXAMIDE HYDROCHLORIDE	280.179	CCN(CC)CCNC(=O)COc1ccc(OC)cc1	HUNIPYLVUPMFCZ-UHFFFAOYSA-N	4045.0		HUNIPYLVUPMFCZ
BRD-K40645748-003-17-9	mefloquine	Launched	adenosine receptor antagonist|hemoglobin antagonist		infectious disease	malaria	0	97.93	MedChemEx	HY-17437A	Mefloquine (hydrochloride)	378.117	O[C@H]([C@H]1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F	XEEQGYMUWCZPDN-DOMZBBRYSA-N	40692.0		XEEQGYMUWCZPDN
BRD-K00004691-001-01-9	megestrol	Launched	progesterone receptor agonist		oncology	breast cancer	0	100.0	CombiBlocks	QN-9272	Megestrol	342.219	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9,12|	VXIMPSPISRVBPZ-NWUMPJBXSA-N	19090.0		VXIMPSPISRVBPZ
BRD-K19507340-001-28-9	megestrol-acetate	Launched	progesterone receptor agonist	NR3C1|PGR	neurology/psychiatry|endocrinology	anorexia|cachexia	0	80.33	Tocris	6285	Megestrol Acetate	384.23	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	11683.0		RQZAXGRLVPAYTJ
BRD-K19507340-001-26-2	megestrol-acetate	Launched	progesterone receptor agonist	NR3C1|PGR	neurology/psychiatry|endocrinology	anorexia|cachexia	0	88.79	TCI	M1949	Megesterol acetate	384.23	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	11683.0		RQZAXGRLVPAYTJ
BRD-K19507340-001-22-1	megestrol-acetate	Launched	progesterone receptor agonist	NR3C1|PGR	neurology/psychiatry|endocrinology	anorexia|cachexia	0	98.58	Selleck	S1304	Megestrol Acetate	384.23	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	11683.0		RQZAXGRLVPAYTJ
BRD-K19507340-001-27-9	megestrol-acetate	Launched	progesterone receptor agonist	NR3C1|PGR	neurology/psychiatry|endocrinology	anorexia|cachexia	0	91.13	MedChemEx	HY-13676	Megestrol Acetate	384.23	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	11683.0		RQZAXGRLVPAYTJ
BRD-K19507340-001-25-4	megestrol-acetate	Launched	progesterone receptor agonist	NR3C1|PGR	neurology/psychiatry|endocrinology	anorexia|cachexia	0	89.31	Selleck	S1304	Megestrol Acetate	384.23	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9,12|	RQZAXGRLVPAYTJ-GQFGMJRRSA-N	11683.0	BRD-K29344105-001-01-6	RQZAXGRLVPAYTJ
BRD-K51324732-001-01-0	meglitinide	Phase 2	potassium channel blocker	CCR2			0	99.32	Enamine	Z224216672		333.077	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O	SWLAMJPTOQZTAE-UHFFFAOYSA-N	41214.0		SWLAMJPTOQZTAE
BRD-K28595280-001-04-5	meglumine	Launched	excipient				0	100.0	MicroSource	1300029	MEGLUMINE	195.111	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	MBBZMMPHUWSWHV-BDVNFPICSA-N	8567.0		MBBZMMPHUWSWHV
BRD-K28595280-001-03-7	meglumine	Launched	excipient				0	89.46	Selleck	S1974	Meglumine	195.111	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	MBBZMMPHUWSWHV-BDVNFPICSA-N	8567.0		MBBZMMPHUWSWHV
BRD-K28595280-001-05-2	meglumine	Launched	excipient				0	98.99	Selleck	S1974	Meglumine	195.111	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	MBBZMMPHUWSWHV-BDVNFPICSA-N	8567.0		MBBZMMPHUWSWHV
BRD-K00495673-001-05-2	meglutol	Launched	HMGCR inhibitor	HMGCR			1	0.0	MicroSource	1506183	MEGLUTOL	162.053	CC(O)(CC(O)=O)CC(O)=O	NPOAOTPXWNWTSH-UHFFFAOYSA-N	1662.0		NPOAOTPXWNWTSH
BRD-K14529030-001-01-9	meisoindigo	Phase 3	STAT inhibitor	STAT3			0	97.04	MedChemEx	HY-13680	Meisoindigo	276.09	CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12	QNOCRUSVMMAKSC-CCEZHUSRSA-N			QNOCRUSVMMAKSC
BRD-K14529030-001-03-9	meisoindigo	Phase 3	STAT inhibitor	STAT3			0	94.2	MedChemEx	HY-13680	Meisoindigo	276.09	CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12	QNOCRUSVMMAKSC-CCEZHUSRSA-N			QNOCRUSVMMAKSC
BRD-K12244279-001-05-8	MEK1-2-inhibitor	Preclinical	MEK inhibitor	MAP2K2			0	95.74	Tocris	1969	SL 327	335.07	Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1	XQRVCODIGHFXKQ-UHFFFAOYSA-N	54483521.0		XQRVCODIGHFXKQ
BRD-K12244279-001-04-1	MEK1-2-inhibitor	Preclinical	MEK inhibitor	MAP2K2			0	90.76	Selleck	S1066	SL-327	335.07	Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1	XQRVCODIGHFXKQ-UHFFFAOYSA-N	54483521.0		XQRVCODIGHFXKQ
BRD-K75989555-001-02-9	melanotan-ii	Launched	melanocortin receptor agonist				0	95.58	MedChemEx	HY-P0267	Melanotan (MT)-II	1023.54	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(N)=O	JDKLPDJLXHXHNV-VEUPWBLKSA-N	134812787.0		JDKLPDJLXHXHNV
BRD-K97530723-001-24-1	melatonin	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB	neurology/psychiatry	sleep cycle support	0	95.68	Tocris	3550	Melatonin	232.121	COc1ccc2[nH]cc(CCNC(C)=O)c2c1	DRLFMBDRBRZALE-UHFFFAOYSA-N	896.0		DRLFMBDRBRZALE
BRD-K97530723-001-20-9	melatonin	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB	neurology/psychiatry	sleep cycle support	0	94.12	Tocris	3550	Melatonin	232.121	COc1ccc2[nH]cc(CCNC(C)=O)c2c1	DRLFMBDRBRZALE-UHFFFAOYSA-N	896.0		DRLFMBDRBRZALE
BRD-K97530723-001-19-1	melatonin	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB	neurology/psychiatry	sleep cycle support	0	93.98	Selleck	S1204	Melatonin	232.121	COc1ccc2[nH]cc(CCNC(C)=O)c2c1	DRLFMBDRBRZALE-UHFFFAOYSA-N	896.0		DRLFMBDRBRZALE
BRD-K97530723-001-25-9	melatonin	Launched	melatonin receptor agonist|nitric oxide synthase inhibitor	ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB	neurology/psychiatry	sleep cycle support	0	95.93	Tocris	3550	Melatonin	232.121	COc1ccc2[nH]cc(CCNC(C)=O)c2c1	DRLFMBDRBRZALE-UHFFFAOYSA-N	896.0		DRLFMBDRBRZALE
BRD-K79392608-335-01-8	meldonium	Launched	gamma butyrobetaine hydroxylase inhibitor	BBOX1	cardiology	coronary artery disease (CAD)	0	60.9	LifeChem	F2173-0055	3-(1,1,1-trimethylhydrazin-1-ium-2-yl)propanoate dihydrate	147.113	C[N+](C)(C)NCCC(O)=O	PVBQYTCFVWZSJK-UHFFFAOYSA-O	123869.0		PVBQYTCFVWZSJK
BRD-A42746051-001-02-9	melengestrol-acetate	Preclinical	progesterone receptor agonist				0	86.88	MicroSource	1505727	MELENGESTROL ACETATE	396.23	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C |a:4,22,27,&1:11,&2:12,&3:24,t:13,16|	UDKABVSQKJNZBH-AKZSSJSASA-N			UDKABVSQKJNZBH
BRD-K18749874-003-09-9	melevodopa	Launched	dopamine precursor|dopamine receptor agonist	DDC	neurology/psychiatry	Parkinson's Disease	0	90.21	Vitas-M	STK874011	Levodopa methyl ester hydrochloride	211.084	COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	XBBDACCLCFWBSI-ZETCQYMHSA-N	23497.0		XBBDACCLCFWBSI
BRD-K18749874-003-08-9	melevodopa	Launched	dopamine precursor|dopamine receptor agonist	DDC	neurology/psychiatry	Parkinson's Disease	0	88.63	Sigma	MFCD00038958	methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate hydrochloride	211.084	COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	XBBDACCLCFWBSI-ZETCQYMHSA-N	23497.0		XBBDACCLCFWBSI
BRD-K01826742-323-07-9	meloxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	98.16	Sigma	MFCD11046047	sodium 2-methyl-3-{[(5-methyl-1,3-thiazol-2-yl)amino]carbonyl}-2H-1,2-benzothiazin-4-olate 1,1-dioxide hydrate	392.035	CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|	ZRVUJXDFFKFLMG-UHFFFAOYSA-N	54677470.0		ZRVUJXDFFKFLMG
BRD-K92984783-003-06-5	melperone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	psychosis	0	84.47	Tocris	2495	Melperone hydrochloride	263.169	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	DKMFBWQBDIGMHM-UHFFFAOYSA-N	15387.0		DKMFBWQBDIGMHM
BRD-K92984783-003-05-7	melperone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	psychosis	0	96.46	Tocris	2495	Melperone hydrochloride	263.169	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	DKMFBWQBDIGMHM-UHFFFAOYSA-N	15387.0		DKMFBWQBDIGMHM
BRD-K92984783-003-07-9	melperone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	psychosis	0	89.15	Tocris	2495	Melperone hydrochloride	263.169	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	DKMFBWQBDIGMHM-UHFFFAOYSA-N	15387.0		DKMFBWQBDIGMHM
BRD-K87827419-001-16-8	melphalan	Launched	DNA alkylating agent|DNA inhibitor		hematologic malignancy	multiple myeloma	0	93.38	MicroSource	1500382	MELPHALAN	304.075	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	SGDBTWWWUNNDEQ-LBPRGKRZSA-N	6918992.0		SGDBTWWWUNNDEQ
BRD-K87827419-001-14-3	melphalan	Launched	DNA alkylating agent|DNA inhibitor		hematologic malignancy	multiple myeloma	0	61.29	MicroSource	1500382	MELPHALAN	304.075	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	SGDBTWWWUNNDEQ-LBPRGKRZSA-N	6918992.0		SGDBTWWWUNNDEQ
BRD-K36394566-300-01-0	melphalan-n-oxide	Phase 1	hypoxia inducible factor inhibitor	HIF1A			0	67.76	Adooq	A14319	(S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide dihydrochloride	320.069	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	GSKQMLGAUOTSKT-LBPRGKRZSA-N	11234795.0		GSKQMLGAUOTSKT
BRD-A07164067-001-01-2	meluadrine	Preclinical					0	98.2	MedChemEx	HY-50291	HOKU-81	243.103	CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl |&1:6,r|	LIXBJWRFCNRAPA-LLVKDONJSA-N	92261245.0		LIXBJWRFCNRAPA
BRD-K91938660-003-10-9	memantine	Launched	glutamate receptor antagonist		neurology/psychiatry	Alzheimer's disease|senile dementia	0	100.0	Tocris	773	Memantine hydrochloride	179.167	C[C@@]12C[C@H]3C[C@@](C)(C1)C[C@](N)(C3)C2	BUGYDGFZZOZRHP-CDECOKDKSA-N			BUGYDGFZZOZRHP
BRD-K78126613-001-30-9	menadione	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis	0	70.29	MedChemEx	HY-B0332	Menadione	172.052	CC1=CC(=O)c2ccccc2C1=O |t:1|	MJVAVZPDRWSRRC-UHFFFAOYSA-N	4055.0		MJVAVZPDRWSRRC
BRD-K78126613-001-28-5	menadione	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis	0	98.17	MicroSource	1502254	MENADIONE	172.052	CC1=CC(=O)c2ccccc2C1=O |t:1|	MJVAVZPDRWSRRC-UHFFFAOYSA-N	4055.0		MJVAVZPDRWSRRC
BRD-K78126613-001-27-7	menadione	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis	0	76.1	Selleck	S1949	Menadione	172.052	CC1=CC(=O)c2ccccc2C1=O |t:1|	MJVAVZPDRWSRRC-UHFFFAOYSA-N	4055.0		MJVAVZPDRWSRRC
BRD-K78126613-001-29-3	menadione	Launched	mitochondrial DNA polymerase inhibitor|phosphatase inhibitor	AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1	gastroenterology|neurology/psychiatry|dermatology|rheumatology	ulcerative colitis|diarrhea|headache|varicose veins|rheumatoid arthritis	0	88.05	Selleck	S1949	Menadione	172.052	CC1=CC(=O)c2ccccc2C1=O |t:1|	MJVAVZPDRWSRRC-UHFFFAOYSA-N	4055.0		MJVAVZPDRWSRRC
BRD-K01826025-236-01-9	menadione-bisulfite	Phase 2	vitamin K	GGCX|VKORC1|VKORC1L1			0	98.12	Sigma	M5750	sodium 2-methyl-1,4-dioxo-1,2,3,4-tetrahydro-2-naphthalenesulfonate	277.015	C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|	WIXFIQKTHUVFDI-LLVKDONJSA-N	1711949.0		WIXFIQKTHUVFDI
BRD-K75864342-001-14-2	menatetrenone	Launched	bone resorption inhibitor		orthopedics	osteoporosis	0	48.49	Sigma	MFCD00079646	2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl]naphthoquinone	444.303	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	DKHGMERMDICWDU-GHDNBGIDSA-N	5282367.0		DKHGMERMDICWDU
BRD-K53852914-001-02-9	menbutone	Launched			gastroenterology	bile stimulation	0	95.74	MedChemEx	HY-B1136	Menbutone	258.089	COc1ccc(C(=O)CCC(O)=O)c2ccccc12	FHGJSJFIQNQBCK-UHFFFAOYSA-N	71818.0		FHGJSJFIQNQBCK
BRD-K53852914-001-01-8	menbutone	Launched			gastroenterology	bile stimulation	0	93.68	MicroSource	1506198	MENBUTONE	258.089	COc1ccc(C(=O)CCC(O)=O)c2ccccc12	FHGJSJFIQNQBCK-UHFFFAOYSA-N	71818.0		FHGJSJFIQNQBCK
BRD-A45889380-300-06-3	mepacrine	Launched	cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator	PLA2G1B	infectious disease	giardiasis	0	89.18	Selleck	S4255	Quinacrine 2HCl	399.208	CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|	GPKJTRJOBQGKQK-MRXNPFEDSA-N	446536.0		GPKJTRJOBQGKQK
BRD-A45889380-300-07-1	mepacrine	Launched	cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator	PLA2G1B	infectious disease	giardiasis	0	95.48	MicroSource	1500522	QUINACRINE HYDROCHLORIDE	399.208	CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|	GPKJTRJOBQGKQK-MRXNPFEDSA-N	446536.0		GPKJTRJOBQGKQK
BRD-A45889380-300-08-9	mepacrine	Launched	cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator	PLA2G1B	infectious disease	giardiasis	0	91.49	Selleck	S4255	Quinacrine 2HCl	399.208	CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|	GPKJTRJOBQGKQK-MRXNPFEDSA-N	446536.0		GPKJTRJOBQGKQK
BRD-A11662333-001-03-3	meparfylon	Preclinical					1	0.0	MicroSource	1506158	MEPARFYLON	98.073	CCC(C)(O)C#C |&1:2|	QXLPXWSKPNOQLE-UHFFFAOYSA-N	6494.0		QXLPXWSKPNOQLE
BRD-K01825575-001-03-9	mepazine	Phase 2	MALT1 inhibitor (JH)	MALT1			0	90.48	ChemDiv	S008-0093		310.15	CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5,r|	CBHCDHNUZWWAPP-OAHLLOKOSA-N	7047378.0		CBHCDHNUZWWAPP
BRD-A62421304-004-19-9	mepenzolate	Launched	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	0	99.16	MedChemEx	HY-17585	Mepenzolate (Bromide)	340.191	C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|	GKNPSSNBBWDAGH-IBGZPJMESA-N	13981865.0		GKNPSSNBBWDAGH
BRD-A62421304-004-18-9	mepenzolate	Launched	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	0	99.17	MicroSource	1500383	MEPENZOLATE BROMIDE	340.191	C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|	GKNPSSNBBWDAGH-IBGZPJMESA-N	13981865.0		GKNPSSNBBWDAGH
BRD-A62421304-004-17-1	mepenzolate	Launched	acetylcholine receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	0	96.66	Selleck	S4375	Mepenzolate Bromide	340.191	C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|	GKNPSSNBBWDAGH-IBGZPJMESA-N	13981865.0		GKNPSSNBBWDAGH
BRD-A55469827-001-07-4	mephenesin	Launched	muscle relaxant		neurology/psychiatry	muscle relaxant	0	99.05	MicroSource	1501140	MEPHENESIN	182.094	Cc1ccccc1OC[C@@H](O)CO |&1:9,r|	JWDYCNIAQWPBHD-VIFPVBQESA-N	6931199.0		JWDYCNIAQWPBHD
BRD-A55469827-001-08-9	mephenesin	Launched	muscle relaxant		neurology/psychiatry	muscle relaxant	0	95.39	MedChemEx	HY-B1283	Mephenesin	182.094	Cc1ccccc1OC[C@@H](O)CO |&1:9,r|	JWDYCNIAQWPBHD-VIFPVBQESA-N	6931199.0		JWDYCNIAQWPBHD
BRD-K18194590-065-08-0	mephentermine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3	cardiology	hypotension	0	93.01	MicroSource	1503250	MEPHENTERMINE SULFATE	163.136	CNC(C)(C)Cc1ccccc1	RXQCGGRTAILOIN-UHFFFAOYSA-N	3677.0		RXQCGGRTAILOIN
BRD-K18194590-003-09-9	mephentermine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3	cardiology	hypotension	0	89.53	Toronto	M224500	mephentermine hydrochloride	163.136	CNC(C)(C)Cc1ccccc1	RXQCGGRTAILOIN-UHFFFAOYSA-N	3677.0		RXQCGGRTAILOIN
BRD-A83937277-001-10-5	mephenytoin	Launched	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	0	98.67	MicroSource	1503709	MEPHENYTOIN	218.106	CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|	GMHKMTDVRCWUDX-LBPRGKRZSA-N	107921.0		GMHKMTDVRCWUDX
BRD-A83937277-001-12-9	mephenytoin	Launched	hydantoin antiepileptic	SCN5A	neurology/psychiatry	seizures	0	86.63	Tocris	3276	Mephenytoin	218.106	CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2,r|	GMHKMTDVRCWUDX-LBPRGKRZSA-N	107921.0		GMHKMTDVRCWUDX
BRD-K78299798-001-03-0	mepiroxol	Preclinical					0	96.09	MicroSource	1504616	MEPIROXOL	125.048	OCc1ccc[n+]([O-])c1	LQYJAVWWKTWWKN-UHFFFAOYSA-N	71668.0		LQYJAVWWKTWWKN
BRD-K78299798-001-02-2	mepiroxol	Preclinical					0	98.37	Selleck	S4333	Mepiroxol	125.048	OCc1ccc[n+]([O-])c1	LQYJAVWWKTWWKN-UHFFFAOYSA-N	71668.0		LQYJAVWWKTWWKN
BRD-K78299798-001-04-8	mepiroxol	Preclinical					0	64.1	Selleck	S4333	Mepiroxol	125.048	OCc1ccc[n+]([O-])c1	LQYJAVWWKTWWKN-UHFFFAOYSA-N	71668.0		LQYJAVWWKTWWKN
BRD-A03216249-003-24-3	mepivacaine	Launched	potassium channel blocker|sodium channel blocker		neurology/psychiatry	local anesthetic	0	97.82	MicroSource	1504148	MEPIVACAINE HYDROCHLORIDE	246.173	CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|	INWLQCZOYSRPNW-CYBMUJFWSA-N	6918904.0		INWLQCZOYSRPNW
BRD-A03216249-003-23-5	mepivacaine	Launched	potassium channel blocker|sodium channel blocker		neurology/psychiatry	local anesthetic	0	97.45	Selleck	S3155	Mepivacaine HCl	246.173	CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|	INWLQCZOYSRPNW-CYBMUJFWSA-N	6918904.0		INWLQCZOYSRPNW
BRD-A03216249-003-25-9	mepivacaine	Launched	potassium channel blocker|sodium channel blocker		neurology/psychiatry	local anesthetic	0	93.69	MedChemEx	HY-B0517A	Mepivacaine (hydrochloride)	246.173	CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|	INWLQCZOYSRPNW-CYBMUJFWSA-N	6918904.0		INWLQCZOYSRPNW
BRD-K18207669-001-03-9	meprednisone	Launched		NR3C1			0	96.1	MedChemEx	HY-B0243	Meprednisone	372.194	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	PIDANAQULIKBQS-RNUIGHNZSA-N	5284587.0		PIDANAQULIKBQS
BRD-K18207669-001-02-4	meprednisone	Launched		NR3C1			0	0.0	Selleck	S1689	Betapar (Meprednisone)	372.194	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11,t:7|	PIDANAQULIKBQS-RNUIGHNZSA-N	5284587.0		PIDANAQULIKBQS
BRD-K65417056-003-10-1	meprylcaine	Preclinical	local anesthetic				0	83.5	MicroSource	1505553	MEPRYLCAINE HYDROCHLORIDE	235.157	CCCNC(C)(C)COC(=O)c1ccccc1	VXJABHHJLXLNMP-UHFFFAOYSA-N	4065.0		VXJABHHJLXLNMP
BRD-K65417056-003-11-9	meprylcaine	Preclinical	local anesthetic				0	87.77	Toronto	M224980	meprylcaine hydrochloride	235.157	CCCNC(C)(C)COC(=O)c1ccccc1	VXJABHHJLXLNMP-UHFFFAOYSA-N	4065.0		VXJABHHJLXLNMP
BRD-A02710418-003-13-4	meptazinol	Launched	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	0	78.49	Tocris	3636	Meptazinol hydrochloride	233.178	CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|	JLICHNCFTLFZJN-OAHLLOKOSA-N	25271754.0		JLICHNCFTLFZJN
BRD-A02710418-003-12-6	meptazinol	Launched	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	0	94.08	Selleck	S3204	Meptazinol HCl	233.178	CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|	JLICHNCFTLFZJN-OAHLLOKOSA-N	25271754.0		JLICHNCFTLFZJN
BRD-A02710418-003-11-8	meptazinol	Launched	opioid receptor agonist	BCHE	neurology/psychiatry	pain relief	0	85.51	Selleck	S3204	Meptazinol HCl	233.178	CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|	JLICHNCFTLFZJN-OAHLLOKOSA-N	25271754.0		JLICHNCFTLFZJN
BRD-K97564742-051-02-8	mepyramine	Launched	histamine receptor antagonist	HRH1	otolaryngology|obstetrics/gynecology	common cold|menstrual pain	0	94.32	Selleck	S4382	Pyrilamine Maleate	285.184	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	YECBIJXISLIIDS-UHFFFAOYSA-N	4992.0		YECBIJXISLIIDS
BRD-K97564742-050-34-9	mepyramine	Launched	histamine receptor antagonist	HRH1	otolaryngology|obstetrics/gynecology	common cold|menstrual pain	0	93.51	Tocris	660	Mepyramine maleate	285.184	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	YECBIJXISLIIDS-UHFFFAOYSA-N	4992.0		YECBIJXISLIIDS
BRD-K97564742-050-32-7	mepyramine	Launched	histamine receptor antagonist	HRH1	otolaryngology|obstetrics/gynecology	common cold|menstrual pain	0	99.13	MicroSource	1500519	PYRILAMINE MALEATE	285.184	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	YECBIJXISLIIDS-UHFFFAOYSA-N	4992.0		YECBIJXISLIIDS
BRD-K97564742-050-31-9	mepyramine	Launched	histamine receptor antagonist	HRH1	otolaryngology|obstetrics/gynecology	common cold|menstrual pain	0	96.39	Tocris	660	Mepyramine maleate	285.184	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	YECBIJXISLIIDS-UHFFFAOYSA-N	4992.0		YECBIJXISLIIDS
BRD-K45216060-001-10-0	mequinol	Launched		TYR	dermatology	skin depigmentation	0	94.54	MicroSource	212037	MEQUINOL	124.052	COc1ccc(O)cc1	NWVVVBRKAWDGAB-UHFFFAOYSA-N	9015.0		NWVVVBRKAWDGAB
BRD-K45216060-001-09-2	mequinol	Launched		TYR	dermatology	skin depigmentation	0	0.0	Selleck	S4077	Mequinol	124.052	COc1ccc(O)cc1	NWVVVBRKAWDGAB-UHFFFAOYSA-N	9015.0		NWVVVBRKAWDGAB
BRD-K45216060-001-11-8	mequinol	Launched		TYR	dermatology	skin depigmentation	0	99.23	Selleck	S4077	Mequinol	124.052	COc1ccc(O)cc1	NWVVVBRKAWDGAB-UHFFFAOYSA-N	9015.0		NWVVVBRKAWDGAB
BRD-K45152786-001-09-9	merbarone	Phase 2	topoisomerase inhibitor	TOP2A			0	76.39	AMS	A001191168	4,6-dioxo-N-phenyl-2-thioxohexahydro-5-pyrimidinecarboxamide	263.036	Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1	GFYRZTLCYQQVHZ-UHFFFAOYSA-N	3000671.0		GFYRZTLCYQQVHZ
BRD-K45152786-001-08-4	merbarone	Phase 2	topoisomerase inhibitor	TOP2A			0	100.0	EMDBio	445800-25MG	Merbarone	263.036	Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1	GFYRZTLCYQQVHZ-UHFFFAOYSA-N	3000671.0		GFYRZTLCYQQVHZ
BRD-K21771665-304-04-2	merbromin	Launched	antiseptic		infectious disease	first-aid antiseptic	1	0.0	MicroSource	1500637	MERBROMIN	705.855	O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12	OHCFGBLQZMYRTR-UHFFFAOYSA-M			OHCFGBLQZMYRTR
BRD-K91601245-001-12-0	mercaptopurine	Launched	immunosuppressant|protein synthesis inhibitor|purine antagonist	HPRT1|IMPDH1|IMPDH2|PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	100.0	Selleck	S1305	Mercaptopurine (6-MP)	152.016	S=c1nc[nH]c2nc[nH]c12	GLVAUDGFNGKCSF-UHFFFAOYSA-N	667490.0		GLVAUDGFNGKCSF
BRD-K91601245-001-16-1	mercaptopurine	Launched	immunosuppressant|protein synthesis inhibitor|purine antagonist	HPRT1|IMPDH1|IMPDH2|PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	100.0	Selleck	S1305	Mercaptopurine (6-MP)	152.016	S=c1nc[nH]c2nc[nH]c12	GLVAUDGFNGKCSF-UHFFFAOYSA-N	667490.0		GLVAUDGFNGKCSF
BRD-K91601245-001-13-8	mercaptopurine	Launched	immunosuppressant|protein synthesis inhibitor|purine antagonist	HPRT1|IMPDH1|IMPDH2|PPAT	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	100.0	MicroSource	1500387	MERCAPTOPURINE	152.016	S=c1nc[nH]c2nc[nH]c12	GLVAUDGFNGKCSF-UHFFFAOYSA-N	667490.0		GLVAUDGFNGKCSF
BRD-A43435802-001-02-0	mercaptosuccinic-acid	Launched					0	100.0	Enamine	Z104478826		149.999	OC(=O)C[C@@H](S)C(O)=O |&1:4,r|	NJRXVEJTAYWCQJ-UWTATZPHSA-N	638130.0		NJRXVEJTAYWCQJ
BRD-A43435802-001-01-2	mercaptosuccinic-acid	Launched					0	0.0	Enamine	Z104478826		149.999	OC(=O)C[C@@H](S)C(O)=O |&1:4,r|	NJRXVEJTAYWCQJ-UWTATZPHSA-N	638130.0		NJRXVEJTAYWCQJ
BRD-K04466929-001-12-9	Merck60	Preclinical	HDAC inhibitor	HDAC1|HDAC2			0		Broad Institute	BRD-K04466929	BRD6929	351.104	CC(=O)Nc1ccc(cc1)C(=O)Nc1cc(ccc1N)-c1cccs1	ABZSPJVXTTUFAA-UHFFFAOYSA-N	6918878.0		ABZSPJVXTTUFAA
BRD-K69726595-001-02-9	mericitabine	Phase 2	HCV inhibitor				0	92.61	MedChemEx	HY-10240	Mericitabine	399.181	CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	MLESJYFEMSJZLZ-MAAOGQSESA-N	16122663.0		MLESJYFEMSJZLZ
BRD-K69726595-001-01-2	mericitabine	Phase 2	HCV inhibitor				0	98.0	MedChemEx	HY-10240	R-7128	399.181	CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	MLESJYFEMSJZLZ-MAAOGQSESA-N	16122663.0		MLESJYFEMSJZLZ
BRD-K09372874-001-01-0	merimepodib	Phase 2	inosine monophosphate dehydrogenase inhibitor	IMPDH1			0	98.21	MedChemEx	HY-13986	Merimepodib	452.17	COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	JBPUGFODGPKTDW-SFHVURJKSA-N	153241.0		JBPUGFODGPKTDW
BRD-K09372874-001-02-9	merimepodib	Phase 2	inosine monophosphate dehydrogenase inhibitor	IMPDH1			0	97.51	MedChemEx	HY-13986	Merimepodib	452.17	COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	JBPUGFODGPKTDW-SFHVURJKSA-N	153241.0		JBPUGFODGPKTDW
BRD-K01612348-001-11-4	meropenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|intra-abdominal infections|meningitis	0	0.0	Key	KS-5224	(4R,5S,6S)-3-({(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid	383.151	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|	DMJNNHOOLUXYBV-PQTSNVLCSA-N	441130.0		DMJNNHOOLUXYBV
BRD-K01612348-001-14-8	meropenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|intra-abdominal infections|meningitis	0	0.0	MicroSource	1502310	MEROPENEM	383.151	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|	DMJNNHOOLUXYBV-PQTSNVLCSA-N	441130.0	BRD-A53925737-001-01-9	DMJNNHOOLUXYBV
BRD-K01612348-001-12-2	meropenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|intra-abdominal infections|meningitis	0	23.73	Selleck	S1381	Meropenem	383.151	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|	DMJNNHOOLUXYBV-PQTSNVLCSA-N	441130.0	BRD-A18115130-001-03-0	DMJNNHOOLUXYBV
BRD-K01612348-001-13-0	meropenem	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections|intra-abdominal infections|meningitis	0	2.99	Selleck	S1381	Meropenem	383.151	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|	DMJNNHOOLUXYBV-PQTSNVLCSA-N	441130.0	BRD-A18115130-001-02-2	DMJNNHOOLUXYBV
BRD-K00003293-001-01-9	mertansine	Phase 2	microtubule inhibitor				0	91.36	MedChemEx	HY-19792	Mertansine	737.275	[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@@H]2C |c:16,t:14|	ANZJBCHSOXCCRQ-UTOUECMYSA-N	131847656.0		ANZJBCHSOXCCRQ
BRD-K28849549-001-12-6	mesalazine	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2	gastroenterology	ulcerative colitis|inflammatory bowel disease	0	15.6	MicroSource	1505993	MESALAMINE	153.043	Nc1ccc(O)c(c1)C(O)=O	KBOPZPXVLCULAV-UHFFFAOYSA-N	4075.0		KBOPZPXVLCULAV
BRD-K28849549-001-13-4	mesalazine	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2	gastroenterology	ulcerative colitis|inflammatory bowel disease	0	90.1	Selleck	S1681	Mesalamine (Lialda)	153.043	Nc1ccc(O)c(c1)C(O)=O	KBOPZPXVLCULAV-UHFFFAOYSA-N	4075.0		KBOPZPXVLCULAV
BRD-K28849549-001-11-8	mesalazine	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist	ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2	gastroenterology	ulcerative colitis|inflammatory bowel disease	0	0.0	Selleck	S1681	Mesalamine	153.043	Nc1ccc(O)c(c1)C(O)=O	KBOPZPXVLCULAV-UHFFFAOYSA-N	4075.0		KBOPZPXVLCULAV
BRD-K49954789-001-02-9	mesna	Launched	antioxidant		urology	hemorrhagic cystitis	0	92.74	MicroSource	1502014	MESNA	141.976	OS(=O)(=O)CCS	ZNEWHQLOPFWXOF-UHFFFAOYSA-N	598.0	BRD-M40783228-001-15-0	ZNEWHQLOPFWXOF
BRD-K49954789-001-03-7	mesna	Launched	antioxidant		urology	hemorrhagic cystitis	0	0.0	Selleck	S1735	Mesna (Uromitexan, Mesnex)	141.976	OS(=O)(=O)CCS	ZNEWHQLOPFWXOF-UHFFFAOYSA-N	598.0	BRD-M40783228-001-16-8	ZNEWHQLOPFWXOF
BRD-K49954789-001-01-1	mesna	Launched	antioxidant		urology	hemorrhagic cystitis	0	0.0	Selleck	S1735	Mesna	141.976	OS(=O)(=O)CCS	ZNEWHQLOPFWXOF-UHFFFAOYSA-N	598.0	BRD-M40783228-001-14-3	ZNEWHQLOPFWXOF
BRD-K01827307-074-10-9	mesoridazine	Launched	dopamine receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	89.42	Selleck	S4334	Mesoridazine Besylate	544.152	CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|	SLVMESMUVMCQIY-AKJBCIBTSA-N	57146948.0		SLVMESMUVMCQIY
BRD-K01827307-074-12-9	mesoridazine	Launched	dopamine receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	88.83	Selleck	S4334	mesoridazine besylate	544.152	CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|	SLVMESMUVMCQIY-AKJBCIBTSA-N	57146948.0		SLVMESMUVMCQIY
BRD-K01827307-074-13-9	mesoridazine	Launched	dopamine receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	68.64	Selleck	S4334	MESORIDAZINE	544.152	CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|	SLVMESMUVMCQIY-AKJBCIBTSA-N	57146948.0		SLVMESMUVMCQIY
BRD-K01827307-074-11-9	mesoridazine	Launched	dopamine receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	96.87	MicroSource	1505500	MESORIDAZINE BESYLATE	544.152	CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23,&1:6|	SLVMESMUVMCQIY-AKJBCIBTSA-N	57146948.0		SLVMESMUVMCQIY
BRD-K69688083-004-24-9	mestinon	Launched	cholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	myasthenia gravis	0	98.59	MedChemEx	HY-B0207A	Pyridostigmine (bromide)	181.098	CN(C)C(=O)Oc1ccc[n+](C)c1	RVOLLAQWKVFTGE-UHFFFAOYSA-N	4991.0		RVOLLAQWKVFTGE
BRD-K69688083-004-23-1	mestinon	Launched	cholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	myasthenia gravis	0	100.0	MicroSource	1503240	PYRIDOSTIGMINE BROMIDE	181.098	CN(C)C(=O)Oc1ccc[n+](C)c1	RVOLLAQWKVFTGE-UHFFFAOYSA-N	4991.0		RVOLLAQWKVFTGE
BRD-K69688083-004-22-3	mestinon	Launched	cholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	myasthenia gravis	0	91.81	Selleck	S1608	Pyridostigmine Bromide	181.098	CN(C)C(=O)Oc1ccc[n+](C)c1	RVOLLAQWKVFTGE-UHFFFAOYSA-N	4991.0		RVOLLAQWKVFTGE
BRD-K31920458-001-24-9	mestranol	Launched	estrogen receptor agonist	ESR1	endocrinology	contraceptive	0	93.82	MedChemEx	HY-B0390	Mestranol	310.193	COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	IMSSROKUHAOUJS-MJCUULBUSA-N	6291.0		IMSSROKUHAOUJS
BRD-K31920458-001-22-8	mestranol	Launched	estrogen receptor agonist	ESR1	endocrinology	contraceptive	0	96.53	Selleck	S2125	Mestranol	310.193	COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	IMSSROKUHAOUJS-MJCUULBUSA-N	6291.0	BRD-K92042497-001-01-4	IMSSROKUHAOUJS
BRD-K31920458-001-23-6	mestranol	Launched	estrogen receptor agonist	ESR1	endocrinology	contraceptive	0	98.35	MicroSource	1500388	MESTRANOL	310.193	COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	IMSSROKUHAOUJS-MJCUULBUSA-N	6291.0	BRD-A14798026-001-02-6	IMSSROKUHAOUJS
BRD-K91336023-003-01-0	mesulergine	Phase 2	dopamine receptor agonist	HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|HTR7			0	94.81	Enzo	AC834	Mesulergine HCl	362.178	CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1	JLVHTNZNKOSCNB-YSVLISHTSA-N	68848.0		JLVHTNZNKOSCNB
BRD-K91336023-003-03-9	mesulergine	Phase 2	dopamine receptor agonist	HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|HTR7			0	95.09	Tocris	1644	Mesulergine hydrochloride	362.178	CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1	JLVHTNZNKOSCNB-YSVLISHTSA-N	68848.0		JLVHTNZNKOSCNB
BRD-K33442414-001-02-6	meta-cresyl-acetate	Preclinical					0	0.0	MicroSource	1506049	meta-CRESYL ACETATE	150.068	CC(=O)Oc1cccc(C)c1	OTGAHJPFNKQGAE-UHFFFAOYSA-N	67406.0		OTGAHJPFNKQGAE
BRD-K16474819-001-09-6	metacetamol	Preclinical	analgesic agent				0	99.02	MicroSource	211175	METACETAMOL	151.063	CC(=O)Nc1cccc(O)c1	QLNWXBAGRTUKKI-UHFFFAOYSA-N	12124.0		QLNWXBAGRTUKKI
BRD-K22518984-001-01-8	metacresol	Launched		INS			0	96.37	MicroSource	1301055	METACRESOL	108.058	Cc1cccc(O)c1	RLSSMJSEOOYNOY-UHFFFAOYSA-N	342.0		RLSSMJSEOOYNOY
BRD-K22518984-001-04-9	metacresol	Launched		INS			0	83.51	MedChemEx	HY-Y0968	m-Cresol	108.058	Cc1cccc(O)c1	RLSSMJSEOOYNOY-UHFFFAOYSA-N	342.0		RLSSMJSEOOYNOY
BRD-K28580965-238-03-9	metafolin	Launched					0	67.8	MedChemEx	HY-17383	Levomefolate (calcium)	459.187	CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12	ZNOVTXRBGFNYRX-STQMWFEESA-N	135398561.0		ZNOVTXRBGFNYRX
BRD-K28580965-238-01-3	metafolin	Launched					0	0.0	MedChemEx	HY-17383	Levomefolate (calcium)	459.187	CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12	ZNOVTXRBGFNYRX-STQMWFEESA-N	135398561.0		ZNOVTXRBGFNYRX
BRD-K28580965-238-02-1	metafolin	Launched					0	0.0	MedChemEx	HY-17383	Levomefolate (calcium)	459.187	CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12	ZNOVTXRBGFNYRX-STQMWFEESA-N	135398561.0		ZNOVTXRBGFNYRX
BRD-K76812510-236-14-8	metamizole	Withdrawn	cyclooxygenase inhibitor|opioid receptor agonist	PTGS1			0	93.08	MicroSource	1503298	DIPYRONE	311.094	CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O	LVWZTYCIRDMTEY-UHFFFAOYSA-N	3111.0		LVWZTYCIRDMTEY
BRD-K95701999-066-06-9	metaphit	Preclinical	phencyclidine receptor acylator				0	36.49	SantaCruz	sc-253003	Metaphit Methanesulfonate	300.166	S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1	FGSGBQAQSPSRJK-UHFFFAOYSA-N	114745.0		FGSGBQAQSPSRJK
BRD-K95701999-001-02-3	metaphit	Preclinical	phencyclidine receptor acylator				0	12.3	Tocris	568	Metaphit	300.166	S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1	FGSGBQAQSPSRJK-UHFFFAOYSA-N	114745.0		FGSGBQAQSPSRJK
BRD-K01826731-065-09-9	metaproterenol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm|asthma|bronchitis|emphysema	0	69.08	Selleck	S4335	Metaproterenol Sulfate	309.088	CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|	LMOINURANNBYCM-LLVKDONJSA-N	25271693.0	BRD-M02190957-065-05-7	LMOINURANNBYCM
BRD-K01826731-065-10-9	metaproterenol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm|asthma|bronchitis|emphysema	0	98.07	Selleck	S4335	metaproterenol sulfate	309.088	CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|	LMOINURANNBYCM-LLVKDONJSA-N	25271693.0	BRD-M02190957-065-06-5	LMOINURANNBYCM
BRD-K96253961-046-04-9	metaraminol	Launched	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	0	47.09	MicroSource	1503251	METARAMINOL BITARTRATE	167.095	C[C@H](N)[C@H](O)c1cccc(O)c1	WXFIGDLSSYIKKV-RCOVLWMOSA-N	5906.0		WXFIGDLSSYIKKV
BRD-K96253961-046-05-6	metaraminol	Launched	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	0	95.01	Selleck	S4336	metaraminol bitartrate	167.095	C[C@H](N)[C@H](O)c1cccc(O)c1	WXFIGDLSSYIKKV-RCOVLWMOSA-N	5906.0		WXFIGDLSSYIKKV
BRD-K96253961-046-03-1	metaraminol	Launched	adrenergic receptor agonist	ADRA1A	cardiology	hypotension	0	86.09	Selleck	S4336	Metaraminol Bitartrate	167.095	C[C@H](N)[C@H](O)c1cccc(O)c1	WXFIGDLSSYIKKV-RCOVLWMOSA-N	5906.0		WXFIGDLSSYIKKV
BRD-K27182532-001-03-9	metatinib	Phase 1	Bcr-Abl kinase inhibitor	ABL1|BCR			0	97.66	MedChemEx	HY-10497	BMS-794833	468.08	Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	PDYXPCKITKHFOZ-UHFFFAOYSA-N	44155856.0		PDYXPCKITKHFOZ
BRD-K27182532-001-02-3	metatinib	Phase 1	Bcr-Abl kinase inhibitor	ABL1|BCR			0	98.07	Selleck	S2201	BMS-794833	468.08	Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	PDYXPCKITKHFOZ-UHFFFAOYSA-N	44155856.0		PDYXPCKITKHFOZ
BRD-A94709349-001-08-3	metaxalone	Launched	muscle relaxant		neurology/psychiatry	muscle pain	0	99.54	MicroSource	1504229	METAXALONE	221.105	Cc1cc(C)cc(OC[C@H]2CNC(=O)O2)c1 |&1:9,r|	IMWZZHHPURKASS-LLVKDONJSA-N	25271694.0		IMWZZHHPURKASS
BRD-A78277353-001-01-9	metazosin	Phase 2	adrenergic receptor antagonist	ADRA1A			0	98.7	Sigma	MFCD00891638	6,7-dimethoxy-2-[4-(2-methoxypropanoyl)-1-piperazinyl]-4-quinazolinamine	375.191	CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2,r|	YEOTYALSMRNXLJ-NSHDSACASA-N	51057264.0		YEOTYALSMRNXLJ
BRD-A38218502-001-01-2	metenkephalin	Phase 2	immunostimulant	OPRD1			0	91.27	MPBio	2190430	[Met5]-ENKEPHALIN	573.226	CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4,&2:8,&3:27,r|	YFGBQHOOROIVKG-BHDDXSALSA-N	73265283.0		YFGBQHOOROIVKG
BRD-K56699285-001-24-3	metergoline	Launched	dopamine receptor agonist|serotonin receptor antagonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia	0	94.0	Tocris	590	Metergoline	403.226	CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13	WZHJKEUHNJHDLS-QTGUNEKASA-N	28693.0		WZHJKEUHNJHDLS
BRD-K56699285-001-25-9	metergoline	Launched	dopamine receptor agonist|serotonin receptor antagonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia	0	93.56	Tocris	590	Metergoline	403.226	CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13	WZHJKEUHNJHDLS-QTGUNEKASA-N	28693.0		WZHJKEUHNJHDLS
BRD-K56699285-001-23-5	metergoline	Launched	dopamine receptor agonist|serotonin receptor antagonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	neurology/psychiatry|endocrinology	seasonal affective disorder|anxiety|hyperprolactinemia	0	85.3	Tocris	590	Metergoline	403.226	CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13	WZHJKEUHNJHDLS-QTGUNEKASA-N	28693.0		WZHJKEUHNJHDLS
BRD-K79602928-003-19-9	metformin	Launched	insulin sensitizer	ACACB|PRKAB1	endocrinology	diabetes mellitus	0	93.76	MicroSource	1505814	METFORMIN HYDROCHLORIDE	129.101	CN(C)C(=N)N=C(N)N	XZWYZXLIPXDOLR-UHFFFAOYSA-N	4091.0		XZWYZXLIPXDOLR
BRD-K79602928-003-21-5	metformin	Launched	insulin sensitizer	ACACB|PRKAB1	endocrinology	diabetes mellitus	0	85.3	Tocris	2864	Metformin hydrochloride	129.101	CN(C)C(=N)N=C(N)N	XZWYZXLIPXDOLR-UHFFFAOYSA-N	4091.0		XZWYZXLIPXDOLR
BRD-K79602928-003-18-1	metformin	Launched	insulin sensitizer	ACACB|PRKAB1	endocrinology	diabetes mellitus	0	92.62	Selleck	S1950	Metformin hydrochloride (Glucophage)	129.101	CN(C)C(=N)N=C(N)N	XZWYZXLIPXDOLR-UHFFFAOYSA-N	4091.0		XZWYZXLIPXDOLR
BRD-K79602928-003-23-9	metformin	Launched	insulin sensitizer	ACACB|PRKAB1	endocrinology	diabetes mellitus	0	58.1	Tocris	2864	Metformin hydrochloride	129.101	CN(C)C(=N)N=C(N)N	XZWYZXLIPXDOLR-UHFFFAOYSA-N	4091.0		XZWYZXLIPXDOLR
BRD-A18056626-003-23-9	methacholine	Launched	acetylcholine receptor agonist	CHRM2|CHRM4	pulmonary	bronchial hyperresponsiveness diagnostic	0	100.0	MedChemEx	HY-A0083	Methacholine (chloride)	160.134	C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|	NZWOPGCLSHLLPA-ZETCQYMHSA-N	6603706.0		NZWOPGCLSHLLPA
BRD-A18056626-003-22-3	methacholine	Launched	acetylcholine receptor agonist	CHRM2|CHRM4	pulmonary	bronchial hyperresponsiveness diagnostic	0	98.32	MicroSource	1500391	METHACHOLINE CHLORIDE	160.134	C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|	NZWOPGCLSHLLPA-ZETCQYMHSA-N	6603706.0		NZWOPGCLSHLLPA
BRD-K00003351-003-01-9	methacycline	Preclinical	protein synthesis inhibitor		pulmonary	bronchitis	0	86.43	MedChemEx	HY-B0449	Methacycline (hydrochloride)	442.138	[H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22,&2:12|	QNJKSUYWBCNWFI-IKHBEOKZSA-N			QNJKSUYWBCNWFI
BRD-K53896891-001-01-2	methanesulfonyl-fluoride	Phase 2	acetylcholinesterase inhibitor	ACHE			1	0.0	Sigma	MFCD00007423	methanesulfonyl fluoride	97.984	CS(F)(=O)=O	KNWQLFOXPQZGPX-UHFFFAOYSA-N	11207.0		KNWQLFOXPQZGPX
BRD-K09859624-004-10-4	methantheline	Launched	acetylcholine receptor antagonist	CHRM1|HRH2	gastroenterology|neurology/psychiatry|urology	peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder	0	53.05	Prestwick	Prestw-1066	Methantheline bromide	340.191	CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12	GZHFODJQISUKAY-UHFFFAOYSA-N	4097.0		GZHFODJQISUKAY
BRD-K09859624-004-11-9	methantheline	Launched	acetylcholine receptor antagonist	CHRM1|HRH2	gastroenterology|neurology/psychiatry|urology	peptic ulcer disease (PUD)|irritable bowel syndrome|pancreatitis|dyskinesia|neurogenic bladder	0	95.7	Toronto	u700650	ulcine bromide	340.191	CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12	GZHFODJQISUKAY-UHFFFAOYSA-N	4097.0		GZHFODJQISUKAY
BRD-K47323024-003-25-1	methapyrilene	Withdrawn	histamine receptor antagonist	HRH1			0	91.22	MicroSource	1503229	METHAPYRILENE HYDROCHLORIDE	261.13	CN(C)CCN(Cc1cccs1)c1ccccn1	HNJJXZKZRAWDPF-UHFFFAOYSA-N	4098.0		HNJJXZKZRAWDPF
BRD-K47323024-003-24-4	methapyrilene	Withdrawn	histamine receptor antagonist	HRH1			0	93.74	Selleck	S4337	Methapyrilene HCl	261.13	CN(C)CCN(Cc1cccs1)c1ccccn1	HNJJXZKZRAWDPF-UHFFFAOYSA-N	4098.0		HNJJXZKZRAWDPF
BRD-K88143662-001-01-5	metharbital	Launched	GABA receptor modulator	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2	neurology/psychiatry	epilepsy	0	99.64	Enamine	Z2205958937	5,5-diethyl-1-methyl-2,4,6(1H,3H,5H)-pyrimidinetrione	198.1	CCC1(CC)C(=O)NC(=O)N(C)C1=O	FWJKNZONDWOGMI-UHFFFAOYSA-N	4099.0		FWJKNZONDWOGMI
BRD-K00002562-001-02-9	methazolamide	Launched	carbonic anhydrase inhibitor	CA1|CA12|CA14|CA2|CA4|CA7	ophthalmology	glaucoma|intraocular pressure	0	90.21	MedChemEx	HY-B0553	Methazolamide	236.004	CC(=O)N=c1sc(nn1C)S(N)(=O)=O	FLOSMHQXBMRNHR-UHFFFAOYSA-N	4100.0		FLOSMHQXBMRNHR
BRD-K30114692-001-15-9	methenamine	Launched	bacterial DNA inhibitor		infectious disease	urinary tract infections	0	100.0	Selleck	S3139	Methenamine	140.106	C1N2CN3CN1CN(C2)C3	VKYKSIONXSXAKP-UHFFFAOYSA-N	4101.0		VKYKSIONXSXAKP
BRD-K30114692-001-16-7	methenamine	Launched	bacterial DNA inhibitor		infectious disease	urinary tract infections	0	95.18	MicroSource	1500394	METHENAMINE	140.106	C1N2CN3CN1CN(C2)C3	VKYKSIONXSXAKP-UHFFFAOYSA-N	4101.0		VKYKSIONXSXAKP
BRD-K02764365-001-13-6	methiazole	Preclinical	anthelmintic agent				0	95.06	Prestwick	Prestw-1080	Methiazole	265.088	COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1	SXJIZQPZESTWLD-UHFFFAOYSA-N	6604471.0		SXJIZQPZESTWLD
BRD-K34388247-236-09-0	methicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	85.33	Sigma	51454	sodium (2S,5R,6R)-6-[(2,6-dimethoxybenzoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	380.104	COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	RJQXTJLFIWVMTO-TYNCELHUSA-N	6087.0		RJQXTJLFIWVMTO
BRD-K34388247-236-08-2	methicillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	84.29	MicroSource	1500395	METHICILLIN SODIUM	380.104	COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	RJQXTJLFIWVMTO-TYNCELHUSA-N	6087.0		RJQXTJLFIWVMTO
BRD-K54416256-001-18-1	methimazole	Launched	antithyroid agent	TPO	endocrinology	hyperthyroidism	0	91.26	Selleck	S1609	Methimazole	114.025	Cn1cc[nH]c1=S	PMRYVIKBURPHAH-UHFFFAOYSA-N	1349907.0		PMRYVIKBURPHAH
BRD-K54416256-001-19-9	methimazole	Launched	antithyroid agent	TPO	endocrinology	hyperthyroidism	0	100.0	MicroSource	1500396	METHIMAZOLE	114.025	Cn1cc[nH]c1=S	PMRYVIKBURPHAH-UHFFFAOYSA-N	1349907.0		PMRYVIKBURPHAH
BRD-A39515206-001-01-9	methionine	Launched		METAP2			0	47.29	Sigma	M0950000	methionine	149.051	CSCC[C@@H](N)C(O)=O |&1:4,r|	FFEARJCKVFRZRR-SCSAIBSYSA-N	84815.0		FFEARJCKVFRZRR
BRD-K00004541-001-01-9	methiopril	Phase 2	angiotensin converting enzyme inhibitor	ACE			0	91.68	Vitas-M	STL026579	Methiapril	273.103	C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1,5,r|	JHFOAISYWJRTIM-PSASIEDQSA-N	667560.0		JHFOAISYWJRTIM
BRD-A31521121-001-25-6	methocarbamol	Launched	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	0	93.82	Selleck	S1736	Methocarbamol	241.095	COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|	GNXFOGHNGIVQEH-MRVPVSSYSA-N	688484.0		GNXFOGHNGIVQEH
BRD-A31521121-001-28-9	methocarbamol	Launched	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	0	95.13	MedChemEx	HY-B0262	Methocarbamol	241.095	COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|	GNXFOGHNGIVQEH-MRVPVSSYSA-N	688484.0		GNXFOGHNGIVQEH
BRD-A31521121-001-26-4	methocarbamol	Launched	muscle relaxant	CA1	neurology/psychiatry	muscle relaxant	0	99.36	MicroSource	1500397	METHOCARBAMOL	241.095	COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10,r|	GNXFOGHNGIVQEH-MRVPVSSYSA-N	688484.0		GNXFOGHNGIVQEH
BRD-K34591242-001-04-3	methoprene-(s)	Preclinical					0	86.73	MicroSource	1504100	METHOPRENE (S)	310.251	COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C	NFGXHKASABOEEW-GYMWBFJFSA-N	1711973.0		NFGXHKASABOEEW
BRD-K34591242-001-05-9	methoprene-(s)	Preclinical					0	11.17	Sigma	MFCD00867612	S-(+)-METHOPRENE	310.251	COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C	NFGXHKASABOEEW-GYMWBFJFSA-N	1711973.0		NFGXHKASABOEEW
BRD-K59456551-001-22-6	methotrexate	Launched	dihydrofolate reductase inhibitor	DHFR	oncology|hematologic malignancy|dermatology|rheumatology	gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis	0	98.9	Selleck	S1210	Abitrexate (Methotrexate)	454.171	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	FBOZXECLQNJBKD-ZDUSSCGKSA-N	126941.0		FBOZXECLQNJBKD
BRD-K59456551-001-19-2	methotrexate	Launched	dihydrofolate reductase inhibitor	DHFR	oncology|hematologic malignancy|dermatology|rheumatology	gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis	0	36.97	Selleck	S1210	Methotrexate	454.171	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	FBOZXECLQNJBKD-ZDUSSCGKSA-N	126941.0		FBOZXECLQNJBKD
BRD-K59456551-001-20-0	methotrexate	Launched	dihydrofolate reductase inhibitor	DHFR	oncology|hematologic malignancy|dermatology|rheumatology	gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis	0	44.47	Tocris	1230	Methotrexate	454.171	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	FBOZXECLQNJBKD-ZDUSSCGKSA-N	126941.0		FBOZXECLQNJBKD
BRD-K59456551-001-27-9	methotrexate	Launched	dihydrofolate reductase inhibitor	DHFR	oncology|hematologic malignancy|dermatology|rheumatology	gestational choriocarcinoma|hydatidiform mole|acute lymphoblastic leukemia (ALL)|psoriasis|rheumatoid arthritis	0	95.18	Tocris	1230	Methotrexate	454.171	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	FBOZXECLQNJBKD-ZDUSSCGKSA-N	126941.0		FBOZXECLQNJBKD
BRD-A39189014-003-21-9	methoxamine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D	cardiology	hypotension	0	94.31	Selleck	S4338	Methoxamine HCl	211.121	COc1ccc(OC)c(c1)C(O)C(C)N	WJAJPNHVVFWKKL-UHFFFAOYSA-N	657286.0		WJAJPNHVVFWKKL
BRD-A39189014-003-22-7	methoxamine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D	cardiology	hypotension	0	97.81	MicroSource	1500399	METHOXAMINE HYDROCHLORIDE	211.121	COc1ccc(OC)c(c1)C(O)C(C)N	WJAJPNHVVFWKKL-UHFFFAOYSA-N	657286.0		WJAJPNHVVFWKKL
BRD-A39189014-003-23-5	methoxamine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D	cardiology	hypotension	0	91.2	Selleck	S4338	2-amino-1-(2,5-dimethoxyphenyl)-1-propanol	211.121	COc1ccc(OC)c(c1)C(O)C(C)N	WJAJPNHVVFWKKL-UHFFFAOYSA-N	657286.0		WJAJPNHVVFWKKL
BRD-K63430059-001-16-4	methoxsalen	Launched	DNA synthesis inhibitor	CYP1A1|CYP1A2|CYP2A13|CYP2A6|CYP3A4	dermatology	psoriasis	0	98.69	Selleck	S1952	Methoxsalen	216.042	COc1c2occc2cc2ccc(=O)oc12	QXKHYNVANLEOEG-UHFFFAOYSA-N	4114.0		QXKHYNVANLEOEG
BRD-K63430059-001-17-2	methoxsalen	Launched	DNA synthesis inhibitor	CYP1A1|CYP1A2|CYP2A13|CYP2A6|CYP3A4	dermatology	psoriasis	0	99.46	MicroSource	1500400	METHOXSALEN	216.042	COc1c2occc2cc2ccc(=O)oc12	QXKHYNVANLEOEG-UHFFFAOYSA-N	4114.0		QXKHYNVANLEOEG
BRD-K79277568-003-04-7	methoxyamine	Phase 2	DNA repair enzyme inhibitor	APEX1			1	0.0	Otava	1270718		47.037	CON	GMPKIPWJBDOURN-UHFFFAOYSA-N	4113.0		GMPKIPWJBDOURN
BRD-K06152156-001-02-6	methoxyflurane	Launched	membrane permeability inhibitor	ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|MT-ND1	neurology/psychiatry	general anaesthetic	1	0.0	Sigma	MFCD00040144	2,2-dichloro-1,1-difluoro-1-methoxyethane	163.961	COC(F)(F)C(Cl)Cl	RFKMCNOHBTXSMU-UHFFFAOYSA-N	4116.0		RFKMCNOHBTXSMU
BRD-K06152156-001-01-8	methoxyflurane	Launched	membrane permeability inhibitor	ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|MT-ND1	neurology/psychiatry	general anaesthetic	1	0.0	MatrixSci	8896		163.961	COC(F)(F)C(Cl)Cl	RFKMCNOHBTXSMU-UHFFFAOYSA-N	4116.0		RFKMCNOHBTXSMU
BRD-A21474126-001-01-6	methoxyphenamine	Launched	adrenergic receptor agonist		pulmonary	asthma	0	98.67	Sigma	PH011732	1-(2-methoxyphenyl)-N-methyl-2-propanamine	179.131	CN[C@@H](C)Cc1ccccc1OC |&1:2,r|	OEHAYUOVELTAPG-VIFPVBQESA-N	6918906.0		OEHAYUOVELTAPG
BRD-K48619321-004-19-9	methscopolamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	gastroenterology	peptic ulcer disease (PUD)	0	97.3	MedChemEx	HY-B0344	Methscopolamine (bromide)	318.171	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	LZCOQTDXKCNBEE-IKIFYQGPSA-N			LZCOQTDXKCNBEE
BRD-K48619321-004-16-8	methscopolamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	gastroenterology	peptic ulcer disease (PUD)	0	98.54	Selleck	S1978	Methscopolamine (Pamine)	318.171	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	LZCOQTDXKCNBEE-IKIFYQGPSA-N			LZCOQTDXKCNBEE
BRD-K48619321-004-17-6	methscopolamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	gastroenterology	peptic ulcer disease (PUD)	0	89.57	Selleck	S1978	Methscopolamine	318.171	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	LZCOQTDXKCNBEE-IKIFYQGPSA-N		BRD-K05224916-004-01-1	LZCOQTDXKCNBEE
BRD-K48619321-004-18-4	methscopolamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	gastroenterology	peptic ulcer disease (PUD)	0	94.22	Selleck	S1978	Methylscopolamine	318.171	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	LZCOQTDXKCNBEE-IKIFYQGPSA-N			LZCOQTDXKCNBEE
BRD-A57592049-001-01-6	methsuximide	Launched	T-type calcium channel blocker	CACNA1G|CACNA1H|CACNA1I	neurology/psychiatry	seizures	0	99.54	MicroSource	1505443	METHSUXIMIDE	203.095	CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|	AJXPJJZHWIXJCJ-GFCCVEGCSA-N	25271978.0		AJXPJJZHWIXJCJ
BRD-A57592049-001-02-9	methsuximide	Launched	T-type calcium channel blocker	CACNA1G|CACNA1H|CACNA1I	neurology/psychiatry	seizures	0	93.69	AMS	M0153	Methsuximide	203.095	CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5,r|	AJXPJJZHWIXJCJ-GFCCVEGCSA-N	25271978.0		AJXPJJZHWIXJCJ
BRD-A95340155-001-09-7	methyclothiazide	Launched	chloride reabsorption inhibitor	SLC12A1|SLC12A3	cardiology	hypertension|edema	0	97.93	Selleck	S4057	Methyclothiazide	358.957	CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|	CESYKOGBSMNBPD-VIFPVBQESA-N	12309469.0		CESYKOGBSMNBPD
BRD-K01292611-003-17-8	methyl-aminolevulinate	Launched	oxidizing agent	FCGR1A|FECH	dermatology	actinic keratosis (AK)	1	0.0	Enzo	AC3187	METHYL AMINOLEVULINATE HCl	145.074	COC(=O)CCC(=O)CN	YUUAYBAIHCDHHD-UHFFFAOYSA-N	157922.0		YUUAYBAIHCDHHD
BRD-K10132944-001-02-9	methyl-nicotinate	Phase 2					0	0.0	Sigma	Y0000398	methyl nicotinate	137.048	COC(=O)c1cccnc1	YNBADRVTZLEFNH-UHFFFAOYSA-N	7151.0		YNBADRVTZLEFNH
BRD-K10132944-001-01-1	methyl-nicotinate	Phase 2					0	0.0	Vitas-M	STK803258		137.048	COC(=O)c1cccnc1	YNBADRVTZLEFNH-UHFFFAOYSA-N	7151.0		YNBADRVTZLEFNH
BRD-K10103010-001-05-9	methyl-salicylate	Launched			endocrinology|neurology/psychiatry	fever|pain relief	0	0.0	MedChemEx	HY-Y0189	Methyl Salicylate	152.047	COC(=O)c1ccccc1O	OSWPMRLSEDHDFF-UHFFFAOYSA-N	4133.0		OSWPMRLSEDHDFF
BRD-K10103010-001-01-1	methyl-salicylate	Launched			endocrinology|neurology/psychiatry	fever|pain relief	0	0.0	Enamine	Z19703590		152.047	COC(=O)c1ccccc1O	OSWPMRLSEDHDFF-UHFFFAOYSA-N	4133.0		OSWPMRLSEDHDFF
BRD-K01827294-050-06-9	methyl-5-hydroxytryptamine	Preclinical					0	46.0	Tocris	557	?-Methyl-5-hydroxytryptamine maleate	306.122	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	LYPCGXKCQDYTFV-SSDOTTSWSA-N	14083218.0		LYPCGXKCQDYTFV
BRD-K01827294-050-05-9	methyl-5-hydroxytryptamine	Preclinical					0	64.4	Tocris	557	?-Methyl-5-hydroxytryptamine maleate	306.122	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	LYPCGXKCQDYTFV-SSDOTTSWSA-N	14083218.0		LYPCGXKCQDYTFV
BRD-K00004543-005-01-9	methylatropine-nitrate	Preclinical	acetylcholine receptor antagonist	CHRM1			0	82.69	Vitas-M	STK108600	3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane	304.191	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3,6,8,&2:13|	PIPAJLPNWZMYQA-HZMVEIRTSA-N			PIPAJLPNWZMYQA
BRD-K00003518-004-01-9	methylbenactyzium-bromide	Preclinical	cholinergic receptor antagonist				0	98.62	MedChemEx	HY-B2070	Methylbenactyzium Bromide	342.207	CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	HDAMOICMOAXFLJ-UHFFFAOYSA-N	4134.0		HDAMOICMOAXFLJ
BRD-K46531780-003-18-9	methylbenzethonium-chloride	Preclinical	other antibiotic				0	64.12	MicroSource	1503253	METHYLBENZETHONIUM CHLORIDE	426.337	Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C	UQOOPIMXBSPVJI-UHFFFAOYSA-N	4135.0		UQOOPIMXBSPVJI
BRD-K46531780-003-19-7	methylbenzethonium-chloride	Preclinical	other antibiotic				0	97.14	Sigma	M7379-10G	Methylbenzethoniuim chloride	426.337	Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C	UQOOPIMXBSPVJI-UHFFFAOYSA-N	4135.0		UQOOPIMXBSPVJI
BRD-K00003534-001-01-9	methylcobalamin	Phase 3	vitamin B				0	27.21	MedChemEx	HY-B0586	Methylcobalamin	1344.596	[H][C@]1(CO)O[C@]([H])(n2cnc3cc(C)c(C)cc23)[C@]([H])(O)[C@]1([H])OP(O)(=O)O[C@H](C)CNC(=O)CC[C@@]1(C)\C2=C(C)\C3=N\C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]([H])(N2[Co+]C)[C@]1([H])CC(N)=O)[C@@](C)(CC(N)=O)[C@]5([H])CCC(N)=O)\[C@@](C)(CC(N)=O)[C@]4([H])CCC(N)=O)\C(C)(C)[C@]3([H])CCC(N)=O |c:41,t:44,46,48,50,53|	JEWJRMKHSMTXPP-WDJKBINPSA-M			JEWJRMKHSMTXPP
BRD-K48578705-001-17-6	methyldopa	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C|DDC	cardiology	hypertension	0	100.0	Selleck	S1642	Methyldopa (Aldomet)	211.084	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	CJCSPKMFHVPWAR-JTQLQIEISA-N	6919173.0		CJCSPKMFHVPWAR
BRD-K48578705-001-19-9	methyldopa	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C|DDC	cardiology	hypertension	0	86.62	Tocris	584	L-(-)-alpha-Methyldopa	211.084	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	CJCSPKMFHVPWAR-JTQLQIEISA-N	6919173.0		CJCSPKMFHVPWAR
BRD-K48578705-001-14-3	methyldopa	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C|DDC	cardiology	hypertension	0	0.0	Selleck	S1642	Methyldopa (Aldomet)	211.084	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	CJCSPKMFHVPWAR-JTQLQIEISA-N	6919173.0		CJCSPKMFHVPWAR
BRD-K48578705-001-15-0	methyldopa	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C|DDC	cardiology	hypertension	0	0.0	Tocris	584	L-(-)-?-Methyldopa	211.084	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	CJCSPKMFHVPWAR-JTQLQIEISA-N	6919173.0		CJCSPKMFHVPWAR
BRD-K48578705-001-16-8	methyldopa	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C|DDC	cardiology	hypertension	0	97.41	MicroSource	1500403	METHYLDOPA	211.084	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	CJCSPKMFHVPWAR-JTQLQIEISA-N	6919173.0		CJCSPKMFHVPWAR
BRD-K82259334-003-02-7	methyldopate	Launched			cardiology	hypertension	0	0.0	Prestwick	Prestw-1038	Methyldopate hydrochloride	239.116	CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1	SVEBYYWCXTVYCR-LBPRGKRZSA-N	17277.0		SVEBYYWCXTVYCR
BRD-K54770538-311-01-0	methylene-blue	Launched	guanylyl cyclase inhibitor|nitric oxide production inhibitor	ACHE	hematology	methemoglobinemia	0	47.14	MicroSource	1505444	METHYLENE BLUE	284.122	CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C	RBTBFTRPCNLSDE-UHFFFAOYSA-N	4139.0		RBTBFTRPCNLSDE
BRD-K54770538-003-14-6	methylene-blue	Launched	guanylyl cyclase inhibitor|nitric oxide production inhibitor	ACHE	hematology	methemoglobinemia	0	37.69	MedChemEx	HY-14536	Methylene Blue	284.122	CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C	RBTBFTRPCNLSDE-UHFFFAOYSA-N	4139.0		RBTBFTRPCNLSDE
BRD-K34685430-050-13-9	methylergometrine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache	0	92.76	Tocris	549	Methylergometrine maleate	339.195	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	UNBRKDKAWYKMIV-QWQRMKEZSA-N	8226.0		UNBRKDKAWYKMIV
BRD-K34685430-050-11-7	methylergometrine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache	0	86.0	Tocris	549	Methylergometrine maleate	339.195	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	UNBRKDKAWYKMIV-QWQRMKEZSA-N	8226.0		UNBRKDKAWYKMIV
BRD-K34685430-050-12-5	methylergometrine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C	hematology|neurology/psychiatry	postpartum hemorrhage (PPH)|migraine headache	0	91.71	MicroSource	1500404	METHYLERGONOVINE MALEATE	339.195	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	UNBRKDKAWYKMIV-QWQRMKEZSA-N	8226.0		UNBRKDKAWYKMIV
BRD-K43192255-048-02-8	methyllycaconitine	Preclinical	acetylcholine receptor antagonist	CHRNA7			0	92.94	Tocris	1029	Methyllycaconitine citrate	682.347	CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	XLTANAWLDBYGFU-VTLKBQQISA-N	5288811.0	BRD-A29043702-048-02-2	XLTANAWLDBYGFU
BRD-K43192255-048-01-0	methyllycaconitine	Preclinical	acetylcholine receptor antagonist	CHRNA7			0	93.67	Tocris	1029	((3S,6S,6aR,7R,7aR,8S,9R,10S,11aS,12R,12aR,13S,14S)-1-ethyl-11a,12-dihydroxy-6,8,10,13-tetramethoxydodecahydro-2H-3,6a,12-(epie	682.347	CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	XLTANAWLDBYGFU-VTLKBQQISA-N	5288811.0	BRD-A29043702-048-03-0	XLTANAWLDBYGFU
BRD-K43192255-048-03-6	methyllycaconitine	Preclinical	acetylcholine receptor antagonist	CHRNA7			0	82.68	Tocris	1029	Methyllycaconitine citrate	682.347	CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	XLTANAWLDBYGFU-VTLKBQQISA-N	5288811.0	BRD-A29043702-048-01-4|BRD-A32164164-048-02-2	XLTANAWLDBYGFU
BRD-K00003599-004-01-9	methylnaltrexone	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1	gastroenterology	constipation	0	92.79	MedChemEx	HY-75766	Methylnaltrexone (Bromide)	356.186	[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O	JVLBPIPGETUEET-WIXLDOGYSA-O	16089915.0		JVLBPIPGETUEET
BRD-K78321730-001-13-9	methylparaben	Launched	other antifungal		dermatology	cosmetic	0	98.44	MedChemEx	HY-N0349	Methyl Paraben	152.047	COC(=O)c1ccc(O)cc1	LXCFILQKKLGQFO-UHFFFAOYSA-N	7456.0		LXCFILQKKLGQFO
BRD-K78321730-001-10-8	methylparaben	Launched	other antifungal		dermatology	cosmetic	0	0.0	Enamine	Z19674820		152.047	COC(=O)c1ccc(O)cc1	LXCFILQKKLGQFO-UHFFFAOYSA-N	7456.0		LXCFILQKKLGQFO
BRD-K35240538-001-24-7	methylprednisolone	Launched	glucocorticoid receptor agonist	NR3C1	endocrinology|rheumatology|dermatology|infectious disease|allergy|hematology|neurology/psychiatry|gastroenterology	hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis	0	84.5	Tocris	4819	Methylprednisolone	374.209	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|	VHRSUDSXCMQTMA-PJHHCJLFSA-N	6741.0		VHRSUDSXCMQTMA
BRD-K35240538-001-25-4	methylprednisolone	Launched	glucocorticoid receptor agonist	NR3C1	endocrinology|rheumatology|dermatology|infectious disease|allergy|hematology|neurology/psychiatry|gastroenterology	hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis	0	90.96	Selleck	S1733	Methylprednisolone	374.209	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|	VHRSUDSXCMQTMA-PJHHCJLFSA-N	6741.0	BRD-K99443616-001-01-3	VHRSUDSXCMQTMA
BRD-K35240538-001-26-2	methylprednisolone	Launched	glucocorticoid receptor agonist	NR3C1	endocrinology|rheumatology|dermatology|infectious disease|allergy|hematology|neurology/psychiatry|gastroenterology	hypercalcemia|thyroiditis|ankylosing spondylitis|bursitis|osteoarthritis|psoriatic arthritis|seborrheic dermatitis|mycosis|allergic rhinitis|psoriasis|anemia|multiple sclerosis|ulcerative colitis|enteritis	0	95.49	MicroSource	1500406	METHYLPREDNISOLONE	374.209	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23,t:27|	VHRSUDSXCMQTMA-PJHHCJLFSA-N	6741.0	BRD-A53176877-001-04-3	VHRSUDSXCMQTMA
BRD-K24452555-001-01-7	methylprednisolone-aceponate	Launched	anti-inflammatory agent|glucocorticoid receptor agonist	NR3C1	endocrinology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|dermatology|neurology/psychiatry|hematology	congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia	0	97.13	Alinda	IVK/0069385	(6alpha,11beta)-21-(acetyloxy)-11-hydroxy-6-methyl-3,20-dioxopregna-1,4-dien-17-yl propionate	472.246	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|	DALKLAYLIPSCQL-YPYQNWSCSA-N	63019.0		DALKLAYLIPSCQL
BRD-K24452555-001-02-9	methylprednisolone-aceponate	Launched	anti-inflammatory agent|glucocorticoid receptor agonist	NR3C1	endocrinology|rheumatology|infectious disease|allergy|pulmonary|gastroenterology|dermatology|neurology/psychiatry|hematology	congenital adrenal hyperplasia|thyroiditis|hypercalcemia|rheumatoid arthritis|bursitis|epicondylitis|allergic rhinitis|asthma|ulcerative colitis|enteritis|osteoarthritis|psoriasis|multiple sclerosis|anemia	0	85.29	Sigma	MFCD00866150	(6alpha,11beta)-21-(acetyloxy)-11-hydroxy-6-methyl-3,20-dioxopregna-1,4-dien-17-yl propionate	472.246	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17,t:13|	DALKLAYLIPSCQL-YPYQNWSCSA-N	63019.0		DALKLAYLIPSCQL
BRD-K00003673-236-01-9	methylprednisolone-sodium-succinate	Launched	glucocorticoid receptor agonist		endocrinology|rheumatology|dermatology|pulmonary|allergy|infectious disease|ophthalmology|gastroenterology|hematology|neurology/psychiatry	hypercalcemia|thyroiditis|osteoarthritis|rheumatoid arthritis|seborrheic dermatitis|asthma|allergic rhinitis|shingles|conjunctivitis|ulcerative colitis|enteritis|anemia|multiple sclerosis|mycosis	0	83.97	MedChemEx	HY-B1060	Methylprednisolone 21-hemisuccinate (sodium salt)	474.225	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C |c:35,t:31|	IMBXEJJVJRTNOW-XYMSELFBSA-N	16923.0		IMBXEJJVJRTNOW
BRD-K11900042-001-14-4	methylthiouracil	Launched			endocrinology	hyperthyroidism	0	100.0	MicroSource	1500408	METHYLTHIOURACIL	142.02	Cc1cc(=O)[nH]c(=S)[nH]1	HWGBHCRJGXAGEU-UHFFFAOYSA-N	667493.0		HWGBHCRJGXAGEU
BRD-K11900042-001-13-6	methylthiouracil	Launched			endocrinology	hyperthyroidism	0	97.72	Selleck	S3138	Methylthiouracil	142.02	Cc1cc(=O)[nH]c(=S)[nH]1	HWGBHCRJGXAGEU-UHFFFAOYSA-N	667493.0		HWGBHCRJGXAGEU
BRD-K35941380-050-27-9	methysergide	Launched	serotonin receptor antagonist	HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	neurology/psychiatry	headache	0	61.35	Tocris	1064	Methysergide maleate	353.21	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|	KPJZHOPZRAFDTN-ZRGWGRIASA-N	9681.0		KPJZHOPZRAFDTN
BRD-K35941380-050-28-9	methysergide	Launched	serotonin receptor antagonist	HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	neurology/psychiatry	headache	0	94.46	Tocris	1064	Methysergide maleate	353.21	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|	KPJZHOPZRAFDTN-ZRGWGRIASA-N	9681.0		KPJZHOPZRAFDTN
BRD-K58265391-001-13-9	meticrane	Launched	diuretic		cardiology	edema	0	96.23	MedChemEx	HY-B0908	Meticrane	275.029	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	FNQQBFNIYODEMB-UHFFFAOYSA-N	4165.0		FNQQBFNIYODEMB
BRD-K58265391-001-11-9	meticrane	Launched	diuretic		cardiology	edema	0	97.41	Selleck	S4339	Meticrane	275.029	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	FNQQBFNIYODEMB-UHFFFAOYSA-N	4165.0		FNQQBFNIYODEMB
BRD-K58265391-001-12-7	meticrane	Launched	diuretic		cardiology	edema	0	97.99	MicroSource	1506077	METICRANE	275.029	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	FNQQBFNIYODEMB-UHFFFAOYSA-N	4165.0		FNQQBFNIYODEMB
BRD-A99388803-001-01-5	metipranolol	Withdrawn	adrenergic receptor antagonist				0	96.55	Aronis	BBC/654	4-[2-hydroxy-3-(isopropylamino)propoxy]-2,3,6-trimethylphenyl acetate	309.194	CC(C)NC[C@@H](O)COc1cc(C)c(OC(C)=O)c(C)c1C |&1:5,r|	BQIPXWYNLPYNHW-OAHLLOKOSA-N	57185490.0		BQIPXWYNLPYNHW
BRD-K83766205-001-04-9	metirosine	Launched	tyrosine hydroxylase inhibitor	TH	cardiology	hypertension	0	100.0	Sigma	MFCD00064201	alpha-Methyl-L-tyrosine	195.09	C[C@](N)(Cc1ccc(O)cc1)C(O)=O	NHTGHBARYWONDQ-JTQLQIEISA-N	6918925.0		NHTGHBARYWONDQ
BRD-K83766205-001-03-8	metirosine	Launched	tyrosine hydroxylase inhibitor	TH	cardiology	hypertension	0	85.79	Enamine	Z1255434943		195.09	C[C@](N)(Cc1ccc(O)cc1)C(O)=O	NHTGHBARYWONDQ-JTQLQIEISA-N	6918925.0		NHTGHBARYWONDQ
BRD-K01826545-050-03-9	metitepine	Preclinical	anti-HCVE2	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7			0	96.88	Tocris	582		356.138	CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14,r|	RLJFTICUTYVZDG-GOSISDBHSA-N	969502.0		RLJFTICUTYVZDG
BRD-K01826531-311-08-9	metixene	Launched	acetylcholine receptor antagonist	CHRM5	neurology/psychiatry	Parkinson's Disease	0	99.05	Sigma	M1808000	Metixene hydrochloride	363.142	CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|	MJFJKKXQDNNUJF-HNNXBMFYSA-N	6604302.0		MJFJKKXQDNNUJF
BRD-K75641298-003-25-0	metoclopramide	Launched	dopamine receptor antagonist|serotonin receptor antagonist	CHRM1|DRD2|HTR3A|HTR3B|HTR4	gastroenterology	gastroparesis|nausea|vomiting	0	98.56	MicroSource	1500410	METOCLOPRAMIDE HYDROCHLORIDE	299.14	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	TTWJBBZEZQICBI-UHFFFAOYSA-N	4168.0		TTWJBBZEZQICBI
BRD-K75641298-001-26-9	metoclopramide	Launched	dopamine receptor antagonist|serotonin receptor antagonist	CHRM1|DRD2|HTR3A|HTR3B|HTR4	gastroenterology	gastroparesis|nausea|vomiting	0	98.84	MedChemEx	HY-17382	Metoclopramide	299.14	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	TTWJBBZEZQICBI-UHFFFAOYSA-N	4168.0		TTWJBBZEZQICBI
BRD-K16484091-001-01-1	metocurine	Launched	acetylcholine receptor antagonist	CHRM2|CHRNA2	neurology/psychiatry	muscle relaxant	0	96.67	Specs	AE-562/43459779		652.351	COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3	JFXBEKISTKFVAB-AJQTZOPKSA-N	21233.0		JFXBEKISTKFVAB
BRD-A61793559-001-15-6	metolazone	Launched	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema|hypertension	0	97.53	MicroSource	2300325	METOLAZONE	365.06	C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|	AQCHWTWZEMGIFD-JTQLQIEISA-N	28125490.0		AQCHWTWZEMGIFD
BRD-A61793559-001-16-4	metolazone	Launched	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema|hypertension	0	54.72	Selleck	S1610	Metolazone (Zaroxolyn)	365.06	C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|	AQCHWTWZEMGIFD-JTQLQIEISA-N	28125490.0		AQCHWTWZEMGIFD
BRD-A61793559-001-14-9	metolazone	Launched	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema|hypertension	0	48.09	Selleck	S1610	Metolazone	365.06	C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|	AQCHWTWZEMGIFD-JTQLQIEISA-N	28125490.0		AQCHWTWZEMGIFD
BRD-A61793559-001-17-9	metolazone	Launched	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema|hypertension	0	97.76	MedChemEx	HY-B0209	Metolazone	365.06	C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1,r|	AQCHWTWZEMGIFD-JTQLQIEISA-N	28125490.0		AQCHWTWZEMGIFD
BRD-K01826568-046-15-9	metoprolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	cardiology	hypertension|angina pectoris|myocardial infarction	0	79.17	Tocris	3256	Metoprolol tartrate	417.2	COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|	IUBSYMUCCVWXPE-AWEZNQCLSA-N	157716.0	BRD-M45038741-045-02-7	IUBSYMUCCVWXPE
BRD-K01826568-046-14-9	metoprolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	cardiology	hypertension|angina pectoris|myocardial infarction	0	90.03	Selleck	S1856	Metoprolol Tartrate	417.2	COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|	IUBSYMUCCVWXPE-AWEZNQCLSA-N	157716.0	BRD-M45038741-046-05-8	IUBSYMUCCVWXPE
BRD-A71725768-001-01-3	metoxibutropate	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2			0	96.65	Specs	AN-652/42191159		312.173	COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11,r|	FVRWRGBTEHAPDI-HNNXBMFYSA-N	836891.0		FVRWRGBTEHAPDI
BRD-A22101059-001-15-5	metrifonate	Phase 3	acetylcholinesterase inhibitor	ACHE			0	43.77	MedChemEx	HY-B1220	Metrifonate	255.923	COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|	NFACJZMKEDPNKN-GSVOUGTGSA-N	6604183.0		NFACJZMKEDPNKN
BRD-A22101059-001-13-0	metrifonate	Phase 3	acetylcholinesterase inhibitor	ACHE			0	58.32	MicroSource	1505765	TRICHLORFON	255.923	COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|	NFACJZMKEDPNKN-GSVOUGTGSA-N	6604183.0		NFACJZMKEDPNKN
BRD-A22101059-001-14-8	metrifonate	Phase 3	acetylcholinesterase inhibitor	ACHE			0	0.0	MedChemEx	HY-B1220	Metrifonate	255.923	COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6,r|	NFACJZMKEDPNKN-GSVOUGTGSA-N	6604183.0		NFACJZMKEDPNKN
BRD-A45543382-001-11-9	metrizamide	Launched	radiopaque medium		radiology	contrast agent	0	87.3	Sigma	MFCD00010577	Metrizamide	788.854	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|	BAQCROVBDNBEEB-KSDLJXBFSA-N	49800036.0		BAQCROVBDNBEEB
BRD-A45543382-001-10-0	metrizamide	Launched	radiopaque medium		radiology	contrast agent	0	91.39	Selleck	S4379	Metrizamide	788.854	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19,23,26,28,&1:20|	BAQCROVBDNBEEB-KSDLJXBFSA-N	49800036.0		BAQCROVBDNBEEB
BRD-K99241550-001-04-3	metrizoic-acid	Launched	radiopaque medium		radiology	contrast agent	0	89.37	Sigma	MFCD00867964	3-(acetylamino)-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoic acid	627.785	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	GGGDNPWHMNJRFN-UHFFFAOYSA-N	2528.0		GGGDNPWHMNJRFN
BRD-K99241550-001-03-5	metrizoic-acid	Launched	radiopaque medium		radiology	contrast agent	0	81.64	TCI	M1363		627.785	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	GGGDNPWHMNJRFN-UHFFFAOYSA-N	2528.0		GGGDNPWHMNJRFN
BRD-K52020312-001-25-0	metronidazole	Launched	DNA inhibitor	CYP2C9|CYP3A4	dermatology	rosacea	0	90.77	Selleck	S1907	Metronidazole	171.064	Cc1ncc(n1CCO)[N+]([O-])=O	VAOCPAMSLUNLGC-UHFFFAOYSA-N	4173.0		VAOCPAMSLUNLGC
BRD-K52020312-001-26-8	metronidazole	Launched	DNA inhibitor	CYP2C9|CYP3A4	dermatology	rosacea	0	99.43	MicroSource	1500412	METRONIDAZOLE	171.064	Cc1ncc(n1CCO)[N+]([O-])=O	VAOCPAMSLUNLGC-UHFFFAOYSA-N	4173.0		VAOCPAMSLUNLGC
BRD-K46862739-001-15-0	metyrapone	Launched	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	0	88.32	Tocris	3292	Metyrapone	226.111	CC(C)(C(=O)c1cccnc1)c1cccnc1	FJLBFSROUSIWMA-UHFFFAOYSA-N	4174.0		FJLBFSROUSIWMA
BRD-K46862739-001-13-5	metyrapone	Launched	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	0	48.46	MicroSource	1506014	METYRAPONE	226.111	CC(C)(C(=O)c1cccnc1)c1cccnc1	FJLBFSROUSIWMA-UHFFFAOYSA-N	4174.0		FJLBFSROUSIWMA
BRD-K46862739-001-14-3	metyrapone	Launched	cytochrome P450 inhibitor	CYP11B1	nephrology	adrenal diagnostic agent	0	92.16	MedChemEx	HY-B1232	Metyrapone	226.111	CC(C)(C(=O)c1cccnc1)c1cccnc1	FJLBFSROUSIWMA-UHFFFAOYSA-N	4174.0		FJLBFSROUSIWMA
BRD-K94441233-001-15-5	mevastatin	Preclinical	HMGCR inhibitor	HMGCR			0	90.19	Tocris	1526	Mevastatin	390.241	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	AJLFOPYRIVGYMJ-INTXDZFKSA-N	64715.0		AJLFOPYRIVGYMJ
BRD-K94441233-001-17-1	mevastatin	Preclinical	HMGCR inhibitor	HMGCR			0	90.88	MicroSource	1601000	MEVASTATIN	390.241	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	AJLFOPYRIVGYMJ-INTXDZFKSA-N	64715.0	BRD-A83177971-001-04-0	AJLFOPYRIVGYMJ
BRD-K94441233-001-19-9	mevastatin	Preclinical	HMGCR inhibitor	HMGCR			0	85.77	Tocris	1526	Mevastatin	390.241	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	AJLFOPYRIVGYMJ-INTXDZFKSA-N	64715.0		AJLFOPYRIVGYMJ
BRD-K94441233-001-16-3	mevastatin	Preclinical	HMGCR inhibitor	HMGCR			0	76.45	Selleck	S4223	Mevastatin	390.241	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	AJLFOPYRIVGYMJ-INTXDZFKSA-N	64715.0	BRD-K31414443-001-01-4	AJLFOPYRIVGYMJ
BRD-K94441233-001-13-0	mevastatin	Preclinical	HMGCR inhibitor	HMGCR			0	87.18	Selleck	S4223	Mevastatin	390.241	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	AJLFOPYRIVGYMJ-INTXDZFKSA-N	64715.0		AJLFOPYRIVGYMJ
BRD-K94441233-001-12-2	mevastatin	Preclinical	HMGCR inhibitor	HMGCR			0	93.53	Tocris	1526	Mevastatin	390.241	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12,t:10|	AJLFOPYRIVGYMJ-INTXDZFKSA-N	64715.0		AJLFOPYRIVGYMJ
BRD-K18613660-001-05-5	mexeneone	Preclinical					0	97.41	MicroSource	1506199	MEXENEONE	242.094	COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	MJVGBKJNTFCUJM-UHFFFAOYSA-N	71645.0		MJVGBKJNTFCUJM
BRD-A64092382-003-18-3	mexiletine	Launched	sodium channel blocker	PLAU|SCN4A|SCN5A	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	0	98.76	MicroSource	1503929	MEXILETINE HYDROCHLORIDE	179.131	C[C@@H](N)COc1c(C)cccc1C |&1:1|	VLPIATFUUWWMKC-SNVBAGLBSA-N	180621.0		VLPIATFUUWWMKC
BRD-A64092382-003-19-1	mexiletine	Launched	sodium channel blocker	PLAU|SCN4A|SCN5A	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	0	90.69	Tocris	2596	Mexiletine hydrochloride	179.131	C[C@@H](N)COc1c(C)cccc1C |&1:1|	VLPIATFUUWWMKC-SNVBAGLBSA-N	180621.0		VLPIATFUUWWMKC
BRD-A64092382-003-17-5	mexiletine	Launched	sodium channel blocker	PLAU|SCN4A|SCN5A	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	0	97.64	Tocris	2596	Mexiletine hydrochloride	179.131	C[C@@H](N)COc1c(C)cccc1C |&1:1|	VLPIATFUUWWMKC-SNVBAGLBSA-N	180621.0		VLPIATFUUWWMKC
BRD-A64092382-003-20-9	mexiletine	Launched	sodium channel blocker	PLAU|SCN4A|SCN5A	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	0	84.51	Tocris	2596	Mexiletine hydrochloride	179.131	C[C@@H](N)COc1c(C)cccc1C |&1:1|	VLPIATFUUWWMKC-SNVBAGLBSA-N	180621.0		VLPIATFUUWWMKC
BRD-A64092382-003-16-7	mexiletine	Launched	sodium channel blocker	PLAU|SCN4A|SCN5A	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	0	94.61	Selleck	S4225	Mexiletine HCl	179.131	C[C@@H](N)COc1c(C)cccc1C |&1:1|	VLPIATFUUWWMKC-SNVBAGLBSA-N	180621.0		VLPIATFUUWWMKC
BRD-K45114938-236-02-6	mezlocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	72.44	Selleck	S4179	Mezlocillin Sodium	539.114	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	YPBATNHYBCGSSN-ZJOBFFGXSA-N	71729966.0	BRD-K53064842-236-01-9	YPBATNHYBCGSSN
BRD-K45114938-236-03-4	mezlocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	86.88	Selleck	S4179	Mezlocillin Sodium	539.114	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	YPBATNHYBCGSSN-ZJOBFFGXSA-N	71729966.0		YPBATNHYBCGSSN
BRD-K45114938-236-01-8	mezlocillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	88.63	Selleck	S4179	Mezlocillin Sodium	539.114	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	YPBATNHYBCGSSN-ZJOBFFGXSA-N	71729966.0		YPBATNHYBCGSSN
BRD-A63444178-001-01-5	ME0328	Preclinical	PARP inhibitor	PARP3			0	99.08	Selleck	S7438	ME0328	321.148	C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1,r|	QIHBWVVVRYYYRO-CYBMUJFWSA-N	136229577.0		QIHBWVVVRYYYRO
BRD-K34328244-001-02-9	MF-101	Phase 3	estrogen receptor agonist	CYP19A1|XDH			0	98.01	MedChemEx	HY-N0377	Liquiritigenin	256.074	Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	FURUXTVZLHCCNA-AWEZNQCLSA-N	114829.0		FURUXTVZLHCCNA
BRD-K34328244-001-01-4	MF-101	Phase 3	estrogen receptor agonist	CYP19A1|XDH			0	98.0	InterBioScreen	STOCK1N-11167		256.074	Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	FURUXTVZLHCCNA-AWEZNQCLSA-N	114829.0		FURUXTVZLHCCNA
BRD-K60230970-001-17-5	MG-132	Preclinical	proteasome inhibitor	PSMB1			0	86.03	Selleck	S2619	MG-132	475.305	CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	TZYWCYJVHRLUCT-VABKMULXSA-N	462382.0		TZYWCYJVHRLUCT
BRD-K60230970-001-13-4	MG-132	Preclinical	proteasome inhibitor	PSMB1			0	66.74	Selleck	S2619	MG-132	475.305	CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	TZYWCYJVHRLUCT-VABKMULXSA-N	462382.0		TZYWCYJVHRLUCT
BRD-K60230970-001-16-7	MG-132	Preclinical	proteasome inhibitor	PSMB1			0	76.23	Selleck	S2619	MG-132	475.305	CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	TZYWCYJVHRLUCT-VABKMULXSA-N	462382.0		TZYWCYJVHRLUCT
BRD-K03128577-005-07-0	MG-624	Preclinical	acetylcholine receptor antagonist	CHRNA7			0	93.43	Tocris	1356	MG 624	324.233	CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	YIMFXBPXUPTIEJ-OUKQBFOZSA-N	5824382.0		YIMFXBPXUPTIEJ
BRD-K03128577-005-08-9	MG-624	Preclinical	acetylcholine receptor antagonist	CHRNA7			0	94.39	Tocris	1356	MG 624	324.233	CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	YIMFXBPXUPTIEJ-OUKQBFOZSA-N	5824382.0		YIMFXBPXUPTIEJ
BRD-K03128577-005-06-2	MG-624	Preclinical	acetylcholine receptor antagonist	CHRNA7			0	58.46	Tocris	1356	MG 624	324.233	CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	YIMFXBPXUPTIEJ-OUKQBFOZSA-N	5824382.0		YIMFXBPXUPTIEJ
BRD-K56277358-001-07-5	MGCD-265	Preclinical	VEGFR inhibitor	AXL|MET			0	92.2	Selleck	S1361	MGCD-265	517.104	Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	UFICVEHDQUKCEA-UHFFFAOYSA-N	24901704.0		UFICVEHDQUKCEA
BRD-K26726854-001-01-0	MI-14	Preclinical	PI4K inhibitor	PI4KB			0	92.97	Tocris	5604	MI 14	450.124	CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12	PSTAJIONBVMKLA-UHFFFAOYSA-N	91758319.0		PSTAJIONBVMKLA
BRD-K26726854-001-02-9	MI-14	Preclinical	PI4K inhibitor	PI4KB			0	93.76	Tocris	5604	MI 14	450.124	CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12	PSTAJIONBVMKLA-UHFFFAOYSA-N	91758319.0		PSTAJIONBVMKLA
BRD-A19661776-003-27-6	mianserin	Launched	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7	neurology/psychiatry	depression	0	98.04	MicroSource	2300292	MIANSERIN HYDROCHLORIDE	264.163	CN1CCN2C(C1)c1ccccc1Cc1ccccc21	UEQUQVLFIPOEMF-UHFFFAOYSA-N	68551.0		UEQUQVLFIPOEMF
BRD-A19661776-003-28-4	mianserin	Launched	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7	neurology/psychiatry	depression	0	94.56	Selleck	S1382	Mianserin hydrochloride	264.163	CN1CCN2C(C1)c1ccccc1Cc1ccccc21	UEQUQVLFIPOEMF-UHFFFAOYSA-N	68551.0		UEQUQVLFIPOEMF
BRD-A19661776-003-26-8	mianserin	Launched	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7	neurology/psychiatry	depression	0	95.35	Tocris	997	Mianserin hydrochloride	264.163	CN1CCN2C(C1)c1ccccc1Cc1ccccc21	UEQUQVLFIPOEMF-UHFFFAOYSA-N	68551.0		UEQUQVLFIPOEMF
BRD-A19661776-003-25-0	mianserin	Launched	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7	neurology/psychiatry	depression	0	25.92	Selleck	S1382	Mianserin HCl	264.163	CN1CCN2C(C1)c1ccccc1Cc1ccccc21	UEQUQVLFIPOEMF-UHFFFAOYSA-N	68551.0		UEQUQVLFIPOEMF
BRD-K42981054-001-02-9	mibampator	Phase 2	glutamate receptor modulator	GRIA1			0	97.74	MedChemEx	HY-10934	Mibampator	438.165	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	ULRDYYKSPCRXAJ-KRWDZBQOSA-N	9889366.0		ULRDYYKSPCRXAJ
BRD-K42981054-001-01-9	mibampator	Phase 2	glutamate receptor modulator	GRIA1			0	99.84	MedChemEx	HY-10934	LY451395	438.165	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	ULRDYYKSPCRXAJ-KRWDZBQOSA-N	9889366.0		ULRDYYKSPCRXAJ
BRD-K09549677-300-04-2	mibefradil	Withdrawn	T-type calcium channel blocker	ANO1|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CATSPER1|CATSPER2|CATSPER3|CATSPER4			0	95.63	Tocris	2198	Mibefradil dihydrochloride	495.29	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	HBNPJJILLOYFJU-VMPREFPWSA-N	60663.0		HBNPJJILLOYFJU
BRD-K09549677-300-03-4	mibefradil	Withdrawn	T-type calcium channel blocker	ANO1|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CATSPER1|CATSPER2|CATSPER3|CATSPER4			0	97.32	Tocris	2198	Mibefradil dihydrochloride	495.29	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	HBNPJJILLOYFJU-VMPREFPWSA-N	60663.0		HBNPJJILLOYFJU
BRD-K09549677-300-09-9	mibefradil	Withdrawn	T-type calcium channel blocker	ANO1|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CATSPER1|CATSPER2|CATSPER3|CATSPER4			0	93.93	Tocris	2198	Mibefradil dihydrochloride	495.29	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	HBNPJJILLOYFJU-VMPREFPWSA-N	60663.0		HBNPJJILLOYFJU
BRD-K40407248-236-01-6	micafungin	Launched	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia|peritonitis|esophageal candidiasis	0	37.78	MedChemEx	HY-16321	Micafungin (sodium)	1269.438	CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O	PIEUQSKUWLMALL-YABMTYFHSA-N	477468.0	BRD-A06596811-236-02-5	PIEUQSKUWLMALL
BRD-K40407248-001-04-9	micafungin	Launched	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia|peritonitis|esophageal candidiasis	0	94.45	MedChemEx	HY-16321	Micafungin (sodium)	1269.438	CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O	PIEUQSKUWLMALL-YABMTYFHSA-N	477468.0		PIEUQSKUWLMALL
BRD-K40407248-236-02-4	micafungin	Launched	fungal 1,3-beta-D-glucan synthase inhibitor		infectious disease	candidemia|peritonitis|esophageal candidiasis	0	38.91	MedChemEx	HY-16321	Micafungin (sodium)	1269.438	CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O	PIEUQSKUWLMALL-YABMTYFHSA-N	477468.0	BRD-A06596811-236-01-7	PIEUQSKUWLMALL
BRD-K01826511-001-16-9	miconazole	Launched	bacterial cell wall synthesis inhibitor	TRPM2|TRPV5	infectious disease|neurology/psychiatry	yeast infection|itching	0	98.41	Selleck	S2536	Miconazole	413.986	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|	BYBLEWFAAKGYCD-SFHVURJKSA-N	1150344.0		BYBLEWFAAKGYCD
BRD-K01826511-008-18-9	miconazole	Launched	bacterial cell wall synthesis inhibitor	TRPM2|TRPV5	infectious disease|neurology/psychiatry	yeast infection|itching	0	96.46	Tocris	3016	Miconazole nitrate	413.986	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7,r|	BYBLEWFAAKGYCD-SFHVURJKSA-N	1150344.0		BYBLEWFAAKGYCD
BRD-K18552138-001-01-8	micronomicin	Launched	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	AvaChem	1979	(1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl 2-amino-2,3,4,6-tetradeoxy-6-(methylamino)-alpha-D-erythro-hexopyranoside	463.301	CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	DNYGXMICFMACRA-XHEDQWPISA-N	3037206.0		DNYGXMICFMACRA
BRD-K18552138-065-01-3	micronomicin	Launched	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	AlfaAesar	J66072	Micronomicin sulfate	463.301	CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	DNYGXMICFMACRA-XHEDQWPISA-N	3037206.0		DNYGXMICFMACRA
BRD-K45163704-001-02-3	midafotel	Phase 3	glutamate receptor antagonist	GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	100.0	Tocris	1265	(2R)-4-[(2E)-3-phosphono-2-propenyl]-2-piperazinecarboxylic acid	250.072	OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	VZXMZMJSGLFKQI-ABVWVHJUSA-N	6435801.0		VZXMZMJSGLFKQI
BRD-K45163704-001-01-5	midafotel	Phase 3	glutamate receptor antagonist	GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	0.0	EMDBio	504840-10MG	(R)-CPPene	250.072	OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	VZXMZMJSGLFKQI-ABVWVHJUSA-N	6435801.0		VZXMZMJSGLFKQI
BRD-K68822425-001-01-6	midecamycin	Launched	protein synthesis inhibitor		infectious disease	respiratory tract infections|ear infections|skin infections	0	0.0	AvaChem	2013	(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-(((2S,4R,5S,6S)-4-hydroxy-4,6-dimethyl-5-(propionyloxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-y;l)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-o	813.451	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:32,34|	DMUAPQTXSSNEDD-RVVOCHMRSA-N			DMUAPQTXSSNEDD
BRD-A79981887-003-16-4	midodrine	Launched	adrenergic receptor agonist		cardiology	hypotension	0	96.09	MicroSource	1503257	MIDODRINE HYDROCHLORIDE	254.127	COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|	PTKSEFOSCHHMPD-JTQLQIEISA-N	13589226.0		PTKSEFOSCHHMPD
BRD-A79981887-001-17-9	midodrine	Launched	adrenergic receptor agonist		cardiology	hypotension	0	80.26	PrincetonBio	PBMR178353	2-Amino-N-[2-(2,5-dimethoxy-phenyl)-2-hydroxy-ethyl]-acetamide	254.127	COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|	PTKSEFOSCHHMPD-JTQLQIEISA-N	13589226.0		PTKSEFOSCHHMPD
BRD-K13646352-001-03-8	midostaurin	Launched	FLT3 inhibitor|KIT inhibitor|PKC inhibitor	FLT3|PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	0	95.95	Enzo	EI370	PKC-412	570.227	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	BMGQWWVMWDBQGC-IIFHNQTCSA-N	9829523.0		BMGQWWVMWDBQGC
BRD-K13646352-001-02-0	midostaurin	Launched	FLT3 inhibitor|KIT inhibitor|PKC inhibitor	FLT3|PRKCG	hematologic malignancy	acute myeloid leukemia (AML)	0	27.88	Enzo	EI-370	PKC-412	570.227	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	BMGQWWVMWDBQGC-IIFHNQTCSA-N	9829523.0		BMGQWWVMWDBQGC
BRD-K37270826-001-29-2	mifepristone	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	AR|NR1I2|NR3C1|PGR	endocrinology	hyperglycemia|diabetes mellitus	0	91.17	Tocris	1479	Mifepristone	429.267	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	VKHAHZOOUSRJNA-GCNJZUOMSA-N	55245.0		VKHAHZOOUSRJNA
BRD-K37270826-001-31-8	mifepristone	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	AR|NR1I2|NR3C1|PGR	endocrinology	hyperglycemia|diabetes mellitus	0	79.2	MicroSource	1505615	MIFEPRISTONE	429.267	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	VKHAHZOOUSRJNA-GCNJZUOMSA-N	55245.0	BRD-A79939557-001-01-7	VKHAHZOOUSRJNA
BRD-K37270826-001-27-6	mifepristone	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	AR|NR1I2|NR3C1|PGR	endocrinology	hyperglycemia|diabetes mellitus	0	95.32	Selleck	S2606	Mifepristone (Mifeprex)	429.267	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	VKHAHZOOUSRJNA-GCNJZUOMSA-N	55245.0		VKHAHZOOUSRJNA
BRD-K37270826-001-32-9	mifepristone	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	AR|NR1I2|NR3C1|PGR	endocrinology	hyperglycemia|diabetes mellitus	0	90.15	Tocris	1479	Mifepristone	429.267	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	VKHAHZOOUSRJNA-GCNJZUOMSA-N	55245.0		VKHAHZOOUSRJNA
BRD-K37270826-001-30-0	mifepristone	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	AR|NR1I2|NR3C1|PGR	endocrinology	hyperglycemia|diabetes mellitus	0	78.61	Selleck	S2606	Mifepristone	429.267	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	VKHAHZOOUSRJNA-GCNJZUOMSA-N	55245.0	BRD-K46504237-001-01-5	VKHAHZOOUSRJNA
BRD-K37270826-001-26-8	mifepristone	Launched	glucocorticoid receptor antagonist|progesterone receptor antagonist	AR|NR1I2|NR3C1|PGR	endocrinology	hyperglycemia|diabetes mellitus	0	79.18	Tocris	1479	Mifepristone	429.267	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18,t:11|	VKHAHZOOUSRJNA-GCNJZUOMSA-N	55245.0		VKHAHZOOUSRJNA
BRD-K00004244-001-01-9	mifobate	Phase 2	PPAR receptor antagonist	PPARG			0	92.31	Tocris	2022	SR 202	358.014	COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7,r|	VQHUQHAPWMNBLP-LLVKDONJSA-N	76958126.0		VQHUQHAPWMNBLP
BRD-K44779798-001-10-7	miglitol	Launched	glucosidase inhibitor	GAA|GANAB|GANC|MGAM	endocrinology	diabetes mellitus	0	100.0	Tocris	4985	Miglitol	207.111	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	IBAQFPQHRJAVAV-ULAWRXDQSA-N	441314.0		IBAQFPQHRJAVAV
BRD-K44779798-001-12-9	miglitol	Launched	glucosidase inhibitor	GAA|GANAB|GANC|MGAM	endocrinology	diabetes mellitus	0	100.0	Tocris	4985	Miglitol	207.111	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	IBAQFPQHRJAVAV-ULAWRXDQSA-N	441314.0		IBAQFPQHRJAVAV
BRD-K44779798-001-11-5	miglitol	Launched	glucosidase inhibitor	GAA|GANAB|GANC|MGAM	endocrinology	diabetes mellitus	0	94.58	Selleck	S2589	Miglitol	207.111	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	IBAQFPQHRJAVAV-ULAWRXDQSA-N	441314.0	BRD-K82665349-001-01-4	IBAQFPQHRJAVAV
BRD-K33251802-001-01-3	miglustat	Launched	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	0	100.0	Enzo	SL230	N-Butyldeoxynojirmycin HCL	219.147	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	UQRORFVVSGFNRO-UTINFBMNSA-N	51634.0		UQRORFVVSGFNRO
BRD-K33251802-003-15-9	miglustat	Launched	glycosyl transferase inhibitor	UGCG	hematology	Gaucher disease	0	75.19	MedChemEx	HY-17020A	Miglustat (hydrochloride)	219.147	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	UQRORFVVSGFNRO-UTINFBMNSA-N	51634.0		UQRORFVVSGFNRO
BRD-K64338723-001-02-9	milacemide	Phase 3	monoamine oxidase inhibitor	MAOB			0	100.0	Enamine	EN300-128867	2-(pentylamino)acetamide	144.126	CCCCCNCC(N)=O	GJNNXIYZWIZFRH-UHFFFAOYSA-N	53569.0		GJNNXIYZWIZFRH
BRD-K64338723-001-01-6	milacemide	Phase 3	monoamine oxidase inhibitor	MAOB			0	92.25	Enamine	Z104536260		144.126	CCCCCNCC(N)=O	GJNNXIYZWIZFRH-UHFFFAOYSA-N	53569.0		GJNNXIYZWIZFRH
BRD-K00003406-001-01-9	milademetan	Phase 1	MDM inhibitor				0	94.54	MedChemEx	HY-101266	Milademetan	617.197	CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O	RYAYYVTWKAOAJF-QISPRATLSA-N	73297272.0		RYAYYVTWKAOAJF
BRD-K00004287-003-01-9	milnacipran	Launched	serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A4	rheumatology	fibromyalgia	0	96.28	Tocris	3286	Milnacipran hydrochloride	246.173	CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|	GJJFMKBJSRMPLA-DZGCQCFKSA-N	6917779.0		GJJFMKBJSRMPLA
BRD-K67080878-001-16-2	milrinone	Launched	phosphodiesterase inhibitor	PDE2A|PDE3A|PDE3B|PDE5A	cardiology	congestive heart failure	0	99.84	MicroSource	1505489	MILRINONE	211.075	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	PZRHRDRVRGEVNW-UHFFFAOYSA-N	4197.0		PZRHRDRVRGEVNW
BRD-K67080878-001-15-4	milrinone	Launched	phosphodiesterase inhibitor	PDE2A|PDE3A|PDE3B|PDE5A	cardiology	congestive heart failure	0	100.0	Selleck	S2484	Milrinone	211.075	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	PZRHRDRVRGEVNW-UHFFFAOYSA-N	4197.0		PZRHRDRVRGEVNW
BRD-K67080878-001-22-9	milrinone	Launched	phosphodiesterase inhibitor	PDE2A|PDE3A|PDE3B|PDE5A	cardiology	congestive heart failure	0	97.86	Tocris	1504	Milrinone	211.075	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	PZRHRDRVRGEVNW-UHFFFAOYSA-N	4197.0		PZRHRDRVRGEVNW
BRD-K01824991-001-04-9	miltefosine	Launched	membrane integrity inhibitor	PLA2G1B	infectious disease	leishmaniasis	0	92.47	MicroSource	1505329	MILTEFOSINE [5mM]	408.324	CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|	PQLXHQMOHUQAKB-UHFFFAOYSA-O	3600.0		PQLXHQMOHUQAKB
BRD-K67642028-001-04-4	mimosine	Preclinical	DNA replication inhibitor	CCL2|SHMT1|SHMT2|TYR			0	50.1	Sigma	MFCD00075909	(2S)-2-amino-3-(3-hydroxy-4-oxo-1(4H)-pyridinyl)propanoic acid	198.064	N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O	WZNJWVWKTVETCG-YFKPBYRVSA-N	6971294.0		WZNJWVWKTVETCG
BRD-K67642028-001-03-6	mimosine	Preclinical	DNA replication inhibitor	CCL2|SHMT1|SHMT2|TYR			0	0.0	Enzo	CC102	Mimosine, L-	198.064	N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O	WZNJWVWKTVETCG-YFKPBYRVSA-N	6971294.0		WZNJWVWKTVETCG
BRD-K02867583-300-15-9	minaprine	Withdrawn	serotonin reuptake inhibitor	ACHE|CHRM1|DRD1|DRD2|HTR2A|HTR2B|HTR2C|MAOA|SLC6A4			0	97.21	MedChemEx	HY-B0884A	Minaprine (dihydrochloride)	298.179	Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	LDMWSLGGVTVJPG-UHFFFAOYSA-N	4199.0		LDMWSLGGVTVJPG
BRD-K02867583-300-08-9	minaprine	Withdrawn	serotonin reuptake inhibitor	ACHE|CHRM1|DRD1|DRD2|HTR2A|HTR2B|HTR2C|MAOA|SLC6A4			0	99.62	MicroSource	1501120	MINAPRINE HYDROCHLORIDE	298.179	Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	LDMWSLGGVTVJPG-UHFFFAOYSA-N	4199.0		LDMWSLGGVTVJPG
BRD-A74347210-001-01-7	minerval	Phase 1/Phase 2	FAAH inhibitor				0	100.0	Sigma	SML0256	(9Z)-2-hydroxy-9-octadecenoic acid	298.251	CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16,r|	JBSOOFITVPOOSY-DOOKAGJSSA-N	11066464.0		JBSOOFITVPOOSY
BRD-K00003346-003-01-9	minocycline	Launched	bacterial 30S ribosomal subunit inhibitor		endocrinology|infectious disease|ophthalmology|urology	fever|respiratory tract infections|psittacosis|trachoma|conjunctivitis|urethritis|chancroid|tularemia|cholera|brucellosis	0	95.77	MedChemEx	HY-17412	Minocycline (hydrochloride)	457.185	[H][C@@]12Cc3c(ccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:19,&2:12|	ZZZRUAITSXLWBH-NOHUXHDNSA-N	129396801.0		ZZZRUAITSXLWBH
BRD-K89337853-001-01-1	minodronic-acid	Launched	bone resorption inhibitor	FDPS|GGPS1	orthopedics	osteoporosis	0	0.0	AKSci	Y0229		322.012	OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O	VMMKGHQPQIEGSQ-UHFFFAOYSA-N	130956.0		VMMKGHQPQIEGSQ
BRD-K89337853-001-02-9	minodronic-acid	Launched	bone resorption inhibitor	FDPS|GGPS1	orthopedics	osteoporosis	0	0.0	AvaChem	2663H	1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyldiphosphonic acid	322.012	OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O	VMMKGHQPQIEGSQ-UHFFFAOYSA-N	130956.0		VMMKGHQPQIEGSQ
BRD-K06902185-001-21-9	minoxidil	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1	endocrinology	androgenetic alopecia	0	93.21	Tocris	583	Minoxidil	209.128	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	ZFMITUMMTDLWHR-UHFFFAOYSA-N			ZFMITUMMTDLWHR
BRD-K06902185-003-01-7	minoxidil	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1	endocrinology	androgenetic alopecia	0	94.83	MicroSource	1500415	MINOXIDIL HYDROCHLORIDE	209.128	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	ZFMITUMMTDLWHR-UHFFFAOYSA-N			ZFMITUMMTDLWHR
BRD-K06902185-001-16-9	minoxidil	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1	endocrinology	androgenetic alopecia	0	92.54	Selleck	S1383	Minoxidil	209.128	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	ZFMITUMMTDLWHR-UHFFFAOYSA-N			ZFMITUMMTDLWHR
BRD-K06902185-001-22-7	minoxidil	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1	endocrinology	androgenetic alopecia	0	96.36	Sigma	MFCD00063409	6-amino-2-imino-4-(1-piperidinyl)-1(2H)-pyrimidinol	209.128	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	ZFMITUMMTDLWHR-UHFFFAOYSA-N		BRD-K14888893-001-14-8	ZFMITUMMTDLWHR
BRD-K06902185-001-17-7	minoxidil	Launched	KATP activator|Kir6 channel (KATP) activator|vasodilator	ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1	endocrinology	androgenetic alopecia	0	94.02	Tocris	583	Minoxidil	209.128	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	ZFMITUMMTDLWHR-UHFFFAOYSA-N			ZFMITUMMTDLWHR
BRD-K30764557-001-01-5	miocamycin	Launched	other antibiotic		infectious disease	urinary tract infections|chlamydia	0	92.27	AvaChem	2845	(2S,3S,4R,6S)-4-acetoxy-6-(((2R,3S,4R,5R,6S)-6-(((4R,5S,6S,7R,9R,10R,11E,13E,16R)-10-acetoxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-4-(propionyloxy)oxacyclohexadeca-11,13-dien-6-yl)oxy)-4-(dimet;hylamino)-5-hydroxy-2-methyltetrahydro-2H-pyran-3-yl)o	897.472	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:38,40|	GQNZGCARKRHPOH-XUDBFGHTSA-N			GQNZGCARKRHPOH
BRD-K39706510-001-03-9	MIRA-1	Preclinical	apoptosis stimulant				0	0.0	Tocris	3362	MIRA-1	183.053	CCC(=O)OCN1C(=O)C=CC1=O |c:9|	YXEWPGYLMHXLPS-UHFFFAOYSA-N	227681.0		YXEWPGYLMHXLPS
BRD-K47949423-001-02-3	mirabegron	Launched	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3	urology	urinary incontinence	0	33.67	Selleck	S4009	Mirabegron	396.162	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	PBAPPPCECJKMCM-IBGZPJMESA-N	9865528.0		PBAPPPCECJKMCM
BRD-K47949423-001-04-9	mirabegron	Launched	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3	urology	urinary incontinence	0	78.36	MedChemEx	HY-14773	Mirabegron	396.162	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	PBAPPPCECJKMCM-IBGZPJMESA-N	9865528.0		PBAPPPCECJKMCM
BRD-K47949423-001-03-1	mirabegron	Launched	adrenergic receptor agonist	ADRB1|ADRB2|ADRB3	urology	urinary incontinence	0	95.25	Selleck	S4009	Mirabegron (YM178)	396.162	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	PBAPPPCECJKMCM-IBGZPJMESA-N	9865528.0		PBAPPPCECJKMCM
BRD-K00003434-001-01-9	miridesap	Preclinical	amyloid protein inhibitor				0	91.03	MedChemEx	HY-101861	Miridesap	340.163	OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O	HZLAWYIBLZNRFZ-VXGBXAGGSA-N	125516.0		HZLAWYIBLZNRFZ
BRD-K55420858-001-02-8	mirin	Preclinical	MRE11A exonuclease inhibitor	MRE11A			0	89.76	Tocris	3190	Mirin	220.031	NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|	YBHQCJILTOVLHD-YVMONPNESA-N	137319711.0		YBHQCJILTOVLHD
BRD-K55420858-001-01-0	mirin	Preclinical	MRE11A exonuclease inhibitor	MRE11A			0	96.61	Sigma	M9948	mirin	220.031	NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|	InChI=1S/C10H8N2O2S/c11-10-12-9(14)8(15-10)5-6-1-3-7(13)4-2-6/h1-5,13H,(H2,11,12,14)/b8-5-	137319711.0		YBHQCJILTOVLHD
BRD-M78068755-001-02-0	miriplatin	Launched	DNA synthesis inhibitor		oncology	hepatocellular carcinoma (HCC)	0	0.0	MedChemEx	HY-16325A	Miriplatin	765.498	[Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|	BGIHRZPJIYJKAZ-JPLLOCSESA-N			BGIHRZPJIYJKAZ
BRD-M78068755-001-01-2	miriplatin	Launched	DNA synthesis inhibitor		oncology	hepatocellular carcinoma (HCC)	1	0.0	MedChemEx	HY-16325A	Miriplatin	765.498	[Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2,&2:7,r|	BGIHRZPJIYJKAZ-JPLLOCSESA-N			BGIHRZPJIYJKAZ
BRD-K82967685-300-01-2	mirodenafil	Launched	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	0	97.2	MedChemEx	HY-14930A	Mirodenafil (dihydrochloride)	531.252	CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	MIJFNYMSCFYZNY-UHFFFAOYSA-N	135497803.0		MIJFNYMSCFYZNY
BRD-K82967685-300-02-9	mirodenafil	Launched	phosphodiesterase inhibitor	PDE5A	urology	erectile dysfunction	0	96.4	MedChemEx	HY-14930A	Mirodenafil (dihydrochloride)	531.252	CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	MIJFNYMSCFYZNY-UHFFFAOYSA-N	135497803.0		MIJFNYMSCFYZNY
BRD-K00003484-074-01-9	mirogabalin-besylate	Preclinical	calcium channel antagonist				0	91.92	MedChemEx	HY-108006	Mirogabalin besylate	209.142	[H][C@@]12C[C@](CN)(CC(O)=O)[C@]1([H])C=C(CC)C2 |t:13|	FTBQORVNHOIASH-CKYFFXLPSA-N	59509752.0		FTBQORVNHOIASH
BRD-A64977602-001-16-7	mirtazapine	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C	neurology/psychiatry	depression	0	98.62	Tocris	2018	Mirtazapine	265.158	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|	RONZAEMNMFQXRA-INIZCTEOSA-N	3085219.0		RONZAEMNMFQXRA
BRD-A64977602-001-15-9	mirtazapine	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C	neurology/psychiatry	depression	0	98.93	MicroSource	1506333	MIRTAZAPINE	265.158	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|	RONZAEMNMFQXRA-INIZCTEOSA-N	3085219.0		RONZAEMNMFQXRA
BRD-A64977602-001-17-9	mirtazapine	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C	neurology/psychiatry	depression	0	92.07	Tocris	2018	Mirtazapine	265.158	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|	RONZAEMNMFQXRA-INIZCTEOSA-N	3085219.0		RONZAEMNMFQXRA
BRD-A64977602-001-13-4	mirtazapine	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C	neurology/psychiatry	depression	0	93.83	Selleck	S2016	Mirtazapine	265.158	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|	RONZAEMNMFQXRA-INIZCTEOSA-N	3085219.0		RONZAEMNMFQXRA
BRD-A64977602-001-14-2	mirtazapine	Launched	adrenergic receptor antagonist|serotonin receptor antagonist	ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C	neurology/psychiatry	depression	0	96.32	Tocris	2018	Mirtazapine	265.158	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5,r|	RONZAEMNMFQXRA-INIZCTEOSA-N	3085219.0		RONZAEMNMFQXRA
BRD-A16263897-001-06-6	misonidazole	Phase 3					0	96.47	Cayman	15606	1-methoxy-3-(2-nitro-1H-imidazol-1-yl)-2-propanol	201.075	COC[C@@H](O)Cn1ccnc1[N+]([O-])=O |&1:3,r|	OBBCSXFCDPPXOL-LURJTMIESA-N	73050801.0		OBBCSXFCDPPXOL
BRD-A72351335-001-04-5	misoprostol	Launched	prostanoid receptor agonist	PTGER2|PTGER3|PTGER4|PTGIR	gastroenterology	duodenal ulcer disease	0	99.4	Sigma	M6807	methyl (11beta,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate	382.272	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10,11,16,&1:4|	OJLOPKGSLYJEMD-URPKTTJQSA-N	5282381.0		OJLOPKGSLYJEMD
BRD-K00003136-001-01-9	mitapivat	Preclinical	pyruvate kinase isozyme activator				0	98.12	MedChemEx	HY-12689	Mitapivat	450.173	O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1	XAYGBKHKBBXDAK-UHFFFAOYSA-N	59634741.0		XAYGBKHKBBXDAK
BRD-K52959329-238-01-9	mitiglinide	Launched	insulin secretagogue	ABCC8|KCNJ10|PPARG	endocrinology	diabetes mellitus	0	98.47	Selleck	S2073	Mitiglinide calcium	315.183	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	WPGGHFDDFPHPOB-BBWFWOEESA-N	121891.0	BRD-M71049352-238-02-2	WPGGHFDDFPHPOB
BRD-K52959329-238-02-9	mitiglinide	Launched	insulin secretagogue	ABCC8|KCNJ10|PPARG	endocrinology	diabetes mellitus	0	96.66	MedChemEx	HY-17398	Mitiglinide (Calcium)	315.183	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	WPGGHFDDFPHPOB-BBWFWOEESA-N	121891.0		WPGGHFDDFPHPOB
BRD-K35882976-001-04-7	mitoflaxone	Phase 2	antitumor agent	VWF			0	98.8	Specs	AN-308/15495081	2-(4-oxo-2-phenyl-4H-chromen-8-yl)acetic acid	280.074	OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1	TZZNWMJZDWYJAZ-UHFFFAOYSA-N	55748.0		TZZNWMJZDWYJAZ
BRD-K59670716-001-20-9	mitomycin-C	Launched	DNA alkylating agent|DNA synthesis inhibitor		oncology	pancreatic cancer|gastric adenocarcinoma	0	94.66	Tocris	3258	Mitomycin C	334.128	CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O |c:10,t:22|	NWIBSHFKIJFRCO-WUDYKRTCSA-N	5746.0		NWIBSHFKIJFRCO
BRD-K00003362-066-01-9	mitoquinone	Launched	antioxidant				0	42.65	MedChemEx	HY-100116A	Mitoquinone (mesylate)	583.298	COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2,t:40|	OIIMUKXVVLRCAF-UHFFFAOYSA-N	11388332.0		OIIMUKXVVLRCAF
BRD-A31204924-001-18-3	mitotane	Launched	antineoplastic agent	CYP11A1|CYP11B1|ESR1	oncology	adrenal cortical carcinoma	0	0.0	MedChemEx	HY-13690	Mitotane	317.954	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|	JWBOIMRXGHLCPP-ZDUSSCGKSA-N	6603772.0		JWBOIMRXGHLCPP
BRD-A31204924-001-14-2	mitotane	Launched	antineoplastic agent	CYP11A1|CYP11B1|ESR1	oncology	adrenal cortical carcinoma	1	96.39	MicroSource	330082	MITOTANE	317.954	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|	JWBOIMRXGHLCPP-ZDUSSCGKSA-N	6603772.0		JWBOIMRXGHLCPP
BRD-A31204924-001-17-5	mitotane	Launched	antineoplastic agent	CYP11A1|CYP11B1|ESR1	oncology	adrenal cortical carcinoma	1	0.0	MedChemEx	HY-13690	Mitotane	317.954	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|	JWBOIMRXGHLCPP-ZDUSSCGKSA-N	6603772.0		JWBOIMRXGHLCPP
BRD-A31204924-001-16-7	mitotane	Launched	antineoplastic agent	CYP11A1|CYP11B1|ESR1	oncology	adrenal cortical carcinoma	1	0.0	Selleck	S1732	Mitotane	317.954	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|	JWBOIMRXGHLCPP-ZDUSSCGKSA-N	6603772.0		JWBOIMRXGHLCPP
BRD-A31204924-001-13-4	mitotane	Launched	antineoplastic agent	CYP11A1|CYP11B1|ESR1	oncology	adrenal cortical carcinoma	1	0.0	Selleck	S1732	Mitotane	317.954	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3,r|	JWBOIMRXGHLCPP-ZDUSSCGKSA-N	6603772.0		JWBOIMRXGHLCPP
BRD-K21680192-300-15-1	mitoxantrone	Launched	topoisomerase inhibitor	TOP2A	neurology/psychiatry|oncology|hematologic malignancy	multiple sclerosis|prostate cancer|acute myeloid leukemia (AML)	0	89.42	MicroSource	1503278	MITOXANTRONE HYDROCHLORIDE	444.201	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	KKZJGLLVHKMTCM-UHFFFAOYSA-N	4212.0		KKZJGLLVHKMTCM
BRD-K21680192-300-16-9	mitoxantrone	Launched	topoisomerase inhibitor	TOP2A	neurology/psychiatry|oncology|hematologic malignancy	multiple sclerosis|prostate cancer|acute myeloid leukemia (AML)	0	96.79	Selleck	S2485	Mitoxantrone Hydrochloride	444.201	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	KKZJGLLVHKMTCM-UHFFFAOYSA-N	4212.0		KKZJGLLVHKMTCM
BRD-K21680192-300-14-4	mitoxantrone	Launched	topoisomerase inhibitor	TOP2A	neurology/psychiatry|oncology|hematologic malignancy	multiple sclerosis|prostate cancer|acute myeloid leukemia (AML)	0	87.64	Selleck	S2485	Mitoxantrone HCl	444.201	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	KKZJGLLVHKMTCM-UHFFFAOYSA-N	4212.0		KKZJGLLVHKMTCM
BRD-A48465967-300-01-1	mivacurium	Launched	acetylcholine receptor antagonist	CHRNA2	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	0	47.83	AKSci	71667		1028.561	COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41,55,&1:7,&2:27|	ILVYCEVXHALBSC-GZICNWBJSA-N	22839211.0		ILVYCEVXHALBSC
BRD-K00003356-001-01-9	mivebresib	Phase 1	bromodomain inhibitor				0	97.87	MedChemEx	HY-100015	Mivebresib	459.106	CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12	RDONXGFGWSSFMY-UHFFFAOYSA-N	71600087.0		RDONXGFGWSSFMY
BRD-K39576764-071-01-6	mivobulin	Phase 2	microtubule inhibitor				0	80.61	Sigma	PH014089	ethyl 5-amino-2-methyl-3-phenyl-1,4-dihydropyrido[4,3-b]pyrazin-7-ylcarbamate 2-hydroxyethanesulfonate	325.154	CCOC(=O)Nc1cc2N=C(C)C(Nc2c(N)n1)c1ccccc1 |t:9|	XOJFFEJRKAIVCH-UHFFFAOYSA-N			XOJFFEJRKAIVCH
BRD-K00003146-318-01-9	MIW-815	Preclinical	interferon inducer				0	96.81	MedChemEx	HY-12885B	ADU-S100 (ammonium salt)	690.059	[H][C@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](O)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@@]([H])([C@@H](O1)n1cnc3c(N)ncnc13)[C@]2([H])O)n1cnc2c(N)ncnc12	IZJJFUQKKZFVLH-YBVMPXGUSA-N			IZJJFUQKKZFVLH
BRD-K21884483-001-04-9	mizolastine	Launched	histamine receptor antagonist	HRH1	allergy	urticaria|allergic rhinitis	0	98.97	MedChemEx	HY-B0164	Mizolastine	432.207	CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1	PVLJETXTTWAYEW-UHFFFAOYSA-N	65906.0		PVLJETXTTWAYEW
BRD-K21884483-001-03-7	mizolastine	Launched	histamine receptor antagonist	HRH1	allergy	urticaria|allergic rhinitis	0	98.43	Selleck	S2107	Mizolastine (Mizollen)	432.207	CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1	PVLJETXTTWAYEW-UHFFFAOYSA-N	65906.0		PVLJETXTTWAYEW
BRD-K88061624-001-20-6	mizoribine	Launched	immunosuppressant|inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant|rheumatology	organ rejection|nephrotic syndrome	0	0.0	MicroSource	1503416	MIZORIBINE	259.08	NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|	OPMVDWXPLVKNQN-AAXBYFMASA-N	11949547.0		OPMVDWXPLVKNQN
BRD-K88061624-001-21-4	mizoribine	Launched	immunosuppressant|inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant|rheumatology	organ rejection|nephrotic syndrome	0	100.0	Selleck	S1384	Mizoribine (Bredinin)	259.08	NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|	OPMVDWXPLVKNQN-AAXBYFMASA-N	11949547.0		OPMVDWXPLVKNQN
BRD-K88061624-001-22-2	mizoribine	Launched	immunosuppressant|inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant|rheumatology	organ rejection|nephrotic syndrome	0	0.0	Selleck	S1384	Mizoribine	259.08	NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|	OPMVDWXPLVKNQN-AAXBYFMASA-N	11949547.0	BRD-K05218031-001-01-9	OPMVDWXPLVKNQN
BRD-K88061624-001-23-9	mizoribine	Launched	immunosuppressant|inosine monophosphate dehydrogenase inhibitor	IMPDH1	transplant|rheumatology	organ rejection|nephrotic syndrome	0	0.0	MedChemEx	HY-17470	Mizoribine	259.08	NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|	OPMVDWXPLVKNQN-AAXBYFMASA-N	11949547.0		OPMVDWXPLVKNQN
BRD-K71315565-001-01-6	MJ-15	Preclinical	cannabinoid receptor antagonist	CNR1			0	92.68	Tocris	4063	MJ 15	470.047	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1	PJEIKJFNEFJFLA-UHFFFAOYSA-N	59377482.0		PJEIKJFNEFJFLA
BRD-K71315565-001-02-9	MJ-15	Preclinical	cannabinoid receptor antagonist	CNR1			0	97.94	Tocris	4063	MJ 15	470.047	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1	PJEIKJFNEFJFLA-UHFFFAOYSA-N	59377482.0		PJEIKJFNEFJFLA
BRD-K91405252-001-01-9	MK-0354	Phase 2	niacin receptor agonist	HCAR2|HCAR3			0	94.22	MedChemEx	HY-13008	MK-0354	176.081	C1Cc2[nH]nc(-c3nn[nH]n3)c2C1	LTQYSJKGRPGMPO-UHFFFAOYSA-N	11159621.0		LTQYSJKGRPGMPO
BRD-K00003190-001-01-9	MK-0557	Phase 3	neuropeptide receptor antagonist				0	97.35	MedChemEx	HY-15411	MK-0557	406.144	Fc1ccccc1-n1ccc(NC(=O)[C@H]2CC[C@]3(CC2)OC(=O)c2ccncc32)n1 |r|	RMYZIRFUCOMQRH-XLOAEROZSA-N			RMYZIRFUCOMQRH
BRD-K00004557-001-01-9	MK-0608	Phase 1	antiviral				0	94.93	Sigma	MFCD14584964	(2R,3R,4R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol	280.117	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc12	IRZRJANZDIOOIF-GAJNKVMBSA-N	3011893.0		IRZRJANZDIOOIF
BRD-K18850819-001-04-6	MK-0752	Phase 1/Phase 2	gamma secretase inhibitor				0	93.39	Selleck	S2660	MK-0752	442.082	OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|	XCGJIFAKUZNNOR-QCKZDCLWSA-N			XCGJIFAKUZNNOR
BRD-K38868394-001-02-9	MK-0773	Phase 2	androgen receptor modulator	AR			0	94.96	MedChemEx	HY-11027	MK-0773	479.27	CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|	GBEUKTWTUSPHEE-JWJWXJQQSA-N	11950726.0		GBEUKTWTUSPHEE
BRD-K38868394-001-01-3	MK-0773	Phase 2	androgen receptor modulator	AR			0	97.69	MedChemEx	HY-11027	MK-0773	479.27	CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|	GBEUKTWTUSPHEE-JWJWXJQQSA-N	11950726.0		GBEUKTWTUSPHEE
BRD-K14175878-036-02-9	MK-0812	Phase 2	CC chemokine receptor antagonist	CCR2			0	95.66	MedChemEx	HY-50669A	MK-0812 (Succinate)	469.255	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	MTMDXAIUENDNDL-RJSMDTJLSA-N	11180808.0		MTMDXAIUENDNDL
BRD-K14175878-001-01-6	MK-0812	Phase 2	CC chemokine receptor antagonist	CCR2			0	97.78	MedChemEx	HY-50669	MK-0812	469.255	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	MTMDXAIUENDNDL-RJSMDTJLSA-N	11180808.0		MTMDXAIUENDNDL
BRD-K16732600-001-02-9	MK-0893	Phase 2	glucagon receptor antagonist	GCGR			0	97.29	MedChemEx	HY-50663	MK 0893	587.138	COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	DNTVJEMGHBIUMW-IBGZPJMESA-N	11570626.0		DNTVJEMGHBIUMW
BRD-K16732600-001-01-7	MK-0893	Phase 2	glucagon receptor antagonist	GCGR			0	98.42	MedChemEx	HY-50663	MK 0893	587.138	COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	DNTVJEMGHBIUMW-IBGZPJMESA-N	11570626.0		DNTVJEMGHBIUMW
BRD-K00003304-001-01-9	MK-1064	Phase 1	orexin receptor antagonist				0	98.07	MedChemEx	HY-19914	MK-1064	461.125	COc1ccc(CNC(=O)c2cc(cnc2-c2ccccn2)-c2cncc(Cl)c2)nc1OC	CKTWQGHVNRYNCM-UHFFFAOYSA-N	44633765.0		CKTWQGHVNRYNCM
BRD-K54256913-001-08-7	MK-1775	Phase 2	WEE1 kinase inhibitor	WEE1			0	91.74	Selleck	S1525	MK-1775	500.265	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	BKWJAKQVGHWELA-UHFFFAOYSA-N	24856436.0		BKWJAKQVGHWELA
BRD-K54256913-001-05-3	MK-1775	Phase 2	WEE1 kinase inhibitor	WEE1			0	88.15	Selleck	S1525	MK-1775	500.265	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)	24856436.0		BKWJAKQVGHWELA
BRD-K00004660-001-01-9	MK-1903	Phase 2	niacin receptor agonist				0	100.0	Enamine	EN300-2008229	rac-(2R,4R)-8,9-diazatricyclo[4.3.0.0,2,4]nona-1(6),7-diene-7-carboxylic acid	164.059	OC(=O)c1n[nH]c2[C@@H]3C[C@@H]3Cc12	CUTZNERBKDMLAP-QWWZWVQMSA-N	49763030.0		CUTZNERBKDMLAP
BRD-K03128512-001-03-6	MK-2048	Preclinical	HIV integrase inhibitor				0	0.0	Selleck	S2765	MK-2048	461.127	CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	JSRREMIKIHJGAA-JTQLQIEISA-N	54698642.0	BRD-K66135050-001-01-7	JSRREMIKIHJGAA
BRD-K03128512-001-02-8	MK-2048	Preclinical	HIV integrase inhibitor				0	61.42	Selleck	S2765	MK-2048	461.127	CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	JSRREMIKIHJGAA-JTQLQIEISA-N	54698642.0		JSRREMIKIHJGAA
BRD-K03128512-001-04-4	MK-2048	Preclinical	HIV integrase inhibitor				0	71.99	Selleck	S2765	MK-2048	461.127	CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	JSRREMIKIHJGAA-JTQLQIEISA-N	54698642.0		JSRREMIKIHJGAA
BRD-K68065987-300-09-1	MK-2206	Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	97.67	Selleck	S1078	MK-2206 2HCl	407.175	NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	ULDXWLCXEDXJGE-UHFFFAOYSA-N	24964624.0		ULDXWLCXEDXJGE
BRD-K68065987-300-01-8	MK-2206	Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0		Stanley		Akt_Compound 1	407.175	NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	ULDXWLCXEDXJGE-UHFFFAOYSA-N	24964624.0		ULDXWLCXEDXJGE
BRD-K68065987-300-03-4	MK-2206	Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0		Selleck	S1078	MK-2206	407.175	NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)	24964624.0		ULDXWLCXEDXJGE
BRD-K43316319-001-01-8	MK-2295	Phase 2	TRPV antagonist	TRPV1			0	97.5	DuPont	A002859262	N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-4-quinazolinamine	434.097	FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1	VTANGSDRFFLTSQ-UHFFFAOYSA-N	11247522.0		VTANGSDRFFLTSQ
BRD-K56405753-001-03-9	MK-2461	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|KDR|MERTK|MET|MST1R|NTRK1|NTRK2|PDGFRB			0	95.82	MedChemEx	HY-50703	MK-2461	495.158	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	44137946.0		JGEBLDKNWBUGRZ
BRD-K56405753-001-02-4	MK-2461	Phase 1/Phase 2	FGFR inhibitor|VEGFR inhibitor	FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|KDR|MERTK|MET|MST1R|NTRK1|NTRK2|PDGFRB			0	93.34	Selleck	S2774	MK-2461	495.158	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	JGEBLDKNWBUGRZ-HXUWFJFHSA-N	44137946.0		JGEBLDKNWBUGRZ
BRD-K27983781-001-01-4	MK-2894	Preclinical	prostaglandin inhibitor	PTGER4			0	92.79	MedChemEx	HY-10413	MK-2894	473.127	Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F	QJZQFVRFJCGDKF-UHFFFAOYSA-N	24952929.0		QJZQFVRFJCGDKF
BRD-K66911501-003-02-9	MK-3207	Phase 2	calcitonin antagonist	CALCA			0	96.27	MedChemEx	HY-10302	MK-3207 (Hydrochloride)	557.224	Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	AZAANWYREOQRFB-SETSBSEESA-N	25019940.0		AZAANWYREOQRFB
BRD-K66911501-003-01-2	MK-3207	Phase 2	calcitonin antagonist	CALCA			0	98.79	MedChemEx	HY-10302	MK-3207 (Hydrochloride)	557.224	Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	AZAANWYREOQRFB-SETSBSEESA-N	25019940.0		AZAANWYREOQRFB
BRD-K95828359-001-01-0	MK-3697	Phase 2	orexin receptor antagonist	HCRTR2			0	97.36	MedChemEx	HY-12301	MK-3697	447.137	COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	VSOUDUXMPUHJEU-UHFFFAOYSA-N	46190695.0		VSOUDUXMPUHJEU
BRD-K95828359-001-02-9	MK-3697	Phase 2	orexin receptor antagonist	HCRTR2			0	87.71	MedChemEx	HY-12301	MK-3697	447.137	COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	VSOUDUXMPUHJEU-UHFFFAOYSA-N	46190695.0		VSOUDUXMPUHJEU
BRD-K00003482-001-01-9	MK-4074	Phase 1	acetyl-CoA carboxylase inhibitor				0	97.17	MedChemEx	HY-107709	MK-4074	565.221	COc1cc(cc2n(cc(C)c12)C1CC1)C(=O)N1CCC2(CC1)CC(=O)c1cc(ccc1O2)-c1cncc(c1)C(O)=O	WDBNGXLHMZSUEI-UHFFFAOYSA-N	24964679.0		WDBNGXLHMZSUEI
BRD-K03886848-001-01-8	MK-5046	Preclinical	bombesin receptor agonist	BRS3|GRPR|NMBR			0	90.83	MedChemEx	HY-14342	MK-5046	444.138	O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F	UJINBEQCDMOAHM-SFHVURJKSA-N	49871766.0		UJINBEQCDMOAHM
BRD-K53665955-001-03-0	MK-5108	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	92.92	Selleck	S2770	MK-5108 (VX-689)	461.098	OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|	LCVIRAZGMYMNNT-VVONHTQRSA-N			LCVIRAZGMYMNNT
BRD-K53665955-001-04-8	MK-5108	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	94.03	Focus	Oct-4618	MK-5108(VX-689)	461.098	OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|	LCVIRAZGMYMNNT-VVONHTQRSA-N			LCVIRAZGMYMNNT
BRD-A73679382-236-01-8	MK-571	Phase 2	leukotriene receptor antagonist	ABCC2|CYSLTR1			0	94.07	MedChemEx	HY-19989A	MK-571 (sodium salt)	514.115	CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|	AXUZQJFHDNNPFG-JORPFSLRSA-N	14325224.0		AXUZQJFHDNNPFG
BRD-K03894385-001-01-1	MK-6096	Phase 2	orexin receptor antagonist	HCRTR1|HCRTR2			0	97.98	MedChemEx	HY-15653	MK-6096	420.196	C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1	NPFDWHQSDBWQLH-QZTJIDSGSA-N	25128145.0		NPFDWHQSDBWQLH
BRD-K00003199-001-01-9	MK-7246	Preclinical	CRTH receptor antagonist				0	92.5	MedChemEx	HY-15853	MK-7246	416.121	CN([C@@H]1CCc2c(CC(O)=O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	JTCAGRAKUAAYDY-OAHLLOKOSA-N	45268455.0		JTCAGRAKUAAYDY
BRD-K00003194-001-01-9	MK-7622	Phase 2	cholinergic receptor agonist				0	92.11	MedChemEx	HY-15618	MK-7622	399.195	Cc1ccc(Cc2cc3c(ncn([C@H]4CCCC[C@@H]4O)c3=O)c3ccccc23)cn1	JUVQLZBJFOGEEO-GOTSBHOMSA-N	46207733.0		JUVQLZBJFOGEEO
BRD-K55512740-001-01-6	MK-8033	Phase 1	c-Met inhibitor	MET			0	91.91	MedChemEx	HY-13299	MK-8033	471.137	Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	VMJFTOSOFDEKTM-UHFFFAOYSA-N	45142457.0		VMJFTOSOFDEKTM
BRD-K55512740-001-02-9	MK-8033	Phase 1	c-Met inhibitor	MET			0	85.68	MedChemEx	HY-13299	MK-8033	471.137	Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	VMJFTOSOFDEKTM-UHFFFAOYSA-N	45142457.0		VMJFTOSOFDEKTM
BRD-K29656036-001-02-5	MK-8245	Phase 2	stearoyl-CoA desaturase inhibitor	SCD			0	96.51	Selleck	S1158	MK-8245	466.04	OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	UJEAABFSXKCSGI-UHFFFAOYSA-N	24988881.0		UJEAABFSXKCSGI
BRD-K29656036-001-03-9	MK-8245	Phase 2	stearoyl-CoA desaturase inhibitor	SCD			0	97.44	MedChemEx	HY-13070	MK-8245	466.04	OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	UJEAABFSXKCSGI-UHFFFAOYSA-N	24988881.0		UJEAABFSXKCSGI
BRD-K00003397-001-01-9	MK-8617	Preclinical	hypoxia inducible factor prolyl hydroxylase inhibitor				0	93.74	MedChemEx	HY-101023	MK-8617	443.159	COc1ccc(cc1)C(NC(=O)c1cnc(nc1O)-c1cccnn1)c1ccc(OC)cc1	WXLPERVDMILVIF-UHFFFAOYSA-N	44230662.0		WXLPERVDMILVIF
BRD-K25279140-001-01-5	MK-8745	Preclinical	Aurora kinase inhibitor	AURKA			0	93.7	Selleck	S7065	MK-8745	431.098	Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	YCRFPWKUUNKNDN-UHFFFAOYSA-N	11676373.0		YCRFPWKUUNKNDN
BRD-K25279140-001-02-9	MK-8745	Preclinical	Aurora kinase inhibitor	AURKA			0	97.88	MedChemEx	HY-13819	MK-8745	431.098	Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	YCRFPWKUUNKNDN-UHFFFAOYSA-N	11676373.0		YCRFPWKUUNKNDN
BRD-K20168484-001-07-9	MK-886	Preclinical	lipoxygenase inhibitor				0	98.24	MedChemEx	HY-14166	MK-886	471.2	CC(C)c1ccc2n(Cc3ccc(Cl)cc3)c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c2c1	QAOAOVKBIIKRNL-UHFFFAOYSA-N	3651377.0		QAOAOVKBIIKRNL
BRD-K86677390-001-02-9	MK-8998	Phase 2	T-type calcium channel blocker				0	97.27	MedChemEx	HY-101096	Calcium channel inhibitor 1	380.171	CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1	IQIKXZMPPBEWAD-CQSZACIVSA-N	24765479.0		IQIKXZMPPBEWAD
BRD-K61695967-003-02-1	MKT-077	Phase 1	HSP inhibitor				0	0.0	Tocris	4621	MKT 077	396.12	CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O	QLYHOWIZHHZGPV-XUTLUUPISA-N	6912334.0		QLYHOWIZHHZGPV
BRD-K61695967-003-01-3	MKT-077	Phase 1	HSP inhibitor				0	49.21	Cayman	14395	1-ethyl-2-{(E)-[(5E)-3-ethyl-5-(3-methyl-1,3-benzothiazol-2(3H)-ylidene)-4-oxo-1,3-thiazolidin-2-ylidene]methyl}pyridinium chloride	396.12	CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O	QLYHOWIZHHZGPV-XUTLUUPISA-N	6912334.0		QLYHOWIZHHZGPV
BRD-K90316462-003-01-1	MK2-IN-1	Preclinical	MAP kinase inhibitor	MAPKAPK2			0	91.11	MedChemEx	HY-12834A	MK2-IN-1 (hydrochloride)	472.167	Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1	LIPNXDIBECKOMJ-UHFFFAOYSA-N	53475321.0		LIPNXDIBECKOMJ
BRD-K59317601-001-05-5	MLN0128	Phase 2	mTOR inhibitor	MTOR|PIK3CA|PIK3CD|PIK3CG			0	97.29	Selleck	S2811	INK 128 (MLN0128)	309.134	CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	GYLDXIAOMVERTK-UHFFFAOYSA-N	45375953.0		GYLDXIAOMVERTK
BRD-K59317601-001-06-9	MLN0128	Phase 2	mTOR inhibitor	MTOR|PIK3CA|PIK3CD|PIK3CG			0	97.6	MedChemEx	HY-13328	Sapanisertib	309.134	CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	GYLDXIAOMVERTK-UHFFFAOYSA-N	45375953.0		GYLDXIAOMVERTK
BRD-K73877023-001-01-9	MLN1117	Phase 2	PI3K inhibitor	PIK3CA			0	97.33	MedChemEx	HY-12285	MLN1117	363.133	Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1	BLGWHBSBBJNKJO-UHFFFAOYSA-N	70798655.0		BLGWHBSBBJNKJO
BRD-K43410529-001-02-3	MLN2480	Phase 1/Phase 2	RAF inhibitor				0	94.64	MedChemEx	HY-15246	MLN 2480	505.01	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F	VWMJHAFYPMOMGF-ZCFIWIBFSA-N	25161177.0		VWMJHAFYPMOMGF
BRD-K83963101-001-08-9	MLN8054	Phase 1	Aurora kinase inhibitor	AURKA			0	91.86	MedChemEx	HY-10180	MLN8054	476.085	OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|	HHFBDROWDBDFBR-UHFFFAOYSA-N	11712649.0		HHFBDROWDBDFBR
BRD-K83963101-001-06-9	MLN8054	Phase 1	Aurora kinase inhibitor	AURKA			0	93.63	Selleck	S1100	MLN8054	476.085	OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|	HHFBDROWDBDFBR-UHFFFAOYSA-N	11712649.0		HHFBDROWDBDFBR
BRD-K15203492-001-01-1	MLN9708	Phase 3	proteasome inhibitor				0	17.51	MedChemEx	HY-10452	MLN9708	516.087	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1	MBOMYENWWXQSNW-AWEZNQCLSA-N	56844015.0		MBOMYENWWXQSNW
BRD-K15203492-001-02-9	MLN9708	Phase 3	proteasome inhibitor				0	0.0	MedChemEx	HY-10452	MLN9708	516.087	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1	MBOMYENWWXQSNW-AWEZNQCLSA-N	56844015.0		MBOMYENWWXQSNW
BRD-K69343602-003-01-3	ML10302	Preclinical	serotonin receptor partial agonist	HTR3A|HTR3B|HTR4			0	94.1	Tocris	3499	ML 10302 hydrochloride	312.124	COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1	RVFIAQAAZUEPPE-UHFFFAOYSA-N	5311299.0		RVFIAQAAZUEPPE
BRD-K69343602-003-02-9	ML10302	Preclinical	serotonin receptor partial agonist	HTR3A|HTR3B|HTR4			0	95.38	Tocris	3499	ML 10302 hydrochloride	312.124	COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1	RVFIAQAAZUEPPE-UHFFFAOYSA-N	5311299.0		RVFIAQAAZUEPPE
BRD-K89306950-001-13-3	ML130	Preclinical	NOD1 inhibitor				0	73.97	Tocris	4354	ML 130	287.073	Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	SRFABRWQVPCPRG-UHFFFAOYSA-N	1088438.0		SRFABRWQVPCPRG
BRD-K89306950-001-12-5	ML130	Preclinical	NOD1 inhibitor				0	96.19	Selleck	S2863	ML130 (Nodinitib-1)	287.073	Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	SRFABRWQVPCPRG-UHFFFAOYSA-N	1088438.0		SRFABRWQVPCPRG
BRD-K89306950-001-14-9	ML130	Preclinical	NOD1 inhibitor				0	96.9	Tocris	4354	ML 130	287.073	Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	SRFABRWQVPCPRG-UHFFFAOYSA-N	1088438.0		SRFABRWQVPCPRG
BRD-K33743361-003-08-9	ML133	Preclinical	potassium channel blocker				0	97.27	Tocris	4549	ML 133 hydrochloride	277.147	COc1ccc(CNCc2cccc3ccccc23)cc1	GIFYKGIODMXYNT-UHFFFAOYSA-N	781301.0		GIFYKGIODMXYNT
BRD-K33743361-003-02-6	ML133	Preclinical	potassium channel blocker				0	97.57	Selleck	S2825	ML133 HCl	277.147	COc1ccc(CNCc2cccc3ccccc23)cc1	GIFYKGIODMXYNT-UHFFFAOYSA-N	781301.0		GIFYKGIODMXYNT
BRD-A28422330-001-10-1	ML141	Preclinical	GTPase inhibitor	CDC42			0	88.19	Tocris	4266	ML 141	407.13	COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|	QBNZBMVRFYREHK-JOCHJYFZSA-N	7454812.0		QBNZBMVRFYREHK
BRD-A28422330-001-11-9	ML141	Preclinical	GTPase inhibitor	CDC42			0	85.73	Tocris	4266	ML 141	407.13	COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8,r,c:11|	QBNZBMVRFYREHK-JOCHJYFZSA-N	7454812.0		QBNZBMVRFYREHK
BRD-K59036917-001-17-5	ML161	Preclinical	protease-activated receptor inhibitor				0	95.17	Tocris	4570	ML 161	360.047	CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	DFOVLSMXPWPCFH-UHFFFAOYSA-N	1048267.0		DFOVLSMXPWPCFH
BRD-K59036917-001-16-7	ML161	Preclinical	protease-activated receptor inhibitor				0	98.28	Selleck	S2916	ML161	360.047	CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	DFOVLSMXPWPCFH-UHFFFAOYSA-N	1048267.0		DFOVLSMXPWPCFH
BRD-K64835161-001-02-8	ML167	Preclinical	CLK inhibitor|DYRK inhibitor	CLK4|DYRK1B			0	90.04	Selleck	S7509	ML167	335.127	Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1	ROCFOIBAEVAOLQ-UHFFFAOYSA-N	44968231.0		ROCFOIBAEVAOLQ
BRD-K77547509-001-04-9	ML179	Preclinical	liver receptor homolog inverse agonist	NR5A2			0	97.61	Tocris	4957	ML 179	422.193	FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1	MFABFKUNLDYKGH-UHFFFAOYSA-N	45100448.0		MFABFKUNLDYKGH
BRD-K77547509-001-03-3	ML179	Preclinical	liver receptor homolog inverse agonist	NR5A2			0	96.66	Tocris	4957	ML 179	422.193	FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1	MFABFKUNLDYKGH-UHFFFAOYSA-N	45100448.0		MFABFKUNLDYKGH
BRD-K27539181-001-09-9	ML193	Preclinical	G protein-coupled receptor antagonist	GPR55			0	97.56	Tocris	4860	ML 193	527.163	Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C	HTSLEZOTMYUPLU-UHFFFAOYSA-N	1261822.0		HTSLEZOTMYUPLU
BRD-K27539181-001-08-5	ML193	Preclinical	G protein-coupled receptor antagonist	GPR55			0	99.09	Tocris	4860	ML 193	527.163	Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C	HTSLEZOTMYUPLU-UHFFFAOYSA-N	1261822.0		HTSLEZOTMYUPLU
BRD-K80021413-001-08-8	ML204	Preclinical	transient receptor potential channel antagonist	TRPC4|TRPC5			0	97.27	MedChemEx	HY-12949	ML204	226.147	Cc1cc(nc2ccccc12)N1CCCCC1	USYRQXDHKXGTCK-UHFFFAOYSA-N	230710.0		USYRQXDHKXGTCK
BRD-K00004301-001-01-9	ML213	Preclinical	potassium channel activator	KCNQ4			0	95.71	Tocris	4519	ML 213	257.178	Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11,14,&2:9,r|	SIQGKPGBLYKQBB-RRFJBIMHSA-N	1219187.0		SIQGKPGBLYKQBB
BRD-K92995792-003-03-9	ML218	Preclinical	T-type calcium channel blocker	CACNA1G|CACNA1H|CACNA1I			0	96.35	Tocris	4507	ML 218 hydrochloride	368.142	CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1	GSJIGYLGKSBYBC-OSYLJGHBSA-N			GSJIGYLGKSBYBC
BRD-K92995792-003-02-9	ML218	Preclinical	T-type calcium channel blocker	CACNA1G|CACNA1H|CACNA1I			0	93.41	Tocris	4507	ML 218 hydrochloride	368.142	CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1	GSJIGYLGKSBYBC-OSYLJGHBSA-N			GSJIGYLGKSBYBC
BRD-K44432556-001-05-5	ML228	Preclinical	hypoxia inducible factor activator	HIF1A			0	97.16	Tocris	4565	ML 228	415.18	C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1	QNRODODTMXCRKU-UHFFFAOYSA-N	46742353.0		QNRODODTMXCRKU
BRD-K44432556-001-01-4	ML228	Preclinical	hypoxia inducible factor activator	HIF1A			0		MLSC/Vanderbilt		VU0418946-1	415.18	C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1	InChI=1S/C27H21N5/c1-3-9-21(10-4-1)22-16-14-20(15-17-22)19-29-27-25(23-11-5-2-6-12-23)31-32-26(30-27)24-13-7-8-18-28-24/h1-18H,19H2,(H,29,30,32)	46742353.0		QNRODODTMXCRKU
BRD-K60020910-001-03-9	ML277	Preclinical	potassium channel activator	KCNQ1			0	95.48	Tocris	4777	ML 277	471.129	COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1	OXQNLLVUVDAEHC-OAQYLSRUSA-N	53347902.0		OXQNLLVUVDAEHC
BRD-K60020910-001-02-5	ML277	Preclinical	potassium channel activator	KCNQ1			0	97.08	Tocris	4777	ML 277	471.129	COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1	OXQNLLVUVDAEHC-OAQYLSRUSA-N	53347902.0		OXQNLLVUVDAEHC
BRD-K48188942-001-03-7	ML281	Preclinical	serine/threonine kinase inhibitor	STK33			0	98.78	Tocris	4880	ML 281	389.12	CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O	HWOYIOLMBQSTQS-UHFFFAOYSA-N	53377448.0		HWOYIOLMBQSTQS
BRD-K48188942-001-01-1	ML281	Preclinical	serine/threonine kinase inhibitor	STK33			0	91.3	Broad Institute		bg-stk33-59	389.12	CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O	HWOYIOLMBQSTQS-UHFFFAOYSA-N	53377448.0		HWOYIOLMBQSTQS
BRD-K51137250-001-02-6	ML297	Preclinical	inward rectifier potassium channel activator	KCNJ3			0	72.69	Tocris	5380	ML 297	328.114	Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1	IEKSMUSSYJUQMY-UHFFFAOYSA-N	56642816.0		IEKSMUSSYJUQMY
BRD-K51137250-001-01-8	ML297	Preclinical	inward rectifier potassium channel activator	KCNJ3			0		Sigma	SML0836	ML297	328.114	Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1	InChI=1S/C17H14F2N4O/c1-11-9-16(23(22-11)13-5-3-2-4-6-13)21-17(24)20-12-7-8-14(18)15(19)10-12/h2-10H,1H3,(H2,20,21,24)	56642816.0		IEKSMUSSYJUQMY
BRD-K24600306-003-02-9	ML298	Preclinical	phospholipase inhibitor	PLD2			0	96.73	Tocris	4895	ML 298 hydrochloride	432.177	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1	XAPVAKKLQGLNOY-UHFFFAOYSA-N	53393916.0		XAPVAKKLQGLNOY
BRD-K24600306-003-01-9	ML298	Preclinical	phospholipase inhibitor	PLD2			0	86.04	Tocris	4895	ML 298 hydrochloride	432.177	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1	XAPVAKKLQGLNOY-UHFFFAOYSA-N	53393916.0		XAPVAKKLQGLNOY
BRD-K92606079-001-02-0	ML314	Preclinical	neurotensin agonist	NTSR1			0	96.62	MedChemEx	HY-16639	ML314	420.216	COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1	SWEOAXMICIJCQC-UHFFFAOYSA-N	53245590.0		SWEOAXMICIJCQC
BRD-K93942811-001-01-3	ML323	Preclinical	ubiquitin specific protease inhibitor	USP1			0	96.64	MedChemEx	HY-17543	ML-323	384.206	CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1	VUIRVWPJNKZOSS-UHFFFAOYSA-N	60167849.0		VUIRVWPJNKZOSS
BRD-K25611237-001-02-1	ML324	Preclinical	histone lysine demethylase inhibitor	KDM4A			0	86.85	MedChemEx	HY-12725	ML324	349.179	CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1	QDBVSOZTVKXUES-UHFFFAOYSA-N	44143209.0		QDBVSOZTVKXUES
BRD-A29014990-001-03-9	ML3403	Preclinical	MAP kinase inhibitor	CYP3A4|MAPK11|MAPK12|MAPK14			0	92.67	Tocris	4586	ML 3403	404.147	CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|	VXPWQNBKEIVYIS-HNNXBMFYSA-N	10938334.0		VXPWQNBKEIVYIS
BRD-A29014990-001-02-3	ML3403	Preclinical	MAP kinase inhibitor	CYP3A4|MAPK11|MAPK12|MAPK14			0	96.63	Tocris	4586	ML 3403	404.147	CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20,r|	VXPWQNBKEIVYIS-HNNXBMFYSA-N	10938334.0		VXPWQNBKEIVYIS
BRD-K33892651-001-04-9	ML347	Preclinical	ALK tyrosine kinase receptor inhibitor	ACVR1|ACVRL1|BMPR1A			0	97.92	Tocris	4945	ML 347	352.132	COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	FVRYPYDPKSZGNS-UHFFFAOYSA-N	44577753.0		FVRYPYDPKSZGNS
BRD-K33892651-001-02-4	ML347	Preclinical	ALK tyrosine kinase receptor inhibitor	ACVR1|ACVRL1|BMPR1A			0	99.36	Selleck	S7148	ML347	352.132	COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	FVRYPYDPKSZGNS-UHFFFAOYSA-N	44577753.0		FVRYPYDPKSZGNS
BRD-K33892651-001-03-2	ML347	Preclinical	ALK tyrosine kinase receptor inhibitor	ACVR1|ACVRL1|BMPR1A			0	99.08	Tocris	4945	ML 347	352.132	COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	FVRYPYDPKSZGNS-UHFFFAOYSA-N	44577753.0		FVRYPYDPKSZGNS
BRD-K81044214-001-06-4	ML348	Preclinical	lysophospholipase inhibitor	LYPLA1			0	97.3	Tocris	5345	ML 348	415.091	FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1	OXKNHBBDOIMFFQ-UHFFFAOYSA-N	3238952.0		OXKNHBBDOIMFFQ
BRD-K81044214-001-07-9	ML348	Preclinical	lysophospholipase inhibitor	LYPLA1			0	98.15	Tocris	5345	ML 348	415.091	FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1	OXKNHBBDOIMFFQ-UHFFFAOYSA-N	3238952.0		OXKNHBBDOIMFFQ
BRD-K02160913-001-02-7	ML365	Preclinical	potassium channel blocker	KCNK3|KCNK9			0	98.91	Tocris	5337	ML 365	360.147	COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1	UTAJHKSGYJSZBR-UHFFFAOYSA-N	46785920.0		UTAJHKSGYJSZBR
BRD-K02160913-001-03-9	ML365	Preclinical	potassium channel blocker	KCNK3|KCNK9			0	97.75	Tocris	5337	ML 365	360.147	COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1	UTAJHKSGYJSZBR-UHFFFAOYSA-N	46785920.0		UTAJHKSGYJSZBR
BRD-K52644305-300-02-9	ML786	Preclinical	RAF inhibitor	BRAF|RAF1			0	82.95	Tocris	5036	ML 786 dihydrochloride	538.219	CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1	GXEGTVQATHKFDH-OAQYLSRUSA-N	50992247.0		GXEGTVQATHKFDH
BRD-K52644305-300-01-3	ML786	Preclinical	RAF inhibitor	BRAF|RAF1			0	91.56	Tocris	5036	ML 786 dihydrochloride	538.219	CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1	GXEGTVQATHKFDH-OAQYLSRUSA-N	50992247.0		GXEGTVQATHKFDH
BRD-K68402494-003-03-5	ML9	Preclinical	myosin light chain kinase inhibitor	TRPC6			0	96.58	Tocris	431	ML 9 hydrochloride	324.07	Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	OZSMSRIUUDGTEP-UHFFFAOYSA-N	4217.0		OZSMSRIUUDGTEP
BRD-K68402494-003-04-3	ML9	Preclinical	myosin light chain kinase inhibitor	TRPC6			0	98.37	Tocris	431	ML 9 hydrochloride	324.07	Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	OZSMSRIUUDGTEP-UHFFFAOYSA-N	4217.0		OZSMSRIUUDGTEP
BRD-K68474068-019-02-9	MM-102	Preclinical	WDR5/MLL interaction inhibitor				0	96.53	Tocris	5307	MM 102	669.381	CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	RZKSQRIPRKWVBU-MHZLTWQESA-N	54766613.0		RZKSQRIPRKWVBU
BRD-K68474068-001-01-8	MM-102	Preclinical	WDR5/MLL interaction inhibitor				0	91.66	Selleck	S7265	MM-102	669.381	CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	RZKSQRIPRKWVBU-MHZLTWQESA-N	54766613.0		RZKSQRIPRKWVBU
BRD-K98353094-001-01-6	MM-11253	Preclinical	retinoid receptor antagonist	RARG			0	98.06	Tocris	3822	MM 11253	462.169	CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O	DPVGXUNWCVEIGT-UHFFFAOYSA-N	10389639.0		DPVGXUNWCVEIGT
BRD-K98353094-001-02-9	MM-11253	Preclinical	retinoid receptor antagonist	RARG			0	97.04	Tocris	3822	MM 11253	462.169	CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O	DPVGXUNWCVEIGT-UHFFFAOYSA-N	10389639.0		DPVGXUNWCVEIGT
BRD-K00004622-001-01-9	MM-206	Preclinical	STAT inhibitor				0	80.34	Sigma	SML1673	2,3,4,5,6-pentafluoro-N-(4-hydroxy-3-phenylsulfanyl-1-naphthyl)benzenesulfonamide	497.018	Oc1c(Sc2ccccc2)cc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccccc12	ZXJHEANDHXHGMV-UHFFFAOYSA-N	102514675.0		ZXJHEANDHXHGMV
BRD-K56077740-001-10-9	MMPX	Preclinical	phosphodiesterase inhibitor				0	97.72	Tocris	552	MMPX	266.138	COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	NBLBCGUCPBXKOV-UHFFFAOYSA-N	155806.0		NBLBCGUCPBXKOV
BRD-K56077740-001-09-2	MMPX	Preclinical	phosphodiesterase inhibitor				0	99.04	Tocris	552	MMPX	266.138	COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	NBLBCGUCPBXKOV-UHFFFAOYSA-N	155806.0		NBLBCGUCPBXKOV
BRD-K78973789-001-02-9	MMV-390048	Preclinical	PI4K inhibitor				0	92.66	AMS	L14545	MMV-390048	393.076	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc(nc1)C(F)(F)F	RTJQABCNNLMCJF-UHFFFAOYSA-N	53311393.0		RTJQABCNNLMCJF
BRD-K50293352-300-03-9	MM77	Preclinical	serotonin receptor antagonist	HTR1A			0	94.34	Tocris	933	MM 77 dihydrochloride	345.205	COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	MQHOGPLXAXSQAJ-UHFFFAOYSA-N	3994476.0		MQHOGPLXAXSQAJ
BRD-K50293352-300-02-1	MM77	Preclinical	serotonin receptor antagonist	HTR1A			0	75.74	Tocris	933	MM 77 dihydrochloride	345.205	COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	MQHOGPLXAXSQAJ-UHFFFAOYSA-N	3994476.0		MQHOGPLXAXSQAJ
BRD-K16183658-001-02-9	MN-64	Preclinical	tankyrase inhibitor	TNKS			0	94.47	Tocris	5084	MN 64	264.115	CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1	PYTOHIUBXSJKQH-UHFFFAOYSA-N	2802462.0		PYTOHIUBXSJKQH
BRD-K16183658-001-01-4	MN-64	Preclinical	tankyrase inhibitor	TNKS			0	96.16	MedChemEx	HY-19351	MN-64	264.115	CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1	PYTOHIUBXSJKQH-UHFFFAOYSA-N	2802462.0		PYTOHIUBXSJKQH
BRD-K63151507-001-02-4	MNITMT	Preclinical	lymphocyte inhibitor				0	98.32	Tocris	2492	MNITMT	240.043	Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	NMBDIMPYACLUDE-UHFFFAOYSA-N	364622.0		NMBDIMPYACLUDE
BRD-K63151507-001-03-9	MNITMT	Preclinical	lymphocyte inhibitor				0	88.88	Tocris	2492	MNITMT	240.043	Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	NMBDIMPYACLUDE-UHFFFAOYSA-N	364622.0		NMBDIMPYACLUDE
BRD-K16485616-001-13-9	mocetinostat	Phase 2	HDAC inhibitor	HDAC1|HDAC11|HDAC2|HDAC3			0	95.98	MedChemEx	HY-12164	mocetinostat	396.17	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	HRNLUBSXIHFDHP-UHFFFAOYSA-N	9865515.0		HRNLUBSXIHFDHP
BRD-K16485616-001-12-1	mocetinostat	Phase 2	HDAC inhibitor	HDAC1|HDAC11|HDAC2|HDAC3			0	94.86	Selleck	S1122	Mocetinostat (MGCD0103)	396.17	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	HRNLUBSXIHFDHP-UHFFFAOYSA-N	9865515.0		HRNLUBSXIHFDHP
BRD-K16485616-001-08-9	mocetinostat	Phase 2	HDAC inhibitor	HDAC1|HDAC11|HDAC2|HDAC3			0	96.2	Selleck	S1122	Mocetinostat (MGCD0103)	396.17	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	HRNLUBSXIHFDHP-UHFFFAOYSA-N	9865515.0		HRNLUBSXIHFDHP
BRD-K07237224-001-22-9	moclobemide	Launched	monoamine oxidase inhibitor	MAOA|MAOB	neurology/psychiatry	depression|anxiety	0	88.7	Tocris	4395	Moclobemide	268.098	Clc1ccc(cc1)C(=O)NCCN1CCOCC1	YHXISWVBGDMDLQ-UHFFFAOYSA-N	4235.0		YHXISWVBGDMDLQ
BRD-K07237224-001-20-4	moclobemide	Launched	monoamine oxidase inhibitor	MAOA|MAOB	neurology/psychiatry	depression|anxiety	0	83.57	Tocris	4395	Moclobemide	268.098	Clc1ccc(cc1)C(=O)NCCN1CCOCC1	YHXISWVBGDMDLQ-UHFFFAOYSA-N	4235.0		YHXISWVBGDMDLQ
BRD-K07237224-001-19-6	moclobemide	Launched	monoamine oxidase inhibitor	MAOA|MAOB	neurology/psychiatry	depression|anxiety	0	94.41	Selleck	S3212	Moclobemide (Ro 111163)	268.098	Clc1ccc(cc1)C(=O)NCCN1CCOCC1	YHXISWVBGDMDLQ-UHFFFAOYSA-N	4235.0		YHXISWVBGDMDLQ
BRD-K25317177-065-01-4	modaline	Preclinical					0	98.29	MicroSource	1506123	MODALINE SULFATE	177.127	Cc1nccnc1N1CCCCC1	BJHCGMHPEKLROM-UHFFFAOYSA-N	17860.0		BJHCGMHPEKLROM
BRD-K25317177-065-02-9	modaline	Preclinical					0		Broad Institute	Modaline sulfate	Modaline sulfate	177.127	Cc1nccnc1N1CCCCC1	BJHCGMHPEKLROM-UHFFFAOYSA-N	17860.0		BJHCGMHPEKLROM
BRD-K34441861-003-06-2	moexipril	Launched	angiotensin converting enzyme inhibitor	ACE|ACE2	cardiology	hypertension	0	73.49	Tocris	2691	Moexipril hydrochloride	498.237	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	UWWDHYUMIORJTA-HSQYWUDLSA-N	91270.0		UWWDHYUMIORJTA
BRD-K34441861-003-08-9	moexipril	Launched	angiotensin converting enzyme inhibitor	ACE|ACE2	cardiology	hypertension	0	87.56	Tocris	2691	Moexipril hydrochloride	498.237	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	UWWDHYUMIORJTA-HSQYWUDLSA-N	91270.0		UWWDHYUMIORJTA
BRD-K34441861-003-05-4	moexipril	Launched	angiotensin converting enzyme inhibitor	ACE|ACE2	cardiology	hypertension	0	72.37	Selleck	S2079	Moexipril HCl	498.237	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	UWWDHYUMIORJTA-HSQYWUDLSA-N	91270.0		UWWDHYUMIORJTA
BRD-K34441861-003-07-0	moexipril	Launched	angiotensin converting enzyme inhibitor	ACE|ACE2	cardiology	hypertension	0	93.18	Selleck	S2079	Moexipril HCl	498.237	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	UWWDHYUMIORJTA-HSQYWUDLSA-N	91270.0		UWWDHYUMIORJTA
BRD-K52598503-003-01-1	mofegiline	Phase 1	monoamine oxidase inhibitor	MAOA|MAOB			0	88.73	MedChemEx	HY-16677A	Mofegiline (hydrochloride)	197.102	NC\C(CCc1ccc(F)cc1)=C\F	VXLBSYHAEKDUSU-JXMROGBWSA-N	6437850.0		VXLBSYHAEKDUSU
BRD-K52598503-003-02-9	mofegiline	Phase 1	monoamine oxidase inhibitor	MAOA|MAOB			0	86.14	MedChemEx	HY-16677A	Mofegiline (hydrochloride)	197.102	NC\C(CCc1ccc(F)cc1)=C\F	VXLBSYHAEKDUSU-JXMROGBWSA-N	6437850.0		VXLBSYHAEKDUSU
BRD-K49372556-001-04-1	mofezolac	Launched	cyclooxygenase inhibitor	PTGS1	rheumatology|orthopedics	rheumatoid arthritis|osteoporosis	0	99.58	Sigma	MFCD00712149	[3,4-bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid	339.111	COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1	DJEIHHYCDCTAAH-UHFFFAOYSA-N	4237.0		DJEIHHYCDCTAAH
BRD-A87673115-001-04-1	moguisteine	Phase 2	ATP-sensitive potassium channel inhibitor				0	97.02	Selleck	S3104	Moguisteine	339.114	CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12,r|	WSYVIAQNTFPTBI-OAHLLOKOSA-N	219046.0		WSYVIAQNTFPTBI
BRD-K01291782-001-02-9	molidustat	Phase 3	hypoxia inducible factor inhibitor	EGLN2			0	90.41	MedChemEx	HY-12654	Molidustat	314.124	O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	IJMBOKOTALXLKS-UHFFFAOYSA-N	59603622.0		IJMBOKOTALXLKS
BRD-K01291782-001-01-1	molidustat	Phase 3	hypoxia inducible factor inhibitor	EGLN2			0	83.4	MedChemEx	HY-12654	Molidustat	314.124	O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	IJMBOKOTALXLKS-UHFFFAOYSA-N	59603622.0		IJMBOKOTALXLKS
BRD-A65280694-003-13-7	molindone	Launched	dopamine receptor antagonist	DRD2|HRH1|HTR2A	neurology/psychiatry	schizophrenia	0	98.2	MicroSource	1506018	MOLINDONE HYDROCHLORIDE	276.184	CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|	KLPWJLBORRMFGK-LBPRGKRZSA-N	6604347.0		KLPWJLBORRMFGK
BRD-A65280694-003-14-9	molindone	Launched	dopamine receptor antagonist	DRD2|HRH1|HTR2A	neurology/psychiatry	schizophrenia	0	94.15	MedChemEx	HY-B1017	Molindone (hydrochloride)	276.184	CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|	KLPWJLBORRMFGK-LBPRGKRZSA-N	6604347.0		KLPWJLBORRMFGK
BRD-K63861289-001-29-9	molsidomine	Launched	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	0	94.11	MedChemEx	HY-B1069	Molsidomine	243.109	CCOC(=O)Nc1c[n+](no1)N1CCOCC1	XLFWDASMENKTKL-UHFFFAOYSA-O	4239.0		XLFWDASMENKTKL
BRD-K63861289-001-19-6	molsidomine	Launched	guanylate cyclase stimulant	GUCY1A3	cardiology	coronary artery disease (CAD)	0	98.74	MicroSource	1500673	MOLSIDOMINE	243.109	CCOC(=O)Nc1c[n+](no1)N1CCOCC1	XLFWDASMENKTKL-UHFFFAOYSA-O	4239.0		XLFWDASMENKTKL
BRD-K50265942-001-01-2	mometasone	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	0.0	Sigma	MFCD02683426	(11beta,16alpha)-9,21-dichloro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione	426.136	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11,t:7|	QLIIKPVHVRXHRI-CXSFZGCWSA-N	441335.0		QLIIKPVHVRXHRI
BRD-K60640630-001-11-0	mometasone-furoate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	94.31	MicroSource	1505367	MOMETASONE FUROATE	520.142	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|	WOFMFGQZHJDGCX-ZULDAHANSA-N	441336.0	BRD-A01139232-001-01-0	WOFMFGQZHJDGCX
BRD-K60640630-001-10-2	mometasone-furoate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	94.94	Selleck	S1987	Mometasone furoate	520.142	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|	WOFMFGQZHJDGCX-ZULDAHANSA-N	441336.0	BRD-K28476963-001-01-8	WOFMFGQZHJDGCX
BRD-K60640630-001-12-9	mometasone-furoate	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	90.13	Tocris	4115	Mometasone furoate	520.142	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11,t:7|	WOFMFGQZHJDGCX-ZULDAHANSA-N	441336.0		WOFMFGQZHJDGCX
BRD-A78377521-001-06-3	monastrol	Preclinical	kinesin inhibitor	KIF11			0	97.92	Tocris	1305	Monastrol	292.088	CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|	LOBCDGHHHHGHFA-GFCCVEGCSA-N	794325.0		LOBCDGHHHHGHFA
BRD-A78377521-001-05-5	monastrol	Preclinical	kinesin inhibitor	KIF11			0	97.94	Tocris	1305	Monastrol	292.088	CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r,c:5|	LOBCDGHHHHGHFA-GFCCVEGCSA-N	794325.0		LOBCDGHHHHGHFA
BRD-K55375480-236-04-9	monensin	Launched	bacterial permeability inducer		infectious disease	gastrointestinal parasites	0	78.9	MedChemEx	HY-N0150	Monensin sodium salt	670.429	CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@H]1O[C@H](C[C@@H]1C)[C@H]1O[C@@](O)(CO)[C@H](C)C[C@@H]1C	GAOZTHIDHYLHMS-KEOBGNEYSA-N	441145.0		GAOZTHIDHYLHMS
BRD-K00004607-001-01-9	monepantel	Preclinical	mTOR inhibitor				0	97.55	MedChemEx	HY-14774	Monepantel	473.063	C[C@](COc1cc(ccc1C(F)(F)F)C#N)(NC(=O)c1ccc(SC(F)(F)F)cc1)C#N	WTERNLDOAPYGJD-SFHVURJKSA-N	44449087.0		WTERNLDOAPYGJD
BRD-K54262262-001-10-8	monobenzone	Launched	melanin inhibitor	TYR	dermatology	skin depigmentation	0	0.0	MicroSource	1503031	MONOBENZONE	200.084	Oc1ccc(OCc2ccccc2)cc1	VYQNWZOUAUKGHI-UHFFFAOYSA-N	7638.0		VYQNWZOUAUKGHI
BRD-K54262262-001-12-4	monobenzone	Launched	melanin inhibitor	TYR	dermatology	skin depigmentation	0	0.0	Sigma	1445506	4-(benzyloxy)phenol	200.084	Oc1ccc(OCc2ccccc2)cc1	VYQNWZOUAUKGHI-UHFFFAOYSA-N	7638.0		VYQNWZOUAUKGHI
BRD-K54262262-001-11-6	monobenzone	Launched	melanin inhibitor	TYR	dermatology	skin depigmentation	0	83.75	Selleck	S1652	Monobenzone (Benoquin)	200.084	Oc1ccc(OCc2ccccc2)cc1	VYQNWZOUAUKGHI-UHFFFAOYSA-N	7638.0		VYQNWZOUAUKGHI
BRD-K54262262-001-09-0	monobenzone	Launched	melanin inhibitor	TYR	dermatology	skin depigmentation	0	77.12	Selleck	S1652	Monobenzone	200.084	Oc1ccc(OCc2ccccc2)cc1	VYQNWZOUAUKGHI-UHFFFAOYSA-N	7638.0		VYQNWZOUAUKGHI
BRD-K65508953-001-13-9	monocrotaline	Preclinical	antitumor agent				0	87.05	MedChemEx	HY-N0750	Monocrotaline	325.153	C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23 |t:10|	QVCMHGGNRFRMAD-XFGHUUIASA-N	9415.0		QVCMHGGNRFRMAD
BRD-A48938994-001-15-8	monoctanoin	Launched			gastroenterology	gallstones	0	0.0	Sigma	MFCD00056652	2,3-dihydroxypropyl octanoate	218.152	CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|	GHBFNMLVSPCDGN-JTQLQIEISA-N	3085369.0		GHBFNMLVSPCDGN
BRD-A48938994-001-14-1	monoctanoin	Launched			gastroenterology	gallstones	0	84.6	Sigma	MFCD00056652	2,3-dihydroxypropyl octanoate	218.152	CCCCCCCC(=O)OC[C@@H](O)CO |&1:11,r|	GHBFNMLVSPCDGN-JTQLQIEISA-N	3085369.0		GHBFNMLVSPCDGN
BRD-K00004695-001-01-9	monomethyl-fumarate	Launched			neurology/psychiatry	multiple sclerosis	0	97.69	CombiBlocks	OR-0777	Monomethyl fumarate	130.027	COC(=O)\C=C\C(O)=O	NKHAVTQWNUWKEO-NSCUHMNNSA-N	5369209.0		NKHAVTQWNUWKEO
BRD-K79926543-001-07-6	monosodium-alpha-luminol	Launched					0	97.04	MedChemEx	HY-15922	Luminol	177.054	Nc1cccc2c1c(=O)[nH][nH]c2=O	HWYHZTIRURJOHG-UHFFFAOYSA-N	10638.0		HWYHZTIRURJOHG
BRD-K79926543-001-08-4	monosodium-alpha-luminol	Launched					0	96.01	Enamine	Z56813244		177.054	Nc1cccc2c1c(=O)[nH][nH]c2=O	HWYHZTIRURJOHG-UHFFFAOYSA-N	10638.0		HWYHZTIRURJOHG
BRD-K79926543-001-09-9	monosodium-alpha-luminol	Launched					0	96.02	MedChemEx	HY-15922	Luminol	177.054	Nc1cccc2c1c(=O)[nH][nH]c2=O	HWYHZTIRURJOHG-UHFFFAOYSA-N	10638.0		HWYHZTIRURJOHG
BRD-A31454688-001-01-6	monostearin	Preclinical					0	92.85	TCI	G0085		358.308	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:21,r|	VBICKXHEKHSIBG-FQEVSTJZSA-N	15560610.0		VBICKXHEKHSIBG
BRD-K69470111-236-10-9	montelukast	Launched	leukotriene receptor antagonist	ALOX5|CYSLTR1	pulmonary|allergy	asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)	0	97.51	Tocris	5904	Montelukast sodium	585.21	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	UCHDWCPVSPXUMX-TZIWLTJVSA-N	5281040.0		UCHDWCPVSPXUMX
BRD-K69470111-001-01-2	montelukast	Launched	leukotriene receptor antagonist	ALOX5|CYSLTR1	pulmonary|allergy	asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)	0	93.75	MicroSource	1505391	MONTELUKAST SODIUM	585.21	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	UCHDWCPVSPXUMX-TZIWLTJVSA-N	5281040.0		UCHDWCPVSPXUMX
BRD-K69470111-236-08-9	montelukast	Launched	leukotriene receptor antagonist	ALOX5|CYSLTR1	pulmonary|allergy	asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)	0	81.19	Selleck	S4211	Montelukast Sodium	585.21	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	UCHDWCPVSPXUMX-TZIWLTJVSA-N	5281040.0		UCHDWCPVSPXUMX
BRD-K69470111-236-09-7	montelukast	Launched	leukotriene receptor antagonist	ALOX5|CYSLTR1	pulmonary|allergy	asthma|allergic rhinitis|exercise-induced bronchoconstriction (EIB)	0	98.68	Selleck	S4211	Montelukast Sodium	585.21	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	UCHDWCPVSPXUMX-TZIWLTJVSA-N	5281040.0		UCHDWCPVSPXUMX
BRD-A51747092-003-03-0	moprolol	Launched	adrenergic receptor antagonist		cardiology|ophthalmology|neurology/psychiatry	hypertension|glaucoma|anxiety	0	95.27	LifeChem	F3314-0163		239.152	COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|	LFTFGCDECFPSQD-NSHDSACASA-N	3034006.0		LFTFGCDECFPSQD
BRD-K21548250-003-20-9	moracizine	Withdrawn	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	0	97.36	Vitas-M	STK370502	ethyl 10-[3-(4-morpholinyl)propanoyl]-10H-phenothiazin-2-ylcarbamate	427.157	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	FUBVWMNBEHXPSU-UHFFFAOYSA-N	34633.0		FUBVWMNBEHXPSU
BRD-K21548250-003-19-1	moracizine	Withdrawn	sodium channel blocker	SCN5A	cardiology	ventricular arrhythmias	0	99.39	Prestwick	Prestw-1051	Moricizine hydrochloride	427.157	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	FUBVWMNBEHXPSU-UHFFFAOYSA-N	34633.0		FUBVWMNBEHXPSU
BRD-K71454870-048-06-3	morantel	Launched	acetylcholine receptor agonist		infectious disease	tapeworm	0	55.48	MicroSource	1503931	MORANTEL CITRATE	220.103	CN1CCCN=C1\C=C\c1sccc1C |c:5|	NVEPPWDVLBMNMB-SNAWJCMRSA-N	5353792.0		NVEPPWDVLBMNMB
BRD-K71454870-046-01-8	morantel	Launched	acetylcholine receptor agonist		infectious disease	tapeworm	0	94.05	Selleck	S5747	Morantel tartrate	220.103	CN1CCCN=C1\C=C\c1sccc1C |c:5|	NVEPPWDVLBMNMB-SNAWJCMRSA-N	5353792.0		NVEPPWDVLBMNMB
BRD-K11590034-002-02-6	morin	Preclinical	cytochrome P450 inhibitor	ADORA2A|ESR2|FASN|MCL1|SLC22A12			0	55.63	Selleck	S2325	Morin Hydrate	302.043	Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	YXOLAZRVSSWPPT-UHFFFAOYSA-N	5281670.0		YXOLAZRVSSWPPT
BRD-K11590034-002-03-4	morin	Preclinical	cytochrome P450 inhibitor	ADORA2A|ESR2|FASN|MCL1|SLC22A12			0	100.0	Selleck	S2325	Morin hydrate (Aurantica)	302.043	Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	YXOLAZRVSSWPPT-UHFFFAOYSA-N	5281670.0		YXOLAZRVSSWPPT
BRD-K11590034-002-04-2	morin	Preclinical	cytochrome P450 inhibitor	ADORA2A|ESR2|FASN|MCL1|SLC22A12			0	88.07	Selleck	S2325	Morin hydrate	302.043	Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	YXOLAZRVSSWPPT-UHFFFAOYSA-N	5281670.0		YXOLAZRVSSWPPT
BRD-A40546373-001-01-8	morinidazole	Launched	other antibiotic	CYP51A1			0	85.47	MedChemEx	HY-15781	Morinidazole	270.133	Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7,r|	GAZGHCHCYRSPIV-JTQLQIEISA-N	102486242.0		GAZGHCHCYRSPIV
BRD-K38938675-001-01-4	morniflumate	Launched	anti-inflammatory agent		neurology/psychiatry	pain relief	0	97.89	AKSci	O651		395.146	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1	LDXSPUSKBDTEKA-UHFFFAOYSA-N	72106.0		LDXSPUSKBDTEKA
BRD-K88786763-003-03-9	moroxydine	Launched	antiviral		infectious disease	influenza A virus infection	0	86.9	MedChemEx	HY-B0420A	Moroxydine (hydrochloride)	171.112	NC(=N)\N=C(/N)N1CCOCC1	KJHOZAZQWVKILO-UHFFFAOYSA-N	71655.0		KJHOZAZQWVKILO
BRD-K00003491-001-01-9	morphothiadin	Preclinical	antiinfective drug				0	94.57	MedChemEx	HY-108917	Morphothiadin	508.058	CCOC(=O)C1=C(CN2CCOCC2)NC(=N[C@@H]1c1ccc(F)cc1Br)c1nccs1 |&1:17,r,c:5,16|	SQGRDKSRFFUBBU-GOSISDBHSA-N	129387808.0		SQGRDKSRFFUBBU
BRD-A39052811-048-12-8	mosapride	Launched	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG)|gastroesophageal reflux disease (GERD)|dyspepsia|irritable bowel syndrome	0	97.15	Tocris	2844	Mosapride citrate	421.157	CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|	YPELFRMCRYSPKZ-INIZCTEOSA-N	9979608.0		YPELFRMCRYSPKZ
BRD-A39052811-048-11-0	mosapride	Launched	serotonin receptor agonist	HTR4	gastroenterology	hypertrophic gastritis (GHG)|gastroesophageal reflux disease (GERD)|dyspepsia|irritable bowel syndrome	0	98.7	Selleck	S1385	Mosapride Citrate	421.157	CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|	YPELFRMCRYSPKZ-INIZCTEOSA-N	9979608.0		YPELFRMCRYSPKZ
BRD-K00004657-001-01-9	motapizone	Preclinical	phosphodiesterase inhibitor				0	93.45	Enamine	Z1691545087	6-[4-(1H-imidazol-1-yl)-2-thienyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone	260.073	CC1=C(NNC(=O)C1)c1cc(cs1)-n1ccnc1 |t:1|	IQHAKYLSMONFMT-UHFFFAOYSA-N			IQHAKYLSMONFMT
BRD-K99616396-001-06-9	motesanib	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FLT1|FLT4|KDR|KIT			0	95.52	MedChemEx	HY-10228	Motesanib	373.19	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	RAHBGWKEPAQNFF-UHFFFAOYSA-N	11667893.0		RAHBGWKEPAQNFF
BRD-K99616396-001-05-1	motesanib	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FLT1|FLT4|KDR|KIT			0	92.99	MedChemEx	HY-10228	Motesanib	373.19	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	RAHBGWKEPAQNFF-UHFFFAOYSA-N	11667893.0		RAHBGWKEPAQNFF
BRD-K99616396-316-04-6	motesanib	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FLT1|FLT4|KDR|KIT			0	64.3	Selleck	S1032	Motesanib Diphosphate (AMG-706)	373.19	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	RAHBGWKEPAQNFF-UHFFFAOYSA-N	11667893.0		RAHBGWKEPAQNFF
BRD-K99616396-316-06-1	motesanib	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FLT1|FLT4|KDR|KIT			0	71.82	MedChemEx	HY-10229	Motesanib (Diphosphate)	373.19	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	RAHBGWKEPAQNFF-UHFFFAOYSA-N	11667893.0		RAHBGWKEPAQNFF
BRD-K99616396-316-05-3	motesanib	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FLT1|FLT4|KDR|KIT			0	81.46	Selleck	S1032	Motesanib Diphosphate	373.19	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	RAHBGWKEPAQNFF-UHFFFAOYSA-N	11667893.0		RAHBGWKEPAQNFF
BRD-K11785681-001-01-2	motolimod	Phase 2	toll-like receptor agonist	TLR8			0	87.75	MedChemEx	HY-13773	Motolimod	458.268	CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9,18|	QSPOQCXMGPDIHI-UHFFFAOYSA-N	16049404.0		QSPOQCXMGPDIHI
BRD-A08899266-001-06-9	moxalactam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections|skin infections|bone and joint infections|pneumonia|urinary tract infections|meningitis	0	0.0	Sigma	43963	Moxalactam Supplement	520.101	CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|	JWCSIUVGFCSJCK-UOXRKKOCSA-N	157009.0		JWCSIUVGFCSJCK
BRD-A08899266-304-05-0	moxalactam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections|gram-negative bacterial infections|skin infections|bone and joint infections|pneumonia|urinary tract infections|meningitis	0	0.0	MicroSource	1500418	MOXALACTAM DISODIUM	520.101	CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2,17,&1:6,c:30|	JWCSIUVGFCSJCK-UOXRKKOCSA-N	157009.0		JWCSIUVGFCSJCK
BRD-K12742203-003-01-7	moxaverine	Launched	phosphodiesterase inhibitor		neurology/psychiatry	spasms	0	99.2	Innovapharm	BBS-00028240	1-benzyl-3-ethyl-6,7-dimethoxyisoquinoline hydrochloride	307.157	CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1	MYCMTMIGRXJNSO-UHFFFAOYSA-N	70882.0		MYCMTMIGRXJNSO
BRD-K00003660-001-01-9	moxidectin	Launched	chloride channel antagonist		infectious disease	gastrointestinal parasites	0	89.94	MedChemEx	HY-B0777	Moxidectin	639.377	[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4,t:6,12,45|	YZBLFMPOMVTDJY-LSGXYNIPSA-N	9832912.0		YZBLFMPOMVTDJY
BRD-K66615216-003-14-8	moxifloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology|pulmonary|infectious disease	sinusitis|bronchitis|pneumonia|skin infections|intra-abdominal infections	0	94.14	MicroSource	1504303	MOXIFLOXACIN HYDROCHLORIDE	401.175	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	FABPRXSRWADJSP-MEDUHNTESA-N	40467042.0		FABPRXSRWADJSP
BRD-K66615216-003-13-0	moxifloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	otolaryngology|pulmonary|infectious disease	sinusitis|bronchitis|pneumonia|skin infections|intra-abdominal infections	0	92.35	Selleck	S1465	Moxifloxacin HCl	401.175	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	FABPRXSRWADJSP-MEDUHNTESA-N	40467042.0		FABPRXSRWADJSP
BRD-K81144366-003-20-9	moxisylyte	Withdrawn	adrenergic receptor antagonist				0	94.89	MedChemEx	HY-B1435	Moxisylyte (hydrochloride)	279.183	CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	VRYMTAVOXVTQEF-UHFFFAOYSA-N	4260.0		VRYMTAVOXVTQEF
BRD-K81144366-003-19-7	moxisylyte	Withdrawn	adrenergic receptor antagonist				0	95.95	MicroSource	1506079	MOXISYLYTE HYDROCHLORIDE	279.183	CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	VRYMTAVOXVTQEF-UHFFFAOYSA-N	4260.0		VRYMTAVOXVTQEF
BRD-K77771411-003-12-3	moxonidine	Launched	imidazoline receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	92.08	Tocris	2282	Moxonidine hydrochloride	241.073	COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|	WPNJAUFVNXKLIM-UHFFFAOYSA-N	4810.0		WPNJAUFVNXKLIM
BRD-K77771411-003-10-7	moxonidine	Launched	imidazoline receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	96.96	Tocris	2282	Moxonidine hydrochloride	241.073	COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|	WPNJAUFVNXKLIM-UHFFFAOYSA-N	4810.0		WPNJAUFVNXKLIM
BRD-K77771411-001-12-7	moxonidine	Launched	imidazoline receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	96.81	Selleck	S2066	Moxonidine	241.073	COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|	WPNJAUFVNXKLIM-UHFFFAOYSA-N	4810.0		WPNJAUFVNXKLIM
BRD-K77771411-003-13-9	moxonidine	Launched	imidazoline receptor agonist	ADRA2A|ADRA2B|ADRA2C	cardiology	hypertension	0	79.7	Tocris	2282	Moxonidine hydrochloride	241.073	COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|	WPNJAUFVNXKLIM-UHFFFAOYSA-N	4810.0		WPNJAUFVNXKLIM
BRD-A31095847-001-03-9	mozavaptan	Launched	vasopressin receptor antagonist	AVPR1A|AVPR1B|AVPR2	endocrinology	hyponatremia	0	95.18	MedChemEx	HY-18346	Mozavaptan	427.226	CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|	WRNXUQJJCIZICJ-DEOSSOPVSA-N	11441742.0		WRNXUQJJCIZICJ
BRD-A31095847-001-02-3	mozavaptan	Launched	vasopressin receptor antagonist	AVPR1A|AVPR1B|AVPR2	endocrinology	hyponatremia	0	97.07	Selleck	S2920	Mozavaptan	427.226	CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3,r|	WRNXUQJJCIZICJ-DEOSSOPVSA-N	11441742.0		WRNXUQJJCIZICJ
BRD-K60690191-003-11-2	MPEP	Preclinical	glutamate receptor antagonist	GRM1|GRM4|GRM5			0	81.5	Tocris	1212	MPEP hydrochloride	193.089	Cc1cccc(n1)C#Cc1ccccc1	NEWKHUASLBMWRE-UHFFFAOYSA-N	3025961.0		NEWKHUASLBMWRE
BRD-K60690191-001-03-3	MPEP	Preclinical	glutamate receptor antagonist	GRM1|GRM4|GRM5			0	97.59	Selleck	S2809	MPEP	193.089	Cc1cccc(n1)C#Cc1ccccc1	NEWKHUASLBMWRE-UHFFFAOYSA-N	3025961.0		NEWKHUASLBMWRE
BRD-K60690191-003-09-6	MPEP	Preclinical	glutamate receptor antagonist	GRM1|GRM4|GRM5			0	95.13	Tocris	1212	MPEP hydrochloride	193.089	Cc1cccc(n1)C#Cc1ccccc1	NEWKHUASLBMWRE-UHFFFAOYSA-N	3025961.0		NEWKHUASLBMWRE
BRD-K45551181-001-03-9	MPI-0479605	Preclinical	mitotic kinase inhibitor	TTK			0	90.62	MedChemEx	HY-12660	MPI-0479605	407.243	Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	OVJBNYKNHXJGSA-UHFFFAOYSA-N	46909588.0		OVJBNYKNHXJGSA
BRD-K45551181-001-01-3	MPI-0479605	Preclinical	mitotic kinase inhibitor	TTK			0	51.57	Selleck	S7488	MPI-0479605	407.243	Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	OVJBNYKNHXJGSA-UHFFFAOYSA-N	46909588.0		OVJBNYKNHXJGSA
BRD-K45551181-001-04-7	MPI-0479605	Preclinical	mitotic kinase inhibitor	TTK			0	94.28	MedChemEx	HY-12660	MPI-0479605	407.243	Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	OVJBNYKNHXJGSA-UHFFFAOYSA-N	46909588.0		OVJBNYKNHXJGSA
BRD-K45551181-001-02-1	MPI-0479605	Preclinical	mitotic kinase inhibitor	TTK			0	93.11	Selleck	S7488	MPI-0479605	407.243	Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	OVJBNYKNHXJGSA-UHFFFAOYSA-N	46909588.0		OVJBNYKNHXJGSA
BRD-K18530250-001-01-6	Mps-BAY-2a	Preclinical	monopolar spindle 1 kinase inhibitor	TTK			0	94.23	Tocris	5562	Mps BAY 2a	476.232	CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12	MDYKTGNHXNTATG-UHFFFAOYSA-N	57381882.0		MDYKTGNHXNTATG
BRD-K18530250-001-02-9	Mps-BAY-2a	Preclinical	monopolar spindle 1 kinase inhibitor	TTK			0	97.37	Tocris	5562	Mps BAY 2a	476.232	CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12	MDYKTGNHXNTATG-UHFFFAOYSA-N	57381882.0		MDYKTGNHXNTATG
BRD-K94853001-300-04-9	Mps1-IN-1	Preclinical	monopolar spindle 1 kinase inhibitor	TTK			0	95.35	Tocris	5142	Mps1-IN-1 dihydrochloride	535.225	COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1	NMJMRSQTDLRCRQ-UHFFFAOYSA-N	25195352.0		NMJMRSQTDLRCRQ
BRD-K94853001-300-01-7	Mps1-IN-1	Preclinical	monopolar spindle 1 kinase inhibitor	TTK			0	85.19	Tocris	5142	Mps1-IN-1 dihydrochloride	535.225	COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1	NMJMRSQTDLRCRQ-UHFFFAOYSA-N	25195352.0		NMJMRSQTDLRCRQ
BRD-K43812936-001-01-9	Mps1-IN-5	Phase 1	protein kinase inhibitor				0	94.51	MedChemEx	HY-12858	Mps1-IN-5	559.169	COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O	NRJKIOCCERLIDG-GOSISDBHSA-N	71599640.0		NRJKIOCCERLIDG
BRD-K43812936-001-02-9	Mps1-IN-5	Phase 1	protein kinase inhibitor				0	89.94	MedChemEx	HY-12858	Empesertib	559.169	COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O	NRJKIOCCERLIDG-GOSISDBHSA-N	71599640.0		NRJKIOCCERLIDG
BRD-A30590053-003-03-9	MR-16728	Preclinical	acetylcholine release enhancer				0	90.64	Tocris	537	MR 16728 hydrochloride	356.283	O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|	AGKAAJMNNVUNDK-JOCHJYFZSA-N	92211530.0		AGKAAJMNNVUNDK
BRD-A30590053-003-02-9	MR-16728	Preclinical	acetylcholine release enhancer				0	93.83	Tocris	537	MR 16728 hydrochloride	356.283	O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|	AGKAAJMNNVUNDK-JOCHJYFZSA-N	92211530.0		AGKAAJMNNVUNDK
BRD-K84883208-001-01-1	MR-948	Phase 1	thromboxane synthase inhibitor	TBXAS1			0	98.9	Enamine	Z1578869664	2-(4-(2-(1H-imidazol-1-yl)ethoxy)phenyl)ethan-1-ol	232.121	OCCc1ccc(OCCn2ccnc2)cc1	LQQIZTXSZOYPPS-UHFFFAOYSA-N	10443938.0		LQQIZTXSZOYPPS
BRD-K44022883-001-01-7	MRK-016	Phase 1	GABA receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	98.16	Tocris	3817	3-tert-butyl-7-(5-methyl-3-isoxazolyl)-2-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]pyrazolo[1,5-d][1,2,4]triazine	368.171	Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C	QYSYOGCIDRANAR-UHFFFAOYSA-N	6918583.0		QYSYOGCIDRANAR
BRD-K44022883-001-02-5	MRK-016	Phase 1	GABA receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	82.88	Tocris	3817	MRK 016	368.171	Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C	QYSYOGCIDRANAR-UHFFFAOYSA-N	6918583.0		QYSYOGCIDRANAR
BRD-K57416838-001-02-9	MRK-409	Phase 1	benzodiazepine receptor agonist				0	94.46	Tocris	4415	MK 0343	397.146	Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F	GOIFCXRIFSYPFG-UHFFFAOYSA-N	22609888.0		GOIFCXRIFSYPFG
BRD-K57416838-001-01-1	MRK-409	Phase 1	benzodiazepine receptor agonist				0	99.45	Sigma	SML0565	7-cyclobutyl-3-(2,6-difluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-6-yl (1-methyl-1H-1,2,4-triazol-5-yl)methyl ether	397.146	Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F	GOIFCXRIFSYPFG-UHFFFAOYSA-N	22609888.0		GOIFCXRIFSYPFG
BRD-K68795758-001-01-1	MRK-560	Preclinical	gamma secretase inhibitor	APP			0	90.05	Tocris	4000	MRK 560	517.021	Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|	WDZVWDXOIGQJIO-UJKQEGAGSA-N			WDZVWDXOIGQJIO
BRD-K68795758-001-02-9	MRK-560	Preclinical	gamma secretase inhibitor	APP			0	94.77	Tocris	4000	MRK 560	517.021	Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|	WDZVWDXOIGQJIO-UJKQEGAGSA-N			WDZVWDXOIGQJIO
BRD-K37618799-001-04-8	MRS-1220	Preclinical	adenosine receptor antagonist	ADORA2B|ADORA3			0	92.13	Tocris	1217	MRS 1220	403.084	Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	TWWFAXQOKNBUCR-UHFFFAOYSA-N	393595.0		TWWFAXQOKNBUCR
BRD-K37618799-001-08-9	MRS-1220	Preclinical	adenosine receptor antagonist	ADORA2B|ADORA3			0		Tocris	1217	MRS 1220	403.084	Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	TWWFAXQOKNBUCR-UHFFFAOYSA-N	393595.0		TWWFAXQOKNBUCR
BRD-K37618799-001-03-0	MRS-1220	Preclinical	adenosine receptor antagonist	ADORA2B|ADORA3			0	92.13	Tocris	1217	MRS 1220	403.084	Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	TWWFAXQOKNBUCR-UHFFFAOYSA-N	393595.0		TWWFAXQOKNBUCR
BRD-A06784547-001-03-9	MRS-1334	Preclinical	adenosine receptor antagonist	ADORA3			0	96.08	Tocris	1385	MRS 1334	522.179	CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|	QFLOJAMZLQXHFS-AREMUKBSSA-N	6604859.0		QFLOJAMZLQXHFS
BRD-A06784547-001-02-6	MRS-1334	Preclinical	adenosine receptor antagonist	ADORA3			0	83.79	Tocris	1385	MRS 1334	522.179	CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11,r,c:5,9|	QFLOJAMZLQXHFS-AREMUKBSSA-N	6604859.0		QFLOJAMZLQXHFS
BRD-A78093359-001-07-9	MRS-1845	Preclinical	calcium channel blocker				0	95.8	Tocris	1866	MRS 1845	398.148	CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|	BITHABUTZRAUGT-IBGZPJMESA-N	92220886.0		BITHABUTZRAUGT
BRD-A78093359-001-06-3	MRS-1845	Preclinical	calcium channel blocker				0	95.21	Tocris	1866	MRS 1845	398.148	CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15,r,c:5,13|	BITHABUTZRAUGT-IBGZPJMESA-N	92220886.0		BITHABUTZRAUGT
BRD-K91135178-001-04-9	MRS-2578	Preclinical	purinergic receptor antagonist	P2RY6			0	27.78	Tocris	2146	MRS 2578	472.063	S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	QOHNRGHTJPFMSL-UHFFFAOYSA-N	16078986.0		QOHNRGHTJPFMSL
BRD-K91135178-001-03-9	MRS-2578	Preclinical	purinergic receptor antagonist	P2RY6			0	21.98	Selleck	S2855	MRS 2578	472.063	S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	QOHNRGHTJPFMSL-UHFFFAOYSA-N	16078986.0		QOHNRGHTJPFMSL
BRD-K91135178-001-02-1	MRS-2578	Preclinical	purinergic receptor antagonist	P2RY6			0	0.0	Selleck	S2855	MRS 2578	472.063	S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	QOHNRGHTJPFMSL-UHFFFAOYSA-N	16078986.0		QOHNRGHTJPFMSL
BRD-K10575656-034-03-9	MRS-3777	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	96.4	Tocris	2403	MRS 3777 hemioxalate	309.159	C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12	ZYVKEIQGOGHCFB-UHFFFAOYSA-N			ZYVKEIQGOGHCFB
BRD-K10575656-034-04-9	MRS-3777	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	97.69	SantaCruz	sc-204105	MRS 3777 hemioxalate	309.159	C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12	ZYVKEIQGOGHCFB-UHFFFAOYSA-N			ZYVKEIQGOGHCFB
BRD-K10575656-034-01-0	MRS-3777	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	97.24	Tocris	2403	MRS 3777 hemioxalate	309.159	C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12	OGCQBCHLFMBCCE-UHFFFAOYSA-N	11771279.0	BRD-M86143595-034-02-6|BRD-M86143595-034-02-6	OGCQBCHLFMBCCE
BRD-K10575656-034-02-9	MRS-3777	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	97.27	Tocris	2403	MRS 3777 hemioxalate	309.159	C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12	OGCQBCHLFMBCCE-UHFFFAOYSA-N	11771279.0		OGCQBCHLFMBCCE
BRD-K00003417-001-01-9	MRX-2843	Phase 1	MER tyrosine kinase inhibitor				0	92.39	MedChemEx	HY-101549	MRX-2843	488.326	CN1CCN(Cc2ccc(cc2)-c2cn([C@H]3CC[C@H](O)CC3)c3nc(NCCC4CC4)ncc23)CC1 |r|	LBEJYFVJIPQSNX-SOAUALDESA-N			LBEJYFVJIPQSNX
BRD-K00004683-001-01-9	MS-424	Phase 2	glutamate transporter modulator				0	92.08	Astatech	52852	(R)-(5-METHYL-4,5-DIHYDRO-1H-PYRAZOL-1-YL)(PYRIDIN-3-YL)METHANONE	189.09	C[C@@H]1C=CNN1C(=O)c1cccnc1 |c:2|	AEHLCVKEOAFFJC-MRVPVSSYSA-N			AEHLCVKEOAFFJC
BRD-K00003381-001-01-9	MSDC-0160	Phase 2	insulin sensitizer				0	98.66	MedChemEx	HY-100550	MSDC 0160	370.099	CCc1ccc(nc1)C(=O)COc1ccc(C[C@@H]2SC(=O)NC2=O)cc1 |&1:17,r|	IRNJSRAGRIZIHD-KRWDZBQOSA-N	36687794.0		IRNJSRAGRIZIHD
BRD-K00004703-001-01-9	MSDC-0602K	Phase 2	mitochondrial pyruvate carrier modulator				0	91.85	AMS	P51721	MSDC 0602	371.083	COc1cccc(c1)C(=O)COc1ccc(Cc2sc(O)nc2O)cc1	JIJXYXYLGRAIGV-UHFFFAOYSA-N	90835967.0		JIJXYXYLGRAIGV
BRD-K25143390-001-01-0	MSX-122	Phase 2	CC chemokine receptor antagonist	CXCR4			0	93.92	MedChemEx	HY-13696	MSX-122	292.144	C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1	PXZXYRKDDXKDTK-UHFFFAOYSA-N	11687907.0		PXZXYRKDDXKDTK
BRD-A28329383-001-03-9	MTPG	Preclinical	glutamate receptor antagonist	GRM2|GRM3			0	100.0	Tocris	855	MTPG	233.091	C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|	OZBFBAYESADVDX-JTQLQIEISA-N	10752093.0		OZBFBAYESADVDX
BRD-A28329383-001-02-1	MTPG	Preclinical	glutamate receptor antagonist	GRM2|GRM3			0	93.8	Tocris	855		233.091	C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|	OZBFBAYESADVDX-JTQLQIEISA-N	10752093.0		OZBFBAYESADVDX
BRD-K19061412-001-03-2	mubritinib	Phase 1	protein tyrosine kinase inhibitor	EGFR|ERBB2			0	96.3	Tocris	3599	TAK 165	468.177	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	ZTFBIUXIQYRUNT-MDWZMJQESA-N	6444692.0		ZTFBIUXIQYRUNT
BRD-K19061412-001-04-0	mubritinib	Phase 1	protein tyrosine kinase inhibitor	EGFR|ERBB2			0	87.21	Tocris	3599	TAK 165	468.177	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	ZTFBIUXIQYRUNT-MDWZMJQESA-N	6444692.0		ZTFBIUXIQYRUNT
BRD-K19061412-001-06-9	mubritinib	Phase 1	protein tyrosine kinase inhibitor	EGFR|ERBB2			0	96.53	Tocris	3599	TAK 165	468.177	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	ZTFBIUXIQYRUNT-MDWZMJQESA-N	6444692.0		ZTFBIUXIQYRUNT
BRD-K19061412-001-02-4	mubritinib	Phase 1	protein tyrosine kinase inhibitor	EGFR|ERBB2			0	96.61	Selleck	S2216	Mubritinib (TAK 165)	468.177	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	ZTFBIUXIQYRUNT-MDWZMJQESA-N	6444692.0		ZTFBIUXIQYRUNT
BRD-K15262564-001-14-3	mupirocin	Launched	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	0	60.91	MicroSource	1505706	MUPIROCIN	500.299	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	MINDHVHHQZYEEK-HBBNESRFSA-N	446596.0		MINDHVHHQZYEEK
BRD-K15262564-001-16-8	mupirocin	Launched	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	0	63.03	Selleck	S4297	Mupirocin	500.299	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	MINDHVHHQZYEEK-HBBNESRFSA-N	446596.0	BRD-K25394084-001-01-0	MINDHVHHQZYEEK
BRD-K15262564-001-15-0	mupirocin	Launched	isoleucyl-tRNA synthetase inhibitor		infectious disease	impetigo	0	93.41	MedChemEx	HY-B0958	Mupirocin	500.299	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	MINDHVHHQZYEEK-HBBNESRFSA-N	446596.0		MINDHVHHQZYEEK
BRD-K60441002-001-04-8	muscimol	Phase 1	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3			0	97.75	Tocris	289	Muscimol	114.043	NCc1cc(=O)[nH]o1	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	4266.0		ZJQHPWUVQPJPQT
BRD-K60441002-001-06-9	muscimol	Phase 1	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3			0	100.0	Tocris	289	Muscimol	114.043	NCc1cc(=O)[nH]o1	ZJQHPWUVQPJPQT-UHFFFAOYSA-N	4266.0		ZJQHPWUVQPJPQT
BRD-K72078047-001-01-7	MUT056399	Phase 1	FABI inhibitor				0	93.76	MedChemEx	HY-18169	MUT056399	293.086	CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F	QUHARGDBJJUOEB-UHFFFAOYSA-N	44208849.0		QUHARGDBJJUOEB
BRD-K90524085-001-08-6	MY-5445	Preclinical	phosphodiesterase inhibitor|platelet aggregation inhibitor	PDE5A			0	99.38	Tocris	432	MY-5445	331.088	Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	CEHQLKSLMFIHBF-UHFFFAOYSA-N	1348.0		CEHQLKSLMFIHBF
BRD-K90524085-001-09-9	MY-5445	Preclinical	phosphodiesterase inhibitor|platelet aggregation inhibitor	PDE5A			0	97.95	Tocris	432	MY-5445	331.088	Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	CEHQLKSLMFIHBF-UHFFFAOYSA-N	1348.0		CEHQLKSLMFIHBF
BRD-K90524085-001-07-8	MY-5445	Preclinical	phosphodiesterase inhibitor|platelet aggregation inhibitor	PDE5A			0	97.93	Tocris	432	MY-5445	331.088	Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	CEHQLKSLMFIHBF-UHFFFAOYSA-N	1348.0		CEHQLKSLMFIHBF
BRD-K92428153-001-07-7	mycophenolate-mofetil	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	IMPDH1|IMPDH2	transplant	organ rejection	0	93.37	Tocris	4102	Mycophenolate mofetil	433.21	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	RTGDFNSFWBGLEC-SYZQJQIISA-N	5281078.0		RTGDFNSFWBGLEC
BRD-K92428153-001-05-1	mycophenolate-mofetil	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	IMPDH1|IMPDH2	transplant	organ rejection	0	91.84	MicroSource	1504567	MYCOPHENOLATE MOFETIL	433.21	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	RTGDFNSFWBGLEC-SYZQJQIISA-N	5281078.0		RTGDFNSFWBGLEC
BRD-K92428153-001-04-4	mycophenolate-mofetil	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	IMPDH1|IMPDH2	transplant	organ rejection	0	95.21	Selleck	S1501	Mycophenolate Mofetil	433.21	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	RTGDFNSFWBGLEC-SYZQJQIISA-N	5281078.0		RTGDFNSFWBGLEC
BRD-K92428153-001-08-9	mycophenolate-mofetil	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	IMPDH1|IMPDH2	transplant	organ rejection	0	94.04	Tocris	4102	Mycophenolate mofetil	433.21	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	RTGDFNSFWBGLEC-SYZQJQIISA-N	5281078.0		RTGDFNSFWBGLEC
BRD-K63750851-001-22-3	mycophenolic-acid	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	IMPDH1|IMPDH2	transplant	organ rejection	0	95.86	Tocris	1505	Mycophenolic acid	320.126	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	HPNSFSBZBAHARI-RUDMXATFSA-N	446541.0		HPNSFSBZBAHARI
BRD-K63750851-001-20-7	mycophenolic-acid	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	IMPDH1|IMPDH2	transplant	organ rejection	0	98.39	MicroSource	1500674	MYCOPHENOLIC ACID	320.126	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	HPNSFSBZBAHARI-RUDMXATFSA-N	446541.0		HPNSFSBZBAHARI
BRD-K63750851-001-18-1	mycophenolic-acid	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	IMPDH1|IMPDH2	transplant	organ rejection	0	96.3	Selleck	S2487	Mycophenolic acid	320.126	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	HPNSFSBZBAHARI-RUDMXATFSA-N	446541.0		HPNSFSBZBAHARI
BRD-K63750851-001-19-9	mycophenolic-acid	Launched	dehydrogenase inhibitor|inositol monophosphatase inhibitor	IMPDH1|IMPDH2	transplant	organ rejection	0	93.47	Tocris	1505	Mycophenolic acid	320.126	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	HPNSFSBZBAHARI-RUDMXATFSA-N	446541.0		HPNSFSBZBAHARI
BRD-K43149758-001-22-7	myricetin	Preclinical	androgen receptor agonist|cytochrome P450 inhibitor	PIK3CG			0	85.14	Selleck	S2326	Myricetin	318.038	Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	IKMDFBPHZNJCSN-UHFFFAOYSA-N	5281672.0		IKMDFBPHZNJCSN
BRD-K43149758-001-23-5	myricetin	Preclinical	androgen receptor agonist|cytochrome P450 inhibitor	PIK3CG			0	94.44	Selleck	S2326	Myricetin (Cannabiscetin)	318.038	Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	IKMDFBPHZNJCSN-UHFFFAOYSA-N	5281672.0		IKMDFBPHZNJCSN
BRD-K48388905-001-12-9	myricitrin	Preclinical	PKC inhibitor	NOS1|PRKCA			0	96.98	Selleck	S2327	Myricitrin	464.095	C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	DCYOADKBABEMIQ-OWMUPTOHSA-N	5281673.0		DCYOADKBABEMIQ
BRD-K88153212-001-01-9	myristyl-nicotinate	Phase 1	topical sunscreen agent				0	0.0	Accela	SY025969	tetradecyl nicotinate	319.251	CCCCCCCCCCCCCCOC(=O)c1cccnc1	TVGLGJWCZSCAEM-UHFFFAOYSA-N	531641.0		TVGLGJWCZSCAEM
BRD-K90410034-003-01-1	M8-B	Preclinical	transient receptor potential channel antagonist	TRPM8			0	93.81	Tocris	5324	M8 B hydrochloride	396.151	COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1	UOGGWHBYFVBUIY-UHFFFAOYSA-N	11675630.0		UOGGWHBYFVBUIY
BRD-K90410034-003-02-9	M8-B	Preclinical	transient receptor potential channel antagonist	TRPM8			0	97.89	Tocris	5324	M8 B hydrochloride	396.151	COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1	UOGGWHBYFVBUIY-UHFFFAOYSA-N	11675630.0		UOGGWHBYFVBUIY
BRD-K77817104-001-02-9	N-(p-amylcinnamoyl)-anthranilic-acid	Preclinical	phospholipase inhibitor				0	93.29	MedChemEx	HY-118628	N-(p-amylcinnamoyl) Anthranilic Acid	337.168	CCCCCc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1	GAMRBCZMOOMBSQ-CCEZHUSRSA-N	5353376.0		GAMRBCZMOOMBSQ
BRD-K57027742-001-01-1	N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide	Preclinical					0	20.21	Key	MS-0738	N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide	378.049	CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	YYLKOELWSMRYHV-UHFFFAOYSA-N	3006985.0		YYLKOELWSMRYHV
BRD-K78844995-001-03-9	N-[2-(piperidinylamino)ethyl]-4-iodobenzamide	Preclinical	sigma receptor ligand				0	95.66	Tocris	763	N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide	358.054	Ic1ccc(cc1)C(=O)NCCN1CCCCC1	WCMWVYQHPUQKHW-UHFFFAOYSA-N	127898.0		WCMWVYQHPUQKHW
BRD-K78844995-001-02-6	N-[2-(piperidinylamino)ethyl]-4-iodobenzamide	Preclinical	sigma receptor ligand				0	98.14	Tocris	763	N-[2-(Piperidinylamino)ethyl]-4-iodobenzamide	358.054	Ic1ccc(cc1)C(=O)NCCN1CCCCC1	WCMWVYQHPUQKHW-UHFFFAOYSA-N	127898.0		WCMWVYQHPUQKHW
BRD-K80653534-001-02-9	N-acetyl-D-glucosamine	Phase 2/Phase 3		B4GALT1|B4GALT2|B4GALT3|B4GALT4|NAGK|NAGLU|NAGPA|RENBP			0	99.1	MedChemEx	HY-A0132	N-Acetyl-D-glucosamine	221.09	CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	MBLBDJOUHNCFQT-LXGUWJNJSA-N	1738118.0		MBLBDJOUHNCFQT
BRD-K80653534-001-01-7	N-acetyl-D-glucosamine	Phase 2/Phase 3		B4GALT1|B4GALT2|B4GALT3|B4GALT4|NAGK|NAGLU|NAGPA|RENBP			0	100.0	Vitas-M	STK801800		221.09	CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	MBLBDJOUHNCFQT-LXGUWJNJSA-N	1738118.0		MBLBDJOUHNCFQT
BRD-A24857382-001-03-4	N-acetyl-tyrosine	Launched					0	96.39	Enamine	Z239130480		223.084	CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4,r|	CAHKINHBCWCHCF-JTQLQIEISA-N	68310.0		CAHKINHBCWCHCF
BRD-K52523550-001-01-5	N-acetylcarnosine	Launched					0	100.0	AKSci	R096		268.117	CC(=O)NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O	BKAYIFDRRZZKNF-VIFPVBQESA-N	9903482.0		BKAYIFDRRZZKNF
BRD-K28121004-001-02-9	N-acetylglycyl-D-glutamic-acid	Preclinical	glutamate receptor agonist				0	100.0	Tocris	395	(2R)-2-{[(acetylamino)acetyl]amino}pentanedioic acid	246.085	CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	CQTYJLQESPLSOP-ZCFIWIBFSA-N	6604718.0		CQTYJLQESPLSOP
BRD-K28121004-001-01-1	N-acetylglycyl-D-glutamic-acid	Preclinical	glutamate receptor agonist				0	76.01	Tocris	395	N-Acetylglycyl-D-glutamic acid	246.085	CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	CQTYJLQESPLSOP-ZCFIWIBFSA-N	6604718.0		CQTYJLQESPLSOP
BRD-A92872453-001-01-8	N-acetylmannosamine	Phase 2					0	100.0	Vitas-M	STK801944		221.09	CC(=O)N[C@H]1[C@@H](O)O[C@@H](CO)[C@@H](O)[C@H]1O |a:5,11,13,&1:4,&2:8|	OVRNDRQMDRJTHS-SHGPDSBTSA-N	11869379.0		OVRNDRQMDRJTHS
BRD-K73700643-001-13-8	N-acetyltryptamine	Preclinical	melatonin receptor agonist				0	98.63	Tocris	357	N-Acetyltryptamine	202.111	CC(=O)NCCc1c[nH]c2ccccc12	NVUGEQAEQJTCIX-UHFFFAOYSA-N	70547.0		NVUGEQAEQJTCIX
BRD-K73700643-001-11-2	N-acetyltryptamine	Preclinical	melatonin receptor agonist				0	95.42	Tocris	357	N-Acetyltryptamine	202.111	CC(=O)NCCc1c[nH]c2ccccc12	NVUGEQAEQJTCIX-UHFFFAOYSA-N	70547.0		NVUGEQAEQJTCIX
BRD-K73700643-001-14-9	N-acetyltryptamine	Preclinical	melatonin receptor agonist				0	93.44	Tocris	357	N-Acetyltryptamine	202.111	CC(=O)NCCc1c[nH]c2ccccc12	NVUGEQAEQJTCIX-UHFFFAOYSA-N	70547.0		NVUGEQAEQJTCIX
BRD-K75390981-300-04-9	N-alpha-methylhistamine-dihydrochloride	Phase 3	histamine receptor agonist	HRH4			0	100.0	Tocris	573	N?-Methylhistamine dihydrochloride	125.095	CNCCc1cnc[nH]1	PHSPJQZRQAJPPF-UHFFFAOYSA-N	912.0		PHSPJQZRQAJPPF
BRD-K00004214-003-01-9	N-benzylnaltrindole	Preclinical	opioid receptor antagonist				0	98.7	Tocris	754	N-Benzylnaltrindole hydrochloride	504.241	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1 |TLB:21:22:7.12.13:4.5.18,23:22:7.12.13:4.5.18|	PSPANKCQVWSVHM-OUDZLNJNSA-N	10006324.0		PSPANKCQVWSVHM
BRD-K64191834-001-03-1	N-cyclohexyl-2-benzothiazolesulfenamide	Preclinical					0	98.95	AKSci	P933	CBS, N-Cyclohexyl-2-benzothiazolesulfenamide	264.075	C1CCC(CC1)NSc1nc2ccccc2s1	DEQZTKGFXNUBJL-UHFFFAOYSA-N	7232.0		DEQZTKGFXNUBJL
BRD-K28030264-001-02-7	N-hydroxynicotinamide	Preclinical					0	96.8	Sigma	MFCD00033801	N-hydroxynicotinamide	138.043	ONC(=O)c1cccnc1	IYCHDNQCHLMLJZ-UHFFFAOYSA-N	71211.0		IYCHDNQCHLMLJZ
BRD-K82236108-001-06-9	N-methyl-(-)ephedrine-[1R,2S]	Preclinical					0		Sigma	235210-5G	( 1R,2S)-(-)-N-Methylephedrine	179.131	C[C@@H]([C@H](O)c1ccccc1)N(C)C	FMCGSUUBYTWNDP-ONGXEEELSA-N	64782.0		FMCGSUUBYTWNDP
BRD-K82236108-001-05-9	N-methyl-(-)ephedrine-[1R,2S]	Preclinical					0	84.7	Sigma	235210-5G	( 1R,2S)-(-)-N-Methylephedrine	179.131	C[C@@H]([C@H](O)c1ccccc1)N(C)C	FMCGSUUBYTWNDP-ONGXEEELSA-N	64782.0		FMCGSUUBYTWNDP
BRD-K82236108-001-04-9	N-methyl-(-)ephedrine-[1R,2S]	Preclinical					0	82.42	MicroSource	2300220	N-METHYL (-)EPHEDRINE [1R,2S]	179.131	C[C@@H]([C@H](O)c1ccccc1)N(C)C	FMCGSUUBYTWNDP-ONGXEEELSA-N	64782.0		FMCGSUUBYTWNDP
BRD-K33445938-001-01-8	N-methylformamide	Phase 2					1	0.0	Sigma	M46705	methylformamide	59.037	CNC=O	ATHHXGZTWNVVOU-UHFFFAOYSA-N	31254.0		ATHHXGZTWNVVOU
BRD-K60060639-005-02-2	N-methyllidocaine-iodide	Preclinical	antiarrhythmic medication				0	98.14	Tocris	1042	N-Methyllidocaine iodide	249.197	CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C	HFRFLLYLVAKRMZ-UHFFFAOYSA-O	168868.0		HFRFLLYLVAKRMZ
BRD-K52732207-001-01-9	N-methylpyrrolidone	Phase 1					0	0.0	Sigma	V001494	1-methyl-2-pyrrolidinone	99.068	CN1CCCC1=O	SECXISVLQFMRJM-UHFFFAOYSA-N	13387.0		SECXISVLQFMRJM
BRD-K62056274-332-02-9	N-methylquipazine	Preclinical	serotonin receptor agonist				0	97.37	Tocris	566	N-Methylquipazine dimaleate	227.142	CN1CCN(CC1)c1ccc2ccccc2n1	HOMWNUXPSJQSSU-UHFFFAOYSA-N	5013.0		HOMWNUXPSJQSSU
BRD-K62056274-332-01-8	N-methylquipazine	Preclinical	serotonin receptor agonist				0	98.26	Tocris	566	N-Methylquipazine dimaleate	227.142	CN1CCN(CC1)c1ccc2ccccc2n1	HOMWNUXPSJQSSU-UHFFFAOYSA-N	5013.0		HOMWNUXPSJQSSU
BRD-K93806173-003-01-8	N-MPPP	Preclinical	opioid receptor agonist				0	97.35	Tocris	783	N-MPPP Hydrochloride	322.205	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1	OVZWUDZIAAHNFG-HXUWFJFHSA-N	190901.0		OVZWUDZIAAHNFG
BRD-K97360717-001-10-9	N-oxydiethylenebenzothiazole-2-sulfenamide	Preclinical					0	0.0	Sigma	MFCD00022870	2-(MORPHOLINOTHIO)-BENZOTHIAZOLE	252.039	C1CN(CCO1)Sc1nc2ccccc2s1	MHKLKWCYGIBEQF-UHFFFAOYSA-N	7619.0		MHKLKWCYGIBEQF
BRD-K97360717-001-09-2	N-oxydiethylenebenzothiazole-2-sulfenamide	Preclinical					0	3.71	Enamine	Z56821717		252.039	C1CN(CCO1)Sc1nc2ccccc2s1	MHKLKWCYGIBEQF-UHFFFAOYSA-N	7619.0		MHKLKWCYGIBEQF
BRD-K39693230-001-01-2	N-salicoylaminophenol	Phase 1/Phase 2	ribonucleotide reductase inhibitor				0	99.07	CombiBlocks	QA-6673		229.074	Oc1ccc(NC(=O)c2ccccc2O)cc1	LGCMKPRGGJRYGM-UHFFFAOYSA-N	4602.0		LGCMKPRGGJRYGM
BRD-K36804890-001-02-9	NAB-2	Preclinical	ubiquitin ligase transport promoter	NEDD4			0	98.33	Tocris	5131	NAB 2	389.129	Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl	CZSLEMCYYGEGKP-UHFFFAOYSA-N	82017756.0		CZSLEMCYYGEGKP
BRD-K36804890-001-01-9	NAB-2	Preclinical	ubiquitin ligase transport promoter	NEDD4			0	97.08	Tocris	5131	NAB 2	389.129	Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl	CZSLEMCYYGEGKP-UHFFFAOYSA-N	82017756.0		CZSLEMCYYGEGKP
BRD-K65146499-001-27-9	nabumetone	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	99.57	MicroSource	1503650	NABUMETONE	228.115	COc1ccc2cc(CCC(C)=O)ccc2c1	BLXXJMDCKKHMKV-UHFFFAOYSA-N	4409.0		BLXXJMDCKKHMKV
BRD-K65146499-001-29-9	nabumetone	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	98.48	MedChemEx	HY-B0559	Nabumetone	228.115	COc1ccc2cc(CCC(C)=O)ccc2c1	BLXXJMDCKKHMKV-UHFFFAOYSA-N	4409.0		BLXXJMDCKKHMKV
BRD-K65146499-001-26-1	nabumetone	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	98.52	Selleck	S4051	Nabumetone	228.115	COc1ccc2cc(CCC(C)=O)ccc2c1	BLXXJMDCKKHMKV-UHFFFAOYSA-N	4409.0		BLXXJMDCKKHMKV
BRD-K01824972-001-05-9	nadide	Launched	free radical scavenger	AHCY|AKR1A1|ALDH2|BLVRA|DHPS|DLD|GALE|HMGCR|HSD17B1|HSD17B4|IMPDH2|MGAM|P2RY11|SORD|TRPM2			0	87.7	Selleck	S2518	NADIDE	664.117	NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|	BAWFJGJZGIEFAR-NNYOXOHSSA-O	5893.0		BAWFJGJZGIEFAR
BRD-K01824972-001-04-9	nadide	Launched	free radical scavenger	AHCY|AKR1A1|ALDH2|BLVRA|DHPS|DLD|GALE|HMGCR|HSD17B1|HSD17B4|IMPDH2|MGAM|P2RY11|SORD|TRPM2			0	86.18	MicroSource	1500419	NADIDE	664.117	NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9,11,23,25,26,28,40,42,&1:14,&2:18|	BAWFJGJZGIEFAR-NNYOXOHSSA-O	5893.0		BAWFJGJZGIEFAR
BRD-A24397426-001-10-4	nadifloxacin	Launched	bacterial DNA gyrase inhibitor		dermatology|infectious disease	acne vulgaris (AV)|skin infections	0	99.02	MicroSource	1502312	NADIFLOXACIN	360.149	C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	JYJTVFIEFKZWCJ-JTQLQIEISA-N	9850038.0		JYJTVFIEFKZWCJ
BRD-A24397426-001-13-9	nadifloxacin	Launched	bacterial DNA gyrase inhibitor		dermatology|infectious disease	acne vulgaris (AV)|skin infections	0	94.34	MedChemEx	HY-B0506	Nadifloxacin	360.149	C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	JYJTVFIEFKZWCJ-JTQLQIEISA-N	9850038.0		JYJTVFIEFKZWCJ
BRD-A24397426-001-09-6	nadifloxacin	Launched	bacterial DNA gyrase inhibitor		dermatology|infectious disease	acne vulgaris (AV)|skin infections	0	96.97	Selleck	S3105	Nadifloxacin	360.149	C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1,r|	JYJTVFIEFKZWCJ-JTQLQIEISA-N	9850038.0		JYJTVFIEFKZWCJ
BRD-A87606379-001-22-4	nadolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology	angina pectoris|hypertension	0	63.89	MicroSource	1503260	NADOLOL	309.194	CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|	VWPOSFSPZNDTMJ-YUELXQCFSA-N	7048578.0		VWPOSFSPZNDTMJ
BRD-A87606379-001-23-2	nadolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3	cardiology	angina pectoris|hypertension	0	0.0	Sigma	MFCD00079476	(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-naphthalenediol	309.194	CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16,18,&1:6|	VWPOSFSPZNDTMJ-YUELXQCFSA-N	7048578.0		VWPOSFSPZNDTMJ
BRD-M06409173-001-02-7	NADPH	Preclinical		DRD2|DRD3|DRD4|GHSR|HTR2A|HTR2C			0	70.0	MedChemEx	HY-F0003A	NADPH (tetracyclohexanamine)	1141.51	NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:37,39,51,53,54,60,72,74,&1:42,&2:46,c:34,t:31|	PTKRUDMLGIIORX-ITGWJZMWSA-N	71312102.0		PTKRUDMLGIIORX
BRD-M06409173-001-01-9	NADPH	Preclinical		DRD2|DRD3|DRD4|GHSR|HTR2A|HTR2C			0	0.0	MedChemEx	HY-F0003A	NADPH (tetracyclohexanamine)	1141.51	NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](OP(O)(O)=O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:37,39,51,53,54,60,72,74,&1:42,&2:46,c:34,t:31|	PTKRUDMLGIIORX-ITGWJZMWSA-N	71312102.0		PTKRUDMLGIIORX
BRD-A71262238-001-08-4	nafadotride	Preclinical	dopamine receptor antagonist	DRD2|DRD3|HTR1A			0	86.99	Tocris	1347	Nafadotride	365.21	CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8,r|	IDZASIQMRGPBCQ-QGZVFWFLSA-N	6604854.0		IDZASIQMRGPBCQ
BRD-K06674495-334-05-7	nafamostat	Launched	serine protease inhibitor	ASIC1|ASIC2|ASIC3|C1R|PRSS1|TPSAB1|TRPM7	cardiology	anticoagulent	0	80.03	Tocris	3081	Nafamostat mesylate	347.138	NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	MQQNFDZXWVTQEH-UHFFFAOYSA-N	4413.0		MQQNFDZXWVTQEH
BRD-K06674495-334-04-0	nafamostat	Launched	serine protease inhibitor	ASIC1|ASIC2|ASIC3|C1R|PRSS1|TPSAB1|TRPM7	cardiology	anticoagulent	0	85.96	Selleck	S1386	Nafamostat mesylate	347.138	NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	MQQNFDZXWVTQEH-UHFFFAOYSA-N	4413.0		MQQNFDZXWVTQEH
BRD-K06674495-334-03-2	nafamostat	Launched	serine protease inhibitor	ASIC1|ASIC2|ASIC3|C1R|PRSS1|TPSAB1|TRPM7	cardiology	anticoagulent	0	89.75	Selleck	S1386	Nafamostat Mesylate	347.138	NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	MQQNFDZXWVTQEH-UHFFFAOYSA-N	4413.0		MQQNFDZXWVTQEH
BRD-K18574842-323-18-9	nafcillin	Launched	bacterial cell wall synthesis inhibitor	CYP1A2|CYP3A4|SLC22A6	infectious disease	gram-positive bacterial infections	0	69.95	MedChemEx	HY-B0555A	Nafcillin (sodium monohydrate)	414.125	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	GPXLMGHLHQJAGZ-JTDSTZFVSA-N	8982.0		GPXLMGHLHQJAGZ
BRD-K18574842-236-17-7	nafcillin	Launched	bacterial cell wall synthesis inhibitor	CYP1A2|CYP3A4|SLC22A6	infectious disease	gram-positive bacterial infections	0	96.54	MicroSource	1500420	NAFCILLIN SODIUM	414.125	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	GPXLMGHLHQJAGZ-JTDSTZFVSA-N	8982.0		GPXLMGHLHQJAGZ
BRD-K18574842-323-11-6	nafcillin	Launched	bacterial cell wall synthesis inhibitor	CYP1A2|CYP3A4|SLC22A6	infectious disease	gram-positive bacterial infections	0	87.42	Selleck	S4042	Nafcillin Sodium	414.125	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	GPXLMGHLHQJAGZ-JTDSTZFVSA-N	8982.0	BRD-K96812051-323-01-2	GPXLMGHLHQJAGZ
BRD-K18574842-323-10-8	nafcillin	Launched	bacterial cell wall synthesis inhibitor	CYP1A2|CYP3A4|SLC22A6	infectious disease	gram-positive bacterial infections	0	95.52	Selleck	S4042	Nafcillin Sodium	414.125	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	GPXLMGHLHQJAGZ-JTDSTZFVSA-N	8982.0		GPXLMGHLHQJAGZ
BRD-A67862938-034-14-9	naftidrofuryl	Launched	adrenergic receptor antagonist		cardiology	claudication	0	92.27	MicroSource	1503419	NAFRONYL OXALATE	383.246	CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|	KBAFPSLPKGSANY-FGZHOGPDSA-N	12898282.0		KBAFPSLPKGSANY
BRD-A67862938-034-15-9	naftidrofuryl	Launched	adrenergic receptor antagonist		cardiology	claudication	0	94.28	MedChemEx	HY-B1107	Naftidrofuryl (oxalate)	383.246	CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10,&2:12|	KBAFPSLPKGSANY-FGZHOGPDSA-N	12898282.0		KBAFPSLPKGSANY
BRD-K74141488-003-11-2	naftifine	Launched	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	98.98	MicroSource	1505446	NAFTIFINE HYDROCHLORIDE	287.167	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	OZGNYLLQHRPOBR-DHZHZOJOSA-N	47641.0		OZGNYLLQHRPOBR
BRD-K74141488-003-12-9	naftifine	Launched	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	99.05	MedChemEx	HY-B0518A	Naftifine (hydrochloride)	287.167	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	OZGNYLLQHRPOBR-DHZHZOJOSA-N	47641.0		OZGNYLLQHRPOBR
BRD-K74141488-003-10-4	naftifine	Launched	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	98.23	Selleck	S3156	Naftifine HCl	287.167	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	OZGNYLLQHRPOBR-DHZHZOJOSA-N	47641.0		OZGNYLLQHRPOBR
BRD-K01826561-003-17-9	naftopidil	Launched	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	0	99.08	Tocris	597	Naftopidil hydrochloride	428.187	COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|	HRRBJVNMSRJFHQ-HXUWFJFHSA-N	6603939.0		HRRBJVNMSRJFHQ
BRD-K01826561-003-16-9	naftopidil	Launched	adrenergic receptor antagonist	ADRA1A	urology	benign prostatic hyperplasia (BPH)	0	91.05	Tocris	597	Naftopidil dihydrochloride	428.187	COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|	HRRBJVNMSRJFHQ-HXUWFJFHSA-N	6603939.0		HRRBJVNMSRJFHQ
BRD-K66404838-001-02-4	nalbuphine	Launched	opioid receptor agonist|opioid receptor antagonist	OPRD1|OPRK1|OPRM1	neurology/psychiatry	pain relief	0	84.9	MicroSource	1501115	NALBUPHINE HYDROCHLORIDE	357.194	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	NETZHAKZCGBWSS-CEDHKZHLSA-N	5311304.0	BRD-A92651262-003-04-7	NETZHAKZCGBWSS
BRD-K66404838-310-01-1	nalbuphine	Launched	opioid receptor agonist|opioid receptor antagonist	OPRD1|OPRK1|OPRM1	neurology/psychiatry	pain relief	0	91.8	Enzo	AC893	Nalbuphine HCl 2H2O	357.194	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	NETZHAKZCGBWSS-CEDHKZHLSA-N	5311304.0		NETZHAKZCGBWSS
BRD-K66404838-003-11-1	nalbuphine	Launched	opioid receptor agonist|opioid receptor antagonist	OPRD1|OPRK1|OPRM1	neurology/psychiatry	pain relief	0	98.22	Sigma	N4396-25MG	Nalbuphine hydrochloride	357.194	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	NETZHAKZCGBWSS-CEDHKZHLSA-N	5311304.0		NETZHAKZCGBWSS
BRD-K89272869-003-01-8	nalfurafine	Launched	opioid receptor agonist	OPRK1|OPRM1	nephrology	uremic pruritus	0	97.5	MedChemEx	HY-12745A	Nalfurafine (hydrochloride)	476.231	CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1	XGZZHZMWIXFATA-UEZBDDGYSA-N	6445230.0		XGZZHZMWIXFATA
BRD-K47886988-001-24-9	nalidixic-acid	Launched	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	0	97.59	MedChemEx	HY-B0398	Nalidixic acid	232.085	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	MHWLWQUZZRMNGJ-UHFFFAOYSA-N	4421.0		MHWLWQUZZRMNGJ
BRD-K47886988-001-22-2	nalidixic-acid	Launched	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	0	96.21	MicroSource	1500756	NALIDIXIC ACID	232.085	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	MHWLWQUZZRMNGJ-UHFFFAOYSA-N	4421.0		MHWLWQUZZRMNGJ
BRD-K47886988-001-21-4	nalidixic-acid	Launched	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	0	97.94	Selleck	S2328	Nalidixic acid	232.085	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	MHWLWQUZZRMNGJ-UHFFFAOYSA-N	4421.0		MHWLWQUZZRMNGJ
BRD-K68407436-003-02-7	nalmefene	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1	pulmonary	respiratory depression	0	82.76	Tocris	4085	Nalmefene hydrochloride	339.183	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O	WJBLNOPPDWQMCH-MBPVOVBZSA-N	5284594.0		WJBLNOPPDWQMCH
BRD-K68407436-003-10-9	nalmefene	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1	pulmonary	respiratory depression	0	81.99	Tocris	4085	Nalmefene hydrochloride	339.183	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O	WJBLNOPPDWQMCH-MBPVOVBZSA-N	5284594.0		WJBLNOPPDWQMCH
BRD-K68407436-003-03-5	nalmefene	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1	pulmonary	respiratory depression	0	97.66	Selleck	S4341	Nalmefene HCl	339.183	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O	WJBLNOPPDWQMCH-MBPVOVBZSA-N	5284594.0		WJBLNOPPDWQMCH
BRD-K41458421-034-01-6	naloxegol	Launched	opioid receptor antagonist	OPRM1	gastroenterology	constipation	0	88.98	MedChemEx	HY-A0118A	Naloxegol (oxalate)	651.362	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45	XNKCCCKFOQNXKV-ZRSCBOBOSA-N	56959087.0		XNKCCCKFOQNXKV
BRD-K67511046-003-16-9	naloxone	Launched	opioid receptor antagonist	CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4	pulmonary	respiratory depression	0	84.75	Selleck	S3066	Naloxone HCl	327.147	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	UZHSEJADLWPNLE-GRGSLBFTSA-N	5284596.0		UZHSEJADLWPNLE
BRD-K67511046-003-14-4	naloxone	Launched	opioid receptor antagonist	CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4	pulmonary	respiratory depression	0	84.79	Selleck	S3066	Naloxone HCl	327.147	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	UZHSEJADLWPNLE-GRGSLBFTSA-N	5284596.0		UZHSEJADLWPNLE
BRD-K67511046-003-15-1	naloxone	Launched	opioid receptor antagonist	CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4	pulmonary	respiratory depression	0	80.06	Tocris	599	Naloxone hydrochloride	327.147	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	UZHSEJADLWPNLE-GRGSLBFTSA-N	5284596.0		UZHSEJADLWPNLE
BRD-K67511046-001-02-3	naloxone	Launched	opioid receptor antagonist	CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4	pulmonary	respiratory depression	0	87.7	MicroSource	1500422	NALOXONE HYDROCHLORIDE	327.147	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	UZHSEJADLWPNLE-GRGSLBFTSA-N	5284596.0	BRD-A23195370-003-01-4	UZHSEJADLWPNLE
BRD-K70898774-001-05-0	naloxone-benzoylhydrazone	Preclinical	opioid receptor antagonist	OPRK1|OPRM1			0	57.66	Tocris	1419	N'-((4R,4aS,12bR)-3-allyl-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)benzohydrazide	445.2	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	AKXCFAYOTIEFOH-XTNAHFASSA-N	9601084.0	BRD-K58239851-001-01-8	AKXCFAYOTIEFOH
BRD-K70898774-001-04-3	naloxone-benzoylhydrazone	Preclinical	opioid receptor antagonist	OPRK1|OPRM1			0	25.45	Tocris	1419	Naloxone benzoylhydrazone	445.2	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	AKXCFAYOTIEFOH-XTNAHFASSA-N	9601084.0		AKXCFAYOTIEFOH
BRD-K70898774-001-03-5	naloxone-benzoylhydrazone	Preclinical	opioid receptor antagonist	OPRK1|OPRM1			0	80.29	Tocris	1419	Naloxone benzoylhydrazone	445.2	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	AKXCFAYOTIEFOH-XTNAHFASSA-N	9601084.0		AKXCFAYOTIEFOH
BRD-K88172511-003-21-1	naltrexone	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1|SIGMAR1	neurology/psychiatry	abstinence from alcohol	0	93.54	MicroSource	1503262	NALTREXONE HYDROCHLORIDE	341.163	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	DQCKKXVULJGBQN-XFWGSAIBSA-N	5360515.0	BRD-A66559694-003-01-8	DQCKKXVULJGBQN
BRD-K88172511-003-22-9	naltrexone	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1|SIGMAR1	neurology/psychiatry	abstinence from alcohol	0	81.68	Tocris	677	Naltrexone hydrochloride	341.163	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	DQCKKXVULJGBQN-XFWGSAIBSA-N	5360515.0		DQCKKXVULJGBQN
BRD-K88172511-003-19-5	naltrexone	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1|SIGMAR1	neurology/psychiatry	abstinence from alcohol	0	75.45	Selleck	S2103	Naltrexone HCl	341.163	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	DQCKKXVULJGBQN-XFWGSAIBSA-N	5360515.0		DQCKKXVULJGBQN
BRD-K88172511-003-20-3	naltrexone	Launched	opioid receptor antagonist	OPRD1|OPRK1|OPRM1|SIGMAR1	neurology/psychiatry	abstinence from alcohol	0	86.11	Selleck	S2103	Naltrexone HCl	341.163	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	DQCKKXVULJGBQN-XFWGSAIBSA-N	5360515.0		DQCKKXVULJGBQN
BRD-K81275354-066-07-9	naltriben	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0	94.03	Tocris	892	Naltriben mesylate	415.178	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O	ZHVWWEYETMPAMX-IFKAHUTRSA-N	5486827.0		ZHVWWEYETMPAMX
BRD-K34088084-003-06-9	naltrindole	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0	92.02	Tocris	740	Naltrindole hydrochloride	414.194	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O	WIYUZYBFCWCCQJ-IFKAHUTRSA-N	5497186.0		WIYUZYBFCWCCQJ
BRD-K18280217-001-01-0	Nampt-IN-1	Preclinical					0	97.45	MedChemEx	HY-12971	Nampt-IN-1	419.151	CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1	QHHSCLARESIWBH-UHFFFAOYSA-N	92044379.0		QHHSCLARESIWBH
BRD-K69195780-004-09-9	NAN-190	Preclinical	serotonin receptor agonist	ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1F			0	95.35	Tocris	553	NAN-190 hydrobromide	393.205	COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	SJDOMIRMMUGQQK-UHFFFAOYSA-N	4431.0		SJDOMIRMMUGQQK
BRD-K69195780-004-08-4	NAN-190	Preclinical	serotonin receptor agonist	ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1F			0	91.6	Tocris	553	NAN-190 hydrobromide	393.205	COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	SJDOMIRMMUGQQK-UHFFFAOYSA-N	4431.0		SJDOMIRMMUGQQK
BRD-A73871920-236-03-6	nanchangmycin	Preclinical	other antibiotic				0	98.79	Selleck	S1450	Nanchangmycin	866.539	CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2,7,11,13,15,19,23,26,28,30,34,36,38,40,42,49,52,59,&1:5,&2:9,&3:17|	FELYAZAWTURXNF-KWJIWYEDSA-N	86278938.0	BRD-A68478444-236-01-8	FELYAZAWTURXNF
BRD-K22064724-001-01-8	napabucasin	Phase 3	STAT inhibitor	STAT3			0	91.09	MedChemEx	HY-13919	Napabucasin	240.042	CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	DPHUWDIXHNQOSY-UHFFFAOYSA-N	10331844.0		DPHUWDIXHNQOSY
BRD-K22064724-001-02-6	napabucasin	Phase 3	STAT inhibitor	STAT3			0	82.25	Tocris	5522	Napabucasin	240.042	CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	DPHUWDIXHNQOSY-UHFFFAOYSA-N	10331844.0		DPHUWDIXHNQOSY
BRD-K00004563-001-01-9	napamezole	Preclinical	adrenergic receptor antagonist|monoamine reuptake inhibitor				0	74.76	Sigma	MFCD00865344	2-(3,4-dihydro-2-naphthalenylmethyl)-4,5-dihydro-1H-imidazole	212.131	C(C1=NCCN1)C1=Cc2ccccc2CC1 |t:1,7|	WETRBJOSGIDJHQ-UHFFFAOYSA-N	55718.0		WETRBJOSGIDJHQ
BRD-K77641333-003-30-9	naphazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA2A	ophthalmology	eye irritation	0	97.77	MedChemEx	HY-B0446	Naphazoline (hydrochloride)	210.116	C(C1=NCCN1)c1cccc2ccccc12 |t:1|	CNIIGCLFLJGOGP-UHFFFAOYSA-N	4436.0		CNIIGCLFLJGOGP
BRD-K77641333-003-26-3	naphazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA2A	ophthalmology	eye irritation	0	94.34	Selleck	S2519	Naphazoline HCl	210.116	C(C1=NCCN1)c1cccc2ccccc12 |t:1|	CNIIGCLFLJGOGP-UHFFFAOYSA-N	4436.0		CNIIGCLFLJGOGP
BRD-K77641333-003-27-1	naphazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA2A	ophthalmology	eye irritation	0	98.84	MicroSource	1500424	NAPHAZOLINE HYDROCHLORIDE	210.116	C(C1=NCCN1)c1cccc2ccccc12 |t:1|	CNIIGCLFLJGOGP-UHFFFAOYSA-N	4436.0		CNIIGCLFLJGOGP
BRD-K13664493-316-02-5	naphthoquine-phosphate	Launched	antimalarial agent		infectious disease	malaria	0	79.04	MedChemEx	HY-17036	Naphthoquine (phosphate)	409.192	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	VEVMYTDOWUQLGI-UHFFFAOYSA-N	9851775.0		VEVMYTDOWUQLGI
BRD-K13664493-316-03-3	naphthoquine-phosphate	Launched	antimalarial agent		infectious disease	malaria	0	71.31	MedChemEx	HY-17036	Naphthoquine (phosphate)	409.192	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	VEVMYTDOWUQLGI-UHFFFAOYSA-N	9851775.0		VEVMYTDOWUQLGI
BRD-K13664493-316-01-7	naphthoquine-phosphate	Launched	antimalarial agent		infectious disease	malaria	0	0.0	MedChemEx	HY-17036	Naphthoquine (phosphate)	409.192	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	VEVMYTDOWUQLGI-UHFFFAOYSA-N	9851775.0		VEVMYTDOWUQLGI
BRD-K91234829-001-01-7	napirimus	Phase 1	immunosuppressant				0	98.99	Enamine	Z2301235074	1-methyl-4-(1-naphthoyl)-1H-pyrrole-2-carboxylic acid	279.09	Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12	CNUPQURTHORUGH-UHFFFAOYSA-N	3047779.0		CNUPQURTHORUGH
BRD-K59197931-236-22-9	naproxen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology	pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever	0	98.9	Selleck	S1626	Naproxen Sodium	230.094	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	CMWTZPSULFXXJA-VIFPVBQESA-N	156391.0		CMWTZPSULFXXJA
BRD-K59197931-236-21-1	naproxen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology	pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever	0	92.07	Tocris	2655	Naproxen sodium	230.094	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	CMWTZPSULFXXJA-VIFPVBQESA-N	156391.0		CMWTZPSULFXXJA
BRD-K59197931-236-20-3	naproxen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology	pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever	0	88.95	Selleck	S1626	Naproxen	230.094	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	CMWTZPSULFXXJA-VIFPVBQESA-N	156391.0		CMWTZPSULFXXJA
BRD-K59197931-001-04-5	naproxen	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry|rheumatology|dental|otolaryngology|endocrinology	pain relief|rheumatoid arthritis|headache|toothache|backache|muscle pain|common cold|fever	0	99.66	MicroSource	1500425	NAPROXEN(+)	230.094	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	CMWTZPSULFXXJA-VIFPVBQESA-N	156391.0		CMWTZPSULFXXJA
BRD-K64114733-066-03-9	naquotinib	Phase 3	EGFR inhibitor				0	89.03	MedChemEx	HY-19803	Naquotinib (mesylate)	562.338	CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C	QKDCLUARMDUUKN-XMMPIXPASA-N	71667668.0		QKDCLUARMDUUKN
BRD-A25608658-001-01-1	narasin	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	100.0	MicroSource	1502035	NARASIN	764.507	CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2,3,5,6,8,10,14,17,19,21,24,30,34,37,41,44,46,49,&1:27,c:41|	VHKXXVVRRDYCIK-OQMITHEGSA-N			VHKXXVVRRDYCIK
BRD-K61337602-003-04-9	naratriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	98.58	MedChemEx	HY-B0197A	Naratriptan (hydrochloride)	335.167	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	AMKVXSZCKVJAGH-UHFFFAOYSA-N	4440.0		AMKVXSZCKVJAGH
BRD-K61337602-003-02-1	naratriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	87.58	Selleck	S1488	Naratriptan	335.167	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	AMKVXSZCKVJAGH-UHFFFAOYSA-N	4440.0		AMKVXSZCKVJAGH
BRD-K61337602-003-03-9	naratriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	88.86	Selleck	S1488	Naratriptan HCl	335.167	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	AMKVXSZCKVJAGH-UHFFFAOYSA-N	4440.0		AMKVXSZCKVJAGH
BRD-K08832567-001-12-9	naringenin	Phase 1	aromatase inhibitor|TRPV antagonist	CYP19A1|CYP1B1|ESR2|GLO1|HSD17B1			0	96.8	MedChemEx	HY-N0100	Naringenin	272.068	Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	FTVWIRXFELQLPI-ZDUSSCGKSA-N	439246.0		FTVWIRXFELQLPI
BRD-K08832567-001-11-5	naringenin	Phase 1	aromatase inhibitor|TRPV antagonist	CYP19A1|CYP1B1|ESR2|GLO1|HSD17B1			0	96.02	Selleck	S2394	Naringenin	272.068	Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	FTVWIRXFELQLPI-ZDUSSCGKSA-N	439246.0		FTVWIRXFELQLPI
BRD-K87122641-001-10-7	naringeninic-acid	Phase 1		HCAR2|PTGR1			0	97.59	Sigma	55823	(2E)-3-(4-hydroxyphenyl)-2-propenoic acid	164.047	OC(=O)\C=C\c1ccc(O)cc1	NGSWKAQJJWESNS-ZZXKWVIFSA-N	637542.0		NGSWKAQJJWESNS
BRD-K87122641-001-08-1	naringeninic-acid	Phase 1		HCAR2|PTGR1			0	69.59	Vitas-M	STL163567		164.047	OC(=O)\C=C\c1ccc(O)cc1	NGSWKAQJJWESNS-ZZXKWVIFSA-N	637542.0		NGSWKAQJJWESNS
BRD-K02953697-001-10-9	naringin	Preclinical	cytochrome P450 inhibitor	SLCO1A2			0	94.5	MedChemEx	HY-N0153	Naringin	580.179	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O	DFPMSGMNTNDNHN-ZPHOTFPESA-N	442428.0		DFPMSGMNTNDNHN
BRD-K02953697-001-09-2	naringin	Preclinical	cytochrome P450 inhibitor	SLCO1A2			0	92.64	Selleck	S2329	Naringin	580.179	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O	DFPMSGMNTNDNHN-ZPHOTFPESA-N	442428.0	BRD-K80718324-001-01-2	DFPMSGMNTNDNHN
BRD-K72522627-001-02-9	naringin-dihydrochalcone	Preclinical	cytochrome P450 inhibitor				0	96.69	MedChemEx	HY-N0119	Naringin Dihydrochalcone	582.195	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	CWBZAESOUBENAP-QVNVHUMTSA-N	9894584.0		CWBZAESOUBENAP
BRD-K38287497-001-02-9	narlaprevir	Phase 3	HCV inhibitor				0	82.93	MedChemEx	HY-10300	Narlaprevir	707.429	CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	RICZEKWVNZFTNZ-LFGITCQGSA-N	11857239.0		RICZEKWVNZFTNZ
BRD-K38287497-001-01-2	narlaprevir	Phase 3	HCV inhibitor				0	95.2	MedChemEx	HY-10300	Narlaprevir	707.429	CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	RICZEKWVNZFTNZ-LFGITCQGSA-N	11857239.0		RICZEKWVNZFTNZ
BRD-K00004235-334-01-9	NAS-181	Preclinical	serotonin receptor antagonist	HTR1B			0	87.91	Tocris	1413	NAS-181	346.189	C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|	RTKDBEOSPDFLGD-QGZVFWFLSA-N	9955015.0		RTKDBEOSPDFLGD
BRD-K17295893-001-02-9	nastorazepide	Phase 2	CCK receptor antagonist	CCKBR			0	98.62	MedChemEx	HY-17617	Nastorazepide	520.269	CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	VIJCCFFEBCOOIE-JOCHJYFZSA-N	9872609.0		VIJCCFFEBCOOIE
BRD-K17295893-238-03-9	nastorazepide	Phase 2	CCK receptor antagonist	CCKBR			0	96.82	Adooq	A13671	Z360, Z 360	520.269	CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	VIJCCFFEBCOOIE-JOCHJYFZSA-N	9872609.0		VIJCCFFEBCOOIE
BRD-K17295893-001-01-0	nastorazepide	Phase 2	CCK receptor antagonist	CCKBR			0	97.38	MedChemEx	HY-17617	Nastorazepide	520.269	CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	VIJCCFFEBCOOIE-JOCHJYFZSA-N	9872609.0		VIJCCFFEBCOOIE
BRD-K90563805-213-01-9	natamycin	Launched	fungal ergosterol inhibitor		ophthalmology|infectious disease	conjunctivitis|fungal keratosis|blepharitis	0	0.0	MicroSource	1505560	NATAMYCIN	665.305	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	NCXMLFZGDNKEPB-FFPOYIOWSA-N	5284447.0	BRD-A00398769-213-01-5	NCXMLFZGDNKEPB
BRD-K90563805-001-03-4	natamycin	Launched	fungal ergosterol inhibitor		ophthalmology|infectious disease	conjunctivitis|fungal keratosis|blepharitis	0	91.43	MedChemEx	HY-B0133	Natamycin	665.305	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	NCXMLFZGDNKEPB-FFPOYIOWSA-N	5284447.0		NCXMLFZGDNKEPB
BRD-K90563805-001-04-2	natamycin	Launched	fungal ergosterol inhibitor		ophthalmology|infectious disease	conjunctivitis|fungal keratosis|blepharitis	0	79.84	MedChemEx	HY-B0133	Natamycin	665.305	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	NCXMLFZGDNKEPB-FFPOYIOWSA-N	5284447.0	BRD-K40312300-001-01-1	NCXMLFZGDNKEPB
BRD-K90563805-001-02-6	natamycin	Launched	fungal ergosterol inhibitor		ophthalmology|infectious disease	conjunctivitis|fungal keratosis|blepharitis	0	87.26	Sigma	MFCD00135085	(1R,3S,5R,7R,12R,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxy;lic acid	665.305	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	NCXMLFZGDNKEPB-FFPOYIOWSA-N	5284447.0		NCXMLFZGDNKEPB
BRD-K90563805-001-05-9	natamycin	Launched	fungal ergosterol inhibitor		ophthalmology|infectious disease	conjunctivitis|fungal keratosis|blepharitis	0	33.15	Selleck	S1517	Natamycin	665.305	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	NCXMLFZGDNKEPB-FFPOYIOWSA-N	5284447.0	BRD-A55960065-001-01-6|BRD-A00773244-001-01-3	NCXMLFZGDNKEPB
BRD-K90563805-001-06-7	natamycin	Launched	fungal ergosterol inhibitor		ophthalmology|infectious disease	conjunctivitis|fungal keratosis|blepharitis	0	0.0	Selleck	S1517	Natamycin	665.305	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27,35,37,39,41|	NCXMLFZGDNKEPB-FFPOYIOWSA-N	5284447.0	BRD-A55960065-001-02-4|BRD-K63692151-001-01-8	NCXMLFZGDNKEPB
BRD-K44353683-001-10-9	nateglinide	Launched	insulin secretagogue	ABCC8|KCNJ10|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	93.05	Tocris	4231	Nateglinide	317.199	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	OELFLUMRDSZNSF-BRWVUGGUSA-N			OELFLUMRDSZNSF
BRD-K44353683-001-08-3	nateglinide	Launched	insulin secretagogue	ABCC8|KCNJ10|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	98.07	Tocris	4231	Nateglinide	317.199	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	OELFLUMRDSZNSF-BRWVUGGUSA-N			OELFLUMRDSZNSF
BRD-K44353683-001-13-9	nateglinide	Launched	insulin secretagogue	ABCC8|KCNJ10|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	93.06	Tocris	4231	Nateglinide	317.199	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	OELFLUMRDSZNSF-BRWVUGGUSA-N			OELFLUMRDSZNSF
BRD-K44353683-001-07-5	nateglinide	Launched	insulin secretagogue	ABCC8|KCNJ10|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	95.78	Selleck	S2489	Nateglinide	317.199	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	OELFLUMRDSZNSF-BRWVUGGUSA-N			OELFLUMRDSZNSF
BRD-K44353683-001-12-5	nateglinide	Launched	insulin secretagogue	ABCC8|KCNJ10|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	95.48	Selleck	S2489	NATEGLINIDE	317.199	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	OELFLUMRDSZNSF-BRWVUGGUSA-N			OELFLUMRDSZNSF
BRD-A84202322-001-02-9	NAV-26	Preclinical	voltage-gated sodium channel blocker	SCN9A			0	96.02	Tocris	4691	NAV 26	434.145	FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|	ICGMZCVSHDKQTE-IBGZPJMESA-N	60201418.0		ICGMZCVSHDKQTE
BRD-A84202322-001-01-7	NAV-26	Preclinical	voltage-gated sodium channel blocker	SCN9A			0	97.97	Tocris	4691	NAV 26	434.145	FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13,r|	ICGMZCVSHDKQTE-IBGZPJMESA-N	60201418.0		ICGMZCVSHDKQTE
BRD-K82850175-001-02-9	navarixin	Phase 2	CC chemokine receptor antagonist	CXCR1|CXCR2			0	91.52	MedChemEx	HY-10198	Navarixin	397.164	CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	RXIUEIPPLAFSDF-CYBMUJFWSA-N	9865554.0		RXIUEIPPLAFSDF
BRD-K82850175-001-01-1	navarixin	Phase 2	CC chemokine receptor antagonist	CXCR1|CXCR2			0	93.85	MedChemEx	HY-10198	SCH 527123	397.164	CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	RXIUEIPPLAFSDF-CYBMUJFWSA-N	9865554.0		RXIUEIPPLAFSDF
BRD-K82746043-001-21-9	navitoclax	Phase 2	BCL inhibitor	BCL2|BCL2L1|BCL2L2			0	96.6	MedChemEx	HY-10087	Navitoclax	973.296	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|	JLYAXFNOILIKPP-KXQOOQHDSA-N	24978538.0		JLYAXFNOILIKPP
BRD-K82746043-001-19-3	navitoclax	Phase 2	BCL inhibitor	BCL2|BCL2L1|BCL2L2			0	94.7	Selleck	S1001	ABT-263 (Navitoclax)	973.296	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|	JLYAXFNOILIKPP-KXQOOQHDSA-N	24978538.0		JLYAXFNOILIKPP
BRD-K82746043-001-15-1	navitoclax	Phase 2	BCL inhibitor	BCL2|BCL2L1|BCL2L2			0	86.22	Selleck	S1001	ABT-263 (Navitoclax)	973.296	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|	JLYAXFNOILIKPP-KXQOOQHDSA-N	24978538.0		JLYAXFNOILIKPP
BRD-K00004670-001-01-9	naxagolide	Phase 3	dopamine receptor agonist				0	92.36	Adooq	A13087	(4aR,10bR)-4-propyl-2,3,4a,5,6,10b-hexahydrobenzo[h][1,4]benzoxazin-9-ol	247.157	CCCN1CCO[C@H]2[C@H]1CCc1ccc(O)cc21	JCSREICEMHWFAY-HUUCEWRRSA-N	57533.0		JCSREICEMHWFAY
BRD-K00004647-001-01-9	NB-001	Preclinical	antiviral				0	93.1	Sigma	SML0060	5-{[2-(6-amino-9H-purin-9-yl)ethyl]amino}-1-pentanol	264.17	Nc1ncnc2n(CCNCCCCCO)cnc12	CVPTTZZCRDVGSU-UHFFFAOYSA-N	2815031.0		CVPTTZZCRDVGSU
BRD-K61177364-003-03-7	NBI-27914	Preclinical	corticotropin releasing factor receptor antagonist	CRHR1			0	94.63	Tocris	1591	NBI 27914 hydrochloride	432.044	CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	KNADXBVKFAUMCR-UHFFFAOYSA-N	176157.0		KNADXBVKFAUMCR
BRD-K61177364-003-09-9	NBI-27914	Preclinical	corticotropin releasing factor receptor antagonist	CRHR1			0	97.16	Tocris	1591	NBI 27914 hydrochloride	432.044	CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	KNADXBVKFAUMCR-UHFFFAOYSA-N	176157.0		KNADXBVKFAUMCR
BRD-K61177364-003-02-9	NBI-27914	Preclinical	corticotropin releasing factor receptor antagonist	CRHR1			0	97.59	Tocris	1591	NBI 27914 hydrochloride	432.044	CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	KNADXBVKFAUMCR-UHFFFAOYSA-N	176157.0		KNADXBVKFAUMCR
BRD-A86523169-001-02-9	NBI-74330-(+/-)	Preclinical	CC chemokine receptor antagonist	CXCR3			0	97.53	Tocris	4528	(+/-)-NBI 74330	605.205	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|	XMRGQUDUVGRCBS-HXUWFJFHSA-N	45784923.0		XMRGQUDUVGRCBS
BRD-A86523169-001-01-0	NBI-74330-(+/-)	Preclinical	CC chemokine receptor antagonist	CXCR3			0	98.26	Tocris	4528	(+/-)-NBI 74330	605.205	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20,r|	XMRGQUDUVGRCBS-HXUWFJFHSA-N	45784923.0		XMRGQUDUVGRCBS
BRD-K15241725-001-02-9	NBI-98782	Preclinical	vesicular monoamine transporter inhibitor				0	85.41	MedChemEx	HY-15793	NBI-98782	319.215	COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC	WEQLWGNDNRARGE-DJIMGWMZSA-N	14580381.0		WEQLWGNDNRARGE
BRD-K11796549-001-05-2	NBQX	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B			0	98.33	Tocris	373	NBQX	336.016	NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	UQNAFPHGVPVTAL-UHFFFAOYSA-N	3272524.0		UQNAFPHGVPVTAL
BRD-K11796549-304-01-9	NBQX	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B			0	92.25	Tocris	1044	NBQX disodium salt	336.016	NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	UQNAFPHGVPVTAL-UHFFFAOYSA-N	3272524.0		UQNAFPHGVPVTAL
BRD-K11796549-001-04-5	NBQX	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B			0	98.85	Tocris	373	NBQX	336.016	NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	UQNAFPHGVPVTAL-UHFFFAOYSA-N	3272524.0		UQNAFPHGVPVTAL
BRD-K11796549-001-06-9	NBQX	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B			0	97.78	Tocris	373	NBQX	336.016	NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	UQNAFPHGVPVTAL-UHFFFAOYSA-N	3272524.0		UQNAFPHGVPVTAL
BRD-K01826782-001-02-9	NCS-382	Preclinical	GABA receptor antagonist	GABBR1|GABBR2|SLC52A2			0	96.9	Tocris	780	NCS-382	218.094	O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|	UADPGHINQMWEAG-FROQITRMSA-N	6604757.0		UADPGHINQMWEAG
BRD-K00004749-001-01-9	NCX-1015	Preclinical	interleukin sythesis stimulator				0	16.19	MedChemEx	HY-101757	NCX-1015	539.216	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+]([O-])=O)cc1 |c:13,t:9|	MJHYBJOMJPGNMM-KGWLDMEJSA-N	9850209.0		MJHYBJOMJPGNMM
BRD-K00004664-001-01-9	NDD-094	Preclinical					0	91.14	Enamine	EN300-5041320	2-[(2-methyl-1H-imidazol-1-yl)methyl]pyridine	173.095	Cc1nccn1Cc1ccccn1	CTUICISGLKIJLG-UHFFFAOYSA-N	10313324.0		CTUICISGLKIJLG
BRD-K17539220-001-01-5	NDT-9513727	Preclinical	complement antagonist	C5AR1			0	91.92	Tocris	3333	NDT 9513727	573.263	CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1	ITACCRHKSPSKKL-UHFFFAOYSA-N	10210160.0		ITACCRHKSPSKKL
BRD-K17539220-001-02-9	NDT-9513727	Preclinical	complement antagonist	C5AR1			0	96.42	Tocris	3333	NDT 9513727	573.263	CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1	ITACCRHKSPSKKL-UHFFFAOYSA-N	10210160.0		ITACCRHKSPSKKL
BRD-K11443721-003-01-6	NE-100	Phase 2	sigma receptor antagonist	SIGMAR1			0	92.52	Tocris	3133	N-{2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethyl}-N-propyl-1-propanamine hydrochloride	355.251	CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	YBLIQJGXRLZBCZ-UHFFFAOYSA-N	9841596.0		YBLIQJGXRLZBCZ
BRD-K11443721-003-02-4	NE-100	Phase 2	sigma receptor antagonist	SIGMAR1			0	89.79	Tocris	3133	NE 100 hydrochloride	355.251	CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	YBLIQJGXRLZBCZ-UHFFFAOYSA-N	9841596.0		YBLIQJGXRLZBCZ
BRD-K00003617-003-01-9	nebivolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	0	96.86	MedChemEx	HY-B0203A	Nebivolol (hydrochloride)	405.175	O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1,5,7,18|	KOHIRBRYDXPAMZ-YHBROIRLSA-N	189562.0		KOHIRBRYDXPAMZ
BRD-A51355958-003-01-9	nebracetam	Phase 3	acetylcholine receptor agonist	CHRM1			0	98.57	Enamine	EN300-119912		204.126	NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|	LCAFGJGYCUMTGS-NSHDSACASA-N	25136943.0		LCAFGJGYCUMTGS
BRD-K14395568-001-17-1	NECA	Launched	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	98.06	Tocris	1691	NECA	308.123	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	JADDQZYHOWSFJD-FLNNQWSLSA-N	448222.0		JADDQZYHOWSFJD
BRD-K14395568-001-18-9	NECA	Launched	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	92.0	Tocris	1691	NECA	308.123	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	JADDQZYHOWSFJD-FLNNQWSLSA-N	448222.0		JADDQZYHOWSFJD
BRD-K14395568-001-16-3	NECA	Launched	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	98.69	Tocris	1691	NECA	308.123	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	JADDQZYHOWSFJD-FLNNQWSLSA-N	448222.0		JADDQZYHOWSFJD
BRD-K01825019-001-06-9	necrostatin-1	Preclinical	RIPK inhibitor	RIPK1			0	77.3	Tocris	2324	Necrostatin-1	259.078	CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|	TXUWMXQFNYDOEZ-NSHDSACASA-N	738301.0		TXUWMXQFNYDOEZ
BRD-K01825019-001-10-9	necrostatin-1	Preclinical	RIPK inhibitor	RIPK1			0	85.56	Selleck	S8037	Necrostatin-1	259.078	CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|	TXUWMXQFNYDOEZ-NSHDSACASA-N	738301.0		TXUWMXQFNYDOEZ
BRD-K01825019-001-08-9	necrostatin-1	Preclinical	RIPK inhibitor	RIPK1			0	94.54	Selleck	S8037	Necrostatin-1	259.078	CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|	TXUWMXQFNYDOEZ-NSHDSACASA-N	738301.0		TXUWMXQFNYDOEZ
BRD-K01825019-001-09-9	necrostatin-1	Preclinical	RIPK inhibitor	RIPK1			0	87.48	Tocris	2324	Necrostatin-1	259.078	CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|	TXUWMXQFNYDOEZ-NSHDSACASA-N	738301.0		TXUWMXQFNYDOEZ
BRD-K68851986-001-01-6	necrostatin-2	Preclinical	necroptosis inhibitor|RIPK inhibitor	RIPK2			0	98.11	MedChemEx	HY-14622	Necrostatin 2	277.062	CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O	WIKGAEMMNQTUGL-SNVBAGLBSA-N	11288934.0		WIKGAEMMNQTUGL
BRD-K73469236-001-01-8	nedaplatin	Launched	DNA inhibitor		oncology	non-small cell lung cancer (NSCLC)|small cell lung cancer|esophageal cancer	1	0.0	MedChemEx	HY-13700	Nedaplatin	301.003	N[Pt]1(N)OC=C(O)O1 |t:4|	AUZDMWWRYCUANI-UHFFFAOYSA-L		BRD-K34751753-318-01-8|BRD-U48121946-000-01-8	AUZDMWWRYCUANI
BRD-K73469236-001-02-9	nedaplatin	Launched	DNA inhibitor		oncology	non-small cell lung cancer (NSCLC)|small cell lung cancer|esophageal cancer	1	0.0	MedChemEx	HY-13700	Nedaplatin	301.003	N[Pt]1(N)OC=C(O)O1 |t:4|	AUZDMWWRYCUANI-UHFFFAOYSA-L			AUZDMWWRYCUANI
BRD-K64716392-001-02-1	nedocromil	Launched	histamine receptor antagonist	CYSLTR1|CYSLTR2|FPR1|HSP90AA1|PTGDR	neurology/psychiatry|ophthalmology	itching|conjunctivitis	0	79.3	MedChemEx	HY-13448	9-ethyl-4,6-dioxo-10-propyl-6,9-dihydro-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylic acid	371.101	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	RQTOOFIXOKYGAN-UHFFFAOYSA-N	50294.0		RQTOOFIXOKYGAN
BRD-K64716392-001-03-9	nedocromil	Launched	histamine receptor antagonist	CYSLTR1|CYSLTR2|FPR1|HSP90AA1|PTGDR	neurology/psychiatry|ophthalmology	itching|conjunctivitis	0	91.97	MedChemEx	HY-13448	Nedocromil	371.101	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	RQTOOFIXOKYGAN-UHFFFAOYSA-N	50294.0		RQTOOFIXOKYGAN
BRD-K64716392-001-01-3	nedocromil	Launched	histamine receptor antagonist	CYSLTR1|CYSLTR2|FPR1|HSP90AA1|PTGDR	neurology/psychiatry|ophthalmology	itching|conjunctivitis	0	76.02	MedChemEx	HY-13448	Nedocromil	371.101	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	RQTOOFIXOKYGAN-UHFFFAOYSA-N	50294.0		RQTOOFIXOKYGAN
BRD-K90789829-001-07-8	nefazodone	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4			0	97.66	MicroSource	1502314	NEFAZODONE HYDROCHLORIDE	469.224	CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	VRBKIVRKKCLPHA-UHFFFAOYSA-N	4449.0		VRBKIVRKKCLPHA
BRD-K90789829-003-12-4	nefazodone	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4			0	93.15	Tocris	2777	Nefazodone hydrochloride	469.224	CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	VRBKIVRKKCLPHA-UHFFFAOYSA-N	4449.0		VRBKIVRKKCLPHA
BRD-K90789829-003-13-9	nefazodone	Withdrawn	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor	ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4			0	96.84	Tocris	2777	Nefazodone hydrochloride	469.224	CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	VRBKIVRKKCLPHA-UHFFFAOYSA-N	4449.0		VRBKIVRKKCLPHA
BRD-K65678996-001-09-7	nefiracetam	Phase 3	acetylcholine receptor agonist|benzodiazepine receptor agonist	CHRM1			0	93.56	Tocris	2851	Nefiracetam	246.137	Cc1cccc(C)c1NC(=O)CN1CCCC1=O	NGHTXZCKLWZPGK-UHFFFAOYSA-N	71157.0		NGHTXZCKLWZPGK
BRD-K65678996-001-05-5	nefiracetam	Phase 3	acetylcholine receptor agonist|benzodiazepine receptor agonist	CHRM1			0	99.27	MicroSource	1502315	NEFIRACETAM	246.137	Cc1cccc(C)c1NC(=O)CN1CCCC1=O	NGHTXZCKLWZPGK-UHFFFAOYSA-N	71157.0		NGHTXZCKLWZPGK
BRD-K65678996-001-04-8	nefiracetam	Phase 3	acetylcholine receptor agonist|benzodiazepine receptor agonist	CHRM1			0	97.62	Selleck	S1969	Nefiracetam	246.137	Cc1cccc(C)c1NC(=O)CN1CCCC1=O	NGHTXZCKLWZPGK-UHFFFAOYSA-N	71157.0		NGHTXZCKLWZPGK
BRD-K01826512-003-11-9	nefopam	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	97.05	Selleck	S4180	Nefopam HCl	289.123	CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|	RGPDEAGGEXEMMM-KRWDZBQOSA-N	184147.0		RGPDEAGGEXEMMM
BRD-K01826512-003-12-9	nefopam	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	98.62	Selleck	S4180	NEFOPAM	289.123	CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|	RGPDEAGGEXEMMM-KRWDZBQOSA-N	184147.0		RGPDEAGGEXEMMM
BRD-K84466663-001-08-9	nelarabine	Launched	DNA synthesis inhibitor|T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	98.83	Tocris	6359	Nelarabine	297.107	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	IXOXBSCIXZEQEQ-UHTZMRCNSA-N	3011155.0		IXOXBSCIXZEQEQ
BRD-K84466663-001-05-4	nelarabine	Launched	DNA synthesis inhibitor|T cell inhibitor	POLA1	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	98.35	Selleck	S1213	Nelarabine	297.107	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	IXOXBSCIXZEQEQ-UHTZMRCNSA-N	3011155.0		IXOXBSCIXZEQEQ
BRD-K74117820-066-10-8	nelfinavir	Launched	HIV protease inhibitor	CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4|CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	0	98.14	Enzo	DL566	NELFINAVIR MESYLATE	567.313	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	QAGYKUNXZHXKMR-HKWSIXNMSA-N	64143.0		QAGYKUNXZHXKMR
BRD-K74117820-001-08-9	nelfinavir	Launched	HIV protease inhibitor	CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4|CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	0	96.21	MedChemEx	HY-15287	Nelfinavir	567.313	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1	64143.0		QAGYKUNXZHXKMR
BRD-K00003315-001-01-9	nelociguat	Preclinical	guanylate cyclase stimulant				0	95.75	MedChemEx	HY-78237	Nelociguat	408.146	COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	FTQHGWIXJSSWOY-UHFFFAOYSA-N	11690019.0		FTQHGWIXJSSWOY
BRD-K00003466-001-01-9	nelotanserin	Phase 2	serotonin receptor inverse agonist				0	96.92	MedChemEx	HY-10559	Nelotanserin	436.035	COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C	COSPVUFTLGQDQL-UHFFFAOYSA-N	11683556.0		COSPVUFTLGQDQL
BRD-K00004662-001-01-9	nemazoline	Phase 2	adrenergic receptor agonist|adrenergic receptor antagonist				0	72.14	Enamine	Z2327673241	2,6-dichloro-4-(4,5-dihydro-1H-imidazol-2-ylmethyl)phenylamine	243.033	Nc1c(Cl)cc(C=C2NCCN2)cc1Cl	OEOYJZUHFXEJEI-UHFFFAOYSA-N			OEOYJZUHFXEJEI
BRD-K00003285-001-01-9	nemiralisib	Phase 2					0	97.29	MedChemEx	HY-19535A	Nemiralisib	440.232	CC(C)N1CCN(Cc2cnc(o2)-c2cc(cc3[nH]ncc23)-c2cccc3[nH]ccc23)CC1	MCIDWGZGWVSZMK-UHFFFAOYSA-N	49784002.0		MCIDWGZGWVSZMK
BRD-K47289124-001-03-9	nemonapride	Launched	dopamine receptor antagonist	DRD2|DRD3|DRD4	neurology/psychiatry	schizophrenia	0	96.96	Tocris	1746	Nemonapride	387.171	CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14,25|	KRVOJOCLBAAKSJ-RDTXWAMCSA-N	156333.0		KRVOJOCLBAAKSJ
BRD-K00003505-001-01-9	nemorexant	Preclinical	orexin receptor antagonist				0	98.29	MedChemEx	HY-109095	Nemorexant	450.157	COc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2ccc(Cl)c(C)c2[nH]1)-n1nccn1	NBGABHGMJVIVBW-QHCPKHFHSA-N	91801202.0		NBGABHGMJVIVBW
BRD-K51911221-001-01-2	nemorubicin	Phase 2	topoisomerase inhibitor	TOP1|TOP2A			0	90.61	MedChemEx	HY-15794	Nemorubicin	643.226	CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	CTMCWCONSULRHO-UHQPFXKFSA-N	65907.0		CTMCWCONSULRHO
BRD-K51911221-001-02-9	nemorubicin	Phase 2	topoisomerase inhibitor	TOP1|TOP2A			0	90.28	MedChemEx	HY-15794	Nemorubicin	643.226	CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	CTMCWCONSULRHO-UHQPFXKFSA-N	65907.0		CTMCWCONSULRHO
BRD-A53539450-004-01-7	neo-gilurytmal	Launched			cardiology	cardiac arrythmia	0	83.33	InterBioScreen	STOCK1N-12913		369.254	CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4,6,10,13,22,25,&1:3,&2:7,&3:9,&4:12|	UAUHEPXILIZYCU-JSQPETPRSA-N			UAUHEPXILIZYCU
BRD-K00003712-001-01-9	neohesperidin	Preclinical					0	92.43	MedChemEx	HY-N0101	Neohesperidin	610.19	[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(OC)c(O)c2)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	ARGKVCXINMKCAZ-UZRWAPQLSA-N	442439.0		ARGKVCXINMKCAZ
BRD-K61032563-001-05-9	neohesperidin-dihydrochalcone	Preclinical					0	93.31	MedChemEx	HY-N0154	Neohesperidin dihydrochalcone	612.205	COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	ITVGXXMINPYUHD-CUVHLRMHSA-N	30231.0		ITVGXXMINPYUHD
BRD-K61032563-001-02-9	neohesperidin-dihydrochalcone	Preclinical					0	94.52	Selleck	S2331	Neohesperidin Dihydrochalcone (Nhdc)	612.205	COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	ITVGXXMINPYUHD-CUVHLRMHSA-N	30231.0	BRD-K33395461-001-01-0	ITVGXXMINPYUHD
BRD-K71013094-326-02-6	neomycin	Launched	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease|gastroenterology	first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections	0	0.0	MedChemEx	HY-B0470	Neomycin (sulfate)	614.312	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N	8378.0	BRD-M08953053-001-01-9	PGBHMTALBVVCIT
BRD-K71013094-001-02-5	neomycin	Launched	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease|gastroenterology	first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections	0	0.0	Sigma	MFCD00242602	(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside	614.312	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N	8378.0		PGBHMTALBVVCIT
BRD-K71013094-065-05-3	neomycin	Launched	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease|gastroenterology	first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections	0	0.0	Selleck	S2568	Neomycin sulfate	614.312	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N	8378.0	BRD-A93778806-065-02-3	PGBHMTALBVVCIT
BRD-K71013094-326-01-8	neomycin	Launched	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease|gastroenterology	first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections	0	0.0	MedChemEx	HY-B0470	Neomycin (sulfate)	614.312	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N	8378.0		PGBHMTALBVVCIT
BRD-K71013094-326-03-4	neomycin	Launched	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease|gastroenterology	first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections	0	0.0	MicroSource	1500427	NEOMYCIN TRISULFATE	614.312	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N	8378.0	BRD-A93490927-326-01-7	PGBHMTALBVVCIT
BRD-K71013094-065-04-6	neomycin	Launched	bacterial 30S ribosomal subunit inhibitor	CXCR4	infectious disease|gastroenterology	first-aid antibiotic|hepatic encephalopathy (HE)|intra-abdominal infections	0	0.0	Selleck	S2568	Neomycin sulfate	614.312	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	PGBHMTALBVVCIT-VCIWKGPPSA-N	8378.0	BRD-A35132579-065-01-1	PGBHMTALBVVCIT
BRD-K18922609-004-25-9	neostigmine	Launched	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	0	98.23	MedChemEx	HY-B0423	Neostigmine (Bromide)	223.145	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	ALWKGYPQUAPLQC-UHFFFAOYSA-N	4456.0		ALWKGYPQUAPLQC
BRD-K18922609-004-24-9	neostigmine	Launched	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	0	0.0	Selleck	S2490	Neostigmine bromide (Prostigmin)	223.145	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	ALWKGYPQUAPLQC-UHFFFAOYSA-N	4456.0		ALWKGYPQUAPLQC
BRD-K18922609-004-22-3	neostigmine	Launched	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	0	0.0	Selleck	S2490	Neostigmine bromide (Prostigmin)	223.145	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	ALWKGYPQUAPLQC-UHFFFAOYSA-N	4456.0		ALWKGYPQUAPLQC
BRD-K18922609-004-23-1	neostigmine	Launched	acetylcholinesterase inhibitor	ACHE	neurology/psychiatry	myasthenia gravis	0	95.35	MicroSource	1500428	NEOSTIGMINE BROMIDE	223.145	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	ALWKGYPQUAPLQC-UHFFFAOYSA-N	4456.0		ALWKGYPQUAPLQC
BRD-K04112579-001-07-0	nepafenac	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	ophthalmology	eye inflammation	0	97.8	Selleck	S1255	Nepafenac	254.106	NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N	QEFAQIPZVLVERP-UHFFFAOYSA-N	151075.0		QEFAQIPZVLVERP
BRD-K09126848-003-03-5	nepicastat	Phase 2	dopamine beta hydroxylase inhibitor	DBH			0	91.33	MedChemEx	HY-13289A	Nepicastat (hydrochloride)	295.095	NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	YZZVIKDAOTXDEB-JTQLQIEISA-N	9796181.0		YZZVIKDAOTXDEB
BRD-K09126848-003-01-9	nepicastat	Phase 2	dopamine beta hydroxylase inhibitor	DBH			0	79.81	MedChemEx	HY-13289A	Nepicastat (hydrochloride)	295.095	NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	YZZVIKDAOTXDEB-JTQLQIEISA-N	9796181.0		YZZVIKDAOTXDEB
BRD-K09126848-003-02-7	nepicastat	Phase 2	dopamine beta hydroxylase inhibitor	DBH			0	81.05	Sigma	SML0940	(S)-5-(aminomethyl)-1-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)-1H-imidazole-2-thiol hydrochloride	295.095	NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	YZZVIKDAOTXDEB-JTQLQIEISA-N	9796181.0		YZZVIKDAOTXDEB
BRD-K85606544-001-13-9	neratinib	Launched	EGFR inhibitor	EGFR|ERBB2|KDR	oncology	breast cancer	0	90.47	MedChemEx	HY-32721	Neratinib	556.199	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	JWNPDZNEKVCWMY-VQHVLOKHSA-N	9915743.0		JWNPDZNEKVCWMY
BRD-K85606544-001-09-1	neratinib	Launched	EGFR inhibitor	EGFR|ERBB2|KDR	oncology	breast cancer	0	90.19	Selleck	S2150	Neratinib (HKI-272)	556.199	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	JWNPDZNEKVCWMY-VQHVLOKHSA-N	9915743.0		JWNPDZNEKVCWMY
BRD-K43647122-001-01-3	nerbacadol	Phase 3	cyclooxygenase inhibitor				0	85.08	Enamine	Z228841354	1-[(5-methyl-4-isoxazolyl)carbonyl]piperidine	194.106	Cc1oncc1C(=O)N1CCCCC1	ZWNGSOLJLMBZFZ-UHFFFAOYSA-N	65865.0		ZWNGSOLJLMBZFZ
BRD-K60212747-001-02-9	neridronic-acid	Launched	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease|Paget's disease	1	0.0	Sigma	MFCD00866995	(6-amino-1-hydroxyhexane-1,1-diyl)bis(phosphonic acid)	277.048	NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O	PUUSSSIBPPTKTP-UHFFFAOYSA-N	71237.0		PUUSSSIBPPTKTP
BRD-K60212747-236-01-1	neridronic-acid	Launched	bone resorption inhibitor	FDPS	endocrinology	brittle bone disease|Paget's disease	1	0.0	Toronto	N390025	Neridronate Sodium Salt	277.048	NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O	PUUSSSIBPPTKTP-UHFFFAOYSA-N	71237.0		PUUSSSIBPPTKTP
BRD-K79989959-001-01-4	nesbuvir	Phase 2	RNA polymerase inhibitor				0	98.31	MedChemEx	HY-14775	Nesbuvir	446.131	CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1	WTDWVLJJJOTABN-UHFFFAOYSA-N	11561383.0		WTDWVLJJJOTABN
BRD-K79989959-001-02-9	nesbuvir	Phase 2	RNA polymerase inhibitor				0	97.17	MedChemEx	HY-14775	Nesbuvir	446.131	CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1	WTDWVLJJJOTABN-UHFFFAOYSA-N	11561383.0		WTDWVLJJJOTABN
BRD-K00003604-315-01-9	netilmicin	Launched	protein synthesis inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-A0086	Netilmicin (sulfate)	475.301	[H][C@]1(O[C@@H]2[C@@H](N)C[C@@H](NCC)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)OC(CN)=CC[C@H]1N |c:32|	CIDUJQMULVCIBT-MQDUPKMGSA-N	441306.0		CIDUJQMULVCIBT
BRD-K97428065-001-01-2	netupitant	Launched	tachykinin antagonist	TACR1	gastroenterology	nausea|vomiting	0	97.52	MedChemEx	HY-16346	Netupitant	578.248	CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1	WAXQNWCZJDTGBU-UHFFFAOYSA-N	6451149.0		WAXQNWCZJDTGBU
BRD-K97428065-001-02-9	netupitant	Launched	tachykinin antagonist	TACR1	gastroenterology	nausea|vomiting	0	94.28	MedChemEx	HY-16346	Netupitant	578.248	CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1	WAXQNWCZJDTGBU-UHFFFAOYSA-N	6451149.0		WAXQNWCZJDTGBU
BRD-K22631935-001-03-5	neurodazine	Preclinical	neurogenesis of non-pluripotent C2C12 myoblast inducer				0	85.65	Tocris	3656	Neurodazine	456.124	COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1	FEEOFPAEDSMOTO-UHFFFAOYSA-N	16112820.0		FEEOFPAEDSMOTO
BRD-K22631935-001-02-7	neurodazine	Preclinical	neurogenesis of non-pluripotent C2C12 myoblast inducer				0	72.73	Tocris	3656	Neurodazine	456.124	COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1	FEEOFPAEDSMOTO-UHFFFAOYSA-N	16112820.0		FEEOFPAEDSMOTO
BRD-K28567778-001-02-7	neuropathiazol	Preclinical	neural stem cell inducer	BMP2|LIF			0	83.16	Tocris	5186	Neuropathiazol	338.109	CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1	MGKYEWWFHSESJN-UHFFFAOYSA-N	11667240.0		MGKYEWWFHSESJN
BRD-K28567778-001-01-9	neuropathiazol	Preclinical	neural stem cell inducer	BMP2|LIF			0		Broad Institute		Neuropathiazol	338.109	CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1	InChI=1S/C19H18N2O2S/c1-3-23-19(22)15-9-11-16(12-10-15)21(2)17-13-24-18(20-17)14-7-5-4-6-8-14/h4-13H,3H2,1-2H3	11667240.0		MGKYEWWFHSESJN
BRD-K00003470-001-01-9	Neu2000	Phase 2	ionotropic glutamate receptor antagonist				0	96.58	MedChemEx	HY-106408	Neu2000	383.039	OC(=O)c1cc(NCc2c(F)c(F)c(c(F)c2F)C(F)(F)F)ccc1O	HABROHXUHNHQMY-UHFFFAOYSA-N	9951955.0		HABROHXUHNHQMY
BRD-K15502390-001-20-9	nevirapine	Launched	non-nucleoside reverse transcriptase inhibitor	CYP1A2|CYP2A6|CYP2B6|CYP2C9|CYP2D6|CYP3A4|CYP3A5	infectious disease	human immunodeficiency virus (HIV-1)	0	99.37	MicroSource	1503842	NEVIRAPINE	266.117	Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12	NQDJXKOVJZTUJA-UHFFFAOYSA-N	4463.0		NQDJXKOVJZTUJA
BRD-K15502390-001-19-1	nevirapine	Launched	non-nucleoside reverse transcriptase inhibitor	CYP1A2|CYP2A6|CYP2B6|CYP2C9|CYP2D6|CYP3A4|CYP3A5	infectious disease	human immunodeficiency virus (HIV-1)	0	98.32	Selleck	S1742	Nevirapine	266.117	Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12	NQDJXKOVJZTUJA-UHFFFAOYSA-N	4463.0		NQDJXKOVJZTUJA
BRD-K70402238-001-02-8	nexturastat-A	Preclinical	HDAC inhibitor	HDAC1|HDAC6			0	93.27	Selleck	S7473	Nexturastat A	341.174	CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	JZWXMCPARMXZQV-UHFFFAOYSA-N	71462653.0		JZWXMCPARMXZQV
BRD-K70402238-001-04-9	nexturastat-A	Preclinical	HDAC inhibitor	HDAC1|HDAC6			0	91.4	MedChemEx	HY-16699	Nexturastat A	341.174	CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	JZWXMCPARMXZQV-UHFFFAOYSA-N	71462653.0		JZWXMCPARMXZQV
BRD-K83354763-001-07-9	NFKB-activation-inhibitor-II	Preclinical	NFkB pathway inhibitor	RELA			0	87.14	MedChemEx	HY-13982	JSH-23	240.163	Cc1ccc(NCCCc2ccccc2)c(N)c1	YMFNPBSZFWXMAD-UHFFFAOYSA-N	16760588.0		YMFNPBSZFWXMAD
BRD-K83354763-001-03-7	NFKB-activation-inhibitor-II	Preclinical	NFkB pathway inhibitor	RELA			0	71.58	Selleck	S7351	JSH-23	240.163	Cc1ccc(NCCCc2ccccc2)c(N)c1	YMFNPBSZFWXMAD-UHFFFAOYSA-N	16760588.0		YMFNPBSZFWXMAD
BRD-K83354763-001-06-0	NFKB-activation-inhibitor-II	Preclinical	NFkB pathway inhibitor	RELA			0	76.84	Selleck	S7351	JSH-23	240.163	Cc1ccc(NCCCc2ccccc2)c(N)c1	YMFNPBSZFWXMAD-UHFFFAOYSA-N	16760588.0		YMFNPBSZFWXMAD
BRD-K89223384-001-05-2	NG-nitro-arginine	Phase 1	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	98.3	Sigma	72750	(2S)-2-amino-5-{[imino(2-oxido-2-oxohydrazino)methyl]amino}pentanoic acid	219.097	N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O	MRAUNPAHJZDYCK-BYPYZUCNSA-N	440005.0		MRAUNPAHJZDYCK
BRD-K89223384-001-04-5	NG-nitro-arginine	Phase 1	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	70.12	ChemDiv	Y041-4623		219.097	N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O	MRAUNPAHJZDYCK-BYPYZUCNSA-N	440005.0		MRAUNPAHJZDYCK
BRD-K05181084-003-04-5	NGB-2904	Preclinical	dopamine receptor antagonist	DRD3			0	96.62	Tocris	2635	NGB 2904	493.169	Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl	YJPWVCIGSHWNON-UHFFFAOYSA-N	9891901.0		YJPWVCIGSHWNON
BRD-K05181084-003-03-7	NGB-2904	Preclinical	dopamine receptor antagonist	DRD3			0	93.54	Tocris	2635	NGB 2904	493.169	Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl	YJPWVCIGSHWNON-UHFFFAOYSA-N	9891901.0		YJPWVCIGSHWNON
BRD-K28639661-001-01-6	NGD-94-1	Phase 1	dopamine receptor antagonist	DRD4			0	97.29	Tocris	3298	2-{4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl}pyrimidine	320.175	C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1	OTVQCHUIPJYASM-UHFFFAOYSA-N	188942.0		OTVQCHUIPJYASM
BRD-K28639661-001-02-9	NGD-94-1	Phase 1	dopamine receptor antagonist	DRD4			0		Tocris	3298	NGD 94-1	320.175	C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1	OTVQCHUIPJYASM-UHFFFAOYSA-N	188942.0		OTVQCHUIPJYASM
BRD-K81779590-003-01-6	NGD-98-2	Preclinical	corticotropin releasing factor receptor antagonist	CRHR1			0	69.89	Tocris	4315	NGD 98-2 hydrochloride	399.177	CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC	PSUFQBRCUSJTDO-UHFFFAOYSA-N	9822241.0		PSUFQBRCUSJTDO
BRD-K81779590-003-02-9	NGD-98-2	Preclinical	corticotropin releasing factor receptor antagonist	CRHR1			0	85.62	Tocris	4315	NGD 98-2 hydrochloride	399.177	CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC	PSUFQBRCUSJTDO-UHFFFAOYSA-N	9822241.0		PSUFQBRCUSJTDO
BRD-K00003490-001-01-9	NGP555	Phase 1	gamma secretase modulator				0	91.35	MedChemEx	HY-108714	NGP555	406.163	CCc1cc(Nc2nc(cs2)-c2ccc(c(F)c2)-n2cnc(C)c2)c(C)cc1C	WDEKUGNKKOGFOA-UHFFFAOYSA-N	46853593.0		WDEKUGNKKOGFOA
BRD-K05653025-001-01-5	NHI-2	Preclinical	lactate dehydrogenase inhibitor	LDHA			0	81.23	Tocris	5363	NHI 2	335.077	COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F	YPPFWRWCZNXINO-UHFFFAOYSA-N	51355147.0		YPPFWRWCZNXINO
BRD-K05653025-001-02-9	NHI-2	Preclinical	lactate dehydrogenase inhibitor	LDHA			0	84.97	Tocris	5363	NHI 2	335.077	COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F	YPPFWRWCZNXINO-UHFFFAOYSA-N	51355147.0		YPPFWRWCZNXINO
BRD-K31086665-005-04-6	NH125	Preclinical	eukaryotic translation elongation factor 2 inhibitor				0	97.8	Selleck	S7436	NH125	397.358	CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C	ZZXUNAFAKNKXFW-UHFFFAOYSA-N	10436840.0	BRD-K70344361-005-01-4	ZZXUNAFAKNKXFW
BRD-K31086665-005-01-2	NH125	Preclinical	eukaryotic translation elongation factor 2 inhibitor				0	0.0	Tocris	3439	NH 125	397.358	CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C	ZZXUNAFAKNKXFW-UHFFFAOYSA-N	10436840.0		ZZXUNAFAKNKXFW
BRD-K03042257-001-01-2	NI-57	Preclinical	bromodomain inhibitor	BRD1|BRPF1|BRPF3			0	97.87	Tocris	5546	NI 57	383.094	COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N	UEMQPCYDWCSVCU-UHFFFAOYSA-N	91827373.0		UEMQPCYDWCSVCU
BRD-K03042257-001-02-0	NI-57	Preclinical	bromodomain inhibitor	BRD1|BRPF1|BRPF3			0	98.42	Cayman	17662	NI-57	383.094	COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N	UEMQPCYDWCSVCU-UHFFFAOYSA-N	91827373.0		UEMQPCYDWCSVCU
BRD-K60237333-001-28-9	niacin	Launched	NAD precursor|vitamin B	DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT	endocrinology	hypertriglyceridemia	0	0.0	Selleck	S1744	Niacin (Nicotinic acid)	123.032	OC(=O)c1cccnc1	PVNIIMVLHYAWGP-UHFFFAOYSA-N	938.0		PVNIIMVLHYAWGP
BRD-K60237333-001-26-3	niacin	Launched	NAD precursor|vitamin B	DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT	endocrinology	hypertriglyceridemia	0	0.0	Selleck	S1744	Nicotinic Acid	123.032	OC(=O)c1cccnc1	PVNIIMVLHYAWGP-UHFFFAOYSA-N	938.0		PVNIIMVLHYAWGP
BRD-K60237333-001-27-1	niacin	Launched	NAD precursor|vitamin B	DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT	endocrinology	hypertriglyceridemia	0	91.85	MicroSource	1500430	NIACIN	123.032	OC(=O)c1cccnc1	PVNIIMVLHYAWGP-UHFFFAOYSA-N	938.0		PVNIIMVLHYAWGP
BRD-K12102668-001-28-9	nialamide	Withdrawn	monoamine oxidase inhibitor	COMT|MAOA|MAOB			0	80.92	MedChemEx	HY-B1199	Nialamide	298.143	O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	NOIIUHRQUVNIDD-UHFFFAOYSA-N	4472.0		NOIIUHRQUVNIDD
BRD-K12102668-001-25-5	nialamide	Withdrawn	monoamine oxidase inhibitor	COMT|MAOA|MAOB			0	95.02	MicroSource	1505986	NIALAMIDE	298.143	O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	NOIIUHRQUVNIDD-UHFFFAOYSA-N	4472.0		NOIIUHRQUVNIDD
BRD-K12102668-001-24-8	nialamide	Withdrawn	monoamine oxidase inhibitor	COMT|MAOA|MAOB			0	92.62	Selleck	S4342	Nialamide	298.143	O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	NOIIUHRQUVNIDD-UHFFFAOYSA-N	4472.0		NOIIUHRQUVNIDD
BRD-A85876464-003-02-9	nibentan	Phase 2	potassium channel blocker				0	93.92	Vitas-M	STL069536	N-[5-(diethylamino)-1-phenylpentyl]-4-nitrobenzamide	383.221	CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|	YRFYIORBFFGPPZ-OAQYLSRUSA-N	1552287.0		YRFYIORBFFGPPZ
BRD-A85876464-001-01-5	nibentan	Phase 2	potassium channel blocker				0	96.69	Vitas-M	STL069536		383.221	CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9,r|	YRFYIORBFFGPPZ-OAQYLSRUSA-N	1552287.0		YRFYIORBFFGPPZ
BRD-K00003382-001-01-9	nicainoprol	Preclinical	angiotensin converting enzyme inhibitor				0	91.7	MedChemEx	HY-100572	Nicainoprol	369.205	CC(C)NC[C@H](O)COc1cccc2CCCN(C(=O)c3cccnc3)c12 |&1:5,r|	AUIHHZBJBKRDIE-SFHVURJKSA-N	76956332.0		AUIHHZBJBKRDIE
BRD-A86871940-001-02-9	nicaraven	Phase 3	free radical scavenger				0	96.4	MedChemEx	HY-100592	Nicaraven	284.127	C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|	KTXBOOWDLPUROC-NSHDSACASA-N	1598447.0		KTXBOOWDLPUROC
BRD-A86871940-001-01-9	nicaraven	Phase 3	free radical scavenger				0	96.43	Selleck	S4265	Nicaraven	284.127	C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1,r|	KTXBOOWDLPUROC-NSHDSACASA-N	1598447.0		KTXBOOWDLPUROC
BRD-A26711594-003-10-6	nicardipine	Launched	calcium channel blocker	ADORA3	cardiology	chronic stable angina|hypertension	0	97.24	MicroSource	1501135	NICARDIPINE HYDROCHLORIDE	479.206	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|	ZBBHBTPTTSWHBA-XMMPIXPASA-N	6603948.0		ZBBHBTPTTSWHBA
BRD-A26711594-003-08-0	nicardipine	Launched	calcium channel blocker	ADORA3	cardiology	chronic stable angina|hypertension	0	92.02	Selleck	S4181	Nicardipine HCl	479.206	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r,c:4,9|	ZBBHBTPTTSWHBA-XMMPIXPASA-N	6603948.0		ZBBHBTPTTSWHBA
BRD-K76810206-001-07-3	nicergoline	Launched	adrenergic receptor antagonist	ADRA1A	rheumatology|neurology/psychiatry|cardiology|hematology	Raynaud's disease|migraine headache|atherosclerosis|thrombosis	0	96.16	MicroSource	1501133	NICERGOLINE	483.116	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	YSEXMKHXIOCEJA-FVFQAYNVSA-N	34040.0		YSEXMKHXIOCEJA
BRD-K76810206-001-10-9	nicergoline	Launched	adrenergic receptor antagonist	ADRA1A	rheumatology|neurology/psychiatry|cardiology|hematology	Raynaud's disease|migraine headache|atherosclerosis|thrombosis	0	95.41	Tocris	604	Nicergoline	483.116	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	YSEXMKHXIOCEJA-FVFQAYNVSA-N	34040.0		YSEXMKHXIOCEJA
BRD-K76810206-001-08-1	nicergoline	Launched	adrenergic receptor antagonist	ADRA1A	rheumatology|neurology/psychiatry|cardiology|hematology	Raynaud's disease|migraine headache|atherosclerosis|thrombosis	0	85.89	Tocris	604	Nicergoline	483.116	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	YSEXMKHXIOCEJA-FVFQAYNVSA-N	34040.0	BRD-A58096341-001-01-2	YSEXMKHXIOCEJA
BRD-K11256763-001-01-5	niceritrol	Launched	NAD precursor		endocrinology	hyperlipidemia	0	97.86	Kemprotec	5/3/68	3-[(3-pyridinylcarbonyl)oxy]-2,2-bis{[(3-pyridinylcarbonyl)oxy]methyl}propyl nicotinate	556.159	O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1	KUEUWHJGRZKESU-UHFFFAOYSA-N	4476.0		KUEUWHJGRZKESU
BRD-K35960502-001-20-0	niclosamide	Launched	DNA replication inhibitor|STAT inhibitor	STAT3	infectious disease	tapeworm	0	97.63	MicroSource	1503265	NICLOSAMIDE	325.986	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	RJMUSRYZPJIFPJ-UHFFFAOYSA-N	4477.0		RJMUSRYZPJIFPJ
BRD-K35960502-001-19-2	niclosamide	Launched	DNA replication inhibitor|STAT inhibitor	STAT3	infectious disease	tapeworm	0	96.43	Selleck	S3030	Niclosamide (Niclocide)	325.986	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	RJMUSRYZPJIFPJ-UHFFFAOYSA-N	4477.0		RJMUSRYZPJIFPJ
BRD-K00003262-001-01-9	nicodicosapent	Preclinical	sterol regulatory element binding protein (SREBP) inhibitor				0	90.76	MedChemEx	HY-17640	Nicodicosapent	449.304	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCNC(=O)c1cccnc1	YYQALOWPCKMFDQ-JLNKQSITSA-N	50991753.0		YYQALOWPCKMFDQ
BRD-K97752965-001-15-6	nicorandil	Launched	nitric oxide donor|potassium channel activator	KCNJ11	cardiology	angina pectoris	0	0.0	MicroSource	1506025	NICORANDIL	211.059	[O-][N+](=O)OCCNC(=O)c1cccnc1	LBHIOVVIQHSOQN-UHFFFAOYSA-N	47528.0		LBHIOVVIQHSOQN
BRD-K97752965-001-14-9	nicorandil	Launched	nitric oxide donor|potassium channel activator	KCNJ11	cardiology	angina pectoris	0	0.0	Tocris	2147	Nicorandil	211.059	[O-][N+](=O)OCCNC(=O)c1cccnc1	LBHIOVVIQHSOQN-UHFFFAOYSA-N	47528.0		LBHIOVVIQHSOQN
BRD-K97752965-001-18-9	nicorandil	Launched	nitric oxide donor|potassium channel activator	KCNJ11	cardiology	angina pectoris	0	85.4	Tocris	2147	Nicorandil	211.059	[O-][N+](=O)OCCNC(=O)c1cccnc1	LBHIOVVIQHSOQN-UHFFFAOYSA-N	47528.0		LBHIOVVIQHSOQN
BRD-K97752965-001-13-1	nicorandil	Launched	nitric oxide donor|potassium channel activator	KCNJ11	cardiology	angina pectoris	0	0.0	Selleck	S1971	Nicorandil	211.059	[O-][N+](=O)OCCNC(=O)c1cccnc1	LBHIOVVIQHSOQN-UHFFFAOYSA-N	47528.0		LBHIOVVIQHSOQN
BRD-K97752965-001-16-4	nicorandil	Launched	nitric oxide donor|potassium channel activator	KCNJ11	cardiology	angina pectoris	0	93.0	Selleck	S1971	Nicorandil (Ikorel)	211.059	[O-][N+](=O)OCCNC(=O)c1cccnc1	LBHIOVVIQHSOQN-UHFFFAOYSA-N	47528.0		LBHIOVVIQHSOQN
BRD-K28912512-001-24-0	nicotinamide	Launched	protein synthesis stimulant	BST1|LDHA|PARP1|SIRT5	dermatology	acne vulgaris (AV)	0	9.77	MicroSource	1505397	NIACINAMIDE	122.048	NC(=O)c1cccnc1	DFPAKSUCGFBDDF-UHFFFAOYSA-N	936.0		DFPAKSUCGFBDDF
BRD-K28912512-001-25-7	nicotinamide	Launched	protein synthesis stimulant	BST1|LDHA|PARP1|SIRT5	dermatology	acne vulgaris (AV)	0	96.39	Selleck	S1899	Nicotinamide (Niacinamide)	122.048	NC(=O)c1cccnc1	DFPAKSUCGFBDDF-UHFFFAOYSA-N	936.0		DFPAKSUCGFBDDF
BRD-K28912512-001-23-2	nicotinamide	Launched	protein synthesis stimulant	BST1|LDHA|PARP1|SIRT5	dermatology	acne vulgaris (AV)	0	86.58	Selleck	S1899	Nicotinamide (Vitamin B3)	122.048	NC(=O)c1cccnc1	DFPAKSUCGFBDDF-UHFFFAOYSA-N	936.0		DFPAKSUCGFBDDF
BRD-K05395900-322-05-4	nicotine	Launched	acetylcholine receptor agonist	CHAT|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB2|CHRNB3|CHRNB4|CYP19A1|TBXAS1|TRPA1	neurology/psychiatry	smoking cessation	0	87.94	MicroSource	2300259	NICOTINE BITARTRATE	162.116	CN1CCC[C@H]1c1cccnc1	SNICXCGAKADSCV-JTQLQIEISA-N	89594.0		SNICXCGAKADSCV
BRD-K76600340-045-04-9	nicotinyl-alcohol-tartrate	Launched			cardiology|neurology/psychiatry	vascular spasm|vertigo	0	88.02	MicroSource	1503038	NICOTINYL ALCOHOL TARTRATE	109.053	OCc1cccnc1	MVQVNTPHUGQQHK-UHFFFAOYSA-N	7510.0		MVQVNTPHUGQQHK
BRD-K76600340-001-06-9	nicotinyl-alcohol-tartrate	Launched			cardiology|neurology/psychiatry	vascular spasm|vertigo	0	92.65	MedChemEx	HY-B0893	3-Pyridinemethanol	109.053	OCc1cccnc1	MVQVNTPHUGQQHK-UHFFFAOYSA-N	7510.0		MVQVNTPHUGQQHK
BRD-K17617556-001-01-3	NIDA-41020	Preclinical	cannabinoid receptor antagonist	CNR1			0	97.58	Tocris	3921	NIDA 41020	458.128	COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	KWDBQJRWPWTGPF-UHFFFAOYSA-N	11037861.0		KWDBQJRWPWTGPF
BRD-K17617556-001-02-9	NIDA-41020	Preclinical	cannabinoid receptor antagonist	CNR1			0	97.2	Tocris	3921	NIDA 41020	458.128	COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	KWDBQJRWPWTGPF-UHFFFAOYSA-N	11037861.0		KWDBQJRWPWTGPF
BRD-K96354014-001-29-4	nifedipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3	cardiology	vasospastic angina|chronic stable angina	0	96.3	MedChemEx	HY-B0284	Nifedipine	346.116	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	HYIMSNHJOBLJNT-UHFFFAOYSA-N	4485.0		HYIMSNHJOBLJNT
BRD-K96354014-001-27-8	nifedipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3	cardiology	vasospastic angina|chronic stable angina	0	51.61	MedChemEx	HY-B0284	Nifedipine	346.116	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	HYIMSNHJOBLJNT-UHFFFAOYSA-N	4485.0		HYIMSNHJOBLJNT
BRD-K96354014-001-15-3	nifedipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3	cardiology	vasospastic angina|chronic stable angina	0	2.68	Tocris	1075	Nifedipine	346.116	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	HYIMSNHJOBLJNT-UHFFFAOYSA-N	4485.0		HYIMSNHJOBLJNT
BRD-K96354014-001-21-1	nifedipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3	cardiology	vasospastic angina|chronic stable angina	0	7.28	Selleck	S1808	Nifedipine (Adalat)	346.116	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	HYIMSNHJOBLJNT-UHFFFAOYSA-N	4485.0		HYIMSNHJOBLJNT
BRD-K96354014-001-17-9	nifedipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3	cardiology	vasospastic angina|chronic stable angina	0	40.86	MicroSource	1500431	NIFEDIPINE	346.116	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	HYIMSNHJOBLJNT-UHFFFAOYSA-N	4485.0		HYIMSNHJOBLJNT
BRD-K96354014-001-14-6	nifedipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3	cardiology	vasospastic angina|chronic stable angina	0	7.58	Selleck	S1808	Nifedipine	346.116	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4,9|	HYIMSNHJOBLJNT-UHFFFAOYSA-N	4485.0		HYIMSNHJOBLJNT
BRD-K32311154-001-01-0	nifekalant	Launched	potassium channel blocker		cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	0	94.25	Prestwick	Prestw-1774	Nifekalant	405.201	Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O	OEBPANQZQGQPHF-UHFFFAOYSA-N	4486.0		OEBPANQZQGQPHF
BRD-A21280314-001-06-8	nifenalol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2			0	87.38	Enamine	Z56755859	2-(isopropylamino)-1-(4-nitrophenyl)ethanol	224.116	CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5,r|	UAORFCGRZIGNCI-LLVKDONJSA-N	202035.0		UAORFCGRZIGNCI
BRD-K47407372-001-16-3	nifenazone	Launched	analgesic agent		neurology/psychiatry	pain relief	0	97.85	Selleck	S4401	Nifenazone	308.127	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	BRZANEXCSZCZCI-UHFFFAOYSA-N	4487.0		BRZANEXCSZCZCI
BRD-K47407372-001-17-1	nifenazone	Launched	analgesic agent		neurology/psychiatry	pain relief	0	99.25	MicroSource	1503230	NIFENAZONE	308.127	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	BRZANEXCSZCZCI-UHFFFAOYSA-N	4487.0		BRZANEXCSZCZCI
BRD-K47407372-001-19-9	nifenazone	Launched	analgesic agent		neurology/psychiatry	pain relief	0	94.09	MedChemEx	HY-17475	Nifenazone	308.127	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	BRZANEXCSZCZCI-UHFFFAOYSA-N	4487.0		BRZANEXCSZCZCI
BRD-K98763141-001-30-8	niflumic-acid	Launched	cyclooxygenase inhibitor	ANO1|CLCN1|CLCNKA|CLCNKB|KCNQ1|PLA2G1B|PLA2G4A|PTGS1|PTGS2|UGT1A9	rheumatology|neurology/psychiatry	joint pain|muscle pain	0	97.55	MicroSource	1502015	NIFLUMIC ACID	282.062	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	JZFPYUNJRRFVQU-UHFFFAOYSA-N	4488.0		JZFPYUNJRRFVQU
BRD-K98763141-001-29-0	niflumic-acid	Launched	cyclooxygenase inhibitor	ANO1|CLCN1|CLCNKA|CLCNKB|KCNQ1|PLA2G1B|PLA2G4A|PTGS1|PTGS2|UGT1A9	rheumatology|neurology/psychiatry	joint pain|muscle pain	0	97.25	Selleck	S3018	Niflumic acid	282.062	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	JZFPYUNJRRFVQU-UHFFFAOYSA-N	4488.0		JZFPYUNJRRFVQU
BRD-K98763141-001-32-9	niflumic-acid	Launched	cyclooxygenase inhibitor	ANO1|CLCN1|CLCNKA|CLCNKB|KCNQ1|PLA2G1B|PLA2G4A|PTGS1|PTGS2|UGT1A9	rheumatology|neurology/psychiatry	joint pain|muscle pain	0	83.83	Tocris	4112	Niflumic acid	282.062	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	JZFPYUNJRRFVQU-UHFFFAOYSA-N	4488.0		JZFPYUNJRRFVQU
BRD-K68188368-001-09-4	nifuroxazide	Launched	bacterial DNA inhibitor		gastroenterology	colitis|diarrhea	0	97.42	MicroSource	1505788	NIFUROXAZIDE	275.054	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	YCWSUKQGVSGXJO-NTUHNPAUSA-N	5337997.0		YCWSUKQGVSGXJO
BRD-K68188368-001-08-6	nifuroxazide	Launched	bacterial DNA inhibitor		gastroenterology	colitis|diarrhea	0	88.01	Selleck	S4182	Nifuroxazide	275.054	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	YCWSUKQGVSGXJO-NTUHNPAUSA-N	5337997.0		YCWSUKQGVSGXJO
BRD-K68188368-001-11-0	nifuroxazide	Launched	bacterial DNA inhibitor		gastroenterology	colitis|diarrhea	0	98.14	Selleck	S4182	Nifuroxazide	275.054	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	YCWSUKQGVSGXJO-NTUHNPAUSA-N	5337997.0		YCWSUKQGVSGXJO
BRD-K85757157-001-02-9	nifursol	Launched	bacterial DNA inhibitor				0	91.98	MedChemEx	HY-B1703	Nifursol	365.024	Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	XXUXXCZCUGIGPP-WLRTZDKTSA-N	9570327.0		XXUXXCZCUGIGPP
BRD-K85757157-001-01-7	nifursol	Launched	bacterial DNA inhibitor				0	96.23	MicroSource	1502316	NIFURSOL	365.024	Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	XXUXXCZCUGIGPP-WLRTZDKTSA-N	9570327.0		XXUXXCZCUGIGPP
BRD-A84020532-001-08-9	nifurtimox	Launched	DNA inhibitor		infectious disease	Chagas disease|African trypanosomiasis	0	88.24	Sigma	MFCD00869254	Nifurtimox	287.058	C[C@H]1CS(=O)(=O)CCN1\N=C\c1ccc(o1)[N+]([O-])=O |&1:1,r|	ARFHIAQFJWUCFH-KIFNTFBYSA-N	6604371.0		ARFHIAQFJWUCFH
BRD-K01825503-003-03-9	niguldipine-(R)-(-)	Preclinical					0	90.73	Tocris	1124	(R)-(-)-Niguldipine hydrochloride	609.284	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |r,c:4,9|	SVJMLYUFVDMUHP-MGBGTMOVSA-N	6918097.0		SVJMLYUFVDMUHP
BRD-K59333713-003-03-8	niguldipine-(S)-(+)	Preclinical	adrenergic receptor antagonist	ADRA1A			0	94.55	Tocris	1123	(S)-(+)-Niguldipine hydrochloride	609.284	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	SVJMLYUFVDMUHP-XIFFEERXSA-N	60602.0		SVJMLYUFVDMUHP
BRD-K59333713-003-04-9	niguldipine-(S)-(+)	Preclinical	adrenergic receptor antagonist	ADRA1A			0	91.51	Tocris	1123	(S)-(+)-Niguldipine hydrochloride	609.284	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	SVJMLYUFVDMUHP-XIFFEERXSA-N	60602.0		SVJMLYUFVDMUHP
BRD-K59333713-003-02-0	niguldipine-(S)-(+)	Preclinical	adrenergic receptor antagonist	ADRA1A			0	87.83	Tocris	1123	(S)-(+)-Niguldipine hydrochloride	609.284	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4,9|	SVJMLYUFVDMUHP-XIFFEERXSA-N	60602.0		SVJMLYUFVDMUHP
BRD-K91544578-001-04-9	nikethamide	Withdrawn	immunostimulant				0	89.13	MedChemEx	HY-B1280	Nikethamide	178.111	CCN(CC)C(=O)c1cccnc1	NCYVXEGFNDZQCU-UHFFFAOYSA-N	5497.0		NCYVXEGFNDZQCU
BRD-K91544578-001-03-8	nikethamide	Withdrawn	immunostimulant				0	96.18	MicroSource	1506157	NIKETHAMIDE	178.111	CCN(CC)C(=O)c1cccnc1	NCYVXEGFNDZQCU-UHFFFAOYSA-N	5497.0		NCYVXEGFNDZQCU
BRD-K81528515-001-15-9	nilotinib	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor	ABL1|KIT	hematologic malignancy	chronic myeloid leukemia (CML)	0	98.83	MedChemEx	HY-10159	Nilotinib	529.184	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	HHZIURLSWUIHRB-UHFFFAOYSA-N	644241.0		HHZIURLSWUIHRB
BRD-K81528515-001-13-8	nilotinib	Launched	Abl kinase inhibitor|Bcr-Abl kinase inhibitor	ABL1|KIT	hematologic malignancy	chronic myeloid leukemia (CML)	0	98.71	Selleck	S1033	Nilotinib (AMN-107)	529.184	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	HHZIURLSWUIHRB-UHFFFAOYSA-N	644241.0		HHZIURLSWUIHRB
BRD-K23566484-001-15-1	nilutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	99.22	MicroSource	1504152	NILUTAMIDE	317.062	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	XWXYUMMDTVBTOU-UHFFFAOYSA-N	4493.0		XWXYUMMDTVBTOU
BRD-K23566484-001-14-4	nilutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	98.06	Tocris	1759	Nilutamide	317.062	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	XWXYUMMDTVBTOU-UHFFFAOYSA-N	4493.0		XWXYUMMDTVBTOU
BRD-K23566484-001-16-9	nilutamide	Launched	androgen receptor antagonist	AR	oncology	prostate cancer	0	94.85	Tocris	1759	Nilutamide	317.062	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	XWXYUMMDTVBTOU-UHFFFAOYSA-N	4493.0		XWXYUMMDTVBTOU
BRD-A84687895-001-05-9	nilvadipine	Launched	calcium channel blocker	CACNA1C|CACNA1D	cardiology	hypertension|cerebral artery occlusion	0	91.35	MedChemEx	HY-14284	Nilvadipine	385.127	COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|	FAIIFDPAEUKBEP-INIZCTEOSA-N	10340038.0		FAIIFDPAEUKBEP
BRD-A84687895-001-03-2	nilvadipine	Launched	calcium channel blocker	CACNA1C|CACNA1D	cardiology	hypertension|cerebral artery occlusion	0	84.73	Selleck	S2721		385.127	COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|	FAIIFDPAEUKBEP-INIZCTEOSA-N	10340038.0		FAIIFDPAEUKBEP
BRD-A84687895-001-04-0	nilvadipine	Launched	calcium channel blocker	CACNA1C|CACNA1D	cardiology	hypertension|cerebral artery occlusion	0	90.2	Selleck	S2721		385.127	COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10,r,c:8,t:4|	FAIIFDPAEUKBEP-INIZCTEOSA-N	10340038.0		FAIIFDPAEUKBEP
BRD-K76775527-001-30-2	nimesulide	Launched	cyclooxygenase inhibitor	LTF|PLA2G2E|PTGS1|PTGS2	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain	0	99.29	MicroSource	1503231	NIMESULIDE	308.047	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	HYWYRSMBCFDLJT-UHFFFAOYSA-N	4495.0		HYWYRSMBCFDLJT
BRD-K76775527-001-29-4	nimesulide	Launched	cyclooxygenase inhibitor	LTF|PLA2G2E|PTGS1|PTGS2	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain	0	98.22	Tocris	2470	Nimesulide	308.047	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	HYWYRSMBCFDLJT-UHFFFAOYSA-N	4495.0		HYWYRSMBCFDLJT
BRD-K76775527-001-28-6	nimesulide	Launched	cyclooxygenase inhibitor	LTF|PLA2G2E|PTGS1|PTGS2	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain	0	97.28	Selleck	S2040	Nimesulide	308.047	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	HYWYRSMBCFDLJT-UHFFFAOYSA-N	4495.0		HYWYRSMBCFDLJT
BRD-K76775527-001-32-9	nimesulide	Launched	cyclooxygenase inhibitor	LTF|PLA2G2E|PTGS1|PTGS2	rheumatology|obstetrics/gynecology	osteoarthritis|menstrual pain	0	95.55	Tocris	2470	Nimesulide	308.047	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	HYWYRSMBCFDLJT-UHFFFAOYSA-N	4495.0		HYWYRSMBCFDLJT
BRD-A58048407-001-20-4	nimodipine	Launched	calcium channel blocker	CFTR|NR3C2	hematology	hemorrhage	0	91.74	MicroSource	1503600	NIMODIPINE	418.174	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|	UIAGMCDKSXEBJQ-LJQANCHMSA-N	157132.0		UIAGMCDKSXEBJQ
BRD-A58048407-001-17-0	nimodipine	Launched	calcium channel blocker	CFTR|NR3C2	hematology	hemorrhage	0	90.17	Selleck	S1747	Nimodipine	418.174	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|	UIAGMCDKSXEBJQ-LJQANCHMSA-N	157132.0		UIAGMCDKSXEBJQ
BRD-A58048407-001-18-8	nimodipine	Launched	calcium channel blocker	CFTR|NR3C2	hematology	hemorrhage	0	93.03	Tocris	600	Nimodipine	418.174	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r,c:7,12|	UIAGMCDKSXEBJQ-LJQANCHMSA-N	157132.0		UIAGMCDKSXEBJQ
BRD-K79145628-001-05-5	nimorazole	Launched	bacterial DNA inhibitor		oncology	head and neck squamous cell carcinoma (HNSCC)	0	96.86	MedChemEx	HY-16349	Nimorazole	226.107	[O-][N+](=O)c1cncn1CCN1CCOCC1	MDJFHRLTPRPZLY-UHFFFAOYSA-N	23009.0		MDJFHRLTPRPZLY
BRD-K79145628-001-07-9	nimorazole	Launched	bacterial DNA inhibitor		oncology	head and neck squamous cell carcinoma (HNSCC)	0	94.17	MedChemEx	HY-16349	Nimorazole	226.107	[O-][N+](=O)c1cncn1CCN1CCOCC1	MDJFHRLTPRPZLY-UHFFFAOYSA-N	23009.0		MDJFHRLTPRPZLY
BRD-K13240081-001-06-1	nimustine	Launched	DNA alkylating agent				0	37.86	MicroSource	1504151	NIMUSTINE	272.079	Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1	QMAZPCHGABINAB-UHFFFAOYSA-N	129009979.0		QMAZPCHGABINAB
BRD-K13240081-003-06-7	nimustine	Launched	DNA alkylating agent				0	0.0	Sigma	MFCD01676942	5-[({[1-(2-chloroethyl)-2-oxohydrazino]carbonyl}amino)methyl]-2-methyl-4-pyrimidinamine hydrochloride	272.079	Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1	QMAZPCHGABINAB-UHFFFAOYSA-N	129009979.0		QMAZPCHGABINAB
BRD-K00003331-001-01-9	NIM811	Phase 2	mitochondrial permeability transition inhibitor				0	87.81	MedChemEx	HY-P0025	NIM811	1201.841	[H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	RPJPZDVUUKWPGT-FOIHOXPVSA-N	6473876.0		RPJPZDVUUKWPGT
BRD-K00003476-075-01-9	ningetinib-tosylate	Preclinical	protein tyrosine kinase inhibitor				0	81.78	MedChemEx	HY-107145	Ningetinib Tosylate	556.212	Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C	VQYYQSZNRVQLIS-UHFFFAOYSA-N	60165029.0		VQYYQSZNRVQLIS
BRD-K49075727-001-09-3	nintedanib	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	0	90.8	Selleck	S1010	BIBF1120 (Vargatef)	539.253	COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1	XZXHXSATPCNXJR-ZIADKAODSA-N			XZXHXSATPCNXJR
BRD-K49075727-001-08-5	nintedanib	Launched	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB	pulmonary	idiopathic pulmonary fibrosis (IPF)	0	89.95	Selleck	S1010	Nintedanib (BIBF 1120)	539.253	COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1	XZXHXSATPCNXJR-ZIADKAODSA-N			XZXHXSATPCNXJR
BRD-K54955827-001-02-2	niraparib	Launched	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	0	95.87	MedChemEx	HY-10619	MK-4827	320.164	NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1	PCHKPVIQAHNQLW-CQSZACIVSA-N	24958200.0		PCHKPVIQAHNQLW
BRD-K54955827-001-01-4	niraparib	Launched	PARP inhibitor	PARP1	oncology	primary peritoneal cancer (PPC)	0	73.95	MedChemEx	HY-10619	MK-4827	320.164	NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1	PCHKPVIQAHNQLW-CQSZACIVSA-N	24958200.0		PCHKPVIQAHNQLW
BRD-K53123955-001-10-5	niridazole	Launched	phosphofructokinase inhibitor		infectious disease	schistosomiasis	0	94.95	Prestwick	Prestw-469	Niridazole	214.016	[O-][N+](=O)c1cnc(s1)N1CCNC1=O	RDXLYGJSWZYTFJ-UHFFFAOYSA-N	6093.0		RDXLYGJSWZYTFJ
BRD-A41063939-001-01-0	nisin	Phase 1	bacterial cell wall synthesis inhibitor				0		Cayman	16532		3351.545	CC[C@@H](C)[C@@H](N)C(=O)N\C(=C/C)C(=O)N[C@H]1CSC[C@@H](NC(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@H]1[C@@H](C)SC[C@@H](NC(=O)CNC(=O)[C@H]2CCCN2C1=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1[C@@H](C)SC[C@@H](NC(=O)CNC(=O)[C@@H](CCSC)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1[C@@H](C)SC[C@H]2NC(=O)[C@@H](NC(=O)[C@@H](C)NC1=O)[C@@H](C)SC[C@@H](NC(=O)[C@@H](Cc1cnc[nH]1)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](C(C)C)C(=O)NC(=C)C(=O)N[C@@H](CCCCN)C(O)=O |&1:2,&2:4,&3:15,&4:19,&5:23,&6:36,&7:40,&8:47,&9:48,&10:52,&12:70,&13:79,&14:80,&15:84,&16:92,&17:100,&18:108,&19:120,&20:128,&21:136,&22:145,&23:146,&24:150,&25:154,&26:158,&28:167,&29:171,&30:184,&31:190,&32:191,&33:198,&34:208,&35:220,r|	NVNLLIYOARQCIX-GSJOZIGCSA-N	16130280.0	BRD-U59029435-000-01-7	NVNLLIYOARQCIX
BRD-A84465106-001-05-3	nisoldipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S	cardiology	hypertension	0	0.12	MicroSource	1505390	NISOLDIPINE	388.163	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|	VKQFCGNPDRICFG-GOSISDBHSA-N	28248400.0		VKQFCGNPDRICFG
BRD-A84465106-001-09-5	nisoldipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S	cardiology	hypertension	0	86.15	MedChemEx	HY-17402	Nisoldipine	388.163	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|	VKQFCGNPDRICFG-GOSISDBHSA-N	28248400.0		VKQFCGNPDRICFG
BRD-A84465106-001-08-7	nisoldipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S	cardiology	hypertension	0	65.89	MedChemEx	HY-17402	Nisoldipine	388.163	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|	VKQFCGNPDRICFG-GOSISDBHSA-N	28248400.0		VKQFCGNPDRICFG
BRD-A84465106-001-03-8	nisoldipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S	cardiology	hypertension	0	0.13	Selleck	S1748	Nisoldipine	388.163	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|	VKQFCGNPDRICFG-GOSISDBHSA-N	28248400.0		VKQFCGNPDRICFG
BRD-A84465106-001-06-1	nisoldipine	Launched	calcium channel blocker	CACNA1C|CACNA1D|CACNA1F|CACNA1S	cardiology	hypertension	0	36.0	Selleck	S1748	Nisoldipine	388.163	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r,c:4,9|	VKQFCGNPDRICFG-GOSISDBHSA-N	28248400.0		VKQFCGNPDRICFG
BRD-K01825513-003-03-9	nisoxetine	Phase 1	norepinephrine reuptake inhibitor	SLC6A2|SLC6A3|SLC6A4			0	88.54	Tocris	1025	Nisoxetine hydrochloride	271.157	CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4,r|	ITJNARMNRKSWTA-OAHLLOKOSA-N	10107248.0		ITJNARMNRKSWTA
BRD-K56707426-001-02-0	nitarsone	Launched			dermatology	blackhead disease	0	89.7	MicroSource	1506182	NITARSONE	246.946	O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	FUUFQLXAIUOWML-UHFFFAOYSA-N	66826.0		FUUFQLXAIUOWML
BRD-K56707426-001-01-2	nitarsone	Launched			dermatology	blackhead disease	0	83.43	Selleck	S4413	Nitarsone	246.946	O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	FUUFQLXAIUOWML-UHFFFAOYSA-N	66826.0		FUUFQLXAIUOWML
BRD-K56707426-001-03-8	nitarsone	Launched			dermatology	blackhead disease	0	100.0	Selleck	S4413	Nitarsone	246.946	O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	FUUFQLXAIUOWML-UHFFFAOYSA-N	66826.0		FUUFQLXAIUOWML
BRD-K96471533-001-08-2	nitazoxanide	Launched	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	0	67.96	MicroSource	1503843	NITAZOXANIDE	307.026	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	YQNQNVDNTFHQSW-UHFFFAOYSA-N	41684.0		YQNQNVDNTFHQSW
BRD-K96471533-001-10-8	nitazoxanide	Launched	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	0	65.1	MedChemEx	HY-B0217	Nitazoxanide	307.026	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	YQNQNVDNTFHQSW-UHFFFAOYSA-N	41684.0		YQNQNVDNTFHQSW
BRD-K96471533-001-11-6	nitazoxanide	Launched	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	0	87.36	MedChemEx	HY-B0217	Nitazoxanide	307.026	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	YQNQNVDNTFHQSW-UHFFFAOYSA-N	41684.0		YQNQNVDNTFHQSW
BRD-K96471533-001-09-0	nitazoxanide	Launched	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	0	81.9	Selleck	S1627	Nitazoxanide (Alinia, Annita)	307.026	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	YQNQNVDNTFHQSW-UHFFFAOYSA-N	41684.0		YQNQNVDNTFHQSW
BRD-K96471533-001-07-4	nitazoxanide	Launched	pyruvate ferredoxin oxidoreductase inhibitor		gastroenterology	diarrhea	0	35.39	Selleck	S1627	Nitazoxanide	307.026	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	YQNQNVDNTFHQSW-UHFFFAOYSA-N	41684.0		YQNQNVDNTFHQSW
BRD-K75551531-001-01-3	nitecapone	Phase 2	catechol O methyltransferase inhibitor	COMT			0	31.32	Cayman	18656	3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione	265.059	CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O	UPMRZALMHVUCIN-UHFFFAOYSA-N	5464105.0		UPMRZALMHVUCIN
BRD-K47887731-001-01-4	nitenpyram	Launched			infectious disease	flea control	0	93.18	Selleck	S4422	Nitenpyram	270.088	CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O	CFRPSFYHXJZSBI-DHZHZOJOSA-N	3034287.0		CFRPSFYHXJZSBI
BRD-K39467894-001-05-9	nithiamide	Preclinical	bacterial DNA inhibitor				0	91.65	MicroSource	1505448	NITHIAMIDE	187.005	CC(=O)Nc1ncc(s1)[N+]([O-])=O	UJRRDDHEMZLWFI-UHFFFAOYSA-N	8798.0		UJRRDDHEMZLWFI
BRD-K39467894-001-04-2	nithiamide	Preclinical	bacterial DNA inhibitor				0	89.07	Selleck	S4232	Nithiamide	187.005	CC(=O)Nc1ncc(s1)[N+]([O-])=O	UJRRDDHEMZLWFI-UHFFFAOYSA-N	8798.0		UJRRDDHEMZLWFI
BRD-K39467894-001-06-7	nithiamide	Preclinical	bacterial DNA inhibitor				0	100.0	Selleck	S4232	Nithiamide	187.005	CC(=O)Nc1ncc(s1)[N+]([O-])=O	UJRRDDHEMZLWFI-UHFFFAOYSA-N	8798.0		UJRRDDHEMZLWFI
BRD-K01109406-001-03-7	nitisinone	Launched	hydroxyphenylpyruvate dioxygenase inhibitor		metabolism	tyrosinemia	0	77.59	Enzo	AC3204	NITISINONE	329.051	OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F	PMHVFNYNPNKNRO-UHFFFAOYSA-N	5289053.0		PMHVFNYNPNKNRO
BRD-K01109406-001-04-5	nitisinone	Launched	hydroxyphenylpyruvate dioxygenase inhibitor		metabolism	tyrosinemia	0	87.67	MedChemEx	HY-B0607	Nitisinone	329.051	OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F	PMHVFNYNPNKNRO-UHFFFAOYSA-N	5289053.0		PMHVFNYNPNKNRO
BRD-A02006392-001-19-8	nitrendipine	Launched	calcium channel blocker	CACNA1D|CACNA2D1|KCNN4	cardiology	hypertension	0	96.27	Tocris	601	Nitrendipine	360.132	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|	PVHUJELLJLJGLN-INIZCTEOSA-N	157702.0		PVHUJELLJLJGLN
BRD-A02006392-001-17-2	nitrendipine	Launched	calcium channel blocker	CACNA1D|CACNA2D1|KCNN4	cardiology	hypertension	0	96.57	MicroSource	1503609	NITRENDIPINE	360.132	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|	PVHUJELLJLJGLN-INIZCTEOSA-N	157702.0		PVHUJELLJLJGLN
BRD-A02006392-001-15-6	nitrendipine	Launched	calcium channel blocker	CACNA1D|CACNA2D1|KCNN4	cardiology	hypertension	0	95.62	Selleck	S2491	Nitrendipine	360.132	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|	PVHUJELLJLJGLN-INIZCTEOSA-N	157702.0		PVHUJELLJLJGLN
BRD-A02006392-001-16-4	nitrendipine	Launched	calcium channel blocker	CACNA1D|CACNA2D1|KCNN4	cardiology	hypertension	0	97.81	Tocris	601	Nitrendipine	360.132	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r,c:5,10|	PVHUJELLJLJGLN-INIZCTEOSA-N	157702.0		PVHUJELLJLJGLN
BRD-K28453807-003-12-9	nitrocaramiphen	Preclinical	cholinergic receptor antagonist	CHRM1			0	87.72	Tocris	469	Nitrocaramiphen hydrochloride	334.189	CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	NSHMVLOWOAQFTP-UHFFFAOYSA-N	3941250.0		NSHMVLOWOAQFTP
BRD-K28453807-003-11-2	nitrocaramiphen	Preclinical	cholinergic receptor antagonist	CHRM1			0	92.79	Tocris	469	Nitrocaramiphen hydrochloride	334.189	CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	NSHMVLOWOAQFTP-UHFFFAOYSA-N	3941250.0		NSHMVLOWOAQFTP
BRD-K00004737-001-01-9	nitroflurbiprofen	Preclinical	cyclooxygenase inhibitor				0	94.51	MedChemEx	HY-U00013	Nitroflurbiprofen	361.133	C[C@@H](C(=O)OCCCCO[N+]([O-])=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1,r|	DLWSRGHNJVLJAH-CQSZACIVSA-N	67513161.0		DLWSRGHNJVLJAH
BRD-K76927775-001-13-4	nitrofurantoin	Launched	DNA inhibitor		infectious disease	urinary tract infections|pyelonephritis	0	64.69	MedChemEx	HY-A0090	Nitrofurantoin	238.034	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	NXFQHRVNIOXGAQ-YCRREMRBSA-N	6604200.0		NXFQHRVNIOXGAQ
BRD-K76927775-001-11-8	nitrofurantoin	Launched	DNA inhibitor		infectious disease	urinary tract infections|pyelonephritis	0	83.96	MedChemEx	HY-A0090	Nitrofurantoin	238.034	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	NXFQHRVNIOXGAQ-YCRREMRBSA-N	6604200.0		NXFQHRVNIOXGAQ
BRD-K76927775-001-10-0	nitrofurantoin	Launched	DNA inhibitor		infectious disease	urinary tract infections|pyelonephritis	0	65.37	MicroSource	1500433	NITROFURANTOIN	238.034	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	NXFQHRVNIOXGAQ-YCRREMRBSA-N	6604200.0		NXFQHRVNIOXGAQ
BRD-K79092138-001-13-9	nitrofurazone	Launched	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	0	86.28	MedChemEx	HY-B0226	Nitrofurazone	198.039	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	IAIWVQXQOWNYOU-FPYGCLRLSA-N	5447130.0		IAIWVQXQOWNYOU
BRD-K79092138-001-10-2	nitrofurazone	Launched	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	0	93.04	Selleck	S1644	Nitrofural	198.039	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	IAIWVQXQOWNYOU-FPYGCLRLSA-N	5447130.0		IAIWVQXQOWNYOU
BRD-K79092138-001-11-0	nitrofurazone	Launched	bacterial DNA inhibitor		infectious disease	first-aid antibiotic	0	98.77	MicroSource	1500434	NITROFURAZONE	198.039	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	IAIWVQXQOWNYOU-FPYGCLRLSA-N	5447130.0		IAIWVQXQOWNYOU
BRD-K76381435-001-09-9	nitromide	Launched			infectious disease	coccidiosis	0	96.65	MedChemEx	HY-B0945	Nitromide	211.023	NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O	UUKWKUSGGZNXGA-UHFFFAOYSA-N	4511.0		UUKWKUSGGZNXGA
BRD-K76381435-001-08-6	nitromide	Launched			infectious disease	coccidiosis	0	99.72	MicroSource	1500435	NITROMIDE	211.023	NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O	UUKWKUSGGZNXGA-UHFFFAOYSA-N	4511.0		UUKWKUSGGZNXGA
BRD-K08927448-001-01-9	nitrosodimethylurea	Preclinical	DNA synthesis inhibitor				0	0.0	Enamine	Z2306534399	1-methyl-1-[(methylamino)carbonyl]-2-oxohydrazine	117.054	CNC(=O)N(C)[NH2+][O-]	RCUSTCPNMVCLLN-UHFFFAOYSA-N	129010104.0		RCUSTCPNMVCLLN
BRD-K97534525-001-24-3	nitroxoline	Launched	cathepsin inhibitor	METAP2	infectious disease	urinary tract infections	0	49.3	MedChemEx	HY-B1159	Nitroxoline	190.038	Oc1ccc([N+]([O-])=O)c2cccnc12	RJIWZDNTCBHXAL-UHFFFAOYSA-N	19910.0		RJIWZDNTCBHXAL
BRD-K97534525-001-23-5	nitroxoline	Launched	cathepsin inhibitor	METAP2	infectious disease	urinary tract infections	0	62.54	MicroSource	1506173	NITROXOLINE	190.038	Oc1ccc([N+]([O-])=O)c2cccnc12	RJIWZDNTCBHXAL-UHFFFAOYSA-N	19910.0		RJIWZDNTCBHXAL
BRD-K73589491-001-13-9	nizatidine	Launched	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD)	0	93.79	MedChemEx	HY-B0310	Nizatidine	331.114	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	SGXXNSQHWDMGGP-IZZDOVSWSA-N	3033637.0		SGXXNSQHWDMGGP
BRD-K73589491-001-11-2	nizatidine	Launched	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD)	0	93.08	MicroSource	1505985	NIZATIDINE	331.114	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	SGXXNSQHWDMGGP-IZZDOVSWSA-N	3033637.0		SGXXNSQHWDMGGP
BRD-K73589491-001-12-0	nizatidine	Launched	histamine receptor antagonist	HRH2	gastroenterology	duodenal ulcer disease|erosive esophagitis (EE)|ulcerative esophagitis (UE)|gastroesophageal reflux disease (GERD)	0	90.94	Selleck	S1890	Nizatidine	331.114	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	SGXXNSQHWDMGGP-IZZDOVSWSA-N	3033637.0	BRD-K46652470-001-09-1	SGXXNSQHWDMGGP
BRD-K84011460-051-01-7	nizofenone	Launched	ion channel antagonist		neurology/psychiatry	stroke	0	99.4	AKSci	67653		412.13	CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O	WZGBZLHGOVJDET-UHFFFAOYSA-N	4514.0		WZGBZLHGOVJDET
BRD-K47441935-001-01-4	NK-252	Preclinical	nuclear factor erythroid derived|like (NRF2) activator	NFE2L2			0	71.07	Tocris	5293	NK 252	285.086	O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1	FNSCFQXZZNCDAI-UHFFFAOYSA-N	71618700.0		FNSCFQXZZNCDAI
BRD-K47441935-001-02-9	NK-252	Preclinical	nuclear factor erythroid derived|like (NRF2) activator	NFE2L2			0	93.73	Tocris	5293	NK 252	285.086	O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1	FNSCFQXZZNCDAI-UHFFFAOYSA-N	71618700.0		FNSCFQXZZNCDAI
BRD-K74796838-236-01-7	NKP-1339	Phase 1	HSP inhibitor				0	0.0	MedChemEx	HY-16350	NKP-1339	477.886	Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1	KNLORLKZMHLRBH-UHFFFAOYSA-J		BRD-U77299140-000-01-0	KNLORLKZMHLRBH
BRD-K74796838-236-02-9	NKP-1339	Phase 1	HSP inhibitor				0	83.77	MedChemEx	HY-16350	NKP-1339	477.886	Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1	KNLORLKZMHLRBH-UHFFFAOYSA-J			KNLORLKZMHLRBH
BRD-A75015151-001-08-9	NKY-80	Preclinical	adenylyl cyclase inhibitor	ADCY5			0	93.25	Tocris	5071	NKY 80	229.085	Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|	SOJUSNIBPPMLCC-SSDOTTSWSA-N	777417.0		SOJUSNIBPPMLCC
BRD-A75015151-001-07-7	NKY-80	Preclinical	adenylyl cyclase inhibitor	ADCY5			0	92.62	Tocris	5071	NKY 80	229.085	Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8,r|	SOJUSNIBPPMLCC-SSDOTTSWSA-N	777417.0		SOJUSNIBPPMLCC
BRD-A62133859-001-03-7	NLG919	Phase 1	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	79.93	MedChemEx	HY-13983	NLG919	282.173	O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|	YTRRAUACYORZLX-WMZOPIPTSA-N	70874604.0		YTRRAUACYORZLX
BRD-A62133859-001-04-5	NLG919	Phase 1	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	75.03	MedChemEx	HY-13983	IDO-IN-7	282.173	O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|	YTRRAUACYORZLX-WMZOPIPTSA-N	70874604.0		YTRRAUACYORZLX
BRD-A62133859-001-01-1	NLG919	Phase 1	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	72.87	Selleck	S7111	NLG919	282.173	O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|	YTRRAUACYORZLX-WMZOPIPTSA-N	70874604.0		YTRRAUACYORZLX
BRD-A62133859-001-02-9	NLG919	Phase 1	indoleamine 2,3-dioxygenase inhibitor	IDO1			0	74.25	Selleck	S7111	NLG919	282.173	O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1,&2:3,r|	YTRRAUACYORZLX-WMZOPIPTSA-N	70874604.0		YTRRAUACYORZLX
BRD-K62414032-001-13-8	NMDA	Preclinical	glutamate receptor agonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	100.0	Tocris	114	NMDA	147.053	CN[C@H](CC(O)=O)C(O)=O	HOKKHZGPKSLGJE-GSVOUGTGSA-N	22880.0	BRD-A02508087-001-02-9	HOKKHZGPKSLGJE
BRD-K62414032-001-12-0	NMDA	Preclinical	glutamate receptor agonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	100.0	Selleck	S7072	NMDA (N-Methyl-D-aspartic acid)	147.053	CN[C@H](CC(O)=O)C(O)=O	HOKKHZGPKSLGJE-GSVOUGTGSA-N	22880.0		HOKKHZGPKSLGJE
BRD-K62414032-001-15-9	NMDA	Preclinical	glutamate receptor agonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	100.0	Tocris	114	NMDA	147.053	CN[C@H](CC(O)=O)C(O)=O	HOKKHZGPKSLGJE-GSVOUGTGSA-N	22880.0		HOKKHZGPKSLGJE
BRD-K58770988-001-01-8	NMS-E973	Preclinical	HSP inhibitor				0	96.76	Selleck	S7282	NMS-E973	454.149	CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	YLQODGGPIHWTHR-UHFFFAOYSA-N	135566652.0	BRD-K29587137-001-01-2	YLQODGGPIHWTHR
BRD-K58770988-001-02-6	NMS-E973	Preclinical	HSP inhibitor				0	97.24	Selleck	S7282	NMS-E973	454.149	CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	YLQODGGPIHWTHR-UHFFFAOYSA-N	135566652.0		YLQODGGPIHWTHR
BRD-K54170555-001-01-8	NMS-P715	Preclinical	protein kinase inhibitor				0	96.6	MedChemEx	HY-12382	NMS-P715	676.31	CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21	JFOAJUGFHDCBJJ-UHFFFAOYSA-N	44556162.0		JFOAJUGFHDCBJJ
BRD-K83699324-001-01-1	NMS-1286937	Phase 2	PLK inhibitor	FLT3|PLK1|PLK2|PLK3			0	96.61	MedChemEx	HY-15828	NMS-1286937	532.216	CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	QHLVBNKYJGBCQJ-UHFFFAOYSA-N	49792852.0		QHLVBNKYJGBCQJ
BRD-K83699324-001-02-9	NMS-1286937	Phase 2	PLK inhibitor	FLT3|PLK1|PLK2|PLK3			0	92.89	MedChemEx	HY-15828	NMS-1286937	532.216	CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	QHLVBNKYJGBCQJ-UHFFFAOYSA-N	49792852.0		QHLVBNKYJGBCQJ
BRD-K26253904-001-03-1	NMS-873	Preclinical	ATPase inhibitor	VCP			0	98.64	MedChemEx	HY-15713	NMS-873	520.16	Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O	UJGTUKMAJVCBIS-UHFFFAOYSA-N	71521142.0		UJGTUKMAJVCBIS
BRD-K26253904-001-01-5	NMS-873	Preclinical	ATPase inhibitor	VCP			0	98.55	Selleck	S7285	NMS-873	520.16	Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O	UJGTUKMAJVCBIS-UHFFFAOYSA-N	71521142.0		UJGTUKMAJVCBIS
BRD-K79424231-001-02-9	NM107	Phase 2	RNA polymerase inhibitor				0	92.3	LifeChem	F9995-0334	NM 107	257.101	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	PPUDLEUZKVJXSZ-VPCXQMTMSA-N	500902.0		PPUDLEUZKVJXSZ
BRD-K00004640-001-01-9	NN-DNJ	Preclinical	glucosidase inhibitor	GBA			0	100.0	Sigma	N6414	(2R,3R,4R,5S)-2-(hydroxymethyl)-1-nonyl-3,4,5-piperidinetriol	289.225	CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	FTSCEGKYKXESFF-LXTVHRRPSA-N	501640.0		FTSCEGKYKXESFF
BRD-K85015012-003-03-7	NNC-05-2090	Preclinical	GABA uptake inhibitor|GAT inhibitor	SLC6A12			0	93.44	Tocris	2747	NNC 05-2090 hydrochloride	414.231	COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	XZZYCJOGZYEPPW-UHFFFAOYSA-N	9888030.0		XZZYCJOGZYEPPW
BRD-K85015012-003-02-9	NNC-05-2090	Preclinical	GABA uptake inhibitor|GAT inhibitor	SLC6A12			0	98.12	Tocris	2747	NNC 05-2090 hydrochloride	414.231	COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	XZZYCJOGZYEPPW-UHFFFAOYSA-N	9888030.0		XZZYCJOGZYEPPW
BRD-K85015012-003-05-9	NNC-05-2090	Preclinical	GABA uptake inhibitor|GAT inhibitor	SLC6A12			0	96.69	Tocris	2747	NNC 05-2090 hydrochloride	414.231	COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	XZZYCJOGZYEPPW-UHFFFAOYSA-N	9888030.0		XZZYCJOGZYEPPW
BRD-K78122587-300-04-3	NNC-55-0396	Preclinical	T-type calcium channel blocker	CATSPER1|CATSPER2|CATSPER3|CATSPER4			0	97.64	Tocris	2268	(1S,2S)-2-{2-[[3-(1H-benzimidazol-2-yl)propyl](methyl)amino]ethyl}-6-fluoro-1-isopropyl-1,2,3,4-tetrahydro-2-naphthalenyl cyclo	491.295	CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1	VHHVPDKNKPNKHY-JDXGNMNLSA-N	9957280.0		VHHVPDKNKPNKHY
BRD-K78122587-300-02-7	NNC-55-0396	Preclinical	T-type calcium channel blocker	CATSPER1|CATSPER2|CATSPER3|CATSPER4			0	97.01	Tocris	2268	NNC 55-0396 dihydrochloride	491.295	CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1	VHHVPDKNKPNKHY-JDXGNMNLSA-N	9957280.0		VHHVPDKNKPNKHY
BRD-K72904818-001-02-9	NNC-63-0532	Preclinical	opioid receptor agonist	OPRL1			0	97.28	Tocris	1780	NNC 63-0532	443.221	COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	AQMPIDSGLFVVPL-UHFFFAOYSA-N	9803475.0	BRD-K36009368-001-03-4	AQMPIDSGLFVVPL
BRD-K72904818-001-03-9	NNC-63-0532	Preclinical	opioid receptor agonist	OPRL1			0	94.99	Tocris	1780	NNC 63-0532	443.221	COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	AQMPIDSGLFVVPL-UHFFFAOYSA-N	9803475.0		AQMPIDSGLFVVPL
BRD-K72904818-001-01-1	NNC-63-0532	Preclinical	opioid receptor agonist	OPRL1			0	95.63	Tocris	1780	NNC 63-0532	443.221	COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	AQMPIDSGLFVVPL-UHFFFAOYSA-N	9803475.0	BRD-K36009368-001-02-6	AQMPIDSGLFVVPL
BRD-K42221274-003-08-5	NNC-711	Preclinical	GABA uptake inhibitor	SIGMAR1|SLC6A1			0	99.12	Tocris	1779	NNC 711	350.163	OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|	NGNALWDRPKNJGR-UHFFFAOYSA-N	4515.0		NGNALWDRPKNJGR
BRD-K42221274-003-09-9	NNC-711	Preclinical	GABA uptake inhibitor	SIGMAR1|SLC6A1			0	97.11	Tocris	1779	NNC 711	350.163	OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|	NGNALWDRPKNJGR-UHFFFAOYSA-N	4515.0		NGNALWDRPKNJGR
BRD-K42221274-003-07-7	NNC-711	Preclinical	GABA uptake inhibitor	SIGMAR1|SLC6A1			0	98.55	Tocris	1779	NNC 711	350.163	OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|	NGNALWDRPKNJGR-UHFFFAOYSA-N	4515.0		NGNALWDRPKNJGR
BRD-K08807999-001-02-4	NO-ASA	Phase 2	cyclooxygenase inhibitor	PTGS2			0	2.28	Enzo	AC1544	NO-ASA	331.069	CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1	IOJUJUOXKXMJNF-UHFFFAOYSA-N	119032.0		IOJUJUOXKXMJNF
BRD-K08807999-001-03-9	NO-ASA	Phase 2	cyclooxygenase inhibitor	PTGS2			0	0.0	Sigma	SML1669	NCX 4016	331.069	CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1	IOJUJUOXKXMJNF-UHFFFAOYSA-N	119032.0		IOJUJUOXKXMJNF
BRD-K06753942-001-14-5	nobiletin	Preclinical	MEK inhibitor	MAP2K1			0	97.88	Selleck	S2333	Nobiletin	402.131	COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	MRIAQLRQZPPODS-UHFFFAOYSA-N	72344.0		MRIAQLRQZPPODS
BRD-K12539581-001-25-2	nocodazole	Preclinical	tubulin polymerization inhibitor	HPGDS			0	94.94	Tocris	1228	Nocodazole	301.052	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1	KYRVNWMVYQXFEU-UHFFFAOYSA-N	4122.0		KYRVNWMVYQXFEU
BRD-K12539581-001-23-7	nocodazole	Preclinical	tubulin polymerization inhibitor	HPGDS			0	95.61	MicroSource	1503266	NOCODAZOLE	301.052	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1	KYRVNWMVYQXFEU-UHFFFAOYSA-N	4122.0		KYRVNWMVYQXFEU
BRD-K12539581-001-21-1	nocodazole	Preclinical	tubulin polymerization inhibitor	HPGDS			0	91.39	Selleck	S2775	Nocodazole	301.052	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1	KYRVNWMVYQXFEU-UHFFFAOYSA-N	4122.0		KYRVNWMVYQXFEU
BRD-K12539581-001-22-9	nocodazole	Preclinical	tubulin polymerization inhibitor	HPGDS			0	95.25	Tocris	1228	Nocodazole	301.052	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1	KYRVNWMVYQXFEU-UHFFFAOYSA-N	4122.0		KYRVNWMVYQXFEU
BRD-K36636143-001-01-0	nolatrexed	Phase 3	thymidylate synthase inhibitor	TYMS			0	95.58	AvaChem	2072	2-amino-6-methyl-5-(4-pyridinylsulfanyl)-4(3H)-quinazolinone	284.073	Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1	XHWRWCSCBDLOLM-UHFFFAOYSA-N	135400184.0		XHWRWCSCBDLOLM
BRD-K27351809-001-10-9	nomegestrol-acetate	Launched	progesterone receptor agonist	PGR	endocrinology	contraceptive	0	100.0	Sigma	MFCD00941390	Nomegestrol acetate	370.214	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|	IIVBFTNIGYRNQY-YQLZSBIMSA-N	91668.0		IIVBFTNIGYRNQY
BRD-K27351809-001-09-5	nomegestrol-acetate	Launched	progesterone receptor agonist	PGR	endocrinology	contraceptive	0	96.56	Prestwick	Prestw-1033	Nomegestrol acetate	370.214	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|	IIVBFTNIGYRNQY-YQLZSBIMSA-N	91668.0		IIVBFTNIGYRNQY
BRD-K27351809-001-11-9	nomegestrol-acetate	Launched	progesterone receptor agonist	PGR	endocrinology	contraceptive	0	81.55	Toronto	n635855	nomegestrol acetate	370.214	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9,12|	IIVBFTNIGYRNQY-YQLZSBIMSA-N	91668.0		IIVBFTNIGYRNQY
BRD-A29644307-050-17-0	nomifensine	Withdrawn	dopamine reuptake inhibitor|noradrenaline uptake inhibitor	DRD2|SLC6A2|SLC6A3			0	96.63	MicroSource	1503267	NOMIFENSINE MALEATE	238.147	CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|	XXPANQJNYNUNES-AWEZNQCLSA-N	55993.0		XXPANQJNYNUNES
BRD-A29644307-050-16-2	nomifensine	Withdrawn	dopamine reuptake inhibitor|noradrenaline uptake inhibitor	DRD2|SLC6A2|SLC6A3			0	89.96	Selleck	S4380	Nomifensine Maleate	238.147	CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|	XXPANQJNYNUNES-AWEZNQCLSA-N	55993.0		XXPANQJNYNUNES
BRD-A29644307-050-18-8	nomifensine	Withdrawn	dopamine reuptake inhibitor|noradrenaline uptake inhibitor	DRD2|SLC6A2|SLC6A3			0	97.52	Selleck	S4380	nomifensine maleate	238.147	CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|	XXPANQJNYNUNES-AWEZNQCLSA-N	55993.0		XXPANQJNYNUNES
BRD-K05907307-001-08-9	nonivamide	Launched	TRPV agonist	TRPV1	rheumatology|neurology/psychiatry	rheumatoid arthritis|muscle pain	0	91.34	MedChemEx	HY-17568	Nonivamide	293.199	CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1	RGOVYLWUIBMPGK-UHFFFAOYSA-N	2998.0		RGOVYLWUIBMPGK
BRD-K05907307-001-07-1	nonivamide	Launched	TRPV agonist	TRPV1	rheumatology|neurology/psychiatry	rheumatoid arthritis|muscle pain	0	92.0	MicroSource	1506172	NONIVAMIDE	293.199	CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1	RGOVYLWUIBMPGK-UHFFFAOYSA-N	2998.0		RGOVYLWUIBMPGK
BRD-K88625236-001-04-2	nonoxynol-9	Launched	membrane integrity inhibitor		endocrinology	contraceptive	0	82.85	MicroSource	1505292	NONOXYNOL-9	616.419	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	FBWNMEQMRUMQSO-UHFFFAOYSA-N	72385.0		FBWNMEQMRUMQSO
BRD-K88625236-001-07-5	nonoxynol-9	Launched	membrane integrity inhibitor		endocrinology	contraceptive	0	0.0	LKT	N5655	26-(4-nonylphenoxy)-3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol	616.419	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	FBWNMEQMRUMQSO-UHFFFAOYSA-N	72385.0		FBWNMEQMRUMQSO
BRD-K88625236-001-05-9	nonoxynol-9	Launched	membrane integrity inhibitor		endocrinology	contraceptive	0	75.19	MedChemEx	HY-B1027	Nonoxinol 9	616.419	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	FBWNMEQMRUMQSO-UHFFFAOYSA-N	72385.0		FBWNMEQMRUMQSO
BRD-K36381762-300-03-5	nor-binaltorphimine	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0	70.58	Tocris	347	nor-Binaltorphimine dihydrochloride	661.315	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	APSUXPSYBJVPPS-YAUKWVCOSA-N	5480230.0		APSUXPSYBJVPPS
BRD-K36381762-300-02-7	nor-binaltorphimine	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0	77.38	Tocris	347	nor-Binaltorphimine dihydrochloride	661.315	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	APSUXPSYBJVPPS-YAUKWVCOSA-N	5480230.0		APSUXPSYBJVPPS
BRD-K36381762-300-04-9	nor-binaltorphimine	Preclinical	opioid receptor antagonist	OPRD1|OPRK1|OPRM1			0	82.82	Tocris	347	nor-Binaltorphimine dihydrochloride	661.315	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	APSUXPSYBJVPPS-YAUKWVCOSA-N	5480230.0		APSUXPSYBJVPPS
BRD-K63165456-001-10-8	norcyclobenzaprine	Preclinical	adrenergic receptor agonist|serotonin receptor antagonist				0	97.82	Prestwick	Prestw-513	Norcyclobenzaprine	261.152	CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|	XECQQDXTQRYYBH-UHFFFAOYSA-N	9918.0		XECQQDXTQRYYBH
BRD-K63165456-003-11-9	norcyclobenzaprine	Preclinical	adrenergic receptor agonist|serotonin receptor antagonist				0	98.26	Toronto	d291560	desmethyl cyclobenzaprine hydrochloride	261.152	CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|	XECQQDXTQRYYBH-UHFFFAOYSA-N	9918.0		XECQQDXTQRYYBH
BRD-K42504537-001-01-6	norelgestromin	Launched		PGR	endocrinology	contraceptive	0	88.48	MedChemEx	HY-G0018	Norgestimate metabolite Norelgestromin	327.22	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C |t:9|	ISHXLNHNDMZNMC-VTKCIJPMSA-N	9568628.0		ISHXLNHNDMZNMC
BRD-K87349682-347-08-9	norepinephrine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder	0	100.0	MedChemEx	HY-13715B	Norepinephrine (bitartrate monohydrate)	169.074	NC[C@H](O)c1ccc(O)c(O)c1	SFLSHLFXELFNJZ-QMMMGPOBSA-N	439260.0		SFLSHLFXELFNJZ
BRD-K87349682-347-02-0	norepinephrine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder	0	0.0	Selleck	S2615	Noradrenaline bitartrate monohydrate	169.074	NC[C@H](O)c1ccc(O)c(O)c1	SFLSHLFXELFNJZ-QMMMGPOBSA-N	439260.0		SFLSHLFXELFNJZ
BRD-K87349682-347-03-8	norepinephrine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder	0	100.0	Selleck	S2615	Noradrenaline bitartrate monohydrate (Levoph	169.074	NC[C@H](O)c1ccc(O)c(O)c1	SFLSHLFXELFNJZ-QMMMGPOBSA-N	439260.0		SFLSHLFXELFNJZ
BRD-K87349682-001-04-9	norepinephrine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2	cardiology|allergy|neurology/psychiatry	hypertension|urticaria|headache|seasonal affective disorder	0	0.0	MicroSource	1500436	NOREPINEPHRINE	169.074	NC[C@H](O)c1ccc(O)c(O)c1	SFLSHLFXELFNJZ-QMMMGPOBSA-N	439260.0		SFLSHLFXELFNJZ
BRD-K92073408-001-15-7	norethindrone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	0	96.5	Selleck	S4040	Norethindrone	298.193	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	VIKNJXKGJWUCNN-XGXHKTLJSA-N	6230.0	BRD-A39415247-001-11-2|BRD-A83260288-001-01-8	VIKNJXKGJWUCNN
BRD-K92073408-001-16-5	norethindrone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	0	98.2	MicroSource	1500437	NORETHINDRONE	298.193	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	VIKNJXKGJWUCNN-XGXHKTLJSA-N	6230.0	BRD-A39415247-001-10-4	VIKNJXKGJWUCNN
BRD-K92073408-001-14-0	norethindrone	Launched	progesterone receptor agonist	PGR	obstetrics/gynecology	endometriosis	0	90.66	Selleck	S4040	Norethindrone	298.193	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	VIKNJXKGJWUCNN-XGXHKTLJSA-N	6230.0	BRD-K01123092-001-01-1	VIKNJXKGJWUCNN
BRD-K96037667-001-04-9	norethindrone-acetate	Launched	progesterone receptor agonist	PGR	endocrinology|orthopedics|obstetrics/gynecology	menopause|osteoporosis|vaginal atrophy	0	90.57	MedChemEx	HY-B1710	Norethindrone acetate	340.204	CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|	IMONTRJLAWHYGT-ZCPXKWAGSA-N	5832.0		IMONTRJLAWHYGT
BRD-K07625016-001-01-2	norethisterone-enanthate	Launched	contraceptive agent		endocrinology	contraceptive	0	96.7	AvaChem	2817	(17beta)-17-ethynyl-3-oxoestr-4-en-17-yl heptanoate	410.282	CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|	APTGJECXMIKIET-WOSSHHRXSA-N	229295.0		APTGJECXMIKIET
BRD-A00758722-001-04-9	noretynodrel	Launched	progestogen hormone	PGR	endocrinology	contraceptive	0	81.73	MicroSource	1500439	NORETHYNODREL	298.193	C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1,18,&1:4,&2:5,&3:15,c:8|	ICTXHFFSOAJUMG-SLHNCBLASA-N	6231.0		ICTXHFFSOAJUMG
BRD-K11196887-001-25-9	norfloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|urology	urinary tract infections|gonorrhea|prostatitis	0	92.82	MedChemEx	HY-B0132	Norfloxacin	319.133	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	OGJPXUAPXNRGGI-UHFFFAOYSA-N	6919051.0		OGJPXUAPXNRGGI
BRD-K11196887-001-22-0	norfloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|urology	urinary tract infections|gonorrhea|prostatitis	0	98.57	Selleck	S1509	Norfloxacin (Norxacin)	319.133	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	OGJPXUAPXNRGGI-UHFFFAOYSA-N	6919051.0		OGJPXUAPXNRGGI
BRD-K11196887-001-20-4	norfloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|urology	urinary tract infections|gonorrhea|prostatitis	0	83.17	Selleck	S1509	Norfloxacin (Norxacin)	319.133	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	OGJPXUAPXNRGGI-UHFFFAOYSA-N	6919051.0		OGJPXUAPXNRGGI
BRD-K11196887-001-21-2	norfloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|urology	urinary tract infections|gonorrhea|prostatitis	0	86.95	MicroSource	1500440	NORFLOXACIN	319.133	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	OGJPXUAPXNRGGI-UHFFFAOYSA-N	6919051.0		OGJPXUAPXNRGGI
BRD-A79769222-001-01-3	norfluoxetine	Phase 1	selective serotonin reuptake inhibitor (SSRI)	HTR2B			0	95.93	Cayman	15900	3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine	295.118	NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3,r|	WIQRCHMSJFFONW-OAHLLOKOSA-N	9797657.0		WIQRCHMSJFFONW
BRD-K38041788-001-02-9	norgestimate	Launched	progesterone receptor agonist	ESR1|PGR	endocrinology	contraceptive	0	60.91	MicroSource	1505562	NORGESTIMATE	369.23	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|	KIQQMECNKUGGKA-NMYWJIRASA-N	6540478.0	BRD-A04756508-001-02-3	KIQQMECNKUGGKA
BRD-K38041788-001-01-1	norgestimate	Launched	progesterone receptor agonist	ESR1|PGR	endocrinology	contraceptive	0	61.05	Sigma	MFCD00867874	(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-nitroso-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate	369.23	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|	KIQQMECNKUGGKA-NMYWJIRASA-N	6540478.0	BRD-A75867198-001-01-9	KIQQMECNKUGGKA
BRD-A14886633-001-01-6	norgestrel	Launched	progesterone receptor agonist	AR|ESR1|PGR|SRD5A1	endocrinology	contraceptive	0	98.29	MicroSource	1500441	NORGESTREL	312.209	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2,6,15,16,19,&1:5,t:9|	WWYNJERNGUHSAO-XUDSTZEESA-N	13109.0		WWYNJERNGUHSAO
BRD-K00003718-001-01-9	nornicotine	Preclinical	acetylcholine receptor agonist				0	82.9	MedChemEx	HY-W002112	3-(Pyrrolidin-2-yl)pyridine	148.1	C1CN[C@H](C1)c1cccnc1 |r|	MYKUKUCHPMASKF-SECBINFHSA-N	93047.0		MYKUKUCHPMASKF
BRD-K91263825-003-23-9	nortriptyline	Launched	tricyclic antidepressant	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|HTR6|KCNJ10|PGRMC1|SIGMAR1|SLC6A2|SLC6A4	neurology/psychiatry	depression	0	98.38	MedChemEx	HY-B1417	Nortriptyline (hydrochloride)	263.167	CNCCC=C1c2ccccc2CCc2ccccc12	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	4543.0		PHVGLTMQBUFIQQ
BRD-K91263825-003-21-4	nortriptyline	Launched	tricyclic antidepressant	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|HTR6|KCNJ10|PGRMC1|SIGMAR1|SLC6A2|SLC6A4	neurology/psychiatry	depression	0	98.98	MicroSource	1500442	NORTRIPTYLINE HYDROCHLORIDE	263.167	CNCCC=C1c2ccccc2CCc2ccccc12	PHVGLTMQBUFIQQ-UHFFFAOYSA-N	4543.0		PHVGLTMQBUFIQQ
BRD-K00003706-003-01-9	norvancomycin	Preclinical					0	87.55	MedChemEx	HY-B1924	Norvancomycin (hydrochloride)	1433.415	[H][C@@]1(C[C@](C)(N)[C@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	NUAQIRUAZSJTAI-YRPZDAAMSA-N	10419027.0		NUAQIRUAZSJTAI
BRD-K89237706-003-02-6	noscapine	Launched	bradykinin receptor antagonist|tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	0	99.16	Selleck	S4363	Noscapine HCl	413.147	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	AKNNEGZIBPJZJG-MSOLQXFVSA-N	275196.0	BRD-K91301684-003-04-8	AKNNEGZIBPJZJG
BRD-K89237706-001-12-9	noscapine	Launched	bradykinin receptor antagonist|tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	0	99.11	Pharmeks	PHAR029677	(3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-2-benzofuran-1(3H)-one	413.147	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	AKNNEGZIBPJZJG-MSOLQXFVSA-N	275196.0		AKNNEGZIBPJZJG
BRD-K89237706-003-11-9	noscapine	Launched	bradykinin receptor antagonist|tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	0	98.76	Tocris	1697	Noscapine hydrochloride	413.147	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	AKNNEGZIBPJZJG-MSOLQXFVSA-N	275196.0		AKNNEGZIBPJZJG
BRD-K89237706-003-03-4	noscapine	Launched	bradykinin receptor antagonist|tubulin polymerization inhibitor	SIGMAR1	pulmonary	cough suppressant	0	98.8	Tocris	1697	Noscapine hydrochloride	413.147	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	AKNNEGZIBPJZJG-MSOLQXFVSA-N	275196.0	BRD-A51393488-003-02-7	AKNNEGZIBPJZJG
BRD-K11411329-001-02-9	NOV-002	Phase 3		GSR			0	100.0	InterBioScreen	STOCK1N-50253	(S)-2-amino-5-(((R)-3-(((R)-2-((R)-4-amino-4-carboxybutanamido)-3-((carboxymethyl)amino)-3-oxopropyl)disulfanyl)-1-((carboxymethyl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid	612.152	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	YPZRWBKMTBYPTK-USZNOCQGSA-N	16401161.0		YPZRWBKMTBYPTK
BRD-K11411329-001-01-3	NOV-002	Phase 3		GSR			0	94.9	InterBioScreen	STOCK1N-50253		612.152	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	YPZRWBKMTBYPTK-USZNOCQGSA-N	16401161.0		YPZRWBKMTBYPTK
BRD-K85307935-236-11-9	novobiocin	Launched	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	0	86.22	MedChemEx	HY-B0425A	Novobiocin (Sodium)	612.232	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	YJQPYGGHQPGBLI-KGSXXDOSSA-N	54675769.0		YJQPYGGHQPGBLI
BRD-K85307935-236-10-3	novobiocin	Launched	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	0	89.03	Selleck	S2492	Novobiocin sodium (Albamycin)	612.232	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	YJQPYGGHQPGBLI-KGSXXDOSSA-N	54675769.0		YJQPYGGHQPGBLI
BRD-K85307935-236-09-5	novobiocin	Launched	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	0	87.89	MicroSource	1500444	NOVOBIOCIN SODIUM	612.232	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	YJQPYGGHQPGBLI-KGSXXDOSSA-N	54675769.0		YJQPYGGHQPGBLI
BRD-K85307935-236-08-7	novobiocin	Launched	bacterial DNA gyrase inhibitor		obstetrics/gynecology	mastitis	0	16.97	Selleck	S2492	Novobiocin Sodium	612.232	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	YJQPYGGHQPGBLI-KGSXXDOSSA-N	54675769.0		YJQPYGGHQPGBLI
BRD-K58277159-001-01-7	NPC-01	Phase 3	steroid				0	93.36	Sigma	MFCD00051131	(11beta)-11-hydroxyandrost-4-ene-3,17-dione	302.188	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	WSCUHXPGYUMQEX-KCZNZURUSA-N	94141.0		WSCUHXPGYUMQEX
BRD-K65275554-001-05-9	NPC-15199	Phase 2	ICAM1 antagonist	PPARG			0	97.42	Tocris	675	NPC 15199	353.163	CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	CBPJQFCAFFNICX-LJQANCHMSA-N	1549477.0		CBPJQFCAFFNICX
BRD-K65275554-001-04-7	NPC-15199	Phase 2	ICAM1 antagonist	PPARG			0	78.5	Tocris	675	NPC 15199	353.163	CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	CBPJQFCAFFNICX-LJQANCHMSA-N	1549477.0		CBPJQFCAFFNICX
BRD-K89272762-001-13-5	NPPB	Preclinical	chloride channel blocker	ANO1|CLCN2|CLCN7|TRPA1			0	96.91	Tocris	593	NPPB	300.111	OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	WBSMIPAMAXNXFS-UHFFFAOYSA-N	4549.0		WBSMIPAMAXNXFS
BRD-K89272762-001-14-9	NPPB	Preclinical	chloride channel blocker	ANO1|CLCN2|CLCN7|TRPA1			0	96.2	Tocris	593	NPPB	300.111	OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	WBSMIPAMAXNXFS-UHFFFAOYSA-N	4549.0		WBSMIPAMAXNXFS
BRD-K89272762-001-12-7	NPPB	Preclinical	chloride channel blocker	ANO1|CLCN2|CLCN7|TRPA1			0	98.44	Tocris	593	NPPB	300.111	OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	WBSMIPAMAXNXFS-UHFFFAOYSA-N	4549.0		WBSMIPAMAXNXFS
BRD-K75506300-003-01-2	NPS-2143	Preclinical	calcium receptor antagonist	CASR			0	98.14	Tocris	3626	NPS 2143 hydrochloride	408.16	CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	PZUJQWHTIRWCID-HXUWFJFHSA-N	6918446.0		PZUJQWHTIRWCID
BRD-K75506300-001-01-6	NPS-2143	Preclinical	calcium receptor antagonist	CASR			0	97.04	Selleck	S2633	NPS-2143	408.16	CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	PZUJQWHTIRWCID-HXUWFJFHSA-N	6918446.0		PZUJQWHTIRWCID
BRD-K75506300-003-02-9	NPS-2143	Preclinical	calcium receptor antagonist	CASR			0	98.55	Tocris	3626	NPS 2143 hydrochloride	408.16	CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	PZUJQWHTIRWCID-HXUWFJFHSA-N	6918446.0		PZUJQWHTIRWCID
BRD-K00004686-001-01-9	NPS-2407	Preclinical	glutamate receptor antagonist				0	79.88	AMS	A002829001	N-(2-methyl-1-phenylpropan-2-yl)quinoxaline-2-carboxamide	305.153	CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1	DQEWVIJXZPUPQA-UHFFFAOYSA-N	9948445.0		DQEWVIJXZPUPQA
BRD-K95600043-001-02-3	NPY-5RA972	Preclinical	neuropeptide receptor antagonist	NPY5R			0	93.27	Tocris	3677	NPY 5RA972	351.195	CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	ZNFMHLDBJPAFEQ-UHFFFAOYSA-N	9884833.0		ZNFMHLDBJPAFEQ
BRD-K95600043-001-01-5	NPY-5RA972	Preclinical	neuropeptide receptor antagonist	NPY5R			0	95.24	Tocris	3677	NPY 5RA972	351.195	CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	ZNFMHLDBJPAFEQ-UHFFFAOYSA-N	9884833.0		ZNFMHLDBJPAFEQ
BRD-K95600043-001-03-9	NPY-5RA972	Preclinical	neuropeptide receptor antagonist	NPY5R			0	93.91	Tocris	3677	NPY 5RA972	351.195	CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	ZNFMHLDBJPAFEQ-UHFFFAOYSA-N	9884833.0		ZNFMHLDBJPAFEQ
BRD-K61918008-001-07-1	NQDI-1	Preclinical	caspase inhibitor	CASP3			0	96.79	MedChemEx	HY-19566	NQDI-1	319.084	CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23	UFJGFNHRMPMALC-UHFFFAOYSA-N	5522952.0		UFJGFNHRMPMALC
BRD-K21865955-003-01-5	NS-018	Phase 1/Phase 2	JAK inhibitor	JAK1|JAK2|JAK3|TYK2			0	92.62	MedChemEx	HY-19631B	NS-018 (hydrochloride)	389.176	C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1	UQTPDWDAYHAZNT-AWEZNQCLSA-N	46866319.0		UQTPDWDAYHAZNT
BRD-K94342292-001-02-9	NS-11021	Preclinical	calcium-activated potassium channel activator	KCNMA1			0	38.32	Tocris	4788	NS 11021	509.97	FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	MDKAFDIKYQMOMF-UHFFFAOYSA-N	24825677.0		MDKAFDIKYQMOMF
BRD-K94342292-001-01-3	NS-11021	Preclinical	calcium-activated potassium channel activator	KCNMA1			0	0.0	Tocris	4788	NS 11021	509.97	FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	MDKAFDIKYQMOMF-UHFFFAOYSA-N	24825677.0		MDKAFDIKYQMOMF
BRD-K00004548-001-01-9	NS-11394	Preclinical	GABA receptor agonist				0	98.14	Sigma	MFCD14635200	3'-[5-(1-hydroxy-1-methylethyl)-1H-benzimidazol-1-yl][1,1'-biphenyl]-2-carbonitrile	353.153	CC(C)(O)c1ccc2n(cnc2c1)-c1cccc(c1)-c1ccccc1C#N	HLKYSQGBIIIQJN-UHFFFAOYSA-N	16747643.0		HLKYSQGBIIIQJN
BRD-K73738482-001-02-5	NS-1643	Preclinical	voltage-gated potassium channel activator	KCNH2|KCNH6|KCNMA1			0	91.34	Tocris	3062	NS 1643	380.06	Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F	NJFVQMRYJZHGME-UHFFFAOYSA-N	10177784.0		NJFVQMRYJZHGME
BRD-K73738482-001-01-7	NS-1643	Preclinical	voltage-gated potassium channel activator	KCNH2|KCNH6|KCNMA1			0	95.1	Stanley		NS-1643	380.06	Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F	NJFVQMRYJZHGME-UHFFFAOYSA-N	10177784.0		NJFVQMRYJZHGME
BRD-K03808106-001-01-9	NS-19504	Preclinical	calcium-activated potassium channel activator	KCNMA1			0	84.54	Tocris	5276	NS 19504	267.967	Nc1ncc(Cc2ccc(Br)cc2)s1	HGWLTZOMQZIUBW-UHFFFAOYSA-N	727750.0		HGWLTZOMQZIUBW
BRD-K03808106-001-02-9	NS-19504	Preclinical	calcium-activated potassium channel activator	KCNMA1			0	92.11	Tocris	5276	NS 19504	267.967	Nc1ncc(Cc2ccc(Br)cc2)s1	HGWLTZOMQZIUBW-UHFFFAOYSA-N	727750.0		HGWLTZOMQZIUBW
BRD-K00004295-001-01-9	NS-309	Preclinical	calcium-activated potassium channel activator	KCNN1|KCNN2|KCNN3|KCNN4			0	94.59	Tocris	3895	NS 309	229.965	O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl	CVOUSAVHMDXCKG-UHFFFAOYSA-N			CVOUSAVHMDXCKG
BRD-K24434292-001-02-1	NS-3623	Preclinical	voltage-gated potassium channel activator	KCNH2			0	86.42	Tocris	4462	NS 3623	426.005	FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1	JXPULDIATMTIIN-UHFFFAOYSA-N	9954236.0		JXPULDIATMTIIN
BRD-K24434292-001-01-3	NS-3623	Preclinical	voltage-gated potassium channel activator	KCNH2			0	96.49	Stanley		NS-3623	426.005	FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1	JXPULDIATMTIIN-UHFFFAOYSA-N	9954236.0		JXPULDIATMTIIN
BRD-K00004309-051-01-9	NS-3861	Preclinical	acetylcholine receptor agonist	CHRNA3|CHRNB4			0	78.64	Tocris	4831	NS 3861	283.003	CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2,5,c:7|	ZJCNRVHZJADROC-VHSXEESVSA-N			ZJCNRVHZJADROC
BRD-K93314017-001-01-7	NS-5806	Preclinical	voltage-gated potassium channel activator	KCND3			0	85.92	Tocris	4166	NS 5806	571.903	FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	UZWJWROOLOOCPQ-UHFFFAOYSA-N	11642685.0		UZWJWROOLOOCPQ
BRD-K93314017-001-02-9	NS-5806	Preclinical	voltage-gated potassium channel activator	KCND3			0	94.89	Tocris	4166	NS 5806	571.903	FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	UZWJWROOLOOCPQ-UHFFFAOYSA-N	11642685.0		UZWJWROOLOOCPQ
BRD-K22667752-001-01-3	NS-8	Phase 2	potassium channel agonist	KCNMA1			0	40.47	Enamine	Z2306534448	2-amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile	215.086	Cc1c([nH]c(N)c1C#N)-c1ccccc1F	KVDWOQGDMAEJLM-UHFFFAOYSA-N	10176749.0		KVDWOQGDMAEJLM
BRD-K34624869-003-02-9	NS-8593	Preclinical	calcium-activated potassium channel modulator	KCNN1|KCNN2|KCNN3			0	96.23	Tocris	4597	NS 8593 hydrochloride	263.142	C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1	XZIZUQSOFMLIIR-CQSZACIVSA-N	11587013.0		XZIZUQSOFMLIIR
BRD-K34624869-003-01-6	NS-8593	Preclinical	calcium-activated potassium channel modulator	KCNN1|KCNN2|KCNN3			0	97.22	Tocris	4597	NS 8593 hydrochloride	263.142	C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1	XZIZUQSOFMLIIR-CQSZACIVSA-N	11587013.0		XZIZUQSOFMLIIR
BRD-K40176866-001-02-9	NS-9283	Preclinical	acetylcholine receptor allosteric modulator	CHRNA4			0	97.5	Tocris	5112	NS 9283	248.07	N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1	HGFXDSQLRSWUBO-UHFFFAOYSA-N	11998180.0		HGFXDSQLRSWUBO
BRD-K40176866-001-01-6	NS-9283	Preclinical	acetylcholine receptor allosteric modulator	CHRNA4			0	97.98	Tocris	5112	NS 9283	248.07	N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1	HGFXDSQLRSWUBO-UHFFFAOYSA-N	11998180.0		HGFXDSQLRSWUBO
BRD-K01826800-305-08-9	NSC-23766	Preclinical	Ras GTPase inhibitor				0	82.99	Tocris	2161	NSC 23766	529.225	CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|	DEFBCZWQLILOJF-MRXNPFEDSA-N	7959890.0		DEFBCZWQLILOJF
BRD-K01826800-305-11-9	NSC-23766	Preclinical	Ras GTPase inhibitor				0	95.29	Selleck	S8031	NSC 23766	529.225	CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|	DEFBCZWQLILOJF-MRXNPFEDSA-N	7959890.0		DEFBCZWQLILOJF
BRD-K01826800-305-13-9	NSC-23766	Preclinical	Ras GTPase inhibitor				0	91.21	Tocris	2161	NSC 23766	529.225	CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|	DEFBCZWQLILOJF-MRXNPFEDSA-N	7959890.0		DEFBCZWQLILOJF
BRD-K01826800-305-07-9	NSC-23766	Preclinical	Ras GTPase inhibitor				0	78.07	Selleck	S8031	NSC 23766	529.225	CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|	DEFBCZWQLILOJF-MRXNPFEDSA-N	7959890.0		DEFBCZWQLILOJF
BRD-K99170882-001-07-9	NSC-319726	Preclinical	p53 activator				0	92.49	Tocris	5065	NSC 319726	234.094	C\C(=N/NC(=S)N1CCC1)c1ccccn1	XDHBUMNIQRLHGO-UKTHLTGXSA-N	5351307.0		XDHBUMNIQRLHGO
BRD-K99170882-001-04-3	NSC-319726	Preclinical	p53 activator				0	75.73	Selleck	S7149	NSC 319726	234.094	C\C(=N/NC(=S)N1CCC1)c1ccccn1	XDHBUMNIQRLHGO-UKTHLTGXSA-N	5351307.0		XDHBUMNIQRLHGO
BRD-K99170882-001-06-8	NSC-319726	Preclinical	p53 activator				0	84.67	Tocris	5065	NSC 319726	234.094	C\C(=N/NC(=S)N1CCC1)c1ccccn1	XDHBUMNIQRLHGO-UKTHLTGXSA-N	5351307.0		XDHBUMNIQRLHGO
BRD-K99170882-001-05-0	NSC-319726	Preclinical	p53 activator				0	95.41	Selleck	S7149	NSC319726	234.094	C\C(=N/NC(=S)N1CCC1)c1ccccn1	XDHBUMNIQRLHGO-UKTHLTGXSA-N	5351307.0		XDHBUMNIQRLHGO
BRD-K13169950-001-14-4	NSC-3852	Preclinical	HDAC inhibitor	HDAC1			0	96.22	Tocris	2521	NSC 3852	174.043	Oc1ccc(N=O)c2cccnc12	RZWRYPGAUIOOMK-UHFFFAOYSA-N	19103.0		RZWRYPGAUIOOMK
BRD-A67975844-001-03-9	NSC-405020	Preclinical	matrix metalloprotease inhibitor	MMP1			0	95.94	Tocris	4902	NSC 405020	259.053	CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|	ARDYECYBETXQFD-MRVPVSSYSA-N	879610.0		ARDYECYBETXQFD
BRD-A67975844-001-02-6	NSC-405020	Preclinical	matrix metalloprotease inhibitor	MMP1			0	95.97	Tocris	4902	NSC 405020	259.053	CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|	ARDYECYBETXQFD-MRVPVSSYSA-N	879610.0		ARDYECYBETXQFD
BRD-A67975844-001-01-8	NSC-405020	Preclinical	matrix metalloprotease inhibitor	MMP1			0	97.07	Selleck	S8072	NSC 405020	259.053	CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3,r|	ARDYECYBETXQFD-MRVPVSSYSA-N	879610.0		ARDYECYBETXQFD
BRD-K64874225-001-05-9	NSC-4644	Phase 2	ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor	PYGM			0	46.92	MedChemEx	HY-N0083	Betulin	442.381	CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12	FVWJYYTZTCVBKE-ROUWMTJPSA-N	72326.0		FVWJYYTZTCVBKE
BRD-K64874225-001-04-7	NSC-4644	Phase 2	ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor	PYGM			0	100.0	Enzo	NP030	Betulin	442.381	CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12	FVWJYYTZTCVBKE-ROUWMTJPSA-N	72326.0		FVWJYYTZTCVBKE
BRD-K73799155-001-01-5	NSC-5844	Preclinical	CC chemokine receptor agonist	CCR1			0	96.41	MedChemEx	HY-100033	NSC5844	382.075	Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1	SSXYXSMMVMVYEV-UHFFFAOYSA-N	221354.0		SSXYXSMMVMVYEV
BRD-K62949423-001-03-1	NSC-625987	Preclinical	CDK inhibitor	CDK2|CDK4			0	0.34	Tocris	2152	NSC 625987	271.067	COc1ccc(OC)c2c1[nH]c1ccccc1c2=S	KFAKESMKRPNZTM-UHFFFAOYSA-N	3004085.0		KFAKESMKRPNZTM
BRD-K62949423-001-04-9	NSC-625987	Preclinical	CDK inhibitor	CDK2|CDK4			0		Tocris	2152	NSC 625987	271.067	COc1ccc(OC)c2c1[nH]c1ccccc1c2=S	KFAKESMKRPNZTM-UHFFFAOYSA-N	3004085.0		KFAKESMKRPNZTM
BRD-K81197548-003-02-2	NSC-632839	Preclinical	ubiquitin specific protease inhibitor	SENP2|USP1|USP2|USP7			0	81.98	Tocris	2647	NSC 632839 hydrochloride	303.162	Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1	PKCYYPHSCUSQDK-AYKLPDECSA-N	5351363.0		PKCYYPHSCUSQDK
BRD-K81197548-003-01-4	NSC-632839	Preclinical	ubiquitin specific protease inhibitor	SENP2|USP1|USP2|USP7			0	90.63	Tocris	2647	NSC 632839 hydrochloride	303.162	Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1	PKCYYPHSCUSQDK-AYKLPDECSA-N	5351363.0		PKCYYPHSCUSQDK
BRD-K81197548-003-03-9	NSC-632839	Preclinical	ubiquitin specific protease inhibitor	SENP2|USP1|USP2|USP7			0	93.86	Tocris	2647	NSC 632839 hydrochloride	303.162	Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1	PKCYYPHSCUSQDK-AYKLPDECSA-N	5351363.0		PKCYYPHSCUSQDK
BRD-K61120504-001-01-6	NSC-636819	Preclinical	histone demethylase inhibitor	KDM4A|KDM4B			0	90.48	Tocris	5287	NSC636819	507.955	[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O	YYZPXBXVBQSBDG-IJIVKGSJSA-N	6288112.0		YYZPXBXVBQSBDG
BRD-K03109492-001-03-0	NSC-663284	Preclinical	CDC inhibitor	CDC25A|CDC25B|CDC25C			0	96.21	Tocris	1867	NSC 663284	321.088	ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|	BMKPVDQDJQWBPD-UHFFFAOYSA-N	379077.0		BMKPVDQDJQWBPD
BRD-K03109492-001-02-2	NSC-663284	Preclinical	CDC inhibitor	CDC25A|CDC25B|CDC25C			0	93.78	Tocris	1867	NSC 663284	321.088	ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|	BMKPVDQDJQWBPD-UHFFFAOYSA-N	379077.0		BMKPVDQDJQWBPD
BRD-K20605374-001-07-9	NSC-697923	Preclinical	ubiquitin-conjugating enzyme inhibitor	UBE2N			0	90.96	Tocris	4858	NSC 697923	267.02	Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	GAUHIPWCDXOLCZ-UHFFFAOYSA-N	394449.0		GAUHIPWCDXOLCZ
BRD-K20605374-001-05-4	NSC-697923	Preclinical	ubiquitin-conjugating enzyme inhibitor	UBE2N			0	92.89	Selleck	S7142	NSC697923	267.02	Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	GAUHIPWCDXOLCZ-UHFFFAOYSA-N	394449.0		GAUHIPWCDXOLCZ
BRD-K20605374-001-06-2	NSC-697923	Preclinical	ubiquitin-conjugating enzyme inhibitor	UBE2N			0	92.61	Tocris	4858	NSC 697923	267.02	Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	GAUHIPWCDXOLCZ-UHFFFAOYSA-N	394449.0		GAUHIPWCDXOLCZ
BRD-K68143200-001-11-7	NSC-95397	Preclinical	CDC inhibitor	CDC25A|CDC25B			0	9.25	Tocris	1547	NSC 95397	310.033	OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|	MAASHDQFQDDECQ-UHFFFAOYSA-N	262093.0		MAASHDQFQDDECQ
BRD-K49811169-004-06-6	NSC-9965	Preclinical	acetylcholine receptor antagonist	CHRNA4|CHRNB2			0	95.89	Enzo	AC738	Dihydro-beta-erythroidine HBr	275.152	CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|	ALSKYCOJJPXPFS-BBRMVZONSA-N	31762.0		ALSKYCOJJPXPFS
BRD-K49811169-004-08-9	NSC-9965	Preclinical	acetylcholine receptor antagonist	CHRNA4|CHRNB2			0	100.0	Tocris	2349	Dihydro-beta-erythroidine hydrobromide	275.152	CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4,11|	ALSKYCOJJPXPFS-BBRMVZONSA-N	31762.0		ALSKYCOJJPXPFS
BRD-K74371986-001-01-7	NSI-189	Phase 2	neurotrophic agent				0	99.38	MedChemEx	HY-13999	NSI-189	366.242	CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1	DYTOQURYRYYNOR-UHFFFAOYSA-N	50922681.0		DYTOQURYRYYNOR
BRD-K74371986-001-02-9	NSI-189	Phase 2	neurotrophic agent				0	99.05	MedChemEx	HY-13999	NSI-189	366.242	CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1	DYTOQURYRYYNOR-UHFFFAOYSA-N	50922681.0		DYTOQURYRYYNOR
BRD-K00004733-001-01-9	NSP-805	Preclinical	phosphodiesterase inhibitor				0	91.88	MedChemEx	HY-19102	NSP-805	297.148	CC1=C(CCC1=O)Nc1ccc(cc1)C1=C(C)CC(=O)NN1 |c:16,t:1|	VSEWBFSTIMFCDL-UHFFFAOYSA-N			VSEWBFSTIMFCDL
BRD-A40413915-003-01-2	NTNCB	Preclinical	neuropeptide receptor antagonist	NPY5R			0	97.68	Tocris	2155	NTNCB hydrochloride	471.219	[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|	ISSSVYKMIIAPTH-ACRUOGEOSA-N			ISSSVYKMIIAPTH
BRD-A40413915-003-02-9	NTNCB	Preclinical	neuropeptide receptor antagonist	NPY5R			0	95.2	Tocris	2155	NTNCB hydrochloride	471.219	[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14,17,&1:21|	ISSSVYKMIIAPTH-ACRUOGEOSA-N			ISSSVYKMIIAPTH
BRD-K07788774-001-01-0	NTRC-824	Preclinical	neurotensin receptor antagonist	NTSR2			0	93.63	Tocris	5438	NTRC 824	553.149	CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O	SOOLLEBJNGCDOZ-FQEVSTJZSA-N	101873359.0		SOOLLEBJNGCDOZ
BRD-K07788774-001-02-9	NTRC-824	Preclinical	neurotensin receptor antagonist	NTSR2			0	93.07	Tocris	5438	NTRC 824	553.149	CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O	SOOLLEBJNGCDOZ-FQEVSTJZSA-N	101873359.0		SOOLLEBJNGCDOZ
BRD-K54708045-001-03-9	nTZDpa	Preclinical	PPAR receptor agonist	PPARG			0	98.0	Tocris	2150	nTZDpa	427.02	OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1	VUPOTURDKDMIGQ-UHFFFAOYSA-N	9954280.0		VUPOTURDKDMIGQ
BRD-K54708045-001-02-1	nTZDpa	Preclinical	PPAR receptor agonist	PPARG			0	97.29	Tocris	2150	nTZDpa	427.02	OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1	VUPOTURDKDMIGQ-UHFFFAOYSA-N	9954280.0		VUPOTURDKDMIGQ
BRD-K54708045-001-05-9	nTZDpa	Preclinical	PPAR receptor agonist	PPARG			0	96.64	Tocris	2150	nTZDpa	427.02	OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1	VUPOTURDKDMIGQ-UHFFFAOYSA-N	9954280.0		VUPOTURDKDMIGQ
BRD-K54098378-001-02-4	NT157	Preclinical	IGF-1 inhibitor	IGF1R			0	50.74	MedChemEx	HY-100037	NT157	410.978	Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O	NIPUPOUEGOSAAO-OWOJBTEDSA-N	135398520.0		NIPUPOUEGOSAAO
BRD-K54098378-001-01-6	NT157	Preclinical	IGF-1 inhibitor	IGF1R			0	66.42	MedChemEx	HY-100037	NT157	410.978	Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O	NIPUPOUEGOSAAO-OWOJBTEDSA-N	135398520.0		NIPUPOUEGOSAAO
BRD-K48692744-001-03-8	NU-1025	Preclinical	PARP inhibitor	PARP1			0	92.99	Tocris	1401	NU 1025	176.059	Cc1nc(=O)c2cccc(O)c2[nH]1	YJDAOHJWLUNFLX-UHFFFAOYSA-N	135398517.0		YJDAOHJWLUNFLX
BRD-K48692744-001-04-9	NU-1025	Preclinical	PARP inhibitor	PARP1			0	94.76	Tocris	1401	NU 1025	176.059	Cc1nc(=O)c2cccc(O)c2[nH]1	YJDAOHJWLUNFLX-UHFFFAOYSA-N	135398517.0		YJDAOHJWLUNFLX
BRD-K48692744-001-02-0	NU-1025	Preclinical	PARP inhibitor	PARP1			0	95.84	Tocris	1401	NU 1025	176.059	Cc1nc(=O)c2cccc(O)c2[nH]1	YJDAOHJWLUNFLX-UHFFFAOYSA-N	135398517.0		YJDAOHJWLUNFLX
BRD-K20976221-001-12-0	NU-2058	Preclinical	cyclin D inhibitor	CCNA2|CDK2			0	91.61	Tocris	3135	NU 2058	247.143	Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1	MWGXGTJJAOZBNW-UHFFFAOYSA-N	4564.0		MWGXGTJJAOZBNW
BRD-K20976221-001-14-6	NU-2058	Preclinical	cyclin D inhibitor	CCNA2|CDK2			0		InterBioScreen	STOCK6S-12824	6-(cyclohexylmethoxy)-9H-purin-2-amine	247.143	Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1	MWGXGTJJAOZBNW-UHFFFAOYSA-N	4564.0		MWGXGTJJAOZBNW
BRD-K03294269-001-08-0	NU-6027	Preclinical	CDK inhibitor	CCNA2|CDK2			0	93.48	Selleck	S7114	NU6027	251.138	Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1	DGWXOLHKVGDQLN-UHFFFAOYSA-N	398148.0		DGWXOLHKVGDQLN
BRD-K03294269-001-09-8	NU-6027	Preclinical	CDK inhibitor	CCNA2|CDK2			0	95.4	Selleck	S7114	NU6027	251.138	Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1	DGWXOLHKVGDQLN-UHFFFAOYSA-N	398148.0		DGWXOLHKVGDQLN
BRD-K09537769-001-06-5	NU-7026	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	PRKDC			0	99.72	MedChemEx	HY-15719	NU 7026	281.105	O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	KKTZALUTXUZPSN-UHFFFAOYSA-N	9860529.0		KKTZALUTXUZPSN
BRD-K09537769-001-04-0	NU-7026	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	PRKDC			0	99.38	Tocris	2828	NU 7026	281.105	O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	KKTZALUTXUZPSN-UHFFFAOYSA-N	9860529.0		KKTZALUTXUZPSN
BRD-K09537769-001-03-2	NU-7026	Preclinical	DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor	PRKDC			0	97.98	Selleck	S2893	NU7026	281.105	O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	KKTZALUTXUZPSN-UHFFFAOYSA-N	9860529.0		KKTZALUTXUZPSN
BRD-K00337317-001-06-6	NU-7441	Preclinical	DNA dependent protein kinase inhibitor	PRKDC			0	98.07	Selleck	S2638	NU7441 (KU-57788)	413.109	O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1	JAMULYFATHSZJM-UHFFFAOYSA-N	11327430.0		JAMULYFATHSZJM
BRD-K00337317-001-08-2	NU-7441	Preclinical	DNA dependent protein kinase inhibitor	PRKDC			0	98.93	Focus	1063131	NU7441	413.109	O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1	InChI=1S/C25H19NO3S/c27-21-15-23(26-11-13-28-14-12-26)29-24-17(6-3-9-20(21)24)19-8-4-7-18-16-5-1-2-10-22(16)30-25(18)19/h1-10,15H,11-14H2	11327430.0		JAMULYFATHSZJM
BRD-A96466199-001-01-4	nuclomedone	Phase 3	immunosuppressant				0	93.86	InterBioScreen	STOCK6S-24941	6-(4-chlorobenzyl)-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidine-5,7(6H)-dione	294.023	Clc1ccc(C[C@H]2C(=O)N=C3SCCN3C2=O)cc1 |r,t:9|	QSKVYHYMQQQAFS-JTQLQIEISA-N	76972174.0		QSKVYHYMQQQAFS
BRD-K00002882-001-02-9	nutlin-3	Preclinical	MDM inhibitor	MDM2|TP53			0	95.27	Tocris	3984	Nutlin-3	580.164	COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8,9,r,t:6|	BDUHCSBCVGXTJM-WUFINQPMSA-N	11433190.0		BDUHCSBCVGXTJM
BRD-K00004743-001-01-9	nuvenzepine	Preclinical	acetylcholine receptor antagonist				0	98.12	MedChemEx	HY-U00119	Nuvenzepine	336.159	CN1CCC(CC1)C(=O)N1c2ccccc2NC(=O)c2cccnc12	HPKYRXAEGNUARA-UHFFFAOYSA-N	65846.0		HPKYRXAEGNUARA
BRD-K15179513-001-06-9	NVP-ADW742	Preclinical	insulin growth factor receptor inhibitor	IGF1R			0	94.85	Tocris	5247	NVP ADW 742	453.253	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|	LSFLAQVDISHMNB-AFARHQOCSA-N			LSFLAQVDISHMNB
BRD-K15179513-001-05-9	NVP-ADW742	Preclinical	insulin growth factor receptor inhibitor	IGF1R			0	95.18	Tocris	5247	NVP ADW 742	453.253	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|	LSFLAQVDISHMNB-AFARHQOCSA-N			LSFLAQVDISHMNB
BRD-K15179513-001-04-2	NVP-ADW742	Preclinical	insulin growth factor receptor inhibitor	IGF1R			0	96.14	Selleck	S1088	NVP-ADW742	453.253	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|	LSFLAQVDISHMNB-AFARHQOCSA-N			LSFLAQVDISHMNB
BRD-K15179513-001-03-4	NVP-ADW742	Preclinical	insulin growth factor receptor inhibitor	IGF1R			0	82.77	Selleck	S1088	NVP-ADW742	453.253	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|	LSFLAQVDISHMNB-AFARHQOCSA-N			LSFLAQVDISHMNB
BRD-K24696047-001-03-9	NVP-AEW541	Preclinical	IGF-1 inhibitor	IGF1R|INSR			0	96.92	MedChemEx	HY-50866	NVP-AEW541	439.237	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|	AECDBHGVIIRMOI-GRGXKFILSA-N			AECDBHGVIIRMOI
BRD-K24696047-001-02-3	NVP-AEW541	Preclinical	IGF-1 inhibitor	IGF1R|INSR			0	94.66	Selleck	S1034	NVP-AEW541	439.237	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|	AECDBHGVIIRMOI-GRGXKFILSA-N			AECDBHGVIIRMOI
BRD-K41859756-001-09-2	NVP-AUY922	Phase 2	HSP inhibitor	HSP90AA1|HSP90AB1			0	96.22	MedChemEx	HY-10215	NVP-AUY922	465.226	CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	NDAZATDQFDPQBD-UHFFFAOYSA-N	135539077.0		NDAZATDQFDPQBD
BRD-K41859756-001-08-4	NVP-AUY922	Phase 2	HSP inhibitor	HSP90AA1|HSP90AB1			0	84.58	Selleck	S1069	Luminespib (AUY-922, NVP-AUY922)	465.226	CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	NDAZATDQFDPQBD-UHFFFAOYSA-N	135539077.0		NDAZATDQFDPQBD
BRD-K41859756-001-06-8	NVP-AUY922	Phase 2	HSP inhibitor	HSP90AA1|HSP90AB1			0	93.57	Selleck	S1069	AUY922 (NVP-AUY922)	465.226	CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	NDAZATDQFDPQBD-UHFFFAOYSA-N	135539077.0		NDAZATDQFDPQBD
BRD-K12184916-001-19-6	NVP-BEZ235	Phase 3	mTOR inhibitor|PI3K inhibitor	ATR|MTOR|PIK3CA|PIK3CD|PIK3CG			0	98.67	Selleck	S1009	BEZ235 (NVP-BEZ235)	469.19	Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	11977753.0		JOGKUKXHTYWRGZ
BRD-K12184916-001-15-4	NVP-BEZ235	Phase 3	mTOR inhibitor|PI3K inhibitor	ATR|MTOR|PIK3CA|PIK3CD|PIK3CG			0	85.4	Selleck	S1009	BEZ235 (NVP-BEZ235, Dactolisib)	469.19	Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1	JOGKUKXHTYWRGZ-UHFFFAOYSA-N	11977753.0		JOGKUKXHTYWRGZ
BRD-K42728290-001-09-1	NVP-BGJ398	Phase 3	FGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|KDR			0	74.48	LCLabs	I-1500	Infigratinib	559.187	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	QADPYRIHXKWUSV-UHFFFAOYSA-N	53235510.0		QADPYRIHXKWUSV
BRD-K42728290-001-11-7	NVP-BGJ398	Phase 3	FGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|KDR			0	89.82	MedChemEx	HY-13311	NVP-BGJ398	559.187	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	QADPYRIHXKWUSV-UHFFFAOYSA-N	53235510.0		QADPYRIHXKWUSV
BRD-K42728290-001-06-7	NVP-BGJ398	Phase 3	FGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|KDR			0	29.43	Selleck	S2183	BGJ398 (NVP-BGJ398)	559.187	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	QADPYRIHXKWUSV-UHFFFAOYSA-N	53235510.0		QADPYRIHXKWUSV
BRD-K42728290-001-08-3	NVP-BGJ398	Phase 3	FGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|KDR			0	60.42	MedChemEx	HY-13311	NVP-BGJ398	559.187	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	QADPYRIHXKWUSV-UHFFFAOYSA-N	53235510.0		QADPYRIHXKWUSV
BRD-K42728290-001-07-5	NVP-BGJ398	Phase 3	FGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|KDR			0	41.46	Selleck	S2183	BGJ398 (NVP-BGJ398)	559.187	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	QADPYRIHXKWUSV-UHFFFAOYSA-N	53235510.0		QADPYRIHXKWUSV
BRD-K79259477-001-06-9	NVP-BHG712	Preclinical	ephrin inhibitor	EPHB4			0	94.8	MedChemEx	HY-13258	NVP-BHG712	503.168	Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	ZCCPLJOKGAACRT-UHFFFAOYSA-N	16747388.0		ZCCPLJOKGAACRT
BRD-K79259477-001-04-9	NVP-BHG712	Preclinical	ephrin inhibitor	EPHB4			0	98.2	Selleck	S2202	NVP-BHG712	503.168	Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	ZCCPLJOKGAACRT-UHFFFAOYSA-N	16747388.0		ZCCPLJOKGAACRT
BRD-K02017404-300-06-2	NVP-BSK805	Preclinical	JAK inhibitor	JAK2			0	87.6	Selleck	S2686	NVP-BSK805 2HCl	490.229	Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1	IBPVXAOOVUAOKJ-UHFFFAOYSA-N	46398810.0		IBPVXAOOVUAOKJ
BRD-K02017404-300-07-0	NVP-BSK805	Preclinical	JAK inhibitor	JAK2			0	92.69	Selleck	S2686	NVP-BSK805 2HCl	490.229	Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1	IBPVXAOOVUAOKJ-UHFFFAOYSA-N	46398810.0		IBPVXAOOVUAOKJ
BRD-K77943374-001-02-8	NVP-BVU972	Preclinical	MET inhibitor	MET			0	98.35	Selleck	S2761	NVP-BVU972	340.144	Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	RNCNPRCUHHDYPC-UHFFFAOYSA-N	44206063.0		RNCNPRCUHHDYPC
BRD-K77943374-001-03-9	NVP-BVU972	Preclinical	MET inhibitor	MET			0	96.68	MedChemEx	HY-15456	NVP-BVU972	340.144	Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	RNCNPRCUHHDYPC-UHFFFAOYSA-N	44206063.0		RNCNPRCUHHDYPC
BRD-K77396579-300-01-0	NVP-DPP728	Phase 2	dipeptidyl peptidase inhibitor	DPP4			0	92.57	Tocris	3506	NVP DPP 728 dihydrochloride	298.154	O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N	VFFZWMWTUSXDCB-ZDUSSCGKSA-N	9796290.0		VFFZWMWTUSXDCB
BRD-K77396579-300-02-9	NVP-DPP728	Phase 2	dipeptidyl peptidase inhibitor	DPP4			0	87.95	Tocris	3506	NVP DPP 728 dihydrochloride	298.154	O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N	VFFZWMWTUSXDCB-ZDUSSCGKSA-N	9796290.0		VFFZWMWTUSXDCB
BRD-K67915505-001-01-2	NVP-HSP990	Phase 1	HSP inhibitor	HSP90AA1|HSP90AB1			0	94.87	MedChemEx	HY-15190	NVP-HSP990	379.144	COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1	WSMQUUGTQYPVPD-OAHLLOKOSA-N	46216556.0		WSMQUUGTQYPVPD
BRD-K21025364-001-04-9	NVP-TAE226	Preclinical	protein tyrosine kinase inhibitor	PTK2			0	88.88	Selleck	S2820	TAE226 (NVP-TAE226)	468.168	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	UYJNQQDJUOUFQJ-UHFFFAOYSA-N	9934347.0		UYJNQQDJUOUFQJ
BRD-K21025364-001-05-6	NVP-TAE226	Preclinical	protein tyrosine kinase inhibitor	PTK2			0	95.2	Selleck	S2820	NVP-TAE226	468.168	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	UYJNQQDJUOUFQJ-UHFFFAOYSA-N	9934347.0		UYJNQQDJUOUFQJ
BRD-K50140147-001-10-1	NVP-TAE684	Preclinical	ALK tyrosine kinase receptor inhibitor	ALK|INSR			0	96.23	Selleck	S1108	TAE684 (NVP-TAE684)	613.26	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	QQWUGDVOUVUTOY-UHFFFAOYSA-N	16038120.0		QQWUGDVOUVUTOY
BRD-K87454346-001-01-1	NVP-TNKS656	Preclinical	tankyrase inhibitor	TNKS2			0	93.82	MedChemEx	HY-13990	NVP-TNKS656	494.253	COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1	DYGBNAYFDZEYBA-UHFFFAOYSA-N	136237316.0		DYGBNAYFDZEYBA
BRD-K01573278-001-03-9	NVP-231	Preclinical	ceramidase inhibitor	CERK			0	96.42	Tocris	3960	NVP 231	431.167	O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1	MVSSJPGNLQPWSW-UHFFFAOYSA-N	4096211.0		MVSSJPGNLQPWSW
BRD-K01573278-001-02-1	NVP-231	Preclinical	ceramidase inhibitor	CERK			0	97.09	MedChemEx	HY-13945	NVP 231	431.167	O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1	MVSSJPGNLQPWSW-UHFFFAOYSA-N	4096211.0		MVSSJPGNLQPWSW
BRD-K28132190-001-02-0	NVS-PAK1-1	Preclinical	p21 activated kinase inhibitor	PAK1			0	99.3	MedChemEx	HY-100519	NVS-PAK1-1	479.17	CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|	OINGHOPGNMYCAB-INIZCTEOSA-N	137125241.0		OINGHOPGNMYCAB
BRD-K46133855-304-04-9	NXY-059	Phase 3	free radical scavenger				0	66.5	MedChemEx	HY-13244	Disufenton sodium	337.029	CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	OVTCHWSLKGENKP-GHXNOFRVSA-N	6913176.0		OVTCHWSLKGENKP
BRD-K46133855-304-02-0	NXY-059	Phase 3	free radical scavenger				0	90.62	Selleck	S6002	NXY-059	337.029	CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	OVTCHWSLKGENKP-GHXNOFRVSA-N	6913176.0		OVTCHWSLKGENKP
BRD-K46133855-304-03-8	NXY-059	Phase 3	free radical scavenger				0	91.94	Tocris	3645	NXY 059	337.029	CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	OVTCHWSLKGENKP-GHXNOFRVSA-N	6913176.0		OVTCHWSLKGENKP
BRD-K21656326-001-01-4	nystatin	Launched	fungal ergosterol inhibitor		infectious disease	esophageal candidiasis|skin infections|yeast infection	0	61.91	Sigma	S______N1638	(1S,3R,4R,7R,9R,11R,15S,16S,17R,18S,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,4,7,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriacont;a-19,21,25,27,29,31-hexaene-36-carboxylic acid	925.503	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|	VQOXZBDYSJBXMA-MSHYPYPPSA-N		BRD-K82677637-001-01-0	VQOXZBDYSJBXMA
BRD-K21656326-001-02-2	nystatin	Launched	fungal ergosterol inhibitor		infectious disease	esophageal candidiasis|skin infections|yeast infection	0	0.0	MedChemEx	HY-17409	Nystatin	925.503	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|	VQOXZBDYSJBXMA-MSHYPYPPSA-N		BRD-K33243830-001-01-6	VQOXZBDYSJBXMA
BRD-K21656326-001-04-9	nystatin	Launched	fungal ergosterol inhibitor		infectious disease	esophageal candidiasis|skin infections|yeast infection	0	75.39	MedChemEx	HY-17409	Nystatin	925.503	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46,48,52,54,56,58|	VQOXZBDYSJBXMA-MSHYPYPPSA-N			VQOXZBDYSJBXMA
BRD-K41143549-003-02-4	N20C	Preclinical	glutamate receptor antagonist				0	95.35	Tocris	2213	N20C hydrochloride	268.158	NC(=O)CNCCC(c1ccccc1)c1ccccc1	BYGXICRJQZKUPA-UHFFFAOYSA-N	6603827.0		BYGXICRJQZKUPA
BRD-K41143549-003-06-9	N20C	Preclinical	glutamate receptor antagonist				0	86.26	Tocris	2213	N20C hydrochloride	268.158	NC(=O)CNCCC(c1ccccc1)c1ccccc1	BYGXICRJQZKUPA-UHFFFAOYSA-N	6603827.0		BYGXICRJQZKUPA
BRD-K60150510-001-16-9	N6-cyclopentyladenosine	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3|SLC29A1			0	96.85	Tocris	1702	N6-Cyclopentyladenosine	335.159	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	SQMWSBKSHWARHU-SDBHATRESA-N	657378.0		SQMWSBKSHWARHU
BRD-K60150510-001-15-6	N6-cyclopentyladenosine	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3|SLC29A1			0	97.75	Tocris	1702	N6-Cyclopentyladenosine	335.159	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	SQMWSBKSHWARHU-SDBHATRESA-N	657378.0		SQMWSBKSHWARHU
BRD-K81807412-001-11-9	N6-methyladenosine	Preclinical					0	96.03	MedChemEx	HY-N0086	N6-Methyladenosine	281.112	CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	VQAYFKKCNSOZKM-IOSLPCCCSA-N	102175.0		VQAYFKKCNSOZKM
BRD-K81807412-001-10-6	N6-methyladenosine	Preclinical					0	97.73	Selleck	S3190	N6-methyladenosine (m6A)	281.112	CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	VQAYFKKCNSOZKM-IOSLPCCCSA-N	102175.0		VQAYFKKCNSOZKM
BRD-K82522873-001-01-1	N6022	Phase 1/Phase 2	alcohol dehydrogenase inhibitor	ADH5			0	96.42	MedChemEx	HY-14984	N6022	414.169	Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O	YVPGZQLRPAGKLA-UHFFFAOYSA-N	44623946.0		YVPGZQLRPAGKLA
BRD-K82522873-001-02-9	N6022	Phase 1/Phase 2	alcohol dehydrogenase inhibitor	ADH5			0	98.67	MedChemEx	HY-14984	N6022	414.169	Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O	YVPGZQLRPAGKLA-UHFFFAOYSA-N	44623946.0		YVPGZQLRPAGKLA
BRD-K63247785-001-01-5	O-acetyl-L-serine	Preclinical		PTGS1			0	96.8	Astatech	50434	(2S)-3-(acetyloxy)-2-aminopropanoic acid	147.053	CC(=O)OC[C@H](N)C(O)=O	VZXPDPZARILFQX-BYPYZUCNSA-N	99478.0		VZXPDPZARILFQX
BRD-K36998189-001-03-5	o-mercapto-benzoic-acid	Preclinical					0	97.04	Enamine	Z1270312072	6-thioxo-1,3-cyclohexadiene-1-carboxylic acid	154.009	OC(=O)c1ccccc1S	NBOMNTLFRHMDEZ-UHFFFAOYSA-N	5443.0		NBOMNTLFRHMDEZ
BRD-K18316707-001-03-5	O-1918	Preclinical	cannabinoid receptor antagonist				0	95.81	Tocris	2288	O-1918	286.193	COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|	ICHJMVMWPKLUKT-JKSUJKDBSA-N	40469923.0		ICHJMVMWPKLUKT
BRD-K18316707-001-02-7	O-1918	Preclinical	cannabinoid receptor antagonist				0	78.26	Tocris	2288	O-1918	286.193	COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|	ICHJMVMWPKLUKT-JKSUJKDBSA-N	40469923.0		ICHJMVMWPKLUKT
BRD-K18316707-001-04-9	O-1918	Preclinical	cannabinoid receptor antagonist				0	97.55	Tocris	2288	O-1918	286.193	COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|	ICHJMVMWPKLUKT-JKSUJKDBSA-N	40469923.0		ICHJMVMWPKLUKT
BRD-K46384212-001-03-7	o-3M3FBS	Preclinical	phospholipase activator				0	98.61	Tocris	1942	o-3M3FBS	343.085	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	SKJJIFRWCCSXGL-UHFFFAOYSA-N	770820.0		SKJJIFRWCCSXGL
BRD-K46384212-001-04-9	o-3M3FBS	Preclinical	phospholipase activator				0	96.89	Tocris	1942	o-3M3FBS	343.085	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	SKJJIFRWCCSXGL-UHFFFAOYSA-N	770820.0		SKJJIFRWCCSXGL
BRD-K46384212-001-02-9	o-3M3FBS	Preclinical	phospholipase activator				0	98.98	Tocris	1942	o-3M3FBS	343.085	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	SKJJIFRWCCSXGL-UHFFFAOYSA-N	770820.0		SKJJIFRWCCSXGL
BRD-K00003113-001-01-9	O-304	Preclinical	AMPK activator				0	95.47	MedChemEx	HY-112233	O-304	378.995	Clc1ccc(Cn2sc(NC(=O)c3ccc(Cl)cc3)nc2=O)cc1	WEDWLYRQKUTOAX-UHFFFAOYSA-N	50923806.0		WEDWLYRQKUTOAX
BRD-K10878147-001-04-9	OAC1	Preclinical	Oct activator				0	94.7	Tocris	4887	OAC-1	237.09	O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	HWJRIFZDXJKJJN-UHFFFAOYSA-N	789882.0		HWJRIFZDXJKJJN
BRD-K10878147-001-03-0	OAC1	Preclinical	Oct activator				0	94.83	Tocris	4887	OAC-1	237.09	O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	HWJRIFZDXJKJJN-UHFFFAOYSA-N	789882.0		HWJRIFZDXJKJJN
BRD-K10878147-001-02-2	OAC1	Preclinical	Oct activator				0	94.71	Selleck	S7217	OAC1	237.09	O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	HWJRIFZDXJKJJN-UHFFFAOYSA-N	789882.0		HWJRIFZDXJKJJN
BRD-K18305454-001-07-4	OAC2	Preclinical	Oct activator	POU5F1			0	97.66	MedChemEx	HY-12884	OAC2	236.095	O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1	JCAFGYWSIWYMOX-UHFFFAOYSA-N	2814138.0		JCAFGYWSIWYMOX
BRD-K15600710-066-04-1	obatoclax	Phase 3	BCL inhibitor	BCL2			0	75.57	Selleck	S1057	Obatoclax Mesylate (GX15-070)	317.153	COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|	RFTSSZJZXOSICM-GRSHGNNSSA-N			RFTSSZJZXOSICM
BRD-K15600710-066-05-8	obatoclax	Phase 3	BCL inhibitor	BCL2			0	96.5	Selleck	S1057	Obatoclax mesylate (GX15-070)	317.153	COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4,t:2|	RFTSSZJZXOSICM-GRSHGNNSSA-N			RFTSSZJZXOSICM
BRD-A75838038-001-01-4	obeticholic-acid	Launched	FXR agonist	NR1H4	gastroenterology	primary biliary cholangitis	0	67.62	Selleck	S7660	Obeticholic Acid	420.324	CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2,&2:3,&3:5,&4:6,&5:9,&6:10,&7:17,&8:21,&9:22,&10:26,&11:29,r|	ZXERDUOLZKYMJM-XNNZWSTBSA-N			ZXERDUOLZKYMJM
BRD-K33588785-300-02-9	obidoxime	Launched	cholinesterase reactivator	ACHE	critical care|neurology/psychiatry	poison antidote|nerve gas poisoning	0	94.9	Vitas-M	STL371145	1,1'-(oxybis(methylene))bis(4-(nitrosomethyl)pyridin-1-ium)	288.122	O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1	HIGRLDNHDGYWQJ-UHFFFAOYSA-P	8251.0		HIGRLDNHDGYWQJ
BRD-K33588785-001-01-9	obidoxime	Launched	cholinesterase reactivator	ACHE	critical care|neurology/psychiatry	poison antidote|nerve gas poisoning	0	100.0	Vitas-M	STL371145		288.122	O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1	HIGRLDNHDGYWQJ-UHFFFAOYSA-P	8251.0		HIGRLDNHDGYWQJ
BRD-K00003399-001-01-9	ocaperidone	Preclinical	serotonin receptor antagonist				0	95.09	MedChemEx	HY-101094	Ocaperidone	420.196	Cc1cccn2c1nc(C)c(CCN1CCC(CC1)c1noc3cc(F)ccc13)c2=O	ZZQNEJILGNNOEP-UHFFFAOYSA-N	71351.0		ZZQNEJILGNNOEP
BRD-K92524032-001-02-1	ochromycinone	Phase 1	STAT inhibitor	STAT3			0	0.0	AnalytiCon	NP-003940		306.089	C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21	ZAWXOCUFQSQDJS-VIFPVBQESA-N	11808929.0		ZAWXOCUFQSQDJS
BRD-K92581468-001-01-6	ocinaplon	Phase 3	GABA receptor modulator	GABRA1|GABRA2|GABRA3|GABRA5			0	99.66	Tocris	4410	2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	301.096	O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1	OQJFBUOFGHPMSR-UHFFFAOYSA-N	216456.0		OQJFBUOFGHPMSR
BRD-K92581468-001-02-9	ocinaplon	Phase 3	GABA receptor modulator	GABRA1|GABRA2|GABRA3|GABRA5			0		Tocris	4410	ocinaplon	301.096	O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1	OQJFBUOFGHPMSR-UHFFFAOYSA-N	216456.0		OQJFBUOFGHPMSR
BRD-K22097830-001-01-9	OCO-1112	Phase 2	cholesterol inhibitor				0	98.74	Enamine	Z1149820700		327.147	CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O	ODLDHXPJRGNTPC-UHFFFAOYSA-N	3081027.0		ODLDHXPJRGNTPC
BRD-K20501889-001-02-0	octadecan-1-ol	Preclinical					1	0.0	Ark	AK114210	Octadecan-1-ol	270.292	CCCCCCCCCCCCCCCCCCO	GLDOVTGHNKAZLK-UHFFFAOYSA-N	8221.0		GLDOVTGHNKAZLK
BRD-K73201113-001-01-3	octamethyltrisiloxane	Preclinical					0	0.0	Sigma	MFCD00008264	1,1,1,3,3,5,5,5-octamethyltrisiloxane	236.108	C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C	CXQXSVUQTKDNFP-UHFFFAOYSA-N	24705.0		CXQXSVUQTKDNFP
BRD-K04568635-300-01-4	octenidine	Launched	membrane integrity inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	99.2	TCI	O0388		550.497	CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1	ZVXNYZWXUADSRV-UHFFFAOYSA-N	51167.0		ZVXNYZWXUADSRV
BRD-K00003688-001-01-9	octinoxate	Launched			dermatology	sunscreen lotion	0	97.22	MedChemEx	HY-B1234	Octinoxate	290.188	CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1 |&1:4|	YBGZDTIWKVFICR-NRMKIYEFSA-N	6993341.0		YBGZDTIWKVFICR
BRD-K00003664-001-01-9	octisalate	Launched			dermatology	sunscreen lotion	0	98.14	MedChemEx	HY-B0929	Octisalate	250.157	CCCC[C@@H](CC)COC(=O)c1ccccc1O |&1:4|	FMRHJJZUHUTGKE-GFCCVEGCSA-N	1550885.0		FMRHJJZUHUTGKE
BRD-K00003605-001-01-9	octocrylene	Launched			dermatology	sunscreen lotion	0	96.3	MedChemEx	HY-A0087	Octocrylene	361.204	CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1 |&1:4|	FMJSMJQBSVNSBF-LJQANCHMSA-N	40424580.0		FMJSMJQBSVNSBF
BRD-A37873789-001-01-9	octodrine	Preclinical	antitumor agent				0	21.54	MicroSource	1505447	OCTODRINE	129.152	CC(C)CCC[C@@H](C)N |&1:6,r|	QNIVIMYXGGFTAK-MRVPVSSYSA-N	6989209.0		QNIVIMYXGGFTAK
BRD-A37873789-003-02-9	octodrine	Preclinical	antitumor agent				0	100.0	MedChemEx	HY-B1233A	Octodrine (hydrochloride)	129.152	CC(C)CCC[C@@H](C)N |&1:6,r|	QNIVIMYXGGFTAK-MRVPVSSYSA-N	6989209.0		QNIVIMYXGGFTAK
BRD-A14240607-003-26-1	octopamine	Preclinical	trace amine associated receptor agonist	F10|TAAR1			0	100.0	MicroSource	1500639	OCTOPAMINE HYDROCHLORIDE	153.079	NCC(O)c1ccc(O)cc1	QHGUCRYDKWKLMG-UHFFFAOYSA-N	657354.0		QHGUCRYDKWKLMG
BRD-A14240607-003-25-3	octopamine	Preclinical	trace amine associated receptor agonist	F10|TAAR1			0	0.0	Tocris	2242	Octopamine hydrochloride	153.079	NCC(O)c1ccc(O)cc1	QHGUCRYDKWKLMG-UHFFFAOYSA-N	657354.0		QHGUCRYDKWKLMG
BRD-A14240607-003-27-9	octopamine	Preclinical	trace amine associated receptor agonist	F10|TAAR1			0	99.2	Selleck	S3188	(+,-)-Octopamine HCl	153.079	NCC(O)c1ccc(O)cc1	QHGUCRYDKWKLMG-UHFFFAOYSA-N	657354.0		QHGUCRYDKWKLMG
BRD-A14240607-003-24-6	octopamine	Preclinical	trace amine associated receptor agonist	F10|TAAR1			0	0.0	Selleck	S3188	(+,-)-Octopamine HCl	153.079	NCC(O)c1ccc(O)cc1	QHGUCRYDKWKLMG-UHFFFAOYSA-N	657354.0		QHGUCRYDKWKLMG
BRD-A64173453-015-03-1	octreotide	Launched	somatostatin receptor agonist	SSTR2|SSTR3|SSTR5	gastroenterology|endocrinology|oncology	diarrhea|acromegaly|carcinoid tumors	0	91.0	MedChemEx	HY-17365	Octreotide (acetate)	1018.44	C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|	DEQANNDTNATYII-KWPKQMLXSA-N			DEQANNDTNATYII
BRD-A64173453-015-02-3	octreotide	Launched	somatostatin receptor agonist	SSTR2|SSTR3|SSTR5	gastroenterology|endocrinology|oncology	diarrhea|acromegaly|carcinoid tumors	0	80.2	MedChemEx	HY-17365	Octreotide (acetate)	1018.44	C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|	DEQANNDTNATYII-KWPKQMLXSA-N			DEQANNDTNATYII
BRD-A64173453-015-01-5	octreotide	Launched	somatostatin receptor agonist	SSTR2|SSTR3|SSTR5	gastroenterology|endocrinology|oncology	diarrhea|acromegaly|carcinoid tumors	0	49.51	MedChemEx	HY-17365	Octreotide (acetate)	1018.44	C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1,&2:3,&3:9,&4:14,&5:18,&6:30,&7:41,&8:55,&9:64,&10:65|	DEQANNDTNATYII-KWPKQMLXSA-N			DEQANNDTNATYII
BRD-K36463073-001-03-9	OC000459	Phase 2	CRTH receptor antagonist	PTGDR2			0	93.19	MedChemEx	HY-15342	OC000459	348.127	Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	FATGTHLOZSXOBC-UHFFFAOYSA-N	11462174.0		FATGTHLOZSXOBC
BRD-K36463073-001-01-3	OC000459	Phase 2	CRTH receptor antagonist	PTGDR2			0	21.45	Selleck	S2822	OC000459	348.127	Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	FATGTHLOZSXOBC-UHFFFAOYSA-N	11462174.0		FATGTHLOZSXOBC
BRD-K36463073-001-02-1	OC000459	Phase 2	CRTH receptor antagonist	PTGDR2			0	78.5	Selleck	S2822	OC000459	348.127	Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	FATGTHLOZSXOBC-UHFFFAOYSA-N	11462174.0		FATGTHLOZSXOBC
BRD-K22822991-001-03-9	odanacatib	Phase 3	cathepsin inhibitor	CTSK			0	97.5	MedChemEx	HY-10042	Odanacatib	525.171	CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	FWIVDMJALNEADT-SFTDATJTSA-N	10152654.0		FWIVDMJALNEADT
BRD-K22822991-001-02-3	odanacatib	Phase 3	cathepsin inhibitor	CTSK			0	98.17	Selleck	S1115	Odanacatib (MK-0822)	525.171	CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	FWIVDMJALNEADT-SFTDATJTSA-N	10152654.0		FWIVDMJALNEADT
BRD-K26015241-001-04-4	ODQ	Preclinical	guanylyl cyclase inhibitor	GUCY1A2|GUCY1A3|GUCY1B3			0	0.0	Tocris	880	ODQ	187.038	O=c1onc2cnc3ccccc3n12	LZMHWZHOZLVYDL-UHFFFAOYSA-N	1456.0		LZMHWZHOZLVYDL
BRD-K26015241-001-03-6	ODQ	Preclinical	guanylyl cyclase inhibitor	GUCY1A2|GUCY1A3|GUCY1B3			0	70.01	Tocris	880	ODQ	187.038	O=c1onc2cnc3ccccc3n12	LZMHWZHOZLVYDL-UHFFFAOYSA-N	1456.0		LZMHWZHOZLVYDL
BRD-K92658264-001-01-8	OF-1	Preclinical	bromodomain inhibitor	BRD1			0	86.25	Tocris	5289	OF 1	439.02	COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C	YUNQZQREIHWDQT-UHFFFAOYSA-N	35397514.0		YUNQZQREIHWDQT
BRD-K92658264-001-02-9	OF-1	Preclinical	bromodomain inhibitor	BRD1			0	95.56	Tocris	5289	OF 1	439.02	COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C	YUNQZQREIHWDQT-UHFFFAOYSA-N	35397514.0		YUNQZQREIHWDQT
BRD-K01826479-213-01-9	ofloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease|otolaryngology|gastroenterology|endocrinology	respiratory tract infections|sinusitis|skin infections|bone and joint infections|intra-abdominal infections|diarrhea|fever|urinary tract infections	0	98.67	MicroSource	1502044	OFLOXACIN	422.197	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1|	GSDSWSVVBLHKDQ-JTQLQIEISA-N	6956357.0		GSDSWSVVBLHKDQ
BRD-K26349472-001-02-1	OG-L002	Preclinical	histone lysine demethylase inhibitor	KDM1A			0	66.65	Selleck	S7237	OG-L002	225.115	N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	DSOJSZXQRJGBCW-CABCVRRESA-N	56639570.0	BRD-A46597779-001-01-5	DSOJSZXQRJGBCW
BRD-K26349472-001-01-3	OG-L002	Preclinical	histone lysine demethylase inhibitor	KDM1A			0	85.35	Selleck	S7237	OG-L002	225.115	N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	DSOJSZXQRJGBCW-CABCVRRESA-N	56639570.0		DSOJSZXQRJGBCW
BRD-K26349472-001-03-9	OG-L002	Preclinical	histone lysine demethylase inhibitor	KDM1A			0	91.37	Selleck	S7237	OG-L002	225.115	N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	DSOJSZXQRJGBCW-CABCVRRESA-N	56639570.0		DSOJSZXQRJGBCW
BRD-K00005341-001-01-9	ogerin	Preclinical	G protein-coupled receptor modulator				0	97.68	MedChemEx	HY-110279	Ogerin	307.143	Nc1nc(NCc2ccccc2)nc(n1)-c1ccccc1CO	MDGIEDNDSFMSLP-UHFFFAOYSA-N	56707820.0		MDGIEDNDSFMSLP
BRD-K92303087-001-01-6	oglemilast	Phase 2	phosphodiesterase inhibitor				0	96.52	MedChemEx	HY-15178	Oglemilast	514.992	CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1	OKFDRAHPFKMAJH-UHFFFAOYSA-N	11387409.0		OKFDRAHPFKMAJH
BRD-K92303087-001-02-9	oglemilast	Phase 2	phosphodiesterase inhibitor				0	93.68	MedChemEx	HY-15178	Oglemilast	514.992	CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1	OKFDRAHPFKMAJH-UHFFFAOYSA-N	11387409.0		OKFDRAHPFKMAJH
BRD-K00003164-001-01-9	oglufanide	Phase 2	VEGF antagonist				0	87.14	MedChemEx	HY-13718	Oglufanide	333.132	N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	LLEUXCDZPQOJMY-AAEUAGOBSA-N	100094.0		LLEUXCDZPQOJMY
BRD-K94083718-001-01-9	OICR-9429	Preclinical	WDR5/MLL interaction inhibitor	WDR5			0	93.82	Tocris	5267	OICR 9429	555.246	CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1	DJOVLOYCGXNVPI-UHFFFAOYSA-N	91623360.0		DJOVLOYCGXNVPI
BRD-K94083718-001-03-9	OICR-9429	Preclinical	WDR5/MLL interaction inhibitor	WDR5			0	95.2	Tocris	5267	OICR 9429	555.246	CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1	DJOVLOYCGXNVPI-UHFFFAOYSA-N	91623360.0		DJOVLOYCGXNVPI
BRD-K18895904-001-16-1	olanzapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	neurology/psychiatry	schizophrenia|bipolar disorder	0	92.16	MicroSource	1505024	OLANZAPINE	312.141	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|	KVWDHTXUZHCGIO-UHFFFAOYSA-N	135398745.0		KVWDHTXUZHCGIO
BRD-K18895904-001-19-5	olanzapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	neurology/psychiatry	schizophrenia|bipolar disorder	0	82.21	Tocris	4349	Olanzapine	312.141	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|	KVWDHTXUZHCGIO-UHFFFAOYSA-N	135398745.0		KVWDHTXUZHCGIO
BRD-K18895904-001-15-3	olanzapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	neurology/psychiatry	schizophrenia|bipolar disorder	0	86.41	Selleck	S2493	Olanzapine	312.141	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|	KVWDHTXUZHCGIO-UHFFFAOYSA-N	135398745.0		KVWDHTXUZHCGIO
BRD-K18895904-001-17-9	olanzapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	neurology/psychiatry	schizophrenia|bipolar disorder	0	95.27	Selleck	S2493	Olanzapine (Zyprexa)	312.141	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|	KVWDHTXUZHCGIO-UHFFFAOYSA-N	135398745.0		KVWDHTXUZHCGIO
BRD-K02113016-001-19-6	olaparib	Launched	PARP inhibitor	PARP1|PARP2	oncology	ovarian cancer	0	98.64	Selleck	S1060	Olaparib	434.175	Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1	FDLYAMZZIXQODN-UHFFFAOYSA-N	23725625.0		FDLYAMZZIXQODN
BRD-K02113016-001-15-4	olaparib	Launched	PARP inhibitor	PARP1|PARP2	oncology	ovarian cancer	0	96.94	Selleck	S1060	Olaparib (AZD2281, Ku-0059436)	434.175	Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1	FDLYAMZZIXQODN-UHFFFAOYSA-N	23725625.0		FDLYAMZZIXQODN
BRD-K95523387-001-10-9	OLDA	Preclinical	TRPV agonist	GPR119			0	86.22	Tocris	1641	OLDA	417.324	CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	QQBPLXNESPTPNU-KTKRTIGZSA-N	5282106.0		QQBPLXNESPTPNU
BRD-K95523387-001-09-6	OLDA	Preclinical	TRPV agonist	GPR119			0	96.21	Tocris	1641	OLDA	417.324	CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	QQBPLXNESPTPNU-KTKRTIGZSA-N	5282106.0		QQBPLXNESPTPNU
BRD-K06644925-001-03-0	oleamide	Preclinical	cannabinoid receptor agonist	HTR7|PLA2G2A			0	100.0	Tocris	878	Oleamide	281.272	CCCCCCCC\C=C/CCCCCCCC(N)=O	FATBGEAMYMYZAF-KTKRTIGZSA-N	5283387.0		FATBGEAMYMYZAF
BRD-K98006098-001-01-6	oleandrin	Phase 1	Na/K-ATPase inhibitor				0	94.85	MedChemEx	HY-13719	Oleandrin	576.33	CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|	JLPDBLFIVFSOCC-XYXFTTADSA-N	11541511.0		JLPDBLFIVFSOCC
BRD-K90647725-001-10-9	oleanolic-acid	Preclinical	G protein-coupled receptor agonist	GPBAR1			0	100.0	Tocris	6026	Oleanolic acid	456.36	CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|	MIJYXULNPSFWEK-GTOFXWBISA-N	10494.0		MIJYXULNPSFWEK
BRD-K90647725-001-07-3	oleanolic-acid	Preclinical	G protein-coupled receptor agonist	GPBAR1			0	90.67	Selleck	S2334	Oleanolic Acid (Caryophyllin)	456.36	CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|	MIJYXULNPSFWEK-GTOFXWBISA-N	10494.0	BRD-A00113255-001-02-6	MIJYXULNPSFWEK
BRD-K90647725-001-06-5	oleanolic-acid	Preclinical	G protein-coupled receptor agonist	GPBAR1			0	89.95	Selleck	S2334	Oleanolic Acid	456.36	CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|	MIJYXULNPSFWEK-GTOFXWBISA-N	10494.0	BRD-A65785035-001-01-2	MIJYXULNPSFWEK
BRD-K66956375-001-11-3	oleoylethanolamide	Preclinical	cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist	CNR1|GPR119|GPR55|PPARA			0	99.32	Tocris	1484	Oleylethanolamide	325.298	CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	BOWVQLFMWHZBEF-KTKRTIGZSA-N	5283454.0		BOWVQLFMWHZBEF
BRD-K18210059-001-01-8	olesoxime	Phase 2/Phase 3	apoptosis stimulant				0	0.0	MedChemEx	HY-14796	TRO 19622	399.35	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|	QNTASHOAVRSLMD-SIWSWZRQSA-N	9930827.0		QNTASHOAVRSLMD
BRD-K18210059-001-02-6	olesoxime	Phase 2/Phase 3	apoptosis stimulant				0	69.73	MedChemEx	HY-14796	TRO 19622	399.35	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|	QNTASHOAVRSLMD-SIWSWZRQSA-N	9930827.0	BRD-A33931310-001-01-7	QNTASHOAVRSLMD
BRD-A00842753-001-01-9	oleuropein	Phase 2	estrogen receptor agonist	GPER1			0	85.99	Selleck	S7867	Oleuropein	540.184	COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7,&2:9,&3:11,&4:14,&5:16,&6:18,&7:23,r,t:4|	RFWGABANNQMHMZ-JIBQERFGSA-N			RFWGABANNQMHMZ
BRD-K00003580-001-01-9	oligomycin-A	Preclinical	ATP synthase inhibitor|ATPase inhibitor	ATP5A1			0	93.31	MedChemEx	HY-16589	Oligomycin A	790.523	[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7,9,35|	MNULEGDCPYONBU-BGLGBHOCSA-N	133268482.0		MNULEGDCPYONBU
BRD-K83144676-001-09-5	olmesartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	95.2	Tocris	4616	Olmesartan	446.207	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	VTRAEEWXHOVJFV-UHFFFAOYSA-N	158781.0		VTRAEEWXHOVJFV
BRD-K83144676-001-08-7	olmesartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	95.02	MedChemEx	HY-17004	Olmesartan	446.207	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	VTRAEEWXHOVJFV-UHFFFAOYSA-N	158781.0		VTRAEEWXHOVJFV
BRD-K83144676-001-06-1	olmesartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	54.02	MicroSource	1505206	OLMESARTAN	446.207	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	VTRAEEWXHOVJFV-UHFFFAOYSA-N	158781.0		VTRAEEWXHOVJFV
BRD-K83144676-001-07-9	olmesartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	22.83	MedChemEx	HY-17004	Olmesartan	446.207	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	VTRAEEWXHOVJFV-UHFFFAOYSA-N	158781.0		VTRAEEWXHOVJFV
BRD-K78485176-001-07-8	olmesartan-medoxomil	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	95.9	MicroSource	1505205	OLMESARTAN MEDOXOMIL	558.223	CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	UQGKUQLKSCSZGY-UHFFFAOYSA-N	130881.0		UQGKUQLKSCSZGY
BRD-K78485176-001-09-4	olmesartan-medoxomil	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	88.44	Tocris	4620	Olmesartan medoxomil	558.223	CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	UQGKUQLKSCSZGY-UHFFFAOYSA-N	130881.0		UQGKUQLKSCSZGY
BRD-K78485176-001-06-0	olmesartan-medoxomil	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	95.49	Selleck	S1604	Olmesartan Medoxomil	558.223	CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	UQGKUQLKSCSZGY-UHFFFAOYSA-N	130881.0		UQGKUQLKSCSZGY
BRD-K78485176-001-10-9	olmesartan-medoxomil	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension	0	95.52	MedChemEx	HY-17005	Olmesartan (medoxomil)	558.223	CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	UQGKUQLKSCSZGY-UHFFFAOYSA-N	130881.0		UQGKUQLKSCSZGY
BRD-K60421517-001-02-2	olmutinib	Launched	Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor	BTK|EGFR	oncology	non-small cell lung cancer (NSCLC)	0	91.76	MedChemEx	HY-19730	Olmutinib	486.184	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	FDMQDKQUTRLUBU-UHFFFAOYSA-N	54758501.0		FDMQDKQUTRLUBU
BRD-K60421517-001-01-4	olmutinib	Launched	Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor	BTK|EGFR	oncology	non-small cell lung cancer (NSCLC)	0	82.69	MedChemEx	HY-19730	Olmutinib	486.184	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	FDMQDKQUTRLUBU-UHFFFAOYSA-N	54758501.0		FDMQDKQUTRLUBU
BRD-K00003151-001-01-9	olodanrigan	Phase 2	angiotensin antagonist				0	97.15	MedChemEx	HY-13106	Olodanrigan	507.205	COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1	GHBCIXGRCZIPNQ-MHZLTWQESA-N	9937291.0		GHBCIXGRCZIPNQ
BRD-K82731415-001-08-9	olomoucine	Preclinical	CDK inhibitor	CDK1|CDK2|CDK5|MAPK1			0	94.52	Tocris	1284	Olomoucine	298.154	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	GTVPOLSIJWJJNY-UHFFFAOYSA-N	4592.0		GTVPOLSIJWJJNY
BRD-K82731415-001-07-0	olomoucine	Preclinical	CDK inhibitor	CDK1|CDK2|CDK5|MAPK1			0	97.73	Tocris	1284	Olomoucine	298.154	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	GTVPOLSIJWJJNY-UHFFFAOYSA-N	4592.0		GTVPOLSIJWJJNY
BRD-K67637637-003-11-8	olopatadine	Launched	histamine receptor antagonist	HRH1|S100A1|S100A12|S100A13|S100A2|S100B	ophthalmology	conjunctivitis	0	93.94	Tocris	4241	Olopatadine hydrochloride	337.168	CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12	JBIMVDZLSHOPLA-LSCVHKIXSA-N	5281071.0		JBIMVDZLSHOPLA
BRD-K67637637-003-12-6	olopatadine	Launched	histamine receptor antagonist	HRH1|S100A1|S100A12|S100A13|S100A2|S100B	ophthalmology	conjunctivitis	0	98.6	Selleck	S2494	Olopatadine HCl	337.168	CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12	JBIMVDZLSHOPLA-LSCVHKIXSA-N	5281071.0	BRD-K06625472-003-01-6	JBIMVDZLSHOPLA
BRD-K20745393-003-01-0	olprinone	Launched	phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	0	99.86	MedChemEx	HY-14254	Olprinone (Hydrochloride)	250.085	Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N	JPAWFIIYTJQOKW-UHFFFAOYSA-N	4593.0		JPAWFIIYTJQOKW
BRD-K57853941-304-04-9	olsalazine	Launched	cyclooxygenase inhibitor	IFNG|TPMT	gastroenterology	ulcerative colitis	0	98.95	MedChemEx	HY-B0174	Olsalazine (Disodium)	302.054	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	QQBDLJCYGRGAKP-FOCLMDBBSA-N			QQBDLJCYGRGAKP
BRD-K57853941-304-03-3	olsalazine	Launched	cyclooxygenase inhibitor	IFNG|TPMT	gastroenterology	ulcerative colitis	0	98.16	MicroSource	1502389	OLSALAZINE SODIUM	302.054	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	QQBDLJCYGRGAKP-FOCLMDBBSA-N			QQBDLJCYGRGAKP
BRD-K57853941-304-02-5	olsalazine	Launched	cyclooxygenase inhibitor	IFNG|TPMT	gastroenterology	ulcerative colitis	0	98.41	Selleck	S4041	Olsalazine Sodium	302.054	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	QQBDLJCYGRGAKP-FOCLMDBBSA-N			QQBDLJCYGRGAKP
BRD-K86972824-001-01-4	oltipraz	Phase 3	nuclear factor erythroid derived|like (NRF2) activator	ANG			0	95.28	MicroSource	1502317	OLTIPRAZ	225.969	Cc1c(ssc1=S)-c1cnccn1	CKNAQFVBEHDJQV-UHFFFAOYSA-N	47318.0		CKNAQFVBEHDJQV
BRD-K86972824-001-02-2	oltipraz	Phase 3	nuclear factor erythroid derived|like (NRF2) activator	ANG			0	97.51	MicroSource	1502317	OLTIPRAZ	225.969	Cc1c(ssc1=S)-c1cnccn1	CKNAQFVBEHDJQV-UHFFFAOYSA-N	47318.0		CKNAQFVBEHDJQV
BRD-K00004611-001-01-9	olumacostat-glasaretil	Phase 3	acetyl-CoA carboxylase inhibitor				0	85.94	MedChemEx	HY-17641	Olumacostat glasaretil	481.304	CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(C)CC(=O)OCC	FYJLDICZGDFWKP-UHFFFAOYSA-N	89497391.0		FYJLDICZGDFWKP
BRD-K31560319-001-02-3	olvanil	Preclinical	TRPV agonist	CNR1|GPR119|TRPV1			0	90.23	Tocris	934	Olvanil	417.324	CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	OPZKBPQVWDSATI-KHPPLWFESA-N	5311093.0		OPZKBPQVWDSATI
BRD-K31560319-001-03-9	olvanil	Preclinical	TRPV agonist	CNR1|GPR119|TRPV1			0	91.96	Tocris	934	Olvanil	417.324	CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	OPZKBPQVWDSATI-KHPPLWFESA-N	5311093.0		OPZKBPQVWDSATI
BRD-K31560319-001-01-5	olvanil	Preclinical	TRPV agonist	CNR1|GPR119|TRPV1			0	94.57	Tocris	934	Olvanil	417.324	CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	OPZKBPQVWDSATI-KHPPLWFESA-N	5311093.0		OPZKBPQVWDSATI
BRD-K00003569-003-01-9	omadacycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	pneumonia	0	95.49	MedChemEx	HY-14865C	Omadacycline (hydrochloride)	556.29	[H][C@@]12Cc3c(cc(CNCC(C)(C)C)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:26,&2:19|	OVIWLBQFYMOVOF-NXSZOOMBSA-N			OVIWLBQFYMOVOF
BRD-K00003265-001-01-9	omapatrilat	Preclinical	metalloproteinase inhibitor	ACE|MME			0	53.07	MedChemEx	HY-18208	Omapatrilat	408.118	[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O	LVRLSYPNFFBYCZ-VGWMRTNUSA-N	656629.0		LVRLSYPNFFBYCZ
BRD-K14171291-001-01-4	omarigliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	85.29	MedChemEx	HY-15981	Omarigliptin	398.122	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	MKMPWKUAHLTIBJ-ISTRZQFTSA-N	46209133.0		MKMPWKUAHLTIBJ
BRD-K14171291-001-02-2	omarigliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	94.52	MedChemEx	HY-15981	Omarigliptin	398.122	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	MKMPWKUAHLTIBJ-ISTRZQFTSA-N	46209133.0		MKMPWKUAHLTIBJ
BRD-K14171291-001-03-9	omarigliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	89.75	MedChemEx	HY-15981	Omarigliptin	398.122	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	MKMPWKUAHLTIBJ-ISTRZQFTSA-N	46209133.0		MKMPWKUAHLTIBJ
BRD-K11072003-001-02-4	ombitasvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	96.54	MedChemEx	HY-13997	Ombitasvir	893.505	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1	PIDFDZJZLOTZTM-KHVQSSSXSA-N	54767916.0		PIDFDZJZLOTZTM
BRD-K11072003-001-01-6	ombitasvir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	56.95	MedChemEx	HY-13997	Ombitasvir	893.505	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1	PIDFDZJZLOTZTM-KHVQSSSXSA-N	54767916.0		PIDFDZJZLOTZTM
BRD-K00003267-003-01-9	ombrabulin	Phase 3	tubulin polymerization inhibitor				0	98.81	MedChemEx	HY-18256	Ombrabulin (hydrochloride)	402.179	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO	IXWNTLSTOZFSCM-YVACAVLKSA-N	6918405.0		IXWNTLSTOZFSCM
BRD-K48830578-001-02-9	OMDM-2	Preclinical	FAAH inhibitor	GPR119			0	89.2	Tocris	1797	OMDM-2	431.34	CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	ICDMLAQPOAVWNH-HAAQQRBASA-N	6604915.0		ICDMLAQPOAVWNH
BRD-K48830578-001-01-9	OMDM-2	Preclinical	FAAH inhibitor	GPR119			0	92.27	Tocris	1797	OMDM-2	431.34	CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	ICDMLAQPOAVWNH-HAAQQRBASA-N	6604915.0		ICDMLAQPOAVWNH
BRD-K36680103-001-01-6	omecamtiv-mecarbil	Phase 3	cardiac myosin activator	MYBPC3			0	94.66	Selleck	S2623	Omecamtiv mecarbil (CK-1827452)	401.186	COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	RFUBTTPMWSKEIW-UHFFFAOYSA-N	11689883.0		RFUBTTPMWSKEIW
BRD-K36680103-001-02-9	omecamtiv-mecarbil	Phase 3	cardiac myosin activator	MYBPC3			0	96.1	MedChemEx	HY-14233	Omecamtiv mecarbil	401.186	COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	RFUBTTPMWSKEIW-UHFFFAOYSA-N	11689883.0		RFUBTTPMWSKEIW
BRD-K53156781-001-01-4	omega-(4-iodophenyl)pentadecanoic-acid	Preclinical					0	13.69	Sigma	MFCD00040778	15-(4-iodophenyl)pentadecanoic acid	444.153	OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1	YAONEUNUMVOKNQ-UHFFFAOYSA-N	123810.0		YAONEUNUMVOKNQ
BRD-K31139048-001-02-4	omega-3-acid-esters	Launched	cholesterol inhibitor				0	0.0	MicroSource	1300030	OMEGA-3-ACID ESTERS (EPA shown)	330.256	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	SSQPWTVBQMWLSZ-AAQCHOMXSA-N	9831415.0		SSQPWTVBQMWLSZ
BRD-K31139048-001-03-2	omega-3-acid-esters	Launched	cholesterol inhibitor				0	71.9	MedChemEx	HY-B0747	Eicosapentaenoic acid (ethyl ester)	330.256	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	SSQPWTVBQMWLSZ-AAQCHOMXSA-N	9831415.0		SSQPWTVBQMWLSZ
BRD-K31139048-001-04-0	omega-3-acid-esters	Launched	cholesterol inhibitor				0	0.0	MedChemEx	HY-B0747	Eicosapentaenoic acid (ethyl ester)	330.256	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	SSQPWTVBQMWLSZ-AAQCHOMXSA-N	9831415.0		SSQPWTVBQMWLSZ
BRD-A55962179-001-23-9	omeprazole	Launched	ATPase inhibitor	ATP4A|CLCN2	gastroenterology	heartburn	0	99.02	MicroSource	1505693	OMEPRAZOLE	345.115	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	SUBDBMMJDZJVOS-DEOSSOPVSA-N	9568614.0		SUBDBMMJDZJVOS
BRD-A55962179-001-24-7	omeprazole	Launched	ATPase inhibitor	ATP4A|CLCN2	gastroenterology	heartburn	0	98.67	Selleck	S1389	Omeprazole (Prilosec)	345.115	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	SUBDBMMJDZJVOS-DEOSSOPVSA-N	9568614.0		SUBDBMMJDZJVOS
BRD-A55962179-001-22-1	omeprazole	Launched	ATPase inhibitor	ATP4A|CLCN2	gastroenterology	heartburn	0	99.07	Tocris	2583	Omeprazole	345.115	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	SUBDBMMJDZJVOS-DEOSSOPVSA-N	9568614.0		SUBDBMMJDZJVOS
BRD-A55962179-001-21-3	omeprazole	Launched	ATPase inhibitor	ATP4A|CLCN2	gastroenterology	heartburn	0	37.67	Selleck	S1389	Omeprazole	345.115	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	SUBDBMMJDZJVOS-DEOSSOPVSA-N	9568614.0		SUBDBMMJDZJVOS
BRD-A56892734-001-09-4	omeprazole-magnesium	Launched	proton pump inhibitor	ATP4A|ATP4B	gastroenterology	gastroesophageal reflux disease (GERD)|heartburn	0	98.99	Vitas-M	STL455071	magnesium 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide	712.199	COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	KWORUUGOSLYAGD-YPPDDXJESA-N	9601083.0		KWORUUGOSLYAGD
BRD-K69035426-001-01-3	omeprazole-sulfide	Phase 1	ATPase inhibitor				0	92.79	AKSci	V1823		329.12	COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1	XURCIPRUUASYLR-UHFFFAOYSA-N	155794.0		XURCIPRUUASYLR
BRD-K00003212-001-01-9	omtriptolide	Preclinical	ERK1 and ERK2 phosphorylation inhibitor				0	93.75	MedChemEx	HY-16363	Omtriptolide	460.173	[H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)CCC(O)=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C |c:30|	HROMYAWHLUOUPY-AHCCQAQQSA-N	6918522.0		HROMYAWHLUOUPY
BRD-K55790047-001-02-9	ON-01500	Preclinical	apoptosis stimulant				0	93.86	MedChemEx	HY-78883	ON 01500	393.125	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1	KUTAVMCJCVADGZ-BQYQJAHWSA-N	11486204.0		KUTAVMCJCVADGZ
BRD-K55790047-001-01-8	ON-01500	Preclinical	apoptosis stimulant				0	74.35	Enamine	Z374851066		393.125	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1	KUTAVMCJCVADGZ-BQYQJAHWSA-N	11486204.0		KUTAVMCJCVADGZ
BRD-K43449605-001-01-0	oncrasin-1	Preclinical	apoptosis stimulant				0	99.67	Tocris	3427	Oncrasin 1	269.061	Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	ZDRQMXCSSAPUMM-UHFFFAOYSA-N	872445.0		ZDRQMXCSSAPUMM
BRD-K43449605-001-02-8	oncrasin-1	Preclinical	apoptosis stimulant				0	95.01	EMDBio	496265	Oncrasin-1	269.061	Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	InChI=1S/C16H12ClNO/c17-14-7-5-12(6-8-14)9-18-10-13(11-19)15-3-1-2-4-16(15)18/h1-8,10-11H,9H2	872445.0		ZDRQMXCSSAPUMM
BRD-K58529924-001-02-3	ONC201	Phase 2	AKT inhibitor|MAP kinase inhibitor	TNFSF10			0	98.82	Selleck	S7963	TIC10	386.211	Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|	VLULRUCCHYVXOH-UHFFFAOYSA-N	73777259.0		VLULRUCCHYVXOH
BRD-K58529924-001-01-5	ONC201	Phase 2	AKT inhibitor|MAP kinase inhibitor	TNFSF10			0	96.29	Cayman	16109	7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one	386.211	Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10,16|	VLULRUCCHYVXOH-UHFFFAOYSA-N	73777259.0		VLULRUCCHYVXOH
BRD-K01826546-001-06-9	ondansetron	Launched	serotonin receptor antagonist	HTR3A|HTR3B	gastroenterology	nausea|vomiting	0	99.41	MicroSource	1502501	ONDANSETRON	293.153	Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|	FELGMEQIXOGIFQ-CYBMUJFWSA-N	667538.0		FELGMEQIXOGIFQ
BRD-K01826546-001-05-9	ondansetron	Launched	serotonin receptor antagonist	HTR3A|HTR3B	gastroenterology	nausea|vomiting	0	97.89	Selleck	S1996	Ondansetron (Zofran)	293.153	Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|	FELGMEQIXOGIFQ-CYBMUJFWSA-N	667538.0		FELGMEQIXOGIFQ
BRD-A80567330-001-01-7	ONO-AE3-208	Preclinical	prostanoid receptor antagonist	PTGER4			0	96.3	Tocris	3565	ONO AE3 208	404.154	C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|	MTDIMKNAJUQTIO-OAHLLOKOSA-N	92978378.0		MTDIMKNAJUQTIO
BRD-A80567330-001-02-9	ONO-AE3-208	Preclinical	prostanoid receptor antagonist	PTGER4			0	96.7	Tocris	3565	ONO AE3 208	404.154	C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1,r|	MTDIMKNAJUQTIO-OAHLLOKOSA-N	92978378.0		MTDIMKNAJUQTIO
BRD-K00003197-001-02-9	ONO-4059	Phase 1	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	97.35	MedChemEx	HY-15771	Tirabrutinib	454.175	CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O	SEJLPXCPMNSRAM-GOSISDBHSA-N	54755438.0		SEJLPXCPMNSRAM
BRD-K00003197-003-01-9	ONO-4059	Phase 1	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	90.93	MedChemEx	HY-15771A	Tirabrutinib (hydrochloride)	454.175	CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O	SEJLPXCPMNSRAM-GOSISDBHSA-N	54755438.0		SEJLPXCPMNSRAM
BRD-K58894520-001-01-1	ONO-4817	Phase 1	matrix metalloprotease inhibitor	MMP8			0	97.35	Sigma	MFCD09971106	N-[(1S,3S)-1-[(ethoxymethoxy)methyl]-4-(hydroxyamino)-3-methyl-4-oxobutyl]-4-phenoxybenzamide	416.195	CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1	HDWWQELUBWGQGA-WMZOPIPTSA-N	9888141.0		HDWWQELUBWGQGA
BRD-K76725781-001-01-9	ONO-8130	Preclinical	prostanoid receptor antagonist	PTGER1			0	92.0	Tocris	5406	ONO 8130	500.144	CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1	IOXMDBQCUCDLAF-UHFFFAOYSA-N	9827317.0		IOXMDBQCUCDLAF
BRD-K76725781-001-02-9	ONO-8130	Preclinical	prostanoid receptor antagonist	PTGER1			0	97.38	Tocris	5406	ONO 8130	500.144	CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1	IOXMDBQCUCDLAF-UHFFFAOYSA-N	9827317.0		IOXMDBQCUCDLAF
BRD-K00003557-001-01-9	ONX-0914	Preclinical	proteasome inhibitor				0	95.31	MedChemEx	HY-13207	ONX-0914	580.29	COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1	WQAVPPWWLLVGFK-VTNASVEKSA-N	23642227.0		WQAVPPWWLLVGFK
BRD-K88554883-001-01-6	ON123300	Preclinical	CDK inhibitor	CDK4|NUAK1|PDGFRB			0	82.31	MedChemEx	HY-12624	ON123300	429.228	CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1	VADOZMZXXRBXNY-UHFFFAOYSA-N	56649281.0		VADOZMZXXRBXNY
BRD-K88554883-001-03-2	ON123300	Preclinical	CDK inhibitor	CDK4|NUAK1|PDGFRB			0	91.24	MedChemEx	HY-12624	ON123300	429.228	CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1	VADOZMZXXRBXNY-UHFFFAOYSA-N	56649281.0		VADOZMZXXRBXNY
BRD-K00004708-001-01-9	OP-0595	Preclinical	beta lactamase inhibitor				0	77.8	AMS	L22071	OP-0595	324.074	NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	RSBPYSTVZQAADE-RQJHMYQMSA-N	73386748.0		RSBPYSTVZQAADE
BRD-K19426040-001-02-9	OPC-21268	Phase 1	vasopressin receptor antagonist	AVPR1A|AVPR2|OXTR			0	93.73	Tocris	3924	OPC 21268	449.231	CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12	KSNUCNRMDYJBKT-UHFFFAOYSA-N	114904.0		KSNUCNRMDYJBKT
BRD-K19426040-001-01-1	OPC-21268	Phase 1	vasopressin receptor antagonist	AVPR1A|AVPR2|OXTR			0	96.93	Sigma	MFCD00903893	N-(3-(4-(4-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)piperidine-1-carbonyl)phenoxy)propyl)acetamide	449.231	CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12	KSNUCNRMDYJBKT-UHFFFAOYSA-N	114904.0		KSNUCNRMDYJBKT
BRD-K66192203-001-01-4	opicapone	Phase 3	catechol O methyltransferase inhibitor	COMT			0	67.45	MedChemEx	HY-14896	Opicapone	411.998	Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O	ASOADIZOVZTJSR-UHFFFAOYSA-N	135565903.0		ASOADIZOVZTJSR
BRD-K66192203-001-02-2	opicapone	Phase 3	catechol O methyltransferase inhibitor	COMT			0	94.71	MedChemEx	HY-14896	Opicapone	411.998	Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O	ASOADIZOVZTJSR-UHFFFAOYSA-N	135565903.0		ASOADIZOVZTJSR
BRD-K43786866-300-02-3	opipramol	Launched	sigma receptor agonist		neurology/psychiatry	generalized anxiety disorder (GAD)	0	97.22	Prestwick	Prestw-1456	Opipramol dihydrochloride	363.231	OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|	YNZFUWZUGRBMHL-UHFFFAOYSA-N	9417.0		YNZFUWZUGRBMHL
BRD-K91438851-001-02-9	oprozomib	Phase 1/Phase 2	proteasome inhibitor				0	93.83	MedChemEx	HY-12113	Oprozomib	532.199	COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1	SWZXEVABPLUDIO-WSZYKNRRSA-N	25067547.0		SWZXEVABPLUDIO
BRD-K18602506-001-09-9	OR-486	Preclinical	catechol O methyltransferase inhibitor	COMT			0	95.46	Tocris	483	OR-486	200.007	Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O	VDCDWNDTNSWDFJ-UHFFFAOYSA-N	3870203.0		VDCDWNDTNSWDFJ
BRD-K18602506-001-08-0	OR-486	Preclinical	catechol O methyltransferase inhibitor	COMT			0	0.0	Tocris	483	OR-486	200.007	Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O	VDCDWNDTNSWDFJ-UHFFFAOYSA-N	3870203.0		VDCDWNDTNSWDFJ
BRD-K55966568-001-10-4	orantinib	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB			0	90.37	Tocris	3335	SU 6668	310.132	Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	5329099.0		NHFDRBXTEDBWCZ
BRD-K55966568-001-09-6	orantinib	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB			0	92.22	Selleck	S1470	TSU-68	310.132	Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	5329099.0		NHFDRBXTEDBWCZ
BRD-K55966568-001-06-2	orantinib	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB			0	85.13	Tocris	3335	SU 6668	310.132	Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	5329099.0		NHFDRBXTEDBWCZ
BRD-K55966568-001-05-4	orantinib	Phase 3	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB			0	87.59	Selleck	S1470	TSU-68 (SU6668, Orantinib)	310.132	Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	NHFDRBXTEDBWCZ-ZROIWOOFSA-N	5329099.0		NHFDRBXTEDBWCZ
BRD-K63001556-001-11-9	orbifloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	0	94.58	MedChemEx	HY-B0915	Orbifloxacin	395.146	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	QIPQASLPWJVQMH-DTORHVGOSA-N	7061800.0		QIPQASLPWJVQMH
BRD-K63001556-001-08-8	orbifloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	0	94.85	MicroSource	1503711	ORBIFLOXACIN	395.146	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	QIPQASLPWJVQMH-DTORHVGOSA-N	7061800.0		QIPQASLPWJVQMH
BRD-K63001556-001-10-4	orbifloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	0	94.27	Selleck	S4150	Orbifloxacin	395.146	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	QIPQASLPWJVQMH-DTORHVGOSA-N	7061800.0	BRD-K68153448-001-01-9	QIPQASLPWJVQMH
BRD-K63001556-001-09-6	orbifloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	urinary tract infections	0	99.48	Selleck	S4150	Orbifloxacin	395.146	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	QIPQASLPWJVQMH-DTORHVGOSA-N	7061800.0		QIPQASLPWJVQMH
BRD-K67068943-001-01-0	ORE1001	Phase 1/Phase 2	angiotensin converting enzyme inhibitor	ACE2			0	94.22	EMDBio	530616-2MG	ACE2 Inhibitor, MLN-4760	427.107	CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O	NTCCRGGIJNDEAB-IRXDYDNUSA-N	448281.0		NTCCRGGIJNDEAB
BRD-K07409305-001-01-1	ORG-12962	Phase 2	serotonin receptor agonist	HTR2A|HTR2B|HTR2C			0	91.07	Key	KD-0713	1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]piperazine	265.059	FC(F)(F)c1ccc(nc1Cl)N1CCNCC1	QZYYPQAYSFBKPW-UHFFFAOYSA-N	9796408.0		QZYYPQAYSFBKPW
BRD-K32853922-003-02-9	ORG-25543	Preclinical	glycine transporter inhibitor	GLRB|SLC6A5			0	97.16	Tocris	4782	Org 25543 hydrochloride	412.236	COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C	ZCYOBMASPXQBSZ-UHFFFAOYSA-N	5311287.0		ZCYOBMASPXQBSZ
BRD-K32853922-003-01-8	ORG-25543	Preclinical	glycine transporter inhibitor	GLRB|SLC6A5			0	97.69	Tocris	4782	Org 25543 hydrochloride	412.236	COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C	ZCYOBMASPXQBSZ-UHFFFAOYSA-N	5311287.0		ZCYOBMASPXQBSZ
BRD-K40002998-001-01-5	ORG-26576	Phase 2	glutamate receptor modulator				0	98.64	AMS	A000267767	(9aS)-8,9,9a,10-tetrahydro-5H,7H-pyrido[3,2-f]pyrrolo[2,1-c][1,4]oxazepin-5-one	204.09	O=C1N2CCC[C@H]2COc2ncccc12	FIKUEZUFASUKAH-QMMMGPOBSA-N	13584912.0		FIKUEZUFASUKAH
BRD-K57597776-001-01-2	ORG-27569	Preclinical	cannabinoid receptor modulator	CNR1			0	91.23	Selleck	S1534	Org 27569	409.192	CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	AHFZDNYNXFMRFQ-UHFFFAOYSA-N	44828492.0		AHFZDNYNXFMRFQ
BRD-K57597776-001-02-9	ORG-27569	Preclinical	cannabinoid receptor modulator	CNR1			0	95.82	Tocris	2957	Org 27569	409.192	CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	AHFZDNYNXFMRFQ-UHFFFAOYSA-N	44828492.0		AHFZDNYNXFMRFQ
BRD-K41434598-003-01-9	ORG-9768	Phase 1	adrenergic receptor antagonist	ADRA2A			0	93.42	Enamine	EN300-124569		161.12	CC1(CN)Cc2ccccc2C1	JOLKQWPKJFRPOU-UHFFFAOYSA-N	22152353.0		JOLKQWPKJFRPOU
BRD-K00003710-001-01-9	oridonin	Preclinical	BCL inhibitor	BCL2			0	84.29	MedChemEx	HY-N0004	Oridonin	364.189	[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O	SDHTXBWLVGWJFT-XKCURVIJSA-N	5321010.0		SDHTXBWLVGWJFT
BRD-K00003704-316-01-9	oritavancin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	skin infections	0	92.78	MedChemEx	HY-B1831A	Oritavancin (diphosphate)	1790.564	[H][C@@]1(C[C@](C)(NCc2ccc(cc2)-c2ccc(Cl)cc2)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@]1([H])C[C@](C)(N)[C@@H](O)[C@H](C)O1)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	VHFGEBVPHAGQPI-LXKZPTCJSA-N	16136912.0		VHFGEBVPHAGQPI
BRD-K63343048-001-13-0	orlistat	Launched	lipase inhibitor	CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP	endocrinology	weight-loss aid	0	100.0	Tocris	3540	Orlistat	495.392	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	AHLBNYSZXLDEJQ-FWEHEUNISA-N	3034010.0		AHLBNYSZXLDEJQ
BRD-K63343048-001-15-5	orlistat	Launched	lipase inhibitor	CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP	endocrinology	weight-loss aid	0	99.2	Selleck	S1629	ORLISTAT	495.392	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	AHLBNYSZXLDEJQ-FWEHEUNISA-N	3034010.0		AHLBNYSZXLDEJQ
BRD-K63343048-001-17-9	orlistat	Launched	lipase inhibitor	CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP	endocrinology	weight-loss aid	0	100.0	Tocris	3540	Orlistat	495.392	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	AHLBNYSZXLDEJQ-FWEHEUNISA-N	3034010.0		AHLBNYSZXLDEJQ
BRD-K63343048-001-12-2	orlistat	Launched	lipase inhibitor	CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP	endocrinology	weight-loss aid	0	100.0	Selleck	S1629	Orlistat	495.392	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	AHLBNYSZXLDEJQ-FWEHEUNISA-N	3034010.0		AHLBNYSZXLDEJQ
BRD-K00004639-001-01-9	ormeloxifene	Launched	selective estrogen receptor modulator (SERM)		endocrinology	contraceptive	0	81.67	Sigma	SML2237	1-(2-{4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-chromen-4-yl]phenoxy}ethyl)pyrrolidine	457.262	COc1ccc2[C@H]([C@H](c3ccccc3)C(C)(C)Oc2c1)c1ccc(OCCN2CCCC2)cc1	XZEUAXYWNKYKPL-WDYNHAJCSA-N	35805.0		XZEUAXYWNKYKPL
BRD-A42759514-001-20-5	ornidazole	Launched	antiprotozoal agent		infectious disease	protozoan infection	0	91.45	MicroSource	1505981	ORNIDAZOLE	219.041	Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|	IPWKIXLWTCNBKN-LURJTMIESA-N	688540.0		IPWKIXLWTCNBKN
BRD-A42759514-001-23-9	ornidazole	Launched	antiprotozoal agent		infectious disease	protozoan infection	0	90.99	MedChemEx	HY-B0508	Ornidazole	219.041	Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|	IPWKIXLWTCNBKN-LURJTMIESA-N	688540.0		IPWKIXLWTCNBKN
BRD-A42759514-001-21-3	ornidazole	Launched	antiprotozoal agent		infectious disease	protozoan infection	0	92.96	Selleck	S3121	Ornidazole	219.041	Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|	IPWKIXLWTCNBKN-LURJTMIESA-N	688540.0		IPWKIXLWTCNBKN
BRD-A42759514-001-19-7	ornidazole	Launched	antiprotozoal agent		infectious disease	protozoan infection	0	83.96	Selleck	S3121	Ornidazole	219.041	Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7,r|	IPWKIXLWTCNBKN-LURJTMIESA-N	688540.0		IPWKIXLWTCNBKN
BRD-K00003333-001-01-9	ornipressin	Preclinical	vasoconstrictor				0	77.29	MedChemEx	HY-P0083	Ornipressin	1041.416	[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O	MUNMIGOEDGHVLE-FGJIEJSYSA-N			MUNMIGOEDGHVLE
BRD-K01825132-003-02-9	ornithine	Launched	NFkB pathway modulator	GPRC6A			0	0.0	MicroSource	1504524	ORNITHINE HYDROCHLORIDE	168.067	Cl.NCCC[C@@H](N)C(O)=O |&1:5,r|	GGTYBZJRPHEQDG-PGMHMLKASA-N	74765349.0		GGTYBZJRPHEQDG
BRD-K32572029-001-05-1	orotic-acid	Phase 2		DHODH			0	100.0	MicroSource	1504525	OROTIC ACID	156.017	OC(=O)c1cc(=O)[nH]c(=O)[nH]1	PXQPEWDEAKTCGB-UHFFFAOYSA-N	967.0		PXQPEWDEAKTCGB
BRD-K32572029-001-04-4	orotic-acid	Phase 2		DHODH			0	100.0	Selleck	S2336	Orotic acid (6-Carboxyuracil)	156.017	OC(=O)c1cc(=O)[nH]c(=O)[nH]1	PXQPEWDEAKTCGB-UHFFFAOYSA-N	967.0		PXQPEWDEAKTCGB
BRD-K05717154-001-02-9	orphanin-fq	Phase 1	opioid receptor agonist	OPRL1|OPRM1			0	0.0	MedChemEx	HY-P0183	Nociceptin	1807.981	CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O	PULGYDLMFSFVBL-SMFNREODSA-N	56947112.0		PULGYDLMFSFVBL
BRD-K05717154-001-01-1	orphanin-fq	Phase 1	opioid receptor agonist	OPRL1|OPRM1			0	63.03	Enzo	AC862	Nociceptin	1807.981	CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O	PULGYDLMFSFVBL-SMFNREODSA-N	56947112.0		PULGYDLMFSFVBL
BRD-A53576514-048-14-3	orphenadrine	Launched	acetylcholine receptor antagonist		neurology/psychiatry	muscle pain	0	98.55	MicroSource	1500447	ORPHENADRINE CITRATE	269.178	CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|	QVYRGXJJSLMXQH-SFHVURJKSA-N	736041.0		QVYRGXJJSLMXQH
BRD-A53576514-048-13-5	orphenadrine	Launched	acetylcholine receptor antagonist		neurology/psychiatry	muscle pain	0	93.94	Selleck	S2054	Orphenadrine Citrate	269.178	CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|	QVYRGXJJSLMXQH-SFHVURJKSA-N	736041.0		QVYRGXJJSLMXQH
BRD-A53576514-048-15-0	orphenadrine	Launched	acetylcholine receptor antagonist		neurology/psychiatry	muscle pain	0	95.13	Selleck	S2054	Orphenadrine hydrochloride	269.178	CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|	QVYRGXJJSLMXQH-SFHVURJKSA-N	736041.0		QVYRGXJJSLMXQH
BRD-K00674894-001-02-2	orteronel	Phase 3	androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor	CYP17A1			0	98.05	Selleck	S1195	TAK-700 (Orteronel)	307.132	CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12	OZPFIJIOIVJZMN-GOSISDBHSA-N	10335364.0		OZPFIJIOIVJZMN
BRD-K00674894-001-01-4	orteronel	Phase 3	androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor	CYP17A1			0	97.87	Selleck	S1195	TAK-700 (Orteronel)	307.132	CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12	OZPFIJIOIVJZMN-GOSISDBHSA-N	10335364.0	BRD-A12409803-001-04-7	OZPFIJIOIVJZMN
BRD-K59711701-300-02-1	ORY-1001	Phase 1/Phase 2	histone lysine demethylase inhibitor	KDM1A			0	92.83	MedChemEx	HY-12782	ORY-1001	230.178	NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1	ALHBJBCQLJZYON-PFSRBDOWSA-N	71543365.0		ALHBJBCQLJZYON
BRD-K59711701-300-01-3	ORY-1001	Phase 1/Phase 2	histone lysine demethylase inhibitor	KDM1A			0	74.14	Selleck	S7795	ORY-1001 (RG-6016)	230.178	NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1	ALHBJBCQLJZYON-PFSRBDOWSA-N	71543365.0		ALHBJBCQLJZYON
BRD-K93767137-001-01-1	oseltamivir-carboxylate	Launched	neuraminidase inhibitor		infectious disease	influenza A virus infection	0	85.81	MedChemEx	HY-13318	Oseltamivir (acid)	284.174	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|	NENPYTRHICXVCS-YNEHKIRRSA-N	449381.0		NENPYTRHICXVCS
BRD-K93767137-001-02-9	oseltamivir-carboxylate	Launched	neuraminidase inhibitor		infectious disease	influenza A virus infection	0	86.82	MedChemEx	HY-13318	Oseltamivir (acid)	284.174	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|	NENPYTRHICXVCS-YNEHKIRRSA-N	449381.0		NENPYTRHICXVCS
BRD-K76011241-001-01-8	oseltamivir-phosphate	Launched	neuraminidase inhibitor	CES1|NEU1|NEU2	infectious disease	influenza A virus infection	0	88.61	MicroSource	1504912	OSELTAMIVIR PHOSPHATE	312.205	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|	VSZGPKBBMSAYNT-RRFJBIMHSA-N	65028.0		VSZGPKBBMSAYNT
BRD-K76011241-011-04-9	oseltamivir-phosphate	Launched	neuraminidase inhibitor	CES1|NEU1|NEU2	infectious disease	influenza A virus infection	0	94.24	MedChemEx	HY-17016	Oseltamivir (phosphate)	312.205	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|	VSZGPKBBMSAYNT-RRFJBIMHSA-N	65028.0		VSZGPKBBMSAYNT
BRD-K76011241-011-02-5	oseltamivir-phosphate	Launched	neuraminidase inhibitor	CES1|NEU1|NEU2	infectious disease	influenza A virus infection	0	93.88	Selleck	S2597	Oseltamivir Phosphate	312.205	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|	VSZGPKBBMSAYNT-RRFJBIMHSA-N	65028.0		VSZGPKBBMSAYNT
BRD-K76011241-001-02-6	oseltamivir-phosphate	Launched	neuraminidase inhibitor	CES1|NEU1|NEU2	infectious disease	influenza A virus infection	0	78.25	Selleck	S2597	Oseltamivir phosphate	312.205	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|	VSZGPKBBMSAYNT-RRFJBIMHSA-N	65028.0	BRD-U75584406-000-01-6	VSZGPKBBMSAYNT
BRD-K60371362-001-01-7	osemozotan	Phase 2/Phase 3	serotonin receptor agonist	HTR1A			0	98.16	Sigma	MFCD17012664	N-[3-(1,3-benzodioxol-5-yloxy)propyl]-N-[(2S)-2,3-dihydro-1,4-benzodioxin-2-ylmethyl]amine	343.142	C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1	MEEQBDCQPIZMLY-HNNXBMFYSA-N	198747.0		MEEQBDCQPIZMLY
BRD-K87124298-001-05-9	OSI-027	Phase 1	mTOR inhibitor	MTOR			0	95.61	MedChemEx	HY-10423	OSI-027	406.175	COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|	JROFGZPOBKIAEW-HAQNSBGRSA-N			JROFGZPOBKIAEW
BRD-K87124298-001-03-4	OSI-027	Phase 1	mTOR inhibitor	MTOR			0	80.31	Selleck	S2624	OSI-027	406.175	COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|	JROFGZPOBKIAEW-HAQNSBGRSA-N			JROFGZPOBKIAEW
BRD-K87124298-001-04-2	OSI-027	Phase 1	mTOR inhibitor	MTOR			0	91.53	Selleck	S2624	OSI-027	406.175	COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|	JROFGZPOBKIAEW-HAQNSBGRSA-N			JROFGZPOBKIAEW
BRD-K73309154-003-03-9	OSI-420	Preclinical	EGFR inhibitor	EGFR			0	96.68	MedChemEx	HY-13256	Desmethyl Erlotinib	379.153	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	KOQIAZNBAWFSQM-UHFFFAOYSA-N	10317566.0		KOQIAZNBAWFSQM
BRD-K73309154-003-02-8	OSI-420	Preclinical	EGFR inhibitor	EGFR			0	96.54	Selleck	S2205	OSI-420	379.153	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	KOQIAZNBAWFSQM-UHFFFAOYSA-N	10317566.0		KOQIAZNBAWFSQM
BRD-K25340465-001-11-1	OSI-930	Phase 1	KIT inhibitor|VEGFR inhibitor	FLT1|KDR|KIT			0	86.5	Selleck	S1220	OSI-930	443.092	FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1	FGTCROZDHDSNIO-UHFFFAOYSA-N	9868037.0		FGTCROZDHDSNIO
BRD-K25340465-001-07-9	OSI-930	Phase 1	KIT inhibitor|VEGFR inhibitor	FLT1|KDR|KIT			0	3.06	Selleck	S1220	OSI-930	443.092	FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1	FGTCROZDHDSNIO-UHFFFAOYSA-N	9868037.0		FGTCROZDHDSNIO
BRD-K00003210-001-01-9	osilodrostat	Launched	cytochrome P450 inhibitor				0	96.89	MedChemEx	HY-16276	Osilodrostat	227.086	Fc1cc(ccc1[C@H]1CCc2cncn12)C#N	USUZGMWDZDXMDG-CYBMUJFWSA-N	44139752.0		USUZGMWDZDXMDG
BRD-K42805893-001-04-9	osimertinib	Launched	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	0	87.75	MedChemEx	HY-15772	AZD-9291	499.27	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	DUYJMQONPNNFPI-UHFFFAOYSA-N	71496458.0		DUYJMQONPNNFPI
BRD-K42805893-001-08-9	osimertinib	Launched	EGFR inhibitor	EGFR	oncology	non-small cell lung cancer (NSCLC)	0	97.69	MedChemEx	HY-15772	Osimertinib	499.27	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	DUYJMQONPNNFPI-UHFFFAOYSA-N	71496458.0		DUYJMQONPNNFPI
BRD-K44184170-001-01-7	ospemifene	Launched	selective estrogen receptor modulator (SERM)	ESR1|ESR2	obstetrics/gynecology|endocrinology	vaginal atrophy|dyspareunia|menopause	0	99.9	Selleck	S4285	2-{4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy}ethanol	378.139	OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	LUMKNAVTFCDUIE-VHXPQNKSSA-N	3036505.0		LUMKNAVTFCDUIE
BRD-K29735307-001-03-9	ostarine	Phase 3	androgen receptor modulator	AR			0	96.9	MedChemEx	HY-13273	Ostarine	389.099	C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	JNGVJMBLXIUVRD-SFHVURJKSA-N	11326715.0		JNGVJMBLXIUVRD
BRD-K29735307-001-02-9	ostarine	Phase 3	androgen receptor modulator	AR			0	97.85	Selleck	S1174	MK-2866 (GTx-024)	389.099	C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	JNGVJMBLXIUVRD-SFHVURJKSA-N	11326715.0		JNGVJMBLXIUVRD
BRD-K78294846-001-13-9	osthol	Preclinical	calcium channel blocker				0	96.58	MedChemEx	HY-N0054	Osthole	244.11	COc1ccc2ccc(=O)oc2c1CC=C(C)C	MBRLOUHOWLUMFF-UHFFFAOYSA-N	10228.0		MBRLOUHOWLUMFF
BRD-K78294846-001-12-4	osthol	Preclinical	calcium channel blocker				0	98.35	Selleck	S2337	Osthole	244.11	COc1ccc2ccc(=O)oc2c1CC=C(C)C	MBRLOUHOWLUMFF-UHFFFAOYSA-N	10228.0		MBRLOUHOWLUMFF
BRD-K42009284-001-01-1	OT-R-antagonist-1	Preclinical	oxytocin receptor antagonist	AVPR1A|OXTR			0	98.05	MedChemEx	HY-15015	OT-R antagonist 1	471.216	CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1	IBXGJPAYWMFXSF-UEEONYLUSA-N	9690136.0		IBXGJPAYWMFXSF
BRD-K80082640-001-02-9	otamixaban	Phase 3	coagulation factor inhibitor	F10			0	96.17	MedChemEx	HY-70035	Otamixaban	446.195	COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1	PFGVNLZDWRZPJW-OPAMFIHVSA-N	5496659.0		PFGVNLZDWRZPJW
BRD-K80082640-001-01-0	otamixaban	Phase 3	coagulation factor inhibitor	F10			0	95.95	MedChemEx	HY-70035	Otamixaban	446.195	COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1	PFGVNLZDWRZPJW-OPAMFIHVSA-N	5496659.0		PFGVNLZDWRZPJW
BRD-A00520476-001-08-2	otenzepad	Phase 3	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5			0	92.55	Tocris	1105	AF-DX 116	421.248	CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|	UBRKDAVQCKZSPO-GOSISDBHSA-N	76966449.0		UBRKDAVQCKZSPO
BRD-A00520476-001-09-9	otenzepad	Phase 3	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5			0	96.5	Tocris	1105	AF-DX 116	421.248	CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|	UBRKDAVQCKZSPO-GOSISDBHSA-N	76966449.0		UBRKDAVQCKZSPO
BRD-A00520476-001-07-4	otenzepad	Phase 3	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5			0	87.13	Tocris	1105	AF-DX 116	421.248	CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6,r|	UBRKDAVQCKZSPO-GOSISDBHSA-N	76966449.0		UBRKDAVQCKZSPO
BRD-K85337334-004-03-9	otilonium	Launched	acetylcholine receptor antagonist	CACNA1C	gastroenterology	irritable bowel syndrome	0	96.31	MedChemEx	HY-B0499A	Otilonium (bromide)	483.322	CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC	NQHNLNLJPDMBFN-UHFFFAOYSA-O	72093.0		NQHNLNLJPDMBFN
BRD-K85337334-004-02-6	otilonium	Launched	acetylcholine receptor antagonist	CACNA1C	gastroenterology	irritable bowel syndrome	0	98.47	Selleck	S3047	Otilonium Bromide	483.322	CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC	NQHNLNLJPDMBFN-UHFFFAOYSA-O	72093.0		NQHNLNLJPDMBFN
BRD-K53417444-003-03-1	OTS167	Phase 1/Phase 2	maternal embryonic leucine zipper kinase inhibitor	MELK			0	95.38	MedChemEx	HY-15512A	OTSSP167 (hydrochloride)	486.159	CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|	DKZYXHCYPUVGAF-JCNLHEQBSA-N			DKZYXHCYPUVGAF
BRD-K53417444-003-04-9	OTS167	Phase 1/Phase 2	maternal embryonic leucine zipper kinase inhibitor	MELK			0	97.18	MedChemEx	HY-15512A	OTSSP167 (hydrochloride)	486.159	CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|	DKZYXHCYPUVGAF-JCNLHEQBSA-N			DKZYXHCYPUVGAF
BRD-K38018935-001-01-1	OTS514	Preclinical	TOPK inhibitor				0	93.47	MedChemEx	HY-18621	OTS514	364.125	C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12	OETLNMOJNONWOY-LBPRGKRZSA-N	67448836.0		OETLNMOJNONWOY
BRD-K43471985-001-05-5	OTX015	Phase 1/Phase 2	bromodomain inhibitor	BRD2|BRD3|BRD4			0	78.71	Selleck	S7360	OTX015	491.118	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|	GNMUEVRJHCWKTO-FQEVSTJZSA-N	9936746.0	BRD-A53775886-001-01-7	GNMUEVRJHCWKTO
BRD-K43471985-001-03-0	OTX015	Phase 1/Phase 2	bromodomain inhibitor	BRD2|BRD3|BRD4			0	98.65	Selleck	S7360	OTX015	491.118	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|	GNMUEVRJHCWKTO-FQEVSTJZSA-N	9936746.0		GNMUEVRJHCWKTO
BRD-K33277808-331-01-3	ouabain	Launched	ATPase inhibitor	ATP1A1	cardiology	hypertension|cardiac arrythmia	0	96.12	MicroSource	1500676	OUABAIN OCTAHYDRATE	584.283	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|	LPMXVESGRSUGHW-VGFRVVOQSA-N	11527152.0	BRD-A68930007-331-01-6	LPMXVESGRSUGHW
BRD-K33277808-001-03-9	ouabain	Launched	ATPase inhibitor	ATP1A1	cardiology	hypertension|cardiac arrythmia	0	95.22	Tocris	1076	Ouabain	584.283	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|	LPMXVESGRSUGHW-VGFRVVOQSA-N	11527152.0		LPMXVESGRSUGHW
BRD-K33277808-001-01-2	ouabain	Launched	ATPase inhibitor	ATP1A1	cardiology	hypertension|cardiac arrythmia	0	94.43	Tocris	1076	Ouabain	584.283	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|	LPMXVESGRSUGHW-VGFRVVOQSA-N	11527152.0		LPMXVESGRSUGHW
BRD-K33277808-001-02-0	ouabain	Launched	ATPase inhibitor	ATP1A1	cardiology	hypertension|cardiac arrythmia	0	93.95	Selleck	S4016	Ouabain	584.283	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|	LPMXVESGRSUGHW-VGFRVVOQSA-N	11527152.0	BRD-A68930007-001-04-9|BRD-K92158972-331-01-3	LPMXVESGRSUGHW
BRD-K98736329-300-02-9	OXA-06	Preclinical	rho associated kinase inhibitor	ROCK1|ROCK2			0	97.04	Tocris	5182	OXA 06 dihydrochloride	331.148	Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12	XUIUXXQVHPEQNM-UHFFFAOYSA-N	24857242.0		XUIUXXQVHPEQNM
BRD-K98736329-300-01-5	OXA-06	Preclinical	rho associated kinase inhibitor	ROCK1|ROCK2			0	96.59	Tocris	5182	OXA 06 dihydrochloride	331.148	Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12	XUIUXXQVHPEQNM-UHFFFAOYSA-N	24857242.0		XUIUXXQVHPEQNM
BRD-K65230684-001-06-9	oxaceprol	Preclinical	anti-inflammatory agent				0	100.0	MedChemEx	HY-17490	Oxaceprol	173.069	CC(=O)N1C[C@H](O)C[C@H]1C(O)=O	BAPRUDZDYCKSOQ-RITPCOANSA-N	65784.0		BAPRUDZDYCKSOQ
BRD-K96786677-323-04-9	oxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	0	91.96	MedChemEx	HY-B0465	Oxacillin (sodium monohydrate)	401.105	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	UWYHMGVUTGAWSP-JKIFEVAISA-N	6196.0		UWYHMGVUTGAWSP
BRD-K96786677-323-02-0	oxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	0	98.27	Selleck	S2563	Oxacillin sodium monohydrate	401.105	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	UWYHMGVUTGAWSP-JKIFEVAISA-N	6196.0		UWYHMGVUTGAWSP
BRD-K96786677-323-03-8	oxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	0	82.09	Selleck	S2563	Oxacillin sodium monohydrate	401.105	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	UWYHMGVUTGAWSP-JKIFEVAISA-N	6196.0	BRD-K71213463-323-01-4	UWYHMGVUTGAWSP
BRD-K96786677-236-02-4	oxacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	staphylococcal infections	0	95.64	MicroSource	1500448	OXACILLIN SODIUM	401.105	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	UWYHMGVUTGAWSP-JKIFEVAISA-N	6196.0	BRD-A66481418-236-04-0	UWYHMGVUTGAWSP
BRD-K36982194-001-01-6	oxacyclohexadecan-2-one	Preclinical	protein kinase inhibitor				0	0.0	Sigma	MFCD00039667	oxacyclohexadecan-2-one	240.209	O=C1CCCCCCCCCCCCCCO1	FKUPPRZPSYCDRS-UHFFFAOYSA-N	235414.0		FKUPPRZPSYCDRS
BRD-K78960041-001-07-3	oxaliplatin	Launched	DNA inhibitor		oncology	colorectal cancer	0	72.43	MicroSource	1502282	OXALIPLATIN	395.044	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	DWAFYCQODLXJNR-BNTLRKBRSA-L	43805.0	BRD-A20035137-001-01-3|BRD-M43490210-001-01-9	DWAFYCQODLXJNR
BRD-K78960041-001-05-7	oxaliplatin	Launched	DNA inhibitor		oncology	colorectal cancer	0	98.79	Selleck	S1224	Oxaliplatin (Eloxatin)	395.044	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	DWAFYCQODLXJNR-BNTLRKBRSA-L	43805.0	BRD-M78823677-034-04-0	DWAFYCQODLXJNR
BRD-K78960041-001-03-2	oxaliplatin	Launched	DNA inhibitor		oncology	colorectal cancer	0	0.0	Tocris	2623	Oxaliplatin	395.044	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	DWAFYCQODLXJNR-BNTLRKBRSA-L	43805.0	BRD-M78823677-034-03-2	DWAFYCQODLXJNR
BRD-K78960041-001-08-9	oxaliplatin	Launched	DNA inhibitor		oncology	colorectal cancer	0	83.1	Tocris	2623	Oxaliplatin	395.044	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	DWAFYCQODLXJNR-BNTLRKBRSA-L	43805.0		DWAFYCQODLXJNR
BRD-K78960041-001-02-4	oxaliplatin	Launched	DNA inhibitor		oncology	colorectal cancer	0	0.0	Selleck	S1224	Oxaliplatin	395.044	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	DWAFYCQODLXJNR-BNTLRKBRSA-L	43805.0	BRD-M78823677-034-02-4	DWAFYCQODLXJNR
BRD-K61279411-001-03-8	oxaloacetate	Phase 2/Phase 3	glutamate release inhibitor				1	0.0	Sigma	MFCD00002592	2-oxosuccinic acid	132.006	OC(=O)C=C(O)C(O)=O	UWYVPFMHMJIBHE-UHFFFAOYSA-N	54676101.0		UWYVPFMHMJIBHE
BRD-K61279411-001-02-0	oxaloacetate	Phase 2/Phase 3	glutamate release inhibitor				1	0.0	Enamine	Z271128590		132.006	OC(=O)C=C(O)C(O)=O	UWYVPFMHMJIBHE-UHFFFAOYSA-N	54676101.0		UWYVPFMHMJIBHE
BRD-K66019333-096-02-0	oxantel	Launched	anthelmintic agent		infectious disease	gastrointestinal parasites	0	36.2	MicroSource	1505982	OXANTEL PAMOATE	216.126	CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|	VRYKTHBAWRESFI-VOTSOKGWSA-N	5281087.0		VRYKTHBAWRESFI
BRD-K66019333-096-03-9	oxantel	Launched	anthelmintic agent		infectious disease	gastrointestinal parasites	0	41.1	MedChemEx	HY-B1344	Oxantel (pamoate)	216.126	CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|	VRYKTHBAWRESFI-VOTSOKGWSA-N	5281087.0		VRYKTHBAWRESFI
BRD-K25394294-001-14-9	oxaprozin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	99.41	MicroSource	1505267	OXAPROZIN	293.105	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	OFPXSFXSNFPTHF-UHFFFAOYSA-N	4614.0		OFPXSFXSNFPTHF
BRD-K25394294-001-16-9	oxaprozin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	97.67	MedChemEx	HY-B0808	Oxaprozin	293.105	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	OFPXSFXSNFPTHF-UHFFFAOYSA-N	4614.0		OFPXSFXSNFPTHF
BRD-K25394294-001-13-1	oxaprozin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	96.5	Selleck	S4230	Oxaprozin	293.105	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	OFPXSFXSNFPTHF-UHFFFAOYSA-N	4614.0		OFPXSFXSNFPTHF
BRD-K22556255-001-08-9	oxatomide	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	97.1	Key	KS-1375	1-[3-(4-benzhydryl-1-piperazinyl)propyl]-1,3-dihydro-2H-benzimidazol-2-one	426.242	O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	BAINIUMDFURPJM-UHFFFAOYSA-N	4615.0		BAINIUMDFURPJM
BRD-K22556255-001-06-9	oxatomide	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	95.48	Vitas-M	STL147112		426.242	O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	BAINIUMDFURPJM-UHFFFAOYSA-N	4615.0		BAINIUMDFURPJM
BRD-K04196797-001-24-4	oxcarbazepine	Launched	sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	77.53	MicroSource	1504243	OXCARBAZEPINE	252.09	NC(=O)N1c2ccccc2CC(=O)c2ccccc12	CTRLABGOLIVAIY-UHFFFAOYSA-N	34312.0		CTRLABGOLIVAIY
BRD-K04196797-001-23-6	oxcarbazepine	Launched	sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	76.73	Selleck	S1391	Oxcarbazepine	252.09	NC(=O)N1c2ccccc2CC(=O)c2ccccc12	CTRLABGOLIVAIY-UHFFFAOYSA-N	34312.0		CTRLABGOLIVAIY
BRD-K04196797-001-25-1	oxcarbazepine	Launched	sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	95.44	Selleck	S1391	Oxcarbazepine	252.09	NC(=O)N1c2ccccc2CC(=O)c2ccccc12	CTRLABGOLIVAIY-UHFFFAOYSA-N	34312.0		CTRLABGOLIVAIY
BRD-K17977438-048-03-2	oxelaidin	Launched	antitussive		pulmonary	cough suppressant	0	89.52	Selleck	S4402	Oxeladin Citrate	335.246	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	IQADUMSPOQKAAO-UHFFFAOYSA-N	4619.0	BRD-M29157795-001-01-5	IQADUMSPOQKAAO
BRD-K17977438-048-02-4	oxelaidin	Launched	antitussive		pulmonary	cough suppressant	0	91.86	MicroSource	1505774	OXELAIDIN CITRATE	335.246	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	IQADUMSPOQKAAO-UHFFFAOYSA-N	4619.0		IQADUMSPOQKAAO
BRD-K17977438-048-06-9	oxelaidin	Launched	antitussive		pulmonary	cough suppressant	0	95.06	MedChemEx	HY-B1216	Oxeladin (citrate)	335.246	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	IQADUMSPOQKAAO-UHFFFAOYSA-N	4619.0		IQADUMSPOQKAAO
BRD-K17977438-048-04-0	oxelaidin	Launched	antitussive		pulmonary	cough suppressant	0	91.21	Selleck	S4402	oxelaidin citrate	335.246	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	IQADUMSPOQKAAO-UHFFFAOYSA-N	4619.0		IQADUMSPOQKAAO
BRD-K56940463-001-14-6	oxethazaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	94.57	MicroSource	1503279	OXETHAZAINE	467.315	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	FTLDJPRFCGDUFH-UHFFFAOYSA-N	4621.0		FTLDJPRFCGDUFH
BRD-K56940463-001-15-9	oxethazaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	98.08	MedChemEx	HY-B0955	Oxethazaine	467.315	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	FTLDJPRFCGDUFH-UHFFFAOYSA-N	4621.0		FTLDJPRFCGDUFH
BRD-K56940463-001-13-8	oxethazaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	94.7	Selleck	S4343	Oxethazaine	467.315	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	FTLDJPRFCGDUFH-UHFFFAOYSA-N	4621.0		FTLDJPRFCGDUFH
BRD-A73891132-001-02-9	OXF-BD-02	Preclinical	bromodomain inhibitor	BRD4			0	96.76	Tocris	4928	OXF BD 02	295.121	Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|	FEQUIPXIENTMJN-SFHVURJKSA-N	70699441.0		FEQUIPXIENTMJN
BRD-A73891132-001-01-0	OXF-BD-02	Preclinical	bromodomain inhibitor	BRD4			0	93.12	Tocris	4928	OXF BD 02	295.121	Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14,r|	FEQUIPXIENTMJN-SFHVURJKSA-N	70699441.0		FEQUIPXIENTMJN
BRD-A33447119-001-11-6	oxfendazole	Launched	anthelmintic agent		infectious disease	lungworms|tapeworm|gastrointestinal roundworms	0	96.17	MicroSource	1505296	OXFENDAZOLE	315.068	COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|	BEZZFPOZAYTVHN-QFIPXVFZSA-N	12940581.0		BEZZFPOZAYTVHN
BRD-A33447119-001-10-8	oxfendazole	Launched	anthelmintic agent		infectious disease	lungworms|tapeworm|gastrointestinal roundworms	0	97.28	Selleck	S1830	Oxfendazole	315.068	COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|	BEZZFPOZAYTVHN-QFIPXVFZSA-N	12940581.0		BEZZFPOZAYTVHN
BRD-K30373577-001-02-9	oxfenicine	Phase 1	carnitine palmitoyltransferase inhibitor	CPT1A|CPT1B			0	100.0	MedChemEx	HY-34588	(???R)-???-Amino-4-hydroxybenzeneacetic acid	167.058	N[C@@H](C(O)=O)c1ccc(O)cc1	LJCWONGJFPCTTL-SSDOTTSWSA-N	89853.0		LJCWONGJFPCTTL
BRD-K30373577-001-01-1	oxfenicine	Phase 1	carnitine palmitoyltransferase inhibitor	CPT1A|CPT1B			0	0.0	Enamine	Z1198149764		167.058	N[C@@H](C(O)=O)c1ccc(O)cc1	LJCWONGJFPCTTL-SSDOTTSWSA-N	89853.0		LJCWONGJFPCTTL
BRD-K52075715-001-07-5	oxibendazole	Launched	tubulin polymerization inhibitor	TUBB|TUBB4B	infectious disease	strongyles	0	89.12	MicroSource	1503373	OXIBENDAZOLE	249.111	CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1	RAOCRURYZCVHMG-UHFFFAOYSA-N	4622.0		RAOCRURYZCVHMG
BRD-K52075715-001-06-7	oxibendazole	Launched	tubulin polymerization inhibitor	TUBB|TUBB4B	infectious disease	strongyles	0	96.34	Selleck	S1851	Oxibendazole	249.111	CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1	RAOCRURYZCVHMG-UHFFFAOYSA-N	4622.0		RAOCRURYZCVHMG
BRD-K56104152-008-04-1	oxiconazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	98.63	MicroSource	1505330	OXICONAZOLE NITRATE	426.981	Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	QRJJEGAJXVEBNE-HKOYGPOVSA-N	5353853.0		QRJJEGAJXVEBNE
BRD-K56104152-008-05-9	oxiconazole	Launched	bacterial cell wall synthesis inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	97.43	MedChemEx	HY-B1324	Oxiconazole nitrate	426.981	Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	QRJJEGAJXVEBNE-HKOYGPOVSA-N	5353853.0		QRJJEGAJXVEBNE
BRD-K41809988-004-10-9	oxidopamine	Preclinical	neurotoxin				0	0.0	Tocris	2547	6-Hydroxydopamine hydrobromide	169.074	NCCc1cc(O)c(O)cc1O	DIVDFFZHCJEHGG-UHFFFAOYSA-N	4624.0		DIVDFFZHCJEHGG
BRD-K41809988-003-09-3	oxidopamine	Preclinical	neurotoxin				0	0.0	MicroSource	1500450	OXIDOPAMINE HYDROCHLORIDE	169.074	NCCc1cc(O)c(O)cc1O	DIVDFFZHCJEHGG-UHFFFAOYSA-N	4624.0		DIVDFFZHCJEHGG
BRD-K20417253-001-02-7	oxiniacic-acid	Preclinical					0	100.0	Vitas-M	STK012697	nicotinic acid 1-oxide	139.027	OC(=O)c1ccc[n+]([O-])c1	FJCFFCXMEXZEIM-UHFFFAOYSA-N	16976.0		FJCFFCXMEXZEIM
BRD-K20417253-001-03-9	oxiniacic-acid	Preclinical					0	100.0	MedChemEx	HY-B1061	Nicotinic acid N-oxide	139.027	OC(=O)c1ccc[n+]([O-])c1	FJCFFCXMEXZEIM-UHFFFAOYSA-N	16976.0		FJCFFCXMEXZEIM
BRD-K20417253-001-01-9	oxiniacic-acid	Preclinical					0	75.78	MicroSource	1506168	OXINIACIC ACID	139.027	OC(=O)c1ccc[n+]([O-])c1	FJCFFCXMEXZEIM-UHFFFAOYSA-N	16976.0		FJCFFCXMEXZEIM
BRD-K78096648-001-05-7	oxiperomide	Phase 2	dopamine receptor antagonist				0	86.05	Enamine	Z130192198		337.179	O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1	NVDBBGBUTKLRSN-UHFFFAOYSA-N	68634.0		NVDBBGBUTKLRSN
BRD-K50677762-001-02-9	oxiracetam	Launched	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	0	100.0	MedChemEx	HY-17554	(R)-Oxiracetam	158.069	NC(=O)CN1C[C@H](O)CC1=O	IHLAQQPQKRMGSS-SCSAIBSYSA-N	3051965.0		IHLAQQPQKRMGSS
BRD-K50677762-001-01-5	oxiracetam	Launched	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	0	100.0	MedChemEx	HY-17554	(R)-Oxiracetam	158.069	NC(=O)CN1C[C@H](O)CC1=O	IHLAQQPQKRMGSS-SCSAIBSYSA-N	3051965.0		IHLAQQPQKRMGSS
BRD-K42596464-048-11-9	oxolamine	Launched	antitussive		pulmonary	cough suppressant	0	43.12	MicroSource	1506027	OXOLAMINE CITRATE	245.153	CCN(CC)CCc1nc(no1)-c1ccccc1	IDCHQQSVJAAUQQ-UHFFFAOYSA-N	13738.0		IDCHQQSVJAAUQQ
BRD-K42596464-048-12-9	oxolamine	Launched	antitussive		pulmonary	cough suppressant	0	78.78	MedChemEx	HY-B1042	Oxolamine (citrate)	245.153	CCN(CC)CCc1nc(no1)-c1ccccc1	IDCHQQSVJAAUQQ-UHFFFAOYSA-N	13738.0		IDCHQQSVJAAUQQ
BRD-K73394555-237-01-1	oxolinic-acid	Preclinical	bacterial DNA gyrase inhibitor				0	95.97	MicroSource	1502030	OXOLINIC ACID	261.064	CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12	KYGZCKSPAKDVKC-UHFFFAOYSA-N	4628.0		KYGZCKSPAKDVKC
BRD-K73394555-001-10-9	oxolinic-acid	Preclinical	bacterial DNA gyrase inhibitor				0	91.25	MedChemEx	HY-B1002	Oxolinic acid	261.064	CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12	KYGZCKSPAKDVKC-UHFFFAOYSA-N	4628.0		KYGZCKSPAKDVKC
BRD-K31468676-237-02-6	oxonic-acid	Preclinical	uricase inhibitor				0	0.0	Sigma	MFCD00010565	potassium 4,6-dihydroxy-1,3,5-triazine-2-carboxylate	157.012	OC(=O)c1nc(=O)[nH]c(=O)[nH]1	RYYCJUAHISIHTL-UHFFFAOYSA-N	4604.0		RYYCJUAHISIHTL
BRD-K31468676-237-01-8	oxonic-acid	Preclinical	uricase inhibitor				0	0.0	AKSci	H840		157.012	OC(=O)c1nc(=O)[nH]c(=O)[nH]1	RYYCJUAHISIHTL-UHFFFAOYSA-N	4604.0	BRD-K13516279-237-01-7	RYYCJUAHISIHTL
BRD-K01942991-005-09-0	oxotremorine-M	Preclinical	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	97.04	Tocris	1067	N,N,N-trimethyl-4-(2-oxo-1-pyrrolidinyl)-2-butyn-1-aminium iodide	195.15	C[N+](C)(C)CC#CCN1CCCC1=O	CANZROMYQDHYHR-UHFFFAOYSA-N	4629.0		CANZROMYQDHYHR
BRD-K01942991-005-08-2	oxotremorine-M	Preclinical	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	83.31	Tocris	1067	Oxotremorine M	195.15	C[N+](C)(C)CC#CCN1CCCC1=O	CANZROMYQDHYHR-UHFFFAOYSA-N	4629.0		CANZROMYQDHYHR
BRD-K21936341-051-04-0	oxotremorine-sesquifumarate	Preclinical	cholinergic receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	68.9	Tocris	843	Oxotremorine sesquifumarate	206.142	O=C1CCCN1CC#CCN1CCCC1	RSDOPYMFZBJHRL-UHFFFAOYSA-N	4630.0	BRD-M50913522-361-03-7	RSDOPYMFZBJHRL
BRD-K21936341-051-08-9	oxotremorine-sesquifumarate	Preclinical	cholinergic receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	79.6	Tocris	843	Oxotremorine sesquifumarate	206.142	O=C1CCCN1CC#CCN1CCCC1	RSDOPYMFZBJHRL-UHFFFAOYSA-N	4630.0		RSDOPYMFZBJHRL
BRD-K21936341-051-03-2	oxotremorine-sesquifumarate	Preclinical	cholinergic receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	69.87	Tocris	843	Oxotremorine sesquifumarate	206.142	O=C1CCCN1CC#CCN1CCCC1	RSDOPYMFZBJHRL-UHFFFAOYSA-N	4630.0	BRD-M50913522-361-02-9	RSDOPYMFZBJHRL
BRD-A43671941-003-11-9	oxprenolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	angina pectoris|hypertension|cardiac arrythmia	0	95.83	Selleck	S4344	Oxprenolol HCl	265.168	CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|	CEMAWMOMDPGJMB-CYBMUJFWSA-N	94423.0	BRD-U77311119-000-01-0	CEMAWMOMDPGJMB
BRD-K59037100-001-15-9	oxybenzone	Launched	lipase inhibitor	LIPE	dermatology	sunscreen lotion	0	98.47	MedChemEx	HY-A0067	Oxybenzone	228.079	COc1ccc(C(=O)c2ccccc2)c(O)c1	DXGLGDHPHMLXJC-UHFFFAOYSA-N	4632.0		DXGLGDHPHMLXJC
BRD-K59037100-001-14-7	oxybenzone	Launched	lipase inhibitor	LIPE	dermatology	sunscreen lotion	0	98.13	MicroSource	1500451	OXYBENZONE	228.079	COc1ccc(C(=O)c2ccccc2)c(O)c1	DXGLGDHPHMLXJC-UHFFFAOYSA-N	4632.0		DXGLGDHPHMLXJC
BRD-K04185004-003-12-7	oxybuprocaine	Launched	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	0	50.78	MicroSource	1505502	BENOXINATE HYDROCHLORIDE	308.21	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	CMHHMUWAYWTMGS-UHFFFAOYSA-N	4633.0		CMHHMUWAYWTMGS
BRD-K04185004-003-11-9	oxybuprocaine	Launched	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	0	89.75	Selleck	S4229	Oxybuprocaine HCl	308.21	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	CMHHMUWAYWTMGS-UHFFFAOYSA-N	4633.0		CMHHMUWAYWTMGS
BRD-K04185004-003-14-3	oxybuprocaine	Launched	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	0	96.85	Selleck	S4229	Benoxinate hydrochloride	308.21	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	CMHHMUWAYWTMGS-UHFFFAOYSA-N	4633.0		CMHHMUWAYWTMGS
BRD-K04185004-003-13-5	oxybuprocaine	Launched	local anesthetic	SCN10A	neurology/psychiatry	local anesthetic	0	94.35	Selleck	S4229	Oxybuprocaine HCl	308.21	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	CMHHMUWAYWTMGS-UHFFFAOYSA-N	4633.0		CMHHMUWAYWTMGS
BRD-K01825580-001-03-9	oxybutynin	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	urology	urinary incontinence	0	95.68	MedChemEx	HY-B0267	Oxybutynin	357.23	CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|	XIQVNETUBQGFHX-QFIPXVFZSA-N	6098167.0		XIQVNETUBQGFHX
BRD-K01825580-001-02-9	oxybutynin	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	urology	urinary incontinence	0	93.85	Selleck	S1754	Oxybutynin (Ditropan)	357.23	CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12,r|	XIQVNETUBQGFHX-QFIPXVFZSA-N	6098167.0		XIQVNETUBQGFHX
BRD-K07283971-001-01-3	oxyclozanide	Launched			infectious disease	fascioliasis	0	95.82	MicroSource	1504940	OXYCLOZANIDE	398.879	Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl	JYWIYHUXVMAGLG-UHFFFAOYSA-N	16779.0	BRD-K13017451-001-01-6	JYWIYHUXVMAGLG
BRD-K73027814-003-01-0	oxyfedrine	Launched	adrenergic receptor agonist		cardiology	angina pectoris	0	94.49	Kemprotec	16777-42-7	3-{[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino}-1-(3-methoxyphenyl)-1-propanone hydrochloride	313.168	COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1	GDYUVHBMFVMBAF-LIRRHRJNSA-N	5489013.0		GDYUVHBMFVMBAF
BRD-K00003713-001-01-9	oxymatrine	Launched					0	91.85	MedChemEx	HY-N0158	Oxymatrine	264.184	[H][C@]12CCC[N@@+]3([O-])CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]	XVPBINOPNYFXID-JARXUMMXSA-N	24864132.0		XVPBINOPNYFXID
BRD-K16195444-003-25-2	oxymetazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR2C	otolaryngology	nasal congestion	0	93.96	Tocris	1142	Oxymetazoline hydrochloride	260.189	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|	WYWIFABBXFUGLM-UHFFFAOYSA-N	4636.0		WYWIFABBXFUGLM
BRD-K16195444-003-26-0	oxymetazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR2C	otolaryngology	nasal congestion	0	99.39	MicroSource	1500453	OXYMETAZOLINE HYDROCHLORIDE	260.189	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|	WYWIFABBXFUGLM-UHFFFAOYSA-N	4636.0		WYWIFABBXFUGLM
BRD-K16195444-003-24-5	oxymetazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR2C	otolaryngology	nasal congestion	0	95.85	Selleck	S2495	Oxymetazoline HCl	260.189	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|	WYWIFABBXFUGLM-UHFFFAOYSA-N	4636.0		WYWIFABBXFUGLM
BRD-A33749298-001-18-3	oxyphenbutazone	Withdrawn	cyclooxygenase inhibitor				0	69.64	MicroSource	1500455	OXYPHENBUTAZONE	324.147	CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|	HFHZKZSRXITVMK-KRWDZBQOSA-N	448033.0		HFHZKZSRXITVMK
BRD-A58193911-003-18-7	oxyphencyclimine	Launched	cholinergic receptor antagonist		gastroenterology	peptic ulcer disease (PUD)	0	97.02	MicroSource	1503932	OXYPHENCYCLIMINE HYDROCHLORIDE	344.21	CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11,c:5|	DUDKAZCAISNGQN-FQEVSTJZSA-N	688541.0		DUDKAZCAISNGQN
BRD-A14208071-004-19-8	oxyphenonium	Launched	cholinergic receptor antagonist	CHRM1|CHRM3	gastroenterology	peptic ulcer disease (PUD)	0	92.38	MicroSource	1505783	OXYPHENONIUM BROMIDE	348.254	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	GFRUPHOKLBPHTQ-UHFFFAOYSA-N	5748.0		GFRUPHOKLBPHTQ
BRD-K31841515-001-07-8	oxypurinol	Phase 2/Phase 3	xanthine oxidase inhibitor	XDH			0	95.0	AlfaAesar	L07160		152.033	O=c1nc2[nH][nH]cc2c(=O)[nH]1	HXNFUBHNUDHIGC-UHFFFAOYSA-N	135398752.0		HXNFUBHNUDHIGC
BRD-K66808046-065-03-7	oxyquinoline	Launched	chelating agent	METAP2	dermatology	cosmetic	0	97.72	MicroSource	1500456	OXYQUINOLINE HEMISULFATE	145.053	Oc1cccc2cccnc12	MCJGNVYPOGVAJF-UHFFFAOYSA-N	1923.0		MCJGNVYPOGVAJF
BRD-K01826559-001-11-9	oxytetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease|urology	chlamydia|urinary tract infections|skin infections|ear infections|gonorrhea|urethritis|Lyme disease	0	0.0	MedChemEx	HY-B0275	Oxytetracycline	460.148	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|	KTUXFHGUHYRDNF-PXOLEDIWSA-N		BRD-A56621826-001-01-3	KTUXFHGUHYRDNF
BRD-K01826559-001-10-9	oxytetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease|urology	chlamydia|urinary tract infections|skin infections|ear infections|gonorrhea|urethritis|Lyme disease	0	0.0	Selleck	S1773	Oxytetracycline (Terramycin)	460.148	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|	KTUXFHGUHYRDNF-PXOLEDIWSA-N			KTUXFHGUHYRDNF
BRD-K01826559-001-08-9	oxytetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease|urology	chlamydia|urinary tract infections|skin infections|ear infections|gonorrhea|urethritis|Lyme disease	0	0.0	Selleck	S2052	Oxytetracycline dihydrate	460.148	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|	KTUXFHGUHYRDNF-PXOLEDIWSA-N		BRD-A78694248-335-01-6	KTUXFHGUHYRDNF
BRD-K01826559-001-09-9	oxytetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease|urology	chlamydia|urinary tract infections|skin infections|ear infections|gonorrhea|urethritis|Lyme disease	0	0.0	Selleck	S1773	Oxytetracycline (Terramycin)	460.148	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,5,7,11,30,&1:8,&2:15,t:8,15|	KTUXFHGUHYRDNF-PXOLEDIWSA-N			KTUXFHGUHYRDNF
BRD-K25243230-001-01-2	oxytocin	Launched	oxytocin receptor agonist	AVPR1A|AVPR1B|AVPR2|OXTR	obstetrics/gynecology	labor induction	0	84.04	Sigma	MFCD00076731	(2S)-1-{[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-sec-butyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbo;nyl}-N-((1S)-1-{[(2-amino-2-oxoethyl)amino]carbonyl}-3	1006.436	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	XNOPRXBHLZRZKH-LGMJNFKNSA-N	133698923.0		XNOPRXBHLZRZKH
BRD-K25243230-001-02-0	oxytocin	Launched	oxytocin receptor agonist	AVPR1A|AVPR1B|AVPR2|OXTR	obstetrics/gynecology	labor induction	0	67.09	MedChemEx	HY-17571	Oxytocin	1006.436	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	XNOPRXBHLZRZKH-LGMJNFKNSA-N	133698923.0	BRD-A80365673-001-01-1	XNOPRXBHLZRZKH
BRD-K53061490-003-15-9	ozagrel	Launched	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	0	97.74	Tocris	1510	Ozagrel hydrochloride	228.09	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	SHZKQBHERIJWAO-AATRIKPKSA-N	5282440.0		SHZKQBHERIJWAO
BRD-K53061490-003-13-9	ozagrel	Launched	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	0	96.99	Selleck	S2067	Ozagrel HCl	228.09	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	SHZKQBHERIJWAO-AATRIKPKSA-N	5282440.0		SHZKQBHERIJWAO
BRD-K53061490-001-02-6	ozagrel	Launched	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	0	95.65	Selleck	S2496	Ozagrel	228.09	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	SHZKQBHERIJWAO-AATRIKPKSA-N	5282440.0		SHZKQBHERIJWAO
BRD-K53061490-003-14-7	ozagrel	Launched	thromboxane synthase inhibitor	TBXAS1	neurology/psychiatry	stroke	0	92.28	Tocris	1510	Ozagrel hydrochloride	228.09	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	SHZKQBHERIJWAO-AATRIKPKSA-N	5282440.0		SHZKQBHERIJWAO
BRD-K46625559-001-01-8	ozanimod	Phase 3	sphingosine 1-phosphate receptor agonist	S1PR1			0	98.03	MedChemEx	HY-12288	Ozanimod	404.185	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO	XRVDGNKRPOAQTN-FQEVSTJZSA-N	52938427.0		XRVDGNKRPOAQTN
BRD-K00003184-001-01-9	ozenoxacin	Phase 3	antiinfective drug				0	97.14	MedChemEx	HY-14957	Ozenoxacin	363.158	CNc1ncc(cc1C)-c1ccc2c(c1C)n(cc(C(O)=O)c2=O)C1CC1	XPIJWUTXQAGSLK-UHFFFAOYSA-N	9863827.0		XPIJWUTXQAGSLK
BRD-A72297358-001-01-8	ozolinone	Phase 3	diuretic				0	78.8	Sigma	PH005634	(2Z)-[3-methyl-4-oxo-5-(1-piperidinyl)-1,3-thiazolidin-2-ylidene]ethanoic acid	256.088	CN1C(=O)[C@@H](S\C1=C/C(O)=O)N1CCCCC1 |&1:4,r|	NQFBZYYUAFJYNS-SKVAFPRGSA-N	76959758.0		NQFBZYYUAFJYNS
BRD-K53849769-001-02-9	O4I1	Preclinical	Oct inducer	POU5F1			0	0.0	Tocris	5639	O4I1	253.11	COc1ccc(COc2ccc(CC#N)cc2)cc1	QJEJLARVLKHYFW-UHFFFAOYSA-N	2774690.0		QJEJLARVLKHYFW
BRD-K53849769-001-01-0	O4I1	Preclinical	Oct inducer	POU5F1			0	0.0	Tocris	5639	O4I1	253.11	COc1ccc(COc2ccc(CC#N)cc2)cc1	QJEJLARVLKHYFW-UHFFFAOYSA-N	2774690.0		QJEJLARVLKHYFW
BRD-K92041145-001-09-5	O6-benzylguanine	Phase 3	O6-alkylguanine-DNA alkyltransferase inhibitor	MGMT			0	98.19	CombiBlocks	OR-2126		241.096	Nc1nc(OCc2ccccc2)c2[nH]cnc2n1	KRWMERLEINMZFT-UHFFFAOYSA-N	4578.0		KRWMERLEINMZFT
BRD-K42336459-001-01-7	p-dimethylinamyl-benzoate	Preclinical					0	26.63	Enamine	Z791135158		235.157	CCCCCOC(=O)c1ccc(cc1)N(C)C	LXTZRIBXKVRLOA-UHFFFAOYSA-N	26890.0		LXTZRIBXKVRLOA
BRD-K42336459-001-02-9	p-dimethylinamyl-benzoate	Preclinical					0	65.76	Enamine	Z791135158	pentyl 4-(dimethylamino)benzoate	235.157	CCCCCOC(=O)c1ccc(cc1)N(C)C	LXTZRIBXKVRLOA-UHFFFAOYSA-N	26890.0		LXTZRIBXKVRLOA
BRD-K11428250-001-02-9	PA-452	Preclinical	retinoid receptor antagonist	RXRA			0	96.69	Tocris	5086	PA 452	439.283	CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C	JJUUTJCZMGZJDZ-UHFFFAOYSA-N	9803242.0		JJUUTJCZMGZJDZ
BRD-K11428250-001-01-0	PA-452	Preclinical	retinoid receptor antagonist	RXRA			0	96.7	Tocris	5086	PA 452	439.283	CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C	JJUUTJCZMGZJDZ-UHFFFAOYSA-N	9803242.0		JJUUTJCZMGZJDZ
BRD-K92991072-001-06-4	PAC-1	Phase 1	caspase activator	CASP3			0	94.39	Tocris	2581	PAC 1	392.221	Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	YQNRVGJCPCNMKT-LFVJCYFKSA-N	9675990.0		YQNRVGJCPCNMKT
BRD-K92991072-001-05-6	PAC-1	Phase 1	caspase activator	CASP3			0	96.41	Tocris	2581	PAC 1	392.221	Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	YQNRVGJCPCNMKT-LFVJCYFKSA-N	9675990.0		YQNRVGJCPCNMKT
BRD-K92991072-001-07-9	PAC-1	Phase 1	caspase activator	CASP3			0	96.12	Tocris	2581	PAC 1	392.221	Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	YQNRVGJCPCNMKT-LFVJCYFKSA-N	9675990.0		YQNRVGJCPCNMKT
BRD-K92991072-001-04-9	PAC-1	Phase 1	caspase activator	CASP3			0	96.88	Selleck	S2738	PAC-1	392.221	Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	YQNRVGJCPCNMKT-LFVJCYFKSA-N	9675990.0		YQNRVGJCPCNMKT
BRD-K62008436-001-25-4	paclitaxel	Launched	tubulin polymerization inhibitor	BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)	0	87.32	Tocris	1097	Taxol	853.331	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	RCINICONZNJXQF-MZXODVADSA-N	36314.0	BRD-A28746609-001-13-1	RCINICONZNJXQF
BRD-K62008436-001-22-1	paclitaxel	Launched	tubulin polymerization inhibitor	BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)	0	91.66	MicroSource	1503908	PACLITAXEL	853.331	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	RCINICONZNJXQF-MZXODVADSA-N	36314.0	BRD-A28746609-001-11-5	RCINICONZNJXQF
BRD-K62008436-001-18-9	paclitaxel	Launched	tubulin polymerization inhibitor	BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)	0	98.1	Selleck	S1150	S1150	853.331	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	RCINICONZNJXQF-MZXODVADSA-N	36314.0		RCINICONZNJXQF
BRD-K62008436-001-23-9	paclitaxel	Launched	tubulin polymerization inhibitor	BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)	0	97.55	Selleck	S1150	Paclitaxel	853.331	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	RCINICONZNJXQF-MZXODVADSA-N	36314.0	BRD-A63610676-001-14-1	RCINICONZNJXQF
BRD-K62008436-001-24-7	paclitaxel	Launched	tubulin polymerization inhibitor	BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	ovarian cancer|breast cancer|non-small cell lung cancer (NSCLC)	0	90.91	Tocris	1097	Taxol	853.331	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	RCINICONZNJXQF-MZXODVADSA-N	36314.0	BRD-A28746609-001-10-7	RCINICONZNJXQF
BRD-K05677083-001-06-9	PACOCF3	Preclinical	phospholipase inhibitor	PLA2G4A			1	0.0	Tocris	1460	PACOCF3	308.233	CCCCCCCCCCCCCCCC(=O)C(F)(F)F	MAHYXYTYTLCTQD-UHFFFAOYSA-N	4670.0		MAHYXYTYTLCTQD
BRD-K05677083-001-05-4	PACOCF3	Preclinical	phospholipase inhibitor	PLA2G4A			1	0.0	Tocris	1460	PACOCF3	308.233	CCCCCCCCCCCCCCCC(=O)C(F)(F)F	MAHYXYTYTLCTQD-UHFFFAOYSA-N	4670.0		MAHYXYTYTLCTQD
BRD-K19034817-001-04-8	pacritinib	Phase 3	FLT3 inhibitor|JAK inhibitor	FLT3|JAK1|JAK2|JAK3			0	91.11	MedChemEx	HY-16379	Pacritinib	472.247	C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|	HWXVIOGONBBTBY-ONEGZZNKSA-N	46216796.0		HWXVIOGONBBTBY
BRD-K19034817-001-01-4	pacritinib	Phase 3	FLT3 inhibitor|JAK inhibitor	FLT3|JAK1|JAK2|JAK3			0	82.93	Selleck	S8057	Pacritinib (SB1518)	472.247	C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|	HWXVIOGONBBTBY-ONEGZZNKSA-N	46216796.0		HWXVIOGONBBTBY
BRD-K19034817-001-02-2	pacritinib	Phase 3	FLT3 inhibitor|JAK inhibitor	FLT3|JAK1|JAK2|JAK3			0	75.43	Selleck	S8057	Pacritinib (SB1518)	472.247	C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|	HWXVIOGONBBTBY-ONEGZZNKSA-N	46216796.0		HWXVIOGONBBTBY
BRD-K00003493-001-01-9	padsevonil	Phase 3	antiepileptic				0	88.29	MedChemEx	HY-109009	Padsevonil	432.045	COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(nc2s1)C(F)(F)F	DCXFIOLWWRXEQH-SSDOTTSWSA-N	52911611.0		DCXFIOLWWRXEQH
BRD-K83631119-001-04-9	paeoniflorin	Preclinical	anticonvulsant				0	92.42	MedChemEx	HY-N0293	Paeoniflorin	480.163	C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	YKRGDOXKVOZESV-WRJNSLSBSA-N	442534.0		YKRGDOXKVOZESV
BRD-K83631119-001-02-1	paeoniflorin	Preclinical	anticonvulsant				0	80.79	Selleck	S2410	Paeoniflorin	480.163	C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	YKRGDOXKVOZESV-WRJNSLSBSA-N	442534.0		YKRGDOXKVOZESV
BRD-K83631119-001-03-9	paeoniflorin	Preclinical	anticonvulsant				0	73.39	Selleck	S2410	Paeoniflorin	480.163	C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	YKRGDOXKVOZESV-WRJNSLSBSA-N	442534.0	BRD-K77265172-001-01-2	YKRGDOXKVOZESV
BRD-K94239562-001-06-9	paeonol	Preclinical	anti-inflammatory agent				0	50.99	MedChemEx	HY-N0159	Paeonol	166.063	COc1ccc(C(C)=O)c(O)c1	UILPJVPSNHJFIK-UHFFFAOYSA-N	11092.0		UILPJVPSNHJFIK
BRD-K94239562-001-05-5	paeonol	Preclinical	anti-inflammatory agent				0	94.76	Selleck	S2339	Paeonol	166.063	COc1ccc(C(C)=O)c(O)c1	UILPJVPSNHJFIK-UHFFFAOYSA-N	11092.0		UILPJVPSNHJFIK
BRD-K68805147-001-01-8	pafuramidine	Phase 3	DNA synthesis inhibitor				0	94.73	MedChemEx	HY-14932	Pafuramidine	364.154	CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC	UKOQVLAXCBRRGH-UHFFFAOYSA-N	6529858.0		UKOQVLAXCBRRGH
BRD-K68805147-001-02-9	pafuramidine	Phase 3	DNA synthesis inhibitor				0	96.24	MedChemEx	HY-14932	Pafuramidine	364.154	CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC	UKOQVLAXCBRRGH-UHFFFAOYSA-N	6529858.0		UKOQVLAXCBRRGH
BRD-K00003428-001-01-9	pagoclone	Phase 2/Phase 3	GABA receptor agonist				0	89.95	MedChemEx	HY-101665	Pagoclone	407.14	CC(C)CCC(=O)C[C@@H]1N(C(=O)c2ccccc12)c1ccc2ccc(Cl)nc2n1 |&1:8,r|	HIUPRQPBWVEQJJ-IBGZPJMESA-N	25273635.0		HIUPRQPBWVEQJJ
BRD-K51313569-001-07-8	palbociclib	Launched	CDK inhibitor	CDK4|CDK6	oncology	breast cancer	0	89.77	Selleck	S1116	Palbociclib	447.238	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	AHJRHEGDXFFMBM-UHFFFAOYSA-N	5330286.0		AHJRHEGDXFFMBM
BRD-K51313569-003-03-3	palbociclib	Launched	CDK inhibitor	CDK4|CDK6	oncology	breast cancer	0	94.04	Selleck	S1116	Palbociclib (PD-0332991) HCl	447.238	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	AHJRHEGDXFFMBM-UHFFFAOYSA-N	5330286.0		AHJRHEGDXFFMBM
BRD-K51313569-001-11-0	palbociclib	Launched	CDK inhibitor	CDK4|CDK6	oncology	breast cancer	0	86.33	Selleck	S1116	Palbociclib (PD-0332991) HCl	447.238	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)	5330286.0		AHJRHEGDXFFMBM
BRD-K12047401-001-02-3	palifosfamide	Phase 3	DNA alkylating agent				0	0.0	MedChemEx	HY-14798	Palifosfamide	219.994	OP(=O)(NCCCl)NCCCl	BKCJZNIZRWYHBN-UHFFFAOYSA-N	100427.0		BKCJZNIZRWYHBN
BRD-K12047401-001-01-5	palifosfamide	Phase 3	DNA alkylating agent				1	0.0	MedChemEx	HY-14798	Palifosfamide	219.994	OP(=O)(NCCCl)NCCCl	BKCJZNIZRWYHBN-UHFFFAOYSA-N	100427.0		BKCJZNIZRWYHBN
BRD-A99888680-001-06-9	paliperidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	93.03	Tocris	4493	Paliperidone	426.207	Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|	PMXMIIMHBWHSKN-IBGZPJMESA-N	9823781.0		PMXMIIMHBWHSKN
BRD-A99888680-001-04-6	paliperidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	96.4	MicroSource	1502318	PALIPERIDONE	426.207	Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|	PMXMIIMHBWHSKN-IBGZPJMESA-N	9823781.0	BRD-K00665454-001-02-2	PMXMIIMHBWHSKN
BRD-A99888680-001-05-3	paliperidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	88.51	Selleck	S1724	Paliperidone (Invega)	426.207	Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|	PMXMIIMHBWHSKN-IBGZPJMESA-N	9823781.0	BRD-K00665454-001-01-4	PMXMIIMHBWHSKN
BRD-A99888680-001-03-8	paliperidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|HTR2A	neurology/psychiatry	schizophrenia	0	92.86	Selleck	S1724	Paliperidone	426.207	Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4,r|	PMXMIIMHBWHSKN-IBGZPJMESA-N	9823781.0		PMXMIIMHBWHSKN
BRD-K58466253-003-15-9	palmatine-chloride	Preclinical	dopamine synthesis inhibitor	CYP3A4			0	89.73	MedChemEx	HY-N0110	Palmatine (chloride)	352.155	COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	QUCQEUCGKKTEBI-UHFFFAOYSA-N	19009.0		QUCQEUCGKKTEBI
BRD-K58466253-003-14-0	palmatine-chloride	Preclinical	dopamine synthesis inhibitor	CYP3A4			0	95.74	Selleck	S2397	Palmatine chloride	352.155	COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	QUCQEUCGKKTEBI-UHFFFAOYSA-N	19009.0		QUCQEUCGKKTEBI
BRD-K91356052-001-04-0	palmitoleic-acid	Preclinical					0	97.5	Sigma	MFCD00004437	(9Z)-9-hexadecenoic acid	254.225	CCCCCC\C=C/CCCCCCCC(O)=O	SECPZKHBENQXJG-FPLPWBNLSA-N	445638.0		SECPZKHBENQXJG
BRD-K01826784-003-09-9	palmitoylcarnitine	Preclinical	protein kinase inhibitor				0	83.5	Tocris	609	(+/-)-Palmitoylcarnitine chloride	400.343	CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|	XOMRRQXKHMYMOC-NRFANRHFSA-O	16903.0		XOMRRQXKHMYMOC
BRD-K01826784-003-08-9	palmitoylcarnitine	Preclinical	protein kinase inhibitor				0	100.0	Tocris	609	(?)-Palmitoylcarnitine chloride	436.319	CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|	XOMRRQXKHMYMOC-NRFANRHFSA-O	16903.0		XOMRRQXKHMYMOC
BRD-K68095457-001-11-9	palmitoylethanolamide	Launched	cannabinoid receptor agonist	CNR2|GPR119|GPR55			0	91.3	MicroSource	1506156	PALMIDROL [5mM]	299.282	CCCCCCCCCCCCCCCC(=O)NCCO	HXYVTAGFYLMHSO-UHFFFAOYSA-N	4671.0		HXYVTAGFYLMHSO
BRD-K68095457-001-10-1	palmitoylethanolamide	Launched	cannabinoid receptor agonist	CNR2|GPR119|GPR55			0	96.53	Tocris	879	Palmitoylethanolamide	299.282	CCCCCCCCCCCCCCCC(=O)NCCO	HXYVTAGFYLMHSO-UHFFFAOYSA-N	4671.0		HXYVTAGFYLMHSO
BRD-A50998626-001-03-9	palomid-529	Phase 1	AKT inhibitor|mTOR inhibitor	MTOR			0	95.63	MedChemEx	HY-14581	Palomid 529	406.142	COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|	YEAHTLOYHVWAKW-CQSZACIVSA-N	86324425.0		YEAHTLOYHVWAKW
BRD-A50998626-001-02-1	palomid-529	Phase 1	AKT inhibitor|mTOR inhibitor	MTOR			0	94.07	Selleck	S2238	Palomid 529 (P529)	406.142	COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25,r|	YEAHTLOYHVWAKW-CQSZACIVSA-N	86324425.0		YEAHTLOYHVWAKW
BRD-K08924299-003-07-9	palonosetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting	0	95.46	MedChemEx	HY-A0021	Palonosetron (Hydrochloride)	296.189	O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2	CPZBLNMUGSZIPR-NVXWUHKLSA-N	6337614.0		CPZBLNMUGSZIPR
BRD-K08924299-003-06-1	palonosetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting	0	97.7	Selleck	S3050	Palonosetron HCl	296.189	O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2	CPZBLNMUGSZIPR-NVXWUHKLSA-N	6337614.0		CPZBLNMUGSZIPR
BRD-K07682953-001-01-8	palosuran	Phase 2	urotensin receptor antagonist	UTS2R			0	98.46	MedChemEx	HY-10655	Palosuran	418.237	Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1	WYJCYXOCHXWTHG-UHFFFAOYSA-N	10173280.0		WYJCYXOCHXWTHG
BRD-K83794243-001-01-8	palovarotene	Phase 3	retinoid receptor agonist	RARG			0	89.92	MedChemEx	HY-14799	Palovarotene	414.231	CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12	YTFHCXIPDIHOIA-DHZHZOJOSA-N	10295295.0		YTFHCXIPDIHOIA
BRD-K83794243-001-02-9	palovarotene	Phase 3	retinoid receptor agonist	RARG			0	93.11	MedChemEx	HY-14799	Palovarotene	414.231	CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12	YTFHCXIPDIHOIA-DHZHZOJOSA-N	10295295.0		YTFHCXIPDIHOIA
BRD-M67659203-001-01-9	pamabrom	Launched	diuretic		gastroenterology	bloating	1	0.0	MicroSource	1505951	PAMABROM	347.059	CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O	ATOTUUBRFJHZQG-UHFFFAOYSA-N	11806.0		ATOTUUBRFJHZQG
BRD-M67659203-001-02-7	pamabrom	Launched	diuretic		gastroenterology	bloating	1	0.0	Sigma	PHR1299-1G	Pamabrom	347.059	CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O	ATOTUUBRFJHZQG-UHFFFAOYSA-N	11806.0		ATOTUUBRFJHZQG
BRD-K58513245-304-03-5	pamidronate	Launched	bone resorption inhibitor	FDPS	endocrinology|oncology|hematologic malignancy	hypercalcemia|Paget's disease|breast cancer|multiple myeloma	1	0.0	Selleck	S1311	Pamidronate Disodium	235.001	NCCC(O)(P(O)(O)=O)P(O)(O)=O	WRUUGTRCQOWXEG-UHFFFAOYSA-N	4674.0		WRUUGTRCQOWXEG
BRD-K58513245-304-02-7	pamidronate	Launched	bone resorption inhibitor	FDPS	endocrinology|oncology|hematologic malignancy	hypercalcemia|Paget's disease|breast cancer|multiple myeloma	1	0.0	Selleck	S1311	Pamidronate Disodium	235.001	NCCC(O)(P(O)(O)=O)P(O)(O)=O	WRUUGTRCQOWXEG-UHFFFAOYSA-N	4674.0		WRUUGTRCQOWXEG
BRD-K00003461-001-01-9	pamiparib	Phase 3	PARP inhibitor				0	97.75	MedChemEx	HY-104044	Pamiparib	298.123	C[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34	DENYZIUJOTUUNY-MRXNPFEDSA-N	135565554.0		DENYZIUJOTUUNY
BRD-K50817623-303-08-9	pancuronium	Launched	acetylcholine receptor antagonist	CHRM2|CHRM3|CHRNA1|CHRNA2	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	0	0.0	Tocris	693	Pancuronium dibromide	572.455	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	GVEAYVLWDAFXET-XGHATYIMSA-N	441289.0		GVEAYVLWDAFXET
BRD-K50817623-303-05-7	pancuronium	Launched	acetylcholine receptor antagonist	CHRM2|CHRM3|CHRNA1|CHRNA2	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	0	100.0	Selleck	S2497	Pancuronium (Pavulon)	572.455	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	GVEAYVLWDAFXET-XGHATYIMSA-N	441289.0		GVEAYVLWDAFXET
BRD-K50817623-303-07-9	pancuronium	Launched	acetylcholine receptor antagonist	CHRM2|CHRM3|CHRNA1|CHRNA2	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	0	99.2	MedChemEx	HY-B0429	Pancuronium (dibromide)	572.455	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	GVEAYVLWDAFXET-XGHATYIMSA-N	441289.0		GVEAYVLWDAFXET
BRD-K50817623-303-06-5	pancuronium	Launched	acetylcholine receptor antagonist	CHRM2|CHRM3|CHRNA1|CHRNA2	critical care|neurology/psychiatry	endotracheal intubation|muscle relaxant	0	0.0	Selleck	S2497	Pancuronium dibromide	572.455	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	GVEAYVLWDAFXET-XGHATYIMSA-N	441289.0	BRD-K25166838-303-01-1	GVEAYVLWDAFXET
BRD-K00004671-001-01-9	panipenem	Preclinical	antibacterial 				0	17.51	Adooq	A13096	(5R,6S)-3-[(3S)-1-(1-aminovinyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid	339.125	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(N)=C)=C(N2C1=O)C(O)=O |c:16|	UIWSCWBHZRPIKR-DLYFRVTGSA-N			UIWSCWBHZRPIKR
BRD-K02130563-001-15-5	panobinostat	Launched	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9	hematologic malignancy	multiple myeloma	0	76.8	MedChemEx	HY-10224	Panobinostat	349.179	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	FPOHNWQLNRZRFC-ZHACJKMWSA-N	6918837.0		FPOHNWQLNRZRFC
BRD-K02130563-001-14-8	panobinostat	Launched	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9	hematologic malignancy	multiple myeloma	0	74.94	MedChemEx	HY-10224	Panobinostat	349.179	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	FPOHNWQLNRZRFC-ZHACJKMWSA-N	6918837.0		FPOHNWQLNRZRFC
BRD-K02130563-001-12-2	panobinostat	Launched	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9	hematologic malignancy	multiple myeloma	0	81.65	Selleck	S1030	Panobinostat	349.179	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	FPOHNWQLNRZRFC-ZHACJKMWSA-N	6918837.0		FPOHNWQLNRZRFC
BRD-K02130563-001-11-4	panobinostat	Launched	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9	hematologic malignancy	multiple myeloma	0	81.62	Selleck	S1030	Panobinostat (LBH589)	349.179	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	FPOHNWQLNRZRFC-ZHACJKMWSA-N	6918837.0		FPOHNWQLNRZRFC
BRD-K68764924-001-03-2	pantethine	Launched	coenzyme A precursor				0	97.01	Sigma	P3280	(2R)-N-[(17R)-17,19-dihydroxy-18,18-dimethyl-3,12,16-trioxo-7,8-dithia-4,11,15-triazanonadec-1-yl]-2,4-dihydroxy-3,3-dimethylbutanamide	554.244	CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO	DJWYOLJPSHDSAL-ROUUACIJSA-N	452306.0		DJWYOLJPSHDSAL
BRD-K68764924-001-05-7	pantethine	Launched	coenzyme A precursor				0	94.77	MedChemEx	HY-B1028	Pantethine	554.244	CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO	DJWYOLJPSHDSAL-ROUUACIJSA-N	452306.0		DJWYOLJPSHDSAL
BRD-K68764924-001-06-9	pantethine	Launched	coenzyme A precursor				0	83.03	MedChemEx	HY-B1028	Pantethine	554.244	CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO	DJWYOLJPSHDSAL-ROUUACIJSA-N	452306.0		DJWYOLJPSHDSAL
BRD-K68764924-001-04-0	pantethine	Launched	coenzyme A precursor				0	82.93	MedChemEx	HY-B1028	Pantethine	554.244	CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO	DJWYOLJPSHDSAL-ROUUACIJSA-N	452306.0		DJWYOLJPSHDSAL
BRD-K00003243-236-01-9	pantoprazole	Launched	ATPase inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|erosive esophagitis (EE)|Zollinger-Ellison syndrome	0	98.13	MedChemEx	HY-17507A	Pantoprazole (sodium)	383.075	COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|	IQPSEEYGBUAQFF-AREMUKBSSA-N	11181988.0		IQPSEEYGBUAQFF
BRD-K29392254-236-05-9	pantothenic-acid	Launched	coenzyme A precursor				0	100.0	MedChemEx	HY-B0430A	D-Pantothenic acid (sodium)	219.111	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	GHOKWGTUZJEAQD-ZETCQYMHSA-N	6613.0		GHOKWGTUZJEAQD
BRD-K29392254-236-01-6	pantothenic-acid	Launched	coenzyme A precursor				0	83.52	MicroSource	1505715	PANTOTHENIC ACID(d) Na salt	219.111	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	GHOKWGTUZJEAQD-ZETCQYMHSA-N	6613.0		GHOKWGTUZJEAQD
BRD-K29392254-001-02-2	pantothenic-acid	Launched	coenzyme A precursor				0	84.04	Selleck	S2498	D-Pantothenic acid	219.111	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	GHOKWGTUZJEAQD-ZETCQYMHSA-N	6613.0		GHOKWGTUZJEAQD
BRD-K29392254-001-03-0	pantothenic-acid	Launched	coenzyme A precursor				0	86.63	Selleck	S2498	D-Pantothenic acid	219.111	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	GHOKWGTUZJEAQD-ZETCQYMHSA-N	6613.0		GHOKWGTUZJEAQD
BRD-K18573821-001-03-9	PAOPA	Preclinical	dopamine receptor modulator	DRD2			0	82.29	Tocris	5041	PAOPA	254.138	NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O	QXHVGEXNEZRSGG-JGVFFNPUSA-N	44281634.0		QXHVGEXNEZRSGG
BRD-K18573821-001-02-4	PAOPA	Preclinical	dopamine receptor modulator	DRD2			0	69.39	Tocris	5041	PAOPA	254.138	NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O	QXHVGEXNEZRSGG-JGVFFNPUSA-N	44281634.0		QXHVGEXNEZRSGG
BRD-K15567136-003-27-2	papaverine	Launched	phosphodiesterase inhibitor	PDE10A|PDE4B|PDE5A	cardiology|hematology|gastroenterology	myocardial infarction|angina pectoris|pulmonary embolism (PE)|colitis|vascular spasm	0	99.78	MicroSource	1500459	PAPAVERINE HYDROCHLORIDE	339.147	COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	XQYZDYMELSJDRZ-UHFFFAOYSA-N	4680.0		XQYZDYMELSJDRZ
BRD-K00003371-001-01-9	paquinimod	Phase 2	S100A9 inhibitor				0	72.44	MedChemEx	HY-100442	Paquinimod	350.163	CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1	DIKSYHCCYVYKRO-UHFFFAOYSA-N	54684617.0		DIKSYHCCYVYKRO
BRD-K62412084-001-08-9	para-toluenesulfonamide	Phase 3		CA12|CA2|CA6|CA9			0	98.19	MedChemEx	HY-79602	p-Tosylamide	171.035	Cc1ccc(cc1)S(N)(=O)=O	LMYRWZFENFIFIT-UHFFFAOYSA-N	6269.0		LMYRWZFENFIFIT
BRD-K62412084-001-07-1	para-toluenesulfonamide	Phase 3		CA12|CA2|CA6|CA9			0	97.72	Enamine	Z45415564		171.035	Cc1ccc(cc1)S(N)(=O)=O	LMYRWZFENFIFIT-UHFFFAOYSA-N	6269.0		LMYRWZFENFIFIT
BRD-K41524689-001-25-0	paracetamol	Launched	cyclooxygenase inhibitor	FAAH|PTGS1|PTGS2|TRPV1	neurology/psychiatry|endocrinology	pain relief|fever	0	75.41	Tocris	1706	Acetaminophen	151.063	CC(=O)Nc1ccc(O)cc1	RZVAJINKPMORJF-UHFFFAOYSA-N	1983.0		RZVAJINKPMORJF
BRD-K41524689-001-23-5	paracetamol	Launched	cyclooxygenase inhibitor	FAAH|PTGS1|PTGS2|TRPV1	neurology/psychiatry|endocrinology	pain relief|fever	0	95.0	MicroSource	1500101	ACETAMINOPHEN	151.063	CC(=O)Nc1ccc(O)cc1	RZVAJINKPMORJF-UHFFFAOYSA-N	1983.0		RZVAJINKPMORJF
BRD-K41524689-001-22-7	paracetamol	Launched	cyclooxygenase inhibitor	FAAH|PTGS1|PTGS2|TRPV1	neurology/psychiatry|endocrinology	pain relief|fever	0	91.93	Tocris	1706	Acetaminophen	151.063	CC(=O)Nc1ccc(O)cc1	RZVAJINKPMORJF-UHFFFAOYSA-N	1983.0		RZVAJINKPMORJF
BRD-K41524689-001-05-2	paracetamol	Launched	cyclooxygenase inhibitor	FAAH|PTGS1|PTGS2|TRPV1	neurology/psychiatry|endocrinology	pain relief|fever	0		Prestwick	Prestw-868	Acetaminophen	151.063	CC(=O)Nc1ccc(O)cc1	InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)	1983.0		RZVAJINKPMORJF
BRD-K40992116-001-10-9	parachlorophenol	Launched	antiinfective drug		infectious disease	first-aid antiseptic	0	16.2	MedChemEx	HY-75103	4-chlorophenol	128.003	Oc1ccc(Cl)cc1	WXNZTHHGJRFXKQ-UHFFFAOYSA-N	4684.0		WXNZTHHGJRFXKQ
BRD-K40992116-001-09-7	parachlorophenol	Launched	antiinfective drug		infectious disease	first-aid antiseptic	0	89.27	MicroSource	1500460	PARACHLOROPHENOL	128.003	Oc1ccc(Cl)cc1	WXNZTHHGJRFXKQ-UHFFFAOYSA-N	4684.0		WXNZTHHGJRFXKQ
BRD-A22128695-001-02-6	paramethadione	Launched	anticonvulsant	CACNA1G	neurology/psychiatry	seizures	0	15.0	MicroSource	1505456	PARAMETHADIONE	157.074	CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|	VQASKUSHBVDKGU-SSDOTTSWSA-N	51380897.0		VQASKUSHBVDKGU
BRD-A22128695-001-03-4	paramethadione	Launched	anticonvulsant	CACNA1G	neurology/psychiatry	seizures	0	0.0	Enamine	Z2327506990	5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione	157.074	CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2,r|	VQASKUSHBVDKGU-SSDOTTSWSA-N	51380897.0		VQASKUSHBVDKGU
BRD-K24084088-001-11-3	paraxanthine	Phase 1	adenosine receptor antagonist				0	97.98	Enzo	AC633	Paraxanthine	180.065	Cn1cnc2[nH]c(=O)n(C)c(=O)c12	QUNWUDVFRNGTCO-UHFFFAOYSA-N	4687.0		QUNWUDVFRNGTCO
BRD-K24084088-001-12-9	paraxanthine	Phase 1	adenosine receptor antagonist				0	94.51	Sigma	MFCD00005727	1,7-Dimethylxanthine	180.065	Cn1cnc2[nH]c(=O)n(C)c(=O)c12	QUNWUDVFRNGTCO-UHFFFAOYSA-N	4687.0		QUNWUDVFRNGTCO
BRD-K02407574-001-09-7	parbendazole	Preclinical	tubulin polymerization inhibitor	TUBB			0	98.82	Prestwick	Prestw-1110	Parbendazole	247.132	CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1	YRWLZFXJFBZBEY-UHFFFAOYSA-N	26596.0		YRWLZFXJFBZBEY
BRD-K00004740-001-01-9	parcetasal	Preclinical	anti-inflammatory agent				0	95.17	MedChemEx	HY-U00100	Parcetasal	313.095	CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1 |&1:9,r|	ZAPRLADYRFPQSH-KRWDZBQOSA-N	76961763.0		ZAPRLADYRFPQSH
BRD-K11851476-003-01-7	pardoprunox	Phase 3	dopamine receptor agonist|serotonin receptor agonist	DRD2|DRD3|DRD4|HTR1A|HTR7			0	96.94	MedChemEx	HY-14958A	Pardoprunox (hydrochloride)	233.116	CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	YVPUUUDAZYFFQT-UHFFFAOYSA-N	6918525.0		YVPUUUDAZYFFQT
BRD-K13800121-001-01-5	parecoxib	Launched	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	0	99.02	MedChemEx	HY-17474	Parecoxib	370.099	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	TZRHLKRLEZJVIJ-UHFFFAOYSA-N	119828.0		TZRHLKRLEZJVIJ
BRD-K13800121-001-03-9	parecoxib	Launched	cyclooxygenase inhibitor	LTF	neurology/psychiatry	pain relief	0	97.05	MedChemEx	HY-17474	Parecoxib	370.099	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	TZRHLKRLEZJVIJ-UHFFFAOYSA-N	119828.0		TZRHLKRLEZJVIJ
BRD-K54799382-003-08-4	parethoxycaine	Preclinical	local anesthetic				0	91.8	ChemBridge	6771521		265.168	CCOc1ccc(cc1)C(=O)OCCN(CC)CC	OWWVHQUOYSPNNE-UHFFFAOYSA-N	7183.0		OWWVHQUOYSPNNE
BRD-K83597974-003-23-9	pargyline	Launched	monoamine oxidase inhibitor	MAOA|MAOB	cardiology	hypertension	0	91.94	MedChemEx	HY-A0091	Pargyline (hydrochloride)	159.105	CN(CC#C)Cc1ccccc1	DPWPWRLQFGFJFI-UHFFFAOYSA-N	4688.0		DPWPWRLQFGFJFI
BRD-K83597974-003-22-2	pargyline	Launched	monoamine oxidase inhibitor	MAOA|MAOB	cardiology	hypertension	0	99.36	MicroSource	1500462	PARGYLINE HYDROCHLORIDE	159.105	CN(CC#C)Cc1ccccc1	DPWPWRLQFGFJFI-UHFFFAOYSA-N	4688.0		DPWPWRLQFGFJFI
BRD-K60585088-001-03-9	paricalcitol	Launched	vitamin D receptor agonist	VDR	nephrology|endocrinology	chronic kidney disease (CKD)|hyperthyroidism	0	94.64	MedChemEx	HY-50919	Paricalcitol	416.329	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1	BPKAHTKRCLCHEA-UBFJEZKGSA-N	5281104.0		BPKAHTKRCLCHEA
BRD-K60585088-001-01-5	paricalcitol	Launched	vitamin D receptor agonist	VDR	nephrology|endocrinology	chronic kidney disease (CKD)|hyperthyroidism	0	98.6	MedChemEx	HY-50919	Paricalcitol	416.329	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1	BPKAHTKRCLCHEA-UBFJEZKGSA-N	5281104.0		BPKAHTKRCLCHEA
BRD-K89920762-001-01-4	paritaprevir	Launched	HCV inhibitor		infectious disease	hepatitis C	0	97.16	MedChemEx	HY-12594	Paritaprevir	765.294	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|	UAUIUKWPKRJZJV-QPLHLKROSA-N	45110509.0		UAUIUKWPKRJZJV
BRD-K36524108-065-06-5	paromomycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	0	0.0	MicroSource	1503228	PAROMOMYCIN SULFATE	615.296	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	UOZODPSAJZTQNH-LSWIJEOBSA-N	165580.0	BRD-A20920572-065-04-7	UOZODPSAJZTQNH
BRD-K36524108-065-04-0	paromomycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	0	97.2	MedChemEx	HY-B0956	Paromomycin (sulfate)	615.296	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	UOZODPSAJZTQNH-LSWIJEOBSA-N	165580.0		UOZODPSAJZTQNH
BRD-K36524108-065-07-3	paromomycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	0	0.0	Sigma	S______P9297		615.296	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	UOZODPSAJZTQNH-LSWIJEOBSA-N	165580.0	BRD-M40700687-001-01-8	UOZODPSAJZTQNH
BRD-K36524108-065-05-7	paromomycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	0	0.0	Selleck	S4183	Paromomycin Sulfate	615.296	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	UOZODPSAJZTQNH-LSWIJEOBSA-N	165580.0	BRD-K25359791-065-01-2	UOZODPSAJZTQNH
BRD-K36524108-065-03-2	paromomycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	amebiasis	0	0.0	Selleck	S4183	Paromomycin Sulfate	615.296	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	UOZODPSAJZTQNH-LSWIJEOBSA-N	165580.0		UOZODPSAJZTQNH
BRD-K37991163-003-14-2	paroxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR2A|SLC6A2|SLC6A4	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder	0	91.01	MicroSource	1504085	PAROXETINE HYDROCHLORIDE	329.143	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	AHOUBRCZNHFOSL-YOEHRIQHSA-N	43815.0		AHOUBRCZNHFOSL
BRD-K37991163-050-18-4	paroxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR2A|SLC6A2|SLC6A4	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder	0	83.25	Tocris	2141	Paroxetine maleate	329.143	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	AHOUBRCZNHFOSL-YOEHRIQHSA-N	43815.0		AHOUBRCZNHFOSL
BRD-K37991163-003-13-4	paroxetine	Launched	selective serotonin reuptake inhibitor (SSRI)	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR2A|SLC6A2|SLC6A4	neurology/psychiatry	depression|obsessive compulsive disorder (OCD)|generalized anxiety disorder (GAD)|panic disorders|posttraumatic stress disorder|social anxiety disorder	0	94.73	Selleck	S3005	Paroxetine HCl	329.143	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	AHOUBRCZNHFOSL-YOEHRIQHSA-N	43815.0		AHOUBRCZNHFOSL
BRD-K07441213-001-20-9	paroxypropione	Launched	gonadotropin inhibitor				0	97.55	MedChemEx	HY-B1353	Paroxypropione	150.068	CCC(=O)c1ccc(O)cc1	RARSHUDCJQSEFJ-UHFFFAOYSA-N	6271.0		RARSHUDCJQSEFJ
BRD-K07441213-001-18-9	paroxypropione	Launched	gonadotropin inhibitor				0	93.24	MicroSource	1506169	PAROXYPROPIONE	150.068	CCC(=O)c1ccc(O)cc1	RARSHUDCJQSEFJ-UHFFFAOYSA-N	6271.0		RARSHUDCJQSEFJ
BRD-K00004594-001-01-9	parsaclisib	Phase 2	PI3K inhibitor				0	97.97	MedChemEx	HY-109068	Parsaclisib	432.148	CCOc1c(cc(Cl)c(F)c1[C@@H]1CNC(=O)C1)[C@H](C)n1nc(C)c2c(N)ncnc12	ZQPDJCIXJHUERQ-QWRGUYRKSA-N	86677874.0		ZQPDJCIXJHUERQ
BRD-K98548675-001-06-7	parthenolide	Phase 1	NFkB pathway inhibitor				0	94.73	Tocris	610	Parthenolide	248.141	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-SLXBATTESA-N	6473881.0		KTEXNACQROZXEV
BRD-K98548675-001-09-9	parthenolide	Phase 1	NFkB pathway inhibitor				0	87.31	Tocris	610	Parthenolide	248.141	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-SLXBATTESA-N	6473881.0		KTEXNACQROZXEV
BRD-K98548675-001-05-9	parthenolide	Phase 1	NFkB pathway inhibitor				0	96.19	Tocris	610	Parthenolide	248.141	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-SLXBATTESA-N	6473881.0		KTEXNACQROZXEV
BRD-K34851558-001-02-3	parthenolide-(-)	Preclinical	NFkB pathway inhibitor	HDAC1			0	96.2	Selleck	S2341	(-)-Parthenolide	248.141	C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|	KTEXNACQROZXEV-QLIGOWBFSA-N	5420805.0		KTEXNACQROZXEV
BRD-K28120222-001-09-9	parthenolide-(alternate-stereo)	Preclinical	NFkB pathway inhibitor	IKBKB|RELA			0	82.0	MedChemEx	HY-N0141	Parthenolide	248.141	C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-PVLRGYAZSA-N	7251185.0		KTEXNACQROZXEV
BRD-K28120222-001-08-4	parthenolide-(alternate-stereo)	Preclinical	NFkB pathway inhibitor	IKBKB|RELA			0	97.8	Prestwick	Prestw-550	Parthenolide	248.141	C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	KTEXNACQROZXEV-PVLRGYAZSA-N	7251185.0		KTEXNACQROZXEV
BRD-K59715032-362-02-9	pasireotide	Launched	somatostatin receptor agonist	SSTR1|SSTR2|SSTR3|SSTR5	endocrinology	Cushing's syndrome|acromegaly	0	92.83	MedChemEx	HY-79135	Pasireotide (ditrifluoroacetate)	1046.501	NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1	VMZMNAABQBOLAK-DBILLSOUSA-N	9941444.0		VMZMNAABQBOLAK
BRD-K59715032-362-01-4	pasireotide	Launched	somatostatin receptor agonist	SSTR1|SSTR2|SSTR3|SSTR5	endocrinology	Cushing's syndrome|acromegaly	0	87.58	MedChemEx	HY-79135	Pasireotide (ditrifluoroacetate)	1046.501	NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1	VMZMNAABQBOLAK-DBILLSOUSA-N	9941444.0		VMZMNAABQBOLAK
BRD-K00003481-001-01-9	PAT-1251	Phase 1	lysyl oxidase inhibitor				0	86.27	MedChemEx	HY-107422	PAT-1251	399.121	NCc1cc(Oc2cccc(c2)C(=O)N2C[C@@H](O)[C@H](F)C2)nc(c1)C(F)(F)F	ODGXXYXJORZPHE-ZIAGYGMSSA-N	122536283.0		ODGXXYXJORZPHE
BRD-K00003170-001-01-9	pavinetant	Phase 2	neurokinin receptor antagonist				0	97.33	MedChemEx	HY-14432	Pavinetant	459.162	CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	QYTBBBAHNIWFOD-NRFANRHFSA-N	23649245.0		QYTBBBAHNIWFOD
BRD-K74514084-003-09-2	pazopanib	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)	0	98.3	Selleck	S1035	Pazopanib HCl (GW786034 HCl)	437.163	CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1	CUIHSIWYWATEQL-UHFFFAOYSA-N	10113978.0		CUIHSIWYWATEQL
BRD-K74514084-001-03-9	pazopanib	Launched	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3	oncology	renal cell carcinoma (RCC)|soft tissue sarcoma (STS)	0	98.32	Selleck	S3012	Pazopanib	437.163	CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1	CUIHSIWYWATEQL-UHFFFAOYSA-N	10113978.0		CUIHSIWYWATEQL
BRD-K66412701-066-09-9	pazufloxacin	Launched	topoisomerase inhibitor		infectious disease	pneumonia|peritonitis|bacterial septicemia	0	96.98	MedChemEx	HY-B0724A	Pazufloxacin (mesylate)	318.102	C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1	XAGMUUZPGZWTRP-ZETCQYMHSA-N	65957.0		XAGMUUZPGZWTRP
BRD-K66412701-066-01-6	pazufloxacin	Launched	topoisomerase inhibitor		infectious disease	pneumonia|peritonitis|bacterial septicemia	0	97.79	MicroSource	1502319	PAZUFLOXACIN MESYLATE	318.102	C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1	XAGMUUZPGZWTRP-ZETCQYMHSA-N	65957.0		XAGMUUZPGZWTRP
BRD-K00003391-236-01-9	PBI-4050	Phase 2/Phase 3	free fatty acid receptor agonist				0	91.94	MedChemEx	HY-100775	PBI-4050 (sodium salt)	206.131	CCCCCc1cccc(CC(O)=O)c1	PEGQOIGYZLJMIB-UHFFFAOYSA-N	24749700.0		PEGQOIGYZLJMIB
BRD-K00004615-001-01-9	PBT-1033	Preclinical	chelating agent				0	83.21	Astatech	P17129	PBT-1033	270.033	CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	YZPOQCQXOSEMAZ-UHFFFAOYSA-N	10016012.0		YZPOQCQXOSEMAZ
BRD-A29289453-001-05-4	PCA-4248	Phase 1	platelet activating factor receptor antagonist	PTAFR			0	91.88	Tocris	571	PCA 4248	361.135	COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|	DHCNAWNKZMNTIS-GFCCVEGCSA-N	6604734.0		DHCNAWNKZMNTIS
BRD-A29289453-001-06-9	PCA-4248	Phase 1	platelet activating factor receptor antagonist	PTAFR			0	91.18	Tocris	571	PCA 4248	361.135	COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|	DHCNAWNKZMNTIS-GFCCVEGCSA-N	6604734.0		DHCNAWNKZMNTIS
BRD-A29289453-001-04-7	PCA-4248	Phase 1	platelet activating factor receptor antagonist	PTAFR			0	87.64	Tocris	571	PCA 4248	361.135	COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11,r,c:4,9|	DHCNAWNKZMNTIS-GFCCVEGCSA-N	6604734.0		DHCNAWNKZMNTIS
BRD-K12867552-001-04-7	PCI-24781	Phase 3	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC6			0	90.76	Selleck	S1090	PCI-24781 (Abexinostat)	397.164	CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO	MAUCONCHVWBMHK-UHFFFAOYSA-N	11749858.0		MAUCONCHVWBMHK
BRD-K00003213-001-01-9	PCI-27483	Phase 2	ERK1 and ERK2 phosphorylation inhibitor				0	93.54	MedChemEx	HY-16382	PCI-27483	596.133	NC(=N)c1ccc2nc([nH]c2c1)-c1cc(CC(=O)N[C@@H](CC(O)=O)C(O)=O)cc(c1O)-c1cc(ccc1O)S(N)(=O)=O	WDJHHCAKBRKCLW-IBGZPJMESA-N	135425273.0		WDJHHCAKBRKCLW
BRD-K71223042-001-03-9	PCI-29732	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	97.95	Tocris	5012	PCI 29732	371.175	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1	GMJUPMONHWAZCP-UHFFFAOYSA-N	22347110.0		GMJUPMONHWAZCP
BRD-K71223042-001-01-5	PCI-29732	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0	0.0	Tocris	5012	PCI 29732	371.175	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1	GMJUPMONHWAZCP-UHFFFAOYSA-N	22347110.0		GMJUPMONHWAZCP
BRD-K88742110-001-11-9	PCI-34051	Preclinical	HDAC inhibitor	HDAC1|HDAC10|HDAC6|HDAC8			0	96.48	Tocris	4643	PCI 34051	296.116	COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	AJRGHIGYPXNABY-UHFFFAOYSA-N	24753719.0		AJRGHIGYPXNABY
BRD-K88742110-001-09-5	PCI-34051	Preclinical	HDAC inhibitor	HDAC1|HDAC10|HDAC6|HDAC8			0	85.17	Tocris	4643	PCI 34051	296.116	COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	AJRGHIGYPXNABY-UHFFFAOYSA-N	24753719.0		AJRGHIGYPXNABY
BRD-K88742110-001-07-9	PCI-34051	Preclinical	HDAC inhibitor	HDAC1|HDAC10|HDAC6|HDAC8			0	80.25	Selleck	S2012	PCI-34051	296.116	COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	AJRGHIGYPXNABY-UHFFFAOYSA-N	24753719.0		AJRGHIGYPXNABY
BRD-K88742110-001-08-7	PCI-34051	Preclinical	HDAC inhibitor	HDAC1|HDAC10|HDAC6|HDAC8			0	88.28	Selleck	S2012	PCI-34051	296.116	COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	AJRGHIGYPXNABY-UHFFFAOYSA-N	24753719.0		AJRGHIGYPXNABY
BRD-K52721684-001-03-0	PCO-400	Phase 1	potassium channel activator	KCNJ8			0	32.31	Enzo	KC131	PCO-400	299.116	CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|	WJBHHTPFTVKZCV-CVEARBPZSA-N	129348.0		WJBHHTPFTVKZCV
BRD-K52721684-001-04-8	PCO-400	Phase 1	potassium channel activator	KCNJ8			0	90.29	SantaCruz	sc-200989	PCO 400	299.116	CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|	WJBHHTPFTVKZCV-CVEARBPZSA-N	129348.0		WJBHHTPFTVKZCV
BRD-K49865102-001-08-4	PD-0325901	Phase 2	MEK inhibitor	MAP2K1			0	95.2	Selleck	S1036	PD0325901	481.995	OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	SUDAHWBOROXANE-SECBINFHSA-N	9826528.0		SUDAHWBOROXANE
BRD-A89337244-001-03-7	PD-102807	Preclinical	acetylcholine receptor antagonist	CHRM4			0	78.87	Tocris	1671	PD 102807	392.174	CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|	VDDUJINYXKGZLV-JOCHJYFZSA-N	92845316.0		VDDUJINYXKGZLV
BRD-A89337244-001-04-9	PD-102807	Preclinical	acetylcholine receptor antagonist	CHRM4			0	90.95	Tocris	1671	PD 102807	392.174	CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|	VDDUJINYXKGZLV-JOCHJYFZSA-N	92845316.0		VDDUJINYXKGZLV
BRD-A89337244-001-02-9	PD-102807	Preclinical	acetylcholine receptor antagonist	CHRM4			0	88.27	Tocris	1671	PD 102807	392.174	CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14,r|	VDDUJINYXKGZLV-JOCHJYFZSA-N	92845316.0		VDDUJINYXKGZLV
BRD-K34657753-001-01-9	PD-118057	Preclinical	potassium channel activator	KCNH2			0	94.44	Sigma	MFCD08705328	2-{4-[2-(3,4-dichlorophenyl)ethyl]anilino}benzoic acid	385.064	OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1	ZCQOSCDABPVAFB-UHFFFAOYSA-N	9864959.0		ZCQOSCDABPVAFB
BRD-K34713073-362-02-9	PD-123319	Phase 1	angiotensin antagonist	AGTR2			0	96.91	Tocris	1361	PD 123319 ditrifluoroacetate	508.247	CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	YSTVFDAKLDMYCR-NDEPHWFRSA-N	5311345.0		YSTVFDAKLDMYCR
BRD-K34713073-001-01-3	PD-123319	Phase 1	angiotensin antagonist	AGTR2			0	95.92	Selleck	S7098	PD123319	508.247	CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	YSTVFDAKLDMYCR-NDEPHWFRSA-N	5311345.0		YSTVFDAKLDMYCR
BRD-K34713073-362-01-9	PD-123319	Phase 1	angiotensin antagonist	AGTR2			0	95.55	Tocris	1361	PD 123319 ditrifluoroacetate	508.247	CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	YSTVFDAKLDMYCR-NDEPHWFRSA-N	5311345.0		YSTVFDAKLDMYCR
BRD-K62456038-003-08-9	PD-128907	Preclinical	dopamine receptor agonist	DRD2|DRD3			0	93.45	MedChemEx	HY-110000	(+)-PD 128907 hydrochloride	249.136	CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	YOILXOMTHPUMRG-TZMCWYRMSA-N	5311346.0		YOILXOMTHPUMRG
BRD-K62456038-003-09-9	PD-128907	Preclinical	dopamine receptor agonist	DRD2|DRD3			0	90.26	Tocris	1243	(+)-PD 128907 hydrochloride	249.136	CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	YOILXOMTHPUMRG-TZMCWYRMSA-N	5311346.0		YOILXOMTHPUMRG
BRD-K62456038-003-07-1	PD-128907	Preclinical	dopamine receptor agonist	DRD2|DRD3			0	89.86	Tocris	1243	(+)-PD 128907 hydrochloride	249.136	CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	YOILXOMTHPUMRG-TZMCWYRMSA-N	5311346.0		YOILXOMTHPUMRG
BRD-K26603252-003-04-9	PD-153035	Phase 1	EGFR inhibitor	EGFR|KDR			0	98.35	MedChemEx	HY-12013	PD153035 (Hydrochloride)	359.027	COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC	LSPANGZZENHZNJ-UHFFFAOYSA-N	4705.0		LSPANGZZENHZNJ
BRD-K13826399-236-01-7	PD-156707	Preclinical	endothelin receptor antagonist	EDNRA|EDNRB			0	71.03	Sigma	PZ0141	sodium (2Z)-2-(1,3-benzodioxol-5-yl)-4-(4-methoxyphenyl)-4-oxo-3-(3,4,5-trimethoxybenzyl)-2-butenoate	506.158	COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1	OFCTYBMKKTVKCR-QQTULTPQSA-N	9871594.0		OFCTYBMKKTVKCR
BRD-K48735772-001-04-8	PD-158780	Preclinical	EGFR inhibitor	EGFR			0	23.87	Tocris	2615	PD 158780	329.028	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1	KFHMLBXBRCITHF-UHFFFAOYSA-N	4707.0		KFHMLBXBRCITHF
BRD-K48735772-001-03-0	PD-158780	Preclinical	EGFR inhibitor	EGFR			0	69.87	Tocris	2615	PD 158780	329.028	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1	KFHMLBXBRCITHF-UHFFFAOYSA-N	4707.0		KFHMLBXBRCITHF
BRD-K48735772-001-01-4	PD-158780	Preclinical	EGFR inhibitor	EGFR			0		Tocris	2615	PD 158780	329.028	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1	InChI=1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20)	4707.0		KFHMLBXBRCITHF
BRD-K12079898-001-03-4	PD-160170	Preclinical	neuropeptide receptor antagonist	NPY1R			0	95.73	Tocris	2200	PD 160170	371.094	CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	YUVNGBZROXQYQH-UHFFFAOYSA-N	9820766.0		YUVNGBZROXQYQH
BRD-K12079898-001-02-6	PD-160170	Preclinical	neuropeptide receptor antagonist	NPY1R			0	97.6	Tocris	2200	PD 160170	371.094	CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	YUVNGBZROXQYQH-UHFFFAOYSA-N	9820766.0		YUVNGBZROXQYQH
BRD-K12079898-001-04-9	PD-160170	Preclinical	neuropeptide receptor antagonist	NPY1R			0	96.79	Tocris	2200	PD 160170	371.094	CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	YUVNGBZROXQYQH-UHFFFAOYSA-N	9820766.0		YUVNGBZROXQYQH
BRD-K97152684-001-02-7	PD-161570	Preclinical	FGFR inhibitor	FGFR1			0	86.49	Tocris	3724	PD 161570	531.228	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl	MKVMEJKNLUWFSQ-UHFFFAOYSA-N	5328135.0		MKVMEJKNLUWFSQ
BRD-K97152684-001-01-9	PD-161570	Preclinical	FGFR inhibitor	FGFR1			0	73.55	Tocris	3724	PD 161570	531.228	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl	MKVMEJKNLUWFSQ-UHFFFAOYSA-N	5328135.0		MKVMEJKNLUWFSQ
BRD-K97152684-001-03-9	PD-161570	Preclinical	FGFR inhibitor	FGFR1			0	92.98	Tocris	3724	PD 161570	531.228	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl	MKVMEJKNLUWFSQ-UHFFFAOYSA-N	5328135.0		MKVMEJKNLUWFSQ
BRD-K93217218-300-01-5	PD-166285	Preclinical	SRC inhibitor	EGFR|FGFR1|PDGFRB|PKMYT1|SRC|WEE1			0	97.44	Tocris	3785	PD 166285 dihydrochloride	511.154	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1	IFPPYSWJNWHOLQ-UHFFFAOYSA-N	5311382.0		IFPPYSWJNWHOLQ
BRD-K93217218-300-03-9	PD-166285	Preclinical	SRC inhibitor	EGFR|FGFR1|PDGFRB|PKMYT1|SRC|WEE1			0	94.49	Tocris	3785	PD 166285 dihydrochloride	511.154	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1	IFPPYSWJNWHOLQ-UHFFFAOYSA-N	5311382.0		IFPPYSWJNWHOLQ
BRD-K60984070-001-02-8	PD-166793	Preclinical	collagenase inhibitor|metalloproteinase inhibitor	MMP13|MMP2|MMP3			0	92.62	Tocris	2520	PD 166793	411.014	CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	GJOCABIDMCKCEG-INIZCTEOSA-N	9887870.0		GJOCABIDMCKCEG
BRD-K60984070-001-01-0	PD-166793	Preclinical	collagenase inhibitor|metalloproteinase inhibitor	MMP13|MMP2|MMP3			0	98.52	Tocris	2520	PD 166793	411.014	CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	GJOCABIDMCKCEG-INIZCTEOSA-N	9887870.0		GJOCABIDMCKCEG
BRD-K60984070-001-03-9	PD-166793	Preclinical	collagenase inhibitor|metalloproteinase inhibitor	MMP13|MMP2|MMP3			0	97.21	Tocris	2520	PD 166793	411.014	CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	GJOCABIDMCKCEG-INIZCTEOSA-N	9887870.0		GJOCABIDMCKCEG
BRD-K47761761-050-07-8	PD-168077	Preclinical	dopamine receptor agonist	DRD2			0	20.24	Tocris	1065	PD 168077 maleate	334.179	Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N	DNULYRGWTFLJQL-UHFFFAOYSA-N	3645619.0		DNULYRGWTFLJQL
BRD-K17702546-001-03-2	PD-168393	Preclinical	EGFR inhibitor	EGFR|ERBB2|SRC			0	96.92	Selleck	S7039	PD168393	368.027	Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	HTUBKQUPEREOGA-UHFFFAOYSA-N	4708.0		HTUBKQUPEREOGA
BRD-K17702546-001-06-5	PD-168393	Preclinical	EGFR inhibitor	EGFR|ERBB2|SRC			0		Selleck	S7039	PD168393	368.027	Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)	4708.0		HTUBKQUPEREOGA
BRD-A82013137-300-01-1	PD-168568	Preclinical	dopamine receptor antagonist	DRD2|DRD4			0	96.65	Tocris	3529	PD 168568 dihydrochloride	349.215	Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|	WQEPZBNLBWDIRZ-OAQYLSRUSA-N	9928335.0		WQEPZBNLBWDIRZ
BRD-A82013137-300-02-9	PD-168568	Preclinical	dopamine receptor antagonist	DRD2|DRD4			0	96.53	Tocris	3529	PD 168568 dihydrochloride	349.215	Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|	WQEPZBNLBWDIRZ-OAQYLSRUSA-N	9928335.0		WQEPZBNLBWDIRZ
BRD-K97764662-001-21-5	PD-173074	Preclinical	FGFR inhibitor|VEGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB			0	85.38	Tocris	3044	PD 173074	523.327	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1	DXCUKNQANPLTEJ-UHFFFAOYSA-N	1401.0		DXCUKNQANPLTEJ
BRD-K97764662-001-20-7	PD-173074	Preclinical	FGFR inhibitor|VEGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB			0	94.27	Selleck	S1264	PD173074	523.327	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1	DXCUKNQANPLTEJ-UHFFFAOYSA-N	1401.0		DXCUKNQANPLTEJ
BRD-K97764662-001-17-3	PD-173074	Preclinical	FGFR inhibitor|VEGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB			0	75.66	Selleck	S1264	PD173074	523.327	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1	DXCUKNQANPLTEJ-UHFFFAOYSA-N	1401.0		DXCUKNQANPLTEJ
BRD-K97764662-001-23-9	PD-173074	Preclinical	FGFR inhibitor|VEGFR inhibitor	FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB			0	94.1	Tocris	3044	PD 173074	523.327	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1	DXCUKNQANPLTEJ-UHFFFAOYSA-N	1401.0		DXCUKNQANPLTEJ
BRD-K04426574-001-02-0	PD-173212	Preclinical	calcium channel blocker	CACNA1B			0	94.02	Tocris	3552	PD 173212	599.409	CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C	GCDHMGROXQUFNR-HEVIKAOCSA-N	9916734.0		GCDHMGROXQUFNR
BRD-K04426574-001-03-9	PD-173212	Preclinical	calcium channel blocker	CACNA1B			0	92.16	Tocris	3552	PD 173212	599.409	CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C	GCDHMGROXQUFNR-HEVIKAOCSA-N	9916734.0		GCDHMGROXQUFNR
BRD-K05104363-001-10-0	PD-184352	Phase 2	MEK inhibitor	MAP2K1|MAP3K1|MAP3K2			0	97.16	Selleck	S1020	PD184352 (CI-1040)	477.976	Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	GFMMXOIFOQCCGU-UHFFFAOYSA-N	6918454.0		GFMMXOIFOQCCGU
BRD-K05104363-001-01-9	PD-184352	Phase 2	MEK inhibitor	MAP2K1|MAP3K1|MAP3K2			0		Axon		PD-184352	477.976	Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)	6918454.0		GFMMXOIFOQCCGU
BRD-K88677950-001-03-9	PD-198306	Preclinical	MAP kinase inhibitor|MEK inhibitor	MAP2K1|MAP2K2			0	96.45	Tocris	2605	PD 198306	476.021	Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	UHAXDAKQGVISBZ-UHFFFAOYSA-N	9956637.0		UHAXDAKQGVISBZ
BRD-K88677950-001-04-9	PD-198306	Preclinical	MAP kinase inhibitor|MEK inhibitor	MAP2K1|MAP2K2			0	96.4	Tocris	2605	PD 198306	476.021	Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	UHAXDAKQGVISBZ-UHFFFAOYSA-N	9956637.0		UHAXDAKQGVISBZ
BRD-A57798112-001-04-9	PD-318088	Preclinical	MEK inhibitor				0	96.17	MedChemEx	HY-12062	PD318088	559.906	OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|	XXSSGBYXSKOLAM-MRVPVSSYSA-N	17753852.0		XXSSGBYXSKOLAM
BRD-A57798112-001-03-7	PD-318088	Preclinical	MEK inhibitor				0	95.69	Selleck	S1568	PD318088	559.906	OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2,r|	XXSSGBYXSKOLAM-MRVPVSSYSA-N	17753852.0		XXSSGBYXSKOLAM
BRD-K82823804-001-04-1	PD-407824	Preclinical	PKC inhibitor	WEE1			0	92.11	Tocris	2694	PD 407824	328.085	Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	IAUZTOZLTFSMIE-UHFFFAOYSA-N	4369491.0		IAUZTOZLTFSMIE
BRD-K82823804-001-06-9	PD-407824	Preclinical	PKC inhibitor	WEE1			0	96.32	Tocris	2694	PD 407824	328.085	Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	IAUZTOZLTFSMIE-UHFFFAOYSA-N	4369491.0		IAUZTOZLTFSMIE
BRD-K82823804-001-05-8	PD-407824	Preclinical	PKC inhibitor	WEE1			0	88.68	Tocris	2694	PD 407824	328.085	Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	IAUZTOZLTFSMIE-UHFFFAOYSA-N	4369491.0		IAUZTOZLTFSMIE
BRD-K77951111-001-05-9	PD-81723	Preclinical	adenosine receptor agonist	ADORA1			0	86.53	Tocris	1363	PD 81723	299.059	Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C	KKDKAWKYGCUOGR-UHFFFAOYSA-N	122028.0		KKDKAWKYGCUOGR
BRD-K77951111-001-04-5	PD-81723	Preclinical	adenosine receptor agonist	ADORA1			0	10.23	Tocris	1363	PD 81723	299.059	Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C	KKDKAWKYGCUOGR-UHFFFAOYSA-N	122028.0		KKDKAWKYGCUOGR
BRD-K62810658-001-11-4	PD-98059	Preclinical	MEK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1			0	91.62	Selleck	S1177	PD98059	267.09	COc1cccc(c1N)-c1cc(=O)c2ccccc2o1	QFWCYNPOPKQOKV-UHFFFAOYSA-N	4713.0		QFWCYNPOPKQOKV
BRD-K62810658-001-15-5	PD-98059	Preclinical	MEK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1			0	94.02	Tocris	1213	PD 98059	267.09	COc1cccc(c1N)-c1cc(=O)c2ccccc2o1	QFWCYNPOPKQOKV-UHFFFAOYSA-N	4713.0		QFWCYNPOPKQOKV
BRD-K62810658-001-12-2	PD-98059	Preclinical	MEK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1			0	93.83	Tocris	1213	PD 98059	267.09	COc1cccc(c1N)-c1cc(=O)c2ccccc2o1	QFWCYNPOPKQOKV-UHFFFAOYSA-N	4713.0		QFWCYNPOPKQOKV
BRD-K00021095-001-01-9	PDD-00017273	Preclinical	PARG inhibitor				0	98.22	MedChemEx	HY-108360	PDD 00017273	514.146	Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1	IFWUBRBMMNTBRZ-UHFFFAOYSA-N	121398766.0		IFWUBRBMMNTBRZ
BRD-K38145871-001-01-8	PDE10-IN-1	Preclinical	phosphodiesterase inhibitor	PDE10A			0	96.99	MedChemEx	HY-12813	PDE10-IN-1	369.17	Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1	ZLHNYULRKIEGAY-HZPDHXFCSA-N	72709059.0		ZLHNYULRKIEGAY
BRD-K26358347-001-02-9	PDP-EA	Preclinical	FAAH activator	FAAH			0	92.74	Tocris	5210	PDP-EA	405.324	CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1	BIOVSNWTCKRADD-UHFFFAOYSA-N	69724031.0		BIOVSNWTCKRADD
BRD-K26358347-001-01-7	PDP-EA	Preclinical	FAAH activator	FAAH			0	96.07	Tocris	5210	PDP-EA	405.324	CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1	BIOVSNWTCKRADD-UHFFFAOYSA-N	69724031.0		BIOVSNWTCKRADD
BRD-K04032780-001-01-8	PD1-PDL-inhibitor-1	Preclinical	programmed death ligand inhibitor	CD274			0	97.25	MedChemEx	HY-19991	PD1-PDL1 inhibitor 1	475.236	COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O	ZBOYJODMIAUJHH-SANMLTNESA-N	91663303.0		ZBOYJODMIAUJHH
BRD-A14577621-001-01-5	peficitinib	Launched	JAK inhibitor	JAK1|JAK2|JAK3	rheumatology	rheumatoid arthritis	0	98.78	Selleck	S7650		326.174	NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13,14,16,18,20,r|	DREIJXJRTLTGJC-ZKVNVPQCSA-N		BRD-A59435073-001-01-5	DREIJXJRTLTGJC
BRD-K55034111-066-18-9	pefloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|urology	gastrointestinal infections|urethritis|gonorrhea|urinary tract infections	0	94.16	MedChemEx	HY-B0147A	Pefloxacin (mesylate)	333.149	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	FHFYDNQZQSQIAI-UHFFFAOYSA-N	6919009.0		FHFYDNQZQSQIAI
BRD-K55034111-066-17-1	pefloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|urology	gastrointestinal infections|urethritis|gonorrhea|urinary tract infections	0	98.47	MicroSource	1505305	PEFLOXACINE MESYLATE	333.149	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	FHFYDNQZQSQIAI-UHFFFAOYSA-N	6919009.0		FHFYDNQZQSQIAI
BRD-K55034111-066-16-3	pefloxacin	Launched	bacterial DNA gyrase inhibitor	TOP2A	infectious disease|urology	gastrointestinal infections|urethritis|gonorrhea|urinary tract infections	0	96.38	Selleck	S1855	Pefloxacin Mesylate	333.149	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	FHFYDNQZQSQIAI-UHFFFAOYSA-N	6919009.0		FHFYDNQZQSQIAI
BRD-K96436774-001-01-8	pelanserin	Phase 2	serotonin receptor antagonist	HTR2A			0	91.31	Enamine	Z379486794		364.19	O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1	WPKPLSFHHBBLRY-UHFFFAOYSA-N	65435.0		WPKPLSFHHBBLRY
BRD-K08799216-001-06-9	pelitinib	Phase 2	EGFR inhibitor	EGFR			0	96.63	MedChemEx	HY-32718	Pelitinib	467.152	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	WVUNYSQLFKLYNI-AATRIKPKSA-N	6445562.0		WVUNYSQLFKLYNI
BRD-K08799216-001-05-3	pelitinib	Phase 2	EGFR inhibitor	EGFR			0	92.07	Selleck	S1392	Pelitinib (EKB-569)	467.152	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	WVUNYSQLFKLYNI-AATRIKPKSA-N	6445562.0		WVUNYSQLFKLYNI
BRD-K00004687-001-01-9	pelrinone	Phase 2	phosphodiesterase inhibitor				0	95.85	AMS	A002839437	2-methyl-4-oxo-6-[(3-pyridinylmethyl)amino]-1,4-dihydro-5-pyrimidinecarbonitrile	241.096	Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1	NZXHFDXOCVIYLO-UHFFFAOYSA-N	135413516.0		NZXHFDXOCVIYLO
BRD-K00003251-001-01-9	pemafibrate	Phase 3	PPAR receptor agonist				0	98.47	MedChemEx	HY-17618	Pemafibrate	490.21	CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(O)=O	ZHKNLJLMDFQVHJ-RUZDIDTESA-N	11526038.0		ZHKNLJLMDFQVHJ
BRD-K32842773-434-01-8	pemetrexed	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	ATIC|DHFR|GART|TYMS	oncology	non-small cell lung cancer (NSCLC)|mesothelioma	0	87.62	Key	KS-1185	disodium (2S)-2-({4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}amino)pentanedioate heptahydrate	427.149	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	135410875.0		WBXPDJSOTKVWSJ
BRD-K32842773-304-05-4	pemetrexed	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	ATIC|DHFR|GART|TYMS	oncology	non-small cell lung cancer (NSCLC)|mesothelioma	0	66.7	MedChemEx	HY-13781	Pemetrexed (disodium hemipenta hydrate)	427.149	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	135410875.0	BRD-M17920320-304-01-2	WBXPDJSOTKVWSJ
BRD-K32842773-380-01-3	pemetrexed	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	ATIC|DHFR|GART|TYMS	oncology	non-small cell lung cancer (NSCLC)|mesothelioma	0	82.5	MedChemEx	HY-13781	Pemetrexed (disodium hemipenta hydrate) (1:2:2.5)	427.149	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	135410875.0	BRD-M18147244-437-01-2	WBXPDJSOTKVWSJ
BRD-K32842773-304-03-9	pemetrexed	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	ATIC|DHFR|GART|TYMS	oncology	non-small cell lung cancer (NSCLC)|mesothelioma	0	17.09	MicroSource	1502390	PEMETREXED	427.149	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	135410875.0		WBXPDJSOTKVWSJ
BRD-K32842773-304-04-7	pemetrexed	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	ATIC|DHFR|GART|TYMS	oncology	non-small cell lung cancer (NSCLC)|mesothelioma	0	86.05	Selleck	S1135	Pemetrexed	427.149	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	135410875.0		WBXPDJSOTKVWSJ
BRD-K32842773-304-06-2	pemetrexed	Launched	dihydrofolate reductase inhibitor|thymidylate synthase inhibitor	ATIC|DHFR|GART|TYMS	oncology	non-small cell lung cancer (NSCLC)|mesothelioma	0	51.07	Selleck	S1135	Pemetrexed	427.149	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	WBXPDJSOTKVWSJ-ZDUSSCGKSA-N	135410875.0	BRD-K55395145-304-01-5	WBXPDJSOTKVWSJ
BRD-K31731454-237-04-9	pemirolast	Launched	mediator release inhibitor	HRH1	pulmonary	asthma	0	93.99	MedChemEx	HY-B0538A	Pemirolast (potassium)	228.076	Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O	HIANJWSAHKJQTH-UHFFFAOYSA-N	57697.0		HIANJWSAHKJQTH
BRD-K31731454-237-03-3	pemirolast	Launched	mediator release inhibitor	HRH1	pulmonary	asthma	0	90.43	MedChemEx	HY-B0538A	Pemirolast (potassium)	228.076	Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O	HIANJWSAHKJQTH-UHFFFAOYSA-N	57697.0		HIANJWSAHKJQTH
BRD-K31731454-237-02-5	pemirolast	Launched	mediator release inhibitor	HRH1	pulmonary	asthma	0	97.42	Selleck	S4008	Pemirolast (BMY 26517) potassium	228.076	Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O	HIANJWSAHKJQTH-UHFFFAOYSA-N	57697.0		HIANJWSAHKJQTH
BRD-K71075093-045-14-7	pempidine	Launched	ganglionic blocker		cardiology	hypertension	0	52.72	MicroSource	1503383	PEMPIDINE TARTRATE	155.167	CN1C(C)(C)CCCC1(C)C	XULIXFLCVXWHRF-UHFFFAOYSA-N	6603.0		XULIXFLCVXWHRF
BRD-K55705469-065-01-0	penbutolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|HTR1A|HTR1B	cardiology	hypertension	0	90.41	MicroSource	1505567	PENBUTOLOL SULFATE	291.22	CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1	KQXKVJAGOJTNJS-HNNXBMFYSA-N	37464.0		KQXKVJAGOJTNJS
BRD-K55705469-065-02-9	penbutolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|HTR1A|HTR1B	cardiology	hypertension	0	92.64	Toronto	P220505	(S)-penbutolol sulfate	291.22	CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1	KQXKVJAGOJTNJS-HNNXBMFYSA-N	37464.0		KQXKVJAGOJTNJS
BRD-K47780086-001-07-9	penciclovir	Launched	DNA directed DNA polymerase inhibitor		dental	cold sore	0	94.53	MicroSource	1502320	PENCICLOVIR	253.117	Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1	JNTOCHDNEULJHD-UHFFFAOYSA-N	135398748.0		JNTOCHDNEULJHD
BRD-K47780086-001-06-1	penciclovir	Launched	DNA directed DNA polymerase inhibitor		dental	cold sore	0	87.21	Selleck	S4184	Penciclovir	253.117	Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1	JNTOCHDNEULJHD-UHFFFAOYSA-N	135398748.0		JNTOCHDNEULJHD
BRD-K47780086-001-10-9	penciclovir	Launched	DNA directed DNA polymerase inhibitor		dental	cold sore	0	100.0	MedChemEx	HY-17424	Penciclovir	253.117	Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1	JNTOCHDNEULJHD-UHFFFAOYSA-N	135398748.0		JNTOCHDNEULJHD
BRD-K47780086-001-08-7	penciclovir	Launched	DNA directed DNA polymerase inhibitor		dental	cold sore	0	0.0	Selleck	S4184	Penciclovir	253.117	Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1	JNTOCHDNEULJHD-UHFFFAOYSA-N	135398748.0		JNTOCHDNEULJHD
BRD-K15409150-001-07-4	penfluridol	Launched	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	0	96.94	MicroSource	1505691	PENFLURIDOL	523.17	OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F	MDLAAYDRRZXJIF-UHFFFAOYSA-N	33630.0		MDLAAYDRRZXJIF
BRD-K15409150-001-05-8	penfluridol	Launched	T-type calcium channel blocker	CACNA1G	neurology/psychiatry	schizophrenia	0	93.21	Selleck	S4151	Penfluridol	523.17	OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F	MDLAAYDRRZXJIF-UHFFFAOYSA-N	33630.0		MDLAAYDRRZXJIF
BRD-K17518951-001-03-0	penicillamine-(D)	Launched	chelating agent		metabolism|rheumatology|nephrology	Wilson's disease|rheumatoid arthritis|cystinuria	1	0.0	Selleck	S1853	Penicillamine (Cuprimine)	149.051	CC(C)(S)[C@@H](N)C(O)=O	VVNCNSJFMMFHPL-VKHMYHEASA-N	6926437.0		VVNCNSJFMMFHPL
BRD-K17518951-001-14-9	penicillamine-(D)	Launched	chelating agent		metabolism|rheumatology|nephrology	Wilson's disease|rheumatoid arthritis|cystinuria	1	100.0	MedChemEx	HY-W017457	2-Amino-3-mercapto-3-methylbutanoic acid	149.051	CC(C)(S)[C@@H](N)C(O)=O	VVNCNSJFMMFHPL-VKHMYHEASA-N	6926437.0		VVNCNSJFMMFHPL
BRD-K17518951-001-04-8	penicillamine-(D)	Launched	chelating agent		metabolism|rheumatology|nephrology	Wilson's disease|rheumatoid arthritis|cystinuria	1	0.0	Selleck	S1853	Penicillamine (Cuprimine)	149.051	CC(C)(S)[C@@H](N)C(O)=O	VVNCNSJFMMFHPL-VKHMYHEASA-N	6926437.0		VVNCNSJFMMFHPL
BRD-K01825697-213-01-9	penicillamine-(racemic)	Launched					0	0.0	MicroSource	1500464	PENICILLAMINE	210.104	CC(C)(S)[C@@H](N)C(O)=O |&1:4|	VVNCNSJFMMFHPL-VKHMYHEASA-N	6926437.0		VVNCNSJFMMFHPL
BRD-K43966364-237-06-9	penicillin-v-potassium	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|ear infections|skin infections|throat infections|cholera|scarlet fever	0	76.25	MedChemEx	HY-B0975	Penicillin V (Potassium)	350.094	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	BPLBGHOLXOTWMN-MBNYWOFBSA-N	6869.0		BPLBGHOLXOTWMN
BRD-K43966364-237-04-8	penicillin-v-potassium	Launched	bacterial cell wall synthesis inhibitor		infectious disease	pneumonia|ear infections|skin infections|throat infections|cholera|scarlet fever	0	90.16	MicroSource	1500467	PENICILLIN V POTASSIUM	350.094	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	BPLBGHOLXOTWMN-MBNYWOFBSA-N	6869.0		BPLBGHOLXOTWMN
BRD-K48996094-001-01-3	pentacosanoic-acid	Preclinical					0	100.0	Cayman	15197		382.381	CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O	MWMPEAHGUXCSMY-UHFFFAOYSA-N	10468.0		MWMPEAHGUXCSMY
BRD-K78789465-001-02-4	pentagastrin	Launched	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic|gastric hypersecretion diagnostic	0	84.48	MicroSource	1506100	PENTAGASTRIN	767.331	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	NEYNJQRKHLUJRU-DZUOILHNSA-N	9853654.0	BRD-K92045627-001-01-0	NEYNJQRKHLUJRU
BRD-K78789465-001-01-6	pentagastrin	Launched	CCK receptor agonist	CCKBR	gastroenterology	anacidity diagnostic|gastric hypersecretion diagnostic	0	84.88	Abblis	AB2000162	Pentagastrin	767.331	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	NEYNJQRKHLUJRU-DZUOILHNSA-N	9853654.0		NEYNJQRKHLUJRU
BRD-K13183738-317-10-2	pentamidine	Launched	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	0	98.99	MicroSource	1500641	PENTAMIDINE ISETHIONATE	340.19	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	XDRYMKDFEDOLFX-UHFFFAOYSA-N	4735.0		XDRYMKDFEDOLFX
BRD-K13183738-300-02-5	pentamidine	Launched	anti-pneumocystis agent	TRDMT1	infectious disease	pneumonia	0	95.88	Selleck	S4007	Pentamidine	340.19	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	XDRYMKDFEDOLFX-UHFFFAOYSA-N	4735.0		XDRYMKDFEDOLFX
BRD-K40621224-001-07-9	pentetic-acid	Phase 2	chelating agent				0	100.0	MedChemEx	HY-B1335	Pentetic acid	393.138	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	QPCDCPDFJACHGM-UHFFFAOYSA-N	3053.0		QPCDCPDFJACHGM
BRD-K40621224-001-06-7	pentetic-acid	Phase 2	chelating agent				0	99.18	MicroSource	1506082	PENTETIC ACID	393.138	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	QPCDCPDFJACHGM-UHFFFAOYSA-N	3053.0		QPCDCPDFJACHGM
BRD-K44942604-346-04-7	pentolinium	Launched	cholinergic receptor antagonist	CHRNA10|CHRNA3|CHRNA4|CHRNB4	cardiology	hypertension	0	76.5	Prestwick	Prestw-188	Pentolinium bitartrate	240.257	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	XSBSKEQEUFOSDD-UHFFFAOYSA-N	5850.0		XSBSKEQEUFOSDD
BRD-K44942604-346-05-4	pentolinium	Launched	cholinergic receptor antagonist	CHRNA10|CHRNA3|CHRNA4|CHRNB4	cardiology	hypertension	0	97.01	Acros	38802		240.257	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	XSBSKEQEUFOSDD-UHFFFAOYSA-N	5850.0		XSBSKEQEUFOSDD
BRD-K91543828-001-02-0	pentostatin	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	0	86.61	MedChemEx	HY-A0006	Pentostatin	268.117	OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|	FPVKHBSQESCIEP-JQCXWYLXSA-N	439693.0		FPVKHBSQESCIEP
BRD-K91543828-001-04-9	pentostatin	Launched	adenosine deaminase inhibitor|ribonucleotide reductase inhibitor	ADA	hematologic malignancy	hairy cell leukemia	0	100.0	Tocris	2033	Pentostatin	268.117	OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|	FPVKHBSQESCIEP-JQCXWYLXSA-N	439693.0		FPVKHBSQESCIEP
BRD-K57569181-001-27-5	pentoxifylline	Launched	phosphodiesterase inhibitor	ADORA1|ADORA2A|ADORA2B|ADRA2B|NT5E|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|TNF	cardiology	claudication	0	99.53	MicroSource	1503611	PENTOXIFYLLINE	278.138	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	4740.0		BYPFEZZEUUWMEJ
BRD-K57569181-001-26-7	pentoxifylline	Launched	phosphodiesterase inhibitor	ADORA1|ADORA2A|ADORA2B|ADRA2B|NT5E|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|TNF	cardiology	claudication	0	98.21	Selleck	S4345	Pentoxifylline	278.138	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	BYPFEZZEUUWMEJ-UHFFFAOYSA-N	4740.0		BYPFEZZEUUWMEJ
BRD-K57718010-001-12-7	pentylenetetrazol	Withdrawn	GABA receptor antagonist				0	42.28	MedChemEx	HY-B1242	Pentylenetetrazol	138.091	C1CCc2nnnn2CC1	CWRVKFFCRWGWCS-UHFFFAOYSA-N	5917.0		CWRVKFFCRWGWCS
BRD-K57718010-001-11-9	pentylenetetrazol	Withdrawn	GABA receptor antagonist				0	76.62	MicroSource	2300347	PENTYLENETETRAZOL	138.091	C1CCc2nnnn2CC1	CWRVKFFCRWGWCS-UHFFFAOYSA-N	5917.0		CWRVKFFCRWGWCS
BRD-K57718010-001-10-1	pentylenetetrazol	Withdrawn	GABA receptor antagonist				0	0.0	Tocris	2687	Pentylenetetrazole	138.091	C1CCc2nnnn2CC1	CWRVKFFCRWGWCS-UHFFFAOYSA-N	5917.0		CWRVKFFCRWGWCS
BRD-K00003426-001-01-9	peposertib	Phase 1/Phase 2	DNA dependent protein kinase inhibitor				0	96.7	MedChemEx	HY-101570	Nedisertib	481.132	COc1ccc(nn1)[C@@H](O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1	MOWXJLUYGFNTAL-DEOSSOPVSA-N	86292849.0		MOWXJLUYGFNTAL
BRD-K13571841-201-16-9	pepstatin	Preclinical	aspartic protease inhibitor	CTSB|CTSD|CTSL|REN			0	84.45	MedChemEx	HY-P0018B	Pepstatin Ammonium	685.463	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	FAXGPCHRFPCXOO-LXTPJMTPSA-N	5478883.0		FAXGPCHRFPCXOO
BRD-K13571841-001-14-4	pepstatin	Preclinical	aspartic protease inhibitor	CTSB|CTSD|CTSL|REN			0	94.54	Enzo	PI120	Pepstatin A	685.463	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	FAXGPCHRFPCXOO-LXTPJMTPSA-N	5478883.0		FAXGPCHRFPCXOO
BRD-K00519864-341-02-5	peramivir	Launched	neuraminidase inhibitor		infectious disease	influenza A virus infection	0	6.63	Selleck	S2716	Peramivir Trihydrate	328.211	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	XRQDFNLINLXZLB-CKIKVBCHSA-N	154234.0		XRQDFNLINLXZLB
BRD-K00519864-341-03-3	peramivir	Launched	neuraminidase inhibitor		infectious disease	influenza A virus infection	0	85.33	Selleck	S2716	Peramivir Trihydrate	328.211	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	XRQDFNLINLXZLB-CKIKVBCHSA-N	154234.0		XRQDFNLINLXZLB
BRD-K00519864-341-04-9	peramivir	Launched	neuraminidase inhibitor		infectious disease	influenza A virus infection	0	100.0	MedChemEx	HY-17015	Peramivir (trihydrate)	328.211	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	XRQDFNLINLXZLB-CKIKVBCHSA-N	154234.0		XRQDFNLINLXZLB
BRD-K00004530-001-01-9	perchlozone	Launched			infectious disease	tuberculosis	0	94.96	Labotest	LT00508348	isonicotinaldehyde thiosemicarbazone	180.047	NC(=S)N\N=C\c1ccncc1	QTSJJDIDTYFLFC-BJMVGYQFSA-N	6433252.0		QTSJJDIDTYFLFC
BRD-K99431849-001-01-7	peretinoin	Phase 3	retinoid receptor agonist	RXRA			0	81.22	MedChemEx	HY-100008	Peretinoin	302.225	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	UUBHZHZSIKRVIV-KCXSXWJSSA-N	6437836.0		UUBHZHZSIKRVIV
BRD-K99431849-001-02-5	peretinoin	Phase 3	retinoid receptor agonist	RXRA			0	85.75	MedChemEx	HY-100008	Peretinoin	302.225	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	UUBHZHZSIKRVIV-KCXSXWJSSA-N	6437836.0		UUBHZHZSIKRVIV
BRD-K16758059-001-01-8	perfluamine	Launched					1	0.0	Oakwood	46164		520.97	FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F	JAJLKEVKNDUJBG-UHFFFAOYSA-N	67645.0		JAJLKEVKNDUJBG
BRD-K92988025-001-02-7	perflubron	Launched	contrast agent		radiology	contrast agent	1	0.0	Sigma	MFCD00042082	1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane	497.891	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	WTWWXOGTJWMJHI-UHFFFAOYSA-N	9873.0		WTWWXOGTJWMJHI
BRD-K92988025-001-01-9	perflubron	Launched	contrast agent		radiology	contrast agent	1	0.0	Oakwood	2311		497.891	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	WTWWXOGTJWMJHI-UHFFFAOYSA-N	9873.0		WTWWXOGTJWMJHI
BRD-K55401595-001-01-8	perfluorodecalin	Launched			dermatology	cosmetic	0	0.0	Sigma	MFCD00010626	1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluorodecahydronaphthalene	461.971	FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F	UWEYRJFJVCLAGH-UHFFFAOYSA-N	9386.0		UWEYRJFJVCLAGH
BRD-K00004546-001-01-9	perfluorohexyloctane	Launched					0	0.0	Sigma	MFCD07784188	1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane	432.112	CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	WRYIIOKOQSICTB-UHFFFAOYSA-N	10477896.0		WRYIIOKOQSICTB
BRD-K60770992-066-27-9	pergolide	Withdrawn	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C			0	98.87	MedChemEx	HY-13720A	Pergolide (mesylate)	314.182	CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	YEHCICAEULNIGD-MZMPZRCHSA-N	47811.0		YEHCICAEULNIGD
BRD-K60770992-066-26-8	pergolide	Withdrawn	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C			0	74.0	Selleck	S4000	Pergolide mesylate	314.182	CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	YEHCICAEULNIGD-MZMPZRCHSA-N	47811.0	BRD-K38689957-066-01-5	YEHCICAEULNIGD
BRD-K60770992-066-25-0	pergolide	Withdrawn	dopamine receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C			0	93.97	Selleck	S4000	Pergolide mesylate	314.182	CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	YEHCICAEULNIGD-MZMPZRCHSA-N	47811.0		YEHCICAEULNIGD
BRD-A19633847-050-32-1	perhexiline	Launched	carnitine palmitoyltransferase inhibitor	CPT1A	cardiology	angina pectoris	0	97.96	MicroSource	1503227	PERHEXILINE MALEATE	277.277	C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|	CYXKNKQEMFBLER-GOSISDBHSA-N	38988177.0		CYXKNKQEMFBLER
BRD-A19633847-050-20-6	perhexiline	Launched	carnitine palmitoyltransferase inhibitor	CPT1A	cardiology	angina pectoris	0		MicroSource	1503227	PERHEXILINE MALEATE	277.277	C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|	InChI=1S/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2/t18-/m1/s1	38988177.0		CYXKNKQEMFBLER
BRD-A89082344-001-07-9	perifosine	Phase 3	AKT inhibitor	AKT1			0	0.0	MedChemEx	HY-50909	1,1-dimethylpiperidinium-4-yl octadecyl phosphate	462.371	CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|	SZFPYBIJACMNJV-UHFFFAOYSA-O	148178.0		SZFPYBIJACMNJV
BRD-A89082344-001-08-7	perifosine	Phase 3	AKT inhibitor	AKT1			0	100.0	MedChemEx	HY-50909	Perifosine	462.371	CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|	SZFPYBIJACMNJV-UHFFFAOYSA-O	148178.0		SZFPYBIJACMNJV
BRD-A89082344-001-06-1	perifosine	Phase 3	AKT inhibitor	AKT1			0	0.0	MedChemEx	HY-50909	Perifosine	462.371	CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|	SZFPYBIJACMNJV-UHFFFAOYSA-O	148178.0		SZFPYBIJACMNJV
BRD-A13323580-001-05-5	perillyl-alcohol	Phase 2	apoptosis stimulant|farnesyltransferase inhibitor	FNTA			1	0.0	Enamine	EN300-97783	(4-isopropenyl-1-cyclohexen-1-yl)methanol	152.12	CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|	NDTYTMIUWGWIMO-SNVBAGLBSA-N	369312.0		NDTYTMIUWGWIMO
BRD-A13323580-001-04-8	perillyl-alcohol	Phase 2	apoptosis stimulant|farnesyltransferase inhibitor	FNTA			1	0.0	Enamine	EN300-97783		152.12	CC(=C)[C@H]1CCC(CO)=CC1 |&1:3,r,c:8|	NDTYTMIUWGWIMO-SNVBAGLBSA-N	369312.0		NDTYTMIUWGWIMO
BRD-K92731339-227-04-9	perindopril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|myocardial infarction|coronary artery disease (CAD)	0	95.89	MicroSource	1505212	PERINDOPRIL ERBUMINE	368.231	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	IPVQLZZIHOAWMC-QXKUPLGCSA-N	40466996.0		IPVQLZZIHOAWMC
BRD-K92731339-227-05-6	perindopril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|myocardial infarction|coronary artery disease (CAD)	0	91.91	Selleck	S1506	Perindopril Erbumine (Aceon)	368.231	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	IPVQLZZIHOAWMC-QXKUPLGCSA-N	40466996.0	BRD-A19924402-227-01-0|BRD-A47830685-227-02-1	IPVQLZZIHOAWMC
BRD-K92731339-227-07-9	perindopril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|myocardial infarction|coronary artery disease (CAD)	0	89.92	MedChemEx	HY-B0130A	Perindopril (erbumine)	368.231	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	IPVQLZZIHOAWMC-QXKUPLGCSA-N	40466996.0		IPVQLZZIHOAWMC
BRD-K92731339-227-08-9	perindopril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|myocardial infarction|coronary artery disease (CAD)	0	92.07	Tocris	4302	Perindopril erbumine	368.231	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	IPVQLZZIHOAWMC-QXKUPLGCSA-N	40466996.0		IPVQLZZIHOAWMC
BRD-K00768353-001-01-8	perindoprilat	Phase 2	angiotensin converting enzyme inhibitor	ACE			0	3.67	MicroSource	1504316	PERINDOPRILAT	340.2	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	ODAIHABQVKJNIY-PEDHHIEDSA-N	72022.0		ODAIHABQVKJNIY
BRD-A25366096-001-09-9	permethrin	Launched			infectious disease	lice	0	0.0	MedChemEx	HY-B0887	Permethrin	390.079	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|	RLLPVAHGXHCWKJ-PKOBYXMFSA-N	40159.0		RLLPVAHGXHCWKJ
BRD-A25366096-001-07-3	permethrin	Launched			infectious disease	lice	0	0.0	MicroSource	1504932	PERMETHRIN	390.079	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|	RLLPVAHGXHCWKJ-PKOBYXMFSA-N	40159.0		RLLPVAHGXHCWKJ
BRD-A25366096-001-08-1	permethrin	Launched			infectious disease	lice	0	0.0	Sigma	MFCD00041809	3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate	390.079	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3,&2:8,r|	RLLPVAHGXHCWKJ-PKOBYXMFSA-N	40159.0		RLLPVAHGXHCWKJ
BRD-K85503079-001-01-0	perospirone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|DRD3|DRD4	neurology/psychiatry	schizophrenia|bipolar disorder	0	98.49	Prestwick	Prestw-1770	Perospirone	426.209	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	FBVFZWUMDDXLLG-HDICACEKSA-N	115368.0		FBVFZWUMDDXLLG
BRD-K85503079-001-02-8	perospirone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD2|DRD3|DRD4	neurology/psychiatry	schizophrenia|bipolar disorder	0	98.77	AKSci	M813		426.209	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	FBVFZWUMDDXLLG-HDICACEKSA-N	115368.0		FBVFZWUMDDXLLG
BRD-K10995081-001-26-1	perphenazine	Launched	dopamine receptor antagonist	CALM1|DRD1|DRD2|HRH1|HTR2A|HTR2C|HTR6|HTR7	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting	0	62.54	MicroSource	1503934	PERPHENAZINE	403.149	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	RGCVKNLCSQQDEP-UHFFFAOYSA-N	4748.0		RGCVKNLCSQQDEP
BRD-K10995081-001-28-7	perphenazine	Launched	dopamine receptor antagonist	CALM1|DRD1|DRD2|HRH1|HTR2A|HTR2C|HTR6|HTR7	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting	0	87.56	MedChemEx	HY-A0077	Perphenazine	403.149	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	RGCVKNLCSQQDEP-UHFFFAOYSA-N	4748.0		RGCVKNLCSQQDEP
BRD-K10995081-001-27-9	perphenazine	Launched	dopamine receptor antagonist	CALM1|DRD1|DRD2|HRH1|HTR2A|HTR2C|HTR6|HTR7	neurology/psychiatry|gastroenterology	schizophrenia|nausea|vomiting	0	87.72	Sigma	Y0001045	2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl}ethanol	403.149	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	RGCVKNLCSQQDEP-UHFFFAOYSA-N	4748.0		RGCVKNLCSQQDEP
BRD-A72716251-001-01-5	peruvoside	Phase 1	cardiac glycoside				0	70.11	Enzo	NP227	Peruvoside	548.299	CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2,3,8,10,13,16,19,20,23,25,28,&1:5,&2:37,t:33|	PMTSPAGBAFCORP-BZEWZVDJSA-N			PMTSPAGBAFCORP
BRD-K04643877-001-03-2	perzinfotel	Phase 2	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B			0	97.0	Sigma	MFCD00912427	2-[8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl]ethylphosphonic acid	260.056	OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O	BDABGOLMYNHHTR-UHFFFAOYSA-N	6918236.0		BDABGOLMYNHHTR
BRD-A93477898-001-04-2	PETCM	Preclinical	caspase activator	CASP3			0	93.77	Tocris	1758	PETCM	238.967	O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1,r|	NGTDJJKTGRNNAU-ZETCQYMHSA-N	736879.0		NGTDJJKTGRNNAU
BRD-K67844266-003-01-9	pevonedistat	Phase 3	nedd activating enzyme inhibitor	NAE1|UBA3			0	94.15	MedChemEx	HY-10484	MLN4924 (hydrochloride)	443.163	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	MPUQHZXIXSTTDU-QXGSTGNESA-N	16720766.0		MPUQHZXIXSTTDU
BRD-K67844266-001-02-1	pevonedistat	Phase 3	nedd activating enzyme inhibitor	NAE1|UBA3			0		Active	A-1139	MLN-4924	443.163	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1	16720766.0		MPUQHZXIXSTTDU
BRD-K54519451-001-02-9	pexidartinib	Launched	tyrosine kinase inhibitor	CSF1R|FLT3|KIT			0	94.9	MedChemEx	HY-16749	Pexidartinib	417.097	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1	JGWRKYUXBBNENE-UHFFFAOYSA-N	25151352.0		JGWRKYUXBBNENE
BRD-K53405000-001-01-0	pexmetinib	Phase 1	MAP kinase inhibitor|TIE tyrosine kinase inhibitor	MAPK14|TEK			0	98.39	Selleck	S7799	Pexmetinib (ARRY-614)	556.26	Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C	LNMRSSIMGCDUTP-UHFFFAOYSA-N	24765037.0		LNMRSSIMGCDUTP
BRD-K53405000-001-02-8	pexmetinib	Phase 1	MAP kinase inhibitor|TIE tyrosine kinase inhibitor	MAPK14|TEK			0	99.4	Selleck	S7799	1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)benzyl)urea	556.26	Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C	LNMRSSIMGCDUTP-UHFFFAOYSA-N	24765037.0		LNMRSSIMGCDUTP
BRD-K00004632-001-01-9	PF-02413873	Phase 1	progesterone receptor antagonist				0	96.06	Sigma	PZ0367	4-({3-cyclopropyl-5-methyl-1-[(methylsulfonyl)methyl]-1H-pyrazol-4-yl}oxy)-2,6-dimethylbenzonitrile	359.13	Cc1c(Oc2cc(C)c(C#N)c(C)c2)c(nn1CS(C)(=O)=O)C1CC1	QSFGZNVRVZHUGV-UHFFFAOYSA-N	16662425.0		QSFGZNVRVZHUGV
BRD-K31519811-001-02-2	PF-02545920	Phase 2	phosphodiesterase inhibitor	PDE10A			0	95.3	Selleck	S2687		392.164	Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1	AZEXWHKOMMASPA-UHFFFAOYSA-N	11581936.0		AZEXWHKOMMASPA
BRD-K07070922-001-01-4	PF-03049423	Phase 2	phosphodiesterase inhibitor	PDE5A			0	97.3	Key	GE-0036	3-[4-(2-hydroxyethyl)-1-piperazinyl]-7-(6-methoxy-3-pyridinyl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one	468.249	CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1	MNLNAGRCHNMKKJ-UHFFFAOYSA-N	24963293.0		MNLNAGRCHNMKKJ
BRD-K61691541-303-02-9	PF-03084014	Phase 3	gamma secretase inhibitor				0	89.41	Tocris	5751	PF 3084014 hydrobromide	489.328	CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	VFCRKLWBYMDAED-REWPJTCUSA-N	46224413.0		VFCRKLWBYMDAED
BRD-K61691541-001-01-1	PF-03084014	Phase 3	gamma secretase inhibitor				0	91.79	MedChemEx	HY-15185	PF-3084014	489.328	CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	VFCRKLWBYMDAED-REWPJTCUSA-N	46224413.0		VFCRKLWBYMDAED
BRD-K37764012-001-04-1	PF-03758309	Phase 1	p21 activated kinase inhibitor	PAK4			0	95.43	MedChemEx	HY-13007	PF-3758309	490.226	CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1	AYCPARAPKDAOEN-LJQANCHMSA-N	25227462.0		AYCPARAPKDAOEN
BRD-K37764012-001-01-7	PF-03758309	Phase 1	p21 activated kinase inhibitor	PAK4			0		Broad Institute		PF-3758309	490.226	CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1	InChI=1S/C25H30N8OS/c1-15-26-18-11-12-35-20(18)23(27-15)29-22-17-13-33(25(2,3)21(17)30-31-22)24(34)28-19(14-32(4)5)16-9-7-6-8-10-16/h6-12,19H,13-14H2,1-5H3,(H,28,34)(H2,26,27,29,30,31)/t19-/m1/s1	25227462.0		AYCPARAPKDAOEN
BRD-K68747584-001-06-9	PF-03814735	Phase 1	Aurora kinase inhibitor	AURKA|AURKB			0	96.21	Tocris	4821	PF 03814735	474.199	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	RYYNGWLOYLRZLK-RBUKOAKNSA-N	51346455.0		RYYNGWLOYLRZLK
BRD-K68747584-001-03-8	PF-03814735	Phase 1	Aurora kinase inhibitor	AURKA|AURKB			0	98.35	Tocris	4821	PF 03814735	474.199	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	RYYNGWLOYLRZLK-RBUKOAKNSA-N	51346455.0		RYYNGWLOYLRZLK
BRD-K68747584-001-02-0	PF-03814735	Phase 1	Aurora kinase inhibitor	AURKA|AURKB			0	99.4	MedChemEx	HY-14574	PF-03814735	474.199	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	RYYNGWLOYLRZLK-RBUKOAKNSA-N	51346455.0		RYYNGWLOYLRZLK
BRD-K51041191-001-02-9	PF-03882845	Phase 1	mineralocorticoid receptor antagonist				0	84.61	Sigma	PZ0031	(S)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[g]indazole-7-carboxylic acid	419.14	OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|	XNULRSOGWPFPBL-AKRCKQFNSA-N	101541332.0		XNULRSOGWPFPBL
BRD-K51041191-001-01-4	PF-03882845	Phase 1	mineralocorticoid receptor antagonist				0	91.12	Sigma	PZ0031	(S)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-2,3,4,5-tetrahydro-1H-benzo[g]indazole-7-carboxylic acid	419.14	OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|	XNULRSOGWPFPBL-AKRCKQFNSA-N	101541332.0		XNULRSOGWPFPBL
BRD-K94420399-001-01-9	PF-04136309	Phase 2	CC chemokine receptor antagonist				0	97.35	MedChemEx	HY-13245	PF-4136309	568.241	O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	ZNSVOHSYDRPBGI-LXWOLXCRSA-N			ZNSVOHSYDRPBGI
BRD-K94420399-001-02-9	PF-04136309	Phase 2	CC chemokine receptor antagonist				0	95.56	MedChemEx	HY-13245	PF-4136309	568.241	O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	ZNSVOHSYDRPBGI-LXWOLXCRSA-N			ZNSVOHSYDRPBGI
BRD-K73319509-001-08-0	PF-04217903	Phase 1	c-Met inhibitor	MET			0	97.26	Selleck	S1094	PF-04217903	372.145	OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	PDMUGYOXRHVNMO-UHFFFAOYSA-N	17754438.0		PDMUGYOXRHVNMO
BRD-K73319509-001-06-4	PF-04217903	Phase 1	c-Met inhibitor	MET			0	91.87	Selleck	S1094	PF-04217903	372.145	OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2	17754438.0		PDMUGYOXRHVNMO
BRD-K54871792-001-01-4	PF-04418948	Phase 1	prostaglandin inhibitor	PTGER2			0	97.38	Selleck	S7211	PF-04418948	409.133	COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1	LWJGMYMNSNVCEM-UHFFFAOYSA-N	25114442.0		LWJGMYMNSNVCEM
BRD-K54871792-001-02-2	PF-04418948	Phase 1	prostaglandin inhibitor	PTGER2			0	99.27	Tocris	4818	PF 04418948	409.133	COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1	LWJGMYMNSNVCEM-UHFFFAOYSA-N	25114442.0		LWJGMYMNSNVCEM
BRD-K50031829-001-01-6	PF-04447943	Phase 2	phosphodiesterase inhibitor	PDE9A			0	97.37	MedChemEx	HY-15441	PF-04447943	395.207	C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1	IWXUVYOOUMLUTQ-CZUORRHYSA-N	135564558.0		IWXUVYOOUMLUTQ
BRD-K50031829-001-02-9	PF-04447943	Phase 2	phosphodiesterase inhibitor	PDE9A			0	92.66	MedChemEx	HY-15441	PF-04447943	395.207	C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1	IWXUVYOOUMLUTQ-CZUORRHYSA-N	135564558.0		IWXUVYOOUMLUTQ
BRD-K86816506-001-02-9	PF-04457845	Phase 2	FAAH inhibitor	FAAH			0	95.61	Tocris	6374	PF 04457845	455.157	FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	BATCTBJIJJEPHM-UHFFFAOYSA-N	24771824.0		BATCTBJIJJEPHM
BRD-K86816506-001-01-8	PF-04457845	Phase 2	FAAH inhibitor	FAAH			0	99.1	MedChemEx	HY-14376	PF-04457845	455.157	FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	BATCTBJIJJEPHM-UHFFFAOYSA-N	24771824.0		BATCTBJIJJEPHM
BRD-K30550578-001-02-9	PF-04620110	Phase 1	diacylglycerol O acyltransferase inhibitor	DGAT1			0	94.07	Tocris	5863	PF 04620110	396.18	Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|	GEVVQZHMFVFGLN-HDJSIYSDSA-N			GEVVQZHMFVFGLN
BRD-K30550578-001-01-3	PF-04620110	Phase 1	diacylglycerol O acyltransferase inhibitor	DGAT1			0	99.59	MedChemEx	HY-13009	PF-04620110	396.18	Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|	GEVVQZHMFVFGLN-HDJSIYSDSA-N			GEVVQZHMFVFGLN
BRD-K07310275-001-02-5	PF-04691502	Phase 2	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA			0	96.68	Selleck	S2743	PF-04691502	425.206	COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|	XDLYKKIQACFMJG-WKILWMFISA-N			XDLYKKIQACFMJG
BRD-K92435527-001-03-9	PF-04885614	Preclinical	voltage-gated sodium channel blocker	SCN10A			0	91.35	Tocris	4916	PF 04885614	285.109	CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1	AGORGFNWYAUYSU-UHFFFAOYSA-N	65459349.0		AGORGFNWYAUYSU
BRD-K92435527-001-01-4	PF-04885614	Preclinical	voltage-gated sodium channel blocker	SCN10A			0	84.39	Tocris	4916	PF 04885614	285.109	CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1	AGORGFNWYAUYSU-UHFFFAOYSA-N	65459349.0		AGORGFNWYAUYSU
BRD-K27755542-001-01-6	PF-04937319	Phase 2	glucokinase activator	GCK			0	97.36	Sigma	PZ0320		432.155	CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1	MASKQITXHVYVFL-UHFFFAOYSA-N	46916694.0		MASKQITXHVYVFL
BRD-K00004635-001-01-9	PF-04995274	Phase 1	serotonin receptor agonist				0	95.7	Sigma	PZ0310	(R)-4-((4-(((4-((tetrahydrofuran-3-yl)oxy)benzo[d]isoxazol-3-yl)oxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol	432.226	OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1	WLLOFQROROXOMO-GOSISDBHSA-N	53354764.0		WLLOFQROROXOMO
BRD-K00003145-001-01-9	PF-05089771	Preclinical	sodium channel blocker				0	92.1	MedChemEx	HY-12883	PF 05089771	498.974	Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1	ZYSCOUXLBXGGIM-UHFFFAOYSA-N	46840946.0		ZYSCOUXLBXGGIM
BRD-K00002423-001-02-9	PF-05175157	Phase 2	acetyl-CoA carboxylase inhibitor				0	97.16	MedChemEx	HY-12942	PF-05175157	405.216	[H]n1c(C)nc2ccc(cc12)C(=O)N1CCC2(CC1)Cc1cnn(C(C)C)c1C(=O)C2	BDXXSFOJPYSYOC-UHFFFAOYSA-N	52934180.0		BDXXSFOJPYSYOC
BRD-K00003097-001-01-9	PF-05180999	Phase 1	phosphodiesterase inhibitor				0	97.87	MedChemEx	HY-111371	PF-05180999	414.153	Cc1nc(-c2cnn(C)c2-c2ccc(cn2)C(F)(F)F)c2c(ncnn12)N1CCC1	CLGCHUKGBICQTE-UHFFFAOYSA-N	60143346.0		CLGCHUKGBICQTE
BRD-K02554563-001-01-6	PF-05190457	Phase 2	growth hormone secretagogue receptor inverse agonist	GHSR			0	87.74	Sigma	PZ0270		512.236	Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1	ZIUDADZJCKGWKR-AREMUKBSSA-N	58438464.0		ZIUDADZJCKGWKR
BRD-K07955840-001-04-9	PF-05212384	Phase 2	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA			0	97.48	Key	FE-0013	N-(4-{[4-(dimethylamino)-1-piperidinyl]carbonyl}phenyl)-N'-{4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}urea	615.328	CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	DWZAEMINVBZMHQ-UHFFFAOYSA-N	44516953.0		DWZAEMINVBZMHQ
BRD-K07955840-001-02-3	PF-05212384	Phase 2	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA			0	78.45	Selleck	S2628	PF-05212384 (PKI-587)	615.328	CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	DWZAEMINVBZMHQ-UHFFFAOYSA-N	44516953.0		DWZAEMINVBZMHQ
BRD-K07955840-001-03-1	PF-05212384	Phase 2	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA			0	82.26	Selleck	S2628	PF-05212384 (PKI-587)	615.328	CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	DWZAEMINVBZMHQ-UHFFFAOYSA-N	44516953.0		DWZAEMINVBZMHQ
BRD-K00004644-001-01-9	PF-06260414	Phase 1	androgen receptor modulator				0	17.39	Sigma	PZ0343	6-[(4R)-4-methyl-1,1-dioxo-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile	302.084	C[C@@H]1CNS(=O)(=O)N(C1)c1ccc2c(nccc2c1)C#N	ZKAVFOXYJCREBQ-SNVBAGLBSA-N	76071881.0		ZKAVFOXYJCREBQ
BRD-K00004638-001-01-9	PF-06273340	Phase 1	tyrosine kinase receptor inhibitor				0	96.55	Sigma	PZ0254	N-[5-[2-amino-7-(2-hydroxy-1,1-dimethyl-ethyl)pyrrolo[2,3-d]pyrimidine-5-carbonyl]-3-pyridyl]-2-(5-chloro-2-pyridyl)acetamide	479.147	CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc12	BPIWZDNVMQQBQX-UHFFFAOYSA-N	66571548.0		BPIWZDNVMQQBQX
BRD-K00003279-001-01-9	PF-06282999	Phase 1	myeloperoxidase inhibitor				0	97.4	MedChemEx	HY-19321	PF-06282999	325.029	COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	ICYNYWFGIDGBRD-UHFFFAOYSA-N	71571306.0		ICYNYWFGIDGBRD
BRD-K00004712-001-01-9	PF-06305591	Phase 1	sodium channel blocker				0	94.3	Sigma	PZ0297	(2R,3S)-3-amino-3-(5-tert-butyl-1H-benzimidazol-2-yl)-2-methyl-propanamide	274.179	C[C@H]([C@H](N)c1nc2cc(ccc2[nH]1)C(C)(C)C)C(N)=O	APWZIFIAVVFPNT-PELKAZGASA-N	71666749.0		APWZIFIAVVFPNT
BRD-K00003731-001-01-9	PF-06409577	Phase 1	protein kinase activator				0	96.7	MedChemEx	HY-103683	PF-06409577	341.082	OC(=O)c1c[nH]c2cc(Cl)c(cc12)-c1ccc(cc1)C1(O)CCC1	FHQXLWCFSUSXBF-UHFFFAOYSA-N	71748255.0		FHQXLWCFSUSXBF
BRD-K00004652-001-01-9	PF-06412562	Phase 1	dopamine receptor partial agonist				0	97.43	Sigma	PZ0357	4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methyl-phenoxy]-1H-pyrazolo[4,3-c]pyridine	331.143	Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C	IDIUJOHYYBNCPC-UHFFFAOYSA-N	74223726.0		IDIUJOHYYBNCPC
BRD-K83114366-001-02-8	PF-06447475	Preclinical	serine/threonine kinase inhibitor	LRRK2			0	99.15	Tocris	5716	PF 06447475	305.128	N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12	BHTWDJBVZQBRKP-UHFFFAOYSA-N	72706840.0		BHTWDJBVZQBRKP
BRD-K83114366-001-01-0	PF-06447475	Preclinical	serine/threonine kinase inhibitor	LRRK2			0	97.77	MedChemEx	HY-12477	PF-06447475	305.128	N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12	BHTWDJBVZQBRKP-UHFFFAOYSA-N	72706840.0		BHTWDJBVZQBRKP
BRD-K00003311-001-01-9	PF-06459988	Phase 2	receptor tyrosine protein kinase inhibitor				0	96.87	MedChemEx	HY-19985	PF-06459988	431.147	CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(C)c2)nc2[nH]cc(Cl)c12)C(=O)C=C	ODMXWZROLKITMS-RISCZKNCSA-N	71535003.0		ODMXWZROLKITMS
BRD-A23124853-001-01-4	PF-06463922	Launched	ALK tyrosine kinase receptor inhibitor	ALK|FES|ROS1	oncology	non-small cell lung cancer (NSCLC)	0	98.98	Selleck	S7536	PF-06463922	406.155	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1,r|	IIXWYSCJSQVBQM-UHFFFAOYSA-N	78162481.0		IIXWYSCJSQVBQM
BRD-K00003296-001-01-9	PF-06650833	Phase 1	kinase inhibitor				0	95.84	MedChemEx	HY-19836	PF06650833	361.144	CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F	JKDGKIBAOAFRPJ-ZBINZKHDSA-N	118414016.0		JKDGKIBAOAFRPJ
BRD-K47084954-001-02-9	PF-06651600	Phase 2/Phase 3	JAK inhibitor				0	95.62	MedChemEx	HY-100754	PF-06651600	285.159	C[C@H]1CC[C@H](CN1C(=O)C=C)Nc1ncnc2[nH]ccc12	CBRJPFGIXUFMTM-WDEREUQCSA-N	118115473.0		CBRJPFGIXUFMTM
BRD-K00004648-001-01-9	PF-06747775	Phase 2	EGFR inhibitor				0	96.39	Sigma	PZ0302	N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methyl-pyrazol-4-yl)amino]-9-methyl-purin-2-yl]pyrrolidin-3-yl]prop-2-enamide	415.188	COc1nn(C)cc1Nc1nc(nc2n(C)cnc12)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C	JYIUNVOCEFIUIU-GHMZBOCLSA-N	91668194.0		JYIUNVOCEFIUIU
BRD-K00004598-001-01-9	PF-06751979	Phase 1	beta secretase inhibitor				0	95.8	MedChemEx	HY-112157	PF-06751979	455.09	C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1nc(NC(=O)c2ccc(OC(F)F)cn2)cs1 |c:7|	ZLZUHACSRMOLLV-RAALSFIWSA-N	118435360.0		ZLZUHACSRMOLLV
BRD-K00003400-001-01-9	PF-06840003	Phase 1	indoleamine 2,3-dioxygenase inhibitor				0	96.34	MedChemEx	HY-101111	PF-06840003	232.065	Fc1ccc2[nH]cc([C@H]3CC(=O)NC3=O)c2c1 |&1:8,r|	MXKLDYKORJEOPR-MRVPVSSYSA-N	118512017.0		MXKLDYKORJEOPR
BRD-K00004750-001-01-9	PF-06873600	Phase 2	CDK inhibitor				0	94.5	MedChemEx	HY-114177	PF-06873600	471.175	C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O	QIEKHLDZKRQLLN-FOIQADDNSA-N	134247638.0		QIEKHLDZKRQLLN
BRD-K00005326-001-01-9	PF-06928215	Preclinical	cyclic GMP-AMP synthase inhibitor				0	95.58	MedChemEx	HY-114182	PF-06928215	380.148	OC(=O)[C@@H]1CCCC[C@@H]1NC(=O)c1cnn2c(O)cc(nc12)-c1ccccc1	PHGTYMRDHDEHLI-HIFRSBDPSA-N			PHGTYMRDHDEHLI
BRD-K31417912-001-01-9	PF-3274167	Phase 2	oxytocin receptor antagonist	AVPR1A|OXTR			0	96.73	MedChemEx	HY-15023	PF-3274167	419.116	COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1	HNIFCPBQMKPRCX-UHFFFAOYSA-N	11683187.0		HNIFCPBQMKPRCX
BRD-K68997413-001-06-9	PF-3845	Preclinical	FAAH inhibitor	FAAH			0	95.56	Tocris	4175	PF 3845	456.177	FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	NBOJHRYUGLRASX-UHFFFAOYSA-N	25154867.0		NBOJHRYUGLRASX
BRD-K68997413-001-05-1	PF-3845	Preclinical	FAAH inhibitor	FAAH			0	96.31	Selleck	S2666	PF-3845	456.177	FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	NBOJHRYUGLRASX-UHFFFAOYSA-N	25154867.0		NBOJHRYUGLRASX
BRD-K00004633-001-01-9	PF-4191834	Preclinical	lipoxygenase inhibitor				0	97.27	Sigma	PZ0360	4-(3-{[4-(1-methyl-1H-pyrazol-5-yl)phenyl]sulfanyl}phenyl)tetrahydro-2H-pyran-4-carboxamide	393.151	Cn1nccc1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	DVNQWYLVSNPCJZ-UHFFFAOYSA-N	24986635.0		DVNQWYLVSNPCJZ
BRD-K11821338-300-01-8	PF-429242	Preclinical	SREBP inhibitor	MBTPS1			0	91.17	Tocris	3354	PF 429242	409.273	CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1	XKPJTOHUPQWSOJ-HSZRJFAPSA-N	23661637.0		XKPJTOHUPQWSOJ
BRD-K11821338-300-02-9	PF-429242	Preclinical	SREBP inhibitor	MBTPS1			0	96.02	Tocris	3354	PF 429242	409.273	CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1	XKPJTOHUPQWSOJ-HSZRJFAPSA-N	23661637.0		XKPJTOHUPQWSOJ
BRD-K93788137-001-04-1	PF-431396	Preclinical	focal adhesion kinase inhibitor	PTK2|PTK2B			0	97.24	Tocris	4278	PF 431396	506.135	CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	POJZIZBONPAWIV-UHFFFAOYSA-N	11598628.0		POJZIZBONPAWIV
BRD-K93788137-001-05-9	PF-431396	Preclinical	focal adhesion kinase inhibitor	PTK2|PTK2B			0	93.64	Tocris	4278	PF 431396	506.135	CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	POJZIZBONPAWIV-UHFFFAOYSA-N	11598628.0		POJZIZBONPAWIV
BRD-K14711741-001-02-1	PF-4708671	Preclinical	ribosomal protein inhibitor	RPS6KB1			0	98.79	Selleck	S2163	PF-4708671	390.178	CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1	FBLPQCAQRNSVHB-UHFFFAOYSA-N	51371303.0		FBLPQCAQRNSVHB
BRD-K14711741-001-05-4	PF-4708671	Preclinical	ribosomal protein inhibitor	RPS6KB1			0	96.75	Tocris	4032	PF 4708671	390.178	CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1	FBLPQCAQRNSVHB-UHFFFAOYSA-N	51371303.0		FBLPQCAQRNSVHB
BRD-K03063480-001-06-6	PF-477736	Phase 1	CHK inhibitor	CHEK1|CHEK2			0	87.14	Selleck	S2904	PF 477736	419.207	Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	NDEXUOWTGYUVGA-LJQANCHMSA-N	135565545.0		NDEXUOWTGYUVGA
BRD-K03063480-001-07-4	PF-477736	Phase 1	CHK inhibitor	CHEK1|CHEK2			0	91.23	Tocris	4277	PF 477736	419.207	Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	NDEXUOWTGYUVGA-LJQANCHMSA-N	135565545.0		NDEXUOWTGYUVGA
BRD-K03063480-001-08-9	PF-477736	Phase 1	CHK inhibitor	CHEK1|CHEK2			0	95.0	Tocris	4277	PF 477736	419.207	Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	NDEXUOWTGYUVGA-LJQANCHMSA-N	135565545.0		NDEXUOWTGYUVGA
BRD-K03063480-001-05-8	PF-477736	Phase 1	CHK inhibitor	CHEK1|CHEK2			0	75.45	Selleck	S2904	PF-477736	419.207	Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	NDEXUOWTGYUVGA-LJQANCHMSA-N	135565545.0		NDEXUOWTGYUVGA
BRD-K43428468-003-04-0	PF-4800567	Preclinical	casein kinase inhibitor	CSNK1D|CSNK1E			0	98.53	Tocris	4281	PF 4800567 hydrochloride	359.115	Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1	AUMDBEHGJRZSOO-UHFFFAOYSA-N	53472153.0		AUMDBEHGJRZSOO
BRD-K43428468-003-01-6	PF-4800567	Preclinical	casein kinase inhibitor	CSNK1D|CSNK1E			0	99.49	Tocris	4281	ppn-ctd2-20-PF4800567	359.115	Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1	AUMDBEHGJRZSOO-UHFFFAOYSA-N	53472153.0		AUMDBEHGJRZSOO
BRD-K78318619-001-03-9	PF-4981517	Preclinical	cytochrome P450 inhibitor	CYP3A4			0	95.79	Tocris	4252	PF 4981517	456.275	Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	WDWIMDKOXZZYHH-FQEVSTJZSA-N	71315139.0		WDWIMDKOXZZYHH
BRD-K78318619-001-02-7	PF-4981517	Preclinical	cytochrome P450 inhibitor	CYP3A4			0	96.16	Selleck	S2921	PF-4981517	456.275	Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	WDWIMDKOXZZYHH-FQEVSTJZSA-N	71315139.0		WDWIMDKOXZZYHH
BRD-K00004642-001-01-9	PF-514273	Preclinical	cannabinoid receptor antagonist				0	92.1	Sigma	SML0389	2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one	451.067	CC(F)(F)CN1CCOc2c(nn(c2-c2ccc(Cl)cc2)-c2ccccc2Cl)C1=O	FJMQJSUOOGOWBD-UHFFFAOYSA-N	11316919.0		FJMQJSUOOGOWBD
BRD-K40302533-003-03-9	PF-5274857	Preclinical	smoothened receptor antagonist	SMO			0	96.18	Tocris	5262	PF 5274857 hydrochloride	436.134	Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	BBVNTTZIOTWDSV-UHFFFAOYSA-N	56956240.0		BBVNTTZIOTWDSV
BRD-K40302533-003-01-7	PF-5274857	Preclinical	smoothened receptor antagonist	SMO			0	92.45	Tocris	5262	PF 5274857 hydrochloride	436.134	Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	BBVNTTZIOTWDSV-UHFFFAOYSA-N	56956240.0		BBVNTTZIOTWDSV
BRD-K40302533-001-02-9	PF-5274857	Preclinical	smoothened receptor antagonist	SMO			0	93.06	Selleck	S2777	PF-5274857	436.134	Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	BBVNTTZIOTWDSV-UHFFFAOYSA-N	56956240.0		BBVNTTZIOTWDSV
BRD-K99545815-001-07-9	PF-562271	Phase 1	focal adhesion kinase inhibitor	PTK2|PTK2B			0	94.15	MedChemEx	HY-10459	PF-562271	507.13	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	MZDKLVOWGIOKTN-UHFFFAOYSA-N	11713159.0		MZDKLVOWGIOKTN
BRD-K99545815-074-02-9	PF-562271	Phase 1	focal adhesion kinase inhibitor	PTK2|PTK2B			0	93.37	Selleck	S2672	PF-00562271	507.13	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	MZDKLVOWGIOKTN-UHFFFAOYSA-N	11713159.0		MZDKLVOWGIOKTN
BRD-K99545815-003-01-0	PF-562271	Phase 1	focal adhesion kinase inhibitor	PTK2|PTK2B			0	92.3	Selleck	S7357	PF-562271 HCl	507.13	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	MZDKLVOWGIOKTN-UHFFFAOYSA-N	11713159.0		MZDKLVOWGIOKTN
BRD-K99545815-074-03-7	PF-562271	Phase 1	focal adhesion kinase inhibitor	PTK2|PTK2B			0	88.33	Selleck	S2672	PF-00562271	507.13	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	MZDKLVOWGIOKTN-UHFFFAOYSA-N	11713159.0		MZDKLVOWGIOKTN
BRD-K99545815-001-06-3	PF-562271	Phase 1	focal adhesion kinase inhibitor	PTK2|PTK2B			0	94.41	Selleck	S2890	PF-562271	507.13	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	MZDKLVOWGIOKTN-UHFFFAOYSA-N	11713159.0		MZDKLVOWGIOKTN
BRD-K79239947-001-06-8	PF-573228	Preclinical	focal adhesion kinase inhibitor	CDK1|CDK2|CDK7|GSK3B|IKBKB			0	96.83	Selleck	S2013	PF-573228	491.124	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	HESLKTSGTIBHJU-UHFFFAOYSA-N	11612883.0		HESLKTSGTIBHJU
BRD-K79239947-001-08-9	PF-573228	Preclinical	focal adhesion kinase inhibitor	CDK1|CDK2|CDK7|GSK3B|IKBKB			0	96.78	Tocris	3239	PF 573228	491.124	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	HESLKTSGTIBHJU-UHFFFAOYSA-N	11612883.0		HESLKTSGTIBHJU
BRD-K79239947-001-07-6	PF-573228	Preclinical	focal adhesion kinase inhibitor	CDK1|CDK2|CDK7|GSK3B|IKBKB			0	97.54	Tocris	3239	PF 573228	491.124	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	HESLKTSGTIBHJU-UHFFFAOYSA-N	11612883.0		HESLKTSGTIBHJU
BRD-K96295391-300-01-7	PF-670462	Preclinical	casein kinase inhibitor	CSNK1D|CSNK1E			0	97.92	MedChemEx	HY-15490	PF-670462	337.17	Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1	WUDBUIUHVNECTM-UHFFFAOYSA-N	11681588.0		WUDBUIUHVNECTM
BRD-K96295391-300-02-5	PF-670462	Preclinical	casein kinase inhibitor	CSNK1D|CSNK1E			0	86.76	Tocris	3316	PF 670462	337.17	Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1	WUDBUIUHVNECTM-UHFFFAOYSA-N	11681588.0		WUDBUIUHVNECTM
BRD-K83213911-001-07-7	PF-750	Preclinical	FAAH inhibitor	FAAH			0	92.71	Tocris	3307	PF 750	345.184	O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1	BIODYGOZWZNCAG-UHFFFAOYSA-N	25154868.0		BIODYGOZWZNCAG
BRD-K83213911-001-08-9	PF-750	Preclinical	FAAH inhibitor	FAAH			0	96.11	Tocris	3307	PF 750	345.184	O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1	BIODYGOZWZNCAG-UHFFFAOYSA-N	25154868.0		BIODYGOZWZNCAG
BRD-K50865540-001-02-3	PF-8380	Preclinical	autotaxin inhibitor	ENPP2			0	87.86	MedChemEx	HY-13344	PF-8380	477.086	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1	JMSUDQYHPSNBSN-UHFFFAOYSA-N	25265312.0		JMSUDQYHPSNBSN
BRD-K50865540-001-01-5	PF-8380	Preclinical	autotaxin inhibitor	ENPP2			0	65.51	MedChemEx	HY-13344	PF-8380	477.086	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1	JMSUDQYHPSNBSN-UHFFFAOYSA-N	25265312.0		JMSUDQYHPSNBSN
BRD-K18289362-001-02-2	PF-915275	Phase 1	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			0	98.29	Tocris	3291	PF 915275	350.084	Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	ZESFDAKNYJQYKO-UHFFFAOYSA-N	23725123.0		ZESFDAKNYJQYKO
BRD-K18289362-001-01-4	PF-915275	Phase 1	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			0	89.67	MedChemEx	HY-18056	PF-915275	350.084	Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	ZESFDAKNYJQYKO-UHFFFAOYSA-N	23725123.0		ZESFDAKNYJQYKO
BRD-K18289362-001-03-9	PF-915275	Phase 1	11-beta hydroxysteroid dehydrogenase inhibitor	HSD11B1			0	96.08	Tocris	3291	PF 915275	350.084	Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	ZESFDAKNYJQYKO-UHFFFAOYSA-N	23725123.0		ZESFDAKNYJQYKO
BRD-K13094524-001-04-2	PFI-1	Preclinical	bromodomain inhibitor	BRD4			0	57.34	Selleck	S1216	PFI-1 (PF-6405761)	347.094	COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	TXZPMHLMPKIUGK-UHFFFAOYSA-N	71271629.0		TXZPMHLMPKIUGK
BRD-K13094524-001-09-1	PFI-1	Preclinical	bromodomain inhibitor	BRD4			0	83.35	Tocris	4445	PFI 1	347.094	COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	TXZPMHLMPKIUGK-UHFFFAOYSA-N	71271629.0		TXZPMHLMPKIUGK
BRD-K13094524-001-07-5	PFI-1	Preclinical	bromodomain inhibitor	BRD4			0	91.99	Selleck	S1216	PFI-1(PF-6405761)	347.094	COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	TXZPMHLMPKIUGK-UHFFFAOYSA-N	71271629.0		TXZPMHLMPKIUGK
BRD-K61524559-001-01-3	PFI-3	Preclinical	bromodomain inhibitor	PBRM1|SMARCA4			0	94.54	Tocris	5072	PFI 3	321.148	Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1	INAICWLVUAKEPB-QSTFCLMHSA-N	78243717.0		INAICWLVUAKEPB
BRD-K61524559-001-03-9	PFI-3	Preclinical	bromodomain inhibitor	PBRM1|SMARCA4			0	0.0	MedChemEx	HY-B0117B	Tigecycline	321.148	Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1	INAICWLVUAKEPB-QSTFCLMHSA-N	78243717.0		INAICWLVUAKEPB
BRD-K13106865-001-01-7	PFI-4	Preclinical	bromodomain inhibitor	BRPF1			0	98.24	Tocris	5576	PFI 4	380.185	COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1	QCIJLRJBZDBVDB-UHFFFAOYSA-N	40642506.0		QCIJLRJBZDBVDB
BRD-K13106865-001-02-9	PFI-4	Preclinical	bromodomain inhibitor	BRPF1			0	95.05	Tocris	5576	PFI 4	380.185	COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1	QCIJLRJBZDBVDB-UHFFFAOYSA-N	40642506.0		QCIJLRJBZDBVDB
BRD-K95573441-001-02-0	PFK-015	Phase 1	phosphofructokinase inhibitor	PFKFB3			0	94.52	MedChemEx	HY-12204	PFK-015	260.095	O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	UJJUKZPBUMCSJZ-BQYQJAHWSA-N	25142799.0		UJJUKZPBUMCSJZ
BRD-K95573441-001-01-2	PFK-015	Phase 1	phosphofructokinase inhibitor	PFKFB3			0	89.21	MedChemEx	HY-12204	PFK-015	260.095	O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	UJJUKZPBUMCSJZ-BQYQJAHWSA-N	25142799.0		UJJUKZPBUMCSJZ
BRD-K28010364-001-01-0	PFK-158	Phase 1	phosphofructokinase inhibitor	PFKFB3			0	90.57	MedChemEx	HY-12203	PFK-158	328.082	FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1	IAJOMYABKVAZCN-AATRIKPKSA-N	71730058.0		IAJOMYABKVAZCN
BRD-K28010364-001-02-9	PFK-158	Phase 1	phosphofructokinase inhibitor	PFKFB3			0	82.39	MedChemEx	HY-12203	PFK-158	328.082	FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1	IAJOMYABKVAZCN-AATRIKPKSA-N	71730058.0		IAJOMYABKVAZCN
BRD-K00004212-001-01-9	PG-9	Preclinical	acetylcholine receptor agonist				0	87.9	Tocris	750	PG-9 maleate	351.083	C[C@@H](C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)c1ccc(Br)cc1 |&1:5,7,10,&2:1,r,TLB:13:12:8.9:5.6.11|	GHDWIFTUSXQYGK-FWYOQMDTSA-N			GHDWIFTUSXQYGK
BRD-A53813595-001-03-4	PGL5001	Phase 2	JNK inhibitor	MAPK10|MAPK8|MAPK9			0	90.93	MedChemEx	HY-14761	AS 602801	457.157	N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|	XCPPIJCBCWUBNT-HXUWFJFHSA-N	76969933.0		XCPPIJCBCWUBNT
BRD-A53813595-001-01-8	PGL5001	Phase 2	JNK inhibitor	MAPK10|MAPK8|MAPK9			0	80.63	MedChemEx	HY-14761	AS 602801	457.157	N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|	XCPPIJCBCWUBNT-HXUWFJFHSA-N	76969933.0		XCPPIJCBCWUBNT
BRD-A53813595-001-02-6	PGL5001	Phase 2	JNK inhibitor	MAPK10|MAPK8|MAPK9			0	89.24	MedChemEx	HY-14761	AS 602801	457.157	N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2,r|	XCPPIJCBCWUBNT-HXUWFJFHSA-N	76969933.0		XCPPIJCBCWUBNT
BRD-K95880107-001-03-9	PH-797804	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK14			0	97.66	Tocris	5866	PH 797804	476.055	CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	KCAJXIDMCNPGHZ-UHFFFAOYSA-N	22049997.0		KCAJXIDMCNPGHZ
BRD-K95880107-001-02-4	PH-797804	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK14			0	97.63	Selleck	S2726	PH-797804	476.055	CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	KCAJXIDMCNPGHZ-UHFFFAOYSA-N	22049997.0		KCAJXIDMCNPGHZ
BRD-K00004641-001-01-9	PHA-543613	Preclinical	nicotinic receptor agonist				0	98.87	Sigma	PZ0135	N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide	271.132	O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1	IPKZCLGGYKRDES-ZDUSSCGKSA-N	9930121.0		IPKZCLGGYKRDES
BRD-K48053228-051-01-7	PHA-568487	Preclinical	nicotinic receptor agonist	CHRNA7			0	79.3	Tocris	3134	PHA 568487	288.147	O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1	LUVXHMJTVXZFPD-ZDUSSCGKSA-N	9932000.0		LUVXHMJTVXZFPD
BRD-K48053228-051-02-9	PHA-568487	Preclinical	nicotinic receptor agonist	CHRNA7			0	98.49	Tocris	3134	PHA 568487	288.147	O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1	LUVXHMJTVXZFPD-ZDUSSCGKSA-N	9932000.0		LUVXHMJTVXZFPD
BRD-K95435023-001-07-7	PHA-665752	Preclinical	c-Met inhibitor	MET			0	88.99	Tocris	2693	PHA 665752	640.168	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	OYONTEXKYJZFHA-SSHUPFPWSA-N	10461815.0		OYONTEXKYJZFHA
BRD-K95435023-001-08-5	PHA-665752	Preclinical	c-Met inhibitor	MET			0	97.63	Selleck	S1070	PHA-665752	640.168	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	OYONTEXKYJZFHA-SSHUPFPWSA-N	10461815.0		OYONTEXKYJZFHA
BRD-K95435023-001-10-1	PHA-665752	Preclinical	c-Met inhibitor	MET			0	89.31	Selleck	S1070	PHA-665752	640.168	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	OYONTEXKYJZFHA-SSHUPFPWSA-N	10461815.0	BRD-K55218890-001-01-8	OYONTEXKYJZFHA
BRD-K95435023-001-11-9	PHA-665752	Preclinical	c-Met inhibitor	MET			0	95.73	Tocris	2693	PHA 665752	640.168	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	OYONTEXKYJZFHA-SSHUPFPWSA-N	10461815.0		OYONTEXKYJZFHA
BRD-K95435023-001-09-3	PHA-665752	Preclinical	c-Met inhibitor	MET			0	95.32	Tocris	2693	PHA 665752	640.168	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	OYONTEXKYJZFHA-SSHUPFPWSA-N	10461815.0		OYONTEXKYJZFHA
BRD-K09443272-001-04-9	PHA-680632	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	93.89	MedChemEx	HY-10178	PHA-680632	501.285	CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	OBWNXGOQPLDDPS-UHFFFAOYSA-N	11249084.0		OBWNXGOQPLDDPS
BRD-K09443272-001-03-3	PHA-680632	Preclinical	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	92.06	Selleck	S1454	PHA-680632	501.285	CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	OBWNXGOQPLDDPS-UHFFFAOYSA-N	11249084.0		OBWNXGOQPLDDPS
BRD-K50000283-001-04-4	PHA-767491	Preclinical	CDC inhibitor	CDK1|RPS6KB1			0	96.2	Selleck	S2742	PHA-767491	213.09	O=C1NCCc2[nH]c(cc12)-c1ccncc1	DKXHSOUZPMHNIZ-UHFFFAOYSA-N	11715767.0		DKXHSOUZPMHNIZ
BRD-K50000283-003-02-4	PHA-767491	Preclinical	CDC inhibitor	CDK1|RPS6KB1			0	98.06	Tocris	3140	PHA 767491 hydrochloride	213.09	O=C1NCCc2[nH]c(cc12)-c1ccncc1	DKXHSOUZPMHNIZ-UHFFFAOYSA-N	11715767.0		DKXHSOUZPMHNIZ
BRD-K64800655-001-11-9	PHA-793887	Phase 1	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CDK7|CDK9			0	81.79	MedChemEx	HY-11001	PHA-793887	361.248	CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	HUXYBQXJVXOMKX-UHFFFAOYSA-N	46191454.0		HUXYBQXJVXOMKX
BRD-K64800655-001-09-0	PHA-793887	Phase 1	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CDK7|CDK9			0	91.57	Selleck	S1487	PHA-793887	361.248	CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	HUXYBQXJVXOMKX-UHFFFAOYSA-N	46191454.0		HUXYBQXJVXOMKX
BRD-K64800655-001-07-4	PHA-793887	Phase 1	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CDK7|CDK9			0	87.02	Selleck	S1487	PHA-793887	361.248	CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	HUXYBQXJVXOMKX-UHFFFAOYSA-N	46191454.0		HUXYBQXJVXOMKX
BRD-K60997853-001-03-9	PHA-848125	Phase 2	CDK inhibitor|growth factor receptor inhibitor	CDK2|CDK4|CDK7|NTRK1			0	98.48	MedChemEx	HY-10424	Milciclib	460.27	CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	RXZMYLDMFYNEIM-UHFFFAOYSA-N	16718576.0		RXZMYLDMFYNEIM
BRD-K60997853-001-02-3	PHA-848125	Phase 2	CDK inhibitor|growth factor receptor inhibitor	CDK2|CDK4|CDK7|NTRK1			0	97.05	Selleck	S2751	Milciclib (PHA-848125)	460.27	CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	RXZMYLDMFYNEIM-UHFFFAOYSA-N	16718576.0		RXZMYLDMFYNEIM
BRD-K00004222-001-01-9	PHCCC	Preclinical	glutamate receptor agonist	GRM1|GRM4			0	91.91	Tocris	1027	PHCCC	294.1	O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3,5|	FPXPIEZPAXSELW-RGNAGUPPSA-N	44572113.0		FPXPIEZPAXSELW
BRD-K81092066-311-01-6	phenacaine	Launched	local anesthetic		neurology/psychiatry	local anesthetic	0	99.16	MPBio	5201349	PHENACAINE HCl MONOHYDRATE	298.168	CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1	QXDAEKSDNVPFJG-UHFFFAOYSA-N	7588.0		QXDAEKSDNVPFJG
BRD-K40905133-001-05-9	phenacemide	Launched	sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures	0	89.55	Sigma	MFCD00007948	N-(PHENYLACETYL)UREA	178.074	NC(=O)NC(=O)Cc1ccccc1	XPFRXWCVYUEORT-UHFFFAOYSA-N	4753.0		XPFRXWCVYUEORT
BRD-K40905133-001-04-9	phenacemide	Launched	sodium channel blocker	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures	0	99.38	MicroSource	1500472	PHENACEMIDE	178.074	NC(=O)NC(=O)Cc1ccccc1	XPFRXWCVYUEORT-UHFFFAOYSA-N	4753.0		XPFRXWCVYUEORT
BRD-K38323065-001-22-9	phenacetin	Withdrawn	cyclooxygenase inhibitor	PTGS1			0	91.12	MedChemEx	HY-B0476	Phenacetin	179.095	CCOc1ccc(NC(C)=O)cc1	CPJSUEIXXCENMM-UHFFFAOYSA-N	4754.0		CPJSUEIXXCENMM
BRD-K38323065-001-19-9	phenacetin	Withdrawn	cyclooxygenase inhibitor	PTGS1			0	99.33	MicroSource	1500642	PHENACETIN	179.095	CCOc1ccc(NC(C)=O)cc1	CPJSUEIXXCENMM-UHFFFAOYSA-N	4754.0		CPJSUEIXXCENMM
BRD-K38323065-001-18-1	phenacetin	Withdrawn	cyclooxygenase inhibitor	PTGS1			0	92.01	Selleck	S2577	Phenacetin	179.095	CCOc1ccc(NC(C)=O)cc1	CPJSUEIXXCENMM-UHFFFAOYSA-N	4754.0		CPJSUEIXXCENMM
BRD-K46937689-001-16-9	phenazone	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	97.12	MedChemEx	HY-B0171	Antipyrine	188.095	Cc1cc(=O)n(-c2ccccc2)n1C	VEQOALNAAJBPNY-UHFFFAOYSA-N	2206.0		VEQOALNAAJBPNY
BRD-K46937689-001-15-0	phenazone	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	99.14	MicroSource	1500128	ANTIPYRINE	188.095	Cc1cc(=O)n(-c2ccccc2)n1C	VEQOALNAAJBPNY-UHFFFAOYSA-N	2206.0		VEQOALNAAJBPNY
BRD-K46937689-001-14-3	phenazone	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	96.59	Selleck	S3173	Antipyrine	188.095	Cc1cc(=O)n(-c2ccccc2)n1C	VEQOALNAAJBPNY-UHFFFAOYSA-N	2206.0		VEQOALNAAJBPNY
BRD-K76304753-003-22-9	phenazopyridine	Launched	local anesthetic	SCN1A	infectious disease	urinary tract infections	0	95.52	MedChemEx	HY-B0985	Phenazopyridine (hydrochloride)	213.101	Nc1ccc(\N=N\c2ccccc2)c(N)n1	QPFYXYFORQJZEC-FOCLMDBBSA-N			QPFYXYFORQJZEC
BRD-K76304753-003-19-5	phenazopyridine	Launched	local anesthetic	SCN1A	infectious disease	urinary tract infections	0	87.46	Selleck	S4235	Phenazopyridine HCl	213.101	Nc1ccc(\N=N\c2ccccc2)c(N)n1	QPFYXYFORQJZEC-FOCLMDBBSA-N			QPFYXYFORQJZEC
BRD-K76304753-003-20-3	phenazopyridine	Launched	local anesthetic	SCN1A	infectious disease	urinary tract infections	0	96.12	MicroSource	1500473	PHENAZOPYRIDINE HYDROCHLORIDE	213.101	Nc1ccc(\N=N\c2ccccc2)c(N)n1	QPFYXYFORQJZEC-FOCLMDBBSA-N			QPFYXYFORQJZEC
BRD-K76304753-003-21-1	phenazopyridine	Launched	local anesthetic	SCN1A	infectious disease	urinary tract infections	0	93.75	Selleck	S4235	Phenazopyridine HCl	213.101	Nc1ccc(\N=N\c2ccccc2)c(N)n1	QPFYXYFORQJZEC-FOCLMDBBSA-N			QPFYXYFORQJZEC
BRD-K87024524-001-04-0	phenelzine	Launched	monoamine oxidase inhibitor	ABAT|AOC3|GAD2|GPT|GPT2|MAOA|MAOB|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	0.0	Sigma	MFCD00047825	1-(2-phenylethyl)hydrazine	136.1	NNCCc1ccccc1	RMUCZJUITONUFY-UHFFFAOYSA-N	3675.0		RMUCZJUITONUFY
BRD-K87024524-065-17-7	phenelzine	Launched	monoamine oxidase inhibitor	ABAT|AOC3|GAD2|GPT|GPT2|MAOA|MAOB|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	80.24	MicroSource	1500476	PHENELZINE SULFATE	136.1	NNCCc1ccccc1	RMUCZJUITONUFY-UHFFFAOYSA-N	3675.0		RMUCZJUITONUFY
BRD-K87024524-065-18-5	phenelzine	Launched	monoamine oxidase inhibitor	ABAT|AOC3|GAD2|GPT|GPT2|MAOA|MAOB|SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	77.3	Sigma	MFCD00050687	sulfuric acid compound with 1-(2-phenylethyl)hydrazine (1:1)	136.1	NNCCc1ccccc1	RMUCZJUITONUFY-UHFFFAOYSA-N	3675.0		RMUCZJUITONUFY
BRD-A66025870-237-06-9	phenethicillin	Launched	bacterial cell wall synthesis inhibitor				0	55.17	Prestwick	Prestw-723	Phenethicillin potassium salt	364.109	C[C@@H](Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O |a:12,13,18,&1:1|	NONJJLVGHLVQQM-ADGXKJENSA-N	8604.0		NONJJLVGHLVQQM
BRD-K56700933-001-03-9	phenethyl-isothiocyanate	Phase 2	anticancer agent	CYP2E1			0	0.0	Sigma	68488	(2-isothiocyanatoethyl)benzene	163.046	S=C=NCCc1ccccc1	IZJDOKYDEWTZSO-UHFFFAOYSA-N	16741.0		IZJDOKYDEWTZSO
BRD-K11399644-003-10-5	phenformin	Withdrawn	AMPK activator	KCNJ8|PRKAA1			0	97.03	MicroSource	1505983	PHENFORMIN HYDROCHLORIDE	205.133	NC(N)=NC(=N)NCCc1ccccc1	ICFJFFQQTFMIBG-UHFFFAOYSA-N	8249.0		ICFJFFQQTFMIBG
BRD-K11399644-003-11-3	phenformin	Withdrawn	AMPK activator	KCNJ8|PRKAA1			0	97.99	MicroSource	1501059	PHENFORMIN HYDROCHLORIDE	205.133	NC(N)=NC(=N)NCCc1ccccc1	ICFJFFQQTFMIBG-UHFFFAOYSA-N	8249.0		ICFJFFQQTFMIBG
BRD-K11399644-003-19-9	phenformin	Withdrawn	AMPK activator	KCNJ8|PRKAA1			0	90.7	MedChemEx	HY-16397A	Phenformin (hydrochloride)	205.133	NC(N)=NC(=N)NCCc1ccccc1	ICFJFFQQTFMIBG-UHFFFAOYSA-N	8249.0		ICFJFFQQTFMIBG
BRD-K11399644-003-09-7	phenformin	Withdrawn	AMPK activator	KCNJ8|PRKAA1			0	93.67	Selleck	S2542	Phenformin HCl	205.133	NC(N)=NC(=N)NCCc1ccccc1	ICFJFFQQTFMIBG-UHFFFAOYSA-N	8249.0		ICFJFFQQTFMIBG
BRD-A33178345-001-01-4	phenindamine	Launched	histamine receptor antagonist	HRH1	allergy|otolaryngology	allergic rhinitis|common cold	0	47.35	AMS	A001025678	2-methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine	261.152	CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|	ISFHAYSTHMVOJR-LJQANCHMSA-N	57086802.0		ISFHAYSTHMVOJR
BRD-A33178345-001-02-2	phenindamine	Launched	histamine receptor antagonist	HRH1	allergy|otolaryngology	allergic rhinitis|common cold	0	41.4	AMS	A001025678	2-methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine	261.152	CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7,r,c:4|	ISFHAYSTHMVOJR-LJQANCHMSA-N	57086802.0		ISFHAYSTHMVOJR
BRD-K70592963-001-33-2	phenindione	Launched	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	0	95.63	MedChemEx	HY-B0325	Phenindione	222.068	O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N	4760.0		NFBAXHOPROOJAW
BRD-K70592963-001-31-6	phenindione	Launched	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	0	87.93	Sigma	1522006	3-hydroxy-2-phenyl-1H-inden-1-one	222.068	O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N	4760.0		NFBAXHOPROOJAW
BRD-K70592963-001-29-0	phenindione	Launched	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	0	80.26	Selleck	S1921	Phenindione (Rectadione)	222.068	O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N	4760.0		NFBAXHOPROOJAW
BRD-K70592963-001-27-4	phenindione	Launched	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	0	16.12	Selleck	S1921	Phenindione	222.068	O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N	4760.0		NFBAXHOPROOJAW
BRD-K70592963-001-32-4	phenindione	Launched	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	0	61.78	MedChemEx	HY-B0325	Phenindione	222.068	O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N	4760.0		NFBAXHOPROOJAW
BRD-K70592963-001-28-2	phenindione	Launched	vitamin K antagonist	VKORC1	hematology	deep vein thrombosis (DVT)	0	0.0	MicroSource	1500477	PHENINDIONE	222.068	O=C1C(C(=O)c2ccccc12)c1ccccc1	NFBAXHOPROOJAW-UHFFFAOYSA-N	4760.0		NFBAXHOPROOJAW
BRD-A23072235-050-17-7	pheniramine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	96.6	Selleck	S4045	Pheniramine Maleate	240.163	CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|	IJHNSHDBIRRJRN-HNNXBMFYSA-N	667440.0		IJHNSHDBIRRJRN
BRD-A23072235-050-18-5	pheniramine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	98.32	MicroSource	1500478	PHENIRAMINE MALEATE	240.163	CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|	IJHNSHDBIRRJRN-HNNXBMFYSA-N	667440.0		IJHNSHDBIRRJRN
BRD-A23072235-050-19-9	pheniramine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis|urticaria	0	92.63	MedChemEx	HY-B0971	Pheniramine (Maleate)	240.163	CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|	IJHNSHDBIRRJRN-HNNXBMFYSA-N	667440.0		IJHNSHDBIRRJRN
BRD-K76549667-001-04-6	phenol	Preclinical		CA1|CA12|CA14|CA2|CA4|CA9	otolaryngology	pharyngitis	0	0.0	Sigma	V800301	phenol	94.042	Oc1ccccc1	ISWSIDIOOBJBQZ-UHFFFAOYSA-N	996.0		ISWSIDIOOBJBQZ
BRD-K19227686-001-19-9	phenolphthalein	Withdrawn	indicator dye	UGT1A9			0	97.58	MedChemEx	HY-D0211	Phenolphthalein	318.089	Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	KJFMBFZCATUALV-UHFFFAOYSA-N	4764.0		KJFMBFZCATUALV
BRD-K19227686-001-18-6	phenolphthalein	Withdrawn	indicator dye	UGT1A9			0	98.24	MicroSource	1500480	PHENOLPHTHALEIN	318.089	Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	KJFMBFZCATUALV-UHFFFAOYSA-N	4764.0		KJFMBFZCATUALV
BRD-K79892937-236-04-9	phenolsulfonphthalein	Launched					0	94.8	MedChemEx	HY-D0169A	Phenol Red (sodium salt)	354.056	Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	BELBBZDIHDAJOR-UHFFFAOYSA-N	4766.0		BELBBZDIHDAJOR
BRD-K79892937-001-02-5	phenolsulfonphthalein	Launched					0	91.1	MicroSource	1500769	PHENOLSULFONPHTHALEIN	354.056	Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	BELBBZDIHDAJOR-UHFFFAOYSA-N	4766.0		BELBBZDIHDAJOR
BRD-K59597909-001-19-2	phenothiazine	Preclinical	dopamine receptor antagonist				0	83.99	MicroSource	1506171	PHENOTHIAZINE	199.046	N1c2ccccc2Sc2ccccc12	WJFKNYWRSNBZNX-UHFFFAOYSA-N	7108.0		WJFKNYWRSNBZNX
BRD-K59597909-001-17-6	phenothiazine	Preclinical	dopamine receptor antagonist				0	86.77	Selleck	S4251	Phenothiazine	199.046	N1c2ccccc2Sc2ccccc12	WJFKNYWRSNBZNX-UHFFFAOYSA-N	7108.0		WJFKNYWRSNBZNX
BRD-K59597909-001-20-0	phenothiazine	Preclinical	dopamine receptor antagonist				0	96.7	Selleck	S4251	Phenothiazine	199.046	N1c2ccccc2Sc2ccccc12	WJFKNYWRSNBZNX-UHFFFAOYSA-N	7108.0		WJFKNYWRSNBZNX
BRD-A22106989-001-06-8	phenothrin	Launched			infectious disease	lice	0	74.08	MicroSource	1504098	PHENOTHRIN	350.188	CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|	SBNFWQZLDJGRLK-SFTDATJTSA-N	187827.0		SBNFWQZLDJGRLK
BRD-A22106989-001-05-0	phenothrin	Launched			infectious disease	lice	0	76.28	Selleck	S4364	Phenothrin	350.188	CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|	SBNFWQZLDJGRLK-SFTDATJTSA-N	187827.0		SBNFWQZLDJGRLK
BRD-A22106989-001-08-9	phenothrin	Launched			infectious disease	lice	0	72.1	Sigma	36193	Phenothrin	350.188	CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4,&2:5,r|	SBNFWQZLDJGRLK-SFTDATJTSA-N	187827.0		SBNFWQZLDJGRLK
BRD-A67799922-003-28-6	phenoxybenzamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	cardiology|endocrinology	hypertension|pheochromocytoma	0	0.0	MedChemEx	HY-B0431A	Phenoxybenzamine (hydrochloride)	303.139	CC(COc1ccccc1)N(CCCl)Cc1ccccc1	QZVCTJOXCFMACW-UHFFFAOYSA-N	657233.0		QZVCTJOXCFMACW
BRD-A67799922-003-26-0	phenoxybenzamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	cardiology|endocrinology	hypertension|pheochromocytoma	0	0.0	Selleck	S2499	Phenoxybenzamine HCl	303.139	CC(COc1ccccc1)N(CCCl)Cc1ccccc1	QZVCTJOXCFMACW-UHFFFAOYSA-N	657233.0		QZVCTJOXCFMACW
BRD-A67799922-003-29-4	phenoxybenzamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	cardiology|endocrinology	hypertension|pheochromocytoma	0	0.0	MedChemEx	HY-B0431A	Phenoxybenzamine (hydrochloride)	303.139	CC(COc1ccccc1)N(CCCl)Cc1ccccc1	QZVCTJOXCFMACW-UHFFFAOYSA-N	657233.0		QZVCTJOXCFMACW
BRD-A67799922-003-27-8	phenoxybenzamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	cardiology|endocrinology	hypertension|pheochromocytoma	0	0.0	Selleck	S2499	Phenoxybenzamine HCl	303.139	CC(COc1ccccc1)N(CCCl)Cc1ccccc1	QZVCTJOXCFMACW-UHFFFAOYSA-N	657233.0		QZVCTJOXCFMACW
BRD-K22009844-001-12-5	phenprobamate	Launched	muscle relaxant		neurology/psychiatry	anxiety|muscle relaxant	0	98.85	Prestwick	Prestw-1776	Phenprobamate	179.095	NC(=O)OCCCc1ccccc1	CAMYKONBWHRPDD-UHFFFAOYSA-N	4770.0		CAMYKONBWHRPDD
BRD-A49838158-001-01-1	phenprocoumon	Launched	vitamin K antagonist	VKORC1	hematology	thrombosis|pulmonary embolism (PE)	0	97.47	Abblis	AB2000540		280.11	CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2,r|	DQDAYGNAKTZFIW-ZDUSSCGKSA-N	54681533.0		DQDAYGNAKTZFIW
BRD-K46580984-001-03-6	phenserine	Phase 3	acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor	ACHE|BCHE			0	83.49	Sigma	MFCD00672748	(3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate	337.179	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	PBHFNBQPZCRWQP-QUCCMNQESA-N	192706.0		PBHFNBQPZCRWQP
BRD-K46580984-001-02-8	phenserine	Phase 3	acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor	ACHE|BCHE			0	63.7	Enzo	AC909	(-)-N-Phenylcarbamoyleseroline	337.179	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	PBHFNBQPZCRWQP-QUCCMNQESA-N	192706.0		PBHFNBQPZCRWQP
BRD-A18043272-001-09-9	phensuximide	Launched	succinimide antiepileptic		neurology/psychiatry	seizures	0	98.87	MicroSource	1505458	PHENSUCCIMIDE	189.079	CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|	WLWFNJKHKGIJNW-SECBINFHSA-N	6604215.0		WLWFNJKHKGIJNW
BRD-A18043272-001-10-7	phensuximide	Launched	succinimide antiepileptic		neurology/psychiatry	seizures	0	95.53	USP	1528002	Phensuximide	189.079	CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5,r|	WLWFNJKHKGIJNW-SECBINFHSA-N	6604215.0		WLWFNJKHKGIJNW
BRD-K90333595-066-24-9	phentolamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	endocrinology|cardiology	pheochromocytoma|hypertension	0	98.72	MedChemEx	HY-B0362A	Phentolamine (mesylate)	281.153	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	MRBDMNSDAVCSSF-UHFFFAOYSA-N	5775.0		MRBDMNSDAVCSSF
BRD-K90333595-003-22-2	phentolamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	endocrinology|cardiology	pheochromocytoma|hypertension	0	99.38	Enzo	AC121	Phentolamine	281.153	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	MRBDMNSDAVCSSF-UHFFFAOYSA-N	5775.0		MRBDMNSDAVCSSF
BRD-K90333595-066-17-9	phentolamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	endocrinology|cardiology	pheochromocytoma|hypertension	0	92.66	Selleck	S2038	Phentolamine Mesylate	281.153	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	MRBDMNSDAVCSSF-UHFFFAOYSA-N	5775.0		MRBDMNSDAVCSSF
BRD-K90333595-003-21-4	phentolamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	endocrinology|cardiology	pheochromocytoma|hypertension	0	90.53	MicroSource	1500691	PHENTOLAMINE HYDROCHLORIDE	281.153	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	MRBDMNSDAVCSSF-UHFFFAOYSA-N	5775.0		MRBDMNSDAVCSSF
BRD-K90333595-066-16-1	phentolamine	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	endocrinology|cardiology	pheochromocytoma|hypertension	0	80.47	Selleck	S2038	Phentolamine Mesylate	281.153	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	MRBDMNSDAVCSSF-UHFFFAOYSA-N	5775.0		MRBDMNSDAVCSSF
BRD-K73157543-001-04-1	phenyl-aminosalicylate	Launched			infectious disease	tuberculosis	0	99.55	MicroSource	305025	PHENYL AMINOSALICYLATE	229.074	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	DNVVZWSVACQWJE-UHFFFAOYSA-N	8609.0		DNVVZWSVACQWJE
BRD-K73157543-001-05-9	phenyl-aminosalicylate	Launched			infectious disease	tuberculosis	0	96.0	FrontierSci	500014575	Phenyl 4-Aminosalicylate	229.074	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	DNVVZWSVACQWJE-UHFFFAOYSA-N	8609.0		DNVVZWSVACQWJE
BRD-K44091963-001-04-9	phenyl-salicylate	Launched	antiseptic		urology	interstitial cystitis (IC)	0	88.66	MedChemEx	HY-B1731	Phenyl Salicylate	214.063	Oc1ccccc1C(=O)Oc1ccccc1	ZQBAKBUEJOMQEX-UHFFFAOYSA-N	8361.0		ZQBAKBUEJOMQEX
BRD-K44091963-001-01-5	phenyl-salicylate	Launched	antiseptic		urology	interstitial cystitis (IC)	0	0.0	Enamine	Z57206005		214.063	Oc1ccccc1C(=O)Oc1ccccc1	ZQBAKBUEJOMQEX-UHFFFAOYSA-N	8361.0		ZQBAKBUEJOMQEX
BRD-K70592483-001-01-0	phenylacetylglutamine	Phase 2	DNA methylase inhibitor|protein synthesis inhibitor				0	89.95	Cayman	16724		264.111	NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O	JFLIEFSWGNOPJJ-JTQLQIEISA-N	92258.0		JFLIEFSWGNOPJJ
BRD-K02729857-001-01-9	phenylbenzimidazole-sulfonic-acid	Launched			dermatology	sunscreen lotion	0	92.52	Vitas-M	STK034479		274.041	OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1	UVCJGUGAGLDPAA-UHFFFAOYSA-N	33919.0		UVCJGUGAGLDPAA
BRD-K10843433-001-26-9	phenylbutazone	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	PTGIS|PTGS1|PTGS2			0	95.68	MedChemEx	HY-B0230	Phenylbutazone	308.152	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	VYMDGNCVAMGZFE-UHFFFAOYSA-N	4781.0		VYMDGNCVAMGZFE
BRD-K10843433-001-23-5	phenylbutazone	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	PTGIS|PTGS1|PTGS2			0	94.51	Selleck	S1654	Phenylbutazone (Butazolidin, Butatron)	308.152	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	VYMDGNCVAMGZFE-UHFFFAOYSA-N	4781.0		VYMDGNCVAMGZFE
BRD-K10843433-001-21-9	phenylbutazone	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	PTGIS|PTGS1|PTGS2			0	69.27	Selleck	S1654	Phenylbutazone	308.152	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	VYMDGNCVAMGZFE-UHFFFAOYSA-N	4781.0		VYMDGNCVAMGZFE
BRD-K10843433-001-22-7	phenylbutazone	Withdrawn	cyclooxygenase inhibitor|prostanoid receptor antagonist	PTGIS|PTGS1|PTGS2			0	98.14	MicroSource	1500482	PHENYLBUTAZONE	308.152	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	VYMDGNCVAMGZFE-UHFFFAOYSA-N	4781.0		VYMDGNCVAMGZFE
BRD-K67102207-236-08-5	phenylbutyrate	Launched	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	0	96.7	MicroSource	1300040	SODIUM PHENYLBUTYRATE	164.084	OC(=O)CCCc1ccccc1	OBKXEAXTFZPCHS-UHFFFAOYSA-N	4775.0		OBKXEAXTFZPCHS
BRD-K67102207-236-10-1	phenylbutyrate	Launched	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	0	70.78	Tocris	2682	Sodium 4-Phenylbutyrate	164.084	OC(=O)CCCc1ccccc1	OBKXEAXTFZPCHS-UHFFFAOYSA-N	4775.0		OBKXEAXTFZPCHS
BRD-K67102207-236-07-7	phenylbutyrate	Launched	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	0	97.03	Tocris	2682	Sodium 4-Phenylbutyrate	164.084	OC(=O)CCCc1ccccc1	OBKXEAXTFZPCHS-UHFFFAOYSA-N	4775.0		OBKXEAXTFZPCHS
BRD-K67102207-236-06-9	phenylbutyrate	Launched	HDAC inhibitor	HDAC1	metabolism	urea cycle disorders	0	93.24	Selleck	S4125	Sodium Phenylbutyrate	164.084	OC(=O)CCCc1ccccc1	OBKXEAXTFZPCHS-UHFFFAOYSA-N	4775.0		OBKXEAXTFZPCHS
BRD-K73381542-003-22-6	phenylephrine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D	otolaryngology|gastroenterology|cardiology	nasal congestion|hemorrhoids|hypotension	0	85.84	Selleck	S2569	Phenylephrine HCl	167.095	CNC[C@H](O)c1cccc(O)c1	SONNWYBIRXJNDC-VIFPVBQESA-N	6041.0		SONNWYBIRXJNDC
BRD-K73381542-003-24-2	phenylephrine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D	otolaryngology|gastroenterology|cardiology	nasal congestion|hemorrhoids|hypotension	0	93.38	Selleck	S2569	Phenylephrine hydrochloride	167.095	CNC[C@H](O)c1cccc(O)c1	SONNWYBIRXJNDC-VIFPVBQESA-N	6041.0		SONNWYBIRXJNDC
BRD-K73381542-003-23-4	phenylephrine	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D	otolaryngology|gastroenterology|cardiology	nasal congestion|hemorrhoids|hypotension	0	93.12	MicroSource	1500483	PHENYLEPHRINE HYDROCHLORIDE	167.095	CNC[C@H](O)c1cccc(O)c1	SONNWYBIRXJNDC-VIFPVBQESA-N	6041.0		SONNWYBIRXJNDC
BRD-K42371134-001-06-6	phenylethyl-alcohol	Preclinical					0	0.0	MicroSource	1505398	PHENYLETHYL ALCOHOL	122.073	OCCc1ccccc1	WRMNZCZEMHIOCP-UHFFFAOYSA-N	6054.0		WRMNZCZEMHIOCP
BRD-K42371134-001-09-9	phenylethyl-alcohol	Preclinical					0	0.0	MedChemEx	HY-B1290	2-Phenylethanol	122.073	OCCc1ccccc1	WRMNZCZEMHIOCP-UHFFFAOYSA-N	6054.0		WRMNZCZEMHIOCP
BRD-K74193284-001-05-9	phenylmercuric-acetate	Preclinical	other antifungal				1	0.0	MedChemEx	HY-B1310	Phenylmercuric acetate	338.023	CC(=O)O[Hg]c1ccccc1	XEBWQGVWTUSTLN-UHFFFAOYSA-M	9905811.0		XEBWQGVWTUSTLN
BRD-K74193284-001-04-8	phenylmercuric-acetate	Preclinical	other antifungal				1	0.0	MicroSource	1500644	PHENYLMERCURIC ACETATE	338.023	CC(=O)O[Hg]c1ccccc1	XEBWQGVWTUSTLN-UHFFFAOYSA-M	9905811.0		XEBWQGVWTUSTLN
BRD-K33422401-001-06-4	phenylmethylsulfonyl-fluoride	Preclinical	serine protease inhibitor				1	0.0	Selleck	S3025	PMSF (Phenylmethylsulfonyl Fluoride)	174.015	FS(=O)(=O)Cc1ccccc1	YBYRMVIVWMBXKQ-UHFFFAOYSA-N	4784.0		YBYRMVIVWMBXKQ
BRD-K33422401-001-05-6	phenylmethylsulfonyl-fluoride	Preclinical	serine protease inhibitor				1	0.0	Selleck	S3025	PMSF	174.015	FS(=O)(=O)Cc1ccccc1	YBYRMVIVWMBXKQ-UHFFFAOYSA-N	4784.0		YBYRMVIVWMBXKQ
BRD-A65683612-001-07-7	phenylpiracetam	Launched	noradrenaline uptake inhibitor		neurology/psychiatry	anxiety|fatigue|depression	0	91.32	MedChemEx	HY-14840	Phenylpiracetam	218.106	NC(=O)CN1C[C@@H](CC1=O)c1ccccc1 |&1:6,r|	LYONXVJRBWWGQO-SNVBAGLBSA-N	781884.0		LYONXVJRBWWGQO
BRD-K55930204-236-23-5	phenytoin	Launched	hydantoin antiepileptic	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	96.16	Selleck	S2524	Phenytoin sodium	252.09	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	CXOFVDLJLONNDW-UHFFFAOYSA-N	1775.0		CXOFVDLJLONNDW
BRD-K55930204-236-24-3	phenytoin	Launched	hydantoin antiepileptic	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	99.77	MicroSource	1500485	PHENYTOIN SODIUM	252.09	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	CXOFVDLJLONNDW-UHFFFAOYSA-N	1775.0		CXOFVDLJLONNDW
BRD-K55930204-001-20-9	phenytoin	Launched	hydantoin antiepileptic	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	98.26	Selleck	S2525	Phenytoin	252.09	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	CXOFVDLJLONNDW-UHFFFAOYSA-N	1775.0		CXOFVDLJLONNDW
BRD-K44400149-003-01-1	PhiKan-083	Preclinical	p53 stabilizing agent	TP53			0	85.55	Tocris	4326	PhiKan 083	238.147	CCn1c2ccccc2c2cc(CNC)ccc12	LBPNOEAFWYTTEB-UHFFFAOYSA-N	4722579.0		LBPNOEAFWYTTEB
BRD-K44400149-003-02-9	PhiKan-083	Preclinical	p53 stabilizing agent	TP53			0	97.41	Tocris	4326	PhiKan 083	238.147	CCn1c2ccccc2c2cc(CNC)ccc12	LBPNOEAFWYTTEB-UHFFFAOYSA-N	4722579.0		LBPNOEAFWYTTEB
BRD-K15563106-001-18-0	phloretin	Launched	sodium/glucose cotransporter inhibitor	AQP9|CLCN3|SLC23A1			0	95.59	Selleck	S2342	Phloretin	274.084	Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1	VGEREEWJJVICBM-UHFFFAOYSA-N	4788.0		VGEREEWJJVICBM
BRD-K73756878-001-07-9	phlorizin	Preclinical	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A11|SLC5A2|SLC5A3			0	97.11	Tocris	4627	Phlorizin	436.137	OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	IOUVKUPGCMBWBT-QNDFHXLGSA-N	6072.0		IOUVKUPGCMBWBT
BRD-K00405906-001-03-9	phloroglucin	Launched			neurology/psychiatry	spasms	0	100.0	Sigma	MFCD00002286	Phloroglucinol	126.032	Oc1cc(O)cc(O)c1	QCDYQQDYXPDABM-UHFFFAOYSA-N	359.0		QCDYQQDYXPDABM
BRD-K00405906-001-01-9	phloroglucin	Launched			neurology/psychiatry	spasms	0	98.67	Vitas-M	STL146346		126.032	Oc1cc(O)cc(O)c1	QCDYQQDYXPDABM-UHFFFAOYSA-N	359.0		QCDYQQDYXPDABM
BRD-K74558903-300-01-5	phortress	Phase 1	aryl hydrocarbon receptor ligand	AHR			0	92.95	Key	GS-1302	(S)-2,6-diamino-N-(4-(5-fluorobenzo[d]thiazol-2-yl)-2-methylphenyl)hexanamide dihydrochloride	386.158	Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1	LFDOEFHQLNGBQQ-HNNXBMFYSA-N	399465.0		LFDOEFHQLNGBQQ
BRD-A10131665-001-02-0	phosphatidylcholine	Launched			infectious disease|dermatology|gastroenterology|cardiology|obstetrics/gynecology	hepatitis B|hepatitis C|eczema|gallbladder disease|cholesterol|premenstrual syndrome	1	0.0	Selleck	S4411	Phosphatidylcholine.	758.57	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|	JLPULHDHAOZNQI-ZTIMHPMXSA-O	446962.0		JLPULHDHAOZNQI
BRD-A10131665-001-03-8	phosphatidylcholine	Launched			infectious disease|dermatology|gastroenterology|cardiology|obstetrics/gynecology	hepatitis B|hepatitis C|eczema|gallbladder disease|cholesterol|premenstrual syndrome	1	0.0	Selleck	S4411	1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine	758.57	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19,&1:22|	JLPULHDHAOZNQI-ZTIMHPMXSA-O	446962.0		JLPULHDHAOZNQI
BRD-K07460388-019-02-9	PHP-501	Preclinical	GABA receptor antagonist	GABRA1|GABRB2|GABRG2			0	95.71	Tocris	4466	PHP 501 trifluoroacetate	319.168	On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1	UHEYIOPHTBWBQN-UHFFFAOYSA-N	46204221.0		UHEYIOPHTBWBQN
BRD-K07460388-019-01-6	PHP-501	Preclinical	GABA receptor antagonist	GABRA1|GABRB2|GABRG2			0	79.59	Tocris	4466	PHP 501 trifluoroacetate	319.168	On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1	UHEYIOPHTBWBQN-UHFFFAOYSA-N	46204221.0		UHEYIOPHTBWBQN
BRD-K59745944-001-05-9	PHT-427	Preclinical	AKT inhibitor|pyruvate dehydrogenase inhibitor	AKT2|PDPK1			0	93.76	Tocris	4598	PHT 427	409.186	CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	BYWWNRBKPCPJMG-UHFFFAOYSA-N	44240850.0		BYWWNRBKPCPJMG
BRD-K59745944-001-04-6	PHT-427	Preclinical	AKT inhibitor|pyruvate dehydrogenase inhibitor	AKT2|PDPK1			0	92.09	Tocris	4598	PHT 427	409.186	CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	BYWWNRBKPCPJMG-UHFFFAOYSA-N	44240850.0		BYWWNRBKPCPJMG
BRD-K59745944-001-03-8	PHT-427	Preclinical	AKT inhibitor|pyruvate dehydrogenase inhibitor	AKT2|PDPK1			0	96.76	Selleck	S1556	PHT-427	409.186	CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	BYWWNRBKPCPJMG-UHFFFAOYSA-N	44240850.0		BYWWNRBKPCPJMG
BRD-K59745944-001-02-0	PHT-427	Preclinical	AKT inhibitor|pyruvate dehydrogenase inhibitor	AKT2|PDPK1			0	87.25	Selleck	S1556	PHT-427	409.186	CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	BYWWNRBKPCPJMG-UHFFFAOYSA-N	44240850.0		BYWWNRBKPCPJMG
BRD-K77115421-001-02-6	phthalylsulfacetamide	Preclinical					0	82.6	Selleck	S4365	Phthalylsulfacetamide	362.057	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	SNWQKAWITMVCQW-UHFFFAOYSA-N	8574.0		SNWQKAWITMVCQW
BRD-K77115421-001-03-4	phthalylsulfacetamide	Preclinical					0	77.69	MicroSource	1505728	PHTHALYLSULFACETAMIDE	362.057	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	SNWQKAWITMVCQW-UHFFFAOYSA-N	8574.0		SNWQKAWITMVCQW
BRD-K77115421-001-05-9	phthalylsulfacetamide	Preclinical					0	94.32	MedChemEx	HY-B0967	Phthalylsulfacetamide	362.057	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	SNWQKAWITMVCQW-UHFFFAOYSA-N	8574.0		SNWQKAWITMVCQW
BRD-K77115421-001-04-2	phthalylsulfacetamide	Preclinical					0	84.21	Selleck	S4365	phthalylsulfacetamide	362.057	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	SNWQKAWITMVCQW-UHFFFAOYSA-N	8574.0		SNWQKAWITMVCQW
BRD-K64659768-001-13-6	phthalylsulfathiazole	Launched	dihydropteroate synthetase inhibitor		infectious disease|gastroenterology	dysentry|colitis	0	80.25	MedChemEx	HY-B1407	Phthalylsulfathiazole	403.03	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	PBMSWVPMRUJMPE-UHFFFAOYSA-N	4806.0		PBMSWVPMRUJMPE
BRD-K64659768-001-12-8	phthalylsulfathiazole	Launched	dihydropteroate synthetase inhibitor		infectious disease|gastroenterology	dysentry|colitis	0	83.45	MicroSource	1502021	PHTHALYLSULFATHIAZOLE	403.03	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	PBMSWVPMRUJMPE-UHFFFAOYSA-N	4806.0		PBMSWVPMRUJMPE
BRD-K76568384-001-03-0	PHTPP	Preclinical	estrogen receptor antagonist	ESR2			0	93.41	Tocris	2662	PHTPP	423.081	Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	AEZPAUSGTAHLOQ-UHFFFAOYSA-N	11201035.0		AEZPAUSGTAHLOQ
BRD-K76568384-001-02-2	PHTPP	Preclinical	estrogen receptor antagonist	ESR2			0	89.89	Tocris	2662	PHTPP	423.081	Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	AEZPAUSGTAHLOQ-UHFFFAOYSA-N	11201035.0		AEZPAUSGTAHLOQ
BRD-K76568384-001-04-9	PHTPP	Preclinical	estrogen receptor antagonist	ESR2			0	95.16	Tocris	2662	PHTPP	423.081	Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	AEZPAUSGTAHLOQ-UHFFFAOYSA-N	11201035.0		AEZPAUSGTAHLOQ
BRD-K25650355-065-02-0	physostigmine	Launched	acetylcholinesterase inhibitor|cholinesterase inhibitor	ACHE|BCHE	cardiology|neurology/psychiatry|ophthalmology|gastroenterology	hypotension|Alzheimer's disease|glaucoma|gastroparesis	0	86.09	MicroSource	2300067	PHYSOSTIGMINE SULFATE	275.163	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	PIJVFDBKTWXHHD-HIFRSBDPSA-N	5983.0		PIJVFDBKTWXHHD
BRD-K25650355-059-19-7	physostigmine	Launched	acetylcholinesterase inhibitor|cholinesterase inhibitor	ACHE|BCHE	cardiology|neurology/psychiatry|ophthalmology|gastroenterology	hypotension|Alzheimer's disease|glaucoma|gastroparesis	0	87.8	Selleck	S4346	Physostigmine Salicylate	275.163	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	PIJVFDBKTWXHHD-HIFRSBDPSA-N	5983.0	BRD-A37052580-059-07-6	PIJVFDBKTWXHHD
BRD-K25650355-059-18-9	physostigmine	Launched	acetylcholinesterase inhibitor|cholinesterase inhibitor	ACHE|BCHE	cardiology|neurology/psychiatry|ophthalmology|gastroenterology	hypotension|Alzheimer's disease|glaucoma|gastroparesis	0	93.77	Selleck	S4346	physostigmine salicylate	275.163	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	PIJVFDBKTWXHHD-HIFRSBDPSA-N	5983.0		PIJVFDBKTWXHHD
BRD-K25650355-059-20-5	physostigmine	Launched	acetylcholinesterase inhibitor|cholinesterase inhibitor	ACHE|BCHE	cardiology|neurology/psychiatry|ophthalmology|gastroenterology	hypotension|Alzheimer's disease|glaucoma|gastroparesis	0	88.71	Selleck	S4346	Physostigmine salicylate	275.163	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	PIJVFDBKTWXHHD-HIFRSBDPSA-N	5983.0		PIJVFDBKTWXHHD
BRD-K76661572-001-07-6	phytonadione	Launched		BGLAP|GGCX	hematology	vitamin K deficiency|anticoagulation reversal	0	2.14	MicroSource	1505485	PHYTONADIONE [5mM]	450.35	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	MBWXNTAXLNYFJB-NKFFZRIASA-N	5284607.0		MBWXNTAXLNYFJB
BRD-K76661572-001-08-4	phytonadione	Launched		BGLAP|GGCX	hematology	vitamin K deficiency|anticoagulation reversal	0	0.0	Sigma	MFCD00214063	2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone	450.35	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	MBWXNTAXLNYFJB-NKFFZRIASA-N	5284607.0		MBWXNTAXLNYFJB
BRD-K05048137-001-03-9	phytosphingosine	Phase 1					0	77.82	Enzo	SL150	Phytosphingosine	317.293	CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO	AERBNCYCJBRYDG-KSZLIROESA-N	122121.0		AERBNCYCJBRYDG
BRD-K05048137-001-01-3	phytosphingosine	Phase 1					0		Avanti	860499P	phytosphingosine 4-hydroxysphinganine	317.293	CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO	InChI=1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/t16-,17+,18-/m0/s1	122121.0		AERBNCYCJBRYDG
BRD-K67868012-003-02-3	PI-103	Preclinical	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC			0	96.95	Tocris	2930	PI 103 hydrochloride	348.122	Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	TUVCWJQQGGETHL-UHFFFAOYSA-N	9884685.0		TUVCWJQQGGETHL
BRD-K67868012-001-07-6	PI-103	Preclinical	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC			0	95.67	Selleck	S1038	PI-103	348.122	Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	TUVCWJQQGGETHL-UHFFFAOYSA-N	9884685.0		TUVCWJQQGGETHL
BRD-K67868012-001-14-2	PI-103	Preclinical	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC			0		Calbiochem	528101	PI-103	348.122	Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2	9884685.0		TUVCWJQQGGETHL
BRD-K97365803-001-04-7	PI-828	Preclinical	PI3K inhibitor				0	92.29	Tocris	2814	8-(4-aminophenyl)-2-(4-morpholinyl)-4H-chromen-4-one	322.132	Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	WUKMIBOGGXMBAC-UHFFFAOYSA-N	25181195.0		WUKMIBOGGXMBAC
BRD-K97365803-001-02-1	PI-828	Preclinical	PI3K inhibitor				0	82.48	Tocris	2814	PI 828	322.132	Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	WUKMIBOGGXMBAC-UHFFFAOYSA-N	25181195.0		WUKMIBOGGXMBAC
BRD-K97365803-001-03-9	PI-828	Preclinical	PI3K inhibitor				0	93.17	Tocris	2814	PI 828	322.132	Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	WUKMIBOGGXMBAC-UHFFFAOYSA-N	25181195.0		WUKMIBOGGXMBAC
BRD-K17026858-305-02-9	pibenzimol	Phase 2	DNA inhibitor				0	94.39	Tocris	5824	Hoechst 33258	424.201	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1	INAAIJLSXJJHOZ-UHFFFAOYSA-N	2392.0		INAAIJLSXJJHOZ
BRD-K17026858-001-01-2	pibenzimol	Phase 2	DNA inhibitor				0	93.13	MedChemEx	HY-15558	Hoechst 33258	424.201	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1	INAAIJLSXJJHOZ-UHFFFAOYSA-N	2392.0		INAAIJLSXJJHOZ
BRD-K02750403-001-02-2	piboserod	Phase 2	serotonin receptor antagonist	HTR2B|HTR4			0	95.02	MedChemEx	HY-15574	Piboserod	369.242	CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1	KVCSJPATKXABRQ-UHFFFAOYSA-N	177336.0		KVCSJPATKXABRQ
BRD-K02750403-001-01-4	piboserod	Phase 2	serotonin receptor antagonist	HTR2B|HTR4			0	96.02	MedChemEx	HY-15574	Piboserod	369.242	CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1	KVCSJPATKXABRQ-UHFFFAOYSA-N	177336.0		KVCSJPATKXABRQ
BRD-A71765060-001-01-4	picartamide	Phase 2	H+/K+-ATPase inhibitor	ATP4A			0	98.26	Enamine	Z2327673151	N-methyl-2-(2-pyridinyl)tetrahydro-2-thiophenecarbothioamide	238.06	CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4,r|	ITNLONMDUMHEOK-NSHDSACASA-N	76960918.0		ITNLONMDUMHEOK
BRD-K91509126-001-26-9	piceatannol	Preclinical	SYK inhibitor	ATP5A1|ATP5B|ATP5C1|IRF3			0	93.02	Tocris	1554	Piceatannol	244.074	Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1	CDRPUGZCRXZLFL-OWOJBTEDSA-N	667639.0		CDRPUGZCRXZLFL
BRD-K91509126-001-25-1	piceatannol	Preclinical	SYK inhibitor	ATP5A1|ATP5B|ATP5C1|IRF3			0	97.51	Selleck	S3026	Piceatannol	244.074	Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1	CDRPUGZCRXZLFL-OWOJBTEDSA-N	667639.0		CDRPUGZCRXZLFL
BRD-K91509126-001-23-6	piceatannol	Preclinical	SYK inhibitor	ATP5A1|ATP5B|ATP5C1|IRF3			0	83.85	Selleck	S3026	Piceatannol	244.074	Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1	CDRPUGZCRXZLFL-OWOJBTEDSA-N	667639.0		CDRPUGZCRXZLFL
BRD-K91509126-001-24-4	piceatannol	Preclinical	SYK inhibitor	ATP5A1|ATP5B|ATP5C1|IRF3			0	39.74	Tocris	1554	Piceatannol	244.074	Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1	CDRPUGZCRXZLFL-OWOJBTEDSA-N	667639.0		CDRPUGZCRXZLFL
BRD-K47642186-001-04-9	piclamilast	Phase 2	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D			0	98.33	Tocris	4525	Piclamilast	380.069	COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	RRRUXBQSQLKHEL-UHFFFAOYSA-N	154575.0		RRRUXBQSQLKHEL
BRD-K47642186-001-02-1	piclamilast	Phase 2	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D			0	99.07	Tocris	4525	Piclamilast	380.069	COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	RRRUXBQSQLKHEL-UHFFFAOYSA-N	154575.0		RRRUXBQSQLKHEL
BRD-K47642186-001-01-3	piclamilast	Phase 2	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D			0	98.27	Enamine	Z1629094848		380.069	COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	RRRUXBQSQLKHEL-UHFFFAOYSA-N	154575.0		RRRUXBQSQLKHEL
BRD-K68653965-001-02-9	picolamine	Preclinical					0	81.94	MedChemEx	HY-Y0047	NSC 59706	108.069	NCc1cccnc1	HDOUGSFASVGDCS-UHFFFAOYSA-N	31018.0		HDOUGSFASVGDCS
BRD-K68653965-001-01-1	picolamine	Preclinical					0	98.78	MicroSource	1506167	PICOLAMINE	108.069	NCc1cccnc1	HDOUGSFASVGDCS-UHFFFAOYSA-N	31018.0		HDOUGSFASVGDCS
BRD-K60612034-001-08-7	picolinic-acid	Phase 2	chelating agent				0	0.0	Enamine	EN300-18459	2-pyridinecarboxylic acid	123.032	OC(=O)c1ccccn1	SIOXPEMLGUPBBT-UHFFFAOYSA-N	1018.0		SIOXPEMLGUPBBT
BRD-K60612034-001-07-9	picolinic-acid	Phase 2	chelating agent				0	0.0	Enamine	Z57968195		123.032	OC(=O)c1ccccn1	SIOXPEMLGUPBBT-UHFFFAOYSA-N	1018.0		SIOXPEMLGUPBBT
BRD-K28492574-001-02-9	piconol	Preclinical					0	87.58	MedChemEx	HY-Y0004	2-Pyridinemethanol	109.053	OCc1ccccn1	SHNUBALDGXWUJI-UHFFFAOYSA-N	11474.0		SHNUBALDGXWUJI
BRD-K28492574-001-01-6	piconol	Preclinical					0	88.45	MicroSource	1506166	PICONOL	109.053	OCc1ccccn1	SHNUBALDGXWUJI-UHFFFAOYSA-N	11474.0		SHNUBALDGXWUJI
BRD-K67277431-001-11-9	picotamide	Launched	thromboxane receptor antagonist|thromboxane synthase inhibitor	TBXA2R	hematology	thrombosis	0	94.18	Sigma	P8477	Picotamide	376.154	COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1	KYWCWBXGRWWINE-UHFFFAOYSA-N	4814.0		KYWCWBXGRWWINE
BRD-K67277431-002-10-5	picotamide	Launched	thromboxane receptor antagonist|thromboxane synthase inhibitor	TBXA2R	hematology	thrombosis	0	99.78	Prestwick	Prestw-119	Picotamide monohydrate	376.154	COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1	KYWCWBXGRWWINE-UHFFFAOYSA-N	4814.0		KYWCWBXGRWWINE
BRD-A91822151-001-05-0	picrotin	Phase 2	GABA receptor antagonist	GLRA1|GLRA2|GLRA3|GLRB			0	100.0	SantaCruz	sc-228947	Picrotin	310.105	CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4,&2:5,&3:9,&4:10,&5:13,&6:15,&7:19,&8:20,r|	RYEFFICCPKWYML-XSVQNFTRSA-N			RYEFFICCPKWYML
BRD-K36461289-001-05-8	picrotoxinin	Preclinical	GABA receptor antagonist	GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B			0	100.0	Selleck	S4405	Picrotoxinin	292.095	CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C	PIMZUZSSNYHVCU-KBLUICEQSA-N	7098683.0		PIMZUZSSNYHVCU
BRD-K36461289-001-06-6	picrotoxinin	Preclinical	GABA receptor antagonist	GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B			0	57.4	Selleck	S4405	Picrotoxinin	292.095	CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C	PIMZUZSSNYHVCU-KBLUICEQSA-N	7098683.0		PIMZUZSSNYHVCU
BRD-K57313110-001-06-8	pidolic-acid	Launched		ADAM28|AMY1A|AMY2A|AMY2B|ANG|CCL8|HCRT|IGLC1|KRTAP5-2|TFF2|VEGFA	dermatology	xerosis cutis	0	92.71	MicroSource	1506185	PIDOLIC ACID	129.043	OC(=O)[C@@H]1CCC(=O)N1	ODHCTXKNWHHXJC-VKHMYHEASA-N	7405.0		ODHCTXKNWHHXJC
BRD-K44442813-001-13-9	pidotimod	Launched	interferon receptor agonist|interleukin receptor agonist		infectious disease	immune adjuvant	0	94.03	MedChemEx	HY-B0944	Pidotimod	244.052	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	UUTKICFRNVKFRG-WDSKDSINSA-N	65944.0		UUTKICFRNVKFRG
BRD-K44442813-001-12-9	pidotimod	Launched	interferon receptor agonist|interleukin receptor agonist		infectious disease	immune adjuvant	0	92.63	MicroSource	1502322	PIDOTIMOD	244.052	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	UUTKICFRNVKFRG-WDSKDSINSA-N	65944.0		UUTKICFRNVKFRG
BRD-K44442813-001-11-1	pidotimod	Launched	interferon receptor agonist|interleukin receptor agonist		infectious disease	immune adjuvant	0	91.7	Selleck	S3106	Pidotimod	244.052	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	UUTKICFRNVKFRG-WDSKDSINSA-N	65944.0		UUTKICFRNVKFRG
BRD-K66874953-004-07-0	pifithrin-alpha	Preclinical	TP53 inhibitor	TP53			0	0.0	Selleck	S2929	Pifithrin-? (PFT?)	286.114	Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N	OLTZHXYLLRJLST-UHFFFAOYSA-N	4817.0		OLTZHXYLLRJLST
BRD-K66874953-004-09-6	pifithrin-alpha	Preclinical	TP53 inhibitor	TP53			0	29.69	Selleck	S2929	Pifithrin-??	286.114	Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N	OLTZHXYLLRJLST-UHFFFAOYSA-N	4817.0		OLTZHXYLLRJLST
BRD-K66874953-004-08-8	pifithrin-alpha	Preclinical	TP53 inhibitor	TP53			0	0.0	Tocris	1267	Pifithrin-? hydrobromide	286.114	Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N	OLTZHXYLLRJLST-UHFFFAOYSA-N	4817.0		OLTZHXYLLRJLST
BRD-K31792052-004-02-7	pifithrin-cyclic	Preclinical	TP53 inhibitor	TP53			0	94.97	Tocris	3843	Cyclic Pifithrin-? hydrobromide	268.103	Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1	IMUKUMUNZJILCG-UHFFFAOYSA-N	443278.0		IMUKUMUNZJILCG
BRD-K31792052-004-03-9	pifithrin-cyclic	Preclinical	TP53 inhibitor	TP53			0	97.07	Tocris	3843	Cyclic Pifithrin-alpha hydrobromide	268.103	Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1	IMUKUMUNZJILCG-UHFFFAOYSA-N	443278.0		IMUKUMUNZJILCG
BRD-K96799727-001-06-6	pifithrin-mu	Preclinical	HSP inhibitor	HSPA1A|TP53			0	93.79	Tocris	2653	Pifithrin-?	181.02	NS(=O)(=O)C#Cc1ccccc1	ZZUZYEMRHCMVTB-UHFFFAOYSA-N	327653.0		ZZUZYEMRHCMVTB
BRD-K96799727-001-05-8	pifithrin-mu	Preclinical	HSP inhibitor	HSPA1A|TP53			0	88.74	Selleck	S2930	Pifithrin-?	181.02	NS(=O)(=O)C#Cc1ccccc1	ZZUZYEMRHCMVTB-UHFFFAOYSA-N	327653.0		ZZUZYEMRHCMVTB
BRD-K96799727-001-07-4	pifithrin-mu	Preclinical	HSP inhibitor	HSPA1A|TP53			0	95.11	Selleck	S2930	Pifithrin-??	181.02	NS(=O)(=O)C#Cc1ccccc1	ZZUZYEMRHCMVTB-UHFFFAOYSA-N	327653.0		ZZUZYEMRHCMVTB
BRD-K30977212-001-02-8	PIK-293	Preclinical	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	96.54	Selleck	S2207	PIK-293	397.165	Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O	KQDBVHKNIYROHU-UHFFFAOYSA-N	53245636.0		KQDBVHKNIYROHU
BRD-K30977212-001-03-6	PIK-293	Preclinical	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	96.72	Selleck	S2207	PIK-293	397.165	Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O	KQDBVHKNIYROHU-UHFFFAOYSA-N	53245636.0		KQDBVHKNIYROHU
BRD-K50631926-001-03-9	PIK-294	Preclinical	PI3K inhibitor	PIK3CB|PIK3CD|PIK3CG			0	97.48	MedChemEx	HY-10303	PIK-294	489.191	Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O	WFSLJOPRIJSOJR-UHFFFAOYSA-N	24905149.0		WFSLJOPRIJSOJR
BRD-K50631926-001-02-3	PIK-294	Preclinical	PI3K inhibitor	PIK3CB|PIK3CD|PIK3CG			0	97.97	Selleck	S2227	PIK-294	489.191	Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O	WFSLJOPRIJSOJR-UHFFFAOYSA-N	24905149.0		WFSLJOPRIJSOJR
BRD-K49371609-003-03-8	PIK-75	Preclinical	DNA protein kinase inhibitor|PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC			0	98.0	Selleck	S1205	PIK-75	450.995	CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	QTHCAAFKVUWAFI-DJKKODMXSA-N	10275789.0		QTHCAAFKVUWAFI
BRD-K29395450-001-06-8	PIK-93	Preclinical	PI3K inhibitor	PI4KB|PIK3C3|PIK3CG			0	92.8	Selleck	S1489	PIK-93	389.027	CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO	JFVNFXCESCXMBC-UHFFFAOYSA-N	6852167.0		JFVNFXCESCXMBC
BRD-K56691760-001-01-2	pikamilone	Phase 1					0	98.59	Enamine	Z235541930		208.085	OC(=O)CCCNC(=O)c1cccnc1	NAJVRARAUNYNDX-UHFFFAOYSA-N	60608.0		NAJVRARAUNYNDX
BRD-A85548292-001-01-8	piketoprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	93.58	Enamine	Z1537384907		344.152	C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	ASFKKFRSMGBFRO-MRXNPFEDSA-N	68571753.0		ASFKKFRSMGBFRO
BRD-A85548292-001-02-9	piketoprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0		Broad Institute	Piketoprofen	Piketoprofen	344.152	C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1,r|	ASFKKFRSMGBFRO-MRXNPFEDSA-N	68571753.0		ASFKKFRSMGBFRO
BRD-K49456274-001-01-9	pilaralisib	Phase 2	PI3K inhibitor				0	95.08	MedChemEx	HY-16526	XL-147	540.135	COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	QINPEPAQOBZPOF-UHFFFAOYSA-N	56599306.0		QINPEPAQOBZPOF
BRD-K49456274-001-03-9	pilaralisib	Phase 2	PI3K inhibitor				0	96.13	MedChemEx	HY-16526	Pilaralisib	540.135	COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	QINPEPAQOBZPOF-UHFFFAOYSA-N	56599306.0		QINPEPAQOBZPOF
BRD-K85090592-003-20-2	pilocarpine	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	ophthalmology|cardiology	glaucoma|hypertension	0	83.07	Tocris	694	Pilocarpine hydrochloride	208.121	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	QCHFTSOMWOSFHM-WPRPVWTQSA-N	5910.0		QCHFTSOMWOSFHM
BRD-K85090592-003-23-9	pilocarpine	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	ophthalmology|cardiology	glaucoma|hypertension	0	88.76	Tocris	694	Pilocarpine hydrochloride	208.121	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	QCHFTSOMWOSFHM-WPRPVWTQSA-N	5910.0		QCHFTSOMWOSFHM
BRD-K85090592-008-22-7	pilocarpine	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	ophthalmology|cardiology	glaucoma|hypertension	0	99.14	MicroSource	1500487	PILOCARPINE NITRATE	208.121	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	QCHFTSOMWOSFHM-WPRPVWTQSA-N	5910.0		QCHFTSOMWOSFHM
BRD-K85090592-003-19-4	pilocarpine	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	ophthalmology|cardiology	glaucoma|hypertension	0	95.8	Tocris	694	Pilocarpine hydrochloride	208.121	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	QCHFTSOMWOSFHM-WPRPVWTQSA-N	5910.0		QCHFTSOMWOSFHM
BRD-K85090592-003-18-6	pilocarpine	Launched	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	ophthalmology|cardiology	glaucoma|hypertension	0	90.14	Selleck	S4231	Pilocarpine HCl	208.121	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	QCHFTSOMWOSFHM-WPRPVWTQSA-N	5910.0		QCHFTSOMWOSFHM
BRD-K83245588-001-01-4	pilsicainide	Launched	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	0	99.35	AKSci	H671		272.189	Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2	BCQTVJKBTWGHCX-UHFFFAOYSA-N	4820.0		BCQTVJKBTWGHCX
BRD-K48832421-001-02-2	PIM-1-Inhibitor-2	Preclinical	Pim kinase inhibitor	PIM1			0	86.98	Tocris	3589	PIM-1 Inhibitor 2	322.062	Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1	AQVFETGXIRKVAQ-UHFFFAOYSA-N	2765355.0		AQVFETGXIRKVAQ
BRD-K48832421-001-01-4	PIM-1-Inhibitor-2	Preclinical	Pim kinase inhibitor	PIM1			0	62.41	Tocris	3589	PIM-1 Inhibitor 2	322.062	Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1	AQVFETGXIRKVAQ-UHFFFAOYSA-N	2765355.0		AQVFETGXIRKVAQ
BRD-K48832421-001-03-9	PIM-1-Inhibitor-2	Preclinical	Pim kinase inhibitor	PIM1			0	96.9	Tocris	3589	PIM-1 Inhibitor 2	322.062	Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1	AQVFETGXIRKVAQ-UHFFFAOYSA-N	2765355.0		AQVFETGXIRKVAQ
BRD-K00003280-300-01-9	PIM-447	Phase 1	Pim kinase inhibitor				0	97.01	MedChemEx	HY-19322B	PIM-447 (dihydrochloride)	440.182	C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F	VRQXRVAKPDCRCI-ZNMIVQPWSA-N	44814409.0		VRQXRVAKPDCRCI
BRD-K83405785-001-01-5	pimavanserin	Launched	serotonin receptor inverse agonist	DRD2|HTR2A	neurology/psychiatry	Parkinson's Disease	0	88.73	MedChemEx	HY-14557	Pimavanserin	427.264	CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	RKEWSXXUOLRFBX-UHFFFAOYSA-N	10071196.0		RKEWSXXUOLRFBX
BRD-K83405785-001-03-9	pimavanserin	Launched	serotonin receptor inverse agonist	DRD2|HTR2A	neurology/psychiatry	Parkinson's Disease	0	98.11	MedChemEx	HY-14557	Pimavanserin	427.264	CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	RKEWSXXUOLRFBX-UHFFFAOYSA-N	10071196.0		RKEWSXXUOLRFBX
BRD-K92107055-001-02-9	pimecrolimus	Launched	calcineurin inhibitor		dermatology	eczema	0	95.57	MedChemEx	HY-13723	Pimecrolimus	809.448	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|	KASDHRXLYQOAKZ-YFMQXNBHSA-N	133659920.0		KASDHRXLYQOAKZ
BRD-K92107055-001-01-9	pimecrolimus	Launched	calcineurin inhibitor		dermatology	eczema	0	90.71	Selleck	S5004	Pimecrolimus	809.448	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|	KASDHRXLYQOAKZ-YFMQXNBHSA-N	133659920.0	BRD-K97729603-001-01-2	KASDHRXLYQOAKZ
BRD-K88090157-050-10-8	pimethixene	Launched	antihistamine		neurology/psychiatry|allergy	attention-deficit/hyperactivity disorder (ADHD)|anxiety|sleep cycle support|allergic rhinitis	0	97.82	MicroSource	1501114	PIMETHIXENE MALEATE	293.124	CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12	NZLVRVYNQYGMAB-UHFFFAOYSA-N	4822.0		NZLVRVYNQYGMAB
BRD-K88090157-050-11-9	pimethixene	Launched	antihistamine		neurology/psychiatry|allergy	attention-deficit/hyperactivity disorder (ADHD)|anxiety|sleep cycle support|allergic rhinitis	0	98.19	Toronto	p445503	pimethixene maleate	293.124	CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12	NZLVRVYNQYGMAB-UHFFFAOYSA-N	4822.0		NZLVRVYNQYGMAB
BRD-K01826269-001-04-9	pimobendan	Launched	calcium sensitizer|phosphodiesterase inhibitor	PDE3A	cardiology	congestive heart failure	0	99.25	MedChemEx	HY-B0204	Pimobendan	334.143	COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23,t:20|	GLBJJMFZWDBELO-LLVKDONJSA-N	7120080.0		GLBJJMFZWDBELO
BRD-K00003127-001-01-9	pimodivir	Phase 3	antiviral				0	95.34	MedChemEx	HY-12353A	Pimodivir	399.151	OC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12	JGPXDNKSIXAZEQ-SBBZOCNPSA-N	67286591.0		JGPXDNKSIXAZEQ
BRD-A67521319-001-01-6	pimonidazole	Phase 3					0	94.99	Cayman	89130		254.138	O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1,r|	WVWOOAYQYLJEFD-JTQLQIEISA-N	6713657.0		WVWOOAYQYLJEFD
BRD-K01292756-001-27-6	pimozide	Launched	dopamine receptor antagonist	CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2	neurology/psychiatry	Tourette's disorder	0	95.41	Tocris	937	Pimozide	461.228	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	YVUQSNJEYSNKRX-UHFFFAOYSA-N	16362.0		YVUQSNJEYSNKRX
BRD-K01292756-001-23-5	pimozide	Launched	dopamine receptor antagonist	CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2	neurology/psychiatry	Tourette's disorder	0	96.89	Selleck	S4358	Pimozide	461.228	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	YVUQSNJEYSNKRX-UHFFFAOYSA-N	16362.0		YVUQSNJEYSNKRX
BRD-K01292756-001-25-0	pimozide	Launched	dopamine receptor antagonist	CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2	neurology/psychiatry	Tourette's disorder	0	97.81	MicroSource	1501134	PIMOZIDE	461.228	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	YVUQSNJEYSNKRX-UHFFFAOYSA-N	16362.0		YVUQSNJEYSNKRX
BRD-K01292756-001-24-3	pimozide	Launched	dopamine receptor antagonist	CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2	neurology/psychiatry	Tourette's disorder	0	96.53	Tocris	937	Pimozide	461.228	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	YVUQSNJEYSNKRX-UHFFFAOYSA-N	16362.0		YVUQSNJEYSNKRX
BRD-A43882281-001-14-8	pinacidil	Launched	ATP channel activator|potassium channel activator	ABCC8|ABCC9	cardiology	hypertension	0	97.33	Selleck	S4366		245.164	C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|	IVVNZDGDKPTYHK-SNVBAGLBSA-N	12428581.0		IVVNZDGDKPTYHK
BRD-A43882281-001-15-5	pinacidil	Launched	ATP channel activator|potassium channel activator	ABCC8|ABCC9	cardiology	hypertension	0	98.87	MicroSource	2300270		245.164	C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|	IVVNZDGDKPTYHK-SNVBAGLBSA-N	12428581.0		IVVNZDGDKPTYHK
BRD-A43882281-002-18-9	pinacidil	Launched	ATP channel activator|potassium channel activator	ABCC8|ABCC9	cardiology	hypertension	0	94.96	MedChemEx	HY-14290A	Pinacidil monohydrate	245.164	C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1,r|	IVVNZDGDKPTYHK-SNVBAGLBSA-N	12428581.0		IVVNZDGDKPTYHK
BRD-K32485706-001-01-5	pinanediol	Preclinical					0	1.44	Sigma	282367-1G	(1S,2R,3R,5S)-(+)-Pinanediol	170.131	CC1(C)[C@H]2C[C@@H]1[C@](C)(O)[C@H](O)C2	MOILFCKRQFQVFS-OORONAJNSA-N	10219606.0		MOILFCKRQFQVFS
BRD-A13175897-004-01-0	pinaverium	Launched	T-type calcium channel blocker	CACNA1C	gastroenterology	irritable bowel syndrome	0	99.42	CombiBlocks	QE-3811		510.222	COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17,19,&2:14,r|	DDHUTBKXLWCZCO-CEMLEFRQSA-N	73416161.0		DDHUTBKXLWCZCO
BRD-K90727284-001-05-0	pincainide	Phase 1	antiarrhythmic				0	96.6	Enamine	Z46160202	2-(1-azepanyl)-N-(2,6-dimethylphenyl)acetamide	260.189	Cc1cccc(C)c1NC(=O)CN1CCCCCC1	RJOUHGWLHPOQSA-UHFFFAOYSA-N	71267.0		RJOUHGWLHPOQSA
BRD-A97701745-001-14-5	pindolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|HTR1A|HTR2A|HTR2B	cardiology	hypertension	0	81.9	Selleck	S4406	Pindolol	248.152	CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|	JZQKKSLKJUAGIC-LLVKDONJSA-N	155030.0		JZQKKSLKJUAGIC
BRD-A97701745-001-18-9	pindolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|HTR1A|HTR2A|HTR2B	cardiology	hypertension	0	92.46	Tocris	994	Pindolol	248.152	CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|	JZQKKSLKJUAGIC-LLVKDONJSA-N	155030.0		JZQKKSLKJUAGIC
BRD-A97701745-001-15-2	pindolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|HTR1A|HTR2A|HTR2B	cardiology	hypertension	0	89.87	Tocris	994	Pindolol	248.152	CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|	JZQKKSLKJUAGIC-LLVKDONJSA-N	155030.0		JZQKKSLKJUAGIC
BRD-A97701745-001-16-0	pindolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|HTR1A|HTR2A|HTR2B	cardiology	hypertension	0	97.25	MicroSource	1500488	PINDOLOL	248.152	CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5,r|	JZQKKSLKJUAGIC-LLVKDONJSA-N	155030.0		JZQKKSLKJUAGIC
BRD-K95598440-001-10-9	pindolol-(-)	Phase 2	adrenergic receptor antagonist|serotonin receptor antagonist	HTR1A			0	93.26	Tocris	1060	(S)-(-)-Pindolol	248.152	CC(C)NC[C@H](O)COc1cccc2[nH]ccc12	JZQKKSLKJUAGIC-NSHDSACASA-N	688095.0		JZQKKSLKJUAGIC
BRD-K95598440-001-09-3	pindolol-(-)	Phase 2	adrenergic receptor antagonist|serotonin receptor antagonist	HTR1A			0	71.68	Tocris	1060	(S)-(-)-Pindolol	248.152	CC(C)NC[C@H](O)COc1cccc2[nH]ccc12	JZQKKSLKJUAGIC-NSHDSACASA-N	688095.0		JZQKKSLKJUAGIC
BRD-K87873585-001-02-9	pinitol	Phase 2	gamma secretase inhibitor				0		CombiBlocks	JRSACHER_006-10-2	D-pinitol	194.079	CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O	DSCFFEYYQKSRSV-KLJZZCKASA-N			DSCFFEYYQKSRSV
BRD-K94689771-001-09-0	pinocembrin	Phase 2	cytochrome P450 inhibitor	CYP1B1			0	0.0	Enzo	NP233	Pinocembrin	256.074	Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	URFCJEUYXNAHFI-ZDUSSCGKSA-N	68071.0		URFCJEUYXNAHFI
BRD-K94689771-001-10-9	pinocembrin	Phase 2	cytochrome P450 inhibitor	CYP1B1			0	97.52	Sigma	MFCD06858345	Pinocembrin	256.074	Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	URFCJEUYXNAHFI-ZDUSSCGKSA-N	68071.0		URFCJEUYXNAHFI
BRD-K01826904-001-08-9	pioglitazone	Launched	insulin sensitizer|PPAR receptor agonist	PPARG|TRPM3	endocrinology	diabetes mellitus	0	97.91	Selleck	S2590		356.119	CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|	HYAFETHFCAUJAY-QGZVFWFLSA-N	29010894.0		HYAFETHFCAUJAY
BRD-K26801045-001-02-9	pipamperone	Launched	dopamine receptor antagonist	DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR2A	neurology/psychiatry	schizophrenia	0	89.65	MicroSource	1505690	PIPAMPERONE	375.232	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	AXKPFOAXAHJUAG-UHFFFAOYSA-N	4830.0		AXKPFOAXAHJUAG
BRD-K26801045-300-01-7	pipamperone	Launched	dopamine receptor antagonist	DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR2A	neurology/psychiatry	schizophrenia	0	92.76	Sigma	P3246-100MG	Pipamperone dihydrochloride	375.232	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	AXKPFOAXAHJUAG-UHFFFAOYSA-N	4830.0		AXKPFOAXAHJUAG
BRD-A21544762-303-01-5	pipecuronium	Launched	neuromuscular blocker	CHRM2|CHRM3|CHRNA2	neurology/psychiatry	anesthetic	0	98.54	Kemprotec	52212-02-9	4,4'-((2S,3S,5S,8R,9S,10S,13S,14S,16S)-3,17-diacetoxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-2,16-diyl)bis(1,1-dimethylpiperazin-1-ium) bromide	602.477	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CC[N+](C)(C)CC1)N1CC[N+](C)(C)CC1 |a:5,7,8,11,13,18,20,22,25,&1:4|	OWWLUIWOFHMHOQ-XGHATYIMSA-N	50192.0		OWWLUIWOFHMHOQ
BRD-K08999871-001-16-9	pipemidic-acid	Launched	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	0	99.07	MedChemEx	HY-B1210	Pipemidic acid	303.133	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	JOHZPMXAZQZXHR-UHFFFAOYSA-N	6921791.0		JOHZPMXAZQZXHR
BRD-K08999871-213-01-5	pipemidic-acid	Launched	topoisomerase inhibitor		infectious disease	gram-negative bacterial infections	0	90.96	MicroSource	1502024	PIPEMIDIC ACID	303.133	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	JOHZPMXAZQZXHR-UHFFFAOYSA-N	6921791.0		JOHZPMXAZQZXHR
BRD-A53561827-004-22-3	pipenzolate	Launched	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	0	94.39	Selleck	S4347	Pipenzolate Bromide	354.207	CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|	WPUKUEMZZRVAKZ-REWPJTCUSA-N	16048561.0		WPUKUEMZZRVAKZ
BRD-A53561827-004-23-1	pipenzolate	Launched	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	0	97.76	MicroSource	1503053	PIPENZOLATE BROMIDE	354.207	CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|	WPUKUEMZZRVAKZ-REWPJTCUSA-N	16048561.0		WPUKUEMZZRVAKZ
BRD-A53561827-004-24-9	pipenzolate	Launched	cholinergic receptor antagonist	CHRM1	neurology/psychiatry	spasms	0	95.14	Selleck	S4347	PIPENZOLATE BROMIDE	354.207	CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2,&2:7|	WPUKUEMZZRVAKZ-REWPJTCUSA-N	16048561.0		WPUKUEMZZRVAKZ
BRD-K16277217-001-10-9	piperacetazine	Launched	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	0	94.04	MicroSource	1503874	PIPERACETAZINE	410.203	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	BTFMCMVEUCGQDX-UHFFFAOYSA-N	19675.0		BTFMCMVEUCGQDX
BRD-K16277217-001-11-9	piperacetazine	Launched	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	0	93.37	MedChemEx	HY-B1152	Piperacetazine	410.203	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	BTFMCMVEUCGQDX-UHFFFAOYSA-N	19675.0		BTFMCMVEUCGQDX
BRD-K86873305-236-17-0	piperacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia	0	96.3	MedChemEx	HY-B1286	Piperacillin (sodium)	517.163	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N	43672.0		IVBHGBMCVLDMKU
BRD-K86873305-236-16-2	piperacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia	0	66.97	MedChemEx	HY-B1286	Piperacillin (sodium)	517.163	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N	43672.0		IVBHGBMCVLDMKU
BRD-K86873305-236-15-4	piperacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia	0	26.27	Sigma	MFCD00917471	sodium (2S,5R,6R)-6-[((2R)-2-{[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino}-2-phenylethanoyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	517.163	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N	43672.0		IVBHGBMCVLDMKU
BRD-K86873305-236-18-8	piperacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia	0	34.75	Selleck	S4222	Piperacillin Sodium	517.163	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N	43672.0	BRD-K67009182-236-01-6	IVBHGBMCVLDMKU
BRD-K86873305-236-19-6	piperacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia	0	81.18	Selleck	S4222	PIPERACILLIN SODIUM	517.163	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N	43672.0		IVBHGBMCVLDMKU
BRD-K86873305-236-14-7	piperacillin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	intra-abdominal infections|skin infections|pelvic inflammatory disease|pneumonia	0	79.83	Selleck	S4222	Piperacillin Sodium	517.163	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	IVBHGBMCVLDMKU-GXNBUGAJSA-N	43672.0		IVBHGBMCVLDMKU
BRD-K27382019-418-01-9	piperaquine-phosphate	Launched	antimalarial agent		infectious disease	malaria	0	96.15	AKSci	H853		534.207	Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1	UCRHFBCYFMIWHC-UHFFFAOYSA-N	122262.0		UCRHFBCYFMIWHC
BRD-K13249881-001-05-9	piperazine	Launched	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	0	100.0	MedChemEx	HY-B0912	Piperazine	86.084	C1CNCCN1	GLUUGHFHXGJENI-UHFFFAOYSA-N	4837.0		GLUUGHFHXGJENI
BRD-K13249881-001-02-3	piperazine	Launched	benzodiazepine receptor agonist	GABRB3	infectious disease	gastrointestinal roundworms	0	100.0	MicroSource	1500490	PIPERAZINE	86.084	C1CNCCN1	GLUUGHFHXGJENI-UHFFFAOYSA-N	4837.0		GLUUGHFHXGJENI
BRD-K95941975-001-01-5	piperazinedione	Phase 2	DNA synthesis inhibitor				0	97.3	Enamine	Z56854487	2,5-piperazinedione	114.043	O=C1CNC(=O)CN1	BXRNXXXXHLBUKK-UHFFFAOYSA-N	7817.0		BXRNXXXXHLBUKK
BRD-A97479839-003-13-3	piperidolate	Launched	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	0	98.09	MicroSource	1502197	PIPERIDOLATE HYDROCHLORIDE	323.189	CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|	KTHVBAZBLKXIHZ-IBGZPJMESA-N	688565.0		KTHVBAZBLKXIHZ
BRD-A97479839-001-14-9	piperidolate	Launched	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	spasms	0	95.69	MedChemEx	HY-B0962A	Piperidolate	323.189	CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|	KTHVBAZBLKXIHZ-IBGZPJMESA-N	688565.0		KTHVBAZBLKXIHZ
BRD-K59522102-001-13-8	piperine	Phase 1	monoamine oxidase inhibitor	MAOA|MAOB|TRPV1			0	43.11	Selleck	S2344	Piperine	285.136	O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	MXXWOMGUGJBKIW-YPCIICBESA-N	638024.0		MXXWOMGUGJBKIW
BRD-K59522102-001-18-9	piperine	Phase 1	monoamine oxidase inhibitor	MAOA|MAOB|TRPV1			0	91.57	MedChemEx	HY-N0144	Piperine	285.136	O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	MXXWOMGUGJBKIW-YPCIICBESA-N	638024.0		MXXWOMGUGJBKIW
BRD-K59522102-001-14-6	piperine	Phase 1	monoamine oxidase inhibitor	MAOA|MAOB|TRPV1			0	94.51	MicroSource	1500873	PIPERINE	285.136	O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	MXXWOMGUGJBKIW-YPCIICBESA-N	638024.0		MXXWOMGUGJBKIW
BRD-K59522102-001-15-3	piperine	Phase 1	monoamine oxidase inhibitor	MAOA|MAOB|TRPV1			0	97.26	Selleck	S2344	Piperine (1-Piperoylpiperidine)	285.136	O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	MXXWOMGUGJBKIW-YPCIICBESA-N	638024.0		MXXWOMGUGJBKIW
BRD-K76452401-001-05-9	piperonyl-butoxide	Launched	cytochrome P450 inhibitor		infectious disease	lice	0	90.25	MedChemEx	HY-B1198	Piperonyl butoxide	338.209	CCCCOCCOCCOCc1cc2OCOc2cc1CCC	FIPWRIJSWJWJAI-UHFFFAOYSA-N	5794.0		FIPWRIJSWJWJAI
BRD-K76452401-001-03-6	piperonyl-butoxide	Launched	cytochrome P450 inhibitor		infectious disease	lice	0	88.86	MicroSource	1504191	PIPERONYL BUTOXIDE	338.209	CCCCOCCOCCOCc1cc2OCOc2cc1CCC	FIPWRIJSWJWJAI-UHFFFAOYSA-N	5794.0		FIPWRIJSWJWJAI
BRD-K15656090-001-04-0	pipobroman	Launched	DNA alkylating agent		hematology	polycythemia vera|thrombocythemia	0	0.0	MicroSource	1503393	PIPOBROMAN	353.958	BrCCC(=O)N1CCN(CC1)C(=O)CCBr	NJBFOOCLYDNZJN-UHFFFAOYSA-N	4842.0		NJBFOOCLYDNZJN
BRD-K15656090-001-06-5	pipobroman	Launched	DNA alkylating agent		hematology	polycythemia vera|thrombocythemia	0	0.0	MedChemEx	HY-16398	Pipobroman	353.958	BrCCC(=O)N1CCN(CC1)C(=O)CCBr	NJBFOOCLYDNZJN-UHFFFAOYSA-N	4842.0		NJBFOOCLYDNZJN
BRD-K15656090-001-07-3	pipobroman	Launched	DNA alkylating agent		hematology	polycythemia vera|thrombocythemia	0	81.16	MedChemEx	HY-16398	Pipobroman	353.958	BrCCC(=O)N1CCN(CC1)C(=O)CCBr	NJBFOOCLYDNZJN-UHFFFAOYSA-N	4842.0		NJBFOOCLYDNZJN
BRD-K00003317-312-01-9	pipofezine	Preclinical	selective serotonin reuptake inhibitor (SSRI)				0	97.43	MedChemEx	HY-A0022A	Azaphen (dihydrochloride monohydrate)	297.159	CN1CCN(CC1)c1cc2N(C)c3ccccc3Oc2nn1	SDYYIRPAZHJOLM-UHFFFAOYSA-N	159977.0		SDYYIRPAZHJOLM
BRD-K00004560-001-01-9	pipotiazine	Launched	dopamine receptor antagonist	DRD1|DRD2|HTR1A|HTR2A	neurology/psychiatry	schizophrenia	0	0.0	Sigma	MFCD00941480	10-{3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl}-N,N-dimethyl-10H-phenothiazine-2-sulfonamide	475.196	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	JOMHSQGEWSNUKU-UHFFFAOYSA-N	62867.0		JOMHSQGEWSNUKU
BRD-K48429278-001-01-3	pipotiazine-palmitate	Launched	dopamine receptor antagonist|serotonin receptor antagonist	DRD1|DRD2|HTR1A|HTR2A	neurology/psychiatry	schizophrenia	0	75.11	Sigma	MFCD00866713	2-[1-(3-{2-[(dimethylamino)sulfonyl]-10H-phenothiazin-10-yl}propyl)-4-piperidinyl]ethyl palmitate	713.426	CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1	KTOYYUONFQWSMW-UHFFFAOYSA-N	37767.0		KTOYYUONFQWSMW
BRD-K19456237-001-27-6	piracetam	Launched	acetylcholine receptor agonist	GRIA1|GRIA2|GRIA3|GRIA4	neurology/psychiatry	senile dementia	0	100.0	MicroSource	1502195	PIRACETAM	142.074	NC(=O)CN1CCCC1=O	GMZVRMREEHBGGF-UHFFFAOYSA-N	4843.0		GMZVRMREEHBGGF
BRD-K19456237-001-26-8	piracetam	Launched	acetylcholine receptor agonist	GRIA1|GRIA2|GRIA3|GRIA4	neurology/psychiatry	senile dementia	0	93.28	Selleck	S3070	Piracetam	142.074	NC(=O)CN1CCCC1=O	GMZVRMREEHBGGF-UHFFFAOYSA-N	4843.0		GMZVRMREEHBGGF
BRD-K83794624-003-02-1	pirarubicin	Launched	topoisomerase inhibitor	TOP2A	oncology	breast cancer	0	71.82	MedChemEx	HY-13725A	Pirarubicin (Hydrochloride)	627.232	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	KMSKQZKKOZQFFG-YXRRJAAWSA-N	11296583.0		KMSKQZKKOZQFFG
BRD-K83794624-003-01-3	pirarubicin	Launched	topoisomerase inhibitor	TOP2A	oncology	breast cancer	0	28.49	MedChemEx	HY-13725A	(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranoside hydrochloride	627.232	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	KMSKQZKKOZQFFG-YXRRJAAWSA-N	11296583.0		KMSKQZKKOZQFFG
BRD-K83794624-001-02-5	pirarubicin	Launched	topoisomerase inhibitor	TOP2A	oncology	breast cancer	0	2.19	Selleck	S1393	Pirarubicin	627.232	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	KMSKQZKKOZQFFG-YXRRJAAWSA-N	11296583.0		KMSKQZKKOZQFFG
BRD-K83794624-001-03-3	pirarubicin	Launched	topoisomerase inhibitor	TOP2A	oncology	breast cancer	0	29.74	Selleck	S1393	Pirarubicin	627.232	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	KMSKQZKKOZQFFG-YXRRJAAWSA-N	11296583.0		KMSKQZKKOZQFFG
BRD-K65992024-001-01-5	pirenoxine	Launched	AGE inhibitor		ophthalmology	cataracts	0	94.2	AKSci	H039		308.043	OC(=O)c1cc(=O)c2c3nc4ccccc4oc3cc(=O)c2[nH]1	OKPNYGAWTYOBFZ-UHFFFAOYSA-N	4846.0		OKPNYGAWTYOBFZ
BRD-K25224017-001-26-9	pirenperone	Preclinical	serotonin receptor antagonist	HTR2A|HTR7			0	95.78	Sigma	MFCD00069332	Pirenperone	393.185	Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	HXCNRYXBZNHDNE-UHFFFAOYSA-N	4847.0		HXCNRYXBZNHDNE
BRD-K25224017-001-25-0	pirenperone	Preclinical	serotonin receptor antagonist	HTR2A|HTR7			0	98.26	Prestwick	Prestw-531	Pirenperone	393.185	Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	HXCNRYXBZNHDNE-UHFFFAOYSA-N	4847.0		HXCNRYXBZNHDNE
BRD-K89375097-300-08-8	pirenzepine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	gastroenterology	peptic ulcer disease (PUD)	0	98.27	MicroSource	1501138	PIRENZEPINE HYDROCHLORIDE	351.17	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	RMHMFHUVIITRHF-UHFFFAOYSA-N	4848.0		RMHMFHUVIITRHF
BRD-K89375097-300-09-9	pirenzepine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	gastroenterology	peptic ulcer disease (PUD)	0	98.33	MedChemEx	HY-17037	Pirenzepine (dihydrochloride)	351.17	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	RMHMFHUVIITRHF-UHFFFAOYSA-N	4848.0		RMHMFHUVIITRHF
BRD-K87990216-001-10-2	piretanide	Launched	glucocorticoid receptor agonist	SLC12A1|SLC12A2	cardiology	hypertension|edema	0	99.31	Prestwick	Prestw-1047	Piretanide	362.094	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	UJEWTUDSLQGTOA-UHFFFAOYSA-N	4849.0		UJEWTUDSLQGTOA
BRD-K96862998-001-17-9	pirfenidone	Launched	TGF beta receptor inhibitor	FURIN|TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	0	96.76	MedChemEx	HY-B0673	Pirfenidone	185.084	Cc1ccc(=O)n(c1)-c1ccccc1	ISWRGOKTTBVCFA-UHFFFAOYSA-N	40632.0		ISWRGOKTTBVCFA
BRD-K96862998-001-14-8	pirfenidone	Launched	TGF beta receptor inhibitor	FURIN|TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	0	95.49	Selleck	S2907	Pirfenidone	185.084	Cc1ccc(=O)n(c1)-c1ccccc1	ISWRGOKTTBVCFA-UHFFFAOYSA-N	40632.0		ISWRGOKTTBVCFA
BRD-K96862998-001-15-5	pirfenidone	Launched	TGF beta receptor inhibitor	FURIN|TNF	pulmonary	idiopathic pulmonary fibrosis (IPF)	0	97.6	Tocris	1093	Pirfenidone	185.084	Cc1ccc(=O)n(c1)-c1ccccc1	ISWRGOKTTBVCFA-UHFFFAOYSA-N	40632.0		ISWRGOKTTBVCFA
BRD-K47936004-003-11-4	piribedil	Launched	dopamine receptor agonist	ADRA1A|ADRA2A|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR2B	neurology/psychiatry	Parkinson's Disease|dizziness	0	87.35	Tocris	1031	Piribedil hydrochloride	298.143	C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1	OQDPVLVUJFGPGQ-UHFFFAOYSA-N	4850.0		OQDPVLVUJFGPGQ
BRD-K00004544-001-01-9	piricapiron	Phase 2	dopamine receptor antagonist|serotonin receptor antagonist	HTR2A			0	94.85	Vitas-M	STK012745	1,8,8-trimethyl-3-{4-[4-(pyridin-2-yl)piperazin-1-yl]butyl}-3-azabicyclo[3.2.1]octane-2,4-dione	398.268	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3,6|	NCMIPRCQUMYAEC-JPYJTQIMSA-N	5545745.0		NCMIPRCQUMYAEC
BRD-K01902415-001-13-3	pirinixic-acid	Preclinical	PPAR receptor agonist	PPARA			0	96.42	Tocris	1312	WY 14643	323.05	Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	SZRPDCCEHVWOJX-UHFFFAOYSA-N	5694.0		SZRPDCCEHVWOJX
BRD-K01902415-001-14-9	pirinixic-acid	Preclinical	PPAR receptor agonist	PPARA			0	94.09	Tocris	1312	WY 14643	323.05	Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	SZRPDCCEHVWOJX-UHFFFAOYSA-N	5694.0		SZRPDCCEHVWOJX
BRD-K01902415-001-10-9	pirinixic-acid	Preclinical	PPAR receptor agonist	PPARA			0	96.66	Selleck	S8029	WY-14643 (Pirinixic Acid)	323.05	Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	SZRPDCCEHVWOJX-UHFFFAOYSA-N	5694.0		SZRPDCCEHVWOJX
BRD-K01902415-001-11-7	pirinixic-acid	Preclinical	PPAR receptor agonist	PPARA			0	97.87	Tocris	1312	WY 14643	323.05	Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	SZRPDCCEHVWOJX-UHFFFAOYSA-N	5694.0		SZRPDCCEHVWOJX
BRD-K01826702-066-07-9	pirlindole	Launched	monoamine oxidase inhibitor	MAOA	neurology/psychiatry	depression	0	90.0	Tocris	724	Pirlindole mesylate	226.147	Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|	IWVRVEIKCBFZNF-ZDUSSCGKSA-N	667444.0		IWVRVEIKCBFZNF
BRD-K00003530-003-01-9	pirmenol	Preclinical	acetylcholine receptor inhibitor				0	74.62	MedChemEx	HY-100795A	Pirmenol (hydrochloride)	338.236	C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1 |a:1,5,&1:11|	APUDBKTWDCXQJA-XQBPLPMBSA-N	76962234.0		APUDBKTWDCXQJA
BRD-A96510685-213-03-7	piroctone-olamine	Launched			infectious disease	fungal infection	0	0.0	MicroSource	1503875	PIROCTONE OLAMINE	237.173	C[C@@H](Cc1cc(C)cc(=O)n1O)CC(C)(C)C |&1:1|	OIQJEQLSYJSNDS-NSHDSACASA-N	38988592.0	BRD-M95050869-001-01-2	OIQJEQLSYJSNDS
BRD-K22261391-001-01-2	pirodavir	Phase 2					0	98.34	MedChemEx	HY-13784	Pirodavir	369.205	CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1	KCHIOGFOPPOUJC-UHFFFAOYSA-N	71345.0		KCHIOGFOPPOUJC
BRD-K22261391-001-02-9	pirodavir	Phase 2					0	95.62	MedChemEx	HY-13784	Pirodavir	369.205	CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1	KCHIOGFOPPOUJC-UHFFFAOYSA-N	71345.0		KCHIOGFOPPOUJC
BRD-K37682401-001-10-9	piromidic-acid	Phase 2	bacterial DNA gyrase inhibitor				0	100.0	MedChemEx	HY-B1043	Piromidic acid	288.122	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	RCIMBBZXSXFZBV-UHFFFAOYSA-N	4855.0		RCIMBBZXSXFZBV
BRD-K37682401-213-01-1	piromidic-acid	Phase 2	bacterial DNA gyrase inhibitor				0	88.48	MicroSource	1502045	PIROMIDIC ACID	288.122	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	RCIMBBZXSXFZBV-UHFFFAOYSA-N	4855.0		RCIMBBZXSXFZBV
BRD-K37682401-001-08-5	piromidic-acid	Phase 2	bacterial DNA gyrase inhibitor				0	63.45	Selleck	S4348	Piromidic Acid	288.122	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	RCIMBBZXSXFZBV-UHFFFAOYSA-N	4855.0		RCIMBBZXSXFZBV
BRD-K37682401-001-09-3	piromidic-acid	Phase 2	bacterial DNA gyrase inhibitor				0	96.79	Selleck	S4348	piromidic acid	288.122	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	RCIMBBZXSXFZBV-UHFFFAOYSA-N	4855.0		RCIMBBZXSXFZBV
BRD-K01826746-001-05-9	piroxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	93.49	Tocris	960	Piroxicam	331.063	CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|	QYSPLQLAKJAUJT-UHFFFAOYSA-N	54676228.0		QYSPLQLAKJAUJT
BRD-K71977764-001-01-2	piroximone	Phase 2	phosphodiesterase inhibitor	PDE3A			0	99.6	Enamine	Z2306534716	4-ethyl-5-isonicotinoyl-1,3-dihydro-2H-imidazol-2-one	217.085	CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1	OQGWJZOWLHWFME-UHFFFAOYSA-N	55263.0		OQGWJZOWLHWFME
BRD-K00004581-001-01-9	pirozadil	Preclinical	hypolipidemic				0	97.32	MedChemEx	HY-100144	Pirozadil	527.179	COc1cc(cc(OC)c1OC)C(=O)OCc1cccc(COC(=O)c2cc(OC)c(OC)c(OC)c2)n1	DIIBXMIIOQXTHW-UHFFFAOYSA-N	68711.0		DIIBXMIIOQXTHW
BRD-K63651590-001-01-3	pirquinozol	Phase 1	histamine release inhibitor				0	98.69	Enamine	Z2467129407	2-(hydroxymethyl)pyrazolo[1,5-c]quinazolin-5(6H)-one	215.069	OCc1cc2c3ccccc3[nH]c(=O)n2n1	XLUKOGNIEDDIMV-UHFFFAOYSA-N	135449340.0		XLUKOGNIEDDIMV
BRD-K43978949-075-03-9	PIT	Preclinical	purinergic receptor antagonist	P2RY1			0	41.7	Tocris	1682	PIT	224.059	[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|	LXEZPPZLNVOLDI-UHFFFAOYSA-N	124334.0		LXEZPPZLNVOLDI
BRD-K43978949-075-02-5	PIT	Preclinical	purinergic receptor antagonist	P2RY1			0	24.71	Tocris	1682	PIT	224.059	[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|	LXEZPPZLNVOLDI-UHFFFAOYSA-N	124334.0		LXEZPPZLNVOLDI
BRD-K75958547-238-03-9	pitavastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	0	96.93	Tocris	4942	Pitavastatin calcium	421.169	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	VGYFMXBACGZSIL-MCBHFWOFSA-N	5282452.0		VGYFMXBACGZSIL
BRD-K75958547-238-04-9	pitavastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	0	94.74	Adooq	A10737	Livalo	421.169	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	VGYFMXBACGZSIL-MCBHFWOFSA-N	5282452.0		VGYFMXBACGZSIL
BRD-K75958547-238-02-8	pitavastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	0	95.88	Tocris	4942	Pitavastatin calcium	421.169	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	VGYFMXBACGZSIL-MCBHFWOFSA-N	5282452.0	BRD-M62817595-238-02-0	VGYFMXBACGZSIL
BRD-K75958547-238-01-0	pitavastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology	hyperlipidemia	0	96.25	Selleck	S1759	Pitavastatin Calcium	421.169	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	VGYFMXBACGZSIL-MCBHFWOFSA-N	5282452.0	BRD-M62817595-238-01-2	VGYFMXBACGZSIL
BRD-K21673112-003-02-1	pitolisant	Launched	histamine receptor antagonist	HRH3			0	93.31	Tocris	3743	BF 2649	295.17	Clc1ccc(CCCOCCCN2CCCCC2)cc1	NNACHAUCXXVJSP-UHFFFAOYSA-N	9948102.0		NNACHAUCXXVJSP
BRD-K21673112-003-01-3	pitolisant	Launched	histamine receptor antagonist	HRH3			0	97.0	Tocris	3743	BF 2649	295.17	Clc1ccc(CCCOCCCN2CCCCC2)cc1	NNACHAUCXXVJSP-UHFFFAOYSA-N	9948102.0		NNACHAUCXXVJSP
BRD-K21673112-003-03-9	pitolisant	Launched	histamine receptor antagonist	HRH3			0	90.58	Tocris	3743	BF 2649 hydrochloride	295.17	Clc1ccc(CCCOCCCN2CCCCC2)cc1	NNACHAUCXXVJSP-UHFFFAOYSA-N	9948102.0		NNACHAUCXXVJSP
BRD-K62264492-001-02-3	pivagabine	Launched	corticotropin releasing factor receptor antagonist	CRHR1|CRHR2	neurology/psychiatry	depression	0	0.0	Enamine	Z85888809	4-[(2,2-dimethylpropanoyl)amino]butanoic acid	187.121	CC(C)(C)C(=O)NCCCC(O)=O	SRPNQDXRVRCTNK-UHFFFAOYSA-N	68888.0		SRPNQDXRVRCTNK
BRD-K62264492-001-01-5	pivagabine	Launched	corticotropin releasing factor receptor antagonist	CRHR1|CRHR2	neurology/psychiatry	depression	0	53.16	Enamine	Z85888809		187.121	CC(C)(C)C(=O)NCCCC(O)=O	SRPNQDXRVRCTNK-UHFFFAOYSA-N	68888.0		SRPNQDXRVRCTNK
BRD-K32791151-001-04-0	pivampicillin	Launched	bacterial cell wall synthesis inhibitor		pulmonary|infectious disease	bronchitis|pneumonia|gynecologic infections	0	38.24	Prestwick	Prestw-1009	Pivampicillin	463.178	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O	ZEMIJUDPLILVNQ-ZXFNITATSA-N	33478.0		ZEMIJUDPLILVNQ
BRD-K20504455-001-01-0	pivanex	Phase 2	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC8			0	0.0	Sigma	MFCD00209896	[(2,2-dimethylpropanoyl)oxy]methyl butyrate	202.121	CCCC(=O)OCOC(=O)C(C)(C)C	GYKLFBYWXZYSOW-UHFFFAOYSA-N	60748.0		GYKLFBYWXZYSOW
BRD-K67100011-001-01-8	pivmecillinam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|gram-negative bacterial infections	0	58.05	Sigma	SML0817	[(2,2-dimethylpropanoyl)oxy]methyl (2S,5R,6R)-6-{[(E)-1-azepanylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate	439.214	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	NPGNOVNWUSPMDP-UTEPHESZSA-N			NPGNOVNWUSPMDP
BRD-K67100011-003-07-1	pivmecillinam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|gram-negative bacterial infections	0	95.37	MedChemEx	HY-B0810A	Pivmecillinam (hydrochloride)	439.214	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	NPGNOVNWUSPMDP-UTEPHESZSA-N			NPGNOVNWUSPMDP
BRD-K67100011-003-06-3	pivmecillinam	Launched	bacterial cell wall synthesis inhibitor		infectious disease	urinary tract infections|gram-negative bacterial infections	0	84.34	Prestwick	Prestw-1053	Pivmecillinam hydrochloride	439.214	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	NPGNOVNWUSPMDP-UTEPHESZSA-N			NPGNOVNWUSPMDP
BRD-K48304345-332-02-4	pixantrone	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy	non-Hodgkin lymphoma (NHL)	0	48.21	MedChemEx	HY-13727A	Pixantrone (dimaleate)	325.154	NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12	PEZPMAYDXJQYRV-UHFFFAOYSA-N	134019.0		PEZPMAYDXJQYRV
BRD-K48304345-332-01-6	pixantrone	Launched	topoisomerase inhibitor	TOP2A	hematologic malignancy	non-Hodgkin lymphoma (NHL)	0	53.02	MedChemEx	HY-13727A	Pixantrone (dimaleate)	325.154	NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12	PEZPMAYDXJQYRV-UHFFFAOYSA-N	134019.0		PEZPMAYDXJQYRV
BRD-K75958195-001-10-9	pizotifen	Launched	serotonin receptor antagonist	HTR1A|HTR2A|HTR2C	neurology/psychiatry	migraine headache	0	94.33	MedChemEx	HY-B0115	Pizotifen	295.139	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	FIADGNVRKBPQEU-UHFFFAOYSA-N	27400.0		FIADGNVRKBPQEU
BRD-K75958195-037-09-4	pizotifen	Launched	serotonin receptor antagonist	HTR1A|HTR2A|HTR2C	neurology/psychiatry	migraine headache	0	98.76	MicroSource	1505003	PIZOTYLINE MALATE	295.139	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	FIADGNVRKBPQEU-UHFFFAOYSA-N	27400.0		FIADGNVRKBPQEU
BRD-K75958195-037-08-6	pizotifen	Launched	serotonin receptor antagonist	HTR1A|HTR2A|HTR2C	neurology/psychiatry	migraine headache	0	99.14	Selleck	S1394	Pizotifen Malate	295.139	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	FIADGNVRKBPQEU-UHFFFAOYSA-N	27400.0		FIADGNVRKBPQEU
BRD-K62374002-001-01-5	PI3K-IN-2	Phase 2	PI3K inhibitor				0	94.14	MedChemEx	HY-12868	PQR309	411.163	Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	ADGGYDAFIHSYFI-UHFFFAOYSA-N	58507717.0		ADGGYDAFIHSYFI
BRD-K00004592-001-01-9	PI3Kd-IN-2	Preclinical	PI3K inhibitor				0	90.49	MedChemEx	HY-102031	PI3Kd-IN-2	588.253	COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1	NVWKNQGHVMMAJW-UHFFFAOYSA-N	91754520.0		NVWKNQGHVMMAJW
BRD-K75528696-001-01-2	PI4KIII-beta-inhibitor-1	Preclinical	PI4K inhibitor	PI4K2B			0	94.57	MedChemEx	HY-100198	PI4KIIIbeta-IN-10	475.124	COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C	PLUYFBRIGUAKBR-UHFFFAOYSA-N	71549093.0		PLUYFBRIGUAKBR
BRD-K11853856-003-02-1	PJ-34	Preclinical	PARP inhibitor	EEF2|PARP1|PARP15|PARP3			0	95.18	Tocris	3255	PJ 34 hydrochloride	295.132	CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	UYJZZVDLGDDTCL-UHFFFAOYSA-N	4858.0		UYJZZVDLGDDTCL
BRD-K11853856-001-01-7	PJ-34	Preclinical	PARP inhibitor	EEF2|PARP1|PARP15|PARP3			0	86.26	Selleck	S2886	PJ34	295.132	CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	UYJZZVDLGDDTCL-UHFFFAOYSA-N	4858.0		UYJZZVDLGDDTCL
BRD-K11853856-001-02-5	PJ-34	Preclinical	PARP inhibitor	EEF2|PARP1|PARP15|PARP3			0	94.69	Selleck	S2886	PJ34	295.132	CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	UYJZZVDLGDDTCL-UHFFFAOYSA-N	4858.0		UYJZZVDLGDDTCL
BRD-K44043890-001-01-4	PK-THPP	Preclinical	potassium channel blocker	KCNK9			0	97.46	Tocris	5338	PK-THPP	468.253	CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1	CJZGRIRZVHNUSM-UHFFFAOYSA-N	53464059.0		CJZGRIRZVHNUSM
BRD-K44043890-001-02-9	PK-THPP	Preclinical	potassium channel blocker	KCNK9			0	96.99	Tocris	5338	PK-THPP	468.253	CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1	CJZGRIRZVHNUSM-UHFFFAOYSA-N	53464059.0		CJZGRIRZVHNUSM
BRD-A41451487-001-12-0	PK-11195	Phase 1	benzodiazepine receptor antagonist	TSPO			0	98.74	Tocris	670	PK 11195	352.134	CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|	RAVIZVQZGXBOQO-CQSZACIVSA-N	24839733.0		RAVIZVQZGXBOQO
BRD-A41451487-001-11-2	PK-11195	Phase 1	benzodiazepine receptor antagonist	TSPO			0	98.79	Tocris	670	PK 11195	352.134	CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2,r|	RAVIZVQZGXBOQO-CQSZACIVSA-N	24839733.0		RAVIZVQZGXBOQO
BRD-K04035716-011-01-9	PK-44	Preclinical	dipeptidyl peptidase inhibitor	DPP4			0	84.96	Tocris	4145	PK 44 phosphate	429.134	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12	LIPWZZYFIVYJSI-MRVPVSSYSA-N	46208486.0		LIPWZZYFIVYJSI
BRD-K04035716-011-02-9	PK-44	Preclinical	dipeptidyl peptidase inhibitor	DPP4			0	91.71	Tocris	4145	PK 44 phosphate	429.134	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12	LIPWZZYFIVYJSI-MRVPVSSYSA-N	46208486.0		LIPWZZYFIVYJSI
BRD-K10115470-001-01-8	PKI-166	Phase 1	EGFR inhibitor	EGFR			0	90.82	Sigma	SML1095	4-(4-{[(1R)-1-phenylethyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenol	330.148	C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1	XRYJULCDUUATMC-CYBMUJFWSA-N	6918403.0		XRYJULCDUUATMC
BRD-A28467416-002-01-0	PKI-179	Phase 1	mTOR inhibitor|PI3K inhibitor	MTOR			0	97.35	EMDBio	526561-5MG	PI 3-K/mTOR Inhibitor III, PKI-179	488.228	O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29,&2:32|	WXUUCRLKXQMWRY-OYRHEFFESA-N	76958312.0		WXUUCRLKXQMWRY
BRD-K27625831-001-02-9	pleconaril	Phase 3					0	91.31	MedChemEx	HY-19952	Pleconaril	381.13	Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1	KQOXLKOJHVFTRN-UHFFFAOYSA-N	1684.0		KQOXLKOJHVFTRN
BRD-K27625831-001-01-1	pleconaril	Phase 3					0	71.1	SantaCruz	sc-391701		381.13	Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1	KQOXLKOJHVFTRN-UHFFFAOYSA-N	1684.0		KQOXLKOJHVFTRN
BRD-K33240821-001-06-2	plerixafor	Launched	CC chemokine receptor antagonist	ACKR3|CCR4|CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL)|multiple myeloma	0	97.85	MedChemEx	HY-10046	Plerixafor	502.447	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	YIQPUIGJQJDJOS-UHFFFAOYSA-N	65015.0		YIQPUIGJQJDJOS
BRD-K33240821-001-03-9	plerixafor	Launched	CC chemokine receptor antagonist	ACKR3|CCR4|CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL)|multiple myeloma	0	0.0	Selleck	S8030	Plerixafor (AMD3100)	502.447	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	YIQPUIGJQJDJOS-UHFFFAOYSA-N	65015.0		YIQPUIGJQJDJOS
BRD-K33240821-400-02-5	plerixafor	Launched	CC chemokine receptor antagonist	ACKR3|CCR4|CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL)|multiple myeloma	0	87.3	MedChemEx	HY-50912	Plerixafor (octahydrochloride)	502.447	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	YIQPUIGJQJDJOS-UHFFFAOYSA-N	65015.0		YIQPUIGJQJDJOS
BRD-K33240821-001-05-4	plerixafor	Launched	CC chemokine receptor antagonist	ACKR3|CCR4|CXCR4	hematologic malignancy	non-Hodgkin lymphoma (NHL)|multiple myeloma	0	0.0	Selleck	S8030	Plerixafor	502.447	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	YIQPUIGJQJDJOS-UHFFFAOYSA-N	65015.0		YIQPUIGJQJDJOS
BRD-K36368047-001-01-7	plicamycin	Launched	alcohol dehydrogenase inhibitor		oncology|endocrinology	testicular carcinoma|Paget's disease|hypercalcemia	0	59.72	Enzo	GR305	Plicamycin (Mithramycin A)	1084.473	CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O	CFCUWKMKBJTWLW-BGLFSJPPSA-N	457831.0		CFCUWKMKBJTWLW
BRD-K36368047-001-02-9	plicamycin	Launched	alcohol dehydrogenase inhibitor		oncology|endocrinology	testicular carcinoma|Paget's disease|hypercalcemia	0	68.85	Sigma	M6891	Mithramycin A Streptomyces plicatus	1084.473	CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O	CFCUWKMKBJTWLW-BGLFSJPPSA-N	457831.0		CFCUWKMKBJTWLW
BRD-K99498722-001-04-2	plinabulin	Phase 3	tubulin polymerization inhibitor				0	78.21	MedChemEx	HY-14444	Plinabulin	336.159	CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	UNRCMCRRFYFGFX-TYPNBTCFSA-N	9949641.0		UNRCMCRRFYFGFX
BRD-K99498722-001-02-6	plinabulin	Phase 3	tubulin polymerization inhibitor				0	78.05	MedChemEx	HY-14444	Plinabulin	336.159	CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	UNRCMCRRFYFGFX-TYPNBTCFSA-N	9949641.0		UNRCMCRRFYFGFX
BRD-K99498722-001-03-4	plinabulin	Phase 3	tubulin polymerization inhibitor				0	49.93	Adooq	A10654	(3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)methylene]-2,5-piperazinedione	336.159	CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	UNRCMCRRFYFGFX-TYPNBTCFSA-N	9949641.0		UNRCMCRRFYFGFX
BRD-A20781140-001-02-5	plovamer-acetate	Phase 2		TAT|TH|YARS|YARS2			0	98.02	Sigma	MFCD00063074	tyrosine	181.074	N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|	OUYCCCASQSFEME-QMMMGPOBSA-N	6942100.0		OUYCCCASQSFEME
BRD-A20781140-001-01-7	plovamer-acetate	Phase 2		TAT|TH|YARS|YARS2			0	81.57	EMDBio	6570-100GM	L-Tyrosine, Free Base	181.074	N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1,r|	OUYCCCASQSFEME-QMMMGPOBSA-N	6942100.0		OUYCCCASQSFEME
BRD-K36137799-001-06-9	plumbagin	Preclinical	anticancer agent				0	89.25	Sigma	MFCD00001682	Plumbagin from Plumbago indica	188.047	CC1=CC(=O)c2c(O)cccc2C1=O |t:1|	VCMMXZQDRFWYSE-UHFFFAOYSA-N	10205.0		VCMMXZQDRFWYSE
BRD-K99149715-001-04-9	plurisin-1	Preclinical	stearoyl-CoA desaturase inhibitor	SCD			0	88.21	Tocris	4847	PluriSln 1	213.09	O=C(NNc1ccccc1)c1ccncc1	HUDWXDLBWRHCKO-UHFFFAOYSA-N	225362.0		HUDWXDLBWRHCKO
BRD-K99149715-001-03-2	plurisin-1	Preclinical	stearoyl-CoA desaturase inhibitor	SCD			0	66.15	Tocris	4847	PluriSln 1	213.09	O=C(NNc1ccccc1)c1ccncc1	HUDWXDLBWRHCKO-UHFFFAOYSA-N	225362.0		HUDWXDLBWRHCKO
BRD-K99149715-001-01-6	plurisin-1	Preclinical	stearoyl-CoA desaturase inhibitor	SCD			0	75.03	Selleck	S8076	PluriSIn #1 (NSC 14613)	213.09	O=C(NNc1ccccc1)c1ccncc1	HUDWXDLBWRHCKO-UHFFFAOYSA-N	225362.0		HUDWXDLBWRHCKO
BRD-K99149715-001-02-4	plurisin-1	Preclinical	stearoyl-CoA desaturase inhibitor	SCD			0	95.05	Selleck	S8076	PluriSIn #1 (NSC 14613)	213.09	O=C(NNc1ccccc1)c1ccncc1	HUDWXDLBWRHCKO-UHFFFAOYSA-N	225362.0		HUDWXDLBWRHCKO
BRD-K16478699-001-09-2	PLX4720	Preclinical	RAF inhibitor	BRAF|KDR			0	97.49	Selleck	S1152	PLX-4720	413.041	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	YZDJQTHVDDOVHR-UHFFFAOYSA-N	24180719.0		YZDJQTHVDDOVHR
BRD-K00003099-001-01-9	PLX51107	Phase 1	bromodomain inhibitor				0	97.86	MedChemEx	HY-111422	PLX51107	438.169	C[C@@H](c1ccccn1)n1cc(-c2ccc(cc2)C(O)=O)c2ncc(cc12)-c1c(C)noc1C	AMSUHYUVOVCWTP-INIZCTEOSA-N	90448953.0		AMSUHYUVOVCWTP
BRD-K79294107-300-02-9	PLX647	Preclinical	receptor tyrosine protein kinase inhibitor	CSF1R|KIT			0	94.1	Tocris	5102	PLX 647 dihydrochloride	382.141	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1	NODCQQSEMCESEC-UHFFFAOYSA-N	11545419.0		NODCQQSEMCESEC
BRD-K79294107-300-01-6	PLX647	Preclinical	receptor tyrosine protein kinase inhibitor	CSF1R|KIT			0	71.86	Tocris	5102	PLX 647 dihydrochloride	382.141	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1	NODCQQSEMCESEC-UHFFFAOYSA-N	11545419.0		NODCQQSEMCESEC
BRD-K53723268-001-01-3	PLX8394	Phase 1/Phase 2	serine/threonine kinase inhibitor	BRAF			0	96.23	MedChemEx	HY-18972	PLX8394	542.135	F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F	YYACLQUDUDXAPA-MRXNPFEDSA-N	90116675.0		YYACLQUDUDXAPA
BRD-A74387232-001-03-9	PMPA	Preclinical	glutamate receptor antagonist	FOLH1			1	84.1	Tocris	1380	PMPA (NAALADase inhibitor)	226.024	OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|	ISEYJGQFXSTPMQ-BYPYZUCNSA-N	11031538.0		ISEYJGQFXSTPMQ
BRD-A74387232-001-02-5	PMPA	Preclinical	glutamate receptor antagonist	FOLH1			1	0.0	Tocris	1380	PMPA (NAALADase inhibitor)	226.024	OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5,r|	ISEYJGQFXSTPMQ-BYPYZUCNSA-N	11031538.0		ISEYJGQFXSTPMQ
BRD-K71731651-001-05-0	PNU-120596	Preclinical	acetylcholine receptor agonist	CHRNA7			0	97.96	Tocris	2498	PNU 120596	311.067	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	CEIIEALEIHQDBX-UHFFFAOYSA-N	311434.0		CEIIEALEIHQDBX
BRD-K71731651-001-04-3	PNU-120596	Preclinical	acetylcholine receptor agonist	CHRNA7			0	98.45	Tocris	2498	PNU 120596	311.067	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	CEIIEALEIHQDBX-UHFFFAOYSA-N	311434.0		CEIIEALEIHQDBX
BRD-K71731651-001-06-9	PNU-120596	Preclinical	acetylcholine receptor agonist	CHRNA7			0	97.93	Tocris	2498	PNU 120596	311.067	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	CEIIEALEIHQDBX-UHFFFAOYSA-N	311434.0		CEIIEALEIHQDBX
BRD-K71731651-001-03-5	PNU-120596	Preclinical	acetylcholine receptor agonist	CHRNA7			0	97.55	Selleck	S2629	PNU-120596	311.067	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	CEIIEALEIHQDBX-UHFFFAOYSA-N	311434.0		CEIIEALEIHQDBX
BRD-K81616657-001-01-4	PNU-142633	Phase 2	serotonin receptor agonist	HTR1D			0	97.37	Tocris	1985	(1S)-1-(2-{4-[4-(aminocarbonyl)phenyl]-1-piperazinyl}ethyl)-N-methyl-3,4-dihydro-1H-2-benzopyran-6-carboxamide	422.232	CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1	PNTVCCRNJOGKGA-QFIPXVFZSA-N	9845148.0		PNTVCCRNJOGKGA
BRD-K04635846-003-01-6	PNU-177864	Preclinical	dopamine receptor antagonist	DRD3			0	92.27	Tocris	3355	PNU 177864 hydrochloride	402.122	CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1	JGGQWSXZZQPZTR-UHFFFAOYSA-N	9887351.0		JGGQWSXZZQPZTR
BRD-K04635846-003-02-9	PNU-177864	Preclinical	dopamine receptor antagonist	DRD3			0	96.5	Tocris	3355	PNU 177864 hydrochloride	402.122	CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1	JGGQWSXZZQPZTR-UHFFFAOYSA-N	9887351.0		JGGQWSXZZQPZTR
BRD-K16551401-003-03-4	PNU-22394	Phase 2	serotonin receptor agonist	HTR2A|HTR2B|HTR2C|MAOA|MAOB			0	87.68	Tocris	2201	PNU 22394 hydrochloride	200.131	Cn1c2CCNCCc2c2ccccc12	ZBXDOQWPGBISAR-UHFFFAOYSA-N	27559.0		ZBXDOQWPGBISAR
BRD-K16551401-003-04-9	PNU-22394	Phase 2	serotonin receptor agonist	HTR2A|HTR2B|HTR2C|MAOA|MAOB			0	86.25	Tocris	2201	PNU 22394 hydrochloride	200.131	Cn1c2CCNCCc2c2ccccc12	ZBXDOQWPGBISAR-UHFFFAOYSA-N	27559.0		ZBXDOQWPGBISAR
BRD-K28863208-001-03-8	PNU-282987	Preclinical	cholinergic receptor agonist	CHRNA7			0	87.67	Tocris	2303	PNU 282987	264.103	Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	WECKJONDRAUFDD-ZDUSSCGKSA-N	9795278.0		WECKJONDRAUFDD
BRD-K28863208-001-02-0	PNU-282987	Preclinical	cholinergic receptor agonist	CHRNA7			0	95.1	Tocris	2303	PNU 282987	264.103	Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	WECKJONDRAUFDD-ZDUSSCGKSA-N	9795278.0		WECKJONDRAUFDD
BRD-K28863208-001-04-9	PNU-282987	Preclinical	cholinergic receptor agonist	CHRNA7			0	91.25	Tocris	2303	PNU 282987	264.103	Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	WECKJONDRAUFDD-ZDUSSCGKSA-N	9795278.0		WECKJONDRAUFDD
BRD-K06341478-003-02-9	PNU-37883	Preclinical	ATP-sensitive potassium channel antagonist				0	96.83	Tocris	2095	PNU 37883 hydrochloride	345.278	C1CCC(CC1)N=C(NC12CC3CC(CC(C3)C1)C2)N1CCOCC1	GKCGWXNLOYTUNC-UHFFFAOYSA-N	64393.0		GKCGWXNLOYTUNC
BRD-K30707190-001-05-8	PNU-74654	Preclinical	beta-catenin inhibitor	CTNNB1|TCF4			0	96.85	Tocris	3534	PNU 74654	320.116	Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	JJEDWBQZCRESJL-DEDYPNTBSA-N	9836739.0		JJEDWBQZCRESJL
BRD-K30707190-001-04-1	PNU-74654	Preclinical	beta-catenin inhibitor	CTNNB1|TCF4			0	91.24	Tocris	3534	PNU 74654	320.116	Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	JJEDWBQZCRESJL-DEDYPNTBSA-N	9836739.0		JJEDWBQZCRESJL
BRD-K30707190-001-01-7	PNU-74654	Preclinical	beta-catenin inhibitor	CTNNB1|TCF4			0	96.25	Tocris	3534	PNU 74654	320.116	Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	JJEDWBQZCRESJL-DEDYPNTBSA-N	9836739.0		JJEDWBQZCRESJL
BRD-K84507776-003-01-4	PNU-89843	Preclinical	benzodiazepine receptor agonist	GABBR1			0	7.39	Tocris	2734	6,7-dimethyl-2,4-di(1-pyrrolidinyl)-7H-pyrrolo[2,3-d]pyrimidine hydrochloride	285.195	Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1	UADIKEUOAMACNA-UHFFFAOYSA-N	154689.0		UADIKEUOAMACNA
BRD-K00003464-001-01-9	pocapavir	Preclinical	Enterovirus capsid inhibitor				0	0.0	MedChemEx	HY-104074	Pocapavir	422.024	COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1	XXMDDBVNWRWNCW-UHFFFAOYSA-N	1455.0		XXMDDBVNWRWNCW
BRD-K47869605-001-32-0	podophyllotoxin	Launched	microtubule inhibitor|tubulin polymerization inhibitor	IGF1R|TOP2A|TUBA4A|TUBB	infectious disease	genital warts	0	94.65	MicroSource	2300332	PODOFILOX	414.131	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	YJGVMLPVUAXIQN-XVVDYKMHSA-N	10607.0		YJGVMLPVUAXIQN
BRD-K47869605-001-34-9	podophyllotoxin	Launched	microtubule inhibitor|tubulin polymerization inhibitor	IGF1R|TOP2A|TUBA4A|TUBB	infectious disease	genital warts	0	95.6	MedChemEx	HY-15552	Podofilox	414.131	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	YJGVMLPVUAXIQN-XVVDYKMHSA-N	10607.0		YJGVMLPVUAXIQN
BRD-K00003535-001-01-9	polaprezinc	Preclinical	chelating agent				0	0.0	MedChemEx	HY-B0729	Polaprezinc	288.02	O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1	VBHDYBCWTAXBNA-FJXQXJEOSA-M			VBHDYBCWTAXBNA
BRD-K35798650-001-01-4	polidocanol	Launched	local anesthetic		dermatology	varicose veins	0	97.44	Sigma	MFCD00043375	3,6,9,12,15,18,21,24,27-nonaoxanonatriacontan-1-ol	582.434	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO	ONJQDTZCDSESIW-UHFFFAOYSA-N	656641.0		ONJQDTZCDSESIW
BRD-K43236057-001-07-1	polydatin	Phase 2	ICAM1 expression inhibitor	ICAM1			0	93.06	Selleck	S2390	Polydatin(Piceid)	390.131	OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	HSTZMXCBWJGKHG-CUYWLFDKSA-N	5281718.0		HSTZMXCBWJGKHG
BRD-K43236057-001-09-7	polydatin	Phase 2	ICAM1 expression inhibitor	ICAM1			0	67.34	Selleck	S2390	Polydatin	390.131	OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	HSTZMXCBWJGKHG-CUYWLFDKSA-N	5281718.0	BRD-K94506759-001-01-9	HSTZMXCBWJGKHG
BRD-A67531813-001-01-6	polyinosine	Preclinical	immunostimulant	HPRT1|IMPDH2|PYGM			0	98.8	Sigma	MFCD00066754	(3,4-dihydroxy-5-(6-hydroxy-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl dihydrogen phosphate	348.047	O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1,&2:2,&3:10,&4:11,r|	GRSZFWQUAKGDAV-SQQSDITASA-N	138454308.0		GRSZFWQUAKGDAV
BRD-A08641215-065-05-5	polymyxin-B-sulfate	Launched	bacterial permeability inducer		ophthalmology	eye infection	0	84.9	Selleck	S1395	POLYMYXIN B SULFATE	1202.75	CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|	WQVJHHACXVLGBL-XLCZGQJLSA-N			WQVJHHACXVLGBL
BRD-A08641215-065-04-8	polymyxin-B-sulfate	Launched	bacterial permeability inducer		ophthalmology	eye infection	0	59.7	MicroSource	1500492	POLYMYXIN B SULFATE	1202.75	CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2,&2:11,&3:18,&4:19,&5:25,&6:32,&7:38,&8:42,&9:49,&10:56,&11:64,&12:75,&13:82|	WQVJHHACXVLGBL-XLCZGQJLSA-N			WQVJHHACXVLGBL
BRD-A15739803-001-01-0	polythiazide	Launched	sodium/chloride cotransporter inhibitor	SLC12A3	cardiology|gastroenterology|rheumatology|nephrology	edema|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|acute glomerulonephritis (AGN)|chronic renal failure|hypertension	0	98.56	Kemprotec	346-18-9	6-chloro-2-methyl-3-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide	438.971	CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2,r|	CYLWJCABXYDINA-JTQLQIEISA-N	12876779.0		CYLWJCABXYDINA
BRD-A12994259-001-02-1	pomalidomide	Launched	angiogenesis inhibitor|tumor necrosis factor production inhibitor		hematologic malignancy	multiple myeloma	0	96.64	Selleck	S1567	Pomalidomide	273.075	Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|	UVSMNLNDYGZFPF-QMMMGPOBSA-N	9965330.0		UVSMNLNDYGZFPF
BRD-A12994259-001-04-7	pomalidomide	Launched	angiogenesis inhibitor|tumor necrosis factor production inhibitor		hematologic malignancy	multiple myeloma	0	98.67	MedChemEx	HY-10984	pomalidomide	273.075	Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|	UVSMNLNDYGZFPF-QMMMGPOBSA-N	9965330.0		UVSMNLNDYGZFPF
BRD-A12994259-001-03-9	pomalidomide	Launched	angiogenesis inhibitor|tumor necrosis factor production inhibitor		hematologic malignancy	multiple myeloma	0		NCI		Pomalidomide	273.075	Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9,r|	InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)/t8-/m0/s1	9965330.0		UVSMNLNDYGZFPF
BRD-K44227013-001-08-0	ponatinib	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)	0	96.33	Selleck	S1490	Ponatinib (AP24534)	532.22	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	PHXJVRSECIGDHY-UHFFFAOYSA-N	24826799.0		PHXJVRSECIGDHY
BRD-K44227013-001-06-4	ponatinib	Launched	Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor	ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK	hematologic malignancy	chronic myeloid leukemia (CML)|acute lymphoblastic leukemia (ALL)	0	83.5	Selleck	S1490	Ponatinib (AP24534)	532.22	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	PHXJVRSECIGDHY-UHFFFAOYSA-N	24826799.0		PHXJVRSECIGDHY
BRD-K44030614-001-01-6	ponesimod	Phase 3	sphingosine 1-phosphate receptor agonist	S1PR1			0	95.0	MedChemEx	HY-10569	Ponesimod	460.122	CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C	LPAUOXUZGSBGDU-STDDISTJSA-N			LPAUOXUZGSBGDU
BRD-K06222852-001-05-7	posaconazole	Launched	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	0	94.29	Selleck	S1257	Posaconazole	700.33	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	RAGOYPUPXAKGKH-XAKZXMRKSA-N	468595.0		RAGOYPUPXAKGKH
BRD-K06222852-001-03-2	posaconazole	Launched	sterol demethylase inhibitor	CYP3A4	infectious disease	oropharyngeal candidiasis	0	81.58	Selleck	S1257	Posaconazole	700.33	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	RAGOYPUPXAKGKH-XAKZXMRKSA-N	468595.0		RAGOYPUPXAKGKH
BRD-K46556543-001-01-4	potassium-canrenoate	Launched	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	0	93.28	MicroSource	1500828	CANRENOIC ACID, POTASSIUM SALT	358.214	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|	PBKZPPIHUVSDNM-WNHSNXHDSA-N	656615.0	BRD-A29322418-237-04-0	PBKZPPIHUVSDNM
BRD-K46556543-237-09-7	potassium-canrenoate	Launched	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	0	84.92	Selleck	S4392	Potassium Canrenoate	358.214	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|	PBKZPPIHUVSDNM-WNHSNXHDSA-N	656615.0		PBKZPPIHUVSDNM
BRD-K46556543-237-11-9	potassium-canrenoate	Launched	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	0	95.3	Selleck	S4392		358.214	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|	PBKZPPIHUVSDNM-WNHSNXHDSA-N	656615.0		PBKZPPIHUVSDNM
BRD-K46556543-237-10-5	potassium-canrenoate	Launched	mineralocorticoid receptor antagonist	NR3C2	cardiology	edema	0	98.01	Selleck	S4392	Potassium Canrenoate	358.214	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6,t:8|	PBKZPPIHUVSDNM-WNHSNXHDSA-N	656615.0		PBKZPPIHUVSDNM
BRD-M55321172-001-03-3	potassium-iodide	Launched			pulmonary	asthma|bronchitis|emphysema	1	0.0	Selleck	S1897	Potassium iodide	166.876	[K].I	KIRAUJWBCMCUBY-UHFFFAOYSA-N			KIRAUJWBCMCUBY
BRD-M55321172-001-02-5	potassium-iodide	Launched			pulmonary	asthma|bronchitis|emphysema	1	0.0	Selleck	S1897	Potassium Iodide	166.876	[K].I	KIRAUJWBCMCUBY-UHFFFAOYSA-N			KIRAUJWBCMCUBY
BRD-K58497451-001-11-9	potassium-p-aminobenzoate	Launched			rheumatology|urology	scleroderma|dermatomyositis|Peyronie's disease	0	99.19	MedChemEx	HY-B1008	4-Aminobenzoic acid	137.048	Nc1ccc(cc1)C(O)=O	ALYNCZNDIQEVRV-UHFFFAOYSA-N	978.0		ALYNCZNDIQEVRV
BRD-K58497451-237-10-7	potassium-p-aminobenzoate	Launched			rheumatology|urology	scleroderma|dermatomyositis|Peyronie's disease	0	100.0	MicroSource	1500113	POTASSIUM p-AMINOBENZOATE	137.048	Nc1ccc(cc1)C(O)=O	ALYNCZNDIQEVRV-UHFFFAOYSA-N	978.0		ALYNCZNDIQEVRV
BRD-K79803033-300-01-3	pozanicline	Phase 2	acetylcholine receptor antagonist	CHRNA4|CHRNB2			0	98.79	Sigma	SML1487		192.126	Cc1ncccc1OC[C@@H]1CCCN1	YRVIKLBSVVNSHF-JTQLQIEISA-N	178052.0		YRVIKLBSVVNSHF
BRD-K50010139-001-02-3	poziotinib	Phase 2	EGFR inhibitor	EGFR|ERBB2|ERBB4			0	99.66	Adooq	A13044	1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one	490.097	COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C	LPFWVDIFUFFKJU-UHFFFAOYSA-N	25127713.0		LPFWVDIFUFFKJU
BRD-K50010139-001-01-5	poziotinib	Phase 2	EGFR inhibitor	EGFR|ERBB2|ERBB4			0	98.73	Selleck	S7358	Poziotinib (HM781-36B)	490.097	COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C	LPFWVDIFUFFKJU-UHFFFAOYSA-N	25127713.0		LPFWVDIFUFFKJU
BRD-K47598052-001-14-1	PP-1	Preclinical	SRC inhibitor	HCK|RET			0	97.73	Selleck	S7060	PP1	281.164	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	ZVPDNRVYHLRXLX-UHFFFAOYSA-N	1400.0		ZVPDNRVYHLRXLX
BRD-K47598052-001-17-9	PP-1	Preclinical	SRC inhibitor	HCK|RET			0	94.71	Tocris	1397	PP 1	281.164	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	ZVPDNRVYHLRXLX-UHFFFAOYSA-N	1400.0		ZVPDNRVYHLRXLX
BRD-K47598052-001-15-8	PP-1	Preclinical	SRC inhibitor	HCK|RET			0	99.39	Tocris	1397	PP 1	281.164	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	ZVPDNRVYHLRXLX-UHFFFAOYSA-N	1400.0		ZVPDNRVYHLRXLX
BRD-K81801188-001-02-8	PP-121	Preclinical	protein tyrosine kinase inhibitor	ABL1|EGFR|HCK|KDR|MTOR|PDGFRA|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC|SRC			0	94.91	Selleck	S2622	PP121	319.155	Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1	NVRXTLZYXZNATH-UHFFFAOYSA-N	24905142.0		NVRXTLZYXZNATH
BRD-K81801188-001-05-1	PP-121	Preclinical	protein tyrosine kinase inhibitor	ABL1|EGFR|HCK|KDR|MTOR|PDGFRA|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC|SRC			0	97.69	Tocris	3894	PP 121	319.155	Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1	NVRXTLZYXZNATH-UHFFFAOYSA-N	24905142.0		NVRXTLZYXZNATH
BRD-K81801188-001-06-9	PP-121	Preclinical	protein tyrosine kinase inhibitor	ABL1|EGFR|HCK|KDR|MTOR|PDGFRA|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC|SRC			0	96.79	Tocris	3894	PP 121	319.155	Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1	NVRXTLZYXZNATH-UHFFFAOYSA-N	24905142.0		NVRXTLZYXZNATH
BRD-K95785537-001-22-3	PP-2	Preclinical	SRC inhibitor	ABL1|LCK|RIPK2|SRC			0	97.04	Selleck	S7008	PP2	301.109	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	PBBRWFOVCUAONR-UHFFFAOYSA-N	4878.0		PBBRWFOVCUAONR
BRD-K95785537-001-26-9	PP-2	Preclinical	SRC inhibitor	ABL1|LCK|RIPK2|SRC			0	97.4	Tocris	1407	PP 2	301.109	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	PBBRWFOVCUAONR-UHFFFAOYSA-N	4878.0		PBBRWFOVCUAONR
BRD-K95785537-001-24-9	PP-2	Preclinical	SRC inhibitor	ABL1|LCK|RIPK2|SRC			0	93.64	Tocris	1407	PP 2	301.109	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	PBBRWFOVCUAONR-UHFFFAOYSA-N	4878.0		PBBRWFOVCUAONR
BRD-K95785537-001-23-1	PP-2	Preclinical	SRC inhibitor	ABL1|LCK|RIPK2|SRC			0	99.23	Tocris	1407	PP 2	301.109	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	PBBRWFOVCUAONR-UHFFFAOYSA-N	4878.0		PBBRWFOVCUAONR
BRD-K00312224-001-10-3	PPT	Preclinical	estrogen receptor agonist	ESR1			0	97.57	Tocris	1426	PPT	386.163	CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	IOTXSIGGFRQYKW-UHFFFAOYSA-N	5040063.0		IOTXSIGGFRQYKW
BRD-K00312224-001-11-9	PPT	Preclinical	estrogen receptor agonist	ESR1			0	97.84	Tocris	1426	PPT	386.163	CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	IOTXSIGGFRQYKW-UHFFFAOYSA-N	5040063.0		IOTXSIGGFRQYKW
BRD-K00312224-001-09-5	PPT	Preclinical	estrogen receptor agonist	ESR1			0	94.6	Tocris	1426	PPT	386.163	CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	IOTXSIGGFRQYKW-UHFFFAOYSA-N	5040063.0		IOTXSIGGFRQYKW
BRD-K72514671-001-02-9	PPY-A	Preclinical	Abl kinase inhibitor	ABL1|BCR			0	97.34	Tocris	4730	PPY A	372.159	COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C	GYQRHHQPEMOLKH-UHFFFAOYSA-N	16750094.0		GYQRHHQPEMOLKH
BRD-K72514671-001-01-4	PPY-A	Preclinical	Abl kinase inhibitor	ABL1|BCR			0	99.07	Tocris	4730	PPY A	372.159	COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C	GYQRHHQPEMOLKH-UHFFFAOYSA-N	16750094.0		GYQRHHQPEMOLKH
BRD-K87112191-001-04-5	PP242	Preclinical	mTOR inhibitor	MTOR|PASK			0	80.36	Selleck	S2218	PP242	308.139	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	MFAQYJIYDMLAIM-UHFFFAOYSA-N	135565635.0		MFAQYJIYDMLAIM
BRD-K87112191-001-06-0	PP242	Preclinical	mTOR inhibitor	MTOR|PASK			0	89.25	Tocris	4257	PP 242	308.139	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	MFAQYJIYDMLAIM-UHFFFAOYSA-N	135565635.0		MFAQYJIYDMLAIM
BRD-K87112191-001-05-2	PP242	Preclinical	mTOR inhibitor	MTOR|PASK			0	76.23	Selleck	S2218	Torkinib (PP242)	308.139	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	MFAQYJIYDMLAIM-UHFFFAOYSA-N	135565635.0		MFAQYJIYDMLAIM
BRD-K67537649-001-03-7	PQ-401	Preclinical	IGF-1 inhibitor	IGF1R			0	95.59	Selleck	S8003	PQ 401	341.093	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	YBLWOZUPHDKFOT-UHFFFAOYSA-N	9549305.0		YBLWOZUPHDKFOT
BRD-K67537649-001-04-5	PQ-401	Preclinical	IGF-1 inhibitor	IGF1R			0	97.12	Tocris	2768	PQ 401	341.093	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	YBLWOZUPHDKFOT-UHFFFAOYSA-N	9549305.0		YBLWOZUPHDKFOT
BRD-K67537649-001-06-9	PQ-401	Preclinical	IGF-1 inhibitor	IGF1R			0	96.8	Tocris	2768	PQ 401	341.093	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	YBLWOZUPHDKFOT-UHFFFAOYSA-N	9549305.0		YBLWOZUPHDKFOT
BRD-K67537649-001-05-2	PQ-401	Preclinical	IGF-1 inhibitor	IGF1R			0	93.94	Tocris	2768	PQ 401	341.093	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	YBLWOZUPHDKFOT-UHFFFAOYSA-N	9549305.0		YBLWOZUPHDKFOT
BRD-K54395039-001-03-9	PR-619	Preclinical	DUB inhibitor				0	95.84	Tocris	4482	PR 619	222.999	Nc1nc(N)c(SC#N)cc1SC#N	ZXOBLNBVNROVLC-UHFFFAOYSA-N	2817763.0		ZXOBLNBVNROVLC
BRD-K54395039-001-01-7	PR-619	Preclinical	DUB inhibitor				0	82.97	Selleck	S7130	PR-619	222.999	Nc1nc(N)c(SC#N)cc1SC#N	ZXOBLNBVNROVLC-UHFFFAOYSA-N	2817763.0		ZXOBLNBVNROVLC
BRD-K54395039-001-02-5	PR-619	Preclinical	DUB inhibitor				0	93.0	Selleck	S7130	PR-619	222.999	Nc1nc(N)c(SC#N)cc1SC#N	ZXOBLNBVNROVLC-UHFFFAOYSA-N	2817763.0		ZXOBLNBVNROVLC
BRD-A41304429-001-17-1	practolol	Withdrawn	adrenergic receptor antagonist	ADRB1			0	87.63	Sigma	SML1462	N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide	266.163	CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|	DURULFYMVIFBIR-CYBMUJFWSA-N	6918924.0		DURULFYMVIFBIR
BRD-A41304429-001-14-8	practolol	Withdrawn	adrenergic receptor antagonist	ADRB1			0	75.52	Prestwick	Prestw-332	Practolol	266.163	CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5,r|	DURULFYMVIFBIR-CYBMUJFWSA-N	6918924.0		DURULFYMVIFBIR
BRD-K00003119-066-01-9	pradefovir	Phase 2	cytochrome P450 activator				0	97.65	MedChemEx	HY-112690A	Pradefovir mesylate	423.086	Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12	GWNHAOBXDGOXRR-HJFSHJIFSA-N	9604654.0		GWNHAOBXDGOXRR
BRD-A74914197-001-02-9	pralatrexate	Launched	dihydrofolate reductase inhibitor	DHFR	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	0	94.33	Selleck	S1497	Pralatrexate	477.176	Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|	OGSBUKJUDHAQEA-ZBFHGGJFSA-N	11155808.0		OGSBUKJUDHAQEA
BRD-A74914197-001-01-1	pralatrexate	Launched	dihydrofolate reductase inhibitor	DHFR	hematologic malignancy	peripheral T-cell lymphoma (PTCL)	0	94.49	Selleck	S1497	Pralatrexate(Folotyn)	477.176	Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22,&1:9|	InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14-,16+/m1/s1	11155808.0		OGSBUKJUDHAQEA
BRD-K84281997-003-09-2	pralidoxime	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	critical care	organophosphate poisoning	0	58.19	MicroSource	1505449	PRALIDOXIME CHLORIDE	137.071	C[n+]1ccccc1\C=N\O	JBKPUQTUERUYQE-UHFFFAOYSA-O	4884.0	BRD-K61327230-003-13-9	JBKPUQTUERUYQE
BRD-K84281997-066-03-2	pralidoxime	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	critical care	organophosphate poisoning	0	46.67	MicroSource	1502043	PRALIDOXIME MESYLATE	137.071	C[n+]1ccccc1\C=N\O	JBKPUQTUERUYQE-UHFFFAOYSA-O	4884.0		JBKPUQTUERUYQE
BRD-K84281997-003-08-4	pralidoxime	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	critical care	organophosphate poisoning	0	96.7	MedChemEx	HY-B1200	Pralidoxime (chloride)	137.071	C[n+]1ccccc1\C=N\O	JBKPUQTUERUYQE-UHFFFAOYSA-O	4884.0		JBKPUQTUERUYQE
BRD-K24221957-003-01-6	pralidoxime-chloride	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	pulmonary	respiratory depression	0	97.1	Sigma	MFCD00011981	2-[(E)-(hydroxyimino)methyl]-1-methylpyridinium chloride	137.071	C[n+]1ccccc1CN=O	MHOAUIZFSQGCNM-UHFFFAOYSA-N	54072659.0		MHOAUIZFSQGCNM
BRD-K00004629-001-01-9	pralmorelin	Launched	growth hormone releasing peptide ligand agonist				0	91.62	Sigma	SML2056	(2S,5R,8S,11S,14R,17R)-17-amino-2-(4-aminobutyl)-5-benzyl-8-(1H-indol-3-ylmethyl)-11-methyl-14-(2-naphthylmethyl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaoctadecan-1-amide	817.428	C[C@@H](N)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	HRNLPPBUBKMZMT-RDRUQFPZSA-N	6918245.0		HRNLPPBUBKMZMT
BRD-K06388322-300-01-3	pramipexole	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	neurology/psychiatry	Parkinson's Disease	0	43.51	Tocris	4174	Pramipexole dihydrochloride	211.114	CCCN[C@H]1CCc2nc(N)sc2C1	FASDKYOPVNHBLU-ZETCQYMHSA-N	119570.0		FASDKYOPVNHBLU
BRD-K06388322-300-10-9	pramipexole	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	neurology/psychiatry	Parkinson's Disease	0	100.0	Tocris	4174	Pramipexole dihydrochloride	211.114	CCCN[C@H]1CCc2nc(N)sc2C1	FASDKYOPVNHBLU-ZETCQYMHSA-N	119570.0		FASDKYOPVNHBLU
BRD-K06388322-001-07-4	pramipexole	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	neurology/psychiatry	Parkinson's Disease	0	97.04	Selleck	S2460	Pramipexole	211.114	CCCN[C@H]1CCc2nc(N)sc2C1	FASDKYOPVNHBLU-ZETCQYMHSA-N	119570.0		FASDKYOPVNHBLU
BRD-K06388322-312-02-6	pramipexole	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	neurology/psychiatry	Parkinson's Disease	0	100.0	Selleck	S2011	Pramipexole dihydrochloride monohydrate	211.114	CCCN[C@H]1CCc2nc(N)sc2C1	FASDKYOPVNHBLU-ZETCQYMHSA-N	119570.0		FASDKYOPVNHBLU
BRD-K21123171-001-02-9	pramiracetam	Launched	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	0	91.48	Selleck	S2594	Pramiracetam	269.21	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	ZULJGOSFKWFVRX-UHFFFAOYSA-N	51712.0		ZULJGOSFKWFVRX
BRD-K21123171-001-03-9	pramiracetam	Launched	acetylcholine receptor agonist		neurology/psychiatry	senile dementia	0	93.06	MedChemEx	HY-17455	Pramiracetam	269.21	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	ZULJGOSFKWFVRX-UHFFFAOYSA-N	51712.0		ZULJGOSFKWFVRX
BRD-K46523383-003-23-9	pramoxine	Launched	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	0	95.7	MedChemEx	HY-B1319	Pramocaine (hydrochloride)	293.199	CCCCOc1ccc(OCCCN2CCOCC2)cc1	DQKXQSGTHWVTAD-UHFFFAOYSA-N	4886.0		DQKXQSGTHWVTAD
BRD-K46523383-003-21-1	pramoxine	Launched	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	0	95.61	Selleck	S4092	Pramoxine HCl	293.199	CCCCOc1ccc(OCCCN2CCOCC2)cc1	DQKXQSGTHWVTAD-UHFFFAOYSA-N	4886.0		DQKXQSGTHWVTAD
BRD-K46523383-003-22-9	pramoxine	Launched	topical anesthetic		dermatology	corticosteroid-responsive dermatoses	0	95.87	MicroSource	1501139	PRAMOXINE HYDROCHLORIDE	293.199	CCCCOc1ccc(OCCCN2CCOCC2)cc1	DQKXQSGTHWVTAD-UHFFFAOYSA-N	4886.0		DQKXQSGTHWVTAD
BRD-A68083442-001-01-6	pranidipine	Phase 2	calcium channel blocker	CACNA1C			0	98.76	AKSci	R730		448.163	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r,c:4,9|	XTFPDGZNWTZCMF-OXHGWOFKSA-N	29986494.0		XTFPDGZNWTZCMF
BRD-K97045029-001-02-7	pranlukast	Launched	leukotriene receptor antagonist	CYSLTR1|CYSLTR2|IL5|MUC2|NFKB1|RNASE3|TNF	pulmonary	bronchospasm|asthma	0	99.8	MedChemEx	HY-B0290	Pranlukast	481.175	O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1	NBQKINXMPLXUET-UHFFFAOYSA-N	4887.0		NBQKINXMPLXUET
BRD-K97045029-001-07-9	pranlukast	Launched	leukotriene receptor antagonist	CYSLTR1|CYSLTR2|IL5|MUC2|NFKB1|RNASE3|TNF	pulmonary	bronchospasm|asthma	0	97.04	Tocris	3026	ONO 1078	481.175	O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1	NBQKINXMPLXUET-UHFFFAOYSA-N	4887.0		NBQKINXMPLXUET
BRD-K97045029-001-04-3	pranlukast	Launched	leukotriene receptor antagonist	CYSLTR1|CYSLTR2|IL5|MUC2|NFKB1|RNASE3|TNF	pulmonary	bronchospasm|asthma	0	98.89	Selleck	S1829	Pranlukast	481.175	O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1	NBQKINXMPLXUET-UHFFFAOYSA-N	4887.0	BRD-K91497079-001-03-3|BRD-U02566398-000-01-1|BRD-K91497079-001-02-5	NBQKINXMPLXUET
BRD-A64610707-001-04-4	pranoprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	94.28	MicroSource	1502324	PRANOPROFEN	255.09	C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|	TVQZAMVBTVNYLA-SECBINFHSA-N	40467222.0		TVQZAMVBTVNYLA
BRD-A64610707-001-03-6	pranoprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	67.79	Selleck	S1960	Pranoprofen	255.09	C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|	TVQZAMVBTVNYLA-SECBINFHSA-N	40467222.0		TVQZAMVBTVNYLA
BRD-A64610707-001-07-9	pranoprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	94.15	MedChemEx	HY-B0336	Pranoprofen	255.09	C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|	TVQZAMVBTVNYLA-SECBINFHSA-N	40467222.0		TVQZAMVBTVNYLA
BRD-A64610707-001-05-1	pranoprofen	Launched	cyclooxygenase inhibitor		neurology/psychiatry	pain relief	0	98.99	Selleck	S1960	Pranoprofen	255.09	C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1,r|	TVQZAMVBTVNYLA-SECBINFHSA-N	40467222.0		TVQZAMVBTVNYLA
BRD-K96527333-001-09-9	prasterone-acetate	Preclinical					0	80.86	MedChemEx	HY-B1405	Dehydroisoandrosterone 3-acetate	330.219	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:23|	NCMZQTLCXHGLOK-ZKHIMWLXSA-N	14709.0		NCMZQTLCXHGLOK
BRD-A83029242-001-08-7	prasugrel	Launched	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction|acute coronary syndrome (ACS)	0	77.49	MedChemEx	HY-15284	Prasugrel	373.115	CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|	DTGLZDAWLRGWQN-LJQANCHMSA-N	51698431.0		DTGLZDAWLRGWQN
BRD-A83029242-001-06-1	prasugrel	Launched	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction|acute coronary syndrome (ACS)	0	62.51	Selleck	S1258	Prasugrel (Effient)	373.115	CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|	DTGLZDAWLRGWQN-LJQANCHMSA-N	51698431.0		DTGLZDAWLRGWQN
BRD-A83029242-001-05-3	prasugrel	Launched	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction|acute coronary syndrome (ACS)	0	83.3	Selleck	S1258	Prasugrel	373.115	CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|	DTGLZDAWLRGWQN-LJQANCHMSA-N	51698431.0		DTGLZDAWLRGWQN
BRD-A83029242-001-07-9	prasugrel	Launched	purinergic receptor antagonist	P2RY12	cardiology	myocardial infarction|acute coronary syndrome (ACS)	0	0.0	MedChemEx	HY-15284	Prasugrel	373.115	CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13,r|	DTGLZDAWLRGWQN-LJQANCHMSA-N	51698431.0		DTGLZDAWLRGWQN
BRD-K46209126-001-06-4	pravadoline	Preclinical	cyclooxygenase inhibitor	CNR1|CNR2			0	99.34	Cayman	10006973	(4-methoxyphenyl){2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl}methanone	378.194	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12	MEUQWHZOUDZXHH-UHFFFAOYSA-N	56463.0		MEUQWHZOUDZXHH
BRD-K60511616-236-07-1	pravastatin	Launched	HMGCR inhibitor	HMGCR|SLCO1B1	endocrinology|cardiology	hypercholesterolemia|myocardial infarction|hyperlipidemia	0	83.54	Tocris	2318	Pravastatin sodium salt	424.246	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|	TUZYXOIXSAXUGO-PZAWKZKUSA-N	54687.0		TUZYXOIXSAXUGO
BRD-K60511616-236-06-3	pravastatin	Launched	HMGCR inhibitor	HMGCR|SLCO1B1	endocrinology|cardiology	hypercholesterolemia|myocardial infarction|hyperlipidemia	0	93.62	Tocris	2318	Pravastatin sodium salt	424.246	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|	TUZYXOIXSAXUGO-PZAWKZKUSA-N	54687.0		TUZYXOIXSAXUGO
BRD-K60511616-236-09-9	pravastatin	Launched	HMGCR inhibitor	HMGCR|SLCO1B1	endocrinology|cardiology	hypercholesterolemia|myocardial infarction|hyperlipidemia	0	86.41	Tocris	2318	Pravastatin sodium salt	424.246	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|	TUZYXOIXSAXUGO-PZAWKZKUSA-N	54687.0		TUZYXOIXSAXUGO
BRD-K60511616-236-08-9	pravastatin	Launched	HMGCR inhibitor	HMGCR|SLCO1B1	endocrinology|cardiology	hypercholesterolemia|myocardial infarction|hyperlipidemia	0	95.56	Selleck	S3036	Pravastatin sodium	424.246	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13,t:11|	TUZYXOIXSAXUGO-PZAWKZKUSA-N	54687.0	BRD-K31447894-236-01-0	TUZYXOIXSAXUGO
BRD-A21858158-001-22-7	praziquantel	Launched	anthelmintic agent		infectious disease	gastrointestinal parasites|cystic hydatid disease|schistosomiasis	0	97.63	Selleck	S1691	Praziquantel	312.184	O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|	FSVJFNAIGNNGKK-QGZVFWFLSA-N	1917817.0		FSVJFNAIGNNGKK
BRD-A21858158-001-23-5	praziquantel	Launched	anthelmintic agent		infectious disease	gastrointestinal parasites|cystic hydatid disease|schistosomiasis	0	99.62	MicroSource	1500494	PRAZIQUANTEL	312.184	O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10,r|	FSVJFNAIGNNGKK-QGZVFWFLSA-N	1917817.0		FSVJFNAIGNNGKK
BRD-K49111258-003-30-5	prazosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7	cardiology	hypertension	0	97.05	Tocris	623	Prazosin hydrochloride	383.159	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	IENZQIKPVFGBNW-UHFFFAOYSA-N	4893.0		IENZQIKPVFGBNW
BRD-K49111258-003-29-7	prazosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7	cardiology	hypertension	0	98.79	MicroSource	1500495	PRAZOSIN HYDROCHLORIDE	383.159	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	IENZQIKPVFGBNW-UHFFFAOYSA-N	4893.0		IENZQIKPVFGBNW
BRD-K49111258-003-27-1	prazosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7	cardiology	hypertension	0	95.26	Selleck	S1424	Prazosin HCl	383.159	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	IENZQIKPVFGBNW-UHFFFAOYSA-N	4893.0		IENZQIKPVFGBNW
BRD-K49111258-003-28-9	prazosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7	cardiology	hypertension	0	97.41	Tocris	623	Prazosin hydrochloride	383.159	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	IENZQIKPVFGBNW-UHFFFAOYSA-N	4893.0		IENZQIKPVFGBNW
BRD-K57304726-003-07-7	PRE-084	Preclinical	sigma receptor agonist	SIGMAR1			0	93.29	Tocris	589	PRE-084 hydrochloride	317.199	O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	RQHKZUBCUZVZEF-UHFFFAOYSA-N	126402.0		RQHKZUBCUZVZEF
BRD-K57304726-003-08-9	PRE-084	Preclinical	sigma receptor agonist	SIGMAR1			0	95.86	Tocris	589	PRE-084 hydrochloride	317.199	O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	RQHKZUBCUZVZEF-UHFFFAOYSA-N	126402.0		RQHKZUBCUZVZEF
BRD-K57304726-003-06-9	PRE-084	Preclinical	sigma receptor agonist	SIGMAR1			0	97.96	Tocris	589	PRE-084 hydrochloride	317.199	O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	RQHKZUBCUZVZEF-UHFFFAOYSA-N	126402.0		RQHKZUBCUZVZEF
BRD-K02908048-003-06-4	preclamol	Phase 2	dopamine receptor agonist	DRD2			0	91.07	SantaCruz	sc-253355		219.162	CCCN1CCC[C@@H](C1)c1cccc(O)c1	HTSNFXAICLXZMA-ZDUSSCGKSA-N	202478.0		HTSNFXAICLXZMA
BRD-A93963402-001-01-6	prednicarbate	Launched	phospholipase activator	PLA2G1B	dermatology|ophthalmology|neurology/psychiatry	eczema|contact dermatitis|itching	0	0.0	MicroSource	1503876	PREDNICARBATE	488.241	CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6,19,22,25,&1:9,&2:10,&3:21,c:17,t:13|	FNPXMHRZILFCKX-HGVFMWMISA-N			FNPXMHRZILFCKX
BRD-A27887842-001-04-0	prednisolone	Launched	glucocorticoid receptor agonist	NR3C1|NR3C2|SERPINA6	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis	0	96.97	MicroSource	1500496	PREDNISOLONE	360.194	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	OIGNJSKKLXVSLS-VWUMJDOOSA-N	5755.0		OIGNJSKKLXVSLS
BRD-A27887842-001-05-7	prednisolone	Launched	glucocorticoid receptor agonist	NR3C1|NR3C2|SERPINA6	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis	0	90.25	Selleck	S1737	Prednisolone	360.194	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	OIGNJSKKLXVSLS-VWUMJDOOSA-N	5755.0	BRD-K00645576-001-01-9	OIGNJSKKLXVSLS
BRD-K45664306-001-19-6	prednisolone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis	0	93.2	Selleck	S2570	Prednisolone acetate (Omnipred)	402.204	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|	LRJOMUJRLNCICJ-JZYPGELDSA-N	5834.0		LRJOMUJRLNCICJ
BRD-A01643550-001-04-9	prednisolone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis	0	91.18	MicroSource	1500497	PREDNISOLONE ACETATE	402.204	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:7,24,27,&1:11,&2:12,&3:21,&4:23,c:19,t:15|	LRJOMUJRLNCICJ-WXLIAARGSA-N	11865455.0		LRJOMUJRLNCICJ
BRD-K45664306-001-20-4	prednisolone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis	0	86.79	Selleck	S2570	Prednisolone acetate (Omnipred)	402.204	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|	LRJOMUJRLNCICJ-JZYPGELDSA-N	5834.0	BRD-K87234558-001-01-0	LRJOMUJRLNCICJ
BRD-K45664306-001-21-9	prednisolone-acetate	Launched	glucocorticoid receptor agonist	NR3C1	ophthalmology|dermatology|infectious disease	conjunctivitis|rosacea|punctate keratitis|shingles|iritis|cyclitis	0	97.37	MedChemEx	HY-B1214	Prednisolone (21-acetate)	402.204	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19,t:15|	LRJOMUJRLNCICJ-JZYPGELDSA-N	5834.0		LRJOMUJRLNCICJ
BRD-A78391468-001-02-8	prednisolone-hemisuccinate	Preclinical	glucocorticoid receptor agonist	NR3C1			0	95.56	MicroSource	1505450	PREDNISOLONE HEMISUCCINATE	460.21	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1,3,15,20,&1:5,&2:6,&3:17,c:13,t:9|	APGDTXUMTIZLCJ-CGVGKPPMSA-N	656804.0		APGDTXUMTIZLCJ
BRD-K00003654-304-01-9	prednisolone-sodium-phosphate	Launched	glucocorticoid receptor agonist	NR3C1	allergy|pulmonary|ophthalmology|infectious disease|rheumatology|endocrinology|neurology/psychiatry|gastroenterology|hematology	allergic rhinitis|asthma|contact dermatitis|mycosis|lupus|hypercalcemia|thyroiditis|congenital adrenal hyperplasia|multiple sclerosis|ulcerative colitis|enteritis|thrombocythemia|pneumonia|meningitis|psoriatic arthritis|rheumatoid arthritis	0	87.18	MedChemEx	HY-B0645	Prednisolone (disodium phosphate)	440.16	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31,t:27|	JDOZJEUDSLGTLU-VWUMJDOOSA-N	72078.0		JDOZJEUDSLGTLU
BRD-A53151380-001-01-2	prednisolone-tebutate	Launched	anti-inflammatory agent				0	96.64	MicroSource	1505451	PREDNISOLONE TEBUTATE	458.267	CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:11,25,28,31,&1:15,&2:16,&3:27,c:23,t:19|	HUMXXHTVHHLNRO-HGVFMWMISA-N			HUMXXHTVHHLNRO
BRD-K85883481-001-26-9	prednisone	Launched	glucocorticoid receptor agonist	HSD11B1|NR3C1	endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry	congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis	0	90.99	MedChemEx	HY-B0214	Prednisone	358.178	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|	XOFYZVNMUHMLCC-ZPOLXVRWSA-N	5865.0		XOFYZVNMUHMLCC
BRD-K85883481-001-22-4	prednisone	Launched	glucocorticoid receptor agonist	HSD11B1|NR3C1	endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry	congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis	0	0.0	Selleck	S1622	Prednisone (Adasone)	358.178	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|	XOFYZVNMUHMLCC-ZPOLXVRWSA-N	5865.0		XOFYZVNMUHMLCC
BRD-K85883481-001-25-7	prednisone	Launched	glucocorticoid receptor agonist	HSD11B1|NR3C1	endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry	congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis	0	95.73	MicroSource	1500499	PREDNISONE	358.178	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|	XOFYZVNMUHMLCC-ZPOLXVRWSA-N	5865.0	BRD-A62525898-001-05-2	XOFYZVNMUHMLCC
BRD-K85883481-001-24-0	prednisone	Launched	glucocorticoid receptor agonist	HSD11B1|NR3C1	endocrinology|rheumatology|infectious disease|dermatology|ophthalmology|hematology|gastroenterology|neurology/psychiatry	congenital adrenal hyperplasia|hypercalcemia|rheumatoid arthritis|psoriatic arthritis|ankylosing spondylitis|bursitis|osteoarthritis|epicondylitis|dermatomyositis|psoriasis|mycosis|conjunctivitis|anemia|ulcerative colitis|enteritis|multiple sclerosis|meningitis	0	0.0	Selleck	S1622	Prednisone	358.178	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13,t:9|	XOFYZVNMUHMLCC-ZPOLXVRWSA-N	5865.0	BRD-K60679745-001-01-1	XOFYZVNMUHMLCC
BRD-K43880410-001-16-9	pregnenolone	Launched	glutamate receptor modulator	SULT2B1	rheumatology	rheumatoid arthritis	0	88.29	MedChemEx	HY-B0151	Pregnenolone	316.24	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|	ORNBQBCIOKFOEO-QGVNFLHTSA-N	8955.0		ORNBQBCIOKFOEO
BRD-K43880410-001-15-1	pregnenolone	Launched	glutamate receptor modulator	SULT2B1	rheumatology	rheumatoid arthritis	0	87.8	MicroSource	1500645	PREGNENOLONE	316.24	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|	ORNBQBCIOKFOEO-QGVNFLHTSA-N	8955.0	BRD-A35054627-001-09-7	ORNBQBCIOKFOEO
BRD-K43880410-001-14-4	pregnenolone	Launched	glutamate receptor modulator	SULT2B1	rheumatology	rheumatoid arthritis	0	98.34	Selleck	S1914	Pregnenolone	316.24	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|	ORNBQBCIOKFOEO-QGVNFLHTSA-N	8955.0	BRD-K52183142-001-01-3	ORNBQBCIOKFOEO
BRD-A35912562-001-02-8	pregnenolone-succinate	Preclinical	GABA receptor negative allosteric modulator	CYP17A1			0	99.33	MicroSource	1505713	PREGNENOLONE SUCCINATE	416.256	CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3,12,15,20,&1:6,&2:7,&3:17,t:9|	OZZAYJQNMKMUSD-VQLNUFJUSA-N			OZZAYJQNMKMUSD
BRD-K46290096-001-02-9	preladenant	Phase 3	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	94.76	MedChemEx	HY-10889	Preladenant	503.239	COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	DTYWJKSSUANMHD-UHFFFAOYSA-N	10117987.0		DTYWJKSSUANMHD
BRD-K46290096-001-01-1	preladenant	Phase 3	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	94.31	MedChemEx	HY-10889	Preladenant	503.239	COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	DTYWJKSSUANMHD-UHFFFAOYSA-N	10117987.0		DTYWJKSSUANMHD
BRD-A10662413-043-11-2	prenylamine	Withdrawn	calcium channel blocker				0	98.19	Prestwick	Prestw-560	Prenylamine lactate	329.214	C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|	IFFPICMESYHZPQ-FQEVSTJZSA-N	181757.0		IFFPICMESYHZPQ
BRD-K45906612-001-01-8	presatovir	Phase 2	RSV fusion inhibitor				0	95.26	MedChemEx	HY-16727	Presatovir	531.182	Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O	GOFXWTVKPWJNGD-UWJYYQICSA-N	58029842.0		GOFXWTVKPWJNGD
BRD-K96671969-001-05-9	pretomanid	Launched	nitric oxide donor	FASN			0	96.03	MedChemEx	HY-10844	Pretomanid	359.073	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1	ZLHZLMOSPGACSZ-NSHDSACASA-N	456199.0		ZLHZLMOSPGACSZ
BRD-K96671969-001-03-1	pretomanid	Launched	nitric oxide donor	FASN			0	96.87	Selleck	S1162	PA-824	359.073	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1	ZLHZLMOSPGACSZ-NSHDSACASA-N	456199.0		ZLHZLMOSPGACSZ
BRD-K17565903-066-22-3	pridinol	Launched	muscle relaxant		neurology/psychiatry	muscle relaxant	0	96.44	Selleck	S4371	Pridinol Methanesulfonate	295.194	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	RQXCLMGKHJWMOA-UHFFFAOYSA-N	4904.0		RQXCLMGKHJWMOA
BRD-K17565903-066-23-1	pridinol	Launched	muscle relaxant		neurology/psychiatry	muscle relaxant	0	98.23	MicroSource	1503077	PRIDINOL METHANESULFONATE	295.194	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	RQXCLMGKHJWMOA-UHFFFAOYSA-N	4904.0		RQXCLMGKHJWMOA
BRD-K17565903-066-24-9	pridinol	Launched	muscle relaxant		neurology/psychiatry	muscle relaxant	0	96.0	Selleck	S4371	PRIDINOL METHANESULFONATE	295.194	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	RQXCLMGKHJWMOA-UHFFFAOYSA-N	4904.0		RQXCLMGKHJWMOA
BRD-K00003473-001-01-9	pridopidine	Phase 2	dopamine receptor antagonist				0	94.48	MedChemEx	HY-10684	Pridopidine	281.145	CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O	YGKUEOZJFIXDGI-UHFFFAOYSA-N	9795739.0		YGKUEOZJFIXDGI
BRD-K01825595-001-03-9	prilocaine	Launched	local anesthetic	SCN5A	neurology/psychiatry	anesthetic	0	82.01	MedChemEx	HY-B0137	Prilocaine	220.158	CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|	MVFGUOIZUNYYSO-NSHDSACASA-N	6603976.0		MVFGUOIZUNYYSO
BRD-K01825595-001-02-9	prilocaine	Launched	local anesthetic	SCN5A	neurology/psychiatry	anesthetic	0	91.74	Selleck	S1619	Prilocaine	220.158	CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4,r|	MVFGUOIZUNYYSO-NSHDSACASA-N	6603976.0		MVFGUOIZUNYYSO
BRD-K00003556-316-01-9	primaquine	Launched	antimalarial agent|DNA inhibitor		infectious disease	malaria	0	81.19	MedChemEx	HY-12651	Primaquine (Diphosphate)	259.168	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |r|	INDBQLZJXZLFIT-NSHDSACASA-N	3044369.0		INDBQLZJXZLFIT
BRD-K15318909-001-12-1	PRIMA1	Preclinical	TP53 inhibitor	ACHE			0	100.0	Tocris	1862	2,2-bis(hydroxymethyl)quinuclidin-3-one	185.105	OCC1(CO)N2CCC(CC2)C1=O	RFBVBRVVOPAAFS-UHFFFAOYSA-N	322968.0		RFBVBRVVOPAAFS
BRD-K15318909-001-10-5	PRIMA1	Preclinical	TP53 inhibitor	ACHE			0	81.98	Tocris	1862	PRIMA-1	185.105	OCC1(CO)N2CCC(CC2)C1=O	RFBVBRVVOPAAFS-UHFFFAOYSA-N	322968.0		RFBVBRVVOPAAFS
BRD-K32247306-001-27-8	primidone	Launched	GABA receptor antagonist	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	95.99	Selleck	S1965	Primidone	218.106	CCC1(C(=O)NCNC1=O)c1ccccc1	DQMZLTXERSFNPB-UHFFFAOYSA-N	4909.0		DQMZLTXERSFNPB
BRD-K32247306-001-30-9	primidone	Launched	GABA receptor antagonist	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	86.25	Tocris	830	Primidone	218.106	CCC1(C(=O)NCNC1=O)c1ccccc1	DQMZLTXERSFNPB-UHFFFAOYSA-N	4909.0		DQMZLTXERSFNPB
BRD-K32247306-001-28-6	primidone	Launched	GABA receptor antagonist	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	97.54	Tocris	830	Primidone	218.106	CCC1(C(=O)NCNC1=O)c1ccccc1	DQMZLTXERSFNPB-UHFFFAOYSA-N	4909.0		DQMZLTXERSFNPB
BRD-K32247306-001-29-4	primidone	Launched	GABA receptor antagonist	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	99.02	MicroSource	1500501	PRIMIDONE	218.106	CCC1(C(=O)NCNC1=O)c1ccccc1	DQMZLTXERSFNPB-UHFFFAOYSA-N	4909.0		DQMZLTXERSFNPB
BRD-K87316765-001-01-4	prinaberel	Phase 2	estrogen receptor agonist	ESR2|NCOA1			0	94.73	MedChemEx	HY-14933	Prinaberel	271.064	Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1	MQIMZDXIAHJKQP-UHFFFAOYSA-N	656954.0		MQIMZDXIAHJKQP
BRD-K00003122-001-01-9	prinomastat	Phase 3	matrix metalloprotease inhibitor				0	91.29	MedChemEx	HY-12170	Prinomastat	423.092	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1	YKPYIPVDTNNYCN-INIZCTEOSA-N	466151.0		YKPYIPVDTNNYCN
BRD-K01662324-066-01-1	priralfinamide	Phase 3	sodium channel blocker	CACNA1B			0	93.13	Tocris	4029	Ralfinamide mesylate	302.143	C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	BHJIBOFHEFDSAU-LBPRGKRZSA-N	5745207.0		BHJIBOFHEFDSAU
BRD-K01662324-001-01-8	priralfinamide	Phase 3	sodium channel blocker	CACNA1B			0	98.67	AMS	A002801679	(2S)-2-({4-[(2-fluorobenzyl)oxy]benzyl}amino)propanamide	302.143	C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	BHJIBOFHEFDSAU-LBPRGKRZSA-N	5745207.0		BHJIBOFHEFDSAU
BRD-K00004547-001-01-9	prisotinol	Phase 2					0	95.47	Sigma	MFCD00867783	6-[2-(isopropylamino)propyl]-3-pyridinol	194.142	CC(C)N[C@H](C)Cc1ccc(O)cn1 |&1:4,r|	WQRPBKUCJBWQRT-SECBINFHSA-N	76965811.0		WQRPBKUCJBWQRT
BRD-K25204779-001-01-1	pritelivir	Phase 2	helicase primase inhibitor				0	98.06	MedChemEx	HY-15303	BAY 57-1293	402.082	CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	IVZKZONQVYTCKC-UHFFFAOYSA-N	491941.0		IVZKZONQVYTCKC
BRD-K25204779-001-02-9	pritelivir	Phase 2	helicase primase inhibitor				0	96.24	MedChemEx	HY-15303	Pritelivir	402.082	CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	IVZKZONQVYTCKC-UHFFFAOYSA-N	491941.0		IVZKZONQVYTCKC
BRD-K00004604-001-01-9	PRLX-93936	Phase 1/Phase 2	voltage-dependent anion selective channel protein inhibitor				0	92.91	Key	GS-9006	3-(2-ethoxyphenyl)-2-(1-piperazinylmethyl)-4(3H)-quinazolinone	364.19	CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O	OBWOSMGNXYUDFB-UHFFFAOYSA-N	11559627.0		OBWOSMGNXYUDFB
BRD-K00004599-001-01-9	PRN1008	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor				0	93.58	MedChemEx	HY-112166	PRN1008	665.324	CC(C)(\C=C(/C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1	LCFFREMLXLZNHE-GBOLQPHISA-N	73388818.0		LCFFREMLXLZNHE
BRD-K00003430-001-01-9	PRN1371	Phase 1	protein tyrosine kinase inhibitor				0	96.05	MedChemEx	HY-101768	PRN1371	560.171	CNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(CC3)C(=O)C=C)c2n1	PUIXMSRTTHLNKI-UHFFFAOYSA-N	118295624.0		PUIXMSRTTHLNKI
BRD-K53605365-001-01-4	proacipimox	Phase 1	cholesterol inhibitor				0	97.66	Enamine	Z2306534452	5-(methoxymethyl)-2-methylpyrazine 1-oxide	154.074	COCc1c[n+]([O-])c(C)cn1	KKKHJYGCTVKQEM-UHFFFAOYSA-N	3068148.0		KKKHJYGCTVKQEM
BRD-K46317332-003-16-0	proadifen	Preclinical	nitric oxide synthase inhibitor	NOS1			0	89.96	Selleck	S4381	Proadifen HCl	353.235	CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	SNTQPLDRUZOSDP-UHFFFAOYSA-N	4910.0		SNTQPLDRUZOSDP
BRD-K46317332-003-17-8	proadifen	Preclinical	nitric oxide synthase inhibitor	NOS1			0	92.91	MicroSource	1502084	PROADIFEN HYDROCHLORIDE	353.235	CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	SNTQPLDRUZOSDP-UHFFFAOYSA-N	4910.0		SNTQPLDRUZOSDP
BRD-K46317332-003-18-6	proadifen	Preclinical	nitric oxide synthase inhibitor	NOS1			0	93.97	Selleck	S4381	proadifen hydrochloride	353.235	CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	SNTQPLDRUZOSDP-UHFFFAOYSA-N	4910.0		SNTQPLDRUZOSDP
BRD-K95237249-001-27-3	probenecid	Launched	uricosuric blocker	PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1	nephrology|rheumatology	hyperuricemia|gout	0	88.0	Tocris	4107	Probenecid	285.103	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	DBABZHXKTCFAPX-UHFFFAOYSA-N	4911.0		DBABZHXKTCFAPX
BRD-K95237249-001-26-5	probenecid	Launched	uricosuric blocker	PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1	nephrology|rheumatology	hyperuricemia|gout	0	98.66	MicroSource	1500502	PROBENECID	285.103	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	DBABZHXKTCFAPX-UHFFFAOYSA-N	4911.0		DBABZHXKTCFAPX
BRD-K95237249-001-28-9	probenecid	Launched	uricosuric blocker	PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1	nephrology|rheumatology	hyperuricemia|gout	0	91.53	Tocris	4107	Probenecid	285.103	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	DBABZHXKTCFAPX-UHFFFAOYSA-N	4911.0		DBABZHXKTCFAPX
BRD-K95237249-001-25-7	probenecid	Launched	uricosuric blocker	PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1	nephrology|rheumatology	hyperuricemia|gout	0	95.89	Selleck	S4022	Probenecid	285.103	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	DBABZHXKTCFAPX-UHFFFAOYSA-N	4911.0		DBABZHXKTCFAPX
BRD-K72029282-001-23-8	probucol	Launched	atherogenesis inhibitor	ABCA1|ABCB11|CES1	cardiology	coronary artery disease (CAD)	0	88.71	MicroSource	1501109	PROBUCOL	516.31	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	FYPMFJGVHOHGLL-UHFFFAOYSA-N	4912.0		FYPMFJGVHOHGLL
BRD-K72029282-001-25-9	probucol	Launched	atherogenesis inhibitor	ABCA1|ABCB11|CES1	cardiology	coronary artery disease (CAD)	0	0.0	Tocris	2775	Probucol	516.31	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	FYPMFJGVHOHGLL-UHFFFAOYSA-N	4912.0		FYPMFJGVHOHGLL
BRD-K72029282-001-22-0	probucol	Launched	atherogenesis inhibitor	ABCA1|ABCB11|CES1	cardiology	coronary artery disease (CAD)	0	93.74	Selleck	S2119	Probucol	516.31	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	FYPMFJGVHOHGLL-UHFFFAOYSA-N	4912.0		FYPMFJGVHOHGLL
BRD-K75089421-003-26-9	procainamide	Launched	sodium channel blocker	DNMT1|SCN5A	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	0	96.86	MedChemEx	HY-A0084	Procainamide (hydrochloride)	235.168	CCN(CC)CCNC(=O)c1ccc(N)cc1	REQCZEXYDRLIBE-UHFFFAOYSA-N	4913.0		REQCZEXYDRLIBE
BRD-K75089421-003-24-5	procainamide	Launched	sodium channel blocker	DNMT1|SCN5A	cardiology	ventricular arrhythmias|ventricular tachycardia (VT)	0	97.98	MicroSource	1500503	PROCAINAMIDE HYDROCHLORIDE	235.168	CCN(CC)CCNC(=O)c1ccc(N)cc1	REQCZEXYDRLIBE-UHFFFAOYSA-N	4913.0		REQCZEXYDRLIBE
BRD-K24616672-003-20-1	procaine	Launched	HMGCR inhibitor	CHRNA2|GRIN3A|HTR3A|KCNMA1|KCNMB1|KCNMB2|KCNMB3|KCNMB4|KCNN1|KCNN2|KCNN3|KCNN4|MAOA|MAOB|RYR1|RYR2|SCN10A|SLC6A3	neurology/psychiatry	anesthetic	0	99.21	MicroSource	1500504	PROCAINE HYDROCHLORIDE	236.152	CCN(CC)CCOC(=O)c1ccc(N)cc1	MFDFERRIHVXMIY-UHFFFAOYSA-N	4914.0		MFDFERRIHVXMIY
BRD-K24616672-003-19-3	procaine	Launched	HMGCR inhibitor	CHRNA2|GRIN3A|HTR3A|KCNMA1|KCNMB1|KCNMB2|KCNMB3|KCNMB4|KCNN1|KCNN2|KCNN3|KCNN4|MAOA|MAOB|RYR1|RYR2|SCN10A|SLC6A3	neurology/psychiatry	anesthetic	0	95.04	Selleck	S4023	Procaine HCl	236.152	CCN(CC)CCOC(=O)c1ccc(N)cc1	MFDFERRIHVXMIY-UHFFFAOYSA-N	4914.0		MFDFERRIHVXMIY
BRD-K13032584-001-01-5	procarbazine	Launched	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	0	36.14	MicroSource	1502326	PROCARBAZINE HYDROCHLORIDE	221.153	CNNCc1ccc(cc1)C(=O)NC(C)C	CPTBDICYNRMXFX-UHFFFAOYSA-N	4915.0		CPTBDICYNRMXFX
BRD-K13032584-003-19-3	procarbazine	Launched	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	0	47.77	Selleck	S1995	Procarbazine hydrochloride (Matulane)	221.153	CNNCc1ccc(cc1)C(=O)NC(C)C	CPTBDICYNRMXFX-UHFFFAOYSA-N	4915.0		CPTBDICYNRMXFX
BRD-K13032584-003-18-5	procarbazine	Launched	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	0	24.7	Selleck	S1995	Procarbazine HCl (Matulane)	221.153	CNNCc1ccc(cc1)C(=O)NC(C)C	CPTBDICYNRMXFX-UHFFFAOYSA-N	4915.0		CPTBDICYNRMXFX
BRD-K13032584-003-21-9	procarbazine	Launched	monoamine oxidase inhibitor		hematologic malignancy	Hodgkin's lymphoma	0	0.0	MedChemEx	HY-13733	Procarbazine (Hydrochloride)	221.153	CNNCc1ccc(cc1)C(=O)NC(C)C	CPTBDICYNRMXFX-UHFFFAOYSA-N	4915.0		CPTBDICYNRMXFX
BRD-K78666826-003-02-4	procaterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma	0	47.03	Tocris	1102	Procaterol hydrochloride	290.163	CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	FKNXQNWAXFXVNW-BLLLJJGKSA-N	688561.0		FKNXQNWAXFXVNW
BRD-K78666826-003-03-9	procaterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma	0	97.34	Tocris	1102	Procaterol hydrochloride	290.163	CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	FKNXQNWAXFXVNW-BLLLJJGKSA-N	688561.0		FKNXQNWAXFXVNW
BRD-K78666826-003-01-6	procaterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma	0	96.33	Tocris	1102	Procaterol hydrochloride	290.163	CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	FKNXQNWAXFXVNW-BLLLJJGKSA-N	688561.0		FKNXQNWAXFXVNW
BRD-K19352500-332-09-4	prochlorperazine	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4	gastroenterology	nausea|vomiting	0	90.92	Tocris	3287	Prochlorperazine dimaleate	373.138	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	WIKYUJGCLQQFNW-UHFFFAOYSA-N	4917.0		WIKYUJGCLQQFNW
BRD-K19352500-332-07-8	prochlorperazine	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4	gastroenterology	nausea|vomiting	0	87.05	Selleck	S4407	Prochlorperazine Dimaleate	373.138	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	WIKYUJGCLQQFNW-UHFFFAOYSA-N	4917.0		WIKYUJGCLQQFNW
BRD-K19352500-070-12-4	prochlorperazine	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4	gastroenterology	nausea|vomiting	0	89.0	MicroSource	1500505	PROCHLORPERAZINE EDISYLATE	373.138	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	WIKYUJGCLQQFNW-UHFFFAOYSA-N	4917.0		WIKYUJGCLQQFNW
BRD-K19352500-332-08-6	prochlorperazine	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4	gastroenterology	nausea|vomiting	0	93.0	Selleck	S4407	prochlorperazine dimaleate	373.138	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	WIKYUJGCLQQFNW-UHFFFAOYSA-N	4917.0		WIKYUJGCLQQFNW
BRD-K54824716-001-04-0	procodazole	Preclinical	immunostimulant				0	98.53	MicroSource	1506175	PROCODAZOLE	190.074	OC(=O)CCc1nc2ccccc2[nH]1	XYWJNTOURDMTPI-UHFFFAOYSA-N	65708.0		XYWJNTOURDMTPI
BRD-K54824716-001-03-2	procodazole	Preclinical	immunostimulant				0	97.25	Selleck	S4408	Procodazole	190.074	OC(=O)CCc1nc2ccccc2[nH]1	XYWJNTOURDMTPI-UHFFFAOYSA-N	65708.0		XYWJNTOURDMTPI
BRD-K72093555-001-03-9	procyanidin-B-2	Phase 2					0	81.11	MedChemEx	HY-N0795	Procyanidin B1	578.142	O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	XFZJEEAOWLFHDH-UKWJTHFESA-N	11250133.0		XFZJEEAOWLFHDH
BRD-K72093555-001-02-8	procyanidin-B-2	Phase 2					0	79.94	SantaCruz	SC-228996	Procyanidin B1	578.142	O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	XFZJEEAOWLFHDH-UKWJTHFESA-N	11250133.0		XFZJEEAOWLFHDH
BRD-K72093555-001-01-0	procyanidin-B-2	Phase 2					0	81.99	SantaCruz	sc-228996		578.142	O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	XFZJEEAOWLFHDH-UKWJTHFESA-N	11250133.0		XFZJEEAOWLFHDH
BRD-K01826750-003-15-9	procyclidine	Launched	acetylcholine receptor antagonist		neurology/psychiatry	parkinsonism|Parkinson's Disease|akathisia|dystonia	0	92.08	MedChemEx	HY-B1487	Procyclidine (hydrochloride)	259.168	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |&1:6|	INDBQLZJXZLFIT-NSHDSACASA-N	3044369.0		INDBQLZJXZLFIT
BRD-K92413528-001-06-9	procysteine	Phase 3	glutathione synthase stimulant				0	93.1	Sigma	MFCD00066092	(4R)-2-oxo-1,3-thiazolidine-4-carboxylic acid	146.999	OC(=O)[C@@H]1CSC(=O)N1	BMLMGCPTLHPWPY-REOHCLBHSA-N	72390.0		BMLMGCPTLHPWPY
BRD-A16311756-003-08-5	profenamine	Launched	butyrylcholinesterase inhibitor|cholinergic receptor antagonist	CHRM1	neurology/psychiatry	Parkinson's Disease	0	45.81	MicroSource	1500293	ETHOPROPAZINE HYDROCHLORIDE	312.166	CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|	CDOZDBSBBXSXLB-HNNXBMFYSA-N	667534.0		CDOZDBSBBXSXLB
BRD-A16311756-003-09-3	profenamine	Launched	butyrylcholinesterase inhibitor|cholinergic receptor antagonist	CHRM1	neurology/psychiatry	Parkinson's Disease	0	39.2	Sigma	MFCD00012653	N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine hydrochloride	312.166	CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|	CDOZDBSBBXSXLB-HNNXBMFYSA-N	667534.0		CDOZDBSBBXSXLB
BRD-K68408467-065-01-8	proflavine-hemisulfate	Phase 2	topical anesthetic	F2			0	87.04	MicroSource	1504305	PROFLAVINE HEMISULFATE	209.095	Nc1ccc2cc3ccc(N)cc3nc2c1	WDVSHHCDHLJJJR-UHFFFAOYSA-N	7099.0		WDVSHHCDHLJJJR
BRD-K68408467-065-02-9	proflavine-hemisulfate	Phase 2	topical anesthetic	F2			0	72.27	MedChemEx	HY-B0883	Proflavine (hemisulfate)	209.095	Nc1ccc2cc3ccc(N)cc3nc2c1	WDVSHHCDHLJJJR-UHFFFAOYSA-N	7099.0		WDVSHHCDHLJJJR
BRD-K64994968-001-32-5	progesterone	Launched	progesterone receptor agonist	CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ESR1|NR3C2|OPRK1|PGR|TRPC5	obstetrics/gynecology|endocrinology	infertility|amenorrhea	0	97.71	MicroSource	1500508	PROGESTERONE	314.225	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|	RJKFOVLPORLFTN-LEKSSAKUSA-N	5994.0	BRD-A67479912-001-03-4	RJKFOVLPORLFTN
BRD-K64994968-001-33-3	progesterone	Launched	progesterone receptor agonist	CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ESR1|NR3C2|OPRK1|PGR|TRPC5	obstetrics/gynecology|endocrinology	infertility|amenorrhea	0	90.93	Selleck	S1705	Progesterone	314.225	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|	RJKFOVLPORLFTN-LEKSSAKUSA-N	5994.0	BRD-K37762555-001-01-4	RJKFOVLPORLFTN
BRD-A19458515-001-01-2	proglumetacin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	0.0	AKSci	H841		843.397	CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9,r|	PTXGHCGBYMQQIG-RRHRGVEJSA-N	76965948.0		PTXGHCGBYMQQIG
BRD-K01826553-236-10-9	proglumide	Withdrawn	CCK receptor antagonist	CCKAR|CCKBR			0	94.44	Tocris	1478	Proglumide sodium salt	334.189	CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|	DGMKFQYCZXERLX-OAHLLOKOSA-N	6603906.0		DGMKFQYCZXERLX
BRD-K28183345-003-11-4	proguanil	Launched	dihydrofolate reductase inhibitor	DHFR	infectious disease	malaria	0	92.08	MicroSource	1504211	CHLOROGUANIDE HYDROCHLORIDE	253.109	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1	SSOLNOMRVKKSON-UHFFFAOYSA-N	6178111.0		SSOLNOMRVKKSON
BRD-A09911125-001-01-4	prolylleucylglycinamide	Phase 2	melanocyte-stimulating hormone release inhibitor				0	32.9	Pharmeks	PHAR208436	N-(1-{[(2-amino-2-oxoethyl)amino]carbonyl}-3-methylbutyl)-2-pyrrolidinecarboxamide	284.185	CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O |&1:4,&2:8,r|	NOOJLZTTWSNHOX-NXEZZACHSA-N	51387302.0		NOOJLZTTWSNHOX
BRD-K06980535-003-26-7	promazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|HRH1|HTR2A|HTR2C	neurology/psychiatry	schizophrenia	0	94.85	MedChemEx	HY-B1225	Promazine (hydrochloride)	284.135	CN(C)CCCN1c2ccccc2Sc2ccccc12	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	4926.0		ZGUGWUXLJSTTMA
BRD-K06980535-003-25-9	promazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|HRH1|HTR2A|HTR2C	neurology/psychiatry	schizophrenia	0	78.48	MicroSource	1500509	PROMAZINE HYDROCHLORIDE	284.135	CN(C)CCCN1c2ccccc2Sc2ccccc12	ZGUGWUXLJSTTMA-UHFFFAOYSA-N	4926.0		ZGUGWUXLJSTTMA
BRD-K75097983-001-01-0	promestriene	Launched	estrogen receptor agonist	ESR1	endocrinology	androgenetic alopecia	0	0.0	Carbosynth	PROMESTRIENE	(17beta)-17-methoxy-3-propoxyestra-1,3,5(10)-triene	328.24	CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC	IUWKNLFTJBHTSD-AANPDWTMSA-N	9883915.0		IUWKNLFTJBHTSD
BRD-A46335897-003-27-8	promethazine	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry|allergy	sedative|allergic rhinitis	0	88.98	MedChemEx	HY-B0781	Promethazine (hydrochloride)	284.135	CC(CN1c2ccccc2Sc2ccccc12)N(C)C	PWWVAXIEGOYWEE-UHFFFAOYSA-N	89044377.0		PWWVAXIEGOYWEE
BRD-A46335897-003-26-0	promethazine	Launched	histamine receptor antagonist	HRH1	neurology/psychiatry|allergy	sedative|allergic rhinitis	0	63.89	MicroSource	1500510	PROMETHAZINE HYDROCHLORIDE	284.135	CC(CN1c2ccccc2Sc2ccccc12)N(C)C	PWWVAXIEGOYWEE-UHFFFAOYSA-N	89044377.0		PWWVAXIEGOYWEE
BRD-K01825804-003-02-9	pronethalol	Withdrawn	adrenergic receptor antagonist				0	97.29	Tocris	829	Pronethalol hydrochloride	229.147	CC(C)NC[C@@H](O)c1ccc2ccccc2c1 |&1:5,r|	HRSANNODOVBCST-OAHLLOKOSA-N	25271722.0		HRSANNODOVBCST
BRD-K54496168-003-01-2	propacetamol	Launched	cyclooxygenase inhibitor	PTGS2	endocrinology|neurology/psychiatry	fever|pain relief	0	94.37	AKSci	K088		264.147	CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1	QTGAJCQTLIRCFL-UHFFFAOYSA-N	68865.0		QTGAJCQTLIRCFL
BRD-K01826541-003-08-9	propafenone	Launched	antiarrhythmic	ADRB1|ADRB2|KCNA5|KCNH2	cardiology	atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias	0	96.8	MedChemEx	HY-B0432A	Propafenone (hydrochloride)	341.199	CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|	JWHAUXFOSRPERK-GOSISDBHSA-N	184819.0		JWHAUXFOSRPERK
BRD-K01826541-001-06-9	propafenone	Launched	antiarrhythmic	ADRB1|ADRB2|KCNA5|KCNH2	cardiology	atrial fibrillation (AF)|ventricular tachycardia (VT)|ventricular arrhythmias	0	96.58	Selleck	S2500	Propafenone HCl	341.199	CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5,r|	JWHAUXFOSRPERK-GOSISDBHSA-N	184819.0		JWHAUXFOSRPERK
BRD-K53382462-001-02-0	propagermanium	Launched	CCR agonist|interferon receptor agonist	CCR2	infectious disease	hepatitis B	1	0.0	Sigma	MFCD00049319	3,3'-(1,3-dioxodigermoxane-1,3-diyl)dipropionic acid	341.885	OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O	XEABSBMNTNXEJM-UHFFFAOYSA-N	83030.0		XEABSBMNTNXEJM
BRD-K90885812-004-25-9	propantheline	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4	gastroenterology	peptic ulcer disease (PUD)	0	94.6	MedChemEx	HY-B1188	Propantheline (bromide)	368.223	CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C	VVWYOYDLCMFIEM-UHFFFAOYSA-N	4934.0		VVWYOYDLCMFIEM
BRD-K90885812-004-24-2	propantheline	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4	gastroenterology	peptic ulcer disease (PUD)	0	80.23	MicroSource	1500511	PROPANTHELINE BROMIDE	368.223	CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C	VVWYOYDLCMFIEM-UHFFFAOYSA-N	4934.0		VVWYOYDLCMFIEM
BRD-K56276053-001-01-8	propatylnitrate	Launched			cardiology	angina pectoris	0	0.0	Sigma	MFCD00137315	2-ethyl-2-((nitrooxy)methyl)propane-1,3-diyl dinitrate	269.05	CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O	YZZCJYJBCUJISI-UHFFFAOYSA-N	66261.0		YZZCJYJBCUJISI
BRD-K59273480-001-10-6	propentofylline	Launched	adenosine reuptake inhibitor|phosphodiesterase inhibitor	PDE1A	neurology/psychiatry	stroke	0	95.57	Enzo	AC648	Propentofylline	306.169	CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12	RBQOQRRFDPXAGN-UHFFFAOYSA-N	4938.0		RBQOQRRFDPXAGN
BRD-K59273480-001-11-9	propentofylline	Launched	adenosine reuptake inhibitor|phosphodiesterase inhibitor	PDE1A	neurology/psychiatry	stroke	0	90.49	Sigma	MFCD00133785	Propentofylline	306.169	CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12	RBQOQRRFDPXAGN-UHFFFAOYSA-N	4938.0		RBQOQRRFDPXAGN
BRD-K14821965-302-06-9	propidium-iodide	Preclinical		ACHE			0	94.88	Tocris	5135	Propidium iodide	414.278	CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	ZDWVWKDAWBGPDN-UHFFFAOYSA-O	4939.0		ZDWVWKDAWBGPDN
BRD-K14821965-302-05-2	propidium-iodide	Preclinical		ACHE			0	37.12	Prestwick	Prestw-792	Propidium iodide	414.278	CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	ZDWVWKDAWBGPDN-UHFFFAOYSA-O	4939.0		ZDWVWKDAWBGPDN
BRD-K76867903-001-03-8	propiolactone	Launched			infectious disease	antiseptic	0	1.17	MicroSource	1503234	PROPIOLACTONE	72.021	O=C1CCO1	VEZXCJBBBCKRPI-UHFFFAOYSA-N	2365.0		VEZXCJBBBCKRPI
BRD-K76867903-001-04-9	propiolactone	Launched			infectious disease	antiseptic	0	20.0	Sigma	P5648	beta-Propiolactone	72.021	O=C1CCO1	VEZXCJBBBCKRPI-UHFFFAOYSA-N	2365.0		VEZXCJBBBCKRPI
BRD-K91244729-003-01-3	propiverine	Launched	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence	0	97.84	Sigma	MFCD01672343	1-methyl-4-piperidinyl diphenyl(propoxy)acetate hydrochloride	367.215	CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1	QPCVHQBVMYCJOM-UHFFFAOYSA-N	4942.0		QPCVHQBVMYCJOM
BRD-K82255054-001-15-9	propofol	Launched	benzodiazepine receptor agonist	FAAH|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|SCN2A|SCN4A	neurology/psychiatry	anesthetic	0	76.91	MicroSource	1505022	PROPOFOL	178.136	CC(C)c1cccc(C(C)C)c1O	OLBCVFGFOZPWHH-UHFFFAOYSA-N	4943.0		OLBCVFGFOZPWHH
BRD-K82255054-001-17-5	propofol	Launched	benzodiazepine receptor agonist	FAAH|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|SCN2A|SCN4A	neurology/psychiatry	anesthetic	0	0.0	Enamine	Z1245735300	2,6-diisopropylphenol	178.136	CC(C)c1cccc(C(C)C)c1O	OLBCVFGFOZPWHH-UHFFFAOYSA-N	4943.0		OLBCVFGFOZPWHH
BRD-K08231299-001-09-9	propoxur	Launched			infectious disease	flea control	0	49.59	MedChemEx	HY-B0916	Propoxur	209.105	CNC(=O)Oc1ccccc1OC(C)C	ISRUGXGCCGIOQO-UHFFFAOYSA-N	4944.0		ISRUGXGCCGIOQO
BRD-K08231299-001-08-1	propoxur	Launched			infectious disease	flea control	0	93.11	MicroSource	330066	PROPOXUR	209.105	CNC(=O)Oc1ccccc1OC(C)C	ISRUGXGCCGIOQO-UHFFFAOYSA-N	4944.0		ISRUGXGCCGIOQO
BRD-K18250272-003-12-9	propoxycaine	Launched	local anesthetic		neurology/psychiatry	anesthetic	0	97.65	MedChemEx	HY-B1243	Propoxycaine (hydrochloride)	294.194	CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	CAJIGINSTLKQMM-UHFFFAOYSA-N	6843.0		CAJIGINSTLKQMM
BRD-K18250272-003-11-0	propoxycaine	Launched	local anesthetic		neurology/psychiatry	anesthetic	0	98.96	MicroSource	1505572	PROPOXYCAINE HYDROCHLORIDE	294.194	CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	CAJIGINSTLKQMM-UHFFFAOYSA-N	6843.0		CAJIGINSTLKQMM
BRD-A10070317-003-30-9	propranolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	cardiology|neurology/psychiatry	hypertension|angina pectoris|migraine headache	0	96.64	MicroSource	1505270	PROPRANOLOL HYDROCHLORIDE (+/-)	259.157	CC(C)NCC(O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-UHFFFAOYSA-N	62882.0		AQHHHDLHHXJYJD
BRD-A10070317-003-28-3	propranolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	cardiology|neurology/psychiatry	hypertension|angina pectoris|migraine headache	0	97.75	Selleck	S4076	Propranolol HCl	259.157	CC(C)NCC(O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-UHFFFAOYSA-N	62882.0		AQHHHDLHHXJYJD
BRD-A10070317-003-29-1	propranolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	cardiology|neurology/psychiatry	hypertension|angina pectoris|migraine headache	0	97.42	Tocris	624	Propranolol hydrochloride	259.157	CC(C)NCC(O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-UHFFFAOYSA-N	62882.0		AQHHHDLHHXJYJD
BRD-K92830582-003-11-9	propranolol-(R)	Preclinical	adrenergic receptor antagonist	ADRB2|ADRB3			0	97.86	Tocris	835	(R)-(+)-Propranolol hydrochloride	259.157	CC(C)NC[C@@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-CQSZACIVSA-N	21138.0		AQHHHDLHHXJYJD
BRD-K92830582-003-10-5	propranolol-(R)	Preclinical	adrenergic receptor antagonist	ADRB2|ADRB3			0	98.07	Tocris	835	(R)-(+)-Propranolol hydrochloride	259.157	CC(C)NC[C@@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-CQSZACIVSA-N	21138.0		AQHHHDLHHXJYJD
BRD-K13994703-003-17-9	propranolol-(S)	Preclinical	adrenergic receptor antagonist	ADRB1|HTR1A|HTR5A|SLC10A1			0	97.47	Tocris	834	(S)-(-)-Propranolol hydrochloride	259.157	CC(C)NC[C@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-AWEZNQCLSA-N	91536.0		AQHHHDLHHXJYJD
BRD-K13994703-003-15-8	propranolol-(S)	Preclinical	adrenergic receptor antagonist	ADRB1|HTR1A|HTR5A|SLC10A1			0	97.96	Tocris	834	(S)-(-)-Propranolol hydrochloride	259.157	CC(C)NC[C@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-AWEZNQCLSA-N	91536.0		AQHHHDLHHXJYJD
BRD-K13994703-003-16-6	propranolol-(S)	Preclinical	adrenergic receptor antagonist	ADRB1|HTR1A|HTR5A|SLC10A1			0	97.21	MicroSource	1500514	DEXPROPRANOLOL HYDROCHLORIDE	259.157	CC(C)NC[C@H](O)COc1cccc2ccccc12	AQHHHDLHHXJYJD-AWEZNQCLSA-N	91536.0		AQHHHDLHHXJYJD
BRD-K15329706-001-01-6	propyl-benzoate	Launched					0	0.0	Enamine	Z53835171		164.084	CCCOC(=O)c1ccccc1	UDEWPOVQBGFNGE-UHFFFAOYSA-N	16846.0		UDEWPOVQBGFNGE
BRD-K15329706-001-02-9	propyl-benzoate	Launched					0	9.32	Sigma	307009	Propyl benzoate	164.084	CCCOC(=O)c1ccccc1	UDEWPOVQBGFNGE-UHFFFAOYSA-N	16846.0		UDEWPOVQBGFNGE
BRD-A19232309-001-08-6	propylene-glycol	Launched					1	0.0	Sigma	V003356	propylene glycol	76.052	C[C@@H](O)CO |&1:1,r|	DNIAPMSPPWPWGF-GSVOUGTGSA-N	259994.0		DNIAPMSPPWPWGF
BRD-K01825844-001-01-9	propylhexedrine	Launched	adrenergic receptor agonist		otolaryngology|endocrinology|allergy	nasal congestion|fever|allergic rhinitis	0	76.33	PrincetonBio	OSSL_312908	1-cyclohexyl-N-methyl-2-propanamine	155.167	CN[C@@H](C)CC1CCCCC1 |&1:2,r|	JCRIVQIOJSSCQD-VIFPVBQESA-N	71197.0		JCRIVQIOJSSCQD
BRD-K60783397-001-12-9	propylparaben	Launched					0	96.88	MedChemEx	HY-N2026	Propylparaben	180.079	CCCOC(=O)c1ccc(O)cc1	QELSKZZBTMNZEB-UHFFFAOYSA-N	7175.0		QELSKZZBTMNZEB
BRD-K60783397-001-09-5	propylparaben	Launched					0	0.0	ChemDiv	0099-0143		180.079	CCCOC(=O)c1ccc(O)cc1	QELSKZZBTMNZEB-UHFFFAOYSA-N	7175.0		QELSKZZBTMNZEB
BRD-K48168960-001-19-2	propylthiouracil	Launched	thyroid peroxidase inhibitor	DIO1|TPO	endocrinology	hyperthyroidism|Grave's disease|goiter	0	97.48	MicroSource	1500515	PROPYLTHIOURACIL	170.051	CCCc1cc(=O)[nH]c(=S)[nH]1	KNAHARQHSZJURB-UHFFFAOYSA-N	657298.0		KNAHARQHSZJURB
BRD-K48168960-001-18-4	propylthiouracil	Launched	thyroid peroxidase inhibitor	DIO1|TPO	endocrinology	hyperthyroidism|Grave's disease|goiter	0	95.14	Selleck	S1988	Propylthiouracil	170.051	CCCc1cc(=O)[nH]c(=S)[nH]1	KNAHARQHSZJURB-UHFFFAOYSA-N	657298.0		KNAHARQHSZJURB
BRD-K06520168-001-03-9	propyphenazone	Preclinical	anti-inflammatory agent				0	89.98	MedChemEx	HY-A0273	Propyphenazone	230.142	CC(C)c1c(C)n(C)n(-c2ccccc2)c1=O	PXWLVJLKJGVOKE-UHFFFAOYSA-N	3778.0		PXWLVJLKJGVOKE
BRD-K54339150-001-01-8	proquazone	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	neurology/psychiatry	pain relief	0	97.0	AMS	A001576823	1-isopropyl-7-methyl-4-phenyl-2(1H)-quinazolinone	278.142	CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1	JTIGKVIOEQASGT-UHFFFAOYSA-N	31508.0		JTIGKVIOEQASGT
BRD-K00005354-001-01-9	proscillaridin-A	Launched			cardiology	congestive heart failure|cardiac arrythmia	0	92.93	Toronto	P838495	proscillaridin A	530.288	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|	MYEJFUXQJGHEQK-ALRJYLEOSA-N	5284613.0		MYEJFUXQJGHEQK
BRD-K97863768-001-06-9	protionamide	Launched			infectious disease	tuberculosis	0	94.39	MicroSource	1505316	PROTIONAMIDE	180.072	CCCc1cc(ccn1)C(N)=S	VRDIULHPQTYCLN-UHFFFAOYSA-N	666418.0		VRDIULHPQTYCLN
BRD-K97863768-001-24-9	protionamide	Launched			infectious disease	tuberculosis	0	92.68	MedChemEx	HY-B0306	Prothionamide	180.072	CCCc1cc(ccn1)C(N)=S	VRDIULHPQTYCLN-UHFFFAOYSA-N	666418.0		VRDIULHPQTYCLN
BRD-K97863768-001-07-9	protionamide	Launched			infectious disease	tuberculosis	0	94.29	Selleck	S1881	Protionamide	180.072	CCCc1cc(ccn1)C(N)=S	VRDIULHPQTYCLN-UHFFFAOYSA-N	666418.0		VRDIULHPQTYCLN
BRD-K00003716-015-01-9	protirelin	Launched	thyrotropin releasing hormone receptor agonist	TRHR	radiology	thyroid function diagnostic	0	92.56	MedChemEx	HY-P0002A	Protirelin (Acetate)	362.17	NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	XNSAINXGIQZQOO-SRVKXCTJSA-N	638678.0		XNSAINXGIQZQOO
BRD-K26813314-001-12-9	protoporphyrin-IX	Preclinical	heme oxygenase inhibitor	HMOX1			0	62.13	MedChemEx	HY-B1247	Protoporphyrin IX	562.258	Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C	HGXFBVDWWKPUKZ-UJJXFSCMSA-N			HGXFBVDWWKPUKZ
BRD-K26813314-001-08-5	protoporphyrin-IX	Preclinical	heme oxygenase inhibitor	HMOX1			0	18.86	MicroSource	1501111	PROTOPORPHYRIN IX	562.258	Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C	HGXFBVDWWKPUKZ-UJJXFSCMSA-N			HGXFBVDWWKPUKZ
BRD-K42098891-003-21-9	protriptyline	Launched	tricyclic antidepressant	SLC6A2|SLC6A4	neurology/psychiatry	depression	0	98.39	MedChemEx	HY-B0949	Protriptyline (hydrochloride)	263.167	CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|	BWPIARFWQZKAIA-UHFFFAOYSA-N	4976.0		BWPIARFWQZKAIA
BRD-K42098891-003-20-5	protriptyline	Launched	tricyclic antidepressant	SLC6A2|SLC6A4	neurology/psychiatry	depression	0	97.0	MicroSource	1505984	PROTRYPTYLINE HYDROCHLORIDE	263.167	CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|	BWPIARFWQZKAIA-UHFFFAOYSA-N	4976.0		BWPIARFWQZKAIA
BRD-A29944538-003-09-9	proxodolol	Launched	adrenergic receptor antagonist				0	92.24	Vitas-M	STL336260	1-(tert-butylamino)-3-{2-[(3-methyl-1,2,4-oxadiazol-5-yl)methoxy]phenoxy}-2-propanol	335.185	Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|	CEDZURSVVKNCSL-ZDUSSCGKSA-N	940099.0		CEDZURSVVKNCSL
BRD-A29944538-003-08-3	proxodolol	Launched	adrenergic receptor antagonist				0	97.24	InterBioScreen	STOCK3S-35298		335.185	Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|	CEDZURSVVKNCSL-ZDUSSCGKSA-N	940099.0		CEDZURSVVKNCSL
BRD-K77171813-034-02-6	proxyfan	Preclinical	histamine receptor modulator	HRH3			0	92.55	Tocris	2477	Proxyfan oxalate	216.126	C(COCc1ccccc1)Cc1cnc[nH]1	WNWALBVQAAIULR-UHFFFAOYSA-N	6421522.0		WNWALBVQAAIULR
BRD-K77171813-034-01-8	proxyfan	Preclinical	histamine receptor modulator	HRH3			0	97.13	Tocris	2477	Proxyfan maleate	216.126	C(COCc1ccccc1)Cc1cnc[nH]1	WNWALBVQAAIULR-UHFFFAOYSA-N	6421522.0		WNWALBVQAAIULR
BRD-K77171813-034-03-9	proxyfan	Preclinical	histamine receptor modulator	HRH3			0	88.87	Tocris	2477	Proxyfan oxalate	216.126	C(COCc1ccccc1)Cc1cnc[nH]1	WNWALBVQAAIULR-UHFFFAOYSA-N	6421522.0		WNWALBVQAAIULR
BRD-K79116891-003-15-1	proxymetacaine	Launched	sodium channel blocker	SCN10A|SCN5A	neurology/psychiatry	anesthetic	0	97.7	MicroSource	1505688	PROPARACAINE HYDROCHLORIDE	294.194	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	KCLANYCVBBTKTO-UHFFFAOYSA-N	4935.0		KCLANYCVBBTKTO
BRD-K79116891-003-16-9	proxymetacaine	Launched	sodium channel blocker	SCN10A|SCN5A	neurology/psychiatry	anesthetic	0	97.08	MedChemEx	HY-66012	Proparacaine (Hydrochloride)	294.194	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	KCLANYCVBBTKTO-UHFFFAOYSA-N	4935.0		KCLANYCVBBTKTO
BRD-K79116891-003-14-4	proxymetacaine	Launched	sodium channel blocker	SCN10A|SCN5A	neurology/psychiatry	anesthetic	0	96.84	Selleck	S1828	Proparacaine HCl	294.194	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	KCLANYCVBBTKTO-UHFFFAOYSA-N	4935.0		KCLANYCVBBTKTO
BRD-A28887267-001-19-3	Proxyphylline	Launched			pulmonary	asthma	0	97.93	MicroSource	1505915	PROXYPHYLLINE	238.107	C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|	KYHQZNGJUGFTGR-ZCFIWIBFSA-N	158962.0		KYHQZNGJUGFTGR
BRD-A28887267-001-20-9	Proxyphylline	Launched			pulmonary	asthma	0	97.97	MedChemEx	HY-B1742	Proxyphylline	238.107	C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1,r|	KYHQZNGJUGFTGR-ZCFIWIBFSA-N	158962.0		KYHQZNGJUGFTGR
BRD-K25835157-001-02-2	PRT062070	Phase 2/Phase 3	JAK inhibitor|SYK inhibitor	SYK			0	87.94	MedChemEx	HY-15999	Cerdulatinib	445.19	CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	BGLPECHZZQDNCD-UHFFFAOYSA-N	44595079.0		BGLPECHZZQDNCD
BRD-K25835157-001-04-8	PRT062070	Phase 2/Phase 3	JAK inhibitor|SYK inhibitor	SYK			0	89.15	MedChemEx	HY-15999	Cerdulatinib	445.19	CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	BGLPECHZZQDNCD-UHFFFAOYSA-N	44595079.0		BGLPECHZZQDNCD
BRD-K25835157-001-01-4	PRT062070	Phase 2/Phase 3	JAK inhibitor|SYK inhibitor	SYK			0	82.33	MedChemEx	HY-15999	Cerdulatinib	445.19	CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	BGLPECHZZQDNCD-UHFFFAOYSA-N	44595079.0		BGLPECHZZQDNCD
BRD-K53734668-003-04-6	PRT062607	Phase 2	SYK inhibitor	FGR|MAP3K9|SYK			0	89.36	Selleck	S8032	PRT062607 (P505-15, BIIB057) HCl	393.203	N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	TXGKRVFSSHPBAJ-JKSUJKDBSA-N	44462758.0	BRD-K98804570-003-01-7	TXGKRVFSSHPBAJ
BRD-K53734668-003-02-0	PRT062607	Phase 2	SYK inhibitor	FGR|MAP3K9|SYK			0	94.89	Selleck	S8032	PRT062607 (P505-15, PRT2607, BIIB057) HCl	393.203	N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	TXGKRVFSSHPBAJ-JKSUJKDBSA-N	44462758.0		TXGKRVFSSHPBAJ
BRD-K53734668-003-01-2	PRT062607	Phase 2	SYK inhibitor	FGR|MAP3K9|SYK			0		Selleck	S8032	PRT062607 (P505-15, PRT2607, BIIB057) HCl	393.203	N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1	44462758.0		TXGKRVFSSHPBAJ
BRD-K32456483-001-02-3	PRT4165	Preclinical	polycomb repressive complex inhibitor	PRC1			0	61.66	MedChemEx	HY-19817	PRT4165	235.063	O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	OMHZFEWYVFWVLI-UHFFFAOYSA-N	207893.0		OMHZFEWYVFWVLI
BRD-K32456483-001-04-9	PRT4165	Preclinical	polycomb repressive complex inhibitor	PRC1			0	62.32	MedChemEx	HY-19817	PRT4165	235.063	O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	OMHZFEWYVFWVLI-UHFFFAOYSA-N	207893.0		OMHZFEWYVFWVLI
BRD-K32456483-001-03-1	PRT4165	Preclinical	polycomb repressive complex inhibitor	PRC1			0	43.25	Tocris	5047	PRT 4165	235.063	O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	OMHZFEWYVFWVLI-UHFFFAOYSA-N	207893.0		OMHZFEWYVFWVLI
BRD-K33681278-001-03-9	prucalopride	Launched	serotonin receptor agonist	HTR4	gastroenterology	constipation	0	98.37	MedChemEx	HY-14151	Prucalopride	367.166	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	ZPMNHBXQOOVQJL-UHFFFAOYSA-N	3052762.0		ZPMNHBXQOOVQJL
BRD-K33681278-036-01-2	prucalopride	Launched	serotonin receptor agonist	HTR4	gastroenterology	constipation	0	97.6	Selleck	S4247	Prucalopride Succinat	367.166	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	ZPMNHBXQOOVQJL-UHFFFAOYSA-N	3052762.0		ZPMNHBXQOOVQJL
BRD-K33681278-001-02-4	prucalopride	Launched	serotonin receptor agonist	HTR4	gastroenterology	constipation	0	97.46	Selleck	S2875	Prucalopride	367.166	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	ZPMNHBXQOOVQJL-UHFFFAOYSA-N	3052762.0		ZPMNHBXQOOVQJL
BRD-A92341659-001-03-2	prulifloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease|pulmonary|gastroenterology	urinary tract infections|bronchitis|diarrhea	0	0.0	MicroSource	1502328	PRULIFLOXACIN	461.106	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|	PWNMXPDKBYZCOO-LLVKDONJSA-N	6556267.0	BRD-A96891111-001-01-8	PWNMXPDKBYZCOO
BRD-A92341659-001-04-0	prulifloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease|pulmonary|gastroenterology	urinary tract infections|bronchitis|diarrhea	0	79.74	MedChemEx	HY-B0024	Prulifloxacin	461.106	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1,r|	PWNMXPDKBYZCOO-LLVKDONJSA-N	6556267.0		PWNMXPDKBYZCOO
BRD-K43837174-003-02-1	pruvanserin	Phase 2	serotonin receptor antagonist	HTR2A|HTR2C			0	98.28	Tocris	4470	EMD 281014 hydrochloride	376.17	Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	AQRLDDAFYYAIJP-UHFFFAOYSA-N	6433122.0		AQRLDDAFYYAIJP
BRD-K43837174-003-01-3	pruvanserin	Phase 2	serotonin receptor antagonist	HTR2A|HTR2C			0	98.48	Sigma	MFCD08056253	7-(4-(4-fluorophenethyl)piperazine-1-carbonyl)-1H-indole-3-carbonitrile hydrochloride	376.17	Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	AQRLDDAFYYAIJP-UHFFFAOYSA-N	6433122.0		AQRLDDAFYYAIJP
BRD-K00004616-001-01-9	PRX-07034	Phase 1	serotonin receptor antagonist				0	86.32	ChemDiv	H025-0367C	N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-N-[2-(methylsulfonyl)-5-piperazinophenyl]amine	453.149	COc1cc(Cl)cc([C@H](C)Nc2cc(ccc2S(C)(=O)=O)N2CCNCC2)c1OC |&1:8,r|	BSLXKMCHXRCBIH-AWEZNQCLSA-N	67147340.0		BSLXKMCHXRCBIH
BRD-K16757695-050-02-5	PRX-08066	Phase 2	serotonin receptor antagonist	HTR2B			0	97.22	Selleck	S8010	PRX-08066 Maleic acid	401.088	Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	IENZFHBNCRQMNP-UHFFFAOYSA-N	11502243.0		IENZFHBNCRQMNP
BRD-K16757695-001-03-9	PRX-08066	Phase 2	serotonin receptor antagonist	HTR2B			0	95.68	MedChemEx	HY-15472	PRX-08066	401.088	Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	IENZFHBNCRQMNP-UHFFFAOYSA-N	11502243.0		IENZFHBNCRQMNP
BRD-K71266197-236-02-7	PSB-06126	Preclinical	NTPDase inhibitor	ENTPD3			0	97.74	Tocris	2574	PSB 06126	444.078	Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	ZHQRPIRGSWEALJ-UHFFFAOYSA-N	25124826.0		ZHQRPIRGSWEALJ
BRD-K71266197-236-03-9	PSB-06126	Preclinical	NTPDase inhibitor	ENTPD3			0	95.53	Tocris	2574	PSB 06126	444.078	Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	ZHQRPIRGSWEALJ-UHFFFAOYSA-N	25124826.0		ZHQRPIRGSWEALJ
BRD-K10177585-003-03-2	PSB-11	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA3			0	97.61	Tocris	2012	PSB 11 hydrochloride	295.143	CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|	RGDHRCXUMURWBJ-LLVKDONJSA-N			RGDHRCXUMURWBJ
BRD-K10177585-003-04-9	PSB-11	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA3			0	90.98	Tocris	2012	PSB 11 hydrochloride	295.143	CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|	RGDHRCXUMURWBJ-LLVKDONJSA-N			RGDHRCXUMURWBJ
BRD-K10177585-003-02-4	PSB-11	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA3			0	96.39	Tocris	2012	PSB 11 hydrochloride	295.143	CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|	RGDHRCXUMURWBJ-LLVKDONJSA-N			RGDHRCXUMURWBJ
BRD-K49027941-001-02-9	PSB-1115	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2B|ADORA3			0	90.87	Tocris	2009	PSB 1115	350.068	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	UYDRRQPGDSIMNU-UHFFFAOYSA-N	5311479.0		UYDRRQPGDSIMNU
BRD-K49027941-001-03-9	PSB-1115	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2B|ADORA3			0	97.08	Tocris	2009	PSB 1115	350.068	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	UYDRRQPGDSIMNU-UHFFFAOYSA-N	5311479.0		UYDRRQPGDSIMNU
BRD-K49027941-001-01-1	PSB-1115	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2B|ADORA3			0	96.91	Tocris	2009	PSB 1115	350.068	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	UYDRRQPGDSIMNU-UHFFFAOYSA-N	5311479.0		UYDRRQPGDSIMNU
BRD-K00004243-001-01-9	PSB-36	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	96.07	Tocris	2019	PSB 36	386.232	[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r,THB:9:1:4:7.8|	CIBIXJYFYPFMTN-FZUGUKJMSA-N			CIBIXJYFYPFMTN
BRD-K05419687-001-01-0	PSB-603	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	98.46	Tocris	3198	PSB 603	528.135	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1	OVHCTHHFOHMNFV-UHFFFAOYSA-N	44185871.0		OVHCTHHFOHMNFV
BRD-K05419687-001-02-9	PSB-603	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	96.79	Tocris	3198	PSB 603	528.135	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1	OVHCTHHFOHMNFV-UHFFFAOYSA-N	44185871.0		OVHCTHHFOHMNFV
BRD-K07798980-001-02-9	PSI-6130	Phase 1	RNA polymerase inhibitor				0	100.0	MedChemEx	HY-10165	PSI-6130	259.097	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	NYPIRLYMDJMKGW-VPCXQMTMSA-N	6481236.0		NYPIRLYMDJMKGW
BRD-K07798980-001-01-9	PSI-6130	Phase 1	RNA polymerase inhibitor				0	100.0	MedChemEx	HY-10165	PSI-6130	259.097	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	NYPIRLYMDJMKGW-VPCXQMTMSA-N	6481236.0		NYPIRLYMDJMKGW
BRD-K00003192-001-01-9	PSI-697	Phase 1	P selectin inhibitor				0	92.55	MedChemEx	HY-15526	PSI-697	367.098	OC(=O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3CCCCc3ccc12	DIEPFYNZGUUVHD-UHFFFAOYSA-N	12004316.0		DIEPFYNZGUUVHD
BRD-K05674516-001-01-7	PSI-7976	Preclinical	HCV inhibitor				0	98.58	MedChemEx	HY-15005A	PSI-7976	529.163	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-YBSJRAAASA-N	45375809.0		TTZHDVOVKQGIBA
BRD-K05674516-001-02-5	PSI-7976	Preclinical	HCV inhibitor				0	98.52	MedChemEx	HY-15005	PSI-7977	529.163	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-YBSJRAAASA-N	45375809.0		TTZHDVOVKQGIBA
BRD-K05674516-001-03-9	PSI-7976	Preclinical	HCV inhibitor				0	94.97	MedChemEx	HY-15005A	PSI-7976	529.163	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-YBSJRAAASA-N	45375809.0		TTZHDVOVKQGIBA
BRD-K25524093-003-02-5	PSN-375963	Preclinical	glucose dependent insulinotropic receptor agonist	GPR119			0	60.28	Tocris	3353	PSN 375963 hydrochloride	285.184	CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	OAVLEYPTWABFLF-UHFFFAOYSA-N	2875918.0		OAVLEYPTWABFLF
BRD-K25524093-003-01-7	PSN-375963	Preclinical	glucose dependent insulinotropic receptor agonist	GPR119			0	65.92	Tocris	3353	PSN 375963 hydrochloride	285.184	CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	OAVLEYPTWABFLF-UHFFFAOYSA-N	2875918.0		OAVLEYPTWABFLF
BRD-K25524093-003-03-9	PSN-375963	Preclinical	glucose dependent insulinotropic receptor agonist	GPR119			0	66.55	Tocris	3353	PSN 375963 hydrochloride	285.184	CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	OAVLEYPTWABFLF-UHFFFAOYSA-N	2875918.0		OAVLEYPTWABFLF
BRD-K33502629-001-01-0	PSNCBAM-1	Preclinical	cannabinoid receptor modulator	CNR1			0	88.92	Tocris	5321	PSNCBAM-1	392.14	Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1	HDAYFSFWIPRJSO-UHFFFAOYSA-N	11560249.0		HDAYFSFWIPRJSO
BRD-K33502629-001-02-9	PSNCBAM-1	Preclinical	cannabinoid receptor modulator	CNR1			0	96.73	Tocris	5321	PSNCBAM-1	392.14	Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1	HDAYFSFWIPRJSO-UHFFFAOYSA-N	11560249.0		HDAYFSFWIPRJSO
BRD-K47264279-001-08-9	psoralen	Launched		MAOA|MAOB	dermatology	psoriasis|eczema|vitiligo	0	91.19	Specs	AA-504/20833002		186.032	O=c1ccc2cc3ccoc3cc2o1	ZCCUUQDIBDJBTK-UHFFFAOYSA-N	6199.0		ZCCUUQDIBDJBTK
BRD-K99092662-001-02-9	PS178990	Phase 1	androgen receptor modulator	AR			0	96.24	Tocris	5274	BMS 564929	305.057	Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N	KEJORAMIZFOODM-PWSUYJOCSA-N	9882972.0		KEJORAMIZFOODM
BRD-K99092662-001-01-1	PS178990	Phase 1	androgen receptor modulator	AR			0	98.09	MedChemEx	HY-12111	BMS-564929	305.057	Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N	KEJORAMIZFOODM-PWSUYJOCSA-N	9882972.0		KEJORAMIZFOODM
BRD-K20850787-001-01-6	PT-2385	Phase 1	hypoxia inducible factor inhibitor	EPAS1			0	96.9	MedChemEx	HY-12867	PT-2385	383.044	CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12	ONBSHRSJOPSEGS-INIZCTEOSA-N	91754484.0		ONBSHRSJOPSEGS
BRD-K00010388-001-01-9	PTC-028	Preclinical	BMI-1 inhibitor				0	93.71	MedChemEx	HY-103696	PTC-028	405.101	Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(cc2)C(F)(F)F)n1	JEZGPBWIZWPDHP-UHFFFAOYSA-N	73427235.0		JEZGPBWIZWPDHP
BRD-K83834509-001-01-1	PTC-209	Preclinical	BMI-1 inhibitor				0	78.13	Selleck	S7372	PTC-209	492.921	COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	XVOOCQSWCCRVDY-UHFFFAOYSA-N	1117196.0		XVOOCQSWCCRVDY
BRD-K83834509-001-04-9	PTC-209	Preclinical	BMI-1 inhibitor				0	81.39	MedChemEx	HY-15888	PTC-209	492.921	COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	XVOOCQSWCCRVDY-UHFFFAOYSA-N	1117196.0		XVOOCQSWCCRVDY
BRD-K83834509-001-03-7	PTC-209	Preclinical	BMI-1 inhibitor				0	85.87	MedChemEx	HY-15888	PTC-209	492.921	COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	XVOOCQSWCCRVDY-UHFFFAOYSA-N	1117196.0		XVOOCQSWCCRVDY
BRD-K83834509-001-02-9	PTC-209	Preclinical	BMI-1 inhibitor				0	76.71	Selleck	S7372	PTC-209	492.921	COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	XVOOCQSWCCRVDY-UHFFFAOYSA-N	1117196.0		XVOOCQSWCCRVDY
BRD-K92870997-001-16-9	pterostilbene	Phase 2/Phase 3	cyclooxygenase inhibitor|PPAR receptor agonist	PTGS2			0	98.33	MedChemEx	HY-N0828	Pterostilbene	256.11	COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1	VLEUZFDZJKSGMX-ONEGZZNKSA-N	5281727.0		VLEUZFDZJKSGMX
BRD-K36529613-001-02-6	PU-H71	Phase 1	HSP inhibitor	HSP90AA1			0	95.73	MedChemEx	HY-11038	PU-H71	512.049	CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	SUPVGFZUWFMATN-UHFFFAOYSA-N	9549213.0		SUPVGFZUWFMATN
BRD-K89048337-001-07-9	puerarin	Phase 2	serotonin receptor antagonist				0	95.49	MedChemEx	HY-N0145	Puerarin	416.111	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	HKEAFJYKMMKDOR-VPRICQMDSA-N	5281807.0		HKEAFJYKMMKDOR
BRD-K89048337-001-08-9	puerarin	Phase 2	serotonin receptor antagonist				0	95.93	Vitas-M	STL146384	Kakonein	416.111	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	HKEAFJYKMMKDOR-VPRICQMDSA-N	5281807.0		HKEAFJYKMMKDOR
BRD-K89048337-001-06-9	puerarin	Phase 2	serotonin receptor antagonist				0	97.51	Selleck	S2346	Puerarin	416.111	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	HKEAFJYKMMKDOR-VPRICQMDSA-N	5281807.0	BRD-K85867784-001-02-3	HKEAFJYKMMKDOR
BRD-K44164034-003-01-1	pumosetrag	Phase 2	serotonin receptor agonist	HTR3A|HTR4			0	98.08	Sigma	SML1038	(R)-7-hydroxy-N-(quinuclidin-3-yl)thieno[3,2-b]pyridine-6-carboxamide hydrochloride	303.104	O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O	AFUWQWYPPZFWCO-LBPRGKRZSA-N	154104.0		AFUWQWYPPZFWCO
BRD-K73397362-001-08-2	purmorphamine	Preclinical	smoothened receptor agonist	SMO			0	85.51	Tocris	4551	Purmorphamine	520.259	C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	FYBHCRQFSFYWPY-UHFFFAOYSA-N	5284329.0		FYBHCRQFSFYWPY
BRD-K73397362-001-06-6	purmorphamine	Preclinical	smoothened receptor agonist	SMO			0	90.0	Selleck	S3042	Purmorphamine	520.259	C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	FYBHCRQFSFYWPY-UHFFFAOYSA-N	5284329.0		FYBHCRQFSFYWPY
BRD-K73397362-001-07-4	purmorphamine	Preclinical	smoothened receptor agonist	SMO			0	94.09	Selleck	S3042	Purmorphamine	520.259	C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	FYBHCRQFSFYWPY-UHFFFAOYSA-N	5284329.0		FYBHCRQFSFYWPY
BRD-K36007650-300-09-9	puromycin	Preclinical	protein synthesis inhibitor	NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1			0	96.84	Tocris	4089	Puromycin dihydrochloride	471.223	COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	RXWNCPJZOCPEPQ-NVWDDTSBSA-N	439530.0		RXWNCPJZOCPEPQ
BRD-K50836978-001-04-9	purvalanol-A	Preclinical	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CSNK1G3|RPS6KA1|SRC			0	97.41	Tocris	1580	Purvalanol A	388.178	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	PMXCMJLOPOFPBT-HNNXBMFYSA-N	456214.0		PMXCMJLOPOFPBT
BRD-K50836978-001-03-3	purvalanol-A	Preclinical	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CSNK1G3|RPS6KA1|SRC			0	95.85	Tocris	1580	Purvalanol A	388.178	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	PMXCMJLOPOFPBT-HNNXBMFYSA-N	456214.0		PMXCMJLOPOFPBT
BRD-K50836978-001-02-5	purvalanol-A	Preclinical	CDK inhibitor	CDK1|CDK2|CDK4|CDK5|CSNK1G3|RPS6KA1|SRC			0	97.56	Tocris	1580	Purvalanol A	388.178	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	PMXCMJLOPOFPBT-HNNXBMFYSA-N	456214.0		PMXCMJLOPOFPBT
BRD-K41564320-001-04-9	purvalanol-B	Preclinical	tyrosine kinase inhibitor	CDK2|CDK4|CDK5|MAPK1|MAPK3|SRPK2			0	96.67	Tocris	1581	Purvalanol B	432.168	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	448991.0		ZKDXRFMOHZVXSG
BRD-K41564320-001-03-8	purvalanol-B	Preclinical	tyrosine kinase inhibitor	CDK2|CDK4|CDK5|MAPK1|MAPK3|SRPK2			0	97.41	Tocris	1581	Purvalanol B	432.168	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	448991.0		ZKDXRFMOHZVXSG
BRD-K41564320-001-02-0	purvalanol-B	Preclinical	tyrosine kinase inhibitor	CDK2|CDK4|CDK5|MAPK1|MAPK3|SRPK2			0	97.82	Tocris	1581	Purvalanol B	432.168	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	ZKDXRFMOHZVXSG-HNNXBMFYSA-N	448991.0		ZKDXRFMOHZVXSG
BRD-K75282878-300-05-3	putrescine	Phase 2	tissue transglutaminase inhibitor	AMD1|KCNJ4|ODC1			1	0.0	Sigma	P6024	1,4-butanediamine dihydrochloride	88.1	NCCCCN	KIDHWZJUCRJVML-UHFFFAOYSA-N	1045.0		KIDHWZJUCRJVML
BRD-A56592690-001-04-3	PX-12	Phase 2	thioredoxin inhibitor	CNR1|TXN			0	95.68	MedChemEx	HY-13734	PX-12	188.044	CC[C@@H](C)SSc1ncc[nH]1 |&1:2,r|	BPBPYQWMFCTCNG-ZCFIWIBFSA-N	86308851.0		BPBPYQWMFCTCNG
BRD-A26835809-300-01-3	PX-478	Phase 1	hypoxia inducible factor inhibitor				0	88.15	Selleck	S7612	PX-478 2HCl	320.069	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|	GSKQMLGAUOTSKT-LBPRGKRZSA-N	11234795.0		GSKQMLGAUOTSKT
BRD-K62277907-001-02-9	PYM50028	Phase 2	neurotrophic agent				0	100.0	MedChemEx	HY-N0073	Sarsasapogenin	416.329	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	GMBQZIIUCVWOCD-WWASVFFGSA-N	92095.0		GMBQZIIUCVWOCD
BRD-K62277907-001-01-6	PYM50028	Phase 2	neurotrophic agent				0	100.0	Enzo	NP272	Sarsasapogenin	416.329	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	GMBQZIIUCVWOCD-WWASVFFGSA-N	92095.0		GMBQZIIUCVWOCD
BRD-K66101666-001-01-5	PYR-41	Preclinical	ubiquitin activating enzyme inhibitor				0	0.0	Selleck	S7129	PYR-41	371.075	CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O	ARGIPZKQJGFSGQ-LCYFTJDESA-N	5335621.0		ARGIPZKQJGFSGQ
BRD-K66101666-001-02-3	PYR-41	Preclinical	ubiquitin activating enzyme inhibitor				0	33.17	Selleck	S7129	PYR-41	371.075	CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O	ARGIPZKQJGFSGQ-LCYFTJDESA-N	5335621.0		ARGIPZKQJGFSGQ
BRD-K82118441-001-03-7	pyrantel	Launched	acetylcholine receptor agonist|nicotinic receptor agonist		infectious disease	gastrointestinal roundworms	0	97.74	Sigma	MFCD00004079	4,4'-methylenebis(3-hydroxy-2-naphthoic acid)	388.095	OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O	WLJNZVDCPSBLRP-UHFFFAOYSA-N	8546.0		WLJNZVDCPSBLRP
BRD-K20672254-096-06-7	pyrantel-pamoate	Launched	neuromuscular blocker		infectious disease	hookworm|tapeworm	0	79.2	MedChemEx	HY-12640	Pyrantel (pamoate)	206.088	CN1CCCN=C1\C=C\c1cccs1 |c:5|	YSAUAVHXTIETRK-AATRIKPKSA-N	708857.0		YSAUAVHXTIETRK
BRD-K20672254-046-05-4	pyrantel-pamoate	Launched	neuromuscular blocker		infectious disease	hookworm|tapeworm	0	94.32	MedChemEx	HY-12641	Pyrantel (tartrate)	206.088	CN1CCCN=C1\C=C\c1cccs1 |c:5|	YSAUAVHXTIETRK-AATRIKPKSA-N	708857.0		YSAUAVHXTIETRK
BRD-K20672254-096-05-9	pyrantel-pamoate	Launched	neuromuscular blocker		infectious disease	hookworm|tapeworm	0	19.44	MedChemEx	HY-12640	Pyrantel (pamoate)	206.088	CN1CCCN=C1\C=C\c1cccs1 |c:5|	YSAUAVHXTIETRK-AATRIKPKSA-N	708857.0		YSAUAVHXTIETRK
BRD-K20672254-046-04-7	pyrantel-pamoate	Launched	neuromuscular blocker		infectious disease	hookworm|tapeworm	0	79.67	MedChemEx	HY-12641	Pyrantel (tartrate)	206.088	CN1CCCN=C1\C=C\c1cccs1 |c:5|	YSAUAVHXTIETRK-AATRIKPKSA-N	708857.0		YSAUAVHXTIETRK
BRD-K20672254-046-03-9	pyrantel-pamoate	Launched	neuromuscular blocker		infectious disease	hookworm|tapeworm	0	66.29	Prestwick	Prestw-212	Pyrantel tartrate	206.088	CN1CCCN=C1\C=C\c1cccs1 |c:5|	YSAUAVHXTIETRK-AATRIKPKSA-N	708857.0		YSAUAVHXTIETRK
BRD-K20672254-096-03-4	pyrantel-pamoate	Launched	neuromuscular blocker		infectious disease	hookworm|tapeworm	0	67.9	MicroSource	1500517	PYRANTEL PAMOATE	206.088	CN1CCCN=C1\C=C\c1cccs1 |c:5|	YSAUAVHXTIETRK-AATRIKPKSA-N	708857.0		YSAUAVHXTIETRK
BRD-K28667793-001-27-3	pyrazinamide	Launched	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	0	92.14	Selleck	S1762	Pyrazinamide	123.043	NC(=O)c1cnccn1	IPEHBUMCGVEMRF-UHFFFAOYSA-N	1046.0		IPEHBUMCGVEMRF
BRD-K28667793-001-28-1	pyrazinamide	Launched	fatty acid synthase inhibitor	FASN	infectious disease	tuberculosis	0	98.54	MicroSource	1500518	PYRAZINAMIDE	123.043	NC(=O)c1cnccn1	IPEHBUMCGVEMRF-UHFFFAOYSA-N	1046.0		IPEHBUMCGVEMRF
BRD-K61693562-300-01-7	pyrazinoylguanidine	Phase 1	diuretic				0	95.97	Enamine	Z1198155666		165.065	NC(=N)NC(=O)c1cnccn1	WNBSDCKJFDZMHT-UHFFFAOYSA-N	137321773.0		WNBSDCKJFDZMHT
BRD-K01567962-001-30-9	pyrazolanthrone	Preclinical	JNK inhibitor	MAPK10|MAPK8|MAPK8IP1|MAPK9|TTK			0	94.51	Tocris	1496	SP 600125	220.064	O=C1c2ccccc2-c2[nH]nc3cccc1c23	ACPOUJIDANTYHO-UHFFFAOYSA-N	8515.0		ACPOUJIDANTYHO
BRD-K01567962-001-23-0	pyrazolanthrone	Preclinical	JNK inhibitor	MAPK10|MAPK8|MAPK8IP1|MAPK9|TTK			0	97.4	Selleck	S1460	SP600125	220.064	O=C1c2ccccc2-c2[nH]nc3cccc1c23	ACPOUJIDANTYHO-UHFFFAOYSA-N	8515.0		ACPOUJIDANTYHO
BRD-K01567962-001-24-8	pyrazolanthrone	Preclinical	JNK inhibitor	MAPK10|MAPK8|MAPK8IP1|MAPK9|TTK			0	96.59	Tocris	1496	SP 600125	220.064	O=C1c2ccccc2-c2[nH]nc3cccc1c23	ACPOUJIDANTYHO-UHFFFAOYSA-N	8515.0		ACPOUJIDANTYHO
BRD-K42607789-001-01-2	pyrazoloacridine	Phase 2	topoisomerase inhibitor	TOP1|TOP2A			0	13.26	Sigma	MFCD00667221	3-(9-methoxy-5-nitropyrazolo[3,4,5-kl]acridin-2(6H)-yl)-N,N-dimethyl-1-propanamine	367.164	COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O	HVRZAFDJOWIDMM-UHFFFAOYSA-N			HVRZAFDJOWIDMM
BRD-K00010129-001-01-9	pyrethrins	Launched			infectious disease	flea control	0	96.88	TRC	P991245	pyrethrin 1	328.204	CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2C)C1(C)C |c:18|	ROVGZAWFACYCSP-VUMXUWRFSA-N	5281045.0		ROVGZAWFACYCSP
BRD-K76204040-001-03-8	pyridoxal	Launched		PDXK	neurology/psychiatry	epilepsy	0	92.3	Vitas-M	STL137770	3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde	167.058	Cc1ncc(CO)c(C=O)c1O	RADKZDMFGJYCBB-UHFFFAOYSA-N	1050.0		RADKZDMFGJYCBB
BRD-K42019693-001-01-5	pyridoxal-isonicotinoyl-hydrazone	Phase 2	apoptosis stimulant				0	93.7	Cayman	19357	Pyridoxal isonicotinoyl hydrazone	286.107	Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O	BQYIXOPJPLGCRZ-REZTVBANSA-N	135409539.0		BQYIXOPJPLGCRZ
BRD-K96669468-300-01-1	pyridoxamine	Phase 3	AGE inhibitor				0	98.7	Sigma	MFCD00012808	4-(aminomethyl)-5-(hydroxymethyl)-2-methyl-3-pyridinol dihydrochloride	168.09	Cc1ncc(CO)c(CN)c1O	NHZMQXZHNVQTQA-UHFFFAOYSA-N	11205997.0		NHZMQXZHNVQTQA
BRD-K14349461-001-04-4	pyridoxine	Launched	vitamin B	DDC|PDXK	metabolism	vitamin B6 deficiency	0	98.43	MicroSource	1505453	PYRIDOXINE	169.074	Cc1ncc(CO)c(CO)c1O	LXNHXLLTXMVWPM-UHFFFAOYSA-N	1054.0		LXNHXLLTXMVWPM
BRD-K14349461-003-13-1	pyridoxine	Launched	vitamin B	DDC|PDXK	metabolism	vitamin B6 deficiency	0	100.0	Selleck	S3113	Pyridoxine HCl	169.074	Cc1ncc(CO)c(CO)c1O	LXNHXLLTXMVWPM-UHFFFAOYSA-N	1054.0		LXNHXLLTXMVWPM
BRD-K88429204-001-38-5	pyrimethamine	Launched	dihydrofolate reductase inhibitor	DHFR|SLC47A1	infectious disease	malaria	0	95.03	Tocris	3918	Pyrimethamine	248.083	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	WKSAUQYGYAYLPV-UHFFFAOYSA-N	4993.0		WKSAUQYGYAYLPV
BRD-K88429204-001-33-6	pyrimethamine	Launched	dihydrofolate reductase inhibitor	DHFR|SLC47A1	infectious disease	malaria	0	98.23	Selleck	S2006	Pyrimethamine	248.083	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	WKSAUQYGYAYLPV-UHFFFAOYSA-N	4993.0		WKSAUQYGYAYLPV
BRD-K88429204-001-34-4	pyrimethamine	Launched	dihydrofolate reductase inhibitor	DHFR|SLC47A1	infectious disease	malaria	0	98.36	Tocris	3918	Pyrimethamine	248.083	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	WKSAUQYGYAYLPV-UHFFFAOYSA-N	4993.0		WKSAUQYGYAYLPV
BRD-K88429204-001-35-1	pyrimethamine	Launched	dihydrofolate reductase inhibitor	DHFR|SLC47A1	infectious disease	malaria	0	99.69	MicroSource	1500520	PYRIMETHAMINE	248.083	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	WKSAUQYGYAYLPV-UHFFFAOYSA-N	4993.0		WKSAUQYGYAYLPV
BRD-K88429204-001-40-9	pyrimethamine	Launched	dihydrofolate reductase inhibitor	DHFR|SLC47A1	infectious disease	malaria	0	95.85	Tocris	3918	Pyrimethamine	248.083	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	WKSAUQYGYAYLPV-UHFFFAOYSA-N	4993.0		WKSAUQYGYAYLPV
BRD-K94659840-001-02-9	pyrintegrin	Preclinical	integrin signaling activator				0	95.74	Tocris	4978	Pyrintegrin	451.168	Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1	QRJTZIJWDLJKQO-UHFFFAOYSA-N	46223724.0		QRJTZIJWDLJKQO
BRD-K94659840-001-01-7	pyrintegrin	Preclinical	integrin signaling activator				0	89.51	Tocris	4978	Pyrintegrin	451.168	Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1	QRJTZIJWDLJKQO-UHFFFAOYSA-N	46223724.0		QRJTZIJWDLJKQO
BRD-K16136380-001-01-7	pyrithione-zinc	Launched	ATP synthase inhibitor	KCNQ1|KCNQ2|KCNQ4|KCNQ5	dermatology	dandruff|cosmetic	1	99.05	MicroSource	1500260	PYRITHIONE ZINC	315.932	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	KTIHEFSORPLWRR-UHFFFAOYSA-L		BRD-U32859412-000-01-6	KTIHEFSORPLWRR
BRD-K16136380-001-03-3	pyrithione-zinc	Launched	ATP synthase inhibitor	KCNQ1|KCNQ2|KCNQ4|KCNQ5	dermatology	dandruff|cosmetic	1	0.0	Selleck	S4075	Zinc Pyrithione	315.932	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	KTIHEFSORPLWRR-UHFFFAOYSA-L		BRD-U31911056-000-01-7	KTIHEFSORPLWRR
BRD-K16136380-001-02-5	pyrithione-zinc	Launched	ATP synthase inhibitor	KCNQ1|KCNQ2|KCNQ4|KCNQ5	dermatology	dandruff|cosmetic	1	0.0	Selleck	S4075	Zinc Pyrithione	315.932	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	KTIHEFSORPLWRR-UHFFFAOYSA-L		BRD-U63926453-000-01-5	KTIHEFSORPLWRR
BRD-K16136380-001-04-9	pyrithione-zinc	Launched	ATP synthase inhibitor	KCNQ1|KCNQ2|KCNQ4|KCNQ5	dermatology	dandruff|cosmetic	1	90.0	MedChemEx	HY-B0572	Zinc Pyrithione	315.932	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	KTIHEFSORPLWRR-UHFFFAOYSA-L			KTIHEFSORPLWRR
BRD-K36116267-001-15-3	pyrithyldione	Withdrawn	psychoactive drug				0	97.73	MicroSource	1503085	PYRITHYLDIONE	167.095	CCC1(CC)C(=O)NC=CC1=O |c:8|	NZASCBIBXNPDMH-UHFFFAOYSA-N	4994.0		NZASCBIBXNPDMH
BRD-K82181219-300-05-9	pyritinol	Launched			rheumatology|neurology/psychiatry	rheumatoid arthritis|senile dementia	0	97.57	MedChemEx	HY-B0910A	Pyrithioxin (dihydrochloride)	368.086	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	SIXLXDIJGIWWFU-UHFFFAOYSA-N	14190.0		SIXLXDIJGIWWFU
BRD-K82181219-001-04-3	pyritinol	Launched			rheumatology|neurology/psychiatry	rheumatoid arthritis|senile dementia	0	96.46	MicroSource	1505762	PYRITINOL	368.086	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	SIXLXDIJGIWWFU-UHFFFAOYSA-N	14190.0		SIXLXDIJGIWWFU
BRD-K73132780-411-01-3	pyronaridine	Phase 3	antimalarial agent				0	74.21	MicroSource	1502329	PYRONARIDINE TETRAPHOSPHATE	517.224	COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	DJUFPMUQJKWIJB-UHFFFAOYSA-N	107771.0		DJUFPMUQJKWIJB
BRD-K73132780-001-01-2	pyronaridine	Phase 3	antimalarial agent				0	86.56	Vitas-M	STK597795	4-[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)amino]-2,6-bis(1-pyrrolidinylmethyl)phenol	517.224	COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	DJUFPMUQJKWIJB-UHFFFAOYSA-N	107771.0		DJUFPMUQJKWIJB
BRD-K00003463-001-01-9	pyrotinib	Phase 3	kinase inhibitor				0	97.45	MedChemEx	HY-104065	Pyrotinib	582.215	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\[C@H]1CCCN1C	SADXACCFNXBCFY-IYNHSRRRSA-N	51039030.0		SADXACCFNXBCFY
BRD-K11663430-001-04-9	pyroxamide	Phase 1	HDAC inhibitor	HDAC1			0	81.48	Cayman	13870	N~1~-hydroxy-N~8~-(3-pyridinyl)octanediamide	265.143	ONC(=O)CCCCCCC(=O)Nc1cccnc1	PTJGLFIIZFVFJV-UHFFFAOYSA-N	4996.0		PTJGLFIIZFVFJV
BRD-K11663430-001-03-1	pyroxamide	Phase 1	HDAC inhibitor	HDAC1			0	79.82	Tocris	4403	Pyroxamide	265.143	ONC(=O)CCCCCCC(=O)Nc1cccnc1	PTJGLFIIZFVFJV-UHFFFAOYSA-N	4996.0		PTJGLFIIZFVFJV
BRD-K11663430-001-02-3	pyroxamide	Phase 1	HDAC inhibitor	HDAC1			0	95.74	Cayman	13870		265.143	ONC(=O)CCCCCCC(=O)Nc1cccnc1	PTJGLFIIZFVFJV-UHFFFAOYSA-N	4996.0		PTJGLFIIZFVFJV
BRD-K80970344-201-10-9	pyrrolidine-dithiocarbamate	Preclinical	NFkB pathway inhibitor	HSD11B1|RELA			0	0.0	Tocris	727	Pyrrolidinedithiocarbamate ammonium	147.018	SC(=S)N1CCCC1	VSWDORGPIHIGNW-UHFFFAOYSA-N	65351.0		VSWDORGPIHIGNW
BRD-K80970344-201-08-6	pyrrolidine-dithiocarbamate	Preclinical	NFkB pathway inhibitor	HSD11B1|RELA			0	0.0	Tocris	727	Pyrrolidinedithiocarbamate ammonium	147.018	SC(=S)N1CCCC1	VSWDORGPIHIGNW-UHFFFAOYSA-N	65351.0		VSWDORGPIHIGNW
BRD-K39479472-096-06-9	pyrvinium-pamoate	Launched	androgen receptor antagonist	AR	infectious disease	pinworm	0	64.19	Sigma	S______P0027		382.228	CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	QMHSXPLYMTVAMK-UHFFFAOYSA-N	5281035.0	BRD-K39479472-373-06-9|BRD-K39479472-373-06-9	QMHSXPLYMTVAMK
BRD-K39479472-096-04-7	pyrvinium-pamoate	Launched	androgen receptor antagonist	AR	infectious disease	pinworm	0	2.67	MicroSource	1500521	PYRVINIUM PAMOATE	382.228	CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	QMHSXPLYMTVAMK-UHFFFAOYSA-N	5281035.0		QMHSXPLYMTVAMK
BRD-K00005336-001-01-9	PZ-2891	Preclinical	pantothenate kinase activator				0	96.3	MedChemEx	HY-124634	PZ-2891	349.19	CC(C)c1ccc(CC(=O)N2CCN(CC2)c2ccc(nn2)C#N)cc1	LGWDVWIZDPGCFG-UHFFFAOYSA-N	132260806.0		LGWDVWIZDPGCFG
BRD-K97714174-001-04-9	P22077	Preclinical	ubiquitin specific protease inhibitor	USP7			0	95.67	Tocris	4485	P 22077	314.984	CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	RMAMGGNACJHXHO-UHFFFAOYSA-N	46931953.0		RMAMGGNACJHXHO
BRD-K97714174-001-02-1	P22077	Preclinical	ubiquitin specific protease inhibitor	USP7			0	96.51	Tocris	4485	P 22077	314.984	CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	RMAMGGNACJHXHO-UHFFFAOYSA-N	46931953.0		RMAMGGNACJHXHO
BRD-K97714174-001-01-3	P22077	Preclinical	ubiquitin specific protease inhibitor	USP7			0	97.13	Selleck	S7133	P22077	314.984	CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	RMAMGGNACJHXHO-UHFFFAOYSA-N	46931953.0		RMAMGGNACJHXHO
BRD-K51791723-003-01-7	P276-00	Phase 2	CDK inhibitor	CDK1|CDK4|CDK9			0	96.63	Selleck	S8058	P276-00	401.103	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	QLUYMIVVAYRECT-OCCSQVGLSA-N	23643976.0		QLUYMIVVAYRECT
BRD-K51791723-003-02-5	P276-00	Phase 2	CDK inhibitor	CDK1|CDK4|CDK9			0	97.85	Selleck	S8058	P276-00	401.103	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	QLUYMIVVAYRECT-OCCSQVGLSA-N	23643976.0		QLUYMIVVAYRECT
BRD-K13606314-001-02-9	P5091	Preclinical	ubiquitin specific protease inhibitor	USP7			0	92.85	MedChemEx	HY-15667	P005091	346.924	CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	LKZLGMAAKNEGCH-UHFFFAOYSA-N	2819993.0		LKZLGMAAKNEGCH
BRD-K13606314-001-01-3	P5091	Preclinical	ubiquitin specific protease inhibitor	USP7			0	97.85	Selleck	S7132	P5091 (P005091)	346.924	CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	LKZLGMAAKNEGCH-UHFFFAOYSA-N	2819993.0		LKZLGMAAKNEGCH
BRD-A09487507-001-02-1	P7C3	Preclinical	NAMPT inhibitor	NAMPT			0	88.39	Tocris	4076	P7C3	471.979	O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|	FZHHRERIIVOATI-KRWDZBQOSA-N	981442.0		FZHHRERIIVOATI
BRD-A09487507-001-03-9	P7C3	Preclinical	NAMPT inhibitor	NAMPT			0	95.81	Tocris	4076	P7C3	471.979	O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1,r|	FZHHRERIIVOATI-KRWDZBQOSA-N	981442.0		FZHHRERIIVOATI
BRD-K59853741-001-01-9	Q-203	Phase 2	ATP synthase inhibitor				0	89.92	Enamine	Z2235679010		556.185	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1	OJICYBSWSZGRFB-UHFFFAOYSA-N	68234908.0		OJICYBSWSZGRFB
BRD-K63631219-001-01-6	quazinone	Phase 2	phosphodiesterase inhibitor	PDE3A|PDE3B			0	97.92	AMS	A000382058	(3R)-6-chloro-3-methyl-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one	235.051	CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|	BHZFZYLBVSWUMT-UHFFFAOYSA-N	135511466.0		BHZFZYLBVSWUMT
BRD-K97399794-001-15-3	quercetin	Launched	polar auxin transport inhibitor	ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness	0	93.07	Tocris	1125	Quercetin	302.043	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	REFJWTPEDVJJIY-UHFFFAOYSA-N	5280343.0		REFJWTPEDVJJIY
BRD-K97399794-001-14-6	quercetin	Launched	polar auxin transport inhibitor	ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness	0	85.0	Selleck	S2391	Quercetin	302.043	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	REFJWTPEDVJJIY-UHFFFAOYSA-N	5280343.0		REFJWTPEDVJJIY
BRD-K97399794-335-05-6	quercetin	Launched	polar auxin transport inhibitor	ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness	0	82.23	Selleck	S2347	Quercetin Dihydrate	302.043	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	REFJWTPEDVJJIY-UHFFFAOYSA-N	5280343.0		REFJWTPEDVJJIY
BRD-K97399794-001-16-1	quercetin	Launched	polar auxin transport inhibitor	ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness	0	91.46	Selleck	S2391	Quercetin (Sophoretin)	302.043	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	REFJWTPEDVJJIY-UHFFFAOYSA-N	5280343.0		REFJWTPEDVJJIY
BRD-K97399794-335-06-4	quercetin	Launched	polar auxin transport inhibitor	ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1	neurology/psychiatry|allergy	fatigue|allergic rhinitis|drowsiness	0	89.52	Selleck	S2347	Quercetin dihydrate (Sophoretin)	302.043	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	REFJWTPEDVJJIY-UHFFFAOYSA-N	5280343.0		REFJWTPEDVJJIY
BRD-K68867920-001-11-0	quetiapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2	neurology/psychiatry	schizophrenia|bipolar disorder	0	97.21	MicroSource	1505187	QUETIAPINE	383.167	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|	URKOMYMAXPYINW-UHFFFAOYSA-N	5002.0		URKOMYMAXPYINW
BRD-K68867920-051-12-3	quetiapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2	neurology/psychiatry	schizophrenia|bipolar disorder	0	97.78	Tocris	4735	Quetiapine hemifumarate	383.167	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|	URKOMYMAXPYINW-UHFFFAOYSA-N	5002.0	BRD-M66874015-051-04-2	URKOMYMAXPYINW
BRD-K68867920-051-11-5	quetiapine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2	neurology/psychiatry	schizophrenia|bipolar disorder	0	98.67	Selleck	S1763	Quetiapine Fumarate	383.167	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|	URKOMYMAXPYINW-UHFFFAOYSA-N	5002.0	BRD-M66874015-051-02-6	URKOMYMAXPYINW
BRD-K39503511-001-03-9	quiflapon	Phase 2	leukotriene synthesis inhibitor	ALOX5|ALOX5AP			0	97.94	MedChemEx	HY-10037	MK-0591	586.206	CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	NZOONKHCNQFYCI-UHFFFAOYSA-N	60923.0		NZOONKHCNQFYCI
BRD-K02995728-003-01-9	quinagolide	Launched	dopamine receptor agonist	DRD2	endocrinology	hyperprolactinemia	0	90.35	MedChemEx	HY-13736A	Quinagolide (hydrochloride)	395.224	CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC	GDFGTRDCCWFXTG-ZIFCJYIRSA-N	3086401.0		GDFGTRDCCWFXTG
BRD-K72222507-003-16-8	quinapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure|angioedema	0	86.77	MicroSource	1503076	QUINAPRIL HYDROCHLORIDE	438.215	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	JSDRRTOADPPCHY-HSQYWUDLSA-N	54892.0		JSDRRTOADPPCHY
BRD-K72222507-003-15-0	quinapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure|angioedema	0	65.36	Selleck	S2581	Quinapril HCl	438.215	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	JSDRRTOADPPCHY-HSQYWUDLSA-N	54892.0		JSDRRTOADPPCHY
BRD-K72222507-003-17-6	quinapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure|angioedema	0	93.01	Selleck	S2581	Quinapril hydrochloride (Accupril)	438.215	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	JSDRRTOADPPCHY-HSQYWUDLSA-N	54892.0		JSDRRTOADPPCHY
BRD-K72222507-003-20-0	quinapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|congestive heart failure|angioedema	0	90.11	Selleck	S2581	QUINAPRILAT	438.215	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	JSDRRTOADPPCHY-HSQYWUDLSA-N	54892.0		JSDRRTOADPPCHY
BRD-K42317111-001-01-7	quinaprilat	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|angioedema	0	0.0	MicroSource	1505455	QUINAPRILAT	410.184	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	FLSLEGPOVLMJMN-YSSFQJQWSA-N	107994.0		FLSLEGPOVLMJMN
BRD-K13261168-300-01-0	quinelorane	Phase 3	dopamine receptor agonist	DRD2|DRD3			0	97.42	Enzo	AC756	LY-163,502	246.184	CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12	TUFADSGTJUOBEH-ZWNOBZJWSA-N	57242.0		TUFADSGTJUOBEH
BRD-K63794707-001-20-9	quinestrol	Launched	estrogen receptor agonist	ESR1|ESR2	endocrinology	menopause	0	89.67	MedChemEx	HY-B1012	Quinestrol	364.24	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C	PWZUUYSISTUNDW-VAFBSOEGSA-N	9046.0		PWZUUYSISTUNDW
BRD-A59303141-001-11-9	quinethazone	Launched	thiazide diuretic		cardiology	hypertension	0	97.25	USP	59400G	quinethazone	289.029	CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|	AGMMTXLNIQSRCG-SECBINFHSA-N	6604207.0		AGMMTXLNIQSRCG
BRD-A59303141-001-10-4	quinethazone	Launched	thiazide diuretic		cardiology	hypertension	0	98.85	MicroSource	1503877	QUINETHAZONE	289.029	CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2,r|	AGMMTXLNIQSRCG-SECBINFHSA-N	6604207.0		AGMMTXLNIQSRCG
BRD-K59632282-001-04-9	quinidine	Launched	sodium channel blocker	KCNA5|KCNA7|KCNH1|KCNH2|KCNH5|KCNK1|KCNK6|SCN5A|SLC29A4	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias	0	85.02	MedChemEx	HY-B1751	Quinidine	324.184	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-LHHVKLHASA-N	441074.0		LOUPRKONTZGTKE
BRD-K59632282-052-03-1	quinidine	Launched	sodium channel blocker	KCNA5|KCNA7|KCNH1|KCNH2|KCNH5|KCNK1|KCNK6|SCN5A|SLC29A4	infectious disease|cardiology	malaria|atrial fibrillation (AF)|ventricular arrhythmias	0	87.9	MicroSource	1500523	QUINIDINE GLUCONATE	324.184	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-LHHVKLHASA-N	441074.0		LOUPRKONTZGTKE
BRD-K07940445-310-02-9	quinine	Launched	hemozoin biocrystallization inhibitor	GP9|KCNB2|KCNN4|SLC29A4	infectious disease	malaria	0	93.42	Selleck	S2502		324.184	COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-WZBLMQSHSA-N	3034034.0	BRD-K99257182-310-01-6	LOUPRKONTZGTKE
BRD-K07940445-001-02-4	quinine	Launched	hemozoin biocrystallization inhibitor	GP9|KCNB2|KCNN4|SLC29A4	infectious disease	malaria	0	94.43	CombiBlocks	OR-4054		324.184	COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-WZBLMQSHSA-N	3034034.0		LOUPRKONTZGTKE
BRD-K07940445-003-07-9	quinine	Launched	hemozoin biocrystallization inhibitor	GP9|KCNB2|KCNN4|SLC29A4	infectious disease	malaria	0	90.17	Tocris	4114	Quinine hydrochloride	324.184	COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	LOUPRKONTZGTKE-WZBLMQSHSA-N	3034034.0		LOUPRKONTZGTKE
BRD-K97028990-001-04-4	quinine-ethyl-carbonate	Launched			infectious disease	malaria	0	92.37	MicroSource	310050	QUININE ETHYL CARBONATE	396.205	CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12	NSBRKSWSLRQPJW-FRMGNDQPSA-N	5702001.0		NSBRKSWSLRQPJW
BRD-K51885093-001-11-2	quinolinic-acid	Preclinical	glutamate receptor agonist				0	94.44	Tocris	225	Quinolinic acid	167.022	OC(=O)c1cccnc1C(O)=O	GJAWHXHKYYXBSV-UHFFFAOYSA-N	1066.0		GJAWHXHKYYXBSV
BRD-K26548821-003-11-3	quinpirol-(-)	Phase 2	dopamine receptor agonist	DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR2B|HTR2C			0	87.54	Tocris	1061	(-)-Quinpirole hydrochloride	219.174	CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	54562.0		FTSUPYGMFAPCFZ
BRD-K26548821-003-14-9	quinpirol-(-)	Phase 2	dopamine receptor agonist	DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR2B|HTR2C			0	100.0	Tocris	1061	(-)-Quinpirole hydrochloride	219.174	CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	54562.0		FTSUPYGMFAPCFZ
BRD-K26548821-003-10-5	quinpirol-(-)	Phase 2	dopamine receptor agonist	DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR2B|HTR2C			0	94.33	Tocris	1061	(-)-Quinpirole hydrochloride	219.174	CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12	FTSUPYGMFAPCFZ-ZWNOBZJWSA-N	54562.0		FTSUPYGMFAPCFZ
BRD-K77925998-050-14-3	quipazine	Preclinical	serotonin receptor agonist	HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4			0	92.6	MicroSource	1503420	QUIPAZINE MALEATE	213.127	C1CN(CCN1)c1ccc2ccccc2n1	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	5011.0		XRXDAJYKGWNHTQ
BRD-K77925998-364-01-5	quipazine	Preclinical	serotonin receptor agonist	HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4			0	81.34	Selleck	S4409	Quipazine Maleate	213.127	C1CN(CCN1)c1ccc2ccccc2n1	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	5011.0		XRXDAJYKGWNHTQ
BRD-K77925998-332-15-9	quipazine	Preclinical	serotonin receptor agonist	HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4			0	97.07	Tocris	629	Quipazine dimaleate	213.127	C1CN(CCN1)c1ccc2ccccc2n1	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	5011.0		XRXDAJYKGWNHTQ
BRD-K77925998-332-04-6	quipazine	Preclinical	serotonin receptor agonist	HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4			0	78.06	Tocris	629	Quipazine dimaleate	213.127	C1CN(CCN1)c1ccc2ccccc2n1	XRXDAJYKGWNHTQ-UHFFFAOYSA-N	5011.0		XRXDAJYKGWNHTQ
BRD-K93918653-001-12-9	quizartinib	Phase 3	FLT3 inhibitor	CSF1R|FLT3|KIT|PDGFRA|PDGFRB|RET			0	97.84	MedChemEx	HY-13001	Quizartinib	560.221	CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	CVWXJKQAOSCOAB-UHFFFAOYSA-N	24889392.0		CVWXJKQAOSCOAB
BRD-K93918653-001-08-9	quizartinib	Phase 3	FLT3 inhibitor	CSF1R|FLT3|KIT|PDGFRA|PDGFRB|RET			0	95.17	Selleck	S1526	Quizartinib (AC220)	560.221	CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	CVWXJKQAOSCOAB-UHFFFAOYSA-N	24889392.0		CVWXJKQAOSCOAB
BRD-K40782193-003-02-9	QX-222	Preclinical	sodium channel blocker				0	98.05	Tocris	1043	QX 222	221.165	Cc1cccc(C)c1NC(=O)C[N+](C)(C)C	QYUXPWDVDMSTKR-UHFFFAOYSA-O	5014.0		QYUXPWDVDMSTKR
BRD-K56596464-003-02-6	QX-314	Preclinical	sodium channel blocker	MAPK14|TGFBR1			0	96.92	Tocris	2313	QX 314 chloride	263.212	CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	PYEBKOFMWAMBFV-UHFFFAOYSA-O	3925.0		PYEBKOFMWAMBFV
BRD-K56596464-003-11-9	QX-314	Preclinical	sodium channel blocker	MAPK14|TGFBR1			0	100.0	Tocris	2313	QX 314 chloride	263.212	CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	PYEBKOFMWAMBFV-UHFFFAOYSA-O	3925.0		PYEBKOFMWAMBFV
BRD-K56596464-004-10-7	QX-314	Preclinical	sodium channel blocker	MAPK14|TGFBR1			0	97.7	Tocris	1014	QX 314 bromide	263.212	CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	PYEBKOFMWAMBFV-UHFFFAOYSA-O	3925.0		PYEBKOFMWAMBFV
BRD-K00004717-001-01-9	R-121919	Preclinical	CRF receptor antagonist				0	97.86	Adooq	A13535	NBI 30775	380.269	CCCN(CCC)c1cc(C)nc2c(c(C)nn12)-c1cnc(cc1C)N(C)C	ANNRUWYFVIGKHA-UHFFFAOYSA-N	9821250.0		ANNRUWYFVIGKHA
BRD-K28442028-001-02-9	R-1479	Phase 1	HCV inhibitor				0	85.76	MedChemEx	HY-10444	R-1479	284.087	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1	ODLGMSQBFONGNG-JVZYCSMKSA-N	457388.0		ODLGMSQBFONGNG
BRD-K28442028-001-01-3	R-1479	Phase 1	HCV inhibitor				0	96.79	MedChemEx	HY-10444	R-1479	284.087	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1	ODLGMSQBFONGNG-JVZYCSMKSA-N	457388.0		ODLGMSQBFONGNG
BRD-K96418224-300-02-9	R-1485	Phase 1	serotonin receptor antagonist	HTR6			0	96.11	Tocris	4964	R 1485 dihydrochloride	377.121	Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1	UPROBLPRPWYJGN-UHFFFAOYSA-N	11689373.0		UPROBLPRPWYJGN
BRD-K96418224-300-01-8	R-1485	Phase 1	serotonin receptor antagonist	HTR6			0	95.77	Tocris	4964	R 1485 dihydrochloride	377.121	Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1	UPROBLPRPWYJGN-UHFFFAOYSA-N	11689373.0		UPROBLPRPWYJGN
BRD-K00004710-001-01-9	R-1487	Phase 1	p38 MAPK inhibitor				0	95.05	AMS	O32755	6-(2,4-Difluorophenoxy)-8-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one	388.135	Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O	KKKRKRMVJRHDMG-UHFFFAOYSA-N	11406590.0		KKKRKRMVJRHDMG
BRD-K83904070-001-01-1	R-268712	Preclinical	serine/threonine kinase inhibitor	TGFBR1			0	91.85	Tocris	5288	R 268712	363.15	Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1	JQGOCCALXFSRHZ-UHFFFAOYSA-N	11703284.0		JQGOCCALXFSRHZ
BRD-K83904070-001-02-9	R-268712	Preclinical	serine/threonine kinase inhibitor	TGFBR1			0	96.21	Tocris	5288	R 268712	363.15	Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1	JQGOCCALXFSRHZ-UHFFFAOYSA-N	11703284.0		JQGOCCALXFSRHZ
BRD-K14870255-001-02-3	R-428	Phase 2	AXL kinase inhibitor	AXL			0	88.26	MedChemEx	HY-15150	R428	506.291	Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1	KXMZDGSRSGHMMK-VWLOTQADSA-N	46215462.0		KXMZDGSRSGHMMK
BRD-K54665485-001-08-7	R-59022	Preclinical	diacylglycerol kinase inhibitor|protein kinase inhibitor	DGKA			0	97.41	Tocris	2194	R 59-022	459.178	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1	MFVJXLPANKSLLD-UHFFFAOYSA-N	3012.0		MFVJXLPANKSLLD
BRD-K54665485-001-07-9	R-59022	Preclinical	diacylglycerol kinase inhibitor|protein kinase inhibitor	DGKA			0	93.63	Tocris	2194	R 59-022	459.178	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1	MFVJXLPANKSLLD-UHFFFAOYSA-N	3012.0		MFVJXLPANKSLLD
BRD-K15588452-003-03-5	R-96544	Preclinical	serotonin receptor antagonist	HTR2A			0	96.58	Tocris	1742	R-96544 hydrochloride	355.215	COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	AFZLABYDOCWQBQ-WOJBJXKFSA-N	10668211.0		AFZLABYDOCWQBQ
BRD-K15588452-003-04-9	R-96544	Preclinical	serotonin receptor antagonist	HTR2A			0	96.14	Tocris	1742	R-96544 hydrochloride	355.215	COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	AFZLABYDOCWQBQ-WOJBJXKFSA-N	10668211.0		AFZLABYDOCWQBQ
BRD-K15588452-003-02-7	R-96544	Preclinical	serotonin receptor antagonist	HTR2A			0	92.89	Tocris	1742	R-96544 hydrochloride	355.215	COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	AFZLABYDOCWQBQ-WOJBJXKFSA-N	10668211.0		AFZLABYDOCWQBQ
BRD-K01826765-236-11-9	rabeprazole	Launched	ATPase inhibitor|gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome	0	93.26	Sigma	MFCD02092688	sodium 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide	382.12	COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|	YREYEVIYCVEVJK-RUZDIDTESA-N	9906855.0		YREYEVIYCVEVJK
BRD-K01826765-236-09-9	rabeprazole	Launched	ATPase inhibitor|gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome	0	53.03	MicroSource	1505943	RABEPRAZOLE SODIUM	382.12	COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|	YREYEVIYCVEVJK-RUZDIDTESA-N	9906855.0		YREYEVIYCVEVJK
BRD-K01826765-236-10-9	rabeprazole	Launched	ATPase inhibitor|gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome	0	98.9	MedChemEx	HY-B0656A	Rabeprazole (sodium)	382.12	COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|	YREYEVIYCVEVJK-RUZDIDTESA-N	9906855.0		YREYEVIYCVEVJK
BRD-K01826765-236-12-9	rabeprazole	Launched	ATPase inhibitor|gastrin inhibitor	ATP4A	gastroenterology	gastroesophageal reflux disease (GERD)|duodenal ulcer disease|Zollinger-Ellison syndrome	0	85.74	Sigma	SML0476	sodium 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide	382.12	COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|	YREYEVIYCVEVJK-RUZDIDTESA-N	9906855.0		YREYEVIYCVEVJK
BRD-A11069678-001-01-8	rac-BHFF	Preclinical	GABA receptor positive allosteric modulator	GABBR1			0	0.0	Tocris	3313	rac BHFF	330.144	CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|	RVNOANDLZIIFHB-MRXNPFEDSA-N	7023847.0		RVNOANDLZIIFHB
BRD-A11069678-001-02-9	rac-BHFF	Preclinical	GABA receptor positive allosteric modulator	GABBR1			0	42.99	Tocris	3313	rac BHFF	330.144	CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11,r|	RVNOANDLZIIFHB-MRXNPFEDSA-N	7023847.0		RVNOANDLZIIFHB
BRD-A08187463-001-12-9	racecadotril	Launched	enkephalinase inhibitor	MME	gastroenterology	diarrhea	0	99.4	MicroSource	1502331	RACECADOTRIL	385.135	CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|	ODUOJXZPIYUATO-LJQANCHMSA-N	60561.0		ODUOJXZPIYUATO
BRD-A08187463-001-14-9	racecadotril	Launched	enkephalinase inhibitor	MME	gastroenterology	diarrhea	0	96.23	MedChemEx	HY-17399	Racecadotril	385.135	CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|	ODUOJXZPIYUATO-LJQANCHMSA-N	60561.0		ODUOJXZPIYUATO
BRD-A08187463-001-11-1	racecadotril	Launched	enkephalinase inhibitor	MME	gastroenterology	diarrhea	0	97.52	Selleck	S2503	Racecadotril	385.135	CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5,r|	ODUOJXZPIYUATO-LJQANCHMSA-N	60561.0		ODUOJXZPIYUATO
BRD-K04111260-001-12-6	raclopride	Launched	dopamine receptor antagonist	DRD2|DRD3|HTR1A			0	96.6	Tocris	1810	Raclopride	346.085	CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC	WAOQONBSWFLFPE-VIFPVBQESA-N	3033769.0		WAOQONBSWFLFPE
BRD-K04111260-001-10-0	raclopride	Launched	dopamine receptor antagonist	DRD2|DRD3|HTR1A			0	93.34	Tocris	1810	Raclopride	346.085	CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC	WAOQONBSWFLFPE-VIFPVBQESA-N	3033769.0		WAOQONBSWFLFPE
BRD-K01825837-003-02-9	ractopamine	Launched	adrenergic receptor agonist		endocrinology	weight-gain aid	0	93.86	Tocris	5252	Ractopamine hydrochloride	301.168	C[C@@H](CCc1ccc(O)cc1)NC[C@@H](O)c1ccc(O)cc1 |&1:1,&2:13,r|	YJQZYXCXBBCEAQ-SCLBCKFNSA-N	9862660.0		YJQZYXCXBBCEAQ
BRD-K13394247-003-01-4	radafaxine	Phase 2	dopamine-norepinephrine reuptake inhibitor	SLC6A3			0	92.33	MedChemEx	HY-17590	Radafaxine (hydrochloride)	255.103	C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1	RCOBKSKAZMVBHT-TVQRCGJNSA-N	9795056.0		RCOBKSKAZMVBHT
BRD-K84683831-001-01-0	radezolid	Phase 2	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor				0	94.62	MedChemEx	HY-14800	Radezolid	438.182	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1	BTTNOGHPGJANSW-IBGZPJMESA-N	11224409.0		BTTNOGHPGJANSW
BRD-K84683831-001-02-9	radezolid	Phase 2	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor				0	92.25	MedChemEx	HY-14800	Radezolid	438.182	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1	BTTNOGHPGJANSW-IBGZPJMESA-N	11224409.0		BTTNOGHPGJANSW
BRD-K00005328-001-01-9	radiprodil	Phase 2	acetylcholine receptor antagonist				0	97.93	MedChemEx	HY-14777	Radiprodil	397.144	Fc1ccc(CC2CCN(CC2)C(=O)C(=O)Nc2ccc3[nH]c(=O)oc3c2)cc1	GKGRZLGAQZPEHO-UHFFFAOYSA-N	10200813.0		GKGRZLGAQZPEHO
BRD-K00004716-001-01-9	radotinib	Phase 3	Bcr-Abl kinase inhibitor				0	95.11	Adooq	A13029	IY-5511	530.179	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cnccn3)c2)cc(c1)C(F)(F)F	DUPWHXBITIZIKZ-UHFFFAOYSA-N	16063245.0		DUPWHXBITIZIKZ
BRD-K00003169-001-01-9	RAD140	Phase 1	androgen receptor modulator				0	96.01	MedChemEx	HY-14383	RAD140	393.099	[H][C@@](C)(O)[C@@]([H])(Nc1ccc(C#N)c(Cl)c1C)c1nnc(o1)-c1ccc(cc1)C#N	XMBUPPIEVAFYHO-KPZWWZAWSA-N	44200882.0		XMBUPPIEVAFYHO
BRD-K93123848-001-06-9	RAF265	Phase 2	RAF inhibitor|VEGFR inhibitor	BRAF			0	98.52	Tocris	6015	RAF 265	518.129	Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	YABJJWZLRMPFSI-UHFFFAOYSA-N	11656518.0		YABJJWZLRMPFSI
BRD-K93123848-001-04-1	RAF265	Phase 2	RAF inhibitor|VEGFR inhibitor	BRAF			0	94.35	Selleck	S2161	RAF265 (CHIR-265)	518.129	Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	YABJJWZLRMPFSI-UHFFFAOYSA-N	11656518.0		YABJJWZLRMPFSI
BRD-K00010389-001-01-9	RAF709	Preclinical	RAF inhibitor				0	96.68	MedChemEx	HY-100510	RAF709	542.214	Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc(OC2CCOCC2)c(c1)N1CCOCC1	FYNMINFUAIDIFL-UHFFFAOYSA-N	90408826.0		FYNMINFUAIDIFL
BRD-K00003227-001-01-9	ralinepag	Phase 3	IP1 prostacyclin receptor agonist				0	91.2	MedChemEx	HY-16751	Ralinepag	431.15	OC(=O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1 |r|	NPDKXVKJRHPDQT-IYARVYRRSA-N			NPDKXVKJRHPDQT
BRD-K63828191-003-34-7	raloxifene	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|oncology	osteoporosis|breast cancer	0	95.46	MicroSource	1505622	RALOXIFENE HYDROCHLORIDE	473.166	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	GZUITABIAKMVPG-UHFFFAOYSA-N	5035.0		GZUITABIAKMVPG
BRD-K63828191-003-35-4	raloxifene	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|oncology	osteoporosis|breast cancer	0	97.6	Tocris	2280	Raloxifene hydrochloride	473.166	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	GZUITABIAKMVPG-UHFFFAOYSA-N	5035.0		GZUITABIAKMVPG
BRD-K63828191-003-33-9	raloxifene	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|oncology	osteoporosis|breast cancer	0	95.52	Tocris	2280	Raloxifene hydrochloride	473.166	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	GZUITABIAKMVPG-UHFFFAOYSA-N	5035.0		GZUITABIAKMVPG
BRD-K63828191-003-32-1	raloxifene	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	ESR1|ESR2	orthopedics|oncology	osteoporosis|breast cancer	0	98.21	Selleck	S1227	Raloxifene HCl	473.166	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	GZUITABIAKMVPG-UHFFFAOYSA-N	5035.0		GZUITABIAKMVPG
BRD-K05658747-001-02-9	raltegravir	Launched	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	92.9	Selleck	S2005	Raltegravir (MK-0518)	444.156	Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	CZFFBEXEKNGXKS-UHFFFAOYSA-N	54671008.0		CZFFBEXEKNGXKS
BRD-K05658747-001-03-7	raltegravir	Launched	HIV integrase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	94.8	Selleck	S2005	Raltegravir (MK-0518)	444.156	Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	CZFFBEXEKNGXKS-UHFFFAOYSA-N	54671008.0		CZFFBEXEKNGXKS
BRD-K08151102-001-11-9	raltitrexed	Launched	thymidylate synthase inhibitor	FPGS|TYMS	oncology	mesothelioma	0	87.83	MedChemEx	HY-10821	Raltitrexed	458.126	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	IVTVGDXNLFLDRM-HNNXBMFYSA-N	135400182.0		IVTVGDXNLFLDRM
BRD-K08151102-001-05-9	raltitrexed	Launched	thymidylate synthase inhibitor	FPGS|TYMS	oncology	mesothelioma	0	93.68	Selleck	S1192	Raltitrexed (Tomudex)	458.126	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	IVTVGDXNLFLDRM-HNNXBMFYSA-N	135400182.0		IVTVGDXNLFLDRM
BRD-K08151102-001-06-9	raltitrexed	Launched	thymidylate synthase inhibitor	FPGS|TYMS	oncology	mesothelioma	0	83.63	Selleck	S1192	Raltitrexed	458.126	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	IVTVGDXNLFLDRM-HNNXBMFYSA-N	135400182.0		IVTVGDXNLFLDRM
BRD-K08586861-001-01-1	ramatroban	Launched	prostanoid receptor antagonist	PTGDR2|TBXA2R	cardiology|pulmonary	coronary artery disease (CAD)|asthma	0	97.83	MedChemEx	HY-B0745	Ramatroban	416.121	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	LDXDSHIEDAPSSA-OAHLLOKOSA-N	123879.0		LDXDSHIEDAPSSA
BRD-K08586861-001-02-9	ramatroban	Launched	prostanoid receptor antagonist	PTGDR2|TBXA2R	cardiology|pulmonary	coronary artery disease (CAD)|asthma	0	97.09	Tocris	2732	BAY-u 3405	416.121	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	LDXDSHIEDAPSSA-OAHLLOKOSA-N	123879.0		LDXDSHIEDAPSSA
BRD-K28761891-001-10-1	ramelteon	Launched	melatonin receptor agonist	MTNR1A|MTNR1B	neurology/psychiatry	insomnia	0	98.49	MicroSource	1505817	RAMELTEON	259.157	CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12	YLXDSYKOBKBWJQ-LBPRGKRZSA-N	208902.0		YLXDSYKOBKBWJQ
BRD-K28761891-001-09-3	ramelteon	Launched	melatonin receptor agonist	MTNR1A|MTNR1B	neurology/psychiatry	insomnia	0	90.4	Selleck	S1259	Ramelteon	259.157	CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12	YLXDSYKOBKBWJQ-LBPRGKRZSA-N	208902.0		YLXDSYKOBKBWJQ
BRD-K85333151-001-01-3	ramifenazone	Launched	cyclooxygenase inhibitor		neurology/psychiatry|endocrinology	pain relief|fever	0	75.76	Key	KS-5044	4-(isopropylamino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one	245.153	CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O	XOZLRRYPUKAKMU-UHFFFAOYSA-N	5037.0		XOZLRRYPUKAKMU
BRD-K85333151-003-13-4	ramifenazone	Launched	cyclooxygenase inhibitor		neurology/psychiatry|endocrinology	pain relief|fever	0	80.52	MicroSource	1503822	RAMIFENAZONE	245.153	CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O	XOZLRRYPUKAKMU-UHFFFAOYSA-N	5037.0		XOZLRRYPUKAKMU
BRD-K89348303-001-14-7	ramipril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	98.06	MicroSource	1505214	RAMIPRIL	416.231	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	HDACQVRGBOVJII-JBDAPHQKSA-N	6992028.0		HDACQVRGBOVJII
BRD-K89348303-001-16-2	ramipril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	94.1	Tocris	5250	Ramipril	416.231	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	HDACQVRGBOVJII-JBDAPHQKSA-N	6992028.0		HDACQVRGBOVJII
BRD-K89348303-001-18-9	ramipril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	95.63	Tocris	5250	Ramipril	416.231	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	HDACQVRGBOVJII-JBDAPHQKSA-N	6992028.0		HDACQVRGBOVJII
BRD-K89348303-001-17-0	ramipril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	96.79	Selleck	S1793	Ramipril	416.231	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	HDACQVRGBOVJII-JBDAPHQKSA-N	6992028.0	BRD-K01296542-001-01-1	HDACQVRGBOVJII
BRD-K85046107-003-03-9	ramosetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting|irritable bowel syndrome	0	98.28	MedChemEx	HY-B0595	Ramosetron (Hydrochloride)	279.137	Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12	NTHPAPBPFQJABD-LLVKDONJSA-N	135418340.0		NTHPAPBPFQJABD
BRD-K85046107-003-01-2	ramosetron	Launched	serotonin receptor antagonist	HTR3A	gastroenterology	nausea|vomiting|irritable bowel syndrome	0	99.58	MedChemEx	HY-B0595	Ramosetron (Hydrochloride)	279.137	Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12	NTHPAPBPFQJABD-LLVKDONJSA-N	135418340.0		NTHPAPBPFQJABD
BRD-K50489389-001-01-8	ranirestat	Phase 3	aldose reductase inhibitor	AKR1B1			0	96.29	MedChemEx	HY-15314	Ranirestat	418.992	Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O	QCVNMNYRNIMDKV-QGZVFWFLSA-N	153948.0		QCVNMNYRNIMDKV
BRD-K30816563-003-03-9	ranitidine	Launched	histamine receptor antagonist	HRH2	gastroenterology	heartburn	0	87.43	Tocris	1967	Ranitidine hydrochloride	314.141	CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1	SYNOVMDJYWJCON-UHFFFAOYSA-N	9883333.0		SYNOVMDJYWJCON
BRD-K01825102-300-04-9	ranolazine	Launched	sodium channel blocker	SCN10A|SCN9A	cardiology	chronic stable angina	0	95.47	Tocris	3118	Ranolazine dihydrochloride	499.2	COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|	XKLMZUWKNUAPSZ-FQEVSTJZSA-N	13560750.0		XKLMZUWKNUAPSZ
BRD-K01825102-300-03-9	ranolazine	Launched	sodium channel blocker	SCN10A|SCN9A	cardiology	chronic stable angina	0	98.05	Selleck	S1425	Ranolazine 2HCl	499.2	COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|	XKLMZUWKNUAPSZ-FQEVSTJZSA-N	13560750.0		XKLMZUWKNUAPSZ
BRD-K02206208-001-01-4	rapastinel	Phase 2	glutamate receptor agonist				0	0.0	MedChemEx	HY-16728	Rapastinel	413.227	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	GIBQQARAXHVEGD-BSOLPCOYSA-N	14539800.0		GIBQQARAXHVEGD
BRD-K58114536-066-03-5	rasagiline	Launched	monoamine oxidase inhibitor	BCL2|MAOB	neurology/psychiatry	Parkinson's Disease	0	82.52	Tocris	4308	Rasagiline mesylate	171.105	C#CCN[C@@H]1CCc2ccccc12	RUOKEQAAGRXIBM-GFCCVEGCSA-N	3052776.0		RUOKEQAAGRXIBM
BRD-K58114536-066-04-3	rasagiline	Launched	monoamine oxidase inhibitor	BCL2|MAOB	neurology/psychiatry	Parkinson's Disease	0	0.0	Selleck	S2102	Rasagiline Mesylate	171.105	C#CCN[C@@H]1CCc2ccccc12	RUOKEQAAGRXIBM-GFCCVEGCSA-N	3052776.0	BRD-K58826770-066-01-3	RUOKEQAAGRXIBM
BRD-K58114536-001-01-6	rasagiline	Launched	monoamine oxidase inhibitor	BCL2|MAOB	neurology/psychiatry	Parkinson's Disease	0	97.01	MicroSource	1502333	RASAGILINE	171.105	C#CCN[C@@H]1CCc2ccccc12	RUOKEQAAGRXIBM-GFCCVEGCSA-N	3052776.0		RUOKEQAAGRXIBM
BRD-K58114536-066-02-7	rasagiline	Launched	monoamine oxidase inhibitor	BCL2|MAOB	neurology/psychiatry	Parkinson's Disease	0	98.6	Selleck	S2102	Rasagiline mesylate	171.105	C#CCN[C@@H]1CCc2ccccc12	RUOKEQAAGRXIBM-GFCCVEGCSA-N	3052776.0		RUOKEQAAGRXIBM
BRD-K77474816-003-14-1	rauwolscine	Preclinical	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR1E|HTR2B			0	87.99	Tocris	891	Rauwolscine hydrochloride	354.194	COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-DIRVCLHFSA-N	643606.0	BRD-A65053077-003-01-0	BLGXFZZNTVWLAY
BRD-K77474816-003-15-9	rauwolscine	Preclinical	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR1E|HTR2B			0	93.77	Tocris	891	Rauwolscine hydrochloride	354.194	COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-DIRVCLHFSA-N	643606.0		BLGXFZZNTVWLAY
BRD-K77474816-003-13-3	rauwolscine	Preclinical	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR1E|HTR2B			0	88.44	Tocris	891	Rauwolscine hydrochloride	354.194	COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-DIRVCLHFSA-N	643606.0		BLGXFZZNTVWLAY
BRD-K86309810-001-02-9	ravoxertinib	Phase 1	ERK1 and ERK2 phosphorylation inhibitor	MAPK1|MAPK3			0	97.32	MedChemEx	HY-15947	Ravoxertinib	440.116	Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1	RZUOCXOYPYGSKL-GOSISDBHSA-N	71727581.0		RZUOCXOYPYGSKL
BRD-K86309810-001-01-5	ravoxertinib	Phase 1	ERK1 and ERK2 phosphorylation inhibitor	MAPK1|MAPK3			0	98.38	Adooq	A13420	(S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one	440.116	Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1	RZUOCXOYPYGSKL-GOSISDBHSA-N	71727581.0		RZUOCXOYPYGSKL
BRD-K03503561-001-01-4	ravuconazole	Phase 2	sterol demethylase inhibitor				0	98.93	Cayman	18750	4-{2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1,3-thiazol-4-yl}benzonitrile	437.112	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	OPAHEYNNJWPQPX-RCDICMHDSA-N	467825.0		OPAHEYNNJWPQPX
BRD-A67036568-001-02-1	RBC8	Preclinical	Ral GTPase inhibitor	RALA|RALB			0	18.72	Tocris	5411	RBC8	424.154	COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|	RFEAEBNMNYRJFD-VGAJERRHSA-N			RFEAEBNMNYRJFD
BRD-A67036568-001-03-9	RBC8	Preclinical	Ral GTPase inhibitor	RALA|RALB			0	84.72	MedChemEx	HY-12873	RBC8	424.154	COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|	RFEAEBNMNYRJFD-VGAJERRHSA-N			RFEAEBNMNYRJFD
BRD-A67036568-001-01-3	RBC8	Preclinical	Ral GTPase inhibitor	RALA|RALB			0	76.21	MedChemEx	HY-12873	RBC8	424.154	COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10,r|	RFEAEBNMNYRJFD-VGAJERRHSA-N			RFEAEBNMNYRJFD
BRD-A15909516-001-07-4	rebamipide	Launched	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD)|gastritis	0	98.27	MicroSource	1505310	REBAMIPIDE	370.072	OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|	ALLWOAVDORUJLA-MRXNPFEDSA-N	969464.0		ALLWOAVDORUJLA
BRD-A15909516-001-09-9	rebamipide	Launched	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD)|gastritis	0	96.85	MedChemEx	HY-B0360	Rebamipide	370.072	OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|	ALLWOAVDORUJLA-MRXNPFEDSA-N	969464.0		ALLWOAVDORUJLA
BRD-A15909516-001-06-6	rebamipide	Launched	free radical scavenger	FPR1	gastroenterology	peptic ulcer disease (PUD)|gastritis	0	98.72	Selleck	S2032	Rebamipide	370.072	OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3,r|	ALLWOAVDORUJLA-MRXNPFEDSA-N	969464.0		ALLWOAVDORUJLA
BRD-K76694128-001-06-8	rebastinib	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	ABL1|BCR|FGR|FLT3|HCK|LYN|SRC			0	74.6	MedChemEx	HY-13024	DCC-2036	553.224	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	WVXNSAVVKYZVOE-UHFFFAOYSA-N	25066467.0		WVXNSAVVKYZVOE
BRD-K76694128-001-07-6	rebastinib	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	ABL1|BCR|FGR|FLT3|HCK|LYN|SRC			0	96.77	MedChemEx	HY-13024	DCC-2036	553.224	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	WVXNSAVVKYZVOE-UHFFFAOYSA-N	25066467.0		WVXNSAVVKYZVOE
BRD-K76694128-001-05-0	rebastinib	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	ABL1|BCR|FGR|FLT3|HCK|LYN|SRC			0	84.1	Selleck	S2634	DCC-2036 (Rebastinib)	553.224	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	WVXNSAVVKYZVOE-UHFFFAOYSA-N	25066467.0		WVXNSAVVKYZVOE
BRD-K76694128-001-04-3	rebastinib	Phase 1/Phase 2	Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor	ABL1|BCR|FGR|FLT3|HCK|LYN|SRC			0	56.43	Selleck	S2634	DCC-2036 (Rebastinib)	553.224	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	WVXNSAVVKYZVOE-UHFFFAOYSA-N	25066467.0		WVXNSAVVKYZVOE
BRD-K77224738-066-02-7	reboxetine	Launched	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	0	96.05	Selleck	S3199		313.168	CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|	CBQGYUDMJHNJBX-RTBURBONSA-N	127151.0		CBQGYUDMJHNJBX
BRD-K77224738-066-09-9	reboxetine	Launched	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	0	95.97	Tocris	1982	Reboxetine mesylate	313.168	CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|	CBQGYUDMJHNJBX-RTBURBONSA-N	127151.0		CBQGYUDMJHNJBX
BRD-K77224738-066-08-9	reboxetine	Launched	adrenergic receptor antagonist	SLC6A2	neurology/psychiatry	depression	0	97.52	MedChemEx	HY-14560C	Reboxetine (mesylate)	313.168	CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10,11|	CBQGYUDMJHNJBX-RTBURBONSA-N	127151.0		CBQGYUDMJHNJBX
BRD-K84924479-300-01-1	Rec-15/2615	Phase 2	adrenergic receptor antagonist	ADRA1A			0	58.81	Tocris	3284	Rec 15/2615 dihydrochloride	495.248	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C	ZZMFJJDBKSYGRM-UHFFFAOYSA-N	9891980.0		ZZMFJJDBKSYGRM
BRD-K84924479-300-02-9	Rec-15/2615	Phase 2	adrenergic receptor antagonist	ADRA1A			0	62.92	Tocris	3284	Rec 15/2615 dihydrochloride	495.248	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C	ZZMFJJDBKSYGRM-UHFFFAOYSA-N	9891980.0		ZZMFJJDBKSYGRM
BRD-K85751432-001-03-3	refametinib	Phase 2	MEK inhibitor	MAP2K1|MAP2K2			0	95.47	MedChemEx	HY-14691	Refametinib	572.009	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	RDSACQWTXKSHJT-NSHDSACASA-N	44182295.0		RDSACQWTXKSHJT
BRD-K85751432-001-04-9	refametinib	Phase 2	MEK inhibitor	MAP2K1|MAP2K2			0	97.42	MedChemEx	HY-14691	Refametinib	572.009	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	RDSACQWTXKSHJT-NSHDSACASA-N	44182295.0		RDSACQWTXKSHJT
BRD-K00003609-001-01-9	regadenoson	Launched	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3	radiology	myocardial perfusion imaging (MPI)	0	95.62	MedChemEx	HY-A0168	Regadenoson	390.14	CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	LZPZPHGJDAGEJZ-AKAIJSEGSA-N	219024.0		LZPZPHGJDAGEJZ
BRD-K16730910-001-07-3	regorafenib	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)	0	97.53	Selleck	S1178	Regorafenib (BAY 73-4506)	482.077	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	FNHKPVJBJVTLMP-UHFFFAOYSA-N	11167602.0		FNHKPVJBJVTLMP
BRD-K16730910-001-10-7	regorafenib	Launched	FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK	oncology	colorectal cancer|gastrointestinal stromal tumors (GIST)	0		Selleck	S1178	Regorafenib (BAY 73-4506)	482.077	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)	11167602.0		FNHKPVJBJVTLMP
BRD-K96720755-001-03-4	relcovaptan	Phase 2	vasopressin receptor antagonist	AVPR1A|AVPR1B|AVPR2|OXTR			0	97.59	Tocris	2310	SR 49059	619.095	COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	CEBYCSRFKCEUSW-NAYZPBBASA-N	60943.0		CEBYCSRFKCEUSW
BRD-K96720755-001-02-6	relcovaptan	Phase 2	vasopressin receptor antagonist	AVPR1A|AVPR1B|AVPR2|OXTR			0	98.48	Tocris	2310	SR 49059	619.095	COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	CEBYCSRFKCEUSW-NAYZPBBASA-N	60943.0		CEBYCSRFKCEUSW
BRD-K96720755-001-04-9	relcovaptan	Phase 2	vasopressin receptor antagonist	AVPR1A|AVPR1B|AVPR2|OXTR			0	98.37	Tocris	2310	SR 49059	619.095	COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	CEBYCSRFKCEUSW-NAYZPBBASA-N	60943.0		CEBYCSRFKCEUSW
BRD-K63018010-001-01-7	relebactam	Launched	beta lactamase inhibitor				0	86.36	MedChemEx	HY-16752	Relebactam	348.11	OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O	SMOBCLHAZXOKDQ-ZJUUUORDSA-N	44129647.0		SMOBCLHAZXOKDQ
BRD-K00003216-001-01-9	relugolix	Phase 3	gonadotropin releasing factor hormone receptor antagonist				0	96.9	MedChemEx	HY-16474	Relugolix	623.176	CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C	AOMXMOCNKJTRQP-UHFFFAOYSA-N	10348973.0		AOMXMOCNKJTRQP
BRD-A36074203-003-08-9	remacemide	Phase 3	glutamate receptor antagonist	GRIN1			0	97.22	Tocris	1622	Remacemide hydrochloride	268.158	C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|	YSGASDXSLKIKOD-KRWDZBQOSA-N	760423.0		YSGASDXSLKIKOD
BRD-A36074203-003-07-6	remacemide	Phase 3	glutamate receptor antagonist	GRIN1			0	97.95	Tocris	1622	Remacemide hydrochloride	268.158	C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|	YSGASDXSLKIKOD-KRWDZBQOSA-N	760423.0		YSGASDXSLKIKOD
BRD-K00004584-001-01-9	remetinostat	Phase 2	HDAC inhibitor				0	0.0	MedChemEx	HY-100365	Remetinostat	323.137	COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1	XDZAHHULFQIBFE-UHFFFAOYSA-N	24875489.0		XDZAHHULFQIBFE
BRD-K89413285-074-01-5	remimazolam	Phase 3	benzodiazepine receptor agonist	GABBR1			0	92.64	MedChemEx	HY-14867A	Remimazolam (benzenesulfonate)	438.069	COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|	CYHWMBVXXDIZNZ-KRWDZBQOSA-N	9867812.0		CYHWMBVXXDIZNZ
BRD-K75349868-001-03-9	remodelin	Preclinical	transferase inhibitor	NAT10			0	82.53	Tocris	5193	Remodelin	282.094	N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1	XAEJIFARBQJLML-UHFFFAOYSA-N	44442376.0		XAEJIFARBQJLML
BRD-K75349868-001-01-5	remodelin	Preclinical	transferase inhibitor	NAT10			0	76.13	Tocris	5193	Remodelin	282.094	N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1	XAEJIFARBQJLML-UHFFFAOYSA-N	44442376.0		XAEJIFARBQJLML
BRD-K54094468-003-12-9	remoxipride	Withdrawn	dopamine receptor antagonist	DRD2|DRD3|DRD4|HTR2A|SIGMAR1			0	94.22	Tocris	916	Remoxipride hydrochloride	370.089	CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	GUJRSXAPGDDABA-NSHDSACASA-N	54477.0		GUJRSXAPGDDABA
BRD-K54094468-003-11-1	remoxipride	Withdrawn	dopamine receptor antagonist	DRD2|DRD3|DRD4|HTR2A|SIGMAR1			0	98.31	Tocris	916	Remoxipride hydrochloride	370.089	CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	GUJRSXAPGDDABA-NSHDSACASA-N	54477.0		GUJRSXAPGDDABA
BRD-K82846253-001-17-0	repaglinide	Launched	insulin secretagogue	ABCC8|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	81.04	Tocris	3805	Repaglinide	452.268	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	FAEKWTJYAYMJKF-QHCPKHFHSA-N	65981.0		FAEKWTJYAYMJKF
BRD-K82846253-001-16-2	repaglinide	Launched	insulin secretagogue	ABCC8|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	97.96	MicroSource	1506035	REPAGLINIDE	452.268	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	FAEKWTJYAYMJKF-QHCPKHFHSA-N	65981.0		FAEKWTJYAYMJKF
BRD-K82846253-001-15-4	repaglinide	Launched	insulin secretagogue	ABCC8|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	99.06	Tocris	3805	Repaglinide	452.268	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	FAEKWTJYAYMJKF-QHCPKHFHSA-N	65981.0		FAEKWTJYAYMJKF
BRD-K82846253-001-14-7	repaglinide	Launched	insulin secretagogue	ABCC8|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	98.44	Selleck	S1426	Repaglinide	452.268	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	FAEKWTJYAYMJKF-QHCPKHFHSA-N	65981.0		FAEKWTJYAYMJKF
BRD-K82846253-001-20-9	repaglinide	Launched	insulin secretagogue	ABCC8|KCNJ11|PPARG	endocrinology	diabetes mellitus	0	97.76	Tocris	3805	Repaglinide	452.268	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	FAEKWTJYAYMJKF-QHCPKHFHSA-N	65981.0		FAEKWTJYAYMJKF
BRD-K58486055-001-02-7	reparixin	Phase 3	CC chemokine receptor antagonist	CXCR1|CXCR2			0	99.13	MedChemEx	HY-15251	Reparixin	283.124	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	KQDRVXQXKZXMHP-LLVKDONJSA-N	9838712.0		KQDRVXQXKZXMHP
BRD-K58486055-001-03-9	reparixin	Phase 3	CC chemokine receptor antagonist	CXCR1|CXCR2			0	96.3	MedChemEx	HY-15251	Reparixin	283.124	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	KQDRVXQXKZXMHP-LLVKDONJSA-N	9838712.0		KQDRVXQXKZXMHP
BRD-K00003447-001-01-9	repotrectinib	Phase 1/Phase 2	receptor tyrosine protein kinase inhibitor				0	98.59	MedChemEx	HY-103022	Repotrectinib	355.144	C[C@H]1CNC(=O)c2cnn3ccc(N[C@H](C)c4cc(F)ccc4O1)nc23	FIKPXCOQUIZNHB-VUWPPUDQSA-N			FIKPXCOQUIZNHB
BRD-K80480517-001-04-0	repsox	Preclinical	TGF beta receptor inhibitor	TGFBR1			0	98.05	Tocris	3742	RepSox	287.117	Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	LBPKYPYHDKKRFS-UHFFFAOYSA-N	449054.0		LBPKYPYHDKKRFS
BRD-K80480517-001-02-4	repsox	Preclinical	TGF beta receptor inhibitor	TGFBR1			0	97.14	Selleck	S7223	RepSox	287.117	Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	LBPKYPYHDKKRFS-UHFFFAOYSA-N	449054.0		LBPKYPYHDKKRFS
BRD-K80480517-001-05-9	repsox	Preclinical	TGF beta receptor inhibitor	TGFBR1			0	97.43	Tocris	3742	RepSox	287.117	Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	LBPKYPYHDKKRFS-UHFFFAOYSA-N	449054.0		LBPKYPYHDKKRFS
BRD-K61567297-001-02-7	resatorvid	Phase 3	toll-like receptor inhibitor	TLR4			0	96.53	MedChemEx	HY-11109	TAK-242	361.055	CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|	LEEIJTHMHDMWLJ-CQSZACIVSA-N	11703255.0		LEEIJTHMHDMWLJ
BRD-K61567297-001-01-9	resatorvid	Phase 3	toll-like receptor inhibitor	TLR4			0	94.18	MedChemEx	HY-11109	TAK-242	361.055	CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|	LEEIJTHMHDMWLJ-CQSZACIVSA-N	11703255.0		LEEIJTHMHDMWLJ
BRD-K95921201-001-15-3	reserpine	Launched	vesicular monoamine transporter inhibitor	SLC18A1|SLC18A2	cardiology	hypertension	0	87.93	Selleck	S1601	Reserpine	608.273	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	QEVHRUUCFGRFIF-MDEJGZGSSA-N	5770.0		QEVHRUUCFGRFIF
BRD-K95921201-001-13-8	reserpine	Launched	vesicular monoamine transporter inhibitor	SLC18A1|SLC18A2	cardiology	hypertension	0	77.7	Tocris	2742	Reserpine	608.273	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	QEVHRUUCFGRFIF-MDEJGZGSSA-N	5770.0		QEVHRUUCFGRFIF
BRD-K95921201-001-19-9	reserpine	Launched	vesicular monoamine transporter inhibitor	SLC18A1|SLC18A2	cardiology	hypertension	0	84.43	Tocris	2742	Reserpine	608.273	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	QEVHRUUCFGRFIF-MDEJGZGSSA-N	5770.0		QEVHRUUCFGRFIF
BRD-K95921201-001-12-0	reserpine	Launched	vesicular monoamine transporter inhibitor	SLC18A1|SLC18A2	cardiology	hypertension	0	74.36	Selleck	S1601	Reserpine	608.273	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	QEVHRUUCFGRFIF-MDEJGZGSSA-N	5770.0		QEVHRUUCFGRFIF
BRD-K95921201-001-14-6	reserpine	Launched	vesicular monoamine transporter inhibitor	SLC18A1|SLC18A2	cardiology	hypertension	0	88.29	MicroSource	1500526	RESERPINE	608.273	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	QEVHRUUCFGRFIF-MDEJGZGSSA-N	5770.0		QEVHRUUCFGRFIF
BRD-K25970317-001-01-6	resibufogenin	Phase 2	Na/K-ATPase inhibitor				0	87.34	MedChemEx	HY-N0815	Resibufogenin	384.23	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1	ATLJNLYIJOCWJE-CWMZOUAVSA-N	6917974.0		ATLJNLYIJOCWJE
BRD-K76210423-001-03-9	resiquimod	Phase 3	toll-like receptor agonist	TLR7|TLR8			0	94.67	Tocris	4536	Resiquimod	314.174	CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	BXNMTOQRYBFHNZ-UHFFFAOYSA-N	159603.0		BXNMTOQRYBFHNZ
BRD-K76210423-001-02-4	resiquimod	Phase 3	toll-like receptor agonist	TLR7|TLR8			0	96.48	Tocris	4536	Resiquimod	314.174	CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	BXNMTOQRYBFHNZ-UHFFFAOYSA-N	159603.0		BXNMTOQRYBFHNZ
BRD-K76210423-001-01-6	resiquimod	Phase 3	toll-like receptor agonist	TLR7|TLR8			0	99.64	MedChemEx	HY-13740	Resiquimod	314.174	CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	BXNMTOQRYBFHNZ-UHFFFAOYSA-N	159603.0		BXNMTOQRYBFHNZ
BRD-K00003123-001-01-9	resmetirom	Phase 3	thyroid hormone receptor agonist				0	96.94	MedChemEx	HY-12216	Resmetirom	434.03	CC(C)c1cc(Oc2c(Cl)cc(cc2Cl)-n2nc(C#N)c(=O)[nH]c2=O)nnc1O	FDBYIYFVSAHJLY-UHFFFAOYSA-N	15981237.0		FDBYIYFVSAHJLY
BRD-K28822270-003-04-9	resminostat	Phase 2	HDAC inhibitor	HDAC1|HDAC3|HDAC6|HDAC8			0	94.62	MedChemEx	HY-14718A	Resminostat (hydrochloride)	349.11	CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1	FECGNJPYVFEKOD-VMPITWQZSA-N	11609955.0		FECGNJPYVFEKOD
BRD-K28822270-001-01-1	resminostat	Phase 2	HDAC inhibitor	HDAC1|HDAC3|HDAC6|HDAC8			0	90.88	Selleck	S2693	Resminostat	349.11	CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1	FECGNJPYVFEKOD-VMPITWQZSA-N	11609955.0		FECGNJPYVFEKOD
BRD-K28822270-001-03-7	resminostat	Phase 2	HDAC inhibitor	HDAC1|HDAC3|HDAC6|HDAC8			0	91.59	Selleck	S2693	Resminostat (RAS2410)	349.11	CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1	FECGNJPYVFEKOD-VMPITWQZSA-N	11609955.0		FECGNJPYVFEKOD
BRD-K74190368-001-08-9	resorcinol	Launched	phosphodiesterase inhibitor	CA12|CA14|CA2|PTGS1	dermatology	acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis	0	0.0	MedChemEx	HY-B0907	Resorcinol	110.037	Oc1cccc(O)c1	GHMLBKRAJCXXBS-UHFFFAOYSA-N	5054.0		GHMLBKRAJCXXBS
BRD-K74190368-001-04-3	resorcinol	Launched	phosphodiesterase inhibitor	CA12|CA14|CA2|PTGS1	dermatology	acne vulgaris (AV)|eczema|psoriasis|seborrheic dermatitis	0	99.52	MicroSource	1500527	RESORCINOL	110.037	Oc1cccc(O)c1	GHMLBKRAJCXXBS-UHFFFAOYSA-N	5054.0		GHMLBKRAJCXXBS
BRD-K85603128-001-03-5	resorcinol-monoacetate	Launched	antiseptic				0	34.04	MicroSource	1503500	RESORCINOL MONOACETATE	152.047	CC(=O)Oc1cccc(O)c1	ZZPKZRHERLGEKA-UHFFFAOYSA-N	5055.0		ZZPKZRHERLGEKA
BRD-K85603128-001-04-3	resorcinol-monoacetate	Launched	antiseptic				0	70.52	MedChemEx	HY-B0894	Resorcinol (monoacetate)	152.047	CC(=O)Oc1cccc(O)c1	ZZPKZRHERLGEKA-UHFFFAOYSA-N	5055.0		ZZPKZRHERLGEKA
BRD-K80738081-001-46-8	resveratrol	Launched	cytochrome P450 inhibitor|SIRT activator	CSNK2A1|NQO2|PTGS1|PTGS2			0	95.03	MedChemEx	HY-16561	Resveratrol	228.079	Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	445154.0		LUKBXSAWLPMMSZ
BRD-K80738081-001-47-6	resveratrol	Launched	cytochrome P450 inhibitor|SIRT activator	CSNK2A1|NQO2|PTGS1|PTGS2			0	83.02	Tocris	1418	Resveratrol	228.079	Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	445154.0		LUKBXSAWLPMMSZ
BRD-K80738081-001-44-3	resveratrol	Launched	cytochrome P450 inhibitor|SIRT activator	CSNK2A1|NQO2|PTGS1|PTGS2			0	72.83	Selleck	S1396	Resveratrol	228.079	Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	445154.0		LUKBXSAWLPMMSZ
BRD-K80738081-001-42-7	resveratrol	Launched	cytochrome P450 inhibitor|SIRT activator	CSNK2A1|NQO2|PTGS1|PTGS2			0	71.47	Selleck	S1396	Resveratrol	228.079	Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	445154.0		LUKBXSAWLPMMSZ
BRD-K80738081-001-43-5	resveratrol	Launched	cytochrome P450 inhibitor|SIRT activator	CSNK2A1|NQO2|PTGS1|PTGS2			0	66.43	Tocris	1418	Resveratrol	228.079	Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	445154.0		LUKBXSAWLPMMSZ
BRD-K00003118-011-01-9	retagliptin	Phase 1	dipeptidyl peptidase inhibitor				0	90.32	MedChemEx	HY-112668	Retagliptin Phosphate	464.128	COC(=O)c1nc(n2CCN(Cc12)C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)C(F)(F)F	WIIAMRXFUJLYEF-SNVBAGLBSA-N	44193830.0		WIIAMRXFUJLYEF
BRD-K33082088-001-03-3	retapamulin	Launched	protein synthesis inhibitor		infectious disease	impetigo	0	100.0	Selleck	S4056	Retapamulin	517.323	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	STZYTFJPGGDRJD-NHUWBDDWSA-N		BRD-K17930269-001-01-8	STZYTFJPGGDRJD
BRD-K67935717-003-02-8	retaspimycin	Phase 3	HSP inhibitor	HSP90AA1			0	0.0	MedChemEx	HY-10210	Retaspimycin (Hydrochloride)	587.321	CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|	OAKGNIRUXAZDQF-FBDSWQSESA-N	25169033.0		OAKGNIRUXAZDQF
BRD-K67935717-003-01-0	retaspimycin	Phase 3	HSP inhibitor	HSP90AA1			0	0.0	MedChemEx	HY-10210	Retaspimycin (Hydrochloride)	587.321	CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17,t:15,28|	OAKGNIRUXAZDQF-FBDSWQSESA-N	25169033.0		OAKGNIRUXAZDQF
BRD-K79884267-001-01-4	retinaldehyde	Launched			dermatology	cosmetic	0	96.68	SantaCruz	sc-210778A		284.214	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O |c:9|	NCYCYZXNIZJOKI-OVSJKPMPSA-N	638015.0		NCYCYZXNIZJOKI
BRD-K22429181-001-15-9	retinol	Launched	retinoid receptor ligand	ALDH1A1|ALDH1A2|ALDH1A3|DHRS3|DHRS4|LRAT|NR2C2|RBP1|RBP3|RDH11|RDH12|RDH13|RDH14|RDH5|RDH8|RETSAT|RHO|RLBP1|RXRA|RXRB|RXRG	dermatology	cosmetic|acne vulgaris (AV)|keratosis	0	0.0	Sigma	MFCD00001552	retinol	286.23	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	445354.0		FPIPGXGPPPQFEQ
BRD-K22429181-001-14-2	retinol	Launched	retinoid receptor ligand	ALDH1A1|ALDH1A2|ALDH1A3|DHRS3|DHRS4|LRAT|NR2C2|RBP1|RBP3|RDH11|RDH12|RDH13|RDH14|RDH5|RDH8|RETSAT|RHO|RLBP1|RXRA|RXRB|RXRG	dermatology	cosmetic|acne vulgaris (AV)|keratosis	0	0.0	MicroSource	1501203	RETINOL	286.23	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|	FPIPGXGPPPQFEQ-OVSJKPMPSA-N	445354.0		FPIPGXGPPPQFEQ
BRD-K65331431-001-06-2	retinyl-acetate	Launched					0	0.0	MicroSource	1503051	RETINYL ACETATE	328.24	CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|	QGNJRVVDBSJHIZ-QHLGVNSISA-N	638034.0		QGNJRVVDBSJHIZ
BRD-K65331431-001-08-8	retinyl-acetate	Launched					0	0.0	Sigma	95140	O~15~-acetylretinol	328.24	CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|	QGNJRVVDBSJHIZ-QHLGVNSISA-N	638034.0		QGNJRVVDBSJHIZ
BRD-K80595380-001-07-2	retinyl-palmitate	Launched					0	0.0	MicroSource	1503604	RETINYL PALMITATE	524.459	CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|	VYGQUTWHTHXGQB-FFHKNEKCSA-N	5280531.0		VYGQUTWHTHXGQB
BRD-K80595380-001-09-8	retinyl-palmitate	Launched					0	0.0	Sigma	R1512	O~15~-palmitoylretinol	524.459	CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|	VYGQUTWHTHXGQB-FFHKNEKCSA-N	5280531.0		VYGQUTWHTHXGQB
BRD-A68281735-001-19-9	REV-5901	Phase 2	leukotriene receptor antagonist|lipoxygenase inhibitor	ALOX5			0	96.91	Sigma	MFCD00211150	1-[3-(2-quinolinylmethoxy)phenyl]-1-hexanol	335.189	CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|	JRLOEMCOOZSCQP-JOCHJYFZSA-N	40428144.0		JRLOEMCOOZSCQP
BRD-A68281735-001-18-6	REV-5901	Phase 2	leukotriene receptor antagonist|lipoxygenase inhibitor	ALOX5			0	94.05	Enzo	EI209	REV-5901	335.189	CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5,r|	JRLOEMCOOZSCQP-JOCHJYFZSA-N	40428144.0		JRLOEMCOOZSCQP
BRD-A51497544-001-01-4	revaprazan	Launched	potassium-competitive acid antagonist	ATP4A	gastroenterology	gastritis	0	0.0	AvaChem	2997	N-(4-fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)pyrimidin-2-amine	362.191	C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1,r|	LECZXZOBEZITCL-MRXNPFEDSA-N	40462255.0		LECZXZOBEZITCL
BRD-K00003198-001-01-9	revefenacin	Launched	cholinergic receptor antagonist				0	97.72	MedChemEx	HY-15851	Revefenacin	597.332	CN(CCN1CCC(CC1)OC(=O)Nc1ccccc1-c1ccccc1)C(=O)c1ccc(CN2CCC(CC2)C(N)=O)cc1	FYDWDCIFZSGNBU-UHFFFAOYSA-N	11753673.0		FYDWDCIFZSGNBU
BRD-K79700588-001-09-7	reversan	Preclinical	MRP inhibitor	ABCC1			0	96.72	Tocris	3722	Reversan	441.216	O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1	JTRXWCLQFAZHGP-UHFFFAOYSA-N	2298706.0		JTRXWCLQFAZHGP
BRD-K79700588-001-10-9	reversan	Preclinical	MRP inhibitor	ABCC1			0	96.48	Tocris	3722	Reversan	441.216	O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1	JTRXWCLQFAZHGP-UHFFFAOYSA-N	2298706.0		JTRXWCLQFAZHGP
BRD-K77286328-001-03-7	reversine	Preclinical	Aurora kinase inhibitor	AURKB|INCENP|MAP2K1			0	83.16	MedChemEx	HY-14711	Reversine	393.228	C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12	ZFLJHSQHILSNCM-UHFFFAOYSA-N	210332.0		ZFLJHSQHILSNCM
BRD-K77286328-001-06-0	reversine	Preclinical	Aurora kinase inhibitor	AURKB|INCENP|MAP2K1			0	82.09	MedChemEx	HY-14711	Reversine	393.228	C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12	ZFLJHSQHILSNCM-UHFFFAOYSA-N	210332.0		ZFLJHSQHILSNCM
BRD-K00005343-001-01-9	reynoutrin	Preclinical	antioxidant				0	100.0	MedChemEx	HY-N1354	Reynoutrin	434.085	O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O	PZZRDJXEMZMZFD-BWYUNELBSA-N	5320861.0		PZZRDJXEMZMZFD
BRD-K20986415-001-02-6	RGB-286638	Phase 1	CDK inhibitor	CDK1|CDK2|CDK3|CDK4|CDK5|CDK6|CDK7|CDK9|FLT3|GSK3B|JAK2|MAP3K7|MAPK9			0	92.93	MedChemEx	HY-15504A	RGB-286638 (free base)	545.275	COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1	XLSYZSRXVVCHLS-UHFFFAOYSA-N	11285002.0		XLSYZSRXVVCHLS
BRD-K20986415-001-01-8	RGB-286638	Phase 1	CDK inhibitor	CDK1|CDK2|CDK3|CDK4|CDK5|CDK6|CDK7|CDK9|FLT3|GSK3B|JAK2|MAP3K7|MAPK9			0	93.17	MedChemEx	HY-15504A	RGB-286638 (free base)	545.275	COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1	XLSYZSRXVVCHLS-UHFFFAOYSA-N	11285002.0		XLSYZSRXVVCHLS
BRD-K61688984-001-02-9	RGFP966	Preclinical	HDAC inhibitor	HDAC3			0	92.17	Selleck	S7229	RGFP966	362.154	Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	BLVQHYHDYFTPDV-VCABWLAWSA-N	56650312.0		BLVQHYHDYFTPDV
BRD-K00004597-001-01-9	RGX-104	Phase 1	LXR agonist				0	94.52	MedChemEx	HY-111498A	RGX-104	595.21	C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F	ZLJZDYOBXVOTSA-XMMPIXPASA-N	10218693.0		ZLJZDYOBXVOTSA
BRD-K89391146-001-09-8	RG108	Preclinical	DNA methyltransferase inhibitor	DNMT1|DNMT3B			0	98.82	Tocris	3295	RG 108	334.095	OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	HPTXLHAHLXOAKV-INIZCTEOSA-N	702558.0		HPTXLHAHLXOAKV
BRD-K89391146-001-12-9	RG108	Preclinical	DNA methyltransferase inhibitor	DNMT1|DNMT3B			0	96.47	Tocris	3295	RG 108	334.095	OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	HPTXLHAHLXOAKV-INIZCTEOSA-N	702558.0		HPTXLHAHLXOAKV
BRD-K89391146-001-08-0	RG108	Preclinical	DNA methyltransferase inhibitor	DNMT1|DNMT3B			0	95.83	Selleck	S2821	RG108	334.095	OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	HPTXLHAHLXOAKV-INIZCTEOSA-N	702558.0		HPTXLHAHLXOAKV
BRD-K32942258-001-04-1	RG1530	Phase 1	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FGFR1|FGFR2			0	39.97	MedChemEx	HY-13737	R1530	356.084	COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|	XXAKBYBCWYYQTL-UHFFFAOYSA-N			XXAKBYBCWYYQTL
BRD-K32942258-001-02-5	RG1530	Phase 1	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FGFR1|FGFR2			0	58.63	MedChemEx	HY-13737	R1530	356.084	COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|	XXAKBYBCWYYQTL-UHFFFAOYSA-N			XXAKBYBCWYYQTL
BRD-K32942258-001-01-7	RG1530	Phase 1	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FGFR1|FGFR2			0	2.25	MedChemEx	HY-13737	R1530	356.084	COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|	XXAKBYBCWYYQTL-UHFFFAOYSA-N			XXAKBYBCWYYQTL
BRD-K32942258-001-03-3	RG1530	Phase 1	FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	FGFR1|FGFR2			0	5.27	Tocris	4885	R 1530	356.084	COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5,8,13|	XXAKBYBCWYYQTL-UHFFFAOYSA-N			XXAKBYBCWYYQTL
BRD-K02389548-001-04-1	RG2833	Phase 1	HDAC inhibitor	HDAC1|HDAC3			0	97.98	MedChemEx	HY-16425	RG2833	339.195	Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	VOPDXHFYDJAYNS-UHFFFAOYSA-N	56654642.0		VOPDXHFYDJAYNS
BRD-K02389548-001-02-5	RG2833	Phase 1	HDAC inhibitor	HDAC1|HDAC3			0	91.76	Selleck	S7292	RG2833 (RGFP109)	339.195	Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	VOPDXHFYDJAYNS-UHFFFAOYSA-N	56654642.0		VOPDXHFYDJAYNS
BRD-K22024824-001-03-7	RG4733	Phase 2	gamma secretase inhibitor	PSEN1			0	98.56	MedChemEx	HY-11102	RO4929097	469.142	CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	OJPLJFIFUQPSJR-INIZCTEOSA-N	49867930.0		OJPLJFIFUQPSJR
BRD-K22024824-001-04-9	RG4733	Phase 2	gamma secretase inhibitor	PSEN1			0	96.37	MedChemEx	HY-11102	RO4929097	469.142	CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	OJPLJFIFUQPSJR-INIZCTEOSA-N	49867930.0		OJPLJFIFUQPSJR
BRD-K13178532-001-01-9	RG7112	Phase 1	MDM inhibitor	MDM2			0	98.54	Selleck	S7030	RG-7112	726.277	CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|	QBGKPEROWUKSBK-QPPIDDCLSA-N	57406853.0		QBGKPEROWUKSBK
BRD-K00004590-001-01-9	RG7800	Preclinical	RNA splicing modifier				0	75.37	MedChemEx	HY-101792	RG7800	416.232	CCc1nc(C)cn2nc(cc12)-c1cc(=O)n2cc(cc(C)c2n1)C1CCN(C)CC1	GYFRQCMDLBNZSF-UHFFFAOYSA-N	89741565.0		GYFRQCMDLBNZSF
BRD-K00004573-001-01-9	RG7834	Preclinical	antiviral				0	94.87	Astatech	41511	(S)-6-ISOPROPYL-10-METHOXY-9-(3-METHOXYPROPOXY)-2-OXO-6,7-DIHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE-3-CARBOXYLIC ACID	401.184	COCCCOc1cc2C[C@@H](C(C)C)n3cc(C(O)=O)c(=O)cc3-c2cc1OC	KBXLMOYQNDMHQT-KRWDZBQOSA-N	134305955.0		KBXLMOYQNDMHQT
BRD-K56047318-001-07-1	RHC-80267	Preclinical	triacylglycerol lipase inhibitor	DAGLA|DAGLB			0	92.28	Tocris	1842	RHC 80267	394.258	O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	RXSVYGIGWRDVQC-UHFFFAOYSA-N	5063.0		RXSVYGIGWRDVQC
BRD-K56047318-001-08-9	RHC-80267	Preclinical	triacylglycerol lipase inhibitor	DAGLA|DAGLB			0	87.32	Tocris	1842	RHC 80267	394.258	O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	RXSVYGIGWRDVQC-UHFFFAOYSA-N	5063.0		RXSVYGIGWRDVQC
BRD-K56047318-001-06-3	RHC-80267	Preclinical	triacylglycerol lipase inhibitor	DAGLA|DAGLB			0	95.7	Tocris	1842	RHC 80267	394.258	O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	RXSVYGIGWRDVQC-UHFFFAOYSA-N	5063.0		RXSVYGIGWRDVQC
BRD-K27335680-001-11-9	rhein	Phase 1		HSP90AA1			0	94.68	MedChemEx	HY-N0105	Rhein	284.032	OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	FCDLCPWAQCPTKC-UHFFFAOYSA-N	10168.0		FCDLCPWAQCPTKC
BRD-K27335680-001-10-0	rhein	Phase 1		HSP90AA1			0	97.12	Selleck	S2400	Rheic Acid	284.032	OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	FCDLCPWAQCPTKC-UHFFFAOYSA-N	10168.0		FCDLCPWAQCPTKC
BRD-K67772619-001-05-1	rheochrysidin	Preclinical	protein tyrosine kinase inhibitor	PTPN1			0	86.96	Selleck	S2395	Rheochrysidin	284.068	COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	FFWOKTFYGVYKIR-UHFFFAOYSA-N	10639.0		FFWOKTFYGVYKIR
BRD-K67772619-001-06-9	rheochrysidin	Preclinical	protein tyrosine kinase inhibitor	PTPN1			0	85.17	Selleck	S2395	PHYSCION	284.068	COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	FFWOKTFYGVYKIR-UHFFFAOYSA-N	10639.0		FFWOKTFYGVYKIR
BRD-K47169076-003-01-6	rhodamine-123	Phase 1					0	93.16	Cayman	16672	3,6-diamino-9-(2-(methoxycarbonyl)phenyl)xanthylium chloride	345.124	COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12	ZWODABSNRKVFCK-UHFFFAOYSA-N			ZWODABSNRKVFCK
BRD-K79555887-001-02-9	RI-1	Preclinical		RAD51			0	87.17	Tocris	6168	RI 1	359.984	ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|	MWSUIZKGNWELRF-UHFFFAOYSA-N	1074953.0		MWSUIZKGNWELRF
BRD-K79555887-001-01-0	RI-1	Preclinical		RAD51			0	90.39	Selleck	S8077	RI-1	359.984	ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|	MWSUIZKGNWELRF-UHFFFAOYSA-N	1074953.0		MWSUIZKGNWELRF
BRD-K60369935-001-19-9	ribavirin	Launched	antiviral	ADK|ENPP1|IMPDH1|IMPDH2|NT5C2	infectious disease	hepatitis C	0	100.0	Tocris	4501	Ribavirin	244.081	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	IWUCXVSUMQZMFG-AFCXAGJDSA-N	37542.0		IWUCXVSUMQZMFG
BRD-K60369935-001-17-5	ribavirin	Launched	antiviral	ADK|ENPP1|IMPDH1|IMPDH2|NT5C2	infectious disease	hepatitis C	0	99.13	Tocris	4501	Ribavirin	244.081	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	IWUCXVSUMQZMFG-AFCXAGJDSA-N	37542.0		IWUCXVSUMQZMFG
BRD-K60369935-001-15-9	ribavirin	Launched	antiviral	ADK|ENPP1|IMPDH1|IMPDH2|NT5C2	infectious disease	hepatitis C	0	99.17	MicroSource	1503938	RIBAVIRIN	244.081	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	IWUCXVSUMQZMFG-AFCXAGJDSA-N	37542.0		IWUCXVSUMQZMFG
BRD-K60369935-001-18-3	ribavirin	Launched	antiviral	ADK|ENPP1|IMPDH1|IMPDH2|NT5C2	infectious disease	hepatitis C	0	100.0	Selleck	S2504	Ribavirin	244.081	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	IWUCXVSUMQZMFG-AFCXAGJDSA-N	37542.0	BRD-K94397152-001-01-6	IWUCXVSUMQZMFG
BRD-K49313711-001-06-9	ribitol	Preclinical					0	100.0	MedChemEx	HY-100582	Ribitol	152.068	OC[C@H](O)[C@H](O)[C@H](O)CO	HEBKCHPVOIAQTA-ZXFHETKHSA-N			HEBKCHPVOIAQTA
BRD-K49313711-001-05-4	ribitol	Preclinical					0	100.0	Selleck	S2612	Ribitol	152.068	OC[C@H](O)[C@H](O)[C@H](O)CO	HEBKCHPVOIAQTA-ZXFHETKHSA-N			HEBKCHPVOIAQTA
BRD-K36788280-001-04-6	ribociclib	Launched	CDK inhibitor	CDK4|CDK6	oncology	breast cancer	0	93.42	MedChemEx	HY-15777	LEE011	434.254	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	RHXHGRAEPCAFML-UHFFFAOYSA-N	44631912.0		RHXHGRAEPCAFML
BRD-K36788280-001-01-2	ribociclib	Launched	CDK inhibitor	CDK4|CDK6	oncology	breast cancer	0	82.54	Selleck	S7440	LEE011	434.254	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	RHXHGRAEPCAFML-UHFFFAOYSA-N	44631912.0		RHXHGRAEPCAFML
BRD-K36788280-001-03-8	ribociclib	Launched	CDK inhibitor	CDK4|CDK6	oncology	breast cancer	0	80.51	Selleck	S7440	Ribociclib (LEE011)	434.254	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	RHXHGRAEPCAFML-UHFFFAOYSA-N	44631912.0		RHXHGRAEPCAFML
BRD-K92760278-001-07-3	riboflavin	Launched	vitamin B	BLVRB|RFK	gastroenterology	jaundice	0	91.09	Selleck	S2540	Riboflavin (Vitamin B2)	376.138	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	AUNGANRZJHBGPY-SCRDCRAPSA-N	493570.0		AUNGANRZJHBGPY
BRD-K92760278-001-06-5	riboflavin	Launched	vitamin B	BLVRB|RFK	gastroenterology	jaundice	0	34.72	Selleck	S2540	Riboflavin (Vitamin B2)	376.138	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	AUNGANRZJHBGPY-SCRDCRAPSA-N	493570.0		AUNGANRZJHBGPY
BRD-K92760278-001-09-9	riboflavin	Launched	vitamin B	BLVRB|RFK	gastroenterology	jaundice	0	64.12	MedChemEx	HY-B0456	Riboflavin	376.138	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	AUNGANRZJHBGPY-SCRDCRAPSA-N	493570.0		AUNGANRZJHBGPY
BRD-K92760278-001-08-1	riboflavin	Launched	vitamin B	BLVRB|RFK	gastroenterology	jaundice	0	87.4	Selleck	S2540	Riboflavin (Vitamin B2)	376.138	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	AUNGANRZJHBGPY-SCRDCRAPSA-N	493570.0		AUNGANRZJHBGPY
BRD-K74227494-001-03-9	riboflavin-tetrabutyrate	Preclinical	antioxidant				0	92.24	MedChemEx	HY-B2239	Riboflavin Tetrabutyrate	656.306	CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2cc(C)c(C)cc2nc2c1nc(=O)[nH]c2=O)OC(=O)CCC	MJNIWUJSIGSWKK-BBANNHEPSA-N	92140.0		MJNIWUJSIGSWKK
BRD-K09229706-236-02-6	riboflavin-5-phosphate-sodium	Launched		BLVRB|DHODH|DPYD|HAO1|HAO2|MT-ND1|NOS1|PNPO|POR|PPCDC|RFK|RPS6KA4|SGK1			0	10.28	MedChemEx	HY-B0964	Riboflavin (phosphate sodium)	456.105	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C	FVTCRASFADXXNN-SCRDCRAPSA-N	643976.0		FVTCRASFADXXNN
BRD-K09229706-236-01-8	riboflavin-5-phosphate-sodium	Launched		BLVRB|DHODH|DPYD|HAO1|HAO2|MT-ND1|NOS1|PNPO|POR|PPCDC|RFK|RPS6KA4|SGK1			0	0.0	Sigma	MFCD00065362	sodium 1-deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)-5-O-(hydroxyphosphinato)-D-ribitol	456.105	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C	FVTCRASFADXXNN-SCRDCRAPSA-N	643976.0		FVTCRASFADXXNN
BRD-K09229706-325-01-9	riboflavin-5-phosphate-sodium	Launched		BLVRB|DHODH|DPYD|HAO1|HAO2|MT-ND1|NOS1|PNPO|POR|PPCDC|RFK|RPS6KA4|SGK1			0	70.1	Sigma	R7774-10G	Riboflavin 5'-phosphate sodium salt hydrate	456.105	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C	FVTCRASFADXXNN-SCRDCRAPSA-N	643976.0		FVTCRASFADXXNN
BRD-K55188888-065-01-2	ribostamycin	Launched	bacterial 30S ribosomal subunit inhibitor	P4HB	infectious disease	human immunodeficiency virus (HIV-1)	0	73.8	MedChemEx	HY-B1228	Ribostamycin (sulfate)	454.227	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	NSKGQURZWSPSBC-VVPCINPTSA-N	33042.0		NSKGQURZWSPSBC
BRD-K55188888-065-02-9	ribostamycin	Launched	bacterial 30S ribosomal subunit inhibitor	P4HB	infectious disease	human immunodeficiency virus (HIV-1)	0	0.0	MedChemEx	HY-B1228	Ribostamycin (sulfate)	454.227	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	NSKGQURZWSPSBC-VVPCINPTSA-N	33042.0		NSKGQURZWSPSBC
BRD-K01826536-065-03-9	ribostamycin-sulfate	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MicroSource	1503939	RIBOSTAMYCIN SULFATE	552.195	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O |a:2,4,6,7,10,12,16,18,21,23,25,27,29,&1:14|	NSKGQURZWSPSBC-NZJHKTKDSA-N			NSKGQURZWSPSBC
BRD-K33682646-001-02-7	ricinoleic-acid	Launched	prostanoid receptor agonist	PTGER3			0	51.56	TCI	R0027		298.251	CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O	WBHHMMIMDMUBKC-QJWNTBNXSA-N	643684.0		WBHHMMIMDMUBKC
BRD-K77897005-001-02-9	ridinilazole	Phase 3	antibacterial				0	97.14	MedChemEx	HY-16753	Ridinilazole	388.144	c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1	UHQFBTAJFNVZIV-UHFFFAOYSA-N	16659285.0		UHQFBTAJFNVZIV
BRD-K31484631-001-12-9	rifabutin	Launched	protein synthesis inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	96.93	MedChemEx	HY-17025	Rifabutin	846.442	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2C4=NC5(CCN(CC(C)C)CC5)NC4=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(=O)c2c(O)c3C |c:36,t:3,15,30,38|	ATEBXHFBFRCZMA-DVAZEERGSA-N			ATEBXHFBFRCZMA
BRD-K01507359-001-23-7	rifampin	Launched	RNA polymerase inhibitor	NR1I2|SLCO1A2|SLCO1B1|SLCO1B3	infectious disease	tuberculosis|meningitis	0	77.49	Selleck	S1764	Rifampin	822.405	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|	JQXXHWHPUNPDRT-YOPQJBRCSA-N	135925261.0	BRD-K66218091-001-01-2	JQXXHWHPUNPDRT
BRD-K01507359-001-24-9	rifampin	Launched	RNA polymerase inhibitor	NR1I2|SLCO1A2|SLCO1B1|SLCO1B3	infectious disease	tuberculosis|meningitis	0	87.66	Tocris	4121	Rifampicin	822.405	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|	JQXXHWHPUNPDRT-YOPQJBRCSA-N	135925261.0		JQXXHWHPUNPDRT
BRD-K01507359-001-22-9	rifampin	Launched	RNA polymerase inhibitor	NR1I2|SLCO1A2|SLCO1B1|SLCO1B3	infectious disease	tuberculosis|meningitis	0	89.01	Selleck	S1764	Rifampin	822.405	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33,t:3,35|	JQXXHWHPUNPDRT-YOPQJBRCSA-N	135925261.0	BRD-K56156786-001-01-6	JQXXHWHPUNPDRT
BRD-K38512030-001-01-7	rifamycin	Launched	DNA directed RNA polymerase inhibitor	SLCO1A2|SLCO1B1|SLCO1B3|SLCO2B1	infectious disease	tuberculosis|leprosy	0	2.86	AvaChem	2841		697.31	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|	HJYYPODYNSCCOU-WURVRSKISA-N	5282048.0		HJYYPODYNSCCOU
BRD-K66048476-236-01-0	rifamycin-sv	Phase 3	RNA synthesis inhibitor				0	96.94	Selleck	S5054		697.31	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23,t:3,25|	HJYYPODYNSCCOU-WURVRSKISA-N	5282048.0		HJYYPODYNSCCOU
BRD-K28346421-001-08-4	rifapentine	Launched	RNA polymerase inhibitor	CYP2C8|CYP2C9|CYP3A4	infectious disease	tuberculosis	0	31.22	Selleck	S1760	Rifapentine	876.452	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|	WDZCUPBHRAEYDL-NAFQJNKLSA-N	136238508.0	BRD-K55889443-001-03-4	WDZCUPBHRAEYDL
BRD-K28346421-001-07-6	rifapentine	Launched	RNA polymerase inhibitor	CYP2C8|CYP2C9|CYP3A4	infectious disease	tuberculosis	0	74.29	MedChemEx	HY-B0269	Rifapentine	876.452	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|	WDZCUPBHRAEYDL-NAFQJNKLSA-N	136238508.0	BRD-K42569090-001-01-8	WDZCUPBHRAEYDL
BRD-K28346421-001-06-8	rifapentine	Launched	RNA polymerase inhibitor	CYP2C8|CYP2C9|CYP3A4	infectious disease	tuberculosis	0	71.91	Selleck	S1760	Rifapentine	876.452	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38,t:3,40|	WDZCUPBHRAEYDL-NAFQJNKLSA-N	136238508.0	BRD-K62325629-001-01-0	WDZCUPBHRAEYDL
BRD-K53484294-001-03-9	rifaximin	Launched	RNA synthesis inhibitor		gastroenterology	diarrhea|irritable bowel syndrome|hepatic encephalopathy (HE)	0	98.57	Tocris	5359	Rifaximin	785.352	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32,t:3,34|	NZCRJKRKKOLAOJ-LGPAXTBISA-N	46783403.0		NZCRJKRKKOLAOJ
BRD-K55187425-236-06-0	rigosertib	Phase 3	cell cycle inhibitor|PLK inhibitor	PLK1			0	71.01	Selleck	S1362	Rigosertib (ON-01910)	451.13	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	OWBFCJROIKNMGD-BQYQJAHWSA-N	6918736.0		OWBFCJROIKNMGD
BRD-K55187425-236-07-8	rigosertib	Phase 3	cell cycle inhibitor|PLK inhibitor	PLK1			0	94.32	MedChemEx	HY-12037	Rigosertib (sodium)	451.13	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	OWBFCJROIKNMGD-BQYQJAHWSA-N	6918736.0		OWBFCJROIKNMGD
BRD-K55187425-236-05-2	rigosertib	Phase 3	cell cycle inhibitor|PLK inhibitor	PLK1			0	81.46	Selleck	S1362	Rigosertib (ON-01910)	451.13	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	OWBFCJROIKNMGD-BQYQJAHWSA-N	6918736.0		OWBFCJROIKNMGD
BRD-K00004676-001-01-9	rilapladib	Phase 2	phospholipase inhibitor				0	96.22	MedChemEx	HY-102004	2-(2-((2,3-difluorobenzyl)thio)-4-oxoquinolin-1(4H)-yl)-N-(1-(2-methoxyethyl)piperidin-4-yl)-N-((4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)methyl)acetamide	735.255	COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12	NNBGCSGCRSCFEA-UHFFFAOYSA-N	9918381.0		NNBGCSGCRSCFEA
BRD-K01638814-051-16-8	rilmenidine	Launched	adrenergic receptor agonist|imidazoline receptor agonist	ADRA2A	cardiology	hypertension	0	0.0	Tocris	790	Rilmenidine hemifumarate	180.126	C1CC1C(NC1=NCCO1)C1CC1 |t:6|	CQXADFVORZEARL-UHFFFAOYSA-N	68712.0	BRD-M62162320-051-04-6	CQXADFVORZEARL
BRD-K01638814-011-01-4	rilmenidine	Launched	adrenergic receptor agonist|imidazoline receptor agonist	ADRA2A	cardiology	hypertension	0	88.74	Selleck	S7548	phosphoric acid compound with N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine (1:1)	180.126	C1CC1C(NC1=NCCO1)C1CC1 |t:6|	CQXADFVORZEARL-UHFFFAOYSA-N	68712.0		CQXADFVORZEARL
BRD-K06240250-001-02-9	rilpivirine	Launched	non-nucleoside reverse transcriptase inhibitor	NR1I2|SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	0	92.64	MedChemEx	HY-10574	Rilpivirine	366.159	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	YIBOMRUWOWDFLG-ONEGZZNKSA-N	6451164.0		YIBOMRUWOWDFLG
BRD-K06240250-001-01-6	rilpivirine	Launched	non-nucleoside reverse transcriptase inhibitor	NR1I2|SCN10A	infectious disease	human immunodeficiency virus (HIV-1)	0	93.71	Selleck	S7303	Rilpivirine	366.159	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	YIBOMRUWOWDFLG-ONEGZZNKSA-N	6451164.0		YIBOMRUWOWDFLG
BRD-K21283037-003-11-2	riluzole	Launched	glutamate inhibitor	KCNK10|KCNK2|KCNK4|KCNN4|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A|SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	0	98.83	Tocris	768	Riluzole	234.007	Nc1nc2ccc(OC(F)(F)F)cc2s1	FTALBRSUTCGOEG-UHFFFAOYSA-N	5070.0		FTALBRSUTCGOEG
BRD-K21283037-001-21-5	riluzole	Launched	glutamate inhibitor	KCNK10|KCNK2|KCNK4|KCNN4|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A|SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	0	99.88	MicroSource	1505348	RILUZOLE	234.007	Nc1nc2ccc(OC(F)(F)F)cc2s1	FTALBRSUTCGOEG-UHFFFAOYSA-N	5070.0		FTALBRSUTCGOEG
BRD-K21283037-001-20-7	riluzole	Launched	glutamate inhibitor	KCNK10|KCNK2|KCNK4|KCNN4|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A|SLC7A11	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)	0	99.07	Selleck	S1614	Riluzole	234.007	Nc1nc2ccc(OC(F)(F)F)cc2s1	FTALBRSUTCGOEG-UHFFFAOYSA-N	5070.0		FTALBRSUTCGOEG
BRD-K01825586-001-02-9	rimantadine	Launched	antiviral|RNA synthesis inhibitor		infectious disease	influenza A virus infection	0	100.0	Selleck	S1964	Rimantadine	179.167	C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|	UBCHPRBFMUDMNC-AAWJQDODSA-N	7048786.0		UBCHPRBFMUDMNC
BRD-K01825586-001-04-9	rimantadine	Launched	antiviral|RNA synthesis inhibitor		infectious disease	influenza A virus infection	0	100.0	Selleck	S1964	Rimantadine (Flumadine)	179.167	C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1,r|	UBCHPRBFMUDMNC-AAWJQDODSA-N	7048786.0		UBCHPRBFMUDMNC
BRD-K70490179-300-01-2	rimcazole	Phase 1	sigma receptor antagonist	SIGMAR1			0	96.68	Tocris	1497	Rimcazole dihydrochloride	321.22	C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1	GUDVQJXODNJRIJ-CALCHBBNSA-N	53389.0		GUDVQJXODNJRIJ
BRD-K55781385-001-01-7	rimegepant	Launched	calcitonin antagonist	CALCA			0	95.12	MedChemEx	HY-15498	BMS-927711	534.219	N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	KRNAOFGYEFKHPB-ANJVHQHFSA-N	51049968.0		KRNAOFGYEFKHPB
BRD-K55781385-001-02-9	rimegepant	Launched	calcitonin antagonist	CALCA			0	94.31	MedChemEx	HY-15498	Rimegepant	534.219	N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	KRNAOFGYEFKHPB-ANJVHQHFSA-N	51049968.0		KRNAOFGYEFKHPB
BRD-K00004645-001-01-9	rimeporide	Phase 1	sodium/hydrogen exchanger inhibitor				0	94.96	Sigma	SML1828	N-carbamimidoyl-2-methyl-4,5-bis(methylsulfonyl)benzamide	333.045	Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O	GROMEQPXDKRRIE-UHFFFAOYSA-N	9799487.0		GROMEQPXDKRRIE
BRD-K31627533-001-09-5	rimexolone	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	ophthalmology	anterior uveitis	0	97.27	Prestwick	Prestw-1020	Rimexolone	370.251	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|	QTTRZHGPGKRAFB-OOKHYKNYSA-N	5311412.0		QTTRZHGPGKRAFB
BRD-K31627533-001-10-3	rimexolone	Launched	glucocorticoid receptor agonist	NR3C1|SERPINA6	ophthalmology	anterior uveitis	0	94.62	USP	1604600	Rimexolone	370.251	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17,t:13|	QTTRZHGPGKRAFB-OOKHYKNYSA-N	5311412.0		QTTRZHGPGKRAFB
BRD-K13296708-001-05-8	rimonabant	Withdrawn	cannabinoid receptor antagonist	CNR1|GPR55			0	97.2	Selleck	S3021	Rimonabant	462.078	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	JZCPYUJPEARBJL-UHFFFAOYSA-N	104850.0		JZCPYUJPEARBJL
BRD-K13296708-003-06-9	rimonabant	Withdrawn	cannabinoid receptor antagonist	CNR1|GPR55			0	96.46	MedChemEx	HY-14137	Rimonabant (Hydrochloride)	462.078	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	JZCPYUJPEARBJL-UHFFFAOYSA-N	104850.0		JZCPYUJPEARBJL
BRD-K84783599-001-01-0	riociguat	Launched	guanylate cyclase stimulant	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3	cardiology	hypertension	0	99.03	MedChemEx	HY-14779	Riociguat	422.162	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	WXXSNCNJFUAIDG-UHFFFAOYSA-N	11304743.0		WXXSNCNJFUAIDG
BRD-K84783599-001-02-9	riociguat	Launched	guanylate cyclase stimulant	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3	cardiology	hypertension	0	93.06	MedChemEx	HY-14779	Riociguat	422.162	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	WXXSNCNJFUAIDG-UHFFFAOYSA-N	11304743.0		WXXSNCNJFUAIDG
BRD-K36379990-001-01-1	riodipine	Phase 2	calcium channel blocker				0	97.87	Sigma	MFCD00728312	dimethyl 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate	367.123	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4,9|	AZVFIZVKGSPGPK-UHFFFAOYSA-N	68909.0		AZVFIZVKGSPGPK
BRD-K48963429-001-02-7	riodoxol	Launched	other antibiotic				1	0.0	Vitas-M	STK279680	2,4,6-triiodo-1,3-benzenediol	487.727	Oc1c(I)cc(I)c(O)c1I	XKFZYVWWXHCHIX-UHFFFAOYSA-N	152256.0		XKFZYVWWXHCHIX
BRD-K48963429-001-01-9	riodoxol	Launched	other antibiotic				1	31.26	Vitas-M	STK279680		487.727	Oc1c(I)cc(I)c(O)c1I	XKFZYVWWXHCHIX-UHFFFAOYSA-N	152256.0		XKFZYVWWXHCHIX
BRD-K53814070-310-01-3	ripasudil	Launched	rho associated kinase inhibitor	ROCK1|ROCK2	ophthalmology	glaucoma|ocular hypertension	0	98.73	MedChemEx	HY-15685	K-115	323.11	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	QSKQVZWVLOIIEV-NSHDSACASA-N	9863672.0		QSKQVZWVLOIIEV
BRD-K53814070-310-02-9	ripasudil	Launched	rho associated kinase inhibitor	ROCK1|ROCK2	ophthalmology	glaucoma|ocular hypertension	0	97.84	MedChemEx	HY-15685	Ripasudil	323.11	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	QSKQVZWVLOIIEV-NSHDSACASA-N	9863672.0		QSKQVZWVLOIIEV
BRD-K57427145-001-01-6	ripazepam	Phase 2	benzodiazepine receptor agonist	GABRA1			0	99.45	Sigma	PH000306	1-ethyl-3-methyl-8-phenyl-4,6-dihydropyrazolo[4,3-e][1,4]diazepin-5(1H)-one	268.132	CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|	YFHYNLHGFKXAIQ-UHFFFAOYSA-N	33474.0		YFHYNLHGFKXAIQ
BRD-K00005241-001-01-9	ripretinib	Phase 3	receptor tyrosine protein kinase inhibitor				0	95.43	MedChemEx	HY-112306	Ripretinib	509.086	CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O	CEFJVGZHQAGLHS-UHFFFAOYSA-N	71584930.0		CEFJVGZHQAGLHS
BRD-K00003506-001-01-9	risdiplam	Phase 2/Phase 3	RNA splicing inhibitor				0	56.36	MedChemEx	HY-109101	Risdiplam	401.196	Cc1cn2nc(cc(C)c2n1)-c1cc(=O)n2cc(ccc2n1)N1CCNC2(CC2)C1	ASKZRYGFUPSJPN-UHFFFAOYSA-N	118513932.0		ASKZRYGFUPSJPN
BRD-K05185389-236-04-4	risedronate	Launched	osteoclast inhibitor	FDPS	orthopedics|endocrinology	osteoporosis|Paget's disease	1	0.0	MicroSource	1505944	RISEDRONATE SODIUM	283.001	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	IIDJRNMFWXDHID-UHFFFAOYSA-N	5245.0		IIDJRNMFWXDHID
BRD-K05185389-236-05-1	risedronate	Launched	osteoclast inhibitor	FDPS	orthopedics|endocrinology	osteoporosis|Paget's disease	1	0.0	Selleck	S1428	Risedronate sodium	283.001	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	IIDJRNMFWXDHID-UHFFFAOYSA-N	5245.0		IIDJRNMFWXDHID
BRD-K05185389-001-02-6	risedronate	Launched	osteoclast inhibitor	FDPS	orthopedics|endocrinology	osteoporosis|Paget's disease	1	0.0	Selleck	S1874	Risedronic acid (Actonel)	283.001	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	IIDJRNMFWXDHID-UHFFFAOYSA-N	5245.0		IIDJRNMFWXDHID
BRD-K05185389-001-03-4	risedronate	Launched	osteoclast inhibitor	FDPS	orthopedics|endocrinology	osteoporosis|Paget's disease	1	0.0	Selleck	S1874	Risedronic acid (Actonel)	283.001	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	IIDJRNMFWXDHID-UHFFFAOYSA-N	5245.0		IIDJRNMFWXDHID
BRD-K05185389-236-03-6	risedronate	Launched	osteoclast inhibitor	FDPS	orthopedics|endocrinology	osteoporosis|Paget's disease	1	0.0	Selleck	S1428	Risedronate sodium	283.001	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	IIDJRNMFWXDHID-UHFFFAOYSA-N	5245.0		IIDJRNMFWXDHID
BRD-K00003471-001-01-9	rislenemdaz	Preclinical	ionotropic glutamate receptor antagonist				0	94.73	MedChemEx	HY-106441A	Rislenemdaz	358.181	Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1	RECBFDWSXWAXHY-IAGOWNOFSA-N	11394238.0		RECBFDWSXWAXHY
BRD-K53857191-001-22-7	risperidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|HTR7	neurology/psychiatry	schizophrenia|bipolar disorder|irritability	0	98.34	MicroSource	1506038	RISPERIDONE	410.212	Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	RAPZEAPATHNIPO-UHFFFAOYSA-N	5073.0		RAPZEAPATHNIPO
BRD-K53857191-001-21-9	risperidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|HTR7	neurology/psychiatry	schizophrenia|bipolar disorder|irritability	0	96.75	Selleck	S1615	Risperidone	410.212	Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	RAPZEAPATHNIPO-UHFFFAOYSA-N	5073.0		RAPZEAPATHNIPO
BRD-K00317371-001-05-3	RITA	Preclinical	MDM inhibitor	MDM2			0	0.0	Selleck	S2781	RITA (NSC 652287)	292.023	OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1	KZENBFUSKMWCJF-UHFFFAOYSA-N	374536.0		KZENBFUSKMWCJF
BRD-K00317371-001-06-1	RITA	Preclinical	MDM inhibitor	MDM2			0	87.3	Selleck	S2781	RITA (NSC 652287)	292.023	OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1	KZENBFUSKMWCJF-UHFFFAOYSA-N	374536.0		KZENBFUSKMWCJF
BRD-K40887525-001-23-5	ritanserin	Phase 3	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7			0	98.51	Tocris	1955	Ritanserin	477.169	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	JUQLTPCYUFPYKE-UHFFFAOYSA-N	5074.0		JUQLTPCYUFPYKE
BRD-K40887525-001-22-7	ritanserin	Phase 3	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7			0	96.23	MicroSource	1503421	RITANSERIN	477.169	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	JUQLTPCYUFPYKE-UHFFFAOYSA-N	5074.0		JUQLTPCYUFPYKE
BRD-K40887525-001-24-9	ritanserin	Phase 3	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7			0	96.66	Tocris	1955	Ritanserin	477.169	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	JUQLTPCYUFPYKE-UHFFFAOYSA-N	5074.0		JUQLTPCYUFPYKE
BRD-K40887525-001-21-9	ritanserin	Phase 3	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7			0	96.93	Tocris	1955	Ritanserin	477.169	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	JUQLTPCYUFPYKE-UHFFFAOYSA-N	5074.0		JUQLTPCYUFPYKE
BRD-K14003026-003-09-0	ritodrine	Withdrawn	adrenergic receptor agonist		obstetrics/gynecology	premature labor	0	98.11	Selleck	S2533		287.152	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|	IOVGROKTTNBUGK-SJKOYZFVSA-N	688570.0		IOVGROKTTNBUGK
BRD-K14003026-003-08-2	ritodrine	Withdrawn	adrenergic receptor agonist		obstetrics/gynecology	premature labor	0	88.6	Selleck	S2533		287.152	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|	IOVGROKTTNBUGK-SJKOYZFVSA-N	688570.0		IOVGROKTTNBUGK
BRD-K14003026-003-10-9	ritodrine	Withdrawn	adrenergic receptor agonist		obstetrics/gynecology	premature labor	0	95.03	MedChemEx	HY-B0452	Ritodrine (hydrochloride)	287.152	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1,12|	IOVGROKTTNBUGK-SJKOYZFVSA-N	688570.0		IOVGROKTTNBUGK
BRD-K51485625-001-08-4	ritonavir	Launched	HIV protease inhibitor	CYP1A2|CYP2B6|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP2E1|CYP3A4|CYP3A5|CYP3A7	infectious disease	human immunodeficiency virus (HIV-1)	0	98.16	Selleck	S1185	Ritonavir	720.313	CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	NCDNCNXCDXHOMX-XGKFQTDJSA-N	392622.0		NCDNCNXCDXHOMX
BRD-K79966802-034-02-9	rivanicline	Phase 2	acetylcholine receptor agonist	CHRNA4|CHRNB2|CXCL8			0	97.21	MedChemEx	HY-13225B	Rivanicline hemioxalate	162.116	CNCC\C=C\c1cccnc1	JUOSGGQXEBBCJB-GORDUTHDSA-N	5310967.0		JUOSGGQXEBBCJB
BRD-K79966802-034-01-2	rivanicline	Phase 2	acetylcholine receptor agonist	CHRNA4|CHRNB2|CXCL8			0	94.98	Enzo	AC228	RJR 2403 fumarate	162.116	CNCC\C=C\c1cccnc1	JUOSGGQXEBBCJB-GORDUTHDSA-N	5310967.0		JUOSGGQXEBBCJB
BRD-K37130656-001-03-8	rivaroxaban	Launched	coagulation factor inhibitor	F10	neurology/psychiatry|hematology|cardiology	stroke|systemic embolism|atrial fibrillation (AF)|deep vein thrombosis (DVT)|pulmonary embolism (PE)	0	32.96	MicroSource	1504372	RIVAROXABAN	435.066	Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O	KGFYHTZWPPHNLQ-AWEZNQCLSA-N	9875401.0		KGFYHTZWPPHNLQ
BRD-K37130656-001-04-6	rivaroxaban	Launched	coagulation factor inhibitor	F10	neurology/psychiatry|hematology|cardiology	stroke|systemic embolism|atrial fibrillation (AF)|deep vein thrombosis (DVT)|pulmonary embolism (PE)	0	96.48	Selleck	S3002	Rivaroxaban	435.066	Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O	KGFYHTZWPPHNLQ-AWEZNQCLSA-N	9875401.0	BRD-A50033377-001-02-8	KGFYHTZWPPHNLQ
BRD-K10706131-046-06-9	rivastigmine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease|Parkinson's Disease|senile dementia	0	94.43	Tocris	4440	Rivastigmine tartrate	250.168	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	XSVMFMHYUFZWBK-NSHDSACASA-N	77991.0		XSVMFMHYUFZWBK
BRD-K10706131-046-04-4	rivastigmine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease|Parkinson's Disease|senile dementia	0	97.16	MicroSource	1505388	RIVASTIGMINE TARTRATE	250.168	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	XSVMFMHYUFZWBK-NSHDSACASA-N	77991.0		XSVMFMHYUFZWBK
BRD-K10706131-046-05-1	rivastigmine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease|Parkinson's Disease|senile dementia	0	91.05	Tocris	4440	Rivastigmine tartrate	250.168	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	XSVMFMHYUFZWBK-NSHDSACASA-N	77991.0		XSVMFMHYUFZWBK
BRD-K10706131-046-02-8	rivastigmine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease|Parkinson's Disease|senile dementia	0	95.27	Selleck	S2087	Rivastigmine Tartrate	250.168	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	XSVMFMHYUFZWBK-NSHDSACASA-N	77991.0		XSVMFMHYUFZWBK
BRD-K10706131-046-03-6	rivastigmine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease|Parkinson's Disease|senile dementia	0	97.89	Tocris	4440	Rivastigmine tartrate	250.168	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	XSVMFMHYUFZWBK-NSHDSACASA-N	77991.0		XSVMFMHYUFZWBK
BRD-K75699339-057-10-7	rizatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	70.67	Tocris	5136	Rizatriptan benzoate	269.164	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	ULFRLSNUDGIQQP-UHFFFAOYSA-N	5078.0		ULFRLSNUDGIQQP
BRD-K75699339-057-08-1	rizatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	93.99	MicroSource	1505189	RIZATRIPTAN BENZOATE	269.164	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	ULFRLSNUDGIQQP-UHFFFAOYSA-N	5078.0		ULFRLSNUDGIQQP
BRD-K75699339-057-09-9	rizatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	83.8	Selleck	S1607	Rizatriptan Benzoate (Maxalt)	269.164	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	ULFRLSNUDGIQQP-UHFFFAOYSA-N	5078.0		ULFRLSNUDGIQQP
BRD-K75699339-057-07-3	rizatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	77.5	Selleck	S1607	Rizatriptan Benzoate	269.164	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	ULFRLSNUDGIQQP-UHFFFAOYSA-N	5078.0		ULFRLSNUDGIQQP
BRD-K19333160-300-02-9	RKI-1447	Preclinical	rho associated kinase inhibitor	CDC42BPA|DMPK|LIMK1|MYLK|PAK1|PKN1|ROCK1|ROCK2			0	95.43	Tocris	5061	RKI 1447 dihydrochloride	326.084	Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	GDVRVPIXWXOKQO-UHFFFAOYSA-N	60138149.0		GDVRVPIXWXOKQO
BRD-K19333160-300-01-9	RKI-1447	Preclinical	rho associated kinase inhibitor	CDC42BPA|DMPK|LIMK1|MYLK|PAK1|PKN1|ROCK1|ROCK2			0	98.46	Tocris	5061	RKI 1447 dihydrochloride	326.084	Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	GDVRVPIXWXOKQO-UHFFFAOYSA-N	60138149.0		GDVRVPIXWXOKQO
BRD-K19333160-001-01-3	RKI-1447	Preclinical	rho associated kinase inhibitor	CDC42BPA|DMPK|LIMK1|MYLK|PAK1|PKN1|ROCK1|ROCK2			0	96.79	Selleck	S7195	RKI-1447	326.084	Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	GDVRVPIXWXOKQO-UHFFFAOYSA-N	60138149.0		GDVRVPIXWXOKQO
BRD-K28773847-001-08-9	RLX	Preclinical					0	95.72	Vitas-M	STL281810	7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one	214.111	O=c1n2CCCCCc2nc2ccccc12	HTLIIBRHXAULMB-UHFFFAOYSA-N	78144.0		HTLIIBRHXAULMB
BRD-K28773847-001-07-7	RLX	Preclinical					0	0.0	Vitas-M	STL281810		214.111	O=c1n2CCCCCc2nc2ccccc12	HTLIIBRHXAULMB-UHFFFAOYSA-N	78144.0		HTLIIBRHXAULMB
BRD-K00010386-001-01-9	RMC-4550	Preclinical	SHIP2 phosphatase inhibitor				0	96.25	MedChemEx	HY-116009	RMC-4550	436.143	C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N	IKUYEYLZXGGCRD-ORAYPTAESA-N	134183206.0		IKUYEYLZXGGCRD
BRD-K41415459-300-02-9	RN-1	Preclinical	histone demethylase inhibitor	KDM1A			0	96.56	Tocris	4977	RN 1 dihydrochloride	379.226	CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1	YAMSXCOVJUUMCT-FCHUYYIVSA-N	45376076.0		YAMSXCOVJUUMCT
BRD-K41415459-300-01-6	RN-1	Preclinical	histone demethylase inhibitor	KDM1A			0	85.64	Tocris	4977	RN 1 dihydrochloride	379.226	CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1	YAMSXCOVJUUMCT-FCHUYYIVSA-N	45376076.0		YAMSXCOVJUUMCT
BRD-K95581532-001-02-3	RN-1734	Preclinical	TRPV antagonist	TRPV4			0	85.01	Tocris	3746	RN 1734	352.078	CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	IHYZMEAZAIFMTN-UHFFFAOYSA-N	3601086.0		IHYZMEAZAIFMTN
BRD-K95581532-001-01-5	RN-1734	Preclinical	TRPV antagonist	TRPV4			0	91.99	Tocris	3746	RN 1734	352.078	CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	IHYZMEAZAIFMTN-UHFFFAOYSA-N	3601086.0		IHYZMEAZAIFMTN
BRD-K95581532-001-03-9	RN-1734	Preclinical	TRPV antagonist	TRPV4			0	94.74	Tocris	3746	RN 1734	352.078	CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	IHYZMEAZAIFMTN-UHFFFAOYSA-N	3601086.0		IHYZMEAZAIFMTN
BRD-K45519571-001-02-6	RN-1747	Preclinical	TRPV agonist	TRPV4			0	96.27	Tocris	3745	RN 1747	395.071	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	ZNLVYSJQUMALEO-UHFFFAOYSA-N	5068295.0		ZNLVYSJQUMALEO
BRD-K45519571-001-01-8	RN-1747	Preclinical	TRPV agonist	TRPV4			0	93.61	Tocris	3745	RN 1747	395.071	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	ZNLVYSJQUMALEO-UHFFFAOYSA-N	5068295.0		ZNLVYSJQUMALEO
BRD-K45519571-001-03-9	RN-1747	Preclinical	TRPV agonist	TRPV4			0	96.5	Tocris	3745	RN 1747	395.071	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	ZNLVYSJQUMALEO-UHFFFAOYSA-N	5068295.0		ZNLVYSJQUMALEO
BRD-A63546914-003-03-8	Ro-04-5595	Preclinical	glutamate receptor antagonist	GRIN2B			0	90.63	Tocris	2005	Ro 04-5595 hydrochloride	331.134	COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|	DSTWURHEHMZWEI-KRWDZBQOSA-N	92169474.0		DSTWURHEHMZWEI
BRD-A63546914-003-04-9	Ro-04-5595	Preclinical	glutamate receptor antagonist	GRIN2B			0	94.07	Tocris	2005	Ro 04-5595 hydrochloride	331.134	COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|	DSTWURHEHMZWEI-KRWDZBQOSA-N	92169474.0		DSTWURHEHMZWEI
BRD-A63546914-003-02-0	Ro-04-5595	Preclinical	glutamate receptor antagonist	GRIN2B			0	80.92	Tocris	2005	Ro 04-5595 hydrochloride	331.134	COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|	DSTWURHEHMZWEI-KRWDZBQOSA-N	92169474.0		DSTWURHEHMZWEI
BRD-K00486786-001-02-2	Ro-08-2750	Preclinical	NGF binding inhibitor	NGF|NGFR			0	93.42	Tocris	2272	Ro 08-2750	270.075	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O	JDEMVNYMYPJJIM-UHFFFAOYSA-N	17756791.0		JDEMVNYMYPJJIM
BRD-K00486786-001-03-9	Ro-08-2750	Preclinical	NGF binding inhibitor	NGF|NGFR			0	96.19	Tocris	2272	Ro 08-2750	270.075	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O	JDEMVNYMYPJJIM-UHFFFAOYSA-N	17756791.0		JDEMVNYMYPJJIM
BRD-K79684402-300-03-6	Ro-10-5824	Preclinical	dopamine receptor agonist	DRD4			0	93.04	Tocris	2329	Ro 10-5824 dihydrochloride	280.169	Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|	KABDATZAOUSYES-UHFFFAOYSA-N	16759175.0		KABDATZAOUSYES
BRD-K79684402-300-02-8	Ro-10-5824	Preclinical	dopamine receptor agonist	DRD4			0	75.4	Tocris	2329	Ro 10-5824 dihydrochloride	280.169	Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|	KABDATZAOUSYES-UHFFFAOYSA-N	16759175.0		KABDATZAOUSYES
BRD-K79684402-300-04-9	Ro-10-5824	Preclinical	dopamine receptor agonist	DRD4			0	86.64	Tocris	2329	Ro 10-5824 dihydrochloride	280.169	Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|	KABDATZAOUSYES-UHFFFAOYSA-N	16759175.0		KABDATZAOUSYES
BRD-A53134341-001-04-0	Ro-106-9920	Preclinical	NFkB pathway inhibitor				0	93.74	Tocris	1778	Ro 106-9920	245.037	O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|	JFSXSNSCPNFCDM-KRWDZBQOSA-N	92510314.0		JFSXSNSCPNFCDM
BRD-A53134341-001-03-2	Ro-106-9920	Preclinical	NFkB pathway inhibitor				0	94.47	Tocris	1778	Ro 106-9920	245.037	O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1,r|	JFSXSNSCPNFCDM-KRWDZBQOSA-N	92510314.0		JFSXSNSCPNFCDM
BRD-K77220725-003-01-5	Ro-1138452	Preclinical	prostanoid receptor antagonist	PTGIR			0	95.11	Tocris	4268	Ro 1138452 hydrochloride	309.184	CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|	GYYRMJMXXLJZAB-UHFFFAOYSA-N	9839644.0		GYYRMJMXXLJZAB
BRD-K77220725-003-02-9	Ro-1138452	Preclinical	prostanoid receptor antagonist	PTGIR			0	96.69	Tocris	4268	Ro 1138452 hydrochloride	309.184	CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|	GYYRMJMXXLJZAB-UHFFFAOYSA-N	9839644.0		GYYRMJMXXLJZAB
BRD-K82823076-001-03-9	Ro-15-4513	Preclinical	GABA benzodiazepine site receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2			0	94.05	Tocris	1997	Ro 15-4513	326.113	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]	CFSOJZTUTOQNIA-UHFFFAOYSA-N	5081.0		CFSOJZTUTOQNIA
BRD-K82823076-001-02-6	Ro-15-4513	Preclinical	GABA benzodiazepine site receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2			0	87.5	Tocris	1997	Ro 15-4513	326.113	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]	CFSOJZTUTOQNIA-UHFFFAOYSA-N	5081.0		CFSOJZTUTOQNIA
BRD-K80778372-001-03-3	Ro-19-4605	Preclinical	GABA benzodiazepine site receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	97.77	Tocris	1995	Ro 19-4603	319.099	CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	ZIGMMUKDYCABPW-UHFFFAOYSA-N	127382.0		ZIGMMUKDYCABPW
BRD-K80778372-001-04-9	Ro-19-4605	Preclinical	GABA benzodiazepine site receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	94.52	Tocris	1995	Ro 19-4603	319.099	CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	ZIGMMUKDYCABPW-UHFFFAOYSA-N	127382.0		ZIGMMUKDYCABPW
BRD-K80778372-001-02-5	Ro-19-4605	Preclinical	GABA benzodiazepine site receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	98.3	Tocris	1995	Ro 19-4603	319.099	CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	ZIGMMUKDYCABPW-UHFFFAOYSA-N	127382.0		ZIGMMUKDYCABPW
BRD-A07207424-001-14-0	Ro-20-1724	Preclinical	phosphodiesterase inhibitor	PDE3A|PDE4A|PDE4B|PDE4C|PDE4D			0	94.99	Tocris	415	Ro 20-1724	278.163	CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|	PDMUULPVBYQBBK-LBPRGKRZSA-N	6998998.0		PDMUULPVBYQBBK
BRD-A07207424-001-13-2	Ro-20-1724	Preclinical	phosphodiesterase inhibitor	PDE3A|PDE4A|PDE4B|PDE4C|PDE4D			0	98.13	Tocris	415	Ro 20-1724	278.163	CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|	PDMUULPVBYQBBK-LBPRGKRZSA-N	6998998.0		PDMUULPVBYQBBK
BRD-A07207424-001-15-9	Ro-20-1724	Preclinical	phosphodiesterase inhibitor	PDE3A|PDE4A|PDE4B|PDE4C|PDE4D			0	90.55	Tocris	415	Ro 20-1724	278.163	CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9,r|	PDMUULPVBYQBBK-LBPRGKRZSA-N	6998998.0		PDMUULPVBYQBBK
BRD-K51541829-050-02-8	Ro-25-6981	Preclinical	glutamate receptor antagonist|monamine transporter modulator	GRIN2B			0	89.37	Tocris	1594	Ro 25-6981 maleate	339.22	C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	WVZSEUPGUDIELE-HTAPYJJXSA-N	6604887.0		WVZSEUPGUDIELE
BRD-K51541829-050-06-9	Ro-25-6981	Preclinical	glutamate receptor antagonist|monamine transporter modulator	GRIN2B			0	95.22	Tocris	1594	Ro 25-6981 maleate	339.22	C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	WVZSEUPGUDIELE-HTAPYJJXSA-N	6604887.0		WVZSEUPGUDIELE
BRD-K51541829-050-01-0	Ro-25-6981	Preclinical	glutamate receptor antagonist|monamine transporter modulator	GRIN2B			0	97.03	Tocris	1594	Ro 25-6981 hydrochloride	339.22	C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	WVZSEUPGUDIELE-HTAPYJJXSA-N	6604887.0		WVZSEUPGUDIELE
BRD-K21672174-001-03-0	Ro-28-1675	Preclinical	glucokinase activator	GCK			0	99.65	MedChemEx	HY-10595	Ro 28-1675	378.107	CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1	NEQSWPCDHDQINX-MRXNPFEDSA-N	9886086.0		NEQSWPCDHDQINX
BRD-K00354853-001-01-2	Ro-3	Preclinical	purinergic receptor antagonist	P2RX3			0	96.35	Tocris	3052	RO-3	302.174	COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C	PYNPWUIBJMVRIG-UHFFFAOYSA-N	11289644.0		PYNPWUIBJMVRIG
BRD-K00354853-001-02-9	Ro-3	Preclinical	purinergic receptor antagonist	P2RX3			0	96.35	Tocris	3052	RO-3	302.174	COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C	PYNPWUIBJMVRIG-UHFFFAOYSA-N	11289644.0		PYNPWUIBJMVRIG
BRD-K78373679-001-03-7	Ro-3306	Preclinical	CDK inhibitor	CDK1			0	94.61	Tocris	4181	Ro 3306	351.05	O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|	XOLMRFUGOINFDQ-YBEGLDIGSA-N	135400873.0		XOLMRFUGOINFDQ
BRD-K78373679-001-04-9	Ro-3306	Preclinical	CDK inhibitor	CDK1			0	95.74	Tocris	4181	Ro 3306	351.05	O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|	XOLMRFUGOINFDQ-YBEGLDIGSA-N	135400873.0		XOLMRFUGOINFDQ
BRD-K00004572-001-01-9	Ro-48-6791	Preclinical	GABA receptor modulator				0	92.98	Astatech	41434	RO48-6791	412.202	CCCN(CCC)Cc1nc(no1)-c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	NOQIYRGMEFBZTI-UHFFFAOYSA-N	9953485.0		NOQIYRGMEFBZTI
BRD-K55192287-051-02-9	Ro-48-8071	Preclinical	oxidosqualene cyclase inhibitor	LSS			0	91.53	Tocris	5389	Ro 48-8071 fumarate	447.121	CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C	CMYCCJYVZIMDFU-UHFFFAOYSA-N	1949.0		CMYCCJYVZIMDFU
BRD-K55192287-051-01-1	Ro-48-8071	Preclinical	oxidosqualene cyclase inhibitor	LSS			0	96.64	MedChemEx	HY-18630A	Ro 48-8071 (fumarate)	447.121	CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C	CMYCCJYVZIMDFU-UHFFFAOYSA-N	1949.0		CMYCCJYVZIMDFU
BRD-K64538373-001-01-4	Ro-4987655	Phase 1	MEK inhibitor	MAP2K1			0	96.87	MedChemEx	HY-14719	RO4987655	565.032	OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	FIMYFEGKMOCQKT-UHFFFAOYSA-N	11548630.0		FIMYFEGKMOCQKT
BRD-K64538373-001-02-9	Ro-4987655	Phase 1	MEK inhibitor	MAP2K1			0	97.43	MedChemEx	HY-14719	RO4987655	565.032	OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	FIMYFEGKMOCQKT-UHFFFAOYSA-N	11548630.0		FIMYFEGKMOCQKT
BRD-K00003149-001-01-9	Ro-5028442	Phase 1	vasopressin receptor antagonist				0	99.2	MedChemEx	HY-12981	RG7713	437.187	CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc32)c2ccc(Cl)cc12	QZXVLRCMAHJVIP-UHFFFAOYSA-N	59657596.0		QZXVLRCMAHJVIP
BRD-K82804538-001-03-6	Ro-5126766	Phase 1	MEK inhibitor|RAF inhibitor	BRAF|MAP2K1|MAP2K2|RAF1			0	91.26	MedChemEx	HY-18652	Ro 5126766	471.101	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	LMMJFBMMJUMSJS-UHFFFAOYSA-N	16719221.0		LMMJFBMMJUMSJS
BRD-K82804538-001-01-0	Ro-5126766	Phase 1	MEK inhibitor|RAF inhibitor	BRAF|MAP2K1|MAP2K2|RAF1			0	96.39	Selleck	S7170	RO5126766 (CH5126766)	471.101	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	LMMJFBMMJUMSJS-UHFFFAOYSA-N	16719221.0		LMMJFBMMJUMSJS
BRD-K82804538-001-02-8	Ro-5126766	Phase 1	MEK inhibitor|RAF inhibitor	BRAF|MAP2K1|MAP2K2|RAF1			0	76.64	MedChemEx	HY-18652	Ro 5126766	471.101	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	LMMJFBMMJUMSJS-UHFFFAOYSA-N	16719221.0		LMMJFBMMJUMSJS
BRD-K00004623-001-01-9	Ro-5263397	Preclinical	trace amine associated receptor agonist				0	83.41	Sigma	SML2225	(4S)-4-(3-fluoro-2-methyl-phenyl)-4,5-dihydrooxazol-2-amine	194.086	Cc1c(F)cccc1[C@H]1COC(N)=N1 |c:13|	IOHOUWIYOVWGHV-SECBINFHSA-N	56835991.0		IOHOUWIYOVWGHV
BRD-K28007504-051-02-0	Ro-60-0175	Preclinical	serotonin receptor agonist	HTR2A|HTR2B|HTR2C			0	88.51	Tocris	1854	Ro 60-0175 fumarate	226.067	C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	XJJZQXUGLLXTHO-ZETCQYMHSA-N	3045227.0		XJJZQXUGLLXTHO
BRD-K28007504-051-03-9	Ro-60-0175	Preclinical	serotonin receptor agonist	HTR2A|HTR2B|HTR2C			0	95.35	Tocris	1854	Ro 60-0175 fumarate	226.067	C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	XJJZQXUGLLXTHO-ZETCQYMHSA-N	3045227.0		XJJZQXUGLLXTHO
BRD-K28007504-051-01-2	Ro-60-0175	Preclinical	serotonin receptor agonist	HTR2A|HTR2B|HTR2C			0	89.78	Tocris	1854	Ro 60-0175 fumarate	226.067	C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	XJJZQXUGLLXTHO-ZETCQYMHSA-N	3045227.0		XJJZQXUGLLXTHO
BRD-K12639498-001-02-1	Ro-61-8048	Preclinical	kynurenine 3-monooxygenase inhibitor	KMO			0	94.35	Tocris	3254	Ro 61-8048	421.04	COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O	NDPBMCKQJOZAQX-UHFFFAOYSA-N	5282337.0		NDPBMCKQJOZAQX
BRD-K12639498-001-01-3	Ro-61-8048	Preclinical	kynurenine 3-monooxygenase inhibitor	KMO			0	98.09	MedChemEx	HY-12347	Ro 61-8048	421.04	COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O	NDPBMCKQJOZAQX-UHFFFAOYSA-N	5282337.0		NDPBMCKQJOZAQX
BRD-K12639498-001-03-9	Ro-61-8048	Preclinical	kynurenine 3-monooxygenase inhibitor	KMO			0	97.11	Tocris	3254	Ro 61-8048	421.04	COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O	NDPBMCKQJOZAQX-UHFFFAOYSA-N	5282337.0		NDPBMCKQJOZAQX
BRD-K91333421-001-01-9	Ro-67-7476	Preclinical	glutamate receptor positive allosteric modulator	GRM1			0	90.92	Tocris	4346	Ro 67-7476	319.104	Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1	DAEHFYNGSSBGSS-KRWDZBQOSA-N	32681978.0		DAEHFYNGSSBGSS
BRD-K91333421-001-02-9	Ro-67-7476	Preclinical	glutamate receptor positive allosteric modulator	GRM1			0	93.68	Tocris	4346	Ro 67-7476	319.104	Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1	DAEHFYNGSSBGSS-KRWDZBQOSA-N	32681978.0		DAEHFYNGSSBGSS
BRD-K58299615-001-04-3	Ro-90-7501	Preclinical	beta amyloid protein neurotoxicity inhibitor	APP			0	80.49	Tocris	2408	Ro 90-7501	340.144	Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	PAGZCEHLFCJSPV-UHFFFAOYSA-N	824226.0		PAGZCEHLFCJSPV
BRD-K58299615-001-03-5	Ro-90-7501	Preclinical	beta amyloid protein neurotoxicity inhibitor	APP			0	90.66	Tocris	2408	Ro 90-7501	340.144	Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	PAGZCEHLFCJSPV-UHFFFAOYSA-N	824226.0		PAGZCEHLFCJSPV
BRD-K58299615-001-05-9	Ro-90-7501	Preclinical	beta amyloid protein neurotoxicity inhibitor	APP			0	88.17	Tocris	2408	Ro 90-7501	340.144	Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	PAGZCEHLFCJSPV-UHFFFAOYSA-N	824226.0		PAGZCEHLFCJSPV
BRD-K57284066-001-02-9	Ro-9187	Preclinical	HCV inhibitor				0	98.91	MedChemEx	HY-10870	RO-9187	284.087	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	ODLGMSQBFONGNG-XZMZPDFPSA-N	11514721.0		ODLGMSQBFONGNG
BRD-K57284066-001-01-6	Ro-9187	Preclinical	HCV inhibitor				0	98.79	MedChemEx	HY-10870	RO-9187	284.087	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	ODLGMSQBFONGNG-XZMZPDFPSA-N	11514721.0		ODLGMSQBFONGNG
BRD-K26169680-003-01-9	robalzotan	Phase 2	serotonin receptor antagonist	HTR1A			0	90.01	Tocris	3282	NAD 299 hydrochloride	318.174	NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1	MQTUXRKNJYPMCG-CYBMUJFWSA-N	3055171.0		MQTUXRKNJYPMCG
BRD-K26169680-003-02-9	robalzotan	Phase 2	serotonin receptor antagonist	HTR1A			0	95.29	Tocris	3282	NAD 299 hydrochloride	318.174	NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1	MQTUXRKNJYPMCG-CYBMUJFWSA-N	3055171.0		MQTUXRKNJYPMCG
BRD-K00003424-001-01-9	roblitinib	Preclinical	FGFR inhibitor				0	94.87	MedChemEx	HY-101568	Roblitinib	506.239	COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N	BHKDKKZMPODMIQ-UHFFFAOYSA-N	118036971.0		BHKDKKZMPODMIQ
BRD-K33610132-001-02-9	rociletinib	Phase 3	EGFR inhibitor	EGFR			0	98.26	Selleck	S7284	CO-1686 (AVL-301)	555.221	COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	HUFOZJXAKZVRNJ-UHFFFAOYSA-N	57335384.0		HUFOZJXAKZVRNJ
BRD-K33610132-001-04-5	rociletinib	Phase 3	EGFR inhibitor	EGFR			0		Selleck	S7284	CO-1686	555.221	COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)	57335384.0		HUFOZJXAKZVRNJ
BRD-K43305603-004-03-6	rocuronium	Launched	acetylcholine receptor antagonist	CHRM2|CHRNA2|HTR3A	neurology/psychiatry	anesthetic	0	96.94	MicroSource	1503846	ROCURONIUM BROMIDE	529.401	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	YXRDKMPIGHSVRX-OOJCLDBCSA-N	441290.0	BRD-A40127632-004-01-8	YXRDKMPIGHSVRX
BRD-K43305603-004-02-8	rocuronium	Launched	acetylcholine receptor antagonist	CHRM2|CHRNA2|HTR3A	neurology/psychiatry	anesthetic	0	100.0	Selleck	S1397	Rocuronium Bromide	529.401	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	YXRDKMPIGHSVRX-OOJCLDBCSA-N	441290.0	BRD-K58951486-004-01-5	YXRDKMPIGHSVRX
BRD-K21733600-001-15-8	rofecoxib	Withdrawn	cyclooxygenase inhibitor	ELN|PTGS2			0	28.93	MicroSource	1504235	ROFECOXIB	314.061	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	RZJQGNCSTQAWON-UHFFFAOYSA-N	5090.0		RZJQGNCSTQAWON
BRD-K21733600-001-24-0	rofecoxib	Withdrawn	cyclooxygenase inhibitor	ELN|PTGS2			0	90.77	MedChemEx	HY-17372	Rofecoxib	314.061	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	RZJQGNCSTQAWON-UHFFFAOYSA-N	5090.0		RZJQGNCSTQAWON
BRD-K21733600-001-23-2	rofecoxib	Withdrawn	cyclooxygenase inhibitor	ELN|PTGS2			0	98.36	Sigma	MFCD00935806	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	314.061	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	RZJQGNCSTQAWON-UHFFFAOYSA-N	5090.0		RZJQGNCSTQAWON
BRD-K21733600-001-19-0	rofecoxib	Withdrawn	cyclooxygenase inhibitor	ELN|PTGS2			0	69.24	Selleck	S3043	Rofecoxib (Vioxx)	314.061	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	RZJQGNCSTQAWON-UHFFFAOYSA-N	5090.0		RZJQGNCSTQAWON
BRD-K21733600-001-14-1	rofecoxib	Withdrawn	cyclooxygenase inhibitor	ELN|PTGS2			0	80.56	Selleck	S3043	Rofecoxib	314.061	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	RZJQGNCSTQAWON-UHFFFAOYSA-N	5090.0		RZJQGNCSTQAWON
BRD-K03194791-001-04-8	roflumilast	Launched	phosphodiesterase inhibitor	PDE4A|PDE4B|PDE4C|PDE4D	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis	0	99.14	Selleck	S2131	Roflumilast	402.035	FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl	MNDBXUUTURYVHR-UHFFFAOYSA-N	449193.0		MNDBXUUTURYVHR
BRD-K00003358-001-01-9	rogaratinib	Phase 2/Phase 3	FGFR inhibitor				0	96.76	MedChemEx	HY-100019	Rogaratinib	466.179	COCc1c(CN2CCNC(=O)C2)n2ncnc(N)c2c1-c1cc2cc(C)cc(OC)c2s1	HNLRRJSKGXOYNO-UHFFFAOYSA-N	71611869.0		HNLRRJSKGXOYNO
BRD-K00003175-001-01-9	rolapitant	Phase 3	neurokinin receptor antagonist				0	94.98	MedChemEx	HY-14751	Rolapitant	500.19	[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)c1ccccc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	FIVSJYGQAIEMOC-ZGNKEGEESA-N	10311306.0		FIVSJYGQAIEMOC
BRD-A34255068-001-38-6	rolipram	Phase 3	phosphodiesterase inhibitor				0	93.18	Tocris	905	Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|	HJORMJIFDVBMOB-GFCCVEGCSA-N	158758.0		HJORMJIFDVBMOB
BRD-A34255068-001-34-5	rolipram	Phase 3	phosphodiesterase inhibitor				0	98.11	MicroSource	1505683	ROLIPRAM	275.152	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|	HJORMJIFDVBMOB-GFCCVEGCSA-N	158758.0		HJORMJIFDVBMOB
BRD-A34255068-001-33-7	rolipram	Phase 3	phosphodiesterase inhibitor				0	97.77	Tocris	905	Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|	HJORMJIFDVBMOB-GFCCVEGCSA-N	158758.0		HJORMJIFDVBMOB
BRD-A34255068-001-32-9	rolipram	Phase 3	phosphodiesterase inhibitor				0	95.22	Selleck	S1430	Rolipram	275.152	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14,r|	HJORMJIFDVBMOB-GFCCVEGCSA-N	158758.0		HJORMJIFDVBMOB
BRD-A62336573-001-03-1	rolitetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	2.99	MicroSource	1505684	ROLITETRACYCLINE	527.227	CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|	YEHCEZXUSLIKDU-IAHYZSEUSA-N			YEHCEZXUSLIKDU
BRD-A62336573-001-04-9	rolitetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	0.0	Selleck	S4352	rolitetracycline	527.227	CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|	YEHCEZXUSLIKDU-IAHYZSEUSA-N			YEHCEZXUSLIKDU
BRD-A62336573-001-02-3	rolitetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	0.0	Selleck	S4352	Rolitetracycline	527.227	CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|	YEHCEZXUSLIKDU-IAHYZSEUSA-N			YEHCEZXUSLIKDU
BRD-A62336573-001-06-4	rolitetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	0.0	Selleck	S4352	ROLITETRACYCLINE	527.227	CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3,4,6,10,35,&1:7,&2:14,t:7,14|	YEHCEZXUSLIKDU-IAHYZSEUSA-N			YEHCEZXUSLIKDU
BRD-K00003283-001-01-9	roluperidone	Phase 2					0	100.0	MedChemEx	HY-19469	Roluperidone	366.174	Fc1ccc(cc1)C(=O)CN1CCC(CN2Cc3ccccc3C2=O)CC1	RNRYULFRLCBRQS-UHFFFAOYSA-N	9799284.0		RNRYULFRLCBRQS
BRD-K38564664-001-01-1	rolziracetam	Phase 2					0	97.8	Sigma	PH000303	dihydro-1H-pyrrolo[1,2-a]pyrrole-3,5(2H,6H)-dione	139.063	O=C1CCC2CCC(=O)N12	IEZDOKQWPWZVQF-UHFFFAOYSA-N	71893.0		IEZDOKQWPWZVQF
BRD-K61397605-001-03-4	romidepsin	Launched	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	0	98.84	MedChemEx	HY-15149	Romidepsin	540.208	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|	OHRURASPPZQGQM-WDCUYUQDSA-N	56840936.0		OHRURASPPZQGQM
BRD-K61397605-001-01-8	romidepsin	Launched	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	0	94.94	Selleck	S3020	Romidepsin (FK228 ,depsipeptide)	540.208	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|	InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20?/m1/s1	56840936.0		OHRURASPPZQGQM
BRD-K94266545-001-25-9	ronidazole	Launched	antiprotozoal agent		infectious disease	histomoniasis|dysentry	0	85.53	MedChemEx	HY-B0565	Ronidazole	200.055	Cn1c(COC(N)=O)ncc1[N+]([O-])=O	PQFRTXSWDXZRRS-UHFFFAOYSA-N	5094.0		PQFRTXSWDXZRRS
BRD-K94266545-001-24-1	ronidazole	Launched	antiprotozoal agent		infectious disease	histomoniasis|dysentry	0	99.46	MicroSource	1501154	RONIDAZOLE	200.055	Cn1c(COC(N)=O)ncc1[N+]([O-])=O	PQFRTXSWDXZRRS-UHFFFAOYSA-N	5094.0		PQFRTXSWDXZRRS
BRD-K94266545-001-23-3	ronidazole	Launched	antiprotozoal agent		infectious disease	histomoniasis|dysentry	0	93.16	Selleck	S4062	Ronidazole	200.055	Cn1c(COC(N)=O)ncc1[N+]([O-])=O	PQFRTXSWDXZRRS-UHFFFAOYSA-N	5094.0		PQFRTXSWDXZRRS
BRD-K15933101-003-07-9	ropinirole	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	neurology/psychiatry	Parkinson's Disease|restless leg syndrome	0	97.66	MicroSource	1505178	ROPINIROLE HYDROCHLORIDE	260.189	CCCN(CCC)CCc1cccc2NC(=O)Cc12	UHSKFQJFRQCDBE-UHFFFAOYSA-N	5095.0		UHSKFQJFRQCDBE
BRD-K15933101-003-06-1	ropinirole	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	neurology/psychiatry	Parkinson's Disease|restless leg syndrome	0	97.67	Selleck	S3189	Ropinirole HCl	260.189	CCCN(CCC)CCc1cccc2NC(=O)Cc12	UHSKFQJFRQCDBE-UHFFFAOYSA-N	5095.0		UHSKFQJFRQCDBE
BRD-K15933101-003-08-9	ropinirole	Launched	dopamine receptor agonist	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	neurology/psychiatry	Parkinson's Disease|restless leg syndrome	0	96.24	Tocris	3680	Ropinirole	260.189	CCCN(CCC)CCc1cccc2NC(=O)Cc12	UHSKFQJFRQCDBE-UHFFFAOYSA-N	5095.0		UHSKFQJFRQCDBE
BRD-K50938786-311-12-9	ropivacaine	Launched	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	0	95.02	MedChemEx	HY-B0563A	Ropivacaine (hydrochloride monohydrate)	274.205	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	ZKMNUMMKYBVTFN-HNNXBMFYSA-N	175805.0		ZKMNUMMKYBVTFN
BRD-K50938786-003-11-8	ropivacaine	Launched	sodium channel blocker	SCN10A	neurology/psychiatry	anesthetic	0	97.16	Selleck	S4058	Ropivacaine HCl	274.205	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	ZKMNUMMKYBVTFN-HNNXBMFYSA-N	175805.0		ZKMNUMMKYBVTFN
BRD-K03384561-001-03-9	roquinimex	Phase 3	angiogenesis inhibitor|tumor necrosis factor production inhibitor				0	95.04	Tocris	1461	Linomide	308.116	CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	SGOOQMRIPALTEL-UHFFFAOYSA-N	54676478.0		SGOOQMRIPALTEL
BRD-K03384561-001-02-7	roquinimex	Phase 3	angiogenesis inhibitor|tumor necrosis factor production inhibitor				0	96.21	Tocris	1461	Linomide	308.116	CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	SGOOQMRIPALTEL-UHFFFAOYSA-N	54676478.0		SGOOQMRIPALTEL
BRD-K00004538-001-01-9	rosamicin	Phase 2	protein synthesis inhibitor				0	95.1	Vitas-M	STK256720	Rosamicin	581.356	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@]2(C)O[C@H]2[C@@H]1C |t:34|	IUPCWCLVECYZRV-WMNDRESDSA-N			IUPCWCLVECYZRV
BRD-K07691486-001-19-7	roscovitine	Phase 2	CDK inhibitor	CDK2|CDK9			0	97.94	Selleck	S1153	seliciclib	354.217	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	BTIHMVBBUGXLCJ-OAHLLOKOSA-N	160355.0		BTIHMVBBUGXLCJ
BRD-K07691486-001-15-5	roscovitine	Phase 2	CDK inhibitor	CDK2|CDK9			0	97.38	Selleck	S1153	Roscovitine (Seliciclib,CYC202)	354.217	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	BTIHMVBBUGXLCJ-OAHLLOKOSA-N	160355.0		BTIHMVBBUGXLCJ
BRD-K33623053-304-01-7	rose-bengal	Launched	contrast agent|immunostimulant		radiology	diagnostic agent	0	44.8	Acros	18945	Rose Bengal, 85%, pure, high purity, Biological stain	971.499	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	VDNLFJGJEQUWRB-UHFFFAOYSA-N	25474.0		VDNLFJGJEQUWRB
BRD-K33623053-304-02-5	rose-bengal	Launched	contrast agent|immunostimulant		radiology	diagnostic agent	0	57.93	SantaCruz	sc-203757		971.499	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	VDNLFJGJEQUWRB-UHFFFAOYSA-N	25474.0	BRD-K36163066-304-01-6	VDNLFJGJEQUWRB
BRD-K36163066-304-02-4	rose-bengal-lactone	Launched	coloring agent		ophthalmology	staining agent	0	73.73	CombiBlocks	QF-7123	disodium 2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3H-xanthen-9-yl)benzoate	971.499	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I	IICCLYANAQEHCI-UHFFFAOYSA-N	69439.0		IICCLYANAQEHCI
BRD-K01826734-003-14-9	rosiglitazone	Withdrawn	insulin sensitizer|PPAR receptor agonist	FFAR1|PPARG|TRPC5|TRPM3			0	98.53	Selleck	S2075		357.115	CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|	YASAKCUCGLMORW-OAHLLOKOSA-N	10021239.0		YASAKCUCGLMORW
BRD-K00003494-001-01-9	rosiptor	Phase 2	SHIP1 phosphatase activator				0	100.0	MedChemEx	HY-109011	Rosiptor	321.267	[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]1(C)CC[C@H](O)C[C@@H]1CO	MDEJTPWQNNMAQF-BVMLLJBZSA-N	76965484.0		MDEJTPWQNNMAQF
BRD-K20313525-001-05-9	rosmarinic-acid	Launched	GABA transaminase inhibitor	MCL1|TYR			0	94.4	Tocris	630	Rosmarinic acid	360.085	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	DOUMFZQKYFQNTF-WUTVXBCWSA-N	5281792.0		DOUMFZQKYFQNTF
BRD-K20313525-001-04-6	rosmarinic-acid	Launched	GABA transaminase inhibitor	MCL1|TYR			0	94.08	Tocris	630	Rosmarinic acid	360.085	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	DOUMFZQKYFQNTF-WUTVXBCWSA-N	5281792.0		DOUMFZQKYFQNTF
BRD-K49841478-001-01-6	rosoxacin	Launched	topoisomerase inhibitor		infectious disease	urinary tract infections	0	98.05	Accela	SY038205	1-ethyl-4-oxo-7-(4-pyridinyl)-1,4-dihydro-3-quinolinecarboxylic acid	294.1	CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1	XBPZXDSZHPDXQU-UHFFFAOYSA-N	287180.0		XBPZXDSZHPDXQU
BRD-K11672787-001-02-3	rostafuroxine	Phase 2	ATPase inhibitor	ATP1A1			0	74.75	Tocris	5315	Rostafuroxin	374.246	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	AEAPORIZZWBIEX-DTBDINHYSA-N	153976.0		AEAPORIZZWBIEX
BRD-K11672787-001-03-9	rostafuroxine	Phase 2	ATPase inhibitor	ATP1A1			0	84.73	Tocris	5315	Rostafuroxin	374.246	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	AEAPORIZZWBIEX-DTBDINHYSA-N	153976.0		AEAPORIZZWBIEX
BRD-K11672787-001-01-5	rostafuroxine	Phase 2	ATPase inhibitor	ATP1A1			0	98.28	MedChemEx	HY-12283	Rostafuroxin	374.246	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	AEAPORIZZWBIEX-DTBDINHYSA-N	153976.0		AEAPORIZZWBIEX
BRD-K82941592-238-03-7	rosuvastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology|cardiology	hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis	0	60.23	MicroSource	1505213	ROSUVASTATIN CALCIUM	481.168	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	BPRHUIZQVSMCRT-VEUZHWNKSA-N	446157.0		BPRHUIZQVSMCRT
BRD-K82941592-238-07-9	rosuvastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology|cardiology	hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis	0	89.96	Pharmeks	PHAR214236	calcium (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate	481.168	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	BPRHUIZQVSMCRT-VEUZHWNKSA-N	446157.0		BPRHUIZQVSMCRT
BRD-K82941592-238-06-9	rosuvastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology|cardiology	hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis	0	95.14	Tocris	6343	Rosuvastatin calcium	481.168	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	BPRHUIZQVSMCRT-VEUZHWNKSA-N	446157.0		BPRHUIZQVSMCRT
BRD-K82941592-238-04-5	rosuvastatin	Launched	HMGCR inhibitor	HMGCR	endocrinology|cardiology	hyperlipidemia|dyslipidemia|hypertriglyceridemia|hypercholesterolemia|atherosclerosis	0	93.46	Selleck	S2169	Rosuvastatin Calcium	481.168	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	BPRHUIZQVSMCRT-VEUZHWNKSA-N	446157.0	BRD-M41627219-238-01-7	BPRHUIZQVSMCRT
BRD-K91111634-003-01-8	rotigotine	Launched	dopamine receptor agonist	ADRA2B|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A	neurology/psychiatry	Parkinson's Disease|restless leg syndrome	0	86.78	Tocris	3896	Rotigotine hydrochloride	315.166	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	KFQYTPMOWPVWEJ-INIZCTEOSA-N	59227.0		KFQYTPMOWPVWEJ
BRD-K91111634-001-01-2	rotigotine	Launched	dopamine receptor agonist	ADRA2B|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A	neurology/psychiatry	Parkinson's Disease|restless leg syndrome	0	98.62	MedChemEx	HY-75502	Rotigotine	315.166	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	KFQYTPMOWPVWEJ-INIZCTEOSA-N	59227.0		KFQYTPMOWPVWEJ
BRD-K91111634-003-02-9	rotigotine	Launched	dopamine receptor agonist	ADRA2B|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A	neurology/psychiatry	Parkinson's Disease|restless leg syndrome	0	93.74	Tocris	3896	Rotigotine hydrochloride	315.166	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	KFQYTPMOWPVWEJ-INIZCTEOSA-N	59227.0		KFQYTPMOWPVWEJ
BRD-K35719256-001-09-9	rotundine	Launched	serotonin receptor agonist	DRD1|DRD2|DRD3|HTR1A	neurology/psychiatry	anxiety|sedative	0	93.72	MedChemEx	HY-N0096	Rotundine	355.178	COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC	AEQDJSLRWYMAQI-KRWDZBQOSA-N	72301.0		AEQDJSLRWYMAQI
BRD-K35719256-001-02-6	rotundine	Launched	serotonin receptor agonist	DRD1|DRD2|DRD3|HTR1A	neurology/psychiatry	anxiety|sedative	0	90.41	Selleck	S2437	Rotundine	355.178	COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC	AEQDJSLRWYMAQI-KRWDZBQOSA-N	72301.0		AEQDJSLRWYMAQI
BRD-K00003502-001-01-9	rovazolac	Preclinical	LXR agonist				0	97.15	MedChemEx	HY-109073	Rovazolac	452.102	CCOC(=O)Cn1nc(cc1-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O)C(F)(F)F	ZUMNJDGBYXHASJ-UHFFFAOYSA-N	89792952.0		ZUMNJDGBYXHASJ
BRD-K22685337-001-15-9	roxarsone	Launched	antiprotozoal agent		endocrinology	weight-gain aid	0	96.01	MedChemEx	HY-B0936	Roxarsone	262.941	Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O	XMVJITFPVVRMHC-UHFFFAOYSA-N	5104.0		XMVJITFPVVRMHC
BRD-K22685337-001-13-4	roxarsone	Launched	antiprotozoal agent		endocrinology	weight-gain aid	0	98.02	MicroSource	1500530	ROXARSONE	262.941	Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O	XMVJITFPVVRMHC-UHFFFAOYSA-N	5104.0		XMVJITFPVVRMHC
BRD-K81855038-003-14-7	roxatidine-acetate	Launched	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis	0	95.7	MedChemEx	HY-B0305A	2-oxo-2-({3-[3-(1-piperidinylmethyl)phenoxy]propyl}amino)ethyl acetate hydrochloride	348.205	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	SMTZFNFIKUPEJC-UHFFFAOYSA-N	5105.0		SMTZFNFIKUPEJC
BRD-K81855038-003-13-9	roxatidine-acetate	Launched	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis	0	97.97	MicroSource	1502334	ROXATIDINE ACETATE HYDROCHLORIDE	348.205	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	SMTZFNFIKUPEJC-UHFFFAOYSA-N	5105.0		SMTZFNFIKUPEJC
BRD-K81855038-003-12-1	roxatidine-acetate	Launched	histamine receptor antagonist	HRH2	gastroenterology	Zollinger-Ellison syndrome|erosive esophagitis (EE)|gastroesophageal reflux disease (GERD)|gastritis	0	95.63	Selleck	S1880	Roxatidine Acetate HCl	348.205	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	SMTZFNFIKUPEJC-UHFFFAOYSA-N	5105.0		SMTZFNFIKUPEJC
BRD-K38684403-001-07-9	roxithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	respiratory tract infections|urinary tract infections|skin infections	0	87.51	MedChemEx	HY-B0435	Roxithromycin	836.525	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	RXZBMPWDPOLZGW-SWCVOMKCSA-N			RXZBMPWDPOLZGW
BRD-K38684403-001-04-7	roxithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	respiratory tract infections|urinary tract infections|skin infections	0	81.55	MicroSource	1503276	ROXITHROMYCIN	836.525	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	RXZBMPWDPOLZGW-SWCVOMKCSA-N			RXZBMPWDPOLZGW
BRD-K38684403-001-05-4	roxithromycin	Launched	bacterial 50S ribosomal subunit inhibitor	MLNR	infectious disease	respiratory tract infections|urinary tract infections|skin infections	0	99.06	Selleck	S2506	Roxithromycin	836.525	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	RXZBMPWDPOLZGW-SWCVOMKCSA-N		BRD-K58211978-001-01-5	RXZBMPWDPOLZGW
BRD-A29148886-003-01-4	RP-001	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR1			0	94.54	Tocris	4289	RP 001 hydrochloride	432.18	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|	WNDDDFYFTSGSEC-HXUWFJFHSA-N	58344861.0		WNDDDFYFTSGSEC
BRD-A29148886-003-02-9	RP-001	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR1			0	96.01	Tocris	4289	RP 001 hydrochloride	432.18	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|	WNDDDFYFTSGSEC-HXUWFJFHSA-N	58344861.0		WNDDDFYFTSGSEC
BRD-K40767677-001-01-1	RP67580	Preclinical					0	44.82	Tocris	1635	(3aR,7aR)-2-[2-(2-methoxyphenyl)ethanimidoyl]-7,7-diphenyloctahydro-4H-isoindol-4-one	438.231	COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1	VWBOQFANCXZMAU-LOSJGSFVSA-N	107686.0		VWBOQFANCXZMAU
BRD-K40767677-001-02-9	RP67580	Preclinical					0		Tocris	1635	RP 67580	438.231	COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1	VWBOQFANCXZMAU-LOSJGSFVSA-N	107686.0		VWBOQFANCXZMAU
BRD-K87973152-001-01-3	RQ-00203078	Preclinical	transient receptor potential channel antagonist	TRPM8			0	93.37	Tocris	5388	RQ 00203078	554.014	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F	IJGQFZYYEHCCIZ-UHFFFAOYSA-N	49783953.0		IJGQFZYYEHCCIZ
BRD-K87973152-001-02-9	RQ-00203078	Preclinical	transient receptor potential channel antagonist	TRPM8			0	95.32	Tocris	5388	RQ 00203078	554.014	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F	IJGQFZYYEHCCIZ-UHFFFAOYSA-N	49783953.0		IJGQFZYYEHCCIZ
BRD-K06894065-001-02-3	RRx-001	Phase 3	glucose 6-phosphate dehydrogenase inhibitor	G6PD			0	0.0	MedChemEx	HY-16438	RRx-001	266.949	[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O	JODKFOVZURLVTG-UHFFFAOYSA-N	15950826.0		JODKFOVZURLVTG
BRD-K06894065-001-01-5	RRx-001	Phase 3	glucose 6-phosphate dehydrogenase inhibitor	G6PD			0	0.0	MedChemEx	HY-16438	RRx-001	266.949	[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O	JODKFOVZURLVTG-UHFFFAOYSA-N	15950826.0		JODKFOVZURLVTG
BRD-K00004000-001-01-9	RS-0481	Phase 2	immunostimulant				0		Broad Institute	RS0481	RS0481	340.125	C[C@@H](NC(=O)[C@@H]1CSCN1C(=O)c1ccccc1)c1ccccc1	MEXWLVVJOPSWLN-PBHICJAKSA-N	5747899.0		MEXWLVVJOPSWLN
BRD-K08640512-003-03-9	RS-100329	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1D			0	96.68	Tocris	1325	RS 100329 hydrochloride	426.188	Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O	RCOBWVAGWYRNHZ-UHFFFAOYSA-N	3567002.0		RCOBWVAGWYRNHZ
BRD-K08640512-003-02-3	RS-100329	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1D			0	97.46	Tocris	1325	RS 100329 hydrochloride	426.188	Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O	RCOBWVAGWYRNHZ-UHFFFAOYSA-N	3567002.0		RCOBWVAGWYRNHZ
BRD-K87048468-003-03-5	RS-102221	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	97.64	Tocris	1050	RS 102221 hydrochloride	612.187	COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	HZZZZODVDSHQRG-UHFFFAOYSA-N	3693566.0		HZZZZODVDSHQRG
BRD-K87048468-003-04-3	RS-102221	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	93.67	Tocris	1050	N-{5-[5-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl}-4-(trifluoromethyl)benzenesulfonamide hydroch	612.187	COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	HZZZZODVDSHQRG-UHFFFAOYSA-N	3693566.0		HZZZZODVDSHQRG
BRD-K87048468-003-02-7	RS-102221	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	84.76	Tocris	1050	RS 102221 hydrochloride	612.187	COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	HZZZZODVDSHQRG-UHFFFAOYSA-N	3693566.0		HZZZZODVDSHQRG
BRD-K87048468-003-05-9	RS-102221	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0		Tocris	1050	RS 102221 hydrochloride	612.187	COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	HZZZZODVDSHQRG-UHFFFAOYSA-N	3693566.0		HZZZZODVDSHQRG
BRD-K83063356-003-03-3	RS-102895	Preclinical	CCR antagonist	CCR2			0	97.44	Tocris	2089	RS 102895 hydrochloride	390.156	FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	HIDWEYPGMLIQSN-UHFFFAOYSA-N	10000456.0		HIDWEYPGMLIQSN
BRD-K83063356-003-04-9	RS-102895	Preclinical	CCR antagonist	CCR2			0	96.19	Tocris	2089	RS 102895 hydrochloride	390.156	FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	HIDWEYPGMLIQSN-UHFFFAOYSA-N	10000456.0		HIDWEYPGMLIQSN
BRD-K83063356-003-02-5	RS-102895	Preclinical	CCR antagonist	CCR2			0	97.17	Tocris	2089	RS 102895 hydrochloride	390.156	FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	HIDWEYPGMLIQSN-UHFFFAOYSA-N	10000456.0		HIDWEYPGMLIQSN
BRD-K90825648-001-02-0	RS-127445	Phase 1	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	95.44	Selleck	S2698	RS-127445	281.133	CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12	ZZZQXCUPAJFVBN-UHFFFAOYSA-N	196968.0		ZZZQXCUPAJFVBN
BRD-K90825648-003-03-9	RS-127445	Phase 1	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	98.16	Tocris	2993	RS 127445 hydrochloride	281.133	CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12	ZZZQXCUPAJFVBN-UHFFFAOYSA-N	196968.0		ZZZQXCUPAJFVBN
BRD-K00004221-300-01-9	RS-16566	Preclinical	serotonin receptor antagonist				0	97.92	Tocris	1015	RS 16566 dihydrochloride	346.156	CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1C[N@@]2CC[C@H]1CC2	OGXMGJGFLBSEJW-HNNXBMFYSA-N	6604794.0		OGXMGJGFLBSEJW
BRD-K76840893-003-03-3	RS-17053	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1D			0	95.74	Tocris	985	RS 17053 hydrochloride	412.192	CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	XLZHXAXXJVKTFM-UHFFFAOYSA-N	3894573.0		XLZHXAXXJVKTFM
BRD-K76840893-003-04-9	RS-17053	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1D			0	97.61	Tocris	985	RS 17053 hydrochloride	412.192	CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	XLZHXAXXJVKTFM-UHFFFAOYSA-N	3894573.0		XLZHXAXXJVKTFM
BRD-K76840893-003-02-5	RS-17053	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1D			0	96.88	Tocris	985	RS 17053 hydrochloride	412.192	CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	XLZHXAXXJVKTFM-UHFFFAOYSA-N	3894573.0		XLZHXAXXJVKTFM
BRD-K01868942-003-02-7	RS-23597-190	Preclinical	serotonin receptor antagonist	HTR4			0	98.28	Tocris	728	RS 23597-190 hydrochloride	326.14	COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1	RLSGBCUXLRMTPF-UHFFFAOYSA-N	182593.0		RLSGBCUXLRMTPF
BRD-K20742498-003-03-9	RS-39604	Preclinical	serotonin receptor antagonist	HTR4			0	94.09	Tocris	991	RS 39604 hydrochloride	553.201	COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1	BKVIWGRFRKLFIO-UHFFFAOYSA-N	5145950.0		BKVIWGRFRKLFIO
BRD-K20742498-003-02-9	RS-39604	Preclinical	serotonin receptor antagonist	HTR4			0	98.29	Tocris	991	RS 39604 hydrochloride	553.201	COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1	BKVIWGRFRKLFIO-UHFFFAOYSA-N	5145950.0		BKVIWGRFRKLFIO
BRD-K26160755-003-03-9	RS-45041-190	Preclinical	imidazoline receptor agonist				0	100.0	Tocris	889	RS 45041-190 hydrochloride	221.072	Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|	IVCMOOBKRRDNHX-UHFFFAOYSA-N	127951.0		IVCMOOBKRRDNHX
BRD-K26160755-003-02-6	RS-45041-190	Preclinical	imidazoline receptor agonist				0	96.87	Tocris	889	RS 45041-190 hydrochloride	221.072	Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|	IVCMOOBKRRDNHX-UHFFFAOYSA-N	127951.0		IVCMOOBKRRDNHX
BRD-K87510569-001-02-8	RS-504393	Preclinical	CC chemokine receptor antagonist	CCL2|CCR2			0	96.5	Tocris	2517	RS 504393	417.205	Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	ODNICNWASXKNNQ-UHFFFAOYSA-N	9953769.0		ODNICNWASXKNNQ
BRD-K87510569-001-03-9	RS-504393	Preclinical	CC chemokine receptor antagonist	CCL2|CCR2			0	97.31	Tocris	2517	RS 504393	417.205	Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	ODNICNWASXKNNQ-UHFFFAOYSA-N	9953769.0		ODNICNWASXKNNQ
BRD-K00004219-003-01-9	RS-56812	Preclinical	serotonin receptor partial agonist	HTR3A			0	98.24	Tocris	988	RS 56812 hydrochloride	311.163	Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12	ZNAPADWWBWFMCQ-HNNXBMFYSA-N	6604789.0		ZNAPADWWBWFMCQ
BRD-K46142322-003-03-9	RS-67333	Preclinical	serotonin receptor partial agonist	HTR4			0	91.72	Tocris	989	RS 67333 hydrochloride	352.192	CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1	JBHLYIVFFLNISJ-UHFFFAOYSA-N	183782.0		JBHLYIVFFLNISJ
BRD-K46142322-003-02-4	RS-67333	Preclinical	serotonin receptor partial agonist	HTR4			0	97.37	Tocris	989	RS 67333 hydrochloride	352.192	CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1	JBHLYIVFFLNISJ-UHFFFAOYSA-N	183782.0		JBHLYIVFFLNISJ
BRD-K50018155-003-03-9	RS-67506	Preclinical	serotonin receptor partial agonist	HTR4			0	91.24	Tocris	990	RS 67506 hydrochloride	417.149	COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	UATDVRSFFGFTAI-UHFFFAOYSA-N	133076.0		UATDVRSFFGFTAI
BRD-K50018155-003-02-1	RS-67506	Preclinical	serotonin receptor partial agonist	HTR4			0	96.93	Tocris	990	RS 67506 hydrochloride	417.149	COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	UATDVRSFFGFTAI-UHFFFAOYSA-N	133076.0		UATDVRSFFGFTAI
BRD-K86600316-003-03-9	RS-79948	Preclinical	adrenergic receptor antagonist	ADRA2A			0	90.88	Tocris	987	RS 79948 hydrochloride	364.182	CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12	UMGBFFAJXFXOIL-MNEFBYGVSA-N	9908992.0		UMGBFFAJXFXOIL
BRD-K86600316-003-02-0	RS-79948	Preclinical	adrenergic receptor antagonist	ADRA2A			0	97.72	Tocris	987	RS 79948 hydrochloride	364.182	CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12	UMGBFFAJXFXOIL-MNEFBYGVSA-N	9908992.0		UMGBFFAJXFXOIL
BRD-K30159788-001-01-9	RSV604	Phase 2	RSV replication inhibitor				0	98.22	MedChemEx	HY-12993	RSV604	388.134	Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|	MTPVBMVUENFFLL-HXUWFJFHSA-N	5279172.0		MTPVBMVUENFFLL
BRD-K56211775-001-02-0	RTA-408	Phase 2	nitric oxide production inhibitor	NFE2L2			0	89.51	MedChemEx	HY-12212	RTA-408	554.332	CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|	RJCWBNBKOKFWNY-IDPLTSGASA-N	71811910.0		RJCWBNBKOKFWNY
BRD-K56211775-001-01-2	RTA-408	Phase 2	nitric oxide production inhibitor	NFE2L2			0	71.05	MedChemEx	HY-12212	RTA-408	554.332	CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|	RJCWBNBKOKFWNY-IDPLTSGASA-N	71811910.0		RJCWBNBKOKFWNY
BRD-K56211775-001-03-8	RTA-408	Phase 2	nitric oxide production inhibitor	NFE2L2			0	90.95	Selleck	S7672	Omaveloxolone (RTA-408)	554.332	CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19,23|	RJCWBNBKOKFWNY-IDPLTSGASA-N	71811910.0	BRD-A96383502-001-01-3	RJCWBNBKOKFWNY
BRD-A33603104-003-02-9	RU-SKI-43	Preclinical	hedgehog pathway inhibitor	HHAT			0	93.99	Tocris	4886	RU-SKI 43 hydrochloride	386.203	CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|	AEENEMOEBJOKGN-UZLBHIALSA-N	93160320.0		AEENEMOEBJOKGN
BRD-A33603104-003-01-8	RU-SKI-43	Preclinical	hedgehog pathway inhibitor	HHAT			0	92.1	Tocris	4886	RU-SKI 43 hydrochloride	386.203	CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2,&2:17|	AEENEMOEBJOKGN-UZLBHIALSA-N	93160320.0		AEENEMOEBJOKGN
BRD-K00234327-001-04-8	RU-24969	Phase 1	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6			0	64.03	MedChemEx	HY-16688	RU 24969	228.126	COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|	KRVMLPUDAOWOGN-UHFFFAOYSA-N	108029.0		KRVMLPUDAOWOGN
BRD-K00234327-001-03-0	RU-24969	Phase 1	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6			0	0.0	MedChemEx	HY-16688	RU 24969	228.126	COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|	KRVMLPUDAOWOGN-UHFFFAOYSA-N	108029.0		KRVMLPUDAOWOGN
BRD-K00234327-036-05-1	RU-24969	Phase 1	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6			0	0.0	Tocris	912	RU 24969 hemisuccinate	228.126	COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|	KRVMLPUDAOWOGN-UHFFFAOYSA-N	108029.0	BRD-M08478673-036-02-1	KRVMLPUDAOWOGN
BRD-K37687387-237-02-9	RU-28318	Phase 2	cytochrome P450 inhibitor	NR3C2			0	96.9	Tocris	1672	RU 28318, potassium salt	402.277	CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|	DNHCHRGCTVRAFT-JEHIOXJOSA-N	3034004.0		DNHCHRGCTVRAFT
BRD-K37687387-237-01-7	RU-28318	Phase 2	cytochrome P450 inhibitor	NR3C2			0	92.75	Tocris	1672	RU 28318, potassium salt	402.277	CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|	DNHCHRGCTVRAFT-JEHIOXJOSA-N	3034004.0		DNHCHRGCTVRAFT
BRD-K85285268-003-01-1	RU-42173	Phase 2	adrenergic receptor agonist	ADRB2			0	9.01	Enzo	AR113	Zilpaterol	261.148	CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O	ZSTCZWJCLIRCOJ-DGCLKSJQSA-N	3086576.0		ZSTCZWJCLIRCOJ
BRD-K62762455-001-02-9	RU-58841	Phase 2	androgen receptor antagonist	AR			0	96.61	MedChemEx	HY-10561	RU 58841	369.13	CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	ARBYGDBJECGMGA-UHFFFAOYSA-N	132981.0		ARBYGDBJECGMGA
BRD-K62762455-001-01-3	RU-58841	Phase 2	androgen receptor antagonist	AR			0	97.49	MedChemEx	HY-10561	RU 58841	369.13	CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	ARBYGDBJECGMGA-UHFFFAOYSA-N	132981.0		ARBYGDBJECGMGA
BRD-K79821389-001-03-5	rubitecan	Phase 3	topoisomerase inhibitor	TOP1			0	94.03	Sigma	MFCD06656294	(4S)-4-ethyl-4-hydroxy-10-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	393.096	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O	VHXNKPBCCMUMSW-FQEVSTJZSA-N	472335.0		VHXNKPBCCMUMSW
BRD-K27677357-003-04-9	ruboxistaurin	Phase 3	PKC inhibitor				0	92.46	MedChemEx	HY-10195B	Ruboxistaurin (hydrochloride)	468.216	CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21 |t:10|	ZCBUQCWBWNUWSU-SFHVURJKSA-N	153999.0		ZCBUQCWBWNUWSU
BRD-K88560311-001-08-9	rucaparib	Phase 3	PARP inhibitor	PARP1|PARP2			0	95.59	Tocris	6230	Rucaparib camsylate	323.143	CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	HMABYWSNWIZPAG-UHFFFAOYSA-N	9931954.0		HMABYWSNWIZPAG
BRD-K88560311-011-07-1	rucaparib	Phase 3	PARP inhibitor	PARP1|PARP2			0	95.32	Selleck	S1098	Rucaparib (AG-014699 , PF-01367338)	323.143	CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	HMABYWSNWIZPAG-UHFFFAOYSA-N	9931954.0		HMABYWSNWIZPAG
BRD-K88560311-011-06-3	rucaparib	Phase 3	PARP inhibitor	PARP1|PARP2			0	87.58	Selleck	S1098	Rucaparib (AG-014699,PF-01367338)	323.143	CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	HMABYWSNWIZPAG-UHFFFAOYSA-N	9931954.0		HMABYWSNWIZPAG
BRD-K61036791-001-01-6	rucinol	Phase 1	tyrosinase inhibitor	TYR			0	98.99	TCI	B3773		166.099	CCCCc1ccc(O)cc1O	CSHZYWUPJWVTMQ-UHFFFAOYSA-N	205912.0		CSHZYWUPJWVTMQ
BRD-K20079257-001-09-6	rufinamide	Launched	voltage-gated sodium channel blocker	GRM5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures	0	98.35	Selleck	S1256	Rufinamide	238.067	NC(=O)c1cn(Cc2c(F)cccc2F)nn1	POGQSBRIGCQNEG-UHFFFAOYSA-N	129228.0		POGQSBRIGCQNEG
BRD-K62374253-001-07-8	rufloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	97.36	MicroSource	1502335	RUFLOXACIN HYDROCHLORIDE	363.105	CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O	NJCJBUHJQLFDSW-UHFFFAOYSA-N	58258.0		NJCJBUHJQLFDSW
BRD-K62374253-003-10-9	rufloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	95.46	MedChemEx	HY-B0902A	Rufloxacin hydrochloride	363.105	CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O	NJCJBUHJQLFDSW-UHFFFAOYSA-N	58258.0		NJCJBUHJQLFDSW
BRD-K98004573-051-03-9	rupatadine	Launched	histamine receptor antagonist|platelet activating factor receptor antagonist	HRH1|PTAFR	allergy	allergic rhinitis|urticaria	0	98.23	MedChemEx	HY-13511A	Rupatadine (Fumarate)	415.182	Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1	WUZYKBABMWJHDL-UHFFFAOYSA-N	133017.0		WUZYKBABMWJHDL
BRD-K98004573-051-02-8	rupatadine	Launched	histamine receptor antagonist|platelet activating factor receptor antagonist	HRH1|PTAFR	allergy	allergic rhinitis|urticaria	0	91.72	Selleck	S3052	Rupatadine Fumarate	415.182	Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1	WUZYKBABMWJHDL-UHFFFAOYSA-N	133017.0		WUZYKBABMWJHDL
BRD-K94723713-001-12-9	rutaecarpine	Preclinical	cyclooxygenase inhibitor	PTGS2			0	94.55	MedChemEx	HY-N0147	Rutaecarpine	287.106	O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12	ACVGWSKVRYFWRP-UHFFFAOYSA-N	65752.0		ACVGWSKVRYFWRP
BRD-K94723713-001-10-6	rutaecarpine	Preclinical	cyclooxygenase inhibitor	PTGS2			0	97.45	Selleck	S2349	Rutaecarpine	287.106	O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12	ACVGWSKVRYFWRP-UHFFFAOYSA-N	65752.0		ACVGWSKVRYFWRP
BRD-K20482099-001-11-0	rutin	Launched	antioxidant|capillary stabilizing agent|nitric oxide scavenger	AKR1C3	rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy	joint pain|nasal congestion|constipation|irritability|allergic rhinitis	0	91.2	MicroSource	300607	RUTIN	610.153	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IKGXIBQEEMLURG-NVPNHPEKSA-N	5280805.0	BRD-A76747559-001-03-1	IKGXIBQEEMLURG
BRD-K20482099-001-12-9	rutin	Launched	antioxidant|capillary stabilizing agent|nitric oxide scavenger	AKR1C3	rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy	joint pain|nasal congestion|constipation|irritability|allergic rhinitis	0	86.23	MedChemEx	HY-N0148	Rutin	610.153	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IKGXIBQEEMLURG-NVPNHPEKSA-N	5280805.0		IKGXIBQEEMLURG
BRD-K20482099-001-09-4	rutin	Launched	antioxidant|capillary stabilizing agent|nitric oxide scavenger	AKR1C3	rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy	joint pain|nasal congestion|constipation|irritability|allergic rhinitis	0	90.04	Selleck	S2350	Rutin (Rutoside)	610.153	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IKGXIBQEEMLURG-NVPNHPEKSA-N	5280805.0		IKGXIBQEEMLURG
BRD-K20482099-001-10-2	rutin	Launched	antioxidant|capillary stabilizing agent|nitric oxide scavenger	AKR1C3	rheumatology|otolaryngology|gastroenterology|neurology/psychiatry|allergy	joint pain|nasal congestion|constipation|irritability|allergic rhinitis	0	87.66	Selleck	S2350	Rutin	610.153	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IKGXIBQEEMLURG-NVPNHPEKSA-N	5280805.0	BRD-K22924152-001-01-4	IKGXIBQEEMLURG
BRD-K53972329-001-07-0	ruxolitinib	Launched	JAK inhibitor	JAK1|JAK2|JAK3|TYK2	hematologic malignancy|hematology	myelofibrosis|polycythemia vera	0	96.54	Selleck	S1378	Ruxolitinib (INCB018424)	306.159	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	HFNKQEVNSGCOJV-OAHLLOKOSA-N	25126798.0	BRD-K19601669-001-02-7|BRD-K19601669-001-02-7	HFNKQEVNSGCOJV
BRD-K53972329-001-01-3	ruxolitinib	Launched	JAK inhibitor	JAK1|JAK2|JAK3|TYK2	hematologic malignancy|hematology	myelofibrosis|polycythemia vera	0	99.11	Chemietek	CT-INCB	INCB018424	306.159	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	HFNKQEVNSGCOJV-OAHLLOKOSA-N	25126798.0		HFNKQEVNSGCOJV
BRD-K19601669-001-04-9	ruxolitinib-(S)	Preclinical	JAK inhibitor	JAK1|JAK2			0	90.52	MedChemEx	HY-50856A	Ruxolitinib (S enantiomer)	306.159	N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	HFNKQEVNSGCOJV-HNNXBMFYSA-N	50878566.0		HFNKQEVNSGCOJV
BRD-K19601669-001-03-5	ruxolitinib-(S)	Preclinical	JAK inhibitor	JAK1|JAK2			0	97.97	Selleck	S2902	S-Ruxolitinib (INCB018424)	306.159	N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	HFNKQEVNSGCOJV-HNNXBMFYSA-N	50878566.0		HFNKQEVNSGCOJV
BRD-K00004579-001-01-9	RV1729	Phase 1	PI3K inhibitor				0	85.07	Astatech	P14335	5-HEXYNAMIDE, 6-[2-[[4-AMINO-3-(3-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]METHYL]-3-[(2-CHLOROPHENYL)METHYL]-3,4-DIHYDRO-4-OXO-5-QUINAZOLINYL]-N,N-BIS(2-METHOXYETHYL)-	734.273	COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc34)n(Cc3ccccc3Cl)c(=O)c12	UBLOHCIYTDRGJH-UHFFFAOYSA-N	52913198.0		UBLOHCIYTDRGJH
BRD-K00091711-001-03-8	RWJ-21757	Phase 2	toll-like receptor agonist	TLR7			0	63.19	Tocris	2719	RWJ 21757	339.118	Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	VDCRFBBZFHHYGT-IOSLPCCCSA-N	135410906.0		VDCRFBBZFHHYGT
BRD-K00091711-001-02-0	RWJ-21757	Phase 2	toll-like receptor agonist	TLR7			0	83.49	Sigma	MFCD00867591	7-allyl-2-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-hydroxy-7,9-dihydro-8H-purin-8-one	339.118	Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	VDCRFBBZFHHYGT-IOSLPCCCSA-N	135410906.0		VDCRFBBZFHHYGT
BRD-K00091711-001-01-2	RWJ-21757	Phase 2	toll-like receptor agonist	TLR7			0	84.99	Tocris	2719	RWJ 21757	339.118	Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	VDCRFBBZFHHYGT-IOSLPCCCSA-N	135410906.0		VDCRFBBZFHHYGT
BRD-K94623186-001-01-5	RWJ-50271	Preclinical	integrin inhibitor	ICAM1			0	97.8	Tocris	4227	RWJ 50271	410.102	Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO	HOFGTYCLOKDAES-UHFFFAOYSA-N	9953357.0		HOFGTYCLOKDAES
BRD-K94623186-001-02-9	RWJ-50271	Preclinical	integrin inhibitor	ICAM1			0	97.49	Tocris	4227	RWJ 50271	410.102	Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO	HOFGTYCLOKDAES-UHFFFAOYSA-N	9953357.0		HOFGTYCLOKDAES
BRD-K07074923-001-01-5	RWJ-67657	Phase 1	MAP kinase inhibitor	MAPK14|PTGS2			0	93.32	Cayman	18718	4-[4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-3-butyn-1-ol	425.19	OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1	QSUSKMBNZQHHPA-UHFFFAOYSA-N	3008319.0		QSUSKMBNZQHHPA
BRD-K07074923-001-02-3	RWJ-67657	Phase 1	MAP kinase inhibitor	MAPK14|PTGS2			0	91.52	Tocris	2999	RWJ 67657	425.19	OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1	QSUSKMBNZQHHPA-UHFFFAOYSA-N	3008319.0		QSUSKMBNZQHHPA
BRD-K66213167-001-02-0	RX-3117	Phase 1/Phase 2	CDK inhibitor|DNA synthesis inhibitor	CDK2|DNMT1			0	66.8	MedChemEx	HY-15228	RX-3117	257.081	Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|	QLLGKCJUPWYJON-HLTSFMKQSA-N	11242315.0		QLLGKCJUPWYJON
BRD-K66213167-001-01-2	RX-3117	Phase 1/Phase 2	CDK inhibitor|DNA synthesis inhibitor	CDK2|DNMT1			0	83.1	MedChemEx	HY-15228	RX-3117	257.081	Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|	QLLGKCJUPWYJON-HLTSFMKQSA-N	11242315.0		QLLGKCJUPWYJON
BRD-A65597028-003-08-1	RX-821002	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C			0	82.66	Tocris	1324	RX 821002 hydrochloride	234.1	CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|	HQGWKNGAKBPTBX-LBPRGKRZSA-N	67743720.0		HQGWKNGAKBPTBX
BRD-A65597028-003-09-9	RX-821002	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C			0	84.31	Tocris	1324	RX 821002 hydrochloride	234.1	CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|	HQGWKNGAKBPTBX-LBPRGKRZSA-N	67743720.0		HQGWKNGAKBPTBX
BRD-A65597028-003-07-3	RX-821002	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C			0	97.1	Tocris	1324	RX 821002 hydrochloride	234.1	CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2,t:14|	HQGWKNGAKBPTBX-LBPRGKRZSA-N	67743720.0		HQGWKNGAKBPTBX
BRD-K06426971-001-02-7	ryuvidine	Preclinical	histone lysine methyltransferase inhibitor	CDK2|CDK4			0	95.12	Tocris	2609	Ryuvidine	284.062	Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|	HFPLHASLIOXVGS-UHFFFAOYSA-N	481747.0		HFPLHASLIOXVGS
BRD-K06426971-001-04-9	ryuvidine	Preclinical	histone lysine methyltransferase inhibitor	CDK2|CDK4			0	95.15	Tocris	2609	Ryuvidine	284.062	Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|	HFPLHASLIOXVGS-UHFFFAOYSA-N	481747.0		HFPLHASLIOXVGS
BRD-K06426971-001-03-5	ryuvidine	Preclinical	histone lysine methyltransferase inhibitor	CDK2|CDK4			0	93.7	Tocris	2609	Ryuvidine	284.062	Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|	HFPLHASLIOXVGS-UHFFFAOYSA-N	481747.0		HFPLHASLIOXVGS
BRD-K23902832-001-01-7	R112	Phase 1	SYK inhibitor	SYK			0	94.95	MedChemEx	HY-16420	R112	312.102	Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1	TVKGTSHBQZEFEE-UHFFFAOYSA-N	9904854.0		TVKGTSHBQZEFEE
BRD-K86687746-001-01-3	R306465	Phase 1	HDAC inhibitor				0	82.42	AdvChemBlocks	A-632	5-pyrimidinecarboxamide-n-hydroxy-2-4-2-naphthalenylsulfonyl-1-piperazinyl	413.116	ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1	MUTBJZVSRNUIHA-UHFFFAOYSA-N	10309899.0		MUTBJZVSRNUIHA
BRD-K20285085-074-04-5	R406	Phase 1	SYK inhibitor	RET|SYK			0	88.93	Selleck	S2194	R406	470.171	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	NHHQJBCNYHBUSI-UHFFFAOYSA-N	11213558.0		NHHQJBCNYHBUSI
BRD-K20285085-074-03-7	R406	Phase 1	SYK inhibitor	RET|SYK			0	93.57	Selleck	S2194	R406	470.171	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	NHHQJBCNYHBUSI-UHFFFAOYSA-N	11213558.0		NHHQJBCNYHBUSI
BRD-K20285085-001-07-1	R406	Phase 1	SYK inhibitor	RET|SYK			0	97.72	Selleck	S1533	R406 (free base)	470.171	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	NHHQJBCNYHBUSI-UHFFFAOYSA-N	11213558.0		NHHQJBCNYHBUSI
BRD-K52233191-001-03-9	R547	Phase 1	CDK inhibitor	CDK1|CDK2|CDK4|CDK7			0	95.73	MedChemEx	HY-10014	R547	441.128	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	JRNJNYBQQYBCLE-UHFFFAOYSA-N	6918852.0		JRNJNYBQQYBCLE
BRD-K52233191-001-02-4	R547	Phase 1	CDK inhibitor	CDK1|CDK2|CDK4|CDK7			0	95.54	Selleck	S2688	R547	441.128	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	JRNJNYBQQYBCLE-UHFFFAOYSA-N	6918852.0		JRNJNYBQQYBCLE
BRD-K10673031-004-03-9	S-isopropylisothiourea	Preclinical	nitric oxide synthase inhibitor	NOS3			0	82.54	Tocris	897	S-Isopropylisothiourea hydrobromide	118.056	CC(C)SC(N)=N	XSSNABKEYXKKMK-UHFFFAOYSA-N	445319.0		XSSNABKEYXKKMK
BRD-K10673031-004-02-0	S-isopropylisothiourea	Preclinical	nitric oxide synthase inhibitor	NOS3			0	94.16	Tocris	897	S-Isopropylisothiourea hydrobromide	118.056	CC(C)SC(N)=N	XSSNABKEYXKKMK-UHFFFAOYSA-N	445319.0		XSSNABKEYXKKMK
BRD-K63123526-001-02-0	S-methylcysteine	Phase 1		CTSD|MGMT			1	100.0	Ark	AK-44172	(2R)-2-amino-3-(methylsulfanyl)propanoic acid	135.035	CSC[C@H](N)C(O)=O	IDIDJDIHTAOVLG-VKHMYHEASA-N	7058174.0		IDIDJDIHTAOVLG
BRD-K63123526-001-01-2	S-methylcysteine	Phase 1		CTSD|MGMT			1	0.0	Ark	AK-44172		135.035	CSC[C@H](N)C(O)=O	IDIDJDIHTAOVLG-VKHMYHEASA-N	7058174.0		IDIDJDIHTAOVLG
BRD-K00024724-001-01-9	S-nitrosoglutathione	Phase 1	nitric oxide stimulant	PTPN1			0		Tocris	603	SNOG	336.074	N[C@@H](CCC(=O)N[C@@H](CS[N+][O-])C(=O)NCC(O)=O)C(O)=O	HYHSBSXUHZOYLX-WDSKDSINSA-N	104858.0		HYHSBSXUHZOYLX
BRD-K59527975-236-01-8	S-sulfo-L-cysteine	Preclinical	glutamate receptor agonist				0	90.28	Tocris	162	S-Sulfo-L-cysteine sodium salt	200.977	N[C@@H](CSS(O)(=O)=O)C(O)=O	NOKPBJYHPHHWAN-REOHCLBHSA-N	7068808.0		NOKPBJYHPHHWAN
BRD-K09774593-001-03-9	S-trityl-L-cysteine	Preclinical	mitotic kinesin inhibitor				0	86.33	Labotest	LT00159603	tritylcysteine	363.129	N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O	DLMYFMLKORXJPO-HXUWFJFHSA-N	7271796.0		DLMYFMLKORXJPO
BRD-K09774593-001-01-7	S-trityl-L-cysteine	Preclinical	mitotic kinesin inhibitor				0	18.45	Tocris	2191	S-Trityl-L-cysteine	363.129	N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O	DLMYFMLKORXJPO-HXUWFJFHSA-N	7271796.0		DLMYFMLKORXJPO
BRD-K09774593-001-02-9	S-trityl-L-cysteine	Preclinical	mitotic kinesin inhibitor				0	92.53	Tocris	2191	S-Trityl-L-cysteine	363.129	N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O	DLMYFMLKORXJPO-HXUWFJFHSA-N	7271796.0		DLMYFMLKORXJPO
BRD-K37635256-001-02-9	S-07662	Preclinical	CAR antagonist	NR1I3			0	96.8	Tocris	5188	S 07662	300.093	Cc1oc2ccccc2c1CNC(=O)NCc1cccs1	UITFWLJMEZPXOF-UHFFFAOYSA-N	2732040.0		UITFWLJMEZPXOF
BRD-K37635256-001-01-4	S-07662	Preclinical	CAR antagonist	NR1I3			0	94.26	Tocris	5188	S 07662	300.093	Cc1oc2ccccc2c1CNC(=O)NCc1cccs1	UITFWLJMEZPXOF-UHFFFAOYSA-N	2732040.0		UITFWLJMEZPXOF
BRD-K60005752-001-02-9	S-111	Phase 2	PARP inhibitor	PARP1			0	73.34	MedChemEx	HY-N0797	(20S)-Protopanaxadiol	460.392	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	PYXFVCFISTUSOO-HKUCOEKDSA-N	11213350.0		PYXFVCFISTUSOO
BRD-K60005752-001-01-9	S-111	Phase 2	PARP inhibitor	PARP1			0	100.0	MedChemEx	HY-N0797	(20S)-Protopanaxadiol	460.392	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	PYXFVCFISTUSOO-HKUCOEKDSA-N	11213350.0		PYXFVCFISTUSOO
BRD-K46766488-003-03-8	S-14506	Preclinical	serotonin receptor agonist	HTR1A			0	99.32	Tocris	1771	S 14506 hydrochloride	407.201	COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	IFMQODYDAUKKEN-UHFFFAOYSA-N	131906.0		IFMQODYDAUKKEN
BRD-K46766488-003-04-9	S-14506	Preclinical	serotonin receptor agonist	HTR1A			0	97.93	Tocris	1771	S 14506 hydrochloride	407.201	COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	IFMQODYDAUKKEN-UHFFFAOYSA-N	131906.0		IFMQODYDAUKKEN
BRD-K46766488-003-02-0	S-14506	Preclinical	serotonin receptor agonist	HTR1A			0	97.75	Tocris	1771	S 14506 hydrochloride	407.201	COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	IFMQODYDAUKKEN-UHFFFAOYSA-N	131906.0		IFMQODYDAUKKEN
BRD-K00004618-001-01-9	S-17092	Preclinical	prolyl endopeptidase inhibitor				0	86.56	Sigma	SML0181	((2S,3aS,7aS)-1-((1R,2R)-2-phenylcyclopropane-1-carbonyl)octahydro-1H-indol-2-yl)(thiazolidin-3-yl)methanone	384.187	O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CCSC1	NXSXRIHXEQSYEZ-KNJMJIDISA-N	9929984.0		NXSXRIHXEQSYEZ
BRD-K00003475-001-01-9	S-3304	Phase 1/Phase 2	matrix metalloprotease inhibitor				0	95.77	MedChemEx	HY-106992	S 3304	464.086	Cc1ccc(cc1)C#Cc1ccc(s1)S(=O)(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O	YWCLDDLVLSQGSZ-JOCHJYFZSA-N	10718956.0		YWCLDDLVLSQGSZ
BRD-K00003455-001-01-9	S-38093	Preclinical	histamine receptor antagonist				0	91.5	MedChemEx	HY-104003	S 38093	288.184	NC(=O)c1ccc(OCCCN2C[C@@H]3CCC[C@@H]3C2)cc1 |r|	MRNMYWNBLVJWKG-GASCZTMLSA-N	70941112.0		MRNMYWNBLVJWKG
BRD-K99819791-001-02-9	SA-47	Preclinical	FAAH inhibitor	FAAH			0	81.6	Tocris	4785	SA 47	334.2	CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1	HSYCMGWPPRTNKH-UHFFFAOYSA-N	9840648.0		HSYCMGWPPRTNKH
BRD-K99819791-001-01-1	SA-47	Preclinical	FAAH inhibitor	FAAH			0	93.41	Tocris	4785	SA 47	334.2	CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1	HSYCMGWPPRTNKH-UHFFFAOYSA-N	9840648.0		HSYCMGWPPRTNKH
BRD-K46493214-001-06-7	saccharin	Launched	DNA polymerase inhibitor	CA1|CA12|CA2|CA9			0	98.63	MicroSource	1501171	SACCHARIN	182.999	O=C1NS(=O)(=O)c2ccccc12	CVHZOJJKTDOEJC-UHFFFAOYSA-N	5143.0		CVHZOJJKTDOEJC
BRD-A24122750-001-03-7	saclofen	Preclinical	GABA receptor antagonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8			0	97.13	Tocris	246	Saclofen	249.023	NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	JYLNVJYYQQXNEK-QMMMGPOBSA-N	57453816.0		JYLNVJYYQQXNEK
BRD-A24122750-001-04-9	saclofen	Preclinical	GABA receptor antagonist	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8			0	94.33	Tocris	246	Saclofen	249.023	NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	JYLNVJYYQQXNEK-QMMMGPOBSA-N	57453816.0		JYLNVJYYQQXNEK
BRD-K91456750-001-01-9	sacubitril	Launched	neprilysin inhibitor	MME	cardiology	congestive heart failure	0	99.1	MedChemEx	HY-15407	AHU-377	411.205	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O	PYNXFZCZUAOOQC-UTKZUKDTSA-N	9811834.0		PYNXFZCZUAOOQC
BRD-K91456750-238-01-7	sacubitril	Launched	neprilysin inhibitor	MME	cardiology	congestive heart failure	0	99.59	MedChemEx	HY-15407A	AHU-377 (hemicalcium salt)	411.205	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O	PYNXFZCZUAOOQC-UTKZUKDTSA-N	9811834.0	BRD-M32063731-001-01-7	PYNXFZCZUAOOQC
BRD-K00003252-001-01-9	sacubitrilat	Preclinical	neprilysin inhibitor				0	97.52	MedChemEx	HY-17620	Sacubitrilat	383.173	[H]N([C@@H](C[C@@H](C)C(O)=O)Cc1ccc(cc1)-c1ccccc1)C(=O)CCC(O)=O	DOBNVUFHFMVMDB-BEFAXECRSA-N	10430040.0		DOBNVUFHFMVMDB
BRD-A96503329-001-01-7	safflower-yellow	Preclinical	anti-inflammatory agent				0	0.0	MedChemEx	HY-N0938	Safflower Yellow	910.217	OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)[C@@H](\C=C2/C(=O)C(=C(O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C1=O |a:2,5,7,9,11,34,38,41,43,45,&1:4,&2:15,&3:20,&4:36,&5:51|	HLUBVUICXYRPPM-DVSWWXTKSA-N			HLUBVUICXYRPPM
BRD-K92613113-001-03-9	safinamide	Launched	dopamine reuptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor	MAOB	neurology/psychiatry	Parkinson's Disease	0	97.0	MedChemEx	HY-70057	Safinamide	302.143	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	NEMGRZFTLSKBAP-LBPRGKRZSA-N	131682.0		NEMGRZFTLSKBAP
BRD-K92613113-066-02-7	safinamide	Launched	dopamine reuptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor	MAOB	neurology/psychiatry	Parkinson's Disease	0	97.9	Selleck	S1472	Safinamide Mesylate	302.143	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	NEMGRZFTLSKBAP-LBPRGKRZSA-N	131682.0		NEMGRZFTLSKBAP
BRD-K93944989-001-08-0	safingol	Phase 1	PKC inhibitor	TRPM3			0	100.0	Enzo	SL125	Dihydrosphingosine	301.298	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	OTKJDMGTUTTYMP-ZWKOTPCHSA-N	91486.0		OTKJDMGTUTTYMP
BRD-K93944989-001-10-9	safingol	Phase 1	PKC inhibitor	TRPM3			0	100.0	Tocris	749	Dihydrosphingosine	301.298	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	OTKJDMGTUTTYMP-ZWKOTPCHSA-N	91486.0		OTKJDMGTUTTYMP
BRD-K90582192-001-01-9	safranal	Phase 2	benzodiazepine receptor agonist	GABBR1			0	0.0	Sigma	MFCD00209531	2,6,6-trimethyl-1,3-cyclohexadiene-1-carbaldehyde	150.104	CC1=C(C=O)C(C)(C)CC=C1 |c:1,9|	SGAWOGXMMPSZPB-UHFFFAOYSA-N	61041.0		SGAWOGXMMPSZPB
BRD-K99433989-001-02-9	SAG	Preclinical	smoothened receptor agonist	SMO|TRPC6			0	96.59	Tocris	4366	SAG	489.164	CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|	VFSUUTYAEQOIMW-YHBQERECSA-N			VFSUUTYAEQOIMW
BRD-K99433989-001-01-3	SAG	Preclinical	smoothened receptor agonist	SMO|TRPC6			0	90.09	Tocris	4366	SAG	489.164	CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|	VFSUUTYAEQOIMW-YHBQERECSA-N			VFSUUTYAEQOIMW
BRD-K15045219-001-01-8	salazodine	Phase 2					0	90.31	Aronis	BBC/534	2-hydroxy-5-[(4-{[(6-methoxy-3-pyridazinyl)amino]sulfonyl}phenyl)diazenyl]benzoic acid	429.074	COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1	YFUATOCFMCWUEH-UHFFFAOYSA-N	65707.0		YFUATOCFMCWUEH
BRD-K64614248-001-13-9	salicin	Phase 1	anti-inflammatory agent				0	89.31	MedChemEx	HY-N0149	Salicin	286.105	OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	NGFMICBWJRZIBI-UJPOAAIJSA-N	439503.0		NGFMICBWJRZIBI
BRD-K64614248-001-12-3	salicin	Phase 1	anti-inflammatory agent				0	99.21	MicroSource	1502255	SALICIN	286.105	OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	NGFMICBWJRZIBI-UJPOAAIJSA-N	439503.0		NGFMICBWJRZIBI
BRD-K64614248-001-11-5	salicin	Phase 1	anti-inflammatory agent				0	96.21	Selleck	S2351	Salicin	286.105	OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	NGFMICBWJRZIBI-UJPOAAIJSA-N	439503.0		NGFMICBWJRZIBI
BRD-K08493205-001-05-9	salicyl-alcohol	Preclinical					0	91.32	MedChemEx	HY-B1419	Salicyl alcohol	124.052	OCc1ccccc1O	CQRYARSYNCAZFO-UHFFFAOYSA-N	5146.0		CQRYARSYNCAZFO
BRD-K08493205-001-04-9	salicyl-alcohol	Preclinical					0	98.21	MicroSource	1500531	SALICYL ALCOHOL	124.052	OCc1ccccc1O	CQRYARSYNCAZFO-UHFFFAOYSA-N	5146.0		CQRYARSYNCAZFO
BRD-K81130846-001-18-9	salicylamide	Launched	analgesic agent		neurology/psychiatry|endocrinology	pain relief|fever	0	95.0	MedChemEx	HY-B0811	Salicylamide	137.048	NC(=O)c1ccccc1O	SKZKKFZAGNVIMN-UHFFFAOYSA-N	5147.0		SKZKKFZAGNVIMN
BRD-K81130846-001-17-4	salicylamide	Launched	analgesic agent		neurology/psychiatry|endocrinology	pain relief|fever	0	98.74	MicroSource	1500532	SALICYLAMIDE	137.048	NC(=O)c1ccccc1O	SKZKKFZAGNVIMN-UHFFFAOYSA-N	5147.0		SKZKKFZAGNVIMN
BRD-K83036479-001-11-9	salicylanilide	Preclinical	other antibiotic				0	96.66	MedChemEx	HY-B1408	Salicylanilide	213.079	Oc1ccccc1C(=O)Nc1ccccc1	WKEDVNSFRWHDNR-UHFFFAOYSA-N	6872.0		WKEDVNSFRWHDNR
BRD-K83036479-001-09-2	salicylanilide	Preclinical	other antibiotic				0	99.27	MicroSource	300618	SALICYLANILIDE	213.079	Oc1ccccc1C(=O)Nc1ccccc1	WKEDVNSFRWHDNR-UHFFFAOYSA-N	6872.0		WKEDVNSFRWHDNR
BRD-K83036479-001-08-4	salicylanilide	Preclinical	other antibiotic				0	98.72	Selleck	S4187	Salicylanilide	213.079	Oc1ccccc1C(=O)Nc1ccccc1	WKEDVNSFRWHDNR-UHFFFAOYSA-N	6872.0		WKEDVNSFRWHDNR
BRD-K93632104-001-20-9	salicylic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	AKR1C1|ASIC3|PTGS1|PTGS2	dermatology|endocrinology|neurology/psychiatry	acne vulgaris (AV)|fever|pain relief	0	98.54	MedChemEx	HY-B0167	Salicylic acid	138.032	OC(=O)c1ccccc1O	YGSDEFSMJLZEOE-UHFFFAOYSA-N	338.0		YGSDEFSMJLZEOE
BRD-K93632104-001-19-8	salicylic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	AKR1C1|ASIC3|PTGS1|PTGS2	dermatology|endocrinology|neurology/psychiatry	acne vulgaris (AV)|fever|pain relief	0	96.34	Selleck	S3137	Sodium salicylate	138.032	OC(=O)c1ccccc1O	YGSDEFSMJLZEOE-UHFFFAOYSA-N	338.0	BRD-M30512773-001-05-5	YGSDEFSMJLZEOE
BRD-K93632104-001-18-0	salicylic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	AKR1C1|ASIC3|PTGS1|PTGS2	dermatology|endocrinology|neurology/psychiatry	acne vulgaris (AV)|fever|pain relief	0	98.74	MicroSource	1500533	SODIUM SALICYLATE	138.032	OC(=O)c1ccccc1O	YGSDEFSMJLZEOE-UHFFFAOYSA-N	338.0	BRD-M30512773-001-06-3	YGSDEFSMJLZEOE
BRD-K93632104-001-17-2	salicylic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist	AKR1C1|ASIC3|PTGS1|PTGS2	dermatology|endocrinology|neurology/psychiatry	acne vulgaris (AV)|fever|pain relief	0	98.29	MicroSource	1500535	SALICYLIC ACID	138.032	OC(=O)c1ccccc1O	YGSDEFSMJLZEOE-UHFFFAOYSA-N	338.0		YGSDEFSMJLZEOE
BRD-K66030860-001-04-4	salidroside	Preclinical	beta amyloid protein neurotoxicity inhibitor	APP			0	97.85	Selleck	S2396	Salidroside (Rhodioloside)	300.121	OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	ILRCGYURZSFMEG-RKQHYHRCSA-N	159278.0		ILRCGYURZSFMEG
BRD-K66030860-001-03-6	salidroside	Preclinical	beta amyloid protein neurotoxicity inhibitor	APP			0	79.16	Selleck	S2396	Salidroside	300.121	OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	ILRCGYURZSFMEG-RKQHYHRCSA-N	159278.0		ILRCGYURZSFMEG
BRD-K23414042-236-05-9	salinomycin	Launched			infectious disease	coccidiosis	0	90.7	Tocris	3637	Salinomycin sodium salt	750.492	CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@H]3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O |c:46|	KQXDHUJYNAXLNZ-XQSDOZFQSA-N	3085092.0		KQXDHUJYNAXLNZ
BRD-K98453471-001-03-9	salirasib	Phase 2	mTOR inhibitor	TRPA1			0	97.66	Tocris	4989	Salirasib	358.197	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	WUILNKCFCLNXOK-CFBAGHHKSA-N	5469318.0		WUILNKCFCLNXOK
BRD-K98453471-001-01-7	salirasib	Phase 2	mTOR inhibitor	TRPA1			0	91.85	MedChemEx	HY-14754	Salirasib	358.197	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	WUILNKCFCLNXOK-CFBAGHHKSA-N	5469318.0		WUILNKCFCLNXOK
BRD-K01826763-104-12-9	salmeterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	26.2	Sigma	MFCD00897708	1-hydroxy-2-naphthoic acid compound with 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol (1:1)	603.32	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	GIIZNNXWQWCKIB-VWLOTQADSA-N	6604001.0		GIIZNNXWQWCKIB
BRD-K01826763-104-11-9	salmeterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	32.14	MedChemEx	HY-17453	Salmeterol (xinafoate)	603.32	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	GIIZNNXWQWCKIB-VWLOTQADSA-N	6604001.0		GIIZNNXWQWCKIB
BRD-K01826763-104-14-9	salmeterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	67.68	MedChemEx	HY-17453	Salmeterol (xinafoate)	603.32	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	GIIZNNXWQWCKIB-VWLOTQADSA-N	6604001.0		GIIZNNXWQWCKIB
BRD-K01826763-104-13-9	salmeterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	28.09	Tocris	4712	Salmeterol xinafoate	603.32	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	GIIZNNXWQWCKIB-VWLOTQADSA-N	6604001.0		GIIZNNXWQWCKIB
BRD-K01826763-104-10-9	salmeterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma|chronic obstructive pulmonary disease (COPD)|bronchospasm	0	43.02	Tocris	4712	Salmeterol xinafoate	603.32	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	GIIZNNXWQWCKIB-VWLOTQADSA-N	6604001.0		GIIZNNXWQWCKIB
BRD-A49952467-001-03-9	salsolinol-1-carboxylic-acid	Preclinical					0	24.5	Tocris	636	Salsolinol-1-carboxylic acid	223.084	C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|	XHGLVMDBZZZXDP-LLVKDONJSA-N	6992720.0		XHGLVMDBZZZXDP
BRD-A49952467-001-02-4	salsolinol-1-carboxylic-acid	Preclinical					0	0.0	Tocris	636	Salsolinol-1-carboxylic acid	223.084	C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1,r|	XHGLVMDBZZZXDP-LLVKDONJSA-N	6992720.0		XHGLVMDBZZZXDP
BRD-A45107007-001-06-7	salubrinal	Preclinical	eukaryotic translation initiation factor inhibitor	EIF2S1			0	94.61	Tocris	2347	Salubrinal	478.019	ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|	LCOIAYJMPKXARU-CVTTXWKISA-N	2305942.0		LCOIAYJMPKXARU
BRD-A45107007-001-03-4	salubrinal	Preclinical	eukaryotic translation initiation factor inhibitor	EIF2S1			0	82.04	Tocris	2347	Salubrinal	478.019	ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|	LCOIAYJMPKXARU-CVTTXWKISA-N	2305942.0		LCOIAYJMPKXARU
BRD-A45107007-001-05-9	salubrinal	Preclinical	eukaryotic translation initiation factor inhibitor	EIF2S1			0	97.81	Selleck	S2923	Salubrinal	478.019	ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|	LCOIAYJMPKXARU-CVTTXWKISA-N	2305942.0		LCOIAYJMPKXARU
BRD-A45107007-001-02-6	salubrinal	Preclinical	eukaryotic translation initiation factor inhibitor	EIF2S1			0	76.9	Selleck	S2923	Salubrinal	478.019	ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4,r|	LCOIAYJMPKXARU-CVTTXWKISA-N	2305942.0		LCOIAYJMPKXARU
BRD-K00005247-001-01-9	salvianolic-acid-A	Phase 1	matrix metalloprotease inhibitor				0	100.0	MedChemEx	HY-N0318	Salvianolic acid A	494.121	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1	YMGFTDKNIWPMGF-UCPJVGPRSA-N	5281793.0		YMGFTDKNIWPMGF
BRD-K18898553-001-01-1	salvianolic-acid-B	Phase 2	EGFR inhibitor|metalloproteinase inhibitor	MMP9			0	95.4	AvaChem	1069	(2R)-2-({(2E)-3-[(2R,3R)-3-({[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethyl]oxy}carbonyl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]-2-propenoyl}oxy)-3-(3,4-dihydroxyphenyl)propano	718.153	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	SNKFFCBZYFGCQN-PDVBOLEISA-N	11629084.0		SNKFFCBZYFGCQN
BRD-K19284129-001-04-9	salvinorin-A	Phase 1	opioid receptor agonist	OPRD1|OPRK1|OPRM1			0	87.61	Tocris	2134	Salvinorin A	432.178	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	OBSYBRPAKCASQB-AGQYDFLVSA-N	128563.0		OBSYBRPAKCASQB
BRD-K19284129-001-02-6	salvinorin-A	Phase 1	opioid receptor agonist	OPRD1|OPRK1|OPRM1			0	96.14	Enzo	NO109	Salvinorin A	432.178	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	OBSYBRPAKCASQB-AGQYDFLVSA-N	128563.0		OBSYBRPAKCASQB
BRD-K01828772-001-06-9	sal003	Preclinical	eukaryotic translation initiation factor inhibitor	EIF2A			0	95.43	Tocris	3657	Sal 003	460.969	Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|	TVNBASWNLOIQML-RFKZRZAASA-N	2252542.0		TVNBASWNLOIQML
BRD-K01828772-001-07-9	sal003	Preclinical	eukaryotic translation initiation factor inhibitor	EIF2A			0	95.48	Selleck	S7437	Sal003	460.969	Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|	TVNBASWNLOIQML-RFKZRZAASA-N	2252542.0		TVNBASWNLOIQML
BRD-K01828772-001-08-9	sal003	Preclinical	eukaryotic translation initiation factor inhibitor	EIF2A			0	95.17	Tocris	3657	Sal 003	460.969	Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|	TVNBASWNLOIQML-RFKZRZAASA-N	2252542.0		TVNBASWNLOIQML
BRD-K01828772-001-13-9	sal003	Preclinical	eukaryotic translation initiation factor inhibitor	EIF2A			0	96.4	Tocris	3657	Sal 003	460.969	Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9,r|	TVNBASWNLOIQML-RFKZRZAASA-N	2252542.0		TVNBASWNLOIQML
BRD-K00004553-001-01-9	SAM-315	Preclinical	serotonin receptor antagonist				0	92.25	Sigma	MFCD18782706	3-(1-naphthylsulfonyl)-5-(1-piperazinyl)-1H-indazole	392.131	O=S(=O)(c1n[nH]c2ccc(cc12)N1CCNCC1)c1cccc2ccccc12	FYOVZCDHYOEKDE-UHFFFAOYSA-N	10430623.0		FYOVZCDHYOEKDE
BRD-K00004552-001-01-9	sameridine	Preclinical	opioid receptor modulator				0	91.84	Sigma	MFCD00864427	N-ethyl-1-hexyl-N-methyl-4-phenyl-4-piperidinecarboxamide	330.267	CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1ccccc1	TYWUGCGYWNSRPS-UHFFFAOYSA-N	65996.0		TYWUGCGYWNSRPS
BRD-K37747025-001-08-2	sanazole	Phase 1					0	98.04	Asinex	BAS 00535149	N-(2-methoxyethyl)-2-(3-nitro-1H-1,2,4-triazol-1-yl)acetamide	229.081	COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O	YKDRHKCETNMLHL-UHFFFAOYSA-N	119163.0		YKDRHKCETNMLHL
BRD-K00003242-001-01-9	sancycline	Preclinical	antitumor agent				0	80.98	MedChemEx	HY-17466	Sancycline	414.143	[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:19,&2:12|	CRNIKQQPTHSPBA-IEPLVVIMSA-N			CRNIKQQPTHSPBA
BRD-K36169695-001-02-9	sangivamycin	Phase 1	DNA inhibitor				0	95.03	Toronto	S112503	sangivamycin	309.107	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12	OBZJZDHRXBKKTJ-JTFADIMSSA-N	14978.0		OBZJZDHRXBKKTJ
BRD-K66898851-003-02-5	sanguinarium-chloride	Phase 1	apoptosis stimulant	CASP3			0	69.49	MicroSource	310035	SANGUINARIUM CHLORIDE	332.092	C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12	INVGWHRKADIJHF-UHFFFAOYSA-N	5154.0		INVGWHRKADIJHF
BRD-K66898851-003-03-3	sanguinarium-chloride	Phase 1	apoptosis stimulant	CASP3			0	92.68	Sigma	S5890	13-methyl[1,3]benzodioxolo[5,6-c][1,3]dioxolo[4,5-i]phenanthridin-13-ium chloride	332.092	C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12	INVGWHRKADIJHF-UHFFFAOYSA-N	5154.0		INVGWHRKADIJHF
BRD-K99741577-001-03-3	SANT-1	Preclinical	smoothened receptor antagonist	SHH|SMO			0	94.89	Tocris	1974	SANT-1	373.227	Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	FOORCIAZMIWALX-JJIBRWJFSA-N	6878030.0		FOORCIAZMIWALX
BRD-K99741577-001-04-9	SANT-1	Preclinical	smoothened receptor antagonist	SHH|SMO			0	95.43	Tocris	1974	SANT-1	373.227	Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	FOORCIAZMIWALX-JJIBRWJFSA-N	6878030.0		FOORCIAZMIWALX
BRD-K99741577-001-01-7	SANT-1	Preclinical	smoothened receptor antagonist	SHH|SMO			0	96.37	Selleck	S7092	SANT-1	373.227	Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	FOORCIAZMIWALX-JJIBRWJFSA-N	6878030.0		FOORCIAZMIWALX
BRD-K99741577-001-02-5	SANT-1	Preclinical	smoothened receptor antagonist	SHH|SMO			0	91.53	Tocris	1974	SANT-1	373.227	Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	FOORCIAZMIWALX-JJIBRWJFSA-N	6878030.0		FOORCIAZMIWALX
BRD-K35781423-001-02-4	SANT-2	Preclinical	smoothened receptor antagonist	SHH|SMO			0	96.19	Tocris	3617	SANT-2	479.161	CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	VQOJFGFKIVFMDH-UHFFFAOYSA-N	1367095.0		VQOJFGFKIVFMDH
BRD-K35781423-001-01-6	SANT-2	Preclinical	smoothened receptor antagonist	SHH|SMO			0	98.44	Tocris	3617	SANT-2	479.161	CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	VQOJFGFKIVFMDH-UHFFFAOYSA-N	1367095.0		VQOJFGFKIVFMDH
BRD-K35781423-001-03-9	SANT-2	Preclinical	smoothened receptor antagonist	SHH|SMO			0	97.6	Tocris	3617	SANT-2	479.161	CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	VQOJFGFKIVFMDH-UHFFFAOYSA-N	1367095.0		VQOJFGFKIVFMDH
BRD-K00003214-001-01-9	sapacitabine	Phase 3	DNA synthesis inhibitor				0	100.0	MedChemEx	HY-16445	Sapacitabine	490.316	CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1	LBGFKUUHOPIEMA-PEARBKPGSA-N	153970.0		LBGFKUUHOPIEMA
BRD-K36859431-300-04-9	sapropterin	Launched	phenylalanine 4-hydroxylase stimulant	NOS3|PAH|TH|TPH1	metabolism	hyperphenylalaninemia (HPA)	0	71.15	Cayman	81880	(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(1H)-pteridinone dihydrochloride	241.117	C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1	FNKQXYHWGSIFBK-RPDRRWSUSA-N	135398654.0		FNKQXYHWGSIFBK
BRD-K36859431-300-03-1	sapropterin	Launched	phenylalanine 4-hydroxylase stimulant	NOS3|PAH|TH|TPH1	metabolism	hyperphenylalaninemia (HPA)	0	0.0	Cayman	81880	(6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(1H)-pteridinone dihydrochloride	241.117	C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1	FNKQXYHWGSIFBK-RPDRRWSUSA-N	135398654.0		FNKQXYHWGSIFBK
BRD-K36859431-300-02-3	sapropterin	Launched	phenylalanine 4-hydroxylase stimulant	NOS3|PAH|TH|TPH1	metabolism	hyperphenylalaninemia (HPA)	0	84.77	Cayman	81880		241.117	C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1	FNKQXYHWGSIFBK-RPDRRWSUSA-N	135398654.0		FNKQXYHWGSIFBK
BRD-K09963420-066-14-9	saquinavir	Launched	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	95.59	Tocris	4418	Saquinavir mesylate	670.384	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	QWAXKHKRTORLEM-UGJKXSETSA-N	441243.0		QWAXKHKRTORLEM
BRD-K09963420-066-12-5	saquinavir	Launched	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	94.64	Tocris	4418	Saquinavir mesylate	670.384	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	QWAXKHKRTORLEM-UGJKXSETSA-N	441243.0		QWAXKHKRTORLEM
BRD-K09963420-066-13-9	saquinavir	Launched	HIV protease inhibitor	CYP3A4	infectious disease	human immunodeficiency virus (HIV-1)	0	97.88	MedChemEx	HY-17003	Saquinavir (Mesylate)	670.384	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	QWAXKHKRTORLEM-UGJKXSETSA-N	441243.0		QWAXKHKRTORLEM
BRD-K75308783-001-07-0	SAR-245409	Phase 1/Phase 2	PI3K inhibitor	MTOR|PIK3CG			0	95.59	Selleck	S1523	SAR245409 (XL765)	599.184	COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1	HJSSPYJVWLTYHG-UHFFFAOYSA-N	49867926.0		HJSSPYJVWLTYHG
BRD-K19540840-001-09-4	saracatinib	Phase 2/Phase 3	SRC inhibitor	ABL1|LCK|SRC|YES1			0	94.01	Selleck	S1006	Saracatinib (AZD0530)	541.209	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	OUKYUETWWIPKQR-UHFFFAOYSA-N	10302451.0		OUKYUETWWIPKQR
BRD-K19540840-001-14-4	saracatinib	Phase 2/Phase 3	SRC inhibitor	ABL1|LCK|SRC|YES1			0		Stanley		Saracatinib	541.209	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)	10302451.0		OUKYUETWWIPKQR
BRD-K08525451-003-06-0	sarafloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	84.45	MicroSource	1505314	SARAFLOXACIN HYDROCHLORIDE	385.124	OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	XBHBWNFJWIASRO-UHFFFAOYSA-N	56208.0		XBHBWNFJWIASRO
BRD-K08525451-003-07-9	sarafloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	95.86	MedChemEx	HY-B0343A	Sarafloxacin (hydrochloride)	385.124	OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	XBHBWNFJWIASRO-UHFFFAOYSA-N	56208.0		XBHBWNFJWIASRO
BRD-K08525451-003-05-2	sarafloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	92.94	Selleck	S1977	Sarafloxacin HCl	385.124	OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	XBHBWNFJWIASRO-UHFFFAOYSA-N	56208.0		XBHBWNFJWIASRO
BRD-K51263939-001-08-6	sarcosine	Phase 2	glycine transporter inhibitor	SLC6A9			0	86.26	Enamine	Z104480276		89.048	CNCC(O)=O	FSYKKLYZXJSNPZ-UHFFFAOYSA-N	7311726.0		FSYKKLYZXJSNPZ
BRD-K00003165-300-01-9	sardomozide	Preclinical	S-adenosylmethionine decarboxylase inhibitor				0	89.7	MedChemEx	HY-13746B	Sardomozide dihydrochloride	230.128	NC(=N)N\N=C1/CCc2c1cccc2C(N)=N	CYPGNVSXMAUSJY-CXUHLZMHSA-N	9576789.0		CYPGNVSXMAUSJY
BRD-A92448440-001-01-3	sari-59-801	Phase 1					0	93.49	Sigma	MFCD00159831	2-(dimethylamino)-1-[2-(3-ethyl-5-methyl-4-isoxazolyl)-1H-indol-3-yl]ethanol	313.179	CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17,r|	GMGOZCSXMVXXRS-HNNXBMFYSA-N	92236766.0		GMGOZCSXMVXXRS
BRD-K79878800-239-02-9	saroglitazar	Launched	PPAR receptor agonist	PPARA|PPARG	endocrinology|cardiology|gastroenterology	diabetes mellitus|dyslipidemia|non-alcoholic steatohepatitis (NASH)	0	67.76	MedChemEx	HY-19937A	Saroglitazar Magnesium	439.182	CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O	MRWFZSLZNUJVQW-DEOSSOPVSA-N	60151560.0		MRWFZSLZNUJVQW
BRD-K79878800-001-01-0	saroglitazar	Launched	PPAR receptor agonist	PPARA|PPARG	endocrinology|cardiology|gastroenterology	diabetes mellitus|dyslipidemia|non-alcoholic steatohepatitis (NASH)	0	51.78	Synnovator	PBLJ6347		439.182	CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O	MRWFZSLZNUJVQW-DEOSSOPVSA-N	60151560.0		MRWFZSLZNUJVQW
BRD-A34358106-003-02-4	sarpogrelate	Launched	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C	endocrinology|cardiology|rheumatology	diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease	0	92.4	Tocris	3739	Sarpogrelate hydrochloride	429.215	COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|	FFYNAVGJSYHHFO-OAQYLSRUSA-N	40468125.0		FFYNAVGJSYHHFO
BRD-A34358106-003-01-6	sarpogrelate	Launched	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C	endocrinology|cardiology|rheumatology	diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease	0	93.14	MedChemEx	HY-10564	Sarpogrelate (hydrochloride)	429.215	COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|	FFYNAVGJSYHHFO-OAQYLSRUSA-N	40468125.0		FFYNAVGJSYHHFO
BRD-A34358106-003-03-9	sarpogrelate	Launched	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C	endocrinology|cardiology|rheumatology	diabetes mellitus|angina pectoris|Raynaud's disease|atherosclerosis|Buerger's disease	0	93.59	Tocris	3739	Sarpogrelate hydrochloride	429.215	COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|	FFYNAVGJSYHHFO-OAQYLSRUSA-N	40468125.0		FFYNAVGJSYHHFO
BRD-K38904395-001-02-3	SAR131675	Preclinical	VEGFR inhibitor	FLT4			0	94.88	Selleck	S2842	SAR131675	358.164	CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	PFMPOBVAYMTUOX-GOSISDBHSA-N	71295845.0		PFMPOBVAYMTUOX
BRD-K38904395-001-03-9	SAR131675	Preclinical	VEGFR inhibitor	FLT4			0	95.92	MedChemEx	HY-15458	SAR131675	358.164	CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	PFMPOBVAYMTUOX-GOSISDBHSA-N	71295845.0		PFMPOBVAYMTUOX
BRD-K72868067-001-02-4	SAR405	Preclinical	PI3K inhibitor	PIK3C3			0	93.1	MedChemEx	HY-12481	SAR405	443.134	C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F	SPDQRCUBFSRAFI-DOMZBBRYSA-N	72709209.0		SPDQRCUBFSRAFI
BRD-K45349653-001-03-9	SAR405838	Phase 1	MDM inhibitor	MDM2			0	63.51	MedChemEx	HY-17493		561.196	CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1	IDKAKZRYYDCJDU-HBMMIIHUSA-N			IDKAKZRYYDCJDU
BRD-K45349653-001-01-1	SAR405838	Phase 1	MDM inhibitor	MDM2			0	87.15	Selleck	S7649	MI-773 (SAR405838)	561.196	CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1	IDKAKZRYYDCJDU-HBMMIIHUSA-N			IDKAKZRYYDCJDU
BRD-K45349653-001-02-9	SAR405838	Phase 1	MDM inhibitor	MDM2			0	48.78	MedChemEx	HY-17493	MI-773	561.196	CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1	IDKAKZRYYDCJDU-HBMMIIHUSA-N			IDKAKZRYYDCJDU
BRD-K56912469-003-02-0	SAR407899	Phase 2	rho associated kinase inhibitor	ROCK1			0	94.32	MedChemEx	HY-15687	SAR407899 (hydrochloride)	244.121	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	IPEXHQGMTHOKQV-UHFFFAOYSA-N	15604510.0		IPEXHQGMTHOKQV
BRD-K56912469-003-01-2	SAR407899	Phase 2	rho associated kinase inhibitor	ROCK1			0	93.29	MedChemEx	HY-15687	SAR407899 (hydrochloride)	244.121	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	IPEXHQGMTHOKQV-UHFFFAOYSA-N	15604510.0		IPEXHQGMTHOKQV
BRD-K48892307-001-05-8	sasapyrine	Launched	NFkB pathway inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	0.82	MicroSource	200331	SALSALATE	258.053	OC(=O)c1ccccc1OC(=O)c1ccccc1O	WVYADZUPLLSGPU-UHFFFAOYSA-N	5161.0		WVYADZUPLLSGPU
BRD-K48892307-001-06-9	sasapyrine	Launched	NFkB pathway inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	97.56	MedChemEx	HY-B1245	Salsalate	258.053	OC(=O)c1ccccc1OC(=O)c1ccccc1O	WVYADZUPLLSGPU-UHFFFAOYSA-N	5161.0		WVYADZUPLLSGPU
BRD-K48892307-001-04-1	sasapyrine	Launched	NFkB pathway inhibitor	PTGS1|PTGS2	rheumatology	osteoarthritis|rheumatoid arthritis	0	97.73	Selleck	S4188	Sasapyrine	258.053	OC(=O)c1ccccc1OC(=O)c1ccccc1O	WVYADZUPLLSGPU-UHFFFAOYSA-N	5161.0		WVYADZUPLLSGPU
BRD-K42497885-001-01-1	satraplatin	Phase 3	DNA alkylating agent				1	0.0	MedChemEx	HY-17576	Satraplatin	497.045	CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O	JWTNVKZACPRKPF-UHFFFAOYSA-J		BRD-K50134774-416-01-3|BRD-U84587623-000-01-5	JWTNVKZACPRKPF
BRD-K42497885-001-02-9	satraplatin	Phase 3	DNA alkylating agent				1	96.09	MedChemEx	HY-17576	Satraplatin	497.045	CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O	JWTNVKZACPRKPF-UHFFFAOYSA-J			JWTNVKZACPRKPF
BRD-K98028353-001-02-8	savolitinib	Phase 3	c-Met inhibitor	MET			0	97.52	MedChemEx	HY-15959	Savolitinib	345.145	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1	XYDNMOZJKOGZLS-NSHDSACASA-N	68289010.0		XYDNMOZJKOGZLS
BRD-K98028353-001-01-0	savolitinib	Phase 3	c-Met inhibitor	MET			0	0.0	MedChemEx	HY-15959	Savolitinib	345.145	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1	XYDNMOZJKOGZLS-NSHDSACASA-N	68289010.0		XYDNMOZJKOGZLS
BRD-K00003546-001-01-9	saxagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	100.0	MedChemEx	HY-10285	Saxagliptin	315.195	N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2	QGJUIPDUBHWZPV-YQBUGCKMSA-N			QGJUIPDUBHWZPV
BRD-K77677632-003-03-4	SB-200646	Preclinical	serotonin receptor antagonist	HTR2B|HTR2C			0	94.64	Tocris	1371	SB 200646 hydrochloride	266.117	Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	OJZZJTLBYXHUSJ-UHFFFAOYSA-N	126769.0		OJZZJTLBYXHUSJ
BRD-K77677632-003-07-9	SB-200646	Preclinical	serotonin receptor antagonist	HTR2B|HTR2C			0	95.25	Tocris	1371	SB 200646 hydrochloride	266.117	Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	OJZZJTLBYXHUSJ-UHFFFAOYSA-N	126769.0		OJZZJTLBYXHUSJ
BRD-K77677632-003-02-6	SB-200646	Preclinical	serotonin receptor antagonist	HTR2B|HTR2C			0	95.8	Tocris	1371	SB 200646 hydrochloride	266.117	Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	OJZZJTLBYXHUSJ-UHFFFAOYSA-N	126769.0		OJZZJTLBYXHUSJ
BRD-K54330070-001-19-6	SB-202190	Preclinical	p38 MAPK inhibitor	AKT1|ALOX5|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1			0	90.9	Tocris	1264	SB 202190	331.112	Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1	QHKYPYXTTXKZST-UHFFFAOYSA-N	5169.0		QHKYPYXTTXKZST
BRD-K54330070-001-16-2	SB-202190	Preclinical	p38 MAPK inhibitor	AKT1|ALOX5|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1			0	83.0	Tocris	1264	SB 202190	331.112	Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1	QHKYPYXTTXKZST-UHFFFAOYSA-N	5169.0		QHKYPYXTTXKZST
BRD-K54330070-001-15-4	SB-202190	Preclinical	p38 MAPK inhibitor	AKT1|ALOX5|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1			0	94.52	Selleck	S1077	SB202190 (FHPI)	331.112	Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1	QHKYPYXTTXKZST-UHFFFAOYSA-N	5169.0		QHKYPYXTTXKZST
BRD-K27141178-003-08-9	SB-203186	Preclinical	serotonin receptor antagonist	HTR4			0	97.84	Tocris	785	SB 203186 hydrochloride	272.152	O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	YGKPIROTKVQCCU-UHFFFAOYSA-N	3272300.0		YGKPIROTKVQCCU
BRD-K27141178-003-07-3	SB-203186	Preclinical	serotonin receptor antagonist	HTR4			0	98.69	Tocris	785	SB 203186 hydrochloride	272.152	O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	YGKPIROTKVQCCU-UHFFFAOYSA-N	3272300.0		YGKPIROTKVQCCU
BRD-K01826796-001-03-9	SB-203580	Preclinical	p38 MAPK inhibitor	AKT1|ALOX5|CHEK1|CYP2D6|CYP3A4|GAK|GSK3B|LCK|MAPK1|MAPK10|MAPK11|MAPK12|MAPK14|MAPK8|MAPK9|PRKCA|RAF1|RIPK2|ROCK1|RPS6KB1|SGK1|SRC|TNF			0	98.22	Selleck	SB203580		377.1	C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|	CDMGBJANTYXAIV-HHHXNRCGSA-N	40467016.0		CDMGBJANTYXAIV
BRD-K01826796-003-02-9	SB-203580	Preclinical	p38 MAPK inhibitor	AKT1|ALOX5|CHEK1|CYP2D6|CYP3A4|GAK|GSK3B|LCK|MAPK1|MAPK10|MAPK11|MAPK12|MAPK14|MAPK8|MAPK9|PRKCA|RAF1|RIPK2|ROCK1|RPS6KB1|SGK1|SRC|TNF			0	94.57	Tocris	1402		377.1	C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|	CDMGBJANTYXAIV-HHHXNRCGSA-N	40467016.0		CDMGBJANTYXAIV
BRD-A22707317-001-11-6	SB-205384	Preclinical	GABA receptor modulator	GABRA3|GABRA5|GABRA6			0	92.06	Tocris	1512	SB 205384	330.104	CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|	JDTZAGLGBRRCJT-JTQLQIEISA-N	15991599.0		JDTZAGLGBRRCJT
BRD-A22707317-001-12-9	SB-205384	Preclinical	GABA receptor modulator	GABRA3|GABRA5|GABRA6			0	92.88	Tocris	1512	SB 205384	330.104	CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|	JDTZAGLGBRRCJT-JTQLQIEISA-N	15991599.0		JDTZAGLGBRRCJT
BRD-A22707317-001-10-8	SB-205384	Preclinical	GABA receptor modulator	GABRA3|GABRA5|GABRA6			0	96.8	Tocris	1512	SB 205384	330.104	CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15,r|	JDTZAGLGBRRCJT-JTQLQIEISA-N	15991599.0		JDTZAGLGBRRCJT
BRD-K36395411-003-03-0	SB-206553	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	94.17	Tocris	1661	SB 206553 hydrochloride	292.132	Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	QJQORSLQNXDVGE-UHFFFAOYSA-N	5163.0		QJQORSLQNXDVGE
BRD-K36395411-003-06-9	SB-206553	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	95.94	Tocris	1661	SB 206553 hydrochloride	292.132	Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	QJQORSLQNXDVGE-UHFFFAOYSA-N	5163.0		QJQORSLQNXDVGE
BRD-K36395411-003-02-2	SB-206553	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	89.59	Tocris	1661	SB 206553 hydrochloride	292.132	Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	QJQORSLQNXDVGE-UHFFFAOYSA-N	5163.0		QJQORSLQNXDVGE
BRD-K30867024-003-03-3	SB-216641	Preclinical	serotonin receptor antagonist	HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C			0	92.59	Tocris	1242	SB 216641 hydrochloride	486.227	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	JRNUKVFYILMMLX-UHFFFAOYSA-N	3292447.0		JRNUKVFYILMMLX
BRD-K59184148-001-21-6	SB-216763	Preclinical	glycogen synthase kinase inhibitor	CCNA2|CDK2|GSK3A|GSK3B			0	98.45	Selleck	S1075	SB216763	370.028	Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|	JCSGFHVFHSKIJH-UHFFFAOYSA-N	176158.0		JCSGFHVFHSKIJH
BRD-K59184148-001-22-4	SB-216763	Preclinical	glycogen synthase kinase inhibitor	CCNA2|CDK2|GSK3A|GSK3B			0	97.33	Tocris	1616	SB 216763	370.028	Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|	JCSGFHVFHSKIJH-UHFFFAOYSA-N	176158.0		JCSGFHVFHSKIJH
BRD-A06352508-001-03-7	SB-218078	Preclinical	CHK inhibitor	CHEK1			0	96.54	Tocris	2560	SB 218078	393.111	O=C1NC(=O)c2c1c1c3ccccc3n3[C@H]4CC[C@@H](O4)n4c5ccccc5c2c4c13 |&1:15,&2:18,r|	OTPNDVKVEAIXTI-UHFFFAOYSA-N	3387354.0		OTPNDVKVEAIXTI
BRD-A06352508-001-05-2	SB-218078	Preclinical	CHK inhibitor	CHEK1			0	95.58	Tocris	2560	SB 218078	393.111	O=C1NC(=O)c2c1c1c3ccccc3n3[C@H]4CC[C@@H](O4)n4c5ccccc5c2c4c13 |&1:15,&2:18,r|	OTPNDVKVEAIXTI-UHFFFAOYSA-N	3387354.0		OTPNDVKVEAIXTI
BRD-K61097567-001-09-3	SB-218795	Preclinical	tachykinin antagonist	TACR3			0	95.63	Tocris	1376	SB 218795	396.147	COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	IUMQXQJZIHWLIN-HSZRJFAPSA-N	6604858.0		IUMQXQJZIHWLIN
BRD-K61097567-001-10-9	SB-218795	Preclinical	tachykinin antagonist	TACR3			0	97.4	Tocris	1376	SB 218795	396.147	COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	IUMQXQJZIHWLIN-HSZRJFAPSA-N	6604858.0		IUMQXQJZIHWLIN
BRD-K61097567-001-08-5	SB-218795	Preclinical	tachykinin antagonist	TACR3			0	89.16	Tocris	1376	SB 218795	396.147	COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	IUMQXQJZIHWLIN-HSZRJFAPSA-N	6604858.0		IUMQXQJZIHWLIN
BRD-K14807180-001-03-9	SB-221284	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	93.32	Tocris	1379	SB 221284	353.081	CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	OQZOXHCRSXYSPM-UHFFFAOYSA-N	443389.0		OQZOXHCRSXYSPM
BRD-K14807180-001-02-5	SB-221284	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	96.67	Tocris	1379	SB 221284	353.081	CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	OQZOXHCRSXYSPM-UHFFFAOYSA-N	443389.0		OQZOXHCRSXYSPM
BRD-K04414442-001-09-1	SB-222200	Preclinical	tachykinin antagonist	TACR3			0	97.1	Tocris	1393	SB 222200	380.189	CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	MQNYRKWJSMQECI-QFIPXVFZSA-N	6604009.0		MQNYRKWJSMQECI
BRD-K04414442-001-10-9	SB-222200	Preclinical	tachykinin antagonist	TACR3			0	97.19	Tocris	1393	SB 222200	380.189	CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	MQNYRKWJSMQECI-QFIPXVFZSA-N	6604009.0		MQNYRKWJSMQECI
BRD-K04414442-001-08-3	SB-222200	Preclinical	tachykinin antagonist	TACR3			0	99.49	Tocris	1393	SB 222200	380.189	CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	MQNYRKWJSMQECI-QFIPXVFZSA-N	6604009.0		MQNYRKWJSMQECI
BRD-K61323504-001-06-5	SB-225002	Preclinical	CC chemokine receptor antagonist	CXCR2			0	95.29	Tocris	2725	SB 225002	350.985	Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	MQBZVUNNWUIPMK-UHFFFAOYSA-N	3854666.0		MQBZVUNNWUIPMK
BRD-K61323504-001-04-0	SB-225002	Preclinical	CC chemokine receptor antagonist	CXCR2			0	97.9	Tocris	2725	SB 225002	350.985	Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	MQBZVUNNWUIPMK-UHFFFAOYSA-N	3854666.0		MQBZVUNNWUIPMK
BRD-K15424032-001-04-4	SB-228357	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	97.89	Tocris	1375	SB 228357	431.126	COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	RRJLJKRFFRZRAF-UHFFFAOYSA-N	443390.0		RRJLJKRFFRZRAF
BRD-K15424032-001-03-6	SB-228357	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	96.95	Tocris	1375	SB 228357	431.126	COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	RRJLJKRFFRZRAF-UHFFFAOYSA-N	443390.0		RRJLJKRFFRZRAF
BRD-K98795921-001-01-7	SB-2343	Phase 1	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	96.34	MedChemEx	HY-16585	VS-5584	354.192	CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	QYBGBLQCOOISAR-UHFFFAOYSA-N	46912230.0		QYBGBLQCOOISAR
BRD-K98795921-001-02-9	SB-2343	Phase 1	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	94.71	MedChemEx	HY-16585	VS-5584	354.192	CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	QYBGBLQCOOISAR-UHFFFAOYSA-N	46912230.0		QYBGBLQCOOISAR
BRD-K82091397-001-04-9	SB-239063	Preclinical	p38 MAPK inhibitor	MAPK11|MAPK14|PTGS2			0	96.09	Tocris	1962	SB 239063	368.165	COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|	ZQUSFAUAYSEREK-WKILWMFISA-N			ZQUSFAUAYSEREK
BRD-K82091397-001-03-0	SB-239063	Preclinical	p38 MAPK inhibitor	MAPK11|MAPK14|PTGS2			0	95.27	Tocris	1962	SB 239063	368.165	COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|	ZQUSFAUAYSEREK-WKILWMFISA-N			ZQUSFAUAYSEREK
BRD-K19412355-001-02-9	SB-242235	Phase 1	p38 MAPK inhibitor	HSPB1|MAPK14			0	91.5	MedChemEx	HY-18306	SB 242235	353.165	COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	PDTYLGXVBIWRIM-UHFFFAOYSA-N	9863367.0		PDTYLGXVBIWRIM
BRD-K19412355-001-01-0	SB-242235	Phase 1	p38 MAPK inhibitor	HSPB1|MAPK14			0	88.4	MedChemEx	HY-18306	SB 242235	353.165	COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	PDTYLGXVBIWRIM-UHFFFAOYSA-N	9863367.0		PDTYLGXVBIWRIM
BRD-K99968849-300-01-4	SB-243213	Phase 1	serotonin receptor inverse agonist	HTR2A|HTR2B|HTR2C|HTR6			0	96.44	Tocris	3527	SB 243213 dihydrochloride	428.146	Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F	ZETBBVYSBABLHL-UHFFFAOYSA-N	443391.0		ZETBBVYSBABLHL
BRD-K99968849-300-02-9	SB-243213	Phase 1	serotonin receptor inverse agonist	HTR2A|HTR2B|HTR2C|HTR6			0	97.34	Tocris	3527	SB 243213 dihydrochloride	428.146	Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F	ZETBBVYSBABLHL-UHFFFAOYSA-N	443391.0		ZETBBVYSBABLHL
BRD-K80639402-003-03-9	SB-258585	Preclinical	serotonin receptor antagonist	HTR6			0	94.76	Tocris	1961	SB 258585 hydrochloride	487.043	COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	BDHMSYNBSBZCAF-UHFFFAOYSA-N	3248571.0		BDHMSYNBSBZCAF
BRD-K80639402-003-02-9	SB-258585	Preclinical	serotonin receptor antagonist	HTR6			0	94.0	Tocris	1961	SB 258585 hydrochloride	487.043	COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	BDHMSYNBSBZCAF-UHFFFAOYSA-N	3248571.0		BDHMSYNBSBZCAF
BRD-A91031770-001-01-8	SB-268262	Preclinical	calcitonin antagonist	CALCA			0	95.7	Tocris	4314	SB 268262	401.05	CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|	YXHLPJQQPOMPGE-HHHXNRCGSA-N	93475590.0		YXHLPJQQPOMPGE
BRD-A91031770-001-02-9	SB-268262	Preclinical	calcitonin antagonist	CALCA			0	97.6	Tocris	4314	SB 268262	401.05	CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13,r|	YXHLPJQQPOMPGE-HHHXNRCGSA-N	93475590.0		YXHLPJQQPOMPGE
BRD-K24201553-003-12-3	SB-269970	Preclinical	serotonin receptor antagonist	HTR7			0	97.96	Tocris	1612	SB 269970 hydrochloride	352.182	CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	HWKROQUZSKPIKQ-MRXNPFEDSA-N	6604889.0		HWKROQUZSKPIKQ
BRD-K24201553-003-10-7	SB-269970	Preclinical	serotonin receptor antagonist	HTR7			0	95.87	Selleck	S2849	SB269970 HCl	352.182	CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	HWKROQUZSKPIKQ-MRXNPFEDSA-N	6604889.0		HWKROQUZSKPIKQ
BRD-K24201553-003-13-9	SB-269970	Preclinical	serotonin receptor antagonist	HTR7			0	96.84	Tocris	1612	SB 269970 hydrochloride	352.182	CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	HWKROQUZSKPIKQ-MRXNPFEDSA-N	6604889.0		HWKROQUZSKPIKQ
BRD-K24201553-003-11-5	SB-269970	Preclinical	serotonin receptor antagonist	HTR7			0	97.46	Tocris	1612	SB 269970 hydrochloride	352.182	CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	HWKROQUZSKPIKQ-MRXNPFEDSA-N	6604889.0		HWKROQUZSKPIKQ
BRD-K82467063-003-01-5	SB-271046	Phase 1	serotonin receptor antagonist	HTR6			0	93.85	Tocris	3368	SB 271046 hydrochloride	451.079	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	LOCQRDBFWSXQQI-UHFFFAOYSA-N	5312149.0		LOCQRDBFWSXQQI
BRD-K82467063-003-04-9	SB-271046	Phase 1	serotonin receptor antagonist	HTR6			0	95.33	Tocris	3368	SB 271046 hydrochloride	451.079	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	LOCQRDBFWSXQQI-UHFFFAOYSA-N	5312149.0		LOCQRDBFWSXQQI
BRD-K82467063-001-02-7	SB-271046	Phase 1	serotonin receptor antagonist	HTR6			0	94.47	Selleck	S2856	SB271046	451.079	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	LOCQRDBFWSXQQI-UHFFFAOYSA-N	5312149.0		LOCQRDBFWSXQQI
BRD-K16107558-001-01-4	SB-297006	Preclinical	CC chemokine receptor antagonist	CCR3			0	91.0	Tocris	4213	SB 297006	342.122	CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1	BEZXGSZPWXRHIN-INIZCTEOSA-N	9840971.0		BEZXGSZPWXRHIN
BRD-K16107558-001-02-9	SB-297006	Preclinical	CC chemokine receptor antagonist	CCR3			0	95.38	Tocris	4213	SB 297006	342.122	CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1	BEZXGSZPWXRHIN-INIZCTEOSA-N	9840971.0		BEZXGSZPWXRHIN
BRD-K78720403-001-02-4	SB-328437	Preclinical	CCR antagonist				0	97.21	Tocris	3650	SB 328437	378.122	COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	VMFGCGRAIBLAFY-IBGZPJMESA-N	10474776.0		VMFGCGRAIBLAFY
BRD-K78720403-001-01-6	SB-328437	Preclinical	CCR antagonist				0	97.15	Tocris	3650	SB 328437	378.122	COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	VMFGCGRAIBLAFY-IBGZPJMESA-N	10474776.0		VMFGCGRAIBLAFY
BRD-K78720403-001-03-9	SB-328437	Preclinical	CCR antagonist				0	95.77	Tocris	3650	SB 328437	378.122	COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	VMFGCGRAIBLAFY-IBGZPJMESA-N	10474776.0		VMFGCGRAIBLAFY
BRD-K41567364-001-05-3	SB-334867	Preclinical	orexin receptor antagonist	HCRTR1|HCRTR2			0	99.08	Tocris	1960	SB 334867	319.107	Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	AKMNUCBQGHFICM-UHFFFAOYSA-N	6604926.0		AKMNUCBQGHFICM
BRD-K41567364-001-04-6	SB-334867	Preclinical	orexin receptor antagonist	HCRTR1|HCRTR2			0	97.98	Tocris	1960	SB 334867	319.107	Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	AKMNUCBQGHFICM-UHFFFAOYSA-N	6604926.0		AKMNUCBQGHFICM
BRD-K61536336-001-02-5	SB-366791	Preclinical	TRPV antagonist	TRPV1			0	99.59	Tocris	1615	SB 366791	287.071	COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	RYAMDQKWNKKFHD-JXMROGBWSA-N	667594.0		RYAMDQKWNKKFHD
BRD-K61536336-001-03-9	SB-366791	Preclinical	TRPV antagonist	TRPV1			0	93.66	Tocris	1615	SB 366791	287.071	COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	RYAMDQKWNKKFHD-JXMROGBWSA-N	667594.0		RYAMDQKWNKKFHD
BRD-K61536336-001-01-7	SB-366791	Preclinical	TRPV antagonist	TRPV1			0	99.25	Tocris	1615	SB 366791	287.071	COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	RYAMDQKWNKKFHD-JXMROGBWSA-N	667594.0		RYAMDQKWNKKFHD
BRD-K03988082-001-01-7	SB-399885	Preclinical	serotonin receptor antagonist	HTR6			0	96.08	Tocris	3189	SB 399885 hydrochloride	445.063	COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC	ATKZKAYWARYLBW-UHFFFAOYSA-N	6918649.0		ATKZKAYWARYLBW
BRD-K03988082-003-02-9	SB-399885	Preclinical	serotonin receptor antagonist	HTR6			0	97.19	Tocris	3189	SB 399885 hydrochloride	445.063	COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC	ATKZKAYWARYLBW-UHFFFAOYSA-N	6918649.0		ATKZKAYWARYLBW
BRD-K53913732-001-07-5	SB-408124	Preclinical	orexin receptor antagonist	HCRTR1|HCRTR2			0	86.92	Tocris	1963	SB 408124	356.145	CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	JTARFZSNUAGHRB-UHFFFAOYSA-N	4331799.0		JTARFZSNUAGHRB
BRD-K53913732-001-06-7	SB-408124	Preclinical	orexin receptor antagonist	HCRTR1|HCRTR2			0	95.35	Selleck	S1545	SB-408124	356.145	CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	JTARFZSNUAGHRB-UHFFFAOYSA-N	4331799.0		JTARFZSNUAGHRB
BRD-K53913732-001-05-9	SB-408124	Preclinical	orexin receptor antagonist	HCRTR1|HCRTR2			0	91.61	Tocris	1963	SB 408124	356.145	CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	JTARFZSNUAGHRB-UHFFFAOYSA-N	4331799.0		JTARFZSNUAGHRB
BRD-K53913732-001-04-2	SB-408124	Preclinical	orexin receptor antagonist	HCRTR1|HCRTR2			0	87.39	Selleck	S1545	SB408124	356.145	CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	JTARFZSNUAGHRB-UHFFFAOYSA-N	4331799.0		JTARFZSNUAGHRB
BRD-K76805682-001-18-9	SB-415286	Preclinical	glycogen synthase kinase inhibitor	GSK3A|GSK3B|RPS6KB1			0	77.81	Tocris	1617	SB 415286	359.031	Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|	PQCXVIPXISBFPN-UHFFFAOYSA-N	4210951.0		PQCXVIPXISBFPN
BRD-K76805682-001-17-5	SB-415286	Preclinical	glycogen synthase kinase inhibitor	GSK3A|GSK3B|RPS6KB1			0	91.95	Selleck	S2729	SB 415286	359.031	Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|	PQCXVIPXISBFPN-UHFFFAOYSA-N	4210951.0		PQCXVIPXISBFPN
BRD-K76805682-001-15-9	SB-415286	Preclinical	glycogen synthase kinase inhibitor	GSK3A|GSK3B|RPS6KB1			0	76.71	Selleck	S2729	SB415286	359.031	Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|	PQCXVIPXISBFPN-UHFFFAOYSA-N	4210951.0		PQCXVIPXISBFPN
BRD-K76805682-001-16-7	SB-415286	Preclinical	glycogen synthase kinase inhibitor	GSK3A|GSK3B|RPS6KB1			0	67.18	Tocris	1617	SB 415286	359.031	Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|	PQCXVIPXISBFPN-UHFFFAOYSA-N	4210951.0		PQCXVIPXISBFPN
BRD-K67298865-001-08-2	SB-431542	Preclinical	TGF beta receptor inhibitor	ACVR1C|TGFBR1			0	96.67	Selleck	S1067	SB431542	384.122	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1	FHYUGAJXYORMHI-UHFFFAOYSA-N	4521392.0		FHYUGAJXYORMHI
BRD-K67298865-001-10-8	SB-431542	Preclinical	TGF beta receptor inhibitor	ACVR1C|TGFBR1			0	98.92	Tocris	1614	SB 431542	384.122	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1	FHYUGAJXYORMHI-UHFFFAOYSA-N	4521392.0		FHYUGAJXYORMHI
BRD-K67298865-001-09-0	SB-431542	Preclinical	TGF beta receptor inhibitor	ACVR1C|TGFBR1			0	96.97	Tocris	1614	SB 431542	384.122	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1	FHYUGAJXYORMHI-UHFFFAOYSA-N	4521392.0		FHYUGAJXYORMHI
BRD-K03665769-001-01-1	SB-452533	Preclinical	TRPV antagonist	TRPV1			0	91.86	Tocris	3265	SB 452533	375.095	CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1	IFJYEGJUQIBBQV-UHFFFAOYSA-N	9842609.0		IFJYEGJUQIBBQV
BRD-K03665769-001-02-9	SB-452533	Preclinical	TRPV antagonist	TRPV1			0	93.09	Tocris	3265	SB 452533	375.095	CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1	IFJYEGJUQIBBQV-UHFFFAOYSA-N	9842609.0		IFJYEGJUQIBBQV
BRD-K40109029-001-02-9	SB-505124	Preclinical	ALK tyrosine kinase receptor inhibitor	TGFBR1			0	98.07	Selleck	S2186	SB505124	335.163	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C	WGZOTBUYUFBEPZ-UHFFFAOYSA-N	9858940.0		WGZOTBUYUFBEPZ
BRD-K37720887-001-07-8	SB-525334	Preclinical	TGF beta receptor inhibitor	TGFBR1			0	95.92	Selleck	S1476	SB525334	343.18	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C	DKPQHFZUICCZHF-UHFFFAOYSA-N	9967941.0		DKPQHFZUICCZHF
BRD-K37720887-001-08-6	SB-525334	Preclinical	TGF beta receptor inhibitor	TGFBR1			0	94.99	Tocris	3211	SB 525334	343.18	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C	DKPQHFZUICCZHF-UHFFFAOYSA-N	9967941.0		DKPQHFZUICCZHF
BRD-K78809024-001-03-2	SB-590885	Preclinical	RAF inhibitor	BRAF			0	87.33	Selleck	SB590885		453.216	CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1	MLSAQOINCGAULQ-QFMPWRQOSA-N	135421339.0		MLSAQOINCGAULQ
BRD-K78809024-001-05-7	SB-590885	Preclinical	RAF inhibitor	BRAF			0	85.56	Selleck	S2220	SB590885	453.216	CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1	MLSAQOINCGAULQ-QFMPWRQOSA-N	135421339.0	BRD-K01253243-001-03-0	MLSAQOINCGAULQ
BRD-K78809024-001-02-4	SB-590885	Preclinical	RAF inhibitor	BRAF			0	80.49	Selleck	S2220	SB590885	453.216	CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1	MLSAQOINCGAULQ-QFMPWRQOSA-N	135421339.0		MLSAQOINCGAULQ
BRD-K08333979-003-01-3	SB-612111	Preclinical	nociceptin/orphanin FQ receptor antagonist	OPRL1			0	88.92	Tocris	3573	SB 612111 hydrochloride	417.163	Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12	OHRDCQFCAWLDBP-SBUREZEXSA-N	10047612.0		OHRDCQFCAWLDBP
BRD-K08333979-003-02-9	SB-612111	Preclinical	nociceptin/orphanin FQ receptor antagonist	OPRL1			0	96.82	Tocris	3573	SB 612111 hydrochloride	417.163	Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12	OHRDCQFCAWLDBP-SBUREZEXSA-N	10047612.0		OHRDCQFCAWLDBP
BRD-K00003485-001-01-9	SB-649868	Phase 2	orexin receptor antagonist				0	98.14	MedChemEx	HY-10806	SB-649868	477.152	Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(s1)-c1ccc(F)cc1	ZJXIUGNEAIHSBI-IBGZPJMESA-N	25195495.0		ZJXIUGNEAIHSBI
BRD-K95292280-001-02-1	SB-657510	Preclinical	urotensin receptor antagonist	UTS2R			0	95.89	Tocris	3571	SB 657510	504.012	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	KQCZCINJGIRLCD-CYBMUJFWSA-N	11272107.0		KQCZCINJGIRLCD
BRD-K95292280-001-01-3	SB-657510	Preclinical	urotensin receptor antagonist	UTS2R			0	95.35	Tocris	3571	SB 657510	504.012	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	KQCZCINJGIRLCD-CYBMUJFWSA-N	11272107.0		KQCZCINJGIRLCD
BRD-K95292280-001-03-9	SB-657510	Preclinical	urotensin receptor antagonist	UTS2R			0	98.3	Tocris	3571	SB 657510	504.012	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	KQCZCINJGIRLCD-CYBMUJFWSA-N	11272107.0		KQCZCINJGIRLCD
BRD-K24968862-001-01-0	SB-683698	Phase 1	integrin antagonist	ITGA4|ITGAV|ITGB1|ITGB7			0	95.84	MedChemEx	HY-15770	TR-14035	473.08	COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	DRSJLVGDSNWQBI-SFHVURJKSA-N	9912743.0		DRSJLVGDSNWQBI
BRD-K24968862-001-02-9	SB-683698	Phase 1	integrin antagonist	ITGA4|ITGAV|ITGB1|ITGB7			0	93.88	MedChemEx	HY-15770	TR-14035	473.08	COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	DRSJLVGDSNWQBI-SFHVURJKSA-N	9912743.0		DRSJLVGDSNWQBI
BRD-K65991129-001-02-9	SB-705498	Phase 2	TRPV antagonist	TRPV1			0	98.38	Selleck	S2773	SB705498	428.046	FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	JYILLRHXRVTRSH-GFCCVEGCSA-N	9910486.0		JYILLRHXRVTRSH
BRD-K65991129-001-03-9	SB-705498	Phase 2	TRPV antagonist	TRPV1			0	98.02	MedChemEx	HY-10633	SB-705498	428.046	FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	JYILLRHXRVTRSH-GFCCVEGCSA-N	9910486.0		JYILLRHXRVTRSH
BRD-K68633027-001-02-9	SB-706375	Preclinical	urotensin receptor antagonist	UTS2R			0	96.57	Tocris	4667	SB 706375	538.038	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F	BPOWQJYAMDEAFF-CYBMUJFWSA-N	21023902.0		BPOWQJYAMDEAFF
BRD-K68633027-001-01-9	SB-706375	Preclinical	urotensin receptor antagonist	UTS2R			0	98.2	Tocris	4667	SB 706375	538.038	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F	BPOWQJYAMDEAFF-CYBMUJFWSA-N	21023902.0		BPOWQJYAMDEAFF
BRD-K78941306-001-03-2	SB-742457	Phase 3	serotonin receptor antagonist	HTR6			0	89.14	Selleck	S2894	SB-742457	353.12	O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	JJZFWROHYSMCMU-UHFFFAOYSA-N	11256720.0		JJZFWROHYSMCMU
BRD-K78941306-001-04-9	SB-742457	Phase 3	serotonin receptor antagonist	HTR6			0	78.01	MedChemEx	HY-14339	Intepirdine	353.12	O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	JJZFWROHYSMCMU-UHFFFAOYSA-N	11256720.0		JJZFWROHYSMCMU
BRD-K78941306-001-02-4	SB-742457	Phase 3	serotonin receptor antagonist	HTR6			0	84.59	Selleck	S2894	SB742457	353.12	O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	JJZFWROHYSMCMU-UHFFFAOYSA-N	11256720.0		JJZFWROHYSMCMU
BRD-K68532323-003-02-8	SB-743921	Phase 1/Phase 2	kinesin-like spindle protein inhibitor	KIF11			0	95.05	Selleck	S2182	SB743921	516.218	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	PGXYIBJJCLWJST-MUUNZHRXSA-N	9936388.0		PGXYIBJJCLWJST
BRD-K68532323-003-05-1	SB-743921	Phase 1/Phase 2	kinesin-like spindle protein inhibitor	KIF11			0	95.39	Tocris	5109	SB 743921 Hydrochloride	516.218	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	PGXYIBJJCLWJST-MUUNZHRXSA-N	9936388.0		PGXYIBJJCLWJST
BRD-K49597925-300-02-9	SB-747651A	Preclinical	kinase inhibitor	AKT1|AKT3|ROCK1|RPS6KA5|RPS6KB1			0	94.5	Tocris	4630	SB 747651A dihydrochloride	342.192	CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N	MBCJUIJWPYUEBX-UHFFFAOYSA-N	11393719.0		MBCJUIJWPYUEBX
BRD-K49597925-300-01-9	SB-747651A	Preclinical	kinase inhibitor	AKT1|AKT3|ROCK1|RPS6KA5|RPS6KB1			0	97.46	Tocris	4630	SB 747651A dihydrochloride	342.192	CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N	MBCJUIJWPYUEBX-UHFFFAOYSA-N	11393719.0		MBCJUIJWPYUEBX
BRD-K45168550-001-02-9	SB-756050	Phase 1	G protein-coupled receptor agonist	GPBAR1			0	97.36	MedChemEx	HY-102016	SB756050	500.129	COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	GJUFPAZNBPFNRI-UHFFFAOYSA-N	1520267.0		GJUFPAZNBPFNRI
BRD-K45168550-001-01-9	SB-756050	Phase 1	G protein-coupled receptor agonist	GPBAR1			0	99.59	Enamine	Z223304562		500.129	COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	GJUFPAZNBPFNRI-UHFFFAOYSA-N	1520267.0		GJUFPAZNBPFNRI
BRD-K49110935-300-01-9	SB-772077B	Preclinical	rho associated kinase inhibitor	ROCK1|ROCK2			0	96.19	Tocris	4118	SB 772077B dihydrochloride	342.155	CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N	PHWHNHYZZNJPLB-QMMMGPOBSA-N	16095343.0		PHWHNHYZZNJPLB
BRD-K49110935-300-02-9	SB-772077B	Preclinical	rho associated kinase inhibitor	ROCK1|ROCK2			0	97.75	Tocris	4118	SB 772077B dihydrochloride	342.155	CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N	PHWHNHYZZNJPLB-QMMMGPOBSA-N	16095343.0		PHWHNHYZZNJPLB
BRD-K86797399-001-04-4	SB-939	Phase 3	HDAC inhibitor	HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC9			0	90.64	Selleck	S1515	Pracinostat (SB939)	358.237	CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	49855250.0		JHDKZFFAIZKUCU
BRD-K86797399-001-05-1	SB-939	Phase 3	HDAC inhibitor	HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC9			0	96.42	Selleck	S1515	SB939 (Pracinostat)	358.237	CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	49855250.0		JHDKZFFAIZKUCU
BRD-K86797399-001-06-9	SB-939	Phase 3	HDAC inhibitor	HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC9			0	94.25	MedChemEx	HY-13322	Pracinostat	358.237	CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC	JHDKZFFAIZKUCU-ZRDIBKRKSA-N	49855250.0		JHDKZFFAIZKUCU
BRD-K71667152-003-09-8	SBE-13	Preclinical	PLK inhibitor	PLK1			0	98.45	Tocris	4292	SBE 13 hydrochloride	442.166	COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC	XNPRQBVQOJZMMA-UHFFFAOYSA-N	4719406.0		XNPRQBVQOJZMMA
BRD-K71667152-003-10-9	SBE-13	Preclinical	PLK inhibitor	PLK1			0	97.54	Tocris	4292	SBE 13 hydrochloride	442.166	COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC	XNPRQBVQOJZMMA-UHFFFAOYSA-N	4719406.0		XNPRQBVQOJZMMA
BRD-K54729176-001-02-8	SBHA	Preclinical	HDAC inhibitor	HDAC1|HDAC3			0	63.62	Tocris	3810	SBHA	204.111	ONC(=O)CCCCCCC(=O)NO	IDQPVOFTURLJPT-UHFFFAOYSA-N	5173.0		IDQPVOFTURLJPT
BRD-K54729176-001-03-9	SBHA	Preclinical	HDAC inhibitor	HDAC1|HDAC3			0	100.0	Tocris	3810	SBHA	204.111	ONC(=O)CCCCCCC(=O)NO	IDQPVOFTURLJPT-UHFFFAOYSA-N	5173.0		IDQPVOFTURLJPT
BRD-K00005340-001-01-9	SBI-115	Preclinical	G protein-coupled receptor antagonist				0	48.8	MedChemEx	HY-111534	SBI-115	340.028	CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1	IJPXOPBVXVPPEW-UHFFFAOYSA-N	18879973.0		IJPXOPBVXVPPEW
BRD-K05361803-001-03-9	SC-10	Preclinical	protein kinase activator	PRKCA			0	97.54	Tocris	430	SC-10	339.106	CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	MJMJERJFCHYXEM-UHFFFAOYSA-N	5175.0		MJMJERJFCHYXEM
BRD-K05361803-001-04-9	SC-10	Preclinical	protein kinase activator	PRKCA			0	96.16	Toronto	h283000	N-(N-heptyl)-5-chloro-1-naphthalenesulfonamide	339.106	CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	MJMJERJFCHYXEM-UHFFFAOYSA-N	5175.0		MJMJERJFCHYXEM
BRD-K40797222-001-01-8	SC-12267	Phase 2	dihydroorotate dehydrogenase inhibitor	IL17A			0	98.78	MedChemEx	HY-14908	Vidofludimus	355.122	COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|	XPRDUGXOWVXZLL-UHFFFAOYSA-N	9820008.0		XPRDUGXOWVXZLL
BRD-K40797222-001-02-9	SC-12267	Phase 2	dihydroorotate dehydrogenase inhibitor	IL17A			0	98.01	MedChemEx	HY-14908	Vidofludimus	355.122	COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|	XPRDUGXOWVXZLL-UHFFFAOYSA-N	9820008.0		XPRDUGXOWVXZLL
BRD-K55305701-003-03-9	SC-144	Preclinical	P glycoprotein inhibitor				0	97.48	Tocris	4963	SC 144 hydrochloride	322.098	Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	UEADAWQSJOWXBK-UHFFFAOYSA-N	400169.0		UEADAWQSJOWXBK
BRD-K55305701-001-01-2	SC-144	Preclinical	P glycoprotein inhibitor				0	90.81	Selleck	S7124	SC144	322.098	Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	UEADAWQSJOWXBK-UHFFFAOYSA-N	400169.0		UEADAWQSJOWXBK
BRD-K55305701-003-01-8	SC-144	Preclinical	P glycoprotein inhibitor				0	65.29	Tocris	4963	SC 144 hydrochloride	322.098	Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	UEADAWQSJOWXBK-UHFFFAOYSA-N	400169.0		UEADAWQSJOWXBK
BRD-K55305701-001-02-0	SC-144	Preclinical	P glycoprotein inhibitor				0	98.43	Selleck	S7124	SC144	322.098	Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	UEADAWQSJOWXBK-UHFFFAOYSA-N	400169.0		UEADAWQSJOWXBK
BRD-K52512893-001-09-7	SC-19220	Preclinical	prostanoid receptor antagonist	PTGER1			0	95.92	Tocris	1206	SC 19220	331.072	CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	KNURFLJTOUGOOQ-UHFFFAOYSA-N	4336830.0		KNURFLJTOUGOOQ
BRD-K52512893-001-10-9	SC-19220	Preclinical	prostanoid receptor antagonist	PTGER1			0	96.83	Tocris	1206	SC 19220	331.072	CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	KNURFLJTOUGOOQ-UHFFFAOYSA-N	4336830.0		KNURFLJTOUGOOQ
BRD-K52512893-001-08-9	SC-19220	Preclinical	prostanoid receptor antagonist	PTGER1			0	94.86	Tocris	1206	SC 19220	331.072	CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	KNURFLJTOUGOOQ-UHFFFAOYSA-N	4336830.0		KNURFLJTOUGOOQ
BRD-K76365178-001-01-5	SC-236	Preclinical	cyclooxygenase inhibitor	PTGS2			0	98.26	Tocris	3919	SC 236	401.021	NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	NSQNZEUFHPTJME-UHFFFAOYSA-N	9865808.0		NSQNZEUFHPTJME
BRD-K76365178-001-02-9	SC-236	Preclinical	cyclooxygenase inhibitor	PTGS2			0	96.98	Tocris	3919	SC 236	401.021	NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	NSQNZEUFHPTJME-UHFFFAOYSA-N	9865808.0		NSQNZEUFHPTJME
BRD-K62715847-003-01-4	SC-51089	Preclinical	prostanoid receptor antagonist	PTGER1			0	88.12	Tocris	3758	SC 51089	422.115	Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1	XDJPQOUDGROSEU-UHFFFAOYSA-N	132749.0		XDJPQOUDGROSEU
BRD-K62715847-003-02-9	SC-51089	Preclinical	prostanoid receptor antagonist	PTGER1			0	96.02	Tocris	3758	SC 51089	422.115	Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1	XDJPQOUDGROSEU-UHFFFAOYSA-N	132749.0		XDJPQOUDGROSEU
BRD-K14767410-001-03-1	SC-560	Preclinical	cyclooxygenase inhibitor	PTGS1			0	97.01	Tocris	1550	SC 560	352.059	COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	PQUGCKBLVKJMNT-UHFFFAOYSA-N	4306515.0		PQUGCKBLVKJMNT
BRD-K14767410-001-04-9	SC-560	Preclinical	cyclooxygenase inhibitor	PTGS1			0	95.65	Tocris	1550	SC 560	352.059	COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	PQUGCKBLVKJMNT-UHFFFAOYSA-N	4306515.0		PQUGCKBLVKJMNT
BRD-K14767410-001-02-3	SC-560	Preclinical	cyclooxygenase inhibitor	PTGS1			0	98.01	Tocris	1550	SC 560	352.059	COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	PQUGCKBLVKJMNT-UHFFFAOYSA-N	4306515.0		PQUGCKBLVKJMNT
BRD-K25875056-001-03-8	SC-9	Preclinical	protein tyrosine kinase activator	PRKCA			0	98.46	Tocris	433	SC-9	401.122	Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	YUXMTDYHFPRPLG-UHFFFAOYSA-N	124172.0		YUXMTDYHFPRPLG
BRD-K25875056-001-04-9	SC-9	Preclinical	protein tyrosine kinase activator	PRKCA			0	98.05	Tocris	433	SC-9	401.122	Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	YUXMTDYHFPRPLG-UHFFFAOYSA-N	124172.0		YUXMTDYHFPRPLG
BRD-K25875056-001-02-0	SC-9	Preclinical	protein tyrosine kinase activator	PRKCA			0	98.14	Tocris	433	SC-9	401.122	Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	YUXMTDYHFPRPLG-UHFFFAOYSA-N	124172.0		YUXMTDYHFPRPLG
BRD-K00005327-001-01-9	scabertopin	Preclinical	anticancer agent				0	94.26	MedChemEx	HY-N1247	Scabertopin	358.142	[H][C@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(\C)=C/C |c:4,t:18|	FTPHYXGWMIZVMP-WQYRJXRXSA-N	93959111.0		FTPHYXGWMIZVMP
BRD-K29562203-004-09-1	SCH-202676	Preclinical	G protein-coupled receptor modulator	CHRM1|CHRM2|DRD1|DRD2			0	2.03	Tocris	1400	SCH 202676 hydrobromide	267.083	CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	FFUBTEITUNMMOK-UHFFFAOYSA-N	682802.0		FFUBTEITUNMMOK
BRD-K29562203-004-12-9	SCH-202676	Preclinical	G protein-coupled receptor modulator	CHRM1|CHRM2|DRD1|DRD2			0	80.2	Tocris	1400	SCH 202676 hydrobromide	267.083	CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	FFUBTEITUNMMOK-UHFFFAOYSA-N	682802.0		FFUBTEITUNMMOK
BRD-K29562203-004-08-3	SCH-202676	Preclinical	G protein-coupled receptor modulator	CHRM1|CHRM2|DRD1|DRD2			0	46.4	Tocris	1400	SCH 202676 hydrobromide	267.083	CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	FFUBTEITUNMMOK-UHFFFAOYSA-N	682802.0		FFUBTEITUNMMOK
BRD-K00004286-001-01-9	SCH-221510	Preclinical	nociceptin/orphanin FQ receptor agonist	OPRL1			0	97.23	Tocris	3240	SCH 221510	397.241	Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9,12,14,r|	LOSJNRBXNQTUNT-FOURXJPJSA-N			LOSJNRBXNQTUNT
BRD-K45435259-003-12-9	SCH-23390	Preclinical	dopamine receptor antagonist	DRD1|DRD5|HTR2C|KCNJ4|KCNJ6			0	96.59	Tocris	925	SCH 23390 hydrochloride	287.108	CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	GOTMKOSCLKVOGG-OAHLLOKOSA-N	3036864.0		GOTMKOSCLKVOGG
BRD-K45435259-003-11-1	SCH-23390	Preclinical	dopamine receptor antagonist	DRD1|DRD5|HTR2C|KCNJ4|KCNJ6			0	96.81	Tocris	925	SCH 23390 hydrochloride	287.108	CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	GOTMKOSCLKVOGG-OAHLLOKOSA-N	3036864.0		GOTMKOSCLKVOGG
BRD-K55748775-001-02-2	SCH-28080	Phase 1	ATPase inhibitor	ATP4A			0	95.57	Tocris	1690	SCH 28080	277.122	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	PYKJFEPAUKAXNN-UHFFFAOYSA-N	108137.0		PYKJFEPAUKAXNN
BRD-K55748775-001-03-9	SCH-28080	Phase 1	ATPase inhibitor	ATP4A			0	92.4	Tocris	1690	SCH 28080	277.122	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	PYKJFEPAUKAXNN-UHFFFAOYSA-N	108137.0		PYKJFEPAUKAXNN
BRD-K02460719-001-01-9	SCH-51344	Preclinical	MTH1 inhibitor	NUDT1			0	83.63	Tocris	5280	SCH 51344	316.154	COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1	YWEGXZZAORIRQR-UHFFFAOYSA-N	9995890.0		YWEGXZZAORIRQR
BRD-K02460719-001-02-9	SCH-51344	Preclinical	MTH1 inhibitor	NUDT1			0	93.73	Tocris	5280	SCH 51344	316.154	COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1	YWEGXZZAORIRQR-UHFFFAOYSA-N	9995890.0		YWEGXZZAORIRQR
BRD-K81225797-001-03-1	SCH-58261	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	95.71	Tocris	2270	SCH 58261	345.134	Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	UTLPKQYUXOEJIL-UHFFFAOYSA-N	176408.0		UTLPKQYUXOEJIL
BRD-K81225797-001-02-3	SCH-58261	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	99.01	Tocris	2270	SCH 58261	345.134	Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	UTLPKQYUXOEJIL-UHFFFAOYSA-N	176408.0		UTLPKQYUXOEJIL
BRD-K81225797-001-05-9	SCH-58261	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	97.57	Tocris	2270	SCH 58261	345.134	Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	UTLPKQYUXOEJIL-UHFFFAOYSA-N	176408.0		UTLPKQYUXOEJIL
BRD-K75009076-001-02-1	SCH-900776	Phase 2	CHK inhibitor	CDK2|CHEK1			0	85.42	Selleck	S2735	MK-8776 (SCH 900776)	375.081	Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	GMIZZEXBPRLVIV-SECBINFHSA-N	46239015.0		GMIZZEXBPRLVIV
BRD-K75009076-001-01-3	SCH-900776	Phase 2	CHK inhibitor	CDK2|CHEK1			0	59.71	Selleck	S2735	MK-8776 (SCH 900776)	375.081	Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	GMIZZEXBPRLVIV-SECBINFHSA-N	46239015.0		GMIZZEXBPRLVIV
BRD-K00003711-001-01-9	schisandrin-B	Preclinical	antioxidant	ATR			0	97.18	MedChemEx	HY-N0089	Schisandrin B	400.189	COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|	RTZKSTLPRTWFEV-QWHCGFSZSA-N	174277.0		RTZKSTLPRTWFEV
BRD-K18878288-001-06-4	schisandrol-B	Phase 3	lipid peroxidase inhibitor				0	97.81	MedChemEx	HY-N0692	(6S,7S)-1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxol-6-ol	416.184	COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	ZWRRJEICIPUPHZ-MYODQAERSA-N	3001662.0		ZWRRJEICIPUPHZ
BRD-K18878288-001-07-2	schisandrol-B	Phase 3	lipid peroxidase inhibitor				0	91.79	MedChemEx	HY-N0692	Schisandrol B	416.184	COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	ZWRRJEICIPUPHZ-MYODQAERSA-N	3001662.0		ZWRRJEICIPUPHZ
BRD-A23127772-001-02-3	sclareol	Preclinical					0	98.63	Selleck	S2354	Sclareol	308.272	CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|	XVULBTBTFGYVRC-SVPXJYONSA-N	56842011.0		XVULBTBTFGYVRC
BRD-A23127772-001-03-1	sclareol	Preclinical					0	100.0	Selleck	S2354	Sclareol	308.272	CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5,6,18,&1:1,&2:11|	XVULBTBTFGYVRC-SVPXJYONSA-N	56842011.0		XVULBTBTFGYVRC
BRD-K72925150-001-10-3	sclareolide	Launched	other antifungal				0	70.03	Selleck	S2355	Sclareolide (Norambreinolide)	250.193	C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	IMKJGXCIJJXALX-SHUKQUCYSA-N	929262.0		IMKJGXCIJJXALX
BRD-K72925150-001-11-1	sclareolide	Launched	other antifungal				0	83.52	Selleck	S2355	Sclareolide	250.193	C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	IMKJGXCIJJXALX-SHUKQUCYSA-N	929262.0	BRD-K35504063-001-01-7	IMKJGXCIJJXALX
BRD-K72925150-001-14-5	sclareolide	Launched	other antifungal				0	100.0	Selleck	S2355	SCLAREOLIDE	250.193	C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	IMKJGXCIJJXALX-SHUKQUCYSA-N	929262.0		IMKJGXCIJJXALX
BRD-K33809398-001-02-6	SCMC-Lys	Launched	mucolytic agent	GSTP1	pulmonary	chronic obstructive pulmonary disease (COPD)	1	83.3	ChemImpex	629	(2R)-2-amino-3-[(carboxymethyl)sulfanyl]propanoic acid	179.025	N[C@@H](CSCC(O)=O)C(O)=O	GBFLZEXEOZUWRN-VKHMYHEASA-N	193653.0		GBFLZEXEOZUWRN
BRD-K33809398-001-01-8	SCMC-Lys	Launched	mucolytic agent	GSTP1	pulmonary	chronic obstructive pulmonary disease (COPD)	1	0.0	ChemImpex	629		179.025	N[C@@H](CSCC(O)=O)C(O)=O	GBFLZEXEOZUWRN-VKHMYHEASA-N	193653.0		GBFLZEXEOZUWRN
BRD-K75923785-003-03-9	scopine	Launched					0	57.59	MedChemEx	HY-B0459A	Scopine (hydrochloride)	155.095	CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	FIMXSEMBHGTNKT-RZVDLVGDSA-N			FIMXSEMBHGTNKT
BRD-K75923785-003-02-1	scopine	Launched					0	100.0	Selleck	S2548	Scopine HCl	155.095	CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	FIMXSEMBHGTNKT-RZVDLVGDSA-N			FIMXSEMBHGTNKT
BRD-K75923785-001-02-5	scopine	Launched					0	100.0	Selleck	S2545	Scopine	155.095	CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	FIMXSEMBHGTNKT-RZVDLVGDSA-N			FIMXSEMBHGTNKT
BRD-K89923877-004-15-4	scopolamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea	0	92.22	Selleck	S2508	Scopolamine HBr	303.147	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	STECJAGHUSJQJN-FWXGHANASA-N			STECJAGHUSJQJN
BRD-K89923877-004-21-9	scopolamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea	0	85.44	Tocris	1414	Scopolamine hydrobromide	303.147	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	STECJAGHUSJQJN-FWXGHANASA-N			STECJAGHUSJQJN
BRD-K89923877-004-20-9	scopolamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea	0	96.26	MedChemEx	HY-N0296A	Scopolamine (hydrobromide)	303.147	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	STECJAGHUSJQJN-FWXGHANASA-N			STECJAGHUSJQJN
BRD-K89923877-004-16-2	scopolamine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI	neurology/psychiatry|gastroenterology	motion sickness|vomiting|nausea	0	96.73	Tocris	1414	Scopolamine hydrobromide	303.147	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	STECJAGHUSJQJN-FWXGHANASA-N			STECJAGHUSJQJN
BRD-A49906757-004-09-8	scopolamine-N-oxide	Preclinical	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4			0	93.9	Prestwick	Prestw-232	Scopolamin-N-oxide hydrobromide	319.142	C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|	GSYQNAMOFFWAPF-SXWCTKSRSA-N			GSYQNAMOFFWAPF
BRD-A49906757-004-10-6	scopolamine-N-oxide	Preclinical	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4			0	91.22	TCI	S0229	Scopalamine N-oxide hydrobormide monohydrate	319.142	C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3,5,7,8,10,14,&1:1,TLB:0:1:4.5.6:8.10,THB:2:1:4.5.6:8.10,9:8:1:4.5.6,9:10:1:4.5.6,11:5:1:8.10|	GSYQNAMOFFWAPF-SXWCTKSRSA-N			GSYQNAMOFFWAPF
BRD-K20548681-001-02-9	SCP-1	Phase 1	analgesic agent				0	97.74	SciExchange	K-037460	2-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)-N-(4-hydroxyphenyl)acetamide	332.047	Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	PUPNJSIFIXXJCH-UHFFFAOYSA-N	667575.0		PUPNJSIFIXXJCH
BRD-K20548681-001-01-3	SCP-1	Phase 1	analgesic agent				0	88.92	Vitas-M	STK134741		332.047	Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	PUPNJSIFIXXJCH-UHFFFAOYSA-N	667575.0		PUPNJSIFIXXJCH
BRD-K22503835-001-12-8	scriptaid	Preclinical	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9			0	93.32	Tocris	2421	Scriptaid	326.127	ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	JTDYUFSDZATMKU-UHFFFAOYSA-N	5186.0		JTDYUFSDZATMKU
BRD-K22503835-001-11-0	scriptaid	Preclinical	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9			0	94.21	Selleck	S8043	Scriptaid	326.127	ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	JTDYUFSDZATMKU-UHFFFAOYSA-N	5186.0		JTDYUFSDZATMKU
BRD-K78496197-001-04-7	SCS	Preclinical					0	84.87	Tocris	2143	SCS	256.085	Oc1ccccc1\C=N\NC(=O)c1ccccc1O	OMCYEZUIYGPHDJ-OQLLNIDSSA-N	135445765.0		OMCYEZUIYGPHDJ
BRD-K78496197-001-03-9	SCS	Preclinical					0	95.27	Tocris	2143	SCS	256.085	Oc1ccccc1\C=N\NC(=O)c1ccccc1O	OMCYEZUIYGPHDJ-OQLLNIDSSA-N	135445765.0		OMCYEZUIYGPHDJ
BRD-K78496197-001-05-9	SCS	Preclinical					0	96.88	Tocris	2143	SCS	256.085	Oc1ccccc1\C=N\NC(=O)c1ccccc1O	OMCYEZUIYGPHDJ-OQLLNIDSSA-N	135445765.0		OMCYEZUIYGPHDJ
BRD-K00003093-001-01-9	SD-0006	Phase 2	p38 MAPK inhibitor				0	94.38	MedChemEx	HY-11087	SD 0006	397.131	OCC(=O)N1CCC(CC1)c1[nH]nc(c1-c1ccncn1)-c1ccc(Cl)cc1	CATQHDWESBRRQA-UHFFFAOYSA-N	9865587.0		CATQHDWESBRRQA
BRD-K91904471-001-02-4	SD-169	Preclinical	p38 MAPK inhibitor	MAPK14			0	97.83	EMDBio	506158-10MG	p38 MAP Kinase Inhibitor VII, SD-169	160.064	NC(=O)c1ccc2[nH]ccc2c1	GQMYQEAXTITUAE-UHFFFAOYSA-N	14973220.0		GQMYQEAXTITUAE
BRD-K24566386-001-01-9	SD-208	Preclinical	TGF beta receptor inhibitor	TGFBR1			0	97.15	Tocris	3269	SD 208	352.064	Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	BERLXWPRSBJFHO-UHFFFAOYSA-N	10316032.0		BERLXWPRSBJFHO
BRD-K24566386-001-03-5	SD-208	Preclinical	TGF beta receptor inhibitor	TGFBR1			0	94.68	Tocris	3269	SD 208	352.064	Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	BERLXWPRSBJFHO-UHFFFAOYSA-N	10316032.0		BERLXWPRSBJFHO
BRD-K51102532-003-02-9	SD-2590	Preclinical	matrix metalloprotease inhibitor	MMP1|MMP13|MMP2			0	89.45	Tocris	4775	SD 2590 hydrochloride	518.133	COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1	NXUHVWMBPOFLMA-UHFFFAOYSA-N	9892815.0		NXUHVWMBPOFLMA
BRD-K51102532-003-01-8	SD-2590	Preclinical	matrix metalloprotease inhibitor	MMP1|MMP13|MMP2			0	93.08	Tocris	4775	SD 2590 hydrochloride	518.133	COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1	NXUHVWMBPOFLMA-UHFFFAOYSA-N	9892815.0		NXUHVWMBPOFLMA
BRD-K01826797-003-04-9	SDM25N	Preclinical	opioid receptor antagonist	OPRD1			0	85.62	Tocris	1410	(4bS,8aS,14bR)-7-(2-methylallyl)-5,6,7,8,14,14b-hexahydro-4,8-methanobenzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol hydro	450.171	CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|	ZFMVWAWSKLAVOE-IFKAHUTRSA-N	9931601.0		ZFMVWAWSKLAVOE
BRD-K01826797-003-03-9	SDM25N	Preclinical	opioid receptor antagonist	OPRD1			0	88.24	Tocris	1410	SDM25N hydrochloride	450.171	CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|	ZFMVWAWSKLAVOE-IFKAHUTRSA-N	9931601.0		ZFMVWAWSKLAVOE
BRD-K01826797-003-02-9	SDM25N	Preclinical	opioid receptor antagonist	OPRD1			0	93.48	Tocris	1410	SDM25N hydrochloride	450.171	CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7,8,15,&1:14,TLB:17:15:4.5.6:11.12.13,THB:16:15:4.5.6:11.12.13|	ZFMVWAWSKLAVOE-IFKAHUTRSA-N	9931601.0		ZFMVWAWSKLAVOE
BRD-K65820248-001-02-6	SDZ-NKT-343	Phase 1	tachykinin antagonist	TACR1			0	97.48	Tocris	2394	SDZ NKT 343	579.248	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	PCVSIMQAFWRUEC-JDXGNMNLSA-N	9851211.0		PCVSIMQAFWRUEC
BRD-K65820248-001-01-8	SDZ-NKT-343	Phase 1	tachykinin antagonist	TACR1			0	97.81	Tocris	2394	SDZ NKT 343	579.248	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	PCVSIMQAFWRUEC-JDXGNMNLSA-N	9851211.0		PCVSIMQAFWRUEC
BRD-K65820248-001-03-9	SDZ-NKT-343	Phase 1	tachykinin antagonist	TACR1			0	96.81	Tocris	2394	SDZ NKT 343	579.248	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	PCVSIMQAFWRUEC-JDXGNMNLSA-N	9851211.0		PCVSIMQAFWRUEC
BRD-K31339597-051-03-9	SDZ-SER-082	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	82.57	Tocris	1255	SDZ SER 082 fumarate	228.163	CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34	YASBOGFWAMXINH-TZMCWYRMSA-N	9859407.0		YASBOGFWAMXINH
BRD-K31339597-051-02-0	SDZ-SER-082	Preclinical	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C			0	13.89	Tocris	1255	SDZ SER 082 fumarate	228.163	CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34	YASBOGFWAMXINH-TZMCWYRMSA-N	9859407.0		YASBOGFWAMXINH
BRD-K39558284-001-02-0	SDZ-WAG-994	Phase 2	adenosine receptor agonist	ADORA1			0	79.99	Tocris	2465	SDZ WAG 994	363.191	CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	JAKAFSGZUXCHLF-LSCFUAHRSA-N	164305.0		JAKAFSGZUXCHLF
BRD-K39558284-001-01-2	SDZ-WAG-994	Phase 2	adenosine receptor agonist	ADORA1			0	89.51	Tocris	2465	SDZ WAG 994	363.191	CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	JAKAFSGZUXCHLF-LSCFUAHRSA-N	164305.0		JAKAFSGZUXCHLF
BRD-K39558284-001-03-9	SDZ-WAG-994	Phase 2	adenosine receptor agonist	ADORA1			0	85.66	Tocris	2465	SDZ WAG 994	363.191	CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	JAKAFSGZUXCHLF-LSCFUAHRSA-N	164305.0		JAKAFSGZUXCHLF
BRD-K15868788-003-08-9	SDZ-205-557	Preclinical	serotonin receptor antagonist	HTR3A|HTR3B			0	97.04	Tocris	2037	SDZ 205-557 hydrochloride	300.124	CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	FFNWMBDISAYHDC-UHFFFAOYSA-N	5191.0		FFNWMBDISAYHDC
BRD-K15868788-003-07-7	SDZ-205-557	Preclinical	serotonin receptor antagonist	HTR3A|HTR3B			0	97.71	Tocris	2037	SDZ 205-557 hydrochloride	300.124	CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	FFNWMBDISAYHDC-UHFFFAOYSA-N	5191.0		FFNWMBDISAYHDC
BRD-A15530910-001-03-9	SDZ-21009	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	HTR1A|HTR1B			0	93.11	Tocris	1516	SDZ 21009	348.205	CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|	SJYFDORQYYEJLB-ZDUSSCGKSA-N	6604875.0		SJYFDORQYYEJLB
BRD-A15530910-001-02-1	SDZ-21009	Preclinical	adrenergic receptor antagonist|serotonin receptor antagonist	HTR1A|HTR1B			0	91.78	Tocris	1516	SDZ 21009	348.205	CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12,r|	SJYFDORQYYEJLB-ZDUSSCGKSA-N	6604875.0		SJYFDORQYYEJLB
BRD-K82266792-001-03-9	SDZ-220-040	Preclinical	glutamate receptor antagonist	GRIN1			0	97.06	Tocris	1251	SDZ 220-040	419.009	N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O	NYZFUZCCDOSQBG-AWEZNQCLSA-N	6604839.0		NYZFUZCCDOSQBG
BRD-K82266792-001-02-1	SDZ-220-040	Preclinical	glutamate receptor antagonist	GRIN1			0	0.0	Tocris	1251	SDZ 220-040	419.009	N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O	NYZFUZCCDOSQBG-AWEZNQCLSA-N	6604839.0		NYZFUZCCDOSQBG
BRD-K27168049-001-03-6	SDZ-220-581	Preclinical	glutamate receptor antagonist	GRIN1			0	97.01	Tocris	1250	SDZ 220-581	369.053	N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	VBRJFXSFCYEZMQ-HNNXBMFYSA-N	128019.0		VBRJFXSFCYEZMQ
BRD-K27168049-001-04-9	SDZ-220-581	Preclinical	glutamate receptor antagonist	GRIN1			0	98.09	Tocris	1250	SDZ 220-581	369.053	N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	VBRJFXSFCYEZMQ-HNNXBMFYSA-N	128019.0		VBRJFXSFCYEZMQ
BRD-K27168049-001-02-8	SDZ-220-581	Preclinical	glutamate receptor antagonist	GRIN1			0	98.62	Tocris	1250	SDZ 220-581	369.053	N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	VBRJFXSFCYEZMQ-HNNXBMFYSA-N	128019.0		VBRJFXSFCYEZMQ
BRD-K74227499-001-02-9	Se-methylselenocysteine	Phase 2					1	100.0	Sigma	MFCD00800565	(2R)-2-amino-3-(methylselanyl)propanoic acid	182.98	C[Se]C[C@H](N)C(O)=O	XDSSPSLGNGIIHP-VKHMYHEASA-N	45266674.0		XDSSPSLGNGIIHP
BRD-K74227499-001-01-1	Se-methylselenocysteine	Phase 2					1	0.0	Acros	30064		182.98	C[Se]C[C@H](N)C(O)=O	XDSSPSLGNGIIHP-VKHMYHEASA-N	45266674.0		XDSSPSLGNGIIHP
BRD-K02965577-001-04-9	secalciferol	Launched	vitamin D receptor agonist	VDR	critical care	bone fracture	0	94.21	MedChemEx	HY-32343	Secalciferol	416.329	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	FCKJYANJHNLEEP-XRWYNYHCSA-N	5283748.0		FCKJYANJHNLEEP
BRD-K02965577-001-03-4	secalciferol	Launched	vitamin D receptor agonist	VDR	critical care	bone fracture	0	81.1	Enzo	DM300	24,25-Dihydroxyvitamin D3	416.329	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	FCKJYANJHNLEEP-XRWYNYHCSA-N	5283748.0		FCKJYANJHNLEEP
BRD-A53472930-001-01-7	seclazone	Phase 1	anti-inflammatory agent				0	99.72	Enamine	Z2306534576	7-chloro-3,3a-dihydro-2H,9H-isoxazolo[3,2-b][1,3]benzoxazin-9-one	225.019	Clc1ccc2O[C@H]3CCON3C(=O)c2c1 |&1:6,r|	XWXVKXXKKLBDDJ-VIFPVBQESA-N	76966156.0		XWXVKXXKKLBDDJ
BRD-K00003454-001-01-9	seclidemstat	Phase 1	histone demethylase inhibitor				0	93.58	MedChemEx	HY-103713	Seclidemstat	450.113	CN1CCN(CC1)S(=O)(=O)c1cccc(c1)C(=O)N\N=C(/C)c1cc(Cl)ccc1O	MVSQDUZRRVBYLA-HYARGMPZSA-N	135565033.0		MVSQDUZRRVBYLA
BRD-A70083328-001-23-5	secnidazole	Launched	acetylcholinesterase inhibitor|microtubule inhibitor		infectious disease	protozoan infection	0	98.16	MicroSource	1505304	SECNIDAZOLE	185.08	C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|	KPQZUUQMTUIKBP-RXMQYKEDSA-N	667451.0		KPQZUUQMTUIKBP
BRD-A70083328-001-22-7	secnidazole	Launched	acetylcholinesterase inhibitor|microtubule inhibitor		infectious disease	protozoan infection	0	88.54	Selleck	S2537	Secnidazole	185.08	C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|	KPQZUUQMTUIKBP-RXMQYKEDSA-N	667451.0		KPQZUUQMTUIKBP
BRD-A70083328-001-24-3	secnidazole	Launched	acetylcholinesterase inhibitor|microtubule inhibitor		infectious disease	protozoan infection	0	99.58	Selleck	S2537	Secnidazole (Flagentyl)	185.08	C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1,r|	KPQZUUQMTUIKBP-RXMQYKEDSA-N	667451.0		KPQZUUQMTUIKBP
BRD-K91733562-001-05-0	secoisolariciresinol-(-)	Phase 2					0	97.1	Sigma	MFCD01075136	(2R,3R)-2,3-bis(4-hydroxy-3-methoxybenzyl)-1,4-butanediol	362.173	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	PUETUDUXMCLALY-HOTGVXAUSA-N	65373.0		PUETUDUXMCLALY
BRD-K91733562-001-06-9	secoisolariciresinol-(-)	Phase 2					0	87.92	Sigma	MFCD01075136	Secoisolariciresinol	362.173	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	PUETUDUXMCLALY-HOTGVXAUSA-N	65373.0		PUETUDUXMCLALY
BRD-K77320845-001-01-2	secoisolariciresinol-diglucoside	Phase 2	antioxidant				0	94.67	AvaChem	2539	(2R,3R)-4-(beta-D-glucopyranosyloxy)-2,3-bis(4-hydroxy-3-methoxybenzyl)butyl beta-D-glucopyranoside	686.279	COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O	SBVBJPHMDABKJV-PGCJWIIOSA-N	9917980.0		SBVBJPHMDABKJV
BRD-K49071277-001-05-9	securinine	Preclinical	GABA receptor antagonist|TP53 activator	GABRA1			0	87.16	MedChemEx	HY-N2079	(-)-Securinine	217.11	O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|	SWZMSZQQJRKFBP-WZRBSPASSA-N	442872.0		SWZMSZQQJRKFBP
BRD-K49071277-001-04-7	securinine	Preclinical	GABA receptor antagonist|TP53 activator	GABRA1			0	94.32	MicroSource	1505334	SECURININE	217.11	O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6,9|	SWZMSZQQJRKFBP-WZRBSPASSA-N	442872.0		SWZMSZQQJRKFBP
BRD-K00003150-001-01-9	segesterone-acetate	Launched	progesterone receptor agonist	PGR			0	90.51	MedChemEx	HY-13071	Nestoron	370.214	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|	CKFBRGLGTWAVLG-GOMYTPFNSA-N	108059.0		CKFBRGLGTWAVLG
BRD-K00003284-236-01-9	seladelpar	Phase 3	PPAR receptor agonist				0	94.96	MedChemEx	HY-19522A	Seladelpar sodium salt	444.122	CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc1ccc(OCC(O)=O)c(C)c1	JWHYSEDOYMYMNM-QGZVFWFLSA-N	11236126.0		JWHYSEDOYMYMNM
BRD-K00003549-001-01-9	selamectin	Launched	nematocide		infectious disease	flea control	0	93.43	MedChemEx	HY-107212	Selamectin	769.44	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@H](O5)C5CCCCC5)O4)OC(=O)[C@]([H])(C=C(C)\C1=N\O)[C@@]23O |c:4,t:6,25,56|	AFJYYKSVHJGXSN-XHKIUTQPSA-N	9578507.0		AFJYYKSVHJGXSN
BRD-K86434416-003-16-9	selegiline	Launched	monoamine oxidase inhibitor	MAOA|MAOB	neurology/psychiatry	Parkinson's Disease	0	87.55	MedChemEx	HY-14199	R-(-)-Deprenyl (hydrochloride)	187.136	C[C@H](Cc1ccccc1)N(C)CC#C	MEZLKOACVSPNER-GFCCVEGCSA-N	26757.0		MEZLKOACVSPNER
BRD-K74664543-001-01-1	selenomethionine	Launched					1	100.0	Ark	AK-81303	(2S)-2-amino-4-(methylselanyl)butanoic acid	196.996	C[Se]CC[C@H](N)C(O)=O	RJFAYQIBOAGBLC-BYPYZUCNSA-N	53262363.0		RJFAYQIBOAGBLC
BRD-K74664543-213-01-2	selenomethionine	Launched					1	0.0	MicroSource	1506163	SELENOMETHIONINE	196.996	C[Se]CC[C@H](N)C(O)=O	RJFAYQIBOAGBLC-BYPYZUCNSA-N	53262363.0		RJFAYQIBOAGBLC
BRD-K00003228-001-01-9	seletalisib	Preclinical	PI3K inhibitor				0	98.01	MedChemEx	HY-16754	Seletalisib	482.087	[O-][n+]1cccc(c1)-c1nc2c(Cl)cccc2cc1[C@@H](Nc1ncnc2cccnc12)C(F)(F)F	LNLJHGXOFYUARS-OAQYLSRUSA-N	56928390.0		LNLJHGXOFYUARS
BRD-K21191422-001-02-3	selexipag	Launched	IP1 prostacyclin receptor agonist|platelet aggregation inhibitor	PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	0	95.22	Tocris	3351	NS 304	496.214	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1	QXWZQTURMXZVHJ-UHFFFAOYSA-N	9913767.0		QXWZQTURMXZVHJ
BRD-K21191422-001-01-5	selexipag	Launched	IP1 prostacyclin receptor agonist|platelet aggregation inhibitor	PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	0	95.84	MedChemEx	HY-14870	NS-304	496.214	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1	QXWZQTURMXZVHJ-UHFFFAOYSA-N	9913767.0		QXWZQTURMXZVHJ
BRD-K48738253-001-02-4	selfotel	Phase 3	glutamate receptor antagonist	GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	56.69	Enzo	AC1301	CGS 19755	223.061	OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1	LPMRCCNDNGONCD-NTSWFWBYSA-N	6604838.0		LPMRCCNDNGONCD
BRD-K48738253-001-03-9	selfotel	Phase 3	glutamate receptor antagonist	GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	0.0	Tocris	1241	CGS 19755	223.061	OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1	LPMRCCNDNGONCD-NTSWFWBYSA-N	6604838.0		LPMRCCNDNGONCD
BRD-K21361524-001-04-9	selinexor	Launched	exportin antagonist	XPO1	hematologic malignancy	multiple myeloma	0	94.85	MedChemEx	HY-17536	Selinexor	443.093	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	DEVSOMFAQLZNKR-RJRFIUFISA-N	71481097.0		DEVSOMFAQLZNKR
BRD-K21361524-001-01-1	selinexor	Launched	exportin antagonist	XPO1	hematologic malignancy	multiple myeloma	0	91.64	Selleck	S7252	KPT-330	443.093	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	DEVSOMFAQLZNKR-RJRFIUFISA-N	71481097.0		DEVSOMFAQLZNKR
BRD-K00003441-001-01-9	selitrectinib	Phase 1/Phase 2	protein tyrosine kinase inhibitor				0	96.6	MedChemEx	HY-101977	Selitrectinib	380.176	[H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1	OEBIHOVSAMBXIB-SJKOYZFVSA-N	129103609.0		OEBIHOVSAMBXIB
BRD-K00003274-001-01-9	selonsertib	Phase 2	MAP kinase activator				0	91.3	MedChemEx	HY-18938	Selonsertib	445.203	CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1	YIDDLAAKOYYGJG-UHFFFAOYSA-N	71245288.0		YIDDLAAKOYYGJG
BRD-K57080016-001-19-1	selumetinib	Phase 3	MEK inhibitor	MAP2K1			0	97.54	Selleck	S1008	selumetinib	456	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO	CYOHGALHFOKKQC-UHFFFAOYSA-N	10127622.0		CYOHGALHFOKKQC
BRD-K57080016-001-15-9	selumetinib	Phase 3	MEK inhibitor	MAP2K1			0	95.17	Selleck	S1008	Selumetinib (AZD6244)	456	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO	CYOHGALHFOKKQC-UHFFFAOYSA-N	10127622.0		CYOHGALHFOKKQC
BRD-K65592642-001-05-9	semagacestat	Phase 3	gamma secretase inhibitor	PSEN1			0	93.94	MedChemEx	HY-10009	Semagacestat	361.2	CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O	PKXWXXPNHIWQHW-RCBQFDQVSA-N	9843750.0		PKXWXXPNHIWQHW
BRD-K21237892-376-01-3	semapimod	Phase 2	cytokine production inhibitor|p38 MAPK inhibitor	MAPK14			0	86.13	Enamine	EN300-260559	N1,N10-bis(3,5-bis(1-(2-carbamimidoylhydrazinyl)vinyl)phenyl)decanediamide tetrahydrochloride	744.452	CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N	PWDYHMBTPGXCSN-UHFFFAOYSA-N	492132.0		PWDYHMBTPGXCSN
BRD-K63504947-001-15-4	semaxanib	Phase 3	VEGFR inhibitor	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET			0	96.75	Tocris	3037	SU 5416	238.111	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	WUWDLXZGHZSWQZ-WQLSENKSSA-N	5329098.0		WUWDLXZGHZSWQZ
BRD-K63504947-001-14-7	semaxanib	Phase 3	VEGFR inhibitor	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET			0	96.1	Selleck	S2845	Semaxanib (SU5416)	238.111	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	WUWDLXZGHZSWQZ-WQLSENKSSA-N	5329098.0		WUWDLXZGHZSWQZ
BRD-K63504947-001-16-2	semaxanib	Phase 3	VEGFR inhibitor	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET			0	95.62	Selleck	S2845	Semaxanib (SU5416)	238.111	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	WUWDLXZGHZSWQZ-WQLSENKSSA-N	5329098.0		WUWDLXZGHZSWQZ
BRD-K63504947-001-18-9	semaxanib	Phase 3	VEGFR inhibitor	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET			0	92.11	Tocris	3037	SU 5416	238.111	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	WUWDLXZGHZSWQZ-WQLSENKSSA-N	5329098.0		WUWDLXZGHZSWQZ
BRD-K63504947-001-17-0	semaxanib	Phase 3	VEGFR inhibitor	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET			0	94.89	Tocris	3037	SU 5416	238.111	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	WUWDLXZGHZSWQZ-WQLSENKSSA-N	5329098.0		WUWDLXZGHZSWQZ
BRD-K13281575-001-13-4	semustine	Phase 3	DNA alkylating agent				0	0.0	MicroSource	1503422	SEMUSTINE	247.109	CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]	JUUWEJHZVBABHQ-UHFFFAOYSA-N	124202178.0		JUUWEJHZVBABHQ
BRD-K13281575-001-14-2	semustine	Phase 3	DNA alkylating agent				0	0.0	Sigma	MFCD00133811	1-(2-chloroethyl)-1-{[(4-methylcyclohexyl)amino]carbonyl}-2-oxohydrazine	247.109	CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]	JUUWEJHZVBABHQ-UHFFFAOYSA-N	124202178.0		JUUWEJHZVBABHQ
BRD-K70614402-001-02-9	SEN-1269	Preclinical	beta amyloid inhibitor	APP			0	95.19	Tocris	4699	SEN 1269	322.143	CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1	MFPAAKZZUIRMKR-UHFFFAOYSA-N	46835756.0		MFPAAKZZUIRMKR
BRD-K70614402-001-01-0	SEN-1269	Preclinical	beta amyloid inhibitor	APP			0	97.39	Tocris	4699	SEN 1269	322.143	CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1	MFPAAKZZUIRMKR-UHFFFAOYSA-N	46835756.0		MFPAAKZZUIRMKR
BRD-K21295289-001-02-9	senicapoc	Phase 3	intermediate conductance potassium channel blocker	KCNN4			0	99.07	MedChemEx	HY-50694	Senicapoc	323.112	NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1	SCTZUZTYRMOMKT-UHFFFAOYSA-N	216327.0		SCTZUZTYRMOMKT
BRD-K21295289-001-01-6	senicapoc	Phase 3	intermediate conductance potassium channel blocker	KCNN4			0	99.76	MedChemEx	HY-50694	Senicapoc	323.112	NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1	SCTZUZTYRMOMKT-UHFFFAOYSA-N	216327.0		SCTZUZTYRMOMKT
BRD-A30370660-001-04-1	sennoside-A	Launched	glycoside agonist		gastroenterology	constipation	0	98.1	MicroSource	1504078	SENNOSIDE A	862.196	OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2,4,12,19,21,24,26,28,56,58,60,&1:11|	QFJIQUOMKJNYLI-QSXPFVSBSA-N	132466065.0		QFJIQUOMKJNYLI
BRD-A53504839-001-01-9	sennoside-protonated	Preclinical					0	40.0	Vitas-M	STL453210	4,4',10,10'-tetrahydroxy-5,5'-bis(3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-9,9'-bianthracene-2,2'-dicarboxylic acid	862.196	OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:19,&4:21,&5:24,&6:26,&7:28,&8:56,&9:58,&10:60,r|	QFJIQUOMKJNYLI-NGMZATEOSA-N			QFJIQUOMKJNYLI
BRD-K28456624-001-03-9	seocalcitol	Phase 3	vitamin D receptor agonist	VDR			0	90.32	MedChemEx	HY-32341	Seocalcitol	454.345	CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LVLLALCJVJNGQQ-SEODYNFXSA-N	5288149.0		LVLLALCJVJNGQQ
BRD-K28456624-001-02-9	seocalcitol	Phase 3	vitamin D receptor agonist	VDR			0	43.09	MedChemEx	HY-32341	Seocalcitol	454.345	CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LVLLALCJVJNGQQ-SEODYNFXSA-N	5288149.0		LVLLALCJVJNGQQ
BRD-K28456624-001-01-1	seocalcitol	Phase 3	vitamin D receptor agonist	VDR			0	92.75	MedChemEx	HY-32341	Seocalcitol	454.345	CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	LVLLALCJVJNGQQ-SEODYNFXSA-N	5288149.0		LVLLALCJVJNGQQ
BRD-K49504902-001-02-9	SEP-227900	Phase 1	D-amino acid oxidase Inhibitor	DAO			0	83.8	Vitas-M	STK894043	4H-furo[3,2-b]pyrrole-5-carboxylic acid	151.027	OC(=O)c1cc2occc2[nH]1	MMAIBGHDBYQYDI-UHFFFAOYSA-N	7141881.0		MMAIBGHDBYQYDI
BRD-K49504902-001-01-6	SEP-227900	Phase 1	D-amino acid oxidase Inhibitor	DAO			0	94.51	Enamine	Z1198172211		151.027	OC(=O)c1cc2occc2[nH]1	MMAIBGHDBYQYDI-UHFFFAOYSA-N	7141881.0		MMAIBGHDBYQYDI
BRD-A60765580-001-03-4	seratrodast	Launched	prostanoid receptor antagonist	TBXA2R	pulmonary	asthma	0	87.19	MedChemEx	HY-B0774	Seratrodast	354.183	CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|	ZBVKEHDGYSLCCC-SFHVURJKSA-N	73346713.0		ZBVKEHDGYSLCCC
BRD-A60765580-001-01-8	seratrodast	Launched	prostanoid receptor antagonist	TBXA2R	pulmonary	asthma	0	67.19	MicroSource	1502336	SERATRODAST	354.183	CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|	ZBVKEHDGYSLCCC-SFHVURJKSA-N	73346713.0		ZBVKEHDGYSLCCC
BRD-A60765580-001-02-6	seratrodast	Launched	prostanoid receptor antagonist	TBXA2R	pulmonary	asthma	0	56.56	MedChemEx	HY-B0774	Seratrodast	354.183	CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r,c:1,t:22|	ZBVKEHDGYSLCCC-SFHVURJKSA-N	73346713.0		ZBVKEHDGYSLCCC
BRD-K65924316-001-07-2	serdemetan	Phase 1	MDM inhibitor	MDM2			0	94.54	Selleck	S1172	JNJ 26854165 (Serdemetan)	328.169	C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1	CEGSUKYESLWKJP-UHFFFAOYSA-N	11609586.0		CEGSUKYESLWKJP
BRD-K65924316-001-03-1	serdemetan	Phase 1	MDM inhibitor	MDM2			0	81.0	Selleck	S1172	JNJ-26854165 (Serdemetan)	328.169	C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1	CEGSUKYESLWKJP-UHFFFAOYSA-N	11609586.0		CEGSUKYESLWKJP
BRD-K38580127-003-15-4	serotonin	Launched	growth factor receptor activator	DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR4|HTR5A|HTR6|HTR7|SLC36A1	neurology/psychiatry	anxiety|depression|sleeplessness	0	80.69	Selleck	S4244	Serotonin HCl	176.095	NCCc1c[nH]c2ccc(O)cc12	QZAYGJVTTNCVMB-UHFFFAOYSA-N	5202.0		QZAYGJVTTNCVMB
BRD-K38580127-003-16-2	serotonin	Launched	growth factor receptor activator	DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR4|HTR5A|HTR6|HTR7|SLC36A1	neurology/psychiatry	anxiety|depression|sleeplessness	0	49.06	Tocris	3547	Serotonin hydrochloride	176.095	NCCc1c[nH]c2ccc(O)cc12	QZAYGJVTTNCVMB-UHFFFAOYSA-N	5202.0		QZAYGJVTTNCVMB
BRD-K38580127-003-17-0	serotonin	Launched	growth factor receptor activator	DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR4|HTR5A|HTR6|HTR7|SLC36A1	neurology/psychiatry	anxiety|depression|sleeplessness	0	76.46	Selleck	S4244	Serotonin HCl	176.095	NCCc1c[nH]c2ccc(O)cc12	QZAYGJVTTNCVMB-UHFFFAOYSA-N	5202.0		QZAYGJVTTNCVMB
BRD-K01825659-008-03-9	sertaconazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis	0	95.54	MedChemEx	HY-B0736A	Sertaconazole (nitrate)	435.997	Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|	JLGKQTAYUIMGRK-LJQANCHMSA-N	25273617.0		JLGKQTAYUIMGRK
BRD-K01825659-001-01-9	sertaconazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis	0	98.39	Selleck	S3161	Sertaconazole nitrate	435.997	Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5,r|	JLGKQTAYUIMGRK-LJQANCHMSA-N	25273617.0	BRD-U65696040-000-01-2	JLGKQTAYUIMGRK
BRD-K69116396-001-04-1	sertindole	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|KCNH2			0	93.27	Prestwick	Prestw-1341	Sertindole	440.178	Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	60149.0		GZKLJWGUPQBVJQ
BRD-K69116396-001-05-9	sertindole	Withdrawn	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|KCNH2			0	93.24	MedChemEx	HY-14543	Sertindole	440.178	Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	GZKLJWGUPQBVJQ-UHFFFAOYSA-N	60149.0		GZKLJWGUPQBVJQ
BRD-K82036761-003-17-9	sertraline	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A3|SLC6A4	neurology/psychiatry|obstetrics/gynecology	depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder	0	82.3	MicroSource	1505262	SERTRALINE HYDROCHLORIDE	305.074	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	VGKDLMBJGBXTGI-SJCJKPOMSA-N	68617.0		VGKDLMBJGBXTGI
BRD-K82036761-003-19-5	sertraline	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A3|SLC6A4	neurology/psychiatry|obstetrics/gynecology	depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder	0	93.69	Tocris	2395	Sertraline hydrochloride	305.074	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	VGKDLMBJGBXTGI-SJCJKPOMSA-N	68617.0		VGKDLMBJGBXTGI
BRD-K82036761-003-16-1	sertraline	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A3|SLC6A4	neurology/psychiatry|obstetrics/gynecology	depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder	0	94.18	Tocris	2395	Sertraline hydrochloride	305.074	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	VGKDLMBJGBXTGI-SJCJKPOMSA-N	68617.0		VGKDLMBJGBXTGI
BRD-K82036761-003-21-9	sertraline	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A3|SLC6A4	neurology/psychiatry|obstetrics/gynecology	depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder	0	98.35	Tocris	2395	Sertraline hydrochloride	305.074	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	VGKDLMBJGBXTGI-SJCJKPOMSA-N	68617.0		VGKDLMBJGBXTGI
BRD-K82036761-003-20-3	sertraline	Launched	selective serotonin reuptake inhibitor (SSRI)	SLC6A3|SLC6A4	neurology/psychiatry|obstetrics/gynecology	depression|obsessive compulsive disorder (OCD)|panic disorders|posttraumatic stress disorder|premenstrual syndrome|social anxiety disorder	0	97.77	Selleck	S4053	Sertraline HCl	305.074	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	VGKDLMBJGBXTGI-SJCJKPOMSA-N	68617.0	BRD-K70464547-003-01-2	VGKDLMBJGBXTGI
BRD-K11631773-001-11-6	sesamin	Preclinical	NFkB pathway inhibitor				0	0.42	Selleck	S2392	Sesamin	354.11	C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	PEYUIKBAABKQKQ-AFHBHXEDSA-N	72307.0	BRD-K04837843-001-01-5	PEYUIKBAABKQKQ
BRD-K11631773-001-10-8	sesamin	Preclinical	NFkB pathway inhibitor				0	99.85	Selleck	S2392	Sesamin (Fagarol)	354.11	C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	PEYUIKBAABKQKQ-AFHBHXEDSA-N	72307.0		PEYUIKBAABKQKQ
BRD-K11631773-001-12-4	sesamin	Preclinical	NFkB pathway inhibitor				0	96.71	Selleck	S2392	Sesamin	354.11	C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	PEYUIKBAABKQKQ-AFHBHXEDSA-N	72307.0		PEYUIKBAABKQKQ
BRD-K24497734-001-01-6	setipiprant	Phase 3	prostaglandin inhibitor	PTGDR2			0	96.5	MedChemEx	HY-16635	Setipiprant	402.138	OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12	IHAXLPDVOWLUOS-UHFFFAOYSA-N	49843471.0		IHAXLPDVOWLUOS
BRD-K36732695-001-02-9	setiptiline	Launched	adrenergic receptor antagonist	HRH1|HTR2A|HTR2C	neurology/psychiatry	depression	0	92.76	MedChemEx	HY-32329	Setiptiline	261.152	CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|	GVPIXRLYKVFFMK-UHFFFAOYSA-N	5205.0		GVPIXRLYKVFFMK
BRD-K36732695-001-01-9	setiptiline	Launched	adrenergic receptor antagonist	HRH1|HTR2A|HTR2C	neurology/psychiatry	depression	0	96.01	MedChemEx	HY-32329	Setiptiline	261.152	CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|	GVPIXRLYKVFFMK-UHFFFAOYSA-N	5205.0		GVPIXRLYKVFFMK
BRD-K00003298-001-01-9	setmelanotide	Phase 3	melanocortin receptor agonist				0	83.94	MedChemEx	HY-19870	Setmelanotide	1116.486	[H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	HDHDTKMUACZDAA-PJHQLSNHSA-N			HDHDTKMUACZDAA
BRD-K05638300-001-02-0	sevoflurane	Launched	membrane integrity inhibitor	ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9|MT-ND1	neurology/psychiatry	anesthetic	1	0.0	Enamine	EN300-123016	1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane	200.007	FCOC(C(F)(F)F)C(F)(F)F	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	5206.0		DFEYYRMXOJXZRJ
BRD-K05638300-001-01-2	sevoflurane	Launched	membrane integrity inhibitor	ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9|MT-ND1	neurology/psychiatry	anesthetic	1	0.0	Enamine	EN300-123016		200.007	FCOC(C(F)(F)F)C(F)(F)F	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	5206.0		DFEYYRMXOJXZRJ
BRD-K15601958-001-03-9	SEW-2871	Preclinical	lysophospholipid receptor agonist	S1PR1			0	98.71	Tocris	2284	SEW 2871	440.042	FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F	OYMNPJXKQVTQTR-UHFFFAOYSA-N	4077460.0		OYMNPJXKQVTQTR
BRD-K15601958-001-05-9	SEW-2871	Preclinical	lysophospholipid receptor agonist	S1PR1			0	0.0	Tocris	2284	SEW 2871	440.042	FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F	OYMNPJXKQVTQTR-UHFFFAOYSA-N	4077460.0		OYMNPJXKQVTQTR
BRD-K42629487-001-08-6	SF-11	Preclinical	neuropeptide receptor antagonist	MCOLN3|NPY2R			0	88.14	Tocris	3898	SF 11	446.203	CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1	PMEQBGAGFZDWQX-UHFFFAOYSA-N	2936384.0		PMEQBGAGFZDWQX
BRD-K42629487-001-09-9	SF-11	Preclinical	neuropeptide receptor antagonist	MCOLN3|NPY2R			0	93.3	Tocris	3898	SF 11	446.203	CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1	PMEQBGAGFZDWQX-UHFFFAOYSA-N	2936384.0		PMEQBGAGFZDWQX
BRD-K24821794-001-04-8	SGC-CBP30	Preclinical	bromodomain inhibitor	CREBBP|EP300			0	96.05	Tocris	4889	SGC-CBP30	508.224	COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl	GEPYBHCJBORHCE-SFHVURJKSA-N	72201027.0		GEPYBHCJBORHCE
BRD-K24821794-001-01-4	SGC-CBP30	Preclinical	bromodomain inhibitor	CREBBP|EP300			0	97.84	Selleck	S7256	SGC-CBP30	508.224	COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl	GEPYBHCJBORHCE-SFHVURJKSA-N	72201027.0		GEPYBHCJBORHCE
BRD-K69577666-001-03-9	SGC-0946	Preclinical	histone lysine methyltransferase inhibitor				0	95.72	Tocris	4541	SGC 0946	617.233	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12	IQCKJUKAQJINMK-HUBRGWSESA-N	56962337.0		IQCKJUKAQJINMK
BRD-K69577666-001-01-3	SGC-0946	Preclinical	histone lysine methyltransferase inhibitor				0	94.14	Selleck	S7079	SGC 0946	617.233	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12	IQCKJUKAQJINMK-HUBRGWSESA-N	56962337.0		IQCKJUKAQJINMK
BRD-K86718786-001-01-7	SGC-707	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT3			0	85.34	Tocris	5367	SGC 707	298.143	O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1	DMIDPTCQPIJYFE-UHFFFAOYSA-N	90642938.0		DMIDPTCQPIJYFE
BRD-K86718786-001-03-9	SGC-707	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT3			0	97.06	Tocris	5367	SGC 707	298.143	O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1	DMIDPTCQPIJYFE-UHFFFAOYSA-N	90642938.0		DMIDPTCQPIJYFE
BRD-K61228301-001-03-9	SGI-1027	Preclinical	DNA methyltransferase inhibitor	DNMT1|DNMT3A|DNMT3B			0	91.55	Tocris	5155	SGI 1027	461.196	Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	QSYLKMKIVWJAAK-UHFFFAOYSA-N	24858111.0		QSYLKMKIVWJAAK
BRD-K61228301-001-01-2	SGI-1027	Preclinical	DNA methyltransferase inhibitor	DNMT1|DNMT3A|DNMT3B			0	90.51	Selleck	S7276	SGI-1027	461.196	Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	QSYLKMKIVWJAAK-UHFFFAOYSA-N	24858111.0		QSYLKMKIVWJAAK
BRD-K80700417-001-07-9	SGI-1776	Phase 1	Pim kinase inhibitor	FLT3|PIM1|PIM2|PIM3			0	95.6	MedChemEx	HY-13287	SGI-1776	405.178	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	MHXGEROHKGDZGO-UHFFFAOYSA-N	24795070.0		MHXGEROHKGDZGO
BRD-K80700417-001-04-2	SGI-1776	Phase 1	Pim kinase inhibitor	FLT3|PIM1|PIM2|PIM3			0	96.84	Selleck	S2198	SGI-1776 free base	405.178	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	MHXGEROHKGDZGO-UHFFFAOYSA-N	24795070.0		MHXGEROHKGDZGO
BRD-K00004650-001-01-9	SGS-742	Preclinical	GABA receptor antagonist	GABBR1|GABBR2			0	0.0	Sigma	SML0475	3-aminopropyl(butyl)phosphinic acid	179.108	CCCCP(O)(=O)CCCN	ONNMDRQRSGKZCN-UHFFFAOYSA-N	130021.0		ONNMDRQRSGKZCN
BRD-K19477839-001-07-6	SGX523	Phase 1	hepatocyte growth factor receptor inhibitor	MET			0	98.41	Selleck	S1112	SGX-523	359.095	Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1	BCZUAADEACICHN-UHFFFAOYSA-N	24779724.0		BCZUAADEACICHN
BRD-A63344375-001-02-9	SHA-68	Preclinical	neuropeptide receptor antagonist	NPSR1			0	97.57	Tocris	4510	SHA 68	445.18	Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|	SFRQIPRTNYHJHP-QHCPKHFHSA-N	52951680.0		SFRQIPRTNYHJHP
BRD-A63344375-001-01-8	SHA-68	Preclinical	neuropeptide receptor antagonist	NPSR1			0	96.69	Tocris	4510	SHA 68	445.18	Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13,r|	SFRQIPRTNYHJHP-QHCPKHFHSA-N	52951680.0		SFRQIPRTNYHJHP
BRD-A92096630-001-02-8	shikimic-acid	Preclinical					0	94.86	Selleck	S2356	Shikimic Acid	174.053	O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|	JXOHGGNKMLTUBP-PBXRRBTRSA-N	11332752.0		JXOHGGNKMLTUBP
BRD-A92096630-001-03-6	shikimic-acid	Preclinical					0	0.0	Selleck	S2356	Shikimic acid (Shikimate)	174.053	O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1,&1:5,&2:7,c:3|	JXOHGGNKMLTUBP-PBXRRBTRSA-N	11332752.0		JXOHGGNKMLTUBP
BRD-K00818915-001-02-9	SHP099	Preclinical	protein tyrosine kinase inhibitor	PTPN11			0	90.04	MedChemEx	HY-100388	SHP099	351.102	CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl	YGUFCDOEKKVKJK-UHFFFAOYSA-N	118238298.0		YGUFCDOEKKVKJK
BRD-K00818915-003-01-8	SHP099	Preclinical	protein tyrosine kinase inhibitor	PTPN11			0	50.02	MedChemEx	HY-100388A	SHP099 (hydrochloride)	351.102	CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl	YGUFCDOEKKVKJK-UHFFFAOYSA-N	118238298.0		YGUFCDOEKKVKJK
BRD-K01826006-003-01-9	SIB-1553A	Phase 2	acetylcholine receptor agonist	CHRNB4			0	94.8	Tocris	4764	4-((2-(1-methylpyrrolidin-2-yl)ethyl)thio)phenol hydrochloride	273.095	CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|	NVZGJSVPOOILDI-LLVKDONJSA-N	10609936.0		NVZGJSVPOOILDI
BRD-K98157055-001-11-9	SIB-1757	Preclinical	glutamate receptor antagonist	GRM5			0	85.19	Tocris	1215	SIB 1757	213.09	C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|	UOJMXHLMOUOGPY-UHFFFAOYSA-N	132466061.0		UOJMXHLMOUOGPY
BRD-K98157055-001-10-9	SIB-1757	Preclinical	glutamate receptor antagonist	GRM5			0	89.53	Tocris	1215	SIB 1757	213.09	C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|	UOJMXHLMOUOGPY-UHFFFAOYSA-N	132466061.0		UOJMXHLMOUOGPY
BRD-K14561059-001-06-9	SIB-1893	Preclinical	glutamate receptor antagonist	GRM4|GRM5			0	87.81	Tocris	1214	SIB 1893	195.105	Cc1cccc(\C=C\c2ccccc2)n1	SISOFUCTXZKSOQ-ZHACJKMWSA-N	5311432.0		SISOFUCTXZKSOQ
BRD-K14561059-001-05-9	SIB-1893	Preclinical	glutamate receptor antagonist	GRM4|GRM5			0	0.0	Tocris	1214	SIB 1893	195.105	Cc1cccc(\C=C\c2ccccc2)n1	SISOFUCTXZKSOQ-ZHACJKMWSA-N	5311432.0		SISOFUCTXZKSOQ
BRD-A43885598-001-09-9	SID-7969543	Preclinical	steroidogenic factor antagonist	NR5A1			0	95.54	Tocris	3440	SID 7969543	452.158	CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|	KWMBIIQCLUIHDI-OAHLLOKOSA-N	2149494.0		KWMBIIQCLUIHDI
BRD-A43885598-001-08-1	SID-7969543	Preclinical	steroidogenic factor antagonist	NR5A1			0	96.71	Tocris	3440	SID 7969543	452.158	CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|	KWMBIIQCLUIHDI-OAHLLOKOSA-N	2149494.0		KWMBIIQCLUIHDI
BRD-A43885598-001-10-9	SID-7969543	Preclinical	steroidogenic factor antagonist	NR5A1			0	96.06	Tocris	3440	SID 7969543	452.158	CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5,r|	KWMBIIQCLUIHDI-OAHLLOKOSA-N	2149494.0		KWMBIIQCLUIHDI
BRD-A62071884-001-06-1	siguazodan	Phase 1	phosphodiesterase inhibitor	PDE3A			0	91.28	Tocris	1148	Siguazodan	284.139	CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|	NUHPODZZKHQQET-VIFPVBQESA-N	6604007.0		NUHPODZZKHQQET
BRD-A62071884-001-04-6	siguazodan	Phase 1	phosphodiesterase inhibitor	PDE3A			0	97.8	Tocris	1148	Siguazodan	284.139	CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r,t:14|	NUHPODZZKHQQET-VIFPVBQESA-N	6604007.0		NUHPODZZKHQQET
BRD-K79759585-048-07-1	sildenafil	Launched	phosphodiesterase inhibitor	PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3	urology	erectile dysfunction	0	96.56	Tocris	3784	Sildenafil citrate	474.205	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	BNRNXUUZRGQAQC-UHFFFAOYSA-N	135398744.0		BNRNXUUZRGQAQC
BRD-K79759585-048-04-8	sildenafil	Launched	phosphodiesterase inhibitor	PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3	urology	erectile dysfunction	0	99.19	MicroSource	1504099	SILDENAFIL CITRATE	474.205	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	BNRNXUUZRGQAQC-UHFFFAOYSA-N	135398744.0		BNRNXUUZRGQAQC
BRD-K79759585-048-03-0	sildenafil	Launched	phosphodiesterase inhibitor	PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3	urology	erectile dysfunction	0	97.92	Selleck	S1431	Sildenafil Citrate	474.205	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	BNRNXUUZRGQAQC-UHFFFAOYSA-N	135398744.0		BNRNXUUZRGQAQC
BRD-K79759585-048-12-9	sildenafil	Launched	phosphodiesterase inhibitor	PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3	urology	erectile dysfunction	0	96.33	Tocris	3784	Sildenafil citrate	474.205	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	BNRNXUUZRGQAQC-UHFFFAOYSA-N	135398744.0		BNRNXUUZRGQAQC
BRD-K80353138-001-12-1	silibinin	Launched	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	0	97.75	MicroSource	1505256	SILIBININ	482.121	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	SEBFKMXJBCUCAI-HKTJVKLFSA-N	31553.0		SEBFKMXJBCUCAI
BRD-K80353138-001-17-9	silibinin	Launched	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	0	98.02	MedChemEx	HY-13748	Silibinin	482.121	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	SEBFKMXJBCUCAI-HKTJVKLFSA-N	31553.0		SEBFKMXJBCUCAI
BRD-K80353138-001-13-9	silibinin	Launched	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	0	93.92	Selleck	S2357	Silibinin (Silybin)	482.121	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	SEBFKMXJBCUCAI-HKTJVKLFSA-N	31553.0		SEBFKMXJBCUCAI
BRD-K80353138-001-16-2	silibinin	Launched	cytochrome P450 inhibitor	ALOX5	gastroenterology	hepatic cirrhosis	0	47.34	Selleck	S2357	Silibinin	482.121	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	SEBFKMXJBCUCAI-HKTJVKLFSA-N	31553.0	BRD-K47267049-001-01-6	SEBFKMXJBCUCAI
BRD-K10906636-001-03-9	silodosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D	urology	benign prostatic hyperplasia (BPH)	0	96.44	MedChemEx	HY-10122	Silodosin	495.234	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	PNCPYILNMDWPEY-QGZVFWFLSA-N	5312125.0		PNCPYILNMDWPEY
BRD-K10906636-001-01-1	silodosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D	urology	benign prostatic hyperplasia (BPH)	0	66.32	Selleck	S1613	Silodosin	495.234	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	PNCPYILNMDWPEY-QGZVFWFLSA-N	5312125.0		PNCPYILNMDWPEY
BRD-K10906636-001-02-9	silodosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D	urology	benign prostatic hyperplasia (BPH)	0	93.88	Selleck	S1613	Silodosin	495.234	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	PNCPYILNMDWPEY-QGZVFWFLSA-N	5312125.0		PNCPYILNMDWPEY
BRD-K68379918-001-01-1	silver-sulfadiazine	Launched	PABA antagonist		critical care	sepsis	1	99.7	Sigma	MFCD00072101	(4-amino-N-(pyrimidin-2-yl)phenylsulfonamido)silver	355.95	Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1	UEJSSZHHYBHCEL-UHFFFAOYSA-N	5459124.0		UEJSSZHHYBHCEL
BRD-K68379918-001-02-9	silver-sulfadiazine	Launched	PABA antagonist		critical care	sepsis	0	0.0	Enzo	AC3249	SILVER SULFADIAZINE	355.95	Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1	UEJSSZHHYBHCEL-UHFFFAOYSA-N	5459124.0	BRD-M11664367-001-01-8	UEJSSZHHYBHCEL
BRD-A06629414-001-02-3	silymarin	Launched					0	47.05	Selleck	S2358	Silymarin	482.121	COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|	FDQAOULAVFHKBX-HKTJVKLFSA-N	11059920.0		FDQAOULAVFHKBX
BRD-A06629414-001-03-1	silymarin	Launched					0	50.9	Selleck	S2358	Silymarin (Silybin B)	482.121	COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|	FDQAOULAVFHKBX-HKTJVKLFSA-N	11059920.0		FDQAOULAVFHKBX
BRD-A06629414-001-04-9	silymarin	Launched					0	37.75	Selleck	S2358	Silymarin (Silybin B)	482.121	COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9,&2:18,&3:21,&4:33,r|	FDQAOULAVFHKBX-HKTJVKLFSA-N	11059920.0		FDQAOULAVFHKBX
BRD-K00003545-001-01-9	simeprevir	Launched	HCV inhibitor	CYP1A2|CYP3A4	infectious disease	hepatitis C	0	91.71	MedChemEx	HY-10241	Simeprevir	749.292	COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|	JTZZSQYMACOLNN-VDWJNHBNSA-N	24873435.0		JTZZSQYMACOLNN
BRD-K00004727-001-01-9	simurosertib	Preclinical	kinase inhibitor				0	91.08	MedChemEx	HY-100888	Simurosertib	341.131	Cc1n[nH]cc1-c1cc2[nH]c(nc(=O)c2s1)[C@H]1CC2CCN1CC2 |&1:16,r|	XGVXKJKTISMIOW-CYBMUJFWSA-N	136443810.0		XGVXKJKTISMIOW
BRD-K22134346-001-28-0	simvastatin	Launched	HMGCR inhibitor	HMGCR|ITGB2	endocrinology|cardiology|neurology/psychiatry	hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia	0	91.31	Tocris	1965	Simvastatin	418.272	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|	RYMZZMVNJRMUDD-HGQWONQESA-N	54454.0		RYMZZMVNJRMUDD
BRD-K22134346-001-22-3	simvastatin	Launched	HMGCR inhibitor	HMGCR|ITGB2	endocrinology|cardiology|neurology/psychiatry	hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia	0	88.23	MicroSource	1504236	SIMVASTATIN	418.272	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|	RYMZZMVNJRMUDD-HGQWONQESA-N	54454.0		RYMZZMVNJRMUDD
BRD-K22134346-001-24-9	simvastatin	Launched	HMGCR inhibitor	HMGCR|ITGB2	endocrinology|cardiology|neurology/psychiatry	hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia	0	88.4	Selleck	S1792	Simvastatin (Zocor)	418.272	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|	RYMZZMVNJRMUDD-HGQWONQESA-N	54454.0		RYMZZMVNJRMUDD
BRD-K22134346-001-21-5	simvastatin	Launched	HMGCR inhibitor	HMGCR|ITGB2	endocrinology|cardiology|neurology/psychiatry	hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia	0	78.82	Tocris	1965	Simvastatin	418.272	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|	RYMZZMVNJRMUDD-HGQWONQESA-N	54454.0		RYMZZMVNJRMUDD
BRD-K22134346-001-30-6	simvastatin	Launched	HMGCR inhibitor	HMGCR|ITGB2	endocrinology|cardiology|neurology/psychiatry	hypercholesterolemia|coronary heart disease|myocardial infarction|stroke|hyperlipidemia	0	10.2	Selleck	S1792	Simvastatin	418.272	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14,t:12|	RYMZZMVNJRMUDD-HGQWONQESA-N	54454.0	BRD-K94986873-001-01-4	RYMZZMVNJRMUDD
BRD-K00003334-001-01-9	sincalide	Preclinical	cholecystokinin agonist				0	80.31	MedChemEx	HY-P0093	Sincalide	1142.351	CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	IZTQOLKUZKXIRV-YRVFCXMDSA-N	9833444.0		IZTQOLKUZKXIRV
BRD-K91100918-001-03-8	sinefungin	Preclinical	DNA methyltransferase inhibitor|RNA synthesis inhibitor	CARM1			0	94.6	Sigma	S8559	Sinefungin	381.176	N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	LMXOHSDXUQEUSF-YECHIGJVSA-N	65482.0		LMXOHSDXUQEUSF
BRD-K83459933-001-05-4	sinomenine	Preclinical	angiogenesis inhibitor				0	92.76	Selleck	S2359	Sinomenine	329.163	COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|	INYYVPJSBIVGPH-QHRIQVFBSA-N	5459308.0		INYYVPJSBIVGPH
BRD-K83459933-003-06-9	sinomenine	Preclinical	angiogenesis inhibitor				0	92.72	Tocris	3848	Sinomenine hydrochloride	329.163	COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|	INYYVPJSBIVGPH-QHRIQVFBSA-N	5459308.0		INYYVPJSBIVGPH
BRD-K53195974-001-02-7	sipatrigine	Phase 2	voltage-gated sodium channel blocker	CACNA1D|SCN10A|SCN1A|SCN3A|SCN4A|SCN5A|SCN9A			0	98.09	Tocris	4044	Sipatrigine	371.047	CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl	PDOCBJADCWMDGL-UHFFFAOYSA-N	60803.0		PDOCBJADCWMDGL
BRD-K53195974-001-01-9	sipatrigine	Phase 2	voltage-gated sodium channel blocker	CACNA1D|SCN10A|SCN1A|SCN3A|SCN4A|SCN5A|SCN9A			0	97.76	Tocris	4044	2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinylamine	371.047	CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl	PDOCBJADCWMDGL-UHFFFAOYSA-N	60803.0		PDOCBJADCWMDGL
BRD-K62384160-001-02-0	siponimod	Launched	sphingosine 1-phosphate receptor modulator	S1PR1	neurology/psychiatry	multiple sclerosis	0	95.58	MedChemEx	HY-12355	Siponimod	516.26	CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F	KIHYPELVXPAIDH-HNSNBQBZSA-N	44599207.0		KIHYPELVXPAIDH
BRD-K62384160-001-01-2	siponimod	Launched	sphingosine 1-phosphate receptor modulator	S1PR1	neurology/psychiatry	multiple sclerosis	0	93.82	Selleck	S7179	BAF312 (Siponimod)	516.26	CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F	KIHYPELVXPAIDH-HNSNBQBZSA-N	44599207.0		KIHYPELVXPAIDH
BRD-K51333959-003-01-3	siramesine	Phase 2	sigma receptor antagonist	ADRA1A|ADRA1B|ADRA1D			0	87.3	MedChemEx	HY-14221A	Siramesine (hydrochloride)	454.242	Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12	XWAONOGAGZNUSF-UHFFFAOYSA-N	9829526.0		XWAONOGAGZNUSF
BRD-K51333959-003-02-9	siramesine	Phase 2	sigma receptor antagonist	ADRA1A|ADRA1B|ADRA1D			0	98.3	MedChemEx	HY-14221A	Siramesine (hydrochloride)	454.242	Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12	XWAONOGAGZNUSF-UHFFFAOYSA-N	9829526.0		XWAONOGAGZNUSF
BRD-K65480835-001-02-9	siremadlin	Preclinical	MDM inhibitor				0	97.81	MedChemEx	HY-18658	Siremadlin	554.124	COc1ncc(-c2nc3C(=O)N([C@H](c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cn(C)c2=O)c(OC)n1	AGBSXNCBIWWLHD-FQEVSTJZSA-N	71678098.0		AGBSXNCBIWWLHD
BRD-K84937637-001-13-1	sirolimus	Launched	mTOR inhibitor	FKBP1A|MTOR	transplant|pulmonary	organ rejection|lymphangioleiomyomatosis	0	95.67	MedChemEx	HY-10219	Rapamycin	913.555	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|	QFJCIRLUMZQUOT-MHOZHFGWSA-N	134812764.0		QFJCIRLUMZQUOT
BRD-K84937637-001-09-9	sirolimus	Launched	mTOR inhibitor	FKBP1A|MTOR	transplant|pulmonary	organ rejection|lymphangioleiomyomatosis	0	95.47	Selleck	S1039	Rapamycin (Sirolimus)	913.555	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|	QFJCIRLUMZQUOT-MHOZHFGWSA-N	134812764.0		QFJCIRLUMZQUOT
BRD-K84937637-001-11-5	sirolimus	Launched	mTOR inhibitor	FKBP1A|MTOR	transplant|pulmonary	organ rejection|lymphangioleiomyomatosis	0	92.23	Selleck	S1039	Rapamycin (Sirolimus)	913.555	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14,33,t:29,31|	QFJCIRLUMZQUOT-MHOZHFGWSA-N	134812764.0	BRD-K79988249-001-01-6	QFJCIRLUMZQUOT
BRD-K16472653-001-01-6	SirReal-2	Preclinical	SIRT inhibitor	SIRT2			0	97.4	Tocris	5457	SirReal 2	420.108	Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1	MENNDDDTIIZDDN-UHFFFAOYSA-N	1096292.0		MENNDDDTIIZDDN
BRD-K16472653-001-02-4	SirReal-2	Preclinical	SIRT inhibitor	SIRT2			0	99.29	Tocris	5457	SirReal2	420.108	Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1	MENNDDDTIIZDDN-UHFFFAOYSA-N	1096292.0		MENNDDDTIIZDDN
BRD-A23747351-001-06-8	sirtinol	Preclinical	SIRT inhibitor	SIRT1|SIRT2			0	11.06	Tocris	3521	Sirtinol	394.168	C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|	UXJFDYIHRJGPFS-OVKKOYPGSA-N			UXJFDYIHRJGPFS
BRD-A23747351-001-07-6	sirtinol	Preclinical	SIRT inhibitor	SIRT1|SIRT2			0	5.37	Selleck	S2804	Sirtinol	394.168	C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|	UXJFDYIHRJGPFS-OVKKOYPGSA-N			UXJFDYIHRJGPFS
BRD-A23747351-001-08-9	sirtinol	Preclinical	SIRT inhibitor	SIRT1|SIRT2			0	1.88	Tocris	3521	Sirtinol	394.168	C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|	UXJFDYIHRJGPFS-OVKKOYPGSA-N			UXJFDYIHRJGPFS
BRD-A23747351-001-05-0	sirtinol	Preclinical	SIRT inhibitor	SIRT1|SIRT2			0	5.76	Selleck	S2804	Sirtinol	394.168	C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1,r|	UXJFDYIHRJGPFS-OVKKOYPGSA-N			UXJFDYIHRJGPFS
BRD-K71772032-001-01-3	sisomicin	Launched	protein synthesis inhibitor		ophthalmology	conjunctivitis|punctate keratitis	0	0.0	MedChemEx	HY-B1222	Sisomicin (sulfate)	447.269	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N	36119.0	BRD-M71798497-001-01-4	URWAJWIAIPFPJE
BRD-K71772032-315-02-5	sisomicin	Launched	protein synthesis inhibitor		ophthalmology	conjunctivitis|punctate keratitis	0	0.0	MedChemEx	HY-B1222	Sisomicin (sulfate)	447.269	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N	36119.0	BRD-M47753525-343-01-2	URWAJWIAIPFPJE
BRD-K71772032-315-01-7	sisomicin	Launched	protein synthesis inhibitor		ophthalmology	conjunctivitis|punctate keratitis	0	11.93	AvaChem	3048	4,6-diamino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl 3-deoxy-4-C-methyl-3-(methylamino)pentopyranoside	447.269	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N	36119.0	BRD-A29840884-001-01-2	URWAJWIAIPFPJE
BRD-K71772032-315-03-9	sisomicin	Launched	protein synthesis inhibitor		ophthalmology	conjunctivitis|punctate keratitis	0	0.0	Selleck	S4540		447.269	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N	36119.0	BRD-K71772032-343-03-9|BRD-K71772032-343-03-9|BRD-K71772032-343-03-9|BRD-K71772032-343-03-9	URWAJWIAIPFPJE
BRD-A68997559-065-04-5	sisomicin-sulfate	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MicroSource	1500536	SISOMICIN SULFATE	447.269	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |a:2,5,7,8,11,13,15,22,24,28,&1:3,c:19|	URWAJWIAIPFPJE-YFMIWBNJSA-N	36119.0		URWAJWIAIPFPJE
BRD-K38905597-003-01-4	SIS3	Preclinical	serine/threonine kinase inhibitor	SMAD3|TGFBR1			0	85.23	Tocris	5291	SIS3	453.205	COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12	IJYPHMXWKKKHGT-VAWYXSNFSA-N	10138988.0		IJYPHMXWKKKHGT
BRD-K38905597-003-02-9	SIS3	Preclinical	serine/threonine kinase inhibitor	SMAD3|TGFBR1			0	96.14	Tocris	5291	SIS3	453.205	COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12	IJYPHMXWKKKHGT-VAWYXSNFSA-N	10138988.0		IJYPHMXWKKKHGT
BRD-K10836013-002-02-9	sitafloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	buruli ulcer	0	98.54	MedChemEx	HY-B0395C	Sitafloxacin (hydrate)	409.1	N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F	PNUZDKCDAWUEGK-CYZMBNFOSA-N	461399.0		PNUZDKCDAWUEGK
BRD-K10836013-001-01-3	sitafloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	buruli ulcer	0	93.27	Selleck	S2152	Sitafloxacin Hydrate	409.1	N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F	PNUZDKCDAWUEGK-CYZMBNFOSA-N	461399.0	BRD-U60340452-000-01-3	PNUZDKCDAWUEGK
BRD-K19416115-366-02-7	sitagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	92.37	MicroSource	1505831	SITAGLIPTIN MONOPHOSPHATE MONOHYDRATE	407.118	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F	MFFMDFFZMYYVKS-SECBINFHSA-N	4369359.0		MFFMDFFZMYYVKS
BRD-K19416115-001-05-3	sitagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	92.63	Selleck	S4002	Sitagliptin phosphate monohydrate	407.118	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F	MFFMDFFZMYYVKS-SECBINFHSA-N	4369359.0	BRD-U27206154-000-01-9	MFFMDFFZMYYVKS
BRD-K63806092-236-05-9	sitaxentan	Withdrawn	endothelin receptor antagonist	EDNRA|EDNRB			0	90.86	MedChemEx	HY-11103	Sitaxsentan (sodium)	454.006	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	PHWXUGHIIBDVKD-UHFFFAOYSA-N	216235.0		PHWXUGHIIBDVKD
BRD-K63806092-236-06-9	sitaxentan	Withdrawn	endothelin receptor antagonist	EDNRA|EDNRB			0	95.83	MedChemEx	HY-11103	Sitaxsentan (sodium)	454.006	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	PHWXUGHIIBDVKD-UHFFFAOYSA-N	216235.0		PHWXUGHIIBDVKD
BRD-K63806092-236-03-4	sitaxentan	Withdrawn	endothelin receptor antagonist	EDNRA|EDNRB			0	29.61	MedChemEx	HY-11103	Sitaxsentan (sodium)	454.006	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	PHWXUGHIIBDVKD-UHFFFAOYSA-N	216235.0		PHWXUGHIIBDVKD
BRD-K63806092-236-02-6	sitaxentan	Withdrawn	endothelin receptor antagonist	EDNRA|EDNRB			0	79.39	Selleck	S3034	Sitaxentan sodium	454.006	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	PHWXUGHIIBDVKD-UHFFFAOYSA-N	216235.0		PHWXUGHIIBDVKD
BRD-K63806092-236-04-2	sitaxentan	Withdrawn	endothelin receptor antagonist	EDNRA|EDNRB			0	93.75	Selleck	S3034	Sitaxentan sodium (TBC-11251)	454.006	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	PHWXUGHIIBDVKD-UHFFFAOYSA-N	216235.0		PHWXUGHIIBDVKD
BRD-K79402892-001-08-9	sitosterol	Preclinical					0	1.26	MedChemEx	HY-N0171	Beta-Sitosterol	414.386	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	KZJWDPNRJALLNS-VJSFXXLFSA-N	222284.0		KZJWDPNRJALLNS
BRD-K79402892-001-06-7	sitosterol	Preclinical					0	0.0	Selleck	S2273	??-Sitosterol	414.386	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	KZJWDPNRJALLNS-VJSFXXLFSA-N	222284.0		KZJWDPNRJALLNS
BRD-K79402892-001-07-5	sitosterol	Preclinical					0	0.0	Selleck	S2273	?-Sitosterol	414.386	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	KZJWDPNRJALLNS-VJSFXXLFSA-N	222284.0	BRD-K16553588-001-01-3	KZJWDPNRJALLNS
BRD-K00003238-001-01-9	sitravatinib	Phase 3	receptor tyrosine protein kinase inhibitor				0	94.75	MedChemEx	HY-16961	Sitravatinib	629.191	COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1	WLAVZAAODLTUSW-UHFFFAOYSA-N	25212148.0		WLAVZAAODLTUSW
BRD-K02152879-236-01-0	sivelestat	Launched	elastase inhibitor	CELA1|ELANE	pulmonary	acute lung injury	0	96.69	Tocris	3535	Sivelestat sodium salt	434.115	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	BTGNGJJLZOIYID-UHFFFAOYSA-N	107706.0		BTGNGJJLZOIYID
BRD-K02152879-414-02-1	sivelestat	Launched	elastase inhibitor	CELA1|ELANE	pulmonary	acute lung injury	0	97.49	MedChemEx	HY-17443B	Sivelestat (sodium tetrahydrate)	434.115	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	BTGNGJJLZOIYID-UHFFFAOYSA-N	107706.0		BTGNGJJLZOIYID
BRD-K02152879-414-01-3	sivelestat	Launched	elastase inhibitor	CELA1|ELANE	pulmonary	acute lung injury	0	78.64	MedChemEx	HY-17443B	Sivelestat (sodium tetrahydrate)	434.115	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	BTGNGJJLZOIYID-UHFFFAOYSA-N	107706.0		BTGNGJJLZOIYID
BRD-K35945299-001-04-2	SJ-172550	Preclinical	MDM inhibitor	MDM4			0	4.61	MedChemEx	HY-16664	SJ-172550	428.114	CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|	RKKFQJXGAQWHBZ-LICLKQGHSA-N	1317464.0		RKKFQJXGAQWHBZ
BRD-K35945299-001-03-4	SJ-172550	Preclinical	MDM inhibitor	MDM4			0	4.71	Tocris	3929	SJ 172550	428.114	CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|	RKKFQJXGAQWHBZ-LICLKQGHSA-N	1317464.0		RKKFQJXGAQWHBZ
BRD-K35945299-001-02-6	SJ-172550	Preclinical	MDM inhibitor	MDM4			0	6.12	MedChemEx	HY-16664	SJ-172550	428.114	CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|	RKKFQJXGAQWHBZ-LICLKQGHSA-N	1317464.0		RKKFQJXGAQWHBZ
BRD-K34798115-001-02-9	SJ-733	Phase 1	ATPase inhibitor				0	97.78	MedChemEx	HY-19556	(+)-SJ733	468.121	Fc1ccc(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)c3ccccc23)c2cccnc2)cc1C#N	VKCPFWKTFZAOTO-LEWJYISDSA-N	89508529.0		VKCPFWKTFZAOTO
BRD-K00003173-001-01-9	SJG-136	Phase 2	DNA intercalating agent				0	54.82	MedChemEx	HY-14573	SJG-136	556.232	COc1cc2c(cc1OCCCOc1cc3N=C[C@@H]4CC(=C)CN4C(=O)c3cc1OC)N=C[C@@H]1CC(=C)CN1C2=O |c:17,35|	RWZVMMQNDHPRQD-SFTDATJTSA-N	393111.0		RWZVMMQNDHPRQD
BRD-K00004226-003-01-9	SK&F-10047-(+)	Phase 1	sigma receptor agonist	SIGMAR1			0	100.0	Tocris	1079	(+)-SK&F 10047 hydrochloride	257.178	C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C	LGQCVMYAEFTEFN-DQYPLSBCSA-N	3036222.0		LGQCVMYAEFTEFN
BRD-K67304264-001-10-1	SKA-31	Preclinical	potassium channel activator	KCNN4			0	92.5	Tocris	3670	SKA 31	200.041	Nc1nc2c(ccc3ccccc23)s1	FECQXVPRUCCUIL-UHFFFAOYSA-N	94880.0		FECQXVPRUCCUIL
BRD-K67304264-001-08-5	SKA-31	Preclinical	potassium channel activator	KCNN4			0	92.73	Tocris	3670	SKA 31	200.041	Nc1nc2c(ccc3ccccc23)s1	FECQXVPRUCCUIL-UHFFFAOYSA-N	94880.0		FECQXVPRUCCUIL
BRD-K67304264-001-11-9	SKA-31	Preclinical	potassium channel activator	KCNN4			0	90.34	Tocris	3670	SKA 31	200.041	Nc1nc2c(ccc3ccccc23)s1	FECQXVPRUCCUIL-UHFFFAOYSA-N	94880.0		FECQXVPRUCCUIL
BRD-K83607951-001-02-2	skepinone-L	Preclinical	p38 MAPK inhibitor	MAPK14			0	97.79	Selleck	S7214	Skepinone-L	425.144	OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	HXMGCTFLLWPVFM-GOSISDBHSA-N	45279963.0		HXMGCTFLLWPVFM
BRD-K83607951-001-04-9	skepinone-L	Preclinical	p38 MAPK inhibitor	MAPK14			0	98.66	MedChemEx	HY-15300	Skepinone-L	425.144	OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	HXMGCTFLLWPVFM-GOSISDBHSA-N	45279963.0		HXMGCTFLLWPVFM
BRD-K01826815-004-03-9	SKF-38393	Preclinical	dopamine receptor agonist	CALY|DRD1|DRD5			0	100.0	Tocris	922	SKF 38393 hydrobromide	255.126	Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|	JUDKOGFHZYMDMF-AWEZNQCLSA-N	6603799.0		JUDKOGFHZYMDMF
BRD-K01826815-004-02-9	SKF-38393	Preclinical	dopamine receptor agonist	CALY|DRD1|DRD5			0	95.94	Tocris	922	SKF 38393 hydrobromide	335.052	Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|	JUDKOGFHZYMDMF-AWEZNQCLSA-N	6603799.0		JUDKOGFHZYMDMF
BRD-A64227845-004-10-9	SKF-77434	Preclinical	dopamine receptor agonist	DRD1			0	97.3	Tocris	1662	SKF 77434 hydrobromide	295.157	Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|	QBUVZVXIRYFENV-KRWDZBQOSA-N	6603997.0		QBUVZVXIRYFENV
BRD-A64227845-004-09-3	SKF-77434	Preclinical	dopamine receptor agonist	DRD1			0	89.0	Tocris	1662	SKF 77434 hydrobromide	295.157	Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|	QBUVZVXIRYFENV-KRWDZBQOSA-N	6603997.0		QBUVZVXIRYFENV
BRD-A09828896-004-12-8	SKF-81297	Preclinical	dopamine receptor agonist	DRD1|DRD5			0	70.56	Tocris	1447	SKF 81297 hydrobromide	289.087	Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1	GHWJEDJMOVUXEC-UHFFFAOYSA-N	11957706.0		GHWJEDJMOVUXEC
BRD-A09828896-004-11-0	SKF-81297	Preclinical	dopamine receptor agonist	DRD1|DRD5			0	94.79	Tocris	1447	SKF 81297 hydrobromide	289.087	Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1	GHWJEDJMOVUXEC-UHFFFAOYSA-N	11957706.0		GHWJEDJMOVUXEC
BRD-A52588987-004-09-0	SKF-83566	Preclinical	dopamine receptor antagonist	DRD1|DRD5			0	97.41	Tocris	1586	SKF 83566 hydrobromide	331.057	CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|	XFTVOHWWEQGXLS-HNNXBMFYSA-N	6604885.0		XFTVOHWWEQGXLS
BRD-A52588987-004-08-2	SKF-83566	Preclinical	dopamine receptor antagonist	DRD1|DRD5			0	97.34	Tocris	1586	SKF 83566 hydrobromide	331.057	CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|	XFTVOHWWEQGXLS-HNNXBMFYSA-N	6604885.0		XFTVOHWWEQGXLS
BRD-K96809896-300-03-9	SKF-86002	Preclinical	p38 MAPK inhibitor	ALOX5|MAPK14			0	94.86	Tocris	2008	SKF 86002 dihydrochloride	297.074	Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1	YOELZIQOLWZLQC-UHFFFAOYSA-N	5228.0		YOELZIQOLWZLQC
BRD-K96809896-300-02-3	SKF-86002	Preclinical	p38 MAPK inhibitor	ALOX5|MAPK14			0	93.26	Tocris	2008	SKF 86002 dihydrochloride	297.074	Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1	YOELZIQOLWZLQC-UHFFFAOYSA-N	5228.0		YOELZIQOLWZLQC
BRD-K01826728-003-08-9	SKF-89976A	Preclinical	GABA uptake inhibitor	SLC6A1			0	91.66	Tocris	1081	SKF 89976A hydrochloride	371.165	OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|	TXQKSMSLZVKQBI-FQEVSTJZSA-N	6604015.0		TXQKSMSLZVKQBI
BRD-K01826728-003-10-9	SKF-89976A	Preclinical	GABA uptake inhibitor	SLC6A1			0	92.35	Tocris	1081	SKF 89976A hydrochloride	335.189	OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|	TXQKSMSLZVKQBI-FQEVSTJZSA-N	6604015.0		TXQKSMSLZVKQBI
BRD-K01826728-003-07-9	SKF-89976A	Preclinical	GABA uptake inhibitor	SLC6A1			0	97.09	Tocris	1081	SKF 89976A hydrochloride	371.165	OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|	TXQKSMSLZVKQBI-FQEVSTJZSA-N	6604015.0		TXQKSMSLZVKQBI
BRD-K49776472-300-03-2	SKF-91488	Preclinical	histamine N-methyltransferase inhibitor	HNMT			0	0.0	Tocris	512	SKF 91488 dihydrochloride	175.114	CN(C)CCCCSC(N)=N	UFYJLJINUGVUHO-UHFFFAOYSA-N	5227.0		UFYJLJINUGVUHO
BRD-K49776472-300-04-9	SKF-91488	Preclinical	histamine N-methyltransferase inhibitor	HNMT			0	78.22	Tocris	512	SKF 91488 dihydrochloride	175.114	CN(C)CCCCSC(N)=N	UFYJLJINUGVUHO-UHFFFAOYSA-N	5227.0		UFYJLJINUGVUHO
BRD-K49776472-300-02-4	SKF-91488	Preclinical	histamine N-methyltransferase inhibitor	HNMT			0	74.58	Tocris	512	SKF 91488 dihydrochloride	175.114	CN(C)CCCCSC(N)=N	UFYJLJINUGVUHO-UHFFFAOYSA-N	5227.0		UFYJLJINUGVUHO
BRD-K01826819-003-04-9	SKF-96365	Preclinical	calcium channel blocker	CYP3A4|PKD2|TRPC1|TRPC3|TRPC4|TRPC5|TRPV2			0	98.58	Tocris	1147	SKF 96365 hydrochloride	402.171	COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|	HLMBXBGDBBCYII-QFIPXVFZSA-N	6604827.0		HLMBXBGDBBCYII
BRD-K20755323-001-06-7	SKI-II	Preclinical	sphingosine kinase inhibitor	SPHK1			0	89.16	Tocris	2097	SKI II	302.028	Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	ZFGXZJKLOFCECI-UHFFFAOYSA-N	753704.0		ZFGXZJKLOFCECI
BRD-K20755323-001-05-9	SKI-II	Preclinical	sphingosine kinase inhibitor	SPHK1			0	84.6	Selleck	S7176	SKI II	302.028	Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	ZFGXZJKLOFCECI-UHFFFAOYSA-N	753704.0		ZFGXZJKLOFCECI
BRD-K20755323-001-07-5	SKI-II	Preclinical	sphingosine kinase inhibitor	SPHK1			0	94.83	Selleck	S7176	SKI II	302.028	Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	ZFGXZJKLOFCECI-UHFFFAOYSA-N	753704.0		ZFGXZJKLOFCECI
BRD-K00004690-001-01-9	SKLB-1028	Preclinical	Abl kinase inhibitor|EGFR inhibitor|FLT3 inhibitor				0	86.39	Astatech	91330	SKLB-1028	443.255	CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc12	WSOHOUHPUOAXIN-UHFFFAOYSA-N	54760385.0		WSOHOUHPUOAXIN
BRD-K29895144-001-01-0	SKLB1002	Preclinical	VEGFR inhibitor	KDR			0	97.72	Selleck	S7258	SKLB1002	320.04	COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC	RQVGFDBMONQTBC-UHFFFAOYSA-N	71461003.0		RQVGFDBMONQTBC
BRD-K29895144-001-02-9	SKLB1002	Preclinical	VEGFR inhibitor	KDR			0	96.48	MedChemEx	HY-13944	SKLB1002	320.04	COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC	RQVGFDBMONQTBC-UHFFFAOYSA-N	71461003.0		RQVGFDBMONQTBC
BRD-K00004304-001-01-9	SLV-319-(+/-)	Phase 2	cannabinoid receptor antagonist	CNR1|DRD2|HTR1A			0	97.15	Tocris	4605	(+/-)-SLV 319	486.068	C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16,r,c:18|	AXJQVVLKUYCICH-OAQYLSRUSA-N	9826744.0		AXJQVVLKUYCICH
BRD-K34445261-001-02-2	SLV-320	Phase 2	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	91.33	Tocris	3344	4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexanol	308.164	O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|	RBZNJGHIKXAKQE-HDJSIYSDSA-N			RBZNJGHIKXAKQE
BRD-K34445261-001-01-4	SLV-320	Phase 2	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	26.62	Tocris	3344	SLV 320	308.164	O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|	RBZNJGHIKXAKQE-HDJSIYSDSA-N			RBZNJGHIKXAKQE
BRD-K70053378-001-02-9	SM-108	Phase 2					0	100.0	Ark	AK-26137	4-hydroxy-1H-imidazole-5-carboxamide	127.038	NC(=O)C1N=CNC1=O |c:4|	PXQCVBRDIZZRGM-UHFFFAOYSA-N	13371802.0		PXQCVBRDIZZRGM
BRD-K70053378-001-01-1	SM-108	Phase 2					0	0.0	Ark	AK-26137		127.038	NC(=O)C1N=CNC1=O |c:4|	PXQCVBRDIZZRGM-UHFFFAOYSA-N	13371802.0		PXQCVBRDIZZRGM
BRD-K06191411-001-02-5	SM-164	Preclinical	XIAP inhibitor	BIRC2|BIRC3|XIAP			0	85.5	MedChemEx	HY-15989	SM-164	1120.67	CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1	LGYDZXNSSLRFJS-IOQQVAQYSA-N	17756618.0		LGYDZXNSSLRFJS
BRD-K06191411-001-01-7	SM-164	Preclinical	XIAP inhibitor	BIRC2|BIRC3|XIAP			0	53.65	MedChemEx	HY-15989	SM-164	1120.67	CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1	LGYDZXNSSLRFJS-IOQQVAQYSA-N	17756618.0		LGYDZXNSSLRFJS
BRD-K00004213-050-01-9	SM-21	Preclinical	sigma receptor antagonist	PGRMC1			0	85.27	Tocris	751	SM-21 maleate	337.144	CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14,16,19,&2:2,r,TLB:22:21:17.18:14.15.20|	WTPAXDRULIZRDJ-ABFRBSLYSA-N			WTPAXDRULIZRDJ
BRD-K08478539-001-13-8	SMER-28	Preclinical	autophagy inducer	SNCA			0	96.8	Tocris	4297	SMER 28	263.006	Brc1ccc2ncnc(NCC=C)c2c1	BCPOLXUSCUFDGE-UHFFFAOYSA-N	1560402.0		BCPOLXUSCUFDGE
BRD-K08478539-001-06-2	SMER-28	Preclinical	autophagy inducer	SNCA			0	100.0	Sigma	S8197	SMER28	263.006	Brc1ccc2ncnc(NCC=C)c2c1	BCPOLXUSCUFDGE-UHFFFAOYSA-N	1560402.0		BCPOLXUSCUFDGE
BRD-K98396737-001-05-9	SMI-4a	Preclinical	Pim kinase inhibitor	PIM1			0	91.18	Tocris	3714	TCS PIM-1 4a	273.007	FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1	NGJLOFCOEOHFKQ-YVMONPNESA-N	1361334.0		NGJLOFCOEOHFKQ
BRD-K00004310-001-01-9	SN-2	Preclinical	transient receptor potential channel agonist	MCOLN3			0	94.95	Tocris	4907	SN 2	255.162	Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9,10,13,15,t:6|	WKLZNTYMDOPBSE-IARIHHJXSA-N			WKLZNTYMDOPBSE
BRD-K89561498-001-03-3	SN-38	Launched	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	0	94.01	Tocris	2684	SN 38	392.137	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	FJHBVJOVLFPMQE-QFIPXVFZSA-N	104842.0		FJHBVJOVLFPMQE
BRD-K89561498-001-02-5	SN-38	Launched	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	0	96.22	Tocris	2684	SN 38	392.137	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	FJHBVJOVLFPMQE-QFIPXVFZSA-N	104842.0		FJHBVJOVLFPMQE
BRD-K89561498-001-04-9	SN-38	Launched	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	0	97.98	Tocris	2684	SN 38	392.137	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	FJHBVJOVLFPMQE-QFIPXVFZSA-N	104842.0		FJHBVJOVLFPMQE
BRD-K89561498-001-01-7	SN-38	Launched	topoisomerase inhibitor	TOP1	oncology	colorectal cancer	0	98.53	Selleck	S4908	SN-38	392.137	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	FJHBVJOVLFPMQE-QFIPXVFZSA-N	104842.0		FJHBVJOVLFPMQE
BRD-K01825672-001-01-9	SN-6	Preclinical	sodium/calcium exchange inhibitor				0	92.27	Tocris	2184	SN-6	402.125	CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|	ZVYIJXLMBWCGHP-RTBURBONSA-N	93088127.0		ZVYIJXLMBWCGHP
BRD-K01825672-001-02-9	SN-6	Preclinical	sodium/calcium exchange inhibitor				0	48.67	Tocris	2184	SN-6	402.125	CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|	ZVYIJXLMBWCGHP-RTBURBONSA-N	93088127.0		ZVYIJXLMBWCGHP
BRD-K01825672-001-04-9	SN-6	Preclinical	sodium/calcium exchange inhibitor				0	49.73	Tocris	2184	SN-6	402.125	CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5,&2:8,r|	ZVYIJXLMBWCGHP-RTBURBONSA-N	93088127.0		ZVYIJXLMBWCGHP
BRD-A67006024-001-05-5	SNAP	Phase 2	nitric oxide donor	PTPN1			1	40.86	Cayman	82250	N-acetyl-3-(nitrososulfanyl)valine	220.052	CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|	MLXCQEWOIZBBDM-YFKPBYRVSA-N			MLXCQEWOIZBBDM
BRD-A67006024-001-04-8	SNAP	Phase 2	nitric oxide donor	PTPN1			1	0.0	Cayman	82250		220.052	CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4,r|	MLXCQEWOIZBBDM-YFKPBYRVSA-N			MLXCQEWOIZBBDM
BRD-A21428877-003-02-7	SNAP-5089	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CACNA1C|CACNA1D			0	64.33	Tocris	2398	SNAP 5089	608.3	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|	FIIXCJGBCCCOQQ-XIFFEERXSA-N	10326374.0		FIIXCJGBCCCOQQ
BRD-A21428877-003-03-9	SNAP-5089	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CACNA1C|CACNA1D			0	65.4	Tocris	2398	SNAP 5089	608.3	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11,c:4,9|	FIIXCJGBCCCOQQ-XIFFEERXSA-N	10326374.0		FIIXCJGBCCCOQQ
BRD-K49702221-003-02-4	SNAP-94847	Preclinical		ADRA1A|DRD2			0	96.02	Tocris	3347	SNAP 94847 hydrochloride	478.243	CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	VMLZFUVIKCGATC-UHFFFAOYSA-N	16756754.0		VMLZFUVIKCGATC
BRD-K49702221-003-01-6	SNAP-94847	Preclinical		ADRA1A|DRD2			0	97.3	Tocris	3347	SNAP 94847 hydrochloride	478.243	CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	VMLZFUVIKCGATC-UHFFFAOYSA-N	16756754.0		VMLZFUVIKCGATC
BRD-K49702221-003-03-9	SNAP-94847	Preclinical		ADRA1A|DRD2			0	96.02	Tocris	3347	SNAP 94847 hydrochloride	478.243	CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	VMLZFUVIKCGATC-UHFFFAOYSA-N	16756754.0		VMLZFUVIKCGATC
BRD-K29546239-001-04-9	SNC-80	Preclinical		OPRD1			0	96.73	Tocris	764	SNC 80	449.304	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	KQWVAUSXZDRQPZ-UMTXDNHDSA-N	123924.0		KQWVAUSXZDRQPZ
BRD-K29546239-001-05-9	SNC-80	Preclinical		OPRD1			0	98.29	Tocris	764	SNC 80	449.304	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	KQWVAUSXZDRQPZ-UMTXDNHDSA-N	123924.0		KQWVAUSXZDRQPZ
BRD-K29546239-001-02-3	SNC-80	Preclinical		OPRD1			0	96.13	Tocris	764	SNC 80	449.304	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	KQWVAUSXZDRQPZ-UMTXDNHDSA-N	123924.0		KQWVAUSXZDRQPZ
BRD-K75016267-001-02-9	SNG-1153	Preclinical	selective estrogen receptor modulator (SERM)	ESR1			0	97.18	MedChemEx	HY-19968	SNG-1153	406.103	CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F	OXHMDMVBLQNMGP-UHFFFAOYSA-N	71621167.0		OXHMDMVBLQNMGP
BRD-K75016267-001-01-7	SNG-1153	Preclinical	selective estrogen receptor modulator (SERM)	ESR1			0	93.39	MedChemEx	HY-19968	SNG-1153	406.103	CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F	OXHMDMVBLQNMGP-UHFFFAOYSA-N	71621167.0		OXHMDMVBLQNMGP
BRD-K71512533-066-03-6	SNS-314	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	96.75	Tocris	4584	SNS 314 mesylate	430.044	Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1	FAYAUAZLLLJJGH-UHFFFAOYSA-N	24995524.0		FAYAUAZLLLJJGH
BRD-K71512533-066-02-8	SNS-314	Phase 1	Aurora kinase inhibitor	AURKA|AURKB|AURKC			0	96.39	Selleck	S1154	SNS-314 Mesylate	430.044	Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1	FAYAUAZLLLJJGH-UHFFFAOYSA-N	24995524.0		FAYAUAZLLLJJGH
BRD-K71281111-001-04-3	SNX-2112	Phase 1	HSP inhibitor				0	97.02	Selleck	S2639	SNX-2112 (PF-04928473)	464.204	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|	ZFVRYNYOPQZKDG-MQMHXKEQSA-N			ZFVRYNYOPQZKDG
BRD-K73197500-001-04-8	SNX-5422	Phase 1/Phase 2	HSP inhibitor	HSP90AA1|HSP90AB1			0	89.48	MedChemEx	HY-10213	PF-04929113	521.225	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|	AVDSOVJPJZVBTC-CTYIDZIISA-N			AVDSOVJPJZVBTC
BRD-K73197500-001-02-2	SNX-5422	Phase 1/Phase 2	HSP inhibitor	HSP90AA1|HSP90AB1			0	80.1	Selleck	S2656	PF-04929113 (SNX-5422)	521.225	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|	AVDSOVJPJZVBTC-CTYIDZIISA-N			AVDSOVJPJZVBTC
BRD-K73197500-001-03-0	SNX-5422	Phase 1/Phase 2	HSP inhibitor	HSP90AA1|HSP90AB1			0	79.62	Selleck	S2656	PF-04929113 (SNX-5422)	521.225	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|	AVDSOVJPJZVBTC-CTYIDZIISA-N			AVDSOVJPJZVBTC
BRD-K85406984-001-03-9	sobetirome	Phase 1/Phase 2	thyroid hormone receptor agonist	THRA|THRB			0	93.88	Tocris	4554	GC 1	328.167	CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	QNAZTOHXCZPOSA-UHFFFAOYSA-N	9862248.0		QNAZTOHXCZPOSA
BRD-K85406984-001-02-8	sobetirome	Phase 1/Phase 2	thyroid hormone receptor agonist	THRA|THRB			0	97.07	Tocris	4554	GC 1	328.167	CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	QNAZTOHXCZPOSA-UHFFFAOYSA-N	9862248.0		QNAZTOHXCZPOSA
BRD-K85406984-001-01-0	sobetirome	Phase 1/Phase 2	thyroid hormone receptor agonist	THRA|THRB			0	97.26	MedChemEx	HY-14823	Sobetirome	328.167	CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	QNAZTOHXCZPOSA-UHFFFAOYSA-N	9862248.0		QNAZTOHXCZPOSA
BRD-K00003174-001-01-9	soblidotin	Phase 2	microtubule inhibitor				0	90.07	MedChemEx	HY-14672	Soblidotin	701.509	[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1	DZMVCVHATYROOS-ZBFGKEHZSA-N	6918315.0		DZMVCVHATYROOS
BRD-K58262380-001-01-0	sobrepin	Launched	mucolytic agent		pulmonary	chest congestion	0	0.0	TCI	S0444		170.131	CC1=CC[C@H](C[C@@H]1O)C(C)(C)O |t:1|	OMDMTHRBGUBUCO-BDAKNGLRSA-N	854498.0		OMDMTHRBGUBUCO
BRD-K87595680-001-05-9	sobuzoxane	Launched	topoisomerase inhibitor		hematologic malignancy	peripheral T-cell lymphoma (PTCL)	0	100.0	Astatech	F52515	[4-[2-[4-(2-METHYLPROPOXYCARBONYLOXYMETHYL)-3,5-DIOXOPIPERAZIN-1-YL]ETHYL]-2,6-DIOXOPIPERAZIN-1-YL]METHYL 2-METHYLPROPYL CARBONATE	514.227	CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	OCOKWVBYZHBHLU-UHFFFAOYSA-N	5233.0		OCOKWVBYZHBHLU
BRD-A67265925-236-01-8	sodium-ascorbate	Launched					1	0.0	Selleck	S4245	Sodium ascorbate	178.048	OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|	SXZYCXMUPBBULW-NEEWWZBLSA-N	6857365.0		SXZYCXMUPBBULW
BRD-A67265925-236-02-6	sodium-ascorbate	Launched					1	0.0	Selleck	S4245	Sodium ascorbate	178.048	OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2,4,&1:8,&2:10|	SXZYCXMUPBBULW-NEEWWZBLSA-N	6857365.0		SXZYCXMUPBBULW
BRD-K05878375-236-05-7	sodium-butyrate	Phase 2	HDAC inhibitor	BCHE|FFAR2|FFAR3|HDAC1|HDAC2|HDAC3|HDAC8			1	0.0	Selleck	S1999	Sodium butyrate	88.052	CCCC(O)=O	FERIUCNNQQJTOY-UHFFFAOYSA-N	264.0		FERIUCNNQQJTOY
BRD-K05878375-236-06-5	sodium-butyrate	Phase 2	HDAC inhibitor	BCHE|FFAR2|FFAR3|HDAC1|HDAC2|HDAC3|HDAC8			1	0.0	Selleck	S1999	Sodium butyrate	88.052	CCCC(O)=O	FERIUCNNQQJTOY-UHFFFAOYSA-N	264.0		FERIUCNNQQJTOY
BRD-A93699261-236-02-6	sodium-danshensu	Preclinical					0	0.0	Selleck	S2401	Sodium Danshensu	198.053	O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|	PAFLSMZLRSPALU-QMMMGPOBSA-N	179536.0		PAFLSMZLRSPALU
BRD-A93699261-236-03-4	sodium-danshensu	Preclinical					0	100.0	Selleck	S2401	Sodium Danshensu	198.053	O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|	PAFLSMZLRSPALU-QMMMGPOBSA-N	179536.0		PAFLSMZLRSPALU
BRD-A93699261-236-04-2	sodium-danshensu	Preclinical					0	0.0	Selleck	S2401	Sodium Danshensu	198.053	O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|	PAFLSMZLRSPALU-QMMMGPOBSA-N	179536.0		PAFLSMZLRSPALU
BRD-M58433298-001-02-4	sodium-dodecyl-sulfate	Launched		ALB			1	98.3	Sigma	74255	sodium dodecyl sulfate	289.145	[Na].CCCCCCCCCCCCOS(O)(=O)=O	ISYOIFGRKUYTGX-UHFFFAOYSA-N			ISYOIFGRKUYTGX
BRD-M58433298-001-01-6	sodium-dodecyl-sulfate	Launched		ALB			1	0.0	Enamine	Z1365432828		289.145	[Na].CCCCCCCCCCCCOS(O)(=O)=O	ISYOIFGRKUYTGX-UHFFFAOYSA-N			ISYOIFGRKUYTGX
BRD-K93201765-236-02-9	sodium-gluconate	Launched					1	0.0	MedChemEx	HY-B1092A	Gluconate (sodium)	196.058	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O	RGHNJXZEOKUKBD-SQOUGZDYSA-N	10690.0		RGHNJXZEOKUKBD
BRD-K93201765-001-01-0	sodium-gluconate	Launched					1	0.0	MicroSource	1300035	SODIUM GLUCONATE	196.058	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O	RGHNJXZEOKUKBD-SQOUGZDYSA-N	10690.0	BRD-M54096567-001-02-7	RGHNJXZEOKUKBD
BRD-K80043866-236-01-1	sodium-gualenate	Launched	antacid		gastroenterology|otolaryngology	peptic ulcer disease (PUD)|pharyngitis	0	99.62	AKSci	R239		278.098	CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O	VIZXMHCBZLGUET-UHFFFAOYSA-N	2275.0		VIZXMHCBZLGUET
BRD-K99308954-304-03-2	sodium-monofluorophosphate	Launched		PYGM	dental	cavities	1	0.0	MicroSource	1506192	SODIUM MONOFLUOROPHOSPHATE	99.973	OP(O)(F)=O	DWYMPOCYEZONEA-UHFFFAOYSA-N	24267.0		DWYMPOCYEZONEA
BRD-K99308954-304-02-4	sodium-monofluorophosphate	Launched		PYGM	dental	cavities	1	0.0	Selleck	S4013	Sodium Monofluorophosphate	99.973	OP(O)(F)=O	DWYMPOCYEZONEA-UHFFFAOYSA-N	24267.0		DWYMPOCYEZONEA
BRD-K99308954-304-04-0	sodium-monofluorophosphate	Launched		PYGM	dental	cavities	1	0.0	Selleck	S4013	Sodium Monofluorophosphate	99.973	OP(O)(F)=O	DWYMPOCYEZONEA-UHFFFAOYSA-N	24267.0		DWYMPOCYEZONEA
BRD-K61230716-236-02-7	sodium-nitrite	Launched	nitric oxide donor		critical care	poison antidote|cyanide poisoning	1	0.0	Selleck	S4074	Sodium Nitrite	45.993	[O-][NH2+][O-]	ROODZSDSPAHHIS-UHFFFAOYSA-N	129009887.0		ROODZSDSPAHHIS
BRD-K61230716-236-03-5	sodium-nitrite	Launched	nitric oxide donor		critical care	poison antidote|cyanide poisoning	1	0.0	Selleck	S4074	Sodium Nitrite	45.993	[O-][NH2+][O-]	ROODZSDSPAHHIS-UHFFFAOYSA-N	129009887.0		ROODZSDSPAHHIS
BRD-K00003606-380-01-9	sodium-nitroprusside	Launched	nitric oxide donor		cardiology	hypertension|congestive heart failure	0	94.4	MedChemEx	HY-A0119	Nitroprusside (disodium dihydrate)	215.948	[O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N	WTISQLWAPBSCSF-UHFFFAOYSA-N			WTISQLWAPBSCSF
BRD-K60600693-314-02-4	sodium-orthovanadate	Preclinical					1	5.51	Selleck	S2000	Sodium orthovanadate	117.947	O[V](O)(O)=O	WQEVDHBJGNOKKO-UHFFFAOYSA-K	417214.0		WQEVDHBJGNOKKO
BRD-K60600693-314-03-2	sodium-orthovanadate	Preclinical					1	0.0	Selleck	S2000	Sodium orthovanadate	117.947	O[V](O)(O)=O	WQEVDHBJGNOKKO-UHFFFAOYSA-K	417214.0		WQEVDHBJGNOKKO
BRD-K77251551-304-03-9	sodium-picosulfate	Launched			gastroenterology	constipation	0	94.85	MedChemEx	HY-B0544	Sodium Picosulfate	437.024	OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1	UJIDKYTZIQTXPM-UHFFFAOYSA-N	5243.0		UJIDKYTZIQTXPM
BRD-K77251551-304-02-9	sodium-picosulfate	Launched			gastroenterology	constipation	0	91.14	Selleck	S4020	Sodium Picosulfate	437.024	OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1	UJIDKYTZIQTXPM-UHFFFAOYSA-N	5243.0		UJIDKYTZIQTXPM
BRD-K00003543-412-01-9	sodium-stibogluconate	Launched	tyrosine phosphatase inhibitor	PTPN6	infectious disease	leishmaniasis	0	0.0	MedChemEx	HY-100595	Stibogluconate (sodium)	677.878	[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO	RPOBPHCDIPHDQL-XCCFGPONSA-L			RPOBPHCDIPHDQL
BRD-K84798689-236-02-9	sodium-tanshinone-II-A-sulfonate	Phase 2	potassium channel activator				0	93.63	Ark	AK128306		374.082	Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O	UJCACMLMPLLRGW-UHFFFAOYSA-N	125782.0		UJCACMLMPLLRGW
BRD-A55664972-236-02-6	sodium-tetradecyl-sulfate	Launched		PROC	dermatology	varicose veins	0	98.56	MicroSource	1300042	SODIUM TETRADECYL SULFATE	294.186	CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4,&2:9|	GROJOWHVXQYQGN-KGLIPLIRSA-N	51382662.0		GROJOWHVXQYQGN
BRD-K01039503-001-01-2	sofalcone	Launched	mucus protecting agent	CBR1	gastroenterology	peptic ulcer disease (PUD)	0	97.31	Cayman	11882		450.204	CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1	GFWRVVCDTLRWPK-KPKJPENVSA-N	5282219.0		GFWRVVCDTLRWPK
BRD-K00026984-001-02-9	sofosbuvir	Launched	HCV inhibitor		infectious disease	hepatitis C|hepatitis C	0	93.26	MedChemEx	HY-15005	Sofosbuvir	529.163	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	TTZHDVOVKQGIBA-IQWMDFIBSA-N	45375808.0	BRD-K05674516-001-02-5	TTZHDVOVKQGIBA
BRD-K00003527-001-01-9	sofosbuvir-impurity-m	Preclinical	antiviral				0	95.1	MedChemEx	HY-I0735	Sofosbuvir impurity M	527.167	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1	WAKQLZVLNOKKHE-BFQGEBBDSA-N	131704521.0		WAKQLZVLNOKKHE
BRD-K00004608-001-01-9	sograzepide	Phase 2	gastrin inhibitor				0	63.93	MedChemEx	HY-14850	Sograzepide	498.238	CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1 |t:12|	YDZYKNJZCVIKPP-VWLOTQADSA-N	9870520.0		YDZYKNJZCVIKPP
BRD-A65562236-001-01-2	solamargine	Phase 3	apoptosis inhibitor				0	100.0	MedChemEx	HY-N0069	Solamargine	867.498	C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1,&2:2,&3:3,&4:5,&5:6,&6:11,&7:14,&8:16,&9:19,&10:22,&11:24,&12:27,&13:29,&14:31,&15:33,&16:35,&17:37,&18:39,&19:41,&20:43,&21:45,&22:47,&23:49,&24:51,&25:54,&26:57,r,t:8|	MBWUSSKCCUMJHO-OXBNUUDKSA-N			MBWUSSKCCUMJHO
BRD-K69215269-001-01-1	solcitinib	Phase 1	JAK inhibitor	JAK1			0	97.64	MedChemEx	HY-16755	Solcitinib	389.185	CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12	MPYACSQFXVMWNO-UHFFFAOYSA-N	44603362.0		MPYACSQFXVMWNO
BRD-K00003600-001-01-9	solifenacin-succinate	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence|urinary frequency	0	97.25	MedChemEx	HY-A0034	Solifenacin	362.199	[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1	FBOUYBDGKBSUES-VXKWHMMOSA-N	154059.0		FBOUYBDGKBSUES
BRD-K32256160-001-01-9	solithromycin	Phase 3	protein synthesis inhibitor				0	96.7	MedChemEx	HY-17593	Solithromycin	844.475	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC	IXXFZUPTQVDPPK-ALZZPGSQSA-N			IXXFZUPTQVDPPK
BRD-K00004707-001-01-9	solriamfetol	Launched	dopamine reuptake inhibitor		neurology/psychiatry	narcolepsy	0	84.07	AMS	Q69522	(R)-2-amino-3-phenylpropyl carbamate	194.106	N[C@@H](COC(N)=O)Cc1ccccc1	UCTRAOBQFUDCSR-SECBINFHSA-N	10130337.0		UCTRAOBQFUDCSR
BRD-K85764479-003-01-0	somantadine	Phase 1	antiviral				0	97.8	ChemBridge	4102463	1-((3r,5r,7r)-adamantan-1-yl)-2-methylpropan-2-amine hydrochloride	207.199	CC(C)(N)CC12CC3CC(CC(C3)C1)C2	OWKXRDQRMTVCEX-UHFFFAOYSA-N	50234.0		OWKXRDQRMTVCEX
BRD-K14681867-001-01-6	somatostatin	Launched	somatostatin receptor agonist	OPRD1|OPRM1|SSTR1|SSTR2|SSTR3|SSTR4|SSTR5	hematology	hemorrhage	0	82.44	Key	HS-2027	(4R,10S,13S,16S,19S,22S,25S,28S,31S,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[({[(2S)-2-aminopropanoyl]amino}acetyl)amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydro;xymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,	1636.717	C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	NHXLMOGPVYXJNR-FMFSXUEQSA-N			NHXLMOGPVYXJNR
BRD-K14681867-001-02-9	somatostatin	Launched	somatostatin receptor agonist	OPRD1|OPRM1|SSTR1|SSTR2|SSTR3|SSTR4|SSTR5	hematology	hemorrhage	0	70.37	Key	HS-2027	(4R,10S,13S,16S,19S,22S,25S,28S,31S,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[({[(2S)-2-aminopropanoyl]amino}acetyl)amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydro	1636.717	C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	NHXLMOGPVYXJNR-FMFSXUEQSA-N			NHXLMOGPVYXJNR
BRD-K69857269-001-03-9	sonepiprazole	Phase 2	dopamine receptor antagonist				0	92.91	Sigma	PZ0174	4-(4-{2-[(1S)-3,4-dihydro-1H-2-benzopyran-1-yl]ethyl}-1-piperazinyl)benzenesulfonamide	401.177	NS(=O)(=O)c1ccc(cc1)N1CCN(CC[C@@H]2OCCc3ccccc23)CC1	WNUQCGWXPNGORO-NRFANRHFSA-N	133079.0		WNUQCGWXPNGORO
BRD-K19796430-001-05-6	sonidegib	Launched	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	0	89.4	Selleck	S2151	LDE225 (NVP-LDE225,Erismodegib)	485.193	C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1	VZZJRYRQSPEMTK-CALCHBBNSA-N	24775005.0		VZZJRYRQSPEMTK
BRD-K19796430-001-09-8	sonidegib	Launched	smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	0	95.51	Selleck	S2151	LDE225 (NVP-LDE225, Erismodegib)	485.193	C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1	VZZJRYRQSPEMTK-CALCHBBNSA-N	24775005.0		VZZJRYRQSPEMTK
BRD-K66845263-001-03-0	sophocarpine	Phase 3					0	96.27	Vitas-M	STK801894	13,14-didehydromatridin-15-one	246.173	O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|	AAGFPTSOPGCENQ-JLNYLFASSA-N	115269.0		AAGFPTSOPGCENQ
BRD-K66845263-001-04-8	sophocarpine	Phase 3					0	1.87	Selleck	S2405	Sophocarpine	246.173	O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|	AAGFPTSOPGCENQ-JLNYLFASSA-N	115269.0	BRD-K10999968-001-01-4	AAGFPTSOPGCENQ
BRD-K66845263-001-02-2	sophocarpine	Phase 3					0	0.0	Selleck	S2405	Sophocarpine	246.173	O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|	AAGFPTSOPGCENQ-JLNYLFASSA-N	115269.0		AAGFPTSOPGCENQ
BRD-K23984367-075-15-2	sorafenib	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)	0	98.3	Selleck	S1040	Sorafenib Tosylate	464.086	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1	MLDQJTXFUGDVEO-UHFFFAOYSA-N	216239.0		MLDQJTXFUGDVEO
BRD-K23984367-001-07-5	sorafenib	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET	oncology	renal cell carcinoma (RCC)|thyroid cancer|hepatocellular carcinoma (HCC)	0	97.97	Selleck	S7397	Sorafenib	464.086	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1	MLDQJTXFUGDVEO-UHFFFAOYSA-N	216239.0		MLDQJTXFUGDVEO
BRD-K00004585-001-01-9	soraprazan	Preclinical	proton pump inhibitor				0	94.94	MedChemEx	HY-100414	Soraprazan	367.19	COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c(C)c(C)nc21)c1ccccc1	PWILYDZRJORZDR-MISYRCLQSA-N	213054.0		PWILYDZRJORZDR
BRD-K88734090-001-07-9	sorbic-acid	Launched					0	0.0	Sigma	MFCD00002703	Sorbic acid	112.052	C\C=C\C=C\C(O)=O	WSWCOQWTEOXDQX-MQQKCMAXSA-N	643460.0		WSWCOQWTEOXDQX
BRD-A89164055-001-04-9	sorbinil	Phase 3	aldose reductase inhibitor	AKR1B1			0	0.0	Sigma	MFCD01569247	6-FLUORO-4-CHROMANONE HYDANTOIN	236.06	Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|	LXANPKRCLVQAOG-NSHDSACASA-N	337359.0		LXANPKRCLVQAOG
BRD-A89164055-001-03-3	sorbinil	Phase 3	aldose reductase inhibitor	AKR1B1			0	98.08	Key	FS-1063		236.06	Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8,r|	LXANPKRCLVQAOG-NSHDSACASA-N	337359.0		LXANPKRCLVQAOG
BRD-A70197423-001-01-3	sorbitan-monostearate	Preclinical					0	0.0	InterBioScreen	STOCK1N-15360		430.329	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|	HVUMOYIDDBPOLL-XWVZOOPGSA-N	16218600.0		HVUMOYIDDBPOLL
BRD-A70197423-001-02-9	sorbitan-monostearate	Preclinical					0	27.6	InterBioScreen	STOCK1N-15360	(R)-2-((2R,3R,4S)-3,4-dihydroxytetrahydrofuran-2-yl)-2-hydroxyethyl stearate	430.329	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23,26,28,&1:21|	HVUMOYIDDBPOLL-XWVZOOPGSA-N	16218600.0		HVUMOYIDDBPOLL
BRD-K66035042-001-15-9	sorbitol	Launched	mucolytic agent		gastroenterology	constipation	0	100.0	MedChemEx	HY-B0400	D-Sorbitol	182.079	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-JGWLITMVSA-N	5780.0		FBPFZTCFMRRESA
BRD-K66035042-001-11-9	sorbitol	Launched	mucolytic agent		gastroenterology	constipation	0	100.0	MicroSource	1300028	MANNITOL	182.079	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-JGWLITMVSA-N	5780.0		FBPFZTCFMRRESA
BRD-K66035042-001-10-1	sorbitol	Launched	mucolytic agent		gastroenterology	constipation	0	100.0	Selleck	S2393	Sorbitol	182.079	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-JGWLITMVSA-N	5780.0		FBPFZTCFMRRESA
BRD-K66035042-001-14-3	sorbitol	Launched	mucolytic agent		gastroenterology	constipation	0	0.0	Selleck	S2393	SORBITOL	182.079	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	FBPFZTCFMRRESA-JGWLITMVSA-N	5780.0		FBPFZTCFMRRESA
BRD-K05850076-001-01-5	sotagliflozin	Phase 3	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2			0	95.58	MedChemEx	HY-15516	LX-4211	424.111	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1	QKDRXGFQVGOQKS-CRSSMBPESA-N	24831714.0		QKDRXGFQVGOQKS
BRD-K05850076-001-02-9	sotagliflozin	Phase 3	sodium/glucose cotransporter inhibitor	SLC5A1|SLC5A2			0	95.34	MedChemEx	HY-15516	Sotagliflozin	424.111	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1	QKDRXGFQVGOQKS-CRSSMBPESA-N	24831714.0		QKDRXGFQVGOQKS
BRD-A33168282-003-18-0	sotalol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|KCNH2	cardiology	atrial fibrillation (AF)|ventricular arrhythmias	0	98.92	MicroSource	1506043	SOTALOL HYDROCHLORIDE	272.119	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	ZBMZVLHSJCTVON-UHFFFAOYSA-N	67108155.0		ZBMZVLHSJCTVON
BRD-A33168282-003-16-4	sotalol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|KCNH2	cardiology	atrial fibrillation (AF)|ventricular arrhythmias	0	95.35	Selleck	S2509	Sotalol	272.119	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	ZBMZVLHSJCTVON-UHFFFAOYSA-N	67108155.0		ZBMZVLHSJCTVON
BRD-A33168282-003-17-2	sotalol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2|KCNH2	cardiology	atrial fibrillation (AF)|ventricular arrhythmias	0	98.02	Tocris	952	Sotalol hydrochloride	272.119	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	ZBMZVLHSJCTVON-UHFFFAOYSA-N	67108155.0		ZBMZVLHSJCTVON
BRD-K16761703-001-05-9	sotrastaurin	Phase 2	PKC inhibitor	PRKCA|PRKCB|PRKCD|PRKCE|PRKCH|PRKCQ			0	98.9	MedChemEx	HY-10343	Sotrastaurin	438.18	CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	10296883.0		OAVGBZOFDPFGPJ
BRD-K16761703-001-03-8	sotrastaurin	Phase 2	PKC inhibitor	PRKCA|PRKCB|PRKCD|PRKCE|PRKCH|PRKCQ			0	96.57	Selleck	S2791	Sotrastaurin	438.18	CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|	OAVGBZOFDPFGPJ-UHFFFAOYSA-N	10296883.0		OAVGBZOFDPFGPJ
BRD-K71900389-001-01-9	SP-100030	Preclinical	NFkB pathway inhibitor	JUN|NFKB1			0	62.11	Tocris	5309	SP 100030	436.998	FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F	GHMKQBWHPQMXSH-UHFFFAOYSA-N	9910975.0		GHMKQBWHPQMXSH
BRD-K71900389-001-02-9	SP-100030	Preclinical	NFkB pathway inhibitor	JUN|NFKB1			0	83.3	Tocris	5309	SP 100030	436.998	FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F	GHMKQBWHPQMXSH-UHFFFAOYSA-N	9910975.0		GHMKQBWHPQMXSH
BRD-K28571773-001-01-6	SP-141	Preclinical	ubiquitin ligase inhibitor	MDM2			0	96.64	Tocris	5332	SP 141	324.126	COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12	AABFWJDLCCDJJN-UHFFFAOYSA-N	59620153.0		AABFWJDLCCDJJN
BRD-K28571773-001-02-9	SP-141	Preclinical	ubiquitin ligase inhibitor	MDM2			0	97.08	Tocris	5332	SP 141	324.126	COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12	AABFWJDLCCDJJN-UHFFFAOYSA-N	59620153.0		AABFWJDLCCDJJN
BRD-K23005288-001-01-8	SP-420	Phase 1					0	85.18	MedChemEx	HY-16912	SP-420	355.109	COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|	YASYAEVZKXPYIZ-MRXNPFEDSA-N	135511704.0		YASYAEVZKXPYIZ
BRD-K68405354-001-07-2	spaglumic-acid	Launched	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis|allergic rhinitis	0	98.11	Prestwick	Prestw-1091	Spaglumic acid	304.091	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	OPVPGKGADVGKTG-BQBZGAKWSA-N	188803.0	BRD-K96659869-001-09-4	OPVPGKGADVGKTG
BRD-K68405354-001-08-0	spaglumic-acid	Launched	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis|allergic rhinitis	0	82.3	Enzo	ALX-151-020-M010	N-acetyl-Asp-Glu-OH	304.091	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	OPVPGKGADVGKTG-BQBZGAKWSA-N	188803.0		OPVPGKGADVGKTG
BRD-K68405354-001-06-4	spaglumic-acid	Launched	glutamate receptor antagonist	GRM3	allergy	allergic conjunctivitis|allergic rhinitis	0	80.26	Tocris	391	Spaglumic acid	304.091	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	OPVPGKGADVGKTG-BQBZGAKWSA-N	188803.0		OPVPGKGADVGKTG
BRD-K07612980-001-08-9	sparfloxacin	Withdrawn	bacterial DNA gyrase inhibitor	TOP2A			0	96.86	MedChemEx	HY-B0308	Sparfloxacin	392.166	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	DZZWHBIBMUVIIW-DTORHVGOSA-N	6956367.0		DZZWHBIBMUVIIW
BRD-K07612980-001-07-9	sparfloxacin	Withdrawn	bacterial DNA gyrase inhibitor	TOP2A			0	91.04	MicroSource	1502338	SPARFLOXACIN	392.166	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	DZZWHBIBMUVIIW-DTORHVGOSA-N	6956367.0	BRD-A26423207-001-01-0	DZZWHBIBMUVIIW
BRD-K07612980-001-04-6	sparfloxacin	Withdrawn	bacterial DNA gyrase inhibitor	TOP2A			0	82.32	Selleck	S1884	Sparfloxacin	392.166	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	DZZWHBIBMUVIIW-DTORHVGOSA-N	6956367.0		DZZWHBIBMUVIIW
BRD-K07612980-001-05-3	sparfloxacin	Withdrawn	bacterial DNA gyrase inhibitor	TOP2A			0	91.61	Selleck	S1884	Sparfloxacin	392.166	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	DZZWHBIBMUVIIW-DTORHVGOSA-N	6956367.0		DZZWHBIBMUVIIW
BRD-A81539525-433-01-5	sparfosate	Phase 3	aspartate carbamoyltransferase inhibitor	CA2|CA4			0	0.0	AMS	A001089261	lithium (2-phosphonatoacetyl)aspartate	255.014	OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|	ZZKNRXZVGOYGJT-GSVOUGTGSA-N	46936683.0		ZZKNRXZVGOYGJT
BRD-K00003253-001-01-9	sparsentan	Phase 3	angiotensin receptor antagonist				0	96.98	MedChemEx	HY-17621	Sparsentan	592.272	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C |t:4|	WRFHGDPIDHPWIQ-UHFFFAOYSA-N	10257882.0		WRFHGDPIDHPWIQ
BRD-K38203080-001-01-2	sparteine-(+)	Launched					0	93.7	Oakwood	361994	(+)-Sparteine	234.21	C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-TUVASFSCSA-N	7014.0		SLRCCWJSBJZJBV
BRD-K86872788-065-01-5	sparteine-(-)	Launched					0	100.0	Oakwood	99249	(-)-Sparteine sulfate	234.21	C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-ZQDZILKHSA-N	644020.0		SLRCCWJSBJZJBV
BRD-K32847234-065-04-6	sparteine-sulfate	Launched					0	100.0	MicroSource	300548	SPARTEINE SULFATE	234.21	C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	SLRCCWJSBJZJBV-NMWPEEMBSA-N	442965.0		SLRCCWJSBJZJBV
BRD-K84964099-001-03-9	spautin-1	Preclinical	deubiquitinase inhibitor	USP10|USP13			0	98.0	Tocris	5197	Spautin 1	271.092	Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1	AWIVHRPYFSSVOG-UHFFFAOYSA-N	51037431.0		AWIVHRPYFSSVOG
BRD-K84964099-001-02-9	spautin-1	Preclinical	deubiquitinase inhibitor	USP10|USP13			0	93.94	Tocris	5197	Spautin 1	271.092	Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1	AWIVHRPYFSSVOG-UHFFFAOYSA-N	51037431.0		AWIVHRPYFSSVOG
BRD-K11905747-300-11-3	spectinomycin	Launched	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis|chronic respiratory disease	0	0.0	MedChemEx	HY-B0438	Spectinomycin (dihydrochloride)	332.158	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	UNFWWIHTNXNPBV-WXKVUWSESA-N	15541.0		UNFWWIHTNXNPBV
BRD-K11905747-300-10-5	spectinomycin	Launched	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis|chronic respiratory disease	0	0.0	MedChemEx	HY-B0438	Spectinomycin (dihydrochloride)	332.158	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	UNFWWIHTNXNPBV-WXKVUWSESA-N	15541.0		UNFWWIHTNXNPBV
BRD-K11905747-300-09-7	spectinomycin	Launched	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis|chronic respiratory disease	0	68.33	Selleck	S2510	Spectinomycin  hydrochloride	332.158	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	UNFWWIHTNXNPBV-WXKVUWSESA-N	15541.0		UNFWWIHTNXNPBV
BRD-K11905747-300-08-9	spectinomycin	Launched	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis|chronic respiratory disease	0	0.0	MicroSource	1500538	SPECTINOMYCIN HYDROCHLORIDE	332.158	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	UNFWWIHTNXNPBV-WXKVUWSESA-N	15541.0		UNFWWIHTNXNPBV
BRD-K11905747-300-12-1	spectinomycin	Launched	bacterial 30S ribosomal subunit inhibitor		pulmonary	airsacculitis|chronic respiratory disease	0	0.0	Selleck	S2510	Spectinomycin HCl	332.158	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	UNFWWIHTNXNPBV-WXKVUWSESA-N	15541.0	BRD-K38300715-300-01-5	UNFWWIHTNXNPBV
BRD-K40438880-305-06-6	spermidine	Preclinical	glutamate receptor modulator	KCNJ4|TXNRD1			0	100.0	Tocris	959	Spermidine trihydrochloride	145.158	NCCCCNCCCN	ATHGHQPFGPMSJY-UHFFFAOYSA-N	1102.0		ATHGHQPFGPMSJY
BRD-K18375018-376-02-3	spermine	Preclinical		CA14|CA4|CA6|CA9|CASR|GRIN1|GRIN2A|KCNJ4|ODC1|SMOX|SMS|TRPM4|TRPM5			0	100.0	Enzo	AC412	Spermine 4HCl	202.216	NCCCNCCCCNCCCN	PFNFFQXMRSDOHW-UHFFFAOYSA-N	1103.0		PFNFFQXMRSDOHW
BRD-K01825110-001-02-9	sphingosylphosphorylcholine	Preclinical	gene expression stimulant	GPR12			0	100.0	EMDBio	567735-10MG	Sphingosylphosphoryl-choline	465.346	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15,17,&1:21|	JLVSPVFPBBFMBE-HXSWCURESA-O	5280613.0		JLVSPVFPBBFMBE
BRD-K55468218-001-26-1	spiperone	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7	neurology/psychiatry	schizophrenia	0	96.07	MicroSource	1501152	SPIPERONE	395.201	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1	DKGZKTPJOSAWFA-UHFFFAOYSA-N	5265.0		DKGZKTPJOSAWFA
BRD-K55468218-003-02-8	spiperone	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|ADRA1D|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7	neurology/psychiatry	schizophrenia	0	92.97	Tocris	995	Spiperone hydrochloride	395.201	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1	DKGZKTPJOSAWFA-UHFFFAOYSA-N	5265.0		DKGZKTPJOSAWFA
BRD-K28192623-066-08-1	spiradoline	Phase 2	opioid receptor agonist	OPRK1			0	97.66	Enzo	AC771	U-62066	424.168	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	NYKCGQQJNVPOLU-ONTIZHBOSA-N	55652.0		NYKCGQQJNVPOLU
BRD-K28192623-001-01-3	spiradoline	Phase 2	opioid receptor agonist	OPRK1			0	98.15	Sigma	U105-25MG	U-62066	424.168	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	NYKCGQQJNVPOLU-ONTIZHBOSA-N	55652.0		NYKCGQQJNVPOLU
BRD-K00003542-001-01-9	spiramycin	Launched	bacterial 50S ribosomal subunit inhibitor		infectious disease	toxoplasmosis|soft tissue infection	0	87.58	MedChemEx	HY-100593	Spiramycin	842.514	CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C |t:12,14|	ACTOXUHEUCPTEW-VTGPZPQGSA-N			ACTOXUHEUCPTEW
BRD-K96684644-300-01-7	spirobromin	Phase 1					0	0.0	MatrixSci	59769		494.089	BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2	JXEICPOBKSQAIU-UHFFFAOYSA-N	72115.0		JXEICPOBKSQAIU
BRD-K90027355-001-16-6	spironolactone	Launched	mineralocorticoid receptor antagonist	AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia	0	72.42	Tocris	2968	Spironolactone	416.202	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	LXMSZDCAJNLERA-ZHYRCANASA-N	5833.0		LXMSZDCAJNLERA
BRD-K90027355-001-21-9	spironolactone	Launched	mineralocorticoid receptor antagonist	AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia	0	90.24	Tocris	2968	Spironolactone	416.202	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	LXMSZDCAJNLERA-ZHYRCANASA-N	5833.0		LXMSZDCAJNLERA
BRD-K90027355-001-19-0	spironolactone	Launched	mineralocorticoid receptor antagonist	AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia	0	95.91	MicroSource	1500539	SPIRONOLACTONE	416.202	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	LXMSZDCAJNLERA-ZHYRCANASA-N	5833.0	BRD-A97808748-001-03-8	LXMSZDCAJNLERA
BRD-K90027355-001-20-8	spironolactone	Launched	mineralocorticoid receptor antagonist	AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia	0	89.92	Selleck	S4054	Spironolactone	416.202	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	LXMSZDCAJNLERA-ZHYRCANASA-N	5833.0	BRD-A71422083-001-15-5|BRD-K30171400-001-01-2	LXMSZDCAJNLERA
BRD-K90027355-001-13-3	spironolactone	Launched	mineralocorticoid receptor antagonist	AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG	endocrinology|cardiology|gastroenterology|rheumatology	hyperaldosteronism|congestive heart failure|hepatic cirrhosis|nephrotic syndrome|hypertension|hypokalemia	0	98.19	Selleck	S4054	spironolactone	416.202	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	LXMSZDCAJNLERA-ZHYRCANASA-N	5833.0		LXMSZDCAJNLERA
BRD-A72483914-001-05-9	spiroxatrine	Preclinical	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A|HTR2B			0	91.09	Tocris	631	Spiroxatrine	379.19	O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|	JVGBTTIJPBFLTE-SFHVURJKSA-N	6603993.0		JVGBTTIJPBFLTE
BRD-A72483914-001-03-7	spiroxatrine	Preclinical	serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A|HTR2B			0	91.05	Tocris	631	Spiroxatrine	379.19	O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16,r|	JVGBTTIJPBFLTE-SFHVURJKSA-N	6603993.0		JVGBTTIJPBFLTE
BRD-K94934625-001-01-5	spizofurone	Withdrawn					0	97.9	Sigma	PH011174	5-acetyl-3H-spiro[benzofuran-2,1'-cyclopropan]-3-one	202.063	CC(=O)c1ccc2OC3(CC3)C(=O)c2c1	SETMGIIITGNLAS-UHFFFAOYSA-N	71755.0		SETMGIIITGNLAS
BRD-K27710560-001-07-5	splitomycin	Preclinical	SIRT inhibitor	SIRT1			0	38.94	Tocris	1542	Splitomicin	198.068	O=C1CCc2c(O1)ccc1ccccc21	ISFPDBUKMJDAJH-UHFFFAOYSA-N	5269.0		ISFPDBUKMJDAJH
BRD-K19203487-001-01-4	SPP301	Phase 3	endothelin receptor antagonist	EDNRA			0	99.69	MedChemEx	HY-15195	Avosentan	479.126	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1	YBWLTKFZAOSWSM-UHFFFAOYSA-N	9912992.0		YBWLTKFZAOSWSM
BRD-K63253858-001-02-9	SPP86	Preclinical	receptor tyrosine protein kinase inhibitor	RET			0	96.2	Tocris	5391	SPP 86	277.133	CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12	JQOIRTDBHMDWMT-UHFFFAOYSA-N	66549796.0		JQOIRTDBHMDWMT
BRD-K63253858-001-01-5	SPP86	Preclinical	receptor tyrosine protein kinase inhibitor	RET			0	98.51	Tocris	5391	SPP 86	277.133	CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12	JQOIRTDBHMDWMT-UHFFFAOYSA-N	66549796.0		JQOIRTDBHMDWMT
BRD-A08772153-001-01-6	SQ-109	Phase 3	bacterial cell wall synthesis inhibitor	FDFT1			0	55.38	MedChemEx	HY-14989	SQ109	330.303	CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|	JFIBVDBTCDTBRH-UNRAVDGJSA-N			JFIBVDBTCDTBRH
BRD-A08772153-001-02-4	SQ-109	Phase 3	bacterial cell wall synthesis inhibitor	FDFT1			0	97.97	MedChemEx	HY-14989	SQ109	330.303	CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|	JFIBVDBTCDTBRH-UNRAVDGJSA-N			JFIBVDBTCDTBRH
BRD-A56987319-001-13-7	SQ-22536	Preclinical	adenylyl cyclase inhibitor	ADCY1			0	96.17	Tocris	1435	SQ 22536	205.096	Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|	UKHMZCMKHPHFOT-ZCFIWIBFSA-N	22879197.0		UKHMZCMKHPHFOT
BRD-A56987319-001-12-9	SQ-22536	Preclinical	adenylyl cyclase inhibitor	ADCY1			0	98.05	Tocris	1435	SQ 22536	205.096	Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10,r|	UKHMZCMKHPHFOT-ZCFIWIBFSA-N	22879197.0		UKHMZCMKHPHFOT
BRD-K00003215-043-01-9	squalamine	Phase 3	antiviral				0	94.7	MedChemEx	HY-16467	Squalamine lactate	627.464	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	UIRKNQLZZXALBI-MSVGPLKSSA-N	72495.0		UIRKNQLZZXALBI
BRD-K00004684-001-01-9	squaric-acid-dibutyl-ester	Preclinical	oxidative stress inducer				0	0.0	AMS	A294391	3,4-dibutoxy-3-cyclobutene-1,2-dione	226.121	CCCCOc1c(OCCCC)c(=O)c1=O	XBRWELTXMQSEIN-UHFFFAOYSA-N	65108.0		XBRWELTXMQSEIN
BRD-K26501486-001-02-9	SR-1078	Preclinical	retinoid receptor agonist	RORA|RORC			0	93.79	Tocris	4874	SR 1078	431.057	OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F	DUXWIYXHHGNUJU-UHFFFAOYSA-N	17980288.0		DUXWIYXHHGNUJU
BRD-K26501486-001-01-3	SR-1078	Preclinical	retinoid receptor agonist	RORA|RORC			0	90.05	Tocris	4874	SR 1078	431.057	OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F	DUXWIYXHHGNUJU-UHFFFAOYSA-N	17980288.0		DUXWIYXHHGNUJU
BRD-K16229414-001-02-9	SR-11302	Preclinical					0	64.05	Tocris	2476	SR-11302	376.24	C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|	RQANARBNMTXCDM-DKOHIBGUSA-N	9976842.0		RQANARBNMTXCDM
BRD-K16229414-001-01-0	SR-11302	Preclinical					0	0.0	Tocris	2476	SR 11302	376.24	C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|	RQANARBNMTXCDM-DKOHIBGUSA-N	9976842.0		RQANARBNMTXCDM
BRD-K60931454-003-01-3	SR-140333	Phase 2	neurokinin receptor antagonist	TACR1			0	94.45	Tocris	4012	SR 140333	619.286	CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1	RPDFDSQFBCJTDY-GAQXSTBRSA-N	108167.0		RPDFDSQFBCJTDY
BRD-K60931454-003-02-9	SR-140333	Phase 2	neurokinin receptor antagonist	TACR1			0	93.26	Tocris	4012	SR 140333	619.286	CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1	RPDFDSQFBCJTDY-GAQXSTBRSA-N	108167.0		RPDFDSQFBCJTDY
BRD-K62814487-001-03-0	SR-1664	Preclinical	PPAR receptor ligand	PPARG			0	94.36	Tocris	4409	SR 1664	547.211	C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O	IIJDFXNUWZTHIM-NRFANRHFSA-N	53239854.0		IIJDFXNUWZTHIM
BRD-K62814487-001-04-8	SR-1664	Preclinical	PPAR receptor ligand	PPARG			0	90.93	Sigma	SML0636	SR1664	547.211	C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O	IIJDFXNUWZTHIM-NRFANRHFSA-N	53239854.0		IIJDFXNUWZTHIM
BRD-K11641193-001-03-9	SR-2211	Preclinical	retinoid receptor inverse agonist	RORC			0	95.83	Tocris	4869	SR 2211	527.181	OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F	KVHKWAZUPPBMLL-UHFFFAOYSA-N	51035449.0		KVHKWAZUPPBMLL
BRD-K11641193-001-02-6	SR-2211	Preclinical	retinoid receptor inverse agonist	RORC			0	92.59	Tocris	4869	SR 2211	527.181	OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F	KVHKWAZUPPBMLL-UHFFFAOYSA-N	51035449.0		KVHKWAZUPPBMLL
BRD-K62562723-003-03-5	SR-2640	Phase 2	leukotriene receptor antagonist	CYSLTR1			0	94.07	Tocris	1804	SR 2640 hydrochloride	370.132	OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	LMPZHLXYBWGGNT-UHFFFAOYSA-N	128355.0		LMPZHLXYBWGGNT
BRD-K62562723-003-08-9	SR-2640	Phase 2	leukotriene receptor antagonist	CYSLTR1			0	95.08	Tocris	1804	SR 2640 hydrochloride	370.132	OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	LMPZHLXYBWGGNT-UHFFFAOYSA-N	128355.0		LMPZHLXYBWGGNT
BRD-K62562723-003-02-7	SR-2640	Phase 2	leukotriene receptor antagonist	CYSLTR1			0	90.01	Tocris	1804	SR 2640 hydrochloride	370.132	OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	LMPZHLXYBWGGNT-UHFFFAOYSA-N	128355.0		LMPZHLXYBWGGNT
BRD-K35629949-001-03-8	SR-27897	Phase 2	CCK receptor antagonist	CCKAR			0	99.12	Tocris	2190	SR 27897	411.044	OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl	ILNRQFBVVQUOLP-UHFFFAOYSA-N	122077.0		ILNRQFBVVQUOLP
BRD-K35629949-001-02-0	SR-27897	Phase 2	CCK receptor antagonist	CCKAR			0	98.17	Tocris	2190	SR 27897	411.044	OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl	ILNRQFBVVQUOLP-UHFFFAOYSA-N	122077.0		ILNRQFBVVQUOLP
BRD-K60952143-001-01-0	SR-3306	Preclinical	JNK inhibitor	MAPK10|MAPK8|MAPK9			0	95.09	MedChemEx	HY-12829	SR-3306	490.223	Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1	QDMXVKKPYBGIAS-UHFFFAOYSA-N	57519510.0		QDMXVKKPYBGIAS
BRD-K43002771-034-02-4	SR-33805	Phase 1	calcium channel blocker				0	97.8	Tocris	1806	SR 33805 oxalate	564.266	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	GCVFQRRBTCHIPK-UHFFFAOYSA-N	9850876.0		GCVFQRRBTCHIPK
BRD-K43002771-034-01-6	SR-33805	Phase 1	calcium channel blocker				0	92.87	Tocris	1806	SR 33805 oxalate	564.266	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	GCVFQRRBTCHIPK-UHFFFAOYSA-N	9850876.0		GCVFQRRBTCHIPK
BRD-K43002771-034-03-9	SR-33805	Phase 1	calcium channel blocker				0	96.02	Tocris	1806	SR 33805 oxalate	564.266	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	GCVFQRRBTCHIPK-UHFFFAOYSA-N	9850876.0		GCVFQRRBTCHIPK
BRD-K50378376-001-02-9	SR-3576	Preclinical	JNK inhibitor	MAPK10			0	96.29	Tocris	5044	SR 3576	501.201	COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC	MTFAYLZZDJGFGV-UHFFFAOYSA-N	70702008.0		MTFAYLZZDJGFGV
BRD-K50378376-001-01-8	SR-3576	Preclinical	JNK inhibitor	MAPK10			0	99.49	Tocris	5044	SR 3576	501.201	COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC	MTFAYLZZDJGFGV-UHFFFAOYSA-N	70702008.0		MTFAYLZZDJGFGV
BRD-A86468475-300-01-3	SR-3677	Preclinical	rho associated kinase inhibitor	ROCK2			0	79.6	Tocris	3667	SR 3677 dihydrochloride	408.18	CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|	OQWZIAVXCYIZNN-OAQYLSRUSA-N	93600633.0		OQWZIAVXCYIZNN
BRD-A86468475-300-02-9	SR-3677	Preclinical	rho associated kinase inhibitor	ROCK2			0	90.89	Tocris	3667	SR 3677 dihydrochloride	408.18	CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|	OQWZIAVXCYIZNN-OAQYLSRUSA-N	93600633.0		OQWZIAVXCYIZNN
BRD-K09397065-003-06-1	SR-57227A	Phase 2	serotonin receptor agonist	HTR3A			0	95.89	Tocris	1205	SR 57227 hydrochloride	211.088	NC1CCN(CC1)c1cccc(Cl)n1	WPVVMKYQOMJPIN-UHFFFAOYSA-N	131747.0		WPVVMKYQOMJPIN
BRD-K09397065-003-07-9	SR-57227A	Phase 2	serotonin receptor agonist	HTR3A			0	90.47	Tocris	1205	SR 57227 hydrochloride	211.088	NC1CCN(CC1)c1cccc(Cl)n1	WPVVMKYQOMJPIN-UHFFFAOYSA-N	131747.0		WPVVMKYQOMJPIN
BRD-K35430135-003-03-1	SR-59230A	Preclinical	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3			0	88.83	Tocris	1511	SR 59230A hydrochloride	325.204	CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	VFDHMSXXELYMRW-ICSRJNTNSA-N	5311452.0		VFDHMSXXELYMRW
BRD-K35430135-003-06-9	SR-59230A	Preclinical	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3			0	94.47	Tocris	1511	SR 59230A hydrochloride	325.204	CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	VFDHMSXXELYMRW-ICSRJNTNSA-N	5311452.0		VFDHMSXXELYMRW
BRD-K35430135-003-02-3	SR-59230A	Preclinical	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3			0	95.68	Tocris	1511	SR 59230A hydrochloride	325.204	CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	VFDHMSXXELYMRW-ICSRJNTNSA-N	5311452.0		VFDHMSXXELYMRW
BRD-K19309090-300-05-5	SR-95639A	Preclinical	acetylcholine receptor agonist	CHRM1			0	98.78	Prestwick	Prestw-406	Morpholinoethylamino-3-benzocyclohepta-(5,6-c)-pyridazine dihydrochloride	324.195	C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1	RUTYAHFAKWVMNH-UHFFFAOYSA-N	195165.0		RUTYAHFAKWVMNH
BRD-K50495309-001-03-8	SRC-kinase-inhibitor-I	Preclinical	SRC inhibitor	CSK|LCK|RIPK2			0	98.13	Tocris	3642	Src I1	373.143	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC	DMWVGXGXHPOEPT-UHFFFAOYSA-N	1474853.0		DMWVGXGXHPOEPT
BRD-K50495309-001-02-0	SRC-kinase-inhibitor-I	Preclinical	SRC inhibitor	CSK|LCK|RIPK2			0	98.18	Tocris	3642	Src I1	373.143	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC	DMWVGXGXHPOEPT-UHFFFAOYSA-N	1474853.0		DMWVGXGXHPOEPT
BRD-K62621335-001-03-9	SRPIN340	Preclinical	serine arginine protein kinase inhibitor	SRPK1|SRPK2			0	95.73	Tocris	5063	SRPIN340	349.14	FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	DWFGGOFPIISJIT-UHFFFAOYSA-N	2797577.0		DWFGGOFPIISJIT
BRD-K62621335-001-02-5	SRPIN340	Preclinical	serine arginine protein kinase inhibitor	SRPK1|SRPK2			0	98.5	Tocris	5063	SRPIN340	349.14	FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	DWFGGOFPIISJIT-UHFFFAOYSA-N	2797577.0		DWFGGOFPIISJIT
BRD-K62621335-001-01-7	SRPIN340	Preclinical	serine arginine protein kinase inhibitor	SRPK1|SRPK2			0	97.53	Selleck	S7270	SRPIN340	349.14	FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	DWFGGOFPIISJIT-UHFFFAOYSA-N	2797577.0		DWFGGOFPIISJIT
BRD-K95926480-003-03-6	SRT1720	Preclinical	SIRT activator	SIRT1			0	93.47	Selleck	S1129	SRT1720	469.168	O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	IASPBORHOMBZMY-UHFFFAOYSA-N	24180125.0		IASPBORHOMBZMY
BRD-K95926480-003-06-9	SRT1720	Preclinical	SIRT activator	SIRT1			0	77.24	MedChemEx	HY-15145	SRT 1720 (Hydrochloride)	469.168	O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	IASPBORHOMBZMY-UHFFFAOYSA-N	24180125.0		IASPBORHOMBZMY
BRD-K48452630-001-01-8	SRT2104	Phase 2	SIRT activator	SIRT1			0	99.71	Selleck	S7792	SRT2104 (GSK2245840)	516.14	Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1	LAMQVIQMVKWXOC-UHFFFAOYSA-N	25108829.0		LAMQVIQMVKWXOC
BRD-K48452630-001-02-6	SRT2104	Phase 2	SIRT activator	SIRT1			0	97.38	MedChemEx	HY-15262	SRT 2104	516.14	Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1	LAMQVIQMVKWXOC-UHFFFAOYSA-N	25108829.0		LAMQVIQMVKWXOC
BRD-K34801930-001-02-9	SRT3190	Preclinical	CC chemokine receptor antagonist				0	98.38	MedChemEx	HY-13021	SRT3190	475.116	C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	QVKPEMXUBULFBM-FZMZJTMJSA-N	59149652.0		QVKPEMXUBULFBM
BRD-K34801930-001-01-9	SRT3190	Preclinical	CC chemokine receptor antagonist				0	98.58	MedChemEx	HY-13021	SRT3190	475.116	C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	QVKPEMXUBULFBM-FZMZJTMJSA-N	59149652.0		QVKPEMXUBULFBM
BRD-K65890018-236-01-1	SSR128129E	Preclinical					0	95.43	Selleck	S7167	SSR128129E	324.111	COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12	SNMCWIDCSPHZRD-UHFFFAOYSA-N	11347895.0		SNMCWIDCSPHZRD
BRD-K65890018-236-02-9	SSR128129E	Preclinical					0	96.61	MedChemEx	HY-15599	SSR128129E	324.111	COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12	SNMCWIDCSPHZRD-UHFFFAOYSA-N	11347895.0		SNMCWIDCSPHZRD
BRD-K00004316-003-01-9	SSR180711	Phase 2	acetylcholine receptor agonist	CHRNA7			0	90.15	Tocris	5559	SSR 180711 hydrochloride	324.047	Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|	RXLOZRCLQMJJLC-UHFFFAOYSA-N	9797360.0		RXLOZRCLQMJJLC
BRD-K00003186-003-01-9	SSR240612	Preclinical	bradykinin receptor antagonist				0	96.86	MedChemEx	HY-15039	SSR240612	756.356	COc1ccc2cc(ccc2c1)S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc1ccc(CN2[C@@H](C)CCC[C@H]2C)cc1)C(=O)N(C)C(C)C)c1ccc2OCOc2c1	QGWIQIAWOCJRPI-WSCVWKGISA-N	9853583.0		QGWIQIAWOCJRPI
BRD-K00004706-001-01-9	ST-1535	Preclinical	adenosine receptor antagonist				0	89.18	AMS	L14959	st-1535	272.15	CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1	CYYQMAWUIRPCNW-UHFFFAOYSA-N	9860294.0		CYYQMAWUIRPCNW
BRD-K73524797-001-02-9	ST-1859	Phase 1	antiamyloidogenic agent				0	96.67	Sigma	MFCD00046470	1,1'-Methylene-di(2-naphthol)	300.115	Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12	ZPANWZBSGMDWON-UHFFFAOYSA-N	14187.0		ZPANWZBSGMDWON
BRD-K73524797-001-01-1	ST-1859	Phase 1	antiamyloidogenic agent				0	95.5	Enamine	Z56948405		300.115	Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12	ZPANWZBSGMDWON-UHFFFAOYSA-N	14187.0		ZPANWZBSGMDWON
BRD-K68470841-001-01-0	ST-2825	Preclinical	myeloid differentiation primary response inhibitor	MYD88			0	97.03	MedChemEx	HY-50937	ST 2825	590.116	NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12	HBLHLJXFIPCEMW-ZJSFPPFMSA-N	24808138.0		HBLHLJXFIPCEMW
BRD-K18905250-003-03-2	ST-91	Preclinical	adrenergic receptor agonist				0	93.75	Tocris	2638	ST 91	217.158	CCc1cccc(CC)c1NC1=NCCN1 |t:12|	IALHTUPVRAQZFI-UHFFFAOYSA-N	20864.0		IALHTUPVRAQZFI
BRD-K18905250-003-02-4	ST-91	Preclinical	adrenergic receptor agonist				0	92.31	Tocris	2638	ST 91	217.158	CCc1cccc(CC)c1NC1=NCCN1 |t:12|	IALHTUPVRAQZFI-UHFFFAOYSA-N	20864.0		IALHTUPVRAQZFI
BRD-K18905250-003-04-9	ST-91	Preclinical	adrenergic receptor agonist				0	96.08	Tocris	2638	ST 91	217.158	CCc1cccc(CC)c1NC1=NCCN1 |t:12|	IALHTUPVRAQZFI-UHFFFAOYSA-N	20864.0		IALHTUPVRAQZFI
BRD-K41783120-001-02-8	STA-5326	Phase 2	interleukin synthesis inhibitor	IL12A			0	98.13	MedChemEx	HY-14644	Apilimod	418.212	Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	HSKAZIJJKRAJAV-KOEQRZSOSA-N	10173277.0		HSKAZIJJKRAJAV
BRD-K41783120-001-04-4	STA-5326	Phase 2	interleukin synthesis inhibitor	IL12A			0	96.42	ApexBio	B3581	apilimod	418.212	Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+	10173277.0		HSKAZIJJKRAJAV
BRD-K68332390-001-04-9	statil	Preclinical	aldose reductase inhibitor				0	95.19	CombiBlocks	QJ-0339	Statil	390.002	OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12	LKBFFDOJUKLQNY-UHFFFAOYSA-N	5278.0		LKBFFDOJUKLQNY
BRD-K17061841-001-03-5	stattic	Preclinical					0	95.9	Selleck	S7024	Stattic	210.994	[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1 |c:7|	ZRRGOUHITGRLBA-UHFFFAOYSA-N	2779853.0		ZRRGOUHITGRLBA
BRD-K40853697-001-20-5	STAT3-inhibitor-VI	Preclinical	STAT inhibitor	STAT3			0	96.39	MedChemEx	HY-15146	NSC 74859	365.057	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	HWNUSGNZBAISFM-UHFFFAOYSA-N	252682.0		HWNUSGNZBAISFM
BRD-K40853697-001-19-7	STAT3-inhibitor-VI	Preclinical	STAT inhibitor	STAT3			0	0.0	Tocris	4655	NSC 74859	365.057	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	HWNUSGNZBAISFM-UHFFFAOYSA-N	252682.0		HWNUSGNZBAISFM
BRD-K40853697-001-12-2	STAT3-inhibitor-VI	Preclinical	STAT inhibitor	STAT3			0	0.0	Selleck	S1155	S3I-201	365.057	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	HWNUSGNZBAISFM-UHFFFAOYSA-N	252682.0		HWNUSGNZBAISFM
BRD-K40853697-001-17-1	STAT3-inhibitor-VI	Preclinical	STAT inhibitor	STAT3			0	58.33	Selleck	S1155	NSC 74859 (S3I-201)	365.057	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	HWNUSGNZBAISFM-UHFFFAOYSA-N	252682.0		HWNUSGNZBAISFM
BRD-K40853697-001-18-9	STAT3-inhibitor-VI	Preclinical	STAT inhibitor	STAT3			0	0.0	MedChemEx	HY-15146	NSC 74859	365.057	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	HWNUSGNZBAISFM-UHFFFAOYSA-N	252682.0		HWNUSGNZBAISFM
BRD-K93880783-001-27-4	stavudine	Launched	DNA directed DNA polymerase inhibitor|nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	79.84	Tocris	4990	Stavudine	224.08	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|	XNKLLVCARDGLGL-JGVFFNPUSA-N	18283.0		XNKLLVCARDGLGL
BRD-K93880783-001-29-9	stavudine	Launched	DNA directed DNA polymerase inhibitor|nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	95.45	Tocris	4990	Stavudine	224.08	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|	XNKLLVCARDGLGL-JGVFFNPUSA-N	18283.0		XNKLLVCARDGLGL
BRD-K93880783-001-26-6	stavudine	Launched	DNA directed DNA polymerase inhibitor|nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	98.62	MicroSource	1502339	STAVUDINE	224.08	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|	XNKLLVCARDGLGL-JGVFFNPUSA-N	18283.0		XNKLLVCARDGLGL
BRD-K93880783-001-28-2	stavudine	Launched	DNA directed DNA polymerase inhibitor|nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	94.29	Selleck	S1398	Stavudine (d4T)	224.08	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|	XNKLLVCARDGLGL-JGVFFNPUSA-N	18283.0	BRD-A06317634-001-10-2	XNKLLVCARDGLGL
BRD-K36739687-001-03-0	stemregenin-1	Preclinical	aryl hydrocarbon receptor antagonist	AHR			0	95.36	Selleck	S2858	StemRegenin 1 (SR1)	429.162	CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12	BGFHMYJZJZLMHW-UHFFFAOYSA-N	46199207.0		BGFHMYJZJZLMHW
BRD-A04506385-001-01-2	stepronin	Launched	mucolytic agent				0	98.87	AKSci	H988		273.013	C[C@@H](SC(=O)c1cccs1)C(=O)NCC(O)=O |&1:1,r|	JNYSEDHQJCOWQU-ZCFIWIBFSA-N	37888256.0		JNYSEDHQJCOWQU
BRD-K93900986-001-15-0	stetaderm	Launched					0	96.74	Sigma	MFCD00003652	(11alpha)-11-hydroxypregn-4-ene-3,20-dione	330.219	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|	BFZHCUBIASXHPK-QJSKAATBSA-N	92730.0		BFZHCUBIASXHPK
BRD-K13049524-001-04-6	STF-083010	Preclinical	serine/threonine kinase inhibitor	ERN1			0	1.02	MedChemEx	HY-15845	STF-083010	317.018	Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1	TVIVJHZHPKNDAQ-MHWRWJLKSA-N	135398515.0		TVIVJHZHPKNDAQ
BRD-K13049524-001-03-8	STF-083010	Preclinical	serine/threonine kinase inhibitor	ERN1			0	0.0	MedChemEx	HY-15845	STF-083010	317.018	Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1	TVIVJHZHPKNDAQ-MHWRWJLKSA-N	135398515.0		TVIVJHZHPKNDAQ
BRD-K39171998-001-05-9	STF-118804	Preclinical	NAMPT inhibitor	NAMPT			0	93.56	Tocris	5207	STF 118804	461.141	Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	DLFCEZOMHBPDGI-UHFFFAOYSA-N	20916937.0		DLFCEZOMHBPDGI
BRD-K39171998-001-04-5	STF-118804	Preclinical	NAMPT inhibitor	NAMPT			0	95.32	Tocris	5207	STF 118804	461.141	Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	DLFCEZOMHBPDGI-UHFFFAOYSA-N	20916937.0		DLFCEZOMHBPDGI
BRD-K39171998-001-01-1	STF-118804	Preclinical	NAMPT inhibitor	NAMPT			0	96.03	Selleck	S7316	STF-118804	461.141	Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	DLFCEZOMHBPDGI-UHFFFAOYSA-N	20916937.0		DLFCEZOMHBPDGI
BRD-K22477529-001-02-7	STF-31	Preclinical	NAMPT inhibitor	NAMPT|SLC2A1			0	95.84	Tocris	4484	STF 31	423.162	CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1	NGQPRVWTFNBUHA-UHFFFAOYSA-N	984333.0		NGQPRVWTFNBUHA
BRD-K22477529-001-01-9	STF-31	Preclinical	NAMPT inhibitor	NAMPT|SLC2A1			0	100.0	Broad Institute			423.162	CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1	NGQPRVWTFNBUHA-UHFFFAOYSA-N	984333.0		NGQPRVWTFNBUHA
BRD-K85479953-001-12-1	STF-62247	Preclinical	autophagy inducer				0	89.5	Selleck	S1041	STF-62247	267.083	Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1	KATNUHQNJGNLPW-UHFFFAOYSA-N	704473.0		KATNUHQNJGNLPW
BRD-K85479953-001-11-3	STF-62247	Preclinical	autophagy inducer				0	80.1	Selleck	S1041	STF-62247	267.083	Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1	KATNUHQNJGNLPW-UHFFFAOYSA-N	704473.0		KATNUHQNJGNLPW
BRD-K41422683-001-02-2	stigmasterol	Preclinical					0	0.0	Selleck	S2361	Stigmasterol (Stigmasterin)	412.371	CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	HCXVJBMSMIARIN-PHZDYDNGSA-N	5280794.0		HCXVJBMSMIARIN
BRD-K41422683-001-05-5	stigmasterol	Preclinical					0	0.0	Selleck	S2361	Stigmasterol	412.371	CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	HCXVJBMSMIARIN-PHZDYDNGSA-N	5280794.0	BRD-K84424780-001-01-0	HCXVJBMSMIARIN
BRD-A72441487-001-05-7	stiripentol	Launched	GABA uptake inhibitor	GABRA3	neurology/psychiatry	epilepsy	0	0.0	Sigma	S6826	(1E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol	234.126	CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4,r|	IBLNKMRFIPWSOY-IYNGYCSASA-N	25271730.0		IBLNKMRFIPWSOY
BRD-K33839500-001-01-0	stobadine	Phase 2	adrenergic receptor antagonist	ADRA1A			0	67.37	Enamine	EN300-191957	(4aR,9bS)-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole	202.147	CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1	CYJQCYXRNNCURD-DGCLKSJQSA-N	108089.0		CYJQCYXRNNCURD
BRD-K07166362-330-01-0	streptomycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	0	0.0	Selleck	S2572	Streptomycin sulfate	581.266	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O	UCSJYZPVAKXKNQ-HZYVHMACSA-N	19649.0	BRD-K91768078-330-01-5|BRD-M30124979-326-01-1	UCSJYZPVAKXKNQ
BRD-K07166362-330-02-8	streptomycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	0	94.3	Selleck	S2572	Streptomycin sulfate	581.266	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O	UCSJYZPVAKXKNQ-HZYVHMACSA-N	19649.0	BRD-K91768078-330-02-3|BRD-M87628937-326-02-2	UCSJYZPVAKXKNQ
BRD-K07166362-065-03-9	streptomycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	tuberculosis	0	0.0	MedChemEx	HY-B0472	Streptomycin (sulfate)	581.266	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O	UCSJYZPVAKXKNQ-HZYVHMACSA-N	19649.0		UCSJYZPVAKXKNQ
BRD-K34411947-001-14-1	streptozotocin	Launched	DNA alkylating agent		oncology	pancreatic cancer	0	0.0	Sigma	S0130	2-deoxy-2-{[(1-methyl-2-oxohydrazino)carbonyl]amino}-alpha-D-glucopyranose	265.091	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	BKWHZSFINQBEQH-GKHCUFPYSA-N	124202159.0		BKWHZSFINQBEQH
BRD-K34411947-001-15-8	streptozotocin	Launched	DNA alkylating agent		oncology	pancreatic cancer	0	0.0	MedChemEx	HY-13753	Streptozocin	265.091	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	BKWHZSFINQBEQH-GKHCUFPYSA-N	124202159.0		BKWHZSFINQBEQH
BRD-K34411947-001-13-3	streptozotocin	Launched	DNA alkylating agent		oncology	pancreatic cancer	0	0.0	Selleck	S1312	Streptozotocin (Zanosar)	265.091	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	BKWHZSFINQBEQH-GKHCUFPYSA-N	124202159.0		BKWHZSFINQBEQH
BRD-K34411947-001-12-5	streptozotocin	Launched	DNA alkylating agent		oncology	pancreatic cancer	0	83.34	MicroSource	1500543	STREPTOZOSIN	265.091	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	BKWHZSFINQBEQH-GKHCUFPYSA-N	124202159.0		BKWHZSFINQBEQH
BRD-K34411947-001-11-7	streptozotocin	Launched	DNA alkylating agent		oncology	pancreatic cancer	0	0.0	Selleck	S1312	Streptozotocin (STZ)	265.091	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	BKWHZSFINQBEQH-GKHCUFPYSA-N	124202159.0		BKWHZSFINQBEQH
BRD-K34411947-001-17-4	streptozotocin	Launched	DNA alkylating agent		oncology	pancreatic cancer	0	0.0	Tocris	1621	Streptozocin	265.091	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	BKWHZSFINQBEQH-GKHCUFPYSA-N	124202159.0	BRD-A25576662-001-02-2	BKWHZSFINQBEQH
BRD-K83146339-001-04-0	strontium-ranelate	Launched	bone formation stimulant|bone resorption inhibitor	CASR	orthopedics|rheumatology	osteoporosis|osteoarthritis	1	0.0	LKT	S7970	strontium 2,2'-(5-carboxylato-4-(carboxylatomethyl)-3-cyanothiophen-2-ylazanediyl)diacetate	513.796	OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N	TWHPPRXFYWSOQF-UHFFFAOYSA-J		BRD-M65265990-001-03-0	TWHPPRXFYWSOQF
BRD-K83146339-001-02-4	strontium-ranelate	Launched	bone formation stimulant|bone resorption inhibitor	CASR	orthopedics|rheumatology	osteoporosis|osteoarthritis	1	0.0	MedChemEx	HY-17397	Strontium Ranelate	513.796	OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N	TWHPPRXFYWSOQF-UHFFFAOYSA-J			TWHPPRXFYWSOQF
BRD-K83146339-001-03-2	strontium-ranelate	Launched	bone formation stimulant|bone resorption inhibitor	CASR	orthopedics|rheumatology	osteoporosis|osteoarthritis	0	0.0	Selleck	S2050	Strontium ranelate (Protelos)	513.796	OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N	TWHPPRXFYWSOQF-UHFFFAOYSA-J		BRD-K88014802-001-01-9|BRD-M65265990-001-02-2	TWHPPRXFYWSOQF
BRD-K83146339-001-05-7	strontium-ranelate	Launched	bone formation stimulant|bone resorption inhibitor	CASR	orthopedics|rheumatology	osteoporosis|osteoarthritis	0	0.0	Selleck	S2050	Strontium ranelate (Protelos)	513.796	OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N	TWHPPRXFYWSOQF-UHFFFAOYSA-J		BRD-K83146339-001-01-6|BRD-K83146339-001-01-6|BRD-K83146339-001-01-6|BRD-K83146339-001-01-6	TWHPPRXFYWSOQF
BRD-K72572686-001-02-9	strychnine	Preclinical	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA10|CHRNA9|GLRA1|GLRA2|GLRA3|GLRB			0	92.76	Sigma	S0532-5G	strychnine	334.168	O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|	QMGVPVSNSZLJIA-FVWCLLPLSA-N	441071.0		QMGVPVSNSZLJIA
BRD-K23106423-001-01-0	substance-P	Phase 1	neurokinin receptor antagonist	TACR1|TACR2|TACR3			0	92.33	Tocris	1156	2-({5-amino-2-[({1-[6-amino-2-({[1-(2-amino-5-{[amino(imino)methyl]amino}pentanoyl)-2-pyrrolidinyl]carbonyl}amino)hexanoyl]-2-pyrrolidinyl}carbonyl)amino]-5-oxopentanoyl}amino)-N~1~-[13-(aminocarbonyl;)-1,4-dibenzyl-10-isobutyl-2,5,8,11-tetraoxo-16-thia-3	1346.728	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	ADNPLDHMAVUMIW-CUZNLEPHSA-N	36511.0		ADNPLDHMAVUMIW
BRD-K45238818-001-02-6	succinic-acid	Launched		ALDH5A1|ASPH|BBOX1|HSD17B6|OXCT1|OXCT2|P3H1|P3H2|P3H3|P4HA1|P4HA2|PLOD1|PLOD3|SDHA|SDHB|SDHC|SDHD|SLC13A1|SLC13A2|SLC13A3|SLC25A10|SUCLA2|SUCLG1|SUCLG2|SUCNR1|TMLHE			0	100.0	Enamine	Z57127453		118.027	OC(=O)CCC(O)=O	KDYFGRWQOYBRFD-UHFFFAOYSA-N	21952380.0		KDYFGRWQOYBRFD
BRD-K00003183-001-01-9	succinobucol	Phase 2/Phase 3	antioxidant	VCAM1			0	99.04	MedChemEx	HY-14937	Succinobucol	616.326	CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	RKSMVPNZHBRNNS-UHFFFAOYSA-N	216325.0		RKSMVPNZHBRNNS
BRD-K45497762-336-03-2	succinylcholine-chloride	Launched		CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10	neurology/psychiatry	muscle relaxant	0	0.0	Sigma	MFCD00150564	trimethyl[2-({4-oxo-4-[2-(trimethylammonio)ethoxy]butanoyl}oxy)ethyl]ammonium dichloride dihydrate	290.221	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	AXOIZCJOOAYSMI-UHFFFAOYSA-N	5314.0		AXOIZCJOOAYSMI
BRD-K45497762-300-01-2	succinylcholine-chloride	Launched		CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10	neurology/psychiatry	muscle relaxant	0	0.0	DuPont	A000521780	trimethyl[2-({4-oxo-4-[2-(trimethylammonio)ethoxy]butanoyl}oxy)ethyl]ammonium dichloride	290.221	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	AXOIZCJOOAYSMI-UHFFFAOYSA-N	5314.0		AXOIZCJOOAYSMI
BRD-K45497762-336-01-6	succinylcholine-chloride	Launched		CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10	neurology/psychiatry	muscle relaxant	0	0.0	Selleck	S4121	Succinylcholine Chloride Dihydrate	290.221	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	AXOIZCJOOAYSMI-UHFFFAOYSA-N	5314.0		AXOIZCJOOAYSMI
BRD-K45497762-336-02-4	succinylcholine-chloride	Launched		CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10	neurology/psychiatry	muscle relaxant	0	66.78	Selleck	S4121	Succinylcholine Chloride Dihydrate	290.221	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	AXOIZCJOOAYSMI-UHFFFAOYSA-N	5314.0		AXOIZCJOOAYSMI
BRD-K01950558-001-15-9	succinylsulfathiazole	Phase 2	dihydrofolate reductase inhibitor	DHFR			0	95.36	MedChemEx	HY-B0921	Succinylsulfathiazole	355.03	OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	SKVLYVHULOWXTD-UHFFFAOYSA-N	5315.0		SKVLYVHULOWXTD
BRD-K01950558-001-14-7	succinylsulfathiazole	Phase 2	dihydrofolate reductase inhibitor	DHFR			0	96.18	MicroSource	1502025	SUCCINYLSULFATHIAZOLE	355.03	OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	SKVLYVHULOWXTD-UHFFFAOYSA-N	5315.0		SKVLYVHULOWXTD
BRD-M71167108-001-01-3	sucralfate	Launched	antacid		gastroenterology	duodenal ulcer disease	0	0.0	MicroSource	1505950	SUCRALFATE [5mM]	2085.522	O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	DTULOKYBGCTCFP-QRLOXDDHSA-A			DTULOKYBGCTCFP
BRD-M71167108-001-02-1	sucralfate	Launched	antacid		gastroenterology	duodenal ulcer disease	0	0.0	Selleck	S4670	SUCRALFATE [5mM]	2085.522	O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	DTULOKYBGCTCFP-QRLOXDDHSA-A			DTULOKYBGCTCFP
BRD-K58968598-001-04-9	sucralose	Launched					0	99.2	MedChemEx	HY-N0614	Sucralose	396.015	OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	BAQAVOSOZGMPRM-QBMZZYIRSA-N	71485.0		BAQAVOSOZGMPRM
BRD-K58968598-001-02-8	sucralose	Launched					0	99.56	MicroSource	1505953	SUCRALOSE	396.015	OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	BAQAVOSOZGMPRM-QBMZZYIRSA-N	71485.0		BAQAVOSOZGMPRM
BRD-K58968598-001-03-6	sucralose	Launched					0	100.0	Selleck	S4214	Sucralose	396.015	OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	BAQAVOSOZGMPRM-QBMZZYIRSA-N	71485.0	BRD-K23414802-001-01-9	BAQAVOSOZGMPRM
BRD-K74724920-001-02-4	sucrose	Launched		ACTA1|ATOX1|C22orf28|LYZ			0	99.8	Sigma	84097	alpha-D-lyxo-hex-5-ulofuranosyl alpha-D-glucopyranoside	342.116	OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O	CZMRCDWAGMRECN-UGDNZRGBSA-N	5988.0		CZMRCDWAGMRECN
BRD-K01294196-001-01-5	sucrose-octaacetate	Preclinical					0	100.0	Acros	41979	Sucrose octaacetate, 98%	678.201	CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O	ZIJKGAXBCRWEOL-SAXBRCJISA-N	31340.0		ZIJKGAXBCRWEOL
BRD-K00004524-001-01-9	sudan-IV	Preclinical					0	62.07	Sigma	MFCD00003893	Sudan IV	380.164	Cc1ccccc1\N=N\c1ccc(\N=N\c2c(O)ccc3ccccc23)c(C)c1	RCTGMCJBQGBLKT-PAMTUDGESA-N			RCTGMCJBQGBLKT
BRD-K00004582-001-01-9	sufugolix	Preclinical	gonadotropin releasing factor hormone receptor antagonist				0	93.8	MedChemEx	HY-100209	Sufugolix	667.206	CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccccc3)c(=O)c2c1CN(C)Cc1ccccc1	UCQSBGOFELXYIN-UHFFFAOYSA-N	3038517.0		UCQSBGOFELXYIN
BRD-K00003322-363-01-9	sugammadex	Launched	neuromuscular blockade reversal agent				0	0.0	MedChemEx	HY-B0079	Sugammadex (sodium)	2000.409	O[C@H]1[C@H](O)[C@H]2O[C@@H]3O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]4O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]5O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]6O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]7O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]8O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]9O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]1O[C@H]2CSCCC(O)=O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O	WHRODDIHRRDWEW-WXUQZJQRSA-N			WHRODDIHRRDWEW
BRD-K44133266-001-13-9	sulbactam	Launched	beta lactamase inhibitor		infectious disease	skin infections|intra-abdominal infections|gynecologic infections	0	89.06	MedChemEx	HY-B0334	Sulbactam	233.036	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	FKENQMMABCRJMK-RITPCOANSA-N	130313.0		FKENQMMABCRJMK
BRD-K44133266-001-10-0	sulbactam	Launched	beta lactamase inhibitor		infectious disease	skin infections|intra-abdominal infections|gynecologic infections	0	98.41	Selleck	S1958	Sulbactam	233.036	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	FKENQMMABCRJMK-RITPCOANSA-N	130313.0	BRD-K85679373-001-01-1	FKENQMMABCRJMK
BRD-K44133266-236-03-7	sulbactam	Launched	beta lactamase inhibitor		infectious disease	skin infections|intra-abdominal infections|gynecologic infections	0	57.32	Selleck	S2551	Sulbactam sodium	233.036	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	FKENQMMABCRJMK-RITPCOANSA-N	130313.0	BRD-K85679373-236-01-3	FKENQMMABCRJMK
BRD-K44133266-001-12-6	sulbactam	Launched	beta lactamase inhibitor		infectious disease	skin infections|intra-abdominal infections|gynecologic infections	0	81.28	Selleck	S1958	SULBACTAM	233.036	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	FKENQMMABCRJMK-RITPCOANSA-N	130313.0		FKENQMMABCRJMK
BRD-K44133266-236-02-9	sulbactam	Launched	beta lactamase inhibitor		infectious disease	skin infections|intra-abdominal infections|gynecologic infections	0	77.03	Selleck	S2551	Sulbactam sodium (Unasyn)	233.036	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	FKENQMMABCRJMK-RITPCOANSA-N	130313.0		FKENQMMABCRJMK
BRD-A63431791-001-01-9	sulbactam-pivoxil	Launched	beta lactamase inhibitor		infectious disease	skin infections	0	85.23	AvaChem	3125	(pivaloyloxy)methyl 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide	347.104	CC(C)(C)C(=O)OCOC(=O)[C@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C |&1:11,&2:13,r|	OHPVYKXTRACOSQ-NXEZZACHSA-N	40537219.0		OHPVYKXTRACOSQ
BRD-K72384124-001-10-9	sulbentine	Preclinical	other antifungal				0	93.39	MedChemEx	HY-B1133	Sulbentine	314.091	S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1	QFVAWNPSRQWSDU-UHFFFAOYSA-N	67686.0		QFVAWNPSRQWSDU
BRD-K72384124-001-08-0	sulbentine	Preclinical	other antifungal				0	94.5	MicroSource	1506106	SULBENTINE	314.091	S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1	QFVAWNPSRQWSDU-UHFFFAOYSA-N	67686.0	BRD-K73698987-001-01-3	QFVAWNPSRQWSDU
BRD-K12539416-001-01-4	sulbutiamine	Launched	acetylcholine receptor antagonist		neurology/psychiatry	asthenia	0	97.93	AKSci	O483		702.298	CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O	CKHJPWQVLKHBIH-GPAWKIAZSA-N	3002120.0		CKHJPWQVLKHBIH
BRD-A70649075-008-30-8	sulconazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	99.7	MicroSource	1501148	SULCONAZOLE NITRATE	396.002	Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	AFNXATANNDIXLG-SFHVURJKSA-N	6604421.0		AFNXATANNDIXLG
BRD-A70649075-008-32-9	sulconazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	99.05	MedChemEx	HY-B1460A	Sulconazole (nitrate)	396.002	Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	AFNXATANNDIXLG-SFHVURJKSA-N	6604421.0		AFNXATANNDIXLG
BRD-A70649075-008-29-0	sulconazole	Launched	sterol demethylase inhibitor		infectious disease	tinea pedis|tinea cruris|tinea corporis	0	98.23	Selleck	S4120	Sulconazole Nitrate	396.002	Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	AFNXATANNDIXLG-SFHVURJKSA-N	6604421.0		AFNXATANNDIXLG
BRD-K59983611-001-21-9	sulfabenzamide	Launched	bacterial antifolate		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	98.4	MicroSource	1500544	SULFABENZAMIDE	276.057	Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1	PBCZLFBEBARBBI-UHFFFAOYSA-N	5319.0		PBCZLFBEBARBBI
BRD-K13486660-001-02-9	sulfacarbamide	Withdrawn					0	100.0	MedChemEx	HY-B1236	Sulfacarbamide	215.036	NC(=O)NS(=O)(=O)c1ccc(N)cc1	WVAKABMNNSMCDK-UHFFFAOYSA-N	11033.0		WVAKABMNNSMCDK
BRD-K13486660-001-01-0	sulfacarbamide	Withdrawn					0	91.78	MicroSource	1506107	SULFACARBAMIDE	215.036	NC(=O)NS(=O)(=O)c1ccc(N)cc1	WVAKABMNNSMCDK-UHFFFAOYSA-N	11033.0		WVAKABMNNSMCDK
BRD-K21520694-236-02-6	sulfacetamide	Launched	PABA antagonist		ophthalmology	conjunctivitis	0	94.36	Selleck	S4081	Sulfacetamide Sodium	214.041	CC(=O)NS(=O)(=O)c1ccc(N)cc1	SKIVFJLNDNKQPD-UHFFFAOYSA-N	5320.0		SKIVFJLNDNKQPD
BRD-K21520694-001-21-4	sulfacetamide	Launched	PABA antagonist		ophthalmology	conjunctivitis	0	0.0	MicroSource	1500545	SULFACETAMIDE	214.041	CC(=O)NS(=O)(=O)c1ccc(N)cc1	SKIVFJLNDNKQPD-UHFFFAOYSA-N	5320.0		SKIVFJLNDNKQPD
BRD-K21520694-236-03-4	sulfacetamide	Launched	PABA antagonist		ophthalmology	conjunctivitis	0	97.83	Selleck	S4081	SULFACETAMIDE	214.041	CC(=O)NS(=O)(=O)c1ccc(N)cc1	SKIVFJLNDNKQPD-UHFFFAOYSA-N	5320.0		SKIVFJLNDNKQPD
BRD-K32021043-001-15-9	sulfachlorpyridazine	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	97.32	MedChemEx	HY-B1781	Sulfachloropyridazine	284.013	Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1	XOXHILFPRYWFOD-UHFFFAOYSA-N	6634.0		XOXHILFPRYWFOD
BRD-K32021043-001-14-3	sulfachlorpyridazine	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	98.26	MicroSource	1501142	SULFACHLORPYRIDAZINE	284.013	Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1	XOXHILFPRYWFOD-UHFFFAOYSA-N	6634.0		XOXHILFPRYWFOD
BRD-K32273377-001-20-9	sulfadiazine	Launched	bacterial antifolate		infectious disease|ophthalmology	malaria|meningitis|urinary tract infections|conjunctivitis|trachoma|chancroid	0	98.02	MedChemEx	HY-B0273	Sulfadiazine	250.052	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	SEEPANYCNGTZFQ-UHFFFAOYSA-N	5215.0		SEEPANYCNGTZFQ
BRD-K32273377-001-17-9	sulfadiazine	Launched	bacterial antifolate		infectious disease|ophthalmology	malaria|meningitis|urinary tract infections|conjunctivitis|trachoma|chancroid	0	99.24	Enamine	Z104472626		250.052	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	SEEPANYCNGTZFQ-UHFFFAOYSA-N	5215.0		SEEPANYCNGTZFQ
BRD-K32273377-001-15-3	sulfadiazine	Launched	bacterial antifolate		infectious disease|ophthalmology	malaria|meningitis|urinary tract infections|conjunctivitis|trachoma|chancroid	0	95.9	Selleck	S1770	Sulfadiazine	250.052	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	SEEPANYCNGTZFQ-UHFFFAOYSA-N	5215.0		SEEPANYCNGTZFQ
BRD-K32273377-001-16-1	sulfadiazine	Launched	bacterial antifolate		infectious disease|ophthalmology	malaria|meningitis|urinary tract infections|conjunctivitis|trachoma|chancroid	0	97.99	MicroSource	1500546	SULFADIAZINE	250.052	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	SEEPANYCNGTZFQ-UHFFFAOYSA-N	5215.0		SEEPANYCNGTZFQ
BRD-K55250441-001-17-9	sulfadoxine	Launched	dihydropteroate synthase inhibitor		infectious disease	malaria	0	94.79	MedChemEx	HY-B0439	Sulfadoxine	310.074	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	PJSFRIWCGOHTNF-UHFFFAOYSA-N	17134.0		PJSFRIWCGOHTNF
BRD-K55250441-001-13-0	sulfadoxine	Launched	dihydropteroate synthase inhibitor		infectious disease	malaria	0	96.8	MicroSource	1506086	SULFADOXINE	310.074	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	PJSFRIWCGOHTNF-UHFFFAOYSA-N	17134.0		PJSFRIWCGOHTNF
BRD-K55250441-001-12-2	sulfadoxine	Launched	dihydropteroate synthase inhibitor		infectious disease	malaria	0	94.76	Selleck	S2511	Sulfadoxine (Sulphadoxine)	310.074	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	PJSFRIWCGOHTNF-UHFFFAOYSA-N	17134.0		PJSFRIWCGOHTNF
BRD-K50859149-001-24-9	sulfafurazole	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	95.88	Tocris	731	Sulfisoxazole	267.068	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	NHUHCSRWZMLRLA-UHFFFAOYSA-N	5344.0		NHUHCSRWZMLRLA
BRD-K50859149-001-18-7	sulfafurazole	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	93.85	Tocris	731	Sulfisoxazole	267.068	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	NHUHCSRWZMLRLA-UHFFFAOYSA-N	5344.0		NHUHCSRWZMLRLA
BRD-K50859149-001-19-5	sulfafurazole	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	97.76	MicroSource	1500555	SULFISOXAZOLE	267.068	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	NHUHCSRWZMLRLA-UHFFFAOYSA-N	5344.0		NHUHCSRWZMLRLA
BRD-K50859149-001-23-7	sulfafurazole	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	97.68	Selleck	S1916	SULFISOXAZOLE ACETYL	267.068	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	NHUHCSRWZMLRLA-UHFFFAOYSA-N	5344.0		NHUHCSRWZMLRLA
BRD-K50859149-001-17-9	sulfafurazole	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	94.88	Selleck	S1916	Sulfisoxazole	267.068	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	NHUHCSRWZMLRLA-UHFFFAOYSA-N	5344.0		NHUHCSRWZMLRLA
BRD-K45086103-001-17-9	sulfaguanidine	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	100.0	MedChemEx	HY-B1267	Sulfaguanidine	214.052	NC(=N)NS(=O)(=O)c1ccc(N)cc1	BRBKOPJOKNSWSG-UHFFFAOYSA-N	5324.0		BRBKOPJOKNSWSG
BRD-K45086103-001-15-5	sulfaguanidine	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	100.0	MicroSource	1501146	SULFAGUANIDINE	214.052	NC(=N)NS(=O)(=O)c1ccc(N)cc1	BRBKOPJOKNSWSG-UHFFFAOYSA-N	5324.0		BRBKOPJOKNSWSG
BRD-K45086103-001-14-8	sulfaguanidine	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	77.69	Selleck	S4175	Sulfaguanidine	214.052	NC(=N)NS(=O)(=O)c1ccc(N)cc1	BRBKOPJOKNSWSG-UHFFFAOYSA-N	5324.0		BRBKOPJOKNSWSG
BRD-K45086103-001-16-3	sulfaguanidine	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	100.0	Selleck	S4175	Sulfaguanidine	214.052	NC(=N)NS(=O)(=O)c1ccc(N)cc1	BRBKOPJOKNSWSG-UHFFFAOYSA-N	5324.0		BRBKOPJOKNSWSG
BRD-K93524252-001-27-9	sulfamerazine	Launched	bacterial antifolate		infectious disease	coccidiosis|cholera	0	98.24	MedChemEx	HY-B0512	Sulfamerazine	264.068	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	QPPBRPIAZZHUNT-UHFFFAOYSA-N	5325.0		QPPBRPIAZZHUNT
BRD-K93524252-001-24-7	sulfamerazine	Launched	bacterial antifolate		infectious disease	coccidiosis|cholera	0	98.29	MicroSource	1500547	SULFAMERAZINE	264.068	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	QPPBRPIAZZHUNT-UHFFFAOYSA-N	5325.0		QPPBRPIAZZHUNT
BRD-K93524252-001-23-9	sulfamerazine	Launched	bacterial antifolate		infectious disease	coccidiosis|cholera	0	98.63	Selleck	S3132	Sulfamerazine	264.068	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	QPPBRPIAZZHUNT-UHFFFAOYSA-N	5325.0		QPPBRPIAZZHUNT
BRD-K87492696-001-18-9	sulfameter	Launched	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	0	99.1	MedChemEx	HY-B0213	Sulfameter	280.063	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	GPTONYMQFTZPKC-UHFFFAOYSA-N	5326.0		GPTONYMQFTZPKC
BRD-K87492696-001-15-7	sulfameter	Launched	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	0	96.7	Selleck	S1618	Sulfameter	280.063	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	GPTONYMQFTZPKC-UHFFFAOYSA-N	5326.0		GPTONYMQFTZPKC
BRD-K87492696-001-16-5	sulfameter	Launched	dihydrofolate reductase inhibitor	DHFR	infectious disease	urinary tract infections	0	98.75	MicroSource	1501155	SULFAMETER	280.063	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	GPTONYMQFTZPKC-UHFFFAOYSA-N	5326.0		GPTONYMQFTZPKC
BRD-K11640013-001-17-9	sulfamethazine	Launched	PABA antagonist		gastroenterology	enteritis	0	96.5	MedChemEx	HY-B0035	Sulfamethazine	278.084	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	ASWVTGNCAZCNNR-UHFFFAOYSA-N	5327.0		ASWVTGNCAZCNNR
BRD-K11640013-236-10-1	sulfamethazine	Launched	PABA antagonist		gastroenterology	enteritis	0	99.35	Prestwick	Prestw-775	Sulfamethazine sodium salt	278.084	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	ASWVTGNCAZCNNR-UHFFFAOYSA-N	5327.0		ASWVTGNCAZCNNR
BRD-K11640013-001-15-8	sulfamethazine	Launched	PABA antagonist		gastroenterology	enteritis	0	97.81	MicroSource	1500548	SULFAMETHAZINE	278.084	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	ASWVTGNCAZCNNR-UHFFFAOYSA-N	5327.0		ASWVTGNCAZCNNR
BRD-K11640013-001-14-1	sulfamethazine	Launched	PABA antagonist		gastroenterology	enteritis	0	96.65	Selleck	S3133	Sulfamethazine	278.084	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	ASWVTGNCAZCNNR-UHFFFAOYSA-N	5327.0		ASWVTGNCAZCNNR
BRD-K31682896-001-26-9	sulfamethizole	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	97.3	MedChemEx	HY-B0333	Sulfamethizole	270.025	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	VACCAVUAMIDAGB-UHFFFAOYSA-N	5328.0		VACCAVUAMIDAGB
BRD-K31682896-001-24-0	sulfamethizole	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	93.08	MicroSource	1500549	SULFAMETHIZOLE	270.025	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	VACCAVUAMIDAGB-UHFFFAOYSA-N	5328.0		VACCAVUAMIDAGB
BRD-K31682896-001-23-2	sulfamethizole	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	92.98	Selleck	S1957	Sulfamethizole	270.025	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	VACCAVUAMIDAGB-UHFFFAOYSA-N	5328.0		VACCAVUAMIDAGB
BRD-K28494619-001-31-9	sulfamethoxazole	Launched	PABA antagonist		infectious disease|gastroenterology	pneumonia|enteritis|urinary tract infections	0	98.01	MedChemEx	HY-B0322	Sulfamethoxazole	253.052	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	JLKIGFTWXXRPMT-UHFFFAOYSA-N	5329.0		JLKIGFTWXXRPMT
BRD-K28494619-001-28-2	sulfamethoxazole	Launched	PABA antagonist		infectious disease|gastroenterology	pneumonia|enteritis|urinary tract infections	0	98.94	MicroSource	1500550	SULFAMETHOXAZOLE	253.052	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	JLKIGFTWXXRPMT-UHFFFAOYSA-N	5329.0		JLKIGFTWXXRPMT
BRD-K28494619-001-27-4	sulfamethoxazole	Launched	PABA antagonist		infectious disease|gastroenterology	pneumonia|enteritis|urinary tract infections	0	97.49	Selleck	S1915	Sulfamethoxazole	253.052	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	JLKIGFTWXXRPMT-UHFFFAOYSA-N	5329.0		JLKIGFTWXXRPMT
BRD-K00938507-001-18-9	sulfamethoxypyridazine	Withdrawn	bacterial antifolate				0	98.28	MedChemEx	HY-B1387	Sulfamethoxypyridazine	280.063	COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	VLYWMPOKSSWJAL-UHFFFAOYSA-N	5330.0		VLYWMPOKSSWJAL
BRD-K00938507-001-17-8	sulfamethoxypyridazine	Withdrawn	bacterial antifolate				0	97.84	MicroSource	1501156	SULFAMETHOXYPYRIDAZINE	280.063	COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	VLYWMPOKSSWJAL-UHFFFAOYSA-N	5330.0		VLYWMPOKSSWJAL
BRD-K00938507-001-16-0	sulfamethoxypyridazine	Withdrawn	bacterial antifolate				0	97.58	Selleck	S4250	Sulfamethoxypyridazine	280.063	COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	VLYWMPOKSSWJAL-UHFFFAOYSA-N	5330.0		VLYWMPOKSSWJAL
BRD-K17205817-001-08-9	sulfametopyrazine	Launched	PABA antagonist		infectious disease	malaria|urinary tract infections|respiratory tract infections	0	98.18	MedChemEx	HY-A0130	Sulfalene	280.063	COc1nccnc1NS(=O)(=O)c1ccc(N)cc1	KXRZBTAEDBELFD-UHFFFAOYSA-N	9047.0		KXRZBTAEDBELFD
BRD-K17205817-001-06-1	sulfametopyrazine	Launched	PABA antagonist		infectious disease	malaria|urinary tract infections|respiratory tract infections	0	96.63	Enamine	Z277559098		280.063	COc1nccnc1NS(=O)(=O)c1ccc(N)cc1	KXRZBTAEDBELFD-UHFFFAOYSA-N	9047.0		KXRZBTAEDBELFD
BRD-K14116214-001-12-9	sulfamonomethoxine	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	90.72	MedChemEx	HY-B0946	Sulfamonomethoxine	280.063	COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1	WMPXPUYPYQKQCX-UHFFFAOYSA-N	5332.0		WMPXPUYPYQKQCX
BRD-K14116214-001-09-6	sulfamonomethoxine	Launched	bacterial antifolate		infectious disease	urinary tract infections	0	97.68	MicroSource	1501147	SULFAMONOMETHOXINE	280.063	COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1	WMPXPUYPYQKQCX-UHFFFAOYSA-N	5332.0		WMPXPUYPYQKQCX
BRD-K19742012-001-02-3	sulfamoxole	Launched	PABA antagonist		infectious disease	urinary tract infections	0	70.9	Sigma	MFCD00005303	4-amino-N-(4,5-dimethyl-1,3-oxazol-2-yl)benzenesulfonamide	267.068	Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C	CYFLXLSBHQBMFT-UHFFFAOYSA-N	12894.0		CYFLXLSBHQBMFT
BRD-K19742012-001-01-5	sulfamoxole	Launched	PABA antagonist		infectious disease	urinary tract infections	0	66.74	SantaCruz	sc-236952		267.068	Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C	CYFLXLSBHQBMFT-UHFFFAOYSA-N	12894.0		CYFLXLSBHQBMFT
BRD-K02594908-001-16-4	sulfanilamide	Launched	carbonic anhydrase inhibitor	CYP2C19|CYP2C9|CYP2D6|CYP2E1|CYP3A4	infectious disease	vulvovaginal candidiasis	0	100.0	MicroSource	1500646	SULFANILAMIDE	172.031	Nc1ccc(cc1)S(N)(=O)=O	FDDDEECHVMSUSB-UHFFFAOYSA-N	5333.0		FDDDEECHVMSUSB
BRD-K02594908-001-15-6	sulfanilamide	Launched	carbonic anhydrase inhibitor	CYP2C19|CYP2C9|CYP2D6|CYP2E1|CYP3A4	infectious disease	vulvovaginal candidiasis	0	97.61	Selleck	S1685	Sulfanilamide	172.031	Nc1ccc(cc1)S(N)(=O)=O	FDDDEECHVMSUSB-UHFFFAOYSA-N	5333.0		FDDDEECHVMSUSB
BRD-K04254814-001-01-8	sulfanilate-zinc	Preclinical					0	0.0	MicroSource	1503301	SULFANILATE ZINC	407.943	Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1	RIUORJCWAHCMSA-UHFFFAOYSA-L	64741.0	BRD-M62362637-001-02-9	RIUORJCWAHCMSA
BRD-K76845197-001-05-4	sulfanitran	Launched			infectious disease	coccidiosis	0	78.09	MicroSource	1503339	SULFANITRAN	335.058	CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O	GWBPFRGXNGPPMF-UHFFFAOYSA-N	5334.0		GWBPFRGXNGPPMF
BRD-K76845197-001-07-9	sulfanitran	Launched			infectious disease	coccidiosis	0	93.2	MedChemEx	HY-B0947	Sulfanitran	335.058	CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O	GWBPFRGXNGPPMF-UHFFFAOYSA-N	5334.0		GWBPFRGXNGPPMF
BRD-K10671814-001-17-9	sulfaphenazole	Launched	dihydropteroate synthetase inhibitor	DHPS	infectious disease	urinary tract infections	0	94.59	MedChemEx	HY-B1218	Sulfaphenazole	314.084	Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1	QWCJHSGMANYXCW-UHFFFAOYSA-N	5335.0		QWCJHSGMANYXCW
BRD-K10671814-001-14-8	sulfaphenazole	Launched	dihydropteroate synthetase inhibitor	DHPS	infectious disease	urinary tract infections	0	95.81	MicroSource	1501143	SULFAPHENAZOLE	314.084	Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1	QWCJHSGMANYXCW-UHFFFAOYSA-N	5335.0		QWCJHSGMANYXCW
BRD-K41406082-001-17-9	sulfapyridine	Launched	PABA antagonist		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	91.28	MedChemEx	HY-B0212	Sulfapyridine	249.057	Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	GECHUMIMRBOMGK-UHFFFAOYSA-N	5336.0		GECHUMIMRBOMGK
BRD-K41406082-001-15-4	sulfapyridine	Launched	PABA antagonist		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	95.98	Selleck	S1617	Sulfapyridine	249.057	Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	GECHUMIMRBOMGK-UHFFFAOYSA-N	5336.0		GECHUMIMRBOMGK
BRD-K41406082-001-16-2	sulfapyridine	Launched	PABA antagonist		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	98.64	MicroSource	1500551	SULFAPYRIDINE	249.057	Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	GECHUMIMRBOMGK-UHFFFAOYSA-N	5336.0		GECHUMIMRBOMGK
BRD-K71133585-236-14-4	sulfaquinoxaline	Launched	vitamin K antagonist		infectious disease	coccidiosis	0	92.12	MicroSource	1501145	SULFAQUINOXALINE SODIUM	300.068	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1	NHZLNPMOSADWGC-UHFFFAOYSA-N	5338.0		NHZLNPMOSADWGC
BRD-K10670311-001-17-1	sulfasalazine	Launched	cyclooxygenase inhibitor	ACAT1|ALOX5|CHUK|IKBKB|PLA2G1B|PPARG|PTGS1|PTGS2|SLC46A1|SLC7A11|TBXAS1	gastroenterology	ulcerative colitis	0	90.02	Tocris	4935	Sulfasalazine	398.068	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	NCEXYHBECQHGNR-QZQOTICOSA-N			NCEXYHBECQHGNR
BRD-K10670311-001-15-5	sulfasalazine	Launched	cyclooxygenase inhibitor	ACAT1|ALOX5|CHUK|IKBKB|PLA2G1B|PPARG|PTGS1|PTGS2|SLC46A1|SLC7A11|TBXAS1	gastroenterology	ulcerative colitis	0	97.78	MicroSource	1500552	SULFASALAZINE	398.068	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	NCEXYHBECQHGNR-QZQOTICOSA-N			NCEXYHBECQHGNR
BRD-K10670311-001-14-8	sulfasalazine	Launched	cyclooxygenase inhibitor	ACAT1|ALOX5|CHUK|IKBKB|PLA2G1B|PPARG|PTGS1|PTGS2|SLC46A1|SLC7A11|TBXAS1	gastroenterology	ulcerative colitis	0	93.5	Selleck	S1576	Sulfasalazine	398.068	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	NCEXYHBECQHGNR-QZQOTICOSA-N			NCEXYHBECQHGNR
BRD-K14705039-236-19-9	sulfathiazole	Launched	dihydropteroate synthase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	97.91	MedChemEx	HY-B0507A	Sulfathiazole (sodium)	255.014	Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	JNMRHUJNCSQMMB-UHFFFAOYSA-N	5340.0		JNMRHUJNCSQMMB
BRD-K14705039-001-16-4	sulfathiazole	Launched	dihydropteroate synthase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	98.28	MicroSource	1500553	SULFATHIAZOLE	255.014	Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	JNMRHUJNCSQMMB-UHFFFAOYSA-N	5340.0		JNMRHUJNCSQMMB
BRD-K14705039-001-15-6	sulfathiazole	Launched	dihydropteroate synthase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	95.73	Selleck	S3116	Sulfathiazole	255.014	Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	JNMRHUJNCSQMMB-UHFFFAOYSA-N	5340.0		JNMRHUJNCSQMMB
BRD-K00003125-001-01-9	sulfatinib	Phase 1	tyrosine kinase inhibitor				0	95.61	MedChemEx	HY-12297	Sulfatinib	480.194	CN(C)CCNS(=O)(=O)Cc1cccc(Nc2nccc(Oc3ccc4[nH]c(C)cc4c3)n2)c1	TTZSNFLLYPYKIL-UHFFFAOYSA-N	52920501.0		TTZSNFLLYPYKIL
BRD-K00004525-001-01-9	sulfinpyrazone	Launched	uricosuric blocker	ABCC1|FPR1|SLC22A12	rheumatology	gout	0	96.76	Sigma	MFCD00057279	(+/-)-Sulfinpyrazone , min. 99 %	404.119	O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5,r|	MBGGBVCUIVRRBF-LJAQVGFWSA-N	25273605.0		MBGGBVCUIVRRBF
BRD-K52416806-001-05-9	sulfisomidin	Preclinical	antibacterial				0	89.68	MedChemEx	HY-B1784	Sulfisomidin	278.084	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1	YZMCKZRAOLZXAZ-UHFFFAOYSA-N	5343.0		YZMCKZRAOLZXAZ
BRD-K84810336-001-01-9	sulfisoxazole-acetyl	Launched	folic acid antagonist		infectious disease|otolaryngology	meningitis|urinary tract infections|otitis|trachoma	0	56.69	MicroSource	1505461	SULFISOXAZOLE ACETYL	309.078	CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1	JFNWFXVFBDDWCX-UHFFFAOYSA-N	6662.0	BRD-K05009775-001-02-0	JFNWFXVFBDDWCX
BRD-A58955223-001-03-8	sulforaphane	Phase 2	anticancer agent|aryl hydrocarbon receptor antagonist	NFE2L2			0	95.09	EMDBio	574215-25MG	D,L-Sulforaphane	177.028	C[S@@](=O)CCCCN=C=S |r|	SUVMJBTUFCVSAD-SNVBAGLBSA-N	9577379.0		SUVMJBTUFCVSAD
BRD-K01827279-001-20-9	sulindac	Launched	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis	0	96.44	MedChemEx	HY-B0008	Sulindac	356.088	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|	MLKXDPUZXIRXEP-LQVWSKNFSA-N	16046677.0		MLKXDPUZXIRXEP
BRD-K01827279-001-11-9	sulindac	Launched	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis	0	81.47	Tocris	1707	Sulindac	356.088	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|	MLKXDPUZXIRXEP-LQVWSKNFSA-N	16046677.0		MLKXDPUZXIRXEP
BRD-K01827279-001-10-9	sulindac	Launched	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis	0	75.39	Selleck	S2007	Sulindac	356.088	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|	MLKXDPUZXIRXEP-LQVWSKNFSA-N	16046677.0		MLKXDPUZXIRXEP
BRD-K01827279-001-13-9	sulindac	Launched	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis	0	95.9	Selleck	S2007	Sulindac (Clinoril)	356.088	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|	MLKXDPUZXIRXEP-LQVWSKNFSA-N	16046677.0		MLKXDPUZXIRXEP
BRD-K01827279-001-12-9	sulindac	Launched	cyclooxygenase inhibitor	AKR1B1	rheumatology	osteoarthritis|rheumatoid arthritis|ankylosing spondylitis	0	67.11	MicroSource	1500556	SULINDAC	356.088	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r,c:1|	MLKXDPUZXIRXEP-LQVWSKNFSA-N	16046677.0		MLKXDPUZXIRXEP
BRD-K38602774-001-03-2	sulisobenzone	Launched			dermatology	sunscreen lotion	0	98.83	MicroSource	1505462	SULISOBENZONE	308.035	COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1	CXVGEDCSTKKODG-UHFFFAOYSA-N	19988.0	BRD-K59265707-001-01-8	CXVGEDCSTKKODG
BRD-K38602774-002-01-4	sulisobenzone	Launched			dermatology	sunscreen lotion	0	97.55	ChemBridge	5304975		308.035	COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1	CXVGEDCSTKKODG-UHFFFAOYSA-N	19988.0		CXVGEDCSTKKODG
BRD-K01824719-001-08-9	sulmazole	Phase 1	adenosine receptor antagonist				0	97.52	SantaCruz	sc-236956	Sulmazole	287.073	COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|	XMFCOYRWYYXZMY-HXUWFJFHSA-N	11859211.0		XMFCOYRWYYXZMY
BRD-K01824719-001-07-9	sulmazole	Phase 1	adenosine receptor antagonist				0	98.4	Prestwick	Prestw-641	Sulmazole	287.073	COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|	XMFCOYRWYYXZMY-HXUWFJFHSA-N	11859211.0		XMFCOYRWYYXZMY
BRD-K29570907-001-07-3	sulmetozine	Launched	gastrin inhibitor	GAST	gastroenterology	peptic ulcer disease (PUD)	0	96.89	Vitas-M	STK877639	4-(3,4,5-trimethoxybenzothioyl)morpholine	297.103	COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1	MVOUIYUWRXPNKD-UHFFFAOYSA-N	65790.0		MVOUIYUWRXPNKD
BRD-K42635745-001-26-9	suloctidil	Withdrawn	adrenergic receptor antagonist				0	79.62	MedChemEx	HY-B1237	Suloctidil	337.244	CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 |&1:9,11|	BFCDFTHTSVTWOG-YLJYHZDGSA-N	657255.0		BFCDFTHTSVTWOG
BRD-K00004713-001-01-9	sulopenem	Phase 3	antibacterial				0	87.61	Sigma	PZ0042	(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1RS,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid	349.011	C[C@@H](O)[C@@H]1[C@H]2SC(S[C@H]3CC[S@@](=O)C3)=C(N2C1=O)C(O)=O |&1:11,c:14|	FLSUCZWOEMTFAQ-PRBGKLEPSA-N	9950244.0		FLSUCZWOEMTFAQ
BRD-K71125014-001-31-9	sulphadimethoxine	Launched	dihydropteroate synthetase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	99.08	MedChemEx	HY-B0337	Sulfadimethoxine	310.074	COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	ZZORFUFYDOWNEF-UHFFFAOYSA-N	5323.0		ZZORFUFYDOWNEF
BRD-K71125014-001-26-3	sulphadimethoxine	Launched	dihydropteroate synthetase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	96.49	Selleck	S1962	Sulphadimethoxine	310.074	COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	ZZORFUFYDOWNEF-UHFFFAOYSA-N	5323.0		ZZORFUFYDOWNEF
BRD-K71125014-001-27-1	sulphadimethoxine	Launched	dihydropteroate synthetase inhibitor		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	97.65	MicroSource	1501144	SULFADIMETHOXINE	310.074	COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	ZZORFUFYDOWNEF-UHFFFAOYSA-N	5323.0		ZZORFUFYDOWNEF
BRD-A55272860-001-16-1	sulpiride	Launched	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	0	98.91	Tocris	894	(RS)-(+/-)-Sulpiride	341.141	CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|	BGRJTUBHPOOWDU-LLVKDONJSA-N	643497.0		BGRJTUBHPOOWDU
BRD-A55272860-001-15-3	sulpiride	Launched	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	0	98.55	MicroSource	1501150	SULPIRIDE	341.141	CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|	BGRJTUBHPOOWDU-LLVKDONJSA-N	643497.0	BRD-A10715913-001-04-6	BGRJTUBHPOOWDU
BRD-A55272860-001-18-9	sulpiride	Launched	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	0	97.3	Tocris	894	(RS)-(+/-)-Sulpiride	341.141	CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|	BGRJTUBHPOOWDU-LLVKDONJSA-N	643497.0		BGRJTUBHPOOWDU
BRD-A55272860-001-14-6	sulpiride	Launched	dopamine receptor antagonist		neurology/psychiatry	schizophrenia	0	97.41	Tocris	894	(RS)-(?)-Sulpiride	341.141	CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6,r|	BGRJTUBHPOOWDU-LLVKDONJSA-N	643497.0		BGRJTUBHPOOWDU
BRD-K00004694-001-01-9	sultamicillin	Launched	antibacterial 		infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	81.3	Bosche	S0258	Sultamicillin	594.145	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C	OPYGFNJSCUDTBT-PMLPCWDUSA-N	444022.0		OPYGFNJSCUDTBT
BRD-K00003488-001-01-9	sultiame	Phase 3	carbonic anhydrase inhibitor	CA2			0	92.35	MedChemEx	HY-108316	Sultiame	290.039	NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O	HMHVCUVYZFYAJI-UHFFFAOYSA-N	5356.0		HMHVCUVYZFYAJI
BRD-K00003312-003-01-9	sultopride	Preclinical	dopamine receptor antagonist				0	89.99	MedChemEx	HY-42849A	Sultopride hydrochloride	354.161	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC |&1:6,r|	UNRHXEPDKXPRTM-ZDUSSCGKSA-N	29010876.0		UNRHXEPDKXPRTM
BRD-K30485548-050-01-6	sumanirole	Phase 3	dopamine receptor agonist	DRD2			0	82.4	Sigma	MFCD09832637	(2Z)-2-butenedioic acid compound with (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (1:1)	203.106	CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23	RKZSNTNMEFVBDT-MRVPVSSYSA-N	9818479.0		RKZSNTNMEFVBDT
BRD-K50938287-001-09-0	sumatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7	neurology/psychiatry	migraine headache	0	54.73	MicroSource	1505372	SUMATRIPTAN	295.135	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	KQKPFRSPSRPDEB-UHFFFAOYSA-N	5358.0		KQKPFRSPSRPDEB
BRD-K50938287-036-16-1	sumatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7	neurology/psychiatry	migraine headache	0	95.23	Tocris	3586	Sumatriptan succinate	295.135	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	KQKPFRSPSRPDEB-UHFFFAOYSA-N	5358.0		KQKPFRSPSRPDEB
BRD-K50938287-036-12-0	sumatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7	neurology/psychiatry	migraine headache	0	90.11	Selleck	S1432	Sumatriptan Succinate	295.135	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	KQKPFRSPSRPDEB-UHFFFAOYSA-N	5358.0		KQKPFRSPSRPDEB
BRD-K50938287-036-13-8	sumatriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7	neurology/psychiatry	migraine headache	0	95.83	Tocris	3586	Sumatriptan succinate	295.135	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	KQKPFRSPSRPDEB-UHFFFAOYSA-N	5358.0		KQKPFRSPSRPDEB
BRD-K36274133-001-02-0	SUN-B-8155	Preclinical	calcitonin agonist	CALCR			0	12.93	Tocris	2550	SUN-B 8155	273.111	C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O	SGJLINMLDNLWOS-CXUHLZMHSA-N			SGJLINMLDNLWOS
BRD-K36274133-001-01-2	SUN-B-8155	Preclinical	calcitonin agonist	CALCR			0	52.27	Tocris	2550	SUN-B 8155	273.111	C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O	SGJLINMLDNLWOS-CXUHLZMHSA-N			SGJLINMLDNLWOS
BRD-K36274133-001-03-9	SUN-B-8155	Preclinical	calcitonin agonist	CALCR			0	70.44	Tocris	2550	SUN-B 8155	273.111	C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O	SGJLINMLDNLWOS-CXUHLZMHSA-N			SGJLINMLDNLWOS
BRD-K71250460-001-02-9	SUN-11602	Preclinical	fibroblast growth factor mimetic	FGFR1			0	90.13	Tocris	4826	SUN 11602	451.295	CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C	KCODNOOPOPTZMO-UHFFFAOYSA-N	22245705.0		KCODNOOPOPTZMO
BRD-K71250460-001-01-1	SUN-11602	Preclinical	fibroblast growth factor mimetic	FGFR1			0	49.28	Tocris	4826	SUN 11602	451.295	CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C	KCODNOOPOPTZMO-UHFFFAOYSA-N	22245705.0		KCODNOOPOPTZMO
BRD-K42828737-001-03-3	sunitinib	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)	0	94.01	MedChemEx	HY-10255A	Sunitinib	398.212	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	WINHZLLDWRZWRT-ATVHPVEESA-N	5329102.0		WINHZLLDWRZWRT
BRD-K42828737-044-09-0	sunitinib	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)	0	88.53	Selleck	S1042	Sunitinib Malate	398.212	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	WINHZLLDWRZWRT-ATVHPVEESA-N	5329102.0		WINHZLLDWRZWRT
BRD-K42828737-044-10-8	sunitinib	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)	0	89.15	Selleck	S1042	Sunitinib Malate (Sutent)	398.212	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	WINHZLLDWRZWRT-ATVHPVEESA-N	5329102.0		WINHZLLDWRZWRT
BRD-K42828737-044-12-4	sunitinib	Launched	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET	oncology	gastrointestinal stromal tumors (GIST)|renal cell carcinoma (RCC)|neuroendocrine tumors of pancreatic origin (PNET)	0	84.41	Tocris	3768	Sunitinib malate	398.212	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	WINHZLLDWRZWRT-ATVHPVEESA-N	5329102.0		WINHZLLDWRZWRT
BRD-A98427211-075-06-1	suplatast	Launched	histamine release inhibitor|immunoglobulin inhibitor		rheumatology	Kimura's disease	0	32.98	MedChemEx	HY-17002	Suplatast (Tosilate)	328.158	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	DYZJXZOQQRXDLE-CQSZACIVSA-O	9957601.0		DYZJXZOQQRXDLE
BRD-A98427211-075-03-8	suplatast	Launched	histamine release inhibitor|immunoglobulin inhibitor		rheumatology	Kimura's disease	0	32.86	Tocris	3543	Suplatast tosylate	328.158	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	DYZJXZOQQRXDLE-CQSZACIVSA-O	9957601.0		DYZJXZOQQRXDLE
BRD-A98427211-075-04-6	suplatast	Launched	histamine release inhibitor|immunoglobulin inhibitor		rheumatology	Kimura's disease	0	33.7	Selleck	S2015	Suplatast tosylate	328.158	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	DYZJXZOQQRXDLE-CQSZACIVSA-O	9957601.0		DYZJXZOQQRXDLE
BRD-A98427211-075-05-3	suplatast	Launched	histamine release inhibitor|immunoglobulin inhibitor		rheumatology	Kimura's disease	0	36.27	MedChemEx	HY-17002	Suplatast (Tosilate)	328.158	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	DYZJXZOQQRXDLE-CQSZACIVSA-O	9957601.0		DYZJXZOQQRXDLE
BRD-A98427211-075-02-0	suplatast	Launched	histamine release inhibitor|immunoglobulin inhibitor		rheumatology	Kimura's disease	0	36.74	Selleck	S2015	Suplatast Tosylate	328.158	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	DYZJXZOQQRXDLE-CQSZACIVSA-O	9957601.0		DYZJXZOQQRXDLE
BRD-A34006693-001-15-4	suprofen	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	97.91	MicroSource	1501161	SUPROFEN	260.051	C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|	MDKGKXOCJGEUJW-SECBINFHSA-N	688581.0		MDKGKXOCJGEUJW
BRD-A34006693-001-14-7	suprofen	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	94.52	Selleck	S1761	Suprofen	260.051	C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|	MDKGKXOCJGEUJW-SECBINFHSA-N	688581.0		MDKGKXOCJGEUJW
BRD-A34006693-001-16-9	suprofen	Withdrawn	cyclooxygenase inhibitor	PTGS1|PTGS2			0	89.97	MedChemEx	HY-B0270	Suprofen	260.051	C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1,r|	MDKGKXOCJGEUJW-SECBINFHSA-N	688581.0		MDKGKXOCJGEUJW
BRD-K70327167-348-13-4	suramin	Launched	DNA synthesis inhibitor	F2|FSHR|P2RY1|P2RY11|P2RY13|P2RY2|PLA2G2A|RYR1|RYR2|SIRT5	infectious disease	African trypanosomiasis|onchocerciasis	0	96.4	MicroSource	1502032	SURAMIN HEXASODIUM	1296.047	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	FIAFUQMPZJWCLV-UHFFFAOYSA-N	5361.0		FIAFUQMPZJWCLV
BRD-K70327167-348-12-6	suramin	Launched	DNA synthesis inhibitor	F2|FSHR|P2RY1|P2RY11|P2RY13|P2RY2|PLA2G2A|RYR1|RYR2|SIRT5	infectious disease	African trypanosomiasis|onchocerciasis	0	0.0	Tocris	1472	Suramin hexasodium salt	1296.047	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	FIAFUQMPZJWCLV-UHFFFAOYSA-N	5361.0		FIAFUQMPZJWCLV
BRD-K98557884-001-01-6	suritozole	Phase 2	GABA receptor inverse agonist	GABBR1			0	91.89	Enamine	Z2306534679	5-(3-fluorophenyl)-2,4-dimethyl-2,4-dihydro-3H-1,2,4-triazole-3-thione	223.058	Cn1nc(-c2cccc(F)c2)n(C)c1=S	IWDUZEHNLHFBRZ-UHFFFAOYSA-N	25431.0		IWDUZEHNLHFBRZ
BRD-K86670086-001-02-5	sutezolid	Phase 2	protein synthesis inhibitor				0	91.81	MedChemEx	HY-10392	Sutezolid	353.121	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1	FNDDDNOJWPQCBZ-ZDUSSCGKSA-N	465951.0		FNDDDNOJWPQCBZ
BRD-K78815826-001-15-9	suxibuzone	Launched	cyclooxygenase inhibitor		rheumatology|neurology/psychiatry	joint pain|muscle pain	0	97.28	MedChemEx	HY-B1079	Suxibuzone	438.179	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	ONWXNHPOAGOMTG-UHFFFAOYSA-N	5362.0		ONWXNHPOAGOMTG
BRD-K78815826-001-13-8	suxibuzone	Launched	cyclooxygenase inhibitor		rheumatology|neurology/psychiatry	joint pain|muscle pain	0	96.64	Selleck	S4367	Suxibuzone	438.179	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	ONWXNHPOAGOMTG-UHFFFAOYSA-N	5362.0		ONWXNHPOAGOMTG
BRD-K78815826-001-14-6	suxibuzone	Launched	cyclooxygenase inhibitor		rheumatology|neurology/psychiatry	joint pain|muscle pain	0	97.83	MicroSource	1501157	SUXIBUZONE	438.179	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	ONWXNHPOAGOMTG-UHFFFAOYSA-N	5362.0		ONWXNHPOAGOMTG
BRD-K00003547-001-01-9	SU014813	Phase 2	PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	KDR			0	67.11	MedChemEx	HY-10501	SU14813	442.202	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	CTNPALGJUAXMMC-PMFHANACSA-N	10138259.0		CTNPALGJUAXMMC
BRD-K02965346-001-07-5	SU11274	Preclinical	hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor	MET			0	96.9	Selleck	S1080	SU11274	567.171	CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1	FPYJSJDOHRDAMT-KQWNVCNZSA-N	9549297.0	BRD-K59067695-001-02-0	FPYJSJDOHRDAMT
BRD-K02965346-001-06-7	SU11274	Preclinical	hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor	MET			0	94.73	Tocris	4101	SU 11274	567.171	CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1	FPYJSJDOHRDAMT-KQWNVCNZSA-N	9549297.0		FPYJSJDOHRDAMT
BRD-K91106808-001-03-9	SU16f	Preclinical	PDGFR tyrosine kinase receptor inhibitor	PDGFRB			0	93.54	Tocris	3304	SU 16f	386.163	Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O	APYYTEJNOZQZNA-MOSHPQCFSA-N	5329150.0		APYYTEJNOZQZNA
BRD-K91106808-001-02-0	SU16f	Preclinical	PDGFR tyrosine kinase receptor inhibitor	PDGFRB			0	91.62	Tocris	3304	SU 16f	386.163	Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O	APYYTEJNOZQZNA-MOSHPQCFSA-N	5329150.0		APYYTEJNOZQZNA
BRD-K32730239-001-02-8	SU3327	Preclinical	JNK inhibitor	MAPK8			0	94.69	Tocris	3607	SU 3327	260.945	Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	NQQBNZBOOHHVQP-UHFFFAOYSA-N	11837140.0		NQQBNZBOOHHVQP
BRD-K32730239-001-01-0	SU3327	Preclinical	JNK inhibitor	MAPK8			0	94.58	Tocris	3607	SU 3327	260.945	Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	NQQBNZBOOHHVQP-UHFFFAOYSA-N	11837140.0		NQQBNZBOOHHVQP
BRD-K32730239-001-03-9	SU3327	Preclinical	JNK inhibitor	MAPK8			0	87.95	Tocris	3607	SU 3327	260.945	Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	NQQBNZBOOHHVQP-UHFFFAOYSA-N	11837140.0		NQQBNZBOOHHVQP
BRD-K20287671-001-07-9	SU4312	Preclinical	PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor	KDR|PDGFRB			0	66.55	Tocris	1459	SU 4312	264.126	CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1	UAKWLVYMKBWHMX-PTNGSMBKSA-N	6450842.0		UAKWLVYMKBWHMX
BRD-K20287671-001-06-9	SU4312	Preclinical	PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor	KDR|PDGFRB			0	67.6	Tocris	1459	SU 4312	264.126	CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1	UAKWLVYMKBWHMX-PTNGSMBKSA-N	6450842.0		UAKWLVYMKBWHMX
BRD-K94883909-001-18-5	SU9516	Preclinical	CDK inhibitor	CDK1|CDK2|CDK4|CDK5			0	70.89	Tocris	2907	SU 9516	241.085	COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1	QNUKRWAIZMBVCU-WCIBSUBMSA-N	5289419.0		QNUKRWAIZMBVCU
BRD-K94883909-001-17-7	SU9516	Preclinical	CDK inhibitor	CDK1|CDK2|CDK4|CDK5			0	87.43	MedChemEx	HY-18629	SU9516	241.085	COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1	QNUKRWAIZMBVCU-WCIBSUBMSA-N	5289419.0		QNUKRWAIZMBVCU
BRD-K15170068-001-03-2	swainsonine	Phase 2	alpha mannosidase inhibitor	MAN2A1			0	97.53	Enzo	S112	Swainsonine	173.105	O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O	FXUAIOOAOAVCGD-WCTZXXKLSA-N	51683.0		FXUAIOOAOAVCGD
BRD-K45385835-001-03-2	SX-011	Preclinical	MAP kinase inhibitor	MAPK14			0	97.88	Tocris	3639	2-(6-chloro-5-{[4-(4-fluorobenzyl)-1-piperidinyl]carbonyl}-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide	483.172	CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	GUTYHDCSDBBMGW-UHFFFAOYSA-N	9935015.0		GUTYHDCSDBBMGW
BRD-K45385835-001-02-4	SX-011	Preclinical	MAP kinase inhibitor	MAPK14			0	83.67	Tocris	3639	SX 011	483.172	CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	GUTYHDCSDBBMGW-UHFFFAOYSA-N	9935015.0		GUTYHDCSDBBMGW
BRD-K00004665-001-01-9	SY-640	Phase 2					0	94.75	Enamine	EN300-1699968	N-[(2H-1,3-benzodioxol-5-yl)methyl]-N-methylacetamide	207.09	CN(Cc1ccc2OCOc2c1)C(C)=O	JIWDGIYBLGMPRV-UHFFFAOYSA-N	9837165.0		JIWDGIYBLGMPRV
BRD-K72106461-001-02-1	SYM-2081	Preclinical	kainate receptor antagonist	GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SLC1A2			1	0.0	Enzo	AC428	SYM 2081	161.069	C[C@H](C[C@H](N)C(O)=O)C(O)=O	KRKRAOXTGDJWNI-DMTCNVIQSA-N	95883.0		KRKRAOXTGDJWNI
BRD-K72106461-001-03-9	SYM-2081	Preclinical	kainate receptor antagonist	GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SLC1A2			1	70.5	Tocris	903	SYM 2081	161.069	C[C@H](C[C@H](N)C(O)=O)C(O)=O	KRKRAOXTGDJWNI-DMTCNVIQSA-N	95883.0		KRKRAOXTGDJWNI
BRD-A77218119-001-04-3	SYM-2206	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	95.25	Tocris	961	8-(4-aminophenyl)-5-methyl-N-propyl[1,3]dioxolo[4,5-g]phthalazine-6(5H)-carboxamide	366.169	CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|	OFUDZKKOKPGXOH-LBPRGKRZSA-N	92209239.0		OFUDZKKOKPGXOH
BRD-A77218119-001-03-5	SYM-2206	Preclinical	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	84.15	Tocris	961	SYM 2206	366.169	CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r,t:7|	OFUDZKKOKPGXOH-LBPRGKRZSA-N	92209239.0		OFUDZKKOKPGXOH
BRD-K33642804-001-01-1	symclosene	Preclinical					0	0.0	MicroSource	1506189	SYMCLOSENE	230.901	Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O	YRIZYWQGELRKNT-UHFFFAOYSA-N	6909.0		YRIZYWQGELRKNT
BRD-K33642804-001-02-9	symclosene	Preclinical					0	0.0	Sigma	176125	Trichloroisocyanuric acid	230.901	Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O	YRIZYWQGELRKNT-UHFFFAOYSA-N	6909.0		YRIZYWQGELRKNT
BRD-K01825585-003-03-9	synephrine	Launched	adrenergic receptor agonist	ADRA1A	otolaryngology	sinusitis	0	100.0	Selleck	S2438	Synephrine HCl	203.071	CNC[C@@H](O)c1ccc(O)cc1 |&1:3|	YRCWQPVGYLYSOX-SECBINFHSA-N	667452.0		YRCWQPVGYLYSOX
BRD-K01825585-003-02-9	synephrine	Launched	adrenergic receptor agonist	ADRA1A	otolaryngology	sinusitis	0	0.0	Selleck	S2438	Synephrine HCl	203.071	CNC[C@@H](O)c1ccc(O)cc1 |&1:3|	YRCWQPVGYLYSOX-SECBINFHSA-N	667452.0		YRCWQPVGYLYSOX
BRD-K12745498-001-02-6	S1P1-agonist-III	Preclinical	sphingosine kinase inhibitor	S1PR1			0	64.83	Tocris	4747	TC-G 1006	415.114	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	MLDQTQOMWDNTNN-UHFFFAOYSA-N	54764919.0		MLDQTQOMWDNTNN
BRD-K12745498-001-03-4	S1P1-agonist-III	Preclinical	sphingosine kinase inhibitor	S1PR1			0	94.83	MedChemEx	HY-12835	S1P1 Agonist III	415.114	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	MLDQTQOMWDNTNN-UHFFFAOYSA-N	54764919.0		MLDQTQOMWDNTNN
BRD-K12745498-001-01-8	S1P1-agonist-III	Preclinical	sphingosine kinase inhibitor	S1PR1			0	76.48	MedChemEx	HY-12835	S1P1 Agonist III	415.114	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	MLDQTQOMWDNTNN-UHFFFAOYSA-N	54764919.0		MLDQTQOMWDNTNN
BRD-K00004653-001-01-9	S15535	Preclinical	serotonin receptor agonist				0	96.36	Sigma	S5321	S15535	336.184	C1C(Cc2ccccc12)N1CCN(CC1)c1cccc2OCCOc12	QJPPEMXOOWNICQ-UHFFFAOYSA-N	132787.0		QJPPEMXOOWNICQ
BRD-K02501528-001-01-1	S18986	Phase 2	glutamate receptor modulator	GRIA1|GRIA2|GRIA3|GRIA4			0	95.87	EMDBio	504983-5MG	S18986	224.062	O=S1(=O)N[C@H]2CCCN2c2ccccc12	MNTIJYGEITVWHU-SNVBAGLBSA-N	637863.0		MNTIJYGEITVWHU
BRD-K48826825-001-02-6	S26948	Preclinical	PPAR receptor agonist	PPARG			0	98.35	Tocris	3690	S26948	519.135	COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	NSMJEHGOMXSLCW-UHFFFAOYSA-N	9958279.0		NSMJEHGOMXSLCW
BRD-K48826825-001-01-8	S26948	Preclinical	PPAR receptor agonist	PPARG			0	89.05	Tocris	3690	S26948	519.135	COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	NSMJEHGOMXSLCW-UHFFFAOYSA-N	9958279.0		NSMJEHGOMXSLCW
BRD-K48826825-001-04-9	S26948	Preclinical	PPAR receptor agonist	PPARG			0	96.39	Tocris	3690	S26948	519.135	COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	NSMJEHGOMXSLCW-UHFFFAOYSA-N	9958279.0		NSMJEHGOMXSLCW
BRD-K96798615-001-01-4	S4	Preclinical	carbonic anhydrase inhibitor	CA12|CA9			0	26.89	Tocris	5577	S4	335.094	Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1	HGVHSNXRZYOTPD-UHFFFAOYSA-N	53342705.0		HGVHSNXRZYOTPD
BRD-K96798615-001-02-9	S4	Preclinical	carbonic anhydrase inhibitor	CA12|CA9			0	91.97	Tocris	5577	S4	335.094	Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1	HGVHSNXRZYOTPD-UHFFFAOYSA-N	53342705.0		HGVHSNXRZYOTPD
BRD-K00003147-001-01-9	S49076	Preclinical	tyrosine kinase inhibitor				0	74.75	MedChemEx	HY-12965	S49076	438.136	O=C1CSC(=O)N1Cc1ccc2NC(=O)\C(=C/c3cc(CN4CCOCC4)c[nH]3)c2c1	AREYWCZYVPSHGS-NVMNQCDNSA-N	49870909.0		AREYWCZYVPSHGS
BRD-K91876515-001-03-9	S63845	Preclinical	MCL1 inhibitor				0	96.1	MedChemEx	HY-100741	S63845	828.212	CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1	ZFBHXVOCZBPADE-SSEXGKCCSA-N	122197581.0		ZFBHXVOCZBPADE
BRD-K31843556-001-05-8	T-0070907	Preclinical	PPAR receptor antagonist	PPARG			0	95.18	Tocris	2301	T 0070907	277.025	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	FRPJSHKMZHWJBE-UHFFFAOYSA-N	2777391.0		FRPJSHKMZHWJBE
BRD-K31843556-001-04-1	T-0070907	Preclinical	PPAR receptor antagonist	PPARG			0	98.04	Tocris	2301	T 0070907	277.025	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	FRPJSHKMZHWJBE-UHFFFAOYSA-N	2777391.0		FRPJSHKMZHWJBE
BRD-K31843556-001-07-9	T-0070907	Preclinical	PPAR receptor antagonist	PPARG			0	86.91	Tocris	2301	T 0070907	277.025	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	FRPJSHKMZHWJBE-UHFFFAOYSA-N	2777391.0		FRPJSHKMZHWJBE
BRD-K31843556-001-03-3	T-0070907	Preclinical	PPAR receptor antagonist	PPARG			0	96.68	Selleck	S2871	T0070907	277.025	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	FRPJSHKMZHWJBE-UHFFFAOYSA-N	2777391.0		FRPJSHKMZHWJBE
BRD-K63516691-003-03-8	T-0156	Preclinical	phosphodiesterase inhibitor	PDE5A			0	98.39	Tocris	1676	T 0156 hydrochloride	583.207	COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	JEMJAABFSYOLAP-UHFFFAOYSA-N	5368.0		JEMJAABFSYOLAP
BRD-K63516691-003-04-9	T-0156	Preclinical	phosphodiesterase inhibitor	PDE5A			0	97.81	Tocris	1676	T 0156 hydrochloride	583.207	COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	JEMJAABFSYOLAP-UHFFFAOYSA-N	5368.0		JEMJAABFSYOLAP
BRD-K63516691-003-02-0	T-0156	Preclinical	phosphodiesterase inhibitor	PDE5A			0	93.62	Tocris	1676	T 0156 hydrochloride	583.207	COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	JEMJAABFSYOLAP-UHFFFAOYSA-N	5368.0		JEMJAABFSYOLAP
BRD-K16605796-001-01-9	T-025	Preclinical	CLK inhibitor				0		Broad Institute		T-025	382.165	CNc1nc(NCc2ncccn2)c2c(c[nH]c2n1)-c1ccc2ncccc2c1	PMWVYONICYRLNY-UHFFFAOYSA-N	133082038.0		PMWVYONICYRLNY
BRD-K23383398-001-10-7	T-0901317	Preclinical	LXR agonist	NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB			0	92.89	Tocris	2373	T 0901317	481.039	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	SGIWFELWJPNFDH-UHFFFAOYSA-N	447912.0		SGIWFELWJPNFDH
BRD-K23383398-001-09-9	T-0901317	Preclinical	LXR agonist	NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB			0	96.75	Tocris	2373	T 0901317	481.039	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	SGIWFELWJPNFDH-UHFFFAOYSA-N	447912.0		SGIWFELWJPNFDH
BRD-K23383398-001-08-1	T-0901317	Preclinical	LXR agonist	NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB			0	96.1	Selleck	S7076	T0901317	481.039	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	SGIWFELWJPNFDH-UHFFFAOYSA-N	447912.0		SGIWFELWJPNFDH
BRD-K23383398-001-11-9	T-0901317	Preclinical	LXR agonist	NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB			0	95.81	Tocris	2373	T 0901317	481.039	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	SGIWFELWJPNFDH-UHFFFAOYSA-N	447912.0		SGIWFELWJPNFDH
BRD-K00004631-001-01-9	T-1095	Preclinical	sodium/glucose cotransporter inhibitor				0	89.4	AMS	M15305	T-1095	516.163	COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O	BXNCIERBDJYIQT-PRDVQWLOSA-N	6918410.0		BXNCIERBDJYIQT
BRD-K84925803-001-01-9	T-5224	Phase 2	AP inhibitor	JUN			0	92.03	MedChemEx	HY-12270	T-5224	517.174	OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O	DALCQQSLNPLQFZ-UHFFFAOYSA-N	23626877.0		DALCQQSLNPLQFZ
BRD-K84925803-001-02-9	T-5224	Phase 2	AP inhibitor	JUN			0	95.74	MedChemEx	HY-12270	T-5224	517.174	OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O	DALCQQSLNPLQFZ-UHFFFAOYSA-N	23626877.0		DALCQQSLNPLQFZ
BRD-K83492904-001-03-9	T-5601640	Preclinical	LIM kinase inhibitor	LIMK2			0	98.0	Tocris	5269	T 5601640	389.099	Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F	XVOKFRPKSAWELK-UHFFFAOYSA-N	9438169.0		XVOKFRPKSAWELK
BRD-K83492904-001-01-9	T-5601640	Preclinical	LIM kinase inhibitor	LIMK2			0	99.12	Tocris	5269	T 5601640	389.099	Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F	XVOKFRPKSAWELK-UHFFFAOYSA-N	9438169.0		XVOKFRPKSAWELK
BRD-K09001147-001-02-4	T-62	Phase 2	adenosine receptor modulator	ADORA2A			0	63.41	Enamine	Z57052872	(2-amino-4,5,6,7-tetrahydro-1-benzothien-3-yl)(4-chlorophenyl)methanone	291.048	Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	OTZVBZFYMFTYKH-UHFFFAOYSA-N	855908.0		OTZVBZFYMFTYKH
BRD-K09001147-001-01-6	T-62	Phase 2	adenosine receptor modulator	ADORA2A			0	42.13	Enamine	Z57052872		291.048	Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	OTZVBZFYMFTYKH-UHFFFAOYSA-N	855908.0		OTZVBZFYMFTYKH
BRD-K00003402-001-01-9	T-807	Phase 2	PET radiotracer				0	85.96	MedChemEx	HY-101184	T807	263.086	Fc1ccc(cn1)-c1ccc2c(c1)[nH]c1ccncc21	GETAAWDSFUCLBS-UHFFFAOYSA-N	71059746.0		GETAAWDSFUCLBS
BRD-K79856806-001-01-0	TA-01	Preclinical	casein kinase inhibitor|MAP kinase inhibitor	CSNK1D|CSNK1E|MAPK14			0	96.68	MedChemEx	HY-100114	TA-01	351.098	Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F	TWPJJJZCYVFUOA-UHFFFAOYSA-N	91691129.0		TWPJJJZCYVFUOA
BRD-K53600683-051-01-5	tabimorelin	Phase 2	growth hormone secretagogue receptor agonist	GHSR			0	92.38	Tocris	2308	Tabimorelin hemifumarate	528.31	CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N	WURGZWOTGMLDJP-ZCYANPAGSA-N	9810101.0	BRD-M26279695-051-02-4	WURGZWOTGMLDJP
BRD-K53600683-051-02-9	tabimorelin	Phase 2	growth hormone secretagogue receptor agonist	GHSR			0	96.19	Tocris	2308	Tabimorelin hemifumarate	528.31	CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N	WURGZWOTGMLDJP-ZCYANPAGSA-N	9810101.0		WURGZWOTGMLDJP
BRD-K73237276-001-02-9	tacalcitol	Launched	vitamin D receptor agonist	VDR	dermatology	psoriasis|chapped lips	0	93.65	MedChemEx	HY-32337	Tacalcitol	416.329	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	BJYLYJCXYAMOFT-RSFVBTMBSA-N	5283734.0		BJYLYJCXYAMOFT
BRD-K73237276-001-01-0	tacalcitol	Launched	vitamin D receptor agonist	VDR	dermatology	psoriasis|chapped lips	0	93.56	MedChemEx	HY-32337	Tacalcitol	416.329	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	BJYLYJCXYAMOFT-RSFVBTMBSA-N	5283734.0		BJYLYJCXYAMOFT
BRD-K52313696-001-14-9	tacedinaline	Phase 3	HDAC inhibitor	HDAC1			0	91.77	Tocris	2952	CI 994	269.116	CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	VAZAPHZUAVEOMC-UHFFFAOYSA-N	2746.0		VAZAPHZUAVEOMC
BRD-K52313696-001-12-3	tacedinaline	Phase 3	HDAC inhibitor	HDAC1			0	97.19	Selleck	S2818	CI994 (Tacedinaline)	269.116	CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	VAZAPHZUAVEOMC-UHFFFAOYSA-N	2746.0		VAZAPHZUAVEOMC
BRD-K81473089-003-24-6	tacrine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease	0	98.02	Selleck	S4357	Tacrine HCl	198.116	Nc1c2CCCCc2nc2ccccc12	YLJREFDVOIBQDA-UHFFFAOYSA-N	1935.0		YLJREFDVOIBQDA
BRD-K81473089-003-26-1	tacrine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease	0	99.35	MicroSource	2300104	TACRINE HYDROCHLORIDE	198.116	Nc1c2CCCCc2nc2ccccc12	YLJREFDVOIBQDA-UHFFFAOYSA-N	1935.0		YLJREFDVOIBQDA
BRD-K81473089-003-27-9	tacrine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease	0	94.62	Tocris	965	Tacrine hydrochloride	198.116	Nc1c2CCCCc2nc2ccccc12	YLJREFDVOIBQDA-UHFFFAOYSA-N	1935.0		YLJREFDVOIBQDA
BRD-K81473089-003-25-3	tacrine	Launched	acetylcholinesterase inhibitor	ACHE|BCHE	neurology/psychiatry	Alzheimer's disease	0	97.59	Tocris	965	Tacrine hydrochloride	198.116	Nc1c2CCCCc2nc2ccccc12	YLJREFDVOIBQDA-UHFFFAOYSA-N	1935.0		YLJREFDVOIBQDA
BRD-K69608737-001-08-6	tacrolimus	Launched	calcineurin inhibitor	FKBP1A	transplant	organ rejection	0	97.24	MedChemEx	HY-13756	tacrolimus	803.482	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|	QJJXYPPXXYFBGM-LFZNUXCKSA-N	445643.0		QJJXYPPXXYFBGM
BRD-K69608737-001-10-2	tacrolimus	Launched	calcineurin inhibitor	FKBP1A	transplant	organ rejection	0	95.5	MicroSource	1503968	TACROLIMUS	803.482	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|	QJJXYPPXXYFBGM-LFZNUXCKSA-N	445643.0	BRD-A96754982-001-01-4	QJJXYPPXXYFBGM
BRD-K69608737-001-09-4	tacrolimus	Launched	calcineurin inhibitor	FKBP1A	transplant	organ rejection	0	92.53	Selleck	S5003	Tacrolimus (FK506)	803.482	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|	QJJXYPPXXYFBGM-LFZNUXCKSA-N	445643.0	BRD-K54509797-001-01-5	QJJXYPPXXYFBGM
BRD-K93645900-001-12-1	tadalafil	Launched	phosphodiesterase inhibitor	PDE11A|PDE5A	urology	erectile dysfunction	0	95.58	MicroSource	1505639	TADALAFIL	389.138	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	WOXKDUGGOYFFRN-IIBYNOLFSA-N	110635.0		WOXKDUGGOYFFRN
BRD-K93645900-001-14-9	tadalafil	Launched	phosphodiesterase inhibitor	PDE11A|PDE5A	urology	erectile dysfunction	0	98.19	Tocris	6311	Tadalafil	389.138	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	WOXKDUGGOYFFRN-IIBYNOLFSA-N	110635.0		WOXKDUGGOYFFRN
BRD-K93645900-001-11-3	tadalafil	Launched	phosphodiesterase inhibitor	PDE11A|PDE5A	urology	erectile dysfunction	0	98.74	Selleck	S1512	Tadalafil	389.138	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	WOXKDUGGOYFFRN-IIBYNOLFSA-N	110635.0		WOXKDUGGOYFFRN
BRD-K23728141-001-01-2	tafamidis-meglumine	Launched	transthyretin amyloid inhibitor	TTR	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	0	99.69	MedChemEx	HY-14852	Tafamidis	306.98	OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1	TXEIIPDJKFWEEC-UHFFFAOYSA-N	11001318.0		TXEIIPDJKFWEEC
BRD-K23728141-001-02-9	tafamidis-meglumine	Launched	transthyretin amyloid inhibitor	TTR	neurology/psychiatry	familial amyloid polyneuropathy (FAP)	0	97.53	MedChemEx	HY-14852	Tafamidis	306.98	OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1	TXEIIPDJKFWEEC-UHFFFAOYSA-N	11001318.0		TXEIIPDJKFWEEC
BRD-A78965079-036-01-8	tafenoquine	Launched	antimalarial agent		infectious disease	malaria	0	82.25	Sigma	SML0396	N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine succinate	463.208	COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(N[C@@H](C)CCCN)c2n1 |&1:25|	LBHLFPGPEGDCJG-HNNXBMFYSA-N	76969188.0		LBHLFPGPEGDCJG
BRD-K65059905-001-02-9	tafluprost	Launched	prostaglandin inhibitor	PTGFR	ophthalmology	glaucoma|ocular hypertension	0	95.14	MedChemEx	HY-B0600	Tafluprost	452.237	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1	WSNODXPBBALQOF-VEJSHDCNSA-N	9868491.0		WSNODXPBBALQOF
BRD-K18320600-001-01-9	tagatose	Launched	phosphorylase inhibitor	PYGL			0	0.0	Sigma	MFCD00134449	D-tagatose	180.063	OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO	BJHIKXHVCXFQLS-PQLUHFTBSA-N	92092.0		BJHIKXHVCXFQLS
BRD-K57155378-001-01-1	TAK-063	Phase 2	phosphodiesterase inhibitor	PDE10A			0	96.14	MedChemEx	HY-12472	TAK-063	428.14	COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1	KVHRYLNQDWXAGI-UHFFFAOYSA-N	46848915.0		KVHRYLNQDWXAGI
BRD-K38793468-001-01-4	TAK-220	Phase 1	CC chemokine receptor antagonist	CCR5			0	96.9	MedChemEx	HY-19974	TAK-220	552.287	CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1	ASSJTMUEFHUKMJ-UHFFFAOYSA-N	5275766.0		ASSJTMUEFHUKMJ
BRD-K00003376-001-01-9	TAK-243	Phase 1	ubiquitin activating enzyme inhibitor				0	95.52	MedChemEx	HY-100487	TAK-243	519.086	NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O	KJDAGXLMHXUAGV-DGWLBADLSA-N	71715374.0		KJDAGXLMHXUAGV
BRD-K80343549-001-03-9	TAK-285	Phase 1	EGFR inhibitor	ERBB2			0	87.32	MedChemEx	HY-15196	TAK-285	547.16	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N	11620908.0		ZYQXEVJIFYIBHZ
BRD-K80343549-001-02-6	TAK-285	Phase 1	EGFR inhibitor	ERBB2			0	95.38	Selleck	S2784	TAK-285	547.16	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	ZYQXEVJIFYIBHZ-UHFFFAOYSA-N	11620908.0		ZYQXEVJIFYIBHZ
BRD-K67262033-001-01-0	TAK-593	Phase 1	VEGFR inhibitor	PDGFRA			0	94.1	MedChemEx	HY-15506	TAK-593	445.186	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1	DZFZXPPHBWCXPQ-UHFFFAOYSA-N	24767976.0		DZFZXPPHBWCXPQ
BRD-K31866293-001-01-6	TAK-632	Preclinical	RAF inhibitor	BRAF			0	97.83	Selleck	S7291	TAK-632	554.104	Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F	OJFKUJDRGJSAQB-UHFFFAOYSA-N	46209401.0		OJFKUJDRGJSAQB
BRD-K71500795-003-02-9	TAK-659	Phase 2	spleen associated tyrosine kinase inhibitor				0	95.02	MedChemEx	HY-100867A	TAK-659 (hydrochloride)	344.176	Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12	MJHOMTRKVMKCNE-NWDGAFQWSA-N	53252276.0		MJHOMTRKVMKCNE
BRD-K52751261-001-08-7	TAK-715	Phase 2	p38 MAPK inhibitor	MAPK14			0	98.88	Tocris	4254	TAK 715	399.141	CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	HEKAIDKUDLCBRU-UHFFFAOYSA-N	9952773.0	BRD-K03865741-001-01-0	HEKAIDKUDLCBRU
BRD-K52751261-001-06-1	TAK-715	Phase 2	p38 MAPK inhibitor	MAPK14			0	96.73	Selleck	S2928	TAK-715	399.141	CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	HEKAIDKUDLCBRU-UHFFFAOYSA-N	9952773.0		HEKAIDKUDLCBRU
BRD-K52751261-001-10-9	TAK-715	Phase 2	p38 MAPK inhibitor	MAPK14			0	97.89	Tocris	4254	TAK 715	399.141	CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	HEKAIDKUDLCBRU-UHFFFAOYSA-N	9952773.0		HEKAIDKUDLCBRU
BRD-K26667523-001-02-5	TAK-733	Phase 1	MEK inhibitor	MAP2K1			0	88.03	Selleck	S2617	TAK-733	504.011	Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	RCLQNICOARASSR-SECBINFHSA-N	24963252.0		RCLQNICOARASSR
BRD-K26667523-001-04-9	TAK-733	Phase 1	MEK inhibitor	MAP2K1			0	98.86	MedChemEx	HY-13449	TAK-733	504.011	Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	RCLQNICOARASSR-SECBINFHSA-N	24963252.0		RCLQNICOARASSR
BRD-K26667523-001-03-3	TAK-733	Phase 1	MEK inhibitor	MAP2K1			0	91.47	Selleck	S2617	TAK-733	504.011	Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	RCLQNICOARASSR-SECBINFHSA-N	24963252.0		RCLQNICOARASSR
BRD-K00003155-003-01-9	TAK-779	Preclinical	CC chemokine receptor antagonist				0	98.08	MedChemEx	HY-13406	TAK-779	495.301	Cc1ccc(cc1)-c1ccc2CCCC(=Cc2c1)C(=O)Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1 |c:15|	XNHZXMPLVSJQFK-UHFFFAOYSA-O	183790.0		XNHZXMPLVSJQFK
BRD-K58501140-001-02-9	TAK-875	Phase 3	insulin secretagogue	FFAR1			0	95.84	MedChemEx	HY-10480	Fasiglifam	524.187	Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1	BZCALJIHZVNMGJ-HSZRJFAPSA-N	24857286.0		BZCALJIHZVNMGJ
BRD-K58501140-002-01-0	TAK-875	Phase 3	insulin secretagogue	FFAR1			0	97.03	Selleck	S2637	TAK-875	524.187	Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1	BZCALJIHZVNMGJ-HSZRJFAPSA-N	24857286.0	BRD-M64443684-002-02-5	BZCALJIHZVNMGJ
BRD-K01683783-001-02-6	TAK-901	Phase 1	Aurora kinase inhibitor	AURKB			0	94.01	Selleck	S2718	TAK-901	504.22	CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	WKDACQVEJIVHMZ-UHFFFAOYSA-N	16124208.0		WKDACQVEJIVHMZ
BRD-K01683783-001-03-9	TAK-901	Phase 1	Aurora kinase inhibitor	AURKB			0	97.57	MedChemEx	HY-12201	TAK-901	504.22	CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	WKDACQVEJIVHMZ-UHFFFAOYSA-N	16124208.0		WKDACQVEJIVHMZ
BRD-K48059512-003-01-0	TAK-960	Phase 1	PLK inhibitor	PLK1			0	98.58	Tocris	5403	TAK 960 hydrochloride	561.268	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1	GWRSATNRNFYMDI-UHFFFAOYSA-N	53357478.0		GWRSATNRNFYMDI
BRD-K48059512-001-01-4	TAK-960	Phase 1	PLK inhibitor	PLK1			0	97.24	MedChemEx	HY-15160	TAK-960	561.268	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1	GWRSATNRNFYMDI-UHFFFAOYSA-N	53357478.0		GWRSATNRNFYMDI
BRD-K37419961-066-03-8	talabostat	Phase 3	dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor	DPP4			0	62.26	MedChemEx	HY-13233A	Talabostat (mesylate)	214.149	CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	FKCMADOPPWWGNZ-YUMQZZPRSA-N	6918572.0		FKCMADOPPWWGNZ
BRD-K37419961-066-02-0	talabostat	Phase 3	dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor	DPP4			0	67.55	MedChemEx	HY-13233A	Talabostat (mesylate)	214.149	CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	FKCMADOPPWWGNZ-YUMQZZPRSA-N	6918572.0		FKCMADOPPWWGNZ
BRD-K37419961-066-01-2	talabostat	Phase 3	dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor	DPP4			0	55.92	MedChemEx	HY-13233A	Talabostat (mesylate)	214.149	CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	FKCMADOPPWWGNZ-YUMQZZPRSA-N	6918572.0		FKCMADOPPWWGNZ
BRD-K50498985-001-03-3	taladegib	Phase 2	smoothened receptor antagonist	DHH|IHH|SMO			0	98.77	MedChemEx	HY-13242	LY2940680	512.195	CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F	SZBGQDXLNMELTB-UHFFFAOYSA-N	49848070.0		SZBGQDXLNMELTB
BRD-K50498985-001-04-9	taladegib	Phase 2	smoothened receptor antagonist	DHH|IHH|SMO			0	99.58	MedChemEx	HY-13242	Taladegib	512.195	CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F	SZBGQDXLNMELTB-UHFFFAOYSA-N	49848070.0		SZBGQDXLNMELTB
BRD-K80359953-001-01-3	talampanel	Phase 2	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	93.0	MedChemEx	HY-15079	Talampanel	337.143	C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|	JACAAXNEHGBPOQ-LLVKDONJSA-N	164509.0		JACAAXNEHGBPOQ
BRD-K80359953-001-02-1	talampanel	Phase 2	glutamate receptor antagonist	GRIA1|GRIA2|GRIA3|GRIA4			0	90.89	Tocris	5032	Talampanel	337.143	C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|	JACAAXNEHGBPOQ-LLVKDONJSA-N	164509.0		JACAAXNEHGBPOQ
BRD-K00004965-342-01-9	talaporfin	Phase 3	photosensitizing agent				0	83.11	MedChemEx	HY-16477	Talaporfin (sodium)	711.29	CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(=O)N[C@@H](CC(O)=O)C(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C	SIEXFRDYNDREBM-WSUYNKMOSA-N			SIEXFRDYNDREBM
BRD-A95755460-001-02-9	talarozole	Phase 2	cytochrome P450 inhibitor	CYP26A1			0	96.25	MedChemEx	HY-14531	Talarozole	377.167	CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|	SNFYYXUGUBUECJ-FQEVSTJZSA-N	76958553.0		SNFYYXUGUBUECJ
BRD-A95755460-001-01-3	talarozole	Phase 2	cytochrome P450 inhibitor	CYP26A1			0	94.65	MedChemEx	HY-14531	Talarozole	377.167	CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5,r|	SNFYYXUGUBUECJ-FQEVSTJZSA-N	76958553.0		SNFYYXUGUBUECJ
BRD-K95142244-001-01-5	talazoparib	Launched	PARP inhibitor	PARP2	oncology	breast cancer	0	97.61	Selleck	S7048	BMN 673	380.12	Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	HWGQMRYQVZSGDQ-HZPDHXFCSA-N	135565082.0		HWGQMRYQVZSGDQ
BRD-K95142244-001-03-9	talazoparib	Launched	PARP inhibitor	PARP2	oncology	breast cancer	0	96.38	MedChemEx	HY-16106	Talazoparib	380.12	Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	HWGQMRYQVZSGDQ-HZPDHXFCSA-N	135565082.0		HWGQMRYQVZSGDQ
BRD-A94276798-001-01-4	talinolol	Launched	adrenergic receptor antagonist	ADRB1	cardiology	hypertension	0	90.03	Cayman	16116		363.252	CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6,r|	MXFWWQICDIZSOA-QGZVFWFLSA-N	156154.0		MXFWWQICDIZSOA
BRD-K75615183-300-04-7	talipexole	Launched	adrenergic receptor agonist|dopamine receptor agonist	ADRA2A|DRD2|HTR3A	infectious disease	genitial herpes	0	83.1	MedChemEx	HY-A0008	6-allyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[4,5-d]azepin-2-ylamine dihydrochloride	209.099	Nc1nc2CCN(CC=C)CCc2s1	DHSSDEDRBUKTQY-UHFFFAOYSA-N	5374.0		DHSSDEDRBUKTQY
BRD-K75615183-300-05-4	talipexole	Launched	adrenergic receptor agonist|dopamine receptor agonist	ADRA2A|DRD2|HTR3A	infectious disease	genitial herpes	0	83.28	MedChemEx	HY-A0008	B-HT 920	209.099	Nc1nc2CCN(CC=C)CCc2s1	DHSSDEDRBUKTQY-UHFFFAOYSA-N	5374.0		DHSSDEDRBUKTQY
BRD-K75615183-300-06-2	talipexole	Launched	adrenergic receptor agonist|dopamine receptor agonist	ADRA2A|DRD2|HTR3A	infectious disease	genitial herpes	0	84.52	MedChemEx	HY-A0008	B-HT 920	209.099	Nc1nc2CCN(CC=C)CCc2s1	DHSSDEDRBUKTQY-UHFFFAOYSA-N	5374.0		DHSSDEDRBUKTQY
BRD-K75615183-300-03-9	talipexole	Launched	adrenergic receptor agonist|dopamine receptor agonist	ADRA2A|DRD2|HTR3A	infectious disease	genitial herpes	0	77.83	Enzo	AC253	B-HT 920 2HCl	209.099	Nc1nc2CCN(CC=C)CCc2s1	DHSSDEDRBUKTQY-UHFFFAOYSA-N	5374.0		DHSSDEDRBUKTQY
BRD-K17555800-003-02-3	talmapimod	Phase 2	p38 MAPK inhibitor	IL1B|MAPK11|MAPK14|MT-CO2|TNF			0	97.0	Tocris	3528	SCIO 469 hydrochloride	512.199	C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	ZMELOYOKMZBMRB-DLBZAZTESA-N	9871074.0		ZMELOYOKMZBMRB
BRD-K17555800-003-01-5	talmapimod	Phase 2	p38 MAPK inhibitor	IL1B|MAPK11|MAPK14|MT-CO2|TNF			0	98.07	Tocris	3528	SCIO 469 hydrochloride	512.199	C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	ZMELOYOKMZBMRB-DLBZAZTESA-N	9871074.0		ZMELOYOKMZBMRB
BRD-K17555800-001-01-9	talmapimod	Phase 2	p38 MAPK inhibitor	IL1B|MAPK11|MAPK14|MT-CO2|TNF			0	95.77	MedChemEx	HY-10406	SCIO-469	512.199	C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	ZMELOYOKMZBMRB-DLBZAZTESA-N	9871074.0		ZMELOYOKMZBMRB
BRD-K47095176-001-02-9	talnetant	Phase 2	tachykinin antagonist	TACR2|TACR3			0	97.97	Tocris	4672	SB 223412	382.168	CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	BIAVGWDGIJKWRM-FQEVSTJZSA-N	5311424.0		BIAVGWDGIJKWRM
BRD-K47095176-001-01-6	talnetant	Phase 2	tachykinin antagonist	TACR2|TACR3			0	98.57	MedChemEx	HY-14552	Talnetant	382.168	CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	BIAVGWDGIJKWRM-FQEVSTJZSA-N	5311424.0		BIAVGWDGIJKWRM
BRD-A98378129-001-03-0	talniflumate	Launched	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	0	93.24	Tocris	2510	Talniflumate	414.083	FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|	ANMLJLFWUCQGKZ-HXUWFJFHSA-N	25273599.0		ANMLJLFWUCQGKZ
BRD-A98378129-001-02-2	talniflumate	Launched	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	0	92.13	Tocris	2510	Talniflumate	414.083	FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|	ANMLJLFWUCQGKZ-HXUWFJFHSA-N	25273599.0		ANMLJLFWUCQGKZ
BRD-A98378129-001-04-9	talniflumate	Launched	cyclooxygenase inhibitor	CLCA1	neurology/psychiatry	pain relief	0	96.4	Tocris	2510	Talniflumate	414.083	FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19,r|	ANMLJLFWUCQGKZ-HXUWFJFHSA-N	25273599.0		ANMLJLFWUCQGKZ
BRD-A02532772-003-01-7	talopram	Phase 2	adrenergic inhibitor	SLC6A2			0	92.77	Tocris	3145	Talopram hydrochloride	295.194	CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|	LJBBMCNHIUJBDU-FQEVSTJZSA-N	76958671.0		LJBBMCNHIUJBDU
BRD-A02532772-003-02-9	talopram	Phase 2	adrenergic inhibitor	SLC6A2			0	96.24	Tocris	3145	Talopram hydrochloride	295.194	CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|	LJBBMCNHIUJBDU-FQEVSTJZSA-N	76958671.0		LJBBMCNHIUJBDU
BRD-K00004651-001-01-9	talsaclidine	Phase 2/Phase 3	acetylcholine receptor agonist				0	0.0	Sigma	T2452	(3R)-3-(2-propynyloxy)-1-azabicyclo[2.2.2]octane	165.115	C#CCO[C@H]1CN2CCC1CC2	XVFJONKUSLSKSW-JTQLQIEISA-N	71792.0		XVFJONKUSLSKSW
BRD-K93869735-001-03-9	taltirelin	Launched	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	0	95.09	MedChemEx	HY-B0596	Taltirelin	405.176	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	LQZAIAZUDWIVPM-SRVKXCTJSA-N	114750.0		LQZAIAZUDWIVPM
BRD-K93869735-001-01-1	taltirelin	Launched	thyrotropin releasing hormone receptor agonist	TRHR	neurology/psychiatry	spinocerebellar ataxia	0	86.52	MedChemEx	HY-B0596	Taltirelin	405.176	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	LQZAIAZUDWIVPM-SRVKXCTJSA-N	114750.0		LQZAIAZUDWIVPM
BRD-K87512222-019-01-7	taltobulin	Phase 1	tubulin polymerization inhibitor				0	96.83	MedChemEx	HY-15584A	Taltobulin (trifluoroacetate)	473.325	CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1	CNTMOLDWXSVYKD-PSRNMDMQSA-N	6918637.0		CNTMOLDWXSVYKD
BRD-K87512222-019-02-9	taltobulin	Phase 1	tubulin polymerization inhibitor				0	89.21	MedChemEx	HY-15584A	Taltobulin (trifluoroacetate)	473.325	CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1	CNTMOLDWXSVYKD-PSRNMDMQSA-N	6918637.0		CNTMOLDWXSVYKD
BRD-K72231366-001-03-9	TAME	Preclinical					0	94.63	MedChemEx	HY-13255	TAME	342.136	COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	FKMJXALNHKIDOD-LBPRGKRZSA-N	1550286.0		FKMJXALNHKIDOD
BRD-K72231366-001-02-3	TAME	Preclinical					0	91.82	Selleck	S2225	TAME	342.136	COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	FKMJXALNHKIDOD-LBPRGKRZSA-N	1550286.0		FKMJXALNHKIDOD
BRD-K36627727-001-05-4	tamibarotene	Launched	retinoid receptor agonist	RARA|RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	0	97.33	Selleck	S4260	Tamibarotene	351.183	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	MUTNCGKQJGXKEM-UHFFFAOYSA-N	108143.0		MUTNCGKQJGXKEM
BRD-K36627727-001-06-2	tamibarotene	Launched	retinoid receptor agonist	RARA|RARB	hematologic malignancy	acute promyelocytic leukemia (APL)	0	99.43	MedChemEx	HY-14652	Tamibarotene	351.183	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)	108143.0		MUTNCGKQJGXKEM
BRD-K00004682-001-01-9	taminadenant	Phase 1/Phase 2	adenosine receptor antagonist				0	89.55	AMS	A232307	5-bromo-2,6-di(pyrazol-1-yl)pyrimidin-4-amine	305.002	Nc1nc(nc(c1Br)-n1cccn1)-n1cccn1	ATFXVNUWQOXRRU-UHFFFAOYSA-N	53466958.0		ATFXVNUWQOXRRU
BRD-K93754473-048-23-6	tamoxifen	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ	oncology	breast cancer	0	97.31	Tocris	999	Tamoxifen citrate	371.225	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	NKANXQFJJICGDU-QPLCGJKRSA-N	2733526.0		NKANXQFJJICGDU
BRD-K93754473-048-27-9	tamoxifen	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ	oncology	breast cancer	0	93.7	Tocris	999	Tamoxifen citrate	371.225	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	NKANXQFJJICGDU-QPLCGJKRSA-N	2733526.0		NKANXQFJJICGDU
BRD-K93754473-048-18-6	tamoxifen	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ	oncology	breast cancer	0	84.13	Selleck	S1972	Tamoxifen Citrate	371.225	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	NKANXQFJJICGDU-QPLCGJKRSA-N	2733526.0		NKANXQFJJICGDU
BRD-K93754473-048-19-4	tamoxifen	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ	oncology	breast cancer	0	89.73	Tocris	999	Tamoxifen citrate	371.225	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	NKANXQFJJICGDU-QPLCGJKRSA-N	2733526.0		NKANXQFJJICGDU
BRD-K93754473-048-20-2	tamoxifen	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ	oncology	breast cancer	0	92.67	MicroSource	1500557	TAMOXIFEN CITRATE	371.225	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	NKANXQFJJICGDU-QPLCGJKRSA-N	2733526.0		NKANXQFJJICGDU
BRD-K93754473-048-21-0	tamoxifen	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ	oncology	breast cancer	0	97.2	Selleck	S1972	Tamoxifen Citrate (Nolvadex)	371.225	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	NKANXQFJJICGDU-QPLCGJKRSA-N	2733526.0		NKANXQFJJICGDU
BRD-K74339692-003-03-1	tamsulosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D	urology	benign prostatic hyperplasia (BPH)	0	90.72	Tocris	3050	Tamsulosin hydrochloride	408.172	CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O	DRHKJLXJIQTDTD-OAHLLOKOSA-N	129211.0		DRHKJLXJIQTDTD
BRD-K74339692-001-01-9	tamsulosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D	urology	benign prostatic hyperplasia (BPH)	0	99.03	Enzo	DL160	Tamsulosin HCl	408.172	CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O	DRHKJLXJIQTDTD-OAHLLOKOSA-N	129211.0		DRHKJLXJIQTDTD
BRD-K99604664-001-02-9	tanaproget	Phase 2	progesterone receptor agonist	PGR			0	98.3	MedChemEx	HY-15606	Tanaproget	297.094	Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N	PYVFWTPEBMRKSR-UHFFFAOYSA-N	4369524.0		PYVFWTPEBMRKSR
BRD-K99604664-001-01-1	tanaproget	Phase 2	progesterone receptor agonist	PGR			0	91.62	MedChemEx	HY-15606	Tanaproget	297.094	Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N	PYVFWTPEBMRKSR-UHFFFAOYSA-N	4369524.0		PYVFWTPEBMRKSR
BRD-K65904673-003-01-0	tandospirone	Launched	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)|dysthymic disorder	0	89.65	Tocris	2854	Tandospirone hydrochloride	383.232	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	CEIJFEGBUDEYSX-FZDBZEDMSA-N	91273.0		CEIJFEGBUDEYSX
BRD-K65904673-001-01-4	tandospirone	Launched	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)|dysthymic disorder	0	98.71	MedChemEx	HY-14558	Tandospirone	383.232	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	CEIJFEGBUDEYSX-FZDBZEDMSA-N	91273.0		CEIJFEGBUDEYSX
BRD-K65904673-003-02-9	tandospirone	Launched	serotonin receptor agonist	HTR1A	neurology/psychiatry	generalized anxiety disorder (GAD)|dysthymic disorder	0	93.23	Tocris	2854	Tandospirone hydrochloride	383.232	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	CEIJFEGBUDEYSX-FZDBZEDMSA-N	91273.0		CEIJFEGBUDEYSX
BRD-K89162000-001-12-9	tandutinib	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	CSF1R|FLT3|KIT|PDGFD|PDGFRB			0	97.46	MedChemEx	HY-10202	Tandutinib	562.327	COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	UXXQOJXBIDBUAC-UHFFFAOYSA-N	3038522.0		UXXQOJXBIDBUAC
BRD-K89162000-001-07-2	tandutinib	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	CSF1R|FLT3|KIT|PDGFD|PDGFRB			0	90.65	MicroSource	1502277	TANDUTINIB	562.327	COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	UXXQOJXBIDBUAC-UHFFFAOYSA-N	3038522.0		UXXQOJXBIDBUAC
BRD-K89162000-001-06-4	tandutinib	Phase 2	FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor	CSF1R|FLT3|KIT|PDGFD|PDGFRB			0	94.36	Selleck	S1043	Tandutinib (MLN518)	562.327	COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	UXXQOJXBIDBUAC-UHFFFAOYSA-N	3038522.0		UXXQOJXBIDBUAC
BRD-K81473043-001-22-9	tanespimycin	Phase 3	HSP inhibitor	HSP90AA1			0	43.69	MedChemEx	HY-10211	Tanespimycin	585.305	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|	AYUNIORJHRXIBJ-FBDSWQSESA-N	59996479.0		AYUNIORJHRXIBJ
BRD-K81473043-001-14-6	tanespimycin	Phase 3	HSP inhibitor	HSP90AA1			0	97.71	Selleck	S1141	17-AAG (Tanespimycin)	585.305	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|	AYUNIORJHRXIBJ-FBDSWQSESA-N	59996479.0		AYUNIORJHRXIBJ
BRD-K81473043-001-23-9	tanespimycin	Phase 3	HSP inhibitor	HSP90AA1			0	94.67	Tocris	1515	17-AAG	585.305	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|	AYUNIORJHRXIBJ-FBDSWQSESA-N	59996479.0		AYUNIORJHRXIBJ
BRD-K81473043-001-19-5	tanespimycin	Phase 3	HSP inhibitor	HSP90AA1			0	78.07	Selleck	S1141	17-AAG (Tanespimycin)	585.305	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7,23,t:15,21,34|	AYUNIORJHRXIBJ-FBDSWQSESA-N	59996479.0	BRD-K34504123-001-01-6	AYUNIORJHRXIBJ
BRD-K25186396-001-10-9	tangeritin	Preclinical	cell cycle inhibitor				0	97.77	MedChemEx	HY-N0133	Tangeretin	372.121	COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	ULSUXBXHSYSGDT-UHFFFAOYSA-N	68077.0		ULSUXBXHSYSGDT
BRD-K25186396-001-09-6	tangeritin	Preclinical	cell cycle inhibitor				0	97.49	Selleck	S2363	Tangeretin	372.121	COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	ULSUXBXHSYSGDT-UHFFFAOYSA-N	68077.0		ULSUXBXHSYSGDT
BRD-K01584643-001-04-9	tannic-acid	Launched	PARG inhibitor	ANO1	gastroenterology	constipation	0	100.0	MedChemEx	HY-B2136	Tannic acid	1700.173	Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1	LRBQNJMCXXYXIU-PPKXGCFTSA-N	16129778.0		LRBQNJMCXXYXIU
BRD-K34073885-001-10-9	tanshinone-I	Phase 2	AP inhibitor	IFNG			0	76.22	MedChemEx	HY-N0134	Tanshinone I	276.079	Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	AIGAZQPHXLWMOJ-UHFFFAOYSA-N	114917.0		AIGAZQPHXLWMOJ
BRD-K34073885-001-07-7	tanshinone-I	Phase 2	AP inhibitor	IFNG			0	35.27	Selleck	S2364	Tanshinone I	276.079	Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	AIGAZQPHXLWMOJ-UHFFFAOYSA-N	114917.0		AIGAZQPHXLWMOJ
BRD-K34073885-001-09-3	tanshinone-I	Phase 2	AP inhibitor	IFNG			0	87.49	Selleck	S2364	Tanshinone I	276.079	Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	AIGAZQPHXLWMOJ-UHFFFAOYSA-N	114917.0		AIGAZQPHXLWMOJ
BRD-K00141480-001-17-9	tanshinone-IIA	Phase 2/Phase 3	anti-inflammatory agent|interleukin inhibitor	IL1B|NR1I2|TNF			0	90.3	Tocris	4426	Tanshinone IIA	294.126	Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21	HYXITZLLTYIPOF-UHFFFAOYSA-N	164676.0		HYXITZLLTYIPOF
BRD-K00141480-001-15-4	tanshinone-IIA	Phase 2/Phase 3	anti-inflammatory agent|interleukin inhibitor	IL1B|NR1I2|TNF			0	78.69	Selleck	S2365	Tanshinone IIA (Tanshinone B)	294.126	Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21	HYXITZLLTYIPOF-UHFFFAOYSA-N	164676.0		HYXITZLLTYIPOF
BRD-K00141480-001-14-7	tanshinone-IIA	Phase 2/Phase 3	anti-inflammatory agent|interleukin inhibitor	IL1B|NR1I2|TNF			0	55.05	Selleck	S2365	Tanshinone IIA	294.126	Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21	HYXITZLLTYIPOF-UHFFFAOYSA-N	164676.0		HYXITZLLTYIPOF
BRD-K00003498-001-01-9	tapinarof	Phase 3	aryl hydrocarbon receptor agonist				0	97.56	MedChemEx	HY-109044	Tapinarof	254.131	CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O	ZISJNXNHJRQYJO-CMDGGOBGSA-N	6439522.0		ZISJNXNHJRQYJO
BRD-K88854110-001-01-5	taprenepag	Phase 2	prostaglandin receptor agonist	PTGER2			0	96.08	MedChemEx	HY-14899	Taprenepag	478.131	OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1	MFFBXYNKZHTCEY-UHFFFAOYSA-N	18376177.0		MFFBXYNKZHTCEY
BRD-K00003568-001-01-9	tarafenacin	Phase 2	acetylcholine receptor antagonist	CHRM3			0	96.05	MedChemEx	HY-14825A	Tarafenacin (D-tartrate)	408.146	Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2	UXZDMXYRRQJIBJ-IBGZPJMESA-N	25147683.0		UXZDMXYRRQJIBJ
BRD-K35169477-001-02-9	taranabant	Phase 3	cannabinoid receptor inverse agonist	CNR1			0	95.82	MedChemEx	HY-10013	Taranabant	515.159	C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N	QLYKJCMUNUWAGO-GAJHUEQPSA-N	11226090.0		QLYKJCMUNUWAGO
BRD-K35169477-001-01-9	taranabant	Phase 3	cannabinoid receptor inverse agonist	CNR1			0	98.67	MedChemEx	HY-10013	Taranabant	515.159	C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N	QLYKJCMUNUWAGO-GAJHUEQPSA-N	11226090.0		QLYKJCMUNUWAGO
BRD-K22227508-015-05-4	targinine	Phase 3	nitric oxide synthase inhibitor	NOS3			0	100.0	Cayman	10005031		188.127	CNC(=N)NCCC[C@H](N)C(O)=O	NTNWOCRCBQPEKQ-YFKPBYRVSA-N	46906075.0		NTNWOCRCBQPEKQ
BRD-K09353376-001-02-1	tariquidar	Phase 3	P glycoprotein inhibitor	ABCB1			0	54.59	Selleck	S8028	Tariquidar	646.279	COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	LGGHDPFKSSRQNS-UHFFFAOYSA-N	148201.0		LGGHDPFKSSRQNS
BRD-K09353376-001-03-9	tariquidar	Phase 3	P glycoprotein inhibitor	ABCB1			0	95.08	Selleck	S8028	Tariquidar	646.279	COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	LGGHDPFKSSRQNS-UHFFFAOYSA-N	148201.0		LGGHDPFKSSRQNS
BRD-K09353376-001-05-4	tariquidar	Phase 3	P glycoprotein inhibitor	ABCB1			0	91.13	MedChemEx	HY-10550	Tariquidar	646.279	COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43)	148201.0		LGGHDPFKSSRQNS
BRD-K36474365-001-09-9	tartaric-acid	Launched	antioxidant				1	100.0	MedChemEx	HY-Y0293	(2R,3R)-2,3-Dihydroxysuccinic acid	150.016	O[C@H]([C@@H](O)C(O)=O)C(O)=O	FEWJPZIEWOKRBE-JCYAYHJZSA-N	444305.0		FEWJPZIEWOKRBE
BRD-K36474365-001-06-6	tartaric-acid	Launched	antioxidant				1	0.0	MicroSource	1300044	TARTARIC ACID (L)	150.016	O[C@H]([C@@H](O)C(O)=O)C(O)=O	FEWJPZIEWOKRBE-JCYAYHJZSA-N	444305.0		FEWJPZIEWOKRBE
BRD-K09426783-300-01-0	TAS-103	Phase 1	topoisomerase inhibitor	TOP1			0	91.54	MedChemEx	HY-13758A	TAS-103 (dihydrochloride)	333.148	CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	ROWSTIYZUWEOMM-UHFFFAOYSA-N	135413533.0		ROWSTIYZUWEOMM
BRD-K09426783-300-03-9	TAS-103	Phase 1	topoisomerase inhibitor	TOP1			0	0.0	MedChemEx	HY-13758A	TAS-103 (dihydrochloride)	333.148	CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	ROWSTIYZUWEOMM-UHFFFAOYSA-N	135413533.0		ROWSTIYZUWEOMM
BRD-K44844162-001-01-6	taselisib	Phase 3	PI3K inhibitor	PIK3CA			0	98.4	MedChemEx	HY-13898	GDC-0032	460.234	CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	BEUQXVWXFDOSAQ-UHFFFAOYSA-N	51001932.0		BEUQXVWXFDOSAQ
BRD-K44844162-001-04-0	taselisib	Phase 3	PI3K inhibitor	PIK3CA			0		MedChemEx	HY-13898	GDC-0032	460.234	CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)	51001932.0		BEUQXVWXFDOSAQ
BRD-K62971431-001-01-9	tasimelteon	Launched	melatonin receptor agonist	MTNR1A|MTNR1B	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder	0	98.42	Synnovator	PBLJ6300	N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide	245.142	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12	PTOIAAWZLUQTIO-GXFFZTMASA-N	10220503.0		PTOIAAWZLUQTIO
BRD-K42495768-001-01-7	tasisulam	Phase 3	apoptosis stimulant				0	98.5	Selleck	S7326	Tasisulam	412.835	Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	WWONFUQGBVOKOF-UHFFFAOYSA-N	10160238.0		WWONFUQGBVOKOF
BRD-K42495768-001-02-5	tasisulam	Phase 3	apoptosis stimulant				0	96.72	Selleck	S7326	Tasisulam	412.835	Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	WWONFUQGBVOKOF-UHFFFAOYSA-N	10160238.0		WWONFUQGBVOKOF
BRD-K14653796-001-02-9	tasquinimod	Phase 3	angiogenesis inhibitor|S100A9 inhibitor	HDAC4			0	96.49	MedChemEx	HY-10528	Tasquinimod	406.114	COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12	ONDYALNGTUAJDX-UHFFFAOYSA-N	54682876.0		ONDYALNGTUAJDX
BRD-K14653796-001-01-1	tasquinimod	Phase 3	angiogenesis inhibitor|S100A9 inhibitor	HDAC4			0	99.3	MedChemEx	HY-10528	Tasquinimod	406.114	COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12	ONDYALNGTUAJDX-UHFFFAOYSA-N	54682876.0		ONDYALNGTUAJDX
BRD-K10415035-001-04-4	tasuldine	Phase 3	mucolytic agent				0	98.77	Labotest	LT02086585	2-[(3-pyridinylmethyl)sulfanyl]pyrimidine	203.052	C(Sc1ncccn1)c1cccnc1	HMCTXMOKMWELFJ-UHFFFAOYSA-N	65666.0		HMCTXMOKMWELFJ
BRD-K10415035-001-03-6	tasuldine	Phase 3	mucolytic agent				0	13.93	Vitas-M	STK829713		203.052	C(Sc1ncccn1)c1cccnc1	HMCTXMOKMWELFJ-UHFFFAOYSA-N	65666.0		HMCTXMOKMWELFJ
BRD-K51474575-001-11-2	taurine	Launched	antioxidant		neurology/psychiatry	anxiety|irritability|sleeplessness	0	0.0	MicroSource	1505463	TAURINE	125.015	NCCS(O)(=O)=O	XOAAWQZATWQOTB-UHFFFAOYSA-N	4068592.0		XOAAWQZATWQOTB
BRD-K51474575-001-10-4	taurine	Launched	antioxidant		neurology/psychiatry	anxiety|irritability|sleeplessness	0	100.0	Selleck	S2008	Taurine	125.015	NCCS(O)(=O)=O	XOAAWQZATWQOTB-UHFFFAOYSA-N	4068592.0		XOAAWQZATWQOTB
BRD-K81062487-001-05-8	taurocholate	Phase 1	G protein-coupled receptor agonist	CEL|FABP6|SLCO1C1			0	100.0	Enzo	BL056	Taurocholic acid sodium salt	515.292	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	WBWWGRHZICKQGZ-HZAMXZRMSA-N	6675.0		WBWWGRHZICKQGZ
BRD-K81062487-236-01-9	taurocholate	Phase 1	G protein-coupled receptor agonist	CEL|FABP6|SLCO1C1			0	92.9	Selleck	S5130	Taurocholic acid sodium salt	515.292	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	WBWWGRHZICKQGZ-HZAMXZRMSA-N	6675.0		WBWWGRHZICKQGZ
BRD-K00003523-236-01-9	tauroglycocholate	Preclinical	membrane permeability enhancer				0	100.0	MedChemEx	HY-B2119	Sodium tauroglycocholate	572.313	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O	URJQSMIFSMHWSP-VVHBOOHCSA-N	119420.0		URJQSMIFSMHWSP
BRD-K98765504-001-01-5	taurolidine	Launched	apoptosis stimulant		infectious disease	catheter-related bloodstream infection	0	0.0	Sigma	T7329	4-[(1,1-dioxido-1,2,4-thiadiazinan-4-yl)methyl]-1,2,4-thiadiazinane 1,1-dioxide	284.061	O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1	AJKIRUJIDFJUKJ-UHFFFAOYSA-N	29566.0		AJKIRUJIDFJUKJ
BRD-K76713213-001-02-1	tavaborole	Launched	leucyl-tRNA synthetase inhibitor		infectious disease	onychomycosis	0	91.53	MedChemEx	HY-10980	AN-2690	152.044	OB1OCc2cc(F)ccc12	LFQDNHWZDQTITF-UHFFFAOYSA-N	11499245.0		LFQDNHWZDQTITF
BRD-K76713213-001-01-3	tavaborole	Launched	leucyl-tRNA synthetase inhibitor		infectious disease	onychomycosis	0	0.0	MedChemEx	HY-10980	AN-2690	152.044	OB1OCc2cc(F)ccc12	LFQDNHWZDQTITF-UHFFFAOYSA-N	11499245.0		LFQDNHWZDQTITF
BRD-K00003254-001-01-9	tavilermide	Phase 3	tyrosine kinase partial agonist				0	85.65	MedChemEx	HY-17622	Tavilermide	580.213	NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O	DVJXNXPFYJIACK-ULQDDVLXSA-N	9808372.0		DVJXNXPFYJIACK
BRD-K94649603-001-14-9	taxifolin	Phase 2	opioid receptor antagonist	ADIPOR2			0	92.46	MedChemEx	HY-N0136	Taxifolin	304.058	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	CXQWRCVTCMQVQX-LSDHHAIUSA-N	439533.0		CXQWRCVTCMQVQX
BRD-K94649603-001-10-6	taxifolin	Phase 2	opioid receptor antagonist	ADIPOR2			0	79.63	Selleck	S2366	Taxifolin (Dihydroquercetin)	304.058	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	CXQWRCVTCMQVQX-LSDHHAIUSA-N	439533.0		CXQWRCVTCMQVQX
BRD-K94649603-001-11-4	taxifolin	Phase 2	opioid receptor antagonist	ADIPOR2			0	97.48	Selleck	S2366	Taxifolin (Dihydroquercetin)	304.058	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	CXQWRCVTCMQVQX-LSDHHAIUSA-N	439533.0		CXQWRCVTCMQVQX
BRD-K76841105-001-04-7	tazarotene	Launched	retinoid receptor agonist	RARA|RARB|RARG|RXRB	dermatology	cosmetic|sunscreen lotion	0	97.04	Selleck	S1569	Tazarotene	351.129	CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1	OGQICQVSFDPSEI-UHFFFAOYSA-N	5381.0		OGQICQVSFDPSEI
BRD-K76841105-001-05-9	tazarotene	Launched	retinoid receptor agonist	RARA|RARB|RARG|RXRB	dermatology	cosmetic|sunscreen lotion	0	97.09	Tocris	3997	Tazarotene	351.129	CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1	OGQICQVSFDPSEI-UHFFFAOYSA-N	5381.0		OGQICQVSFDPSEI
BRD-K11215326-001-02-9	tazemetostat	Launched	histone lysine methyltransferase inhibitor	EZH2			0	48.86	Selleck	S7128	EPZ-6438	572.336	CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1	NSQSAUGJQHDYNO-UHFFFAOYSA-N	66558664.0		NSQSAUGJQHDYNO
BRD-K11215326-001-03-7	tazemetostat	Launched	histone lysine methyltransferase inhibitor	EZH2			0	93.46	Selleck	S7128	EPZ-6438 (E7438)	572.336	CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1	NSQSAUGJQHDYNO-UHFFFAOYSA-N	66558664.0		NSQSAUGJQHDYNO
BRD-K14312455-001-03-9	tazobactam	Launched	beta lactamase inhibitor		infectious disease	pneumonia	0	96.16	MedChemEx	HY-B1418	Tazobactam	300.053	C[C@]1(Cn2ccnn2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	LPQZKKCYTLCDGQ-WEDXCCLWSA-N	123630.0		LPQZKKCYTLCDGQ
BRD-K56405978-001-01-5	TBA-354	Phase 1					0	96.43	MedChemEx	HY-12485	TBA-354	436.099	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1	ZXSGSFMORAILEY-HNNXBMFYSA-N	49836057.0		ZXSGSFMORAILEY
BRD-M77041484-001-03-4	TBOA-(DL)	Preclinical	excitatory amino acid transporter inhibitor	SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7			0	87.38	Tocris	1223	(2R,3R)-2-amino-3-(benzyloxy)succinic acid compound with (2S,3S)-2-amino-3-(benzyloxy)succinic acid (1:1)	239.079	N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	CSEZCYBVEGIYNG-MFBWXLJUSA-N	90479771.0		CSEZCYBVEGIYNG
BRD-M77041484-001-02-6	TBOA-(DL)	Preclinical	excitatory amino acid transporter inhibitor	SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7			0	91.0	Tocris	1223	DL-TBOA	239.079	N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	CSEZCYBVEGIYNG-MFBWXLJUSA-N	90479771.0		CSEZCYBVEGIYNG
BRD-M77041484-001-01-8	TBOA-(DL)	Preclinical	excitatory amino acid transporter inhibitor	SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7			0	81.5	Tocris	1223	DL-TBOA	239.079	N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	CSEZCYBVEGIYNG-MFBWXLJUSA-N	90479771.0		CSEZCYBVEGIYNG
BRD-A12147465-003-01-4	TC-A-2317	Preclinical	Aurora kinase inhibitor	AURKA			0	92.69	Tocris	4066	TC-A 2317 hydrochloride	356.232	C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|	XHHRGYCOEVNAKV-ZDUSSCGKSA-N	24783396.0		XHHRGYCOEVNAKV
BRD-A12147465-003-02-9	TC-A-2317	Preclinical	Aurora kinase inhibitor	AURKA			0	89.17	Tocris	4066	TC-A 2317 hydrochloride	356.232	C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|	XHHRGYCOEVNAKV-ZDUSSCGKSA-N	24783396.0		XHHRGYCOEVNAKV
BRD-K29660062-300-01-2	TC-ASK-10	Preclinical	MAP kinase inhibitor	MAP3K5|MAP3K6			0	95.66	Tocris	4825	TC ASK 10	359.175	CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1	SMJAMOAYGIVKRI-UHFFFAOYSA-N	24944925.0		SMJAMOAYGIVKRI
BRD-K29660062-001-01-6	TC-ASK-10	Preclinical	MAP kinase inhibitor	MAP3K5|MAP3K6			0	97.32	Focus	Oct-4803	TC ASK 10 2HCl	359.175	CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1	SMJAMOAYGIVKRI-UHFFFAOYSA-N	24944925.0		SMJAMOAYGIVKRI
BRD-K15256258-001-03-9	TC-E-5002	Preclinical	histone demethylase inhibitor	KDM2A|KDM4A|KDM4C|KDM5A|KDM6A|KDM7A|PHF8			0	81.78	Tocris	5089	TC-E 5002	285.194	ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1	NEHSERYKENINRH-UHFFFAOYSA-N	71735843.0		NEHSERYKENINRH
BRD-K15256258-001-01-3	TC-E-5002	Preclinical	histone demethylase inhibitor	KDM2A|KDM4A|KDM4C|KDM5A|KDM6A|KDM7A|PHF8			0	96.52	Tocris	5089	TC-E502	285.194	ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1	NEHSERYKENINRH-UHFFFAOYSA-N	71735843.0		NEHSERYKENINRH
BRD-K15256258-001-02-1	TC-E-5002	Preclinical	histone demethylase inhibitor	KDM2A|KDM4A|KDM4C|KDM5A|KDM6A|KDM7A|PHF8			0	80.04	Tocris	5089	TC-E 5002	285.194	ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1	NEHSERYKENINRH-UHFFFAOYSA-N	71735843.0		NEHSERYKENINRH
BRD-A66521565-001-03-9	TC-E-5006	Preclinical	gamma secretase modulator	APP			0	96.96	Tocris	4898	TC-E 5006	499.213	C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|	ONYWALXTZFPKAS-WINIVTDRSA-N	97289132.0		ONYWALXTZFPKAS
BRD-A66521565-001-01-8	TC-E-5006	Preclinical	gamma secretase modulator	APP			0	97.66	Tocris	4898	TC-E 5006	499.213	C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1,&2:9,r|	ONYWALXTZFPKAS-WINIVTDRSA-N	97289132.0		ONYWALXTZFPKAS
BRD-K26041695-001-02-5	TC-F-2	Preclinical	FAAH inhibitor	FAAH			0	96.64	Tocris	4355	TC-F 2	439.201	CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O	NXTBLPPTZRPJCA-IBGZPJMESA-N	25198728.0		NXTBLPPTZRPJCA
BRD-K26041695-001-01-7	TC-F-2	Preclinical	FAAH inhibitor	FAAH			0	98.4	Tocris	4355	TC-F 2	439.201	CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O	NXTBLPPTZRPJCA-IBGZPJMESA-N	25198728.0		NXTBLPPTZRPJCA
BRD-K16497916-001-02-9	TC-FPR-43	Preclinical	formyl peptide receptor agonist	FPR2			0	95.53	Tocris	4624	TC-FPR 43	384.135	CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C	PAEBEUZTAPIOIO-UHFFFAOYSA-N	24776341.0		PAEBEUZTAPIOIO
BRD-K16497916-001-01-6	TC-FPR-43	Preclinical	formyl peptide receptor agonist	FPR2			0	97.83	Tocris	4624	TC-FPR 43	384.135	CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C	PAEBEUZTAPIOIO-UHFFFAOYSA-N	24776341.0		PAEBEUZTAPIOIO
BRD-K27010807-050-02-9	TC-G-1000	Preclinical	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C			0	93.6	Tocris	5021	TC-G 1000	230.088	Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|	RLKWQKZPCMICPS-UHFFFAOYSA-N	10220232.0		RLKWQKZPCMICPS
BRD-K27010807-050-01-3	TC-G-1000	Preclinical	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C			0	77.34	Tocris	5021	TC-G 1000	230.088	Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|	RLKWQKZPCMICPS-UHFFFAOYSA-N	10220232.0		RLKWQKZPCMICPS
BRD-K76989898-001-02-9	TC-G-1004	Preclinical	adenosine receptor antagonist	ADORA2A			0	95.87	Tocris	4407	TC-G 1004	421.223	COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C	JENSDTKXNVHSSN-UHFFFAOYSA-N	25074316.0		JENSDTKXNVHSSN
BRD-K76989898-001-01-1	TC-G-1004	Preclinical	adenosine receptor antagonist	ADORA2A			0	90.59	Tocris	4407	TC-G 1004	421.223	COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C	JENSDTKXNVHSSN-UHFFFAOYSA-N	25074316.0		JENSDTKXNVHSSN
BRD-K16939217-001-02-9	TC-G-1005	Preclinical	G protein-coupled receptor agonist	GPBAR1			0	94.65	Tocris	5129	TC-G 1005	399.195	Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1	JQULIQJSYPZQMA-UHFFFAOYSA-N	71450251.0		JQULIQJSYPZQMA
BRD-K16939217-001-01-3	TC-G-1005	Preclinical	G protein-coupled receptor agonist	GPBAR1			0	87.66	Tocris	5129	TC-G 1005	399.195	Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1	JQULIQJSYPZQMA-UHFFFAOYSA-N	71450251.0		JQULIQJSYPZQMA
BRD-K87199310-001-01-4	TC-G-1008	Preclinical	G protein-coupled receptor agonist	GPR39			0	98.28	Tocris	5355	TC-G 1008	418.098	CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1	DRSZMILOMUPIBJ-UHFFFAOYSA-N	91826086.0		DRSZMILOMUPIBJ
BRD-K87199310-001-02-9	TC-G-1008	Preclinical	G protein-coupled receptor agonist	GPR39			0	97.69	Tocris	5355	TC-G 1008	418.098	CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1	DRSZMILOMUPIBJ-UHFFFAOYSA-N	91826086.0		DRSZMILOMUPIBJ
BRD-K45044657-001-02-2	TC-H-106	Preclinical	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC8			0	89.32	Tocris	4270	TC-H 106	339.195	Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1	WTKBRPXPNAKVEQ-UHFFFAOYSA-N	16070100.0		WTKBRPXPNAKVEQ
BRD-K45044657-001-01-4	TC-H-106	Preclinical	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC8			0		Stanley		BRD-9-3	339.195	Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1	InChI=1S/C20H25N3O2/c1-15-11-13-16(14-12-15)22-19(24)9-3-2-4-10-20(25)23-18-8-6-5-7-17(18)21/h5-8,11-14H,2-4,9-10,21H2,1H3,(H,22,24)(H,23,25)	16070100.0		WTKBRPXPNAKVEQ
BRD-K17621556-001-02-9	TC-I-15	Preclinical	integrin inhibitor	ITGA2|ITGB1			0	93.34	Tocris	4527	TC-I 15	520.145	CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1	XKLHCUGVLCGKKX-RBUKOAKNSA-N	90488948.0		XKLHCUGVLCGKKX
BRD-K17621556-001-01-5	TC-I-15	Preclinical	integrin inhibitor	ITGA2|ITGB1			0	96.07	Tocris	4527	TC-I 15	520.145	CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1	XKLHCUGVLCGKKX-RBUKOAKNSA-N	90488948.0		XKLHCUGVLCGKKX
BRD-A83792282-001-02-9	TC-I-2000	Preclinical	transient receptor potential channel antagonist	TRPM8			0	96.77	Tocris	4632	TC-I 2000	414.136	Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|	ADCDUDFEGFKKQH-NRFANRHFSA-N	57326391.0		ADCDUDFEGFKKQH
BRD-A83792282-001-01-6	TC-I-2000	Preclinical	transient receptor potential channel antagonist	TRPM8			0	96.49	Tocris	4632	TC-I 2000	414.136	Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17,r|	ADCDUDFEGFKKQH-NRFANRHFSA-N	57326391.0		ADCDUDFEGFKKQH
BRD-K05262258-001-01-3	TC-I-2014	Preclinical	transient receptor potential channel antagonist	TRPM8			0	94.45	Tocris	5410	TC-I 2014	467.143	FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|	VSMFCZZEKTVDHM-UHFFFAOYSA-N	135883253.0		VSMFCZZEKTVDHM
BRD-K05262258-001-02-9	TC-I-2014	Preclinical	transient receptor potential channel antagonist	TRPM8			0	95.86	Tocris	5410	TC-I 2014	467.143	FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|	VSMFCZZEKTVDHM-UHFFFAOYSA-N	135883253.0		VSMFCZZEKTVDHM
BRD-K32031961-001-02-9	TC-LPA5-4	Preclinical	lysophosphatidic acid receptor antagonist	LPAR5			0	95.56	Tocris	4708	TC LPA5 4	410.14	COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O	BNALUYKEGYUHQC-UHFFFAOYSA-N	66552906.0		BNALUYKEGYUHQC
BRD-K32031961-001-01-7	TC-LPA5-4	Preclinical	lysophosphatidic acid receptor antagonist	LPAR5			0	96.94	Tocris	4708	TC LPA5 4	410.14	COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O	BNALUYKEGYUHQC-UHFFFAOYSA-N	66552906.0		BNALUYKEGYUHQC
BRD-K76792630-001-02-9	TC-Mps1-12	Preclinical	monopolar spindle 1 kinase inhibitor	TTK			0	95.69	Tocris	4750	TC Mps1 12	324.17	CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N	XDEFNAWAKYQBQY-UHFFFAOYSA-N	70682875.0		XDEFNAWAKYQBQY
BRD-K76792630-001-01-2	TC-Mps1-12	Preclinical	monopolar spindle 1 kinase inhibitor	TTK			0	98.5	Tocris	4750	TC Mps1 12	324.17	CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N	XDEFNAWAKYQBQY-UHFFFAOYSA-N	70682875.0		XDEFNAWAKYQBQY
BRD-K78161388-001-02-9	TC-N-1752	Preclinical	sodium channel blocker	SCN9A			0	97.34	Tocris	4435	TC-N 1752	516.21	CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C	QLKAFHZJICDACE-UHFFFAOYSA-N	53361524.0		QLKAFHZJICDACE
BRD-K78161388-001-01-2	TC-N-1752	Preclinical	sodium channel blocker	SCN9A			0	98.27	Tocris	4435	TC-N 1752	516.21	CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C	QLKAFHZJICDACE-UHFFFAOYSA-N	53361524.0		QLKAFHZJICDACE
BRD-K79608170-001-03-9	TC-NTR1-17	Preclinical	neurotensin agonist	NTSR1			0	97.7	Tocris	5087	TC NTR1 17	522.167	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O	ZQUSYVORYNBGLG-FQEVSTJZSA-N	44157038.0		ZQUSYVORYNBGLG
BRD-K79608170-001-02-1	TC-NTR1-17	Preclinical	neurotensin agonist	NTSR1			0	98.19	Tocris	5087	TC NTR1 17	522.167	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O	ZQUSYVORYNBGLG-FQEVSTJZSA-N	44157038.0		ZQUSYVORYNBGLG
BRD-K54297077-001-01-8	TC-O-9311	Preclinical	G protein-coupled receptor agonist	GPR139			0	95.21	Tocris	4255	TC-O 9311	365.138	COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12	KPTMSQHTGZMEFU-UHFFFAOYSA-N	3376937.0		KPTMSQHTGZMEFU
BRD-K54297077-001-02-9	TC-O-9311	Preclinical	G protein-coupled receptor agonist	GPR139			0	95.92	Tocris	4255	TC-O 9311	365.138	COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12	KPTMSQHTGZMEFU-UHFFFAOYSA-N	3376937.0		KPTMSQHTGZMEFU
BRD-K55013981-001-02-9	TC-OT-39	Preclinical	oxytocin receptor agonist|vasopressin receptor agonist	AVPR1A|OXT			0	95.77	Tocris	4625	TC OT 39	600.299	CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12	KSNHHKZYKYNBEI-NDEPHWFRSA-N	135413563.0		KSNHHKZYKYNBEI
BRD-K55013981-001-01-3	TC-OT-39	Preclinical	oxytocin receptor agonist|vasopressin receptor agonist	AVPR1A|OXT			0	96.28	Tocris	4625	TC OT 39	600.299	CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12	KSNHHKZYKYNBEI-NDEPHWFRSA-N	135413563.0		KSNHHKZYKYNBEI
BRD-K34362291-001-02-9	TC-S-7003	Preclinical	SRC inhibitor	LCK			0	84.21	Tocris	3567	TC-S 7003	530.254	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1	BHJJWVDKNXABFS-UHFFFAOYSA-N	11785878.0		BHJJWVDKNXABFS
BRD-K34362291-001-01-5	TC-S-7003	Preclinical	SRC inhibitor	LCK			0	94.27	Tocris	3567	TC-S 7003	530.254	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1	BHJJWVDKNXABFS-UHFFFAOYSA-N	11785878.0		BHJJWVDKNXABFS
BRD-K89517477-001-03-9	TC-S-7004	Preclinical	DYRK inhibitor	DYRK1A|DYRK1B			0	95.46	Tocris	5088	TC-S 7004	497.066	COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1	CQKBSRPVZZLCJE-UHFFFAOYSA-N	57523919.0		CQKBSRPVZZLCJE
BRD-K89517477-001-01-4	TC-S-7004	Preclinical	DYRK inhibitor	DYRK1A|DYRK1B			0	95.75	Tocris	5088	TC-S 7004	497.066	COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1	CQKBSRPVZZLCJE-UHFFFAOYSA-N	57523919.0		CQKBSRPVZZLCJE
BRD-K89584803-001-02-9	TC-S-7005	Preclinical	PLK inhibitor	PLK2			0	98.12	Tocris	4459	TC-S 7005	359.127	C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1	DAAGOCSHXCDWDY-ZDUSSCGKSA-N	24971422.0		DAAGOCSHXCDWDY
BRD-K89584803-001-01-9	TC-S-7005	Preclinical	PLK inhibitor	PLK2			0	99.07	Tocris	4459	TC-S 7005	359.127	C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1	DAAGOCSHXCDWDY-ZDUSSCGKSA-N	24971422.0		DAAGOCSHXCDWDY
BRD-K51776215-001-03-9	TC-S-7006	Preclinical	MAP kinase inhibitor	MAP3K8			0	94.67	Tocris	5240	TC-S 7006	404.095	Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl	NMEUKWOOQOHUNA-UHFFFAOYSA-N	9549300.0		NMEUKWOOQOHUNA
BRD-K51776215-001-02-5	TC-S-7006	Preclinical	MAP kinase inhibitor	MAP3K8			0	88.42	Tocris	5240	TC-S 7006	404.095	Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl	NMEUKWOOQOHUNA-UHFFFAOYSA-N	9549300.0		NMEUKWOOQOHUNA
BRD-K21894922-001-01-9	TC-S-7009	Preclinical	hypoxia inducible factor inhibitor	EPAS1			0	96.72	Tocris	5243	TC-S 7009	308.011	[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12	CDQUJZKBRAFWNG-UHFFFAOYSA-N	70697712.0		CDQUJZKBRAFWNG
BRD-K21894922-001-02-9	TC-S-7009	Preclinical	hypoxia inducible factor inhibitor	EPAS1			0	97.41	Tocris	5243	TC-S 7009	308.011	[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12	CDQUJZKBRAFWNG-UHFFFAOYSA-N	70697712.0		CDQUJZKBRAFWNG
BRD-K87461578-001-02-9	TC-SP-14	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR1			0	96.27	Tocris	4363	TC-SP 14	450.121	OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1	GVXGVDIXINMAAL-UHFFFAOYSA-N	51346934.0		GVXGVDIXINMAAL
BRD-K87461578-001-01-5	TC-SP-14	Preclinical	sphingosine 1-phosphate receptor agonist	S1PR1			0	86.12	Tocris	4363	TC-SP 14	450.121	OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1	GVXGVDIXINMAAL-UHFFFAOYSA-N	51346934.0		GVXGVDIXINMAAL
BRD-K27536248-001-03-9	TCID	Preclinical					0	80.05	Tocris	5179	TCID	281.881	Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl	IDLAOWFFKWRNHB-UHFFFAOYSA-N	2729042.0		IDLAOWFFKWRNHB
BRD-K27536248-001-01-7	TCID	Preclinical					0	1.81	Selleck	S7140	TCID	281.881	Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl	IDLAOWFFKWRNHB-UHFFFAOYSA-N	2729042.0		IDLAOWFFKWRNHB
BRD-K27536248-001-02-5	TCID	Preclinical					0	55.04	Selleck	S7140	TCID	281.881	Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl	IDLAOWFFKWRNHB-UHFFFAOYSA-N	2729042.0		IDLAOWFFKWRNHB
BRD-K09787262-001-02-7	TCN201	Preclinical	glutamate receptor antagonist	GRIN2A			0	94.39	Tocris	4154	TCN 201	461.061	Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1	FYIBXBFDXNPBSF-UHFFFAOYSA-N	4787937.0		FYIBXBFDXNPBSF
BRD-K09787262-001-01-9	TCN201	Preclinical	glutamate receptor antagonist	GRIN2A			0	97.03	Tocris	4154	TCN 201	461.061	Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1	FYIBXBFDXNPBSF-UHFFFAOYSA-N	4787937.0		FYIBXBFDXNPBSF
BRD-K09787262-001-03-9	TCN201	Preclinical	glutamate receptor antagonist	GRIN2A			0	96.47	Tocris	4154	TCN 201	461.061	Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1	FYIBXBFDXNPBSF-UHFFFAOYSA-N	4787937.0		FYIBXBFDXNPBSF
BRD-K77915400-001-01-6	TCN238	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	90.73	Tocris	4259	TCN 238	197.095	Nc1nccc(\C=C\c2ccccc2)n1	LNUXNUNUGIHCPA-VOTSOKGWSA-N	46911068.0		LNUXNUNUGIHCPA
BRD-K77915400-001-02-9	TCN238	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	90.68	Tocris	4259	TCN 238	197.095	Nc1nccc(\C=C\c2ccccc2)n1	LNUXNUNUGIHCPA-VOTSOKGWSA-N	46911068.0		LNUXNUNUGIHCPA
BRD-K68358632-001-02-9	TCS-HDAC6-20b	Preclinical	HDAC inhibitor	HDAC6			0	100.0	Tocris	4805	TCS HDAC6 20b	480.302	CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2	DQZMLPMCOMRJOR-MOVGKWKRSA-N	23636017.0		DQZMLPMCOMRJOR
BRD-K68358632-001-01-0	TCS-HDAC6-20b	Preclinical	HDAC inhibitor	HDAC6			0	100.0	Tocris	4805	TCS HDAC6 20b	480.302	CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2	DQZMLPMCOMRJOR-MOVGKWKRSA-N	23636017.0		DQZMLPMCOMRJOR
BRD-K29424831-003-02-1	TCS-OX2-29	Preclinical	orexin receptor antagonist	HCRTR2			0	84.85	Tocris	3371	TCS OX2 29	397.237	COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C	COFVZFLCAOUMJT-OAQYLSRUSA-N	10408514.0		COFVZFLCAOUMJT
BRD-K29424831-003-01-3	TCS-OX2-29	Preclinical	orexin receptor antagonist	HCRTR2			0	98.33	Tocris	3371	TCS OX2 29	397.237	COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C	InChI=1S/C23H31N3O3/c1-23(2,3)21(25-14-16-6-9-24-10-7-16)22(27)26-11-8-17-12-19(28-4)20(29-5)13-18(17)15-26/h6-7,9-10,12-13,21,25H,8,11,14-15H2,1-5H3/t21-/m1/s1	10408514.0		COFVZFLCAOUMJT
BRD-K08902330-001-01-3	TCS-PIM-1-1	Preclinical	Pim kinase inhibitor	PIM1			0	96.33	Tocris	2979	TCS PIM-1 1	366	Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1	SVSYJTYGPLVUOZ-UHFFFAOYSA-N	1235170.0		SVSYJTYGPLVUOZ
BRD-K08902330-001-02-9	TCS-PIM-1-1	Preclinical	Pim kinase inhibitor	PIM1			0	97.43	Tocris	2979	TCS PIM-1 1	366	Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1	SVSYJTYGPLVUOZ-UHFFFAOYSA-N	1235170.0		SVSYJTYGPLVUOZ
BRD-K00004294-001-01-9	TCS-2002	Preclinical	glycogen synthase kinase inhibitor	GSK3B			0	94.75	Tocris	3869	TCS 2002	338.073	Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19,r|	RCKYSTKYIVULEK-DEOSSOPVSA-N	44247646.0		RCKYSTKYIVULEK
BRD-K49461364-001-02-8	TCS-21311	Preclinical	JAK inhibitor	JAK3			0	96.02	Tocris	4221	TCS 21311	526.183	CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|	CLGRAWDGLMENOD-UHFFFAOYSA-N	50925411.0		CLGRAWDGLMENOD
BRD-K49461364-001-01-0	TCS-21311	Preclinical	JAK inhibitor	JAK3			0	96.69	AcmeBio	AB7977		526.183	CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|	CLGRAWDGLMENOD-UHFFFAOYSA-N	50925411.0		CLGRAWDGLMENOD
BRD-K19958299-001-01-1	TCS-2210	Preclinical	neural stem cell inducer				0	87.06	Tocris	3877	TCS 2210	323.127	ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1	ZOFZKGFBKISZRI-UHFFFAOYSA-N	44607172.0		ZOFZKGFBKISZRI
BRD-K19958299-001-02-9	TCS-2210	Preclinical	neural stem cell inducer				0	94.21	Tocris	3877	TCS 2210	323.127	ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1	ZOFZKGFBKISZRI-UHFFFAOYSA-N	44607172.0		ZOFZKGFBKISZRI
BRD-K55216666-001-01-4	TCS-2314	Preclinical	integrin inhibitor	ITGA4|ITGB1			0	97.08	Tocris	3900	TCS 2314	522.248	Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1	ITXAAOWFOURIHK-DEOSSOPVSA-N	11226207.0		ITXAAOWFOURIHK
BRD-K55216666-001-02-9	TCS-2314	Preclinical	integrin inhibitor	ITGA4|ITGB1			0	96.53	Tocris	3900	TCS 2314	522.248	Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1	ITXAAOWFOURIHK-DEOSSOPVSA-N	11226207.0		ITXAAOWFOURIHK
BRD-K81935556-001-01-0	TCS-3035	Preclinical	G protein-coupled receptor agonist	GPR35			0	58.4	Tocris	4244	TCS 3035	279.02	OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1	WXMCOLGPDOYHNK-UITAMQMPSA-N	2295463.0		WXMCOLGPDOYHNK
BRD-K81935556-001-02-9	TCS-3035	Preclinical	G protein-coupled receptor agonist	GPR35			0	93.12	Tocris	4244	TCS 3035	279.02	OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1	WXMCOLGPDOYHNK-UITAMQMPSA-N	2295463.0		WXMCOLGPDOYHNK
BRD-K81376179-001-04-8	TCS-359	Preclinical	FLT3 inhibitor	FLT3			0	93.25	Tocris	2591	TCS 359	360.114	COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	FSPQCTGGIANIJZ-UHFFFAOYSA-N	1048845.0		FSPQCTGGIANIJZ
BRD-K81376179-001-07-9	TCS-359	Preclinical	FLT3 inhibitor	FLT3			0	95.75	Tocris	2591	TCS 359	360.114	COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	FSPQCTGGIANIJZ-UHFFFAOYSA-N	1048845.0		FSPQCTGGIANIJZ
BRD-K81376179-001-03-0	TCS-359	Preclinical	FLT3 inhibitor	FLT3			0	95.0	Selleck	S8023	TCS 359	360.114	COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	FSPQCTGGIANIJZ-UHFFFAOYSA-N	1048845.0		FSPQCTGGIANIJZ
BRD-K81376179-001-06-3	TCS-359	Preclinical	FLT3 inhibitor	FLT3			0	91.83	Tocris	2591	TCS 359	360.114	COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	FSPQCTGGIANIJZ-UHFFFAOYSA-N	1048845.0		FSPQCTGGIANIJZ
BRD-K81376179-001-05-5	TCS-359	Preclinical	FLT3 inhibitor	FLT3			0	85.04	Selleck	S8023	TCS 359	360.114	COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	FSPQCTGGIANIJZ-UHFFFAOYSA-N	1048845.0		FSPQCTGGIANIJZ
BRD-A16560607-001-02-5	TCS-5861528	Preclinical	transient receptor potential channel antagonist	TRPA1			0	97.49	Tocris	3938	TCS 5861528	369.18	CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|	ZUTUWJYMCADJHD-GFCCVEGCSA-N	1116244.0		ZUTUWJYMCADJHD
BRD-A16560607-001-04-9	TCS-5861528	Preclinical	transient receptor potential channel antagonist	TRPA1			0	96.47	Tocris	3938	TCS 5861528	369.18	CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2,r|	ZUTUWJYMCADJHD-GFCCVEGCSA-N	1116244.0		ZUTUWJYMCADJHD
BRD-K00003278-003-01-9	TCV-309	Preclinical	platelet activating factor receptor antagonist				0	70.33	MedChemEx	HY-19121A	TCV-309 (chloride)	593.176	CCC[n+]1cc(Br)cc(c1)C(=O)N(CCC(=O)NCCOC(=O)N1CCc2ccccc2C1)c1ccccc1	NWWZMECSQFUIGC-UHFFFAOYSA-O	6918167.0		NWWZMECSQFUIGC
BRD-K01825674-001-01-9	TC1	Preclinical	beta-secretase inhibitor	BACE1			0	95.78	Tocris	2669	TC 1	297.153	O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|	FYGREZKTJIXWIH-APDWONGJSA-N			FYGREZKTJIXWIH
BRD-K01825674-001-02-9	TC1	Preclinical	beta-secretase inhibitor	BACE1			0	96.9	Tocris	2669	TC 1	297.153	O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1,&2:2,&3:3,&4:4,&5:5,&6:6,&7:7,&8:8,&9:10,&10:11,r,TLB:13:12:2.5:7.11|	InChI=1S/C19H20FNO/c20-9-3-1-2-8(6-9)4-5-21-18-14-10-7-11-13-12(10)15(18)17(13)19(21,22)16(11)14/h1-3,6,10-18,22H,4-5,7H2/t10-,11+,12+,13-,14+,15+,16-,17+,18-,19-/m1/s1			FYGREZKTJIXWIH
BRD-K24227647-364-02-3	TC2559	Preclinical	acetylcholine receptor agonist	CHRNA4			0	67.12	Tocris	2737	(2E)-2-butenedioic acid compound with (3E)-4-(5-ethoxy-3-pyridinyl)-N-methyl-3-buten-1-amine (2:1)	206.142	CCOc1cncc(\C=C\CCNC)c1	HFZDMKMXPGRKCK-GQCTYLIASA-N	9823180.0		HFZDMKMXPGRKCK
BRD-K24227647-364-01-5	TC2559	Preclinical	acetylcholine receptor agonist	CHRNA4			0	75.02	Tocris	2737	TC 2559 difumarate	206.142	CCOc1cncc(\C=C\CCNC)c1	HFZDMKMXPGRKCK-GQCTYLIASA-N	9823180.0		HFZDMKMXPGRKCK
BRD-K00003308-001-01-9	TD139	Phase 2	anti-inflammatory agent				0	97.78	MedChemEx	HY-19940	TD139	648.181	OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2cccc(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1	YGIDGBAHDZEYMT-MQFIMZJJSA-N	73774610.0		YGIDGBAHDZEYMT
BRD-K28224173-001-03-9	tebipenem	Launched	bacterial cell wall synthesis inhibitor	CNR1	infectious disease|otolaryngology	pneumonia|otitis	0	99.48	MedChemEx	HY-B0396	Tebipenem pivoxil	497.165	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19,t:14|	SNUDIPVBUUXCDG-QHSBEEBCSA-N	9892071.0		SNUDIPVBUUXCDG
BRD-K00003289-001-01-9	tecadenoson	Phase 2	adenosine receptor agonist	ADORA1			0	97.17	MedChemEx	HY-19661	Tecadenoson	337.139	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12	OESBDSFYJMDRJY-BAYCTPFLSA-N	158795.0		OESBDSFYJMDRJY
BRD-K41662846-003-02-3	tecalcet	Phase 2	calcium-sensing receptor agonist	CASR			0	95.01	Tocris	3815	R 568 hydrochloride	303.139	COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl	ZVQUCWXZCKWZBP-CQSZACIVSA-N	158797.0		ZVQUCWXZCKWZBP
BRD-K41662846-003-01-5	tecalcet	Phase 2	calcium-sensing receptor agonist	CASR			0	96.0	Cayman	17415	(R)-3-(2-chlorophenyl)-N-(1-(3-methoxyphenyl)ethyl)propan-1-amine hydrochloride	303.139	COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl	ZVQUCWXZCKWZBP-CQSZACIVSA-N	158797.0		ZVQUCWXZCKWZBP
BRD-K48195801-001-01-6	tecastemizole	Phase 3	histamine receptor antagonist	KCNH2			0	91.7	ChemPacific	58024	1-(4-fluorobenzyl)-N-(piperidin-4-yl)-1H-benzo[d]imidazol-2-amine	324.175	Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1	SFOVDSLXFUGAIV-UHFFFAOYSA-N	123618.0		SFOVDSLXFUGAIV
BRD-K24312986-001-01-2	tecovirimat	Launched	orthopoxvirus egress inhibitor		infectious disease	smallpox	0	98.79	MedChemEx	HY-14805	Tecovirimat	376.103	FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|	CSKDFZIMJXRJGH-VWLPUNTISA-N	16124688.0		CSKDFZIMJXRJGH
BRD-K24312986-001-02-9	tecovirimat	Launched	orthopoxvirus egress inhibitor		infectious disease	smallpox	0	95.95	MedChemEx	HY-14805	Tecovirimat	376.103	FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|	CSKDFZIMJXRJGH-VWLPUNTISA-N	16124688.0		CSKDFZIMJXRJGH
BRD-K59436580-001-01-7	tedizolid	Launched	bacterial 50S ribosomal subunit inhibitor		infectious disease	skin infections	0	98.73	MedChemEx	HY-14855	Tedizolid	370.119	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O	XFALPSLJIHVRKE-GFCCVEGCSA-N	11234049.0		XFALPSLJIHVRKE
BRD-K59436580-001-03-9	tedizolid	Launched	bacterial 50S ribosomal subunit inhibitor		infectious disease	skin infections	0	96.85	MedChemEx	HY-14855	Tedizolid	370.119	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O	XFALPSLJIHVRKE-GFCCVEGCSA-N	11234049.0		XFALPSLJIHVRKE
BRD-K89121095-001-02-5	tedizolid-phosphate	Launched	protein synthesis inhibitor		infectious disease	skin infections	0	94.69	MedChemEx	HY-14855B	Tedizolid (phosphate)	450.085	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	QCGUSIANLFXSGE-GFCCVEGCSA-N	11476460.0		QCGUSIANLFXSGE
BRD-K89121095-304-01-5	tedizolid-phosphate	Launched	protein synthesis inhibitor		infectious disease	skin infections	0	0.0	Annova	L06022		450.085	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	QCGUSIANLFXSGE-GFCCVEGCSA-N	11476460.0		QCGUSIANLFXSGE
BRD-K89121095-001-01-7	tedizolid-phosphate	Launched	protein synthesis inhibitor		infectious disease	skin infections	0	78.8	MedChemEx	HY-14855B	Tedizolid (phosphate)	450.085	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	QCGUSIANLFXSGE-GFCCVEGCSA-N	11476460.0		QCGUSIANLFXSGE
BRD-K88743730-050-03-3	tegaserod	Withdrawn	serotonin receptor partial agonist	HTR2A|HTR2B|HTR2C|HTR4			0	50.46	MicroSource	1505215	TEGASEROD MALEATE	301.19	CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12	IKBKZGMPCYNSLU-RGVLZGJSSA-N	135409453.0		IKBKZGMPCYNSLU
BRD-K88743730-050-04-1	tegaserod	Withdrawn	serotonin receptor partial agonist	HTR2A|HTR2B|HTR2C|HTR4			0	95.01	MedChemEx	HY-14153A	Tegaserod (maleate)	301.19	CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12	IKBKZGMPCYNSLU-RGVLZGJSSA-N	135409453.0		IKBKZGMPCYNSLU
BRD-K88743730-050-05-8	tegaserod	Withdrawn	serotonin receptor partial agonist	HTR2A|HTR2B|HTR2C|HTR4			0	85.6	Tocris	4613	Tegaserod maleate	301.19	CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12	IKBKZGMPCYNSLU-RGVLZGJSSA-N	135409453.0		IKBKZGMPCYNSLU
BRD-K26701552-001-02-9	tegobuvir	Phase 3	HCV inhibitor|protease inhibitor				0	96.11	MedChemEx	HY-10544	Tegobuvir	517.114	Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1	XBEQSQDCBSKCHJ-UHFFFAOYSA-N	23649154.0		XBEQSQDCBSKCHJ
BRD-K26701552-001-01-8	tegobuvir	Phase 3	HCV inhibitor|protease inhibitor				0	95.88	MedChemEx	HY-10544	Tegobuvir	517.114	Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1	XBEQSQDCBSKCHJ-UHFFFAOYSA-N	23649154.0		XBEQSQDCBSKCHJ
BRD-K07712545-001-02-9	teicoplanin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	39.06	MedChemEx	HY-A0097	Teicoplanin	1877.557	CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	BJNLLBUOHPVGFT-SZRRLYCBSA-N			BJNLLBUOHPVGFT
BRD-K07712545-001-01-8	teicoplanin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	56.59	MedChemEx	HY-A0097	Teicoplanin	1877.557	CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	BJNLLBUOHPVGFT-SZRRLYCBSA-N			BJNLLBUOHPVGFT
BRD-A09761158-001-02-1	teicoplanin-A2-1	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	46.55	MicroSource	1505707	TEICOPLANIN [A(2-1) shown]	1875.541	CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|	YMWQIYMUNZBOOV-FEHVOAPLSA-N			YMWQIYMUNZBOOV
BRD-A09761158-001-03-9	teicoplanin-A2-1	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	0.0	Selleck	S1399	TEICOPLANIN [A(2-1) shown]	1875.541	CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12,13,15,17,21,35,51,58,71,73,75,78,80,82,87,91,107,110,112,114,121,&1:31,&2:105|	YMWQIYMUNZBOOV-FEHVOAPLSA-N			YMWQIYMUNZBOOV
BRD-K96571715-001-01-4	teicoplanin-A2-3	Launched	bacterial cell wall synthesis inhibitor		infectious disease	gram-positive bacterial infections	0	9.36	Selleck	S1399	Teicoplanin	1891.572	CC(C)CCCCCCCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1NC(C)=O)[C@@H]1NC(=O)[C@@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	FHBQKTSCJKPYIO-VHULWTHOSA-N			FHBQKTSCJKPYIO
BRD-K51528698-003-01-4	teijin-compound-1	Preclinical	CC chemokine receptor antagonist	CCR2			0	98.07	Tocris	3664	Teijin compound 1	439.127	FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1	BAOQJSULMWXFRK-GOSISDBHSA-N	44453327.0		BAOQJSULMWXFRK
BRD-K51528698-003-02-9	teijin-compound-1	Preclinical	CC chemokine receptor antagonist	CCR2			0	94.09	Tocris	3664	Teijin compound 1	439.127	FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1	BAOQJSULMWXFRK-GOSISDBHSA-N	44453327.0		BAOQJSULMWXFRK
BRD-K72912098-001-04-9	telaprevir	Launched	HCV inhibitor	CTSA|PGR	infectious disease	hepatitis C	0	93.92	MedChemEx	HY-10235	Telaprevir	679.406	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	BBAWEDCPNXPBQM-GDEBMMAJSA-N	3010818.0		BBAWEDCPNXPBQM
BRD-K72912098-001-03-1	telaprevir	Launched	HCV inhibitor	CTSA|PGR	infectious disease	hepatitis C	0	68.45	Selleck	S1538	Telaprevir (VX-950)	679.406	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	BBAWEDCPNXPBQM-GDEBMMAJSA-N	3010818.0	BRD-K83470352-001-01-2	BBAWEDCPNXPBQM
BRD-K72912098-001-02-3	telaprevir	Launched	HCV inhibitor	CTSA|PGR	infectious disease	hepatitis C	0	86.41	Selleck	S1538	Telaprevir (VX-950)	679.406	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	BBAWEDCPNXPBQM-GDEBMMAJSA-N	3010818.0		BBAWEDCPNXPBQM
BRD-K84564571-001-03-9	telatinib	Phase 2	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	KDR			0	97.97	MedChemEx	HY-10527	Telatinib	409.094	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	QFCXANHHBCGMAS-UHFFFAOYSA-N	9808844.0		QFCXANHHBCGMAS
BRD-K84564571-001-02-4	telatinib	Phase 2	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	KDR			0	93.51	Selleck	S2231	Telatinib	409.094	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	QFCXANHHBCGMAS-UHFFFAOYSA-N	9808844.0		QFCXANHHBCGMAS
BRD-K15976406-001-03-3	telbivudine	Launched	DNA polymerase inhibitor		infectious disease	hepatitis B	0	93.99	Selleck	S1651	Telbivudine	242.09	Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O	IQFYYKKMVGJFEH-CSMHCCOUSA-N	159269.0		IQFYYKKMVGJFEH
BRD-K15976406-001-04-1	telbivudine	Launched	DNA polymerase inhibitor		infectious disease	hepatitis B	0	97.7	Selleck	S1651	ppn-lmp-63	242.09	Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O	IQFYYKKMVGJFEH-CSMHCCOUSA-N	159269.0		IQFYYKKMVGJFEH
BRD-K91159026-001-02-9	telcagepant	Phase 3	calcitonin antagonist	CALCRL|RAMP1			0	97.22	MedChemEx	HY-32709	Telcagepant	566.206	Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F	CGDZXLJGHVKVIE-DNVCBOLYSA-N	11319053.0		CGDZXLJGHVKVIE
BRD-K91159026-001-01-7	telcagepant	Phase 3	calcitonin antagonist	CALCRL|RAMP1			0	96.64	MedChemEx	HY-32709	MK-0974	566.206	Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F	CGDZXLJGHVKVIE-DNVCBOLYSA-N	11319053.0		CGDZXLJGHVKVIE
BRD-K06147391-003-03-5	telenzepine	Phase 3	acetylcholine receptor antagonist	CHRM1			0	95.42	MicroSource	1504187	TELENZEPINE HYDROCHLORIDE	370.146	CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1	VSWPGAIWKHPTKX-UHFFFAOYSA-N	5387.0		VSWPGAIWKHPTKX
BRD-K06147391-300-06-8	telenzepine	Phase 3	acetylcholine receptor antagonist	CHRM1			0	98.14	Tocris	1122	Telenzepine dihydrochloride	370.146	CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1	VSWPGAIWKHPTKX-UHFFFAOYSA-N	5387.0		VSWPGAIWKHPTKX
BRD-K82240271-001-02-9	telithromycin	Launched	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor	CYP1A2|CYP2D6|CYP3A4|CYP3A5|CYP3A7	infectious disease	pneumonia	0	89.32	MedChemEx	HY-A0062	Telithromycin	811.473	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC	LJVAJPDWBABPEJ-PIRKDXADSA-N			LJVAJPDWBABPEJ
BRD-K82240271-001-01-8	telithromycin	Launched	bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor	CYP1A2|CYP2D6|CYP3A4|CYP3A5|CYP3A7	infectious disease	pneumonia	0	81.67	Cayman	17315	(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-(4-(4-(pyridin-3-yl)-1H-imidazo;l-1-yl)butyl)octahydro-2H-[1]oxacyclotetradecino[4,3-d	811.473	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC	LJVAJPDWBABPEJ-PIRKDXADSA-N			LJVAJPDWBABPEJ
BRD-A05523972-001-01-5	telmesteine	Launched	mucolytic agent		pulmonary	cough suppressant	0	96.9	TCI	T1974		205.041	CCOC(=O)N1CSC[C@@H]1C(O)=O |&1:9,r|	XBJWOGLKABXFJE-RXMQYKEDSA-N	25271872.0		XBJWOGLKABXFJE
BRD-K73999723-001-11-3	telmisartan	Launched	angiotensin receptor antagonist	AGTR1|PPARG	cardiology	hypertension	0	99.08	MicroSource	1505261	TELMISARTAN	514.237	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	RMMXLENWKUUMAY-UHFFFAOYSA-N	65999.0		RMMXLENWKUUMAY
BRD-K73999723-001-13-9	telmisartan	Launched	angiotensin receptor antagonist	AGTR1|PPARG	cardiology	hypertension	0	97.91	Tocris	5139	Telmisartan	514.237	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	RMMXLENWKUUMAY-UHFFFAOYSA-N	65999.0		RMMXLENWKUUMAY
BRD-K73999723-001-14-9	telmisartan	Launched	angiotensin receptor antagonist	AGTR1|PPARG	cardiology	hypertension	0	97.04	Tocris	5139	Telmisartan	514.237	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	RMMXLENWKUUMAY-UHFFFAOYSA-N	65999.0		RMMXLENWKUUMAY
BRD-K73999723-001-10-5	telmisartan	Launched	angiotensin receptor antagonist	AGTR1|PPARG	cardiology	hypertension	0	98.63	Selleck	S1738	Telmisartan	514.237	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	RMMXLENWKUUMAY-UHFFFAOYSA-N	65999.0		RMMXLENWKUUMAY
BRD-K63178091-001-01-1	telotristat	Launched	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	0	94.93	MedChemEx	HY-13055B	Telotristat	546.139	Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	NCLGDOBQAWBXRA-PGRDOPGGSA-N	25025298.0		NCLGDOBQAWBXRA
BRD-K63178091-001-02-9	telotristat	Launched	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	0	91.25	MedChemEx	HY-13055B	Telotristat	546.139	Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	NCLGDOBQAWBXRA-PGRDOPGGSA-N	25025298.0		NCLGDOBQAWBXRA
BRD-K94559059-091-03-2	telotristat-ethyl	Launched	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	0	99.27	MedChemEx	HY-13055	(benzoylamino)acetic acid compound with ethyl (2S)-2-amino-3-{4-[2-amino-6-({(1R)-1-[4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl]-2,2,2-trifluoroethyl}oxy)-4-pyrimidinyl]phenyl}propanoate (1:1)	574.171	CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	MDSQOJYHHZBZKA-GBXCKJPGSA-N	25181577.0		MDSQOJYHHZBZKA
BRD-K94559059-091-02-4	telotristat-ethyl	Launched	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	0	83.87	Selleck	S2173	Telotristat Etiprate (LX 1606 Hippurate)	574.171	CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	MDSQOJYHHZBZKA-GBXCKJPGSA-N	25181577.0		MDSQOJYHHZBZKA
BRD-K94559059-091-01-6	telotristat-ethyl	Launched	tryptophan hydroxylase inhibitor	TPH1	gastroenterology	diarrhea	0	91.78	MedChemEx	HY-13055	LX1606 (Hippurate)	574.171	CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	MDSQOJYHHZBZKA-GBXCKJPGSA-N	25181577.0		MDSQOJYHHZBZKA
BRD-K00004596-001-01-9	telratolimod	Preclinical	toll-like receptor agonist				0	12.91	MedChemEx	HY-109104	Telratolimod	593.467	CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12	RRTPWQXEERTRRK-UHFFFAOYSA-N	56833311.0		RRTPWQXEERTRRK
BRD-K00003467-001-01-9	temanogrel	Preclinical	serotonin receptor antagonist				0	95.3	MedChemEx	HY-10560	Temanogrel	436.211	COc1cccc(c1)C(=O)Nc1ccc(OCCN2CCOCC2)c(c1)-c1ccnn1C	ZEOQUKRCASTCFR-UHFFFAOYSA-N	11604525.0		ZEOQUKRCASTCFR
BRD-K51805276-001-09-3	temefos	Launched	cholinesterase inhibitor				0	46.31	MicroSource	330062	TEMEFOS	465.99	COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1	WWJZWCUNLNYYAU-UHFFFAOYSA-N	5392.0		WWJZWCUNLNYYAU
BRD-K51805276-001-10-9	temefos	Launched	cholinesterase inhibitor				0	83.67	MedChemEx	HY-B1120	Temephos	465.99	COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1	WWJZWCUNLNYYAU-UHFFFAOYSA-N	5392.0		WWJZWCUNLNYYAU
BRD-K10784860-003-02-3	temocapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology|nephrology	hypertension|congestive heart failure|diabetic nephropathy|coronary artery disease (CAD)	0	97.25	Selleck	S2099	Temocapril HCl	476.144	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	FIQOFIRCTOWDOW-BJLQDIEVSA-N	443874.0		FIQOFIRCTOWDOW
BRD-K10784860-003-03-9	temocapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology|nephrology	hypertension|congestive heart failure|diabetic nephropathy|coronary artery disease (CAD)	0	96.52	MedChemEx	HY-B0384	Temocapril (hydrochloride)	476.144	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	FIQOFIRCTOWDOW-BJLQDIEVSA-N	443874.0		FIQOFIRCTOWDOW
BRD-K63712959-001-02-9	temoporfin	Launched	radical formation stimulant		oncology	head and neck squamous cell carcinoma (HNSCC)	0	78.81	MedChemEx	HY-16488	Temoporfin	680.242	Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2	JGLSWAGTNWZKQU-WWMKMEMESA-N			JGLSWAGTNWZKQU
BRD-K63712959-001-01-8	temoporfin	Launched	radical formation stimulant		oncology	head and neck squamous cell carcinoma (HNSCC)	0	85.6	MedChemEx	HY-16488	Temoporfin	680.242	Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2	JGLSWAGTNWZKQU-WWMKMEMESA-N			JGLSWAGTNWZKQU
BRD-K32107296-001-20-1	temozolomide	Launched	DNA alkylating agent	MGMT	oncology	glioblastoma|astrocytoma	0	83.49	Tocris	2706	Temozolomide	194.055	Cn1nnc2c(ncn2c1=O)C(N)=O	BPEGJWRSRHCHSN-UHFFFAOYSA-N	5394.0		BPEGJWRSRHCHSN
BRD-K32107296-001-16-9	temozolomide	Launched	DNA alkylating agent	MGMT	oncology	glioblastoma|astrocytoma	0	97.56	MicroSource	1502289	TEMOZOLAMIDE	194.055	Cn1nnc2c(ncn2c1=O)C(N)=O	BPEGJWRSRHCHSN-UHFFFAOYSA-N	5394.0		BPEGJWRSRHCHSN
BRD-K32107296-001-15-1	temozolomide	Launched	DNA alkylating agent	MGMT	oncology	glioblastoma|astrocytoma	0	97.32	Tocris	2706	Temozolomide	194.055	Cn1nnc2c(ncn2c1=O)C(N)=O	BPEGJWRSRHCHSN-UHFFFAOYSA-N	5394.0		BPEGJWRSRHCHSN
BRD-K32107296-001-14-4	temozolomide	Launched	DNA alkylating agent	MGMT	oncology	glioblastoma|astrocytoma	0	96.15	Selleck	S1237	Temozolomide	194.055	Cn1nnc2c(ncn2c1=O)C(N)=O	BPEGJWRSRHCHSN-UHFFFAOYSA-N	5394.0		BPEGJWRSRHCHSN
BRD-K95053546-001-03-5	tempol	Phase 2	free radical scavenger				0	100.0	Selleck	S2910	Tempol (4-Hydroxy-TEMPO)	173.142	CC1(C)CC(O)CC(C)(C)N1O	CSGAUKGQUCHWDP-UHFFFAOYSA-N	5395.0	BRD-U44097393-000-01-2	CSGAUKGQUCHWDP
BRD-K95053546-001-02-7	tempol	Phase 2	free radical scavenger				0	81.74	Acros	17505		173.142	CC1(C)CC(O)CC(C)(C)N1O	CSGAUKGQUCHWDP-UHFFFAOYSA-N	5395.0		CSGAUKGQUCHWDP
BRD-K95053546-001-01-9	tempol	Phase 2	free radical scavenger				0	79.52	Selleck	S2910	Tempol	173.142	CC1(C)CC(O)CC(C)(C)N1O	CSGAUKGQUCHWDP-UHFFFAOYSA-N	5395.0		CSGAUKGQUCHWDP
BRD-K08177763-001-05-9	temsirolimus	Launched	mTOR inhibitor	MTOR	oncology	renal cell carcinoma (RCC)	0	96.7	Tocris	5264	Temsirolimus	1029.602	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14,33,t:29,31|	CBPNZQVSJQDFBE-NRNHWJPGSA-N	134812825.0		CBPNZQVSJQDFBE
BRD-K00005242-001-01-9	TEN-010	Preclinical	bromodomain inhibitor				0	94.38	MedChemEx	HY-117286	(S)-JQ-35	539.223	CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|	PKQXLRYFPSZKDU-QFIPXVFZSA-N	54670351.0		PKQXLRYFPSZKDU
BRD-K00003263-001-01-9	tenalisib	Phase 2	PI3K inhibitor				0	97.79	MedChemEx	HY-17645	Tenalisib	415.144	CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1	HDXDQPRPFRKGKZ-INIZCTEOSA-N	86291103.0		HDXDQPRPFRKGKZ
BRD-K00003201-001-01-9	tenapanor	Launched	sodium/hydrogen exchanger inhibitor				0	82.6	MedChemEx	HY-15991	Tenapanor	1142.31	CN1C[C@@H](c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c2cccc(c2)[C@@H]2CN(C)Cc3c(Cl)cc(Cl)cc23)c2cc(Cl)cc(Cl)c2C1	DNHPDWGIXIMXSA-CXNSMIOJSA-N	71587953.0		DNHPDWGIXIMXSA
BRD-A42270467-001-04-4	tenatoprazole	Phase 2	ATPase inhibitor	IDO1			0	95.62	MicroSource	1502342	TENATOPRAZOLE	346.11	COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	ZBFDAUIVDSSISP-DEOSSOPVSA-N	11552393.0		ZBFDAUIVDSSISP
BRD-K48068743-001-01-6	teneligliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	96.62	MedChemEx	HY-14806	Teneligliptin	426.22	Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1	WGRQANOPCQRCME-PMACEKPBSA-N	11949652.0		WGRQANOPCQRCME
BRD-K48068743-001-02-9	teneligliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	88.14	MedChemEx	HY-14806	Teneligliptin	426.22	Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1	WGRQANOPCQRCME-PMACEKPBSA-N	11949652.0		WGRQANOPCQRCME
BRD-K00004279-001-01-9	tenidap	Phase 3	cyclooxygenase inhibitor	KCNJ4|PTGS1			0	93.72	Tocris	2580	Tenidap	320.002	NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6,r|	IGPDWKCUDHIIRL-LLVKDONJSA-N			IGPDWKCUDHIIRL
BRD-A41835910-001-02-2	tenilsetam	Phase 3	AGE inhibitor				0	59.54	Enamine	EN300-93479	3-(2-thienyl)-2-piperazinone	182.051	O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|	BBACKDMGYMXYLE-SSDOTTSWSA-N	52539208.0		BBACKDMGYMXYLE
BRD-A41835910-001-01-4	tenilsetam	Phase 3	AGE inhibitor				0	54.53	LifeChem	F2147-0982		182.051	O=C1NCCN[C@@H]1c1cccs1 |&1:6,r|	BBACKDMGYMXYLE-SSDOTTSWSA-N	52539208.0		BBACKDMGYMXYLE
BRD-K10362825-001-03-4	teniposide	Launched	topoisomerase inhibitor	TOP2A|TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	87.92	Selleck	S1787	Teniposide (Vumon)	656.156	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12	NRUKOCRGYNPUPR-QBPJDGROSA-N	452548.0		NRUKOCRGYNPUPR
BRD-K10362825-001-04-2	teniposide	Launched	topoisomerase inhibitor	TOP2A|TOP2B	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	96.09	Selleck	S1787	Teniposide	656.156	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12	NRUKOCRGYNPUPR-QBPJDGROSA-N	452548.0	BRD-K94631066-001-01-3	NRUKOCRGYNPUPR
BRD-K15891719-213-01-1	tenofovir	Launched	HIV integrase inhibitor|nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)|hepatitis B	0	72.17	MicroSource	1502393	TENOFOVIR	287.078	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	SGOIRFVFHAKUTI-ZCFIWIBFSA-N	464205.0		SGOIRFVFHAKUTI
BRD-K15891719-001-05-1	tenofovir	Launched	HIV integrase inhibitor|nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)|hepatitis B	0	100.0	Selleck	S1401	Tenofovir (Viread)	287.078	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	SGOIRFVFHAKUTI-ZCFIWIBFSA-N	464205.0		SGOIRFVFHAKUTI
BRD-K15891719-001-04-4	tenofovir	Launched	HIV integrase inhibitor|nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)|hepatitis B	0	70.77	Selleck	S1401	Tenofovir	287.078	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	SGOIRFVFHAKUTI-ZCFIWIBFSA-N	464205.0		SGOIRFVFHAKUTI
BRD-A25988899-001-01-6	tenofovir-alafenamide	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	hepatitis B	0	93.68	Selleck	S7856	Tenofovir Alafenamide (GS-7340)	476.194	CC(C)OC(=O)[C@@H](C)NP(=O)(CO[C@@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1 |&1:6,&2:9,&3:13,r|	LDEKQSIMHVQZJK-FOCZCJQRSA-N			LDEKQSIMHVQZJK
BRD-K61868322-051-06-4	tenofovir-disoproxil	Launched	nucleoside reverse transcriptase inhibitor	CYP1A2	infectious disease	human immunodeficiency virus (HIV-1)|hepatitis B	0	95.24	Selleck	S1400	Tenofovir Disoproxil Fumarate	519.173	CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C	JFVZFKDSXNQEJW-CQSZACIVSA-N	5481350.0		JFVZFKDSXNQEJW
BRD-K61868322-050-01-7	tenofovir-disoproxil	Launched	nucleoside reverse transcriptase inhibitor	CYP1A2	infectious disease	human immunodeficiency virus (HIV-1)|hepatitis B	0	84.55	Selleck	S1400	Tenofovir Disoproxil Fumarate	519.173	CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C	JFVZFKDSXNQEJW-CQSZACIVSA-N	5481350.0		JFVZFKDSXNQEJW
BRD-K05977823-001-05-3	tenovin-1	Preclinical	SIRT inhibitor|TP53 activator	SIRT1			0	95.56	Tocris	3365	Tenovin-1	369.151	CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	WOWJIWFCOPZFGV-UHFFFAOYSA-N	1013376.0		WOWJIWFCOPZFGV
BRD-K05977823-001-06-9	tenovin-1	Preclinical	SIRT inhibitor|TP53 activator	SIRT1			0	96.5	Tocris	3365	Tenovin-1	369.151	CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	WOWJIWFCOPZFGV-UHFFFAOYSA-N	1013376.0		WOWJIWFCOPZFGV
BRD-K05977823-001-04-6	tenovin-1	Preclinical	SIRT inhibitor|TP53 activator	SIRT1			0	0.0	Selleck	S8000	Tenovin-1	369.151	CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	WOWJIWFCOPZFGV-UHFFFAOYSA-N	1013376.0		WOWJIWFCOPZFGV
BRD-K05977823-001-03-8	tenovin-1	Preclinical	SIRT inhibitor|TP53 activator	SIRT1			0	0.0	Selleck	S8000	Tenovin-1	369.151	CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	WOWJIWFCOPZFGV-UHFFFAOYSA-N	1013376.0		WOWJIWFCOPZFGV
BRD-K13949769-001-01-7	tenovin-6	Preclinical	SIRT inhibitor	SIRT1|SIRT2|SIRT3			0	91.3	Selleck	S4900	Tenovin-6	454.24	CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	BVJSXSQRIUSRCO-UHFFFAOYSA-N	24772043.0		BVJSXSQRIUSRCO
BRD-K13949769-003-01-3	tenovin-6	Preclinical	SIRT inhibitor	SIRT1|SIRT2|SIRT3			0	93.0	Selleck	S4900	Tenovin-6	454.24	CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	BVJSXSQRIUSRCO-UHFFFAOYSA-N	24772043.0		BVJSXSQRIUSRCO
BRD-K13949769-001-02-9	tenovin-6	Preclinical	SIRT inhibitor	SIRT1|SIRT2|SIRT3			0	96.44	MedChemEx	HY-15510	Tenovin-6	454.24	CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	BVJSXSQRIUSRCO-UHFFFAOYSA-N	24772043.0		BVJSXSQRIUSRCO
BRD-A22844106-001-29-9	tenoxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology|orthopedics	rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis	0	76.11	MedChemEx	HY-B0440	Tenoxicam	337.019	CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|	LZNWYQJJBLGYLT-UHFFFAOYSA-N	54677971.0		LZNWYQJJBLGYLT
BRD-A22844106-001-26-0	tenoxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology|orthopedics	rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis	0	98.19	MicroSource	1503142	TENOXICAM	337.019	CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|	LZNWYQJJBLGYLT-UHFFFAOYSA-N	54677971.0		LZNWYQJJBLGYLT
BRD-A22844106-001-25-2	tenoxicam	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology|orthopedics	rheumatoid arthritis|osteoarthritis|ankylosing spondylitis|tendinitis|bursitis|periarthritis	0	93.59	Selleck	S2512	Tenoxicam	337.019	CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|	LZNWYQJJBLGYLT-UHFFFAOYSA-N	54677971.0		LZNWYQJJBLGYLT
BRD-K91298281-001-01-3	tenylidone	Preclinical					0	71.2	MicroSource	1506108	TENYLIDONE	286.049	O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1	KHXBULXCCPIELT-DCIPZJNNSA-N	1550999.0		KHXBULXCCPIELT
BRD-K91298281-001-09-9	tenylidone	Preclinical					0	64.52	ChemDiv	8008-2113	2,6-bis[(E)-1-(2-thienyl)methylidene]-1-cyclohexanone	286.049	O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1	KHXBULXCCPIELT-DCIPZJNNSA-N	1550999.0		KHXBULXCCPIELT
BRD-K89714990-001-01-5	tepoxalin	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor	ALOX5	rheumatology|orthopedics	rheumatoid arthritis|hip dysplasia	0	98.03	MicroSource	1504107	TEPOXALIN	385.119	COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1	XYKWNRUXCOIMFZ-UHFFFAOYSA-N	59757.0		XYKWNRUXCOIMFZ
BRD-K89714990-001-02-3	tepoxalin	Launched	cyclooxygenase inhibitor|lipoxygenase inhibitor	ALOX5	rheumatology|orthopedics	rheumatoid arthritis|hip dysplasia	0	97.32	Toronto	T103250	tepoxalin	385.119	COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1	XYKWNRUXCOIMFZ-UHFFFAOYSA-N	59757.0		XYKWNRUXCOIMFZ
BRD-K01826017-001-02-9	TEPP-46	Preclinical	pyruvate kinase isozyme activator	PKM			0	97.55	MedChemEx	HY-18657	TEPP-46	372.071	Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|	ZWKJWVSEDISQIS-RUZDIDTESA-N	60156291.0		ZWKJWVSEDISQIS
BRD-K01826017-001-01-9	TEPP-46	Preclinical	pyruvate kinase isozyme activator	PKM			0	86.53	MedChemEx	HY-18657	TEPP-46	372.071	Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|	ZWKJWVSEDISQIS-RUZDIDTESA-N	60156291.0		ZWKJWVSEDISQIS
BRD-K11510141-001-04-2	teprenone	Launched	mucus protecting agent		dermatology	cosmetic	0	0.0	MedChemEx	HY-B0779	Teprenone	330.292	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	HUCXKZBETONXFO-NJFMWZAGSA-N	5282199.0		HUCXKZBETONXFO
BRD-K11510141-001-03-4	teprenone	Launched	mucus protecting agent		dermatology	cosmetic	0	82.34	MedChemEx	HY-B0779	Teprenone	330.292	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	HUCXKZBETONXFO-NJFMWZAGSA-N	5282199.0		HUCXKZBETONXFO
BRD-K11510141-001-02-6	teprenone	Launched	mucus protecting agent		dermatology	cosmetic	0	77.7	SantaCruz	sc-252851		330.292	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	HUCXKZBETONXFO-NJFMWZAGSA-N	5282199.0		HUCXKZBETONXFO
BRD-K11510141-001-01-8	teprenone	Launched	mucus protecting agent		dermatology	cosmetic	0	79.43	SantaCruz	sc-252851		330.292	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	HUCXKZBETONXFO-NJFMWZAGSA-N	5282199.0		HUCXKZBETONXFO
BRD-K76788410-001-01-6	terameprocol	Phase 1/Phase 2	lipoxygenase inhibitor	BIRC5|CDK1			0	99.1	Sigma	MFCD11113155	4-[(2S,3R)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene	358.214	COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC	ORQFDHFZSMXRLM-IYBDPMFKSA-N	476861.0		ORQFDHFZSMXRLM
BRD-K01826569-003-19-9	terazosin	Launched	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D	urology|cardiology	benign prostatic hyperplasia (BPH)|hypertension	0	96.26	Tocris	1506	Terazosin hydrochloride	387.191	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23,r|	VCKUSRYTPJJLNI-CQSZACIVSA-N	1398859.0		VCKUSRYTPJJLNI
BRD-K68132782-003-14-6	terbinafine	Launched	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis|tinea cruris|tinea corporis	0	98.42	MicroSource	1505392	TERBINAFINE HYDROCHLORIDE	291.199	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	DOMXUEMWDBAQBQ-WEVVVXLNSA-N	1549008.0		DOMXUEMWDBAQBQ
BRD-K68132782-003-13-8	terbinafine	Launched	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis|tinea cruris|tinea corporis	0	98.76	Selleck	S2557	Terbinafine HCl	291.199	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	DOMXUEMWDBAQBQ-WEVVVXLNSA-N	1549008.0		DOMXUEMWDBAQBQ
BRD-K68132782-001-03-3	terbinafine	Launched	fungal squalene epoxidase inhibitor	SQLE	infectious disease	tinea pedis|tinea cruris|tinea corporis	0	96.48	Selleck	S1725	Terbinafine	291.199	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	DOMXUEMWDBAQBQ-WEVVVXLNSA-N	1549008.0		DOMXUEMWDBAQBQ
BRD-A50157456-065-21-4	terbutaline	Launched	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm|bronchitis|emphysema	0	93.35	MedChemEx	HY-B0802	Terbutaline (sulfate)	225.136	CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|	XWTYSIMOBUGWOL-LLVKDONJSA-N	11354816.0	BRD-M79902621-065-06-7	XWTYSIMOBUGWOL
BRD-A50157456-065-20-6	terbutaline	Launched	adrenergic receptor agonist	ADRB2	pulmonary	bronchospasm|bronchitis|emphysema	0	81.89	MicroSource	1500558	TERBUTALINE HEMISULFATE	225.136	CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|	XWTYSIMOBUGWOL-LLVKDONJSA-N	11354816.0		XWTYSIMOBUGWOL
BRD-K01826018-001-01-9	terciprazine	Phase 1					0	94.14	PrincetonBio	OSSK_922544	1-[(1-ethynylcyclohexyl)oxy]-3-{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}-2-propanol	410.218	O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1,r|	SDKXUWMRKYQIFU-HXUWFJFHSA-N	30844635.0		SDKXUWMRKYQIFU
BRD-K86204871-001-17-9	terconazole	Launched	sterol demethylase inhibitor		infectious disease	vulvovaginal candidiasis	0	95.98	MedChemEx	HY-B1790	Terconazole	531.18	CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1	BLSQLHNBWJLIBQ-OZXSUGGESA-N	441383.0		BLSQLHNBWJLIBQ
BRD-K86204871-001-16-2	terconazole	Launched	sterol demethylase inhibitor		infectious disease	vulvovaginal candidiasis	0	78.39	MicroSource	1503847	TERCONAZOLE	531.18	CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1	BLSQLHNBWJLIBQ-OZXSUGGESA-N	441383.0		BLSQLHNBWJLIBQ
BRD-A06352418-001-25-9	terfenadine	Withdrawn	histamine receptor antagonist	HRH1|KCNH1|KCNH2			0	97.86	MicroSource	1503708	TERFENADINE	471.314	CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|	GUGOEEXESWIERI-PMERELPUSA-N	6604035.0		GUGOEEXESWIERI
BRD-A06352418-001-27-5	terfenadine	Withdrawn	histamine receptor antagonist	HRH1|KCNH1|KCNH2			0	88.87	Tocris	3948	Terfenadine	471.314	CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|	GUGOEEXESWIERI-PMERELPUSA-N	6604035.0		GUGOEEXESWIERI
BRD-A06352418-001-24-2	terfenadine	Withdrawn	histamine receptor antagonist	HRH1|KCNH1|KCNH2			0	95.16	Selleck	S4353	Terfenadine	471.314	CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|	GUGOEEXESWIERI-PMERELPUSA-N	6604035.0		GUGOEEXESWIERI
BRD-A06352418-001-28-9	terfenadine	Withdrawn	histamine receptor antagonist	HRH1|KCNH1|KCNH2			0	95.01	Tocris	3948	Terfenadine	471.314	CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10,r|	GUGOEEXESWIERI-PMERELPUSA-N	6604035.0		GUGOEEXESWIERI
BRD-A89207210-001-01-6	terguride	Launched	dopamine receptor agonist|serotonin receptor antagonist	ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	neurology/psychiatry	Parkinson's Disease	0	94.68	Kemprotec	37686-84-3	1,1-diethyl-3-((9S)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)urea	340.226	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8,&1:10,&2:11|	JOAHPSVPXZTVEP-YXJHDRRASA-N	443951.0		JOAHPSVPXZTVEP
BRD-A42699921-001-02-8	teriflunomide	Launched	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	0	87.02	Selleck	S4169	Teriflunomide	270.062	CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|	NABQBYDEMLGCEO-SNVBAGLBSA-N			NABQBYDEMLGCEO
BRD-A42699921-001-04-4	teriflunomide	Launched	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	0	88.62	Tocris	5069	Teriflunomide	270.062	CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|	NABQBYDEMLGCEO-SNVBAGLBSA-N			NABQBYDEMLGCEO
BRD-A42699921-001-03-6	teriflunomide	Launched	dihydroorotate dehydrogenase inhibitor	DHODH	neurology/psychiatry	multiple sclerosis	0	99.84	Selleck	S4169	Teriflunomide	270.062	CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3,r|	NABQBYDEMLGCEO-SNVBAGLBSA-N			NABQBYDEMLGCEO
BRD-K73451719-001-01-2	terlipressin	Launched	vasopressin receptor agonist	AVPR1A	cardiology	hypotension	0	86.38	Key	HS-2028	(S)-N-((S)-6-amino-1-(2-amino-2-oxoethylamino)-1-oxohexan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-19-(2-(2-(2-aminoacetamido)acetamido)acetamido)-13-benzyl-16-;(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8	1226.496	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	BENFXAYNYRLAIU-WBNRJDGRSA-N	133566182.0		BENFXAYNYRLAIU
BRD-A33479817-003-03-7	terodiline	Withdrawn	cholinergic receptor antagonist				0	97.58	Sigma	MFCD00941402	N-(tert-butyl)-4,4-diphenyl-2-butanamine hydrochloride	281.214	C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|	UISARWKNNNHPGI-INIZCTEOSA-N	9925740.0		UISARWKNNNHPGI
BRD-A39935389-001-06-9	teroxirone	Phase 1	DNA inhibitor				0	100.0	Sigma	MFCD00080670	Tris(2,3-epoxypropyl) isocyanurate	297.096	O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|	OUPZKGBUJRBPGC-CIUDSAMLSA-N	11197252.0		OUPZKGBUJRBPGC
BRD-A39935389-001-05-9	teroxirone	Phase 1	DNA inhibitor				0	100.0	ChemDiv	0168-0391		297.096	O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4,&2:11,&3:18,r|	OUPZKGBUJRBPGC-CIUDSAMLSA-N	11197252.0		OUPZKGBUJRBPGC
BRD-K00003674-002-01-9	terpene	Preclinical					0	0.0	MedChemEx	HY-B1063	Terpin (hydrate)	172.146	CC(C)(O)[C@H]1CC[C@](C)(O)CC1 |&1:7,&2:4|	RBNWAMSGVWEHFP-CZMCAQCFSA-N			RBNWAMSGVWEHFP
BRD-K00024725-001-01-9	terreic-acid-(-)	Preclinical	Bruton's tyrosine kinase (BTK) inhibitor	BTK			0		Tocris	1405	(-)-Terric acid	154.027	C[C@@H]1C(=O)[C@H]2O[C@H]2C(=O)C1=O |&1:1|	NYFMSQHOGRWGFD-OOVQLBIQSA-N			NYFMSQHOGRWGFD
BRD-K43975632-001-01-1	terutroban	Phase 3	prostanoid receptor antagonist	TBXA2R			0	95.89	MedChemEx	HY-16991	Terutroban	407.096	Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1	HWEOXFSBSQIWSY-MRXNPFEDSA-N	9938840.0		HWEOXFSBSQIWSY
BRD-K15507868-001-04-5	tesaglitazar	Phase 3	insulin sensitizer|PPAR receptor agonist	PPARA|PPARG			0	91.0	Tocris	3965	Tesaglitazar	408.124	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	CXGTZJYQWSUFET-IBGZPJMESA-N	208901.0		CXGTZJYQWSUFET
BRD-K15507868-001-03-7	tesaglitazar	Phase 3	insulin sensitizer|PPAR receptor agonist	PPARA|PPARG			0	96.97	Cayman	16791		408.124	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	CXGTZJYQWSUFET-IBGZPJMESA-N	208901.0		CXGTZJYQWSUFET
BRD-K00004564-001-01-9	tetomilast	Phase 2	phosphodiesterase inhibitor	PDE4D			0	93.74	Sigma	MFCD00936868	6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]-2-pyridinecarboxylic acid	370.099	CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O	XDBHURGONHZNJF-UHFFFAOYSA-N	3025803.0		XDBHURGONHZNJF
BRD-K95739795-001-04-5	tetrabenazine	Launched	vesicular monoamine transporter inhibitor	SLC18A1|SLC18A2	infectious disease|neurology/psychiatry	cholera|Huntington's disease	0	93.02	Tocris	2175	Tetrabenazine	317.199	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	MKJIEFSOBYUXJB-HOCLYGCPSA-N	11634155.0		MKJIEFSOBYUXJB
BRD-K95739795-001-03-7	tetrabenazine	Launched	vesicular monoamine transporter inhibitor	SLC18A1|SLC18A2	infectious disease|neurology/psychiatry	cholera|Huntington's disease	0	87.1	Tocris	2175	Tetrabenazine	317.199	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	MKJIEFSOBYUXJB-HOCLYGCPSA-N	11634155.0		MKJIEFSOBYUXJB
BRD-K95739795-001-05-9	tetrabenazine	Launched	vesicular monoamine transporter inhibitor	SLC18A1|SLC18A2	infectious disease|neurology/psychiatry	cholera|Huntington's disease	0	88.22	Tocris	2175	Tetrabenazine	317.199	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	MKJIEFSOBYUXJB-HOCLYGCPSA-N	11634155.0		MKJIEFSOBYUXJB
BRD-K45071273-003-24-9	tetracaine	Launched	membrane integrity inhibitor	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	anesthetic	0	93.56	Selleck	S2573	Tetracaine HCl	264.184	CCCCNc1ccc(cc1)C(=O)OCCN(C)C	GKCBAIGFKIBETG-UHFFFAOYSA-N	5411.0		GKCBAIGFKIBETG
BRD-K45071273-003-25-6	tetracaine	Launched	membrane integrity inhibitor	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	anesthetic	0	98.82	MicroSource	1500564	TETRACAINE HYDROCHLORIDE	264.184	CCCCNc1ccc(cc1)C(=O)OCCN(C)C	GKCBAIGFKIBETG-UHFFFAOYSA-N	5411.0		GKCBAIGFKIBETG
BRD-K00003352-003-01-9	tetracycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease|dermatology	respiratory tract infections|pneumonia|skin infections|urinary tract infections|acne vulgaris (AV)|plague|psittacosis	0	52.63	MedChemEx	HY-B0474	Tetracycline (hydrochloride)	444.153	[H][C@@]12C[C@@]3([H])[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:24,&2:5|	MUHBBHLZPHKTTR-VHOYBAKPSA-N	129396784.0		MUHBBHLZPHKTTR
BRD-K47539947-001-03-7	tetradecylthioacetic-acid	Phase 2	lipid peroxidase inhibitor				0	100.0	Enzo	GR236	Tetradecylthioacetic acid	288.212	CCCCCCCCCCCCCCSCC(O)=O	IPBCWPPBAWQYOO-UHFFFAOYSA-N	114924.0		IPBCWPPBAWQYOO
BRD-K47539947-001-04-9	tetradecylthioacetic-acid	Phase 2	lipid peroxidase inhibitor				0	100.0	Sigma	T1698	Tetradecylthioacetic acid	288.212	CCCCCCCCCCCCCCSCC(O)=O	IPBCWPPBAWQYOO-UHFFFAOYSA-N	114924.0		IPBCWPPBAWQYOO
BRD-K41298358-395-02-6	tetraethylenepentamine	Phase 2/Phase 3	superoxide dismutase inhibitor	SOD1|SOD2			0	73.12	Selleck	S4410	Tetraethylenepentamine 5HCl	189.195	NCCNCCNCCNCCN	FAGUFWYHJQFNRV-UHFFFAOYSA-N	8197.0		FAGUFWYHJQFNRV
BRD-K41298358-395-03-4	tetraethylenepentamine	Phase 2/Phase 3	superoxide dismutase inhibitor	SOD1|SOD2			0	99.86	Selleck	S4410	tetraethylenepentamine pentahydrochloride	189.195	NCCNCCNCCNCCN	FAGUFWYHJQFNRV-UHFFFAOYSA-N	8197.0		FAGUFWYHJQFNRV
BRD-K41298358-395-04-2	tetraethylenepentamine	Phase 2/Phase 3	superoxide dismutase inhibitor	SOD1|SOD2			0	63.5	Selleck	S4410	Tetraethylenepentamine 5HCl	189.195	NCCNCCNCCNCCN	FAGUFWYHJQFNRV-UHFFFAOYSA-N	8197.0		FAGUFWYHJQFNRV
BRD-A36978621-001-01-9	tetrahydrofolic-acid	Launched		FOLR2			0	0.0	Sigma	MFCD00135583	(2S)-2-[(4-{[(2-amino-4-oxo-1,4,5,6,7,8-hexahydro-6-pteridinyl)methyl]amino}benzoyl)amino]pentanedioic acid	445.171	Nc1nc(=O)c2N[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:19,&1:7|	MSTNYGQPCMXVAQ-RYUDHWBXSA-N	135398650.0		MSTNYGQPCMXVAQ
BRD-K01825583-003-03-9	tetrahydropapaverine	Preclinical					0	97.07	Selleck	S2367	Tetrahydropapaverine hydrochloride	379.155	COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|	YXWQTVWJNHKSCC-MRXNPFEDSA-N	688594.0		YXWQTVWJNHKSCC
BRD-K01825583-003-02-9	tetrahydropapaverine	Preclinical					0	97.58	Selleck	S2367	Tetrahydropapaverine HCl	379.155	COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|	YXWQTVWJNHKSCC-MRXNPFEDSA-N	688594.0		YXWQTVWJNHKSCC
BRD-A86248581-001-01-4	tetrahydrouridine	Phase 2	cytidine deaminase inhibitor	CDA			0	100.0	EMDBio	584222-10MG	Tetrahydrouridine	248.101	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2,4,5,7,&1:12|	UCKYOOZPSJFJIZ-FMDGEEDCSA-N	9543506.0		UCKYOOZPSJFJIZ
BRD-A28856712-003-25-2	tetrahydrozoline	Launched	adrenergic receptor agonist		ophthalmology	eye irritation	0	93.25	Selleck	S4043		200.131	C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|	BYJAVTDNIXVSPW-LBPRGKRZSA-N	716128.0		BYJAVTDNIXVSPW
BRD-A28856712-003-26-0	tetrahydrozoline	Launched	adrenergic receptor agonist		ophthalmology	eye irritation	0	97.41	MicroSource	1500567		200.131	C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|	BYJAVTDNIXVSPW-LBPRGKRZSA-N	716128.0		BYJAVTDNIXVSPW
BRD-A28856712-003-27-9	tetrahydrozoline	Launched	adrenergic receptor agonist		ophthalmology	eye irritation	0	96.74	MedChemEx	HY-B0556A	Tetrahydrozoline (hydrochloride)	200.131	C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5,c:2|	BYJAVTDNIXVSPW-LBPRGKRZSA-N	716128.0		BYJAVTDNIXVSPW
BRD-K36889451-001-01-1	tetramethylthiuram-monosulfide	Preclinical					0	94.7	AKSci	O362	Tetramethylthiuram monosulfide	208.016	CN(C)C(=S)SC(=S)N(C)C	REQPQFUJGGOFQL-UHFFFAOYSA-N	7347.0		REQPQFUJGGOFQL
BRD-A46393198-003-16-6	tetramisole	Launched	immunostimulant	ALPPL2|CHRNA3	infectious disease	gastrointestinal parasites	0	99.58	MicroSource	1505679	TETRAMIZOLE HYDROCHLORIDE	204.072	C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N	26879.0		HLFSDGLLUJUHTE
BRD-A46393198-003-15-8	tetramisole	Launched	immunostimulant	ALPPL2|CHRNA3	infectious disease	gastrointestinal parasites	0	97.3	Selleck	S4094	Tetramisole HCl	204.072	C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4,c:5|	HLFSDGLLUJUHTE-SNVBAGLBSA-N	26879.0		HLFSDGLLUJUHTE
BRD-K08078237-001-19-8	tetrandrine	Preclinical	calcium channel blocker	SLC6A3			0	97.19	Selleck	S2403	Tetrandrine (Fanchinine)	622.304	COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34	WVTKBKWTSCPRNU-KYJUHHDHSA-N	73078.0		WVTKBKWTSCPRNU
BRD-K08078237-001-20-6	tetrandrine	Preclinical	calcium channel blocker	SLC6A3			0	73.47	Selleck	S2403	Tetrandrine	622.304	COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34	WVTKBKWTSCPRNU-KYJUHHDHSA-N	73078.0	BRD-K59640580-001-07-1	WVTKBKWTSCPRNU
BRD-A14757586-001-03-2	tetrazol-5-yl-glycine-(RS)	Preclinical	glutamate receptor agonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	0.0	Tocris	312	(RS)-(Tetrazol-5-yl)glycine	143.044	N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|	UKBRUIZWQZHXFL-PVQJCKRUSA-N	15024268.0		UKBRUIZWQZHXFL
BRD-A14757586-001-04-9	tetrazol-5-yl-glycine-(RS)	Preclinical	glutamate receptor agonist	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	100.0	Tocris	312	(RS)-(Tetrazol-5-yl)glycine	143.044	N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1,r|	UKBRUIZWQZHXFL-PVQJCKRUSA-N	15024268.0		UKBRUIZWQZHXFL
BRD-A52660433-066-03-9	tetrindole	Phase 3	monoamine oxidase inhibitor	MAOA			0	93.81	Tocris	723	Tetrindole mesylate	294.21	C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1	AUXCHYJDVJZEPG-UHFFFAOYSA-N	54792409.0		AUXCHYJDVJZEPG
BRD-A52660433-066-02-1	tetrindole	Phase 3	monoamine oxidase inhibitor	MAOA			0	93.92	Tocris	723	Tetrindole mesylate	294.21	C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1	AUXCHYJDVJZEPG-UHFFFAOYSA-N	54792409.0		AUXCHYJDVJZEPG
BRD-K90177246-001-05-5	tetroquinone	Preclinical					0	0.0	MicroSource	1503330	TETROQUINONE	172.001	OC1C(=O)C(=O)C(O)C(=O)C1=O	GQPHQLHUIDOQTA-UHFFFAOYSA-N	36689751.0		GQPHQLHUIDOQTA
BRD-K90177246-001-06-3	tetroquinone	Preclinical					0	0.0	CombiBlocks	QB-724	Tetrahydroxyquinone	172.001	OC1C(=O)C(=O)C(O)C(=O)C1=O	GQPHQLHUIDOQTA-UHFFFAOYSA-N	36689751.0		GQPHQLHUIDOQTA
BRD-K97101532-001-02-8	tezacaftor	Launched	CFTR channel agonist		pulmonary	cystic fibrosis	0	96.27	Selleck	S7059	VX-661	520.182	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	MJUVRTYWUMPBTR-MRXNPFEDSA-N	46199646.0		MJUVRTYWUMPBTR
BRD-K97101532-001-03-9	tezacaftor	Launched	CFTR channel agonist		pulmonary	cystic fibrosis	0	96.52	MedChemEx	HY-15448	Tezacaftor	520.182	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	MJUVRTYWUMPBTR-MRXNPFEDSA-N	46199646.0		MJUVRTYWUMPBTR
BRD-K57708067-001-02-9	TFC-007	Preclinical	prostaglandin inhibitor	HPGDS			0	93.06	Tocris	5108	TFC 007	487.222	O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1	NLSSUSRERAMBTA-UHFFFAOYSA-N	16040067.0		NLSSUSRERAMBTA
BRD-K57708067-001-01-3	TFC-007	Preclinical	prostaglandin inhibitor	HPGDS			0	95.55	Tocris	5108	TFC 007	487.222	O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1	NLSSUSRERAMBTA-UHFFFAOYSA-N	16040067.0		NLSSUSRERAMBTA
BRD-K97072811-001-11-4	TG-003	Preclinical	CLK inhibitor	CLK1|CLK4|DYRK1A|DYRK1B			0	96.35	Selleck	S7320	TG003	249.082	CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O	BGVLELSCIHASRV-QPEQYQDCSA-N	1893668.0		BGVLELSCIHASRV
BRD-K97072811-001-13-9	TG-003	Preclinical	CLK inhibitor	CLK1|CLK4|DYRK1A|DYRK1B			0	96.57	Tocris	4336	TG 003	249.082	CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O	BGVLELSCIHASRV-QPEQYQDCSA-N	1893668.0		BGVLELSCIHASRV
BRD-K14560436-001-01-4	TG-02	Phase 1/Phase 2	CDK inhibitor|FLT3 inhibitor|JAK inhibitor	CDK1|CDK2|CDK7|CDK9|FLT3|JAK2			0	96.17	MedChemEx	HY-15166	SB1317	372.195	CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|	VXBAJLGYBMTJCY-NSCUHMNNSA-N	16739650.0		VXBAJLGYBMTJCY
BRD-K14560436-001-02-9	TG-02	Phase 1/Phase 2	CDK inhibitor|FLT3 inhibitor|JAK inhibitor	CDK1|CDK2|CDK7|CDK9|FLT3|JAK2			0	96.86	MedChemEx	HY-15166	SB1317	372.195	CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|	VXBAJLGYBMTJCY-NSCUHMNNSA-N	16739650.0		VXBAJLGYBMTJCY
BRD-K18424115-003-02-9	TG-100572	Preclinical	SRC inhibitor|VEGFR inhibitor	KDR|SRC			0	86.19	MedChemEx	HY-10185	TG 100572 (Hydrochloride)	475.178	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	AQSSMEORRLJZLU-UHFFFAOYSA-N	11712625.0		AQSSMEORRLJZLU
BRD-K18424115-003-01-3	TG-100572	Preclinical	SRC inhibitor|VEGFR inhibitor	KDR|SRC			0	89.41	MedChemEx	HY-10185	TG 100572 (Hydrochloride)	475.178	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	AQSSMEORRLJZLU-UHFFFAOYSA-N	11712625.0		AQSSMEORRLJZLU
BRD-K46392623-001-03-9	TG-100713	Preclinical	PI3K inhibitor				0	96.93	Tocris	4264	TG 100713	254.092	Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	UOORQSPLBHUQDQ-UHFFFAOYSA-N	17751063.0		UOORQSPLBHUQDQ
BRD-K46392623-001-02-5	TG-100713	Preclinical	PI3K inhibitor				0	92.96	Selleck	S2870	TG100713	254.092	Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	UOORQSPLBHUQDQ-UHFFFAOYSA-N	17751063.0		UOORQSPLBHUQDQ
BRD-K12735121-001-02-9	TG-100801	Phase 2	SRC inhibitor|VEGFR inhibitor	CSK|FGFR1|FLT1|FLT4|KDR|SRC			0	80.28	MedChemEx	HY-10186	TG 100801	579.204	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl	JMGXJHWTVBGOKG-UHFFFAOYSA-N	11973736.0		JMGXJHWTVBGOKG
BRD-K12735121-001-01-4	TG-100801	Phase 2	SRC inhibitor|VEGFR inhibitor	CSK|FGFR1|FLT1|FLT4|KDR|SRC			0	89.33	MedChemEx	HY-10186	TG 100801	579.204	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl	JMGXJHWTVBGOKG-UHFFFAOYSA-N	11973736.0		JMGXJHWTVBGOKG
BRD-K39841531-001-04-9	TG-101209	Preclinical	JAK inhibitor	JAK2|JAK3			0	95.64	MedChemEx	HY-10410	TG101209	509.257	CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	JVDOKQYTTYUYDV-UHFFFAOYSA-N	16722832.0		JVDOKQYTTYUYDV
BRD-K39841531-001-02-1	TG-101209	Preclinical	JAK inhibitor	JAK2|JAK3			0	94.67	Selleck	S2692	TG101209	509.257	CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	JVDOKQYTTYUYDV-UHFFFAOYSA-N	16722832.0		JVDOKQYTTYUYDV
BRD-K52579889-001-01-9	TGR-1202	Phase 3	PI3K inhibitor				0	94.1	MedChemEx	HY-12279	TGR-1202	571.183	CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12	IUVCFHHAEHNCFT-INIZCTEOSA-N	72950888.0		IUVCFHHAEHNCFT
BRD-A41692738-001-10-0	TGX-221	Preclinical	PI3K inhibitor	PIK3CB|PIK3CD			0	91.18	Selleck	S1169	TGX-221	364.19	C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|	CPRAGQJXBLMUEL-MRXNPFEDSA-N	51601993.0		CPRAGQJXBLMUEL
BRD-A41692738-001-07-6	TGX-221	Preclinical	PI3K inhibitor	PIK3CB|PIK3CD			0	90.26	Selleck	S1169	TGX-221	364.19	C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1,r|	CPRAGQJXBLMUEL-MRXNPFEDSA-N	51601993.0		CPRAGQJXBLMUEL
BRD-K64785675-001-04-0	TG100-115	Phase 1/Phase 2	PI3K inhibitor	PIK3CA|PIK3CB|PIK3CD|PIK3CG			0	94.74	Selleck	S1352	TG100-115	346.118	Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1	UJIAQDJKSXQLIT-UHFFFAOYSA-N	10427712.0		UJIAQDJKSXQLIT
BRD-K20958582-001-02-9	TH-302	Phase 3	DNA alkylating agent				0	84.58	MedChemEx	HY-10535	Evofosfamide	446.931	Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	UGJWRPJDTDGERK-UHFFFAOYSA-N	11984561.0		UGJWRPJDTDGERK
BRD-K20958582-001-01-4	TH-302	Phase 3	DNA alkylating agent				0	88.37	MedChemEx	HY-10535	TH-302	446.931	Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	UGJWRPJDTDGERK-UHFFFAOYSA-N	11984561.0		UGJWRPJDTDGERK
BRD-K01054709-001-01-3	TH-588	Preclinical	MTH1 inhibitor	NUDT1			0	97.39	MedChemEx	HY-12814	TH588	294.044	Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl	PNMYJIOQIAEYQL-UHFFFAOYSA-N	73389731.0		PNMYJIOQIAEYQL
BRD-K87548127-300-01-1	thaliblastine	Phase 2	DNA inhibitor				0	0.0	InterBioScreen	STOCK1N-51856		696.341	COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC	ZCTJIMXXSXQXRI-KYJUHHDHSA-N	21470.0		ZCTJIMXXSXQXRI
BRD-A93255169-001-28-3	thalidomide	Launched	tumor necrosis factor production inhibitor	TNF	oncology	myeloma	0	99.0	Tocris	652	Thalidomide	258.064	O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|	UEJJHQNACJXSKW-VIFPVBQESA-N	92142.0		UEJJHQNACJXSKW
BRD-A93255169-001-27-5	thalidomide	Launched	tumor necrosis factor production inhibitor	TNF	oncology	myeloma	0	98.54	Selleck	S1193	Thalidomide	258.064	O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3,r|	UEJJHQNACJXSKW-VIFPVBQESA-N	92142.0		UEJJHQNACJXSKW
BRD-K60842365-001-03-9	theaflavin	Preclinical	antiviral				0	78.41	MedChemEx	HY-N0243	Theaflavin	564.127	O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc(cc12)[C@H]1Oc2cc(O)cc(O)c2C[C@H]1O	SPQUOZYCYRJYJU-ZKSIBHASSA-N			SPQUOZYCYRJYJU
BRD-K34888156-213-01-4	theobromine	Launched	phosphodiesterase inhibitor	ADORA1|ADORA2A|PDE4B			0	98.78	MicroSource	1500649	THEOBROMINE	180.065	Cn1cnc2n(C)c(=O)[nH]c(=O)c12	YAPQBXQYLJRXSA-UHFFFAOYSA-N	5429.0		YAPQBXQYLJRXSA
BRD-K34888156-001-12-9	theobromine	Launched	phosphodiesterase inhibitor	ADORA1|ADORA2A|PDE4B			0	96.61	MedChemEx	HY-N0138	Theobromine	180.065	Cn1cnc2n(C)c(=O)[nH]c(=O)c12	YAPQBXQYLJRXSA-UHFFFAOYSA-N	5429.0		YAPQBXQYLJRXSA
BRD-K34888156-001-11-2	theobromine	Launched	phosphodiesterase inhibitor	ADORA1|ADORA2A|PDE4B			0	95.14	Selleck	S2368	Theobromine	180.065	Cn1cnc2n(C)c(=O)[nH]c(=O)c12	YAPQBXQYLJRXSA-UHFFFAOYSA-N	5429.0		YAPQBXQYLJRXSA
BRD-K38380126-001-04-9	thiamet-g	Preclinical	GLCNAC phosphotransferase inhibitor	MGEA5			0	89.66	Tocris	4390	Thiamet G	248.083	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|	PPAIMZHKIXDJRN-FMDGEEDCSA-N	24808478.0		PPAIMZHKIXDJRN
BRD-K38380126-001-02-2	thiamet-g	Preclinical	GLCNAC phosphotransferase inhibitor	MGEA5			0	82.81	Tocris	4390	Thiamet G	248.083	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|	PPAIMZHKIXDJRN-FMDGEEDCSA-N	24808478.0		PPAIMZHKIXDJRN
BRD-K38380126-001-01-4	thiamet-g	Preclinical	GLCNAC phosphotransferase inhibitor	MGEA5			0	95.3	Selleck	S7213	Thiamet G	248.083	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|	PPAIMZHKIXDJRN-FMDGEEDCSA-N	24808478.0		PPAIMZHKIXDJRN
BRD-K95785345-003-16-9	thiamine	Launched	vitamin B	SLC19A2|SLC19A3|TPK1	metabolism	thiamine deficiency	0	68.1	MedChemEx	HY-A0100	Thiamine monochloride	265.112	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	JZRWCGZRTZMZEH-UHFFFAOYSA-N	1130.0		JZRWCGZRTZMZEH
BRD-K95785345-300-15-5	thiamine	Launched	vitamin B	SLC19A2|SLC19A3|TPK1	metabolism	thiamine deficiency	0	90.48	MicroSource	1505464	THIAMINE	265.112	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	JZRWCGZRTZMZEH-UHFFFAOYSA-N	1130.0		JZRWCGZRTZMZEH
BRD-K95785345-300-14-8	thiamine	Launched	vitamin B	SLC19A2|SLC19A3|TPK1	metabolism	thiamine deficiency	0	96.41	Selleck	S3211	Thiamine HCl (Vitamin B1)	265.112	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	JZRWCGZRTZMZEH-UHFFFAOYSA-N	1130.0		JZRWCGZRTZMZEH
BRD-A09994331-003-02-4	thiamine-pyrophosphate	Launched			hematology	anemia	0	0.0	ChemImpex	461	Thiamine pyrophosphate	425.045	Cc1c(CCOP(O)(=O)OP(O)(O)=O)sc[n+]1Cc1cnc(C)nc1N |&1:6|	AYEKOFBPNLCAJY-UHFFFAOYSA-O	1132.0		AYEKOFBPNLCAJY
BRD-K79711234-001-18-3	thiamphenicol	Launched	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	0	98.69	MicroSource	1503136	THIAMPHENICOL	355.005	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	OTVAEFIXJLOWRX-NXEZZACHSA-N	27200.0		OTVAEFIXJLOWRX
BRD-K79711234-001-20-9	thiamphenicol	Launched	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	0	93.07	MedChemEx	HY-B0479	Thiamphenicol	355.005	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	OTVAEFIXJLOWRX-NXEZZACHSA-N	27200.0		OTVAEFIXJLOWRX
BRD-K79711234-001-17-5	thiamphenicol	Launched	bacterial 50S ribosomal subunit inhibitor		infectious disease	pelvic inflammatory disease	0	95.24	Selleck	S2583	Thiamphenicol	355.005	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	OTVAEFIXJLOWRX-NXEZZACHSA-N	27200.0		OTVAEFIXJLOWRX
BRD-A23970436-236-04-2	thiamylal	Launched	glutamate receptor antagonist	GABRA1	neurology/psychiatry	sedative	0	52.77	MicroSource	1900002	THIAMYLAL SODIUM	254.109	CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3,&2:5|	XLOMZPUITCYLMJ-MRVPVSSYSA-N	3033021.0		XLOMZPUITCYLMJ
BRD-K03164761-001-04-9	thiazovivin	Preclinical	rho associated kinase inhibitor				0	95.64	Tocris	3845	Thiazovivin	311.084	O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1	DOBKQCZBPPCLEG-UHFFFAOYSA-N	46209426.0		DOBKQCZBPPCLEG
BRD-K03164761-001-02-1	thiazovivin	Preclinical	rho associated kinase inhibitor				0	96.94	Selleck	S1459	Thiazovivin	311.084	O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1	DOBKQCZBPPCLEG-UHFFFAOYSA-N	46209426.0		DOBKQCZBPPCLEG
BRD-K69600043-001-08-9	thiethylperazine	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD4	gastroenterology	nausea	0	93.3	AMS	10232	Thiethylperazine	399.18	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	XCTYLCDETUVOIP-UHFFFAOYSA-N	5440.0		XCTYLCDETUVOIP
BRD-K69600043-328-05-5	thiethylperazine	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD4	gastroenterology	nausea	0	91.84	Prestwick	Prestw-1068	Thiethylperazine dimalate	399.18	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	XCTYLCDETUVOIP-UHFFFAOYSA-N	5440.0		XCTYLCDETUVOIP
BRD-K69600043-328-09-9	thiethylperazine	Launched	dopamine receptor antagonist	DRD1|DRD2|DRD4	gastroenterology	nausea	0	81.1	Toronto	t344495	thiethylperazine dimalate	399.18	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	XCTYLCDETUVOIP-UHFFFAOYSA-N	5440.0		XCTYLCDETUVOIP
BRD-K26619122-001-02-1	thiocolchicoside	Launched	GABA receptor antagonist	GABRA1|GABRB2|GABRG2|GLRA1|GLRB	neurology/psychiatry	muscle relaxant	0	96.58	Prestwick	Prestw-539	Thiocolchicoside	563.183	COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	LEQAKWQJCITZNK-AXHKHJLKSA-N	9915886.0		LEQAKWQJCITZNK
BRD-K26619122-001-03-9	thiocolchicoside	Launched	GABA receptor antagonist	GABRA1|GABRB2|GABRG2|GLRA1|GLRB	neurology/psychiatry	muscle relaxant	0	38.67	Sigma	SML1476-5MG	Thiocolchiside	563.183	COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	LEQAKWQJCITZNK-AXHKHJLKSA-N	9915886.0		LEQAKWQJCITZNK
BRD-A16347691-001-13-1	thioctic-acid	Launched	reducing agent	ACHE|PTGS2	nephrology	diabetic nephropathy	0	94.83	MicroSource	1503941	THIOCTIC ACID	206.044	OC(=O)CCCC[C@H]1CCSS1 |&1:7,r|	AGBQKNBQESQNJD-ZETCQYMHSA-N	445125.0		AGBQKNBQESQNJD
BRD-K54521836-001-02-1	thiodiglycol	Preclinical					0	95.75	MicroSource	1503325	THIODIGLYCOL	122.04	OCCSCCO	YODZTKMDCQEPHD-UHFFFAOYSA-N	5447.0		YODZTKMDCQEPHD
BRD-K54521836-001-03-9	thiodiglycol	Preclinical					0	0.0	Oakwood	95104	2,2'-thiodiethanol	122.04	OCCSCCO	YODZTKMDCQEPHD-UHFFFAOYSA-N	5447.0		YODZTKMDCQEPHD
BRD-K49350383-001-15-2	thioguanine	Launched	purine antagonist	IMPDH1|IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	0	99.23	MicroSource	1504530	TIOGUANINE	167.027	Nc1nc2nc[nH]c2c(=S)[nH]1	WYWHKKSPHMUBEB-UHFFFAOYSA-N	2723601.0		WYWHKKSPHMUBEB
BRD-K49350383-001-13-7	thioguanine	Launched	purine antagonist	IMPDH1|IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	0	100.0	Selleck	S1774	Thioguanine	167.027	Nc1nc2nc[nH]c2c(=S)[nH]1	WYWHKKSPHMUBEB-UHFFFAOYSA-N	2723601.0		WYWHKKSPHMUBEB
BRD-K49350383-001-14-5	thioguanine	Launched	purine antagonist	IMPDH1|IMPDH2	hematologic malignancy	acute myeloid leukemia (AML)	0	100.0	MicroSource	1500573	THIOGUANINE	167.027	Nc1nc2nc[nH]c2c(=S)[nH]1	WYWHKKSPHMUBEB-UHFFFAOYSA-N	2723601.0		WYWHKKSPHMUBEB
BRD-K61443650-236-14-9	thiomersal	Launched	other antibiotic	OXCT1	infectious disease	preservative	0	98.29	MedChemEx	HY-19588	Thimerosal	384.011	CC[Hg]Sc1ccccc1C(O)=O	HXQVQGWHFRNKMS-UHFFFAOYSA-M	67361.0		HXQVQGWHFRNKMS
BRD-K61443650-236-13-1	thiomersal	Launched	other antibiotic	OXCT1	infectious disease	preservative	0	95.81	MicroSource	1500572	THIMEROSAL	384.011	CC[Hg]Sc1ccccc1C(O)=O	HXQVQGWHFRNKMS-UHFFFAOYSA-M	67361.0		HXQVQGWHFRNKMS
BRD-A72603112-236-05-7	thiopental	Launched	GABA receptor antagonist	FAAH	neurology/psychiatry	anesthetic	0	61.09	Key	KS-1432	5-ethyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione	242.109	CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|	IUJDSEJGGMCXSG-SSDOTTSWSA-N	3033017.0		IUJDSEJGGMCXSG
BRD-A72603112-236-04-0	thiopental	Launched	GABA receptor antagonist	FAAH	neurology/psychiatry	anesthetic	0	63.17	MicroSource	1900005	THIOPENTAL SODIUM	242.109	CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3,&2:5|	IUJDSEJGGMCXSG-SSDOTTSWSA-N	3033017.0		IUJDSEJGGMCXSG
BRD-A85424553-001-07-9	thioperamide	Preclinical	histamine receptor antagonist	HRH3|HRH4			0	95.41	Tocris	644	Thioperamide	292.172	S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r,c:18,20|	JFAYRTHYLOZRNL-CQSZACIVSA-N	6604452.0		JFAYRTHYLOZRNL
BRD-K90168339-001-09-4	thiophanate	Preclinical					0	94.28	Sigma	MFCD00055294	methyl [2-({[(methoxycarbonyl)amino]carbothioyl}amino)anilino]carbothioylcarbamate	342.046	COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC	QGHREAKMXXNCOA-UHFFFAOYSA-N	3032791.0		QGHREAKMXXNCOA
BRD-K90168339-001-08-6	thiophanate	Preclinical					0	80.69	MicroSource	1503974	THIOPHANATE	342.046	COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC	QGHREAKMXXNCOA-UHFFFAOYSA-N	3032791.0		QGHREAKMXXNCOA
BRD-K08619574-001-07-9	thioproperazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A	neurology/psychiatry	schizophrenia	0	97.81	Sigma	MFCD00867741	N,N-dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine-2-sulfonamide	446.181	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	VZYCZNZBPPHOFY-UHFFFAOYSA-N	9429.0		VZYCZNZBPPHOFY
BRD-K08619574-334-05-4	thioproperazine	Launched	dopamine receptor antagonist	ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A	neurology/psychiatry	schizophrenia	0	77.82	Prestwick	Prestw-149	Thioproperazine dimesylate	446.181	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	VZYCZNZBPPHOFY-UHFFFAOYSA-N	9429.0		VZYCZNZBPPHOFY
BRD-A84481105-003-31-3	thioridazine	Withdrawn	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7			0	94.6	Selleck	S4374	Thioridazine HCl	370.154	CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1	KLBQZWRITKRQQV-UHFFFAOYSA-N	66062.0		KLBQZWRITKRQQV
BRD-A84481105-003-32-1	thioridazine	Withdrawn	dopamine receptor antagonist	DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7			0	75.46	MicroSource	1500575	THIORIDAZINE HYDROCHLORIDE	370.154	CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1	KLBQZWRITKRQQV-UHFFFAOYSA-N	66062.0		KLBQZWRITKRQQV
BRD-A56012032-001-14-8	thiorphan	Phase 1	membrane metalloendopeptidase inhibitor	MME			0	0.0	Enzo	PI113	Thiorphan (DL)	253.077	OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|	LJJKNPQAGWVLDQ-SNVBAGLBSA-N	4369380.0		LJJKNPQAGWVLDQ
BRD-A56012032-001-15-5	thiorphan	Phase 1	membrane metalloendopeptidase inhibitor	MME			0	38.61	Sigma	T6031	[(2-benzyl-3-sulfanylpropanoyl)amino]acetic acid	253.077	OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7,r|	LJJKNPQAGWVLDQ-SNVBAGLBSA-N	4369380.0		LJJKNPQAGWVLDQ
BRD-K58049875-001-03-9	thiostrepton	Launched	FOXM1 inhibitor|protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	0	96.6	MedChemEx	HY-B0990	Thiostrepton	1663.492	CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|	NSFFHOGKXHRQEW-AIHSUZKVSA-N	16154490.0	BRD-A89819812-001-02-8	NSFFHOGKXHRQEW
BRD-K58049875-001-01-3	thiostrepton	Launched	FOXM1 inhibitor|protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	0	91.54	MedChemEx	HY-B0990	Thiostrepton	1663.492	CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|	NSFFHOGKXHRQEW-AIHSUZKVSA-N	16154490.0	BRD-A86083681-001-01-4	NSFFHOGKXHRQEW
BRD-K58049875-001-02-1	thiostrepton	Launched	FOXM1 inhibitor|protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	0	72.2	Selleck	S4354	thiostrepton	1663.492	CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|	NSFFHOGKXHRQEW-AIHSUZKVSA-N	16154490.0	BRD-A91347104-001-01-5	NSFFHOGKXHRQEW
BRD-K58049875-001-04-7	thiostrepton	Launched	FOXM1 inhibitor|protein synthesis inhibitor	FOXM1	obstetrics/gynecology	mastitis	0	78.02	Selleck	S4354	Thiostrepton	1663.492	CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7,41,61|	NSFFHOGKXHRQEW-AIHSUZKVSA-N	16154490.0	BRD-A89819812-001-01-0|BRD-A51799737-001-01-0	NSFFHOGKXHRQEW
BRD-K09631521-001-12-3	thiotepa	Launched	cytochrome P450 inhibitor	CYP2B6|CYP3A4	oncology	breast cancer|ovarian cancer|bladder cancer	0	83.39	MedChemEx	HY-17574	Thio-TEPA	189.049	S=P(N1CC1)(N1CC1)N1CC1	FOCVUCIESVLUNU-UHFFFAOYSA-N	5453.0		FOCVUCIESVLUNU
BRD-K09631521-001-09-9	thiotepa	Launched	cytochrome P450 inhibitor	CYP2B6|CYP3A4	oncology	breast cancer|ovarian cancer|bladder cancer	0	42.47	MicroSource	1503324	THIOTEPA	189.049	S=P(N1CC1)(N1CC1)N1CC1	FOCVUCIESVLUNU-UHFFFAOYSA-N	5453.0		FOCVUCIESVLUNU
BRD-K09631521-001-11-5	thiotepa	Launched	cytochrome P450 inhibitor	CYP2B6|CYP3A4	oncology	breast cancer|ovarian cancer|bladder cancer	0	69.58	MedChemEx	HY-17574	Thio-TEPA	189.049	S=P(N1CC1)(N1CC1)N1CC1	FOCVUCIESVLUNU-UHFFFAOYSA-N	5453.0		FOCVUCIESVLUNU
BRD-K04175245-001-14-9	thiothixene	Launched	dopamine receptor antagonist	DRD1|DRD2|HRH1|HTR2A	neurology/psychiatry	schizophrenia	0	96.15	MedChemEx	HY-108324	(Z)-Thiothixene	443.17	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1	GFBKORZTTCHDGY-UWVJOHFNSA-N	941651.0		GFBKORZTTCHDGY
BRD-K29254801-001-14-7	thiram	Launched		JAK2	ophthalmology	contact dermatitis	0	97.98	MicroSource	1503322	THIRAM	239.988	CN(C)C(=S)SSC(=S)N(C)C	KUAZQDVKQLNFPE-UHFFFAOYSA-N	5455.0		KUAZQDVKQLNFPE
BRD-K00003401-001-01-9	THK5351	Phase 2	PET radiotracer 				0	96.78	MedChemEx	HY-101183	THK5351	327.138	CNc1ccc(cn1)-c1ccc2cc(OC[C@H](O)CF)ccc2n1	DLVXFZWSPCOWSN-CQSZACIVSA-N	91936858.0		DLVXFZWSPCOWSN
BRD-K13387373-004-16-9	thonzonium	Launched	ATPase inhibitor		infectious disease	ear infections	0	91.35	MedChemEx	HY-B1246	Thonzonium (bromide)	511.438	CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	IOYZYMQFUSNATM-UHFFFAOYSA-N	5456.0		IOYZYMQFUSNATM
BRD-K13387373-004-15-2	thonzonium	Launched	ATPase inhibitor		infectious disease	ear infections	0	88.27	MicroSource	1503873	THONZONIUM BROMIDE	511.438	CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	IOYZYMQFUSNATM-UHFFFAOYSA-N	5456.0		IOYZYMQFUSNATM
BRD-K13387373-004-14-5	thonzonium	Launched	ATPase inhibitor		infectious disease	ear infections	0	94.95	Selleck	S4355	Thonzonium Bromide	511.438	CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	IOYZYMQFUSNATM-UHFFFAOYSA-N	5456.0		IOYZYMQFUSNATM
BRD-K88405679-003-03-1	thonzylamine	Launched	antihistamine		neurology/psychiatry	itching	0	91.69	MicroSource	1503135	THONZYLAMINE HYDROCHLORIDE	286.179	COc1ccc(CN(CCN(C)C)c2ncccn2)cc1	GULNIHOSWFYMRN-UHFFFAOYSA-N	5457.0		GULNIHOSWFYMRN
BRD-K88405679-001-04-9	thonzylamine	Launched	antihistamine		neurology/psychiatry	itching	0		WuXi	EW21509-13-P1	THONZYLAMINE	286.179	COc1ccc(CN(CCN(C)C)c2ncccn2)cc1	GULNIHOSWFYMRN-UHFFFAOYSA-N	5457.0		GULNIHOSWFYMRN
BRD-M01344114-348-01-0	threo-2-methylisocitrate-(DL)	Preclinical	isocitrate lyase substrate				0	93.35	MedChemEx	HY-16581A	DL-threo-2-methylisocitrate (sodium)	206.043	[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9,23,&1:7,&2:21|	ZSOGGZWFKNMGJN-WREOTHMNSA-N			ZSOGGZWFKNMGJN
BRD-K00004602-001-01-9	thymalfasin	Launched	immune response modulator		infectious disease	hepatitis B|hepatitis C	0	100.0	Key	HS-2030	(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S,38S,41S,44S,47S,50S,53S,56S,59S,62S,65S,68S,71S,74S,77S,80S)-2-((S)-2-acetamido-3-hydroxypropanamido)-82-amino-38,47,53,56-tetrakis(4-aminobutyl)-29-sec-b	3106.504	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O	NZVYCXVTEHPMHE-ZSUJOUNUSA-N	16130571.0		NZVYCXVTEHPMHE
BRD-K17458574-001-07-7	thymol	Launched	GABA receptor positive allosteric modulator	TRPA1	infectious disease	ringworm|antiseptic	0	0.0	Enamine	Z57127464		150.104	CC(C)c1ccc(C)cc1O	MGSRCZKZVOBKFT-UHFFFAOYSA-N	6989.0		MGSRCZKZVOBKFT
BRD-K17458574-001-08-9	thymol	Launched	GABA receptor positive allosteric modulator	TRPA1	infectious disease	ringworm|antiseptic	0	0.0	Sigma	MFCD00002309	Thymol	150.104	CC(C)c1ccc(C)cc1O	MGSRCZKZVOBKFT-UHFFFAOYSA-N	6989.0		MGSRCZKZVOBKFT
BRD-K36617478-001-01-5	thymol-iodide	Preclinical					0	50.02	SantaCruz	sc-215985	Thymol iodide	549.987	CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C	SHOKWSLXDAIZPP-UHFFFAOYSA-N	11088.0		SHOKWSLXDAIZPP
BRD-K43977121-001-06-9	thymopentin	Launched	immune response stimulator				0	94.22	Key	HS-2029	(6S,9S,12S,15S,18S)-1,6-diamino-9-(4-aminobutyl)-12-(carboxymethyl)-18-(4-hydroxybenzyl)-1-imino-15-isopropyl-7,10,13,16-tetraoxo-2,8,11,14,17-pentaazanonadecan-19-oic acid	679.365	CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	PSWFFKRAVBDQEG-YGQNSOCVSA-N	451417.0		PSWFFKRAVBDQEG
BRD-K66401437-001-03-3	THZ1	Preclinical	CDK inhibitor	CDK7			0	92.24	MedChemEx	HY-80013	THZ1	565.199	CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	OBJNFLYHUXWUPF-IZZDOVSWSA-N	73602827.0		OBJNFLYHUXWUPF
BRD-K02135007-001-01-8	THZ1-R	Preclinical	CDK inhibitor	CDK7			0	90.43	MedChemEx	HY-19988	THZ1-R	567.215	CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	TUERFPPIPKZNKE-UHFFFAOYSA-N	119081415.0		TUERFPPIPKZNKE
BRD-K95902121-001-01-0	THZ2	Preclinical	CDK inhibitor	CDK7			0	91.43	MedChemEx	HY-12280	THZ2	565.199	CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	FONRCZUZCHXWBD-VGOFMYFVSA-N	78357763.0		FONRCZUZCHXWBD
BRD-K77695569-001-33-9	tiabendazole	Launched	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms|hookworm	0	97.54	MedChemEx	HY-B0263	Thiabendazole	201.036	c1nc(cs1)-c1nc2ccccc2[nH]1	WJCNZQLZVWNLKY-UHFFFAOYSA-N	5430.0		WJCNZQLZVWNLKY
BRD-K77695569-001-29-2	tiabendazole	Launched	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms|hookworm	0	97.95	Selleck	S1739	Thiabendazole	201.036	c1nc(cs1)-c1nc2ccccc2[nH]1	WJCNZQLZVWNLKY-UHFFFAOYSA-N	5430.0		WJCNZQLZVWNLKY
BRD-K77695569-001-30-0	tiabendazole	Launched	angiogenesis inhibitor		infectious disease	gastrointestinal roundworms|hookworm	0	99.12	MicroSource	1500570	THIABENDAZOLE	201.036	c1nc(cs1)-c1nc2ccccc2[nH]1	WJCNZQLZVWNLKY-UHFFFAOYSA-N	5430.0		WJCNZQLZVWNLKY
BRD-K60160658-003-12-0	tiagabine	Launched	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	0	87.28	Tocris	4256	Tiagabine hydrochloride	375.133	Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C	PBJUNZJWGZTSKL-MRXNPFEDSA-N	60648.0		PBJUNZJWGZTSKL
BRD-K60160658-003-11-2	tiagabine	Launched	GABA uptake inhibitor	SLC6A1	neurology/psychiatry	seizures	0	95.06	Enzo	AC3267	TIAGABINE HYDROCHLORIDE	375.133	Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C	PBJUNZJWGZTSKL-MRXNPFEDSA-N	60648.0		PBJUNZJWGZTSKL
BRD-K01826304-001-01-9	tianeptine	Launched	selective serotonin reuptake enhancer (SSRE)	OPRD1|OPRK1|OPRM1	neurology/psychiatry|pulmonary|gastroenterology	depression|asthma|irritable bowel syndrome	0	98.15	MedChemEx	HY-90003	Tianeptine	436.122	CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|	JICJBGPOMZQUBB-OAQYLSRUSA-N	37888263.0		JICJBGPOMZQUBB
BRD-K01826304-001-02-9	tianeptine	Launched	selective serotonin reuptake enhancer (SSRE)	OPRD1|OPRK1|OPRM1	neurology/psychiatry|pulmonary|gastroenterology	depression|asthma|irritable bowel syndrome	0	97.87	MedChemEx	HY-90003	Tianeptine	436.122	CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8,r|	JICJBGPOMZQUBB-OAQYLSRUSA-N	37888263.0		JICJBGPOMZQUBB
BRD-K57432881-003-21-8	tiapride	Launched	dopamine receptor antagonist	DRD2|DRD3	neurology/psychiatry	dyskinesia|abstinence from alcohol|psychosis	0	98.27	MicroSource	1503086	TIAPRIDE HYDROCHLORIDE	328.146	CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O	JTVPZMFULRWINT-UHFFFAOYSA-N	5467.0		JTVPZMFULRWINT
BRD-K57432881-003-22-9	tiapride	Launched	dopamine receptor antagonist	DRD2|DRD3	neurology/psychiatry	dyskinesia|abstinence from alcohol|psychosis	0	97.11	MedChemEx	HY-B1196	Tiapride (hydrochloride)	328.146	CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O	JTVPZMFULRWINT-UHFFFAOYSA-N	5467.0		JTVPZMFULRWINT
BRD-A72988804-001-11-1	tiaprofenic-acid	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis	0	94.01	Sigma	MFCD00866089	2-(5-benzoyl-2-thienyl)propanoic acid	260.051	C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|	GUHPRPJDBZHYCJ-SECBINFHSA-N	181380.0		GUHPRPJDBZHYCJ
BRD-A72988804-001-10-3	tiaprofenic-acid	Launched	cyclooxygenase inhibitor	PTGS2	rheumatology	rheumatoid arthritis	0	70.18	Prestwick	Prestw-496	Tiaprofenic acid	260.051	C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1,r|	GUHPRPJDBZHYCJ-SECBINFHSA-N	181380.0		GUHPRPJDBZHYCJ
BRD-K27293958-001-01-5	tiaramide	Launched	anti-inflammatory agent		pulmonary	asthma	0	99.54	Sigma	PH010339	5-chloro-3-{2-[4-(2-hydroxyethyl)-1-piperazinyl]-2-oxoethyl}-1,3-benzothiazol-2(3H)-one	355.076	OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O	HTJXMOGUGMSZOG-UHFFFAOYSA-N	5469.0		HTJXMOGUGMSZOG
BRD-A82522119-001-01-7	tibolone	Launched	androgen receptor agonist|estrogen receptor agonist|progesterone receptor agonist	ESR1	obstetrics/gynecology	endometriosis	0	93.9	MicroSource	1502343	TIBOLONE	312.209	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1,10,13,15,18,&1:22,t:3|	WZDGZWOAQTVYBX-TZTUDTKPSA-N	124484332.0		WZDGZWOAQTVYBX
BRD-K25838957-001-02-9	ticagrelor	Launched	purinergic receptor antagonist	P2RY12	cardiology	acute coronary syndrome (ACS)|myocardial infarction	0	97.4	MedChemEx	HY-10064	Ticagrelor	522.186	CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1	OEKWJQXRCDYSHL-FNOIDJSQSA-N	9871419.0		OEKWJQXRCDYSHL
BRD-K29229654-304-04-6	ticarcillin	Launched	lactamase inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MicroSource	1505678	TICARCILLIN DISODIUM	384.045	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O	OHKOGUYZJXTSFX-KZFFXBSXSA-N	36921.0	BRD-A91757199-001-01-1	OHKOGUYZJXTSFX
BRD-K29229654-304-02-0	ticarcillin	Launched	lactamase inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	Selleck	S3193	Ticarcillin sodium	384.045	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O	OHKOGUYZJXTSFX-KZFFXBSXSA-N	36921.0	BRD-A91757199-304-01-9	OHKOGUYZJXTSFX
BRD-K29229654-304-03-8	ticarcillin	Launched	lactamase inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	Selleck	S3193	Ticarcillin sodium	384.045	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O	OHKOGUYZJXTSFX-KZFFXBSXSA-N	36921.0	BRD-A91757199-304-02-7	OHKOGUYZJXTSFX
BRD-K29229654-304-05-3	ticarcillin	Launched	lactamase inhibitor		infectious disease	gram-negative bacterial infections	0	0.0	MedChemEx	HY-B1175	Ticarcillin (disodium)	384.045	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O	OHKOGUYZJXTSFX-KZFFXBSXSA-N	36921.0		OHKOGUYZJXTSFX
BRD-K00603606-003-24-0	ticlopidine	Launched	purinergic receptor antagonist	P2RY12	hematology|neurology/psychiatry	thrombosis|stroke	0	98.54	MicroSource	1505677	TICLOPIDINE HYDROCHLORIDE	263.054	Clc1ccccc1CN1CCc2sccc2C1	PHWBOXQYWZNQIN-UHFFFAOYSA-N	5472.0		PHWBOXQYWZNQIN
BRD-K00603606-003-23-2	ticlopidine	Launched	purinergic receptor antagonist	P2RY12	hematology|neurology/psychiatry	thrombosis|stroke	0	96.47	Selleck	S1984	Ticlopidine HCl	263.054	Clc1ccccc1CN1CCc2sccc2C1	PHWBOXQYWZNQIN-UHFFFAOYSA-N	5472.0		PHWBOXQYWZNQIN
BRD-K00603606-003-25-9	ticlopidine	Launched	purinergic receptor antagonist	P2RY12	hematology|neurology/psychiatry	thrombosis|stroke	0	94.92	Tocris	3931	Ticlopidine hydrochloride	263.054	Clc1ccccc1CN1CCc2sccc2C1	PHWBOXQYWZNQIN-UHFFFAOYSA-N	5472.0		PHWBOXQYWZNQIN
BRD-K19939891-001-05-4	TIC10	Phase 2	AKT inhibitor|TRAIL modulator	AKT1|MAPK1			0	95.04	Selleck	S7127	TIC10	386.211	Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|	RSAQARAFWMUYLL-UHFFFAOYSA-N	336423.0		RSAQARAFWMUYLL
BRD-K19939891-001-06-9	TIC10	Phase 2	AKT inhibitor|TRAIL modulator	AKT1|MAPK1			0	90.3	MedChemEx	HY-15615	TIC10 isomer	386.211	Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18,t:10|	RSAQARAFWMUYLL-UHFFFAOYSA-N	336423.0		RSAQARAFWMUYLL
BRD-K81330143-001-02-2	tideglusib	Phase 2	glycogen synthase kinase inhibitor	GSK3B			0	0.0	Selleck	S2823	Tideglusib	334.078	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	PMJIHLSCWIDGMD-UHFFFAOYSA-N	11313622.0		PMJIHLSCWIDGMD
BRD-K81330143-001-04-8	tideglusib	Phase 2	glycogen synthase kinase inhibitor	GSK3B			0	96.84	Selleck	S2823	Tideglusib	334.078	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	PMJIHLSCWIDGMD-UHFFFAOYSA-N	11313622.0		PMJIHLSCWIDGMD
BRD-K81330143-001-06-9	tideglusib	Phase 2	glycogen synthase kinase inhibitor	GSK3B			0	92.51	MedChemEx	HY-14872	Tideglusib	334.078	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	PMJIHLSCWIDGMD-UHFFFAOYSA-N	11313622.0		PMJIHLSCWIDGMD
BRD-K34098590-001-02-1	tienilic-acid	Withdrawn	cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor	CYP2C9|SLC12A1			0	99.37	Sigma	MFCD00867339	[2,3-dichloro-4-(2-thienylcarbonyl)phenoxy]acetic acid	329.952	OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl	AGHANLSBXUWXTB-UHFFFAOYSA-N	38409.0		AGHANLSBXUWXTB
BRD-A92800748-001-05-5	tie2-kinase-inhibitor	Preclinical	TIE tyrosine kinase inhibitor	KDR|MAPK14			0	93.92	Selleck	S1577	Tie2 kinase inhibitor	439.135	COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|	SINQIEAULQKUPD-JGCGQSQUSA-N	92852530.0		SINQIEAULQKUPD
BRD-K20568871-001-01-1	tifenazoxide	Phase 1	ATP-sensitive potassium channel agonist	ABCC8|KCNJ11			0	94.29	Sigma	SML0553	6-chloro-N-(1-methylcyclopropyl)-4H-thieno[3,2-e][1,2,4]thiadiazin-3-amine 1,1-dioxide	290.99	CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|	KYSFUHHFTIGRJN-UHFFFAOYSA-N	135410911.0		KYSFUHHFTIGRJN
BRD-K00003349-001-01-9	tigecycline	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	skin infections|pneumonia|intra-abdominal infections	0	0.0	MedChemEx	HY-B0117	Tigecycline	585.28	[H][C@@]12Cc3c(cc(NC(=O)CNC(C)(C)C)c(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:28,&2:21|	CGZOGNUFXMNYEI-PBZRBWFISA-N			CGZOGNUFXMNYEI
BRD-K36796419-011-03-9	tilmicosin	Launched	bacterial 50S ribosomal subunit inhibitor		pulmonary	bovine respiratory disease (BRD)	0	67.94	MedChemEx	HY-B0905A	Tilmicosin (phosphate)	868.566	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:43,46|	JTSDBFGMPLKDCD-UYPDHHONSA-N	16225190.0		JTSDBFGMPLKDCD
BRD-K34568562-300-05-9	tilorone	Launched	interferon inducer		infectious disease|gastroenterology|neurology/psychiatry	influenza A virus infection|diarrhea|hepatitis B|multiple sclerosis|urinary tract infections|virus herpes simplex (HSV)|hepatitis C	0	93.55	MedChemEx	HY-B1080	Tilorone (dihydrochloride)	410.257	CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1	MPMFCABZENCRHV-UHFFFAOYSA-N	5475.0		MPMFCABZENCRHV
BRD-K34568562-001-04-3	tilorone	Launched	interferon inducer		infectious disease|gastroenterology|neurology/psychiatry	influenza A virus infection|diarrhea|hepatitis B|multiple sclerosis|urinary tract infections|virus herpes simplex (HSV)|hepatitis C	0	86.28	MicroSource	2300009	TILORONE	410.257	CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1	MPMFCABZENCRHV-UHFFFAOYSA-N	5475.0		MPMFCABZENCRHV
BRD-K10845183-304-01-6	tiludronate	Launched	bone resorption inhibitor|osteoclast inhibitor	ATP6V1A|MMP2|PTPN1	orthopedics	navicular syndrome	0	100.0	Enzo	AC3269	TILUDRONATE DISODIUM	317.928	OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O	DKJJVAGXPKPDRL-UHFFFAOYSA-N	60937.0		DKJJVAGXPKPDRL
BRD-A64406146-001-01-2	timofibrate	Phase 2	cholesterol inhibitor|lipase clearing factor inhibitor	LPL			0	98.06	Enamine	Z398944758		329.049	CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|	QSNOWCXXECLALL-LLVKDONJSA-N	51371472.0		QSNOWCXXECLALL
BRD-A64406146-001-02-9	timofibrate	Phase 2	cholesterol inhibitor|lipase clearing factor inhibitor	LPL			0		Broad Institute	Timofibrate	Timofibrate	329.049	CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17,r|	QSNOWCXXECLALL-LLVKDONJSA-N	51371472.0		QSNOWCXXECLALL
BRD-K08806317-050-30-9	timolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	ophthalmology	ocular hypertension|glaucoma	0	84.93	Tocris	649	(S)-Timolol maleate	316.157	CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1	BLJRIMJGRPQVNF-JTQLQIEISA-N	33624.0		BLJRIMJGRPQVNF
BRD-K08806317-050-29-1	timolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	ophthalmology	ocular hypertension|glaucoma	0	94.28	Tocris	649	(S)-Timolol maleate	316.157	CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1	BLJRIMJGRPQVNF-JTQLQIEISA-N	33624.0		BLJRIMJGRPQVNF
BRD-K08806317-051-01-8	timolol	Launched	adrenergic receptor antagonist	ADRB1|ADRB2	ophthalmology	ocular hypertension|glaucoma	0	91.13	Selleck	S4123	Timolol Maleate	316.157	CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1	BLJRIMJGRPQVNF-JTQLQIEISA-N	33624.0		BLJRIMJGRPQVNF
BRD-K00003683-001-01-9	timonacic	Launched	antioxidant				0	100.0	MedChemEx	HY-B1169	Timonacic	133.02	OC(=O)[C@H]1CSCN1 |&1:3|	DZLNHFMRPBPULJ-GSVOUGTGSA-N	6973610.0		DZLNHFMRPBPULJ
BRD-K00004663-001-01-9	tinazoline	Launched	adrenergic receptor agonist				0	44.23	Enamine	Z2306534731	3-(4,5-dihydro-1H-imidazol-2-ylsulfanyl)-1H-indole	217.067	C1CN=C(N1)Sc1c[nH]c2ccccc12 |c:2|	JENBDJGHNIOHAJ-UHFFFAOYSA-N	68818.0		JENBDJGHNIOHAJ
BRD-K89125793-001-31-9	tinidazole	Launched	antiprotozoal agent		infectious disease|obstetrics/gynecology	giardiasis|amebiasis|bacterial vaginosis|trichomoniasis	0	75.17	MedChemEx	HY-B0177	Tinidazole	247.063	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	HJLSLZFTEKNLFI-UHFFFAOYSA-N	5479.0		HJLSLZFTEKNLFI
BRD-K89125793-001-25-2	tinidazole	Launched	antiprotozoal agent		infectious disease|obstetrics/gynecology	giardiasis|amebiasis|bacterial vaginosis|trichomoniasis	0	89.68	Selleck	S4068	Tinidazole	247.063	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	HJLSLZFTEKNLFI-UHFFFAOYSA-N	5479.0		HJLSLZFTEKNLFI
BRD-K89125793-001-26-0	tinidazole	Launched	antiprotozoal agent		infectious disease|obstetrics/gynecology	giardiasis|amebiasis|bacterial vaginosis|trichomoniasis	0	97.63	MicroSource	1502127	TINIDAZOLE	247.063	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	HJLSLZFTEKNLFI-UHFFFAOYSA-N	5479.0		HJLSLZFTEKNLFI
BRD-K89125793-001-27-8	tinidazole	Launched	antiprotozoal agent		infectious disease|obstetrics/gynecology	giardiasis|amebiasis|bacterial vaginosis|trichomoniasis	0	98.57	Selleck	S4068	Tinidazole	247.063	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	HJLSLZFTEKNLFI-UHFFFAOYSA-N	5479.0		HJLSLZFTEKNLFI
BRD-K84313779-003-03-9	tinoridine	Launched	anti-inflammatory agent		neurology/psychiatry	pain relief	0	94.02	MedChemEx	HY-111354	Tinoridine hydrochloride	316.125	CCOC(=O)c1c(N)sc2CN(Cc3ccccc3)CCc12	PFENFDGYVLAFBR-UHFFFAOYSA-N	5480.0		PFENFDGYVLAFBR
BRD-K00003630-001-01-9	tioconazole	Launched	sterol demethylase inhibitor		infectious disease	yeast infection	0	98.21	MedChemEx	HY-B0319	Tioconazole	385.981	Clc1sccc1CO[C@@H](Cn1ccnc1)c1ccc(Cl)cc1Cl |&1:8|	QXHHHPZILQDDPS-HNNXBMFYSA-N	28125518.0		QXHHHPZILQDDPS
BRD-K75649340-001-13-1	tioguanine	Launched	purine antagonist		hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)	0	100.0	Prestwick	Prestw-347	Thioguanosine	299.069	Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	OTDJAMXESTUWLO-UUOKFMHZSA-N	2724387.0		OTDJAMXESTUWLO
BRD-K75649340-002-14-9	tioguanine	Launched	purine antagonist		hematologic malignancy	acute myeloid leukemia (AML)|acute lymphoblastic leukemia (ALL)|chronic myeloid leukemia (CML)	0	100.0	Toronto	A611850	2-amino-6-mercaptopurine-D-riboside hydrate	299.069	Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	OTDJAMXESTUWLO-UUOKFMHZSA-N	2724387.0		OTDJAMXESTUWLO
BRD-A85295731-001-06-4	tiopronin	Launched	chelating agent|reducing agent		urology	kidney stones	0	91.45	MedChemEx	HY-B0373	Tiopronin	163.03	C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|	YTGJWQPHMWSCST-GSVOUGTGSA-N	208825.0		YTGJWQPHMWSCST
BRD-A85295731-001-05-6	tiopronin	Launched	chelating agent|reducing agent		urology	kidney stones	0	85.3	Sigma	MFCD00004861	[(2-sulfanylpropanoyl)amino]acetic acid	163.03	C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|	YTGJWQPHMWSCST-GSVOUGTGSA-N	208825.0		YTGJWQPHMWSCST
BRD-A85295731-001-03-1	tiopronin	Launched	chelating agent|reducing agent		urology	kidney stones	0	47.22	MicroSource	1506190	TIOPRONIN	163.03	C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|	YTGJWQPHMWSCST-GSVOUGTGSA-N	208825.0		YTGJWQPHMWSCST
BRD-A85295731-001-02-3	tiopronin	Launched	chelating agent|reducing agent		urology	kidney stones	0	63.22	Selleck	S2062	Tiopronin	163.03	C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|	YTGJWQPHMWSCST-GSVOUGTGSA-N	208825.0		YTGJWQPHMWSCST
BRD-A85295731-001-04-9	tiopronin	Launched	chelating agent|reducing agent		urology	kidney stones	0	59.81	Selleck	S2062	Tiopronin (Thiola)	163.03	C[C@@H](S)C(=O)NCC(O)=O |&1:1,r|	YTGJWQPHMWSCST-GSVOUGTGSA-N	208825.0		YTGJWQPHMWSCST
BRD-K11107424-001-02-9	tiotidine	Phase 2	histamine receptor antagonist	HRH2			0	96.18	Tocris	826	Tiotidine	312.094	CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N	YDDXVAXDYKBWDX-UHFFFAOYSA-N	50287.0		YDDXVAXDYKBWDX
BRD-K62782754-337-02-5	tiotropium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema	0	90.47	Selleck	S2547	Tiotropium Bromide hydrate	392.099	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1	LERNTVKEWCAPOY-DZZGSBJMSA-N			LERNTVKEWCAPOY
BRD-K62782754-337-03-3	tiotropium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema	0	93.69	Selleck	S2547	Tiotropium Bromide hydrate	392.099	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1	LERNTVKEWCAPOY-DZZGSBJMSA-N			LERNTVKEWCAPOY
BRD-K41876534-001-14-9	tioxolone	Preclinical	carbonic anhydrase inhibitor	CA2			0	91.59	MedChemEx	HY-B0483	Tioxolone	167.988	Oc1ccc2sc(=O)oc2c1	SLYPOVJCSQHITR-UHFFFAOYSA-N	72139.0		SLYPOVJCSQHITR
BRD-K41876534-001-13-7	tioxolone	Preclinical	carbonic anhydrase inhibitor	CA2			0	93.15	MicroSource	1503094	TIOXOLONE	167.988	Oc1ccc2sc(=O)oc2c1	SLYPOVJCSQHITR-UHFFFAOYSA-N	72139.0		SLYPOVJCSQHITR
BRD-K41876534-001-12-9	tioxolone	Preclinical	carbonic anhydrase inhibitor	CA2			0	90.58	Selleck	S2603	Tioxolone	167.988	Oc1ccc2sc(=O)oc2c1	SLYPOVJCSQHITR-UHFFFAOYSA-N	72139.0		SLYPOVJCSQHITR
BRD-K00004627-001-01-9	tipelukast	Phase 2	leukotriene receptor antagonist				0	97.11	Sigma	SML2369	4-(6-acetyl-3-{3-[(4-acetyl-3-hydroxy-2-propylphenyl)sulfanyl]propoxy}-2-propylphenoxy)butanoic acid	530.234	CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O	KPWYNAGOBXLMSE-UHFFFAOYSA-N	9893228.0		KPWYNAGOBXLMSE
BRD-K62965247-001-04-9	tipifarnib	Phase 3	farnesyltransferase inhibitor	FNTA|FNTB			0	96.02	Selleck	S1453	Tipifarnib	488.117	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	PLHJCIYEEKOWNM-HHHXNRCGSA-N	159324.0		PLHJCIYEEKOWNM
BRD-K62965247-001-05-6	tipifarnib	Phase 3	farnesyltransferase inhibitor	FNTA|FNTB			0	99.07	Selleck	S1453	Tipifarnib	488.117	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1	159324.0		PLHJCIYEEKOWNM
BRD-K11973162-003-02-9	tipiracil	Launched	thymidine phosphorylase inhibitor		oncology	colorectal cancer	0	90.4	MedChemEx	HY-A0063	Tipiracil (hydrochloride)	242.057	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	QQHMKNYGKVVGCZ-UHFFFAOYSA-N	6323266.0		QQHMKNYGKVVGCZ
BRD-K11973162-003-01-8	tipiracil	Launched	thymidine phosphorylase inhibitor		oncology	colorectal cancer	0	100.0	MedChemEx	HY-A0063	Tipiracil (hydrochloride)	242.057	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	QQHMKNYGKVVGCZ-UHFFFAOYSA-N	6323266.0		QQHMKNYGKVVGCZ
BRD-K30882994-001-02-4	tiplaxtinin	Phase 1	plasminogen activator inhibitor	SERPINE1			0	90.86	Tocris	5565	Tiplaxtinin	439.103	OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1	ODXQFEWQSHNQNI-UHFFFAOYSA-N	6450819.0		ODXQFEWQSHNQNI
BRD-K30882994-001-01-6	tiplaxtinin	Phase 1	plasminogen activator inhibitor	SERPINE1			0	91.15	MedChemEx	HY-15253	Tiplaxtinin	439.103	OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1	ODXQFEWQSHNQNI-UHFFFAOYSA-N	6450819.0		ODXQFEWQSHNQNI
BRD-A10039652-001-02-0	tipranavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	88.06	MedChemEx	HY-15148	Tipranavir	602.206	CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|	MYXACKZCYFKMTE-WWKQIGMOSA-N			MYXACKZCYFKMTE
BRD-A10039652-001-01-2	tipranavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	86.82	MedChemEx	HY-15148	Tipranavir	602.206	CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|	MYXACKZCYFKMTE-WWKQIGMOSA-N			MYXACKZCYFKMTE
BRD-A10039652-001-03-9	tipranavir	Launched	HIV protease inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	85.3	MedChemEx	HY-15148	Tipranavir	602.206	CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3,16,&1:15|	MYXACKZCYFKMTE-WWKQIGMOSA-N			MYXACKZCYFKMTE
BRD-A73566563-001-01-6	tiprenolol	Phase 2	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3			0	96.46	Enamine	Z2301686183	1-(isopropylamino)-3-[2-(methylsulfanyl)phenoxy]-2-propanol	255.129	CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10,r|	CSUNLSYSEQIDMO-NSHDSACASA-N	76966339.0		CSUNLSYSEQIDMO
BRD-K77552740-004-01-0	tiquizium	Launched	acetylcholine receptor antagonist		neurology/psychiatry	spasms	0	97.14	AKSci	R610		330.135	C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1	ZGSDGGRVFIYKKE-OXQOHEQNSA-N	72160.0		ZGSDGGRVFIYKKE
BRD-K75250001-001-01-3	tiracizine	Withdrawn	sodium channel blocker	SCN5A			0	98.01	ChemDiv	4119-0057		367.19	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1	KJAMZCVTJDTESW-UHFFFAOYSA-N	71264.0		KJAMZCVTJDTESW
BRD-K92968657-001-02-4	tirapazamine	Phase 3	DNA inhibitor				0	94.15	Adooq	A12754	4-hydroxy-3-imino-3,4-dihydrobenzo[e][1,2,4]triazine 1-oxide	178.049	Nc1n[n+]([O-])c2ccccc2[n+]1[O-]	ORYDPOVDJJZGHQ-UHFFFAOYSA-N	135413511.0	BRD-K75058612-001-01-1	ORYDPOVDJJZGHQ
BRD-K92968657-001-01-6	tirapazamine	Phase 3	DNA inhibitor				0	95.16	MedChemEx	HY-13767	Tirapazamine	178.049	Nc1n[n+]([O-])c2ccccc2[n+]1[O-]	ORYDPOVDJJZGHQ-UHFFFAOYSA-N	135413511.0		ORYDPOVDJJZGHQ
BRD-K51087630-001-01-6	tirasemtiv	Phase 2	troponin activator				0	99.62	MedChemEx	HY-15964	Tirasemtiv	230.117	CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C	RSQGZEAXODVTOL-UHFFFAOYSA-N	23729157.0		RSQGZEAXODVTOL
BRD-K51087630-001-02-9	tirasemtiv	Phase 2	troponin activator				0	97.78	MedChemEx	HY-15964	Tirasemtiv	230.117	CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C	RSQGZEAXODVTOL-UHFFFAOYSA-N	23729157.0		RSQGZEAXODVTOL
BRD-K61236135-001-08-2	tiratricol	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	Refetoff syndrome	0	92.5	Selleck	s4185	Tiratricol	621.763	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	UOWZUVNAGUAEQC-UHFFFAOYSA-N	5803.0		UOWZUVNAGUAEQC
BRD-K61236135-001-09-0	tiratricol	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	Refetoff syndrome	0	86.7	MicroSource	1506047	TIRATRICOL	621.763	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	UOWZUVNAGUAEQC-UHFFFAOYSA-N	5803.0		UOWZUVNAGUAEQC
BRD-K61236135-001-10-8	tiratricol	Launched	thyroid hormone stimulant	THRA|THRB	endocrinology	Refetoff syndrome	0	88.86	Selleck	S4185	Tiratricol, 3,3',5-triiodothyroacetic acid	621.763	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	UOWZUVNAGUAEQC-UHFFFAOYSA-N	5803.0		UOWZUVNAGUAEQC
BRD-K37872686-003-01-9	tirofiban	Launched	platelet aggregation inhibitor|structural glycoprotein antagonist	ITGA2B|ITGB3	cardiology	myocardial infarction|refactory angina	0	97.97	Enzo	AC3271	TIROFIBAN HYDROCHLORIDE	440.234	CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O	COKMIXFXJJXBQG-NRFANRHFSA-N	60947.0		COKMIXFXJJXBQG
BRD-K60284353-001-02-9	titanocene-dichloride	Phase 2	apoptosis stimulant				0	44.98	Sigma	324826-10G	Bis(cyclopentadienyl)titaniumIVdichloride	247.964	Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|	XKLWATAZDMHTSH-UHFFFAOYSA-L	11075829.0		XKLWATAZDMHTSH
BRD-K60284353-001-01-3	titanocene-dichloride	Phase 2	apoptosis stimulant				0	98.9	Oakwood	99333	dichloro[di(2,4-cyclopentadien-1-yl)]titanium	247.964	Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4,6,10,12|	XKLWATAZDMHTSH-UHFFFAOYSA-L	11075829.0		XKLWATAZDMHTSH
BRD-K33379087-001-07-5	tivantinib	Phase 3	tyrosine kinase inhibitor	MET			0	98.79	MedChemEx	HY-50686	Tivantinib	369.148	O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23	UCEQXRCJXIVODC-PMACEKPBSA-N	11494412.0		UCEQXRCJXIVODC
BRD-K53414658-001-08-2	tivozanib	Launched	VEGFR inhibitor	FLT1|FLT4|KDR|KIT|PDGFRA|PDGFRB	oncology	renal cell carcinoma (RCC)	0	97.41	Selleck	S1207	Tivozanib (AV-951)	454.104	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	SPMVMDHWKHCIDT-UHFFFAOYSA-N	9911830.0		SPMVMDHWKHCIDT
BRD-K53414658-001-02-5	tivozanib	Launched	VEGFR inhibitor	FLT1|FLT4|KDR|KIT|PDGFRA|PDGFRB	oncology	renal cell carcinoma (RCC)	0		Selleck	S1207	AV-951(Tivozanib)	454.104	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	SPMVMDHWKHCIDT-UHFFFAOYSA-N	9911830.0		SPMVMDHWKHCIDT
BRD-K06335600-003-22-3	tizanidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C|NISCH	neurology/psychiatry	spasms	0	94.26	Tocris	3609	Tizanidine hydrochloride	253.019	Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|	XFYDIVBRZNQMJC-UHFFFAOYSA-N	5487.0		XFYDIVBRZNQMJC
BRD-K06335600-003-20-7	tizanidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C|NISCH	neurology/psychiatry	spasms	0	98.81	Tocris	3609	Tizanidine hydrochloride	253.019	Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|	XFYDIVBRZNQMJC-UHFFFAOYSA-N	5487.0		XFYDIVBRZNQMJC
BRD-K06335600-003-19-9	tizanidine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C|NISCH	neurology/psychiatry	spasms	0	96.85	Selleck	S1437	Tizanidine HCl	253.019	Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|	XFYDIVBRZNQMJC-UHFFFAOYSA-N	5487.0		XFYDIVBRZNQMJC
BRD-K66097663-001-01-8	TMC-353121	Phase 2	RSV fusion inhibitor				0	93.17	MedChemEx	HY-11097	TMC353121	558.332	Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	DKORMNNYNRPTBJ-UHFFFAOYSA-N	11249932.0		DKORMNNYNRPTBJ
BRD-K66097663-001-02-9	TMC-353121	Phase 2	RSV fusion inhibitor				0	96.14	MedChemEx	HY-11097	TMC353121	558.332	Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	DKORMNNYNRPTBJ-UHFFFAOYSA-N	11249932.0		DKORMNNYNRPTBJ
BRD-K49659468-436-01-2	TMC647055	Phase 2	RNA polymerase inhibitor				0	97.37	MedChemEx	HY-15591A	TMC647055 (Choline salt)	606.251	COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|	UOBYJVFBFSLCTQ-UHFFFAOYSA-N	44556044.0		UOBYJVFBFSLCTQ
BRD-K24527118-001-01-6	TMN-355	Preclinical	cyclophilin inhibitor	PPIA			0	94.31	Tocris	4152	TMN 355	380.073	Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12	SFNLLCUAISZNRV-UHFFFAOYSA-N	44249042.0		SFNLLCUAISZNRV
BRD-K24527118-001-02-9	TMN-355	Preclinical	cyclophilin inhibitor	PPIA			0	96.06	Tocris	4152	TMN 355	380.073	Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12	SFNLLCUAISZNRV-UHFFFAOYSA-N	44249042.0		SFNLLCUAISZNRV
BRD-K49119234-003-03-4	TMPH	Preclinical					0	92.43	Tocris	2438	TMPH hydrochloride	269.235	CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	PWWKJRFUJIFGGD-UHFFFAOYSA-N	11207937.0		PWWKJRFUJIFGGD
BRD-K49119234-003-02-6	TMPH	Preclinical					0	100.0	Tocris	2438	TMPH hydrochloride	269.235	CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	PWWKJRFUJIFGGD-UHFFFAOYSA-N	11207937.0		PWWKJRFUJIFGGD
BRD-K49119234-003-04-9	TMPH	Preclinical					0	100.0	Tocris	2438	TMPH hydrochloride	269.235	CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	PWWKJRFUJIFGGD-UHFFFAOYSA-N	11207937.0		PWWKJRFUJIFGGD
BRD-K96233303-001-02-7	TMS	Preclinical					0	94.2	Tocris	1509	TMS	300.136	COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	JDBCWSHYEQUBLW-AATRIKPKSA-N	5354004.0		JDBCWSHYEQUBLW
BRD-K96233303-001-03-9	TMS	Preclinical					0	96.72	Tocris	1509	TMS	300.136	COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	JDBCWSHYEQUBLW-AATRIKPKSA-N	5354004.0		JDBCWSHYEQUBLW
BRD-K96233303-001-01-9	TMS	Preclinical					0	89.41	Tocris	1509	TMS	300.136	COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	JDBCWSHYEQUBLW-AATRIKPKSA-N	5354004.0		JDBCWSHYEQUBLW
BRD-K53597484-001-02-7	TNP-470	Phase 2	methionine aminopeptidase inhibitor	METAP2			0	75.74	Sigma	MFCD00870281	(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-butenyl)-2-oxiranyl]-1-oxaspiro[2.5]oct-6-yl chloroacetylcarbamate	401.161	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl	MSHZHSPISPJWHW-PVDLLORBSA-N	369976.0		MSHZHSPISPJWHW
BRD-K05619559-001-10-1	tobramycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	bacterial septicemia|respiratory tract infections|meningitis|skin infections|urinary tract infections	0	0.0	MicroSource	1500579	TOBRAMYCIN	467.259	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	NLVFBUXFDBBNBW-PBSUHMDJSA-N	36294.0		NLVFBUXFDBBNBW
BRD-K05619559-001-12-7	tobramycin	Launched	bacterial 30S ribosomal subunit inhibitor		infectious disease	bacterial septicemia|respiratory tract infections|meningitis|skin infections|urinary tract infections	0	100.0	Selleck	S2514	Tobramycin	467.259	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	NLVFBUXFDBBNBW-PBSUHMDJSA-N	36294.0	BRD-K96342952-001-01-2	NLVFBUXFDBBNBW
BRD-K01826767-001-05-9	tocainide	Launched	sodium channel blocker	SCN5A	cardiology	cardiac arrythmia	0	95.34	Sigma	MFCD00072010	TOCAINIDE	192.126	C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1,r|	BUJAGSGYPOAWEI-SECBINFHSA-N	3080825.0		BUJAGSGYPOAWEI
BRD-K62040061-001-01-0	toceranib	Launched	protein tyrosine kinase inhibitor	FLT1|FLT3|KDR|PDGFRA|PDGFRB	oncology	cutaneous mast cell tumors	0	92.31	MedChemEx	HY-10330	Toceranib	396.196	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	SRSGVKWWVXWSJT-ATVHPVEESA-N	5329106.0		SRSGVKWWVXWSJT
BRD-K62040061-011-02-7	toceranib	Launched	protein tyrosine kinase inhibitor	FLT1|FLT3|KDR|PDGFRA|PDGFRB	oncology	cutaneous mast cell tumors	0	81.99	MedChemEx	HY-10330A	Toceranib (phosphate)	396.196	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	SRSGVKWWVXWSJT-ATVHPVEESA-N	5329106.0		SRSGVKWWVXWSJT
BRD-K62040061-011-01-9	toceranib	Launched	protein tyrosine kinase inhibitor	FLT1|FLT3|KDR|PDGFRA|PDGFRB	oncology	cutaneous mast cell tumors	0	83.49	MedChemEx	HY-10330A	Toceranib (phosphate)	396.196	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	SRSGVKWWVXWSJT-ATVHPVEESA-N	5329106.0		SRSGVKWWVXWSJT
BRD-K57305459-001-02-9	tocofersolan	Launched	antioxidant		cardiology	cerebral cholesterosis	0	0.0	MedChemEx	HY-B0717	Tocofersolan	574.423	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1	AOBORMOPSGHCAX-AZAGJHQNSA-N	9938056.0		AOBORMOPSGHCAX
BRD-K57305459-001-01-4	tocofersolan	Launched	antioxidant		cardiology	cerebral cholesterosis	0	0.0	MedChemEx	HY-B0717	Tocofersolan	574.423	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1	AOBORMOPSGHCAX-AZAGJHQNSA-N	9938056.0	BRD-U58371969-000-01-8	AOBORMOPSGHCAX
BRD-K68553471-003-12-3	todralazine	Launched	antihypertensive agent		cardiology	hypertension	0	89.59	MicroSource	1501174	TODRALAZINE HYDROCHLORIDE	232.096	CCOC(=O)NNc1nncc2ccccc12	WGZDBVOTUVNQFP-UHFFFAOYSA-N	5501.0		WGZDBVOTUVNQFP
BRD-K31283835-048-03-6	tofacitinib	Launched	JAK inhibitor	JAK1|JAK2|JAK3	rheumatology	rheumatoid arthritis	0	98.2	Tocris	4556	CP 690550 citrate	312.17	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	UJLAWZDWDVHWOW-YPMHNXCESA-N	9926791.0		UJLAWZDWDVHWOW
BRD-K31283835-001-08-4	tofacitinib	Launched	JAK inhibitor	JAK1|JAK2|JAK3	rheumatology	rheumatoid arthritis	0	96.12	Selleck	S2789	Tofacitinib (CP-690550,Tasocitinib)	312.17	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	UJLAWZDWDVHWOW-YPMHNXCESA-N	9926791.0	BRD-K36280065-001-01-1	UJLAWZDWDVHWOW
BRD-K31283835-048-04-4	tofacitinib	Launched	JAK inhibitor	JAK1|JAK2|JAK3	rheumatology	rheumatoid arthritis	0	97.2	Selleck	S5001	Tofacitinib (CP-690550) Citrate	312.17	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	UJLAWZDWDVHWOW-YPMHNXCESA-N	9926791.0	BRD-K36280065-048-01-2	UJLAWZDWDVHWOW
BRD-K94830213-001-01-3	tofisopam	Launched	cytochrome P450 inhibitor|phosphodiesterase inhibitor	CYP3A4	neurology/psychiatry	anxiety|abstinence from alcohol	0	80.14	Sigma	MFCD00823171	1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine d_1_	382.189	CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2,t:6|	LOUZDJSQOFXLAP-UHFFFAOYSA-N	129009868.0		LOUZDJSQOFXLAP
BRD-K96344439-002-02-7	tofogliflozin	Launched	sodium/glucose cotransporter inhibitor	GCK	endocrinology	diabetes mellitus	0	95.64	MedChemEx	HY-13413	Tofogliflozin (hydrate)	386.173	CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1	VWVKUNOPTJGDOB-BDHVOXNPSA-N	46908929.0		VWVKUNOPTJGDOB
BRD-K96344439-002-01-9	tofogliflozin	Launched	sodium/glucose cotransporter inhibitor	GCK	endocrinology	diabetes mellitus	0	94.27	MedChemEx	HY-13413	Tofogliflozin (hydrate)	386.173	CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1	VWVKUNOPTJGDOB-BDHVOXNPSA-N	46908929.0		VWVKUNOPTJGDOB
BRD-A60498477-001-01-2	tolamolol	Phase 3	adrenergic receptor antagonist	ADRB1|ADRB2|ADRB3			0	94.9	Sigma	MFCD00864712	4-(2-{[2-hydroxy-3-(2-methylphenoxy)propyl]amino}ethoxy)benzamide	344.174	Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9,r|	SKQDKFOTIPJUSV-INIZCTEOSA-N	66743765.0		SKQDKFOTIPJUSV
BRD-K32164935-001-29-0	tolazamide	Launched	ATP channel blocker	ABCC8|KCNJ1|KCNJ10|KCNJ11	endocrinology	diabetes mellitus	0	79.42	Selleck	S4356	Tolazamide	311.13	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	OUDSBRTVNLOZBN-UHFFFAOYSA-N	5503.0		OUDSBRTVNLOZBN
BRD-K32164935-001-30-8	tolazamide	Launched	ATP channel blocker	ABCC8|KCNJ1|KCNJ10|KCNJ11	endocrinology	diabetes mellitus	0	97.65	MicroSource	1501201	TOLAZAMIDE	311.13	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	OUDSBRTVNLOZBN-UHFFFAOYSA-N	5503.0		OUDSBRTVNLOZBN
BRD-K32164935-001-31-6	tolazamide	Launched	ATP channel blocker	ABCC8|KCNJ1|KCNJ10|KCNJ11	endocrinology	diabetes mellitus	0	94.65	Selleck	S4356	tolazamide	311.13	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	OUDSBRTVNLOZBN-UHFFFAOYSA-N	5503.0		OUDSBRTVNLOZBN
BRD-K46211610-003-27-9	tolazoline	Launched	adrenergic receptor antagonist	ADRA1A|ADRA2A|ADRA2B|ADRA2C|HRH1|HRH2	neurology/psychiatry	reverse sedative	0	90.75	MedChemEx	HY-A0066A	Tolazoline (hydrochloride)	160.1	C(C1=NCCN1)c1ccccc1 |t:1|	JIVZKJJQOZQXQB-UHFFFAOYSA-N	5504.0		JIVZKJJQOZQXQB
BRD-K46211610-003-26-7	tolazoline	Launched	adrenergic receptor antagonist	ADRA1A|ADRA2A|ADRA2B|ADRA2C|HRH1|HRH2	neurology/psychiatry	reverse sedative	0	98.11	MicroSource	1500580	TOLAZOLINE HYDROCHLORIDE	160.1	C(C1=NCCN1)c1ccccc1 |t:1|	JIVZKJJQOZQXQB-UHFFFAOYSA-N	5504.0		JIVZKJJQOZQXQB
BRD-K46211610-003-25-9	tolazoline	Launched	adrenergic receptor antagonist	ADRA1A|ADRA2A|ADRA2B|ADRA2C|HRH1|HRH2	neurology/psychiatry	reverse sedative	0	94.27	Selleck	S4124	Tolazoline HCl	160.1	C(C1=NCCN1)c1ccccc1 |t:1|	JIVZKJJQOZQXQB-UHFFFAOYSA-N	5504.0		JIVZKJJQOZQXQB
BRD-K85119730-001-31-9	tolbutamide	Launched	ATP channel blocker	ABCC8|KCNJ1|KCNJ11|KCNJ8	endocrinology	diabetes mellitus	0	98.46	MedChemEx	HY-B0401	Tolbutamide	270.104	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	JLRGJRBPOGGCBT-UHFFFAOYSA-N	5505.0		JLRGJRBPOGGCBT
BRD-K85119730-001-28-9	tolbutamide	Launched	ATP channel blocker	ABCC8|KCNJ1|KCNJ11|KCNJ8	endocrinology	diabetes mellitus	0	98.93	MicroSource	1500581	TOLBUTAMIDE	270.104	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	JLRGJRBPOGGCBT-UHFFFAOYSA-N	5505.0		JLRGJRBPOGGCBT
BRD-K85119730-001-27-1	tolbutamide	Launched	ATP channel blocker	ABCC8|KCNJ1|KCNJ11|KCNJ8	endocrinology	diabetes mellitus	0	95.31	Selleck	S2443	Tolbutamide	270.104	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	JLRGJRBPOGGCBT-UHFFFAOYSA-N	5505.0		JLRGJRBPOGGCBT
BRD-K10852020-001-07-9	tolcapone	Withdrawn	catechol O methyltransferase inhibitor	COMT			0	100.0	Tocris	5864	Tolcapone	273.064	Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	MIQPIUSUKVNLNT-UHFFFAOYSA-N	4659569.0		MIQPIUSUKVNLNT
BRD-K10852020-001-04-5	tolcapone	Withdrawn	catechol O methyltransferase inhibitor	COMT			0	96.0	Selleck	S4021	Tolcapone	273.064	Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	MIQPIUSUKVNLNT-UHFFFAOYSA-N	4659569.0		MIQPIUSUKVNLNT
BRD-K10852020-001-05-2	tolcapone	Withdrawn	catechol O methyltransferase inhibitor	COMT			0	99.4	Selleck	S4021	Tolcapone	273.064	Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	MIQPIUSUKVNLNT-UHFFFAOYSA-N	4659569.0		MIQPIUSUKVNLNT
BRD-K50133271-001-20-9	tolfenamic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist		neurology/psychiatry	migraine headache	0	99.01	MedChemEx	HY-B0335	Tolfenamic Acid	261.056	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	YEZNLOUZAIOMLT-UHFFFAOYSA-N	610479.0		YEZNLOUZAIOMLT
BRD-K50133271-001-18-7	tolfenamic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist		neurology/psychiatry	migraine headache	0	98.71	MicroSource	1501198	TOLFENAMIC ACID	261.056	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	YEZNLOUZAIOMLT-UHFFFAOYSA-N	610479.0		YEZNLOUZAIOMLT
BRD-K50133271-001-17-9	tolfenamic-acid	Launched	cyclooxygenase inhibitor|prostanoid receptor antagonist		neurology/psychiatry	migraine headache	0	98.21	Selleck	S1959	Tolfenamic Acid	261.056	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	YEZNLOUZAIOMLT-UHFFFAOYSA-N	610479.0		YEZNLOUZAIOMLT
BRD-K41772907-001-02-0	tolimidone	Phase 2	SRC activator	LYN|SRC			0	96.66	Tocris	4582	MLR 1023	202.074	Cc1cccc(Oc2cnc(=O)[nH]c2)c1	HJQILFPVRNHTIG-UHFFFAOYSA-N	39065.0		HJQILFPVRNHTIG
BRD-K41772907-001-01-2	tolimidone	Phase 2	SRC activator	LYN|SRC			0	99.28	Axon	1941		202.074	Cc1cccc(Oc2cnc(=O)[nH]c2)c1	HJQILFPVRNHTIG-UHFFFAOYSA-N	39065.0		HJQILFPVRNHTIG
BRD-K82562631-325-06-9	tolmetin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	91.36	MedChemEx	HY-B1489	Tolmetin (sodium dihydrate)	257.105	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	UPSPUYADGBWSHF-UHFFFAOYSA-N	5509.0		UPSPUYADGBWSHF
BRD-K82562631-325-04-7	tolmetin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	90.84	Selleck	S4360	Tolmetin Sodium	257.105	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	UPSPUYADGBWSHF-UHFFFAOYSA-N	5509.0		UPSPUYADGBWSHF
BRD-K82562631-236-04-6	tolmetin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	rheumatology	rheumatoid arthritis|osteoarthritis	0	98.68	MicroSource	1500582	TOLMETIN SODIUM	257.105	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	UPSPUYADGBWSHF-UHFFFAOYSA-N	5509.0		UPSPUYADGBWSHF
BRD-K44273375-001-27-9	tolnaftate	Launched	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis|tinea corporis	0	99.03	MedChemEx	HY-B0370	Tolnaftate	307.103	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	FUSNMLFNXJSCDI-UHFFFAOYSA-N	5510.0		FUSNMLFNXJSCDI
BRD-K44273375-001-25-0	tolnaftate	Launched	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis|tinea corporis	0	99.91	MicroSource	1500583	TOLNAFTATE	307.103	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	FUSNMLFNXJSCDI-UHFFFAOYSA-N	5510.0		FUSNMLFNXJSCDI
BRD-K44273375-001-24-3	tolnaftate	Launched	fungal squalene epoxidase inhibitor		infectious disease	tinea pedis|tinea corporis	0	99.26	Selleck	S2058	Tolnaftate	307.103	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	FUSNMLFNXJSCDI-UHFFFAOYSA-N	5510.0		FUSNMLFNXJSCDI
BRD-K82687598-001-01-6	tolonidine	Launched	adrenergic receptor antagonist	ADRA2A			0	98.87	Enamine	Z2412196366	N-(2-chloro-4-methylphenyl)-4,5-dihydro-1H-imidazol-2-amine	209.072	Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|	KWBTZIFLQYYPTH-UHFFFAOYSA-N	72138.0		KWBTZIFLQYYPTH
BRD-K94882685-003-09-2	tolonium	Launched			hematology	methemoglobinemia	0	48.61	MicroSource	1506191	TOLONIUM CHLORIDE	270.106	Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C	KZEUBCUXBNEMSQ-UHFFFAOYSA-O	91311512.0		KZEUBCUXBNEMSQ
BRD-K94882685-003-10-0	tolonium	Launched			hematology	methemoglobinemia	0	90.9	Sigma	T3260-5G	Toluidine blue	270.106	Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C	KZEUBCUXBNEMSQ-UHFFFAOYSA-O	91311512.0		KZEUBCUXBNEMSQ
BRD-A67182178-001-01-7	toloxatone	Launched	monoamine oxidase inhibitor	MAOA|MAOB	neurology/psychiatry	depression	0	99.02	Sigma	MFCD00865391	5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one	207.09	Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9,r|	MXUNKHLAEDCYJL-JTQLQIEISA-N	13753599.0		MXUNKHLAEDCYJL
BRD-A27732521-003-08-3	tolperisone	Launched	voltage-gated sodium channel blocker	CYP2C19|CYP2D6	neurology/psychiatry|infectious disease|rheumatology|cardiology	muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease	0	97.96	MicroSource	1501194	TOLPERISONE HYDROCHLORIDE	245.178	C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|	FSKFPVLPFLJRQB-AWEZNQCLSA-N	688589.0		FSKFPVLPFLJRQB
BRD-A27732521-003-07-5	tolperisone	Launched	voltage-gated sodium channel blocker	CYP2C19|CYP2D6	neurology/psychiatry|infectious disease|rheumatology|cardiology	muscle relaxant|multiple sclerosis|encephalomyelitis|ankylosing spondylitis|atherosclerosis|Raynaud's disease	0	96.21	Selleck	S4200	Tolperisone HCl	245.178	C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|	FSKFPVLPFLJRQB-AWEZNQCLSA-N	688589.0		FSKFPVLPFLJRQB
BRD-K85693895-001-02-9	tolrestat	Withdrawn	aldose reductase inhibitor	AKR1A1|AKR1B1|AKR1B10			0	79.87	MedChemEx	HY-16500	Tolrestat	357.065	COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	LUBHDINQXIHVLS-UHFFFAOYSA-N	53359.0		LUBHDINQXIHVLS
BRD-K85693895-001-03-7	tolrestat	Withdrawn	aldose reductase inhibitor	AKR1A1|AKR1B1|AKR1B10			0	89.37	MedChemEx	HY-16500	Tolrestat	357.065	COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	LUBHDINQXIHVLS-UHFFFAOYSA-N	53359.0		LUBHDINQXIHVLS
BRD-K85693895-001-01-1	tolrestat	Withdrawn	aldose reductase inhibitor	AKR1A1|AKR1B1|AKR1B10			0	62.6	MedChemEx	HY-16500	Tolrestat	357.065	COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	LUBHDINQXIHVLS-UHFFFAOYSA-N	53359.0		LUBHDINQXIHVLS
BRD-K54316499-046-06-0	tolterodine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence|urinary frequency	0	90.63	Tocris	3761	Tolterodine L-tartrate	325.241	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	OOGJQPCLVADCPB-HXUWFJFHSA-N	443879.0		OOGJQPCLVADCPB
BRD-K54316499-046-05-2	tolterodine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence|urinary frequency	0	88.01	Selleck	S2550	Tolterodine tartrate (Detrol LA)	325.241	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	OOGJQPCLVADCPB-HXUWFJFHSA-N	443879.0		OOGJQPCLVADCPB
BRD-K54316499-046-09-9	tolterodine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence|urinary frequency	0	89.98	Tocris	3761	Tolterodine L-tartrate	325.241	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	OOGJQPCLVADCPB-HXUWFJFHSA-N	443879.0		OOGJQPCLVADCPB
BRD-K54316499-046-04-5	tolterodine	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	urology	urinary incontinence|urinary frequency	0	82.53	Selleck	S2550	Tolterodine tartrate	325.241	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	OOGJQPCLVADCPB-HXUWFJFHSA-N	443879.0		OOGJQPCLVADCPB
BRD-K64514229-001-07-9	toltrazuril	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	98.46	MedChemEx	HY-B0175	Toltrazuril	425.066	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	OCINXEZVIIVXFU-UHFFFAOYSA-N	68591.0		OCINXEZVIIVXFU
BRD-K64514229-001-05-2	toltrazuril	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	99.46	MicroSource	1505681	TOLTRAZURIL	425.066	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	OCINXEZVIIVXFU-UHFFFAOYSA-N	68591.0		OCINXEZVIIVXFU
BRD-K64514229-001-04-5	toltrazuril	Launched	antiprotozoal agent		infectious disease	coccidiosis	0	98.38	Selleck	S4044	Toltrazuril	425.066	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	OCINXEZVIIVXFU-UHFFFAOYSA-N	68591.0		OCINXEZVIIVXFU
BRD-A82035391-001-03-5	tolvaptan	Launched	vasopressin receptor antagonist	AVPR1A|AVPR2	endocrinology|cardiology|gastroenterology	hyponatremia|congestive heart failure|hepatic cirrhosis	0	97.1	Tocris	5181	Tolvaptan	448.155	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|	GYHCTFXIZSNGJT-XMMPIXPASA-N	443894.0		GYHCTFXIZSNGJT
BRD-A82035391-001-04-9	tolvaptan	Launched	vasopressin receptor antagonist	AVPR1A|AVPR2	endocrinology|cardiology|gastroenterology	hyponatremia|congestive heart failure|hepatic cirrhosis	0	97.96	Tocris	5181	Tolvaptan	448.155	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|	GYHCTFXIZSNGJT-XMMPIXPASA-N	443894.0		GYHCTFXIZSNGJT
BRD-A82035391-001-02-7	tolvaptan	Launched	vasopressin receptor antagonist	AVPR1A|AVPR2	endocrinology|cardiology|gastroenterology	hyponatremia|congestive heart failure|hepatic cirrhosis	0	98.54	Selleck	S2593	Tolvaptan	448.155	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20,r|	GYHCTFXIZSNGJT-XMMPIXPASA-N	443894.0		GYHCTFXIZSNGJT
BRD-K00003487-001-01-9	tomeglovir	Preclinical	antiviral				0	97.71	MedChemEx	HY-108261	Tomeglovir	441.172	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1ccc(NC(=O)C(C)(C)CO)cc1	OSQAKHSYTKBSPB-UHFFFAOYSA-N	475330.0		OSQAKHSYTKBSPB
BRD-K74765201-001-16-7	tomelukast	Phase 3	leukotriene receptor antagonist	CYSLTR1			0	94.74	Enzo	RA101	LY-171883	318.169	CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O	MWYHLEQJTQJHSS-UHFFFAOYSA-N	3969.0		MWYHLEQJTQJHSS
BRD-K74765201-001-07-6	tomelukast	Phase 3	leukotriene receptor antagonist	CYSLTR1			0		Enzo	RA-101	LY 171883	318.169	CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O	MWYHLEQJTQJHSS-UHFFFAOYSA-N	3969.0		MWYHLEQJTQJHSS
BRD-K00003361-001-01-9	tomivosertib	Phase 2	MAPK-interacting kinase inhibitor				0	96.64	MedChemEx	HY-100022	Tomivosertib	340.165	Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1	HKTBYUWLRDZAJK-UHFFFAOYSA-N	118598754.0		HKTBYUWLRDZAJK
BRD-K36970462-001-01-6	tonabersat	Phase 2	gap junction modulator|nitric oxide production inhibitor				0	99.82	MedChemEx	HY-15204	Tonabersat	391.099	CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	XLIIRNOPGJTBJD-ROUUACIJSA-N	6918324.0		XLIIRNOPGJTBJD
BRD-K36970462-001-02-9	tonabersat	Phase 2	gap junction modulator|nitric oxide production inhibitor				0	97.32	MedChemEx	HY-15204	Tonabersat	391.099	CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	XLIIRNOPGJTBJD-ROUUACIJSA-N	6918324.0		XLIIRNOPGJTBJD
BRD-K00003325-001-01-9	topilutamide	Preclinical	androgen receptor antagonist				0	95.48	MedChemEx	HY-19470	Topilutamide	403.06	C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O |&1:1,r|	YCNCRLKXSLARFT-NSHDSACASA-N	76958749.0		YCNCRLKXSLARFT
BRD-K29653726-001-16-7	topiramate	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|migraine headache	0	94.04	Tocris	3620	Topiramate	339.099	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	KJADKKWYZYXHBB-XBWDGYHZSA-N	5284627.0		KJADKKWYZYXHBB
BRD-K29653726-001-15-9	topiramate	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|migraine headache	0	100.0	MicroSource	1505801	TOPIRAMATE	339.099	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	KJADKKWYZYXHBB-XBWDGYHZSA-N	5284627.0		KJADKKWYZYXHBB
BRD-K29653726-001-14-2	topiramate	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|migraine headache	0	100.0	Tocris	3620	Topiramate	339.099	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	KJADKKWYZYXHBB-XBWDGYHZSA-N	5284627.0		KJADKKWYZYXHBB
BRD-K29653726-001-13-4	topiramate	Launched	carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist	CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|migraine headache	0	100.0	Selleck	S1438	Topiramate	339.099	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	KJADKKWYZYXHBB-XBWDGYHZSA-N	5284627.0		KJADKKWYZYXHBB
BRD-K77561571-001-01-1	topiroxostat	Launched	xanthine oxidase inhibitor	XDH	rheumatology|nephrology	gout|hyperuricemia	0	99.78	MedChemEx	HY-14874	Topiroxostat	248.081	N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1	UBVZQGOVTLIHLH-UHFFFAOYSA-N	5288320.0		UBVZQGOVTLIHLH
BRD-K77561571-001-02-9	topiroxostat	Launched	xanthine oxidase inhibitor	XDH	rheumatology|nephrology	gout|hyperuricemia	0	96.01	MedChemEx	HY-14874	Topiroxostat	248.081	N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1	UBVZQGOVTLIHLH-UHFFFAOYSA-N	5288320.0		UBVZQGOVTLIHLH
BRD-K55696337-003-25-1	topotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	small cell lung cancer|cervical cancer	0	24.11	MedChemEx	HY-13768A	Topotecan (Hydrochloride)	421.164	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N	60700.0		UCFGDBYHRUNTLO
BRD-K55696337-003-21-0	topotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	small cell lung cancer|cervical cancer	0	41.05	MicroSource	1505820	TOPOTECAN HYDROCHLORIDE	421.164	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N	60700.0		UCFGDBYHRUNTLO
BRD-K55696337-003-23-6	topotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	small cell lung cancer|cervical cancer	0	29.04	Key	KS-1410	(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione hydrochloride	421.164	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N	60700.0		UCFGDBYHRUNTLO
BRD-K55696337-003-22-8	topotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	small cell lung cancer|cervical cancer	0	42.85	Selleck	S1231	Topotecan HCl	421.164	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N	60700.0		UCFGDBYHRUNTLO
BRD-K55696337-003-24-4	topotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	small cell lung cancer|cervical cancer	0	76.92	MedChemEx	HY-13768A	Topotecan (Hydrochloride)	421.164	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N	60700.0		UCFGDBYHRUNTLO
BRD-K55696337-003-20-2	topotecan	Launched	topoisomerase inhibitor	TOP1|TOP1MT	oncology	small cell lung cancer|cervical cancer	0	33.95	Selleck	S1231	Topotecan HCl	421.164	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	UCFGDBYHRUNTLO-QHCPKHFHSA-N	60700.0		UCFGDBYHRUNTLO
BRD-K30480208-001-18-5	torasemide	Launched	electrolyte reabsorption inhibitor|thromboxane receptor antagonist	SLC12A1	cardiology	edema|congestive heart failure|hypertension	0	99.36	MicroSource	1505211	TORSEMIDE	348.126	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	NGBFQHCMQULJNZ-UHFFFAOYSA-N	51371498.0		NGBFQHCMQULJNZ
BRD-K30480208-001-19-9	torasemide	Launched	electrolyte reabsorption inhibitor|thromboxane receptor antagonist	SLC12A1	cardiology	edema|congestive heart failure|hypertension	0	99.03	MedChemEx	HY-B0247	Torsemide	348.126	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	NGBFQHCMQULJNZ-UHFFFAOYSA-N	51371498.0		NGBFQHCMQULJNZ
BRD-K30480208-001-17-7	torasemide	Launched	electrolyte reabsorption inhibitor|thromboxane receptor antagonist	SLC12A1	cardiology	edema|congestive heart failure|hypertension	0	97.07	Selleck	S1698	Torsemide	348.126	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	NGBFQHCMQULJNZ-UHFFFAOYSA-N	51371498.0		NGBFQHCMQULJNZ
BRD-K55675242-001-02-2	torcetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	91.57	Tocris	4184	Torcetrapib	600.167	CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	CMSGWTNRGKRWGS-NQIIRXRSSA-N	159325.0		CMSGWTNRGKRWGS
BRD-K55675242-001-03-0	torcetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	96.12	Selleck	S2792	Torcetrapib	600.167	CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	CMSGWTNRGKRWGS-NQIIRXRSSA-N	159325.0	BRD-K64622987-001-01-4	CMSGWTNRGKRWGS
BRD-K55675242-001-04-9	torcetrapib	Phase 3	cholesteryl ester transfer protein inhibitor	CETP			0	96.58	Tocris	4184	Torcetrapib	600.167	CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	CMSGWTNRGKRWGS-NQIIRXRSSA-N	159325.0		CMSGWTNRGKRWGS
BRD-K91822704-003-08-9	torcitabine	Phase 2	DNA polymerase inhibitor	DCK|TK2			0	84.6	MedChemEx	HY-17564	2'-Deoxycytidine (hydrochloride)	227.091	Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	CKTSBUTUHBMZGZ-SHYZEUOFSA-N	13711.0		CKTSBUTUHBMZGZ
BRD-K91822704-003-07-2	torcitabine	Phase 2	DNA polymerase inhibitor	DCK|TK2			0	100.0	MedChemEx	HY-17564	2'-Deoxycytidine (hydrochloride)	227.091	Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	CKTSBUTUHBMZGZ-SHYZEUOFSA-N	13711.0		CKTSBUTUHBMZGZ
BRD-K51350053-048-16-5	toremifene	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	0	95.2	MicroSource	1505682	TOREMIFENE CITRATE	405.186	CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	XFCLJVABOIYOMF-QPLCGJKRSA-N	3005573.0		XFCLJVABOIYOMF
BRD-K51350053-048-18-9	toremifene	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	0	95.88	MedChemEx	HY-B0005	Toremifene (Citrate)	405.186	CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	XFCLJVABOIYOMF-QPLCGJKRSA-N	3005573.0		XFCLJVABOIYOMF
BRD-K51350053-048-17-3	toremifene	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	0	97.25	Selleck	S1776	Toremifene Citrate (Fareston, Acapodene)	405.186	CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	XFCLJVABOIYOMF-QPLCGJKRSA-N	3005573.0		XFCLJVABOIYOMF
BRD-K51350053-048-15-7	toremifene	Launched	estrogen receptor antagonist|selective estrogen receptor modulator (SERM)	ESR1	oncology	breast cancer	0	89.49	Selleck	S1776	Toremifene Citrate	405.186	CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	XFCLJVABOIYOMF-QPLCGJKRSA-N	3005573.0		XFCLJVABOIYOMF
BRD-K40175214-001-11-6	torin-1	Preclinical	mTOR inhibitor	MTOR			0	89.49	Selleck	S2827	Torin 1	607.22	CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	AKCRNFFTGXBONI-UHFFFAOYSA-N	49836027.0		AKCRNFFTGXBONI
BRD-K40175214-001-13-2	torin-1	Preclinical	mTOR inhibitor	MTOR			0	95.98	Selleck	S2827	Torin 1	607.22	CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	AKCRNFFTGXBONI-UHFFFAOYSA-N	49836027.0		AKCRNFFTGXBONI
BRD-K40175214-001-15-9	torin-1	Preclinical	mTOR inhibitor	MTOR			0	89.04	Tocris	4247	Torin 1	607.22	CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	AKCRNFFTGXBONI-UHFFFAOYSA-N	49836027.0		AKCRNFFTGXBONI
BRD-K68174511-001-06-6	torin-2	Preclinical	mTOR inhibitor	MTOR			0	97.22	Selleck	S2817	Torin 2	432.12	Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	GUXXEUUYCAYESJ-UHFFFAOYSA-N	51358113.0		GUXXEUUYCAYESJ
BRD-K68174511-001-08-2	torin-2	Preclinical	mTOR inhibitor	MTOR			0	97.57	Tocris	4248	Torin 2	432.12	Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	GUXXEUUYCAYESJ-UHFFFAOYSA-N	51358113.0		GUXXEUUYCAYESJ
BRD-K68174511-001-09-9	torin-2	Preclinical	mTOR inhibitor	MTOR			0	96.39	Tocris	4248	Torin 2	432.12	Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	GUXXEUUYCAYESJ-UHFFFAOYSA-N	51358113.0		GUXXEUUYCAYESJ
BRD-K92241597-001-11-0	tosedostat	Phase 2	peptidase inhibitor	ANPEP|LAP3|NPEPPS			0	63.33	Tocris	3595	CHR 2797	406.21	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	FWFGIHPGRQZWIW-SQNIBIBYSA-N	15547703.0		FWFGIHPGRQZWIW
BRD-K92241597-001-09-4	tosedostat	Phase 2	peptidase inhibitor	ANPEP|LAP3|NPEPPS			0	78.86	Selleck	S1522	Tosedostat (CHR2797)	406.21	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	FWFGIHPGRQZWIW-SQNIBIBYSA-N	15547703.0		FWFGIHPGRQZWIW
BRD-K92241597-001-06-0	tosedostat	Phase 2	peptidase inhibitor	ANPEP|LAP3|NPEPPS			0	93.96	Tocris	3595	CHR 2797	406.21	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	FWFGIHPGRQZWIW-SQNIBIBYSA-N	15547703.0		FWFGIHPGRQZWIW
BRD-K92241597-001-12-9	tosedostat	Phase 2	peptidase inhibitor	ANPEP|LAP3|NPEPPS			0	83.33	Tocris	3595	CHR 2797	406.21	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	FWFGIHPGRQZWIW-SQNIBIBYSA-N	15547703.0		FWFGIHPGRQZWIW
BRD-K92241597-001-05-2	tosedostat	Phase 2	peptidase inhibitor	ANPEP|LAP3|NPEPPS			0	74.99	Selleck	S1522	Tosedostat (CHR2797)	406.21	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	FWFGIHPGRQZWIW-SQNIBIBYSA-N	15547703.0		FWFGIHPGRQZWIW
BRD-K01825158-003-02-9	tosufloxacin	Launched	bacterial DNA gyrase inhibitor		infectious disease	gram-negative bacterial infections	0	97.24	Prestwick	Prestw-1464	Tosufloxacin hydrochloride	440.086	N[C@H]1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F |&1:1|	WUWFMDMBOJLQIV-JTQLQIEISA-N	488360.0		WUWFMDMBOJLQIV
BRD-K26420709-001-01-7	toyocamycin	Phase 1	serine/threonine kinase inhibitor	ERN1			0	99.13	Sigma	T3580	4-amino-7-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile	291.097	Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	XOKJUSAYZUAMGJ-WOUKDFQISA-N	11824.0		XOKJUSAYZUAMGJ
BRD-K93045741-001-02-9	tozadenant	Phase 3	adenosine receptor antagonist	ADORA2A			0	95.9	MedChemEx	HY-10995	Tozadenant	406.167	COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	XNBRWUQWSKXMPW-UHFFFAOYSA-N	11618368.0		XNBRWUQWSKXMPW
BRD-K93045741-001-01-0	tozadenant	Phase 3	adenosine receptor antagonist	ADORA2A			0	96.14	MedChemEx	HY-10995	Tozadenant	406.167	COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	XNBRWUQWSKXMPW-UHFFFAOYSA-N	11618368.0		XNBRWUQWSKXMPW
BRD-K59369769-001-23-7	tozasertib	Phase 2	Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor	AURKA|AURKB|AURKC|LCK			0	97.69	Selleck	S1048	Tozasertib	464.211	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	GCIKSSRWRFVXBI-UHFFFAOYSA-N	5494449.0		GCIKSSRWRFVXBI
BRD-K59369769-001-20-3	tozasertib	Phase 2	Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor	AURKA|AURKB|AURKC|LCK			0	95.49	Selleck	S1048	VX-680 (Tozasertib, MK-0457)	464.211	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	GCIKSSRWRFVXBI-UHFFFAOYSA-N	5494449.0		GCIKSSRWRFVXBI
BRD-K87941707-001-02-9	TP-003	Preclinical	GABA receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	95.5	Tocris	4414	TP 003	407.125	CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N	SJMMDWXJSSJHOQ-UHFFFAOYSA-N	10001434.0		SJMMDWXJSSJHOQ
BRD-K87941707-001-01-0	TP-003	Preclinical	GABA receptor inverse agonist	GABRA1|GABRA2|GABRA3|GABRA5			0	94.29	Tocris	4414	TP 003	407.125	CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N	SJMMDWXJSSJHOQ-UHFFFAOYSA-N	10001434.0		SJMMDWXJSSJHOQ
BRD-K84034737-001-01-1	TP-0903	Phase 1/Phase 2	AXL kinase inhibitor	AXL			0	98.07	MedChemEx	HY-12963	TP-0903	515.187	CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl	YUAALFPUEOYPNX-UHFFFAOYSA-N	56839178.0		YUAALFPUEOYPNX
BRD-K00005239-001-01-9	TP-3654	Phase 1	1,4,5-trisphosphate inhibitor				0	96.51	MedChemEx	HY-101126	TP-3654	418.198	CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|	XRNVABDYQLHODA-JCNLHEQBSA-N			XRNVABDYQLHODA
BRD-K51575138-001-15-7	TPCA-1	Preclinical	IKK inhibitor	IKBKB			0	98.05	Tocris	2559	TPCA-1	279.048	NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	SAYGKHKXGCPTLX-UHFFFAOYSA-N	9903786.0		SAYGKHKXGCPTLX
BRD-K51575138-001-13-2	TPCA-1	Preclinical	IKK inhibitor	IKBKB			0	98.3	Tocris	2559	TPCA-1	279.048	NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	SAYGKHKXGCPTLX-UHFFFAOYSA-N	9903786.0		SAYGKHKXGCPTLX
BRD-K51575138-001-12-4	TPCA-1	Preclinical	IKK inhibitor	IKBKB			0	95.7	Selleck	S2824	TPCA-1	279.048	NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	SAYGKHKXGCPTLX-UHFFFAOYSA-N	9903786.0		SAYGKHKXGCPTLX
BRD-K00004542-001-01-9	TPPS4	Phase 1					0	40.2	Vitas-M	STK568251	4,4',4'',4'''-porphyrin-5,10,15,20-tetrayltetrabenzenesulfonic acid	934.074	OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2	PBHVCRIXMXQXPD-LWQDQPMZSA-N			PBHVCRIXMXQXPD
BRD-K00003313-001-01-9	trabectedin	Phase 3	antitumor agent				0	85.45	MedChemEx	HY-50936	Trabectedin	761.262	[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1cc(O)c(OC)cc31 |THB:16:15:2.3.12:17.19.20|	PKVRCIRHQMSYJX-AIFWHQITSA-N	108150.0		PKVRCIRHQMSYJX
BRD-K00004698-001-01-9	trabodenoson	Phase 3	adenosine receptor agonist				0	81.93	AMS	L13970	Trabodenoson	380.144	O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	AQLVRTWKJDTWQQ-SDBHATRESA-N	11610599.0		AQLVRTWKJDTWQQ
BRD-K34154330-003-07-9	tracazolate	Phase 2	GABA receptor modulator	GABRA1			0	92.72	Tocris	1558	Tracazolate hydrochloride	304.19	CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	PCTRYMLLRKWXGF-UHFFFAOYSA-N	5522.0		PCTRYMLLRKWXGF
BRD-K34154330-003-06-4	tracazolate	Phase 2	GABA receptor modulator	GABRA1			0	98.96	Tocris	1558	Tracazolate hydrochloride	304.19	CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	PCTRYMLLRKWXGF-UHFFFAOYSA-N	5522.0		PCTRYMLLRKWXGF
BRD-K00003222-001-01-9	tradipitant	Phase 3	neurokinin receptor antagonist				0	97.43	MedChemEx	HY-16732	Tradipitant	587.095	FC(F)(F)c1cc(Cn2nnc(c2-c2ccncc2)-c2ncccc2C(=O)c2ccccc2Cl)cc(c1)C(F)(F)F	CAVRKWRKTNINFF-UHFFFAOYSA-N	9916461.0		CAVRKWRKTNINFF
BRD-K30071764-001-03-0	TRAM-34	Preclinical	potassium channel antagonist	KCNN4			0	0.0	MedChemEx	HY-13519	TRAM-34	344.108	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1	KBFUQFVFYYBHBT-UHFFFAOYSA-N	656734.0		KBFUQFVFYYBHBT
BRD-K30071764-001-02-2	TRAM-34	Preclinical	potassium channel antagonist	KCNN4			0	0.0	MedChemEx	HY-13519	TRAM-34	344.108	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1	KBFUQFVFYYBHBT-UHFFFAOYSA-N	656734.0		KBFUQFVFYYBHBT
BRD-K81341251-001-02-9	TRAM-39	Preclinical	calcium-activated potassium channel activator	KCNN4			0	98.14	Tocris	4952	TRAM 39	303.081	Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1	JHNRTPKGSCVKKC-UHFFFAOYSA-N	9861261.0		JHNRTPKGSCVKKC
BRD-K81341251-001-01-9	TRAM-39	Preclinical	calcium-activated potassium channel activator	KCNN4			0	93.57	Tocris	4952	TRAM 39	303.081	Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1	JHNRTPKGSCVKKC-UHFFFAOYSA-N	9861261.0		JHNRTPKGSCVKKC
BRD-K12343256-001-18-8	trametinib	Launched	MEK inhibitor	MAP2K1|MAP2K2	oncology	melanoma	0	88.74	Selleck	S2673	Trametinib	615.078	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	11707110.0		LIRYPHYGHXZJBZ
BRD-K12343256-001-14-7	trametinib	Launched	MEK inhibitor	MAP2K1|MAP2K2	oncology	melanoma	0	94.67	MedChemEx	HY-10999	trametinib	615.078	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	11707110.0		LIRYPHYGHXZJBZ
BRD-K12343256-001-11-3	trametinib	Launched	MEK inhibitor	MAP2K1|MAP2K2	oncology	melanoma	0	93.36	Selleck	S2673	GSK1120212 (Trametinib)	615.078	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	11707110.0		LIRYPHYGHXZJBZ
BRD-K12343256-001-08-9	trametinib	Launched	MEK inhibitor	MAP2K1|MAP2K2	oncology	melanoma	0	76.41	Selleck	S2673	Trametinib (GSK1120212)	615.078	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	LIRYPHYGHXZJBZ-UHFFFAOYSA-N	11707110.0		LIRYPHYGHXZJBZ
BRD-K82234479-001-09-4	tramiprosate	Phase 3	beta amyloid protein neurotoxicity inhibitor	APP			0	100.0	MicroSource	1501125	TRAMIPROSATE	139.03	NCCCS(O)(=O)=O	SNKZJIOFVMKAOJ-UHFFFAOYSA-N	6991996.0		SNKZJIOFVMKAOJ
BRD-K82234479-001-10-9	tramiprosate	Phase 3	beta amyloid protein neurotoxicity inhibitor	APP			0	100.0	Tocris	3619	Tramiprosate	139.03	NCCCS(O)(=O)=O	SNKZJIOFVMKAOJ-UHFFFAOYSA-N	6991996.0		SNKZJIOFVMKAOJ
BRD-K28550399-001-03-9	trandolapril	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension|myocardial infarction	0	89.87	MedChemEx	HY-B0592	Trandolapril	430.247	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O	VXFJYXUZANRPDJ-WTNASJBWSA-N	5484727.0		VXFJYXUZANRPDJ
BRD-K15014948-001-11-1	tranexamic-acid	Launched	antifibrinolytic|plasminogen activator inhibitor	PLG	hematology	hemophilia	0	97.0	MedChemEx	HY-B0149	Tranexamic acid	157.11	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	GYDJEQRTZSCIOI-LJGSYFOKSA-N			GYDJEQRTZSCIOI
BRD-K15014948-001-10-3	tranexamic-acid	Launched	antifibrinolytic|plasminogen activator inhibitor	PLG	hematology	hemophilia	0	83.58	MedChemEx	HY-B0149	Tranexamic acid	157.11	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	GYDJEQRTZSCIOI-LJGSYFOKSA-N			GYDJEQRTZSCIOI
BRD-K15014948-213-01-3	tranexamic-acid	Launched	antifibrinolytic|plasminogen activator inhibitor	PLG	hematology	hemophilia	0	0.0	MicroSource	1502026	TRANEXAMIC ACID	157.11	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	GYDJEQRTZSCIOI-LJGSYFOKSA-N			GYDJEQRTZSCIOI
BRD-K15014948-001-09-5	tranexamic-acid	Launched	antifibrinolytic|plasminogen activator inhibitor	PLG	hematology	hemophilia	0	0.0	Selleck	S1875	Tranexamic acid (Transamin)	157.11	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	GYDJEQRTZSCIOI-LJGSYFOKSA-N			GYDJEQRTZSCIOI
BRD-K15014948-001-12-9	tranexamic-acid	Launched	antifibrinolytic|plasminogen activator inhibitor	PLG	hematology	hemophilia	0	6.99	Selleck	S1875	Tranexamic Acid	157.11	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	GYDJEQRTZSCIOI-LJGSYFOKSA-N		BRD-K79165417-001-01-7	GYDJEQRTZSCIOI
BRD-K17849083-001-34-5	tranilast	Launched	angiogenesis inhibitor	HPGDS|HRH1	pulmonary	asthma	0	89.96	Tocris	1098	Tranilast	327.111	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	NZHGWWWHIYHZNX-CSKARUKUSA-N	5282230.0		NZHGWWWHIYHZNX
BRD-K17849083-001-31-1	tranilast	Launched	angiogenesis inhibitor	HPGDS|HRH1	pulmonary	asthma	0	96.73	MicroSource	1505333	TRANILAST	327.111	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	NZHGWWWHIYHZNX-CSKARUKUSA-N	5282230.0		NZHGWWWHIYHZNX
BRD-K17849083-001-32-9	tranilast	Launched	angiogenesis inhibitor	HPGDS|HRH1	pulmonary	asthma	0	99.75	Selleck	S1439	Tranilast (SB 252218)	327.111	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	NZHGWWWHIYHZNX-CSKARUKUSA-N	5282230.0		NZHGWWWHIYHZNX
BRD-K17849083-001-29-5	tranilast	Launched	angiogenesis inhibitor	HPGDS|HRH1	pulmonary	asthma	0	85.68	Selleck	S1439	Tranilast	327.111	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	NZHGWWWHIYHZNX-CSKARUKUSA-N	5282230.0		NZHGWWWHIYHZNX
BRD-K17849083-001-30-3	tranilast	Launched	angiogenesis inhibitor	HPGDS|HRH1	pulmonary	asthma	0	79.42	Tocris	1098	Tranilast	327.111	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	NZHGWWWHIYHZNX-CSKARUKUSA-N	5282230.0		NZHGWWWHIYHZNX
BRD-K26222048-001-02-9	trans-10,cis-12-conjugated-linoleic-acid	Launched					0	28.07	Cayman	90145	10(E),12(Z)-Conjugated Linoleic Acid	280.24	CCCCC\C=C/C=C/CCCCCCCCC(O)=O	GKJZMAHZJGSBKD-NMMTYZSQSA-N	5282800.0		GKJZMAHZJGSBKD
BRD-K26222048-001-01-7	trans-10,cis-12-conjugated-linoleic-acid	Launched					0	95.61	Cayman	90145		280.24	CCCCC\C=C/C=C/CCCCCCCCC(O)=O	GKJZMAHZJGSBKD-NMMTYZSQSA-N	5282800.0		GKJZMAHZJGSBKD
BRD-K42959922-001-01-5	trans-2-undecenoic-acid	Preclinical					0	90.54	AlfaAesar	L11579	trans-2-Undecenoic acid, tech. 80%	184.146	CCCCCCCC\C=C\C(O)=O	IGBBVTAVILYDIO-MDZDMXLPSA-N	5282728.0		IGBBVTAVILYDIO
BRD-K75080769-001-02-9	trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid	Preclinical					0	95.64	Key	EH-0718	4-(8-(3-fluorophenyl)-1,7-naphthyridin-6-yl)cyclohexane-1-carboxylic acid	350.143	OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1	XWVBOPKUSVZZPJ-UHFFFAOYSA-N	9924539.0		XWVBOPKUSVZZPJ
BRD-K75080769-001-01-6	trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid	Preclinical					0	94.05	Key	EH-0718		350.143	OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1	XWVBOPKUSVZZPJ-UHFFFAOYSA-N	9924539.0		XWVBOPKUSVZZPJ
BRD-K91614056-001-03-9	trans-4-hydroxycrotonic-acid	Preclinical	gamma hydroxybutyric acid ligand				1	0.0	Tocris	538	trans-4-Hydroxycrotonic acid	102.032	OC\C=C\C(O)=O	RMQJECWPWQIIPW-OWOJBTEDSA-N	6155526.0		RMQJECWPWQIIPW
BRD-K91614056-001-02-2	trans-4-hydroxycrotonic-acid	Preclinical	gamma hydroxybutyric acid ligand				1	0.0	Tocris	538	trans-4-Hydroxycrotonic acid	102.032	OC\C=C\C(O)=O	RMQJECWPWQIIPW-OWOJBTEDSA-N	6155526.0		RMQJECWPWQIIPW
BRD-K26273521-001-08-9	trans-4-methoxycinnamic-acid	Preclinical					0	95.36	Sigma	MFCD00004398	4-Methoxycinnamic acid, predominantly trans	178.063	COc1ccc(\C=C\C(O)=O)cc1	AFDXODALSZRGIH-QPJJXVBHSA-N	699414.0		AFDXODALSZRGIH
BRD-K26273521-001-07-3	trans-4-methoxycinnamic-acid	Preclinical					0	96.49	Vitas-M	STK005095		178.063	COc1ccc(\C=C\C(O)=O)cc1	AFDXODALSZRGIH-QPJJXVBHSA-N	699414.0		AFDXODALSZRGIH
BRD-K00003217-304-01-9	transcrocetinate	Preclinical	glutamate receptor antagonist				0	0.0	MedChemEx	HY-16502	Transcrocetinate disodium	328.167	C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	PANKHBYNKQNAHN-MQQNZMFNSA-N	5281232.0		PANKHBYNKQNAHN
BRD-K00003699-065-01-9	tranylcypromine	Launched	monoamine oxidase inhibitor	KDM1A|MAOA|MAOB	neurology/psychiatry	depression	0	77.31	MedChemEx	HY-B1496	Tranylcypromine (hemisulfate)	133.089	N[C@H]1C[C@@H]1c1ccccc1 |&1:1,3|	AELCINSCMGFISI-BDAKNGLRSA-N	26070.0		AELCINSCMGFISI
BRD-K69837166-003-03-8	trap-101	Preclinical	nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist	OPRL1			0	96.57	Tocris	2508	Trap 101	397.273	CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|	DCRGHMJXEBSRQG-UHFFFAOYSA-N	11494970.0		DCRGHMJXEBSRQG
BRD-K69837166-003-02-0	trap-101	Preclinical	nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist	OPRL1			0	97.83	Tocris	2508	Trap 101	397.273	CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|	DCRGHMJXEBSRQG-UHFFFAOYSA-N	11494970.0		DCRGHMJXEBSRQG
BRD-K69837166-003-04-9	trap-101	Preclinical	nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist	OPRL1			0	97.53	Tocris	2508	Trap 101	397.273	CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|	DCRGHMJXEBSRQG-UHFFFAOYSA-N	11494970.0		DCRGHMJXEBSRQG
BRD-K95763993-001-20-9	trapidil	Launched	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	0	98.72	MedChemEx	HY-B1016	Trapidil	205.133	CCN(CC)c1cc(C)nc2ncnn12	GSNOZLZNQMLSKJ-UHFFFAOYSA-N	5531.0		GSNOZLZNQMLSKJ
BRD-K95763993-001-19-3	trapidil	Launched	PDGFR tyrosine kinase receptor inhibitor	PDGFRA	cardiology	coronary artery disease (CAD)	0	97.83	Prestwick	Prestw-1012	Trapidil	205.133	CCN(CC)c1cc(C)nc2ncnn12	GSNOZLZNQMLSKJ-UHFFFAOYSA-N	5531.0		GSNOZLZNQMLSKJ
BRD-K23976833-001-02-9	travoprost	Launched	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension|glaucoma	0	86.76	MedChemEx	HY-B0584	Travoprost	500.239	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	MKPLKVHSHYCHOC-AHTXBMBWSA-N	5282226.0		MKPLKVHSHYCHOC
BRD-K23976833-001-01-0	travoprost	Launched	prostanoid receptor agonist	PTGFR	ophthalmology	ocular hypertension|glaucoma	0	95.41	Enzo	AC3276	TRAVOPROST	500.239	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	MKPLKVHSHYCHOC-AHTXBMBWSA-N	5282226.0		MKPLKVHSHYCHOC
BRD-K38158531-001-02-1	traxoprodil	Phase 2	glutamate receptor antagonist	GRIN2B			0	93.36	EMDBio	504523-5MG	CP-101,606	327.183	C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1	QEMSVZNTSXPFJA-HNAYVOBHSA-N	219101.0		QEMSVZNTSXPFJA
BRD-K70778732-003-27-5	trazodone	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4	neurology/psychiatry	depression	0	94.42	MicroSource	1503121	TRAZODONE HYDROCHLORIDE	371.151	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	PHLBKPHSAVXXEF-UHFFFAOYSA-N	5533.0		PHLBKPHSAVXXEF
BRD-K70778732-003-26-7	trazodone	Launched	adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor	ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4	neurology/psychiatry	depression	0	97.98	Selleck	S2582	Trazodone HCl	371.151	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	PHLBKPHSAVXXEF-UHFFFAOYSA-N	5533.0		PHLBKPHSAVXXEF
BRD-A20686268-001-01-4	trebenzomine	Phase 2					0	53.54	Sigma	PH007494	N,N-dimethyl-N-(2-methyl-3,4-dihydro-2H-chromen-3-yl)amine	191.131	C[C@H]1Oc2ccccc2C[C@@H]1N(C)C |&1:1,&2:10,r|	FDJAKSHVOONYHX-KOLCDFICSA-N	76963054.0		FDJAKSHVOONYHX
BRD-K36407194-001-02-9	trelagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	78.61	MedChemEx	HY-15408	Trelagliptin	357.16	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O	IWYJYHUNXVAVAA-OAHLLOKOSA-N	15983988.0		IWYJYHUNXVAVAA
BRD-K08619838-303-06-9	tremorine	Preclinical	acetylcholine receptor agonist				0	84.2	Vitas-M	STL432313	1-[4-(1-pyrrolidinyl)-2-butynyl]pyrrolidine	192.163	C(C#CCN1CCCC1)N1CCCC1	JSUAJTLKVREZHV-UHFFFAOYSA-N	5534.0		JSUAJTLKVREZHV
BRD-K08619838-300-05-7	tremorine	Preclinical	acetylcholine receptor agonist				0	100.0	Prestwick	Prestw-331	Tremorine dihydrochloride	192.163	C(C#CCN1CCCC1)N1CCCC1	JSUAJTLKVREZHV-UHFFFAOYSA-N	5534.0		JSUAJTLKVREZHV
BRD-K20902145-001-01-2	treosulfan	Launched	DNA synthesis inhibitor		oncology	ovarian cancer	0	0.0	MedChemEx	HY-16503	Treosulfan	278.013	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	YCPOZVAOBBQLRI-WDSKDSINSA-N	9882105.0		YCPOZVAOBBQLRI
BRD-K20902145-001-02-0	treosulfan	Launched	DNA synthesis inhibitor		oncology	ovarian cancer	0	0.0	MedChemEx	HY-16503	Treosulfan	278.013	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	YCPOZVAOBBQLRI-WDSKDSINSA-N	9882105.0		YCPOZVAOBBQLRI
BRD-K37543758-001-01-3	trepibutone	Launched	cholinergic receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4	gastroenterology	irritable bowel syndrome	0	97.79	AvaChem	1611	4-oxo-4-(2,4,5-triethoxyphenyl)butanoic acid	310.142	CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O	YPTFHLJNWSJXKG-UHFFFAOYSA-N	5536.0		YPTFHLJNWSJXKG
BRD-K19706299-236-02-9	treprostinil	Launched	prostanoid receptor agonist	P2RY12|PPARD|PTGIR	pulmonary	pulmonary arterial hypertension (PAH)	0	97.03	MedChemEx	HY-16504	Treprostinil (sodium)	390.241	CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O	PAJMKGZZBBTTOY-ZFORQUDYSA-N	6918140.0		PAJMKGZZBBTTOY
BRD-K84663978-003-03-7	trequinsin	Phase 1	phosphodiesterase inhibitor	PDE5A			0	96.03	Tocris	2337	Trequinsin hydrochloride	405.205	COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	MCMSJVMUSBZUCN-YYDJUVGSSA-N			MCMSJVMUSBZUCN
BRD-K84663978-003-02-9	trequinsin	Phase 1	phosphodiesterase inhibitor	PDE5A			0	95.94	Tocris	2337	Trequinsin hydrochloride	405.205	COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	MCMSJVMUSBZUCN-YYDJUVGSSA-N			MCMSJVMUSBZUCN
BRD-K84663978-003-05-9	trequinsin	Phase 1	phosphodiesterase inhibitor	PDE5A			0	94.75	Tocris	2337	Trequinsin hydrochloride	405.205	COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	MCMSJVMUSBZUCN-YYDJUVGSSA-N			MCMSJVMUSBZUCN
BRD-K08748705-001-08-2	tretazicar	Phase 2	DNA replication inhibitor	NQO2			0	92.47	Sigma	MFCD00869490	5-(1-aziridinyl)-2,4-dinitrobenzamide	252.049	NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O	WOCXQMCIOTUMJV-UHFFFAOYSA-N	89105.0		WOCXQMCIOTUMJV
BRD-K71879491-001-51-5	tretinoin	Launched	retinoid receptor agonist|retinoid receptor ligand	ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	0	84.83	MedChemEx	HY-14649	Retinoic acid	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N	444795.0		SHGAZHPCJJPHSC
BRD-K71879491-001-47-3	tretinoin	Launched	retinoid receptor agonist|retinoid receptor ligand	ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	0	21.25	Sigma	T1850000	retinoic acid	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N	444795.0		SHGAZHPCJJPHSC
BRD-K71879491-001-39-0	tretinoin	Launched	retinoid receptor agonist|retinoid receptor ligand	ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	0	34.51	MicroSource	1502016	TRETINOIN	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N	444795.0		SHGAZHPCJJPHSC
BRD-K71879491-001-44-0	tretinoin	Launched	retinoid receptor agonist|retinoid receptor ligand	ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	0	64.55	Selleck	S1653	All-trans Retinoic Acid (Tretinoin)	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N	444795.0		SHGAZHPCJJPHSC
BRD-K71879491-001-48-1	tretinoin	Launched	retinoid receptor agonist|retinoid receptor ligand	ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	0	40.72	MedChemEx	HY-14649	Retinoic acid	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N	444795.0		SHGAZHPCJJPHSC
BRD-K71879491-001-38-2	tretinoin	Launched	retinoid receptor agonist|retinoid receptor ligand	ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	0	23.7	Tocris	695	Retinoic acid	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N	444795.0		SHGAZHPCJJPHSC
BRD-K71879491-001-37-4	tretinoin	Launched	retinoid receptor agonist|retinoid receptor ligand	ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG	hematologic malignancy	acute promyelocytic leukemia (APL)	0	8.36	Selleck	S1653	Tretinoin	300.209	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	SHGAZHPCJJPHSC-YCNIQYBTSA-N	444795.0		SHGAZHPCJJPHSC
BRD-K92844263-001-12-9	triacetin	Launched					0	0.0	MedChemEx	HY-B0896	Triacetin	218.079	CC(=O)OCC(COC(C)=O)OC(C)=O	URAYPUMNDPQOKB-UHFFFAOYSA-N	5541.0		URAYPUMNDPQOKB
BRD-K92844263-001-09-8	triacetin	Launched					0	85.32	MicroSource	1500585	TRIACETIN	218.079	CC(=O)OCC(COC(C)=O)OC(C)=O	URAYPUMNDPQOKB-UHFFFAOYSA-N	5541.0		URAYPUMNDPQOKB
BRD-K77554836-001-15-9	triamcinolone	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	80.13	MedChemEx	HY-B0328	Triamcinolone	394.179	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|	GFNANZIMVAIWHM-OBYCQNJPSA-N	31307.0		GFNANZIMVAIWHM
BRD-K77554836-001-11-6	triamcinolone	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	94.01	Selleck	S1933	Triamcinolone (Aristocort)	394.179	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|	GFNANZIMVAIWHM-OBYCQNJPSA-N	31307.0		GFNANZIMVAIWHM
BRD-K77554836-001-14-0	triamcinolone	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	85.81	MicroSource	1500586	TRIAMCINOLONE	394.179	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|	GFNANZIMVAIWHM-OBYCQNJPSA-N	31307.0	BRD-A37780065-001-04-5	GFNANZIMVAIWHM
BRD-K77554836-001-13-2	triamcinolone	Launched	glucocorticoid receptor agonist	NR3C1	dermatology	corticosteroid-responsive dermatoses	0	51.58	Selleck	S1933	Triamcinolone	394.179	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14,t:10|	GFNANZIMVAIWHM-OBYCQNJPSA-N	31307.0	BRD-K97780336-001-01-9	GFNANZIMVAIWHM
BRD-K53790871-001-20-9	triamcinolone-acetonide	Launched	glucocorticoid receptor agonist|immunosuppressant	NR3C1|SERPINA6	dermatology	corticosteroid-responsive dermatoses	0	91.09	MedChemEx	HY-B0636	Triamcinolone acetonide	434.21	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14,t:10|	YNDXUCZADRHECN-JNQJZLCISA-N	6436.0		YNDXUCZADRHECN
BRD-K00003338-001-01-9	triamcinolone-hexacetonide	Launched	anti-inflammatory agent				0	80.82	MedChemEx	HY-U00103	Triamcinolone hexacetonide	532.284	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)CC(C)(C)C |c:13,t:9|	TZIZWYVVGLXXFV-FLRHRWPCSA-N	21826.0		TZIZWYVVGLXXFV
BRD-K92049597-001-21-9	triamterene	Launched	sodium channel blocker	SCNN1A|SCNN1B|SCNN1D|SCNN1G	endocrinology|cardiology	hypokalemia|hypertension|edema	0	98.47	MedChemEx	HY-B0575	Triamterene	253.108	Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1	FNYLWPVRPXGIIP-UHFFFAOYSA-N	5546.0		FNYLWPVRPXGIIP
BRD-K92049597-001-20-8	triamterene	Launched	sodium channel blocker	SCNN1A|SCNN1B|SCNN1D|SCNN1G	endocrinology|cardiology	hypokalemia|hypertension|edema	0	99.47	MicroSource	1500589	TRIAMTERENE	253.108	Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1	FNYLWPVRPXGIIP-UHFFFAOYSA-N	5546.0		FNYLWPVRPXGIIP
BRD-K92049597-001-19-0	triamterene	Launched	sodium channel blocker	SCNN1A|SCNN1B|SCNN1D|SCNN1G	endocrinology|cardiology	hypokalemia|hypertension|edema	0	96.26	Selleck	S4080	Triamterene	253.108	Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1	FNYLWPVRPXGIIP-UHFFFAOYSA-N	5546.0		FNYLWPVRPXGIIP
BRD-K01669786-001-03-0	triapine	Phase 2	ribonucleotide reductase inhibitor	RRM1|RRM2			0	99.17	MedChemEx	HY-10082	Triapine	195.058	NC(=S)N\N=C\c1ncccc1N	XMYKNCNAZKMVQN-NYYWCZLTSA-N	9571836.0		XMYKNCNAZKMVQN
BRD-K01669786-001-01-4	triapine	Phase 2	ribonucleotide reductase inhibitor	RRM1|RRM2			0	62.57	Selleck	S7470	Triapine	195.058	NC(=S)N\N=C\c1ncccc1N	XMYKNCNAZKMVQN-NYYWCZLTSA-N	9571836.0		XMYKNCNAZKMVQN
BRD-K01669786-001-02-2	triapine	Phase 2	ribonucleotide reductase inhibitor	RRM1|RRM2			0	99.04	Selleck	S7470	Triapine	195.058	NC(=S)N\N=C\c1ncccc1N	XMYKNCNAZKMVQN-NYYWCZLTSA-N	9571836.0		XMYKNCNAZKMVQN
BRD-A60294240-001-04-9	tribenoside	Launched	anti-inflammatory agent|capillary stabilizing agent				0	58.56	ChemImpex	28418	Tribenoside	478.236	CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|	ULLNJSBQMBKOJH-JPHCZMGXSA-N	12874922.0		ULLNJSBQMBKOJH
BRD-A60294240-001-03-7	tribenoside	Launched	anti-inflammatory agent|capillary stabilizing agent				0	63.93	Prestwick	Prestw-1019	Tribenoside	478.236	CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5,6,24,33,&1:3|	ULLNJSBQMBKOJH-JPHCZMGXSA-N	12874922.0		ULLNJSBQMBKOJH
BRD-K09118247-001-04-9	tribomsalan	Preclinical					0	95.09	Sigma	MFCD00045740	3,5-DIBROMO-N-(4-BROMO-PHENYL)-2-HYDROXY-BENZAMIDE	446.811	Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1	KVSKGMLNBAPGKH-UHFFFAOYSA-N	14868.0		KVSKGMLNBAPGKH
BRD-K09118247-001-03-3	tribomsalan	Preclinical					0	97.22	Vitas-M	STK301503		446.811	Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1	KVSKGMLNBAPGKH-UHFFFAOYSA-N	14868.0		KVSKGMLNBAPGKH
BRD-K69632891-001-02-9	tribromoethanol	Preclinical	analgesic agent				1	0.0	MedChemEx	HY-B1372	Tribromoethyl alcohol	279.773	OCC(Br)(Br)Br	YFDSDPIBEUFTMI-UHFFFAOYSA-N	6400.0		YFDSDPIBEUFTMI
BRD-K69632891-001-01-3	tribromoethanol	Preclinical	analgesic agent				1	0.0	MicroSource	1504342	TRIBROMOETHANOL	279.773	OCC(Br)(Br)Br	YFDSDPIBEUFTMI-UHFFFAOYSA-N	6400.0		YFDSDPIBEUFTMI
BRD-K38969488-001-01-6	tributyrin	Phase 1	HDAC inhibitor				0	0.0	Sigma	MFCD00009392	2,3-bis(butyryloxy)propyl butyrate	302.173	CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC	UYXTWWCETRIEDR-UHFFFAOYSA-N	6050.0		UYXTWWCETRIEDR
BRD-K24790130-001-07-1	tricaprylin	Launched			dermatology	cosmetic	0	85.71	MicroSource	1504370	CAPRYILIDENE	470.361	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	VLPFTAMPNXLGLX-UHFFFAOYSA-N	10850.0		VLPFTAMPNXLGLX
BRD-K24790130-001-09-9	tricaprylin	Launched			dermatology	cosmetic	0	0.0	Sigma	MFCD00036236	Glyceryl trioctanoate	470.361	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	VLPFTAMPNXLGLX-UHFFFAOYSA-N	10850.0		VLPFTAMPNXLGLX
BRD-A28940325-001-23-2	trichlormethiazide	Launched	chloride channel blocker	PTGS1|PTGS2|SLC12A1	cardiology	hypertension|edema	0	46.71	Selleck	S1667	Trichlormethiazide	378.902	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|	LMJSLTNSBFUCMU-QMMMGPOBSA-N	12444480.0		LMJSLTNSBFUCMU
BRD-A28940325-001-24-0	trichlormethiazide	Launched	chloride channel blocker	PTGS1|PTGS2|SLC12A1	cardiology	hypertension|edema	0	100.0	MicroSource	1500590	TRICHLORMETHIAZIDE	378.902	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|	LMJSLTNSBFUCMU-QMMMGPOBSA-N	12444480.0		LMJSLTNSBFUCMU
BRD-A28940325-001-25-7	trichlormethiazide	Launched	chloride channel blocker	PTGS1|PTGS2|SLC12A1	cardiology	hypertension|edema	0	43.72	Selleck	S1667	Trichlormethiazide (Achletin)	378.902	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9,r|	LMJSLTNSBFUCMU-QMMMGPOBSA-N	12444480.0		LMJSLTNSBFUCMU
BRD-K42090719-001-07-3	trichloroacetic-acid	Launched			dermatology	warts	1	0.0	Enamine	Z104473288	trichloroacetic acid	161.904	OC(=O)C(Cl)(Cl)Cl	YNJBWRMUSHSURL-UHFFFAOYSA-N	6421.0		YNJBWRMUSHSURL
BRD-K42090719-001-06-5	trichloroacetic-acid	Launched			dermatology	warts	1	0.0	Enamine	Z104473288		161.904	OC(=O)C(Cl)(Cl)Cl	YNJBWRMUSHSURL-UHFFFAOYSA-N	6421.0		YNJBWRMUSHSURL
BRD-K46435528-001-05-1	trichloroethylene	Preclinical					1	0.0	Sigma	MFCD00000838	1,1,2-trichloroethylene	129.914	ClC=C(Cl)Cl	XSTXAVWGXDQKEL-UHFFFAOYSA-N	6575.0		XSTXAVWGXDQKEL
BRD-K46435528-001-04-4	trichloroethylene	Preclinical					1	0.0	MicroSource	1301056	TRICHLOROETHYLENE	129.914	ClC=C(Cl)Cl	XSTXAVWGXDQKEL-UHFFFAOYSA-N	6575.0		XSTXAVWGXDQKEL
BRD-K68202742-001-16-5	trichostatin-a	Phase 1	HDAC inhibitor	HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9			0	98.67	Selleck	S1045	Trichostatin A (TSA)	302.163	C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	RTKIYFITIVXBLE-QEQCGCAPSA-N	444732.0		RTKIYFITIVXBLE
BRD-K68202742-001-13-2	trichostatin-a	Phase 1	HDAC inhibitor	HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9			0	74.83	Selleck	S1045	Trichostatin A (TSA)	302.163	C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	RTKIYFITIVXBLE-QEQCGCAPSA-N	444732.0		RTKIYFITIVXBLE
BRD-K80431395-001-04-0	triciribine	Phase 1/Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	73.08	Tocris	2151	API-2	320.123	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	HOGVTUZUJGHKPL-HTVVRFAVSA-N	65399.0		HOGVTUZUJGHKPL
BRD-K80431395-001-12-9	triciribine	Phase 1/Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	95.13	Tocris	2151	API-2	320.123	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	HOGVTUZUJGHKPL-HTVVRFAVSA-N	65399.0		HOGVTUZUJGHKPL
BRD-K80431395-001-08-1	triciribine	Phase 1/Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	95.07	Tocris	2151	API-2	320.123	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	HOGVTUZUJGHKPL-HTVVRFAVSA-N	65399.0		HOGVTUZUJGHKPL
BRD-K80431395-001-09-9	triciribine	Phase 1/Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	82.54	Selleck	S1117	Triciribine	320.123	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	HOGVTUZUJGHKPL-HTVVRFAVSA-N	65399.0	BRD-K85975921-001-01-0	HOGVTUZUJGHKPL
BRD-K80431395-001-07-3	triciribine	Phase 1/Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	93.15	Selleck	S1117	Triciribine (Triciribine phosphate)	320.123	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	HOGVTUZUJGHKPL-HTVVRFAVSA-N	65399.0		HOGVTUZUJGHKPL
BRD-K00004666-001-01-9	triciribine-phosphate	Phase 1/Phase 2	AKT inhibitor				0	95.69	Adooq	A11033	VQD-002,TCN-P	400.09	Cn1nc(N)c2cn([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)c3ncnc1c23	URLYINUFLXOMHP-HTVVRFAVSA-N	43860.0		URLYINUFLXOMHP
BRD-K81916719-001-15-9	triclabendazole	Launched	microtubule inhibitor	DNMT1	infectious disease	tapeworm	0	97.28	MedChemEx	HY-B0621	Triclabendazole	357.95	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	NQPDXQQQCQDHHW-UHFFFAOYSA-N	50248.0		NQPDXQQQCQDHHW
BRD-K81916719-001-14-7	triclabendazole	Launched	microtubule inhibitor	DNMT1	infectious disease	tapeworm	0	94.89	MicroSource	1505786	TRICLABENDAZOLE	357.95	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	NQPDXQQQCQDHHW-UHFFFAOYSA-N	50248.0		NQPDXQQQCQDHHW
BRD-K81916719-001-13-9	triclabendazole	Launched	microtubule inhibitor	DNMT1	infectious disease	tapeworm	0	98.03	Selleck	S4114	Triclabendazole	357.95	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	NQPDXQQQCQDHHW-UHFFFAOYSA-N	50248.0		NQPDXQQQCQDHHW
BRD-K25029121-001-07-9	triclocarban	Launched	other antibiotic		infectious disease	first-aid antiseptic	0	96.34	MedChemEx	HY-B1805	Triclocarban	313.978	Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	ICUTUKXCWQYESQ-UHFFFAOYSA-N	7547.0		ICUTUKXCWQYESQ
BRD-K25029121-001-05-8	triclocarban	Launched	other antibiotic		infectious disease	first-aid antiseptic	0	97.9	ChemDiv	8003-0506		313.978	Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	ICUTUKXCWQYESQ-UHFFFAOYSA-N	7547.0		ICUTUKXCWQYESQ
BRD-K41731458-001-15-1	triclosan	Launched	antibacterial agent	DNMT1	infectious disease	first-aid antiseptic	0	99.42	MicroSource	1505465	TRICLOSAN	287.951	Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl	XEFQLINVKFYRCS-UHFFFAOYSA-N	5564.0		XEFQLINVKFYRCS
BRD-A22152765-003-10-0	tridihexethyl	Launched	acetylcholine receptor antagonist		gastroenterology|ophthalmology	peptic ulcer disease (PUD)|nystagmus	0	94.0	Prestwick	Prestw-1042	Tridihexethyl chloride	318.28	CC[N+](CC)(CC)CC[C@@](O)(C1CCCCC1)c1ccccc1 |&1:9|	NPRHVSBSZMAEIN-NRFANRHFSA-N	6604470.0		NPRHVSBSZMAEIN
BRD-K37111771-300-02-6	trientine	Launched	chelating agent	CA14	metabolism	Wilson's disease	0	100.0	MicroSource	1505675	TRIENTINE HYDROCHLORIDE	146.153	NCCNCCNCCN	VILCJCGEZXAXTO-UHFFFAOYSA-N	5565.0		VILCJCGEZXAXTO
BRD-K37111771-001-09-9	trientine	Launched	chelating agent	CA14	metabolism	Wilson's disease	0	100.0	Sigma	MFCD00008169	Triethylenetetramine	146.153	NCCNCCNCCN	VILCJCGEZXAXTO-UHFFFAOYSA-N	5565.0		VILCJCGEZXAXTO
BRD-K00005342-001-01-9	trifloxystrobin	Preclinical	mitochondrial electron transport inhibitor				0	97.32	MedChemEx	HY-123230	Trifloxystrobin	408.13	CO\N=C(\C(=O)OC)c1ccccc1CO\N=C(/C)c1cccc(c1)C(F)(F)F	ONCZDRURRATYFI-TVJDWZFNSA-N	11664966.0		ONCZDRURRATYFI
BRD-K89732114-300-20-9	trifluoperazine	Launched	dopamine receptor antagonist	ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1	neurology/psychiatry	schizophrenia	0	94.55	MedChemEx	HY-B0532A	Trifluoperazine (dihydrochloride)	407.164	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	ZEWQUBUPAILYHI-UHFFFAOYSA-N	5566.0		ZEWQUBUPAILYHI
BRD-K89732114-300-15-4	trifluoperazine	Launched	dopamine receptor antagonist	ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1	neurology/psychiatry	schizophrenia	0	96.64	Selleck	S3201	Trifluoperazine 2HCl	407.164	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	ZEWQUBUPAILYHI-UHFFFAOYSA-N	5566.0		ZEWQUBUPAILYHI
BRD-K89732114-300-14-7	trifluoperazine	Launched	dopamine receptor antagonist	ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1	neurology/psychiatry	schizophrenia	0	93.65	MicroSource	1500591	TRIFLUOPERAZINE HYDROCHLORIDE	407.164	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	ZEWQUBUPAILYHI-UHFFFAOYSA-N	5566.0		ZEWQUBUPAILYHI
BRD-K89732114-300-13-9	trifluoperazine	Launched	dopamine receptor antagonist	ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1	neurology/psychiatry	schizophrenia	0	80.96	Selleck	S3201	Trifluoperazine 2HCl	407.164	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	ZEWQUBUPAILYHI-UHFFFAOYSA-N	5566.0		ZEWQUBUPAILYHI
BRD-K63675182-003-25-9	triflupromazine	Launched	dopamine receptor antagonist	CHRM1|CHRM2|DRD1|DRD2|HTR2B	neurology/psychiatry|gastroenterology	psychosis|nausea|vomiting	0	97.93	MedChemEx	HY-B0909	Triflupromazine (hydrochloride)	352.122	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	XSCGXQMFQXDFCW-UHFFFAOYSA-N	5568.0		XSCGXQMFQXDFCW
BRD-K63675182-003-23-6	triflupromazine	Launched	dopamine receptor antagonist	CHRM1|CHRM2|DRD1|DRD2|HTR2B	neurology/psychiatry|gastroenterology	psychosis|nausea|vomiting	0	96.33	MicroSource	1503118	TRIFLUPROMAZINE HYDROCHLORIDE	352.122	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	XSCGXQMFQXDFCW-UHFFFAOYSA-N	5568.0		XSCGXQMFQXDFCW
BRD-K63675182-003-22-8	triflupromazine	Launched	dopamine receptor antagonist	CHRM1|CHRM2|DRD1|DRD2|HTR2B	neurology/psychiatry|gastroenterology	psychosis|nausea|vomiting	0	94.76	Selleck	S4372	Triflupromazine HCl	352.122	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	XSCGXQMFQXDFCW-UHFFFAOYSA-N	5568.0		XSCGXQMFQXDFCW
BRD-K03243820-001-24-6	trifluridine	Launched	DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	0	90.75	Tocris	4460	Trifluorothymidine	296.062	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	VSQQQLOSPVPRAZ-RRKCRQDMSA-N	6256.0	BRD-A64485570-001-12-8	VSQQQLOSPVPRAZ
BRD-K03243820-001-25-3	trifluridine	Launched	DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	0	96.52	MicroSource	1504183	TRIFLURIDINE	296.062	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	VSQQQLOSPVPRAZ-RRKCRQDMSA-N	6256.0	BRD-A64485570-001-11-0	VSQQQLOSPVPRAZ
BRD-K03243820-001-23-8	trifluridine	Launched	DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	0	95.32	Selleck	S1778	Trifluridine (Viroptic)	296.062	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	VSQQQLOSPVPRAZ-RRKCRQDMSA-N	6256.0		VSQQQLOSPVPRAZ
BRD-K03243820-001-22-0	trifluridine	Launched	DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor	TYMS	infectious disease	virus herpes simplex (HSV)	0	88.53	Selleck	S1778	Trifluridine	296.062	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	VSQQQLOSPVPRAZ-RRKCRQDMSA-N	6256.0		VSQQQLOSPVPRAZ
BRD-K71696703-001-08-7	triflusal	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	NFKB1|NOS2|PDE10A|PTGS1	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)	0	0.0	MedChemEx	HY-B0531	2-(acetyloxy)-4-(trifluoromethyl)benzoic acid	248.03	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	RMWVZGDJPAKBDE-UHFFFAOYSA-N	9458.0		RMWVZGDJPAKBDE
BRD-K71696703-001-11-1	triflusal	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	NFKB1|NOS2|PDE10A|PTGS1	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)	0	86.04	MedChemEx	HY-B0531	Triflusal	248.03	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	RMWVZGDJPAKBDE-UHFFFAOYSA-N	9458.0		RMWVZGDJPAKBDE
BRD-K71696703-001-07-9	triflusal	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	NFKB1|NOS2|PDE10A|PTGS1	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)	0	94.75	Selleck	S3200	Triflusal	248.03	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	RMWVZGDJPAKBDE-UHFFFAOYSA-N	9458.0		RMWVZGDJPAKBDE
BRD-K71696703-001-09-5	triflusal	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	NFKB1|NOS2|PDE10A|PTGS1	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)	0	0.0	MedChemEx	HY-B0531	Triflusal	248.03	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	RMWVZGDJPAKBDE-UHFFFAOYSA-N	9458.0		RMWVZGDJPAKBDE
BRD-K71696703-001-06-1	triflusal	Launched	cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor	NFKB1|NOS2|PDE10A|PTGS1	neurology/psychiatry|cardiology	stroke|myocardial infarction|atrial fibrillation (AF)	0	0.0	Selleck	S3200	Triflusal	248.03	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	RMWVZGDJPAKBDE-UHFFFAOYSA-N	9458.0		RMWVZGDJPAKBDE
BRD-K69231085-003-05-7	trigonelline	Phase 1					0	100.0	Enzo	NP322	Trigonelline HCl	138.056	C[n+]1cccc(c1)C(O)=O	WWNNZCOKKKDOPX-UHFFFAOYSA-O	5571.0		WWNNZCOKKKDOPX
BRD-K00003691-003-01-9	trihexyphenidyl	Launched	acetylcholine receptor antagonist	CHRM1	neurology/psychiatry	parkinsonism	0	93.48	MedChemEx	HY-B1277	Trihexyphenidyl (hydrochloride)	301.241	O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|	HWHLPVGTWGOCJO-HXUWFJFHSA-N	207845.0		HWHLPVGTWGOCJO
BRD-K00003412-300-01-9	trilaciclib	Phase 2	CDK inhibitor				0	86.11	MedChemEx	HY-101467A	Trilaciclib hydrochloride	446.254	CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1	PDGKHKMBHVFCMG-UHFFFAOYSA-N	68029831.0		PDGKHKMBHVFCMG
BRD-A04497688-001-05-9	trilostane	Launched	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor		endocrinology	Cushing's syndrome	0	87.59	MicroSource	1504566	TRILOSTANE	329.199	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|	RLQVKDVIBJCQGE-PORJLZOZSA-N	5311487.0	BRD-A99644790-001-02-4	RLQVKDVIBJCQGE
BRD-A04497688-001-03-4	trilostane	Launched	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor		endocrinology	Cushing's syndrome	0	99.44	MedChemEx	HY-14281	Trilostane	329.199	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|	RLQVKDVIBJCQGE-PORJLZOZSA-N	5311487.0		RLQVKDVIBJCQGE
BRD-A04497688-001-04-2	trilostane	Launched	3beta-hydroxy-delta5-steroid dehydrogenase inhibitor		endocrinology	Cushing's syndrome	0	94.4	Selleck	S1404	Trilostane	329.199	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1,4,5,8,10,15,19,22,&1:13|	RLQVKDVIBJCQGE-PORJLZOZSA-N	5311487.0	BRD-A66155091-001-01-8	RLQVKDVIBJCQGE
BRD-K36851334-001-12-1	TRIM	Preclinical					0	0.0	Tocris	919	TRIM	212.056	FC(F)(F)c1ccccc1-n1ccnc1	WZBWBNCQUTXYEL-UHFFFAOYSA-N	1359.0		WZBWBNCQUTXYEL
BRD-K00003635-050-01-9	trimebutine	Launched	opioid receptor agonist	OPRD1|OPRK1|OPRM1	gastroenterology	irritable bowel syndrome	0	96.27	MedChemEx	HY-B0380A	Trimebutine (maleate)	387.205	CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|	LORDFXWUHHSAQU-JOCHJYFZSA-N	13248159.0		LORDFXWUHHSAQU
BRD-K88366685-300-07-9	trimetazidine	Launched	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	0	98.63	MedChemEx	HY-B0968	Trimetazidine (dihydrochloride)	266.163	COc1ccc(CN2CCNCC2)c(OC)c1OC	UHWVSEOVJBQKBE-UHFFFAOYSA-N	21109.0		UHWVSEOVJBQKBE
BRD-K88366685-300-06-0	trimetazidine	Launched	3-ketoacyl CoA thiolase inhibitor	ACAA2	cardiology	angina pectoris	0	93.14	MicroSource	1506088	TRIMETAZIDINE DIHYDROCHLORIDE	266.163	COc1ccc(CN2CCNCC2)c(OC)c1OC	UHWVSEOVJBQKBE-UHFFFAOYSA-N	21109.0		UHWVSEOVJBQKBE
BRD-K16606819-001-10-1	trimethadione	Launched	oxazolidine antiepileptic	CACNA1G|CACNA1H|CACNA1I	neurology/psychiatry	seizures	0	12.34	MicroSource	1505466	TRIMETHADIONE	143.058	CN1C(=O)OC(C)(C)C1=O	IRYJRGCIQBGHIV-UHFFFAOYSA-N	5576.0		IRYJRGCIQBGHIV
BRD-K16606819-001-13-5	trimethadione	Launched	oxazolidine antiepileptic	CACNA1G|CACNA1H|CACNA1I	neurology/psychiatry	seizures	0	0.0	MedChemEx	HY-A0092	Trimethadione	143.058	CN1C(=O)OC(C)(C)C1=O	IRYJRGCIQBGHIV-UHFFFAOYSA-N	5576.0		IRYJRGCIQBGHIV
BRD-K16606819-001-11-9	trimethadione	Launched	oxazolidine antiepileptic	CACNA1G|CACNA1H|CACNA1I	neurology/psychiatry	seizures	0	0.0	Sigma	MFCD00047084	3,5,5-trimethyl-1,3-oxazolidine-2,4-dione	143.058	CN1C(=O)OC(C)(C)C1=O	IRYJRGCIQBGHIV-UHFFFAOYSA-N	5576.0		IRYJRGCIQBGHIV
BRD-K16606819-001-12-7	trimethadione	Launched	oxazolidine antiepileptic	CACNA1G|CACNA1H|CACNA1I	neurology/psychiatry	seizures	0	0.0	MedChemEx	HY-A0092	Trimethadione	143.058	CN1C(=O)OC(C)(C)C1=O	IRYJRGCIQBGHIV-UHFFFAOYSA-N	5576.0		IRYJRGCIQBGHIV
BRD-K34415467-003-13-0	trimethobenzamide	Launched	histamine receptor antagonist	DRD2	gastroenterology	vomiting|nausea|gastroenteritis	0	98.53	MicroSource	1500594	TRIMETHOBENZAMIDE HYDROCHLORIDE	388.2	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	FEZBIKUBAYAZIU-UHFFFAOYSA-N	5577.0		FEZBIKUBAYAZIU
BRD-K34415467-003-14-8	trimethobenzamide	Launched	histamine receptor antagonist	DRD2	gastroenterology	vomiting|nausea|gastroenteritis	0	99.34	CombiBlocks	QW-6647	Trimethobenzamide hydrochloride	388.2	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	FEZBIKUBAYAZIU-UHFFFAOYSA-N	5577.0		FEZBIKUBAYAZIU
BRD-K07208025-001-31-3	trimethoprim	Launched	dihydrofolate reductase inhibitor	DHFR|TYMS	infectious disease|gastroenterology	urinary tract infections|ear infections|diarrhea	0	98.65	MicroSource	1500595	TRIMETHOPRIM	290.138	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	IEDVJHCEMCRBQM-UHFFFAOYSA-N	5578.0		IEDVJHCEMCRBQM
BRD-K07208025-001-29-7	trimethoprim	Launched	dihydrofolate reductase inhibitor	DHFR|TYMS	infectious disease|gastroenterology	urinary tract infections|ear infections|diarrhea	0	98.69	Selleck	S3129	Trimethoprim	290.138	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	IEDVJHCEMCRBQM-UHFFFAOYSA-N	5578.0		IEDVJHCEMCRBQM
BRD-A56241705-003-01-2	trimethoquinol	Launched	adrenergic receptor antagonist	ADRB2|ADRB3	pulmonary	asthma	0	85.22	Sigma	PH013924	1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydro-6,7-isoquinolinediol hydrochloride	345.158	COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|	RGVPOXRFEPSFGH-CQSZACIVSA-N	12224034.0		RGVPOXRFEPSFGH
BRD-K24483849-001-01-8	trimethylolpropane-triacrylate	Preclinical					0	75.72	Sigma	MFCD00008628	2,2-bis[(acryloyloxy)methyl]butyl acrylate	296.126	CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C	DAKWPKUUDNSNPN-UHFFFAOYSA-N	27423.0		DAKWPKUUDNSNPN
BRD-K53220666-001-02-6	trimetozine	Launched	sedative		neurology/psychiatry	sedative	0	99.51	MicroSource	1504214	TRIMETOZINE	281.126	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	XWVOEFLBOSSYGM-UHFFFAOYSA-N	12478.0		XWVOEFLBOSSYGM
BRD-K53220666-001-03-9	trimetozine	Launched	sedative		neurology/psychiatry	sedative	0	95.43	Sigma	MFCD00023351	4-(3,4,5-TRIMETHOXYBENZOYL)-MORPHOLINE	281.126	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	XWVOEFLBOSSYGM-UHFFFAOYSA-N	12478.0		XWVOEFLBOSSYGM
BRD-K13642819-001-02-9	trimetrexate	Phase 3	dihydrofolate reductase inhibitor	DHFR			0	97.2	MedChemEx	HY-10373	Trimetrexate	369.18	COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC	NOYPYLRCIDNJJB-UHFFFAOYSA-N	5583.0		NOYPYLRCIDNJJB
BRD-K01825162-050-02-9	trimipramine	Launched	norepinephrine reputake inhibitor|tricyclic antidepressant	SLC6A2|SLC6A3|SLC6A4	neurology/psychiatry	depression	0	95.57	MedChemEx	HY-B1213	Trimipramine (maleate)	294.21	C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|	ZSCDBOWYZJWBIY-INIZCTEOSA-N	6604024.0		ZSCDBOWYZJWBIY
BRD-K54790157-001-16-9	trioxsalen	Launched	DNA synthesis inhibitor		dermatology	vitiligo|eczema	0	95.43	MedChemEx	HY-B1157	Trioxsalen	228.079	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	FMHHVULEAZTJMA-UHFFFAOYSA-N	5585.0		FMHHVULEAZTJMA
BRD-K54790157-001-15-5	trioxsalen	Launched	DNA synthesis inhibitor		dermatology	vitiligo|eczema	0	97.99	MicroSource	1500596	TRIOXSALEN	228.079	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	FMHHVULEAZTJMA-UHFFFAOYSA-N	5585.0		FMHHVULEAZTJMA
BRD-K57033106-048-04-4	tripelennamine	Launched	histamine receptor antagonist	HRH1	pulmonary|allergy	asthma|allergic rhinitis|urticaria	0	96.05	MicroSource	1500597	TRIPELENNAMINE CITRATE	255.174	CN(C)CCN(Cc1ccccc1)c1ccccn1	UFLGIAIHIAPJJC-UHFFFAOYSA-N	5587.0		UFLGIAIHIAPJJC
BRD-K57033106-003-19-7	tripelennamine	Launched	histamine receptor antagonist	HRH1	pulmonary|allergy	asthma|allergic rhinitis|urticaria	0	96.93	Selleck	S3146	Tripelennamine HCl	255.174	CN(C)CCN(Cc1ccccc1)c1ccccn1	UFLGIAIHIAPJJC-UHFFFAOYSA-N	5587.0		UFLGIAIHIAPJJC
BRD-K57033106-003-20-9	tripelennamine	Launched	histamine receptor antagonist	HRH1	pulmonary|allergy	asthma|allergic rhinitis|urticaria	0	92.02	MedChemEx	HY-17428	Tripelennamine (hydrochloride)	255.174	CN(C)CCN(Cc1ccccc1)c1ccccn1	UFLGIAIHIAPJJC-UHFFFAOYSA-N	5587.0		UFLGIAIHIAPJJC
BRD-K11742128-003-23-4	triprolidine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	98.84	MicroSource	1500598	TRIPROLIDINE HYDROCHLORIDE	278.178	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	CBEQULMOCCWAQT-WOJGMQOQSA-N	5282443.0		CBEQULMOCCWAQT
BRD-K11742128-003-22-6	triprolidine	Launched	histamine receptor antagonist	HRH1	allergy	allergic rhinitis	0	95.08	Tocris	662	trans-Triprolidine hydrochloride	278.178	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	CBEQULMOCCWAQT-WOJGMQOQSA-N	5282443.0		CBEQULMOCCWAQT
BRD-K19427720-001-01-6	triptan	Phase 1	serotonin receptor agonist	HTR1B|HTR1D			0	0.0	Sigma	92340	2,2,3-trimethylbutane	100.125	CC(C)C(C)(C)C	ZISSAWUMDACLOM-UHFFFAOYSA-N	10044.0		ZISSAWUMDACLOM
BRD-K39484304-001-14-0	triptolide	Phase 3	RNA polymerase inhibitor	RELA			0	90.44	Tocris	3253	Triptolide	360.157	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|	DFBIRQPKNDILPW-CIVMWXNOSA-N	107985.0		DFBIRQPKNDILPW
BRD-K39484304-001-16-5	triptolide	Phase 3	RNA polymerase inhibitor	RELA			0	97.24	Selleck	S3604	Triptolide (PG490)	360.157	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|	DFBIRQPKNDILPW-CIVMWXNOSA-N	107985.0	BRD-K81258678-001-01-0	DFBIRQPKNDILPW
BRD-K39484304-001-11-6	triptolide	Phase 3	RNA polymerase inhibitor	RELA			0	98.14	Selleck	S3604	Triptolide	360.157	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|	InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1	107985.0		DFBIRQPKNDILPW
BRD-K62685538-001-01-7	triptorelin	Launched	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology|endocrinology|obstetrics/gynecology	prostate cancer|breast cancer|precocious puberty|endometriosis|myoma|gender dysphoria	0	93.55	Enzo	DL310	Triptorelin acetate	1310.631	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	VXKHXGOKWPXYNA-PGBVPBMZSA-N	25074470.0		VXKHXGOKWPXYNA
BRD-K62685538-001-02-9	triptorelin	Launched	gonadotropin releasing factor hormone receptor agonist	GNRHR	oncology|endocrinology|obstetrics/gynecology	prostate cancer|breast cancer|precocious puberty|endometriosis|myoma|gender dysphoria	0	96.28	MedChemEx	HY-12551	Luteinizing hormone-releasing factor	1310.631	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	VXKHXGOKWPXYNA-PGBVPBMZSA-N	25074470.0		VXKHXGOKWPXYNA
BRD-K76375510-237-01-1	troclosene	Launched					0	0.0	MicroSource	1506193	TROCLOSENE POTASSIUM	196.939	Cln1c(=O)[nH]c(=O)n(Cl)c1=O	CEJLBZWIKQJOAT-UHFFFAOYSA-N	16726.0		CEJLBZWIKQJOAT
BRD-K76375510-001-02-9	troclosene	Launched					0	0.0	Sigma	MFCD20529107	1,3-dichloro-6-hydroxy-1,3,5-triazine-2,4(1H,3H)-dione	196.939	Cln1c(=O)[nH]c(=O)n(Cl)c1=O	CEJLBZWIKQJOAT-UHFFFAOYSA-N	16726.0		CEJLBZWIKQJOAT
BRD-K00003124-389-01-9	trodusquemine	Phase 1	tyrosine phosphatase inhibitor				0	95.5	MedChemEx	HY-12219A	MSI-1436 lactate	684.522	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	WUJVPODXELZABP-FWJXURDUSA-N	9917968.0		WUJVPODXELZABP
BRD-K83502127-001-01-6	trofinetide	Phase 2	cytokine production inhibitor	IFNG|IL6|TNF			0	44.1	Sigma	MFCD00144405	(2S)-2-({[(2S)-1-(aminoacetyl)-2-pyrrolidinyl]carbonyl}amino)pentanedioic acid	301.127	NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O	JJGBXTYGTKWGAT-YUMQZZPRSA-N	3080768.0		JJGBXTYGTKWGAT
BRD-A91386192-001-07-9	trofosfamide	Launched	DNA alkylating agent		oncology	medulloblastoma	0	0.0	Sigma	MFCD00866435	N,N,3-tris(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide	322.017	ClCCN(CCCl)[P@@]1(=O)OCCCN1CCCl |&1:7,r|	UMKFEPPTGMDVMI-KRWDZBQOSA-N	9576166.0		UMKFEPPTGMDVMI
BRD-A13084692-001-20-7	troglitazone	Withdrawn	insulin sensitizer|PPAR receptor agonist	CYP2C8|PPARG|TRPM3			0	93.99	Tocris	3114	Troglitazone	441.161	Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|	GXPHKUHSUJUWKP-NTKDMRAZSA-N	9824580.0		GXPHKUHSUJUWKP
BRD-A13084692-001-17-3	troglitazone	Withdrawn	insulin sensitizer|PPAR receptor agonist	CYP2C8|PPARG|TRPM3			0	87.12	Enzo	GR210	Troglitazone	441.161	Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6,r|	GXPHKUHSUJUWKP-NTKDMRAZSA-N	9824580.0		GXPHKUHSUJUWKP
BRD-K38310698-001-05-0	troleandomycin	Launched	protein synthesis inhibitor		infectious disease|pulmonary|otolaryngology	pneumonia|bronchitis|tonsillitis|sinusitis	0	92.6	Enzo	BML-EI249-0010	Troleandomycin	813.451	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	LQCLVBQBTUVCEQ-FBZTUZAPSA-N			LQCLVBQBTUVCEQ
BRD-A17846016-001-14-9	trolox	Launched	antioxidant				0	100.0	Tocris	6002	Trolox	250.121	Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|	GLEVLJDDWXEYCO-AWEZNQCLSA-N	688071.0		GLEVLJDDWXEYCO
BRD-A17846016-001-13-9	trolox	Launched	antioxidant				0	76.18	Enzo	FR105	Trolox	250.121	Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6,r|	GLEVLJDDWXEYCO-AWEZNQCLSA-N	688071.0		GLEVLJDDWXEYCO
BRD-K91422571-001-02-9	tromaril	Launched	prostanoid receptor antagonist		ophthalmology	eye inflammation	0	96.68	Enamine	EN300-154627	2-[(2-phenylethyl)amino]benzoic acid	241.11	OC(=O)c1ccccc1NCCc1ccccc1	HLNLBEFKHHCAMV-UHFFFAOYSA-N	31635.0		HLNLBEFKHHCAMV
BRD-K91422571-001-01-8	tromaril	Launched	prostanoid receptor antagonist		ophthalmology	eye inflammation	0	99.33	Enamine	Z381346304		241.11	OC(=O)c1ccccc1NCCc1ccccc1	HLNLBEFKHHCAMV-UHFFFAOYSA-N	31635.0		HLNLBEFKHHCAMV
BRD-K47978074-001-04-9	trometamol	Launched		AMD1|CANT1|DCN|NEIL1|VEGFA			0	100.0	MedChemEx	HY-D0227	Tri(hydroxymethyl)aminomethane	121.074	NC(CO)(CO)CO	LENZDBCJOHFCAS-UHFFFAOYSA-N	6503.0		LENZDBCJOHFCAS
BRD-K47978074-001-03-2	trometamol	Launched		AMD1|CANT1|DCN|NEIL1|VEGFA			0	98.51	MicroSource	1300050	TROMETHAMINE	121.074	NC(CO)(CO)CO	LENZDBCJOHFCAS-UHFFFAOYSA-N	6503.0		LENZDBCJOHFCAS
BRD-K47978074-001-02-4	trometamol	Launched		AMD1|CANT1|DCN|NEIL1|VEGFA			0	100.0	Selleck	S4176	Trometamol	121.074	NC(CO)(CO)CO	LENZDBCJOHFCAS-UHFFFAOYSA-N	6503.0		LENZDBCJOHFCAS
BRD-A84389633-001-05-7	tropanyl-3,5-dimethylbenzoate	Preclinical	serotonin receptor antagonist	HTR3A|HTR3B			0	94.98	Tocris	641	Tropanyl-3,5-dimethylbenzoate	273.173	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2,&2:5,&3:7,r,TLB:0:1:3.4:6.7.8|	HDDNYFLPWFSBLN-ZSHCYNCHSA-N			HDDNYFLPWFSBLN
BRD-A34603619-001-01-9	tropesin	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2			0	99.27	Sigma	MFCD00896425	3-({[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl}oxy)-2-phenylpropanoic acid	505.129	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24,r|	UCCJWNPWWPJKGL-XMMPIXPASA-N	12606305.0		UCCJWNPWWPJKGL
BRD-A79672927-001-22-3	tropicamide	Launched	acetylcholine receptor antagonist	CHRM3|CHRM4	ophthalmology	mydriasis diagnostic|cycloplegia diagnostic	0	93.71	Tocris	909	Tropicamide	284.152	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|	BGDKAVGWHJFAGW-INIZCTEOSA-N	688595.0		BGDKAVGWHJFAGW
BRD-A79672927-001-23-9	tropicamide	Launched	acetylcholine receptor antagonist	CHRM3|CHRM4	ophthalmology	mydriasis diagnostic|cycloplegia diagnostic	0	92.47	Tocris	909	Tropicamide	284.152	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|	BGDKAVGWHJFAGW-INIZCTEOSA-N	688595.0		BGDKAVGWHJFAGW
BRD-A79672927-001-19-9	tropicamide	Launched	acetylcholine receptor antagonist	CHRM3|CHRM4	ophthalmology	mydriasis diagnostic|cycloplegia diagnostic	0	98.11	Tocris	909	Tropicamide	284.152	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|	BGDKAVGWHJFAGW-INIZCTEOSA-N	688595.0		BGDKAVGWHJFAGW
BRD-A79672927-001-20-7	tropicamide	Launched	acetylcholine receptor antagonist	CHRM3|CHRM4	ophthalmology	mydriasis diagnostic|cycloplegia diagnostic	0	99.63	MicroSource	1500599	TROPICAMIDE	284.152	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|	BGDKAVGWHJFAGW-INIZCTEOSA-N	688595.0		BGDKAVGWHJFAGW
BRD-A79672927-001-18-1	tropicamide	Launched	acetylcholine receptor antagonist	CHRM3|CHRM4	ophthalmology	mydriasis diagnostic|cycloplegia diagnostic	0	90.13	Selleck	S1913	Tropicamide	284.152	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12,r|	BGDKAVGWHJFAGW-INIZCTEOSA-N	688595.0		BGDKAVGWHJFAGW
BRD-K00003480-001-01-9	tropifexor	Phase 2	FXR agonist				0	98.24	MedChemEx	HY-107418	Tropifexor	603.145	OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 |TLB:9:13:16.15:19.20.18|	VYLOOGHLKSNNEK-PIIMJCKOSA-N			VYLOOGHLKSNNEK
BRD-K50866992-003-10-3	tropisetron	Launched	serotonin receptor antagonist	GLRA1|GLRA2|GLRB|HTR3A|HTR4	gastroenterology	nausea|vomiting	0	98.27	Selleck	S1898	Tropisetron	284.152	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	ZNRGQMMCGHDTEI-ITGUQSILSA-N		BRD-A79226577-003-19-3	ZNRGQMMCGHDTEI
BRD-K50866992-003-09-5	tropisetron	Launched	serotonin receptor antagonist	GLRA1|GLRA2|GLRB|HTR3A|HTR4	gastroenterology	nausea|vomiting	0	98.6	Tocris	2459	Tropisetron hydrochloride	284.152	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	ZNRGQMMCGHDTEI-ITGUQSILSA-N		BRD-M19407551-300-01-6	ZNRGQMMCGHDTEI
BRD-K50866992-003-11-9	tropisetron	Launched	serotonin receptor antagonist	GLRA1|GLRA2|GLRB|HTR3A|HTR4	gastroenterology	nausea|vomiting	0	97.96	Tocris	2459	Tropisetron hydrochloride	284.152	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	ZNRGQMMCGHDTEI-ITGUQSILSA-N			ZNRGQMMCGHDTEI
BRD-K00003641-003-01-9	trospium	Launched	acetylcholine receptor antagonist	CHRM1	urology	urinary incontinence|urinary frequency	0	89.72	MedChemEx	HY-B0461	Trospium (chloride)	392.223	[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1,4,7|	OYYDSUSKLWTMMQ-JKHIJQBDSA-N			OYYDSUSKLWTMMQ
BRD-K00494077-066-02-7	trovafloxacin	Withdrawn	bacterial DNA gyrase inhibitor	TOP2A			0	94.93	Tocris	3863	Trovafloxacin mesylate	416.11	N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	WVPSKSLAZQPAKQ-CDMJZVDBSA-N			WVPSKSLAZQPAKQ
BRD-K00494077-066-01-9	trovafloxacin	Withdrawn	bacterial DNA gyrase inhibitor	TOP2A			0	97.94	Enzo	AC2304	Trovafloxacin mesylate	416.11	N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	WVPSKSLAZQPAKQ-CDMJZVDBSA-N			WVPSKSLAZQPAKQ
BRD-K00494077-066-03-9	trovafloxacin	Withdrawn	bacterial DNA gyrase inhibitor	TOP2A			0	90.95	Tocris	3863	Trovafloxacin mesylate	416.11	N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	WVPSKSLAZQPAKQ-CDMJZVDBSA-N			WVPSKSLAZQPAKQ
BRD-A35868371-005-01-6	troventol	Phase 1					0	95.22	MatrixSci	59775		332.223	CCC(CO)(C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1 |&1:2,&2:13,&3:10,TLB:7:8:11.12:15|	QFWSRMACUIYPGS-ZVBHREPYSA-N	16007396.0		QFWSRMACUIYPGS
BRD-K00989047-001-01-2	trovirdine	Phase 1	non-nucleoside reverse transcriptase inhibitor				0	96.32	MedChemEx	HY-15349	Trovirdine	336.004	Brc1ccc(NC(=S)NCCc2ccccn2)nc1	HOCFDYZWQYGULA-UHFFFAOYSA-N	3000870.0		HOCFDYZWQYGULA
BRD-K73529671-001-05-9	troxerutin	Launched	antioxidant				0	88.54	MedChemEx	HY-N0139	Troxerutin	742.232	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IYVFNTXFRYQLRP-VVSTWUKXSA-N	5486699.0		IYVFNTXFRYQLRP
BRD-K73529671-001-04-5	troxerutin	Launched	antioxidant				0	90.3	MicroSource	1505245	TROXERUTIN	742.232	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IYVFNTXFRYQLRP-VVSTWUKXSA-N	5486699.0	BRD-A74160776-001-04-4	IYVFNTXFRYQLRP
BRD-K73529671-001-02-9	troxerutin	Launched	antioxidant				0	88.81	Selleck	S2369	Troxerutin	742.232	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IYVFNTXFRYQLRP-VVSTWUKXSA-N	5486699.0		IYVFNTXFRYQLRP
BRD-K73529671-001-03-7	troxerutin	Launched	antioxidant				0	86.51	Selleck	S2369	Troxerutin	742.232	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	IYVFNTXFRYQLRP-VVSTWUKXSA-N	5486699.0	BRD-K03928833-001-01-5	IYVFNTXFRYQLRP
BRD-A68589262-001-04-3	troxipide	Launched	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	0	91.33	Selleck	S4128	Troxipide	294.158	COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|	YSIITVVESCNIPR-NSHDSACASA-N	40467000.0		YSIITVVESCNIPR
BRD-A68589262-001-06-9	troxipide	Launched	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	0	91.95	MedChemEx	HY-B0758	Troxipide	294.158	COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|	YSIITVVESCNIPR-NSHDSACASA-N	40467000.0		YSIITVVESCNIPR
BRD-A68589262-001-05-0	troxipide	Launched	glucosamine synthetase stimulant		gastroenterology	gastroesophageal reflux disease (GERD)	0	90.85	Selleck	S4128	Troxipide	294.158	COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15,r|	YSIITVVESCNIPR-NSHDSACASA-N	40467000.0		YSIITVVESCNIPR
BRD-K35626314-003-01-1	TRV130	Phase 3	opioid receptor agonist	OPRM1			0	90.27	MedChemEx	HY-16655A	TRV130 (hydrochloride)	386.203	COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1	DMNOVGJWPASQDL-OAQYLSRUSA-N	66553195.0		DMNOVGJWPASQDL
BRD-K76973696-001-12-6	tryptanthrin	Preclinical	cyclooxygenase inhibitor	IDO1			0	99.15	Enzo	NP467	Tryptanthrin	248.059	O=C1c2ccccc2-n2c1nc1ccccc1c2=O	VQQVWGVXDIPORV-UHFFFAOYSA-N	73549.0		VQQVWGVXDIPORV
BRD-K76973696-001-14-2	tryptanthrin	Preclinical	cyclooxygenase inhibitor	IDO1			0	93.84	Selleck	S5686	Tryptanthrin	248.059	O=C1c2ccccc2-n2c1nc1ccccc1c2=O	VQQVWGVXDIPORV-UHFFFAOYSA-N	73549.0		VQQVWGVXDIPORV
BRD-K83776863-001-08-9	tryptophan	Launched	serotonin receptor partial agonist	CASR|IDO1|SLC36A1|WARS|WARS2	neurology/psychiatry|gastroenterology	anxiety|bloating|constipation|fatigue|sleeplessness	0	98.59	Sigma	T4196	L-tryptophan	204.09	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	QIVBCDIJIAJPQS-VIFPVBQESA-N	6923516.0		QIVBCDIJIAJPQS
BRD-K83776863-001-05-5	tryptophan	Launched	serotonin receptor partial agonist	CASR|IDO1|SLC36A1|WARS|WARS2	neurology/psychiatry|gastroenterology	anxiety|bloating|constipation|fatigue|sleeplessness	0	0.0	MicroSource	1500600	TRYPTOPHAN (L)	204.09	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	QIVBCDIJIAJPQS-VIFPVBQESA-N	6923516.0		QIVBCDIJIAJPQS
BRD-K00004685-001-01-9	TS-011	Preclinical	delayed vasospasm antagonist				0	85.42	AMS	A729731	3-chloro-4-morpholino-N-(nitrosomethyl)aniline	255.077	[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1	CQMCOBQPZDLWIX-UHFFFAOYSA-N			CQMCOBQPZDLWIX
BRD-K49685476-001-15-9	TTNPB	Phase 1	retinoid receptor agonist	RARA|RARB|RARG			0	91.34	Tocris	761	TTNPB	348.209	C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	FOIVPCKZDPCJJY-JQIJEIRASA-N	5289501.0		FOIVPCKZDPCJJY
BRD-K49685476-001-14-2	TTNPB	Phase 1	retinoid receptor agonist	RARA|RARB|RARG			0	76.41	Selleck	S4627	TTNPB (Arotinoid Acid)	348.209	C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	FOIVPCKZDPCJJY-JQIJEIRASA-N	5289501.0		FOIVPCKZDPCJJY
BRD-K49685476-001-16-7	TTNPB	Phase 1	retinoid receptor agonist	RARA|RARB|RARG			0	84.72	Selleck	S4627	TTNPB	348.209	C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	FOIVPCKZDPCJJY-JQIJEIRASA-N	5289501.0		FOIVPCKZDPCJJY
BRD-K64852730-001-02-9	TTP-22	Preclinical	casein kinase inhibitor	CSNK2A1			0	96.07	Tocris	4432	TTP 22	330.05	Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12	RAOULLCLLOGTDA-UHFFFAOYSA-N	1536915.0		RAOULLCLLOGTDA
BRD-K64852730-001-01-7	TTP-22	Preclinical	casein kinase inhibitor	CSNK2A1			0	98.64	Tocris	4432	TTP 22	330.05	Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12	RAOULLCLLOGTDA-UHFFFAOYSA-N	1536915.0		RAOULLCLLOGTDA
BRD-K44590731-001-02-9	TU-2100	Phase 2					0	93.4	Vitas-M	STK379708	bis[2-(ethoxycarbonyl)phenyl] nonanedioate	484.21	CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	LIBAUACOIKWWKP-UHFFFAOYSA-N	4342838.0		LIBAUACOIKWWKP
BRD-K44590731-001-01-7	TU-2100	Phase 2					0	98.81	Vitas-M	STK379708		484.21	CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	LIBAUACOIKWWKP-UHFFFAOYSA-N	4342838.0		LIBAUACOIKWWKP
BRD-A19958636-065-04-4	tuaminoheptane	Launched			otolaryngology	nasal congestion	0	100.0	MicroSource	1500601	TUAMINOHEPTANE SULFATE	115.136	CCCCC[C@@H](C)N |&1:5|	VSRBKQFNFZQRBM-SSDOTTSWSA-N	6992808.0		VSRBKQFNFZQRBM
BRD-A19958636-001-05-9	tuaminoheptane	Launched			otolaryngology	nasal congestion	0	0.0	MedChemEx	HY-B0952	2-Aminoheptane	115.136	CCCCC[C@@H](C)N |&1:5|	VSRBKQFNFZQRBM-SSDOTTSWSA-N	6992808.0		VSRBKQFNFZQRBM
BRD-K00627859-003-03-7	tubastatin-A	Preclinical	HDAC inhibitor	HDAC6			0	92.67	Selleck	S2627	Tubastatin A HCl	335.163	CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	GOVYBPLHWIEHEJ-UHFFFAOYSA-N	49850262.0		GOVYBPLHWIEHEJ
BRD-K00627859-001-07-2	tubastatin-A	Preclinical	HDAC inhibitor	HDAC6			0	46.55	Selleck	S8049	Tubastatin A	335.163	CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	GOVYBPLHWIEHEJ-UHFFFAOYSA-N	49850262.0		GOVYBPLHWIEHEJ
BRD-K00627859-001-06-4	tubastatin-A	Preclinical	HDAC inhibitor	HDAC6			0	0.32	Selleck	S8049	Tubastatin A	335.163	CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	GOVYBPLHWIEHEJ-UHFFFAOYSA-N	49850262.0		GOVYBPLHWIEHEJ
BRD-K99621550-300-01-8	tubocurarine	Launched	acetylcholine receptor antagonist	ACHE|CHRNA2|HTR3A|HTR3B|KCNN1|KCNN2|KCNN3|ZACN	neurology/psychiatry	anesthetic	0	93.49	MicroSource	1500602	TUBOCURARINE CHLORIDE	609.296	COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4	JFJZZMVDLULRGK-URLMMPGGSA-O	6000.0		JFJZZMVDLULRGK
BRD-K99621550-300-04-9	tubocurarine	Launched	acetylcholine receptor antagonist	ACHE|CHRNA2|HTR3A|HTR3B|KCNN1|KCNN2|KCNN3|ZACN	neurology/psychiatry	anesthetic	0	97.35	Tocris	2820	(+)-Tubocurarine chloride	609.296	COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4	JFJZZMVDLULRGK-URLMMPGGSA-O	6000.0		JFJZZMVDLULRGK
BRD-K26026438-001-01-0	tucatinib	Phase 3	EGFR inhibitor	ERBB2			0	94.53	MedChemEx	HY-16069	Irbinitinib	480.202	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|	SDEAXTCZPQIFQM-UHFFFAOYSA-N	51039094.0		SDEAXTCZPQIFQM
BRD-K95216408-001-02-9	tucidinostat	Phase 3	HDAC inhibitor				0	88.6	MedChemEx	HY-109015	Tucidinostat	390.149	Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	SZMJVTADHFNAIS-BJMVGYQFSA-N	12136798.0		SZMJVTADHFNAIS
BRD-K00003336-001-01-9	tuftsin	Preclinical	macrophage activator				0	95.02	MedChemEx	HY-P0240	Tuftsin	500.307	C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	IESDGNYHXIOKRW-YXMSTPNBSA-N	156080.0		IESDGNYHXIOKRW
BRD-K56086081-001-01-7	TUG-770	Preclinical	free fatty acid receptor agonist	FFAR1			0	96.74	MedChemEx	HY-15697	TUG-770	307.101	OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N	KIZUBVPJNPVIIN-UHFFFAOYSA-N	66553168.0		KIZUBVPJNPVIIN
BRD-K24282351-001-02-9	TUG-891	Preclinical	free fatty acid receptor agonist	FFAR4			0	97.1	Tocris	4601	TUG 891	364.147	Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1	LPGBXHWIQNZEJB-UHFFFAOYSA-N	57522038.0		LPGBXHWIQNZEJB
BRD-K24282351-001-01-4	TUG-891	Preclinical	free fatty acid receptor agonist	FFAR4			0	97.49	Tocris	4601	TUG 891	364.147	Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1	LPGBXHWIQNZEJB-UHFFFAOYSA-N	57522038.0		LPGBXHWIQNZEJB
BRD-K00003719-003-01-9	tulobuterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	asthma	0	91.87	MedChemEx	HY-W011733	Tulobuterol hydrochloride	227.108	CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|	YREYLAVBNPACJM-NSHDSACASA-N	688591.0		YREYLAVBNPACJM
BRD-K00005240-001-01-9	tulrampator	Phase 2	antidepressant 				0	96.55	MedChemEx	HY-109046	Tulrampator	380.128	Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1	JHCFQXNWYDLBOG-UHFFFAOYSA-N	24857397.0		JHCFQXNWYDLBOG
BRD-K28360340-001-08-3	TW-37	Preclinical	BCL inhibitor	BCL2|BCL2L1|MCL1			0	91.58	Selleck	S1121	TW-37	573.219	CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	PQAPVTKIEGUPRN-UHFFFAOYSA-N	11455910.0		PQAPVTKIEGUPRN
BRD-K28360340-001-05-9	TW-37	Preclinical	BCL inhibitor	BCL2|BCL2L1|MCL1			0	41.78	Selleck	S1121	TW-37	573.219	CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	PQAPVTKIEGUPRN-UHFFFAOYSA-N	11455910.0		PQAPVTKIEGUPRN
BRD-K94176593-001-09-4	TWS-119	Preclinical	glycogen synthase kinase inhibitor	GSK3B|JUN|MYC			0	94.08	Selleck	S1590	TWS119	318.112	Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	VPVLEBIVXZSOMQ-UHFFFAOYSA-N	9549289.0		VPVLEBIVXZSOMQ
BRD-K94176593-362-01-7	TWS-119	Preclinical	glycogen synthase kinase inhibitor	GSK3B|JUN|MYC			0	96.31	Tocris	3835	TWS 119	318.112	Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	VPVLEBIVXZSOMQ-UHFFFAOYSA-N	9549289.0		VPVLEBIVXZSOMQ
BRD-K94176593-362-10-9	TWS-119	Preclinical	glycogen synthase kinase inhibitor	GSK3B|JUN|MYC			0	96.85	Tocris	3835	TWS 119	318.112	Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	VPVLEBIVXZSOMQ-UHFFFAOYSA-N	9549289.0		VPVLEBIVXZSOMQ
BRD-K36040345-001-02-9	TXA127	Phase 2	angiotensin receptor agonist				0	96.53	MedChemEx	HY-12403	Angiotensin (1-7)	898.466	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O	PVHLMTREZMEJCG-GDTLVBQBSA-N	46878481.0		PVHLMTREZMEJCG
BRD-K36040345-001-01-1	TXA127	Phase 2	angiotensin receptor agonist				0	81.74	MedChemEx	HY-12403	Angiotensin (1-7)	898.466	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O	PVHLMTREZMEJCG-GDTLVBQBSA-N	46878481.0		PVHLMTREZMEJCG
BRD-K66584608-001-02-1	TY-52156	Preclinical	sphingosine 1-phosphate receptor antagonist	S1PR3			0	33.59	Tocris	5328	TY 52156	363.091	CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1	XONRRGIRSGNWFP-UHFFFAOYSA-N	16046248.0		XONRRGIRSGNWFP
BRD-K66584608-001-03-9	TY-52156	Preclinical	sphingosine 1-phosphate receptor antagonist	S1PR3			0	88.43	MedChemEx	HY-19736	TY-52156	363.091	CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1	XONRRGIRSGNWFP-UHFFFAOYSA-N	16046248.0		XONRRGIRSGNWFP
BRD-K66584608-001-01-3	TY-52156	Preclinical	sphingosine 1-phosphate receptor antagonist	S1PR3			0	78.39	MedChemEx	HY-19736	TY-52156	363.091	CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1	XONRRGIRSGNWFP-UHFFFAOYSA-N	16046248.0		XONRRGIRSGNWFP
BRD-K37753391-046-02-4	tylosin	Launched	protein synthesis inhibitor		infectious disease|gastroenterology	gram-positive bacterial infections|colitis	0	24.27	MicroSource	1505312	TYLOSIN TARTRATE	915.519	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|	WBPYTXDJUQJLPQ-CQICKBAWSA-N	134129704.0		WBPYTXDJUQJLPQ
BRD-K37753391-001-05-9	tylosin	Launched	protein synthesis inhibitor		infectious disease|gastroenterology	gram-positive bacterial infections|colitis	0	100.0	MedChemEx	HY-B0519A	Tylosin	915.519	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|	WBPYTXDJUQJLPQ-CQICKBAWSA-N	134129704.0		WBPYTXDJUQJLPQ
BRD-K37753391-046-03-2	tylosin	Launched	protein synthesis inhibitor		infectious disease|gastroenterology	gram-positive bacterial infections|colitis	0	94.95	Selleck	S3162	Tylosin tartrate	915.519	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46,49|	WBPYTXDJUQJLPQ-CQICKBAWSA-N	134129704.0	BRD-K90749417-046-01-8	WBPYTXDJUQJLPQ
BRD-K64414150-001-01-7	tymazoline	Launched			allergy	allergic rhinitis	0	53.77	Sigma	MFCD00867736	2-[(2-isopropyl-5-methylphenoxy)methyl]-4,5-dihydro-1H-imidazole	232.158	CC(C)c1ccc(C)cc1OCC1=NCCN1 |t:13|	QRORCRWSRPKEHR-UHFFFAOYSA-N	34154.0		QRORCRWSRPKEHR
BRD-K76064317-001-08-1	tyrphostin-AG-1296	Preclinical	FLT3 inhibitor	FLT3			0	99.91	Selleck	S8024	Tyrphostin AG 1296	266.106	COc1cc2ncc(nc2cc1OC)-c1ccccc1	QNOXYUNHIGOWNY-UHFFFAOYSA-N	2049.0		QNOXYUNHIGOWNY
BRD-K76064317-001-07-3	tyrphostin-AG-1296	Preclinical	FLT3 inhibitor	FLT3			0	97.98	Selleck	S8024	Tyrphostin AG 1296	266.106	COc1cc2ncc(nc2cc1OC)-c1ccccc1	QNOXYUNHIGOWNY-UHFFFAOYSA-N	2049.0		QNOXYUNHIGOWNY
BRD-K68336408-001-10-9	tyrphostin-AG-1478	Preclinical	EGFR inhibitor	EGFR|MAPK14			0	98.06	Selleck	S2728	AG-1478 (Tyrphostin AG-1478)	315.077	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	GFNNBHLJANVSQV-UHFFFAOYSA-N	2051.0		GFNNBHLJANVSQV
BRD-K49657628-001-14-8	tyrphostin-AG-18	Preclinical	EGFR inhibitor|tyrosine kinase inhibitor	EGFR			0	79.52	Tocris	493	AG 18	186.043	Oc1ccc(C=C(C#N)C#N)cc1O	VTJXFTPMFYAJJU-UHFFFAOYSA-N	2052.0		VTJXFTPMFYAJJU
BRD-K49657628-001-13-0	tyrphostin-AG-18	Preclinical	EGFR inhibitor|tyrosine kinase inhibitor	EGFR			0	50.16	Selleck	S8009	AG-18	186.043	Oc1ccc(C=C(C#N)C#N)cc1O	VTJXFTPMFYAJJU-UHFFFAOYSA-N	2052.0		VTJXFTPMFYAJJU
BRD-K49657628-001-15-5	tyrphostin-AG-18	Preclinical	EGFR inhibitor|tyrosine kinase inhibitor	EGFR			0	87.88	Selleck	S8009	AG 18 (Tyrphostin 23)	186.043	Oc1ccc(C=C(C#N)C#N)cc1O	VTJXFTPMFYAJJU-UHFFFAOYSA-N	2052.0		VTJXFTPMFYAJJU
BRD-K34533029-001-09-9	tyrphostin-AG-494	Preclinical	EGFR inhibitor	EGFR			0	93.17	Tocris	619	AG 494	280.085	Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O	HKHOVJYOELRGMV-XYOKQWHBSA-N	5328771.0		HKHOVJYOELRGMV
BRD-K34533029-001-08-5	tyrphostin-AG-494	Preclinical	EGFR inhibitor	EGFR			0	92.4	Tocris	619	AG 494	280.085	Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O	HKHOVJYOELRGMV-XYOKQWHBSA-N	5328771.0		HKHOVJYOELRGMV
BRD-K87919739-001-07-5	tyrphostin-AG-825	Preclinical	protein tyrosine kinase inhibitor	ERBB2			0	67.33	Tocris	1555	AG 825	397.055	COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O	KXDONFLNGBQLTN-WUXMJOGZSA-N	6091659.0		KXDONFLNGBQLTN
BRD-K87919739-001-08-9	tyrphostin-AG-825	Preclinical	protein tyrosine kinase inhibitor	ERBB2			0	87.11	Tocris	1555	AG 825	397.055	COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O	KXDONFLNGBQLTN-WUXMJOGZSA-N	6091659.0		KXDONFLNGBQLTN
BRD-K17415526-001-04-9	tyrphostin-AG-835	Preclinical	protein tyrosine kinase inhibitor	EGFR			0	93.62	Tocris	579	Tyrphostin B44, (+) enantiomer	308.116	C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	UMGQVUWXNOJOSJ-DGGAMASNSA-N	5328769.0		UMGQVUWXNOJOSJ
BRD-K17415526-001-03-5	tyrphostin-AG-835	Preclinical	protein tyrosine kinase inhibitor	EGFR			0	93.78	Tocris	579	Tyrphostin B44, (+) enantiomer	308.116	C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	UMGQVUWXNOJOSJ-DGGAMASNSA-N	5328769.0		UMGQVUWXNOJOSJ
BRD-K59469039-001-09-8	tyrphostin-AG-879	Preclinical	tyrosine kinase inhibitor	ERBB2|KDR|NTRK1			0	96.11	Selleck	S2816	Tyrphostin AG 879 (AG 879)	316.161	CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C	XRZYELWZLNAXGE-KPKJPENVSA-N	135419190.0		XRZYELWZLNAXGE
BRD-K59469039-001-08-0	tyrphostin-AG-879	Preclinical	tyrosine kinase inhibitor	ERBB2|KDR|NTRK1			0	91.01	Selleck	S2816	Tyrphostin AG 879	316.161	CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C	XRZYELWZLNAXGE-KPKJPENVSA-N	135419190.0		XRZYELWZLNAXGE
BRD-K60184833-001-06-9	tyrphostin-AG-99	Preclinical	tyrosine kinase inhibitor	EGFR			0	94.33	Tocris	497	AG 99	204.053	NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	USOXQZNJFMKTKJ-XVNBXDOJSA-N	5328768.0		USOXQZNJFMKTKJ
BRD-K60184833-001-05-6	tyrphostin-AG-99	Preclinical	tyrosine kinase inhibitor	EGFR			0	96.88	Tocris	497	AG 99	204.053	NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	USOXQZNJFMKTKJ-XVNBXDOJSA-N	5328768.0		USOXQZNJFMKTKJ
BRD-K40255344-001-17-6	tyrphostin-A9	Preclinical	protein tyrosine kinase inhibitor|tyrosine kinase inhibitor				0	94.87	Selleck	S2895	Tyrphostin 9	282.173	CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	MZOPWQKISXCCTP-UHFFFAOYSA-N	5614.0		MZOPWQKISXCCTP
BRD-K40255344-001-13-5	tyrphostin-A9	Preclinical	protein tyrosine kinase inhibitor|tyrosine kinase inhibitor				0	95.09	Enzo	EI-215	Tyrphostin 9	282.173	CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	InChI=1S/C18H22N2O/c1-17(2,3)14-8-12(7-13(10-19)11-20)9-15(16(14)21)18(4,5)6/h7-9,21H,1-6H3	5614.0		MZOPWQKISXCCTP
BRD-K03635852-001-02-0	U-0124	Preclinical	MEK inhibitor				0	94.09	Tocris	1868	U0124	226.035	CSC(=N)C(C#N)C(C#N)C(=N)SC	GXGXSVFKGDVBMD-UHFFFAOYSA-N	75645652.0		GXGXSVFKGDVBMD
BRD-K03635852-001-03-9	U-0124	Preclinical	MEK inhibitor				0	82.65	Tocris	1868	U0124	226.035	CSC(=N)C(C#N)C(C#N)C(=N)SC	GXGXSVFKGDVBMD-UHFFFAOYSA-N	75645652.0		GXGXSVFKGDVBMD
BRD-K18787491-001-10-2	U-0126	Preclinical	MEK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1			0	93.15	Selleck	S1102	U0126-EtOH	380.088	Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	54539763.0	BRD-M37437038-001-01-8	ZCHZSBUNJOCWCW
BRD-K18787491-001-08-6	U-0126	Preclinical	MEK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1			0	90.68	Tocris	1144	U0126	380.088	Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	54539763.0		ZCHZSBUNJOCWCW
BRD-K18787491-001-14-9	U-0126	Preclinical	MEK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1			0	37.81	Tocris	1144	U0126	380.088	Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	54539763.0		ZCHZSBUNJOCWCW
BRD-K18787491-001-11-0	U-0126	Preclinical	MEK inhibitor	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1			0	60.55	Selleck	S1102	U0126-EtOH	380.088	Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N	ZCHZSBUNJOCWCW-UHFFFAOYSA-N	54539763.0	BRD-M92812175-001-01-7	ZCHZSBUNJOCWCW
BRD-K08953028-001-09-6	U-0521	Preclinical	catechol O methyltransferase inhibitor	COMT			0	98.18	SantaCruz	sc-200745		180.079	CC(C)C(=O)c1ccc(O)c(O)c1	VDQLKIBLTMPAHI-UHFFFAOYSA-N	21632.0		VDQLKIBLTMPAHI
BRD-K77867004-001-04-9	U-104	Phase 1/Phase 2	carbonic anhydrase inhibitor	CA1|CA12|CA2|CA9			0	95.2	Tocris	4540	U 104	309.058	NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	YJQZNWPYLCNRLP-UHFFFAOYSA-N	310360.0		YJQZNWPYLCNRLP
BRD-K77867004-001-02-7	U-104	Phase 1/Phase 2	carbonic anhydrase inhibitor	CA1|CA12|CA2|CA9			0	96.73	Selleck	S2866	U-104	309.058	NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	YJQZNWPYLCNRLP-UHFFFAOYSA-N	310360.0		YJQZNWPYLCNRLP
BRD-K77867004-001-03-5	U-104	Phase 1/Phase 2	carbonic anhydrase inhibitor	CA1|CA12|CA2|CA9			0	96.75	Tocris	4540	U 104	309.058	NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	YJQZNWPYLCNRLP-UHFFFAOYSA-N	310360.0		YJQZNWPYLCNRLP
BRD-K22025381-003-02-9	U-18666A	Preclinical	oxidosqualene cyclase inhibitor				0	95.6	Tocris	1638	U 18666A	387.314	CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|	DMZCCFMMPHJWQY-BKWLFHPQSA-N	9954083.0		DMZCCFMMPHJWQY
BRD-K22025381-003-01-9	U-18666A	Preclinical	oxidosqualene cyclase inhibitor				0	99.54	Tocris	1638	U 18666A	387.314	CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|	DMZCCFMMPHJWQY-BKWLFHPQSA-N	9954083.0		DMZCCFMMPHJWQY
BRD-K53532120-003-10-3	U-50488-(-)	Preclinical	opioid receptor agonist	OPRK1			0	96.56	Tocris	496	(-)-U-50488 hydrochloride	368.142	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	VQLPLYSROCPWFF-ROUUACIJSA-N	6604724.0		VQLPLYSROCPWFF
BRD-K53532120-003-12-9	U-50488-(-)	Preclinical	opioid receptor agonist	OPRK1			0	95.74	Tocris	496	(-)-U-50488 hydrochloride	368.142	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	VQLPLYSROCPWFF-ROUUACIJSA-N	6604724.0		VQLPLYSROCPWFF
BRD-K53532120-003-11-1	U-50488-(-)	Preclinical	opioid receptor agonist	OPRK1			0	97.11	Tocris	495	(?)-U-50488 hydrochloride	368.142	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	VQLPLYSROCPWFF-ROUUACIJSA-N	6604724.0	BRD-M57185017-300-01-9	VQLPLYSROCPWFF
BRD-K53532120-003-09-5	U-50488-(-)	Preclinical	opioid receptor agonist	OPRK1			0	96.86	Tocris	496	(-)-U-50488 hydrochloride	368.142	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	VQLPLYSROCPWFF-ROUUACIJSA-N	6604724.0		VQLPLYSROCPWFF
BRD-K20995441-001-03-9	U-54494A	Preclinical	opioid receptor agonist	OPRK1			0	94.81	Tocris	498	U-54494A hydrochloride	354.127	CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	JUBNVWGVNWIXMB-SJORKVTESA-N	183470.0		JUBNVWGVNWIXMB
BRD-K20995441-001-02-5	U-54494A	Preclinical	opioid receptor agonist	OPRK1			0	96.38	Tocris	498	U-54494A hydrochloride	354.127	CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	JUBNVWGVNWIXMB-SJORKVTESA-N	183470.0		JUBNVWGVNWIXMB
BRD-K77070363-001-01-5	U-75799E	Phase 1	growth hormone releasing factor agonist	GHSR			0	86.33	Adooq	A13464	(2S,5R,8S,11S,14R,17S)-17-amino-2-(4-aminobutyl)-5-benzyl-18-(1H-imidazol-5-yl)-8,14-bis(1H-indol-3-ylmethyl)-11-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaoctadecan-1-amide	872.445	C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	WZHKXNSOCOQYQX-FUAFALNISA-N	9919153.0		WZHKXNSOCOQYQX
BRD-K70281171-050-08-9	U-99194	Preclinical	dopamine receptor antagonist	DRD3			0	94.8	Tocris	1357	U 99194 maleate	277.204	CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1	UOLJKAPABHXFRE-UHFFFAOYSA-N	5626.0		UOLJKAPABHXFRE
BRD-K38966689-300-02-9	UAMC-00039	Preclinical	dipeptidyl peptidase inhibitor	DPP4|DPP7			0	95.29	Tocris	4954	UAMC 00039 dihydrochloride	309.161	N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1	DNVZYSMOLXCOLY-HNNXBMFYSA-N	11232124.0		DNVZYSMOLXCOLY
BRD-K38966689-300-01-5	UAMC-00039	Preclinical	dipeptidyl peptidase inhibitor	DPP4|DPP7			0	84.99	Tocris	4954	UAMC 00039 dihydrochloride	309.161	N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1	DNVZYSMOLXCOLY-HNNXBMFYSA-N	11232124.0		DNVZYSMOLXCOLY
BRD-A14574269-051-03-0	UB-165	Preclinical	acetylcholine receptor agonist	CHRNA3|CHRNA4|CHRNB2			0	90.79	Tocris	1348	2-(6-chloropyridin-3-yl)-9-azabicyclo[4.2.1]non-2-ene fumarate	234.092	Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|	TVSNVPGPFGAKPT-JQWIXIFHSA-N	6604855.0		TVSNVPGPFGAKPT
BRD-A14574269-051-02-2	UB-165	Preclinical	acetylcholine receptor agonist	CHRNA3|CHRNA4|CHRNB2			0	77.62	Tocris	1348	UB 165 fumarate	234.092	Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11,&2:14,t:8,THB:4:7:12.13:15|	TVSNVPGPFGAKPT-JQWIXIFHSA-N	6604855.0		TVSNVPGPFGAKPT
BRD-K59574735-001-13-9	ubenimex	Launched	leukotriene synthesis inhibitor	LTA4H|RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	0	92.27	Tocris	1956	Bestatin	308.174	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	VGGGPCQERPFHOB-RDBSUJKOSA-N	72172.0		VGGGPCQERPFHOB
BRD-K59574735-001-11-8	ubenimex	Launched	leukotriene synthesis inhibitor	LTA4H|RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	0	91.72	Selleck	S1591	Ubenimex (Bestatin)	308.174	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	VGGGPCQERPFHOB-RDBSUJKOSA-N	72172.0		VGGGPCQERPFHOB
BRD-K59574735-001-12-6	ubenimex	Launched	leukotriene synthesis inhibitor	LTA4H|RNPEP	hematologic malignancy	acute myeloid leukemia (AML)	0	84.66	Tocris	1956	Bestatin	308.174	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	VGGGPCQERPFHOB-RDBSUJKOSA-N	72172.0		VGGGPCQERPFHOB
BRD-A45499626-001-04-9	UBP-296	Preclinical	glutamate receptor antagonist	GRIK1			0	95.4	Tocris	2078	UBP 296	333.096	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|	UUIYULWYHDSXHL-NSHDSACASA-N	6420161.0		UUIYULWYHDSXHL
BRD-A45499626-001-03-6	UBP-296	Preclinical	glutamate receptor antagonist	GRIK1			0	76.19	Tocris	2078	UBP 296	333.096	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1,r|	UUIYULWYHDSXHL-NSHDSACASA-N	6420161.0		UUIYULWYHDSXHL
BRD-K79753741-001-02-5	UBP-302	Preclinical	glutamate receptor antagonist	GRIK1			0	62.06	Tocris	2079	UBP 302	333.096	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	UUIYULWYHDSXHL-NSHDSACASA-N	6420161.0		UUIYULWYHDSXHL
BRD-K79753741-001-03-3	UBP-302	Preclinical	glutamate receptor antagonist	GRIK1			0	96.2	Tocris	2079	2-[(3-[(2S)-2-amino-2-carboxyethyl]-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl)methyl]benzoic acid	333.096	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	UUIYULWYHDSXHL-NSHDSACASA-N	6420161.0		UUIYULWYHDSXHL
BRD-K79753741-001-01-7	UBP-302	Preclinical	glutamate receptor antagonist	GRIK1			0	77.8	Tocris	2079	UBP 302	333.096	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	UUIYULWYHDSXHL-NSHDSACASA-N	6420161.0		UUIYULWYHDSXHL
BRD-K09597601-001-01-2	UBP-310	Preclinical	glutamate receptor antagonist	GRIK1|GRIK5			0	66.8	Tocris	3621	UBP 310	353.068	Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O	ZTAZUCRXCRXNSU-VIFPVBQESA-N	6420160.0		ZTAZUCRXCRXNSU
BRD-K09597601-001-02-9	UBP-310	Preclinical	glutamate receptor antagonist	GRIK1|GRIK5			0	92.8	Tocris	3621	UBP 310	353.068	Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O	ZTAZUCRXCRXNSU-VIFPVBQESA-N	6420160.0		ZTAZUCRXCRXNSU
BRD-K73610817-001-10-9	UC-112	Preclinical	XIAP inhibitor	XIAP			0	79.04	Tocris	5251	UC 112	348.184	Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12	LTGLGIQQZXSLLF-UHFFFAOYSA-N	3426979.0		LTGLGIQQZXSLLF
BRD-K73610817-001-09-7	UC-112	Preclinical	XIAP inhibitor	XIAP			0	85.21	Tocris	5251	UC 112	348.184	Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12	LTGLGIQQZXSLLF-UHFFFAOYSA-N	3426979.0		LTGLGIQQZXSLLF
BRD-K50325075-001-03-9	UCL-2077	Preclinical	slow afterhyperpolarization channel blocker				0	91.48	Tocris	2661	UCL 2077	350.178	C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	PQFNWDHABGBCHB-UHFFFAOYSA-N	24868317.0		PQFNWDHABGBCHB
BRD-K50325075-001-02-1	UCL-2077	Preclinical	slow afterhyperpolarization channel blocker				0	99.33	Tocris	2661	UCL 2077	350.178	C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	PQFNWDHABGBCHB-UHFFFAOYSA-N	24868317.0		PQFNWDHABGBCHB
BRD-K50325075-001-04-9	UCL-2077	Preclinical	slow afterhyperpolarization channel blocker				0	97.88	Tocris	2661	UCL 2077	350.178	C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	PQFNWDHABGBCHB-UHFFFAOYSA-N	24868317.0		PQFNWDHABGBCHB
BRD-K00003266-001-01-9	udenafil	Launched	phosphodiesterase inhibitor		urology	erectile dysfunction	0	98.08	MedChemEx	HY-18253	Udenafil	516.252	CCCOc1ccc(cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1)S(=O)(=O)NCC[C@@H]1CCCN1C |&1:30,r|	IYFNEFQTYQPVOC-KRWDZBQOSA-N	135564686.0		IYFNEFQTYQPVOC
BRD-K20480395-001-01-6	UF-010	Preclinical	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC8			0	76.99	Tocris	5588	UF 010	270.037	CCCCNNC(=O)c1ccc(Br)cc1	BVQCFCYPFJOOAV-UHFFFAOYSA-N	4596836.0		BVQCFCYPFJOOAV
BRD-K20480395-001-02-9	UF-010	Preclinical	HDAC inhibitor	HDAC1|HDAC2|HDAC3|HDAC8			0	85.11	Tocris	5588	UF 010	270.037	CCCCNNC(=O)c1ccc(Br)cc1	BVQCFCYPFJOOAV-UHFFFAOYSA-N	4596836.0		BVQCFCYPFJOOAV
BRD-K84173274-001-01-6	ufenamate	Launched	cyclooxygenase inhibitor	PTGS1|PTGS2	dermatology	eczema|dermatitis	0	98.96	AvaChem	3123	butyl 2-[3-(trifluoromethyl)anilino]benzoate	337.129	CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	JDLSRXWHEBFHNC-UHFFFAOYSA-N	5632.0		JDLSRXWHEBFHNC
BRD-K66715657-050-02-9	UH-232-(+)	Preclinical	dopamine receptor antagonist	DRD2|DRD3|DRD4|HTR1A			0	86.89	Tocris	775	(+)-UH 232 maleate	275.225	CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	BTOJYCTUJJHANF-WMLDXEAASA-N	6604756.0		BTOJYCTUJJHANF
BRD-K66715657-050-01-0	UH-232-(+)	Preclinical	dopamine receptor antagonist	DRD2|DRD3|DRD4|HTR1A			0	90.44	Tocris	775	(+)-UH 232 maleate	275.225	CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	BTOJYCTUJJHANF-WMLDXEAASA-N	6604756.0		BTOJYCTUJJHANF
BRD-K57011718-001-02-3	UK-356618	Preclinical	metalloproteinase inhibitor	MMP13|MMP14|MMP2|MMP3|MMP9			0	89.38	Tocris	4187	UK 356618	557.325	C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1	JJHRUUKMPWUYIB-HVOSOHGQSA-N	10370504.0		JJHRUUKMPWUYIB
BRD-K57011718-001-01-5	UK-356618	Preclinical	metalloproteinase inhibitor	MMP13|MMP14|MMP2|MMP3|MMP9			0		Tocris	4187	UK 356618	557.325	C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1	InChI=1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24,28,31,41H,12-13,18,22H2,1-5H3,(H,35,40)(H,36,39)(H,37,38)/t24-,28-,31-/m1/s1	10370504.0		JJHRUUKMPWUYIB
BRD-K06294530-001-03-1	UK-383367	Phase 1	procollagen C-endopeptidase inhibitor	BMP1			0	64.9	Tocris	4188	UK 383367	324.18	NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	ARJCBSRIPGJMAD-LLVKDONJSA-N	9818682.0		ARJCBSRIPGJMAD
BRD-K06294530-001-01-5	UK-383367	Phase 1	procollagen C-endopeptidase inhibitor	BMP1			0	90.91	Selleck	S2224	UK 383367	324.18	NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	ARJCBSRIPGJMAD-LLVKDONJSA-N	9818682.0		ARJCBSRIPGJMAD
BRD-K06294530-001-04-9	UK-383367	Phase 1	procollagen C-endopeptidase inhibitor	BMP1			0	90.13	Tocris	4188	UK 383367	324.18	NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	ARJCBSRIPGJMAD-LLVKDONJSA-N	9818682.0		ARJCBSRIPGJMAD
BRD-K06294530-001-02-3	UK-383367	Phase 1	procollagen C-endopeptidase inhibitor	BMP1			0	95.33	Selleck	S2224	UK 383367	324.18	NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	ARJCBSRIPGJMAD-LLVKDONJSA-N	9818682.0		ARJCBSRIPGJMAD
BRD-K19558579-001-01-0	UK-5099	Preclinical	monocarboxylate transporter inhibitor	SLC16A1			0	90.92	Tocris	4186	UK 5099	288.09	OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N	BIZNHCWFGNKBBZ-JLHYYAGUSA-N	6438504.0		BIZNHCWFGNKBBZ
BRD-K19558579-001-02-9	UK-5099	Preclinical	monocarboxylate transporter inhibitor	SLC16A1			0	95.88	Tocris	4186	UK 5099	288.09	OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N	BIZNHCWFGNKBBZ-JLHYYAGUSA-N	6438504.0		BIZNHCWFGNKBBZ
BRD-K00003367-001-01-9	uki-1	Preclinical	urokinase inhibitor				0	100.0	MedChemEx	HY-100415	UKI-1	613.33	CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(N)=N)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	ISJSHQTWOHGCMM-NDEPHWFRSA-N	9895193.0		ISJSHQTWOHGCMM
BRD-A61633223-001-02-8	ulifloxacin	Launched			infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	79.96	Ark	AK-56509	6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid	349.09	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|	SUXQDLLXIBLQHW-MRVPVSSYSA-N	40490637.0		SUXQDLLXIBLQHW
BRD-A61633223-001-01-0	ulifloxacin	Launched			infectious disease	gram-negative bacterial infections|gram-positive bacterial infections	0	58.82	AKSci	I873		349.09	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1,r|	SUXQDLLXIBLQHW-MRVPVSSYSA-N	40490637.0		SUXQDLLXIBLQHW
BRD-K64381438-001-02-0	ulipristal	Launched	progesterone receptor antagonist	PGR	endocrinology	contraceptive	0	0.0	Selleck	S3081	Ulipristal	475.272	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|	OOLLAFOLCSJHRE-ZHAKMVSLSA-N	130904.0	BRD-K55641198-001-01-0	OOLLAFOLCSJHRE
BRD-K64381438-001-03-8	ulipristal	Launched	progesterone receptor antagonist	PGR	endocrinology	contraceptive	0	91.0	Selleck	S3081	Ulipristal	475.272	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|	OOLLAFOLCSJHRE-ZHAKMVSLSA-N	130904.0	BRD-K76197012-001-01-2	OOLLAFOLCSJHRE
BRD-K64381438-001-04-9	ulipristal	Launched	progesterone receptor antagonist	PGR	endocrinology	contraceptive	0	95.69	MedChemEx	HY-16508	Ulipristal (acetate)	475.272	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29,36|	OOLLAFOLCSJHRE-ZHAKMVSLSA-N	130904.0		OOLLAFOLCSJHRE
BRD-K46692793-004-01-8	umeclidinium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema	0	98.3	MedChemEx	HY-12100	Umeclidinium (bromide)	428.259	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	FVTWTVQXNAJTQP-UHFFFAOYSA-N	11519070.0		FVTWTVQXNAJTQP
BRD-K46692793-004-02-9	umeclidinium	Launched	acetylcholine receptor antagonist	CHRM1|CHRM2|CHRM3	pulmonary	chronic obstructive pulmonary disease (COPD)|bronchitis|emphysema	0	96.71	MedChemEx	HY-12100	Umeclidinium (bromide)	428.259	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	FVTWTVQXNAJTQP-UHFFFAOYSA-N	11519070.0		FVTWTVQXNAJTQP
BRD-K30933884-001-01-0	unbs-5162	Phase 1	CC chemokine receptor antagonist				0	97.44	MedChemEx	HY-16509	UNBS5162	326.138	CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	WCKZRLOUKYFJDY-UHFFFAOYSA-N	16048966.0		WCKZRLOUKYFJDY
BRD-K30933884-001-02-9	unbs-5162	Phase 1	CC chemokine receptor antagonist				0	94.26	MedChemEx	HY-16509	UNBS5162	326.138	CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	WCKZRLOUKYFJDY-UHFFFAOYSA-N	16048966.0		WCKZRLOUKYFJDY
BRD-K77428767-001-01-7	UNC0224	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	93.47	Tocris	3861	UNC0224	485.348	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	XIVUGRBSBIXXJE-UHFFFAOYSA-N	44251522.0		XIVUGRBSBIXXJE
BRD-K77428767-001-02-5	UNC0224	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	77.86	Tocris	3861	UNC 0224	485.348	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	XIVUGRBSBIXXJE-UHFFFAOYSA-N	44251522.0		XIVUGRBSBIXXJE
BRD-K74236984-001-04-8	UNC0321	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	91.24	MedChemEx	HY-10930	UNC0321	515.358	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	AULLUGALUBVBDD-UHFFFAOYSA-N	46901937.0		AULLUGALUBVBDD
BRD-K74236984-001-05-5	UNC0321	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	87.18	MedChemEx	HY-10930	UNC0321	515.358	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	AULLUGALUBVBDD-UHFFFAOYSA-N	46901937.0		AULLUGALUBVBDD
BRD-K13060017-001-01-3	UNC0631	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	96.26	MedChemEx	HY-13808	UNC0631	635.489	COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	XFAXSWXKPQWHDW-UHFFFAOYSA-N	53315868.0		XFAXSWXKPQWHDW
BRD-K13060017-001-02-1	UNC0631	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	93.78	MedChemEx	HY-13808	UNC 0631	635.489	COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	XFAXSWXKPQWHDW-UHFFFAOYSA-N	53315868.0		XFAXSWXKPQWHDW
BRD-K86856088-001-06-9	UNC0638	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	94.36	MedChemEx	HY-15273	UNC0638	509.373	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	QOECJCJVIMVJGX-UHFFFAOYSA-N	46224516.0		QOECJCJVIMVJGX
BRD-K86856088-001-07-7	UNC0638	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	78.85	MedChemEx	HY-15273	UNC0638	509.373	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	QOECJCJVIMVJGX-UHFFFAOYSA-N	46224516.0		QOECJCJVIMVJGX
BRD-K86856088-001-08-5	UNC0638	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	93.3	Tocris	4343	UNC 0638	509.373	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	QOECJCJVIMVJGX-UHFFFAOYSA-N	46224516.0		QOECJCJVIMVJGX
BRD-K60130390-001-02-1	UNC0642	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	97.06	MedChemEx	HY-13980	UNC0642	546.349	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	RNAMYOYQYRYFQY-UHFFFAOYSA-N	53315878.0		RNAMYOYQYRYFQY
BRD-K60130390-001-04-7	UNC0642	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	86.97	Tocris	5132	UNC 0642	546.349	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	RNAMYOYQYRYFQY-UHFFFAOYSA-N	53315878.0		RNAMYOYQYRYFQY
BRD-K60130390-001-03-9	UNC0642	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	92.66	MedChemEx	HY-13980	UNC0642	546.349	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	RNAMYOYQYRYFQY-UHFFFAOYSA-N	53315878.0		RNAMYOYQYRYFQY
BRD-K87465484-001-02-7	UNC0646	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	90.65	MedChemEx	HY-13807	UNC0646	621.473	COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	OUKWLRHRXOPODD-UHFFFAOYSA-N	53315882.0		OUKWLRHRXOPODD
BRD-K87465484-001-04-3	UNC0646	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	76.6	Tocris	4342	UNC 0646	621.473	COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	OUKWLRHRXOPODD-UHFFFAOYSA-N	53315882.0		OUKWLRHRXOPODD
BRD-K87465484-001-03-5	UNC0646	Preclinical	histone lysine methyltransferase inhibitor	EHMT2			0	84.43	MedChemEx	HY-13807	UNC0646	621.473	COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	OUKWLRHRXOPODD-UHFFFAOYSA-N	53315882.0		OUKWLRHRXOPODD
BRD-K02988401-001-01-2	UNC0737	Preclinical	histone lysine methyltransferase inhibitor	EHMT1|EHMT2			0	82.62	SGC	UNC0737	UNC0737	523.389	COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C	ATORKVYCKKBNTF-UHFFFAOYSA-N	52953431.0		ATORKVYCKKBNTF
BRD-K83189926-001-05-9	UNC1215	Preclinical	L3MBTL antagonist	L3MBTL3			0	96.21	Tocris	4666	UNC 1215	529.342	O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	PQOOIERVZAXHBP-UHFFFAOYSA-N	57339144.0		PQOOIERVZAXHBP
BRD-K83189926-001-03-1	UNC1215	Preclinical	L3MBTL antagonist	L3MBTL3			0	78.18	Selleck	S7088	UNC1215	529.342	O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	PQOOIERVZAXHBP-UHFFFAOYSA-N	57339144.0		PQOOIERVZAXHBP
BRD-K83189926-001-04-9	UNC1215	Preclinical	L3MBTL antagonist	L3MBTL3			0	93.94	Selleck	S7088	UNC1215	529.342	O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	PQOOIERVZAXHBP-UHFFFAOYSA-N	57339144.0		PQOOIERVZAXHBP
BRD-K26989966-001-05-0	UNC1999	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	96.39	Tocris	4904	UNC 1999	569.348	CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	DPJNKUOXBZSZAI-UHFFFAOYSA-N	72551585.0		DPJNKUOXBZSZAI
BRD-K26989966-001-04-3	UNC1999	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	86.6	Selleck	S7165	UNC1999	569.348	CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	DPJNKUOXBZSZAI-UHFFFAOYSA-N	72551585.0		DPJNKUOXBZSZAI
BRD-K26989966-001-03-5	UNC1999	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	92.38	Selleck	S7165	UNC1999	569.348	CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	DPJNKUOXBZSZAI-UHFFFAOYSA-N	72551585.0		DPJNKUOXBZSZAI
BRD-K91283740-003-01-6	UNC2025	Preclinical	FLT3 inhibitor|MER tyrosine kinase inhibitor	FLT3|MERTK			0	96.41	MedChemEx	HY-12344A	UNC2025 (hydrochloride)	476.326	CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|	MJSHVHLADKXCML-RQNOJGIXSA-N			MJSHVHLADKXCML
BRD-K01773560-001-01-6	UNC2250	Preclinical	MER tyrosine kinase inhibitor	MERTK			0	93.06	Selleck	S7342	UNC2250	440.29	CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|	HSYSSKFCQHXOBP-MXVIHJGJSA-N			HSYSSKFCQHXOBP
BRD-K01773560-001-02-4	UNC2250	Preclinical	MER tyrosine kinase inhibitor	MERTK			0	95.44	Selleck	S7342	UNC2250	440.29	CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|	HSYSSKFCQHXOBP-MXVIHJGJSA-N			HSYSSKFCQHXOBP
BRD-K01773560-001-03-9	UNC2250	Preclinical	MER tyrosine kinase inhibitor	MERTK			0	92.79	MedChemEx	HY-15797	UNC2250	440.29	CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|	HSYSSKFCQHXOBP-MXVIHJGJSA-N			HSYSSKFCQHXOBP
BRD-K60635008-001-02-9	UNC2327	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT3			0	96.72	Tocris	5057	UNC 2327	319.11	O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1	MYTRGTBDVGKKRO-UHFFFAOYSA-N	71583615.0		MYTRGTBDVGKKRO
BRD-K60635008-001-01-5	UNC2327	Preclinical	protein arginine N-methyltransferase inhibitor	PRMT3			0	97.06	Tocris	5057	UNC 2327	319.11	O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1	MYTRGTBDVGKKRO-UHFFFAOYSA-N	71583615.0		MYTRGTBDVGKKRO
BRD-K46344388-001-02-9	UNC3230	Preclinical	phosphatidyl-inositol activator	PIP5K1C			0	89.8	Tocris	5271	UNC 3230	344.131	NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1	RZCNASHHHSKTGP-UHFFFAOYSA-N	46355372.0		RZCNASHHHSKTGP
BRD-K46344388-001-01-3	UNC3230	Preclinical	phosphatidyl-inositol activator	PIP5K1C			0	96.42	Tocris	5271	UNC 3230	344.131	NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1	RZCNASHHHSKTGP-UHFFFAOYSA-N	46355372.0		RZCNASHHHSKTGP
BRD-K21906513-001-03-2	UNC669	Preclinical	L3MBTL antagonist	L3MBTL1			0	69.7	Selleck	S7373	UNC669	337.079	Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	CQERVFFAOOUFEQ-UHFFFAOYSA-N	46931242.0		CQERVFFAOOUFEQ
BRD-K21906513-001-04-0	UNC669	Preclinical	L3MBTL antagonist	L3MBTL1			0	95.32	Selleck	S7373	UNC669	337.079	Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	CQERVFFAOOUFEQ-UHFFFAOYSA-N	46931242.0		CQERVFFAOOUFEQ
BRD-K21906513-001-05-9	UNC669	Preclinical	L3MBTL antagonist	L3MBTL1			0	91.33	MedChemEx	HY-15839	UNC 669	337.079	Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	CQERVFFAOOUFEQ-UHFFFAOYSA-N	46931242.0		CQERVFFAOOUFEQ
BRD-K22229656-003-02-9	UNC926	Preclinical	MBT inhibitor	L3MBTL1			0	96.06	Tocris	4516	UNC 926 hydrochloride	336.084	Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1	OWGLFIKZKQOYHZ-UHFFFAOYSA-N	61041645.0		OWGLFIKZKQOYHZ
BRD-K22229656-003-01-5	UNC926	Preclinical	MBT inhibitor	L3MBTL1			0	95.92	Tocris	4516	UNC 926 hydrochloride	336.084	Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1	OWGLFIKZKQOYHZ-UHFFFAOYSA-N	61041645.0		OWGLFIKZKQOYHZ
BRD-K19189338-001-03-2	undecylenic-acid	Launched	other antifungal		infectious disease	tinea pedis|tinea corporis	1	25.82	MicroSource	1505468	UNDECYLENIC ACID	184.146	OC(=O)CCCCCCCCC=C	FRPZMMHWLSIFAZ-UHFFFAOYSA-N	5634.0		FRPZMMHWLSIFAZ
BRD-K19189338-001-05-7	undecylenic-acid	Launched	other antifungal		infectious disease	tinea pedis|tinea corporis	1	5.79	MedChemEx	HY-B0914	10-Undecenoic acid	184.146	OC(=O)CCCCCCCCC=C	FRPZMMHWLSIFAZ-UHFFFAOYSA-N	5634.0		FRPZMMHWLSIFAZ
BRD-K00003286-001-01-9	upadacitinib	Launched	JAK inhibitor				0	91.62	MedChemEx	HY-19569	Upadacitinib	380.157	CC[C@@H]1CN(C[C@@H]1c1cnc2cnc3[nH]ccc3n12)C(=O)NCC(F)(F)F	WYQFJHHDOKWSHR-MNOVXSKESA-N	58557659.0		WYQFJHHDOKWSHR
BRD-K00003218-001-01-9	upamostat	Phase 2	serine protease inhibitor				0	42.18	MedChemEx	HY-16511	Upamostat	629.325	CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(=N)NO)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	HUASEDVYRABWCV-NDEPHWFRSA-N	9852201.0		HUASEDVYRABWCV
BRD-K77950083-001-04-1	UPF-1069	Preclinical	PARP inhibitor	PARP2			0	95.76	Tocris	3736	UPF 1069	279.09	O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	JJWMRRNGWSITSQ-UHFFFAOYSA-N	25015515.0		JJWMRRNGWSITSQ
BRD-K77950083-001-03-3	UPF-1069	Preclinical	PARP inhibitor	PARP2			0	97.99	Tocris	3736	UPF 1069	279.09	O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	JJWMRRNGWSITSQ-UHFFFAOYSA-N	25015515.0		JJWMRRNGWSITSQ
BRD-K77950083-001-02-5	UPF-1069	Preclinical	PARP inhibitor	PARP2			0	97.33	Selleck	S8038	UPF 1069	279.09	O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	JJWMRRNGWSITSQ-UHFFFAOYSA-N	25015515.0		JJWMRRNGWSITSQ
BRD-K77950083-001-05-9	UPF-1069	Preclinical	PARP inhibitor	PARP2			0	97.51	Tocris	3736	UPF 1069	279.09	O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	JJWMRRNGWSITSQ-UHFFFAOYSA-N	25015515.0		JJWMRRNGWSITSQ
BRD-K00003526-001-01-9	uprifosbuvir	Preclinical	antiviral				0	87.25	MedChemEx	HY-I0515	Sofosbuvir impurity K	545.133	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1	SFPFZQKYPOWCSI-IQWMDFIBSA-N	117885113.0		SFPFZQKYPOWCSI
BRD-K38332599-001-01-3	uprosertib	Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	87.27	MedChemEx	HY-15965	GSK2141795	428.062	Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	AXTAPYRUEKNRBA-JTQLQIEISA-N	51042438.0		AXTAPYRUEKNRBA
BRD-K38332599-001-02-9	uprosertib	Phase 2	AKT inhibitor	AKT1|AKT2|AKT3			0	87.01	MedChemEx	HY-15965	Uprosertib	428.062	Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	AXTAPYRUEKNRBA-JTQLQIEISA-N	51042438.0		AXTAPYRUEKNRBA
BRD-K80129304-001-10-9	uracil	Launched		DPYD|UCKL1			0	100.0	MedChemEx	HY-I0960	Uracil	112.027	O=c1cc[nH]c(=O)[nH]1	ISAKRJDGNUQOIC-UHFFFAOYSA-N	1174.0		ISAKRJDGNUQOIC
BRD-K80129304-001-09-9	uracil	Launched		DPYD|UCKL1			0	100.0	MicroSource	1502345	URACIL	112.027	O=c1cc[nH]c(=O)[nH]1	ISAKRJDGNUQOIC-UHFFFAOYSA-N	1174.0		ISAKRJDGNUQOIC
BRD-K80129304-001-08-1	uracil	Launched		DPYD|UCKL1			0	100.0	Selleck	S4177	Uracil	112.027	O=c1cc[nH]c(=O)[nH]1	ISAKRJDGNUQOIC-UHFFFAOYSA-N	1174.0		ISAKRJDGNUQOIC
BRD-K10180294-001-07-3	uracil-mustard	Launched	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	0	69.59	MedChemEx	HY-13544	Uramustine	251.023	ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O	IDPUKCWIGUEADI-UHFFFAOYSA-N	6194.0		IDPUKCWIGUEADI
BRD-K10180294-001-04-0	uracil-mustard	Launched	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	0	64.37	Sigma	MFCD00085645	5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione	251.023	ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O	IDPUKCWIGUEADI-UHFFFAOYSA-N	6194.0		IDPUKCWIGUEADI
BRD-K10180294-001-06-5	uracil-mustard	Launched	DNA synthesis inhibitor		hematologic malignancy	non-Hodgkin lymphoma (NHL)	0	57.62	MedChemEx	HY-13544	Uramustine	251.023	ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O	IDPUKCWIGUEADI-UHFFFAOYSA-N	6194.0		IDPUKCWIGUEADI
BRD-K73196317-003-15-5	urapidil	Launched	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	0	94.14	MicroSource	1503100	URAPIDIL HYDROCHLORIDE	387.227	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	ICMGLRUYEQNHPF-UHFFFAOYSA-N	5639.0		ICMGLRUYEQNHPF
BRD-K73196317-003-21-9	urapidil	Launched	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	0	97.84	Tocris	1772	Urapidil hydrochloride	387.227	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	ICMGLRUYEQNHPF-UHFFFAOYSA-N	5639.0		ICMGLRUYEQNHPF
BRD-K73196317-003-13-0	urapidil	Launched	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	0	95.8	Selleck	S2025	Urapidil HCl	387.227	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	ICMGLRUYEQNHPF-UHFFFAOYSA-N	5639.0		ICMGLRUYEQNHPF
BRD-K73196317-003-14-8	urapidil	Launched	adrenergic receptor antagonist	HTR1A	cardiology	hypertension	0	97.01	Tocris	1772	Urapidil hydrochloride	387.227	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	ICMGLRUYEQNHPF-UHFFFAOYSA-N	5639.0		ICMGLRUYEQNHPF
BRD-K92169341-001-14-9	URB597	Phase 1	FAAH inhibitor	FAAH|FAAH2|TRPA1			0	95.44	Tocris	4612	URB 597	338.163	NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	ROFVXGGUISEHAM-UHFFFAOYSA-N	1383884.0		ROFVXGGUISEHAM
BRD-K92169341-001-12-0	URB597	Phase 1	FAAH inhibitor	FAAH|FAAH2|TRPA1			0	69.15	Tocris	4612	URB 597	338.163	NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	ROFVXGGUISEHAM-UHFFFAOYSA-N	1383884.0		ROFVXGGUISEHAM
BRD-K92169341-001-11-2	URB597	Phase 1	FAAH inhibitor	FAAH|FAAH2|TRPA1			0	80.92	Selleck	S2631	URB597	338.163	NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	ROFVXGGUISEHAM-UHFFFAOYSA-N	1383884.0		ROFVXGGUISEHAM
BRD-K92169341-001-10-4	URB597	Phase 1	FAAH inhibitor	FAAH|FAAH2|TRPA1			0	4.07	Selleck	S2631	URB597	338.163	NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	ROFVXGGUISEHAM-UHFFFAOYSA-N	1383884.0		ROFVXGGUISEHAM
BRD-K88052444-001-10-9	urea	Launched	hydroxy radical formation stimulant	ARG1|CA2|CTNNB1	dermatology	psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis	0	100.0	MedChemEx	HY-Y0271	Urea	60.032	NC(N)=O	XSQUKJJJFZCRTK-UHFFFAOYSA-N	1176.0		XSQUKJJJFZCRTK
BRD-K88052444-001-08-8	urea	Launched	hydroxy radical formation stimulant	ARG1|CA2|CTNNB1	dermatology	psoriasis|xerosis cutis|ichthyosis vulgaris|eczema|keratosis|dermatitis	0	100.0	MicroSource	1500604	UREA	60.032	NC(N)=O	XSQUKJJJFZCRTK-UHFFFAOYSA-N	1176.0		XSQUKJJJFZCRTK
BRD-K24297741-001-05-2	urethane	Preclinical	local anesthetic				1	0.0	MicroSource	1503304	URETHANE	89.048	CCOC(N)=O	JOYRKODLDBILNP-UHFFFAOYSA-N	5641.0		JOYRKODLDBILNP
BRD-K24297741-001-07-9	urethane	Preclinical	local anesthetic				1	0.0	MedChemEx	HY-B1207	Urethane	89.048	CCOC(N)=O	JOYRKODLDBILNP-UHFFFAOYSA-N	5641.0		JOYRKODLDBILNP
BRD-K01295354-001-02-8	uric-acid	Phase 3		PYGL			0	100.0	Enamine	Z104473370		168.028	O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	LEHOTFFKMJEONL-UHFFFAOYSA-N	1175.0		LEHOTFFKMJEONL
BRD-K13050303-001-18-1	uridine	Phase 2	dopamine receptor agonist	LSM6|TYMP			0	82.91	Selleck	S2029	Uridine	244.07	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	DRTQHJPVMGBUCF-XVFCMESISA-N	6029.0	BRD-K32566431-001-01-4	DRTQHJPVMGBUCF
BRD-K13050303-001-17-3	uridine	Phase 2	dopamine receptor agonist	LSM6|TYMP			0	97.91	Selleck	S2029	Uridine	244.07	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	DRTQHJPVMGBUCF-XVFCMESISA-N	6029.0		DRTQHJPVMGBUCF
BRD-K18323388-001-01-1	uridine-triacetate	Launched			nephrology	orotic aciduria	0	96.02	Bepharm	B7900		370.101	CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O	AUFUWRKPQLGTGF-FMKGYKFTSA-N	20058.0		AUFUWRKPQLGTGF
BRD-K01825013-385-04-9	uridine-5'-triphosphate	Launched	purinergic receptor activator	P2RY11|P2RY2|P2RY4|P2RY6|UCK2			0	0.0	CombiBlocks	SS-7954		483.969	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1,2,18,19,&1:5,&2:9|	PGAVKCOVUIYSFO-XVFCMESISA-N	6133.0	BRD-K01825013-335-04-9	PGAVKCOVUIYSFO
BRD-K66908976-001-01-8	URMC-099	Preclinical	mixed lineage kinase inhibitor	CDKL2|DAPK3|FLT3|LRRK2|MAP3K10|MAP3K11|MAP3K2|MAP3K9|SRPK2			0	91.98	MedChemEx	HY-12599	URMC-099	421.227	CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1	QKKIWEILHCXECO-UHFFFAOYSA-N	54764565.0		QKKIWEILHCXECO
BRD-K00003383-001-01-9	urolithin-A	Phase 3	antioxidant				0	94.6	MedChemEx	HY-100599	Urolithin A	228.042	Oc1ccc2c(c1)oc(=O)c1cc(O)ccc21	RIUPLDUFZCXCHM-UHFFFAOYSA-N	5488186.0		RIUPLDUFZCXCHM
BRD-K45245728-236-02-9	ursodeoxycholyltaurine	Phase 3	cholesterol inhibitor				0	93.5	MedChemEx	HY-19696A	Tauroursodeoxycholate (Sodium)	499.297	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	BHTRKEVKTKCXOH-LBSADWJPSA-N	9848818.0		BHTRKEVKTKCXOH
BRD-K45245728-335-01-4	ursodeoxycholyltaurine	Phase 3	cholesterol inhibitor				0	100.0	Enzo	AC2330	Tauroursodeoxy cholic acid dihydrate	499.297	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	BHTRKEVKTKCXOH-LBSADWJPSA-N	9848818.0		BHTRKEVKTKCXOH
BRD-K15697815-001-15-4	ursodiol	Launched	nuclear factor erythroid derived|like (NRF2) activator	AKR1C2|NR1H4	gastroenterology	gallstones	0	100.0	MicroSource	1500605	URSODIOL	392.293	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-UZVSRGJWSA-N	31401.0		RUDATBOHQWOJDD
BRD-K15697815-001-16-2	ursodiol	Launched	nuclear factor erythroid derived|like (NRF2) activator	AKR1C2|NR1H4	gastroenterology	gallstones	0	100.0	Selleck	S1643	Ursodiol	392.293	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	RUDATBOHQWOJDD-UZVSRGJWSA-N	31401.0	BRD-K87300616-001-01-9	RUDATBOHQWOJDD
BRD-K68185022-001-12-2	ursolic-acid	Phase 2/Phase 3	ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor	HSD11B1|PLA2G1B|PTPN1|PYGM			0	89.83	Sigma	Y0001523	(3beta,9alpha)-3-hydroxyurs-12-en-28-oic acid	456.36	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	WCGUUGGRBIKTOS-GPOJBZKASA-N	64945.0		WCGUUGGRBIKTOS
BRD-K68185022-001-14-8	ursolic-acid	Phase 2/Phase 3	ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor	HSD11B1|PLA2G1B|PTPN1|PYGM			0	90.07	Selleck	S2370	Ursolic Acid	456.36	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	WCGUUGGRBIKTOS-GPOJBZKASA-N	64945.0	BRD-A61767428-001-01-9	WCGUUGGRBIKTOS
BRD-A99182808-001-05-8	usniacin-(+)	Preclinical	MAP kinase activator	PTPN1			0	76.57	Selleck	S2252	(+)-Usniacin	344.09	CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21,&1:3,t:6|	ZQHDVMCIDXEICF-GOSISDBHSA-N			ZQHDVMCIDXEICF
BRD-A12417644-001-07-6	usniacin-(+)	Preclinical	MAP kinase activator	PTPN1			0	92.95	Selleck	S2252	(+)-Usniacin (D-Usnic acid)	344.09	CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|	ZQHDVMCIDXEICF-SFHVURJKSA-N		BRD-A99182808-001-04-1	ZQHDVMCIDXEICF
BRD-A12417644-001-06-8	usniacin-(+)	Preclinical	MAP kinase activator	PTPN1			0	12.38	Selleck	S2252	(+)-Usniacin	344.09	CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O |a:21,&1:3,t:6|	ZQHDVMCIDXEICF-SFHVURJKSA-N		BRD-A99182808-001-03-3	ZQHDVMCIDXEICF
BRD-K75052463-001-01-4	V-51	Phase 1	adrenergic receptor antagonist				0	98.78	ChemBridge	5259117	1-(4-fluorophenyl)-4-(3,4,5-trimethoxybenzyl)piperazine	360.185	COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC	KKCOGNFFBYOKMA-UHFFFAOYSA-N	1376860.0		KKCOGNFFBYOKMA
BRD-K00003306-001-01-9	vaborbactam	Launched	beta lactamase inhibitor				0	95.26	MedChemEx	HY-19930	Vaborbactam	297.084	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)Cc1cccs1	IOOWNWLVCOUUEX-WPRPVWTQSA-N	56649692.0		IOOWNWLVCOUUEX
BRD-K00003407-001-01-9	vadadustat	Phase 3	hypoxia inducible factor prolyl hydroxylase inhibitor				0	98.2	MedChemEx	HY-101277	Vadadustat	306.041	OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1	JGRXMPYUTJLTKT-UHFFFAOYSA-N	23634441.0		JGRXMPYUTJLTKT
BRD-K00004630-001-01-9	val-tyr	Preclinical	angiotensin converting enzyme inhibitor				0	100.0	Sigma	V5626	(2S)-2-{[(2S)-2-amino-3-methylbutanoyl]amino}-3-(4-hydroxyphenyl)propanoic acid	280.142	CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	VEYJKJORLPYVLO-RYUDHWBXSA-N	7009555.0		VEYJKJORLPYVLO
BRD-K46435977-003-12-9	valaciclovir	Launched	DNA polymerase inhibitor		infectious disease	shingles|virus herpes simplex (HSV)	0	96.9	MicroSource	1505368	VALACYCLOVIR HYDROCHLORIDE	324.155	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O	HDOVUKNUBWVHOX-QMMMGPOBSA-N	135398742.0		HDOVUKNUBWVHOX
BRD-K46435977-003-11-1	valaciclovir	Launched	DNA polymerase inhibitor		infectious disease	shingles|virus herpes simplex (HSV)	0	97.83	Selleck	S1876	Valaciclovir HCl	324.155	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O	HDOVUKNUBWVHOX-QMMMGPOBSA-N	135398742.0		HDOVUKNUBWVHOX
BRD-K46435977-003-13-7	valaciclovir	Launched	DNA polymerase inhibitor		infectious disease	shingles|virus herpes simplex (HSV)	0	91.85	Selleck	S1876	Valaciclovir	324.155	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O	HDOVUKNUBWVHOX-QMMMGPOBSA-N	135398742.0		HDOVUKNUBWVHOX
BRD-K00003233-001-01-9	valbenazine	Launched	vesicular monoamine transporter inhibitor		neurology/psychiatry	dyskinesia	0	88.74	MedChemEx	HY-16771	Valbenazine	418.283	[H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCc1cc(OC)c(OC)cc21	GEJDGVNQKABXKG-CFKGEZKQSA-N	24795069.0		GEJDGVNQKABXKG
BRD-K12994359-001-19-2	valdecoxib	Withdrawn	cyclooxygenase inhibitor	CA12|PTGS2			0	85.93	Tocris	4206	Valdecoxib	314.073	Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1	LNPDTQAFDNKSHK-UHFFFAOYSA-N	119607.0		LNPDTQAFDNKSHK
BRD-K12994359-001-18-4	valdecoxib	Withdrawn	cyclooxygenase inhibitor	CA12|PTGS2			0	98.16	Selleck	S4049	Valdecoxib	314.073	Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1	LNPDTQAFDNKSHK-UHFFFAOYSA-N	119607.0		LNPDTQAFDNKSHK
BRD-A56613951-004-01-1	valethamate	Launched	acetylcholine receptor antagonist	CHRM1|CHRM4|CHRM5	obstetrics/gynecology	labor induction	0	90.39	Sigma	MFCD00031617	N,N-diethyl-N-methyl-2-[(3-methyl-2-phenylpentanoyl)oxy]ethanaminium bromide	306.243	CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2,&2:4|	UPPMZCXMQRVMME-SJLPKXTDSA-N	38989053.0		UPPMZCXMQRVMME
BRD-K01825663-001-01-9	valganciclovir	Launched	DNA synthesis inhibitor		infectious disease	cytomegalovirus (CMV)	0	100.0	Selleck	S4050	Valganciclovir HCl	354.165	CC(C)[C@H](N)C(=O)OC[C@@H](CO)OCn1cnc2c1[nH]c(N)nc2=O |a:3,&1:9|	WPVFJKSGQUFQAP-BDAKNGLRSA-N	135483663.0	BRD-A08013053-003-01-2	WPVFJKSGQUFQAP
BRD-K22938173-003-02-9	valnemulin	Launched	bacterial 50S ribosomal subunit inhibitor		infectious disease|gastroenterology	dysentry|colitis|pneumonia	0	93.2	MedChemEx	HY-B0027	Valnemulin (Hydrochloride)	564.36	CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@@]1(C)[C@H](C)CC3	LLYYNOVSVPBRGV-MVNKZKPCSA-N	9850878.0		LLYYNOVSVPBRGV
BRD-A96644976-001-01-5	valnoctamide	Launched	arachidonic acid acylation inhibitor|benzodiazepine receptor agonist		neurology/psychiatry	sleeplessness	0	61.43	Sigma	V4765	2-ethyl-3-methylpentanamide	143.131	CC[C@@H](C)[C@@H](CC)C(N)=O |&1:2,&2:4,r|	QRCJOCOSPZMDJY-RNFRBKRXSA-N	36689722.0		QRCJOCOSPZMDJY
BRD-K41260949-236-15-0	valproic-acid	Launched	benzodiazepine receptor agonist|HDAC inhibitor	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures|seizures	0	96.04	Selleck	S1168	Valproic acid sodium salt (Sodium valproate)	144.115	CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N	3121.0		NIJJYAXOARWZEE
BRD-K41260949-236-18-4	valproic-acid	Launched	benzodiazepine receptor agonist|HDAC inhibitor	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures|seizures	0	41.51	EMDBio	676380-5GM	Valproic Acid, Sodium Salt	144.115	CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N	3121.0		NIJJYAXOARWZEE
BRD-K41260949-236-17-6	valproic-acid	Launched	benzodiazepine receptor agonist|HDAC inhibitor	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures|seizures	0	31.39	Enzo	550-304	Valproic Acid, Sodium Salt	144.115	CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N	3121.0		NIJJYAXOARWZEE
BRD-K41260949-001-18-2	valproic-acid	Launched	benzodiazepine receptor agonist|HDAC inhibitor	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures|seizures	0	65.88	Sigma	MFCD00002672	2-propylpentanoic acid	144.115	CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N	3121.0		NIJJYAXOARWZEE
BRD-K41260949-236-21-8	valproic-acid	Launched	benzodiazepine receptor agonist|HDAC inhibitor	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures|seizures	0	2.38	Tocris	2815	Valproic acid, sodium salt	144.115	CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N	3121.0		NIJJYAXOARWZEE
BRD-K41260949-236-20-0	valproic-acid	Launched	benzodiazepine receptor agonist|HDAC inhibitor	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures|seizures	0	42.1	Selleck	S1703	Divalproex sodium	144.115	CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N	3121.0	BRD-M19962486-236-03-2	NIJJYAXOARWZEE
BRD-K41260949-236-16-8	valproic-acid	Launched	benzodiazepine receptor agonist|HDAC inhibitor	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures|seizures	0	96.83	MicroSource	1500606	VALPROATE SODIUM	144.115	CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N	3121.0		NIJJYAXOARWZEE
BRD-K41260949-236-19-2	valproic-acid	Launched	benzodiazepine receptor agonist|HDAC inhibitor	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	epilepsy|seizures|seizures	0	23.5	Selleck	S1703	Divalproex Sodium	144.115	CCCC(CCC)C(O)=O	NIJJYAXOARWZEE-UHFFFAOYSA-N	3121.0	BRD-M19962486-236-02-4	NIJJYAXOARWZEE
BRD-K54698528-001-01-2	valpromide	Launched	epoxide hydolase inhibitor		neurology/psychiatry	epilepsy	0	60.96	Sigma	MFCD00051534	2-propylpentanamide	143.131	CCCC(CCC)C(N)=O	OMOMUFTZPTXCHP-UHFFFAOYSA-N	71113.0		OMOMUFTZPTXCHP
BRD-K32804101-001-01-8	valrocemide	Phase 2					0	99.0	Enamine	Z1505862723	N-(2-amino-2-oxoethyl)-2-propylpentanamide	200.152	CCCC(CCC)C(=O)NCC(N)=O	RALGCAOVRLYSMA-UHFFFAOYSA-N	6918293.0		RALGCAOVRLYSMA
BRD-K72951360-001-01-4	valrubicin	Launched	DNA inhibitor|topoisomerase inhibitor	TOP2A	oncology	bladder cancer	0	97.11	MedChemEx	HY-13772	Valrubicin	723.214	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	ZOCKGBMQLCSHFP-KQRAQHLDSA-N	454216.0		ZOCKGBMQLCSHFP
BRD-K72951360-001-02-9	valrubicin	Launched	DNA inhibitor|topoisomerase inhibitor	TOP2A	oncology	bladder cancer	0	91.96	MedChemEx	HY-13772	Valrubicin	723.214	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	ZOCKGBMQLCSHFP-KQRAQHLDSA-N	454216.0		ZOCKGBMQLCSHFP
BRD-K45158365-001-11-4	valsartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure|congestive heart failure	0	99.42	MicroSource	1505209	VALSARTAN	435.227	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	ACWBQPMHZXGDFX-QFIPXVFZSA-N	60846.0		ACWBQPMHZXGDFX
BRD-K45158365-001-12-2	valsartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure|congestive heart failure	0	96.45	Tocris	4216	Valsartan	435.227	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	ACWBQPMHZXGDFX-QFIPXVFZSA-N	60846.0		ACWBQPMHZXGDFX
BRD-K45158365-001-10-6	valsartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure|congestive heart failure	0	98.71	Selleck	S1894	Valsartan	435.227	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	ACWBQPMHZXGDFX-QFIPXVFZSA-N	60846.0		ACWBQPMHZXGDFX
BRD-K45158365-001-13-9	valsartan	Launched	angiotensin receptor antagonist	AGTR1	cardiology	hypertension|congestive heart failure|congestive heart failure	0	97.87	Tocris	4216	Valsartan	435.227	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	ACWBQPMHZXGDFX-QFIPXVFZSA-N	60846.0		ACWBQPMHZXGDFX
BRD-K19412342-001-01-6	valspodar	Phase 3	P glycoprotein inhibitor	ABCB1			0	43.76	MedChemEx	HY-17384	Valspodar	1213.841	C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	YJDYDFNKCBANTM-QCWCSKBGSA-N	5281884.0		YJDYDFNKCBANTM
BRD-K19412342-001-02-4	valspodar	Phase 3	P glycoprotein inhibitor	ABCB1			0	35.79	MedChemEx	HY-17384	Valspodar	1213.841	C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	YJDYDFNKCBANTM-QCWCSKBGSA-N	5281884.0		YJDYDFNKCBANTM
BRD-K91065602-003-08-9	vancomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	0	88.21	Tocris	5506	Vancomycin HCl	1447.43	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	MYPYJXKWCTUITO-LYRMYLQWSA-N	14969.0		MYPYJXKWCTUITO
BRD-K91065602-003-07-9	vancomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	0	71.7	MedChemEx	HY-17362	Vancomycin (hydrochloride)	1447.43	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	MYPYJXKWCTUITO-LYRMYLQWSA-N	14969.0		MYPYJXKWCTUITO
BRD-K91065602-001-01-8	vancomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	0	81.45	MicroSource	1500607	VANCOMYCIN HYDROCHLORIDE	1447.43	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	MYPYJXKWCTUITO-LYRMYLQWSA-N	14969.0		MYPYJXKWCTUITO
BRD-K91065602-003-05-5	vancomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	0	88.61	Selleck	S2575	Vancomycin HCl (Vancocin)	1447.43	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	MYPYJXKWCTUITO-LYRMYLQWSA-N	14969.0	BRD-K60071190-003-01-7	MYPYJXKWCTUITO
BRD-K91065602-003-04-8	vancomycin	Launched	bacterial cell wall synthesis inhibitor		infectious disease	endocarditis	0	70.31	Selleck	S2575	Vancomycin HCl (Vancocin)	1447.43	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	MYPYJXKWCTUITO-LYRMYLQWSA-N	14969.0		MYPYJXKWCTUITO
BRD-K77625799-001-13-9	vandetanib	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA	oncology	medullary thyroid cancer (MTC)	0	98.52	MedChemEx	HY-10260	Vandetanib	474.107	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	UHTHHESEBZOYNR-UHFFFAOYSA-N	3081361.0		UHTHHESEBZOYNR
BRD-K77625799-001-07-7	vandetanib	Launched	EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor	EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA	oncology	medullary thyroid cancer (MTC)	0	97.69	Selleck	S1046	Vandetanib (ZD6474)	474.107	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	UHTHHESEBZOYNR-UHFFFAOYSA-N	3081361.0		UHTHHESEBZOYNR
BRD-K24258499-001-08-9	vanillin	Preclinical		ABAT|ALDH5A1			0	98.63	MedChemEx	HY-N0098	Vanillin	152.047	COc1cc(C=O)ccc1O	MWOOGOJBHIARFG-UHFFFAOYSA-N	1183.0		MWOOGOJBHIARFG
BRD-K24258499-001-05-8	vanillin	Preclinical		ABAT|ALDH5A1			0	93.59	Selleck	S3071	Vanillin	152.047	COc1cc(C=O)ccc1O	MWOOGOJBHIARFG-UHFFFAOYSA-N	1183.0		MWOOGOJBHIARFG
BRD-K33510429-001-03-1	vanillylacetone	Preclinical					0	98.97	Selleck	S2371	Vanillylacetone	194.094	COc1cc(CCC(C)=O)ccc1O	OJYLAHXKWMRDGS-UHFFFAOYSA-N	31211.0		OJYLAHXKWMRDGS
BRD-K33510429-001-02-3	vanillylacetone	Preclinical					0	35.5	Selleck	S2371	Vanillylacetone	194.094	COc1cc(CCC(C)=O)ccc1O	OJYLAHXKWMRDGS-UHFFFAOYSA-N	31211.0		OJYLAHXKWMRDGS
BRD-K00003445-001-01-9	vaniprevir	Phase 3	serine protease inhibitor				0	90.47	MedChemEx	HY-10243	Vaniprevir	757.372	CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1	KUQWGLQLLVFLSM-ONAXAZCASA-N	24765256.0		KUQWGLQLLVFLSM
BRD-K26502378-001-07-9	vanitiolide	Preclinical					0	92.27	MicroSource	1504348	VANITIOLIDE	253.077	COc1cc(ccc1O)C(=S)N1CCOCC1	WQYRHRAZNNRDIA-UHFFFAOYSA-N	72146.0		WQYRHRAZNNRDIA
BRD-K26502378-001-08-9	vanitiolide	Preclinical					0	95.56	Sigma	MFCD00089682	4-(4-HYDROXY-3-METHOXYPHENYLTHIOCARBONYL)MORPHOLINE	253.077	COc1cc(ccc1O)C(=S)N1CCOCC1	WQYRHRAZNNRDIA-UHFFFAOYSA-N	72146.0		WQYRHRAZNNRDIA
BRD-K32501161-300-07-0	vanoxerine	Phase 3	dopamine reuptake inhibitor	SLC6A3			0	96.73	Tocris	421	GBR 12909 dihydrochloride	450.248	Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	NAUWTFJOPJWYOT-UHFFFAOYSA-N	3455.0		NAUWTFJOPJWYOT
BRD-K32501161-300-12-9	vanoxerine	Phase 3	dopamine reuptake inhibitor	SLC6A3			0	95.28	Tocris	421	GBR 12909 dihydrochloride	450.248	Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	NAUWTFJOPJWYOT-UHFFFAOYSA-N	3455.0		NAUWTFJOPJWYOT
BRD-K32501161-300-06-2	vanoxerine	Phase 3	dopamine reuptake inhibitor	SLC6A3			0	96.24	Tocris	421	GBR 12909 dihydrochloride	450.248	Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	NAUWTFJOPJWYOT-UHFFFAOYSA-N	3455.0		NAUWTFJOPJWYOT
BRD-K00004577-001-01-9	vapendavir	Phase 2	antiviral				0	97.98	Astatech	F18154	1,2-BENZISOXAZOLE, 3-ETHOXY-6-[2-[1-(6-METHYL-3-PYRIDAZINYL)-4-PIPERIDINYL]ETHOXY]-	382.2	CCOc1noc2cc(OCCC3CCN(CC3)c3ccc(C)nn3)ccc12	DKSVBVKHUICELN-UHFFFAOYSA-N	504457.0		DKSVBVKHUICELN
BRD-K13926615-003-03-3	vardenafil	Launched	phosphodiesterase inhibitor	PDE5A|PDE6G|PDE6H	urology	erectile dysfunction	0	99.24	MicroSource	1505374	VARDENAFIL HYDROCHLORIDE	488.221	CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	SECKRCOLJRRGGV-UHFFFAOYSA-N	135400189.0		SECKRCOLJRRGGV
BRD-K13926615-003-09-9	vardenafil	Launched	phosphodiesterase inhibitor	PDE5A|PDE6G|PDE6H	urology	erectile dysfunction	0	92.97	MedChemEx	HY-B0442A	Vardenafil (hydrochloride)	488.221	CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	SECKRCOLJRRGGV-UHFFFAOYSA-N	135400189.0		SECKRCOLJRRGGV
BRD-K13926615-394-02-8	vardenafil	Launched	phosphodiesterase inhibitor	PDE5A|PDE6G|PDE6H	urology	erectile dysfunction	0	98.82	Selleck	S2515	Vardenafil HCl Trihydrate	488.221	CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	SECKRCOLJRRGGV-UHFFFAOYSA-N	135400189.0		SECKRCOLJRRGGV
BRD-K18855837-045-02-9	varenicline	Launched	acetylcholine receptor agonist	CHRNA3|CHRNA4|CHRNA6|CHRNA7	neurology/psychiatry	smoking cessation	0	97.1	Tocris	3754	Varenicline tartrate	211.111	C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1,5|	JQSHBVHOMNKWFT-DTORHVGOSA-N	5310966.0		JQSHBVHOMNKWFT
BRD-K09711437-001-04-3	varespladib	Phase 3	secretory phospholipase inhibitor	PLA2G2A			0	98.89	Selleck	S1110	Varespladib (LY315920)	380.137	CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1	BHLXTPHDSZUFHR-UHFFFAOYSA-N	155815.0		BHLXTPHDSZUFHR
BRD-K73028949-001-02-8	vasopressin	Launched	vasopressin receptor agonist	AVPR1A|AVPR1B|AVPR2|OXTR	gastroenterology	abdominal distension	0	85.73	Sigma	MFCD00076738		1083.438	N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	KBZOIRJILGZLEJ-PLCMWKKKSA-N	133698096.0		KBZOIRJILGZLEJ
BRD-K70163715-300-04-0	vatalanib	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	EGFR|FLT1|FLT4|KDR|PDGFRB			0	58.08	Selleck	S1101	Vatalanib (PTK787) 2HCl	346.099	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	YCOYDOIWSSHVCK-UHFFFAOYSA-N	151194.0		YCOYDOIWSSHVCK
BRD-K70163715-036-01-6	vatalanib	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	EGFR|FLT1|FLT4|KDR|PDGFRB			0	99.48	Tocris	5680	Vatalanib succinate	346.099	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	YCOYDOIWSSHVCK-UHFFFAOYSA-N	151194.0		YCOYDOIWSSHVCK
BRD-K70163715-300-05-7	vatalanib	Phase 3	KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor	EGFR|FLT1|FLT4|KDR|PDGFRB			0	88.66	Selleck	S1101	Vatalanib dihydrochloride (PTK787)	346.099	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	YCOYDOIWSSHVCK-UHFFFAOYSA-N	151194.0		YCOYDOIWSSHVCK
BRD-K00003277-003-01-9	vatinoxan	Preclinical	adrenergic receptor antagonist				0	95.42	MedChemEx	HY-19057A	Vatinoxan hydrochloride	418.167	[H][C@@]12C[C@@]3(CNC(=O)N3CCNS(C)(=O)=O)CCN1CCc1c2oc2ccccc12	GTBKISRCRQUFNL-OXJNMPFZSA-N	163952.0		GTBKISRCRQUFNL
BRD-K36338614-001-01-3	VBY-825	Preclinical	cathepsin inhibitor	CTSB|CTSL|CTSS			0	69.77	MedChemEx	HY-15958	VBY-825	535.176	CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1	PPUXXDKQNAHHON-BJLQDIEVSA-N	70945511.0		PPUXXDKQNAHHON
BRD-K36338614-001-02-1	VBY-825	Preclinical	cathepsin inhibitor	CTSB|CTSL|CTSS			0	83.23	MedChemEx	HY-15958	VBY-825	535.176	CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1	PPUXXDKQNAHHON-BJLQDIEVSA-N	70945511.0		PPUXXDKQNAHHON
BRD-K75956464-237-01-5	VCH-916	Phase 1	HCV inhibitor				0	98.31	MedChemEx	HY-13465	VCH-916	459.244	CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|	LNYKGELUODVSNS-YSXIEMCBSA-N			LNYKGELUODVSNS
BRD-K75956464-237-02-9	VCH-916	Phase 1	HCV inhibitor				0	91.97	MedChemEx	HY-13465	VCH-916	459.244	CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r,t:29|	LNYKGELUODVSNS-YSXIEMCBSA-N			LNYKGELUODVSNS
BRD-K26756394-001-04-9	VE-821	Preclinical	ATR kinase inhibitor	ATR			0	94.76	MedChemEx	HY-14731	VE-821	368.094	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	DUIHHZKTCSNTGM-UHFFFAOYSA-N	51000408.0		DUIHHZKTCSNTGM
BRD-K26756394-001-02-2	VE-821	Preclinical	ATR kinase inhibitor	ATR			0	97.3	Selleck	S8007	VE-821	368.094	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	DUIHHZKTCSNTGM-UHFFFAOYSA-N	51000408.0		DUIHHZKTCSNTGM
BRD-K04701033-001-04-7	VE-822	Phase 2	ATR kinase inhibitor	ATM|ATR|MTOR|PIK3CG			0	88.53	MedChemEx	HY-13902	VE-822	463.168	CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	JZCWLJDSIRUGIN-UHFFFAOYSA-N	59472121.0		JZCWLJDSIRUGIN
BRD-K04701033-001-01-3	VE-822	Phase 2	ATR kinase inhibitor	ATM|ATR|MTOR|PIK3CG			0	38.92	Selleck	S7102	VE-822	463.168	CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	JZCWLJDSIRUGIN-UHFFFAOYSA-N	59472121.0		JZCWLJDSIRUGIN
BRD-K04701033-001-03-9	VE-822	Phase 2	ATR kinase inhibitor	ATM|ATR|MTOR|PIK3CG			0	83.19	Selleck	S7102	VE-822	463.168	CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	JZCWLJDSIRUGIN-UHFFFAOYSA-N	59472121.0		JZCWLJDSIRUGIN
BRD-K00003503-001-01-9	vecabrutinib	Phase 1/Phase 2	Bruton's tyrosine kinase (BTK) inhibitor				0	97.63	MedChemEx	HY-109078	Vecabrutinib	529.162	NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(c2)C(F)(F)F)C1=O)c1ncnc(N)c1F	QLRRJMOBVVGXEJ-XHSDSOJGSA-N	72547837.0		QLRRJMOBVVGXEJ
BRD-K20168442-004-08-9	vecuronium	Launched	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	0	100.0	MedChemEx	HY-B0118A	Vecuronium (bromide)	557.432	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	BGSZAXLLHYERSY-XQIGCQGXSA-N	39765.0		BGSZAXLLHYERSY
BRD-K20168442-004-07-1	vecuronium	Launched	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	0	94.79	MicroSource	1505709	VECURONIUM BROMIDE	557.432	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	BGSZAXLLHYERSY-XQIGCQGXSA-N	39765.0	BRD-A82463680-004-02-5	BGSZAXLLHYERSY
BRD-K20168442-004-06-3	vecuronium	Launched	acetylcholine receptor antagonist	CHRNA2	neurology/psychiatry	muscle relaxant	0	96.73	Selleck	S1405	Vecuronium Bromide	557.432	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	BGSZAXLLHYERSY-XQIGCQGXSA-N	39765.0	BRD-K07365190-004-01-7	BGSZAXLLHYERSY
BRD-K00004714-001-01-9	vedaprofen	Launched	anti-inflammatory agent	PTGS2	neurology/psychiatry|endocrinology	pain relief|fever	0	98.74	Sigma	SML1721	2-(4-cyclohexyl-1-naphthyl)propanoic acid	282.162	C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1,r|	VZUGVMQFWFVFBX-ZDUSSCGKSA-N	25271747.0		VZUGVMQFWFVFBX
BRD-K00004580-001-01-9	velaresol	Preclinical					0	0.0	AMS	O33789	velaresol	238.084	OC(=O)CCCCOc1cccc(O)c1C=O	NSUDGNLOXMLAEB-UHFFFAOYSA-N	72162.0		NSUDGNLOXMLAEB
BRD-K00003235-001-01-9	veledimex	Phase 2	cytochrome P450 inhibitor				0	97.45	MedChemEx	HY-16785	Veledimex	438.288	CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C	LZWZPGLVHLSWQX-XMMPIXPASA-N	57751161.0		LZWZPGLVHLSWQX
BRD-K12852738-001-01-2	veliflapon	Phase 3	leukotriene synthesis inhibitor	ALOX5AP			0	99.55	Sigma	SML0411	(2R)-cyclopentyl[4-(2-quinolinylmethoxy)phenyl]ethanoic acid	361.168	OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1	ZEYYDOLCHFETHQ-JOCHJYFZSA-N	123723.0		ZEYYDOLCHFETHQ
BRD-K87142802-001-06-9	veliparib	Phase 3	PARP inhibitor	PARP1|PARP2			0	98.6	MedChemEx	HY-10129	Veliparib	244.132	C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1	JNAHVYVRKWKWKQ-CYBMUJFWSA-N	11960529.0		JNAHVYVRKWKWKQ
BRD-K06357403-001-02-2	velneperit	Phase 2	neuropeptide receptor antagonist	NPY5R			0	78.79	MedChemEx	HY-14423	Velneperit	407.149	CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|	WGEWUYACXPEFPO-AULYBMBSSA-N			WGEWUYACXPEFPO
BRD-K06357403-001-01-4	velneperit	Phase 2	neuropeptide receptor antagonist	NPY5R			0	84.28	MedChemEx	HY-14423	Velneperit	407.149	CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|	WGEWUYACXPEFPO-AULYBMBSSA-N			WGEWUYACXPEFPO
BRD-K00003133-001-01-9	velpatasvir	Launched	antiviral		infectious disease	hepatitis C	0	98.09	MedChemEx	HY-12530	Velpatasvir	882.406	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)c1ccccc1)c1nc(c[nH]1)-c1ccc-2c(COc3cc4c5nc([nH]c5ccc4cc-23)[C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(=O)OC)C(C)C)c1	FHCUMDQMBHQXKK-CDIODLITSA-N	67683363.0		FHCUMDQMBHQXKK
BRD-K56343971-001-14-8	vemurafenib	Launched	RAF inhibitor	BRAF|RAF1	oncology	melanoma	0	98.63	Selleck	S1267	Vemurafenib	489.073	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	GPXBXXGIAQBQNI-UHFFFAOYSA-N	42611257.0		GPXBXXGIAQBQNI
BRD-K56343971-001-12-2	vemurafenib	Launched	RAF inhibitor	BRAF|RAF1	oncology	melanoma	0	98.74	MedChemEx	HY-12057	vemurafinib	489.073	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	GPXBXXGIAQBQNI-UHFFFAOYSA-N	42611257.0		GPXBXXGIAQBQNI
BRD-K56343971-001-10-6	vemurafenib	Launched	RAF inhibitor	BRAF|RAF1	oncology	melanoma	0	95.69	Selleck	S1267	Vemurafenib (PLX4032, RG7204)	489.073	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	GPXBXXGIAQBQNI-UHFFFAOYSA-N	42611257.0		GPXBXXGIAQBQNI
BRD-K62391742-001-08-9	venetoclax	Launched	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	96.96	Selleck	S8048	Venetoclax	867.318	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|	LQBVNQSMGBZMKD-UHFFFAOYSA-N	49846579.0		LQBVNQSMGBZMKD
BRD-K62391742-001-09-7	venetoclax	Launched	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	97.4	Adooq	A12500	2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfon;yl)benzamide	867.318	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|	LQBVNQSMGBZMKD-UHFFFAOYSA-N	49846579.0		LQBVNQSMGBZMKD
BRD-K62391742-001-03-0	venetoclax	Launched	BCL inhibitor	BCL2	hematologic malignancy	chronic lymphocytic leukemia (CLL)	0	95.48	Selleck	S8048	ABT-199 (GDC-0199)	867.318	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|	LQBVNQSMGBZMKD-UHFFFAOYSA-N	49846579.0		LQBVNQSMGBZMKD
BRD-K01826548-003-14-9	venlafaxine	Launched	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder	0	86.09	Tocris	2917	Venlafaxine hydrochloride	313.181	COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|	PNVNVHUZROJLTJ-MRXNPFEDSA-N	11846746.0		PNVNVHUZROJLTJ
BRD-K01826548-003-12-9	venlafaxine	Launched	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder	0	94.66	Selleck	S1441	Venlafaxine	313.181	COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|	PNVNVHUZROJLTJ-MRXNPFEDSA-N	11846746.0		PNVNVHUZROJLTJ
BRD-K01826548-003-13-9	venlafaxine	Launched	adrenergic inhibitor|norepinephrine reuptake inhibitor|serotoninnorepinephrine reuptake inhibitor (SNRI)	SLC6A2|SLC6A4	neurology/psychiatry	depression|generalized anxiety disorder (GAD)|panic disorders|social anxiety disorder	0	96.92	MicroSource	1504171	VENLAFAXINE HYDROCHLORIDE	313.181	COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|	PNVNVHUZROJLTJ-MRXNPFEDSA-N	11846746.0		PNVNVHUZROJLTJ
BRD-K32330832-001-02-8	VER-155008	Preclinical	HSP inhibitor	HSPA1A			0	92.19	Tocris	3803	VER 155008	555.119	Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12	ZXGGCBQORXDVTE-UMCMBGNQSA-N	25195348.0		ZXGGCBQORXDVTE
BRD-K32330832-001-01-0	VER-155008	Preclinical	HSP inhibitor	HSPA1A			0	99.77	WuXi	TH02357-035	VER155008	555.119	Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12	ZXGGCBQORXDVTE-UMCMBGNQSA-N	25195348.0		ZXGGCBQORXDVTE
BRD-K38548312-001-01-0	VER-49009	Preclinical	HSP inhibitor	HSP90AA1			0	98.19	Selleck	S7458	VER-49009	387.099	CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	HUNAOTXNHVALTN-UHFFFAOYSA-N	4369536.0	BRD-K20177260-001-01-0	HUNAOTXNHVALTN
BRD-K38548312-001-02-9	VER-49009	Preclinical	HSP inhibitor	HSP90AA1			0	97.67	MedChemEx	HY-15986	VER-49009	387.099	CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	HUNAOTXNHVALTN-UHFFFAOYSA-N	4369536.0		HUNAOTXNHVALTN
BRD-K00003433-001-01-9	veralipride	Preclinical	dopamine receptor antagonist				0	97.67	MedChemEx	HY-101797	Veralipride	383.151	COc1cc(cc(C(=O)NC[C@@H]2CCCN2CC=C)c1OC)S(N)(=O)=O |&1:11,r|	RYJXBGGBZJGVQF-LBPRGKRZSA-N	989438.0		RYJXBGGBZJGVQF
BRD-A09533288-003-29-6	verapamil	Launched	calcium channel blocker	CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CYP3A4|KCNA10|KCNA7|KCNH2|KCNJ11|NALCN|SCN5A|SLC29A4|SLC6A4	cardiology	hypertension	0	93.02	Selleck	S4202	Verapamil HCl	454.283	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|	SGTNSNPWRIOYBX-UHFFFAOYSA-N	2520.0		SGTNSNPWRIOYBX
BRD-A09533288-003-31-2	verapamil	Launched	calcium channel blocker	CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CYP3A4|KCNA10|KCNA7|KCNH2|KCNJ11|NALCN|SCN5A|SLC29A4|SLC6A4	cardiology	hypertension	0	97.04	MicroSource	2300307	VERAPAMIL HYDROCHLORIDE	454.283	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|	SGTNSNPWRIOYBX-UHFFFAOYSA-N	2520.0		SGTNSNPWRIOYBX
BRD-K36201510-001-06-7	verbascoside	Phase 2/Phase 3	NFkB pathway inhibitor|PKC inhibitor				0	79.95	MedChemEx	HY-N0021	Verbascoside	624.205	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	FBSKJMQYURKNSU-ZLSOWSIRSA-N	5281800.0		FBSKJMQYURKNSU
BRD-K47929404-001-01-0	vercirnon	Phase 3	CC chemokine receptor antagonist	CCR9			0	95.9	MedChemEx	HY-15724	Vercirnon	444.091	CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1	JRWROCIMSDXGOZ-UHFFFAOYSA-N	10343454.0		JRWROCIMSDXGOZ
BRD-K00004674-001-01-9	verdinexor	Preclinical	exportin antagonist				0	95.01	Adooq	A16078	(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin-2-yl)acrylohydrazide	442.098	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2ccccn2)n1	OPAKEJZFFCECPN-XQRVVYSFSA-N	71492799.0		OPAKEJZFFCECPN
BRD-K00004612-001-01-9	verdiperstat	Phase 3	myeloperoxidase inhibitor				0	91.59	MedChemEx	HY-17646	Verdiperstat	253.088	CC(C)OCCn1c2cc[nH]c2c(=O)[nH]c1=S	FVJCUZCRPIMVLB-UHFFFAOYSA-N	11528958.0		FVJCUZCRPIMVLB
BRD-K00003234-001-01-9	vericiguat	Phase 3	guanylate cyclase stimulant				0	96.29	MedChemEx	HY-16774	Vericiguat	426.136	COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncc(F)cc12	QZFHIXARHDBPBY-UHFFFAOYSA-N	54674461.0		QZFHIXARHDBPBY
BRD-K36741660-001-01-1	verinurad	Phase 2	urate transporter inhibitor	SLC22A12			0	98.04	MedChemEx	HY-16733	Verinurad	348.093	CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O	YYBOLPLTQDKXPM-UHFFFAOYSA-N	54767229.0		YYBOLPLTQDKXPM
BRD-K19741547-003-01-7	vernakalant	Launched	potassium channel blocker	KCNA5	cardiology	atrial fibrillation (AF)	0	97.82	MedChemEx	HY-14183	Vernakalant (Hydrochloride)	349.225	COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC	VBHQKCBVWWUUKN-KZNAEPCWSA-N	9930049.0		VBHQKCBVWWUUKN
BRD-K19741547-003-02-9	vernakalant	Launched	potassium channel blocker	KCNA5	cardiology	atrial fibrillation (AF)	0	90.63	MedChemEx	HY-14183	Vernakalant (Hydrochloride)	349.225	COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC	VBHQKCBVWWUUKN-KZNAEPCWSA-N	9930049.0		VBHQKCBVWWUUKN
BRD-K81849500-001-08-9	verteporfin	Launched	photosensitizing agent		ophthalmology	macular degeneration	0	51.2	Tocris	5305	Verteporfin	718.3	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	VLGTZPSSBIXGAI-SUPIZNKRSA-N			VLGTZPSSBIXGAI
BRD-K81849500-001-07-7	verteporfin	Launched	photosensitizing agent		ophthalmology	macular degeneration	0	67.61	MedChemEx	HY-B0146	Verteporfin	718.3	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	VLGTZPSSBIXGAI-SUPIZNKRSA-N			VLGTZPSSBIXGAI
BRD-K81849500-001-06-9	verteporfin	Launched	photosensitizing agent		ophthalmology	macular degeneration	0	48.37	Tocris	5305		718.3	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	VLGTZPSSBIXGAI-SUPIZNKRSA-N			VLGTZPSSBIXGAI
BRD-K81849500-001-02-8	verteporfin	Launched	photosensitizing agent		ophthalmology	macular degeneration	0	69.27	Selleck	S1786	Verteporfin (Visudyne)	718.3	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	VLGTZPSSBIXGAI-SUPIZNKRSA-N			VLGTZPSSBIXGAI
BRD-K81849500-001-05-1	verteporfin	Launched	photosensitizing agent		ophthalmology	macular degeneration	0	50.29	Cayman	17334		718.3	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	VLGTZPSSBIXGAI-SUPIZNKRSA-N			VLGTZPSSBIXGAI
BRD-K81849500-001-01-0	verteporfin	Launched	photosensitizing agent		ophthalmology	macular degeneration	0	18.31	Selleck	S1786	Verteporfin (Visudyne)	718.3	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44,t:42|	VLGTZPSSBIXGAI-SUPIZNKRSA-N			VLGTZPSSBIXGAI
BRD-K00003229-001-01-9	verubecestat	Phase 3	beta secretase inhibitor				0	97.57	MedChemEx	HY-16759	Verubecestat	409.102	CN1C(N)=N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |c:3|	YHYKUSGACIYRML-KRWDZBQOSA-N	51352361.0		YHYKUSGACIYRML
BRD-K42673188-001-01-1	verubulin	Phase 2	tubulin polymerization inhibitor	TUBB			0	99.3	Key	EE-0048	N-(4-methoxyphenyl)-N,2-dimethyl-4-quinazolinamine	279.137	COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12	SNHCRNMVYDHVDT-UHFFFAOYSA-N	11414799.0		SNHCRNMVYDHVDT
BRD-K42673188-003-01-7	verubulin	Phase 2	tubulin polymerization inhibitor	TUBB			0	97.89	Tocris	5231	MPC 6827 hydrochloride	279.137	COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12	SNHCRNMVYDHVDT-UHFFFAOYSA-N	11414799.0		SNHCRNMVYDHVDT
BRD-K00003180-001-01-9	verucerfont	Phase 2	corticotropin releasing factor receptor antagonist				0	99.36	MedChemEx	HY-14875	Verucerfont	406.212	CC[C@H](Nc1cc(C)nc2c(c(C)nn12)-c1ccc(OC)cc1C)c1nc(C)no1	VKHVAUKFLBBZFJ-SFHVURJKSA-N	11596613.0		VKHVAUKFLBBZFJ
BRD-K14765469-003-13-0	vesamicol	Preclinical	acetylcholinesterase inhibitor	SLC18A3			0	93.39	Tocris	653	(+/-)-Vesamicol hydrochloride	259.194	O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	YSSBJODGIYRAMI-IAGOWNOFSA-N	659840.0		YSSBJODGIYRAMI
BRD-K14765469-003-14-9	vesamicol	Preclinical	acetylcholinesterase inhibitor	SLC18A3			0	90.99	Tocris	653	(+/-)-Vesamicol hydrochloride	259.194	O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	YSSBJODGIYRAMI-IAGOWNOFSA-N	659840.0		YSSBJODGIYRAMI
BRD-K14765469-003-12-2	vesamicol	Preclinical	acetylcholinesterase inhibitor	SLC18A3			0	97.14	Tocris	653	(?)-Vesamicol hydrochloride	259.194	O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	YSSBJODGIYRAMI-IAGOWNOFSA-N	659840.0		YSSBJODGIYRAMI
BRD-K13414800-001-01-3	vesnarinone	Launched	phosphodiesterase inhibitor	KCNH2|PDE3A	cardiology	congestive heart failure	0	88.52	MedChemEx	HY-15297	Vesnarinone	395.185	COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1	ZVNYJIZDIRKMBF-UHFFFAOYSA-N	5663.0		ZVNYJIZDIRKMBF
BRD-A32269193-001-02-9	VGX-1027	Phase 1	tumor necrosis factor receptor antagonist	TLR4			0	97.21	MedChemEx	HY-15507	VGX-1027	205.074	OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|	MUFJHYRCIHHATF-SECBINFHSA-N	92981775.0		MUFJHYRCIHHATF
BRD-A32269193-001-01-5	VGX-1027	Phase 1	tumor necrosis factor receptor antagonist	TLR4			0	97.76	Selleck	S7515	VGX-1027	205.074	OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4,r,c:6|	MUFJHYRCIHHATF-SECBINFHSA-N	92981775.0		MUFJHYRCIHHATF
BRD-K84748119-050-03-9	vicriviroc	Phase 3	CC chemokine receptor antagonist	CCR5			0	98.7	MedChemEx	HY-17377	Vicriviroc (maleate)	533.298	COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F	CNPVJJQCETWNEU-CYFREDJKSA-N	3009355.0		CNPVJJQCETWNEU
BRD-K84748119-050-01-1	vicriviroc	Phase 3	CC chemokine receptor antagonist	CCR5			0	97.42	MedChemEx	HY-17377	Vicriviroc (maleate)	533.298	COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F	CNPVJJQCETWNEU-CYFREDJKSA-N	3009355.0		CNPVJJQCETWNEU
BRD-K72093121-001-17-1	vidarabine	Launched	antiviral	ADA	infectious disease	virus herpes simplex (HSV)|varicella-zoster virus (VZV)	0	97.49	MicroSource	1500609	VIDARABINE	267.097	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	OIRDTQYFTABQOQ-UHTZMRCNSA-N	21704.0		OIRDTQYFTABQOQ
BRD-K72093121-001-16-3	vidarabine	Launched	antiviral	ADA	infectious disease	virus herpes simplex (HSV)|varicella-zoster virus (VZV)	0	98.16	Selleck	S1784	Vidarabine	267.097	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	OIRDTQYFTABQOQ-UHTZMRCNSA-N	21704.0		OIRDTQYFTABQOQ
BRD-K01825700-213-01-9	vigabatrin	Launched	GABA aminotransferase inhibitor	ABAT|SLC32A1	neurology/psychiatry	seizures|spasms	0	0.0	MicroSource	1502036	VIGABATRIN	190.132	N[C@@H](CCC(O)=O)C=C |&1:1|	PJDFLNIOAUIZSL-RXMQYKEDSA-N	40466946.0		PJDFLNIOAUIZSL
BRD-K01825700-001-02-9	vigabatrin	Launched	GABA aminotransferase inhibitor	ABAT|SLC32A1	neurology/psychiatry	seizures|spasms	0	0.0	Tocris	808	Vigabatrin	129.079	N[C@@H](CCC(O)=O)C=C |&1:1|	PJDFLNIOAUIZSL-RXMQYKEDSA-N	40466946.0		PJDFLNIOAUIZSL
BRD-M36487418-001-05-5	vilanterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	0	54.71	MedChemEx	HY-14300A	Vilanterol (trifenatate)	773.289	OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl	KLOLZALDXGTNQE-JIDHJSLPSA-N	44482554.0	BRD-M36487418-001-04-8|BRD-M36487418-001-04-8|BRD-M36487418-001-04-8|BRD-M36487418-001-04-8	KLOLZALDXGTNQE
BRD-M36487418-001-03-0	vilanterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	0	0.0	MedChemEx	HY-14300A	Vilanterol (trifenatate)	773.289	OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl	KLOLZALDXGTNQE-JIDHJSLPSA-N	44482554.0		KLOLZALDXGTNQE
BRD-M36487418-001-01-4	vilanterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	0	0.0	MedChemEx	HY-14300A	Vilanterol (trifenatate)	773.289	OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl	KLOLZALDXGTNQE-JIDHJSLPSA-N	44482554.0		KLOLZALDXGTNQE
BRD-M36487418-001-02-2	vilanterol	Launched	adrenergic receptor agonist	ADRB2	pulmonary	chronic obstructive pulmonary disease (COPD)	0	0.0	MedChemEx	HY-14300A	Vilanterol (trifenatate)	773.289	OC(=O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCOCc1c(Cl)cccc1Cl	KLOLZALDXGTNQE-JIDHJSLPSA-N	44482554.0		KLOLZALDXGTNQE
BRD-K58010567-003-02-2	vilazodone	Launched	serotonin reuptake inhibitor	DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4	neurology/psychiatry	depression	0	94.7	MicroSource	1504418	VILAZODONE HYDROCHLORIDE	441.216	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	SGEGOXDYSFKCPT-UHFFFAOYSA-N	6918314.0		SGEGOXDYSFKCPT
BRD-K58010567-003-04-9	vilazodone	Launched	serotonin reuptake inhibitor	DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4	neurology/psychiatry	depression	0	90.8	Tocris	6202	Vilazodone hydrochloride	441.216	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	SGEGOXDYSFKCPT-UHFFFAOYSA-N	6918314.0		SGEGOXDYSFKCPT
BRD-K58010567-003-01-4	vilazodone	Launched	serotonin reuptake inhibitor	DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4	neurology/psychiatry	depression	0	86.87	Selleck	S4259	Vilazodone HCl	441.216	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	SGEGOXDYSFKCPT-UHFFFAOYSA-N	6918314.0		SGEGOXDYSFKCPT
BRD-K58010567-003-03-0	vilazodone	Launched	serotonin reuptake inhibitor	DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4	neurology/psychiatry	depression	0	98.4	Selleck	S4259	Vilazodone Hydrochloride	441.216	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	SGEGOXDYSFKCPT-UHFFFAOYSA-N	6918314.0		SGEGOXDYSFKCPT
BRD-K00003565-001-01-9	vildagliptin	Launched	dipeptidyl peptidase inhibitor	DPP4	endocrinology	diabetes mellitus	0	85.64	MedChemEx	HY-14291	Vildagliptin	303.195	O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N	SYOKIDBDQMKNDQ-NHMCJKAESA-N			SYOKIDBDQMKNDQ
BRD-A59198242-003-03-9	viloxazine	Launched	norepinephrine reuptake inhibitor	SLC6A2	neurology/psychiatry	depression	0	92.59	ChemDiv	ZC03-0028	2-[(2-ethoxyphenoxy)methyl]morpholine	237.136	CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|	YWPHCCPCQOJSGZ-LLVKDONJSA-N	12226596.0		YWPHCCPCQOJSGZ
BRD-A59198242-003-02-9	viloxazine	Launched	norepinephrine reuptake inhibitor	SLC6A2	neurology/psychiatry	depression	0	98.75	Prestwick	Prestw-1361	Viloxazine hydrochloride	237.136	CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|	YWPHCCPCQOJSGZ-LLVKDONJSA-N	12226596.0		YWPHCCPCQOJSGZ
BRD-K06519765-065-01-6	vinblastine	Launched	microtubule inhibitor|tubulin polymerization inhibitor	JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma	0	96.33	MedChemEx	HY-13780	Vinblastine (sulfate)	810.42	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N	13342.0		JXLYSJRDGCGARV
BRD-K06519765-065-02-4	vinblastine	Launched	microtubule inhibitor|tubulin polymerization inhibitor	JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma	0	78.77	MedChemEx	HY-13780	Vinblastine (sulfate)	810.42	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N	13342.0	BRD-K01188359-065-23-1	JXLYSJRDGCGARV
BRD-K06519765-001-03-7	vinblastine	Launched	microtubule inhibitor|tubulin polymerization inhibitor	JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma	0	3.33	MedChemEx	HY-17418	Vinblastine	810.42	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N	13342.0	BRD-K01188359-001-03-8	JXLYSJRDGCGARV
BRD-K06519765-065-04-0	vinblastine	Launched	microtubule inhibitor|tubulin polymerization inhibitor	JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma	0	41.82	MicroSource	1500611	VINBLASTINE SULFATE	810.42	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N	13342.0	BRD-A55594068-065-04-9	JXLYSJRDGCGARV
BRD-K06519765-001-02-9	vinblastine	Launched	microtubule inhibitor|tubulin polymerization inhibitor	JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma	0	16.82	Selleck	S1248	Vinblastine	810.42	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N	13342.0	BRD-K01188359-001-04-6|BRD-A39708826-001-01-0	JXLYSJRDGCGARV
BRD-K06519765-001-01-1	vinblastine	Launched	microtubule inhibitor|tubulin polymerization inhibitor	JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma	0	81.03	Selleck	S1248	Vinblastine	810.42	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N	13342.0	BRD-A66484359-001-01-9	JXLYSJRDGCGARV
BRD-K06519765-065-03-2	vinblastine	Launched	microtubule inhibitor|tubulin polymerization inhibitor	JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1	hematologic malignancy|infectious disease|oncology	Hodgkin's lymphoma|true histiocytic lymphoma (THL)|mycosis|small lymphocytic lymphoma (SLL)|testicular carcinoma|Kaposi sarcoma	0	68.04	Tocris	1256	Vinblastine sulfate	810.42	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	JXLYSJRDGCGARV-CFWMRBGOSA-N	13342.0	BRD-K12515392-065-01-7	JXLYSJRDGCGARV
BRD-K40227168-001-12-9	vinburnine	Launched	adrenergic receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4	neurology/psychiatry	stroke	0	98.61	Enzo	NP088	Eburnamonine, (-)-	294.173	CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	WYJAPUKIYAZSEM-MOPGFXCFSA-N	71203.0		WYJAPUKIYAZSEM
BRD-K40227168-001-13-9	vinburnine	Launched	adrenergic receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4	neurology/psychiatry	stroke	0	89.33	MedChemEx	HY-B1180	Vinburnine	294.173	CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	WYJAPUKIYAZSEM-MOPGFXCFSA-N	71203.0		WYJAPUKIYAZSEM
BRD-K40902647-001-10-9	vincamine	Withdrawn	adrenergic receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4			0	99.37	MedChemEx	HY-B1021	Vincamine	354.194	CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC	RXPRRQLKFXBCSJ-GIVPXCGWSA-N	15376.0		RXPRRQLKFXBCSJ
BRD-K12251893-065-06-2	vincristine	Launched	tubulin polymerization inhibitor	TUBA4A|TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	52.52	MicroSource	1505672	VINCRISTINE SULFATE	824.4	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	OGWKCGZFUXNPDA-CFWMRBGOSA-N	5388993.0	BRD-A60414806-065-02-4	OGWKCGZFUXNPDA
BRD-K12251893-065-01-3	vincristine	Launched	tubulin polymerization inhibitor	TUBA4A|TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	90.52	MedChemEx	HY-N0488	Vincristine (sulfate)	824.4	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	OGWKCGZFUXNPDA-CFWMRBGOSA-N	5388993.0		OGWKCGZFUXNPDA
BRD-K12251893-065-05-4	vincristine	Launched	tubulin polymerization inhibitor	TUBA4A|TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	61.6	Selleck	S1241	Vincristine	824.4	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	OGWKCGZFUXNPDA-CFWMRBGOSA-N	5388993.0	BRD-K98953900-065-01-2	OGWKCGZFUXNPDA
BRD-K12251893-065-02-1	vincristine	Launched	tubulin polymerization inhibitor	TUBA4A|TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	82.69	MedChemEx	HY-N0488	Vincristine (sulfate)	824.4	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	OGWKCGZFUXNPDA-CFWMRBGOSA-N	5388993.0	BRD-K49229349-065-02-4	OGWKCGZFUXNPDA
BRD-K12251893-065-04-7	vincristine	Launched	tubulin polymerization inhibitor	TUBA4A|TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	76.33	Tocris	1257	Vincristine sulfate	824.4	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	OGWKCGZFUXNPDA-CFWMRBGOSA-N	5388993.0	BRD-K49229349-065-01-6	OGWKCGZFUXNPDA
BRD-K12251893-065-03-9	vincristine	Launched	tubulin polymerization inhibitor	TUBA4A|TUBB	hematologic malignancy	acute lymphoblastic leukemia (ALL)	0	77.22	Selleck	S1241	Vincristine Sulfate	824.4	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	OGWKCGZFUXNPDA-CFWMRBGOSA-N	5388993.0	BRD-A60578817-065-01-5	OGWKCGZFUXNPDA
BRD-K59753975-001-02-6	vindesine	Launched	tubulin polymerization inhibitor	TUBB|TUBB1	oncology	breast cancer|non-small cell lung cancer (NSCLC)|melanoma	0	78.54	AvaChem	2181	methyl (5S,7S,9S)-9-((3aR,3a1R,4R,5S,5aR,10bR)-5-carbamoyl-3a-ethyl-4,5-dihydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl)-5-ethyl-5-hydroxy-1,4,5,6,7,8,9;,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]	753.41	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|	HHJUWIANJFBDHT-KOTLKJBCSA-N	40839.0		HHJUWIANJFBDHT
BRD-K64120610-046-01-9	vinflunine	Launched	microtubule inhibitor		oncology	bladder cancer	0	95.03	Selleck	S2209	Vinflunine Tartrate	830.407	CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|	NOSAJPUYIASWEH-USRBKURZSA-N	11967282.0	BRD-A52946717-045-01-7	NOSAJPUYIASWEH
BRD-K64120610-001-01-4	vinflunine	Launched	microtubule inhibitor		oncology	bladder cancer	0	95.66	AvaChem	2180	methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-9-((4R,6R,8S)-4-(1,1-difluoroethyl)-8-(methoxycarbonyl)-1,3,4,5,6,7,8,9-octahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-3a-ethyl-5-hydroxy-8-methoxy-6-methyl-;3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]c	830.407	CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|	NOSAJPUYIASWEH-USRBKURZSA-N	11967282.0	BRD-K10549975-001-01-8	NOSAJPUYIASWEH
BRD-K04269837-346-01-8	vinorelbine	Launched	tubulin polymerization inhibitor	TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	non-small cell lung cancer (NSCLC)	0	24.99	MedChemEx	HY-12053A	Vinorelbine (ditartrate)	778.394	CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|	GBABOYUKABKIAF-IELIFDKJSA-N	5311497.0		GBABOYUKABKIAF
BRD-K04269837-346-03-9	vinorelbine	Launched	tubulin polymerization inhibitor	TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	oncology	non-small cell lung cancer (NSCLC)	0	27.23	MedChemEx	HY-12053A		778.394	CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46,t:2|	GBABOYUKABKIAF-IELIFDKJSA-N	5311497.0		GBABOYUKABKIAF
BRD-K53318339-001-24-9	vinpocetine	Launched	phosphodiesterase inhibitor|sodium channel blocker	PDE1A|PDE1C	neurology/psychiatry	stroke|senile dementia	0	98.68	MicroSource	1503115	VINPOCETINE	350.199	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|	DDNCQMVWWZOMLN-IRLDBZIGSA-N	443955.0		DDNCQMVWWZOMLN
BRD-K53318339-001-27-9	vinpocetine	Launched	phosphodiesterase inhibitor|sodium channel blocker	PDE1A|PDE1C	neurology/psychiatry	stroke|senile dementia	0	95.34	Tocris	757	Vinpocetine	350.199	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|	DDNCQMVWWZOMLN-IRLDBZIGSA-N	443955.0		DDNCQMVWWZOMLN
BRD-K53318339-001-23-1	vinpocetine	Launched	phosphodiesterase inhibitor|sodium channel blocker	PDE1A|PDE1C	neurology/psychiatry	stroke|senile dementia	0	98.62	Tocris	757	Vinpocetine	350.199	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|	DDNCQMVWWZOMLN-IRLDBZIGSA-N	443955.0		DDNCQMVWWZOMLN
BRD-K53318339-001-26-4	vinpocetine	Launched	phosphodiesterase inhibitor|sodium channel blocker	PDE1A|PDE1C	neurology/psychiatry	stroke|senile dementia	0	91.18	Selleck	S2110	Vinpocetine (Cavinton)	350.199	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|	DDNCQMVWWZOMLN-IRLDBZIGSA-N	443955.0	BRD-K25429851-001-01-5	DDNCQMVWWZOMLN
BRD-A42379279-065-03-8	viomycin	Launched	protein synthesis inhibitor		infectious disease	tuberculosis	0	39.8	Prestwick	Prestw-1113	Viomycin sulfate	685.326	NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C=NC(N)=O)[C@H]1C[C@H](O)N=C(N)N1 |a:4,10,15,23,29,42,&1:40,&2:35,w:35.35,t:45|	NSWGELWYFNCPHU-RWOORDGESA-N			NSWGELWYFNCPHU
BRD-K56565215-001-01-9	vipadenant	Phase 1	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	94.33	MedChemEx	HY-10857	Vipadenant	321.134	Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N	HQSBCDPYXDGTCL-UHFFFAOYSA-N	21874557.0		HQSBCDPYXDGTCL
BRD-K44827188-001-06-0	vismodegib	Launched	hedgehog pathway inhibitor|smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	0	98.12	Selleck	S1082	Vismodegib (GDC-0449)	420.01	CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1	BPQMGSKTAYIVFO-UHFFFAOYSA-N	24776445.0		BPQMGSKTAYIVFO
BRD-K44827188-001-04-5	vismodegib	Launched	hedgehog pathway inhibitor|smoothened receptor antagonist	SMO	oncology	basal cell carcinoma (BCC)	0	97.05	Broad Institute			420.01	CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1	InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)	24776445.0		BPQMGSKTAYIVFO
BRD-K00003375-004-01-9	visomitin	Preclinical	antioxidant				0	71.8	MedChemEx	HY-100474	Visomitin	537.292	CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1,38|	ZFUDULLGKXSPPH-UHFFFAOYSA-N	16679092.0		ZFUDULLGKXSPPH
BRD-K00003629-001-01-9	vitamin-B12	Launched			hematology	megaloblastic anemia	0	95.98	MedChemEx	HY-B0315	Vitamin B12	1355.575	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |c:16,20,24,t:22,26,29|	RMRCNWBMXRMIRW-WZHZPDAFSA-M			RMRCNWBMXRMIRW
BRD-K97091514-001-11-4	vitamin-E	Launched	LDL oxidation inhibitor|PKC inhibitor	ALOX5|DGKA|NR1I2|PPP2CA|PPP2CB|PRKCA|PRKCB|SEC14L2|SEC14L3|SEC14L4			0	0.0	CombiBlocks	QE-9484	(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol	430.381	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1	GVJHHUAWPYXKBD-IEOSBIPESA-N	14985.0		GVJHHUAWPYXKBD
BRD-K00003141-003-01-9	vixotrigine	Phase 2	sodium channel blocker				0	86.82	MedChemEx	HY-12796A	Raxatrigine hydrochloride	314.143	NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(OCc2ccccc2F)cc1	JESCETIFNOFKEU-SJORKVTESA-N	16046068.0		JESCETIFNOFKEU
BRD-K00003343-001-01-9	VLX1570	Phase 1/Phase 2	deubiquitinase inhibitor				0	93.32	MedChemEx	HY-12471	VLX1570	469.109	[O-][N+](=O)c1cc(\C=C2/CCN(C\C(=C/c3ccc(F)c(c3)[N+]([O-])=O)C2=O)C(=O)C=C)ccc1F	SCKXBVLYWLLALY-CZCYGEDCSA-N	71523377.0		SCKXBVLYWLLALY
BRD-K26122255-001-01-7	VLX600	Phase 1	antitumor agent|ubiquitin C-terminal hydrolase inhibitor	TP53|USP14			0	87.51	Enamine	EN300-395210	(1Z)-1-(2-pyridinyl)ethanone (6-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)hydrazone	317.139	CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	UQOSBPRTQFFUOA-UHFFFAOYSA-N	6806409.0		UQOSBPRTQFFUOA
BRD-K26122255-001-02-9	VLX600	Phase 1	antitumor agent|ubiquitin C-terminal hydrolase inhibitor	TP53|USP14			0	86.93	ChemDiv	1927-8053		317.139	C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	UQOSBPRTQFFUOA-NHDPSOOVSA-N	6413301.0		UQOSBPRTQFFUOA
BRD-K89053832-001-01-0	VLX600	Phase 1	antitumor agent|ubiquitin C-terminal hydrolase inhibitor	TP53|USP14			0		ChemDiv	1927-8053		317.139	C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	InChI=1S/C17H15N7/c1-10-6-5-7-12-14(10)19-16-15(12)22-24-17(20-16)23-21-11(2)13-8-3-4-9-18-13/h3-9H,1-2H3,(H2,19,20,23,24)/b21-11-	6413301.0		UQOSBPRTQFFUOA
BRD-K00005338-001-01-9	VL285	Preclinical	PROTAC				0	95.21	MedChemEx	HY-111663	VL285	532.214	CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C	HEDFFPYRFJKXQP-VJTSUQJLSA-N	71667162.0		HEDFFPYRFJKXQP
BRD-K00003472-001-01-9	voclosporin	Phase 3	calcineurin inhibitor				0	92.03	MedChemEx	HY-106638	Voclosporin	1213.841	[H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	BICRTLVBTLFLRD-PTWUADNWSA-N	6918486.0		BICRTLVBTLFLRD
BRD-K66850609-001-06-6	voglibose	Launched	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus|hyperglycemia	0	86.6	Tocris	3596	Voglibose	267.132	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	FZNCGRZWXLXZSZ-CIQUZCHMSA-N	444020.0		FZNCGRZWXLXZSZ
BRD-K66850609-001-05-8	voglibose	Launched	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus|hyperglycemia	0	100.0	Tocris	3596	Voglibose	267.132	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	FZNCGRZWXLXZSZ-CIQUZCHMSA-N	444020.0		FZNCGRZWXLXZSZ
BRD-K66850609-001-07-4	voglibose	Launched	glucosidase inhibitor	MGAM	endocrinology	diabetes mellitus|hyperglycemia	0	100.0	Selleck	S4101	Voglibose	267.132	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	FZNCGRZWXLXZSZ-CIQUZCHMSA-N	444020.0	BRD-K59331299-001-01-2	FZNCGRZWXLXZSZ
BRD-K69776681-001-06-1	volasertib	Phase 3	PLK inhibitor	PLK1			0	94.7	MedChemEx	HY-12137	Volasertib	618.401	CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	SXNJFOWDRLKDSF-STROYTFGSA-N			SXNJFOWDRLKDSF
BRD-K69776681-001-03-8	volasertib	Phase 3	PLK inhibitor	PLK1			0	95.76	Selleck	S2235	Volasertib (BI 6727)	618.401	CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	SXNJFOWDRLKDSF-STROYTFGSA-N			SXNJFOWDRLKDSF
BRD-K69776681-001-07-9	volasertib	Phase 3	PLK inhibitor	PLK1			0		Focus	1066053	Volasertib	618.401	CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1			SXNJFOWDRLKDSF
BRD-K23647661-001-03-0	volinanserin	Phase 3	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C|KCNH2			0	90.77	Tocris	4173	MDL 100907	373.205	COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	HXTGXYRHXAGCFP-OAQYLSRUSA-N	5311271.0		HXTGXYRHXAGCFP
BRD-K23647661-001-02-2	volinanserin	Phase 3	serotonin receptor antagonist	HTR2A|HTR2B|HTR2C|KCNH2			0	98.59	Cayman	15936		373.205	COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	HXTGXYRHXAGCFP-OAQYLSRUSA-N	5311271.0		HXTGXYRHXAGCFP
BRD-K32768103-001-04-9	vonoprazan	Launched	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	0	88.47	MedChemEx	HY-100007	Vonoprazan	345.095	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	BFDBKMOZYNOTPK-UHFFFAOYSA-N	15981397.0		BFDBKMOZYNOTPK
BRD-K32768103-051-02-6	vonoprazan	Launched	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	0	84.24	Selleck	S8016	TAK-438	345.095	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	BFDBKMOZYNOTPK-UHFFFAOYSA-N	15981397.0		BFDBKMOZYNOTPK
BRD-K32768103-051-03-4	vonoprazan	Launched	potassium-competitive acid antagonist	ATP4A	gastroenterology	peptic ulcer disease (PUD)	0	88.52	Selleck	S8016	Vonoprazan Fumarate (TAK-438)	345.095	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	BFDBKMOZYNOTPK-UHFFFAOYSA-N	15981397.0		BFDBKMOZYNOTPK
BRD-K93442924-001-03-4	vorapaxar	Launched	thrombin inhibitor	F2R	cardiology	myocardial infarction|peripheral artery disease (PAD)	0	98.32	Adooq	A12832	ethyl (1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-ylcarbamate	492.242	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1	ZBGXUVOIWDMMJE-QHNZEKIYSA-N	10077130.0		ZBGXUVOIWDMMJE
BRD-K00003460-001-01-9	vorasidenib	Preclinical	isocitrate dehydrogenase inhibitor				0	97.5	MedChemEx	HY-104042	Vorasidenib	414.079	C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(n1)-c1cccc(Cl)n1)C(F)(F)F	QCZAWDGAVJMPTA-RNFRBKRXSA-N	117817422.0		QCZAWDGAVJMPTA
BRD-K23677682-003-01-2	voreloxin	Phase 3	topoisomerase inhibitor	TOP2A			0	93.26	MedChemEx	HY-16518	Voreloxin (Hydrochloride)	401.116	CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	XZAFZXJXZHRNAQ-STQMWFEESA-N	9952884.0		XZAFZXJXZHRNAQ
BRD-K23677682-003-04-9	voreloxin	Phase 3	topoisomerase inhibitor	TOP2A			0	97.57	MedChemEx	HY-16518	Voreloxin (Hydrochloride)	401.116	CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	XZAFZXJXZHRNAQ-STQMWFEESA-N	9952884.0		XZAFZXJXZHRNAQ
BRD-K06557128-001-07-0	voriconazole	Launched	cytochrome P450 inhibitor	CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1	infectious disease	esophageal candidiasis|aspergillosis|skin infections	0	99.42	MicroSource	1502346	VORICONAZOLE	349.115	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	BCEHBSKCWLPMDN-MGPLVRAMSA-N	71616.0		BCEHBSKCWLPMDN
BRD-K06557128-001-08-8	voriconazole	Launched	cytochrome P450 inhibitor	CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1	infectious disease	esophageal candidiasis|aspergillosis|skin infections	0	80.0	Selleck	S1442	Voriconazole	349.115	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	BCEHBSKCWLPMDN-MGPLVRAMSA-N	71616.0		BCEHBSKCWLPMDN
BRD-K06557128-001-10-9	voriconazole	Launched	cytochrome P450 inhibitor	CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1	infectious disease	esophageal candidiasis|aspergillosis|skin infections	0	90.51	Tocris	3760	Voriconazole	349.115	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	BCEHBSKCWLPMDN-MGPLVRAMSA-N	71616.0		BCEHBSKCWLPMDN
BRD-K06557128-001-06-2	voriconazole	Launched	cytochrome P450 inhibitor	CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1	infectious disease	esophageal candidiasis|aspergillosis|skin infections	0	88.29	Selleck	S1442	Voriconazole	349.115	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	BCEHBSKCWLPMDN-MGPLVRAMSA-N	71616.0		BCEHBSKCWLPMDN
BRD-K81418486-001-66-9	vorinostat	Launched	HDAC inhibitor	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	0	86.94	Tocris	4652	SAHA	264.147	ONC(=O)CCCCCCC(=O)Nc1ccccc1	WAEXFXRVDQXREF-UHFFFAOYSA-N	5311.0		WAEXFXRVDQXREF
BRD-K81418486-001-51-7	vorinostat	Launched	HDAC inhibitor	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	0	74.04	Tocris	4652	SAHA	264.147	ONC(=O)CCCCCCC(=O)Nc1ccccc1	WAEXFXRVDQXREF-UHFFFAOYSA-N	5311.0		WAEXFXRVDQXREF
BRD-K81418486-001-47-5	vorinostat	Launched	HDAC inhibitor	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	0	99.7	Selleck	S1047	Vorinostat (SAHA)	264.147	ONC(=O)CCCCCCC(=O)Nc1ccccc1	WAEXFXRVDQXREF-UHFFFAOYSA-N	5311.0		WAEXFXRVDQXREF
BRD-K81418486-001-44-2	vorinostat	Launched	HDAC inhibitor	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)	0	90.8	Selleck	S1047	Vorinostat (SAHA, MK0683)	264.147	ONC(=O)CCCCCCC(=O)Nc1ccccc1	WAEXFXRVDQXREF-UHFFFAOYSA-N	5311.0		WAEXFXRVDQXREF
BRD-K53963539-001-01-8	vortioxetine	Launched	serotonin receptor agonist|serotonin receptor antagonist	HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4	neurology/psychiatry	depression	0	86.75	MicroSource	1506319	VORTIOXETINE	298.15	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	YQNWZWMKLDQSAC-UHFFFAOYSA-N	9966051.0		YQNWZWMKLDQSAC
BRD-K53963539-004-02-0	vortioxetine	Launched	serotonin receptor agonist|serotonin receptor antagonist	HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4	neurology/psychiatry	depression	0	95.12	Selleck	S8021	Vortioxetine (Lu AA21004) HBr	298.15	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	YQNWZWMKLDQSAC-UHFFFAOYSA-N	9966051.0		YQNWZWMKLDQSAC
BRD-K53963539-001-03-9	vortioxetine	Launched	serotonin receptor agonist|serotonin receptor antagonist	HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4	neurology/psychiatry	depression	0	91.15	MedChemEx	HY-15414	Vortioxetine	298.15	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	YQNWZWMKLDQSAC-UHFFFAOYSA-N	9966051.0		YQNWZWMKLDQSAC
BRD-K00004725-001-01-9	voruciclib	Phase 1	CDK9 inhibitor				0	97.7	Astatech	40984	VORUCICLIB	469.09	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F	MRPGRAKIAJJGMM-OCCSQVGLSA-N	67409219.0		MRPGRAKIAJJGMM
BRD-K43639297-001-01-9	voxelotor	Launched	hemoglobin modulator				0	96.07	MedChemEx	HY-18681	Hemoglobin Modulators-1	337.143	CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	FWCVZAQENIZVMY-UHFFFAOYSA-N	71602803.0		FWCVZAQENIZVMY
BRD-K56291712-001-01-0	voxtalisib	Phase 2	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA			0	99.19	MedChemEx	HY-15900	SAR245409	270.123	CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	RGHYDLZMTYDBDT-UHFFFAOYSA-N	16123056.0		RGHYDLZMTYDBDT
BRD-K56291712-001-02-9	voxtalisib	Phase 2	mTOR inhibitor|PI3K inhibitor	MTOR|PIK3CA			0	92.69	MedChemEx	HY-15900	Voxtalisib	270.123	CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	RGHYDLZMTYDBDT-UHFFFAOYSA-N	16123056.0		RGHYDLZMTYDBDT
BRD-K21071223-001-02-8	VP-20629	Phase 1	beta amyloid antagonist	PLA2G2E|SLC36A1			0	99.13	ChemDiv	5830-0516		189.079	OC(=O)CCc1c[nH]c2ccccc12	GOLXRNDWAUTYKT-UHFFFAOYSA-N	3744.0		GOLXRNDWAUTYKT
BRD-K09877029-001-01-2	VS-4718	Phase 1	focal adhesion kinase inhibitor				0	98.41	MedChemEx	HY-13917	PND-1186	501.199	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	IGUBBWJDMLCRIK-UHFFFAOYSA-N	25073775.0		IGUBBWJDMLCRIK
BRD-K09877029-001-02-9	VS-4718	Phase 1	focal adhesion kinase inhibitor				0	98.38	MedChemEx	HY-13917	PND-1186	501.199	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	IGUBBWJDMLCRIK-UHFFFAOYSA-N	25073775.0		IGUBBWJDMLCRIK
BRD-K72005722-001-01-2	VT-464	Phase 2	cytochrome P450 inhibitor	CYP17A1			0	98.44	MedChemEx	HY-15996	VT-464	399.121	CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	ZBRAJOQFSNYJMF-SFHVURJKSA-N	78357816.0		ZBRAJOQFSNYJMF
BRD-K72005722-001-02-9	VT-464	Phase 2	cytochrome P450 inhibitor	CYP17A1			0	95.05	MedChemEx	HY-15996	Seviteronel	399.121	CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	ZBRAJOQFSNYJMF-SFHVURJKSA-N	78357816.0		ZBRAJOQFSNYJMF
BRD-K81694556-003-02-9	VTP-27999	Phase 1	renin inhibitor	REN			0	89.62	MedChemEx	HY-76652	VTP-27999 (Hydrochloride)	524.277	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	NXWASIVXQMMPLM-ZXMXYHOLSA-N	16126898.0		NXWASIVXQMMPLM
BRD-K81694556-003-01-9	VTP-27999	Phase 1	renin inhibitor	REN			0	92.33	MedChemEx	HY-76652	VTP-27999 (Hydrochloride)	524.277	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	NXWASIVXQMMPLM-ZXMXYHOLSA-N	16126898.0		NXWASIVXQMMPLM
BRD-K11046126-001-03-9	VUF10166	Preclinical	serotonin receptor antagonist	HTR3A|HTR3B			0	97.1	Tocris	4532	VUF 10166	262.099	CN1CCN(CC1)c1nc2ccccc2nc1Cl	FFXVTQDGTKEXHF-UHFFFAOYSA-N	24278976.0		FFXVTQDGTKEXHF
BRD-K11046126-001-02-0	VUF10166	Preclinical	serotonin receptor antagonist	HTR3A|HTR3B			0	94.56	Selleck	S2865	VUF 10166	262.099	CN1CCN(CC1)c1nc2ccccc2nc1Cl	FFXVTQDGTKEXHF-UHFFFAOYSA-N	24278976.0		FFXVTQDGTKEXHF
BRD-K90082312-001-02-9	VUF10460	Preclinical	histamine receptor agonist	HRH4			0	94.6	Tocris	4769	VUF 10460	269.164	CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1	NIJGWJIOMPHDBP-UHFFFAOYSA-N	25129523.0		NIJGWJIOMPHDBP
BRD-K90082312-001-01-5	VUF10460	Preclinical	histamine receptor agonist	HRH4			0	96.93	Tocris	4769	VUF 10460	269.164	CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1	NIJGWJIOMPHDBP-UHFFFAOYSA-N	25129523.0		NIJGWJIOMPHDBP
BRD-A93717708-051-02-9	VUF11207	Preclinical	CC chemokine receptor agonist	ACKR3			0	97.54	Tocris	4780	VUF 11207 fumarate	470.258	COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|	JVRRRKAXHMGUHZ-JIKIWWBOSA-N	97018453.0		JVRRRKAXHMGUHZ
BRD-A93717708-051-01-2	VUF11207	Preclinical	CC chemokine receptor agonist	ACKR3			0	97.09	Tocris	4780	VUF 11207 fumarate	470.258	COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|	JVRRRKAXHMGUHZ-JIKIWWBOSA-N	97018453.0		JVRRRKAXHMGUHZ
BRD-K48535733-003-02-0	VU0155069	Preclinical	phospholipase inhibitor	PLD1			0	97.24	Tocris	3575	VU 0155069	462.182	C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	DRIMIUYGTDAQOX-KRWDZBQOSA-N	25105713.0		DRIMIUYGTDAQOX
BRD-K48535733-003-01-2	VU0155069	Preclinical	phospholipase inhibitor	PLD1			0	97.48	Tocris	3575	VU 0155069	462.182	C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	DRIMIUYGTDAQOX-KRWDZBQOSA-N	25105713.0		DRIMIUYGTDAQOX
BRD-K48535733-003-03-9	VU0155069	Preclinical	phospholipase inhibitor	PLD1			0	96.98	Tocris	3575	VU 0155069	462.182	C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	DRIMIUYGTDAQOX-KRWDZBQOSA-N	25105713.0		DRIMIUYGTDAQOX
BRD-K24187789-001-02-5	VU0238429	Preclinical	acetylcholine receptor allosteric modulator	CHRM5			0	95.11	Tocris	3634	VU 0238429	351.072	COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	CKLGZXFOLMHCMC-UHFFFAOYSA-N	42633508.0		CKLGZXFOLMHCMC
BRD-K24187789-001-01-7	VU0238429	Preclinical	acetylcholine receptor allosteric modulator	CHRM5			0	94.95	Tocris	3634	VU 0238429	351.072	COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	CKLGZXFOLMHCMC-UHFFFAOYSA-N	42633508.0		CKLGZXFOLMHCMC
BRD-K24187789-001-03-9	VU0238429	Preclinical	acetylcholine receptor allosteric modulator	CHRM5			0	94.63	Tocris	3634	VU 0238429	351.072	COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	CKLGZXFOLMHCMC-UHFFFAOYSA-N	42633508.0		CKLGZXFOLMHCMC
BRD-K27074404-001-08-4	VU0240551	Preclinical	potassium/chloride cotransporter inhibitor	SLC12A5			0	97.16	MedChemEx	HY-16689	VU 0240551	342.061	Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1	WJRWSLORVIHRNX-UHFFFAOYSA-N	7211972.0		WJRWSLORVIHRNX
BRD-K86109159-001-03-9	VU0357121	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	93.83	Tocris	4437	VU 0357121	305.123	CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	AHCYOTLTLQTPSU-UHFFFAOYSA-N	2296132.0		AHCYOTLTLQTPSU
BRD-K86109159-001-02-6	VU0357121	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	97.46	Selleck	S2795	VU 0357121	305.123	CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	AHCYOTLTLQTPSU-UHFFFAOYSA-N	2296132.0		AHCYOTLTLQTPSU
BRD-K83649660-003-03-0	VU0360172	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	77.87	Tocris	4323	VU 0360172 hydrochloride	294.117	Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1	NEMHWVUKNWAKTM-UHFFFAOYSA-N	53318624.0		NEMHWVUKNWAKTM
BRD-K83649660-003-04-9	VU0360172	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	94.7	Tocris	4323	VU 0360172 hydrochloride	294.117	Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1	NEMHWVUKNWAKTM-UHFFFAOYSA-N	53318624.0		NEMHWVUKNWAKTM
BRD-K45462423-001-04-5	VU0361737	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	96.69	Tocris	3707	VU 0361737	262.051	COc1cc(NC(=O)c2ccccn2)ccc1Cl	ARYUXFNGXHNNDM-UHFFFAOYSA-N	44191096.0		ARYUXFNGXHNNDM
BRD-K45462423-001-03-7	VU0361737	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	98.82	Tocris	3707	VU 0361737	262.051	COc1cc(NC(=O)c2ccccn2)ccc1Cl	ARYUXFNGXHNNDM-UHFFFAOYSA-N	44191096.0		ARYUXFNGXHNNDM
BRD-K45462423-001-05-9	VU0361737	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	95.65	Tocris	3707	VU 0361737	262.051	COc1cc(NC(=O)c2ccccn2)ccc1Cl	ARYUXFNGXHNNDM-UHFFFAOYSA-N	44191096.0		ARYUXFNGXHNNDM
BRD-K45462423-001-02-9	VU0361737	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	97.81	Selleck	S2892	VU 0361737	262.051	COc1cc(NC(=O)c2ccccn2)ccc1Cl	ARYUXFNGXHNNDM-UHFFFAOYSA-N	44191096.0		ARYUXFNGXHNNDM
BRD-K72687424-001-04-9	VU0364439	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	98.19	Tocris	4371	VU 0364439	421.005	Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	IXHCGJXBIHHIEF-UHFFFAOYSA-N	46934289.0		IXHCGJXBIHHIEF
BRD-K72687424-001-03-4	VU0364439	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	96.29	Tocris	4371	VU 0364439	421.005	Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	IXHCGJXBIHHIEF-UHFFFAOYSA-N	46934289.0		IXHCGJXBIHHIEF
BRD-K72687424-001-02-6	VU0364439	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	95.49	Selleck	S8035	VU 0364439	421.005	Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	IXHCGJXBIHHIEF-UHFFFAOYSA-N	46934289.0		IXHCGJXBIHHIEF
BRD-K93317811-003-02-2	VU0364739	Preclinical	phospholipase inhibitor	PLD2			0	95.98	Tocris	4171	VU 0364739 hydrochloride	446.212	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1	MSTXJJGAXXJCBY-UHFFFAOYSA-N	46937439.0		MSTXJJGAXXJCBY
BRD-K93317811-003-04-9	VU0364739	Preclinical	phospholipase inhibitor	PLD2			0	95.43	Tocris	4171	VU 0364739 hydrochloride	446.212	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1	MSTXJJGAXXJCBY-UHFFFAOYSA-N	46937439.0		MSTXJJGAXXJCBY
BRD-K66527818-001-03-9	VU0364770	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	92.79	Tocris	4469	VU 0364770	232.04	Clc1cccc(NC(=O)c2ccccn2)c1	SUYUTNCKIOLMAJ-UHFFFAOYSA-N	836002.0		SUYUTNCKIOLMAJ
BRD-K66527818-001-02-6	VU0364770	Preclinical	glutamate receptor positive allosteric modulator	GRM4			0	96.96	Selleck	S2862	VU 0364770	232.04	Clc1cccc(NC(=O)c2ccccn2)c1	SUYUTNCKIOLMAJ-UHFFFAOYSA-N	836002.0		SUYUTNCKIOLMAJ
BRD-K68674163-001-01-7	VU0422288	Preclinical	glutamate receptor positive allosteric modulator	GRM3			0	96.47	Tocris	5378	VU 0422288	359.023	Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1	MZRLPXFGQKQHST-UHFFFAOYSA-N	73058507.0		MZRLPXFGQKQHST
BRD-K68674163-001-02-9	VU0422288	Preclinical	glutamate receptor positive allosteric modulator	GRM3			0	97.98	Tocris	5378	VU 0422288	359.023	Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1	MZRLPXFGQKQHST-UHFFFAOYSA-N	73058507.0		MZRLPXFGQKQHST
BRD-K12483104-001-01-2	VU10010	Preclinical	acetylcholine receptor allosteric modulator	CHRM4			0	94.64	Tocris	3141	VU 10010	345.07	Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1	FPRULFHDSFKYBV-UHFFFAOYSA-N	714286.0		FPRULFHDSFKYBV
BRD-K12483104-001-02-9	VU10010	Preclinical	acetylcholine receptor allosteric modulator	CHRM4			0	95.73	Tocris	3141	VU 10010	345.07	Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1	FPRULFHDSFKYBV-UHFFFAOYSA-N	714286.0		FPRULFHDSFKYBV
BRD-K87727457-001-01-5	VU152100	Preclinical	acetylcholine receptor allosteric modulator	CHRM4			0	93.58	Tocris	3383	VU 152100	341.12	COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1	MDNWGCQSCGNTKH-UHFFFAOYSA-N	864492.0		MDNWGCQSCGNTKH
BRD-K87727457-001-02-9	VU152100	Preclinical	acetylcholine receptor allosteric modulator	CHRM4			0	95.97	Tocris	3383	VU 152100	341.12	COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1	MDNWGCQSCGNTKH-UHFFFAOYSA-N	864492.0		MDNWGCQSCGNTKH
BRD-K48371964-001-06-5	VU1545	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	96.37	Tocris	3325	VU 1545	402.113	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1	BRAZLURTFMCAHU-UHFFFAOYSA-N	11625520.0		BRAZLURTFMCAHU
BRD-K48371964-001-07-9	VU1545	Preclinical	glutamate receptor positive allosteric modulator	GRM5			0	95.44	Tocris	3325	VU 1545	402.113	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1	BRAZLURTFMCAHU-UHFFFAOYSA-N	11625520.0		BRAZLURTFMCAHU
BRD-K54783522-001-02-9	VU29	Preclinical	glutamate receptor potentiator	GRM5			0	97.54	Tocris	4458	VU 29	384.122	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1	KIALCSMRIHRFPL-UHFFFAOYSA-N	11610682.0		KIALCSMRIHRFPL
BRD-K54783522-001-01-8	VU29	Preclinical	glutamate receptor potentiator	GRM5			0	98.04	Tocris	4458	VU 29	384.122	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1	KIALCSMRIHRFPL-UHFFFAOYSA-N	11610682.0		KIALCSMRIHRFPL
BRD-K72063794-003-01-0	VU591	Preclinical	potassium channel blocker	KCNJ1			0	87.5	Tocris	4197	VU 591 hydrochloride	368.087	[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1	ZQPXNYLXYNRFNP-UHFFFAOYSA-N	44123657.0		ZQPXNYLXYNRFNP
BRD-K72063794-003-02-9	VU591	Preclinical	potassium channel blocker	KCNJ1			0	96.72	Tocris	4197	VU 591 hydrochloride	368.087	[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1	ZQPXNYLXYNRFNP-UHFFFAOYSA-N	44123657.0		ZQPXNYLXYNRFNP
BRD-K93725829-001-03-8	VX-11e	Preclinical	MAP kinase inhibitor	MAPK1			0	97.32	MedChemEx	HY-14178	VX-11e	499.098	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1	WUTVMXLIGHTZJC-OAQYLSRUSA-N	11634725.0		WUTVMXLIGHTZJC
BRD-K70610771-001-03-9	VX-222	Phase 2	HCV inhibitor				0	96.13	MedChemEx	HY-75800	VX-222	445.229	C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|	WPMJNLCLKAKMLA-UGLKCIBTSA-N			WPMJNLCLKAKMLA
BRD-K70610771-001-02-9	VX-222	Phase 2	HCV inhibitor				0	97.92	Selleck	S1480	VX-222 (VCH-222, Lomibuvir)	445.229	C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|	WPMJNLCLKAKMLA-UGLKCIBTSA-N			WPMJNLCLKAKMLA
BRD-K07736136-001-04-6	VX-702	Phase 2	p38 MAPK inhibitor	IL1B|IL6|MAPK11|MAPK12|MAPK14|TNF			0	93.86	Selleck	S6005	VX-702	404.09	NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	FYSRKRZDBHOFAY-UHFFFAOYSA-N	10341154.0		FYSRKRZDBHOFAY
BRD-K07736136-001-05-9	VX-702	Phase 2	p38 MAPK inhibitor	IL1B|IL6|MAPK11|MAPK12|MAPK14|TNF			0	93.37	Tocris	3916	VX 702	404.09	NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	FYSRKRZDBHOFAY-UHFFFAOYSA-N	10341154.0		FYSRKRZDBHOFAY
BRD-K07736136-001-03-8	VX-702	Phase 2	p38 MAPK inhibitor	IL1B|IL6|MAPK11|MAPK12|MAPK14|TNF			0	60.41	Selleck	S6005	VX-702	404.09	NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	FYSRKRZDBHOFAY-UHFFFAOYSA-N	10341154.0		FYSRKRZDBHOFAY
BRD-K91900765-001-08-4	VX-745	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK12|MAPK14			0	64.75	MedChemEx	HY-10328	VX-745	434.981	Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	VEPKQEUBKLEPRA-UHFFFAOYSA-N	3038525.0		VEPKQEUBKLEPRA
BRD-K91900765-001-07-6	VX-745	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK12|MAPK14			0	78.69	MedChemEx	HY-10328	VX-745	434.981	Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	VEPKQEUBKLEPRA-UHFFFAOYSA-N	3038525.0		VEPKQEUBKLEPRA
BRD-K91900765-001-05-0	VX-745	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK12|MAPK14			0	67.26	Selleck	S1458	VX-745	434.981	Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	VEPKQEUBKLEPRA-UHFFFAOYSA-N	3038525.0		VEPKQEUBKLEPRA
BRD-K91900765-001-06-8	VX-745	Phase 2	p38 MAPK inhibitor	MAPK11|MAPK12|MAPK14			0	64.96	Selleck	S1458	VX-745	434.981	Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	VEPKQEUBKLEPRA-UHFFFAOYSA-N	3038525.0		VEPKQEUBKLEPRA
BRD-K78430341-001-02-5	VX-765	Phase 2	caspase inhibitor	CASP1			0	97.92	Selleck	S2228	VX-765	508.209	CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	SJDDOCKBXFJEJB-MOKWFATOSA-N	11398092.0		SJDDOCKBXFJEJB
BRD-A00559310-003-02-9	W-54011	Preclinical	anaphylatoxin chemotactic receptor antagonist	C5AR1			0	88.69	Tocris	5455	W 54011	456.278	COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|	DVYASSBBADJRAS-MUUNZHRXSA-N	59597209.0		DVYASSBBADJRAS
BRD-A00559310-003-01-1	W-54011	Preclinical	anaphylatoxin chemotactic receptor antagonist	C5AR1			0	89.3	MedChemEx	HY-16992A	W-54011	456.278	COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|	DVYASSBBADJRAS-MUUNZHRXSA-N	59597209.0		DVYASSBBADJRAS
BRD-K01129913-001-01-5	walrycin-B	Preclinical	transcriptional regulatory protein WalR				0	88.74	MedChemEx	HY-18219	Walrycin B	337.079	Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F	XRVMPTWWKLKLPB-UHFFFAOYSA-N	3164070.0		XRVMPTWWKLKLPB
BRD-K25991148-001-02-9	warfarin	Launched	vitamin K antagonist	VKORC1	hematology|cardiology	deep vein thrombosis (DVT)|pulmonary embolism (PE)|atrial fibrillation (AF)|myocardial infarction	0	98.92	MedChemEx	HY-B0687	Warfarin	308.105	CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|	PJVWKTKQMONHTI-HNNXBMFYSA-N	54688261.0		PJVWKTKQMONHTI
BRD-K69812556-050-11-9	WAY-100635	Phase 1	serotonin receptor antagonist	HTR1A			0	97.88	MedChemEx	HY-10349A	WAY-100635 Maleate	422.268	COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	SBPRIAGPYFYCRT-UHFFFAOYSA-N	5684.0		SBPRIAGPYFYCRT
BRD-K69812556-305-02-0	WAY-100635	Phase 1	serotonin receptor antagonist	HTR1A			0	95.59	Selleck	S2663	WAY-100635 Maleate	422.268	COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	SBPRIAGPYFYCRT-UHFFFAOYSA-N	5684.0		SBPRIAGPYFYCRT
BRD-A62021152-003-04-2	WAY-161503	Preclinical	serotonin receptor agonist	HTR2C			0	94.85	Tocris	1801	8,9-dichloro-2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)-one hydrochloride	271.028	Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|	PHGWDAICBXUJDU-SNVBAGLBSA-N	6604916.0		PHGWDAICBXUJDU
BRD-A62021152-003-03-4	WAY-161503	Preclinical	serotonin receptor agonist	HTR2C			0	78.8	Tocris	1801	WAY 161503 hydrochloride	271.028	Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|	PHGWDAICBXUJDU-SNVBAGLBSA-N	6604916.0		PHGWDAICBXUJDU
BRD-K36198571-001-03-8	WAY-170523	Preclinical	metalloproteinase inhibitor	MMP13			0	97.03	Tocris	2633	WAY 170523	613.188	Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	FARMEEAGJWMFSZ-UHFFFAOYSA-N	9830392.0		FARMEEAGJWMFSZ
BRD-K36198571-001-02-0	WAY-170523	Preclinical	metalloproteinase inhibitor	MMP13			0	96.24	Tocris	2633	WAY 170523	613.188	Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	FARMEEAGJWMFSZ-UHFFFAOYSA-N	9830392.0		FARMEEAGJWMFSZ
BRD-K36198571-001-04-9	WAY-170523	Preclinical	metalloproteinase inhibitor	MMP13			0	93.94	Tocris	2633	WAY 170523	613.188	Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	FARMEEAGJWMFSZ-UHFFFAOYSA-N	9830392.0		FARMEEAGJWMFSZ
BRD-K08223200-001-02-9	WAY-200070	Preclinical	estrogen receptor agonist	ERBB2|ERBB3|ERBB4|ESR2			0	93.36	Tocris	3366	WAY 200070	304.969	Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	BAAILVWEAXFTSF-UHFFFAOYSA-N	135418373.0		BAAILVWEAXFTSF
BRD-K08223200-001-01-1	WAY-200070	Preclinical	estrogen receptor agonist	ERBB2|ERBB3|ERBB4|ESR2			0	93.82	Tocris	3366	WAY 200070	304.969	Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	BAAILVWEAXFTSF-UHFFFAOYSA-N	135418373.0		BAAILVWEAXFTSF
BRD-K08223200-001-03-9	WAY-200070	Preclinical	estrogen receptor agonist	ERBB2|ERBB3|ERBB4|ESR2			0	96.79	Tocris	3366	WAY 200070	304.969	Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	BAAILVWEAXFTSF-UHFFFAOYSA-N	135418373.0		BAAILVWEAXFTSF
BRD-K08657056-300-01-1	WAY-207024	Preclinical	gonadotropin releasing factor hormone receptor antagonist	GNRHR|HRH2|TACR2			0	95.82	Tocris	3890	WAY 207024 dihydrochloride	476.269	CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1	AVEVJMZJJJDOCI-UHFFFAOYSA-N	11496610.0		AVEVJMZJJJDOCI
BRD-K08657056-300-02-9	WAY-207024	Preclinical	gonadotropin releasing factor hormone receptor antagonist	GNRHR|HRH2|TACR2			0	98.01	Tocris	3890	WAY 207024 dihydrochloride	476.269	CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1	AVEVJMZJJJDOCI-UHFFFAOYSA-N	11496610.0		AVEVJMZJJJDOCI
BRD-K63483542-300-01-6	WAY-208466	Preclinical	serotonin receptor agonist	DRD2|HTR2A|HTR2C|HTR6|HTR7			0	96.89	Tocris	3904	WAY 208466 dihydrochloride	347.11	CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1	SFSFIDVAEMDPIP-UHFFFAOYSA-N	10337743.0		SFSFIDVAEMDPIP
BRD-K63483542-300-02-9	WAY-208466	Preclinical	serotonin receptor agonist	DRD2|HTR2A|HTR2C|HTR6|HTR7			0	97.67	Tocris	3904	WAY 208466 dihydrochloride	347.11	CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1	SFSFIDVAEMDPIP-UHFFFAOYSA-N	10337743.0		SFSFIDVAEMDPIP
BRD-K96758128-001-02-6	WAY-213613	Preclinical	glutamate inhibitor	SLC1A2			0	92.48	Tocris	2652	WAY 213613	414.003	N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	BNYDDAAZMBUFRG-ZDUSSCGKSA-N	11531745.0		BNYDDAAZMBUFRG
BRD-K96758128-001-01-8	WAY-213613	Preclinical	glutamate inhibitor	SLC1A2			0	97.19	Tocris	2652	WAY 213613	414.003	N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	BNYDDAAZMBUFRG-ZDUSSCGKSA-N	11531745.0		BNYDDAAZMBUFRG
BRD-K96758128-001-03-9	WAY-213613	Preclinical	glutamate inhibitor	SLC1A2			0	96.14	Tocris	2652	WAY 213613	414.003	N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	BNYDDAAZMBUFRG-ZDUSSCGKSA-N	11531745.0		BNYDDAAZMBUFRG
BRD-K00004556-001-01-9	WAY-255348	Preclinical	progesterone receptor antagonist				0	92.87	Sigma	MFCD18782604	5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile	283.112	Cn1c(ccc1-c1cc2c(NC(=O)C2(C)C)c(F)c1)C#N	KIOOLNRTWPFVHX-UHFFFAOYSA-N	11543746.0		KIOOLNRTWPFVHX
BRD-K61871885-001-01-3	WAY-316606	Preclinical	secreted frizzled related protein inhibitor	SFRP1			0	93.0	MedChemEx	HY-10858	WAY 316606	448.074	FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1	ITBGJNVZJBVPLJ-UHFFFAOYSA-N	16727102.0		ITBGJNVZJBVPLJ
BRD-K61871885-003-01-9	WAY-316606	Preclinical	secreted frizzled related protein inhibitor	SFRP1			0	94.21	Tocris	4767	WAY 316606 hydrochloride	448.074	FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1	ITBGJNVZJBVPLJ-UHFFFAOYSA-N	16727102.0		ITBGJNVZJBVPLJ
BRD-K54640016-001-05-9	WAY-362450	Phase 1	FXR agonist	NR1H4			0	94.08	MedChemEx	HY-50911	Turofexorate isopropyl	438.175	CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|	INASOKQDNHHMRE-UHFFFAOYSA-N	10026128.0		INASOKQDNHHMRE
BRD-K54640016-001-04-7	WAY-362450	Phase 1	FXR agonist	NR1H4			0	91.54	Selleck	S2694	XL335	438.175	CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|	INASOKQDNHHMRE-UHFFFAOYSA-N	10026128.0		INASOKQDNHHMRE
BRD-K85920262-001-02-1	WAY-600	Preclinical	mTOR inhibitor	MTOR			0	93.96	Selleck	S2689	WAY-600	494.254	C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	FPEIJQLXFHKLJV-UHFFFAOYSA-N	25229526.0		FPEIJQLXFHKLJV
BRD-K85920262-001-04-9	WAY-600	Preclinical	mTOR inhibitor	MTOR			0	82.6	MedChemEx	HY-15272	WAY-600	494.254	C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	FPEIJQLXFHKLJV-UHFFFAOYSA-N	25229526.0		FPEIJQLXFHKLJV
BRD-K55430733-003-02-4	WAY-629	Preclinical	serotonin receptor agonist	HTR2C			0	66.92	Tocris	2173	WAY 629 hydrochloride	226.147	C1CCc2c(C1)n1CCNCc3cccc2c13	OIGHTPDWPMLMGT-UHFFFAOYSA-N	6604933.0		OIGHTPDWPMLMGT
BRD-K55430733-003-03-9	WAY-629	Preclinical	serotonin receptor agonist	HTR2C			0	81.9	Tocris	2173	WAY 629 hydrochloride	226.147	C1CCc2c(C1)n1CCNCc3cccc2c13	OIGHTPDWPMLMGT-UHFFFAOYSA-N	6604933.0		OIGHTPDWPMLMGT
BRD-A01493904-003-13-9	WB-4101	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A			0	94.03	Tocris	946	WB 4101 hydrochloride	345.158	COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|	GYSZUJHYXCZAKI-AWEZNQCLSA-N	13305910.0		GYSZUJHYXCZAKI
BRD-A01493904-003-12-1	WB-4101	Preclinical	adrenergic receptor antagonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A			0	96.8	Tocris	946	WB 4101 hydrochloride	345.158	COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|	GYSZUJHYXCZAKI-AWEZNQCLSA-N	13305910.0		GYSZUJHYXCZAKI
BRD-K47726410-001-01-2	WDR5-0103	Preclinical	histone lysine methyltransferase inhibitor	WDR5			0	97.86	Tocris	5323	WDR5 0103	383.185	COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1	ZPLBXOVTSNRBFB-UHFFFAOYSA-N	6457069.0		ZPLBXOVTSNRBFB
BRD-K47726410-001-02-0	WDR5-0103	Preclinical	histone lysine methyltransferase inhibitor	WDR5			0	99.17	Vitas-M	STK892274	WDR5 0103	383.185	COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1	ZPLBXOVTSNRBFB-UHFFFAOYSA-N	6457069.0		ZPLBXOVTSNRBFB
BRD-K55487946-001-01-3	WEHI-345-analog	Preclinical	SRC inhibitor				0	95.92	MedChemEx	HY-100112	WEHI-345 (analog)	415.212	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C	ZCZGSEXBXXYQQC-UHFFFAOYSA-N	56602558.0		ZCZGSEXBXXYQQC
BRD-K50199947-001-03-4	WH-4-023	Preclinical	SRC inhibitor	LCK|SRC			0	81.92	Tocris	5413	WH-4-023	568.28	COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1	NBTNHSGBRGTFJS-UHFFFAOYSA-N	11844351.0		NBTNHSGBRGTFJS
BRD-K50199947-001-07-9	WH-4-023	Preclinical	SRC inhibitor	LCK|SRC			0	97.53	Tocris	5413	WH-4-023	568.28	COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1	NBTNHSGBRGTFJS-UHFFFAOYSA-N	11844351.0		NBTNHSGBRGTFJS
BRD-K07487750-001-05-8	WHI-P154	Preclinical	JAK inhibitor	EGFR|JAK1|JAK2|JAK3			0	86.53	Tocris	3115	WHI-P 154	375.022	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	CBIAKDAYHRWZCU-UHFFFAOYSA-N	3795.0		CBIAKDAYHRWZCU
BRD-K07487750-001-03-3	WHI-P154	Preclinical	JAK inhibitor	EGFR|JAK1|JAK2|JAK3			0	84.23	Selleck	S2867	WHI-P154	375.022	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	CBIAKDAYHRWZCU-UHFFFAOYSA-N	3795.0		CBIAKDAYHRWZCU
BRD-K07487750-001-04-1	WHI-P154	Preclinical	JAK inhibitor	EGFR|JAK1|JAK2|JAK3			0	90.22	Selleck	S2867	WHI-P154	375.022	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	CBIAKDAYHRWZCU-UHFFFAOYSA-N	3795.0		CBIAKDAYHRWZCU
BRD-K07487750-001-06-9	WHI-P154	Preclinical	JAK inhibitor	EGFR|JAK1|JAK2|JAK3			0	87.47	Tocris	3115	WHI-P 154	375.022	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	CBIAKDAYHRWZCU-UHFFFAOYSA-N	3795.0		CBIAKDAYHRWZCU
BRD-K19316653-001-02-0	WIKI4	Preclinical	tankyrase inhibitor|WNT pathway inhibitor	TNKS2			0	98.16	MedChemEx	HY-16910	WIKI4	521.152	COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1	RNUXIZKXJOGYQP-UHFFFAOYSA-N	2984337.0		RNUXIZKXJOGYQP
BRD-K30930903-001-01-3	WIN-18446	Preclinical	aldehyde dehydrogenase inhibitor	ALDH1A2			0	97.79	DuPont	A001467449	2,2-dichloro-N-{8-[(dichloroacetyl)amino]octyl}acetamide	364.028	ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl	FAOMZVDZARKPFJ-UHFFFAOYSA-N	15134.0		FAOMZVDZARKPFJ
BRD-K22662557-300-02-5	WIN-64338	Preclinical	bradykinin receptor antagonist	BDKRB2			0	93.6	Tocris	1057	WIN 64338 hydrochloride	711.513	CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	UKMJWGFHXMGRNG-QLKFWGTOSA-O	132928.0		UKMJWGFHXMGRNG
BRD-K22662557-300-03-9	WIN-64338	Preclinical	bradykinin receptor antagonist	BDKRB2			0	95.15	Tocris	1057	WIN 64338 hydrochloride	711.513	CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	UKMJWGFHXMGRNG-QLKFWGTOSA-O	132928.0		UKMJWGFHXMGRNG
BRD-K22662557-300-01-7	WIN-64338	Preclinical	bradykinin receptor antagonist	BDKRB2			0	95.81	Tocris	1057	WIN 64338 hydrochloride	711.513	CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	UKMJWGFHXMGRNG-QLKFWGTOSA-O	132928.0		UKMJWGFHXMGRNG
BRD-A18579359-001-05-9	wiskostatin	Preclinical	actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor	WASL			0	95.1	Tocris	4434	Wiskostatin	423.979	CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|	XUBJEDZHBUPBKL-CYBMUJFWSA-N	981326.0		XUBJEDZHBUPBKL
BRD-A18579359-001-04-9	wiskostatin	Preclinical	actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor	WASL			0	91.47	Tocris	4434	Wiskostatin	423.979	CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4,r|	XUBJEDZHBUPBKL-CYBMUJFWSA-N	981326.0		XUBJEDZHBUPBKL
BRD-K78455053-001-03-9	wnt-c59	Preclinical	porcupine inhibitor	PORCN			0	97.36	Tocris	5148	Wnt-C59	379.168	Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	KHZOJCQBHJUJFY-UHFFFAOYSA-N	57519544.0		KHZOJCQBHJUJFY
BRD-K78455053-001-02-0	wnt-c59	Preclinical	porcupine inhibitor	PORCN			0	97.95	Tocris	5148	Wnt-C59	379.168	Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	KHZOJCQBHJUJFY-UHFFFAOYSA-N	57519544.0		KHZOJCQBHJUJFY
BRD-K78455053-001-01-2	wnt-c59	Preclinical	porcupine inhibitor	PORCN			0	98.11	Selleck	S7037	Wnt-C59 (C59)	379.168	Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	KHZOJCQBHJUJFY-UHFFFAOYSA-N	57519544.0		KHZOJCQBHJUJFY
BRD-K87343924-001-16-9	wortmannin	Preclinical	PI3K inhibitor	PI4KA|PI4KB|PIK3CA|PIK3CD|PIK3CG|PIK3R1|PLK1|PRKDC			0	93.41	MedChemEx	HY-10197	Wortmannin	428.147	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|	QDLHCMPXEPAAMD-QAIWCSMKSA-N	312145.0		QDLHCMPXEPAAMD
BRD-K87343924-001-12-3	wortmannin	Preclinical	PI3K inhibitor	PI4KA|PI4KB|PIK3CA|PIK3CD|PIK3CG|PIK3R1|PLK1|PRKDC			0	43.25	Selleck	S2758	Wortmannin	428.147	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|	QDLHCMPXEPAAMD-QAIWCSMKSA-N	312145.0		QDLHCMPXEPAAMD
BRD-K87343924-001-15-6	wortmannin	Preclinical	PI3K inhibitor	PI4KA|PI4KB|PIK3CA|PIK3CD|PIK3CG|PIK3R1|PLK1|PRKDC			0	56.11	Selleck	S2758	Wortmannin	428.147	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|	QDLHCMPXEPAAMD-QAIWCSMKSA-N	312145.0	BRD-K62662086-001-01-2|BRD-A75409952-001-12-3	QDLHCMPXEPAAMD
BRD-K05445342-001-05-3	WP1066	Phase 1	STAT inhibitor	STAT3			0	87.63	Selleck	S2796	WP1066	355.032	C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	VFUAJMPDXIRPKO-LQELWAHVSA-N	11210478.0		VFUAJMPDXIRPKO
BRD-K05445342-001-02-0	WP1066	Phase 1	STAT inhibitor	STAT3			0	65.16	Selleck	S2796	WP1066	355.032	C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	VFUAJMPDXIRPKO-LQELWAHVSA-N	11210478.0		VFUAJMPDXIRPKO
BRD-K05445342-001-06-9	WP1066	Phase 1	STAT inhibitor	STAT3			0	90.12	MedChemEx	HY-15312	WP1066	355.032	C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	VFUAJMPDXIRPKO-LQELWAHVSA-N	11210478.0		VFUAJMPDXIRPKO
BRD-K43644456-001-03-2	WP1130	Preclinical	deubiquitinase inhibitor	JAK2|UCHL5|USP14|USP9X			0	70.22	Selleck	S2243	Degrasyn (WP1130)	383.063	CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	LIDOPKHSVQTSJY-VMEIHUARSA-N	11222830.0		LIDOPKHSVQTSJY
BRD-K43644456-001-04-0	WP1130	Preclinical	deubiquitinase inhibitor	JAK2|UCHL5|USP14|USP9X			0	88.88	Selleck	S2243	WP1130	383.063	CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	LIDOPKHSVQTSJY-VMEIHUARSA-N	11222830.0		LIDOPKHSVQTSJY
BRD-K00005248-001-01-9	WP921	Preclinical					0	93.05	Enamine	Z2301535497	WP 921	210.021	OC(=O)Cn1nnnc1-c1ccsc1	DDVAZOPRCKAYOV-UHFFFAOYSA-N	3035658.0		DDVAZOPRCKAYOV
BRD-K45973863-001-01-4	WR99210	Preclinical	dihydrofolate reductase inhibitor	TYMS	infectious disease	malaria	0	98.92	Sigma	MFCD01679034	6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine	393.053	CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3,6|	MJZJYWCQPMNPRM-UHFFFAOYSA-N	121750.0		MJZJYWCQPMNPRM
BRD-K49389158-001-02-9	WWL-113	Preclinical	carboxylesterase inhibitor	CES3			0	98.37	Tocris	5259	WWL 113	466.189	CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1	AKIIPHDGVCFVCC-UHFFFAOYSA-N	17759482.0		AKIIPHDGVCFVCC
BRD-K49389158-001-01-3	WWL-113	Preclinical	carboxylesterase inhibitor	CES3			0	97.33	Tocris	5259	WWL 113	466.189	CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1	AKIIPHDGVCFVCC-UHFFFAOYSA-N	17759482.0		AKIIPHDGVCFVCC
BRD-K83176916-001-01-4	WWL-123	Preclinical	monoacylglycerol lipase inhibitor	ABHD6			0	96.0	Tocris	5317	WWL 123	436.179	CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O	UUJGYRHAOHORFC-UHFFFAOYSA-N	90209976.0		UUJGYRHAOHORFC
BRD-K83176916-001-02-9	WWL-123	Preclinical	monoacylglycerol lipase inhibitor	ABHD6			0	96.84	Tocris	5317	WWL 123	436.179	CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O	UUJGYRHAOHORFC-UHFFFAOYSA-N	90209976.0		UUJGYRHAOHORFC
BRD-K43419711-001-01-4	WY-16922	Phase 1	histamine release inhibitor				0	96.26	Sigma	PH006760	ethyl [2-(aminocarbonyl)-3-methoxyanilino](oxo)acetate	266.09	CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O	GGLRYZACPLNCKB-UHFFFAOYSA-N	198325.0		GGLRYZACPLNCKB
BRD-K00003540-001-01-9	WYE-125132	Preclinical	mTOR inhibitor	MTOR			0	96.04	MedChemEx	HY-10044	WYE-132	519.259	CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16,19|	QLHHRYZMBGPBJG-OYRHEFFESA-N	25227469.0		QLHHRYZMBGPBJG
BRD-K77008974-001-04-9	WYE-354	Preclinical	mTOR inhibitor	MTOR			0	95.6	MedChemEx	HY-12034	WYE-354	495.223	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	IMXHGCRIEAKIBU-UHFFFAOYSA-N	44219749.0		IMXHGCRIEAKIBU
BRD-K77008974-001-03-2	WYE-354	Preclinical	mTOR inhibitor	MTOR			0	93.46	Selleck	S1266	WYE-354	495.223	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	IMXHGCRIEAKIBU-UHFFFAOYSA-N	44219749.0		IMXHGCRIEAKIBU
BRD-K49900195-300-01-8	WYE-687	Preclinical	mTOR inhibitor	MTOR			0	94.1	Tocris	4282	WYE 687	528.26	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1	VDOCQQKGPJENHJ-UHFFFAOYSA-N	25229450.0		VDOCQQKGPJENHJ
BRD-K49900195-300-02-9	WYE-687	Preclinical	mTOR inhibitor	MTOR			0	92.03	Tocris	4282	WYE 687 dihydrochloride	528.26	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1	VDOCQQKGPJENHJ-UHFFFAOYSA-N	25229450.0		VDOCQQKGPJENHJ
BRD-K73293050-001-03-1	WZ-3146	Preclinical	EGFR inhibitor	EGFR			0	95.83	Selleck	S1170	WZ3146	464.173	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	APHGZZPEOCCYNO-UHFFFAOYSA-N	44607360.0		APHGZZPEOCCYNO
BRD-K72420232-001-13-1	WZ-4002	Preclinical	EGFR inhibitor	EGFR|ERBB2			0	92.97	Selleck	S1173	WZ4002	494.183	COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	ITTRLTNMFYIYPA-UHFFFAOYSA-N	44607530.0		ITTRLTNMFYIYPA
BRD-K72420232-001-12-3	WZ-4002	Preclinical	EGFR inhibitor	EGFR|ERBB2			0	83.41	Selleck	S1173	WZ4002	494.183	COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	ITTRLTNMFYIYPA-UHFFFAOYSA-N	44607530.0		ITTRLTNMFYIYPA
BRD-K45909031-001-01-5	WZ4003	Preclinical	AMPK inhibitor	NUAK1|NUAK2			0	95.12	Selleck	S7317	WZ4003	496.199	CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1	SDGJBAUIGHSMRI-UHFFFAOYSA-N	72200024.0		SDGJBAUIGHSMRI
BRD-K81728688-001-07-7	WZ8040	Preclinical	EGFR inhibitor	EGFR			0	93.65	Selleck	S1179	WZ8040	480.15	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	KIISCIGBPUVZBF-UHFFFAOYSA-N	44607531.0		KIISCIGBPUVZBF
BRD-K81728688-001-04-4	WZ8040	Preclinical	EGFR inhibitor	EGFR			0	94.06	Selleck	S1179	WZ8040	480.15	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	KIISCIGBPUVZBF-UHFFFAOYSA-N	44607531.0		KIISCIGBPUVZBF
BRD-K25359048-001-03-9	WZ811	Preclinical	CC chemokine receptor antagonist	CXCR4			0	94.05	Tocris	3951	WZ 811	290.153	C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	KBVFRXIGQQRMEF-UHFFFAOYSA-N	11565518.0		KBVFRXIGQQRMEF
BRD-K25359048-001-02-6	WZ811	Preclinical	CC chemokine receptor antagonist	CXCR4			0	93.63	Selleck	S2912	WZ811	290.153	C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	KBVFRXIGQQRMEF-UHFFFAOYSA-N	11565518.0		KBVFRXIGQQRMEF
BRD-K88358234-003-05-5	xaliproden	Phase 3	serotonin receptor agonist	HTR1A			0	99.21	Tocris	2491	Xaliproden hydrochloride	381.17	FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|	WJJYZXPHLSLMGE-UHFFFAOYSA-N	128919.0		WJJYZXPHLSLMGE
BRD-K88358234-003-04-8	xaliproden	Phase 3	serotonin receptor agonist	HTR1A			0	99.44	Tocris	2491	Xaliproden hydrochloride	381.17	FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|	WJJYZXPHLSLMGE-UHFFFAOYSA-N	128919.0		WJJYZXPHLSLMGE
BRD-K88358234-003-06-9	xaliproden	Phase 3	serotonin receptor agonist	HTR1A			0	97.9	Tocris	2491	Xaliproden hydrochloride	381.17	FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|	WJJYZXPHLSLMGE-UHFFFAOYSA-N	128919.0		WJJYZXPHLSLMGE
BRD-A59337442-051-07-9	xamoterol	Phase 3	adrenergic receptor agonist	ADRB1			0	87.58	Tocris	950	Xamoterol hemifumarate	339.179	OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	DXPOSRCHIDYWHW-UHFFFAOYSA-N	6917710.0	BRD-M39942365-051-06-2	DXPOSRCHIDYWHW
BRD-A59337442-051-06-1	xamoterol	Phase 3	adrenergic receptor agonist	ADRB1			0	86.69	Tocris	950	(2E)-2-butenedioic acid compound with N-(2-{[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino}ethyl)-4-morpholinecarboxamide (1:2)	339.179	OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	DXPOSRCHIDYWHW-UHFFFAOYSA-N	6917710.0	BRD-M39942365-051-07-0	DXPOSRCHIDYWHW
BRD-A59337442-051-05-3	xamoterol	Phase 3	adrenergic receptor agonist	ADRB1			0	84.25	Tocris	950	Xamoterol hemifumarate	339.179	OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	DXPOSRCHIDYWHW-UHFFFAOYSA-N	6917710.0	BRD-M39942365-051-05-4	DXPOSRCHIDYWHW
BRD-K72815923-034-02-0	xanomeline	Phase 3	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6|HTR7			0	83.31	Tocris	3569	Xanomeline oxalate	281.156	CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|	JOLJIIDDOBNFHW-UHFFFAOYSA-N	60809.0		JOLJIIDDOBNFHW
BRD-K72815923-034-01-2	xanomeline	Phase 3	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6|HTR7			0	97.8	MedChemEx	HY-13410	Xanomeline (oxalate)	281.156	CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|	JOLJIIDDOBNFHW-UHFFFAOYSA-N	60809.0		JOLJIIDDOBNFHW
BRD-K27135764-001-08-7	xanthone	Preclinical	antimalarial agent				0	97.15	Selleck	S2372	Xanthone	196.052	O=c1c2ccccc2oc2ccccc12	JNELGWHKGNBSMD-UHFFFAOYSA-N	7020.0		JNELGWHKGNBSMD
BRD-K27135764-001-09-5	xanthone	Preclinical	antimalarial agent				0	97.2	Selleck	S2372	XANTHONE	196.052	O=c1c2ccccc2oc2ccccc12	JNELGWHKGNBSMD-UHFFFAOYSA-N	7020.0		JNELGWHKGNBSMD
BRD-K12762134-001-10-4	XAV-939	Preclinical	tankyrase inhibitor	TNKS|TNKS2			0	95.63	Tocris	3748	XAV 939	312.054	FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1	KLGQSVMIPOVQAX-UHFFFAOYSA-N	135418940.0		KLGQSVMIPOVQAX
BRD-K12762134-001-07-0	XAV-939	Preclinical	tankyrase inhibitor	TNKS|TNKS2			0	96.8	Tocris	3748	XAV 939	312.054	FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1	KLGQSVMIPOVQAX-UHFFFAOYSA-N	135418940.0		KLGQSVMIPOVQAX
BRD-K12762134-001-06-2	XAV-939	Preclinical	tankyrase inhibitor	TNKS|TNKS2			0	95.05	Selleck	S1180	XAV-939	312.054	FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1	KLGQSVMIPOVQAX-UHFFFAOYSA-N	135418940.0		KLGQSVMIPOVQAX
BRD-K45875383-001-02-0	XBD173	Phase 2	benzodiazepine receptor ligand	TSPO			0	94.47	Tocris	5281	AC 5216	401.185	CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	NBMBIEOUVBHEBM-UHFFFAOYSA-N	6433109.0		NBMBIEOUVBHEBM
BRD-K45875383-001-03-9	XBD173	Phase 2	benzodiazepine receptor ligand	TSPO			0	98.27	Tocris	5281	AC 5216	401.185	CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	NBMBIEOUVBHEBM-UHFFFAOYSA-N	6433109.0		NBMBIEOUVBHEBM
BRD-K45875383-001-01-2	XBD173	Phase 2	benzodiazepine receptor ligand	TSPO			0	99.75	MedChemEx	HY-15527	Emapunil	401.185	CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	NBMBIEOUVBHEBM-UHFFFAOYSA-N	6433109.0		NBMBIEOUVBHEBM
BRD-K69211575-001-01-9	XD-14	Preclinical	bromodomain inhibitor	BRD2|BRD3|BRD4|BRDT			0	87.21	Tocris	5489	XD 14	421.167	CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1	DPBKLIVPNYGQQG-UHFFFAOYSA-N	52670832.0		DPBKLIVPNYGQQG
BRD-K69211575-001-02-9	XD-14	Preclinical	bromodomain inhibitor	BRD2|BRD3|BRD4|BRDT			0	86.91	Tocris	5489	XD 14	421.167	CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1	DPBKLIVPNYGQQG-UHFFFAOYSA-N	52670832.0		DPBKLIVPNYGQQG
BRD-K42748308-300-03-9	XE-991	Preclinical	potassium channel blocker	KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5			0	97.5	Tocris	2000	XE 991 dihydrochloride	376.158	O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	KHJFBUUFMUBONL-UHFFFAOYSA-N	656732.0		KHJFBUUFMUBONL
BRD-K42748308-300-02-0	XE-991	Preclinical	potassium channel blocker	KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5			0	98.74	Tocris	2000	XE 991 dihydrochloride	376.158	O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	KHJFBUUFMUBONL-UHFFFAOYSA-N	656732.0		KHJFBUUFMUBONL
BRD-K99506538-001-03-8	xenalipin	Phase 2					0	98.55	Enamine	Z56854445	4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxylic acid	266.055	OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F	IQOMYCGTGFGDFN-UHFFFAOYSA-N	55251.0		IQOMYCGTGFGDFN
BRD-A21446384-001-01-1	xibenolol	Phase 3	adrenergic receptor antagonist				0	98.27	PrincetonBio	OSSK_690214	1-(tert-butylamino)-3-(2,3-dimethylphenoxy)-2-propanol	251.189	Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C |&1:8,r|	RKUQLAPSGZJLGP-ZDUSSCGKSA-N	12179892.0		RKUQLAPSGZJLGP
BRD-K79633074-001-01-8	xilobam	Phase 1					0	88.42	Enamine	Z203043368		245.153	CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	PAXRPWSXCPTPCA-QINSGFPZSA-N	6434391.0		PAXRPWSXCPTPCA
BRD-K27393415-001-01-0	xipamide	Launched	carbonic anhydrase inhibitor	SLC12A3	cardiology	edema|hypertension	0	99.61	OxChem	AX8031911		354.044	Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O	MTZBBNMLMNBNJL-UHFFFAOYSA-N	26618.0		MTZBBNMLMNBNJL
BRD-K04266228-001-04-6	XL019	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	71.68	MedChemEx	HY-13775	XL019	444.227	O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	ISOCDPQFIXDIMS-QHCPKHFHSA-N	57990869.0		ISOCDPQFIXDIMS
BRD-K04266228-001-05-3	XL019	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	85.4	MedChemEx	HY-13775	XL019	444.227	O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	ISOCDPQFIXDIMS-QHCPKHFHSA-N	57990869.0		ISOCDPQFIXDIMS
BRD-K04266228-001-02-0	XL019	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	59.13	Selleck	S7036	XL019	444.227	O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	ISOCDPQFIXDIMS-QHCPKHFHSA-N	57990869.0		ISOCDPQFIXDIMS
BRD-K04266228-001-03-8	XL019	Phase 1	JAK inhibitor	JAK1|JAK2|JAK3			0	74.61	Selleck	S7036	XL019	444.227	O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	ISOCDPQFIXDIMS-QHCPKHFHSA-N	57990869.0		ISOCDPQFIXDIMS
BRD-K00003439-001-01-9	XL041	Preclinical	LXR agonist				0	98.23	MedChemEx	HY-101973	XL041	608.111	CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O	HNAJDMYOTDNOBK-UHFFFAOYSA-N	49787490.0		HNAJDMYOTDNOBK
BRD-K95901403-001-04-5	XL147	Phase 2	PI3K inhibitor	PIK3CA|PIK3CD|PIK3CG			0	96.66	Selleck	S1118	XL-147 analog	448.078	Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	MQMKRQLTIWPEDM-UHFFFAOYSA-N	1893730.0		MQMKRQLTIWPEDM
BRD-K95901403-001-06-9	XL147	Phase 2	PI3K inhibitor	PIK3CA|PIK3CD|PIK3CG			0	96.39	MedChemEx	HY-11105	Pilaralisib analogue	448.078	Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	MQMKRQLTIWPEDM-UHFFFAOYSA-N	1893730.0		MQMKRQLTIWPEDM
BRD-K14274271-001-02-8	XL228	Phase 1	Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor	IGF1R|SRC			0	96.72	MedChemEx	HY-15749	XL228	437.265	CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1	ALKJNCZNEOTEMP-UHFFFAOYSA-N	59757974.0		ALKJNCZNEOTEMP
BRD-K14274271-001-01-0	XL228	Phase 1	Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor	IGF1R|SRC			0	70.02	MedChemEx	HY-15749	XL228	437.265	CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1	ALKJNCZNEOTEMP-UHFFFAOYSA-N	59757974.0		ALKJNCZNEOTEMP
BRD-K03549949-001-02-9	XL388	Preclinical	mTOR inhibitor	MTOR			0	96.66	Tocris	4893	XL 388	455.132	Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	LNFBAYSBVQBKFR-UHFFFAOYSA-N	59604787.0		LNFBAYSBVQBKFR
BRD-K03549949-001-01-0	XL388	Preclinical	mTOR inhibitor	MTOR			0	97.77	Selleck	S7035	XL388	455.132	Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	LNFBAYSBVQBKFR-UHFFFAOYSA-N	59604787.0		LNFBAYSBVQBKFR
BRD-K03765900-001-01-9	XL647	Phase 3	EGFR inhibitor|VEGFR inhibitor	EGFR|EPHB4|ERBB2|FLT4|KDR			0	95.23	MedChemEx	HY-13314	XL-647	490.134	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	HVXKQKFEHMGHSL-QKDCVEJESA-N			HVXKQKFEHMGHSL
BRD-K00003558-001-01-9	XL888	Phase 1	HSP inhibitor				0	97.08	MedChemEx	HY-13313	XL888	503.29	[H][C@]1(C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)C(=O)C1CC1)NC(=O)c1cc(N[C@H](C)CC)c(cc1C)C(N)=O |TLB:9:8:4.5:1.2.7|	LHGWWAFKVCIILM-HLRQEUIKSA-N			LHGWWAFKVCIILM
BRD-K48449981-001-02-7	XMD17-109	Preclinical	MAP kinase inhibitor	MAPK7			0	98.26	Tocris	5393	ERK5-IN-1	638.369	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	XVBGRTMNFNMINE-UHFFFAOYSA-N	71604307.0		XVBGRTMNFNMINE
BRD-K48449981-001-01-9	XMD17-109	Preclinical	MAP kinase inhibitor	MAPK7			0	93.73	MedChemEx	HY-15665	XMD17-109	638.369	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	XVBGRTMNFNMINE-UHFFFAOYSA-N	71604307.0		XVBGRTMNFNMINE
BRD-K50387473-001-11-0	XMD8-92	Preclinical	MAP kinase inhibitor	DCLK2|MAPK7|PLK4|TNK1			0	88.71	MedChemEx	HY-14443	XMD8-92	474.238	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	QAPAJIZPZGWAND-UHFFFAOYSA-N	46843772.0		QAPAJIZPZGWAND
BRD-K50387473-001-09-4	XMD8-92	Preclinical	MAP kinase inhibitor	DCLK2|MAPK7|PLK4|TNK1			0	82.01	MedChemEx	HY-14443	XMD8-92	474.238	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	QAPAJIZPZGWAND-UHFFFAOYSA-N	46843772.0		QAPAJIZPZGWAND
BRD-K50387473-001-10-2	XMD8-92	Preclinical	MAP kinase inhibitor	DCLK2|MAPK7|PLK4|TNK1			0	80.87	Tocris	4132	XMD 8-92	474.238	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	QAPAJIZPZGWAND-UHFFFAOYSA-N	46843772.0		QAPAJIZPZGWAND
BRD-K21565985-003-24-9	xylazine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	anesthetic	0	97.88	MedChemEx	HY-B0443A	Xylazine (hydrochloride)	220.103	Cc1cccc(C)c1NC1=NCCCS1 |t:10|	BPICBUSOMSTKRF-UHFFFAOYSA-N	5707.0		BPICBUSOMSTKRF
BRD-K21565985-001-22-5	xylazine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	anesthetic	0	99.59	MicroSource	1501200	XYLAZINE	220.103	Cc1cccc(C)c1NC1=NCCCS1 |t:10|	BPICBUSOMSTKRF-UHFFFAOYSA-N	5707.0		BPICBUSOMSTKRF
BRD-K21565985-003-02-3	xylazine	Launched	adrenergic receptor agonist	ADRA2A|ADRA2B|ADRA2C	neurology/psychiatry	anesthetic	0	97.88	Selleck	S2516	Xylazine HCl	220.103	Cc1cccc(C)c1NC1=NCCCS1 |t:10|	BPICBUSOMSTKRF-UHFFFAOYSA-N	5707.0		BPICBUSOMSTKRF
BRD-K08356259-003-25-9	xylometazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	otolaryngology|allergy	nasal congestion|allergic rhinitis	0	90.12	MedChemEx	HY-B0475	Xylometazoline (hydrochloride)	244.194	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|	HUCJFAOMUPXHDK-UHFFFAOYSA-N	5709.0		HUCJFAOMUPXHDK
BRD-K08356259-003-24-7	xylometazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	otolaryngology|allergy	nasal congestion|allergic rhinitis	0	98.38	MicroSource	1500614	XYLOMETAZOLINE HYDROCHLORIDE	244.194	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|	HUCJFAOMUPXHDK-UHFFFAOYSA-N	5709.0		HUCJFAOMUPXHDK
BRD-K08356259-003-23-9	xylometazoline	Launched	adrenergic receptor agonist	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	otolaryngology|allergy	nasal congestion|allergic rhinitis	0	95.02	Selleck	S2576	Xylometazoline HCl	244.194	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|	HUCJFAOMUPXHDK-UHFFFAOYSA-N	5709.0		HUCJFAOMUPXHDK
BRD-K10759144-001-03-5	xylose	Launched					0	0.0	Selleck	S2124	Xylose	150.053	OC[C@@H](O)[C@H](O)[C@@H](O)C=O	PYMYPHUHKUWMLA-VPENINKCSA-N	644160.0		PYMYPHUHKUWMLA
BRD-K10759144-001-04-3	xylose	Launched					0	100.0	Selleck	S2124	Xylose	150.053	OC[C@@H](O)[C@H](O)[C@@H](O)C=O	PYMYPHUHKUWMLA-VPENINKCSA-N	644160.0		PYMYPHUHKUWMLA
BRD-K09317629-004-02-9	Y-11	Preclinical	focal adhesion kinase inhibitor	PTK2			0	100.0	Tocris	4498	Y 11	185.14	OCC[N+]12CN3CN(CN(C3)C1)C2	SQWGHMPVSMSPNY-UHFFFAOYSA-N	427018.0		SQWGHMPVSMSPNY
BRD-K09317629-004-01-7	Y-11	Preclinical	focal adhesion kinase inhibitor	PTK2			0	99.12	Tocris	4498	Y 11	185.14	OCC[N+]12CN3CN(CN(C3)C1)C2	SQWGHMPVSMSPNY-UHFFFAOYSA-N	427018.0		SQWGHMPVSMSPNY
BRD-K94832621-001-03-1	Y-134	Preclinical	estrogen receptor antagonist	ESR1|ESR2			0	91.22	Tocris	2676	Y 134	472.182	CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	LQEOPHGPHCWOAC-UHFFFAOYSA-N	11784736.0		LQEOPHGPHCWOAC
BRD-K94832621-001-02-3	Y-134	Preclinical	estrogen receptor antagonist	ESR1|ESR2			0	93.3	Tocris	2676	Y 134	472.182	CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	LQEOPHGPHCWOAC-UHFFFAOYSA-N	11784736.0		LQEOPHGPHCWOAC
BRD-K94832621-001-04-9	Y-134	Preclinical	estrogen receptor antagonist	ESR1|ESR2			0	93.94	Tocris	2676	Y 134	472.182	CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	LQEOPHGPHCWOAC-UHFFFAOYSA-N	11784736.0		LQEOPHGPHCWOAC
BRD-K45117373-001-02-9	Y-26763	Phase 1	potassium channel activator	KCNJ8			0	95.72	Tocris	2076	Y-26763	276.111	CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	IWTCFIIOUXJOOV-OLZOCXBDSA-N	121878.0		IWTCFIIOUXJOOV
BRD-K45117373-001-03-9	Y-26763	Phase 1	potassium channel activator	KCNJ8			0	96.19	Tocris	2076	Y-26763	276.111	CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	IWTCFIIOUXJOOV-OLZOCXBDSA-N	121878.0		IWTCFIIOUXJOOV
BRD-K42679050-001-02-1	Y-27152	Phase 1	potassium channel activator	KCNJ8			0	99.08	Tocris	2077	Y-27152	366.158	CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	RHFUXPCCELGMFC-UXHICEINSA-N	6918184.0		RHFUXPCCELGMFC
BRD-K42679050-001-03-9	Y-27152	Phase 1	potassium channel activator	KCNJ8			0	97.79	Tocris	2077	Y-27152	366.158	CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	RHFUXPCCELGMFC-UXHICEINSA-N	6918184.0		RHFUXPCCELGMFC
BRD-K44084986-300-09-2	Y-27632	Preclinical	rho associated kinase inhibitor	PKIA|PKN2|PRKACA|PRKCE|ROCK1|ROCK2			0	99.62	Selleck	S1049	Y-27632 2HCl	247.168	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	IYOZTVGMEWJPKR-IJLUTSLNSA-N			IYOZTVGMEWJPKR
BRD-K44084986-300-08-4	Y-27632	Preclinical	rho associated kinase inhibitor	PKIA|PKN2|PRKACA|PRKCE|ROCK1|ROCK2			0	94.59	Tocris	1254	Y-27632 dihydrochloride	247.168	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	IYOZTVGMEWJPKR-IJLUTSLNSA-N			IYOZTVGMEWJPKR
BRD-K44084986-300-07-6	Y-27632	Preclinical	rho associated kinase inhibitor	PKIA|PKN2|PRKACA|PRKCE|ROCK1|ROCK2			0	85.52	Selleck	S1049	Y-27632 2HCl	247.168	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	IYOZTVGMEWJPKR-IJLUTSLNSA-N			IYOZTVGMEWJPKR
BRD-K48449073-034-02-7	Y-29794	Preclinical	prolyl endopeptidase inhibitor	PREP			0	64.16	Tocris	1634	Y-29794 oxalate	418.211	CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1	HAGHKJDWBDSFKC-UHFFFAOYSA-N	195609.0		HAGHKJDWBDSFKC
BRD-K48449073-034-03-9	Y-29794	Preclinical	prolyl endopeptidase inhibitor	PREP			0	89.89	Tocris	1634	Y-29794 oxalate	418.211	CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1	HAGHKJDWBDSFKC-UHFFFAOYSA-N	195609.0		HAGHKJDWBDSFKC
BRD-K96259238-001-01-4	Y-320	Preclinical	interleukin inhibitor	IL17A			0	93.42	Selleck	S7516	Y-320	504.204	Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	BWZNJVZTAWBIFG-UHFFFAOYSA-N	22227931.0		BWZNJVZTAWBIFG
BRD-K96259238-001-02-9	Y-320	Preclinical	interleukin inhibitor	IL17A			0	96.38	MedChemEx	HY-15898	Y-320	504.204	Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	BWZNJVZTAWBIFG-UHFFFAOYSA-N	22227931.0		BWZNJVZTAWBIFG
BRD-K56751279-300-04-9	Y-39983	Phase 2	rho associated kinase inhibitor	ROCK1|ROCK2			0	95.39	MedChemEx	HY-10069	Y-33075 (dihydrochloride)	280.132	C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	JTVBXQAYBIJXRP-SNVBAGLBSA-N	9810884.0		JTVBXQAYBIJXRP
BRD-K56751279-300-01-4	Y-39983	Phase 2	rho associated kinase inhibitor	ROCK1|ROCK2			0	97.51	MedChemEx	HY-10069	Y-33075 (dihydrochloride)	280.132	C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	JTVBXQAYBIJXRP-SNVBAGLBSA-N	9810884.0		JTVBXQAYBIJXRP
BRD-K60476892-001-16-1	YC-1	Preclinical	guanylyl cyclase activator	GUCY1A2|GUCY1A3|GUCY1B3|HIF1A			0	93.54	Tocris	4307	YC 1	304.121	OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12	OQQVFCKUDYMWGV-UHFFFAOYSA-N	5712.0		OQQVFCKUDYMWGV
BRD-K60476892-001-17-9	YC-1	Preclinical	guanylyl cyclase activator	GUCY1A2|GUCY1A3|GUCY1B3|HIF1A			0	95.49	Tocris	4307	YC 1	304.121	OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12	OQQVFCKUDYMWGV-UHFFFAOYSA-N	5712.0		OQQVFCKUDYMWGV
BRD-K91403886-003-01-4	YIL-781	Preclinical	ghrelin receptor antagonist	GHSR			0	79.24	Tocris	3959	YIL 781	409.217	CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1	FRKXOBMDEXCHHD-SFHVURJKSA-N	23631116.0		FRKXOBMDEXCHHD
BRD-K91403886-003-02-9	YIL-781	Preclinical	ghrelin receptor antagonist	GHSR			0	95.61	Tocris	3959	YIL 781	409.217	CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1	FRKXOBMDEXCHHD-SFHVURJKSA-N	23631116.0		FRKXOBMDEXCHHD
BRD-A62182663-001-04-8	YK-4-279	Preclinical	apoptosis inhibitor	EWSR1|FLI1			0	95.76	Tocris	4067	YK 4-279	365.022	COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|	HLXSCTYHLQHQDJ-KRWDZBQOSA-N	93948843.0		HLXSCTYHLQHQDJ
BRD-A62182663-001-03-0	YK-4-279	Preclinical	apoptosis inhibitor	EWSR1|FLI1			0	98.2	MedChemEx	HY-14507	YK-4-279	365.022	COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11,r|	HLXSCTYHLQHQDJ-KRWDZBQOSA-N	93948843.0		HLXSCTYHLQHQDJ
BRD-K00003390-003-01-9	YL0919	Preclinical	selective serotonin reuptake inhibitor (SSRI)				0	96.45	MedChemEx	HY-100769	YL0919	298.168	OC1(Cn2ccccc2=O)CCN(Cc2ccccc2)CC1	BGMVOROUOUVVRV-UHFFFAOYSA-N	54673543.0		BGMVOROUOUVVRV
BRD-K09436144-001-01-7	YM-022	Phase 2	CCK receptor antagonist	CCKBR			0	99.62	Sigma	MFCD00917023	N-(3-methylphenyl)-N'-{(3R)-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl}urea	516.216	Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|	YCXFHPUBGMMWJQ-PMERELPUSA-N	122130.0		YCXFHPUBGMMWJQ
BRD-K76703230-004-09-9	YM-155	Phase 2	survivin inhibitor	BIRC5			0	63.9	MedChemEx	HY-10194	YM-155	363.146	COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O	OTSOOHRUMBRSHZ-UHFFFAOYSA-N	10126189.0		OTSOOHRUMBRSHZ
BRD-K76703230-004-04-1	YM-155	Phase 2	survivin inhibitor	BIRC5			0	93.58	Selleck	S1130	YM155 (Sepantronium Bromide)	363.146	COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O	OTSOOHRUMBRSHZ-UHFFFAOYSA-N	10126189.0	BRD-U99450240-000-01-2	OTSOOHRUMBRSHZ
BRD-K76703230-004-03-3	YM-155	Phase 2	survivin inhibitor	BIRC5			0	87.81	MedChemEx	HY-10194	YM-155	363.146	COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O	OTSOOHRUMBRSHZ-UHFFFAOYSA-N	10126189.0		OTSOOHRUMBRSHZ
BRD-K48488978-001-05-3	YM-201636	Preclinical	PI3K inhibitor				0	95.9	Selleck	S1219	YM201636	467.171	Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	YBPIBGNBHHGLEB-UHFFFAOYSA-N	9956222.0		YBPIBGNBHHGLEB
BRD-K52087522-300-02-9	YM-244769	Preclinical	sodium/calcium exchange inhibitor				0	93.37	Tocris	4544	YM 244769	443.165	Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1	JZMLHJRKSJXARY-UHFFFAOYSA-N	11442117.0		JZMLHJRKSJXARY
BRD-K52087522-300-01-2	YM-244769	Preclinical	sodium/calcium exchange inhibitor				0	94.4	Tocris	4544	YM 244769	443.165	Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1	JZMLHJRKSJXARY-UHFFFAOYSA-N	11442117.0		JZMLHJRKSJXARY
BRD-K59650319-003-03-3	YM-298198	Preclinical	glutamate receptor antagonist	GRM1			0	61.48	Tocris	2448	YM 298198 hydrochloride	342.151	CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C	KCBXOMYXOBVLED-UHFFFAOYSA-N	9819432.0		KCBXOMYXOBVLED
BRD-K59650319-003-04-9	YM-298198	Preclinical	glutamate receptor antagonist	GRM1			0	82.45	Tocris	2448	YM 298198 hydrochloride	342.151	CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C	KCBXOMYXOBVLED-UHFFFAOYSA-N	9819432.0		KCBXOMYXOBVLED
BRD-K48059230-003-02-9	YM-298198-desmethyl	Preclinical	glutamate receptor antagonist	GRM1			0	68.02	Tocris	2447	Desmethyl-YM 298198	328.136	Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1	VWOMTTIMBHBPBI-UHFFFAOYSA-N	11716890.0		VWOMTTIMBHBPBI
BRD-K48059230-003-03-9	YM-298198-desmethyl	Preclinical	glutamate receptor antagonist	GRM1			0	87.86	Tocris	2447	Desmethyl-YM 298198	328.136	Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1	VWOMTTIMBHBPBI-UHFFFAOYSA-N	11716890.0		VWOMTTIMBHBPBI
BRD-K38398115-001-01-9	YM-511	Phase 2	aromatase inhibitor	CYP19A1			0	98.92	Tocris	3278	4-[(4-bromobenzyl)(4H-1,2,4-triazol-4-yl)amino]benzonitrile	353.028	Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	GGPPBTSXFROGAE-UHFFFAOYSA-N	177865.0		GGPPBTSXFROGAE
BRD-K38398115-001-02-9	YM-511	Phase 2	aromatase inhibitor	CYP19A1			0		Tocris	3278	YM 511	353.028	Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	GGPPBTSXFROGAE-UHFFFAOYSA-N	177865.0		GGPPBTSXFROGAE
BRD-K42563464-001-02-7	YM-58483	Preclinical	calcium channel blocker	TRPC3|TRPC5|TRPM4			0	89.27	Tocris	3939	YM 58483	421.043	Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	XPRZIORDEVHURQ-UHFFFAOYSA-N	2455.0		XPRZIORDEVHURQ
BRD-K42563464-001-01-9	YM-58483	Preclinical	calcium channel blocker	TRPC3|TRPC5|TRPM4			0	99.86	EMDBio	203890-5MG	CRAC Channel Inhibitor, BTP2	421.043	Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	XPRZIORDEVHURQ-UHFFFAOYSA-N	2455.0		XPRZIORDEVHURQ
BRD-K91716465-001-01-2	YM-750	Phase 1	ACAT inhibitor	SOAT1			0	98.4	Tocris	3039	N-cycloheptyl-N-(9H-fluoren-2-ylmethyl)-N'-mesitylurea	452.283	Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1	FMLJREWZCZHGGW-UHFFFAOYSA-N	9911716.0		FMLJREWZCZHGGW
BRD-K91716465-001-02-9	YM-750	Phase 1	ACAT inhibitor	SOAT1			0		Tocris	3039	YM 750	452.283	Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1	FMLJREWZCZHGGW-UHFFFAOYSA-N	9911716.0		FMLJREWZCZHGGW
BRD-K06712146-001-03-8	YM-90709	Preclinical	IL5 inhibitor	CSF2RB|IL5RA			0	88.31	MedChemEx	HY-19969	YM-90709	359.163	COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	HIXSPVQXXDULHS-UHFFFAOYSA-N	1103147.0		HIXSPVQXXDULHS
BRD-K06712146-001-04-9	YM-90709	Preclinical	IL5 inhibitor	CSF2RB|IL5RA			0	95.6	Tocris	1675	YM 90709	359.163	COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	HIXSPVQXXDULHS-UHFFFAOYSA-N	1103147.0		HIXSPVQXXDULHS
BRD-K06712146-001-02-0	YM-90709	Preclinical	IL5 inhibitor	CSF2RB|IL5RA			0	0.0	Tocris	1675	YM 90709	359.163	COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	HIXSPVQXXDULHS-UHFFFAOYSA-N	1103147.0		HIXSPVQXXDULHS
BRD-K12932420-001-03-1	YM-976	Phase 1	phosphodiesterase inhibitor	PDE4A			0	96.89	Tocris	1821	YM 976	313.098	CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	MNHXYNNKDDXKNP-UHFFFAOYSA-N	6604918.0		MNHXYNNKDDXKNP
BRD-K12932420-001-04-9	YM-976	Phase 1	phosphodiesterase inhibitor	PDE4A			0	98.61	Tocris	1821	YM 976	313.098	CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	MNHXYNNKDDXKNP-UHFFFAOYSA-N	6604918.0		MNHXYNNKDDXKNP
BRD-K12932420-001-02-3	YM-976	Phase 1	phosphodiesterase inhibitor	PDE4A			0	97.79	Tocris	1821	YM 976	313.098	CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	MNHXYNNKDDXKNP-UHFFFAOYSA-N	6604918.0		MNHXYNNKDDXKNP
BRD-K04622161-001-04-9	YO-01027	Preclinical	gamma secretase inhibitor				0	97.84	Tocris	4489	DBZ	463.171	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	QSHGISMANBKLQL-OWJWWREXSA-N	11454028.0		QSHGISMANBKLQL
BRD-K04622161-001-03-1	YO-01027	Preclinical	gamma secretase inhibitor				0	96.71	Tocris	4489	DBZ	463.171	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	QSHGISMANBKLQL-OWJWWREXSA-N	11454028.0		QSHGISMANBKLQL
BRD-K04622161-001-02-3	YO-01027	Preclinical	gamma secretase inhibitor				0	95.52	Selleck	S2711	YO-01027	463.171	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	QSHGISMANBKLQL-OWJWWREXSA-N	11454028.0		QSHGISMANBKLQL
BRD-K88570498-001-01-9	yoda-1	Preclinical	piezo channel activator	PIEZO1			0	96.08	Tocris	5586	Yoda 1	353.957	Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1	BQNXBSYSQXSXPT-UHFFFAOYSA-N	2746822.0		BQNXBSYSQXSXPT
BRD-K88570498-001-02-9	yoda-1	Preclinical	piezo channel activator	PIEZO1			0	94.7	Tocris	5586	Yoda 1	353.957	Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1	BQNXBSYSQXSXPT-UHFFFAOYSA-N	2746822.0		BQNXBSYSQXSXPT
BRD-K35586044-003-15-4	yohimbine	Launched	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|KCNJ1|KCNJ10|KCNJ11|KCNJ12|KCNJ14|KCNJ15|KCNJ8	cardiology	cardiac arrythmia|bradycardia	0	97.72	Tocris	1127	Yohimbine hydrochloride	354.194	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-SCYLSFHTSA-N	8969.0		BLGXFZZNTVWLAY
BRD-K35586044-003-14-7	yohimbine	Launched	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|KCNJ1|KCNJ10|KCNJ11|KCNJ12|KCNJ14|KCNJ15|KCNJ8	cardiology	cardiac arrythmia|bradycardia	0	93.67	Selleck	S2373	Yohimbine HCl	354.194	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-SCYLSFHTSA-N	8969.0		BLGXFZZNTVWLAY
BRD-K35586044-003-16-2	yohimbine	Launched	adrenergic receptor antagonist	ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|KCNJ1|KCNJ10|KCNJ11|KCNJ12|KCNJ14|KCNJ15|KCNJ8	cardiology	cardiac arrythmia|bradycardia	0	95.74	MicroSource	1500663	YOHIMBINE HYDROCHLORIDE	354.194	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	BLGXFZZNTVWLAY-SCYLSFHTSA-N	8969.0	BRD-A87445400-003-04-4	BLGXFZZNTVWLAY
BRD-K06208435-003-08-2	YS-035	Preclinical	calcium channel blocker				0	96.03	Tocris	416	YS-035 hydrochloride	359.21	COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	OXZMQFKVNVQMLI-UHFFFAOYSA-N	5714.0		OXZMQFKVNVQMLI
BRD-K06208435-003-09-9	YS-035	Preclinical	calcium channel blocker				0	94.98	Tocris	416	YS-035 hydrochloride	359.21	COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	OXZMQFKVNVQMLI-UHFFFAOYSA-N	5714.0		OXZMQFKVNVQMLI
BRD-K00004746-001-01-9	YS-201	Preclinical	calcium receptor antagonist				0	93.12	MedChemEx	HY-U00137	YS-201	457.221	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCCCC1 |&1:12,r,c:5,10|	LBSRZVRITCRLIU-JOCHJYFZSA-N	29942219.0		LBSRZVRITCRLIU
BRD-K53438416-001-02-9	YZ9	Preclinical	phosphofructokinase inhibitor	MIF|PFKFB3			0	95.85	Tocris	5048	YZ9	234.053	CCOC(=O)c1cc2ccc(O)cc2oc1=O	IETDBZQIWIJQJG-UHFFFAOYSA-N	5289613.0		IETDBZQIWIJQJG
BRD-K53438416-001-01-9	YZ9	Preclinical	phosphofructokinase inhibitor	MIF|PFKFB3			0	97.18	Tocris	5048	YZ9	234.053	CCOC(=O)c1cc2ccc(O)cc2oc1=O	IETDBZQIWIJQJG-UHFFFAOYSA-N	5289613.0		IETDBZQIWIJQJG
BRD-K81865756-001-02-5	Y16	Preclinical	rho associated kinase inhibitor	RHOA			0	63.43	MedChemEx	HY-12649	Y16	384.147	Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1	ITMLWGWTDWJSRZ-PXLXIMEGSA-N	989521.0		ITMLWGWTDWJSRZ
BRD-K81865756-001-01-7	Y16	Preclinical	rho associated kinase inhibitor	RHOA			0	62.91	MedChemEx	HY-12649	Y16	384.147	Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1	ITMLWGWTDWJSRZ-PXLXIMEGSA-N	989521.0		ITMLWGWTDWJSRZ
BRD-K01826799-003-03-9	zacopride	Phase 2	serotonin receptor antagonist	HTR3A|HTR3B|HTR4|HTR5A			0	97.84	Tocris	1795	Zacopride hydrochloride	345.101	COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|	FEROPKNOYKURCJ-ZDUSSCGKSA-N	9819593.0		FEROPKNOYKURCJ
BRD-K01826799-003-02-9	zacopride	Phase 2	serotonin receptor antagonist	HTR3A|HTR3B|HTR4|HTR5A			0	94.28	Tocris	1795	Zacopride hydrochloride	345.101	COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13,THB:12:13:16.17:19.20|	FEROPKNOYKURCJ-ZDUSSCGKSA-N	9819593.0		FEROPKNOYKURCJ
BRD-K71289571-001-11-4	zafirlukast	Launched	leukotriene receptor antagonist	CYSLTR1|CYSLTR2	pulmonary	asthma	0	95.1	Selleck	S1633	Zafirlukast	575.209	COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C	YEEZWCHGZNKEEK-UHFFFAOYSA-N	5717.0		YEEZWCHGZNKEEK
BRD-K85925969-001-17-4	zalcitabine	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	100.0	MicroSource	1502360	ZALCITABINE	211.096	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	WREGKURFCTUGRC-POYBYMJQSA-N	24066.0		WREGKURFCTUGRC
BRD-K85925969-001-16-6	zalcitabine	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	95.49	Selleck	S1719	Zalcitabine	211.096	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	WREGKURFCTUGRC-POYBYMJQSA-N	24066.0		WREGKURFCTUGRC
BRD-K85925969-001-19-9	zalcitabine	Launched	nucleoside reverse transcriptase inhibitor		infectious disease	human immunodeficiency virus (HIV-1)	0	98.78	MedChemEx	HY-17392	Zalcitabine	211.096	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	WREGKURFCTUGRC-POYBYMJQSA-N	24066.0		WREGKURFCTUGRC
BRD-A26032986-050-03-9	zaldaride	Phase 3	calmodulin antagonist	CALM1			0	96.11	Tocris	2255	CGS 9343B	428.221	C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|	HTGCJAAPDHZCHL-SANMLTNESA-N	92460626.0		HTGCJAAPDHZCHL
BRD-A26032986-050-02-1	zaldaride	Phase 3	calmodulin antagonist	CALM1			0	95.7	Tocris	2255	CGS 9343B	428.221	C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|	HTGCJAAPDHZCHL-SANMLTNESA-N	92460626.0		HTGCJAAPDHZCHL
BRD-A26032986-050-04-9	zaldaride	Phase 3	calmodulin antagonist	CALM1			0	95.95	Tocris	2255	CGS 9343B	428.221	C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|	HTGCJAAPDHZCHL-SANMLTNESA-N	92460626.0		HTGCJAAPDHZCHL
BRD-K12261274-001-02-4	zaltidine	Phase 3	histamine receptor antagonist	HRH2			0	88.8	MedChemEx	HY-15541	Zaltidine	222.069	Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1	GIMNAEMRNXUAQP-UHFFFAOYSA-N	56051.0		GIMNAEMRNXUAQP
BRD-K12261274-001-01-6	zaltidine	Phase 3	histamine receptor antagonist	HRH2			0	41.48	MedChemEx	HY-15541	Zaltidine	222.069	Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1	GIMNAEMRNXUAQP-UHFFFAOYSA-N	56051.0		GIMNAEMRNXUAQP
BRD-A00578795-001-04-3	zaltoprofen	Launched	cyclooxygenase inhibitor		endocrinology|neurology/psychiatry	fever|pain relief	0	97.2	Selleck	S3008	Zaltoprofen	298.066	C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|	MUXFZBHBYYYLTH-SNVBAGLBSA-N	13306545.0		MUXFZBHBYYYLTH
BRD-A00578795-001-05-9	zaltoprofen	Launched	cyclooxygenase inhibitor		endocrinology|neurology/psychiatry	fever|pain relief	0	94.42	MedChemEx	HY-B0619	Zaltoprofen	298.066	C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1,r|	MUXFZBHBYYYLTH-SNVBAGLBSA-N	13306545.0		MUXFZBHBYYYLTH
BRD-K11984358-001-01-3	ZAMI-633	Phase 3	urease inhibitor				1	0.0	PrincetonBio	OSSM_091798	N-hydroxypropanamide	89.048	CCC(=O)NO	RSIPQHOWTCNEBI-UHFFFAOYSA-N	75743.0		RSIPQHOWTCNEBI
BRD-K80451230-051-03-4	zamifenacin	Phase 3	acetylcholine receptor antagonist	CHRM3			0	96.5	Tocris	2579	Zamifenacin fumarate	415.215	C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	BDNFQGRSKSQXRI-XMMPIXPASA-N	3086618.0		BDNFQGRSKSQXRI
BRD-K80451230-051-02-6	zamifenacin	Phase 3	acetylcholine receptor antagonist	CHRM3			0	97.71	Tocris	2579	Zamifenacin fumarate	415.215	C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	BDNFQGRSKSQXRI-XMMPIXPASA-N	3086618.0		BDNFQGRSKSQXRI
BRD-K80451230-051-04-9	zamifenacin	Phase 3	acetylcholine receptor antagonist	CHRM3			0	91.68	Tocris	2579	Zamifenacin fumarate	415.215	C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	BDNFQGRSKSQXRI-XMMPIXPASA-N	3086618.0		BDNFQGRSKSQXRI
BRD-K23067689-001-04-9	zanamivir	Launched	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	0	100.0	MedChemEx	HY-13210	Zanamivir	332.133	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|	ARAIBEBZBOPLMB-UFGQHTETSA-N	60855.0		ARAIBEBZBOPLMB
BRD-K23067689-001-03-9	zanamivir	Launched	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	0	29.28	Selleck	S3007	Zanamivir	332.133	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|	ARAIBEBZBOPLMB-UFGQHTETSA-N	60855.0	BRD-K75153898-001-01-5	ARAIBEBZBOPLMB
BRD-K23067689-001-02-1	zanamivir	Launched	neuraminidase inhibitor	NEU2	infectious disease	influenza A virus infection	0	100.0	Selleck	S3007	Zanamivir (Relenza)	332.133	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|	ARAIBEBZBOPLMB-UFGQHTETSA-N	60855.0		ARAIBEBZBOPLMB
BRD-K00003413-001-01-9	zanubrutinib	Launched	Bruton's tyrosine kinase (BTK) inhibitor				0	92.97	MedChemEx	HY-101474A	Zanubrutinib	471.227	NC(=O)c1c2NCC[C@@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1	RNOAOAWBMHREKO-QFIPXVFZSA-N	135565884.0		RNOAOAWBMHREKO
BRD-K44825564-065-01-4	ZAPA	Preclinical					1	0.0	Tocris	180	ZAPA sulfate	146.015	NC(=N)S\C=C/C(O)=O	QEYNZJBVNYDZKZ-UPHRSURJSA-N	6604703.0		QEYNZJBVNYDZKZ
BRD-K44825564-065-02-9	ZAPA	Preclinical					1	100.0	Tocris	180	ZAPA sulfate	146.015	NC(=N)S\C=C/C(O)=O	QEYNZJBVNYDZKZ-UPHRSURJSA-N	6604703.0		QEYNZJBVNYDZKZ
BRD-K16542329-001-16-8	zaprinast	Phase 2	phosphodiesterase inhibitor	GPR35|PDE1A|PDE4D|PDE5A|PDE9A			0	98.4	Tocris	947	Zaprinast	271.107	CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1	REZGGXNDEMKIQB-UHFFFAOYSA-N	135399235.0		REZGGXNDEMKIQB
BRD-K16542329-001-14-3	zaprinast	Phase 2	phosphodiesterase inhibitor	GPR35|PDE1A|PDE4D|PDE5A|PDE9A			0	99.0	MicroSource	1501199	ZAPRINAST	271.107	CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1	REZGGXNDEMKIQB-UHFFFAOYSA-N	135399235.0		REZGGXNDEMKIQB
BRD-K16542329-001-13-5	zaprinast	Phase 2	phosphodiesterase inhibitor	GPR35|PDE1A|PDE4D|PDE5A|PDE9A			0	99.3	Tocris	947	Zaprinast	271.107	CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1	REZGGXNDEMKIQB-UHFFFAOYSA-N	135399235.0		REZGGXNDEMKIQB
BRD-K37561857-001-18-9	zardaverine	Phase 2	phosphodiesterase inhibitor	PDE4D			0	97.81	Tocris	1046	Zardaverine	268.066	COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	HJMQDJPMQIHLPB-UHFFFAOYSA-N	5723.0		HJMQDJPMQIHLPB
BRD-K37561857-001-17-1	zardaverine	Phase 2	phosphodiesterase inhibitor	PDE4D			0	99.64	Tocris	1046	Zardaverine	268.066	COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	HJMQDJPMQIHLPB-UHFFFAOYSA-N	5723.0		HJMQDJPMQIHLPB
BRD-K37561857-001-15-5	zardaverine	Phase 2	phosphodiesterase inhibitor	PDE4D			0	99.0	Tocris	1046	Zardaverine	268.066	COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	HJMQDJPMQIHLPB-UHFFFAOYSA-N	5723.0		HJMQDJPMQIHLPB
BRD-K92446736-003-03-0	zatebradine	Phase 3	HCN channel blocker	HCN1|HCN2|HCN3|HCN4			0	94.13	MedChemEx	HY-13422	Zatebradine (hydrochloride)	456.262	COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	KEDQCFRVSHYKLR-UHFFFAOYSA-N	65637.0		KEDQCFRVSHYKLR
BRD-K92446736-001-01-8	zatebradine	Phase 3	HCN channel blocker	HCN1|HCN2|HCN3|HCN4			0	93.18	MedChemEx	HY-13422A	Zatebradine	456.262	COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	KEDQCFRVSHYKLR-UHFFFAOYSA-N	65637.0		KEDQCFRVSHYKLR
BRD-K92446736-003-02-2	zatebradine	Phase 3	HCN channel blocker	HCN1|HCN2|HCN3|HCN4			0	79.37	Tocris	2202	Zatebradine hydrochloride	456.262	COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	KEDQCFRVSHYKLR-UHFFFAOYSA-N	65637.0		KEDQCFRVSHYKLR
BRD-K22829793-001-04-9	ZCL-278	Preclinical	CDC inhibitor	CDC42			0	90.13	Tocris	4794	ZCL 278	582.975	Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	XKZDWYDHEBCGCG-UHFFFAOYSA-N	1791111.0		XKZDWYDHEBCGCG
BRD-K22829793-001-03-6	ZCL-278	Preclinical	CDC inhibitor	CDC42			0	91.54	Tocris	4794	ZCL 278	582.975	Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	XKZDWYDHEBCGCG-UHFFFAOYSA-N	1791111.0		XKZDWYDHEBCGCG
BRD-K22829793-001-02-8	ZCL-278	Preclinical	CDC inhibitor	CDC42			0	88.66	Selleck	S7293	ZCL 278	582.975	Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	XKZDWYDHEBCGCG-UHFFFAOYSA-N	1791111.0		XKZDWYDHEBCGCG
BRD-K22829793-001-01-0	ZCL-278	Preclinical	CDC inhibitor	CDC42			0	88.78	Selleck	S7293	ZCL278	582.975	Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	XKZDWYDHEBCGCG-UHFFFAOYSA-N	1791111.0		XKZDWYDHEBCGCG
BRD-K00004620-001-01-9	ZD-0947	Preclinical	potassium channel activator				0	90.69	Sigma	SML2055	3-[(4S)-5-oxo-2-(trifluoromethyl)-1,4,5,6,7,8-hexahydro-4-quinolinyl]benzonitrile	318.098	FC(F)(F)C1=C[C@H](C2=C(CCCC2=O)N1)c1cccc(c1)C#N |t:4,7|	RUVMMEREJMHLOS-LBPRGKRZSA-N	9818432.0		RUVMMEREJMHLOS
BRD-K64157027-003-02-7	ZD-2079	Phase 2	adrenergic receptor agonist	ADRB3			0	96.4	Tocris	2154	ZD 2079	315.147	O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	SRBPKVWITYPHQR-KRWDZBQOSA-N	158794.0		SRBPKVWITYPHQR
BRD-K64157027-003-03-9	ZD-2079	Phase 2	adrenergic receptor agonist	ADRB3			0	94.27	Tocris	2154	ZD 2079	315.147	O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	SRBPKVWITYPHQR-KRWDZBQOSA-N	158794.0		SRBPKVWITYPHQR
BRD-K28971625-003-02-9	ZD-7114	Phase 1	adrenergic receptor agonist	ADRB3			0	90.51	Tocris	930	ZD 7114 hydrochloride	418.21	COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	RVMBDLSFFNKKLG-SFHVURJKSA-N	121877.0		RVMBDLSFFNKKLG
BRD-K28971625-003-01-4	ZD-7114	Phase 1	adrenergic receptor agonist	ADRB3			0	97.54	Tocris	930	ZD 7114 hydrochloride	418.21	COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	RVMBDLSFFNKKLG-SFHVURJKSA-N	121877.0		RVMBDLSFFNKKLG
BRD-K11373525-003-03-9	ZD-7155	Preclinical	angiotensin receptor antagonist	AGTR1			0	97.68	Tocris	1211	ZD 7155 hydrochloride	438.217	CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1	BFVNEYDCFJNLGN-UHFFFAOYSA-N	4673492.0		BFVNEYDCFJNLGN
BRD-K11373525-003-02-1	ZD-7155	Preclinical	angiotensin receptor antagonist	AGTR1			0	97.94	Tocris	1211	ZD 7155 hydrochloride	438.217	CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1	BFVNEYDCFJNLGN-UHFFFAOYSA-N	4673492.0		BFVNEYDCFJNLGN
BRD-K18678457-003-03-6	ZD-7288	Phase 2	HCN channel blocker	HCN1|HCN2|HCN3|HCN4			0	97.52	Tocris	1000	ZD 7288	257.177	CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1	JABSKGQQWUDVRU-UHFFFAOYSA-N	123984.0		JABSKGQQWUDVRU
BRD-K18678457-003-04-9	ZD-7288	Phase 2	HCN channel blocker	HCN1|HCN2|HCN3|HCN4			0	100.0	Tocris	1000	ZD 7288	256.169	CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1	JABSKGQQWUDVRU-UHFFFAOYSA-N	123984.0		JABSKGQQWUDVRU
BRD-K18678457-003-02-8	ZD-7288	Phase 2	HCN channel blocker	HCN1|HCN2|HCN3|HCN4			0	96.69	Tocris	1000	ZD 7288	257.177	CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1	JABSKGQQWUDVRU-UHFFFAOYSA-N	123984.0		JABSKGQQWUDVRU
BRD-K90033078-001-08-7	zeatin	Phase 1					0	96.05	TimTec	ST057583	(2E)-2-methyl-4-(7H-purin-6-ylamino)-2-buten-1-ol	219.112	C\C(CO)=C/CNc1ncnc2nc[nH]c12	UZKQTCBAMSWPJD-FARCUNLSSA-N	449093.0		UZKQTCBAMSWPJD
BRD-K87714311-001-02-7	zebularine	Preclinical	DNA methyltransferase inhibitor	CDA|DNMT1			0	0.0	Tocris	2293	Zebularine	228.075	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	RPQZTTQVRYEKCR-WCTZXXKLSA-N	100016.0		RPQZTTQVRYEKCR
BRD-K87714311-001-05-9	zebularine	Preclinical	DNA methyltransferase inhibitor	CDA|DNMT1			0	100.0	Tocris	2293	Zebularine	228.075	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	RPQZTTQVRYEKCR-WCTZXXKLSA-N	100016.0		RPQZTTQVRYEKCR
BRD-K87714311-001-04-3	zebularine	Preclinical	DNA methyltransferase inhibitor	CDA|DNMT1			0	0.0	Selleck	S7113	Zebularine	228.075	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	RPQZTTQVRYEKCR-WCTZXXKLSA-N	100016.0	BRD-K58673634-001-01-2	RPQZTTQVRYEKCR
BRD-K87714311-001-03-5	zebularine	Preclinical	DNA methyltransferase inhibitor	CDA|DNMT1			0	71.32	Selleck	S7113	Zebularine	228.075	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	RPQZTTQVRYEKCR-WCTZXXKLSA-N	100016.0	BRD-A01145011-001-07-1	RPQZTTQVRYEKCR
BRD-K31553034-001-03-0	zibotentan	Phase 3	endothelin receptor antagonist	EDNRA			0	95.3	Selleck	S1456	Zibotentan (ZD4054)	424.095	COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1	FJHHZXWJVIEFGJ-UHFFFAOYSA-N	9910224.0		FJHHZXWJVIEFGJ
BRD-K72903603-001-24-4	zidovudine	Launched	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)	0	96.81	Selleck	S2579	Zidovudine	267.097	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	HBOMLICNUCNMMY-XLPZGREQSA-N	35370.0		HBOMLICNUCNMMY
BRD-K72903603-001-27-9	zidovudine	Launched	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)	0	94.55	MedChemEx	HY-17413	Zidovudine	267.097	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	HBOMLICNUCNMMY-XLPZGREQSA-N	35370.0		HBOMLICNUCNMMY
BRD-K72903603-001-26-9	zidovudine	Launched	nucleoside reverse transcriptase inhibitor	TERT	infectious disease	human immunodeficiency virus (HIV-1)|acquired immunodeficiency syndrome (AIDS)	0	92.72	Selleck	S2579	ZIDOVUDINE [AZT]	267.097	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	HBOMLICNUCNMMY-XLPZGREQSA-N	35370.0		HBOMLICNUCNMMY
BRD-A56359832-001-15-2	zileuton	Launched	leukotriene synthesis inhibitor|lipoxygenase inhibitor	ALOX5	pulmonary	asthma	0	79.77	Tocris	3308	Zileuton	236.062	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|	MWLSOWXNZPKENC-SSDOTTSWSA-N	10681296.0		MWLSOWXNZPKENC
BRD-A56359832-001-12-9	zileuton	Launched	leukotriene synthesis inhibitor|lipoxygenase inhibitor	ALOX5	pulmonary	asthma	0	78.81	MicroSource	1505906	ZILEUTON	236.062	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|	MWLSOWXNZPKENC-SSDOTTSWSA-N	10681296.0		MWLSOWXNZPKENC
BRD-A56359832-001-13-7	zileuton	Launched	leukotriene synthesis inhibitor|lipoxygenase inhibitor	ALOX5	pulmonary	asthma	0	92.71	Selleck	S1443	Zileuton	236.062	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|	MWLSOWXNZPKENC-SSDOTTSWSA-N	10681296.0		MWLSOWXNZPKENC
BRD-A56359832-001-11-1	zileuton	Launched	leukotriene synthesis inhibitor|lipoxygenase inhibitor	ALOX5	pulmonary	asthma	0	85.03	Selleck	S1443	Zileuton	236.062	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|	MWLSOWXNZPKENC-SSDOTTSWSA-N	10681296.0		MWLSOWXNZPKENC
BRD-A56359832-001-16-9	zileuton	Launched	leukotriene synthesis inhibitor|lipoxygenase inhibitor	ALOX5	pulmonary	asthma	0	61.81	MedChemEx	HY-14164	Zileuton	236.062	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1,r|	MWLSOWXNZPKENC-SSDOTTSWSA-N	10681296.0		MWLSOWXNZPKENC
BRD-K42816473-001-01-0	zilpaterol	Launched	adrenergic receptor agonist	ADRB2	endocrinology	weight-gain aid	0	97.26	Cayman	16484	(6S,7S)-7-(isopropylamino)-6,7,8,9-tetrahydro-2,9a-diazabenzo[cd]azulene-1,6-diol	261.148	CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O	ZSTCZWJCLIRCOJ-AAEUAGOBSA-N	25218684.0		ZSTCZWJCLIRCOJ
BRD-K46914825-300-07-9	zimelidine	Withdrawn	selective serotonin reuptake inhibitor (SSRI)	MAOA|MAOB|SLC6A4			0	94.42	Tocris	1767	Zimelidine dihydrochloride	316.058	CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	OYPPVKRFBIWMSX-SXGWCWSVSA-N	5365247.0		OYPPVKRFBIWMSX
BRD-K46914825-300-01-0	zimelidine	Withdrawn	selective serotonin reuptake inhibitor (SSRI)	MAOA|MAOB|SLC6A4			0	95.65	Tocris	1767	Zimelidine dihydrochloride	316.058	CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	OYPPVKRFBIWMSX-SXGWCWSVSA-N	5365247.0		OYPPVKRFBIWMSX
BRD-K13330768-001-01-1	zinc-undecylenate	Launched	other antifungal		infectious disease	tinea pedis	1	0.0	MicroSource	1505467	ZINC UNDECYLENATE [4mM]	430.206	C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C	YMCOHQVWOBMDCZ-UHFFFAOYSA-L	11179.0	BRD-K86452172-410-01-8	YMCOHQVWOBMDCZ
BRD-K13330768-001-02-9	zinc-undecylenate	Launched	other antifungal		infectious disease	tinea pedis	1	0.0	MedChemEx	HY-B0914A	10-Undecenoic acid (zinc salt)	430.206	C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C	YMCOHQVWOBMDCZ-UHFFFAOYSA-L	11179.0		YMCOHQVWOBMDCZ
BRD-K26598477-001-01-0	zindotrine	Phase 2	phosphodiesterase inhibitor				0	0.0	Labotest	LT00032874	8-methyl-6-(1-piperidinyl)[1,2,4]triazolo[4,3-b]pyridazine	217.133	Cc1cc(nn2cnnc12)N1CCCCC1	YYHWOTFWBVRTQD-UHFFFAOYSA-N	41856.0		YYHWOTFWBVRTQD
BRD-K29582115-066-01-2	ziprasidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A4	neurology/psychiatry	schizophrenia|bipolar disorder	0	94.98	MicroSource	1503850	ZIPRASIDONE MESYLATE	412.112	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	MVWVFYHBGMAFLY-UHFFFAOYSA-N	60854.0		MVWVFYHBGMAFLY
BRD-K29582115-003-03-1	ziprasidone	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A4	neurology/psychiatry	schizophrenia|bipolar disorder	0	90.61	Selleck	S1444	Ziprasidone HCl	412.112	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	MVWVFYHBGMAFLY-UHFFFAOYSA-N	60854.0		MVWVFYHBGMAFLY
BRD-K00003431-001-01-9	ziritaxestat	Phase 3	autotaxin inhibitor				0	94.19	MedChemEx	HY-101772	Ziritaxestat	588.243	CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1	REQQVBGILUTQNN-UHFFFAOYSA-N	90420193.0		REQQVBGILUTQNN
BRD-K05151076-001-03-4	ZK-164015	Preclinical	estrogen receptor antagonist	ESR1|ESR2			0	87.31	Tocris	2183	ZK 164015	513.291	CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	LYJSJVYJLZOMCD-UHFFFAOYSA-N	9806489.0		LYJSJVYJLZOMCD
BRD-K05151076-001-02-6	ZK-164015	Preclinical	estrogen receptor antagonist	ESR1|ESR2			0	94.03	Tocris	2183	ZK 164015	513.291	CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	LYJSJVYJLZOMCD-UHFFFAOYSA-N	9806489.0		LYJSJVYJLZOMCD
BRD-K05151076-001-04-9	ZK-164015	Preclinical	estrogen receptor antagonist	ESR1|ESR2			0	93.85	Tocris	2183	ZK 164015	513.291	CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	LYJSJVYJLZOMCD-UHFFFAOYSA-N	9806489.0		LYJSJVYJLZOMCD
BRD-K67525671-001-03-3	ZK-200775	Phase 2	kainate receptor antagonist				0	97.52	Tocris	2345	ZK 200775	409.065	OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	WZMQMKNCWDCCMT-UHFFFAOYSA-N	208953.0		WZMQMKNCWDCCMT
BRD-K67525671-001-02-5	ZK-200775	Phase 2	kainate receptor antagonist				0	97.04	Tocris	2345	ZK 200775	409.065	OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	WZMQMKNCWDCCMT-UHFFFAOYSA-N	208953.0		WZMQMKNCWDCCMT
BRD-K67525671-001-04-9	ZK-200775	Phase 2	kainate receptor antagonist				0	98.5	Tocris	2345	ZK 200775	409.065	OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	WZMQMKNCWDCCMT-UHFFFAOYSA-N	208953.0		WZMQMKNCWDCCMT
BRD-K91825936-001-02-0	ZK-811752	Phase 2	CC chemokine receptor antagonist	CCR1			0	98.41	Tocris	3496	BX 471	434.152	C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	XQYASZNUFDVMFH-CQSZACIVSA-N	512282.0		XQYASZNUFDVMFH
BRD-K91825936-001-01-2	ZK-811752	Phase 2	CC chemokine receptor antagonist	CCR1			0	100.0	MedChemEx	HY-12080	BX471	434.152	C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	XQYASZNUFDVMFH-CQSZACIVSA-N	512282.0		XQYASZNUFDVMFH
BRD-K91825936-001-03-9	ZK-811752	Phase 2	CC chemokine receptor antagonist	CCR1			0	98.17	Tocris	3496	BX 471	434.152	C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	XQYASZNUFDVMFH-CQSZACIVSA-N	512282.0		XQYASZNUFDVMFH
BRD-K33882852-003-03-6	ZK-93423	Phase 3	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2			0	96.03	Tocris	1994	ZK 93423 hydrochloride	390.158	CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	ALBKMJDFBZVHAK-UHFFFAOYSA-N	121926.0		ALBKMJDFBZVHAK
BRD-K33882852-003-04-9	ZK-93423	Phase 3	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2			0	94.16	Tocris	1994	ZK 93423 hydrochloride	390.158	CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	ALBKMJDFBZVHAK-UHFFFAOYSA-N	121926.0		ALBKMJDFBZVHAK
BRD-K33882852-003-02-8	ZK-93423	Phase 3	benzodiazepine receptor agonist	GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2			0	95.26	Tocris	1994	ZK 93423 hydrochloride	390.158	CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	ALBKMJDFBZVHAK-UHFFFAOYSA-N	121926.0		ALBKMJDFBZVHAK
BRD-K68392338-003-03-8	ZK-93426	Phase 1	benzodiazepine receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA5			0	97.17	Tocris	1996	ZK 93426 hydrochloride	312.147	CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	VMDUABMKBUKKPG-UHFFFAOYSA-N	115210.0		VMDUABMKBUKKPG
BRD-K68392338-003-04-9	ZK-93426	Phase 1	benzodiazepine receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA5			0	92.36	Tocris	1996	ZK 93426 hydrochloride	312.147	CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	VMDUABMKBUKKPG-UHFFFAOYSA-N	115210.0		VMDUABMKBUKKPG
BRD-K68392338-003-02-0	ZK-93426	Phase 1	benzodiazepine receptor antagonist	GABRA1|GABRA2|GABRA3|GABRA5			0	92.94	Tocris	1996	ZK 93426 hydrochloride	312.147	CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	VMDUABMKBUKKPG-UHFFFAOYSA-N	115210.0		VMDUABMKBUKKPG
BRD-K73073971-001-02-9	ZLN005	Preclinical					0	95.17	MedChemEx	HY-17538	ZLN005	250.147	CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	LQUNNCQSFFKSSK-UHFFFAOYSA-N	899323.0		LQUNNCQSFFKSSK
BRD-K73073971-001-01-7	ZLN005	Preclinical					0	98.14	Selleck	S7447	ZLN005	250.147	CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	LQUNNCQSFFKSSK-UHFFFAOYSA-N	899323.0		LQUNNCQSFFKSSK
BRD-K64103579-003-01-5	ZLN024	Preclinical	AMPK activator	PRKAA1|PRKAB1|PRKAG1			0	89.0	Tocris	5285	ZLN 024 hydrochloride	323.993	Cc1ccc(OCCSc2ncccn2)c(Br)c1	KWJRSHZSULRJHE-UHFFFAOYSA-N	1825716.0		KWJRSHZSULRJHE
BRD-K64103579-003-02-9	ZLN024	Preclinical	AMPK activator	PRKAA1|PRKAB1|PRKAG1			0	93.76	Tocris	5285	ZLN 024 hydrochloride	323.993	Cc1ccc(OCCSc2ncccn2)c(Br)c1	KWJRSHZSULRJHE-UHFFFAOYSA-N	1825716.0		KWJRSHZSULRJHE
BRD-A62209527-001-05-9	ZM-226600	Preclinical	Kir6 channel (KATP) activator				0	93.11	Tocris	882	ZM 226600	373.06	C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|	LJLXQHHFAKVTNP-OAHLLOKOSA-N	92211533.0		LJLXQHHFAKVTNP
BRD-A62209527-001-04-5	ZM-226600	Preclinical	Kir6 channel (KATP) activator				0	95.64	Tocris	882		373.06	C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|	LJLXQHHFAKVTNP-OAHLLOKOSA-N	92211533.0		LJLXQHHFAKVTNP
BRD-K19605405-001-03-5	ZM-241385	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	91.03	Tocris	1036	ZM 241385	337.129	Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	PWTBZOIUWZOPFT-UHFFFAOYSA-N	176407.0		PWTBZOIUWZOPFT
BRD-K19605405-001-04-9	ZM-241385	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	97.7	Tocris	1036	ZM 241385	337.129	Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	PWTBZOIUWZOPFT-UHFFFAOYSA-N	176407.0		PWTBZOIUWZOPFT
BRD-K19605405-001-02-7	ZM-241385	Preclinical	adenosine receptor antagonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	99.1	Tocris	1036	ZM 241385	337.129	Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	PWTBZOIUWZOPFT-UHFFFAOYSA-N	176407.0		PWTBZOIUWZOPFT
BRD-K41337261-003-02-8	ZM-306416	Preclinical	Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor	EGFR|FLT1|FLT4|KDR			0	96.64	Tocris	2499	ZM 306416 hydrochloride	333.068	COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	YHUIUSRCUKUUQA-UHFFFAOYSA-N	5329006.0		YHUIUSRCUKUUQA
BRD-K41337261-003-04-9	ZM-306416	Preclinical	Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor	EGFR|FLT1|FLT4|KDR			0	96.37	Tocris	2499	ZM 306416 hydrochloride	333.068	COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	YHUIUSRCUKUUQA-UHFFFAOYSA-N	5329006.0		YHUIUSRCUKUUQA
BRD-K41337261-001-03-0	ZM-306416	Preclinical	Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor	EGFR|FLT1|FLT4|KDR			0	97.56	Selleck	S2897	ZM 306416	333.068	COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	YHUIUSRCUKUUQA-UHFFFAOYSA-N	5329006.0		YHUIUSRCUKUUQA
BRD-K67831364-003-04-1	ZM-323881	Preclinical	VEGFR inhibitor	KDR			0	81.64	Tocris	2475	ZM 323881 hydrochloride	375.138	Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	NVBNDZZLJRYRPD-UHFFFAOYSA-N	16759369.0		NVBNDZZLJRYRPD
BRD-K67831364-003-06-9	ZM-323881	Preclinical	VEGFR inhibitor	KDR			0	91.71	Tocris	2475	ZM 323881 hydrochloride	375.138	Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	NVBNDZZLJRYRPD-UHFFFAOYSA-N	16759369.0		NVBNDZZLJRYRPD
BRD-K67831364-003-05-8	ZM-323881	Preclinical	VEGFR inhibitor	KDR			0	95.74	Tocris	2475	ZM 323881 hydrochloride	375.138	Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	NVBNDZZLJRYRPD-UHFFFAOYSA-N	16759369.0		NVBNDZZLJRYRPD
BRD-K67831364-003-03-3	ZM-323881	Preclinical	VEGFR inhibitor	KDR			0	93.36	Selleck	S2896	ZM 323881 HCl	375.138	Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	NVBNDZZLJRYRPD-UHFFFAOYSA-N	16759369.0		NVBNDZZLJRYRPD
BRD-K73789395-001-09-9	ZM-336372	Preclinical	RAF inhibitor	BRAF|LCK|MAPK14|RAF1			0	76.38	Selleck	S2720	ZM 336372	389.174	CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	PYEFPDQFAZNXLI-UHFFFAOYSA-N	5730.0		PYEFPDQFAZNXLI
BRD-K73789395-001-13-1	ZM-336372	Preclinical	RAF inhibitor	BRAF|LCK|MAPK14|RAF1			0	92.91	Selleck	S2720	ZM 336372	389.174	CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	PYEFPDQFAZNXLI-UHFFFAOYSA-N	5730.0		PYEFPDQFAZNXLI
BRD-K73789395-001-14-9	ZM-336372	Preclinical	RAF inhibitor	BRAF|LCK|MAPK14|RAF1			0	89.4	Tocris	1321	ZM 336372	389.174	CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	PYEFPDQFAZNXLI-UHFFFAOYSA-N	5730.0		PYEFPDQFAZNXLI
BRD-K73789395-001-10-7	ZM-336372	Preclinical	RAF inhibitor	BRAF|LCK|MAPK14|RAF1			0	92.9	Tocris	1321	ZM 336372	389.174	CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	PYEFPDQFAZNXLI-UHFFFAOYSA-N	5730.0		PYEFPDQFAZNXLI
BRD-K40624912-003-17-9	ZM-39923	Preclinical	JAK inhibitor	JAK1|JAK3			0	93.58	Tocris	1367	ZM 39923 hydrochloride	331.194	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	JSASWRWALCMOQP-UHFFFAOYSA-N	3797.0		JSASWRWALCMOQP
BRD-K40624912-003-15-5	ZM-39923	Preclinical	JAK inhibitor	JAK1|JAK3			0	19.95	Tocris	1367	ZM 39923 hydrochloride	331.194	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	JSASWRWALCMOQP-UHFFFAOYSA-N	3797.0		JSASWRWALCMOQP
BRD-K40624912-003-12-2	ZM-39923	Preclinical	JAK inhibitor	JAK1|JAK3			0	4.74	Selleck	S8004	ZM 39923 HCl	331.194	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	JSASWRWALCMOQP-UHFFFAOYSA-N	3797.0		JSASWRWALCMOQP
BRD-K40624912-003-13-0	ZM-39923	Preclinical	JAK inhibitor	JAK1|JAK3			0	56.8	Tocris	1367	ZM 39923 hydrochloride	331.194	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	JSASWRWALCMOQP-UHFFFAOYSA-N	3797.0		JSASWRWALCMOQP
BRD-K40624912-003-14-8	ZM-39923	Preclinical	JAK inhibitor	JAK1|JAK3			0	70.56	Selleck	S8004	ZM 39923 HCl	331.194	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	JSASWRWALCMOQP-UHFFFAOYSA-N	3797.0		JSASWRWALCMOQP
BRD-K72703948-001-10-1	ZM-447439	Preclinical	Aurora kinase inhibitor	AURKA|AURKB			0	96.51	Tocris	2458	ZM 447439	513.238	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	OGNYUTNQZVRGMN-UHFFFAOYSA-N	9914412.0		OGNYUTNQZVRGMN
BRD-K72703948-001-09-3	ZM-447439	Preclinical	Aurora kinase inhibitor	AURKA|AURKB			0	93.96	Selleck	S1103	ZM 447439	513.238	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	OGNYUTNQZVRGMN-UHFFFAOYSA-N	9914412.0		OGNYUTNQZVRGMN
BRD-K72703948-001-12-7	ZM-447439	Preclinical	Aurora kinase inhibitor	AURKA|AURKB			0	96.27	Tocris	2458	ZM 447439	513.238	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	OGNYUTNQZVRGMN-UHFFFAOYSA-N	9914412.0		OGNYUTNQZVRGMN
BRD-K46654563-238-02-9	zofenopril-calcium	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	97.08	MedChemEx	HY-B0655	Zofenopril (calcium)	429.107	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	IAIDUHCBNLFXEF-MNEFBYGVSA-N	92400.0		IAIDUHCBNLFXEF
BRD-K46654563-238-01-0	zofenopril-calcium	Launched	angiotensin converting enzyme inhibitor	ACE	cardiology	hypertension	0	99.29	MedChemEx	HY-B0655	Zofenopril (calcium)	429.107	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	IAIDUHCBNLFXEF-MNEFBYGVSA-N	92400.0	BRD-M85357167-001-01-2	IAIDUHCBNLFXEF
BRD-K08996725-332-07-9	zolantidine	Preclinical	histamine receptor antagonist				0	98.14	Tocris	1070	Zolantidine dimaleate	381.187	C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	KUBONGDXTUOOLM-UHFFFAOYSA-N	91769.0		KUBONGDXTUOOLM
BRD-K08996725-332-01-7	zolantidine	Preclinical	histamine receptor antagonist				0	90.72	Tocris	1070	Zolantidine dimaleate	381.187	C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	KUBONGDXTUOOLM-UHFFFAOYSA-N	91769.0		KUBONGDXTUOOLM
BRD-K84253429-001-06-9	zoledronic-acid	Launched	bone resorption inhibitor	FDPS|GGPS1	endocrinology	Paget's disease	1	0.0	Tocris	6111	Zoledronic Acid	271.996	OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O	XRASPMIURGNCCH-UHFFFAOYSA-N	68740.0		XRASPMIURGNCCH
BRD-K84253429-001-04-4	zoledronic-acid	Launched	bone resorption inhibitor	FDPS|GGPS1	endocrinology	Paget's disease	1	0.0	Selleck	S1314	Zoledronic Acid (Zoledronate)	271.996	OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O	XRASPMIURGNCCH-UHFFFAOYSA-N	68740.0		XRASPMIURGNCCH
BRD-K84253429-001-03-6	zoledronic-acid	Launched	bone resorption inhibitor	FDPS|GGPS1	endocrinology	Paget's disease	1	0.0	Selleck	S1314	Zoledronic Acid	271.996	OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O	XRASPMIURGNCCH-UHFFFAOYSA-N	68740.0		XRASPMIURGNCCH
BRD-K00003264-001-01-9	zoliflodacin	Phase 3	antibacterial 				0	99.28	MedChemEx	HY-17647	Zoliflodacin	487.15	[H][C@]12[C@H](C)O[C@H](C)CN1c1c(CC22C(=O)NC(=O)NC2=O)cc2c(noc2c1F)N1[C@@H](C)COC1=O	ZSWMIFNWDQEXDT-ZESJGQACSA-N	76685216.0		ZSWMIFNWDQEXDT
BRD-K45125084-001-01-4	zolimidine	Launched	mucus protecting agent		gastroenterology	peptic ulcer disease (PUD)|gastroesophageal reflux disease (GERD)	0	89.09	Enamine	Z82177056	2-[4-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridine	272.062	CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1	VSLIUWLPFRVCDL-UHFFFAOYSA-N	14652.0		VSLIUWLPFRVCDL
BRD-K54314721-001-12-9	zolmitriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	95.58	Tocris	4657	Zolmitriptan	287.163	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	60857.0		ULSDMUVEXKOYBU
BRD-K54314721-001-11-0	zolmitriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	93.99	Tocris	4657	Zolmitriptan	287.163	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	60857.0		ULSDMUVEXKOYBU
BRD-K54314721-001-10-2	zolmitriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	95.65	MicroSource	1505281	ZOLMITRIPTAN	287.163	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	60857.0		ULSDMUVEXKOYBU
BRD-K54314721-001-09-4	zolmitriptan	Launched	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	neurology/psychiatry	migraine headache	0	91.68	Selleck	S1649	Zolmitriptan	287.163	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	ULSDMUVEXKOYBU-ZDUSSCGKSA-N	60857.0		ULSDMUVEXKOYBU
BRD-K81326768-236-12-5	zomepirac	Withdrawn	prostaglandin synthesis inhibitor	PTGDR2			0	95.49	MedChemEx	HY-B0890	Zomepirac (sodium salt)	291.066	Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	ZXVNMYWKKDOREA-UHFFFAOYSA-N	5733.0		ZXVNMYWKKDOREA
BRD-K81326768-236-11-7	zomepirac	Withdrawn	prostaglandin synthesis inhibitor	PTGDR2			0	91.59	Sigma	MFCD00057223	sodium [5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]acetate	291.066	Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	ZXVNMYWKKDOREA-UHFFFAOYSA-N	5733.0		ZXVNMYWKKDOREA
BRD-K81326768-001-04-0	zomepirac	Withdrawn	prostaglandin synthesis inhibitor	PTGDR2			0	79.63	MicroSource	1500615	ZOMEPIRAC SODIUM	291.066	Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	ZXVNMYWKKDOREA-UHFFFAOYSA-N	5733.0		ZXVNMYWKKDOREA
BRD-K14571191-001-01-6	zometapine	Phase 2					0	99.02	Sigma	PH000288	4-(3-chlorophenyl)-1,3-dimethyl-1,6,7,8-tetrahydropyrazolo[3,4-e][1,4]diazepine	274.099	Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1 |c:9|	YCWROMXNZZIJDQ-UHFFFAOYSA-N	135410917.0		YCWROMXNZZIJDQ
BRD-K43992824-300-01-0	zoniporide	Phase 3	sodium/hydrogen exchanger inhibitor	SLC9A1			0	96.95	Tocris	2727	Zoniporide dihydrochloride	320.139	NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12	GDXBRVCQGGKXJY-UHFFFAOYSA-N	6433110.0		GDXBRVCQGGKXJY
BRD-K43992824-300-02-9	zoniporide	Phase 3	sodium/hydrogen exchanger inhibitor	SLC9A1			0	97.75	Tocris	2727	Zoniporide dihydrochloride	320.139	NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12	GDXBRVCQGGKXJY-UHFFFAOYSA-N	6433110.0		GDXBRVCQGGKXJY
BRD-K48300629-001-17-8	zonisamide	Launched	sodium channel blocker|T-type calcium channel blocker	CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures|epilepsy	0	89.14	Tocris	2625	Zonisamide	212.026	NS(=O)(=O)Cc1noc2ccccc12	UBQNRHZMVUUOMG-UHFFFAOYSA-N	5734.0		UBQNRHZMVUUOMG
BRD-K48300629-001-14-5	zonisamide	Launched	sodium channel blocker|T-type calcium channel blocker	CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures|epilepsy	0	98.12	Tocris	2625	Zonisamide	212.026	NS(=O)(=O)Cc1noc2ccccc12	UBQNRHZMVUUOMG-UHFFFAOYSA-N	5734.0		UBQNRHZMVUUOMG
BRD-K48300629-001-13-7	zonisamide	Launched	sodium channel blocker|T-type calcium channel blocker	CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	neurology/psychiatry	seizures|epilepsy	0	96.45	Selleck	S1445	Zonisamide	212.026	NS(=O)(=O)Cc1noc2ccccc12	UBQNRHZMVUUOMG-UHFFFAOYSA-N	5734.0		UBQNRHZMVUUOMG
BRD-K47710001-001-03-7	zopolrestat	Phase 2		AKR1B1|AKR1B10			0	99.72	Sigma	MFCD00865476	(4-oxo-3-{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl}-3,4-dihydro-1-phthalazinyl)acetic acid	419.055	OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12	BCSVCWVQNOXFGL-UHFFFAOYSA-N	1613.0		BCSVCWVQNOXFGL
BRD-K70557564-305-04-4	zosuquidar	Phase 3	P glycoprotein inhibitor	ABCB1|ABCB4			0	92.34	Tocris	5456	Zosuquidar trihydrochloride	527.238	O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F	IHOVFYSQUDPMCN-DBEBIPAYSA-N			IHOVFYSQUDPMCN
BRD-K70557564-305-03-6	zosuquidar	Phase 3	P glycoprotein inhibitor	ABCB1|ABCB4			0	96.07	Selleck	S1481	Zosuquidar (LY335979) 3HCl	527.238	O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F	IHOVFYSQUDPMCN-DBEBIPAYSA-N			IHOVFYSQUDPMCN
BRD-K46843573-001-01-9	zotarolimus	Launched	mTOR inhibitor	FKBP1A	cardiology	coronary artery restenosis	0	87.25	Adooq	A11950		965.573	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14,33,t:29,31|	CGTADGCBEXYWNE-GYKXXMIGSA-N			CGTADGCBEXYWNE
BRD-K64557645-001-02-4	zotepine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA2B|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR6|HTR7|SLC6A2|SLC6A4	neurology/psychiatry	schizophrenia	0	97.88	Prestwick	Prestw-1368	Zotepine	331.08	CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|	HDOZVRUNCMBHFH-UHFFFAOYSA-N	5736.0		HDOZVRUNCMBHFH
BRD-K64557645-001-03-9	zotepine	Launched	dopamine receptor antagonist|serotonin receptor antagonist	ADRA2B|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR6|HTR7|SLC6A2|SLC6A4	neurology/psychiatry	schizophrenia	0	97.3	Tocris	3996	Zotepine	331.08	CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|	HDOZVRUNCMBHFH-UHFFFAOYSA-N	5736.0		HDOZVRUNCMBHFH
BRD-K66353228-001-15-9	zoxazolamine	Phase 2	myorelaxant				0	97.71	MedChemEx	HY-B1307	Zoxazolamine	168.009	Nc1nc2cc(Cl)ccc2o1	YGCODSQDUUUKIV-UHFFFAOYSA-N	6103.0		YGCODSQDUUUKIV
BRD-K66353228-001-14-6	zoxazolamine	Phase 2	myorelaxant				0	98.37	MicroSource	1504216	ZOXAZOLAMINE	168.009	Nc1nc2cc(Cl)ccc2o1	YGCODSQDUUUKIV-UHFFFAOYSA-N	6103.0		YGCODSQDUUUKIV
BRD-K66353228-001-13-8	zoxazolamine	Phase 2	myorelaxant				0	97.56	Selleck	S4233	Zoxazolamine	168.009	Nc1nc2cc(Cl)ccc2o1	YGCODSQDUUUKIV-UHFFFAOYSA-N	6103.0		YGCODSQDUUUKIV
BRD-K35984734-001-02-9	ZSET1446	Preclinical	nicotinic receptor agonist				0	95.54	MedChemEx	HY-11013	ZSET1446	236.095	O=C1N=C2C=CC=CN2C11Cc2ccccc2C1 |c:4,6,t:2|	QZWYXEBIQWJXAR-UHFFFAOYSA-N	10220323.0		QZWYXEBIQWJXAR
BRD-K63068307-001-10-9	ZSTK-474	Phase 1/Phase 2	PI3K inhibitor	PIK3CB|PIK3CD|PIK3CG			0	96.15	MedChemEx	HY-50847	ZSTK474	417.172	FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	HGVNLRPZOWWDKD-UHFFFAOYSA-N	11647372.0		HGVNLRPZOWWDKD
BRD-K63068307-001-08-9	ZSTK-474	Phase 1/Phase 2	PI3K inhibitor	PIK3CB|PIK3CD|PIK3CG			0	98.66	Selleck	S1072	ZSTK474	417.172	FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	HGVNLRPZOWWDKD-UHFFFAOYSA-N	11647372.0		HGVNLRPZOWWDKD
BRD-K28761384-001-10-9	zuclopenthixol	Launched	dopamine receptor antagonist	ADRA1A|ADRA2A|DRD1|DRD2|DRD5|HRH1|HTR2A	neurology/psychiatry	schizophrenia|bipolar disorder	0	94.95	MedChemEx	HY-A0163	Zuclopenthixol	400.138	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1	WFPIAZLQTJBIFN-DVZOWYKESA-N	5311507.0		WFPIAZLQTJBIFN
BRD-K28761384-300-01-0	zuclopenthixol	Launched	dopamine receptor antagonist	ADRA1A|ADRA2A|DRD1|DRD2|DRD5|HRH1|HTR2A	neurology/psychiatry	schizophrenia|bipolar disorder	0	97.19	Prestwick	Prestw-998	Zuclopenthixol dihydrochloride	400.138	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1	WFPIAZLQTJBIFN-DVZOWYKESA-N	5311507.0		WFPIAZLQTJBIFN
BRD-K00003448-001-01-9	zuranolone	Phase 3	GABA receptor agonist				0	92.59	MedChemEx	HY-103040	Zuranolone	409.273	[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H]	HARRKNSQXBRBGZ-GVKWWOCJSA-N	86294073.0		HARRKNSQXBRBGZ
BRD-K16037980-001-01-1	Z160	Phase 2	N-type calcium channel blocker	CACNA2D1			0	89.44	MedChemEx	HY-14462	NP118809	460.251	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	VCPMZDWBEWTGNW-UHFFFAOYSA-N	4988454.0		VCPMZDWBEWTGNW
BRD-K16037980-001-02-9	Z160	Phase 2	N-type calcium channel blocker	CACNA2D1			0	97.39	MedChemEx	HY-14462	NP118809	460.251	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	VCPMZDWBEWTGNW-UHFFFAOYSA-N	4988454.0		VCPMZDWBEWTGNW
BRD-K04603573-376-01-3	1,12-Besm	Phase 2	polyamine biosynthesis inhibitor				0	96.1	Tocris	500	N~1~,N~4~-bis[3-(ethylamino)propyl]-1,4-butanediamine tetrahydrochloride	258.278	CCNCCCNCCCCNCCCNCC	PGMIWVSHZMWSSI-UHFFFAOYSA-N	4283.0		PGMIWVSHZMWSSI
BRD-K06817181-001-02-3	1,2,3,4,5,6-hexabromocyclohexane	Preclinical	JAK inhibitor	JAK2			0	0.0	Tocris	2291	1,2,3,4,5,6-Hexabromocyclohexane	551.557	BrC1C(Br)C(Br)C(Br)C(Br)C1Br	QFQZKISCBJKVHI-UHFFFAOYSA-N	74603.0		QFQZKISCBJKVHI
BRD-K06817181-001-03-9	1,2,3,4,5,6-hexabromocyclohexane	Preclinical	JAK inhibitor	JAK2			0	38.29	Tocris	2291	1,2,3,4,5,6-Hexabromocyclohexane	551.557	BrC1C(Br)C(Br)C(Br)C(Br)C1Br	QFQZKISCBJKVHI-UHFFFAOYSA-N	74603.0		QFQZKISCBJKVHI
BRD-K41853443-001-03-9	1,3-dipropyl-8-phenylxanthine	Preclinical	adenosine receptor antagonist				0	95.79	Tocris	486	1,3-Dipropyl-8-phenylxanthine	312.159	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1	CLIGSMOZKDCDRZ-UHFFFAOYSA-N	128784.0		CLIGSMOZKDCDRZ
BRD-K41853443-001-02-9	1,3-dipropyl-8-phenylxanthine	Preclinical	adenosine receptor antagonist				0	97.89	Tocris	486	1,3-Dipropyl-8-phenylxanthine	312.159	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1	CLIGSMOZKDCDRZ-UHFFFAOYSA-N	128784.0		CLIGSMOZKDCDRZ
BRD-K22346679-001-06-3	1,4-butanediol	Phase 1	benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist	MAN1B1|PLA2G2A|PLA2G2E			1	0.0	Sigma	68891	1,4-butanediol	90.068	OCCCCO	WERYXYBDKMZEQL-UHFFFAOYSA-N	8064.0		WERYXYBDKMZEQL
BRD-K53083666-001-01-0	1,5-dicaffeoylquinic-acid	Phase 1					0	0.0	AnalytiCon	NP-000244		516.127	O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O	YDDUMTOHNYZQPO-PSEXTPKNSA-N	6474640.0		YDDUMTOHNYZQPO
BRD-K53083666-001-02-9	1,5-dicaffeoylquinic-acid	Phase 1					0	95.94	MedChemEx	HY-N1412	1,3-Dicaffeoylquinic acid	516.127	O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O	YDDUMTOHNYZQPO-PSEXTPKNSA-N	6474640.0		YDDUMTOHNYZQPO
BRD-K88956297-003-01-9	1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium	Preclinical					0	94.41	BidePharm	BD51690	1-((Z)-3-Chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium chloride	215.106	Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2	LDLCEGCJYSDJLX-UPHRSURJSA-N	5846454.0		LDLCEGCJYSDJLX
BRD-K01825681-050-02-9	1-(1,2-diphenylethyl)piperidine-(+/-)	Preclinical	glutamate receptor antagonist				0	92.15	Tocris	360	(+/-)-1-(1,2-Diphenylethyl)piperidine maleate	265.183	C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|	JQWJJJYHVHNXJH-LJQANCHMSA-N	44574903.0		JQWJJJYHVHNXJH
BRD-K01825681-050-01-9	1-(1,2-diphenylethyl)piperidine-(+/-)	Preclinical	glutamate receptor antagonist				0	98.04	Tocris	360	(?)-1-(1,2-Diphenylethyl)piperidine maleate	381.194	C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|	JQWJJJYHVHNXJH-LJQANCHMSA-N	44574903.0		JQWJJJYHVHNXJH
BRD-A95802703-001-01-0	1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol	Preclinical					0	92.38	Enamine	Z1672746675	1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol	257.118	CC(C)NC[C@@H](O)COc1cc(C)ccc1Cl |&1:5,r|	NJEIOWSBPCZKTL-LLVKDONJSA-N	39359445.0		NJEIOWSBPCZKTL
BRD-K96055017-003-02-7	1-acetyl-4-methylpiperazine	Preclinical	acetylcholine receptor agonist				0	90.28	Tocris	351	1-Acetyl-4-methylpiperazine hydrochloride	142.111	CN1CCN(CC1)C(C)=O	YSDBJKNOEWSFGA-UHFFFAOYSA-N	550758.0		YSDBJKNOEWSFGA
BRD-K96055017-003-03-9	1-acetyl-4-methylpiperazine	Preclinical	acetylcholine receptor agonist				0	73.57	Tocris	351	1-Acetyl-4-methylpiperazine hydrochloride	142.111	CN1CCN(CC1)C(C)=O	YSDBJKNOEWSFGA-UHFFFAOYSA-N	550758.0		YSDBJKNOEWSFGA
BRD-K03273112-001-01-8	1-azakenpaullone	Preclinical	glycogen synthase kinase inhibitor	CCNB1|CDK1|CDK5|GSK3B			0	90.5	Selleck	S7193	1-Azakenpaullone	327.001	Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	NTSBZVCEIVPKBJ-UHFFFAOYSA-N	6538897.0		NTSBZVCEIVPKBJ
BRD-K03273112-001-02-6	1-azakenpaullone	Preclinical	glycogen synthase kinase inhibitor	CCNB1|CDK1|CDK5|GSK3B			0	95.26	Selleck	S7193	1-Azakenpaullone	327.001	Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	NTSBZVCEIVPKBJ-UHFFFAOYSA-N	6538897.0		NTSBZVCEIVPKBJ
BRD-K89665618-003-04-9	1-deoxymannojirimycin	Preclinical	alpha mannosidase inhibitor	MAN2A1			0	85.0	Tocris	1259	1-Deoxymannojirimycin hydrochloride	163.084	OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	LXBIFEVIBLOUGU-KVTDHHQDSA-N	72258.0		LXBIFEVIBLOUGU
BRD-K89665618-003-02-5	1-deoxymannojirimycin	Preclinical	alpha mannosidase inhibitor	MAN2A1			0	100.0	Tocris	1259	1-Deoxymannojirimycin hydrochloride	163.084	OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	LXBIFEVIBLOUGU-KVTDHHQDSA-N	72258.0		LXBIFEVIBLOUGU
BRD-K70586315-001-03-2	1-EBIO	Preclinical	potassium channel activator	KCNN1|KCNN2|KCNN3|KCNN4			0	96.47	Tocris	1041	1-EBIO	162.079	CCn1c2ccccc2[nH]c1=O	CXUCKELNYMZTRT-UHFFFAOYSA-N	82320.0		CXUCKELNYMZTRT
BRD-K70586315-001-04-9	1-EBIO	Preclinical	potassium channel activator	KCNN1|KCNN2|KCNN3|KCNN4			0	93.65	Tocris	1041	1-EBIO	162.079	CCn1c2ccccc2[nH]c1=O	CXUCKELNYMZTRT-UHFFFAOYSA-N	82320.0		CXUCKELNYMZTRT
BRD-K70586315-001-02-4	1-EBIO	Preclinical	potassium channel activator	KCNN1|KCNN2|KCNN3|KCNN4			0	96.95	Tocris	1041	1-EBIO	162.079	CCn1c2ccccc2[nH]c1=O	CXUCKELNYMZTRT-UHFFFAOYSA-N	82320.0		CXUCKELNYMZTRT
BRD-K08288352-001-03-6	1-ethyl-2-pyrrolidone	Preclinical	transdermal absorption-enhancing compound				0	98.42	CombiBlocks	QA-6551	1-Ethyl-2-pyrrolidone	113.084	CCN1CCCC1=O	ZFPGARUNNKGOBB-UHFFFAOYSA-N	17595.0		ZFPGARUNNKGOBB
BRD-K35114608-001-01-7	1-hexadecanal	Preclinical	sphingosine 1-phosphate receptor substrate	DBI|RHO			0	0.0	DuPont	A001212276	palmitaldehyde	240.245	CCCCCCCCCCCCCCCC=O	NIOYUNMRJMEDGI-UHFFFAOYSA-N	984.0		NIOYUNMRJMEDGI
BRD-K37203094-001-02-5	1-hexadecanol	Launched			dermatology	cosmetic	1	0.0	Selleck	S4173	1-Hexadecanol	242.261	CCCCCCCCCCCCCCCCO	BXWNKGSJHAJOGX-UHFFFAOYSA-N	2682.0		BXWNKGSJHAJOGX
BRD-K37203094-001-03-3	1-hexadecanol	Launched			dermatology	cosmetic	1	0.0	Selleck	S4173	1-Hexadecanol	242.261	CCCCCCCCCCCCCCCCO	BXWNKGSJHAJOGX-UHFFFAOYSA-N	2682.0		BXWNKGSJHAJOGX
BRD-K37203094-001-06-6	1-hexadecanol	Launched			dermatology	cosmetic	1	0.0	Selleck	S4173	C16:0 PALMITYL	242.261	CCCCCCCCCCCCCCCCO	BXWNKGSJHAJOGX-UHFFFAOYSA-N	2682.0		BXWNKGSJHAJOGX
BRD-K29542628-001-03-9	1-naphthyl-PP1	Preclinical	SRC inhibitor	SRC			0	98.62	Tocris	3063	1-Naphthyl PP1	317.164	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12	XSHQBIXMLULFEV-UHFFFAOYSA-N	4877.0		XSHQBIXMLULFEV
BRD-K29542628-001-04-7	1-naphthyl-PP1	Preclinical	SRC inhibitor	SRC			0	96.3	Tocris	3063	1-Naphthyl PP1	317.164	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12	XSHQBIXMLULFEV-UHFFFAOYSA-N	4877.0		XSHQBIXMLULFEV
BRD-K03083257-001-01-6	1-octacosanol	Phase 2					0	1.71	Acros	25813	1-Octacosanol, 90+%	410.449	CCCCCCCCCCCCCCCCCCCCCCCCCCCCO	CNNRPFQICPFDPO-UHFFFAOYSA-N	68406.0		CNNRPFQICPFDPO
BRD-K09338665-001-08-9	1-octanol	Phase 2		GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1			1	0.0	Enamine	Z104473500	1-octanol	130.136	CCCCCCCCO	KBPLFHHGFOOTCA-UHFFFAOYSA-N	957.0		KBPLFHHGFOOTCA
BRD-K09338665-001-07-1	1-octanol	Phase 2		GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1			1	0.0	Enamine	Z104473500		130.136	CCCCCCCCO	KBPLFHHGFOOTCA-UHFFFAOYSA-N	957.0		KBPLFHHGFOOTCA
BRD-K31491153-003-07-9	1-phenylbiguanide	Preclinical	serotonin receptor agonist	HTR3A|HTR3B			0	96.75	Tocris	969	1-Phenylbiguanide hydrochloride	177.101	NC(N)=NC(=N)Nc1ccccc1	CUQCMXFWIMOWRP-UHFFFAOYSA-N	4780.0		CUQCMXFWIMOWRP
BRD-K31491153-003-05-9	1-phenylbiguanide	Preclinical	serotonin receptor agonist	HTR3A|HTR3B			0	95.79	Tocris	969	1-Phenylbiguanide hydrochloride	177.101	NC(N)=NC(=N)Nc1ccccc1	CUQCMXFWIMOWRP-UHFFFAOYSA-N	4780.0		CUQCMXFWIMOWRP
BRD-A37752546-001-01-9	1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime	Preclinical					0	98.81	Sigma	MFCD00900589	(1E)-1-(2-hydroxy-5-methylphenyl)-1-dodecanone oxime	305.235	CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|	NFONIVRMILHYLH-GOSISDBHSA-N			NFONIVRMILHYLH
BRD-A37752546-001-02-9	1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime	Preclinical					0	83.97	Sigma	MFCD00900589	(1E)-1-(2-hydroxy-5-methylphenyl)-1-dodecanone oxime	305.235	CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|	NFONIVRMILHYLH-GOSISDBHSA-N			NFONIVRMILHYLH
BRD-K27853494-003-04-7	1S,2R-phenylpropanolamine	Withdrawn	adrenergic receptor agonist				0	98.2	MicroSource	1500484	1S,2R-PHENYLPROPANOLAMINE HYDROCHLORIDE	151.1	C[C@@H](N)[C@@H](O)c1ccccc1	DLNKOYKMWOXYQA-VXNVDRBHSA-N	26934.0		DLNKOYKMWOXYQA
BRD-K96631475-001-03-2	10-deacetylbaccatin	Preclinical	antitumor agent				0	95.89	MedChemEx	HY-16565	10-Deacetylbaccatin III	544.231	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|	YWLXLRUDGLRYDR-ZHPRIASZSA-N	154272.0		YWLXLRUDGLRYDR
BRD-K96631475-001-02-4	10-deacetylbaccatin	Preclinical	antitumor agent				0	93.27	Selleck	S2409	10-DAB (10-Deacetylbaccatin)	544.231	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|	YWLXLRUDGLRYDR-ZHPRIASZSA-N	154272.0		YWLXLRUDGLRYDR
BRD-K96631475-001-04-0	10-deacetylbaccatin	Preclinical	antitumor agent				0	82.54	Selleck	S2409	10-Deacetylbaccatin-III	544.231	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|	YWLXLRUDGLRYDR-ZHPRIASZSA-N	154272.0	BRD-K61920224-001-01-8	YWLXLRUDGLRYDR
BRD-K70792160-003-04-6	10-DEBC	Preclinical	AKT inhibitor	PIM1			0	97.32	Tocris	2558	10-DEBC hydrochloride	344.166	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	GYBXAGDWMCJZJK-UHFFFAOYSA-N	10521421.0		GYBXAGDWMCJZJK
BRD-K70792160-003-07-9	10-DEBC	Preclinical	AKT inhibitor	PIM1			0	96.07	Tocris	2558	10-DEBC hydrochloride	344.166	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	GYBXAGDWMCJZJK-UHFFFAOYSA-N	10521421.0		GYBXAGDWMCJZJK
BRD-K70792160-003-06-1	10-DEBC	Preclinical	AKT inhibitor	PIM1			0	87.3	Tocris	2558	10-DEBC hydrochloride	344.166	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	GYBXAGDWMCJZJK-UHFFFAOYSA-N	10521421.0		GYBXAGDWMCJZJK
BRD-K63784565-001-08-9	10-hydroxycamptothecin	Preclinical	topoisomerase inhibitor	TOP1			0	97.94	MedChemEx	HY-N0095	(S)-10-Hydroxycamptothecin	364.106	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	HAWSQZCWOQZXHI-FQEVSTJZSA-N	97226.0		HAWSQZCWOQZXHI
BRD-K63784565-001-05-4	10-hydroxycamptothecin	Preclinical	topoisomerase inhibitor	TOP1			0	4.36	Selleck	S2423	(S)-10-Hydroxycamptothecin	364.106	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	HAWSQZCWOQZXHI-FQEVSTJZSA-N	97226.0		HAWSQZCWOQZXHI
BRD-K63784565-001-06-2	10-hydroxycamptothecin	Preclinical	topoisomerase inhibitor	TOP1			0	96.85	Selleck	S2423	10-Hydroxycamptothecin	364.106	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	HAWSQZCWOQZXHI-FQEVSTJZSA-N	97226.0		HAWSQZCWOQZXHI
BRD-K49460120-001-06-6	10058-F4	Preclinical	c-Myc inhibitor				0	80.51	Tocris	4406	10058-F4	249.028	CCc1ccc(\C=C2\SC(=S)NC2=O)cc1	SVXDHPADAXBMFB-JXMROGBWSA-N	1271002.0		SVXDHPADAXBMFB
BRD-K49460120-001-05-8	10058-F4	Preclinical	c-Myc inhibitor				0	95.6	Selleck	S7153	10058-F4	249.028	CCc1ccc(\C=C2\SC(=S)NC2=O)cc1	SVXDHPADAXBMFB-JXMROGBWSA-N	1271002.0		SVXDHPADAXBMFB
BRD-K49460120-001-02-5	10058-F4	Preclinical	c-Myc inhibitor				0	82.34	Selleck	S7153	10058-F4	249.028	CCc1ccc(\C=C2\SC(=S)NC2=O)cc1	SVXDHPADAXBMFB-JXMROGBWSA-N	1271002.0		SVXDHPADAXBMFB
BRD-K68552125-001-05-3	12-O-tetradecanoylphorbol-13-acetate	Phase 2	PKC activator	KCNT2|TRPV4			0	97.9	Enzo	PE160	Phorbol 12 myristate 13 acetate	616.398	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|	PHEDXBVPIONUQT-RGYGYFBISA-N	27924.0		PHEDXBVPIONUQT
BRD-K68552125-001-07-9	12-O-tetradecanoylphorbol-13-acetate	Phase 2	PKC activator	KCNT2|TRPV4			0	96.97	Sigma	P8139	phorbol 12-myristate 13-acetate	616.398	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33,t:22|	PHEDXBVPIONUQT-RGYGYFBISA-N	27924.0		PHEDXBVPIONUQT
BRD-K30237152-300-02-5	1400W	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	89.27	Tocris	1415	1400W dihydrochloride	177.127	CC(=N)NCc1cccc(CN)c1	RODUKNYOEVZQPR-UHFFFAOYSA-N	1433.0		RODUKNYOEVZQPR
BRD-K92301463-001-05-5	16,16-dimethylprostaglandin-e2	Phase 2	prostanoid receptor agonist	HPGD			0	100.0	Enzo	PG021	16,16-Dimethyl-prostaglandin E2	380.256	CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	QAOBBBBDJSWHMU-WMBBNPMCSA-N	5283066.0		QAOBBBBDJSWHMU
BRD-K92301463-001-06-9	16,16-dimethylprostaglandin-e2	Phase 2	prostanoid receptor agonist	HPGD			0	0.0	Sigma	MFCD00151141	(5Z,11beta,13E,15R)-11,15-dihydroxy-16,16-dimethyl-9-oxoprosta-5,13-dien-1-oic acid	380.256	CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	QAOBBBBDJSWHMU-WMBBNPMCSA-N	5283066.0		QAOBBBBDJSWHMU
BRD-K70264088-001-17-9	17-hydroxyprogesterone-caproate	Launched	progesterone receptor agonist	AR|ESR1|ESR2|NR1H4|NR1I2|NR3C1|PGR	obstetrics/gynecology	spontaneous preterm birth	0	89.88	MedChemEx	HY-B0742	Hydroxyprogesterone caproate	428.293	CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|	DOMWKUIIPQCAJU-LJHIYBGHSA-N	169870.0		DOMWKUIIPQCAJU
BRD-K07395323-001-01-0	17-PA	Preclinical	glucocorticoid receptor agonist				0	0.0	Tocris	2681	17-PA	350.261	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|	SINAMTXBCYKFDL-WBJZGETLSA-N	25068278.0	BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2|BRD-A34299591-001-23-2	SINAMTXBCYKFDL
BRD-K07395323-001-02-9	17-PA	Preclinical	glucocorticoid receptor agonist				0	94.15	Tocris	2681	17-PA	350.261	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|	SINAMTXBCYKFDL-WBJZGETLSA-N	25068278.0		SINAMTXBCYKFDL
BRD-K78092779-001-01-6	2'-C-methylguanosine	Preclinical	HCV inhibitor				0	99.3	Sigma	MFCD13194756	(2R,3R,4R,5R)-2-(2-amino-6-hydroxy-9H-purin-9-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol	297.107	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c1[nH]c(N)nc2=O	NVKAMPJSWMHVDK-GITKWUPZSA-N	135433495.0		NVKAMPJSWMHVDK
BRD-K63932022-001-02-3	2'-MeCCPA	Preclinical	adenosine receptor agonist	ADORA1			0	95.81	Tocris	2281	2'-MeCCPA	383.136	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	MMPAUXMIDJWGFO-ROMFRFKVSA-N	10475082.0		MMPAUXMIDJWGFO
BRD-K63932022-001-01-5	2'-MeCCPA	Preclinical	adenosine receptor agonist	ADORA1			0	95.78	Tocris	2281	2'-MeCCPA	383.136	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	MMPAUXMIDJWGFO-ROMFRFKVSA-N	10475082.0		MMPAUXMIDJWGFO
BRD-K63932022-001-03-9	2'-MeCCPA	Preclinical	adenosine receptor agonist	ADORA1			0	94.88	Tocris	2281	2'-MeCCPA	383.136	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	MMPAUXMIDJWGFO-ROMFRFKVSA-N	10475082.0		MMPAUXMIDJWGFO
BRD-K44602126-001-01-3	2,3-cis/exo-camphanediol	Phase 1					0	0.0	BroadPharm	BP-30021		170.131	CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O	AYEOSGBMQHXVER-DQUBFYRCSA-N	11768995.0		AYEOSGBMQHXVER
BRD-A75263867-001-01-1	2,3-cis/exo-pinanediol	Phase 1					0	0.0	Maybridge	JFD01247		170.131	CC1(C)C2CC1[C@](C)(O)[C@H](O)C2	MOILFCKRQFQVFS-VUMZSGCYSA-N	12518181.0		MOILFCKRQFQVFS
BRD-K61734568-003-03-9	2,3-DCPE	Preclinical	BCL-XL downregulator	BCL2L1			0	95.44	Tocris	2137	2,3-DCPE hydrochloride	263.048	OCCNCCCOc1cccc(Cl)c1Cl	QVEIRCZEBQRCTR-UHFFFAOYSA-N	2250975.0		QVEIRCZEBQRCTR
BRD-K61734568-003-02-1	2,3-DCPE	Preclinical	BCL-XL downregulator	BCL2L1			0	100.0	Tocris	2137	2,3-DCPE hydrochloride	263.048	OCCNCCCOc1cccc(Cl)c1Cl	QVEIRCZEBQRCTR-UHFFFAOYSA-N	2250975.0		QVEIRCZEBQRCTR
BRD-K97833335-001-08-2	2,4-dinitrochlorobenzene	Phase 2	thioredoxin inhibitor	TXN			0	0.0	Sigma	C3762	1-chloro-2,4-dinitrobenzene	201.978	[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O	VYZAHLCBVHPDDF-UHFFFAOYSA-N	6.0		VYZAHLCBVHPDDF
BRD-K21910317-001-12-3	2,4-dinitrophenol	Preclinical	ATP synthase inhibitor	APP			0	98.95	MicroSource	330008	2,4-DINITROPHENOL	184.012	Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O	UFBJCMHMOXMLKC-UHFFFAOYSA-N	1493.0		UFBJCMHMOXMLKC
BRD-K29791386-001-01-8	2,5-furandimethanol	Phase 2	hemoglobin modulator	HBB			0	0.0	Key	TS-01680	furan-2,5-diyldimethanol	128.047	OCc1ccc(CO)o1	DSLRVRBSNLHVBH-UHFFFAOYSA-N	74663.0		DSLRVRBSNLHVBH
BRD-A21276153-001-01-1	2,6-dimethylpiperidine	Preclinical					1	0.0	MicroSource	1301019	NANOFIN	113.12	C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|	SDGKUVSVPIIUCF-KNVOCYPGSA-N	641768.0		SDGKUVSVPIIUCF
BRD-A21276153-001-02-9	2,6-dimethylpiperidine	Preclinical					1	0.0	MedChemEx	HY-B1191	Nanofin	113.12	C[C@H]1CCC[C@@H](C)N1 |&1:1,&2:5,r|	SDGKUVSVPIIUCF-KNVOCYPGSA-N	641768.0		SDGKUVSVPIIUCF
BRD-K46989997-001-01-8	2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one	Preclinical					0	80.5	Enamine	EN300-01894	2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one	254.028	ClC=C1Nc2sc3CCCCc3c2C(=O)N1	UTWSZXBGTLNPOV-UHFFFAOYSA-N			UTWSZXBGTLNPOV
BRD-K75167327-001-01-6	2-(1-adamantylamino)benzoic-acid	Preclinical					0	97.76	Enamine	T0514-6571	2-[(1-adamantylcarbonyl)amino]benzoic acid	299.152	OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2	XKZLSYWCDJZTMW-UHFFFAOYSA-N	2847479.0		XKZLSYWCDJZTMW
BRD-A66788520-001-01-7	2-(3-mercaptopropyl)pentanedioic-acid	Phase 1	glutamate carboxypeptidase inhibitor	FOLH1			0	84.2	Tocris	5033	2-(3-mercaptopropyl)pentanedioic acid	206.061	OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|	FNLNSQHJKVQCBP-ZCFIWIBFSA-N	11735892.0		FNLNSQHJKVQCBP
BRD-A66788520-001-02-9	2-(3-mercaptopropyl)pentanedioic-acid	Phase 1	glutamate carboxypeptidase inhibitor	FOLH1			0		Tocris	5033	2-MPPA	206.061	OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5,r|	FNLNSQHJKVQCBP-ZCFIWIBFSA-N	11735892.0		FNLNSQHJKVQCBP
BRD-K91868854-001-04-9	2-[1-(4-piperonyl)piperazinyl]benzothiazole	Preclinical	serotonin receptor agonist	HTR4			0	96.43	Tocris	736	2-[1-(4-Piperonyl)piperazinyl]benzothiazole	353.12	C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1	BYHKGNWKJMGHGE-UHFFFAOYSA-N	127902.0		BYHKGNWKJMGHGE
BRD-K91868854-001-03-6	2-[1-(4-piperonyl)piperazinyl]benzothiazole	Preclinical	serotonin receptor agonist	HTR4			0	99.23	Tocris	736	2-[1-(4-Piperonyl)piperazinyl]benzothiazole	353.12	C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1	BYHKGNWKJMGHGE-UHFFFAOYSA-N	127902.0		BYHKGNWKJMGHGE
BRD-K32681104-001-11-6	2-aminobenzenesulfonamide	Preclinical	carbonic anhydrase inhibitor	CA12|CA14|CA2|CA6|CA9			0	99.54	Prestwick	Prestw-913	2-Aminobenzenesulfonamide	172.031	Nc1ccccc1S(N)(=O)=O	YAZSBRQTAHVVGE-UHFFFAOYSA-N	72894.0		YAZSBRQTAHVVGE
BRD-K32681104-001-12-9	2-aminobenzenesulfonamide	Preclinical	carbonic anhydrase inhibitor	CA12|CA14|CA2|CA6|CA9			0		MedChemEx	HY-B2147	2-Aminobenzenesulfonamide	172.031	Nc1ccccc1S(N)(=O)=O	YAZSBRQTAHVVGE-UHFFFAOYSA-N	72894.0		YAZSBRQTAHVVGE
BRD-K13346085-001-05-9	2-APB	Preclinical	1,4,5-trisphosphate inhibitor	TRPC1|TRPC3|TRPC4|TRPC5|TRPC6|TRPC7|TRPM2|TRPM3|TRPM6|TRPV1|TRPV6			0	0.0	Tocris	1224	2-APB	225.132	NCCOB(c1ccccc1)c1ccccc1	BLZVCIGGICSWIG-UHFFFAOYSA-N	1598.0		BLZVCIGGICSWIG
BRD-K13346085-001-04-7	2-APB	Preclinical	1,4,5-trisphosphate inhibitor	TRPC1|TRPC3|TRPC4|TRPC5|TRPC6|TRPC7|TRPM2|TRPM3|TRPM6|TRPV1|TRPV6			0	0.0	Tocris	1224	2-APB	225.132	NCCOB(c1ccccc1)c1ccccc1	BLZVCIGGICSWIG-UHFFFAOYSA-N	1598.0		BLZVCIGGICSWIG
BRD-K22745370-003-02-3	2-BFI	Preclinical	imidazoline receptor ligand	ADRA2A|ADRA2B|ADRA2C|MAOA|MAOB			0	97.63	Tocris	348	2-BFI hydrochloride	186.079	C1CN=C(N1)c1cc2ccccc2o1 |c:2|	YTJOHEUHUVBKSB-UHFFFAOYSA-N	3080926.0		YTJOHEUHUVBKSB
BRD-K70088346-001-02-4	2-chloro-N6-cyclopentyladenosine	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	97.57	Tocris	1705	2-Chloro-N6-cyclopentyladenosine	369.12	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	XSMYYYQVWPZWIZ-IDTAVKCVSA-N	123807.0		XSMYYYQVWPZWIZ
BRD-K70088346-001-06-9	2-chloro-N6-cyclopentyladenosine	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	93.87	Tocris	1705	2-Chloro-N6-cyclopentyladenosine	369.12	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	XSMYYYQVWPZWIZ-IDTAVKCVSA-N	123807.0		XSMYYYQVWPZWIZ
BRD-K70088346-001-01-6	2-chloro-N6-cyclopentyladenosine	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B|ADORA3			0	98.41	Tocris	1705	2-Chloro-N6-cyclopentyladenosine	369.12	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	XSMYYYQVWPZWIZ-IDTAVKCVSA-N	123807.0		XSMYYYQVWPZWIZ
BRD-K79511609-001-20-0	2-chloroadenosine	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B			0	98.42	Tocris	3136	2-Chloroadenosine	301.058	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	BIXYYZIIJIXVFW-UUOKFMHZSA-N	8974.0		BIXYYZIIJIXVFW
BRD-K79511609-001-21-9	2-chloroadenosine	Preclinical	adenosine receptor agonist	ADORA1|ADORA2A|ADORA2B			0	95.86	Tocris	3136	2-Chloroadenosine	301.058	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	BIXYYZIIJIXVFW-UUOKFMHZSA-N	8974.0		BIXYYZIIJIXVFW
BRD-K84075000-001-06-9	2-chloropyrazine	Preclinical					0	0.0	MedChemEx	HY-Y0109	Pyrazin-2-yl chloride	113.998	Clc1cnccn1	GELVZYOEQVJIRR-UHFFFAOYSA-N	73277.0		GELVZYOEQVJIRR
BRD-K84075000-001-05-5	2-chloropyrazine	Preclinical					0	94.15	Prestwick	Prestw-1087	2-Chloropyrazine	113.998	Clc1cnccn1	GELVZYOEQVJIRR-UHFFFAOYSA-N	73277.0		GELVZYOEQVJIRR
BRD-K92588747-051-03-9	2-CMDO	Preclinical	dopamine receptor antagonist	DRD2|DRD4			0	92.34	Tocris	782	2-CMDO	326.119	CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|	OTKUTGIVEREJLL-UHFFFAOYSA-N	32224.0		OTKUTGIVEREJLL
BRD-K92588747-051-02-7	2-CMDO	Preclinical	dopamine receptor antagonist	DRD2|DRD4			0	95.69	Tocris	782	2-CMDO	326.119	CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|	OTKUTGIVEREJLL-UHFFFAOYSA-N	32224.0		OTKUTGIVEREJLL
BRD-A55902763-001-01-3	2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose	Preclinical			oncology|endocrinology	pancreatic cancer|hypoglycemia	0	0.0	Labotest	LT00452082	2-deoxy-2-{[(1-methyl-2-oxohydrazino)carbonyl]amino}hexose	265.091	CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO |&1:7,&2:10,&3:12,&4:14,r|	VUVHIMLGTHRGQZ-YTLHQDLWSA-N			VUVHIMLGTHRGQZ
BRD-K97808269-001-02-7	2-deoxyglucose	Phase 2	glycolysis inhibitor	SLC2A1|SLC2A2|SLC2A3|SLC2A4			0	100.0	Enzo	AC1512	2-Deoxyglucose	164.068	OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O	PMMURAAUARKVCB-ZXXMMSQZSA-N	9062.0		PMMURAAUARKVCB
BRD-K97808269-001-03-9	2-deoxyglucose	Phase 2	glycolysis inhibitor	SLC2A1|SLC2A2|SLC2A3|SLC2A4			0	100.0	MedChemEx	HY-13966	2-Deoxy-D-glucose	164.068	OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O	PMMURAAUARKVCB-ZXXMMSQZSA-N	9062.0		PMMURAAUARKVCB
BRD-K04843302-001-02-5	2-ethoxybenzoic-acid	Phase 1	analgesic agent				0	97.32	Enamine	Z111665440	2-ethoxybenzoic acid	166.063	CCOc1ccccc1C(O)=O	XDZMPRGFOOFSBL-UHFFFAOYSA-N	67252.0		XDZMPRGFOOFSBL
BRD-A55455283-001-02-1	2-ethyl-1,3-hexanediol	Preclinical					1	0.0	Sigma	MFCD00004578	2-ethyl-1,3-hexanediol	146.131	CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|	RWLALWYNXFYRGW-JGVFFNPUSA-N	7057924.0		RWLALWYNXFYRGW
BRD-A55455283-001-01-3	2-ethyl-1,3-hexanediol	Preclinical					1	0.0	TCI	E0119		146.131	CCC[C@@H](O)[C@@H](CC)CO |&1:3,&2:5,r|	RWLALWYNXFYRGW-JGVFFNPUSA-N	7057924.0		RWLALWYNXFYRGW
BRD-A53037300-001-01-0	2-fluoro-2-deoxy-D-galactose	Phase 1		LCT			0	100.0	SantaCruz	sc-220725		182.059	OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2,&2:4,&3:6,&4:8,&5:10,r|	ZCXUVYAZINUVJD-AIECOIEWSA-N	445913.0		ZCXUVYAZINUVJD
BRD-K00004677-001-01-9	2-fluorofucose	Phase 1					0	0.0	Apollo	BICL4256	2-Deoxy-2-fluoro-L-fucose	166.064	C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O |&1:3|	IRKXGKIPOMIQOD-QYESYBIKSA-N	446098.0		IRKXGKIPOMIQOD
BRD-A52169337-001-01-9	2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione	Preclinical					0	72.68	MedChemEx	HY-N0567	2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-;2-yl)cyclohexane-1,3,5-trione	612.169	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|	BWKBPVRNWJFLSC-FROSJQSHSA-N			BWKBPVRNWJFLSC
BRD-A52169337-001-02-7	2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione	Preclinical					0	76.37	MedChemEx	HY-N0567	Hydroxysafflor yellow A	612.169	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2,4,5,7,9,30,32,35,37,39,&1:11,&2:14,&3:28|	BWKBPVRNWJFLSC-FROSJQSHSA-N			BWKBPVRNWJFLSC
BRD-K41866823-001-01-3	2-hydroxyethyl-salicylate	Launched			neurology/psychiatry	pain relief	0	97.62	Acros	17410	2-Hydroxyethyl salicylate	182.058	OCCOC(=O)c1ccccc1O	LVYLCBNXHHHPSB-UHFFFAOYSA-N	6880.0		LVYLCBNXHHHPSB
BRD-K82027074-001-08-3	2-hydroxyflutamide	Phase 2	androgen receptor antagonist	AR			0	97.66	Sigma	MFCD00563126	2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide	292.067	CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	YPQLFJODEKMJEF-UHFFFAOYSA-N	91649.0		YPQLFJODEKMJEF
BRD-K82027074-001-07-5	2-hydroxyflutamide	Phase 2	androgen receptor antagonist	AR			0	99.33	Enamine	Z1603855929		292.067	CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	YPQLFJODEKMJEF-UHFFFAOYSA-N	91649.0		YPQLFJODEKMJEF
BRD-A27924917-001-03-3	2-hydroxysaclofen	Preclinical	GABA receptor antagonist	GABBR1|GABBR2			0	96.08	Tocris	245	2-Hydroxysaclofen	265.018	NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	WBSMZVIMANOCNX-SECBINFHSA-N	7005135.0		WBSMZVIMANOCNX
BRD-A27924917-001-04-9	2-hydroxysaclofen	Preclinical	GABA receptor antagonist	GABBR1|GABBR2			0	91.07	Tocris	245	2-Hydroxysaclofen	265.018	NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2,r|	WBSMZVIMANOCNX-SECBINFHSA-N	7005135.0		WBSMZVIMANOCNX
BRD-K07954936-001-02-9	2-iminobiotin	Phase 2	nitric oxide synthase inhibitor	NOS1|NOS2			0	0.0	Sigma	MFCD00066150	2-Iminobiotin	243.104	NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|	WWVANQJRLPIHNS-ZKWXMUAHSA-N	135678104.0		WWVANQJRLPIHNS
BRD-K07954936-001-01-3	2-iminobiotin	Phase 2	nitric oxide synthase inhibitor	NOS1|NOS2			0	90.08	BroadPharm	BP-20532		243.104	NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|	WWVANQJRLPIHNS-ZKWXMUAHSA-N	135678104.0		WWVANQJRLPIHNS
BRD-K56634222-001-03-0	2-iodohippuric-acid	Preclinical					0	98.84	Enamine	Z85887266		304.955	OC(=O)CNC(=O)c1ccccc1I	CORFWQGVBFFZHF-UHFFFAOYSA-N	8614.0		CORFWQGVBFFZHF
BRD-K56634222-001-04-9	2-iodohippuric-acid	Preclinical					0	98.45	Sigma	MFCD00002694	2-Iodohippuric acid	304.955	OC(=O)CNC(=O)c1ccccc1I	CORFWQGVBFFZHF-UHFFFAOYSA-N	8614.0		CORFWQGVBFFZHF
BRD-K25649279-001-03-9	2-iodomelatonin	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B|NQO2			0	96.09	Tocris	737	2-Iodomelatonin	358.018	COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1	FJDDSMSDZHURBJ-UHFFFAOYSA-N	115348.0		FJDDSMSDZHURBJ
BRD-K25649279-001-02-0	2-iodomelatonin	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B|NQO2			0	89.11	Tocris	737	2-Iodomelatonin	358.018	COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1	FJDDSMSDZHURBJ-UHFFFAOYSA-N	115348.0		FJDDSMSDZHURBJ
BRD-K44408410-001-21-8	2-methoxyestradiol	Phase 2	hypoxia inducible factor inhibitor	COMT|CYP19A1|CYP1A1|CYP1B1|HIF1A|TUBB			0	90.4	Tocris	1807	2-Methoxyestradiol	302.188	COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	CQOQDQWUFQDJMK-SSTWWWIQSA-N	66414.0		CQOQDQWUFQDJMK
BRD-K44408410-001-22-6	2-methoxyestradiol	Phase 2	hypoxia inducible factor inhibitor	COMT|CYP19A1|CYP1A1|CYP1B1|HIF1A|TUBB			0	91.3	Selleck	S1233	2-Methoxyestradiol (2-MeOE2)	302.188	COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	CQOQDQWUFQDJMK-SSTWWWIQSA-N	66414.0	BRD-K42136116-001-01-6	CQOQDQWUFQDJMK
BRD-K44408410-001-17-6	2-methoxyestradiol	Phase 2	hypoxia inducible factor inhibitor	COMT|CYP19A1|CYP1A1|CYP1B1|HIF1A|TUBB			0	97.09	Tocris	1807	2-Methoxyestradiol	302.188	COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	CQOQDQWUFQDJMK-SSTWWWIQSA-N	66414.0		CQOQDQWUFQDJMK
BRD-K64137799-003-03-3	2-methyl-5-hydroxytryptamine	Preclinical	serotonin receptor agonist	HTR1B|HTR1D|HTR1E|HTR1F|HTR3A|HTR3B|HTR6			0	86.53	Tocris	558	3-(2-aminoethyl)-2-methyl-1H-indol-5-ol hydrochloride	190.111	Cc1[nH]c2ccc(O)cc2c1CCN	WYWNEDARFVJQSG-UHFFFAOYSA-N	1574.0		WYWNEDARFVJQSG
BRD-K64137799-003-02-5	2-methyl-5-hydroxytryptamine	Preclinical	serotonin receptor agonist	HTR1B|HTR1D|HTR1E|HTR1F|HTR3A|HTR3B|HTR6			0	97.17	Tocris	558	2-Methyl-5-hydroxytryptamine hydrochloride	190.111	Cc1[nH]c2ccc(O)cc2c1CCN	WYWNEDARFVJQSG-UHFFFAOYSA-N	1574.0		WYWNEDARFVJQSG
BRD-K22327730-001-02-9	2-methyl-5-nitrophenol	Preclinical					0	86.08	MedChemEx	HY-41508	2-Methyl-5-nitrophenol	153.043	Cc1ccc(cc1O)[N+]([O-])=O	UMFDLIXUUJMPSI-UHFFFAOYSA-N	93576.0		UMFDLIXUUJMPSI
BRD-K22327730-001-01-1	2-methyl-5-nitrophenol	Preclinical					0	0.0	Enamine	Z415740552		153.043	Cc1ccc(cc1O)[N+]([O-])=O	UMFDLIXUUJMPSI-UHFFFAOYSA-N	93576.0		UMFDLIXUUJMPSI
BRD-K68534611-001-07-8	2-methylimidazole	Preclinical	cholesterol inhibitor				0	93.95	Sigma	Y0001320	2-methyl-1H-imidazole	82.053	Cc1ncc[nH]1	LXBGSDVWAMZHDD-UHFFFAOYSA-N	12749.0		LXBGSDVWAMZHDD
BRD-A51407134-001-02-7	2-octyldodecan-1-ol	Preclinical					1	0.0	Sigma	MFCD01310428	2-octyl-1-dodecanol	298.324	CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|	LEACJMVNYZDSKR-FQEVSTJZSA-N	73415990.0		LEACJMVNYZDSKR
BRD-A51407134-001-01-9	2-octyldodecan-1-ol	Preclinical					1	0.0	Bepharm	B77854	2-Octyldodecan-1-ol	298.324	CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10,r|	LEACJMVNYZDSKR-FQEVSTJZSA-N	73415990.0		LEACJMVNYZDSKR
BRD-K77087341-001-02-4	2-oleoylglycerol	Phase 1	glucose dependent insulinotropic receptor ligand	GPR119			0	94.8	Cayman	16537	2-hydroxy-1-(hydroxymethyl)ethyl (9Z)-9-octadecenoate	356.293	CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO	UPWGQKDVAURUGE-KTKRTIGZSA-N	5319879.0		UPWGQKDVAURUGE
BRD-K89712525-001-03-9	2-oxoglutaric-acid	Preclinical		OXGR1			1	100.0	MedChemEx	HY-W013636	2-Ketoglutaric acid	146.022	OC(=O)CCC(=O)C(O)=O	KPGXRSRHYNQIFN-UHFFFAOYSA-N	51.0		KPGXRSRHYNQIFN
BRD-K89712525-001-02-1	2-oxoglutaric-acid	Preclinical		OXGR1			1	0.0	Enamine	Z57127547		146.022	OC(=O)CCC(=O)C(O)=O	KPGXRSRHYNQIFN-UHFFFAOYSA-N	51.0		KPGXRSRHYNQIFN
BRD-K89712525-001-04-9	2-oxoglutaric-acid	Preclinical		OXGR1			1		MedChemEx	HY-W013636	2-Ketoglutaric acid	146.022	OC(=O)CCC(=O)C(O)=O	KPGXRSRHYNQIFN-UHFFFAOYSA-N	51.0		KPGXRSRHYNQIFN
BRD-K86587225-236-02-5	2-oxopropanoate	Preclinical	pyruvate dehydrogenase kinase inhibitor	ABAT			0	76.6	Sigma	MFCD00002586	sodium 2-oxopropanoate	88.016	OC(=C)C(O)=O	FEWFXBUNENSNBQ-UHFFFAOYSA-N	37873.0		FEWFXBUNENSNBQ
BRD-K41869275-001-03-6	2-phenylmelatonin	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B			0	97.9	Tocris	680	2-Phenylmelatonin	308.152	COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	OFCLARYYBGKCHN-UHFFFAOYSA-N	4018512.0		OFCLARYYBGKCHN
BRD-K41869275-001-04-9	2-phenylmelatonin	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B			0	96.1	Tocris	680	2-Phenylmelatonin	308.152	COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	OFCLARYYBGKCHN-UHFFFAOYSA-N	4018512.0		OFCLARYYBGKCHN
BRD-K41869275-001-02-8	2-phenylmelatonin	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B			0	93.49	Tocris	680	2-Phenylmelatonin	308.152	COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	OFCLARYYBGKCHN-UHFFFAOYSA-N	4018512.0		OFCLARYYBGKCHN
BRD-A04661934-001-03-9	2-PMDQ	Preclinical	adrenergic receptor antagonist	ADRA1A			0	97.31	Tocris	627	2-PMDQ	361.19	O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|	ONSOQRPYFKDOEB-INIZCTEOSA-N			ONSOQRPYFKDOEB
BRD-A04661934-001-02-9	2-PMDQ	Preclinical	adrenergic receptor antagonist	ADRA1A			0	93.6	Tocris	627	2-PMDQ	361.19	O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11,r,t:10|	ONSOQRPYFKDOEB-INIZCTEOSA-N			ONSOQRPYFKDOEB
BRD-K17874705-300-04-0	2-pyridylethylamine	Preclinical	histamine receptor agonist	HRH1			0	97.88	Tocris	2478	2-Pyridylethylamine dihydrochloride	122.084	NCCc1ccccn1	XPQIPUZPSLAZDV-UHFFFAOYSA-N	75919.0		XPQIPUZPSLAZDV
BRD-K17874705-300-03-2	2-pyridylethylamine	Preclinical	histamine receptor agonist	HRH1			0	90.42	Tocris	2478	2-Pyridylethylamine dihydrochloride	122.084	NCCc1ccccn1	XPQIPUZPSLAZDV-UHFFFAOYSA-N	75919.0		XPQIPUZPSLAZDV
BRD-K89072800-001-02-9	2-TEDC	Preclinical	lipoxygenase inhibitor	ALOX12			0	93.92	Tocris	645	2-TEDC	315.057	Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O	KCGLTUBCAGZLHP-XYOKQWHBSA-N	6069552.0		KCGLTUBCAGZLHP
BRD-K89072800-001-01-8	2-TEDC	Preclinical	lipoxygenase inhibitor	ALOX12			0	94.84	Tocris	645	2-TEDC	315.057	Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O	KCGLTUBCAGZLHP-XYOKQWHBSA-N	6069552.0		KCGLTUBCAGZLHP
BRD-K58819470-001-06-9	2-thiouracil	Preclinical					0	100.0	MedChemEx	HY-B0503	2-Thiouracil	128.004	O=c1cc[nH]c(=S)[nH]1	ZEMGGZBWXRYJHK-UHFFFAOYSA-N	1269845.0		ZEMGGZBWXRYJHK
BRD-K58819470-001-05-9	2-thiouracil	Preclinical					0	100.0	MicroSource	1503973	2-THIOURACIL	128.004	O=c1cc[nH]c(=S)[nH]1	ZEMGGZBWXRYJHK-UHFFFAOYSA-N	1269845.0		ZEMGGZBWXRYJHK
BRD-K58819470-001-04-2	2-thiouracil	Preclinical					0	96.52	Selleck	S3100	2-Thiouracil	128.004	O=c1cc[nH]c(=S)[nH]1	ZEMGGZBWXRYJHK-UHFFFAOYSA-N	1269845.0		ZEMGGZBWXRYJHK
BRD-K00005345-001-01-9	20-HETE	Preclinical	ion channel antagonist				0	0.0	MedChemEx	HY-15598	20-HETE	320.235	OCCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	NNDIXBJHNLFJJP-DTLRTWKJSA-N	5283157.0		NNDIXBJHNLFJJP
BRD-K28343777-001-01-6	20-hydroxyecdysone	Phase 2	ecdysone receptor modulator				0	92.15	Selleck	S2417	20-Hydroxyecdysone	480.309	CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C |t:16|	NKDFYOWSKOHCCO-HMIIXLFTSA-N	25749233.0		NKDFYOWSKOHCCO
BRD-K45662124-050-02-3	3'-fluorobenzylspiperone	Preclinical	dopamine receptor ligand	DRD2			0	93.86	Tocris	701	3'-Fluorobenzylspiperone maleate	503.238	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	DXZKTRNEOISOCA-UHFFFAOYSA-N	3248000.0		DXZKTRNEOISOCA
BRD-K45662124-050-03-9	3'-fluorobenzylspiperone	Preclinical	dopamine receptor ligand	DRD2			0	93.33	Tocris	701	3'-Fluorobenzylspiperone maleate	503.238	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	DXZKTRNEOISOCA-UHFFFAOYSA-N	3248000.0		DXZKTRNEOISOCA
BRD-K45662124-050-01-5	3'-fluorobenzylspiperone	Preclinical	dopamine receptor ligand	DRD2			0	93.65	Tocris	701	3'-Fluorobenzylspiperone maleate	503.238	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	DXZKTRNEOISOCA-UHFFFAOYSA-N	3248000.0		DXZKTRNEOISOCA
BRD-K82903013-001-02-9	3,3'-dichlorobenzaldazine	Preclinical	glutamate receptor modulator	GRM5			0	92.82	Tocris	1952	DCB	276.022	Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1	XMOVWXSCYLINBJ-BEQMOXJMSA-N	6861557.0		XMOVWXSCYLINBJ
BRD-K82903013-001-01-4	3,3'-dichlorobenzaldazine	Preclinical	glutamate receptor modulator	GRM5			0	96.54	Tocris	1952	DCB	276.022	Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1	XMOVWXSCYLINBJ-BEQMOXJMSA-N	6861557.0	BRD-K50339813-001-01-1	XMOVWXSCYLINBJ
BRD-K37846922-001-09-4	3,3'-diindolylmethane	Phase 3	CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor	AR|HIF1A|IFNG|PI3			0	87.7	Enzo	GR207	Diindolylmethane	246.116	C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	VFTRKSBEFQDZKX-UHFFFAOYSA-N	3071.0		VFTRKSBEFQDZKX
BRD-K37846922-001-10-2	3,3'-diindolylmethane	Phase 3	CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor	AR|HIF1A|IFNG|PI3			0	93.17	Sigma	D9568	3,3-diindolemethane	246.116	C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	VFTRKSBEFQDZKX-UHFFFAOYSA-N	3071.0		VFTRKSBEFQDZKX
BRD-A49947412-001-03-9	3,4-DCPG-(+/-)	Preclinical	glutamate receptor agonist	GRM8			0	0.0	Tocris	1394	(RS)-3,4-DCPG	239.043	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|	IJVMOGKBEVRBPP-SSDOTTSWSA-N	6604849.0		IJVMOGKBEVRBPP
BRD-A49947412-001-02-0	3,4-DCPG-(+/-)	Preclinical	glutamate receptor agonist	GRM8			0	0.0	Tocris	1394	(RS)-3,4-DCPG	239.043	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1,r|	IJVMOGKBEVRBPP-SSDOTTSWSA-N	6604849.0		IJVMOGKBEVRBPP
BRD-K06204668-001-03-9	3,4-DCPG-(R)	Preclinical	glutamate receptor antagonist				0	100.0	Tocris	1395	(R)-3,4-DCPG	239.043	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	IJVMOGKBEVRBPP-SSDOTTSWSA-N	6604849.0		IJVMOGKBEVRBPP
BRD-K06204668-001-02-6	3,4-DCPG-(R)	Preclinical	glutamate receptor antagonist				0	0.0	Tocris	1395	(R)-3,4-DCPG	239.043	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	IJVMOGKBEVRBPP-SSDOTTSWSA-N	6604849.0		IJVMOGKBEVRBPP
BRD-K86305586-001-03-9	3,4-DCPG-(S)	Preclinical	glutamate receptor agonist	GRM8			0	0.0	Tocris	1302	(S)-3,4-DCPG	239.043	N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	IJVMOGKBEVRBPP-ZETCQYMHSA-N	16062593.0		IJVMOGKBEVRBPP
BRD-K86305586-001-02-3	3,4-DCPG-(S)	Preclinical	glutamate receptor agonist	GRM8			0	0.0	Tocris	1302	(S)-3,4-DCPG	239.043	N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	IJVMOGKBEVRBPP-ZETCQYMHSA-N	16062593.0		IJVMOGKBEVRBPP
BRD-K42205652-001-02-7	3,4-methylenedioxy-beta-nitrostyrene	Preclinical	SRC inhibitor|SYK inhibitor	SRC|SYK			0	88.09	Selleck	S4921	MNS (3,4-Methylenedioxy-?-nitrostyrene, MDBN)	193.038	[O-][N+](=O)\C=C\c1ccc2OCOc2c1	KFLWBZPSJQPRDD-ONEGZZNKSA-N	672296.0		KFLWBZPSJQPRDD
BRD-K42205652-001-05-0	3,4-methylenedioxy-beta-nitrostyrene	Preclinical	SRC inhibitor|SYK inhibitor	SRC|SYK			0	96.95	Selleck	S4921	MNS (3,4-Methylenedioxy-??-nitrostyrene)	193.038	[O-][N+](=O)\C=C\c1ccc2OCOc2c1	KFLWBZPSJQPRDD-ONEGZZNKSA-N	672296.0		KFLWBZPSJQPRDD
BRD-K57796080-001-04-9	3,5-DHPG-(S)	Preclinical	glutamate receptor agonist	GRM1			0	100.0	Tocris	805	(S)-3,5-DHPG	183.053	N[C@H](C(O)=O)c1cc(O)cc(O)c1	HOOWCUZPEFNHDT-ZETCQYMHSA-N	71668376.0		HOOWCUZPEFNHDT
BRD-K57796080-001-03-7	3,5-DHPG-(S)	Preclinical	glutamate receptor agonist	GRM1			0	0.0	Tocris	805	(S)-3,5-DHPG	183.053	N[C@H](C(O)=O)c1cc(O)cc(O)c1	HOOWCUZPEFNHDT-ZETCQYMHSA-N	71668376.0		HOOWCUZPEFNHDT
BRD-A55464252-001-01-2	3-(4-methylbenzylidene)camphor	Launched	endocrine disruptor		dermatology	sunscreen lotion	0	98.91	AlfaAesar	A16566	3-(4-Methylbenzylidene)camphor, 99+%	254.167	Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|	HEOCBCNFKCOKBX-LBONJMQPSA-N	38988322.0		HEOCBCNFKCOKBX
BRD-A55464252-001-02-0	3-(4-methylbenzylidene)camphor	Launched	endocrine disruptor		dermatology	sunscreen lotion	0	93.62	Selleck	S3704	3-(4-Methylbenzylidene)camphor, 99+%	254.167	Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7,&2:10,r|	HEOCBCNFKCOKBX-LBONJMQPSA-N	38988322.0		HEOCBCNFKCOKBX
BRD-K00004218-003-01-9	3-alpha-bis-(4-fluorophenyl)-methoxytropane	Preclinical	dopamine uptake inhibitor	CHRM1|SLC6A2|SLC6A3|SLC6A4			0	95.34	Tocris	918	3alpha-Bis-(4-fluorophenyl) methoxytropane hydrochloride	343.175	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2,5,7|	MHNSOBBJZCWUGS-PMOLBWCYSA-N			MHNSOBBJZCWUGS
BRD-A43598550-001-09-4	3-alpha-hydroxy-5-beta-androstan-17-one	Preclinical		HSD17B11|IGHG2|SULT2A1			0	100.0	Prestwick	Prestw-697	3-alpha-Hydroxy-5-beta-androstan-17-one	290.225	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1,5,8,10,14,16,&1:4|	QGXBDMJGAMFCBF-BNSUEQOYSA-N	5880.0		QGXBDMJGAMFCBF
BRD-K08703257-001-12-1	3-amino-benzamide	Phase 2	PARP inhibitor	PARP1			0	96.89	Selleck	S1132	INO-1001	136.064	NC(=O)c1cccc(N)c1	GSCPDZHWVNUUFI-UHFFFAOYSA-N	1645.0		GSCPDZHWVNUUFI
BRD-K08703257-001-13-9	3-amino-benzamide	Phase 2	PARP inhibitor	PARP1			0	97.46	Tocris	788	3-Aminobenzamide	136.064	NC(=O)c1cccc(N)c1	GSCPDZHWVNUUFI-UHFFFAOYSA-N	1645.0		GSCPDZHWVNUUFI
BRD-K49721826-001-02-7	3-anilinopropan-1-ol	Preclinical					0	11.05	Enamine	Z104584292		151.1	OCCCNc1ccccc1	GZYBSURBYCLNSM-UHFFFAOYSA-N	410467.0		GZYBSURBYCLNSM
BRD-K49721826-001-03-9	3-anilinopropan-1-ol	Preclinical					0	29.93	Enamine	Z104584292	3-anilino-1-propanol	151.1	OCCCNc1ccccc1	GZYBSURBYCLNSM-UHFFFAOYSA-N	410467.0		GZYBSURBYCLNSM
BRD-K38370968-050-02-9	3-AQC	Preclinical	serotonin receptor agonist	HTR3A			0	88.85	Tocris	666	3-AQC	279.148	C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	IDOXKFDPDOIUMG-UHFFFAOYSA-N	3073499.0		IDOXKFDPDOIUMG
BRD-K38370968-050-01-3	3-AQC	Preclinical	serotonin receptor agonist	HTR3A			0	78.92	Tocris	666	3-AQC	279.148	C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	IDOXKFDPDOIUMG-UHFFFAOYSA-N	3073499.0		IDOXKFDPDOIUMG
BRD-K24689407-001-07-1	3-bromo-7-nitroindazole	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	97.43	Tocris	735	3-Bromo-7-nitroindazole	240.949	[O-][N+](=O)c1cccc2c(Br)[nH]nc12	NFSTZPMYAZRZPC-UHFFFAOYSA-N	1649.0		NFSTZPMYAZRZPC
BRD-K24689407-001-08-9	3-bromo-7-nitroindazole	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	95.87	Tocris	735	3-Bromo-7-nitroindazole	240.949	[O-][N+](=O)c1cccc2c(Br)[nH]nc12	NFSTZPMYAZRZPC-UHFFFAOYSA-N	1649.0		NFSTZPMYAZRZPC
BRD-K24689407-001-06-3	3-bromo-7-nitroindazole	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	97.63	Tocris	735	3-Bromo-7-nitroindazole	240.949	[O-][N+](=O)c1cccc2c(Br)[nH]nc12	NFSTZPMYAZRZPC-UHFFFAOYSA-N	1649.0		NFSTZPMYAZRZPC
BRD-K00004535-001-01-9	3-bromocamphor	Launched					0	3.7	Pharmeks	PHAR003359	(1S,3R,4R)-3-bromo-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one	230.031	[H][C@]1(Br)[C@@H]2CC[C@@](C)(C1=O)C2(C)C |&1:1,3,6|	NJQADTYRAYFBJN-BYULHYEWSA-N	3006542.0		NJQADTYRAYFBJN
BRD-K92980438-001-05-8	3-bromopyruvate	Preclinical	hexokinase inhibitor	HK2			0	0.0	MedChemEx	HY-19992	3-Bromopyruvic acid	165.927	OC(=O)C(O)=CBr	CHNJCELMWMIDSC-UHFFFAOYSA-N	129924149.0		CHNJCELMWMIDSC
BRD-K92980438-001-04-1	3-bromopyruvate	Preclinical	hexokinase inhibitor	HK2			1	0.0	MedChemEx	HY-19992	3-Bromopyruvic acid	165.927	OC(=O)C(O)=CBr	CHNJCELMWMIDSC-UHFFFAOYSA-N	129924149.0		CHNJCELMWMIDSC
BRD-K92980438-001-03-3	3-bromopyruvate	Preclinical	hexokinase inhibitor	HK2			1	0.0	Enamine	EN300-67360		165.927	OC(=O)C(O)=CBr	CHNJCELMWMIDSC-UHFFFAOYSA-N	129924149.0		CHNJCELMWMIDSC
BRD-K76592088-001-02-1	3-carboxy-4-hydroxyphenylglycine-(R)	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C			0	85.96	Tocris	328	(R)-3-Carboxy-4-hydroxyphenylglycine	211.048	N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-SSDOTTSWSA-N	6604713.0		CHZBCZTXSTWCIG
BRD-K76592088-001-03-9	3-carboxy-4-hydroxyphenylglycine-(R)	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C			0	100.0	Tocris	328	(R)-3-Carboxy-4-hydroxyphenylglycine	211.048	N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-SSDOTTSWSA-N	6604713.0		CHZBCZTXSTWCIG
BRD-K61585876-001-01-0	3-carboxy-4-hydroxyphenylglycine-(S)	Preclinical	glutamate receptor antagonist	GRM1|GRM5			0	87.81	Tocris	329	(S)-3-Carboxy-4-hydroxyphenylglycine	211.048	N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-ZETCQYMHSA-N	5311460.0		CHZBCZTXSTWCIG
BRD-K61585876-001-02-9	3-carboxy-4-hydroxyphenylglycine-(S)	Preclinical	glutamate receptor antagonist	GRM1|GRM5			0	100.0	Tocris	329	(S)-3-Carboxy-4-hydroxyphenylglycine	211.048	N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	CHZBCZTXSTWCIG-ZETCQYMHSA-N	5311460.0		CHZBCZTXSTWCIG
BRD-K00004217-003-01-9	3-CPMT	Preclinical	dopamine reuptake inhibitor				0	94.3	Tocris	917	3-CPMT	341.155	CN1[C@H]2CC[C@@H]1C[C@@H](C2)O[C@H](c1ccccc1)c1ccc(Cl)cc1 |&1:2,5,7,&2:10,r,THB:0:1:3.4:6.7.8|	OCAXFDULERPAJM-IVAOSVALSA-N			OCAXFDULERPAJM
BRD-A79431551-001-01-1	3-deazaadenosine	Phase 2	adenosylhomocysteinase inhibitor	AHCY			0	100.0	Enzo	AC992	3-Deazaadenosine	266.102	Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10,12,&1:15,&2:17|	DBZQFUNLCALWDY-GPUHXXMPSA-N	12769724.0		DBZQFUNLCALWDY
BRD-K77791657-001-01-1	3-deazaneplanocin-A	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	85.44	Selleck	S7120	3-Deazaneplanocin A (DZNeP)	262.107	Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|	OMKHWTRUYNAGFG-IEBDPFPHSA-N	73087.0	BRD-K55942458-001-01-7	OMKHWTRUYNAGFG
BRD-K77791657-003-02-9	3-deazaneplanocin-A	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	74.2	MedChemEx	HY-12186	3-Deazaneplanocin A (hydrochloride)	262.107	Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|	OMKHWTRUYNAGFG-IEBDPFPHSA-N	73087.0		OMKHWTRUYNAGFG
BRD-K77791657-003-01-7	3-deazaneplanocin-A	Preclinical	histone lysine methyltransferase inhibitor	EZH2			0	97.43	Selleck	S7120	3-deazaneplanocin A (DZNeP) HCl	262.107	Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|	OMKHWTRUYNAGFG-IEBDPFPHSA-N	73087.0		OMKHWTRUYNAGFG
BRD-A26105646-001-06-1	3-deazauridine	Preclinical	cytidine deaminase inhibitor				0	99.3	AMS	A001578548	1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyridine-2,4(1H,3H)-dione	243.074	OC[C@H]1O[C@@H]([C@@H](O)[C@@H]1O)n1ccc(O)cc1=O |&1:2,&2:4,&3:5,&4:7,r|	CBOKZNLSFMZJJA-PRQTWWFRSA-N			CBOKZNLSFMZJJA
BRD-A66143912-001-01-1	3-hydroxy-3-phenylpentanamide	Phase 1	GABA receptor modulator				0	96.14	Enamine	Z2327510224	3-hydroxy-3-phenylpentanamide	193.11	CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2,r|	MOHYRCCDARWQRM-LLVKDONJSA-N	101592120.0		MOHYRCCDARWQRM
BRD-K43187796-001-02-3	3-indolebutyric-acid	Preclinical		B2M|HLA-A|TRAC|TRBC1			0	97.58	Selleck	S2253	3-Indolebutyric acid (IBA)	203.095	OC(=O)CCCc1c[nH]c2ccccc12	JTEDVYBZBROSJT-UHFFFAOYSA-N	8617.0		JTEDVYBZBROSJT
BRD-A87125127-001-02-2	3-MATIDA	Preclinical	glutamate receptor antagonist	GRM1			0	0.0	Tocris	2196	3-MATIDA	215.025	Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|	KOMWRBFEDDEWEP-RXMQYKEDSA-N	92327883.0		KOMWRBFEDDEWEP
BRD-A87125127-001-03-9	3-MATIDA	Preclinical	glutamate receptor antagonist	GRM1			0	80.0	Tocris	2196	3-MATIDA	215.025	Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6,r|	KOMWRBFEDDEWEP-RXMQYKEDSA-N	92327883.0		KOMWRBFEDDEWEP
BRD-K01825682-074-02-9	3-methyl-GABA	Preclinical	GABA aminotransferase activator	ABAT			0	100.0	Tocris	386	3-Methyl-GABA	117.079	C[C@@H](CN)CC(O)=O |&1:1|	CZGLBWZXGIAIBU-SCSAIBSYSA-N	6604938.0		CZGLBWZXGIAIBU
BRD-K01825682-077-01-9	3-methyl-GABA	Preclinical	GABA aminotransferase activator	ABAT			0	71.72	Tocris	386	3-Methyl-GABA	405.055	C[C@@H](CN)CC(O)=O |&1:1|	CZGLBWZXGIAIBU-SCSAIBSYSA-N	6604938.0	BRD-M64651705-077-02-0	CZGLBWZXGIAIBU
BRD-K81647657-001-04-3	3-methyladenine	Preclinical	PI3K inhibitor	PI3			0	100.0	Selleck	S2767	3-Methyladenine	149.07	Cn1cnc(=N)c2[nH]cnc12	ZPBYVFQJHWLTFB-UHFFFAOYSA-N	135398661.0		ZPBYVFQJHWLTFB
BRD-K81647657-001-05-0	3-methyladenine	Preclinical	PI3K inhibitor	PI3			0	63.4	Selleck	S2767	3-Methyladenine (3-MA)	149.07	Cn1cnc(=N)c2[nH]cnc12	ZPBYVFQJHWLTFB-UHFFFAOYSA-N	135398661.0		ZPBYVFQJHWLTFB
BRD-K62581435-001-04-9	3-MPPI	Preclinical	adrenergic receptor ligand	ADRA1A			0	95.53	Tocris	581	3-MPPI	419.196	COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	AQASGOHUMGAWJJ-UHFFFAOYSA-N	4013695.0		AQASGOHUMGAWJJ
BRD-K62581435-001-03-8	3-MPPI	Preclinical	adrenergic receptor ligand	ADRA1A			0	86.55	Tocris	581	3-MPPI	419.196	COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	AQASGOHUMGAWJJ-UHFFFAOYSA-N	4013695.0		AQASGOHUMGAWJJ
BRD-K58413118-001-01-8	3PO	Preclinical	phosphofructokinase inhibitor	PFKFB3			0	92.61	MedChemEx	HY-19824	3PO	210.079	O=C(\C=C\c1cccnc1)c1ccncc1	UOWGYMNWMDNSTL-ONEGZZNKSA-N	5720233.0		UOWGYMNWMDNSTL
BRD-K51799616-001-05-5	4,4'-DDT	Preclinical					0	0.0	SantaCruz	sc-238975	4,4'-DDT	351.915	Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl	YVGGHNCTFXOJCH-UHFFFAOYSA-N	3036.0		YVGGHNCTFXOJCH
BRD-K49545903-003-01-4	4,4-pentamethylenepiperidine	Preclinical	M2 channel blocker				0	100.0	Tocris	3692	4,4-Pentamethylenepiperidine hydrochloride	153.152	C1CCC2(CC1)CCNCC2	LIZKZVQBLDHKCY-UHFFFAOYSA-N	417412.0		LIZKZVQBLDHKCY
BRD-K49545903-003-02-9	4,4-pentamethylenepiperidine	Preclinical	M2 channel blocker				0	100.0	Tocris	3692	4,4-Pentamethylenepiperidine hydrochloride	153.152	C1CCC2(CC1)CCNCC2	LIZKZVQBLDHKCY-UHFFFAOYSA-N	417412.0		LIZKZVQBLDHKCY
BRD-K97118047-001-03-8	4,5,6,7-tetrabromobenzotriazole	Preclinical	casein kinase inhibitor	AKT1|CHEK1|CSNK2A1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1			0	95.81	Tocris	2275	TBB	430.69	Brc1c(Br)c(Br)c2n[nH]nc2c1Br	OMZYUVOATZSGJY-UHFFFAOYSA-N	1694.0		OMZYUVOATZSGJY
BRD-K97118047-001-06-9	4,5,6,7-tetrabromobenzotriazole	Preclinical	casein kinase inhibitor	AKT1|CHEK1|CSNK2A1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1			0	96.0	Tocris	2275	TBB	430.69	Brc1c(Br)c(Br)c2n[nH]nc2c1Br	OMZYUVOATZSGJY-UHFFFAOYSA-N	1694.0		OMZYUVOATZSGJY
BRD-K97118047-001-04-6	4,5,6,7-tetrabromobenzotriazole	Preclinical	casein kinase inhibitor	AKT1|CHEK1|CSNK2A1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1			0	97.69	Tocris	2275	TBB	430.69	Brc1c(Br)c(Br)c2n[nH]nc2c1Br	OMZYUVOATZSGJY-UHFFFAOYSA-N	1694.0		OMZYUVOATZSGJY
BRD-K00003517-001-01-9	4-(aminomethyl)benzoic-acid	Preclinical	hemostatic agent				0	0.0	MedChemEx	HY-B1258	4-(Aminomethyl)benzoic acid	151.063	NCc1ccc(cc1)C(O)=O	QCTBMLYLENLHLA-UHFFFAOYSA-N	65526.0		QCTBMLYLENLHLA
BRD-K47337578-034-03-3	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	Preclinical	serotonin receptor antagonist	HTR2A			0	93.98	Tocris	523	4F 4PP oxalate	339.2	Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	FTJXZACAQRDRNT-UHFFFAOYSA-N	5234410.0		FTJXZACAQRDRNT
BRD-K47337578-034-04-9	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	Preclinical	serotonin receptor antagonist	HTR2A			0	93.33	Tocris	523	4F 4PP oxalate	339.2	Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	FTJXZACAQRDRNT-UHFFFAOYSA-N	5234410.0		FTJXZACAQRDRNT
BRD-K47337578-034-02-5	4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	Preclinical	serotonin receptor antagonist	HTR2A			0	97.38	Tocris	523	4F 4PP oxalate	339.2	Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	FTJXZACAQRDRNT-UHFFFAOYSA-N	5234410.0		FTJXZACAQRDRNT
BRD-K97019106-005-02-9	4-acetyl-1,1-dimethylpiperazinium	Preclinical	acetylcholine receptor agonist				0	87.43	Tocris	352	4-Acetyl-1,1-dimethylpiperazinium iodide	157.134	CC(=O)N1CC[N+](C)(C)CC1	MSBLMBWXUVQCDY-UHFFFAOYSA-N	4392675.0		MSBLMBWXUVQCDY
BRD-K97019106-005-03-9	4-acetyl-1,1-dimethylpiperazinium	Preclinical	acetylcholine receptor agonist				0	100.0	Tocris	352	4-Acetyl-1,1-dimethylpiperazinium iodide	157.134	CC(=O)N1CC[N+](C)(C)CC1	MSBLMBWXUVQCDY-UHFFFAOYSA-N	4392675.0		MSBLMBWXUVQCDY
BRD-K65544384-001-15-8	4-aminohippuric-acid	Launched		SLC22A6	nephrology	renal diagnostic agent	0	100.0	MicroSource	1503069	AMINOHIPPURIC ACID	194.069	Nc1ccc(cc1)C(=O)NCC(O)=O	HSMNQINEKMPTIC-UHFFFAOYSA-N	2148.0		HSMNQINEKMPTIC
BRD-K65544384-236-01-0	4-aminohippuric-acid	Launched		SLC22A6	nephrology	renal diagnostic agent	0	83.36	Selleck	S4414	Sodium 4-aminohippurate Hydrate	194.069	Nc1ccc(cc1)C(=O)NCC(O)=O	HSMNQINEKMPTIC-UHFFFAOYSA-N	2148.0		HSMNQINEKMPTIC
BRD-K65544384-236-03-6	4-aminohippuric-acid	Launched		SLC22A6	nephrology	renal diagnostic agent	0	85.47	MedChemEx	HY-A0080	Aminohippurate (sodium)	194.069	Nc1ccc(cc1)C(=O)NCC(O)=O	HSMNQINEKMPTIC-UHFFFAOYSA-N	2148.0		HSMNQINEKMPTIC
BRD-K65544384-001-14-1	4-aminohippuric-acid	Launched		SLC22A6	nephrology	renal diagnostic agent	0	96.42	Selleck	S2883	4-Aminohippuric Acid	194.069	Nc1ccc(cc1)C(=O)NCC(O)=O	HSMNQINEKMPTIC-UHFFFAOYSA-N	2148.0		HSMNQINEKMPTIC
BRD-K65544384-236-02-8	4-aminohippuric-acid	Launched		SLC22A6	nephrology	renal diagnostic agent	0	76.08	Selleck	S4414	SodiuM 4-aMinohippurate hydrate	194.069	Nc1ccc(cc1)C(=O)NCC(O)=O	HSMNQINEKMPTIC-UHFFFAOYSA-N	2148.0		HSMNQINEKMPTIC
BRD-A80383043-001-03-3	4-carboxy-3-hydroxyphenylglycine-(RS)	Preclinical	glutamate receptor agonist|glutamate receptor antagonist	GRM1			0	0.0	Tocris	310	(RS)-4-Carboxy-3-hydroxyphenylglycine	211.048	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|	GXZSAQLJWLCLOX-SSDOTTSWSA-N	6604709.0		GXZSAQLJWLCLOX
BRD-A80383043-001-04-9	4-carboxy-3-hydroxyphenylglycine-(RS)	Preclinical	glutamate receptor agonist|glutamate receptor antagonist	GRM1			0	0.0	Tocris	310	(RS)-4-Carboxy-3-hydroxyphenylglycine	211.048	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1,r|	GXZSAQLJWLCLOX-SSDOTTSWSA-N	6604709.0		GXZSAQLJWLCLOX
BRD-K74133873-001-01-7	4-carboxy-3-hydroxyphenylglycine-(S)	Preclinical	glutamate receptor agonist|glutamate receptor antagonist	GRM1|GRM2			0	0.0	Tocris	320	(S)-4-Carboxy-3-hydroxyphenylglycine	211.048	N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1	GXZSAQLJWLCLOX-ZETCQYMHSA-N	5311455.0		GXZSAQLJWLCLOX
BRD-K74133873-001-02-9	4-carboxy-3-hydroxyphenylglycine-(S)	Preclinical	glutamate receptor agonist|glutamate receptor antagonist	GRM1|GRM2			0	0.0	Tocris	320	(S)-4-Carboxy-3-hydroxyphenylglycine	211.048	N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1	GXZSAQLJWLCLOX-ZETCQYMHSA-N	5311455.0		GXZSAQLJWLCLOX
BRD-K39160765-003-03-9	4-chlorophenylguanidine	Preclinical	urokinase inhibitor	PLAUR			0	92.23	Tocris	442	4-Chlorophenylguanidine hydrochloride	169.041	NC(=N)Nc1ccc(Cl)cc1	ZSJNJAJDBNFVCA-UHFFFAOYSA-N	2757788.0		ZSJNJAJDBNFVCA
BRD-K39160765-003-02-9	4-chlorophenylguanidine	Preclinical	urokinase inhibitor	PLAUR			0	94.15	Tocris	442	4-Chlorophenylguanidine hydrochloride	169.041	NC(=N)Nc1ccc(Cl)cc1	ZSJNJAJDBNFVCA-UHFFFAOYSA-N	2757788.0		ZSJNJAJDBNFVCA
BRD-A54139254-001-10-9	4-CMTB	Preclinical	free fatty acid receptor agonist	FFAR2			0	92.55	Tocris	4642	4-CMTB	294.059	CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|	AZYDQCGCBQYFSE-GFCCVEGCSA-N	854190.0		AZYDQCGCBQYFSE
BRD-A54139254-001-09-2	4-CMTB	Preclinical	free fatty acid receptor agonist	FFAR2			0	95.73	Tocris	4642	4-CMTB	294.059	CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3,r|	AZYDQCGCBQYFSE-GFCCVEGCSA-N	854190.0		AZYDQCGCBQYFSE
BRD-K29313239-005-10-9	4-DAMP	Preclinical	cholinergic receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5			0	95.95	Tocris	482	4-DAMP	324.196	C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1	HYJRTXSYDAFGJK-UHFFFAOYSA-N	1734.0		HYJRTXSYDAFGJK
BRD-K29313239-005-09-4	4-DAMP	Preclinical	cholinergic receptor antagonist	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5			0	0.0	Tocris	482	4-DAMP	324.196	C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1	HYJRTXSYDAFGJK-UHFFFAOYSA-N	1734.0		HYJRTXSYDAFGJK
BRD-A32796301-001-01-6	4-galactosyllactose	Preclinical					0	96.9	Key	MD-0231	4-O-(4-O-beta-D-galactopyranosyl-beta-D-galactopyranosyl)-D-glucopyranose	504.169	OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O |a:2,4,6,7,9,11,13,14,16,21,25,28,30,32,&1:18|	FYGDTMLNYKFZSV-QGAOIPDPSA-N	67743883.0		FYGDTMLNYKFZSV
BRD-K91758890-001-10-0	4-HQN	Preclinical	PARP inhibitor	PARP1			0	96.43	Tocris	2192	4-HQN	146.048	O=c1nc[nH]c2ccccc12	QMNUDYFKZYBWQX-UHFFFAOYSA-N	135408753.0		QMNUDYFKZYBWQX
BRD-K91758890-001-11-9	4-HQN	Preclinical	PARP inhibitor	PARP1			0	95.6	Tocris	2192	4-HQN	146.048	O=c1nc[nH]c2ccccc12	QMNUDYFKZYBWQX-UHFFFAOYSA-N	135408753.0		QMNUDYFKZYBWQX
BRD-K49759007-001-12-9	4-hydroxy-phenazone	Preclinical					0	92.54	MedChemEx	HY-B2150	4-Hydroxyantipyrine	204.09	Cc1c(O)c(=O)n(-c2ccccc2)n1C	SKVPTPMWXJSBTF-UHFFFAOYSA-N	98889.0		SKVPTPMWXJSBTF
BRD-K49759007-001-11-9	4-hydroxy-phenazone	Preclinical					0	80.58	Prestwick	Prestw-30	Antipyrine, 4-hydroxy	204.09	Cc1c(O)c(=O)n(-c2ccccc2)n1C	SKVPTPMWXJSBTF-UHFFFAOYSA-N	98889.0		SKVPTPMWXJSBTF
BRD-K62537556-001-02-5	4-IBP	Preclinical	sigma receptor agonist	SIGMAR1			0	98.48	Tocris	748	4-IBP	420.07	Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1	HELCSESNNDZLFM-UHFFFAOYSA-N	132995.0		HELCSESNNDZLFM
BRD-K66664625-001-02-9	4-iodo-L-phenylalanine	Preclinical		DPP4			0	76.53	MedChemEx	HY-W011472	H-D-Phe(4-I)-OH	290.976	N[C@H](Cc1ccc(I)cc1)C(O)=O	PZNQZSRPDOEBMS-MRVPVSSYSA-N	7047041.0		PZNQZSRPDOEBMS
BRD-K66664625-001-01-2	4-iodo-L-phenylalanine	Preclinical		DPP4			0	87.58	Key	PS-6219		290.976	N[C@H](Cc1ccc(I)cc1)C(O)=O	PZNQZSRPDOEBMS-MRVPVSSYSA-N	7047041.0		PZNQZSRPDOEBMS
BRD-K25690923-001-02-4	4-iodo-6-phenylpyrimidine	Preclinical	macrophage migration inhibiting factor inhibitor	MIF			0	98.51	Tocris	3429	4-IPP	281.965	Ic1cc(ncn1)-c1ccccc1	ZTCJXHNJVLUUMR-UHFFFAOYSA-N	817368.0		ZTCJXHNJVLUUMR
BRD-K73303757-001-21-6	4-methylgenistein	Preclinical	protein tyrosine kinase inhibitor	CYP19A1|ESRRA|ESRRB|ESRRG|FASN			0	95.83	Selleck	S2377	Biochanin A	284.068	COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	WUADCCWRTIWANL-UHFFFAOYSA-N	5280373.0		WUADCCWRTIWANL
BRD-K70821460-300-02-4	4-methylhistamine	Preclinical	histamine receptor agonist	HRH4			0	90.32	Tocris	2342	4-Methylhistamine dihydrochloride	125.095	Cc1nc[nH]c1CCN	UGYXPZQILZRKJJ-UHFFFAOYSA-N	37463.0		UGYXPZQILZRKJJ
BRD-K81316007-001-02-9	4-mu-8C	Preclinical	IRE1 inhibitor	ERN1			0	93.44	Tocris	4479	4mu8C	204.042	Cc1cc(=O)oc2c(C=O)c(O)ccc12	RTHHSXOVIJWFQP-UHFFFAOYSA-N	12934390.0		RTHHSXOVIJWFQP
BRD-K81316007-001-01-8	4-mu-8C	Preclinical	IRE1 inhibitor	ERN1			0	94.67	Selleck	S7272	4?8C	204.042	Cc1cc(=O)oc2c(C=O)c(O)ccc12	RTHHSXOVIJWFQP-UHFFFAOYSA-N	12934390.0		RTHHSXOVIJWFQP
BRD-K00004224-001-01-9	4-P-PDOT	Preclinical	melatonin receptor antagonist	MTNR1A|MTNR1B			0	95.99	Tocris	1034	4-P-PDOT	279.162	CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5,7|	RCYLUNPFECYGDW-AEFFLSMTSA-N	24750357.0		RCYLUNPFECYGDW
BRD-K41024817-325-01-0	4-phenolsulfonic-acid	Preclinical					0	92.14	Acros	12398	4-Phenolsulfonic acid, sodium salt dihydrate, 99%	173.999	Oc1ccc(cc1)S(O)(=O)=O	FEPBITJSIHRMRT-UHFFFAOYSA-N	4765.0		FEPBITJSIHRMRT
BRD-A40504327-003-02-9	4-phenyl-1,2,3,4-tetrahydroisoquinoline	Preclinical	dopamine release inhibitor				0	94.82	Tocris	730	4-Phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride	209.12	C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|	OSZMNJRKIPAVOS-HNNXBMFYSA-N	11820407.0		OSZMNJRKIPAVOS
BRD-A40504327-003-03-9	4-phenyl-1,2,3,4-tetrahydroisoquinoline	Preclinical	dopamine release inhibitor				0	0.0	Tocris	730		209.12	C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9,r|	OSZMNJRKIPAVOS-HNNXBMFYSA-N	11820407.0	BRD-A40504327-001-03-9|BRD-A40504327-001-03-9	OSZMNJRKIPAVOS
BRD-K78061844-050-02-7	4-PPBP	Preclinical	sigma receptor ligand	SIGMAR1			0	96.19	Tocris	620	4-PPBP maleate	293.214	C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	HQGDPZPNAXRCSA-UHFFFAOYSA-N	3035672.0		HQGDPZPNAXRCSA
BRD-K78061844-050-03-9	4-PPBP	Preclinical	sigma receptor ligand	SIGMAR1			0	95.73	Tocris	620	4-PPBP maleate	293.214	C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	HQGDPZPNAXRCSA-UHFFFAOYSA-N	3035672.0		HQGDPZPNAXRCSA
BRD-K78061844-050-01-9	4-PPBP	Preclinical	sigma receptor ligand	SIGMAR1			0	85.32	Tocris	620	4-PPBP maleate	293.214	C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	HQGDPZPNAXRCSA-UHFFFAOYSA-N	3035672.0		HQGDPZPNAXRCSA
BRD-K42108215-001-01-5	4-propylbenzoic-acid	Preclinical					0	0.0	Maybridge	BTB09874		164.084	CCCc1ccc(cc1)C(O)=O	ATZHGRNFEFVDDJ-UHFFFAOYSA-N	137601.0		ATZHGRNFEFVDDJ
BRD-K04552268-001-02-4	4-pyrimidinecarbonitrile	Preclinical					0	0.0	Enamine	Z1116387809	4-pyrimidinecarbonitrile	105.033	N#Cc1ccncn1	ZIEWSZYVEDTXGH-UHFFFAOYSA-N	10313094.0		ZIEWSZYVEDTXGH
BRD-K06338106-001-01-4	4-tert-butylphenol	Preclinical					0	0.0	Enamine	Z57127886		150.104	CC(C)(C)c1ccc(O)cc1	QHPQWRBYOIRBIT-UHFFFAOYSA-N	7393.0		QHPQWRBYOIRBIT
BRD-K06338106-001-04-9	4-tert-butylphenol	Preclinical					0	80.77	Sigma	MFCD00002367	4-tert-Butylphenol	150.104	CC(C)(C)c1ccc(O)cc1	QHPQWRBYOIRBIT-UHFFFAOYSA-N	7393.0		QHPQWRBYOIRBIT
BRD-A18598741-001-01-2	4BP-TQS	Preclinical	nicotinic receptor agonist	CHRNA7			0	72.37	Tocris	4234	4BP-TQS	404.019	NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|	YNCXHXYZTLIZTO-RLFYNMQTSA-N	6979017.0		YNCXHXYZTLIZTO
BRD-A18598741-001-02-9	4BP-TQS	Preclinical	nicotinic receptor agonist	CHRNA7			0	90.97	Tocris	4234	4BP-TQS	404.019	NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9,&2:10,&3:14,r,c:12|	YNCXHXYZTLIZTO-RLFYNMQTSA-N	6979017.0		YNCXHXYZTLIZTO
BRD-K00004308-001-01-9	4EGI-1	Preclinical	protein synthesis inhibitor	EIF4E			0	74.01	Tocris	4800	4EGI-1	449.996	OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1	KFRKRECSIYXARE-UHFFFAOYSA-N	2831024.0		KFRKRECSIYXARE
BRD-K67173685-001-07-7	4E1RCat	Preclinical	protein synthesis inhibitor	EIF4E|EIF4G1			0	65.3	Tocris	4215	4E1RCat	478.116	OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|	BBQRBOIMSKMFFO-LTGZKZEYSA-N	16195554.0		BBQRBOIMSKMFFO
BRD-K67173685-001-08-5	4E1RCat	Preclinical	protein synthesis inhibitor	EIF4E|EIF4G1			0	65.99	Selleck	S7370	4E1RCat	478.116	OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|	BBQRBOIMSKMFFO-LTGZKZEYSA-N	16195554.0	BRD-K56468417-001-01-2	BBQRBOIMSKMFFO
BRD-K67173685-001-09-9	4E1RCat	Preclinical	protein synthesis inhibitor	EIF4E|EIF4G1			0	93.94	Tocris	4215	4E1RCat	478.116	OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|	BBQRBOIMSKMFFO-LTGZKZEYSA-N	16195554.0		BBQRBOIMSKMFFO
BRD-K67173685-001-06-9	4E1RCat	Preclinical	protein synthesis inhibitor	EIF4E|EIF4G1			0	93.43	Selleck	S7370	4E1RCat	478.116	OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|	BBQRBOIMSKMFFO-LTGZKZEYSA-N	16195554.0		BBQRBOIMSKMFFO
BRD-K11773281-001-02-0	4SC-202	Phase 1	HDAC inhibitor	HDAC1			0	96.41	MedChemEx	HY-16012A	4SC-202 (free base)	447.137	Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	PRXXYMVLYKJITB-IZZDOVSWSA-N	15985904.0		PRXXYMVLYKJITB
BRD-K11773281-001-01-2	4SC-202	Phase 1	HDAC inhibitor	HDAC1			0	92.54	MedChemEx	HY-16012A	4SC-202 (free base)	447.137	Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	PRXXYMVLYKJITB-IZZDOVSWSA-N	15985904.0		PRXXYMVLYKJITB
BRD-K11773281-075-02-4	4SC-202	Phase 1	HDAC inhibitor	HDAC1			0	93.08	Selleck	S7555	4SC-202	447.137	Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	PRXXYMVLYKJITB-IZZDOVSWSA-N	15985904.0		PRXXYMVLYKJITB
BRD-K11773281-075-01-6	4SC-202	Phase 1	HDAC inhibitor	HDAC1			0	74.16	MedChemEx	HY-16012	4SC-202	447.137	Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	PRXXYMVLYKJITB-IZZDOVSWSA-N	15985904.0		PRXXYMVLYKJITB
BRD-K00004289-001-01-9	5'-chloro-5'-deoxy-ENBA-(+/-)	Preclinical	adenosine receptor agonist	ADORA1			0	92.56	Tocris	3576	(+/-)-5'-Chloro-5'-deoxy-ENBA	379.141	O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1,2,6,7,&1:17,20,&2:15|	PVJGDYDNVNCGBT-CYDCOVMPSA-N			PVJGDYDNVNCGBT
BRD-K60287130-001-06-5	5,7-dichlorokynurenic-acid	Preclinical	glutamate receptor antagonist	GLRA2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	96.57	Tocris	286	5,7-Dichlorokynurenic acid	256.965	OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1	BGKFPRIGXAVYNX-UHFFFAOYSA-N	1779.0		BGKFPRIGXAVYNX
BRD-K60287130-001-05-7	5,7-dichlorokynurenic-acid	Preclinical	glutamate receptor antagonist	GLRA2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	98.43	Tocris	286	5,7-Dichlorokynurenic acid	256.965	OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1	BGKFPRIGXAVYNX-UHFFFAOYSA-N	1779.0		BGKFPRIGXAVYNX
BRD-K60287130-001-08-9	5,7-dichlorokynurenic-acid	Preclinical	glutamate receptor antagonist	GLRA2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D			0	94.01	Tocris	286	5,7-Dichlorokynurenic acid	256.965	OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1	BGKFPRIGXAVYNX-UHFFFAOYSA-N	1779.0		BGKFPRIGXAVYNX
BRD-K58146797-001-01-2	5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one	Preclinical					0	0.0	AMS	A002683787	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one	223.051	CCn1c(n[nH]c1=O)-c1ccc(Cl)cc1	PXINDYJACXPZIN-UHFFFAOYSA-N	35793.0		PXINDYJACXPZIN
BRD-K87535339-001-01-6	5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione	Preclinical		TLR7			0	98.58	Berry	PRA 10047		316.048	Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	TZYVRXZQAWPIAB-FCLHUMLKSA-N	135409474.0	BRD-A99177285-001-01-9	TZYVRXZQAWPIAB
BRD-K57631554-003-07-0	5-aminolevulinic-acid	Launched	oxidizing agent	ALAD	oncology|dermatology	glioma|actinic keratosis (AK)	0	100.0	MicroSource	1504184	AMINOLEVULINIC ACID HYDROCHLORIDE	131.058	NCC(=O)CCC(O)=O	ZGXJTSGNIOSYLO-UHFFFAOYSA-N	7048523.0		ZGXJTSGNIOSYLO
BRD-K57631554-003-06-2	5-aminolevulinic-acid	Launched	oxidizing agent	ALAD	oncology|dermatology	glioma|actinic keratosis (AK)	0	100.0	Selleck	S2553	5-Aminolevulinic acid HCl	131.058	NCC(=O)CCC(O)=O	ZGXJTSGNIOSYLO-UHFFFAOYSA-N	7048523.0		ZGXJTSGNIOSYLO
BRD-K33690734-001-02-3	5-BDBD	Preclinical	purinergic receptor antagonist	P2RX4			0	98.81	Tocris	3579	5-BDBD	354	Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|	NKYMVQPXXTZHSF-UHFFFAOYSA-N	9841560.0		NKYMVQPXXTZHSF
BRD-K33690734-001-01-5	5-BDBD	Preclinical	purinergic receptor antagonist	P2RX4			0	98.15	Tocris	3579	5-BDBD	354	Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|	NKYMVQPXXTZHSF-UHFFFAOYSA-N	9841560.0		NKYMVQPXXTZHSF
BRD-K33690734-001-03-9	5-BDBD	Preclinical	purinergic receptor antagonist	P2RX4			0	97.79	Tocris	3579	5-BDBD	354	Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|	NKYMVQPXXTZHSF-UHFFFAOYSA-N	9841560.0		NKYMVQPXXTZHSF
BRD-K92382976-050-02-9	5-carboxamidotryptamine	Preclinical	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7			0	94.32	Tocris	458	5-Carboxamidotryptamine maleate	203.106	NCCc1c[nH]c2ccc(cc12)C(N)=O	WKZLNEWVIAGNAW-UHFFFAOYSA-N	1809.0		WKZLNEWVIAGNAW
BRD-K92382976-050-01-1	5-carboxamidotryptamine	Preclinical	serotonin receptor agonist	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7			0	90.34	Tocris	458	5-Carboxamidotryptamine maleate	203.106	NCCc1c[nH]c2ccc(cc12)C(N)=O	WKZLNEWVIAGNAW-UHFFFAOYSA-N	1809.0		WKZLNEWVIAGNAW
BRD-K73381198-001-01-1	5-fluoro-3-pyridyl-methanol	Preclinical					0	96.92	Manchester	B12130		127.043	OCc1cncc(F)c1	GGGJYJXAFSEWNM-UHFFFAOYSA-N	152449.0		GGGJYJXAFSEWNM
BRD-K00004679-001-01-9	5-fluoropyrimidine	Phase 3	kinase inhibitor				0	0.0	AMS	A102809	5-fluoropyrimidine	98.028	Fc1cncnc1	KSPDSMOWMQFPBL-UHFFFAOYSA-N	69605.0		KSPDSMOWMQFPBL
BRD-K24844714-001-25-2	5-fluorouracil	Launched	thymidylate synthase inhibitor	DPYD|TYMS	oncology	colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma	0	86.87	MicroSource	1500305	FLUOROURACIL	130.018	Fc1c[nH]c(=O)[nH]c1=O	GHASVSINZRGABV-UHFFFAOYSA-N	3385.0		GHASVSINZRGABV
BRD-K24844714-001-24-5	5-fluorouracil	Launched	thymidylate synthase inhibitor	DPYD|TYMS	oncology	colorectal cancer|breast cancer|pancreatic cancer|gastric adenocarcinoma	0	100.0	Selleck	S1209	Fluorouracil (5-Fluoracil, 5-FU)	130.018	Fc1c[nH]c(=O)[nH]c1=O	GHASVSINZRGABV-UHFFFAOYSA-N	3385.0		GHASVSINZRGABV
BRD-K34437622-001-08-0	5-FP	Phase 1	thymidylate synthase inhibitor	TYMS			0	0.0	Sigma	MFCD00223678	5-fluoro-2-pyrimidinol	114.023	Fc1cnc(=O)[nH]c1	HPABFFGQPLJKBP-UHFFFAOYSA-N	101498.0		HPABFFGQPLJKBP
BRD-K34437622-001-06-4	5-FP	Phase 1	thymidylate synthase inhibitor	TYMS			0	0.0	Maybridge	JFD02014		114.023	Fc1cnc(=O)[nH]c1	HPABFFGQPLJKBP-UHFFFAOYSA-N	101498.0		HPABFFGQPLJKBP
BRD-K86799112-001-04-6	5-HMF	Phase 2					0	82.24	Sigma	MFCD00003234	5-(hydroxymethyl)-2-furaldehyde	126.032	OCc1ccc(C=O)o1	NOEGNKMFWQHSLB-UHFFFAOYSA-N	237332.0		NOEGNKMFWQHSLB
BRD-K86799112-001-02-0	5-HMF	Phase 2					0	84.12	OxChem	AX8022137		126.032	OCc1ccc(C=O)o1	NOEGNKMFWQHSLB-UHFFFAOYSA-N	237332.0		NOEGNKMFWQHSLB
BRD-K86799112-001-03-8	5-HMF	Phase 2					0	0.0	Sigma	53407	5-(hydroxymethyl)-2-furaldehyde	126.032	OCc1ccc(C=O)o1	NOEGNKMFWQHSLB-UHFFFAOYSA-N	237332.0		NOEGNKMFWQHSLB
BRD-K01666923-236-01-9	5-hydroxydecanoic-acid	Preclinical					0	64.0	Enzo	BML-KC141-0100	5-hydroxydecanoate sodium salt	211.131	CCCCC[C@@H](O)CCCC(O)=O |&1:5|	LMHJFKYQYDSOQO-SECBINFHSA-N	13309539.0	BRD-A96977263-236-01-3	LMHJFKYQYDSOQO
BRD-K03871161-001-01-9	5-hydroxyectoine	Preclinical					0	97.0	Sigma	MFCD01863080	(4S,5S)-5-hydroxy-2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid	158.069	CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|	KIIBBJKLKFTNQO-WHFBIAKZSA-N	40488256.0		KIIBBJKLKFTNQO
BRD-K03871161-001-02-9	5-hydroxyectoine	Preclinical					0	100.0	Sigma	MFCD01863080	(4S,5S)-5-hydroxy-2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid	158.069	CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|	KIIBBJKLKFTNQO-WHFBIAKZSA-N	40488256.0		KIIBBJKLKFTNQO
BRD-K24603946-001-05-9	5-hydroxymethyl-tolterodine	Phase 1	acetylcholine receptor antagonist	CHRM3			0	96.55	MedChemEx	HY-76569	Desfesoterodine	341.235	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	DUXZAXCGJSBGDW-HXUWFJFHSA-N	9819382.0		DUXZAXCGJSBGDW
BRD-K24603946-001-02-1	5-hydroxymethyl-tolterodine	Phase 1	acetylcholine receptor antagonist	CHRM3			0	84.18	Selleck	S2659	5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)	341.235	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	DUXZAXCGJSBGDW-HXUWFJFHSA-N	9819382.0		DUXZAXCGJSBGDW
BRD-K24603946-001-03-9	5-hydroxymethyl-tolterodine	Phase 1	acetylcholine receptor antagonist	CHRM3			0	93.56	Selleck	S2659	5-hydroxymethyl tolterodine (PNU 200577)	341.235	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	DUXZAXCGJSBGDW-HXUWFJFHSA-N	9819382.0		DUXZAXCGJSBGDW
BRD-A73930134-001-02-2	5-hydroxytryptophan	Launched	neurotransmitter	SLC36A1|SLC36A2	neurology/psychiatry	insomnia	0	0.0	Selleck	S2374	5-hydroxytryptophan (5-HTP)	220.085	N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|	LDCYZAJDBXYCGN-VIFPVBQESA-N	6971044.0		LDCYZAJDBXYCGN
BRD-A73930134-001-03-0	5-hydroxytryptophan	Launched	neurotransmitter	SLC36A1|SLC36A2	neurology/psychiatry	insomnia	0	97.09	Selleck	S2374	5-hydroxytryptophan (5-HTP)	220.085	N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|	LDCYZAJDBXYCGN-VIFPVBQESA-N	6971044.0		LDCYZAJDBXYCGN
BRD-A73930134-001-04-8	5-hydroxytryptophan	Launched	neurotransmitter	SLC36A1|SLC36A2	neurology/psychiatry	insomnia	0	95.93	Selleck	S2374	5-hydroxytryptophan (5-HTP)	220.085	N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1,r|	LDCYZAJDBXYCGN-VIFPVBQESA-N	6971044.0		LDCYZAJDBXYCGN
BRD-K90065682-300-03-4	5-iodo-A-85380	Phase 2	acetylcholine receptor agonist				0	93.6	Tocris	1518	3-[(2S)-2-azetidinylmethoxy]-5-iodopyridine dihydrochloride	289.992	Ic1cncc(OC[C@@H]2CCN2)c1	RKVRGRXOYDTUEY-QMMMGPOBSA-N	6604876.0		RKVRGRXOYDTUEY
BRD-K90065682-300-02-6	5-iodo-A-85380	Phase 2	acetylcholine receptor agonist				0	81.19	Tocris	1518	5-Iodo-A-85380 dihydrochloride	289.992	Ic1cncc(OC[C@@H]2CCN2)c1	RKVRGRXOYDTUEY-QMMMGPOBSA-N	6604876.0		RKVRGRXOYDTUEY
BRD-K45437867-005-04-1	5-methylfurmethiodide	Preclinical	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	95.87	Tocris	588	N,N,N-trimethyl(5-methyl-2-furyl)methanaminium iodide	154.123	Cc1ccc(C[N+](C)(C)C)o1	KOWVJDFMEZKDDT-UHFFFAOYSA-N	4141.0		KOWVJDFMEZKDDT
BRD-K45437867-005-03-3	5-methylfurmethiodide	Preclinical	acetylcholine receptor agonist	CHRM1|CHRM2|CHRM3|CHRM4			0	81.16	Tocris	588	5-Methylfurmethiodide	154.123	Cc1ccc(C[N+](C)(C)C)o1	KOWVJDFMEZKDDT-UHFFFAOYSA-N	4141.0		KOWVJDFMEZKDDT
BRD-K06050544-001-03-1	5-methylhydantoin-(D)	Preclinical					0	0.0	Selleck	S4378	Methylhydantoin-5-(D)	114.043	C[C@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-UWTATZPHSA-N	1615267.0		VMAQYKGITHDWKL
BRD-K06050544-001-04-9	5-methylhydantoin-(D)	Preclinical					0	0.0	Selleck	S4378	(D)-5-methylhydantoin	114.043	C[C@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-UWTATZPHSA-N	1615267.0		VMAQYKGITHDWKL
BRD-K56033645-001-07-5	5-methylhydantoin-(L)	Preclinical					0	89.08	Prestwick	Prestw-860	Methylhydantoin-5-(L)	114.043	C[C@@H]1NC(=O)NC1=O	VMAQYKGITHDWKL-REOHCLBHSA-N	6419931.0		VMAQYKGITHDWKL
BRD-K00004681-001-01-9	5-octanoylsalicylic-acid	Preclinical	protein kinase activator				0	94.63	AMS	A132116	2-hydroxy-5-octanoylbenzoic acid	264.136	CCCCCCCC(=O)c1ccc(O)c(c1)C(O)=O	IXIGWKNBFPKCCD-UHFFFAOYSA-N	9838158.0		IXIGWKNBFPKCCD
BRD-K48329353-001-03-9	6,7-dehydro-17-acetoxy-progesterone	Preclinical	steroidal progestin				0	100.0	InterBioScreen	STOCK1N-54662	(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate	370.214	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|	URXWVWVPMJSAJD-KOORYGTMSA-N	200136.0		URXWVWVPMJSAJD
BRD-K48329353-001-01-3	6,7-dehydro-17-acetoxy-progesterone	Preclinical	steroidal progestin				0	81.26	InterBioScreen	STOCK1N-54662		370.214	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9,t:11|	URXWVWVPMJSAJD-KOORYGTMSA-N	200136.0		URXWVWVPMJSAJD
BRD-K00656370-001-10-5	6-aminochrysene	Phase 2	transferase inhibitor				0	30.33	Sigma	MFCD00003699	6-chrysenamine	243.105	Nc1cc2c3ccccc3ccc2c2ccccc12	KIVUHCNVDWYUNP-UHFFFAOYSA-N	17534.0		KIVUHCNVDWYUNP
BRD-K30284967-001-01-8	6-aminopenicillanic-acid	Preclinical					0	0.0	Enamine	Z1269203097		216.057	CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O	NGHVIOIJCVXTGV-ALEPSDHESA-N	7057887.0		NGHVIOIJCVXTGV
BRD-K30284967-001-02-9	6-aminopenicillanic-acid	Preclinical					0	100.0	Sigma	A70909	(+)-6-Aminopenicillanic acid	216.057	CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O	NGHVIOIJCVXTGV-ALEPSDHESA-N	7057887.0		NGHVIOIJCVXTGV
BRD-K62929068-001-26-9	6-benzylaminopurine	Preclinical	purinergic receptor activator				0	98.08	Sigma	MFCD00005572	N6-Benzyladenine	225.101	C(Nc1ncnc2nc[nH]c12)c1ccccc1	NWBJYWHLCVSVIJ-UHFFFAOYSA-N	62389.0		NWBJYWHLCVSVIJ
BRD-K62929068-001-16-5	6-benzylaminopurine	Preclinical	purinergic receptor activator				0	99.22	Prestwick	Prestw-189	Aminopurine, 6-benzyl	225.101	C(Nc1ncnc2nc[nH]c12)c1ccccc1	NWBJYWHLCVSVIJ-UHFFFAOYSA-N	62389.0		NWBJYWHLCVSVIJ
BRD-K34663752-001-10-9	6-chloromelatonin	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B			0	97.22	Tocris	443	6-Chloromelatonin	266.082	COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	LUINDDOUWHRIPW-UHFFFAOYSA-N	1858.0		LUINDDOUWHRIPW
BRD-K34663752-001-11-9	6-chloromelatonin	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B			0	95.65	Tocris	443	6-Chloromelatonin	266.082	COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	LUINDDOUWHRIPW-UHFFFAOYSA-N	1858.0		LUINDDOUWHRIPW
BRD-K34663752-001-09-1	6-chloromelatonin	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B			0	95.73	Tocris	443	6-Chloromelatonin	266.082	COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	LUINDDOUWHRIPW-UHFFFAOYSA-N	1858.0		LUINDDOUWHRIPW
BRD-K84924563-001-04-9	6-diazo-5-oxo-L-norleucine	Preclinical	glutamate receptor antagonist|glutaminase inhibitor				0	0.0	Sigma	D2141	(2S)-2-amino-6-diazo-5-oxohexanoic acid	172.072	N[C@@H](CCC(=O)C[N+]#N)C(O)=O	UUTYCZUIECRVAL-YFKPBYRVSA-O	73707377.0		UUTYCZUIECRVAL
BRD-K84924563-001-03-8	6-diazo-5-oxo-L-norleucine	Preclinical	glutamate receptor antagonist|glutaminase inhibitor				0	0.0	ChemImpex	7038		172.072	N[C@@H](CCC(=O)C[N+]#N)C(O)=O	UUTYCZUIECRVAL-YFKPBYRVSA-O	73707377.0		UUTYCZUIECRVAL
BRD-K49236613-001-03-9	6-iodo-nordihydrocapsaicin	Preclinical	TRPV antagonist	TRPV1			0	88.59	Tocris	1975	6-Iodonordihydrocapsaicin	419.096	CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	AAORACFZMYMFCG-UHFFFAOYSA-N	5149140.0		AAORACFZMYMFCG
BRD-K49236613-001-02-3	6-iodo-nordihydrocapsaicin	Preclinical	TRPV antagonist	TRPV1			0	92.2	Tocris	1975	6-Iodonordihydrocapsaicin	419.096	CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	AAORACFZMYMFCG-UHFFFAOYSA-N	5149140.0		AAORACFZMYMFCG
BRD-K77756533-001-01-4	7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one	Preclinical					0	99.06	Vitas-M	STL281810	7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one	214.111	O=C1N2CCCCC=C2Nc2ccccc12 |c:7|	HBEJFHWHFIAMAI-UHFFFAOYSA-N			HBEJFHWHFIAMAI
BRD-K65377893-001-08-2	7-aminocephalosporanic-acid	Preclinical	beta lactamase inhibitor				0	0.0	Selleck	S2530	7-Aminocephalosporanic acid	272.047	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|	HSHGZXNAXBPPDL-HZGVNTEJSA-N	7058093.0	BRD-K15457970-001-01-4	HSHGZXNAXBPPDL
BRD-K65377893-001-07-4	7-aminocephalosporanic-acid	Preclinical	beta lactamase inhibitor				0	100.0	Selleck	S2530	7-Aminocephalosporanic acid	272.047	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|	HSHGZXNAXBPPDL-HZGVNTEJSA-N	7058093.0		HSHGZXNAXBPPDL
BRD-K84214706-001-06-5	7-chlorokynurenic-acid	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C			0	97.33	Tocris	237	7-Chlorokynurenic acid	223.004	OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1	UAWVRVFHMOSAPU-UHFFFAOYSA-N	1884.0		UAWVRVFHMOSAPU
BRD-K84214706-001-05-7	7-chlorokynurenic-acid	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C			0	99.07	Tocris	237	7-Chlorokynurenic acid	223.004	OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1	UAWVRVFHMOSAPU-UHFFFAOYSA-N	1884.0		UAWVRVFHMOSAPU
BRD-K84214706-001-07-9	7-chlorokynurenic-acid	Preclinical	glutamate receptor antagonist	GRIN1|GRIN2A|GRIN2B|GRIN2C			0	97.86	Tocris	237	7-Chlorokynurenic acid	223.004	OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1	UAWVRVFHMOSAPU-UHFFFAOYSA-N	1884.0		UAWVRVFHMOSAPU
BRD-K01826780-004-09-9	7-hydroxy-DPAT	Preclinical	dopamine receptor agonist	DRD2|DRD3			0	84.83	Tocris	706	7-(dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol hydrobromide	327.12	CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|	BLYMJBIZMIGWFK-HNNXBMFYSA-N	23928184.0		BLYMJBIZMIGWFK
BRD-K01826780-004-08-9	7-hydroxy-DPAT	Preclinical	dopamine receptor agonist	DRD2|DRD3			0	89.47	Tocris	706	7-Hydroxy-DPAT hydrobromide	327.12	CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|	BLYMJBIZMIGWFK-HNNXBMFYSA-N	23928184.0		BLYMJBIZMIGWFK
BRD-K01826780-004-07-9	7-hydroxy-DPAT	Preclinical	dopamine receptor agonist	DRD2|DRD3			0	82.69	Tocris	706	7-Hydroxy-DPAT hydrobromide	327.12	CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|	BLYMJBIZMIGWFK-HNNXBMFYSA-N	23928184.0		BLYMJBIZMIGWFK
BRD-K01825667-050-01-9	7-hydroxy-PIPAT	Preclinical	dopamine receptor ligand	DRD3			0	54.71	Tocris	719	7-Hydroxy-PIPAT maleate	487.086	CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|	RTMIJLQPWFKAFE-GZTQLTBSSA-N	10317104.0		RTMIJLQPWFKAFE
BRD-K45293975-001-02-0	7-hydroxystaurosporine	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG			0	80.79	EMDBio	539644-500UG	UCN-01	482.195	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	3078519.0		PBCZSGKMGDDXIJ
BRD-K45293975-001-01-2	7-hydroxystaurosporine	Phase 2	CDK inhibitor|CHK inhibitor|PKC inhibitor	CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG			0	53.11	EMDBio	539644	UCN-01	482.195	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	PBCZSGKMGDDXIJ-KRUBCLEUSA-N	3078519.0		PBCZSGKMGDDXIJ
BRD-K07785030-001-01-6	7-keto-DHEA	Launched	steroid				0	98.83	ChemImpex	24167	(3beta)-7,17-dioxoandrost-5-en-3-yl acetate	344.199	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1 |c:24|	VVSMJVQHDZUPIL-XFKPDKBWSA-N	9798229.0		VVSMJVQHDZUPIL
BRD-K53156626-001-01-3	7-methoxytacrine	Phase 2	acetylcholinesterase inhibitor	ACHE			0	98.23	Enamine	Z2327883841	7-methoxy-1,2,3,4-tetrahydro-9-acridinylamine	228.126	COc1ccc2nc3CCCCc3c(N)c2c1	APQPVVOYBLOJDY-UHFFFAOYSA-N	119053.0		APQPVVOYBLOJDY
BRD-K41592905-001-01-6	7-methylxanthine	Phase 2	adenosine receptor antagonist				0	100.0	Sigma	MFCD00037979	7-methyl-3,7-dihydro-1H-purine-2,6-dione	166.049	Cn1cnc2[nH]c(=O)[nH]c(=O)c12	PFWLFWPASULGAN-UHFFFAOYSA-N	68374.0		PFWLFWPASULGAN
BRD-K04430056-001-18-5	7-nitroindazole	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	93.01	Tocris	602	7-Nitroindazole	163.038	[O-][N+](=O)c1cccc2c[nH]nc12	PQCAUHUKTBHUSA-UHFFFAOYSA-N	1893.0		PQCAUHUKTBHUSA
BRD-K04430056-236-02-1	7-nitroindazole	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	91.17	Tocris	800	7-NINA	163.038	[O-][N+](=O)c1cccc2c[nH]nc12	PQCAUHUKTBHUSA-UHFFFAOYSA-N	1893.0		PQCAUHUKTBHUSA
BRD-K04430056-001-17-7	7-nitroindazole	Preclinical	nitric oxide synthase inhibitor	NOS1|NOS2|NOS3			0	96.6	Tocris	602	7-Nitroindazole	163.038	[O-][N+](=O)c1cccc2c[nH]nc12	PQCAUHUKTBHUSA-UHFFFAOYSA-N	1893.0		PQCAUHUKTBHUSA
BRD-A09554849-236-08-9	8-bromo-cAMP	Preclinical	PKA activator				0	96.24	Tocris	1140	8-Bromo-cAMP, sodium salt	406.963	Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|	DVKQVRZMKBDMDH-UUOKFMHZSA-N	32014.0		DVKQVRZMKBDMDH
BRD-A09554849-236-07-6	8-bromo-cAMP	Preclinical	PKA activator				0	89.36	Tocris	1140	8-Bromo-cAMP, sodium salt	406.963	Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7,9,16,17,&1:12|	DVKQVRZMKBDMDH-UUOKFMHZSA-N	32014.0		DVKQVRZMKBDMDH
BRD-A00077618-236-08-9	8-bromo-cGMP	Preclinical	PKA activator	PRKG1			0	90.87	Tocris	1089	8-Bromo-cGMP, sodium salt	422.958	Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|	YUFCOOWNNHGGOD-UMMCILCDSA-N	135419186.0		YUFCOOWNNHGGOD
BRD-A00077618-236-07-6	8-bromo-cGMP	Preclinical	PKA activator	PRKG1			0	87.24	Tocris	1089	8-Bromo-cGMP, sodium salt	422.958	Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10,12,19,20,&1:15|	YUFCOOWNNHGGOD-UMMCILCDSA-N	135419186.0		YUFCOOWNNHGGOD
BRD-K01826732-004-09-9	8-hydroxy-DPAT	Preclinical	serotonin receptor agonist	HTR5A|HTR7			0	85.08	Tocris	529	8-Hydroxy-DPAT hydrobromide	247.194	CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|	ASXGJMSKWNBENU-AWEZNQCLSA-N	10125797.0		ASXGJMSKWNBENU
BRD-K01826732-004-08-9	8-hydroxy-DPAT	Preclinical	serotonin receptor agonist	HTR5A|HTR7			0	93.13	Tocris	529	8-Hydroxy-DPAT hydrobromide	327.12	CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|	ASXGJMSKWNBENU-AWEZNQCLSA-N	10125797.0		ASXGJMSKWNBENU
BRD-A60594020-034-01-1	8-hydroxy-PIPAT	Preclinical	dopamine receptor ligand	DRD2|DRD3			0	97.35	Tocris	797	8-Hydroxy-PIPAT	371.075	CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|	QBXHUZJZYDSLRH-MDDUGHTDSA-N	15288637.0		QBXHUZJZYDSLRH
BRD-A60594020-034-02-9	8-hydroxy-PIPAT	Preclinical	dopamine receptor ligand	DRD2|DRD3			0	93.54	Tocris	797	8-Hydroxy-PIPAT oxalate	371.075	CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|	QBXHUZJZYDSLRH-MDDUGHTDSA-N	15288637.0		QBXHUZJZYDSLRH
BRD-A07232941-001-03-5	8-M-PDOT	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B			0	86.71	Tocris	1035	8-M-PDOT	233.142	CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|	RVIGBTUDFAGRTQ-NSHDSACASA-N	92211535.0		RVIGBTUDFAGRTQ
BRD-A07232941-001-02-7	8-M-PDOT	Preclinical	melatonin receptor agonist	MTNR1A|MTNR1B			0	97.76	Tocris	1035	8-M-PDOT	233.142	CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5,r|	RVIGBTUDFAGRTQ-NSHDSACASA-N	92211535.0		RVIGBTUDFAGRTQ
BRD-K03044000-001-01-8	80841-78-7	Preclinical					0	0.0	Sigma	671975	4-(chloromethyl)-5-methyl-1,3-dioxol-2-one	147.993	Cc1oc(=O)oc1CCl	QCLFSYYUWPUWQR-UHFFFAOYSA-N	9855518.0		QCLFSYYUWPUWQR
BRD-K00535541-001-04-8	9-aminoacridine	Preclinical					0	89.89	Selleck	S4303	9-Aminoacridine	194.084	Nc1c2ccccc2nc2ccccc12	XJGFWWJLMVZSIG-UHFFFAOYSA-N	7019.0		XJGFWWJLMVZSIG
BRD-K00535541-001-05-5	9-aminoacridine	Preclinical					0	94.54	MicroSource	1500810	AMINACRINE	194.084	Nc1c2ccccc2nc2ccccc12	XJGFWWJLMVZSIG-UHFFFAOYSA-N	7019.0		XJGFWWJLMVZSIG
BRD-K00535541-001-06-3	9-aminoacridine	Preclinical					0	92.92	Selleck	S4303	9-Aminoacridine;9-Aminoacridine;Aminoacrid	194.084	Nc1c2ccccc2nc2ccccc12	XJGFWWJLMVZSIG-UHFFFAOYSA-N	7019.0		XJGFWWJLMVZSIG
BRD-K09291936-001-13-3	9-aminocamptothecin	Phase 2	topoisomerase inhibitor	TOP1			0	91.91	Sigma	MFCD00909855	(4S)-10-amino-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	363.122	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O	FUXVKZWTXQUGMW-FQEVSTJZSA-N	72402.0		FUXVKZWTXQUGMW
BRD-K09291936-001-14-9	9-aminocamptothecin	Phase 2	topoisomerase inhibitor	TOP1			0		Cayman	17232	9-aminocamptothecin	363.122	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O	FUXVKZWTXQUGMW-FQEVSTJZSA-N	72402.0		FUXVKZWTXQUGMW
BRD-K62607075-001-04-9	9-anthracenecarboxylic-acid	Preclinical		ANO1|CLCN1			0	88.03	Tocris	963	9-AC	222.068	OC(=O)c1c2ccccc2cc2ccccc12	XGWFJBFNAQHLEF-UHFFFAOYSA-N	2201.0		XGWFJBFNAQHLEF
BRD-K62607075-001-03-6	9-anthracenecarboxylic-acid	Preclinical		ANO1|CLCN1			0	73.91	Tocris	963	9-AC	222.068	OC(=O)c1c2ccccc2cc2ccccc12	XGWFJBFNAQHLEF-UHFFFAOYSA-N	2201.0		XGWFJBFNAQHLEF
